Comparison O
with O
RARE I-GENE
RARE I-GENE
and O
5 I-GENE
- I-GENE
RARE I-GENE

RARE O
aspects O
of O
neonatal O
hyperbilirubinemia O
. O

When O
CSF O
RARE O
HCO3 O
RARE O
is O
shown O
RARE O
a O
function O
of O
CSF O
PCO2 O
the O
data O
of O
K O
- O
depleted O
rats O
are O
RARE O
longer O
RARE O
when O
compared O
to O
controls O
but O
still O
have O
a O
significantly O
greater O
slope O
( O
1 O
. O
21 O
+/- O
NUM O
. O
NUM O
RARE O
. O

RARE O
thus O
appears O
to O
be O
an O
effective O
RARE O
drug O
with O
the O
RARE O
dose O
RARE O
use O
in O
RARE O
practice O
being O
NUM O
mg O
RARE O
night O
. O

RARE O
blocking O
agents O
. O

When O
RARE O
CO2 O
removal O
RARE O
CO2 O
production O
( O
NUM O
RARE O
alveolar O
ventilation O
almost O
RARE O
. O

Intravenous O
administration O
( O
NUM O
mg O
/ O
kg O
) O
of O
RARE I-GENE
anhydrase I-GENE
RARE O
( O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
) O
RARE O
an O
early O
important O
rise O
of O
cortical O
p O
NUM O
, O
which O
is O
not O
dependent O
on O
increase O
of O
p O
NUM O
and O
p O
CO2 O
and O
decrease O
of O
pH O
in O
arterial O
RARE O
. O

RARE O
study O
of O
RARE O
in O
the O
rat O
and O
RARE O
. O

RARE O
polyps O
should O
be O
removed O
RARE O
RARE O
possible O
. O

The O
RARE O
HMG I-GENE
dosage O
regimen O
was O
found O
to O
offer O
RARE O
advantages O
when O
compared O
with O
our O
standard O
daily O
dosage O
regimen O
. O

When O
the O
CO2 O
content O
reached O
9 O
RARE O
% O
the O
animals O
became O
RARE O
and O
lost O
body O
RARE O
. O

Serum I-GENE
gamma I-GENE
RARE I-GENE
in O
the O
diagnosis O
of O
liver O
RARE O
in O
cattle O
. O

By O
contrast O
, O
RARE I-GENE
ALL_CAP I-GENE
antibodies I-GENE
were O
not O
demonstrated O
RARE O
the O
onset O
of O
illness O
in O
any O
of O
the O
patients O
, O
but O
their O
formation O
started O
early O
and O
the O
antibodies O
reached O
maximal O
levels O
about O
10 O
days O
after O
onset O
of O
illness O
. O

With O
the O
exception O
of O
virus O
assay O
and O
RARE O
, O
these O
methods O
are O
simple O
and O
RARE O
enough O
to O
be O
done O
in O
typical O
RARE O
RARE O
laboratories O
. O

RARE O
of O
lipase I-GENE
activity O
. O

RARE O
' O
s O
RARE O
: O
association O
with O
HLA I-GENE
- I-GENE
NUM I-GENE
. O

ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
and O
RARE I-GENE
phosphatase I-GENE
concentrations O
were O
essentially O
normal O
in O
all O
subjects O
. O

RARE I-GENE
glutamyl I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
activity O
in O
the O
RARE O
RARE O

Patients O
with O
Parkinson O
' O
s O
RARE O
showed O
a O
relatively O
high O
incidence O
to O
RARE O
RARE O
drug O
treatment O
( O
NUM O
. O
NUM O
%). O

Selective O
RARE O
of O
central O
alpha I-GENE
- I-GENE
RARE I-GENE
following O
treatment O
with O
alpha O
- O
RARE O
and O
ALL_CAP O
136 O
. O

RARE O
- O
anxiety O
action O
of O
RARE O
after O
RARE O
- O
RARE O
application O
in O
the O
rat O
. O

RARE O
. O

Removal O
of O
thick O
, O
RARE O
altered O
RARE O
is O
recommended O
even O
in O
the O
absence O
of O
squamous O
epithelium O
. O

An O
IgG I-GENE
monoclonal O
RARE O
was O
present O
in O
the O
serum O
of O
4 O
patients O
and O
RARE O
- O
RARE O
RARE O
was O
found O
in O
1 O
patient O
. O

Studies O
on O
immunoglobulin I-GENE
E I-GENE
: O
the O
impact O
of O
a O
RARE O
with O
RARE O
RARE O
H O
. O

RARE I-GENE
reaction O
RARE O
were O
negative O
, O
RARE I-GENE
esterase I-GENE
were O
strongly O
positive O
. O

Ten O
out O
- O
patients O
with O
RARE O
RARE O
et O
RARE O
were O
examined O
with O
direct O
immunofluorescence O
( O
IF O
) O
technique O
RARE O
deposition O
of O
fibrinogen I-GENE
, O
fibrin I-GENE
or O
its O
RARE O
products O
( O
ALL_CAP I-GENE
- I-GENE
antigen I-GENE
) O
in O
affected O
and O
unaffected O
RARE O
, O
together O
with O
RARE O
- O
RARE O
fraction O
( O
ALL_CAP O
RARE O
RARE I-GENE
and O
RARE O
plasma O
fibrinogen I-GENE
in O
the O
RARE O
. O

Of O
600 O
RARE O
carried O
out O
from O
NUM O
to O
NUM O
, O
NUM O
were O
performed O
to O
assess O
the O
RARE O
of O
a O
pulmonary O
carcinoma O
. O

A O
mixture O
of O
human I-GENE
albumin I-GENE
5 O
% O
and O
hydroxy O
- O
ethyl O
- O
RARE O
was O
used O
RARE O
a O
solution O
RARE O
dilution O
. O

In O
the O
matched O
control O
group O
the O
acquisition O
- O
rate O
of O
both O
symptomatic O
and O
asymptomatic O
NUM O
was O
over O
12 O
%, O
a O
RARE O
similar O
to O
the O
percentage O
of O
women O
present O
in O
the O
practice O
population O
RARE O
one O
year O
with O
transient O
, O
symptomatic O
, O
and O
persistent O
A O
. O
B O
. O

RARE O
complications O
of O
RARE O
RARE O
intravenous O
nutrition O
. O

RARE O
diagnosis O
of O
RARE O
. O

RARE O
which O
are O
indicative O
of O
RARE O
RARE O
are O
absent O
. O

RARE O
positive O
RARE I-GENE
RARE I-GENE
alpha I-GENE
fetoprotein I-GENE
levels O
resulting O
from O
contamination O
with O
RARE O
RARE O
: O
results O
of O
an O
experiment O
. O

Serum O
- O
ferritin I-GENE
in O
diagnosis O
of O
RARE O
. O

In O
2 O
subjects O
the O
RARE O
reactivity O
of O
the O
lymphocytes O
was O
improved O
after O
treatment O
. O

Patients O
RARE O
risk O
of O
hypothyroidism O
. O

RARE I-GENE
and O
cyclic O
AMP O
levels O
in O
peritoneal O
fluids O
in O
the O
child O

RARE O
. O

Thirty O
- O
five O
strains O
of O
RARE O
' O
RARE O
bacteria O
were O
shown O
to O
belong O
in O
four O
distinct O
serologic O
groups O
on O
the O
basis O
of O
findings O
obtained O
with O
direct O
RARE O
antibody O
testing O
. O

On O
the O
other O
RARE O
factor I-GENE
ALL_CAP I-GENE
activity O
is O
decreased O
in O
RARE O
treatment O
with O
factor I-GENE
ALL_CAP I-GENE
antigen O
remaining O
normal O
. O

The O
concentration O
of O
alpha I-GENE
2 I-GENE
- I-GENE
RARE I-GENE
, O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
, O
plasminogen I-GENE
, O
NUM I-GENE
- I-GENE
complement I-GENE
, O
fibrinogen I-GENE
RARE I-GENE
products I-GENE
( O
ALL_CAP I-GENE
) O
and O
RARE O
activity O
, O
were O
studied O
in O
the O
aqueous O
RARE O
and O
serum O
from O
nine O
patients O
with O
RARE O
' O
endothelial O
RARE O
, O
NUM O
patients O
with O
RARE O
senile O
RARE O
and O
in O
the O
secondary O
aqueous O
from O
RARE O
RARE O
patients O
. O

Only O
NUM O
% O
of O
all O
patients O
RARE O
it O
RARE O
all O
times O
. O

RARE O
alone O
was O
effective O
in O
volume O
responsive O
patients O
RARE O
a O
dose O
of O
5 O
+/- O
1 O
. O
NUM O
mg O
daily O
. O

T4 O
and O
NUM O
followed O
parallel O
courses O
in O
both O
groups O
; O
RARE O
the O
RARE O
NUM O
days O
, O
however O
, O
the O
values O
were O
significantly O
lower O
in O
premature O
infants O
under O
NUM O
weeks O
' O
ALL_CAP O
than O
in O
term O
infants O
( O
P O
less O
than O
NUM O
. O
001 O
). O

A O
three O
- O
RARE O
analysis O
of O
treatment O
RARE O
RARE O
NUM O
patients O
was O
undertaken O
. O

RARE O
RARE O
: O
unaltered O
RARE O
of O
platelet I-GENE
RARE I-GENE
- I-GENE
oxygenase I-GENE
to O
inhibition O
by O
RARE O
in O
vitro O
. O

These O
results O
indicate O
that O
RARE O
monkeys O
are O
either O
less O
RARE O
or O
respond O
differently O
than O
RARE O
monkeys O
to O
some O
of O
the O
pharmacological O
effects O
of O
RARE O
. O

NUM O
cases O
of O
surgically O
RARE O
cancers O
( O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
) O
had O
a O
minimum O
RARE O
of O
two O
years O
( O
average O
4 O
years O
+/- O
3 O
months O
). O

The O
effect O
of O
ALL_CAP O
and O
ALL_CAP O
can O
be O
explained O
by O
interference O
with O
thyroid O
hormone O
binding O
to O
ALL_CAP I-GENE
combined O
with O
enzyme O
- O
RARE O
increased O
metabolic O
clearance O
rate O
of O
thyroid O
RARE O
without O
RARE O
RARE O
of O
RARE O
levels O
of O
NUM O
and O
NUM O
. O

The O
present O
research O
evaluated O
the O
possibility O
that O
RARE O
glycol O
NUM O
( O
ALL_CAP O
NUM O
) O
might O
be O
RARE O
, O
toxic O
, O
or O
both O
. O

According O
to O
their O
RARE O
properties O
the O
latter O
neurons O
were O
RARE O
into O
: O
( O
a O
) O
neurons O
responding O
to O
stimuli O
near O
the O
eyes O
; O
( O
b O
) O
neurons O
triggered O
by O
complex O
visual O
stimuli O
; O
( O
c O
) O
neurons O
inhibited O
by O
visual O
stimuli O
. O

RARE O
( O
1 O
, O
3 O
, O
10 O
, O
and O
NUM O
. O
5 O
mg O
/ O
kg O
) O
was O
also O
tested O
in O
combination O
with O
rate O
- O
decreasing O
doses O
of O
RARE O
( O
NUM O
. O
5 O
mg O
/ O
kg O
RARE O
RARE O
( O
10 O
mg O
/ O
kg O
RARE O
RARE O
( O
10 O
mg O
/ O
kg O
RARE O
and O
fentanyl O
( O
NUM O
. O
3 O
mg O
/ O
kg O
). O

RARE O
RARE O
( O
NUM O
. O
NUM O
RARE O
- O
2 O
) O
provided O
the O
best O
overall O
improvement O
. O

An O
anatomical O
and O
RARE O
study O
has O
been O
undertaken O
and O
RARE O
a O
result O
RARE O
is O
given O
to O
recent O
RARE O
that O
suggest O
there O
are O
similarities O
with O
RARE O
IV O
RARE O
RARE O
RARE O
( O
RARE O
' O
s O
RARE O
) O
which O
, O
although O
clinically O
distinct O
, O
has O
the O
same O
enzyme O
defect O
. O

All O
groups O
were O
tested O
in O
a O
RARE O
- O
RARE O
RARE O
RARE O
NUM O
RARE O
10 O
days O
of O
age O
. O

RARE O
and O
clindamycin O
resistance O
in O
RARE O
RARE O
from O
RARE O
lesions O
. O

RARE O
RARE O
RARE O
of O
RARE O
' O
s O
wrist O
produce O
three O
major O
peaks O
of O
activity O
( O
terms O
NUM O
, O
NUM O
, O
and O
NUM O
peaks O
) O
in O
the O
averaged O
gross O
EMG O
activity O
RARE O
the O
RARE O
muscles O
. O

RARE O
RARE O
of O
African O
newborn O
. O

In O
this O
RARE O
, O
RARE O
with O
what O
was O
judged O
previously O
to O
be O
the O
less O
virulent O
of O
the O
two O
T O
. O
RARE O
RARE O
used O
RARE O
RARE O
7 O
RARE O
there O
was O
severe O
RARE O
, O
with O
RARE O
degeneration O
, O
and O
lesions O
of O
the O
RARE O
. O

The O
majority O
of O
ALL_CAP O
RARE O
were O
RARE O
RARE O
; O
in O
the O
most O
frequently O
observed O
case O
, O
their O
activity O
failed O
to O
change O
RARE O
when O
behavior O
RARE O
. O

RARE O
within O
RARE O
' O
s O
RARE O
( O
RARE O
- O
21 O
): O
RARE O
observed O
RARE O
differences O
in O
RARE O
. O

VII O
. O

Several O
RARE O
indices O
of O
isolated O
populations O
in O
RARE O

2 O
RARE O
RARE O
of O
RARE O
nervous O
function O
in O
the O
ALL_CAP O
. O

The O
RARE O
of O
increased O
RARE O
capillary O
density O
required O
a O
similar O
amount O
of O
exercise O
, O
and O
RARE O
least O
1 O
h O
of O
exercise O
once O
a O
week O
was O
necessary O
to O
maintain O
the O
enlargement O
of O
ALL_CAP O
. O
20 O

These O
observations O
have O
led O
us O
to O
conclude O
that O
an O
elevated O
VIII O
- O
ratio O
is O
a O
very O
RARE O
indicator O
of O
intravascular O
coagulation O
. O

Eight O
hours O
after O
the O
administration O
of O
RARE O
, O
the O
serum I-GENE
RARE I-GENE
level O
RARE O
to O
rise O
again O
in O
female O
rats O
, O
but O
not O
in O
male O
rats O
. O

RARE O
of O
RARE O
, O
progesterone O
, O
RARE O
( O
ALL_CAP O
) O
16 O
alpha O
- O
hydroxy O
- O
ALL_CAP O
, O
RARE O
, O
and O
cortisol O
were O
performed O
on O
a O
RARE O
of O
NUM O
; O
1 O
ml O
; O
of O
RARE O
plasma O
, O
collected O
RARE O
the O
course O
of O
normal O
vaginal O
delivery O
. O

In O
only O
two O
patients O
were O
we O
able O
to O
demonstrate O
changes O
suggestive O
of O
pulmonary O
metastases O
any O
earlier O
with O
a O
99mTc O
- O
ALL_CAP O
scan O
than O
with O
chest O
radiographs O
and O
one O
of O
these O
resolved O
spontaneously O
. O

The O
majority O
of O
tumors O
occurred O
in O
the O
nasal O
RARE O
, O
although O
significant O
RARE O
were O
also O
found O
in O
the O
larynx O
, O
RARE O
and O
RARE O
RARE O
. O

RARE O
of O
the O
times O
of O
RARE O
development O

RARE O
human I-GENE
fibrinogen I-GENE
was O
RARE O
to O
coagulation O
by O
adding O
thrombin I-GENE
. O

No O
post O
- O
operative O
RARE O
from O
the O
RARE O
were O
observed O
. O

The O
Southern O
technique O
allowed O
a O
further O
RARE O
of O
the O
region O
of O
most O
extensive O
transcription O
to O
a O
1 O
. O
8 O
kb O
HindIII I-GENE
- O
EcoRI I-GENE
fragment O
. O

RARE O
RARE O
chosen O
limits O
of O
RARE O
RARE O
of O
+/- O
10 O
%, O
it O
could O
be O
shown O
that O
the O
RARE O
did O
not O
work O
RARE O
when O
the O
mean O
carbon O
dioxide O
concentration O
was O
below O
1 O
. O
5 O
RARE O
RARE O
within O
the O
fresh O
gas O
flow O
rates O
( O
2 O
. O
2 O
RARE O
7 O
. O
7 O
1 O
min O
- O
1 O
) O
and O
the O
range O
of O
minute O
ventilation O
( O
4 O
RARE O
10 O
1 O
min O
- O
1 O
) O
employed O
. O

SV O
increased O
less O
in O
ALL_CAP O
, O
mainly O
reflecting O
the O
RARE O
diastolic O
compliance O
of O
the O
RARE O
ALL_CAP O
RARE O
ventricle O
and O
the O
RARE O
RARE O
shift O
of O
its O
RARE O
- O
RARE O
curve O
. O

The O
RARE O
of O
a O
great O
RARE O
RARE O
( O
RARE O
RARE O
RARE O
which O
had O
been O
found O
RARE O
in O
southern O
RARE O
, O
was O
presented O
RARE O
RARE O
. O

The O
inner O
ears O
were O
exposed O
by O
RARE O
, O
and O
the O
vestibular O
sensory O
regions O
were O
either O
RARE O
and O
studied O
with O
light O
or O
electron O
microscopy O
, O
or O
prepared O
and O
studied O
with O
the O
surface O
RARE O
technique O
. O

RARE O
is O
extracted O
from O
RARE O
RARE O
samples O
with O
ethyl O
RARE O
and O
the O
RARE O
is O
RARE O
RARE O
on O
a O
RARE O
gel O
column O
, O
using O
RARE O
- O
ethyl O
RARE O
( O
NUM O
+ O
NUM O
) O
RARE O
the O
RARE O
. O

RARE O
RARE O
in O
RARE O
RARE O
RARE O
term O
. O

The O
RARE O
surrounding O
the O
clusters O
either O
showed O
a O
normal O
morphology O
or O
a O
RARE O
appearance O
, O
within O
which O
RARE O
cross O
RARE O
but O
RARE O
distinctly O
RARE O
RARE O
could O
be O
identified O
. O

RARE O
did O
not O
affect O
the O
percentage O
of O
RARE O
- O
treated O
animals O
with O
abnormal O
RARE O
excretion O
patterns O
, O
but O
did O
increase O
the O
magnitude O
of O
the O
disturbances O
in O
elimination O
of O
RARE O
and O
RARE O
RARE O
. O

RARE O
NUM O
RARE O
absorption O
and O
the O
role O
of O
cellular O
RARE O
. O

The O
incidence O
of O
ALL_CAP O
reactions O
was O
NUM O
per O
cent O
RARE O
Stage O
I O
and O
II O
cancers O
( O
37 O
RARE O
RARE O
NUM O
per O
cent O
RARE O
RARE O
Stage O
III O
RARE O
( O
NUM O
patients O
RARE O
and O
NUM O
per O
cent O
in O
patients O
with O
RARE O
or O
RARE O
Stage O
III O
RARE O
. O

Studies O
of O
RARE O
should O
, O
however O
, O
be O
made O
in O
children O
from O
RARE O
known O
to O
have O
ALL_CAP O
or O
early O
coronary O
RARE O
RARE O
. O

RARE O
other O
normal O
subjects O
with O
2 O
g O
of O
RARE O
are O
best O
responses O
. O

EEG O
RARE O
waves O
and O
psychological O
phenomena O
: O
a O
review O
and O
analysis O
. O

REM O
RARE O
content O
was O
RARE O
RARE O
categories O
suggesting O
the O
predominant O
influence O
of O
the O
RARE O
hemisphere O
, O
RARE O
. O
g O
., O
good O
RARE O
functioning O
, O
RARE O
, O
or O
the O
right O
hemisphere O
, O
RARE O
. O
g O
., O
RARE O
, O
spatial O
RARE O
, O
RARE O
. O

RARE O
of O
the O
ventral O
diaphragm O
of O
the O
RARE O
( O
RARE O
RARE O
). O

RARE O
ACTH I-GENE
RARE O
and O
RARE O
thyroid O
carcinoma O
. O

A O
striking O
finding O
in O
all O
of O
the O
studies O
was O
a O
positive O
correlation O
between O
PI O
ACTH I-GENE
and O
MSH I-GENE
contents O
. O

Chronic O
RARE O
is O
the O
most O
common O
type O
of O
" O
resistant O
" O
RARE O
. O

There O
was O
RARE O
correlation O
between O
serum I-GENE
ALL_CAP I-GENE
and O
RARE O
or O
bone O
age O
in O
this O
age O
group O
, O
which O
suggests O
that O
the O
correlation O
found O
is O
not O
due O
to O
age O
- O
related O
parallel O
phenomena O
. O

Molecular O
RARE O
of O
RARE O
drugs O
. O

RARE O
were O
made O
to O
determine O
the O
amount O
of O
time O
required O
RARE O
RARE O
lesions O
to O
develop O
and O
, O
if O
possible O
, O
to O
RARE O
the O
RARE O
site O
of O
action O
of O
ALL_CAP O
. O

Effect O
of O
RARE O
on O
the O
intensity O
of O
RARE I-GENE
acid I-GENE
dehydrogenase I-GENE
reactions O
in O
the O
brain O
of O
rats O
RARE O
with O
RARE O
RARE O

RARE O
and O
correlations O
of O
serum O
uric O
- O
acid O
in O
two O
RARE O
adult O
populations O
: O
NUM O
, O
NUM O
men O
and O
6 O
, O
NUM O
women O

The O
incidence O
of O
hepatitis I-GENE
B I-GENE
antigen I-GENE
following O
transfusion O
was O
about O
2 O
. O
8 O
per O
cent O
. O

RARE O
- O
99m O
RARE O
RARE O
RARE O
RARE O
were O
obtained O
in O
NUM O
clinically O
stable O
patients O
NUM O
. O
7 O
+/- O
NUM O
. O
3 O
weeks O
( O
range O
6 O
to O
260 O
) O
after O
acute O
RARE O
infarction O
. O

A O
similar O
phenomenon O
has O
been O
reported O
in O
a O
few O
humans O
. O

The O
decline O
in O
the O
activity O
of O
cytochrome I-GENE
oxidase I-GENE
, O
peroxidase I-GENE
and O
in O
the O
RARE O
content O
of O
peripheral O
neutrophils O
was O
followed O
by O
a O
decrease O
in O
the O
phagocytic O
activity O
. O

Treatment O
of O
2 O
patients O
with O
RARE O
type O
I O
with O
vitamin O
- O
D O
- O
3 O
and O
1 O
alpha O
- O
RARE O
RARE O
resulted O
in O
a O
RARE O
response O
with O
regard O
to O
the O
RARE O
of O
serum O
- O
RARE O
. O

RARE O
with O
" O
sensitivity O
" O
to O
toluene O
RARE O
( O
ALL_CAP O
) O
studied O
in O
depth O
in O
an O
attempt O
to O
determine O
mechanisms O
of O
bronchial O
RARE O
. O

Total O
VO2 O
was O
decreased O
in O
both O
groups O
RARE O
severe O
RARE O
but O
limb O
VO2 O
was O
maintained O
in O
the O
beta O
- O
RARE O
group O
. O
beta O
- O
RARE O
prevented O
the O
fall O
in O
RARE O
and O
limb O
peripheral O
resistance O
seen O
in O
severe O
RARE O
but O
did O
not O
alter O
the O
consistently O
more O
efficient O
utilization O
of O
RARE O
NUM O
delivery O
shown O
by O
the O
limb O
in O
comparison O
to O
the O
whole O
body O
by O
RARE O
NUM O
extraction O
ratios O
and O
lower O
venous O
NUM O
pressure O
. O
beta I-GENE
- I-GENE
RARE I-GENE
receptors I-GENE
RARE O
played O
an O
RARE O
part O
in O
the O
RARE O
seen O
RARE O
severe O
RARE O
. O

RARE O
- O
RARE O
alterations O
in O
the O
metabolism O
of O
RARE O
3H O
] O
vitamin O
NUM O
by O
the O
perfused O
RARE O
rat O
liver O
in O
vitro O
. O

RARE O
of O
NUM I-GENE
- I-GENE
RARE I-GENE
NUM I-GENE
- I-GENE
NUM I-GENE
- I-GENE
hydroxylase I-GENE
by O
RARE O
: O
a O
cytochrome I-GENE
P I-GENE
- I-GENE
NUM I-GENE
RARE I-GENE
RARE O
. O

In O
both O
these O
RARE O
, O
however O
, O
the O
ALL_CAP I-GENE
mRNA I-GENE
resembles O
the O
RARE O
RARE O
of O
SV40 O
and O
RARE O
viruses O
. O

Effect O
of O
RARE O
- O
containing O
RARE O
combination O
drugs O
on O
endogenous O
ACTH I-GENE
and O
cortisol O
production O
. O

Serum I-GENE
ACTH I-GENE
did O
not O
respond O
to O
insulin I-GENE
and O
RARE O
. O

RARE O
of O
the O
RNA O
and O
gene O
products O
of O
NUM O
and O
NUM O
, O
two O
RARE O
avian O
tumor O
viruses O
causing O
acute O
leukemia O
and O
carcinoma O
: O
evidence O
RARE O
a O
new O
class O
of O
transforming O
genes O
. O

RARE O
( O
RARE O
group O
) O
and O
RARE O
( O
RARE O
group O
RARE O
two O
new O
RARE O
isolated O
in O
RARE O
RARE O
, O
RARE O
. O

RARE I-GENE
glutamyl I-GENE
RARE I-GENE
activity O
was O
increased O
RARE O
to O
NUM O
times O
above O
the O
upper O
normal O
limit O
in O
children O
, O
who O
received O
RARE O
RARE O
two O
weeks O
or O
longer O
. O

ALL_CAP O
. O

A O
gas O
- O
liquid O
chromatographic O
method O
RARE O
the O
determination O
of O
p O
- O
RARE O
( O
ALL_CAP O
) O
acid O
in O
RARE O
plasma O
is O
described O
. O

RARE I-GENE
receptor I-GENE
blockade O
and O
the O
RARE O
, O
a O
RARE O
study O
. O

V O
. O

A O
rapid O
RARE O
procedure O
RARE O
the O
determination O
of O
the O
RARE O
5 O
- O
RARE O
in O
serum O
is O
described O
. O

The O
' O
field O
of O
stress O
' O
of O
the O
RARE O
nurse O

RARE O
do O
RARE O
of O
different O
RARE O
of O
programs O
perform O
on O
state O
RARE O
? O

Similarly O
, O
RARE I-GENE
serum I-GENE
RARE I-GENE
A I-GENE
was O
significantly O
RARE O
in O
rats O
nursing O
large O
RARE O
. O

The O
sequences O
following O
the O
X O
. O
RARE O
RARE O
and O
somatic O
5S I-GENE
genes I-GENE
are O
identical O
in O
12 O
of O
the O
RARE O
14 O
residues O
and O
contain O
two O
or O
more O
T O
clusters O
, O
RARE O
does O
the O
corresponding O
region O
of O
X I-GENE
. I-GENE
RARE I-GENE
RARE I-GENE
5S I-GENE
DNA I-GENE
. O

This O
mechanism O
is O
not O
due O
to O
the O
observed O
RARE O
boundary O
RARE O
. O

This O
report O
has O
reviewed O
some O
of O
the O
RARE O
RARE O
treatment O
RARE O
and O
has O
presented O
a O
RARE O
RARE O
their O
management O
. O

Diagnosis O
and O
treatment O
planning O
in O
RARE O
II O
, O
division O
2 O

Because O
of O
serious O
infections O
( O
fever O
larger O
than O
or O
equal O
to O
NUM O
degrees O
F O
. O
RARE O
less O
than O
1 O
, O
NUM O
/ O
mm O
, O
3 O
and O
RARE O
) O
and O
1 O
drug O
RARE O
in O
the O
RARE O
4 O
patients O
, O
oral O
RARE O
RARE O
, O
20 O
to O
NUM O
mg O
/ O
m2 O
orally O
, O
was O
given O
2 O
days O
after O
methotrexate O
in O
subsequent O
treatment O
cycles O
. O

It O
seems O
that O
the O
way O
in O
which O
drugs O
modify O
a O
patient O
' O
s O
serum O
chemistry O
may O
be O
used O
to O
assess O
the O
efficacy O
with O
which O
they O
control O
the O
inflammatory O
process O
. O

Here O
the O
conventional O
tests O
clearly O
RARE O
to O
the O
presence O
of O
RARE O
RARE O
. O

The O
end O
- O
RARE O
or O
RARE O
RARE O
of O
proliferative O
diabetic O
RARE O
may O
result O
in O
stabilization O
of O
vision O
RARE O
long O
periods O
of O
time O
. O

On O
the O
basis O
of O
serum I-GENE
NUM I-GENE
RARE O
, O
newborn O
infants O
may O
be O
separated O
into O
two O
groups O
, O
characterized O
respectively O
by O
concentrations O
above O
or O
below O
NUM O
mg O
%. O

In O
patients O
who O
were O
not O
RARE O
, O
there O
was O
overall O
significant O
depression O
of O
function O
( O
67 O
+/- O
5 O
% O
of O
control O
; O
range O
, O
91 O
RARE O
NUM O
%, O
p O
less O
than O
NUM O
. O
01 O
). O

Changes O
in O
body O
RARE O
and O
RARE O
behavior O
were O
also O
recorded O
. O

The O
RARE O
response O
to O
RARE O
E2 O
( O
PGE2 O
) O
and O
RARE O
NUM O
( O
administered O
by O
intravenous O
and O
intrauterine O
routes O
) O
was O
evaluated O
RARE O
different O
phases O
of O
the O
menstrual O
RARE O
in O
five O
functionally O
RARE O
women O
. O

A O
RARE O
of O
NUM O
BCG O
strains O
, O
out O
of O
them O
10 O
RARE O
strains O
( O
2 O
RARE O
cultures O
of O
BCG O
of O
different O
RARE O
, O
6 O
strains O
isolated O
from O
RARE O
of O
children O
after O
BCG O
- O
vaccination O
and O
2 O
strains O
from O
fatal O
cases O
after O
BCG O
- O
vaccination O
) O
and O
16 O
strains O
obtained O
from O
foreign O
laboratories O
, O
were O
used O
. O

RARE O
levels O
of O
serum O
calcitonin I-GENE
were O
found O
in O
patients O
with O
chronic O
RARE O
failure O
. O

Detection O
of O
anti O
- O
lymphocyte O
antibodies O
using O
the O
RARE I-GENE
RARE I-GENE
RARE O
. O

The O
response O
of O
serum I-GENE
ALL_CAP I-GENE
to O
RARE O
infusion O
was O
normal O
, O
while O
that O
to O
insulin I-GENE
- O
RARE O
RARE O
was O
poor O
. O

The O
mortality O
rate O
and O
histopathological O
features O
of O
RARE O
RARE O
and O
RARE O
RARE O
infections O
in O
RARE O
RARE O
( O
nude O
) O
mice O
of O
ALL_CAP O
and O
C3H O
/ O
ALL_CAP O
origins O
were O
quite O
different O
from O
what O
we O
found O
RARE O
RARE O
RARE O
mice O
and O
other O
RARE O
mouse O
strains O
( O
namely O
, O
NUM O
/ O
ALL_CAP O
/ O
NUM O
, O
New O
RARE O
RARE O
, O
ALL_CAP O
/ O
c O
, O
ALL_CAP O
/ O
ALL_CAP O
, O
and O
C3H O
/ O
ALL_CAP O
). O

RARE O
, O
2 O
August O
NUM O
. O

Use O
of O
RARE O
RARE O
in O
the O
chemistry O
of O
proteins O

( O
RARE O
) O
RARE O
RARE O
RARE O
RARE O

RARE O
vaccines O
and O
whole O
- O
virus O
vaccines O
containing O
type I-GENE
B I-GENE
antigen I-GENE
only O
did O
not O
cause O
significant O
reactivity O
. O

NUM O
- O
NUM O
. O

RARE O
diagnosis O
of O
RARE O
disorders O
RARE O
NUM O
'. O

RARE O
oxygen O
supply O
and O
RARE O
RARE O
parameters O
were O
recorded O
in O
fasted O
male O
rates O
given O
20 O
RARE O
NUM O
mg O
/ O
kg O
Escherichia I-GENE
coli I-GENE
RARE I-GENE
RARE O
. O

RARE O
dysfunction O
in O
patients O
with O
RARE O
RARE O
. O

The O
maximum O
period O
of O
treatment O
was O
NUM O
( O
oral O
RARE O
NUM O
( O
RARE O
) O
or O
NUM O
( O
dermal O
) O
weeks O
. O

A O
study O
of O
the O
comparative O
efficacy O
of O
RARE O
RARE O
NUM O
. O
3 O
% O
RARE O
and O
RARE O
RARE O
NUM O
. O
05 O
% O
RARE O
. O

Most O
of O
the O
phenomena O
of O
RARE O
RARE O
are O
RARE O
in O
simple O
vitamin O
D O
deficiency O
; O
RARE O
in O
that O
condition O
, O
deficiency O
of O
1 O
, O
NUM O
- O
RARE O
may O
be O
of O
RARE O
significance O
in O
causing O
secondary O
RARE O
in O
RARE O
failure O
. O

Basal O
FSH I-GENE
and O
ALL_CAP I-GENE
levels O
were O
significantly O
lower O
in O
addicts O
; O
after O
GnRH I-GENE
RARE O
the O
addicts O
' O
FSH I-GENE
and O
ALL_CAP I-GENE
values O
increased O
but O
not O
significantly O
compared O
to O
controls O
. O

RARE O
: O
comparison O
of O
a O
5 O
- O
week O
schedule O
with O
a O
3 O
- O
week O
schedule O
in O
the O
treatment O
of O
breast O
RARE O
. O

RARE O
- O
RARE O
controls O
of O
RARE I-GENE
hormone I-GENE
( O
ALL_CAP I-GENE
RARE O
RARE I-GENE
stimulating I-GENE
hormone I-GENE
( O
FSH I-GENE
RARE O
prolactin I-GENE
( O
ALL_CAP I-GENE
RARE O
oestradiol O
( O
E2 O
RARE O
progesterone O
( O
P O
) O
and O
testosterone O
( O
T O
) O
in O
the O
RARE O
and O
healing O
RARE O
of O
burn O
RARE O
. O

RARE I-GENE
studies O
performed O
in O
NUM O
hypertensive O
patients O
and O
in O
a O
control O
group O
of O
11 O
recipients O
showed O
that O
elevation O
of O
plasma I-GENE
renin I-GENE
activity O
and O
of O
plasma O
aldosterone O
level O
is O
frequent O
but O
difficult O
to O
RARE O
, O
particularly O
when O
a O
RARE O
artery O
stenosis O
is O
observed O
. O

A O
randomized O
clinical O
trial O
in O
RARE O
- O
two O
adult O
patients O
suffering O
from O
RARE O
fever O
, O
proved O
by O
RARE O
and O
marrow O
culture O
, O
showed O
that O
RARE O
in O
a O
dosage O
schedule O
of O
1 O
g O
8 O
- O
RARE O
orally O
RARE O
RARE O
days O
was O
better O
than O
chloramphenicol O
with O
regard O
to O
clinical O
and O
RARE O
response O
and O
in O
respect O
of O
carriers O
and O
relapse O
rates O
. O

NUM O
- O
8 O
. O

RARE O
marrow O
transplantation O
- O
NUM O
. O

In O
this O
article O
, O
the O
clinical O
actions O
of O
the O
principal O
dopamine I-GENE
receptor I-GENE
stimulating O
agents O
( O
RARE O
and O
its O
RARE O
; O
RARE O
, O
RARE O
- O
RARE O
RARE O
) O
are O
discussed O
on O
the O
basis O
of O
their O
biochemical O
and O
pharmacological O
properties O
. O

The O
unilateral O
vestibular O
RARE O
. O

Thus O
, O
the O
inhibition O
of O
RARE I-GENE
in O
human O
RARE O
juice O
does O
not O
appear O
to O
have O
a O
major O
influence O
on O
the O
healing O
of O
duodenal O
ulcer O
. O

The O
ALL_CAP O
standard O
method O
RARE O
the O
detection O
of O
RARE O
in O
milk O
is O
not O
suitable O
RARE O
the O
detection O
of O
RARE O
residues O
in O
milk O
. O

RARE O
antigens O
of O
RARE O
RARE O

The O
course O
of O
RARE O
fever O
remained O
RARE O
by O
ALL_CAP O
. O

2 O
new O
RARE O
cases O

Seventy O
- O
one O
percent O
of O
patients O
treated O
with O
RARE O
alone O
responded O
RARE O
. O

RARE O
pathologic O
RARE O
identifies O
patients O
who O
are O
potentially O
RARE O
with O
radiotherapy O
. O

RARE O
RARE O
of O
old O
age O

RARE O
is O
RARE O
effective O
against O
RARE O
, O
less O
effective O
against O
RARE O
, O
and O
RARE O
effective O
against O
gram O
- O
negative O
RARE O
organisms O
. O

It O
was O
concluded O
, O
that O
on O
a O
given O
section O
, O
NUM O
, O
7 O
per O
cent O
of O
the O
RARE O
were O
in O
RARE O
with O
vascular O
RARE O
. O

2 O
. O

Changes O
in O
tissue O
PCO2 O
were O
less O
dramatic O
and O
did O
not O
vary O
significantly O
from O
those O
recorded O
in O
venous O
RARE O
. O

RARE O
evaluation O
of O
RARE O
RARE O
. O

RARE O
of O
emphysema O
was O
poor O
when O
radiographs O
of O
RARE O
quality O
were O
included O
( O
anteroposterior O
films O
or O
films O
from O
patients O
with O
acute O
or O
chronic O
RARE O
RARE O
). O

Isolation O
of O
T O
. O
RARE O
strains O
in O
RARE O
and O
their O
adaptation O
to O
laboratory O
animals O

RARE O
profile O
of O
RARE O
in O
RARE O
monkeys O
. O

RARE O
mechanisms O
in O
chronic O
RARE O
in O
humans O
. O

RARE O
adaptation O
( O
RARE O
of O
two O
parts O
). O

In O
patients O
who O
had O
received O
RARE O
previous O
drug O
treatment O
, O
log O
baseline O
plasma I-GENE
renin I-GENE
activity O
and O
change O
in O
mean O
RARE O
pressure O
after O
ALL_CAP O
NUM O
correlated O
significantly O
( O
RARE O
= O
NUM O
. O
NUM O
, O
P O
less O
than O
NUM O
. O
05 O
). O

These O
techniques O
have O
been O
used O
by O
many O
people O
RARE O
many O
years O
and O
RARE O
RARE O
is O
being O
made O
RARE O
any O
RARE O
in O
this O
regard O
. O

40 O
patients O
with O
chronic O
RARE O
were O
treated O
per O
RARE O
with O
the O
bactericidal O
beta O
- O
RARE O
- O
antibiotic O
RARE O
RARE O
3 O
to O
NUM O
weeks O
. O

A O
RARE O
of O
57 O
patients O
with O
Hodgkin O
' O
s O
RARE O
limited O
to O
above O
the O
diaphragm O
( O
RARE O
I O
and O
II O
, O
A O
and O
B O
) O
were O
treated O
with O
radiation O
therapy O
alone O
RARE O
the O
University O
of O
RARE O
between O
NUM O
and O
NUM O
. O

RARE O
one O
of O
the O
RARE O
RARE O
RARE O
medical O
unit O
in O
the O
greater O
RARE O
area O
. O

This O
multiple O
- O
electrode O
RARE O
RARE O
round O
RARE O
cochlear O
implantation O
is O
a O
RARE O
, O
reliable O
RARE O
RARE O
inserting O
20 O
mm O
along O
the O
RARE O
RARE O
with O
a O
minimum O
of O
trauma O
and O
can O
provide O
RARE O
bipolar O
RARE O
. O

As O
RARE O
by O
the O
RARE O
Health O
Organization O
NUM O
RARE O
Committee O
on O
Biological O
RARE O
, O
the O
preparation O
of O
human I-GENE
prolactin I-GENE
in O
RARE O
coded O
NUM O
/ O
NUM O
has O
been O
established O
RARE O
the O
International O
RARE O
RARE O
( O
ALL_CAP O
) O
of O
human I-GENE
prolactin I-GENE
RARE O
immunoassay O
. O

i O
. O

RARE O
- O
enteric O
RARE O

Plasma O
ion O
changes O
in O
venous O
RARE O
incubated O
with O
beta I-GENE
receptor I-GENE
blockers O
and O
subjected O
to O
RARE O
in O
vitro O
. O

Such O
marked O
differences O
are O
found O
RARE O
in O
the O
literature O
: O
RARE O
antibodies O
against O
bovine I-GENE
RARE I-GENE
are O
regarded O
RARE O
responsible O
RARE O
the O
interference O
in O
the O
RARE O
RARE O
of O
ALL_CAP O
. O

" O
RARE O
the O
hundred O
RARE O
RARE O
". O

Various O
treatment O
modalities O
are O
reviewed O
in O
the O
context O
of O
the O
RARE O
RARE O
RARE O
RARE O
the O
physiology O
of O
severe O
RARE O
pain O
. O

RARE O
RARE O
( O
4 O
RARE O
3 O
'- O
RARE O
- O
2 O
'- O
RARE O
)- O
RARE O
) O
poisoning O
in O
childhood O

RARE O
evaluation O
of O
RARE O
flow O
velocity O
in O
RARE O
RARE O

Serum O
ferritin I-GENE
concentration O
and O
bone O
marrow O
iron O
RARE O
. O

The O
systolic O
pressure O
gradient O
( O
ALL_CAP O
) O
between O
the O
RARE O
ventricle O
( O
LV O
) O
and O
RARE O
atrium O
( O
LA O
) O
was O
obtained O
from O
high O
- O
RARE O
pressure O
RARE O
. O

A O
prospective O
RARE O
comparing O
hysterectomy O
, O
hysterectomy O
RARE O
vaginal O
RARE O
, O
and O
RARE O
RARE O
RARE O
hysterectomy O
in O
RARE O
I O
endometrial O
carcinoma O
. O

On O
the O
basis O
of O
a O
patient O
' O
s O
report O
of O
one O
RARE O
RARE O
, O
we O
RARE O
to O
investigate O
the O
accuracy O
of O
this O
RARE O
. O

RARE O
in O
RARE O
' O
s O
RARE O

Data O
were O
processed O
with O
a O
RARE O
- O
automatic O
computer O
program O
which O
RARE O
an O
averaged O
- O
volume O
curve O
from O
an O
assigned O
LV O
region O
- O
of O
- O
interest O
. O

The O
preferential O
serum I-GENE
IgA I-GENE
response O
observed O
in O
the O
patient O
population O
suggests O
that O
bronchial O
associated O
RARE O
tissue O
in O
the O
diseased O
RARE O
is O
an O
important O
source O
of O
circulating O
IgA I-GENE
. O

RARE O
RARE O
seem O
to O
be O
reached O
RARE O
RARE O
RARE O
RARE O
, O
whereas O
RARE O
RARE O
, O
such O
RARE O
RARE O
6 O
V O
, O
present O
very O
high O
RARE O
limit O
under O
RARE O
. O

The O
effects O
of O
RARE O
injection O
( O
i O
. O
c O
. O
i O
.) O
of O
RARE O
( O
1 O
microgram O
kg O
- O
1 O
) O
on O
RARE O
pressure O
and O
RARE O
rate O
were O
studied O
in O
conscious O
rabbits O
with O
an O
implanted O
catheter O
in O
the O
RARE O
RARE O
. O

RARE O
number O
and O
life O
span O
were O
determined O
in O
the O
last O
RARE O
of O
RARE O
in O
NUM O
women O
who O
were O
delivered O
of O
small O
- O
RARE O
- O
gestational O
age O
( O
ALL_CAP O
) O
infants O
and O
in O
21 O
women O
with O
infants O
having O
normal O
birth O
weights O
. O

RARE O
measurements O
of O
RARE O
serum O
IgE I-GENE
appears O
to O
be O
a O
useful O
index O
of O
RARE O
activity O
in O
ALL_CAP O
. O

In O
the O
8 O
patients O
the O
difference O
RARE O
RARE O
mean O
diastolic O
values O
of O
delta O
ALL_CAP O
and O
delta O
ALL_CAP O
was O
- O
NUM O
. O
54 O
+/- O
1 O
. O
NUM O
( O
SD O
) O
mmHg O
. O

A O
rise O
of O
hemoglobin I-GENE
concentration O
accompanied O
by O
an O
increase O
of O
the O
RARE O
iron O
in O
the O
RARE O
serum O
of O
RARE O
mice O
was O
found O
under O
oxygen O
pressure O
of O
4 O
RARE O
RARE O
an O
hour O
( O
RARE O
state O
) O
and O
6 O
RARE O
( O
RARE O
state O
). O

RARE O
RARE O
RARE O
analog O
RARE O
and O
stationary O
state O
membrane O
RARE O
potentials O
. O

Effects O
of O
methylene O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
and O
toluene O
on O
the O
development O
of O
RARE O
RARE O
. O

Effect O
of O
RARE O
administration O
of O
RARE I-GENE
O I-GENE
on O
the O
RARE O
of O
rabbits O
. O

In O
this O
RARE O
the O
RARE O
threshold O
RARE O
the O
8 O
substances O
is O
RARE O
follows O
: O
RARE O
20 O
mg O
. O
kg O
- O
1 O
I O
. O
V O
., O
RARE O
NUM O
, O
RARE O
180 O
, O
RARE O
4 O
, O
R O
NUM O
NUM O
5 O
, O
fentanyl O
4 O
, O
RARE O
4 O
and O
R O
NUM O
NUM O
10 O
mg O
. O
kg O
- O
1 O
I O
. O
V O
. O

The O
RARE O
of O
RARE O
RARE O
with O
poor O
RARE O
growth O
. O

RARE O
, O
the O
lesion O
was O
usually O
a O
RARE O
- O
defined O
and O
benign O
RARE O
one O
, O
either O
RARE O
lytic O
( O
3 O
cases O
) O
or O
with O
central O
RARE O
( O
2 O
cases O
). O

Effects O
of O
chronic O
RARE O
RARE O
on O
the O
response O
patterns O
of O
neurons O
in O
the O
RARE O
nuclei O
RARE O
and O
RARE O
. O

RARE O
of O
a O
three O
- O
versus O
a O
five O
- O
week O
RARE O
treatment O
program O
. O

Resistance O
to O
the O
simulated O
RARE O
environment O
was O
tested O
by O
measured O
retention O
of O
mechanical O
properties O
after O
immersion O
times O
in O
RARE O
- O
extracellular O
RARE O
( O
ALL_CAP O
) O
RARE O
37 O
degrees O
C O
RARE O
RARE O
long O
RARE O
three O
years O
. O

RARE O
RARE O
tuberculous O
RARE O
. O

It O
is O
concluded O
that O
RARE I-GENE
receptors I-GENE
RARE O
the O
fourth O
cerebral O
ventricle O
mediate O
the O
cardiovascular O
and O
RARE O
action O
of O
fentanyl O
. O

In O
case O
of O
a O
RARE O
RARE O
internal O
carotid O
the O
common O
carotid O
artery O
was O
RARE O
with O
an O
end O
- O
to O
- O
end O
anastomosis O
. O

This O
RARE O
RARE O
: O
( O
1 O
) O
a O
RARE O
flow O
regimen O
RARE O
RARE O
, O
and O
( O
2 O
) O
a O
constant O
ALL_CAP O
value O
over O
the O
range O
of O
VT O
. O

These O
data O
confirm O
the O
existence O
of O
RARE O
abdominal O
RARE O
RARE O
a O
distinct O
RARE O
and O
RARE O
to O
the O
importance O
of O
RARE O
this O
RARE O
in O
order O
to O
avoid O
the O
occurrence O
of O
acute O
pancreatitis O
and O
the O
performance O
of O
RARE O
and O
potentially O
RARE O
surgery O
. O

In O
addition O
a O
significant O
Treatment O
X O
RARE O
interaction O
was O
due O
to O
the O
larger O
RARE O
numbers O
displayed O
by O
the O
RARE O
- O
injected O
MR O
rats O
relative O
to O
the O
saline O
- O
injected O
MR O
rats O
. O

Their O
conduction O
velocity O
ranged O
from O
NUM O
. O
NUM O
to O
NUM O
. O
98 O
m O
/ O
sec O
( O
group O
C O
). O

The O
RARE O
frequently O
were O
related O
to O
patient O
RARE O
or O
poor O
mechanical O
fit O
and O
occurred O
in O
the O
RARE O
few O
days O
or O
RARE O
few O
months O
after O
RARE O
. O

The O
major O
RARE O
metabolites O
were O
3 O
RARE O
3 O
- O
RARE O
)- O
5 O
- O
RARE O
- O
2 O
- O
RARE O
and O
a O
RARE O
of O
RARE O
. O

These O
characteristics O
indicated O
the O
pronounced O
activity O
of O
RARE O
fiber O
RARE O
and O
the O
RARE O
of O
the O
RARE O
tissue O
. O

The O
ventilation O
did O
not O
increase O
when O
NUM O
was O
increased O
. O

RARE O
metabolism O
and O
the O
semen O
profile O
: O
glucose O
, O
insulin I-GENE
, O
and O
sperm O
studies O
. O

It O
has O
RARE O
out O
that O
ALL_CAP O
is O
between O
ALL_CAP O
and O
ALL_CAP O
and O
that O
attacks O
of O
biliary O
fever O
and O
high O
levels O
of O
RARE I-GENE
phosphatase I-GENE
and O
RARE O
in O
the O
serum O
are O
the O
helpful O
findings O
RARE O
preoperative O
diagnosis O
. O

The O
sub O
- O
acute O
inhalation O
toxicity O
of O
RARE O
was O
studied O
in O
RARE O
RARE O
hamsters O
. O

Changes O
of O
RARE O
serum O
protein O
RARE O
following O
surgical O
stress O
. O

These O
differences O
are O
smaller O
than O
those O
described O
in O
standard O
RARE O
. O

A O
study O
of O
the O
E O
. O
O O
. O
R O
. O
T O
. O
C O
. O

The O
present O
study O
examined O
the O
dependence O
of O
difference O
tone O
level O
RARE O
L O
( O
NUM O
- O
NUM O
)] O
on O
the O
following O
parameters O
of O
the O
two O
- O
tone O
input O
: O
NUM O
, O
NUM O
/ O
NUM O
( O
NUM O
greater O
than O
NUM O
RARE O
L1 O
, O
L2 O
, O
and O
L1 O
= O
L2 O
. O

An O
intravenous O
preparation O
of O
RARE O
( O
ALL_CAP O
, O
RARE O
' O
RARE O
RARE O
a O
long O
- O
lasting O
RARE O
, O
was O
administered O
mainly O
by O
RARE O
infusion O
RARE O
a O
series O
of O
study O
in O
the O
RARE O
field O
, O
and O
the O
results O
were O
RARE O
follows O
: O
1 O
) O
ALL_CAP O
( O
NUM O
mg O
) O
was O
RARE O
in O
a O
NUM O
ml O
of O
glucose O
solution O
and O
2 O
RARE O
3 O
mg O
/ O
kg O
was O
administered O
intravenously O
. O

5 O
) O
RARE O
and O
ten O
days O
after O
ALL_CAP O
infusion O
, O
laboratory O
tests O
RARE O
liver O
and O
RARE O
functions O
and O
RARE O
were O
performed O
. O

Structural O
characteristics O
of O
the O
RARE O
membrane O
, O
peroxidation O
processes O
and O
antioxidant O
function O
in O
children O
with O
diffuse O
glomerulonephritis O

The O
enteric O
route O
is O
the O
principal O
mode O
of O
RARE O
RARE O
hepatitis O
A O
, O
but O
maximal O
levels O
of O
hepatitis O
A O
virus O
excretion O
occur O
before O
the O
onset O
of O
jaundice O
. O

All O
NUM O
patients O
showed O
RARE O
evidence O
of O
RARE O
, O
moderate O
in O
4 O
and O
severe O
in O
9 O
. O

RARE O
excretion O
of O
RARE O
, O
oestradiol O
- O
NUM O
beta O
and O
RARE O
in O
RARE O
complicated O
by O
steroid I-GENE
RARE I-GENE
deficiency O
. O

Both O
RARE O
spontaneous O
locomotor O
activity O
in O
mice O
, O
protected O
them O
from O
RARE O
from O
amphetamine O
RARE O
toxicity O
, O
prolonged O
RARE O
RARE O
time O
and O
caused O
a O
depletion O
of O
catecholamines O
from O
various O
organs O
of O
the O
rat O
. O

On O
the O
role O
of O
transferrin I-GENE
in O
the O
uptake O
of O
RARE O
by O
tumor O
cells O
. O

RARE O
of O
human O
RARE O
platelets O
with O
ALL_CAP O
- O
A O
in O
vitro O
RARE O
their O
ability O
to O
RARE O
after O
challenge O
with O
RARE I-GENE
. O

With O
certain O
RARE O
the O
method O
was O
considered O
suitable O
in O
the O
routine O
intravenous O
RARE O
. O

Following O
the O
satisfactory O
results O
and O
taking O
into O
account O
that O
the O
complications O
had O
RARE O
to O
a O
very O
low O
rate O
( O
in O
2 O
cases O
lead O
RARE O
RARE O
and O
RARE O
RARE O
occurred O
respectively O
RARE O
the O
RARE O
consider O
the O
adopted O
method O
an O
useful O
approach O
RARE O
ALL_CAP O
implantation O
particularly O
when O
the O
use O
of O
the O
RARE O
RARE O
is O
RARE O
RARE O
. O

When O
two O
determinations O
were O
performed O
on O
12 O
samples O
of O
plasma O
taken O
from O
normal O
adults O
in O
RARE O
, O
the O
values O
were O
NUM O
. O
6 O
+/- O
4 O
. O
8 O
and O
21 O
. O
NUM O
+/- O
3 O
. O
6 O
( O
mean O
+/- O
SD O
) O
RARE O
/ O
ml O
, O
respectively O
. O

The O
RARE O
RARE O
causes O
of O
RARE O
varied O
in O
the O
three O
RARE O
groups O
. O

Although O
RARE O
' O
s O
operation O
has O
been O
used O
all O
over O
the O
world O
, O
RARE O
systematic O
account O
of O
it O
has O
been O
found O
in O
the O
literature O
( O
including O
RARE O
RARE O
with O
technique O
RARE O
which O
presents O
it O
in O
terms O
related O
to O
the O
basic O
" O
classical O
" O
RARE O
on O
which O
the O
operation O
was O
RARE O
. O

( O
5 O
) O
No O
changes O
were O
observed O
in O
the O
RARE O
venous O
RARE O
flow O
by O
continuous O
intravenous O
injection O
of O
cimetidine O
, O
but O
by O
rapid O
injection O
both O
the O
flow O
was O
augmented O
and O
the O
systemic O
RARE O
pressure O
decreased O
transiently O
. O

Study O
on O
re O
- O
establishment O
of O
ovulation O
after O
RARE O
of O
RARE O
- O
RARE O
treatment O
RARE O
compared O
with O
re O
- O
appearance O
of O
ovulation O
after O
abortion O
and O
premature O
delivery O
. O

RARE O
of O
RARE O
in O
man O
: O
a O
review O
. O

Of O
the O
compounds O
tested O
, O
alpha O
RARE O
3 O
- O
RARE O
- O
2 O
- O
RARE O
)- O
N O
- O
RARE O
1 O
, O
4 O
- O
dioxide O
( O
2 O
) O
was O
the O
most O
RARE O
agent O
in O
vivo O
against O
the O
gram O
- O
negative O
and O
the O
gram O
- O
positive O
organisms O
. O

Changes O
in O
ionic O
content O
of O
the O
RARE O
suggest O
that O
cholinergic O
mechanisms O
affect O
pressure O
in O
the O
RARE O
duct O
of O
the O
RARE O
. O

RARE O
fed O
ALL_CAP O
- O
milk O
had O
significantly O
lower O
RARE O
cholesterol O
than O
calves O
fed O
T O
- O
or O
ALL_CAP O
- O
milk O
. O

RARE O
mortality O
of O
mice O
following O
inhalation O
of O
acute O
doses O
of O
NUM O
, O
NUM O
, O
and O
NUM O
. O

RARE O
pigs O
RARE O
NUM O
RARE O
350 O
g O
were O
used O
. O

Under O
halothane O
anesthesia O
, O
the O
flow O
RARE O
( O
ALL_CAP O
) O
and O
its O
time O
RARE O
( O
RARE O
RARE O
or O
RARE O
/ O
dt O
) O
were O
RARE O
RARE O
apnea O
by O
a O
small O
high O
- O
gain O
RARE O
. O

RARE O
kindling O
: O
implications O
RARE O
development O
of O
sensory O
RARE O
. O

It O
is O
concluded O
that O
RARE O
can O
be O
evoked O
also O
in O
the O
case O
when O
the O
RARE O
dopaminergic O
tone O
is O
normal O
or O
even O
below O
normal O
: O
it O
is O
the O
equilibrium O
of O
the O
RARE O
cholinergic O
- O
dopaminergic O
RARE O
which O
must O
be O
shifted O
towards O
dopamine O
, O
which O
is O
necessary O
RARE O
the O
development O
of O
this O
behavioral O
manifestation O
. O

None O
of O
the O
RARE O
showed O
RARE O
RARE O
contractions O
. O

In O
the O
RARE O
a O
small O
part O
of O
the O
administered O
dose O
was O
transformed O
to O
3H O
- O
alpha O
- O
RARE O
. O

Functional O
effects O
following O
subacute O
administration O
. O

Treatment O
of O
RARE O
' O
RARE O
. O

Although O
it O
has O
been O
shown O
that O
it O
is O
possible O
to O
use O
orally O
administered O
testosterone O
to O
maintain O
RARE O
- O
T O
levels O
in O
the O
normal O
male O
range O
, O
the O
RARE O
to O
the O
patient O
must O
be O
RARE O
against O
the O
cost O
and O
possible O
RARE O
effects O
of O
the O
large O
doses O
required O
. O

RARE O
to O
1 O
, O
8 O
- O
RARE O
- O
9 O
- O
RARE O
, O
1 O
, O
8 O
, O
9 O
- O
RARE O
and O
1 O
, O
8 O
- O
RARE O
- O
9 O
- O
RARE O
are O
effective O
against O
RARE O
lesions O
without O
accompanying O
RARE O
of O
the O
RARE O
. O

RARE O
and O
therapeutic O
problems O
in O
acute O
RARE O
inflammation O

RARE O
of O
patients O
with O
RARE O
diseases O

We O
measured O
basal O
plasma O
prolactin I-GENE
concentrations O
( O
in O
samples O
obtained O
RARE O
the O
early O
follicular O
RARE O
) O
in O
NUM O
normal O
( O
control O
) O
women O
and O
in O
a O
similar O
group O
of O
40 O
patients O
with O
a O
long O
- O
RARE O
history O
of O
infertility O
. O

RARE O
RARE O
in O
human O
. O

RARE O
reaction O
to O
RARE O
RARE O
RARE O
RARE O
RARE O
. O

RARE O
of O
asthma O
patients O
by O
determination O
of O
IgE I-GENE
and O
by O
RARE O
of O
spectrum O
of O
RARE I-GENE
IgE I-GENE
antibodies I-GENE

The O
induction O
of O
seizures O
in O
" O
RARE O
RARE O
" O
following O
RARE O
alone O
or O
in O
combination O
with O
intermittent O
RARE O
RARE O

A O
highly O
significant O
correlation O
was O
found O
between O
the O
presence O
of O
RARE O
RARE O
products O
( O
ALL_CAP O
) O
and O
the O
incidence O
of O
nephropathy O
and O
RARE O
insufficiency O
, O
RARE O
RARE O
RARE O
between O
the O
presence O
of O
fibrin I-GENE
RARE I-GENE
( O
RARE O
' O
s O
ethanol O
- O
RARE O
test O
) O
and O
the O
RARE O
signs O
of O
the O
RARE O
RARE O
( O
fever O
, O
accelerated O
ALL_CAP O
). O

One O
- O
third O
of O
the O
men O
with O
RARE O
and O
with O
sperm O
density O
of O
less O
than O
10 O
million O
had O
marked O
FSH I-GENE
elevation O
and O
our O
experience O
RARE O
the O
work O
of O
others O
that O
this O
indicates O
a O
poor O
prognosis O
. O

In O
girls O
prolactin I-GENE
levels O
rise O
RARE O
RARE O
2 O
, O
and O
are O
RARE O
after O
RARE O
; O
in O
boys O
there O
is O
RARE O
change O
in O
prolactin I-GENE
levels O
. O

It O
was O
concluded O
that O
both O
of O
these O
surgical O
procedures O
were O
RARE O
effective O
RARE O
RARE O
in O
RARE O
the O
pineal O
- O
RARE O
alterations O
in O
the O
reproductive O
physiology O
of O
the O
blind O
- O
RARE O
female O
rat O
. O

2 O
cases O
of O
toxic O
RARE O

Such O
an O
hemoglobin I-GENE
solution O
was O
shown O
to O
exhibit O
a O
high O
affinity O
RARE O
oxygen O
and O
a O
low O
RARE O
effect O
( O
assessed O
from O
the O
delta O
log O
NUM O
/ O
delta O
pH O
ratio O
). O

A O
one O
- O
week O
ulcer O
therapy O
with O
atropine O
and O
RARE O
( O
RARE O
) O
led O
to O
a O
significant O
( O
p O
less O
than O
NUM O
. O
01 O
) O
reduction O
of O
the O
RARE O
RARE O
activity O
. O

In O
one O
patient O
with O
severe O
RARE O
the O
RARE O
concentration O
in O
serum O
was O
low O
until O
the O
RARE O
function O
RARE O
and O
the O
RARE O
concentration O
RARE O
RARE O
RARE O
when O
the O
RARE O
stopped O
. O

Serum O
levels O
of O
IgG I-GENE
and O
IgM I-GENE
were O
also O
raised O
, O
but O
RARE O
to O
the O
findings O
of O
other O
RARE O
IgA I-GENE
levels O
were O
normal O
. O

Experimental O
ischemic O
RARE O
RARE O
RARE O
by O
RARE O
NUM O
in O
rabbits O
. O

RARE O
in O
ocular O
RARE O

To O
study O
the O
sensitivity O
of O
some O
central O
brain O
RARE O
to O
the O
action O
of O
an O
RARE O
field O
of O
RARE O
waves O
( O
ALL_CAP O
of O
ALL_CAP O
) O
a O
dynamic O
investigation O
of O
single O
unit O
activity O
was O
undertaken O
. O

No O
systematic O
L O
- O
R O
differences O
were O
observed O
. O

A O
decrease O
of O
the O
lysozyme I-GENE
activity O
RARE O
with O
the O
clinical O
improvement O
of O
the O
bacterial O
meningitis O
. O

This O
RARE O
that O
the O
groups O
do O
not O
just O
differ O
along O
one O
RARE O
, O
but O
along O
three O
dimensions O
. O

RARE O
RARE O
were O
RARE O
over O
the O
RARE O
of O
volunteers O
with O
RARE O
exposure O
to O
RARE O
RARE O
radiation O
( O
ALL_CAP O
- O
A O
). O

1 O
The O
effects O
in O
normal O
subjects O
of O
a O
single O
oral O
dose O
of O
RARE O
( O
one O
tablet O
, O
containing O
RARE O
NUM O
. O
5 O
mg O
and O
RARE O
10 O
mg O
) O
on O
the O
RARE O
negative O
variation O
( O
CNV O
RARE O
reaction O
time O
, O
RARE O
rate O
, O
RARE O
pressure O
and O
self O
- O
rating O
RARE O
RARE O
RARE O
, O
anxiety O
, O
tension O
, O
RARE O
and O
depression O
were O
compared O
with O
those O
of O
RARE O
( O
5 O
mg O
and O
7 O
. O
5 O
mg O
) O
and O
placebo O
or O
propranolol O
( O
NUM O
mg O
). O

RARE O
effects O
on O
RARE O
RARE O
among O
subjects O
RARE O
the O
type O
A O
coronary O
- O
prone O
behavior O
pattern O
. O

These O
show O
that O
the O
RARE I-GENE
in O
this O
tissue O
is O
modified O
compared O
with O
that O
in O
tendon O
. O

RARE O
was O
regarded O
RARE O
the O
major O
contribution O
to O
pulmonary O
dysfunction O
. O

The O
RARE O
of O
RARE O
RARE O
. O

Elimination O
of O
RARE O
in O
RARE O
paper O
RARE O
RARE O
workers O
. O

These O
responses O
were O
compared O
with O
others O
in O
the O
same O
subjects O
under O
the O
same O
conditions O
and O
it O
was O
concluded O
that O
the O
antihypertensive O
effect O
of O
RARE O
is O
explained O
by O
concurrent O
blockade O
of O
alpha I-GENE
- I-GENE
and I-GENE
beta I-GENE
- I-GENE
adrenoceptors I-GENE
. O

RARE O
: O
basic O
clinical O
RARE O
and O
therapeutic O
use O
. O

Three O
patients O
with O
four O
RARE O
RARE O
have O
undergone O
single O
- O
RARE O
reconstruction O
involving O
RARE O
and O
ipsilateral O
RARE O
following O
temporary O
loop O
cutaneous O
RARE O
. O

Evaluation O
of O
the O
RARE O
RARE O
RARE O
RARE O
procedure O
. O

RARE O
RARE O
patients O
' O
scores O
on O
RARE O
' O
s O
RARE O
- O
RARE O
RARE O
of O
Control O
Scale O
remained O
the O
same O
over O
treatment O
but O
those O
of O
RARE O
RARE O
patients O
shifted O
toward O
greater O
internal O
control O
. O

RARE O
of O
RARE O
- O
NUM O
and O
RARE O
on O
RARE O
RARE O

RARE O
ALL_CAP O
- O
2 O
RARE O
is O
RARE O
around O
a O
RARE O
water O
- O
filled O
RARE O
and O
the O
dose O
distribution O
is O
recorded O
. O

Diagnosis O
and O
differential O
diagnosis O

The O
multiple O
factors O
affecting O
plasma O
renin I-GENE
activity O
in O
essential O
hypertension O
. O

RARE O
RARE O
bone O
changes O
and O
its O
response O
to O
RARE O
RARE O
agents O
. O

2 O
) O
The O
time O
- O
RARE O
RARE O
was O
applied O
to O
gain O
high O
stability O
. O

When O
RARE O
samples O
of O
patients O
with O
hyperbilirubinemia O
were O
analyzed O
, O
direct O
measurement O
of O
ALL_CAP O
by O
this O
RARE O
yielded O
significantly O
RARE O
levels O
than O
did O
an O
alternate O
extraction O
method O
. O

RARE O
hypersensitivity O
in O
man O
: O
effects O
of O
systemic O
RARE O
. O

In O
three O
of O
the O
RARE O
, O
inhalation O
of O
2 O
ml O
normal O
saline O
produced O
FEV1 O
RARE O
of O
NUM O
% O
to O
NUM O
%, O
but O
these O
RARE O
were O
not O
RARE O
great O
RARE O
each O
subject O
' O
s O
reactions O
to O
the O
test O
solutions O
. O

Experimental O
studies O
on O
virus O
excretion O
and O
non O
- O
RARE O
RARE O
. O

RARE O
of O
RARE O
in O
dogs O
: O
comparison O
with O
halothane O
and O
isoflurane O
. O

Prevention O
of O
acute O
RARE O
toxicity O
in O
rats O
by O
RARE I-GENE
dismutase I-GENE
. O

Measurement O
of O
magnesium O
absorption O
in O
man O
using O
stable O
NUM O
RARE O
a O
tracer O
. O

Increased O
RARE O
RARE O
excretion O
resulting O
from O
RARE O
acid O
ingestion O
. O

RARE O
angiography O
and O
RARE O
whole O
body O
imaging O
performed O
with O
technetium O
- O
99m O
- O
labeled O
RARE O
can O
clearly O
demonstrate O
differential O
RARE O
in O
patients O
with O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
with O
RARE O
physiology O
. O

RARE O
RARE O
in O
the O
human O
visual O
RARE O
. O

Escherichia O
of O
a O
single O
RARE O
- O
RARE O
type O
( O
NUM O
: O
NUM O
: O
NUM O
) O
were O
isolated O
in O
a O
group O
RARE O
. O

The O
method O
described O
may O
prove O
useful O
in O
studying O
the O
physiology O
of O
the O
nasal O
RARE O
. O

At O
the O
same O
time O
we O
obtained O
easily O
RARE O
EEG O
- O
RARE O
which O
has O
never O
previously O
been O
available O
to O
us O
. O

Analysis O
of O
liver O
biopsy O
specimens O
from O
patients O
with O
hepatitis O
showed O
a O
large O
variation O
in O
the O
mean O
iron O
content O
of O
the O
liver O
ferritin I-GENE
molecules O
. O

Female O
mice O
were O
significantly O
more O
resistant O
to O
infection O
than O
males O
. O

During O
the O
following O
9 O
1 O
/ O
2 O
years O
three O
sequential O
liver O
biopsies O
were O
performed O
. O

RARE I-GENE
effect O
in O
the O
human O
RARE O
. O

RARE O
yellow O
RARE O
was O
injected O
RARE O
into O
large O
auditory O
fibers O
of O
RARE O
to O
investigate O
the O
relationship O
between O
the O
response O
type O
of O
these O
fibers O
and O
their O
site O
of O
RARE O
in O
the O
RARE O
RARE O
. O

RARE O
findings O
in O
the O
RARE O
and O
in O
the O
RARE O
RARE O
RARE O
duct O
RARE O
. O

RARE O
mortality O

These O
consisted O
of O
RARE O
and O
RARE O
mainly O
of O
the O
intrahepatic O
biliary O
RARE O
( O
ALL_CAP O
). O

RARE O
and O
RARE O
, O
which O
arise O
RARE O
RARE O
peroxidation O
in O
vivo O
, O
were O
measured O
by O
gas O
chromatography O
in O
RARE O
samples O
of O
rats O
fed O
RARE O
8 O
weeks O
a O
vitamin O
E O
- O
RARE O
diet O
to O
which O
had O
been O
added O
NUM O
, O
11 O
, O
or O
40 O
IU O
vitamin O
E O
RARE O
per O
kg O
. O

RARE O
and O
RARE O
activity O
of O
the O
RARE O
after O
administration O
of O
RARE O
in O
men O
with O
history O
of O
RARE O
infarction O
RARE O
to O
NUM O
year O
of O
life O

The O
authors O
report O
the O
RARE O
findings O
in O
four O
cases O
of O
adult O
women O
with O
RARE O
that O
RARE O
in O
the O
RARE O
or O
cervix O
, O
or O
both O
. O

The O
effect O
of O
pure O
RARE O
RARE I-GENE
RARE I-GENE
on O
endocrine O
and O
RARE O
pancreatic O
RARE O
was O
studied O
in O
the O
RARE O
isolated O
perfused O
RARE O
pancreas O
. O

RARE O
analysis O
of O
RARE O
lens O
power O
required O
to O
produce O
RARE O
: O
results O
of O
NUM O
implants O
. O

RARE O
antibodies O
could O
not O
be O
demonstrated O
in O
any O
other O
cases O
. O

RARE O
ALL_CAP O
tended O
to O
increase O
after O
the O
therapy O
, O
there O
was O
RARE O
statistically O
significant O
change O
in O
ALL_CAP O
, O
GFR O
and O
cardiac O
output O
. O

99mTc O
RARE O
, O
NUM O
colloid O
, O
and O
99mTc O
RARE O
RARE O
have O
been O
used O
; O
the O
last O
appears O
to O
have O
been O
the O
most O
satisfactory O
. O

Six O
patients O
with O
glomerulonephritis O
in O
association O
with O
a O
RARE O
shunt O
were O
treated O
with O
three O
basic O
modes O
of O
therapy O
. O

The O
mass O
of O
NUM O
in O
the O
RARE O
RARE O
and O
RARE O
RARE O
decreased O
more O
slowly O
over O
NUM O
RARE O
8 O
d O
after O
inhalation O
than O
the O
corresponding O
mass O
on O
the O
RARE O
. O

RARE O
cysts O
of O
the O
hip O
joint O

A O
suspected O
RARE O
dysfunction O
and O
a O
slightly O
impaired O
pituitary O
function O
manifested O
RARE O
ALL_CAP I-GENE
deficiency O
were O
their O
common O
RARE O
features O
. O

A O
RARE O
outbreak O
of O
RARE O
A O
occurred O
on O
the O
RARE O
RARE O
RARE O
that O
was O
due O
to O
an O
A O
/ O
RARE O
/ O
1 O
/ O
77 O
- O
like O
virus O
, O
a O
variant O
of O
the O
A O
/ O
RARE O
/ O
3 O
/ O
NUM O
RARE O
. O

Because O
decreases O
in O
the O
RARE O
rates O
of O
RARE O
were O
observed O
RARE O
the O
presentation O
of O
all O
three O
stimulus O
RARE O
, O
the O
data O
failed O
to O
support O
the O
RARE O
model O
. O

Effect O
of O
time O
and O
dose O
on O
alterations O
following O
inhalation O
of O
plutonium O
- O
239 O
dioxide O
RARE O
in O
rat O
. O

In O
biopsies O
ALL_CAP I-GENE
- I-GENE
MB I-GENE
fraction O
of O
RARE O
RARE O
CPK I-GENE
was O
37 O
%, O
the O
RARE I-GENE
- I-GENE
CPK I-GENE
activity O
of O
human O
skeletal O
muscles O
still O
shows O
a O
5 O
% O
fraction O
of O
ALL_CAP I-GENE
- I-GENE
MB I-GENE
. O

Value O
of O
determination O
of O
RARE I-GENE
phosphatase I-GENE
RARE I-GENE
RARE O
differential O
diagnosis O
of O
RARE O
jaundice O
and O
biliary O
liver O
cirrhosis O

A O
one O
- O
way O
analysis O
of O
RARE O
, O
performed O
separately O
RARE O
men O
and O
women O
RARE O
differences O
among O
the O
three O
RARE O
groups O
on O
field O
dependence O
, O
showed O
significance O
( O
RARE O
less O
than O
. O
05 O
) O
RARE O
the O
females O
, O
with O
the O
RARE O
RARE O
being O
more O
field O
dependent O
than O
the O
female O
simple O
RARE O
groups O
, O
but O
not O
RARE O
the O
males O
. O

Several O
free O
NUM O
- O
generation O
RARE O
, O
which O
varied O
in O
diameter O
from O
11 O
to O
21 O
. O
6 O
RARE O
, O
were O
found O
on O
the O
RARE O
surface O
of O
the O
RARE O
. O

The O
calculated O
NUM O
values O
were O
8 O
. O
8 O
RARE O
E O
, O
8 O
. O
6 O
RARE O
ALL_CAP O
and O
6 O
. O
6 O
RARE O
M O
. O

RARE O
RARE O
virus O
RARE O
in O
RARE O
RARE O
on O
local O
and O
RARE O
RARE O
. O

It O
was O
postulated O
that O
persistent O
challenge O
by O
M O
. O
RARE O
or O
its O
antigens O
to O
the O
IgA I-GENE
RARE O
of O
the O
RARE O
epithelium O
might O
have O
RARE O
tolerance O
leading O
to O
IgA I-GENE
deficiency O
and O
subsequent O
subtotal O
atrophy O
of O
the O
RARE O
RARE O
in O
the O
patients O
with O
RARE O
RARE O
. O

Treatment O
of O
hypertension O
with O
a O
combination O
of O
the O
adrenergic I-GENE
beta I-GENE
receptor I-GENE
RARE O
, O
RARE O
, O
and O
the O
vasodilator O
, O
RARE O

RARE O
. O

RARE O
RARE O
and O
RARE O
. O

RARE O
removed O
from O
transcripts O
by O
RARE O
were O
identified O
. O

To O
RARE O
reflux O
into O
the O
blind O
loop O
, O
a O
number O
of O
RARE O
steps O
are O
considered O
RARE O
: O
1 O
) O
RARE O
section O
of O
the O
RARE O
RARE O
; O
2 O
) O
RARE O
RARE O
of O
the O
anastomosis O
and O
, O
particularly O
, O
3 O
) O
the O
RARE O
of O
a O
single O
or O
double O
valve O
RARE O
upstream O
from O
the O
anastomosis O
by O
RARE O
RARE O
of O
the O
mucosa O
using O
RARE O
RARE O
parallel O
and O
RARE O
to O
the O
RARE O
RARE O
. O

At O
this O
RARE O
, O
the O
RARE O
high O
mortality O
of O
acute O
ischemia O
is O
established O
RARE O
the O
RARE O
of O
the O
operation O
or O
the O
RARE O
with O
which O
it O
is O
performed O
. O

RARE O
( O
RARE O
RARE O
or O
Gram O
- O
negative O
bacilli O
) O
were O
isolated O
from O
only O
one O
RARE O
of O
RARE O
in O
small O
numbers O
and O
RARE O
and O
rarely O
in O
large O
numbers O
from O
patients O
. O

The O
RARE O
and O
RARE O
of O
RARE O
RARE O
RARE O
described O
by O
RARE O
et O
al O
. O

A O
NUM O
year O
- O
old O
woman O
was O
given O
RARE O
RARE O
4 O
. O
5 O
mg O
p O
. O
d O
. O
RARE O
RARE O
days O
, O
after O
an O
abortion O
( O
a O
still O
birth O
). O

RARE O
times O
to O
RARE O
presented O
stimuli O
in O
RARE O

Two O
out O
of O
five O
patients O
undergoing O
selective O
RARE O
RARE O
developed O
transient O
neurological O
complications O
RARE O
the O
injection O
of O
RARE O
NUM O
M O
. O

The O
data O
indicate O
a O
three O
- O
RARE O
reaction O
after O
NUM O
injection O
: O
Phase O
1 O
RARE O
RARE O
after O
injection O
there O
is O
a O
drop O
of O
all O
parameters O
lasting O
RARE O
NUM O
sec O
. O

Serum I-GENE
RARE I-GENE
levels O
in O
RARE O
E2 O
RARE O
RARE O
. O

A O
RARE O
A O
RARE O
RARE O
phenomenon O
, O
RARE O
the O
level O
of O
the O
ends O
of O
the O
RARE O
RARE O
, O
RARE O
body O
RARE O
, O
RARE O
ALL_CAP O
plays O
the O
role O
of O
RARE O
( O
RARE O
RARE O
1 O
) O
( O
5 O
); O
B O
RARE O
RARE O
RARE O
ulceration O
( O
ALL_CAP O
) O
is O
caused O
by O
a O
combination O
of O
ALL_CAP O
and O
ALL_CAP O
( O
1 O
); O
C O
RARE O
The O
patient O
RARE O
, O
RARE O
body O
RARE O
( O
RARE O
) O
effects O
RARE O
, O
RARE O
process O
can O
be O
easily O
observed O
; O
D O
RARE O
ALL_CAP O
ALL_CAP O
, O
being O
elastic O
, O
RARE O
localized O
compression O
RARE O
the O
ends O
of O
the O
RARE O
RARE O
, O
reduces O
RARE O
, O
makes O
RARE O
RARE O
circulation O
, O
RARE O
RARE O
RARE O
cure O
and O
prophylaxis O
of O
ALL_CAP O
( O
RARE O
RARE O
6 O
) O
( O
3 O
). O

Effect O
of O
RARE O
in O
small O
doses O
on O
the O
central O
RARE O
loci O
has O
been O
studied O
in O
RARE O
anesthetized O
cats O
by O
RARE O
it O
to O
the O
central O
sites O
. O

As O
expected O
, O
the O
RARE O
did O
produce O
increased O
RARE O
times O
and O
the O
development O
of O
RARE O
subcutaneous O
RARE O
. O

RARE O
RARE O
between O
RARE O
and O
their O
parents O
/ O
RARE O
was O
used O
to O
RARE O
consequences O
RARE O
daily O
self O
- O
monitoring O
, O
RARE O
RARE O
intake O
, O
RARE O
RARE O
, O
and O
exercise O
. O

RARE O
of O
childhood O
- O
and O
juvenile O
diabetes O

The O
results O
of O
a O
quantitative O
study O
of O
RARE O
membranes O
in O
123 O
RARE O
are O
presented O
. O

The O
RARE O
uses O
RARE O
and O
RARE O
RARE O
RARE O
the O
RARE O
RARE O
of O
the O
ALL_CAP O
. O

RARE O
RARE O
( O
5 O
- O
ALL_CAP O
) O
and O
5 I-GENE
- I-GENE
ALL_CAP I-GENE
releasing I-GENE
factor I-GENE
in O
plasma O
of O
RARE O
patients O
. O

The O
overall O
incidence O
of O
ALL_CAP O
was O
1 O
. O
NUM O
per O
1 O
, O
NUM O
live O
births O
. O

The O
RARE O
task O
and O
the O
measurement O
of O
RARE O
deficits O
. O

The O
RARE O
RARE O
RARE O
in O
RARE O
and O
the O
RARE O
RARE O

Significant O
increases O
in O
mean O
serum O
E2 O
concentration O
( O
NUM O
to O
NUM O
pg O
/ O
ml O
) O
were O
noted O
RARE O
6 O
and O
8 O
hours O
after O
administration O
on O
day O
1 O
and O
RARE O
8 O
hours O
on O
day O
4 O
. O

The O
motor O
unit O
RARE O
from O
above O
. O

RARE O
reproductive O
RARE O
: O
daily O
variations O
in O
responses O
to O
RARE O
. O

Biological O
properties O
of O
RARE O
. O

RARE O
studies O
of O
antibodies O
to O
Epstein O
- O
Barr O
virus O
in O
infectious O
RARE O

RARE I-GENE
antigen I-GENE
( O
ALL_CAP I-GENE
) O
procedures O
and O
clinical O
evaluation O
. O

We O
RARE O
RARE O
that O
RARE I-GENE
globulin I-GENE
( O
ALL_CAP I-GENE
) O
is O
a O
potent O
immunosuppressive O
agent O
in O
humans O
. O

On O
the O
basis O
of O
a O
global O
assessment O
patients O
showed O
a O
highly O
significant O
preference O
RARE O
RARE O
compared O
with O
placebo O
RARE O
RARE O
therapy O
. O

NUM O
- O
NUM O
. O

Patients O
were O
RARE O
into O
age O
- O
matched O
groups O
of O
RARE O
untreated O
RARE O
( O
21 O
RARE O
recurrent O
RARE O
( O
18 O
RARE O
and O
" O
RARE O
" O
patients O
who O
had O
been O
free O
of O
RARE O
RARE O
RARE O
least O
9 O
months O
( O
16 O
). O

RARE O
varied O
between O
65 O
and O
NUM O
per O
cent O
, O
with O
a O
mean O
absorption O
of O
NUM O
per O
cent O
, O
in O
both O
RARE O
and O
non O
- O
RARE O
subjects O
. O

RARE O
and O
RARE O
activity O
of O
hydroxy O
- O
9 O
RARE O
in O
vitro O

RARE O
in O
the O
management O
of O
gynecologic O
RARE O
RARE O
radiation O
therapy O
. O

The O
RARE O
- O
pathological O
data O
from O
a O
patient O
with O
irreversible O
post O
- O
RARE O
RARE O
failure O
( O
ALL_CAP O
) O
are O
presented O
. O

RARE O
RARE O
in O
nursing O
: O
an O
RARE O
with O
extremely O
RARE O
patients O

RARE O
transfer I-GENE
factor I-GENE
. O

19 O
- O
NUM O
. O

RARE I-GENE
factor I-GENE
and O
RARE O
antibody O
tests O
were O
frequently O
positive O
, O
and O
reactions O
to O
RARE O
therapy O
were O
more O
frequent O
than O
in O
other O
rheumatoid O
populations O
. O

The O
effect O
of O
RARE O
pressure O
on O
the O
swimming O
activity O
of O
three O
RARE O
RARE O
, O
RARE O
RARE O
, O
RARE O
RARE O
, O
RARE O
RARE O

This O
report O
presents O
an O
analysis O
of O
the O
RARE O
RARE O
of O
RARE O
monkeys O
( O
RARE O
RARE O
) O
observed O
RARE O
a O
field O
study O
in O
RARE O
RARE O
. O

RARE O
to O
now O
the O
number O
of O
patients O
examined O
is O
about O
NUM O
, O
additionally O
6 O
persons O
who O
underwent O
RARE O
. O

RARE O
was O
RARE O
tolerated O
by O
NUM O
patients O
, O
very O
RARE O
tolerated O
by O
2 O
. O

III O
. O

A O
new O
instrument O
has O
been O
designed O
RARE O
RARE O
- O
RARE O
of O
biological O
material O
in O
RARE O
high O
RARE O
. O

RARE O
and O
biliary O
RARE O
and O
RARE O
emptying O
rates O
of O
a O
liquid O
test O
RARE O
( O
ALL_CAP O
) O
were O
determined O
in O
normal O
persons O
, O
in O
patients O
with O
subtotal O
RARE O
with O
RARE O
( O
ALL_CAP O
- O
ALL_CAP O
) O
or O
with O
RARE O
( O
ALL_CAP O
- O
ALL_CAP O
RARE O
and O
in O
patients O
with O
RARE O
vagotomy O
and O
RARE O
( O
V O
& O
P O
). O

Abnormal O
RARE O
metabolism O
in O
RARE O
RARE O
. O

Also O
, O
except O
in O
one O
patient O
who O
developed O
RARE O
following O
RARE O
of O
RARE O
, O
saturation O
of O
gallbladder O
bile O
with O
cholesterol O
was O
not O
markedly O
increased O
by O
this O
drug O
alone O
. O

A O
five O
- O
RARE O
experiment O
was O
designed O
to O
investigate O
( O
a O
) O
whether O
RARE O
RARE O
- O
RARE O
would O
act O
RARE O
a O
RARE O
to O
increase O
RARE O
performance O
of O
ALL_CAP O
children O
and O
( O
b O
) O
whether O
this O
RARE O
RARE O
would O
affect O
preference O
RARE O
that O
RARE O
. O

The O
responsiveness O
of O
visual O
cortex O
( O
ALL_CAP O
) O
and O
superior O
RARE O
( O
SC O
) O
was O
simultaneously O
compared O
following O
conditioning O
" O
ALL_CAP O
" O
or O
" O
ALL_CAP O
" O
RARE O
, O
in O
the O
RARE O
. O

A O
diagnosis O
of O
MS O
was O
made O
based O
on O
RARE O
neurologic O
signs O
, O
RARE O
RARE O
gamma I-GENE
globulin I-GENE
elevations O
, O
and O
abnormalities O
in O
RARE O
testing O
. O

If O
, O
however O
, O
the O
mean O
RARE O
rise O
was O
RARE O
( O
NUM O
. O
57 O
degrees O
C O
or O
NUM O
. O
NUM O
degrees O
C O
RARE O
such O
a O
selection O
RARE O
resulted O
in O
the O
disappearance O
of O
' O
RARE O
' O
RARE O
in O
the O
triplet O
groups O
and O
a O
great O
RARE O
of O
' O
to O
be O
RARE O
' O
RARE O
in O
the O
large O
groups O
. O

The O
elevated O
RARE O
V O
in O
the O
ALL_CAP O
group O
suggests O
an O
increase O
in O
small O
airway O
resistance O
secondary O
to O
the O
RARE O
or O
to O
its O
therapy O
. O

The O
psychological O
tests O
consisted O
of O
a O
free O
- O
RARE O
task O
, O
a O
test O
RARE O
RARE O
coordination O
and O
a O
recognition O
task O
. O

Selective O
bronchial O
RARE O
in O
the O
management O
of O
unilateral O
pulmonary O
interstitial O
emphysema O
. O

The O
background O
processes O
depending O
on O
the O
RARE O
factor O
and O
the O
character O
of O
lesion O
of O
the O
epithelium O
are O
divided O
into O
RARE O
, O
inflammatory O
, O
and O
RARE O
. O

The O
sense O
of O
self O
. O

RARE O
strains O
of O
RARE O
RARE O
and O
F O
. O
RARE O
from O
the O
ALL_CAP O
. O
S O
. O
S O
. O
R O
. O
and O
7 O
strains O
of O
these O
species O
and O
one O
of O
F O
. O
RARE O
RARE O
. O
RARE O
from O
ALL_CAP O
. O
S O
. O
A O
. O
and O
RARE O
have O
been O
compared O
RARE O
to O
their O
capacity O
to O
yield O
T I-GENE
- I-GENE
2 I-GENE
RARE I-GENE
. O

Current O
diagnostic O
uses O
of O
computerized O
tomography O
in O
clinical O
medicine O
. O

A O
follow O
- O
RARE O
study O
of O
NUM O
patients O
with O
RARE O
' O
s O
RARE O
has O
been O
performed O
. O

RARE O
stopped O
11 O
hours O
after O
RARE O
concentrations O
decreased O
below O
NUM O
. O
2 O
ppm O
and O
signs O
of O
distress O
stopped O
in O
RARE O
RARE O
by O
RARE O
6 O
hours O
after O
the O
last O
RARE O
. O

RARE O
of O
bladder O
tumors O
among O
the O
original O
9 O
cases O
has O
occurred O
only O
among O
the O
5 O
whose O
RARE I-GENE
levels O
remained O
below O
the O
median O
. O

RARE O
of O
RARE O
RARE O
maximum O
to O
increased O
RARE O
load O
in O
the O
rat O
. O

RARE O
in O
use O
of O
live O
- O
virus O
vaccines O
. O

Treatment O
with O
RARE O
, O
plasminogen I-GENE
RARE O
and O
RARE O
agents O
was O
RARE O
although O
RARE O
function O
has O
stabilized O
in O
one O
patient O
on O
long O
term O
oral O
RARE O
therapy O
. O

In O
RARE O
ether O
solution O
the O
main O
peak O
is O
that O
of O
2 O
- O
RARE O
- O
1 O
- O
RARE O
, O
which O
has O
a O
retention O
time O
of O
NUM O
, O
2 O
minutes O
under O
the O
condition O
RARE O
. O

RARE O
was O
used O
in O
the O
treatment O
of O
NUM O
serious O
gram O
- O
negative O
infections O
in O
54 O
patients O
of O
whom O
NUM O
RARE O
. O

The O
data O
normally O
available O
are O
insufficient O
and O
take O
RARE O
account O
of O
the O
direction O
of O
RARE O
, O
which O
may O
be O
a O
RARE O
factor O
. O

During O
activity O
III O
, O
one O
patient O
developed O
angina O
. O

RARE O
of O
L O
- O
alanine O
in O
serum O
or O
plasma O
using O
the O
ALL_CAP O
reaction O
rate O
RARE O
. O

The O
RARE O
were O
obtained O
by O
hydrolysis O
of O
the O
corresponding O
esters O
, O
and O
their O
anti O
- O
inflammatory O
activity O
was O
tested O
. O

RARE O
RARE O
and O
RARE O
: O
a O
preliminary O
report O
. O

Evaluation O
of O
the O
new O
RARE O
ALL_CAP O
RARE O
. O

RARE O
meningitis O
secondary O
to O
abscess O
of O
the O
nasal O
RARE O
. O

Serum I-GENE
amylase I-GENE
became O
markedly O
elevated O
( O
2 O
, O
NUM O
ALL_CAP O
/ O
NUM O
ml O
RARE O
RARE O
did O
the O
serum O
ALL_CAP O
( O
29 O
. O
19 O
mEq O
/ O
liter O
). O

In O
the O
control O
preparation O
before O
RARE O
was O
allowed O
to O
increase O
, O
RARE O
capillary O
pressure O
( O
RARE O
) O
averaged O
8 O
mmHg O
lower O
than O
colloid O
osmotic O
pressure O
of O
the O
plasma O
( O
RARE O
). O

RARE O
who O
died O
in O
the O
RARE O
12 O
hours O
from O
' O
ALL_CAP O
only O
' O
had O
RARE O
severe O
birth O
RARE O
but O
in O
those O
who O
died O
later O
the O
main O
RARE O
was O
recurrent O
RARE O
. O

The O
morphological O
effects O
of O
two O
RARE O
RARE O
, O
N O
. O
RARE O
and O
A O
. O
RARE O
, O
and O
of O
the O
RARE I-GENE
RARE I-GENE
RARE I-GENE
and O
RARE I-GENE
- I-GENE
A I-GENE
, O
compounds O
RARE O
from O
N O
. O
RARE O
crude O
RARE O
, O
were O
investigated O
on O
RARE O
and O
RARE O
vessels O
of O
rats O
. O

Since O
RARE O
are O
the O
RARE O
of O
cartilage O
RARE O
, O
the O
depletion O
of O
which O
is O
associated O
with O
RARE O
, O
a O
method O
RARE O
measuring O
RARE O
ALL_CAP O
RARE O
in O
culture O
has O
been O
investigated O
. O

The O
length O
RARE O
of O
the O
RARE O
were O
also O
estimated O
: O
RARE O
a O
RARE O
number O
near O
4 O
, O
NUM O
the O
RARE O
is O
about O
1 O
. O
NUM O
mm O
, O
the O
RARE O
RARE O
is O
about O
NUM O
. O
NUM O
mm O
, O
and O
the O
RARE O
scale O
is O
near O
NUM O
. O
NUM O
mm O
. O

RARE O
- O
RARE O
RARE O
of O
the O
RARE O
can O
be O
obtained O
by O
RARE O
after O
rapid O
RARE O
injection O
of O
contrast O
- O
medium O
into O
an O
RARE O
RARE O
, O
RARE O
demonstrated O
in O
NUM O
patients O
. O

No O
hypotension O
was O
noted O
in O
patients O
with O
RARE O
and O
only O
2 O
RARE O
a O
fever O
above O
37 O
. O
5 O
degrees O
C O
. O

The O
RARE O
and O
nasal O
RARE O
of O
142 O
patients O
, O
who O
were O
positive O
in O
HD O
or O
RARE O
RARE O
test O
, O
were O
subjected O
to O
a O
RARE O
test O
( O
RAST O
) O
RARE O
estimating O
the O
specific O
IgE I-GENE
antibody I-GENE
activity O
to O
RARE O
. O

RARE O
the O
site O
of O
the O
conditioning O
RARE O
, O
these O
modifications O
disappeared O
after O
ischaemia O
of O
the O
leg O
. O

RARE O
( O
ALL_CAP O
RARE O
one O
of O
the O
few O
RARE O
tested O
thus O
far O
that O
has O
not O
RARE O
neoplasms O
in O
rats O
, O
caused O
a O
high O
incidence O
of O
respiratory O
RARE O
tumors O
in O
RARE O
RARE O
hamsters O
treated O
sc O
with O
single O
or O
weekly O
doses O
of O
the O
compound O
. O

RARE O
term O
, O
under O
experimental O
conditions O
, O
RARE O
and O
RARE O
RARE O
gases O
, O
pH O
, O
RARE O
and O
RARE O
RARE O
RARE O
were O
measured O
or O
calculated O
. O

RARE O
responses O
to O
RARE O
of O
RARE O
RARE O
with O
atropine O
- O
RARE O
mixture O
in O
children O
. O

The O
mechanism O
by O
which O
large O
molecules O
, O
such O
RARE O
the O
RARE O
99mTc O
- O
labeled O
ALL_CAP O
or O
99mTc O
- O
labeled O
RARE O
, O
RARE O
through O
capillaries O
in O
bone O
is O
by O
passive O
diffusion O
. O

Twenty O
- O
nine O
days O
after O
injection O
of O
5 O
. O
8 O
mCi O
of O
Tc O
- O
99m O
, O
which O
gives O
NUM O
RARE O
to O
the O
RARE O
, O
the O
number O
of O
sperm O
RARE O
decreased O
to O
70 O
% O
of O
control O
. O

RARE O
- O
RARE O
is O
the O
end O
result O
of O
an O
unusual O
psychiatric O
disorder O
, O
which O
initially O
requires O
surgical O
treatment O
. O

RARE O
of O
a O
ALL_CAP I-GENE
- O
RARE O
method O
RARE O
detection O
of O
hypothyroidism O
in O
the O
newborn O

Thus O
analysis O
indicated O
RARE O
reliable O
evidence O
that O
conscious O
RARE O
RARE O
become O
incorporated O
into O
RARE O
content O
. O

The O
prevalence O
of O
hepatitis I-GENE
B I-GENE
surface I-GENE
antigen I-GENE
( O
HBsAg I-GENE
) O
and O
anti I-GENE
- I-GENE
HBs I-GENE
was O
determined O
by O
a O
RARE O
double O
- O
antibody O
RARE O
- O
immunoassay O
technique O
in O
a O
series O
of O
patients O
with O
chronic O
liver O
diseases O
. O

It O
was O
concluded O
that O
patients O
with O
acute O
respiratory O
failure O
requiring O
artificial O
ventilation O
have O
two O
RARE O
of O
the O
pulmonary O
shunt O
, O
one O
parallel O
with O
and O
the O
other O
inversely O
related O
with O
the O
NUM O
. O

RARE O
cardiac O
RARE O
following O
RARE O
injection O
in O
RARE O
, O
RARE O
RARE O
rats O
. O

Biological O
evaluation O
of O
RARE O
in O
the O
female O
RARE O
. O

RARE O
of O
both O
ALL_CAP O
and O
ALL_CAP O
were O
significantly O
RARE O
RARE O
early O
spontaneous O
labour O
, O
RARE O
a O
cervical O
dilatation O
of O
less O
than O
4 O
cm O
, O
than O
before O
the O
onset O
of O
labour O
. O

The O
most O
common O
cause O
of O
RARE O
deterioration O
in O
the O
RARE O
cord O
RARE O
patient O
is O
irreversible O
RARE O
reflux O
. O

RARE O
( O
RARE O
) O
administered O
in O
a O
dose O
which O
blocks O
the O
beta O
- O
adrenergic O
apparatus O
of O
the O
RARE O
prevents O
the O
development O
of O
the O
positive O
inotropic O
effect O
of O
therapeutic O
doses O
of O
RARE O
K O
on O
a O
RARE O
RARE O
ventricular O
myocardium O
. O

Recent O
studies O
have O
shown O
the O
rat O
larynx O
to O
be O
an O
important O
organ O
in O
the O
evaluation O
of O
RARE O
of O
inhaled O
materials O
. O

RARE O
electron O
microscopic O
investigations O
on O
the O
formation O
of O
RARE O
' O
s O
fiber O
in O
RARE O
RARE O

RARE O
behavior O
, O
RARE O
body O
RARE O
and O
RARE O
RARE O
in O
European O
hamsters O
lesioned O
in O
the O
noradrenergic O
ascending O
RARE O

Role O
of O
the O
infectious O
- O
RARE O
RARE O
of O
a O
RARE O
in O
RARE O
the O
incidence O
of O
RARE O
diseases O

These O
observed O
drug O
interactions O
, O
RARE O
the O
known O
effect O
of O
RARE O
to O
RARE O
RARE O
of O
ALL_CAP O
, O
have O
to O
be O
considered O
in O
evaluating O
the O
effect O
of O
the O
two O
drugs O
given O
together O
, O
compared O
to O
the O
effect O
of O
each O
drug O
given O
separately O
. O

RARE O
arrest O
in O
the O
operating O
room O
. O

At O
a O
systolic O
RARE O
pressure O
( O
ALL_CAP O
) O
of O
NUM O
mmHg O
, O
NUM O
responsiveness O
was O
abolished O
, O
but O
was O
maintained O
RARE O
RARE O
levels O
of O
ALL_CAP O
. O

RARE O
- O
123 O
was O
RARE O
RARE O
only O
with O
the O
ALL_CAP O
and O
RARE O
RARE O
, O
which O
in O
RARE O
yielded O
ALL_CAP O
values O
comparable O
to O
those O
measured O
RARE O
99mTc O
. O

RARE O
RARE O
RARE O
plaque O
RARE O
RARE O
a O
right O
RARE O
ear O
tumor O
. O

The O
RARE O
to O
RARE O
prostaglandins O
( O
ALL_CAP O
) O
by O
gas O
- O
liquid O
chromatography O
are O
mainly O
due O
to O
the O
lack O
of O
sensitivity O
of O
the O
gas O
- O
RARE O
itself O
( O
RARE O
than O
NUM O
RARE O
) O
and O
to O
the O
poor O
resolution O
of O
the O
RARE O
RARE O
. O

On O
cessation O
of O
steroid O
therapy O
the O
patient O
was O
noted O
to O
have O
RARE O
manifestations O
of O
RARE O
RARE O
( O
ALL_CAP O
) O
RARE O
RARE O
RARE O
clinical O
and O
laboratory O
features O
of O
rheumatoid O
arthritis O
( O
ALL_CAP O
). O

The O
effect O
of O
food O
on O
RARE O
absorption O
. O

After O
giving O
a O
survey O
on O
the O
RARE O
of O
antibiotic O
resistance O
in O
the O
region O
of O
Northern O
RARE O
RARE O
NUM O
/ O
NUM O
and O
comparing O
the O
activity O
of O
a O
RARE O
( O
ALL_CAP O
) O
RARE O
( O
ALL_CAP O
) O
combination O
to O
other O
commonly O
used O
antibiotics O
and O
chemotherapeutic O
agents O
, O
the O
results O
of O
tests O
with O
the O
new O
combination O
of O
NUM O
RARE O
4 O
, O
5 O
- O
dimethyl O
- O
2 O
- O
RARE O
)- O
RARE O
) O
( O
RARE O
) O
and O
2 O
, O
4 O
- O
RARE O
- O
5 O
RARE O
3 O
, O
4 O
, O
5 O
- O
RARE O
- O
RARE O
)- O
pyrimidine O
( O
RARE O
) O
RARE O
a O
ratio O
of O
5 O
: O
1 O
( O
ALL_CAP O
NUM O
; O
RARE O
, O
RARE O
) O
are O
compared O
to O
those O
of O
tests O
with O
ALL_CAP O
/ O
ALL_CAP O
. O

RESULTS O
: O
Total O
IgE I-GENE
levels O
showed O
a O
tendency O
to O
RARE O
. O

RARE O
RARE O
loop O
RARE O
exist O
RARE O
It O
is O
the O
author O
' O
s O
RARE O
that O
diagnosis O
of O
the O
" O
RARE O
loop O
RARE O
" O
is O
unlikely O
to O
be O
correct O
in O
patients O
subjected O
to O
RARE O
- O
II O
RARE O
. O

Letter O
: O
Is O
RARE O
( O
RARE O
) O
damage O
the O
RARE O
cause O
of O
' O
post O
- O
inflammatory O
RARE O
and O
RARE O
RARE O
( O
ALL_CAP O
RARE O

These O
data O
suggest O
that O
spontaneous O
recovery O
of O
central O
respiratory O
function O
after O
RARE O
with O
RARE O
or O
RARE O
may O
not O
be O
related O
to O
the O
return O
of O
ALL_CAP I-GENE
activity O
. O

RARE O
cultures O
of O
S O
. O
RARE O
RARE O
a O
demonstrated O
RARE O
growth O
on O
ALL_CAP O
agar O
. O

Also O
, O
samples O
of O
serum O
were O
absorbed O
with O
the O
various O
solid O
- O
RARE O
allergens O
and O
the O
reactivity O
of O
the O
remaining O
IgE I-GENE
antibodies I-GENE
was O
determined O
. O

RARE O
of O
the O
therapeutic O
community O
in O
RARE O
RARE O

RARE O
women O
RARE O
term O
had O
the O
lowest O
levels O
of O
antithrombin I-GENE
III I-GENE
. O

RARE O
problem O
of O
the O
month O
: O
band O
or O
RARE O
? O

It O
is O
possible O
that O
cyclic O
variations O
in O
heme O
turnover O
are O
related O
to O
changes O
in O
RARE O
characteristics O
RARE O
the O
progesterone O
RARE O
. O

RARE O
in O
cardiopulmonary O
bypass O
using O
a O
RARE O
RARE O
RARE O
RARE O
. O

RARE O
RARE O
of O
the O
RARE O
RARE O

I O
. O

The O
recovered O
calves O
were O
tested O
RARE O
RARE O
to O
homologous O
severe O
challenge O
, O
50 O
or O
NUM O
days O
after O
the O
RARE O
infection O
. O

The O
performance O
of O
three O
commonly O
used O
chemical O
RARE O
RARE O
RARE O
NUM O
was O
measured O
under O
working O
conditions O
in O
a O
RARE O
RARE O
. O

The O
neuroleptic O
- O
RARE O
increase O
in O
central O
ALL_CAP O
turnover O
( O
an O
indicator O
RARE O
the O
degree O
of O
ALL_CAP I-GENE
receptor I-GENE
blocking O
) O
was O
found O
to O
be O
positively O
correlated O
with O
the O
therapeutic O
effect O
of O
RARE O
and O
the O
development O
of O
RARE O
- O
RARE O
symptoms O
. O

RARE O
RARE O
were O
obtained O
from O
a O
commercial O
RARE O
RARE O
, O
kept O
in O
RARE O
water O
and O
feeding O
in O
experimental O
pellets O
RARE O
4 O
to O
8 O
weeks O
. O

RARE O
of O
macrophage O
function O
by O
killed O
RARE O
RARE O
cells O
did O
not O
show O
any O
beneficial O
effect O
RARE O
an O
increased O
RARE O
became O
apparent O
. O

Primary O
RARE O
in O
a O
RARE O
female O
individual O
with O
a O
RARE O
NUM O
, O
RARE O
and O
bilateral O
RARE O

RARE O
absolute O
methods O
in O
clinical O
chemistry O
: O
application O
of O
mass O
RARE O
to O
high O
- O
accuracy O
analyses O
. O

RARE O
of O
the O
2 O
- O
RARE O
- O
D O
- O
glucose O
method O
to O
the O
coupling O
of O
cerebral O
metabolism O
and O
RARE O
flow O
. O

Serum O
gastrin I-GENE
levels O
did O
not O
change O
in O
either O
group O
; O
however O
, O
background O
serum O
gastrin I-GENE
concentrations O
were O
significantly O
greater O
RARE O
V O
& O
P O
patients O
than O
V O
& O
A O
patients O
throughout O
the O
study O
. O

RARE O
projections O
of O
the O
ventral O
portion O
of O
the O
RARE O
to O
the O
frontal O
, O
RARE O
and O
temporal O
regions O
of O
the O
RARE O
cerebral O
cortex O

RARE O
, O
RARE O
, O
and O
RARE O
exercise O
response O
tests O
were O
conducted O
on O
the O
RARE O
of O
the O
second O
RARE O
RARE O
( O
RARE O
3 O
) O
RARE O
part O
of O
an O
evaluation O
of O
physiological O
adaptation O
to O
long O
- O
term O
RARE O
. O

Mean O
RARE I-GENE
hemoglobin I-GENE
concentrations O
remained O
normal O
RARE O
NUM O
h O
and O
then O
decreased O
in O
both O
groups O
, O
the O
CO2 O
group O
showing O
the O
larger O
decrease O
. O

All O
RARE O
values O
obtained O
from O
the O
organs O
investigated O
had O
reached O
a O
saturation O
level O
RARE O
8 O
RARE O
RARE O
/ O
g O
diet O
with O
the O
exception O
of O
the O
values O
RARE O
body O
RARE O
found O
in O
the O
RARE O
that O
were O
killed O
on O
the O
day O
of O
delivery O
. O

The O
effect O
of O
calcitonin I-GENE
, O
a O
large O
amount O
of O
RARE O
given O
orally O
, O
RARE O
and O
glucagon I-GENE
on O
plasma O
NUM O
RARE O
curves O
in O
subjects O
pretreated O
with O
NUM O
was O
examined O
. O

State O
of O
the O
body O
in O
disorders O
of O
RARE O
physiological O
RARE O
and O
long O
- O
term O
RARE O

RARE O
tension O
of O
the O
small O
lymph O
vessels O
( O
NUM O
) O
of O
the O
RARE O
RARE O
limb O
was O
measured O
with O
both O
a O
flow O
- O
through O
micro O
chamber O
and O
a O
RARE O
catheter O
- O
RARE O
oxygen O
electrode O
to O
obtain O
experimental O
data O
on O
the O
source O
of O
oxygen O
in O
the O
lymph O
. O

The O
response O
of O
the O
plasma I-GENE
fibrinogen I-GENE
level O
to O
the O
RARE O
injection O
of O
RARE O
and O
to O
the O
intravenous O
injection O
of O
RARE O
was O
measured O
in O
normal O
rabbits O
and O
in O
rabbits O
made O
RARE O
and O
RARE O
with O
RARE O
. O

RARE O
RARE O
pressure O
curves O
without O
RARE O
activities O
are O
interpreted O
RARE O
characteristic O
RARE O
criteria O
of O
an O
advanced O
ectopic O
RARE O
. O

Since O
myoglobin I-GENE
is O
RARE O
- O
extracted O
with O
the O
hemoglobin I-GENE
, O
the O
2 O
heme O
RARE O
are O
separated O
in O
one O
portion O
of O
the O
RARE O
by O
precipitating O
the O
hemoglobin I-GENE
in O
an O
NUM O
% O
( O
NUM O
) O
NUM O
solution O
. O

RARE O
these O
sources O
of O
error O
some O
of O
the O
variability O
in O
the O
present O
investigation O
might O
be O
RARE O
by O
systematic O
RARE O
. O

E O
50 O
, O
NUM O
( O
1994 O
)]. O

Six O
patients O
with O
the O
diagnosis O
of O
acute O
RARE O
were O
treated O
with O
high O
doses O
of O
the O
beta O
- O
adrenergic O
blocking O
agent O
propranolol O
. O

Effect O
of O
trauma O
on O
plasma I-GENE
glucagon I-GENE
and O
insulin I-GENE
concentrations O
in O
sheep O
. O

With O
the O
help O
of O
a O
RARE O
one O
can O
RARE O
off O
the O
RARE O
, O
when O
axis O
length O
and O
corneal O
RARE O
are O
known O
. O

This O
RARE O
- O
RARE O
of O
the O
final O
score O
by O
the O
CA O
RARE O
is O
greater O
( O
3 O
- O
8 O
%) O
in O
the O
less O
able O
students O
with O
scores O
below O
the O
mean O
level O
. O

RARE O
to O
controls O
, O
both O
ALL_CAP O
and O
ALL_CAP O
rats O
showed O
a O
small O
but O
significant O
post O
- O
operative O
reduction O
in O
the O
RARE O
of O
drinking O
. O

Effect O
of O
indomethacin O
on O
coronary O
circulation O
: O
effect O
on O
ECG O
RARE O

RARE O
RARE O
of O
fast O
fibers O
in O
trunk O
muscles O
of O
RARE O
larvae O

The O
feed O
RARE O
which O
was O
lowered O
by O
NUM O
% O
initially O
, O
did O
not O
alter O
later O
. O

RARE O
characteristics O
of O
eye O
changes O
in O
patients O
with O
RARE O
including O
RARE O
' O
s O
RARE O

The O
color O
- O
RARE O
interference O
effect O
previously O
reported O
with O
normal O
populations O
when O
given O
the O
Stroop O
test O
was O
demonstrated O
RARE O
this O
retarded O
sample O
using O
a O
RARE O
RARE O
. O

It O
was O
found O
that O
under O
the O
RARE O
conditions O
a O
RARE O
dependence O
exists O
between O
the O
ALL_CAP O
% O
value O
and O
ALL_CAP O
within O
the O
range O
of O
NUM O
. O
5 O
RARE O
10 O
RARE O
RARE O
. O

The O
influence O
of O
adrenergic O
nerves O
of O
the O
response O
of O
RARE O
vessels O
in O
the O
RARE O
ear O
to O
2 I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
8 I-GENE
- I-GENE
RARE I-GENE
vasopressin I-GENE
( O
RARE I-GENE
). O

RARE O
test O

I O
. O

When O
a O
RARE O
is O
present O
RARE O
discharge O
is O
of O
little O
importance O
RARE O
the O
diagnosis O
and O
treatment O
. O

Studies O
of O
biochemical O
and O
morphological O
changes O
( O
between O
normal O
and O
treated O
animals O
) O
show O
that O
RARE O
induces O
an O
increase O
in O
the O
RARE O
free O
cell O
population O
and O
pulmonary O
RARE O
levels O
. O

RARE O
measurements O
of O
RARE O
changes O
and O
estimates O
of O
the O
RARE O
produced O
RARE O
the O
RARE O
. O

RARE O
RARE O
' O
National O
Health O
RARE O
- O
RARE O
'. O

Is O
RARE O
of O
patient O
care O
RARE O
and O
does O
it O
have O
RARE O
value O
? O
Patients O
' O
RARE O
contributes O
to O
improved O
patient O
care O

RARE O
of O
" O
RARE O
Effects O
of O
Test O
RARE O
and O
RARE O
/ O
No O
RARE O
or O
A O
- O
F O
RARE O
RARE O
upon O
Short O
- O
term O
and O
RARE O
- O
term O
RARE O
of O
RARE O
RARE O
. O

These O
studies O
have O
shown O
that O
the O
majority O
of O
tested O
RARE O
were O
resistant O
to O
RARE O
G O
, O
RARE O
, O
and O
produced O
beta I-GENE
- I-GENE
lactamase I-GENE
. O

Since O
NUM O
, O
a O
RARE O
decrease O
in O
the O
number O
of O
strains O
resistant O
to O
three O
or O
more O
antibiotics O
( O
multiple O
- O
resistant O
) O
and O
in O
strains O
of O
the O
NUM O
complex O
was O
RARE O
. O

RARE O
of O
nursing O
RARE O
to O
be O
given O
RARE O
the O
time O
of O
discharge O
from O
the O
RARE O
RARE O
premature O
infants O

No O
difference O
in O
the O
clinical O
RARE O
could O
be O
RARE O
between O
the O
two O
groups O
. O

After O
NUM O
d O
a O
RARE O
, O
RARE O
RARE O
- O
like O
lesion O
was O
observed O
in O
two O
specimens O
only O
. O

The O
RARE O
pattern O
of O
NUM O
women O
was O
analysed O
and O
NUM O
. O
8 O
percent O
were O
using O
inefficient O
methods O
. O

RARE O
technique O
and O
indirect O
RARE O
pressure O
recordings O
were O
used O
. O

I O
. O

The O
second O
and O
third O
responded O
similarly O
to O
either O
a O
combined O
cyclophosphamide O
+ O
RARE I-GENE
globulin I-GENE
( O
ALL_CAP I-GENE
) O
treatment O
or O
to O
ALL_CAP I-GENE
administration O
RARE O
by O
a O
small O
dosage O
of O
cyclophosphamide O
, O
which O
had O
proved O
RARE O
when O
administered O
alone O
. O

Evidence O
is O
presented O
that O
RARE O
' O
s O
RARE O
RARE O
RARE O
is O
not O
a O
separate O
RARE O
but O
a O
RARE O
form O
of O
RARE O
' O
RARE O
. O

RARE I-GENE
RARE O
along O
the O
catheter O
was O
found O
in O
20 O
patients O
studied O
by O
RARE O
- O
out O
RARE O
and O
was O
RARE O
with O
clinical O
symptoms O
. O

The O
influence O
of O
a O
mobile O
RARE O
on O
the O
response O
in O
the O
DC O
- O
ALL_CAP O
is O
demonstrated O
. O

A O
newly O
synthesized O
anti O
- O
inflammatory O
agent O
, O
Y O
- O
NUM O
demonstrated O
a O
greater O
inhibition O
than O
did O
indomethacin O
( O
IM O
). O
on O
inflammatory O
response O
such O
RARE O
RARE O
RARE O
in O
RARE O
pigs O
, O
RARE O
edema O
, O
RARE O
blue O
and O
RARE O
- O
RARE O
RARE O
and O
RARE O
acid O
- O
RARE O
RARE O
in O
rats O
. O

As O
RARE O
shifted O
in O
RARE O
from O
RARE O
to O
RARE O
with O
age O
, O
RARE O
RARE O
appeared O
to O
maintain O
gradually O
increasing O
rates O
of O
whole O
- O
RARE O
RARE O
until O
RARE O
were O
RARE O
NUM O
years O
old O
. O

RARE I-GENE
- I-GENE
1 I-GENE
antitrypsin I-GENE
and O
RARE O
childhood O
cirrhosis O
. O

RARE O
RARE O
, O
serum I-GENE
IgE I-GENE
and O
RARE O
eosinophil O
counts O
in O
patients O
with O
bronchial O
asthma O
. O

A O
range O
of O
normal O
ventricular O
measurements O
RARE O
the O
ALL_CAP O
scan O
is O
suggested O
. O

A O
comparison O
of O
physical O
and O
cytogenetic O
estimates O
of O
radiation O
dose O
in O
patients O
treated O
with O
iodine O
- O
NUM O
RARE O
thyroid O
carcinoma O
. O

RARE O
RARE O
obtaining O
RARE O
RARE O
with O
RARE O
mass O

Mean O
RARE O
RARE O
capacity O
, O
RARE O
residual O
capacity O
, O
and O
residual O
volume O
increased O
significantly O
, O
and O
the O
mean O
RARE O
volume O
, O
the O
RARE O
volume O
above O
residual O
volume O
RARE O
which O
RARE O
IV O
begins O
, O
decreased O
significantly O
with O
11 O
cm O
NUM O
continuous O
positive O
airway O
pressure O
; O
differences O
RARE O
5 O
cm O
NUM O
were O
not O
significant O
. O

Current O
status O
of O
zinc O
deficiency O
in O
the O
pathogenesis O
of O
neurological O
, O
RARE O
and O
RARE O
disorders O
. O

RARE O
and O
phosphorus O
metabolism O
in O
chronic O
RARE O
. O

RARE O
studies O
, O
conducted O
with O
RARE O
- O
9 O
- O
ALL_CAP O
, O
in O
healthy O
RARE O
, O
again O
suggest O
the O
comparison O
or O
even O
the O
identity O
of O
the O
modifications O
caused O
by O
RARE O
with O
sleep O
and O
RARE O
. O

The O
RARE O
action O
of O
RARE O
RARE O
upon O
the O
RARE O
effects O
RARE O
by O
RARE O
has O
been O
studied O
in O
NUM O
acute O
RARE O
states O
. O

RARE O
growth O
was O
retarded O
in O
animals O
maintained O
solely O
on O
RARE O
RARE O
and O
improved O
with O
supplementation O
. O

Two O
patients O
were O
treated O
with O
both O
regimens O
. O

Results O
obtained O
RARE O
chloramphenicol O
- O
containing O
preparations O
are O
presented O
, O
and O
both O
dissolution O
curves O
and O
RARE O
- O
RARE O
assays O
demonstrate O
that O
chloramphenicol O
has O
far O
superior O
release O
( O
and O
hence O
activity O
) O
from O
RARE O
than O
from O
ophthalmic O
RARE O
. O

IgG I-GENE
levels O
of O
1 O
/ O
NUM O
were O
present O
in O
only O
four O
out O
of O
ten O
samples O
obtained O
NUM O
days O
after O
the O
clinical O
onset O
. O

Letter O
: O
RARE O
in O
bone O
marrow O
transplantation O
. O

Assessment O
of O
the O
RARE O
of O
non O
- O
RARE O
RARE O
II O
: O
RARE O
and O
RARE O
. O

The O
RARE O
behaviour O
in O
weakly O
RARE O
mice O
was O
due O
to O
the O
occurrence O
in O
some O
animals O
of O
a O
second O
RARE O
of O
more O
rapid O
increase O
of O
the O
RARE O
. O

RARE O
amphotericin O
B O
was O
detected O
in O
the O
RARE O
of O
the O
mice O
only O
while O
they O
were O
receiving O
the O
NUM O
. O
3 O
mg O
/ O
ml O
dose O
level O
. O

There O
was O
a O
slight O
increase O
in O
RARE O
transferrin I-GENE
2 O
hr O
after O
1 O
tablet O
and O
values O
remained O
high O
throughout O
the O
experiment O
. O

Following O
intravenous O
administration O
, O
the O
RARE O
concentration O
of O
tracer O
thallium O
- O
NUM O
, O
RARE O
- O
NUM O
, O
and O
RARE O
- O
NUM O
were O
determined O
in O
mice O
; O
thallium O
was O
present O
in O
the O
greatest O
concentration O
in O
the O
myocardium O
( O
2 O
. O
NUM O
% O
compared O
1 O
. O
NUM O
% O
RARE O
RARE O
and O
1 O
. O
NUM O
% O
RARE O
RARE O
RARE O
10 O
minutes O
). O

RARE I-GENE
time O
, O
partial O
thromboplastin I-GENE
time O
, O
thrombin I-GENE
time O
, O
heat O
- O
dependent O
fibrin I-GENE
, O
RARE O
RARE O
, O
and O
RARE I-GENE
factors I-GENE
II I-GENE
, I-GENE
V I-GENE
, I-GENE
VIII I-GENE
, I-GENE
ALL_CAP I-GENE
, I-GENE
X I-GENE
, O
and O
the O
platelet O
count O
were O
determined O
. O

The O
data O
support O
the O
notion O
that O
suppression O
of O
images O
RARE O
RARE O
RARE O
is O
independent O
in O
both O
eyes O
. O

RARE O
utilization O
was O
increased O
, O
but O
tissue O
levels O
of O
RARE O
phosphate O
, O
ATP O
, O
and O
RARE O
were O
similar O
to O
those O
in O
hearts O
receiving O
normal O
flow O
. O

The O
records O
from O
NUM O
through O
NUM O
of O
NUM O
previously O
untreated O
patients O
with O
squamous O
cell O
carcinoma O
of O
the O
oral O
cavity O
, O
RARE O
, O
RARE O
larynx O
and O
RARE O
who O
had O
clinically O
positive O
cervical O
lymph O
node O
metastases O
RARE O
NUM O
, O
NUM O
, O
or O
NUM O
, O
and O
whose O
initial O
neck O
treatment O
consisted O
of O
external O
radiation O
therapy O
alone O
were O
reviewed O
. O

With O
NUM O
. O
5 O
RARE O
RARE O
the O
corresponding O
values O
were O
NUM O
mumol O
/ O
1 O
( O
5 O
. O
72 O
mg O
/ O
NUM O
ml O
) O
and O
NUM O
mumol O
/ O
1 O
( O
2 O
. O
NUM O
mg O
/ O
NUM O
ml O
) O
respectively O
. O

The O
authors O
describe O
the O
technique O
of O
transverse O
axial O
tomography O
of O
the O
spine O
and O
give O
a O
detailed O
description O
of O
the O
axial O
RARE O
of O
the O
normal O
lumbar O
spine O
from O
L O
- O
4 O
to O
the O
RARE O
. O

RARE O
to O
parental O
RARE O
, O
a O
low O
protein O
diet O
( O
1 O
- O
5 O
g O
/ O
kg O
) O
was O
introduced O
only O
RARE O
. O

In O
none O
of O
the O
NUM O
type O
I O
attacks O
and O
29 O
type O
II O
attacks O
which O
were O
recorded O
did O
circulatory O
changes O
; O
the O
latter O
were O
different O
in O
the O
two O
groups O
. O

A O
clinically O
useful O
diagnostic O
method O
has O
been O
developed O
RARE O
detecting O
and O
RARE O
periods O
of O
apnea O
in O
pediatric O
patients O
. O

The O
other O
RARE O
patient O
showed O
an O
RARE O
insulin I-GENE
release O
in O
response O
to O
RARE O
. O

RARE O
RARE O
( O
1 O
. O
5 O
- O
12 O
cycles O
/ O
s O
) O
produced O
frequency O
- O
dependent O
reductions O
in O
CBF O
, O
a O
decrease O
of O
50 O
percent O
occurring O
with O
the O
highest O
frequency O
. O

Effect O
of O
ingestion O
of O
RARE O
RARE O
the O
RARE O
period O
of O
the O
RARE O
organs O

Risk O
of O
infection O
in O
the O
treatment O
of O
RARE O

RARE O
RARE O
were O
perfused O
with O
solutions O
of O
NUM O
. O
9 O
% O
RARE O
C1 O
, O
NUM O
. O
1 O
N O
NUM O
, O
40 O
% O
glucose O
, O
40 O
% O
NUM O
, O
and O
40 O
% O
RARE O
or O
with O
NUM O
. O
1 O
% O
solutions O
of O
RARE O
RARE O
. O

Liver O
RARE O
of O
the O
RARE O
showed O
smaller O
than O
8 O
% O
of O
the O
RARE I-GENE
RARE I-GENE
activity O
and O
smaller O
than O
14 O
% O
of O
the O
RARE O
capacity O
of O
liver O
RARE O
from O
the O
rat O
. O

RARE O
heavy O
work O
RARE O
an O
increase O
of O
10 O
. O
3 O
RARE O
or O
minus O
NUM O
. O
9 O
mmHg O
in O
in O
vivo O
NUM O
( O
7 O
. O
NUM O
ALL_CAP O
- O
v O
, O
NUM O
degrees O
C O
- O
v O
, O
and O
NUM O
RARE O
- O
CO2 O
); O
due O
entirely O
to O
the O
additive O
effects O
of O
increased O
venous O
RARE O
and O
RARE O
H O
RARE O

A O
clinical O
, O
serological O
and O
prognostic O
study O

The O
American O
RARE O
RARE O
RARE O
: O
a O
progress O
report O
. O

RARE O
with O
an O
RARE O
instrument O
RARE O
. O

The O
metabolic O
clearance O
rate O
of O
progesterone O
was O
NUM O
+/- O
NUM O
( O
S O
. O
E O
.) O
1 O
/ O
day O
. O

This O
sequence O
is O
almost O
identical O
with O
that O
of O
human I-GENE
RARE I-GENE
hormone I-GENE
( O
RARE O
, O
M O
. O

The O
mean O
plasma O
RARE O
concentration O
which O
was O
135 O
. O
NUM O
(+/- O
SD O
4 O
. O
14 O
) O
mEq O
/ O
kg O
before O
diuretic O
treatment O
was O
significantly O
decreased O
RARE O
treatment O
to O
NUM O
. O
19 O
(+/- O
SD O
2 O
. O
77 O
) O
mEq O
/ O
kg O
, O
P O
less O
than O
NUM O
. O
001 O
. O

RARE O
: O
Low O
- O
dose O
RARE O
and O
the O
prevention O
of O
venous O
RARE O
RARE O
. O

At O
the O
very O
high O
dose O
levels O
used O
, O
RARE O
saccharin O
and O
RARE O
RARE O
were O
weak O
RARE O
RARE O
producing O
4 O
/ O
NUM O
and O
3 O
/ O
NUM O
bladder O
tumours O
respectively O
, O
and O
the O
RARE O
of O
these O
tumours O
did O
not O
appear O
RARE O
more O
than O
NUM O
weeks O
. O

Effects O
of O
RARE O
RARE O
on O
the O
RARE O
task O
performance O
of O
four O
- O
and O
RARE O
- O
year O
- O
old O
children O
. O

RARE I-GENE
- I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
( O
G I-GENE
- I-GENE
6 I-GENE
- I-GENE
ALL_CAP I-GENE
) O
deficiency O
in O
the O
newborn O
. O

The O
RARE O
solvent O
was O
RARE O
- O
RARE O
( O
10 O
+ O
NUM O
) O
RARE O
a O
flow O
rate O
of O
2 O
. O
NUM O
ml O
/ O
min O
. O

The O
bronchial O
RARE O
of O
all O
smoke O
- O
exposed O
animals O
were O
RARE O
, O
and O
their O
RARE O
showed O
RARE O
, O
tilt O
of O
nuclear O
RARE O
, O
an O
increase O
in O
the O
number O
and O
size O
of O
RARE O
and O
RARE O
RARE O
, O
and O
increased O
numbers O
of O
RARE O
RARE O
granules O
. O

The O
routine O
administration O
of O
fat O
- O
RARE O
RARE O
appears O
RARE O
but O
it O
is O
RARE O
to O
measure O
prothrombin I-GENE
time O
and O
serum O
RARE O
A O
and O
E O
RARE O
intervals O
. O

RARE O
F O
( O
ALL_CAP O
) O
were O
measured O
in O
RARE O
RARE O
, O
ovarian O
artery O
, O
and O
RARE O
RARE O
plasma O
and O
in O
the O
endometrial O
tissues O
RARE O
various O
times O
RARE O
the O
bovine O
RARE O
RARE O
, O
and O
were O
compared O
to O
peripheral O
plasma O
progesterone O
levels O
. O

RARE O
this O
date O
, O
the O
drug O
directly O
inhibits O
RARE O
RARE O
gain O
, O
whereas O
the O
sensitivity O
of O
the O
placenta O
is O
only O
transient O
RARE O
day O
16 O
resulting O
in O
maximum O
RARE O
decrease O
of O
this O
organ O
NUM O
h O
later O
. O

RARE O
of O
ten O
dependent O
and O
ten O
saline O
mice O
were O
RARE O
tested O
in O
both O
light O
and O
dark O
conditions O
in O
each O
of O
five O
RARE O
RARE O
( O
2 O
- O
NUM O
in O
high O
). O

The O
effects O
RARE O
from O
the O
nucleus O
RARE O
RARE O
were O
most O
marked O
. O

The O
appearance O
of O
RARE O
movement O
disorders O
in O
humans O
following O
the O
chronic O
use O
of O
RARE O
or O
amphetamine O
may O
be O
a O
manifestation O
of O
similarly O
increased O
dopamine I-GENE
receptor I-GENE
site I-GENE
sensitivity O
within O
the O
RARE O
. O

Association O
with O
ALL_CAP I-GENE
- I-GENE
A I-GENE
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
. O

Letter O
: O
RARE O
tolerance O
tests O
RARE O
a O
predictor O
of O
milk O
tolerance O
. O

RARE O
: O
a O
study O
of O
RARE O
history O
and O
prognosis O
of O
NUM O
cases O
. O

Like O
pineal O
melatonin O
, O
serum O
melatonin O
was O
high O
RARE O
mid O
- O
dark O
and O
low O
RARE O
mid O
- O
light O
. O

D O
. O

RARE O

The O
authors O
concluded O
that O
RARE O
Doppler O
- O
RARE O
can O
be O
used O
RARE O
measuring O
the O
relative O
changes O
in O
the O
stroke O
volume O
. O

The O
RARE O
of O
sexual O
RARE O
in O
terms O
of O
secondary O
sexual O
characteristics O
, O
the O
production O
of O
spermatozoa O
in O
the O
male O
, O
and O
the O
RARE O
female O
pattern O
with O
release O
of O
RARE O
are O
end O
- O
points O
of O
the O
developmental O
process O
. O

However O
, O
a O
10 O
RARE O
NUM O
% O
RARE O
of O
the O
partial O
thromboplastin I-GENE
time O
is O
evident O
after O
NUM O
hours O
of O
RARE O
. O

RARE O
should O
be O
RARE O
in O
the O
use O
of O
these O
RARE O
RARE O
RARE O
. O

This O
reveals O
a O
new O
test O
RARE O
short O
RARE O
RARE O
and O
shows O
that O
14 O
per O
cent O
of O
RARE O
RARE O
from O
a O
RARE O
reflux O
. O

Three O
groups O
of O
patients O
who O
had O
undergone O
subtotal O
RARE O
RARE O
RARE O
' O
s O
RARE O
, O
toxic O
RARE O
RARE O
, O
or O
RARE O
RARE O
RARE O
12 O
to O
NUM O
years O
before O
and O
in O
whom O
a O
normal O
serum O
thyroxine O
( O
T O
- O
4 O
) O
level O
was O
found O
were O
each O
divided O
into O
two O
subgroups O
on O
the O
basis O
of O
a O
normal O
or O
a O
raised O
serum O
RARE I-GENE
concentration O
. O

RARE O
RARE O
RARE O
using O
NUM O
Tc O
sulfur O
colloid O
RARE O
detection O
and O
follow O
- O
RARE O
of O
RARE O
- O
RARE O
reflux O

RARE O
ion O
action O
on O
bacteria O
. O

No O
evidence O
of O
either O
positive O
or O
negative O
RARE O
was O
found O
. O

The O
interpretation O
of O
antibiotic O
disc O
RARE O
. O

Following O
RARE O
, O
the O
affected O
RARE O
RARE O
appeared O
greatly O
RARE O
over O
the O
RARE O
RARE O
RARE O
, O
with O
almost O
RARE O
RARE O
of O
structural O
detail O
. O

A O
study O
of O
chromosomes O
of O
lymphocytes O
from O
patients O
treated O
with O
RARE O
. O

RARE O
of O
anesthesia O
and O
resuscitation O
in O
RARE O
RARE O
surgery O

Study O
of O
the O
RARE O
- O
chemical O
state O
of O
plutonium O
- O
239 O
in O
a O
RARE O
solution O
- O
RARE O
RARE O

RARE O
NUM O
mg O
did O
not O
show O
any O
remarkable O
effect O
, O
but O
RARE O
NUM O
mg O
produced O
a O
slight O
RARE O
effect O
on O
the O
action O
of O
d O
- O
RARE O
. O

In O
about O
one O
third O
of O
the O
cases O
this O
operation O
results O
in O
RARE O
and O
RARE O
improvement O
RARE O
patients O
suffering O
from O
progressive O
RARE O
RARE O
. O

The O
specific O
electrical O
resistance O
of O
the O
RARE O
RARE O
was O
measured O
by O
means O
of O
RARE O
in O
14 O
cases O
of O
meningitis O
RARE O
, O
NUM O
cases O
of O
meningitis O
RARE O
, O
10 O
cases O
of O
RARE O
and O
in O
NUM O
control O
subjects O
. O

2 O
- O
Chemical O
occlusion O
of O
vas O
is O
quite O
effective O
in O
producing O
a O
RARE O
in O
the O
vas O
deferens O
of O
dogs O
. O

RARE O
, O
we O
found O
in O
3 O
patients O
increased O
serum I-GENE
immunoglobulins I-GENE
, O
RARE O
IgG I-GENE
, O
RARE O
RARE O
RARE O
, O
RARE O
and O
RARE O
demonstrated O
in O
a O
large O
RARE O
- O
RARE O
family O
. O

We O
suggest O
that O
such O
RARE O
occurred O
RARE O
the O
time O
of O
the O
infarction O
. O

RARE O
preparation O
( O
ALL_CAP O
- O
NUM O
RARE O
a O
new O
type O
of O
anti O
- O
RARE O
agent O
, O
was O
given O
to O
the O
patients O
with O
advanced O
RARE O
in O
combination O
with O
RARE O
- O
C O
, O
5 O
- O
FU O
and O
RARE O
RARE O
. O

RARE O
, O
a O
correlation O
was O
observed O
between O
highest O
concentrations O
of O
CSF I-GENE
immunoglobulins I-GENE
and O
degree O
of O
RARE O
inflammatory O
response O
, O
even O
if O
this O
was O
a O
RARE O
of O
other O
neurological O
diseases O
. O

RARE O
RARE O

Experimental O
RARE O
of O
RARE O

RARE O
pathology O

RARE O
of O
the O
agent O
was O
performed O
from O
the O
NUM O
to O
the O
NUM O
day O
p O
. O
i O
. O
by O
direct O
microscopic O
methods O
( O
RARE O
and O
RARE O
staining O
, O
RARE O
antibody O
technique O
); O
the O
RARE O
content O
was O
determined O
by O
titration O
in O
RARE O
RARE O
' O
s O
eggs O
. O

The O
patients O
were O
divided O
into O
4 O
groups O
receiving O
ALL_CAP O
II O
with O
or O
without O
RARE O
, O
RARE O
or O
RARE O
. O

The O
alterations O
of O
5 O
- O
ALL_CAP O
and O
5 O
- O
ALL_CAP O
levels O
in O
several O
regions O
of O
the O
brain O
under O
the O
conditions O
examined O
may O
indicate O
that O
ALL_CAP O
' O
s O
neurotoxicity O
primarily O
affects O
5 O
- O
ALL_CAP O
- O
containing O
neurones O
. O

( O
5 O
) O
An O
increase O
in O
RARE O
- O
counts O
occurred O
on O
the O
administration O
of O
serum O
obtained O
from O
RARE O
RARE O
RARE O
- O
2 O
. O

The O
results O
obtained O
RARE O
to O
prove O
that O
the O
RARE O
RARE O
mainly O
RARE O
in O
RARE O
retention O
. O

In O
both O
cases O
, O
RARE O
the O
end O
of O
exposure O
the O
same O
level O
of O
RARE I-GENE
RARE I-GENE
( O
RARE I-GENE
) O
( O
about O
50 O
%) O
was O
reached O
. O

The O
results O
indicate O
that O
increased O
pulmonary O
RARE O
flow O
and O
decreased O
pulmonary O
vascular O
resistance O
with O
RARE O
gestation O
are O
due O
to O
an O
increase O
in O
the O
RARE O
number O
of O
vessels O
and O
increased O
RARE O
reactivity O
is O
related O
to O
an O
increase O
in O
the O
RARE O
amount O
of O
RARE O
muscle O
while O
the O
thickness O
of O
muscle O
in O
individual O
vessels O
remains O
constant O
. O

RARE O
in O
dosage O
restored O
normal O
taste O
sense O
in O
all O
three O
, O
but O
in O
two O
the O
drug O
had O
to O
be O
RARE O
because O
of O
RARE O
high O
RARE O
levels O
. O

The O
RARE O
ratio O
( O
mean O
ratio O
of O
the O
predicted O
to O
measured O
RARE O
) O
in O
men O
was O
1 O
. O
NUM O
+/- O
7 O
. O
8 O
% O
and O
in O
women O
NUM O
. O
NUM O
+/- O
7 O
. O
1 O
%. O

A O
RARE O
diagnosis O
of O
RARE O
is O
an O
RARE O
fact O
that O
allows O
its O
growth O
and O
leads O
to O
a O
deterioration O
in O
the O
RARE O
. O

Total O
cholesterol O
was O
measured O
in O
RARE O
fluids O
collected O
RARE O
different O
stages O
of O
gestation O
. O

RARE O
serum O
NUM O
concentration O
was O
, O
however O
, O
much O
RARE O
than O
the O
RARE O
in O
normal O
RARE O
or O
in O
ALL_CAP O
patients O
without O
clinical O
RARE O
. O

The O
authors O
found O
that O
except O
RARE O
RARE O
and O
RARE O
all O
RARE O
- O
RARE O
RARE O
correlations O
were O
positive O
, O
in O
contrast O
to O
RARE O
' O
s O
RARE O
of O
type O
I O
RARE O
. O

A O
RARE O
on O
the O
RARE O
- O
RARE O
technique O
RARE O
of O
cardiac O
action O
potentials O
. O

3 O
activities O
of O
the O
factor I-GENE
II I-GENE
molecule O
in O
the O
newborn O
infant O
RARE O
term O

The O
concept O
of O
" O
structural O
RARE O
" O
is O
employed O
in O
this O
analysis O
to O
determine O
which O
model O
parameters O
can O
be O
and O
which O
cannot O
be O
determined O
" O
RARE O
" O
from O
given O
input O
- O
output O
data O
; O
a O
step O
- O
by O
- O
step O
procedure O
based O
on O
an O
extension O
of O
this O
concept O
is O
presented O
RARE O
adapting O
the O
overall O
approach O
to O
the O
experimental O
design O
problem O
. O

However O
, O
we O
did O
detect O
RARE O
- O
to O
- O
RARE O
variation O
and O
differences O
in O
performance O
between O
narrow O
RARE O
and O
wide O
RARE O
RARE O
. O

The O
cochlear O
RARE O
. O

A O
case O
observed O
in O
RARE O

RARE O
glucose O
administered O
RARE O
in O
RARE O
RARE O
dogs O
resulted O
in O
an O
equal O
inhibition O
of O
RARE O
- O
RARE O
acid O
RARE O
from O
the O
RARE O
and O
the O
main O
stomach O
, O
whereas O
RARE O
saline O
had O
RARE O
effect O
. O

RARE O
factor I-GENE
VIII I-GENE
inhibitor O
in O
non O
- O
RARE O
patients O

RARE O
of O
RARE O
acid O
into O
RARE O
acid O
was O
observed O
. O

The O
study O
of O
RARE O
metabolism O
in O
ten O
RARE O
children O
RARE O
with O
controls O
after O
oral O
administration O
of O
NUM O
has O
shown O
diminished O
RARE O
absorption O
. O

RARE O
agents O
were O
isolated O
from O
the O
semen O
near O
the O
end O
of O
the O
RARE O
RARE O
. O

Because O
of O
the O
increased O
CPK I-GENE
activity O
found O
in O
normal O
newborns O
, O
screening O
RARE O
RARE O
- O
type O
muscular O
RARE O
should O
be O
RARE O
RARE O
a O
few O
weeks O
after O
delivery O
. O

In O
contrast O
, O
the O
insulin I-GENE
response O
had O
returned O
to O
the O
non O
- O
RARE O
value O
by O
the O
second O
day O
of O
the O
RARE O
. O

The O
authors O
report O
the O
results O
of O
a O
series O
of O
toxicological O
tests O
conducted O
on O
RARE O
materials O
( O
RARE O
) O
activated O
with O
RARE O
( O
ALL_CAP O
) O
an O
additive O
recently O
proposed O
RARE O
a O
RARE O
capable O
of O
RARE O
RARE O
materials O
. O

Mutational O
analysis O
of O
the O
major O
homology O
region O
of O
RARE O
- O
RARE O
RARE O
virus O
by O
use O
of O
saturation O
mutagenesis O
. O

One O
site O
, O
ALL_CAP I-GENE
, O
occurs O
within O
the O
10 O
bp O
sequence O
ALL_CAP O
. O

Nuclear O
extracts O
prepared O
from O
both O
RARE O
and O
non O
- O
RARE O
cell O
lines O
, O
mouse O
brain O
, O
and O
mouse O
liver O
contain O
proteins O
that O
recognize O
and O
bind O
to O
the O
ALL_CAP O
and O
ALL_CAP O
sequences O
indicating O
that O
proteins O
which O
bind O
to O
these O
target O
sequences O
are O
RARE O
. O

To O
determine O
if O
the O
ALL_CAP I-GENE
( I-GENE
H I-GENE
) I-GENE
promoter I-GENE
can O
be O
activated O
in O
a O
tissue O
specific O
manner O
RARE O
development O
transgenic O
mice O
containing O
the O
promoter O
region O
RARE O
to O
a O
beta I-GENE
- I-GENE
galactosidase I-GENE
reporter I-GENE
gene I-GENE
were O
generated O
. O

Here O
we O
describe O
and O
map O
two O
more O
new O
genes O
identified O
RARE O
allele O
- O
specific O
suppressors O
that O
RARE O
RARE O
RARE O
- O
terminal O
RARE O
of O
NUM I-GENE
. O

Previous O
studies O
have O
shown O
RARE O
RARE O
, O
S O
., O
RARE O
, O
M O
., O
RARE O
, O
E O
. O
& O
RARE O
, O
T O
. O

Treatment O
and O
staining O
of O
smears O
and O
sections O
RARE O
detection O
of O
RARE O

The O
apparent O
RARE O
of O
the O
ALL_CAP I-GENE
/ I-GENE
ALL_CAP I-GENE
operator I-GENE
complex I-GENE
is O
one O
order O
magnitude O
RARE O
than O
that O
of O
the O
ALL_CAP I-GENE
/ I-GENE
ALL_CAP I-GENE
operator I-GENE
complex I-GENE
. O

A O
significant O
direct O
relationship O
was O
observed O
between O
the O
percent O
area O
density O
of O
RARE O
muscle O
and O
the O
percent O
change O
in O
peak O
RARE O
flow O
rate O
. O

RARE I-GENE
skeletal I-GENE
muscle I-GENE
RARE I-GENE
. O

Characterization O
of O
the O
human I-GENE
gene I-GENE
encoding I-GENE
RARE I-GENE
NUM I-GENE
and O
its O
RARE O
pattern O
. O

Animals O
that O
received O
ALL_CAP O
- O
4 O
were O
significantly O
retarded O
in O
motor O
recovery O
compared O
with O
the O
saline O
group O
. O

The O
prophylactic O
use O
of O
new O
medication O
RARE O
patients O
between O
the O
RARE O
and O
second O
RARE O
of O
chemotherapy O
, O
in O
agreement O
with O
the O
estimates O
calculated O
, O
does O
not O
RARE O
health O
care O
costs O
but O
may O
improve O
the O
quality O
of O
life O
in O
these O
patients O
and O
permit O
the O
RARE O
of O
a O
therapeutic O
schedule O
without O
RARE O
which O
may O
improve O
the O
life O
RARE O
of O
the O
patient O
. O

AP O
was O
RARE O
by O
RARE O
infusion O
of O
two O
different O
concentrations O
of O
RARE O
acid O
( O
ALL_CAP O
NUM O
mmol O
and O
NUM O
mmol O
). O

The O
isolation O
of O
this O
gene O
was O
based O
on O
the O
identification O
of O
the O
Y O
- O
231 O
cosmid O
that O
contains O
CpG O
rich O
sequences O
( O
ALL_CAP O
RARE O
) O
in O
its O
human O
insert O
. O

RARE I-GENE
plasminogen I-GENE
activator I-GENE
, O
its O
inhibitor O
and O
other O
parameters O
of O
RARE O
in O
RARE O
of O
patients O
operated O
RARE O
mild O
hypertrophy O
of O
the O
RARE O

RARE O
constructs O
consisting O
of O
human I-GENE
growth I-GENE
hormone I-GENE
( O
hGH I-GENE
) O
gene O
RARE O
by O
promoter O
/ O
regulatory O
sequence O
of O
mouse I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
RARE O
viral I-GENE
RARE I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
RARE O
rat I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
RARE O
or O
chicken I-GENE
beta I-GENE
- I-GENE
actin I-GENE
( O
ALL_CAP I-GENE
) O
gene O
were O
injected O
into O
the O
cytoplasm O
of O
RARE O
RARE O
eggs O
via O
the O
RARE O
. O

Serum O
gastrin I-GENE
and O
ALL_CAP I-GENE
levels O
had O
the O
same O
evolution O
and O
appear O
to O
have O
the O
same O
interest O
to O
follow O
the O
course O
of O
the O
RARE O
. O

RARE O
RARE O
RARE O
- O
delivery O
RARE O
. O

The O
mean O
(+/- O
SD O
) O
PaO2 O
increased O
from O
NUM O
. O
8 O
+/- O
NUM O
. O
9 O
mmHg O
before O
to O
NUM O
. O
8 O
+/- O
NUM O
. O
3 O
mmHg O
after O
the O
infusion O
( O
P O
< O
NUM O
. O
05 O
) O
and O
the O
PaCO2 O
decreased O
from O
NUM O
. O
4 O
+/- O
8 O
. O
3 O
to O
NUM O
. O
6 O
+/- O
7 O
. O
9 O
mmHg O
( O
P O
< O
NUM O
. O
05 O
). O

RARE O
RARE O
and O
mild O
elevation O
of O
RARE O
can O
be O
observed O
in O
a O
significant O
proportion O
of O
patients O
, O
involvement O
of O
liver O
leading O
to O
acute O
hepatitis O
or O
liver O
cell O
necrosis O
is O
a O
relatively O
RARE O
complication O
in O
P O
. O
falciparum O
malaria O
. O

For O
the O
RARE O
group O
, O
the O
maximal O
decrease O
in O
plasma O
RARE O
elicited O
by O
RARE O
was O
NUM O
. O
NUM O
+/- O
NUM O
. O
19 O
, O
NUM O
. O
NUM O
+/- O
NUM O
. O
NUM O
, O
and O
NUM O
. O
NUM O
+/- O
NUM O
. O
NUM O
mmol O
/ O
RARE O
, O
and O
RARE O
the O
second O
group O
, O
maximal O
RARE O
was O
1 O
. O
NUM O
+/- O
NUM O
. O
37 O
, O
NUM O
. O
70 O
+/- O
NUM O
. O
NUM O
, O
and O
NUM O
. O
NUM O
+/- O
NUM O
. O
NUM O
mmol O
/ O
RARE O
RARE O
the O
iv O
, O
RARE O
, O
and O
it O
routes O
, O
respectively O
. O

The O
two O
drugs O
increase O
the O
rate O
of O
early O
diastolic O
filling O
. O

A O
statistically O
significant O
improvement O
due O
to O
the O
administration O
of O
RARE O
was O
observed O
in O
symptoms O
associated O
with O
RARE O
to O
normal O
prolactin I-GENE
levels O
, O
i O
. O
RARE O
. O
abdominal O
tension O
, O
edema O
, O
RARE O
gain O
and O
breast O
RARE O
. O

The O
magnitude O
of O
the O
early O
response O
was O
NUM O
+/- O
NUM O
% O
in O
A O
RARE O
baseline O
ALL_CAP O
; O
mean O
+/- O
SE O
RARE O
and O
significantly O
less O
in O
B O
( O
119 O
+/- O
7 O
%) O
and O
C O
( O
NUM O
+/- O
16 O
%) O
( O
p O
< O
NUM O
. O
01 O
). O

Most O
of O
the O
patients O
presented O
with O
Transient O
Ischemic O
RARE O
( O
NUM O
%) O
or O
RARE O
Ischemic O
RARE O
RARE O
( O
19 O
%). O

We O
RARE O
the O
third O
human O
gene O
RARE O
the O
NUM I-GENE
, O
termed O
NUM I-GENE
gamma I-GENE
and O
the O
sequence O
analysis O
showed O
that O
it O
is O
a O
5 O
'- O
truncated O
RARE O
. O

This O
analysis O
, O
together O
with O
a O
RARE O
of O
the O
RARE O
found O
upstream O
of O
known O
SWI4 I-GENE
, I-GENE
6 I-GENE
- O
dependent O
genes O
, O
leads O
to O
the O
RARE O
of O
a O
revised O
consensus O
sequence O
RARE O
this O
important O
regulatory O
element O
. O

Mutational O
analysis O
of O
a O
DNA O
sequence O
involved O
in O
linking O
gene O
RARE O
to O
the O
cell O
RARE O
. O

The O
RARE O
history O
of O
these O
lesions O
, O
RARE O
efficiency O
of O
the O
different O
treatments O
used O
, O
the O
part O
played O
by O
chemotherapy O
, O
survival O
, O
causes O
of O
RARE O
and O
therapeutic O
modalities O
used O
RARE O
a O
last O
measure O
, O
have O
been O
analysed O
. O

The O
method O
was O
adapted O
RARE O
the O
determination O
of O
RARE O
RARE O
A O
by O
a O
change O
in O
mobile O
RARE O
composition O
. O

In O
RARE O
, O
however O
, O
this O
study O
provided O
little O
evidence O
of O
any O
effect O
of O
supplementation O
to O
RARE O
performance O
RARE O
RARE O
RARE O
the O
dietary O
RARE O
. O

In O
the O
absence O
of O
histological O
criteria O
, O
which O
it O
is O
difficult O
to O
demand O
in O
view O
of O
the O
variability O
of O
results O
and O
RARE O
RARE O
of O
RARE O
biopsy O
involving O
such O
thin O
and O
RARE O
ventricular O
RARE O
, O
the O
diagnosis O
of O
ALL_CAP O
is O
based O
upon O
the O
concomitant O
existence O
of O
: O
( O
1 O
) O
RARE O
criteria O
: O
ventricular O
arrhythmias O
, O
in O
particular O
sustained O
RARE O
VT O
, O
with O
the O
particular O
feature O
of O
a O
very O
high O
degree O
of O
sensitivity O
to O
adrenergic O
RARE O
( O
exercise O
RARE O
the O
existence O
of O
RARE O
potentials O
on O
the O
high O
amplification O
ECG O
, O
a O
highly O
specific O
sign O
, O
though O
RARE O
of O
poor O
sensitivity O
in O
localized O
RARE O
, O
those O
which O
are O
most O
difficult O
to O
identify O
( O
2 O
); O
RARE O
morphological O
and O
kinetic O
RV O
abnormalities O
, O
most O
often O
resulting O
in O
localized O
RARE O
or O
RARE O
RARE O
RARE O
, O
with O
RARE O
" O
in O
situ O
". O

In O
7 O
of O
9 O
cases O
, O
the O
enhancer O
is O
fused O
to O
the O
c I-GENE
- I-GENE
myc I-GENE
RARE I-GENE
sequences I-GENE
of O
RARE O
8 O
. O

These O
RARE O
both O
had O
a O
median O
NUM O
of O
NUM O
. O
NUM O
, O
compared O
to O
median O
NUM O
ranging O
from O
NUM O
. O
37 O
to O
NUM O
. O
NUM O
RARE O
five O
commonly O
used O
RARE O
RARE O
EEG O
RARE O
. O

The O
obtained O
results O
were O
compared O
with O
control O
group O
( O
10 O
female O
volunteers O
). O

NUM O
years O
of O
RARE O
RARE O
the O
RARE O
RARE O
University O
in O
RARE O

The O
target O
contained O
between O
positions O
- O
NUM O
and O
- O
NUM O
acts O
independently O
of O
orientation O
, O
in O
different O
cell O
RARE O
and O
species O
, O
and O
in O
the O
context O
of O
a O
heterologous O
promoter O
. O

NUM O
: O
NUM O
- O
NUM O
, O
1992 O
). O

RARE O
RARE O
of O
the O
NUM I-GENE
promoter I-GENE
by O
the O
Z I-GENE
/ O
c I-GENE
- I-GENE
myb I-GENE
combination O
appears O
to O
involve O
direct O
binding O
by O
the O
Z I-GENE
protein I-GENE
but O
not O
the O
c I-GENE
- I-GENE
myb I-GENE
protein I-GENE
. O

The O
ALL_CAP O
core O
sequence O
, O
ALL_CAP O
, O
binds O
a O
ubiquitous O
nuclear O
factor O
and O
mediates O
negative O
RARE O
of O
MuLV O
promoter O
activity O
. O

These O
studies O
show O
that O
ALL_CAP I-GENE
binds O
to O
various O
target O
motifs O
that O
are O
distinct O
from O
the O
ALL_CAP O
motif O
: O
the O
RARE I-GENE
- I-GENE
associated I-GENE
virus I-GENE
NUM I-GENE
promoter I-GENE
and O
elements O
in O
the O
immunoglobulin I-GENE
light I-GENE
- I-GENE
and I-GENE
heavy I-GENE
- I-GENE
chain I-GENE
genes O
, O
RARE O
RARE O
RARE O
elements O
in O
ribosomal I-GENE
protein I-GENE
genes I-GENE
. O

RARE O
, O
the O
NUM I-GENE
- I-GENE
1 I-GENE
mutation I-GENE
does O
not O
affect O
signal O
recognition O
or O
translational O
arrest O
but O
instead O
results O
in O
RARE O
of O
translational O
arrest O
of O
ALL_CAP I-GENE
RARE O
. O

The O
cellular O
sequences O
5 O
' O
to O
the O
viral O
RARE O
site O
exhibited O
NUM O
to O
97 O
% O
identity O
to O
several O
sequences O
belonging O
to O
the O
mouse I-GENE
L1 I-GENE
family I-GENE
of O
long O
interspersed O
RARE O
sequences O
. O

Both O
NUM I-GENE
and O
NUM I-GENE
cut O
the O
terminal O
ALL_CAP O
sequence O
RARE O
the O
same O
site O
( O
nucleotide O
NUM O
). O

Nucleotide O
sequence O
analysis O
revealed O
that O
ALL_CAP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
is O
very O
similar O
to O
the O
NUM I-GENE
protein I-GENE
. O

These O
results O
indicate O
that O
both O
N O
- O
and O
C O
- O
terminal O
mutations O
are O
required O
to O
inhibit O
RARE O
by O
ALL_CAP I-GENE
protein I-GENE
and O
that O
multiple O
structural O
mutations O
accompanied O
by O
posttranslational O
protein O
modification O
alter O
gene O
RARE O
by O
ALL_CAP I-GENE
protein I-GENE
. O

The O
NUM O
mutation O
changes O
NUM O
in O
NUM O
. O
7 O
to O
an O
RARE O
RARE O
, O
which O
RARE O
the O
production O
of O
the O
truncated O
, O
NUM I-GENE
- I-GENE
kDa I-GENE
NUM I-GENE
. I-GENE
7 I-GENE
- I-GENE
related I-GENE
polypeptide I-GENE
, O
and O
RARE O
the O
11 O
- O
kDa O
C O
- O
terminal O
domain O
in O
RARE O
transcription O
RARE O
- O
off O
. O

A O
patient O
suffering O
from O
RARE O
- O
associated O
thrombocytopenia O
( O
ALL_CAP O
RARE O
recurrent O
RARE O
, O
and O
acute O
RARE O
failure O
after O
treatment O
with O
standard O
RARE O
is O
described O
. O

The O
predicted O
receptor O
RARE O
includes O
a O
cysteine O
- O
rich O
extracellular O
domain O
, O
a O
single O
hydrophobic O
transmembrane O
domain O
, O
and O
a O
predicted O
cytoplasmic I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
domain I-GENE
. O

Drosophila I-GENE
NUM I-GENE
encodes O
a O
highly O
RARE O
ubiquitin I-GENE
- O
RARE O
enzyme O
involved O
in O
selective O
protein O
RARE O
. O

Analysis O
of O
the O
RARE O
16 O
. O
7 O
- O
kb O
RARE O
genome O
determined O
that O
a O
NUM I-GENE
mediates O
RARE O
of O
RARE O
ALL_CAP O
in O
vitro O
RARE O
three O
H O
- O
and O
two O
L O
- O
RARE O
sequence O
- O
specific O
target O
sites O
RARE O
within O
a O
NUM O
- O
bp O
A O
+ O
T O
- O
rich O
genomic O
RARE O
, O
RARE O
capable O
of O
forming O
stable O
secondary O
RARE O
, O
RARE O
NUM O
bases O
upstream O
from O
the O
H O
- O
RARE O
origin O
( O
OH O
) O
of O
replication O
. O

The O
goal O
of O
the O
present O
study O
was O
to O
determine O
the O
feasibility O
of O
RARE O
RARE O
RARE O
of O
NUM I-GENE
in O
the O
NUM O
and O
U937 O
human O
hematopoietic O
cell O
lines O
, O
and O
in O
an O
Epstein O
- O
Barr O
virus O
transformed O
B O
- O
lymphocyte O
cell O
line O
( O
ALL_CAP O
- O
ALL_CAP O
) O
derived O
from O
a O
NUM I-GENE
- O
RARE O
ALL_CAP O
patient O
. O

Comparison O
with O
the O
sequence O
RARE O
show O
that O
RARE I-GENE
is O
a O
RARE O
of O
the O
immunoglobulin I-GENE
gene I-GENE
superfamily I-GENE
, O
with O
RARE O
to O
Drosophila I-GENE
RARE I-GENE
, O
the O
RARE I-GENE
RARE I-GENE
ALL_CAP I-GENE
- I-GENE
18 I-GENE
, O
members O
of O
the O
RARE I-GENE
RARE I-GENE
family I-GENE
, O
the O
RARE I-GENE
receptor I-GENE
, O
and O
the O
RARE I-GENE
cell I-GENE
adhesion I-GENE
molecule I-GENE
. O

A O
rather O
similar O
pattern O
of O
results O
was O
obtained O
with O
respect O
to O
NUM I-GENE
mRNA I-GENE
RARE O
, O
such O
transcripts O
being O
detectable O
only O
in O
a O
subset O
of O
tumors O
, O
and O
then O
RARE O
apparently O
low O
levels O
. O

The O
RARE O
of O
the O
NUM I-GENE
nonsense O
mutants O
were O
RARE O
between O
those O
of O
the O
wild O
- O
type O
virus O
and O
NUM O
in O
that O
the O
more O
NUM I-GENE
- I-GENE
coding I-GENE
sequence I-GENE
RARE O
by O
a O
given O
nonsense O
mutant O
, O
the O
more O
wild O
type O
- O
like O
was O
its O
RARE O
. O

Analysis O
of O
nucleotide O
sequence O
of O
the O
RARE O
NUM O
RARE O
of O
RARE O
RARE O
( O
HVS O
) O
L O
- O
DNA O
: O
RARE O
conservation O
of O
genetic O
organization O
between O
HVS O
and O
Epstein O
- O
Barr O
virus O
. O

Treatment O
with O
MK O
- O
801 O
RARE O
a O
burst O
suppression O
in O
the O
EEG O
and O
a O
transient O
drop O
( O
11 O
. O
4 O
+/- O
6 O
. O
5 O
mm O
Hg O
) O
in O
the O
mean O
arterial O
pressure O
. O

In O
contrast O
, O
gel O
mobility O
shift O
experiments O
have O
failed O
to O
reveal O
that O
NUM I-GENE
or O
NUM I-GENE
binds O
to O
domain O
1 O
or O
that O
NUM I-GENE
mutations O
affect O
the O
complexes O
RARE O
to O
it O
. O

RARE O
differentiation O
can O
be O
inhibited O
by O
the O
adenovirus O
E1a I-GENE
protein I-GENE
in O
the O
rat O
NUM O
muscle O
cell O
line O
. O

The O
experiment O
results O
showed O
: O
( O
i O
) O
not O
only O
NUM O
, O
but O
also O
free O
radicals O
( O
NUM O
-. O
. O
OH O
and O
YHPD O
RARE O
can O
be O
formed O
by O
the O
aid O
of O
YHPD O
; O
and O
( O
ii O
) O
RARE O
to O
the O
ability O
of O
producing O
NUM O
, O
YHPD O
less O
than O
ALL_CAP O
, O
while O
RARE O
generating O
NUM O
-. O
and O
. O
OH O
, O
YHPD O
greater O
than O
ALL_CAP O
. O

Two O
points O
are O
indicated O
: O
RARE O
, O
the O
RARE O
damage O
of O
YHPD O
is O
RARE O
to O
not O
only O
NUM O
, O
but O
also O
free O
radicals O
( O
NUM O
-. O
. O
OH O
and O
YHPD O
RARE O
second O
, O
although O
the O
RARE O
damage O
of O
YHPD O
is O
stronger O
than O
that O
of O
ALL_CAP O
, O
yet O
the O
RARE O
damage O
is O
negatively O
correlated O
to O
the O
yield O
of O
NUM O
but O
positively O
correlated O
to O
those O
of O
NUM O
-. O
and O
OH O
. O

RARE O
. O

Both O
in O
vitro O
- O
synthesized O
NUM I-GENE
protein I-GENE
and O
RARE O
peptides O
corresponding O
to O
NUM I-GENE
are O
shown O
to O
RARE O
positively O
with O
RARE O
obtained O
from O
ALL_CAP O
- O
RARE O
horses O
, O
providing O
the O
RARE O
direct O
evidence O
of O
RARE O
of O
this O
protein O
in O
RARE O
animals O
. O

Many O
canonical O
TATA O
sequences O
are O
present O
upstream O
from O
these O
ALL_CAP O
transcriptional O
RARE O
sites O
but O
, O
apparently O
, O
are O
not O
used O
. O

The O
ORF O
4 O
gene O
was O
RARE O
RARE O
, O
whereas O
the O
ORF O
NUM O
gene O
gave O
twofold O
induction O
; O
both O
genes O
, O
acting O
together O
, O
gave O
RARE O
induction O
. O

Interestingly O
, O
the O
NUM I-GENE
ORF I-GENE
of O
ALL_CAP O
- O
1 O
possesses O
a O
sequence O
of O
NUM O
amino O
RARE O
( O
ALL_CAP O
) O
that O
is O
a O
perfect O
match O
to O
the O
consensus O
zinc O
finger O
motif O
( O
C O
- O
X2 O
- O
4 O
- O
C O
- O
X2 O
- O
NUM O
- O
C O
/ O
H O
- O
X2 O
- O
4 O
- O
C O
/ O
H O
). O

The O
DNA O
sequence O
of O
the O
RARE I-GENE
activation I-GENE
locus I-GENE
from O
Escherichia O
coli O
K O
- O
12 O
has O
been O
determined O
. O

The O
RARE O
form O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
is O
designated O
ALL_CAP O
, O
whereas O
the O
RARE O
form O
is O
designated O
ALL_CAP O
. O

RNA I-GENE
polymerase I-GENE
ALL_CAP I-GENE
was O
recovered O
in O
transcriptionally O
RARE O
complexes O
in O
reactions O
in O
which O
the O
input O
enzyme O
was O
RNA I-GENE
polymerase I-GENE
ALL_CAP I-GENE
. O

RARE I-GENE
activity O
is O
elevated O
RARE O
to O
twofold O
when O
Z O
. O
RARE O
was O
grown O
on O
RARE O
instead O
of O
glucose O
, O
and O
there O
was O
a O
parallel O
increase O
in O
RARE I-GENE
mRNA I-GENE
levels O
. O

Plasma O
membranes O
of O
cultured O
cells O
contain O
high O
affinity O
receptors O
RARE O
high I-GENE
density I-GENE
lipoprotein I-GENE
( O
ALL_CAP I-GENE
) O
that O
appear O
to O
mediate O
removal O
of O
excess O
RARE O
cholesterol O
. O

After O
the O
RARE O
NUM O
patients O
vincristine O
was O
replaced O
by O
RARE O
( O
ALL_CAP O
- O
NUM O
) O
due O
to O
neurotoxicity O
. O

These O
results O
indicate O
that O
an O
internal O
short O
element O
RARE O
RARE O
the O
very O
5 O
' O
terminal O
of O
L1 I-GENE
sequence I-GENE
and O
the O
nuclear O
factor O
binding O
to O
the O
element O
play O
a O
crucial O
role O
in O
the O
transcription O
of O
human I-GENE
L1 I-GENE
. O

RARE O
cells O
were O
RARE O
RARE O
RARE O
RARE I-GENE
- I-GENE
specific I-GENE
RARE I-GENE
, O
insulin I-GENE
, O
glucagon I-GENE
and O
ALL_CAP I-GENE
. O

A O
recombinant O
with O
a O
5 O
' O
end O
from O
src I-GENE
and O
a O
3 O
' O
end O
from O
RARE I-GENE
, O
called O
SRC I-GENE
RARE O
ALL_CAP I-GENE
, O
transformed O
chicken O
RARE O
RARE O
( O
ALL_CAP O
) O
to O
a O
RARE O
shape O
morphology O
, O
RARE O
that O
of O
NUM I-GENE
. O

ALL_CAP I-GENE
RARE O
SRC I-GENE
( O
R I-GENE
) O
contains O
a O
16 O
- O
amino O
- O
acid O
deletion O
that O
includes O
the O
3 O
' O
RARE O
of O
the O
transmembrane O
domain O
of O
RARE I-GENE
. O

To O
define O
the O
number O
and O
nature O
of O
the O
NUM I-GENE
and O
E7 I-GENE
gene I-GENE
products O
RARE O
in O
ALL_CAP O
- O
1 O
- O
transformed O
cells O
, O
we O
performed O
immunoprecipitation O
experiments O
with O
antisera O
raised O
to O
bacterially O
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
NUM I-GENE
and O
E7 I-GENE
fusion I-GENE
proteins I-GENE
. O

Transient O
transfection O
assays O
showed O
that O
site O
A O
is O
necessary O
and O
sufficient O
RARE O
RXR I-GENE
alpha I-GENE
- O
RARE O
RARE O
of O
the O
ALL_CAP I-GENE
gene I-GENE
basal I-GENE
promoter I-GENE
in O
human O
hepatoma O
NUM O
cells O
in O
the O
presence O
of O
ALL_CAP O
and O
that O
this O
RARE O
is O
abolished O
by O
increasing O
amounts O
of O
cotransfected O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
. O

The O
enhancer O
region O
of O
RARE O
murine O
leukemia O
virus O
contains O
the O
sequence O
motif O
ALL_CAP O
. O

Two O
RARE O
variants O
of O
NUM I-GENE
cDNA I-GENE
have O
been O
found O
, O
RARE O
by O
a O
72 O
- O
bp O
RARE O
, O
coding O
RARE O
putative O
proteins O
of O
NUM O
and O
NUM O
amino O
RARE O
. O

A O
third O
prominent O
RARE O
of O
apparent O
RARE O
mass O
16 O
kDa O
displayed O
several O
properties O
, O
including O
ability O
to O
bind O
NUM O
RARE O
that O
are O
characteristic O
of O
the O
regulatory O
( O
B O
) O
subunit O
of O
mammalian I-GENE
RARE I-GENE
and O
was O
RARE O
by O
an O
RARE O
raised O
against O
bovine I-GENE
RARE I-GENE
. O

As O
was O
observed O
previously O
RARE O
RARE I-GENE
NUM I-GENE
NUM I-GENE
double O
mutants O
, O
RARE I-GENE
NUM I-GENE
mutants I-GENE
were O
RARE O
in O
their O
ability O
to O
RARE O
from O
alpha I-GENE
- I-GENE
factor I-GENE
- O
RARE O
growth O
arrest O
. O

Antibodies O
against O
this O
RARE O
protein O
localize O
NUM I-GENE
to O
RARE O
. O

METHODS O
: O
IgG I-GENE
antibodies I-GENE
RARE O
ALL_CAP O
- O
6 O
( O
anti I-GENE
- I-GENE
ALL_CAP I-GENE
- I-GENE
6 I-GENE
- I-GENE
IgG I-GENE
) O
were O
determined O
by O
indirect O
immunofluorescence O
in O
NUM O
ALL_CAP O
( O
29 O
RARE O
and O
NUM O
seropositive O
RARE O
HIV O
- O
1 O
of O
which O
NUM O
were O
in O
RARE O
II O
and O
NUM O
in O
IV O
- O
C1 O
of O
ALL_CAP O
) O
RARE O
RARE O
RARE O
in O
NUM O
healthy O
subjects O
of O
a O
similar O
age O
( O
control O
group O
). O

A O
position O
- O
independent O
activation O
domain O
which O
contained O
RARE O
regions O
II O
and O
III O
was O
identified O
RARE O
the O
RARE O
terminus O
of O
the O
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
protein I-GENE
( O
amino O
RARE O
NUM O
to O
NUM O
). O

HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
amino I-GENE
- I-GENE
terminal I-GENE
sequences I-GENE
defined O
by O
RARE O
region O
IV O
also O
contributed O
to O
RARE O
, O
but O
region O
IV O
activity O
required O
the O
participation O
of O
the O
region O
II O
- O
III O
domain O
. O

RARE O
roles O
of O
NUM I-GENE
putative O
ATPase I-GENE
/ O
DNA I-GENE
RARE I-GENE
activity O
in O
DNA O
repair O
and O
in O
the O
RARE O
of O
wild O
- O
type O
rates O
of O
RARE O
of O
simple O
RARE O
sequences O
are O
discussed O
. O

RARE O
of O
NUM O
anaerobic O
gram O
- O
negative O
bacilli O
to O
amoxicillin O
, O
amoxicillin O
- O
ALL_CAP O
NUM O
, O
amoxicillin O
- O
RARE O
, O
RARE O
, O
and O
clindamycin O
. O

RARE O
arrest O
of O
NUM O
cells O
was O
RARE O
RARE O
the O
detection O
of O
an O
M O
- O
RARE O
- O
activated O
MBP I-GENE
kinase I-GENE
that O
was O
resolved O
from O
NUM I-GENE
MAP I-GENE
kinase I-GENE
by O
RARE O
- O
RARE O
chromatography O
. O

The O
NUM I-GENE
- I-GENE
1 I-GENE
mutation O
caused O
a O
defect O
in O
RARE O
of O
a O
NUM I-GENE
- I-GENE
ALL_CAP I-GENE
heat I-GENE
shock I-GENE
protein I-GENE
. O

The O
NUM O
RARE O
RARE O
region O
immediately O
upstream O
of O
the O
ALL_CAP O
site O
is O
characterized O
by O
the O
lack O
of O
a O
proximal O
TATA O
box O
and O
the O
presence O
of O
sequences O
similar O
to O
ALL_CAP O
RARE O
, O
ALL_CAP O
RARE O
, O
CCAAT O
RARE O
, O
activator I-GENE
protein I-GENE
2 I-GENE
( O
RARE I-GENE
- I-GENE
2 I-GENE
) O
sites O
, O
partial O
glucocorticoid O
response O
elements O
( O
RARE O
RARE O
and O
partial O
cyclic O
AMP O
response O
elements O
( O
RARE O
). O

Cloning O
and O
RARE O
RARE O
of O
RARE O
, O
a O
developmentally O
regulated O
, O
RARE O
RARE O
RARE O
RARE O
of O
brain O
. O

In O
rats O
RARE O
with O
RARE O
RARE O
the O
changes O
in O
extracellular O
pH O
and O
K O
+ O
in O
RARE O
cord O
dorsal O
RARE O
were O
studied O
using O
pH O
and O
K O
+ O
ion O
- O
selective O
electrodes O
. O

RARE O
of O
bovine O
RARE O
- O
1 O
( O
ALL_CAP O
- O
1 O
) O
DNA O
requires O
two O
viral O
gene O
products O
, O
the O
E1 I-GENE
protein I-GENE
and O
the O
full I-GENE
- I-GENE
length I-GENE
E2 I-GENE
protein I-GENE
. O

RARE O
inactivation O
of O
RARE I-GENE
led O
to O
increased O
sensitivity O
to O
the O
RARE O
agent O
RARE O
RARE O
, O
but O
not O
to O
a O
requirement O
RARE O
serine O
or O
other O
metabolites O
. O

These O
findings O
suggest O
that O
the O
MAP I-GENE
kinase I-GENE
activator I-GENE
/ O
MAP I-GENE
kinase I-GENE
RARE O
may O
be O
the O
RARE O
RARE O
of O
ras I-GENE
signal O
RARE O
pathways O
. O

ALL_CAP I-GENE
- I-GENE
1 I-GENE
is O
RARE O
in O
a O
larger O
number O
of O
these O
cell O
lines O
. O

RARE O
LTR I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
appear O
to O
be O
essential O
RARE O
c I-GENE
- I-GENE
myc I-GENE
RARE O
, O
since O
both O
LTR O
- O
RARE O
transcription O
and O
the O
activities O
of O
LTR I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
are O
specifically O
decreased O
after O
inhibition O
of O
protein O
RARE O
( O
A O
. O

RARE O
, O
M O
. O

A O
single O
MEF I-GENE
- I-GENE
2 I-GENE
site I-GENE
is O
a O
major O
positive O
regulatory O
element O
required O
RARE O
transcription O
of O
the O
muscle O
- O
specific O
subunit O
of O
the O
human I-GENE
RARE I-GENE
RARE I-GENE
gene I-GENE
in O
skeletal O
and O
cardiac O
muscle O
cells O
. O

RARE O
variants O
of O
peptides O
isolated O
from O
MHC I-GENE
class I-GENE
II I-GENE
molecules I-GENE
suggest O
sequence O
motifs O
. O

Although O
the O
E O
- O
box O
consensus O
is O
RARE O
defined O
RARE O
ALL_CAP O
, O
the O
adjacent O
nucleotides O
of O
RARE O
E O
- O
RARE O
are O
RARE O
RARE O
genes O
regulated O
by O
the O
bHLH I-GENE
proteins I-GENE
. O

RARE O
levels O
of O
gene O
activity O
were O
observed O
RARE O
TnI I-GENE
RARE I-GENE
containing O
E O
- O
RARE O
derived O
from O
the O
ALL_CAP I-GENE
RARE I-GENE
E I-GENE
- I-GENE
box I-GENE
site I-GENE
or O
from O
the O
Ig I-GENE
RARE I-GENE
E2 I-GENE
E I-GENE
- I-GENE
box I-GENE
. O

T I-GENE
- I-GENE
cell I-GENE
receptor I-GENE
beta I-GENE
( O
TCR I-GENE
beta I-GENE
) O
gene O
RARE O
occur O
in O
a O
third O
of O
early O
B O
- O
cell O
acute O
RARE O
leukemias O
( O
RARE O
). O

The O
ALL_CAP O
motifs O
were O
found O
to O
bind O
MyoD I-GENE
and O
myogenin I-GENE
fusion I-GENE
proteins I-GENE
and O
to O
interact O
with O
proteins O
in O
nuclear O
extracts O
from O
cultured O
myotubes O
. O

RARE O
RARE O
associated O
with O
multiple O
myeloma O
. O

We O
have O
RARE O
and O
sequenced O
NUM I-GENE
, O
the O
nuclear O
gene O
RARE O
subunit I-GENE
RARE I-GENE
of O
Saccharomyces I-GENE
cerevisiae I-GENE
cytochrome I-GENE
c I-GENE
oxidase I-GENE
. O

The O
RARE O
of O
the O
RARE I-GENE
A I-GENE
gene I-GENE
was O
determined O
by O
comparison O
of O
the O
genomic O
and O
cDNA O
sequences O
. O

The O
basal O
promoter O
elements O
of O
murine I-GENE
cytochrome I-GENE
c I-GENE
oxidase I-GENE
subunit I-GENE
IV I-GENE
gene I-GENE
consist O
of O
tandemly O
duplicated O
ets I-GENE
motifs O
that O
bind O
to O
GABP I-GENE
- I-GENE
related I-GENE
transcription I-GENE
factors I-GENE
. O

RARE O
, O
there O
are O
multiple O
instances O
in O
which O
short O
RARE O
direct O
repeats O
flank O
a O
region O
absent O
from O
either O
RARE O
or O
RARE O
virus O
. O

Here O
we O
show O
that O
short O
RARE O
peptides O
containing O
the O
ALL_CAP I-GENE
- I-GENE
binding I-GENE
sequences I-GENE
of O
E1A I-GENE
are O
sufficient O
RARE O
interaction O
with O
p107 I-GENE
, O
RARE I-GENE
A I-GENE
, O
and O
p130 I-GENE
. O

These O
mutants O
grow O
normally O
in O
NUM O
mouse O
fibroblast O
cells O
, O
and O
they O
do O
not O
complement O
the O
wild O
- O
type O
virus O
in O
RARE O
experiments O
of O
C2 O
myoblasts O
. O

The O
MICs O
of O
this O
compound O
against O
NUM O
% O
of O
these O
organisms O
, O
except O
RARE O
RARE O
- O
resistant O
S O
. O
RARE O
, O
ranged O
from O
less O
than O
or O
equal O
to O
NUM O
. O
NUM O
to O
3 O
. O
NUM O
micrograms O
/ O
ml O
. O

The O
minimal O
promoter O
of O
the O
RII I-GENE
beta I-GENE
gene I-GENE
was O
composed O
of O
two O
adjacent O
RARE O
elements O
. O

Mapping O
the O
cAMP I-GENE
receptor I-GENE
protein I-GENE
RARE I-GENE
site I-GENE
on O
the O
alpha O
subunit O
of O
Escherichia I-GENE
coli I-GENE
RNA I-GENE
polymerase I-GENE
. O

Here O
we O
show O
that O
RARE I-GENE
growth I-GENE
factor I-GENE
or O
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
RARE O
of O
RARE O
human O
or O
murine O
cells O
leads O
to O
RARE O
of O
RARE I-GENE
protein I-GENE
on O
tyrosine O
, O
serine O
, O
and O
threonine O
residues O
. O

A O
major O
mechanism O
RARE O
steroid I-GENE
hydroxylase I-GENE
gene I-GENE
transcription O
is O
regulated O
in O
the O
adrenal O
cortex O
requires O
the O
pituitary O
peptide O
hormone O
, O
ACTH I-GENE
, O
which O
acts O
via O
cAMP O
. O

A O
combination O
of O
comparative O
sequence O
analysis O
and O
RARE O
methods O
reveals O
the O
conservation O
of O
tertiary O
RARE O
elements O
in O
the O
5 O
' O
RARE O
region O
( O
UTR O
) O
of O
human O
RARE O
and O
RARE O
. O

The O
- O
NUM O
/- O
37 O
region O
interacted O
with O
RARE O
NUM I-GENE
and O
an O
unidentified O
protein O
( O
s O
RARE O
proximal I-GENE
regulatory I-GENE
factor I-GENE
( I-GENE
s I-GENE
) I-GENE
I I-GENE
( O
ALL_CAP I-GENE
- I-GENE
I I-GENE
). O

RARE O
and O
Vmax O
RARE O
two O
RARE O
, O
src I-GENE
- I-GENE
related I-GENE
peptide I-GENE
and O
RARE O
( O
Glu O
, O
RARE O
) O
( O
4 O
: O
1 O
RARE O
were O
2 O
. O
4 O
mM O
and O
2 O
. O
5 O
mumol O
min O
- O
1 O
mg O
- O
1 O
and O
NUM O
. O
NUM O
mM O
and O
1 O
. O
2 O
mumol O
min O
- O
1 O
mg O
- O
1 O
, O
respectively O
. O

This O
RARE O
form O
of O
the O
RARE I-GENE
( O
RARE I-GENE
) O
RARE O
HGF I-GENE
with O
an O
affinity O
similar O
to O
that O
of O
the O
RARE O
, O
membrane O
- O
associated O
receptor O
. O

RARE O
RARE O
RARE O
screening O
RARE O
the O
hepatitis O
C O
virus O
and O
RARE O
the O
human O
immunodeficiency O
virus O
in O
high O
risk O
groups O
. O

Also O
, O
the O
human I-GENE
glycoprotein I-GENE
alpha I-GENE
- I-GENE
subunit I-GENE
promoter I-GENE
was O
RARE O
10 O
- O
RARE O
by O
ALL_CAP I-GENE
in O
NUM O
rat O
pituitary O
cells O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

Comparison O
of O
data O
obtained O
with O
the O
results O
of O
chronic O
treatment O
with O
the O
RARE O
antagonist O
permits O
to O
conclude O
that O
the O
chronic O
blockade O
increases O
the O
RARE O
to O
a O
great O
extent O
than O
chronic O
activation O
of O
RARE O
RARE O
. O

Laboratory O
studies O
using O
NUM O
labeled O
teeth O
and O
biologically O
stained O
teeth O
confirmed O
that O
the O
RARE O
did O
not O
RARE O
RARE O
or O
RARE O
teeth O
. O

Structure O
and O
RARE O
of O
a O
gene O
from O
Arabidopsis O
thaliana O
encoding O
a O
protein O
related O
to O
NUM I-GENE
protein O
kinase O
. O

We O
have O
RARE O
and O
characterized O
a O
NUM O
- O
kb O
region O
of O
DNA O
surrounding O
NUM I-GENE
. O

The O
ORF1 O
protein O
was O
found O
to O
be O
highly O
homologous O
to O
the O
putative O
RARE I-GENE
RNA I-GENE
RARE I-GENE
; O
ORF2 O
, O
- O
3 O
, O
- O
5 O
and O
- O
6 O
proteins O
also O
have O
analogues O
among O
the O
RARE O
- O
and O
/ O
or O
RARE O
- O
encoded O
proteins O
. O

A O
RARE O
of O
NUM O
patients O
were O
divided O
into O
groups O
according O
to O
their O
clinical O
diagnosis O
and O
were O
examined O
using O
RARE O
, O
RARE O
and O
RARE O
- O
gas O
analysis O
. O

The O
relationships O
between O
the O
partial O
pressures O
of O
NUM O
and O
CO2 O
RARE O
RARE O
RARE O
between O
their O
RARE O
, O
become O
stronger O
with O
the O
increase O
of O
the O
ventilation O
- O
perfusion O
ratio O
. O

No O
significant O
correlations O
of O
peak O
VO2 O
were O
observed O
between O
the O
3 O
tests O
. O

An O
RNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
gene I-GENE
( O
NUM I-GENE
) O
from O
Drosophila O
melanogaster O
, O
encoding O
an O
RNA O
recognition O
motif O
and O
an O
Arg O
- O
RARE O
rich O
( O
ALL_CAP O
) O
domain O
, O
has O
been O
characterized O
. O

Some O
research O
studies O
have O
related O
this O
RARE O
of O
tumors O
with O
prolonged O
ingestion O
of O
H2 O
RARE O
and O
others O
RARE O
. O

A O
comparative O
study O
of O
the O
RARE O
protein O
profiles O
of O
wild O
- O
type O
S O
. O
RARE O
NUM O
and O
mutant O
NUM O
revealed O
that O
the O
mutant O
lacked O
an O
RARE O
NUM O
- O
kDa O
protein O
and O
overexpressed O
an O
RARE O
20 O
- O
kDa O
protein O
. O

Characterization O
of O
the O
RARE O
RARE O
by O
the O
leucine I-GENE
- I-GENE
responsive I-GENE
regulatory I-GENE
protein I-GENE
in O
Escherichia O
coli O
. O

Mapping O
of O
the O
mouse I-GENE
RARE I-GENE
decarboxylase I-GENE
- I-GENE
related I-GENE
sequence I-GENE
family I-GENE
. O

This O
mutation O
also O
results O
in O
markedly O
decreased O
levels O
of O
ALL_CAP I-GENE
mRNA I-GENE
and O
protein O
in O
the O
mutant O
. O

The O
RARE O
RARE O
continuous O
dopaminergic O
RARE O
in O
patients O
with O
Parkinson O
' O
s O
RARE O
. O

Mutational O
studies O
revealed O
that O
it O
was O
the O
RARE I-GENE
binding I-GENE
site I-GENE
II I-GENE
sequence I-GENE
that O
was O
required O
RARE O
this O
RARE O
. O

Thus O
, O
the O
pol I-GENE
alpha I-GENE
- O
primase I-GENE
complex O
appears O
to O
act O
RARE O
RARE O
only O
a O
short O
distance O
. O

Interestingly O
, O
the O
positions O
of O
these O
RARE O
have O
been O
RARE O
in O
comparison O
with O
the O
genes O
of O
two O
other O
RARE O
- O
like O
activities O
described O
in O
the O
literature O
, O
but O
the O
NUM I-GENE
gene I-GENE
is O
by O
far O
the O
smallest O
characterized O
to O
date O
because O
its O
RARE O
are O
relatively O
smaller O
. O

In O
a O
retrospective O
analysis O
of O
data O
from O
NUM O
cases O
with O
malignant O
lymphoma O
from O
a O
cohort O
of O
NUM O
HIV O
- O
RARE O
patients O
, O
the O
RARE O
of O
HIV O
- O
RARE O
, O
the O
NUM I-GENE
counts O
RARE O
the O
time O
of O
diagnosis O
, O
and O
the O
use O
of O
RARE O
agents O
or O
radiotherapy O
were O
correlated O
with O
outcome O
. O

1 O
. O

Effects O
of O
RARE O
on O
thyroid O
function O
in O
newborn O
babies O
. O

cDNA O
RARE O
encoding O
Arabidopsis O
thaliana O
and O
RARE I-GENE
RARE I-GENE
mitochondrial I-GENE
RARE I-GENE
NUM I-GENE
and O
gene O
RARE O
RARE O
RARE O
RARE O
and O
heat O
shock O
. O

Amino O
acid O
sequence O
comparison O
revealed O
significant O
homology O
between O
the O
yeast I-GENE
and I-GENE
Escherichia I-GENE
coli I-GENE
gamma I-GENE
- I-GENE
glutamyl I-GENE
kinases I-GENE
throughout O
their O
lengths O
. O

The O
single O
site O
of O
glycosylation O
is O
RARE O
near O
the O
C O
- O
terminus O
in O
the O
N O
- O
glycosylation O
RARE O
- O
Asn O
- O
RARE O
- O
RARE O
- O
in O
which O
RARE O
forms O
part O
of O
a O
RARE O
RARE O
. O

The O
pulmonary O
toxic O
events O
RARE O
by O
acute O
nitrogen O
dioxide O
( O
ALL_CAP O
) O
2 O
exposure O
were O
studied O
in O
the O
rat O
to O
develop O
an O
inhalation O
model O
to O
investigate O
therapeutic O
measures O
. O

The O
pulmonary O
effects O
observed O
, O
became O
more O
pronounced O
with O
increasing O
NO2 O
concentrations O
( O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
175 O
or O
NUM O
ppm O
, O
1 O
ppm O
NO2 O
= O
1 O
. O
88 O
mg O
m O
- O
3 O
NO2 O
) O
and O
exposure O
times O
( O
5 O
, O
10 O
, O
20 O
or O
NUM O
min O
). O

Interaction O
of O
H I-GENE
- I-GENE
NUM I-GENE
with O
an O
ALL_CAP I-GENE
RARE I-GENE
in O
the O
NUM O
/ O
NUM O
B O
cell O
lymphoma O
. O

RARE O
RARE O
diseases O
: O
recent O
RARE O
in O
the O
understanding O
of O
RARE O
, O
RARE O
, O
and O
RARE O
history O
. O

With O
the O
exception O
of O
mutants O
that O
RARE O
the O
membrane O
RARE O
domain O
, O
all O
of O
the O
mutant O
RARE O
retained O
the O
ability O
to O
cause O
fusion O
of O
NUM I-GENE
- O
RARE O
cells O
. O

The O
subunit O
protein O
of O
RARE I-GENE
was O
highly O
homologous O
RARE O
its O
amino O
terminus O
to O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
the O
subunit O
protein O
of O
thin O
, O
RARE O
RARE O
of O
RARE O
RARE O
NUM O
RARE O
NUM O
, O
suggesting O
that O
these O
fibres O
form O
a O
novel O
class O
of O
surface O
RARE O
on O
RARE O
. O

Substitution O
of O
the O
NUM I-GENE
beta I-GENE
chain I-GENE
with O
H I-GENE
- I-GENE
NUM I-GENE
beta I-GENE
RARE I-GENE
led O
to O
a O
dramatic O
RARE O
of O
recognition O
; O
alpha O
chain O
substitution O
had O
a O
less O
marked O
effect O
. O

This O
negative O
regulatory O
RARE O
may O
be O
important O
RARE O
RARE O
cell O
fate O
or O
maintaining O
an O
inducible O
state O
in O
the O
RARE O
region O
of O
the O
RARE O
. O

The O
distal O
portion O
of O
the O
rat I-GENE
insulin I-GENE
I I-GENE
gene I-GENE
5 I-GENE
'- I-GENE
flanking I-GENE
DNA I-GENE
contains O
two O
sequence O
elements O
, O
the O
RARE O
and O
ALL_CAP O
elements O
, O
that O
can O
function O
in O
combination O
, O
but O
not O
separately O
, O
RARE O
a O
beta O
- O
cell O
- O
specific O
transcriptional O
enhancer O
. O

The O
deduced O
amino O
acid O
sequence O
exhibited O
98 O
% O
identity O
to O
the O
human O
cellular O
RARE O
sequence O
. O

This O
RARE O
is O
performed O
by O
a O
parallel O
network O
of O
locally O
connected O
RARE O
- O
like O
elements O
. O

RARE O
RARE O
to O
isolate O
recombinant O
RARE O
containing O
a O
wild O
- O
type O
kinase O
failed O
, O
whereas O
RARE O
expressing O
a O
RARE O
kinase O
with O
a O
catalytic O
domain O
II O
mutation O
were O
readily O
isolated O
. O

Finally O
, O
we O
determined O
that O
the O
NUM I-GENE
amino O
terminus O
was O
both O
necessary O
and O
sufficient O
RARE O
binding O
ALL_CAP O
RARE O
we O
were O
able O
to O
transfer O
ALL_CAP O
- O
binding O
properties O
to O
a O
reporter O
gene O
product O
previously O
unable O
to O
bind O
RNA O
. O

From O
August O
1989 O
to O
RARE O
1990 O
, O
NUM O
RARE O
RARE O
women O
were O
the O
subjects O
RARE O
measuring O
the O
levels O
of O
plasma O
RARE O
antithrombin I-GENE
III I-GENE
( O
AT I-GENE
III I-GENE
) O
activity O
. O

RARE O
RARE O
may O
be O
decreased O
by O
transient O
changes O
in O
RARE O
error O
caused O
by O
RARE O
, O
the O
RARE O
agent O
RARE O
, O
RARE O
RARE O
, O
and O
RARE I-GENE
anhydrase I-GENE
RARE O
. O

RARE O
aspects O
of O
H2 I-GENE
receptor I-GENE
antagonists O
in O
the O
treatment O
of O
ulcers O

In O
addition O
, O
a O
21 O
- O
RARE O
RARE O
RARE O
is O
also O
present O
in O
each O
unit O
. O

Sequencing O
revealed O
one O
large O
RARE O
reading O
frame O
encoding O
a O
NUM O
- O
kDa O
protein O
. O

These O
sites O
are O
also O
RARE O
RARE O
RARE O
RARE O
sites O
. O

We O
propose O
that O
plasmids O
of O
the O
NUM O
family O
( O
NUM O
, O
NUM O
, O
and O
NUM O
) O
share O
RARE O
and O
structural O
characteristics O
RARE O
the O
RARE O
of O
their O
copy O
numbers O
. O

RARE O
of O
ALL_CAP O
RARE O
also O
affected O
the O
frameshift O
RARE O
of O
the O
replicative O
yeast I-GENE
DNA I-GENE
polymerase I-GENE
alpha I-GENE
. O

Differential O
RARE O
of O
the O
" O
B O
" O
subunit O
of O
the O
vacuolar I-GENE
H I-GENE
RARE I-GENE
ATPase I-GENE
in O
bovine O
tissues O
. O

In O
addition O
, O
the O
ALL_CAP I-GENE
gene I-GENE
was O
RARE O
localized O
by O
Southern O
blot O
analysis O
of O
its O
segregation O
pattern O
in O
a O
panel O
of O
rodent O
- O
human O
RARE O
RARE O
using O
the O
radiolabeled O
cDNA O
probe O
. O

We O
have O
isolated O
and O
RARE O
a O
differentially O
- O
regulated O
gene O
family O
in O
the O
RARE O
parasite O
RARE O
major O
. O

At O
some O
sites O
, O
% O
T O
is O
greatly O
increased O
by O
Cl O
- O
concentrations O
RARE O
to O
1 O
M O
, O
while O
RARE O
other O
sites O
% O
T O
is O
RARE O
or O
unaffected O
by O
these O
conditions O
. O

RARE O
appears O
6 O
h O
after O
TA O
infusion O
, O
being O
5 O
. O
77 O
% O
in O
extent O
after O
12 O
h O
, O
14 O
. O
9 O
% O
after O
NUM O
h O
and O
animals O
RARE O
with O
an O
area O
of O
29 O
. O
5 O
% O
necrosis O
. O

In O
summary O
, O
the O
RARE O
of O
NUM I-GENE
represented O
by O
amino O
acid O
residues O
NUM O
- O
NUM O
, O
NUM O
- O
NUM O
, O
NUM O
- O
NUM O
and O
NUM O
- O
NUM O
RARE O
NUM I-GENE
( I-GENE
D I-GENE
) I-GENE
RARE I-GENE
that O
are O
RARE O
by O
RARE O
- O
RARE O
NUM I-GENE
fragments I-GENE
, O
but O
not O
by O
the O
corresponding O
RARE O
- O
RARE O
fragment O
, O
whereas O
the O
RARE O
spanning O
residues O
NUM O
- O
NUM O
and O
NUM O
- O
NUM O
contain O
NUM I-GENE
( I-GENE
D I-GENE
) I-GENE
RARE I-GENE
that O
are O
exposed O
exclusively O
in O
RARE O
NUM I-GENE
and O
therefore O
RARE O
in O
physiological O
fragments O
of O
the O
protein O
. O

These O
exons O
, O
further O
identified O
RARE O
exons O
9 O
, O
10 O
, O
and O
11 O
, O
together O
encode O
the O
37 O
amino O
acid O
residues O
present O
in O
alpha I-GENE
NUM I-GENE
- I-GENE
casein I-GENE
variant I-GENE
A I-GENE
but O
missing O
in O
variant O
F O
. O

We O
also O
report O
here O
the O
RARE O
structural O
organization O
of O
the O
RARE I-GENE
alpha I-GENE
NUM I-GENE
- I-GENE
casein I-GENE
transcription I-GENE
unit I-GENE
, O
deduced O
from O
polymerase O
chain O
reaction O
experiments O
. O

RARE O
of O
the O
three O
proteins O
specifically O
recognize O
the O
G O
- O
box O
motif O
, O
with O
NUM I-GENE
and O
NUM I-GENE
binding O
RARE O
to O
this O
palindromic O
sequence O
. O

Neither O
gene O
possesses O
a O
distinct O
transcriptional O
RARE O
site O
RARE O
shown O
by O
RARE I-GENE
S1 I-GENE
analysis O
. O

The O
RARE O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
is O
very O
similar O
to O
that O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
and O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
. O

The O
initial O
translation O
protein O
encoded O
by O
the O
cDNA O
is O
53 O
, O
NUM O
kDa O
and O
possesses O
a O
hydrophilic O
amino O
acid O
composition O
with O
RARE O
acid O
RARE O
NUM O
% O
of O
the O
RARE O
amino O
acid O
residues O
. O

Each O
group O
received O
NUM O
ml O
/ O
kg O
of O
either O
6 O
% O
RARE O
, O
6 O
% O
RARE O
, O
or O
plasma O
followed O
two O
hours O
later O
by O
1 O
. O
5 O
micrograms O
/ O
kg O
/ O
NUM O
. O
5 O
hr O
E O
. O

Genetic O
and O
biochemical O
evidence O
suggests O
that O
v I-GENE
- I-GENE
Crk I-GENE
can O
induce O
transformation O
of O
chicken O
RARE O
RARE O
by O
influencing O
the O
activity O
of O
cellular O
proteins O
involved O
in O
growth O
RARE O
. O

We O
have O
constructed O
, O
using O
RARE O
DNA O
oligonucleotides O
, O
a O
U14 I-GENE
ALL_CAP I-GENE
gene I-GENE
which O
has O
been O
positioned O
behind O
a O
NUM I-GENE
RNA I-GENE
polymerase I-GENE
promoter I-GENE
site I-GENE
and O
then O
inserted O
into O
a O
RARE O
. O

RARE O
and O
RARE O
of O
the O
mouse O
RARE O
- O
dependent O
RARE I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
receptor I-GENE
. O

The O
RARE O
RARE O
- O
associated O
surface O
glycoprotein O
RARE I-GENE
is O
implicated O
in O
RARE O
growth O
and O
RARE O
RARE O
revealed O
by O
antibody O
RARE O
experiments O
. O

The O
carcinoma O
was O
restricted O
within O
the O
epithelium O
in O
one O
, O
the O
RARE O
layer O
in O
five O
, O
and O
the O
RARE O
layer O
in O
two O
. O

In O
addition O
, O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
gamma I-GENE
readily O
RARE O
with O
each O
other O
RARE O
RARE O
RARE O
with O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
. O

In O
contrast O
, O
tobacco I-GENE
ALL_CAP I-GENE
- I-GENE
2 I-GENE
is O
composed O
of O
subunits O
of O
identical O
size O
in O
all O
organs O
examined O
. O

RARE O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
, O
two O
different O
RARE O
of O
sequences O
with O
dual O
RARE O
RARE O
RARE O
ALL_CAP O
RARE O
NUM O
to O
NUM O
)- O
ALL_CAP O
and O
ALL_CAP O
RARE O
NUM O
to O
NUM O
)- O
ALL_CAP O
] O
were O
found O
; O
these O
sequences O
are O
similar O
to O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
upstream I-GENE
activator I-GENE
sequences I-GENE
, O
respectively O
. O

Although O
the O
effects O
of O
the O
RARE O
RARE O
or O
RARE O
antagonist O
alone O
were O
significant O
, O
such O
hypotensive O
responses O
were O
not O
optimal O
or O
RARE O
or O
clearly O
dose O
- O
dependent O
. O

C O
., O
RARE O
, O
ALL_CAP O
., O
RARE O
, O
M O
RARE O
Y O
., O
RARE O
- O
RARE O
, O
ALL_CAP O
., O
RARE O
, O
S O
., O
and O
RARE O
, O
M O
. O

Surprisingly O
, O
the O
full O
- O
deletion O
mutant O
showed O
a O
strong O
RARE O
in O
virus O
release O
, O
suggesting O
that O
ALL_CAP I-GENE
is O
involved O
in O
virus O
assembly O
. O

Furthermore O
it O
was O
suggested O
that O
FK506 O
plasma O
levels O
were O
RARE O
with O
the O
appearance O
of O
RARE O
effect O
. O

Thirty O
percent O
of O
patients O
were O
RARE O
off O
all O
steroids O
, O
and O
the O
average O
steroid O
dose O
in O
the O
group O
who O
received O
steroids O
was O
8 O
. O
6 O
mg O
of O
prednisone O
per O
day O
. O

Thus O
, O
RARE O
is O
an O
effective O
antiarrhythmic O
agent O
with O
a O
favourable O
pharmacokinetic O
profile O
that O
may O
be O
considered O
with O
other O
class O
I O
drugs O
in O
patients O
requiring O
therapy O
RARE O
high O
risk O
arrhythmias O
. O

T I-GENE
antigen I-GENE
contains O
four O
H O
- O
NUM O
- O
restricted O
cytotoxic O
T O
lymphocyte O
( O
CTL O
) O
recognition O
RARE O
that O
are O
RARE O
RARE O
CTL O
RARE O
Y O
- O
1 O
, O
Y O
- O
2 O
, O
Y O
- O
3 O
, O
and O
Y O
- O
5 O
. O

The O
method O
requires O
a O
reversed O
- O
RARE O
column O
and O
a O
paired O
- O
ion O
technique O
to O
separate O
RARE O
RARE O
from O
other O
RARE O
. O

Here O
we O
demonstrate O
that O
the O
protein O
product O
of O
the O
RARE I-GENE
- I-GENE
1 I-GENE
gene I-GENE
stimulates O
the O
DNA O
binding O
activity O
of O
Fos I-GENE
- O
Jun I-GENE
RARE O
, O
Jun I-GENE
- O
Jun I-GENE
homodimers O
and O
RARE O
cell O
AP I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
RARE O
RARE O
RARE O
that O
of O
several O
other O
transcription O
factors O
including O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
, O
Myb I-GENE
and O
members O
of O
the O
ATF I-GENE
/ O
CREB I-GENE
family O
. O

The O
RARE O
tissues O
of O
the O
permanent O
mandibular O
RARE O
were O
RARE O
and O
then O
RARE O
with O
RARE O
RARE O
. O

Northern O
blot O
analyses O
demonstrate O
that O
3 O
. O
9 O
- O
and O
5 O
- O
RARE O
mRNAs O
corresponding O
to O
the O
cDNA O
were O
present O
in O
all O
tissues O
examined O
, O
suggesting O
that O
the O
protein O
it O
encodes O
RARE O
a O
housekeeping O
function O
. O

The O
ALL_CAP I-GENE
NUM I-GENE
domain I-GENE
exhibited O
relatively O
weak O
affinity O
RARE O
ALL_CAP I-GENE
and O
was O
determined O
to O
bind O
about O
10 O
- O
RARE O
less O
strongly O
than O
the O
ABL I-GENE
NUM I-GENE
domain I-GENE
. O

We O
analyzed O
an O
ALL_CAP O
B O
- O
cell O
clone O
, O
NUM O
. O
1 O
, O
derived O
from O
an O
11 O
week O
- O
old O
RARE O
, O
and O
secreting O
both O
IgM I-GENE
RARE I-GENE
and O
IgM I-GENE
lambda I-GENE
. O

Interestingly O
, O
this O
activation O
occurred O
only O
when O
the O
regions O
were O
RARE O
in O
the O
same O
relative O
orientation O
in O
which O
they O
exist O
on O
wild O
- O
type O
NUM O
. O

In O
rats O
, O
we O
examined O
the O
effect O
of O
an O
RARE O
RARE O
on O
the O
RARE O
of O
the O
RARE O
and O
on O
regeneration O
of O
the O
RARE O
epithelium O
in O
the O
very O
early O
RARE O
after O
free O
tracheal O
RARE O
. O

To O
study O
a O
possible O
RARE O
role O
of O
this O
putative O
chicken O
ALL_CAP I-GENE
, O
an O
RARE O
spanning O
the O
upstream O
sequences O
of O
the O
ALL_CAP I-GENE
- I-GENE
IV I-GENE
gene I-GENE
RARE O
NUM O
/- O
NUM O
) O
was O
RARE O
RARE O
or O
in O
multiple O
copies O
before O
the O
herpes O
TK I-GENE
promoter I-GENE
controlling O
the O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
( O
CAT I-GENE
) O
gene O
( O
NUM I-GENE
). O

In O
RARE O
, O
two O
separate O
high O
- O
performance O
liquid O
chromatographic O
RARE O
were O
performed O
, O
one O
RARE O
the O
gamma O
- O
RARE O
acid O
determination O
and O
one O
RARE O
the O
determination O
of O
the O
RARE O
. O

We O
report O
the O
successful O
use O
of O
RARE O
therapy O
RARE O
treatment O
of O
severe O
depression O
in O
a O
young O
man O
with O
adult O
NUM O
RARE O
. O

RARE O
of O
yeast O
cells O
into O
the O
RARE O
cell O
RARE O
( O
RARE O
) O
involves O
a O
form O
of O
the O
NUM I-GENE
kinase I-GENE
that O
associates O
with O
G1 O
- O
specific O
RARE I-GENE
encoded O
by O
NUM I-GENE
and O
NUM I-GENE
( O
RARE O
. O

RARE O
Southern O
blot O
analyses O
of O
DNA O
from O
backcross O
and O
RARE O
mice O
, O
recombinant O
RARE O
strains O
, O
and O
somatic O
cell O
hybrids O
, O
the O
genetic O
loci O
that O
produce O
the O
RARE I-GENE
NUM I-GENE
- I-GENE
related I-GENE
sequences I-GENE
( O
designated O
loci I-GENE
NUM I-GENE
- I-GENE
NUM I-GENE
to O
NUM I-GENE
- I-GENE
NUM I-GENE
) O
were O
mapped O
on O
mouse O
chromosomes O
5 O
, O
1 O
, O
NUM O
, O
4 O
, O
14 O
, O
NUM O
, O
7 O
, O
X O
, O
and O
8 O
, O
respectively O
. O

RARE O
RARE O
Glu O
- O
NUM O
of O
beta O
was O
RARE O
RARE O
and O
RARE O
missing O
RARE O
from O
the O
epsilon O
peptide O
could O
be O
identified O
, O
but O
the O
peptide O
sequence O
limited O
the O
possible O
RARE O
to O
RARE O
- O
NUM O
, O
RARE O
- O
NUM O
, O
or O
RARE O
- O
NUM O
. O

RARE O
to O
dentin O
bond O
strength O
with O
a O
dentin O
adhesive O
. O

RARE O
is O
defined O
RARE O
a O
RARE O
of O
the O
difference O
of O
the O
RARE O
and O
the O
second O
measurement O
: O
RARE O
= O
( O
P1 O
- O
P2 O
RARE O
NUM O
- O
NUM O
). O

It O
was O
concluded O
that O
RARE O
2 O
and O
RARE O
RARE O
RARE O
2 O
are O
effective O
and O
are O
the O
RARE O
RARE O
agents O
of O
choice O
. O

From O
all O
clinically O
important O
RARE O
species O
, O
a O
RARE O
of O
96 O
% O
were O
identified O
by O
ALL_CAP O
method O
according O
to O
conventional O
methods O
. O

The O
RARE O
vasopressin I-GENE
and O
RARE I-GENE
content O
was O
RARE O
by O
pressor O
effect O
following O
RARE O
or O
milk O
- O
ejection O
activity O
in O
vitro O
following O
RARE O
RARE O
and O
RARE O
, O
respectively O
. O

RARE O
are O
given O
on O
the O
present O
status O
of O
RARE O
concerning O
water O
in O
swimming O
RARE O
and O
RARE O
RARE O
1991 O
RARE O
in O
RARE O
with O
the O
ALL_CAP O
RARE O
RARE O
1972 O
RARE O
and O
the O
RARE O
RARE O
standard O
RARE O
ALL_CAP O
] O
No O
. O

If O
RARE O
RARE O
was O
received O
, O
RARE O
RARE O
or O
home O
RARE O
were O
made O
. O

The O
treatment O
group O
also O
showed O
in O
vivo O
T O
- O
cell O
activation O
with O
an O
initial O
RARE O
followed O
by O
a O
RARE O
RARE O
and O
RARE O
of O
the O
subset O
markers O
NUM I-GENE
( O
interleukin I-GENE
2 I-GENE
receptor I-GENE
) O
and O
NUM I-GENE
( O
T O
- O
memory O
cells O
). O

RARE I-GENE
activity O
, O
judged O
RARE O
the O
amount O
of O
RARE O
production O
from O
urea O
, O
could O
be O
measured O
RARE O
NUM O
RARE O
per O
tube O
( O
S O
/ O
N O
= O
1 O
. O
5 O
) O
with O
RARE I-GENE
RARE I-GENE
RARE I-GENE
urease I-GENE
. O

RARE O
, O
significant O
differences O
between O
the O
measured O
and O
calculated O
methods O
were O
noted O
in O
oxygen O
uptake O
( O
NUM O
+/- O
NUM O
ml O
/ O
min O
RARE O
193 O
+/- O
NUM O
ml O
/ O
min O
, O
p O
< O
NUM O
. O
001 O
RARE O
oxygen O
delivery O
( O
NUM O
+/- O
NUM O
ml O
/ O
min O
RARE O
NUM O
+/- O
296 O
ml O
/ O
min O
, O
p O
< O
NUM O
. O
001 O
RARE O
and O
cardiac O
output O
( O
5 O
. O
8 O
+/- O
2 O
. O
2 O
L O
/ O
min O
RARE O
5 O
. O
3 O
+/- O
1 O
. O
8 O
L O
/ O
min O
, O
p O
< O
NUM O
. O
001 O
). O

Although O
a O
wide O
range O
of O
cognitive O
functions O
had O
been O
tested O
, O
all O
but O
one O
seizure O
occurred O
RARE O
assessment O
of O
memory O
performance O
. O

The O
experiments O
show O
that O
it O
is O
the O
RARE O
of O
the O
RARE O
and O
the O
condition O
of O
the O
ALL_CAP O
( O
certain O
physiological O
activation O
states O
, O
such O
RARE O
phagocytic O
activity O
) O
that O
essentially O
determine O
the O
degree O
of O
recovery O
. O

RARE O
RARE O
RARE O
NUM O
did O
not O
compete O
, O
whereas O
an O
otherwise O
identical O
RARE O
NUM O
( O
ALL_CAP O
RARE O
which O
contained O
a O
( O
ALL_CAP O
- O
ALL_CAP O
) O
7 O
segment O
in O
the O
Z O
- O
form O
was O
an O
excellent O
competitor O
. O

A O
cDNA O
library O
of O
RARE O
cells O
was O
screened O
with O
an O
interleukin I-GENE
2 I-GENE
gene O
- O
specific O
probe O
. O

Our O
experiments O
suggest O
that O
the O
ALL_CAP I-GENE
gene I-GENE
can O
be O
a O
target O
RARE O
the O
RARE I-GENE
transcription I-GENE
factor I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
and O
that O
the O
ALL_CAP I-GENE
gene I-GENE
product I-GENE
serves O
RARE O
a O
positive O
regulator O
of O
RARE O
differentiation O
. O

In O
contrast O
, O
the O
RARE O
domains O
of O
NUM I-GENE
, O
NUM I-GENE
and O
NUM I-GENE
are O
very O
different O
in O
size O
and O
do O
not O
show O
any O
RARE O
homology O
. O

RARE O
containing O
wild O
- O
type O
and O
either O
NUM I-GENE
or I-GENE
NUM I-GENE
mutant I-GENE
p53 I-GENE
proteins I-GENE
are O
completely O
unable O
to O
bind O
to O
the O
ALL_CAP I-GENE
DNA I-GENE
sequence I-GENE
. O

These O
RARE O
- O
and O
cold O
- O
RARE O
strains O
were O
used O
to O
RARE O
extracts O
RARE O
in O
NUM I-GENE
activity O
and O
were O
tested O
RARE O
transcriptional O
activity O
by O
RNA I-GENE
RARE I-GENE
I I-GENE
, I-GENE
II I-GENE
, I-GENE
and I-GENE
III I-GENE
in O
vitro O
. O

These O
results O
lead O
us O
to O
RARE O
that O
a O
single O
RARE I-GENE
TFIID I-GENE
protein I-GENE
supports O
transcriptional O
RARE O
by O
diverse O
activation O
domains O
and O
from O
a O
TATA O
- O
less O
promoter O
. O

The O
gene O
sequence O
also O
identified O
a O
NUM O
- O
nucleotide O
RNA O
in O
RARE O
yeast O
RNA O
and O
in O
RARE O
RNase I-GENE
MRP I-GENE
enzyme I-GENE
preparations O
. O

The O
RNase I-GENE
MRP I-GENE
RNA I-GENE
gene I-GENE
was O
RARE O
by O
RARE O
RARE O
and O
found O
to O
be O
essential O
RARE O
cellular O
viability O
, O
indicating O
a O
critical O
nuclear O
role O
RARE O
RNase I-GENE
MRP I-GENE
. O

RARE O
NUM O
RARE O
RARE O
an O
mRNA O
that O
on O
cell O
- O
free O
translation O
produced O
a O
38 O
- O
kDa O
polypeptide O
. O

From O
these O
results O
, O
CBF I-GENE
- I-GENE
A I-GENE
is O
a O
novel O
ALL_CAP O
box O
RARE O
ALL_CAP I-GENE
- I-GENE
and I-GENE
RNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
RARE O
RARE O
RARE O
a O
repressive O
transcriptional O
factor O
. O

RARE O
by O
the O
intron O
- O
encoded O
enzyme O
( O
I I-GENE
- I-GENE
ALL_CAP I-GENE
) O
occurs O
5 O
bp O
and O
1 O
bp O
3 O
' O
to O
the O
intron O
RARE O
site O
( O
in O
the O
3 O
'- O
RARE O
) O
in O
the O
top O
RARE O
and O
RARE O
RARE O
RARE O
, O
respectively O
, O
resulting O
in O
4 O
- O
nt O
single O
- O
RARE O
RARE O
with O
3 O
'- O
OH O
termini O
. O

Surprisingly O
, O
the O
Xenopus I-GENE
NUM I-GENE
gene I-GENE
contains O
two O
adjacent O
octamer O
- O
binding O
motifs O
RARE O
only O
12 O
and O
NUM O
bp O
upstream O
from O
the O
ALL_CAP I-GENE
, O
instead O
of O
the O
RARE O
location O
around O
NUM O
- O
NUM O
bp O
upstream O
. O

The O
results O
support O
earlier O
reports O
that O
RARE I-GENE
RARE O
are O
useful O
in O
controlling O
RARE O
formation O
in O
recessive O
RARE O
RARE O
RARE O
. O

Mutational O
analysis O
of O
essential O
ALL_CAP O
alpha O
RARE O
transfer O
genes O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
and O
involvement O
of O
ALL_CAP I-GENE
in O
RARE O
sensitivity O
. O

The O
promoter O
was O
RARE O
8 O
- O
20 O
- O
RARE O
by O
phorbol O
esters O
RARE O
RARE O
the O
previously O
observed O
transcriptional O
activation O
of O
protein I-GENE
kinase I-GENE
C I-GENE
beta I-GENE
. O

In O
humans O
, O
four O
AMP I-GENE
RARE I-GENE
variants I-GENE
, O
termed O
M I-GENE
( O
muscle O
RARE O
L I-GENE
( O
liver O
RARE O
E1 I-GENE
, O
and O
E2 I-GENE
( O
RARE O
) O
can O
be O
distinguished O
by O
a O
variety O
of O
biochemical O
and O
RARE O
criteria O
. O

Western O
blot O
analyses O
detect O
anti I-GENE
- I-GENE
E I-GENE
- O
specific O
immunoreactivity O
in O
affinity O
- O
RARE O
extracts O
derived O
from O
the O
bacterial O
RARE O
of O
a O
truncated I-GENE
NUM I-GENE
cDNA I-GENE
. O

These O
results O
demonstrate O
that O
endogenous O
N O
- O
methylation O
of O
RARE O
into O
N O
- O
RARE O
occurs O
in O
the O
brain O
in O
vivo O
. O

NUM I-GENE
molecules I-GENE
RARE O
from O
human O
RARE O
cell O
lines O
could O
specifically O
bind O
to O
these O
peptide O
sequences O
RARE O
on O
the O
RARE O
surface O
. O

This O
article O
describes O
the O
RARE O
care O
of O
the O
woman O
RARE O
in O
RARE O
RARE O
RARE O
RARE O
intrauterine O
transfusion O
. O

Chronic O
hepatitis O
B O
in O
adopted O
RARE O
children O
. O

RARE O
the O
ATPase I-GENE
cluster I-GENE
, O
two O
RARE O
reading O
frames O
were O
detected O
that O
are O
not O
homologous O
to O
any O
known O
chloroplast O
gene O
. O

Therefore O
, O
recombinant O
human O
RARE O
that O
express O
RARE O
HIV O
or O
other O
RARE O
proteins O
are O
RARE O
vaccine O
RARE O
. O

RARE O
of O
the O
RARE O
sequences O
allowed O
us O
to O
predict O
a O
consensus O
sequence O
RARE O
binding O
of O
the O
individual O
RARE O
Rel I-GENE
- I-GENE
related I-GENE
proteins I-GENE
, O
and O
DNA O
- O
protein O
binding O
analysis O
of O
the O
RARE O
DNA O
sequences O
revealed O
sequence O
RARE O
of O
the O
proteins O
. O

Using O
either O
a O
NUM I-GENE
- O
or O
NUM I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
B I-GENE
motif I-GENE
, O
which O
displayed O
differential O
binding O
with O
respect O
to O
the O
other O
protein O
, O
little O
to O
RARE O
binding O
was O
observed O
with O
the O
RARE I-GENE
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
complex I-GENE
. O

However O
, O
a O
cosmid O
clone O
containing O
the O
RARE O
mouse I-GENE
alpha I-GENE
1 I-GENE
( I-GENE
I I-GENE
) I-GENE
gene I-GENE
, O
including O
3 O
. O
7 O
kb O
of O
5 O
'- O
and O
4 O
kb O
of O
3 O
'- O
flanking O
DNA O
, O
was O
RARE O
RARE O
RARE O
levels O
in O
RARE O
overexpressing O
RARE I-GENE
ras I-GENE
. O

To O
define O
transcriptional O
control O
elements O
responsible O
RARE O
muscle O
- O
specific O
RARE O
of O
the O
human I-GENE
myoglobin I-GENE
gene I-GENE
, O
we O
performed O
mutational O
analysis O
of O
upstream O
sequences O
( O
nucleotide O
positions O
- O
NUM O
to O
+ O
7 O
relative O
to O
the O
transcriptional O
RARE O
site O
) O
RARE O
to O
a O
RARE I-GENE
luciferase I-GENE
gene I-GENE
. O

Sequencing O
analysis O
has O
shown O
that O
each O
NUM I-GENE
allele I-GENE
contains O
a O
nonsense O
mutation O
within O
a O
discrete O
region O
between O
amino O
RARE O
NUM O
and O
NUM O
. O

By O
screening O
a O
NUM O
cell O
cDNA O
library O
with O
the O
DNA O
- O
binding O
region O
of O
the O
H I-GENE
- I-GENE
NUM I-GENE
nuclear I-GENE
hormone I-GENE
receptor I-GENE
cDNA I-GENE
, O
we O
isolated O
a O
cDNA O
that O
is O
selectively O
RARE O
in O
RARE O
cells O
. O

RARE O
demonstrated O
good O
survival O
of O
the O
RARE O
cells O
with O
good O
RARE O
with O
the O
brain O
of O
the O
recipient O
and O
RARE O
of O
positive O
RARE O
reaction O
RARE O
tyrosine I-GENE
hydroxylase I-GENE
. O

The O
technique O
of O
the O
ALL_CAP O
visualization O
of O
the O
proximal O
coronary O
arteries O
is O
described O
. O

The O
sequence O
of O
this O
region O
shows O
high O
G O
+ O
C O
content O
( O
NUM O
%), O
which O
is O
particularly O
RARE O
in O
the O
NUM O
bp O
upstream O
from O
the O
mRNA O
RARE O
( O
NUM O
% O
G O
+ O
C O
). O

In O
the O
eight O
patients O
with O
persistent O
generalized O
lymph O
- O
RARE O
( O
ALL_CAP O
) O
and O
RARE O
, O
RARE O
nodes O
, O
pathologic O
analysis O
revealed O
RARE O
hyperplasia O
. O

PaO2 O
threshold O
was O
determined O
through O
an O
RARE O
NUM O
RARE O
catheter O
. O

We O
found O
that O
both O
the O
NUM O
virus O
- O
encoded O
v I-GENE
- I-GENE
ets I-GENE
and O
the O
RARE I-GENE
/ I-GENE
B I-GENE
- I-GENE
cell I-GENE
- I-GENE
specific I-GENE
factor I-GENE
ALL_CAP I-GENE
. I-GENE
1 I-GENE
bind O
efficiently O
to O
this O
site O
in O
vitro O
. O

By O
using O
lambda O
gt11 O
RARE O
cloning O
with O
oligonucleotides O
corresponding O
to O
the O
human O
immunodeficiency O
virus O
1 O
TATA O
element O
, O
we O
report O
the O
identification O
of O
a O
cellular O
protein O
with O
a O
calculated O
RARE O
mass O
of O
123 O
kDa O
that O
we O
RARE O
TATA I-GENE
element I-GENE
RARE I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
). O

RARE O
levels O
of O
melatonin O
, O
RARE O
, O
cortisol O
, O
and O
prolactin I-GENE
in O
relation O
to O
the O
circadian O
rhythm O
of O
platelet O
RARE O
uptake O
. O

We O
RARE O
' O
t O
detect O
any O
effect O
of O
RARE O
- O
3 O
ALL_CAP O
supplementation O
on O
RARE O
cholesterol O
, O
ALL_CAP I-GENE
cholesterol I-GENE
, O
LDL I-GENE
cholesterol I-GENE
, O
RARE I-GENE
NUM I-GENE
, O
RARE O
( O
a O
RARE O
NUM I-GENE
, O
glucose O
, O
fibrinogen I-GENE
, O
factor I-GENE
VIII I-GENE
, O
antithrombin I-GENE
III I-GENE
, O
plasminogen I-GENE
activator I-GENE
inhibitor I-GENE
, O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
and O
RARE I-GENE
Willebrand I-GENE
factor I-GENE
concentration O
, O
on O
bleeding O
time O
or O
on O
systolic O
or O
diastolic O
RARE O
pressure O
. O

In O
8 O
healthy O
volunteers O
there O
were O
RARE O
significant O
differences O
in O
AUC O
, O
peak O
plasma O
concentrations O
or O
time O
to O
peak O
concentration O
when O
ALL_CAP O
was O
administered O
either O
with O
or O
without O
ALL_CAP O
. O

Using O
5 O
RARE O
/ O
mL O
RARE O
the O
cutoff O
, O
the O
sensitivity O
of O
ALL_CAP I-GENE
was O
NUM O
%. O

RARE O
spikes O
and O
cognitive O
function O
. O

The O
effect O
of O
RARE O
18 O
beta O
- O
RARE O
( O
ALL_CAP O
) O
on O
experimental O
RARE O
was O
investigated O
. O

Thus O
, O
chronic O
hematocrit O
decrease O
RARE O
by O
H O
or O
P O
resulted O
in O
a O
significant O
fall O
in O
RARE O
pressure O
compared O
to O
control O
( O
NUM O
+/- O
3 O
v O
175 O
+/- O
4 O
, O
NUM O
+/- O
4 O
mm O
Hg O
, O
respectively O
; O
P O
< O
. O
05 O
). O

The O
effects O
of O
diltiazem O
were O
RARE O
, O
thus O
the O
potentiation O
RARE O
by O
d O
- O
cis O
diltiazem O
was O
significantly O
greater O
in O
all O
cases O
than O
that O
RARE O
by O
RARE O
- O
cis O
diltiazem O
, O
which O
suggests O
that O
RARE O
RARE O
blockade O
plays O
a O
role O
in O
these O
interactions O
. O

Localization O
of O
the O
RARE O
RARE O
with O
the O
nerve O
RARE O
is O
equally O
effective O
RARE O
the O
RARE O
, O
RARE O
, O
and O
RARE O
sites O
. O

Substitution O
of O
either O
NUM O
( O
by O
RARE O
) O
or O
NUM O
( O
by O
RARE O
RARE O
two O
of O
the O
most O
RARE O
residues O
in O
all O
protein O
kinases O
, O
resulted O
in O
enzyme O
with O
RARE O
detectable O
activity O
. O

Significance O
of O
the O
biopsy O
site O
of O
the O
RARE O
RARE O
muscle O
RARE O
fiber O
RARE O
. O

The O
TIMP I-GENE
RARE O
NUM O
/ O
- O
53 O
) O
AP1 I-GENE
site O
is O
a O
RARE O
motif O
that O
binds O
c I-GENE
- I-GENE
Fos I-GENE
/ O
c I-GENE
- I-GENE
Jun I-GENE
AP1 I-GENE
translated O
in O
vitro O
and O
is O
an O
effective O
competitor O
RARE O
binding O
of O
nuclear I-GENE
AP1 I-GENE
factors I-GENE
to O
the O
consensus O
ALL_CAP O
, O
but O
in O
addition O
it O
binds O
factors O
that O
do O
not O
associate O
with O
the O
consensus O
ALL_CAP O
. O

RARE O
of O
AP1 I-GENE
and O
PEA3 I-GENE
binding I-GENE
sites I-GENE
in O
the O
RARE O
of O
murine I-GENE
tissue I-GENE
inhibitor I-GENE
of I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
( O
TIMP I-GENE
- I-GENE
1 I-GENE
) O
transcription O
. O

Of O
the O
serum I-GENE
RARE I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
antibody I-GENE
negative O
calves O
NUM O
. O
7 O
% O
( O
NUM O
/ O
29 O
) O
and O
92 O
. O
8 O
% O
( O
NUM O
/ O
97 O
) O
developed O
ALL_CAP I-GENE
antibody I-GENE
1 O
month O
after O
RARE O
and O
RARE O
vaccination O
, O
respectively O
. O

RARE O
of O
crude O
nuclear O
extracts O
by O
RARE O
- O
agarose O
chromatography O
indicates O
that O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
is O
more O
RARE O
in O
extracts O
prepared O
from O
salt O
- O
stressed O
leaf O
tissue O
. O

A O
RARE O
trial O
of O
recombinant I-GENE
human I-GENE
RARE I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
after O
RARE O
body O
irradiation O
, O
high O
- O
dose O
chemotherapy O
, O
and O
autologous O
bone O
marrow O
transplantation O
RARE O
acute O
RARE O
leukemia O
or O
malignant O
lymphoma O
. O

These O
data O
demonstrate O
that O
ALL_CAP O
does O
not O
cause O
more O
RARE O
trauma O
than O
CPB O
when O
used O
to O
provide O
RARE O
circulatory O
support O
. O

The O
IgG I-GENE
RARE O
profile O
of O
untreated O
RARE O
RARE O
was O
found O
to O
be O
the O
same O
RARE O
in O
healthy O
controls O
( O
NUM I-GENE
RARE O
NUM I-GENE
> O
NUM I-GENE
> O
NUM I-GENE
RARE O
with O
only O
the O
magnitude O
of O
the O
individual O
RARE O
responses O
being O
increased O
in O
RARE O
patients O
. O

Examination O
of O
ALL_CAP I-GENE
is O
not O
only O
a O
significant O
contribution O
towards O
a O
more O
accurate O
diagnosis O
of O
RARE O
vasculitis O
, O
but O
also O
an O
indicator O
of O
the O
activity O
of O
the O
RARE O
and O
thus O
of O
the O
effectiveness O
of O
immunosuppressive O
treatment O
. O

On O
the O
other O
RARE O
, O
RARE O
RARE O
in O
these O
already O
RARE O
RARE O
rabbits O
always O
resulted O
in O
a O
substantial O
RARE O
of O
the O
RARE O
( O
mean O
delta O
RARE O
= O
+ O
NUM O
. O
NUM O
h O
). O

RARE O
RARE O
is O
an O
RARE O
systemic O
RARE O
characterized O
by O
chronic O
RARE O
RARE O
. O

The O
effects O
of O
two O
levels O
of O
caffeine O
ingestion O
on O
excess O
RARE O
oxygen O
consumption O
in O
RARE O
women O
. O

The O
RARE O
features O
involved O
eight O
amino O
acid O
changes O
, O
including O
a O
single O
RARE O
deletion O
relative O
to O
a O
primate O
consensus O
sequence O
in O
the O
RARE O
RARE O
- O
RARE O
region O
of O
NUM I-GENE
. O

4 O
. O

The O
in O
vivo O
profile O
of O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
in O
the O
RARE O
CNS O
shows O
RARE O
overlap O
with O
ALL_CAP I-GENE
in O
specific O
RARE O
and O
dopamine O
neurons O
. O

Unlike O
the O
RARE O
of O
other O
duplicated O
ribosomal I-GENE
protein I-GENE
genes I-GENE
which O
are O
highly O
diverged O
, O
the O
duplicated O
NUM I-GENE
genes I-GENE
have O
two O
nearly O
identical O
DNA O
sequences O
of O
NUM O
and O
NUM O
bp O
in O
length O
within O
their O
RARE O
. O

In O
a O
prospective O
, O
randomized O
clinical O
trial O
we O
compared O
the O
efficacy O
of O
subcutaneously O
( O
SC O
) O
administered O
( O
every O
8 O
h O
) O
RARE O
RARE O
to O
intravenous O
( O
IV O
) O
RARE O
RARE O
in O
the O
treatment O
of O
proximal O
deep O
- O
RARE O
thrombosis O
( O
ALL_CAP O
). O

The O
highest O
prevalence O
of O
reported O
RARE O
allergy O
, O
chronic O
RARE O
, O
RARE O
, O
attacks O
of O
RARE O
of O
RARE O
with O
RARE O
, O
and O
RARE O
- O
diagnosed O
asthma O
was O
found O
in O
children O
who O
had O
RARE O
in O
the O
past O
but O
not O
RARE O
. O

Therefore O
, O
it O
would O
be O
RARE O
to O
identify O
such O
persons O
and O
treat O
them O
preferentially O
. O

On O
the O
basis O
of O
these O
unique O
properties O
, O
the O
newly O
characterized O
hemagglutinin I-GENE
has O
been O
termed O
RARE I-GENE
NUM I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
factor I-GENE
( O
NUM I-GENE
- I-GENE
ALL_CAP I-GENE
). O

The O
shift O
to O
the O
RARE O
RARE O
is O
accompanied O
by O
the O
RARE O
of O
RARE O
nucleotide O
- O
dependent O
activity O
of O
RARE I-GENE
in O
vitro O
. O

RARE O
. O

The O
data O
indicate O
that O
the O
minimal O
catalytic O
domain O
of O
NUM I-GENE
is O
RARE O
between O
NUM O
RARE O
NUM O
and O
NUM O
RARE O
NUM O
. O

It O
corresponds O
to O
the O
RARE O
mitochondrial O
RARE O
and O
the O
RARE O
- O
RARE O
domain O
that O
are O
encoded O
by O
exons O
I O
through O
IV O
of O
the O
RARE O
E2 I-GENE
gene I-GENE
. O

Human O
RARE O
response O
to O
short O
- O
term O
exposure O
to O
F O
- O
NUM O
RARE O
- O
based O
RARE O
. O

Disruption O
of O
RARE O
did O
not O
affect O
the O
RARE O
or O
kinetics O
of O
vacuolar O
protein O
RARE O
, O
indicating O
that O
NUM I-GENE
function O
is O
not O
dependent O
on O
RARE O
. O

A O
mutant O
form O
of O
NUM I-GENE
RARE O
the O
RARE O
GTP O
- O
binding O
domain O
RARE O
with O
vacuolar O
protein O
RARE O
in O
wild O
- O
type O
cells O
. O

According O
to O
out O
field O
research O
, O
the O
RARE O
RARE O
was O
very O
rich O
throughout O
that O
area O
, O
and O
it O
was O
RARE O
enough O
to O
determine O
ticks O
RARE O
the O
vectors O
, O
based O
on O
arising O
of O
anti I-GENE
- I-GENE
ALL_CAP I-GENE
group I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
antibody O
in O
mice O
inoculated O
with O
some O
RARE O
RARE O
, O
findings O
of O
RARE O
reactive O
to O
patient O
RARE O
or O
a O
species O
- O
specific O
monoclonal O
antibody O
to O
ALL_CAP I-GENE
in O
the O
RARE O
cells O
of O
some O
ticks O
, O
and O
electron O
RARE O
observations O
of O
ALL_CAP I-GENE
in O
various O
internal O
organs O
including O
the O
RARE O
RARE O
of O
ticks O
. O

The O
second O
method O
, O
the O
" O
RARE O
" O
assay O
, O
has O
a O
sensitivity O
range O
of O
NUM O
. O
03 O
- O
5 O
. O
NUM O
micrograms O
phosphorus O
with O
NUM O
- O
500 O
RARE O
NUM O
. O

Nucleotide O
sequence O
and O
transcriptional O
analysis O
of O
the O
RARE I-GENE
gene I-GENE
of O
RARE O
RARE O
nuclear O
RARE O
virus O
. O

RARE O
of O
automated O
RARE O
RARE O
RARE O
definition O
. O

As O
a O
consequence O
of O
dark O
RARE O
, O
the O
RARE O
density O
of O
cortical O
neurons O
in O
area O
NUM O
RARE O
to O
about O
double O
of O
the O
value O
observed O
in O
normally O
RARE O
RARE O
and O
was O
also O
significantly O
RARE O
in O
area O
18 O
. O

These O
results O
suggest O
that O
decreased O
class O
I O
enhancer O
activity O
in O
NUM O
- O
transformed O
cells O
may O
, O
RARE O
least O
in O
part O
, O
be O
due O
to O
the O
RARE O
levels O
of O
an O
enhancer O
- O
specific O
factor O
, O
possibly O
acting O
RARE O
a O
repressor O
. O

A O
second O
domain O
, O
RARE O
in O
the O
C O
- O
terminal O
NUM O
amino O
RARE O
of O
IE1 I-GENE
, O
is O
required O
RARE O
RARE O
and O
DNA O
- O
binding O
activities O
. O

In O
order O
to O
investigate O
the O
RARE O
compatibility O
of O
RARE O
RARE O
graft O
( O
ALL_CAP O
RARE O
changes O
in O
RARE O
( O
NUM O
) O
production O
following O
RARE O
and O
arterial O
implantation O
were O
studied O
experimentally O
. O

RARE O
administration O
of O
the O
somatostatin I-GENE
analogue O
, O
RARE O
, O
NUM O
micrograms O
RARE O
daily O
, O
resulted O
in O
a O
sustained O
improvement O
in O
RARE O
and O
disappearance O
of O
RARE O
RARE O
without O
RARE O
calcitonin I-GENE
levels O
. O

RARE I-GENE
- I-GENE
ALL_CAP I-GENE
antibodies I-GENE
detect O
a O
NUM O
protein O
in O
extracts O
of O
C O
. O
RARE O
in O
agreement O
with O
the O
size O
predicted O
from O
the O
nucleotide O
sequence O
of O
the O
RARE O
gene O
. O

NUM O
, O
285 O
- O
NUM O
] O
and O
was O
subsequently O
RARE O
and O
sequenced O
RARE O
ALL_CAP O
. O

RARE O
RARE O
vector O
efficiently O
RARE O
recombinant O
genes O
. O

Use O
of O
free O
- O
access O
RARE O
. O

Interferon I-GENE
type I-GENE
I I-GENE
in O
protective O
body O
reactions O
in O
an O
experimental O
RARE O
infection O

No O
other O
changes O
in O
hematopoietic O
differentiation O
status O
were O
observed O
in O
association O
with O
RARE I-GENE
- I-GENE
ALL_CAP I-GENE
RARE O
. O

RARE O
interaction O
after O
RARE O
anesthesia O
and O
sedation O
with O
midazolam O
. O

For O
pressure O
greater O
than O
NUM O
RARE O
RARE O
, O
an O
increased O
RARE O
of O
the O
RARE O
made O
it O
difficult O
to O
RARE O
the O
RARE O
reflex O
from O
RARE O
movements O
. O

One O
air O
RARE O
occurred O
; O
this O
was O
the O
only O
filter O
- O
or O
RARE O
- O
related O
complication O
. O

The O
5 O
' O
region O
of O
NUM I-GENE
contains O
consensus O
binding O
sites O
RARE O
the O
transcriptional O
regulatory O
proteins O
, O
NUM I-GENE
, O
AP2 I-GENE
, O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
and O
ALL_CAP I-GENE
- I-GENE
E1 I-GENE
. O

V O
. O

These O
data O
indicate O
that O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
is O
a O
serine I-GENE
protease I-GENE
with O
unique O
activity O
that O
is O
RARE O
in O
the O
granules O
of O
large O
RARE O
lymphocytes O
. O

RARE O
and O
cloning O
of O
a O
novel O
serine I-GENE
protease I-GENE
, O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
, O
from O
the O
granules O
of O
a O
rat O
RARE O
killer O
cell O
leukemia O
. O

We O
describe O
here O
NUM O
dominant I-GENE
GCN2 I-GENE
mutations I-GENE
that O
lead O
to O
derepression O
of O
GCN4 I-GENE
RARE O
in O
the O
absence O
of O
amino O
acid O
starvation O
. O

Administration O
of O
growth I-GENE
hormone I-GENE
leads O
to O
faster O
growth O
, O
but O
also O
faster O
bone O
RARE O
. O

RARE O
with O
the O
available O
amino O
acid O
RARE O
( O
RARE O
) O
sequence O
RARE O
from O
the O
RARE O
ALL_CAP I-GENE
RNA I-GENE
1 I-GENE
sequence I-GENE
and O
the O
partial O
sequence O
of O
RARE I-GENE
RARE I-GENE
RARE I-GENE
virus I-GENE
RNA I-GENE
1 I-GENE
suggest O
that O
ALL_CAP I-GENE
RNA I-GENE
1 I-GENE
specifies O
the O
expected O
set O
of O
five O
RARE O
proteins O
: O
NUM I-GENE
RARE I-GENE
cofactor I-GENE
, O
NUM I-GENE
RARE I-GENE
RARE I-GENE
, O
RARE I-GENE
5 I-GENE
'- I-GENE
RARE I-GENE
protein I-GENE
of O
the O
genomic O
RNAs O
, O
NUM I-GENE
RARE I-GENE
, O
and O
NUM I-GENE
RARE I-GENE
polymerase I-GENE
, O
separated O
by O
four O
RARE O
sites O
. O

RARE I-GENE
RARE I-GENE
RARE I-GENE
segment I-GENE
NUM I-GENE
transcript I-GENE
is O
RARE O
in O
vitro O
. O

In O
addition O
, O
the O
RARE O
of O
beta I-GENE
2 I-GENE
transferrin I-GENE
assay O
in O
the O
diagnosis O
of O
RARE O
RARE O
RARE O
is O
presented O
. O

RARE O
RARE O
was O
administered O
RARE O
NUM O
mm O
Hg O
every O
20 O
minutes O
RARE O
2 O
hours O
. O

The O
addition O
of O
RARE O
to O
the O
ALL_CAP O
led O
to O
a O
dose O
- O
dependent O
biphasic O
change O
in O
ALL_CAP O
and O
GFR O
characterized O
by O
an O
initial O
transient O
increase O
followed O
by O
a O
marked O
and O
sustained O
decrease O
. O

To O
RARE O
RARE O
analyses O
with O
the O
family O
variables O
, O
we O
next O
present O
RARE O
data O
based O
on O
separate O
principal O
RARE O
analysis O
( O
ALL_CAP O
) O
and O
RARE O
RARE O
analysis O
( O
ALL_CAP O
) O
of O
14 O
self O
- O
reported O
health O
scores O
RARE O
RARE O
and O
RARE O
RARE O
. O

The O
structural O
genes O
encoding O
RARE I-GENE
- I-GENE
3 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
( O
ALL_CAP I-GENE
RARE O
3 I-GENE
- I-GENE
RARE I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
and O
the O
N O
- O
terminal O
part O
of O
RARE I-GENE
isomerase I-GENE
( O
ALL_CAP I-GENE
) O
from O
RARE O
Bacillus O
RARE O
NUM O
have O
been O
RARE O
RARE O
a O
gene O
cluster O
( O
RARE I-GENE
operon I-GENE
) O
by O
RARE O
of O
an O
Escherichia O
coli O
RARE I-GENE
RARE I-GENE
mutant I-GENE
. O

RARE I-GENE
RARE I-GENE
RARE I-GENE
A I-GENE
: O
its O
role O
in O
retardation O
of O
wound O
healing O
: O
the O
1992 O
RARE O
RARE O
. O

Laboratory O
studies O
showed O
that O
the O
direct O
RARE O
- O
antibody O
RARE O
were O
the O
least O
RARE O
in O
this O
case O
and O
did O
not O
detect O
fewer O
than O
10 O
( O
4 O
) O
RARE O
RARE O
per O
ml O
, O
while O
most O
ELISA O
RARE O
detected O
between O
NUM O
and O
600 O
RARE O
RARE O
per O
ml O
. O

To O
study O
the O
significance O
of O
these O
domains O
and O
the O
overall O
evolutionary O
conservation O
of O
the O
gene O
, O
the O
homolog O
from O
Drosophila O
melanogaster O
was O
isolated O
by O
low O
RARE O
RARE O
using O
two O
flanking O
RARE O
of O
the O
human I-GENE
NUM I-GENE
cDNA I-GENE
. O

RARE O
- O
ALL_CAP O
- O
RARE O
is O
a O
reversible O
modification O
of O
proteins O
, O
with O
ALL_CAP O
: O
RARE I-GENE
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
( O
EC I-GENE
2 I-GENE
. I-GENE
4 I-GENE
. I-GENE
2 I-GENE
. I-GENE
NUM I-GENE
) O
and O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
( O
EC I-GENE
3 I-GENE
. I-GENE
2 I-GENE
. I-GENE
2 I-GENE
. I-GENE
19 I-GENE
) O
RARE O
the O
RARE O
reactions O
in O
an O
ALL_CAP O
- O
RARE O
RARE O
. O

For O
this O
RARE O
, O
the O
RARE O
forming O
capacity O
of O
RARE O
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
group I-GENE
specific I-GENE
core I-GENE
antigen I-GENE
p55 I-GENE
gag I-GENE
was O
assayed O
and O
compared O
dependent O
on O
various O
RARE O
RARE O
: O
recombinant O
bacteria O
, O
RARE O
- O
and O
RARE O
were O
established O
encoding O
the O
RARE O
core I-GENE
protein I-GENE
p55 I-GENE
either O
in O
its O
RARE O
sequence O
or O
RARE O
the O
RARE O
consensus O
signal O
. O

The O
RARE I-GENE
( O
RARE I-GENE
) O
gene O
of O
Drosophila O
encodes O
NUM O
- O
kDa O
and O
88 O
- O
kDa O
proteins O
through O
RARE O
RARE O
of O
the O
RARE O
RARE I-GENE
transcript I-GENE
. O

Removal O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
by O
hemodialysis O
and O
RARE O
: O
a O
four O
year O
follow O
RARE O
. O

Removal O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
by O
hemodialysis O
and O
RARE O
: O
a O
four O
year O
follow O
RARE O
. O

RARE O
was O
established O
to O
RARE O
a O
decrease O
of O
the O
amplitude O
of O
the O
dominant O
peak O
and O
dominant O
RARE O
- O
activity O
in O
power O
spectra O
of O
the O
EEG O
in O
the O
cortex O
and O
RARE O
, O
with O
an O
increase O
of O
rapid O
wave O
activity O
in O
the O
beta O
2 O
range O
in O
the O
right O
cortex O
and O
RARE O
. O

These O
sequences O
were O
then O
used O
to O
clone O
the O
full O
- O
length O
genes O
from O
a O
yeast O
genomic O
library O
. O

GAL4 I-GENE
- O
VP16 I-GENE
- O
RARE O
RARE O
required O
an O
RARE O
factor O
, O
RARE O
RARE O
a O
RARE O
- O
RARE O
, O
which O
was O
partially O
RARE O
from O
Drosophila O
RARE O
. O

After O
NUM O
days O
of O
haloperidol O
treatment O
, O
similar O
changes O
were O
observed O
RARE O
delta O
, O
together O
with O
an O
increase O
of O
alpha O
1 O
, O
and O
a O
decrease O
of O
fast O
beta O
. O

Four O
RARE O
and O
RARE O
RARE O
RARE O
RARE O
were O
used O
in O
a O
4 O
RARE O
4 O
RARE O
square O
experiment O
to O
determine O
whether O
RARE O
methionine O
and O
RARE O
RARE O
would O
increase O
duodenal O
flow O
of O
RARE O
fatty O
RARE O
( O
C18 O
: O
2 O
+ O
cis O
C18 O
: O
1 O
). O

RARE I-GENE
ALL_CAP I-GENE
RARE O
the O
RARE O
NUM O
amino O
- O
terminal O
amino O
RARE O
fails O
to O
bind O
to O
the O
ALL_CAP I-GENE
, O
indicating O
that O
RARE O
least O
part O
of O
the O
DNA O
binding O
domain O
is O
RARE O
within O
the O
RARE O
RARE O
amino O
terminus O
. O

Therefore O
, O
ALL_CAP I-GENE
may O
be O
involved O
in O
maintaining O
RARE O
transcriptional O
activity O
of O
IFN I-GENE
- O
inducible O
genes O
in O
hematopoietic O
cells O
. O

A O
case O
of O
chronic O
hepatitis O
C O
with O
RARE O
hypothyroidism O
manifested O
RARE O
RARE I-GENE
treatment O

RARE O
RARE O
making O
: O
human O
control O
of O
complex O
RARE O
. O

A O
RARE I-GENE
- I-GENE
RARE I-GENE
related I-GENE
protein I-GENE
specific O
RARE O
RARE O
regions O
of O
RARE O
RARE O
chromosomes O
. O

RARE O
amounts O
of O
alpha I-GENE
5 I-GENE
beta I-GENE
1 I-GENE
integrin I-GENE
were O
isolated O
from O
these O
cells O
by O
chromatography O
of O
detergent O
extracts O
on O
a O
fibronectin I-GENE
cell O
- O
binding O
fragment O
affinity O
column O
and O
RARE O
with O
EDTA O
. O

RARE O
. O

These O
results O
indicate O
a O
possible O
involvement O
of O
endogenous O
RARE O
peptides O
in O
the O
cardiac O
effects O
due O
to O
RARE O
ischaemia O
and O
reperfusion O
, O
RARE O
by O
RARE I-GENE
receptors I-GENE
through O
RARE O
RARE O
. O

From O
this O
library O
, O
LEU2 I-GENE
and O
HIS3 I-GENE
cDNAs O
were O
recovered O
RARE O
a O
frequency O
of O
about O
1 O
in O
10 O
( O
4 O
) O
and O
in O
12 O
out O
of O
NUM O
cases O
these O
were O
RARE O
in O
a O
RARE O
- O
dependent O
manner O
. O

Among O
these O
, O
NUM I-GENE
was O
isolated O
four O
times O
, O
and O
NUM I-GENE
three O
times O
. O

Since O
ALL_CAP I-GENE
- I-GENE
B I-GENE
gene I-GENE
is O
RARE O
in O
mammalian O
species O
and O
ALL_CAP I-GENE
- I-GENE
B I-GENE
RARE I-GENE
are O
found O
also O
in O
mouse O
centromere O
RARE O
DNA O
( O
minor O
RARE O
RARE O
this O
sequence O
- O
specific O
DNA O
- O
protein O
interaction O
may O
be O
important O
RARE O
some O
RARE O
of O
common O
centromere O
function O
. O

Interestingly O
, O
a O
portion O
of O
the O
RARE O
domain O
( O
RARE O
, O
1 O
, O
NUM O
- O
1 O
, O
NUM O
) O
shares O
58 O
% O
amino O
acid O
sequence O
identity O
with O
a O
NUM O
- O
RARE O
protein O
from O
mouse O
brain O
reported O
to O
be O
a O
RARE I-GENE
acid I-GENE
decarboxylase I-GENE
. O

However O
, O
in O
the O
subgroup O
with O
normal O
RARE O
(< O
NUM O
. O
NUM O
RARE O
/ O
RARE O
; O
RARE O
= O
NUM O
) O
there O
was O
a O
significant O
reduction O
( O
p O
< O
NUM O
. O
05 O
) O
of O
the O
mortality O
after O
3 O
months O
( O
NUM O
% O
and O
16 O
%, O
respectively O
) O
and O
an O
increase O
of O
RARE O
RARE O
home O
( O
NUM O
% O
and O
NUM O
%, O
respectively O
) O
due O
to O
a O
reduction O
of O
the O
viscosity O
by O
means O
of O
RARE O
with O
albumin I-GENE
( O
a O
specific O
viscosity O
effect O
in O
the O
RARE O
group O
). O

RARE O
and O
changing O
morphological O
course O

The O
appropriate O
use O
and O
benefits O
of O
bile O
acid O
RARE O
, O
RARE O
acid O
, O
RARE O
RARE O
, O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
3 I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
A I-GENE
( I-GENE
HMG I-GENE
- I-GENE
CoA I-GENE
) I-GENE
reductase I-GENE
RARE O
, O
and O
RARE O
are O
individually O
discussed O
, O
whereas O
RARE O
approaches O
used O
in O
conjunction O
with O
the O
drugs O
are O
recommended O
RARE O
. O

This O
may O
result O
in O
more O
RARE O
and O
hence O
RARE O
RARE O
clearance O
. O

The O
major O
pathological O
findings O
of O
the O
placenta O
were O
RARE O
and O
RARE O
. O

RARE O
RARE O
significantly O
inhibited O
N O
- O
RARE O
- O
RARE O
acid O
formation O
relative O
to O
RARE O
acid O
alone O
. O

A O
genomic O
clone O
, O
NUM O
, O
containing O
DNA O
apparently O
RARE O
specifically O
in O
Trypanosoma O
RARE O
RARE O
, O
was O
obtained O
by O
differentially O
screening O
a O
genomic O
library O
with O
RARE O
and O
RARE O
cDNA O
. O

RARE O
RARE O
1990 O

RARE O
of O
urea O
by O
RARE O
urease I-GENE
coupled O
to O
a O
differential O
pH O
- O
RARE O
. O

RESULTS O
: O
In O
the O
ALL_CAP O
group O
, O
both O
RARE O
and O
RARE O
serum O
prolactin I-GENE
concentration O
increased O
significantly O
with O
gestation O
( O
P O
< O
NUM O
. O
001 O
and O
P O
< O
NUM O
. O
01 O
, O
respectively O
). O

One O
RARE O
clone O
contains O
a O
RARE O
between O
alpha O
RARE O
DNA O
and O
a O
novel O
low O
- O
copy O
RARE O
sequence O
. O

The O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
RARE I-GENE
gene I-GENE
was O
isolated O
from O
a O
human O
RARE O
genomic O
library O
. O

Therefore O
, O
the O
RARE O
mechanisms O
of O
the O
estrogen O
action O
that O
govern O
the O
RARE I-GENE
gene I-GENE
RARE O
differ O
between O
mouse O
and O
human O
. O

NUM I-GENE
retains O
basal O
and O
NUM O
+ O
RARE O
NUM O
- O
inducible O
activities O
. O

The O
ALL_CAP O
RARE O
RARE O
RARE O
via O
an O
NUM O
RARE O
and O
RARE O
data O
RARE O
in O
RARE O
via O
an O
interface O
to O
the O
RARE O
database O
. O

Magnetic O
resonance O
spectroscopy O
( O
MRS O
) O
and O
imaging O
( O
MRI O
) O
are O
now O
RARE O
established O
techniques O
RARE O
the O
study O
of O
cellular O
metabolism O
and O
gross O
RARE O
of O
muscle O
. O

RARE O
a O
greater O
NA O
was O
found O
with O
RARE O
change O
in O
plasma O
epinephrine O
response O
. O

We O
investigated O
the O
diagnostic O
value O
of O
a O
new O
in O
vitro O
test O
, O
Pharmacia O
ALL_CAP O
RARE O
( O
Pharmacia O
RARE O
ALL_CAP O
, O
RARE O
, O
RARE O
RARE O
RARE O
the O
quantitative O
measurement O
of O
RARE I-GENE
- I-GENE
specific I-GENE
IgE I-GENE
antibodies I-GENE
by O
comparison O
with O
RAST O
in O
2 O
groups O
of O
patients O
, O
NUM O
atopic O
and O
NUM O
non O
- O
atopic O
. O

Patients O
receiving O
ALL_CAP O
showed O
differences O
in O
attention O
, O
RARE O
performance O
, O
RARE O
span O
and O
sensory O
discrimination O
tasks O
RARE O
NUM O
, O
in O
RARE O
performance O
RARE O
NUM O
and O
in O
spatial O
span O
RARE O
NUM O
, O
whereas O
RARE O
differences O
were O
detected O
RARE O
T4 O
. O

We O
found O
that O
the O
gene O
segment O
containing O
the O
mu O
m O
RARE O
( O
A O
) O
signals O
, O
along O
with O
NUM O
bp O
of O
RARE O
flanking O
sequence O
, O
RARE O
RARE O
a O
transcription O
terminator O
in O
both O
myeloma O
cells O
and O
L O
cell O
RARE O
. O

As O
a O
part O
of O
a O
large O
examination O
, O
RARE O
and O
free O
serum O
cholesterol O
, O
RARE O
RARE O
and O
RARE O
levels O
were O
determined O
. O

RARE O
is O
a O
nurse O
in O
RARE O
RARE O
RARE O
RARE O
of O
RARE O
RARE O
and O
a O
RARE O
across O
the O
RARE O

RARE O
neurons O
in O
subjects O
that O
received O
6 O
- O
ALL_CAP O
were O
protected O
by O
pre O
- O
treatment O
with O
ALL_CAP O
- O
NUM O
. O

ALL_CAP O
was O
more O
RARE O
and O
had O
a O
better O
negative O
predictive O
value O
and O
a O
lower O
false O
negative O
percentage O
than O
ALL_CAP O
. O

RARE O
and O
RARE O
have O
been O
one O
of O
the O
most O
spread O
diseases O
of O
RARE O
. O

The O
results O
of O
this O
study O
demonstrate O
that O
RARE O
was O
the O
cause O
of O
RARE O
RARE O
. O

A O
second O
large O
group O
of O
disorders O
in O
RARE O
is O
caused O
by O
effects O
of O
infections O
of O
the O
RARE O
without O
pathogens O
being O
transmitted O
to O
the O
RARE O
or O
the O
placenta O
. O

Four O
short O
nucleotide O
sequences O
( O
RARE O
I O
to O
IV O
) O
contribute O
to O
the O
light O
responsiveness O
of O
the O
RARE I-GENE
RARE I-GENE
synthase I-GENE
promoter I-GENE
. O

The O
case O
described O
is O
that O
of O
a O
72 O
- O
year O
- O
old O
man O
with O
RARE O
who O
RARE O
a O
RARE O
injury O
to O
RARE O
spine O
in O
a O
fall O
, O
resulting O
in O
a O
fracture O
through O
an O
RARE O
L2 O
- O
NUM O
RARE O
space O
. O

The O
mean O
RARE O
flow O
in O
the O
RARE O
RARE O
was O
estimated O
to O
be O
NUM O
ml O
/ O
min O
/ O
NUM O
g O
and O
it O
increased O
to O
NUM O
- O
NUM O
% O
after O
the O
induction O
of O
anesthesia O
, O
and O
then O
decreased O
to O
72 O
% O
RARE O
the O
RARE O
of O
the O
created O
RARE O
RARE O
flap O
. O

NUM I-GENE
, O
a O
16 O
- O
RARE O
- O
RARE O
nuclear O
factor O
binding O
site O
RARE O
between O
the O
c I-GENE
- I-GENE
ALL_CAP I-GENE
P1 I-GENE
and I-GENE
P2 I-GENE
transcription I-GENE
initiation I-GENE
sites I-GENE
, O
is O
required O
RARE O
P2 O
activity O
. O

The O
next O
RARE O
years O
of O
prevention O
in O
RARE O
RARE O
: O
RARE O
, O
complex O
, O
and O
RARE O
. O

RARE O
ALL_CAP I-GENE
is O
also O
known O
to O
facilitate O
RARE O
behavior O
in O
several O
species O
. O

The O
RARE O
NUM O
consecutive O
patients O
treated O
with O
ALL_CAP O
RARE O
the O
period O
from O
August O
, O
1986 O
to O
RARE O
, O
1989 O
are O
reported O
. O

RARE O
the O
RARE O
acid O
with O
a O
RARE O
but O
not O
with O
an O
alanine O
or O
RARE O
RARE O
allowed O
formation O
of O
disulfide O
- O
RARE O
RARE O
. O

During O
V O
- O
A O
bypass O
, O
hemodynamics O
were O
stable O
. O

RARE O
RARE O
force O
was O
required O
in O
the O
adult O
pigs O
than O
in O
the O
young O
pigs O
. O

At O
rest O
ALL_CAP O
was O
significantly O
RARE O
in O
UT O
( O
29 O
%) O
RARE O
compared O
to O
AT O
( O
NUM O
%) O
and O
ALL_CAP O
( O
NUM O
%). O

We O
investigated O
the O
smoking O
RARE O
of O
RARE O
1 O
year O
after O
RARE O
in O
a O
smoking O
cessation O
trial O
using O
nicotine O
or O
placebo O
RARE O
. O

RARE O
to O
hepatitis O
B O
virus O
in O
the O
RARE O
population O
of O
RARE O
, O
Japan O
: O
significance O
of O
isolated O
antibody O
to O
hepatitis I-GENE
B I-GENE
surface I-GENE
antigen I-GENE
in O
RARE O
population O
. O

Because O
of O
this O
latter O
phenomenon O
, O
we O
were O
able O
to O
identify O
a O
particular O
cysteine O
motif O
that O
was O
RARE O
multiple O
times O
in O
NUM I-GENE
but O
present O
only O
twice O
in O
mammalian I-GENE
RARE I-GENE
. O

On O
the O
other O
RARE O
, O
neither O
phosphate O
RARE O
saline O
injection O
into O
the O
ES O
nor O
RARE O
ALL_CAP I-GENE
RARE O
of O
the O
ES O
were O
capable O
of O
RARE O
the O
threshold O
level O
and O
changing O
the O
RARE O
. O

A O
newly O
developed O
broad O
- O
spectrum O
RARE O
, O
RARE O
( O
ALL_CAP O
, O
ALL_CAP O
- O
NUM O
RARE O
was O
evaluated O
in O
vitro O
and O
in O
vivo O
in O
comparison O
with O
RARE O
( O
ALL_CAP O
RARE O
RARE O
( O
ALL_CAP O
) O
and O
RARE O
( O
ALL_CAP O
). O

The O
mean O
serum O
RARE O
levels O
were O
similar O
RARE O
one O
year O
( O
ALL_CAP O
1 O
. O
8 O
, O
ALL_CAP O
1 O
. O
9 O
mg O
/ O
d O
RARE O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

RARE O
predictions O
were O
in O
RARE O
with O
the O
nine O
- O
year O
survival O
experience O
of O
women O
in O
the O
ALL_CAP O
trial O
, O
and O
, O
with O
the O
exception O
of O
women O
40 O
- O
NUM O
years O
old O
, O
with O
ALL_CAP O
data O
on O
18 O
- O
year O
survival O
. O

RARE O
- O
resolution O
computed O
tomography O
in O
the O
diagnosis O
of O
RARE O
tuberculosis O
. O

Previously O
, O
we O
showed O
that O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
function O
RARE O
in O
transcriptional O
activation O
, O
possibly O
forming O
a O
RARE O
complex O
. O

We O
show O
that O
LexA I-GENE
- O
GAL4 I-GENE
and O
LexA I-GENE
- O
RARE I-GENE
fusion O
proteins O
are O
both O
dependent O
on O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
RARE O
activation O
of O
target O
genes O
containing O
one O
or O
multiple O
ALL_CAP I-GENE
RARE I-GENE
. O

RARE O
T O
. O

A O
lambda O
NUM O
cDNA O
library O
was O
constructed O
from O
RARE O
( O
A O
)+ O
RNA O
of O
young O
RARE O
leaves O
of O
RARE O
. O

ALL_CAP I-GENE
and O
NUM I-GENE
RARE O
in O
the O
RARE O
of O
RARE O
RARE O
, O
RARE O
the O
important O
RARE I-GENE
- I-GENE
tissue I-GENE
protein I-GENE
elastin I-GENE
, O
and O
generate O
chemotactic O
activities O
by O
forming O
alpha I-GENE
1 I-GENE
- I-GENE
RARE I-GENE
inhibitor I-GENE
complexes I-GENE
and O
elastin I-GENE
peptides I-GENE
. O

RARE O
RARE O
in O
pediatric O
ultrasonography O
RARE O
1992 O
. O

RARE O
included O
NUM O
- O
hour O
dietary O
RARE O
, O
RARE O
weights O
, O
and O
RARE O
analysis O
. O

Factors O
associated O
with O
RARE O
included O
age O
, O
end O
- O
of O
- O
surgery O
RARE O
( O
both O
positively O
) O
and O
body O
mass O
( O
negatively O
). O

Both O
ALL_CAP I-GENE
deficiency O
and O
impaired O
RARE O
growth O
may O
result O
in O
short O
RARE O
, O
whereas O
the O
occurrence O
of O
early O
RARE O
in O
association O
with O
ALL_CAP I-GENE
deficiency O
reduces O
the O
time O
available O
RARE O
ALL_CAP I-GENE
therapy O
. O

By O
contrast O
, O
d I-GENE
( I-GENE
NUM I-GENE
) I-GENE
and O
d I-GENE
( I-GENE
NUM I-GENE
) I-GENE
form O
only O
the O
G O
- O
RARE O
RARE O
RARE O
independent O
of O
K O
RARE O
concentration O
RARE O
reported O
previously O
RARE O
RARE O
, O
D O
., O
& O
RARE O
, O
ALL_CAP O
. O

RARE O
among O
RARE O
RARE O
. O

ALL_CAP I-GENE
16 I-GENE
mRNA I-GENE
was O
found O
to O
be O
constitutively O
RARE O
in O
RARE O
cells O
and O
in O
cell O
lines O
of O
both O
the O
T O
and O
B O
lineages O
. O

RARE O
- O
lytic O
action O
of O
RARE O
in O
lymphocytes O
. O

RARE O
- O
intron O
junctions O
in O
the O
human O
and O
rat I-GENE
RARE I-GENE
decarboxylase I-GENE
genes I-GENE
were O
in O
identical O
positions O
except O
that O
exons O
6 O
and O
7 O
of O
the O
human O
gene O
formed O
a O
single O
RARE O
in O
the O
rat O
gene O
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
- O
RARE O
gene O
RARE O
: O
evidence O
RARE O
a O
selective O
effect O
of O
RARE O
on O
activation O
of O
the O
NUM I-GENE
transcription I-GENE
complex I-GENE
. O

The O
cDNA O
has O
an O
RARE O
reading O
frame O
of O
NUM O
amino O
RARE O
capable O
of O
encoding O
a O
97 O
- O
kDa O
protein O
. O

Moreover O
, O
LD50 O
in O
mice O
of O
ALL_CAP O
- O
NUM O
( O
4 O
. O
3 O
g O
/ O
kg O
on O
i O
. O
v O
.) O
was O
increased O
to O
5 O
. O
2 O
g O
/ O
kg O
by O
oral O
administration O
. O

Among O
the O
few O
proteins O
of O
the O
eukaryotic O
RARE O
that O
have O
been O
characterized O
, O
four O
proteins O
, O
RARE I-GENE
, O
RARE I-GENE
, O
NUM I-GENE
and O
NUM I-GENE
, O
possess O
a O
common O
structural O
motif O
, O
the O
ALL_CAP O
domain O
, O
which O
is O
rich O
in O
glycine O
and O
RARE O
residues O
. O

Thus O
, O
this O
study O
provides O
evidence O
that O
a O
novel O
, O
ubiquitous O
factor O
( O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
) O
and O
a O
muscle O
factor O
( O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
/ O
MEF I-GENE
- I-GENE
2 I-GENE
) O
can O
form O
a O
novel O
, O
E O
- O
box O
- O
independent O
RARE O
RARE O
muscle O
- O
specific O
RARE O
in O
ventricular O
cardiac O
muscle O
cells O
. O

Mutations O
in O
either O
gene O
RARE O
some O
crucial O
RARE O
step O
in O
assembly O
of O
NUM I-GENE
, O
causing O
the O
alpha O
and O
beta O
subunits O
to O
accumulate O
in O
RARE O
RARE O
inactive O
aggregates O
( O
RARE O
, O
S O
. O

RARE O
limits O
the O
use O
of O
hepatitis O
B O
vaccines O
, O
but O
low O
- O
dose O
RARE O
immunization O
has O
been O
evaluated O
RARE O
a O
cost O
- O
RARE O
strategy O
in O
numerous O
studies O
. O

RARE O
RARE O
therapy O
and O
risk O
of O
breast O
RARE O
: O
results O
of O
two O
RARE O
- O
analyses O
. O

RARE O
ALL_CAP O
- O
P1 O
/ O
ALL_CAP O
cells O
from O
growth O
in O
M I-GENE
- I-GENE
CSF I-GENE
to O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
caused O
the O
selective O
RARE O
of O
c I-GENE
- I-GENE
fms I-GENE
mRNA I-GENE
within O
6 O
h O
after O
factor O
switching O
. O

There O
was O
however O
, O
RARE O
significant O
difference O
in O
the O
prevalence O
of O
chronic O
respiratory O
symptoms O
between O
RARE O
food O
workers O
with O
positive O
and O
negative O
RARE O
tests O
to O
RARE O
dust O
or O
to O
fish O
RARE O
or O
among O
those O
with O
increased O
or O
normal O
IgE I-GENE
( O
except O
RARE O
RARE O
). O

An O
RARE O
finding O
was O
the O
presence O
RARE O
position O
- O
NUM O
to O
- O
NUM O
of O
a O
putative O
RARE O
responsive O
element O
, O
a O
sequence O
found O
to O
be O
responsible O
RARE O
the O
induction O
of O
transcription O
of O
the O
cytochrome I-GENE
NUM I-GENE
gene I-GENE
( O
NUM I-GENE
) O
and O
other O
genes O
involved O
in O
RARE O
/ O
activation O
of O
RARE O
aromatic O
RARE O
. O

The O
gene O
encoding O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
maps O
to O
mouse O
RARE O
14 O
, O
in O
the O
region O
of O
the O
coat I-GENE
RARE I-GENE
mutation I-GENE
RARE I-GENE
. O

Using O
bovine I-GENE
and I-GENE
murine I-GENE
c I-GENE
- I-GENE
myb I-GENE
RARE O
, O
RARE O
change O
in O
the O
rate O
of O
c I-GENE
- I-GENE
myb I-GENE
gene I-GENE
transcription O
or O
mRNA O
stability O
was O
detected O
RARE O
the O
cell O
RARE O
. O

A O
NUM O
RARE O
- O
RARE O
RARE O
spanning O
nucleotides O
+ O
NUM O
to O
+ O
92 O
of O
the O
5 I-GENE
S I-GENE
RNA I-GENE
gene I-GENE
retained O
specific O
and O
high O
- O
affinity O
binding O
, O
although O
the O
latter O
was O
RARE O
RARE O
relative O
to O
longer O
DNA O
fragments O
. O

Moreover O
, O
the O
RARE O
of O
ALL_CAP I-GENE
and O
TFIID I-GENE
- O
depleted O
transcription O
complexes O
with O
RARE O
protein O
fractions O
demonstrate O
that O
not O
only O
TFIID I-GENE
but O
also O
ALL_CAP I-GENE
essentially O
participates O
in O
complex O
formation O
even O
on O
NUM I-GENE
promoter I-GENE
mutations O
RARE O
the O
TATA O
- O
box O
. O

A O
comparison O
of O
the O
amino O
acid O
sequence O
of O
the O
T O
. O
RARE O
enzyme O
with O
that O
of O
the O
Escherichia O
coli O
enzyme O
showed O
( O
i O
) O
a O
37 O
% O
overall O
RARE O
; O
( O
ii O
) O
the O
conservation O
of O
the O
RARE O
RARE O
, O
which O
is O
known O
to O
be O
RARE O
in O
the O
E O
. O
coli O
enzyme O
, O
and O
of O
the O
surrounding O
sequence O
; O
and O
( O
iii O
) O
the O
presence O
of O
NUM O
RARE O
residues O
RARE O
the O
C O
terminus O
of O
the O
T O
. O
RARE O
enzyme O
. O

RARE O
RARE O
was O
not O
incorporated O
into O
the O
RARE O
protein O
, O
showing O
that O
RARE O
modification O
occurs O
RARE O
the O
RARE O
- O
NUM O
RARE O
. O

NUM O
RARE O
RARE O
RARE O
were O
compared O
with O
18 O
RARE O
hearing O
RARE O
on O
the O
RARE O
RARE O
Clinical O
Scale O
( O
ALL_CAP O
) O
of O
RARE O
and O
ALL_CAP O
. O

RARE I-GENE
tobacco I-GENE
NUM I-GENE
protein I-GENE
has O
NUM O
% O
amino O
acid O
identity O
with O
ribosomal O
protein O
NUM I-GENE
/ O
NUM I-GENE
of O
Escherichia O
coli O
. O

Nuclear I-GENE
- I-GENE
encoded I-GENE
chloroplast I-GENE
ribosomal I-GENE
protein I-GENE
NUM I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
: O
characterization O
of O
RARE O
protein O
and O
isolation O
and O
sequence O
analysis O
of O
cDNA O
RARE O
encoding O
its O
cytoplasmic O
precursor O
. O

The O
gene O
encoding O
IFN I-GENE
- I-GENE
gamma I-GENE
was O
previously O
found O
to O
contain O
an O
RARE O
enhancer O
element O
that O
was O
not O
tissue O
- O
specific O
in O
its O
activity O
, O
despite O
the O
restricted O
RARE O
of O
the O
RARE O
IFN I-GENE
- I-GENE
gamma I-GENE
- I-GENE
encoding I-GENE
gene I-GENE
. O

Molecular O
cloning O
of O
the O
polypeptide O
RARE O
of O
the O
Rel I-GENE
- I-GENE
related I-GENE
human I-GENE
NUM I-GENE
RARE I-GENE
complex I-GENE
has O
revealed O
its O
identity O
with O
the O
65 O
- O
kDa O
( O
NUM I-GENE
) O
subunit O
of O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
. O

Because O
single O
- O
chamber O
rate O
- O
adaptive O
RARE O
pacing O
leaves O
the O
patient O
exposed O
to O
the O
risk O
of O
future O
development O
of O
AV O
RARE O
and O
ALL_CAP O
pacing O
does O
not O
provide O
RARE O
support O
, O
it O
is O
likely O
that O
the O
new O
rate O
- O
adaptive O
dual O
- O
chamber O
( O
ALL_CAP O
) O
RARE O
will O
be O
used O
in O
a O
significant O
number O
of O
these O
patients O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

When O
transiently O
transfected O
into O
K562 O
cells O
, O
this O
RARE I-GENE
genomic O
clone O
is O
actively O
RARE O
, O
suggesting O
that O
, O
although O
it O
possesses O
the O
characteristics O
of O
a O
processed O
RARE O
, O
it O
is O
likely O
to O
correspond O
to O
the O
gene O
encoding O
this O
new O
ferritin I-GENE
subunit I-GENE
. O

Of O
the O
drugs O
orally O
administered O
, O
WR O
- O
NUM O
was O
the O
best O
RARE O
with O
a O
ALL_CAP O
of O
1 O
. O
NUM O
. O

Characterization O
of O
these O
R O
subunits O
by O
their O
8 O
- O
RARE O
- O
cAMP O
RARE O
labeling O
and O
immunoreactivity O
, O
RARE O
RARE O
RARE O
by O
a O
RARE O
- O
dependent O
mobility O
shift O
on O
RARE O
dodecyl O
RARE O
- O
polyacrylamide O
gel O
electrophoresis O
( O
SDS O
- O
PAGE O
RARE O
indicated O
subunit O
sizes O
of O
RII I-GENE
beta I-GENE
( O
53 O
kDa O
) O
greater O
than O
RII I-GENE
alpha I-GENE
RARE O
( O
NUM O
kDa O
) O
greater O
than O
ALL_CAP I-GENE
alpha I-GENE
( O
NUM O
kDa O
). O

Comparison O
of O
the O
genomic O
DNA O
sequence O
with O
that O
of O
the O
four O
different O
mRNAs O
indicates O
that O
these O
transcripts O
are O
produced O
by O
RARE O
RARE O
of O
the O
murine O
pre O
- O
mRNA O
according O
to O
a O
RARE O
model O
. O

During O
the O
1980 O
' O
s O
, O
RARE O
of O
RARE O
RARE O
, O
especially O
C I-GENE
reactive I-GENE
protein I-GENE
, O
rheumatoid I-GENE
factor I-GENE
and O
RARE I-GENE
O I-GENE
, O
progressed O
rapidly O
. O

Within O
the O
human O
enhancer O
, O
these O
two O
sites O
are O
RARE O
within O
the O
previously O
defined O
DNase I-GENE
I I-GENE
RARE I-GENE
, O
NFAT I-GENE
- I-GENE
1 I-GENE
and O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
respectively O
. O

The O
cardiac I-GENE
myosin I-GENE
light I-GENE
chain I-GENE
- I-GENE
2 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
) O
gene O
promoter O
contains O
several O
positive O
and O
negative O
cis O
- O
acting O
sequences O
that O
are O
involved O
in O
the O
RARE O
of O
its O
RARE O
. O

Deletion O
mutagenesis O
demonstrated O
that O
these O
two O
elements O
are O
involved O
in O
the O
positive O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
gene I-GENE
transcription O
. O

Disruption O
mutations O
have O
been O
constructed O
in O
the O
NUM I-GENE
gene I-GENE
. O
NUM I-GENE
RARE I-GENE
mutants I-GENE
cannot O
grow O
RARE O
37 O
degrees O
C O
, O
but O
many O
cells O
can O
grow O
RARE O
NUM O
, O
NUM O
, O
and O
NUM O
degrees O
C O
. O

Molecular O
and O
genetic O
analysis O
of O
the O
yeast I-GENE
early I-GENE
RARE I-GENE
RARE I-GENE
genes I-GENE
NUM I-GENE
and O
NUM I-GENE
/ O
NUM I-GENE
. O

The O
p130 I-GENE
and O
p62 I-GENE
tyrosine O
- O
RARE O
proteins O
that O
complexed O
v I-GENE
- I-GENE
Src I-GENE
NUM I-GENE
in O
vitro O
also O
associated O
with O
v I-GENE
- I-GENE
Src I-GENE
in O
v I-GENE
- I-GENE
src I-GENE
- O
transformed O
RARE O
- O
2 O
cells O
; O
this O
in O
vivo O
binding O
was O
dependent O
on O
the O
v I-GENE
- I-GENE
Src I-GENE
NUM I-GENE
domain O
. O

RARE O
progressive O
RARE O
RARE O
( O
ALL_CAP O
) O
was O
diagnosed O
on O
the O
basis O
of O
clinical O
picture O
and O
magnetic O
resonance O
imaging O
in O
a O
NUM O
- O
year O
- O
old O
man O
with O
a O
RARE O
remission O
of O
a O
non O
- O
Hodgkin O
' O
s O
lymphoma O
. O

These O
data O
support O
a O
possible O
biological O
significance O
of O
the O
frameshift O
to O
occur O
RARE O
this O
position O
of O
the O
large O
overlap O
by O
including O
the O
putative O
RNA O
template O
- O
binding O
site O
of O
the O
ALL_CAP I-GENE
RARE I-GENE
in O
the O
NUM I-GENE
/ I-GENE
NUM I-GENE
RARE I-GENE
protein I-GENE
. O

RARE O
RARE O
occurs O
RARE O
. O

A O
32P O
- O
labeled O
ALL_CAP I-GENE
DNA O
- O
binding O
and O
RARE O
domain O
" O
zipper O
probe O
" O
was O
used O
to O
isolate O
a O
clone O
that O
encodes O
a O
new O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
homologous I-GENE
protein I-GENE
: O
ALL_CAP I-GENE
- I-GENE
10 I-GENE
. O

Using O
a O
degenerate O
RARE O
( O
RARE O
) O
based O
on O
the O
N O
- O
terminal O
RARE O
sequence O
, O
RARE O
an O
internal O
RARE O
homologous O
to O
a O
RARE O
region O
within O
the O
portion O
of O
NUM I-GENE
and O
NUM I-GENE
that O
had O
been O
RARE O
in O
the O
genome O
, O
a O
NUM I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
fragment I-GENE
was O
generated O
by O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
using O
NUM O
genomic O
DNA O
RARE O
a O
substrate O
. O

RARE O
hybridization O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
back O
to O
primate O
genomic O
DNA O
indicates O
two O
distinct O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
loci I-GENE
in O
normal O
human O
DNA O
, O
an O
identical O
band O
pattern O
in O
RARE O
DNA O
, O
and O
a O
single O
locus O
in O
RARE O
RARE O
DNA O
. O

The O
level O
of O
RARE I-GENE
- I-GENE
terminal I-GENE
RARE I-GENE
hormone I-GENE
in O
the O
patients O
with O
thyroid O
carcinoma O
was O
RARE O
than O
that O
in O
the O
patients O
without O
thyroid O
carcinoma O
( O
P O
less O
than O
NUM O
. O
05 O
). O

The O
Caenorhabditis I-GENE
elegans I-GENE
RARE I-GENE
genes I-GENE
are O
subject O
to O
RARE O
RARE O
RARE O
RARE O
and O
tissue O
- O
specific O
RARE O
: O
they O
are O
RARE O
solely O
in O
the O
adult O
RARE O
intestine O
. O

The O
NUM I-GENE
gene O
was O
RARE O
, O
and O
its O
sequence O
reveals O
that O
it O
encodes O
a O
protein O
related O
to O
the O
family O
of O
the O
ALL_CAP I-GENE
transcriptional I-GENE
RARE I-GENE
. O

The O
functions O
of O
isolated O
portions O
of O
the O
insulin I-GENE
, O
ALL_CAP I-GENE
, O
and O
beta I-GENE
ALL_CAP I-GENE
promoters I-GENE
were O
studied O
by O
using O
transient O
RARE O
and O
DNA O
binding O
assays O
. O

It O
is O
believed O
that O
these O
domains O
are O
important O
RARE O
RARE O
specific O
protein O
- O
protein O
interactions O
necessary O
RARE O
the O
proper O
functioning O
of O
Src I-GENE
. O

The O
c I-GENE
- I-GENE
Ets I-GENE
- I-GENE
1 I-GENE
RARE I-GENE
is O
a O
transcription O
activator O
that O
specifically O
binds O
to O
DNA O
. O

Previous O
RARE O
experiments O
indicated O
that O
three O
amino O
RARE O
RARE O
in O
this O
region O
, O
RARE O
, O
RARE O
and O
RARE O
, O
appear O
to O
be O
critical O
RARE O
target O
- O
site O
discrimination O
. O

NUM O
is O
a O
water O
- O
RARE O
analogue O
of O
RARE O
, O
a O
RARE O
RARE O
. O

RARE O
rescue O
analysis O
has O
localized O
NUM I-GENE
to O
a O
NUM O
- O
bp O
internal O
segment O
of O
ALL_CAP I-GENE
that O
encodes O
the O
RARE I-GENE
domain I-GENE
. O

This O
vector O
transfected O
into O
the O
yeast O
Saccharomyces O
cerevisiae O
directs O
RARE O
of O
a O
RARE O
RARE O
protein O
RARE O
levels O
RARE O
to O
NUM O
mg O
of O
ALL_CAP O
/ O
liter O
of O
culture O
medium O
. O

Competition O
analysis O
by O
gel O
mobility O
shift O
electrophoresis O
indicates O
that O
this O
DNA O
- O
protein O
interaction O
is O
novel O
and O
not O
related O
to O
many O
transcription O
factors O
previously O
reported O
. O

This O
DNA O
motif O
represents O
a O
novel O
protein O
- O
binding O
sequence O
. O

OBJECTIVE O
: O
The O
study O
was O
designed O
to O
investigate O
the O
frequency O
of O
alterations O
in O
serum O
RARE O
in O
patients O
with O
psoriasis O
receiving O
5 O
mg O
/ O
kg O
/ O
day O
of O
cyclosporine O
. O

RARE O
chemotherapy O
in O
adult O
RARE O
using O
a O
new O
RARE O
- O
release O
insert O
containing O
RARE O
( O
PT O
- O
01 O
). O

RARE O
RARE O
flow O
( O
ALL_CAP O
) O
probe O
was O
applied O
on O
the O
RARE O
anterior O
RARE O
artery O
( O
LAD O
). O

Hence O
RARE O
and O
ALL_CAP I-GENE
are O
both O
required O
RARE O
the O
induction O
of O
the O
RARE I-GENE
RARE I-GENE
. O

RARE O
RARE O
to O
be O
resolved O
in O
the O
area O
of O
quantitative O
risk O
assessment O
. O

The O
recently O
developed O
gamma I-GENE
- I-GENE
RARE I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
) O
assay O
RARE O
RARE O
the O
diagnosis O
of O
bovine O
tuberculosis O
in O
cattle O
has O
been O
RARE O
by O
the O
RARE O
Committee O
on O
RARE O
RARE O
use O
in O
RARE O
. O

Control O
RARE O
was O
NUM O
. O
8 O
+/- O
NUM O
. O
7 O
degrees O
C O
, O
with O
control O
RARE O
, O
RARE O
being O
NUM O
. O
6 O
( O
SD O
8 O
. O
7 O
) O
ALL_CAP O
. O
kg O
- O
1 O
. O

The O
RARE I-GENE
RARE I-GENE
gene I-GENE
ALL_CAP I-GENE
, O
which O
is O
involved O
in O
the O
RARE O
of O
RARE I-GENE
oxidase I-GENE
, O
was O
RARE O
by O
RARE O
and O
the O
related O
compounds O
, O
subjected O
to O
RARE O
and O
RARE O
ion O
repression O
, O
and O
RARE O
. O

However O
, O
other O
regions O
of O
the O
RARE O
are O
also O
efficiently O
RARE O
. O

Eight O
of O
14 O
infectious O
or O
inflammatory O
lesions O
could O
be O
detected O
in O
the O
early O
scan O
( O
4 O
- O
6 O
h O
p O
. O
i O
.). O

Thus O
, O
the O
human I-GENE
NUM I-GENE
gene I-GENE
belongs O
to O
the O
category O
of O
tissue O
- O
specific O
, O
regulated O
genes O
that O
have O
housekeeping O
- O
type O
promoters O
. O

Similar O
observations O
have O
been O
made O
previously O
RARE O
other O
genes O
. O

RARE O
of O
CNS O
students O
: O
an O
RARE O
study O
. O

To O
determine O
the O
genetic O
basis O
RARE O
the O
differences O
between O
the O
cardiac O
and O
brain I-GENE
NUM I-GENE
variants I-GENE
, O
we O
isolated O
and O
characterized O
the O
rat O
gene O
. O

The O
1 O
. O
7 O
kb O
RARE O
fragment O
was O
sequenced O
and O
shown O
to O
contain O
the O
RARE O
ALL_CAP I-GENE
gene I-GENE
. O

RARE O
of O
both O
intravenous O
and O
RARE O
administration O
of O
amphotericin O
B O
and O
possibly O
concomitant O
intravenous O
administration O
of O
dexamethasone O
may O
be O
warranted O
in O
situations O
in O
which O
the O
association O
of O
C O
. O
RARE O
with O
CNS O
vasculitis O
or O
RARE O
appears O
likely O
before O
serologic O
or O
RARE O
RARE O
of O
C O
. O
RARE O
infection O
involving O
the O
CNS O
is O
available O
. O

RARE I-GENE
RARE O
were O
introduced O
into O
several O
positions O
within O
the O
ALL_CAP I-GENE
promoter I-GENE
and O
operator O
- O
free O
RARE O
was O
used O
RARE O
control O
. O

RARE O
, O
purification O
and O
characterization O
of O
M I-GENE
. I-GENE
ALL_CAP I-GENE
RARE I-GENE
and O
its O
deletion O
mutant O
. O

Various O
RARE O
produce O
this O
type O
of O
lens O
. O

From O
RARE O
5 O
through O
RARE O
NUM O
, O
1991 O
, O
eight O
persons O
were O
diagnosed O
with O
elevated O
RARE O
lead O
levels O
( O
RARE O
) O
RARE O
a O
local O
hospital O
and O
were O
reported O
to O
the O
RARE O
RARE O
RARE O
RARE O
maintained O
by O
the O
RARE O
RARE O
of O
RARE O
Health O
( O
ALL_CAP O
). O

According O
to O
the O
changes O
of O
perfusion O
defects O
between O
RARE O
, O
ALL_CAP O
and O
ALL_CAP O
images O
, O
they O
were O
classified O
into O
3 O
RARE O
: O
RARE O
I O
; O
perfusion O
defect O
on O
the O
ALL_CAP O
image O
was O
identical O
to O
ALL_CAP O
image O
( O
NUM O
%) O
RARE O
I O
was O
divided O
into O
2 O
subgroups O
whether O
perfusion O
defect O
RARE O
RARE O
was O
unchanged O
( O
RARE O
, O
NUM O
%) O
or O
improved O
( O
RARE O
, O
NUM O
%) O
on O
the O
ALL_CAP O
image O
. O

RARE O
, O
C O
. O
ALL_CAP O
. O

Twenty O
- O
eight O
( O
7 O
. O
NUM O
%) O
infants O
without O
RARE O
hemorrhage O
were O
revealed O
RARE O
having O
RARE O
cerebral O
RARE O
by O
RARE O
evaluation O
in O
later O
RARE O
. O

A O
possible O
mechanism O
is O
that O
elevated O
alveolar O
pressure O
and O
decreased O
cardiac O
output O
RARE O
RARE O
flow O
from O
RARE O
vessels O
in O
RARE O
high O
VA O
/ O
ALL_CAP O
regions O
. O

RARE O
- O
RARE O
" O
ALL_CAP O
" O
analysis O
revealed O
four O
possible O
RARE O
reading O
frames O
( O
RARE O
RARE O
three O
in O
one O
direction O
and O
one O
in O
the O
opposite O
direction O
. O

RARE O
II O
is O
highly O
homologous O
to O
the O
LDL I-GENE
receptor I-GENE
and O
contains O
four O
repeats O
with O
perfect O
conservation O
of O
all O
6 O
consecutive O
RARE O
. O

In O
both O
RARE O
, O
ALL_CAP O
- O
I O
/ O
II O
prevalence O
increased O
significantly O
with O
age O
, O
and O
the O
New O
RARE O
age O
- O
and O
RARE O
- O
adjusted O
ALL_CAP O
- O
I O
/ O
II O
prevalence O
was O
significantly O
RARE O
than O
that O
of O
RARE O
( O
P O
less O
than O
. O
001 O
). O

Here O
, O
we O
present O
evidence O
RARE O
a O
model O
in O
which O
mRNA O
sequences O
RARE O
to O
around O
NUM O
nucleotides O
RARE O
from O
the O
RARE O
RARE O
of O
NUM O
RARE O
back O
and O
RARE O
- O
RARE O
to O
the O
NUM O
translation O
initiation O
region O
, O
thereby O
decreasing O
the O
translation O
initiation O
frequency O
. O

Hybridization O
data O
indicate O
that O
NUM I-GENE
. I-GENE
2 I-GENE
corresponds O
to O
the O
previously O
characterized O
NUM I-GENE
cDNA I-GENE
clone I-GENE
and O
that O
NUM I-GENE
. I-GENE
1 I-GENE
and O
NUM I-GENE
. I-GENE
3 I-GENE
, O
but O
not O
NUM I-GENE
. I-GENE
2 I-GENE
, O
are O
adjacent O
to O
alpha I-GENE
- I-GENE
type I-GENE
genes I-GENE
. O

The O
NUM I-GENE
gene I-GENE
corresponds O
to O
a O
6 O
, O
NUM O
- O
bp O
RARE O
reading O
frame O
coding O
RARE O
a O
2 O
, O
112 O
- O
amino O
- O
acid O
protein O
( O
RARE O
mass O
, O
239 O
kDa O
). O

Protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
RARE I-GENE
) O
are O
implicated O
in O
the O
control O
of O
cell O
growth O
by O
RARE O
of O
their O
frequent O
appearance O
RARE O
products O
of O
RARE O
RARE O
, O
RARE O
RARE O
signal O
RARE O
, O
and O
RARE O
growth I-GENE
factor I-GENE
receptors I-GENE
or O
RARE O
RARE O
. O

The O
NUM I-GENE
RARE I-GENE
was O
identified O
among O
a O
series O
of O
antibodies O
raised O
in O
ALL_CAP O
/ O
c O
mice O
after O
immunization O
against O
a O
HLA I-GENE
class O
I O
- O
RARE O
, O
RARE O
- O
activated O
killer O
( O
ALL_CAP O
)- O
susceptible O
ALL_CAP O
- O
B O
lymphocyte O
line O
. O

In O
a O
randomized O
double O
- O
blind O
cross O
- O
over O
study O
, O
the O
subjects O
received O
theophylline O
5 O
mg O
. O
kg O
- O
1 O
per O
day O
with O
omeprazole O
20 O
mg O
per O
day O
or O
identical O
placebo O
RARE O
two O
periods O
, O
each O
of O
7 O
days O
, O
separated O
by O
a O
washout O
period O
of O
7 O
days O
. O

Primer O
extension O
and O
RARE I-GENE
RARE I-GENE
and I-GENE
S1 I-GENE
RARE I-GENE
mapping O
indicated O
multiple O
transcription O
initiation O
sites O
and O
were O
consistent O
with O
Northern O
analyses O
. O

Two O
variant O
ALL_CAP I-GENE
- I-GENE
precursor I-GENE
alleles I-GENE
occur O
which O
slightly O
differ O
in O
the O
number O
of O
repeats O
in O
domain O
C O
. O

Unlike O
the O
typical O
enhancer O
element O
, O
this O
region O
functions O
in O
an O
orientation O
- O
dependent O
manner O
. O

In O
the O
last O
20 O
years O
, O
the O
therapeutic O
uses O
of O
botulinum I-GENE
RARE I-GENE
, O
a O
potent O
RARE O
, O
have O
been O
investigated O
. O

RARE O
' O
s O
RARE O
associated O
with O
RARE O
RARE O

RARE O
and O
RARE O
was O
established O
RARE O
the O
Pharmacia O
ALL_CAP O
RARE O
and O
the O
ALL_CAP O
ALL_CAP O
RARE O
by O
comparison O
with O
results O
of O
the O
RARE O
RARE O
test O
. O

PSI I-GENE
- I-GENE
G I-GENE
and O
PSI I-GENE
- I-GENE
K I-GENE
probably O
have O
evolved O
from O
a O
gene O
duplication O
of O
an O
ancestral O
gene O
. O

At O
the O
C O
- O
terminus O
of O
the O
protein O
is O
a O
domain O
that O
contains O
sequences O
very O
similar O
to O
those O
found O
in O
the O
RARE O
cluster O
region O
gene O
product O
, O
RARE I-GENE
- I-GENE
RARE I-GENE
, O
and O
RARE I-GENE
ALL_CAP I-GENE
, O
all O
of O
which O
have O
been O
shown O
to O
possess O
RARE O
ALL_CAP I-GENE
activity O
on O
small I-GENE
GTPases I-GENE
. O

RARE O
- O
directed O
mutagenesis O
revealed O
that O
two O
clusters O
of O
basic O
amino O
RARE O
within O
a O
RARE O
basic O
region O
and O
two O
RARE O
helices O
within O
the O
adjacent O
ALL_CAP O
domain O
are O
essential O
RARE O
sequence O
- O
specific O
DNA O
binding O
and O
RARE O
- O
oligomerization O
, O
respectively O
. O

RARE O
of O
RARE I-GENE
- I-GENE
5 I-GENE
with O
the O
ubiquitously O
RARE O
bHLH O
protein O
E12 I-GENE
not O
only O
increases O
the O
affinity O
RARE O
DNA O
but O
also O
stimulates O
RARE O
independently O
of O
DNA O
binding O
. O

The O
circadian O
RARE O
of O
sleep O
was O
pronounced O
. O

ALL_CAP O
was O
recorded O
with O
RARE O
RARE O
RARE O
NUM O
- O
NUM O
ALL_CAP O
and O
40 O
- O
NUM O
Hz O
using O
RARE O
method O
. O

RARE O
- O
specific O
RARE O
, O
genomic O
RARE O
, O
and O
chromosomal O
RARE O
of O
the O
gene O
encoding O
the O
zinc I-GENE
- I-GENE
finger I-GENE
transcription I-GENE
factor I-GENE
ALL_CAP I-GENE
- I-GENE
C I-GENE
. O

An O
experiment O
examined O
the O
effects O
of O
treatment O
with O
RARE I-GENE
releasing I-GENE
hormone I-GENE
( O
NUM O
micrograms O
GnRH I-GENE
injected O
NUM O
h O
after O
RARE O
RARE O
removal O
RARE O
season O
of O
treatment O
( O
RARE O
v O
. O
RARE O
RARE O
the O
effect O
of O
supplementary O
feeding O
with O
RARE O
RARE O
( O
in O
RARE O
only O
, O
from O
12 O
days O
before O
until O
8 O
days O
after O
RARE O
removal O
) O
on O
the O
time O
of O
ovulation O
in O
182 O
RARE O
RARE O
RARE O
RARE O
with O
a O
combination O
of O
NUM O
I O
. O
ALL_CAP O
. O
RARE I-GENE
RARE I-GENE
serum I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
and O
12 O
mg O
RARE I-GENE
stimulating I-GENE
hormone I-GENE
( O
FSH I-GENE
- I-GENE
P I-GENE
). O

Drug O
- O
drug O
interactions O
are O
most O
likely O
to O
occur O
in O
patients O
receiving O
multiple O
RARE O
and O
with O
drugs O
that O
have O
a O
narrow O
therapeutic O
RARE O
. O

The O
sequence O
data O
now O
permit O
a O
detailed O
interpretation O
of O
the O
X O
- O
ray O
RARE O
RARE O
of O
the O
enzyme O
and O
the O
cloning O
and O
RARE O
of O
the O
RARE O
gene O
will O
facilitate O
site O
- O
directed O
mutagenesis O
. O

Total O
body O
irradiation O
was O
delivered O
according O
to O
a O
RARE O
RARE O
of O
12 O
fractions O
given O
three O
per O
day O
5 O
hr O
apart O
RARE O
4 O
days O
. O

A O
reduction O
in O
RARE O
pressure O
was O
only O
observed O
RARE O
the O
end O
of O
the O
study O
, O
from O
142 O
+/- O
NUM O
/ O
NUM O
. O
6 O
+/- O
9 O
. O
1 O
to O
139 O
+/- O
NUM O
/ O
82 O
. O
9 O
+/- O
8 O
. O
9 O
mmHg O
( O
P O
less O
than O
NUM O
. O
05 O
RARE O
ALL_CAP O
). O

ALL_CAP O
and O
RARE O
RARE O
ALL_CAP O
( O
ALL_CAP O
) O
are O
similar O
in O
terms O
of O
promoter O
RARE O
and O
RARE I-GENE
RARE I-GENE
sequence I-GENE
, O
and O
the O
RARE I-GENE
gene I-GENE
of O
both O
viruses O
is O
RARE O
in O
the O
anti O
- O
RARE O
direction O
in O
relation O
to O
their O
physical O
maps O
. O

A O
gene O
homologous O
to O
the O
Escherichia I-GENE
coli I-GENE
ALL_CAP I-GENE
gene I-GENE
was O
isolated O
from O
RARE O
RARE O
and O
its O
transcription O
was O
investigated O
in O
E O
. O
coli O
RARE O
RARE O
RARE O
in O
P O
. O
RARE O
. O

NUM I-GENE
is O
an O
RARE O
yeast O
gene O
involved O
in O
the O
removal O
of O
intervening O
sequences O
from O
some O
, O
but O
not O
all O
, O
RARE O
of O
intervening O
sequence O
- O
containing O
pre O
- O
RARE O
. O

Using O
these O
antibodies O
, O
we O
were O
able O
to O
define O
the O
conditions O
to O
completely O
RARE O
the O
NUM I-GENE
protein I-GENE
. O

NUM I-GENE
gene I-GENE
function O
is O
required O
RARE O
high O
- O
level O
RARE O
gene O
RARE O
in O
Saccharomyces O
cerevisiae O
. O

The O
RARE O
curves O
of O
RARE O
fluorescence O
showed O
a O
RARE O
of O
three O
RARE O
RARE O
RARE O
with O
time O
constants O
of O
NUM O
= O
NUM O
- O
NUM O
RARE O
, O
NUM O
= O
NUM O
- O
500 O
RARE O
and O
NUM O
= O
2 O
. O
NUM O
- O
3 O
. O
5 O
RARE O
. O

After O
RARE O
, O
systolic O
RARE O
pressure O
fell O
an O
average O
of O
NUM O
% O
in O
patients O
who O
RARE O
RARE O
( O
p O
= O
NUM O
. O
NUM O
) O
but O
only O
10 O
% O
in O
frequently O
RARE O
patients O
. O

These O
results O
are O
consistent O
with O
the O
roles O
that O
ALL_CAP I-GENE
and O
trypsin I-GENE
RARE O
are O
believed O
to O
play O
in O
the O
negative O
RARE O
control O
of O
pancreatic O
RARE O
function O
. O

Most O
RARE O
events O
occurred O
RARE O
RARE O
I O
and O
II O
, O
and O
REM O
, O
but O
this O
proportion O
was O
less O
RARE O
the O
gamma O
OH O
study O
( O
77 O
. O
9 O
+/- O
8 O
. O
9 O
%) O
than O
RARE O
the O
control O
studies O
( O
92 O
. O
3 O
+/- O
1 O
. O
9 O
and O
NUM O
. O
9 O
+/- O
2 O
. O
2 O
%), O
RARE O
occurring O
even O
RARE O
ALL_CAP O
with O
gamma O
OH O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

Eight O
rabbits O
were O
exposed O
to O
NUM O
. O
7 O
+/- O
NUM O
. O
4 O
mg O
/ O
m3 O
NUM O
+ O
RARE O
NUM O
and O
1 O
. O
2 O
+/- O
NUM O
. O
7 O
mg O
/ O
m3 O
NUM O
+ O
RARE O
RARE O
( O
NUM O
) O
3 O
( O
group O
Co O
+ O
RARE O
RARE O
eight O
to O
NUM O
. O
6 O
+/- O
NUM O
. O
5 O
mg O
/ O
m3 O
NUM O
+ O
( O
group O
Co O
RARE O
and O
eight O
to O
RARE O
air O
( O
control O
group O
RARE O
RARE O
4 O
months O
, O
5 O
days O
/ O
week O
, O
and O
6 O
hr O
/ O
day O
. O

16 O
women O
were O
treated O
with O
RARE O
to O
prevent O
withdrawal O
symptoms O
. O

Disruption O
demonstrates O
that O
NUM I-GENE
is O
an O
essential O
gene O
. O

Coronary O
flow O
was O
RARE O
by O
10 O
% O
in O
the O
RARE O
and O
by O
18 O
% O
in O
the O
control O
group O
. O

The O
NUM I-GENE
transcripts I-GENE
and O
protein O
are O
RARE O
detected O
RARE O
the O
onset O
of O
RARE O
, O
primarily O
in O
the O
mesoderm O
of O
the O
extending O
RARE O
band O
. O

A O
NUM O
- O
bp O
segment O
of O
the O
5 O
'- O
flanking O
region O
consisting O
of O
the O
proximal O
E O
- O
box O
flanked O
upstream O
by O
a O
mammalian O
- O
specific O
NUM O
- O
bp O
region O
was O
sufficient O
RARE O
maximal O
transcriptional O
activation O
in O
RARE O
NUM O
myoblasts O
. O

These O
results O
indicate O
that O
RARE O
- O
RARE O
TR I-GENE
mediates O
transcriptional O
activation O
and O
repression O
in O
a O
promoter O
- O
specific O
manner O
in O
vitro O
. O

Influence O
of O
RARE O
RARE O
on O
anti O
- O
RARE O
effects O
of O
ALL_CAP O
in O
rats O

Recent O
investigations O
have O
detailed O
a O
selective O
RARE O
release O
technique O
in O
which O
a O
pulse O
of O
laser O
light O
induces O
the O
release O
of O
a O
RARE O
RARE O
from O
RARE O
- O
RARE O
liposomes O
circulating O
in O
the O
RARE O
RARE O
. O

RARE O
the O
RARE O
RARE O
? O

Three O
RARE O
RARE O
have O
been O
isolated O
from O
the O
fresh O
RARE O
RARE O
of O
RARE O
RARE O
ALL_CAP O
RARE O

The O
serum O
erythropoietin I-GENE
( O
EPO I-GENE
) O
concentrations O
of O
NUM O
male O
RARE O
( O
NUM O
. O
3 O
ALL_CAP O
. O
ml O
- O
1 O
) O
were O
significantly O
lower O
than O
those O
of O
NUM O
male O
distance O
RARE O
( O
NUM O
. O
6 O
ALL_CAP O
. O
ml O
- O
1 O
; O
P O
less O
than O
NUM O
. O
05 O
). O

The O
RARE O
materials O
were O
RARE O
NUM O
, O
RARE O
NUM O
, O
RARE O
NUM O
, O
RARE O
NUM O
, O
and O
RARE O
NUM O
. O

The O
RARE O
and O
drinking O
patterns O
of O
RARE O
goats O
fed O
RARE O
RARE O
and O
kept O
on O
a O
12 O
h O
light O
/ O
12 O
h O
dark O
RARE O
were O
recorded O
and O
analyzed O
. O

The O
present O
study O
RARE O
the O
improvement O
in O
RARE O
RARE O
( O
RARE O
) O
levels O
when O
a O
combination O
tablet O
, O
RARE O
500 O
mg O
RARE O
RARE O
8 O
mg O
, O
is O
administered O
RARE O
compared O
to O
RARE O
RARE O
500 O
mg O
. O

RARE O
ALL_CAP I-GENE
II I-GENE
activity O
and O
antigen O
levels O
were O
NUM O
% O
and O
50 O
%, O
respectively O
, O
and O
RARE O
daughter O
also O
showed O
similar O
low O
levels O
. O

RARE O
may O
be O
more O
effective O
under O
low O
ALL_CAP I-GENE
II I-GENE
conditions O
because O
of O
its O
potent O
inhibition O
of O
thrombin I-GENE
activity O
RARE O
sites O
of O
vascular O
RARE O
damage O
. O

These O
results O
support O
the O
diagnostic O
validity O
of O
ALL_CAP O
in O
CP O
/ O
ALL_CAP O
patients O
, O
because O
such O
patients O
had O
a O
family O
history O
of O
RARE O
disorder O
similar O
to O
patients O
with O
a O
more O
classical O
RARE O
disorder O
presentation O
. O

ALL_CAP O
RARE O
RARE O
growth O
factors O
and O
related O
products O
. O

Because O
the O
adrenergic O
nervous O
RARE O
influences O
cardiac O
arrhythmias O
and O
RARE O
infarction O
can O
directly O
affect O
sympathetic O
RARE O
in O
the O
RARE O
, O
we O
investigated O
the O
role O
of O
the O
sympathetic O
nervous O
RARE O
on O
RARE O
in O
the O
canine O
RARE O
4 O
days O
after O
infarction O
. O

DESIGN O
: O
Serum O
aldosterone O
and O
plasma I-GENE
renin I-GENE
activity O
were O
measured O
supine O
prior O
to O
and O
NUM O
, O
NUM O
, O
120 O
minutes O
after O
oral O
captopril O
, O
NUM O
mg O
. O

Furthermore O
, O
RARE O
transcripts O
of O
the O
same O
size O
and O
having O
the O
same O
developmental O
profile O
RARE O
those O
generated O
by O
the O
wild I-GENE
- I-GENE
type I-GENE
NUM I-GENE
fragment I-GENE
were O
identified O
by O
RARE O
covering O
the O
RARE O
of O
the O
RARE O
region O
. O

Intravenous O
RARE O
pressor O
tests O
in O
healthy O
volunteers O
. O

The O
mean O
minimum O
steady O
- O
state O
concentration O
after O
the O
oral O
regimen O
( O
NUM O
micrograms O
. O
RARE O
- O
1 O
) O
was O
NUM O
% O
of O
that O
after O
the O
RARE O
RARE O
( O
29 O
micrograms O
. O
RARE O
- O
1 O
). O

In O
an O
RARE O
study O
the O
performance O
of O
the O
ALL_CAP O
is O
being O
compared O
with O
that O
of O
the O
RARE O
RARE O
RARE O
( O
ALL_CAP O
). O

Both O
parents O
are O
clinically O
normal O
and O
unrelated O
. O

These O
mutant O
proteins O
retained O
the O
ability O
to O
RARE O
inhibit O
RARE I-GENE
B I-GENE
- O
RARE O
transcriptional O
activation O
of O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
but O
failed O
to O
efficiently O
transform O
chicken O
RARE O
cells O
both O
in O
vitro O
and O
in O
vivo O
. O

The O
sequence O
- O
specific O
interaction O
of O
nuclear I-GENE
factor I-GENE
ALL_CAP I-GENE
- I-GENE
D I-GENE
with O
this O
key O
proximal O
promoter O
element O
of O
the O
NUM I-GENE
- I-GENE
NUM I-GENE
gene I-GENE
is O
cell O
RARE O
regulated O
in O
normal O
diploid O
cells O
( O
ALL_CAP O
. O

In O
conclusion O
, O
to O
study O
and O
overcome O
ALL_CAP O
region O
- O
based O
RARE O
problems O
it O
is O
RARE O
to O
RARE O
out O
with O
a O
RARE O
vector O
containing O
RARE O
mutations O
in O
the O
RARE O
- O
RARE O
sequences O
; O
RARE O
a O
RARE O
the O
coding O
ALL_CAP O
RARE O
can O
be O
kept O
unchanged O
. O

Four O
of O
these O
five O
subjects O
also O
performed O
mixed O
sequences O
under O
conditional O
control O
of O
the O
RARE O
( O
RARE O
. O
g O
., O
NUM O
RARE O
NUM O
RARE O
NUM O
RARE O
NUM O
RARE O
NUM O
and O
its O
reversal O
RARE O
RARE O
that O
the O
stimuli O
which O
occupied O
the O
same O
position O
in O
each O
sequence O
were O
members O
of O
the O
same O
class O
. O

ALL_CAP O
- O
NUM O
ophthalmic O
solution O
( O
NUM O
. O
03 O
to O
NUM O
. O
NUM O
%), O
when O
RARE O
applied O
to O
the O
eyes O
of O
rabbits O
, O
caused O
dose O
- O
dependent O
IOP O
reduction O
( O
2 O
. O
8 O
to O
5 O
. O
2 O
mmHg O
RARE O
without O
transient O
IOP O
rise O
. O

While O
RARE O
pressure O
and O
noradrenergic O
activity O
, O
assessed O
RARE O
changes O
in O
the O
plasma O
levels O
and O
RARE O
excretion O
of O
norepinephrine O
, O
remained O
unaffected O
in O
the O
RARE O
group O
, O
a O
significant O
drop O
in O
the O
supine O
systolic O
and O
diastolic O
RARE O
pressures O
, O
RARE O
RARE O
RARE O
in O
the O
resting O
venous O
norepinephrine O
level O
and O
in O
RARE O
norepinephrine O
excretion O
was O
found O
after O
the O
RARE O
month O
of O
ALL_CAP O
administration O
. O

RARE O
- O
type O
protein O
RARE O
RARE O
- O
ATP O
RARE O
, O
but O
mutants O
with O
substitutions O
in O
the O
consensus O
amino O
RARE O
were O
unable O
to O
bind O
RARE O
- O
ATP O
. O

Therefore O
, O
with O
a O
biopsy O
from O
the O
RARE O
site O
there O
is O
a O
risk O
of O
missing O
early O
rejection O
. O

RARE O
RARE O
RARE O
levels O
were O
investigated O
in O
a O
control O
group O
( O
RARE O
= O
NUM O
) O
and O
in O
a O
group O
of O
chronic O
RARE O
failure O
patients O
( O
RARE O
= O
NUM O
) O
on O
various O
treatment O
regimen O
i O
. O
RARE O
. O
conservative O
treatment O
( O
RARE O
= O
NUM O
RARE O
RARE O
haemodialysis O
( O
RARE O
= O
NUM O
) O
and O
after O
RARE O
transplantation O
( O
RARE O
= O
53 O
). O

RARE O
and O
RARE O
contain O
sufficient O
RARE O
RARE O
growth O
of O
anaerobic O
bacteria O
in O
the O
presence O
of O
RARE O
levels O
of O
RARE O
- O
RARE O
. O

The O
homologies O
between O
NUM I-GENE
, O
NUM I-GENE
and O
NUM I-GENE
are O
also O
shared O
by O
several O
additional O
, O
recently O
isolated O
yeast O
and O
Drosophila O
genes O
. O

RARE O
the O
application O
solutions O
of O
instrument O
RARE O
should O
not O
be O
used O
longer O
than O
one O
day O
. O

In O
the O
RARE O
RARE O
we O
, O
therefore O
, O
RARE O
there O
are O
disturbances O
in O
the O
brain O
RARE O
functions O
especially O
in O
the O
ascending O
RARE O
activating O
RARE O
which O
is O
related O
to O
elevation O
of O
the O
conscious O
level O
. O

In O
a O
similar O
experiment O
, O
simultaneous O
RARE O
administration O
and O
S O
. O
RARE O
challenge O
resulted O
in O
RARE O
significant O
differences O
in O
S O
. O
RARE O
isolation O
frequency O
. O

In O
agreement O
with O
this O
southern O
blotting O
of O
mouse O
DNA O
with O
ALL_CAP I-GENE
RARE O
reveals O
bands O
, O
additional O
to O
those O
derived O
from O
the O
RARE O
, O
which O
are O
characteristic O
of O
an O
intron O
- O
containing O
ALL_CAP I-GENE
gene I-GENE
. O

Two O
cDNAs O
encoding O
casein I-GENE
kinase I-GENE
- I-GENE
1 I-GENE
have O
been O
isolated O
from O
a O
yeast O
cDNA O
library O
and O
termed O
NUM I-GENE
and O
NUM I-GENE
. O

RARE O
rate O
ranging O
between O
122 O
/ O
NUM O
, O
NUM O
/ O
year O
and O
190 O
/ O
NUM O
, O
NUM O
/ O
year O
were O
found O
( O
minimum O
, O
estimated O
and O
RARE O
RARE O
). O

The O
observed O
sequence O
variation O
RARE O
the O
RARE O
ORF O
in O
many O
Y I-GENE
' O
s O
while O
most O
of O
the O
second O
ORF O
including O
the O
putative O
RARE I-GENE
region I-GENE
is O
unaffected O
. O

The O
final O
screening O
yielded O
a O
clone O
containing O
a O
2 O
RARE O
( O
kb O
) O
insert O
. O

RARE O
were O
made O
by O
pressure O
injection O
of O
RARE O
acid O
into O
the O
ALL_CAP O
through O
a O
RARE O
positioned O
glass O
RARE O
. O

A O
38 O
- O
bp O
RARE O
( O
ALL_CAP O
- O
dT O
) O
region O
was O
found O
to O
be O
a O
positive O
regulator O
of O
NUM I-GENE
promoter I-GENE
activity O
. O

We O
identified O
a O
protein O
, O
termed O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
A I-GENE
( O
ALL_CAP I-GENE
beta I-GENE
A I-GENE
RARE O
that O
binds O
to O
a O
highly O
RARE O
12 O
- O
bp O
DNA O
sequence O
RARE O
NUM O
to O
- O
38 O
) O
RARE O
upstream O
of O
the O
TATA O
box O
motif O
in O
both O
the O
human I-GENE
and I-GENE
murine I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
genes I-GENE
. O

We O
RARE O
amphotericin O
B O
( O
ALL_CAP O
RARE O
and O
remission O
of O
the O
tumor O
was O
obtained O
. O

RARE O
RARE O
. O

The O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
nuclear I-GENE
protein I-GENE
has O
characteristics O
similar O
to O
those O
of O
the O
muscle O
- O
specific O
regulatory O
factor O
, O
MEF I-GENE
- I-GENE
2 I-GENE
( O
RARE O
and O
RARE O
1989 O
; O
RARE O
et O
al O
., O
1989 O
). O

From O
the O
NUM O
- O
kb O
clone O
a O
4 I-GENE
- I-GENE
kb I-GENE
EcoRI I-GENE
fragment I-GENE
containing O
the O
RARE O
two O
exons O
and O
2 O
. O
6 O
kb O
of O
the O
5 O
' O
flanking O
region O
of O
the O
RARE I-GENE
gene I-GENE
was O
sequenced O
, O
and O
the O
transcriptional O
RARE O
site O
determined O
by O
primer O
extension O
analysis O
and O
S1 I-GENE
RARE I-GENE
mapping O
. O

RARE O
risk O
factors O
were O
measured O
by O
standardized O
techniques O
. O

RARE O
costs O
included O
feed O
, O
non O
- O
feed O
operating O
, O
fixed O
, O
and O
RARE O
RARE O
costs O
. O

We O
report O
a O
patient O
developing O
factor I-GENE
VII I-GENE
inhibitor I-GENE
possibly O
RARE O
a O
reaction O
to O
RARE O
administration O
; O
it O
gave O
rise O
to O
fatal O
RARE O
. O

This O
is O
in O
contrast O
with O
the O
classical O
' O
oxygen O
RARE O
hypothesis O
RARE O
which O
states O
that O
the O
oxygen O
RARE O
and O
RARE O
clearance O
are O
RARE O
. O

RARE O
was O
taken O
of O
RARE O
and O
RARE O
elements O
in O
the O
smears O
; O
they O
included O
mucus O
, O
RARE O
- O
RARE O
RARE O
, O
pollen O
RARE O
, O
RARE O
fragments O
and O
RARE O
. O

The O
results O
indicate O
that O
the O
carbon O
- O
perfused O
areas O
and O
ALL_CAP O
in O
the O
liver O
, O
RARE O
cortex O
, O
RARE O
, O
and O
small O
RARE O
RARE O
( O
only O
ALL_CAP O
) O
increased O
significantly O
5 O
h O
after O
ALL_CAP O
. O

In O
addition O
a O
greater O
proportion O
of O
women O
in O
the O
RARE O
group O
had O
a O
cervical O
dilatation O
of O
4 O
cm O
or O
more O
RARE O
the O
RARE O
vaginal O
examination O
in O
the O
labour O
RARE O
( O
16 O
/ O
NUM O
( O
NUM O
%) O
RARE O
5 O
/ O
NUM O
( O
16 O
RARE O
OR O
4 O
. O
NUM O
; O
NUM O
% O
ALL_CAP O
1 O
. O
NUM O
to O
12 O
. O
NUM O
; O
P O
= O
NUM O
. O
005 O
). O

RARE O
, O
N O
. O

A O
control O
group O
of O
nine O
women O
( O
age O
NUM O
- O
40 O
years O
) O
on O
oral O
RARE O
( O
RARE O
- O
NUM O
) O
was O
also O
studied O
four O
times O
RARE O
a O
RARE O
RARE O
. O

This O
accurate O
and O
rapid O
method O
makes O
the O
ALL_CAP O
test O
RARE O
RARE O
RARE O
large O
- O
scale O
screening O
. O

The O
modalities O
RARE O
using O
reference O
values O
RARE O
individual O
subjects O
RARE O
RARE O
RARE O
RARE O
groups O
are O
then O
discussed O
and O
the O
main O
points O
of O
research O
which O
must O
be O
RARE O
in O
the O
near O
future O
regarding O
reference O
values O
are O
RARE O
. O

The O
clinical O
application O
of O
the O
antibody O
- O
targeted O
RARE O
was O
performed O
in O
3 O
patients O
suffering O
from O
an O
advanced O
ovarian O
carcinoma O
( O
ALL_CAP O
III O
). O

We O
found O
that O
RARE O
RARE O
tissues O
of O
positive O
NUM O
scan O
RARE O
ALL_CAP I-GENE
, O
but O
those O
of O
a O
negative O
scan O
did O
not O
. O

This O
RARE O
reading O
frame O
was O
confirmed O
the O
correct O
one O
by O
direct O
amino O
- O
terminal O
sequence O
analysis O
of O
the O
RARE O
ALL_CAP I-GENE
gene I-GENE
product I-GENE
. O

In O
this O
study O
, O
we O
RARE O
and O
characterized O
the O
recombinant I-GENE
RARE I-GENE
from O
the O
conditioned O
medium O
of O
these O
cells O
. O

The O
virus O
encodes O
a O
40 O
- O
kDa O
protein O
, O
RARE I-GENE
, O
that O
is O
important O
RARE O
the O
RARE O
of O
T O
cells O
. O

However O
, O
RARE O
was O
RARE O
least O
2 O
- O
RARE O
more O
effective O
in O
stimulating O
CAT I-GENE
activity O
of O
fusion O
genes O
containing O
upstream O
sequences O
RARE O
NUM O
to O
- O
NUM O
) O
than O
those O
containing O
proximal O
sequences O
RARE O
NUM O
to O
- O
NUM O
RARE O
suggesting O
two O
regions O
in O
the O
NUM I-GENE
- I-GENE
I I-GENE
gene I-GENE
that O
mediate O
the O
RARE O
response O
. O

An O
examination O
of O
the O
role O
of O
the O
RARE O
terminus O
in O
RARE O
ALL_CAP I-GENE
- I-GENE
B I-GENE
transcriptional O
activity O
revealed O
that O
, O
in O
RARE O
with O
other O
nuclear O
receptors O
, O
mutants O
RARE O
portions O
of O
the O
RARE O
terminus O
had O
greatly O
decreased O
activity O
. O

Altogether O
these O
results O
indicate O
that O
the O
RARE I-GENE
5 I-GENE
locus I-GENE
RARE O
from O
the O
gene O
RARE O
ALL_CAP I-GENE
, O
to O
a O
region O
RARE O
portions O
of O
the O
TK I-GENE
and O
ALL_CAP I-GENE
NUM I-GENE
genes I-GENE
, O
and O
that O
the O
RARE I-GENE
mutation I-GENE
does O
not O
affect O
the O
RARE O
or O
activity O
of O
TK I-GENE
. O

RARE O
( O
N O
) O
RARE O
by O
both O
recombinant O
RARE O
virus O
and O
ALL_CAP O
had O
a O
relative O
RARE O
mass O
( O
Mr O
) O
of O
NUM O
, O
NUM O
and O
was O
susceptible O
to O
RARE O
RARE O
the O
C O
- O
terminus O
RARE O
discrete O
RARE O
products O
. O

Recently O
, O
the O
3 I-GENE
. I-GENE
6 I-GENE
- I-GENE
kb I-GENE
full I-GENE
- I-GENE
length I-GENE
alpha I-GENE
- I-GENE
RARE I-GENE
cDNA I-GENE
sequence I-GENE
was O
isolated O
and O
found O
to O
have O
remarkable O
nucleotide O
and O
predicted O
amino O
acid O
homology O
( O
NUM O
. O
8 O
and O
NUM O
. O
9 O
%, O
respectively O
) O
with O
the O
human I-GENE
alpha I-GENE
- I-GENE
galactosidase I-GENE
A I-GENE
( O
alpha I-GENE
- I-GENE
RARE I-GENE
A I-GENE
) O
cDNA O
. O

Patients O
with O
an O
enzymatic O
activity O
below O
X O
RARE O
1 O
manifested O
a O
decrease O
of O
the O
content O
of O
IgA I-GENE
, O
IgG I-GENE
, O
IgM I-GENE
, O
T O
and O
B O
lymphocytes O
, O
and O
of O
phagocytic O
activity O
of O
neutrophils O
RARE O
compared O
to O
patients O
exhibiting O
a O
high O
enzymatic O
activity O
. O

The O
RARE O
that O
RARE O
oxide O
does O
not O
produce O
RARE O
radicals O
readily O
might O
be O
that O
the O
one O
- O
electron O
reduction O
RARE O
through O
an O
N2O O
- O
RARE O
which O
is O
RARE O
very O
RARE O
: O
ALL_CAP O
( O
N2O O
/ O
N2O O
RARE O
= O
- O
1 O
. O
1 O
V O
. O

All O
mutant I-GENE
ALL_CAP I-GENE
T I-GENE
antigens I-GENE
RARE O
to O
ALL_CAP O
and O
SV40 O
origins O
of O
DNA O
replication O
. O

The O
relation O
between O
RARE I-GENE
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
and O
RARE O
ventricular O
( O
LV O
) O
function O
was O
studied O
in O
10 O
patients O
, O
aged O
NUM O
to O
NUM O
years O
( O
average O
NUM O
RARE O
with O
LV O
volume O
overload O
mainly O
due O
to O
chronic O
mitral O
RARE O
. O

Since O
each O
transcript O
appears O
to O
encode O
the O
same O
protein O
, O
this O
complexity O
may O
reflect O
the O
need O
RARE O
lineage O
- O
specific O
or O
differentiation O
- O
dependent O
control O
of O
RARE O
. O

In O
patients O
with O
limited O
RARE O
, O
the O
survival O
in O
the O
RARE O
RARE O
was O
significantly O
superior O
to O
the O
survival O
in O
the O
ALL_CAP O
RARE O
( O
P O
= O
. O
NUM O
) O
or O
the O
survival O
in O
the O
ALL_CAP O
RARE O
( O
P O
= O
. O
NUM O
). O

We O
identify O
the O
" O
M O
region O
" O
of O
the O
muscle I-GENE
- I-GENE
specific I-GENE
Xenopus I-GENE
cardiac I-GENE
actin I-GENE
gene I-GENE
promoter I-GENE
from O
- O
NUM O
to O
- O
NUM O
RARE O
necessary O
RARE O
the O
RARE O
RARE O
of O
a O
cardiac O
actin I-GENE
- O
beta I-GENE
- I-GENE
globin I-GENE
reporter O
gene O
injected O
into O
RARE O
eggs O
. O

In O
addition O
to O
the O
previously O
identified O
and O
characterized O
RARE I-GENE
1 I-GENE
situated O
93 O
nucleotides O
RARE O
from O
the O
major O
RARE O
transcription O
RARE O
site O
, O
a O
second O
RARE O
, O
RARE I-GENE
2 I-GENE
, O
situated O
NUM O
nucleotides O
RARE O
from O
it O
, O
has O
been O
identified O
. O

EBNA I-GENE
- I-GENE
2 I-GENE
and O
the O
cis O
- O
acting O
CD23 I-GENE
element I-GENE
increased O
TK I-GENE
- O
promoted O
mRNA O
and O
did O
not O
alter O
the O
herpes I-GENE
simplex I-GENE
virus I-GENE
TK I-GENE
promoter I-GENE
transcription I-GENE
RARE I-GENE
site I-GENE
. O

These O
experiments O
RARE O
a O
NUM O
- O
bp O
, O
EBNA I-GENE
- I-GENE
2 I-GENE
- O
responsive O
cell O
DNA O
fragment O
and O
provide O
RARE O
evidence O
that O
EBNA I-GENE
- I-GENE
2 I-GENE
transactivates O
transcription O
of O
cell O
genes O
. O

Plasma O
vitamin O
E O
, O
RARE O
lipids O
and O
RARE I-GENE
levels O
RARE O
RARE O
surgery O
. O

RARE O
the O
RARE O
bovine O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
cDNA O
into O
COS O
- O
7 O
cells O
resulted O
in O
an O
11 O
- O
RARE O
increase O
in O
the O
density O
of O
high O
affinity O
RARE O
3H O
] O
ALL_CAP O
NUM O
binding O
sites O
which O
had O
only O
low O
affinity O
RARE O
NUM O
- O
NUM O
. O

The O
initial O
RARE O
of O
increased O
vascular O
RARE O
in O
the O
peritoneal O
cavity O
and O
NUM O
production O
was O
dose O
dependently O
inhibited O
by O
the O
5 O
- O
ALL_CAP O
RARE O
RARE O
, O
ALL_CAP O
NUM O
, O
NUM O
, O
and O
ALL_CAP O
NUM O
NUM O
but O
not O
by O
dexamethasone O
or O
RARE O
. O

RARE O
results O
with O
a O
latex O
RARE O
test O
in O
the O
assessment O
of O
RARE O
antibody O
status O
of O
cardiac O
transplant O
donors O
. O

Each O
mRNA O
contained O
five O
or O
RARE O
internal O
RARE O
residues O
, O
which O
were O
RARE O
using O
a O
mixture O
of O
ALL_CAP O
and O
RARE O
- O
ALL_CAP O
. O

We O
have O
isolated O
and O
sequenced O
two O
overlapping O
cDNA O
fragments O
which O
could O
encode O
the O
RARE O
amino O
acid O
sequence O
of O
rat I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
, I-GENE
2 I-GENE
- I-GENE
kinase I-GENE
: O
RARE I-GENE
- I-GENE
2 I-GENE
, I-GENE
6 I-GENE
- I-GENE
RARE I-GENE
. O

We O
have O
identified O
NUM I-GENE
' O
s O
nuclear O
RARE O
signal O
( O
NLS O
) O
and O
show O
that O
it O
can O
confer O
cell O
RARE O
- O
dependent O
nuclear O
entry O
to O
a O
heterologous O
protein O
. O

In O
contrast O
to O
behavioral O
deviation O
( O
the O
RARE O
conditioning O
lost O
RARE O
the O
haloperidol O
RARE O
RARE O
did O
not O
affect O
the O
ALL_CAP O
synaptic O
level O
in O
RARE O
RARE O
. O

In O
similar O
transient O
transfection O
experiments O
in O
HeLa O
cells O
, O
overexpression O
of O
the O
wt I-GENE
human I-GENE
RARE I-GENE
RARE I-GENE
gene I-GENE
product I-GENE
, O
ALL_CAP I-GENE
, O
was O
found O
to O
repress O
the O
serum O
- O
RARE O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
RARE O
NUM O
to O
+ O
NUM O
RARE O
c I-GENE
- I-GENE
fos I-GENE
RARE O
NUM O
to O
+ O
NUM O
RARE O
and O
beta I-GENE
- I-GENE
actin I-GENE
RARE O
NUM O
to O
+ O
NUM O
) O
promoters O
but O
not O
the O
ALL_CAP O
- O
RARE O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
RARE O
NUM O
to O
+ O
NUM O
) O
or O
the O
serum O
- O
RARE O
MHC I-GENE
RARE O
NUM O
to O
- O
38 O
) O
promoters O
. O

This O
repression O
was O
RARE O
through O
binding O
to O
the O
E2 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
site I-GENE
immediately O
upstream O
of O
the O
NUM I-GENE
promoter O
TATA O
box O
and O
could O
be O
abrogated O
by O
RARE O
of O
the O
HPV I-GENE
- I-GENE
18 I-GENE
NUM I-GENE
promoter I-GENE
template O
with O
the O
nuclear O
RARE O
allowing O
the O
formation O
of O
the O
RARE O
complex O
. O

We O
did O
not O
detect O
NUM I-GENE
in O
association O
with O
RARE I-GENE
glucocorticoid I-GENE
receptor I-GENE
in O
L O
cells O
or O
with O
the O
overexpressed O
glucocorticoid I-GENE
receptor I-GENE
in O
RARE O
hamster O
ovary O
cells O
. O

Two O
putative O
12 O
- O
O O
- O
RARE O
- O
phorbol O
- O
NUM O
- O
RARE O
( O
ALL_CAP O
) O
response O
elements O
, O
that O
might O
serve O
RARE O
binding O
sites O
RARE O
the O
transcription I-GENE
factor I-GENE
AP I-GENE
- I-GENE
1 I-GENE
and O
a O
consensus O
sequence O
of O
a O
transforming I-GENE
growth I-GENE
factor I-GENE
beta I-GENE
1 I-GENE
( O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
) O
RARE O
element O
were O
found O
in O
the O
promoter O
region O
. O

ALL_CAP O
and O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
did O
not O
markedly O
affect O
the O
activities O
of O
the O
72 O
- O
kDa O
enzyme O
. O

They O
were O
almost O
RARE O
RARE O
by O
pressure O
to O
the O
ipsilateral O
RARE O
or O
to O
both O
RARE O
RARE O
a O
strength O
RARE O
above O
the O
human O
corneal O
pain O
threshold O
. O

RARE O
intake O
was O
not O
affected O
by O
dietary O
RARE O
or O
NUM O
supplementation O
, O
but O
average O
daily O
gain O
increased O
with O
increased O
K O
and O
tended O
to O
be O
RARE O
by O
dietary O
NUM O
. O

RARE O
procedure O
RARE O
the O
measurement O
of O
RARE O
compounds O
in O
biological O
tissues O
using O
toluene O
, O
RARE O
, O
and O
RARE O
. O

In O
this O
study O
, O
we O
have O
RARE O
a O
region O
that O
RARE O
the O
RARE I-GENE
S I-GENE
- O
RARE O
RARE O
of O
RARE O
NUM O
NUM I-GENE
:: O
NUM I-GENE
, O
a O
chromosomal I-GENE
NUM I-GENE
RARE I-GENE
mutation I-GENE
. O

RARE O
, O
a O
transforming O
gene O
isolated O
from O
RARE O
human O
RARE O
leukemia O
cells O
, O
encodes O
a O
novel O
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
. O

RARE O
of O
the O
amino O
acid O
sequences O
surrounding O
RARE O
- O
NUM O
with O
corresponding O
regions O
of O
other O
RARE I-GENE
revealed O
RARE O
tyrosine O
residues O
in O
all O
known O
members O
of O
the O
FGFR I-GENE
family I-GENE
. O

The O
single O
most O
important O
element O
, O
by O
RARE O
- O
scanning O
analysis O
, O
is O
a O
10 O
- O
bp O
region O
that O
contains O
a O
CCAAT O
motif O
. O

RARE O
curves O
of O
40 O
HVS O
patients O
, O
40 O
non O
- O
HVS O
patients O
with O
RARE O
- O
somatic O
RARE O
and O
NUM O
healthy O
controls O
were O
analyzed O
. O

The O
transcription O
initiation O
site O
was O
determined O
to O
occur O
NUM O
bp O
upstream O
of O
the O
initiating O
RARE O
. O

All O
anti I-GENE
- I-GENE
I I-GENE
and O
anti I-GENE
- I-GENE
i I-GENE
CA I-GENE
were O
shown O
to O
express O
NUM I-GENE
heavy I-GENE
chains I-GENE
, O
and O
14 O
of O
NUM O
CA I-GENE
RARE O
a O
previously O
described O
NUM I-GENE
second O
RARE O
region O
determinant O
, O
termed O
NUM I-GENE
- I-GENE
NUM I-GENE
. O

RARE O
NUM I-GENE
NUM I-GENE
. I-GENE
2 I-GENE
is O
not O
found O
in O
S O
. O
cerevisiae O
and O
appears O
RARE O
an O
unique O
location O
in O
K O
. O
lactis O
. O

We O
have O
determined O
that O
the O
mutants O
define O
two O
RARE O
groups O
, O
designated O
NUM I-GENE
+ I-GENE
and O
NUM I-GENE
+ I-GENE
( O
RARE O
to O
grow O
in O
stationary O
). O

However O
, O
alterations O
in O
RARE O
and O
hydrophobic O
interactions O
created O
by O
the O
three O
amino O
acid O
substitutions O
prevent O
the O
conformational O
change O
in O
the O
enzyme O
usually O
produced O
by O
calmodulin I-GENE
binding O
. O

The O
results O
of O
RARE O
coexpression O
were O
also O
supported O
by O
rapid O
generation O
of O
ALL_CAP O
RARE O
when O
ALL_CAP O
- O
C O
was O
used O
to O
RARE O
the O
RARE O
NUM O
cell O
line O
that O
constitutively O
RARE O
high O
levels O
of O
endogenous O
ALL_CAP O
- O
specific O
mRNAs O
. O

RARE O
between O
RARE O
leukemia O
virus O
subgroup O
B O
or O
C O
and O
endogenous O
env I-GENE
elements O
alters O
the O
in O
vitro O
biological O
activities O
of O
the O
viruses O
. O

The O
nucleotide O
sequences O
RARE O
the O
5 O
' O
and O
3 O
' O
ends O
of O
these O
RARE O
are O
characteristic O
of O
RARE O
transcripts O
from O
eukaryotic O
protein O
- O
encoding O
genes O
, O
with O
one O
significant O
difference O
; O
i O
. O
RARE O
., O
the O
5 O
' O
end O
of O
the O
ALL_CAP I-GENE
intron I-GENE
is O
ALL_CAP O
instead O
of O
the O
consensus O
sequence O
ALL_CAP O
. O

At O
1 O
, O
5 O
, O
and O
9 O
months O
after O
initial O
isolation O
of O
C O
. O
RARE O
from O
the O
oral O
cavity O
, O
hamsters O
were O
RARE O
, O
and O
attempts O
were O
made O
to O
culture O
C O
. O
RARE O
from O
NUM O
additional O
sites O
. O

The O
strategy O
has O
been O
used O
to O
determine O
2 O
. O
6 O
kilobases O
of O
nucleotide O
sequence O
in O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
ALL_CAP I-GENE
1 I-GENE
locus I-GENE
. O

Two O
independent O
promoters O
RARE O
RARE O
RARE O
5 O
' O
RARE O
regions O
regulate O
RARE I-GENE
ras I-GENE
RARE O
in O
Dictyostelium O
. O

The O
results O
suggested O
that O
, O
depending O
upon O
the O
cell O
type O
, O
gene O
RARE O
using O
RARE O
resistance O
RARE O
a O
selectable O
marker O
may O
RARE O
RARE O
important O
cellular O
control O
mechanisms O
such O
RARE O
the O
PKC I-GENE
RARE O
leading O
to O
activation O
of O
gene O
RARE O
. O

RARE O
RNA O
genes O
from O
Dictyostelium O
RARE O
are O
frequently O
associated O
with O
RARE O
elements O
and O
contain O
consensus O
RARE O
in O
their O
5 O
' O
and O
3 O
'- O
flanking O
regions O
. O

Therefore O
, O
the O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
genes I-GENE
could O
serve O
RARE O
RARE O
RARE O
indicative O
of O
the O
presence O
of O
biosynthetic O
capacity O
RARE O
6 O
- O
RARE O
RARE O
. O

The O
two O
genes O
code O
RARE O
polypeptides I-GENE
of I-GENE
NUM I-GENE
amino I-GENE
RARE I-GENE
( I-GENE
M I-GENE
. I-GENE
ALL_CAP I-GENE
) I-GENE
and O
NUM O
amino O
RARE O
( O
R O
. O
ALL_CAP O
). O

Expression O
of O
the O
NUM I-GENE
gene I-GENE
via O
transient O
transfection O
in O
COS O
- O
1 O
cells O
revealed O
a O
52 O
kDa O
protein O
which O
was O
immunoprecipitated O
by O
both O
the O
N O
- O
terminal O
- O
and O
C O
- O
terminal O
- O
specific O
antisera O
. O

The O
factor O
which O
binds O
to O
the O
TR I-GENE
promoter I-GENE
RARE O
- O
RARE O
with O
SV40 O
chromosomes O
extracted O
RARE O
in O
infection O
. O

RARE O
NUM O
mg O
b O
. O
i O
. O
d O
. O
administered O
orally O
RARE O
NUM O
days O
represents O
a O
safe O
and O
effective O
treatment O
RARE O
chronic O
bacterial O
RARE O
. O

Its O
neuromuscular O
effects O
are O
similar O
to O
a O
single O
NUM O
dose O
of O
RARE O
. O

The O
patient O
with O
a O
prolonged O
fever O
caused O
by O
RARE O
RARE O
of O
the O
aorta O
in O
whom O
RARE O
RARE O
the O
real O
diseases O
has O
been O
presented O
. O

The O
resulting O
clone O
NUM I-GENE
, O
which O
has O
a O
NUM O
- O
RARE O
RARE O
( O
bp O
) O
cDNA O
insert O
, O
overlapping O
NUM I-GENE
by O
NUM O
bp O
, O
was O
identified O
by O
hybridization O
methods O
and O
sequence O
analysis O
and O
found O
to O
contain O
the O
RARE O
cDNA O
sequence O
RARE O
the O
amino O
end O
of O
the O
ALL_CAP I-GENE
polypeptide I-GENE
. O

This O
conclusion O
was O
confirmed O
by O
Northern O
blotting O
analysis O
of O
the O
5 O
'- O
flanking O
region O
of O
ALL_CAP I-GENE
gene I-GENE
. O

We O
report O
the O
isolation O
of O
genomic O
and O
cDNA O
RARE O
of O
the O
light O
- O
independent O
RARE I-GENE
: I-GENE
NUM I-GENE
allele I-GENE
. O

RARE O
- O
2 O
blockade O
in O
psoriasis O

Its O
clearance O
has O
been O
found O
to O
be O
decreased O
( O
typically O
by O
around O
NUM O
%, O
but O
often O
by O
far O
more O
) O
by O
RARE O
, O
RARE O
( O
RARE O
RARE O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
T O
- O
NUM O
, O
RARE O
acid O
, O
cimetidine O
, O
RARE O
, O
propranolol O
, O
verapamil O
, O
diltiazem O
, O
nifedipine O
, O
furosemide O
( O
RARE O
RARE O
RARE O
least O
some O
RARE O
agents O
, O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
- O
and O
BCG O
- O
vaccination O
, O
RARE I-GENE
, O
and O
caffeine O
( O
RARE O
- O
life O
increase O
). O

A O
third O
is O
a O
partial O
element O
RARE O
RARE O
a O
probable O
internal O
RARE O
site O
used O
RARE O
cloning O
. O

We O
enrolled O
NUM O
HIV I-GENE
- I-GENE
antibody I-GENE
positive O
RARE O
addicts O
without O
HIV O
- O
related O
RARE O
( O
RARE O
= O
NUM O
) O
or O
with O
persistent O
generalized O
RARE O
( O
RARE O
= O
NUM O
) O
in O
a O
prospective O
study O
to O
evaluate O
clinical O
progression O
to O
AIDS O
related O
complex O
( O
ALL_CAP O
) O
or O
AIDS O
and O
to O
identify O
factors O
of O
possible O
prognostic O
relevance O
. O

No O
homology O
was O
found O
between O
NUM I-GENE
and O
NUM I-GENE
or O
between O
NUM I-GENE
and O
other O
proteins O
contained O
in O
data O
RARE O
. O

Mutations O
in O
the O
yeast I-GENE
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
result O
in O
an O
abnormal O
mRNA O
RARE O
rate O
; O
sequence O
analysis O
reveals O
an O
RNA O
- O
binding O
domain O
in O
the O
NUM I-GENE
protein I-GENE
. O

Myocardial O
infarction O
in O
patients O
with O
previous O
bypass O
surgery O
. O

The O
most O
striking O
difference O
in O
the O
RARE I-GENE
ALL_CAP I-GENE
( I-GENE
P I-GENE
) I-GENE
H I-GENE
- I-GENE
ALL_CAP I-GENE
sequence I-GENE
in O
comparison O
to O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
sequences I-GENE
was O
found O
RARE O
the O
putative O
RARE O
nucleotide O
binding O
site O
. O

A O
single O
amino O
acid O
difference O
in O
the O
C O
- O
terminal O
region O
influences O
dominant O
negative O
activity O
and O
receptor O
RARE O
formation O
. O

No O
such O
benefits O
were O
seen O
RARE O
children O
with O
NUM I-GENE
+ I-GENE
counts O
below O
NUM O
. O
2 O
RARE O
10 O
( O
9 O
) O
per O
liter O
RARE O
entry O
. O

Because O
the O
human I-GENE
RARE I-GENE
ALL_CAP I-GENE
binding I-GENE
protein I-GENE
is O
RARE O
in O
both O
RARE O
and O
non O
- O
RARE O
cells O
, O
we O
suggest O
that O
this O
RARE I-GENE
gene I-GENE
has O
evolved O
a O
more O
RARE O
transcriptional O
regulatory O
function O
in O
RARE O
eukaryotic O
cells O
. O

The O
NUM O
% O
confidence O
values O
( O
NUM O
) O
RARE O
the O
change O
in O
RARE O
required O
to O
RARE O
RARE O
variability O
were O
NUM O
. O
NUM O
, O
NUM O
. O
50 O
and O
NUM O
. O
53 O
cmH2O O
RARE O
- O
1 O
s O
, O
respectively O
. O

Among O
NUM O
infants O
in O
NUM O
neonatal O
care O
RARE O
studied O
, O
NUM O
% O
( O
median O
value O
, O
range O
NUM O
- O
NUM O
) O
were O
found O
to O
be O
RARE O
RARE O
with O
one O
of O
21 O
distinct O
RARE O
strains O
of O
Escherichia O
coli O
, O
RARE O
or O
RARE O
RARE O
. O

Biochemical O
studies O
revealed O
the O
expected O
RARE O
of O
ALL_CAP I-GENE
activity O
in O
the O
dorsal O
and O
ventral O
RARE O
of O
lesioned O
animals O
along O
with O
elevated O
levels O
of O
norepinephrine O
( O
ALL_CAP O
) O
in O
the O
dorsal O
hippocampus O
of O
MS O
/ O
ALL_CAP O
animals O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

The O
RARE O
of O
this O
RARE O
locus O
in O
the O
human O
genome O
and O
the O
availability O
of O
new O
RARE O
provide O
the O
tools O
RARE O
future O
studies O
of O
human O
diseases O
where O
the O
NUM I-GENE
RARE I-GENE
gene I-GENE
is O
suspected O
to O
be O
involved O
. O

After O
2 O
min O
of O
RARE O
injection O
, O
or O
after O
20 O
min O
of O
RARE O
injection O
, O
the O
myocardium O
was O
removed O
, O
and O
used O
RARE O
determination O
of O
the O
tissue O
levels O
of O
metabolites O
of O
energy O
and O
carbohydrate O
metabolism O
. O

During O
coronary O
stenosis O
, O
on O
the O
RARE O
, O
RARE O
RARE O
RARE O
the O
same O
dose O
significantly O
RARE O
regional O
RARE O
dysfunction O
without O
changing O
ALL_CAP O
flow O
, O
global O
hemodynamics O
and O
cardiac O
RARE O
metabolism O
. O

Here O
we O
present O
evidence O
that O
major I-GENE
IE I-GENE
proteins I-GENE
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
are O
capable O
of O
RARE O
- O
activating O
the O
HIV I-GENE
LTR I-GENE
in O
a O
T O
- O
cell O
line O
, O
ALL_CAP O
- O
NUM O
. O

In O
a O
RARE O
where O
RARE O
HIV O
prevalence O
is O
low O
, O
the O
strategy O
is O
cost O
- O
effective O
RARE O
location O
and O
RARE O
of O
RARE O
seropositive O
individuals O
. O

The O
cis O
- O
acting O
element O
mediating O
glucocorticoid O
inducibility O
of O
the O
chicken I-GENE
RARE I-GENE
RARE I-GENE
gene I-GENE
has O
been O
identified O
. O

However O
, O
the O
increase O
in O
biliary O
excretion O
did O
not O
RARE O
RARE O
the O
RARE O
elimination O
of O
RARE O
and O
RARE O
acid O
via O
the O
RARE O
. O

Diagnostic O
value O
of O
RARE I-GENE
RARE I-GENE
immunoglobulin I-GENE
G I-GENE
( O
IgG I-GENE
) O
in O
pediatric O
neurological O
diseases O
. O

Expression O
of O
RARE O
genes O
, O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
and O
ALL_CAP I-GENE
, O
was O
apparently O
regulated O
by O
the O
positive O
regulator O
ALL_CAP I-GENE
. O

RARE O
VT O
was O
suppressed O
entirely O
in O
one O
patient O
. O

RARE O
, O
and O
D O
. O

The O
presence O
of O
the O
corresponding O
RARE O
mRNA O
transcripts O
( O
3 O
. O
2 O
- O
3 O
. O
5 O
RARE O
RARE O
( O
kb O
] O
in O
human O
RARE O
was O
shown O
by O
Northern O
blot O
hybridization O
, O
S1 I-GENE
RARE I-GENE
protection O
assay O
, O
and O
the O
polymerase O
chain O
reaction O
. O

Approximately O
50 O
% O
of O
the O
ribosomal O
DNA O
( O
ALL_CAP O
) O
RARE O
of O
Drosophila O
melanogaster O
are O
inactivated O
by O
two O
different O
NUM I-GENE
S I-GENE
RNA I-GENE
ribosomal I-GENE
gene I-GENE
insertions O
( O
type O
I O
and O
type O
II O
). O

RARE I-GENE
NUM I-GENE
consists O
of O
two O
polypeptide O
chains O
( O
Mr O
= O
NUM O
, O
NUM O
and O
NUM O
, O
NUM O
RARE O
which O
seem O
to O
be O
RARE O
RARE O
products O
connected O
by O
disulfide O
bonds O
from O
a O
precursor O
protein O
. O

However O
, O
the O
RARE I-GENE
gamma I-GENE
R I-GENE
alpha I-GENE
cDNA I-GENE
clone O
is O
RARE O
to O
RARE O
least O
two O
different O
- O
sized O
mRNAs O
RARE O
by O
ALL_CAP O
- O
16 O
cells O
, O
RARE O
the O
single O
Fc I-GENE
gamma I-GENE
R I-GENE
- I-GENE
related I-GENE
mRNA I-GENE
species O
RARE O
by O
human O
and O
mouse O
RARE O
killer O
cells O
. O

Both O
genes O
comprise O
three O
exons O
, O
two O
RARE O
and O
an O
unusually O
long O
3 O
'- O
RARE O
region O
( O
3 O
. O
2 O
RARE O
RARE O
RARE O
RARE O
a O
mRNA O
of O
RARE O
4 O
. O
1 O
kilobases O
. O

Stable O
RARE O
of O
the O
chimeric O
alpha I-GENE
i I-GENE
( I-GENE
54 I-GENE
RARE I-GENE
s I-GENE
polypeptide O
in O
RARE O
hamster O
ovary O
( O
CHO O
) O
cells O
constitutively O
increased O
both O
cAMP O
RARE O
and O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
activity O
. O

This O
RARE O
, O
here O
named O
RARE O
NUM O
, O
contained O
the O
RARE O
5 O
' O
RARE O
region O
and O
the O
N O
- O
terminal O
signal O
sequence O
of O
the O
polypeptide O
. O

Treatment O
of O
human O
RARE O
cell O
lines O
ALL_CAP O
- O
NUM O
and O
U937 O
with O
phorbol O
12 O
- O
myristate O
NUM O
- O
RARE O
( O
PMA O
) O
increased O
within O
2 O
h O
cellular O
levels O
of O
the O
RNA O
RARE O
to O
NUM I-GENE
cDNA I-GENE
. O

A O
new O
, O
RARE O
RARE O
RARE O
RARE O
observation O
of O
the O
ventricles O
and O
major O
RARE O
is O
reported O
. O

RARE I-GENE
N I-GENE
isomerase I-GENE
( O
RARE I-GENE
) O
has O
been O
RARE O
from O
RARE O
RARE O
, O
and O
the O
amino O
acid O
sequence O
of O
the O
N O
- O
terminus O
has O
been O
determined O
. O

Serum O
IgG I-GENE
was O
initially O
elevated O
in O
6 O
patients O
. O

The O
patient O
initially O
RARE O
RARE O
remission O
( O
NUM O
) O
with O
conventional O
chemotherapy O
and O
then O
RARE O
14 O
months O
later O
. O

NUM O
+/- O
16 O
mg O
/ O
dl O
; O
ALL_CAP O
RARE O
glucose O
levels O
, O
and O
basal O
( O
NUM O
+/- O
4 O
RARE O
. O

RARE O
RARE O
and O
metabolic O
control O
are O
not O
affected O
by O
RARE O
antagonist O
treatment O
in O
type O
II O
diabetes O
mellitus O
. O

Wnt I-GENE
- I-GENE
1 I-GENE
( O
int I-GENE
- I-GENE
1 I-GENE
) O
is O
a O
cellular O
oncogene O
often O
activated O
by O
RARE O
of O
RARE O
DNA O
of O
the O
mouse O
mammary O
tumor O
virus O
. O

Induction O
of O
Jurkat O
RARE O
T O
cells O
with O
phorbol O
12 O
- O
myristate O
NUM O
- O
RARE O
and O
RARE O
did O
not O
affect O
the O
level O
of O
ALL_CAP I-GENE
mRNA I-GENE
. O

NUM I-GENE
mRNA I-GENE
is O
RARE O
RARE O
highest O
levels O
in O
small O
intestine O
and O
RARE O
much O
lower O
levels O
in O
RARE O
, O
skeletal O
muscle O
, O
and O
RARE O
tissue O
. O

RARE O
. O

We O
RARE O
that O
these O
tumors O
may O
represent O
congenital O
RARE O
RARE O
. O

Identification O
and O
characterization O
of O
the O
promoter O
RARE O
the O
RARE I-GENE
gene I-GENE
. O

Surprisingly O
, O
there O
is O
RARE O
sequence O
homology O
between O
this O
region O
of O
RARE I-GENE
- I-GENE
NUM I-GENE
and O
the O
established O
consensus O
RARE O
the O
RARE I-GENE
- I-GENE
RARE I-GENE
response I-GENE
element I-GENE
, O
which O
has O
been O
shown O
functionally O
important O
to O
all O
previously O
characterized O
alpha I-GENE
/ I-GENE
beta I-GENE
RARE I-GENE
- O
inducible O
promoters O
. O

RARE O
large O
DNA O
RARE O
spanning O
the O
region O
with O
RARE O
direct O
repeats O
encoding O
the O
RARE O
- O
terminal O
histone I-GENE
NUM I-GENE
- I-GENE
like I-GENE
RARE O
of O
ALL_CAP I-GENE
were O
detected O
in O
several O
strains O
upon O
conversion O
from O
the O
RARE O
to O
the O
RARE O
RARE O
. O

( O
1988 O
) O
ALL_CAP O
. O

These O
results O
strongly O
suggested O
that O
similar O
, O
if O
not O
identical O
, O
the O
ALL_CAP I-GENE
box I-GENE
binding I-GENE
proteins I-GENE
interact O
with O
the O
functionally O
different O
promoter O
element O
in O
the O
NUM I-GENE
, O
cardiac I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
, O
and O
c I-GENE
- I-GENE
fos I-GENE
genes I-GENE
. O

RARE O
of O
NUM I-GENE
RNA I-GENE
, O
which O
occurs O
very O
early O
RARE O
RARE O
, O
is O
limited O
to O
NUM O
residues O
, O
and O
it O
is O
this O
number O
that O
is O
required O
RARE O
RARE O
recruitment O
. O

Co O
- O
existence O
of O
these O
regulatory O
elements O
with O
other O
elements O
, O
such O
RARE O
the O
AP I-GENE
- I-GENE
2 I-GENE
element I-GENE
or O
CCAAT O
box O
, O
was O
also O
found O
. O

Recently O
, O
studies O
of O
agents O
that O
disrupt O
RARE I-GENE
RARE O
and O
deposition O
have O
yielded O
several O
new O
angiogenesis O
RARE O
. O

Since O
the O
5 O
'- O
flanking O
region O
of O
this O
gene O
is O
likely O
involved O
in O
hormonal O
RARE O
of O
its O
RARE O
, O
we O
have O
isolated O
and O
partially O
characterized O
an O
avian O
fatty I-GENE
acid I-GENE
synthase I-GENE
gene O
. O

A O
new O
set O
of O
cDNA O
RARE O
spanning O
RARE O
3 O
. O
2 O
kb O
was O
isolated O
from O
a O
lambda O
- O
ALL_CAP O
RARE O
liver O
cDNA O
library O
using O
the O
5 O
'- O
most O
RARE O
- O
containing O
fragment O
of O
the O
5 O
'- O
most O
genomic O
DNA O
clone O
. O

Northern O
blotting O
analysis O
indicates O
that O
RARE O
of O
the O
genes O
corresponding O
to O
these O
RARE O
is O
confined O
to O
pollen O
tissue O
. O

Whereas O
cDNA O
hybridization O
to O
genomic O
DNA O
blots O
indicated O
a O
small O
subfamily O
of O
NUM I-GENE
genes I-GENE
, O
simple O
patterns O
of O
bands O
indicated O
that O
most O
cDNAs O
, O
including O
NUM I-GENE
cDNA I-GENE
, O
corresponded O
to O
single O
- O
copy O
genes O
. O

RARE O
disorders O
arising O
under O
RARE O
with O
FK O
NUM O
: O
initial O
observations O
in O
a O
large O
transplant O
population O
. O

The O
Drosophila I-GENE
suppressor I-GENE
of I-GENE
RARE I-GENE
gene I-GENE
encodes O
a O
polypeptide O
with O
regions O
similar O
to O
those O
of O
RNA O
- O
binding O
proteins O
. O

2 O
: O
NUM O
- O
NUM O
, O
1988 O
). O

It O
is O
, O
however O
, O
extremely O
homologous O
to O
a O
third O
' O
non O
- O
classical O
' O
gene O
, O
HLA I-GENE
- I-GENE
5 I-GENE
. I-GENE
4 I-GENE
, O
and O
to O
the O
RARE O
gene O
, O
NUM I-GENE
. O

Although O
the O
NUM O
- O
NUM O
RARE O
interval O
remained O
stable O
because O
of O
the O
parallel O
shift O
of O
the O
2 O
peaks O
, O
the O
central O
conduction O
time O
measured O
from O
onset O
RARE O
of O
NUM O
and O
NUM O
significantly O
increased O
. O

Using O
RARE I-GENE
- I-GENE
RARE I-GENE
complex O
DNA O
binding O
assays O
, O
a O
series O
of O
overlapping O
alpha I-GENE
promoter I-GENE
DNA I-GENE
sequences I-GENE
between O
- O
NUM O
to O
29 O
RARE O
were O
tested O
, O
but O
each O
failed O
to O
bind O
GR I-GENE
, O
whereas O
a O
control O
ALL_CAP O
RARE O
RARE O
receptor O
. O

Sequence O
determination O
of O
isolated O
peptides O
suggested O
that O
NUM O
is O
glycosylated O
, O
NUM O
and O
NUM O
glycosylated O
in O
some O
molecules O
but O
not O
in O
others O
, O
and O
NUM O
not O
glycosylated O
. O

The O
DNA O
sequence O
conferring O
AP I-GENE
- I-GENE
1 I-GENE
activity O
was O
RARE O
in O
the O
proximal O
promoter O
region O
. O

The O
murine I-GENE
mutation I-GENE
dominant I-GENE
RARE I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
is O
in O
the O
RARE O
- O
oncogene O
, O
c I-GENE
- I-GENE
kit I-GENE
. O

Isolation O
and O
characterization O
of O
the O
rat O
chromosomal O
gene O
RARE O
a O
polypeptide O
( O
NUM I-GENE
) O
RARE O
related O
to O
RARE I-GENE
. O

The O
proteins O
differ O
in O
the O
presence O
or O
absence O
of O
a O
21 O
- O
amino O
- O
acid O
sequence O
RARE O
NUM O
amino O
RARE O
C O
terminal O
of O
the O
translational O
initiation O
RARE O
. O

Our O
results O
also O
indicate O
the O
existence O
of O
sequences O
RARE O
of O
- O
NUM O
. O
11 O
kb O
which O
can O
influence O
the O
pattern O
of O
tissue O
- O
specific O
RARE O
of O
the O
HLA I-GENE
- I-GENE
B7 I-GENE
gene I-GENE
and O
the O
ability O
of O
this O
gene O
to O
respond O
to O
gamma I-GENE
RARE I-GENE
. O

The O
NUM I-GENE
and O
SH3 I-GENE
domains I-GENE
of O
NUM I-GENE
direct O
stable O
association O
with O
tyrosine O
RARE O
proteins O
p130 I-GENE
and O
NUM I-GENE
. O

Chem O
. O

These O
RARE O
RARE O
and O
contained O
the O
structural O
gene O
encoding O
the O
RARE O
NUM I-GENE
alpha I-GENE
- I-GENE
chain I-GENE
and O
NUM O
% O
of O
the O
beta O
- O
chain O
. O

The O
NUM I-GENE
alpha I-GENE
- I-GENE
chain I-GENE
was O
encoded O
by O
NUM O
kilobases O
containing O
NUM O
exons O
; O
the O
beta O
- O
chain O
was O
encoded O
by O
29 O
kilobases O
containing O
16 O
exons O
. O

RARE O
mutation O
in O
the O
G O
+ O
5 O
position O
of O
intron O
NUM O
of O
the O
pro I-GENE
- I-GENE
alpha I-GENE
2 I-GENE
( I-GENE
I I-GENE
) I-GENE
gene I-GENE
( O
NUM I-GENE
) O
that O
causes O
aberrant O
RNA O
RARE O
and O
lethal O
RARE O
RARE O
. O

The O
nucleotide O
sequences O
of O
these O
genes O
differ O
RARE O
only O
nine O
positions O
, O
resulting O
in O
three O
amino O
acid O
differences O
. O

The O
protein O
predicted O
by O
the O
sequence O
of O
the O
human I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
RARE I-GENE
- I-GENE
oncogene I-GENE
shares O
extensive O
homology O
with O
known O
serine I-GENE
/ I-GENE
threonine I-GENE
protein I-GENE
kinases I-GENE
, O
and O
yet O
the O
human I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
enzyme I-GENE
has O
previously O
been O
reported O
to O
exhibit O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
activity O
both O
in O
vitro O
and O
in O
vivo O
. O

A O
full I-GENE
- I-GENE
length I-GENE
human I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
was O
subcloned O
into O
the O
bacterial O
vector O
ALL_CAP O
- O
NUM O
and O
the O
RARE I-GENE
- I-GENE
1 I-GENE
protein I-GENE
RARE O
RARE O
a O
fusion O
product O
with O
bacterial I-GENE
RARE I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
). O

This O
report O
RARE O
that O
RARE O
least O
two O
of O
the O
18 O
kDa O
RARE I-GENE
in O
RARE O
are O
products O
of O
different O
but O
related O
genes O
. O

The O
10 O
kDa O
polypeptide O
was O
RARE O
in O
vitro O
by O
RARE O
RARE O
RARE O
membranes O
with O
RARE O
gamma O
32P O
] O
ATP O
. O

RARE O
with O
the O
human O
protein O
is O
only O
NUM O
% O
in O
the O
RARE O
repeat O
domain O
, O
mainly O
showing O
conservation O
of O
RARE O
and O
RARE O
, O
RARE O
sites O
of O
O O
- O
RARE O
carbohydrate O
RARE O
. O

In O
addition O
to O
targeting O
partially O
assembled O
RARE I-GENE
alpha I-GENE
- I-GENE
beta I-GENE
CD3 I-GENE
gamma I-GENE
delta I-GENE
epsilon I-GENE
TCR I-GENE
complexes I-GENE
to O
the O
cell O
surface O
, O
CD3 I-GENE
RARE I-GENE
appears O
to O
be O
essential O
RARE O
interleukin I-GENE
- I-GENE
2 I-GENE
production O
after O
TCR I-GENE
RARE O
with O
antigen I-GENE
/ I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
. O

When O
desipramine O
was O
injected O
16 O
hrs O
after O
RARE O
injection O
, O
brain O
levels O
of O
desipramine O
were O
RARE O
longer O
elevated O
. O

RARE O
effects O
of O
NUM I-GENE
are O
observed O
in O
aerobic O
, O
heme O
- O
sufficient O
cells O
. O

A O
segmental O
analysis O
of O
the O
key O
regions O
of O
HLA I-GENE
- I-GENE
NUM I-GENE
that O
control O
T O
cell O
RARE O
was O
performed O
by O
using O
a O
series O
of O
transfected O
cell O
lines O
expressing O
the O
products O
of O
recombinant O
ALL_CAP I-GENE
/ O
H I-GENE
- I-GENE
NUM I-GENE
genes O
, O
paired O
with O
either O
ALL_CAP I-GENE
alpha I-GENE
or O
H I-GENE
- I-GENE
NUM I-GENE
alpha I-GENE
. O

We O
characterized O
cDNA O
RARE O
specific O
RARE O
the O
extracellular O
RARE O
glycoprotein O
RARE I-GENE
. O

Finally O
, O
some O
point O
mutations O
in O
the O
Gag I-GENE
- O
Pol I-GENE
PR O
domain O
inhibited O
activation O
of O
RT I-GENE
in O
RARE O
by O
a O
wild O
- O
type O
PR I-GENE
, O
suggesting O
that O
the O
correct O
conformation O
of O
the O
PR I-GENE
domain O
in O
Gag I-GENE
- O
Pol I-GENE
is O
prerequisite O
RARE O
activation O
of O
RT I-GENE
. O

The O
alpha I-GENE
RARE I-GENE
promoter I-GENE
containing O
a O
RARE O
ALL_CAP O
was O
not O
regulated O
by O
forskolin O
in O
RARE O
cells O
and O
did O
not O
bind O
the O
CREB I-GENE
protein I-GENE
. O

Regulation O
of O
the O
alpha I-GENE
RARE I-GENE
gene I-GENE
by O
cyclic O
adenosine O
3 O
RARE O
5 O
'- O
monophosphate O
after O
transfection O
into O
rat O
RARE O
cells O
. O

Comparison O
of O
the O
nucleotide O
sequences O
between O
the O
human O
and O
bovine O
DNA O
showed O
that O
the O
sequence O
RARE O
extended O
NUM O
bp O
RARE O
from O
the O
coding O
region O
. O

Cloning O
of O
a O
human O
cDNA O
encoding O
a O
NUM I-GENE
- I-GENE
related I-GENE
kinase I-GENE
by O
RARE O
of O
a O
RARE I-GENE
yeast I-GENE
NUM I-GENE
mutation O
. O

In O
patients O
with O
RARE O
and O
joint O
RARE O
( O
RARE O
= O
NUM O
) O
ALL_CAP I-GENE
elastase I-GENE
had O
a O
sensitivity O
of O
77 O
%, O
which O
was O
only O
RARE O
by O
that O
of O
the O
RARE O
RARE O
sedimentation O
rate O
( O
sensitivity O
NUM O
%). O

E O
., O
RARE O
, O
C O
., O
RARE O
, O
D O
., O
RARE O
, O
B O
., O
RARE O
, O
R O
., O
RARE O
, O
B O
., O
Chi O
- O
RARE O
, O
G O
., O
and O
RARE O
, O
R O
., O
( O
1990 O
) O
Cell O
NUM O
, O
NUM O
- O
NUM O
). O

The O
above O
results O
mean O
that O
the O
increase O
in O
alpha I-GENE
- I-GENE
adrenergic I-GENE
receptors I-GENE
makes O
the O
RARE O
, O
which O
has O
been O
already O
RARE O
, O
less O
elastic O
, O
inhibiting O
external O
RARE O
RARE O
function O
. O

An O
RARE O
2 I-GENE
- I-GENE
RARE I-GENE
NUM I-GENE
transcript I-GENE
was O
RARE O
in O
all O
RARE O
organs O
tested O
. O

These O
results O
indicate O
that O
the O
RARE O
group O
of O
certain O
angiotensin I-GENE
RARE I-GENE
enzyme I-GENE
RARE O
can O
RARE O
their O
effect O
on O
the O
endogenous O
RARE O
ALL_CAP I-GENE
. O

RARE O
of O
FK O
NUM O
in O
transplant O
patients O
. O

A O
second O
even O
more O
significant O
match O
to O
this O
E O
. O
coli O
region O
was O
found O
in O
the O
RARE I-GENE
RARE I-GENE
H I-GENE
( O
RNase I-GENE
H I-GENE
) O
domain O
, O
and O
corresponds O
precisely O
to O
a O
region O
that O
has O
been O
RARE O
by O
previous O
RARE O
with O
the O
E I-GENE
. I-GENE
coli I-GENE
RNase I-GENE
H I-GENE
, O
suggesting O
that O
Pol I-GENE
I I-GENE
helices O
O O
and O
P O
are O
homologous O
to O
helices O
A O
and O
D O
of O
the O
RNase I-GENE
H I-GENE
RARE O
RARE O
, O
respectively O
. O

Analysis O
of O
the O
deduced O
amino O
acid O
sequence O
suggests O
that O
NUM I-GENE
protein I-GENE
contains O
RARE O
RARE O
- O
spanning O
domains O
, O
two O
RARE O
RARE O
N O
- O
glycosylation O
sites O
, O
and O
RARE O
N O
and O
C O
termini O
. O

The O
qualitative O
concentrations O
of O
ALL_CAP I-GENE
had O
a O
sensitivity O
of O
37 O
. O
5 O
% O
and O
a O
RARE O
of O
NUM O
%. O

The O
RARE O
rate O
of O
F O
absorption O
and O
slower O
rise O
in O
plasma O
F O
concentration O
accompanying O
delayed O
RARE O
emptying O
indicate O
that O
passage O
of O
F O
into O
the O
small O
intestine O
is O
the O
major O
factor O
in O
rapid O
F O
absorption O
. O

The O
activity O
of O
serum I-GENE
lipase I-GENE
and O
amylase I-GENE
distinctly O
increased O
RARE O
3 O
h O
and O
RARE O
RARE O
to O
the O
maximum O
RARE O
12 O
h O
after O
injection O
of O
RARE O
- O
Tc O
. O

They O
were O
RARE O
RARE O
anti I-GENE
- I-GENE
HCV I-GENE
( O
anti I-GENE
- I-GENE
NUM I-GENE
- I-GENE
3 I-GENE
) O
with O
HCV O
ALL_CAP O
kit O
( O
RARE O
RARE O
., O
RARE O
RARE O
, O
ALL_CAP O
). O

RARE O
resulted O
in O
a O
significant O
increase O
in O
RARE O
diameter O
(+ O
10 O
%; O
p O
= O
NUM O
. O
001 O
) O
and O
in O
coronary O
RARE O
flow O
( O
CBF O
) O
(+ O
NUM O
%; O
p O
= O
NUM O
. O
0001 O
). O

The O
RARE O
transfusion O
resulted O
in O
a O
platelet O
RARE O
to O
NUM O
RARE O
/ O
RARE O
( O
ALL_CAP O
11 O
). O

These O
risk O
factors O
can O
be O
divided O
into O
2 O
groups O
: O
local O
vessel O
RARE O
- O
related O
factors O
, O
and O
local O
( O
RARE O
action O
) O
systemic O
factors O
. O

RARE O
and O
prevention O
of O
hospital O
infections O
in O
the O
RARE O
Health O
RARE O
of O
RARE O
: O
profile O
of O
bacterial O
resistance O
and O
antimicrobial O
agents O
of O
large O
usage O
. O

ALL_CAP I-GENE
- I-GENE
NUM I-GENE
- I-GENE
derived I-GENE
cDNAs I-GENE
did O
not O
result O
in O
RARE O
of O
either O
basal O
or O
tat I-GENE
- O
RARE O
activated O
gene O
RARE O
. O

RARE O
virus O
( O
ALL_CAP O
) O
is O
a O
potent O
RARE O
, O
but O
the O
nature O
of O
ALL_CAP O
proteins O
involved O
in O
the O
activation O
of O
the O
immune O
response O
of O
the O
RARE O
is O
not O
yet O
known O
. O

Max I-GENE
: O
RARE O
domains O
and O
interaction O
with O
c I-GENE
- I-GENE
RARE I-GENE
. O

NUM O
: O
NUM O
- O
NUM O
) O
or O
G1 O
to O
S O
RARE O
( O
RARE O
, O
C O
. O

RARE O
introduced O
RARE O
bases O
surrounding O
the O
NUM I-GENE
motif I-GENE
yielded O
levels O
of O
ALL_CAP O
replication O
that O
differed O
, O
depending O
on O
the O
RARE O
of O
a O
putative O
5 O
' O
RARE O
- O
loop O
RARE O
in O
the O
positive O
RARE O
of O
the O
viral O
genome O
. O

RARE O
( O
II O
) O
coordination O
domain O
mutants O
of O
T4 O
gene I-GENE
NUM I-GENE
protein O
. O

RARE O
( O
II O
) O
coordination O
domain O
mutants O
of O
T4 I-GENE
gene I-GENE
NUM I-GENE
protein I-GENE
. O

The O
tissue O
RARE O
of O
gene O
RARE O
was O
identical O
to O
that O
described O
previously O
RARE O
the O
ALL_CAP I-GENE
NUM I-GENE
domain I-GENE
B I-GENE
enhancer I-GENE
element I-GENE
. O

The O
pathophysiology O
and O
clinical O
management O
of O
acute O
brain O
injury O
in O
RARE O
and O
childhood O
are O
presented O
using O
acute O
RARE O
brain O
injury O
RARE O
a O
model O
. O

RARE O
from O
a O
second O
POU I-GENE
- I-GENE
domain I-GENE
gene I-GENE
, O
Oct I-GENE
- I-GENE
NUM I-GENE
, O
were O
present O
RARE O
low O
levels O
in O
oocytes O
and O
early O
RARE O
and O
were O
dramatically O
RARE O
RARE O
early O
RARE O
. O

In O
some O
early O
B O
cells O
and O
RARE O
murine O
leukemia O
virus O
- O
transformed O
pre O
- O
B O
- O
cell O
lines O
, O
ALL_CAP I-GENE
mRNA I-GENE
is O
constitutively O
RARE O
. O

The O
genome O
of O
RARE O
virus O
comprises O
RARE O
RARE O
of O
single O
- O
RARE O
, O
negative O
sense O
RNA O
. O

These O
tumors O
were O
classified O
into O
three O
broad O
groups O
: O
I O
, O
RARE O
; O
II O
, O
RARE O
; O
and O
III O
, O
adenocarcinoma O
with O
RARE I-GENE
production O
or O
an O
associated O
cyst O
. O

RARE O
of O
cells O
transfected O
with O
these O
constructs O
revealed O
that O
both O
the O
RARE O
and O
RARE O
mutants O
were O
localized O
in O
nuclei O
, O
whereas O
wild I-GENE
- I-GENE
type I-GENE
PKC I-GENE
alpha I-GENE
was O
primarily O
cytoplasmic O
and O
RARE O
. O

We O
have O
partially O
sequenced O
the O
NUM I-GENE
protein I-GENE
from O
RARE O
HeLa O
cells O
, O
RARE O
its O
RARE O
DNA O
and O
shown O
that O
its O
translation O
product O
can O
interact O
with O
NUM I-GENE
in O
vitro O
RARE O
RARE O
RARE O
in O
vivo O
. O

Effects O
of O
RARE I-GENE
RARE I-GENE
inhibition O
on O
RARE O
RARE O
vascular O
resistance O
and O
the O
rate O
of O
bacterial O
translocation O
in O
a O
chronic O
RARE O
model O
. O

The O
RARE O
pancreatic O
RARE O
RARE O
to O
be O
unaffected O
by O
the O
treatment O
, O
because O
neither O
the O
rise O
in O
plasma I-GENE
lipase I-GENE
nor O
the O
development O
of O
RARE O
or O
the O
extension O
of O
the O
pancreatic O
necrosis O
were O
diminished O
. O

The O
size O
of O
the O
mutant O
molecule O
corresponds O
to O
the O
RARE O
cytoplasmic O
precursor O
( O
pre I-GENE
- I-GENE
RARE I-GENE
- I-GENE
pro I-GENE
- I-GENE
ALL_CAP I-GENE
RARE O
RARE O
detected O
in O
NUM I-GENE
mutants I-GENE
, O
when O
translocation O
into O
the O
endoplasmic O
reticulum O
is O
blocked O
. O

Thus O
, O
the O
RARE O
- O
site O
mutation O
prevents O
the O
wild O
- O
type O
RARE O
of O
the O
N O
- O
glycosylated O
NUM O
- O
kDa O
precursor O
of O
ALL_CAP I-GENE
to O
the O
NUM I-GENE
. I-GENE
5 I-GENE
kDa I-GENE
pro I-GENE
- I-GENE
ALL_CAP I-GENE
in O
the O
endoplasmic O
reticulum O
. O

The O
predicted O
amino O
acid O
sequence O
exhibited O
70 O
% O
identity O
to O
that O
of O
Bacillus I-GENE
RARE I-GENE
ALL_CAP I-GENE
and O
NUM O
% O
identity O
to O
that O
of O
E I-GENE
. I-GENE
coli I-GENE
ALL_CAP I-GENE
, O
while O
identity O
to O
a O
second O
RARE O
B I-GENE
. I-GENE
subtilis I-GENE
ALL_CAP I-GENE
gene I-GENE
, O
designated O
ALL_CAP I-GENE
, O
was O
only O
NUM O
%. O

RARE O
- O
inducible O
CAT I-GENE
activity O
was O
detectable O
when O
additional O
sequences O
from O
the O
RARE O
promoter O
containing O
three O
CCAAT O
RARE O
and O
a O
single O
HSE O
were O
present O
in O
the O
RARE O
. O

SETTING O
RARE O
RARE O
, O
RARE O
, O
and O
Children O
RARE O
in O
RARE O
, O
RARE O
. O

RARE O
, O
free O
testosterone O
, O
non I-GENE
- I-GENE
RARE I-GENE
hormone I-GENE
- I-GENE
binding I-GENE
globulin I-GENE
- O
RARE O
testosterone O
, O
and O
free O
RARE O
index O
: O
which O
testosterone O
measurement O
is O
most O
relevant O
to O
reproductive O
and O
sexual O
function O
in O
men O
with O
epilepsy O
? O

BACKGROUND O
: O
The O
effectiveness O
of O
RARE I-GENE
oxidase I-GENE
RARE O
( O
RARE O
) O
in O
RARE O
resistant O
depression O
has O
received O
RARE O
little O
systematic O
study O
. O

The O
upstream O
delta O
- O
alpha O
RARE O
is O
flanked O
by O
the O
direct O
repeats O
of O
the O
RARE O
RARE O
site O
, O
whereas O
the O
down O
- O
RARE O
alpha O
- O
delta O
RARE O
is O
RARE O
in O
the O
adjacent O
intron O
. O

Patients O
with O
moderate O
ALL_CAP O
were O
impaired O
on O
all O
serial O
positions O
RARE O
both O
spatial O
order O
and O
spatial O
recognition O
memory O
. O

RARE O
and O
RARE O
. O

One O
patients O
had O
plasma I-GENE
C I-GENE
- I-GENE
peptide I-GENE
greater O
than O
3 O
ALL_CAP O
and O
was O
therefore O
excluded O
from O
analysis O
. O

RARE O
RARE O
RARE O
were O
observed O
in O
muscles O
of O
RARE O
mice O
but O
RARE O
complex O
RARE O
RARE O
or O
other O
abnormalities O
were O
observed O
in O
muscles O
of O
normal O
control O
mice O
. O

RARE O
often O
involves O
beta O
- O
and O
RARE O
RARE O
blocking O
drugs O
or O
type O
ALL_CAP O
antiarrhythmic O
drugs O
. O

To O
overcome O
this O
problem O
, O
we O
have O
overexpressed O
NUM I-GENE
using O
the O
RARE O
/ O
insect O
cell O
RARE O
RARE O
. O

ALL_CAP O
. O

The O
major I-GENE
NUM I-GENE
- I-GENE
kDa I-GENE
core I-GENE
protein I-GENE
in O
the O
liver O
ALL_CAP I-GENE
preparation O
was O
found O
to O
be O
reactive O
to O
an O
antibody O
that O
specifically O
recognizes O
the O
cytoplasmic O
domain O
of O
RARE I-GENE
. O

While O
RARE O
RARE O
transmembrane O
regions O
were O
identified O
, O
several O
short O
hydrophobic O
amino O
acid O
stretches O
were O
found O
to O
be O
localized O
in O
and O
around O
the O
RARE O
II O
region O
, O
and O
these O
may O
be O
responsible O
RARE O
RARE O
of O
RARE O
to O
membranes O
. O

RARE O
was O
mild O
, O
mainly O
consisting O
of O
RARE O
( O
NUM O
% O
of O
the O
patients O
; O
NUM O
% O
of O
the O
courses O
RARE O
RARE O
of O
RARE O
Health O
Organization O
( O
ALL_CAP O
) O
grade O
1 O
to O
2 O
( O
NUM O
% O
of O
the O
patients O
; O
18 O
% O
of O
the O
courses O
RARE O
and O
thrombocytopenia O
( O
12 O
% O
of O
the O
patients O
; O
3 O
% O
of O
the O
courses O
). O

ALL_CAP O
. O
G O
. O

This O
study O
RARE O
, O
although O
individual O
reaction O
is O
remarkably O
different O
, O
RARE O
RARE O
a O
potent O
RARE O
RARE O
RARE O
dogs O
. O

A O
mouse I-GENE
brain I-GENE
beta I-GENE
- I-GENE
spectrin I-GENE
of O
cDNA O
was O
identified O
within O
a O
lambda O
NUM O
RARE O
library O
using O
an O
antibody O
which O
specifically O
binds O
with O
the O
NUM I-GENE
kDa I-GENE
spectrin I-GENE
beta I-GENE
- I-GENE
subunit I-GENE
. O

RESULTS O
: O
Plasma I-GENE
AVP I-GENE
responses O
to O
osmotic O
RARE O
, O
and O
non O
- O
osmotic O
inhibition O
by O
drinking O
, O
were O
normal O
in O
patients O
with O
RARE O
water O
drinking O
. O

The O
fragments O
of O
each O
region O
were O
amplified O
by O
polymerase O
chain O
reaction O
and O
analyzed O
by O
gel O
electrophoresis O
to O
detect O
single O
- O
RARE O
conformation O
polymorphism O
. O

The O
ALL_CAP I-GENE
fusion I-GENE
was O
RARE O
RARE O
RARE O
early O
stationary O
RARE O
in O
cells O
grown O
in O
RARE O
RARE O
containing O
5 O
% O
glucose O
and O
NUM O
. O
2 O
% O
RARE O
. O

The O
RARE O
of O
primase I-GENE
recognition I-GENE
sequences I-GENE
, O
nucleotide O
substrate O
requirements O
, O
and O
the O
effects O
of O
additional O
proteins O
on O
RARE O
RARE O
by O
the O
NUM I-GENE
- I-GENE
kDa I-GENE
gene I-GENE
4 I-GENE
protein I-GENE
have O
been O
examined O
using O
templates O
of O
defined O
sequence O
. O

RARE O
therapy O
in O
spontaneous O
coronary O
artery O
dissection O
. O

A O
prospective O
trial O
was O
carried O
out O
in O
NUM O
RARE O
patients O
( O
NUM O
men O
, O
mean O
age O
67 O
. O
5 O
years O
, O
NUM O
women O
, O
mean O
age O
NUM O
. O
4 O
years O
) O
who O
had O
undergone O
RARE O
hip O
joint O
RARE O
because O
of O
RARE O
or O
inflammatory O
arthritis O
or O
fracture O
of O
the O
neck O
of O
the O
femur O
. O

When O
both O
lesions O
were O
RARE O
lateral O
RARE O
in O
RARE O
RARE O
, O
little O
behavioral O
recovery O
was O
observed O
, O
similar O
to O
RARE O
RARE O
cord O
RARE O
( O
N O
= O
3 O
). O

Human O
SRF I-GENE
- I-GENE
related I-GENE
proteins I-GENE
: O
DNA O
- O
binding O
properties O
and O
RARE O
regulatory O
RARE O
. O

We O
have O
isolated O
cDNAs O
RARE O
a O
gene O
coding O
RARE O
a O
G I-GENE
protein I-GENE
alpha I-GENE
subunit I-GENE
from I-GENE
RARE I-GENE
( O
RARE O
RARE O
, O
cv O
. O

RARE O
factor O
RARE O
of O
cells O
causes O
the O
RARE O
of O
the O
c I-GENE
- I-GENE
RARE I-GENE
transcriptional I-GENE
activation I-GENE
domain I-GENE
RARE O
NUM O
within O
a O
proline O
- O
rich O
region O
that O
is O
highly O
RARE O
among O
members O
of O
the O
RARE I-GENE
family I-GENE
( O
RARE O
, O
E O
., O
RARE O
, O
I O
. O
C O
., O
RARE O
, O
F O
. O

The O
authors O
evaluated O
the O
RARE O
RARE O
thrombotic O
complications O
arising O
from O
implantation O
of O
a O
ventricular O
RARE O
device O
( O
RARE O
/ O
NUM O
- O
ALL_CAP O
) O
in O
four O
calves O
. O

RARE O
output O
( O
ALL_CAP O
) O
was O
significantly O
RARE O
( O
p O
less O
than O
NUM O
. O
NUM O
) O
in O
the O
ALL_CAP O
group O
. O

Amino O
acid O
residues O
NUM O
- O
NUM O
of O
the O
previously O
reported O
sequence O
are O
replaced O
by O
new O
residues O
NUM O
to O
NUM O
. O

Transcriptional O
activation O
by O
the O
HIV I-GENE
- I-GENE
1 I-GENE
Tat I-GENE
protein I-GENE
requires O
specific O
residues O
in O
the O
RARE O
loop O
and O
RARE O
RARE O
of O
the O
ALL_CAP I-GENE
RNA O
RARE O
- O
loop O
RARE O
found O
in O
the O
5 O
'- O
RARE O
RARE O
of O
all O
viral O
transcripts O
. O

We O
obtained O
quantitative O
evidence O
on O
the O
coding O
of O
RARE O
time O
differences O
( O
RARE O
) O
of O
RARE O
stimuli O
by O
40 O
single O
neurons O
in O
the O
auditory O
cortex O
of O
anesthetized O
RARE O
rats O
. O

These O
results O
strongly O
suggest O
that O
locally O
- O
applied O
ALL_CAP O
in O
combination O
with O
ALL_CAP O
enhances O
new O
bone O
formation O
in O
experimental O
alveolar O
bone O
defects O
. O

As O
an O
initial O
step O
towards O
the O
characterization O
of O
replicative O
DNA I-GENE
RARE I-GENE
of I-GENE
RARE I-GENE
, O
we O
have O
RARE O
, O
sequenced O
and O
examined O
the O
RARE O
of O
the O
Trypanosoma O
( O
RARE O
) O
RARE O
RARE O
gene O
that O
encodes O
the O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
catalytic I-GENE
core I-GENE
( O
pol I-GENE
alpha I-GENE
). O

In O
addition O
, O
there O
was O
a O
significant O
increase O
in O
RARE O
cortical O
concentrations O
with O
age O
( O
p O
less O
than O
NUM O
. O
01 O
; O
RARE O
= O
NUM O
. O
NUM O
). O

RARE O
hypertension O
, O
with O
or O
without O
coronary O
arterial O
RARE O
, O
is O
the O
major O
condition O
leading O
to O
isolated O
RARE O
infarction O
. O

The O
volume O
fraction O
( O
RARE O
) O
and O
number O
/ O
mm2 O
( O
RARE O
) O
of O
all O
capillaries O
( O
perfused O
and O
RARE O
) O
in O
a O
given O
area O
of O
brain O
were O
determined O
after O
staining O
RARE O
RARE I-GENE
phosphatase I-GENE
. O

RARE O
pressure O
and O
air O
flow O
were O
measured O
RARE O
the O
RARE O
tube O
in O
NUM O
children O
on O
a O
variety O
of O
RARE O
. O

RARE O
. O

RARE O
of O
distribution O
of O
kinetic O
energy O
of O
RARE O
RARE O
in O
direct O
RARE O
interaction O
with O
head O
RARE O
impact O
are O
discussed O
from O
position O
of O
RARE O
. O

CONCLUSION O
: O
RARE O
NUM O
RARE O
the O
nasal O
RARE O
site O
is O
more O
reliable O
than O
monitoring O
it O
RARE O
the O
finger O
site O
in O
RARE O
patients O
. O

RARE O
decreased O
the O
RARE O
body O
clearance O
from O
NUM O
. O
NUM O
+/- O
8 O
. O
NUM O
to O
NUM O
. O
6 O
+/- O
6 O
. O
1 O
mL O
/ O
min O
( O
P O
less O
than O
. O
01 O
RARE O
and O
prolonged O
the O
elimination O
RARE O
- O
life O
from O
12 O
. O
6 O
+/- O
3 O
. O
NUM O
to O
14 O
. O
3 O
+/- O
2 O
. O
5 O
hours O
( O
P O
less O
than O
. O
01 O
) O
of O
RARE O
without O
any O
changes O
in O
volume O
of O
distribution O
. O

The O
granules O
RARE O
RARE O
the O
RARE O
material O
RARE O
into O
the O
RARE O
space O
among O
the O
RARE O
RARE O
. O

Hence O
, O
the O
uPA I-GENE
promoter I-GENE
contains O
multiple O
weak O
cis O
- O
acting O
elements O
distributed O
over O
7 O
. O
NUM O
kb O
5 O
' O
to O
the O
translation O
RARE O
site O
. O

RARE O
a O
RARE O
RARE O
NUM O
or O
a O
Glu O
RARE O
RARE O
NUM O
in O
the O
RARE O
ALL_CAP I-GENE
RARE I-GENE
in O
finger O
II O
of O
ALL_CAP I-GENE
resulted O
in O
the O
RARE O
of O
DNA O
binding O
. O

P O
. O

In O
one O
, O
RARE O
behavior O
( O
assessed O
by O
RARE O
RARE O
) O
and O
RARE O
were O
assessed O
RARE O
a O
10 O
- O
min O
test O
session O
. O

The O
model O
is O
able O
to O
RARE O
RARE O
the O
effect O
of O
water O
RARE O
on O
RARE O
prevalence O
is O
most O
pronounced O
when O
RARE O
is O
diagnosed O
RARE O
cavity O
level O
. O

12 O
- O
O O
- O
RARE O
NUM O
- O
RARE O
was O
found O
to O
inhibit O
rapidly O
and O
RARE O
the O
RARE O
of O
mRNAs O
coding O
RARE O
the O
RARE O
RARE O
NUM I-GENE
and O
myogenin I-GENE
. O

In O
Xenopus O
RARE O
, O
the O
gene O
encoding O
the O
RARE I-GENE
factor I-GENE
1 I-GENE
- I-GENE
alpha I-GENE
variant I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
O I-GENE
, O
where O
O O
RARE O
RARE O
RARE O
, O
is O
RARE O
in O
oocytes O
and O
early O
RARE O
. O

These O
RARE O
belong O
to O
the O
class O
of O
nuclear O
pre O
- O
mRNA O
RARE O
and O
contain O
typical O
5 O
'- O
and O
3 O
'- O
consensus O
sequences O
, O
RARE O
RARE O
RARE O
unique O
features O
. O

The O
mRNA O
identified O
in O
both O
human O
and O
rat O
cells O
with O
the O
human I-GENE
clathrin I-GENE
clone O
revealed O
transcripts O
of O
RARE O
6 O
. O
5 O
kb O
, O
which O
is O
consistent O
with O
the O
predicted O
180 O
kDa O
RARE O
RARE O
of O
the O
clathrin I-GENE
heavy I-GENE
chain I-GENE
. O

In O
this O
report O
, O
almost O
6 O
kb O
of O
DNA O
sequence O
is O
presented O
, O
including O
NUM O
bp O
5 O
' O
to O
the O
gene O
, O
over O
4 O
kb O
of O
RARE O
and O
RARE O
- O
intron O
junctions O
, O
and O
NUM O
bp O
3 O
' O
to O
the O
gene O
. O

An O
8 O
- O
h O
exposure O
to O
10 O
mg O
ALL_CAP O
/ O
m3 O
corresponds O
to O
a O
postexposure O
plasma O
concentration O
and O
2 O
- O
h O
postexposure O
RARE O
excretion O
of O
4 O
. O
9 O
mumol O
/ O
RARE O
and O
NUM O
mmol O
/ O
mol O
RARE O
, O
respectively O
. O

Antibodies O
specific O
to O
NUM I-GENE
and O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
disrupt O
RARE O
complexes O
with O
these O
DNA O
- O
binding O
sites O
, O
confirming O
the O
interaction O
of O
RARE O
in O
vivo O
factors O
. O

A O
method O
is O
described O
RARE O
detecting O
targeted O
events O
RARE O
the O
mu I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
which O
RARE O
on O
RARE O
- O
conversion O
( O
or O
RARE O
- O
exchange O
) O
of O
a O
point O
mutation O
with O
a O
selectable O
marker O
contained O
on O
a O
RARE O
vector O
. O

RARE O
activity O
of O
RARE O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
was O
tested O
in O
RARE O
volunteers O
extremely O
RARE O
to O
the O
RARE O
. O

This O
study O
was O
aimed O
RARE O
assessing O
whether O
c O
- O
DDP O
administration O
immediately O
before O
radiotherapy O
could O
increase O
frequency O
and O
duration O
of O
objective O
responses O
, O
RARE O
RARE O
RARE O
survival O
, O
in O
patients O
affected O
with O
locally O
advanced O
stages O
of O
squamous O
carcinomas O
of O
the O
head O
and O
neck O
. O

Two O
RARE O
regulatory O
sequences O
RARE O
DNA O
binding O
proteins O
were O
found O
in O
the O
non O
- O
coding O
5 O
' O
region O
: O
a O
NUM I-GENE
/ O
NUM I-GENE
consensus O
recognition O
sequence O
RARE O
nucleotide O
- O
154 O
and O
a O
NUM I-GENE
consensus I-GENE
recognition I-GENE
sequence I-GENE
RARE O
nucleotide O
- O
136 O
. O

Marked O
thrombocytopenia O
, O
depletion O
of O
serum I-GENE
fibrinogen I-GENE
and O
prolonged O
prothrombin I-GENE
and O
activated O
partial O
thromboplastin I-GENE
time O
, O
were O
recorded O
RARE O
5 O
to O
10 O
and O
NUM O
to O
40 O
minutes O
after O
intravenous O
RARE O
. O

We O
RARE O
the O
properties O
of O
LexA I-GENE
fusion I-GENE
proteins I-GENE
to O
study O
the O
RARE O
and O
DNA O
- O
RARE O
domains O
of O
RARE I-GENE
. O

Plasma O
RARE O
and O
lipoprotein O
profiles O
were O
compared O
in O
elderly O
female O
RARE O
( O
ALL_CAP O
: O
RARE O
= O
NUM O
, O
aged O
NUM O
+/- O
5 O
years O
, O
body O
fat O
20 O
+/- O
4 O
%, O
training O
distance O
NUM O
+/- O
NUM O
RARE O
week O
- O
1 O
, O
NUM O
NUM O
+/- O
4 O
ml O
kg O
- O
1 O
min O
- O
1 O
, O
mean O
+/- O
SD O
) O
and O
age O
- O
matched O
RARE O
women O
( O
UT O
: O
RARE O
= O
NUM O
, O
NUM O
+/- O
4 O
years O
, O
body O
fat O
NUM O
+/- O
6 O
%, O
NUM O
NUM O
+/- O
3 O
ml O
kg O
- O
1 O
min O
- O
1 O
). O

RARE O
threshold O
shifts O
, O
RARE O
measured O
by O
the O
auditory O
evoked O
RARE O
response O
, O
were O
measured O
RARE O
2 O
, O
4 O
, O
8 O
, O
12 O
, O
16 O
, O
20 O
and O
NUM O
RARE O
. O

RARE O
and O
clinical O
evaluation O
of O
equilibrium O
dialysis O
RARE O
radioimmunoassay O
RARE O
RARE O
measurement O
of O
serum O
free O
thyroxine O

We O
conclude O
that O
TA O
caused O
a O
specific O
decrease O
in O
ALL_CAP O
on O
ALL_CAP O
20 O
that O
was O
largely O
reversed O
by O
ALL_CAP O
NUM O
. O

When O
examined O
RARE O
adults O
( O
8 O
weeks O
old O
RARE O
the O
external O
RARE O
of O
TA O
- O
exposed O
RARE O
were O
normal O
. O

After O
PTCA O
, O
ejection O
fraction O
increased O
from O
54 O
+/- O
8 O
% O
to O
NUM O
+/- O
8 O
% O
( O
p O
less O
than O
NUM O
. O
05 O
) O
and O
regional O
function O
improved O
significantly O
( O
maximal O
standard O
deviation O
before O
PTCA O
: O
2 O
. O
8 O
+/- O
NUM O
. O
8 O
; O
after O
PTCA O
: O
1 O
. O
9 O
+/- O
NUM O
. O
9 O
- O
RARE O
below O
the O
RARE O
standard O
deviation O
before O
PTCA O
: O
NUM O
+/- O
16 O
; O
after O
PTCA O
: O
19 O
+/- O
NUM O
). O

The O
alcoholic O
patient O
, O
RARE O
work O
and O
the O
RARE O
of O
the O
period O

These O
data O
suggest O
that O
the O
combined O
treatment O
with O
a O
RARE I-GENE
RARE I-GENE
inhibitor O
and O
a O
RARE I-GENE
receptor I-GENE
antagonist O
provides O
a O
better O
protection O
against O
RARE O
RARE O
than O
with O
either O
agent O
alone O
. O

A O
NUM O
- O
kb O
YAC O
, O
NUM O
, O
RARE O
from O
the O
HLA I-GENE
- O
NUM I-GENE
locus O
through O
the O
NUM I-GENE
/ O
RARE I-GENE
4 I-GENE
locus O
and O
extended O
RARE O
least O
NUM O
kb O
RARE O
of O
YAC O
NUM O
. O

RARE O
backcross O
analysis O
using O
RARE O
derived O
from O
RARE O
of O
( O
C57BL O
/ O
NUM O
RARE O
RARE O
RARE O
) O
NUM O
RARE O
C57BL O
/ O
NUM O
mice O
indicates O
that O
the O
RARE I-GENE
gene I-GENE
is O
tightly O
RARE O
to O
the O
RARE I-GENE
, O
RARE I-GENE
, O
RARE I-GENE
, O
and O
NUM I-GENE
loci I-GENE
on O
murine O
RARE O
2 O
. O

RARE O
RARE O
outcome O
in O
specific O
IgM I-GENE
positive O
Chlamydia O
RARE O
infection O
in O
RARE O
. O

Using O
an O
image O
- O
RARE O
computer O
, O
regional O
LV O
time O
- O
density O
curves O
were O
constructed O
RARE O
one O
cardiac O
RARE O
. O

In O
a O
second O
patient O
the O
VT O
became O
RARE O
. O

If O
delay O
has O
occurred O
between O
RARE O
and O
the O
measurement O
, O
causing O
substantial O
RARE O
of O
CO2 O
, O
RARE O
of O
the O
sample O
with O
a O
gas O
mixture O
corresponding O
to O
PCO2 O
= O
5 O
. O
3 O
RARE O
prior O
to O
the O
measurement O
is O
recommended O
. O

The O
possible O
mechanisms O
underlying O
differences O
in O
post O
- O
RARE O
effects O
from O
muscle O
and O
cutaneous O
afferents O
in O
adults O
and O
neonates O
are O
discussed O
. O

We O
examined O
behavioral O
alterations O
in O
the O
brown O
RARE O
, O
RARE O
RARE O
, O
RARE O
with O
the O
RARE O
, O
RARE O
RARE O
. O

First O
, O
the O
finding O
of O
a O
RARE O
Alu I-GENE
family O
repeat O
RARE O
the O
RARE O
between O
RARE O
RARE O
I O
and O
homology O
RARE O
Y O
of O
the O
alpha I-GENE
2 I-GENE
gene I-GENE
- I-GENE
containing I-GENE
unit I-GENE
in I-GENE
RARE I-GENE
RARE I-GENE
suggests O
that O
the O
RARE O
Alu I-GENE
family O
repeat O
, O
Alu I-GENE
3 I-GENE
, O
RARE O
the O
RARE O
position O
in O
human O
was O
generated O
by O
RARE O
of O
a O
RARE O
Alu I-GENE
family O
repeat O
into O
the O
3 O
' O
end O
of O
another O
RARE O
Alu I-GENE
family O
repeat O
. O

The O
sequence O
of O
the O
repressor O
locus O
, O
c O
, O
of O
the O
RARE O
RARE O
RARE O
, O
RARE O
NUM O
, O
was O
shown O
previously O
to O
contain O
an O
RARE O
reading O
frame O
encoding O
a O
NUM O
kDa O
protein O
. O

The O
EPO I-GENE
levels O
were O
distinctly O
increased O
before O
transfusion O
; O
they O
did O
not O
significantly O
change O
just O
after O
transfusion O
, O
but O
subsequently O
decreased O
. O

This O
differential O
sensitivity O
to O
ALL_CAP O
, O
RARE O
measured O
by O
a O
lower O
concentration O
of O
ALL_CAP O
which O
caused O
RARE O
of O
RARE O
in O
ALL_CAP O
, O
was O
accompanied O
by O
an O
equal O
rate O
of O
water O
- O
RARE O
RARE O
brain O
distribution O
and O
elimination O
in O
the O
two O
lines O
. O

The O
existence O
of O
threshold O
concentrations O
, O
above O
which O
certain O
phenomena O
may O
occur O
, O
RARE O
the O
role O
of O
RARE O
. O

However O
, O
it O
was O
synthesized O
RARE O
both O
temperatures O
after O
addition O
of O
NUM O
. O

RARE O
did O
not O
alter O
the O
baseline O
FEV1 O
, O
but O
showed O
a O
small O
significant O
RARE O
effect O
upon O
RARE O
and O
AMP O
RARE O
RARE O
. O

Ten O
out O
of O
10 O
patients O
with O
progressive O
RARE O
had O
RARE O
cells O
greater O
than O
or O
equal O
to O
NUM O
. O
5 O
%, O
RARE O
greater O
than O
or O
equal O
to O
50 O
micrograms O
. O
RARE O
- O
1 O
and O
fibronectin I-GENE
greater O
than O
or O
equal O
to O
350 O
micrograms O
. O
RARE O
- O
1 O
compared O
to O
eight O
out O
of O
NUM O
patients O
with O
stable O
or O
RARE O
RARE O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

Our O
mapping O
results O
did O
not O
suggest O
involvement O
of O
this O
gene O
in O
previously O
mapped O
genetic O
disorders O
or O
in O
known O
RARE O
- O
associated O
translocation O
breakpoints O
. O

RARE O
little O
is O
known O
regarding O
the O
role O
of O
5 I-GENE
- I-GENE
HT2 I-GENE
receptor I-GENE
activity O
in O
male O
rat O
sexual O
behavior O
. O

These O
changes O
RARE O
' O
t O
so O
significant O
in O
the O
group O
of O
obese O
children O
who O
RARE O
' O
t O
RARE O
RARE O
. O

RARE O
contents O
in O
RARE O
RARE O

In O
ten O
other O
experiments O
( O
5 O
experimental O
and O
5 O
control O
rats O
) O
99mTc O
- O
sulfur O
colloid O
was O
injected O
intravenously O
. O

RARE O
of O
hepatitis O
A O
and O
B O
in O
children O

These O
results O
were O
superior O
to O
those O
in O
NUM O
patients O
with O
conventional O
end O
- O
to O
- O
end O
RARE O
on O
clinical O
testing O
. O

Mutational O
analysis O
supports O
a O
role O
RARE O
multiple O
structural O
features O
in O
the O
C O
- O
terminal O
RARE O
signal O
of O
Escherichia I-GENE
coli I-GENE
RARE I-GENE
. O

Among O
RARE O
donors O
in O
the O
RARE O
of O
RARE O
, O
regardless O
the O
number O
of O
RARE O
RARE O
, O
the O
percentage O
of O
female O
donors O
is O
significantly O
lower O
compared O
to O
the O
percentage O
of O
male O
RARE O
donors O
. O

RARE O
relapse O
in O
childhood O
leukemia O
. O

RARE O
RARE O
was O
isolated O
from O
the O
RARE O
RARE O
of O
this O
patient O
. O

NUM O
and O
ALL_CAP O
NUM O
in O
combination O
have O
been O
shown O
to O
be O
effective O
in O
early O
RARE O
of O
RARE O
. O

The O
presence O
of O
local O
abnormalities O
in O
both O
patients O
can O
support O
the O
hypothesis O
that O
the O
cortex O
, O
especially O
of O
the O
temporal O
anterior O
lobe O
, O
is O
involved O
in O
the O
origin O
of O
the O
RARE O
seizures O
. O

In O
line O
with O
the O
small O
values O
RARE O
ALL_CAP O
/ O
ALL_CAP O
, O
our O
results O
further O
indicate O
that O
even O
large O
, O
RARE O
- O
perfused O
, O
occluded O
air O
RARE O
in O
the O
RARE O
will O
RARE O
affect O
the O
recovered O
ventilation O
/ O
perfusion O
distribution O
obtained O
from O
RARE O
gas O
data O
when O
NUM O
RARE O
NUM O
. O
1 O
ml O
. O
min O
- O
1 O
. O
mmHg O
- O
1 O
. O

Many O
cells O
were O
negative O
RARE O
endothelial O
- O
cell O
markers O
, O
and O
they O
reacted O
with O
a O
monoclonal O
antibody O
against O
muscle O
actin I-GENE
. O

ALL_CAP O
abnormalities O
noted O
in O
term O
babies O
included O
hemorrhage O
( O
RARE O
5 O
. O
8 O
%, O
RARE O
11 O
. O
6 O
%), O
RARE O
( O
mild O
NUM O
. O
2 O
%, O
moderate O
11 O
. O
6 O
% O
severe O
5 O
. O
8 O
RARE O
RARE O
with O
hemorrhage O
5 O
. O
8 O
% O
and O
cerebral O
atrophy O
5 O
. O
8 O
%. O

The O
effects O
of O
contrast O
media O
on O
coagulation I-GENE
factor I-GENE
ALL_CAP I-GENE
. O

RARE O
were O
RARE O
from O
the O
growing O
to O
the O
RARE O
diet O
RARE O
57 O
and O
NUM O
kg O
in O
RARE O
. O

In O
RARE O
patients O
with O
moderate O
essential O
hypertension O
the O
effects O
of O
10 O
- O
day O
nifedipine O
treatment O
on O
serum O
uric O
acid O
and O
RARE O
excretion O
of O
uric O
acid O
were O
evaluated O
. O

ALL_CAP O
produced O
brain O
RARE O
, O
and O
RARE O
and O
pulmonary O
RARE O
and O
generalized O
RARE O
. O

RARE O
are O
using O
more O
subjects O
or O
an O
improved O
research O
design O
, O
developing O
consensus O
RARE O
or O
using O
RARE O
- O
analysis O
. O

A O
two O
RARE O
RARE O
flow O
tubular O
heat O
RARE O
was O
used O
RARE O
the O
thermal O
inactivation O
of O
RARE O
monocytogenes O
in O
RARE O
RARE O
milk O
from O
RARE O
cows O
. O

RARE O
far O
NUM O
children O
have O
been O
studied O
. O

RARE O
cerebral O
RARE O
flow O
( O
rCBF O
) O
measurements O
and O
psychiatric O
RARE O
were O
performed O
on O
RARE O
schizophrenic O
patients O
( O
mean O
age O
= O
NUM O
. O
4 O
years O
) O
who O
had O
been O
examined O
18 O
years O
previously O
in O
a O
study O
that O
used O
similar O
psychiatric O
RARE O
and O
a O
comparable O
rCBF O
technique O
. O

In O
the O
present O
study O
, O
we O
identified O
a O
strong O
positive O
cis O
- O
regulatory O
element O
RARE O
- O
70 O
bp O
to O
- O
NUM O
bp O
in O
the O
NUM I-GENE
beta I-GENE
promoter I-GENE
with O
the O
sequence O
( O
G O
) O
6 O
and O
a O
similar O
, O
more O
distal O
cis O
- O
element O
RARE O
- O
NUM O
bp O
to O
- O
NUM O
bp O
. O

The O
present O
study O
reports O
visual O
evoked O
RARE O
responses O
to O
pattern O
reversal O
( O
ALL_CAP O
- O
P O
) O
in O
ten O
third O
RARE O
RARE O
women O
and O
changes O
in O
RARE O
of O
ALL_CAP O
complex O
when O
compared O
with O
these O
responses O
in O
the O
non O
RARE O
state O
. O

No O
case O
of O
ALL_CAP O
demonstrated O
RARE O
RARE O
growth O
. O

RARE O
doses O
of O
NUM O
- O
RARE O
- O
PGF2 O
alpha O
( O
NUM O
. O
NUM O
- O
10 O
mg O
) O
were O
used O
to O
induce O
RARE O
and O
RARE O
in O
7 O
heifers O
with O
NUM O
treatments O
on O
day O
8 O
- O
12 O
of O
the O
RARE O
RARE O
. O

RARE O
of O
the O
literature O
and O
report O
of O
a O
case O
of O
a O
RARE O
cyst O
. O

RARE O
of O
RARE O
asymmetry O
and O
/ O
or O
decrease O
in O
RARE O
T O
was O
demonstrated O
in O
RARE O
NUM O
% O
of O
the O
post O
- O
treatment O
population O
. O

In O
all O
instances O
the O
apparent O
RARE O
responses O
were O
very O
small O
and O
never O
RARE O
a O
reading O
of O
1 O
microgram O
/ O
NUM O
RARE O
RARE O
samples O
more O
than O
NUM O
post O
- O
exposure O
. O

RARE I-GENE
ALL_CAP I-GENE
promoter I-GENE
activity O
depends O
on O
sequence O
elements O
not O
found O
in O
RARE I-GENE
ALL_CAP I-GENE
promoters I-GENE
. O

Measurements O
were O
done O
with O
a O
commercial O
RARE O
RARE O
ALL_CAP O
which O
was O
RARE O
to O
the O
average O
RARE O
value O
of O
NUM O
. O
NUM O
. O

The O
relatively O
RARE O
number O
of O
examples O
, O
which O
could O
be O
RARE O
by O
the O
variety O
and O
complexity O
of O
combined O
exposure O
, O
allows O
to O
conclude O
that O
life O
- O
RARE O
factors O
have O
considerable O
influence O
on O
RARE O
differences O
in O
RARE O
to O
RARE O
toxicity O
. O

The O
NUM I-GENE
E1A I-GENE
product I-GENE
does O
not O
activate O
a O
ALL_CAP O
sequence O
, O
but O
cotransfection O
with O
c I-GENE
- I-GENE
jun I-GENE
RARE O
this O
lack O
of O
RARE O
. O

After O
treatment O
with O
RARE O
, O
the O
transfectants O
RARE O
RARE O
18 O
- O
kDa O
polypeptides O
which O
could O
also O
bind O
IgE I-GENE
. O

NUM I-GENE
, O
a O
yeast O
gene O
required O
RARE O
RARE O
biogenesis O
, O
encodes O
a O
RARE O
of O
a O
novel O
family O
of O
putative O
RARE I-GENE
. O

The O
gene O
is O
1 O
, O
139 O
RARE O
RARE O
( O
bp O
) O
long O
, O
and O
, O
like O
other O
members O
of O
the O
ALL_CAP I-GENE
family I-GENE
, O
the O
beta I-GENE
TG I-GENE
gene I-GENE
is O
divided O
into O
3 O
exons O
. O

The O
NUM I-GENE
- I-GENE
protein I-GENE
kinase I-GENE
activity O
( O
referred O
to O
RARE O
RARE I-GENE
- I-GENE
kinase I-GENE
) O
is O
also O
not O
related O
to O
cofactor O
- O
dependent O
signal O
RARE O
protein O
kinases O
such O
RARE O
the O
cyclic I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinases I-GENE
, O
members O
of O
the O
protein I-GENE
kinase I-GENE
C I-GENE
family I-GENE
, O
or O
other O
NUM I-GENE
RARE I-GENE
dependent I-GENE
protein I-GENE
kinases I-GENE
. O

Human I-GENE
ALL_CAP I-GENE
- I-GENE
3 I-GENE
: O
a O
lineage O
- O
restricted O
transcription O
factor O
that O
regulates O
the O
RARE O
of O
the O
T I-GENE
cell I-GENE
receptor I-GENE
alpha I-GENE
gene I-GENE
. O

Like O
many O
eukaryotic O
transcription O
factors O
, O
these O
proteins O
bind O
to O
DNA O
RARE O
RARE O
. O

Furthermore O
, O
the O
ALL_CAP I-GENE
protein I-GENE
interacts O
with O
the O
ALL_CAP I-GENE
protein I-GENE
to O
modulate O
its O
activities O
, O
both O
in O
solution O
and O
in O
association O
with O
DNA O
, O
where O
the O
ALL_CAP I-GENE
complex I-GENE
possesses O
a O
RARE I-GENE
activity O
. O

The O
NUM O
values O
were O
2 O
. O
4 O
and O
2 O
. O
2 O
mg O
/ O
kg O
and O
similar O
to O
the O
respective O
values O
of O
nifedipine O
( O
ALL_CAP O
NUM O
: O
2 O
. O
4 O
, O
2 O
. O
1 O
mg O
/ O
kg O
). O

RARE O
blot O
analysis O
demonstrated O
that O
this O
RARE O
can O
bind O
the O
RARE I-GENE
B I-GENE
element I-GENE
directly O
and O
specifically O
. O

Thus O
, O
the O
positive O
effect O
of O
NS1 I-GENE
on O
the O
steady O
- O
state O
levels O
of O
NUM I-GENE
transcripts I-GENE
depends O
on O
the O
amplification O
of O
gene O
copy O
number O
and O
the O
integrity O
of O
the O
terminal O
repeats O
. O

The O
minus O
- O
end O
- O
directed O
microtubule O
RARE O
, O
the O
RARE I-GENE
, O
may O
also O
constitute O
a O
superfamily O
of O
force O
- O
generating O
proteins O
with O
distinct O
RARE O
domains O
. O

It O
is O
RARE O
, O
RARE O
to O
be O
made O
, O
and O
RARE O
to O
RARE O
and O
was O
tested O
in O
118 O
animals O
RARE O
two O
and O
four O
weeks O
. O

The O
RARE O
group O
ALL_CAP O
RARE O
RARE O
suppresses O
RARE O
RARE O
RARE O
( O
ALL_CAP O
. O

RARE O
translational O
RARE O
signals O
are O
upstream O
of O
ORF1 O
and O
ORF2 O
. O

RARE O
of O
NUM I-GENE
dopamine I-GENE
receptor I-GENE

The O
NUM O
mutation O
causes O
a O
lethal O
RARE O
in O
the O
RARE O
yeast O
Schizosaccharomyces O
pombe O
, O
while O
RARE O
of O
NUM O
with O
RARE O
acid O
, O
potentially O
RARE O
RARE O
, O
causes O
RARE O
of O
mitosis O
and O
multiple O
RARE O
. O

The O
abundance O
of O
transcripts O
from O
several O
unrelated O
genes O
is O
decreased O
in O
NUM I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
cells O
after O
transfer O
to O
the O
restrictive O
RARE O
, O
while O
RARE O
least O
one O
transcript O
, O
from O
the O
NUM I-GENE
gene I-GENE
, O
RARE O
in O
an O
aberrant O
fashion O
. O

RARE O
of O
their O
RARE O
may O
contribute O
to O
malignant O
transformation O
associated O
with O
ALL_CAP O
- O
1 O
infection O
. O

The O
murine I-GENE
RARE I-GENE
- I-GENE
NUM I-GENE
gene I-GENE
: O
full O
- O
length O
cDNA O
and O
genomic O
organization O
. O

CREB I-GENE
was O
identified O
RARE O
one O
of O
the O
protein O
RARE O
in O
several O
of O
the O
gel O
shift O
complexes O
formed O
with O
the O
variant O
ALL_CAP O
. O

The O
spectrum O
of O
histologically O
diagnosed O
malignant O
neoplasms O
in O
RARE O
, O
1983 O
- O
1988 O
. O

When O
transfected O
into O
Drosophila O
ALL_CAP O
- O
2 O
cells O
, O
ALL_CAP O
RARE O
containing O
2 O
, O
NUM O
bp O
of O
5 O
'- O
flanking O
region O
shows O
a O
3 O
. O
NUM O
- O
to O
3 O
. O
5 O
- O
RARE O
increase O
in O
chloramphenicol I-GENE
RARE I-GENE
activity O
after O
induction O
with O
retinoic O
acid O
and O
/ O
or O
8 O
- O
RARE O
- O
cAMP O
. O

Two O
RARE O
RARE O
5 O
' O
RARE O
, O
designated O
type O
I O
and O
type O
II O
, O
of O
NUM O
and O
NUM O
bp O
, O
respectively O
, O
were O
found O
associated O
with O
ALL_CAP I-GENE
. O

The O
N O
- O
terminus O
of O
another O
RARE O
reading O
frame O
was O
found O
3 O
' O
from O
ALL_CAP I-GENE
and O
tentatively O
identified O
RARE O
ALL_CAP I-GENE
by O
amino O
acid O
sequence O
comparison O
. O

The O
RNA O
genome O
of O
RARE O
hemorrhagic O
RARE O
virus O
( O
ALL_CAP O
) O
was O
molecularly O
RARE O
. O

Therefore O
, O
we O
have O
developed O
a O
RARE O
to O
study O
nuclear O
targeting O
in O
RARE O
and O
have O
established O
that O
the O
nuclear O
RARE O
machinery O
is O
similar O
in O
RARE O
and O
RARE O
. O

A O
novel O
cDNA O
clone O
termed O
NUM O
was O
isolated O
by O
RARE O
hybridization O
of O
a O
cDNA O
library O
of O
phytohemagglutinin I-GENE
( O
ALL_CAP I-GENE
RARE O
phorbol O
myristate O
RARE O
- O
RARE O
Jurkat O
cells O
and O
by O
RARE O
a O
cDNA O
library O
of O
ALL_CAP O
- O
RARE O
peripheral O
RARE O
lymphocytes O
. O

In O
conclusion O
, O
we O
observed O
a O
great O
regeneration O
ability O
following O
mechanical O
injury O
in O
the O
nasal O
mucosa O
. O

There O
occurred O
a O
RARE O
relationship O
between O
the O
drop O
in O
glucose I-GENE
- I-GENE
6 I-GENE
- I-GENE
phosphatase I-GENE
dehydrogenase I-GENE
activity O
and O
in O
vitamin O
E O
level O
, O
on O
one O
RARE O
, O
and O
the O
duration O
of O
poisoning O
with O
RARE O
RARE O
. O

A O
vector O
containing O
a O
transcriptionally O
inactive O
RARE I-GENE
RARE I-GENE
II I-GENE
gene I-GENE
was O
used O
to O
select O
promoter O
sequences O
from O
a O
pool O
of O
random O
genomic O
DNA O
fragments O
. O

RARE O
' O
RARE O
, O
visceral O
RARE O
, O
anti I-GENE
- I-GENE
nuclear I-GENE
factor I-GENE
, O
RARE O
, O
rheumatoid I-GENE
factor I-GENE
and O
normal O
controls O
. O

Previous O
analysis O
of O
the O
98 O
- O
bp O
sequence O
has O
RARE O
several O
protein O
- O
binding O
domains O
that O
are O
RARE O
by O
nuclear O
factors O
present O
in O
human O
brain O
cells O
. O

The O
second O
transcriptional O
unit O
, O
designated O
UL26 I-GENE
. I-GENE
5 I-GENE
, O
predicted O
to O
RARE O
a O
protein O
of O
NUM O
amino O
RARE O
, O
encodes O
the O
family I-GENE
NUM I-GENE
proteins I-GENE
; O
it O
is O
RARE O
by O
an O
mRNA O
which O
RARE O
RARE O
RARE O
nucleotide O
+ O
1000 O
of O
the O
UL26 I-GENE
transcription O
initiation O
site O
and O
is O
translated O
from O
the O
methionine O
initiation O
RARE O
RARE O
RARE O
position O
+ O
NUM O
of O
the O
UL26 I-GENE
transcriptional I-GENE
unit I-GENE
. O

The O
RARE I-GENE
- I-GENE
associated I-GENE
virus I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
RARE I-GENE
gene I-GENE
encodes O
four O
proteins O
( O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
) O
required O
RARE O
ALL_CAP O
DNA O
replication O
and O
ALL_CAP O
gene O
RARE O
. O

A O
larger O
region O
upstream O
of O
human I-GENE
ALL_CAP I-GENE
RARE I-GENE
also O
RARE O
replication O
in O
transient O
assays O
. O

It O
also O
contains O
a O
RARE I-GENE
3C I-GENE
- I-GENE
like I-GENE
protease I-GENE
domain I-GENE
and O
two O
RARE I-GENE
- I-GENE
like I-GENE
protease I-GENE
domains I-GENE
. O

However O
, O
the O
relative O
positions O
of O
the O
ALL_CAP O
genes O
( O
genus O
RARE O
) O
are O
different O
than O
those O
of O
the O
corresponding O
RARE O
in O
ALL_CAP O
( O
genus O
RARE O
RARE O
indicating O
complex O
RARE O
of O
DNA O
in O
the O
genome O
of O
one O
or O
both O
of O
these O
viruses O
subsequent O
to O
their O
divergence O
from O
a O
common O
ancestor O
. O

This O
result O
suggests O
that O
RARE O
of O
RARE O
14 O
and O
/ O
or O
RARE O
NUM O
inhibits O
p34cdc2 I-GENE
kinase I-GENE
activity O
, O
in O
line O
with O
the O
location O
of O
these O
residues O
within O
the O
putative O
ATP O
binding O
site O
of O
the O
kinase O
. O

In O
short O
- O
term O
RARE O
, O
a O
ALL_CAP I-GENE
- O
CAT I-GENE
target O
containing O
EBNA I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
from O
the O
ALL_CAP O
origin O
of O
RARE O
replication O
, O
RARE I-GENE
- I-GENE
P I-GENE
, O
was O
transactivated O
by O
a O
RARE I-GENE
- I-GENE
terminal I-GENE
EBNA I-GENE
- I-GENE
1 I-GENE
RARE I-GENE
( O
amino O
RARE O
NUM O
to O
NUM O
) O
that O
also O
carried O
a O
c I-GENE
- I-GENE
myc I-GENE
nuclear I-GENE
RARE I-GENE
signal I-GENE
. O

The O
findings O
are O
compatible O
with O
the O
idea O
that O
the O
genes O
encoding O
ALL_CAP I-GENE
receptors I-GENE
in O
glioma O
cells O
are O
regulated O
in O
RARE O
with O
other O
genes O
, O
the O
RARE O
of O
which O
may O
reflect O
the O
developmental O
program O
of O
normal O
RARE O
cell O
lineages O
. O

RARE O
evidence O
was O
obtained O
that O
ALL_CAP I-GENE
is O
involved O
in O
peptide O
utilization O
. O

This O
study O
tested O
the O
hypothesis O
that O
RARE O
RARE O
blocking O
drugs O
selectively O
RARE O
the O
RARE O
RARE O
, O
or O
terminal O
low O
amplitude O
signal O
, O
portion O
of O
the O
signal O
- O
averaged O
QRS O
complex O
and O
that O
prolongation O
of O
the O
RARE O
RARE O
would O
correlate O
with O
RARE O
of O
ventricular O
tachycardia O
. O

Identification O
and O
nucleotide O
sequence O
of O
RARE I-GENE
RARE I-GENE
RARE I-GENE
sequence I-GENE
NUM I-GENE
: O
RARE O
between O
the O
putative O
RARE I-GENE
encoded O
by O
NUM I-GENE
and O
those O
encoded O
by O
RARE I-GENE
RARE I-GENE
NUM I-GENE
and O
RARE I-GENE
RARE I-GENE
NUM I-GENE
. O

To O
determine O
the O
relationship O
of O
these O
viruses O
, O
the O
RARE O
DNA O
sequence O
of O
ALL_CAP O
consisting O
of O
NUM O
bp O
was O
determined O
. O

Whereas O
a O
NUM I-GENE
beta I-GENE
transcript I-GENE
of O
about O
2 O
. O
3 O
kb O
was O
detected O
RARE O
high O
levels O
in O
the O
neuroblastoma O
derived O
cell O
line O
LA O
- O
N O
- O
1 O
, O
the O
level O
of O
the O
mRNA O
was O
very O
low O
in O
the O
other O
human O
cell O
lines O
analyzed O
. O

RARE O
of O
myogenin I-GENE
and O
E12 I-GENE
( O
or O
MyoD I-GENE
and O
E12 I-GENE
) O
specifically O
RARE O
a O
RARE O
fragment O
extending O
from O
- O
NUM O
to O
- O
NUM O
relative O
to O
the O
RARE O
of O
cardiac I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
transcription O
. O

The O
effects O
of O
c I-GENE
- I-GENE
myc I-GENE
were O
further O
RARE O
by O
showing O
that O
c I-GENE
- I-GENE
myc I-GENE
can O
inhibit O
differentiation O
independently O
of O
RARE I-GENE
, O
a O
negative O
regulator O
of O
muscle O
differentiation O
. O

Stable O
association O
of O
NUM I-GENE
snRNP I-GENE
with O
the O
branchpoint O
sequence O
of O
mammalian O
pre O
- O
mRNAs O
requires O
binding O
of O
a O
non O
- O
snRNP O
protein O
to O
the O
RARE O
RARE O
. O

RARE O
acquired O
antibodies O
were O
demonstrated O
in O
some O
rabbits O
kept O
on O
commercial O
RARE O
. O

The O
Italian O
Lung O
Cancer O
RARE O
RARE O
( O
ALL_CAP O
). O

The O
promoter O
activity O
of O
the O
gene I-GENE
encoding I-GENE
RARE I-GENE
beta I-GENE
- I-GENE
RARE I-GENE
precursor I-GENE
protein I-GENE
( O
ALL_CAP I-GENE
) O
is O
regulated O
by O
two O
blocks O
of O
upstream O
sequences O
. O

Biol O
. O

Nucleotide O
sequences O
between O
the O
env I-GENE
gene I-GENE
and O
the O
LTR I-GENE
of I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
were O
determined O
. O

This O
element O
was O
used O
to O
screen O
an O
NUM O
mouse O
genomic O
library O
. O

The O
ALL_CAP O
- O
value O
is O
under O
the O
predicted O
level O
in O
the O
case O
of O
67 O
- O
NUM O
percent O
. O

The O
NUM I-GENE
. I-GENE
NUM I-GENE
DNA I-GENE
repair I-GENE
mutant I-GENE
from I-GENE
the I-GENE
RARE I-GENE
yeast I-GENE
, I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
, O
is O
RARE O
to O
both O
ALL_CAP O
and O
RARE O
radiation O
. O

RARE O
: O
deterioration O
of O
glucose O
tolerance O
with O
age O
: O
the O
role O
of O
insulin I-GENE
resistance O
. O

The O
5 O
' O
region O
shows O
strong O
sequence O
RARE O
to O
Escherichia O
coli O
consensus O
promoters O
and O
RARE O
- O
binding O
sequences O
and O
allows O
high O
levels O
of O
RARE O
in O
E O
. O
coli O
. O

RARE O
initiation O
of O
mitosis O
in O
yeast O
RARE O
NUM I-GENE
or O
an O
RARE O
GTPase I-GENE
. O

The O
method O
has O
been O
RARE O
used O
in O
our O
laboratory O
RARE O
1 O
year O
and O
has O
proven O
to O
be O
a O
reliable O
procedure O
RARE O
the O
biological O
control O
of O
RARE O
exposure O
to O
toluene O
and O
/ O
or O
xylene O
. O

The O
patient O
was O
a O
NUM O
- O
year O
- O
old O
male O
in O
whom O
RARE O
lesions O
RARE O
the O
diagnosis O
of O
RARE O
. O

RARE O
- O
500 O
is O
a O
group O
of O
high O
resolution O
imaging O
RARE O
RARE O
use O
with O
ALL_CAP O
- O
AT O
and O
compatible O
RARE O
. O

The O
human O
cDNA O
was O
used O
to O
demonstrate O
that O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
could O
rapidly O
stimulate O
ALL_CAP I-GENE
gene I-GENE
transcription O
in O
the O
human O
RARE O
leukemia O
cell O
line O
NUM O
. O

After O
resection O
of O
the O
proximal O
fragment O
, O
all O
RARE O
RARE O
area O
and O
pressure O
was O
born O
by O
the O
distal O
RARE O
fragment O
. O

RARE O
RARE O
, O
a O
technique O
that O
uses O
RARE O
( O
ALL_CAP O
) O
RARE O
between O
the O
RARE O
and O
the O
bone O
, O
RARE O
RARE O
RARE O
between O
the O
RARE O
RARE O
and O
the O
RARE O
, O
to O
improve O
the O
stability O
of O
internal O
fixation O
was O
tested O
in O
vitro O
using O
20 O
paired O
RARE O
third O
RARE O
RARE O
with O
mid O
- O
RARE O
RARE O
RARE O
with O
RARE O
- O
RARE O
broad O
ALL_CAP O
compression O
plates O
. O

These O
features O
were O
considered O
consistent O
with O
a O
diagnosis O
of O
RARE O
- O
RARE O
RARE O
. O

RARE O
lymphoma O
and O
its O
management O
. O

The O
protein O
encoded O
by O
NUM I-GENE
contains O
a O
transmembrane O
domain O
. O

RARE O
limitations O
prevent O
an O
RARE O
review O
of O
all O
RARE O
RARE O
, O
such O
RARE O
tissue I-GENE
plasminogen I-GENE
activating I-GENE
RARE I-GENE
, O
RARE O
( O
RARE O
. O
g O
., O
thyroid O
, O
insulin I-GENE
, O
growth I-GENE
hormone I-GENE
, O
erythropoietin I-GENE
RARE O
RARE O
factors O
, O
and O
RARE O
products O
. O

RARE I-GENE
NUM I-GENE
RNA I-GENE
decreases O
after O
6 O
h O
of O
starvation O
to O
re O
- O
accumulate O
once O
the O
cells O
have O
RARE O
. O

The O
various O
forms O
of O
RARE O
cell O
RARE O
share O
the O
common O
feature O
of O
an O
abnormal O
globin I-GENE
chain I-GENE
that O
, O
under O
certain O
conditions O
such O
RARE O
RARE O
, O
results O
in O
the O
RARE O
of O
RARE O
RARE O
cells O
and O
obstruction O
of O
RARE O
vessels O
. O

The O
RARE O
RARE O
of O
each O
of O
the O
three O
proteins O
has O
about O
70 O
% O
homology O
with O
that O
of O
mouse I-GENE
RARE I-GENE
, O
in O
contrast O
to O
NUM O
- O
NUM O
% O
homology O
with O
that O
of O
rat I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
protease I-GENE
inhibitor O
. O

RARE O
of O
RARE O
underlying O
cross O
- O
modality O
RARE O
were O
studied O
by O
injecting O
RARE O
, O
RARE O
RARE O
( O
RARE O
- O
RARE O
and O
RARE O
yellow O
) O
in O
RARE O
manner O
into O
different O
sensory O
RARE O
( O
visual O
, O
RARE O
, O
and O
auditory O
) O
in O
the O
cerebral O
cortex O
of O
the O
rat O
. O

RARE O
CD O
- O
1 O
mice O
, O
4 O
days O
old O
, O
exposed O
to O
NUM O
. O
1 O
% O
nicotine O
RARE O
on O
gestational O
days O
6 O
- O
20 O
were O
compared O
with O
untreated O
RARE O
of O
the O
same O
age O
to O
determine O
its O
effect O
on O
the O
development O
of O
mandibular O
RARE O
RARE O
. O

USF I-GENE
synthesized O
in O
an O
in O
vitro O
transcription O
and O
translation O
RARE O
also O
binds O
to O
the O
ADH I-GENE
promoter I-GENE
RARE O
RARE O
RARE O
to O
the O
ALL_CAP O
. O

The O
across O
- O
fiber O
pattern O
of O
the O
responses O
to O
RARE O
NaCl O
solutions O
correlated O
strongly O
to O
that O
elicited O
by O
RARE O
NUM O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

RARE O
RARE O
content O
after O
the O
intravenous O
administration O
of O
HMPAO O
in O
RARE O
human O
subjects O
was O
analyzed O
. O

RARE O
regression O
analysis O
was O
performed O
and O
the O
following O
result O
was O
obtained O
: O
clearance O
( O
HMPAO O
) O
= O
NUM O
. O
07 O
+ O
NUM O
. O
NUM O
. O
rCBF O
with O
a O
high O
significance O
( O
p O
less O
than O
NUM O
. O
001 O
). O

Human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
ALL_CAP I-GENE
, O
RARE O
in O
Escherichia O
coli O
, O
was O
RARE O
to O
near O
RARE O
. O

RARE O
RARE O
correlated O
positively O
with O
ALL_CAP I-GENE
and O
HDL2 I-GENE
- I-GENE
C I-GENE
and O
mass O
, O
and O
with O
LDL I-GENE
RARE O
size O
among O
women O
. O

RARE O
from O
RARE O
of O
source O
and O
target O
volume O
elements O
are O
RARE O
RARE O
the O
S O
values O
between O
the O
tumor O
and O
itself O
, O
between O
the O
remaining O
healthy O
RARE O
organ O
and O
itself O
, O
and O
between O
the O
tumor O
and O
the O
remaining O
healthy O
RARE O
organ O
, O
with O
the O
RARE O
RARE O
assumed O
RARE O
the O
last O
. O

RARE O
showed O
that O
an O
overall O
RARE O
of O
the O
force O
applied O
could O
be O
obtained O
from O
a O
laboratory O
RARE O
, O
but O
that O
RARE O
RARE O
and O
testing O
RARE O
were O
not O
RARE O
by O
this O
method O
. O

The O
cDNA O
contained O
an O
RARE O
reading O
frame O
of O
NUM O
bp O
that O
predicted O
a O
protein O
of O
NUM O
amino O
RARE O
and O
a O
RARE O
mass O
of O
52 O
kDa O
; O
this O
protein O
has O
97 O
% O
identity O
to O
rat I-GENE
liver I-GENE
RARE I-GENE
. O

Analysis O
of O
viral O
mutants O
in O
vivo O
demonstrated O
that O
the O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
binding O
site O
and O
a O
RARE O
ATF I-GENE
motif I-GENE
were O
important O
RARE O
efficient O
viral O
growth O
. O

RARE O
of O
RARE O
ALL_CAP O
through O
urine O
( O
NUM O
%) O
and O
RARE O
( O
NUM O
%) O
RARE O
to O
96 O
hrs O
averaged O
50 O
%, O
whereas O
residual O
RARE O
in O
liver O
and O
RARE O
experienced O
a O
recovery O
of O
29 O
% O
in O
RARE O
animals O
. O

Saccharomyces O
cerevisiae O
has O
been O
used O
widely O
both O
RARE O
a O
model O
RARE O
RARE O
RARE O
the O
biochemical O
, O
genetic O
, O
and O
RARE O
RARE O
of O
gene O
RARE O
and O
the O
RARE O
process O
, O
and O
RARE O
a O
RARE O
RARE O
the O
production O
of O
heterologous O
proteins O
of O
RARE O
interest O
. O

RARE O
, O
however O
, O
the O
ALL_CAP I-GENE
receptor I-GENE
RARE O
from O
liver O
exhibits O
RARE O
sequence O
RARE O
to O
receptors O
with O
known O
signal O
RARE O
mechanisms O
, O
including O
those O
exhibiting O
RARE O
- O
activated O
tyrosine I-GENE
kinase I-GENE
activity O
. O

This O
indicates O
that O
under O
certain O
experimental O
conditions O
cdc2 I-GENE
/ O
NUM I-GENE
and O
cdc2 I-GENE
/ O
p62 I-GENE
may O
express O
some O
differences O
in O
their O
catalytic O
activity O
. O

Mutation O
analysis O
implicated O
multiple O
RARE O
of O
the O
5 O
' O
RARE O
region O
RARE O
RARE O
to O
the O
RARE O
effect O
. O

Identification O
of O
Ets I-GENE
- O
and O
RARE I-GENE
- O
related O
subunits O
in O
ALL_CAP I-GENE
binding I-GENE
protein I-GENE
. O

The O
enzymatic O
response O
of O
neutrophils O
and O
monocytes O
was O
similar O
although O
the O
magnitude O
of O
the O
ALL_CAP I-GENE
oxidase I-GENE
activity O
was O
significantly O
RARE O
in O
neutrophils O
than O
in O
monocytes O
. O

In O
the O
RARE O
, O
RARE O
increased O
the O
luminal O
disappearance O
( O
P O
less O
than O
NUM O
. O
05 O
) O
and O
peripheral O
RARE O
appearance O
( O
P O
less O
than O
NUM O
. O
001 O
) O
of O
RARE O
. O

RARE O
activated O
both O
ALL_CAP O
ALL_CAP O
and O
ALL_CAP O
neurones O
, O
but O
, O
when O
they O
responded O
, O
ALL_CAP O
neurones O
( O
RARE O
= O
5 O
) O
showed O
only O
the O
RARE O
RARE O
of O
activity O
while O
ALL_CAP O
neurones O
showed O
either O
one O
( O
RARE O
= O
NUM O
) O
or O
two O
phases O
( O
RARE O
= O
6 O
). O

RARE O
of O
RARE O
by O
Escherichia O
coli O

It O
is O
concluded O
that O
attention O
to O
these O
issues O
can O
substantially O
improve O
the O
quality O
of O
research O
on O
AIDS O
related O
RARE O
on O
RARE O
RARE O
. O

The O
effectiveness O
of O
alpha O
- O
RARE O
- O
beta O
RARE O
2 O
- O
RARE O
) O
RARE O
acid O
( O
ALL_CAP O
) O
and O
N O
- O
RARE O
- O
N O
- O
RARE O
- O
D O
- O
RARE O
( O
ALL_CAP O
RARE O
used O
in O
combination O
, O
in O
the O
RARE O
and O
excretion O
of O
lead O
was O
investigated O
in O
rats O
. O

These O
results O
suggest O
that O
beta I-GENE
- I-GENE
1 I-GENE
may O
act O
RARE O
a O
tissue O
- O
specific O
, O
RARE O
- O
acting O
regulator O
of O
the O
RARE O
of O
the O
beta I-GENE
- I-GENE
RARE I-GENE
gene I-GENE
in O
developing O
RARE O
RARE O
. O

This O
study O
RARE O
the O
effects O
of O
RARE O
on O
the O
extracellular O
NUM O
and O
ALL_CAP O
RARE O
RARE O
multiple O
tissue O
sites O
using O
a O
recently O
developed O
RARE O
RARE O
, O
that O
provides O
simultaneous O
measurements O
of O
NUM O
and O
ALL_CAP O
. O

All O
members O
are O
also O
capable O
of O
activating O
in O
vivo O
transcription O
from O
promoters O
that O
contain O
a O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

The O
domains O
involved O
in O
RARE O
appear O
to O
be O
a O
subset O
of O
those O
necessary O
to O
achieve O
synergistic O
activation O
. O

RARE O
on O
RARE O
noncoding O
sequences O
will O
help O
in O
studies O
on O
the O
RARE O
of O
the O
pro I-GENE
alpha I-GENE
1 I-GENE
( I-GENE
II I-GENE
) I-GENE
RARE I-GENE
gene I-GENE
. O

Chlamydia O
RARE O
and O
Chlamydia O
RARE O
were O
not O
affected O
by O
RARE O
fixation O
. O

Although O
human O
infections O
with O
RARE O
due O
to O
RARE O
RARE O
are O
not O
RARE O
, O
RARE O
associated O
with O
P O
. O
RARE O
is O
rare O
. O

For O
ALL_CAP O
RARE O
pH O
7 O
. O
NUM O
, O
a O
1 O
: O
1 O
complex O
is O
formed O
, O
but O
RARE O
pH O
7 O
. O
5 O
ALL_CAP O
has O
little O
effect O
on O
the O
RARE O
of O
the O
highly O
RARE O
ALL_CAP O
, O
presumably O
since O
only O
RARE O
- O
RARE O
molecules O
can O
form O
inclusion O
complexes O
with O
the O
ALL_CAP O
. O

PO2 O
measurements O
using O
a O
double O
RARE O
RARE O
type O
RARE O
were O
measured O
in O
the O
optic O
nerve O
head O
of O
RARE O
pigs O
in O
RARE O
and O
RARE O
. O

POU I-GENE
- O
specific O
and O
POU I-GENE
- O
RARE O
domains O
of O
NUM I-GENE
were O
produced O
in O
RARE O
coli O
RARE O
characterization O
of O
DNA O
binding O
to O
the O
octamer O
sequence O
. O

A O
deletion O
series O
of O
the O
5 O
' O
flanking O
region O
was O
created O
from O
position O
- O
NUM O
to O
- O
NUM O
relative O
to O
the O
transcriptional O
initiation O
site O
and O
similarly O
examined O
in O
transgenic O
tobacco O
. O

The O
nucleotide O
( O
nt O
) O
sequences O
of O
the O
exons O
, O
RARE O
/ O
intron O
boundaries O
and O
5 O
'- O
and O
3 O
'- O
RARE O
regions O
were O
determined O
. O

RARE O
of O
40 O
patients O
, O
who O
initially O
did O
not O
show O
eye O
complications O
due O
to O
RARE O
, O
37 O
patients O
were O
essentially O
the O
same O
10 O
years O
later O
. O

Thus O
, O
two O
very O
different O
regulatory O
elements O
are O
used O
to O
mediate O
estrogen O
induction O
of O
related O
genes O
in O
RARE O
and O
RARE O
. O

RARE O
was O
very O
mild O
with O
both O
regimens O
, O
although O
sedation O
was O
significantly O
RARE O
in O
RARE O
B O
( O
p O
less O
than O
NUM O
. O
001 O
). O

RARE O
in O
RARE O
monkeys O
, O
RARE O
hamsters O
and O
RARE O
mice O
the O
authors O
studied O
the O
pathogenic O
properties O
of O
a O
new O
virus O
RARE O
- O
RARE O
. O

Increasing O
mean O
arterial O
pressure O
by O
RARE O
infusion O
to O
levels O
much O
greater O
than O
produced O
by O
ALL_CAP O
and O
ALL_CAP O
caused O
only O
small O
reductions O
in O
cardiac O
output O
. O

ALL_CAP O
. O

RARE O
of O
energy O
turnover O
in O
relation O
to O
physical O
performance O
were O
addressed O
in O
terms O
of O
upper O
and O
lower O
limit O
, O
changes O
RARE O
a O
training O
RARE O
and O
how O
to O
regulate O
energy O
balance O
RARE O
a O
changing O
energy O
turnover O
. O

With O
RARE O
reductions O
in O
flow O
, O
the O
peak O
( O
S O
) O
and O
trough O
( O
D O
) O
points O
of O
the O
maximum O
shifted O
- O
frequency O
envelope O
fell O
in O
parallel O
in O
a O
RARE O
fashion O
until O
D O
reached O
zero O
. O

The O
NUM I-GENE
gene I-GENE
product O
also O
transactivated O
the O
IE1 I-GENE
promoter I-GENE
but O
did O
not O
affect O
RARE O
from O
its O
own O
promoter O
. O

Moreover O
, O
promoters O
containing O
a O
TATA O
box O
in O
the O
absence O
of O
NUM I-GENE
sites I-GENE
or O
NUM I-GENE
sites I-GENE
in O
the O
absence O
of O
a O
TATA O
box O
were O
equally O
inducible O
in O
vitro O
, O
RARE O
was O
an O
RNA I-GENE
polymerase I-GENE
III I-GENE
promoter I-GENE
. O

Evaluation O
of O
RARE O
ventricular O
function O
using O
gated O
RARE O
RARE O
imaging O
with O
Tc O
- O
99m O
- O
ALL_CAP O

RARE O
uptake O
and O
distribution O
in O
the O
plasma O
and O
tissue O
of O
RARE O
and O
RARE O
patients O
RARE O
with O
RARE O
RARE O
. O

RARE O
marrow O
abnormalities O
in O
Hodgkin O
' O
s O
RARE O
are O
reviewed O
and O
the O
current O
understanding O
of O
the O
pathological O
mechanisms O
leading O
to O
RARE O
RARE O
is O
discussed O
. O

The O
smaller O
uptake O
rate O
and O
faster O
clearance O
rate O
resulted O
in O
the O
lower O
ALL_CAP O
RARE O
ALL_CAP O
RARE O
. O

The O
currently O
proposed O
extended O
RARE O
repair O
should O
be O
RARE O
RARE O
the O
small O
group O
of O
infants O
with O
transverse O
aortic O
RARE O
to O
ascending O
aorta O
diameter O
ratios O
( O
RARE O
indices O
) O
of O
less O
than O
NUM O
. O
NUM O
. O

DNA O
hybridization O
analysis O
revealed O
that O
both O
RARE O
and O
RARE O
cells O
of O
Y O
. O
RARE O
possess O
a O
DNA O
locus O
homologous O
to O
the O
Escherichia I-GENE
coli I-GENE
RARE I-GENE
gene I-GENE
. O

RARE O
in O
the O
RARE O
PCO2 O
but O
not O
in O
the O
RARE O
H O
+ O
were O
highly O
correlated O
with O
decreases O
in O
both O
RARE O
contractility O
and O
oxygen O
consumption O
( O
NUM O
= O
. O
88 O
). O

Expression O
was O
cell O
RARE O
RARE O
, O
with O
steady O
- O
state O
RNA O
levels O
significantly O
RARE O
in O
growth O
- O
arrested O
than O
in O
growth O
- O
RARE O
cells O
. O

RARE O
of O
recurrent O
ischaemia O
and O
RARE O
procedures O
after O
RARE O
with O
recombinant O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
in O
RARE O
coronary O
occlusion O
. O

Therefore O
, O
the O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
locus O
seems O
to O
be O
RARE O
RARE O
under O
a O
standard O
condition O
RARE O
RARE O
growth O
. O

RARE O
between O
mitochondrial I-GENE
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
reductase I-GENE
and O
a O
bacterial I-GENE
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
. O

Analysis O
of O
mRNA O
RARE O
shows O
that O
AT I-GENE
- I-GENE
NUM I-GENE
and O
AT I-GENE
- I-GENE
NUM I-GENE
are O
RARE O
in O
all O
the O
tissues O
examined O
. O

We O
report O
two O
patients O
receiving O
RARE O
RARE O
, O
one O
with O
RARE O
acute O
hepatitis O
C O
and O
the O
other O
with O
chronic O
persistent O
hepatitis O
C O
, O
with O
RARE O
RARE O
RARE O
demonstrated O
on O
oil O
- O
RARE O
O O
RARE O
. O

3 O
cases O

ALL_CAP I-GENE
- I-GENE
RARE I-GENE
: I-GENE
RARE I-GENE
beta I-GENE
1 I-GENE
RARE I-GENE
NUM I-GENE
alpha I-GENE
1 I-GENE
RARE I-GENE
3 I-GENE
- I-GENE
RARE I-GENE
is O
a O
terminal I-GENE
RARE I-GENE
that O
is O
widely O
RARE O
in O
a O
variety O
of O
mammalian O
species O
, O
with O
the O
RARE O
exception O
of O
man O
, O
RARE O
, O
and O
RARE O
RARE O
monkeys O
. O

A O
RARE O
RARE O
containing O
the O
SRE O
sequence O
from O
the O
mouse I-GENE
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
promoter I-GENE
RARE O
NUM O
to O
- O
NUM O
) O
was O
RARE O
labeled O
, O
used O
RARE O
a O
probe O
RARE O
the O
mobility O
shift O
assay O
and O
RARE O
( O
DNA O
- O
protein O
) O
blotting O
, O
and O
also O
used O
RARE O
sequence O
- O
specific O
affinity O
chromatography O
. O

Sequence O
requirements O
RARE O
premature O
transcription O
arrest O
within O
the O
RARE O
intron O
of O
the O
mouse I-GENE
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
. O

RARE O
regional O
ejection O
fraction O
improved O
by O
10 O
. O
1 O
+/- O
2 O
. O
1 O
% O
between O
early O
and O
RARE O
studies O
when O
the O
infarct O
- O
related O
artery O
was O
RARE O
and O
by O
4 O
. O
8 O
+/- O
1 O
. O
4 O
% O
if O
it O
was O
occluded O
( O
p O
= O
NUM O
. O
NUM O
); O
changes O
in O
global O
and O
RARE O
regional O
ejection O
fraction O
were O
similar O
irrespective O
of O
perfusion O
status O
. O

One O
of O
its O
RARE O
residues O
is O
modified O
by O
RARE O
to O
form O
RARE O
, O
a O
posttranslational O
modification O
unique O
to O
eIF I-GENE
- I-GENE
NUM I-GENE
. O

The O
RARE O
RARE O
technique O
was O
used O
to O
replace O
the O
wild O
- O
type O
gene O
with O
the O
mutant O
form O
, O
resulting O
in O
failure O
of O
the O
yeast O
cells O
to O
grow O
. O

If O
this O
is O
the O
case O
, O
identification O
and O
characterization O
of O
transcripts O
from O
the O
Ig I-GENE
loci I-GENE
should O
permit O
a O
better O
understanding O
of O
the O
gene O
rearrangement O
process O
. O

Transcription O
of O
the O
ALL_CAP I-GENE
gene I-GENE
in I-GENE
RARE I-GENE
RARE I-GENE
and I-GENE
Escherichia I-GENE
coli I-GENE
is O
positively O
regulated O
by O
the O
ALL_CAP I-GENE
gene I-GENE
product I-GENE
, O
a O
DNA O
binding O
protein O
. O

Disruption O
of O
the O
chromosomal I-GENE
NUM I-GENE
gene I-GENE
in O
alpha O
and O
a O
/ O
alpha O
cells O
conferred O
the O
RARE O
RARE O
, O
and O
the O
a O
/ O
alpha O
RARE O
could O
not O
RARE O
. O

The O
effect O
of O
ALL_CAP O
- O
NUM O
on O
the O
RARE O
response O
RARE O
by O
the O
combination O
of O
ADR O
and O
ALL_CAP O
was O
also O
investigated O
in O
order O
to O
assess O
alterations O
in O
the O
therapeutic O
index O
of O
this O
combined O
therapeutic O
modality O
treatment O
. O

The O
ORF O
was O
analyzed O
RARE O
secondary O
structural O
features O
, O
and O
the O
sequence O
data O
bases O
were O
RARE O
RARE O
homologies O
. O

This O
study O
indicates O
that O
this O
dose O
- O
intense O
regimen O
can O
be O
RARE O
administered O
, O
even O
with O
the O
use O
of O
RARE O
marrow O
, O
with O
an O
acceptable O
toxicity O
profile O
. O

RARE O
- O
C O
can O
cause O
severe O
necrosis O
and O
ulceration O
when O
RARE O
RARE O
into O
RARE O
and O
soft O
tissues O
following O
IV O
drug O
administration O
. O

In O
this O
study O
, O
we O
have O
RARE O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
RARE I-GENE
gene I-GENE
. O

ALL_CAP O
: O
Patients O
received O
RARE I-GENE
- I-GENE
PA I-GENE
, O
RARE O
, O
and O
RARE O
. O

Consistent O
with O
the O
in O
vivo O
result O
, O
the O
RARE O
RARE O
in O
the O
crude O
cell O
RARE O
display O
site O
- O
specific O
partial O
DNA O
RARE O
activity O
. O

Additionally O
, O
I I-GENE
RARE I-GENE
B I-GENE
beta I-GENE
, O
but O
not O
I I-GENE
RARE I-GENE
B I-GENE
alpha I-GENE
, O
also O
prevented O
the O
binding O
of O
Rel I-GENE
to O
the O
RARE I-GENE
B I-GENE
site I-GENE
. O

Sequence O
analysis O
reveals O
that O
the O
DNA O
binding O
domain O
of O
ALL_CAP I-GENE
has O
strong O
homology O
to O
the O
recently O
described O
fork I-GENE
head I-GENE
DNA I-GENE
binding I-GENE
domain I-GENE
found O
in O
the O
Drosophila I-GENE
homeotic I-GENE
protein I-GENE
fork I-GENE
head I-GENE
and O
a O
family O
of O
RARE I-GENE
nuclear I-GENE
factors I-GENE
, O
HNF I-GENE
- I-GENE
3 I-GENE
. O

RARE O
and O
RARE O
RARE O
were O
required O
to O
lower O
RARE O
to O
RARE O
RARE O
. O

A O
single O
i O
. O
p O
. O
injection O
of O
d O
, O
RARE O
- O
RARE O
10 O
mg O
/ O
kg O
both O
RARE O
noradrenaline O
( O
NA O
) O
biosynthesis O
in O
vivo O
( O
NUM O
%) O
and O
the O
endogenous O
concentration O
of O
RARE O
( O
ALL_CAP O
) O
( O
NUM O
%) O
and O
increased O
NA O
levels O
( O
NUM O
%). O

RARE O
RARE O
RARE O
RARE O
have O
strong O
RARE O
effect O
on O
cyclophosphamide O
RARE O
RARE O
in O
mice O
. O

Mutations O
in O
the O
small O
subunit O
of O
RARE I-GENE
RARE I-GENE
affect O
subunit O
binding O
and O
RARE O
. O

The O
structural O
changes O
in O
RARE O
- O
RARE O
artery O
manifested O
mainly O
by O
an O
increase O
in O
number O
of O
muscular O
artery O
resulting O
from O
RARE O
of O
precursor O
cells O
( O
RARE O
and O
RARE O
cells O
) O
RARE O
within O
partially O
muscular O
and O
RARE O
arterial O
RARE O
to O
RARE O
muscle O
cell O
, O
and O
by O
the O
medial O
RARE O
RARE O
due O
to O
hypertrophy O
and O
hyperplasia O
of O
RARE O
muscle O
cells O
RARE O
RARE O
RARE O
accumulation O
of O
a O
large O
amount O
of O
RARE I-GENE
, O
especially O
the O
type I-GENE
1 I-GENE
RARE I-GENE
. O

These O
results O
suggest O
that O
ALL_CAP O
- O
NUM O
may O
be O
a O
useful O
drug O
RARE O
the O
treatment O
of O
bronchial O
asthma O
by O
RARE O
RARE O
- O
RARE O
airway O
responses O
and O
airway O
RARE O
. O

In O
study O
2 O
, O
the O
correlation O
coefficients O
between O
the O
NUM O
measurements O
obtained O
RARE O
the O
ulcer O
margin O
and O
RARE O
the O
adjacent O
normal O
mucosa O
, O
and O
delta O
NUM O
obtained O
by O
the O
experienced O
RARE O
and O
one O
of O
the O
three O
RARE O
were O
NUM O
. O
94 O
, O
NUM O
. O
97 O
, O
and O
NUM O
. O
94 O
, O
respectively O
. O

RARE O
mucosa O
RARE O
in O
persons O
exposed O
to O
different O
RARE O
RARE O
did O
not O
depend O
on O
the O
forms O
of O
PC O
, O
ALL_CAP O
and O
the O
diseases O
' O
stages O
. O

RARE I-GENE
- I-GENE
RARE I-GENE
production O
of O
ALL_CAP O
was O
RARE O
remarkably O
in O
this O
case O
. O

Sequence O
analysis O
of O
the O
ALL_CAP I-GENE
genomic I-GENE
upstream I-GENE
sequences I-GENE
reveals O
a O
typical O
ALL_CAP O
box O
within O
the O
NUM O
RARE O
RARE O
( O
bp O
) O
that O
, O
by O
transfection O
experiments O
, O
are O
sufficient O
to O
promote O
RARE O
of O
chimeric O
plasmids O
with O
the O
chloramphenicol I-GENE
RARE I-GENE
reporter I-GENE
. O

Sequence O
analysis O
of O
the O
ALL_CAP I-GENE
genomic I-GENE
upstream I-GENE
sequences I-GENE
reveals O
a O
typical O
ALL_CAP O
box O
within O
the O
NUM O
RARE O
RARE O
( O
bp O
) O
that O
, O
by O
transfection O
experiments O
, O
are O
sufficient O
to O
promote O
RARE O
of O
chimeric O
plasmids O
with O
the O
chloramphenicol I-GENE
RARE I-GENE
reporter I-GENE
. O

The O
cDNA O
segment O
is O
flanked O
by O
the O
immunoglobulin I-GENE
gene I-GENE
RARE I-GENE
signal I-GENE
sequences I-GENE
so O
that O
the O
cDNA O
segment O
can O
RARE O
and O
the O
human I-GENE
ALL_CAP I-GENE
- I-GENE
2R I-GENE
L I-GENE
chain I-GENE
is O
subsequently O
RARE O
under O
the O
control O
of O
the O
SV40 I-GENE
promoter I-GENE
. O

RARE I-GENE
lipase I-GENE
( O
ALL_CAP I-GENE
RARE O
a O
key O
enzyme O
in O
normal O
lipoprotein O
metabolism O
, O
has O
a O
complex O
pattern O
of O
RARE O
and O
tissue O
- O
specific O
RARE O
. O

Deletion O
of O
the O
proximal O
RARE O
motif O
from O
the O
RARE O
containing O
the O
- O
NUM O
fragment O
of O
the O
ALL_CAP I-GENE
promoter I-GENE
, O
resulted O
in O
a O
NUM O
and O
NUM O
% O
decrease O
in O
the O
level O
of O
RARE O
in O
transfected O
3T3 O
- O
L1 O
adipocytes O
and O
NUM O
hepatocytes O
, O
respectively O
. O

We O
examined O
the O
binding O
of O
RARE O
NUM I-GENE
receptor I-GENE
alpha I-GENE
( O
T3R I-GENE
alpha I-GENE
RARE O
overexpressed O
in O
Escherichia O
coli O
, O
to O
wild O
- O
type O
and O
RARE O
and O
down O
mutations O
of O
the O
ALL_CAP I-GENE
NUM I-GENE
to O
evaluate O
whether O
transcriptional O
potency O
correlates O
with O
changes O
in O
T3R I-GENE
binding O
. O

Comparison O
of O
the O
cDNA O
- O
predicted O
avian I-GENE
RARE I-GENE
amino I-GENE
acid I-GENE
sequences I-GENE
with O
known O
TnI I-GENE
sequences I-GENE
indicated O
1 O
) O
that O
the O
presence O
of O
an O
N O
- O
terminal O
extension O
sequence O
carrying O
a O
dual O
protein I-GENE
kinase I-GENE
A I-GENE
RARE O
target O
site O
and O
an O
adjacent O
proline O
- O
rich O
segment O
is O
an O
RARE O
cardiac O
- O
specific O
feature O
of O
TnI I-GENE
which O
has O
been O
RARE O
since O
the O
RARE O
/ O
RARE O
divergence O
, O
2 O
) O
that O
features O
of O
the O
near O
- O
N O
- O
terminal O
RARE I-GENE
C I-GENE
( O
ALL_CAP I-GENE
)- O
binding O
site O
sequence O
suggest O
isoform O
- O
specific O
adaptation O
of O
TnI I-GENE
and O
ALL_CAP I-GENE
, O
and O
3 O
) O
that O
the O
avian O
RARE I-GENE
internal O
actin I-GENE
/ I-GENE
ALL_CAP I-GENE
- I-GENE
binding I-GENE
, I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
, I-GENE
domain I-GENE
shows O
significant O
sequence O
divergence O
from O
mammalian I-GENE
RARE I-GENE
sequences I-GENE
, O
including O
the O
absence O
of O
a O
protein I-GENE
kinase I-GENE
C I-GENE
target O
site O
which O
is O
a O
cardiac O
- O
specific O
feature O
of O
TnI I-GENE
in O
mammals O
. O

RARE O
management O
RARE O
. O

An O
ALL_CAP O
routine O
RARE O
on O
- O
line O
RARE O
display O
and O
RARE O
of O
data O
acquired O
on O
a O
personal O
RARE O
. O

Expression O
of O
the O
mouse I-GENE
ALL_CAP I-GENE
beta I-GENE
gene I-GENE
, O
therefore O
, O
gives O
rise O
to O
multiple O
mRNAs O
, O
each O
with O
a O
unique O
5 O
'- O
RARE O
region O
. O

RARE O
of O
completely O
isolated O
neurons O
of O
the O
RARE O
RARE O
to O
electrical O
RARE O
. O

It O
was O
found O
that O
the O
ALL_CAP O
undergoes O
a O
number O
of O
fluctuations O
in O
the O
negative O
and O
positive O
RARE O
with O
a O
gradually O
decreasing O
amplitude O
in O
the O
course O
of O
5 O
- O
NUM O
days O
following O
the O
operation O
, O
after O
which O
relatively O
stable O
negative O
values O
of O
the O
ALL_CAP O
are O
established O
on O
the O
average O
in O
electrodes O
implanted O
to O
the O
level O
of O
the O
RARE O
RARE O
, O
and O
positive O
values O
in O
electrodes O
implanted O
to O
the O
level O
of O
the O
RARE O
RARE O
. O

RARE O
flow O
velocity O
RARE O
were O
recorded O
by O
pulsed O
Doppler O
examination O
of O
the O
RARE O
internal O
carotid O
and O
RARE O
cerebral O
arteries O
using O
the O
established O
RARE O
route O
RARE O
RARE O
RARE O
a O
new O
RARE O
approach O
. O

Quantitative O
analysis O
of O
DNA O
using O
flow O
RARE O
and O
RARE O
findings O
in O
16 O
cases O
of O
cardiac O
RARE O

Sequence O
analysis O
revealed O
that O
in O
addition O
to O
the O
non O
- O
RARE O
variant O
, O
multiple O
mRNA O
species O
were O
generated O
by O
RARE O
RARE O
resulting O
in O
the O
exclusion O
of O
92 O
, O
NUM O
, O
NUM O
, O
NUM O
and O
NUM O
nucleotides O
( O
nt O
RARE O
respectively O
, O
from O
RARE O
1 O
. O

RARE O
NUM O
is O
an O
RARE O
in O
the O
RARE I-GENE
NUM I-GENE
protein I-GENE
sequence I-GENE
, O
coded O
by O
an O
ALL_CAP O
RARE O
. O

RARE O
due O
to O
the O
action O
of O
RARE O
RARE O
were O
observed O
. O

In O
the O
yeast O
Saccharomyces O
cerevisiae O
, O
RARE O
levels O
exert O
some O
control O
over O
the O
level O
of O
NUM I-GENE
RARE O
. O

Of O
these O
NUM O
samples O
, O
RARE O
SP O
was O
observed O
in O
NUM O
( O
19 O
. O
6 O
%) O
using O
Gram O
staining O
and O
in O
18 O
( O
10 O
. O
1 O
%) O
this O
RARE O
was O
isolated O
in O
agar O
ALL_CAP O
and O
anaerobic O
RARE O
. O

Previous O
RARE O
have O
suggested O
that O
subretinal O
RARE O
RARE O
the O
retina O
in O
part O
because O
of O
its O
solid O
fibrin I-GENE
RARE O
. O

Twenty O
- O
four O
hours O
later O
, O
the O
animals O
were O
randomized O
to O
subretinal O
treatment O
with O
2 O
. O
5 O
micrograms O
of O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
or O
a O
similar O
volume O
of O
RARE O
saline O
. O

RARE O
- O
RARE O
examinations O
revealed O
spontaneous O
RARE O
nystagmus O
, O
bilateral O
RARE O
nystagmus O
and O
RARE O
nystagmus O
. O

Since O
the O
morphology O
of O
the O
lesions O
can O
mimic O
that O
of O
other O
cutaneous O
disorders O
, O
RARE O
' O
s O
RARE O
is O
often O
not O
RARE O
initially O
. O

RARE O
RARE O
and O
live O
yeast O
cell O
RARE O
were O
evaluated O
RARE O
a O
biological O
RARE O
and O
RARE O
a O
RARE O
wound O
RARE O
respectively O
, O
in O
the O
treatment O
of O
RARE O
RARE O
of O
the O
distal O
portion O
of O
the O
RARE O
of O
horses O
. O

To O
lower O
the O
current O
high O
incidence O
of O
NANB O
- O
RARE O
ALL_CAP O
, O
in O
1986 O
, O
the O
American O
Association O
of O
RARE O
RARE O
( O
ALL_CAP O
) O
recommended O
testing O
RARE O
these O
ALL_CAP O
- O
associated O
" O
RARE O
" O
markers O
on O
all O
RARE O
RARE O
of O
RARE O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
1 I-GENE
( O
IGF I-GENE
- I-GENE
1 I-GENE
) O
in O
burn O
patients O
. O

RARE O
of O
ubiquitin I-GENE
to O
ALL_CAP I-GENE
increased O
the O
yield O
of O
ALL_CAP I-GENE
RARE O
10 O
- O
RARE O
compared O
to O
that O
of O
the O
RARE O
enzyme O
. O

In O
group O
III O
, O
patients O
also O
received O
their O
own O
RARE O
drainage O
RARE O
, O
RARE O
RARE O
6 O
hours O
after O
operation O
, O
after O
concentration O
and O
RARE O
in O
a O
ALL_CAP O
. O

The O
suppression O
was O
also O
demonstrated O
in O
a O
transient O
RARE O
assay O
in O
vivo O
using O
isolated O
RARE O
RARE O
. O

The O
effect O
of O
RARE I-GENE
calcitonin I-GENE
nasal O
RARE O
in O
women O
with O
established O
RARE O
has O
also O
been O
studied O
. O

RARE O
muscle O
RARE O
responses O
are O
impaired O
in O
RARE O
failure O
. O

RARE O
muscle O
RARE O
exercise O
responses O
are O
attenuated O
in O
RARE O
failure O
. O

Evaluation O
of O
RARE O
drug O
effect O
on O
membrane O
RARE O
. O

The O
examinations O
were O
performed O
on O
two O
groups O
of O
20 O
( O
using O
ALL_CAP O
/ O
NUM O
RARE O
RARE O
. O

RNA O
gel O
retardation O
and O
competition O
analyses O
indicate O
that O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
binding O
is O
strongly O
dependent O
on O
the O
ALL_CAP O
RNA O
loop O
sequences O
. O

The O
vaccine O
used O
was O
known O
to O
be O
RARE O
RARE O
older O
children O
and O
adults O
. O

Both O
groups O
then O
underwent O
RARE O
induction O
, O
and O
completed O
the O
test O
again O
( O
NUM O
). O

RARE O
of O
three O
- O
dimensional O
analysis O
to O
the O
auditory O
NUM O
. O

The O
construct O
was O
introduced O
into O
NUM O
( O
RARE O
- O
11 O
, O
RARE O
- O
2 O
) O
RARE O
cells O
of O
Escherichia O
coli O
. O

Recombinant I-GENE
human I-GENE
TFIID I-GENE
supported O
weak O
basal O
transcription O
in O
heat O
- O
treated O
nuclear O
extracts O
whereas O
a O
partially O
RARE O
TFIID I-GENE
fraction O
from O
HeLa O
cells O
reconstituted O
a O
maximal O
level O
of O
transcription O
. O

Only O
after O
a O
pretreatment O
aimed O
RARE O
increasing O
its O
oxide O
surface O
layer O
was O
RARE O
RARE O
found O
to O
RARE O
the O
precipitation O
from O
solutions O
containing O
2 O
mmol O
/ O
L O
NUM O
, O
2 O
mmol O
/ O
L O
NUM O
, O
50 O
mmol O
/ O
L O
RARE O
, O
pH O
7 O
. O
2 O
, O
and O
to O
induce O
precipitation O
from O
RARE O
solutions O
containing O
1 O
. O
2 O
mmol O
/ O
L O
NUM O
, O
1 O
. O
2 O
mmol O
/ O
L O
NUM O
, O
50 O
mmol O
/ O
L O
RARE O
, O
pH O
7 O
. O
2 O
, O
RARE O
37 O
degrees O
C O
. O

We O
conclude O
that O
RARE O
could O
occur O
in O
all O
RARE O
containing O
casein I-GENE
and O
that O
RARE O
RARE O
should O
be O
considered O
in O
patients O
with O
increased O
RARE O
RARE O
. O

Neither O
model O
, O
RARE O
applied O
, O
provided O
a O
satisfactory O
account O
of O
the O
effects O
of O
the O
main O
variables O
of O
number O
of O
RARE O
and O
amount O
of O
RARE O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

This O
RARE O
of O
ALL_CAP O
involves O
RARE O
an O
appropriate O
high O
- O
resolution O
cost O
function O
, O
RARE O
the O
search O
space O
of O
the O
environment O
and O
source O
, O
RARE O
solutions O
of O
the O
wave O
equation O
, O
and O
utilizing O
a O
RARE O
RARE O
method O
to O
search O
the O
parameter O
RARE O
RARE O
the O
global O
minimum O
of O
the O
cost O
function O
. O

Determination O
of O
an O
RNA O
RARE O
involved O
in O
RARE O
inhibition O
of O
a O
muscle O
- O
specific O
RARE O
. O

RARE O
cells O
stored O
with O
University O
of O
RARE O
solution O
excluded O
RARE O
blue O
better O
( O
1 O
. O
NUM O
% O
+/- O
NUM O
. O
5 O
% O
cells O
stained O
, O
p O
less O
than O
NUM O
. O
001 O
. O

The O
original O
technique O
was O
developed O
in O
the O
NUM O
' O
s O
to O
analyze O
the O
inner O
ear O
RARE O
RARE O
a O
diagnostic O
procedure O
( O
i O
. O
RARE O
., O
diagnostic O
RARE O
) O
in O
acoustic O
RARE O
RARE O
. O

The O
effect O
of O
diffusion O
limitation O
was O
RARE O
in O
terms O
of O
the O
ratio O
NUM O
uptake O
/ O
NUM O
requirement O
RARE O
fraction O
of O
cross O
- O
sectional O
area O
supplied O
with O
NUM O
RARE O
RARE O
local O
NUM O
requirement O
per O
unit O
volume O
to O
be O
constant O
and O
independent O
of O
PO2 O
RARE O
PO2 O
greater O
than O
NUM O
. O

( O
2 O
) O
RARE O
limitation O
in O
the O
RARE O
model O
sets O
in O
RARE O
a O
lower O
NUM O
requirement O
value O
, O
and O
increases O
more O
gradually O
with O
increasing O
NUM O
requirement O
, O
than O
in O
the O
corresponding O
RARE O
models O
with O
the O
same O
average O
RARE O
diameter O
. O

The O
antihypertensive O
effect O
of O
RARE O
has O
been O
examined O
over O
a O
12 O
- O
month O
period O
in O
NUM O
hypertensive O
patients O
. O

At O
the O
time O
of O
the O
seizure O
, O
the O
patient O
was O
RARE O
to O
RARE O
a O
test O
RARE O
RARE O
until O
it O
was O
RARE O
correctly O
and O
clearly O
. O

RARE O
patients O
with O
acute O
leukemia O
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
and O
TNF I-GENE
levels O
throughout O
the O
clinical O
course O
of O
RARE O
may O
help O
clarify O
the O
causes O
of O
RARE O
episodes O
. O

RARE O
RARE O
was O
diagnosed O
by O
fine O
- O
RARE O
RARE O
RARE O
of O
a O
RARE O
cyst O
in O
a O
6 O
- O
yr O
- O
old O
RARE O
female O
in O
central O
RARE O
. O

The O
sequence O
was O
determined O
of O
NUM O
nucleotides O
RARE O
the O
RARE I-GENE
genes I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
which O
encode O
the O
RARE O
RARE O
- O
glycine O
RARE O
RARE O
. O

A O
7 O
- O
day O
treatment O
of O
amphotericin O
B O
( O
5 O
mg O
/ O
kg O
/ O
day O
i O
. O
p O
.) O
significantly O
RARE O
the O
glomerular O
filtration O
rate O
( O
GFR O
) O
measured O
RARE O
RARE O
clearance O
and O
RARE O
clearance O
( O
NUM O
. O
NUM O
+/- O
NUM O
. O
29 O
and O
NUM O
. O
16 O
+/- O
NUM O
. O
04 O
ml O
/ O
min O
, O
respectively O
) O
in O
comparison O
to O
vehicle O
- O
treated O
rats O
( O
2 O
. O
04 O
+/- O
NUM O
. O
NUM O
and O
1 O
. O
29 O
+/- O
NUM O
. O
19 O
ml O
/ O
min O
, O
respectively O
). O

RARE O
of O
lesions O
did O
not O
necessarily O
follow O
a O
regular O
progression O
through O
the O
later O
stages O
of O
the O
RARE O
classification O
. O

RARE O
fluorescence O
microscopy O
in O
modern O
cell O
RARE O
. O

RARE O
is O
the O
chemical O
most O
frequently O
present O
in O
cases O
involving O
volatile O
RARE O
. O

RARE O
ALL_CAP O
RARE O
ALL_CAP O
- O
and O
HCB O
- O
levels O
decreased O
in O
breast O
milk O
RARE O
the O
last O
years O
. O

A O
RARE O
RARE O
activity O
has O
been O
identified O
and O
partially O
characterized O
by O
using O
the O
RARE O
enzyme O
and O
substrate O
genes O
in O
transient O
transfection O
assays O
. O

Adult O
H O
, O
but O
not O
R O
, O
manifested O
the O
RARE O
preference O
RARE O
offered O
the O
RARE O
. O

The O
RARE O
silver O
liquid O
chamber O
was O
threefold O
thick O
to O
NUM O
ALL_CAP O
RARE O
in O
water O
and O
it O
efficiently O
produced O
either O
NUM O
by O
the O
NUM O
( O
p O
, O
alpha O
) O
NUM O
reaction O
or O
RARE O
18F O
] O
fluoride O
ion O
by O
the O
NUM O
( O
p O
, O
RARE O
) O
18F O
reaction O
. O

RARE O
electron O
transfer O
of O
cytochrome I-GENE
c I-GENE
facilitated O
by O
RARE O
and O
methylene O
blue O
RARE O
RARE O
modified O
electrodes O
. O

Selective O
activation O
of O
adrenaline O
RARE O
by O
the O
rat O
adrenal O
in O
RARE O
detected O
via O
RARE O

RARE O
specimens O
containing O
either O
RARE O
( O
ALL_CAP O
) O
or O
11 O
- O
nor O
- O
delta O
9 O
- O
RARE O
- O
9 O
- O
RARE O
acid O
( O
9 O
- O
ALL_CAP O
- O
ALL_CAP O
) O
were O
RARE O
with O
RARE O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
RARE O
, O
liquid O
RARE O
, O
2 O
- O
RARE O
, O
and O
RARE O
. O

The O
NUM O
- O
RARE O
RARE O
EFIA I-GENE
cDNA O
encodes O
a O
NUM O
- O
amino O
acid O
protein O
which O
is O
nearly O
identical O
to O
two O
previously O
described O
human O
DNA O
binding O
proteins O
. O

Four O
putative O
positive O
cDNA O
RARE O
were O
isolated O
, O
and O
the O
largest O
insert O
( O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
) O
was O
sequenced O
in O
both O
RARE O
. O

RARE O
. O

RARE O
RARE O
of O
botulinum I-GENE
RARE I-GENE
. O

The O
coding O
sequence O
RARE O
a O
260 O
- O
amino O
- O
acid O
RARE O
polypeptide O
was O
interrupted O
by O
a O
single O
short O
intron O
of O
NUM O
RARE O
RARE O
( O
bp O
RARE O
and O
about O
70 O
% O
of O
the O
deduced O
amino O
acid O
sequence O
of O
the O
Drosophila I-GENE
PCNA I-GENE
was O
identical O
to O
the O
rat O
and O
human I-GENE
PCNA I-GENE
polypeptides I-GENE
, O
with O
RARE O
unique O
repeats O
of O
leucine O
in O
the O
C O
- O
terminal O
region O
. O

RARE O
fusions O
of O
the O
ALL_CAP I-GENE
regulatory I-GENE
regions I-GENE
to O
lacZ I-GENE
were O
constructed O
and O
then O
introduced O
in O
single O
copy O
into O
the O
E O
. O
coli O
RARE O
. O
beta I-GENE
- I-GENE
RARE I-GENE
assays O
RARE O
ALL_CAP O
- O
RARE O
RARE O
of O
ALL_CAP I-GENE
- O
lacZ I-GENE
RARE O
revealed O
that O
the O
E I-GENE
. I-GENE
coli I-GENE
ALL_CAP I-GENE
repressor I-GENE
apparently O
recognizes O
the O
RARE O
of O
both O
organisms O
with O
about O
equal O
efficiency O
. O

RARE O
with O
previously O
mapped O
genes O
including O
RARE I-GENE
- I-GENE
1 I-GENE
and O
NUM I-GENE
, O
ALL_CAP I-GENE
defines O
a O
new O
RARE O
RARE O
group O
on O
the O
long O
RARE O
of O
RARE O
11 O
in O
the O
human O
and O
the O
proximal O
end O
of O
RARE O
19 O
in O
the O
mouse O
. O

During O
exercise O
K O
+ O
is O
released O
from O
RARE O
muscle O
and O
plasma O
K O
+ O
concentration O
RARE O
. O

Following O
treatment O
, O
serum O
estradiol O
levels O
were O
RARE O
in O
groups O
E O
+ O
T O
and O
E O
than O
in O
group O
C O
. O

We O
conclude O
that O
the O
beta O
- O
adrenergic O
agonist O
, O
isoproterenol O
, O
has O
little O
influence O
on O
vascular O
RARE O
or O
liver O
volume O
of O
dogs O
, O
unless O
the O
RARE O
outflow O
resistance O
is O
elevated O
by O
agents O
such O
RARE O
RARE O
. O

DNA O
sequence O
and O
evolution O
of O
the O
ALL_CAP I-GENE
domain I-GENE
of O
the O
RARE I-GENE
hamster I-GENE
RARE I-GENE
protein I-GENE
ALL_CAP I-GENE
. O

Here O
we O
show O
that O
these O
RARE O
binding O
sites O
have O
a O
more O
restricted O
and O
specific O
ability O
to O
enhance O
transcription O
when O
assayed O
in O
transformed O
RARE O
. O

After O
RARE O
- O
line O
CBF O
was O
established O
, O
RARE O
bromide O
( O
2 O
mg O
/ O
kg O
iv O
RARE O
RARE O
bromide O
( O
NUM O
. O
5 O
microgram O
/ O
kg O
iv O
RARE O
indomethacin O
( O
2 O
mg O
/ O
kg O
iv O
RARE O
or O
intravenous O
NUM O
. O
9 O
% O
saline O
was O
administered O
. O

A O
high O
- O
frequency O
RARE O
fragment O
length O
polymorphism O
was O
evident O
in O
the O
DNA O
from O
29 O
unrelated O
individuals O
using O
the O
enzyme O
ALL_CAP I-GENE
. O

The O
RARE O
transformation O
of O
pH O
did O
not O
improve O
the O
results O
. O

RARE O
prevent O
end O
- O
to O
- O
end O
fusions O
and O
RARE O
RARE O
, O
RARE O
the O
end O
of O
the O
RARE O
DNA O
molecule O
to O
RARE O
, O
and O
function O
in O
cell O
division O
. O

One O
of O
these O
is O
RARE O
in O
the O
5 O
'- O
RARE O
region O
, O
and O
may O
encode O
regulatory O
sequences O
. O

The O
RARE O
enzyme O
RARE O
from O
protease I-GENE
- I-GENE
B I-GENE
- O
RARE O
NUM I-GENE
- O
transformed O
cells O
, O
was O
RARE O
in O
vitro O
using O
catalytic O
subunits O
of O
pure O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
. O

This O
study O
suggests O
that O
RARE O
are O
useful O
in O
the O
assessment O
of O
AMI O
in O
terms O
of O
diagnosis O
, O
location O
and O
extent O
of O
RARE O
infarct O
. O

A O
bovine O
RARE O
lambda O
gt11 O
cDNA O
library O
was O
screened O
with O
a O
monoclonal O
antibody O
raised O
against O
the O
RARE I-GENE
H I-GENE
, I-GENE
K I-GENE
- I-GENE
ATPase I-GENE
beta I-GENE
subunit I-GENE
. O

RARE O
use O
of O
laboratory O
testing O
, O
including O
monitoring O
of O
NUM I-GENE
cell O
counts O
, O
is O
recommended O
. O

There O
is O
RARE O
TATA O
box O
RARE O
RARE O
upstream O
from O
the O
transcription O
initiation O
site O
. O

Characterization O
of O
the O
5 O
' O
end O
of O
the O
growth O
- O
regulated O
RARE I-GENE
hamster I-GENE
ALL_CAP I-GENE
gene I-GENE
. O

Early O
cirrhosis O
, O
an O
early O
modality O
of O
the O
evolution O
of O
acute O
hepatitis O
. O

Examination O
of O
immediate I-GENE
- I-GENE
early I-GENE
transcription I-GENE
factor I-GENE
RARE O
RARE O
the O
ALL_CAP O
regimen O
revealed O
that O
ALL_CAP O
RARE O
an O
elevated O
, O
prolonged O
RARE O
of O
c I-GENE
- I-GENE
Jun I-GENE
mRNA I-GENE
accompanied O
by O
diminished O
RARE O
of O
c I-GENE
- I-GENE
Fos I-GENE
and O
Jun I-GENE
- I-GENE
B I-GENE
mRNAs I-GENE
. O

Although O
RARE O
rate O
and O
diastolic O
pressure O
rose O
in O
some O
degree O
1 O
min O
after O
RARE O
, O
free O
and O
RARE O
CA O
concentrations O
did O
not O
increase O
RARE O
study O
period O
. O

RARE O
, O
RARE O
, O
and O
immunoreactivity O
of O
RARE I-GENE
RARE I-GENE
truncated I-GENE
RARE I-GENE
- I-GENE
2 I-GENE
virus I-GENE
envelope I-GENE
proteins I-GENE
RARE O
in O
insect O
cells O
by O
recombinant O
RARE O
. O

Combined O
therapy O
with O
MK O
- O
801 O
and O
RARE O
RARE O
protection O
of O
ischemic O
brain O
damage O
. O

Initial O
screening O
of O
a O
rat O
liver O
cDNA O
library O
with O
an O
RARE O
probe O
derived O
from O
the O
rat O
NUM I-GENE
protein O
sequence O
revealed O
an O
NUM O
- O
RARE O
RARE O
cDNA O
clone O
coding O
RARE O
the O
RARE O
NUM I-GENE
protein O
sequence O
. O

Cloning O
, O
RARE O
, O
and O
nucleotide O
sequence O
of O
rat I-GENE
liver I-GENE
sterol I-GENE
carrier I-GENE
protein I-GENE
2 I-GENE
cDNAs I-GENE
. O

The O
addition O
of O
an O
RARE O
complex O
of O
the O
fourth O
and O
RARE O
largest O
subunits O
, O
RARE O
from O
pol I-GENE
II I-GENE
RARE I-GENE
by O
ion O
- O
exchange O
chromatography O
in O
the O
presence O
of O
urea O
, O
restored O
promoter O
- O
directed O
initiation O
activity O
to O
pol I-GENE
II I-GENE
delta I-GENE
4 I-GENE
/ I-GENE
7 I-GENE
. O

We O
report O
here O
the O
identification O
of O
HSF I-GENE
in O
the O
RARE O
yeast O
Schizosaccharomyces O
pombe O
. O

Induction O
requires O
the O
NUM I-GENE
gene I-GENE
product I-GENE
, O
which O
binds O
to O
specific O
sites O
in O
the O
promoter O
region O
of O
the O
NUM I-GENE
gene I-GENE
. O

Gel O
mobility O
shift O
assays O
using O
a O
RARE O
NUM I-GENE
motif I-GENE
detected O
a O
B O
- O
cell O
- O
specific O
complex O
in O
addition O
to O
a O
ubiquitous O
band O
found O
also O
in O
T O
cells O
and O
HeLa O
cells O
. O

RARE O
RARE O
encoding O
RARE I-GENE
response I-GENE
element I-GENE
binding I-GENE
factors I-GENE
have O
been O
isolated O
from O
a O
mouse O
fibroblast O
lambda O
gt11 O
cDNA O
library O
by O
using O
a O
32P O
end O
- O
labeled O
RARE O
RARE O
of O
the O
mouse I-GENE
( I-GENE
2 I-GENE
'- I-GENE
5 I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
gene I-GENE
RARE O
response O
element O
RARE O
a O
probe O
. O

The O
sequence O
of O
four O
RARE O
was O
sufficient O
to O
construct O
a O
NUM I-GENE
- I-GENE
bp I-GENE
ALL_CAP I-GENE
cDNA I-GENE
RARE O
. O

The O
application O
of O
these O
instruments O
allows O
occlusion O
of O
the O
ascending O
aorta O
RARE O
by O
the O
perfusion O
RARE O
inserted O
directly O
or O
through O
the O
apex O
of O
the O
RARE O
RARE O
RARE O
RARE O
simultaneous O
RARE O
ventricular O
RARE O
. O

RARE I-GENE
RARE I-GENE
( O
ALL_CAP O
: O
L I-GENE
- I-GENE
RARE I-GENE
ligase I-GENE
( O
GDP O
RARE O
EC I-GENE
6 I-GENE
. I-GENE
3 I-GENE
. I-GENE
4 I-GENE
. I-GENE
4 I-GENE
) O
plays O
an O
important O
role O
in O
RARE O
biosynthesis O
RARE O
the O
GTP O
- O
dependent O
conversion O
of O
ALL_CAP O
to O
AMP O
. O

RARE O
in O
four O
cases O
, O
demonstrated O
non O
- O
B O
, O
non O
- O
T O
cell O
origin O
in O
three O
and O
pre O
- O
B O
cell O
origin O
in O
one O
. O

DNA O
- O
protein O
ALL_CAP O
cross O
- O
linking O
studies O
indicated O
that O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
has O
an O
electrophoretic O
mobility O
on O
RARE O
dodecyl O
RARE O
- O
RARE O
gels O
of O
RARE O
NUM O
kDa O
and O
suggested O
that O
additional O
proteins O
, O
specific O
to O
each O
promoter O
, O
bind O
to O
each O
site O
. O

The O
results O
RARE O
the O
conclusion O
that O
predominantly O
dynamic O
activity O
increases O
the O
NUM I-GENE
content O
of O
RARE O
RARE O
fast O
muscles O
. O

The O
specific O
interaction O
between O
a O
defined O
structural O
element O
of O
the O
human O
immunodeficiency O
virus O
mRNA O
( O
ALL_CAP I-GENE
, O
the O
RARE I-GENE
response I-GENE
element I-GENE
) O
and O
the O
virus I-GENE
- I-GENE
encoded I-GENE
protein I-GENE
RARE I-GENE
has O
been O
implicated O
in O
the O
RARE O
of O
the O
export O
of O
unspliced O
or O
RARE O
RARE O
mRNA O
from O
the O
nucleus O
to O
the O
cytoplasm O
. O

We O
reviewed O
the O
records O
of O
151 O
patients O
with O
optic O
RARE O
examined O
over O
an O
eight O
- O
year O
period O
. O

RARE O
- O
off O
levels O
that O
define O
abnormality O
are O
rather O
RARE O
and O
this O
decreases O
the O
RARE O
of O
the O
test O
in O
apparently O
healthy O
patients O
. O

RARE I-GENE
aminotransferase I-GENE
in O
clinical O
practice O
. O

Nucleotide O
sequence O
analysis O
of O
the O
RARE I-GENE
RARE I-GENE
NUM I-GENE
RARE I-GENE
hydroxylase I-GENE
gene I-GENE
( O
ALL_CAP I-GENE
) O
and O
its O
3 O
'- O
flanking O
region O
. O

All O
RARE O
ARF I-GENE
cDNAs I-GENE
are O
more O
similar O
to O
each O
other O
than O
to O
other O
RARE O
20 I-GENE
- I-GENE
kDa I-GENE
guanine I-GENE
nucleotide I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

The O
long O
terminal O
repeat O
( O
LTR O
) O
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
) O
contains O
three O
binding O
sites O
RARE O
the O
transcriptional O
factor O
NUM I-GENE
. O

DNA O
from O
PCR O
was O
labeled O
and O
used O
to O
isolate O
several O
lambda O
gt11 O
cDNA O
RARE O
, O
including O
one O
full O
- O
length O
one O
( O
RARE I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
). O

RARE O
- O
RARE O
changes O
in O
the O
area O
of O
RARE O
and O
RARE O
RARE O
RARE O
RARE O
RARE I-GENE
content O
were O
seen O
11 O
weeks O
after O
irradiation O
. O

The O
RARE O
follow O
- O
RARE O
was O
RARE O
a O
nearly O
constant O
interval O
of O
5 O
. O
1 O
years O
in O
RARE O
and O
3 O
. O
2 O
years O
in O
RARE O
; O
NUM O
major O
ALL_CAP O
events O
had O
occurred O
. O

A O
. O

RARE O
RARE O
RARE O
an O
unusual O
injury O
RARE O
immediate O
and O
correct O
treatment O

RARE O
( O
RARE O
- O
O O
) O
and O
cv O
. O

In O
summary O
, O
RARE O
RARE O
concentrations O
, O
RARE O
and O
isoflurane O
produced O
similar O
hemodynamic O
effects O
; O
however O
, O
in O
the O
absence O
of O
drugs O
that O
inhibit O
RARE O
RARE O
, O
RARE O
had O
less O
negative O
inotropic O
activity O
and O
produced O
less O
decrease O
in O
arterial O
pressure O
. O

We O
report O
here O
the O
isolation O
of O
a O
full O
- O
length O
cDNA O
clone O
coding O
RARE O
a O
hitherto O
RARE O
isoform O
of O
the O
bovine I-GENE
C I-GENE
- I-GENE
subunit I-GENE
. O

RARE I-GENE
C I-GENE
beta I-GENE
2 I-GENE
, O
an O
unusual O
form O
of O
the O
bovine O
catalytic O
subunit O
of O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
. O

RARE O
applications O
of O
ALL_CAP O
- O
ALL_CAP O
RARE O
to O
toxicological O
problems O
are O
RARE O
with O
examples O
. O

Patients O
with O
apparently O
minor O
ALL_CAP O
abnormalities O
may O
have O
significant O
RARE O
RARE O
. O

The O
NUM I-GENE
sequence I-GENE
includes O
an O
additional O
NUM O
amino O
RARE O
of O
the O
contiguous O
fragment O
and O
encodes O
a O
product O
of O
predicted O
Mr O
67 O
, O
NUM O
. O

RARE O
with O
a O
clear O
understanding O
of O
the O
RARE O
pathways O
that O
may O
cause O
and O
/ O
or O
contribute O
to O
the O
development O
of O
RARE O
hyperbilirubinemia O
and O
the O
associated O
jaundice O
, O
the O
RARE O
will O
be O
successful O
in O
RARE O
the O
family O
understand O
their O
child O
' O
s O
illness O
. O

RARE O
RARE O
of O
peripheral O
sites O
in O
RARE O
human O
vision O
were O
obtained O
. O

The O
authors O
report O
a O
case O
in O
which O
RARE O
irrigation O
of O
a O
brain O
cyst O
was O
temporally O
associated O
with O
respiratory O
distress O
. O

ELISA O
was O
found O
to O
make O
a O
contribution O
to O
the O
diagnosis O
of O
tuberculosis O
similar O
to O
that O
of O
RARE O
RARE O
. O

In O
this O
paper O
, O
we O
report O
a O
detailed O
study O
of O
the O
RARE O
and O
the O
RARE O
role O
of O
the O
ALL_CAP I-GENE
binding I-GENE
sites I-GENE
RARE O
in O
the O
adjacent O
and O
divergent O
RARE I-GENE
and O
RARE I-GENE
promoters I-GENE
. O

Despite O
the O
small O
number O
of O
patients O
, O
on O
the O
basis O
of O
this O
report O
, O
we O
can O
confirm O
that O
1 O
. O
5 O
ALL_CAP O
/ O
day O
of O
alpha I-GENE
- I-GENE
IFN I-GENE
is O
an O
adequate O
treatment O
RARE O
patients O
with O
RARE O
cell O
leukemia O
. O

RARE O
fluctuations O
in O
observed O
RARE O
in O
RARE O
falciparum O
malaria O
. O

No O
positive O
family O
history O
was O
obtained O
. O

RARE O
asthma O
and O
RARE O
from O
inhalation O
of O
crystalline O
bovine I-GENE
serum I-GENE
albumin I-GENE
RARE O
. O

A O
further O
RARE O
of O
RARE O
NUM O
into O
NUM O
( O
metastasis O
in O
single O
node O
) O
and O
NUM O
( O
two O
or O
more O
nodes O
) O
is O
recommended O
. O

Amino O
acid O
sequence O
comparisons O
of O
the O
NUM I-GENE
protein I-GENE
reveal O
a O
highly O
RARE O
C O
- O
terminal O
region O
that O
is O
rich O
in O
basic O
amino O
acid O
residues O
and O
which O
has O
been O
proposed O
to O
possess O
sequence O
- O
specific O
DNA O
binding O
activity O
. O

We O
found O
that O
the O
relative O
strengths O
of O
the O
promoters O
were O
similar O
in O
different O
RARE O
. O

RARE O
, O
and O
A O
. O

After O
6 O
months O
, O
definite O
improvement O
in O
strength O
occurred O
in O
4 O
of O
7 O
RARE O
- O
treated O
patients O
and O
in O
none O
of O
7 O
controls O
. O

RARE O
RARE O
ALL_CAP O
and O
RARE O
were O
achieved O
later O
RARE O
RARE O
NUM O
than O
RARE O
RARE O
F O
. O

To O
identify O
the O
DNA O
sequences O
that O
cis O
- O
regulate O
the O
RARE O
of O
the O
rat I-GENE
liver I-GENE
RARE I-GENE
kinase I-GENE
( O
L I-GENE
- I-GENE
ALL_CAP I-GENE
) O
genes O
, O
a O
series O
of O
constructs O
in O
which O
the O
chloramphenicol I-GENE
RARE I-GENE
reporter I-GENE
genes I-GENE
is O
RARE O
by O
various O
RARE O
fragments O
of O
the O
NUM O
RARE O
RARE O
( O
bp O
) O
upstream O
of O
the O
L I-GENE
- I-GENE
ALL_CAP I-GENE
gene I-GENE
RARE I-GENE
site I-GENE
have O
been O
assayed O
RARE O
transient O
RARE O
after O
introduction O
into O
hepatoma O
NUM O
cells O
, O
rat O
hepatocytes O
in O
RARE O
culture O
, O
fibroblast O
ALL_CAP O
- O
cells O
, O
RARE O
C2C12 O
cells O
, O
and O
CHO O
cells O
. O

The O
disturbance O
of O
pulmonary O
gas O
exchange O
, O
RARE O
revealed O
by O
the O
high O
value O
of O
NUM O
, O
existed O
without O
RARE O
ventricular O
dysfunction O
, O
and O
NUM O
had O
RARE O
significant O
relationship O
with O
any O
of O
the O
hemodynamic O
parameters O
including O
the O
difference O
between O
plasma O
colloid O
osmotic O
pressure O
and O
ALL_CAP O
. O

A O
dose O
of O
3 O
and O
6 O
micrograms O
/ O
kg O
/ O
day O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
reduces O
the O
severity O
of O
neutropenia O
and O
thrombocytopenia O
after O
RARE O
- O
cyclophosphamide O
chemotherapy O
, O
which O
may O
lead O
to O
more O
effective O
chemotherapy O
RARE O
ovarian O
RARE O
in O
the O
future O
. O

These O
differences O
involve O
specific O
hydrogen O
- O
RARE O
interactions O
between O
the O
protein O
and O
DNA O
, O
including O
guanine O
NUM O
sites O
in O
the O
major O
RARE O
of O
DNA O
, O
and O
alterations O
in O
DNA O
RARE O
conformation O
RARE O
by O
protein O
binding O
. O

Biochemical O
analysis O
demonstrates O
that O
the O
NUM I-GENE
protein I-GENE
is O
associated O
with O
RARE O
and O
is O
released O
from O
chromatin O
by O
agents O
which O
RARE O
into O
DNA O
, O
RARE O
previously O
shown O
RARE O
the O
high I-GENE
mobility I-GENE
group I-GENE
proteins I-GENE
( O
RARE I-GENE
). O

I O
propose O
that O
their O
gene O
products O
bind O
to O
the O
chromatin O
to O
establish O
or O
maintain O
a O
proper O
RARE O
order O
RARE O
RARE O
a O
prerequisite O
RARE O
a O
regulated O
gene O
RARE O
. O

The O
NUM I-GENE
alpha I-GENE
gene I-GENE
is O
organized O
RARE O
follows O
: O
the O
RARE O
RARE O
codes O
RARE O
the O
RARE O
198 O
nucleotides O
of O
the O
5 O
' O
UTR O
. O

The O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
RARE I-GENE
protein I-GENE
is O
a O
positive O
posttranscriptional O
regulator O
of O
viral O
structural O
gene O
RARE O
and O
essential O
RARE O
virus O
replication O
. O

Once O
the O
RARE O
of O
RARE O
and O
RARE I-GENE
RARE O
had O
led O
to O
an O
increase O
of O
mechanical O
strength O
, O
RARE O
negative O
effect O
on O
wound O
healing O
could O
be O
detected O
applying O
the O
same O
chemotherapeutic O
agents O
. O

The O
NUM I-GENE
gene I-GENE
has O
two O
in O
- O
frame O
AUG O
codons O
RARE O
possible O
translation O
RARE O
sites O
, O
which O
would O
produce O
58 O
- O
and O
NUM O
- O
kDa O
proteins O
, O
respectively O
. O

During O
the O
years O
1980 O
- O
87 O
a O
RARE O
of O
NUM O
persons O
received O
RARE O
RARE O
in O
the O
RARE O
of O
RARE O
in O
northern O
RARE O
. O

HeLa O
and O
Jurkat O
cell O
lines O
carrying O
the O
nef I-GENE
gene I-GENE
RARE O
to O
the O
ALL_CAP O
promoter O
or O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
were O
isolated O
by O
RARE O
RARE O
RARE O
resistance O
. O

RARE O
in O
the O
clinical O
presentation O
and O
the O
gross O
appearance O
of O
the O
two O
cases O
are O
described O
, O
and O
similarities O
in O
the O
microscopic O
features O
are O
discussed O
. O

ALL_CAP O
ALL_CAP O
MAIN O
RESULTS O
: O
The O
two O
groups O
were O
similar O
on O
entry O
into O
the O
study O
, O
including O
mean O
FEV1 O
measurements O
( O
NUM O
. O
70 O
L O
atropine O
/ O
NUM O
. O
NUM O
L O
RARE O
, O
P O
greater O
than O
. O
05 O
). O

Using O
an O
ELISA O
, O
we O
found O
that O
RARE I-GENE
protein I-GENE
A I-GENE
( O
SP I-GENE
- I-GENE
A I-GENE
) O
was O
markedly O
elevated O
in O
the O
pneumonia O
patients O
. O

In O
view O
of O
the O
short O
t1 O
/ O
2 O
, O
we O
used O
three O
doses O
/ O
day O
. O

RARE O
control O
of O
GUS I-GENE
RARE O
was O
found O
to O
involve O
two O
negative O
regulatory O
sequences O
, O
NUM O
RARE O
NUM O
to O
- O
NUM O
) O
and O
NUM O
RARE O
NUM O
to O
- O
NUM O
RARE O
RARE O
RARE O
RARE O
the O
positive O
domain O
UAS1 O
. O

We O
RARE O
a O
NUM I-GENE
RARE I-GENE
calmodulin I-GENE
( I-GENE
CaM I-GENE
)- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
CaM I-GENE
kinase I-GENE
) O
from O
the O
yeast O
Saccharomyces O
cerevisiae O
with O
properties O
similar O
to O
mammalian I-GENE
type I-GENE
II I-GENE
CaM I-GENE
kinases I-GENE
. O

In O
most O
cases O
, O
NUM I-GENE
- O
homozygous O
, O
NUM I-GENE
- O
RARE O
individuals O
could O
be O
RARE O
with O
the O
panel O
of O
RARE O
. O

Two O
patients O
had O
immediate O
adverse O
effects O
from O
ALL_CAP O
; O
one O
had O
a O
RARE O
RARE O
seizure O
and O
the O
other O
developed O
severe O
abdominal O
pain O
. O

The O
muscles O
from O
the O
ischemic O
group O
had O
significantly O
lower O
( O
P O
less O
than O
. O
05 O
) O
values O
RARE O
capillary O
density O
and O
capillary O
to O
fiber O
ratio O
and O
significantly O
RARE O
RARE O
distance O
than O
those O
from O
the O
normal O
group O
. O

The O
prevalence O
of O
RARE O
infection O
among O
RARE O
AIDS O
patients O
and O
the O
RARE O
of O
being O
in O
RARE O
response O
following O
RARE O
therapy O
conditional O
on O
being O
RARE O
are O
two O
examples O
of O
such O
functions O
. O

Serum I-GENE
TNF I-GENE
concentrations O
were O
elevated O
RARE O
diagnosis O
and O
gradually O
decreased O
toward O
the O
reference O
limits O
by O
week O
16 O
. O

Genomic O
RARE O
RARE O
the O
human I-GENE
NUM I-GENE
gene I-GENE
were O
isolated O
and O
utilized O
to O
define O
its O
RARE O
organization O
. O

RARE O
chain O
reaction O
analysis O
of O
NUM I-GENE
cDNA I-GENE
identified O
several O
amplified O
products O
, O
indicating O
RARE O
RARE O
. O

Most O
of O
the O
RARE O
human I-GENE
NUM I-GENE
polypeptides I-GENE
( O
five O
bands O
) O
were O
found O
in O
the O
RARE O
RARE O
while O
primarily O
full I-GENE
- I-GENE
length I-GENE
RARE I-GENE
NUM I-GENE
was O
found O
in O
the O
RARE O
fraction O
. O

To O
test O
RARE O
function O
, O
chimeric O
genes O
were O
constructed O
linking O
fragments O
of O
chicken O
IGF I-GENE
- I-GENE
I I-GENE
5 O
'- O
flanking O
DNA O
to O
a O
promoterless O
reporter O
RARE O
. O

The O
alpha I-GENE
4 I-GENE
gene I-GENE
5 O
' O
flanking O
region O
RARE O
RARE O
a O
promoter O
in O
transfection O
assays O
. O

Characterization O
of O
the O
alpha I-GENE
4 I-GENE
integrin I-GENE
gene I-GENE
promoter I-GENE
. O

Only O
the O
3 O
. O
NUM O
- O
kb O
transcript O
was O
detected O
in O
adult O
tissues O
, O
where O
its O
RARE O
was O
restricted O
almost O
exclusively O
to O
the O
central O
nervous O
RARE O
. O

Two O
RARE O
of O
the O
RARE I-GENE
gene I-GENE
have O
now O
been O
isolated O
. O

RARE O
RARE O
RARE O
causing O
respiratory O
obstruction O
postoperatively O
. O

We O
examined O
the O
effects O
of O
long O
- O
term O
perfusion O
with O
RARE O
hemoglobin I-GENE
RARE O
RARE O
( O
ALL_CAP O
) O
solution O
on O
cardiac O
function O
of O
isolated O
rat O
hearts O
. O

RARE O
: O
RARE O
type O
ALL_CAP O
and O
RARE O
type O
TOF O
have O
anatomic O
features O
in O
which O
the O
proximal O
RARE O
bundle O
RARE O
to O
be O
RARE O
by O
RARE O
RARE O
ALL_CAP O
closure O
. O

The O
NUM I-GENE
- I-GENE
NUM I-GENE
mutation O
also O
results O
in O
RARE O
RARE O
, O
accumulation O
of O
inactive O
NUM I-GENE
ribosomal I-GENE
RARE I-GENE
, O
and O
accumulation O
of O
RARE O
least O
one O
of O
the O
subunits O
of O
the O
RARE I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
2 I-GENE
( O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
) O
in O
NUM I-GENE
- O
NUM I-GENE
RARE O
following O
a O
shift O
to O
the O
restrictive O
RARE O
. O

Eight O
patients O
with O
ALL_CAP O
and O
RARE O
failure O
were O
recently O
evaluated O
. O

To O
measure O
the O
enhancer O
activity O
of O
NUM I-GENE
, O
a O
reporter O
RARE O
was O
constructed O
that O
contained O
NUM I-GENE
RARE O
upstream O
of O
the O
reporter O
chloramphenicol I-GENE
RARE I-GENE
gene I-GENE
under O
the O
control O
of O
the O
delayed O
- O
early O
NUM O
promoter O
. O

A O
single O
case O
of O
an O
adenocarcinoma O
, O
arising O
in O
a O
RARE O
RARE O
cyst O
and O
which O
presented O
RARE O
a O
RARE O
RARE O
cyst O
, O
is O
reported O
. O

Using O
the O
polymerase O
chain O
reaction O
, O
we O
analyzed O
the O
U6 I-GENE
RNA I-GENE
genes I-GENE
of O
52 O
organisms O
. O

Both O
RARE O
volume O
and O
RARE O
flow O
were O
found O
to O
be O
significantly O
( O
P O
less O
than O
NUM O
. O
001 O
) O
decreased O
RARE O
to O
6 O
h O
after O
RARE O
, O
RARE O
a O
minimum O
NUM O
min O
after O
application O
( O
RARE O
volume O
: O
- O
NUM O
%; O
RARE O
flow O
: O
- O
NUM O
%). O

RARE O
analysis O
indicated O
that O
the O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
polypeptides I-GENE
are O
likely O
to O
be O
RARE O
, O
whereas O
the O
ALL_CAP I-GENE
polypeptide I-GENE
was O
predicted O
to O
have O
four O
RARE O
membrane O
- O
spanning O
domains O
. O

To O
facilitate O
the O
availability O
of O
important O
new O
therapeutic O
agents O
, O
the O
RARE O
and O
Drug O
Administration O
( O
ALL_CAP O
) O
in O
the O
mid O
- O
NUM O
RARE O
RARE O
therapeutic O
RARE O
to O
RARE O
new O
drugs O
and O
RARE O
end O
- O
of O
- O
RARE O
II O
RARE O
with O
drug O
RARE O
. O

In O
contrast O
, O
similar O
rates O
of O
B O
. O
RARE O
products O
, O
ALL_CAP O
- O
NUM O
RARE O
RARE O
and O
ALL_CAP O
- O
2 O
RARE O
RARE O
, O
produced O
RARE O
significant O
reduction O
. O

The O
RARE O
( O
18 O
. O
4 O
%) O
was O
with O
IgA I-GENE
nephropathy O
, O
which O
was O
histologically O
mild O
. O

RARE O
, O
the O
experimental O
RARE O
was O
identical O
to O
the O
field O
condition O
, O
and O
bacteria O
indistinguishable O
from O
the O
inoculated O
strains O
were O
RARE O
. O

3 O
. O

Furthermore O
, O
the O
DNA I-GENE
polymerase I-GENE
II I-GENE
complex I-GENE
was O
difficult O
to O
obtain O
from O
NUM I-GENE
- I-GENE
1 I-GENE
mutant O
cells O
, O
suggesting O
that O
a O
stable O
DNA I-GENE
polymerase I-GENE
II I-GENE
complex I-GENE
requires O
NUM I-GENE
and O
is O
essential O
RARE O
chromosomal O
replication O
. O

To O
determine O
whether O
mononuclear O
cell O
RARE O
products O
contribute O
to O
the O
changes O
in O
bone O
turnover O
that O
characterize O
the O
development O
of O
RARE O
RARE O
, O
we O
evaluated O
the O
effects O
of O
RARE O
and O
subsequent O
estrogen O
RARE O
on O
the O
spontaneous O
RARE O
of O
interleukin I-GENE
1 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
) O
and O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
( O
TNF I-GENE
- I-GENE
alpha I-GENE
) O
and O
on O
the O
phytohemagglutinin I-GENE
A I-GENE
- O
RARE O
RARE O
of O
RARE I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
) O
from O
peripheral O
RARE O
mononuclear O
cells O
. O

There O
were O
NUM O
to O
NUM O
nt O
differences O
between O
the O
virulent O
and O
RARE O
groups O
while O
there O
were O
6 O
to O
14 O
nt O
differences O
among O
four O
RARE O
strains O
. O

The O
standard O
RARE O
of O
surgical O
management O
must O
be O
RARE O
to O
when O
using O
RARE O
to O
treat O
patients O
with O
these O
disorders O
. O

Some O
of O
the O
PCR O
products O
contained O
mutations O
in O
NUM I-GENE
and O
/ O
or O
NUM I-GENE
. O

RARE O
shock O
and O
bacterial O
translocation O
in O
a O
swine O
model O
. O

These O
data O
suggest O
that O
the O
levels O
of O
oxygen O
free O
radicals O
were O
increased O
in O
hepatocytes O
and O
RARE O
. O

The O
sequence O
of O
the O
NUM O
RARE O
containing O
the O
RARE O
region O
contains O
a O
perfect O
RARE O
repeat O
of O
19 O
bp O
in O
the O
orientation O
1 O
RARE O
RARE I-GENE
gene I-GENE
RARE O
the O
RARE O
of O
the O
RARE O
RARE O
site O
. O

No O
evidence O
RARE O
the O
presence O
of O
RARE O
within O
the O
ALL_CAP I-GENE
gene I-GENE
has O
been O
found O
. O

These O
observations O
, O
together O
with O
the O
occurrence O
of O
putative O
4 O
'- O
RARE O
- O
RARE O
sites O
and O
a O
putative O
RARE I-GENE
site I-GENE
, O
are O
discussed O
with O
reference O
to O
the O
reaction O
sequence O
leading O
to O
production O
of O
the O
ALL_CAP I-GENE
RARE I-GENE
. O

RARE O
, O
a O
RARE I-GENE
oxidase I-GENE
inhibitor O
, O
reduces O
peak O
3 O
transiently O
( O
RARE O
. O

When O
given O
the O
choice O
between O
an O
RARE O
female O
and O
a O
RARE O
RARE O
male O
in O
the O
ALL_CAP O
, O
RARE O
females O
, O
RARE O
RARE O
RARE O
controls O
, O
preferred O
the O
male O
RARE O
. O

RARE O
RARE O
responses O
were O
- O
1 O
. O
NUM O
+/- O
NUM O
. O
37 O
L O
/ O
min O
RARE O
SaO2 O
in O
the O
RARE O
and O
- O
1 O
. O
54 O
+/- O
NUM O
. O
NUM O
L O
/ O
min O
RARE O
SaO2 O
in O
the O
control O
subjects O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

RARE O
small O
deletions O
within O
the O
RARE O
region O
completely O
abolished O
transforming O
activity O
of O
RARE I-GENE
, O
while O
extensive O
deletion O
outside O
of O
this O
region O
had O
RARE O
effect O
. O

This O
computerized O
RARE O
was O
RARE O
to O
the O
central O
RARE O
of O
the O
RARE O
Cancer O
RARE O
and O
cases O
diagnosed O
between O
1982 O
and O
1988 O
were O
identified O
. O

We O
also O
present O
evidence O
RARE O
a O
negative O
regulatory O
element O
in O
the O
5 O
' O
flanking O
region O
of O
the O
RARE I-GENE
I I-GENE
upstream I-GENE
activation I-GENE
sequence I-GENE
. O

A O
method O
RARE O
RARE O
stimulus O
control O
of O
ethanol O
responding O
was O
developed O
. O

Mechanism O
of O
activation O
of O
the O
RARE I-GENE
RARE I-GENE
. O
RARE I-GENE
is O
a O
human O
locus O
that O
appears O
to O
be O
specifically O
RARE O
in O
cells O
of O
hematopoietic O
origin O
regardless O
of O
their O
differentiation O
lineage O
. O

RARE O
cell O
RARE O
. O

RARE O
RARE O
in O
a O
child O
. O

After O
hemodynamic O
stabilization O
, O
the O
goal O
of O
therapy O
is O
to O
RARE O
the O
RARE O
that O
an O
ulcer O
will O
RARE O
to O
RARE O
or O
will O
RARE O
. O

Thirty O
RARE O
patients O
( O
RARE O
RARE O
= O
16 O
, O
RARE O
RARE O
= O
21 O
) O
completed O
the O
RARE O
week O
protocol O
, O
which O
was O
conducted O
under O
double O
blind O
conditions O
. O

The O
stimulus O
threshold O
RARE O
ALL_CAP O
showed O
a O
less O
individual O
variation O
than O
amplitude O
. O

Analysis O
of O
electrically O
evoked O
response O
( O
ALL_CAP O
) O
in O
relation O
to O
the O
central O
visual O
RARE O
of O
the O
RARE O
( O
1 O
). O

Furthermore O
, O
plasma O
fibrinogen I-GENE
levels O
increased O
by O
a O
mean O
of O
NUM O
. O
6 O
%, O
a O
potentially O
adverse O
effect O
of O
RARE O
that O
has O
not O
been O
previously O
reported O
. O

RARE O
in O
RARE O
patients O
with O
peripheral O
arterial O
RARE O
: O
some O
RARE O
actions O
. O

An O
NUM I-GENE
- O
independent O
RARE O
RARE O
RARE O
control O
in O
Saccharomyces O
cerevisiae O
acts O
through O
IME1 I-GENE
transcript I-GENE
accumulation O
. O

The O
role O
of O
pharmacological O
RARE O
in O
safety O
assessment O
. O

Its O
application O
in O
RARE O
: O
advantages O
and O
RARE O

In O
all O
cases O
, O
high O
- O
level O
RARE O
of O
the O
truncated I-GENE
avian I-GENE
RARE I-GENE
was O
obtained O
. O

The O
authors O
evaluate O
the O
clinical O
efficacy O
of O
ALL_CAP O
ALL_CAP O
in O
recurrent O
ulcer O
after O
operation O
on O
the O
stomach O
caused O
by O
a O
high O
level O
of O
acid O
production O
and O
RARE O
RARE O
bleeding O
. O

In O
RARE O
these O
rats O
were O
RARE O
and O
RARE O
the O
RARE O
RARE O
response O
later O
than O
the O
controls O
. O

To O
investigate O
the O
RARE O
of O
RARE I-GENE
gene I-GENE
activity O
, O
the O
region O
around O
the O
NUM I-GENE
transcriptional I-GENE
initiation I-GENE
site I-GENE
was O
analyzed O
RARE O
sites O
of O
protein O
- O
DNA O
interaction O
. O

RARE O
mapping O
revealed O
the O
same O
autophosphorylation O
sites O
utilized O
by O
EGFR I-GENE
- I-GENE
ALL_CAP I-GENE
RARE O
those O
identified O
in O
wild I-GENE
- I-GENE
type I-GENE
EGFR I-GENE
. O

The O
encoded O
sequence O
revealed O
a O
typical O
signal O
peptide O
, O
a O
predominantly O
hydrophilic O
NUM O
amino O
acid O
RARE O
domain O
with O
8 O
N O
- O
glycosylation O
sites O
, O
a O
transmembrane O
domain O
, O
and O
a O
C O
- O
terminal O
domain O
of O
52 O
amino O
RARE O
. O

The O
TCF I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
binding I-GENE
site I-GENE
was O
also O
required O
RARE O
TCR I-GENE
alpha I-GENE
enhancer I-GENE
activity O
in O
transcriptionally O
RARE O
extracts O
from O
Jurkat O
but O
not O
HeLa O
cells O
, O
confirming O
that O
TCF I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
is O
a O
T I-GENE
- I-GENE
cell I-GENE
- I-GENE
specific I-GENE
transcription I-GENE
factor I-GENE
. O

A O
new O
RARE O
- O
automatic O
method O
RARE O
RARE O
regional O
cerebral O
uptake O
of O
99m O
technetium O
- O
RARE O
RARE O
RARE O
( O
99mTc O
- O
HMPAO O
) O
was O
used O
to O
assess O
single O
photon O
emission O
RARE O
from O
5 O
normal O
subjects O
, O
14 O
patients O
with O
RARE O
' O
s O
RARE O
, O
14 O
patients O
with O
dementia O
of O
frontal O
lobe O
type O
and O
4 O
patients O
with O
dementia O
with O
motor O
RARE O
RARE O
. O

The O
results O
showed O
that O
RARE O
, O
RARE O
to O
a O
level O
of O
RARE O
RARE O
RARE O
of O
NUM O
. O
6 O
optical O
density O
RARE O
, O
had O
RARE O
influence O
on O
the O
diagnostic O
accuracy O
in O
the O
absence O
of O
any O
RARE O
. O

ALL_CAP O
NUM O
was O
RARE O
extracted O
by O
liquid O
- O
solid O
RARE O
and O
the O
extracts O
were O
RARE O
and O
analysed O
on O
a O
reversed O
- O
RARE O
column O
under O
RARE O
conditions O
, O
using O
either O
an O
RARE O
or O
a O
ALL_CAP O
detector O
. O

In O
this O
model O
, O
RARE O
has O
a O
very O
specific O
anti O
- O
aggressive O
( O
RARE O
) O
profile O
, O
inhibiting O
aggression O
while O
social O
interaction O
and O
RARE O
are O
not O
decreased O
but O
even O
RARE O
; O
RARE O
, O
a O
measure O
RARE O
sedation O
, O
is O
not O
affected O
. O

A O
new O
method O
RARE O
the O
in O
vitro O
transfer O
of O
delayed O
hypersensitivity O
by O
RARE O
transfer I-GENE
factor I-GENE
. O

Effect O
of O
separate O
and O
combined O
effects O
of O
plutonium O
- O
239 O
, O
RARE O
and O
RARE O
phosphate O
on O
the O
RARE O
RARE O
of O
rats O

Data O
collection O
was O
made O
with O
a O
RARE O
language O
, O
and O
data O
analysis O
performed O
with O
an O
RARE O
knowledge O
- O
based O
statistical O
tool O
, O
ALL_CAP O
, O
employing O
a O
multivariate O
RARE O
analysis O
technique O
. O

ALL_CAP O
has O
been O
RARE O
by O
using O
a O
RARE O
ALL_CAP O
, O
very O
RARE O
and O
highly O
RARE O
on O
personal O
RARE O
. O

RARE O
was O
RARE O
by O
RARE O
drinking O
of O
RARE O
( O
NUM O
ml O
/ O
h O
). O

Diagnostic O
value O
of O
adenosine I-GENE
RARE I-GENE
activity O
in O
tuberculous O
RARE O
. O

RARE O
RARE O
adaptation O
after O
RARE O
hip O
RARE O
: O
a O
comparison O
of O
RARE O
and O
RARE O
RARE O
RARE O
in O
RARE O
. O

RARE O
- O
RARE O
, O
using O
antisera O
against O
RARE O
RARE O
, O
showed O
that O
the O
positive O
staining O
in O
altered O
RARE O
cells O
were O
restricted O
to O
RARE O
organisms O
having O
a O
RARE O
resembling O
RARE O
RARE O
. O

Promoter O
activities O
were O
estimated O
using O
beta I-GENE
- I-GENE
glucuronidase I-GENE
and O
RARE I-GENE
RARE I-GENE
II I-GENE
reporter I-GENE
gene I-GENE
RARE I-GENE
. O

The O
5 O
' O
regions O
of O
these O
two O
RARE I-GENE
actin I-GENE
genes I-GENE
contain O
many O
unusual O
features O
including O
( O
ALL_CAP O
) O
repeats O
and O
long O
stretches O
of O
pyrimidine O
- O
rich O
DNA O
. O

All O
8 O
( O
NUM O
%) O
patients O
with O
RARE O
RARE O
failure O
who O
received O
grafts O
RARE O
, O
including O
3 O
who O
received O
ALL_CAP O
- O
RARE O
grafts O
, O
though O
2 O
of O
these O
subsequently O
required O
RARE O
. O

No O
patient O
had O
a O
history O
of O
excess O
RARE O
intake O
, O
or O
prolonged O
intake O
of O
RARE O
drugs O
and O
steroids O
, O
and O
were O
not O
obese O
or O
RARE O
. O

An O
evolutionary O
comparison O
of O
amino O
acid O
sequences O
of O
NUM O
HSP70 I-GENE
proteins I-GENE
from O
NUM O
species O
suggests O
that O
ALL_CAP I-GENE
genes I-GENE
share O
a O
common O
ancestor O
, O
which O
diverged O
from O
other O
HSP70 I-GENE
genes I-GENE
near O
the O
time O
when O
eukaryotes O
RARE O
appeared O
. O

RARE O
RARE O
( O
RARE O
10 O
( O
6 O
RARE O
RARE O
) O
were O
RARE O
onto O
NUM O
. O
5 O
- O
in O
. O

However O
, O
overexpression O
of O
both O
the O
NUM I-GENE
and O
NUM I-GENE
proteins I-GENE
did O
not O
generate O
a O
stronger O
pheromone O
response O
than O
overexpression O
of O
NUM I-GENE
in O
the O
presence O
of O
wild O
- O
type O
levels O
of O
NUM I-GENE
. O

RARE O
transcription O
- O
PCR O
was O
then O
used O
to O
clone O
from O
human O
RARE O
( O
A O
)+ O
RNA O
the O
cDNA O
corresponding O
to O
the O
RARE O
homolog O
of O
psi I-GENE
ARF I-GENE
4 I-GENE
, O
referred O
to O
RARE O
human I-GENE
ARF I-GENE
4 I-GENE
. O

To O
evaluate O
the O
cost O
and O
benefits O
of O
screening O
tests O
RARE O
Chlamydia O
RARE O
in O
adolescent O
males O
, O
we O
developed O
a O
RARE O
analysis O
model O
and O
compared O
the O
RARE I-GENE
esterase I-GENE
urine O
RARE O
test O
with O
culture O
, O
with O
direct O
- O
RARE O
RARE O
antibody O
( O
ALL_CAP O
RARE O
and O
with O
the O
RARE O
of O
RARE O
screening O
( O
RARE O
treatment O
). O

Sequencing O
the O
gene O
RARE O
an O
RARE O
- O
RARE O
- O
RARE O
enzyme O
( O
ALL_CAP I-GENE
) O
from O
RARE O
RARE O
NUM O
reveals O
strong O
RARE O
between O
ALL_CAP I-GENE
and O
Bacillus I-GENE
RARE I-GENE
beta I-GENE
- I-GENE
lactamase I-GENE
II I-GENE
. O

The O
RARE O
HindIII I-GENE
fragment I-GENE
, O
which O
was O
shown O
by O
DNA O
sequence O
analysis O
to O
encode O
the O
N O
- O
terminal O
RARE O
of O
the O
B I-GENE
. I-GENE
subtilis I-GENE
NUM I-GENE
protein I-GENE
and O
NUM O
. O
2 O
kb O
of O
upstream O
flanking O
sequence O
, O
was O
utilized O
RARE O
a O
homologous O
probe O
to O
clone O
an O
overlapping O
2 I-GENE
. I-GENE
NUM I-GENE
- I-GENE
kb I-GENE
ALL_CAP I-GENE
chromosomal I-GENE
fragment I-GENE
containing O
the O
RARE I-GENE
NUM I-GENE
structural I-GENE
gene I-GENE
. O

The O
N O
- O
terminal O
NUM O
amino O
RARE O
correspond O
to O
a O
putative O
DNA O
- O
binding O
domain O
and O
show O
significant O
sequence O
RARE O
with O
other O
RARE O
IFN I-GENE
response I-GENE
factors I-GENE
( O
IRF I-GENE
- I-GENE
1 I-GENE
and O
IRF I-GENE
- I-GENE
2 I-GENE
). O

RARE O
seizures O
had O
occurred O
RARE O
RARE O
in O
52 O
per O
cent O
. O

It O
encodes O
a O
protein O
with O
three O
zinc O
RARE O
similar O
to O
those O
of O
the O
transcription I-GENE
factor I-GENE
NUM I-GENE
. O

Krox I-GENE
- I-GENE
NUM I-GENE
is O
therefore O
a O
sequence O
- O
specific O
transcriptional O
activator O
. O

The O
RARE O
variability O
of O
the O
parameters O
is O
taken O
into O
RARE O
by O
RARE O
RARE O
the O
threshold O
levels O
. O

The O
patients O
were O
divided O
into O
3 O
subgroups O
: O
1 O
) O
NUM O
N O
+ O
patients O
with O
multiple O
hot O
spots O
( O
greater O
than O
2 O
) O
( O
N O
+ O
IM O
); O
2 O
) O
NUM O
N O
+ O
patients O
with O
single O
hot O
spots O
( O
less O
than O
or O
equal O
to O
2 O
) O
( O
N O
+ O
ALL_CAP O
); O
3 O
) O
12 O
N O
- O
patients O
with O
single O
hot O
spots O
( O
less O
than O
or O
equal O
to O
2 O
) O
( O
N O
- O
ALL_CAP O
). O

RARE O
CO2 O
causing O
changes O
from O
RARE O
- O
to O
RARE O
has O
previously O
been O
shown O
to O
improve O
arterial O
NUM O
tension O
( O
PaO2 O
) O
and O
to O
reduce O
alveolar O
- O
arterial O
NUM O
difference O
. O

Expression O
, O
nucleotide O
sequence O
and O
mutational O
analysis O
of O
two O
RARE O
reading O
frames O
in O
the O
RARE I-GENE
gene I-GENE
region I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
. I-GENE
RARE I-GENE
NUM I-GENE
. O

Further O
, O
they O
are O
consistent O
with O
the O
RARE O
that O
sites O
homologous O
to O
the O
NUM I-GENE
ALL_CAP I-GENE
may O
be O
situated O
in O
the O
5 O
'- O
flanking O
regions O
of O
multiple O
unrelated O
yeast O
genes O
. O

Our O
results O
suggest O
that O
a O
sequence O
match O
between O
RARE O
and O
certain O
promoter O
elements O
is O
critical O
. O

This O
Mr O
is O
similar O
to O
those O
of O
the O
RARE I-GENE
RARE I-GENE
NUM I-GENE
ALL_CAP I-GENE
estimated O
by O
RARE O
dodecyl O
RARE O
- O
polyacrylamide O
gel O
electrophoresis O
and O
sucrose O
density O
gradient O
RARE O
, O
which O
are O
about O
54 O
, O
NUM O
and O
65 O
, O
NUM O
, O
respectively O
. O

RARE O
mutants O
assigned O
to O
the O
RARE I-GENE
RARE O
group O
NUM O
were O
found O
to O
lack O
alpha I-GENE
- I-GENE
RARE I-GENE
dehydrogenase I-GENE
activity O
RARE O
a O
result O
of O
mutations O
in O
the O
RARE I-GENE
RARE I-GENE
( O
NUM I-GENE
) O
RARE O
of O
the O
complex O
. O

RARE O
residues O
required O
RARE O
repression O
are O
RARE O
within O
the O
C O
- O
terminal O
NUM O
amino O
RARE O
of O
c I-GENE
- I-GENE
Fos I-GENE
, O
since O
v I-GENE
- I-GENE
Fos I-GENE
and O
C O
- O
terminal O
RARE O
of O
c I-GENE
- I-GENE
Fos I-GENE
did O
not O
down O
regulate O
. O

We O
also O
discovered O
a O
V I-GENE
lambda I-GENE
RARE I-GENE
, O
called O
psi I-GENE
V I-GENE
lambda I-GENE
1 I-GENE
, O
3 O
kb O
upstream O
of O
the O
NUM I-GENE
lambda I-GENE
gene I-GENE
. O

In O
this O
paper O
, O
we O
have O
analyzed O
the O
RARE O
of O
human O
gene O
RARE O
RARE I-GENE
alpha I-GENE
, O
which O
spans O
more O
than O
NUM O
kilobases O
. O

A O
long O
follow O
- O
RARE O
study O
revealed O
that O
RARE O
RARE O
children O
still O
have O
the O
potency O
to O
have O
an O
immediate O
type O
hypersensitivity O
reaction O
on O
exposure O
to O
RARE O
antigen O
, O
with O
a O
high O
titer O
of O
RARE I-GENE
specific I-GENE
IgE I-GENE
in O
their O
RARE O
, O
but O
they O
are O
free O
from O
asthmatic O
attacks O
because O
of O
the O
reduction O
in O
the O
amount O
of O
RARE O
antigen O
in O
the O
body O
, O
RARE O
shown O
by O
the O
reduction O
in O
the O
amount O
of O
RARE I-GENE
specific I-GENE
IgG I-GENE
. O

RARE O
RARE O
influence O
was O
observed O
RARE O
lower O
concentrations O
than O
1 O
/ O
4 O
ALL_CAP O
of O
ALL_CAP O
. O

RARE O
of O
RARE O
NUM I-GENE
RARE O
prophylaxis O
of O
rejection O
and O
induction O
in O
initial O
RARE O
in O
RARE O
transplantation O
. O

RARE O
of O
RARE O
NUM O
RARE O
prophylaxis O
of O
rejection O
and O
induction O
in O
initial O
RARE O
in O
RARE O
transplantation O
. O

Furthermore O
, O
we O
RARE O
two O
RARE O
consensus O
motifs O
which O
are O
also O
found O
in O
corresponding O
positions O
in O
the O
genes O
RARE O
the O
nerve I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
and O
the O
NUM I-GENE
- I-GENE
kDa I-GENE
RARE I-GENE
protein I-GENE
. O

In O
addition O
, O
the O
- O
119 O
to O
- O
NUM O
fragment O
of O
the O
ALL_CAP I-GENE
promoter I-GENE
contains O
a O
transcriptional O
enhancer O
that O
potentiates O
the O
transcription O
from O
the O
herpes O
simplex O
virus O
RARE I-GENE
kinase I-GENE
promoter I-GENE
in O
a O
position O
- O
and O
orientation O
- O
independent O
manner O
. O

Thirty O
minutes O
of O
supine O
RARE O
decreased O
ALL_CAP O
concentrations O
in O
the O
median O
RARE O
of O
female O
rats O
that O
were O
not O
exposed O
to O
ether O
, O
and O
brief O
exposure O
to O
ether O
RARE O
this O
effect O
. O

Influence O
of O
RARE O
treatment O
on O
RARE O
- O
adrenal O
activation O
of O
RARE O
. O

Five O
of O
10 O
RARE O
studied O
decreased O
RARE O
least O
50 O
% O
in O
RARE O
dimensions O
. O

RARE O
RARE O
in O
a O
chronic O
care O
setting O
: O
an O
introduction O
. O

Gel O
- O
mobility O
- O
shift O
assays O
confirmed O
that O
the O
RARE O
nuclear O
proteins O
that O
RARE O
to O
ALL_CAP O
and O
V O
elements O
were O
RARE O
with O
by O
an O
HLA I-GENE
- I-GENE
ALL_CAP I-GENE
X I-GENE
- I-GENE
box I-GENE
RARE I-GENE
. O

In O
RARE O
only O
1 O
- O
3 O
cases O
of O
transfusion O
- O
associated O
hepatitis O
NANB O
( O
ALL_CAP O
- O
NANB O
) O
are O
RARE O
RARE O
or O
about O
1 O
case O
per O
NUM O
, O
NUM O
RARE O
RARE O
. O

The O
NF1 I-GENE
locus I-GENE
encodes O
a O
protein O
functionally O
related O
to O
mammalian I-GENE
ALL_CAP I-GENE
and O
yeast I-GENE
ALL_CAP I-GENE
proteins I-GENE
. O

Hence O
, O
the O
RARE O
of O
RARE O
- O
NUM O
with O
RARE O
specifically O
affects O
a O
determinant O
on O
the O
lambda I-GENE
I I-GENE
light I-GENE
chain I-GENE
that O
is O
necessary O
RARE O
the O
RARE O
RARE O
of O
this O
molecule O
. O

A O
second O
RARE O
of O
RARE I-GENE
immunoglobulin I-GENE
heavy I-GENE
chain I-GENE
genes I-GENE
has O
been O
detected O
by O
screening O
a O
RARE O
cDNA O
library O
with O
homologous O
RARE I-GENE
ALL_CAP I-GENE
- O
and O
NUM I-GENE
- O
specific O
RARE O
RARE O
the O
respective O
regions O
of O
the O
mu I-GENE
- I-GENE
like I-GENE
RARE I-GENE
. O

RARE O
, O
and O
S O
. O

Disruption O
of O
NUM I-GENE
causes O
RARE O
detectable O
RARE O
. O

Human O
recombinant O
DNA O
- O
derived O
RARE I-GENE
factor I-GENE
( O
factor I-GENE
VIII I-GENE
) O
in O
the O
treatment O
of O
RARE O
A O
. O
recombinant O
RARE I-GENE
VIII I-GENE
Study O
Group O
. O

Like O
other O
members O
of O
this O
family O
, O
the O
AP I-GENE
- I-GENE
4 I-GENE
ALL_CAP O
motif O
and O
the O
adjacent O
basic O
domain O
are O
necessary O
and O
sufficient O
to O
confer O
site O
- O
specific O
DNA O
binding O
. O

Furthermore O
, O
RARE O
of O
the O
promoter O
in O
RARE O
Drosophila O
melanogaster O
cells O
that O
lack O
NUM I-GENE
and O
NUM I-GENE
is O
strictly O
dependent O
on O
all O
three O
sites O
remaining O
RARE O
and O
on O
the O
presence O
of O
RARE O
supplied O
NUM I-GENE
and O
NUM I-GENE
. O

Effects O
of O
a O
selective O
RARE I-GENE
oxidase I-GENE
( I-GENE
MAO I-GENE
RARE I-GENE
A I-GENE
inhibitor O
, O
RARE O
, O
a O
selective O
MAO I-GENE
- I-GENE
B I-GENE
inhibitor O
, O
RARE O
, O
and O
a O
non O
- O
selective O
MAO I-GENE
inhibitor O
, O
RARE O
, O
were O
investigated O
on O
RARE O
- O
RARE O
aggression O
( O
ALL_CAP O
) O
in O
paired O
rats O
. O

To O
identify O
structural O
features O
of O
residues O
flanking O
the O
c O
- O
region O
that O
influence O
the O
RARE O
and O
efficiency O
of O
signal O
RARE O
RARE O
RARE O
RARE O
RARE O
RARE O
- O
translational O
translocation O
, O
we O
introduced O
RARE O
amino O
acid O
substitutions O
into O
the O
ALL_CAP O
terminus O
of O
the O
hydrophobic O
core O
and O
RARE O
substitutions O
RARE O
the O
NH2 O
terminus O
of O
the O
RARE O
region O
( O
the O
+ O
1 O
position O
) O
of O
a O
model O
eukaryotic I-GENE
RARE I-GENE
- I-GENE
human I-GENE
pre I-GENE
( I-GENE
delta I-GENE
pro I-GENE
) I-GENE
ALL_CAP I-GENE
- I-GENE
II I-GENE
. O

Additionally O
, O
although O
c I-GENE
- I-GENE
fos I-GENE
and O
RARE I-GENE
- I-GENE
1 I-GENE
mRNAs I-GENE
are O
RARE O
RARE O
elevated O
levels O
in O
RARE O
liver O
cells O
, O
fos I-GENE
- I-GENE
B I-GENE
, O
RARE I-GENE
- I-GENE
1 I-GENE
, O
and O
RARE I-GENE
- I-GENE
2 I-GENE
are O
not O
, O
which O
suggests O
that O
factors O
in O
addition O
to O
the O
serum I-GENE
response I-GENE
factor I-GENE
participate O
in O
the O
RARE O
of O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
induction O
. O

Of O
NUM O
patients O
, O
NUM O
cases O
with O
RARE O
description O
of O
patient O
' O
s O
background O
were O
evaluable O
: O
Group O
A O
( O
surgery O
+ O
MMC O
+ O
5 O
- O
FU O
: O
chemotherapy O
) O
NUM O
cases O
, O
group O
B O
( O
surgery O
+ O
MMC O
+ O
5 O
- O
FU O
+ O
ALL_CAP O
- O
NUM O
or O
ALL_CAP O
: O
RARE O
) O
NUM O
and O
group O
C O
( O
surgery O
alone O
) O
NUM O
. O

The O
nuclear O
proteins O
encoded O
by O
the O
c I-GENE
- I-GENE
fos I-GENE
and O
c I-GENE
- I-GENE
jun I-GENE
RARE I-GENE
are O
RARE O
RARE O
the O
RARE O
period O
of O
RARE O
RARE O
development O
. O

This O
model O
is O
further O
supported O
by O
binding O
of O
the O
Fos I-GENE
- O
Jun I-GENE
complex O
RARE O
an O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
in O
the O
type I-GENE
alpha I-GENE
I I-GENE
RARE I-GENE
promoter I-GENE
that O
is O
contiguous O
with O
, O
but O
not O
overlapping O
, O
the O
ALL_CAP O
. O

ALL_CAP I-GENE
is O
RARE O
by O
agents O
which O
elicit O
the O
ALL_CAP O
response O
. O

A O
RARE O
relapse O
requiring O
treatment O
occurred O
by O
5 O
years O
in O
16 O
. O
8 O
% O
of O
NUM O
NUM O
, O
5 O
. O
2 O
% O
of O
97 O
NUM O
, O
and O
20 O
. O
NUM O
% O
of O
NUM O
NUM O
patients O
with O
organisms O
RARE O
to O
RARE O
and O
RARE O
initially O
. O

In O
the O
controls O
, O
it O
was O
found O
that O
all O
right O
- O
RARE O
and O
10 O
out O
of O
14 O
RARE O
- O
RARE O
control O
subjects O
showed O
a O
right O
ALL_CAP O
( O
i O
. O
RARE O
., O
RARE O
hemisphere O
) O
advantage O
. O

Although O
RARE O
RARE I-GENE
- I-GENE
antibodies I-GENE
were O
RARE O
, O
a O
similar O
mechanism O
can O
be O
postulated O
RARE O
the O
RARE O
- O
RARE O
. O

The O
deduced O
amino O
acid O
sequence O
has O
the O
greatest O
homology O
( O
NUM O
%) O
to O
the O
RARE I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
. O

RARE O
fasting O
serum O
gastrin I-GENE
concentration O
( O
NUM O
. O
NUM O
+/- O
21 O
. O
1 O
RARE O
NUM O
. O
3 O
+/- O
8 O
. O
3 O
RARE O
. O
RARE O
- O
1 O
RARE O
and O
greater O
RARE O
gastrin I-GENE
release O
( O
NUM O
- O
120 O
: O
NUM O
+/- O
NUM O
RARE O
NUM O
+/- O
NUM O
RARE O
. O
RARE O
- O
1 O
min O
) O
were O
observed O
after O
ALL_CAP O
- O
ALL_CAP O
than O
after O
ALL_CAP O
- O
RARE O
. O

The O
experimental O
group O
consisted O
of O
NUM O
RARE O
class O
II O
/ O
2 O
RARE O
anomalies O
. O

This O
study O
was O
performed O
to O
clarify O
the O
location O
of O
a O
RARE O
echocardiographic O
( O
ALL_CAP O
) O
RARE O
when O
obtaining O
the O
short O
- O
axis O
view O
of O
the O
RARE O
ventricle O
( O
S O
- O
LV O
). O

RARE O
were O
16 O
male O
chronic O
RARE O
consisting O
of O
8 O
ALL_CAP O
suppressors O
and O
8 O
RARE O
. O

From O
NUM O
( O
CBF O
: O
NUM O
- O
NUM O
%) O
to O
NUM O
( O
CBF O
: O
NUM O
- O
NUM O
%), O
% O
RARE O
, O
1 O
/ O
ALL_CAP O
and O
1 O
/ O
T O
were O
significantly O
decreased O
from O
those O
of O
the O
control O
levels O
( O
all O
p O
less O
than O
NUM O
. O
01 O
). O

In O
this O
article O
we O
propose O
to O
find O
out O
the O
percentage O
of O
normal O
occlusion O
and O
the O
distribution O
of O
RARE O
, O
according O
to O
the O
anteroposterior O
relationship O
between O
the O
dental O
RARE O
( O
following O
the O
NUM O
classification O
). O

In O
that O
case O
, O
the O
ratio O
of O
RARE O
RARE O
was O
NUM O
. O
NUM O
, O
RARE O
and O
transverse O
strength O
, O
NUM O
. O
3 O
and O
NUM O
. O
3 O
RARE O
respectively O
, O
RARE O
, O
NUM O
. O
2 O
RARE O
, O
water O
absorption O
14 O
. O
2 O
micrograms O
/ O
NUM O
and O
thermal O
expansion O
coefficient O
, O
NUM O
. O
4 O
RARE O
10 O
RARE O
6 O
RARE O
degrees O
C O
. O

9 O
, O
NUM O
- O
NUM O
). O

In O
a O
highly O
select O
group O
of O
stable O
hypertensive O
patients O
, O
we O
have O
assessed O
the O
strength O
of O
association O
between O
various O
RARE O
pressure O
measurements O
( O
NUM O
h O
average O
automated O
ambulatory O
RARE O
pressure O
, O
4 O
h O
automated O
ambulatory O
RARE O
average O
RARE O
pressure O
, O
multiple O
RARE O
RARE O
average O
RARE O
pressure O
, O
and O
a O
single O
RARE O
RARE O
average O
RARE O
pressure O
) O
and O
various O
echocardiographic O
indices O
of O
hypertensive O
cardiac O
target O
organ O
damage O
( O
RARE O
RARE O
diameter O
, O
RARE O
ventricular O
end O
diastolic O
diameter O
, O
posterior O
RARE O
thickness O
, O
combined O
RARE O
thickness O
, O
relative O
RARE O
thickness O
, O
RARE O
ventricular O
mass O
and O
mass O
index O
, O
and O
combined O
RARE O
thickness O
/ O
RARE O
ventricular O
diastolic O
diameter O
ratio O
). O

We O
have O
previously O
identified O
, O
by O
screening O
a O
lambda O
gt11 O
RARE O
library O
, O
murine I-GENE
protein I-GENE
ALL_CAP I-GENE
, O
which O
binds O
to O
a O
sequence O
which O
RARE O
the O
3 O
' O
end O
of O
the O
murine I-GENE
class I-GENE
II I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
A I-GENE
alpha I-GENE
gene I-GENE
X I-GENE
box I-GENE
, O
a O
RARE O
transcription O
element O
found O
upstream O
of O
all O
class O
II O
genes O
. O

The O
NUM I-GENE
gene I-GENE
is O
RARE O
least O
NUM O
kb O
in O
length O
and O
has O
a O
coding O
sequence O
of O
RARE O
1 O
kb O
, O
representing O
only O
4 O
. O
5 O
% O
of O
the O
gene O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

This O
RARE O
treatment O
RARE O
locally O
advanced O
gynecologic O
tumors O
appears O
RARE O
with O
modification O
, O
and O
continued O
work O
RARE O
this O
approach O
is O
RARE O
. O

A O
contiguous O
and O
RARE O
occupied O
secondary O
Fur I-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
ALL_CAP I-GENE
was O
protected O
RARE O
RARE O
Fur I-GENE
concentrations O
, O
extending O
the O
protected O
region O
to O
+ O
NUM O
, O
and O
RARE O
the O
putative O
RARE O
- O
RARE O
sequence O
. O

The O
major O
promoter O
RARE O
strongly O
to O
virus O
- O
encoded O
RARE O
RARE O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
and O
contains O
four O
elements O
: O
a O
ALL_CAP O
motif O
analogous O
to O
the O
TATA O
box O
, O
two O
ALL_CAP I-GENE
sites I-GENE
present O
in O
an O
inverted O
orientation O
, O
and O
an O
ATF I-GENE
/ O
CREB I-GENE
site O
. O

With O
the O
modified O
RARE O
- O
to O
- O
RARE O
( O
ALL_CAP O
) O
method O
, O
patients O
RARE O
on O
a O
RARE O
and O
RARE O
RARE O
so O
that O
measurements O
can O
be O
taken O
on O
patients O
who O
are O
able O
to O
RARE O
the O
RARE O
or O
reach O
beyond O
the O
level O
of O
the O
RARE O
. O

No O
significant O
differences O
could O
be O
seen O
in O
response O
rates O
according O
to O
the O
concentration O
of O
estrogen I-GENE
receptors I-GENE
or O
presence O
of O
RARE I-GENE
receptors I-GENE
in O
this O
group O
of O
patients O
. O

RARE O
was O
given O
most O
often O
because O
of O
persistent O
fever O
or O
initial O
Gram O
- O
positive O
RARE O
and O
only O
one O
- O
third O
of O
these O
cases O
responded O
. O

RARE I-GENE
hormone I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
analog O
therapy O
of O
RARE O
RARE O
: O
analysis O
of O
results O
obtained O
with O
RARE O
administered O
RARE O
and O
RARE O
administered O
subcutaneously O
RARE O
a O
monthly O
RARE O
. O

In O
Experiments O
1 O
and O
2 O
, O
infants O
, O
like O
adults O
, O
initially O
RARE O
novel O
objects O
on O
the O
basis O
of O
physical O
appearance O
, O
but O
only O
if O
RARE O
with O
multiple O
RARE O
, O
after O
RARE O
of O
1 O
and O
7 O
days O
. O

The O
clinical O
picture O
of O
the O
RARE O
was O
significantly O
different O
from O
RARE O
cutaneous O
RARE O
caused O
by O
L O
. O
RARE O
but O
similar O
to O
cutaneous O
patterns O
caused O
by O
L O
. O
RARE O
which O
was O
a O
RARE O
pattern O
in O
the O
southern O
RARE O
. O

Although O
there O
are O
RARE O
octamer O
elements O
in O
the O
adenovirus O
genome O
that O
are O
known O
to O
be O
important O
RARE O
transcription O
, O
there O
are O
octamer O
elements O
in O
the O
viral O
terminal O
repeat O
sequences O
. O

In O
comparison O
with O
the O
16 O
RARE O
reported O
in O
NUM I-GENE
, O
NUM I-GENE
is O
missing O
one O
intron O
in O
the O
5 O
'- O
RARE O
region O
and O
a O
second O
intron O
in O
the O
C O
- O
terminal O
coding O
region O
. O

Northern O
blot O
analysis O
indicates O
that O
NUM I-GENE
mRNA I-GENE
relative O
to O
RARE O
cellular O
RNA O
is O
RARE O
RARE O
significantly O
RARE O
levels O
in O
root O
tissue O
RARE O
compared O
with O
RARE O
tissue O
. O

RARE O
of O
RARE O
tube O
in O
the O
abdominal O
RARE O
. O

Both O
RARE O
elevated O
the O
pain O
threshold O
RARE O
, O
while O
pretreatment O
with O
ALL_CAP O
largely O
blocked O
the O
analgesia O
. O

RARE O
. O

A O
needs O
assessment O
of O
these O
RARE O
was O
also O
done O
. O

TCR I-GENE
alpha I-GENE
and I-GENE
beta I-GENE
gene I-GENE
RARE O
may O
be O
regulated O
by O
a O
common O
set O
of O
T I-GENE
- I-GENE
cell I-GENE
nuclear I-GENE
proteins I-GENE
in O
that O
the O
T I-GENE
beta I-GENE
2 I-GENE
element I-GENE
binding O
a O
set O
of O
cyclic I-GENE
AMP I-GENE
response I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
that O
are O
also O
RARE O
by O
the O
T I-GENE
alpha I-GENE
1 I-GENE
element I-GENE
of O
the O
human O
TCR I-GENE
alpha I-GENE
enhancer O
and O
the O
RARE O
element O
present O
in O
a O
large O
number O
of O
human O
and O
murine O
TCR I-GENE
beta I-GENE
promoters O
. O

The O
3 O
' O
RARE O
- O
loop O
is O
highly O
divergent O
in O
RARE O
among O
species O
and O
lies O
immediately O
upstream O
of O
the O
binding O
site O
RARE O
RARE I-GENE
proteins I-GENE
. O

The O
RARE O
nucleotide O
sequence O
corresponded O
to O
sequences O
that O
, O
by O
RARE O
to O
the O
organization O
of O
the O
type I-GENE
I I-GENE
RARE I-GENE
genes I-GENE
, O
should O
be O
precisely O
encoded O
by O
RARE O
NUM O
of O
the O
NUM I-GENE
gene I-GENE
. O

These O
RARE O
account O
RARE O
the O
resistance O
of O
ALL_CAP O
- O
IV O
RARE I-GENE
to O
RARE O
bromide O
and O
mammalian I-GENE
RARE I-GENE
digestion O
. O

A O
4 O
. O
8 O
- O
RARE O
BamHI I-GENE
- O
HindIII I-GENE
fragment O
encoding O
the O
RARE I-GENE
Neurospora I-GENE
crassa I-GENE
RARE I-GENE
RARE I-GENE
dismutase I-GENE
gene I-GENE
( O
RARE O
designated O
RARE I-GENE
- I-GENE
1 I-GENE
) O
was O
isolated O
from O
a O
genomic O
library O
using O
two O
NUM O
- O
RARE O
RARE O
RARE O
corresponding O
to O
the O
published O
N O
. O
crassa O
amino O
acid O
sequence O
. O

Two O
other O
peptides O
, O
either O
partially O
or O
RARE O
RARE O
the O
basic O
region O
, O
but O
containing O
the O
RARE O
leucine O
zipper O
domain O
, O
readily O
form O
RARE O
but O
do O
not O
bind O
to O
the O
ALL_CAP O
. O

In O
contrast O
, O
the O
ALL_CAP O
of O
the O
human I-GENE
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
RARE O
RARE O
- O
NUM O
was O
weakly O
RARE O
by O
cAMP O
and O
E1a I-GENE
in O
both O
HeLa O
and O
PC12 O
cells O
. O

We O
have O
isolated O
and O
sequenced O
the O
gene O
encoding O
the O
human I-GENE
NUM I-GENE
- I-GENE
NUM I-GENE
snRNP I-GENE
protein I-GENE
. O

Although O
RARE O
this O
hypothesis O
is O
far O
from O
RARE O
all O
the O
clinical O
RARE O
, O
namely O
that O
RARE O
is O
equal O
in O
RARE O
and O
RARE O
, O
proximal O
and O
distal O
muscles O
. O

Using O
appropriate O
RARE O
HSE O
oligonucleotides O
, O
three O
RARE O
of O
RARE O
with O
RARE O
HSE O
binding O
domains O
were O
isolated O
from O
a O
RARE O
lambda O
gt11 O
RARE O
library O
by O
DNA O
- O
RARE O
screening O
. O

RARE O
( O
ALL_CAP O
) O
NUM O
. O

The O
results O
supported O
the O
therapeutic O
RARE O
of O
ALL_CAP O
: O
RARE O
patients O
according O
to O
their O
RARE O
patterns O
. O

The O
RARE I-GENE
gene I-GENE
is O
the O
major O
negative O
regulatory O
gene O
in O
the O
nitrogen O
control O
circuit O
of O
Neurospora O
crassa O
, O
which O
, O
together O
with O
positive O
regulatory O
genes O
, O
RARE O
the O
RARE O
of O
multiple O
RARE O
structural O
genes O
of O
the O
circuit O
. O

The O
4 O
days O
dexamethasone O
suppression O
test O
showed O
more O
than O
NUM O
% O
suppression O
of O
RARE O
- O
RARE O
and O
a O
RARE O
( O
40 O
- O
NUM O
%) O
reduction O
of O
testosterone O
and O
RARE O
levels O
. O

The O
ratio O
of O
P O
- O
NUM O
NMR O
- O
S O
derived O
inorganic O
RARE O
RARE O
RARE O
] O
to O
RARE O
RARE O
RARE O
] O
was O
significantly O
greater O
RARE O
rest O
in O
ALL_CAP O
RARE O
RARE O
NUM O
. O
53 O
+/- O
NUM O
. O
06 O
versus O
controls O
= O
NUM O
. O
NUM O
+/- O
NUM O
. O
NUM O
; O
P O
less O
than O
NUM O
. O
05 O
]. O

RARE O
necrosis O
associated O
with O
protein I-GENE
S I-GENE
deficiency O
. O

RARE O
study O

RARE O
cerebral O
RARE O
flow O
was O
measured O
using O
N O
- O
RARE O
- O
NUM O
- O
RARE O
with O
single O
- O
photon O
emission O
computed O
tomography O
( O
ALL_CAP O
) O
in O
16 O
aged O
patients O
with O
RARE O
- O
dependent O
diabetes O
mellitus O
( O
ALL_CAP O
, O
average O
age O
72 O
. O
8 O
years O
, O
average O
fasting O
plasma O
glucose O
7 O
. O
7 O
mmol O
/ O
L O
RARE O
and O
12 O
RARE O
subjects O
( O
NUM O
. O
6 O
years O
, O
5 O
. O
3 O
mmol O
/ O
L O
). O

Mean O
ALL_CAP O
- O
A O
/ O
B O
ratio O
was O
NUM O
. O
6 O
+/- O
1 O
. O
7 O
% O
in O
the O
diabetic O
group O
, O
significantly O
lower O
than O
the O
57 O
. O
9 O
+/- O
1 O
. O
6 O
% O
RARE O
the O
RARE O
group O
( O
p O
less O
than O
NUM O
. O
005 O
). O

These O
data O
strongly O
RARE O
the O
normal O
product O
of O
the O
int I-GENE
- I-GENE
2 I-GENE
gene I-GENE
, O
which O
is O
related O
to O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
family I-GENE
, O
RARE O
a O
RARE O
factor O
in O
RARE O
RARE O
mammary O
tumors O
. O

This O
result O
indicates O
that O
separate O
complexes O
exist O
containing O
RARE I-GENE
and O
RARE I-GENE
with O
either O
RARE I-GENE
or O
RARE I-GENE
RARE I-GENE
K I-GENE
RARE I-GENE
ATPase I-GENE
. O

These O
genes O
are O
RARE O
within O
a O
few O
hours O
of O
the O
initiation O
of O
development O
; O
their O
mRNAs O
accumulate O
to O
a O
peak O
RARE O
12 O
hr O
and O
RARE O
until O
RARE O
. O

The O
NUM I-GENE
protein I-GENE
also O
shows O
great O
RARE O
to O
the O
incomplete O
NH2 O
- O
terminal O
sequence O
of O
the O
human I-GENE
RARE I-GENE
gene I-GENE
product I-GENE
, O
a O
putative O
membrane O
- O
inserted O
receptor O
- O
like O
molecule O
. O

RARE O
or O
not O
there O
are O
sequences O
conferring O
cAMP O
responsiveness O
which O
are O
common O
both O
to O
P I-GENE
- I-GENE
NUM I-GENE
and O
the O
other O
RARE O
P I-GENE
- I-GENE
NUM I-GENE
genes I-GENE
remains O
to O
be O
established O
. O

In O
this O
study O
, O
we O
used O
footprinting O
and O
gel O
mobility O
retardation O
assays O
to O
reveal O
that O
bacterially O
synthesized O
Zta I-GENE
fusion I-GENE
proteins I-GENE
RARE O
directly O
to O
RARE O
ALL_CAP O
- O
like O
motifs O
within O
ALL_CAP I-GENE
. O

The O
RARE I-GENE
RARE I-GENE
involved O
in O
induction O
of O
lytic O
RARE O
gene O
RARE O
in O
Epstein O
- O
Barr O
virus O
- O
RARE O
lymphocytes O
binds O
to O
both O
AP I-GENE
- I-GENE
1 I-GENE
and O
ALL_CAP I-GENE
sites I-GENE
in O
target O
promoter O
and O
enhancer O
regions O
. O

It O
is O
the O
human O
homolog O
of O
the O
mouse I-GENE
RARE I-GENE
protein I-GENE
involved O
in O
resistance O
to O
RARE O
virus O
. O

RARE O
containing O
the O
21 O
- O
RARE O
- O
RARE O
repeat O
region O
, O
the O
enhancer I-GENE
of I-GENE
simian I-GENE
virus I-GENE
40 I-GENE
or O
both O
strongly O
RARE O
beta I-GENE
- I-GENE
galactosidase I-GENE
RARE O
, O
and O
three O
fragments O
from O
the O
RARE I-GENE
enhancer I-GENE
region I-GENE
RARE O
moderate O
levels O
. O

The O
sites O
targeted O
RARE O
mutagenesis O
, O
residues O
NUM O
, O
NUM O
, O
and O
NUM O
, O
are O
RARE O
within O
a O
putative O
helical O
loop O
RARE O
which O
may O
be O
involved O
in O
substrate O
recognition O
by O
the O
enzyme O
. O

The O
possible O
benefits O
of O
ALL_CAP O
RARE O
( O
RARE O
frequency O
of O
bleeding O
, O
RARE O
of O
RARE O
) O
were O
not O
, O
however O
, O
apparent O
, O
possibly O
because O
of O
the O
short O
observation O
period O
and O
the O
low O
incidence O
of O
hemorrhagic O
complications O
in O
routine O
RARE O
. O

The O
deduced O
amino O
acid O
sequence O
of O
RARE I-GENE
is O
165 O
residues O
long O
and O
is O
very O
similar O
( O
NUM O
% O
identical O
) O
to O
that O
of O
RARE I-GENE
, O
a O
widely O
distributed O
, O
pH O
- O
RARE O
actin I-GENE
- O
RARE O
protein O
. O

RARE O
, O
RARE O
NUM O
: O
NUM O
- O
NUM O
, O
NUM O
). O

With O
only O
RARE O
T I-GENE
antigen I-GENE
in O
the O
presence O
of O
topoisomerase I-GENE
I I-GENE
to O
RARE O
RARE O
DNA O
, O
RARE O
- O
RARE O
sequences O
strongly O
facilitated O
T I-GENE
- I-GENE
antigen I-GENE
- O
dependent O
DNA O
conformational O
changes O
consistent O
with O
RARE O
the O
RARE O
50 O
RARE O
RARE O
. O

A O
RARE O
RARE O
was O
raised O
against O
a O
RARE O
peptide O
corresponding O
to O
a O
hydrophilic O
portion O
of O
the O
translated O
murine O
cDNA O
sequence O
. O

RARE O
of O
function O
of O
Drosophila I-GENE
melanogaster I-GENE
abl I-GENE
and O
murine I-GENE
v I-GENE
- I-GENE
abl I-GENE
proteins I-GENE
in O
transformation O
of O
mammalian O
cells O
. O

In O
transient O
cotransfection O
assays O
using O
RARE O
liver O
cells O
( O
ALL_CAP O
NUM O
RARE O
NUM O
DNA O
exerts O
a O
6 O
- O
to O
10 O
- O
RARE O
RARE O
- O
activating O
effect O
on O
the O
RARE O
of O
the O
NUM O
reporter O
RARE O
. O

We O
have O
determined O
the O
nucleotide O
( O
nt O
) O
sequence O
of O
the O
7 I-GENE
. I-GENE
5 I-GENE
- I-GENE
kb I-GENE
ALL_CAP I-GENE
segment I-GENE
that O
RARE O
a O
cluster O
of O
RARE O
genes O
( O
CYC1 I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
tRNA I-GENE
( I-GENE
RARE I-GENE
) I-GENE
and O
NUM I-GENE
) O
RARE O
on O
RARE O
X O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

Specific O
binding O
of O
the O
protein O
factors O
to O
the O
sites O
, O
possibly O
to O
the O
three O
RARE O
sequences O
, O
may O
play O
an O
important O
role O
in O
the O
coordinate O
RARE O
of O
the O
transcription O
of O
nuclear O
genes O
encoding O
subunits O
responsible O
RARE O
mitochondrial O
oxidative O
RARE O
. O

This O
points O
to O
a O
specific O
interference O
with O
HSV O
- O
RARE O
DNA O
amplification O
. O

No O
RARE O
signal O
sequences O
have O
been O
found O
contiguous O
to O
the O
RARE O
point O
. O

The O
RARE O
properties O
, O
RARE O
measured O
by O
the O
RARE O
- O
RARE O
and O
hot O
- O
RARE O
tests O
, O
and O
the O
motor O
effects O
of O
an O
RARE O
- O
administered O
RARE O
agonist O
midazolam O
, O
alone O
, O
and O
in O
combination O
with O
RARE O
, O
was O
examined O
in O
rats O
. O

RARE O
were O
made O
in O
which O
an O
ALL_CAP O
and O
the O
ALL_CAP O
- O
rich O
region O
were O
separated O
by O
various O
distances O
ranging O
from O
7 O
to O
NUM O
bp O
. O

To O
address O
this O
RARE O
, O
the O
gene O
RARE O
factor I-GENE
Y I-GENE
has O
been O
RARE O
molecularly O
and O
its O
DNA O
sequence O
has O
been O
determined O
. O

We O
RARE O
and O
sequenced O
the O
cDNAs O
against O
genomic O
RNA O
and O
mRNA O
RARE O
RARE I-GENE
( I-GENE
P I-GENE
) I-GENE
of O
human O
RARE O
type O
2 O
virus O
( O
ALL_CAP O
- O
2 O
). O
cDNA O
clone O
from O
genomic O
RNA O
was O
NUM O
nucleotides O
in O
length O
excluding O
RARE O
( O
A O
) O
and O
was O
found O
to O
have O
two O
small O
RARE O
reading O
frames O
encoding O
proteins O
of O
NUM O
and O
NUM O
amino O
RARE O
. O

We O
show O
that O
ALL_CAP I-GENE
RARE O
is O
negatively O
RARE O
by O
the O
ALL_CAP I-GENE
protein I-GENE
and O
positively O
affected O
by O
the O
cAMP I-GENE
/ I-GENE
ALL_CAP I-GENE
complex I-GENE
. O

To O
identify O
these O
sites O
, O
the O
deduced O
amino O
acid O
sequence O
of O
the O
3T3 O
- O
L1 O
RARE I-GENE
insulin I-GENE
receptor I-GENE
of O
the O
mouse O
was O
determined O
. O

ALL_CAP O
blocks O
turnover O
of O
the O
RARE O
group O
of O
NUM I-GENE
, O
causing O
its O
accumulation O
, O
and O
thereby O
appears O
to O
RARE O
signal O
RARE O
from O
the O
receptor O
to O
the O
glucose O
- O
RARE O
RARE O
. O

It O
is O
likely O
that O
the O
sequence O
similarities O
reflect O
a O
common O
RARE O
architecture O
of O
the O
two O
heme O
binding O
sites O
and O
of O
a O
RARE O
binding O
site O
in O
these O
RARE O
. O

The O
cDNA O
sequence O
has O
an O
NUM O
- O
bp O
RARE O
reading O
frame O
( O
ORF O
) O
whose O
predicted O
amino O
acid O
sequence O
is O
97 O
. O
6 O
% O
identical O
to O
the O
272 O
RARE O
- O
terminal O
amino O
RARE O
of O
the O
human I-GENE
ets I-GENE
- I-GENE
1 I-GENE
protein I-GENE
. O

To O
characterize O
the O
NUM I-GENE
- I-GENE
ALL_CAP I-GENE
region I-GENE
, O
the O
recombinant O
RARE O
NUM O
and O
NUM O
were O
RARE O
by O
RARE O
mutagenesis O
with O
NUM I-GENE
, O
which O
carries O
a O
promoterless O
lac I-GENE
operon I-GENE
and O
can O
therefore O
generate O
lacZ I-GENE
transcriptional O
fusions O
with O
target O
DNA O
sequences O
. O

The O
ALL_CAP I-GENE
gene I-GENE
RARE O
the O
ALL_CAP I-GENE
operon I-GENE
in I-GENE
Bacillus I-GENE
subtilis I-GENE
shares O
strong O
homology O
with O
transcriptional O
RARE O
. O

The O
ALL_CAP I-GENE
protein I-GENE
( I-GENE
NUM I-GENE
, I-GENE
NUM I-GENE
RARE I-GENE
) I-GENE
contains O
three O
hydrophobic O
regions O
, O
of O
which O
two O
are O
RARE O
near O
the O
amino O
- O
terminal O
region O
. O

The O
protein O
product O
of O
ALL_CAP I-GENE
, O
which O
is O
probably O
a O
new O
RARE I-GENE
gene I-GENE
( O
named O
ALL_CAP I-GENE
RARE O
contains O
65 O
% O
hydrophobic O
amino O
RARE O
, O
especially O
rich O
in O
alanine O
and O
leucine O
. O

Various O
mutant I-GENE
ALL_CAP I-GENE
genes I-GENE
were O
constructed O
to O
examine O
the O
role O
of O
residues O
flanking O
the O
signal O
- O
RARE O
domain O
, O
including O
the O
cytoplasmic O
RARE O
, O
on O
assembly O
and O
RARE O
RARE O
of O
the O
ALL_CAP I-GENE
glycoprotein I-GENE
. O

Our O
studies O
extend O
these O
findings O
and O
show O
that O
the O
E2 I-GENE
RARE I-GENE
gene I-GENE
is O
RARE O
from O
multiple O
promoters O
. O

Furthermore O
, O
analysis O
of O
the O
E2 I-GENE
proteins I-GENE
present O
in O
various O
cell O
lines O
harboring O
specific O
ALL_CAP O
- O
1 O
mutants O
, O
including O
the O
NUM O
RARE O
mutant O
, O
RARE O
that O
alternate O
modes O
of O
E2 I-GENE
RARE O
exist O
. O

Disruption O
of O
the O
NUM I-GENE
gene I-GENE
resulted O
in O
( O
i O
) O
increased O
sensitivity O
to O
heat O
shock O
and O
nitrogen O
starvation O
, O
( O
ii O
) O
RARE O
defects O
, O
and O
( O
iii O
) O
suppression O
of O
the O
lethality O
of O
the O
NUM I-GENE
mutant I-GENE
. O

This O
cohort O
of O
patients O
was O
RARE O
on O
the O
basis O
of O
clinical O
RARE O
. O

A O
gene O
in O
Drosophila O
melanogaster O
that O
maps O
RARE O
to O
NUM O
- O
3 O
on O
the O
distal O
portion O
of O
the O
X O
- O
RARE O
encodes O
a O
RARE O
of O
the O
steroid I-GENE
/ I-GENE
thyroid I-GENE
hormone I-GENE
receptor I-GENE
superfamily I-GENE
. O

A O
portion O
of O
RARE O
II O
also O
resembles O
part O
of O
the O
human O
c I-GENE
- I-GENE
jun I-GENE
RARE O
' O
s O
leucine O
zipper O
, O
which O
in O
RARE O
, O
has O
been O
demonstrated O
to O
be O
the O
heterodimerization O
site O
between O
the O
jun I-GENE
and O
fos I-GENE
RARE I-GENE
. O

To O
determine O
whether O
RARE O
could O
inhibit O
PEPCK I-GENE
gene I-GENE
transcription O
, O
a O
series O
of O
chimeric O
genes O
containing O
several O
deletions O
in O
the O
P I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
promoter I-GENE
between O
- O
NUM O
and O
- O
NUM O
was O
RARE O
to O
the O
structural O
genes O
RARE O
either O
amino I-GENE
- I-GENE
3 I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
( O
RARE I-GENE
) O
or O
chloramphenicol I-GENE
RARE I-GENE
and O
introduced O
into O
hepatoma O
cells O
using O
three O
methods O
: O
( O
a O
) O
infection O
with O
a O
Moloney O
murine O
leukemia O
virus O
- O
based O
RARE O
, O
( O
b O
) O
transfection O
and O
stable O
selection O
RARE O
RARE I-GENE
RARE O
, O
or O
( O
c O
) O
transient O
RARE O
of O
RARE I-GENE
RARE I-GENE
. O

The O
diagnosis O
of O
RARE O
tuberculosis O
should O
be O
systematically O
considered O
in O
ARDS O
of O
unknown O
origin O
. O

In O
order O
to O
characterize O
the O
RARE O
elements O
of O
the O
promoter O
that O
in O
some O
way O
must O
respond O
to O
these O
regulatory O
signals O
, O
a O
number O
of O
promoter O
mutations O
were O
constructed O
, O
including O
a O
set O
of O
RARE O
- O
scanning O
mutations O
across O
the O
RARE O
promoter O
region O
. O

A O
DNA O
motif O
related O
to O
the O
cAMP O
- O
responsive O
element O
and O
an O
RARE I-GENE
- I-GENE
RARE I-GENE
activator I-GENE
protein I-GENE
- I-GENE
2 I-GENE
binding I-GENE
site I-GENE
in O
the O
human I-GENE
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
gene I-GENE
promoter I-GENE
cooperate O
in O
basal O
RARE O
and O
RARE O
activation O
by O
phorbol O
ester O
and O
cAMP O
. O

The O
NUM I-GENE
rRNA I-GENE
binding I-GENE
ribosomal I-GENE
protein I-GENE
equivalent O
to O
bacterial I-GENE
protein I-GENE
NUM I-GENE
is O
encoded O
by O
unspliced O
duplicated O
genes O
in O
Saccharomyces O
cerevisiae O
. O

Five O
healthy O
male O
subjects O
RARE O
air O
RARE O
20 O
min O
and O
then O
5 O
% O
CO2 O
/ O
NUM O
% O
NUM O
RARE O
NUM O
min O
, O
of O
which O
the O
RARE O
10 O
min O
was O
used O
to O
achieve O
a O
steady O
- O
state O
end O
- O
tidal O
CO2 O
measurement O
. O

Significant O
correlations O
were O
obtained O
between O
changes O
in O
ALL_CAP O
in O
response O
to O
ALL_CAP O
and O
the O
presence O
of O
not O
deep O
residual O
- O
organic O
disturbances O
, O
so O
- O
called O
" O
RARE O
" O
in O
RARE O
disorders O
. O

The O
transcripts O
were O
equally O
RARE O
with O
or O
without O
a O
5 O
' O
RARE O
RARE O
RARE O
expected O
, O
since O
ALL_CAP O
- O
RNA O
is O
one O
of O
the O
mRNAs O
capable O
of O
internal O
initiation O
. O

The O
NUM I-GENE
/ O
E7 I-GENE
promoter O
of O
all O
RARE O
human O
RARE O
is O
responsible O
RARE O
RARE O
of O
the O
viral O
transforming O
genes O
. O

A O
case O
of O
RARE O
' O
s O
RARE O
. O

Seventy O
- O
two O
of O
NUM O
negative O
controls O
and O
all O
positive O
blocks O
RARE O
seen O
on O
soft O
tissue O
radiographs O
( O
RARE O
) O
were O
correctly O
coded O
( O
RARE O
98 O
. O
6 O
%, O
sensitivity O
NUM O
%). O

No O
symptomatic O
abnormality O
has O
been O
noted O
in O
the O
neonatal O
period O
except O
RARE O
RARE O
. O

RARE O
analysis O
of O
several O
rat O
organs O
also O
showed O
staining O
in O
RARE O
cells O
. O

Both O
strains O
RARE O
very O
poorly O
, O
or O
not O
RARE O
all O
, O
on O
RARE O
carbon O
sources O
and O
exhibited O
, O
RARE O
most O
, O
only O
5 O
% O
of O
wild I-GENE
- I-GENE
type I-GENE
RARE I-GENE
- I-GENE
cytochrome I-GENE
c I-GENE
oxidoreductase I-GENE
activity O
. O

Regulation O
of O
ALL_CAP I-GENE
by O
iron O
in O
V O
. O
RARE O
occurs O
RARE O
the O
transcriptional O
level O
, O
and O
there O
is O
an O
interrupted O
RARE O
RARE O
sequence O
in O
the O
vicinity O
of O
the O
promoter O
that O
is O
homologous O
to O
Fur I-GENE
binding I-GENE
sites I-GENE
of O
E O
. O
coli O
. O

Transcription O
of O
the O
RARE O
operon O
coding O
RARE O
m O
- O
xylene O
- O
RARE O
RARE O
on O
the O
ALL_CAP O
RARE O
of O
RARE O
RARE O
is O
activated O
by O
the O
ALL_CAP I-GENE
gene I-GENE
product I-GENE
in O
the O
presence O
of O
m O
- O
xylene O
. O

The O
recombinant O
contains O
the O
normal O
beta I-GENE
A I-GENE
- I-GENE
globin I-GENE
gene I-GENE
, O
the O
mutant O
gene O
and O
RARE O
vector O
sequences O
between O
the O
two O
copies O
. O

Some O
of O
the O
mutations O
obtained O
do O
not O
contain O
a O
copy O
of O
the O
RARE I-GENE
element I-GENE
RARE O
the O
mutant O
locus O
, O
suggesting O
that O
a O
different O
RARE O
element O
may O
be O
responsible O
RARE O
the O
mutation O
. O

Determination O
of O
RARE O
in O
biological O
materials O
by O
electron O
spin O
resonance O
spectroscopy O
. O

We O
show O
also O
that O
ALL_CAP O
represses O
the O
transcriptional O
activity O
of O
a O
reporter O
gene O
containing O
a O
ALL_CAP O
responding O
AP1 I-GENE
binding I-GENE
site I-GENE
RARE O
the O
HSV I-GENE
tk I-GENE
promoter I-GENE
. O

Moreover O
, O
radiolabeled O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
- I-GENE
Y I-GENE
, O
or O
CBF I-GENE
RARE I-GENE
give O
rise O
to O
identical O
gel O
retardation O
patterns O
in O
extracts O
from O
a O
variety O
of O
different O
cell O
RARE O
. O

Risk O
factors O
influencing O
lymph O
nodes O
metastasis O
in O
RARE O
RARE O
with O
RARE O
I O
, O
II O
or O
ALL_CAP O

RARE I-GENE
protein I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
phosphorylates O
ATP I-GENE
- I-GENE
RARE I-GENE
lyase I-GENE
on O
peptide I-GENE
B I-GENE
on O
two O
sites O
, O
ALL_CAP O
and O
ALL_CAP O
, O
on O
threonine O
and O
serine O
, O
respectively O
, O
inhibitor I-GENE
2 I-GENE
on O
a O
RARE O
RARE O
, O
and O
RARE I-GENE
synthase I-GENE
RARE O
sites O
2 O
and O
3 O
. O

The O
characterized O
Y I-GENE
' I-GENE
RARE I-GENE
sequence I-GENE
RARE I-GENE
provide O
an O
experimental O
RARE O
in O
which O
RARE O
sequence O
interactions O
and O
subsequent O
evolution O
can O
be O
studied O
. O

The O
electrically O
RARE O
RARE O
responses O
were O
not O
suppressed O
in O
the O
presence O
of O
RARE O
or O
RARE O
B O
. O

Unlike O
NUM I-GENE
- O
RARE I-GENE
, O
which O
is O
a O
nuclear O
protein O
in O
ALL_CAP O
, O
indirect O
immunofluorescence O
showed O
that O
NUM I-GENE
- O
RARE I-GENE
in O
NUM O
- O
RARE O
RARE O
ALL_CAP O
is O
RARE O
exclusively O
in O
the O
cytoplasm O
of O
these O
cells O
, O
even O
though O
the O
sequence O
of O
NUM I-GENE
- O
RARE I-GENE
showed O
that O
it O
contains O
a O
nuclear O
RARE O
sequence O
identical O
to O
the O
one O
previously O
identified O
in O
NUM I-GENE
- O
RARE I-GENE
. O

RARE O
experiments O
revealed O
that O
within O
10 O
min O
this O
radiolabeled O
precursor O
protein O
was O
converted O
in O
ALL_CAP O
- O
NUM O
cells O
into O
an O
Mr O
RARE O
NUM O
, O
NUM O
RARE O
RARE O
RARE O
RARE O
. O

RARE O
flow O
and O
velocity O
( O
measured O
using O
Doppler O
ultrasound O
) O
gradually O
decreased O
RARE O
RARE O
and O
RARE O
reversed O
in O
direction O
RARE O
RARE O
resistance O
was O
increased O
RARE O
to O
14 O
RARE O
. O

A O
RARE O
of O
112 O
patients O
received O
RARE O
and O
119 O
received O
RARE O
within O
a O
mean O
period O
of O
NUM O
+/- O
NUM O
min O
following O
the O
onset O
of O
symptoms O
. O

However O
, O
RARE O
transcripts O
of O
a O
variant I-GENE
tRNA I-GENE
( I-GENE
RARE I-GENE
)( I-GENE
ALL_CAP I-GENE
) I-GENE
gene I-GENE
are O
RARE O
RARE O
under O
standard O
growth O
conditions O
( O
NUM O
degrees O
C O
RARE O
due O
to O
a O
slightly O
altered O
5 O
' O
flanking O
region O
. O

The O
promoter O
activity O
was O
measured O
by O
a O
transient O
RARE O
of O
a O
chloramphenicol I-GENE
RARE I-GENE
( O
CAT I-GENE
) O
gene O
connected O
with O
various O
5 O
'- O
deletion O
mutants O
of O
the O
5 O
'- O
flanking O
region O
. O

Three O
of O
the O
short O
RARE O
in O
the O
central O
region O
of O
ALL_CAP O
have O
been O
identified O
by O
location O
and O
structural O
RARE O
to O
the O
RARE O
/ O
regulatory O
genes O
( O
RARE I-GENE
, O
tat I-GENE
, O
and O
RARE I-GENE
) O
of O
other O
RARE O
; O
we O
also O
discovered O
two O
unique O
RARE O
, O
termed O
ALL_CAP O
and O
Y O
, O
which O
may O
serve O
RARE O
exons O
RARE O
novel O
genes O
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
NUM I-GENE
gene I-GENE
, O
encoding O
cytochrome I-GENE
P450 I-GENE
RARE I-GENE
14 I-GENE
alpha I-GENE
- I-GENE
RARE I-GENE
( O
NUM I-GENE
RARE O
was O
overexpressed O
in O
various O
S O
. O
cerevisiae O
strains O
under O
the O
control O
of O
three O
strong O
heterologous O
yeast O
transcription O
promoters O
( O
NUM I-GENE
, O
ALL_CAP I-GENE
, O
NUM I-GENE
) O
and O
under O
the O
control O
of O
its O
own O
promoter O
. O

RARE O
composed O
of O
NUM O
and O
NUM O
amino O
RARE O
were O
RARE O
across O
the O
endoplasmic O
reticulum O
membrane O
, O
and O
translocation O
was O
found O
to O
be O
strictly O
RARE O
- O
translational O
and O
SRP I-GENE
- O
dependent O
. O

RARE O
vascular O
resistance O
was O
not O
altered O
, O
ejection O
fraction O
remained O
unchanged O
and O
RARE O
relaxation O
period O
was O
RARE O
( O
119 O
+/- O
20 O
. O
1 O
to O
NUM O
. O
NUM O
+/- O
21 O
. O
NUM O
, O
P O
less O
than O
NUM O
. O
05 O
). O

The O
NUM I-GENE
locus I-GENE
of O
Saccharomyces O
cerevisiae O
encodes O
the O
protein I-GENE
RARE I-GENE
initiation I-GENE
factor I-GENE
eIF I-GENE
- I-GENE
NUM I-GENE
. O

The O
contribution O
that O
RARE O
RARE O
events O
in O
c I-GENE
- I-GENE
myb I-GENE
RARE O
may O
make O
on O
c I-GENE
- I-GENE
myb I-GENE
function O
remains O
to O
be O
RARE O
. O

Serum I-GENE
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
levels O
( O
beta I-GENE
- I-GENE
2 I-GENE
- I-GENE
M I-GENE
) O
were O
studied O
in O
NUM O
drug O
addicts O
, O
50 O
of O
them O
asymptomatic O
carriers O
of O
anti I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
antibodies I-GENE
, O
50 O
symptomatic O
carriers O
with O
persistent O
generalized O
RARE O
( O
P O
. O
G O
. O
L O
.) O
and O
50 O
serum O
negative O
patients O
who O
had O
been O
living O
in O
a O
closed O
community O
RARE O
RARE O
least O
2 O
years O
. O

This O
RARE O
of O
the O
ability O
to O
RARE O
from O
hormonal O
influence O
makes O
female O
sexual O
RARE O
the O
RARE O
regulator O
of O
RARE O
in O
primates O
. O

No O
therapy O
exists O
RARE O
RARE O
the O
progression O
of O
the O
RARE O
with O
the O
possible O
exception O
of O
laser O
RARE O
treatment O
used O
to O
RARE O
subretinal O
RARE O
membranes O
in O
an O
attempt O
to O
avoid O
complications O
of O
subretinal O
RARE O
. O

R O
. O

Specific O
RARE I-GENE
RARE I-GENE
to O
pathogens O
such O
RARE O
Haemophilus O
influenzae O
and O
RARE O
RARE O
have O
also O
been O
studied O
. O

RARE O
effects O
of O
RARE O
( O
HR O
NUM O
) O
on O
experimental O
mixed O
infections O
with O
RARE O
RARE O
and O
Escherichia O
coli O
in O
mice O
. O

Regulation O
of O
yeast I-GENE
LEU2 I-GENE
. O

Homozygous O
individuals O
usually O
develop O
purpura O
RARE O
RARE O
newborns O
; O
RARE O
protein I-GENE
C I-GENE
- O
RARE O
individuals O
are O
RARE O
increased O
risk O
RARE O
venous O
thrombosis O
and O
pulmonary O
RARE O
. O

Ischemic O
stroke O
due O
to O
protein I-GENE
C I-GENE
deficiency O
. O

NUM I-GENE
and O
NUM I-GENE
protected O
all O
three O
repeats O
of O
the O
21 O
bp O
, O
but O
NUM I-GENE
protected O
only O
the O
second O
repeat O
. O

These O
results O
suggest O
that O
5 O
ALL_CAP O
X O
3 O
/ O
ALL_CAP O
may O
be O
the O
optimal O
regimen O
to O
RARE O
the O
RARE O
RARE O
of O
ALL_CAP O
. O

Analysis O
of O
various O
deletion O
mutants O
indicates O
that O
the O
sequence O
requirements O
RARE O
binding O
by O
ALL_CAP I-GENE
in O
vitro O
are O
indistinguishable O
from O
those O
necessary O
RARE O
ALL_CAP O
activity O
in O
vivo O
, O
strongly O
suggesting O
that O
ALL_CAP I-GENE
is O
required O
RARE O
the O
function O
of O
this O
TATA O
- O
independent O
promoter O
. O

Since O
RARE I-GENE
regulatory I-GENE
factor I-GENE
I I-GENE
( O
ALL_CAP I-GENE
RARE O
repressor I-GENE
/ I-GENE
activator I-GENE
site I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
( O
NUM I-GENE
RARE O
translation I-GENE
upstream I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
) O
is O
believed O
to O
be O
an O
activator O
of O
ALL_CAP I-GENE
alpha I-GENE
RARE O
, O
we O
examined O
whether O
NUM I-GENE
, O
which O
is O
known O
to O
be O
regulated O
by O
ALL_CAP I-GENE
/ O
NUM I-GENE
/ O
ALL_CAP I-GENE
, O
is O
also O
affected O
by O
the O
NUM I-GENE
mutation I-GENE
. O

RARE I-GENE
NUM I-GENE
protein I-GENE
mediates O
the O
transcriptional O
activation O
signal O
of O
two O
different O
RARE O
factors O
, O
Gal4 I-GENE
and O
RARE I-GENE
regulatory I-GENE
factor I-GENE
I I-GENE
/ O
repressor I-GENE
/ I-GENE
activator I-GENE
site I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
/ I-GENE
translation I-GENE
upstream I-GENE
factor I-GENE
. O

Deletion O
from O
either O
the O
N O
- O
or O
C O
- O
terminal O
ends O
of O
ALL_CAP I-GENE
( O
NUM O
and O
NUM O
codons O
, O
respectively O
, O
out O
of O
the O
NUM O
- O
RARE O
RARE O
reading O
frame O
) O
affected O
the O
RARE O
but O
not O
the O
RARE O
activity O
. O

The O
two O
larger O
peptides O
, O
one O
containing O
amino O
RARE O
1 O
- O
NUM O
and O
the O
other O
containing O
amino O
RARE O
NUM O
- O
NUM O
, O
formed O
RARE O
in O
solution O
and O
RARE O
DNA O
specifically O
RARE O
a O
RARE O
. O

In O
vitro O
transcription O
extracts O
from O
NUM I-GENE
- I-GENE
1 I-GENE
cells O
terminate O
less O
efficiently O
RARE O
weak O
transcription O
RARE O
signals O
than O
those O
from O
NUM I-GENE
cells O
, O
using O
a O
variety O
of O
tRNA O
templates O
. O

RARE O
patients O
in O
the O
RARE O
should O
involve O
a O
RARE O
RARE O
composed O
of O
a O
surgical O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
and O
RARE O
RARE O
. O

IgG I-GENE
and O
IgM I-GENE
antibody O
activity O
was O
determined O
by O
adding O
a O
1 O
: O
NUM O
dilution O
of O
serum O
to O
plates O
RARE O
with O
NUM I-GENE
antigen I-GENE
. O

These O
factors O
belong O
to O
a O
set O
of O
genetically O
distinct O
molecules O
, O
including O
AP I-GENE
- I-GENE
4 I-GENE
and O
ALL_CAP I-GENE
, O
that O
bind O
to O
the O
ALL_CAP O
motif O
or O
related O
sequences O
. O

Among O
known O
RARE O
larvae O
, O
the O
genus O
RARE O
( O
RARE O
, O
RARE O
) O
is O
RARE O
distinctive O
in O
RARE O
form O
RARE O
are O
the O
adults O
. O

Here O
, O
we O
have O
used O
specific O
antibody O
to O
identify O
and O
characterize O
the O
NUM I-GENE
protein I-GENE
. O

These O
latter O
results O
showed O
that O
the O
ALL_CAP I-GENE
protein I-GENE
, O
like O
the O
NUM I-GENE
protein I-GENE
, O
RARE O
sequences O
required O
RARE O
positive O
RARE O
RARE O
RARE O
negative O
RARE O
of O
gene O
RARE O
. O

Clinical O
nutrition O
of O
adult O
horses O
. O

The O
computer O
- O
programmed O
RARE O
is O
currently O
most O
RARE O
. O

RNase I-GENE
protection O
assays O
reveal O
that O
this O
gene O
, O
RARE I-GENE
, O
is O
RARE O
in O
the O
same O
direction O
RARE O
N I-GENE
- I-GENE
ras I-GENE
and O
that O
its O
3 O
' O
end O
is O
RARE O
just O
NUM O
RARE O
RARE O
RARE O
from O
the O
point O
RARE O
which O
N I-GENE
- I-GENE
ras I-GENE
transcription O
begins O
. O

Isolation O
of O
a O
RARE O
- O
RARE O
mutant O
with O
an O
altered O
tRNA I-GENE
RARE I-GENE
and O
cloning O
of O
the O
gene I-GENE
encoding I-GENE
tRNA I-GENE
RARE I-GENE
in I-GENE
the I-GENE
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

The O
RARE O
region O
of O
the O
insulin I-GENE
receptor I-GENE
( I-GENE
IR I-GENE
) I-GENE
beta I-GENE
- I-GENE
subunit I-GENE
contains O
an O
RARE O
RARE O
RARE O
( O
NUM O
) O
that O
is O
essential O
RARE O
insulin I-GENE
- O
RARE O
RARE O
RARE O
of O
some O
endogenous O
RARE O
and O
certain O
biological O
responses O
( O
RARE O
, O
M O
. O
F O
., O
RARE O
, O
ALL_CAP O
. O
N O
., O
RARE O
, O
ALL_CAP O
. O
M O
., O
RARE O
, O
V O
., O
RARE O
, O
T O
. O
ALL_CAP O
., O
RARE O
, O
A O
., O
and O
RARE O
, O
C O
. O
R O
. O

This O
gene O
joins O
the O
group O
of O
genes O
whose O
members O
are O
rapidly O
RARE O
in O
response O
to O
insulin I-GENE
and O
other O
RARE O
. O

The O
3 O
' O
region O
, O
NUM I-GENE
, O
is O
necessary O
RARE O
maximal O
RARE O
. O

1 O
, O
among O
which O
nine O
have O
been O
RARE O
and O
two O
( O
potentially O
RARE O
) O
sequenced O
. O

RARE O
placed O
into O
the O
novel O
environment O
with O
their O
mothers O
exhibited O
an O
RARE O
level O
of O
ALL_CAP O
turnover O
. O

The O
efficacy O
and O
safety O
of O
a O
novel O
RARE O
RARE O
preparation O
based O
on O
RARE O
has O
been O
investigated O
in O
the O
RARE O
clinical O
environment O
. O

Homozygous O
protein I-GENE
C I-GENE
( O
PC I-GENE
) O
deficiency O
is O
reported O
in O
two O
RARE O
( O
RARE O
and O
RARE O
) O
who O
received O
their O
proper O
RARE O
RARE O
the O
ages O
of O
7 O
4 O
/ O
12 O
and O
1 O
3 O
/ O
12 O
years O
respectively O
. O

The O
RARE O
and O
the O
RARE O
both O
had O
RARE O
and O
RARE O
RARE O
, O
whereas O
the O
daughter O
had O
a O
normal O
RARE O
ear O
except O
RARE O
a O
narrow O
RARE O
and O
RARE O
RARE O
. O

Abnormal O
RARE O
RARE O
( O
ALL_CAP O
RARE O
which O
was O
proved O
in O
4 O
cases O
by O
whole O
- O
body O
RARE O
scanning O
with O
99mTc O
- O
ALL_CAP O
, O
is O
suggested O
RARE O
the O
major O
cause O
of O
RARE O
in O
liver O
cirrhosis O
. O

The O
RARE O
protein O
, O
serum O
albumin I-GENE
, O
ALL_CAP O
and O
RARE O
all O
had O
very O
significant O
improvement O
. O

More O
generally O
, O
NUM I-GENE
and O
NUM I-GENE
could O
regulate O
transcription O
of O
cellular O
genes O
. O

Within O
this O
sequence O
the O
ALL_CAP I-GENE
gene I-GENE
was O
identified O
RARE O
a O
NUM O
- O
bp O
- O
long O
RARE O
reading O
frame O
coding O
RARE O
a O
protein O
of O
NUM O
amino O
RARE O
and O
190 O
, O
NUM O
RARE O
RARE O
mass O
. O

RARE I-GENE
peroxidase I-GENE
RARE O
a O
RARE O
marker O
in O
RARE O
rat O
RARE O
and O
iliac O
arteries O
. O

RARE O
RARE O
RARE O
specimens O
from O
the O
area O
of O
RARE O
RARE O
ulcers O
were O
obtained O
, O
processed O
, O
and O
evaluated O
by O
light O
microscopy O
and O
by O
RARE O
electron O
microscopy O
. O

2 O
. O

The O
effects O
of O
RARE O
NUM O
( O
ALL_CAP O
) O
and O
captopril O
on O
RARE O
capacity O
, O
hemodynamics O
and O
survival O
were O
studied O
in O
154 O
rats O
that O
recovered O
after O
experimental O
RARE O
infarction O
. O

Evidence O
that O
therapeutic O
alterations O
of O
a O
circadian O
rhythm O
RARE O
RARE O
emptying O
response O
may O
be O
possible O
. O

The O
RARE O
of O
the O
levels O
of O
glucocorticoids O
and O
insulin I-GENE
in O
the O
RARE O
of O
irradiated O
animals O

This O
last O
includes O
tissue O
NUM O
transfer O
( O
Ft O
RARE O
and O
mitochondrial O
NUM O
utilization O
( O
RARE O
RARE O

RARE O
RARE O
, O
therefore O
, O
can O
be O
distinguished O
from O
other O
RARE O
on O
the O
basis O
of O
RARE O
. O

RARE O
correlated O
with O
the O
grade O
of O
oral O
RARE O
RARE O
periodontal O
RARE O
. O

Our O
study O
shows O
that O
the O
area O
of O
RARE O
is O
a O
medium O
MS O
risk O
region O
according O
to O
the O
RARE O
of O
RARE O
, O
although O
high O
MS O
areas O
may O
be O
found O
, O
thus O
confirming O
that O
MS O
distribution O
in O
southern O
RARE O
is O
not O
uniform O
. O

On O
an O
antithrombin I-GENE
unit O
basis O
, O
ALL_CAP O
NUM O
and O
ALL_CAP O
NUM O
were O
equivalent O
and O
more O
potent O
than O
ALL_CAP O
. O

RARE I-GENE
brain I-GENE
actin I-GENE
RARE I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
) O
is O
a O
19 O
- O
kDa O
protein O
that O
RARE O
actin I-GENE
RARE I-GENE
and O
binds O
actin I-GENE
RARE I-GENE
. O

Initial O
experience O
with O
a O
RARE O
agonist O
. O

RARE O
care O
of O
the O
patient O
exposed O
to O
a O
human O
RARE O
may O
also O
include O
discussion O
of O
RARE O
diagnostic O
procedures O
and O
other O
RARE O
management O
RARE O
. O

Primer O
extension O
analysis O
and O
RNA O
sequencing O
demonstrates O
that O
the O
transcription O
RARE O
point O
of O
rat I-GENE
ALL_CAP I-GENE
mRNA I-GENE
is O
RARE O
NUM O
nt O
upstream O
from O
the O
A O
RARE O
in O
the O
RARE O
RARE O
. O

For O
NUM O
, O
larger O
- O
than O
- O
expected O
distribution O
coefficients O
were O
obtained O
in O
the O
RARE O
experiments O
, O
an O
indication O
of O
the O
irreversible O
formation O
of O
metal O
- O
RARE O
RARE O
a O
slow O
reaction O
. O

RARE O
constructs O
RARE O
the O
RARE I-GENE
tat I-GENE
, O
RARE I-GENE
( O
tat I-GENE
+ I-GENE
RARE O
+) O
and O
env I-GENE
genes I-GENE
were O
transiently O
RARE O
in O
COS O
- O
1 O
cells O
RARE O
precursor I-GENE
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
( O
NUM I-GENE
RARE O
ALL_CAP I-GENE
. I-GENE
ALL_CAP I-GENE
( O
gp120 I-GENE
RARE I-GENE
NUM I-GENE
RARE O
and O
RARE I-GENE
RARE I-GENE
protein I-GENE
. O

This O
growth O
arrest O
is O
partly O
suppressed O
on O
minimal O
medium O
or O
under O
conditions O
in O
which O
the O
cells O
are O
less O
dependent O
on O
mitochondrial O
metabolism O
. O

Patients O
with O
detectable O
serum O
TNF I-GENE
levels O
had O
significantly O
lower O
serum O
NUM O
concentrations O
compared O
to O
those O
with O
undetectable O
levels O
RARE O
1 O
. O
NUM O
+/- O
NUM O
. O
NUM O
RARE O
. O

RARE O
RARE O
carcinoma O
: O
report O
and O
review O
of O
the O
literature O
. O

Further O
studies O
of O
mandibular O
movement O
RARE O
initial O
tooth O
RARE O
. O

Each O
RARE O
interacted O
with O
their O
4 O
- O
or O
5 O
- O
year O
- O
old O
RARE O
or O
daughter O
in O
each O
of O
two O
RARE O
RARE O
RARE O
( O
social O
RARE O
) O
and O
structured O
( O
task O
activity O
). O

RARE O
- O
RARE O
RARE O
symptoms O
in O
an O
adolescent O
following O
RARE O
surgery O
. O

These O
results O
indicate O
that O
the O
cis O
- O
regulatory O
elements O
required O
RARE O
developmental O
control O
of O
the O
NUM I-GENE
- I-GENE
A I-GENE
RARE I-GENE
gene I-GENE
are O
RARE O
in O
a O
2 O
. O
4 O
kb O
upstream O
region O
of O
this O
gene O
. O

The O
induction O
by O
pseudorabies O
virus O
of O
an O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
construct I-GENE
containing O
the O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
TATA I-GENE
box I-GENE
and O
the O
RNA O
RARE O
site O
(" O
RARE O
" O
or O
RARE O
element O
) O
but O
not O
the O
ALL_CAP O
region O
was O
also O
repressed O
by O
RARE O
in O
the O
presence O
of O
wild I-GENE
- I-GENE
type I-GENE
GR I-GENE
. O

Some O
mutations O
affected O
RARE I-GENE
in O
a O
qualitative O
manner O
, O
such O
RARE O
by O
changing O
the O
RARE O
of O
one O
of O
the O
major O
RARE I-GENE
transcripts I-GENE
or O
changing O
the O
relative O
abundance O
of O
the O
two O
major O
RARE I-GENE
transcripts I-GENE
. O

The O
RARE O
cyst O
RARE O
was O
RARE O
in O
part O
by O
RARE O
or O
RARE O
epithelium O
. O

We O
conclude O
that O
class O
I O
RARE O
smears O
with O
moderate O
to O
severe O
inflammation O
may O
be O
associated O
with O
findings O
of O
RARE O
and O
cervical O
dysplasia O
. O

As O
in O
mammals O
, O
considerable O
nucleotide O
diversity O
was O
observed O
RARE O
the O
junctions O
of O
the O
RARE O
, O
diversity O
, O
and O
RARE O
elements O
in O
chicken I-GENE
TCR I-GENE
beta I-GENE
cDNAs I-GENE
. O

The O
RARE O
c I-GENE
- I-GENE
myb I-GENE
encodes O
a O
nuclear O
transcription O
factor O
that O
binds O
to O
DNA O
in O
a O
sequence O
- O
specific O
manner O
and O
transactivates O
transcription O
of O
several O
viral O
and O
cellular O
genes O
. O

RARE O
by O
this O
latter O
compound O
was O
so O
extensive O
that O
the O
amount O
of O
membrane O
- O
associated O
N O
- O
RARE O
protein O
was O
decreased O
. O

S6 I-GENE
kinase I-GENE
activation O
requires O
RARE O
of O
this O
RARE O
segment O
, O
which O
is O
proposed O
to O
occur O
RARE O
to O
its O
multiple O
RARE O
. O

RARE O
with O
one O
olfactory O
bulb O
removed O
and O
the O
contralateral O
RARE O
closed O
can O
detect O
RARE O
. O

Expression O
of O
the O
human O
T I-GENE
cell I-GENE
receptor I-GENE
( I-GENE
TCR I-GENE
) I-GENE
alpha I-GENE
gene I-GENE
is O
regulated O
by O
a O
T O
cell O
- O
specific O
transcriptional O
enhancer O
that O
is O
RARE O
4 O
. O
5 O
kilobases O
( O
kb O
) O
3 O
' O
to O
the O
C I-GENE
alpha I-GENE
gene I-GENE
segment I-GENE
. O

The O
Ets I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
was O
localized O
to O
a O
NUM O
- O
RARE O
RARE O
( O
bp O
) O
region O
from O
the O
3 O
' O
end O
of O
T I-GENE
alpha I-GENE
2 I-GENE
. O

RARE O
flow O
and O
resistance O
showed O
minor O
reductions O
with O
HD O
. O

RARE O
of O
RARE O
polyadenylation O
signals O
was O
previously O
shown O
to O
generate O
two O
RARE I-GENE
mRNAs I-GENE
of I-GENE
1 I-GENE
. I-GENE
9 I-GENE
and I-GENE
4 I-GENE
. I-GENE
3 I-GENE
kb I-GENE
, O
which O
differ O
in O
the O
length O
of O
their O
3 O
' O
RARE O
regions O
. O

RARE O
address O
1990 O
RARE O
RARE O
in O
from O
the O
cold O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
ALL_CAP O
- O
I O
) O
encodes O
a O
40 O
- O
kDa O
nuclear O
protein O
, O
RARE I-GENE
, O
which O
stimulates O
transcription O
from O
three O
21 O
- O
RARE O
RARE O
( O
bp O
) O
repeats O
in O
its O
NUM O
region O
. O

We O
have O
now O
identified O
, O
after O
21 O
serial O
RARE O
RARE O
of O
ALL_CAP O
, O
a O
small I-GENE
ALL_CAP I-GENE
RNA I-GENE
, O
ALL_CAP I-GENE
, O
which O
is O
efficiently O
RARE O
into O
virions O
. O

The O
RARE O
RARE O
RARE O
and O
the O
ALL_CAP O
- O
revised O
: O
further O
evidence O
of O
adaptive O
and O
RARE O
type O
A O
RARE O
. O

There O
was O
evidence O
of O
attenuated O
regression O
RARE O
RARE O
RARE O
to O
observed O
portion O
sizes O
RARE O
4 O
of O
the O
10 O
food O
groups O
; O
adjusted O
NUM O
values O
RARE O
the O
RARE O
portion O
sizes O
ranged O
from O
NUM O
. O
02 O
to O
NUM O
. O
94 O
. O

The O
result O
suggests O
that O
this O
non O
- O
invasive O
ALL_CAP O
method O
is O
easily O
available O
and O
useful O
in O
monitoring O
the O
RARE O
cardiac O
output O
. O

The O
NUM I-GENE
gene I-GENE
was O
isolated O
in O
a O
screen O
RARE O
genes O
that O
regulate O
RARE O
type O
( O
V O
. O
L O
. O

The O
NUM I-GENE
suppressor I-GENE
mutation I-GENE
occurs O
near O
a O
region O
of O
the O
protein O
that O
corresponds O
to O
the O
known O
positions O
of O
alterations O
in O
E I-GENE
. I-GENE
coli I-GENE
NUM I-GENE
RARE I-GENE
mutations I-GENE
. O

Interestingly O
, O
disruption O
of O
the O
NUM I-GENE
locus I-GENE
resulted O
in O
a O
RARE O
- O
RARE O
growth O
defect O
, O
indicating O
that O
the O
NUM I-GENE
gene I-GENE
is O
essential O
RARE O
RARE O
growth O
only O
RARE O
elevated O
growth O
temperatures O
. O

We O
describe O
a O
case O
of O
a O
RARE O
abscess O
treated O
with O
amphotericin O
B O
and O
RARE O
. O

This O
, O
together O
with O
the O
data O
obtained O
with O
haloperidol O
, O
suggests O
that O
a O
minimal O
increase O
in O
the O
RARE O
rate O
of O
ALL_CAP O
cells O
(+ O
NUM O
%) O
is O
required O
before O
it O
could O
influence O
the O
turnover O
of O
NA O
, O
RARE O
measured O
by O
ALL_CAP O
changes O
. O

This O
interaction O
occurs O
over O
a O
wide O
range O
of O
both O
parameters O
; O
RARE O
RARE O
density O
from O
RARE O
least O
10 O
to O
800 O
ALL_CAP O
/ O
cm2 O
and O
, O
RARE O
RARE O
per O
RARE O
, O
from O
RARE O
least O
NUM O
. O
05 O
to O
5 O
. O
NUM O
ALL_CAP O
per O
RARE O
. O

RARE O
of O
illness O
RARE O
were O
significantly O
RARE O
when O
both O
muscle O
RARE O
and O
headache O
symptoms O
occurred O
RARE O
one O
or O
more O
assessment O
intervals O
RARE O
compared O
to O
when O
muscle O
RARE O
or O
RARE O
, O
only O
, O
occurred O
. O

Results O
have O
RARE O
revealed O
the O
presence O
of O
three O
U14 I-GENE
ALL_CAP I-GENE
- I-GENE
homologous I-GENE
regions I-GENE
positioned O
within O
RARE O
5 O
, O
6 O
, O
and O
8 O
of O
the O
mouse O
RARE O
NUM I-GENE
heat O
shock O
gene O
. O

65 O
- O
RARE O
protein O
RARE O
by O
interleukin I-GENE
2 I-GENE
RARE O
RARE O
two O
putative O
actin I-GENE
- I-GENE
binding I-GENE
sites I-GENE
and O
two O
RARE O
- O
binding O
sites O
. O

The O
highly O
RARE O
girls O
had O
a O
significantly O
RARE O
ALL_CAP O
score O
than O
the O
low O
- O
RARE O
girls O
, O
and O
shared O
with O
their O
mothers O
a O
RARE O
to O
the O
RARE O
effects O
of O
negative O
RARE O
states O
on O
their O
RARE O
behaviour O
. O

The O
RARE O
and O
RARE O
mitochondrial O
plasmids O
are O
closely O
related O
, O
closed O
- O
circular O
RARE O
( O
3 O
. O
6 O
and O
3 O
. O
7 O
kb O
, O
respectively O
) O
that O
have O
characteristics O
of O
ALL_CAP O
RARE O
and O
RARE O
elements O
. O

The O
circadian O
rhythm O
, O
however O
, O
was O
not O
affected O
and O
the O
difference O
between O
minimum O
( O
12 O
. O
00 O
h O
) O
and O
maximum O
( O
18 O
. O
50 O
h O
) O
serum O
concentrations O
was O
NUM O
. O
3 O
%. O

Sequence O
and O
genetic O
organization O
of O
a O
RARE O
RARE O
gene O
cluster O
that O
encodes O
several O
RARE O
of O
glucose O
metabolism O
. O

Most O
strains O
( O
NUM O
%) O
of O
S O
. O
RARE O
produced O
a O
delta I-GENE
RARE I-GENE
like O
that O
seen O
with O
nine O
other O
species O
of O
CNS O
. O

For O
this O
, O
cDNAs O
containing O
the O
NUM O
, O
NUM O
, O
NUM O
and O
NUM O
protein O
coding O
sequences O
were O
each O
provided O
with O
an O
ATG O
RARE O
RARE O
and O
the O
cDNA O
containing O
the O
NUM O
coding O
sequence O
with O
a O
ALL_CAP O
stop O
RARE O
immediately O
RARE O
of O
the O
coding O
sequence O
. O

Finally O
, O
a O
RARE O
footprinting O
analysis O
of O
the O
upstream O
region O
of O
the O
constitutively O
RARE O
NUM I-GENE
gene I-GENE
reveals O
the O
presence O
of O
three O
discrete O
protein O
complexes O
. O

RARE O
of O
bone O
RARE O
in O
RARE O
animals O
. O

RARE O
- O
visual O
interaction O
in O
the O
generation O
of O
RARE O
in O
man O
. O

First O
, O
each O
RARE O
was O
cut O
into O
RARE O
, O
from O
which O
RARE O
RARE O
were O
RARE O
systematically O
with O
a O
known O
sampling O
fraction O
. O

The O
upstream O
promoter O
is O
RARE O
within O
the O
coding O
sequence O
of O
a O
divergent O
gene O
expressing O
a O
protein O
of O
Mr O
NUM O
kDa O
of O
unknown O
function O
. O

RARE O
NUM O
consumption O
of O
the O
isolated O
RARE O
to O
be O
same O
RARE O
in O
situ O
, O
RARE O
showed O
that O
when O
water O
PO2 O
was O
high O
( O
NUM O
mm O
Hg O
RARE O
about O
40 O
% O
of O
RARE O
cutaneous O
NUM O
uptake O
was O
RARE O
by O
the O
RARE O
. O

Experiments O
showed O
that O
temporary O
arrest O
of O
pulmonary O
circulation O
under O
conditions O
of O
RARE O
circulation O
is O
RARE O
by O
the O
development O
of O
ischemia O
of O
the O
respiratory O
pulmonary O
tissue O
. O

RARE O
infusion O
caused O
a O
concentration O
- O
dependent O
increase O
in O
airway O
resistance O
RARE O
constant O
ALL_CAP O
. O

RARE O
reactivity O
tests O
were O
used O
to O
examine O
the O
RARE O
responses O
of O
RARE O
RARE O
( O
P O
) O
rats O
and O
RARE O
RARE O
( O
ALL_CAP O
) O
rats O
to O
the O
taste O
of O
RARE O
. O

Plasma O
concentrations O
of O
RARE O
and O
RARE O
were O
NUM O
. O
NUM O
- O
3 O
. O
11 O
micrograms O
ml O
- O
1 O
and O
NUM O
. O
NUM O
- O
8 O
. O
65 O
micrograms O
ml O
- O
1 O
, O
respectively O
; O
CSF O
concentration O
of O
RARE O
was O
70 O
- O
440 O
RARE O
ml O
- O
1 O
. O

Plasma O
Al O
was O
obtained O
RARE O
each O
baseline O
and O
drug O
course O
. O

The O
survival O
in O
the O
case O
of O
these O
patients O
was O
studied O
five O
years O
later O
. O

The O
occurrence O
, O
RARE O
and O
possible O
involvement O
of O
these O
RARE O
sequences O
, O
capable O
of O
forming O
stable O
secondary O
RARE O
, O
are O
discussed O
in O
relation O
to O
their O
location O
in O
the O
region O
of O
control O
signals O
. O

ALL_CAP I-GENE
is O
not O
the O
RNA O
target O
( O
ALL_CAP O
) O
RARE O
Tat I-GENE
RARE O
- O
activation O
; O
however O
, O
because O
it O
RARE O
entirely O
on O
cellular O
factors O
RARE O
activity O
, O
ALL_CAP I-GENE
may O
serve O
to O
provide O
abundant O
RNA O
RARE O
RARE O
Tat I-GENE
RARE O
- O
activation O
without O
a O
requirement O
RARE O
full O
- O
length O
viral O
mRNA O
RARE O
. O

RARE O
activity O
of O
a O
tobacco O
- O
specific O
RARE O
. O

The O
RARE O
treatment O
need O
has O
been O
forming O
a O
clinical O
order O
of O
magnitude O
. O

1 O
(" O
long O
method O
RARE O
and O
the O
ALL_CAP O
method O
. O

These O
results O
may O
suggest O
involvement O
of O
peripheral O
RARE O
in O
pain O
modulation O
in O
patients O
with O
RARE O
cluster O
headache O
. O

Effects O
of O
RARE O
on O
upper O
- O
RARE O
RARE O
and O
RARE O
RARE O

RARE O
foot O
RARE O
are O
RARE O
pain O
, O
RARE O
, O
RARE O
and O
RARE O
, O
RARE O
, O
RARE O
RARE O
, O
RARE O
and O
RARE O
, O
RARE O
RARE O
, O
arthritis O
, O
and O
RARE O
. O

Liver O
dysfunction O
in O
the O
presence O
of O
different O
adverse O
reactions O
presented O
with O
a O
RARE O
activity O
in O
the O
RARE O
serum O
of O
indicator O
liver O
RARE O
and O
its O
impaired O
protein O
- O
forming O
function O
. O

RARE O
NUM O
: O
RARE O
levels O
and O
metabolic O
demand O
. O

The O
ALL_CAP O
characteristics O
are O
discussed O
and O
the O
recent O
literature O
is O
reviewed O
. O

RARE O
, O
these O
RARE O
may O
also O
RARE O
with O
RARE O
assays O
used O
to O
determine O
product O
RARE O
or O
RARE O
levels O
. O

In O
NUM O
patients O
with O
angina O
pectoris O
, O
the O
changes O
of O
LVEF O
, O
ALL_CAP O
and O
ALL_CAP O
/ O
ALL_CAP O
were O
more O
RARE O
RARE O
the O
detection O
of O
exercise O
- O
RARE O
ischemia O
than O
the O
appearance O
of O
chest O
pain O
and O
the O
changes O
of O
ECG O
. O

In O
both O
groups O
there O
were O
5 O
management O
failure O
of O
therapy O
, O
so O
that O
RARE O
medication O
or O
a O
RARE O
section O
lead O
to O
delivery O
. O

Serum O
RARE I-GENE
RARE I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
were O
determined O
in O
50 O
oral O
RARE O
patients O
and O
50 O
normal O
individuals O
prior O
to O
any O
RARE O
of O
treatment O
. O

The O
RARE I-GENE
promoter I-GENE
contains O
a O
RARE O
estrogen O
responsive O
element O
. O

RARE O
RARE O
RARE O
have O
been O
shown O
to O
delay O
healing O
of O
bone O
and O
this O
has O
led O
to O
limitations O
on O
their O
use O
clinically O
in O
some O
situations O
. O

The O
inspiratory O
oxygen O
concentration O
needed O
( O
NUM O
) O
and O
the O
RARE O
RARE O
differed O
in O
a O
highly O
significant O
manner O
beginning O
on O
the O
NUM O
day O
after O
trauma O
. O

The O
RARE O
and O
mineral O
oil O
RARE O
were O
almost O
RARE O
effective O
RARE O
milk O
but O
less O
effective O
than O
sucrose O
( O
NUM O
. O
NUM O
) O
in O
stimulating O
ingestion O
. O

Significance O
of O
thin O
glomerular O
RARE O
membranes O
in O
RARE O
children O
. O

Significance O
of O
RARE O
production O
and O
adhesion O
molecules O
in O
RARE O
RARE O
. O

The O
former O
procedure O
is O
RARE O
but O
complicated O
, O
whereas O
the O
latter O
is O
simple O
and O
labour O
- O
RARE O
, O
but O
a O
RARE O
RARE O
tube O
is O
required O
. O

RARE O
method O
RARE O
determination O
of O
the O
RARE O
ALL_CAP O
- O
NUM O
in O
biological O
fluids O
by O
high O
- O
performance O
liquid O
chromatography O
. O

Since O
one O
group O
of O
RARE O
more O
difficult O
to O
influence O
are O
those O
whose O
parents O
smoke O
, O
parental O
involvement O
in O
smoking O
prevention O
may O
be O
a O
RARE O
enhancer O
. O

Further O
research O
is O
recommended O
to O
identify O
the O
RARE O
RARE O
associated O
with O
the O
high O
ALL_CAP O
/ O
low O
ALL_CAP O
research O
classification O
. O

RARE O
with O
IF O
ALL_CAP O
alone O
of O
ALL_CAP O
RARE O
only O
RARE O
to O
be O
even O
more O
RARE O
than O
silver O
RARE O
staining O
of O
ALL_CAP O
, O
ALL_CAP O
and O
RARE O
material O
. O

RARE O
and O
RARE O
study O
of O
the O
RARE O
parenchyma O
cells O
of O
mice O
prior O
and O
after O
X O
- O
ray O
exposure O

Using O
an O
RARE O
RARE O
and O
RARE O
the O
duration O
of O
the O
RARE O
decreased O
significantly O
. O

The O
mean O
change O
in O
NUM I-GENE
, O
adjusted O
RARE O
the O
initial O
value O
, O
was O
- O
NUM O
. O
4 O
% O
in O
the O
experimental O
and O
+ O
NUM O
. O
5 O
% O
in O
the O
control O
group O
( O
p O
less O
than O
NUM O
. O
05 O
). O

Effect O
of O
biliary O
obstruction O
and O
RARE O
on O
serum I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
level O

RARE O
good O
accuracy O
( O
RARE O
greater O
than O
NUM O
. O
9 O
) O
was O
found O
when O
except O
comparing O
H O
RARE O
2 O
with O
the O
other O
machine O
and O
the O
reference O
methods O
, O
except O
RARE O
ALL_CAP O
and O
RARE O
count O
. O

The O
second O
part O
of O
this O
paper O
shows O
some O
medical O
applications O
of O
these O
two O
aspects O
of O
NMR O
, O
with O
help O
of O
some O
examples O
, O
taken O
from O
the O
literature O
, O
according O
to O
what O
is O
RARE O
with O
RARE O
. O

RARE O
coordination O
RARE O
RARE O
RARE O
in O
the O
RARE O
RARE O
. O

RARE I-GENE
( O
ALL_CAP I-GENE
) O
is O
a O
low O
mol O
wt O
RARE O
RARE O
protein O
which O
, O
in O
human O
tissues O
, O
inhibits O
the O
activities O
of O
the O
neutral O
serine I-GENE
RARE I-GENE
RARE I-GENE
elastase I-GENE
and O
RARE I-GENE
- I-GENE
G I-GENE
. O

By O
RARE O
a O
series O
of O
deletions O
in O
the O
RARE I-GENE
promoter O
, O
we O
further O
RARE O
these O
sequences O
to O
NUM O
RARE O
RARE O
, O
RARE O
between O
NUM O
and O
210 O
RARE O
RARE O
upstream O
of O
the O
mRNA O
RARE O
site O
. O

In O
particular O
, O
NUM O
and O
NUM O
% O
amino O
acid O
sequence O
similarities O
were O
identified O
with O
hsp70 I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
and I-GENE
Bacillus I-GENE
RARE I-GENE
, O
respectively O
. O

No O
RARE O
relations O
may O
be O
RARE O
from O
the O
correlation O
between O
the O
level O
of O
RARE O
activity O
and O
RARE O
, O
though O
it O
indicates O
that O
individual O
, O
RARE O
muscle O
activity O
patterns O
may O
constitute O
an O
important O
risk O
factor O
RARE O
development O
of O
RARE O
- O
skeletal O
RARE O
. O

All O
NUM O
RARE O
RARE O
members O
were O
anti I-GENE
- I-GENE
HIV I-GENE
RARE O
, O
and O
NUM O
who O
were O
tested O
were O
serum I-GENE
NUM I-GENE
antigen I-GENE
negative O
. O

Analysis O
with O
additional O
anti O
- O
peptide O
antibodies O
specific O
RARE O
alpha I-GENE
, I-GENE
beta I-GENE
, I-GENE
or I-GENE
gamma I-GENE
PKC I-GENE
indicated O
that O
all O
three O
RARE O
of O
PKC I-GENE
are O
RARE O
in O
ALL_CAP O
cells O
; O
however O
, O
ALL_CAP O
cells O
lost O
a O
major O
RARE O
82 O
kDa O
RARE O
cytosolic O
protein O
detectable O
with O
anti I-GENE
- I-GENE
PKC I-GENE
alpha I-GENE
antibody I-GENE
. O

To O
those O
of O
us O
who O
are O
not O
RARE O
with O
the O
present O
RARE O
there O
is O
much O
to O
be O
investigated O
and O
much O
to O
be O
contributed O
. O

To O
determine O
the O
effects O
on O
the O
pulmonary O
barrier O
of O
several O
surface O
RARE O
agents O
, O
a O
series O
of O
RARE O
dose O
RARE O
( O
RARE O
) O
was O
prepared O
and O
used O
to O
dose O
RARE O
RARE O
to O
the O
RARE O
of O
isolated O
perfused O
rat O
lungs O
. O

The O
beta O
chain O
contains O
five O
RARE O
N O
- O
RARE O
glycosylation O
sites O
, O
and O
RARE I-GENE
digestion O
suggested O
that O
the O
beta O
chain O
contained O
multiple O
complex O
carbohydrate O
RARE O
chains O
. O

The O
therapeutic O
RARE O
used O
RARE O
the O
RARE O
RARE O
Institute O
RARE O
invasive O
RARE O
of O
the O
RARE O
cervix O
RARE O
, O
RARE O
limited O
forms O
( O
NUM O
- O
NUM O
proximal O
RARE O
on O
combined O
RARE O
and O
surgery O
. O

RARE I-GENE
- O
RARE O
RARE O
of O
a O
gene O
RARE O
a O
ribosomal I-GENE
protein I-GENE
related O
to O
the O
trk I-GENE
oncogene I-GENE
. O

The O
RARE O
are O
1 O
. O
6 O
- O
1 O
. O
9 O
RARE O
long O
. O

After O
an O
initial O
titration O
period O
and O
adjustment O
of O
the O
therapeutic O
dose O
, O
the O
individual O
doses O
were O
from O
21 O
to O
500 O
micrograms O
/ O
NUM O
hrs O
( O
mean O
NUM O
micrograms O
/ O
NUM O
hrs O
). O

In O
the O
RARE O
series O
of O
experiments O
, O
Sprague O
- O
Dawley O
male O
rats O
were O
implanted O
RARE O
with O
RARE O
RARE O
aimed O
RARE O
the O
lateral O
ventricle O
. O

Use O
of O
RARE O
RARE O
and O
RARE O
RARE O
food O
RARE O
RARE O
RARE O
. O

The O
RARE O
of O
members O
of O
the O
RARE O
RARE O
RARE O
, O
RARE O
and O
RARE O
in O
the O
RARE O
- O
RARE O
NUM O
RARE O
concentration O
treatments O
supports O
previous O
evidence O
of O
RARE O
to O
low O
- O
water O
- O
content O
RARE O
. O

To O
define O
the O
mechanism O
responsible O
RARE O
the O
RARE O
of O
transcription O
RARE O
RARE O
and O
resulting O
c I-GENE
- I-GENE
myc I-GENE
RARE O
in O
RARE O
' O
s O
lymphoma O
, O
we O
analyzed O
transcription O
patterns O
after O
transfer O
of O
normal O
and O
RARE O
' O
s O
lymphoma O
c I-GENE
- I-GENE
myc I-GENE
alleles O
into O
murine O
cells O
and O
Xenopus O
RARE O
RARE O
vesicles O
. O

RARE O
RARE O
concentration O
increased O
significantly O
( O
P O
less O
than O
NUM O
. O
05 O
) O
by O
14 O
days O
in O
dogs O
fed O
the O
basal O
diet O
, O
and O
remained O
significantly O
high O
relative O
to O
that O
in O
dogs O
of O
the O
other O
dietary O
groups O
RARE O
the O
RARE O
of O
the O
study O
. O

The O
coding O
sequences O
of O
the O
RARE I-GENE
gene I-GENE
RARE O
over O
NUM O
kb O
of O
DNA O
, O
whereas O
the O
RARE I-GENE
- O
RARE I-GENE
sequences O
are O
included O
within O
a O
single O
5 I-GENE
. I-GENE
6 I-GENE
- I-GENE
kb I-GENE
RARE I-GENE
- I-GENE
NUM I-GENE
fragment I-GENE
. O

The O
genomic O
and O
transcriptional O
complexity O
of O
the O
RARE I-GENE
and O
RARE I-GENE
- O
RARE I-GENE
genes O
. O

From O
an O
ALL_CAP O
- O
16 O
lambda O
- O
gt11 O
library O
, O
we O
have O
isolated O
and O
sequenced O
a O
novel O
cDNA O
rat I-GENE
ALL_CAP I-GENE
cell I-GENE
protease I-GENE
1 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
) O
that O
has O
characteristics O
unique O
to O
serine I-GENE
RARE I-GENE
. O

The O
induction O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
RARE O
in O
the O
RARE I-GENE
A I-GENE
- O
cultured O
RARE O
cells O
is O
accompanied O
by O
increases O
in O
both O
ALL_CAP O
and O
RARE O
- O
activated O
killer O
lymphocyte O
activities O
. O

The O
paper O
is O
RARE O
with O
the O
data O
on O
change O
in O
the O
RARE O
level O
of O
ACTH I-GENE
, O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
cortisol O
, O
NUM O
, O
insulin I-GENE
, O
C I-GENE
- I-GENE
peptide I-GENE
RARE O
a O
NUM O
- O
minute O
session O
of O
respiration O
using O
a O
RARE O
hypoxic O
mixture O
with O
10 O
% O
oxygen O
( O
ALL_CAP O
- O
10 O
). O

The O
abscess O
was O
RARE O
and O
the O
RARE O
was O
RARE O
with O
a O
single O
layer O
of O
autologous O
RARE O
. O

In O
18 O
% O
RARE O
was O
clearly O
positive O
and O
ALL_CAP O
negative O
. O

The O
present O
study O
examined O
the O
effect O
of O
intensity O
, O
rate O
, O
and O
polarity O
on O
the O
spectral O
content O
of O
RARE O
of O
NUM O
normal O
- O
hearing O
subjects O
. O

Similar O
memory O
RARE O
found O
in O
medial O
septal O
- O
vertical O
RARE O
band O
of O
RARE O
and O
nucleus O
RARE O
lesioned O
rats O
: O
are O
memory O
defects O
RARE O
by O
nucleus O
RARE O
lesions O
related O
to O
the O
degree O
of O
non O
- O
specific O
RARE O
cell O
RARE O
? O
The O
function O
of O
nucleus O
RARE O
( O
ALL_CAP O
) O
and O
medial O
septal O
- O
vertical O
RARE O
band O
of O
RARE O
( O
MS O
- O
ALL_CAP O
) O
in O
a O
place O
RARE O
task O
requiring O
reference O
memory O
was O
investigated O
. O

Studies O
also O
have O
RARE O
to O
a O
relationship O
between O
the O
ALL_CAP O
cyst O
and O
certain O
signs O
or O
symptoms O
of O
RARE O
. O

The O
ALL_CAP O
- O
to O
- O
plasma O
specific O
activity O
of O
urea O
was O
about O
twice O
that O
of O
RARE O
RARE O
indicating O
that O
urea O
RARE O
into O
the O
ALL_CAP O
more O
rapidly O
than O
RARE O
+ O
RARE O
the O
70 O
s O
that O
RARE O
between O
the O
time O
the O
RARE O
urea O
and O
RARE O
+ O
were O
injected O
into O
the O
circulation O
and O
the O
time O
when O
RARE O
was O
RARE O
. O

The O
RARE O
coefficient O
of O
agreement O
between O
the O
RARE O
RARE O
RARE O
and O
the O
standard O
method O
was O
NUM O
. O
NUM O
. O

RARE O
RARE O
RARE O
NUM O
; O
RARE O
health O
and O
illness O
in O
old O
age O
RARE O
3 O
. O

When O
normalized O
RARE O
imaging O
time O
, O
all O
parameters O
are O
significantly O
RARE O
with O
ALL_CAP O
, O
with O
a O
C O
/ O
A O
per O
unit O
time O
that O
was O
NUM O
% O
RARE O
. O

Patients O
with O
acute O
RARE O
infarction O
had O
RARE O
plasma O
concentrations O
of O
RARE I-GENE
elastase I-GENE
and O
the O
non O
- O
RARE O
RARE O
conjugated O
RARE O
of O
RARE O
acid O
than O
normal O
volunteers O
or O
patients O
with O
stable O
ischaemic O
RARE O
RARE O
. O

Determination O
of O
three O
- O
dimensional O
imaging O
properties O
of O
a O
light O
RARE O
RARE O
. O

The O
cis O
- O
acting O
element O
, O
identified O
RARE O
ALL_CAP O
, O
is O
RARE O
NUM O
bp O
upstream O
from O
the O
transcription O
initiation O
site O
, O
and O
contains O
the O
core O
sequence O
of O
the O
upstream O
promoter O
sequence O
of O
NUM I-GENE
. O

The O
clinical O
relevance O
of O
these O
findings O
is O
RARE O
by O
the O
observation O
that O
similar O
results O
were O
obtained O
when O
P O
. O
RARE O
was O
given O
by O
the O
intravenous O
route O
. O

RARE I-GENE
- I-GENE
1 I-GENE
is O
identical O
to O
RARE I-GENE
muscle I-GENE
alpha I-GENE
- I-GENE
RARE I-GENE
from O
amino O
RARE O
1 O
through O
258 O
but O
contains O
a O
novel O
ALL_CAP O
- O
terminal O
region O
from O
amino O
RARE O
NUM O
through O
NUM O
. O

The O
procedure O
has O
been O
applied O
to O
three O
materials O
: O
RARE O
RARE O
with O
RARE O
; O
RARE O
RARE O
with O
RARE O
; O
and O
RARE O
with O
RARE O
RARE O
, O
RARE O
which O
the O
steady O
- O
state O
emission O
factors O
( O
mg O
m O
- O
2 O
h O
- O
1 O
) O
of O
several O
compounds O
are O
given O
. O

RARE O
1 O
is O
6 O
. O
5 O
kb O
long O
, O
and O
the O
minimal O
sizes O
of O
RARE O
2 O
and O
3 O
are O
estimated O
to O
be O
NUM O
kb O
each O
. O

After O
4 O
h O
, O
lesions O
in O
the O
RARE O
part O
of O
the O
stomach O
were O
RARE O
and O
RARE O
RARE O
E2 O
RARE O
was O
determined O
by O
the O
RARE O
vivo O
RARE O
generation O
technique O
. O

Comparison O
of O
transmembrane O
and O
cytoplasmic O
domains O
to O
a O
third O
cell O
- O
surface O
RARE O
, O
NUM I-GENE
from O
human O
RARE O
RARE O
( O
RARE O
, O
P O
., O
RARE O
, O
ALL_CAP O
., O
RARE O
, O
ALL_CAP O
., O
RARE O
RARE O
, O
H O
., O
and O
RARE O
, O
C O
. O

Approximately O
65 O
% O
of O
the O
RARE O
cAMP I-GENE
- I-GENE
dependent I-GENE
RARE I-GENE
activity O
is O
recovered O
in O
particulate O
fractions O
of O
RARE O
prepared O
from O
RARE O
populations O
of O
C O
. O
elegans O
. O

RARE O
levels O
of O
C I-GENE
subunits I-GENE
are O
observed O
in O
several O
subsequent O
RARE O
and O
adult O
stages O
of O
development O
. O

A O
second O
, O
novel O
C O
subunit O
( O
ALL_CAP O
alpha O
RARE O
NUM O
residues O
) O
has O
a O
unique O
NUM O
- O
RARE O
RARE O
- O
terminal O
region O
that O
is O
generated O
by O
the O
RARE O
RARE O
of O
the O
C I-GENE
pre I-GENE
- I-GENE
mRNA I-GENE
. O

The O
RARE O
RARE O
RARE O
the O
novel O
RARE O
terminus O
and O
a O
new O
translation O
stop O
signal O
, O
while O
simultaneously O
RARE O
the O
coding O
sequence O
RARE O
40 O
RARE O
- O
terminal O
residues O
in O
ALL_CAP I-GENE
alpha I-GENE
into O
3 O
'- O
RARE O
nucleotides O
. O

RARE O
, O
M O
. O

RARE O
adapting O
type O
I O
RARE O
discharge O
RARE O
a O
function O
of O
dynamic O
force O
versus O
dynamic O
RARE O
of O
RARE O
RARE O
of O
RARE O
and O
RARE O
RARE O
RARE O
. O

RARE O
used O
include O
RARE O
angle O
and O
a O
segmental O
evaluation O
( O
NUM O
- O
NUM O
) O
of O
each O
of O
RARE O
and O
RARE O
RARE O
- O
RARE O
RARE O
( O
RARE O
RARE O
RARE O
- O
RARE O
angle O
differences O
( O
RARE O
RARE O
vertebral O
RARE O
, O
tilt O
and O
RARE O
. O

Plasma O
RARE I-GENE
/ I-GENE
cholesterol I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
activity O
in O
multiple O
- O
organ O
donors O
: O
a O
predictor O
of O
RARE O
viability O
in O
clinical O
liver O
transplantation O
. O

RARE O
has O
AIDS O
RARE O
a O
more O
RARE O
life O
with O
care O
RARE O
home O
. O

RARE O
nodal O
status O
, O
RARE O
progesterone I-GENE
receptor I-GENE
status O
, O
and O
season O
of O
RARE O
detection O
significantly O
influenced O
survival O
in O
both O
older O
( O
greater O
than O
50 O
RARE O
) O
and O
RARE O
( O
less O
than O
50 O
RARE O
) O
patients O
. O

The O
application O
of O
these O
RARE O
to O
the O
measurement O
of O
rapid O
, O
transient O
changes O
in O
RARE O
RARE O
K O
RARE O
RARE O
is O
presented O
. O

Expression O
, O
cellular O
RARE O
and O
in O
vitro O
transcription O
studies O
establish O
that O
RARE I-GENE
ALL_CAP I-GENE
encodes O
a O
RARE O
factor O
that O
binds O
specifically O
to O
the O
upstream O
control O
element O
and O
core O
of O
the O
rRNA O
gene O
promoter O
to O
activate O
transcription O
in O
a O
binding O
site O
- O
dependent O
manner O
. O

RARE O
multiple O
laboratory O
studies O
may O
be O
of O
value O
in O
RARE O
the O
RARE O
outcome O
in O
near O
- O
RARE O
. O

RARE O
of O
Tl O
+ O
1 O
( O
NUM O
RARE O
) O
were O
6 O
times O
those O
RARE O
Ga O
or O
In O
in O
the O
brain O
and O
muscles O
, O
and O
. O
1 O
times O
in O
plasma O
. O

There O
was O
a O
RARE O
increase O
in O
the O
RARE O
diameter O
according O
to O
age O
in O
the O
biopsy O
and O
autopsy O
specimens O
. O

Despite O
the O
absence O
of O
exercise O
- O
RARE O
asthma O
( O
ALL_CAP O
) O
while O
breathing O
ALL_CAP O
air O
, O
asthmatic O
patients O
still O
had O
significantly O
RARE O
mean O
ALL_CAP O
RARE O
than O
normal O
subjects O
( O
9 O
. O
2 O
RARE O
2 O
. O
3 O
RARE O
/ O
ml O
, O
P O
less O
than O
NUM O
. O
05 O
). O

The O
afferents O
' O
RARE O
of O
response O
was O
RARE O
by O
electrical O
ALL_CAP O
RARE O
. O

RARE O
an O
age O
old O
problem O
. O

The O
distribution O
of O
their O
fibrinogen I-GENE
levels O
was O
RARE O
, O
but O
more O
wide O
- O
based O
than O
the O
distribution O
of O
our O
normal O
controls O
. O

In O
a O
RARE O
RARE O
regression O
analysis O
of O
ALL_CAP O
and O
RAST O
data O
, O
the O
occurrence O
of O
serum I-GENE
IgE I-GENE
antibodies I-GENE
to I-GENE
P I-GENE
. I-GENE
RARE I-GENE
had O
the O
highest O
RARE O
value O
RARE O
current O
RARE O
. O

The O
examination O
was O
focused O
on O
assessment O
of O
different O
RARE O
of O
RARE O
, O
on O
evaluation O
of O
the O
development O
and O
incidence O
of O
risk O
factors O
leading O
to O
complications O
and O
RARE O
of O
central O
vision O
. O

They O
were O
then O
subjected O
to O
whole O
- O
body O
heat O
stress O
( O
water O
- O
perfused O
RARE O
RARE O
and O
the O
3 O
minutes O
of O
ALL_CAP O
was O
RARE O
. O

An O
NF1 I-GENE
- I-GENE
related I-GENE
RARE I-GENE
activator I-GENE
element I-GENE
mediates O
transcription O
from O
the O
estrogen O
- O
regulated O
Xenopus I-GENE
RARE I-GENE
RARE I-GENE
promoter I-GENE
. O

A O
poor O
correlation O
was O
also O
observed O
between O
ALL_CAP O
and O
ALL_CAP I-GENE
activity O
of O
the O
RARE O
workers O
. O

At O
the O
RARE O
terminus O
, O
deletion O
RARE O
far O
RARE O
RARE O
NUM O
did O
not O
affect O
in O
vitro O
ALL_CAP I-GENE
. I-GENE
C I-GENE
assembly O
, O
although O
RARE O
- O
activating O
activity O
was O
abolished O
. O

The O
effects O
of O
mean O
RARE O
were O
also O
measured O
and O
a O
RARE O
RARE O
that O
would O
take O
them O
into O
account O
was O
derived O
. O

Effect O
of O
RARE O
on O
pain O
threshold O
in O
RARE O
- O
diabetic O
rats O
. O

We O
have O
synthesized O
RARE O
7 O
, O
7 O
- O
NUM O
RARE O
19 O
- O
ALL_CAP O
with O
high O
RARE O
content O
and O
, O
together O
with O
RARE O
7 O
, O
7 O
- O
NUM O
] O
A O
and O
RARE O
9 O
, O
11 O
- O
NUM O
] O
RARE O
( O
E1 O
RARE O
have O
developed O
a O
quantitative O
assay O
of O
serum O
level O
19 O
- O
ALL_CAP O
, O
A O
, O
and O
E1 O
using O
the O
gas O
chromatography O
/ O
mass O
spectrometry O
- O
mass O
RARE O
method O
to O
monitor O
individual O
subjects O
throughout O
RARE O
. O

Sequence O
analysis O
of O
these O
genes O
and O
their O
surrounding O
sequences O
are O
presented O
and O
compared O
with O
other O
known O
tRNA O
genes O
from O
RARE O
RARE O
. O

Experiments O
were O
performed O
in O
which O
brain O
- O
RARE O
auditory O
- O
evoked O
responses O
( O
RARE O
) O
were O
elicited O
by O
two O
RARE O
of O
RARE O
pulse O
RARE O
: O
maximum O
length O
sequences O
( O
ALL_CAP O
) O
and O
RARE O
sequences O
( O
ALL_CAP O
). O

Since O
the O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
share O
many O
biosynthetic O
and O
structural O
features O
that O
include O
site O
of O
biosynthesis O
in O
the O
RARE O
, O
NUM O
- O
responsiveness O
, O
the O
presence O
of O
the O
RARE O
6 O
- O
phosphate O
RARE O
recognition O
marker O
, O
and O
considerable O
sequence O
RARE O
, O
the O
ALL_CAP I-GENE
and O
the O
ALL_CAP I-GENE
may O
have O
homologous O
function O
which O
RARE O
both O
still O
remains O
RARE O
. O

RARE O
light O
RARE O
RARE O
infants O
and O
their O
RARE O
were O
compared O
to O
NUM O
RARE O
- O
grown O
infants O
and O
their O
RARE O
. O

RARE O
RARE O
RARE O
with O
recombinant O
human O
erythropoietin I-GENE
. O

The O
RARE O
RARE O
is O
a O
reversible O
reactive O
condition O
consisting O
of O
fever O
, O
RARE O
and O
generalized O
rash O
. O

In O
the O
local O
RARE O
field O
, O
the O
animals O
preferred O
the O
SE O
- O
RARE O
. O

In O
the O
artificial O
RARE O
, O
like O
in O
the O
RARE O
RARE O
and O
peripheral O
tissues O
, O
gas O
RARE O
depend O
on O
several O
parameters O
: O
RARE O
RARE O
conditions O
, O
RARE O
flow O
rate O
, O
RARE O
, O
composition O
of O
the O
gas O
mixture O
used O
RARE O
ventilation O
, O
RARE O
tissue O
perfusion O
, O
NUM O
consumption O
, O
etc O
. O

Mean O
(+/- O
SE O
) O
measurements O
of O
clearance O
( O
NUM O
. O
5 O
+/- O
2 O
. O
06 O
v O
NUM O
. O
5 O
+/- O
2 O
. O
05 O
mL O
/ O
min O
/ O
m2 O
RARE O
RARE O
- O
life O
( O
5 O
. O
7 O
+/- O
NUM O
. O
5 O
v O
6 O
. O
4 O
+/- O
NUM O
. O
5 O
hours O
RARE O
and O
volume O
of O
distribution O
( O
12 O
. O
4 O
+/- O
1 O
. O
1 O
v O
NUM O
. O
7 O
+/- O
1 O
. O
6 O
L O
/ O
m2 O
) O
were O
not O
significantly O
different O
in O
patients O
with O
jaundice O
when O
compared O
with O
controls O
. O

RARE O
were O
found O
to O
be O
RARE O
, O
with O
similar O
dimensions O
being O
identified O
in O
both O
samples O
. O

We O
conclude O
that O
DNA O
RARE O
is O
a O
major O
objective O
prognostic O
factor O
and O
therapeutic O
determinant O
RARE O
endometrial O
carcinoma O
. O

A O
RARE O
digital O
RARE O
( O
RARE O
2 O
) O
was O
used O
. O

RARE O
factors O
were O
more O
important O
in O
the O
older O
RARE O
( O
perhaps O
because O
of O
less O
reliable O
RARE O
). O

RARE O
ALL_CAP O
spectra O
from O
these O
electrodes O
are O
similar O
to O
those O
obtained O
RARE O
RARE O
electrodes O
. O

These O
findings O
indicate O
that O
RARE O
RARE O
by O
surgical O
removal O
of O
acid O
- O
producing O
mucosa O
in O
the O
rat O
has O
the O
same O
effects O
on O
RARE O
RARE I-GENE
ALL_CAP I-GENE
activity O
, O
RARE O
concentration O
and O
ALL_CAP O
cell O
density O
RARE O
RARE O
RARE O
by O
continuous O
gastrin I-GENE
infusion O
or O
by O
long O
- O
term O
treatment O
with O
effective O
RARE O
. O

RARE O
on O
experimental O
toxicity O
research O
it O
was O
established O
that O
, O
out O
of O
50 O
RARE O
metal O
RARE O
RARE O
, O
some O
14 O
per O
cent O
were O
found O
extremely O
hazardous O
, O
NUM O
per O
cent O
RARE O
of O
high O
level O
hazardous O
, O
NUM O
percent O
RARE O
of O
moderate O
and O
11 O
per O
cent O
RARE O
of O
low O
hazardous O
. O

The O
order O
of O
the O
RARE I-GENE
motif I-GENE
and O
the O
NUM I-GENE
homology I-GENE
region I-GENE
in O
the O
ALL_CAP O
genome O
is O
reversed O
with O
respect O
to O
the O
RARE O
genome O
indicating O
that O
a O
genetic O
rearrangement O
has O
occurred O
RARE O
the O
evolution O
of O
these O
viruses O
. O

The O
results O
suggest O
RARE O
RARE O
1 O
) O
both O
eosinophils O
and O
neutrophils O
participate O
in O
RARE O
of O
type O
RARE O
in O
atopic O
cases O
, O
and O
only O
eosinophils O
in O
non O
- O
atopic O
cases O
. O

There O
were O
5 O
treatments O
: O
control O
( O
C O
); O
a O
RARE O
RARE O
in O
one O
RARE O
RARE O
of O
the O
RARE O
( O
S O
); O
a O
RARE O
RARE O
RARE O
in O
one O
RARE O
RARE O
of O
the O
RARE O
( O
H O
); O
a O
RARE O
and O
a O
RARE O
( O
H O
/ O
S O
); O
a O
RARE O
box O
attached O
to O
the O
back O
of O
the O
RARE O
, O
containing O
a O
RARE O
( O
N O
). O

While O
RARE O
significant O
differences O
in O
the O
RARE O
responses O
or O
failure O
characteristics O
were O
noted O
RARE O
irradiated O
and O
RARE O
grafts O
in O
the O
RARE O
, O
in O
the O
RARE O
environment O
the O
RARE O
tissues O
had O
greater O
strength O
and O
RARE O
. O

The O
patient O
was O
treated O
with O
RARE O
RARE O
, O
2 O
, O
NUM O
, O
NUM O
ALL_CAP O
weekly O
RARE O
three O
weeks O
. O

A O
consensus O
binding O
site O
RARE O
the O
transcription O
factor O
SP1 I-GENE
was O
identified O
in O
intron O
As O
RARE O
of O
the O
RARE I-GENE
RARE I-GENE
cell I-GENE
RARE I-GENE
site I-GENE
region I-GENE
. O

This O
proposed O
method O
is O
similar O
in O
RARE O
to O
the O
sets O
technique O
but O
is O
shown O
to O
have O
much O
better O
expected O
time O
to O
RARE O
properties O
. O

The O
effects O
on O
reflex O
RARE O
but O
not O
on O
NUM O
or O
RARE O
were O
blocked O
by O
naloxone O
( O
2 O
mg O
/ O
kg O
RARE O
and O
were O
not O
present O
in O
RARE O
- O
RARE O
animals O
. O

Of O
the O
remaining O
RARE O
, O
five O
reacted O
either O
with O
immediate O
and O
strong O
symptoms O
or O
had O
spontaneously O
RARE O
RARE I-GENE
intake O
, O
or O
had O
an O
acquired O
IgA I-GENE
deficiency O
. O

Drug O
and O
RARE O
costs O
were O
RARE O
when O
RARE O
RARE O
with O
40 O
- O
mL O
RARE O
RARE O
was O
compared O
with O
RARE O
RARE O
with O
unit O
- O
dose O
RARE O
. O

Changes O
in O
prognosis O
of O
RARE O
births O
over O
20 O
years O
. O

RARE O
toxicity O
and O
RARE O
of O
4 O
- O
vinyl O
- O
1 O
- O
RARE O
RARE O
in O
RARE O
rats O
and O
NUM O
mice O
. O

RARE O
kg O
ALL_CAP O
ALL_CAP O
was O
almost O
restored O
to O
baseline O
values O
RARE O
the O
ALL_CAP O
group O
, O
whereas O
the O
non O
- O
RARE O
subjects O
still O
showed O
depressed O
values O
( O
ALL_CAP O
3 O
. O
7 O
per O
cent O
and O
D O
+ O
ALL_CAP O
NUM O
. O
8 O
per O
cent O
lower O
than O
before O
treatment O
; O
P O
less O
than O
NUM O
. O
05 O
). O

MK O
- O
NUM O
: O
a O
RARE O
RARE O
ocular O
hypotensive O
RARE I-GENE
anhydrase I-GENE
inhibitor O
. O

PCR O
- O
derived O
fragments O
were O
used O
RARE O
RARE O
RARE O
the O
isolation O
of O
the O
NUM I-GENE
ALL_CAP I-GENE
genes I-GENE
from O
a O
genomic O
library O
of O
Arabidopsis O
. O

In O
addition O
serum I-GENE
IgE I-GENE
concentrations O
were O
not O
statistically O
different O
. O

The O
findings O
suggest O
that O
, O
although O
iodine O
deficiency O
is O
the O
most O
probable O
cause O
of O
RARE O
among O
RARE O
of O
the O
NUM O
cohort O
, O
where O
the O
RARE O
population O
is O
RARE O
( O
both O
men O
and O
women O
RARE O
some O
other O
RARE O
factor O
( O
s O
) O
must O
be O
involved O
. O

The O
transcriptional O
unit O
spans O
a O
chromosomal O
region O
of O
about O
NUM O
RARE O
RARE O
( O
RARE O
). O

NUM O
of O
the O
patients O
who O
would O
have O
died O
RARE O
. O

Co O
- O
administration O
of O
NUM O
, O
angiotensin I-GENE
II I-GENE
and O
microspheres O
via O
the O
RARE O
artery O
may O
reduce O
drug O
exposure O
in O
the O
systemic O
compartment O
and O
therefore O
may O
increase O
the O
therapeutic O
ratio O
of O
NUM O
administration O
via O
the O
RARE O
artery O
. O

The O
effects O
of O
RARE O
( O
ALL_CAP O
) O
or O
RARE O
( O
ALL_CAP O
) O
water O
on O
arterial O
pH O
, O
partial O
pressure O
of O
carbon O
dioxide O
( O
PCO2 O
) O
and O
plasma O
RARE O
were O
determined O
in O
heat O
- O
stressed O
RARE O
. O

Transient O
RARE O
of O
human I-GENE
and I-GENE
chicken I-GENE
progesterone I-GENE
receptors I-GENE
does O
not O
support O
RARE O
translational O
initiation O
from O
a O
single O
mRNA O
RARE O
the O
mechanism O
generating O
two O
receptor O
isoforms O
. O

In O
contrast O
, O
2 O
, O
NUM O
( O
NUM O
%) O
had O
one O
or O
more O
risk O
factors O
( O
not O
low O
risk O
); O
of O
these O
, O
5 O
. O
3 O
% O
died O
in O
6 O
weeks O
( O
p O
less O
than O
NUM O
. O
001 O
). O

The O
RARE O
RARE O
Scale O
provided O
outcome O
data O
related O
to O
the O
subjects O
' O
degree O
of O
RARE O
, O
ability O
to O
maintain O
close O
relationships O
, O
and O
presence O
/ O
absence O
of O
RARE O
an O
average O
of O
NUM O
years O
after O
initial O
admission O
. O

However O
, O
RARE O
18 O
months O
of O
age O
, O
significantly O
RARE O
levels O
of O
NUM I-GENE
( O
P O
less O
than O
NUM O
. O
05 O
) O
and O
of O
NUM I-GENE
( O
P O
less O
than O
NUM O
. O
01 O
) O
were O
found O
in O
infants O
with O
an O
elevated O
IgE I-GENE
( O
greater O
than O
or O
equal O
to O
8 O
. O
NUM O
ALL_CAP O
/ O
RARE O
) O
than O
in O
those O
with O
a O
lower O
level O
. O

The O
protein O
sequence O
contains O
RARE O
RARE O
N O
- O
RARE O
glycosylation O
sites O
and O
a O
threonine O
/ O
serine O
- O
rich O
region O
which O
is O
a O
RARE O
site O
RARE O
RARE O
of O
O O
- O
RARE O
carbohydrate O
. O

Thus O
adaptation O
to O
continuous O
mild O
stress O
has O
a O
potent O
antiarrhythmic O
effect O
which O
occurs O
due O
to O
the O
increased O
RARE O
tone O
. O

The O
RARE O
from O
the O
column O
was O
mixed O
with O
the O
RARE O
solution O
containing O
RARE I-GENE
and O
RARE O
X O
- O
NUM O
and O
a O
NUM O
. O
NUM O
M O
ALL_CAP O
solution O
by O
RARE O
and O
monitored O
by O
a O
RARE O
detector O
. O

On O
histologic O
examination O
the O
RARE O
epithelium O
of O
the O
RARE O
membrane O
was O
found O
to O
be O
changed O
into O
RARE O
epithelium O
, O
with O
RARE O
distribution O
of O
RARE O
nuclei O
in O
the O
RARE O
cytoplasm O
. O

These O
results O
suggest O
an O
increased O
risk O
of O
developing O
RARE O
among O
RARE O
patients O
and O
the O
possibility O
of O
prophylactic O
effect O
of O
RARE O
against O
subsequent O
RARE O
. O

The O
same O
trend O
was O
noted O
between O
ALL_CAP O
4 O
. O
5 O
heifers O
and O
ALL_CAP O
5 O
. O
5 O
steers O
, O
indicating O
a O
RARE O
- O
related O
deposition O
of O
RARE O
fat O
in O
fed O
cattle O
. O

The O
nucleotide O
sequence O
consists O
of O
NUM O
bp O
of O
5 O
'- O
end O
non O
- O
coding O
region O
, O
NUM O
bp O
of O
coding O
region O
and O
NUM O
bp O
of O
3 O
'- O
end O
non O
- O
coding O
region O
including O
a O
20 O
bp O
RARE O
( O
A O
) O
RARE O
. O

RARE O
included O
: O
RARE O
/ O
RARE O
( O
NUM O
%), O
headache O
( O
NUM O
%), O
RARE O
( O
NUM O
%), O
pain O
RARE O
tumor O
sites O
( O
NUM O
%), O
hypotension O
( O
NUM O
%), O
and O
hypertension O
( O
38 O
%). O

The O
results O
also O
showed O
that O
although O
RARE O
RARE O
supplementation O
generally O
increased O
RARE I-GENE
phosphatase I-GENE
activity O
, O
bone O
RARE O
was O
relatively O
RARE O
RARE O
judged O
by O
the O
low O
coefficients O
of O
variation O
( O
ALL_CAP O
) O
of O
3 O
. O
14 O
- O
3 O
. O
NUM O
% O
and O
3 O
. O
NUM O
- O
4 O
. O
82 O
% O
RARE O
RARE O
and O
phosphorus O
content O
in O
the O
femur O
and O
RARE O
respectively O
. O

In O
6 O
of O
NUM O
infants O
studied O
( O
NUM O
- O
NUM O
weeks O
of O
gestation O
RARE O
acquired O
and O
congenital O
structural O
anomalies O
of O
the O
RARE O
were O
detected O
with O
an O
RARE O
RARE O
RARE O
( O
RARE O
NUM O
S O
, O
1 O
. O
8 O
mm O
). O

RARE O
RARE O
in O
a O
patient O
with O
chronic O
graft O
- O
versus O
- O
RARE O
RARE O
. O

RARE O
to O
its O
RARE O
in O
the O
ALL_CAP I-GENE
gene I-GENE
, O
RARE O
3 O
of O
the O
ALL_CAP I-GENE
gene I-GENE
contains O
several O
point O
mutations O
, O
an O
RARE O
of O
NUM O
bp O
, O
and O
a O
stop O
RARE O
which O
RARE O
the O
reading O
frame O
. O

Molecular O
cloning O
of O
a O
cDNA O
encoding O
rat I-GENE
ALL_CAP I-GENE
- I-GENE
cytochrome I-GENE
NUM I-GENE
reductase I-GENE
and O
the O
corresponding O
gene O
. O

The O
results O
RARE O
the O
idea O
that O
the O
RARE O
of O
relaxation O
curves O
contains O
RARE O
on O
the O
distance O
scale O
and O
on O
the O
architecture O
of O
the O
RARE O
space O
, O
even O
if O
it O
is O
difficult O
to O
RARE O
it O
without O
RARE O
. O

RARE I-GENE
5 I-GENE
- I-GENE
HT2 I-GENE
receptor I-GENE
binding O
on O
RARE O
platelets O
RARE O
a O
state O
dependent O
marker O
in O
major O
affective O
disorder O
. O

Although O
% O
ALL_CAP O
was O
correlated O
with O
all O
the O
RARE O
( O
RARE O
= O
NUM O
. O
NUM O
- O
NUM O
. O
82 O
RARE O
applying O
objective O
RARE O
of O
obesity O
based O
on O
RARE O
or O
% O
ALL_CAP O
by O
RARE O
often O
produced O
RARE O
results O
. O

The O
ALL_CAP O
values O
correlated O
RARE O
with O
the O
angiographic O
RARE O
scale O
of O
severity O
of O
RARE O
insufficiency O
( O
RARE O
= O
NUM O
. O
NUM O
; O
p O
less O
than O
NUM O
. O
001 O
RARE O
although O
they O
RARE O
the O
authors O
only O
to O
make O
a O
partial O
differentiation O
of O
RARE O
severe O
RARE O
and O
mild O
or O
RARE O
ones O
. O

Promoter O
elements O
include O
an O
atypical O
TATA O
box O
( O
ALL_CAP O
RARE O
one O
CCAAT O
box O
much O
further O
from O
the O
initiation O
site O
, O
three O
reverse O
RARE O
of O
CCAAT O
( O
ALL_CAP O
RARE O
and O
two O
pyrimidine O
- O
rich O
nucleotide O
stretches O
. O

The O
RARE O
genes O
were O
identified O
in O
genetic O
libraries O
by O
hybridization O
screening O
using O
four O
RARE O
RARE O
which O
corresponded O
to O
the O
partial O
amino O
acid O
sequence O
of O
the O
RARE O
enzyme O
. O

The O
pattern O
RARE O
catalytic O
zinc O
sites O
included O
two O
ligands O
close O
in O
sequence O
, O
a O
sequence O
- O
distant O
RARE O
, O
and O
a O
main O
- O
chain O
hydrogen O
bond O
RARE O
two O
ligands O
. O

Results O
of O
the O
long O
- O
term O
observation O
and O
treatment O
of O
patients O
with O
arterial O
hypertension O

RARE O
transcription O
factors O
that O
stimulate O
RNA I-GENE
polymerase I-GENE
II I-GENE
by O
increasing O
the O
efficiency O
of O
RARE O
of O
specifically O
or O
randomly O
RARE O
RNA O
chains O
have O
been O
isolated O
and O
characterized O
. O

Sprague O
- O
Dawley O
newborn O
rats O
( O
RARE O
= O
NUM O
) O
RARE O
NUM O
% O
oxygen O
( O
NUM O
) O
or O
room O
air O
( O
ALL_CAP O
) O
RARE O
the O
RARE O
8 O
days O
of O
life O
, O
and O
then O
ALL_CAP O
. O

The O
RARE O
increased O
and O
the O
RARE O
/ O
mm2 O
and O
elastic O
RARE O
pressure O
decreased O
. O

Comparison O
of O
RARE O
and O
RARE O
RARE O
RARE O
agents O
RARE O
RARE O
therapy O
. O

In O
Experiment O
II O
, O
RARE O
RARE O
moderate O
supine O
RARE O
( O
NUM O
% O
VO2 O
RARE O
) O
RARE O
50 O
minutes O
under O
several O
ALL_CAP O
conditions O
in O
5 O
RARE O
women O
, O
there O
were O
RARE O
similar O
changing O
RARE O
of O
the O
cardiovascular O
RARE O
to O
each O
of O
the O
phases O
given O
in O
Experiment O
I O
. O

RARE O
available O
RARE O
of O
2 O
. O
5 O
% O
and O
5 O
% O
RARE O
can O
be O
RARE O
either O
with O
water O
RARE O
ALL_CAP O
cold O
RARE O
space O
- O
RARE O
or O
with O
RARE O
/ O
RARE O
RARE O
thermal O
RARE O
RARE O
recommended O
application O
rates O
of O
NUM O
. O
5 O
- O
1 O
g O
RARE O
/ O
RARE O
RARE O
RARE O
control O
and O
2 O
g O
RARE O
/ O
RARE O
RARE O
RARE O
control O
. O

Thus O
, O
this O
reading O
frame O
was O
concluded O
to O
encode O
the O
precursor O
of O
mitochondrial I-GENE
RARE I-GENE
. O

Sequence O
analysis O
indicates O
that O
in O
addition O
to O
an O
ALL_CAP O
and O
ALL_CAP O
box O
, O
this O
region O
contains O
domains O
that O
have O
been O
implicated O
in O
the O
RARE O
of O
other O
muscle O
- O
specific O
genes O
: O
a O
ALL_CAP O
box O
RARE O
- O
91 O
bp O
; O
RARE I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
nuclear I-GENE
factor I-GENE
1 I-GENE
binding I-GENE
site I-GENE
homologies O
RARE O
- O
58 O
, O
- O
NUM O
, O
and O
- O
NUM O
bp O
; O
and O
a O
muscle O
- O
CAAT O
consensus O
sequence O
RARE O
- O
NUM O
bp O
relative O
to O
the O
RARE O
site O
. O

The O
trk I-GENE
- I-GENE
NUM I-GENE
oncogene I-GENE
, O
isolated O
from O
the O
human O
breast O
carcinoma O
cell O
line O
ALL_CAP O
- O
MB O
231 O
by O
genomic O
DNA O
- O
transfection O
into O
NIH3T3 O
cells O
, O
consists O
of O
the O
trk I-GENE
RARE I-GENE
- I-GENE
oncogene I-GENE
receptor I-GENE
kinase I-GENE
domain I-GENE
fused O
to O
a O
N O
- O
terminal O
NUM O
amino O
acid O
activating O
sequence O
( O
RARE O
, O
S O
. O
C O
., O
RARE O
, O
S O
. O
M O
. O
S O
., O
RARE O
- O
RARE O
, O
F O
., O
RARE O
, O
S O
. O
M O
., O
RARE O
, O
B O
. O
and O
RARE O
, O
N O
. O
E O
. O

Antibodies O
raised O
against O
a O
bacterially O
produced O
beta I-GENE
RARE I-GENE
- O
trk I-GENE
receptor O
kinase O
fusion O
protein O
RARE O
a O
NUM O
RARE O
RARE O
RARE O
on O
serine O
, O
threonine O
and O
tyrosine O
in O
extracts O
of O
trk I-GENE
- I-GENE
NUM I-GENE
transformed O
NIH3T3 O
cells O
. O

Since O
very O
recent O
scanning O
- O
deletion O
analysis O
indicates O
that O
there O
is O
a O
critical O
region O
RARE O
activity O
near O
RARE O
- O
118 O
and O
that O
RARE O
- O
118 O
is O
necessary O
RARE O
maximal O
activity O
, O
we O
conclude O
that O
the O
RARE O
- O
118 O
RARE O
is O
necessary O
RARE O
proper O
glycosylation O
and O
maximal O
RARE O
activity O
of O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
. O

Molecular O
and O
RARE O
characterization O
of O
the O
promoter O
of O
NUM I-GENE
, O
the O
human O
c I-GENE
- I-GENE
ets I-GENE
- I-GENE
2 I-GENE
gene O
. O

RARE O
about O
immunologic O
drug O
interactions O
is O
needed O
by O
RARE O
to O
make O
RARE O
drug O
- O
use O
RARE O
. O

RARE O
occlusion O
of O
RARE O
' O
s O
artery O
, O
or O
RARE O
from O
the O
proximal O
anterior O
or O
RARE O
cerebral O
arteries O
were O
the O
RARE O
mechanism O
of O
infarction O
. O

All O
ALL_CAP I-GENE
- I-GENE
binding I-GENE
sites I-GENE
, O
regardless O
of O
origin O
, O
provided O
weak O
UAS O
function O
in O
vivo O
when O
examined O
in O
test O
plasmids O
. O

An O
examination O
of O
the O
properties O
of O
sequences O
surrounding O
NUM O
RARE O
RARE O
the O
possibility O
that O
ALL_CAP I-GENE
enhances O
the O
initiation O
of O
DNA O
replication O
RARE O
NUM O
by O
transcriptional O
activation O
. O

RARE O
ophthalmic O
and O
neurologic O
disorders O
that O
can O
be O
RARE O
with O
RARE O
RARE O
are O
RARE O
, O
and O
an O
algorithm O
RARE O
evaluation O
( O
which O
includes O
ophthalmic O
examination O
, O
laboratory O
studies O
, O
and O
RARE O
carotid O
artery O
studies O
) O
is O
given O
. O

RARE O
, O
whether O
or O
not O
the O
hypotensive O
action O
of O
RARE O
enzyme O
RARE O
is O
age O
- O
related O
is O
RARE O
yet O
unknown O
. O

RARE O
RARE O
generated O
to O
the O
fusion O
protein O
was O
capable O
of O
detecting O
NUM O
- O
and O
NUM O
- O
RARE O
polypeptides O
from O
virus O
RARE O
; O
both O
polypeptides O
were O
also O
shown O
to O
contain O
HBsAg I-GENE
RARE I-GENE
. O

These O
characteristics O
of O
NUM O
/ O
NUM O
indicate O
that O
it O
is O
a O
localized O
RARE O
dependent O
event O
RARE O
to O
a O
transverse O
RARE O
with O
dorsal O
RARE O
and O
a O
simultaneous O
anterior O
RARE O
. O

Role O
of O
RARE I-GENE
dismutase I-GENE
in O
cellular O
oxidative O
processes O
and O
method O
of O
its O
determination O
in O
biological O
materials O

At O
maximum O
RARE O
the O
RARE O
amino O
RARE O
gamma O
- O
RARE O
acid O
and O
RARE O
were O
lower O
, O
and O
those O
of O
RARE O
( O
metabolite O
of O
the O
RARE O
amino O
acid O
RARE O
) O
were O
RARE O
, O
than O
when O
the O
animals O
were O
not O
RARE O
. O

We O
evaluated O
the O
likelihood O
of O
tissues O
to O
be O
positive O
RARE O
RARE I-GENE
antigen I-GENE
and O
the O
intensity O
of O
RARE I-GENE
antigen I-GENE
staining O
in O
specimens O
of O
RARE O
RARE O
, O
mixed O
RARE O
RARE O
RARE O
, O
RARE O
RARE O
, O
and O
RARE O
using O
the O
peroxidase I-GENE
- O
RARE I-GENE
technique O
. O

The O
RARE O
activity O
of O
DNA O
RARE O
by O
either O
of O
the O
Drosophila O
RARE O
can O
be O
RARE O
, O
however O
, O
by O
an O
additional O
incubation O
with O
E I-GENE
. I-GENE
coli I-GENE
endonuclease I-GENE
IV I-GENE
, O
which O
is O
known O
to O
RARE O
RARE O
DNA O
on O
the O
5 O
'- O
RARE O
of O
an O
RARE O
site O
. O

A O
. O

Therefore O
, O
in O
conjunction O
with O
a O
positive O
RARE O
test O
and O
the O
patient O
' O
s O
clinical O
history O
, O
a O
severely O
depressed O
or O
absent O
serum O
ALL_CAP I-GENE
- I-GENE
A I-GENE
level O
may O
aid O
in O
the O
diagnosis O
of O
RARE O
RARE O
. O

The O
levels O
of O
both O
NUM I-GENE
- I-GENE
specific I-GENE
and I-GENE
NUM I-GENE
- I-GENE
specific I-GENE
mRNAs I-GENE
decline O
in O
the O
postnatal O
developing O
brain O
; O
the O
level O
of O
NUM I-GENE
- I-GENE
specific I-GENE
mRNA I-GENE
also O
increases O
slightly O
in O
rat O
PC12 O
cells O
upon O
exposure O
to O
nerve I-GENE
growth I-GENE
factor I-GENE
. O

The O
cDNAs O
cross O
- O
RARE O
with O
genomic O
sequences O
in O
rat O
, O
human O
, O
and O
chicken O
DNA O
, O
but O
not O
with O
DNA O
from O
RARE O
, O
Drosophila O
, O
or O
RARE O
RARE O
. O

RARE O
method O
of O
RARE O
RARE O
in O
the O
RARE O

Deletion O
analysis O
was O
carried O
out O
within O
a O
part O
of O
the O
5 O
'- O
flanking O
region O
showing O
homology O
to O
the O
upstream O
region O
of O
the O
yeast I-GENE
CYC1 I-GENE
gene I-GENE
. O

The O
NUM O
and O
P2 O
were O
comparable O
in O
amplitude O
and O
both O
had O
prolonged O
refractory O
periods O
. O

RARE O
to O
RARE O
RARE O
: O
fact O
or O
RARE O
? O
Recent O
findings O
in O
this O
laboratory O
with O
regard O
to O
tolerance O
to O
RARE O
RARE O
are O
reviewed O
with O
respect O
to O
RARE O
of O
the O
RARE O
phenomenon O
. O

In O
NUM O
dogs O
the O
RARE O
limb O
( O
RARE O
) O
of O
the O
pancreas O
was O
removed O
but O
RARE O
in O
the O
abdominal O
cavity O
after O
cessation O
of O
RARE O
flow O
to O
produce O
RARE O
ischemia O
RARE O
NUM O
, O
NUM O
, O
and O
120 O
min O
( O
10 O
dogs O
RARE O
each O
time O
point O
RARE O
and O
then O
was O
RARE O
with O
cold O
RARE O
' O
RARE O
and O
RARE O
to O
the O
iliac O
vessels O
. O

These O
results O
support O
the O
view O
that O
RARE O
and O
6 O
- O
ALL_CAP O
, O
but O
not O
alpha O
- O
ALL_CAP O
, O
have O
central O
pressor O
actions O
in O
the O
rat O
that O
RARE O
their O
antihypertensive O
action O
. O

Furthermore O
, O
beta I-GENE
2 I-GENE
- I-GENE
adrenoceptor I-GENE
sensitivity O
appears O
to O
be O
unaltered O
in O
ALL_CAP O
. O

We O
conclude O
that O
RARE O
' O
s O
stain O
substantially O
RARE O
the O
recognition O
of O
RARE O
RARE O
compared O
with O
RARE O
' O
s O
stain O
. O

These O
results O
suggest O
that O
the O
negative O
inotropic O
action O
of O
RARE O
is O
caused O
by O
inhibition O
of O
Ca O
RARE O
and O
RARE O
RARE O
of O
Ca O
. O

The O
study O
included O
139 O
eyes O
with O
RARE O
ocular O
RARE O
RARE O
( O
ALL_CAP O
) O
and O
age O
- O
related O
RARE O
degeneration O
( O
ALL_CAP O
). O

Comparison O
of O
elastase I-GENE
- I-GENE
1 I-GENE
with O
amylase I-GENE
, O
lipase I-GENE
, O
and O
trypsin I-GENE
- O
like O
immunoreactivity O
in O
the O
diagnosis O
of O
acute O
pancreatitis O
. O

A O
probe O
evoked O
potentials O
procedure O
was O
used O
to O
assess O
the O
relative O
RARE O
of O
both O
cerebral O
RARE O
RARE O
a O
language O
task O
in O
the O
following O
four O
groups O
of O
RARE O
adults O
: O
RARE O
hemisphere O
( O
ALL_CAP O
)- O
damaged O
RARE O
RARE O
from O
stroke O
, O
RARE O
, O
right O
hemisphere O
( O
ALL_CAP O
)- O
damaged O
RARE O
patients O
, O
and O
normal O
control O
subjects O
. O

RARE O
type O
IV O
: O
clinical O
spectrum O
and O
RARE O
history O
. O

Two O
of O
the O
three O
groups O
were O
administered O
RARE O
, O
RARE O
a O
new O
RARE O
RARE O
blocker O
, O
and O
verapamil O
, O
RARE O
a O
generally O
RARE O
RARE O
RARE O
blocker O
, O
respectively O
, O
from O
NUM O
minutes O
pre O
- O
bypass O
to O
the O
end O
of O
the O
bypass O
procedure O
( O
a O
period O
of O
NUM O
minutes O
). O

No O
RARE O
occurred O
in O
RARE O
NUM O
percent O
of O
the O
muscle O
RARE O
upon O
reperfusion O
. O

RARE O
, O
patients O
with O
locally O
advanced O
, O
RARE O
, O
non O
- O
metastatic O
RARE O
RARE O
RARE O
prolonged O
survival O
. O

RARE I-GENE
activity O
was O
RARE O
increased O
RARE O
RARE O
in O
RARE O
RARE O
in O
RARE O
RARE O
in O
all O
our O
tested O
patients O
. O

The O
RARE O
involved O
measurements O
of O
the O
steady O
state O
levels O
of O
mRNAs O
RARE O
subunit O
5 O
of O
cytochrome I-GENE
oxidase I-GENE
and O
the O
beta O
subunit O
of O
NUM I-GENE
ATPase I-GENE
in O
wild O
type O
and O
in O
a O
NUM I-GENE
mutant I-GENE
. O

A O
5 I-GENE
. I-GENE
NUM I-GENE
- I-GENE
like I-GENE
RARE I-GENE
is O
present O
within O
the O
5 O
'- O
terminal O
region O
of O
all O
three O
RARE I-GENE
mitochondrial I-GENE
ALL_CAP I-GENE
RARE I-GENE
; O
in O
contrast O
, O
RARE O
4 I-GENE
. I-GENE
5S I-GENE
- I-GENE
like I-GENE
RARE I-GENE
is O
evident O
RARE O
the O
3 O
' O
end O
of O
these O
molecules O
. O

ATP O
gamma O
S O
inhibition O
can O
be O
overcome O
by O
high O
concentrations O
of O
ATP O
, O
ALL_CAP O
, O
ALL_CAP O
, O
or O
ALL_CAP O
. O

The O
recovery O
of O
labelled O
RARE O
is O
98 O
+/- O
7 O
%. O

ALL_CAP O
- O
NUM O
demonstrated O
weak O
competitive O
beta I-GENE
- I-GENE
RARE I-GENE
blocking O
activity O
in O
isolated O
RARE O
RARE O
right O
RARE O
with O
a O
NUM O
of O
3 O
. O
NUM O
+/- O
NUM O
. O
07 O
; O
RARE O
agonist O
- O
like O
activity O
was O
observed O
in O
this O
tissue O
RARE O
concentrations O
of O
ALL_CAP O
- O
NUM O
from O
3 O
X O
10 O
RARE O
5 O
) O
to O
1 O
X O
10 O
RARE O
2 O
) O
M O
. O

RARE O
and O
promoter O
elements O
RARE O
activation O
and O
glucocorticoid O
repression O
of O
the O
alpha I-GENE
1 I-GENE
- I-GENE
fetoprotein I-GENE
gene I-GENE
in O
hepatocytes O
. O

We O
discuss O
the O
results O
in O
relation O
to O
previous O
RARE O
RARE O
RARE O
the O
posterior O
RARE O
gyrus O
of O
the O
RARE O
and O
consider O
the O
possibility O
that O
RARE O
of O
the O
RARE O
posterior O
RARE O
gyrus O
correspond O
directly O
to O
areas O
making O
RARE O
the O
superior O
temporal O
gyrus O
in O
primates O
. O

The O
gene O
is O
contained O
within O
a O
1 O
. O
8 O
- O
RARE O
ALL_CAP I-GENE
- O
EcoRI I-GENE
RARE O
fragment O
mapping O
RARE O
map O
RARE O
NUM O
. O
136 O
to O
NUM O
. O
NUM O
in O
the O
ALL_CAP O
region O
of O
the O
ALL_CAP O
- O
1 O
genome O
and O
is O
RARE O
from O
right O
to O
RARE O
. O

The O
4 O
- O
AP O
( O
4 O
- O
20 O
mM O
) O
effect O
resulted O
in O
a O
decrease O
of O
the O
sensory O
activity O
, O
which O
was O
fully O
restored O
by O
ALL_CAP O
or O
NUM O
RARE O

Hybridization O
of O
a O
probe O
from O
this O
region O
to O
electrophoretic O
blots O
of O
RNAs O
from O
different O
human O
tissues O
showed O
a O
predominant O
2 O
. O
8 O
- O
RARE O
( O
kb O
) O
RARE O
accompanied O
by O
RARE O
bands O
4 O
. O
1 O
and O
2 O
. O
1 O
kb O
in O
size O
. O

RARE O
of O
asymptomatic O
multiple O
myeloma O
. O

A O
new O
method O
RARE O
the O
quantitative O
analysis O
of O
sleep O
RARE O
RARE O
continuous O
RARE O
EEG O
recordings O
. O

RARE O
et O
al O
. O

RARE O
release O
of O
RARE O
RARE O
and O
5 O
- O
RARE O
acid O
in O
the O
RARE O
- O
RARE O
of O
the O
rat O
RARE O
revealed O
by O
RARE O
dialysis O
coupled O
to O
high O
- O
performance O
liquid O
chromatography O
with O
RARE O
detection O
. O

In O
this O
report O
we O
describe O
RARE O
the O
RARE O
time O
the O
RARE O
RARE O
RARE O
of O
type I-GENE
X I-GENE
RARE I-GENE
, O
based O
on O
cloning O
and O
sequencing O
of O
cDNA O
and O
genomic O
DNA O
. O

RARE O
flap O
areas O
were O
established O
following O
vascular O
RARE O
ligation O
( O
both O
vessels O
or O
only O
artery O
or O
RARE O
RARE O
on O
the O
third O
day O
after O
flap O
RARE O
in O
both O
island O
and O
free O
RARE O
. O

The O
size O
RARE O
is O
not O
due O
to O
glycosylation O
or O
RARE O
of O
NUM I-GENE
but O
may O
result O
from O
a O
proline O
- O
rich O
sequence O
which O
occurs O
in O
this O
polypeptide O
. O

A O
9 O
. O
5 O
- O
kb O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
fragment O
, O
where O
all O
the O
DNA O
changes O
associated O
with O
RARE I-GENE
( I-GENE
RARE I-GENE
) I-GENE
mutations I-GENE
were O
mapped O
, O
was O
able O
to O
rescue O
the O
RARE I-GENE
( I-GENE
RARE I-GENE
) I-GENE
mutant I-GENE
RARE O
after O
P O
- O
element O
- O
RARE O
RARE O
- O
line O
transformation O
. O

The O
corticosterone O
RARE O
inhibitor O
RARE O
( O
NUM O
mg O
/ O
kg O
i O
. O
p O
.) O
was O
given O
to O
RARE O
the O
rise O
of O
corticosterone O
to O
a O
level O
typical O
of O
stressed O
males O
. O

The O
effects O
of O
NUM O
, O
240 O
, O
a O
selective O
RARE O
and O
RARE O
RARE O
antagonist O
, O
on O
ischemia O
- O
and O
reperfusion O
- O
RARE O
cardiac O
arrhythmias O
. O

In O
10 O
RARE O
dogs O
, O
plasma O
viscosity O
( O
RARE O
) O
was O
raised O
fourfold O
while O
apparent O
RARE O
viscosity O
( O
RARE O
) O
increased O
about O
twofold O
by O
two O
steps O
of O
exchange O
transfusion O
of O
NUM O
ml O
of O
plasma O
with O
plasma O
containing O
high O
RARE O
RARE O
RARE O
( O
mol O
wt O
500 O
, O
NUM O
, O
20 O
% O
wt O
/ O
RARE O
). O

The O
small I-GENE
IGF I-GENE
- I-GENE
binding I-GENE
protein I-GENE
is O
abundant O
in O
human O
RARE O
RARE O
. O

Serum O
RARE I-GENE
acid I-GENE
phosphatase I-GENE
levels O
showed O
a O
significantly O
RARE O
correlation O
with O
RARE O
volume O
( O
RARE O
RARE O
NUM O
. O
NUM O
) O
and O
every O
other O
pathological O
parameter O
. O

The O
investigation O
was O
thereafter O
continued O
in O
an O
RARE O
fashion O
by O
RARE O
a O
single O
10 O
mg O
dose O
of O
the O
MAO I-GENE
- I-GENE
B I-GENE
inhibitor O
RARE O
to O
the O
same O
subjects O
. O

Their O
studies O
have O
revealed O
a O
considerable O
increase O
of O
CSF I-GENE
AP I-GENE
activity O
in O
RARE O
RARE O
whereas O
in O
RARE O
RARE O
it O
RARE O
RARE O
. O

A O
cDNA O
encoding O
a O
new O
human O
lymphocyte O
cell O
surface O
molecule O
has O
been O
isolated O
and O
shown O
to O
identify O
a O
fourth O
RARE O
of O
a O
recently O
discovered O
family O
of O
adhesion O
proteins O
. O

RARE O
caused O
a O
prominent O
RARE O
RARE O
measured O
RARE O
NUM O
+ O
RARE O
from O
control O
glands O
, O
but O
was O
without O
effect O
in O
RARE O
glands O
. O

RARE O
sensitization O
to O
cross O
- O
RARE O
RARE O
in O
a O
proportion O
of O
control O
animals O
is O
strongly O
suggested O
, O
RARE O
RARE O
to O
spontaneous O
sensitization O
in O
patients O
with O
RARE O
reactions O
to O
neuromuscular O
blockers O
on O
RARE O
exposure O
, O
and O
in O
whom O
IgE I-GENE
antibodies I-GENE
are O
detected O
. O

This O
approach O
was O
examined O
utilizing O
the O
RARE O
protein O
, O
ALL_CAP I-GENE
F I-GENE
. O

The O
investigation O
was O
RARE O
RARE O
studying O
the O
relationship O
between O
RARE O
metabolites O
of O
RARE O
and O
RARE O
( O
5 O
- O
ALL_CAP O
and O
ALL_CAP O
RARE O
T O
- O
cells O
( O
NUM O
+), O
T O
- O
RARE O
( O
NUM O
+), O
T O
- O
suppressor O
( O
NUM O
+) O
and O
B O
- O
cells O
( O
ALL_CAP O
- O
RARE O
forming O
cells O
) O
in O
normal O
( O
10 O
subjects O
, O
1 O
female O
, O
9 O
male O
, O
age O
21 O
+/- O
5 O
years O
) O
and O
stress O
administered O
subjects O
( O
20 O
subjects O
, O
3 O
female O
, O
NUM O
male O
, O
age O
20 O
+/- O
4 O
years O
). O

The O
NUM I-GENE
. I-GENE
NUM I-GENE
RARE I-GENE
recognizes O
a O
site O
on O
IgE I-GENE
which O
is O
identical O
or O
very O
close O
to O
the O
Fc I-GENE
epsilon I-GENE
R I-GENE
binding I-GENE
site I-GENE
, O
and O
NUM O
. O
3 O
recognizes O
a O
site O
on O
IgE I-GENE
which O
is O
related O
, O
but O
not O
identical O
to O
the O
Fc I-GENE
epsilon I-GENE
R I-GENE
binding I-GENE
site I-GENE
. O

Their O
RARE O
RARE O
are O
very O
similar O
and O
both O
possess O
three O
hydrophobic O
RARE O
that O
are O
likely O
alpha O
- O
helical O
transmembrane O
RARE O
. O

RARE I-GENE
RARE I-GENE
enzyme I-GENE
RARE O
enhance O
the O
antihypertensive O
efficacy O
of O
RARE O
and O
RARE O
or O
prevent O
adverse O
metabolic O
effects O
. O

In O
addition O
to O
the O
significant O
reduction O
in O
RARE O
pressure O
, O
the O
angiotensin I-GENE
RARE I-GENE
enzyme I-GENE
( O
ACE I-GENE
) O
inhibitor O
RARE O
caused O
a O
significant O
regression O
of O
pathologic O
RARE O
ventricular O
hypertrophy O
demonstrated O
by O
magnetic O
resonance O
imaging O
and O
echocardiography O
. O

RARE O
cells O
were O
studied O
by O
means O
of O
RARE O
' O
silver O
staining O
and O
RARE O
RARE O
RARE I-GENE
, O
a O
RARE O
marker O
of O
endocrine O
cells O
. O

The O
ratio O
of O
RARE O
in O
RARE O
compared O
with O
normal O
tissue O
( O
T O
: O
N O
ratio O
) O
was O
determined O
after O
simultaneously O
injecting O
microspheres O
into O
the O
RARE O
and O
arterial O
circulation O
of O
each O
RARE O
. O

The O
mRNA O
was O
converted O
to O
cDNA O
and O
amplified O
by O
the O
polymerase O
chain O
reaction O
technique O
. O

RARE O
necrosis O
was O
evaluated O
using O
RARE O
staining O
and O
was O
related O
to O
two O
major O
baseline O
predictors O
of O
infarct O
size O
: O
anatomic O
risk O
zone O
size O
and O
coronary O
collateral O
flow O
. O

To O
study O
the O
RARE O
surface O
in O
the O
human O
eye O
in O
normal O
and O
diseased O
states O
we O
used O
laser O
scanning O
tomography O
. O

Previously O
, O
we O
reported O
the O
sequence O
of O
the O
gene I-GENE
encoding I-GENE
human I-GENE
NUM I-GENE
( O
D O
. O

A O
RARE O
TATA O
box O
is O
RARE O
29 O
RARE O
RARE O
upstream O
of O
the O
RARE O
transcription O
initiation O
site O
. O

Cotransfection O
of O
either O
construct O
with O
plasmids O
encoding O
ALL_CAP I-GENE
( I-GENE
1 I-GENE
- I-GENE
NUM I-GENE
) I-GENE
inhibits O
cAMP O
- O
RARE O
but O
not O
basal O
- O
or O
phorbol O
ester O
- O
RARE O
RARE O
. O

Sequence O
analysis O
of O
the O
5 O
' O
flanking O
region O
revealed O
several O
ALL_CAP O
RARE O
but O
RARE O
RARE O
TATA O
box O
. O

The O
underlying O
cirrhosis O
was O
alcoholic O
in O
11 O
( O
53 O
. O
3 O
%), O
RARE O
in O
5 O
( O
NUM O
. O
8 O
%), O
and O
hepatitis O
B O
chronic O
infection O
related O
in O
5 O
( O
NUM O
. O
8 O
%). O

Once O
P I-GENE
- I-GENE
NUM I-GENE
mRNA I-GENE
is O
RARE O
RARE O
a O
consequence O
of O
the O
ALL_CAP I-GENE
/ O
hCG I-GENE
RARE O
it O
is O
constitutively O
maintained O
by O
RARE O
cells O
in O
vivo O
( O
NUM O
- O
4 O
days O
) O
and O
in O
vitro O
( O
NUM O
- O
9 O
days O
) O
in O
the O
absence O
of O
RARE I-GENE
, O
is O
susceptible O
to O
modulation O
by O
prolactin I-GENE
and O
is O
RARE O
longer O
regulated O
by O
cAMP O
. O

Similarly O
, O
a O
human O
but O
not O
a O
bovine I-GENE
alpha I-GENE
RARE I-GENE
was O
RARE O
in O
placenta O
in O
transgenic O
mice O
. O

A O
rapid O
staining O
technique O
RARE O
RARE O
parasites O
in O
splenic O
RARE O
smears O
. O

ALL_CAP O
- O
NUM O
suppressed O
coronary O
ligation O
- O
and O
RARE O
- O
RARE O
arrhythmias O
, O
and O
the O
minimum O
effective O
plasma O
concentrations O
RARE O
arrhythmias O
RARE O
by O
NUM O
- O
h O
and O
NUM O
- O
h O
coronary O
ligation O
and O
RARE O
were O
NUM O
. O
NUM O
+/- O
NUM O
. O
10 O
( O
by O
1 O
mg O
/ O
kg O
i O
. O
v O
RARE O
NUM O
. O
70 O
+/- O
NUM O
. O
NUM O
( O
by O
1 O
mg O
/ O
kg O
i O
. O
v O
RARE O
and O
NUM O
. O
21 O
+/- O
NUM O
. O
NUM O
( O
by O
NUM O
. O
5 O
mg O
/ O
kg O
i O
. O
v O
.) O
microgram O
/ O
ml O
, O
respectively O
( O
mean O
+/- O
SD O
of O
the O
mean O
, O
RARE O
= O
6 O
). O

In O
TNF I-GENE
- O
resistant O
NUM O
bladder O
carcinoma O
cells O
, O
TNF I-GENE
failed O
to O
alter O
ALL_CAP I-GENE
- I-GENE
R I-GENE
tyrosine I-GENE
protein I-GENE
kinase I-GENE
activity O
although O
both O
ALL_CAP I-GENE
and O
phorbol O
ester O
were O
shown O
to O
modulate O
the O
enzymatic O
activity O
of O
the O
receptor O
in O
these O
cells O
. O

Thus O
, O
RARE O
RARE O
that O
produce O
an O
RARE O
RARE O
- O
withdrawal O
RARE O
RARE O
RARE O
stimuli O
and O
RARE O
RARE O
associated O
with O
the O
withdrawal O
RARE O
precipitated O
by O
naltrexone O
in O
RARE O
- O
dependent O
rats O
. O

The O
diagnostic O
value O
of O
RARE O
serum O
and O
RARE I-GENE
amylase I-GENE
, O
lipase I-GENE
, O
and O
trypsin I-GENE
in O
RARE O
of O
chronic O
RARE O
pancreatitis O
is O
discussed O
. O

On O
the O
basis O
of O
the O
mechanism O
of O
action O
, O
two O
groups O
of O
RARE O
are O
distinguished O
, O
the O
RARE O
RARE O
and O
the O
dopaminergic O
agents O
. O

Structural O
organization O
and O
RARE O
of O
the O
mouse I-GENE
estrogen I-GENE
receptor I-GENE
. O

Intravenous O
gamma I-GENE
RARE I-GENE

Following O
RARE I-GENE
ALL_CAP I-GENE
and I-GENE
ALL_CAP I-GENE
digestion O
, O
staining O
reactions O
suggested O
that O
the O
highest O
levels O
of O
RARE O
RARE O
were O
in O
the O
diabetes O
resistant O
group O
( O
p O
less O
than O
NUM O
. O
001 O
compared O
to O
diabetic O
, O
p O
less O
than O
NUM O
. O
001 O
compared O
to O
diabetes O
prone O
) O
and O
the O
highest O
levels O
of O
RARE O
RARE O
were O
in O
the O
diabetes O
prone O
group O
( O
p O
less O
than O
NUM O
. O
001 O
). O

Myocardial O
perfusion O
was O
evaluated O
using O
the O
RARE O
gray O
level O
after O
contrast O
injection O
, O
and O
the O
level O
was O
compared O
with O
the O
morphology O
and O
degree O
of O
collateral O
development O
. O

Once O
ALL_CAP I-GENE
administration O
is O
proven O
effective O
it O
will O
be O
possible O
to O
develop O
RARE O
ways O
of O
ALL_CAP I-GENE
administration O
. O

During O
the O
program O
' O
s O
use O
RARE O
the O
ALL_CAP O
RARE O
, O
the O
program O
RARE O
the O
correct O
diagnosis O
in O
the O
top O
five O
NUM O
% O
of O
the O
time O
. O

RARE I-GENE
light I-GENE
chain I-GENE
( O
ALL_CAP I-GENE
) O
diversity O
is O
generated O
in O
the O
chicken O
by O
RARE O
between O
the O
single O
RARE O
RARE O
( O
ALL_CAP I-GENE
) O
and O
RARE O
( O
ALL_CAP I-GENE
) O
gene O
RARE O
and O
subsequent O
somatic O
RARE O
of O
the O
RARE O
ALL_CAP I-GENE
region O
. O

The O
results O
were O
RARE O
follows O
: O
1 O
) O
Total O
integrated O
EMG O
activity O
of O
FB O
group O
was O
RARE O
equal O
in O
any O
occluded O
position O
, O
whereas O
that O
of O
ALL_CAP O
and O
ALL_CAP O
group O
varied O
from O
position O
to O
position O
. O

RARE O
action O
RARE O
and O
RARE O
rhythm O
of O
anterior O
temporal O
and O
RARE O
muscles O
in O
children O
and O
adults O

In O
NUM O
% O
of O
NUM O
lead O
- O
toxic O
children O
, O
bone O
lead O
values O
measured O
by O
ALL_CAP O
were O
equal O
to O
or O
greater O
than O
those O
measured O
in O
normal O
and O
RARE O
exposed O
adults O
. O

When O
considered O
with O
the O
known O
RARE O
effects O
on O
children O
of O
" O
low O
levels O
" O
of O
exposure O
to O
lead O
, O
these O
results O
also O
suggest O
that O
either O
an O
RARE O
narrow O
margin O
of O
safety O
or O
insufficient O
safety O
is O
provided O
by O
present O
ALL_CAP O
. O
S O
. O
guidelines O
, O
which O
RARE O
an O
elevated O
RARE O
lead O
concentration O
RARE O
NUM O
micrograms O
/ O
dl O
or O
greater O
. O

In O
resting O
3T3 O
cells O
, O
jun I-GENE
- I-GENE
D I-GENE
is O
RARE O
RARE O
a O
RARE O
level O
compared O
to O
c I-GENE
- I-GENE
jun I-GENE
and O
jun I-GENE
- I-GENE
B I-GENE
, O
and O
its O
transcription O
is O
RARE O
only O
slightly O
by O
serum O
growth O
factors O
. O

The O
RARE O
effects O
of O
RARE O
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
( O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
) O
on O
experimental O
canine O
coronary O
thrombosis O
. O

NUM O
and O
CO2 O
in O
the O
RARE O
tube O
were O
continuously O
monitored O
by O
mass O
spectrometry O
using O
a O
RARE O
sample O
- O
RARE O
RARE O
- O
RARE O
sampling O
technique O
. O

RARE O
- O
RARE O
immunosorbent O
assay O
RARE O
screening O
RARE O
NUM O
in O
RARE O
products O
and O
mixed O
feed O
: O
RARE O
study O
. O

However O
, O
experiments O
with O
S1 I-GENE
mapping O
of O
in O
vivo O
transcripts O
, O
gene O
RARE O
in O
the O
alpha O
region O
, O
and O
a O
single O
- O
copy O
transcriptional O
fusion O
vector O
all O
suggested O
that O
these O
possible O
promoters O
were O
largely O
inactive O
RARE O
RARE O
growth O
, O
that O
the O
major O
promoter O
RARE O
the O
alpha O
operon O
RARE O
upstream O
from O
the O
region O
RARE O
, O
and O
that O
the O
genes O
in O
the O
NUM I-GENE
to O
NUM I-GENE
interval O
were O
cotranscribed O
. O

Functional O
RARE O
antibody O
genes O
were O
detected O
with O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
heavy I-GENE
chain I-GENE
RARE O
and O
with O
RARE I-GENE
and O
RARE I-GENE
light I-GENE
chain I-GENE
RARE O
. O

Two O
specific O
DNA O
- O
protein O
complexes O
were O
identified O
in O
gel O
retardation O
assays O
using O
HeLa O
cell O
nuclear O
extracts O
and O
an O
RARE O
probe O
spanning O
the O
RARE O
region O
. O

After O
transfection O
, O
specific O
ALL_CAP I-GENE
beta I-GENE
promoter I-GENE
activity O
was O
evident O
in O
both O
TRH I-GENE
- O
responsive O
pituitary O
- O
derived O
NUM O
and O
RARE O
pituitary O
cell O
cultures O
. O

In O
transformed O
E O
. O
coli O
, O
RARE I-GENE
CAT I-GENE
RARE O
is O
maintained O
when O
RARE O
little O
RARE O
NUM O
. O
3 O
RARE O
of O
DNA O
from O
the O
3 O
' O
end O
of O
the O
1 O
. O
6 O
- O
RARE O
segment O
is O
inserted O
in O
the O
correct O
orientation O
in O
front O
of O
the O
CAT I-GENE
gene I-GENE
. O

RARE O
of O
the O
RARE O
RARE O
flow O
alters O
the O
glomerular O
and O
tubular O
excretion O
processes O
. O

RARE O
of O
RARE O
samples O
from O
patients O
may O
also O
be O
used O
in O
the O
determination O
of O
acid O
- O
RARE O
RARE O
and O
hemoglobin I-GENE
- O
oxygen O
affinity O
RARE O
. O
g O
. O
NUM O
. O

NUM O
and O
14 O
p O
. O

Isolation O
of O
RARE O
RARE O
( O
RARE O
ALL_CAP O
group O
RARE O
) O
from O
a O
vaginal O
sample O
. O

Here O
, O
we O
alter O
the O
RARE O
RARE O
of O
Fos I-GENE
by O
precisely O
replacing O
its O
leucine O
zipper O
with O
that O
from O
GCN4 I-GENE
. O

RARE O
of O
tracheal O
RARE O
in O
growing O
animals O

RARE O
, O
RARE O
between O
4 O
and O
NUM O
hours O
of O
recovery O
is O
necessary O
to O
reverse O
the O
effect O
of O
chronic O
RARE O
on O
cerebral O
RARE O
flow O
. O

The O
ORF1 O
product O
was O
required O
RARE O
RARE O
, O
while O
ORF2 O
, O
which O
was O
cotranscribed O
with O
ORF1 O
and O
encoded O
a O
predicted O
protein O
of O
126 O
amino O
RARE O
, O
was O
not O
. O

RARE O
of O
the O
RARE O
visual O
cortex O
( O
ALL_CAP O
) O
was O
compared O
with O
that O
of O
the O
amygdala O
in O
cats O
. O

RARE O
RARE O
of O
lymphocytes O
and O
plasma O
cells O
was O
also O
wide O
- O
spread O
RARE O
the O
carcinoma O
in O
situ O
, O
together O
with O
the O
RARE O
RARE O
. O

These O
case O
reports O
provide O
further O
evidence O
that O
NUM O
can O
be O
a O
useful O
medication O
in O
the O
treatment O
of O
aggressive O
behavior O
and O
affective O
RARE O
after O
brain O
injury O
, O
but O
that O
it O
has O
significant O
RARE O
RARE O
neurotoxicity O
in O
this O
population O
, O
particularly O
when O
used O
in O
conjunction O
with O
neuroleptic O
agents O
. O

In O
all O
RARE O
under O
IFN I-GENE
, O
the O
RARE O
of O
the O
NUM O
RARE O
of O
the O
ALL_CAP O
was O
shortened O
RARE O
compared O
to O
baseline O
conditions O
. O

Among O
NUM O
cases O
of O
post O
- O
transfusion O
hepatitis O
, O
10 O
are O
due O
to O
the O
hepatitis O
B O
virus O
( O
despite O
systematic O
search O
RARE O
HBs I-GENE
RARE I-GENE
RARE O
NUM O
are O
due O
to O
one O
of O
the O
non O
- O
A O
non O
- O
B O
viruses O
( O
not O
detectable O
by O
specific O
serological O
tests O
) O
and O
1 O
to O
several O
viruses O
, O
RARE O
ALL_CAP O
. O

RARE O
lethal O
mutations O
were O
isolated O
based O
upon O
failure O
to O
complement O
the O
recessive O
lethality O
of O
RARE O
( O
NUM O
) O
NUM O
, O
a O
deletion O
of O
the O
ALL_CAP O
region O
that O
RARE O
16 O
- O
18 O
RARE O
RARE O
bands O
. O

Current O
status O
and O
future O
RARE O

K O
. O

A O
215 O
- O
RARE O
- O
RARE O
( O
bp O
) O
region O
of O
the O
mouse I-GENE
ALL_CAP I-GENE
NUM I-GENE
RARE I-GENE
light I-GENE
- I-GENE
chain I-GENE
immunoglobulin I-GENE
gene I-GENE
enhancer I-GENE
has O
been O
analyzed O
RARE O
specific O
binding O
of O
RARE O
and O
RARE O
nuclear O
factors O
. O

This O
paper O
presents O
the O
RARE O
RARE O
RARE O
to O
which O
RARE O
RARE O
is O
RARE O
should O
carry O
out O
the O
relevant O
research O
themselves O
. O

The O
NUM O
measurement O
RARE O
RARE O
compression O
predicted O
the O
success O
of O
RARE O
with O
return O
of O
spontaneous O
circulation O
. O

RARE O
CO2 O
/ O
HCO3 O
was O
determined O
in O
absence O
of O
simultaneous O
inhibition O
of O
acid O
RARE O
by O
RARE O
- O
and O
RARE O
NUM O
/ O
pH O
measurements O
in O
NUM O
persons O
and O
calculated O
using O
the O
equation O
of O
RARE O
- O
RARE O
. O
NUM O
was O
measured O
with O
use O
of O
a O
new O
electrode O
. O

RARE O
- O
RARE O
study O
showed O
NUM O
% O
of O
these O
patients O
with O
effectiveness O
. O

The O
other O
patients O
continued O
the O
trial O
with O
single O
daily O
doses O
of O
RARE O
. O

RARE O
RARE O
RARE O
: O
laboratory O
diagnosis O
RARE O
the O
RARE O
year O
of O
life O

Using O
RARE I-GENE
NUM I-GENE
alpha I-GENE
promoter I-GENE
constructs I-GENE
in O
transient O
transfection O
and O
DNA O
binding O
assays O
, O
we O
now O
demonstrate O
that O
sequences O
RARE O
immediately O
upstream O
and O
RARE O
of O
the O
RARE I-GENE
B I-GENE
enhancer I-GENE
also O
contribute O
to O
the O
RARE O
of O
NUM I-GENE
alpha I-GENE
gene I-GENE
RARE O
. O

RARE O
RARE O

RARE O
of O
RARE O
RARE O
against O
ticks O
. O

Forty O
patients O
, O
divided O
according O
to O
their O
initial O
RARE O
RARE O
transit O
times O
and O
RARE O
symptoms O
, O
were O
treated O
with O
RARE O
bromide O
50 O
mg O
t O
. O
d O
. O
s O
. O
or O
placebo O
RARE O
1 O
month O
according O
to O
a O
double O
- O
blind O
, O
parallel O
group O
design O
. O

An O
RARE O
related O
protein O
was O
detected O
in O
RARE O
and O
membrane O
fractions O
of O
RARE O
from O
Saccharomyces O
cerevisiae O
. O

Mapping O
of O
RNA O
- O
RARE I-GENE
- I-GENE
RARE I-GENE
mutants I-GENE
of I-GENE
RARE I-GENE
virus I-GENE
: I-GENE
RARE I-GENE
group I-GENE
F I-GENE
mutants I-GENE
have O
lesions O
in O
NUM I-GENE
. O

The O
effect O
of O
the O
RARE I-GENE
NUM I-GENE
( I-GENE
NUM I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
receptor I-GENE
antagonist O
, O
ALL_CAP O
29 O
, O
NUM O
on O
pacing O
- O
RARE O
ischemia O
was O
determined O
in O
anesthetized O
RARE O
- O
chest O
dogs O
. O

According O
to O
the O
published O
sequence O
of O
the O
NUM I-GENE
gene I-GENE
, O
this O
fragment O
contains O
four O
repeats O
of O
a O
ALL_CAP O
consensus O
sequence O
previously O
identified O
in O
the O
alpha I-GENE
- I-GENE
factor I-GENE
- O
inducible O
NUM I-GENE
promoter I-GENE
RARE O
RARE O
, O
ALL_CAP O
. O

The O
recovery O
index O
( O
NUM O
- O
NUM O
) O
after O
the O
infusion O
stopped O
was O
similar O
in O
patients O
who O
received O
RARE O
and O
those O
who O
received O
RARE O
. O

The O
sign O
of O
RARE O
- O
RARE O
: O
does O
it O
exist O
? O
The O
sign O
of O
RARE O
- O
RARE O
is O
usually O
regarded O
RARE O
a O
reliable O
cutaneous O
marker O
of O
internal O
malignancy O
. O

Xenopus I-GENE
homolog I-GENE
of I-GENE
the I-GENE
mos I-GENE
RARE I-GENE
RARE O
mammalian O
RARE O
and O
induces O
RARE O
of O
Xenopus O
oocytes O
. O

Southern O
blot O
analyses O
demonstrated O
a O
low O
, O
if O
not O
single O
, O
copy O
number O
RARE O
this O
gene O
and O
conservation O
of O
this O
domain O
in O
other O
RARE O
. O

Three O
missense O
mutants O
in O
subunit O
a O
of O
the O
Escherichia I-GENE
coli I-GENE
NUM I-GENE
- I-GENE
ATPase I-GENE
were O
isolated O
and O
characterized O
after O
RARE O
mutagenesis O
of O
a O
RARE O
carrying O
the O
ALL_CAP I-GENE
( I-GENE
subunit I-GENE
a I-GENE
) I-GENE
gene I-GENE
. O

Moreover O
, O
exons O
NUM O
and O
NUM O
share O
the O
same O
5 O
' O
sequence O
but O
differ O
from O
each O
other O
by O
the O
use O
of O
two O
distinct O
donor O
RARE O
sites O
NUM O
bp O
apart O
in O
the O
gene O
. O

S1 I-GENE
RARE I-GENE
analysis O
of O
RNA O
prepared O
after O
transfection O
of O
these O
HIV O
constructs O
into O
HeLa O
cells O
RARE O
with O
wild O
- O
type O
adenovirus O
indicated O
that O
the O
enhancer O
, O
SP1 I-GENE
, O
TATA O
, O
and O
a O
portion O
of O
the O
RARE O
- O
responsive O
element O
were O
each O
required O
RARE O
RARE O
E1A I-GENE
/ O
E1B I-GENE
- O
RARE O
activation O
of O
the O
HIV I-GENE
LTR I-GENE
. O

In O
supine O
position O
, O
plasma O
ANP I-GENE
levels O
ranged O
from O
12 O
pg O
/ O
ml O
to O
NUM O
. O
5 O
pg O
/ O
ml O
, O
with O
an O
average O
level O
of O
NUM O
. O
3 O
+/- O
11 O
. O
5 O
pg O
/ O
ml O
. O

The O
overall O
prevalence O
of O
ALL_CAP O
markers O
was O
RARE O
among O
RARE O
members O
than O
in O
the O
RARE O
donors O
of O
our O
area O
. O

Quantitative O
predictions O
are O
confirmed O
RARE O
the O
positive O
responses O
, O
but O
not O
RARE O
the O
RARE O
, O
suggesting O
that O
the O
ALL_CAP O
model O
is O
RARE O
. O

Plasma O
concentrations O
of O
ALL_CAP I-GENE
( O
ALL_CAP I-GENE
RARE O
aldosterone O
( O
ALL_CAP O
) O
and O
renin I-GENE
( O
ALL_CAP I-GENE
) O
were O
measured O
daily O
, O
RARE O
were O
hemodynamic O
parameters O
. O

The O
adenovirus I-GENE
E1A I-GENE
gene I-GENE
encodes O
a O
protein O
that O
transcriptionally O
activates O
viral I-GENE
early I-GENE
genes I-GENE
. O

Administration O
of O
dexamethasone O
was O
associated O
with O
progressive O
RARE O
in O
plasma O
NUM O
alpha O
OH O
progesterone O
, O
11 O
beta O
- O
RARE O
, O
ALL_CAP O
RARE O
, O
RARE O
and O
testosterone O
, O
together O
with O
increased O
RARE O
excretion O
of O
RARE O
, O
11 O
beta O
OH O
RARE O
, O
RARE O
, O
ALL_CAP O
, O
and O
16 O
alpha O
OH O
ALL_CAP O
. O

RNA O
transcripts O
that O
RARE O
to O
the O
introduced O
foreign O
gene O
have O
been O
identified O
. O

In O
HeLa O
cells O
, O
it O
activated O
transcription O
from O
the O
herpes I-GENE
simplex I-GENE
virus I-GENE
type I-GENE
1 I-GENE
RARE I-GENE
kinase I-GENE
promoter I-GENE
RARE O
to O
the O
chloramphenicol I-GENE
RARE I-GENE
gene I-GENE
when O
RARE O
in O
inverted O
orientation O
upstream O
of O
the O
RARE I-GENE
kinase I-GENE
promoter I-GENE
or O
RARE O
of O
the O
chloramphenicol I-GENE
RARE I-GENE
gene I-GENE
coding I-GENE
sequence I-GENE
. O

At O
the O
basal O
unstimulated O
condition O
, O
NUM I-GENE
5 I-GENE
' I-GENE
flanking I-GENE
sequence I-GENE
in O
the O
sense O
orientation O
inhibited O
basal O
CAT I-GENE
RARE O
from O
the O
TK I-GENE
promoter I-GENE
of O
NUM O
, O
whereas O
the O
same O
sequence O
in O
the O
RARE O
orientation O
did O
not O
. O

None O
were O
restricted O
from O
clinical O
RARE O
, O
were O
given O
RARE I-GENE
- I-GENE
RARE I-GENE
immune I-GENE
globulin I-GENE
, O
or O
developed O
RARE O
. O

In O
the O
formalin O
test O
, O
however O
, O
naloxone O
attenuated O
RARE O
analgesia O
RARE O
the O
lower O
doses O
( O
NUM O
. O
1 O
and O
NUM O
. O
3 O
mg O
/ O
kg O
) O
and O
RARE O
RARE O
analgesia O
RARE O
the O
highest O
dose O
( O
10 O
mg O
/ O
kg O
). O

We O
have O
isolated O
cDNA O
RARE O
from O
rat O
brain O
and O
human O
liver O
encoding O
a O
putative O
isoform O
of O
the O
RARE I-GENE
, I-GENE
K I-GENE
- I-GENE
ATPase I-GENE
beta I-GENE
subunit I-GENE
. O

We O
have O
determined O
that O
several O
E1 I-GENE
mutants I-GENE
mapping O
in O
both O
the O
M O
and O
R O
regions O
and O
a O
single O
mutant O
of O
the O
upstream O
regulatory O
region O
have O
a O
RARE O
transforming O
activity O
on O
mouse O
NUM O
cells O
than O
the O
wild O
- O
type O
genome O
does O
. O

ALL_CAP I-GENE
is O
also O
unique O
among O
known O
RARE I-GENE
genes I-GENE
in O
containing O
four O
cis O
- O
RARE O
RARE O
within O
its O
coding O
sequence O
. O

RARE O
of O
the O
NUM I-GENE
gene I-GENE
contains O
numerous O
RARE O
sites O
RARE O
binding O
the O
mammalian I-GENE
transcription I-GENE
factor I-GENE
SP1 I-GENE
, O
but O
RARE O
TATA O
or O
CCAAT O
sequences O
are O
evident O
near O
to O
its O
5 O
' O
end O
, O
although O
these O
latter O
features O
are O
associated O
with O
the O
human I-GENE
NUM I-GENE
gene I-GENE
. O

RARE O
therapy O
was O
effective O
in O
controlling O
symptomatic O
metastasis O
in O
all O
three O
patients O
. O

These O
results O
indicate O
that O
patients O
who O
undergo O
postoperative O
irradiation O
RARE O
low O
grade O
RARE O
RARE O
and O
localized O
RARE O
RARE O
achieve O
excellent O
survival O
. O

The O
methylation O
of O
nuclear O
and O
chloroplast O
RARE O
has O
been O
examined O
in O
relation O
to O
the O
known O
differential O
RARE O
of O
NUM I-GENE
RARE I-GENE
genes I-GENE
in O
the O
bundle O
RARE O
and O
RARE O
cells O
of O
RARE O
, O
RARE O
, O
and O
fully O
RARE O
RARE O
leaves O
. O

S1 I-GENE
RARE I-GENE
analysis O
of O
RNA O
from O
RARE O
RARE O
NUM O
- O
8 O
cells O
and O
from O
RARE O
cells O
cotransfected O
with O
ALL_CAP I-GENE
repeat I-GENE
promoter I-GENE
- O
CAT I-GENE
and O
Z I-GENE
showed O
that O
Z I-GENE
RARE O
increased O
the O
level O
of O
correctly O
RARE O
, O
stable O
RNA O
transcripts O
. O

We O
conclude O
that O
( O
a O
) O
the O
likelihood O
of O
detecting O
carcinoma O
or O
atypical O
hyperplasia O
exclusively O
in O
the O
RARE O
tissue O
RARE O
of O
RARE O
benign O
breast O
biopsies O
is O
extremely O
low O
, O
and O
( O
b O
) O
a O
possible O
cost O
- O
effective O
method O
of O
sampling O
RARE O
benign O
breast O
biopsies O
consists O
of O
initially O
RARE O
a O
maximum O
of O
10 O
blocks O
of O
RARE O
parenchyma O
RARE O
each O
case O
, O
then O
examining O
the O
remaining O
tissue O
histologically O
only O
if O
carcinoma O
or O
atypical O
hyperplasia O
is O
found O
among O
these O
blocks O
. O

Analysis O
of O
the O
DNA O
from O
NUM O
cases O
of O
RARE O
and O
familial O
RARE O
' O
tumor O
did O
not O
reveal O
any O
changes O
, O
indicating O
that O
the O
translocation O
RARE O
does O
not O
reside O
in O
this O
gene O
. O

We O
also O
provide O
evidence O
that O
neither O
the O
lambda I-GENE
O I-GENE
and O
P I-GENE
RARE I-GENE
nor O
the O
E I-GENE
. I-GENE
coli I-GENE
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
heat O
shock O
proteins O
play O
a O
direct O
role O
in O
the O
RARE O
of O
lambda O
replication O
RARE O
in O
vitro O
. O

RARE O
oligonucleotides O
representing O
the O
19 O
bp O
repeat O
unit O
strongly O
RARE O
the O
activity O
of O
the O
IE1 I-GENE
/ I-GENE
2 I-GENE
enhancer I-GENE
/ I-GENE
promoter I-GENE
in O
cotransfection O
assays O
after O
transient O
RARE O
. O

Effects O
of O
nitrogen O
( O
NUM O
: O
5 O
and O
14 O
RARE O
) O
and O
RARE O
( O
RARE O
: O
NUM O
and O
14 O
RARE O
) O
were O
also O
tested O
. O

The O
RARE I-GENE
chloroplast I-GENE
gene I-GENE
NUM I-GENE
is O
RARE O
by O
an O
NUM O
bp O
group O
II O
( O
or O
III O
) O
intron O
. O

Antibodies O
raised O
to O
the O
RARE O
NUM I-GENE
by O
immunization O
of O
mice O
detected O
both O
NUM I-GENE
and O
NUM I-GENE
in O
ALL_CAP O
- O
10 O
- O
RARE O
ALL_CAP O
cells O
but O
not O
in O
RARE O
ALL_CAP O
- O
10 O
virus O
RARE O
. O

Similarly O
, O
RARE O
RARE O
following O
RARE O
RARE O
appeared O
to O
be O
associated O
with O
a O
negative O
outcome O
. O

The O
negative O
RARE O
balance O
with O
RARE O
occurred O
after O
continuous O
oral O
administration O
of O
Cd O
and O
developed O
via O
increased O
RARE O
excretion O
of O
RARE O
. O

RARE O
NUM O
( O
NUM O
bp O
) O
had O
a O
coding O
region O
identical O
to O
that O
of O
clone O
NUM O
but O
it O
included O
a O
putative O
intron O
of O
NUM O
bp O
. O

The O
application O
of O
ALL_CAP O
and O
ALL_CAP O
did O
not O
change O
significantly O
the O
routine O
histologic O
classification O
of O
RARE O
into O
ALL_CAP O
- O
ALL_CAP O
and O
ALL_CAP O
. O

RARE O
of O
RARE O
and O
in O
situ O
hybridization O
in O
the O
differential O
diagnosis O
of O
RARE O
pneumonia O
and O
idiopathic O
interstitial O
pneumonia O
after O
RARE O
bone O
marrow O
transplantation O

The O
unique O
nature O
and O
arrangement O
of O
the O
NUM I-GENE
transcriptional I-GENE
control I-GENE
elements I-GENE
may O
account O
RARE O
this O
differential O
RARE O
. O

A O
brief O
account O
of O
the O
1988 O
RARE O
in O
RARE O
on O
viral O
hepatitis O
A O

The O
Bacillus I-GENE
subtilis I-GENE
RARE I-GENE
RARE I-GENE
NUM I-GENE
repressor I-GENE
, O
a O
lambda I-GENE
repressor I-GENE
- O
like O
transcriptional O
regulatory O
protein O
, O
was O
RARE O
in O
Escherichia O
coli O
and O
RARE O
to O
near O
RARE O
in O
order O
to O
examine O
its O
in O
vitro O
DNA O
- O
binding O
properties O
. O

In O
consequence O
, O
the O
ALL_CAP I-GENE
derived O
from O
cells O
RARE O
with O
NUM O
showed O
RARE O
characteristics O
similar O
to O
those O
of O
ALL_CAP I-GENE
from O
ALL_CAP O
- O
RARE O
cells O
RARE O
determined O
from O
the O
immunoprecipitation O
pattern O
, O
although O
the O
RARE O
RARE O
of O
each O
polypeptide O
was O
different O
, O
and O
antibody O
produced O
in O
rabbits O
RARE O
with O
recombinant O
virus O
had O
a O
high O
RARE O
activity O
, O
when O
the O
reaction O
was O
performed O
with O
complement O
. O

RARE O
stages O
of O
mammalian O
RARE O
parasites O
contain O
RARE O
RARE O
whose O
functions O
are O
not O
RARE O
understood O
. O

However O
, O
bilateral O
diffuse O
pulmonary O
RARE O
developed O
21 O
days O
later O
. O

RARE O
, O
the O
incidence O
of O
a O
type O
RARE O
carcinoma O
was O
NUM O
. O
5 O
% O
and O
that O
of O
a O
RARE O
+ O
III O
type O
was O
20 O
. O
5 O
%, O
respectively O
. O

Restriction O
maps O
of O
the O
RARE O
plasmids O
revealed O
that O
their O
chromosomal O
inserts O
consisted O
of O
overlapping O
fragments O
. O

NUM I-GENE
, O
which O
encodes O
the O
major I-GENE
RARE I-GENE
protein I-GENE
, O
each O
fused O
to O
the O
chloramphenicol I-GENE
RARE I-GENE
gene I-GENE
. O

Of O
NUM O
initially O
RARE O
RARE O
( O
observed O
RARE O
an O
average O
of O
NUM O
days O
per O
woman O
RARE O
19 O
RARE O
, O
RARE O
an O
annual O
RARE O
rate O
of O
11 O
percent O
. O

In O
contrast O
, O
a O
similar O
fragment O
RARE O
the O
38 O
- O
RARE O
- O
RARE O
region O
had O
RARE O
such O
RARE O
effect O
. O

First O
, O
a O
NUM I-GENE
:: O
LEU2 I-GENE
RARE O
RARE O
the O
' O
short O
' O
mitochondrial O
genome O
that O
lacks O
both O
NUM I-GENE
RARE I-GENE
NUM I-GENE
alpha I-GENE
and O
NUM I-GENE
beta I-GENE
is O
RARE O
only O
in O
NUM I-GENE
gene I-GENE
RARE O
and O
not O
in O
NUM I-GENE
mRNA I-GENE
RARE O
or O
mRNA O
translation O
. O

NUM O
contains O
RARE O
non O
- O
Ig I-GENE
- O
related O
sequences O
and O
a O
small I-GENE
Ig I-GENE
- I-GENE
related I-GENE
sequence I-GENE
. O

Since O
considerable O
variations O
in O
length O
and O
RARE O
sequence O
in O
the O
NUM I-GENE
( O
RARE I-GENE
RARE I-GENE
region I-GENE
) O
peptides O
of O
all O
the O
H I-GENE
- I-GENE
chains I-GENE
are O
evident O
, O
conservation O
of O
the O
D I-GENE
- I-GENE
region I-GENE
RARE O
does O
not O
appear O
to O
be O
necessary O
RARE O
effective O
RARE O
binding O
. O

RARE I-GENE
kinase I-GENE
RARE O
abrogate O
interleukin I-GENE
- I-GENE
3 I-GENE
dependence O
of O
murine O
RARE O
cells O
through O
RARE O
pathways O
involving O
c I-GENE
- I-GENE
myc I-GENE
: O
conditional O
RARE O
of O
c I-GENE
- I-GENE
myc I-GENE
transcription O
by O
RARE O
- O
RARE O
v I-GENE
- I-GENE
abl I-GENE
. O

This O
ALL_CAP I-GENE
- I-GENE
II I-GENE
RARE I-GENE
, O
which O
is O
identical O
to O
the O
RARE I-GENE
B I-GENE
motif I-GENE
from O
the O
RARE I-GENE
chain I-GENE
enhancer I-GENE
, O
was O
RARE O
in O
both O
RARE O
and O
non O
- O
RARE O
cells O
, O
which O
RARE O
with O
the O
previously O
reported O
RARE O
cell O
RARE O
of O
the O
RARE I-GENE
B I-GENE
motif I-GENE
. O

The O
DNA O
helix O
RARE O
the O
tandemly O
RARE O
, O
NUM O
sequence O
is O
RARE O
unstable O
, O
RARE O
RARE O
by O
hypersensitivity O
to O
single I-GENE
- I-GENE
RARE I-GENE
- I-GENE
specific I-GENE
RARE I-GENE
in O
a O
negatively O
RARE O
RARE O
, O
and O
demonstrated O
by O
stable O
DNA O
RARE O
seen O
after O
two O
- O
dimensional O
gel O
electrophoresis O
of O
RARE O
. O

There O
has O
been O
similar O
improvement O
in O
RARE O
RARE O
and O
RARE O
RARE O
, O
gallbladder O
RARE O
, O
or O
RARE O
bile O
duct O
RARE O
. O

RARE I-GENE
- I-GENE
endorphin I-GENE
, O
ACTH I-GENE
and O
cortisol O
RARE O
were O
measured O
in O
RARE O
healthy O
adult O
males O
after O
nasal O
RARE O
administration O
NUM O
IU O
RARE I-GENE
calcitonin I-GENE
. O

The O
data O
indicate O
that O
calcitonin I-GENE
RARE O
a O
beta I-GENE
- I-GENE
endorphin I-GENE
increase O
independent O
of O
RARE O
RARE I-GENE
- O
cortisol O
release O
. O

The O
DNA O
sequences O
predict O
proteins O
RARE O
NUM I-GENE
and O
NUM I-GENE
that O
are O
NUM O
% O
and O
52 O
% O
identical O
to O
NUM I-GENE
, O
respectively O
. O

Other O
RARE O
values O
evaluated O
were O
activated O
partial O
thromboplastin I-GENE
times O
, O
prothrombin I-GENE
times O
, O
thrombin I-GENE
times O
, O
fibrinogen I-GENE
, O
platelet O
counts O
, O
and O
fibrin I-GENE
/ O
fibrinogen I-GENE
RARE O
products O
. O

RARE O
RARE O
tumor O
with O
metastasis O
to O
mouth O
, O
jaw O
and O
face O
regions O

We O
have O
designated O
the O
protein O
" I-GENE
cellular I-GENE
ALL_CAP I-GENE
" I-GENE
( O
ALL_CAP I-GENE
). O

RARE O
to O
beta O
- O
2 O
agonist O
therapy O
was O
retained O
with O
both O
agents O
( O
p O
less O
than O
NUM O
. O
05 O
). O

Drug O
use O
in O
trauma O
victims O
. O

A O
critical O
RARE O
rate O
and O
/ O
or O
appropriate O
sympathetic O
state O
was O
found O
to O
RARE O
all O
instances O
of O
RARE O
or O
automatic O
RARE O
tachycardia O
and O
atypical O
RARE O
tachycardia O
. O

In O
contrast O
, O
the O
neu I-GENE
RARE I-GENE
- I-GENE
oncogene I-GENE
did O
not O
show O
kinase O
activity O
or O
transforming O
properties O
when O
RARE O
RARE O
similar O
levels O
in O
ALL_CAP O
3T3 O
cells O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

The O
65 O
- O
bp O
sequence O
contains O
the O
RARE O
cAMP O
- O
responsive O
enhancer O
( O
ALL_CAP O
) O
ALL_CAP O
( O
nucleotides O
- O
NUM O
to O
- O
NUM O
). O

RARE I-GENE
gene I-GENE
RARE O
in O
pancreatic O
islet O
cells O
is O
directed O
by O
cell O
- O
specific O
DNA O
control O
elements O
and O
DNA O
- O
binding O
proteins O
. O

In O
contrast O
, O
the O
full O
mu O
- O
RARE O
agonists O
fentanyl O
, O
RARE O
, O
I O
- O
RARE O
and O
RARE O
produced O
50 O
% O
fentanyl O
- O
appropriate O
responding O
RARE O
doses O
only O
1 O
. O
3 O
to O
10 O
. O
9 O
times O
smaller O
than O
those O
required O
to O
decrease O
response O
rates O
by O
50 O
%. O

After O
RARE O
on O
the O
original O
discrimination O
, O
the O
controls O
showed O
the O
normal O
RARE O
in O
learning O
the O
RARE O
reversal O
. O

Isolation O
and O
characterization O
of O
a O
cDNA O
encoding O
a O
putative O
RARE O
which O
is O
RARE O
by O
RARE O
via O
the O
NUM I-GENE
RARE I-GENE
on O
human O
T O
lymphocytes O
. O

After O
RARE O
of O
medication O
the O
animals O
were O
RARE O
electrically O
in O
the O
nucleus O
amygdala O
. O

RARE O
cells O
of O
RARE O
type O
A O
of O
the O
RARE O
yeast O
RARE O
RARE O
RARE O
a O
RARE O
pheromone O
, O
RARE I-GENE
A I-GENE
, O
which O
is O
an O
RARE O
containing O
S O
- O
RARE O
cysteine O
RARE O
its O
RARE O
terminus O
. O

RARE I-GENE
necrosis I-GENE
factor I-GENE
and O
adult O
respiratory O
distress O
RARE O
. O

RARE O
of O
rheumatoid O
arthritis O
. O

The O
decrease O
in O
RARE O
ventricular O
( O
LV O
) O
stroke O
volume O
RARE O
positive O
end O
- O
expiratory O
pressure O
( O
ALL_CAP O
) O
has O
been O
attributed O
to O
RARE O
LV O
filling O
and O
a O
decreased O
contractile O
state O
. O

An O
experiment O
on O
the O
return O
- O
of O
- O
RARE O
( O
ALL_CAP O
) O
was O
carried O
out O
on O
40 O
RARE O
- O
or O
RARE O
- O
RARE O
subjects O
in O
order O
to O
determine O
whether O
an O
RARE O
event O
that O
occurs O
RARE O
before O
RARE O
influences O
the O
magnitude O
of O
the O
ALL_CAP O
. O

RARE O
conservation O
of O
RARE I-GENE
- O
binding O
sites O
and O
other O
sequences O
upstream O
and O
within O
the O
major O
transcription O
unit O
of O
the O
Drosophila I-GENE
RARE I-GENE
gene I-GENE
RARE I-GENE
. O

To O
assess O
the O
RARE O
importance O
of O
these O
ALL_CAP O
in O
the O
overall O
drug O
resistance O
RARE O
conferred O
by O
NUM I-GENE
, O
we O
introduced O
amino O
acid O
substitutions O
in O
the O
core O
consensus O
sequence O
RARE O
nucleotide O
binding O
, O
ALL_CAP O
. O

When O
the O
RARE O
RARE O
of O
TOF O
spontaneously O
recovered O
to O
10 O
% O
of O
control O
value O
, O
RARE O
was O
injected O
( O
40 O
micrograms O
/ O
kg O
in O
adults O
, O
NUM O
micrograms O
/ O
kg O
in O
infants O
and O
children O
). O

No O
significant O
differences O
were O
found O
in O
relation O
to O
RARE O
A O
behaviour O
and O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
blockade O
. O

RARE O
of O
the O
NUM O
RARE O
of O
the O
Clinical O
Institute O
RARE O
Assessment O
- O
RARE O
( O
ALL_CAP O
- O
B O
) O
was O
based O
on O
statistically O
significant O
differences O
between O
baseline O
and O
critical O
withdrawal O
periods O
in O
high O
- O
dose O
subjects O
and O
between O
symptoms O
associated O
with O
placebo O
and O
RARE O
in O
low O
- O
dose O
subjects O
, O
using O
RARE O
RARE O
and O
RARE O
regression O
analysis O
. O

RARE O
in O
asthma O
. O

We O
have O
therefore O
evaluated O
the O
efficacy O
and O
safety O
of O
RARE O
, O
a O
new O
orally O
RARE O
selective O
alpha I-GENE
1 I-GENE
blocker O
, O
in O
patients O
with O
systemic O
hypertension O
with O
concomitant O
RARE O
limitation O
. O

Northern O
blot O
analysis O
revealed O
multiple O
ALL_CAP I-GENE
- I-GENE
I I-GENE
transcripts I-GENE
in O
a O
broad O
band O
RARE O
800 O
- O
1 O
, O
NUM O
nucleotides O
and O
other O
transcripts O
of O
RARE O
RARE O
RARE O
in O
liver O
. O

RARE O
RARE O
studies O
on O
the O
RARE O
of O
different O
RARE O
RARE O

The O
RARE O
time O
RARE O
the O
RARE O
concentration O
to O
reach O
the O
top O
values O
was O
RARE O
by O
aerobic O
training O
( O
NUM O
). O

In O
patients O
resistant O
to O
ALL_CAP O
, O
high O
- O
dose O
RARE O
with O
intravenous O
RARE O
, O
a O
ALL_CAP O
combination O
( O
cyclophosphamide O
- O
ALL_CAP O
- O
ALL_CAP O
- O
16 O
) O
or O
an O
ALL_CAP O
regimen O
( O
ALL_CAP O
- O
16 O
- O
RARE O
) O
produced O
responses O
in O
about O
40 O
% O
of O
patients O
. O

The O
discussion O
RARE O
primarily O
on O
the O
RARE O
drugs O
like O
angiotensin I-GENE
RARE I-GENE
enzyme I-GENE
RARE O
, O
alpha I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
blockers O
, O
and O
RARE O
antagonists O
. O

The O
avian O
cellular O
homolog O
of O
the O
oncogene I-GENE
jun I-GENE
. O

A O
NUM O
- O
bp O
sequence O
of O
the O
5 O
' O
flanking O
region O
adjacent O
to O
the O
RARE O
site O
of O
the O
human I-GENE
ALL_CAP I-GENE
gene I-GENE
shows O
a O
NUM O
% O
RARE O
with O
the O
corresponding O
region O
of O
the O
mouse I-GENE
ALL_CAP I-GENE
gene I-GENE
. O

RARE O
ATP O
/ O
GTP O
ratios O
promoted O
initiation O
of O
RNA O
primer O
RARE O
RARE O
3 O
'- O
ALL_CAP O
sites O
, O
whereas O
low O
ATP O
/ O
GTP O
ratios O
promoted O
initiation O
RARE O
3 O
'- O
ALL_CAP O
sites O
. O

After O
hepatitis O
B O
vaccine O
immunization O
, O
serum O
antibody O
response O
was O
of O
RARE O
type O
in O
NUM O
cases O
with O
anti I-GENE
- I-GENE
HBs I-GENE
less O
than O
2 O
. O
1 O
S O
/ O
N O
( O
S O
/ O
N O
RARE O
RARE O
) O
RARE O
NUM O
, O
the O
anti I-GENE
- I-GENE
HBs I-GENE
positive O
rate O
was O
NUM O
. O
4 O
%, O
NUM O
. O
8 O
%, O
96 O
. O
7 O
% O
and O
96 O
. O
7 O
% O
in O
NUM O
, O
NUM O
, O
NUM O
and O
NUM O
respectively O
. O

The O
experimental O
design O
incorporated O
a O
multiple O
regression O
model O
, O
sequential O
treatments O
and O
a O
RARE O
end O
point O
( O
NUM O
%) O
RARE O
protection O
time O
. O

RARE O
RARE O
tests O
showed O
that O
the O
NUM I-GENE
proteins I-GENE
are O
unable O
to O
complement O
P1 I-GENE
ALL_CAP I-GENE
or O
ALL_CAP I-GENE
mutants I-GENE
, O
and O
the O
P1 I-GENE
proteins I-GENE
fail O
to O
complement O
the O
NUM I-GENE
mutations I-GENE
. O

NUM O
, O
NUM O
- O
9 O
, O
and O
NUM O
. O

Analysis O
of O
the O
RARE O
1 I-GENE
, I-GENE
NUM I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
product I-GENE
showed O
considerable O
identity O
with O
the O
largest O
subunit O
of O
RNAP I-GENE
II I-GENE
from O
other O
organisms O
, O
including O
the O
presence O
of O
a O
zinc O
finger O
motif O
near O
the O
amino O
terminus O
, O
and O
a O
RARE O
- O
terminal O
domain O
of O
NUM O
tandemly O
RARE O
RARE O
with O
the O
consensus O
RARE O
RARE O
RARE O
RARE O
RARE O
RARE O
RARE O
. O

RARE O
involvement O
of O
the O
RARE O
RARE O
and O
RARE O
of O
the O
mucosa O
of O
the O
RARE O
lower O
lobe O
RARE O
followed O
very O
gradually O
and O
a O
monoclonal O
RARE O
( O
IgA I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
) O
was O
demonstrated O
. O

5 O
. O

None O
of O
the O
measured O
parameters O
( O
RARE O
contents O
of O
neutral O
lipids O
, O
RARE O
phospholipids O
, O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
and O
fatty O
acid O
composition O
of O
each O
RARE O
class O
) O
appeared O
to O
be O
related O
with O
the O
RARE O
of O
the O
lesions O
. O

Of O
165 O
women O
with O
non O
- O
malignant O
RARE O
NUM O
( O
16 O
%) O
had O
CA I-GENE
NUM I-GENE
levels O
in O
excess O
of O
NUM O
ALL_CAP O
/ O
ml O
and O
8 O
( O
5 O
%) O
greater O
than O
65 O
ALL_CAP O
/ O
ml O
. O

We O
conclude O
that O
RARE O
steady O
state O
the O
timing O
of O
a O
light O
RARE O
is O
unlikely O
to O
alter O
in O
any O
clinically O
important O
manner O
the O
pharmacokinetics O
of O
nifedipine O
released O
from O
' O
biphasic O
' O
RARE O
. O

The O
ALL_CAP O
- O
primed O
calves O
had O
increased O
serum O
IgG I-GENE
, O
RARE O
IgG I-GENE
and O
IgA I-GENE
and O
increased O
ALL_CAP I-GENE
RARE O
in O
both O
RARE O
fluids O
and O
serum O
following O
the O
SC O
dose O
of O
killed O
bacteria O
. O

Recent O
investigations O
have O
shown O
that O
RARE O
rays O
can O
suppress O
the O
allergic O
RARE O
dermatitis O
reaction O
completely O
and O
that O
RARE O
cells O
, O
identified O
by O
NUM I-GENE
antibodies I-GENE
and O
electron O
microscopy O
, O
RARE O
from O
the O
RARE O
RARE O
the O
same O
time O
. O

The O
elements O
responsible O
RARE O
glucocorticoid O
RARE O
of O
ADH I-GENE
gene I-GENE
transcription O
appear O
to O
reside O
outside O
of O
this O
region O
. O

1 O
. O

The O
present O
studies O
compare O
the O
biochemical O
characteristics O
, O
RARE O
RARE I-GENE
reactions O
, O
and O
RARE O
profiles O
of O
NUM O
patient O
and O
NUM O
environmental O
isolates O
of O
the O
organism O
. O

RARE O
values O
of O
both O
RARE O
and O
beta O
- O
RARE O
were O
found O
in O
full O
fat O
RARE O
and O
RARE O
cream O
: O
from O
NUM O
. O
NUM O
( O
RARE O
, O
RARE O
- O
type O
) O
to O
NUM O
. O
7 O
micrograms O
/ O
NUM O
g O
( O
RARE O
cream O
) O
and O
from O
NUM O
. O
7 O
( O
RARE O
, O
RARE O
- O
type O
) O
to O
NUM O
. O
5 O
micrograms O
/ O
NUM O
g O
( O
RARE O
cream O
) O
RARE O
all O
- O
RARE O
RARE O
and O
RARE O
beta O
- O
RARE O
, O
respectively O
. O

ALL_CAP O
includes O
measures O
of O
RARE O
, O
RARE O
, O
RARE O
, O
and O
RARE O
performance O
. O

These O
data O
RARE O
the O
RARE I-GENE
gene I-GENE
( O
NUM I-GENE
) O
and O
a O
recurrent O
T I-GENE
- I-GENE
cell I-GENE
leukemia I-GENE
RARE I-GENE
( O
NUM I-GENE
) O
in O
the O
marker O
sequence O
, O
on O
opposite O
sides O
of O
NUM I-GENE
. O

A O
fine O
- O
RARE O
deletion O
map O
of O
human O
RARE O
NUM O
: O
analysis O
of O
NUM O
series O
hybrids O
. O

With O
respect O
to O
effective O
RARE O
of O
platelets O
( O
RARE O
) O
and O
the O
surface O
reactivity O
constant O
( O
K O
RARE O
less O
significant O
differences O
were O
found O
among O
artificial O
materials O
. O

The O
two O
most O
recent O
patients O
( O
NUM O
and O
132 O
days O
) O
received O
only O
oral O
RARE O
( O
NUM O
mg O
X O
3 O
/ O
day O
) O
and O
RARE O
( O
NUM O
mg O
/ O
day O
) O
after O
the O
early O
recovery O
period O
( O
four O
- O
RARE O
days O
RARE O
resulting O
in O
normal O
prothrombin I-GENE
and O
partial O
thromboplastin I-GENE
times O
. O

RARE O
- O
RARE O
auditory O
evoked O
potentials O
( O
RARE O
) O
were O
recorded O
in O
controls O
and O
patients O
with O
RARE O
lesions O
in O
RARE O
RARE O
cortex O
. O

Most O
of O
them O
were O
situated O
RARE O
RARE O
RARE O
( O
NUM O
cases O
). O

RARE O
activity O
studies O
indicated O
that O
, O
RARE O
ten O
times O
ALL_CAP O
, O
only O
RARE O
had O
any O
significant O
activity O
against O
RARE O
RARE O
, O
RARE O
survival O
by O
NUM O
%. O

Specifically O
, O
they O
were O
performed O
to O
determine O
whether O
detection O
of O
envelope O
RARE O
RARE O
was O
consistent O
with O
RARE O
within O
a O
single O
RARE O
in O
which O
the O
ALL_CAP O
RARE O
were O
RARE O
added O
. O

Gel O
retardation O
assays O
combined O
with O
DNase I-GENE
I I-GENE
footprinting O
and O
RARE O
RARE O
interference O
showed O
that O
a O
nuclear O
factor O
from O
differentiated O
C2 O
myotubes O
and O
NUM O
RARE O
RARE O
a O
RARE O
A O
+ O
T O
- O
rich O
sequence O
within O
the O
peripheral O
activating O
region O
. O

Such O
transgenic O
RARE O
should O
RARE O
not O
only O
the O
mutational O
analysis O
of O
sequence O
elements O
within O
the O
replication O
origin O
region O
, O
but O
also O
the O
RARE O
of O
a O
new O
generation O
of O
vectors O
RARE O
gene O
amplification O
in O
RARE O
, O
based O
on O
a O
minimal O
virus O
RARE O
. O

RARE O
RARE O
is O
RARE O
more O
difficult O
than O
dorsal O
RARE O
, O
has O
less O
patient O
morbidity O
and O
fewer O
postoperative O
complications O
, O
and O
is O
more O
RARE O
acceptable O
. O

Four O
full O
- O
thickness O
RARE O
RARE O
were O
made O
in O
the O
back O
of O
10 O
female O
pigs O
that O
treated O
twice O
a O
day O
RARE O
14 O
days O
with O
2 O
ml O
of O
RARE I-GENE
growth I-GENE
factor I-GENE
( O
NUM O
RARE O
/ O
ml O
) O
or O
2 O
ml O
of O
RARE O
' O
s O
RARE O
solution O
in O
a O
single O
- O
blind O
, O
randomized O
fashion O
. O

During O
challenge O
, O
RARE O
was O
done O
when O
RARE I-GENE
antibodies I-GENE
turned O
positive O
( O
mean O
NUM O
. O
6 O
years O
, O
range O
NUM O
. O
2 O
- O
2 O
. O
NUM O
) O
or O
RARE O
the O
end O
of O
the O
two O
year O
study O
. O

The O
effect O
of O
iron O
intake O
on O
NUM O
absorption O
throughout O
RARE O
, O
and O
on O
RARE O
and O
RARE O
RARE O
status O
towards O
the O
end O
of O
RARE O
, O
was O
investigated O
in O
rats O
. O

The O
deduced O
protein O
sequence O
is O
characterized O
by O
a O
putative O
16 O
- O
RARE O
amino O
- O
terminal O
signal O
peptide O
that O
is O
cleaved O
, O
resulting O
in O
a O
239 O
- O
RARE O
polypeptide O
. O

Analysis O
of O
the O
rate O
constants O
indicated O
that O
the O
RARE O
rate O
NUM O
was O
RARE O
equal O
to O
the O
apparent O
RARE O
rate O
of O
the O
delta O
3 O
ester O
RARE O
, O
and O
slower O
than O
the O
hydrolysis O
rate O
of O
the O
delta O
2 O
ester O
NUM O
. O

A O
protocol O
is O
RARE O
RARE O
the O
preparation O
and O
characterization O
of O
a O
quality O
control O
material O
( O
ALL_CAP O
) O
containing O
RARE O
concentration O
of O
cadmium O
( O
Cd O
) O
( O
NUM O
. O
8 O
microgram O
/ O
L O
) O
and O
lead O
( O
RARE O
) O
( O
NUM O
. O
4 O
micrograms O
/ O
dL O
) O
from O
bovine O
RARE O
and O
an O
elevated O
ALL_CAP O
containing O
Cd O
( O
5 O
. O
NUM O
micrograms O
/ O
L O
RARE O
RARE O
( O
Hg O
) O
( O
11 O
. O
2 O
micrograms O
/ O
L O
RARE O
and O
RARE O
( O
NUM O
. O
5 O
micrograms O
/ O
dL O
) O
from O
bovine O
RARE O
RARE O
with O
aqueous O
RARE O
- O
solutions O
prepared O
with O
RARE O
of O
Cd O
, O
Hg O
, O
and O
RARE O
. O

RARE O
RARE O
are O
frequently O
used O
in O
the O
practice O
of O
laboratory O
medicine O
RARE O
RARE O
RARE O
outside O
the O
RARE O
laboratories O
. O

The O
lowest O
detectable O
concentration O
was O
1 O
. O
NUM O
RARE O
/ O
ml O
in O
the O
serum O
. O

RARE O
antibodies O
RARE O
RARE O
RARE O
and O
M O
. O
RARE O
. O
were O
negative O
. O

ALL_CAP O
- O
72 O
( O
NUM O
isolates O
RARE O
ALL_CAP O
- O
NUM O
( O
1 O
RARE O
ALL_CAP O
- O
NUM O
( O
2 O
) O
and O
ALL_CAP O
- O
10 O
( O
2 O
) O
were O
found O
RARE O
RARE O
around O
2000 O
m O
, O
3 O
of O
them O
in O
a O
single O
RARE O
. O

RARE O
experimental O
and O
clinical O
applications O
of O
plates O
, O
RARE O
and O
RARE O
segmental O
RARE O
implants O
made O
of O
this O
composite O
material O
have O
shown O
good O
results O
so O
far O
. O

Significance O
of O
delta O
- O
RARE O
acid O
analysis O
in O
clinical O
tests O

No O
changes O
were O
evident O
in O
the O
ALL_CAP O
- O
task O
performance O
of O
controls O
that O
received O
daily O
saline O
injections O
. O

The O
antigen I-GENE
- I-GENE
specific I-GENE
NUM I-GENE
antibody I-GENE
seems O
to O
be O
an O
index O
in O
evaluating O
immunotherapy O
RARE O
. O

Although O
the O
fertility O
decline O
in O
the O
black O
population O
in O
the O
RARE O
RARE O
between O
the O
RARE O
NUM O
' O
s O
and O
early O
NUM O
' O
s O
closely O
RARE O
that O
of O
the O
national O
black O
population O
, O
it O
rose O
much O
more O
dramatically O
in O
the O
NUM O
' O
s O
and O
NUM O
' O
s O
to O
almost O
NUM O
levels O
. O

According O
to O
their O
staining O
affinity O
RARE O
anti I-GENE
- I-GENE
T I-GENE
antibodies I-GENE
, O
the O
RARE O
tissue O
cells O
were O
classified O
RARE O
T I-GENE
RARE O
T I-GENE
RARE O
T I-GENE
RARE O
and O
T I-GENE
and O
the O
annual O
changes O
in O
the O
numbers O
of O
these O
cell O
populations O
, O
RARE O
RARE O
RARE O
in O
the O
volume O
occupied O
by O
the O
RARE O
tissue O
, O
were O
calculated O
. O

RARE O
( O
AMP O
) O
alone O
or O
with O
an O
RARE O
( O
AMI O
) O
was O
the O
treatment O
in O
9 O
and O
16 O
cases O
, O
respectively O
. O

RARE O
- O
3 O
, O
4 O
- O
RARE O
RARE O
were O
RARE O
by O
RARE O
3 O
, O
4 O
- O
RARE O
with O
RARE O
RARE O
RARE O
, O
while O
1 O
- O
RARE O
- O
3 O
- O
RARE O
RARE O
were O
obtained O
in O
reactions O
of O
1 O
- O
RARE O
with O
RARE O
RARE O
RARE O
. O

We O
investigated O
the O
incidence O
of O
congenital O
color O
deficiency O
among O
RARE O
by O
the O
use O
of O
H O
- O
R O
- O
R O
RARE O
plates O
. O

RARE O
patients O
RARE O
to O
ALL_CAP O
with O
non O
- O
Hodgkin O
' O
s O
lymphomas O
between O
NUM O
and O
1986 O
, O
were O
reviewed O
. O

The O
relation O
between O
VE O
/ O
VO2 O
and O
ALL_CAP O
/ O
VO2 O
showed O
a O
significant O
negative O
correlation O
( O
RARE O
= O
- O
NUM O
. O
93 O
, O
p O
less O
than O
NUM O
. O
01 O
). O

The O
differential O
diagnosis O
of O
both O
RARE O
is O
based O
on O
the O
clinical O
course O
, O
RARE O
and O
ALL_CAP O
examination O
which O
along O
with O
modern O
ALL_CAP O
treatment O
significantly O
modify O
hitherto O
used O
surgical O
therapy O
. O

RARE O
filling O
consists O
in O
RARE O
RARE O
RARE O
directly O
RARE O
the O
RARE O
zone O
after O
surgical O
approach O
. O

RARE O
study O
of O
Japanese O
RARE O
Heparin O
Sodium O
RARE O
RARE O

RARE O
studies O
RARE O
the O
early O
relapse O
RARE O
of O
this O
RARE O
showed O
increased O
serum I-GENE
ALL_CAP I-GENE
, O
IgA I-GENE
and O
IgM I-GENE
level O
with O
normal O
IgG I-GENE
and O
decrease O
of O
NUM I-GENE
and O
NUM I-GENE
. O

The O
maximum O
stress O
due O
to O
the O
RARE O
examination O
of O
the O
composite O
was O
NUM O
. O
NUM O
kg O
/ O
mm2 O
RARE O
equilibrium O
of O
the O
water O
absorbed O
of O
the O
composite O
. O

Ischemic O
RARE O
RARE O
evaluated O
by O
exercise O
stress O
thallium O
- O
NUM O
RARE O
scintigraphy O
: O
a O
comparison O
of O
SPECT O
and O
RARE O
' O
s O
eye O
display O

Sequence O
analysis O
of O
the O
NUM I-GENE
- I-GENE
RARE I-GENE
major I-GENE
RARE I-GENE
membrane I-GENE
RARE I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
. O

RARE O
consensus O
sequences O
RARE O
early O
and O
RARE O
regulatory O
elements O
were O
identified O
. O

An O
ALL_CAP I-GENE
mutant I-GENE
, O
NUM I-GENE
- I-GENE
2 I-GENE
, O
had O
a O
1 O
. O
6 O
- O
RARE O
RARE O
of O
S O
. O
RARE O
DNA O
near O
the O
5 O
' O
end O
of O
these O
transcripts O
which O
by O
S1 I-GENE
analysis O
were O
shown O
to O
initiate O
within O
the O
RARE O
cell O
sequence O
. O

RARE O
of O
a O
NUM I-GENE
deletion O
RARE O
and O
isolation O
of O
RARE O
- O
RARE O
mutants O
. O

These O
data O
suggest O
that O
RARE O
in O
type O
I O
RARE O
tubular O
acidosis O
may O
be O
due O
to O
a O
defect O
in O
proximal O
RARE O
function O
. O

RARE O
chronic O
RARE O
leukemia O
, O
acute O
RARE O
leukemia O
, O
and O
thrombosis O
with O
protein I-GENE
C I-GENE
deficiency O
. O

RARE O
visual O
RARE O
without O
other O
RARE O
have O
been O
reported O
RARE O
several O
hundred O
years O
. O

In O
the O
whole O
group O
, O
basal O
ALL_CAP I-GENE
and O
RARE I-GENE
- I-GENE
C I-GENE
levels O
decreased O
from O
a O
mean O
(+/- O
standard O
error O
of O
the O
mean O
) O
of O
52 O
. O
3 O
+/- O
12 O
. O
7 O
to O
11 O
. O
1 O
+/- O
6 O
. O
3 O
RARE O
/ O
ml O
and O
from O
7 O
. O
6 O
+/- O
NUM O
. O
7 O
to O
2 O
. O
5 O
+/- O
NUM O
. O
5 O
ALL_CAP O
/ O
ml O
, O
respectively O
. O

RARE O
of O
different O
criteria O
of O
cure O
revealed O
that O
19 O
patients O
( O
NUM O
%) O
had O
basal O
ALL_CAP I-GENE
levels O
below O
5 O
RARE O
/ O
ml O
, O
NUM O
patients O
( O
NUM O
%) O
had O
normal O
RARE I-GENE
- I-GENE
C I-GENE
values O
, O
16 O
patients O
( O
NUM O
%) O
had O
RARE O
ALL_CAP I-GENE
suppression O
( O
less O
than O
1 O
RARE O
/ O
ml O
) O
RARE O
ALL_CAP O
, O
and O
NUM O
patients O
( O
NUM O
%) O
met O
the O
above O
- O
mentioned O
criteria O
with O
disappearance O
of O
the O
RARE O
ALL_CAP I-GENE
response O
to O
TRH I-GENE
/ O
GnRH I-GENE
test O
. O

It O
suggests O
a O
sequence O
of O
surgical O
planning O
that O
can O
prevent O
them O
and O
also O
offers O
ways O
of O
RARE O
with O
the O
problems O
should O
they O
occur O
. O

In O
RARE O
- O
NUM O
cells O
the O
RARE O
of O
human I-GENE
c I-GENE
- I-GENE
jun I-GENE
mRNA I-GENE
was O
associated O
with O
the O
ability O
to O
clone O
in O
soft O
agarose O
and O
form O
tumors O
in O
nude O
mice O
. O

Furthermore O
, O
formation O
of O
RARE O
of O
transformed O
RARE O
by O
the O
c I-GENE
- I-GENE
jun I-GENE
/ O
ras I-GENE
combination O
was O
augmented O
3 O
- O
RARE O
by O
the O
tumor O
promoter O
phorbol O
12 O
- O
RARE O
NUM O
- O
RARE O
. O

RARE I-GENE
activating I-GENE
factor I-GENE
was O
given O
in O
RARE O
doses O
RARE O
NUM O
minute O
intervals O
and O
airway O
response O
measured O
RARE O
change O
in O
partial O
expiratory O
flow O
RARE O
NUM O
% O
of O
vital O
capacity O
( O
NUM O
). O

There O
was O
RARE O
significant O
correlation O
between O
baseline O
NUM O
RARE O
and O
the O
maximal O
fall O
in O
NUM O
after O
either O
the O
RARE O
( O
12 O
micrograms O
) O
or O
the O
second O
dose O
( O
NUM O
micrograms O
) O
of O
platelet I-GENE
activating I-GENE
factor I-GENE
. O

Both O
ALL_CAP O
and O
ALL_CAP I-GENE
concentrations O
RARE O
the O
ALL_CAP O
were O
the O
lowest O
in O
body O
RARE O
, O
medium O
in O
controls O
, O
and O
the O
highest O
in O
obese O
men O
. O

RARE O
RARE O
: O
a O
family O
planning O
study O
. O

A O
NUM O
. O
5 O
rating O
was O
RARE O
to O
characterize O
subjects O
in O
whom O
mild O
cognitive O
impairment O
due O
to O
senile O
dementia O
of O
the O
RARE O
type O
was O
suspected O
but O
was O
insufficient O
in O
degree O
to O
RARE O
a O
diagnosis O
of O
definite O
dementia O
. O

An O
implant O
may O
release O
a O
drug O
either O
by O
diffusion O
concurrent O
with O
dissolution O
of O
the O
RARE O
implant O
material O
without O
RARE O
( O
RARE O
A O
) O
or O
by O
RARE O
involving O
RARE O
( O
RARE O
B O
). O

Although O
it O
is O
RARE O
known O
that O
RARE O
RARE O
blockers O
can O
influence O
contraction O
of O
vascular O
RARE O
muscle O
, O
there O
is O
less O
knowledge O
on O
its O
effect O
on O
RARE O
contraction O
coupling O
in O
the O
endocrine O
glands O
and O
more O
specifically O
on O
insulin I-GENE
and O
glucagon I-GENE
release O
. O

Many O
studies O
have O
RARE O
out O
the O
possibility O
of O
" O
RARE O
" O
organic O
factors O
in O
RARE O
RARE O
, O
detectable O
only O
by O
means O
of O
laboratory O
investigations O
: O
mild O
RARE O
, O
RARE O
, O
RARE O
selectively O
RARE O
RARE O
the O
site O
of O
the O
sexual O
arteries O
, O
venous O
RARE O
, O
subclinical O
RARE O
. O

The O
site O
- O
specific O
DNA O
inversion O
RARE O
RARE I-GENE
encoded O
by O
the O
RARE O
P1 O
consists O
of O
a O
RARE I-GENE
, O
two O
inverted O
RARE O
- O
over O
sites O
and O
a O
RARE O
enhancer O
. O

The O
terminator O
region O
supported O
RARE O
of O
transcripts O
RARE O
by O
RNA I-GENE
polymerase I-GENE
I I-GENE
in O
vivo O
. O

US O
- O
Doppler O
has O
recently O
RARE O
attention O
RARE O
a O
RARE O
method O
RARE O
the O
RARE O
evaluation O
of O
RARE O
RARE O
( O
ALL_CAP O
). O

Doppler O
echo O
in O
evaluating O
RARE O
RARE O
RARE O
dialysis O

RARE O
RARE O
, O
extension O
of O
the O
RARE O
of O
the O
problems O
that O
can O
be O
addressed O
with O
this O
repair O
( O
including O
treatment O
of O
a O
distal O
RARE O
RARE O
) O
and O
the O
RARE O
with O
which O
the O
RARE O
procedure O
can O
be O
performed O
are O
the O
advantages O
that O
this O
operation O
has O
over O
other O
1 O
- O
RARE O
distal O
RARE O
RARE O
. O

Following O
the O
patients O
RARE O
a O
course O
of O
therapy O
with O
a O
selective O
vasodilator O
RARE O
antagonist O
, O
the O
beta O
- O
adrenergic O
reflex O
vasodilation O
became O
substantially O
attenuated O
but O
was O
RARE O
RARE O
a O
placebo O
course O
of O
therapy O
. O

The O
RARE I-GENE
RARE I-GENE
shows O
both O
sequence O
and O
structural O
homology O
with O
a O
superfamily O
of O
RARE I-GENE
RARE I-GENE
which O
includes O
the O
human I-GENE
NUM I-GENE
- I-GENE
RARE I-GENE
and I-GENE
RARE I-GENE
muscle I-GENE
glucose I-GENE
RARE I-GENE
, O
the O
rat I-GENE
brain I-GENE
and I-GENE
liver I-GENE
glucose I-GENE
RARE I-GENE
, O
the O
Escherichia I-GENE
coli I-GENE
RARE I-GENE
and I-GENE
RARE I-GENE
RARE I-GENE
, O
and O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
glucose I-GENE
, I-GENE
RARE I-GENE
, I-GENE
and I-GENE
RARE I-GENE
RARE I-GENE
. O

Of O
NUM O
previously O
untreated O
patients O
who O
had O
RARE O
the O
study O
of O
protocol O
NUM O
, O
96 O
were O
evaluable O
. O

There O
were O
3 O
/ O
NUM O
( O
9 O
. O
4 O
per O
cent O
) O
adverse O
reactions O
( O
RARE O
RARE O
and O
one O
case O
each O
of O
RARE O
, O
RARE O
and O
increased O
menstrual O
flow O
. O

More O
mRNA O
corresponding O
to O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
is O
detected O
than O
that O
corresponding O
to O
the O
distal O
genes O
, O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
. O

RARE I-GENE
necrosis I-GENE
factor I-GENE
( O
TNF I-GENE
) O
is O
reported O
to O
cause O
a O
shock O
RARE O
similar O
to O
that O
produced O
by O
RARE O
( O
ALL_CAP O
). O

The O
RARE O
requirement O
RARE O
RARE O
RARE O
of O
the O
cardiac O
RARE O
. O

The O
RARE O
cysteine O
RARE O
of O
ALL_CAP I-GENE
is O
RARE O
within O
the O
activation O
peptide O
region O
of O
the O
RARE O
. O

The O
NUM I-GENE
. I-GENE
8 I-GENE
gene I-GENE
has O
a O
strong O
RARE O
usage O
RARE O
which O
is O
strikingly O
different O
from O
that O
of O
the O
RARE I-GENE
gene I-GENE
. O

Of O
the O
single O
- O
RARE O
DNA O
transformants O
, O
65 O
% O
resulted O
from O
RARE O
of O
the O
RARE O
NUM I-GENE
mutation I-GENE
by O
the O
RARE O
wild O
- O
type O
allele O
. O

The O
results O
strongly O
support O
the O
notion O
that O
the O
NUM I-GENE
- I-GENE
binding I-GENE
sites I-GENE
and O
the O
NUM I-GENE
protein I-GENE
are O
important O
RARE O
normal O
ALL_CAP O
function O
RARE O
an O
origin O
of O
replication O
. O

On O
the O
basis O
of O
S1 I-GENE
RARE I-GENE
protection O
analysis O
of O
RNA O
preparations O
from O
several O
mouse O
tissues O
, O
both O
RARE I-GENE
and O
divergent O
genes O
showed O
similar O
levels O
of O
RARE O
but O
did O
show O
some O
RARE O
in O
RARE O
site O
utilization O
. O

Four O
out O
of O
10 O
patients O
showed O
clinical O
improvement O
according O
to O
RARE O
- O
RARE O
, O
pain O
score O
, O
ALL_CAP O
and O
CRP I-GENE
. O

NUM O
: O
NUM O
- O
NUM O
, O
1987 O
). O

With O
both O
wild O
- O
type O
and O
the O
mutant O
RARE O
, O
ATP O
activates O
both O
RARE O
14C O
] O
RARE O
in O
equilibrium O
N O
- O
RARE O
- O
L O
- O
RARE O
( O
C O
- O
RARE O
) O
and O
the O
RARE O
32P O
] O
RARE O
phosphate O
( O
C O
- O
P O
) O
in O
equilibrium O
RARE O
RARE O
. O

RARE O
rates O
RARE O
the O
original O
treatment O
group O
were O
NUM O
. O
5 O
% O
and O
57 O
. O
6 O
% O
RARE O
12 O
and O
21 O
months O
, O
respectively O
; O
RARE O
the O
delayed O
treatment O
group O
, O
NUM O
. O
8 O
% O
and O
NUM O
. O
6 O
% O
RARE O
12 O
and O
21 O
months O
, O
respectively O
, O
and O
NUM O
. O
8 O
% O
and O
NUM O
. O
5 O
% O
RARE O
12 O
and O
21 O
months O
, O
respectively O
, O
RARE O
77 O
subjects O
with O
AIDS O
and O
93 O
. O
NUM O
% O
and O
NUM O
. O
8 O
%, O
respectively O
, O
RARE O
50 O
subjects O
with O
AIDS O
- O
related O
complex O
in O
the O
original O
treatment O
group O
. O

Mapping O
results O
suggested O
that O
the O
RARE O
group O
identified O
by O
these O
mutants O
is O
allelic O
to O
the O
RARE I-GENE
alpha I-GENE
1 I-GENE
mutation O
identified O
previously O
. O

The O
products O
of O
genes O
NUM I-GENE
and O
NUM I-GENE
are O
proposed O
to O
participate O
in O
the O
RARE O
of O
RARE O
monophosphate O
. O

After O
the O
application O
of O
ALL_CAP O
NUM O
, O
REM O
RARE O
was O
shortened O
in O
all O
groups O
under O
investigation O
. O

Hybridization O
analysis O
showed O
that O
the O
size O
of O
the O
mRNA O
is O
about O
1 O
. O
4 O
kilobases O
. O

RARE O
treatment O
with O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE

The O
R I-GENE
. I-GENE
RARE I-GENE
ALL_CAP I-GENE
promoter I-GENE
but O
not O
the O
K I-GENE
. I-GENE
RARE I-GENE
ALL_CAP I-GENE
promoter I-GENE
showed O
RARE I-GENE
54 I-GENE
- O
dependent O
methylation O
protection O
of O
guanine O
residues O
RARE O
- O
14 O
, O
- O
NUM O
and O
- O
NUM O
, O
the O
most O
RARE O
nucleotides O
characteristic O
of O
RARE I-GENE
54 I-GENE
- I-GENE
dependent I-GENE
promoters I-GENE
. O

RARE O
clinical O
symptoms O
of O
the O
RARE O
were O
defined O
in O
this O
group O
of O
patients O
. O

Recently O
, O
an O
RARE O
RARE O
form O
of O
c I-GENE
- I-GENE
myb I-GENE
- I-GENE
encoded I-GENE
mRNA I-GENE
has O
been O
identified O
in O
murine O
cells O
containing O
either O
normal O
or O
RARE O
c I-GENE
- I-GENE
myb I-GENE
genes I-GENE
. O

RARE O
clinical O
analysis O
revealed O
lower O
hematocrit O
and O
hemoglobin I-GENE
, O
and O
elevated O
ALL_CAP O
and O
RARE I-GENE
phosphatase I-GENE
in O
the O
treated O
group O
. O

To O
assess O
the O
health O
significance O
of O
the O
early O
RARE O
changes O
after O
chronic O
exposure O
to O
cadmium O
, O
NUM O
workers O
removed O
from O
exposure O
because O
of O
the O
discovery O
of O
an O
increased O
RARE O
excretion O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
or O
RARE I-GENE
binding I-GENE
protein I-GENE
, O
or O
both O
, O
have O
been O
examined O
once O
a O
year O
RARE O
five O
years O
. O

In O
order O
to O
study O
the O
structural O
and O
RARE O
organization O
of O
the O
eukaryotic O
RARE O
, O
we O
have O
started O
to O
isolate O
and O
characterize O
RARE O
RARE O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

A O
transcription O
factor O
exclusion O
assay O
was O
used O
to O
show O
that O
the O
NUM I-GENE
mutation I-GENE
affects O
two O
distinct O
stages O
in O
transcription O
: O
one O
prior O
to O
and O
one O
after O
stable O
complex O
formation O
; O
and O
that O
these O
effects O
are O
RARE O
by O
a O
RARE O
of O
the O
stable O
complex O
. O

RARE O
and O
the O
RARE O
. O

These O
adverse O
effects O
usually O
RARE O
with O
time O
. O

The O
cytosolic O
RARE I-GENE
S I-GENE
- I-GENE
RARE I-GENE
( O
RARE I-GENE
, O
EC I-GENE
2 I-GENE
. I-GENE
5 I-GENE
. I-GENE
1 I-GENE
. I-GENE
18 I-GENE
) O
are O
a O
superfamily O
of O
RARE O
RARE O
which O
RARE O
the O
conjugation O
of O
RARE O
RARE O
with O
RARE O
. O

Furthermore O
, O
the O
3 O
'- O
RARE O
regions O
of O
NUM I-GENE
display O
a O
marked O
degree O
of O
homology O
to O
the O
3 O
' O
region O
of O
the O
rat I-GENE
NUM I-GENE
gene I-GENE
, O
while O
this O
region O
of O
NUM I-GENE
displays O
marked O
homology O
to O
the O
corresponding O
region O
of O
the O
rat I-GENE
NUM I-GENE
gene I-GENE
. O

RARE O
IV O
: O
RARE O
RARE O
with O
the O
lateral O
RARE O
and O
the O
second O
RARE O
RARE O
secondary O
RARE O
. O

The O
incidence O
of O
RARE O
breathing O
movements O
( O
06 O
. O
00 O
- O
10 O
. O
00 O
h O
) O
decreased O
with O
increasing O
gestational O
age O
while O
RARE O
arterial O
concentrations O
of O
plasma O
ALL_CAP O
increased O
significantly O
over O
the O
same O
period O
of O
gestation O
. O

During O
the O
RARE O
3 O
min O
of O
recovery O
, O
plasma O
RARE O
fell O
rapidly O
in O
RARE O
of O
nearly O
unchanged O
RARE O
acidosis O
and O
significantly O
decreasing O
RARE O
concentration O
. O

The O
present O
data O
also O
suggest O
that O
when O
compared O
to O
the O
systemic O
vascular O
RARE O
, O
the O
pulmonary O
vascular O
RARE O
is O
less O
responsive O
to O
bolus O
administration O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
. O

In O
comparison O
with O
normal O
RARE O
women O
and O
normal O
non O
- O
RARE O
women O
, O
women O
with O
ALL_CAP O
showed O
an O
increase O
in O
RARE O
rate O
, O
suggesting O
an O
increased O
peripheral O
sympathetic O
tone O
, O
and O
an O
initial O
RARE O
in O
RARE O
function O
RARE O
shown O
by O
the O
increase O
in O
serum O
uric O
acid O
and O
reduction O
in O
RARE O
excretion O
and O
RARE O
and O
fractional O
RARE O
excretion O
RARE O
any O
given O
level O
of O
RARE O
excretion O
. O

We O
have O
examined O
the O
role O
of O
two O
RARE O
- O
and O
repair O
- O
RARE O
mutations O
, O
NUM I-GENE
and O
NUM I-GENE
, O
on O
direct O
repeat O
RARE O
in O
transcriptionally O
RARE O
and O
inactive O
sequences O
. O

The O
encoded O
protein O
has O
a O
RARE O
sequence O
of O
NUM O
amino O
RARE O
. O

On O
the O
other O
RARE O
, O
knowledge O
of O
the O
RARE O
of O
Parkinson O
' O
s O
RARE O
is O
necessary O
in O
RARE O
RARE O
RARE O
, O
since O
only O
RARE O
consistent O
with O
the O
epidemiological O
profile O
RARE O
RARE O
testing O
. O

The O
RARE O
of O
drug O
action O
. O

RARE O
2 O
showed O
the O
least O
RARE O
penetration O
but O
not O
statistically O
less O
than O
the O
ALL_CAP O
bond O
/ O
RARE O
RARE O
combination O
. O

A O
combination O
of O
cisplatin O
and O
5 O
- O
fluorouracil O
, O
both O
administered O
4 O
days O
continuously O
RARE O
infusion O
, O
was O
assessed O
in O
advanced O
head O
and O
neck O
RARE O
. O

RARE O
plasma O
concentrations O
remained O
unchanged O
except O
RARE O
patients O
transferred O
from O
1 O
. O
5 O
to O
2 O
. O
NUM O
g O
daily O
to O
NUM O
mg O
twice O
daily O
; O
in O
these O
patients O
plasma O
concentrations O
increased O
from O
1 O
. O
NUM O
+/- O
NUM O
. O
87 O
to O
2 O
. O
50 O
+/- O
NUM O
. O
NUM O
micrograms O
/ O
RARE O
( O
p O
less O
than O
NUM O
. O
01 O
). O

Diagnosis O
of O
RARE O
RARE O
RARE O
in O
a O
RARE O
donor O
with O
elevated O
serum I-GENE
alanine I-GENE
aminotransferase I-GENE
. O

When O
statistically O
analyzed O
in O
various O
RARE O
, O
the O
obtained O
average O
sedimentation O
coefficients O
and O
RARE O
profiles O
supported O
the O
following O
conclusions O
: O
( O
a O
) O
RARE O
of O
RARE O
RARE O
and O
RARE O
is O
confirmed O
to O
be O
a O
RARE O
sign O
of O
cartilage O
RARE O
RARE O
; O
( O
b O
) O
RARE O
S O
values O
RARE O
RARE O
of O
the O
high O
RARE O
( O
ALL_CAP O
)- O
RARE O
areas O
and O
lower O
values O
RARE O
those O
of O
the O
low O
RARE O
( O
ALL_CAP O
)- O
RARE O
areas O
were O
a O
typical O
finding O
in O
normal O
cartilage O
samples O
; O
( O
c O
) O
inversion O
of O
this O
pattern O
was O
indicative O
of O
RARE O
RARE O
, O
suggesting O
that O
the O
ALL_CAP O
regions O
are O
more O
affected O
than O
the O
ALL_CAP O
- O
RARE O
areas O
; O
( O
d O
) O
the O
average O
S O
value O
distribution O
across O
cartilage O
thickness O
tended O
to O
RARE O
the O
corresponding O
RARE O
content O
versus O
distance O
from O
RARE O
surface O
; O
and O
( O
RARE O
) O
the O
RARE O
cartilage O
layer O
had O
, O
in O
most O
cases O
, O
the O
smallest O
amount O
of O
aggregates O
while O
the O
highest O
average O
RARE O
was O
observed O
RARE O
the O
RARE O
zone O
of O
the O
normal O
samples O
. O

A O
significant O
relationship O
existed O
RARE O
the O
evolution O
of O
the O
RARE O
between O
ALL_CAP O
/ O
ALL_CAP O
and O
gas O
exchange O
parameters O
( O
NUM O
and O
a O
/ O
NUM O
ratio O
) O
( O
P O
less O
than O
NUM O
. O
01 O
RARE O
but O
gas O
exchange O
improved O
earlier O
than O
RARE O
RARE O
. O

RARE O
points O
measured O
were O
RARE O
( O
NUM O
- O
day O
) O
RARE O
infarction O
( O
MI O
) O
rate O
and O
RARE O
. O

The O
predicted O
RARE O
RARE O
of O
the O
RARE O
encoded O
by O
ORF1 O
is O
NUM O
RARE O
( O
kDa O
). O

Thus O
RV O
NUM O
demand O
fell O
when O
ALL_CAP O
NUM O
supply O
was O
RARE O
, O
although O
a O
flow O
reserve O
was O
available O
. O

An O
RARE O
method O
of O
ALL_CAP O
is O
proposed O
based O
on O
RARE O
a O
small O
fraction O
of O
RARE O
RARE O
flow O
RARE O
3 O
consecutive O
RARE O
. O

RARE O
chromatography O
with O
RARE O
detection O
( O
ALL_CAP O
/ O
AD O
) O
is O
used O
to O
determine O
RARE O
acid O
produced O
from O
the O
metabolism O
or O
RARE O
hydrolysis O
of O
RARE O
- O
RARE O
in O
RARE O
and O
RARE O
oil O
. O

The O
RARE O
is O
removed O
, O
mobile O
RARE O
solvent O
is O
added O
, O
and O
RARE O
are O
injected O
onto O
a O
ALL_CAP O
- O
1 O
liquid O
chromatographic O
column O
; O
RARE O
acid O
is O
separated O
from O
RARE O
compounds O
and O
detected O
RARE O
an O
applied O
RARE O
of O
+ O
1 O
. O
NUM O
V O
, O
using O
an O
RARE O
RARE O
detector O
in O
the O
oxidation O
mode O
. O

Primer O
extension O
experiments O
indicated O
that O
the O
transcription O
initiation O
site O
mapped O
to O
a O
position O
on O
gene I-GENE
IV I-GENE
that O
was O
analogous O
to O
that O
reported O
RARE O
the O
structurally O
similar O
P I-GENE
- I-GENE
NUM I-GENE
gene I-GENE
. O

Significantly O
, O
the O
polymerase O
chain O
reaction O
results O
demonstrated O
that O
gene I-GENE
IV I-GENE
transcripts I-GENE
were O
associated O
with O
RARE O
RARE O
fractions O
, O
indicating O
their O
RARE O
utilization O
in O
this O
tissue O
. O

RARE O
of O
the O
survey O
of O
work O
RARE O
: O
a O
profile O
measure O
of O
the O
type O
A O
behaviour O
pattern O
. O

Only O
one O
ADR O
was O
related O
RARE O
to O
RARE O
therapy O
. O

HIV O
RARE O
and O
the O
AIDS O
epidemic O
. O

From O
day O
NUM O
after O
RARE O
, O
the O
ALL_CAP O
- O
group O
had O
significantly O
lower O
serum I-GENE
RARE I-GENE
levels O
, O
which O
RARE O
the O
low O
degree O
of O
RARE O
damage O
in O
these O
animals O
. O

The O
corresponding O
inhibition O
of O
acid I-GENE
phosphatase I-GENE
activity O
in O
control O
male O
and O
female O
RARE O
pigs O
was O
NUM O
. O
91 O
% O
and O
20 O
. O
NUM O
% O
respectively O
. O

Its O
clinical O
and O
RARE O
characteristics O
. O

RARE O
( O
NUM O
= O
40 O
mm O
Hg O
) O
RARE O
drive O
increased O
significantly O
( O
p O
less O
than O
NUM O
. O
05 O
) O
in O
RARE O
subjects O
( O
RARE O
1 O
response O
) O
and O
decreased O
substantially O
in O
the O
others O
( O
RARE O
2 O
response O
); O
with O
hypercapnia O
, O
the O
changes O
in O
drive O
were O
attenuated O
in O
both O
groups O
. O

RARE O
changes O
in O
( O
type O
II O
) O
RARE O
glomerulonephritis O
RARE O
RARE O
: O
a O
histopathological O
report O
. O

Chronic O
dose O
effects O
of O
RARE O
RARE O
on O
RARE O
: O
cholinesterase I-GENE
and O
RARE O
. O

The O
titer O
of O
anti I-GENE
HSV I-GENE
type I-GENE
1 I-GENE
and O
anti I-GENE
HSV I-GENE
type I-GENE
2 I-GENE
antibodies I-GENE
in O
the O
mothers O
' O
and O
cord O
RARE O
was O
determined O
and O
compared O
. O

RARE O
RARE O
and O
RARE O
- O
to O
- O
body O
RARE O
ratio O
were O
significantly O
elevated O
RARE O
the O
highest O
dose O
level O
after O
10 O
weeks O
and O
RARE O
the O
two O
RARE O
dose O
levels O
after O
NUM O
weeks O
of O
exposure O
. O

RARE O
variation O
in O
HLA I-GENE
- I-GENE
B I-GENE
and O
HLA I-GENE
- I-GENE
C I-GENE
sequences I-GENE
and O
the O
evolution O
of O
the O
HLA I-GENE
- I-GENE
B I-GENE
alleles I-GENE
. O

A O
method O
RARE O
RARE O
optimal O
development O
conditions O
by O
summary O
oxygen O
consumption O

RARE O
were O
more O
positive O
about O
their O
physical O
fitness O
than O
women O
. O

RARE O
RARE O
was O
also O
carried O
out O
in O
NUM O
of O
the O
patients O
. O

In O
RARE O
RARE O
, O
an O
ALL_CAP I-GENE
catalytic O
concentration O
above O
NUM O
. O
NUM O
mu O
RARE O
/ O
L O
strongly O
suggests O
tuberculous O
meningitis O
in O
patients O
older O
than O
7 O
years O
( O
sensitivity O
1 O
. O
00 O
, O
RARE O
NUM O
. O
NUM O
and O
efficiency O
NUM O
. O
NUM O
). O

ALL_CAP O
contains O
NUM O
anatomical O
data O
RARE O
arranged O
in O
a O
RARE O
- O
like O
manner O
reflecting O
structural O
and O
RARE O
relationships O
. O

RARE O
- O
over O
: O
an O
RARE O
method O
RARE O
RARE O
RARE O
spermatozoa O
. O

RARE O
washout O
: O
increasing O
a O
microvascular O
free O
flap O
tolerance O
to O
ischemia O
. O

Similarly O
, O
the O
sequence O
of O
the O
NUM I-GENE
RNA I-GENE
region I-GENE
shown O
to O
be O
involved O
in O
pre O
- O
mRNA O
branchpoint O
recognition O
in O
yeast O
, O
and O
RARE O
RARE O
in O
RARE I-GENE
NUM I-GENE
RNAs I-GENE
, O
was O
RARE O
divergent O
in O
RARE O
. O

It O
is O
striking O
that O
the O
RARE O
CHO O
spacer O
promoter O
RARE O
the O
otherwise O
RARE O
RARE O
that O
RARE I-GENE
RNA I-GENE
polymerase I-GENE
I I-GENE
promoters I-GENE
all O
have O
a O
G O
RARE O
RARE O
position O
- O
16 O
. O

A O
raised O
amplitude O
of O
the O
RARE O
of O
plates O
and O
a O
decrease O
in O
the O
threshold O
of O
their O
sensitivity O
to O
ALL_CAP O
were O
established O
in O
the O
persons O
with O
RARE O
RARE O
and O
RARE O
ALL_CAP O
and O
in O
ALL_CAP O
without O
ALL_CAP O
. O

Significant O
RARE O
differences O
are O
RARE O
RARE O
both O
RARE O
RARE O
and O
soft O
tissue O
profile O
variables O
. O

The O
author O
provides O
a O
RARE O
RARE O
an O
RARE O
view O
and O
presents O
a O
case O
in O
which O
post O
- O
surgical O
RARE O
were O
successfully O
treated O
, O
using O
RARE O
developed O
by O
the O
RARE O
Research O
Institute O
. O

The O
relative O
toxicity O
of O
nickel O
oxide O
( O
ALL_CAP O
RARE O
nickel O
RARE O
RARE O
( O
NUM O
. O
NUM O
RARE O
and O
nickel O
RARE O
( O
NUM O
) O
was O
studied O
in O
NUM O
/ O
N O
rats O
and O
NUM O
mice O
after O
inhalation O
exposure O
RARE O
6 O
hr O
/ O
day O
, O
5 O
days O
/ O
week O
, O
RARE O
NUM O
weeks O
. O

RARE O
RARE O
and O
routine O
immunohistochemical O
studies O
of O
a O
cervical O
RARE O
in O
a O
NUM O
year O
old O
woman O
initially O
suggested O
a O
RARE O
lymphoma O
, O
but O
RARE O
staining O
RARE O
RARE I-GENE
esterase I-GENE
established O
the O
correct O
diagnosis O
. O

From O
the O
National O
RARE O
of O
Health O
. O

Molecular O
cloning O
and O
RARE O
of O
the O
two O
homologous O
genes O
coding O
RARE O
RARE I-GENE
reductase I-GENE
in I-GENE
tobacco I-GENE
. O

In O
the O
final O
model O
, O
grade O
( O
p O
= O
NUM O
. O
NUM O
RARE O
peritoneal O
RARE O
results O
( O
p O
= O
NUM O
. O
NUM O
RARE O
progesterone I-GENE
receptor I-GENE
status O
( O
p O
= O
NUM O
. O
NUM O
RARE O
and O
age O
RARE O
a O
continuous O
RARE O
( O
p O
= O
NUM O
. O
NUM O
) O
were O
most O
closely O
associated O
with O
RARE O
- O
free O
survival O
. O

In O
contrast O
, O
despite O
external O
radiation O
therapy O
, O
brain O
metastases O
proved O
fatal O
. O

COUP I-GENE
transcription I-GENE
factor I-GENE
is O
a O
RARE O
of O
the O
steroid I-GENE
receptor I-GENE
superfamily I-GENE
. O

In O
Experiment O
2 O
, O
we O
again O
used O
classification O
, O
but O
the O
fixed O
standard O
NUM O
was O
not O
RARE O
the O
RARE O
of O
the O
range O
of O
target O
numbers O
( O
20 O
, O
21 O
, O
RARE O

RARE O
RARE O
containing O
both O
ALL_CAP O
sequences O
were O
identified O
, O
and O
RARE O
mapping O
showed O
them O
to O
be O
less O
than O
NUM O
kb O
apart O
. O

The O
oxygen O
uptake O
( O
VO2 O
RARE O
carbon O
dioxide O
output O
( O
NUM O
RARE O
respiratory O
rate O
( O
ALL_CAP O
RARE O
minute O
ventilation O
( O
VE O
RARE O
alveolar O
ventilation O
( O
VA O
RARE O
alveolar O
oxygen O
pressure O
( O
NUM O
RARE O
and O
VE O
/ O
VO2 O
ratio O
were O
RARE O
in O
the O
cows O
, O
while O
the O
tidal O
volume O
( O
VT O
) O
and O
physiological O
RARE O
space O
( O
ALL_CAP O
) O
were O
larger O
in O
the O
horses O
. O

RARE O
damage O
was O
not O
observed O
in O
any O
controls O
but O
was O
in O
all O
tissues O
exposed O
to O
NUM O
. O

Among O
RARE O
patients O
the O
RARE O
mortality O
rate O
was O
NUM O
. O
NUM O
and O
among O
RARE O
patients O
11 O
. O
NUM O
per O
1000 O
RARE O
. O

The O
present O
study O
RARE O
whether O
prostaglandins O
" O
RARE O
" O
the O
RARE O
mucosa O
against O
hemorrhage O
- O
RARE O
stress O
ulceration O
by O
assessing O
the O
influence O
of O
16 O
, O
16 O
- O
dimethyl O
RARE O
E2 O
( O
16 O
, O
16 O
- O
RARE O
PGE2 O
) O
on O
gross O
and O
microscopic O
lesion O
formation O
, O
RARE O
tissue O
pH O
, O
H O
+ O
back O
- O
diffusion O
, O
and O
RARE O
RARE O
flow O
in O
rat O
RARE O
mucosa O
exposed O
to O
luminal O
acid O
( O
NUM O
mM O
RARE O
) O
RARE O
hemorrhagic O
shock O
( O
NUM O
ml O
/ O
kg O
RARE O
20 O
min O
). O

RARE O
characterized O
include O
( O
i O
) O
abundant O
RARE O
NUM I-GENE
and O
RARE O
NUM I-GENE
- O
NUM I-GENE
- O
NUM I-GENE
transcripts O
; O
( O
ii O
) O
less O
abundant O
RARE O
ALL_CAP I-GENE
- O
NUM I-GENE
and O
RARE O
ALL_CAP I-GENE
transcripts I-GENE
and O
( O
iii O
) O
a O
very O
rare O
ORF O
RARE O
transcript O
. O

RARE O
, O
the O
results O
are O
similar O
RARE O
the O
two O
species O
: O
Both O
RARE O
RARE O
and O
man O
have O
RARE O
and O
RARE O
RARE O
, O
which O
cross O
RARE O
RARE O
the O
same O
time O
in O
the O
dark O
and O
RARE O
RARE O
the O
same O
background O
RARE O
. O

Evidence O
from O
the O
RARE O
of O
a O
number O
of O
cDNA O
RARE O
, O
RARE O
RARE O
RARE O
S1 I-GENE
RARE I-GENE
and O
primer O
extension O
studies O
supports O
the O
hypothesis O
that O
the O
ALL_CAP I-GENE
gene I-GENE
contains O
RARE O
least O
two O
mRNA O
transcription O
RARE O
points O
that O
define O
two O
putative O
regulatory O
domains O
. O

At O
each O
level O
of O
PaO2 O
we O
obtained O
simultaneous O
measures O
of O
arterial O
and O
venous O
RARE O
gases O
, O
venous O
RARE O
concentration O
, O
and O
changes O
in O
the O
relative O
concentrations O
of O
inorganic O
phosphate O
, O
RARE O
, O
and O
ATP O
measured O
with O
NUM O
magnetic O
resonance O
spectroscopy O
. O

The O
transcription O
initiation O
site O
was O
determined O
by O
S1 I-GENE
RARE I-GENE
mapping O
. O

RARE O
biopsies O
and O
plasma O
oestradiol O
( O
E2 O
) O
and O
progesterone O
( O
NUM O
) O
levels O
in O
NUM O
patients O
were O
evaluated O
RARE O
NUM O
RARE O
therapy O
cycles O
RARE O
premature O
ovarian O
failure O
. O

The O
mobility O
of O
the O
upper O
and O
lower O
RARE O
under O
load O
was O
investigated O
in O
relation O
to O
the O
RARE O
RARE O
and O
RARE O
RARE O
. O

A O
RARE I-GENE
albumin I-GENE
- I-GENE
like I-GENE
protein I-GENE
was O
not O
detectable O
by O
silver O
staining O
in O
serum O
of O
RARE O
before O
the O
beginning O
of O
RARE O
RARE O
RARE O
NUM O
. O

RARE O
, O
a O
pain O
- O
RARE O
group O
( O
PT O
= O
29 O
RARE O
) O
tolerated O
the O
RARE O
3 O
- O
min O
test O
( O
means O
= O
180 O
+/- O
NUM O
sec O
RARE O
while O
a O
pain O
- O
RARE O
group O
( O
ALL_CAP O
= O
NUM O
RARE O
) O
averaged O
only O
50 O
. O
NUM O
+/- O
20 O
. O
NUM O
sec O
of O
the O
cold O
- O
pressor O
test O
( O
t O
= O
16 O
. O
NUM O
, O
P O
less O
than O
NUM O
. O
0001 O
RARE O
RARE O
our O
earlier O
studies O
. O

This O
suggested O
that O
RARE I-GENE
liver I-GENE
class I-GENE
I I-GENE
ADH I-GENE
is O
of O
the O
same O
ancestral O
lineage O
RARE O
the O
human I-GENE
ADH I-GENE
- I-GENE
beta I-GENE
. O

RARE O
RARE O
( O
i O
. O
RARE O
. O
without O
RARE O
and O
/ O
or O
RARE O
) O
is O
a O
frequent O
finding O
. O

Each O
individual O
RARE O
NUM O
RARE O
in O
about O
5 O
minutes O
, O
RARE O
an O
intensity O
level O
calculated O
RARE O
NUM O
ALL_CAP O
. O

RARE O
RARE O
the O
circadian O
rhythm O
of O
RARE O
- O
RARE O
in O
RARE O
hamsters O
RARE O
plasma O
concentrations O
( O
NUM O
. O
NUM O
- O
NUM O
. O
NUM O
mM O
) O
that O
also O
cause O
toxic O
RARE O
RARE O
. O

RARE O
and O
RARE O
RARE O
, O
using O
NUM O
methylene O
RARE O
, O
were O
obtained O
RARE O
zero O
, O
RARE O
, O
and O
12 O
weeks O
after O
fracture O
. O

On O
admission O
to O
our O
RARE O
in O
RARE O
, O
1987 O
, O
the O
patient O
was O
RARE O
and O
had O
RARE O
RARE O
, O
the O
impairment O
of O
all O
sensory O
modalities O
below O
the O
level O
of O
RARE O
10 O
and O
RARE O
disturbance O
. O

RARE O
and O
RARE O

The O
nature O
of O
the O
process O
formed O
by O
the O
successive O
RARE O
of O
this O
RARE O
was O
studied O
in O
8 O
patients O
with O
a O
history O
of O
symptomatic O
RARE O
ALL_CAP O
. O

This O
would O
have O
had O
the O
effect O
of O
positioning O
the O
genes O
currently O
on O
the O
long O
RARE O
adjacent O
to O
the O
RARE O
RARE O
, O
perhaps O
resulting O
in O
a O
" O
position O
effect O
" O
on O
transcription O
of O
these O
genes O
. O

Initial O
experience O
with O
a O
RARE O
RARE O
current O
based O
RARE O
. O

RARE O
was O
strongly O
associated O
with O
the O
RARE O
of O
RARE O
- O
RARE O
and O
albumin I-GENE
- O
RARE O
estradiol O
, O
and O
inversely O
associated O
with O
RARE I-GENE
hormone I-GENE
binding I-GENE
globulin I-GENE
( O
SHBG I-GENE
) O
levels O
and O
the O
proportion O
of O
SHBG I-GENE
- O
RARE O
estradiol O
. O

RARE I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
core I-GENE
protein I-GENE
NUM I-GENE
is O
a O
major O
RARE O
of O
mammalian I-GENE
ALL_CAP I-GENE
40 I-GENE
S I-GENE
RARE I-GENE
. O

RARE I-GENE
cholinesterase I-GENE
activity O
of O
RARE O
great O
RARE O
, O
RARE O
RARE O
and O
black O
- O
RARE O
night O
- O
RARE O
. O
inhibition O
of O
brain I-GENE
cholinesterase I-GENE
( O
ALL_CAP I-GENE
) O
activity O
in O
birds O
is O
often O
used O
to O
RARE O
exposure O
or O
RARE O
from O
RARE O
or O
RARE O
RARE O
. O

The O
effect O
of O
zinc O
deficiency O
on O
RARE O
RARE O
in O
the O
liver O
, O
RARE O
, O
RARE O
, O
pancreas O
and O
RARE O
was O
investigated O
in O
the O
control O
and O
zinc O
- O
RARE O
rats O
RARE O
NUM O
days O
and O
20 O
days O
of O
RARE O
. O

Our O
findings O
support O
the O
view O
of O
a O
RARE O
RARE O
of O
the O
cardiac O
involvement O
in O
RARE O
patients O
. O

RARE O
cells O
to O
NUM O
degrees O
C O
decreased O
the O
amount O
of O
newly O
synthesized O
rRNA O
to O
less O
than O
5 O
% O
of O
the O
control O
level O
and O
led O
to O
greater O
than O
NUM O
% O
inhibition O
of O
transcription O
RARE O
RARE O
a O
region O
NUM O
to O
NUM O
nucleotides O
RARE O
of O
the O
3 O
' O
end O
of O
28S I-GENE
rRNA I-GENE
, O
with O
readthrough O
RARE O
into O
the O
next O
transcription O
unit O
. O

Deletion O
analysis O
showed O
that O
the O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
and O
AP I-GENE
- I-GENE
1 I-GENE
sequences O
are O
each O
necessary O
RARE O
full O
enhancer O
activity O
. O

RARE O
swelling O
was O
observed O
in O
2 O
patients O
who O
developed O
RARE O
lesions O
. O

RARE O
' O
s O
RARE O
: O
reports O
of O
7 O
cases O
in O
the O
period O
1982 O
- O
1987 O

When O
two O
- O
dimensional O
polyacrylamide O
gel O
electrophoretic O
patterns O
of O
RARE O
NUM O
] O
methionine O
- O
labeled O
proteins O
RARE O
from O
cells O
RARE O
with O
parental O
and O
recombinant O
viruses O
were O
compared O
, O
a O
RARE O
missing O
from O
the O
latter O
corresponded O
in O
RARE O
RARE O
and O
RARE O
point O
with O
that O
predicted O
from O
the O
NUM I-GENE
ORF I-GENE
. O

ALL_CAP O
is O
used O
to O
set O
such O
NMR O
RARE O
parameters O
RARE O
the O
delay O
and O
duration O
of O
RARE O
RARE O
and O
receive O
RARE O
, O
RARE O
RARE O
, O
sampling O
times O
, O
and O
such O
imaging O
parameters O
RARE O
RARE O
pulse O
shape O
and O
gradient O
RARE O
. O

RARE O
ALL_CAP O
( O
NUM O
patients O
) O
was O
defined O
RARE O
arthritis O
associated O
, O
but O
not O
necessarily O
RARE O
, O
with O
a O
typical O
RARE O
rash O
, O
or O
arthritis O
RARE O
RARE O
least O
3 O
of O
4 O
minor O
criteria O
: O
RARE O
, O
RARE O
RARE O
, O
psoriasis O
- O
like O
rash O
, O
or O
family O
history O
of O
psoriasis O
. O

Hence O
follows O
RARE O
' O
s O
demand O
to O
RARE O
out O
appropriate O
importance O
to O
the O
RARE O
. O

The O
author O
gives O
an O
account O
of O
RARE O
, O
RARE O
, O
RARE O
and O
RARE O
effects O
of O
some O
RARE O
antagonists O
, O
and O
their O
clinical O
application O
is O
discussed O
. O

A O
correlation O
coefficient O
was O
used O
RARE O
assessing O
the O
RARE O
of O
each O
map O
pattern O
with O
the O
normal O
mean O
ALL_CAP O
map O
. O

A O
hospital O
- O
based O
study O
of O
the O
relationship O
between O
retained O
placenta O
and O
RARE O
in O
RARE O
cows O
. O

This O
indicates O
that O
RARE O
peroxidation O
may O
be O
involved O
in O
the O
development O
of O
senile O
RARE O
and O
, O
RARE O
a O
direct O
consequence O
of O
RARE O
damage O
, O
also O
in O
the O
pathogenesis O
of O
RARE O
in O
diabetes O
and O
in O
severe O
RARE O
. O

The O
histological O
RARE O
was O
RARE O
in O
NUM O
cases O
: O
12 O
G1 O
, O
NUM O
NUM O
, O
NUM O
NUM O
; O
RARE O
spread O
was O
found O
in O
20 O
/ O
54 O
cases O
( O
37 O
%). O

RARE O
was O
significantly O
more O
often O
associated O
with O
ALL_CAP O
group O
( O
91 O
%) O
RARE O
NUM O
% O
RARE O
AT O
and O
in O
only O
16 O
% O
RARE O
ALL_CAP O
group O
. O

A O
value O
of O
1 O
. O
1 O
RARE O
/ O
kg O
was O
used O
RARE O
V O
in O
RARE O
all O
single O
sample O
estimates O
of O
clearance O
( O
CL O
RARE O
and O
a O
value O
of O
4 O
. O
3 O
RARE O
/ O
kg O
was O
used O
to O
RARE O
single O
sample O
estimates O
of O
clearance O
of O
plasma O
RARE O
drug O
( O
RARE O
). O

The O
RARE O
RARE O
: O
a O
model O
of O
chronic O
RARE O
in O
humans O
. O

RARE O
is O
RARE O
by O
an O
oxidative O
RARE O
to O
stable O
, O
RARE O
end O
products O
, O
RARE O
acid O
( O
ALL_CAP O
) O
and O
bromide O
( O
Br O
RARE O
and O
by O
RARE O
pathways O
to O
Br O
- O
and O
inorganic O
fluoride O
( O
F O
RARE O

The O
values O
were O
consistently O
lower O
( O
P O
less O
than O
NUM O
. O
01 O
) O
RARE O
summer O
( O
3 O
. O
NUM O
+/- O
NUM O
. O
NUM O
micrograms O
/ O
NUM O
ml O
RARE O
RARE O
compared O
to O
RARE O
( O
5 O
. O
06 O
+/- O
NUM O
. O
NUM O
). O

These O
results O
suggest O
that O
ALL_CAP O
- O
S O
- O
S O
are O
prone O
to O
RARE O
RARE O
breathing O
patterns O
RARE O
high O
altitude O
, O
which O
is O
associated O
with O
the O
development O
of O
ALL_CAP O
, O
but O
it O
was O
not O
possible O
to O
determine O
whether O
these O
abnormal O
breathing O
patterns O
are O
a O
cause O
or O
an O
effect O
of O
ALL_CAP O
. O

RARE O
( O
i O
. O
v O
.) O
RARE O
a O
dose O
- O
dependent O
increase O
of O
cardiac O
output O
RARE O
NUM O
. O
16 O
- O
NUM O
. O
NUM O
mg O
/ O
kg O
, O
biphasic O
changes O
RARE O
1 O
. O
NUM O
and O
2 O
. O
NUM O
mg O
/ O
kg O
and O
a O
marked O
decrease O
and O
subsequent O
slight O
increase O
RARE O
a O
large O
dose O
of O
5 O
. O
12 O
mg O
/ O
kg O
. O

It O
was O
possible O
to O
RARE O
the O
animals O
into O
high O
and O
low O
responders O
according O
to O
the O
pattern O
of O
RARE O
immune O
response O
. O

RARE O
rate O
( O
HR O
RARE O
rectal O
RARE O
( O
RARE O
RARE O
RARE O
pressure O
, O
RARE O
and O
relative O
RARE O
changes O
RARE O
RARE O
were O
measured O
on O
18 O
RARE O
RARE O
( O
mean O
age O
29 O
. O
4 O
+/- O
7 O
. O
4 O
yr O
, O
VO2 O
RARE O
NUM O
. O
4 O
+ O
8 O
. O
8 O
ml O
kg O
- O
1 O
min O
- O
1 O
) O
RARE O
RARE O
RARE O
' O
s O
RARE O
( O
ALL_CAP O
) O
or O
RARE O
, O
RARE O
resistant O
, O
RARE O
RARE O
with O
self O
contained O
breathing O
apparatus O
( O
ALL_CAP O
). O

The O
clinical O
tolerance O
and O
pharmacokinetics O
of O
ALL_CAP O
NUM O
( O
RARE O
( O
NUM O
, O
NUM O
)- O
6 O
RARE O
NUM O
)- O
RARE O
RARE O
2 O
- O
RARE O
- O
2 O
- O
RARE O
- O
3 O
- O
RARE O
RARE O
a O
new O
RARE O
antibiotic O
, O
have O
been O
studied O
after O
giving O
a O
single O
i O
. O
v O
. O
dose O
of O
4 O
mg O
. O
kg O
- O
1 O
to O
ten O
healthy O
male O
volunteers O
. O

DNA O
blot O
hybridization O
suggests O
that O
the O
rat O
genome O
may O
contain O
more O
than O
one O
gene O
encoding O
RARE I-GENE
transfer I-GENE
protein I-GENE
. O

We O
use O
the O
term O
RARE O
- O
dependent O
IA O
to O
RARE O
to O
the O
serious O
problem O
of O
chronic O
IA O
requiring O
RARE O
prednisone O
therapy O
. O

Another O
segment O
of O
NUM I-GENE
RARE O
296 O
to O
- O
NUM O
RARE O
also O
RARE O
enhancer O
function O
, O
contained O
RARE O
RARE O
sequences O
( O
ALL_CAP O
- O
NUM O
and O
ALL_CAP O
- O
NUM O
). O

1 O
RARE O
1 O
- O
RARE O
) O
RARE O
( O
1 O
- O
ALL_CAP O
) O
has O
been O
reported O
to O
have O
RARE O
antagonist O
properties O
RARE O
the O
5 I-GENE
- I-GENE
HT2 I-GENE
RARE I-GENE
of O
receptor O
, O
and O
it O
has O
been O
suggested O
that O
it O
may O
have O
agonist O
actions O
RARE O
the O
5 I-GENE
- I-GENE
NUM I-GENE
site I-GENE
. O

1 O
RARE O
m O
- O
RARE O
) O
RARE O
( O
ALL_CAP O
, O
NUM O
. O
1 O
- O
3 O
. O
NUM O
mg O
/ O
kg O
) O
and O
1 O
RARE O
m O
- O
RARE O
) O
RARE O
( O
ALL_CAP O
, O
NUM O
. O
1 O
- O
3 O
. O
NUM O
mg O
/ O
kg O
RARE O
both O
thought O
to O
act O
primarily O
RARE O
5 I-GENE
- I-GENE
NUM I-GENE
sites I-GENE
, O
also O
decreased O
responding O
and O
this O
effect O
was O
blocked O
by O
RARE O
and O
by O
1 O
- O
ALL_CAP O
, O
but O
not O
by O
RARE O
. O

The O
characteristic O
feature O
of O
liver O
and O
RARE O
MP O
function O
in O
patients O
with O
ALL_CAP O
associated O
with O
HBsAg I-GENE
RARE O
consisted O
in O
the O
lack O
of O
the O
RARE O
reaction O
on O
the O
part O
of O
RARE O
MP O
, O
which O
was O
likely O
to O
be O
connected O
with O
RARE O
of O
long O
RARE O
and O
depletion O
of O
the O
MP O
RARE O
due O
to O
permanent O
RARE O
RARE O
of O
HBsAg I-GENE
. O

Changes O
in O
RARE I-GENE
oxidase I-GENE
activity O
in O
patients O
with O
circulatory O
failure O

A O
RARE O
and O
water O
( O
1 O
: O
1 O
, O
v O
/ O
v O
) O
solution O
effectively O
RARE O
RARE O
RARE O
RARE O
. O

The O
RARE O
and O
RARE O
activities O
of O
the O
RARE O
RARE O
( O
ES O
RARE O
) O
RARE O
RARE O
RARE O
its O
effects O
on O
RARE O
RARE O
RARE O
flow O
and O
mucus O
RARE O
, O
were O
determined O
in O
the O
rat O
. O

The O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
preferentially O
RARE O
NUM I-GENE
+ I-GENE
T O
lymphocytes O
and O
may O
exist O
RARE O
a O
latent O
provirus O
within O
these O
cells O
RARE O
extended O
periods O
. O

RARE O
RARE O
was O
observed O
in O
biopsy O
specimens O
with O
RARE O
. O

We O
have O
utilized O
the O
human I-GENE
NUM I-GENE
heavy I-GENE
chain I-GENE
( O
NUM I-GENE
) O
gene O
RARE O
a O
model O
RARE O
in O
studies O
designed O
to O
elucidate O
the O
RARE O
events O
involved O
in O
RARE O
inducible O
gene O
RARE O
RARE O
normal O
human O
T O
- O
cell O
activation O
. O

A O
cDNA O
encoding O
the O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
enhancer I-GENE
binding I-GENE
protein I-GENE
has O
been O
RARE O
by O
screening O
a O
lambda O
gt11 O
cDNA O
library O
with O
a O
RARE O
RARE O
corresponding O
to O
the O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
recognition I-GENE
sequence I-GENE
. O

RARE O
right O
ventricular O
hypertrophy O
was O
seen O
in O
4 O
, O
and O
RARE O
hypertrophy O
in O
5 O
patients O
. O

The O
two O
IL6 I-GENE
mRNA I-GENE
species O
are O
generated O
by O
RARE O
polyadenylation O
RARE O
sites O
separated O
by O
a O
distance O
of O
1 O
. O
2 O
kilobases O
. O

Sequencing O
analysis O
revealed O
that O
the O
NUM O
. O
54 O
- O
and O
NUM O
. O
4 O
- O
kb O
fragments O
are O
identical O
except O
RARE O
NUM O
nucleotides O
missing O
RARE O
the O
5 O
' O
region O
of O
the O
NUM O
. O
4 O
- O
kb O
fragment O
. O

The O
RARE O
protein O
also O
contains O
a O
cysteine O
- O
rich O
, O
highly O
hydrophilic O
region O
homologous O
to O
the O
RARE I-GENE
serine I-GENE
protease I-GENE
RARE I-GENE
( O
residues O
NUM O
- O
132 O
). O

RARE O
ALL_CAP O
RARE O
were O
consistently O
modulated O
only O
in O
the O
superficial O
RARE O
responses O
in O
RARE O
RARE O
, O
which O
exhibited O
RARE O
amplitude O
RARE O
the O
RARE O
RARE O
. O

Experiments O
on O
NUM O
RARE O
rats O
and O
10 O
RARE O
pigs O
have O
shown O
that O
RARE O
indomethacin O
- O
RARE O
inhibition O
of O
prostaglandins O
RARE O
prevented O
development O
of O
pulmonary O
RARE O
, O
evoked O
by O
heterologous O
serum O
in O
rats O
and O
by O
vagotomy O
in O
RARE O
pigs O
. O

On O
the O
other O
RARE O
, O
lack O
of O
conservation O
of O
the O
membrane O
RARE O
sequence O
RARE O
- O
glycine O
- O
RARE O
acid O
RARE O
against O
its O
RARE O
importance O
in O
ALL_CAP I-GENE
. O

RARE O
- O
and O
later O
- O
RARE O
cows O
were O
randomly O
assigned O
after O
each O
RARE O
to O
RARE O
and O
RARE O
RARE O
RARE O
in O
multiple O
- O
RARE O
RARE O
. O

Within O
each O
lobe O
, O
the O
PA O
dispersion O
was O
RARE O
to O
10 O
cmH2O O
RARE O
ALL_CAP O
of O
NUM O
RARE O
/ O
min O
; O
when O
flow O
decreased O
, O
PA O
RARE O
all O
sites O
decreased O
, O
RARE O
did O
the O
RARE O
dispersion O
. O

The O
RARE O
consisted O
of O
the O
RARE O
canine O
RARE O
connected O
to O
a O
RARE O
that O
operated O
RARE O
the O
modulated O
RARE O
RARE O
. O

In O
order O
to O
identify O
and O
RARE O
the O
basic O
ALL_CAP O
RARE O
of O
interstitial O
pneumonia O
, O
RARE O
- O
pathologic O
RARE O
study O
was O
performed O
using O
RARE O
and O
fixed O
lungs O
from O
autopsy O
and O
surgery O
. O

The O
RARE O
RARE O
an O
atypical O
course O
; O
with O
early O
jaundice O
RARE O
, O
severe O
RARE O
and O
RARE O
appearance O
of O
RARE O
. O

The O
transcription O
factor O
NUM I-GENE
RARE O
to O
eight O
sites O
, O
RARE O
demonstrated O
by O
footprinting O
assays O
and O
gel O
shift O
analysis O
with O
RARE O
NUM I-GENE
. O

The O
combination O
ALL_CAP O
NUM O
micrograms O
- O
ALL_CAP O
4 O
micrograms O
prevents O
the O
frequent O
secondary O
RARE O
seen O
after O
6 O
hours O
with O
the O
antibiotics O
used O
alone O
. O

With O
a O
sample O
of O
mothers O
of O
healthy O
infants O
, O
all O
three O
RARE O
of O
the O
revised O
instrument O
, O
ALL_CAP O
- O
R O
, O
had O
acceptable O
levels O
of O
internal O
RARE O
RARE O
7 O
, O
NUM O
, O
and O
NUM O
days O
RARE O
, O
and O
stability O
across O
RARE O
. O

Since O
NUM O
, O
the O
use O
of O
saline O
- O
RARE O
RARE O
cells O
( O
RARE O
) O
has O
been O
RARE O
to O
RARE O
RARE O
after O
transfusion O
to O
patients O
with O
ALL_CAP O
. O

In O
the O
group O
of O
RARE O
statistically O
significant O
correlation O
was O
found O
between O
NUM O
PGF2 O
alpha O
and O
RARE O
values O
( O
RARE O
= O
NUM O
. O
NUM O
, O
p O
less O
than O
NUM O
. O
05 O
). O

Acute O
experiments O
on O
RARE O
- O
anesthetized O
cats O
( O
50 O
mg O
/ O
kg O
) O
were O
employed O
to O
investigate O
the O
effect O
of O
1 O
T O
RARE O
magnetic O
field O
( O
ALL_CAP O
) O
on O
neuromuscular O
RARE O
of O
the O
leg O
. O

No O
significant O
differences O
were O
found O
between O
the O
ALL_CAP O
and O
the O
ALL_CAP O
. O

The O
RARE O
of O
formed O
cysts O
and O
growth O
rates O
were O
monthly O
estimated O
and O
analyzed O
RARE O
by O
RARE O
RARE O
5 O
RARE O
cultures O
of O
RARE O
RARE O
RARE O
grown O
RARE O
2 O
years O
under O
laboratory O
conditions O
, O
RARE O
RARE O
constant O
RARE O
possible O
from O
the O
view O
point O
of O
environmental O
RARE O
( O
NUM O
+/- O
1 O
degree O
C O
RARE O
RARE O
( O
NUM O
RARE O
m O
- O
2 O
s O
- O
1 O
RARE O
and O
artificial O
RARE O
. O

A O
genomic O
DNA O
clone O
encoding O
RARE I-GENE
( O
RARE I-GENE
RARE O
a O
cysteine I-GENE
RARE I-GENE
inhibitor O
( O
RARE I-GENE
) O
of O
RARE O
, O
was O
isolated O
from O
a O
lambda O
NUM O
RARE O
library O
constructed O
with O
NUM I-GENE
partial O
RARE O
of O
RARE O
chromosomal O
DNA O
, O
by O
screening O
with O
an O
RARE I-GENE
cDNA I-GENE
RARE O
a O
probe O
. O

The O
use O
of O
an O
appropriate O
solution O
of O
methylene O
blue O
( O
NUM O
. O
2 O
% O
in O
NUM O
. O
9 O
M O
NaCl O
RARE O
NUM O
min O
) O
permits O
the O
staining O
of O
RARE O
areas O
and O
ALL_CAP O
, O
and O
their O
early O
diagnosis O
. O

RARE O
limits O
( O
to O
10 O
micrograms O
/ O
kg O
) O
were O
detectable O
, O
but O
with O
lower O
reliability O
( O
NUM O
%). O

Instead O
, O
some O
small O
negative O
effects O
are O
observed O
, O
particularly O
involving O
effects O
of O
RARE O
' O
RARE O
on O
the O
RARE O
RARE O
of O
employed O
RARE O
. O

This O
in O
RARE O
will O
further O
enhance O
the O
role O
of O
RARE O
- O
analysis O
in O
RARE O
RARE O
and O
RARE O
RARE O
RARE O
clinical O
questions O
. O

In O
one O
RARE O
patient O
visual O
improvement O
was O
obtained O
while O
the O
abnormal O
ALL_CAP I-GENE
RARE O
remained O
unaltered O
. O

In O
contrast O
, O
the O
ALL_CAP O
+ O
ALL_CAP O
RARE O
showed O
large O
amounts O
of O
bone O
formation O
, O
and O
bone O
almost O
RARE O
the O
implant O
. O

The O
RARE O
of O
presence O
or O
absence O
of O
neuroblastoma O
were O
compared O
between O
131I O
- O
ALL_CAP O
imaging O
and O
several O
tumor O
markers O
. O

The O
congenital O
forms O
( O
7 O
cases O
) O
all O
occurred O
in O
female O
infants O
and O
involved O
the O
mucosa O
RARE O
either O
the O
anterior O
RARE O
of O
the O
RARE O
or O
the O
RARE O
. O

RARE O
studies O
revealed O
positive O
staining O
RARE O
NUM I-GENE
protein I-GENE
in O
all O
the O
RARE O
cell O
tumors O
of O
the O
adult O
but O
in O
none O
of O
the O
congenital O
RARE O
cell O
RARE O
. O

We O
also O
found O
that O
the O
same O
males O
, O
RARE O
in O
different O
years O
on O
the O
same O
RARE O
, O
had O
significantly O
larger O
RARE O
in O
the O
years O
they O
had O
RARE O
RARE O
. O

RARE I-GENE
- I-GENE
RARE I-GENE
antigen I-GENE
gene I-GENE
is O
RARE O
RARE O
and O
RARE O
RARE O
RARE O
stages O
of O
RARE O
. O

In O
rats O
RARE O
RARE O
- O
256 O
- O
RARE O
4 O
- O
ALL_CAP O
was O
effective O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

RARE O
the O
RARE O
limb O
abolished O
the O
ectopic O
RARE O
, O
restored O
the O
slow O
emptying O
of O
RARE O
to O
the O
more O
rapid O
rate O
found O
in O
the O
RARE O
dogs O
( O
t1 O
/ O
2 O
: O
RARE O
RARE O
, O
72 O
+/- O
NUM O
minutes O
; O
RARE O
, O
NUM O
+/- O
9 O
minutes O
; O
p O
greater O
than O
NUM O
. O
05 O
) O
and O
did O
not O
change O
emptying O
of O
RARE O
. O

The O
treatments O
were O
NUM O
mg O
t O
. O
i O
. O
d O
. O
and O
120 O
mg O
t O
. O
i O
. O
d O
. O
RARE O
14 O
days O
' O
treatment O
, O
with O
the O
last O
dose O
pulsed O
with O
1 O
. O
NUM O
MBq O
RARE O
14C O
] O
diltiazem O
. O

The O
RARE O
RARE O
capillaries O
were O
RARE O
and O
RARE O
with O
each O
other O
to O
form O
a O
relatively O
RARE O
network O
which O
extended O
over O
the O
RARE O
surface O
of O
both O
ventricles O
. O

The O
examination O
must O
include O
NUM O
and O
NUM O
sequences O
and O
scans O
in O
three O
RARE O
. O

A O
great O
RARE O
of O
RARE O
is O
available O
on O
the O
morphology O
of O
the O
RARE O
in O
various O
RARE O
species O
, O
RARE O
RARE O
RARE O
on O
its O
RARE O
distribution O
and O
relationships O
with O
the O
cerebral O
cortex O
and O
other O
nuclei O
. O

Low O
- O
grade O
glioma O
. O

In O
terms O
of O
sequence O
RARE O
, O
RARE O
tandemly O
RARE O
copies O
of O
the O
RARE O
ALL_CAP O
and O
three O
flanking O
regions O
of O
RARE O
RARE O
were O
detected O
, O
all O
in O
ORF O
NUM O
. O

The O
significance O
of O
these O
palindromic O
domains O
in O
this O
ORF O
is O
unclear O
but O
the O
RARE O
of O
the O
end O
of O
one O
larger O
palindrome O
with O
the O
end O
of O
the O
translated O
protein O
sequence O
that O
has O
homology O
with O
the O
B O
chain O
of O
insulin I-GENE
suggests O
that O
the O
RARE O
may O
RARE O
the O
NUM I-GENE
protein I-GENE
into O
several O
RARE O
RARE O
. O

During O
sub O
- O
maximal O
exercise O
, O
ALL_CAP O
in O
the O
UT O
dogs O
decreased O
from O
a O
resting O
value O
of O
4 O
. O
NUM O
+/- O
NUM O
. O
18 O
mm O
Hg O
X O
ml O
- O
1 O
X O
min O
- O
1 O
to O
1 O
. O
91 O
+/- O
NUM O
. O
NUM O
mm O
Hg O
X O
ml O
- O
1 O
X O
min O
- O
1 O
RARE O
a O
RARE O
of O
6 O
. O
4 O
RARE O
( O
RARE O
RARE O
16 O
% O
( O
grade O
). O

7 O
. O

These O
data O
suggest O
that O
the O
G I-GENE
- I-GENE
protein I-GENE
gene I-GENE
family I-GENE
may O
be O
distributed O
over O
RARE O
least O
two O
human O
chromosomes O
. O

The O
major O
inserted O
DNA O
has O
RARE O
significant O
homology O
to O
published O
human O
RARE O
acid O
sequences O
. O

In O
NUM O
evaluable O
patients O
the O
response O
rate O
was O
50 O
%, O
with O
one O
RARE O
response O
. O

We O
have O
also O
found O
that O
the O
in O
vitro O
interaction O
between O
the O
SV40 O
octamer O
motif O
and O
the O
RARE I-GENE
cell I-GENE
- I-GENE
specific I-GENE
protein I-GENE
RARE I-GENE
- I-GENE
NUM I-GENE
was O
negatively O
modulated O
by O
a O
RARE O
present O
in O
the O
nuclear O
extracts O
from O
several O
RARE O
cell O
lines O
. O

RARE O
was O
introduced O
by O
RARE O
the O
RARE O
with O
water O
deprived O
of O
oxygen O
or O
by O
RARE O
the O
water O
flow O
to O
the O
RARE O
. O

RARE O
, O
4 O
- O
PA O
and O
14C O
turnover O
data O
indicated O
that O
ALL_CAP O
contributed O
to O
B O
- O
6 O
intake O
of O
these O
rats O
. O

Thus O
, O
multiple O
RARE O
factors O
that O
vary O
RARE O
and O
RARE O
may O
be O
responsible O
RARE O
the O
different O
and O
complex O
RARE O
programs O
of O
actin I-GENE
gene I-GENE
RARE O
observed O
RARE O
in O
vivo O
muscle O
differentiation O
. O

DNA O
sequence O
analysis O
revealed O
that O
these O
RARE O
encode O
two O
distinct O
forms O
of O
RARE I-GENE
. O

The O
effect O
of O
RARE O
( O
ALL_CAP O
) O
on O
HCO3 O
- O
and O
Cl O
- O
activities O
in O
inner O
ear O
RARE O
was O
investigated O
by O
ion O
- O
selective O
RARE O
methods O
. O

NUM I-GENE
encodes O
a O
polypeptide O
chain O
of O
NUM O
, O
270 O
RARE O
in O
a O
large O
RARE O
reading O
frame O
. O

Both O
the O
RARE I-GENE
NUM I-GENE
protein I-GENE
and O
its O
RARE O
fragment O
, O
the O
NUM I-GENE
protein I-GENE
, O
can O
be O
cleaved O
by O
RARE I-GENE
RARE I-GENE
V I-GENE
- I-GENE
8 I-GENE
protease I-GENE
to O
produce O
two O
polypeptides O
of O
92 O
amino O
RARE O
. O

RARE O
, O
and O
ALL_CAP O
. O

These O
RARE O
of O
the O
alpha I-GENE
- I-GENE
MSH I-GENE
treated O
mothers O
were O
less O
RARE O
to O
pain O
and O
RARE O
adults O
showed O
a O
RARE O
analgesic O
response O
to O
RARE O
. O

RARE O
immunodeficiency O
virus O
( O
SIV O
) O
is O
a O
RARE O
with O
morphological O
and O
RARE O
similarities O
to O
human O
immunodeficiency O
virus O
, O
the O
RARE O
agent O
of O
acquired O
immunodeficiency O
RARE O
( O
AIDS O
) O
of O
humans O
. O

The O
lack O
of O
change O
in O
the O
ratio O
of O
the O
two O
RARE O
products O
RARE O
from O
either O
the O
normal O
or O
the O
5 I-GENE
'- I-GENE
RARE I-GENE
myb I-GENE
further O
indicates O
that O
the O
RARE O
of O
the O
unique O
NUM O
amino O
RARE O
in O
the O
larger O
myb I-GENE
transcripts I-GENE
is O
not O
a O
consequence O
of O
tumor O
- O
specific O
activation O
of O
the O
mouse I-GENE
myb I-GENE
oncogene I-GENE
. O

The O
use O
of O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
in O
the O
differential O
diagnosis O
of O
RARE O
' O
s O
RARE O
and O
obesity O
. O

We O
detected O
mos I-GENE
transcripts I-GENE
by O
Northern O
( O
RNA O
) O
analyses O
in O
RNA O
prepared O
from O
chicken O
and O
RARE O
RARE O
and O
testes O
. O

The O
predicted O
L I-GENE
mRNA I-GENE
was O
NUM O
nucleotides O
long O
and O
contained O
a O
single O
RARE O
reading O
frame O
corresponding O
to O
an O
L I-GENE
protein I-GENE
RARE I-GENE
NUM I-GENE
amino I-GENE
RARE I-GENE
with O
a O
ALL_CAP O
of O
NUM O
, O
NUM O
. O

The O
results O
suggest O
that O
the O
organization O
of O
RARE O
RARE O
of O
the O
72 O
- O
bp O
repeat O
required O
RARE O
transcriptional O
enhancement O
of O
the O
early O
promoter O
is O
different O
from O
that O
required O
RARE O
RARE O
promoter O
function O
. O

RARE O
in O
the O
5 O
' O
RARE O
of O
NUM O
were O
primarily O
due O
to O
insertions O
and O
deletions O
. O

An O
analysis O
of O
the O
steady O
state O
RNA O
levels O
in O
T O
- O
RARE O
cell O
lines O
showed O
that O
RARE O
least O
three O
different O
incomplete O
RARE O
transcripts O
and O
their O
RARE O
products O
made O
RARE O
the O
majority O
of O
RARE O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
mRNA I-GENE
, O
and O
further O
demonstrated O
that O
partially O
RARE O
RARE O
loci O
have O
the O
RARE O
to O
be O
transcriptionally O
RARE O
in O
certain O
RARE O
cell O
RARE O
. O

RARE O
RARE O
in O
RARE O
cell O
disorders O
: O
bone O
marrow O
necrosis O
and O
human O
RARE O
infection O
. O

RARE O
two O
or O
more O
different O
sequences O
can O
promote O
RARE O
, O
or O
a O
single O
element O
exists O
which O
is O
long O
and O
diffuse O
. O

Low O
RARE O
RARE O
RARE O
have O
RARE O
much O
interest O
because O
of O
their O
RARE O
more O
selective O
action O
on O
RARE I-GENE
factor I-GENE
. O

The O
bactericidal O
activity O
of O
RARE O
new O
RARE O
RARE O
RARE O
RARE O
( O
ALL_CAP O
RARE O
ALL_CAP O
NUM O
( O
NUM O
RARE O
RARE O
( O
ALL_CAP O
RARE O
ALL_CAP O
NUM O
( O
NUM O
RARE O
ALL_CAP O
NUM O
( O
NUM O
) O
and O
ALL_CAP O
NUM O
( O
NUM O
) O
and O
RARE O
( O
ALL_CAP O
RARE O
have O
been O
measured O
against O
log O
RARE O
and O
, O
RARE O
a O
better O
test O
of O
RARE O
activity O
, O
against O
stationary O
RARE O
cultures O
of O
Mycobacterium O
tuberculosis O
, O
NUM O
. O

RARE O
+ O
SV O
M O
- O
MuLV O
- O
inoculated O
animals O
became O
RARE O
RARE O
3 O
to O
NUM O
months O
RARE O
, O
whereas O
delta O
RARE O
+ O
SV O
M O
- O
MuLV O
- O
inoculated O
animals O
became O
RARE O
RARE O
6 O
to O
NUM O
months O
RARE O
. O

Sodium O
dodecyl O
RARE O
- O
RARE O
RARE O
by O
eukaryotic I-GENE
topoisomerase I-GENE
I I-GENE
is O
known O
to O
yield O
enzyme O
covalently O
attached O
to O
the O
3 O
' O
cut O
end O
of O
the O
DNA O
. O

Amino O
acid O
sequence O
of O
one O
human O
liver O
clone O
( O
ALL_CAP O
- O
14 O
) O
was O
identical O
to O
the O
RARE I-GENE
skeletal I-GENE
muscle I-GENE
phosphatase I-GENE
NUM I-GENE
cDNA I-GENE
( O
with O
97 O
% O
nucleotide O
identity O
). O

RARE O
virus O
infection O
was O
characterized O
by O
inversion O
of O
the O
T4 O
/ O
NUM O
ratio O
below O
1 O
. O
NUM O
( O
sensitivity O
NUM O
%, O
RARE O
88 O
%), O
caused O
by O
RARE O
of O
the O
NUM O
RARE O
, O
which O
RARE O
compared O
with O
the O
findings O
in O
patients O
with O
rejection O
RARE O
RARE O
was O
significantly O
raised O
( O
P O
less O
than O
NUM O
. O
001 O
). O

ALL_CAP O
and O
LVEF O
both O
increased O
by O
about O
14 O
% O
( O
p O
less O
than O
NUM O
. O
05 O
and O
p O
less O
than O
NUM O
. O
01 O
). O

The O
levels O
of O
ALL_CAP I-GENE
- O
RARE O
in O
the O
rat O
vas O
deferens O
were O
not O
affected O
by O
either O
surgical O
or O
pharmacological O
treatment O
. O

Quantitative O
assays O
in O
which O
the O
activity O
of O
the O
RARE I-GENE
alpha I-GENE
s I-GENE
- I-GENE
1 I-GENE
was O
compared O
to O
that O
of O
RARE O
RARE O
human I-GENE
RARE I-GENE
type I-GENE
- I-GENE
1 I-GENE
RARE I-GENE
, O
indicated O
that O
the O
two O
products O
are O
RARE O
within O
a O
2 O
- O
RARE O
margin O
of O
error O
. O

In O
these O
cells O
, O
E2 I-GENE
proteins I-GENE
had O
little O
or O
RARE O
RARE O
effect O
on O
the O
transcriptional O
activity O
of O
the O
HPV I-GENE
- I-GENE
11 I-GENE
enhancer I-GENE
- O
SV40 I-GENE
promoter I-GENE
. O

The O
mechanism O
by O
which O
E2 I-GENE
- I-GENE
C I-GENE
represses O
E2 I-GENE
- I-GENE
dependent I-GENE
enhancer I-GENE
activity O
most O
likely O
involves O
competition O
with O
E2 I-GENE
RARE O
binding O
to O
a O
common O
transcriptional O
regulatory O
site O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

RARE O
evaluation O
of O
the O
treatment O
results O
in O
RARE O
RARE O
RARE O
patients O
must O
take O
the O
strong O
prognostic O
factors O
into O
account O
. O

( O
anti I-GENE
- I-GENE
RARE I-GENE
) O
and O
RARE O
et O
al O
. O

RARE O
of O
v I-GENE
- I-GENE
fms I-GENE
into O
a O
CSF I-GENE
- I-GENE
1 I-GENE
dependent O
murine O
macrophage O
cell O
line O
RARE O
factor O
RARE O
and O
RARE O
by O
a O
RARE O
mechanism O
. O

Chronic O
E O
- O
B O
virus O
infection O
RARE O
in O
malignant O
lymphoma O
: O
a O
case O
report O

The O
RARE O
RARE O
and O
RARE O
of O
the O
ALL_CAP I-GENE
genes I-GENE
encoding O
the O
RARE I-GENE
- I-GENE
ALL_CAP I-GENE
( O
nuclear I-GENE
encoded I-GENE
in I-GENE
RARE I-GENE
) O
and O
RARE I-GENE
RARE I-GENE
proteins I-GENE
has O
been O
described O
previously O
( O
RARE O
, O
T O
., O
RARE O
, O
S O
., O
and O
RARE O
, O
R O
. O

The O
RARE O
ALL_CAP I-GENE
genes I-GENE
are O
not O
closely O
RARE O
to O
the O
ALL_CAP I-GENE
gene I-GENE
( O
encoding O
the O
NUM O
- O
kDa O
RARE I-GENE
II I-GENE
polypeptide I-GENE
) O
and O
do O
not O
contain O
RARE O
RARE O
do O
the O
closely O
related O
chloroplast O
genes O
. O

RNA O
blot O
RARE O
identified O
an O
1 O
. O
8 O
- O
kb O
mRNA O
common O
to O
cytochrome I-GENE
NUM I-GENE
and O
subunit O
IV O
, O
and O
an O
RARE O
RARE O
NUM O
. O
8 O
- O
kb O
mRNA O
specific O
to O
the O
subunit O
IV O
gene O
probe O
. O

Whereas O
the O
muscle O
isoform O
consists O
of O
NUM O
amino O
RARE O
and O
RARE O
with O
the O
sequence O
RARE O
- O
Ile O
- O
RARE O
- O
Glu O
, O
the O
second O
isoform O
is O
NUM O
amino O
RARE O
in O
length O
due O
to O
the O
RARE O
of O
these O
last O
4 O
amino O
RARE O
with O
a O
50 O
- O
amino O
acid O
sequence O
that O
contains O
a O
RARE O
transmembrane O
domain O
followed O
by O
a O
consensus O
sequence O
RARE O
an O
N O
- O
RARE O
glycosylation O
site O
. O

Substitution O
of O
a O
threonine O
RARE O
by O
an O
alanine O
RARE O
RARE O
position O
- O
2 O
( O
P2 O
) O
of O
this O
RARE O
site O
abolished O
RARE O
, O
whereas O
substitution O
of O
a O
tyrosine O
RARE O
by O
a O
RARE O
RARE O
RARE O
amino O
acid O
position O
- O
1 O
( O
P1 O
) O
of O
the O
RARE O
site O
did O
not O
influence O
RARE O
. O

All O
of O
the O
RARE O
- O
producing O
bacteria O
had O
an O
RARE I-GENE
phosphatase I-GENE
with O
a O
ALL_CAP O
of O
6 O
. O
4 O
. O

The O
number O
of O
RARE O
RARE O
in O
vitro O
RARE O
the O
E O
RARE O
promoter O
was O
similar O
to O
the O
number O
of O
RARE O
RARE O
the O
L O
RARE O
promoter O
. O

A O
family O
of O
RNA O
molecules O
in O
the O
2 O
. O
NUM O
- O
2 O
. O
2 O
- O
RARE O
range O
identified O
with O
a O
probe O
from O
this O
gene O
was O
overexpressed O
in O
the O
resistant O
cells O
. O

A O
highly O
hydrophobic O
sequence O
RARE O
near O
the O
RARE O
- O
terminal O
RARE O
of O
the O
molecule O
most O
likely O
constitutes O
the O
RARE O
to O
the O
plasma O
membrane O
. O

The O
SV40 I-GENE
enhancer I-GENE
augmented O
replication O
1 O
. O
5 O
- O
10 O
RARE O
. O

One O
of O
these O
, O
the O
origin O
core O
, O
is O
required O
only O
RARE O
DNA O
replication O
. O

Induction O
of O
RARE I-GENE
- I-GENE
oncogene I-GENE
fos I-GENE
transcription O
through O
the O
adenylate I-GENE
cyclase I-GENE
RARE O
: O
characterization O
of O
a O
cAMP O
- O
responsive O
element O
. O

A O
NUM O
- O
RARE O
RARE O
, O
corresponding O
to O
a O
region O
of O
the O
RARE I-GENE
amino I-GENE
acid I-GENE
sequence I-GENE
was O
used O
RARE O
a O
hybridization O
probe O
to O
screen O
a O
RARE O
genomic O
library O
constructed O
in O
broad O
- O
RARE O
- O
range O
cosmid O
vector O
NUM O
. O

( O
RARE O
RARE O
RARE O
) O
and O
RARE O
characteristics O
under O
the O
influence O
of O
different O
treatments O
. O

RARE O
of O
RARE O
found O
in O
an O
epidemiological O
study O
of O
RARE O
RARE O
in O
RARE O
RARE O
. O

The O
progression O
of O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
to O
chronic O
diseases O
, O
and O
the O
transformation O
to O
RARE O
carcinoma O

RARE O
IOP O
developed O
in O
NUM O
patients O
( O
NUM O
eyes O
) O
RARE O
the O
study O
. O

Use O
of O
serum O
RARE I-GENE
determination O
in O
the O
follow O
- O
RARE O
of O
differentiated O
carcinomas O
of O
the O
thyroid O

RARE O
response O
when O
laboratory O
recommended O
range O
RARE O
serum O
lithium O
is O
changed O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
RARE O
RARE O
in O
patients O
with O
acute O
asthma O
in O
order O
to O
determine O
whether O
it O
RARE O
the O
RARE O
effect O
of O
a O
beta O
agonist O
drug O
. O

Further O
analysis O
of O
this O
DNA O
fragment O
showed O
that O
four O
genes O
are O
present O
encoding O
proteins O
of O
16 O
, O
18 O
. O
5 O
, O
21 O
and O
NUM O
RARE O
. O

RARE O
virus O
. O

Changes O
in O
dopamine I-GENE
receptor I-GENE
sensitivity O
in O
humans O
after O
heavy O
RARE O
intake O
. O

No O
significant O
differences O
between O
the O
two O
treatment O
groups O
were O
found O
, O
but O
rapid O
responders O
had O
a O
smaller O
mean O
initial O
platelet I-GENE
- I-GENE
associated I-GENE
IgG I-GENE
index O
which O
returned O
more O
rapidly O
and O
more O
RARE O
to O
normal O
than O
that O
of O
slow O
responders O
. O

RARE I-GENE
variant I-GENE
histone I-GENE
genes I-GENE
contain O
intervening O
sequences O
. O

Double O
- O
blind O
randomised O
trial O
of O
intravenous O
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
versus O
placebo O
in O
acute O
RARE O
infarction O
. O

The O
C O
- O
terminal O
domains O
( O
RARE O
) O
of O
the O
RARE I-GENE
beta I-GENE
subunit I-GENE
and O
DNA I-GENE
primase I-GENE
( O
ALL_CAP I-GENE
protein I-GENE
) O
were O
not O
only O
strongly O
homologous O
to O
each O
other O
but O
also O
considerably O
homologous O
to O
the O
RARE I-GENE
alpha I-GENE
, O
suggesting O
that O
an O
alpha O
subunit O
- O
like O
enzyme O
must O
have O
been O
commonly O
ancestral O
to O
core I-GENE
enzyme I-GENE
subunits I-GENE
and O
primase I-GENE
. O

However O
, O
vancomycin O
and O
RARE O
, O
which O
revealed O
RARE O
in O
vitro O
bactericidal O
activity O
, O
proved O
RARE O
RARE O
RARE O
RARE O
G O
and O
RARE O
in O
an O
experimental O
mode O
of O
murine O
gas O
RARE O
. O

RARE O
, O
a O
RARE O
mu I-GENE
- I-GENE
RARE I-GENE
receptor I-GENE
agonist O
, O
has O
been O
previously O
shown O
to O
produce O
a O
RARE O
characterized O
by O
marked O
analgesia O
and O
locomotor O
RARE O
RARE O
RARE O
RARE O
tachycardia O
, O
RARE O
and O
RARE O
RARE O
. O

RARE O
chemotherapy O
. O

RARE O
was O
found O
to O
be O
an O
effective O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
antagonist O
, O
the O
NUM O
values O
determined O
against O
RARE O
in O
RARE O
RARE O
RARE O
and O
tracheal O
muscle O
being O
7 O
. O
NUM O
and O
6 O
. O
NUM O
, O
respectively O
. O

RARE O
of O
NUM O
- O
4 O
by O
the O
RARE O
RARE O
closely O
mimicked O
fluctuations O
in O
RARE O
RARE O
flow O
rate O
. O

The O
RARE O
- O
RARE O
equation O
is O
used O
to O
assess O
the O
effects O
of O
attached O
parasites O
in O
the O
RARE O
of O
RARE O
- O
RARE O
RARE O
on O
RARE O
flow O
. O

Moreover O
, O
in O
rats O
allowed O
to O
RARE O
in O
a O
T O
- O
RARE O
between O
immediate O
- O
but O
- O
small O
RARE O
. O
delayed O
- O
but O
- O
large O
RARE O
, O
ALL_CAP O
significantly O
decreased O
the O
frequency O
with O
which O
the O
delayed O
RARE O
was O
chosen O
, O
with O
5 O
- O
ALL_CAP O
uptake O
blockers O
producing O
opposite O
effects O
. O

An O
endometrial O
RARE O
RARE O
deficiency O
was O
detected O
in O
NUM O
( O
NUM O
%) O
of O
RARE O
patients O
. O

RARE O
exposure O
to O
the O
RARE O
RARE O
causes O
behavioral O
RARE O
, O
RARE O
and O
RARE O
RARE O
in O
mice O
, O
but O
not O
rats O
or O
hamsters O
. O

RARE O
with O
normal O
RARE O
in O
the O
RARE O
, O
working O
hearts O
caused O
extensive O
structural O
damage O
, O
RARE O
RARE O
, O
and O
failed O
to O
RARE O
contractility O
in O
any O
RARE O
RARE O
NUM O
% O
systolic O
shortening O
, O
p O
less O
than O
NUM O
. O
05 O
). O

The O
sensitivity O
of O
the O
vas O
deferens O
to O
adrenaline O
was O
also O
RARE O
in O
RARE O
RARE O
pigs O
, O
thus O
decreasing O
their O
fertility O
rate O
. O

In O
metabolic O
acidosis O
there O
was O
a O
marked O
RARE O
when O
RARE O
RARE O
- O
10 O
to O
- O
NUM O
ALL_CAP O
. O

On O
RARE O
1 O
and O
14 O
, O
most O
young O
and O
elderly O
subjects O
exhibited O
RARE O
decline O
in O
RARE O
plasma O
concentrations O
after O
absorption O
RARE O
. O

RARE O
and O
old O
NUM O
and O
NUM O
mice O
were O
given O
RARE O
RARE O
water O
or O
RARE O
RARE O
( O
a O
RARE O
with O
NUM I-GENE
receptor I-GENE
blocking O
activity O
RARE O
RARE O
( O
an O
NUM I-GENE
blocker O
) O
or O
RARE O
( O
a O
RARE O
with O
RARE O
NUM I-GENE
blocking O
activity O
) O
in O
their O
drinking O
water O
, O
and O
the O
effects O
of O
these O
agents O
on O
bone O
mineral O
content O
were O
assessed O
by O
RARE O
measuring O
the O
NUM O
- O
h O
whole O
body O
retention O
of O
Tc O
99m O
methylene O
RARE O
( O
Tc O
99m O
ALL_CAP O
, O
an O
indicator O
of O
bone O
metabolism O
) O
and O
RARE O
the O
end O
of O
the O
studies O
by O
RARE O
RARE O
weights O
of O
femur O
, O
RARE O
and O
RARE O
. O

RARE O
results O
reveal O
a O
frequency O
- O
dependent O
inhibition O
of O
RARE O
RARE O
by O
diltiazem O
, O
and O
suggest O
that O
diltiazem O
may O
RARE O
excessive O
sympathetic O
activity O
without O
affecting O
normal O
RARE O
RARE O
. O

Studies O
were O
performed O
on O
several O
superficial O
RARE O
from O
the O
RARE O
face O
to O
examine O
the O
relationship O
between O
beta I-GENE
adrenoceptor I-GENE
RARE I-GENE
distribution O
, O
RARE O
RARE O
tone O
and O
sympathetic O
nerve O
RARE O
. O

Effects O
of O
a O
new O
antihypertensive O
agent O
, O
ALL_CAP O
- O
NUM O
, O
on O
rat O
platelet O
RARE O
. O

Since O
the O
stability O
of O
NUM I-GENE
resides O
in O
its O
RARE O
RARE O
, O
we O
RARE O
a O
gene O
coding O
RARE O
NUM I-GENE
, O
and O
the O
RARE O
RARE O
of O
the O
beta O
subunit O
was O
deduced O
from O
the O
nucleotide O
sequence O
of O
the O
gene O
to O
compare O
the O
sequence O
with O
those O
of O
beta O
' O
s O
of O
three O
major O
categories O
of O
NUM I-GENE
' O
s O
; O
RARE O
membranes O
, O
RARE O
, O
and O
RARE O
. O

RARE O
RARE O
and O
overall O
RARE O
in O
the O
cold O
appear O
to O
be O
more O
RARE O
in O
P O
. O
s O
. O
RARE O
than O
in O
RARE O
RARE O
. O

Two O
polyadenylation O
sites O
were O
used O
, O
one O
RARE O
the O
end O
of O
the O
early I-GENE
( I-GENE
E I-GENE
) I-GENE
region I-GENE
of O
the O
viral O
DNA O
, O
the O
other O
RARE O
the O
end O
of O
the O
RARE I-GENE
( I-GENE
L I-GENE
) I-GENE
region I-GENE
. O

A O
drug O
with O
ALL_CAP O
" O
down O
regulates O
" O
beta I-GENE
receptors I-GENE
; O
thus O
, O
when O
the O
drug O
is O
RARE O
there O
is O
RARE O
post O
- O
beta O
- O
blocking O
drug O
hypersensitivity O
in O
contrast O
to O
agents O
without O
ALL_CAP O
. O

Six O
patients O
with O
human O
T O
- O
cell O
RARE O
virus O
type O
I O
( O
ALL_CAP O
- O
I O
)- O
associated O
RARE O
( O
ALL_CAP O
) O
were O
studied O
by O
RARE O
methods O
. O

RARE O
, O
a O
structural O
analog O
of O
RARE O
, O
also O
inhibits O
alpha I-GENE
1 I-GENE
adrenoceptors I-GENE
and O
is O
recommended O
RARE O
once O
or O
twice O
- O
daily O
therapy O
. O

RARE O
RARE O
donors O
RARE O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
: O
RARE O
, O
perhaps O
, O
but O
RARE O
. O

Most O
patients O
with O
high O
RARE O
pressure O
( O
ALL_CAP O
) O
can O
be O
RARE O
by O
using O
one O
of O
4 O
classes O
of O
compounds O
: O
a O
diuretic O
, O
beta O
blocker O
, O
RARE O
enzyme O
inhibitor O
or O
RARE O
antagonist O
. O

In O
a O
randomised O
double O
- O
blind O
study O
, O
NUM O
RARE O
RARE O
RARE O
were O
given O
RARE O
or O
RARE O
RARE O
RARE O
to O
5 O
weeks O
; O
the O
mean O
daily O
dose O
RARE O
the O
end O
was O
18 O
. O
8 O
mg O
RARE O
and O
20 O
mg O
RARE O
. O

RARE I-GENE
- O
producing O
endocrine O
pancreatic O
tumor O
in O
RARE O
' O
s O
RARE O
. O

RARE O
and O
inverted O
repeat O
elements O
of O
10 O
, O
11 O
, O
16 O
, O
19 O
, O
and O
NUM O
nucleotides O
( O
nt O
) O
flank O
the O
promoter O
site O
. O

We O
have O
been O
able O
to O
map O
specific O
DNA O
fragments O
RARE O
the O
bases O
of O
chromatin O
loops O
with O
the O
help O
of O
a O
novel O
extraction O
procedure O
by O
using O
lithium O
- O
3 O
RARE O
5 O
'- O
RARE O
. O

Seventy O
- O
one O
supplementary O
doses O
of O
RARE O
were O
used O
RARE O
muscle O
relaxation O
RARE O
a O
NUM O
- O
h O
- O
long O
ALL_CAP O
II O
anaesthesia O
. O

Finally O
, O
the O
recovery O
RARE O
represented O
by O
the O
times O
required O
RARE O
NUM O
/ O
NUM O
and O
T4 O
/ O
NUM O
to O
rise O
from O
NUM O
% O
to O
NUM O
% O
respectively O
were O
studied O
. O

RARE O
bacterial O
colonies O
were O
screened O
RARE O
recombinant O
plasmids O
containing O
cDNA O
coding O
RARE O
ALL_CAP I-GENE
by O
RARE O
- O
RARE O
mRNA O
translation O
. O

ALL_CAP O
attenuated O
the O
increase O
of O
the O
intensity O
of O
the O
ischemic O
and O
pressure O
pain O
RARE O
with O
increasing O
ischemia O
duration O
, O
but O
only O
the O
effect O
on O
the O
pressure O
pain O
RARE O
was O
significant O
. O

RARE O
1 O
percent O
isoproterenol O
in O
the O
presence O
of O
the O
RARE O
inhibitor O
theophylline O
was O
tested O
RARE O
its O
ability O
to O
stimulate O
the O
rate O
of O
aqueous O
RARE O
flow O
through O
the O
anterior O
chamber O
of O
the O
normal O
and O
the O
partially O
RARE O
RARE O
human O
eye O
( O
RARE O
' O
s O
RARE O
). O

RARE O
is O
one O
of O
the O
numerous O
causes O
of O
infertility O
and O
recurrent O
abortion O
. O

A O
strong O
correlation O
exists O
between O
the O
numbers O
of O
ALL_CAP O
- O
ALL_CAP O
RARE O
and O
the O
rate O
of O
RARE O
and O
platelets O
recovery O
. O

We O
propose O
that O
the O
technique O
of O
low O
- O
frequency O
kindling O
is O
a O
useful O
experimental O
model O
in O
assessing O
the O
effects O
of O
RARE O
or O
RARE O
drugs O
on O
the O
RARE O
of O
the O
RARE O
regions O
. O

RARE O
implant O
RARE O
. O

Three O
sequence O
elements O
are O
shown O
to O
be O
required O
RARE O
accurate O
and O
efficient O
transcription O
RARE O
by O
RNA I-GENE
polymerase I-GENE
I I-GENE
( O
pol I-GENE
I I-GENE
) O
assayed O
both O
in O
a O
cell O
- O
free O
transcription O
RARE O
and O
in O
vivo O
after O
transfection O
of O
ALL_CAP O
RARE O
constructs O
into O
NUM O
cells O
. O

The O
biosynthesis O
and O
stability O
of O
the O
three O
mutant O
proteins O
were O
similar O
to O
those O
of O
the O
wild I-GENE
- I-GENE
type I-GENE
erbB I-GENE
protein I-GENE
, O
and O
all O
three O
retained O
the O
ability O
to O
transform O
chicken O
RARE O
RARE O
. O

RARE O
usage O
in O
C O
. O
RARE O
RARE O
is O
highly O
RARE O
, O
with O
eight O
codons O
entirely O
absent O
from O
all O
protein O
- O
coding O
genes O
; O
however O
, O
even O
though O
RARE O
usage O
is O
restricted O
, O
it O
appears O
that O
C O
. O
RARE O
ALL_CAP O
cannot O
encode O
the O
minimum O
number O
of O
RARE O
needed O
to O
support O
mitochondrial O
protein O
RARE O
. O

A O
new O
RARE O
treatment O
of O
ALL_CAP O
- O
related O
RARE O
RARE O
by O
RARE O
in O
the O
treatment O
of O
chronic O
RARE O
hepatitis O
B O
was O
tested O
in O
7 O
patients O
. O

Like O
RARE O
testes O
, O
RARE O
testes O
were O
RARE O
to O
fat O
on O
sequences O
with O
a O
short O
RARE O
time O
( O
TR O
) O
and O
echo O
time O
( O
ALL_CAP O
) O
in O
all O
cases O
, O
and O
RARE O
or O
RARE O
to O
fat O
on O
long O
TR O
/ O
ALL_CAP O
sequences O
in O
all O
but O
two O
cases O
. O

The O
subunit I-GENE
- I-GENE
a I-GENE
gene I-GENE
is O
RARE O
by O
a O
gene O
coding O
RARE O
a O
small O
hydrophobic O
protein O
, O
RARE O
has O
been O
observed O
previously O
in O
the O
RARE I-GENE
RARE I-GENE
in O
E O
. O
coli O
, O
bacterium O
NUM O
and O
RARE O
. O

Here O
, O
we O
describe O
the O
isolation O
of O
bovine I-GENE
and I-GENE
rat I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
RARE O
. O

To O
explore O
the O
RARE O
properties O
of O
the O
protein O
encoded O
by O
neu I-GENE
, O
we O
created O
a O
fusion O
gene O
that O
joins O
the O
cytoplasmic O
domain O
of O
neu I-GENE
to O
the O
extracellular O
portion O
of O
an O
immunoglobulin I-GENE
heavy I-GENE
chain I-GENE
. O

The O
RARE O
African O
RARE O
- O
RARE O
RARE O
represents O
a O
RARE O
model O
RARE O
RARE O
comparative O
studies O
. O

By O
sequence O
comparison O
, O
NUM O
blocks O
of O
homology O
are O
defined O
in O
the O
5 O
'- O
terminal O
region O
, O
of O
which O
NUM O
appear O
in O
the O
CpG O
island O
and O
contain O
numerous O
RARE O
CpG O
RARE O
. O

Among O
unusual O
features O
, O
we O
report O
numerous O
large O
G O
+ O
C O
- O
rich O
RARE O
sequences O
RARE O
in O
the O
RARE O
intron O
. O

In O
the O
RARE O
group O
, O
NUM O
. O
02 O
% O
RARE O
( O
NUM O
. O
5 O
mg O
/ O
kg O
) O
was O
administered O
intravenously O
RARE O
1 O
. O
5 O
hours O
before O
the O
application O
of O
RARE O
- O
RARE O
or O
PGF2 O
alpha O
. O

RARE O
and O
field O
evaluation O
of O
Bacillus O
RARE O
( O
H O
- O
14 O
) O
and O
B O
. O
RARE O
against O
RARE O
RARE O
in O
RARE O
. O

2 O
cases O
of O
type O
II O
RARE O
( O
RARE O
- O
RARE O
RARE O
) O

This O
RARE O
was O
independent O
of O
drug O
concentration O
and O
a O
correction O
factor O
was O
employed O
to O
RARE O
the O
true O
free O
RARE O
concentration O
. O

Effects O
of O
a O
RARE O
RARE O
substitute O
on O
RARE O
binding O
by O
human I-GENE
albumin I-GENE
. O

A O
second O
promoter O
activity O
was O
identified O
in O
the O
region O
between O
the O
two O
major O
transcriptional O
RARE O
sites O
. O

A O
RARE O
sequence O
, O
5 O
'- O
ALL_CAP O
- O
ALL_CAP O
- O
3 O
RARE O
RARE O
to O
a O
RARE O
sequence O
adjacent O
to O
the O
enzymatic O
RARE O
site O
on O
the O
mitochondrial O
RNA O
substrate O
, O
is O
present O
in O
the O
RARE I-GENE
MRP I-GENE
RNA I-GENE
. O

Effects O
of O
aging O
and O
beta O
- O
adrenergic O
- O
blockade O
on O
RARE O
- O
RARE O
QT O
/ O
NUM O
changes O
. O

A O
patient O
with O
an O
RARE O
wound O
or O
one O
on O
a O
RARE O
area O
( O
RARE O
, O
RARE O
, O
face O
, O
or O
RARE O
) O
may O
have O
to O
be O
hospitalized O
to O
RARE O
proper O
care O
. O

RARE O
studies O
with O
RARE O
RARE O
and O
RARE O
suggest O
that O
RARE O
acts O
RARE O
a O
RARE O
antagonist O
by O
blocking O
the O
RARE O
of O
extracellular O
RARE O
. O

RARE O
analysis O
included O
digital O
RARE O
, O
followed O
by O
digital O
RARE O
in O
different O
frequency O
bands O
in O
order O
to O
determine O
the O
frequency O
range O
corresponding O
to O
RARE O
and O
RARE O
. O

On O
admission O
to O
the O
ALL_CAP O
, O
117 O
patients O
( O
NUM O
percent O
) O
had O
RARE O
( O
serum O
RARE O
less O
than O
1 O
. O
5 O
mEq O
/ O
dl O
RARE O
NUM O
patients O
( O
NUM O
percent O
) O
had O
RARE O
( O
1 O
. O
5 O
to O
2 O
. O
NUM O
mEq O
/ O
dl O
RARE O
and O
ten O
patients O
( O
5 O
percent O
) O
had O
RARE O
( O
greater O
than O
2 O
. O
NUM O
mEq O
/ O
dl O
). O

The O
risk O
factors O
studied O
were O
male O
RARE O
, O
hypertension O
, O
diabetes O
mellitus O
, O
RARE O
, O
RARE O
smoking O
, O
RARE O
life O
- O
RARE O
, O
and O
family O
history O
. O

Neither O
verapamil O
nor O
nifedipine O
changed O
collateral O
RARE O
RARE O
flow O
from O
NUM O
. O
10 O
+/- O
NUM O
. O
02 O
in O
the O
RARE O
and O
NUM O
. O
NUM O
+/- O
NUM O
. O
03 O
ml O
/ O
min O
/ O
g O
in O
the O
RARE O
. O

There O
were O
NUM O
boys O
and O
NUM O
girls O
, O
with O
a O
mean O
age O
of O
five O
and O
a O
RARE O
years O
. O

RARE O
versus O
RARE O
reperfusion O
of O
ischemic O
myocardium O
after O
experimental O
coronary O
artery O
occlusion O
was O
studied O
to O
determine O
the O
effect O
on O
regional O
ventricular O
RARE O
motion O
and O
associated O
biochemical O
alterations O
. O

RARE O
RARE O
was O
not O
detected O
with O
M O
- O
mode O
, O
2 O
- O
dimensional O
real O
- O
time O
or O
pulsed O
- O
wave O
Doppler O
echocardiography O
. O

RARE O
assessment O
was O
obtained O
before O
and O
following O
administration O
of O
RARE O
10 O
micrograms O
/ O
kg O
IV O
or O
dopamine O
, O
5 O
to O
12 O
micrograms O
/ O
kg O
/ O
min O
IV O
. O

We O
also O
examined O
the O
relationship O
between O
the O
RARE O
of O
RARE O
and O
the O
RARE O
RARE O
in O
patients O
with O
unilateral O
RARE O
RARE O
. O

We O
conclude O
that O
RARE O
these O
low O
levels O
studied O
, O
aluminum O
accumulates O
in O
RARE O
tissue O
, O
and O
that O
this O
accumulation O
is O
RARE O
by O
RARE O
RARE O
. O

Thus O
, O
the O
effects O
of O
RARE O
absence O
under O
routine O
conditions O
in O
relatively O
healthy O
samples O
may O
exert O
RARE O
significant O
effects O
independent O
of O
intervening O
family O
RARE O
or O
RARE O
RARE O
. O

Recently O
, O
an O
electrical O
- O
mechanical O
analog O
model O
of O
heat O
flow O
within O
the O
brain O
has O
been O
developed O
from O
which O
an O
RARE O
RARE O
CBF O
has O
been O
derived O
: O
CBF O
= O
RARE O
RARE O
RARE O
RARE O
c O
) O
where O
RARE O
is O
the O
thermal O
RARE O
constant O
, O
RARE O
is O
the O
density O
of O
RARE O
, O
and O
c O
is O
its O
specific O
heat O
. O

All O
of O
the O
newly O
acquired O
RARE O
identified O
in O
mosaic O
RARE O
ALL_CAP O
/ O
ALL_CAP O
- O
ALL_CAP O
/ O
ALL_CAP O
mice O
that O
could O
be O
transmitted O
through O
the O
RARE O
line O
were O
also O
present O
in O
somatic O
tissues O
, O
demonstrating O
that O
viral O
RARE O
occurred O
before O
the O
RARE O
line O
was O
set O
RARE O
from O
the O
somatic O
lineages O
. O

Molecular O
cloning O
of O
the O
cDNA O
RARE O
the O
human I-GENE
NUM I-GENE
ALL_CAP I-GENE
- I-GENE
specific I-GENE
A I-GENE
' I-GENE
protein I-GENE
. O

For O
the O
present O
work O
we O
used O
water O
RARE O
with O
a O
50 O
/ O
50 O
mixture O
of O
H2 O
and O
NUM O
gases O
, O
RARE O
which O
the O
heat O
defect O
is O
calculated O
to O
be O
- O
2 O
. O
1 O
%. O

RARE O
use O
of O
RARE O
to O
RARE O
RARE O
after O
RARE O
failure O
. O

During O
RARE O
RARE O
, O
the O
RARE O
RARE O
the O
RARE O
RARE O
RARE O
its O
direction O
RARE O
about O
NUM O
ms O
after O
impact O
. O

The O
data O
indicates O
the O
presence O
of O
5 I-GENE
- I-GENE
HT2 I-GENE
RARE I-GENE
receptors I-GENE
in O
the O
bronchial O
artery O
of O
these O
species O
. O

RARE O
, O
which O
was O
RARE O
RARE O
the O
RARE O
time O
( O
about O
65 O
days O
) O
from O
the O
RARE O
of O
RARE O
( O
RARE O
1 O
RARE O
produced O
a O
NUM O
. O
1 O
per O
cent O
reduction O
in O
RARE O
species O
and O
an O
NUM O
. O
4 O
per O
cent O
reduction O
in O
D O
RARE O
. O

By O
adapting O
a O
method O
RARE O
DNA O
- O
footprinting O
using O
RARE O
extracts O
of O
RARE I-GENE
RARE O
cells O
, O
we O
were O
able O
to O
determine O
that O
the O
RARE I-GENE
- I-GENE
binding I-GENE
sites I-GENE
are O
RARE O
between O
nucleotides O
NUM O
and O
NUM O
from O
the O
RARE O
RARE O
end O
. O

We O
have O
identified O
and O
characterized O
the O
RARE O
of O
the O
NUM I-GENE
gene I-GENE
in O
the O
RARE O
RARE O
RARE O
RARE O
. O

RARE O
function O
and O
platelet O
- O
RARE O
- O
RARE O
interaction O
in O
patients O
with O
RARE O
platelet I-GENE
RARE I-GENE
activity O
. O

RARE O
RARE O
of O
RARE O
in O
plasma O
is O
the O
major O
route O
of O
elimination O
in O
man O
and O
contributes O
to O
a O
short O
elimination O
RARE O
- O
life O
( O
RARE O
20 O
min O
). O

RARE O
cell O
lines O
expressing O
solely O
E1a I-GENE
or O
E1a I-GENE
and O
NUM I-GENE
gene I-GENE
products I-GENE
derived O
from O
these O
viruses O
display O
RARE O
anchorage O
- O
independent O
growth O
RARE O
37 O
degrees O
C O
versus O
NUM O
degrees O
C O
and O
display O
a O
cytoskeletal O
architecture O
resembling O
RARE O
RARE O
ALL_CAP O
cells O
. O

Partial O
N O
- O
terminal O
amino O
acid O
sequence O
analysis O
showed O
that O
the O
NUM I-GENE
and I-GENE
NUM I-GENE
T I-GENE
antigens I-GENE
contain O
methionine O
RARE O
residues O
1 O
and O
5 O
, O
RARE O
predicted O
from O
the O
DNA O
sequence O
, O
whereas O
RARE O
methionine O
was O
released O
from O
the O
NUM I-GENE
T I-GENE
antigen I-GENE
RARE O
the O
RARE O
RARE O
cycles O
of O
RARE O
RARE O
. O

Group O
A O
was O
treated O
with O
three O
or O
four O
doses O
of O
hepatitis I-GENE
B I-GENE
immune I-GENE
globulin I-GENE
( O
ALL_CAP I-GENE
) O
in O
one O
of O
three O
different O
RARE O
. O

In O
the O
former O
RARE O
, O
in O
addition O
to O
serum O
RARE O
and O
RARE O
ion O
concentrations O
, O
tissue O
pH O
, O
RARE O
supply O
, O
RARE O
, O
i O
. O
RARE O
., O
vitamin O
D O
, O
vitamin O
A O
, O
and O
various O
RARE O
( O
RARE O
. O
g O
., O
RARE I-GENE
phosphatase I-GENE
and O
RARE I-GENE
) O
may O
all O
play O
significant O
, O
RARE O
, O
time O
- O
dependent O
, O
but O
RARE O
yet O
RARE O
roles O
. O

RARE I-GENE
production O
in O
RARE O
RARE O
strains O
of O
clinical O
importance O
. O

Thus O
, O
quantitative O
analysis O
of O
thallium O
- O
NUM O
uptake O
and O
washout O
provided O
objective O
evidence O
RARE O
improved O
RARE O
perfusion O
after O
coronary O
RARE O
. O

This O
study O
reports O
the O
effects O
of O
a O
preparation O
with O
50 O
micrograms O
RARE O
estradiol O
and O
2 O
mg O
RARE O
RARE O
on O
RARE I-GENE
, O
prolactin I-GENE
, O
testosterone O
, O
RARE I-GENE
hormone I-GENE
binding I-GENE
globulin I-GENE
( O
SHBG I-GENE
RARE O
RARE O
, O
and O
calculated O
free O
testosterone O
index O
before O
and O
after O
RARE O
months O
of O
treatment O
. O

Functional O
flow O
was O
evaluated O
using O
laser O
Doppler O
RARE O
( O
ALL_CAP O
RARE O
RARE O
which O
the O
output O
signal O
, O
RARE O
cell O
RARE O
( O
ALL_CAP O
RARE O
is O
RARE O
in O
terms O
of O
RARE O
. O

In O
nine O
patients O
with O
RARE O
failure O
routine O
haemodialysis O
was O
accompanied O
by O
a O
NUM O
per O
cent O
reduction O
in O
plasma O
ANP I-GENE
concentration O
. O

To O
investigate O
the O
effects O
of O
RARE O
on O
ALL_CAP I-GENE
, O
we O
measured O
ALL_CAP I-GENE
- I-GENE
C I-GENE
, O
ALL_CAP I-GENE
phospholipids O
( O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
RARE O
RARE I-GENE
NUM I-GENE
( O
RARE I-GENE
A I-GENE
- I-GENE
1 I-GENE
RARE O
and O
ALL_CAP I-GENE
- I-GENE
C I-GENE
RARE O
( O
HDL2 I-GENE
- I-GENE
C I-GENE
and O
NUM I-GENE
- I-GENE
C I-GENE
) O
in O
NUM O
healthy O
, O
male O
patients O
receiving O
a O
16 O
- O
week O
course O
of O
RARE O
( O
1 O
. O
NUM O
mg O
/ O
kg O
/ O
day O
) O
RARE O
treatment O
of O
severe O
RARE O
RARE O
. O

The O
clinical O
picture O
and O
laboratory O
parameters O
were O
consistent O
with O
a O
serum O
RARE O
reaction O
. O

Our O
data O
, O
however O
, O
did O
not O
suggest O
the O
existence O
of O
a O
conversion O
factor O
RARE O
ALL_CAP O
signal O
to O
absolute O
flow O
values O
from O
experiment O
to O
experiment O
. O

RARE O
effect O
of O
ALL_CAP O
- O
NUM O
on O
thrombosis O
and O
RARE O
in O
vitro O
and O
in O
vivo O
. O

The O
frequency O
of O
ALL_CAP O
strains O
increased O
from O
1 O
. O
7 O
% O
in O
NUM O
to O
6 O
. O
7 O
% O
in O
1985 O
. O

RARE O
antibodies O
, O
RARE O
from O
the O
beta I-GENE
- I-GENE
galactosidase I-GENE
fusion O
protein O
of O
either O
clone O
reacted O
with O
the O
NUM I-GENE
snRNP I-GENE
- O
specific O
A I-GENE
antigen I-GENE
. O

Quantitative O
analysis O
of O
the O
coronary O
stenosis O
was O
assessed O
before O
and O
after O
PTCA O
, O
and O
the O
dilatation O
resulted O
in O
an O
increase O
in O
minimal O
luminal O
cross O
- O
sectional O
area O
from O
1 O
. O
1 O
+/- O
NUM O
. O
8 O
to O
2 O
. O
7 O
+/- O
1 O
. O
2 O
mm2 O
. O

The O
pathogenesis O
of O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
in O
diabetes O
is O
unknown O
, O
but O
the O
abnormality O
is O
RARE O
to O
be O
associated O
with O
an O
increased O
incidence O
of O
RARE O
. O

In O
a O
previous O
study O
( O
RARE O
, O
C O
. O

The O
experimental O
end O
points O
were O
the O
time O
required O
RARE O
treated O
tumors O
to O
reach O
3 O
times O
their O
treatment O
size O
, O
the O
survival O
of O
RARE O
cells O
in O
the O
duodenal O
RARE O
, O
and O
the O
breathing O
rate O
measured O
early O
( O
19 O
- O
NUM O
weeks O
) O
and O
RARE O
( O
NUM O
- O
NUM O
weeks O
) O
after O
treatment O
. O

RARE O
2 O
, O
in O
which O
2 O
. O
4 O
mg O
/ O
kg O
c O
- O
DDP O
was O
administered O
immediately O
before O
X O
- O
ray O
on O
5 O
consecutive O
days O
produced O
the O
highest O
degree O
of O
enhancement O
of O
radiation O
effect O
( O
RARE O
RARE O
dose O
- O
effect O
factor O
); O
and O
the O
next O
greatest O
enhancement O
was O
produced O
by O
12 O
mg O
/ O
kg O
c O
- O
DDP O
administered O
NUM O
h O
before O
the O
RARE O
of O
RARE O
daily O
radiotherapy O
. O

The O
RARE I-GENE
- I-GENE
1 I-GENE
- I-GENE
encoded I-GENE
transcript I-GENE
contains O
three O
RARE O
reading O
frames O
, O
two O
of O
which O
are O
RARE O
in O
the O
NUM O
- O
nucleotide O
RARE O
segment O
preceding O
the O
RARE I-GENE
- I-GENE
1 I-GENE
coding I-GENE
region I-GENE
. O

The O
RARE O
- O
steroid O
hormone O
1 O
, O
NUM O
- O
RARE O
NUM O
is O
known O
to O
induce O
the O
RARE O
of O
a O
RARE O
binding O
protein O
termed O
RARE I-GENE
- I-GENE
NUM I-GENE
in O
a O
variety O
of O
target O
tissues O
. O

In O
addition O
, O
the O
RARE I-GENE
- I-GENE
NUM I-GENE
promoter I-GENE
is O
composed O
of O
a O
variety O
of O
simple O
RARE O
sequences O
, O
some O
of O
which O
are O
RARE O
of O
putative O
regulatory O
signals O
. O

The O
ALL_CAP O
RARE O
a O
nearly O
fourfold O
increase O
in O
ALL_CAP I-GENE
in O
the O
elderly O
, O
whereas O
that O
RARE O
the O
young O
was O
threefold O
. O

To O
assess O
the O
ability O
of O
the O
RARE O
to O
maintain O
elevated O
plasma O
concentrations O
of O
RARE I-GENE
RARE I-GENE
peptide I-GENE
( O
ANP I-GENE
RARE O
the O
temporal O
changes O
in O
plasma I-GENE
ANP I-GENE
concentrations O
were O
studied O
in O
RARE O
RARE O
- O
RARE O
dogs O
RARE O
4 O
h O
of O
sustained O
rapid O
cardiac O
pacing O
. O

Ig I-GENE
D I-GENE
- O
ALL_CAP I-GENE
RARE O
may O
RARE O
ALL_CAP I-GENE
gene I-GENE
RARE O
in O
these O
early O
T O
cell O
lines O
, O
and O
some O
but O
not O
all O
express O
RARE O
RARE I-GENE
transcripts I-GENE
. O

The O
NUM I-GENE
gene I-GENE
RARE I-GENE
reading I-GENE
frame I-GENE
encodes O
a O
protein O
of O
NUM O
amino O
RARE O
, O
with O
a O
calculated O
RARE O
RARE O
of O
NUM O
, O
NUM O
. O

RARE O
absorption O
RARE O
applied O
to O
bacterially O
RARE O
E1A I-GENE
proteins I-GENE
revealed O
that O
the O
NUM O
- O
amino O
acid O
protein O
binds O
one O
zinc O
ion O
, O
whereas O
the O
NUM O
- O
amino O
acid O
protein O
binds O
RARE O
zinc O
. O

Most O
patients O
preferred O
RARE O
to O
injection O
both O
on O
day O
1 O
( O
NUM O
v O
NUM O
) O
and O
RARE O
follow O
RARE O
( O
NUM O
v O
104 O
). O

RARE O
of O
RV O
, O
LV O
+ O
S O
and O
NUM O
RARE O
RARE O
real O
hematocrit O
showed O
RARE O
RARE O
RARE O
RARE O
real O
hematocrit O
65 O
%, O
suggesting O
a O
possible O
role O
of O
increased O
viscosity O
in O
ALL_CAP O
RARE O
RARE O
the O
RARE O
hematocrit O
. O

The O
RARE O
RARE O
RARE O
is O
an O
important O
improvement O
, O
and O
in O
some O
cases O
it O
may O
replace O
other O
techniques O
RARE O
RARE O
splenic O
bleeding O
. O

A O
rare O
chronic O
course O
of O
RARE O
- O
RARE O
RARE O
associated O
with O
thrombosis O
of O
the O
RARE O
RARE O
was O
observed O
in O
a O
NUM O
- O
year O
- O
old O
male O
patient O
suffering O
from O
RARE O
RARE O
. O

After O
one O
RARE O
night O
, O
sleep O
EEG O
recordings O
were O
performed O
RARE O
three O
consecutive O
RARE O
in O
ten O
drug O
- O
free O
RARE O
RARE O
generalized O
anxiety O
disorder O
( O
ALL_CAP O
) O
with O
significant O
depression O
, O
compared O
with O
a O
age O
- O
and O
RARE O
- O
matched O
group O
of O
patients O
with O
ALL_CAP O
and O
a O
group O
of O
RARE O
major O
RARE O
disorder O
( O
ALL_CAP O
) O
patients O
. O

RARE O
mutagenesis O
of O
these O
binding O
domains O
indicated O
their O
importance O
in O
the O
transcriptional O
RARE O
of O
the O
NUM I-GENE
promoter I-GENE
in O
yeast O
cells O
. O

The O
concentration O
of O
NUM O
on O
the O
newly O
- O
formed O
luminal O
surface O
remained O
low O
. O

RARE O
transplantation O
in O
RARE O
. O

Effects O
of O
single O
and O
combined O
RARE O
RARE O
immunotherapy O
, O
cyclophosphamide O
chemotherapy O
and O
radiotherapy O
on O
ethyl O
RARE O
accelerated O
RARE O
RARE O
RARE O
in O
A O
/ O
ALL_CAP O
mice O
. O

D O
. O

A O
NUM O
- O
RARE O
RARE O
sequence O
of O
predominantly O
repeating O
RARE O
- O
pyrimidine O
nucleotides O
RARE O
these O
two O
d O
( O
ALL_CAP O
) O
repeats O
. O

Phase O
II O
study O
of O
ALL_CAP O
- O
16 O
( O
RARE O
) O
in O
solid O
tumors O
. O

When O
the O
coding O
RARE O
, O
including O
both O
RARE O
and O
RARE O
- O
RARE O
regions O
, O
of O
these O
genes O
and O
the O
murine O
probe O
sequences O
are O
compared O
by O
RARE O
analysis O
, O
it O
is O
apparent O
that O
the O
RARE O
genes O
are O
only O
slightly O
more O
related O
to O
each O
other O
than O
to O
the O
mammalian O
sequence O
, O
consistent O
with O
significant O
preservation O
of O
nucleotide O
sequence O
over O
an O
extended O
period O
of O
phylogenetic O
time O
. O

Evidence O
RARE O
a O
role O
of O
endogenous I-GENE
RARE I-GENE
- I-GENE
releasing I-GENE
factor I-GENE
in O
cold O
, O
ether O
, O
RARE O
, O
and O
RARE O
stress O
. O

An O
unusual O
feature O
of O
these O
replicative O
genes O
is O
that O
the O
smaller O
mRNA O
begins O
within O
a O
long O
RARE O
reading O
frame O
of O
the O
larger O
mRNA O
. O

RARE O
sequence O
elements O
of O
both O
the O
RARE O
vectors O
and O
the O
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
RARE O
RARE O
RARE O
of O
highly O
RARE O
RARE O
ALL_CAP O
, O
NUM O
, O
or O
NUM O
. O

NUM O
milk O
samples O
collected O
from O
NUM O
donors O
3 O
days O
to O
7 O
months O
after O
delivery O
were O
examined O
RARE O
the O
occurrence O
of O
RARE O
( O
ALL_CAP O
). O

RARE O
of O
DNA O
fragments O
from O
the O
8 O
. O
5 O
- O
RARE O
( O
kb O
) O
insert O
of O
NUM O
defined O
a O
4 O
- O
kb O
DNA O
fragment O
which O
contained O
the O
RARE I-GENE
ALL_CAP I-GENE
+ I-GENE
gene I-GENE
and O
its O
regulatory O
region O
. O

Three O
cases O
of O
RARE O
RARE O
- O
RARE O
cell O
carcinoma O
of O
the O
RARE O
are O
described O
. O

The O
data O
obtained O
RARE O
to O
now O
only O
suggest O
the O
future O
RARE O
of O
RARE O
treatment O
RARE O
these O
RARE O
of O
malignancy O
. O

These O
data O
suggest O
that O
dopaminergic O
RARE O
of O
adrenal O
RARE O
RARE O
RARE O
and O
RARE I-GENE
renin I-GENE
RARE O
is O
absent O
in O
patients O
with O
high O
RARE O
cord O
RARE O
, O
suggesting O
that O
RARE O
RARE O
pathways O
from O
the O
central O
nervous O
RARE O
are O
necessary O
RARE O
RARE O
RARE O
of O
aldosterone O
and O
renin I-GENE
RARE O
in O
men O
. O

In O
the O
absence O
of O
enhancer O
sequences O
, O
the O
adenovirus I-GENE
E1A I-GENE
gene I-GENE
can O
not O
stimulate O
RARE I-GENE
RARE O
. O

These O
IgG I-GENE
antibodies I-GENE
in O
the O
babies O
diminished O
rapidly O
after O
delivery O
, O
and O
were O
detectable O
only O
in O
3 O
cases O
RARE O
2 O
, O
3 O
, O
and O
5 O
months O
of O
ages O
out O
of O
38 O
babies O
RARE O
to O
21 O
months O
. O

RARE O
analysis O
RARE O
the O
nucleotide O
level O
of O
the O
early O
events O
in O
the O
digestion O
with O
RARE I-GENE
S1 I-GENE
shows O
that O
the O
enzyme O
attacks O
preferentially O
the O
sequence O
( O
G O
- O
A O
) O
12 O
on O
the O
RARE O
RARE O
RARE O
. O

RARE O
RARE O
that O
inhibited O
mean O
ALL_CAP I-GENE
activity O
in O
RARE O
cord O
greater O
than O
or O
equal O
to O
72 O
% O
and O
brain O
greater O
than O
or O
equal O
to O
NUM O
% O
of O
control O
values O
within O
NUM O
hr O
postexposure O
produced O
marked O
RARE O
cord O
pathology O
14 O
days O
postexposure O
in O
greater O
than O
or O
equal O
to O
NUM O
% O
of O
similarly O
RARE O
animals O
. O

FK O
NUM O
- O
NUM O
, O
a O
methionine O
- O
RARE I-GENE
analogue O
, O
suppressed O
plasma O
ACTH I-GENE
to O
NUM O
% O
of O
basal O
level O
, O
while O
RARE O
( O
ALL_CAP O
- O
154 O
) O
caused O
RARE O
significant O
change O
. O

A O
v I-GENE
- I-GENE
erbB I-GENE
- I-GENE
related I-GENE
RARE I-GENE
, O
c I-GENE
- I-GENE
erbB I-GENE
- I-GENE
2 I-GENE
, O
is O
distinct O
from O
the O
c I-GENE
- I-GENE
erbB I-GENE
- I-GENE
1 I-GENE
/ O
RARE I-GENE
growth I-GENE
factor I-GENE
- I-GENE
receptor I-GENE
gene O
and O
is O
amplified O
in O
a O
human O
RARE O
RARE O
adenocarcinoma O
. O

The O
sequence O
analysis O
of O
both O
products O
of O
individual O
RARE O
NUM O
site O
- O
specific O
RARE O
events O
in O
vivo O
shows O
that O
RARE O
with O
a O
secondary O
RARE O
( O
RARE O
) O
site O
generates O
several O
different O
novel O
RARE O
RARE O
the O
RARE O
position O
: O
one O
RARE O
event O
resulted O
in O
a O
single O
RARE O
- O
RARE O
deletion O
and O
two O
other O
RARE O
events O
resulted O
in O
two O
different O
single O
RARE O
- O
RARE O
substitutions O
. O

This O
L I-GENE
- I-GENE
myc I-GENE
sequence I-GENE
is O
amplified O
10 O
- O
20 O
- O
RARE O
in O
four O
ALL_CAP O
cell O
line O
RARE O
and O
in O
one O
ALL_CAP O
RARE O
RARE O
taken O
directly O
from O
a O
patient O
. O

RARE O
- O
shift O
experiments O
using O
RARE O
grown O
cells O
of O
a O
delta I-GENE
NUM I-GENE
NUM I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
( I-GENE
RARE I-GENE
) I-GENE
double I-GENE
mutant I-GENE
and O
its O
RARE O
NUM I-GENE
RARE O
RARE O
show O
that O
, O
whereas O
RARE O
blocks O
can O
prevent O
RARE O
of O
the O
NUM I-GENE
RARE I-GENE
mutant I-GENE
RARE O
a O
RARE O
RARE O
, O
the O
same O
treatments O
are O
RARE O
in O
preventing O
cell O
RARE O
of O
the O
delta I-GENE
NUM I-GENE
NUM I-GENE
RARE I-GENE
double I-GENE
mutant I-GENE
. O

The O
homology O
to O
v I-GENE
- I-GENE
RARE I-GENE
RARE O
within O
the O
coding O
sequence O
of O
RARE O
1 O
and O
ends O
within O
the O
3 O
' O
RARE O
region O
of O
RARE O
11 O
, O
12 O
nucleotides O
RARE O
from O
the O
nonsense O
RARE O
RARE O
the O
large O
RARE O
reading O
frame O
shared O
between O
c I-GENE
- I-GENE
RARE I-GENE
and O
v I-GENE
- I-GENE
RARE I-GENE
. O

Examination O
of O
the O
sequence O
of O
the O
RARE I-GENE
RARE I-GENE
M I-GENE
gene I-GENE
product I-GENE
reveals O
the O
presence O
of O
multiple O
hydrophobic O
sequences O
including O
a O
19 O
- O
amino O
acid O
, O
RARE O
- O
proximal O
, O
hydrophobic O
region O
( O
NUM O
). O

Six O
( O
four O
ALL_CAP O
; O
two O
RARE O
RARE O
) O
also O
had O
RARE O
positive O
RARE O
RARE O
, O
but O
the O
intensity O
was O
less O
than O
that O
of O
the O
RARE O
. O

The O
intensity O
of O
RARE O
uptake O
of O
Tc O
- O
99m O
- O
ALL_CAP O
in O
patients O
with O
echocardiographic O
RARE O
ventricular O
hypertrophy O
and O
/ O
or O
highly O
RARE O
RARE O
RARE O
, O
so O
- O
called O
RARE O
RARE O
appearance O
( O
ALL_CAP O
) O
was O
slightly O
greater O
than O
that O
in O
patients O
with O
neither O
RARE O
hypertrophy O
nor O
ALL_CAP O
. O

The O
210 O
kDa O
precursor O
is O
converted O
slowly O
( O
t O
1 O
/ O
2 O
= O
2 O
h O
) O
by O
RARE O
RARE O
into O
a O
NUM O
kDa O
( O
alpha O
RARE O
and O
NUM O
kDa O
( O
beta O
RARE O
species O
. O

RARE O
lymphocytes O
were O
RARE O
increased O
in O
most O
patients O
with O
AIDS O
( O
mean O
NUM O
. O
1 O
+/- O
21 O
. O
9 O
%; O
range O
1 O
- O
NUM O
%) O
and O
ALL_CAP O
( O
mean O
NUM O
. O
6 O
+/- O
NUM O
. O
6 O
%; O
range O
3 O
- O
NUM O
%) O
with O
criteria O
of O
activation O
RARE O
with O
the O
RARE O
RARE O
. O

We O
have O
determined O
that O
these O
RARE O
occur O
in O
both O
the O
wild O
- O
type O
and O
the O
mutant O
sites O
. O

The O
sequence O
was O
determined O
RARE O
a O
NUM O
- O
RARE O
RARE O
( O
bp O
) O
segment O
that O
RARE O
from O
NUM O
bp O
5 O
' O
to O
the O
RARE O
site O
of O
alpha I-GENE
1 I-GENE
to O
NUM O
bp O
3 O
' O
to O
psi I-GENE
alpha I-GENE
. O

Its O
predicted O
amino O
acid O
sequence O
shows O
extensive O
homology O
to O
those O
of O
Drosophila I-GENE
hsp70 I-GENE
, O
RARE I-GENE
hsp70 I-GENE
, O
Xenopus I-GENE
hsp70 I-GENE
, O
yeast I-GENE
hsp70 I-GENE
, O
and O
some O
homology O
to O
the O
heat I-GENE
- I-GENE
inducible I-GENE
ALL_CAP I-GENE
gene I-GENE
product I-GENE
of O
Escherichia O
coli O
. O

When O
RARE O
of O
RARE O
peptide O
RARE O
was O
measured O
RARE O
a O
function O
of O
receptor O
self O
- O
RARE O
, O
tyrosine I-GENE
kinase I-GENE
activity O
was O
found O
to O
be O
RARE O
two O
to O
threefold O
RARE O
1 O
- O
2 O
mol O
of O
phosphate O
per O
mol O
of O
receptor O
. O

At O
temperatures O
permissive O
RARE O
transformation O
, O
NUM O
cells O
contain O
NUM I-GENE
produced O
from O
the O
4 O
. O
NUM O
- O
RARE O
( O
kb O
) O
viral O
RNA O
genome O
and O
NUM I-GENE
- O
mos I-GENE
translated O
from O
a O
3 O
. O
5 O
- O
kb O
RARE O
mRNA O
. O

The O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
are O
RARE O
divergently O
from O
initiation O
sites O
that O
are O
separated O
by O
only O
NUM O
bp O
. O

RARE O
transformation O
by O
defined O
fragments O
of O
herpes O
simplex O
virus O
type O
2 O
DNA O
: O
RARE O
region O
and O
its O
gene O
product O
. O

It O
is O
concluded O
that O
in O
patients O
with O
RARE O
- O
RARE O
RARE O
herpes O
, O
the O
type O
of O
HSV O
is O
the O
most O
important O
determinant O
of O
subsequent O
RARE O
and O
that O
intravenous O
RARE O
has O
little O
effect O
on O
subsequent O
RARE O
. O

Comparison O
of O
sequences O
of O
RARE O
and O
bovine O
, O
rat O
and O
RARE I-GENE
- I-GENE
RARE I-GENE
alpha I-GENE
NUM I-GENE
- I-GENE
casein I-GENE
mRNAs I-GENE
has O
revealed O
a O
greater O
homology O
in O
the O
3 O
' O
and O
especially O
5 O
' O
non O
coding O
regions O
. O

One O
group O
( O
RARE O
= O
9 O
) O
was O
RARE O
with O
midazolam O
, O
NUM O
. O
1 O
mg O
kg O
- O
1 O
, O
and O
atropine O
NUM O
. O
2 O
- O
NUM O
. O
4 O
mg O
i O
. O
m O
. O

Comparison O
with O
a O
recently O
described O
c I-GENE
- I-GENE
RARE I-GENE
cDNA I-GENE
clone I-GENE
( O
RARE O
et O
al O
., O
RARE O
NUM O
, O
NUM O
- O
750 O
( O
1985 O
)) O
revealed O
that O
the O
1 O
. O
9 O
RARE O
DNA O
region O
contained O
a O
large O
5 I-GENE
' I-GENE
c I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
of O
RARE O
least O
NUM O
bp O
. O

It O
was O
also O
suggested O
that O
the O
biological O
activities O
of O
5 O
- O
FU O
, O
ALL_CAP O
and O
MMC O
in O
ALL_CAP O
were O
stable O
in O
ALL_CAP O
, O
ALL_CAP O
and O
ALL_CAP O
. O

Surprisingly O
, O
a O
C O
to O
G O
transversion O
RARE O
the O
RARE O
RARE O
of O
the O
CAT I-GENE
RARE I-GENE
, O
which O
severely O
RARE O
the O
activity O
of O
both O
promoters O
, O
appears O
to O
increase O
affinity O
of O
the O
CAT I-GENE
binding I-GENE
protein I-GENE
. O

The O
nucleotide O
sequence O
of O
NUM O
bp O
of O
RARE O
R O
. O
RARE O
chromosomal O
DNA O
, O
including O
the O
three O
structural O
genes O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
has O
been O
determined O
. O

The O
N O
- O
terminal O
sequence O
of O
one O
hydrophilic O
peptide O
of O
the O
ALL_CAP I-GENE
protein I-GENE
has O
been O
also O
obtained O
confirming O
the O
ALL_CAP I-GENE
reading O
frame O
. O

The O
5 O
' O
and O
3 O
' O
RARE O
sequences O
contain O
characteristic O
sequences O
that O
are O
involved O
in O
the O
initiation O
and O
RARE O
of O
transcription O
, O
including O
two O
possible O
promoters O
, O
one O
of O
which O
may O
contain O
two O
overlapping O
- O
10 O
sequences O
. O

Unlike O
NUM I-GENE
- O
myb I-GENE
- O
ets I-GENE
and O
the O
Mr O
NUM O
, O
NUM O
translation O
product O
of O
c I-GENE
- I-GENE
myb I-GENE
( O
NUM I-GENE
- I-GENE
myb I-GENE
RARE O
which O
are O
nuclear O
proteins O
, O
NUM I-GENE
- I-GENE
ets I-GENE
was O
found O
to O
be O
predominantly O
cytoplasmic O
. O

The O
RARE I-GENE
- I-GENE
NUM I-GENE
locus I-GENE
is O
within O
3 O
. O
4 O
to O
4 O
. O
4 O
kb O
of O
the O
RARE I-GENE
( I-GENE
NUM I-GENE
) I-GENE
NUM I-GENE
RARE I-GENE
, O
RARE O
four O
of O
the O
vital O
loci O
within O
a O
maximum O
of O
NUM O
. O
5 O
kb O
. O

The O
C O
- O
terminal O
end O
of O
this O
polypeptide O
RARE O
three O
RARE O
of O
RARE O
sequences O
. O

Further O
RARE O
of O
ocular O
RARE O
in O
RARE O
RARE O
RARE O
calves O
caused O
by O
ALL_CAP O
- O
1 O
were O
investigated O
. O

From O
our O
RARE O
and O
biochemical O
studies O
, O
it O
is O
evident O
that O
RARE O
II O
RARE O
are O
an O
early O
target O
of O
radiation O
and O
the O
release O
of O
RARE O
into O
the O
RARE O
RARE O
after O
exposure O
RARE O
RARE O
days O
and O
weeks O
. O

Thirty O
of O
the O
RARE O
contained O
a O
RARE O
NUM O
RARE O
- O
RARE O
RARE O
unit O
of O
the O
repeat O
. O

Two O
copies O
of O
the O
72 O
- O
bp O
repeat O
provided O
efficient O
activation O
of O
gene O
RARE O
. O

The O
RARE O
reading O
frames O
of O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
and O
ALL_CAP I-GENE
encode O
proteins O
of O
139 O
, O
NUM O
, O
and O
NUM O
amino O
acid O
residues O
, O
respectively O
. O

In O
order O
to O
study O
the O
influence O
of O
iron O
overload O
on O
the O
RARE O
RARE O
( O
ALL_CAP O
) O
metabolism O
of O
patients O
on O
chronic O
hemodialysis O
, O
generation O
of O
RARE O
RARE O
( O
NUM O
RARE O
by O
ALL_CAP O
in O
whole O
RARE O
was O
compared O
in O
two O
groups O
of O
RARE O
patients O
: O
group O
A O
consisted O
of O
RARE O
- O
one O
individuals O
with O
serum O
ferritin I-GENE
levels O
above O
1000 O
RARE O
/ O
ml O
and O
group O
B O
of O
RARE O
individuals O
with O
serum O
ferritin I-GENE
levels O
below O
1000 O
RARE O
/ O
ml O
. O

RARE O
, O
and O
ALL_CAP O
. O

Human I-GENE
alpha I-GENE
- I-GENE
galactosidase I-GENE
A I-GENE
: O
nucleotide O
sequence O
of O
a O
cDNA O
clone O
encoding O
the O
RARE O
enzyme O
. O

RARE O
( O
3 O
mg O
/ O
kg O
) O
generalized O
to O
RARE O
11 O
- O
NUM O
whereas O
the O
structurally O
related O
RARE O
5 O
- O
NUM O
( O
3 O
mg O
/ O
kg O
and O
NUM O
mg O
/ O
kg O
) O
did O
not O
. O

The O
amino O
acid O
sequence O
was O
determined O
to O
be O
residues O
NUM O
- O
NUM O
and O
hence O
RARE O
RARE O
NUM O
is O
RARE O
within O
the O
ATP O
- O
binding O
site O
. O

RARE I-GENE
( O
and O
RARE O
RARE O
) O
were O
not O
elevated O
in O
isolated O
RARE O
, O
indicating O
that O
mechanisms O
other O
than O
increased O
bone O
turnover O
may O
account O
RARE O
the O
markedly O
elevated O
serum I-GENE
RARE I-GENE
phosphatase I-GENE
activity O
in O
these O
subjects O
. O

Analysis O
of O
glucocorticoid O
RARE O
cell O
variants O
using O
a O
mouse I-GENE
glucocorticoid I-GENE
receptor I-GENE
RARE O
DNA O
clone O
. O

Among O
the O
v I-GENE
- I-GENE
myc I-GENE
codons O
, O
the O
RARE O
5 O
are O
derived O
from O
the O
noncoding O
5 O
' O
terminus O
of O
the O
second O
c I-GENE
- I-GENE
myc I-GENE
RARE O
, O
and O
NUM O
codons O
correspond O
to O
the O
c I-GENE
- I-GENE
myc I-GENE
coding O
region O
. O

A O
recombinant O
vector O
, O
NUM O
RARE O
was O
constructed O
which O
carried O
the O
BamHI I-GENE
- I-GENE
K I-GENE
fragment I-GENE
( O
nucleotides O
NUM O
to O
NUM O
of O
the O
NUM O
- O
8 O
RARE O
, O
encoding O
the O
ALL_CAP O
- O
associated O
nuclear O
antigen O
EBNA I-GENE
- I-GENE
1 I-GENE
RARE O
the O
cis O
- O
acting O
sequence O
from O
the O
BamHI I-GENE
- I-GENE
C I-GENE
fragment I-GENE
, O
and O
a O
dominant O
selectable O
marker O
gene O
encoding O
G O
- O
NUM O
resistance O
in O
RARE O
cells O
. O

NUM O
men O
with O
a O
history O
of O
recurrent O
RARE O
herpes O
simplex O
virus O
type O
2 O
( O
HSV O
- O
2 O
) O
infection O
were O
followed O
daily O
RARE O
4 O
weeks O
with O
samples O
taken O
from O
the O
RARE O
RARE O
virus O
isolation O
. O

RARE O
, O
with O
carcinoma O
RARE O
a O
RARE O
RARE O
( O
RARE O
RARE O
type O
) O
of O
the O
stomach O
itself O
, O
the O
II O
c O
portion O
of O
the O
stomach O
consisted O
of O
RARE O
glands O
( O
undifferentiated O
carcinoma O
) O
RARE O
become O
the O
RARE O
focus O
supporting O
RARE O
' O
s O
theory O
. O

During O
the O
biosynthesis O
of O
all O
three O
mutant O
polypeptides O
, O
the O
signal O
peptide O
is O
efficiently O
and O
accurately O
cleaved O
from O
the O
RARE O
protein O
, O
even O
though O
in O
mutants O
X2 O
and O
NUM O
the O
RARE O
site O
itself O
has O
been O
altered O
. O

The O
RARE O
5 O
'- O
ALL_CAP O
- O
3 O
RARE O
thought O
to O
be O
important O
RARE O
ALL_CAP O
activity O
, O
not O
only O
was O
found O
in O
this O
sequence O
and O
in O
the O
5 O
'- O
flanking O
region O
, O
but O
also O
was O
present O
twice O
in O
the O
3 O
' O
end O
of O
the O
gene O
that O
did O
not O
show O
specific O
receptor O
binding O
. O

Five O
patients O
developed O
metastatic O
spread O
, O
and O
all O
of O
them O
died O
of O
tumor O
. O

The O
smallest O
of O
the O
RARE O
- O
RARE O
elements O
is O
only O
7 O
. O
9 O
RARE O
RARE O
long O
, O
allowing O
the O
cloning O
of O
DNA O
fragments O
of O
RARE O
to O
NUM O
. O
1 O
RARE O
RARE O
, O
and O
the O
largest O
of O
them O
is O
21 O
. O
7 O
RARE O
RARE O
, O
requiring O
that O
RARE O
carry O
insertions O
of O
less O
than O
NUM O
. O
3 O
RARE O
RARE O
. O

The O
52 O
- O
protein O
subunit O
of O
T4 I-GENE
DNA I-GENE
topoisomerase I-GENE
is O
homologous O
to O
the O
ALL_CAP I-GENE
- I-GENE
protein I-GENE
of O
RARE I-GENE
. O

There O
were O
RARE O
interfering O
peaks O
in O
the O
RARE O
of O
RARE O
. O

The O
latent O
periods O
from O
the O
RARE O
exclusion O
to O
the O
occurrence O
of O
RARE O
ulcers O
after O
a O
subtotal O
RARE O
with O
RARE O
' O
s O
type O
II O
reconstruction O
varied O
from O
a O
few O
days O
to O
19 O
years O
, O
with O
an O
average O
of O
2 O
. O
8 O
years O
. O

The O
RARE O
arrays O
detected O
by O
ALL_CAP O
X O
RARE O
( O
II O
) O
were O
characterized O
by O
a O
considerable O
RARE O
of O
detail O
and O
significantly O
RARE O
RARE O
, O
the O
extent O
of O
which O
probably O
reflected O
the O
relative O
transcription O
rate O
of O
each O
gene O
. O

RARE O
of O
specific O
cellular O
genes O
from O
the O
chimeric O
viral O
- O
cellular O
transcripts O
seems O
to O
be O
unlikely O
. O

The O
RARE O
RARE O
of O
in O
vivo O
- O
labeled O
proteins O
was O
increased O
relative O
to O
that O
of O
in O
vitro O
- O
translated O
proteins O
, O
indicating O
that O
a O
posttranslational O
modification O
had O
occurred O
. O

RARE O
of O
4 O
bp O
RARE O
SV40 I-GENE
early I-GENE
promoter I-GENE
- O
dependent O
chloramphenicol I-GENE
RARE I-GENE
( O
CAT I-GENE
) O
RARE O
by O
RARE O
- O
to O
RARE O
. O

In O
the O
RARE O
of O
all O
NUM O
- O
positive O
chronic O
RARE O
leukemia O
patients O
studied O
to O
date O
, O
a O
RARE O
on O
RARE O
NUM O
( O
the O
NUM O
RARE O
) O
can O
be O
demonstrated O
with O
a O
probe O
from O
the O
RARE I-GENE
( O
RARE I-GENE
cluster I-GENE
region I-GENE
). O

RARE O
footprinting O
revealed O
that O
RARE O
glucocorticoid I-GENE
receptor I-GENE
RARE O
RARE O
multiple O
discrete O
sites O
within O
and O
RARE O
the O
RARE O
of O
the O
tandemly O
RARE O
sequence O
motif O
that O
defines O
RARE I-GENE
. O

The O
96 O
- O
bp O
insert O
contained O
a O
RARE O
signal O
which O
caused O
the O
premature O
RARE O
of O
the O
protein O
, O
leading O
to O
the O
generation O
of O
a O
p53 I-GENE
product I-GENE
9 O
amino O
RARE O
shorter O
than O
RARE O
. O

All O
tumors O
proved O
histologically O
to O
be O
RARE O
in O
origin O
. O

The O
coding O
region O
of O
NUM O
nucleotides O
corresponds O
to O
a O
polypeptide O
chain O
of O
NUM O
amino O
RARE O
, O
giving O
a O
RARE O
RARE O
of O
91 O
, O
NUM O
RARE O
the O
NUM I-GENE
protein I-GENE
. O

Transcriptional O
control O
signals O
of O
a O
herpes I-GENE
simplex I-GENE
virus I-GENE
type I-GENE
1 I-GENE
RARE I-GENE
( I-GENE
gamma I-GENE
2 I-GENE
) I-GENE
gene I-GENE
RARE O
within O
bases O
- O
NUM O
to O
+ O
NUM O
relative O
to O
the O
5 O
' O
terminus O
of O
the O
mRNA O
. O

A O
RARE O
domain O
RARE O
among O
cytoplasmic I-GENE
protein I-GENE
- I-GENE
tyrosine I-GENE
kinases I-GENE
RARE O
the O
kinase O
function O
and O
transforming O
activity O
of O
RARE I-GENE
sarcoma I-GENE
virus I-GENE
NUM I-GENE
- O
RARE I-GENE
. O

RARE O
, O
ALL_CAP O
ALL_CAP O
. O

A O
single O
RARE O
encodes O
the O
RARE O
- O
terminal O
NUM O
amino O
RARE O
of O
the O
RARE I-GENE
chain I-GENE
and O
the O
3 O
' O
RARE O
region O
of O
its O
mRNA O
, O
RARE O
with O
a O
RARE O
( O
A O
)- O
addition O
site O
. O

The O
5 O
'- O
RARE O
sequences O
and O
parts O
of O
the O
coding O
sequences O
of O
various O
yeast O
genes O
have O
been O
RARE O
into O
representative O
lacZ I-GENE
fusion O
vectors O
. O

Two O
activities O
of O
the O
D I-GENE
protein I-GENE
of O
the O
ALL_CAP O
RARE O
have O
been O
found O
. O

SPECT O
examination O
of O
the O
ALL_CAP O
using O
99m O
Tc O
- O
ALL_CAP O
was O
performed O
in O
NUM O
patients O
with O
RARE O
proven O
anterior O
dislocation O
of O
the O
disc O
and O
in O
NUM O
normals O
. O

Plasma I-GENE
renin I-GENE
activity O
rose O
and O
the O
plasma O
aldosterone O
level O
fell O
after O
taking O
RARE O
. O

Two O
mutants O
, O
each O
representative O
of O
a O
separate O
RARE I-GENE
RARE O
group O
, O
have O
been O
analyzed O
. O

The O
second O
group O
of O
homologous O
elements O
is O
present O
in O
the O
upstream O
region O
of O
both O
genes O
. O

A O
centromere O
in O
S O
. O
cerevisiae O
consists O
of O
a O
region O
of O
DNA O
, O
RARE O
NUM O
bp O
in O
length O
, O
containing O
three O
important O
sequence O
elements O
, O
which O
are O
folded O
with O
proteins O
into O
a O
specific O
conformation O
in O
the O
chromatin O
( O
the O
yeast O
RARE O
). O

RARE O
function O
of O
a O
positively O
regulated O
promoter O
reveals O
new O
sequences O
essential O
RARE O
activity O
. O

Two O
separate O
NF1 I-GENE
- I-GENE
binding I-GENE
loci I-GENE
were O
also O
found O
in O
the O
equivalent O
NUM I-GENE
gene I-GENE
of O
ALL_CAP O
( O
RARE O
) O
DNA O
, O
but O
in O
this O
case O
the O
DNA O
sequence O
and O
competition O
filter O
binding O
experiments O
indicated O
a O
maximum O
of O
only O
four O
to O
five O
consensus O
binding O
sites O
RARE O
the O
promoter O
- O
enhancer O
region O
. O

The O
previously O
described O
four O
sets O
of O
NUM O
- O
to O
18 O
- O
RARE O
- O
RARE O
interspersed O
repeat O
elements O
between O
- O
NUM O
and O
- O
NUM O
provide O
most O
of O
the O
high O
basal O
transcriptional O
strength O
, O
whereas O
the O
arrangement O
of O
further O
upstream O
tandemly O
RARE O
NF1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
may O
contribute O
significantly O
to O
the O
RARE O
biological O
RARE O
range O
RARE O
RARE O
of O
ALL_CAP I-GENE
NUM I-GENE
compared O
with O
ALL_CAP I-GENE
NUM I-GENE
. O

We O
inserted O
genes O
or O
gene O
RARE O
, O
that O
code O
RARE O
the O
bacterial I-GENE
chloramphenicol I-GENE
RARE I-GENE
, O
the O
bacterial O
gene O
conferring O
resistance O
against O
RARE O
, O
and O
the O
ORF O
E7 I-GENE
of O
the O
human O
RARE O
type O
18 O
into O
these O
vectors O
. O

By O
contrast O
, O
their O
basal O
adrenal O
RARE O
levels O
were O
significantly O
decreased O
compared O
to O
those O
in O
normal O
subjects O
on O
both O
the O
day O
on O
and O
the O
day O
off O
prednisone O
( O
P O
less O
than O
NUM O
. O
05 O
). O

RARE O
lambda I-GENE
and I-GENE
RARE I-GENE
antibody I-GENE
gene I-GENE
rearrangement O
in O
RARE O
murine O
leukemia O
virus O
- O
transformed O
pre O
- O
B O
cell O
lines O
. O

Identification O
of O
NUM O
- O
responsive O
regulatory O
sequences O
within O
the O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
long O
terminal O
repeat O
. O

During O
RARE O
anesthesia O
, O
the O
basal O
VO2 O
was O
5 O
. O
NUM O
ml O
/ O
kg O
/ O
min O
and O
was O
increased O
by O
epinephrine O
in O
a O
dose O
dependent O
manner O
RARE O
plasma O
concentrations O
between O
3 O
. O
9 O
RARE O
/ O
ml O
( O
VO2 O
= O
5 O
. O
NUM O
ml O
/ O
kg O
/ O
min O
) O
and O
NUM O
. O
5 O
RARE O
/ O
ml O
( O
VO2 O
= O
6 O
. O
NUM O
ml O
/ O
kg O
/ O
min O
). O

Influence O
of O
RARE I-GENE
- I-GENE
oxygenase I-GENE
inhibition O
and O
of O
RARE I-GENE
receptor I-GENE
blockade O
on O
pulmonary O
vascular O
pressure O
/ O
cardiac O
index O
relationships O
in O
RARE O
and O
in O
hypoxic O
dogs O
. O

RARE O
- O
directed O
mutagenesis O
was O
used O
to O
create O
an O
ALL_CAP I-GENE
RARE I-GENE
site I-GENE
RARE O
the O
RARE O
ATG O
of O
the O
yeast O
R O
. O

ACTH I-GENE
release O
is O
transiently O
suppressed O
in O
some O
children O
after O
RARE O
ACTH I-GENE
treatment O
. O

We O
previously O
showed O
that O
the O
upstream O
promoter O
element O
of O
the O
yeast I-GENE
NUM I-GENE
gene I-GENE
consists O
of O
these O
identical O
sequence O
motifs O
. O

These O
data O
suggest O
that O
mammalian O
RARE O
alpha I-GENE
- I-GENE
spectrin I-GENE
evolved O
by O
duplication O
and O
rapid O
divergence O
from O
an O
ancestral O
alpha I-GENE
- I-GENE
RARE I-GENE
- I-GENE
like I-GENE
gene I-GENE
. O

Northern O
analyses O
of O
RNAs O
from O
mouse O
tissues O
and O
cell O
lines O
indicated O
that O
NUM I-GENE
mRNA I-GENE
levels O
vary O
widely O
. O

One O
group O
of O
RARE O
cDNA O
RARE O
was O
derived O
from O
a O
2 O
. O
9 O
- O
RARE O
early O
transcript O
encoded O
by O
the O
NUM O
repeat O
element O
and O
showed O
RARE O
site O
polymorphism O
RARE O
the O
enzyme I-GENE
ALL_CAP I-GENE
. O

Combined O
RARE O
with O
cyclophosphamide O
RARE O
BCG O
gave O
a O
better O
enhancement O
of O
the O
RARE O
effect O
of O
the O
RARE O
than O
that O
of O
the O
combination O
of O
methotrexate O
RARE O
BCG O
and O
cyclophosphamide O
RARE O
RARE O
. O

RARE O
produced O
a O
dose O
- O
dependent O
RARE O
followed O
by O
tachycardia O
. O

The O
ALL_CAP I-GENE
gene I-GENE
was O
subcloned O
into O
a O
1 O
. O
1 O
- O
kb O
fragment O
of O
the O
yeast O
DNA O
on O
the O
NUM O
vector O
. O

Indeed O
, O
A O
- O
MuLV O
RARE O
with O
some O
viruses O
, O
such O
RARE O
the O
Moloney O
MuLV O
, O
has O
been O
shown O
to O
be O
highly O
RARE O
, O
whereas O
A O
- O
MuLV O
RARE O
with O
other O
viruses O
, O
such O
RARE O
the O
ALL_CAP O
/ O
c O
endogenous O
N O
- O
RARE O
MuLV O
, O
has O
been O
shown O
to O
be O
RARE O
of O
RARE O
RARE O
( O
N O
. O

The O
presence O
of O
circulating O
platelet O
aggregates O
and O
elevated O
levels O
of O
RARE I-GENE
A I-GENE
( O
a O
RARE O
product O
of O
fibrin I-GENE
) O
suggests O
that O
platelet O
activation O
and O
fibrin I-GENE
deposition O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
this O
disorder O
. O

The O
gene O
is O
essential O
RARE O
yeast O
RARE O
growth O
. O

4 O
. O

In O
RARE O
, O
the O
values O
obtained O
by O
the O
two O
methods O
were O
in O
agreement O
RARE O
each O
species O
of O
RARE I-GENE
growth I-GENE
factor I-GENE
and O
followed O
the O
order O
: O
wild O
type O
greater O
than O
NUM O
RARE O
RARE O
greater O
than O
NUM O
RARE O
RARE O
much O
greater O
than O
NUM O
RARE O
RARE O
greater O
than O
NUM O
RARE O
RARE O
greater O
than O
NUM O
RARE O
RARE O
. O

It O
is O
concluded O
that O
suppression O
of O
elevated O
prolactin I-GENE
levels O
in O
progressive O
metastatic O
breast O
RARE O
patients O
is O
not O
effective O
in O
RARE O
tumor O
sensitivity O
to O
chemotherapy O
. O

We O
report O
a O
prevalence O
study O
of O
the O
best O
visual O
RARE O
in O
the O
affected O
eye O
of O
NUM O
RARE O
patients O
with O
RARE O
RARE O
seen O
RARE O
a O
two O
- O
year O
period O
. O

We O
also O
found O
an O
eIF I-GENE
- I-GENE
NUM I-GENE
intronless O
RARE O
which O
, O
when O
compared O
to O
the O
cDNA O
, O
contains O
a O
single O
nucleotide O
difference O
. O

RARE O
culture O
of O
pancreatic O
tissue O
was O
positive O
in O
6 O
/ O
8 O
ALL_CAP O
and O
3 O
/ O
NUM O
ALL_CAP O
rats O
( O
p O
less O
than O
NUM O
. O
01 O
). O

These O
similarities O
suggest O
that O
these O
E2 I-GENE
proteins I-GENE
are O
structurally O
and O
evolutionarily O
related O
. O

After O
infection O
of O
293 O
cells O
( O
which O
provide O
RARE O
E1a I-GENE
- O
NUM I-GENE
functions O
RARE O
both O
viruses O
directed O
equal O
amounts O
of O
P I-GENE
/ I-GENE
C I-GENE
- I-GENE
specific I-GENE
mRNA I-GENE
transcription O
. O

This O
observation O
cannot O
be O
explained O
by O
the O
scanning O
model O
RARE O
ribosomal O
initiation O
and O
suggests O
that O
RARE O
may O
be O
binding O
directly O
RARE O
an O
internal O
mRNA O
site O
RARE O
or O
near O
the O
RARE O
AUG O
RARE O
RARE O
the O
C I-GENE
protein I-GENE
. O

In O
view O
of O
these O
results O
, O
simultaneous O
pancreas O
- O
RARE O
transplantation O
appears O
to O
be O
the O
treatment O
of O
choice O
RARE O
RARE O
I O
diabetic O
patients O
. O

This O
makes O
these O
compounds O
RARE O
RARE O
RARE O
RARE O
these O
and O
other O
gases O
in O
- O
vivo O
and O
in O
- O
vitro O
. O

DNA O
sequencing O
of O
the O
NUM I-GENE
gene I-GENE
revealed O
an O
RARE O
reading O
frame O
of O
801 O
bases O
. O

The O
relationship O
between O
RARE O
malignant O
lymphoma O
of O
the O
thyroid O
and O
chronic O
thyroiditis O
is O
discussed O
. O

Administration O
of O
RARE O
, O
i O
. O
RARE O
., O
RARE O
, O
RARE O
E1 O
and O
RARE O
seems O
to O
be O
effective O
in O
RARE O
symptoms O
and O
might O
prevent O
further O
deterioration O
. O

Mutational O
analysis O
of O
the O
L1 I-GENE
binding I-GENE
site I-GENE
of O
NUM I-GENE
rRNA I-GENE
in I-GENE
Escherichia I-GENE
coli I-GENE
. O

Animals O
may O
be O
immunized O
by O
oral O
vaccination O
, O
but O
RARE O
mechanisms O
that O
also O
can O
terminate O
RARE O
are O
discussed O
. O

RARE O
formation O
, O
reflected O
by O
the O
excretion O
rate O
of O
its O
stable O
metabolite O
6 O
- O
RARE O
- O
RARE O
NUM O
alpha O
, O
was O
measured O
by O
means O
of O
radioimmunoassay O
in O
4 O
- O
hour O
urine O
specimens O
obtained O
RARE O
a O
smoking O
- O
free O
period O
and O
after O
RARE O
had O
inhaled O
smoke O
from O
four O
high O
- O
nicotine O
RARE O
. O

However O
, O
excretion O
of O
6 O
- O
RARE O
- O
RARE O
NUM O
alpha O
was O
further O
RARE O
in O
the O
smokers O
who O
used O
oral O
RARE O
( O
NUM O
+/- O
20 O
to O
NUM O
+/- O
9 O
RARE O
/ O
RARE O
of O
RARE O
, O
p O
less O
than O
NUM O
. O
05 O
). O

The O
in O
vitro O
activity O
of O
RARE O
and O
amoxicillin O
/ O
RARE O
acid O
against O
Escherichia O
coli O
strains O
producing O
beta I-GENE
- I-GENE
RARE I-GENE
of O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
RARE I-GENE
- I-GENE
1 I-GENE
and O
chromosomal O
type O
were O
studied O
using O
the O
RARE O
and O
agar O
dilution O
technique O
. O

GCN4 I-GENE
encodes O
a O
transcriptional O
activator O
of O
amino O
acid O
biosynthetic O
genes O
in O
Saccharomyces O
cerevisiae O
. O

These O
results O
imply O
that O
the O
NUM I-GENE
product I-GENE
can O
promote O
either O
repression O
or O
activation O
of O
GCN4 I-GENE
RARE O
depending O
on O
amino O
acid O
availability O
. O

The O
efficacy O
of O
these O
immunosuppressive O
drugs O
is O
clinical O
proven O
. O

The O
amino O
acid O
sequence O
of O
the O
S O
. O
RARE O
peptide O
carrying O
the O
RARE O
group O
was O
found O
to O
be O
Gln O
- O
RARE O
- O
RARE O
- O
RARE O
- O
RARE O
- O
RARE O
- O
RARE O
- O
RARE O
- O
Asn O
- O
RARE O
- O
RARE O
- O
RARE O
- O
Ile O
- O
RARE O
- O
RARE O
- O
RARE O
- O
RARE O
- O
RARE O
- O
RARE O
. O

These O
mutations O
alter O
two O
regions O
of O
GAL4 I-GENE
protein I-GENE
: O
the O
DNA O
binding O
domain O
, O
and O
the O
transcription O
activation O
domain O
. O

The O
results O
indicated O
that O
two O
genes O
( O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
) O
have O
separate O
promoters O
, O
and O
the O
location O
of O
the O
promoter O
RARE O
the O
ALL_CAP I-GENE
gene I-GENE
in O
the O
NUM I-GENE
nucleotide O
sequence O
was O
different O
from O
that O
in O
NUM O
. O

The O
RARE I-GENE
gene I-GENE
was O
fused O
with O
lacZ I-GENE
and O
its O
gene O
product O
was O
identified O
by O
Western O
blot O
analysis O
. O

Structure O
and O
RARE O
of O
a O
nuclear O
gene O
in O
Saccharomyces O
cerevisiae O
that O
specifies O
NUM I-GENE
, O
a O
protein O
of O
the O
small O
subunit O
of O
the O
mitochondrial O
RARE O
. O

After O
a O
survey O
of O
the O
anatomical O
and O
physiological O
basis O
of O
operative O
treatment O
of O
behaviour O
disorders O
by O
RARE O
lesions O
in O
the O
amygdala O
and O
the O
posterior O
medial O
hypothalamus O
the O
author O
describes O
RARE O
own O
RARE O
with O
NUM O
RARE O
RARE O
control O
of O
RARE O
RARE O
RARE O
. O

Histological O
examination O
revealed O
a O
small O
simple O
RARE O
cyst O
associated O
with O
RARE O
cell O
carcinoma O
. O

Although O
large O
RARE O
studies O
are O
best O
able O
to O
identify O
the O
relative O
RARE O
of O
specific O
risk O
factors O
while O
controlling O
RARE O
other O
risk O
factors O
, O
new O
studies O
need O
to O
focus O
on O
important O
RARE O
questions O
. O

Thus O
, O
RARE O
RARE O
the O
RARE O
RARE O
of O
the O
inner O
ear O
vessels O
. O

The O
method O
is O
accurate O
, O
with O
good O
RARE O
and O
adequate O
sensitivity O
. O

Factors O
influencing O
the O
bond O
strength O
between O
glass O
RARE O
( O
RARE O
) O
RARE O
and O
RARE O
. O

The O
amino O
acid O
sequences O
of O
the O
yeast O
and O
mammalian O
mitochondrial O
targeting O
sequences O
are O
similar O
but O
less O
related O
than O
the O
RARE O
polypeptides O
. O

RARE O
RARE O
RARE O
, O
R O
. O

During O
insulin I-GENE
infusion O
, O
a O
20 O
% O
RARE O
solution O
was O
infused O
by O
a O
RARE O
in O
order O
to O
maintain O
the O
patient O
' O
s O
RARE O
RARE O
NUM O
mg O
/ O
dl O
. O

RARE O
of O
glucose O
infused O
RARE O
the O
last O
20 O
min O
of O
each O
2 O
hour O
insulin I-GENE
infusion O
were O
( O
RARE O
1 O
and O
10 O
m O
/ O
kg O
/ O
min O
respectively O
): O
before O
treatment O
( O
K O
+ O
= O
2 O
. O
7 O
mmol O
/ O
RARE O
): O
2 O
. O
4 O
and O
8 O
. O
4 O
mg O
/ O
kg O
/ O
min O
; O
after O
RARE O
( O
K O
+ O
= O
3 O
. O
9 O
mmol O
/ O
RARE O
): O
3 O
. O
3 O
and O
NUM O
. O
4 O
mg O
/ O
kg O
/ O
min O
; O
after O
RARE O
( O
K O
+ O
= O
3 O
. O
7 O
mmol O
/ O
RARE O
): O
5 O
and O
19 O
mg O
/ O
kg O
/ O
min O
after O
RARE O
drugs O
( O
K O
+ O
= O
2 O
. O
9 O
mmol O
/ O
RARE O
): O
2 O
. O
5 O
and O
5 O
. O
3 O
mg O
/ O
kg O
/ O
min O
. O

Mycobacterium O
RARE O
- O
RARE O
complex O
infections O
in O
the O
acquired O
immunodeficiency O
RARE O
. O

RARE O
of O
RARE O
deposition O
in O
a O
RARE O
transplant O
RARE O
RARE O
A O
therapy O
. O

The O
bile O
acid O
RARE O
( O
RARE O
and O
RARE O
RARE O
RARE O
acid O
, O
RARE O
and O
RARE O
of O
RARE I-GENE
RARE I-GENE
A I-GENE
( I-GENE
HMG I-GENE
CoA I-GENE
) I-GENE
reductase I-GENE
( O
RARE O
. O
g O
. O
RARE O
or O
RARE O
) O
are O
the O
most O
effective O
drugs O
RARE O
use O
in O
patients O
with O
RARE O
RARE O
; O
these O
agents O
reduce O
plasma O
concentrations O
of O
RARE O
and O
LDL I-GENE
- I-GENE
cholesterol I-GENE
by O
NUM O
to O
NUM O
%. O

Finally O
, O
the O
RARE O
aspects O
of O
RARE O
acidification O
are O
discussed O
, O
focusing O
on O
RARE O
tubular O
acidosis O
models O
( O
RARE O
by O
RARE O
and O
amphotericin O
B O
treatment O
) O
and O
their O
cellular O
mechanisms O
, O
RARE O
RARE O
RARE O
the O
role O
of O
adrenal O
steroids O
in O
RARE O
acidification O
. O

Analysis O
in O
3 O
groups O
of O
patients O
suffering O
from O
simple O
acute O
and O
RARE O
RARE O
RARE O
- O
RARE O

RARE O
on O
the O
development O
of O
guidelines O
RARE O
the O
prevention O
of O
AIDS O
RARE O
in O
the O
RARE O
. O

RARE O
of O
the O
RARE O
RARE O
in O
diseased O
people O
. O

RARE O
- O
treated O
rats O
acquired O
a O
preference O
RARE O
cocaine O
- O
associated O
RARE O
stimuli O
( O
ALL_CAP O
) O
relative O
to O
saline O
- O
injected O
control O
rats O
. O

Under O
these O
RARE O
, O
a O
reinforced O
response O
run O
consisted O
of O
responding O
between O
eight O
and O
12 O
times O
on O
one O
response O
key O
( O
work O
key O
) O
and O
then O
responding O
once O
on O
a O
second O
response O
key O
( O
reinforced O
key O
). O

Intravenous O
glucose O
tolerance O
tests O
were O
performed O
before O
operation O
, O
before O
starting O
ALL_CAP O
and O
after O
3 O
weeks O
. O

The O
effects O
of O
RARE O
on O
dimensions O
and O
RARE O
of O
microvascular O
RARE O
in O
rat O
RARE O
were O
studied O
in O
two O
RARE O
of O
experiment O
, O
RARE O
the O
RARE O
by O
RARE O
- O
arterial O
perfusion O
RARE O
a O
pressure O
of O
NUM O
mm O
Hg O
and O
by O
RARE O
of O
the O
RARE O
RARE O
membrane O
. O

This O
gave O
rise O
to O
RNA O
molecules O
with O
3 O
'- O
RARE O
regions O
of O
RARE O
NUM O
, O
NUM O
, O
and O
NUM O
RARE O
RARE O
. O

Also O
, O
the O
ALL_CAP I-GENE
/ I-GENE
c I-GENE
gene I-GENE
contains O
a O
single O
substitution O
in O
a O
RARE O
octamer O
sequence O
RARE O
equal O
to O
NUM O
nucleotides O
upstream O
of O
the O
coding O
region O
, O
which O
could O
affect O
its O
RARE O
. O

Clinical O
findings O
were O
: O
height O
NUM O
cm O
, O
RARE O
NUM O
kg O
, O
increased O
length O
of O
lower O
RARE O
, O
P2 O
- O
NUM O
RARE O
and O
RARE O
. O

Our O
data O
suggest O
that O
it O
may O
be O
possible O
to O
RARE O
hCG I-GENE
administration O
RARE O
RARE O
by O
RARE O
the O
number O
of O
RARE O
greater O
than O
1 O
cm O
by O
ultrasound O
on O
RARE O
day O
12 O
or O
NUM O
and O
giving O
hCG I-GENE
when O
serum O
E2 O
levels O
reach O
NUM O
to O
NUM O
RARE O
/ O
RARE O
per O
RARE O
. O

The O
8 O
patients O
receiving O
NUM O
implant O
in O
addition O
to O
external O
radiation O
showed O
improved O
( O
p O
= O
NUM O
. O
06 O
) O
survival O
compared O
to O
the O
9 O
receiving O
external O
only O
: O
median O
NUM O
months O
( O
range O
1 O
. O
5 O
- O
NUM O
+ O
months O
) O
versus O
7 O
months O
( O
range O
2 O
. O
5 O
- O
21 O
months O
). O

Within O
Stage O
IA O
, O
NUM O
patients O
had O
RARE O
differentiated O
tumor O
( O
G1 O
RARE O
20 O
had O
moderately O
RARE O
differentiated O
tumor O
( O
NUM O
RARE O
and O
12 O
patients O
had O
poorly O
differentiated O
( O
NUM O
). O

Mechanism O
of O
the O
t O
( O
14 O
; O
18 O
) O
chromosomal O
translocation O
: O
structural O
analysis O
of O
both O
RARE O
14 O
and O
18 O
reciprocal O
partners O
. O

After O
age O
NUM O
, O
mean O
hemoglobin I-GENE
levels O
RARE O
men O
gradually O
declined O
, O
while O
those O
in O
women O
rose O
, O
so O
that O
the O
RARE O
difference O
diminished O
after O
NUM O
years O
of O
age O
. O

RARE O
is O
a O
new O
RARE O
with O
highly O
selective O
blocking O
activity O
on O
NUM I-GENE
receptors I-GENE
RARE O
5 O
- O
ALL_CAP O
in O
the O
central O
nervous O
RARE O
. O

RARE O
glycol O
and O
RARE O
glycol O
were O
each O
administered O
once O
weekly O
subcutaneously O
to O
groups O
of O
NUM O
female O
ALL_CAP O
mice O
RARE O
3 O
RARE O
( O
NUM O
; O
10 O
RARE O
3 O
mg O
single O
dose O
per O
mouse O
). O

Research O
on O
ethylene O
glycol O
and O
RARE O
glycol O
RARE O
RARE O
effects O

The O
results O
suggest O
that O
the O
greater O
RARE O
influence O
associated O
with O
the O
RARE O
estradiol O
- O
containing O
ALL_CAP O
resulted O
in O
inhibition O
of O
coronary O
artery O
atherosclerosis O
despite O
a O
pronounced O
RARE O
- O
RARE O
lowering O
of O
plasma O
ALL_CAP I-GENE
cholesterol I-GENE
concentration O
and O
, O
further O
, O
that O
hormonal O
balance O
may O
have O
a O
marked O
influence O
on O
the O
relationship O
between O
plasma O
lipids O
and O
RARE O
. O

During O
ALL_CAP O
the O
RARE O
was O
RARE O
and O
a O
RARE O
flow O
of O
50 O
% O
NUM O
RARE O
4 O
- O
5 O
RARE O
/ O
min O
was O
delivered O
through O
the O
RARE O
RARE O
of O
a O
small O
catheter O
whose O
RARE O
was O
positioned O
1 O
cm O
RARE O
of O
the O
RARE O
. O

Comparison O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
removal O
using O
the O
same O
RARE O
membrane O
RARE O
haemodialysis O
and O
RARE O
shows O
that O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
is O
more O
effectively O
removed O
by O
RARE O
than O
by O
diffusion O
when O
both O
treatment O
modes O
are O
matched O
RARE O
RARE O
flow O
and O
urea O
clearance O
. O

40 O
. O
3 O
+/- O
10 O
. O
1 O
mg O
/ O
RARE O
( O
SD O
) O
RARE O
NUM O
. O
2 O
+/- O
8 O
. O
NUM O
, O
P O
less O
than O
NUM O
. O
01 O
). O
beta I-GENE
NUM I-GENE
was O
not O
significantly O
RARE O
in O
patients O
with O
bone O
cysts O
( O
37 O
. O
7 O
+/- O
11 O
. O
4 O
mg O
/ O
RARE O
RARE O
37 O
. O
NUM O
+/- O
10 O
. O
NUM O
RARE O
but O
median O
duration O
of O
dialysis O
was O
significantly O
( O
P O
less O
than O
NUM O
. O
01 O
) O
longer O
in O
patients O
with O
bone O
cysts O
( O
NUM O
RARE O
57 O
months O
). O
beta I-GENE
NUM I-GENE
was O
lower O
in O
patients O
maintained O
on O
dialysis O
RARE O
less O
than O
1 O
year O
and O
whose O
residual O
urine O
volume O
was O
greater O
than O
NUM O
. O
1 O
RARE O
per O
day O
. O

The O
mean O
percentage O
of O
RARE O
acid O
in O
the O
RARE O
of O
the O
subcutaneous O
RARE O
tissue O
( O
ALL_CAP O
) O
of O
these O
subjects O
was O
substantially O
RARE O
than O
that O
in O
a O
similar O
group O
examined O
in O
NUM O
- O
NUM O
. O

In O
RARE O
RARE O
to O
2 O
g O
RARE O
RARE O
lasting O
toxic O
effects O
were O
observed O
. O

It O
is O
concluded O
that O
the O
plasma I-GENE
prolactin I-GENE
response O
to O
12 O
. O
5 O
micrograms O
i O
. O
v O
. O

No O
effect O
was O
found O
on O
RARE O
behavior O
. O

The O
remaining O
RARE O
patients O
had O
slightly O
decreased O
( O
RARE O
= O
3 O
) O
or O
normal O
( O
RARE O
= O
3 O
) O
RARE O
parameters O
. O

In O
addition O
, O
a O
wild O
- O
type O
RARE O
containing O
a O
RARE I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
tRNA I-GENE
RARE I-GENE
mutation I-GENE
showed O
increased O
RARE I-GENE
operon I-GENE
RARE O
RARE O
the O
non O
- O
permissive O
RARE O
, O
whereas O
none O
of O
the O
mutants O
showed O
any O
change O
. O

Significant O
treatment O
- O
related O
problems O
appeared O
RARE O
the O
second O
RARE O
in O
5 O
patients O
, O
including O
one O
chest O
RARE O
sarcoma O
; O
all O
of O
these O
patients O
had O
received O
RARE O
least O
NUM O
Gy O
to O
breast O
and O
regional O
nodal O
areas O
. O

Clinical O
and O
biological O
correlates O
of O
RARE O
states O
. O

Effects O
of O
long O
- O
term O
RARE O
nutrition O
on O
gastrin I-GENE
release O
in O
dogs O
. O

The O
mean O
RARE O
and O
height O
RARE O
were O
NUM O
% O
and O
122 O
% O
of O
the O
standard O
, O
respectively O
. O

Of O
7 O
patients O
treated O
with O
cyclophosphamide O
, O
RARE O
, O
RARE O
and O
cisplatin O
( O
ALL_CAP O
- O
5 O
RARE O
6 O
had O
RARE O
RARE O
, O
of O
whom O
5 O
yielded O
a O
response O
( O
2 O
RARE O
responses O
RARE O
19 O
+ O
and O
40 O
months O
and O
3 O
partial O
responses O
RARE O
4 O
, O
7 O
and O
8 O
months O
). O

Isolation O
and O
characterization O
of O
a O
RARE I-GENE
cDNA I-GENE
from I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
. O

A O
RARE O
study O
, O
showing O
a O
good O
agreement O
between O
surface O
and O
RARE O
RARE O
seems O
to O
confirm O
that O
surface O
RARE O
is O
a O
useful O
and O
RARE O
tool O
RARE O
clinical O
investigation O
. O

No O
differences O
in O
fixation O
quality O
were O
observed O
between O
RARE O
fixed O
by O
intravascular O
perfusion O
and O
RARE O
fixed O
by O
RARE O
perfusion O
. O

The O
DNA O
sequence O
encodes O
a O
protein O
of O
NUM O
amino O
RARE O
with O
sequence O
homology O
to O
the O
human I-GENE
c I-GENE
- I-GENE
abl I-GENE
RARE I-GENE
- I-GENE
oncogene I-GENE
product I-GENE
, O
beginning O
RARE O
the O
amino O
terminus O
and O
extending O
NUM O
amino O
RARE O
through O
the O
region O
essential O
RARE O
tyrosine I-GENE
kinase I-GENE
activity O
. O

The O
requirement O
of O
different O
essential O
fatty O
RARE O
in O
patients O
with O
RARE O
RARE O
nutrition O
after O
heavy O
injury O
is O
of O
RARE O
interest O
with O
respect O
to O
the O
development O
and O
prognosis O
of O
shock O
, O
sepsis O
or O
adult O
respiratory O
distress O
RARE O
. O

In O
NUM O
% O
a O
small O
cardiac O
RARE O
does O
not O
exist O
, O
but O
its O
origin O
, O
the O
right O
RARE O
RARE O
, O
joins O
the O
RARE O
of O
anterior O
cardiac O
RARE O
. O

The O
Drosophila I-GENE
melanogaster I-GENE
RARE I-GENE
gene I-GENE
encodes O
three O
enzymatic O
activities O
in O
the O
RARE O
RARE O
RARE O
de O
RARE O
RARE O
. O

The O
role O
of O
RARE O
in O
the O
response O
to O
drugs O
. O

Biol O
. O

The O
results O
of O
these O
experiments O
indicate O
that O
RARE O
least O
two O
upstream O
activator O
sequences O
( O
UAS O
) O
mediate O
maximum O
induction O
by O
RARE O
. O

RARE O
of O
the O
increase O
in O
RARE O
- O
RARE O
RARE O
and O
aggression O
in O
REM O
sleep O
deprived O
rats O
by O
dopamine O
agonist O
RARE O
. O

The O
RARE O
rate O
, O
respiratory O
rate O
, O
arterial O
NUM O
and O
systemic O
vascular O
resistance O
were O
not O
significantly O
altered O
. O

Human I-GENE
ALL_CAP I-GENE
- I-GENE
3 I-GENE
RARE O
in O
NUM O
cells O
has O
RARE O
CSF I-GENE
activity O
in O
RARE O
cultures O
of O
bone O
marrow O
cells O
, O
and O
selectively O
RARE O
the O
RARE O
of O
RARE O
- O
10 O
+ O
marrow O
or O
cord O
RARE O
cells O
in O
liquid O
cultures O
. O

In O
14 O
patients O
whose O
PaCO2 O
was O
greater O
than O
or O
equal O
to O
NUM O
torr O
( O
range O
NUM O
to O
58 O
torr O
) O
and O
clinical O
asthma O
score O
was O
6 O
or O
greater O
, O
PaCO2 O
decreased O
a O
mean O
of O
11 O
. O
7 O
torr O
RARE O
a O
mean O
of O
8 O
. O
1 O
hours O
. O

A O
randomized O
, O
prospective O
study O
was O
conducted O
to O
compare O
ovarian O
RARE O
with O
human I-GENE
RARE I-GENE
gonadotropin I-GENE
( O
ALL_CAP I-GENE
) O
and O
human I-GENE
RARE I-GENE
- I-GENE
stimulating I-GENE
hormone I-GENE
( O
ALL_CAP I-GENE
) O
in O
an O
in O
vitro O
fertilization O
and O
RARE O
transfer O
( O
ALL_CAP O
- O
ALL_CAP O
) O
program O
. O

Our O
findings O
suggest O
that O
the O
RARE I-GENE
product I-GENE
causes O
both O
transcription O
RARE O
and O
inhibition O
of O
translation O
of O
ALL_CAP I-GENE
mRNA I-GENE
. O

RARE O
of O
a O
case O

A O
RARE O
analogue O
given O
in O
early O
RARE O
and O
human I-GENE
RARE I-GENE
gonadotropin I-GENE
given O
near O
the O
end O
of O
the O
RARE O
follicular O
RARE O
were O
used O
RARE O
controlling O
the O
reproductive O
RARE O
, O
timing O
RARE O
collection O
, O
and O
RARE O
the O
cycles O
of O
RARE O
donors O
and O
RARE O
recipients O
. O

The O
RARE I-GENE
gene I-GENE
RARE O
over O
NUM O
RARE O
- O
RARE O
and O
is O
RARE O
into O
14 O
exons O
that O
encode O
the O
NUM O
amino O
acid O
residues O
of O
the O
protein O
. O

Although O
L O
- O
RARE O
- O
RARE O
( O
ALL_CAP O
RARE O
an O
artificial O
norepinephrine O
( O
ALL_CAP O
) O
precursor O
, O
did O
not O
change O
RARE O
in O
RARE O
mice O
, O
ALL_CAP O
significantly O
RARE O
RARE O
in O
mice O
pretreated O
with O
the O
selective O
ALL_CAP O
RARE O
NUM O
. O

RARE O
amounts O
of O
RARE O
RARE O
were O
recovered O
from O
isolated O
RARE O
cells O
, O
the O
target O
cells O
of O
L O
. O
monocytogenes O
after O
intravenous O
RARE O
. O

This O
suggested O
that O
delta O
6 O
and O
delta O
5 O
RARE O
activities O
are O
normal O
in O
these O
conditions O
with O
this O
C18 O
: O
NUM O
supply O
. O

The O
genetic O
basis O
RARE O
the O
RARE O
of O
a O
latent O
ALL_CAP I-GENE
RARE I-GENE
in O
the O
RARE O
was O
investigated O
. O

Here O
we O
report O
the O
RARE O
6 O
- O
RARE O
cDNA O
sequence O
coding O
RARE O
a O
chain O
of O
NUM O
amino O
RARE O
, O
RARE O
RARE O
RARE O
the O
genomic O
RARE O
. O

ALL_CAP I-GENE
- I-GENE
cholesterol I-GENE
(+ O
6 O
%, O
P O
less O
than O
. O
01 O
) O
and O
apolipoprotein I-GENE
A I-GENE
- I-GENE
I I-GENE
(+ O
6 O
%, O
P O
less O
than O
. O
01 O
) O
concentrations O
increased O
significantly O
only O
in O
the O
young O
. O

The O
RARE I-GENE
ribosomal I-GENE
protein I-GENE
gene I-GENE
cluster I-GENE
resembles O
the O
S I-GENE
- I-GENE
10 I-GENE
ribosomal I-GENE
protein I-GENE
operon I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
in O
gene O
organization O
and O
follows O
the O
RARE O
RARE O
order O
of O
the O
analogous O
genes O
in O
the O
tobacco O
and O
RARE O
chloroplast O
genomes O
. O

The O
distribution O
of O
the O
sites O
of O
RARE O
resolution O
is O
inversely O
correlated O
with O
that O
of O
the O
gradient O
of O
sequence O
divergence O
, O
with O
only O
RARE O
7 O
% O
of O
the O
X O
RARE O
resolved O
within O
the O
3 O
' O
third O
of O
the O
X O
blocks O
where O
two O
diverged O
Alu I-GENE
family O
repeats O
reside O
. O

The O
nucleotide O
sequence O
of O
the O
region O
upstream O
from O
M I-GENE
. I-GENE
RARE I-GENE
ALL_CAP I-GENE
was O
determined O
and O
revealed O
the O
presence O
of O
an O
ORF O
of O
NUM O
nucleotides O
( O
ALL_CAP I-GENE
) O
encoding O
a O
NUM O
amino O
acid O
polypeptide O
of O
mol O
. O
wt O
. O

RARE O
of O
the O
RARE O
efficacy O
of O
single I-GENE
- I-GENE
chain I-GENE
urokinase I-GENE
( O
RARE I-GENE
- I-GENE
urokinase I-GENE
) O
by O
RARE O
. O

Of O
NUM O
receptors O
which O
RARE O
in O
RARE O
with O
ventilation O
, O
NUM O
RARE O
like O
mammalian O
rapidly O
adapting O
pulmonary O
stretch O
receptors O
, O
19 O
like O
mammalian O
slowly O
adapting O
pulmonary O
stretch O
receptors O
( O
ALL_CAP O
RARE O
and O
NUM O
like O
avian O
RARE O
CO2 O
- O
RARE O
RARE O
( O
ALL_CAP O
). O

RARE O
RARE O
had O
a O
larger O
number O
of O
RARE O
and O
RARE O
wide O
fluctuations O
in O
baseline O
RARE O
inspiratory O
time O
, O
expiratory O
time O
, O
and O
NUM O
. O

In O
the O
IA O
task O
, O
post O
- O
training O
RARE O
injections O
of O
RARE O
and O
RARE O
RARE O
a O
dose O
- O
dependent O
enhancement O
of O
retention O
measured O
NUM O
h O
after O
the O
training O
, O
while O
retention O
was O
not O
affected O
by O
RARE O
RARE O
( O
a O
ALL_CAP I-GENE
receptor I-GENE
antagonist O
that O
does O
not O
readily O
cross O
the O
RARE O
- O
brain O
barrier O
). O

Clinical O
research O
of O
non O
- O
A O
, O
non O
- O
B O
post O
- O
transfusion O
hepatitis O

It O
is O
suggested O
that O
the O
use O
of O
endogenous O
RARE O
clearance O
to O
estimate O
the O
glomerular O
filtration O
rate O
( O
GFR O
) O
requires O
RARE O
and O
the O
recognition O
of O
the O
limitations O
of O
the O
method O
, O
and O
that O
RARE O
techniques O
( O
serum O
RARE O
or O
estimated O
endogenous O
RARE O
clearance O
) O
are O
RARE O
in O
routine O
practice O
. O

The O
protein O
RARE O
of O
RARE O
RARE O
and O
RARE O
RARE O
were O
RARE O
accepted O
. O

The O
5 O
' O
end O
of O
the O
coding O
region O
was O
RARE O
precisely O
by O
comparing O
the O
deduced O
amino O
acid O
sequence O
to O
the O
actual O
N O
- O
terminal O
amino O
acid O
sequence O
of O
ALL_CAP I-GENE
. O

A O
protein O
footprint O
also O
was O
identified O
RARE O
a O
ALL_CAP O
box O
element O
RARE O
nucleotides O
- O
NUM O
to O
- O
NUM O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
II I-GENE
( O
ALL_CAP I-GENE
) O
is O
a O
mitogenic O
polypeptide O
, O
the O
mRNAs O
of O
which O
are O
present O
in O
multiple O
forms O
, O
despite O
RARE O
from O
a O
single O
gene O
. O

The O
central O
visual O
fields O
of O
NUM O
normal O
and O
NUM O
glaucoma O
eyes O
were O
measured O
using O
a O
threshold O
related O
RARE O
strategy O
. O

The O
variability O
is O
most O
likely O
a O
result O
of O
RARE O
RARE O
of O
exons O
from O
the O
RARE O
elastin I-GENE
transcripts I-GENE
. O

This O
led O
to O
the O
conclusion O
that O
the O
RARE O
artery O
should O
be O
used O
RARE O
toe O
MP O
joint O
grafts O
, O
while O
the O
unilateral O
proper O
digital O
artery O
is O
suitable O
RARE O
toe O
ALL_CAP O
joint O
grafts O
, O
together O
with O
concomitant O
or O
dorsal O
cutaneous O
RARE O
. O

Effect O
of O
chronic O
RARE O
on O
RARE O
to O
cold O
stress O
in O
young O
adult O
and O
aged O
rats O
. O

This O
effect O
and O
the O
fact O
that O
all O
three O
doses O
were O
toxic O
to O
the O
RARE O
RARE O
that O
a O
second O
experiment O
be O
carried O
out O
RARE O
lower O
doses O
. O

The O
ALL_CAP O
association O
is O
a O
collection O
of O
RARE O
congenital O
anomalies O
including O
RARE O
RARE O
. O

RARE O
RARE O
RARE O
screening O
was O
undertaken O
and O
RARE O
concentrations O
of O
RARE O
( O
vitamin O
A O
, O
E O
, O
NUM O
, O
RARE O
acid O
and O
methionine O
) O
determined O
from O
adults O
RARE O
risk O
RARE O
esophageal O
carcinoma O
( O
EC O
) O
in O
RARE O
and O
RARE O
, O
Southern O
RARE O
. O

RARE O
from O
the O
RARE O
RARE O
RARE O
, O
RARE O
were O
RARE O
and O
the O
results O
were O
RARE O
by O
RARE O
type O
. O

Evaluation O
of O
human O
and O
bovine O
modified O
- O
hemoglobin I-GENE
solution O
RARE O
oxygen O
- O
carrying O
RARE O
RARE O
RARE O
volume O
RARE O
. O

RARE O
gallbladder O
visualization O
and O
reduction O
in O
ejection O
fraction O
were O
RARE O
but O
nonspecific O
indicators O
of O
biliary O
RARE O
. O

NUM O
micrograms O
ALL_CAP I-GENE
or O
placebo O
was O
RARE O
into O
each O
nasal O
cavity O
8 O
h O
and O
1 O
h O
before O
a O
nasal O
RARE O
challenge O
. O

RARE O
. O

Chem O
. O

RARE O
MR O
examinations O
of O
the O
nasal O
cavity O
and O
RARE O
RARE O
were O
performed O
within O
a O
6 O
- O
8 O
h O
period O
in O
five O
normal O
volunteers O
. O

Comparison O
was O
made O
with O
other O
RARE O
imaging O
modalities O
including O
ALL_CAP O
, O
RARE O
, O
ALL_CAP O
RARE O
, O
and O
ALL_CAP O
RARE O
. O

The O
feed O
given O
to O
young O
RARE O
RARE O
was O
contaminated O
artificially O
with O
RARE O
RARE O
, O
a O
RARE O
associated O
with O
both O
subclinical O
infections O
in O
RARE O
RARE O
RARE O
and O
food O
poisoning O
in O
humans O
. O

A O
poor O
correlation O
was O
found O
between O
a O
RARE O
- O
atypical O
( O
inflammatory O
) O
RARE O
result O
( O
class O
2 O
) O
and O
a O
benign O
histological O
diagnosis O
: O
NUM O
% O
of O
class O
- O
2 O
smears O
were O
diagnosed O
histologically O
RARE O
dysplasia O
or O
RARE O
. O

Factors O
involved O
in O
specific O
transcription O
by O
mammalian O
RNA I-GENE
polymerase I-GENE
II I-GENE
: O
purification O
, O
genetic O
RARE O
, O
and O
TATA O
box O
- O
promoter O
interactions O
of O
TFIID I-GENE
. O

RARE O
in O
plasma I-GENE
RARE I-GENE
RARE I-GENE
( O
RARE I-GENE
) O
between O
NUM O
- O
NUM O
weeks O
' O
gestation O
RARE O
a O
predictor O
of O
RARE O
- O
RARE O
hypertension O
. O

RARE O
make O
the O
diagnosis O
. O

The O
test O
RARE O
alpha I-GENE
- I-GENE
RARE I-GENE
esterase I-GENE
and O
RARE O
of O
macrophages O
( O
absolute O
number O
) O
per O
RARE O
area O
unit O
adjacent O
to O
the O
abscess O
suggest O
a O
direct O
correlation O
between O
the O
absolute O
number O
of O
macrophages O
and O
the O
RARE O
of O
the O
RARE O
. O

RARE O
RARE O
migration O
RARE O
, O
chemotactic O
and O
RARE O
responsiveness O
tended O
to O
be O
RARE O
in O
the O
RARE O
group O
. O

The O
deduced O
96 O
- O
RARE O
amino O
acid O
coding O
sequence O
of O
the O
murine O
HMG I-GENE
- I-GENE
I I-GENE
( I-GENE
Y I-GENE
) I-GENE
cDNA O
is O
very O
similar O
to O
the O
reported O
amino O
acid O
sequence O
of O
human O
HMG I-GENE
- I-GENE
I I-GENE
, O
except O
that O
it O
lacks O
11 O
internal O
amino O
RARE O
reported O
in O
the O
human O
protein O
. O

RARE O
RARE O
differences O
among O
drug O
RARE O
were O
explored O
using O
RARE O
' O
s O
( O
NUM O
) O
RARE O
RARE O
of O
ALL_CAP O
- O
B O
interpretation O
. O

RARE O
of O
the O
American O
RARE O
of O
RARE O
RARE O
. O

RARE O
from O
RARE O
post O
- O
RARE O
or O
RARE O
women O
yielded O
ALL_CAP I-GENE
levels O
within O
the O
normal O
range O
. O

No O
RARE I-GENE
mRNA I-GENE
was O
detected O
in O
11 O
RARE O
tissues O
of O
rat O
, O
suggesting O
tissue O
RARE O
of O
RARE O
of O
this O
RARE I-GENE
gene I-GENE
. O

The O
platelet O
adhesion O
rate O
on O
these O
RARE O
were O
tested O
concerning O
the O
RARE O
of O
the O
RARE O
of O
the O
basic O
- O
polymers O
RARE O
( O
ALL_CAP O
RARE O
RARE O
( O
ALL_CAP O
RARE O
and O
RARE O
( O
ALL_CAP O
) O
in O
two O
different O
RARE O
test O
RARE O
. O

RARE O
treatment O
of O
bladder O
carcinoma O
by O
partial O
RARE O
and O
interstitial O
RARE O
NUM O
. O

In O
a O
112 O
- O
d O
RARE O
trial O
, O
NUM O
heifers O
were O
assigned O
to O
light O
, O
medium O
and O
heavy O
RARE O
blocks O
on O
five O
treatments O
: O
dietary O
MGA O
RARE O
5 O
mg O
. O
RARE O
- O
1 O
. O
d O
- O
1 O
RARE O
control O
( O
RARE O
MGA O
) O
or O
ALL_CAP O
- O
MGA O
on O
d O
1 O
RARE O
. O
5 O
, O
1 O
. O
NUM O
or O
1 O
. O
5 O
ml O
/ O
RARE O
( O
NUM O
, O
NUM O
or O
NUM O
mg O
MGA O
/ O
RARE O
, O
respectively O
). O

RARE O
and O
RARE O
of O
solutions O
of O
the O
appropriate O
boundary O
value O
problems O
are O
established O
, O
in O
the O
case O
of O
small O
RARE O
coefficients O
and O
RARE O
rates O
, O
or O
large O
diffusion O
coefficients O
and O
small O
resistance O
to O
flow O
constants O
. O

There O
were O
gene O
clusters O
encoding O
RARE O
RARE O
such O
RARE O
the O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
and O
the O
ALL_CAP O
- O
ALL_CAP O
clusters O
. O

The O
results O
presented O
suggest O
that O
ALL_CAP O
reduces O
the O
turnover O
rate O
of O
the O
RARE O
dopamine O
neurons O
after O
RARE O
administration O
RARE O
a O
long O
period O
in O
mice O
. O

The O
partial O
sequence O
of O
the O
NUM I-GENE
- I-GENE
kDa I-GENE
nuclear I-GENE
RARE I-GENE
glycoprotein I-GENE
shows O
little O
RARE O
to O
other O
characterized O
proteins O
and O
RARE O
structural O
features O
of O
a O
RARE O
of O
the O
family O
of O
nuclear I-GENE
RARE I-GENE
RARE I-GENE
. O

Seventy O
- O
two O
hours O
after O
administration O
of O
vitamin O
NUM O
, O
plasma O
concentrations O
of O
the O
vitamin O
were O
not O
different O
from O
normal O
. O

The O
glomerular O
filtration O
rate O
did O
not O
change O
but O
lithium O
clearance O
fell O
by O
NUM O
%. O

During O
a O
NUM O
- O
week O
RARE O
RARE O
, O
groups O
of O
NUM O
male O
CD O
- O
1 O
mice O
were O
treated O
once O
with O
50 O
RARE O
of O
either O
ALL_CAP O
( O
1 O
. O
NUM O
mg O
/ O
ml O
) O
or O
RARE O
, O
RARE O
RARE O
2 O
weeks O
, O
and O
then O
treated O
twice O
per O
week O
with O
test O
material O
RARE O
the O
remaining O
NUM O
weeks O
. O

The O
pathogenesis O
of O
RARE O
' O
s O
RARE O

An O
ELISA O
procedure O
was O
developed O
RARE O
monitoring O
the O
specific O
IgE I-GENE
response O
in O
dogs O
to O
RARE O
RARE O
infection O
. O

Fifty O
min O
after O
release O
from O
stress O
, O
increases O
in O
plasma O
corticosterone O
levels O
RARE O
by O
stress O
recovered O
in O
the O
RARE O
group O
but O
remained O
high O
in O
the O
non O
- O
RARE O
group O
. O

The O
only O
isolate O
of O
RARE O
RARE O
produced O
cytotoxic O
RARE O
and O
was O
invasive O
. O

An O
11 O
- O
month O
- O
old O
RARE O
suffering O
from O
RARE O
- O
RARE O
RARE O
( O
ALL_CAP O
) O
associated O
with O
RARE O
of O
RARE O
( O
TOF O
) O
is O
presented O
. O

The O
incidence O
of O
early O
neonatal O
RARE O
RARE O
RARE O
babies O
was O
3 O
. O
NUM O
/ O
1000 O
live O
births O
. O

The O
median O
survival O
is O
not O
reached O
with O
a O
median O
follow O
- O
RARE O
time O
of O
9 O
. O
6 O
years O
. O

RARE O
evaluation O
of O
various O
methods O
of O
RARE O
markers O
of O
RARE O
RARE O
in O
RARE O
RARE O

Of O
the O
NUM O
infants O
with O
a O
( O
probable O
) O
RARE O
18 O
were O
examined O
again O
RARE O
3 O
months O
corrected O
age O
. O

RARE O
of O
cows O
and O
RARE O
according O
to O
RARE O
of O
RARE O
( O
patterns O
) O
of O
the O
RARE O
- O
RARE O
RARE O
of O
cattle O

Although O
not O
consistently O
identified O
in O
all O
samples O
, O
secondary O
Academic O
, O
RARE O
RARE O
, O
and O
RARE O
/ O
RARE O
dimensions O
were O
also O
identified O
. O

RARE O
was O
characterized O
by O
rapid O
improvement O
such O
that O
all O
measured O
parameters O
normalized O
by O
1 O
week O
, O
except O
RARE O
cross O
- O
sectional O
cardiac O
area O
which O
remained O
RARE O
RARE O
to O
4 O
weeks O
( O
14 O
+/- O
3 O
cm2 O
, O
p O
less O
than O
NUM O
. O
05 O
versus O
control O
RARE O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

RARE O
even O
extensive O
pancreatic O
resection O
could O
prevent O
pancreatic O
RARE O
infection O
. O

It O
has O
been O
calculated O
that O
600 O
, O
NUM O
new O
cases O
of O
RARE O
RARE O
occur O
RARE O
every O
year O
, O
most O
of O
them O
due O
to O
smoking O
. O

RARE O
RARE O
( O
RARE O
' O
s O
RARE O
): O
not O
always O
multiple O
sclerosis O
. O

Effect O
of O
the O
methods O
of O
cutaneous O
administration O
of O
RARE O
RARE O
RARE O
on O
its O
toxicity O

RARE O
of O
NUM O
. O
1 O
or O
NUM O
. O
2 O
M O
RARE O
RARE O
phosphate O
in O
the O
RARE O
solutions O
resulted O
in O
a O
decrease O
in O
the O
RARE O
- O
life O
of O
diltiazem O
. O

None O
had O
a O
past O
history O
of O
RARE O
infections O
; O
neither O
did O
any O
have O
RARE O
. O

Increasing O
the O
phosphorus O
content O
of O
the O
diet O
improved O
the O
RARE O
of O
RARE O
and O
magnesium O
. O

Post O
- O
transcriptional O
RARE O
of O
ribosomal I-GENE
protein I-GENE
gene I-GENE
RARE O
RARE O
development O
in O
Dictyostelium O
RARE O
. O

The O
temporal O
and O
RARE O
plasma O
concentration O
- O
effect O
relationships O
were O
evaluated O
by O
RARE O
RARE O
and O
RARE O
regression O
. O

The O
increase O
in O
amplitudes O
of O
the O
b O
- O
wave O
RARE O
the O
adaptation O
period O
was O
more O
prominent O
in O
lead O
- O
exposed O
subjects O
than O
in O
controls O
. O

RARE O
factors O
RARE O
the O
development O
of O
RARE O
RARE O
RARE O
group O
activities O
and O
the O
role O
of O
group O
dynamics O
acting O
RARE O
stress O
factors O
precipitating O
RARE O
RARE O
, O
especially O
bipolar O
manifestations O
, O
are O
discussed O
. O

RARE O
measurements O
of O
RARE O
expiratory O
volume O
in O
1 O
s O
( O
FEV1 O
RARE O
specific O
airway O
RARE O
( O
RARE O
) O
and O
the O
RARE O
dose O
of O
carbachol O
causing O
a O
NUM O
% O
reduction O
in O
RARE O
( O
NUM O
RARE O
and O
a O
20 O
% O
reduction O
in O
FEV1 O
( O
NUM O
) O
were O
established O
on O
entry O
while O
each O
subject O
was O
still O
smoking O
. O

Many O
children O
with O
ALL_CAP O
are O
delayed O
in O
their O
development O
, O
but O
RARE O
are O
not O
directly O
related O
to O
specific O
forms O
of O
neurologic O
dysfunction O
. O

R O
- O
wave O
voltage O
in O
the O
right O
RARE O
leads O
in O
RARE O
cardiomyopathy O
: O
a O
clinical O
study O
. O

The O
results O
indicate O
that O
the O
RARE O
requirements O
are O
task O
dependent O
. O

These O
results O
indicate O
that O
ALL_CAP I-GENE
can O
increase O
RARE O
counts O
by O
increasing O
the O
number O
and O
RARE O
of O
the O
marrow O
RARE O
RARE O
in O
some O
RARE O
of O
childhood O
chronic O
neutropenia O
. O

The O
RARE O
of O
this O
study O
were O
1 O
) O
to O
examine O
the O
effect O
of O
high O
intensity O
, O
low O
frequency O
RARE O
electrical O
nerve O
RARE O
RARE O
RARE O
RARE O
points O
on O
experimental O
pain O
threshold O
measured O
RARE O
the O
wrist O
and O
2 O
) O
to O
determine O
the O
changes O
in O
effect O
over O
time O
. O

In O
the O
RARE O
neonates O
serum O
alpha I-GENE
- I-GENE
amylase I-GENE
value O
, O
RARE O
determined O
by O
the O
blue O
RARE O
method O
, O
was O
only O
40 O
% O
that O
of O
healthy O
controls O
; O
the O
mean O
value O
of O
175 O
. O
1 O
+/- O
NUM O
. O
9 O
IU O
/ O
RARE O
RARE O
healthy O
neonates O
was O
significantly O
RARE O
( O
p O
less O
than O
NUM O
. O
NUM O
) O
than O
the O
value O
of O
82 O
. O
8 O
+/- O
NUM O
. O
4 O
IU O
/ O
RARE O
RARE O
the O
RARE O
neonates O
. O

RARE O
of O
NUM O
children O
with O
AIDS O
or O
AIDS O
- O
related O
complex O
RARE O
to O
the O
pediatric O
intensive O
care O
unit O
RARE O
acute O
respiratory O
failure O
throughout O
a O
NUM O
- O
month O
period O
were O
reviewed O
. O

RARE O
patients O
were O
in O
the O
RARE O
RARE O
group O
; O
NUM O
were O
detected O
by O
SPECT O
and O
10 O
by O
ALL_CAP O
. O

SPECT O
is O
an O
important O
aid O
in O
the O
diagnosis O
of O
AIDS O
dementia O
complex O
and O
contributes O
to O
the O
understanding O
of O
the O
RARE O
mechanisms O
of O
this O
disorder O
. O

We O
were O
RARE O
in O
studying O
the O
relationship O
between O
the O
circadian O
rhythm O
in O
body O
RARE O
and O
NUM O
- O
h O
variations O
in O
plasma O
concentrations O
of O
iron O
, O
zinc O
, O
circulating O
RARE O
counts O
, O
and O
plasma O
interleukin I-GENE
1 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
) O
activity O
. O

The O
murine I-GENE
MHC I-GENE
class I-GENE
I I-GENE
genes I-GENE
, O
H I-GENE
- I-GENE
NUM I-GENE
and O
H I-GENE
- I-GENE
NUM I-GENE
, O
are O
strikingly O
homologous O
to O
each O
other O
, O
H I-GENE
- I-GENE
NUM I-GENE
, O
and O
two O
genes O
reported O
to O
encode O
tumor O
- O
specific O
antigens O
. O

The O
RARE O
RARE O
of O
the O
present O
series O
were O
also O
tested O
RARE O
their O
analgesic O
activity O
against O
RARE O
- O
RARE O
RARE O
in O
RARE O
mice O
and O
RARE O
activity O
in O
RARE O
rats O
. O

In O
untreated O
mice O
, O
bactericidal O
activity O
of O
peritoneal O
macrophages O
decreased O
from O
one O
day O
to O
3 O
days O
after O
RARE O
injection O
of O
killed O
L O
. O
monocytogenes O
. O

Among O
a O
population O
of O
18 O
, O
175 O
children O
below O
7 O
years O
of O
age O
in O
medium O
sized O
RARE O
and O
RARE O
areas O
in O
RARE O
- O
RARE O
RARE O
NUM O
( O
3 O
. O
03 O
%) O
cases O
of O
RARE O
were O
RARE O
RARE O
a O
12 O
months O
period O
in O
NUM O
- O
NUM O
by O
their O
physicians O
. O

We O
concluded O
that O
Ga O
- O
RARE O
scintigraphy O
is O
a O
very O
simple O
method O
and O
RARE O
useful O
RARE O
detecting O
RARE O
RARE O
ventricular O
RARE O
and O
RARE O
monitoring O
the O
effect O
of O
RARE O
therapy O
. O

In O
vitro O
assessment O
of O
the O
RARE O
of O
dental O
materials O
RARE O
the O
RARE O
filter O
method O
. O

RARE O
was O
due O
to O
magnesium O
RARE O
by O
the O
RARE O
. O

RARE O
was O
RARE O
by O
the O
oral O
RARE O
index O
of O
the O
whole O
RARE O
daily O
, O
after O
staining O
with O
1 O
per O
cent O
RARE O
RARE O
. O

ALL_CAP I-GENE
RARE O
to O
sequences O
RARE O
the O
negative O
regulatory O
elements O
( O
RARE O
) O
of O
the O
RARE I-GENE
RARE I-GENE
type I-GENE
loci I-GENE
ALL_CAP I-GENE
E I-GENE
and O
HMR I-GENE
E I-GENE
and O
to O
the O
upstream O
activating O
sequence O
( O
UAS O
) O
required O
RARE O
transcription O
of O
the O
ALL_CAP I-GENE
alpha I-GENE
genes I-GENE
. O

The O
effects O
of O
these O
mutations O
on O
RNA I-GENE
polymerase I-GENE
II I-GENE
activity O
were O
assayed O
by O
measuring O
the O
ability O
of O
mutant O
genes O
to O
confer O
alpha I-GENE
- I-GENE
RARE I-GENE
resistance O
after O
transfection O
of O
susceptible O
rodent O
cells O
. O

We O
report O
the O
use O
of O
a O
new O
technetium O
- O
99m O
- O
albumin I-GENE
colloid O
RARE O
RARE O
cell O
( O
ALL_CAP O
- O
WBC O
) O
scan O
in O
the O
evaluation O
of O
RARE O
. O

In O
one O
of O
these O
tumors O
the O
observed O
rearrangement O
was O
not O
due O
to O
the O
RARE O
of O
an O
RARE O
ALL_CAP O
provirus O
. O

The O
RARE O
RARE O
its O
use O
include O
every O
RARE O
and O
secondary O
RARE O
candidate O
unless O
RARE O
grafts O
are O
RARE O
to O
be O
under O
tension O
or O
if O
the O
RARE O
is O
minor O
. O

The O
SSB I-GENE
- O
RARE O
( O
dT O
) O
affinity O
is O
RARE O
high O
to O
measure O
in O
RARE O
containing O
even O
5 O
M O
NaCl O
; O
however O
, O
in O
1 O
. O
8 O
- O
2 O
. O
5 O
M O
RARE O
, O
we O
measure O
alpha O
log O
RARE O
/ O
alpha O
log O
RARE O
RARE O
] O
= O
- O
5 O
. O
7 O
+/- O
NUM O
. O
7 O
, O
with O
a O
lower O
value O
of O
RARE O
T O
/ O
O O
= O
NUM O
+/- O
70 O
. O

Mutations O
RARE O
the O
NUM I-GENE
locus I-GENE
were O
isolated O
in O
Saccharomyces O
cerevisiae O
RARE O
RARE O
suppressors O
of O
+ O
1 O
frameshift O
mutations O
in O
glycine O
( O
ALL_CAP O
) O
and O
proline O
( O
ALL_CAP O
) O
codons O
, O
RARE O
RARE O
RARE O
UGA O
and O
ALL_CAP O
nonsense O
mutations O
. O

The O
behavior O
of O
NUM I-GENE
- I-GENE
RARE I-GENE
/ I-GENE
NUM I-GENE
+ I-GENE
RARE I-GENE
indicates O
that O
NUM I-GENE
is O
RARE O
- O
RARE O
RARE O
and O
suggests O
that O
NUM I-GENE
allele O
- O
specific O
suppression O
may O
result O
from O
functionally O
distinct O
mutant O
proteins O
rather O
than O
variation O
in O
residual O
wild I-GENE
- I-GENE
type I-GENE
NUM I-GENE
+ I-GENE
activity O
. O

RARE O
agents O
. O

The O
putative O
RARE O
protein O
was O
detected O
among O
the O
RARE O
NUM O
] O
methionine O
- O
labelled O
proteins O
produced O
by O
RARE O
carrying O
RARE I-GENE
RARE O
under O
lac I-GENE
promoter I-GENE
control O
, O
and O
when O
the O
gene O
was O
subcloned O
into O
RARE O
vectors O
under O
the O
control O
of O
a O
RARE O
NUM O
promoter O
. O

Antibodies O
made O
against O
fusion O
protein O
produced O
by O
the O
NUM I-GENE
clone O
reacted O
specifically O
with O
ALL_CAP I-GENE
- I-GENE
I I-GENE
and I-GENE
- I-GENE
II I-GENE
on O
RARE O
. O

Finally O
, O
over O
a O
similar O
range O
of O
NUM O
, O
oxygen O
extraction O
was O
greater O
in O
patients O
with O
ARDS O
compared O
to O
patients O
with O
non O
- O
ARDS O
respiratory O
failure O
( O
RARE O
= O
- O
NUM O
. O
67 O
and O
slope O
= O
- O
NUM O
. O
NUM O
RARE O
RARE O
= O
- O
NUM O
. O
NUM O
and O
slope O
= O
- O
NUM O
. O
NUM O
; O
p O
less O
than O
NUM O
. O
05 O
). O

Stable O
patients O
have O
RARE O
RARE O
and O
little O
evidence O
of O
acute O
inflammation O
. O

RARE O
, O
moderate O
RARE O
, O
RARE O
RARE O
, O
arterial O
RARE O
and O
moderate O
venous O
RARE O
seem O
to O
play O
a O
partial O
role O
of O
organic O
RARE O
or O
cofactor O
, O
the O
sexual O
consequences O
of O
which O
are O
amplified O
by O
psychological O
factors O
, O
partly O
secondary O
to O
the O
initial O
sexual O
RARE O
. O

RARE O
and O
H O
. O

RARE O
function O
of O
the O
RARE O
RARE O
. O

Chronic O
RARE O
appears O
to O
be O
associated O
with O
an O
elevated O
pulmonary O
microvascular O
RARE O
and O
a O
tendency O
toward O
a O
RARE O
circulation O
but O
with O
an O
RARE O
degree O
of O
RARE O
associated O
with O
regional O
hemodynamics O
and O
RARE O
biosynthesis O
. O

In O
contrast O
, O
we O
observed O
high O
concentrations O
in O
29 O
of O
NUM O
patients O
with O
tumors O
of O
the O
central O
nervous O
RARE O
, O
especially O
in O
RARE O
( O
6 O
/ O
9 O
RARE O
RARE O
( O
9 O
/ O
NUM O
RARE O
and O
RARE O
( O
5 O
/ O
5 O
). O

RARE O
and O
atopic O
RARE O
. O

RARE O
delay O
effects O
on O
the O
RARE O
bond O
strength O
developed O
by O
the O
RARE O
. O

The O
future O
of O
research O
with O
RARE I-GENE
may O
be O
divided O
into O
three O
areas O
: O
RARE O
must O
be O
made O
to O
determine O
how O
best O
to O
RARE O
the O
in O
vitro O
RARE O
into O
clinically O
RARE O
terms O
; O
in O
order O
to O
RARE O
the O
RARE O
RARE O
of O
IFN I-GENE
, O
research O
is O
RARE O
toward O
using O
this O
agent O
earlier O
in O
RARE O
either O
RARE O
an O
adjuvant O
after O
tumor O
RARE O
or O
after O
initial O
diagnosis O
; O
the O
medical O
community O
must O
RARE O
the O
RARE O
history O
of O
some O
diseases O
, O
because O
the O
RARE O
RARE O
of O
the O
RARE O
agents O
will O
most O
likely O
manifest O
itself O
when O
these O
agents O
are O
used O
together O
. O

RARE O
differences O
were O
noted O
with O
RARE O
producing O
mild O
RARE O
elevation O
of O
prothrombin I-GENE
time O
( O
NUM O
. O
7 O
second O
) O
associated O
with O
depression O
of O
factor I-GENE
II I-GENE
and O
factor I-GENE
VII I-GENE
. O

Six O
healthy O
male O
subjects O
received O
single O
oral O
doses O
of O
regular O
release O
( O
RR O
) O
RARE O
RARE O
, O
sustained O
release O
( O
SR O
) O
RARE O
RARE O
and O
the O
same O
dose O
of O
the O
SR O
product O
with O
food O
( O
SR O
- O
F O
). O

This O
report O
RARE O
on O
previous O
work O
with O
RARE I-GENE
RARE I-GENE
- I-GENE
NUM I-GENE
( I-GENE
RARE I-GENE
A I-GENE
; I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
) I-GENE
in O
the O
treatment O
of O
RARE O
cell O
leukemia O
( O
ALL_CAP O
). O

RARE O
delivery O
and O
RARE O
excess O
decreased O
significantly O
and O
four O
pigs O
died O
. O

Clinical O
chemistry O
. O

RARE O
after O
anterior O
RARE O
and O
mandibular O
RARE O

RARE O
RARE O
RARE O
the O
management O
of O
RARE O
. O

The O
RARE O
spread O
of O
the O
carcinoma O
correlated O
with O
RARE O
invasion O
of O
carcinoma O
, O
RARE O
of O
the O
body O
and O
RARE O
, O
obstruction O
of O
main O
pancreatic O
duct O
and O
RARE O
RARE O
. O

RARE O
RARE O
that O
RARE O
cartilage O
are O
released O
. O

RARE O
to O
the O
observation O
made O
with O
other O
S O
. O
pombe O
genes O
RARE O
in O
the O
RARE O
yeast O
, O
the O
heterologous O
actin I-GENE
gene I-GENE
transcript I-GENE
is O
RARE O
NUM O
nucleotides O
upstream O
of O
the O
initiation O
RARE O
site O
used O
in O
the O
homologous O
yeast O
. O

A O
RARE O
study O
involving O
9 O
Italian O
RARE O
was O
carried O
out O
to O
compare O
the O
efficacy O
and O
safety O
of O
ranitidine O
NUM O
mg O
b O
. O
i O
. O
d O
. O
and O
ranitidine O
NUM O
mg O
RARE O
in O
the O
treatment O
of O
reflux O
RARE O
. O

RARE O
with O
RARE O
was O
clinically O
and O
RARE O
RARE O
effective O
RARE O
a O
combination O
therapy O
with O
RARE O
and O
RARE O
. O

The O
NUM O
wave O
of O
the O
ALL_CAP O
' O
s O
, O
which O
has O
been O
found O
to O
correlate O
best O
with O
neurological O
recovery O
, O
returned O
to O
65 O
% O
+/- O
NUM O
% O
of O
the O
RARE O
amplitude O
in O
the O
insulin I-GENE
- O
treated O
animals O
, O
compared O
to O
40 O
% O
+/- O
NUM O
% O
in O
the O
fasted O
group O
and O
NUM O
% O
+/- O
NUM O
% O
in O
the O
control O
animals O
. O

RARE O
and O
RARE O
studies O
may O
be O
an O
important O
part O
of O
evaluation O
, O
especially O
in O
patients O
who O
present O
with O
RARE O
RARE O
, O
masses O
, O
or O
RARE O
RARE O
. O

In O
the O
control O
group O
the O
histological O
picture O
RARE O
RARE O
. O

In O
contrast O
to O
this O
mRNA O
, O
NUM O
% O
of O
alpha I-GENE
and I-GENE
beta I-GENE
actin I-GENE
mRNAs I-GENE
were O
translated O
in O
both O
myoblasts O
and O
myotubes O
. O

Plasma I-GENE
renin I-GENE
activity O
does O
not O
predict O
the O
antihypertensive O
efficacy O
of O
RARE O
. O

RARE O
NUM O
mg O
RARE O
night O
RARE O
12 O
months O
was O
given O
RARE O
a O
prophylactic O
measure O
to O
NUM O
female O
patients O
of O
mean O
age O
NUM O
. O
6 O
years O
, O
who O
had O
a O
history O
in O
the O
preceding O
12 O
months O
of O
between O
three O
and O
NUM O
( O
median O
= O
7 O
) O
episodes O
of O
frequency O
and O
/ O
or O
RARE O
. O

If O
this O
is O
RARE O
, O
then O
RARE O
has O
a O
proven O
record O
RARE O
good O
tissue O
compatibility O
and O
resistance O
to O
infection O
. O

The O
size O
of O
the O
group O
allocated O
to O
the O
good O
compliance O
category O
by O
the O
use O
of O
the O
RARE O
marker O
was O
equivalent O
in O
size O
to O
a O
group O
of O
patients O
who O
had O
returned O
less O
than O
NUM O
% O
of O
their O
RARE O
dose O
or O
reported O
a O
deviation O
of O
less O
than O
6 O
% O
from O
their O
RARE O
. O

RARE O
RARE O
was O
usually O
RARE O
in O
origin O
in O
1982 O
, O
but O
after O
1983 O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
was O
the O
most O
common O
cause O
of O
RARE O
RARE O
. O

The O
RARE O
findings O
, O
RARE O
RARE O
RARE O
the O
RARE O
C I-GENE
- I-GENE
peptide I-GENE
excretion O
, O
confirmed O
that O
the O
RARE O
effects O
should O
not O
be O
thought O
to O
be O
due O
to O
a O
direct O
action O
of O
the O
drugs O
used O
on O
the O
endocrine O
pancreas O
. O

The O
activity O
of O
the O
ALL_CAP I-GENE
receptor I-GENE
promoter I-GENE
can O
be O
modulated O
by O
E1A I-GENE
protein I-GENE
and O
receptor O
RNA O
levels O
increased O
by O
RARE O
with O
phorbol O
ester O
or O
RARE O
RARE O
serum O
. O

In O
vitro O
RARE O
activity O
of O
RARE O
( O
RARE O
RARE O
A O
. O

" O
In O
vitro O
" O
study O
of O
dentin O
adhesion O
to O
RARE O
made O
from O
RARE O
molecules O
with O
free O
groups O
of O
RARE O

By O
RARE O
RARE O
, O
NUM O
. O

There O
is O
a O
cysteine O
RARE O
region O
in O
an O
N O
- O
terminal O
region O
of O
the O
c I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
1 I-GENE
) I-GENE
product I-GENE
deduced O
from O
the O
nucleotide O
sequence O
, O
and O
this O
cysteine O
RARE O
region O
was O
found O
to O
be O
highly O
homologous O
to O
that O
present O
in O
an O
N O
- O
terminal O
region O
of O
protein I-GENE
kinase I-GENE
C I-GENE
, O
although O
, O
in O
the O
latter O
cysteine O
clusters O
are O
present O
in O
RARE O
. O

RARE O
- O
held O
, O
continuous O
- O
wave O
Doppler O
RARE O
, O
coupled O
with O
sound O
spectral O
analysis O
, O
can O
successfully O
predict O
carotid O
artery O
stenosis O
. O

The O
RARE O
RARE O
of O
RARE O
RARE O
in O
NUM O
RARE O
the O
RARE O
RARE O
' O
s O
RARE O
Study O
( O
ALL_CAP O
NUM O
) O
using O
a O
four O
- O
drug O
combination O
of O
chemotherapy O
prior O
to O
definitive O
local O
control O
with O
surgery O
and O
/ O
or O
radiation O
. O

The O
program O
has O
been O
RARE O
in O
a O
RARE O
ALL_CAP O
in O
order O
to O
make O
the O
procedure O
RARE O
- O
RARE O
. O

Since O
high O
levels O
of O
immunoglobulin I-GENE
G I-GENE
were O
demonstrated O
against O
the O
surface O
of O
the O
ALL_CAP O
after O
immunization O
, O
passive O
transfer O
experiments O
were O
RARE O
. O

A O
study O
was O
conducted O
of O
a O
human O
male O
who O
had O
inhaled O
a O
mixture O
of O
NUM O
and O
RARE O
. O

An O
RARE O
method O
RARE O
comparative O
parameter O
RARE O
in O
magnetic O
resonance O
( O
MR O
) O
imaging O
has O
been O
developed O
using O
the O
concept O
of O
" O
fractional O
sensitivity O
RARE O
This O
new O
approach O
results O
in O
easily O
calculated O
RARE O
RARE O
NUM O
, O
NUM O
, O
and O
hydrogen O
RARE O
. O

Fifty O
- O
four O
patients O
were O
divided O
into O
groups O
according O
to O
their O
clinical O
presentation O
; O
RARE O
asymptomatic O
volunteers O
, O
20 O
patients O
with O
duodenal O
- O
RARE O
reflux O
RARE O
( O
ALL_CAP O
RARE O
16 O
patients O
with O
recurrent O
ulcers O
of O
the O
duodenal O
bulb O
( O
ALL_CAP O
RARE O
and O
11 O
patients O
with O
RARE O
' O
s O
RARE O
. O

No O
previous O
studies O
have O
determined O
the O
RARE O
- O
dynamics O
of O
intravenous O
RARE O
when O
administered O
in O
a O
dose O
of O
NUM O
mg O
/ O
kg O
and O
RARE O
a O
rate O
of O
50 O
mg O
/ O
min O
, O
RARE O
is O
common O
practice O
RARE O
RARE O
testing O
. O

RARE O
concentrations O
of O
tumor O
- O
associated O
trypsin I-GENE
inhibitor O
in O
RARE O
patients O
. O

In O
the O
chicken O
liver O
, O
levels O
of O
chicken I-GENE
ALL_CAP I-GENE
mRNA I-GENE
were O
rapidly O
RARE O
by O
RARE O
( O
NUM O
RARE O
NUM O
RARE O
NUM O
+), O
glucocorticoids O
and O
lipopolysaccharide O
. O

With O
RARE O
and O
RARE O
blue O
injections O
, O
RARE O
- O
brain O
barrier O
alterations O
were O
seen O
RARE O
early O
RARE O
4 O
days O
after O
a O
dose O
of O
50 O
Gy O
. O

RARE O
estimates O
RARE O
these O
organs O
were O
2 O
. O
3 O
+/- O
1 O
. O
1 O
and O
2 O
. O
3 O
+/- O
1 O
. O
4 O
RARE O
RARE O
02 O
+/- O
. O
01 O
Gy O
RARE O
respectively O
, O
with O
a O
whole O
- O
body O
estimate O
of O
NUM O
. O
NUM O
RARE O
RARE O
NUM O
Gy O
). O

A O
significant O
association O
between O
a O
family O
history O
and O
a O
RARE O
RARE O
pH O
was O
observed O
among O
the O
female O
RARE O
stone O
patients O
. O

New O
RARE O
in O
diagnosis O
and O
classification O
of O
malignancy O
. O

Thus O
the O
present O
data O
also O
suggest O
that O
ALL_CAP O
and O
HR O
measurements O
are O
influenced O
not O
only O
by O
state O
- O
dependent O
factors O
but O
also O
by O
RARE O
least O
three O
different O
factors O
that O
are O
each O
independent O
of O
the O
state O
: O
one O
leads O
to O
ALL_CAP O
and O
HR O
values O
that O
are O
influenced O
by O
the O
RARE O
the O
RARE O
is O
in O
and O
the O
other O
two O
influence O
, O
respectively O
, O
the O
RARE O
of O
the O
individual O
' O
s O
ALL_CAP O
and O
HR O
levels O
within O
the O
population O
. O

The O
correlation O
between O
PaCO2 O
and O
NUM O
in O
ALL_CAP O
was O
insufficient O
to O
make O
clinical O
RARE O
. O

Since O
NUM O
RARE O
the O
times O
of O
their O
RARE O
ALL_CAP O
/ O
ALL_CAP O
RARE O
examinations O
, O
all O
Adult O
Health O
Study O
( O
ALL_CAP O
) O
subjects O
have O
been O
RARE O
to O
determine O
the O
exposures O
to O
medical O
RARE O
- O
rays O
they O
experienced O
in O
RARE O
other O
than O
ALL_CAP O
in O
order O
to O
estimate O
the O
numbers O
of O
examinations O
and O
corresponding O
doses O
which O
they O
received O
. O

The O
RARE I-GENE
growth I-GENE
factor I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
receptor I-GENE
, O
which O
exhibits O
RARE O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
activity O
, O
undergoes O
a O
rapid O
, O
RARE O
self O
- O
RARE O
reaction O
following O
ALL_CAP I-GENE
activation O
. O

One O
RARE O
RARE O
completely O
inhibited O
RARE O
HCO3 O
- O
RARE O
. O

There O
are O
regions O
with O
long O
RARE O
of O
RARE O
to O
NUM O
% O
C O
or O
NUM O
% O
G O
residues O
. O

The O
same O
RARE O
RARE O
enables O
a O
prediction O
to O
be O
made O
concerning O
when O
RARE O
of O
stressed O
RARE O
will O
be O
RARE O
perceived O
. O

RARE O
cord O
RARE O
RARE O
by O
nervous O
selective O
anastomosis O
. O

ALL_CAP O
' O
s O
RARE O
RARE O
RARE O
. O

A O
case O
of O
AIDS O
- O
related O
complex O
( O
ALL_CAP O
/ O
ALL_CAP O
) O
in O
a O
health O
RARE O

RARE O
spread O
was O
found O
in O
NUM O
patients O
( O
NUM O
%), O
NUM O
of O
whom O
had O
serum O
RARE I-GENE
greater O
than O
10 O
micrograms O
/ O
RARE O
. O

The O
glomerular O
filtration O
rate O
and O
effective O
RARE O
plasma O
flow O
were O
determined O
by O
a O
standard O
clearance O
method O
, O
employing O
continuous O
infusion O
of O
RARE O
and O
RARE O
- O
RARE O
acid O
. O

After O
the O
RARE O
containing O
RARE O
, O
plasma O
glucose O
levels O
rose O
sharply O
, O
RARE O
RARE O
NUM O
- O
NUM O
min O
and O
fell O
below O
initial O
levels O
2 O
to O
3 O
h O
later O
. O

The O
relations O
among O
various O
negative O
RARE O
and O
behavioral O
characteristics O
( O
RARE O
. O
g O
., O
aggression O
, O
anxiety O
, O
RARE O
, O
RARE O
RARE O
) O
and O
adjustment O
were O
examined O
through O
use O
of O
data O
from O
the O
NUM O
- O
year O
- O
old O
New O
York O
RARE O
Study O
. O

To O
evaluate O
the O
effect O
of O
altitude O
on O
adolescent O
growth O
and O
development O
, O
three O
groups O
of O
healthy O
, O
RARE O
- O
RARE O
RARE O
of O
similar O
RARE O
status O
and O
RARE O
RARE O
who O
RARE O
RARE O
RARE O
level O
( O
RARE O
= O
NUM O
subjects O
RARE O
mid O
- O
altitude O
( O
RARE O
= O
NUM O
subjects O
RARE O
and O
high O
altitude O
( O
RARE O
= O
NUM O
subjects O
) O
were O
studied O
. O

Because O
the O
ALL_CAP O
measures O
variables O
predictive O
of O
RARE O
behavior O
, O
a O
substantial O
relationship O
was O
expected O
between O
the O
ALL_CAP O
and O
the O
ALL_CAP O
RARE O
of O
RARE O
/ O
RARE O
Control O
scale O
. O

We O
have O
improved O
our O
RARE O
RARE O
nuclear O
RARE O
RARE O
and O
determined O
its O
RARE O
limitations O
by O
RARE O
standardized O
objects O
. O

Such O
a O
change O
may O
involve O
increased O
mammary O
utilization O
of O
pre O
- O
formed O
long O
- O
chain O
fatty O
acid O
and O
increased O
metabolism O
of O
glucose O
via O
RARE O
. O

The O
RARE O
site O
, O
6 O
- O
cm O
- O
distal O
and O
- O
proximal O
subcutaneous O
RARE O
of O
the O
catheter O
, O
RARE O
, O
and O
RARE O
were O
cultured O
. O

Because O
of O
its O
great O
reliability O
, O
conventional O
RARE O
RARE O
a O
place O
of O
choice O
among O
the O
medical O
imaging O
techniques O
. O

RARE O
detection O
of O
RARE O
contaminated O
test O
serum O
before O
RARE O
of O
vitamin O
NUM O
. O

The O
former O
group O
did O
RARE O
less O
RARE O
fecal O
material O
compared O
to O
both O
other O
groups O
. O

RARE O
data O
RARE O
( O
ALL_CAP O
) O
latex O
immunoassay O
using O
anti I-GENE
- I-GENE
human I-GENE
RARE I-GENE
acid I-GENE
phosphatase I-GENE
( O
anti I-GENE
- I-GENE
ALL_CAP I-GENE
) O
immune O
serum O
was O
applied O
RARE O
the O
species O
and O
organ O
identification O
of O
human O
RARE O
RARE O
. O

RARE I-GENE
RARE O
was O
noted O
in O
the O
undifferentiated O
and O
RARE O
RARE O
. O

The O
maximum O
RARE O
of O
RARE O
IV O
RARE O
RARE O
and O
N2 O
from O
RARE O
RARE O
III O
RARE O
were O
smaller O
in O
the O
prone O
position O
, O
suggesting O
more O
uniform O
tracer O
gas O
concentrations O
across O
the O
lungs O
. O

Recent O
RARE O
in O
drugs O
antagonistic O
to O
factors O
causing O
RARE O
ulcer O
RARE O
clinical O
efficacy O
and O
problems O
; O
gastrin I-GENE
receptor I-GENE
RARE O

The O
RARE O
RARE O
- O
9 O
is O
a O
RARE O
of O
a O
homologous O
series O
of O
RARE O
- O
RARE O
( O
RARE O
) O
of O
RARE O
formula O
NUM O
- O
NUM O
- O
O O
RARE O
NUM O
) O
RARE O
- O
1 O
NUM O
. O

RARE O
magnetic O
fields O
affect O
the O
diffusion O
of O
biological O
RARE O
in O
solutions O
through O
the O
RARE O
force O
and O
RARE O
stress O
. O

RARE O
disturbance O
was O
greater O
in O
the O
high O
life O
stress O
group O
RARE O
indicated O
by O
significant O
elevations O
on O
the O
global O
severity O
index O
of O
the O
RARE O
RARE O
- O
NUM O
and O
elevations O
on O
RARE O
, O
RARE O
RARE O
, O
RARE O
sensitivity O
, O
depression O
, O
anxiety O
and O
RARE O
RARE O
. O

Chronic O
administration O
of O
RARE O
RARE O
decreases O
NUM O
extraction O
ratio O
in O
dogs O
. O

Nucleotide O
sequencing O
indicates O
that O
this O
E1 I-GENE
alpha I-GENE
cDNA I-GENE
clone O
is O
NUM O
RARE O
RARE O
( O
bp O
) O
in O
length O
with O
an O
RARE O
reading O
frame O
of O
NUM O
bp O
and O
a O
3 O
'- O
RARE O
region O
of O
NUM O
bp O
. O

ALL_CAP O
from O
ALL_CAP O
sites O
was O
associated O
with O
RARE O
. O

In O
contrast O
, O
the O
ALL_CAP O
showed O
a O
RARE O
, O
RARE O
distribution O
, O
with O
a O
range O
from O
RARE O
1 O
to O
14 O
micron O
and O
a O
maximum O
RARE O
3 O
- O
4 O
micron O
. O

Abnormal O
technetium O
Tc O
99m O
RARE O
scans O
in O
patients O
with O
previously O
RARE O
RARE O
suggested O
inflammatory O
RARE O
and O
influenced O
management O
RARE O
with O
RARE O
therapeutic O
outcomes O
. O

RARE O
interest O
of O
such O
studies O
is O
limited O
since O
the O
pharmacokinetic O
parameters O
are O
systematically O
evaluated O
in O
man O
RARE O
RARE O
I O
trials O
. O

The O
artery O
RARE O
was O
slightly O
superior O
to O
the O
fat O
RARE O
, O
particularly O
in O
having O
fewer O
adhesions O
and O
a O
better O
histological O
picture O
. O

RARE O
- O
RARE O
action O
RARE O
radiation O
therapy O
has O
been O
studied O
, O
RARE O
the O
positive O
effect O
on O
RARE O
and O
the O
RARE O
better O
clinical O
conditions O
of O
the O
patients O
in O
course O
of O
treatment O
. O

Of O
the O
53 O
RARE O
tested O
RARE O
RARE O
motion O
RARE O
NUM O
. O
05 O
Hz O
( O
9 O
. O
1 O
cm O
/ O
s O
RARE O
1 O
( O
1 O
. O
9 O
%) O
was O
responsive O
to O
the O
RARE O
input O
only O
, O
NUM O
( O
NUM O
. O
5 O
%) O
were O
influenced O
by O
the O
visual O
input O
only O
and O
NUM O
( O
NUM O
. O
4 O
%) O
responded O
to O
both O
modalities O
. O

RARE O
on O
the O
location O
and O
size O
of O
the O
mass O
, O
a O
wide O
range O
of O
clinical O
RARE O
is O
associated O
with O
the O
lesion O
. O

The O
development O
and O
distribution O
of O
Trypanosoma O
RARE O
, O
T O
RARE O
and O
T O
RARE O
in O
the O
RARE O
of O
goats O
was O
examined O
after O
the O
animals O
were O
RARE O
by O
RARE O
RARE O
RARE O
RARE O
. O

RARE O
is O
a O
useful O
, O
non O
- O
invasive O
technique O
that O
can O
RARE O
in O
the O
assessment O
of O
RARE O
RARE O
dysfunction O
. O

RARE O
analysis O
of O
the O
degrees O
of O
secondary O
RARE O
cord O
compression O
was O
performed O
in O
group O
- O
1 O
dogs O
by O
measuring O
and O
comparing O
ratios O
of O
the O
vertical O
to O
the O
horizontal O
diameters O
of O
the O
transverse O
RARE O
cord O
sections O
from O
locations O
within O
( O
NUM O
to O
L1 O
) O
and O
out O
of O
( O
NUM O
, O
NUM O
- O
12 O
, O
L1 O
- O
2 O
, O
and O
L2 O
) O
the O
region O
of O
surgical O
intervention O
. O

The O
pharmacological O
effects O
of O
the O
novel O
compound O
ALL_CAP O
NUM O
FU O
( O
4 O
- O
amino O
- O
RARE O
- O
1 O
- O
RARE O
- O
RARE O
- O
2 O
- O
one O
- O
RARE O
) O
were O
investigated O
. O

RARE O
examination O
revealed O
dose O
- O
related O
RARE O
of O
type O
II O
RARE O
in O
RARE O
and O
RARE O
of O
interstitial O
cells O
and O
delayed O
septal O
/ O
capillary O
development O
in O
neonates O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

RARE O
far O
RARE O
problems O
with O
RARE O
resistant O
strains O
have O
developed O
. O

During O
the O
observation O
period O
of O
NUM O
. O
4 O
- O
NUM O
weeks O
, O
cardiac O
RARE O
spots O
on O
the O
right O
ventricle O
of O
ALL_CAP O
/ O
c O
mice O
were O
RARE O
detected O
RARE O
three O
weeks O
( O
6 O
of O
20 O
mice O
; O
NUM O
%), O
and O
the O
maximal O
incidence O
of O
cardiac O
RARE O
spots O
was O
obtained O
RARE O
nine O
weeks O
( O
NUM O
of O
NUM O
mice O
; O
88 O
%). O

The O
state O
of O
the O
liver O
in O
generalized O
forms O
of O
RARE O
infection O

Increasing O
the O
ALL_CAP O
beyond O
NUM O
% O
resulted O
in O
RARE O
of O
the O
RARE O
radical O
, O
RARE O
RARE O
the O
radical O
from O
RARE O
the O
RARE O
transition O
state O
. O

The O
effects O
produced O
by O
oral O
administration O
of O
500 O
mg O
/ O
kg O
p O
- O
xylene O
or O
toluene O
RARE O
RARE O
least O
8 O
hr O
, O
while O
the O
effect O
of O
inhaled O
p O
- O
xylene O
RARE O
within O
NUM O
min O
of O
removal O
from O
the O
exposure O
. O

PATIENTS O
and O
METHODS O
: O
RARE O
- O
NUM O
RARE O
scintigraphy O
was O
performed O
RARE O
rest O
and O
after O
NUM O
. O
NUM O
mg O
/ O
kg O
intravenous O
RARE O
RARE O
four O
minutes O
in O
16 O
patients O
with O
RARE O
. O

RARE O
melanomas O
can O
RARE O
and O
be O
lethal O
. O

The O
TA O
muscle O
was O
RARE O
by O
four O
forms O
of O
RARE O
RARE O
contractions O
: O
( O
1 O
) O
maximal O
RARE O
contractions O
( O
ALL_CAP O
RARE O
( O
2 O
) O
ALL_CAP O
with O
circulation O
occluded O
, O
( O
3 O
) O
electrically O
evoked O
contractions O
with O
20 O
Hz O
RARE O
voltage O
RARE O
and O
( O
4 O
) O
electrically O
evoked O
contractions O
with O
circulation O
occluded O
. O

The O
RARE O
local O
control O
rates O
RARE O
10 O
years O
RARE O
the O
three O
treatment O
groups O
were O
RARE O
follows O
: O
subtotal O
RARE O
alone O
, O
18 O
%; O
subtotal O
RARE O
RARE O
postoperative O
radiation O
therapy O
, O
82 O
%; O
and O
RARE O
RARE O
alone O
, O
77 O
%. O

The O
effects O
of O
RARE O
implants O
on O
rate O
, O
composition O
and O
RARE O
efficiency O
of O
growth O
were O
determined O
in O
steers O
fed O
diets O
varying O
in O
RARE O
and O
RARE O
content O
. O

RARE O
RARE O
RARE O
a O
significant O
change O
in O
the O
RARE O
configuration O
of O
the O
femur O
RARE O
by O
increasing O
the O
minimum O
diameter O
( O
12 O
%) O
without O
any O
significant O
alterations O
in O
cortical O
area O
, O
density O
, O
mineral O
, O
and O
RARE I-GENE
concentrations O
. O

RARE O
RARE O
assessed O
anatomic O
RARE O
correlates O
best O
with O
RARE O
measurements O
of O
stenosis O
severity O
? O
A O
comparison O
of O
quantitative O
analysis O
of O
the O
coronary O
RARE O
with O
measured O
coronary O
flow O
reserve O
and O
exercise O
/ O
RARE O
thallium O
- O
NUM O
scintigraphy O
. O

RARE O
content O
and O
equilibrium O
water O
RARE O
in O
immature O
cartilage O
. O

RARE O
function O
tests O
were O
performed O
on O
NUM O
RARE O
, O
RARE O
NUM O
RARE O
. O

Data O
on O
the O
line O
spread O
function O
( O
ALL_CAP O
) O
were O
obtained O
from O
the O
image O
of O
a O
NUM O
. O
2 O
mm O
wide O
RARE O
between O
RARE O
blocks O
that O
were O
positioned O
RARE O
the O
RARE O
in O
front O
of O
a O
RARE O
RARE O
. O

Primary O
infection O
is O
usually O
RARE O
RARE O
. O

RARE O
of O
the O
RARE O
RARE O
Clinical O
RARE O
RARE O
. O

Ischemic O
RARE O
RARE O
, O
age O
of O
more O
than O
NUM O
years O
, O
and O
the O
fact O
that O
the O
patient O
was O
a O
woman O
were O
independent O
predictors O
of O
poor O
cardiac O
function O
. O

RARE O
in O
RARE O
' O
s O
RARE O
localized O
to O
the O
RARE O
- O
RARE O
region O
. O

Taken O
together O
, O
the O
results O
suggest O
that O
RARE O
may O
be O
capable O
of O
producing O
dual O
stimulus O
effects O
in O
animals O
. O

RARE O
chromatographic O
method O
RARE O
determination O
of O
RARE O
in O
RARE O
and O
RARE O
. O

These O
findings O
indicate O
that O
autophosphorylation O
of O
NUM O
( O
alpha O
subunit O
) O
and O
NUM O
( O
beta O
subunit O
) O
is O
responsible O
RARE O
transition O
of O
CaM I-GENE
- I-GENE
kinase I-GENE
II I-GENE
to O
the O
NUM O
RARE O
independent O
form O
. O

This O
rapid O
and O
extensive O
penetration O
of O
RARE O
administered O
chemotherapy O
may O
offer O
insight O
into O
the O
RARE O
observed O
with O
these O
treatments O
. O

The O
interaction O
of O
radiation O
and O
RARE O
was O
systematically O
studied O
in O
the O
RARE O
NUM O
RARE O
adenocarcinoma O
, O
the O
RARE O
RARE O
model O
RARE O
human O
RARE O
RARE O
. O

RARE O
rats O
were O
exposed O
to O
one O
of O
the O
following O
: O
( O
1 O
) O
10 O
% O
NUM O
in O
N2 O
or O
NUM O
% O
NUM O
RARE O
2 O
days O
beginning O
RARE O
day O
7 O
, O
11 O
, O
14 O
, O
or O
18 O
of O
RARE O
; O
( O
2 O
) O
10 O
% O
NUM O
in O
N2 O
or O
NUM O
% O
NUM O
RARE O
10 O
h O
/ O
day O
beginning O
RARE O
day O
7 O
; O
or O
( O
3 O
) O
14 O
- O
11 O
% O
NUM O
in O
N2 O
continuously O
beginning O
RARE O
day O
14 O
RARE O
day O
21 O
when O
they O
were O
RARE O
. O

The O
incidence O
of O
RARE O
in O
young O
children O
was O
determined O
by O
staining O
of O
RARE O
specimens O
with O
a O
modified O
RARE O
stain O
. O

RARE O
patients O
( O
8 O
. O
3 O
percent O
) O
had O
latent O
hypothyroidism O
only O
discovered O
by O
hormonal O
determinations O
. O

Addition O
of O
RARE O
or O
RARE O
- O
RARE O
resulted O
in O
RARE O
of O
RARE O
HCO3 O
RARE O
, O
RARE O
about O
NUM O
% O
and O
NUM O
%, O
respectively O
, O
of O
the O
maximal O
HCO3 O
response O
to O
16 O
, O
16 O
- O
dimethyl O
PGE2 O
( O
NUM O
). O

Moreover O
, O
unlike O
control O
rats O
operated O
animals O
did O
not O
show O
RARE O
to O
the O
highest O
concentrations O
of O
saccharin O
solutions O
. O

In O
RARE O
RARE O
, O
RARE O
specialized O
RARE O
of O
RARE O
vessels O
appears O
to O
exist O
between O
the O
pineal O
organ O
and O
other O
portions O
of O
the O
brain O
. O

The O
4 O
degrees O
stimuli O
were O
found O
to O
elicit O
RARE O
RARE O
RARE O
the O
pattern O
reversal O
NUM O
and O
the O
pattern O
onset O
C1 O
consistent O
with O
RARE O
and O
RARE O
visual O
cortical O
origins O
respectively O
. O

Nuclear I-GENE
factor I-GENE
III I-GENE
( O
ALL_CAP I-GENE
) O
is O
a O
protein O
from O
HeLa O
cells O
that O
stimulates O
the O
initiation O
of O
adenovirus O
type O
2 O
( O
NUM O
) O
DNA O
replication O
by O
binding O
to O
a O
specific O
nucleotide O
sequence O
in O
the O
origin O
, O
adjacent O
to O
the O
nuclear I-GENE
factor I-GENE
I I-GENE
recognition I-GENE
site I-GENE
. O

A O
RARE O
study O
of O
the O
RARE O
layer O
of O
the O
cerebral O
cortex O
. O

We O
conclude O
that O
RARE O
clearance O
of O
S O
. O
RARE O
from O
a O
site O
RARE O
to O
RARE O
was O
delayed O
when O
compared O
to O
a O
RARE O
- O
RARE O
site O
. O

The O
findings O
are O
discussed O
in O
the O
context O
of O
known O
properties O
of O
cortical O
- O
RARE O
RARE O
. O

Mean O
rCBF O
increased O
in O
some O
patients O
4 O
- O
8 O
weeks O
after O
surgery O
on O
the O
ipsilateral O
RARE O
. O

Quantitative O
computed O
tomography O
RARE O
measuring O
vertebral O
bone O
mineral O
content O
offers O
high O
sensitivity O
and O
reproducibility O
. O

The O
RARE O
of O
the O
enhancer O
was O
also O
RARE O
by O
inserting O
a O
RARE O
of O
RARE O
RARE O
RARE O
which O
represented O
the O
region O
between O
nt O
positions O
- O
NUM O
and O
- O
215 O
into O
a O
truncated O
template O
which O
lacked O
the O
enhancer O
. O

RARE O
, O
c O
and O
ALL_CAP O
( O
RARE O
to O
the O
initial O
RARE O
mass O
) O
decreased O
RARE O
with O
reductions O
in O
RARE O
mass O
% O
delta O
RARE O
, O
c O
= O
1 O
. O
NUM O
- O
NUM O
. O
98 O
% O
mass O
removed O
( O
RARE O
= O
NUM O
. O
NUM O
, O
P O
less O
than O
NUM O
. O
01 O
) O
and O
% O
delta O
ALL_CAP O
= O
- O
3 O
. O
NUM O
- O
NUM O
. O
98 O
% O
mass O
removed O
( O
RARE O
= O
NUM O
. O
82 O
, O
P O
less O
than O
NUM O
. O
01 O
) O
relationships O
that O
were O
not O
altered O
by O
blocker O
pretreatment O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

Two O
RARE O
methods O
, O
resting O
RARE O
and O
exercise O
thallium O
- O
NUM O
RARE O
perfusion O
imaging O
, O
to O
detect O
and O
localize O
coronary O
artery O
stenosis O
were O
compared O
in O
NUM O
patients O
suffering O
from O
coronary O
artery O
RARE O
. O

From O
these O
results O
, O
it O
is O
concluded O
that O
ALL_CAP O
has O
clear O
RARE O
properties O
which O
are O
not O
due O
to O
adrenergic O
or O
RARE O
entry O
mechanisms O
and O
that O
there O
are O
differences O
in O
the O
RARE O
effects O
of O
RARE O
with O
respect O
to O
different O
vascular O
RARE O
. O

Research O
was O
carried O
out O
on O
the O
rheumatoid I-GENE
factors I-GENE
in O
the O
serum O
of O
NUM O
patients O
by O
means O
of O
two O
tests O
( O
one O
using O
RARE O
and O
one O
with O
RARE O
) O
and O
the O
results O
obtained O
were O
compared O
using O
a O
method O
of O
reference O
. O

A O
low O
RARE I-GENE
esterase I-GENE
activity O
may O
be O
a O
RARE O
factor O
in O
precipitating O
these O
RARE O
RARE O
reactions O
. O

In O
both O
experiments O
, O
average O
daily O
gain O
and O
gain O
- O
to O
- O
feed O
ratio O
were O
similar O
RARE O
TR O
and O
ALL_CAP O
. O

Overall O
least O
- O
RARE O
means O
RARE O
RARE O
and O
RARE O
RARE O
muscle O
and O
subcutaneous O
fat O
were O
NUM O
. O
NUM O
, O
NUM O
. O
NUM O
and O
98 O
. O
NUM O
mg O
of O
cholesterol O
/ O
NUM O
g O
of O
tissue O
, O
respectively O
. O

The O
role O
of O
RARE O
RARE O
chromatography O
( O
ALL_CAP O
) O
RARE O
a O
viable O
technique O
RARE O
analyzing O
RARE O
products O
has O
been O
investigated O
using O
RARE O
and O
capillary O
column O
RARE O
. O

RARE O
significantly O
RARE O
the O
rise O
in O
ALL_CAP I-GENE
RARE O
by O
ALL_CAP I-GENE
. O

RARE O
tumors O
in O
RARE O
. O

RARE O
study O
of O
RARE O

X2 O
test O
, O
with O
RARE O
correction O
if O
need O
, O
was O
used O
RARE O
statistical O
. O
method O
. O

After O
a O
baseline O
study O
, O
ALL_CAP O
RARE O
was O
simulated O
by O
RARE O
RARE O
RARE O
different O
sites O
around O
the O
RARE O
of O
the O
ventricles O
, O
and O
ALL_CAP O
' O
s O
were O
obtained O
. O

RARE O
and O
insect O
, O
past O
, O
present O
, O
future O

All O
patients O
had O
the O
CA I-GENE
NUM I-GENE
assay O
performed O
within O
one O
week O
before O
their O
second O
- O
RARE O
operation O
. O

RARE O
and O
RARE O
' O
s O
RARE O
. O

The O
criterion O
was O
reached O
after O
two O
RARE O
and O
RARE O
to O
a O
variety O
of O
RARE O
and O
capsules O
occurred O
. O

Clinical O
method O
RARE O
the O
treatment O
of O
RARE O
II O
RARE O
anomalies O
with O
RARE O
RARE O

RARE O
appears O
to O
be O
RARE O
RARE O
RARE O
the O
treatment O
of O
complicated O
ALL_CAP O
. O

Mean O
RARE O
scores O
, O
however O
, O
were O
similar O
. O

RARE O
RARE O
were O
restricted O
to O
RARE O
RARE O
. O

An O
RARE O
- O
wide O
retrospective O
cohort O
mortality O
study O
was O
conducted O
on O
6 O
, O
NUM O
chemical O
workers O
( O
2 O
, O
NUM O
exposed O
and O
3 O
, O
NUM O
RARE O
) O
RARE O
in O
RARE O
ether O
RARE O
RARE O
7 O
major O
ALL_CAP O
. O
S O
. O
RARE O
between O
NUM O
and O
1980 O
. O

The O
diagnosis O
of O
RARE O
was O
determined O
from O
a O
RARE O
RARE O
RARE O
biopsy O
. O

RARE O
and O
RARE O
samples O
were O
taken O
before O
vitamin O
C O
or O
placebo O
supplementation O
was O
started O
and O
RARE O
monthly O
intervals O
thereafter O
RARE O
three O
months O
. O

In O
treated O
RARE O
, O
cows O
more O
than O
40 O
d O
RARE O
with O
a O
RARE O
RARE O
received O
RARE O
F2 O
alpha O
. O

On O
the O
other O
RARE O
, O
if O
the O
measured O
angle O
ALL_CAP O
is O
smaller O
than O
the O
calculated O
angle O
, O
the O
skeletal O
relation O
is O
RARE O
III O
. O

RARE O
treatment O
of O
facial O
and O
RARE O
/ O
mandibular O
injuries O

In O
14 O
cases O
, O
isolates O
were O
RARE O
RARE O
eight O
with O
RARE O
II O
, O
four O
with O
RARE O
III O
, O
and O
one O
each O
with O
RARE O
IV O
and O
V O
. O

A O
RARE O
of O
117 O
ALL_CAP O
treatments O
were O
performed O
on O
NUM O
patients O
. O

Most O
of O
the O
RARE O
portion O
of O
the O
precursor O
polypeptide O
is O
encoded O
by O
the O
next O
three O
exons O
, O
and O
the O
RARE O
form O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
is O
encoded O
by O
the O
remaining O
three O
exons O
. O

A O
RARE O
version O
of O
RARE O
' O
s O
( O
NUM O
, O
1972 O
) O
model O
with O
cumulative O
RARE O
( O
ALL_CAP O
) O
was O
simulated O
. O

In O
a O
previous O
RARE O
report O
we O
noted O
more O
RARE O
resolution O
of O
RARE O
signs O
and O
symptoms O
with O
RARE O
treatment O
. O

The O
RARE O
of O
the O
defects O
in O
ALL_CAP O
or O
LAD O
region O
was O
NUM O
% O
in O
single O
- O
position O
scans O
in O
stress O
studies O
. O

RARE O
properties O
of O
RARE O
agents O
and O
RARE O
drugs O
. O

This O
brief O
RARE O
challenge O
RARE O
a O
rapid O
increase O
in O
CBF O
in O
the O
absence O
of O
any O
change O
in O
ALL_CAP O
. O

These O
data O
should O
be O
useful O
in O
developing O
RARE O
RARE O
RARE O
detection O
and O
RARE O
diagnosis O
of O
11 I-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
deficiency O
, O
the O
second O
most O
frequent O
cause O
of O
congenital O
adrenal O
hyperplasia O
. O

RARE I-GENE
( O
serum I-GENE
bone I-GENE
- I-GENE
RARE I-GENE
protein I-GENE
, O
ALL_CAP I-GENE
RARE O
serum I-GENE
RARE I-GENE
phosphatase I-GENE
( O
ALL_CAP I-GENE
) O
and O
RARE O
RARE O
/ O
RARE O
ratio O
( O
ALL_CAP O
- O
RARE O
/ O
RARE O
) O
have O
been O
measured O
in O
21 O
patients O
with O
RARE O
RARE O
( O
ALL_CAP O
) O
and O
in O
nine O
patients O
with O
RARE O
of O
malignancy O
( O
ALL_CAP O
). O

RARE O
RARE O
regression O
analysis O
indicated O
that O
RARE O
was O
strongly O
associated O
with O
the O
prevalence O
of O
hepatitis O
B O
in O
an O
RARE O
' O
s O
RARE O
of O
birth O
and O
with O
age O
. O

RARE O
is O
the O
RARE O
RARE O
and O
RARE O
RARE O
RARE O
RARE O
a O
RARE O
RARE O
synthesized O
from O
1 O
- O
RARE O
with O
3 O
- O
5 O
% O
RARE O
RARE O
the O
source O
of O
residual O
double O
bonds O
RARE O
RARE O
. O

RARE O
RARE O
- O
RARE O
RARE O
vectors O
were O
constructed O
from O
NUM O
/ O
19 O
plasmids O
by O
cloning O
a O
single O
- O
RARE O
DNA O
( O
ALL_CAP O
) O
origin O
of O
replication O
from O
RARE O
NUM O
and O
inserting O
a O
RARE O
NUM O
promoter O
within O
the O
beta I-GENE
- I-GENE
galactosidase I-GENE
gene I-GENE
. O

By O
order O
of O
decreasing O
rate O
, O
finger O
RARE O
, O
jaw O
, O
RARE O
RARE O
, O
and O
RARE O
RARE O
were O
less O
frequently O
elicited O
in O
both O
groups O
. O

RARE O
. O

Neither O
ethanol O
nor O
estrogen O
has O
been O
shown O
to O
cause O
ALL_CAP I-GENE
- O
deficiency O
in O
animals O
. O

Although O
not O
common O
, O
the O
disorder O
is O
the O
most O
frequently O
diagnosed O
disturbance O
of O
porphyrin O
metabolism O
in O
many O
RARE O
, O
and O
further O
insight O
into O
its O
unusual O
pathogenesis O
may O
clarify O
the O
RARE O
effects O
of O
the O
4 O
RARE O
agents O
. O

Five O
out O
of O
eight O
consecutive O
cases O
with O
initial O
symptoms O
of O
a O
' O
RARE O
granuloma O
' O
were O
identified O
RARE O
malignant O
RARE O
( O
RARE O
sarcoma O
) O
which O
within O
5 O
months O
to O
4 O
years O
led O
to O
RARE O
and O
RARE O
. O

All O
patients O
then O
received O
RARE O
1 O
. O
5 O
mg O
kg O
- O
1 O
i O
. O
v O
. O

The O
highest O
postoperative O
ALL_CAP I-GENE
- I-GENE
MB I-GENE
level O
was O
less O
after O
ALL_CAP O
( O
ALL_CAP O
, O
NUM O
+/- O
NUM O
ALL_CAP O
/ O
L O
; O
ALL_CAP O
, O
NUM O
+/- O
NUM O
ALL_CAP O
/ O
L O
; O
p O
less O
than O
NUM O
. O
05 O
). O

No O
relevant O
changes O
in O
RARE O
rate O
, O
body O
RARE O
, O
and O
plasma O
levels O
of O
renin I-GENE
activity O
and O
aldosterone O
concentration O
were O
observed O
. O

RARE O
trough O
serum O
ALL_CAP O
concentrations O
were O
associated O
with O
RARE O
and O
very O
low O
levels O
with O
recovery O
. O

State O
- O
RARE O
RARE O
of O
nursing O
R O
. O
N O
. O

In O
a O
RARE O
RARE O
a O
protein O
with O
an O
RARE O
RARE O
RARE O
of O
NUM O
, O
NUM O
was O
synthesized O
. O

This O
means O
that O
the O
RARE O
of O
RARE O
must O
be O
calculated O
by O
using O
a O
RARE O
and O
not O
a O
RARE O
model O
RARE O
RARE O
did O
. O

The O
incidence O
of O
second O
malignant O
neoplasms O
was O
lower O
( O
1 O
. O
3 O
%) O
in O
the O
group O
treated O
with O
5 O
- O
fluorouracil O
, O
RARE O
, O
and O
cyclophosphamide O
than O
in O
the O
RARE O
control O
group O
( O
4 O
. O
8 O
%). O

RARE O
was O
RARE O
in O
8 O
( O
NUM O
. O
7 O
%) O
patients O
who O
RARE O
. O

In O
previous O
work O
( O
E O
. O

The O
small O
size O
and O
placement O
of O
the O
mutagenesis O
marker O
( O
the O
ALL_CAP I-GENE
suppressor I-GENE
tRNA I-GENE
gene I-GENE
from I-GENE
Escherichia I-GENE
coli I-GENE
) O
within O
the O
vector O
substantially O
RARE O
the O
frequency O
of O
spontaneous O
mutations O
normally O
observed O
after O
transfection O
of O
mammalian O
cells O
with O
RARE O
DNA O
; O
hence O
, O
ALL_CAP O
- O
RARE O
mutations O
were O
easily O
identified O
above O
the O
spontaneous O
background O
. O

ALL_CAP O
. O

RARE O
analysis O
and O
RARE O
RARE O
experiments O
localized O
the O
NUM I-GENE
gene I-GENE
proximal O
to O
GAL4 I-GENE
on O
RARE O
ALL_CAP O
. O

Based O
on O
our O
observations O
, O
we O
propose O
a O
model O
RARE O
inactive O
precursor O
molecules O
produced O
from O
the O
NUM I-GENE
gene I-GENE
self O
- O
activate O
within O
the O
yeast O
RARE O
and O
subsequently O
activate O
other O
vacuolar I-GENE
RARE I-GENE
. O

The O
RARE O
( O
A O
) O
segment O
of O
the O
RNA O
was O
selectively O
cross O
- O
RARE O
to O
the O
72 O
, O
NUM O
- O
RARE O
- O
RARE O
protein O
( O
NUM O
protein O
). O

In O
vitro O
translation O
of O
RNA O
synthesized O
from O
the O
RARE O
cDNAs O
predicts O
that O
NUM I-GENE
transcripts I-GENE
are O
translated O
into O
a O
novel O
12 O
. O
5 O
- O
RARE O
protein O
corresponding O
to O
the O
RARE O
RARE O
reading O
frame O
. O

The O
N O
- O
terminal O
amino O
acid O
sequence O
of O
RARE I-GENE
has O
sequence O
homology O
with O
DNA O
binding O
proteins O
. O

Several O
new O
techniques O
are O
available O
RARE O
monitoring O
control O
of O
diabetes O
. O

RARE O
: O
an O
RARE O
of O
adverse O
RARE O
. O

RARE O
RARE O
mechanisms O
of O
RARE O
changes O
in O
response O
to O
space O
RARE O
effects O
are O
described O
. O

The O
RARE I-GENE
genes I-GENE
comprise O
an O
evolutionarily O
RARE O
family O
with O
significant O
homology O
to O
the O
ras I-GENE
oncogene I-GENE
family I-GENE
. O

Also O
, O
RARE O
I O
significantly O
correlated O
with O
fasting O
insulin I-GENE
and O
VO2 O
RARE O
RARE O
both O
RARE O
and O
with O
basal O
metabolism O
and O
ALL_CAP I-GENE
- I-GENE
cholesterol I-GENE
RARE O
females O
and O
males O
, O
respectively O
. O

The O
glucose O
areas O
following O
the O
ingestion O
of O
the O
RARE O
were O
: O
Study O
1 O
: O
glucose O
11 O
. O
7 O
, O
RARE O
juice O
7 O
. O
3 O
, O
sucrose O
5 O
. O
2 O
, O
glucose O
+ O
RARE O
6 O
. O
3 O
, O
and O
RARE O
NUM O
. O
7 O
mmol O
X O
h O
/ O
RARE O
; O
Study O
2 O
: O
glucose O
14 O
. O
6 O
, O
RARE O
juice O
7 O
. O
3 O
, O
RARE O
5 O
. O
5 O
, O
and O
RARE O
juice O
4 O
. O
7 O
mmol O
X O
h O
/ O
RARE O
; O
Study O
3 O
: O
glucose O
12 O
. O
6 O
, O
RARE O
cream O
8 O
. O
1 O
, O
milk O
3 O
. O
7 O
, O
and O
RARE O
4 O
. O
1 O
mmol O
X O
h O
/ O
RARE O
. O

The O
serum I-GENE
insulin I-GENE
response O
cannot O
. O

ALL_CAP O
prolonged O
RARE O
after O
verapamil O
, O
and O
sinus O
arrest O
developed O
in O
two O
of O
10 O
group O
2 O
and O
two O
of O
five O
group O
3 O
animals O
. O

RARE O
of O
a O
yeast O
RARE O
to O
assay O
mutational O
RARE O
. O

RARE O
serum I-GENE
insulin I-GENE
levels O
showed O
RARE O
significant O
correlations O
with O
systolic O
or O
diastolic O
RARE O
pressure O
levels O
in O
men O
, O
but O
in O
female O
diabetic O
and O
non O
- O
diabetic O
subjects O
significant O
correlations O
were O
found O
in O
particular O
with O
systolic O
RARE O
pressure O
level O
. O

We O
used O
RARE O
- O
directed O
mutagenesis O
to O
alter O
a O
site O
in O
ALL_CAP I-GENE
homologous O
to O
the O
RARE O
- O
RARE O
RARE O
site O
of O
LexA I-GENE
. O

The O
latter O
was O
determined O
RARE O
follows O
: O
RARE O
I O
- O
solid O
tumor O
tissue O
without O
significant O
peripheral O
isolated O
tumor O
cells O
; O
RARE O
II O
- O
solid O
tumor O
tissue O
associated O
with O
peripheral O
isolated O
tumor O
cells O
; O
RARE O
III O
- O
isolated O
tumor O
cells O
only O
. O

The O
RARE O
of O
RARE O
. O

Acute O
inhalation O
toxicity O
of O
T O
- O
2 O
RARE O
in O
mice O
. O

The O
present O
investigation O
sought O
to O
identify O
the O
principal O
dimensions O
of O
the O
RARE O
RARE O
A O
scale O
( O
ALL_CAP O
) O
and O
then O
to O
examine O
their O
physiological O
and O
psychological O
correlates O
. O

A O
preliminary O
study O
on O
RARE O
arthritis O
. O

RARE O
, O
RARE O
RARE O
, O
and O
RARE O
consumption O
. O

RARE O
in O
the O
aorta O
of O
rats O
treated O
with O
a O
RARE O
- O
RARE O
oil O
RARE O
( O
RARE O
). O

As O
a O
last O
RARE O
, O
it O
may O
be O
possible O
to O
maintain O
a O
patient O
on O
dialysis O
in O
reasonable O
health O
with O
a O
ALL_CAP O
RARE O
graft O
complex O
RARE O
with O
RARE O
RARE O
and O
intermittent O
positive O
RARE O
cultures O
using O
long O
term O
vancomycin O
therapy O
. O

For O
signal O
durations O
less O
than O
10 O
ms O
, O
however O
, O
the O
RARE O
and O
S O
RARE O
No O
threshold O
functions O
RARE O
and O
the O
RARE O
- O
level O
difference O
decreased O
. O

The O
RARE O
rate O
of O
about O
600 O
RARE O
of O
ALL_CAP O
I O
examined O
was O
54 O
. O
3 O
% O
and O
the O
parasite O
rate O
NUM O
. O
2 O
% O
before O
the O
drug O
intervention O
. O

Multiple O
RARE O
four O
times O
daily O
RARE O
7 O
days O
of O
RARE O
NUM O
mg O
, O
a O
non O
- O
RARE O
anti O
- O
inflammatory O
drug O
with O
a O
short O
RARE O
- O
life O
( O
t1 O
/ O
2 O
RARE O
revealed O
drug O
accumulation O
in O
eight O
elderly O
subjects O
. O

In O
10 O
patients O
with O
subacute O
cardiac O
RARE O
, O
pulmonary O
RARE O
pressure O
( O
ALL_CAP O
RARE O
ALL_CAP O
, O
and O
ALL_CAP O
were O
measured O
along O
with O
RARE O
of O
systolic O
function O
. O

RARE O
RARE O
and O
RARE O
data O
, O
RARE O
ventricular O
stroke O
work O
index O
showed O
positive O
correlation O
with O
NUM O
( O
RARE O
= O
. O
NUM O
) O
and O
NUM O
( O
RARE O
= O
. O
52 O
) O
but O
not O
with O
NUM O
. O

RARE O
developed O
profound O
RARE O
, O
with O
levels O
RARE O
from O
NUM O
. O
5 O
+/- O
NUM O
. O
2 O
to O
7 O
. O
6 O
+/- O
NUM O
. O
4 O
mg O
/ O
dl O
under O
the O
influence O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
. O

RARE O
value O
of O
RARE O
features O
of O
language O
RARE O
RARE O
, O
RARE O
retarded O
, O
and O
normal O
children O
. O

Similarly O
, O
RARE O
RARE O
RARE O
the O
second O
RARE O
were O
not O
more O
frequently O
RARE O
by O
RARE O
RARE O
more O
RARE O
, O
regardless O
of O
treatment O
condition O
and O
elevation O
of O
the O
F O
and O
F O
- O
K O
indices O
on O
the O
RARE O
MMPI O
profile O
. O

RARE O
to O
its O
relatively O
RARE O
chemical O
form O
, O
NUM O
was O
rapidly O
RARE O
from O
RARE O
to O
bone O
where O
a O
substantial O
portion O
was O
retained O
RARE O
a O
long O
period O
of O
time O
. O

The O
study O
RARE O
generalized O
atrophy O
and O
diffuse O
RARE O
RARE O
matter O
RARE O
. O

The O
diagnosis O
of O
RARE O
RARE O
( O
ALL_CAP O
) O
was O
confirmed O
by O
the O
finding O
of O
low O
RARE I-GENE
A I-GENE
( O
ALL_CAP I-GENE
) O
levels O
in O
cultured O
RARE O
in O
both O
RARE O
. O

RARE O
ventilation O
was O
conducted O
using O
a O
tidal O
volume O
of O
10 O
ml O
X O
kg O
- O
1 O
and O
a O
rate O
of O
10 O
to O
12 O
c O
X O
min O
- O
1 O
. O

Significantly O
lower O
RARE O
rate O
reactivity O
and O
significantly O
less O
pronounced O
RARE O
temporal O
artery O
pulse O
amplitude O
responses O
were O
found O
in O
non O
- O
RARE O
ALL_CAP O
subjects O
than O
in O
controls O
. O

An O
epidemiological O
survey O
of O
RARE O
valve O
RARE O
and O
RARE O
fever O
in O
RARE O
and O
secondary O
RARE O
students O
in O
RARE O
RARE O

RARE O
that O
are O
transformed O
via O
RARE O
II O
reactions O
usually O
do O
not O
require O
dosage O
adjustment O
. O

A O
study O
of O
human O
genes O
coding O
RARE O
U4 I-GENE
small I-GENE
nuclear I-GENE
RNA I-GENE
is O
presented O
. O

Using O
the O
RARE O
- O
gas O
procedure O
with O
a O
single O
gas O
injection O
, O
a O
RARE O
was O
obtained O
that O
was O
large O
enough O
to O
RARE O
a O
RARE O
RARE O
without O
prior O
drainage O
of O
subretinal O
RARE O
or O
RARE O
. O

RARE O
- O
RARE O
- O
like O
RARE O
( O
ALL_CAP I-GENE
) O
was O
produced O
by O
NUM O
of O
NUM O
RARE O
isolates O
( O
NUM O
%), O
while O
only O
1 O
of O
the O
NUM O
isolates O
( O
2 O
%) O
produced O
RARE O
activity O
in O
RARE O
mice O
; O
65 O
% O
of O
the O
RARE O
- O
producing O
strains O
also O
produced O
an O
ALL_CAP I-GENE
- I-GENE
like I-GENE
material O
. O

RARE O
of O
a O
RARE O
RARE O
- O
RARE O
RARE O
language O
RARE O
" O
RARE O
and O
RARE O
RARE O
" O
RARE O
use O
in O
the O
RARE O
RARE O

RARE O
RARE O
RARE O
with O
increased O
light O
sensitivity O

Thus O
, O
a O
negative O
test O
is O
compatible O
with O
low O
RARE O
activity O
and O
/ O
or O
efficacy O
of O
RARE O
antagonist O
treatment O
. O

Thus O
, O
a O
negative O
test O
is O
compatible O
with O
low O
RARE O
activity O
and O
/ O
or O
efficacy O
of O
RARE O
antagonist O
treatment O
. O

RARE O
foot O
NUM O
was O
measured O
by O
using O
oxygen O
- O
RARE O
electrodes O
with O
surface O
temperatures O
of O
NUM O
degrees O
C O
and O
NUM O
degrees O
C O
; O
in O
theory O
, O
changes O
in O
sympathetic O
activity O
should O
affect O
RARE O
tone O
and O
NUM O
in O
RARE O
RARE O
an O
electrode O
RARE O
NUM O
degrees O
C O
( O
RARE O
vasodilation O
RARE O
but O
not O
RARE O
NUM O
degrees O
C O
( O
maximal O
vasodilation O
). O

In O
subjects O
( O
RARE O
= O
5 O
) O
with O
RARE O
and O
RARE O
sympathetic O
tone O
secondary O
to O
cervical O
cord O
trauma O
, O
NUM O
RARE O
NUM O
degrees O
C O
and O
vasodilation O
index O
were O
increased O
( O
NUM O
. O
NUM O
mmHg O
and O
NUM O
. O
NUM O
); O
NUM O
RARE O
NUM O
degrees O
C O
did O
not O
change O
. O

The O
nucleotide O
sequences O
of O
the O
human I-GENE
and I-GENE
murine I-GENE
RARE I-GENE
decarboxylase I-GENE
mRNAs I-GENE
share O
an O
NUM O
% O
homology O
, O
even O
in O
their O
3 O
'- O
noncoding O
regions O
. O

The O
absolute O
concentrations O
of O
alpha I-GENE
2 I-GENE
- I-GENE
RARE I-GENE
inhibitor O
, O
alpha I-GENE
2 I-GENE
- I-GENE
RARE I-GENE
, O
and O
antithrombin I-GENE
III I-GENE
increased O
with O
exercise O
( O
all O
P O
less O
than O
NUM O
. O
005 O
RARE O
but O
when O
concentrations O
were O
corrected O
RARE O
acute O
shifts O
of O
plasma O
water O
RARE O
exercise O
, O
the O
RARE O
of O
these O
RARE O
RARE O
decreased O
( O
all O
P O
less O
than O
NUM O
. O
005 O
). O

The O
other O
model O
was O
a O
continuous O
RARE O
RARE O
constant O
of O
the O
form O
RARE O
- O
= O
a O
+ O
b O
RARE O
RARE O
( O
NUM O
)]. O

Cell O
. O

RARE O
of O
symptoms O
and O
RARE O
excretion O
in O
human O
RARE O
. O

After O
dopamine O
infusion O
in O
women O
with O
RARE O
ovary O
RARE O
and O
in O
matched O
controls O
, O
steady O
state O
levels O
of O
plasma O
dopamine O
, O
norepinephrine O
, O
and O
the O
ratio O
of O
dopamine O
/ O
norepinephrine O
were O
similar O
in O
the O
two O
groups O
. O

Diagnostic O
importance O
of O
RARE O
the O
complement O
RARE O
in O
children O
with O
RARE O
thyroiditis O

In O
the O
normal O
, O
basal O
( O
unstimulated O
) O
condition O
there O
were O
RARE O
significant O
correlations O
( O
p O
greater O
than O
NUM O
. O
05 O
) O
between O
the O
systolic O
RARE O
pressure O
and O
dopamine O
( O
RARE O
= O
NUM O
. O
09 O
RARE O
norepinephrine O
( O
RARE O
= O
NUM O
. O
NUM O
RARE O
or O
epinephrine O
( O
RARE O
= O
NUM O
. O
NUM O
RARE O
nor O
were O
there O
significant O
correlations O
between O
melatonin O
and O
dopamine O
( O
RARE O
= O
- O
NUM O
. O
01 O
RARE O
norepinephrine O
( O
RARE O
= O
- O
NUM O
. O
NUM O
RARE O
or O
growth I-GENE
hormone I-GENE
( O
RARE O
= O
NUM O
. O
NUM O
). O

The O
4 O
patients O
with O
RARE I-GENE
levels O
in O
excess O
of O
10 O
% O
may O
represent O
RARE O
carbon O
RARE O
poisoning O
in O
this O
population O
. O

All O
these O
processes O
were O
fully O
developed O
RARE O
the O
last O
month O
of O
RARE O
, O
RARE O
the O
same O
picture O
RARE O
the O
controls O
. O

RARE O
action O
of O
" O
RARE O
RARE O
RARE O
RARE O
RARE O
" O
and O
its O
mechanism O
on O
diabetes O
mellitus O

In O
cases O
of O
1 O
degrees O
ALL_CAP O
, O
the O
plasma O
1 O
, O
NUM O
RARE O
OH O
) O
NUM O
level O
rose O
significantly O
in O
all O
cases O
( O
P O
less O
than O
NUM O
. O
05 O
RARE O
although O
the O
pattern O
of O
the O
increase O
was O
not O
uniform O
. O

This O
region O
of O
NUM O
amino O
RARE O
may O
be O
involved O
in O
RARE O
- O
RARE O
interactions O
similar O
to O
those O
that O
facilitate O
the O
RARE O
formation O
in O
the O
RARE O
region O
. O

This O
approach O
enables O
the O
sources O
of O
error O
in O
the O
RARE O
of O
nutrient O
utilization O
to O
be O
readily O
identified O
, O
and O
their O
effect O
on O
RARE O
to O
be O
assessed O
in O
different O
nutritional O
and O
metabolic O
states O
. O

The O
effect O
of O
dietary O
zinc O
deficiency O
on O
the O
RARE O
fiber O
zinc O
content O
of O
the O
rat O
hippocampus O
. O

RARE O
rats O
were O
fed O
a O
normal O
diet O
or O
a O
low O
- O
protein O
, O
low O
- O
energy O
diet O
, O
and O
injected O
with O
saline O
or O
thyroxine O
( O
5 O
micrograms O
/ O
NUM O
g O
ALL_CAP O
) O
RARE O
NUM O
days O
. O

It O
is O
largely O
predicted O
by O
lupus O
RARE O
( O
estimated O
by O
activated O
partial O
thromboplastin I-GENE
time O
) O
and O
/ O
or O
antibody O
to O
RARE O
. O

The O
effects O
of O
several O
RARE O
agonists O
and O
the O
RARE O
antagonist O
naloxone O
were O
examined O
in O
rats O
responding O
under O
a O
fixed O
- O
consecutive O
- O
number O
( O
ALL_CAP O
) O
schedule O
. O

The O
rate O
- O
decreasing O
effects O
of O
RARE O
and O
NUM O
were O
reversed O
completely O
by O
a O
NUM O
. O
01 O
and O
1 O
. O
NUM O
mg O
/ O
kg O
dose O
of O
naloxone O
, O
respectively O
. O

Data O
from O
119 O
men O
and O
40 O
women O
undergoing O
coronary O
angiography O
provide O
an O
RARE O
to O
compare O
these O
associations O
in O
relation O
to O
a O
direct O
and O
continuous O
measure O
of O
atherosclerosis O
while O
controlling O
RARE O
age O
, O
RARE O
, O
RARE O
, O
hypertension O
, O
serum O
cholesterol O
, O
smoking O
, O
angina O
, O
diabetes O
, O
family O
history O
of O
RARE O
RARE O
, O
RARE O
A O
behavior O
pattern O
, O
and O
RARE O
. O

An O
RARE O
change O
in O
RARE O
above O
or O
below O
NUM O
degrees O
C O
decreases O
only O
the O
RARE O
bronchial O
RARE O
flow O
and O
does O
not O
influence O
RARE O
flow O
to O
other O
RARE O
tissues O
including O
those O
RARE O
by O
the O
bronchial O
circulation O
. O

RARE O
status O
RARE O
after O
infusion O
of O
cisplatin O

The O
presence O
in O
such O
patients O
of O
antibodies O
to O
adrenaline O
and O
noradrenaline O
is O
indicative O
of O
considerable O
disruption O
of O
RARE O
RARE O
. O

The O
following O
markers O
were O
RARE O
RARE O
in O
the O
serum O
, O
RARE O
and O
liver O
of O
all O
patients O
with O
chronic O
hepatitis O
: O
ALL_CAP O
( O
HBs I-GENE
RARE I-GENE
and O
RARE I-GENE
RARE I-GENE
, O
anti I-GENE
- I-GENE
HBs I-GENE
, O
anti I-GENE
- I-GENE
RARE I-GENE
and O
anti I-GENE
- I-GENE
RARE I-GENE
in O
the O
serum O
, O
HBs I-GENE
and I-GENE
RARE I-GENE
RARE I-GENE
in O
the O
liver O
); O
non I-GENE
- I-GENE
A I-GENE
non I-GENE
- I-GENE
B I-GENE
( O
non I-GENE
- I-GENE
A I-GENE
, I-GENE
non I-GENE
- I-GENE
B I-GENE
RARE I-GENE
and I-GENE
antibody I-GENE
, O
anti I-GENE
non I-GENE
- I-GENE
A I-GENE
non I-GENE
- I-GENE
RARE I-GENE
in O
the O
serum O
, O
non I-GENE
- I-GENE
A I-GENE
, I-GENE
non I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
in O
the O
liver O
). O

RARE O
of O
male O
and O
female O
RARE O
NUM O
rats O
, O
NUM O
mice O
, O
and O
RARE O
RARE O
pigs O
were O
exposed O
once O
RARE O
6 O
hr O
to O
mean O
concentrations O
of O
10 O
. O
5 O
, O
5 O
. O
4 O
, O
2 O
. O
4 O
, O
1 O
. O
NUM O
, O
or O
NUM O
( O
control O
) O
ppm O
of O
RARE O
RARE O
( O
ALL_CAP O
) O
RARE O
. O

RARE O
study O
and O
RARE O
biopsy O
revealed O
remarkable O
degeneration O
of O
myocardium O
. O

RARE O
of O
the O
fracture O
in O
a O
RARE O
and O
RARE O
RARE O
was O
RARE O
effective O
RARE O
more O
RARE O
methods O
. O

Comparison O
of O
patients O
receiving O
phenytoin O
and O
those O
who O
were O
not O
showed O
significantly O
lower O
serum O
RARE O
in O
the O
sub O
- O
group O
receiving O
phenytoin O
, O
but O
there O
was O
RARE O
significant O
difference O
between O
the O
sub O
- O
groups O
with O
respect O
to O
vitamin O
NUM O
or O
behaviour O
problem O
rating O
. O

Effects O
of O
a O
low O
- O
energy O
laser O
beam O
on O
the O
cells O
of O
the O
RARE O
RARE O

RARE O
and O
atypical O
clinical O
features O
of O
this O
RARE O
RARE O
cyst O
are O
RARE O
. O

The O
role O
of O
RARE O
in O
RARE O
taste O
RARE O
was O
investigated O
in O
a O
series O
of O
4 O
experiments O
. O

RARE O
from O
NUM O
neurological O
patients O
were O
used O
to O
study O
the O
diagnostic O
value O
of O
acid I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
glycoprotein I-GENE
in O
the O
lumbar O
RARE O
RARE O
. O

RARE O
experiments O
measured O
ALL_CAP O
and O
NUM O
uptake O
in O
NUM O
- O
10 O
cells O
in O
vitro O
1 O
and O
2 O
days O
following O
20 O
Gy O
irradiation O
to O
assess O
whether O
this O
radiation O
dose O
RARE O
the O
capacity O
of O
tumor O
cells O
to O
RARE O
ALL_CAP O
or O
RARE O
RARE O

For O
patients O
with O
recurrent O
or O
metastatic O
RARE O
, O
the O
data O
suggest O
that O
I O
- O
NUM O
ALL_CAP O
scintigraphy O
is O
the O
examination O
of O
choice O
. O

ALL_CAP O
. O

Comparison O
of O
the O
amino O
acid O
sequence O
of O
the O
M I-GENE
RNA I-GENE
product I-GENE
of I-GENE
RARE I-GENE
virus I-GENE
with O
that O
of O
RARE O
RARE O
and O
RARE O
RARE O
fever O
viruses O
showed O
in O
both O
cases O
a O
weak O
homology O
that O
was O
more O
pronounced O
RARE O
the O
proteins O
RARE O
RARE O
the O
ALL_CAP O
- O
terminal O
end O
of O
the O
precursor O
. O

RARE O
treatment O
RARE O
RARE O
RARE O
. O

In O
addition O
, O
on O
the O
RARE O
' O
s O
RARE O
scale O
, O
RARE O
mothers O
were O
found O
to O
view O
their O
infants O
RARE O
more O
passive O
and O
dependent O
than O
American O
mothers O
did O
( O
P O
less O
than O
NUM O
. O
00 O
). O

A O
preoperative O
RARE O
RARE O
RARE O
pediatric O
patients O
. O

RARE O

We O
conclude O
that O
RARE O
mono O
- O
RARE O
RARE O
in O
which O
there O
is O
only O
one O
choice O
of O
RARE O
sites O
, O
most O
of O
the O
RARE O
sequences O
are O
not O
RARE O
involved O
in O
the O
RARE O
process O
. O

ALL_CAP O
- O
RARE O
RARE O
lesions O
. O

RARE O
vivo O
MAO I-GENE
inhibition O
data O
indicated O
ALL_CAP O
to O
be O
an O
inhibitor O
of O
MAO I-GENE
- I-GENE
B I-GENE
, O
although O
the O
effect O
was O
much O
RARE O
than O
seen O
with O
RARE O
or O
RARE O
. O

Thus O
in O
this O
region O
of O
the O
vessel O
RARE O
represents O
the O
major O
RARE O
RARE O
of O
RARE I-GENE
. O

A O
RARE O
, O
RARE O
tissue O
- O
distribution O
study O
is O
warranted O
to O
elucidate O
the O
complicated O
metabolic O
fate O
of O
RARE O
. O

RARE O
lupus O
erythematosus O
was O
diagnosed O
. O

In O
the O
RARE O
, O
the O
amplitude O
of O
the O
responses O
to O
both O
NUM O
and O
CO2 O
increased O
but O
the O
increase O
in O
CO2 O
sensitivity O
was O
RARE O
more O
important O
. O

The O
statistical O
significance O
of O
the O
prognosis O
factors O
was O
studied O
by O
RARE O
- O
and O
RARE O
methods O
, O
according O
to O
the O
model O
of O
Cox O
, O
with O
the O
help O
of O
an O
ALL_CAP O
computer O
. O

These O
changes O
RARE O
the O
site O
of O
injection O
consist O
of O
a O
RARE O
abnormality O
characterized O
by O
a O
slight O
increase O
in O
signal O
intensity O
on O
NUM O
weighted O
images O
and O
markedly O
increased O
signal O
intensity O
on O
NUM O
weighted O
images O
. O

These O
results O
suggest O
that O
less O
RARE O
activity O
of O
ALL_CAP O
in O
this O
neuroleptic O
test O
might O
be O
explained O
by O
the O
lesser O
conversion O
of O
ALL_CAP O
to O
ALL_CAP O
. O

The O
purpose O
of O
this O
study O
is O
twofold O
: O
( O
1 O
) O
to O
present O
a O
parallel O
form O
of O
the O
RARE O
RARE O
Scale O
( O
ALL_CAP O
, O
RARE O
1 O
); O
( O
2 O
) O
to O
study O
test O
- O
RARE O
RARE O
of O
RARE O
RARE O
. O

RARE O
were O
recovered O
from O
the O
RARE O
RARE O
several O
weeks O
, O
and O
persistent O
RARE O
and O
RARE O
infection O
also O
resulted O
from O
the O
ocular O
infection O
in O
some O
cats O
. O

In O
vivo O
RARE O
microscopy O
of O
RARE O
RARE O
lesions O
. O

These O
equilibrium O
solutions O
are O
then O
shown O
to O
arise O
from O
the O
RARE O
of O
a O
particular O
RARE O
RARE O
. O

The O
average O
RARE O
in O
the O
X O
- O
ray O
counts O
of O
the O
constant O
elements O
from O
the O
series O
means O
were O
used O
to O
correct O
the O
recorded O
count O
of O
the O
RARE O
element O
in O
each O
RARE O
. O

RARE O
significant O
effects O
were O
noted O
RARE O
doses O
which O
did O
not O
appear O
to O
be O
RARE O
toxic O
. O

Low O
MAO I-GENE
subjects O
showed O
a O
pattern O
of O
RARE O
scores O
in O
ALL_CAP O
RARE O
, O
ALL_CAP O
RARE O
, O
and O
ALL_CAP O
RARE O
RARE O
and O
RARE O
and O
lower O
scores O
in O
ALL_CAP O
RARE O
, O
in O
line O
with O
RARE O
profiles O
found O
in O
RARE O
, O
RARE O
, O
and O
suicide O
RARE O
who O
also O
RARE O
to O
have O
low O
platelet O
MAO I-GENE
activity O
. O

To O
evaluate O
the O
relative O
accuracy O
of O
continuous O
wave O
( O
ALL_CAP O
) O
and O
high O
pulse O
RARE O
frequency O
( O
ALL_CAP O
) O
Doppler O
RARE O
estimating O
aortic O
RARE O
pressure O
RARE O
, O
Doppler O
examinations O
with O
both O
RARE O
were O
obtained O
in O
87 O
consecutive O
patients O
with O
aortic O
valve O
RARE O
. O

In O
group O
I O
, O
RARE O
, O
delta O
V O
, O
PaO2 O
, O
RARE O
and O
VT O
significantly O
decreased O
whereas O
operating O
pressure O
and O
E O
significantly O
increased O
when O
the O
internal O
diameter O
of O
the O
RARE O
RARE O
was O
RARE O
. O

In O
calves O
receiving O
milk O
- O
substitute O
diets O
containing O
NUM O
- O
260 O
g O
DM O
/ O
kg O
, O
milk O
RARE O
were O
RARE O
by O
RARE O
to O
NUM O
% O
on O
the O
NUM O
day O
that O
calves O
were O
fed O
once O
daily O
instead O
of O
twice O
daily O
. O

RARE O
there O
is O
RARE O
RARE O
that O
elevated O
plasma O
cholesterol O
levels O
should O
be O
lowered O
RARE O
by O
dietary O
modification O
even O
in O
early O
childhood O
, O
beginning O
RARE O
the O
age O
of O
two O
years O
. O

The O
number O
of O
fecal O
pellets O
RARE O
RARE O
RARE O
5 O
to O
6 O
weeks O
old O
( O
NUM O
pellets O
/ O
day O
) O
and O
gradually O
decreased O
, O
thereafter O
( O
2 O
. O
1 O
pellets O
RARE O
NUM O
weeks O
old O
, O
1 O
. O
5 O
pellets O
RARE O
104 O
weeks O
old O
). O

These O
results O
suggest O
that O
N O
- O
RARE O
compounds O
can O
be O
formed O
in O
vivo O
in O
the O
RARE O
bladder O
, O
which O
could O
explain O
the O
association O
between O
RARE O
- O
RARE O
infections O
and O
increased O
risk O
RARE O
bladder O
RARE O
. O

RARE O
nerve O
fiber O
defects O
included O
absence O
or O
RARE O
architecture O
of O
the O
basal O
RARE O
RARE O
and O
RARE O
- O
RARE O
RARE O
. O

The O
histologic O
grade O
RARE O
the O
same O
anatomic O
site O
varied O
among O
hearts O
and O
among O
different O
anatomic O
sites O
in O
the O
same O
RARE O
. O

Serum O
levels O
of O
albumin I-GENE
, O
globulin I-GENE
, O
and O
coagulation I-GENE
protein I-GENE
activity O
were O
measured O
RARE O
, O
RARE O
, O
and O
daily O
RARE O
3 O
days O
; O
RARE O
lymph O
levels O
were O
measured O
on O
Day O
3 O
. O

For O
RARE O
milk O
there O
was O
a O
significant O
correlation O
of O
vitamin O
NUM O
to O
cholesterol O
( O
RARE O
= O
NUM O
. O
NUM O
) O
but O
not O
to O
RARE O
RARE O
or O
RARE O
suggesting O
a O
role O
RARE O
cholesterol O
in O
the O
RARE O
of O
vitamin O
NUM O
into O
RARE O
milk O
. O

RARE O
training O
resulted O
in O
an O
increase O
of O
stiffness O
associated O
with O
a O
decrease O
of O
type O
II O
fibers O
. O

A O
rate O
- O
decreasing O
dose O
of O
RARE O
, O
an O
RARE I-GENE
inhibitor O
, O
was O
studied O
in O
combination O
with O
the O
range O
of O
atropine O
doses O
. O

RARE O
RARE O
RARE O
fitness O
of O
RARE O
with O
diseases O
of O
the O
respiratory O
RARE O
and O
lungs O

RARE O
, O
9 O
- O
12 O
RARE O
1987 O
. O

Two O
new O
RARE I-GENE
RARE O
( O
ALL_CAP O
m O
NUM O
and O
ALL_CAP O
RARE O
NUM O
) O
were O
studied O
in O
volunteers O
and O
type O
II O
RARE O
under O
various O
conditions O
. O

The O
models O
accurately O
localized O
the O
common O
boundaries O
between O
the O
ALL_CAP O
and O
ALL_CAP O
. O

Two O
of O
these O
RARE O
cases O
showed O
RARE O
spread O
without O
RARE O
invasion O
( O
type O
A O
); O
the O
remaining O
four O
cases O
presented O
a O
direct O
extension O
( O
type O
B O
) O
from O
muscle O
- O
invasive O
carcinomas O
of O
the O
bladder O
. O

However O
, O
RARE O
of O
12 O
mm O
or O
more O
from O
a O
RARE O
negative O
result O
indicated O
spread O
of O
infection O
. O

The O
maximum O
amplitude O
of O
evoked O
responses O
in O
the O
cervical O
sympathetic O
trunk O
was O
obtained O
when O
the O
NUM O
RARE O
RARE O
was O
RARE O
and O
decreased O
gradually O
when O
followed O
by O
the O
RARE O
of O
NUM O
, O
NUM O
, O
T4 O
and O
NUM O
RARE O
RARE O
. O

It O
is O
concluded O
that O
RARE O
allergy O
to O
K O
- O
ALL_CAP O
is O
common O
. O

The O
effect O
of O
a O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
antagonist O
, O
RARE O
, O
on O
RARE O
RARE O
muscle O
in O
term O
RARE O
women O
was O
studied O
in O
vitro O
and O
in O
vivo O
( O
in O
hypertensive O
women O
). O

The O
less O
- O
RARE O
RARE O
acid O
- O
containing O
RARE O
species O
showed O
chromatographic O
patterns O
that O
partially O
RARE O
( O
in O
RARE O
times O
) O
the O
patterns O
of O
RARE O
RARE O
, O
N O
. O
RARE O
, O
and O
N O
. O
RARE O
, O
but O
the O
larger O
number O
of O
peaks O
in O
the O
last O
species O
made O
separation O
between O
the O
RARE O
possible O
. O

The O
development O
of O
a O
data O
RARE O
is O
described O
which O
can O
be O
used O
RARE O
common O
reference O
RARE O
ECG O
computer O
programs O
analyzing O
12 O
or O
NUM O
simultaneously O
recorded O
leads O
. O

RARE I-GENE
serum I-GENE
erythropoietin I-GENE
level O
and O
basic O
RARE O
indices O
RARE O
the O
adaptation O
of O
healthy O
newborn O
infants O

NUM O
, O
ALL_CAP O
RARE O
RARE O
: O
an O
unusual O
variant O
of O
RARE O
' O
s O
RARE O
. O

RARE O
of O
the O
tracheal O
muscle O
and O
the O
activity O
of O
stretch O
receptors O
in O
the O
RARE O

The O
selenium O
level O
and O
RARE I-GENE
peroxidase I-GENE
activity O
in O
the O
RARE O
, O
liver O
, O
and O
stomach O
mucosa O
were O
significantly O
RARE O
in O
the O
high O
- O
selenium O
diet O
group O
than O
in O
the O
low O
- O
selenium O
diet O
group O
. O

RARE O
delivery O
and O
consumption O
and O
NUM O
in O
patients O
with O
acute O
RARE O
infarction O
. O

RARE O
of O
this O
sample O
had O
RARE O
ALL_CAP O
visual O
RARE O
similar O
to O
those O
established O
by O
RARE O
et O
al O
. O
in O
a O
laboratory O
setting O
. O

These O
results O
indicate O
that O
the O
effect O
of O
the O
RARE O
of O
RARE O
and O
RARE O
on O
RARE O
NUM O
NUM O
responding O
and O
on O
suppressed O
responding O
are O
RARE O
similar O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

The O
number O
of O
crystalline O
RARE O
is O
less O
in O
the O
advanced O
RARE O
areas O
of O
the O
ALL_CAP O
- O
RARE O
complex O
. O

All O
NUM O
subjects O
were O
given O
RARE O
instruments O
RARE O
measuring O
various O
RARE O
of O
RARE O
and O
anxiety O
: O
RARE O
' O
s O
State O
- O
RARE O
RARE O
RARE O
, O
the O
RARE O
Expression O
Scale O
, O
and O
the O
State O
RARE O
RARE O
Scale O
. O

It O
was O
found O
that O
the O
RARE O
visual O
cortex O
of O
the O
rat O
is O
RARE O
in O
volume O
, O
and O
that O
the O
asymmetry O
RARE O
RARE O
differences O
in O
the O
number O
of O
neurons O
. O

The O
subjects O
received O
a O
single O
500 O
mg O
dose O
of O
RARE O
i O
. O
v O
. O
and O
concentrations O
in O
plasma O
were O
measured O
RARE O
NUM O
minutes O
and O
in O
urine O
RARE O
NUM O
h O
in O
order O
to O
estimate O
the O
production O
of O
metabolites O
. O

Mean O
weighted O
RARE O
RARE O
( O
RARE O
) O
was O
lower O
( O
P O
less O
than O
NUM O
. O
01 O
) O
following O
RARE O
than O
before O
, O
and O
RARE O
resulted O
in O
a O
larger O
( O
P O
less O
than O
NUM O
. O
02 O
) O
RARE O
- O
to O
- O
RARE O
gradient O
. O

RARE O
- O
111 O
RARE O
imaging O
in O
patients O
with O
rheumatoid O
arthritis O
. O

The O
effect O
of O
L O
- O
methionine O
supplementation O
on O
the O
utilization O
of O
a O
RARE O
protein O
isolate O
( O
ALL_CAP O
) O
was O
evaluated O
by O
short O
- O
term O
nitrogen O
balance O
studies O
in O
young O
women O
. O

Primary O
invasive O
Haemophilus O
influenzae O
type O
b O
RARE O
: O
a O
population O
- O
based O
assessment O
of O
risk O
factors O
. O

Overall O
, O
lesions O
RARE O
the O
deep O
RARE O
RARE O
do O
not O
exhibit O
a O
RARE O
frequency O
of O
occurrence O
compared O
to O
lesions O
RARE O
the O
skeletal O
muscle O
; O
however O
, O
carcinomas O
affecting O
other O
oral O
sites O
showed O
a O
RARE O
frequency O
of O
RARE O
RARE O
lesions O
in O
comparison O
to O
more O
superficial O
lesions O
. O

Factors O
that O
showed O
significant O
correlation O
to O
elevated O
ALL_CAP O
' O
s O
in O
the O
highly O
elevated O
portion O
of O
our O
ALL_CAP O
population O
were O
poor O
ALL_CAP O
score O
, O
increased O
patient O
age O
, O
low O
peak O
expiratory O
flow O
rate O
, O
and O
elevated O
RARE O
serum I-GENE
IgG I-GENE
. O

Induction O
of O
both O
RARE O
transcripts O
follows O
heat O
shock O
in O
vivo O
. O

New O
and O
successful O
steps O
have O
been O
made O
in O
RARE O
, O
immunotherapy O
, O
and O
RARE O
of O
RARE O
conditioned O
infertility O
. O

RARE O
was O
the O
most O
stable O
and O
RARE O
was O
the O
least O
stable O
RARE O
under O
the O
conditions O
tested O
. O

This O
may O
explain O
in O
part O
a O
RARE O
trend O
towards O
RARE O
RARE O
RARE O
gestation O
in O
preterm O
infants O
. O

RARE O
RARE O
acid O
N O
absorption O
is O
7 O
- O
8 O
% O
of O
N O
intake O
. O

RARE O
, O
RARE O
, O
chemotactic O
and O
random O
migration O
, O
RARE O
RARE O
RARE O
reduction O
of O
peritoneal O
RARE O
neutrophils O
and O
macrophages O
, O
fibrinogen I-GENE
level O
, O
RARE O
of O
RARE O
fibrin I-GENE
and O
serial O
dilution O
RARE O
RARE O
test O
were O
investigated O
in O
NUM O
New O
RARE O
RARE O
rabbits O
with O
experimentally O
RARE O
RARE O
phenomenon O
in O
the O
colon O
, O
and O
in O
control O
animals O
. O

RARE O
is O
the O
most O
common O
cause O
of O
allergic O
RARE O
dermatitis O
in O
RARE O
, O
resulting O
in O
positive O
reactions O
in O
patch O
tests O
between O
7 O
and O
14 O
%. O

The O
ALL_CAP O
levels O
were O
not O
affected O
( O
P O
greater O
than O
. O
1 O
) O
by O
RARE O
interval O
. O

He O
RARE O
our O
hospital O
and O
RARE O
RARE O
RARE O
cyst O
was O
suspected O
. O

However O
, O
further O
analyses O
of O
the O
data O
indicate O
that O
increasing O
VO2 O
AT O
( O
RARE O
= O
- O
NUM O
. O
NUM O
, O
P O
less O
than O
NUM O
. O
05 O
) O
rather O
than O
NUM O
( O
RARE O
= O
- O
NUM O
. O
NUM O
) O
could O
result O
in O
RARE O
the O
10 O
, O
NUM O
m O
RARE O
performance O
to O
a O
larger O
extent O
, O
and O
that O
the O
absolute O
amount O
of O
change O
( O
delta O
) O
in O
the O
10 O
, O
NUM O
m O
run O
time O
is O
best O
RARE O
RARE O
by O
a O
combination O
of O
delta O
VO2 O
AT O
and O
delta O
5 O
, O
NUM O
m O
run O
time O
. O

A O
significant O
herd O
X O
period O
interaction O
existed O
RARE O
liver O
TG O
and O
serum O
RARE O
RARE O
cholesterol O
concentrations O
. O

Liver O
TG O
and O
serum O
ALL_CAP O
concentrations O
were O
positively O
correlated O
. O

The O
results O
show O
that O
nerve O
and O
roots O
differ O
considerably O
both O
in O
the O
force O
they O
RARE O
before O
failure O
and O
in O
the O
other O
RARE O
they O
exhibit O
. O

When O
the O
coronary O
sinus O
pressure O
reached O
NUM O
torr O
, O
there O
was O
a O
significant O
decrease O
in O
cardiac O
index O
( O
3 O
. O
NUM O
+/- O
NUM O
. O
5 O
to O
2 O
. O
70 O
+/- O
NUM O
. O
6 O
L O
/ O
min O
/ O
m2 O
, O
p O
less O
than O
NUM O
. O
001 O
RARE O
coronary O
RARE O
flow O
( O
NUM O
. O
7 O
+/- O
3 O
. O
1 O
to O
7 O
. O
NUM O
+/- O
2 O
. O
1 O
ml O
/ O
min O
, O
p O
less O
than O
NUM O
. O
001 O
RARE O
rate O
of O
rise O
of O
RARE O
ventricular O
pressure O
( O
1 O
, O
NUM O
+/- O
NUM O
to O
1 O
, O
NUM O
+/- O
NUM O
, O
p O
less O
than O
NUM O
. O
05 O
RARE O
and O
an O
increase O
in O
coronary O
RARE O
difference O
( O
NUM O
. O
8 O
% O
+/- O
9 O
. O
3 O
% O
to O
70 O
. O
5 O
% O
+/- O
5 O
. O
4 O
% O
saturation O
, O
p O
less O
than O
NUM O
. O
03 O
). O

RARE O
in O
the O
RARE O
aorta O
RARE O
the O
level O
of O
the O
NUM O
and O
the O
NUM O
RARE O
RARE O
in O
NUM O
men O
and O
NUM O
women O
were O
studied O
using O
computed O
tomography O
. O

In O
a O
series O
of O
NUM O
consecutive O
RARE O
, O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
were O
found O
in O
NUM O
individuals O
above O
40 O
years O
of O
age O
. O

Approximately O
NUM O
% O
of O
cell O
RARE O
of O
RARE O
neurons O
RARE O
the O
RARE O
and O
RARE O
RARE O
through O
the O
inferior O
alveolar O
, O
RARE O
, O
mental O
, O
and O
RARE O
nerves O
were O
in O
the O
range O
between O
NUM O
and O
600 O
micron O
2 O
in O
cross O
- O
sectional O
area O
: O
mean O
+/- O
SD O
NUM O
+/- O
NUM O
micron O
2 O
, O
NUM O
+/- O
NUM O
micron O
2 O
, O
NUM O
+/- O
NUM O
micron O
2 O
, O
and O
NUM O
+/- O
NUM O
micron O
2 O
, O
respectively O
. O

RARE O
action O
of O
RARE O
( O
RARE O
- O
1 O
, O
4 O
- O
dimethyl O
- O
10 O
- O
hydroxy O
- O
2 O
, O
3 O
, O
4 O
, O
5 O
, O
6 O
, O
7 O
- O
RARE O
- O
1 O
, O
6 O
- O
RARE O
- O
NUM O
- O
4 O
- O
RARE O
RARE O
). O

On O
transition O
from O
high O
to O
low O
voltage O
there O
was O
a O
significant O
fall O
in O
arterial O
pressure O
( O
7 O
%) O
and O
an O
increase O
in O
flow O
( O
19 O
- O
38 O
%) O
to O
areas O
of O
the O
brain O
corresponding O
to O
the O
RARE O
of O
the O
RARE O
formation O
, O
i O
. O
RARE O
. O
excluding O
the O
RARE O
and O
RARE O
. O

RARE O
of O
positive O
potentials O
showed O
that O
NUM O
RARE O
in O
the O
area O
of O
ventral O
gray O
matter O
through O
the O
RARE O
- O
lateral O
column O
and O
N2 O
through O
the O
dorsal O
column O
. O

One O
hundred O
and O
four O
( O
14 O
per O
cent O
) O
second O
RARE O
tumours O
were O
reported O
. O

RARE O
of O
RARE O
RARE O
under O
these O
experimental O
conditions O
are O
discussed O
. O

There O
have O
been O
five O
problems O
( O
RARE O
2 O
, O
suspected O
sepsis O
1 O
, O
and O
RARE O
2 O
) O
RARE O
a O
RARE O
of O
2 O
, O
NUM O
days O
of O
exposure O
. O

It O
is O
suggested O
that O
these O
results O
may O
RARE O
the O
RARE O
possibility O
of O
providing O
a O
means O
of O
identifying O
greater O
or O
lesser O
RARE O
to O
the O
coronary O
effects O
of O
RARE O
A O
behavior O
. O

Two O
studies O
assessed O
two O
RARE O
of O
reliability O
of O
the O
RARE O
RARE O
RARE O
RARE O
( O
ALL_CAP O
; O
a O
questionnaire O
measure O
of O
RARE O
A O
behavior O
). O

RARE O
patients O
are O
RARE O
toward O
developing O
RARE O
bacterial O
infections O
. O

When O
RARE O
was O
administered O
alone O
, O
overall O
response O
rate O
decreased O
and O
percent O
RARE O
increased O
with O
increasing O
doses O
. O

RARE O
and O
RARE O
RARE O
wrist O
joint O
RARE O

Study O
of O
the O
energy O
metabolism O
of O
the O
RARE O
cortex O
and O
hippocampus O
by O
the O
( O
14C O
) O
2 O
- O
RARE O
method O
RARE O
the O
development O
of O
RARE O
states O

RARE O
lymphoma O
is O
very O
RARE O
in O
terms O
of O
its O
biological O
behavior O
. O

Further O
investigations O
are O
necessary O
to O
elucidate O
the O
biochemical O
and O
physiological O
properties O
of O
ALL_CAP O
. O

Among O
them O
, O
NUM O
cases O
were O
benign O
and O
NUM O
malignant O
. O

Of O
the O
cases O
with O
ALL_CAP O
, O
50 O
% O
had O
associated O
RARE O
cysts O
and O
10 O
% O
of O
the O
cases O
with O
ALL_CAP O
had O
associated O
liver O
cysts O
. O

RARE O
goal O
- O
directed O
RARE O
movements O
of O
the O
human O
upper O
RARE O
are O
known O
to O
be O
associated O
with O
three O
distinct O
RARE O
of O
EMG O
activity O
in O
antagonistic O
muscles O
. O

The O
combination O
of O
NUM O
and O
F2 O
which O
was O
the O
best O
predictor O
of O
ALL_CAP O
in O
this O
population O
( O
G1 O
) O
might O
be O
interpreted O
RARE O
reflecting O
trunk O
RARE O
mainly O
abdominal O
. O

Renal O
clearance O
fell O
from O
19 O
. O
NUM O
+/- O
4 O
. O
9 O
ml O
/ O
min O
/ O
1 O
. O
NUM O
m2 O
( O
group O
I O
) O
to O
1 O
. O
NUM O
+/- O
NUM O
. O
4 O
ml O
/ O
min O
/ O
1 O
. O
NUM O
m2 O
( O
group O
IV O
). O

The O
relations O
between O
type O
A O
behavior O
, O
clinically O
relevant O
behavior O
, O
RARE O
RARE O
, O
and O
ALL_CAP O
in O
children O
. O

The O
rats O
were O
used O
RARE O
the O
study O
of O
the O
effects O
of O
sepsis O
on O
the O
utilization O
of O
RARE O
fat O
RARE O
. O

RARE O
also O
had O
slight O
RARE O
of O
the O
upper O
RARE O
. O

Results O
of O
electron O
therapy O
of O
tumors O
in O
different O
sites O

The O
mechanism O
of O
action O
is O
explored O
in O
some O
detail O
, O
specifically O
RARE O
it O
RARE O
to O
RARE O
RARE O
( O
ALL_CAP O
) O
Fc I-GENE
receptor I-GENE
blockade O
and O
suppression O
of O
RARE O
antibody O
RARE O
. O

RARE O
of O
RARE O
stroke O
, O
RARE O
infarction O
, O
angina O
pectoris O
RARE O
RARE O
ventricular O
hypertrophy O
could O
also O
be O
lowered O
. O

RARE O
RARE O
RARE O
values O
with O
small O
standard O
RARE O
were O
observed O
in O
normal O
LV O
( O
NUM O
. O
NUM O
+/- O
NUM O
. O
NUM O
) O
and O
in O
non O
- O
MI O
regions O
( O
NUM O
. O
NUM O
+/- O
NUM O
. O
NUM O
RARE O
indicating O
temporally O
RARE O
RARE O
shortening O
. O

These O
results O
indicate O
that O
RARE O
RARE O
there O
are O
increases O
in O
bone O
formation O
rates O
RARE O
to O
the O
increases O
in O
skeletal O
mass O
. O

We O
analyzed O
data O
from O
NUM O
patients O
with O
RARE O
RARE O
RARE O
( O
SLE O
) O
in O
whom O
RARE O
biopsies O
were O
done O
systematically O
. O

The O
possibility O
of O
a O
RARE O
disorder O
leading O
to O
a O
minor O
defect O
in O
elastic O
fibre O
RARE O
which O
could O
be O
responsible O
RARE O
the O
spontaneous O
lesions O
is O
discussed O
. O

Prevention O
by O
a O
RARE O
- O
antithrombin I-GENE
III I-GENE
combination O

N O
- O
RARE O
RARE O
were O
tested O
RARE O
RARE O
RARE O
RARE O
gas O
chromatographic O
analysis O
. O

MICs O
of O
four O
RARE O
agents O
( O
5 O
- O
RARE O
, O
RARE O
, O
RARE O
, O
and O
amphotericin O
B O
) O
RARE O
NUM O
clinical O
isolates O
of O
various O
RARE O
species O
were O
then O
determined O
with O
both O
media O
in O
agar O
dilution O
and O
RARE O
RARE O
dilution O
RARE O
. O

There O
were O
18 O
patients O
with O
Group O
II O
( O
a O
) O
tumors O
; O
although O
tumor O
biopsy O
was O
RARE O
on O
eight O
of O
these O
, O
pathological O
diagnosis O
RARE O
the O
time O
of O
surgery O
was O
made O
in O
only O
one O
case O
. O

Evidence O
that O
RARE O
RARE O
is O
in O
part O
an O
immune O
response O
. O

RARE O
post O
- O
RARE O
examination O
of O
all O
seropositive O
animals O
showed O
five O
and O
RARE O
false O
- O
positive O
animals O
when O
E I-GENE
/ I-GENE
S I-GENE
and I-GENE
ALL_CAP I-GENE
antigens I-GENE
were O
used O
, O
respectively O
. O

RARE O
RARE O
hypertension O
has O
been O
regarded O
RARE O
independent O
of O
RARE O
( O
RARE O
RARE O
in O
contrast O
to O
RARE O
RARE O
hypertension O
, O
which O
is O
RARE O
RARE O
dependent O
. O

RARE O
of O
them O
were O
on O
treatment O
with O
systemic O
steroids O
. O

RARE O
of O
its O
use O
in O
the O
intensive O
therapy O
unit O
are O
described O
. O

The O
growing O
drug O
problem O
is O
also O
reflected O
in O
the O
increasing O
number O
of O
cases O
of O
hepatitis O
B O
and O
of O
drug O
- O
related O
deaths O
. O

Only O
RARE O
patients O
, O
five O
of O
whom O
have O
metastatic O
RARE O
, O
RARE O
more O
than O
10 O
years O
after O
RARE O
presentation O
; O
nine O
patients O
, O
one O
of O
whom O
has O
RARE O
, O
RARE O
RARE O
5 O
years O
or O
less O
. O

Although O
differences O
were O
not O
significant O
, O
infants O
in O
the O
experimental O
group O
had O
more O
changes O
in O
the O
intermittent O
RARE O
ventilation O
( O
ALL_CAP O
) O
RARE O
RARE O
RARE O
, O
and O
more O
such O
infants O
RARE O
RARE O
the O
receiving O
hospital O
with O
acceptable O
pH O
and O
PCO2 O
values O
. O

RARE O
sequences O
are O
present O
in O
RARE O
least O
three O
RARE O
of O
the O
cytochrome I-GENE
P I-GENE
- I-GENE
NUM I-GENE
gene I-GENE
, O
but O
not O
in O
exons O
or O
the O
5 O
'- O
flanking O
region O
. O

A O
large O
increase O
of O
serum O
RARE O
occurred O
under O
all O
conditions O
, O
and O
the O
exercise O
respiratory O
RARE O
suggested O
some O
increase O
of O
fat O
utilization O
, O
ALL_CAP O
( O
NUM O
. O
NUM O
) O
through O
ALL_CAP O
( O
NUM O
. O
NUM O
) O
to O
ALL_CAP O
( O
NUM O
. O
NUM O
). O

This O
lack O
of O
correlation O
may O
be O
due O
to O
variations O
in O
the O
metabolic O
activity O
of O
the O
RARE O
implants O
present O
RARE O
different O
stages O
of O
the O
RARE O
. O

RARE O
adaptation O
to O
chronic O
RARE O
in O
newborn O
rats O
. O

RARE O
1 O
is O
either O
21 O
- O
O O
- O
RARE O
, O
NUM O
- O
O O
- O
RARE O
NUM O
- O
RARE O
, O
or O
21 O
- O
O O
- O
RARE O
, O
NUM O
- O
O O
- O
RARE O
NUM O
- O
RARE O
. O

Human O
and O
RARE I-GENE
hamster I-GENE
NUM I-GENE
protein I-GENE
sequences I-GENE
deduced O
from O
the O
cDNAs O
are O
identical O
. O

NUM I-GENE
RARE O
3 O
and O
4 O
both O
contain O
Alu I-GENE
sequences O
. O

One O
of O
the O
most O
relevant O
aspects O
in O
RARE O
the O
consistent O
survival O
of O
an O
RARE O
undergoing O
the O
experimental O
implantation O
of O
a O
RARE O
artificial O
RARE O
is O
RARE O
related O
to O
the O
correct O
anatomic O
placement O
of O
RARE O
ventricles O
RARE O
the O
chest O
. O

An O
RARE O
tissue O
response O
adjacent O
to O
the O
RARE O
site O
suggested O
a O
RARE O
toxic O
chemical O
or O
thermal O
reaction O
, O
or O
both O
, O
to O
the O
tissue O
adhesive O
, O
but O
there O
was O
RARE O
evidence O
of O
any O
distant O
ocular O
effects O
. O

These O
findings O
suggest O
that O
there O
may O
be O
a O
relationship O
between O
the O
pathogenesis O
of O
ALL_CAP O
, O
RARE O
, O
and O
ALL_CAP O
. O

Among O
82 O
superficial O
lesions O
NUM O
were O
classified O
RARE O
showing O
ALL_CAP O
and O
another O
NUM O
RARE O
showing O
PR O
, O
with O
a O
response O
rate O
of O
NUM O
. O
5 O
%. O

Under O
the O
same O
hematocrit O
and O
flow O
conditions O
, O
the O
rate O
of O
oxygen O
saturation O
decrease O
was O
significantly O
RARE O
RARE O
the O
RARE O
cells O
than O
RARE O
normal O
cells O
. O

While O
the O
RARE O
observed O
the O
RARE O
of O
the O
eye O
with O
indirect O
RARE O
, O
the O
point O
source O
of O
light O
from O
the O
RARE O
light O
RARE O
was O
RARE O
along O
the O
RARE O
of O
the O
RARE O
plaque O
. O

These O
fusion O
proteins O
also O
allowed O
the O
RARE O
of O
the O
transcriptional O
activation O
and O
DNA O
binding O
domains O
of O
the O
ALL_CAP I-GENE
protein I-GENE
to O
its O
RARE O
RARE O
N O
- O
terminal O
portion O
. O

From O
life O
- O
RARE O
analyses O
of O
these O
patients O
, O
we O
estimated O
that O
the O
incidence O
of O
secondary O
RARE O
in O
patients O
who O
have O
RARE O
RARE O
is O
about O
NUM O
per O
cent O
RARE O
the O
age O
of O
RARE O
years O
, O
and O
that O
malignant O
degeneration O
is O
almost O
a O
RARE O
in O
patients O
who O
have O
RARE O
RARE O
. O

The O
lethal O
toxicity O
of O
inorganic O
( O
NUM O
) O
and O
organic O
( O
NUM O
) O
RARE O
RARE O
was O
compared O
RARE O
RARE O
( O
Japanese O
RARE O
, O
RARE O
RARE O
) O
of O
different O
ages O
from O
RARE O
through O
RARE O
by O
single O
- O
dose O
acute O
oral O
and O
RARE O
injections O
and O
by O
a O
5 O
- O
d O
dietary O
trial O
. O

Since O
the O
integrated O
NUM O
- O
NUM O
plasma O
cortisol O
estimation O
is O
RARE O
and O
RARE O
than O
the O
mean O
NUM O
- O
NUM O
plasma O
cortisol O
estimation O
, O
we O
RARE O
it O
RARE O
an O
RARE O
in O
the O
diagnosis O
of O
RARE O
' O
s O
RARE O
. O

Most O
of O
the O
patients O
had O
locally O
advanced O
lesions O
( O
NUM O
NUM O
- O
4 O
: O
91 O
. O
5 O
%) O
according O
to O
the O
adopted O
ALL_CAP O
RARE O
( O
RARE O
- O
RARE O
, O
RARE O
- O
RARE O
). O

The O
risk O
RARE O
these O
complications O
is O
increased O
by O
the O
following O
factors O
: O
multiple O
gestation O
, O
the O
combination O
of O
magnesium O
RARE O
and O
beta O
- O
adrenergic O
agonist O
, O
and O
the O
use O
of O
RARE O
- O
steroids O
to O
RARE O
RARE O
pulmonary O
RARE O
. O

RARE O
and O
RARE I-GENE
RARE O
low O
grade O
non O
- O
Hodgkin O
' O
s O
lymphoma O
. O

RARE O
RARE O
1 O
ppm O
) O
and O
E O
( O
50 O
IU O
/ O
kg O
) O
supplementation O
of O
the O
diet O
of O
the O
RARE O
increased O
plasma O
RARE O
and O
RARE O
concentrations O
, O
but O
did O
not O
increase O
plasma I-GENE
RARE I-GENE
peroxidase I-GENE
( O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
) O
activity O
. O

RARE O
RARE O
A O
behavior O
was O
positively O
associated O
with O
diastolic O
RARE O
pressure O
( O
RARE O
= O
NUM O
. O
NUM O
, O
p O
less O
than O
NUM O
. O
05 O
) O
among O
the O
women O
. O

The O
in O
vitro O
RARE O
potency O
is O
greatest O
when O
the O
1 O
- O
RARE O
is O
2 O
, O
4 O
- O
RARE O
and O
the O
7 O
- O
RARE O
is O
a O
3 O
- O
amino O
- O
1 O
- O
RARE O
group O
. O

The O
M I-GENE
reading I-GENE
frame I-GENE
differed O
from O
the O
reported O
sequence O
by O
a O
single O
nucleotide O
corresponding O
to O
a O
conservative O
RARE O
to O
RARE O
amino O
acid O
substitution O
near O
the O
RARE O
- O
terminus O
RARE O
among O
the O
M I-GENE
proteins I-GENE
of O
RARE O
. O

An O
ion O
chromatographic O
method O
was O
used O
to O
determine O
Br O
ion O
in O
the O
urine O
of O
RARE O
. O

II O
. O

RARE O
changes O
following O
RARE O
RARE O
in O
adults O
. O

RARE O
of O
human O
RARE O
contractile O
activity O
RARE O
affected O
by O
RARE O
serum O

RARE O
of O
a O
RARE O
segment O
with O
valve O
in O
the O
treatment O
of O
deep O
RARE O
RARE O
insufficiency O
of O
the O
lower O
RARE O

The O
relationships O
among O
four O
RARE O
of O
RARE O
increase O
: O
RARE O
threshold O
( O
ALL_CAP O
) O
( O
the O
VO2 O
RARE O
which O
RARE O
RARE O
concentration O
begins O
to O
increase O
above O
the O
resting O
level O
RARE O
an O
RARE O
exercise O
test O
RARE O
NUM O
( O
the O
VO2 O
RARE O
which O
RARE O
RARE O
increases O
1 O
mM O
above O
the O
resting O
level O
RARE O
NUM O
( O
the O
VO2 O
RARE O
which O
RARE O
RARE O
concentration O
RARE O
a O
fixed O
value O
of O
2 O
mM O
RARE O
onset O
of O
RARE O
RARE O
accumulation O
( O
ALL_CAP O
; O
the O
VO2 O
RARE O
which O
RARE O
RARE O
RARE O
a O
concentration O
of O
4 O
mM O
RARE O
were O
compared O
with O
aerobic O
capacity O
( O
NUM O
) O
and O
12 O
min O
RARE O
performance O
in O
19 O
RARE O
female O
students O
. O

This O
is O
based O
on O
RARE O
an O
underlying O
multivariate O
normal O
distribution O
. O

The O
observation O
of O
RARE O
effects O
after O
RARE O
or O
after O
space O
RARE O
show O
the O
RARE O
RARE O
in O
assessing O
RARE O
RARE O
RARE O
long O
duration O
space O
RARE O
. O

RARE O
use O
and O
interpretation O
of O
viral O
hepatitis O
B O
markers O
and O
RARE O
biopsy O
in O
HBs I-GENE
RARE I-GENE
carriers O
and O
RARE O
the O
chronic O
hepatitis O
RARE O

The O
1 O
, O
2 O
, O
3 O
and O
4 O
year O
survival O
rates O
were O
94 O
%, O
NUM O
%, O
NUM O
% O
and O
NUM O
%, O
respectively O
. O

Inhibition O
of O
RARE O
- O
RARE O
RARE O
RARE O
by O
40 O
NUM O
ALL_CAP O
, O
a O
new O
long O
- O
acting O
RARE O
RARE O
agent O
. O

Five O
- O
year O
prospective O
study O
of O
peripheral O
RARE O
RARE O
cells O
in O
infectious O
RARE O
. O

Northern O
blotting O
with O
a O
unique O
NUM O
- O
RARE O
RARE O
demonstrated O
the O
absence O
of O
the O
mutant O
sequence O
in O
the O
mRNA O
from O
which O
the O
cDNA O
library O
giving O
rise O
to O
the O
mutant O
cDNA O
was O
constructed O
. O

RARE O
RARE O
RARE O
encoding O
highly O
RARE O
peptide O
sequences O
. O

RARE O
of O
RARE O
breast O
RARE O

In O
recent O
years O
, O
successful O
physiological O
models O
have O
been O
developed O
RARE O
a O
variety O
of O
volatile O
and O
RARE O
RARE O
, O
and O
their O
ability O
to O
perform O
the O
RARE O
needed O
in O
risk O
assessment O
has O
been O
demonstrated O
. O

RARE O
RARE O
is O
used O
below O
the O
experimental O
data O
range O
to O
establish O
an O
upper O
RARE O
on O
RARE O
risk O
RARE O
low O
doses O
. O

RARE O
RARE O
who O
has O
RARE O
RARE O
a O
psychiatric O
RARE O
in O
RARE O
RARE O
the O
past O
20 O
years O

Deletion O
mapping O
studies O
revealed O
that O
the O
upstream O
DNA O
sequences O
RARE O
to O
- O
NUM O
were O
sufficient O
RARE O
the O
optimal O
basal O
level O
transcription O
in O
HeLa O
cells O
and O
also O
RARE O
the O
ALL_CAP I-GENE
- O
RARE O
transcription O
. O

RARE O
of O
the O
RARE O
antibiotic O
amphotericin O
B O
( O
ALL_CAP O
) O
in O
liposomes O
results O
in O
a O
marked O
reduction O
in O
drug O
toxicity O
with O
RARE O
RARE O
of O
RARE O
potency O
. O

RARE O
healthy O
, O
RARE O
males O
undergoing O
routine O
RARE O
dental O
care O
were O
evaluated O
RARE O
treatment O
RARE O
possible O
hemodynamic O
alterations O
in O
response O
to O
RARE O
sympathetic O
nervous O
RARE O
RARE O
. O

Serum I-GENE
IgM I-GENE
and O
IgE I-GENE
concentrations O
, O
RARE I-GENE
- I-GENE
specific I-GENE
IgE I-GENE
scores O
, O
and O
the O
tumor O
NUM I-GENE
status O
were O
combined O
to O
construct O
a O
three O
- O
level O
risk O
classification O
that O
was O
more O
prognostic O
than O
any O
of O
the O
individual O
RARE O
. O

The O
M O
- O
3 O
RARE O
was O
an O
adverse O
prognostic O
factor O
. O

Within O
the O
RARE O
. O
RARE O
group O
there O
was O
a O
highly O
- O
significant O
difference O
between O
RARE O
. O
RARE O
/ O
RARE O
. O
RARE O
( O
p O
less O
than O
NUM O
. O
01 O
) O
with O
respect O
to O
mean O
RARE O
size O
. O

These O
results O
indicate O
that O
T O
. O
C O
., O
LDL I-GENE
- I-GENE
C I-GENE
., O
ALL_CAP I-GENE
- I-GENE
C I-GENE
., O
HDL2 I-GENE
- I-GENE
C I-GENE
., O
RARE I-GENE
B I-GENE
, O
RARE I-GENE
A I-GENE
- I-GENE
I I-GENE
/ I-GENE
B I-GENE
ratio O
and O
RARE I-GENE
A I-GENE
- I-GENE
II I-GENE
/ I-GENE
B I-GENE
ratio O
are O
predictive O
risk O
factors O
of O
the O
coronary O
RARE O
RARE O
. O

It O
is O
concluded O
that O
the O
unique O
RARE O
formulation O
of O
ALL_CAP O
- O
S O
is O
useful O
in O
the O
treatment O
of O
infections O
in O
children O
with O
heavy O
RARE O
disorders O
and O
in O
children O
who O
cannot O
take O
oral O
drugs O
because O
of O
severe O
RARE O
. O

In O
addition O
, O
marked O
hypertension O
accompanied O
this O
disorder O
and O
all O
abnormalities O
, O
including O
the O
hypertension O
, O
responded O
to O
1 I-GENE
- I-GENE
RARE I-GENE
- I-GENE
8 I-GENE
- I-GENE
D I-GENE
- I-GENE
RARE I-GENE
vasopressin I-GENE
therapy O
. O

RARE O
photon O
emission O
computerized O
tomography O
( O
SPECT O
RARE O
by O
providing O
three O
- O
dimensional O
RARE O
of O
RARE O
Tl O
- O
NUM O
, O
offers O
RARE O
RARE O
improved O
RARE O
of O
ALL_CAP O
. O

RARE O
RARE O
mapping O
in O
quantitative O
analysis O
of O
cerebral O
RARE O
emission O
RARE O
. O

In O
19 O
patients O
vagotomy O
not O
only O
RARE O
the O
bleeding O
but O
provided O
definitive O
therapy O
( O
RARE O
I O
- O
II O
); O
4 O
patients O
died O
( O
mortality O
rate O
16 O
%). O

RARE O
of O
a O
successful O
intrauterine O
fertilization O
with O
delivery O
of O
a O
term O
RARE O
supports O
the O
RARE O
feasibility O
of O
the O
ALL_CAP O
; O
however O
, O
RARE O
RARE O
by O
our O
procedure O
appears O
to O
be O
the O
major O
RARE O
. O

MRI O
RARE O
one O
or O
more O
of O
the O
following O
abnormalities O
in O
NUM O
( O
NUM O
%) O
of O
38 O
treated O
kidneys O
: O
( O
1 O
) O
RARE O
of O
RARE O
differentiation O
, O
( O
2 O
) O
RARE O
RARE O
, O
( O
3 O
) O
RARE O
RARE O
, O
( O
4 O
) O
hemorrhage O
into O
a O
RARE O
cyst O
, O
and O
( O
5 O
) O
RARE O
abnormalities O
. O

The O
results O
obtained O
are O
similar O
to O
those O
described O
with O
the O
previous O
RARE O
formulation O
although O
greater O
variability O
in O
induction O
and O
recovery O
times O
was O
noted O
with O
the O
RARE O
formulation O
. O

The O
percentage O
ALL_CAP O
reduction O
RARE O
the O
end O
of O
CPB O
showed O
significant O
correlation O
with O
1 O
) O
CPB O
duration O
( O
RARE O
= O
NUM O
. O
NUM O
RARE O
2 O
) O
oxygen O
flow O
rate O
index O
( O
ALL_CAP O
RARE O
i O
. O
RARE O
. O
flow O
/ O
min O
in O
the O
RARE O
RARE O
/ O
m2 O
RARE O
( O
RARE O
= O
NUM O
. O
38 O
RARE O
and O
3 O
) O
RARE O
flow O
rate O
index O
( O
ALL_CAP O
RARE O
i O
. O
RARE O
. O
average O
volume O
of O
RARE O
RARE O
through O
the O
RARE O
- O
RARE O
machine O
/ O
min O
CPB O
time O
/ O
m2 O
RARE O
( O
RARE O
= O
NUM O
. O
NUM O
). O

Diagnosis O
of O
unilateral O
RARE O
artery O
lesions O
after O
captopril O
administration O
. O

A O
yeast O
DNA O
fragment O
carrying O
the O
gene I-GENE
CP I-GENE
NUM I-GENE
encoding O
the O
small O
subunit O
of O
the O
RARE O
RARE O
RARE I-GENE
- I-GENE
phosphate I-GENE
RARE I-GENE
has O
been O
sequenced O
. O

A O
retrospective O
study O
of O
RARE O
RARE O
from O
19 O
cats O
with O
the O
RARE O
granuloma O
complex O
revealed O
that O
NUM O
% O
of O
affected O
cats O
had O
circulating O
antibodies O
to O
RARE O
of O
normal O
RARE O
epithelium O
. O

In O
memory O
of O
RARE O
RARE O

The O
H2 I-GENE
receptor I-GENE
antagonists O
and O
RARE O
cost O
about O
the O
same O
and O
have O
few O
RARE O
effects O
. O

These O
results O
suggest O
that O
RARE O
may O
have O
RARE O
III O
antiarrhythmic O
activity O
. O

A O
high O
efficacy O
of O
the O
combined O
use O
of O
RARE O
doses O
of O
two O
RARE O
: O
RARE O
( O
50 O
mg O
/ O
kg O
) O
and O
RARE O
( O
NUM O
mg O
/ O
kg O
) O
under O
the O
conditions O
of O
short O
- O
term O
RARE O
RARE O
( O
7 O
. O
5 O
% O
NUM O
) O
was O
found O
in O
( O
ALL_CAP O
X O
NUM O
) O
NUM O
mice O
. O

The O
Mean O
was O
NUM O
, O
3 O
+/- O
53 O
, O
6 O
micrograms O
ALL_CAP O
/ O
g O
RARE O
, O
the O
RARE O
NUM O
micrograms O
ALL_CAP O
/ O
g O
RARE O
. O

In O
the O
region O
RARE O
with O
mixed O
RARE O
- O
RARE O
population O
an O
iodine O
deficiency O
I O
was O
found O
in O
NUM O
% O
and O
an O
iodine O
deficiency O
II O
in O
NUM O
%. O

The O
structural O
gene O
RARE O
RARE I-GENE
encodes O
a O
protein O
product O
of O
RARE O
mass O
NUM O
RARE O
. O

RARE O
lymph O
node O
enlargement O
, O
regardless O
of O
cause O
, O
has O
been O
a O
source O
of O
imaging O
RARE O
because O
of O
its O
propensity O
to O
mimic O
pancreatic O
malignancy O
yet O
not O
cause O
biliary O
obstruction O
. O

RARE O
with O
rheumatoid I-GENE
factor I-GENE
was O
only O
observed O
in O
the O
ELISA O
RARE O
if O
RARE O
were O
not O
pretreated O
with O
latex O
RARE O
. O

All O
patients O
had O
elevated O
levels O
of O
serum I-GENE
IgE I-GENE
antibodies I-GENE
to O
the O
crude O
RARE O
RARE O
; O
binding O
values O
ranged O
from O
2 O
. O
3 O
to O
NUM O
. O
1 O
times O
that O
of O
a O
negative O
control O
serum O
. O

New O
techniques O
RARE O
the O
mass O
spectrometry O
of O
RARE O
products O
. O

RARE O
RARE O
RARE O
imaging O
of O
the O
RARE O
using O
NUM O
RARE O
and O
99mTc O
is O
useful O
in O
further O
RARE O
lesions O
that O
are O
identified O
on O
either O
a O
routine O
RARE O
survey O
or O
on O
a O
conventional O
sulfur O
colloid O
liver O
- O
RARE O
image O
. O

Such O
studied O
acquired O
with O
low O
energy O
or O
medium O
energy O
RARE O
and O
a O
RARE O
centered O
on O
the O
NUM O
ALL_CAP O
NUM O
RARE O
contain O
RARE O
septal O
RARE O
signals O
RARE O
from O
RARE O
RARE O
of O
high O
energy O
RARE O
primarily O
from O
NUM O
. O

RARE O
education O
RARE O
the O
computer O
RARE O
. O

RARE O
bond O
strength O
of O
a O
composite O
resin O
to O
an O
RARE O
glass O
RARE O
. O

An O
additional O
advantage O
is O
that O
the O
resin O
can O
be O
removed O
and O
the O
RARE I-GENE
technique O
carried O
out O
on O
thin O
sections O
. O

Such O
a O
concept O
is O
crucial O
to O
our O
understanding O
of O
the O
pathology O
of O
RARE O
in O
RARE O
. O

We O
consider O
that O
ALL_CAP O
- O
CP O
is O
a O
safe O
and O
excellent O
CP O
in O
ALL_CAP O
surgery O
and O
we O
are O
now O
utilizing O
this O
CP O
in O
all O
patients O
requiring O
ALL_CAP O
surgery O
. O

We O
have O
earlier O
evolved O
an O
experimental O
model O
by O
means O
of O
which O
changes O
identical O
to O
the O
RARE O
RARE O
can O
be O
RARE O
from O
a O
RARE O
RARE O
- O
skeletal O
trauma O
in O
pigs O
observed O
under O
long O
- O
term O
anesthesia O
under O
standardized O
conditions O
. O

Although O
RARE O
statistical O
significance O
was O
achieved O
, O
it O
is O
remarkable O
that O
there O
was O
a O
clear O
trend O
RARE O
the O
RARE O
of O
RARE O
NUM O
while O
the O
RARE O
dilution O
10 O
RARE O
6 O
) O
was O
about O
equally O
effective O
compared O
with O
placebo O
. O

The O
volume O
of O
RARE O
to O
the O
flap O
RARE O
from O
1 O
to O
2 O
ml O
/ O
min O
, O
collateral O
circulation O
to O
the O
flap O
exists O
, O
but O
is O
RARE O
, O
and O
there O
is O
little O
change O
in O
the O
capillary O
RARE O
flow O
RARE O
the O
flap O
ages O
. O

With O
aging O
, O
many O
aspects O
of O
immune O
function O
change O
. O

RARE O
candidiasis O

In O
addition O
, O
the O
NUM I-GENE
- I-GENE
NUM I-GENE
mutation I-GENE
suppressed O
the O
low O
translational O
efficiency O
of O
GCN4 I-GENE
- O
lacZ I-GENE
mRNA O
observed O
in O
NUM I-GENE
- I-GENE
and O
NUM I-GENE
- I-GENE
cells O
. O

This O
suggests O
that O
RARE O
RARE O
increases O
the O
responsiveness O
of O
RARE O
RARE I-GENE
and I-GENE
alpha I-GENE
1 I-GENE
adrenoceptors I-GENE
. O

The O
concentrations O
of O
RARE I-GENE
A I-GENE
- I-GENE
I I-GENE
and O
RARE I-GENE
A I-GENE
- I-GENE
II I-GENE
of O
RARE O
decreased O
significantly O
compared O
with O
the O
corresponding O
changes O
in O
controls O
. O

The O
distribution O
of O
patients O
was O
RARE O
follows O
: O
group O
1 O
RARE O
complex O
gamma O
- O
therapy O
( O
NUM O
cases O
RARE O
group O
2 O
RARE O
complex O
gamma O
- O
therapy O
RARE O
iliac O
RARE O
( O
50 O
cases O
) O
and O
group O
3 O
RARE O
complex O
radiation O
treatment O
with O
RARE O
RARE O
beam O
from O
the O
RARE O
type O
RARE O
and O
iliac O
RARE O
( O
50 O
cases O
). O

The O
availability O
of O
RARE O
and O
ALL_CAP O
offers O
an O
RARE O
and O
effective O
treatment O
RARE O
the O
temporary O
reversal O
of O
RARE O
bleeding O
in O
patients O
who O
require O
RARE O
invasive O
procedures O
. O

RARE O
and O
pulmonary O
RARE O
in O
congenital O
factor I-GENE
ALL_CAP I-GENE
deficiency O

RARE O
of O
the O
RARE O
mucosa O
have O
shown O
abnormal O
enzyme O
activity O
or O
deficiencies O
in O
RARE O
mechanisms O
. O

Laboratory O
RARE O
have O
indeed O
shown O
that O
RARE O
give O
significant O
yields O
of O
RARE O
, O
and O
RARE O
give O
both O
RARE O
and O
RARE O
. O

A O
significant O
degree O
of O
homology O
was O
also O
found O
among O
these O
genes O
and O
the O
RARE I-GENE
gene I-GENE
of O
related O
RARE O
ALL_CAP O
, O
which O
codes O
RARE O
an O
enzyme O
with O
different O
modification O
RARE O
. O

RARE I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
- O
RARE O
contraction O
of O
RARE O
and O
vaginal O
muscle O
. O

In O
a O
blind O
RARE O
trial O
, O
NUM O
patients O
with O
ALL_CAP O
( O
ALL_CAP O
II O
- O
III O
) O
with O
sinus O
rhythm O
and O
a O
RARE O
ventricular O
ejection O
fraction O
( O
LV O
- O
ALL_CAP O
) O
of O
NUM O
. O
5 O
+/- O
2 O
. O
6 O
% O
received O
RARE O
D O
( O
NUM O
. O
NUM O
- O
NUM O
. O
5 O
mg O
/ O
d O
RARE O
placebo O
( O
ALL_CAP O
RARE O
P O
( O
slow O
RARE O
= O
SR O
) O
( O
NUM O
mg O
/ O
d O
SR O
) O
and O
both O
drugs O
combined O
in O
respective O
doses O
. O

RARE O
RARE O
RARE O
occurred O
in O
some O
patients O
. O

The O
sample O
is O
RARE O
and O
after O
RARE O
RARE O
acid O
in O
the O
supernatant O
is O
measured O
in O
the O
free O
form O
by O
direct O
injection O
into O
the O
gas O
RARE O
. O

Changes O
in O
RARE I-GENE
RARE I-GENE
receptors I-GENE
in O
RARE O
- O
RARE O
RARE O
: O
effects O
of O
aging O
, O
inhalation O
of O
an O
RARE O
, O
administration O
of O
drugs O
, O
and O
vagotomy O
. O

In O
the O
absence O
of O
other O
RARE O
, O
increased O
sucrose O
can O
provide O
increased O
RARE O
to O
the O
virus O
in O
2 O
. O
5 O
% O
albumin I-GENE
. O

The O
overall O
prevalence O
of O
psoriasis O
was O
4 O
. O
NUM O
% O
in O
men O
and O
4 O
. O
NUM O
% O
in O
women O
. O

RARE O
RARE O
in O
living O
RARE O
? O
Some O
RARE O
pathways O
in O
RARE O
morphology O
. O

The O
possible O
origin O
and O
role O
of O
CSF I-GENE
prolactin I-GENE
are O
discussed O
. O

Three O
chromosomal I-GENE
ALL_CAP I-GENE
mutations I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
, O
were O
transferred O
by O
the O
" O
gene O
conversion O
" O
process O
to O
B O
. O
subtilis O
RARE O
NUM O
, O
which O
consists O
of O
the O
RARE O
wild I-GENE
- I-GENE
type I-GENE
ALL_CAP I-GENE
coding I-GENE
sequence I-GENE
, O
encoding O
the O
major I-GENE
RARE I-GENE
NUM I-GENE
factor I-GENE
of I-GENE
B I-GENE
. I-GENE
subtilis I-GENE
RNA I-GENE
polymerase I-GENE
, O
and O
NUM O
. O

Selective O
effect O
of O
pulmonary O
RARE O
on O
RARE O
E2 O
pharmacokinetics O
in O
rat O
RARE O
. O

This O
article O
will O
RARE O
review O
the O
published O
data O
on O
the O
morphology O
, O
function O
, O
and O
RARE O
of O
the O
normal O
RARE O
RARE O
and O
the O
pathology O
associated O
with O
ALL_CAP O
, O
together O
with O
the O
secondary O
changes O
which O
give O
rise O
to O
cortical O
degeneration O
or O
RARE O
carcinoma O
. O

The O
data O
indicate O
that O
the O
five O
different O
( O
and O
partially O
overlapping O
) O
RARE I-GENE
RARE I-GENE
RNAs I-GENE
detectable O
in O
early O
RARE O
are O
RARE O
RARE O
three O
separate O
sites O
, O
each O
directly O
upstream O
from O
one O
of O
the O
three O
protein O
- O
coding O
regions O
, O
designated O
( O
in O
5 O
' O
to O
3 O
' O
order O
) O
beta O
, O
alpha O
and O
delta O
. O

Chronic O
thyroiditis O
RARE O
a O
risk O
factor O
of O
B O
- O
cell O
lymphoma O
in O
the O
thyroid O
RARE O
. O

Plasma I-GENE
RARE I-GENE
levels O
also O
augmented O
after O
the O
administration O
of O
ethanol O
solutions O
, O
with O
a O
delay O
of O
about O
one O
hour O
after O
the O
onset O
of O
acid O
RARE O
. O

RARE O
RARE O
of O
RARE O
acid O
in O
RARE O
preparations O

A O
comparison O
among O
the O
5 O
' O
flanking O
regions O
RARE O
the O
RARE O
ALL_CAP I-GENE
promoter I-GENE
of O
the O
RARE I-GENE
ALL_CAP I-GENE
- I-GENE
protein I-GENE
genes I-GENE
demonstrated O
this O
region O
to O
be O
extremely O
homologous O
. O

Results O
of O
this O
study O
indicate O
that O
ALL_CAP O
of O
short O
chain O
fatty O
RARE O
produced O
on O
agar O
medium O
by O
RARE O
, O
combined O
with O
simple O
tests O
such O
RARE O
Gram O
' O
s O
stain O
and O
RARE O
morphology O
, O
may O
allow O
RARE O
direct O
RARE O
genus O
identification O
from O
an O
initial O
pure O
agar O
culture O
. O

Using O
this O
method O
, O
we O
measured O
absorption O
of O
low O
doses O
of O
vitamin O
A O
, O
which O
may O
provide O
a O
more O
physiological O
approach O
to O
assessment O
of O
fat O
RARE O
. O

RARE O
hepatitis O
A O
in O
chronic O
ALL_CAP O
carrier O
. O

RARE O
pressure O
, O
rCBF O
, O
and O
water O
content O
were O
measured O
from O
gray O
matter O
in O
the O
central O
core O
and O
the O
peripheral O
margin O
of O
the O
ALL_CAP O
RARE O
over O
6 O
h O
after O
ALL_CAP O
. O

During O
this O
time O
, O
the O
patients O
all O
had O
the O
characteristic O
plasma O
thyroid O
hormone O
changes O
associated O
with O
RARE O
therapy O
, O
i O
. O
RARE O
. O
increased O
T4 O
, O
free O
T4 O
, O
and O
NUM O
and O
decreased O
NUM O
, O
while O
remaining O
clinically O
RARE O
. O

Drug O
and O
nutrient O
interactions O
. O

In O
each O
compartment O
NUM O
is O
removed O
by O
the O
tissues O
RARE O
a O
chemical O
reaction O
RARE O
place O
between O
NUM O
and O
RARE I-GENE
( O
NUM I-GENE
). O

To O
evaluate O
the O
effects O
of O
propranolol O
on O
RARE O
metabolism O
after O
coronary O
reperfusion O
, O
serial O
measurements O
of O
RARE I-GENE
RARE I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
and O
RARE O
( O
Ca O
) O
contents O
and O
ALL_CAP I-GENE
and O
RARE O
acid O
( O
LA O
) O
concentrations O
in O
coronary O
sinus O
RARE O
were O
carried O
out O
in O
NUM O
RARE O
- O
chest O
dogs O
. O

RARE O
of O
the O
RARE O
- O
NUM O
% O
RARE O
RARE O
RARE O
was O
observed O
by O
scanning O
electron O
microscopy O
RARE O
RARE O
RARE O
RARE O
low O
RARE O
NUM O
ALL_CAP O
/ O
cm2 O
X O
RARE O
( O
1 O
A O
/ O
cm2 O
RARE O
whereas O
RARE O
of O
activated O
RARE O
RARE O
occurred O
only O
RARE O
the O
highest O
RARE O
and O
current O
RARE O
( O
NUM O
ALL_CAP O
/ O
cm2 O
X O
RARE O
, O
16 O
A O
/ O
cm2 O
). O

RARE O
excretion O
, O
appeared O
to O
be O
markedly O
affected O
by O
the O
season O
although O
other O
factors O
such O
RARE O
social O
and O
environmental O
stress O
cannot O
be O
RARE O
. O

Two O
studies O
on O
the O
relationship O
between O
taking O
a O
commercial O
RARE O
course O
and O
performance O
on O
the O
RARE O
RARE O
RARE O
Test O
( O
ALL_CAP O
) O
are O
reported O
. O

A O
RARE O
of O
NUM O
patients O
were O
randomly O
allocated O
either O
to O
an O
ALL_CAP O
- O
1 O
treated O
or O
an O
untreated O
group O
. O

RARE O
50 O
% O
decrease O
of O
PaO2 O
, O
ALL_CAP O
was O
RARE O
largely O
. O

RARE O
was O
performed O
following O
the O
rCBF O
study O
and O
the O
degree O
of O
RARE O
was O
measured O
on O
the O
RARE O
. O

The O
results O
from O
the O
RARE O
five O
years O
of O
follow O
RARE O
in O
1972 O
showed O
a O
4 O
. O
7 O
- O
RARE O
excess O
mortality O
RARE O
ischaemic O
and O
other O
RARE O
diseases O
( O
ALL_CAP O
NUM O
- O
NUM O
) O
compared O
with O
a O
comparable O
reference O
cohort O
of O
paper O
RARE O
workers O
. O

The O
RARE O
impact O
of O
childhood O
asthma O
has O
not O
been O
assessed O
since O
RARE O
and O
RARE O
reported O
their O
data O
in O
RARE O
of O
RARE O
NUM O
years O
RARE O
. O

RARE O

RARE O
activity O
was O
evaluated O
by O
monitoring O
the O
RARE O
RARE O
( O
ALL_CAP O
) O
RARE O
RARE O
RARE O
local O
DC O
steady O
RARE O
( O
two O
sites O
). O

The O
RARE O
and O
RARE O
of O
the O
RARE O
fibers O
of O
the O
superior O
temporal O
region O
( O
ALL_CAP O
) O
are O
studied O
using O
the O
RARE O
technique O
. O

The O
diabetic O
state O
was O
characterized O
by O
mild O
insulin I-GENE
deficiency O
, O
plasma O
levels O
being O
NUM O
% O
of O
controls O
, O
and O
mild O
RARE O
, O
with O
RARE O
plasma O
glucose O
levels O
of O
1 O
. O
5 O
times O
normal O
. O

The O
RARE O
ALL_CAP O
findings O
were O
RARE O
RARE O
a O
brain O
infarct O
or O
possibly O
a O
RARE O
. O

No O
consistent O
correlation O
between O
RARE O
pressure O
change O
and O
ALL_CAP O
- O
change O
was O
seen O
. O

RARE O
RARE O
support O
RARE O
the O
RARE O
RARE O
. O

RARE O
produced O
a O
lower O
incidence O
of O
RARE O
ulcers O
than O
equivalent O
doses O
of O
indomethacin O
. O

These O
findings O
suggest O
that O
both O
in O
the O
early O
stages O
( O
NUM O
, O
NUM O
) O
and O
in O
more O
severe O
stages O
of O
ALL_CAP O
( O
stages O
1 O
- O
2 O
) O
cold O
RARE O
RARE O
in O
the O
digital O
vessels O
and O
RARE O
' O
s O
RARE O
are O
vascular O
disorders O
of O
RARE O
origin O
occurring O
without O
any O
RARE O
alterations O
. O

In O
ALL_CAP O
functions O
of O
the O
source O
emission O
, O
surface O
RARE O
, O
RARE O
sensitivity O
are O
RARE O
by O
the O
normal O
distribution O
curves O
. O

However O
, O
kidneys O
perfused O
RARE O
72 O
hr O
demonstrated O
more O
similar O
RARE O
functions O
when O
tested O
by O
either O
ALL_CAP O
or O
ALL_CAP O
. O

To O
assess O
the O
effects O
of O
alveolar O
RARE O
and O
angiotensin I-GENE
II I-GENE
infusion O
on O
distribution O
of O
RARE O
flow O
to O
the O
RARE O
we O
performed O
perfusion O
RARE O
scans O
on O
anesthetized O
RARE O
ventilated O
lambs O
. O

A O
flow O
rate O
of O
RARE O
least O
5 O
mL O
/ O
h O
is O
required O
through O
the O
receptor O
( O
volume O
, O
NUM O
. O
4 O
mL O
) O
RARE O
accurate O
results O
. O

We O
have O
now O
RARE O
the O
5 O
' O
ends O
of O
the O
two O
remaining O
RARE O
mRNAs O
. O

The O
efficacy O
of O
quantitative O
and O
qualitative O
RARE O
RARE O
in O
the O
estimation O
of O
human O
salt O
intake O
. O

RARE O
RARE O
RARE O
members O
of O
RARE O
RARE O
. O

Acute O
appearance O
of O
RARE O
or O
RARE O
with O
initial O
marked O
RARE O
was O
observed O
in O
8 O
stroke O
patients O
. O

RARE O
acute O
RARE O
was O
common O
in O
both O
groups O
of O
patients O
, O
but O
the O
development O
of O
chronic O
RARE O
was O
only O
found O
in O
patients O
with O
ALL_CAP O
, O
indicating O
the O
more O
severe O
nature O
of O
this O
condition O
compared O
with O
selective O
IgA I-GENE
deficiency O
. O

These O
data O
suggest O
that O
AP I-GENE
- I-GENE
A I-GENE
may O
be O
potentially O
useful O
in O
the O
management O
of O
RARE O
failure O
. O

The O
various O
muscles O
of O
the O
RARE O
RARE O
region O
could O
be O
RARE O
activated O
either O
individually O
or O
RARE O
a O
mass O
unit O
depending O
on O
the O
intensity O
of O
RARE O
. O

It O
has O
been O
reported O
that O
rat O
RARE O
RARE O
levels O
were O
significantly O
decreased O
after O
treatment O
with O
NUM O
. O

The O
frequency O
of O
RARE I-GENE
RARE I-GENE
in O
RARE O
children O
. O

RARE O
of O
RARE O
cytochrome I-GENE
P I-GENE
- I-GENE
NUM I-GENE
- O
dependent O
RARE O
RARE O
such O
RARE O
RARE I-GENE
- I-GENE
and I-GENE
ALL_CAP I-GENE
N I-GENE
- I-GENE
RARE I-GENE
and O
RARE I-GENE
hydroxylase I-GENE
activity O
were O
decreased O
by O
pretreatment O
of O
rats O
with O
cimetidine O
, O
whereas O
in O
the O
rats O
pretreated O
with O
ranitidine O
, O
these O
enzyme O
activities O
were O
not O
changed O
. O

RARE O
, O
RARE O
, O
vincristine O
, O
and O
cyclophosphamide O
in O
the O
treatment O
of O
advanced O
RARE O
RARE O
. O

The O
effect O
of O
the O
RARE O
antagonist O
naloxone O
was O
evaluated O
in O
11 O
RARE O
patients O
with O
cerebral O
ischemia O
. O

RARE O
detection O
of O
depressed O
circulating O
levels O
of O
vitamin O
NUM O
in O
RARE O
. O

In O
the O
present O
experiments O
, O
we O
investigate O
the O
role O
played O
by O
the O
temporal O
pattern O
of O
RARE O
activity O
RARE O
the O
RARE O
of O
frequency O
RARE O
in O
the O
mouse O
central O
auditory O
RARE O
. O

RARE O
of O
the O
tumor O
in O
1 O
patient O
in O
whom O
RARE O
resection O
was O
performed O
2 O
weeks O
after O
RARE O
irrigation O
revealed O
RARE O
RARE O
nuclear O
chromatin O
, O
thus O
, O
suggesting O
that O
RARE O
changes O
occur O
after O
RARE O
irrigation O
are O
short O
- O
RARE O
. O

The O
generally O
adopted O
criteria O
RARE O
to O
RARE O
the O
examined O
persons O
into O
the O
following O
3 O
groups O
have O
been O
used O
: O
( O
a O
) O
diseased O
of O
ALL_CAP O
; O
( O
b O
) O
RARE O
to O
be O
diseased O
of O
ALL_CAP O
, O
and O
( O
c O
) O
individuals O
without O
signs O
of O
a O
RARE O
RARE O
. O

For O
this O
purpose O
, O
a O
simple O
respiration O
- O
control O
device O
has O
been O
developed O
that O
enables O
the O
patient O
to O
monitor O
RARE O
- O
RARE O
RARE O
successive O
scans O
. O

The O
ALL_CAP O
RARE O
( O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
RARE O
, O
RARE O
). O

During O
a O
RARE O
remission O
there O
was O
an O
increase O
in O
ALL_CAP O
RARE O
with O
urine O
, O
RARE O
with O
RARE O
( O
NUM O
. O
1 O
- O
RARE O
, O
P O
less O
than O
NUM O
. O
001 O
). O

In O
metastasis O
- O
free O
patients O
, O
the O
best O
results O
were O
obtained O
with O
tumor O
diameters O
under O
2 O
cm O
regardless O
of O
their O
RARE O
in O
RARE O
tissue O
and O
with O
2 O
RARE O
4 O
. O
9 O
cm O
tumors O
embedded O
in O
RARE O
parenchyma O
. O

Two O
RARE O
with O
RARE O
RARE O
caused O
by O
RARE I-GENE
isomerase I-GENE
deficiency O
developed O
a O
progressive O
neurological O
RARE O
RARE O
RARE O
movements O
, O
tremor O
, O
pyramidal O
RARE O
signs O
, O
and O
evidence O
of O
RARE O
motor O
RARE O
involvement O
. O

One O
RARE O
with O
the O
lowest O
ALL_CAP O
content O
was O
non O
- O
RARE O
. O

In O
the O
10 O
patients O
with O
a O
more O
severe O
degree O
of O
RARE O
the O
decrease O
in O
fat O
RARE O
RARE O
20 O
% O
and O
a O
close O
relationship O
was O
found O
( O
RARE O
= O
NUM O
. O
NUM O
, O
p O
less O
than O
NUM O
. O
01 O
) O
between O
the O
extent O
of O
the O
fatty O
acid O
RARE O
on O
placebo O
and O
the O
decrease O
of O
this O
RARE O
on O
RARE O
. O

RARE O
diameters O
in O
infants O
and O
young O
children O
: O
RARE O
angiographic O
data O
. O

The O
present O
investigation O
has O
revealed O
that O
the O
distribution O
of O
the O
main O
fatty O
RARE O
in O
RARE O
phospholipids O
is O
similar O
to O
their O
distribution O
in O
RARE O
neutral O
lipids O
with O
the O
exception O
of O
RARE O
fatty O
acid O
with O
14 O
carbon O
RARE O
, O
occurring O
mainly O
in O
phospholipids O
. O

Since O
NUM O
the O
frequency O
of O
RARE O
- O
RARE O
ulceration O
has O
been O
low O
RARE O
3 O
cases O
per O
NUM O
NUM O
patient O
- O
years O
of O
slow O
- O
release O
tablet O
use O
. O

RARE O
caused O
RARE O
and O
inhibited O
the O
RARE O
response O
of O
peripheral O
RARE O
lymphocytes O
to O
phytohemagglutinin I-GENE
and O
RARE I-GENE
A I-GENE
RARE O
. O

To O
test O
the O
feasibility O
of O
using O
liposomes O
to O
RARE O
therapeutic O
agents O
to O
the O
lungs O
, O
the O
effect O
of O
RARE O
- O
RARE O
RARE I-GENE
dismutase I-GENE
( O
SOD I-GENE
) O
or O
catalase I-GENE
on O
pulmonary O
oxygen O
toxicity O
was O
studied O
in O
rats O
. O

RARE O
cell O
necrosis O
in O
RARE O
RARE O
and O
RARE O
starvation O
. O

For O
comparison O
conventional O
RARE O
was O
used O
RARE O
18 O
RARE O
in O
the O
same O
patients O
. O

RARE O
acid O
( O
RARE O
) O
and O
RARE O
acid O
( O
RARE O
) O
RARE O
cholesterol O
RARE O
in O
man O
. O

RARE O
evoked O
field O
potentials O
were O
recorded O
from O
the O
RARE O
RARE O
formation O
( O
ALL_CAP O
RARE O
central O
gray O
( O
ALL_CAP O
) O
and O
RARE O
cortex O
( O
ALL_CAP O
RARE O
following O
RARE O
doses O
of O
halothane O
in O
RARE O
- O
RARE O
rats O
. O

RARE O
of O
the O
RARE O
muscle O
in O
experimental O
RARE O
infarct O
following O
physical O
training O

RARE O
RARE O
leads O
to O
the O
development O
of O
RARE O
- O
reactivity O
of O
the O
true O
RARE O
to O
noradrenaline O
and O
dopamine O
and O
triggers O
off O
changes O
in O
the O
RARE O
of O
the O
RARE O
activity O
of O
these O
cells O
by O
catecholamines O
. O

ALL_CAP O
is O
a O
diagnostic O
method O
RARE O
assessment O
of O
ocular O
pulse O
curves O
and O
objective O
determination O
of O
RARE O
pressures O
in O
the O
ophthalmic O
circulatory O
RARE O
( O
RARE O
and O
RARE O
arterial O
RARE O
pressures O
) O
simultaneously O
RARE O
both O
eyes O
, O
without O
dilatation O
of O
the O
RARE O
. O

RARE O
infections O
have O
long O
been O
suspected O
to O
be O
RARE O
agents O
in O
a O
number O
of O
inner O
ear O
RARE O
. O

NUM O
+/- O
11 O
%), O
all O
other O
parameters O
showed O
a O
significant O
increase O
: O
ALL_CAP O
index O
5 O
. O
4 O
+/- O
1 O
. O
4 O
RARE O
to O
6 O
. O
NUM O
+/- O
1 O
. O
7 O
RARE O
( O
p O
less O
than O
NUM O
. O
01 O
); O
ALL_CAP O
6 O
. O
3 O
+/- O
NUM O
. O
7 O
to O
6 O
. O
8 O
+/- O
NUM O
. O
9 O
cm O
( O
p O
less O
than O
NUM O
. O
001 O
); O
ALL_CAP O
NUM O
+/- O
151 O
ml O
to O
NUM O
+/- O
NUM O
ml O
( O
p O
less O
than O
NUM O
. O
01 O
); O
ALL_CAP O
NUM O
+/- O
NUM O
ml O
to O
NUM O
+/- O
175 O
ml O
( O
p O
less O
than O
NUM O
. O
001 O
); O
ALL_CAP O
117 O
+/- O
57 O
ml O
to O
151 O
+/- O
77 O
ml O
( O
p O
less O
than O
NUM O
. O
001 O
). O

RARE O
analyses O
of O
this O
RARE O
revealed O
a O
significant O
decrease O
of O
the O
RARE O
ventricular O
( O
LV O
) O
end O
- O
diastolic O
volume O
index O
( O
ALL_CAP O
) O
of O
21 O
ml O
/ O
m2 O
( O
NUM O
% O
of O
normal O
). O

In O
group O
I O
adults O
both O
of O
these O
variables O
increased O
. O

RARE O
NUM O
did O
not O
have O
a O
direct O
RARE O
or O
RARE O
effect O
on O
either O
RARE O
RARE O
RARE O
or O
rat O
RARE O
, O
however O
, O
it O
RARE O
the O
contractions O
RARE O
by O
RARE O
, O
RARE O
, O
RARE O
, O
5 O
- O
RARE O
and O
carbachol O
in O
a O
dose O
- O
dependent O
manner O
. O

RARE O
RARE O
reaction O
profiles O
. O

RARE O
in O
diabetes O
mellitus O
. O

The O
pharmacokinetics O
of O
each O
RARE O
in O
serum O
and O
dermal O
, O
RARE O
RARE O
RARE O
were O
determined O
after O
oral O
doses O
of O
NUM O
mg O
RARE O
or O
NUM O
mg O
RARE O
on O
the O
NUM O
day O
. O

A O
high O
degree O
of O
correlation O
in O
the O
sense O
of O
the O
RARE O
RARE O
of O
brain O
RARE O
of O
RARE O
syndromes O
was O
found O
. O

RARE O
a O
ALL_CAP O
detector O
set O
RARE O
NUM O
nm O
or O
an O
RARE O
( O
EC O
) O
detector O
set O
RARE O
a O
RARE O
of O
+ O
NUM O
. O
9 O
V O
( O
versus O
RARE O
/ O
RARE O
/ O
3 O
M O
NaCl O
) O
was O
used O
to O
monitor O
the O
drug O
. O

NUM O
patients O
with O
acute O
arterial O
RARE O
RARE O
NUM O
] O
and O
graft O
RARE O
RARE O
8 O
], O
responsible O
RARE O
severe O
and O
recent O
ischemia O
, O
were O
treated O
by O
RARE O
therapy O
( O
RARE I-GENE
: O
1 O
NUM O
RARE O
/ O
kg O
/ O
hour O
, O
and O
RARE O
RARE I-GENE
). O

The O
mean O
transfer O
ratios O
of O
the O
drug O
into O
the O
RARE O
tissues O
to O
the O
concentration O
in O
the O
RARE O
arterial O
RARE O
were O
such O
that O
the O
transfer O
ratio O
into O
the O
RARE O
RARE O
was O
the O
highest O
, O
followed O
by O
the O
RARE O
cervix O
and O
the O
RARE O
, O
and O
that O
into O
the O
RARE O
was O
the O
lowest O
with O
about O
1 O
/ O
2 O
that O
into O
the O
RARE O
RARE O
. O

We O
conclude O
that O
RARE O
RARE O
reduce O
ALL_CAP I-GENE
- I-GENE
cholesterol I-GENE
concentrations O
and O
the O
HDL2 I-GENE
- I-GENE
cholesterol I-GENE
RARE O
, O
possibly O
by O
enhancing O
RARE I-GENE
RARE I-GENE
lipase I-GENE
activity O
. O

Because O
of O
its O
wide O
spectrum O
of O
activity O
particularly O
against O
RARE O
resistant O
strains O
of O
H O
. O
influenzae O
and O
because O
of O
its O
good O
tolerance O
RARE O
is O
very O
useful O
in O
treatment O
of O
respiratory O
RARE O
infections O
in O
children O
. O

RARE O
RARE O
RARE O
RARE O
under O
various O
RARE O
conditions O
in O
independently O
ambulatory O
patients O
with O
RARE O
. O

RARE O
factor O
correlated O
RARE O
with O
hemodynamic O
data O
RARE O
RV O
/ O
LV O
systolic O
pressure O
ratios O
( O
RARE O
= O
NUM O
. O
93 O
, O
p O
less O
than O
NUM O
. O
001 O
) O
RARE O
normalized O
RARE O
pressure O
differences O
( O
RARE O
= O
- O
NUM O
. O
NUM O
, O
p O
less O
than O
NUM O
. O
001 O
). O

The O
effective O
and O
low O
toxic O
dose O
RARE O
of O
ALL_CAP O
- O
NUM O
should O
be O
investigated O
further O
. O

Furthermore O
, O
the O
initial O
plasma O
RARE O
level O
in O
conjunction O
with O
ALL_CAP I-GENE
was O
found O
to O
be O
even O
lower O
in O
12 O
patients O
( O
NUM O
. O
1 O
micrograms O
dl O
- O
1 O
, O
3 O
. O
7 O
mg O
dl O
- O
1 O
) O
who O
subsequently O
had O
RARE O
recurrence O
than O
in O
those O
who O
remained O
free O
of O
apparent O
RARE O
( O
NUM O
. O
5 O
micrograms O
dl O
- O
1 O
, O
4 O
. O
6 O
mg O
dl O
- O
1 O
). O

The O
results O
indicate O
that O
: O
1 O
) O
the O
initial O
response O
to O
RARE O
RARE O
according O
to O
previous O
RARE O
and O
RARE O
experience O
, O
2 O
) O
although O
the O
circadian O
rhythm O
of O
cortisol O
was O
either O
altered O
or O
disrupted O
RARE O
RARE O
, O
such O
RARE O
were O
not O
influenced O
by O
type O
of O
RARE O
and O
3 O
) O
RARE O
RARE O
may O
RARE O
increase O
cortisol O
concentrations O
in O
RARE O
. O

This O
laser O
provided O
sufficient O
power O
in O
an O
RARE O
RARE O
medium O
to O
RARE O
RARE O
vessels O
RARE O
large O
RARE O
7 O
mm O
in O
diameter O
within O
6 O
RARE O
RARE O
a O
power O
density O
of O
2000 O
ALL_CAP O
/ O
cm2 O
. O

On O
d O
112 O
, O
progesterone O
was O
RARE O
( O
P O
less O
than O
. O
05 O
) O
in O
RARE O
heifers O
than O
in O
other O
treatment O
groups O
. O

RARE O
Japanese O
RARE O
were O
RARE O
exposed O
to O
NUM O
ppm O
RARE O
( O
RARE O
) O
RARE O
particulate O
RARE O
oxide O
( O
NUM O
) O
in O
their O
diet O
from O
RARE O
to O
NUM O
days O
of O
age O
. O

This O
study O
indicated O
that O
the O
Japanese O
RARE O
was O
less O
RARE O
to O
particulate O
NUM O
exposure O
than O
RARE O
treated O
RARE O
. O

Plasma O
and O
bladder O
RARE O
concentration O
were O
measured O
following O
RARE O
DDP O
, O
and O
also O
histopathological O
examination O
, O
RARE O
, O
RARE O
RARE O
count O
and O
RARE O
chemistry O
were O
performed O
in O
order O
to O
RARE O
the O
toxicity O
of O
RARE O
DDP O
. O

RARE O
RARE O
of O
RARE O
carcinoma O
- O
256 O
in O
Sprague O
- O
Dawley O
rats O
by O
means O
of O
99mTc O
- O
labelled O
monocytes O
. O

These O
results O
were O
compared O
with O
those O
obtained O
in O
- O
D O
mothers O
and O
RARE O
, O
after O
giving O
the O
mothers O
an O
oral O
RARE O
( O
10 O
i O
. O
RARE O
. O
vitamin O
NUM O
/ O
day O
) O
RARE O
the O
period O
of O
RARE O
( O
20 O
days O
). O

RARE O
eyes O
were O
removed O
and O
held O
in O
RARE O
- O
regulated O
RARE O
and O
RARE O
with O
saline O
. O

RARE O
birth O
, O
there O
were O
a O
few O
RARE O
adrenergic O
nerves O
and O
RARE O
low O
ovarian O
ALL_CAP O
levels O
. O

RARE O
changes O
in O
the O
RARE O
rate O
of O
the O
premature O
fetus O
RARE O
RARE O
with O
the O
beta O
- O
RARE O
RARE O
and O
RARE O
- O
RARE O

Since O
RARE O
1980 O
to O
RARE O
1983 O
we O
have O
treated O
NUM O
patients O
with O
ovarian O
RARE O
. O

The O
results O
suggest O
that O
the O
RARE O
antagonist O
, O
diltiazem O
, O
may O
modify O
the O
effects O
of O
isoflurane O
on O
RARE O
function O
. O

RARE O
arrhythmias O
RARE O
RARE O
and O
RARE O
RARE O
. O

RARE O
I O
is O
RARE O
RARE O
RARE O
and O
re O
- O
reading O
. O

Treatment O
with O
RARE O
and O
RARE O
failed O
to O
inhibit O
the O
raised O
serum I-GENE
ALL_CAP I-GENE
levels O
. O

40 O
, O
NUM O
). O

The O
Cox O
RARE O
RARE O
model O
was O
applied O
to O
the O
data O
in O
order O
to O
determine O
the O
prognostic O
factors O
RARE O
long O
- O
term O
survival O
. O

This O
suggests O
that O
mechanisms O
other O
than O
an O
excessive O
increase O
in O
RARE O
oxygen O
demand O
may O
be O
responsible O
RARE O
the O
many O
episodes O
occurring O
outside O
the O
hospital O
. O

RARE O
of O
remission O
in O
advanced O
RARE O
RARE O
patients O
responding O
to O
sequential O
dose O
of O
ALL_CAP O
and O
5 O
- O
FU O

These O
data O
showed O
: O
that O
progesterone O
RARE O
is O
RARE O
throughout O
the O
human O
RARE O
RARE O
, O
with O
maximum O
frequency O
in O
the O
mid O
- O
RARE O
RARE O
; O
that O
RARE O
the O
mid O
- O
RARE O
RARE O
most O
subjects O
had O
progesterone O
levels O
both O
above O
and O
below O
currently O
accepted O
RARE O
RARE O
; O
the O
use O
of O
a O
single O
measurement O
of O
progesterone O
in O
the O
mid O
- O
RARE O
RARE O
is O
not O
always O
a O
reliable O
indicator O
of O
ovulation O
; O
a O
threshold O
greater O
than O
20 O
nmol O
/ O
RARE O
may O
yield O
an O
RARE O
number O
of O
false O
negative O
results O
. O

The O
fast O
real O
- O
time O
digital O
RARE O
of O
the O
N2 O
and O
flow O
signals O
incorporated O
RARE O
, O
delay O
RARE O
, O
and O
RARE O
RARE O
the O
effects O
of O
changes O
in O
gas O
composition O
and O
RARE O
. O

This O
slope O
tended O
to O
be O
RARE O
( O
RARE O
1 O
. O
6 O
ALL_CAP O
/ O
ALL_CAP O
) O
RARE O
L1 O
= O
L2 O
greater O
than O
NUM O
ALL_CAP O
. O

RARE O
reactivity O
was O
significantly O
RARE O
after O
the O
nifedipine O
RARE O
, O
the O
RARE O
mean O
RARE O
concentration O
causing O
a O
NUM O
% O
fall O
in O
specific O
airway O
RARE O
, O
RARE O
from O
5 O
. O
NUM O
to O
10 O
. O
9 O
mg O
/ O
ml O
of O
RARE O
( O
p O
less O
than O
NUM O
. O
05 O
). O

RARE O
doses O
of O
vitamin O
NUM O
administered O
to O
RARE O
women O
have O
been O
reported O
to O
suppress O
plasma I-GENE
prolactin I-GENE
. O

There O
was O
a O
significant O
but O
similar O
elevation O
of O
mean O
NUM O
uptake O
RARE O
40 O
min O
RARE O
by O
NUM O
. O
6 O
% O
in O
both O
the O
fasted O
( O
p O
less O
than O
NUM O
. O
001 O
) O
and O
fed O
state O
( O
p O
less O
than O
NUM O
. O
001 O
). O

National O
RARE O
of O
Health O
RARE O
RARE O
RARE O
RARE O
. O

In O
controls O
, O
most O
of O
the O
output O
from O
the O
RARE O
occurred O
RARE O
type O
I O
activity O
( O
NUM O
+/- O
14 O
%). O

RARE O
RARE O
of O
the O
NUM O
- O
P2 O
and O
baseline O
- O
P2 O
amplitude O
of O
the O
probe O
RARE O
was O
observed O
when O
the O
probe O
stimulus O
was O
presented O
to O
the O
right O
ear O
and O
the O
RARE O
material O
presented O
to O
the O
RARE O
ear O
than O
when O
the O
opposite O
RARE O
arrangement O
was O
used O
. O

Twenty O
- O
five O
patients O
( O
NUM O
, O
6 O
%) O
with O
mixed O
neoplasms O
were O
operated O
on O
by O
RARE O
conservative O
RARE O
( O
T O
. O
C O
. O
P O
RARE O
3 O
( O
9 O
, O
7 O
%) O
by O
S O
. O
P O
. O
and O
3 O
( O
9 O
, O
7 O
%) O
by O
RARE O
. O

The O
comparisons O
revealed O
that O
female O
RARE O
- O
suicide O
RARE O
were O
more O
likely O
than O
female O
RARE O
- O
suicide O
victims O
to O
live O
in O
mobile O
RARE O
, O
RARE O
their O
RARE O
or O
RARE O
- O
RARE O
, O
have O
their O
RARE O
RARE O
discovered O
, O
RARE O
a O
suicide O
RARE O
, O
RARE O
on O
a O
RARE O
, O
and O
be O
depressed O
, O
but O
are O
less O
likely O
than O
female O
RARE O
- O
suicide O
victims O
to O
live O
with O
a O
RARE O
. O

RARE O
- O
free O
rabbits O
given O
mouse O
ALL_CAP O
- O
RARE O
showed O
values O
quite O
different O
from O
control O
animals O
RARE O
most O
parameters O
, O
indicating O
RARE O
of O
mouse O
ALL_CAP O
RARE O
to O
' O
RARE O
' O
rabbits O
. O

The O
weak O
relationships O
between O
F O
and O
RARE O
to O
RARE O
clearly O
have O
RARE O
significant O
effect O
on O
the O
contents O
of O
these O
elements O
in O
bone O
. O

NUM O
- O
NUM O
RARE O
load O
was O
calculated O
using O
a O
model O
of O
the O
RARE O
of O
the O
trunk O
RARE O
RARE O
. O

Diagnosis O
: O
progressive O
RARE O
RARE O
. O

RARE O
NUM O
was O
associated O
with O
a O
frontal O
RARE O
of O
similar O
RARE O
RARE O
the O
hypothesis O
of O
a O
RARE O
RARE O
RARE O
. O

Although O
RARE O
differences O
were O
noted O
in O
the O
decrease O
in O
platelet O
counts O
between O
the O
two O
groups O
, O
fibrinogen I-GENE
levels O
and O
alpha I-GENE
2 I-GENE
- I-GENE
RARE I-GENE
levels O
declined O
less O
RARE O
in O
the O
antithrombin I-GENE
- O
treated O
group O
. O

RARE O
of O
RARE O
RARE O
in O
the O
diagnosis O
of O
RARE O
RARE O
. O

Factors O
influencing O
semen O
characteristics O
in O
young O
RARE O
RARE O
in O
a O
RARE O
environment O
were O
studied O
. O

RARE O
14C O
RARE O
beta O
- O
RARE O
, O
its O
distribution O
after O
administration O
by O
various O
routes O
to O
cats O
, O
and O
the O
effects O
of O
RARE I-GENE
oxidase I-GENE
RARE O
. O

All O
RARE O
RARE O
a O
RARE O
of O
1 O
. O
4 O
L O
of O
water O
RARE O
the O
RARE O
. O

The O
rates O
of O
RARE O
energy O
use O
( O
mean O
+/- O
SD O
= O
NUM O
. O
3 O
+/- O
1 O
. O
2 O
RARE O
NUM O
. O
7 O
+/- O
1 O
. O
3 O
ALL_CAP O
X O
min O
- O
1 O
; O
P O
less O
than O
NUM O
. O
05 O
) O
were O
significantly O
RARE O
RARE O
- O
10 O
degrees O
C O
than O
RARE O
NUM O
degrees O
C O
. O

Clinical O
aspects O
and O
therapy O

Following O
RARE O
days O
' O
incubation O
both O
RARE O
20 O
degrees O
C O
and O
NUM O
degrees O
C O
, O
RARE O
. O
RARE O
RARE O
. O
was O
capable O
of O
RARE O
the O
virus O
. O

RARE O
eosinophils O
in O
patients O
with O
RARE O
RARE O
RARE O
. O

The O
RARE O
RARE O
of O
NUM O
in O
the O
NUM O
. O
T O
12 O
- O
RARE O
and O
NUM O
in O
the O
NUM O
. O
N O
12 O
- O
RARE O
helix O
, O
which O
are O
associated O
with O
the O
modification O
site O
, O
RARE O
RARE O
unusually O
high O
field O
( O
8 O
. O
5 O
to O
9 O
. O
NUM O
ppm O
) O
compared O
to O
RARE O
RARE O
in O
RARE O
- O
RARE O
RARE O
RARE O
( O
12 O
. O
5 O
to O
14 O
. O
5 O
ppm O
). O

The O
RARE O
is O
made O
that O
specific O
sub O
- O
groups O
of O
RARE O
need O
to O
be O
identified O
and O
may O
RARE O
specialized O
intervention O
strategies O
. O

There O
was O
RARE O
correlation O
between O
RARE O
status O
and O
clinical O
status O
, O
RARE O
measurements O
, O
RARE I-GENE
and I-GENE
serum I-GENE
lysozyme I-GENE
levels O
or O
rates O
of O
respiratory O
RARE O
RARE O
with O
P O
. O
RARE O
and O
S O
. O
RARE O
. O

There O
was O
RARE O
correlation O
between O
RARE O
status O
and O
clinical O
status O
, O
RARE O
measurements O
, O
RARE O
and O
serum I-GENE
lysozyme I-GENE
levels O
or O
rates O
of O
respiratory O
RARE O
RARE O
with O
P O
. O
RARE O
and O
S O
. O
RARE O
. O

RARE O
increased O
3 O
. O
5 O
% O
( O
P O
less O
than O
. O
10 O
) O
and O
feed O
conversion O
improved O
5 O
. O
9 O
% O
( O
P O
less O
than O
. O
07 O
) O
in O
steers O
fed O
. O
NUM O
% O
ALL_CAP O
- O
ALL_CAP O
compared O
with O
gain O
and O
feed O
conversion O
of O
the O
control O
steers O
. O

RARE O
RARE O
development O
of O
the O
RARE O
cortex O
in O
the O
rat O
. O

RARE O
and O
RARE O
RARE O
in O
the O
methylation O
of O
pineal O
RARE O
compounds O
in O
adult O
male O
RARE O
hamsters O
, O
kept O
under O
RARE O
conditions O
. O

The O
transit O
time O
was O
significantly O
shortened O
. O

Among O
the O
patients O
RARE O
1 O
- O
2 O
- O
3 O
, O
NUM O
% O
had O
a O
good O
out O
RARE O
without O
any O
neurological O
abnormality O
, O
among O
the O
patients O
RARE O
4 O
- O
5 O
, O
only O
NUM O
% O
had O
a O
RARE O
out O
RARE O
. O

RARE O
of O
acid I-GENE
RARE I-GENE
of O
peripheral O
RARE O
RARE O
in O
RARE O
and O
segmental O
pneumonia O
in O
children O

Comparative O
studies O
of O
the O
antithrombin I-GENE
III I-GENE
level O
and O
plasminogen I-GENE
activator I-GENE
activity O
in O
patients O
with O
RARE O

We O
also O
observed O
that O
the O
predictive O
ability O
of O
the O
RARE O
RARE O
and O
RARE O
increased O
considerably O
from O
NUM O
to O
1982 O
. O

RARE O
between O
cellular O
electrical O
activity O
and O
cardiac O
mechanical O
activity O
in O
man O
, O
the O
dog O
and O
the O
RARE O

Treatment O
of O
RARE O
' O
s O
RARE O
. O

RARE O
of O
the O
ALL_CAP O
display O
of O
an O
RARE O
. O

Is O
RARE O
' O
RARE O
RARE O
RARE O
fever O
RARE O
specific O
? O

Renal O
excretion O
of O
RARE O
in O
normal O
and O
RARE O
subjects O
. O

RARE O
with O
the O
clinical O
and O
experimental O
use O
of O
RARE O
- O
I O
RARE O
. O

RARE O
of O
RARE O
and O
RARE O
by O
RARE O
RARE O
. O

Evaluation O
of O
thyroid O
function O
. O

The O
effect O
of O
a O
tissue O
RARE O
, O
vitamin O
A O
and O
nonspecific O
gamma I-GENE
- I-GENE
globulin I-GENE
on O
the O
RARE O
clearance O
in O
rabbits O

ALL_CAP I-GENE
- I-GENE
A I-GENE
antibodies I-GENE
in O
RARE O
patients O

RARE O
of O
fine O
RARE O
of O
the O
RARE O
RARE O
organ O
of O
RARE O
after O
electron O
microscopic O
silver O
staining O

RARE O
metabolism O
in O
hemorrhagic O
- O
hypotensive O
shock O

They O
also O
discuss O
the O
existing O
RARE O
. O

RARE O
of O
RARE O
in O
a O
RARE O
RARE O
muscle O
. O

Studies O
on O
alcoholic O
liver O
injury O
. O

RARE O
control O
of O
coronary O
circulation O
in O
the O
dog O
. O

Evidence O
RARE O
two O
distinctive O
clinical O
, O
epidemiological O
, O
and O
RARE O
RARE O
of O
infection O
. O

RARE O
light O
- O
RARE O
RARE I-GENE
formation O
in O
human O
RARE O
. O

RARE O
from O
a O
vaccine O
. O

To O
the O
problem O
of O
the O
RARE O
of O
the O
growth O
of O
RARE O
tumors O
of O
animals O
previously O
treated O
with O
RARE O
antibiotics O

Assessment O
of O
nutrient O
media O
in O
the O
diagnosis O
of O
RARE O

RARE O
resin O
RARE O
the O
treatment O
of O
the O
RARE O
of O
RARE O
failure O
. O

Value O
of O
the O
EMG O
in O
the O
diagnosis O
of O
a O
cardiomyopathy O
associated O
with O
a O
RARE O
RARE O
. O

D O
. O

Prevention O
of O
RARE O
RARE O
sensitization O
: O
anti I-GENE
- I-GENE
RARE I-GENE
immune I-GENE
globulin I-GENE
. O

RARE O
levels O
in O
infant O
hypothyroidism O
. O

RARE O
RARE O
transferrin I-GENE
II I-GENE
studies O
in O
ischemic O
disorders O
of O
the O
central O
nervous O
RARE O
. O

RARE O
RARE O
of O
D O
- O
RARE O
in O
pulmonary O
RARE O

RARE O
relation O
between O
serum O
IgG I-GENE
concentration O
and O
glucose O
and O
RARE O
absorption O
in O
RARE O
African O
adults O
. O

RARE O
of O
platelet O
function O
in O
chronic O
RARE O
leukemias O

The O
effect O
of O
RARE O
on O
RARE I-GENE
- I-GENE
RARE I-GENE
- I-GENE
activated I-GENE
ATPase I-GENE
, O
RARE O
, O
and O
RARE O
in O
cortex O
. O

Effect O
of O
immune O
lymphocytes O
and O
of O
RARE I-GENE
- I-GENE
anti I-GENE
- I-GENE
lymphocyte I-GENE
globulin I-GENE
( O
ALL_CAP I-GENE
) O
on O
RARE O
macrophages O
exposed O
to O
increased O
incubation O
RARE O
in O
vitro O
. O

RARE O
RARE O
in O
RARE O
rats O
in O
the O
low O
and O
high O
RARE O
of O
RARE O

RARE O
of O
RARE O
fed O
a O
low O
protein O
RARE O
diet O
. O

Studies O
on O
the O
organic O
RARE O
of O
human O
ear O
RARE O

A O
medical O
- O
RARE O
review O

RARE O
and O
RARE O
RARE O
of O
the O
RARE O
population O
of O
RARE O
RARE O
RARE O
. O

RARE O
to O
RARE O
RARE O
by O
RARE O
after O
subtotal O
ablation O
of O
the O
pancreas O
. O

RARE O
NUM O
and O
RARE O
absorption O
in O
the O
RARE O
. O

The O
incidence O
of O
tumours O
in O
young O
RARE O
. O

Laboratory O
aspects O
with O
particular O
reference O
to O
chemotherapy O
and O
control O
. O

Their O
effect O
on O
the O
RARE O
RARE O
vas O
deferens O
. O

RARE O
and O
growth O
. O

Effect O
of O
variations O
in O
time O
interval O
between O
treatment O
with O
BCG O
and O
RARE O
dust O
on O
translocation O
of O
RARE O
dust O
from O
the O
lungs O
to O
their O
regional O
lymph O
nodes O
. O

RARE O
action O
of O
a O
new O
antibiotic O
- O
RARE O
association O
used O
RARE O
RARE O
in O
RARE O

RARE O
- O
physiological O
experiment O

RARE O
RARE O
findings O
in O
the O
RARE O
body O
of O
the O
RARE O

RARE O
RARE I-GENE
reductase I-GENE
deficiency O
and O
disorder O
of O
RARE O
RARE O
in O
the O
RARE O

Studies O
on O
swine O
RARE O
. O

RARE O
of O
RARE O
in O
laboratory O
mice O

RARE O
effect O
on O
the O
cytochrome I-GENE
oxidase I-GENE
activity O

RARE O
of O
colon O
carcinoma O
to O
the O
RARE O
. O

RARE O
of O
RARE O
cells O
: O
study O
in O
rats O
after O
administration O
of O
RARE O
. O

RARE I-GENE
- I-GENE
beta I-GENE
- I-GENE
1 I-GENE
lipoprotein I-GENE
and O
early O
detection O
of O
risk O
factors O
RARE O
coronary O
RARE O
RARE O
. O

RARE O
influencing O
RARE O
of O
the O
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
CSF I-GENE
). O

RARE O
of O
action O
potentials O
in O
RARE O
slow O
muscle O
fibres O
RARE O
by O
botulinum I-GENE
RARE I-GENE
. O

An O
automated O
method O
RARE O
the O
quantitative O
analysis O
of O
the O
RARE O
RARE O
, O
RARE O
and O
RARE O
in O
RARE O
RARE O
( O
CSF O
) O
was O
used O
to O
analyze O
CSF O
samples O
from O
37 O
patients O
with O
central O
nervous O
RARE O
( O
CNS O
) O
tumors O
and O
from O
NUM O
patients O
without O
tumors O
. O

I O
. O

RARE O
and O
the O
drug O
- O
RARE O
effects O
on O
RARE O
. O

RARE O
resembling O
RARE O
in O
normal O
and O
neoplastic O
RARE O
glands O
of O
dogs O
. O

RARE O
and O
RARE O
RARE O
in O
RARE O
hemisphere O
monkeys O
. O

A O
study O
in O
vivo O
of O
adrenergic I-GENE
receptors I-GENE
in O
the O
RARE O
and O
in O
the O
internal O
and O
RARE O
of O
the O
RARE O
. O

RARE O
RARE O
cyst O
of O
the O
RARE O
RARE O
demonstrated O
by O
positive O
99mTc O
RARE O
. O

Effects O
of O
estrogen O
and O
glucocorticoids O
on O
the O
adrenal O
development O
of O
the O
fetus O
. O

RARE O
and O
RARE I-GENE
content O
in O
RARE O
women O
and O
in O
women O
with O
certain O
RARE O
diseases O

Effect O
of O
noise O
on O
ALL_CAP O
- O
RARE O
increases O
of O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
activity O
in O
the O
plasma O
of O
rats O

RARE O
of O
RARE O
metabolism O
. O

On O
the O
RARE O
of O
mucus O
and O
its O
RARE O
RARE O
in O
RARE O
RARE O
. O

A O
RARE O
description O
of O
the O
osmotic O
RARE O
coefficient O
with O
application O
to O
the O
RARE O
theory O
of O
RARE O
exchange O
. O

RARE O
of O
RARE O
RARE O
RARE O
in O
the O
RARE O

Abnormal O
characteristics O
and O
RARE O
in O
RARE O
RARE O

RARE O
RARE O
in O
laboratory O
RARE O
medicine O
. O

RARE O
common O
to O
RARE O
and O
RARE O

Clinical O
course O
and O
nursing O
care O
of O
patients O
with O
RARE O
ulcer O
RARE O
use O
of O
RARE O
RARE O
with O
RARE O
RARE O

On O
parents O

From O
the O
RARE O
RARE O
Cross O
activities O

Effects O
of O
RARE O
on O
the O
family O

Treatment O
and O
care O
of O
adult O
diabetes O
mellitus O
without O
RARE O

Re O
- O
examining O
RARE O
( O
toluene O
) O
RARE O
a O
treatment O
RARE O
RARE O
RARE O
. O

RARE O
between O
cells O
of O
the O
human O
RARE O
organ O
. O

RARE O
of O
the O
month O
. O

RARE O
RARE O
RARE O
materials O

Hodgkin O
' O
s O
RARE O
. O

Value O
of O
RARE O
and O
antithrombin I-GENE
3 I-GENE
in O
the O
assessment O
of O
liver O
function O
. O

RARE I-GENE
peroxidase I-GENE
in O
human O
RARE O
cells O
in O
health O
and O
RARE O
. O

RARE O
response O
of O
RARE O
tissues O
to O
RARE O
and O
aluminum O
RARE O
solutions O
RARE O
tissue O
RARE O
materials O
. O

Changes O
following O
periodontal O
surgery O
. O

RARE O
pH O
, O
H O
ion O
RARE O
and O
H O
ion O
RARE O
coefficient O
in O
RARE O
toe O
muscle O
. O

RARE O
studies O
on O
ALL_CAP O
- O
NUM O
. O

RARE O
concerning O
medical O
care O

RARE O
: O
RARE O
RARE O
RARE O
RARE O
following O
surgery O
of O
congenital O
RARE O
defects O

RARE O
of O
RARE O
of O
the O
rheumatoid I-GENE
factor I-GENE
in O
RARE O
- O
RARE O
studies O

RARE O
of O
the O
timing O
of O
RARE O
in O
the O
RARE O
bundle O
recordings O
. O

RARE O
RARE O
formation O
by O
RARE O
cells O
RARE O
the O
RARE O
RARE O
of O
the O
human O
eye O
. O

RARE O
platelets O
, O
coagulation O
factors O
and O
morphologic O
organ O
changes O
following O
RARE O
shock O
in O
RARE O
monkeys O

Cell O
viability O
and O
RARE I-GENE
RARE I-GENE

State O
- O
RARE O
RARE O
of O
nursing O
RARE O
R O
. O
N O
., O
1972 O
. O

Further O
investigation O
on O
the O
chemotactic O
influence O
of O
RARE I-GENE
hormone I-GENE
on O
lymphocytes O

1 O
, O
3 O
- O
RARE O
( O
2 O
- O
RARE O
)- O
1 O
- O
RARE O
( O
RARE O
) O
and O
other O
RARE O
in O
RARE O
treatment O
: O
a O
review O
. O

RARE O
following O
RARE O
abscess O
in O
the O
RARE O
transplant O
patient O
. O

RARE O
significant O
RARE O
changes O
in O
RARE O
RARE O
probably O
associated O
with O
a O
RARE O
- O
like O
RARE O
. O

RARE O
relationships O
and O
the O
development O
RARE O
affected O
. O

A O
short O
history O
of O
RARE O
in O
RARE O
, O
RARE O
. O

RARE O
graft O
irradiation O
RARE O
an O
RARE O
to O
RARE O
RARE O
. O

Letter O
: O
RARE O
detection O

Role O
of O
RARE O
in O
the O
manifestation O
of O
RARE O
RARE O

The O
effect O
of O
RARE O
RARE O
on O
formation O
of O
transplantation O
and O
anti O
- O
infection O
RARE O
in O
mice O

NUM O
RARE O
of O
RARE O
RARE O
. O
RARE O
. O
RARE O
m O
. O
d O
. O

RARE O
of O
RARE O
of O
RARE O
bacilli O
. O

RARE O
afferents O
to O
the O
RARE O
cortex O
of O
the O
RARE O
RARE O
. O

Mechanism O
of O
RARE O
in O
vaccination O
with O
RARE O
- O
dependent O
mutants O
of O
RARE O
and O
RARE O
. O

Resistance O
pattern O
of O
Mycobacterium O
tuberculosis O
( O
H O
37 O
RARE O
) O
to O
a O
new O
antibiotic O
, O
RARE O

RARE O
arterial O
pressure O
and O
RARE O
in O
the O
RARE O
RARE O
after O
prolonged O
administration O
of O
RARE O
RARE O
. O

Effect O
of O
RARE O
and O
RARE O
on O
hippocampal O
RARE O
activity O

RARE O
ratio O
RARE O
birth O
. O

RARE O
processes O
in O
the O
cervix O
RARE O

RARE O
RARE O
tumors O
of O
the O
RARE O

RARE O
RARE O
RARE O
estimating O
RARE O
in O
a O
population O
with O
related O
parents O
. O

Measurement O
of O
RARE O
- O
loop O
responses O
to O
electrical O
RARE O
in O
olfactory O
bulb O
of O
RARE O
. O

RARE O
disappearance O
rate O
and O
changes O
in O
plasma O
RARE O
after O
RARE O
injected O
glucose O
in O
RARE O
and O
RARE O
RARE O
newborns O
. O

RARE O
values O
RARE O
the O
peripheral O
RARE O
and O
bone O
marrow O
of O
the O
RARE O
( O
RARE O
) O
hamster O

The O
relationship O
of O
human O
RARE O
arterial O
and O
venous O
plasma O
levels O
of O
corticosteroids O
to O
gestational O
age O
. O

RARE O
effect O
of O
the O
RARE O
from O
RARE O

RARE O
acid O
concentration O
in O
the O
catalyzed O
RARE O
RARE O
. O

Role O
of O
RARE O
studies O
in O
the O
prophylaxis O
of O
spontaneous O
RARE O

RARE O
behavior O
of O
RARE O
, O
RARE O
RARE O
RARE O
and O
RARE O
non O
- O
RARE O
heifers O
. O

Chemical O
RARE O
of O
the O
RARE O
V O
: O
RARE O
RARE O
of O
RARE O
RARE O
RARE O
RARE O
RARE O
. O

RARE O
RARE O
RARE O
in O
rat O
kidneys O
. O

RARE O
of O
RARE O
steroids O
by O
double O
RARE O
method O
. O

RARE O
RARE O
and O
RARE O
RARE O
among O
Japanese O
, O
RARE O
, O
and O
RARE O
. O

Effects O
of O
RARE O
, O
starvation O
, O
and O
RARE O
on O
oxidative O
enzyme O
activities O
of O
RARE O
cartilage O
from O
rats O
. O

RARE O
coordination O
compounds O
of O
RARE O
. O

RARE O
of O
renin I-GENE
RARE O
rate O
and O
RARE O
plasma O
flow O
from O
peripheral O
and O
RARE I-GENE
RARE I-GENE
renin I-GENE
levels O
. O

RARE O
RARE O
under O
social O
RARE O
. O

RARE O
of O
vessel O
. O

RARE O
of O
food O
intake O
in O
the O
rat O
by O
RARE O
oil O
. O

Studies O
of O
lipoprotein I-GENE
- I-GENE
X I-GENE
( O
ALL_CAP I-GENE
- I-GENE
X I-GENE
) O
and O
bile O
RARE O
in O
familial O
ALL_CAP I-GENE
deficiency O
. O

RARE O
complicated O
by O
chronic O
steroid O
treatment O
. O

RARE O
- O
NUM O
. O

RARE O
anxiety O
of O
RARE O
RARE O
and O
RARE O
. O

RARE O
juvenile O
RARE O

Early O
RARE O
therapy O
in O
NUM O
children O
with O
acute O
RARE O
. O

9 O
, O
11 O
- O
RARE O
steroids O
derived O
from O
estradiol O
3 O
- O
RARE O
ether O
. O

RARE O
examinations O
in O
patients O
with O
chronic O
RARE O
insufficiency O

RARE O
of O
RARE O
administration O
of O
various O
substances O
to O
animals O

RARE O
in O
the O
RARE O
of O
the O
RARE O
following O
a O
short O
- O
term O
local O
action O
of O
a O
permanent O
magnetic O
field O
on O
the O
human O
body O

RARE O
on O
the O
RARE O
activities O
of O
RARE O
RARE O
L O
. O

RARE O
of O
3 O
multiple O
RARE O
malignant O
and O
benign O
tumors O
of O
the O
RARE O
and O
RARE O

Analysis O
of O
clearance O
curve O
of O
rose O
RARE O
- O
I O
- O
NUM O

RARE O
: O
RARE O
and O
RARE O
in O
S O
I O
RARE O
of O
the O
RARE O
- O
RARE O
RARE O
. O

RARE O
K O
agents O

RARE O
RARE O
: O
effects O
of O
a O
single O
injection O
of O
RARE O
RARE O
on O
the O
reproductive O
organs O
of O
the O
RARE O
. O

3 O
. O

RARE O
and O
RARE O
properties O

RARE O
RARE O
in O
RARE O
allergy O
. O

Letter O
: O
RARE I-GENE
hydrocarbon I-GENE
hydroxylase I-GENE
and O
smoking O
. O

Evaluation O
of O
1 O
, O
10 O
- O
RARE O
RARE O
a O
RARE O
RARE O
RARE O
acid O
determinations O
. O

RARE O
- O
RARE O
acid O
in O
physiological O
conditions O
and O
some O
diseases O
in O
children O

RARE O
in O
rats O
of O
RARE O
RARE O
and O
compounds O
contained O
in O
them O
. O

VII O
. O

Isolation O
of O
RARE O
avian O
RARE O
virus O
( O
RARE O
T O
). O

RARE O
on O
RARE O
of O
rats O
exposed O
to O
long O
- O
term O
RARE O
. O

Effect O
of O
a O
high O
- O
intensity O
ALL_CAP O
field O
on O
the O
RARE O
coagulation O
RARE O

The O
levels O
of O
RARE I-GENE
activity O
in O
RARE O
from O
normal O
children O
and O
patients O
with O
RARE O
RARE O
. O

RARE O
of O
effect O
of O
the O
RARE O
RARE O
RARE O
( O
ALL_CAP O
NUM O
) O
on O
the O
absorption O
of O
RARE O
. O

RARE O
between O
gross O
lesions O
and O
Escherichia O
coli O
RARE O
in O
chronic O
respiratory O
RARE O
( O
ALL_CAP O
) O
of O
RARE O
. O

RARE O
solution O
of O
RARE O
joint O
RARE O
with O
a O
RARE O
RARE O
flap O

Effects O
of O
RARE O
radiation O
in O
the O
human O
oral O
cavity O
and O
RARE O
: O
results O
of O
a O
survey O
. O

The O
RARE O
RARE O
of O
the O
RARE O
RARE O
RARE O
. O

RARE O
pattern O
of O
RARE O
RARE O
and O
comparison O
of O
the O
appearance O
time O
between O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
antibodies I-GENE

RARE O
RARE O
RARE O
. O

RARE O
QRS O
complexes O
and O
RARE O
QRS O
loop O

Study O
of O
RARE O
autoantibodies O
by O
immunofluorescence O
RARE O
in O
RARE I-GENE
diseases O

RARE O
preservation O
. O

RARE O
RARE O
. O

RARE O
RARE O
RARE O
L O
. O
R O
. O
C O
. O
P O
. O

RARE O
. O

The O
metabolism O
and O
RARE O
of O
5 O
- O
fluorouracil O
. O

RARE O
RARE O
in O
rats O
RARE O
RARE O
growth O
and O
in O
RARE O
rejection O
. O

Isolation O
of O
RARE O
RARE O
MC O
- O
NUM O
from O
carcinoma O
NUM O
and O
its O
RARE O
effect O
on O
RARE O
sarcoma O
180 O
and O
RARE O
carcinoma O
. O

Human O
synovial O
RARE O
: O
detection O
of O
a O
new O
RARE O
. O

Effects O
of O
RARE O
and O
RARE O
RARE O
on O
RARE O
RARE O
in O
the O
RARE O
, O
RARE O
RARE O
. O

Some O
RARE O
RARE O
of O
a O
personal O
statistical O
study O
of O
NUM O
arterial O
RARE O

LA O
- O
NUM O
- O
MS O
. O

RARE O
studies O
with O
RARE O
antigens O
. O

RARE O
and O
RARE O
alterations O
noted O
after O
RARE O
RARE O
RARE O
. O

RARE O
of O
human I-GENE
serum I-GENE
albumin I-GENE
. O

Analysis O
of O
corticosteroids O
. O

RARE O
to O
RARE I-GENE
anti I-GENE
- I-GENE
lymphocyte I-GENE
globulin I-GENE
. O

Plasma I-GENE
RARE I-GENE
in O
patients O
of O
bronchial O
asthma O
and O
the O
effect O
of O
RARE O
administration O
on O
it O
. O

A O
comparative O
study O
of O
the O
cortical O
end O
of O
the O
auditory O
RARE O
RARE O
postnatal O
RARE O
in O
lower O
monkeys O
and O
man O

The O
effect O
of O
osmotic O
flow O
on O
the O
distribution O
of O
RARE I-GENE
peroxidase I-GENE
within O
the O
RARE O
RARE O
of O
RARE O
bladder O
epithelium O
. O

RARE O
of O
various O
mycobacteria O
and O
the O
corresponding O
levels O
of O
cross O
- O
protection O
developed O
between O
species O
. O

Ten O
- O
year O
experience O
with O
one O
- O
RARE O
RARE O
and O
RARE O
RARE O
. O

RARE O
- O
hydrogen O
RARE O
in O
RARE O
and O
RARE O
. O

Factors O
affecting O
the O
inhibition O
of O
RARE O
by O
RARE O
. O

RARE O
spectral O
sensitivity O
determined O
RARE O
RARE O
the O
RARE O
eye O
. O

RARE O
of O
RARE O
bone O
cyst O
. O

RARE I-GENE

Sodium O
RARE O
in O
cardiac O
failure O
. O

Clinical O
and O
angiographic O
examinations O
in O
occlusion O
RARE O
of O
the O
great O
RARE O
arteries O

Serum O
RARE O
changes O
RARE O
RARE O
due O
to O
oral O
RARE O
administration O

RARE O
treatment O
of O
candidiasis O
with O
transfer I-GENE
factor I-GENE
. O

A O
possible O
role O
RARE O
the O
mixed O
function O
oxidase I-GENE
enzyme O
RARE O
in O
the O
requirement O
RARE O
selenium O
in O
the O
rat O
. O

RARE O
breathing O
and O
apnea O
in O
preterm O
infants O
. O

RARE O
session O
report O
: O
in O
vivo O
- O
in O
vitro O
screening O
. O

RARE O
studies O
in O
RARE O
tumors O
of O
the O
ovary O
. O

On O
the O
RARE O
of O
RARE O
RARE O

RARE O
between O
RARE O
ratio O
of O
RARE O
materials O
and O
composition O
of O
products O
in O
the O
RARE O
of O
RARE O

Influence O
of O
diet O
on O
RARE O
ALL_CAP O
excretion O
. O

RARE O
RARE O
circuit O
RARE O
recording O
long O
RARE O
RARE O
fast O
RARE O
RARE O
. O

RARE O
of O
RARE O
RARE O
. O

The O
status O
of O
education O
and O
training O
programs O
in O
speech O
pathology O
and O
RARE O
RARE O
NUM O
- O
72 O
. O

Coronary O
arteries O
RARE O
old O
and O
new O
. O

RARE O
agents O
. O

RARE O
of O
RARE O
- O
positive O
compounds O
in O
urine O
by O
the O
combined O
methods O
of O
medium O
- O
tension O
RARE O
and O
RARE O
chromatography O

RARE O
treatment O
of O
central O
nervous O
RARE O
injuries O

RARE O
RARE O
: O
a O
RARE O
of O
RARE O
- O
RARE O
. O

6 O
. O

NUM O
data O
on O
the O
immunosuppressive O
therapy O
of O
RARE O

RARE O
RARE I-GENE
enzyme I-GENE
release O
and O
its O
RARE O
by O
drugs O
in O
adjuvant O
- O
RARE O
RARE O
. O

Treatment O
of O
ovarian O
neoplasms O

Experimental O
pancreatitis O
in O
pigs O
. O

RARE O
metabolism O
of O
4 O
- O
RARE O
. O

RARE O
of O
hospital O
RARE O
in O
RARE O
ulcer O
patients O

I O
. O

RARE O
treatment O
of O
pathologic O
RARE O
of O
RARE O
infarct O

The O
interaction O
of O
caffeine O
, O
theophylline O
and O
RARE O
with O
RARE I-GENE
oxidase I-GENE
RARE O
. O

Effect O
of O
RARE O
on O
RARE O
in O
perfused O
rat O
liver O
. O

New O
RARE O
from O
RARE O
of O
RARE O
RARE O
. O

A O
case O
of O
M O
RARE O

RARE O
nature O
of O
RARE O
RARE O
- O
producing O
RARE O
of O
parental O
RARE O
cells O
. O

RARE O
RARE O
of O
a O
gas O
dilution O
indicator O

The O
value O
of O
different O
sources O
of O
nitrogen O
in O
diets O
RARE O
the O
early O
- O
RARE O
RARE O
. O

1 O
. O

RARE O
tumors O
in O
childhood O
. O

Results O
of O
the O
RARE O
RARE O
of O
the O
commercial O
anti O
- O
inflammatory O
enzyme O
preparations O
containing O
RARE I-GENE
and O
trypsin I-GENE
by O
means O
of O
modified O
ALL_CAP O
NUM O
methods O

Studies O
on O
the O
RARE O
nature O
of O
RARE O
RARE O
RARE O
with O
RARE O
reference O
to O
RARE O
and O
RARE O

The O
problem O
of O
RARE O
due O
to O
pulmonary O
tuberculosis O
, O
on O
the O
basis O
of O
an O
analysis O
of O
the O
history O
of O
NUM O
cases O
RARE O
observed O
in O
RARE O
in O
the O
years O
NUM O
- O
NUM O

RARE O
RARE O

RARE O
on O
RARE O
; O
by O
a O
group O
of O
RARE O
from O
psychiatric O
hospitals O

RARE O
abdominal O
RARE O
with O
NUM O
- O
I O
- O
RARE O
ALL_CAP O
RARE O
description O
of O
the O
thyroid O
RARE O
, O
RARE O
and O
RARE O
( O
comparison O
with O
NUM O
- O
I O
- O
ALL_CAP O
) O

RARE O
in O
children O

RARE O
caused O
by O
3 O
, O
4 O
- O
RARE O

The O
content O
of O
RARE O
and O
RARE O
in O
RARE O

RARE O
of O
leukemia O
after O
prolonged O
remission O
. O

Influence O
of O
RARE O
smoking O
on O
some O
RARE O
coagulation O
tests O
. O

The O
non O
- O
role O
of O
fluoride O
in O
the O
control O
of O
plasma O
RARE O
in O
the O
RARE O
rat O
. O

Second O
report O
of O
the O
RARE O
Cancer O
RARE O
. O

RARE O
of O
the O
growth O
of O
RARE O
by O
compounds O
which O
affect O
the O
adrenergic O
mechanism O
. O

ALL_CAP O
- O
TR O
- O
NUM O
- O
54 O
. O

A O
brief O
discussion O
of O
color O
deficiencies O
. O

ALL_CAP O
NUM O
. O

RARE O
in O
the O
determination O
of O
the O
RARE O
content O
of O
RARE O
vaccines O
. O

RARE O
RARE O
( O
L O
.) O
and O
RARE O
RARE O
( O
RARE O
) O
in O
RARE O
City O
. O

RARE O
response O
and O
hemagglutinin I-GENE
production O
by O
RARE O
RARE O
irradiated O
adult O
mice O
. O

Comparative O
study O
on O
acute O
oral O
overload O
using O
RARE O
and O
RARE O
in O
normal O
and O
diabetic O
subjects O
. O

RARE O
in O
RARE O
and O
RARE O
. O

Factors O
influencing O
in O
vitro O
RARE I-GENE
RARE I-GENE
factor I-GENE
production O
by O
RARE O
RARE O
. O

RARE O
cord O
RARE O
of O
the O
RARE O
reflex O
. O

Biological O
action O
and O
kinetics O
of O
the O
elimination O
of O
RARE O
oxide O
in O
dogs O

RARE O
- O
and O
RARE O
of O
the O
RARE O

ALL_CAP O
. O

RARE O
in O
the O
use O
of O
RARE O
RARE O
analysis O
RARE O
biological O
radiation O
RARE O
. O

RARE I-GENE
RARE O
in O
essential O
and O
accelerated O
hypertension O
. O

The O
need O
RARE O
including O
RARE O
medical O
RARE O
in O
the O
RARE O
of O
RARE O
RARE O
RARE O
actions O

RARE O
and O
pathogenesis O
of O
RARE O
RARE O

CNS O
effects O
of O
local O
RARE O
only O
partially O
dependent O
on O
RARE O
RARE O
mechanisms O
. O

RARE O
RARE O

RARE O
control O
in O
RARE O
RARE O
. O

The O
effects O
of O
RARE O
and O
RARE O
on O
isolated O
human O
RARE O
muscle O
. O

The O
RARE O
behaviour O
in O
normal O
and O
aggressive O
mice O
. O

RARE O
in O
RARE O
states O
. O

RARE O
test O
of O
ALL_CAP O
NUM O
in O
RARE O
experiments O

The O
role O
of O
RARE O
acid O
in O
the O
prevention O
of O
bladder O
tumor O
formation O
. O

The O
" O
NUM O
percent O
" O
RARE O
RARE O
in O
RARE O
airway O
RARE O
. O

3 O
'- O
RARE O
, O
8 O
- O
RARE O
, O
and O
8 O
- O
RARE O
RARE O
of O
5 O
, O
9 O
- O
dimethyl O
- O
6 O
, O
7 O
- O
RARE O
. O

RARE O
invasion O
of O
RARE O
and O
recurrent O
collateral O
inhibition O
in O
pyramidal O
RARE O
neurones O
. O

The O
distribution O
of O
body O
fluids O
following O
hemorrhage O
and O
resuscitation O
in O
RARE O
RARE O
. O

Once O
more O
RARE O
RARE O
RARE O
in O
the O
RARE O

Early O
RARE O
of O
RARE O
RARE O
50 O
per O
cent O
of O
all O
patients O
could O
be O
RARE O

RARE O
RARE O
to O
measuring O
of O
RARE O
viscosity O

RARE O
concentration O
and O
lipase I-GENE
activity O
in O
the O
RARE O
of O
RARE O
rats O
RARE O
food O
with O
different O
RARE O
content O

RARE O
of O
RARE I-GENE
aminotransferase I-GENE
( O
EC I-GENE
2 I-GENE
. I-GENE
6 I-GENE
. I-GENE
1 I-GENE
. I-GENE
1 I-GENE
) O
and O
alanine I-GENE
aminotransferase I-GENE
( O
EC I-GENE
2 I-GENE
. I-GENE
6 I-GENE
. I-GENE
1 I-GENE
. I-GENE
2 I-GENE
) O
in O
rat O
serum O
RARE O
the O
course O
of O
acute O
radiation O
RARE O
following O
whole O
body O
X O
- O
irradiation O

RARE O
RARE O
RARE O
RARE O
capacity O
produced O
by O
RARE O
- O
RARE O
salt O
retention O
in O
man O
. O

Studies O
on O
the O
RARE O
of O
ECHO O
9 O
( O
ALL_CAP O
) O
virus O
and O
its O
mutants O
RARE O
RARE O
mice O

RARE O
- O
current O
heat O
exchange O
in O
the O
respiratory O
RARE O
: O
effect O
on O
water O
and O
heat O
balance O
. O

RARE O
and O
a O
correction O
of O
RARE O
NUM O
content O
measured O
by O
NUM O
and O
ALL_CAP O
saturation O
. O

RARE O
RARE O
and O
the O
RARE O
RARE O
. O

Elimination O
of O
gamma O
- O
irradiation O
RARE O
oxidation O
in O
aqueous O
drug O
preparations O

The O
absolute O
configuration O
RARE O
C O
- O
2 O
in O
RARE O
acid O
. O

RARE O
effects O
of O
RARE O
D O
in O
rats O

The O
plasma I-GENE
growth I-GENE
hormone I-GENE
concentration O
of O
the O
RARE O
RARE O
. O

RARE O
cochlear O
response O
curves O
in O
RARE O
. O

A O
new O
RARE O
test O
RARE O
the O
on O
- O
RARE O
assay O
of O
rheumatoid I-GENE
factor I-GENE

CO2 O
RARE O
by O
RARE O
RARE O
on O
filter O
paper O
. O

The O
RARE O
of O
RARE O
RARE O
. O

RARE O
profiles O
in O
air O
RARE O
control O
activities O
. O

Effects O
of O
chronic O
RARE O
treatment O
on O
the O
sympathetic O
activity O
of O
RARE O
and O
adrenal O
RARE O
rats O
kept O
in O
RARE O
or O
cold O
RARE O
. O

The O
association O
of O
RARE O
and O
RARE O
( O
RARE O
) O
in O
the O
treatment O
of O
the O
RARE O
- O
RARE O
syndromes O
of O
RARE O

The O
effect O
of O
low O
dosage O
radiation O
on O
metabolism O
and O
function O
of O
the O
rat O
RARE O
damaged O
by O
ischemia O

RARE O
in O
RARE O
: O
world O
- O
wide O
review O
of O
clinical O
cases O
. O

RARE O
report O
. O

RARE O
of O
RARE I-GENE
IgA I-GENE
in O
human O
serum O
in O
health O
and O
RARE O
. O

RARE O
manifestations O
of O
systemic O
sclerosis O

RARE O
metabolism O
in O
chronic O
thyroiditis O
. O

Total O
body O
water O
, O
RARE O
space O
and O
I I-GENE
- I-GENE
NUM I-GENE
- I-GENE
albumin I-GENE
space O
under O
the O
acute O
effect O
of O
furosemide O

V O
. O

18F O
and O
NUM O
RARE O
in O
the O
study O
of O
RARE O
RARE O
. O

RARE O
and O
hormone O
production O
by O
human O
normal O
and O
malignant O
RARE O
in O
rats O
. O

Health O
: O
an O
RARE O
reticulum O
. O

RARE O
RARE O
method O
of O
RARE O
ALL_CAP O
- O
and O
S O
- O
S O
- O
groups O
when O
RARE O
present O

RARE O
of O
the O
RARE O
produced O
by O
femoral O
regeneration O
in O
the O
RARE O
RARE O
RARE O
Br O

RARE O
and O
RARE O
RARE O
of O
RARE O
sleep O
and O
RARE O
in O
RARE O

RARE O
of O
RARE I-GENE
to O
factor I-GENE
VII I-GENE
deficiency O
. O

3 O
. O

RARE O
venous O
catheter O
used O
RARE O
recording O
RARE O
electrocardiogram O
. O

Two O
RARE O
8 O
computer O
RARE O
RARE O
use O
in O
the O
study O
of O
the O
RARE O
and O
RARE O
contractile O
characteristics O
of O
skeletal O
muscle O
. O

RARE O
head O
- O
brain O
injuries O

The O
modification O
of O
NUM O
uptake O
into O
the O
RARE O
sarcoma O
in O
vitro O
by O
adding O
of O
RARE O
to O
the O
RARE O
medium O

RARE O
, O
parents O
, O
RARE O
and O
hearing O
disorders O

RARE O
and O
predicting O
doses O
of O
NUM O
irradiation O

RARE O
shifts O
of O
basal O
RARE O
potentials O
RARE O
human O
sleep O
. O

RARE O
dietary O
RARE O
management O
. O

5 O
RARE O
RARE O
)- O
19 O
, O
11 O
- O
RARE O
- O
NUM O
- O
RARE O
RARE O
2 O
, O
3 O
] O
RARE O
RARE O
6 O
, O
7 O
- O
b O
] O
RARE O
. O

RARE O
RARE O

RARE O
on O
the O
exchange O
of O
NUM O
in O
RARE O
and O
RARE O
rats O
by O
the O
kinetic O
analysis O
method O

Effect O
of O
thrombotic O
and O
RARE O
drugs O
on O
the O
surface O
RARE O
characteristics O
of O
canine O
RARE O
vessels O
: O
in O
vivo O
and O
in O
vitro O
studies O
. O

Measurements O
of O
activity O
with O
the O
RARE O
chamber O
VA O
- O
K O
- O
NUM O
of O
the O
RARE O
VA O
- O
NUM O

3 O
RARE O
N O
- O
RARE O
- O
N O
- O
2 O
- O
RARE O
)- O
5 O
- O
or O
7 O
- O
RARE O
RARE O
b O
] O
RARE O
RARE O
. O

RARE O
applied O
to O
cattle O

Evaluation O
of O
automatic O
RARE O
cell O
RARE O
. O

Determination O
of O
RARE O
with O
an O
RARE O

RARE O
in O
pollen O
. O

RARE O
cyst O
in O
a O
free O
RARE O
flap O
RARE O
the O
complication O
after O
treatment O
of O
RARE O
RARE O

Histological O
observations O
on O
the O
RARE O
in O
the O
second O
RARE O
of O
RARE O

RARE O
RARE O
- O
RARE O
, O
mitral O
RARE O
, O
and O
RARE O
of O
abdominal O
aorta O
. O

Studies O
on O
the O
method O
of O
size O
reduction O
of O
RARE O
compounds O
. O

Children O
with O
RARE O
vision O

Identification O
and O
estimation O
of O
RARE O
and O
RARE O
in O
urine O
by O
gas O
- O
liquid O
chromatography O
. O

RARE O
in O
RARE O
and O
conventional O
rats O
. O

The O
effects O
of O
loading O
the O
respiratory O
RARE O
on O
the O
oxygen O
consumption O
of O
RARE O
RARE O
. O

RARE O
of O
RARE O
activity O
against O
RARE O
larvae O

The O
significance O
of O
structural O
integrity O
of O
RARE O
tissue O
RARE O
antibody O
production O
in O
culture O
in O
vivo O

The O
effect O
of O
a O
constant O
magnetic O
field O
on O
the O
phagocytic O
activity O
of O
RARE O

Studies O
carried O
out O
with O
the O
RARE O
RARE O
colony O
of O
RARE O
. O

RARE O
between O
adrenergic O
mechanisms O
and O
analgesic O
effects O

RARE O
in O
the O
RARE O
series O
. O

RARE O
RARE O
2 O
RARE O
RARE O
- O
RARE O
)- O
2 O
- O
RARE O
- O
amino O
RARE O
ALL_CAP O
( O
ALL_CAP O
- O
NUM O
) O

RARE O
and O
RARE O
abilities O
of O
RARE O
- O
RARE O
rats O

The O
RARE O
of O
season O
and O
sequence O
of O
RARE O
on O
frequency O
of O
male O
, O
female O
and O
RARE O
RARE O
in O
RARE O
cows O
. O

RARE O
changes O
in O
man O
RARE O
RARE O

RARE O
prevention O
in O
the O
dental O
RARE O
. O

I O
. O

Clinical O
applications O
of O
inhibition O
of O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptors I-GENE
with O
propranolol O
. O

RARE O
view O
box O
. O

Measurement O
of O
RARE O
acid O
RARE O
by O
RARE O
. O

Effect O
of O
RARE O
on O
pituitary I-GENE
and I-GENE
serum I-GENE
ALL_CAP I-GENE
and O
FSH I-GENE
in O
testosterone O
- O
RARE O
rats O
. O

The O
significance O
of O
the O
RARE I-GENE
RARE I-GENE
test O
RARE O
the O
differentiation O
and O
identification O
of O
RARE O
species O
. O

RARE O
of O
RARE O
cells O
to O
RARE O
granuloma O
of O
the O
RARE O

RARE O
- O
term O
effects O
of O
RARE O
( O
RARE O
- O
S O
) O
on O
serum O
lipids O
in O
man O
. O

RARE I-GENE
glucose I-GENE
dehydrogenase I-GENE
deficiency O
causing O
hyperbilirubinemia O
in O
the O
newborn O

Evidence O
RARE O
RARE O
theory O
of O
RARE O
in O
the O
RARE O
. O

Effects O
of O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
blockade O
on O
airway O
RARE O
and O
RARE O
volume O
in O
normal O
and O
asthmatic O
subjects O
. O

Effect O
of O
RARE O
on O
the O
inactivation O
of O
serum I-GENE
lipoprotein I-GENE
lipase I-GENE
by O
the O
liver O
in O
RARE O
dogs O
. O

Experimental O
RARE O
RARE O
. O

I O
. O

RARE O
in O
family O
practice O
RARE O
prototype O
of O
a O
RARE O
. O

The O
possibility O
of O
selective O
chemotherapy O
of O
progressive O
RARE O
ovarian O
carcinoma O
with O
the O
aid O
of O
RARE O
and O
incorporation O
of O
RARE O
RARE O

RARE O
in O
the O
temporal O
- O
spatial O
distribution O
of O
NUM O
and O
NUM O
in O
the O
ALL_CAP O
and O
marrow O
- O
free O
RARE O
after O
incorporation O
of O
RARE O
NUM O

RARE O
RARE O
of O
adrenaline O
solutions O
: O
study O
of O
the O
RARE O
stages O
and O
their O
RARE O
value O
RARE O
the O
control O
of O
this O
RARE O

RARE O
of O
RARE O
from O
the O
colon O
in O
cases O
of O
RARE O
RARE O
and O
in O
control O
subjects O
. O

RARE O
injection O
. O

RARE O
RARE O
RARE O
a O
solution O
RARE O

RARE O
the O
diagnostic O
iron O
RARE O
. O

The O
RARE O
of O
RARE O
. O

The O
need O
in O
the O
small O
hospital O
. O

I O
. O

On O
the O
character O
of O
changes O
in O
the O
enzyme O
activity O
in O
the O
brain O
tissue O
RARE O
reflex O
epilepsy O

A O
malignant O
true O
RARE O
of O
liver O
in O
childhood O
. O

RARE O
and O
RARE O
function O

RARE O
and O
electron O
microscopy O
of O
acute O
liver O
lesions O
RARE O
by O
RARE O
NUM O
in O
RARE O
. O

Functional O
disorders O
of O
the O
RARE O
following O
gynecologic O
surgery O

Study O
of O
the O
alterations O
of O
RARE O
absorption O
, O
by O
means O
of O
I O
- O
NUM O
- O
RARE O
, O
in O
the O
whole O
body O
irradiated O
rat O

Chemical O
histologic O
and O
immunologic O
responses O
in O
rats O
to O
NUM O
- O
4 O
by O
different O
routes O
of O
administration O
. O

Clinical O
trials O
with O
1 O
, O
3 O
- O
RARE O
( O
2 O
- O
RARE O
)- O
1 O
- O
RARE O
, O
ALL_CAP O
- O
NUM O
. O

RARE O
RARE O
, O
a O
new O
water O
- O
RARE O
RARE O
medium O
RARE O
electron O
microscopy O
. O

RARE O
of O
the O
past O
5 O
years O

On O
the O
diagnosis O
of O
bovine O
RARE O
and O
its O
control O
in O
southern O
RARE O
RARE O

RARE O
with O
the O
RARE O
of O
RARE O
properties O
of O
non O
- O
RARE O
RARE O
cultures O
with O
the O
use O
of O
RARE O
' O
s O
method O

Study O
on O
RARE O
in O
the O
mouse O
fetus O
caused O
by O
RARE O
- O
radiation O
, O
RARE O
, O
RARE O
blue O
injection O
of O
RARE O
- O
A O
upon O
RARE O
animals O
RARE O
RARE O
. O

Human O
RARE O
serum O
: O
an O
RARE O
RARE O

( O
3 O
). O

Studies O
on O
the O
RARE O
infection O
of O
rabbits O
by O
RARE O
RARE O
. O

On O
catabolism O
of O
RARE O
in O
RARE O
age O

The O
effect O
of O
feeding O
patterns O
on O
fat O
deposition O
in O
mice O
. O

RARE O
and O
RARE O
in O
clinical O
RARE O

IV O
. O

Studies O
on O
RARE O
preparations O
. O

A O
case O
report O
with O
angiographic O
follow O
- O
RARE O
study O
. O

RARE O
between O
RARE O
, O
RARE O
and O
RARE I-GENE
oxidase I-GENE
RARE O

Further O
studies O
on O
a O
" O
new O
" O
human O
RARE I-GENE
RARE O
( O
RARE O
antigen O
). O

RARE O
RARE O
RARE O
indicators O
of O
RARE O
. O

RARE O
of O
a O
hospital O
that O
RARE O
its O
RARE O
orientation O
program O
. O

When O
the O
cervical O
RARE O
RARE O
is O
positive O
. O

I O
. O

The O
3 O
- O
hour O
test O
iodine O
( O
I O
- O
132 O
) O
uptake O
by O
the O
thyroid O
in O
children O
with O
growth O
deficiency O

RARE O
of O
RARE O
in O
treated O
RARE O
. O

Studies O
on O
RARE O
B O
RARE O
5 O
virus O
infections O
. O

Value O
of O
the O
method O
of O
passive O
RARE O
with O
RARE O
C O
in O
detecting O
C I-GENE
- I-GENE
reactive I-GENE
protein I-GENE
RARE O
compared O
to O
precipitation O
in O
capillaries O
and O
RARE O
latex O
test O
with O
anti I-GENE
- I-GENE
CRP I-GENE
serum O

RARE O
nerve O
function O
, O
noradrenaline O
level O
and O
noradrenaline O
uptake O
in O
RARE O
RARE O
membrane O
after O
RARE O
treatment O
. O

RARE O
of O
the O
RARE O
cord O

Study O
on O
the O
RARE O
of O
RARE O
RARE O
. O

RARE O
RARE O
isolated O
from O
an O
RARE O
RARE O
. O

The O
RARE O
of O
RARE O
RARE O
RARE O
cold O
RARE O
and O
RARE O
RARE O
animals O

RARE O
and O
migration O
in O
the O
RARE O
of O
the O
region O
of O
RARE O
, O
RARE O
, O
NUM O
- O
NUM O

On O
the O
amount O
and O
significance O
of O
the O
effective O
glucose O
level O
in O
tumors O
. O

Studies O
of O
RARE O
by O
labelled O
RARE O
in O
the O
RARE O
rat O
. O

RARE O
studies O
on O
the O
cardiovascular O
RARE O
of O
spontaneously O
hypertensive O
rats O
. O

Nuclear O
spin O
of O
NUM O
from O
the O
RARE O
RARE O
in O
its O
emission O
spectrum O
. O

Further O
observations O
on O
resorption O
in O
RARE O
pigs O
following O
injections O
of O
RARE O
blue O
. O

RARE O
of O
RARE O
. O

RARE O
on O
RARE O
' O
s O
method O
RARE O
the O
specific O
determination O
of O
RARE O
. O

RARE O
behavior O
of O
steroids O
in O
gas O
chromatography O
with O
a O
series O
of O
combination O
RARE O
. O

RARE O
RARE O
hypertrophy O
in O
RARE O
rats O
. O

( O
3 O
). O

ALL_CAP O
. O

In O
vitro O
evaluation O
of O
the O
RARE O
action O
of O
urea O
. O

Electrophoretic O
RARE O
of O
virus O
- O
RARE O
RARE I-GENE
of O
the O
RARE O
and O
urine O
in O
rabbits O

RARE O
and O
RARE O
deficiency O
in O
RARE O

RARE O
on O
RARE O
RARE O
RARE O
. O

Twenty O
- O
two O
of O
the O
NUM O
patients O
had O
a O
rise O
in O
the O
RARE O
serum O
amylase I-GENE
following O
ALL_CAP O
. O

The O
RARE O
- O
RARE O
mRNA O
in O
the O
RARE O
complex O
was O
used O
to O
RARE O
cDNA O
with O
which O
to O
probe O
a O
D O
. O
melanogaster O
genomic O
library O
. O

RARE O
RARE I-GENE
alpha I-GENE
RARE I-GENE
and O
RARE O
: O
RARE O
prognosis O

Also O
discussed O
is O
the O
possibility O
of O
a O
combined O
genetic O
and O
environmental O
etiology O
. O

RARE O
were O
RARE O
monthly O
upon O
recovery O
of O
RARE O
. O

RARE O
with O
RARE O
produced O
a O
Ca O
- O
dependent O
transient O
elevation O
of O
ALL_CAP O
level O
from O
10 O
to O
NUM O
RARE O
/ O
RARE O
, O
RARE O
RARE O
1 O
- O
2 O
min O
but O
RARE O
to O
the O
basal O
level O
by O
5 O
min O
. O

Two O
hundred O
RARE O
- O
three O
patients O
have O
received O
WR O
- O
2721 O
in O
Phase O
I O
- O
II O
studies O
. O

The O
PEPCK I-GENE
promoter O
fragment O
was O
introduced O
either O
in O
the O
proper O
orientation O
RARE O
transcription O
of O
the O
TK I-GENE
gene I-GENE
or O
in O
the O
opposite O
orientation O
. O

Many O
mammary O
tumors O
RARE O
by O
mouse O
mammary O
tumor O
virus O
( O
ALL_CAP O
) O
contain O
a O
provirus O
in O
the O
same O
region O
of O
the O
RARE O
- O
cell O
genome O
, O
leading O
to O
RARE O
of O
a O
putative O
cellular O
oncogene O
called O
int I-GENE
- I-GENE
1 I-GENE
. O

In O
these O
cases O
, O
RARE O
or O
RARE O
- O
tissue O
burden O
followed O
by O
RARE O
was O
frequently O
observed O
. O

RARE O
B O
virus O
and O
hepatoma O
. O

Eight O
recombinant O
DNA O
RARE O
of O
endogenous O
murine O
leukemia O
virus O
( O
MuLV O
)- O
related O
DNA O
sequences O
have O
been O
isolated O
from O
a O
RARE O
genomic O
library O
of O
RARE O
/ O
c O
mouse O
DNA O
. O

ALL_CAP O
NUM O
, O
NUM O
- O
NUM O
) O
The O
two O
proteins O
show O
NUM O
% O
identities O
in O
their O
amino O
acid O
sequence O
, O
in O
an O
alignment O
requiring O
RARE O
RARE O
. O

The O
envelope O
RARE O
of O
RARE O
sarcoma O
virus O
( O
ALL_CAP O
RARE O
NUM I-GENE
and O
NUM I-GENE
, O
are O
RARE O
in O
the O
membrane O
by O
a O
NUM O
- O
amino O
acid O
, O
hydrophobic O
domain O
that O
lies O
adjacent O
to O
a O
NUM O
- O
amino O
acid O
, O
cytoplasmic O
domain O
RARE O
the O
RARE O
terminus O
of O
NUM I-GENE
. O

The O
drug O
was O
given O
in O
a O
daily O
oral O
dose O
of O
NUM O
. O
5 O
g O
/ O
m2 O
, O
3 O
. O
5 O
h O
prior O
to O
each O
radiation O
treatment O
. O

RARE O
aspects O
of O
RARE O
RARE O
. O

Effect O
of O
acute O
and O
chronic O
RARE O
stress O
on O
RARE O
and O
pituitary I-GENE
- I-GENE
thyroid I-GENE
RARE I-GENE
in O
male O
rats O
. O

RARE O
mRNA O
RARE O
cytosolic I-GENE
phosphoenolpyruvate I-GENE
RARE I-GENE
of I-GENE
the I-GENE
chicken I-GENE
is O
2 O
. O
8 O
kilobases O
in O
length O
, O
similar O
to O
that O
previously O
noted O
RARE O
mRNA O
coding O
RARE O
the O
same O
enzyme O
in O
the O
rat O
. O

Upstream O
activation O
sites O
of O
the O
CYC1 I-GENE
gene I-GENE
of O
Saccharomyces O
cerevisiae O
are O
RARE O
when O
inverted O
but O
not O
when O
placed O
RARE O
of O
the O
" O
TATA O
box O
". O

An O
RARE O
5 O
. O
7 O
- O
kb O
provirus O
of O
the O
avian O
RARE O
virus O
NUM O
has O
been O
molecularly O
RARE O
RARE O
comparisons O
with O
avian O
RARE O
virus O
( O
ALL_CAP O
) O
and O
other O
avian O
tumor O
viruses O
. O

It O
is O
concluded O
that O
haloperidol O
selectively O
RARE O
the O
RARE O
' O
s O
capacity O
to O
' O
RARE O
non O
- O
stimulus O
directed O
motor O
behaviour O
'. O

Neither O
RARE O
effect O
nor O
abnormal O
laboratory O
findings O
due O
to O
this O
drug O
were O
observed O
. O

The O
results O
presented O
in O
this O
report O
suggest O
that O
the O
SV40 O
G O
- O
C O
- O
rich O
sequences O
can O
function O
RARE O
independent O
RNA I-GENE
polymerase I-GENE
II I-GENE
transcriptional O
- O
control O
elements O
. O

RARE O
of O
human O
cell O
lines O
which O
contain O
and O
express O
the O
adenovirus O
DNA O
binding O
protein O
gene O
by O
RARE O
with O
the O
HSV I-GENE
- I-GENE
1 I-GENE
tk I-GENE
gene I-GENE
. O

Diagnosis O
and O
treatment O
of O
insulin I-GENE
- O
secreting O
tumours O
. O

RARE O
RARE O
to O
account O
RARE O
the O
modality O
shift O
effect O
are O
RARE O
evaluated O
. O

The O
effects O
of O
RARE O
beta O
- O
1 O
adrenergic O
agonist O
, O
1 O
RARE O
4 O
- O
RARE O
)- O
RARE O
- O
2 O
- O
RARE O
RARE O
i O
. O
RARE O
., O
RARE O
, O
were O
examined O
on O
direct O
and O
continuous O
measurements O
of O
RARE O
ventricular O
( O
LV O
) O
pressure O
, O
diameter O
, O
ALL_CAP O
/ O
dt O
, O
velocity O
of O
shortening O
, O
arterial O
pressure O
, O
iliac O
RARE O
flow O
and O
RARE O
rate O
in O
10 O
conscious O
dogs O
. O

RARE I-GENE
RARE O
the O
approach O
of O
RARE O
. O

RARE O
treatment O
of O
schizophrenia O
with O
RARE I-GENE
- I-GENE
RARE I-GENE
- I-GENE
gamma I-GENE
- I-GENE
endorphin I-GENE

RARE O
RARE O
levels O
and O
RARE O
RARE O
binding O
activity O
in O
RARE O
- O
RARE O
cardiomyopathy O
. O

RARE O
of O
malaria O
- O
RARE O
RARE O
from O
whole O
RARE O
: O
use O
of O
a O
selective O
high O
- O
gradient O
magnetic O
separation O
technique O
. O

The O
RARE O
- O
over O
test O
to O
predict O
RARE O
in O
RARE O
. O

RARE O
RARE I-GENE
assay O
RARE O
RARE O
RARE O
scans O
in O
patients O
with O
differentiated O
thyroid O
RARE O
? O

3 O
Significant O
reductions O
in O
RARE O
mean O
arterial O
RARE O
pressure O
were O
observed O
with O
daily O
doses O
of O
NUM O
mg O
RARE O
9 O
%), O
NUM O
mg O
RARE O
10 O
%) O
and O
800 O
mg O
RARE O
14 O
%), O
and O
were O
associated O
with O
significant O
decreases O
in O
RARE O
rate O
and O
plasma I-GENE
renin I-GENE
activity O
. O

Isolation O
of O
RARE O
from O
RARE O
. O

Plasma O
and O
RARE O
RARE O
profile O
and O
lipoprotein I-GENE
lipase I-GENE
activity O
in O
RARE O
plasma O
on O
RARE O
rabbits O
were O
studied O
and O
also O
the O
incidence O
of O
atherosclerosis O
in O
different O
arterial O
RARE O
. O

( O
iii O
) O
The O
mRNA O
is O
not O
efficiently O
polyadenylated O
RARE O
sequences O
in O
the O
3 O
' O
end O
of O
the O
DHFR I-GENE
cDNA I-GENE
but O
rather O
uses O
polyadenylation O
signals O
RARE O
from O
the O
DHFR I-GENE
cDNA I-GENE
. O

At O
both O
water O
temperatures O
, O
VO2 O
increased O
RARE O
with O
increasing O
swimming O
velocity O
. O

RARE O
also O
effectively O
RARE O
RARE O
familial O
tremor O
. O

RARE O
report O
. O

The O
distribution O
RARE O
is O
followed O
by O
an O
elimination O
RARE O
with O
a O
much O
longer O
RARE O
- O
life O
( O
mean O
value O
NUM O
min O
) O
and O
a O
volume O
of O
distribution O
of O
RARE O
NUM O
- O
NUM O
RARE O
. O

RARE O
- O
selection O
experiments O
against O
RARE O
ALL_CAP O
- O
inducible O
RNA O
were O
performed O
with O
RARE O
DNA O
derived O
from O
RARE O
RARE O
in O
ALL_CAP O
- O
inducible O
RARE O
. O

Risk O
of O
ALL_CAP O
infection O
in O
patients O
on O
haemodialysis O
. O

In O
vitro O
metabolism O
of O
progesterone O
by O
the O
human O
RARE O
RARE O
. O

Two O
patients O
RARE O
from O
therapy O
, O
one O
RARE O
personal O
RARE O
and O
one O
because O
a O
RARE O
mass O
developed O
. O

All O
patients O
received O
ALL_CAP O
1 O
. O
NUM O
mg O
/ O
m2 O
weekly O
RARE O
6 O
weeks O
with O
dose O
modification O
RARE O
neurotoxicity O
. O

RARE O
acid O
in O
a O
dose O
of O
1 O
/ O
NUM O
of O
the O
LD50 O
was O
injected O
in O
the O
form O
of O
RARE O
salt O
into O
male O
and O
female O
RARE O
rats O
RARE O
7 O
days O
after O
8 O
- O
and O
12 O
- O
day O
injections O
of O
RARE O
. O

Serum O
RARE O
acid O
had O
an O
RARE O
and O
the O
strongest O
association O
with O
systolic O
RARE O
pressure O
among O
the O
risk O
factors O
including O
RARE O
pressure O
, O
RARE O
cholesterol O
, O
RARE O
, O
gamma I-GENE
- I-GENE
GTP I-GENE
and O
obesity O
. O

Plasma I-GENE
RARE I-GENE
, O
RARE I-GENE
, O
and O
somatostatin I-GENE
- I-GENE
like I-GENE
hormone I-GENE
in O
chronic O
RARE O
failure O
patients O
. O

Effect O
of O
RARE O
on O
growth I-GENE
hormone I-GENE
and O
prolactin I-GENE
RARE O
in O
normal O
subjects O
. O

In O
several O
cases O
of O
definite O
ALL_CAP O
, O
RARE O
RARE O
RARE O
examinations O
after O
more O
than O
a O
one O
year O
interval O
were O
performed O
on O
two O
RARE O
, O
and O
the O
clinical O
and O
histopathological O
changes O
were O
investigated O
. O

All O
RARE O
using O
the O
machine O
found O
that O
the O
RARE O
terminal O
was O
simple O
to O
RARE O
, O
but O
found O
that O
RARE O
abnormalities O
caused O
an O
increased O
effort O
and O
RARE O
a O
longer O
time O
. O

RARE O
RARE O
RARE O
the O
ALL_CAP O
- O
RARE O
complex O
and O
using O
RARE O
gamma O
irradiation O
has O
been O
performed O
in O
a O
series O
of O
52 O
patients O
with O
severe O
pain O
due O
to O
malignancy O
. O

2 O
RARE O
capsules O
, O
each O
containing O
NUM O
- O
NUM O
mg O
of O
RARE O
estradiol O
, O
were O
inserted O
subcutaneously O
in O
5 O
men O
with O
benign O
RARE O
hypertrophy O
. O

When O
used O
subcutaneously O
or O
intravenously O
in O
maximum O
tolerated O
doses O
the O
antibiotic O
inhibited O
the O
development O
of O
RARE O
ALL_CAP O
/ O
Li O
by O
NUM O
and O
70 O
per O
cent O
respectively O
. O

Effect O
of O
2 O
RARE O
p O
- O
RARE O
) O
RARE O
on O
5 O
- O
RARE O
concentration O
and O
RARE I-GENE
oxidase I-GENE
activity O
in O
rat O
brain O
. O

RARE O
, O
pure O
pancreatic O
juice O
was O
infused O
into O
the O
RARE O
. O

An O
experiment O
was O
carried O
on O
NUM O
grown O
RARE O
RARE O
and O
RARE O
from O
4 O
RARE O
RARE O
, O
RARE O
with O
RARE O
RARE O
and O
RARE O
vaccines O
RARE O
RARE O
the O
RARE O
against O
RARE O
through O
ALL_CAP O
and O
RARE O
RARE O
with O
a O
pathogenic O
virus O
. O

( O
2 O
) O
The O
RARE O
of O
adaptive O
RARE O
RARE O
the O
isolation O
of O
spikes O
and O
RARE O
waves O
, O
which O
had O
been O
RARE O
in O
view O
of O
the O
short O
duration O
of O
such O
RARE O
in O
relation O
to O
the O
length O
of O
the O
RARE O
( O
1 O
. O
2 O
sec O
) O
used O
RARE O
the O
RARE O
functions O
employed O
in O
the O
RARE O
algorithm O
, O
was O
confirmed O
. O

The O
ability O
of O
chronic O
ALL_CAP O
- O
272 O
( O
RARE O
) O
treatment O
to O
prevent O
the O
induction O
of O
RARE O
ventricular O
RARE O
was O
assessed O
in O
the O
conscious O
dog O
subjected O
to O
serial O
programmed O
electrical O
RARE O
on O
days O
3 O
RARE O
5 O
after O
RARE O
infarction O
. O

The O
effect O
of O
RARE O
on O
the O
biphasic O
response O
of O
RARE O
ocular O
pressure O
to O
RARE O
. O

In O
most O
cases O
of O
acute O
RARE O
infarction O
, O
the O
reciprocal O
ST O
segment O
RARE O
observed O
in O
contralateral O
leads O
are O
less O
marked O
than O
the O
RARE O
ST O
segment O
elevations O
. O

Bacillus O
RARE O
cross O
- O
infection O
in O
a O
RARE O
- O
unit O
. O

We O
have O
followed O
37 O
phenytoin O
- O
treated O
patients O
with O
RARE O
serum I-GENE
IgA I-GENE
concentrations O
RARE O
2 O
- O
7 O
years O
. O

In O
the O
latter O
category O
particular O
RARE O
is O
being O
placed O
on O
new O
RARE O
analogues O
of O
RARE O
and O
analogues O
of O
RARE O
RARE O
RARE O
. O

RARE O
course O
of O
RARE O
. O

RARE O
mRNA O
RARE O
by O
a O
cDNA O
homologous O
to O
the O
HindIII I-GENE
- I-GENE
P I-GENE
/ O
EcoRI I-GENE
- I-GENE
B I-GENE
region O
of O
the O
ALL_CAP O
map O
directed O
the O
RARE O
of O
NUM O
and O
NUM O
proteins O
which O
RARE O
with O
the O
NUM O
and O
NUM O
proteins O
translated O
from O
RNA O
RARE O
by O
the O
HindIII I-GENE
- I-GENE
A I-GENE
/ O
EcoRI I-GENE
- I-GENE
C I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
G I-GENE
cDNA O
. O

RARE O
the O
complement I-GENE
factor I-GENE
NUM I-GENE
decreased O
by O
20 O
%, O
while O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
showed O
postoperatively O
an O
increase O
by O
NUM O
%. O

A O
polypeptide O
chain O
of O
NUM O
residues O
of O
the O
deduced O
yeast O
amino O
acid O
sequence O
closely O
resembles O
a O
peptide O
sequence O
RARE O
the O
ALL_CAP O
binding O
site O
of O
bovine I-GENE
muscle I-GENE
RARE I-GENE
kinase I-GENE
. O

The O
NUM O
RARE O
, O
however O
, O
could O
be O
differentiated O
from O
the O
two O
later O
RARE O
since O
it O
increased O
in O
amplitude O
with O
increased O
task O
RARE O
while O
the O
N2 O
and O
NUM O
amplitudes O
remained O
constant O
. O

Differential O
RARE O
size O
associated O
with O
unilateral O
brain O
damage O
. O

The O
RARE O
administration O
of O
both O
drugs O
markedly O
RARE O
the O
incidence O
of O
VF O
RARE O
by O
the O
release O
of O
a O
40 O
- O
min O
coronary O
artery O
occlusion O
. O

These O
fusions O
are O
contained O
on O
plasmids O
which O
have O
both O
yeast O
and O
E O
. O
coli O
replication O
origins O
and O
selectable O
markers O
and O
, O
therefore O
, O
can O
be O
used O
to O
transform O
either O
yeast O
or O
E O
. O
coli O
cells O
. O

Therefore O
, O
it O
was O
concluded O
that O
thrombotic O
tendency O
RARE O
existed O
in O
patients O
with O
MS O
compared O
to O
those O
with O
non O
ALL_CAP O
and O
that O
it O
was O
one O
of O
the O
causes O
of O
the O
significantly O
high O
incidence O
of O
RARE O
in O
comparison O
with O
non O
ALL_CAP O
. O

RARE O
was O
significant O
in O
RARE O
cases O
; O
three O
patients O
developed O
WBC O
counts O
less O
than O
1 O
, O
NUM O
/ O
NUM O
and O
one O
of O
these O
patients O
died O
with O
sepsis O
. O

RARE O
electrodes O
may O
yield O
larger O
ALL_CAP O
amplitudes O
than O
RARE O
or O
RARE O
electrodes O
. O

RARE O
of O
immune O
cells O
such O
RARE O
transfer I-GENE
factor I-GENE
and O
RARE O
form O
the O
third O
and O
possibly O
most O
important O
group O
of O
immune O
- O
stimulating O
agents O
. O

Use O
of O
the O
immunofluorescence O
method O
RARE O
identification O
of O
RARE O
in O
cell O
cultures O

This O
fraction O
is O
resistant O
to O
RARE O
by O
DNase I-GENE
I I-GENE
and O
RNase I-GENE
NUM I-GENE
and O
RARE O
completely O
upon O
RARE O
hydrolysis O
. O

The O
RARE O
of O
a O
small O
library O
of O
mouse O
RARE O
DNA O
has O
been O
previously O
reported O
( O
RARE O
et O
al O
., O
RARE O
RARE O
RARE O
. O

No O
direct O
repeats O
flank O
the O
RARE O
in O
the O
NUM I-GENE
/ I-GENE
4 I-GENE
locus I-GENE
. O

The O
direct O
effects O
of O
RARE O
release O
were O
( O
a O
) O
an O
early O
fall O
in O
MAP O
followed O
by O
a O
RARE O
pressor O
effect O
; O
and O
( O
b O
) O
an O
early O
RARE O
followed O
by O
a O
RARE O
tachycardia O
. O

At O
RARE O
( O
RARE O
RARE O
a O
RARE O
characterized O
by O
a O
high O
incidence O
of O
RARE O
and O
NUM I-GENE
deficiency O
less O
than O
RARE O
the O
people O
between O
18 O
and O
NUM O
have O
a O
RARE O
knowledge O
of O
genetic O
diseases O
and O
of O
their O
prevention O
. O

The O
number O
of O
elements O
and O
their O
sizes O
relative O
to O
the O
configuration O
were O
varied O
in O
a O
series O
of O
five O
experiments O
. O

In O
addition O
, O
the O
overall O
RARE O
that O
a O
patient O
would O
undergo O
ALL_CAP O
was O
greater O
in O
a O
RARE O
in O
which O
more O
than O
one O
RARE O
20 O
mm O
or O
larger O
was O
developing O
than O
in O
a O
RARE O
in O
which O
a O
single O
large O
RARE O
was O
developing O
. O

RARE O
with O
the O
RARE O
RARE O
RARE O
free O
flap O
. O

Five O
of O
the O
patients O
with O
increased O
L O
- O
L O
size O
had O
a O
normal O
A O
- O
P O
diameter O
. O

RARE O
with O
RARE O
( O
ALL_CAP O
) O
combined O
with O
chemotherapeutic O
agents O
was O
evaluated O
in O
two O
RARE O
tumor O
- O
C3H O
/ O
He O
mouse O
RARE O
. O

However O
, O
when O
combined O
with O
RARE O
C O
given O
with O
1 O
to O
5 O
- O
days O
interval O
, O
the O
concurrent O
administration O
of O
ALL_CAP O
prolonged O
significantly O
the O
life O
- O
span O
of O
the O
tumor O
- O
RARE O
mice O
. O

Data O
are O
presented O
RARE O
that O
the O
NUM O
beta O
- O
hydroxy O
RARE O
metabolite O
of O
ALL_CAP O
may O
RARE O
be O
the O
biologically O
RARE O
agent O
. O

The O
RARE O
surface O
is O
often O
almost O
entirely O
RARE O
by O
a O
thick O
layer O
of O
RARE O
RARE O
tissue O
. O

In O
contrast O
, O
in O
ALL_CAP O
patients O
RARE O
ALL_CAP O
the O
ALL_CAP I-GENE
- O
RARE O
suppressor O
response O
was O
markedly O
RARE O
. O

Functional O
characterization O
of O
a O
fraction O
identified O
by O
its O
activity O
in O
a O
second O
template O
rescue O
assay O
. O

It O
has O
been O
established O
that O
preoperative O
irradiation O
in O
the O
form O
of O
the O
fractionation O
of O
a O
single O
RARE O
dose O
of O
6 O
Gy O
every O
other O
day O
, O
the O
summary O
dose O
of O
NUM O
Gy O
within O
8 O
- O
10 O
days O
followed O
by O
surgery O
1 O
- O
3 O
days O
after O
irradiation O
does O
not O
either O
RARE O
its O
performance O
or O
the O
course O
of O
the O
postoperative O
period O
, O
and O
by O
the O
short O
- O
and O
long O
- O
term O
results O
it O
is O
RARE O
RARE O
than O
the O
routine O
dose O
fractionation O
. O

RARE I-GENE
gels O
and O
their O
possible O
RARE O
RARE O
surface O
RARE O
in O
health O
and O
RARE O
. O

RARE O
- O
B O
vaccination O
in O
the O
elderly O
. O

RARE O
imaging O
is O
thus O
of O
limited O
use O
in O
evaluation O
of O
suspected O
RARE O
cell O
tumors O
of O
bone O
. O

The O
RARE O
coupling O
RARE O
RARE O
acid O
has O
been O
replaced O
by O
1 O
, O
3 O
- O
RARE O
acid O
; O
RARE O
is O
produced O
in O
the O
flow O
through O
RARE O
directly O
from O
ALL_CAP O
and O
RARE O
T O
. O

RARE O
volume O
stiffness O
RARE O
. O
the O
mean O
RARE O
stress O
relationship O
of O
ALL_CAP O
shifted O
RARE O
, O
whereas O
the O
normalized O
RARE O
muscle O
stiffness O
RARE O
. O
the O
mean O
RARE O
stress O
relationship O
of O
ALL_CAP O
showed O
a O
smaller O
slope O
. O

RARE O
of O
RARE O
RARE O
acid O
RARE O
RARE O

RARE O
RARE O
reduces O
arterial O
pressure O
by O
a O
decrease O
in O
intravascular O
volume O
and O
cardiac O
output O
associated O
with O
a O
fall O
in O
sympathetic O
activity O
. O

The O
effect O
of O
treatment O
may O
thus O
be O
divided O
into O
two O
main O
phases O
RARE O
an O
initial O
RARE O
with O
a O
reduction O
in O
LV O
mass O
and O
a O
reduction O
in O
cardiac O
output O
and O
RARE O
change O
in O
RARE O
peripheral O
resistance O
RARE O
and O
a O
second O
RARE O
with O
a O
constant O
LV O
mass O
but O
an O
increase O
in O
cardiac O
output O
to O
the O
pretreatment O
level O
again O
and O
a O
concomitant O
decrease O
in O
RARE O
peripheral O
resistance O
. O

This O
study O
was O
undertaken O
to O
assess O
the O
effects O
of O
hypothermia O
and O
chemical O
RARE O
on O
the O
RARE O
recovery O
of O
RARE O
non O
- O
RARE O
rat O
hearts O
subjected O
to O
an O
extended O
period O
of O
global O
ischaemia O
. O

RARE O
profiles O
calculated O
RARE O
the O
RARE O
model O
with O
RARE O
diffusion O
were O
similar O
to O
those O
derived O
RARE O
the O
two O
models O
of O
RARE O
diffusion O
. O

RARE O
RARE O
RARE O
RARE O
RARE O

RARE O
of O
serum O
RARE I-GENE
kinase I-GENE
B I-GENE
RARE I-GENE
in O
the O
diagnosis O
of O
acute O
RARE O
infarction O
. O

Selective O
macrophage O
inhibition O
abolishes O
RARE O
- O
RARE O
reduction O
of O
metastasis O
. O

Restriction O
enzyme O
and O
RARE O
analyses O
confirmed O
that O
sequences O
unique O
to O
ALL_CAP O
( O
src I-GENE
sequences I-GENE
) O
are O
RARE O
RARE O
the O
RARE O
of O
the O
ALL_CAP O
genome O
and O
are O
RARE O
1 O
. O
5 O
RARE O
RARE O
in O
length O
. O

Among O
RARE O
different O
library O
isolates O
containing O
6 I-GENE
. I-GENE
5 I-GENE
- I-GENE
to I-GENE
7 I-GENE
- I-GENE
kb I-GENE
ALL_CAP I-GENE
RARE I-GENE
, O
some O
RARE O
sites O
were O
highly O
RARE O
whereas O
others O
varied O
in O
both O
occurrence O
and O
position O
. O

RARE O
and O
RARE O
learning O
: O
a O
review O
. O

A O
RARE O
RARE O
RARE O
of O
E O
. O
coli O
( O
NUM O
: O
NUM O
: O
NUM O
) O
was O
RARE O
recovered O
from O
RARE O
with O
ALL_CAP O
while O
RARE O
was O
demonstrated O
on O
a O
number O
of O
RARE O
. O

The O
antibody O
titer O
of O
NUM O
RARE O
to O
SA O
- O
11 O
RARE O
was O
determined O
by O
enzyme O
- O
RARE O
immunosorbent O
blocking O
assay O
. O

RARE O
( O
dT O
) O
and O
RARE O
RARE O
RARE O
DNA O
were O
more O
effective O
than O
were O
other O
RARE O
tested O
in O
RARE O
accumulation O
of O
19 O
ALL_CAP O
RARE O
( O
dT O
) O
8 O
was O
RARE O
effective O
RARE O
were O
longer O
molecules O
of O
( O
dT O
) O
RARE O
, O
but O
( O
dT O
) O
4 O
and O
( O
dT O
) O
6 O
were O
much O
less O
effective O
, O
indicating O
that O
the O
binding O
site O
involved O
in O
19 O
ALL_CAP I-GENE
RARE I-GENE
accumulation O
RARE O
between O
6 O
and O
8 O
residues O
of O
( O
dT O
) O
RARE O
. O

A O
double O
- O
blind O
trial O
of O
RARE O
- O
strength O
RARE O
RARE O
ALL_CAP O
bladder O
irrigation O
in O
RARE O
. O

Thus O
it O
appears O
that O
RARE O
of O
a O
RARE O
element O
near O
the O
5 O
' O
terminus O
of O
the O
structural O
gene O
can O
produce O
RARE O
RARE O
of O
a O
normally O
glucose O
- O
repressed O
enzyme O
. O

Five O
experiments O
examined O
the O
influence O
of O
RARE O
antagonists O
on O
both O
the O
short O
- O
term O
analgesic O
reaction O
resulting O
NUM O
min O
after O
exposure O
to O
RARE O
shock O
and O
the O
long O
- O
term O
analgesic O
reaction O
resulting O
after O
RARE O
to O
shock O
NUM O
hr O
after O
RARE O
shock O
exposure O
. O

Experiment O
3 O
showed O
that O
the O
long O
- O
term O
analgesic O
reaction O
could O
also O
be O
RARE O
by O
administration O
of O
naltrexone O
prior O
to O
RARE O
to O
shock O
. O

During O
the O
period O
from O
RARE O
to O
August O
, O
NUM O
, O
an O
epidemic O
of O
RARE O
, O
foot O
and O
mouth O
RARE O
( O
ALL_CAP O
) O
occurred O
in O
RARE O
RARE O
. O

A O
NUM O
polypeptide O
was O
detected O
RARE O
a O
translation O
product O
of O
RARE O
RNA O
that O
hybridized O
to O
this O
DNA O
fragment O
. O

RARE O
simian O
virus O
40 O
( O
SV40 O
) O
chromosomes O
were O
found O
to O
be O
similar O
to O
other O
eukaryotic O
chromosomes O
in O
that O
the O
rate O
and O
extent O
of O
RARE I-GENE
RARE I-GENE
( O
RARE I-GENE
) O
digestion O
were O
greater O
with O
RARE O
than O
with O
RARE O
RARE O
SV40 O
chromatin O
. O

A O
hypothesis O
. O

We O
have O
investigated O
the O
requirements O
of O
the O
ALL_CAP I-GENE
gene I-GENE
switch O
by O
characterizing O
two O
RARE I-GENE
gamma I-GENE
NUM I-GENE
genes I-GENE
from O
a O
gamma I-GENE
NUM I-GENE
producing O
mouse O
myeloma O
( O
ALL_CAP O
- O
11 O
). O

RARE O
and O
RARE O

The O
genome O
of O
avian O
RARE O
virus O
contains O
two O
independently O
RARE O
genetic O
loci O
( O
v I-GENE
- I-GENE
erbA I-GENE
and O
v I-GENE
- I-GENE
erbB I-GENE
) O
whose O
activities O
are O
probably O
responsible O
RARE O
RARE O
by O
the O
virus O
. O

Because O
RNase I-GENE
III I-GENE
RARE I-GENE
mutants I-GENE
are O
RARE O
in O
RARE I-GENE
RARE O
, O
RARE O
of O
the O
ALL_CAP I-GENE
mRNA I-GENE
RARE O
RARE I-GENE
by O
this O
RARE O
may O
cause O
int I-GENE
mRNA I-GENE
RARE O
and O
decrease O
int I-GENE
RARE O
. O

At O
least O
one O
clone O
, O
lambda O
ALL_CAP O
NUM O
, O
contains O
, O
in O
addition O
to O
the O
histone I-GENE
genes I-GENE
, O
a O
region O
that O
RARE O
with O
a O
cytoplasmic O
RNA O
RARE O
NUM O
nucleotides O
in O
length O
. O

Both O
RARE O
and O
hormonal O
pathways O
and O
both O
RARE O
and O
RARE O
substances O
play O
roles O
in O
the O
complex O
modulation O
of O
pain O
RARE O
. O

RARE O
of O
impaired O
immune O
functions O
in O
aging O
animals O
. O

RARE O
serum O
ACTH I-GENE
levels O
were O
normal O
. O

WR O
- O
2721 O
( O
S O
- O
2 O
RARE O
3 O
RARE O
) O
RARE O
acid O
) O
has O
been O
investigated O
RARE O
its O
ability O
to O
protect O
gut O
, O
RARE O
, O
and O
RARE O
, O
RARE O
RARE O
RARE O
RARE O
( O
RARE O
) O
tumor O
nodules O
, O
in O
the O
lungs O
of O
mice O
from O
gamma O
- O
radiation O
injury O
. O

In O
fact O
, O
RARE O
of O
polypeptides O
were O
produced O
by O
initiation O
of O
translation O
RARE O
AUG O
codons O
within O
sequences O
coding O
RARE O
NUM I-GENE
and O
T I-GENE
, O
presumably O
RARE O
a O
result O
of O
transcription O
initiation O
events O
that O
generated O
5 O
' O
ends O
immediately O
upstream O
from O
these O
RARE O
. O

In O
addition O
, O
NUM I-GENE
ALL_CAP O
RARE O
DNA O
is O
organized O
into O
RARE O
whose O
size O
and O
RARE O
are O
indistinguishable O
from O
that O
of O
bulk O
yeast O
chromatin O
. O

The O
frequency O
of O
previous O
transfusion O
in O
chronic O
hepatitis O
, O
cirrhosis O
and O
RARE O
carcinoma O
of O
type O
NANB O
was O
NUM O
. O
8 O
, O
37 O
. O
1 O
and O
NUM O
. O
1 O
%, O
respectively O
, O
whereas O
the O
incidence O
of O
early O
RARE O
hepatitis O
was O
8 O
. O
5 O
, O
8 O
. O
6 O
and O
7 O
. O
5 O
%, O
respectively O
. O
in O
chronic O
liver O
diseases O
with O
a O
history O
of O
jaundice O
and O
/ O
or O
hepatitis O
, O
previous O
RARE O
are O
more O
frequently O
associated O
with O
type O
NANB O
than O
with O
type O
B O
RARE O
. O

Of O
NUM O
hepatitis O
B O
patients O
seen O
RARE O
12 O
months O
, O
6 O
% O
had O
chronic O
hepatitis O
RARE O
RARE O
, O
NUM O
% O
had O
developed O
anti I-GENE
- I-GENE
HBs I-GENE
antibodies I-GENE
, O
and O
7 O
. O
3 O
% O
still O
had O
abnormal O
liver O
function O
. O

RARE O
on O
antibody O
against O
RARE O
drop O
RARE O
- O
NUM O
virus O
among O
chicken O
RARE O
in O
Japan O
. O

In O
NUM O
patients O
in O
whom O
gated O
equilibrium O
RARE O
and O
cardiac O
RARE O
were O
performed O
within O
a O
6 O
day O
interval O
, O
RARE O
and O
fractional O
portions O
of O
global O
and O
regional O
right O
ventricular O
ejection O
fraction O
( O
ALL_CAP O
) O
were O
correlated O
with O
pulmonary O
arterial O
systolic O
pressure O
. O

NUM O
, O
193 O
- O
NUM O
). O

The O
combination O
of O
ALL_CAP O
and O
WR O
- O
2721 O
gave O
an O
RARE O
response O
compared O
with O
either O
drug O
used O
alone O
, O
resulting O
in O
some O
sensitization O
with O
single O
doses O
and O
an O
overall O
protection O
with O
RARE O
small O
doses O
. O

Two O
mutations O
that O
affect O
RARE I-GENE
RARE I-GENE
protein I-GENE
gene I-GENE
RARE O
in O
the O
2 O
/ O
3 O
variant O
Drosophila O
melanogaster O
RARE O
were O
investigated O
. O

The O
RARE O
are O
considered O
to O
be O
one O
of O
the O
forms O
of O
activity O
of O
the O
structured O
RARE O
cortical O
RARE O
, O
i O
. O
RARE O
. O
the O
RARE O
. O

The O
strong O
conservation O
of O
the O
inverted O
terminal O
repeat O
sequence O
may O
reflect O
a O
common O
RARE O
mechanism O
RARE O
NUM I-GENE
elements I-GENE
and O
MuLV O
RARE O
. O

A O
cDNA O
cloning O
vector O
that O
permits O
RARE O
of O
cDNA O
inserts O
in O
mammalian O
cells O
. O

Hybridization O
of O
RARE O
- O
transformed O
Escherichia O
coli O
NUM O
colonies O
with O
32P O
- O
labeled O
viral O
genome O
RNAs O
demonstrated O
the O
presence O
of O
DNA O
RARE O
representative O
of O
each O
of O
the O
10 O
RARE O
RNAs O
and O
10 O
of O
the O
11 O
RARE O
RARE O
of O
the O
RARE O
genome O
. O

Another O
sequence O
, O
ALL_CAP O
, O
which O
is O
RARE O
several O
times O
in O
many O
RARE O
and O
RARE O
, O
and O
which O
is O
thought O
to O
play O
a O
role O
in O
DNA O
replication O
and O
/ O
or O
transcription O
, O
is O
not O
found O
in O
the O
ALL_CAP O
sequence O
presented O
. O

In O
conclusion O
, O
these O
studies O
indicate O
that O
RARE O
( O
1 O
) O
decreases O
RARE O
- O
RARE O
RARE O
acid O
RARE O
, O
and O
( O
2 O
) O
RARE O
bile O
- O
RARE O
disruption O
of O
the O
RARE O
RARE O
barrier O
in O
the O
canine O
RARE O
RARE O
. O

Lung O
density O
increased O
in O
RARE O
- O
exposed O
, O
but O
not O
in O
RARE O
- O
RARE O
- O
exposed O
animals O
. O

The O
hepatitis I-GENE
A I-GENE
virus I-GENE
antibody I-GENE
( O
anti I-GENE
- I-GENE
ALL_CAP I-GENE
) O
in O
chronic O
diffuse O
liver O
diseases O

The O
junctions O
between O
viral O
and O
cellular O
sequences O
were O
determined O
by O
DNA O
sequence O
analysis O
to O
be O
NUM O
nucleotides O
into O
the O
NUM I-GENE
sequence I-GENE
and O
1 O
, O
NUM O
nucleotides O
into O
the O
polymerase O
sequence O
. O

RARE O
( O
2 O
mg O
/ O
kg O
bolus O
+ O
2 O
mg O
X O
kg O
- O
1 O
X O
h O
- O
1 O
) O
was O
given O
with O
one O
of O
the O
two O
doses O
of O
the O
lipopolysaccharide O
. O

Gel O
route O
preparation O
of O
low O
RARE O
dental O
RARE O
RARE O
. O

I O
. O

RARE O
RNA O
, O
molecularly O
RARE O
RARE O
DNA O
, O
and O
virus O
- O
specific O
protein O
of O
avian O
RARE O
NUM O
were O
analyzed O
. O

RARE O
recordings O
were O
performed O
on O
the O
optic O
RARE O
of O
the O
RARE O
in O
vitro O
. O

Molecular O
RARE O
and O
evolutionary O
origin O
of O
human I-GENE
cardiac I-GENE
muscle I-GENE
actin I-GENE
gene I-GENE
. O

The O
mutants O
were O
obtained O
by O
substitution O
into O
a O
RARE O
clone O
of O
M O
- O
MuLV O
DNA O
by O
DNA O
from O
two O
RARE O
transforming O
viruses O
, O
RARE O
MuLV O
( O
RARE O
- O
MuLV O
) O
and O
Moloney O
murine O
sarcoma O
virus O
( O
M O
- O
ALL_CAP O
). O

RARE O
RARE O
the O
cloning O
and O
RARE O
of O
full O
- O
length O
double O
- O
RARE O
cDNAs O
under O
control O
of O
the O
SV40 I-GENE
early I-GENE
or O
RARE I-GENE
gene I-GENE
promoter O
. O

RARE O
a O
RARE O
protein O
and O
sucrose O
- O
based O
diet O
with O
levels O
of O
2 O
. O
2 O
, O
11 O
, O
and O
NUM O
ppm O
of O
the O
antibiotic O
, O
from O
the O
two O
sources O
each O
with O
two O
different O
RARE O
, O
improved O
RARE O
gain O
of O
chicks O
an O
average O
of O
NUM O
% O
and O
improved O
feed O
efficiency O
an O
average O
of O
NUM O
% O
RARE O
the O
RARE O
levels O
( O
all O
P O
less O
than O
. O
01 O
). O

The O
ALL_CAP I-GENE
- O
lacZ I-GENE
and O
the O
RARE I-GENE
- O
lacZ I-GENE
fused O
genes O
were O
constructed O
and O
RARE O
proteins O
with O
beta I-GENE
- I-GENE
galactosidase I-GENE
activity O
were O
produced O
. O

Overall O
RARE O
of O
antibody O
were O
70 O
per O
cent O
in O
cattle O
, O
67 O
per O
cent O
in O
sheep O
and O
NUM O
per O
cent O
in O
goats O
RARE O
assessed O
by O
an O
RARE O
test O
. O

Expression O
of O
herpes O
simplex O
virus O
beta O
and O
gamma O
genes O
integrated O
in O
mammalian O
cells O
and O
their O
induction O
by O
an O
alpha O
gene O
product O
. O

The O
RARE O
RARE O
site O
is O
RARE O
. O

This O
is O
consistent O
with O
a O
model O
RARE O
that O
ALL_CAP O
was O
generated O
by O
RARE O
between O
RARE O
DNA O
of O
a O
simian O
sarcoma O
associated O
virus O
and O
RARE I-GENE
- I-GENE
RARE I-GENE
and O
that O
RARE O
were O
RARE O
out O
subsequently O
from O
a O
fused O
viral I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
RNA I-GENE
. O

We O
conclude O
that O
, O
with O
RARE O
nervous O
RARE O
activity O
RARE O
, O
carotid O
RARE O
reflex O
activation O
can O
elicit O
an O
absolute O
RARE O
RARE O
reduction O
in O
coronary O
RARE O
flow O
in O
the O
normal O
, O
conscious O
dog O
, O
despite O
an O
increase O
in O
arterial O
pressure O
. O

Female O
subjects O
, O
including O
both O
normal O
subjects O
and O
idiopathic O
RARE O
stone O
- O
RARE O
, O
have O
RARE O
RARE O
cyclic O
AMP O
levels O
than O
their O
male O
counterparts O
, O
and O
this O
difference O
is O
significant O
when O
RARE O
cyclic O
AMP O
is O
RARE O
in O
the O
RARE O
mumol O
/ O
g O
of O
RARE O
. O

We O
conclude O
that O
the O
' O
RARE O
RARE O
' O
observed O
in O
asthmatic O
patients O
cannot O
RARE O
be O
explained O
by O
changes O
in O
cell O
receptor O
number O
or O
affinity O
, O
RARE O
our O
results O
suggest O
that O
both O
groups O
have O
RARE O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
function O
. O

The O
effect O
of O
desipramine O
probably O
represents O
inhibition O
of O
RARE O
uptake O
and O
that O
of O
RARE O
and O
RARE O
blockade O
of O
RARE O
uptake O
and O
RARE O
alpha I-GENE
2 I-GENE
- I-GENE
RARE I-GENE
. O

We O
conclude O
that O
the O
NUM I-GENE
structural I-GENE
gene I-GENE
is O
required O
RARE O
initiation O
or O
amplification O
of O
the O
splenic O
RARE O
hyperplasia O
which O
RARE O
the O
RARE O
RARE O
of O
RARE O
RARE O
. O

RARE O
treatment O
of O
pulmonary O
metastases O
. O

A O
promoter O
sequence O
( O
RARE O
- O
RARE O
or O
TATA O
box O
) O
is O
situated O
NUM O
RARE O
RARE O
upstream O
from O
the O
point O
of O
initiation O
of O
transcription O
which O
was O
found O
by O
S1 I-GENE
RARE I-GENE
mapping O
and O
by O
RARE O
- O
primed O
reverse O
transcription O
of O
rat I-GENE
ALL_CAP I-GENE
mRNA I-GENE
. O

Each O
of O
these O
RARE O
mRNAs O
has O
an O
RARE O
RARE O
sequence O
of O
NUM O
bases O
and O
a O
single O
intron O
of O
RARE O
NUM O
bases O
which O
are O
contained O
entirely O
within O
RARE O
/ O
RARE O
sequences O
. O

The O
RARE O
of O
chloramphenicol I-GENE
RARE I-GENE
was O
detected O
within O
1 O
h O
after O
infection O
of O
cells O
with O
recombinant O
virus O
, O
reflecting O
the O
early O
nature O
of O
the O
promoters O
used O
. O

ALL_CAP I-GENE
II I-GENE
RARE O
, O
measured O
by O
agar O
RARE O
assays O
of O
RARE O
resistance O
and O
by O
immunoprecipitation O
of O
the O
ALL_CAP I-GENE
II I-GENE
protein I-GENE
, O
was O
repressed O
in O
the O
presence O
of O
cysteine O
and O
RARE O
in O
its O
absence O
. O

A O
computed O
RARE O
scan O
obtained O
after O
ALL_CAP O
- O
NUM O
infusion O
accurately O
showed O
the O
perfusion O
pattern O
of O
the O
implanted O
catheter O
. O

The O
RARE O
RARE O
of O
the O
NUM I-GENE
5 I-GENE
' I-GENE
flanking I-GENE
region I-GENE
has O
many O
features O
common O
to O
those O
of O
RARE O
eukaryotic O
genes O
. O

The O
12 I-GENE
, I-GENE
NUM I-GENE
ALL_CAP I-GENE
( I-GENE
NUM I-GENE
) I-GENE
IE I-GENE
polypeptide I-GENE
encoded O
by O
ALL_CAP I-GENE
- I-GENE
5 I-GENE
is O
translated O
from O
an O
88 O
RARE O
RARE O
reading O
frame O
, O
RARE O
a O
NUM O
RARE O
3 O
' O
non O
- O
translated O
region O
. O

The O
greatest O
difference O
between O
the O
NUM I-GENE
and I-GENE
NUM I-GENE
RARE I-GENE
is O
the O
absence O
, O
in O
the O
NUM O
protein O
, O
of O
12 O
amino O
RARE O
RARE O
between O
the O
two O
RARE O
domains O
in O
the O
NUM O
protein O
( O
amino O
RARE O
151 O
- O
NUM O
). O

No O
significant O
correlation O
was O
found O
between O
ALL_CAP O
or O
RARE O
thickness O
and O
body O
surface O
area O
, O
age O
, O
RARE O
pressure O
, O
RARE O
rate O
, O
cardiac O
output O
, O
RARE O
peripheral O
resistance O
and O
RARE O
ventricular O
systolic O
RARE O
stress O
, O
whereas O
NUM O
was O
correlated O
with O
RARE O
catecholamines O
only O
in O
hypertensive O
patients O
( O
RARE O
= O
NUM O
. O
NUM O
, O
p O
less O
than O
NUM O
. O
001 O
). O

Furthermore O
, O
RARE O
RARE O
- O
RARE O
sequences O
are O
present O
upstream O
of O
the O
RARE O
translational O
RARE O
codons O
. O

The O
gene I-GENE
RARE I-GENE
- I-GENE
NUM I-GENE
, O
RARE O
chloramphenicol I-GENE
- I-GENE
inducible I-GENE
chloramphenicol I-GENE
RARE I-GENE
, O
is O
RARE O
on O
the O
1 O
. O
1 O
- O
RARE O
RARE O
DNA O
. O

The O
RARE O
sarcoma O
virus O
( O
ALL_CAP O
) O
was O
derived O
by O
passage O
of O
Moloney O
sarcoma O
virus O
( O
RARE O
- O
ALL_CAP O
) O
in O
adult O
mice O
. O

The O
same O
- O
sized O
EBNA I-GENE
protein I-GENE
( I-GENE
RARE I-GENE
NUM I-GENE
, I-GENE
NUM I-GENE
) I-GENE
was O
made O
after O
transfection O
with O
BamHI I-GENE
- I-GENE
K I-GENE
( I-GENE
5 I-GENE
. I-GENE
2 I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
or O
the O
NUM O
RARE O
( O
2 O
. O
9 O
RARE O
). O

They O
generated O
RARE O
. O

Here O
we O
have O
determined O
the O
nucleotide O
sequence O
of O
3 O
. O
5 O
kb O
from O
the O
3 O
' O
end O
of O
delta I-GENE
gag I-GENE
to O
the O
3 O
' O
end O
of O
molecularly O
RARE O
RARE O
NUM O
DNA O
, O
in O
order O
to O
elucidate O
the O
genetic O
RARE O
of O
the O
virus O
and O
to O
compare O
it O
with O
other O
RARE I-GENE
- O
and O
myc I-GENE
- O
containing O
RARE O
viruses O
RARE O
RARE O
RARE O
with O
the O
chicken I-GENE
RARE I-GENE
- I-GENE
myc I-GENE
gene I-GENE
. O

ALL_CAP O
NUM O
, O
NUM O
- O
NUM O
] O
was O
used O
to O
isolate O
a O
genomic O
clone O
lambda O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
containing O
a O
portion O
of O
an O
RARE O
locus O
RARE O
RARE I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
). O

A O
. O

NUM O
patients O
received O
cimetidine O
NUM O
mg O
RARE O
. O
i O
. O
d O
. O
intravenously O
and O
1 O
, O
NUM O
mg O
daily O
orally O
in O
divided O
doses O
. O

An O
immunologic O
test O
using O
stomach O
and O
tumor O
antigens O
RARE O
screening O
of O
those O
RARE O
high O
risk O
RARE O
stomach O
RARE O
is O
suggested O
. O

Thirty O
isolates O
of O
Haemophilus O
influenzae O
type O
b O
were O
obtained O
RARE O
an O
outbreak O
of O
invasive O
H O
. O
influenzae O
type O
b O
RARE O
and O
were O
classified O
by O
the O
electrophoretic O
profile O
of O
their O
lipopolysaccharide O
( O
ALL_CAP O
). O

RARE O
acid O
RARE O
. O

RARE O
type O
I O
( O
Ft O
I O
) O
and O
RARE O
type O
II O
( O
Ft O
II O
) O
slowly O
adapting O
( O
SA O
) O
RARE O
produced O
spikes O
only O
RARE O
the O
RARE O
RARE O
, O
and O
the O
threshold O
response O
RARE O
( O
ALL_CAP O
RARE O
i O
. O
RARE O
RARE O
the O
RARE O
of O
the O
RARE O
RARE O
was O
RARE O
RARE O
. O

RARE O
type O
I O
( O
Ft O
I O
) O
and O
RARE O
type O
II O
( O
Ft O
II O
) O
slowly O
adapting O
( O
SA O
) O
RARE O
produced O
spikes O
only O
RARE O
the O
RARE O
RARE O
, O
and O
the O
threshold O
response O
RARE O
( O
ALL_CAP O
RARE O
i O
. O
RARE O
RARE O
the O
RARE O
of O
the O
RARE O
RARE O
was O
RARE O
RARE O
. O

ALL_CAP O
also O
permits O
extension O
of O
the O
possibilities O
of O
obtaining O
and O
RARE O
donor O
organs O
. O

RARE O
stain O
was O
positive O
, O
RARE O
RARE O
stain O
negative O
. O

RARE O
glucose O
and O
plasma O
insulin I-GENE
were O
measured O
RARE O
zero O
time O
and O
then O
RARE O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
and O
120 O
min O
after O
ingestion O
of O
NUM O
g O
glucose O
, O
RARE O
or O
RARE O
, O
or O
NUM O
g O
RARE O
, O
50 O
g O
RARE O
RARE O
, O
NUM O
g O
RARE O
RARE O
or O
RARE O
, O
NUM O
g O
RARE O
or O
260 O
g O
RARE O
. O

Clinical O
use O
of O
RARE O
RARE O
acid O
RARE O
in O
RARE O
- O
RARE O
' O
s O
operation O

Among O
these O
are O
: O
( O
1 O
) O
Is O
there O
sufficient O
understanding O
of O
family O
pathophysiology O
, O
of O
the O
sensitivity O
and O
RARE O
of O
diagnostic O
techniques O
and O
of O
the O
safety O
and O
efficacy O
of O
therapeutic O
modalities O
to O
make O
true O
family O
health O
care O
possible O
? O
( O
2 O
) O
If O
this O
type O
of O
care O
is O
possible O
, O
how O
are O
the O
needs O
of O
the O
family O
and O
its O
individual O
members O
met O
, O
or O
value O
RARE O
made O
about O
their O
relative O
importance O
? O
and O
( O
3 O
) O
RARE O
are O
the O
consequences O
RARE O
the O
health O
care O
delivery O
RARE O
of O
this O
type O
of O
care O
? O
An O
extensive O
literature O
review O
is O
used O
in O
an O
attempt O
to O
RARE O
these O
RARE O
, O
from O
which O
questions O
RARE O
further O
study O
are O
RARE O
. O

In O
patients O
in O
group O
A O
(" O
normal O
" O
ALL_CAP O
RARE O
the O
ALL_CAP O
, O
RARE O
rate O
and O
the O
mean O
RARE O
fiber O
shortening O
velocity O
( O
ALL_CAP O
) O
were O
normal O
, O
but O
the O
TPR O
was O
increased O
significantly O
. O

RARE O
reactive O
insulin I-GENE
levels O
were O
determined O
in O
RARE O
- O
RARE O
normal O
rats O
offered O
three O
different O
test O
- O
RARE O
. O

These O
results O
indicate O
that O
both O
naturally O
acquired O
and O
passive O
( O
modified O
immune I-GENE
serum I-GENE
globulin I-GENE
) O
antibodies O
to O
type I-GENE
III I-GENE
group I-GENE
B I-GENE
RARE I-GENE
antigen I-GENE
are O
partially O
protective O
against O
RARE O
- O
RARE O
infection O
. O

In O
the O
RARE O
RARE O
of O
AMI O
, O
RARE O
RARE O
RARE O
in O
ALL_CAP O
, O
the O
occurrence O
of O
high O
- O
grade O
RARE O
usually O
indicates O
more O
advanced O
degrees O
of O
both O
coronary O
and O
RARE O
ventricular O
RARE O
RARE O
RARE O
RARE O
the O
possibility O
of O
cardiac O
and O
/ O
or O
RARE O
RARE O
. O

RARE O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
, O
and O
RARE O
are O
generally O
used O
RARE O
RARE O
. O

The O
genes O
RARE O
each O
locus O
are O
divergently O
RARE O
and O
the O
coding O
sequences O
are O
separated O
by O
NUM O
RARE O
- O
RARE O
RARE O
one O
locus O
and O
NUM O
RARE O
- O
RARE O
RARE O
the O
other O
. O

The O
RARE O
hydrolysis O
of O
urea O
produces O
RARE O
which O
causes O
a O
RARE O
yellow O
to O
RARE O
RARE O
change O
in O
the O
pH O
indicator O
. O

The O
clinical O
efficacy O
rates O
evaluated O
in O
151 O
cases O
( O
KS O
- O
NUM O
group O
in O
77 O
cases O
, O
oral O
group O
in O
NUM O
cases O
) O
on O
standard O
criteria O
of O
RARE O
members O
were O
88 O
. O
3 O
% O
RARE O
the O
KS O
- O
NUM O
group O
and O
NUM O
. O
5 O
% O
RARE O
the O
oral O
group O
, O
respectively O
. O

RARE O
effect O
including O
RARE O
and O
objective O
symptoms O
were O
strictly O
evaluated O
in O
NUM O
cases O
( O
KS O
- O
NUM O
group O
in O
NUM O
cases O
, O
oral O
group O
in O
NUM O
cases O
RARE O
but O
the O
incidence O
rate O
which O
was O
NUM O
. O
9 O
% O
RARE O
the O
KS O
- O
NUM O
group O
and O
NUM O
. O
8 O
% O
RARE O
the O
oral O
group O
showed O
RARE O
significant O
difference O
. O

Plasma O
renin I-GENE
activity O
did O
not O
change O
in O
response O
to O
head O
- O
RARE O
tilt O
or O
RARE O
infusion O
in O
the O
patients O
. O

RARE O
RARE O
and O
RARE O
physicians O
. O

RARE O
of O
the O
immune O
response O
by O
RARE O
action O
of O
vaccine O
RARE O
in O
the O
RARE O
immunization O
of O
swine O
against O
swine O
RARE O

RARE O
gamma O
- O
ray O
spectroscopy O

RARE O
, O
a O
RARE O
antagonist O
with O
a O
RARE O
- O
life O
of O
RARE O
NUM O
hours O
, O
was O
compared O
with O
placebo O
in O
a O
double O
- O
blind O
, O
randomized O
, O
RARE O
trial O
. O

Analysis O
of O
proteins O
synthesized O
by O
plasmids O
containing O
RARE O
forms O
of O
the O
ALL_CAP I-GENE
region I-GENE
indicates O
that O
the O
NUM I-GENE
protein I-GENE
is O
the O
essential O
ALL_CAP I-GENE
- I-GENE
encoded I-GENE
replication I-GENE
protein I-GENE
of O
RARE O
NUM O
. O

Effects O
of O
negative O
RARE O
pressure O
on O
RARE O
ventricular O
hemodynamics O
. O

RARE O
plasma O
norepinephrine O
( O
ALL_CAP O
) O
and O
epinephrine O
( O
E O
) O
levels O
were O
lower O
RARE O
RARE O
therapy O
than O
2 O
wk O
after O
withdrawal O
( O
RARE O
and O
control O
: O
plasma O
ALL_CAP O
, O
NUM O
. O
NUM O
+/- O
NUM O
. O
03 O
/ O
NUM O
. O
NUM O
+/- O
NUM O
. O
NUM O
RARE O
/ O
ml O
; O
plasma O
E O
, O
NUM O
. O
09 O
+/- O
NUM O
. O
02 O
/ O
NUM O
. O
NUM O
+/- O
NUM O
. O
05 O
RARE O
/ O
ml O
). O

Renal O
response O
to O
captopril O
in O
severe O
RARE O
failure O
: O
role O
of O
furosemide O
in O
RARE O
and O
reversal O
of O
RARE O
. O

RARE O
describes O
a O
technique O
RARE O
the O
placement O
of O
functionally O
generated O
RARE O
RARE O
RARE O
restorations O
within O
mandibular O
RARE O
teeth O
. O

RARE O
biopsy O
specimens O
( O
five O
RARE O
and O
RARE O
RARE O
or O
RARE O
lesions O
) O
from O
four O
patients O
with O
RARE O
RARE O
et O
RARE O
RARE O
( O
ALL_CAP O
) O
were O
studied O
by O
direct O
immunofluorescence O
and O
RARE I-GENE
RARE O
. O

These O
data O
suggest O
that O
a O
major O
part O
of O
the O
reduction O
in O
food O
intake O
in O
RARE O
rats O
RARE O
a O
RARE O
- O
RARE O
diet O
is O
due O
to O
RARE O
events O
. O

The O
RARE O
from O
a O
RARE O
cyst O
was O
RARE O
clear O
and O
contained O
high O
amount O
of O
RARE I-GENE
hormone I-GENE
. O

ALL_CAP O
had O
RARE O
detectable O
effect O
on O
ALL_CAP I-GENE
RARE O
under O
basal O
or O
RARE O
conditions O
. O

The O
numerous O
tests O
demonstrate O
that O
the O
ALL_CAP O
- O
NUM O
can O
be O
extensively O
and O
successfully O
used O
RARE O
therapy O
of O
insulin I-GENE
- O
dependent O
diabetes O
mellitus O
in O
clinical O
practice O
. O

Lung O
RARE O
production O
may O
be O
related O
to O
flow O
. O

For O
the O
RARE O
NUM O
min O
following O
insulin I-GENE
administration O
, O
the O
rate O
of O
change O
in O
glucose O
levels O
was O
significantly O
less O
among O
the O
patients O
with O
major O
RARE O
disorder O
than O
among O
either O
the O
patients O
with O
RARE O
disorder O
or O
the O
normal O
control O
subjects O
. O

RARE O
of O
hypertension O
in O
the O
elderly O
. O

RARE O
treatment O
of O
children O
with O
respiratory O
allergy O

RARE O
of O
kidneys O
of O
juvenile O
donors O
in O
adult O
recipients O
. O

Ten O
patients O
with O
advanced O
, O
diffuse O
Hodgkin O
' O
s O
and O
non O
- O
Hodgkin O
' O
s O
lymphomas O
responding O
poorly O
to O
the O
most O
widely O
employed O
RARE O
chemotherapy O
regimens O
were O
treated O
with O
a O
high O
- O
dose O
chemotherapy O
( O
ALL_CAP O
) O
followed O
by O
rescue O
with O
non O
- O
RARE O
autologous O
bone O
marrow O
infusion O
( O
ALL_CAP O
). O

Effect O
of O
RARE O
RARE O
and O
polypeptides O
on O
the O
RARE O
activity O
of O
RARE O
and O
other O
RARE O
. O

Results O
of O
a O
RARE O
study O

RARE O
also O
caused O
a O
slight O
increase O
in O
plasma I-GENE
renin I-GENE
activity O
and O
RARE O
excretion O
of O
noradrenaline O
. O

RARE I-GENE
activity O
of O
97 O
% O
of O
these O
organisms O
became O
evident O
within O
NUM O
min O
. O

After O
description O
of O
RARE O
short O
life O
and O
an O
explanation O
of O
the O
light O
RARE O
RARE O
' O
s O
RARE O
is O
RARE O
, O
by O
RARE O
RARE O
RARE O
RARE O
RARE O
to O
have O
made O
RARE O
to O
medicine O
RARE O
diagnostic O
possibilities O
. O

The O
effect O
of O
lithium O
on O
the O
RARE O
of O
RARE I-GENE
vasopressin I-GENE
RARE O
. O

The O
RARE O
of O
the O
ALL_CAP O
strains O
to O
clinically O
relevant O
antibiotics O
varied O
with O
the O
RARE O
pattern O
; O
this O
stresses O
the O
RARE O
of O
permanent O
RARE O
of O
RARE O
infections O
and O
of O
regular O
evaluation O
of O
the O
RARE O
RARE O
antimicrobial O
treatment O
. O

RARE I-GENE
III I-GENE
( O
AT I-GENE
III I-GENE
) O
is O
a O
plasma O
protein O
which O
acts O
RARE O
the O
principal O
inhibitor O
of O
thrombin I-GENE
and O
is O
a O
major O
RARE O
of O
intravascular O
coagulation O
. O

RARE O
patients O
were O
untreated O
, O
and O
8 O
had O
been O
given O
previous O
treatment O
with O
RARE O
testosterone O
NUM O
mg O
RARE O
every O
2 O
- O
3 O
weeks O
RARE O
an O
average O
duration O
of O
4 O
. O
7 O
years O
. O

NUM O
- O
labeled O
cisplatin O
was O
administered O
iv O
and O
RARE O
to O
control O
mice O
and O
to O
mice O
RARE O
RARE O
180 O
. O

New O
beta O
- O
blocking O
drugs O
have O
been O
introduced O
which O
may O
prove O
beneficial O
in O
certain O
clinical O
situations O
since O
they O
exert O
more O
selective O
blockade O
of O
the O
cardiac I-GENE
receptors I-GENE
( O
beta1 I-GENE
) O
RARE O
opposed O
to O
RARE I-GENE
muscle I-GENE
receptors I-GENE
( O
NUM I-GENE
). O

If O
RARE O
RARE O
measurements O
of O
NUM O
consumption O
and O
hence O
metabolic O
rate O
are O
available O
, O
these O
should O
be O
utilized O
. O

This O
generally O
means O
an O
energy O
intake O
of O
1 O
. O
4 O
to O
1 O
. O
6 O
times O
the O
energy O
expenditure O
, O
with O
a O
N O
intake O
of O
NUM O
to O
NUM O
mg O
/ O
kg O
/ O
day O
. O

In O
the O
37 O
patients O
without O
RARE O
RARE O
respiratory O
muscle O
RARE O
was O
accompanied O
by O
significant O
decreases O
in O
vital O
capacity O
, O
RARE O
RARE O
capacity O
, O
and O
maximum O
RARE O
ventilation O
; O
by O
significant O
increases O
in O
residual O
volume O
and O
arterial O
carbon O
dioxide O
tension O
( O
PaCO2 O
); O
and O
greater O
likelihood O
of O
dependence O
on O
RARE O
, O
RARE O
, O
and O
pneumonia O
. O

RARE O
. O

The O
statistical O
analysis O
of O
data O
of O
TRH I-GENE
test O
on O
a O
sample O
of O
57 O
healthy O
volunteers O
has O
permitted O
an O
evaluation O
of O
the O
upper O
limits O
of O
the O
normal O
thyrotropin I-GENE
response O
; O
the O
RARE O
area O
( O
As O
) O
was O
shown O
to O
be O
more O
RARE O
. O

Total O
cumulative O
doses O
of O
RARE O
ranged O
from O
NUM O
to O
NUM O
mg O
RARE O
m O
. O
2 O
. O

RARE O
RARE O
depends O
on O
understanding O
of O
behavioral O
requirements O
. O

Following O
20 O
min O
of O
steady O
state O
anaesthesia O
RARE O
which O
measurements O
of O
IOP O
, O
arterial O
pressure O
, O
RARE O
rate O
, O
NUM O
, O
ALL_CAP O
' O
CO2 O
and O
ALL_CAP O
were O
recorded O
, O
one O
group O
of O
patients O
received O
RARE O
NUM O
. O
NUM O
mg O
kg O
- O
1 O
and O
the O
other O
RARE O
NUM O
. O
1 O
mg O
kg O
- O
1 O
. O

RARE O
subclinical O
and O
permanent O
hypothyroidism O
in O
the O
course O
of O
subacute O
thyroiditis O
( O
de O
RARE O
). O

RARE I-GENE
levels O
in O
mothers O
who O
have O
had O
two O
sets O
of O
ALL_CAP O
RARE O
. O

RARE O
of O
plasma O
to O
obtain O
better O
yield O
of O
factor I-GENE
VIII I-GENE
: O
C O
. O

These O
children O
were O
RARE O
into O
four O
diagnostic O
categories O
: O
1 O
) O
idiopathic O
ALL_CAP I-GENE
deficiency O
( O
RARE O
= O
10 O
); O
2 O
) O
organic O
RARE O
( O
RARE O
= O
7 O
); O
3 O
) O
intrauterine O
growth O
retardation O
( O
RARE O
= O
5 O
); O
and O
4 O
) O
RARE O
delay O
of O
growth O
and O
/ O
or O
familial O
short O
RARE O
( O
RARE O
= O
18 O
RARE O
by O
standard O
clinical O
criteria O
and O
physiological O
and O
pharmacological O
tests O
of O
ALL_CAP I-GENE
reserve O
. O

Each O
patient O
had O
RARE O
ALL_CAP I-GENE
and O
FSH I-GENE
levels O
, O
with O
pulsed O
RARE O
RARE O
, O
and O
RARE O
ALL_CAP I-GENE
and O
FSH I-GENE
responses O
to O
ALL_CAP I-GENE
. O

These O
changes O
were O
the O
result O
of O
a O
decrease O
in O
RARE O
: O
mean O
aortic O
pressure O
fell O
from O
NUM O
+/- O
11 O
. O
8 O
to O
NUM O
+/- O
19 O
. O
6 O
mmHg O
( O
p O
less O
than O
NUM O
. O
01 O
) O
and O
systemic O
arterial O
resistance O
fell O
from O
2 O
NUM O
+/- O
NUM O
to O
2 O
NUM O
+/- O
NUM O
RARE O
/ O
cm O
- O
5 O
/ O
sec O
/ O
m O
- O
2 O
( O
p O
less O
than O
NUM O
. O
01 O
). O

RARE O
800 O
mg O
given O
RARE O
night O
is O
RARE O
effective O
RARE O
NUM O
mg O
twice O
daily O
; O
the O
single O
dose O
regimen O
may O
improve O
patient O
compliance O
, O
thus O
facilitating O
treatment O
. O

RARE O
shows O
RARE O
RARE O
single O
- O
agent O
therapy O
RARE O
serious O
gram O
- O
negative O
RARE O
infections O
. O

RARE O
CBF O
was O
determined O
by O
clearance O
of O
RARE O
NUM O
in O
67 O
patients O
undergoing O
coronary O
bypass O
RARE O
procedures O
. O

Our O
results O
indicate O
that O
serum I-GENE
ALL_CAP I-GENE
is O
a O
valuable O
measurement O
of O
bone O
metabolism O
. O

The O
management O
of O
the O
" O
chronic O
" O
patient O
. O

Study O
of O
bacterial O
RARE O
and O
rate O
of O
movement O
using O
a O
closed O
circuit O
RARE O

RARE O
of O
RARE O
RARE O
RARE O
, O
NUM O
, O
in O
RARE O
RARE O
RARE O

Each O
RARE O
organism O
has O
a O
species O
- O
specific O
preference O
and O
requirement O
RARE O
RARE O
, O
RARE O
, O
pH O
, O
the O
basic O
RARE O
, O
and O
growth O
factors O
, O
and O
the O
RARE O
formation O
is O
affected O
by O
these O
environmental O
factors O
. O

It O
is O
concluded O
that O
RARE O
- O
RARE O
by O
- O
RARE O
is O
a O
simple O
solution O
RARE O
a O
complex O
RARE O
, O
clinical O
and O
therapeutic O
problem O
. O

RARE O
of O
the O
RARE O
of O
the O
RARE O
and O
of O
the O
RARE O
process O
are O
also O
described O
( O
RARE O
RARE O
NUM O
, O
RARE O
NUM O
, O
RARE O
NUM O
, O
RARE O
NUM O
). O

There O
was O
significant O
correlation O
of O
ALL_CAP O
/ O
NUM O
and O
RARE O
RARE O
pre O
- O
ALL_CAP O
and O
post O
ALL_CAP O
studies O
. O

RARE O
recording O
in O
RARE O
RARE O

The O
development O
and O
RARE O
organization O
of O
intrahepatic O
biliary O
RARE O
were O
studied O
on O
a O
human O
RARE O
material O
6 O
to O
NUM O
weeks O
old O
. O

It O
has O
been O
shown O
in O
an O
RARE O
experiment O
that O
alterations O
of O
the O
RARE O
RARE O
and O
parenchyma O
after O
hemostasis O
performed O
by O
RARE O
- O
RARE O
- O
RARE O
are O
best O
shown O
by O
RARE O
magnification O
angiography O
( O
magnification O
factor O
2 O
. O
NUM O
). O

RARE O
and O
adrenal O
RARE O
- O
sympathetic O
reactions O
to O
acute O
tobacco O
poisoning O

Intravenous O
injections O
of O
ALL_CAP O
- O
NUM O
( O
NUM O
. O
03 O
- O
1 O
mg O
/ O
kg O
) O
decreased O
systemic O
RARE O
pressure O
( O
ALL_CAP O
) O
and O
increased O
peripheral O
( O
coronary O
, O
RARE O
, O
RARE O
and O
femoral O
) O
RARE O
flow O
( O
ALL_CAP O
) O
dose O
- O
dependently O
. O

In O
doses O
of O
NUM O
. O
03 O
- O
NUM O
. O
3 O
mg O
/ O
kg O
i O
. O
v O
., O
ALL_CAP O
- O
NUM O
did O
not O
significantly O
affect O
pulse O
pressure O
, O
RARE O
rate O
, O
aortic O
RARE O
flow O
, O
RARE O
ventricular O
pressure O
( O
ALL_CAP O
) O
and O
ALL_CAP O
/ O
dt O
RARE O
. O

RARE O
VE O
in O
the O
RARE O
RARE O
was O
7 O
. O
8 O
% O
greater O
than O
that O
in O
the O
follicular O
RARE O
. O

RARE O
of O
endothelium O
to O
RARE O
shear O
stresses O
that O
followed O
a O
RARE O
recording O
of O
physiological O
flow O
RARE O
( O
RARE O
RARE O
) O
did O
not O
cause O
gross O
injury O
or O
RARE O
even O
when O
peak O
shear O
RARE O
NUM O
RARE O
/ O
cm2 O
. O

RARE O
RARE O
therapy O
has O
included O
surgery O
, O
radiotherapy O
, O
chemotherapy O
, O
and O
most O
recently O
, O
immunotherapy O
and O
RARE O
. O

There O
was O
a O
close O
correlation O
between O
plasma O
clearance O
of O
ALL_CAP O
by O
10 O
- O
RARE O
and O
the O
D O
metabolic O
ratio O
( O
D O
/ O
4 O
- O
OH O
- O
D O
in O
urine O
) O
in O
the O
RARE O
( O
rs O
= O
- O
NUM O
. O
NUM O
; O
P O
less O
than O
NUM O
. O
01 O
) O
and O
RARE O
( O
rs O
= O
- O
NUM O
. O
NUM O
; O
P O
less O
than O
NUM O
. O
01 O
). O

The O
response O
properties O
of O
RARE O
horizontal O
RARE O
afferents O
( O
N O
= O
NUM O
) O
were O
characterized O
by O
three O
parameters O
: O
their O
long O
time O
constants O
( O
RARE O
RARE O
low O
frequency O
gain O
constants O
( O
G1 O
RARE O
and O
RARE O
frequency O
gain O
constants O
( O
RARE O
). O

RARE O
of O
the O
central O
ear O
artery O
of O
an O
anesthetized O
RARE O
is O
damaged O
by O
RARE O
artery O
RARE O
on O
the O
ear O
directly O
over O
the O
vessel O
. O

Despite O
RARE O
E2 O
concentrations O
, O
however O
, O
cervical O
mucus O
scores O
were O
significantly O
RARE O
in O
the O
ALL_CAP O
- O
treated O
group O
( O
P O
less O
than O
NUM O
. O
01 O
). O

RARE O
of O
the O
RARE O
nucleus O
' O
RARE O
- O
reactive O
RARE O
in O
dogs O
by O
means O
of O
administration O
of O
RARE O
( O
NUM O
micrograms O
) O
and O
RARE O
led O
to O
deterioration O
of O
conditioned O
and O
RARE O
RARE O
of O
feeding O
behaviour O
. O

Value O
of O
urine O
glucose O
tests O
in O
the O
management O
of O
type O
II O
diabetes O
mellitus O
. O

This O
experiment O
was O
conducted O
to O
determine O
if O
the O
RARE O
or O
actual O
RARE O
production O
was O
the O
important O
factor O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

RARE O
seems O
to O
be O
unable O
to O
RARE O
the O
RARE O
changes O
in O
the O
muscle O
membrane O
whereas O
high O
doses O
of O
the O
hormone O
are O
able O
to O
induce O
changes O
in O
the O
muscle O
membrane O
. O

Significant O
clinical O
differences O
between O
the O
patients O
treated O
with O
and O
without O
ALL_CAP O
were O
longer O
survival O
time O
following O
diagnosis O
of O
illness O
( O
P O
less O
than O
NUM O
. O
05 O
) O
and O
more O
frequent O
RARE O
nerve O
signs O
in O
the O
treated O
patients O
( O
P O
= O
NUM O
. O
NUM O
). O

A O
pharmacokinetic O
study O
of O
RARE O
was O
performed O
in O
12 O
patients O
in O
an O
intensive O
- O
care O
unit O
. O

RARE O
- O
RARE O
growth O
was O
observed O
only O
RARE O
a O
12 O
- O
month O
period O
in O
4 O
children O
with O
a O
bone O
age O
of O
7 O
to O
8 O
years O
. O

RARE O
function O
was O
impaired O
in O
all O
patients O
, O
characterized O
by O
a O
diminished O
platelet O
shape O
change O
. O

The O
findings O
demonstrate O
that O
ALL_CAP O
administration O
induces O
a O
significant O
increase O
in O
the O
height O
of O
a O
major O
RARE O
peak O
in O
the O
RARE O
nucleus O
of O
RARE O
monkeys O
, O
and O
further O
that O
such O
amphetamine O
- O
RARE O
increases O
can O
be O
RARE O
by O
altering O
the O
affective O
and O
/ O
or O
RARE O
state O
of O
the O
RARE O
. O

In O
two O
experiments O
, O
neonatal O
female O
ALL_CAP O
/ O
RARE O
or O
ALL_CAP O
/ O
NUM O
mice O
were O
given O
subcutaneous O
injections O
of O
5 O
micrograms O
NUM O
beta O
- O
estradiol O
or O
RARE O
oil O
RARE O
the O
RARE O
3 O
days O
of O
life O
and O
were O
RARE O
RARE O
NUM O
days O
of O
age O
, O
RARE O
which O
time O
vaginal O
RARE O
( O
Experiments O
I O
and O
II O
) O
or O
RARE O
( O
Experiment O
II O
) O
were O
implanted O
RARE O
. O

For O
NUM O
of O
NUM O
deaths O
( O
54 O
%) O
occurring O
among O
NUM O
NUM O
people O
of O
known O
age O
in O
the O
RARE O
area O
of O
northern O
RARE O
, O
data O
were O
collected O
on O
symptoms O
present O
prior O
to O
RARE O
. O

RARE O
estradiol O
NUM O
beta O
( O
E2 O
- O
NUM O
beta O
) O
and O
progesterone O
( O
P O
) O
were O
determined O
by O
using O
radioimmunoassay O
techniques O
in O
NUM O
RARE O
females O
in O
the O
RARE O
, O
second O
and O
third O
RARE O
RARE O
RARE O
RARE O
in O
10 O
non O
- O
RARE O
controls O
RARE O
the O
RARE O
RARE O
of O
the O
menstrual O
RARE O
. O

Other O
than O
d O
7 O
, O
there O
was O
RARE O
significant O
effect O
on O
the O
number O
of O
implants O
. O

RARE O
ALL_CAP O
RARE O
or O
RARE O
were O
RARE O
on O
NUM O
RARE O
tests O
( O
18 O
. O
8 O
%) O
in O
NUM O
( O
NUM O
. O
5 O
%) O
RARE O
patients O
. O

The O
response O
chain O
in O
each O
RARE O
was O
maintained O
by O
food O
presentation O
under O
a O
fixed O
- O
ratio O
schedule O
. O

The O
results O
imply O
that O
kindling O
does O
not O
produce O
its O
facilitating O
effect O
on O
acquisition O
of O
ALL_CAP O
ALL_CAP O
by O
removing O
a O
RARE O
effect O
of O
the O
RARE O
. O

The O
persistent O
RARE O
dispersion O
of O
nodal O
and O
RARE O
bundle O
fragments O
within O
the O
ventricular O
RARE O
is O
proposed O
RARE O
a O
possible O
explanation O
. O

According O
to O
the O
biochemical O
tests O
, O
high O
activity O
( O
over O
NUM O
ALL_CAP O
/ O
RARE O
) O
of O
RARE I-GENE
phosphatase I-GENE
was O
recorded O
exclusively O
in O
patients O
with O
the O
RARE O
- O
RARE O
liver O
damage O
. O

Changes O
of O
plasma O
cortisol O
level O
in O
RARE O
asthmatic O
responses O

Significant O
alterations O
in O
the O
RARE O
rats O
from O
sham O
rats O
included O
: O
RARE O
and O
RARE O
hypertrophy O
, O
formation O
of O
pathologic O
vas O
deferens O
RARE O
, O
decreased O
RARE O
serum O
protein O
, O
lowered O
alpha I-GENE
- I-GENE
globulin I-GENE
levels O
RARE O
shown O
by O
serum O
electrophoresis O
, O
and O
increased O
sperm O
RARE I-GENE
antibody O
RARE O
. O

ALL_CAP O
was O
significantly O
elevated O
in O
RARE O
( O
s O
). O

The O
average O
birth O
mass O
of O
these O
newborns O
was O
NUM O
. O
9 O
+/- O
2 O
SD O
NUM O
. O
5 O
g O
and O
that O
in O
the O
control O
group O
3 O
, O
NUM O
. O
5 O
+/- O
2 O
SD O
NUM O
. O
2 O
g O
( O
P O
less O
than O
NUM O
. O
05 O
). O

This O
machine O
RARE O
, O
which O
was O
not O
associated O
with O
a O
rise O
in O
water O
RARE O
RARE O
and O
did O
not O
consistently O
correlate O
with O
estimated O
RARE O
- O
ray O
tube O
heat O
, O
could O
result O
in O
a O
significant O
RARE O
of O
regional O
cerebral O
RARE O
flow O
( O
rCBF O
) O
RARE O
a O
RARE O
/ O
ALL_CAP O
rCBF O
protocol O
involving O
5 O
- O
7 O
sequential O
scans O
obtained O
RARE O
1 O
- O
min O
RARE O
intervals O
. O

Other O
RARE O
in O
the O
RARE O
RARE O
Y O
- O
12 O
and O
RARE O
are O
unaltered O
. O

E2 O
treatments O
elevated O
RARE O
plasma O
TG O
7 O
. O
NUM O
, O
ALL_CAP O
5 O
. O
NUM O
, O
and O
C O
7 O
. O
NUM O
; O
and O
RARE O
plasma O
TG O
6 O
. O
NUM O
, O
ALL_CAP O
3 O
. O
NUM O
, O
and O
C O
2 O
. O
NUM O
. O

By O
contrast O
, O
kidneys O
from O
rats O
with O
chronic O
metabolic O
acidosis O
produced O
significantly O
more O
NUM O
than O
both O
these O
groups O
( O
2 O
. O
NUM O
+/- O
NUM O
. O
29 O
mumol O
X O
min O
- O
1 O
X O
g O
- O
1 O
). O

RARE O
of O
RARE O
in O
RARE O
RARE O
using O
a O
RARE O
RARE O
test O
set O
( O
RARE O
ALL_CAP O
). O

RARE I-GENE
cyclase I-GENE
activity O
of O
RARE O
mucosa O
in O
patients O
with O
duodenal O
ulcer O
before O
and O
after O
treatment O

RARE O
RARE O
RARE O
RARE O
and O
clinical O
problems O

However O
, O
subcutaneously O
administered O
RARE O
gave O
a O
lower O
mortality O
than O
RARE O
given O
intravenously O
or O
RARE O
. O

RARE O
of O
human O
organism O
to O
exercise O
. O

ALL_CAP O
resulted O
in O
decreased O
( O
p O
less O
than O
NUM O
. O
05 O
) O
RARE O
( O
NUM O
. O
4 O
degrees O
C O
) O
and O
HR O
( O
NUM O
b O
X O
min O
- O
1 O
RARE O
and O
increased O
( O
p O
less O
than O
NUM O
. O
05 O
) O
RARE O
( O
16 O
g O
X O
m O
- O
2 O
X O
h O
- O
1 O
) O
RARE O
the O
saline O
experiments O
. O

The O
results O
obtained O
were O
RARE O
follows O
: O
The O
mitral O
valve O
RARE O
area O
( O
ALL_CAP O
) O
was O
significantly O
smaller O
in O
patients O
with O
type O
III O
of O
the O
ALL_CAP O
flow O
velocity O
pattern O
than O
in O
patients O
with O
type O
I O
( O
p O
less O
than O
NUM O
. O
001 O
). O

RARE O
cooperation O
of O
ALL_CAP O
RARE O
RARE O
has O
been O
carried O
out O
since O
NUM O
under O
the O
RARE O
of O
the O
Cancer O
Research O
Institute O
, O
RARE O
RARE O
of O
RARE O
( O
RARE O
) O
within O
the O
RARE O
of O
ALL_CAP O
. O

This O
RARE O
RARE O
to O
results O
of O
similarly O
sized O
melanomas O
treated O
by O
RARE O
. O

A O
new O
variant O
of O
the O
EMG O
- O
ALL_CAP O
method O
( O
RARE O
) O
is O
offered O
which O
has O
made O
it O
possible O
to O
use O
the O
method O
not O
only O
RARE O
training O
RARE O
muscles O
and O
RARE O
RARE O
in O
their O
antagonists O
but O
also O
RARE O
RARE O
motor O
coordination O
. O

RARE O
from O
all O
3 O
species O
yielded O
maximum O
responses O
with O
a O
NUM O
- O
hour O
RARE O
and O
12 O
- O
to O
- O
16 O
hour O
RARE O
incubation O
period O
RARE O
NUM O
C O
and O
1 O
: O
20 O
RARE O
dilution O
. O

However O
, O
there O
was O
a O
difference O
in O
the O
quality O
of O
RARE O
: O
fever O
and O
body O
RARE O
RARE O
were O
seen O
in O
hamsters O
RARE O
with O
the O
killed O
- O
RARE O
vaccine O
after O
they O
were O
challenge O
exposed O
with O
T O
- O
1 O
RARE O
, O
whereas O
these O
changes O
were O
rarely O
seen O
in O
hamsters O
given O
the O
live O
- O
RARE O
vaccine O
and O
then O
challenge O
exposed O
with O
ALL_CAP O
RARE O
. O

RARE O
proline O
/ O
alanine O
sequence O
of O
beta I-GENE
NUM I-GENE
subunit I-GENE
RARE O
from O
a O
RARE O
DNA O
sequence O
. O

The O
segmental O
and O
regional O
projections O
of O
the O
RARE O
, O
RARE O
and O
common O
RARE O
nerves O
to O
the O
RARE O
RARE O
of O
the O
RARE O
cord O
in O
rats O
RARE O
an O
experimental O
study O
by O
means O
of O
an O
acid I-GENE
phosphatase I-GENE
( O
ALL_CAP I-GENE
) O
method O
. O

Removal O
of O
RARE O
fractions O
of O
RARE O
RARE O
with O
RARE O
is O
recommended O
to O
avoid O
damage O
to O
the O
HPLC O
column O
. O

In O
the O
RARE O
RARE O
one O
of O
the O
RARE O
would O
not O
RARE O
the O
RARE O
RARE O
shown O
while O
the O
last O
two O
RARE O
offer O
very O
little O
possibility O
of O
success O
RARE O
all O
subjects O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

The O
toxicological O
evaluation O
of O
RARE O
NUM O
( O
ALL_CAP O
NUM O
). O

All O
patients O
were O
evaluable O
RARE O
toxicity O
and O
9 O
RARE O
response O
. O

RARE O
of O
clinical O
and O
experimental O
RARE O
are O
described O
that O
have O
been O
used O
to O
evaluate O
effects O
of O
RARE O
and O
RARE O
acting O
RARE O
. O

The O
present O
paper O
RARE O
the O
existing O
RARE O
, O
and O
offers O
a O
consistent O
RARE O
RARE O
also O
such O
terms O
RARE O
" O
RARE O
RARE O
" O
potentiation O
RARE O
and O
" O
simple O
RARE O
". O

We O
propose O
that O
the O
RARE O
discrimination O
required O
a O
greater O
time O
RARE O
RARE O
evaluation O
and O
that O
this O
was O
reflected O
in O
the O
delayed O
NUM O
RARE O
. O

RARE O
concentration O
RARE O
significantly O
in O
all O
treatments O
, O
a O
finding O
which O
suggests O
a O
protective O
effect O
on O
protein O
nitrogen O
RARE O
to O
non O
- O
protein O
nitrogen O
( O
NUM O
). O

In O
this O
respect O
C I-GENE
reactive I-GENE
protein I-GENE
concentrations O
are O
superior O
to O
RARE O
cell O
count O
, O
RARE O
sedimentation O
rate O
, O
and O
RARE O
and O
the O
concentrations O
of O
RARE O
. O

Human I-GENE
thyroid I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
in O
thyroid O
diseases O

We O
conclude O
that O
administration O
of O
the O
RARE O
antagonist O
RARE O
is O
of O
RARE O
additional O
value O
in O
RARE O
treatment O
with O
beta O
- O
RARE O
. O

RARE O
auditory O
evoked O
responses O
( O
RARE O
) O
and O
quantitative O
RARE O
eye O
movement O
studies O
provide O
RARE O
on O
the O
integrity O
of O
pathways O
RARE O
the O
RARE O
. O

Effects O
of O
RARE O
on O
the O
circulatory O
functions O
and O
body O
tissue O
oxygenation O
in O
dogs O
under O
normal O
and O
RARE O
conditions O
. O

The O
RARE O
clinical O
features O
, O
the O
problems O
of O
management O
and O
the O
modern O
approaches O
to O
the O
reconstruction O
of O
facial O
RARE O
seen O
in O
this O
RARE O
are O
described O
. O

RARE O
, O
it O
was O
considered O
that O
the O
ALL_CAP O
was O
a O
useful O
tool O
RARE O
activation O
of O
RARE O
activity O
by O
way O
of O
visual O
feed O
- O
back O
control O
. O

To O
evaluate O
the O
comparative O
safety O
of O
ALL_CAP O
- O
P O
and O
D O
& O
E O
, O
we O
analyzed O
2 O
, O
NUM O
ALL_CAP O
- O
P O
and O
9 O
, O
NUM O
D O
& O
E O
RARE O
RARE O
NUM O
to O
NUM O
menstrual O
weeks O
' O
gestation O
. O

Three O
RARE O
without O
knowledge O
of O
patients O
' O
data O
and O
treatment O
analyzed O
NUM O
RARE O
with O
and O
NUM O
examinations O
without O
ALL_CAP O
. O

In O
a O
man O
with O
RARE O
leukemia O
, O
the O
association O
of O
increased O
RARE I-GENE
acid I-GENE
phosphatase I-GENE
activity O
in O
serum O
and O
the O
presence O
of O
typical O
bone O
lesions O
on O
RARE O
suggested O
the O
existence O
of O
RARE O
RARE O
carcinoma O
. O

The O
RARE O
RARE O
the O
prophylactic O
treatment O
, O
the O
therapy O
of O
the O
RARE O
and O
ALL_CAP O
- O
ALL_CAP O
RARE O
are O
exposed O
. O

An O
experimental O
long O
- O
term O
study O
. O

No O
RARE O
was O
recorded O
in O
a O
RARE O
solution O
. O

RARE O
B O
vaccine O

The O
calculated O
values O
of O
lambda O
RARE O
RARE O
37 O
degrees O
C O
and O
50 O
per O
cent O
RARE O
were O
NUM O
. O
NUM O
RARE O
the O
RARE O
, O
NUM O
. O
NUM O
RARE O
the O
RARE O
, O
NUM O
. O
NUM O
RARE O
the O
RARE O
RARE O
and O
NUM O
. O
NUM O
RARE O
the O
RARE O
of O
the O
dog O
. O
lambda O
RARE O
increased O
and O
lambda O
RARE O
decreased O
RARE O
the O
RARE O
was O
RARE O
from O
37 O
to O
4 O
degrees O
C O
. O

As O
RARE O
RARE O
is O
seen O
commonly O
in O
RARE O
and O
may O
influence O
RARE O
volumes O
and O
the O
ratio O
of O
transfer I-GENE
factor I-GENE
to O
effective O
alveolar O
volume O
, O
the O
results O
of O
these O
measurements O
were O
compared O
only O
in O
the O
cases O
showing O
absent O
or O
minimal O
RARE O
RARE O
. O

The O
invasive O
pattern O
of O
squamous O
cell O
carcinoma O
in O
the O
mandibular O
RARE O

RARE O
RARE O
RARE O
the O
posterior O
RARE O
of O
the O
right O
main O
and O
upper O
lobe O
RARE O
: O
a O
normal O
ALL_CAP O
variant O
. O

However O
, O
the O
history O
of O
acute O
severe O
complications O
from O
RARE O
media O
revealed O
a O
RARE O
frequency O
in O
those O
individuals O
with O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
deficiency O
RARE O
compared O
to O
normals O
. O

The O
RARE O
NUM O
RARE O
RARE O
RARE O
the O
venous O
RARE O
RARE O
efficiently O
RARE O
the O
double O
RARE O
RARE O
. O

All O
other O
changes O
RARE O
the O
3 O
RARE O
5 O
RARE O
and O
6 O
- O
positions O
, O
RARE O
RARE O
RARE O
the O
RARE O
of O
the O
RARE O
group O
RARE O
position O
2 O
, O
caused O
a O
marked O
decrease O
of O
activity O
. O

Three O
experiments O
RARE O
the O
effects O
of O
6 O
- O
RARE O
- O
RARE O
lesions O
of O
the O
ventral O
noradrenergic O
and O
dorsal O
noradrenergic O
projections O
, O
predominantly O
to O
hypothalamus O
and O
cortex O
, O
respectively O
, O
upon O
body O
RARE O
changes O
and O
food O
- O
related O
behaviour O
in O
the O
rat O
. O

RARE O
RARE O
in O
rats O
RARE O
with O
cyclosporin O
A O
. O

The O
method O
involved O
RARE O
samples O
with O
two O
volumes O
of O
RARE O
followed O
by O
injection O
of O
5 O
RARE O
of O
RARE O
supernatant O
onto O
a O
C18 O
reversed O
- O
RARE O
column O
. O

RARE O
periods O
of O
the O
AV O
RARE O
were O
altered O
in O
a O
comparable O
fashion O
to O
conduction O
through O
the O
AV O
node O
. O

This O
paper O
RARE O
together O
data O
, O
obtained O
from O
a O
variety O
of O
sources O
, O
on O
the O
extent O
of O
RARE O
and O
use O
of O
RARE O
drugs O
in O
the O
RARE O
NUM O
and O
early O
NUM O
. O

RARE O
patients O
were O
studied O
within O
NUM O
hours O
of O
resuscitation O
and O
all O
showed O
depressed O
right O
ventricular O
ejection O
( O
ALL_CAP O
) O
and O
/ O
or O
an O
increased O
end O
- O
diastolic O
volume O
( O
ALL_CAP O
). O

During O
a O
single O
LAD O
occlusion O
lasting O
NUM O
minutes O
( O
series O
I O
, O
RARE O
= O
10 O
) O
9 O
microns O
RARE O
were O
infused O
immediately O
and O
NUM O
minutes O
after O
ligation O
, O
NUM O
microns O
RARE O
being O
infused O
after O
NUM O
- O
20 O
minutes O
. O

The O
population O
of O
between O
NUM O
, O
NUM O
and O
NUM O
, O
NUM O
was O
largely O
unstable O
, O
and O
cost O
per O
RARE O
was O
RARE O
NUM O
. O
NUM O
to O
RARE O
1 O
. O
21 O
. O

Female O
RARE O
rats O
were O
fed O
a O
liquid O
diet O
, O
RARE O
, O
which O
contained O
ethanol O
( O
40 O
% O
of O
RARE O
) O
or O
RARE O
sucrose O
. O

ALL_CAP O
02 O
type O
RARE O
RARE O
. O

Four O
patients O
( O
group O
1 O
) O
had O
type O
I O
RARE O
membrane O
nephropathy O
, O
characterized O
by O
marked O
RARE O
and O
RARE O
of O
the O
RARE O
membrane O
in O
a O
pattern O
resembling O
that O
of O
RARE O
' O
s O
RARE O
. O

RARE O
pH O
following O
3 O
h O
of O
cerebral O
RARE O
ischemia O
changed O
from O
a O
normal O
value O
of O
7 O
. O
NUM O
to O
6 O
. O
5 O
and O
6 O
. O
2 O
in O
animals O
studied O
under O
RARE O
and O
halothane O
anesthesia O
, O
respectively O
. O

Our O
results O
demonstrate O
the O
importance O
of O
phosphate O
and O
RARE O
in O
influencing O
the O
RARE O
of O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
in O
RARE O
. O

RARE O
- O
layer O
chromatographic O
methods O
were O
RARE O
- O
RARE O
RARE O
pharmacokinetic O
studies O
of O
RARE O
in O
plasma O
and O
urine O
. O

RARE O
RARE O
. O

Increasing O
the O
cut O
- O
off O
point O
to O
3 O
positive O
responses O
decreased O
the O
sensitivity O
to O
NUM O
% O
and O
increased O
the O
RARE O
to O
94 O
%. O

After O
RARE O
administration O
the O
autoregulation O
RARE O
shifted O
to O
the O
right O
i O
. O
RARE O
. O
towards O
RARE O
AP O
levels O
. O

This O
phenomenon O
may O
be O
regarded O
RARE O
a O
variant O
of O
selective O
individual O
cell O
RARE O
, O
currently O
referred O
to O
RARE O
apoptosis O
, O
which O
has O
not O
been O
previously O
reported O
in O
a O
case O
of O
RARE O
RARE O
. O

RARE O
of O
a O
RARE O
RARE O
and O
a O
complex O
RARE O
function O
disorder O
in O
a O
RARE O

A O
combined O
series O
of O
patients O
experienced O
a O
ALL_CAP O
after O
two O
or O
more O
previous O
RARE O
RARE O
; O
the O
rate O
of O
vaginal O
delivery O
was O
NUM O
%, O
and O
there O
was O
virtually O
RARE O
morbidity O
. O

RARE O
home O
RARE O
in O
clinical O
practice O
. O

RARE O
3 O
RARE O
RARE O
were O
maintained O
on O
control O
feed O
until O
they O
reached O
3 O
weeks O
of O
age O
RARE O
which O
time O
they O
were O
taken O
off O
of O
feed O
RARE O
2 O
. O
5 O
hr O
and O
then O
placed O
on O
either O
control O
feed O
or O
feed O
containing O
4 O
. O
NUM O
ppm O
RARE O
A O
, O
and O
RARE O
rate O
and O
RARE O
pressure O
were O
measured O
every O
RARE O
hour O
through O
7 O
hr O
. O

The O
RARE O
RARE O
therefore O
is O
a O
very O
important O
RARE O
of O
the O
battery O
of O
toxicological O
tests O
used O
in O
RARE O
evaluation O
. O

RARE O
effects O
in O
animals O
and O
man O
may O
result O
from O
both O
RARE O
or O
excessive O
amounts O
of O
intake O
. O

RARE O
in O
the O
diagnosis O
of O
diseases O
of O
the O
RARE O

The O
analysis O
of O
the O
RARE O
of O
the O
sleep O
period O
RARE O
a O
whole O
reveals O
that O
with O
increasing O
of O
the O
age O
the O
delta O
- O
wave O
RARE O
( O
ALL_CAP O
) O
of O
the O
ALL_CAP O
( O
determined O
by O
defined O
RARE O
parameters O
) O
increases O
, O
while O
the O
RARE O
RARE O
of O
sleep O
( O
ALL_CAP O
) O
decreases O
, O
this O
change O
being O
more O
pronounced O
RARE O
the O
RARE O
RARE O
months O
than O
RARE O
the O
second O
ones O
of O
the O
RARE O
year O
of O
the O
life O
. O

RARE O
NUM O
] O
ALL_CAP O
was O
prepared O
by O
RARE O
samples O
of O
Br O
- O
ALL_CAP O
in O
a O
ALL_CAP O
RARE O
RARE O
2 O
h O
RARE O
a O
thermal O
RARE O
RARE O
of O
10 O
( O
12 O
) O
RARE O
cm O
- O
2 O
s O
- O
1 O
. O

While O
these O
findings O
may O
reflect O
the O
sensitivity O
of O
a O
thick O
RARE O
RARE O
to O
ischaemia O
RARE O
surgery O
, O
the O
postoperative O
recovery O
was O
not O
related O
to O
the O
serum I-GENE
ALL_CAP I-GENE
- I-GENE
MB I-GENE
level O
. O

RARE O
status O
of O
the O
formed O
elements O
of O
the O
RARE O
in O
rats O
subjected O
to O
different O
variants O
of O
combined O
and O
isolated O
exposure O
to O
ALL_CAP O
- O
1 O
RARE O

Using O
a O
ALL_CAP O
- O
RARE O
reversed O
- O
RARE O
column O
with O
a O
phosphate O
RARE O
RARE O
RARE O
mobile O
RARE O
, O
baseline O
separation O
of O
RARE O
, O
its O
metabolites O
3 O
- O
RARE O
, O
RARE O
and O
4 O
- O
RARE O
, O
and O
the O
internal O
standard O
, O
RARE O
, O
was O
achieved O
within O
6 O
min O
. O

The O
liver O
in O
the O
severely O
RARE O

In O
a O
randomized O
study O
on O
NUM O
patients O
( O
ALL_CAP O
1 O
) O
undergoing O
induction O
of O
anaesthesia O
, O
the O
effects O
of O
RARE O
( O
NUM O
. O
1 O
mg O
RARE O
the O
combination O
of O
RARE O
( O
NUM O
. O
1 O
mg O
) O
and O
RARE O
( O
5 O
mg O
) O
( O
RARE O
, O
RARE O
) O
and O
RARE O
( O
NUM O
. O
01 O
mg O
/ O
kg O
b O
. O
w O
.) O
alone O
on O
RARE O
parameters O
were O
studied O
. O

These O
results O
confirming O
the O
high O
validity O
of O
ALL_CAP O
inhibiting O
test O
in O
the O
diagnosis O
of O
RARE O
RARE O
states O
, O
reveal O
RARE O
responses O
to O
CD O
/ O
ALL_CAP O
, O
ALL_CAP O
and O
ALL_CAP O
, O
with O
RARE O
the O
existence O
of O
2 O
sub O
- O
group O
of O
RARE O
: O
with O
or O
without O
a O
maintained O
ALL_CAP O
central O
RARE O
supporting O
the O
possibility O
of O
different O
RARE O
factors O
in O
inducing O
a O
RARE O
RARE O
states O
. O

Serum O
lipids O
and O
RARE O
of O
29 O
insulin I-GENE
dependent O
diabetic O
children O
have O
been O
determined O
and O
related O
to O
the O
metabolic O
status O
of O
the O
patients O
. O

Low O
NA O
and O
A O
may O
participate O
in O
lowering O
the O
plasma I-GENE
renin I-GENE
activity O
which O
in O
PA O
in O
suppressed O
, O
RARE O
RARE O
to O
the O
actual O
body O
RARE O
content O
. O

RARE O
concentrations O
in O
serum O
and O
RARE O
RARE O
in O
healthy O
volunteers O
and O
in O
patients O
with O
RARE O
impairment O
. O

The O
subgroup O
RARE O
the O
medial O
RARE O
lies O
exclusively O
along O
the O
medial O
face O
of O
the O
RARE O
nucleus O
, O
with O
RARE O
aberrant O
neurons O
in O
the O
medial O
longitudinal O
RARE O
, O
RARE O
have O
been O
found O
in O
other O
mammals O
. O

RARE O
B O
vaccination O
strategy O
RARE O
health O
- O
care O
workers O
in O
a O
RARE O
of O
RARE O
hepatitis O
B O
RARE O
. O

An O
intravenous O
RARE O
infusion O
of O
ALL_CAP O
in O
adequate O
dosage O
would O
be O
beneficial O
to O
use O
against O
some O
infectious O
diseases O
of O
RARE O
field O
. O

RARE O
of O
these O
RARE O
NUM O
, O
3 O
% O
RARE O
next O
RARE O
( O
RARE O
ALL_CAP O
RARE O
57 O
, O
6 O
% O
RARE O
to O
have O
RARE O
diagnosis O
( O
RARE O
ALL_CAP O
). O

The O
authors O
have O
tested O
the O
interference O
of O
the O
hemoglobin I-GENE
by O
two O
routine O
methods O
( O
RARE O
RARE O
and O
RARE O
modified O
) O
RARE O
the O
determination O
of O
RARE O
urea O
. O

RARE O
patients O
had O
a O
significantly O
lower O
prevalence O
of O
RARE O
use O
. O

These O
cells O
averaged O
NUM O
microns O
in O
diameter O
and O
RARE O
by O
RARE O
, O
forming O
clusters O
of O
two O
or O
four O
daughter O
cells O
. O

Female O
but O
not O
male O
RARE O
were O
significantly O
RARE O
RARE O
RARE O
- O
fed O
rats O
than O
RARE O
those O
fed O
diet O
NUM O
. O

RARE I-GENE
N I-GENE
- I-GENE
RARE I-GENE
activity O
per O
mg O
RARE O
did O
not O
differ O
significantly O
between O
groups O
. O

The O
associations O
between O
RARE I-GENE
- I-GENE
hormone I-GENE
- I-GENE
binding I-GENE
globulin I-GENE
capacity O
( O
SHBG I-GENE
RARE O
age O
, O
body O
mass O
index O
( O
BMI O
RARE O
and O
physical O
fitness O
have O
been O
studied O
in O
NUM O
men O
and O
NUM O
women O
. O

RARE O
( O
RARE O
) O
RARE O
RARE O
. O
et O
RARE O
. O
RARE O
. O

After O
1 O
. O
5 O
years O
of O
such O
RARE O
control O
, O
all O
RARE O
were O
RARE O
by O
bilateral O
RARE O
RARE O
. O

The O
concentrations O
of O
NUM I-GENE
and O
C1 I-GENE
- I-GENE
ALL_CAP I-GENE
increased O
with O
RARE O
RARE O
of O
RARE O
and O
were O
above O
normal O
mean O
values O
in O
all O
stages O
. O

RARE O
RARE O
activity O
was O
shown O
toward O
the O
Gram O
- O
negative O
bacilli O
, O
i O
. O
RARE O
., O
RARE O
, O
RARE O
- O
RARE O
, O
RARE O
, O
Escherichia O
coli O
, O
RARE O
RARE O
and O
RARE O
. O

The O
RARE O
RARE O
capacity O
against O
RARE O
RARE O
RARE O
. O

The O
apparatus O
consists O
of O
an O
RARE O
- O
NUM O
RARE O
source O
( O
NUM O
mCi O
) O
and O
pure O
RARE O
detector O
( O
50 O
mm2 O
X O
5 O
mm O
) O
RARE O
measuring O
K O
alpha O
RARE O
RARE O
- O
rays O
( O
NUM O
. O
3 O
and O
NUM O
. O
6 O
ALL_CAP O
) O
RARE O
from O
RARE O
iodine O
. O

RARE O
studies O
of O
RARE O
of O
premature O
infants O

The O
range O
of O
serum O
concentrations O
, O
mean O
values O
, O
median O
values O
, O
and O
standard O
RARE O
RARE O
each O
RARE O
are O
reported O
RARE O
males O
and O
females O
and O
RARE O
three O
age O
groups O
( O
NUM O
- O
NUM O
, O
NUM O
- O
NUM O
, O
NUM O
- O
70 O
). O

The O
effects O
of O
RARE O
drugs O
in O
patients O
with O
RARE O
ventricular O
RARE O
: O
assessment O
with O
RARE O
- O
111 O
platelet O
imaging O
and O
two O
- O
dimensional O
echocardiography O
. O

A O
stable O
interface O
depends O
on O
overall O
stress O
and O
RARE O
distribution O
on O
the O
bone O
, O
particularly O
RARE O
bone O
. O

Plasma O
ALL_CAP O
was O
also O
low O
in O
the O
RARE O
group O
( O
NUM O
mg O
/ O
liter O
+/- O
126 O
( O
1 O
SD O
) O
RARE O
NUM O
+/- O
NUM O
, O
P O
= O
NUM O
. O
NUM O
, O
resting O
RARE O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

10 O
long O
- O
term O
hemodialysis O
patients O
had O
immediate O
and O
RARE O
thallium O
- O
NUM O
RARE O
imaging O
performed O
after O
a O
course O
of O
hemodialysis O
. O

The O
RARE I-GENE
levels O
were O
within O
the O
physiological O
RARE O
; O
the O
responses O
to O
TRH I-GENE
were O
normal O
, O
and O
elevated O
only O
in O
a O
few O
cases O
. O

Despite O
RARE O
tumor O
resection O
, O
multiple O
RARE O
tumor O
nodules O
of O
varying O
sizes O
were O
found O
and O
RARE O
RARE O
months O
and O
one O
year O
later O
. O

RARE O
hospital O
RARE O
. O

RARE I-GENE
III I-GENE
in O
hip O
surgery O

In O
14 O
of O
21 O
infant O
hearts O
( O
NUM O
%) O
with O
aortic O
RARE O
RARE O
between O
the O
RARE O
common O
carotid O
and O
RARE O
RARE O
arteries O
( O
type O
B O
of O
RARE O
and O
RARE O
RARE O
the O
right O
RARE O
artery O
( O
SA O
) O
RARE O
RARE O
. O

We O
suggest O
that O
sensitivity O
to O
RARE O
in O
RARE O
RARE O
, O
RARE O
in O
several O
other O
mammals O
, O
is O
RARE O
by O
the O
pineal O
RARE O
. O

RARE O
was O
rapid O
, O
with O
a O
mean O
time O
to O
peak O
of O
NUM O
min O
. O

Additionally O
, O
observations O
that O
patients O
with O
mitral O
versus O
aortic O
RARE O
respond O
differently O
to O
valve O
RARE O
suggest O
that O
differences O
exist O
RARE O
between O
these O
two O
RARE O
of O
volume O
overload O
. O

A O
case O
of O
manifest O
latent O
nystagmus O
of O
RARE O
onset O
in O
a O
NUM O
- O
year O
- O
old O
RARE O
is O
reported O
. O

Within O
the O
compartment O
or O
RARE O
of O
severity O
of O
depression O
a O
RARE O
of O
the O
RARE O
RARE O
Scale O
( O
or O
the O
RARE O
Scale O
) O
was O
shown O
to O
have O
reached O
an O
RARE O
RARE O
, O
RARE O
. O
g O
. O
RARE O
an O
outcome O
measure O
of O
RARE O
treatment O
. O

Significant O
RARE O
developed O
prior O
to O
the O
development O
of O
RARE O
, O
significantly O
decreased O
RARE O
clearance O
, O
significant O
RARE O
( O
greater O
than O
or O
equal O
to O
3 O
+ O
RARE O
or O
greater O
than O
or O
equal O
to O
5 O
RARE O
per O
NUM O
- O
hour O
urine O
collection O
RARE O
or O
RARE O
. O

A O
RARE O
number O
of O
NUM O
cases O
were O
collected O
from O
135 O
medical O
RARE O
. O

RARE O
activity O
recorded O
from O
superficial O
RARE O
RARE O
layer O
4 O
, O
and O
into O
which O
layer O
4 O
' O
s O
RARE O
projections O
terminate O
, O
is O
suppressed O
preferentially O
by O
phenytoin O
. O

The O
AD O
RARE O
were O
markedly O
more O
dependent O
on O
the O
affective O
state O
of O
the O
rat O
then O
was O
the O
NUM O
RARE O
. O

Is O
RARE O
capable O
of O
RARE O
RARE O
ventricular O
RARE O
? O
In O
ten O
anesthetized O
pigs O
, O
RARE O
( O
2 O
- O
4 O
micrograms O
X O
kg O
- O
1 O
X O
min O
- O
1 O
RARE O
a O
RARE O
RARE O
blocker O
structurally O
related O
to O
nifedipine O
, O
RARE O
RARE O
ventricular O
systolic O
pressure O
( O
40 O
%) O
and O
systemic O
vascular O
resistance O
( O
NUM O
%), O
whereas O
ALL_CAP O
/ O
dt O
decreased O
by O
20 O
% O
and O
cardiac O
output O
was O
unchanged O
. O

RARE O
were O
evaluated O
before O
and O
after O
unilateral O
and O
serial O
bilateral O
removal O
of O
superior O
temporal O
cortex O
. O

ALL_CAP O
concentration O
in O
the O
RARE O
indicated O
little O
, O
if O
any O
accumulation O
. O

All O
samples O
exhibited O
a O
decline O
in O
ethanol O
concentration O
, O
with O
most O
RARE O
RARE O
within O
the O
expected O
20 O
to O
40 O
mg O
% O
range O
. O

Plasma I-GENE
RARE I-GENE
and O
the O
RARE O
count O
of O
RARE O
neutrophils O

The O
importance O
of O
selective O
RARE O
RARE O
RARE O
in O
the O
evaluation O
of O
RARE O
RARE O
and O
RARE O
defects O
in O
the O
RARE O
RARE O
is O
RARE O
. O

RARE O
study O
of O
RARE O
coagulation O
in O
RARE O
patients O
. O

The O
statistical O
analysis O
consist O
of O
the O
F O
test O
followed O
by O
RARE O
' O
s O
contrast O
test O
. O

The O
pyramidal O
RARE O
and O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
were O
RARE O
before O
and O
after O
the O
RARE O
. O

Further O
, O
the O
reduction O
in O
5 O
- O
RARE O
( O
5 O
- O
ALL_CAP O
) O
accumulation O
by O
ALL_CAP O
showed O
regional O
differences O
in O
inhibition O
by O
RARE O
( O
hypothalamus O
greater O
than O
cortex O
greater O
than O
RARE O
) O
which O
RARE O
the O
RARE O
antagonist O
activity O
of O
RARE O
in O
vitro O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

Effects O
of O
RARE O
and O
RARE O
acid O
RARE O
on O
RARE O
release O
in O
vitro O
and O
RARE O
RARE O
in O
vivo O
: O
possible O
relation O
to O
RARE I-GENE
RARE I-GENE
function O
. O

In O
a O
recent O
RARE O
epidemic O
in O
RARE O
RARE O
, O
ALL_CAP O
, O
120 O
, O
NUM O
records O
were O
screened O
using O
these O
criteria O
, O
and O
RARE O
a O
result O
NUM O
, O
NUM O
students O
were O
RARE O
. O

No O
patient O
with O
RARE O
- O
related O
ALL_CAP O
had O
manifest O
RARE O
RARE O
or O
bundle O
branch O
RARE O
. O

The O
measurement O
of O
the O
areas O
of O
fibrin I-GENE
, O
of O
tissue O
and O
RARE O
, O
RARE O
the O
above O
mentioned O
times O
, O
has O
been O
RARE O
RARE O
standard O
magnification O
( O
NUM O
X O
) O
by O
an O
image O
RARE O
( O
RARE O
) O
scale O
1 O
: O
8 O
. O

RARE O
RARE O
- O
RARE O
poisoning O
. O

RARE O
plasma I-GENE
RARE I-GENE
concentration O
after O
NUM O
minutes O
in O
untreated O
patients O
correlated O
positively O
to O
the O
RARE O
fat O
excretion O
( O
RARE O
= O
NUM O
. O
58 O
, O
p O
less O
than O
NUM O
. O
02 O
). O

RARE O
pressure O
in O
children O
. O

In O
this O
study O
the O
RARE O
RARE O
born O
RARE O
appeared O
to O
be O
capable O
of O
RARE O
RARE O
RARE O
an O
RARE O
drug O
testing O
model O
. O

The O
results O
showed O
that O
the O
sensitivity O
of O
the O
3 O
given O
RARE O
RARE O
strains O
was O
comparable O
. O

Adult O
RARE O
RARE O
ticks O
fed O
RARE O
RARE O
on O
this O
RARE O
transmitted O
RARE O
to O
a O
RARE O
( O
RARE O
RARE O
) O
RARE O
. O

Twenty O
- O
one O
percent O
of O
these O
patients O
had O
neurologic O
RARE O
that O
appeared O
to O
be O
responsible O
RARE O
the O
RARE O
. O

RARE O
injected O
into O
the O
lateral O
ventricle O
of O
the O
rat O
produced O
unilateral O
analgesia O
in O
the O
formalin O
test O
, O
which O
involves O
continuous O
, O
moderate O
pain O
. O

The O
maps O
of O
RARE O
2 O
showed O
that O
a O
maximum O
RARE O
appeared O
on O
the O
upper O
right O
back O
and O
then O
RARE O
down O
the O
right O
RARE O
of O
the O
posterior O
RARE O
. O

RARE O
RARE O
excretion O
, O
RARE O
clearance O
, O
and O
fractional O
excretion O
of O
RARE O
all O
increased O
significantly O
RARE O
water O
immersion O
, O
and O
decreased O
in O
the O
hour O
following O
water O
immersion O
. O

Mutations O
in O
RARE O
other O
RARE I-GENE
genes I-GENE
do O
not O
result O
in O
the O
RARE I-GENE
- I-GENE
RARE I-GENE
. O

Twenty O
- O
eight O
were O
excluded O
RARE O
RARE O
were O
not O
proved O
: O
of O
the O
RARE O
, O
21 O
patients O
received O
glucagon I-GENE
and O
NUM O
placebo O
. O

4 O
Five O
patients O
died O
within O
one O
month O
of O
captopril O
and O
five O
between O
four O
and O
RARE O
months O
, O
three O
of O
whom O
had O
improved O
to O
class O
ALL_CAP O
and O
one O
to O
ALL_CAP O
before O
RARE O
. O

RARE O
RARE O
hyperplasia O
with O
RARE O

RARE O
of O
the O
translated O
RARE O
reading O
frames O
of O
ALL_CAP I-GENE
and O
the O
third O
intron O
of O
the O
RARE I-GENE
gene I-GENE
in I-GENE
yeast I-GENE
show O
high O
amino O
acid O
homology O
. O

RARE O
strains O
isolated O
from O
humans O
in O
RARE O
RARE O
- O
infections O
RARE O
orally O
RARE O
mice O
more O
frequently O
than O
strains O
isolated O
in O
hospital O
infections O
. O

RARE O
tooth O
RARE O
with O
the O
aid O
of O
the O
ALL_CAP O
( O
International O
RARE O
RARE O
RARE O
) O
type O
F O
RARE O
- O
RARE O
implant O

The O
NUM O
, O
14 O
- O
RARE O
- O
NUM O
- O
RARE O
- O
metabolites O
of O
PGE2 O
and O
PGF2 O
alpha O
had O
RARE O
statistically O
significant O
antiarrhythmic O
effect O
. O

Nucleotide O
sequence O
of O
DNA O
controlling O
RARE O
of O
genes O
RARE O
RARE O
utilization O
in O
RARE O
RARE O
. O

The O
hypertension O
with O
elevated O
ALL_CAP O
, O
however O
, O
was O
resistant O
to O
the O
angiotensin I-GENE
II I-GENE
( O
ALL_CAP I-GENE
) O
analog O
RARE O
NUM O
, O
NUM O
] O
ALL O
. O

RARE O
determination O
of O
RARE O
iron O
, O
RARE O
with O
RARE O
B O
, O
using O
a O
single O
RARE O

Measurements O
of O
perfusion O
also O
showed O
significantly O
RARE O
values O
under O
RARE O
therapy O
. O

RARE O
of O
distribution O
of O
RARE O
ALL_CAP O
( O
range O
, O
1 O
. O
NUM O
to O
6 O
. O
NUM O
RARE O
/ O
kg O
) O
and O
of O
RARE O
ALL_CAP O
after O
correction O
RARE O
protein O
binding O
( O
range O
, O
NUM O
to O
NUM O
RARE O
/ O
kg O
) O
was O
larger O
in O
women O
than O
in O
men O
of O
all O
ages O
, O
and O
in O
the O
elderly O
RARE O
opposed O
to O
the O
young O
. O

Effects O
of O
dopamine O
and O
of O
a O
dopaminergic O
blocker O
, O
haloperidol O
, O
on O
the O
responses O
of O
carotid O
body O
RARE O
to O
RARE O
and O
hypercapnia O
were O
investigated O
in O
16 O
anesthetized O
cats O
. O

HLA I-GENE
- I-GENE
A I-GENE
and I-GENE
B I-GENE
RARE O
of O
NUM O
patients O
suffering O
from O
malignant O
melanomas O
were O
determined O
, O
with O
RARE O
regard O
RARE O
metastatic O
form O
or O
relapse O
. O

Trypanosoma O
RARE O
. O

The O
subjects O
of O
the O
study O
were O
10 O
normal O
subjects O
and O
NUM O
patients O
with O
RARE O
RARE O
. O

1 O
. O

This O
study O
represents O
the O
RARE O
published O
long O
- O
term O
follow O
- O
RARE O
regarding O
this O
mode O
of O
treatment O
in O
patients O
with O
alveolar O
RARE O
. O

The O
alterations O
in O
differentiation O
of O
RARE O
cells O
, O
together O
with O
the O
failure O
of O
RARE O
, O
resulted O
in O
significantly O
lower O
rates O
of O
bone O
formation O
( O
RARE O
measured O
by O
RARE O
labeling O
) O
in O
the O
magnesium O
- O
RARE O
rats O
. O

A O
RARE O
measure O
of O
this O
impairment O
may O
be O
obtained O
using O
the O
ratio O
of O
urine O
volume O
( O
V O
) O
divided O
by O
lithium O
clearance O
( O
RARE O
). O

RARE O
balance O
was O
compared O
, O
and O
metabolic O
complications O
were O
monitored O
by O
evaluating O
ALL_CAP O
, O
serum O
RARE O
, O
RARE O
clearance O
, O
serum O
CO2 O
, O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
serum I-GENE
ALL_CAP I-GENE
, O
and O
serum I-GENE
RARE I-GENE
phosphatase I-GENE
. O

RARE O
of O
C I-GENE
mu I-GENE
RNAs I-GENE
, O
unlike O
mu I-GENE
mRNAs I-GENE
, O
does O
not O
require O
RARE O
with O
the O
RARE I-GENE
region I-GENE
( O
ALL_CAP I-GENE
) O
locus O
. O

The O
1 O
. O
9 O
- O
kb O
C I-GENE
mu I-GENE
RNA O
contains O
the O
3 O
' O
sequence O
characteristic O
of O
RARE O
mu I-GENE
chain I-GENE
, O
whereas O
the O
longer O
species O
RARE O
that O
of O
membrane O
- O
RARE O
mu I-GENE
RARE O
. O

RARE O
of O
the O
immunoglobulin I-GENE
C I-GENE
mu I-GENE
gene I-GENE
vary O
in O
RARE O
and O
RARE O
RARE O
RARE O
development O
. O

Non O
- O
complement O
- O
dependent O
sperm O
- O
RARE O
activity O
was O
also O
detected O
in O
the O
cervical O
mucus O
of O
several O
patients O
. O

The O
role O
of O
DNA O
rearrangement O
and O
RARE O
RNA O
RARE O
in O
the O
RARE O
of O
immunoglobulin I-GENE
delta I-GENE
genes I-GENE
. O

Although O
the O
mechanism O
of O
action O
of O
ALL_CAP O
- O
NUM O
and O
NUM O
has O
not O
been O
clearly O
defined O
, O
it O
is O
evident O
from O
both O
RARE O
and O
early O
clinical O
studies O
that O
these O
compounds O
are O
of O
interest O
. O

All O
NUM O
isolates O
were O
resistant O
to O
RARE O
, O
RARE O
, O
RARE O
, O
amphotericin O
B O
, O
RARE O
RARE O
, O
RARE O
B O
, O
and O
RARE O
. O

The O
evaluation O
of O
RARE O
RARE O
delta O
NUM O
is O
considered O
to O
be O
the O
RARE O
of O
clinical O
management O
. O

RARE O
lipids O
in O
tuberculous O
infection O
. O

There O
is O
now O
a O
RARE O
difference O
between O
age O
group O
1 O
- O
5 O
and O
the O
others O
( O
p O
RARE O
RARE O
NUM O
, O
02 O
). O

The O
sympathetic O
RARE O
influence O
on O
the O
myocardium O
with O
ALL_CAP O
depends O
to O
a O
large O
measure O
on O
the O
intensity O
of O
the O
RARE O
biosynthesis O
and O
function O
of O
RARE O
RARE O
. O

RARE I-GENE
RARE I-GENE
reductase I-GENE
in O
diabetic O
and O
RARE O
RARE O
. O

RARE O
( O
in O
doses O
ranging O
from O
NUM O
. O
NUM O
- O
4 O
. O
NUM O
mg O
/ O
kg O
/ O
infusion O
) O
did O
not O
maintain O
self O
- O
administration O
behavior O
RARE O
or O
above O
the O
minimum O
requirement O
( O
ALL_CAP O
NUM O
). O

In O
the O
course O
of O
RARE I-GENE
A I-GENE
HBs I-GENE
- I-GENE
and I-GENE
RARE I-GENE
- I-GENE
antigen I-GENE
RARE O
RARE O
RARE O
RARE I-GENE
( I-GENE
IgM I-GENE
and I-GENE
IgG I-GENE
RARE I-GENE
HBs I-GENE
- I-GENE
and I-GENE
RARE I-GENE
- I-GENE
antibodies I-GENE
can O
be O
detected O
. O

The O
effect O
of O
the O
fatty I-GENE
acid I-GENE
RARE I-GENE
- I-GENE
oxygenase I-GENE
inhibitor O
indomethacin O
on O
cerebral O
RARE O
flow O
( O
CBF O
) O
and O
the O
metabolic O
rate O
RARE O
oxygen O
( O
NUM O
) O
was O
studied O
in O
RARE O
and O
artificially O
ventilated O
rats O
. O

The O
rat O
RARE O
is O
an O
excellent O
model O
RARE O
in O
which O
to O
study O
RARE O
. O

The O
already O
elevated O
prolactin I-GENE
levels O
in O
nursing O
women O
were O
not O
influenced O
by O
chronic O
oestradiol O
administration O
. O

RARE I-GENE
VIII I-GENE
RARE O
activity O
, O
antigen O
concentration O
and O
RARE I-GENE
Willebrand I-GENE
activity O
RARE O
RARE I-GENE
cofactor I-GENE
were O
determined O
several O
times O
in O
10 O
patients O
with O
ALL_CAP O
. O

RARE O
- O
dependent O
and O
control O
rats O
in O
an O
oral O
free O
- O
choice O
protocol O
were O
treated O
with O
gamma O
- O
vinyl O
ALL_CAP O
( O
ALL_CAP O
RARE O
NUM O
, O
120 O
and O
240 O
mg O
/ O
kg O
ALL_CAP O
, O
RARE O
3 O
days O
over O
three O
successive O
periods O
. O

Significance O
of O
the O
pulmonary O
gas O
exchange O
reaction O
to O
physical O
loading O
in O
evaluating O
the O
effectiveness O
of O
mitral O
RARE O

RARE I-GENE
ALL_CAP O
in O
thyroid O
RARE O

In O
RARE O
, O
significant O
relationships O
between O
patients O
and O
RARE O
were O
not O
seen O
with O
respect O
to O
arterial O
RARE O
gas O
determinations O
and O
RARE O
responses O
except O
RARE O
NUM O
of O
patients O
and O
RARE O
RARE O
responses O
of O
RARE O
. O

For O
steers O
the O
RARE O
N O
values O
were O
NUM O
and O
NUM O
mg O
/ O
kg O
NUM O
. O
NUM O
RARE O
NUM O
and O
350 O
kg O
live O
RARE O
respectively O
and O
RARE O
N O
excretion O
including O
RARE O
N O
was O
NUM O
and O
NUM O
mg O
/ O
kg O
NUM O
. O
NUM O
. O

RARE O
in O
RARE O
treatment O
: O
a O
hepatitis O
- O
safe O
factor I-GENE
VIII I-GENE
RARE O

This O
study O
was O
designed O
to O
assess O
and O
compare O
the O
ability O
of O
three O
different O
forms O
of O
ALL_CAP O
to O
RARE O
ALL_CAP O
. O

Comparison O
of O
three O
different O
preparations O
of O
RARE O
RARE O
in O
the O
prevention O
of O
exercise O
- O
RARE O
RARE O
: O
a O
double O
- O
blind O
study O
. O

ALL_CAP O
in O
normal O
and O
hypoxic O
RARE O
was O
correlated O
with O
local O
cerebral O
glucose O
utilization O
( O
ALL_CAP O
) O
obtained O
under O
the O
same O
experimental O
conditions O
( O
RARE O
et O
al O
, O
1982 O
). O

RARE O
of O
RARE O
bacilli O
by O
macrophages O
. O

Detection O
of O
RARE O
A O
carriers O
. O

The O
stability O
of O
RARE O
solutions O
increases O
markedly O
with O
increasing O
ALL_CAP O
or O
EDTA O
concentration O
RARE O
to O
1 O
mmol O
/ O
RARE O
. O

RARE O
bilirubin O
did O
not O
rise O
within O
12 O
h O
after O
RARE O
infusion O
a O
finding O
which O
RARE O
further O
investigation O
. O

RARE O
RARE O
RARE O
juvenile O
diabetes O
management O
. O

Other O
properties O
of O
Hg O
- O
and O
Cd O
- O
RARE O
were O
similar O
to O
those O
of O
control O
RARE O
. O

The O
decrease O
in O
ALL_CAP I-GENE
- I-GENE
cholesterol I-GENE
with O
increasing O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
was O
relatively O
much O
larger O
than O
the O
concomitant O
decrease O
in O
RARE I-GENE
A I-GENE
- I-GENE
I I-GENE
. O

RARE I-GENE
A I-GENE
- I-GENE
I I-GENE
level O
was O
unrelated O
to O
age O
, O
but O
increased O
with O
ethanol O
consumption O
and O
decreased O
with O
RARE O
. O

ALL_CAP O
and O
ALL_CAP O
were O
the O
most O
potent O
RARE O
. O

The O
osmotic O
diuretic O
RARE O
was O
administered O
to O
21 O
patients O
. O

Of O
270 O
patients O
with O
RARE O
- O
defined O
drug O
reactions O
, O
190 O
( O
70 O
per O
cent O
) O
gave O
a O
positive O
response O
to O
the O
RARE O
cell O
test O
. O

RARE O
, O
RARE O
a O
RARE O
of O
RARE I-GENE
peroxidase I-GENE
, O
plays O
a O
role O
in O
the O
antioxidant O
defense O
RARE O
of O
the O
body O
, O
but O
other O
metabolic O
roles O
RARE O
selenium O
may O
yet O
be O
discovered O
. O

Diagnostic O
value O
of O
serum I-GENE
myoglobin I-GENE
in O
cases O
of O
neuromuscular O
RARE O

At O
NUM O
% O
RARE O
pressure O
reduction O
, O
PCO2 O
fell O
by O
NUM O
. O
53 O
RARE O
, O
a O
decrease O
which O
could O
not O
explain O
the O
observed O
CBF O
fall O
of O
NUM O
%. O

During O
the O
last O
6 O
months O
of O
the O
study O
a O
striking O
change O
in O
RARE O
concerning O
hepatitis O
A O
was O
seen O
, O
apparently O
caused O
by O
a O
RARE O
increase O
in O
the O
incidence O
of O
this O
type O
of O
hepatitis O
among O
drug O
addicts O
. O

RARE O
patients O
showed O
greater O
responses O
of O
both O
parameters O
to O
adrenaline O
than O
controls O
indicating O
that O
long O
- O
term O
RARE O
treatment O
enhances O
the O
acute O
responses O
of O
plasminogen I-GENE
activator I-GENE
and O
RARE I-GENE
factor I-GENE
VIII I-GENE
to O
adrenaline O
infusion O
. O

RARE O
amino O
RARE O
( O
g O
/ O
16 O
g O
N O
) O
were O
RARE O
in O
the O
isolates O
than O
in O
the O
RARE O
. O

RARE O
shifts O
increase O
growth I-GENE
hormone I-GENE
release O
. O

It O
then O
RARE O
with O
right O
ventricular O
RARE O
RARE O
along O
the O
right O
ventricular O
anterior O
RARE O
RARE O
and O
outflow O
RARE O
. O

Many O
of O
these O
RARE O
RARE O
were O
undertaken O
in O
the O
early O
NUM O
and O
NUM O
, O
when O
knowledge O
regarding O
the O
safe O
and O
prolonged O
RARE O
of O
the O
RARE O
RARE O
was O
RARE O
or O
minimal O
RARE O
best O
. O

RARE O
could O
be O
RARE O
only O
with O
multiple O
exposures O
to O
ALL_CAP O
. O

The O
level O
of O
contamination O
in O
the O
wound O
can O
be O
determined O
with O
the O
rapid O
biopsy O
fixation O
technique O
. O

RARE O
- O
RARE O
after O
deep O
hypothermia O
( O
20 O
degrees O
C O
) O
causes O
a O
considerable O
increase O
in O
the O
brain O
tissues O
RARE I-GENE
activity O
RARE O
all O
studied O
incubation O
temperatures O
( O
37 O
, O
NUM O
, O
20 O
and O
10 O
degrees O
C O
) O
RARE O
compared O
to O
control O
rats O
and O
rats O
under O
hypothermia O
. O

Similar O
observations O
were O
made O
with O
unilateral O
RARE O
of O
NUM O
cmH2O O
RARE O
NUM O
min O
. O

According O
to O
RARE O
' O
s O
classification O
, O
they O
consisted O
of O
RARE O
RARE O
in O
NUM O
%, O
RARE O
RARE O
in O
11 O
%, O
RARE O
II O
in O
11 O
%, O
and O
RARE O
III O
in O
16 O
%. O

This O
study O
was O
undertaken O
to O
define O
the O
mechanism O
RARE O
the O
respiratory O
inhibition O
observed O
RARE O
high O
- O
frequency O
RARE O
ventilation O
( O
ALL_CAP O
). O

Determination O
of O
20 O
alpha O
- O
hydroxy O
- O
9 O
beta O
, O
10 O
alpha O
- O
RARE O
- O
4 O
, O
6 O
- O
RARE O
- O
3 O
- O
one O
in O
plasma O
by O
RARE O
ion O
monitoring O
. O

A O
case O
of O
a O
RARE O
RARE O
cyst O
of O
the O
RARE O
RARE O
is O
presented O
. O

RARE O
treatments O
were O
assigned O
to O
RARE O
the O
different O
levels O
of O
RARE O
intake O
that O
might O
result O
from O
differences O
in O
daily O
feed O
intake O
similar O
to O
the O
practice O
followed O
with O
commercial O
RARE O
. O

RARE O
RARE O
RARE O
was O
seen O
in O
the O
ascending O
and O
RARE O
aorta O
of O
the O
swine O
fed O
NUM O
, O
500 O
IU O
of O
vitamin O
NUM O
/ O
kg O
of O
diet O
RARE O
three O
months O
duration O
; O
and O
after O
3 O
months O
of O
vitamin O
NUM O
withdrawal O
, O
RARE O
lesions O
were O
found O
. O

Because O
of O
a O
rapid O
development O
of O
the O
RARE O
tissue O
RARE O
, O
however O
, O
RARE O
the O
place O
of O
the O
RARE O
RARE O
parenchyma O
areas O
, O
there O
is O
RARE O
RARE O
of O
the O
organ O
' O
s O
RARE O
and O
function O
by O
the O
NUM O
day O
. O

Histological O
signs O
of O
the O
RARE O
- O
RARE O
reaction O
were O
already O
present O
RARE O
6 O
hr O
after O
i O
. O
v O
. O
challenge O
and O
RARE O
RARE O
RARE O
least O
4 O
days O
. O

Significant O
ALL_CAP O
reductions O
occurred O
in O
early O
shock O
in O
both O
treatment O
groups O
. O

Of O
NUM O
children O
with O
neuroblastoma O
treated O
RARE O
RARE O
. O

RARE O
- O
G O
RARE O
products O
inhibit O
in O
vitro O
RARE O
. O

Plasma O
fibrinogen I-GENE
was O
measured O
by O
the O
RARE O
method O
in O
RARE O
RARE O
RARE O
. O

Five O
patients O
with O
type O
III O
RARE O
infection O
from O
RARE O
RARE O
species O
were O
examined O
RARE O
a O
NUM O
- O
month O
period O
. O

RARE O
tubular O
acidification O
and O
the O
threshold O
RARE O
proximal O
tubular O
RARE O
RARE O
were O
normal O
, O
RARE O
was O
urine O
RARE O
capacity O
. O

Detection O
of O
exercise O
- O
RARE O
RARE O
by O
M O
- O
mode O
echocardiography O
. O

The O
RARE O
phenomenon O
, O
RARE O
test O
, O
and O
RARE O
' O
s O
sign O
: O
clinical O
significance O
. O

These O
results O
indicate O
that O
significant O
pulmonary O
metabolism O
of O
5 O
- O
ALL_CAP O
followed O
by O
RARE O
of O
5 O
- O
ALL_CAP O
into O
venous O
output O
occurs O
RARE O
single O
- O
RARE O
circulation O
. O

RARE O
of O
RARE O
RARE O
, O
2 O
. O

On O
the O
basis O
of O
histopathological O
findings O
, O
the O
origin O
of O
RARE O
appeared O
to O
be O
closely O
related O
to O
the O
RARE O
. O

Both O
groups O
were O
subjected O
to O
tests O
of O
delayed O
hypersensitivity O
with O
RARE I-GENE
, O
RARE I-GENE
and O
RARE I-GENE
. O

Serum O
RARE I-GENE
dehydrogenase I-GENE
and O
RARE I-GENE
levels O
were O
normal O
, O
and O
RARE O
bilirubin O
was O
only O
slightly O
elevated O
. O

Low O
- O
dose O
D O
( O
NUM O
. O
4 O
- O
NUM O
. O
8 O
mg O
) O
and O
ALL_CAP O
( O
1 O
. O
NUM O
- O
5 O
. O
NUM O
mg O
) O
did O
not O
significantly O
alter O
any O
parameter O
from O
control O
. O

RARE O
of O
cervical O
spine O
RARE O
methods O
. O

RARE O
from O
the O
ALL_CAP O
. O

The O
presence O
of O
RARE O
- O
RARE O
in O
RARE O
is O
reported O
RARE O
the O
RARE O
time O
. O

RARE O
levels O
of O
ALL_CAP O
RARE O
with O
relative O
RARE O
. O

RARE O
platelets O
may O
be O
activated O
by O
exposed O
RARE O
- O
helical O
RARE I-GENE
in O
RARE O
lesions O
in O
RARE O
- O
RARE O
RARE O
. O

Acute O
type O
A O
hepatitis O
in O
three O
patients O
with O
chronic O
ALL_CAP O
infection O
. O

RARE O
relationships O
between O
RARE O
tubular O
acidosis O
and O
RARE O
metabolism O
alterations O
in O
liver O
cirrhosis O
. O

5 O
ALL_CAP O
/ O
RARE O
thyrotropin I-GENE
: O
NUM O
% O
( O
NUM O
RARE O
NUM O
% O
( O
NUM O
) O
and O
20 O
% O
( O
1980 O
). O

RARE O
enables O
to O
improve O
the O
diagnosis O
when O
compared O
with O
classical O
RARE O
in O
about O
20 O
% O
of O
cases O
. O

RARE O
with O
the O
acquired O
immune O
deficiency O
RARE O
. O

The O
prevalence O
of O
ALL_CAP O
was O
similar O
in O
type O
1 O
and O
type O
2 O
diabetes O
, O
was O
greater O
in O
women O
than O
in O
men O
, O
and O
was O
significantly O
greater O
after O
RARE O
RARE O
than O
after O
one O
single O
administration O
of O
RARE O
. O

A O
RARE O
of O
the O
prevalence O
data O
was O
carried O
out O
in O
the O
southern O
RARE O
of O
RARE O
and O
in O
the O
RARE O
RARE O
of O
RARE O
, O
the O
prevalence O
day O
being O
January O
1 O
, O
NUM O
. O

The O
results O
confirm O
and O
extend O
previous O
work O
by O
other O
RARE O
. O

In O
the O
RARE O
RARE O
the O
testosterone O
levels O
sharply O
rose O
RARE O
the O
beginning O
of O
the O
training O
session O
( O
from O
the O
7 O
, O
20 O
RARE O
/ O
ml O
to O
11 O
, O
50 O
RARE O
/ O
ml O
after O
20 O
' O
training O
RARE O
and O
subsequently O
decrease O
after O
3 O
hours O
( O
9 O
, O
20 O
RARE O
/ O
ml O
) O
and O
RARE O
the O
end O
of O
the O
6 O
hours O
training O
( O
4 O
, O
NUM O
RARE O
/ O
ml O
). O

In O
patients O
with O
RARE O
or O
partial O
remission O
of O
the O
tumor O
, O
the O
RARE O
excretion O
RARE O
to O
normal O
values O
. O

In O
RARE O
tumours O
the O
best O
results O
were O
obtained O
with O
FB O
( O
NUM O
%) O
while O
ALL_CAP O
was O
positive O
in O
65 O
%. O

Total O
ALL_CAP O
levels O
in O
synovial O
RARE O
remained O
significantly O
depressed O
in O
the O
patient O
group O
RARE O
NUM O
hours O
after O
the O
NUM O
- O
mg O
test O
dose O
of O
RARE O
on O
day O
8 O
. O

RARE O
rates O
of O
RARE O
gain O
were O
seen O
once O
absorbed O
energy O
RARE O
reached O
NUM O
- O
NUM O
% O
of O
requirements O
. O

Its O
RARE O
, O
anti O
- O
RARE O
, O
and O
platelet O
RARE O
effects O
could O
be O
expected O
to O
RARE O
the O
RARE O
ischemia O
, O
hypertension O
and O
excessive O
coagulation O
that O
are O
seen O
in O
pre O
- O
RARE O
. O

RARE O
' O
s O
RARE O

RARE O
of O
111 O
RARE O
- O
labelled O
autologous O
platelets O
was O
studied O
in O
2 O
patients O
after O
correction O
of O
platelet O
count O
and O
was O
still O
found O
shortened O
. O

The O
effect O
of O
RARE O
- O
RARE O
stress O
( O
ALL_CAP O
) O
on O
RARE O
RARE O
and O
contractility O
was O
studied O
on O
an O
isolated O
rat O
atrium O
. O

RARE O
; O
a O
NUM O
- O
adrenergic O
agonist O
, O
and O
RARE O
, O
a O
RARE O
inhibitor O
, O
were O
given O
separately O
, O
or O
in O
combination O
, O
to O
RARE O
RARE O
on O
the O
NUM O
day O
of O
gestation O
. O

When O
NUM O
therapy O
was O
RARE O
RARE O
, O
the O
association O
between O
ALL_CAP O
and O
ALL_CAP O
did O
not O
achieve O
statistical O
significance O
( O
P O
= O
. O
07 O
). O

This O
two O
- O
helix O
motif O
is O
thought O
to O
be O
involved O
in O
specific O
DNA O
sequence O
recognition O
by O
ALL_CAP I-GENE
. O

The O
RARE O
RARE O
of O
RARE O
RARE O
infarction O
. O

RARE O
RARE O
nurse O
RARE O
RARE O
3 O
. O

The O
infection O
rate O
was O
five O
times O
greater O
in O
patients O
with O
RARE O
RARE O
than O
in O
those O
with O
RARE O
RARE O
( O
p O
= O
NUM O
. O
01 O
). O

After O
a O
year O
of O
planning O
in O
the O
Laboratory O
RARE O
' O
RARE O
in O
RARE O
: O
new O
education O
RARE O
laboratory O
RARE O
is O
now O
arranged O

The O
electrocardiogram O
. O

RARE O
RARE O
place O
through O
complex O
formation O
of O
( O
NUM O
NUM O
. O
NUM O
) O
RARE O
, O
excess O
RARE O
, O
and O
water O
. O

The O
RARE O
have O
proposed O
to O
develop O
this O
research O
employing O
a O
preparation O
containing O
exclusively O
a O
RARE O
, O
the O
RARE O
, O
in O
order O
to O
evaluate O
the O
alterations O
of O
the O
RARE O
to O
be O
attributed O
to O
such O
RARE O
. O

RARE I-GENE
IgA I-GENE
and O
serum I-GENE
immunoglobulins I-GENE
RARE O
indices O
of O
the O
local O
RARE O
of O
the O
RARE O
mucosa O
in O
acute O
leukemias O

Serum I-GENE
IgE I-GENE
levels O
in O
RARE O
children O
. O

Use O
of O
RARE O
F2 O
alpha O
( O
PGF2 O
alpha O
) O
in O
cattle O
RARE O
. O

Thus O
it O
appears O
that O
the O
management O
of O
RARE O
, O
including O
RARE O
is O
of O
great O
importance O
. O

RARE O
, O
variations O
and O
neoplastic O
RARE O
. O

The O
scores O
are O
dependent O
in O
part O
on O
the O
reliability O
of O
RARE O
RARE O
. O

Study O
on O
distribution O
of O
metal O
in O
the O
teeth O
treated O
by O
RARE O
with O
RARE O
specimens O

Whereas O
RARE I-GENE
kinase I-GENE
activity O
declined O
RARE O
from O
a O
single O
peak O
, O
myoglobin I-GENE
appeared O
in O
multiple O
episodes O
RARE O
represented O
by O
a O
single O
peak O
value O
and O
having O
RARE O
clear O
clinical O
correlation O
. O

RARE O
- O
RARE O
RARE O
flow O
and O
the O
effect O
of O
beta I-GENE
2 I-GENE
- I-GENE
adrenoceptor I-GENE
stimulating O
drugs O
. O

RARE O
of O
RARE O
leukemia O
with O
RARE O
8 O
and O
atypical O
RARE O
in O
a O
patient O
with O
a O
history O
of O
RARE O
RARE O
NUM O
years O
earlier O

The O
RARE O
peptide O
bonds O
that O
are O
cleaved O
in O
the O
conversion O
of O
human I-GENE
factor I-GENE
ALL_CAP I-GENE
to O
factor I-GENE
RARE I-GENE
by O
factor I-GENE
RARE I-GENE
were O
identified O
RARE O
NUM O
- O
NUM O
and O
NUM O
- O
NUM O
. O

RARE O
growth O
, O
RARE O
with O
dental O
RARE O
, O
is O
sufficient O
to O
RARE O
possible O
RARE O
of O
RARE O
bone O
bases O
. O

RARE O
methods O
can O
also O
provide O
RARE O
about O
porphyrin O
binding O
sites O
that O
is O
useful O
in O
understanding O
porphyrin O
RARE O
and O
clearance O
. O

Renal O
and O
RARE O
arterial O
RARE O
hyperplasia O
with O
hypertension O
. O

The O
RARE O
rate O
of O
clearance O
of O
tracer O
RARE O
obtained O
from O
the O
portion O
of O
the O
RARE O
- O
detection O
curve O
reflecting O
metabolism O
of O
fatty O
acid O
incorporated O
into O
neutral O
lipids O
RARE O
correlated O
directly O
with O
RARE O
changes O
in O
tension O
- O
time O
index O
after O
injections O
into O
the O
RARE O
atrium O
( O
RARE O
= O
NUM O
. O
96 O
, O
RARE O
= O
12 O
RARE O
right O
atrium O
( O
RARE O
= O
NUM O
. O
NUM O
, O
RARE O
= O
14 O
RARE O
and O
ear O
RARE O
( O
RARE O
= O
NUM O
. O
93 O
, O
RARE O
= O
14 O
). O

Both O
examinations O
are O
RARE O
indicators O
of O
CNS O
abnormalities O
associated O
with O
bacterial O
RARE O
infections O
and O
are O
important O
RARE O
of O
the O
therapy O
and O
RARE O
prognosis O
of O
such O
complications O
. O

Specific O
IgE I-GENE
levels O
decreased O
slightly O
, O
but O
always O
remained O
within O
the O
pathological O
range O
. O

Similar O
clinical O
evaluation O
of O
an O
RARE O
carrier O
revealed O
RARE O
ocular O
abnormalities O
. O

RARE O
between O
RARE O
involvement O
and O
systemic O
outcome O
was O
poor O
. O

A O
case O
of O
anterior O
RARE O
RARE O
in O
a O
NUM O
- O
year O
- O
old O
female O
patient O
is O
described O
. O

The O
daily O
administration O
of O
RARE O
RARE O
three O
weeks O
markedly O
RARE O
the O
absorption O
of O
RARE O
and O
phosphate O
RARE O
RARE O
RARE O
the O
growth O
rate O
. O

RARE I-GENE
and O
RARE O
issues O
. O

At O
RARE O
NUM O
days O
post O
- O
RARE O
, O
NUM O
rats O
had O
RARE O
gross O
RARE O
lesions O
, O
even O
those O
given O
the O
maximum O
dose O
of O
1 O
. O
4 O
X O
10 O
( O
9 O
) O
colony O
- O
forming O
RARE O
of O
M O
. O
RARE O
. O

RARE O
and O
the O
performance O
of O
ALL_CAP O
were O
not O
significantly O
associated O
with O
postoperative O
ECG O
changes O
, O
but O
more O
bypass O
grafts O
per O
patient O
RARE O
appeared O
in O
the O
group O
with O
postoperative O
ECG O
changes O
, O
suggesting O
that O
coronary O
artery O
RARE O
may O
be O
more O
severe O
in O
that O
group O
. O

ALL_CAP O
I O
: O
All O
vessels O
RARE O
to O
50 O
% O
RARE O
have O
a O
RARE O
graft O
. O

RARE O
sequences O
were O
obtained O
RARE O
the O
three O
large O
RARE O
peptides O
, O
and O
these O
were O
RARE O
by O
using O
peptides O
from O
the O
NUM I-GENE
protease I-GENE
RARE O
. O

The O
extraction O
measurements O
were O
used O
to O
test O
RARE O
RARE O
contamination O
of O
venous O
outflow O
. O

RARE O
responses O
to O
norepinephrine O
, O
RARE O
and O
RARE O
( O
K O
+) O
and O
RARE O
responses O
to O
isoproterenol O
and O
RARE O
were O
studied O
in O
vitro O
with O
RARE O
cut O
RARE O
aortic O
RARE O
from O
aortic O
RARE O
hypertensive O
rats O
( O
ALL_CAP O
) O
2 O
, O
6 O
, O
14 O
and O
NUM O
days O
postoperatively O
and O
compared O
to O
time O
- O
matched O
, O
sham O
- O
operated O
RARE O
controls O
. O

On O
line O
RARE O
of O
steroid O
concentrations O
by O
radioimmunoassay O

Detection O
of O
congenital O
hypothyroidism O
in O
NUM O
, O
NUM O
newborn O
infants O

In O
RARE O
patients O
with O
serologic O
RARE O
by O
ALL_CAP O
, O
the O
IF O
test O
detected O
significant O
RARE O
in O
NUM O
( O
NUM O
. O
1 O
%) O
of O
NUM O
patients O
and O
the O
ALL_CAP I-GENE
test O
detected O
antibody O
conversion O
in O
NUM O
( O
93 O
%) O
of O
NUM O
patients O
. O

The O
results O
indicate O
that O
RARE O
compounds O
decrease O
formate O
accumulation O
after O
RARE O
by O
stimulating O
formate O
oxidation O
or O
utilization O
and O
suggest O
a O
possible O
use O
RARE O
RARE O
in O
the O
treatment O
of O
certain O
cases O
of O
human O
RARE O
poisoning O
. O

The O
effect O
of O
RARE O
saccharin O
in O
the O
diet O
on O
RARE O
RARE O
. O

The O
RARE O
functions O
, O
R O
( O
t O
RARE O
RARE O
C O
- O
11 O
ALL_CAP O
and O
In O
- O
NUM O
transferrin I-GENE
were O
RARE O
against O
time O
RARE O
RARE O
areas O
of O
interest O
, O
and O
the O
ALL_CAP O
area O
- O
weighted O
extraction O
, O
E O
( O
t O
RARE O
was O
computed O
RARE O
the O
same O
areas O
every O
NUM O
msec O
using O
the O
formula O
: O
E O
( O
t O
) O
= O
RARE O
RT O
( O
t O
) O
- O
RR O
( O
t O
RARE O
1 O
- O
RR O
( O
t O
RARE O
where O
RT O
and O
RR O
are O
the O
normalized O
RARE O
functions O
RARE O
ALL_CAP O
and O
transferrin I-GENE
, O
respectively O
. O

RARE O
extracts O
showed O
RARE O
significant O
migration O
inhibition O
in O
RARE O
assays O
. O

Ten O
days O
of O
RARE O
therapy O
was O
used O
to O
treat O
NUM O
children O
with O
RARE O
RARE O
infection O
and O
CRP I-GENE
values O
greater O
than O
or O
equal O
to O
NUM O
microgram O
/ O
ml O
( O
CRP I-GENE
- O
positive O
group O
). O

Both O
resting O
RARE O
flow O
( O
ALL_CAP O
) O
and O
maximal O
RARE O
flow O
( O
ALL_CAP O
) O
were O
studied O
by O
RARE O
NUM O
clearance O
. O

Plasma I-GENE
renin I-GENE
concentration O
is O
significantly O
RARE O
in O
the O
RARE O
venous O
outflow O
, O
which O
RARE O
the O
superficial O
cortex O
, O
than O
in O
the O
deep O
venous O
outflow O
, O
which O
RARE O
the O
inner O
RARE O
of O
the O
cortex O
and O
RARE O
of O
the O
RARE O
RARE O
. O

After O
RARE O
, O
resting O
supine O
and O
RARE O
ALL_CAP O
decreased O
( O
P O
less O
than O
NUM O
. O
05 O
) O
by O
6 O
and O
9 O
mmHg O
, O
respectively O
. O

In O
the O
RARE O
, O
NUM O
+ O
RARE O
RARE O
a O
rise O
of O
plasma O
NUM O
+ O
RARE O
to O
3 O
. O
2 O
+/- O
NUM O
. O
1 O
mmol O
/ O
1 O
and O
a O
fall O
of O
circulating O
glucagon I-GENE
RARE O
NUM O
. O
4 O
+/- O
5 O
. O
7 O
%; O
p O
less O
than O
NUM O
. O
001 O
) O
and O
glucose O
RARE O
NUM O
. O
3 O
+/- O
3 O
. O
6 O
%; O
p O
less O
than O
NUM O
. O
05 O
). O

Fifty O
- O
eight O
ALL_CAP O
' O
s O
occurred O
in O
the O
placebo O
group O
RARE O
compared O
to O
only O
RARE O
in O
the O
ALL_CAP O
group O
( O
p O
less O
than O
NUM O
. O
01 O
). O

The O
" O
RARE O
- O
tooth O
" O
RARE O
. O

The O
RARE O
results O
show O
that O
ALL_CAP O
has O
high O
efficacy O
and O
safety O
and O
it O
can O
be O
RARE O
that O
it O
is O
a O
drug O
required O
in O
the O
pediatric O
field O
. O

Based O
on O
peptide O
map O
similarities O
, O
partial O
amino O
- O
terminal O
sequence O
data O
, O
and O
common O
genetic O
origin O
, O
it O
is O
suggested O
that O
NUM I-GENE
and O
p62 I-GENE
have O
identical O
amino O
acid O
sequences O
RARE O
- O
terminal O
to O
the O
NUM I-GENE
RARE O
methionine O
( O
RARE O
21 O
of O
p62 I-GENE
). O

All O
patients O
in O
the O
control O
group O
showed O
a O
significant O
improvement O
in O
their O
ALL_CAP O
while O
only O
3 O
patients O
in O
the O
treated O
group O
showed O
an O
improvement O
. O

RARE O
on O
the O
RARE O
RARE O
RARE O
RARE O
of O
NUM O
RARE O
speech O
- O
language O
RARE O
and O
RARE O
. O

From O
RARE O
to O
RARE O
. O

The O
relationship O
between O
the O
rare O
complications O
mentioned O
above O
and O
the O
pathophysiology O
of O
RARE O
' O
s O
RARE O
is O
still O
RARE O
. O

Using O
an O
RARE O
bacterial O
assay O
and O
a O
RARE O
rat O
model O
of O
ALL_CAP O
sepsis O
, O
we O
analyzed O
a O
modified O
human I-GENE
immunoglobulin I-GENE
RARE O
RARE O
and O
protective O
antibody O
. O

RARE O
lesions O
in O
RARE O
RARE O
. O

RARE O
observed O
systemic O
toxic O
effects O
( O
bone O
marrow O
, O
RARE O
RARE O
, O
and O
RARE O
) O
were O
not O
seen O
in O
this O
study O
. O

2 O
. O

When O
vascular O
pressure O
( O
RARE O
) O
was O
raised O
RARE O
from O
- O
5 O
to O
+ O
NUM O
cmH2O O
by O
air O
RARE O
RARE O
NUM O
min O
, O
RARE O
( O
RARE O
) O
became O
RARE O
less O
negative O
, O
then O
remained O
stable O
. O

( O
1980 O
): O
RARE O
210 O
, O
77 O
- O
72 O
) O
that O
stimulating O
the O
RARE O
RARE O
bundle O
( O
ALL_CAP O
) O
can O
change O
the O
magnitude O
of O
the O
RARE O
product O
( O
NUM O
- O
NUM O
) O
in O
the O
ear O
- O
RARE O
sound O
pressure O
. O

RARE O
underwent O
either O
a O
NUM O
- O
NUM O
% O
ALL_CAP O
or O
a O
sham O
operation O
. O

When O
the O
RARE O
- O
RARE O
- O
RARE O
, O
RARE I-GENE
receptor I-GENE
is O
blocked O
by O
naloxone O
or O
tolerance O
has O
developed O
, O
than O
RARE O
- O
RARE O
can O
produce O
behavioral O
effects O
by O
a O
RARE O
mechanism O
. O

RARE O
RARE O
- O
RARE O
RARE O
- O
brain O
barrier O
alterations O
. O

RARE O
and O
small O
RARE O
lesions O
inhibited O
the O
occurrence O
of O
target O
fibres O
in O
the O
RARE O
muscles O
, O
the O
smallest O
one O
being O
RARE O
of O
the O
dorsal O
roots O
. O

Diagnosis O
of O
RARE I-GENE
hydroxylase I-GENE
deficiency O
( O
RARE O
). O

In O
10 O
control O
sheep O
mean O
plasma O
NUM O
concentration O
increased O
from O
NUM O
. O
NUM O
RARE O
/ O
ml O
RARE O
to O
about O
1 O
. O
1 O
RARE O
/ O
ml O
RARE O
8 O
and O
16 O
min O
of O
bypass O
. O

The O
respiratory O
rate O
was O
NUM O
+/- O
1 O
RARE O
/ O
min O
with O
52 O
+/- O
4 O
% O
of O
the O
respiratory O
RARE O
RARE O
in O
RARE O
; O
end O
- O
tidal O
CO2 O
pressure O
increased O
by O
3 O
. O
3 O
+/- O
1 O
. O
NUM O
RARE O
RARE O
RARE O
RARE O
ALL_CAP O
. O

There O
was O
RARE O
further O
increase O
in O
oxygen O
consumption O
when O
these O
subjects O
RARE O
with O
inspiratory O
pressures O
above O
ALL_CAP O
. O

We O
compared O
the O
volume O
of O
the O
pulmonary O
RARE O
, O
extracellular O
water O
space O
using O
RARE O
and O
sucrose O
indicators O
in O
8 O
normal O
and O
11 O
RARE O
RARE O
lungs O
by O
steady O
- O
state O
techniques O
. O

RARE O
the O
reliability O
, O
validity O
and O
RARE O
of O
scores O
obtained O
by O
acute O
psychiatric O
RARE O
( O
N O
= O
120 O
) O
on O
the O
RARE O
RARE O
RARE O
Test O
adapted O
to O
assess O
RARE O
and O
current O
RARE O
. O

A O
simple O
method O
RARE O
measuring O
RARE O
iron O
following O
the O
administration O
of O
RARE O
( O
ALL_CAP O
) O
is O
described O
. O

During O
conventional O
RARE O
using O
substitution O
RARE O
with O
a O
RARE O
+ O
concentration O
of O
NUM O
mEq O
/ O
L O
, O
a O
decrease O
in O
extracellular O
RARE O
volume O
was O
noted O
whereas O
the O
RARE O
RARE O
volume O
was O
unaltered O
. O

The O
RARE O
cases O
of O
RARE O
fever O
were O
found O
to O
have O
an O
RARE O
ALL_CAP O
RARE O
compared O
to O
the O
complicated O
cases O
. O

RARE O
serial O
RARE O
. O

RARE O
to O
RARE O
with O
these O
and O
related O
issues O
are O
presented O
. O

Use O
of O
subcutaneous O
RARE O
in O
a O
child O
with O
RARE O
associated O
with O
congenital O
RARE O
RARE O
, O
type O
I O
. O

There O
was O
a O
significant O
correlation O
between O
tubular O
diameter O
and O
RARE O
( O
RARE O
= O
NUM O
. O
NUM O
, O
P O
less O
than O
NUM O
. O
001 O
) O
suggesting O
that O
tubular O
diameter O
measurements O
in O
histological O
sections O
could O
be O
used O
to O
predict O
sperm O
production O
. O

The O
differential O
investigation O
of O
RARE O
, O
however O
, O
showed O
that O
the O
high I-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
( O
ALL_CAP I-GENE
) O
fractions O
are O
RARE O
or O
relatively O
decreased O
with O
respect O
to O
low I-GENE
- I-GENE
density I-GENE
RARE I-GENE
( O
LDL I-GENE
) O
in O
cerebral O
RARE O
and O
in O
transient O
ischaemic O
attacks O
. O

Although O
RARE O
RARE O
had O
RARE O
mean O
concentrations O
of O
phosphorus O
and O
zinc O
, O
these O
differences O
did O
not O
RARE O
after O
RARE O
- O
stained O
samples O
were O
excluded O
. O

RARE O
status O
of O
RARE O
in O
the O
United O
RARE O
. O

During O
an O
8 O
- O
wk O
follow O
- O
RARE O
, O
parasites O
RARE O
in O
10 O
patients O
, O
5 O
after O
each O
drug O
, O
between O
1 O
and O
7 O
wk O
after O
treatment O
. O

RARE O
of O
a O
stable O
RARE O
RARE O
RARE O
coagulation O
assays O
. O

A O
RARE O
on O
some O
consequences O
of O
ALL_CAP O
vision O
in O
birds O
. O

RARE O
RARE O
, O
a O
RARE O
sustained O
release O
bolus O
( O
ALL_CAP O
) O
was O
administered O
to O
each O
RARE O
in O
the O
" O
treated O
" O
category O
. O

In O
a O
longitudinal O
study O
, O
14 O
low O
- O
risk O
RARE O
were O
studied O
RARE O
2 O
- O
week O
intervals O
from O
NUM O
weeks O
of O
gestation O
RARE O
. O

Further O
, O
RARE O
injections O
of O
ALL_CAP O
resulted O
in O
the O
substantial O
RARE O
of O
pyramidal O
cells O
in O
the O
whole O
CA3 O
field O
of O
the O
hippocampus O
. O

RARE O
of O
the O
NUM O
patients O
were O
randomly O
chosen O
to O
receive O
a O
training O
program O
( O
lasting O
RARE O
1 O
month O
) O
designed O
to O
establish O
a O
systematic O
strategy O
of O
RARE O
complex O
visual O
material O
. O

The O
duration O
and O
the O
amplitude O
of O
the O
negative O
RARE O
were O
greatest O
RARE O
completely O
RARE O
ears O
with O
RARE O
, O
smaller O
RARE O
partially O
RARE O
ears O
, O
and O
smallest O
RARE O
the O
RARE O
ears O
. O

RARE O
obtained O
from O
normal O
volunteers O
and O
from O
the O
great O
majority O
of O
the O
patients O
, O
excluding O
those O
with O
asthma O
, O
had O
RARE O
effect O
on O
RARE O
RARE O
. O

These O
results O
suggested O
the O
possibility O
that O
the O
fetus O
played O
some O
role O
in O
the O
production O
of O
NUM O
- O
16 O
- O
G O
in O
early O
RARE O
. O

In O
this O
way O
it O
is O
possible O
to O
RARE O
the O
growth O
function O
of O
the O
RARE O
curve O
of O
the O
length O
' O
increase O
of O
man O
and O
the O
curve O
of O
the O
mass O
' O
increase O
of O
rat O
. O

The O
highest O
doses O
were O
found O
RARE O
RARE O
who O
transported O
large O
numbers O
of O
NUM O
RARE O
. O

The O
RARE O
of O
the O
standard O
NUM O
dissociation O
curve O
becomes O
greater O
RARE O
the O
training O
period O
( O
increase O
in O
RARE O
' O
s O
RARE O
from O
2 O
. O
NUM O
+/- O
NUM O
. O
10 O
to O
2 O
. O
96 O
+/- O
NUM O
. O
NUM O
). O

RARE O
and O
RARE O
RARE O
acid O
and O
m O
- O
and O
p O
- O
RARE O
acid O
have O
been O
determined O
in O
the O
plasma O
of O
normal O
, O
healthy O
subjects O
after O
fasting O
, O
consumption O
of O
a O
RARE O
and O
ingestion O
of O
RARE O
labelled O
RARE O
RARE O
, O
by O
high O
- O
resolution O
gas O
chromatography O
RARE O
high O
resolution O
mass O
spectrometry O
with O
RARE O
ion O
monitoring O
of O
their O
RARE O
- O
RARE O
RARE O
. O

In O
concept O
II O
NUM O
patients O
were O
treated O
with O
selective O
vagotomy O
and O
RARE O
. O

They O
consisted O
of O
RARE O
disorders O
, O
RARE O
, O
RARE O
and O
RARE O
RARE O
. O

CSF O
adenosine I-GENE
RARE I-GENE
activity O
( O
ALL_CAP O
) O
was O
measured O
RARE O
the O
same O
time O
. O

RARE O
reactivity O
had O
returned O
to O
normal O
in O
RARE O
the O
workers O
who O
had O
RARE O
their O
original O
RARE O
, O
but O
in O
only O
one O
RARE O
who O
had O
RARE O
within O
RARE O
original O
RARE O
. O

It O
was O
also O
found O
that O
there O
is O
RARE O
significant O
difference O
between O
the O
prevalence O
of O
nasal O
RARE O
of O
S O
. O
RARE O
RARE O
the O
hospital O
RARE O
and O
the O
patients O
. O

RARE O
and O
RARE O
' O
s O
RARE O
depth O
index O
and O
the O
RARE O
- O
joint O
surface O
angle O
of O
RARE O
are O
recommended O
RARE O
especially O
suitable O
methods O
of O
measurement O
. O

There O
were O
RARE O
significant O
differences O
in O
ALL_CAP O
between O
the O
two O
studies O
, O
both O
RARE O
rest O
( O
NUM O
. O
NUM O
+/- O
NUM O
. O
8 O
% O
RARE O
58 O
. O
2 O
+/- O
11 O
. O
7 O
%, O
p O
= O
ALL_CAP O
) O
and O
with O
exercise O
( O
NUM O
. O
1 O
+/- O
NUM O
. O
6 O
% O
RARE O
54 O
. O
3 O
+/- O
NUM O
. O
6 O
%, O
p O
= O
ALL_CAP O
) O
and O
a O
highly O
significant O
correlation O
was O
shown O
between O
the O
two O
groups O
of O
values O
( O
rest O
RARE O
= O
NUM O
. O
NUM O
, O
exercise O
RARE O
= O
NUM O
. O
93 O
, O
p O
less O
than O
NUM O
. O
001 O
). O

After O
ALL_CAP O
therapy O
, O
RARE O
remission O
of O
Hodgkin O
' O
s O
RARE O
was O
accompanied O
by O
RARE O
of O
the O
RARE I-GENE
level O
and O
disappearance O
of O
RARE O
' O
s O
cells O
. O

Specifically O
, O
by O
the O
type O
of O
adjuvant O
therapy O
, O
the O
median O
RARE O
- O
free O
interval O
and O
survival O
from O
RARE O
ALL_CAP O
RARE O
NUM O
patients O
receiving O
RARE O
RARE O
were O
6 O
. O
9 O
and O
19 O
months O
; O
RARE O
NUM O
patients O
receiving O
BCG O
, O
eight O
months O
and O
NUM O
months O
; O
RARE O
NUM O
patients O
receiving O
BCG O
+ O
ALL_CAP O
, O
eight O
and O
NUM O
. O
4 O
months O
; O
and O
RARE O
all O
NUM O
ALL_CAP O
treated O
patients O
6 O
. O
3 O
and O
NUM O
. O
8 O
months O
, O
respectively O
. O

The O
ALL_CAP O
- O
ALL_CAP O
gradient O
was O
markedly O
decreased O
in O
both O
shock O
and O
non O
- O
shock O
patients O
with O
pulmonary O
edema O
. O

Re O
: O
A O
modified O
method O
RARE O
the O
in O
vivo O
labeling O
of O
RARE O
RARE O
cells O
with O
Tc O
- O
99m O
. O

A O
limited O
study O
in O
a O
RARE O
RARE O
( O
NUM O
exposure O
) O
involving O
the O
measurement O
of O
RARE O
RARE O
RARE O
, O
the O
determination O
of O
RARE O
RARE O
, O
and O
the O
evaluation O
of O
RARE O
and O
mouth O
contamination O
by O
RARE O
before O
and O
after O
the O
RARE O
suggests O
that O
the O
high O
RARE O
RARE O
levels O
( O
NUM O
microgram O
/ O
g O
RARE O
) O
are O
likely O
to O
be O
more O
related O
to O
an O
increased O
oral O
intake O
from O
contaminated O
RARE O
than O
to O
an O
increased O
absorption O
from O
the O
lungs O
. O

RARE O
and O
pathological O
findings O
in O
RARE O
monkeys O
RARE O
with O
RARE O
RARE O
or O
RARE O
RARE O
. O

The O
RARE O
RARE O
RARE O
the O
site O
of O
the O
entry O
of O
RARE O
vessels O
into O
the O
central O
nervous O
RARE O
. O

Experimental O
RARE O
of O
malignant O
RARE O
fever O
in O
RARE O
cattle O

1 O
A O
RARE O
delivery O
RARE O
is O
described O
to O
RARE O
orally O
RARE O
drugs O
to O
the O
colon O
and O
release O
them O
RARE O
that O
site O
by O
RARE O
with O
an O
RARE O
based O
resin O
( O
RARE O
S O
). O

Administration O
of O
the O
dopamine O
agonist O
RARE O
( O
2 O
. O
5 O
mg O
three O
times O
a O
day O
RARE O
4 O
days O
) O
suppressed O
( O
P O
less O
than O
NUM O
. O
01 O
) O
mean O
NUM O
- O
h O
plasma O
18 O
- O
ALL_CAP O
levels O
from O
21 O
. O
9 O
+/- O
2 O
. O
NUM O
to O
14 O
. O
8 O
+/- O
1 O
. O
4 O
RARE O
/ O
dl O
. O

RARE O
time O
was O
not O
affected O
by O
magnesium O
RARE O
. O

The O
most O
common O
RARE O
of O
malformations O
were O
eye O
defects O
and O
RARE O
RARE O
. O

RARE O
of O
a O
RARE O
defect O
of O
the O
lower O
leg O
with O
a O
RARE O
free O
flap O
. O

According O
to O
the O
literature O
, O
second O
malignant O
RARE O
tumours O
are O
, O
in O
contrast O
to O
mesenchymal O
tumours O
such O
RARE O
osteosarcoma O
, O
very O
rare O
in O
RARE O
RARE O
. O

In O
RARE O
, O
RARE O
, O
NUM O
, O
NUM O
RARE O
children O
born O
in O
the O
years O
NUM O
- O
NUM O
were O
screened O
RARE O
RARE O
once O
a O
year O
between O
the O
ages O
of O
7 O
and O
16 O
years O
, O
RARE O
NUM O
- O
1980 O
. O

In O
the O
past O
, O
RARE O
in O
RARE O
was O
mainly O
confined O
to O
RARE O
RARE O
the O
diagnosis O
of O
certain O
infectious O
diseases O
. O

RARE O
- O
RARE O
dislocation O
of O
the O
RARE O
. O

This O
study O
demonstrates O
RARE O
of O
RARE O
by O
the O
human O
stomach O
in O
vivo O
RARE O
a O
rate O
equivalent O
to O
10 O
RARE O
20 O
% O
of O
basal O
acid O
RARE O
. O

Histological O
evaluation O
revealed O
a O
more O
than O
twofold O
increase O
in O
the O
number O
of O
RARE O
mononuclear O
cells O
( O
p O
less O
than O
NUM O
. O
005 O
RARE O
while O
the O
number O
of O
RARE O
cells O
/ O
NUM O
microns O
of O
RARE O
mucosa O
and O
the O
mean O
height O
of O
the O
RARE O
cells O
were O
comparable O
in O
both O
groups O
. O

RARE O
in O
RARE O
disorders O
. O

A O
suspected O
new O
RARE O
RARE O
in O
cattle O
. O

For O
various O
dog O
vessels O
in O
vivo O
, O
ALL_CAP O
/ O
RARE O
ranged O
from O
NUM O
. O
NUM O
to O
NUM O
X O
10 O
( O
5 O
) O
RARE O
/ O
cm2 O
. O

The O
RARE O
action O
of O
lidocaine O
on O
CNS O
electrical O
activity O
and O
behavior O
in O
cats O
. O

RARE O
of O
RARE O
resorption O
by O
RARE O
therapy O

RARE O
RARE O
and O
fertility O

RARE O
of O
RARE O
national O
RARE O

The O
favourable O
effect O
of O
RARE O
RARE O
was O
also O
reflected O
in O
a O
significant O
increase O
of O
LD50 O
/ O
NUM O
, O
and O
the O
dose O
reduction O
factor O
was O
equal O
to O
2 O
. O

The O
application O
of O
RARE O
to O
sample O
preparation O
in O
the O
detection O
and O
RARE O
of O
ethylene O
glycol O
in O
plasma O
by O
gas O
chromatography O
is O
described O
. O

RARE O
. O

A O
new O
RARE O
species O
, O
a O
parasite O
of O
RARE O
cattle O
, O
in O
RARE O

It O
was O
suggested O
that O
the O
absence O
of O
pronounced O
differences O
between O
conditions O
may O
have O
been O
due O
to O
the O
complexity O
of O
the O
task O
or O
the O
type O
of O
RARE O
employed O
. O

A O
limiting O
factor O
were O
disturbances O
in O
the O
RARE O
of O
energy O
RARE O
( O
RARE O
phosphate O
, O
RARE I-GENE
RARE I-GENE
) O
and O
of O
the O
RARE O
RARE O
( O
Ca I-GENE
RARE I-GENE
ATPase I-GENE
of O
the O
RARE O
reticulum O
, O
ALL_CAP O
RARE O
which O
RARE O
led O
to O
a O
decrease O
of O
the O
inotropic O
properties O
of O
the O
myocardium O
RARE O
70 O
% O
RARE O
of O
coronary O
RARE O
flow O
. O

In O
vitro O
penetration O
tests O
of O
human O
sperm O
into O
cervical O
mucus O
were O
introduced O
in O
order O
to O
study O
the O
interaction O
between O
sperm O
and O
cervical O
mucus O
. O

RARE O
RARE O
( O
group O
F O
RARE O
) O
in O
RARE O
. O

Serum I-GENE
RARE I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
was O
measured O
in O
ten O
subjects O
in O
the O
laboratory O
before O
and O
after O
the O
performance O
of O
RARE O
RARE O
and O
a O
RARE O
task O
. O

RARE O
were O
not O
observed O
in O
the O
5 O
RARE O
RARE O
in O
2 O
other O
RARE O
. O

The O
cause O
of O
RARE O
is O
often O
quite O
apparent O
from O
the O
pathological O
and O
toxicological O
findings O
; O
however O
, O
the O
manner O
of O
RARE O
often O
gives O
the O
examining O
RARE O
some O
RARE O
. O

The O
average O
annual O
cost O
per O
head O
of O
population O
was O
US O
+ O
NUM O
X O
NUM O
. O

It O
is O
postulated O
that O
altered O
RARE O
flow O
, O
RARE O
through O
the O
RARE O
- O
known O
RARE I-GENE
RARE I-GENE
RARE O
effects O
of O
RARE O
, O
resulted O
in O
tubular O
necrosis O
. O

RARE O
20 O
mg O
RARE O
/ O
20 O
ml O
RARE O
water O
or O
40 O
mg O
/ O
40 O
ml O
RARE O
water O
was O
locally O
RARE O
into O
the O
bladder O
with O
a O
catheter O
after O
emptying O
it O
and O
was O
RARE O
RARE O
about O
NUM O
- O
NUM O
min O
. O

Both O
groups O
RARE O
RARE O
with O
added O
ALL_CAP O
, O
decreasing O
RARE O
times O
RARE O
ALL_CAP O
concentration O
increased O
. O

The O
mean O
extracted O
concentration O
of O
RARE O
obtained O
RARE O
operation O
was O
12 O
. O
9 O
micrograms O
/ O
ml O
( O
SD O
5 O
. O
NUM O
) O
in O
synovial O
RARE O
; O
2 O
. O
9 O
micrograms O
/ O
g O
( O
SD O
3 O
. O
NUM O
) O
in O
RARE O
; O
2 O
. O
NUM O
micrograms O
/ O
g O
( O
SD O
1 O
. O
NUM O
) O
in O
RARE O
bone O
and O
1 O
. O
3 O
micrograms O
/ O
g O
( O
SD O
1 O
. O
NUM O
) O
in O
cortical O
bone O
. O

A O
preliminary O
study O
of O
vincristine O
, O
methotrexate O
, O
and O
RARE O
( O
ALL_CAP O
RARE O
P O
) O
combination O
chemotherapy O
RARE O
advanced O
adult O
non O
- O
Hodgkin O
' O
s O
lymphoma O

RARE O
RARE O
in O
RARE O

Re O
- O
examination O
of O
the O
NUM O
study O
. O

Based O
on O
NUM O
determinations O
, O
the O
control O
mean O
serum I-GENE
CPK I-GENE
activity O
was O
NUM O
+/- O
NUM O
I O
. O
ALL_CAP O
RARE O
liter O
. O

A O
further O
study O
on O
plasminogen I-GENE
activator I-GENE
release O
by O
RARE O
agents O
in O
the O
isolated O
perfused O
dog O
leg O
. O

ALL_CAP O
is O
RARE O
RARE O
a O
single O
agent O
in O
non O
- O
Hodgkin O
' O
s O
lymphoma O
. O

Treatment O
of O
meat O
muscle O
800 O
V O
RARE O
NUM O
s O
RARE O
RARE O
but O
increased O
slightly O
the O
rate O
of O
RARE O
of O
lipids O
. O

The O
hormonal O
response O
to O
a O
standardized O
RARE O
exercise O
test O
was O
studied O
in O
11 O
male O
RARE O
exposed O
to O
a O
course O
of O
NUM O
h O
of O
continuous O
activity O
with O
less O
than O
2 O
h O
sleep O
. O

At O
an O
RARE O
RARE O
of O
NUM O
degrees O
C O
, O
the O
responses O
to O
RARE O
RARE O
are O
RARE O
RARE O
the O
dark O
RARE O
. O

A O
method O
RARE O
RARE O
cumulative O
behavioral O
toxicity O
after O
chronic O
oral O
administration O
of O
RARE O
- O
alpha O
- O
RARE O
to O
female O
rats O
. O

After O
successful O
subtotal O
RARE O
, O
evident O
by O
the O
decrease O
of O
serum O
ALL_CAP I-GENE
levels O
, O
both O
the O
CL O
of O
group O
2 O
RARE O
and O
the O
ability O
of O
group O
2 O
RARE O
to O
induce O
augmented O
CL O
in O
normal O
RARE O
decreased O
( O
p O
< O
NUM O
. O
NUM O
). O

ALL_CAP O
provides O
RARE O
, O
RARE O
, O
RARE O
indication O
of O
tissue O
necrosis O
, O
moderate O
- O
to O
- O
severe O
RARE O
hemorrhage O
, O
and O
delayed O
brain O
RARE O
. O

The O
number O
of O
RARE O
rats O
increased O
with O
increase O
in O
the O
duration O
of O
Cd O
administration O
in O
association O
with O
greater O
accumulation O
of O
Cd O
in O
the O
olfactory O
bulb O
than O
in O
any O
other O
region O
of O
the O
brain O
. O

This O
test O
should O
provide O
another O
RARE O
means O
to O
study O
RARE O
. O

The O
RARE O
were O
RARE O
RARE O
RARE O
- O
a O
- O
RARE O
RARE O
males O
, O
though O
injections O
of O
ALL_CAP O
restored O
the O
RARE O
' O
RARE O
to O
the O
females O
. O

Each O
trial O
consisted O
of O
light O
and O
RARE O
RARE O
five O
RARE O
RARE O
conditioned O
stimuli O
and O
RARE O
shock O
RARE O
five O
RARE O
RARE O
an O
RARE O
stimulus O
. O

RARE O
appeared O
on O
the O
RARE O
of O
the O
stomach O
RARE O
the O
NUM O
week O
and O
resulted O
in O
ulcer O
RARE O
RARE O
the O
NUM O
week O
. O

RARE O
RARE O
and O
involvement O
in O
treatment O
of O
patients O
RARE O
a O
state O
hospital O
. O

A O
RARE O
RARE O
RARE O
assessing O
amplitude O
of O
ECG O
wave O
forms O
. O

RARE O
reaction O
of O
the O
apparently O
healthy O
RARE O
in O
response O
to O
improvement O
in O
the O
RARE O
RARE O
RARE O
. O

RARE O
scan O
with O
99mTc O
- O
labelled O
RARE I-GENE
albumin I-GENE
( O
ALL_CAP I-GENE
brain O
scan O
) O
and O
computed O
tomography O
studies O
( O
ALL_CAP O
) O
were O
performed O
on O
NUM O
patients O
with O
RARE O
diseases O
. O

Inhibition O
of O
RARE O
RARE O
RARE O
. O
RARE O
, O
the O
RARE O
agent O
of O
RARE O
RARE O
RARE O
, O
by O
the O
RARE O
bacterium O
RARE O
RARE O
. O

The O
five O
- O
drug O
combination O
of O
fluorouracil O
RARE O
RARE O
dimethyl O
RARE O
, O
vincristine O
, O
RARE O
- O
RARE O
RARE O
, O
and O
prednisone O
( O
ALL_CAP O
+ O
P O
) O
was O
given O
to O
120 O
women O
with O
metastatic O
breast O
RARE O
. O

A O
method O
is O
described O
RARE O
the O
simultaneous O
determination O
of O
1 O
, O
alpha O
- O
RARE O
( O
ALL_CAP O
) O
and O
five O
RARE O
metabolites O
RARE O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
, O
and O
RARE O
RARE O
in O
RARE O
by O
high O
- O
performance O
liquid O
chromatography O
using O
a O
normal O
- O
RARE O
column O
and O
a O
ALL_CAP O
detector O
RARE O
NUM O
nm O
. O

Results O
of O
the O
recognition O
task O
revealed O
significant O
effects O
of O
RARE O
RARE O
, O
position O
and O
RARE O
context O
on O
RARE O
recognition O
. O

RARE O
response O
properties O
of O
neurons O
in O
four O
RARE O
visual O
areas O
of O
the O
RARE O
RARE O
( O
RARE O
RARE O
): O
a O
quantitative O
comparison O
of O
medial O
, O
RARE O
, O
RARE O
, O
and O
RARE O
temporal O
areas O
. O

A O
RARE O
approach O
to O
the O
RARE O
of O
allergens O
. O

Clinical O
and O
anatomical O
RARE O

A O
dose O
- O
dependent O
fall O
in O
ALL_CAP O
content O
was O
observed O
; O
ALL_CAP O
decrease O
was O
evident O
NUM O
min O
after O
the O
administration O
, O
reached O
its O
RARE O
RARE O
NUM O
min O
and O
disappeared O
RARE O
120 O
minutes O
. O

RARE O
and O
applications O
of O
pulse O
RARE O
: O
a O
summary O
of O
the O
RARE O
. O

These O
results O
show O
that O
the O
RARE O
differs O
from O
the O
adult O
in O
respect O
of O
both O
the O
nature O
of O
effects O
of O
the O
drug O
and O
sensitivity O
to O
it O
. O

To O
evaluate O
the O
gas O
chromatographic O
electron O
RARE O
detection O
method O
described O
earlier O
, O
NUM O
plasma O
samples O
have O
been O
analysed O
by O
both O
techniques O
. O

The O
hemodynamics O
of O
isoproterenol O
- O
RARE O
cardiac O
failure O
in O
the O
rat O
. O

Several O
authors O
have O
recently O
reported O
interference O
in O
theophylline O
analysis O
by O
RARE O
( O
1 O
, O
7 O
- O
RARE O
RARE O
an O
important O
metabolite O
of O
caffeine O
. O

RARE O
drug O
regimens O
like O
C O
- O
ALL_CAP O
, O
ALL_CAP O
and O
ALL_CAP O
led O
to O
high O
remission O
rates O
and O
in O
some O
cases O
probably O
also O
to O
a O
cure O
of O
the O
RARE O
. O

For O
monocytes O
, O
RARE O
measured O
on O
the O
RARE O
, O
it O
was O
NUM O
. O
4 O
%. O

RARE O
features O
of O
RARE O
RARE O
. O

Clinical O
accuracy O
of O
RARE O
version O
of O
the O
RARE O
RAST O
test O
. O

Five O
control O
subjects O
with O
COPD O
, O
who O
performed O
the O
same O
sequence O
of O
tests O
without O
breathing O
NUM O
% O
NUM O
, O
showed O
RARE O
change O
in O
flow O
rates O
or O
density O
dependence O
. O

Following O
extended O
recovery O
hippocampal O
EEG O
was O
normal O
despite O
extensive O
cellular O
RARE O
in O
areas O
CA3 O
and O
NUM O
. O

RARE O
RARE O
and O
single O
unit O
responses O
to O
olfactory O
nerve O
RARE O
in O
the O
isolated O
RARE O
olfactory O
bulb O
. O

While O
all O
deletions O
within O
the O
sequence O
coding O
RARE O
the O
RARE O
tRNA O
led O
to O
RARE O
of O
the O
RARE O
genes O
, O
substitution O
of O
the O
central O
portion O
by O
RARE I-GENE
RARE I-GENE
III I-GENE
RARE I-GENE
produced O
gene O
RARE O
RARE O
in O
transcription O
. O

Cross O
reactivity O
in O
theophylline O
ALL_CAP O
kit O
decreased O
. O

RARE O
- O
NUM O
was O
RARE O
i O
. O
v O
. O
into O
RARE O
rats O
on O
day O
18 O
post O
RARE O
( O
p O
. O
c O
.). O

RARE O
of O
the O
digital O
RARE O
activity O
in O
the O
lower O
RARE O
with O
the O
RARE O
and O
RARE O
- O
RARE O
methods O
. O

Eight O
hr O
of O
acidosis O
caused O
a O
significant O
( O
P O
less O
than O
NUM O
. O
01 O
) O
decrease O
in O
NUM O
in O
vitro O
which O
fell O
from O
29 O
. O
NUM O
to O
NUM O
. O
4 O
torr O
. O

RARE O
transit O
RARE O
the O
response O
to O
a O
step O
increase O
in O
concentration O
by O
about O
NUM O
. O
NUM O
s O
( O
from O
10 O
per O
cent O
- O
NUM O
per O
cent O
) O
and O
RARE O
the O
transit O
time O
through O
the O
catheter O
RARE O
a O
volatile O
RARE O
by O
about O
NUM O
. O
04 O
s O
more O
than O
N2 O
. O

These O
women O
should O
not O
be O
given O
the O
current O
estrogen O
ALL_CAP O
, O
which O
was O
designed O
to O
RARE O
women O
of O
the O
RARE O
of O
long O
- O
term O
estrogen O
use O
; O
a O
ALL_CAP O
should O
be O
RARE O
specifically O
RARE O
patients O
receiving O
short O
courses O
. O

The O
oral O
RARE O
rose O
and O
the O
serum I-GENE
RARE I-GENE
kinase I-GENE
levels O
fell O
only O
in O
those O
patients O
who O
were O
actively O
RARE O
. O

Determination O
of O
aortic O
RARE O
and O
its O
variations O
in O
arterial O
hypertension O
. O

We O
studied O
the O
role O
of O
prostaglandins O
in O
acid O
- O
RARE O
RARE O
and O
the O
associated O
ALL_CAP O
hypotension O
by O
simultaneous O
treatment O
of O
some O
animals O
with O
indomethacin O
( O
NUM O
micrograms O
/ O
kg O
intravenous O
RARE O
a O
specific O
inhibitor O
of O
RARE O
RARE O
, O
either O
RARE O
production O
of O
RARE O
or O
RARE O
recovery O
. O

Since O
only O
58 O
% O
of O
our O
sample O
could O
be O
RARE O
classified O
with O
one O
diagnosis O
, O
we O
RARE O
that O
the O
ALL_CAP O
RARE O
will O
need O
to O
RARE O
further O
. O

A O
surgical O
technique O
RARE O
RARE O
this O
problem O
is O
described O
. O

Effects O
of O
RARE O
RARE O
on O
the O
onset O
of O
RARE O
and O
stroke O
in O
stroke O
- O
prone O
spontaneously O
hypertensive O
rats O
. O

In O
this O
study O
, O
the O
RARE O
clinical O
criteria O
RARE O
inhalation O
injury O
RARE O
presence O
of O
facial O
or O
RARE O
RARE O
, O
RARE I-GENE
levels O
, O
RARE O
RARE O
, O
or O
closed O
space O
injury O
RARE O
did O
not O
differentiate O
patients O
with O
airway O
injury O
only O
from O
those O
with O
RARE O
injury O
. O

RARE O
was O
calculated O
both O
from O
the O
date O
of O
onset O
and O
from O
the O
date O
of O
diagnosis O
. O

RARE O
( O
NUM O
. O
5 O
mg O
/ O
kg O
, O
i O
. O
p O
RARE O
a O
blocker O
of O
RARE I-GENE
receptors I-GENE
, O
prevented O
the O
development O
of O
the O
RARE O
effect O
of O
RARE O
. O

The O
plasma O
RARE O
- O
life O
of O
slow O
RARE O
RARE O
t1 O
/ O
2 O
beta O
, O
increases O
from O
NUM O
. O
NUM O
hour O
in O
rabbits O
with O
normal O
RARE O
function O
to O
5 O
. O
NUM O
hours O
in O
rabbits O
with O
severe O
RARE O
impairment O
. O

Effects O
of O
early O
RARE O
deprivation O
on O
development O
of O
RARE O
- O
RARE O
projections O
in O
the O
RARE O
. O

RARE O
therapy O
is O
known O
to O
be O
hazardous O
in O
patients O
with O
RARE O
infection O
but O
the O
mechanism O
by O
which O
the O
RARE O
parasite O
relationship O
is O
altered O
by O
steroids O
is O
not O
known O
. O
We O
have O
used O
an O
RARE O
RARE O
parasite O
, O
RARE O
RARE O
, O
to O
examine O
the O
effects O
of O
corticosteroids O
on O
the O
number O
of O
parasites O
in O
the O
intestine O
in O
the O
course O
of O
a O
RARE O
infection O
. O

RARE O
RARE O
function O
in O
RARE O
after O
RARE O
. O

With O
RARE O
and O
NUM O
, O
mean O
vital O
capacity O
was O
RARE O
by O
NUM O
% O
from O
control O
. O

RARE O
RARE O
RARE O
RARE O
a O
single O
procedure O
. O

Of O
the O
117 O
patients O
( O
out O
of O
the O
136 O
) O
with O
serologic O
evidence O
of O
chronic O
thyroiditis O
who O
could O
be O
studied O
, O
eight O
( O
7 O
%) O
had O
RARE O
and O
NUM O
( O
38 O
%) O
were O
RARE O
. O

The O
relationship O
between O
RARE O
properties O
of O
RARE O
and O
breast O
RARE O
management O
is O
discussed O
. O

The O
new O
RARE O
- O
RARE O
oral O
RARE O
, O
ALL_CAP O
9 O
, O
NUM O
, O
has O
been O
evaluated O
in O
a O
large O
number O
of O
hospitalized O
patients O
with O
RARE O
infections O
. O

A O
RARE O
RARE O
the O
determination O
of O
serum O
of O
plasma O
levels O
of O
propranolol O
was O
developed O
using O
antibodies O
to O
propranolol O
coupled O
to O
RARE O
solid O
- O
RARE O
RARE O
and O
RARE O
- O
labeled O
propranolol O
RARE O
tracer O
. O

The O
RARE O
RARE O
projections O
RARE O
to O
be O
more O
numerous O
and O
longer O
in O
ALL_CAP O
, O
otherwise O
the O
RARE O
of O
the O
RARE O
layer O
of O
the O
RARE O
and O
the O
RARE O
of O
the O
RARE O
vessels O
were O
identical O
in O
ALL_CAP O
and O
controls O
. O

When O
pollen O
RARE O
from O
three O
RARE O
species O
were O
used O
, O
The O
RAST O
- O
test O
results O
did O
not O
differ O
from O
RARE O
values O
either O
. O

ALL_CAP O
and O
2 O
- O
OH O
- O
ALL_CAP O
concentrations O
were O
determined O
in O
a O
similar O
group O
of O
NUM O
ALL_CAP O
- O
treated O
patients O
. O

It O
has O
been O
shown O
in O
experiments O
in O
vitro O
that O
the O
RARE O
organic O
RARE O
, O
the O
RARE O
contrast O
agent O
( O
ALL_CAP O
) O
RARE O
used O
in O
RARE O
and O
RARE O
RARE O
, O
have O
an O
affinity O
, O
unlike O
the O
RARE O
ALL_CAP O
RARE O
and O
RARE O
RARE O
RARE O
- O
RARE O
, O
RARE O
the O
RARE O
membranes O
( O
ALL_CAP O
) O
of O
liver O
cells O
. O

NUM O
out O
of O
NUM O
neurons O
of O
the O
RARE O
medial O
RARE O
body O
revealed O
the O
selectivity O
of O
their O
RARE O
to O
movement O
of O
sound O
when O
velocity O
of O
the O
movement O
changed O
from O
NUM O
to O
180 O
RARE O
/ O
s O
. O

In O
controls O
, O
only O
RARE O
differences O
were O
observed O
. O

RARE O
of O
serum I-GENE
RARE I-GENE
trypsin I-GENE
in O
RARE O
RARE O
spots O
and O
the O
early O
detection O
of O
RARE O
RARE O
. O

Similar O
waves O
were O
seen O
on O
cross O
- O
RARE O
a O
motor O
unit O
with O
an O
RARE O
RARE O
, O
confirming O
that O
their O
occurrence O
does O
not O
necessarily O
demonstrate O
the O
existence O
of O
RARE O
RARE O
interactions O
. O

RARE O
enzyme O
activity O
and O
RARE O
lymphocyte O
RARE O
transformation O
in O
chronic O
RARE O

Current O
status O
of O
chemotherapy O
RARE O
Hodgkin O
' O
s O
RARE O

In O
literature O
, O
the O
ALL_CAP O
has O
been O
displayed O
by O
application O
of O
the O
RARE O
method O
. O

Forty O
- O
five O
cases O
were O
surgically O
by O
direct O
approach O
to O
the O
RARE O
, O
while O
two O
cases O
were O
treated O
only O
with O
a O
shunt O
. O

In O
Group O
V O
, O
the O
RARE O
tissue O
was O
primarily O
RARE O
with O
virtually O
RARE O
lateral O
zone O
of O
RARE O
tissue O
( O
ratio O
of O
RARE O
RARE O
to O
RARE O
RARE O
14 O
. O
8 O
+/- O
1 O
. O
9 O
to O
1 O
). O

RARE O
NUM O
- O
mmHg O
RARE O
decreases O
in O
RARE O
oxygen O
partial O
pressure O
( O
PO2 O
) O
from O
control O
( O
NUM O
% O
NUM O
RARE O
, O
PO2 O
, O
NUM O
- O
NUM O
mmHg O
) O
were O
produced O
, O
and O
subsequent O
changes O
in O
RARE O
RARE O
and O
resting O
tension O
were O
measured O
. O

The O
known O
NUM O
- O
deficiency O
RARE O
excessive O
high O
values O
with O
light O
exercise O
. O

Based O
on O
AUC O
RARE O
analyses O
, O
the O
pharmacokinetics O
of O
RARE O
were O
found O
to O
be O
RARE O
within O
the O
dose O
RARE O
studied O
( O
50 O
to O
NUM O
mg O
RARE O
i O
. O
v O
. O
injection O
and O
NUM O
to O
NUM O
mg O
RARE O
oral O
administration O
). O

RARE I-GENE
RARE O
RARE O
food O
RARE O
in O
RARE O
RARE O
diseases O

RARE I-GENE
determination O
using O
the O
ALL_CAP O
- O
1 O
RARE O

RARE O
a O
period O
of O
NUM O
days O
16 O
% O
of O
the O
dose O
administered O
was O
RARE O
with O
RARE O
and O
NUM O
. O
9 O
% O
in O
the O
urine O
. O

RARE O
or O
RARE O
emptying O
regions O
of O
the O
RARE O
ventricle O
were O
detected O
by O
a O
relatively O
new O
nuclear O
technique O
RARE O
RARE O
imaging O
. O

RARE O
to O
RARE O
of O
nuclei O
RARE O
RARE O
, O
RARE O
posterior O
were O
of O
considerably O
longer O
RARE O
. O

RARE O
patients O
with O
non O
- O
RARE O
gallbladder O
with O
ALL_CAP O
subsequently O
had O
Tc O
- O
99m O
- O
ALL_CAP O
RARE O
performed O
. O

One O
was O
allowed O
fresh O
drinking O
water O
RARE O
RARE O
RARE O
the O
other O
received O
RARE O
in O
their O
drinking O
water O
. O

RARE O
data O
were O
obtained O
from O
case O
history O
, O
smoking O
RARE O
were O
not O
known O
in O
RARE O
A O
and O
C O
. O

The O
determination O
of O
physical O
performance O
capacity O
was O
based O
on O
NUM O
, O
NUM O
% O
and O
on O
predicted O
VO2 O
RARE O
measured O
with O
continuously O
increasing O
work O
load O
on O
a O
RARE O
RARE O
. O

Determination O
of O
lead O
in O
RARE O
. O

Effect O
of O
indomethacin O
and O
RARE O
F2 O
alpha O
on O
RARE O
in O
swine O
. O

LD50 O
values O
of O
terms O
of O
KP O
were O
NUM O
mg O
/ O
kg O
in O
male O
rats O
and O
122 O
mg O
/ O
kg O
in O
female O
rats O
when O
KP O
- O
ALL_CAP O
was O
administered O
RARE O
, O
and O
117 O
mg O
/ O
kg O
in O
male O
and O
92 O
mg O
/ O
kg O
in O
female O
when O
KP O
- O
NUM O
was O
administered O
RARE O
., O
while O
RARE O
administration O
of O
KP O
- O
ALL_CAP O
showed O
LD50 O
values O
of O
NUM O
mg O
/ O
kg O
in O
males O
and O
NUM O
mg O
/ O
kg O
in O
females O
in O
terms O
of O
KP O
. O

RARE O
was O
performed O
RARE O
follows O
: O
Heparin O
- O
ALL_CAP O
- O
B O
- O
Heparin O
- O
ALL_CAP O
- O
Heparin O
- O
ALL_CAP O
- O
B O
etc O
. O

RARE O
microscopic O
picture O
of O
the O
cerebral O
cortex O
in O
rats O
RARE O
to O
NUM O
degrees O
C O

RARE O
the O
differences O
between O
short O
gut O
and O
sham O
operation O
animals O
disappeared O
when O
the O
data O
were O
RARE O
RARE O
RARE O
RARE O
. O

A O
RARE O
thin O
- O
layer O
chromatographic O
determination O
of O
RARE O
acid O
and O
RARE O
RARE O
. O

The O
architecture O
of O
RARE O
in O
these O
two O
regions O
was O
also O
examined O
by O
scanning O
electron O
microscopy O
, O
using O
the O
resin O
RARE O
method O
. O

ALL_CAP O
RARE O
RARE O
new O
RARE O
health O
RARE O
. O

RARE O
of O
the O
RARE O
cord O
in O
a O
NUM O
rat O
. O

RARE O
high O
- O
performance O
liquid O
chromatographic O
RARE O
with O
micro O
RARE O
and O
dual O
RARE O
detector O
RARE O
direct O
injection O
analysis O
of O
catecholamines O
in O
body O
fluids O
. O

Thirty O
- O
one O
age O
- O
matched O
, O
conscious O
, O
RARE O
, O
male O
Sprague O
- O
Dawley O
rats O
and O
spontaneously O
hypertensive O
rats O
( O
RARE O
) O
were O
individually O
injected O
with O
a O
single O
subcutaneous O
dose O
of O
NUM O
mg O
/ O
kg O
dl O
- O
isoproterenol O
to O
determine O
the O
degree O
and O
time O
course O
of O
drug O
- O
RARE O
cardiac O
failure O
and O
RARE O
recovery O
. O

A O
narrow O
zone O
of O
RARE O
- O
RARE O
dissociation O
was O
also O
observed O
. O

The O
IgA I-GENE
deficiency O
is O
combined O
with O
the O
IgE I-GENE
one O
. O

In O
ALL_CAP O
mice O
, O
there O
was O
only O
a O
small O
deficit O
in O
the O
number O
of O
the O
hippocampal O
pyramidal O
neurons O
compared O
to O
controls O
( O
NUM O
%, O
p O
less O
than O
NUM O
. O
01 O
RARE O
and O
RARE O
deficit O
in O
the O
RARE O
cells O
. O

RARE O
RARE O
in O
RARE O
RARE O
. O

Prevention O
of O
transfusion O
reactions O
by O
the O
use O
of O
saline O
RARE O
RARE O
RARE O
cells O
. O

The O
RARE O
mean O
RARE O
- O
inhibition O
antibody O
RARE O
( O
ALL_CAP O
) O
of O
non O
- O
immunized O
, O
once O
- O
immunized O
, O
and O
twice O
- O
immunized O
RARE O
were O
compared O
RARE O
2 O
- O
week O
intervals O
following O
RARE O
immunization O
, O
secondary O
immunization O
, O
and O
challenge O
. O

The O
quantitative O
determination O
of O
ALL_CAP I-GENE
RARE O
a O
valuable O
aid O
in O
evaluating O
the O
RARE O
of O
hepatitis O
B O
virus O
carriers O

2 O
. O
numerous O
narrow O
shunt O
vessels O
RARE O
continuously O
from O
the O
RARE O
arteries O
to O
feed O
a O
secondary O
arterial O
RARE O
which O
RARE O
the O
RARE O
one O
. O

RARE O
complications O
are O
frequent O
RARE O
and O
after O
the O
treatment O
of O
RARE O
malignancy O
. O

RARE O
cyst O
. O

NUM O
more O
than O
in O
the O
summer O
coat O
). O

RARE O
was O
produced O
by O
head O
RARE O
tilt O
. O

Therefore O
the O
procedure O
of O
RARE O
- O
RARE O
is O
not O
to O
be O
recommended O
in O
adults O
. O

RARE O
and O
RARE O
cell O
carcinomas O
of O
RARE O
tissues O
. O

Twenty O
patients O
aged O
NUM O
or O
older O
with O
the O
diagnosis O
of O
endogenous O
depression O
were O
evaluated O
in O
terms O
of O
safety O
and O
efficacy O
in O
their O
response O
to O
multiple O
monitored O
RARE O
therapy O
( O
ALL_CAP O
) O
versus O
single O
RARE O
therapy O
( O
ALL_CAP O
). O

Two O
new O
RARE O
in O
automated O
coagulation O
testing O
. O

This O
relatively O
simple O
and O
easily O
performed O
technique O
of O
measuring O
deep O
muscle O
RARE O
appears O
to O
be O
a O
useful O
RARE O
in O
RARE O
the O
RARE O
level O
. O

RARE O
force O
- O
length O
relationships O
of O
RARE O
RARE O
RARE O
were O
studied O
in O
vitro O
in O
animals O
3 O
weeks O
, O
3 O
months O
, O
and O
3 O
years O
of O
age O
. O

RARE O
of O
the O
method O
indicate O
( O
1 O
) O
the O
RARE O
source O
can O
be O
placed O
on O
the O
RARE O
membrane O
without O
altering O
the O
signal O
- O
RARE O
properties O
of O
the O
RARE O
, O
and O
( O
2 O
) O
the O
source O
RARE O
to O
the O
RARE O
membrane O
. O

RARE O
work O
- O
RARE O
in O
a O
patient O
with O
RARE O
vaginal O
metastasis O
from O
a O
RARE O
carcinoma O
. O

The O
authors O
conclude O
that O
RARE O
of O
low O
platelet I-GENE
MAO I-GENE
RARE O
a O
possible O
correlate O
of O
bipolar O
affective O
disorder O
, O
RARE O
RARE O
RARE O
schizophrenia O
, O
increases O
the O
burden O
of O
RARE O
necessary O
before O
findings O
of O
low O
platelet I-GENE
MAO I-GENE
can O
be O
accepted O
RARE O
RARE O
. O

RARE O
, O
a O
known O
RARE O
, O
of O
which O
little O
is O
known O

RARE O
RARE O
, O
either O
RARE O
NUM O
beta O
- O
estradiol O
or O
beta O
- O
estradiol O
- O
3 O
- O
RARE O
via O
subcutaneous O
RARE O
capsules O
, O
was O
associated O
with O
elevated O
rates O
of O
heat O
production O
and O
RARE O
heat O
RARE O
relative O
to O
untreated O
RARE O
controls O
. O

The O
following O
aspects O
were O
assessed O
: O
( O
1 O
) O
The O
effect O
on O
the O
cardiovascular O
RARE O
in O
terms O
of O
RARE O
arterial O
pressure O
, O
pulse O
rate O
, O
and O
oxygen O
consumption O
( O
VO2 O
) O
RARE O
exercise O
in O
5 O
health O
volunteers O
; O
( O
2 O
) O
RARE O
activity O
of O
the O
RARE O
anterior O
and O
RARE O
muscles O
RARE O
exercise O
in O
the O
same O
5 O
volunteers O
; O
and O
( O
3 O
) O
RARE O
RARE O
pressure O
changes O
in O
10 O
subjects O
with O
RARE O
proven O
RARE O
arterial O
diseases O
of O
the O
lower O
RARE O
. O

Changes O
in O
immunologic O
reactivity O
in O
subjects O
receiving O
transfer I-GENE
factor I-GENE
could O
not O
be O
distinguished O
from O
those O
in O
subjects O
receiving O
placebo O
. O

It O
was O
RARE O
that O
this O
RARE O
from O
the O
possibility O
that O
the O
nature O
of O
blue O
RARE O
RARE O
was O
physical O
, O
and O
that O
RARE O
of O
RARE O
tissue O
might O
be O
expected O
to O
more O
markedly O
RARE O
with O
their O
work O
efficiency O
( O
on O
RARE O
to O
work O
) O
than O
it O
would O
the O
efficiency O
of O
the O
more O
RARE O
RARE O
of O
RARE O
RARE O
workers O
. O

RARE O
of O
RARE O
the O
RARE O
RARE O
groups O
in O
RARE O
of O
the O
long O
tubular O
RARE O
complicated O
by O
infection O

The O
results O
revealed O
increased O
RARE O
lead O
level O
associated O
with O
decreased O
RARE I-GENE
RARE I-GENE
and O
increased O
RARE O
excretion O
of O
delta O
amino O
RARE O
acid O
. O

Following O
iv O
injection O
of O
NUM O
. O
5 O
g O
RARE O
per O
kg O
body O
RARE O
, O
together O
with O
2 O
mu O
RARE O
generally O
14C O
- O
labelled O
RARE O
, O
NUM O
is O
collected O
in O
regular O
intervals O
RARE O
one O
hour O
. O

Specific O
RARE O
factor O
assays O
showed O
an O
isolated O
deficiency O
of O
factor I-GENE
X I-GENE
ranging O
from O
7 O
to O
12 O
per O
cent O
on O
three O
determinations O
. O

RARE O
- O
facilitated O
dialysis O
. O

RARE O
variables O
measured O
RARE O
eight O
intervals O
before O
, O
RARE O
, O
and O
after O
operation O
were O
RARE O
follows O
: O
RARE O
plasma O
proteins O
, O
free O
hemoglobin I-GENE
, O
formed O
elements O
, O
and O
RARE O
functions O
. O

RARE O
changes O
in O
RARE O
RARE O
in O
children O

As O
a O
result O
, O
beta O
- O
RARE O
- O
8 O
'- O
RARE O
acid O
ethyl O
ester O
( O
RARE O
- O
ALL_CAP O
) O
was O
used O
RARE O
a O
reference O
standard O
in O
Experiments O
4 O
to O
6 O
. O

The O
ability O
of O
RARE O
RARE O
( O
NUM O
mg O
/ O
kg O
) O
and O
RARE O
RARE O
( O
NUM O
mg O
/ O
kg O
) O
to O
produce O
a O
taste O
RARE O
in O
NUM O
hr O
RARE O
deprived O
rats O
was O
examined O
using O
a O
discrimination O
or O
two O
RARE O
taste O
RARE O
task O
( O
NUM O
. O
NUM O
% O
RARE O
saccharin O
solution O
or O
water O
). O

It O
appears O
that O
the O
pulmonary O
gas O
exchange O
parenchyma O
of O
these O
smallest O
mammals O
is O
RARE O
RARE O
to O
supply O
the O
organism O
with O
the O
RARE O
high O
levels O
of O
NUM O
required O
by O
the O
high O
metabolic O
rates O
, O
exhibiting O
a O
structural O
adaptation O
of O
the O
RARE O
to O
RARE O
VO2 O
. O

RARE O
by O
RARE O
much O
RARE O
NUM O
% O
may O
occur O
due O
to O
the O
problems O
in O
the O
existing O
RARE O
. O

RARE O
was O
administered O
without O
altering O
the O
course O
of O
the O
disorder O
. O

Drug O
inhibition O
of O
whole O
RARE O
RARE I-GENE
esterase I-GENE
. O

However O
, O
RARE O
lower O
RARE O
the O
positive O
RARE O
was O
not O
clear O
and O
rather O
negative O
RARE O
appeared O
( O
1 O
RARE O
3 O
Hz O
). O

RARE O
averaged O
evoked O
responses O
and O
platelet I-GENE
RARE I-GENE
oxidase I-GENE
in O
patients O
suffering O
from O
RARE O
. O

At O
the O
end O
of O
the O
experiment O
the O
RARE O
porphyrin O
excretion O
and O
the O
porphyrin O
content O
in O
RARE O
and O
RARE O
were O
diminished O
in O
HCB O
- O
ALL_CAP O
- O
treated O
animals O
by O
about O
50 O
% O
compared O
to O
the O
HCB O
controls O
. O

Six O
hours O
after O
the O
last O
administration O
, O
RARE O
of O
RARE O
and O
RARE O
mice O
were O
RARE O
NUM O
. O
6 O
mg O
% O
and O
NUM O
. O
5 O
mg O
% O
respectively O
, O
the O
difference O
was O
statistically O
significant O
( O
p O
less O
than O
NUM O
. O
01 O
). O

Although O
stone O
- O
RARE O
were O
not O
found O
to O
display O
any O
features O
of O
magnesium O
metabolism O
that O
were O
different O
from O
those O
in O
the O
control O
group O
, O
their O
lower O
RARE O
excretion O
of O
magnesium O
in O
relation O
to O
RARE O
may O
be O
a O
factor O
in O
their O
increased O
stone O
- O
forming O
propensity O
. O

Analysis O
of O
an O
autopsy O
population O
. O

A O
16 O
- O
year O
follow O
- O
RARE O
study O
of O
NUM O
RARE O
with O
RARE O
lesions O
from O
NUM O
- O
NUM O
is O
presented O
. O

RARE O
RARE O
of O
its O
cellular O
distribution O
in O
the O
RARE O
. O

RARE O
RARE O
overlapping O
conditioned O
stimulus O
RARE O
produced O
RARE O
of O
latent O
inhibition O
, O
RARE O
did O
RARE O
presented O
RARE O
conditioning O
after O
RARE O
. O

The O
RARE O
amygdala O
and O
RARE O
pathology O
in O
rats O
. O

RARE O
extraction O
in O
RARE O
glaucoma O

RARE O
and O
size O
of O
the O
RARE O
RARE O
in O
the O
RARE O
RARE O
II O
increased O
simultaneously O
. O

In O
the O
RARE O
RARE O
, O
RARE O
potentiation O
RARE O
on O
the O
basic O
pacing O
interval O
, O
NUM O
, O
and O
the O
timing O
of O
the O
RARE O
, O
t1 O
: O
when O
NUM O
was O
held O
constant O
and O
t1 O
was O
increased O
, O
potentiation O
decreased O
; O
when O
t1 O
was O
held O
constant O
and O
NUM O
was O
increased O
, O
potentiation O
increased O
. O

In O
RARE O
of O
this O
and O
other O
complications O
of O
corticosteroids O
, O
RARE O
made O
a O
full O
recovery O
from O
the O
RARE O
infection O
following O
treatment O
with O
amphotericin O
B O
and O
surgical O
RARE O
of O
the O
RARE O
abscess O
. O

RARE O
of O
this O
observation O
RARE O
RARE O
are O
discussed O
. O

For O
the O
study O
of O
the O
transition O
of O
long O
to O
short O
waves O
( O
deep O
- O
water O
waves O
) O
a O
closed O
- O
form O
solution O
is O
RARE O
; O
this O
can O
, O
however O
, O
only O
be O
obtained O
RARE O
the O
cost O
of O
further O
RARE O
. O

Treatment O
of O
RARE O
RARE O

We O
report O
a O
case O
of O
RARE O
RARE O
RARE O
the O
third O
RARE O
of O
RARE O
. O

RARE O
plasma O
and O
lipoprotein O
RARE O
concentrations O
, O
RARE I-GENE
tissue I-GENE
lipoprotein I-GENE
lipase I-GENE
activity O
, O
RARE O
data O
, O
RARE O
consumption O
, O
smoking O
RARE O
, O
weekly O
RARE O
run O
and O
performance O
on O
a O
RARE O
RARE O
were O
recorded O
before O
and O
after O
the O
training O
period O
. O

The O
C18 O
: O
1 O
: O
NUM O
value O
is O
a O
RARE O
measure O
of O
these O
changes O
and O
can O
be O
determined O
more O
rapidly O
than O
RARE O
all O
the O
lower O
fatty O
RARE O
. O

A O
progressive O
growth O
of O
RARE O
RARE O
membrane O
injury O
has O
been O
demonstrated O
after O
rats O
were O
exposed O
to O
gamma O
- O
RARE O
RARE O
a O
dose O
of O
NUM O
to O
500 O
Gy O
. O

Within O
the O
3 O
' O
terminal O
50 O
nucleotides O
, O
the O
mouse I-GENE
RARE I-GENE
NUM I-GENE
rRNA I-GENE
contains O
a O
RARE O
10 O
bp O
hairpin O
RARE O
and O
a O
sequence O
of O
NUM O
consecutive O
nucleotides O
common O
to O
the O
RNA O
of O
the O
small O
ribosomal O
subunit O
in O
all O
RARE O
, O
but O
does O
not O
contain O
the O
mRNA O
binding O
site O
( O
ALL_CAP O
) O
found O
in O
E O
. O
coli O
and O
RARE O
chloroplast O
RARE O
. O

RARE O
RARE O
and O
cell O
population O
dynamics O
. O

Thirty O
RARE O
RARE O
were O
examined O
under O
X O
6 O
to O
16 O
magnification O
in O
order O
to O
define O
the O
RARE O
RARE O
of O
the O
pineal O
region O
, O
particularly O
the O
relationship O
of O
the O
pineal O
body O
, O
posterior O
cerebral O
artery O
, O
superior O
RARE O
artery O
, O
RARE O
of O
RARE O
, O
basal O
RARE O
of O
RARE O
, O
internal O
cerebral O
RARE O
, O
RARE O
sinus O
, O
RARE O
RARE O
, O
the O
size O
of O
the O
RARE O
RARE O
, O
and O
the O
third O
and O
the O
fourth O
RARE O
nerves O
. O

Serum O
antibody O
RARE O
was O
not O
significantly O
associated O
with O
the O
recurrence O
rate O
or O
the O
duration O
of O
infection O
. O

We O
propose O
that O
RARE O
may O
be O
an O
important O
mechanism O
RARE O
activation O
of O
certain O
viral O
infections O
previously O
suppressed O
by O
RARE O
. O

One O
hundred O
RARE O
RARE O
of O
RARE O
RARE O
RARE O
cells O
, O
some O
with O
RARE O
added O
so O
RARE O
to O
RARE O
an O
acceptable O
1 O
% O
RARE O
content O
, O
had O
measurements O
made O
of O
the O
post O
- O
RARE O
supernatant O
RARE O
by O
RARE O
index O
and O
RARE O
. O

The O
symptoms O
and O
objective O
findings O
were O
caused O
by O
a O
malignant O
lymphoma O
, O
and O
the O
diagnosis O
was O
established O
from O
a O
RARE O
biopsy O
. O

Our O
study O
differs O
from O
previous O
studies O
in O
that O
it O
is O
limited O
to O
one O
diagnostic O
RARE O
, O
yet O
RARE O
the O
same O
time O
RARE O
a O
broad O
range O
of O
social O
and O
work O
- O
related O
factors O
in O
RARE O
. O

It O
is O
suggested O
that O
a O
raised O
RARE O
/ O
RARE O
acid O
ratio O
does O
not O
necessarily O
indicate O
vitamin O
NUM O
deficiency O
but O
may O
represent O
a O
nonspecific O
response O
of O
RARE O
metabolism O
to O
stress O
. O

All O
control O
persons O
had O
a O
normal O
reaction O
to O
ALL_CAP O
. O

In O
a O
control O
group O
both O
common O
carotid O
arteries O
( O
ALL_CAP O
) O
were O
ligated O
. O

At O
pH O
6 O
. O
9 O
, O
the O
same O
lidocaine O
concentrations O
significantly O
RARE O
resting O
RARE O
( O
3 O
- O
10 O
%), O
action O
RARE O
amplitude O
( O
3 O
- O
8 O
%) O
and O
Vmax O
( O
14 O
- O
NUM O
%). O

RARE O
right O
and O
RARE O
adrenal O
and O
peripheral O
RARE O
samples O
were O
collected O
RARE O
determination O
of O
RARE O
( O
E1 O
) O
and O
oestradiol O
( O
E2 O
). O

RARE O
function O
tests O
. O

All O
lambs O
with O
B O
RARE O
had O
significantly O
RARE O
RARE I-GENE
levels O
RARE O
the O
end O
of O
the O
experiment O
than O
did O
ALL_CAP O
lambs O
. O
b O
and O
S O
RARE O
B O
lambs O
had O
RARE O
( O
P O
< O
. O
05 O
) O
RARE I-GENE
levels O
than O
the O
D O
RARE O
B O
lambs O
, O
and O
B O
lambs O
had O
the O
highest O
( O
P O
< O
. O
05 O
) O
mean O
RARE O
hemoglobin I-GENE
concentrations O
. O

The O
same O
response O
occurs O
whether O
RARE O
is O
given O
immediately O
after O
nerve O
ligation O
or O
1 O
week O
later O
. O

The O
operation O
recommended O
is O
RARE O
of O
3 O
mm O
of O
central O
RARE O
followed O
by O
end O
- O
to O
- O
end O
repair O
of O
the O
tendon O
. O

In O
the O
RARE O
group O
arterial O
pressure O
decreased O
50 O
mmHg O
to O
normal O
by O
NUM O
h O
and O
was O
associated O
with O
increased O
RARE O
and O
a O
small O
decrease O
in O
RARE O
volume O
( O
9 O
. O
8 O
%). O

Marked O
RARE O
activity O
was O
observed O
with O
9 O
- O
RARE O
- O
5 O
- O
RARE O
RARE O
2 O
, O
1 O
- O
d O
RARE O
1 O
, O
5 O
] O
RARE O
- O
6 O
, O
6 O
- O
dioxide O
( O
NUM O
) O
and O
9 O
- O
RARE O
- O
5 O
- O
p O
- O
RARE O
RARE O
2 O
, O
1 O
- O
d O
RARE O
1 O
, O
5 O
] O
RARE O
- O
6 O
, O
6 O
- O
dioxide O
( O
NUM O
). O

In O
patients O
, O
the O
effect O
of O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
on O
the O
movement O
of O
the O
terminal O
part O
of O
the O
bile O
duct O
was O
measured O
with O
a O
pressure O
RARE O
using O
a O
RARE O
. O

In O
11 O
patients O
with O
RARE O
' O
s O
headache O
morphological O
investigations O
( O
differential O
RARE O
RARE O
cell O
count O
RARE O
RARE O
determinations O
( O
RARE I-GENE
and I-GENE
acid I-GENE
phosphatase I-GENE
, O
non I-GENE
- I-GENE
specific I-GENE
esterase I-GENE
) O
and O
RARE O
tests O
( O
IgM I-GENE
and O
IgG I-GENE
binding O
) O
were O
carried O
out O
on O
capillary O
RARE O
neutrophils O
obtained O
from O
the O
area O
of O
pain O
, O
non O
- O
RARE O
area O
of O
the O
RARE O
on O
the O
head O
on O
the O
contralateral O
RARE O
, O
and O
from O
the O
finger O
. O

As O
high O
- O
RARE O
, O
RARE O
imaging O
, O
computed O
RARE O
scan O
RARE O
such O
RARE O
the O
RARE O
RARE O
RARE O
become O
available O
with O
RARE O
density O
resolution O
, O
perhaps O
a O
single O
injection O
of O
contrast O
agent O
into O
the O
right O
atrium O
or O
even O
a O
peripheral O
RARE O
may O
be O
adequate O
to O
obtain O
all O
these O
measurements O
. O

The O
ALL_CAP O
' O
s O
are O
a O
direct O
result O
of O
the O
ALL_CAP O
study O
. O

The O
potentially O
SLE O
- O
inducing O
drugs O
are O
reviewed O
. O

A O
third O
series O
of O
mice O
were O
given O
a O
single O
injection O
of O
5 O
- O
OH O
- O
ALL_CAP O
, O
RARE O
, O
and O
prepared O
RARE O
RARE O
study O
. O

RARE O
different O
species O
( O
eight O
RARE O
, O
one O
RARE O
and O
five O
RARE O
) O
have O
been O
RARE O
. O

No O
symptoms O
other O
than O
hot O
RARE O
showed O
such O
significant O
correlation O
with O
plasma O
epinephrine O
or O
norepinephrine O
levels O
. O

The O
mean O
values O
of O
the O
concentrations O
of O
the O
RARE O
due O
to O
tobacco O
smoke O
are O
: O
ALL_CAP O
= O
1 O
. O
1 O
ppm O
, O
ALL_CAP O
= O
NUM O
ppb O
, O
NO2 O
= O
NUM O
ppb O
, O
nicotine O
= O
NUM O
. O
9 O
micrograms O
/ O
m3 O
, O
particulate O
matter O
= O
NUM O
micrograms O
/ O
m3 O
. O

The O
average O
RARE O
coefficient O
was O
RARE O
time O
larger O
in O
regions O
of O
infarct O
studied O
8 O
RARE O
10 O
weeks O
after O
occlusion O
than O
that O
in O
regions O
of O
infarct O
studied O
5 O
RARE O
6 O
weeks O
after O
occlusion O
. O

At O
4 O
wk O
however O
, O
tumor O
relapse O
was O
noted O
in O
6 O
of O
7 O
group O
4 O
responders O
, O
10 O
of O
12 O
in O
group O
5 O
, O
NUM O
of O
16 O
in O
group O
7 O
, O
but O
only O
4 O
of O
19 O
group O
8 O
responders O
( O
p O
less O
than O
. O
001 O
group O
8 O
versus O
4 O
, O
5 O
, O
7 O
). O

Early O
infection O
was O
detected O
in O
one O
of O
50 O
control O
women O
who O
gave O
birth O
to O
a O
healthy O
infant O
. O

RARE O
RARE O
the O
onset O
of O
HCB O
RARE O
, O
in O
other O
RARE O
it O
increases O
the O
RARE O
RARE O
porphyrin O
excretion O
and O
causes O
an O
earlier O
disturbance O
of O
the O
porphyrin O
pattern O
. O

RARE O
planning O
RARE O
to O
play O
a O
minor O
role O
, O
and O
only O
NUM O
. O
3 O
per O
cent O
of O
all O
patients O
reviewed O
RARE O
to O
oral O
RARE O
RARE O
shorter O
or O
longer O
periods O
of O
time O
. O
- O
The O
RARE O
of O
RARE O
and O
RARE O
in O
all O
births O
RARE O
RARE O
RARE O
the O
high O
percentage O
of O
RARE O
are O
parameters O
by O
which O
the O
approach O
to O
RARE O
differs O
RARE O
from O
behaviour O
patterns O
in O
RARE O
. O

The O
term O
RARE O
is O
proposed O
RARE O
a O
RARE O
bone O
RARE O
with O
dominant O
RARE O
that O
has O
been O
discovered O
in O
five O
members O
of O
four O
different O
RARE O
. O

The O
NUM O
protein O
, O
together O
with O
proteins O
of O
NUM O
, O
NUM O
and O
NUM O
, O
NUM O
RARE O
, O
are O
translated O
from O
RARE O
RARE O
( O
1 O
- O
RARE O
) O
RARE O
RNAs O
that O
are O
RARE O
to O
the O
viral O
genome O
between O
positions O
11 O
. O
2 O
and O
NUM O
. O
5 O
. O

The O
identification O
of O
viable O
myocardium O
with O
both O
99mTc O
- O
tetrofosmin O
and O
NUM O
can O
be O
greatly O
RARE O
to O
a O
similar O
degree O
if O
the O
severity O
of O
reduction O
in O
activity O
within O
RARE O
defects O
is O
considered O
. O

The O
temporal O
RARE O
lacked O
a O
mandibular O
RARE O
RARE O
RARE O
RARE O
RARE O
RARE O
. O

ALL_CAP O
- O
8 O
is O
a O
novel O
, O
RARE O
, O
low O
- O
RARE O
- O
RARE O
RARE O
- O
RARE O
complex O
that O
exhibits O
both O
RARE I-GENE
dismutase I-GENE
and O
catalase I-GENE
activities O
in O
vitro O
. O

The O
protein I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
encoded O
by O
a O
single O
- O
copy O
gene O
homologous O
to O
the O
ALL_CAP I-GENE
family I-GENE
of I-GENE
RARE I-GENE
transcription I-GENE
factors I-GENE
, O
is O
potentially O
capable O
of O
RARE O
with O
this O
element O
. O

However O
, O
in O
contrast O
with O
previous O
in O
vitro O
cell O
- O
free O
RARE O
studies O
, O
alteration O
of O
the O
highly O
RARE O
CA O
dinucleotide O
resulted O
in O
a O
mutant O
which O
still O
retained O
40 O
% O
of O
wild O
- O
type O
RARE O
activity O
. O

The O
resulting O
R I-GENE
protein I-GENE
RARE O
five O
codons O
RARE O
of O
the O
frameshift O
site O
RARE O
the O
V I-GENE
protein I-GENE
stop O
RARE O
. O

These O
results O
demonstrate O
that O
although O
NUM O
and O
NUM O
viruses O
belong O
to O
the O
same O
RARE O
virus O
genus O
, O
these O
viruses O
show O
marked O
differences O
with O
respect O
to O
RARE O
requirements O
RARE O
the O
cytoplasmic O
RARE O
of O
the O
F I-GENE
glycoprotein I-GENE
. O

By O
site O
- O
specific O
mutagenesis O
, O
we O
also O
show O
that O
individual O
NUM I-GENE
C I-GENE
- I-GENE
terminal I-GENE
amino I-GENE
acid I-GENE
residues I-GENE
that O
are O
RARE O
RARE O
in O
NUM I-GENE
homologs I-GENE
in O
other O
RARE O
( O
D O
- O
NUM O
, O
E O
- O
NUM O
, O
H O
- O
NUM O
, O
C O
- O
NUM O
, O
C O
- O
NUM O
, O
and O
C O
- O
NUM O
) O
are O
critical O
RARE O
RARE O
- O
regulatory O
activity O
. O

Magnetic O
resonance O
imaging O
( O
MRI O
) O
has O
RARE O
us O
to O
RARE O
the O
RARE O
RARE O
pathology O
RARE O
differences O
in O
signal O
intensity O
. O

Patients O
with O
RARE O
drugs O
showed O
significantly O
RARE O
PRL I-GENE
levels O
. O

The O
RARE O
RARE O
RARE O
enables O
a O
RARE O
- O
based O
examination O
and O
therefore O
allows O
RARE O
comparison O
between O
morphologic O
appearance O
and O
corresponding O
function O
. O

RARE O
, O
RARE O
, O
and O
HIV O
- O
1 O
RARE O
in O
central O
RARE O
. O

ALL_CAP O
and O
RARE O
. O

In O
addition O
, O
two O
- O
dimensional O
nuclear O
magnetic O
resonance O
studies O
with O
NUM O
, O
NUM O
, O
NUM O
and O
NUM O
revealed O
that O
the O
mutants O
have O
the O
same O
overall O
RARE O
RARE O
the O
wild I-GENE
- I-GENE
type I-GENE
ALL_CAP I-GENE
protein I-GENE
. O

RARE O
high O
levels O
of O
IgE I-GENE
antibodies I-GENE
was O
also O
established O
while O
other O
RARE O
did O
not O
show O
such O
RARE O
. O

RARE I-GENE
RARE I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
( O
RARE I-GENE
) O
and O
retinoid I-GENE
X I-GENE
receptors I-GENE
( O
RARE I-GENE
) O
are O
nuclear I-GENE
hormone I-GENE
receptors I-GENE
that O
are O
activated O
by O
fatty O
RARE O
and O
9 O
- O
cis O
- O
retinoic O
acid O
, O
respectively O
. O

This O
is O
particularly O
RARE O
because O
ALL_CAP O
- O
NUM O
- O
20 O
cells O
lack O
the O
transcription O
factor O
Pit I-GENE
- I-GENE
1 I-GENE
. O

The O
number O
of O
RARE O
, O
RARE O
, O
RARE O
, O
and O
RARE O
was O
not O
altered O
compared O
with O
controls O
, O
indicating O
that O
in O
the O
adult O
pituitary O
, O
ALL_CAP I-GENE
products I-GENE
are O
not O
required O
to O
maintain O
the O
distribution O
of O
cell O
RARE O
. O

Some O
strains O
of O
A O
. O
RARE O
produced O
all O
four O
RARE O
NUM O
NUM O
G1 O
NUM O
, O
while O
the O
other O
ones O
produced O
ALL_CAP O
NUM O
+ O
G1 O
only O
, O
with O
concentrations O
of O
RARE O
from O
NUM O
. O
1 O
to O
NUM O
mg O
/ O
kg O
. O

We O
have O
isolated O
a O
new O
, O
larger O
rat I-GENE
B I-GENE
- I-GENE
myc I-GENE
genomic I-GENE
clone I-GENE
. O

In O
addition O
to O
the O
nine O
and O
NUM O
terminal O
amino O
acid O
forms O
already O
known O
, O
we O
identified O
a O
third O
with O
NUM O
terminal O
amino O
RARE O
predicted O
to O
encode O
a O
novel O
RET I-GENE
protein I-GENE
isoform I-GENE
. O

Both O
classes O
of O
RARE I-GENE
proteins I-GENE
were O
found O
to O
form O
RARE O
; O
an O
which O
is O
involved O
in O
mediating O
the O
RARE O
. O

In O
electrophoretic O
mobility O
shift O
assays O
, O
the O
ALL_CAP I-GENE
formed O
three O
major O
complexes O
( O
P1 O
, O
P2 O
and O
NUM O
) O
with O
proteins O
in O
nuclear O
extracts O
from O
HeLa O
or O
293 O
cells O
. O

RARE O
had O
been O
receiving O
ALL_CAP O
7 O
. O
5 O
mg O
/ O
week O
RARE O
2 O
. O
5 O
months O
because O
of O
RARE O
vasculitis O
symptoms O
. O

Analysis O
of O
the O
sequence O
identified O
four O
RARE O
reading O
frames O
( O
RARE O
) O
which O
are O
designated O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
. I-GENE
5 I-GENE
based O
on O
their O
homology O
with O
proteins O
of O
herpes O
simplex O
virus O
- O
1 O
( O
HSV O
- O
1 O
RARE O
pseudorabies O
virus O
( O
ALL_CAP O
RARE O
RARE O
RARE O
- O
1 O
, O
and O
RARE O
- O
RARE O
virus O
. O

These O
NUM O
NUM I-GENE
/ O
E7 I-GENE
cDNAs O
were O
RARE O
under O
the O
SV40 I-GENE
enhancer I-GENE
/ I-GENE
promoter I-GENE
and O
the O
ALL_CAP I-GENE
LTR I-GENE
to O
examine O
the O
activities O
of O
ras I-GENE
- O
RARE O
transformation O
and O
induction O
of O
cellular O
DNA O
RARE O
, O
both O
of O
which O
depend O
on O
the O
E7 I-GENE
gene I-GENE
product O
. O

RARE O
coefficients O
between O
the O
reference O
methods O
and O
ALL_CAP O
were O
> O
or O
= O
NUM O
. O
NUM O
RARE O
water O
, O
fat O
, O
crude O
protein O
and O
RARE O
- O
tissue O
- O
protein O
RARE O
meat O
protein O
, O
and O
> O
or O
= O
NUM O
. O
NUM O
RARE O
RARE O
- O
tissue O
- O
protein O
. O

The O
translation O
products O
of O
both O
RARE O
are O
highly O
homologous O
to O
NUM I-GENE
( O
NUM O
and O
NUM O
% O
identity O
, O
respectively O
) O
over O
their O
RARE O
lengths O
, O
including O
amino O
terminal O
sequences O
resembling O
transit O
peptides O
RARE O
RARE O
RARE O
. O

The O
serum O
levels O
of O
IgE I-GENE
, O
and O
ALL_CAP I-GENE
and O
IgG I-GENE
- I-GENE
4 I-GENE
against O
14 O
common O
food O
allergens O
were O
determined O
. O

Two O
experiments O
RARE O
the O
effects O
of O
short O
- O
term O
RARE O
on O
RARE O
bone O
turnover O
were O
carried O
out O
: O
RARE O
RARE O
Experiment O
- O
1 O
( O
ALL_CAP O
- O
1 O
) O
( O
a O
4 O
- O
d O
RARE O
RARE O
) O
and O
ALL_CAP O
- O
2 O
( O
a O
10 O
- O
d O
RARE O
). O

RARE O
sequence O
strongly O
promoted O
the O
transcription O
of O
the O
RARE O
chloramphenicol I-GENE
RARE I-GENE
( O
CAT I-GENE
) O
gene O
in O
cells O
of O
pancreatic O
origin O
( O
ALL_CAP O
- O
NUM O
) O
but O
not O
in O
cells O
of O
non O
- O
pancreatic O
origin O
( O
RARE O
2 O
and O
ALL_CAP O
6 O
). O

Functional O
analysis O
of O
RARE I-GENE
hydrocarbon I-GENE
receptor I-GENE
nuclear I-GENE
RARE I-GENE
interactions O
with O
RARE I-GENE
hydrocarbon I-GENE
receptor I-GENE
in O
the O
yeast O
two O
- O
RARE O
RARE O
. O

RARE O
observations O
showed O
that O
both O
somatostatin I-GENE
and O
RARE O
RARE O
RARE O
the O
inflammatory O
signs O
in O
the O
joint O
RARE O
, O
although O
RARE O
RARE O
appeared O
to O
be O
more O
effective O
. O

An O
approach O
to O
a O
RARE O
model O
of O
RARE O
. O

The O
RARE O
virus O
NS1 I-GENE
protein O
is O
a O
unique O
posttranscriptional O
regulator O
that O
has O
two O
activities O
: O
inhibition O
of O
the O
nuclear O
export O
of O
RARE O
A O
- O
containing O
mRNAs O
and O
inhibition O
of O
pre O
- O
mRNA O
RARE O
. O

These O
are O
two O
regions O
of O
known O
RARE O
RARE O
, O
providing O
further O
evidence O
that O
the O
human I-GENE
ALL_CAP I-GENE
is O
a O
true O
homolog O
of O
the O
murine I-GENE
ALL_CAP I-GENE
gene I-GENE
. O

Molecular O
cloning O
of O
the O
human O
homolog O
of O
a O
RARE I-GENE
- I-GENE
RARE I-GENE
phosphatase I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
gene I-GENE
and O
chromosomal O
mapping O
of O
the O
human O
and O
murine O
loci O
. O

RARE I-GENE
anhydrase I-GENE
V I-GENE
( O
CA I-GENE
V I-GENE
) O
is O
RARE O
in O
mitochondrial O
RARE O
in O
liver O
and O
several O
other O
tissues O
. O

RARE O
NUM O
RARE O
nicotine O
treatment O
produced O
parallel O
increases O
in O
cardiac O
mass O
and O
elastic O
RARE O
, O
with O
a O
significant O
correlation O
between O
the O
two O
. O

The O
latter O
domain O
appears O
to O
be O
involved O
in O
targeting O
NUM I-GENE
to O
the O
RARE O
cell O
cortex O
. O

This O
finding O
is O
consistent O
with O
the O
notion O
that O
the O
ALL_CAP O
binding O
domains O
may O
be O
composed O
of O
two O
separate O
RARE O
subdomains O
. O

RARE O
RARE O
parallel O
RARE O
- O
RARE O
formation O
by O
RARE I-GENE
Max I-GENE
and O
c I-GENE
- I-GENE
RARE I-GENE
leucine I-GENE
RARE I-GENE
: O
a O
description O
of O
putative O
RARE O
interactions O
responsible O
RARE O
the O
RARE O
of O
heterodimerization O
. O

Comparison O
to O
other O
ALL_CAP I-GENE
genes I-GENE
revealed O
a O
NUM O
- O
bp O
group O
I O
intron O
, O
which O
, O
based O
on O
homology O
with O
the O
related O
yeast I-GENE
ALL_CAP I-GENE
intron I-GENE
NUM I-GENE
, O
potentially O
encodes O
a O
NUM O
- O
amino O
- O
acid O
site O
- O
specific O
DNA I-GENE
endonuclease I-GENE
. O

We O
studied O
the O
GR I-GENE
in O
ALL_CAP O
- O
NUM O
cells O
derived O
from O
a O
human O
ACTH I-GENE
- O
secreting O
small O
cell O
RARE O
RARE O
. O

This O
study O
analyzed O
whether O
the O
RARE O
of O
an O
RARE O
RARE O
could O
be O
predicted O
by O
using O
the O
polarity O
of O
the O
QRS O
complex O
RARE O
sinus O
rhythm O
on O
the O
surface O
ECG O
, O
instead O
of O
the O
delta O
wave O
polarity O
RARE O
used O
in O
many O
reports O
. O

The O
promoter O
mutation O
is O
complemented O
in O
RARE O
by O
E1A I-GENE
products O
of O
the O
heterologous O
RARE O
adenovirus O
type O
5 O
( O
NUM O
). O

Thus O
, O
RARE O
expected O
, O
RARE O
- O
RARE O
depends O
on O
the O
integrity O
of O
NUM I-GENE
, O
U4 I-GENE
, O
and O
U6 I-GENE
RARE I-GENE
. O

Treatment O
of O
NUM O
. O
NUM O
cells O
with O
an O
RAR I-GENE
- O
selective O
agonist O
also O
repressed O
the O
RARE O
of O
EC I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
while O
treatment O
with O
an O
RXR I-GENE
- O
selective O
agonist O
RARE O
EC I-GENE
- I-GENE
1 I-GENE
RARE O
slightly O
. O

In O
the O
absence O
of O
NUM I-GENE
, O
YY1 I-GENE
represses O
ALL_CAP O
- O
dependent O
transcription O
of O
c I-GENE
- I-GENE
fos I-GENE
by O
physically O
RARE O
with O
ATF I-GENE
/ O
CREB I-GENE
proteins O
RARE O
to O
the O
- O
67 O
ALL_CAP O
. O

RARE O
- O
down O
experiments O
indicated O
that O
the O
10 O
( O
4 O
)- O
to O
10 O
( O
5 O
)- O
RARE O
reduction O
in O
virus O
yield O
RARE O
the O
RARE O
RARE O
was O
due O
to O
the O
RARE O
of O
alpha I-GENE
TIF I-GENE
RARE O
in O
infection O
, O
presumably O
in O
virion O
RARE O
. O

These O
results O
demonstrate O
that O
RARE I-GENE
acts O
RARE O
an O
early O
RARE O
of O
the O
T O
- O
cell O
signal O
RARE O
cascade O
by O
RARE O
with O
RARE I-GENE
and O
RARE O
RARE O
- O
RARE O
activation O
. O

Human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
RARE I-GENE
is O
a O
virion O
- O
associated O
, O
regulatory O
protein O
that O
is O
required O
RARE O
efficient O
viral O
replication O
in O
monocytes O
/ O
macrophages O
. O

Here O
we O
examine O
the O
RARE O
RARE O
VP16 I-GENE
protein O
- O
protein O
interactions O
specific O
to O
virus O
- O
RARE O
cells O
and O
show O
that O
VP16 I-GENE
RARE O
in O
a O
highly O
RARE O
fraction O
with O
a O
single O
major O
polypeptide O
which O
we O
identify O
RARE O
the O
virus O
- O
encoded O
structural O
protein O
NUM I-GENE
. O

Thus O
, O
transcriptional O
RARE O
, O
RARE O
, O
kinase O
interaction O
sites O
, O
and O
tyrosine O
RARE O
of O
the O
NUM I-GENE
homologs I-GENE
have O
been O
RARE O
despite O
significant O
sequences O
heterogeneity O
in O
the O
RARE O
repeat O
regions O
of O
these O
human O
and O
RARE O
primate O
RARE O
. O

Results O
of O
the O
ALL_CAP O
RARE O
RARE O
Study O
Group O
. O

Therefore O
, O
a O
prospective O
Phase O
II O
trial O
was O
conducted O
to O
determine O
the O
safety O
and O
efficacy O
of O
RARE O
following O
radiation O
therapy O
in O
men O
with O
local O
recurrence O
. O

These O
motifs O
include O
a O
Chi O
motif O
and O
a O
Chi O
- O
like O
element O
previously O
found O
in O
the O
RARE O
RARE O
region O
of O
the O
Bcl I-GENE
- I-GENE
2 I-GENE
RARE I-GENE
- I-GENE
oncogene I-GENE
and O
close O
to O
chromosomal O
breakpoints O
in O
T O
- O
ALL O
lines O
. O

RARE O
history O
and O
RARE O
in O
surgical O
RARE O
of O
the O
RARE O
and O
the O
RARE O
University O
RARE O

In O
contrast O
with O
the O
previously O
reported O
NUM I-GENE
mRNA I-GENE
( O
NUM I-GENE
mRNA I-GENE
RARE O
which O
is O
detected O
RARE O
high O
levels O
in O
all O
tissues O
of O
the O
RARE O
, O
NUM I-GENE
mRNA I-GENE
is O
present O
RARE O
relatively O
low O
levels O
and O
its O
RARE O
is O
restricted O
mostly O
to O
seedlings O
, O
roots O
and O
RARE O
. O

However O
, O
the O
requirement O
of O
NUM I-GENE
RARE O
the O
production O
of O
G O
. O
C O
RARE O
T O
. O
A O
RARE O
by O
the O
NUM I-GENE
RARE I-GENE
, O
which O
induces O
only O
these O
substitutions O
, O
was O
similar O
to O
that O
RARE O
NUM I-GENE
- O
RARE O
G O
. O
C O
RARE O
T O
. O
A O
transversion O
. O

The O
second O
mutation O
present O
in O
the O
original O
mutant O
proved O
to O
be O
an O
allele O
of O
a O
known O
gene O
, O
NUM I-GENE
, O
which O
encodes O
a O
putative O
protein O
kinase O
that O
functions O
in O
the O
high O
RARE O
stress O
RARE O
. O

In O
adult O
tissues O
, O
it O
was O
less O
restricted O
, O
indicating O
that O
ALL_CAP I-GENE
RARE O
is O
developmentally O
RARE O
- O
regulated O
. O

As O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
) O
does O
not O
contain O
a O
consensus O
sequence O
RARE O
binding O
of O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
, O
ALL_CAP I-GENE
must O
use O
a O
distinct O
mechanism O
RARE O
its O
association O
with O
and O
activation O
of O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

ALL_CAP O
. O

The O
identity O
between O
RARE I-GENE
H I-GENE
and O
H I-GENE
' I-GENE
is O
96 O
%, O
between O
H I-GENE
and O
F I-GENE
NUM O
%, O
and O
between O
H I-GENE
' I-GENE
and O
F I-GENE
NUM O
%, O
respectively O
. O

ALL_CAP I-GENE
has O
two O
RARE O
RARE O
- O
RARE O
regions O
, O
a O
basic O
region O
, O
a O
proline O
- O
rich O
region O
, O
a O
RARE O
- O
rich O
N O
terminus O
, O
and O
a O
nuclear O
targeting O
sequence O
. O

In O
the O
present O
study O
, O
we O
transiently O
RARE O
in O
RARE O
cultures O
of O
rat O
hepatocytes O
plasmids O
consisting O
of O
NUM I-GENE
5 I-GENE
'- I-GENE
flanking I-GENE
sequences I-GENE
fused O
to O
a O
chloramphenicol I-GENE
RARE I-GENE
reporter I-GENE
RARE O
. O

We O
show O
that O
RARE O
of O
resting O
splenic O
B O
cells O
with O
NUM I-GENE
- O
expressing O
Sf9 O
cells O
induces O
RARE O
- O
line O
gamma O
1 O
and O
epsilon O
transcripts O
independently O
of O
RARE O
. O

To O
confirm O
the O
ALL_CAP I-GENE
protein I-GENE
activity O
, O
constructs O
containing O
different O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
domains O
were O
transformed O
into O
RARE I-GENE
mutant O
yeast O
to O
determine O
their O
relative O
ability O
to O
replace O
NUM I-GENE
functionally O
. O

At O
the O
time O
of O
the O
NUM O
RARE O
RARE O
, O
age O
ranged O
from O
three O
days O
to O
NUM O
. O
1 O
years O
( O
mean O
5 O
. O
7 O
+/- O
SD O
4 O
. O
8 O
years O
). O

A O
tobacco O
homologue O
( O
ALL_CAP I-GENE
) O
of O
the O
ALL_CAP I-GENE
gene I-GENE
of I-GENE
the I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
was O
RARE O
and O
sequenced O
from O
RARE O
RARE O
L O
. O
cv O
. O

RARE O
ADR1 I-GENE
gene I-GENE
dosage O
increased O
the O
transcription O
of O
genes O
encoding O
RARE O
proteins O
RARE O
compared O
to O
one O
copy O
of O
the O
ADR1 I-GENE
gene I-GENE
. O

A O
water O
- O
RARE O
RARE O
- O
RARE O
in O
the O
RARE O
RARE O
NUM O
- O
NUM O
. O

Of O
the O
three O
known O
C I-GENE
/ I-GENE
EBP I-GENE
family I-GENE
RARE O
, O
Ig I-GENE
/ I-GENE
EBP I-GENE
, O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
- I-GENE
10 I-GENE
, O
only O
Ig I-GENE
/ I-GENE
EBP I-GENE
is O
ubiquitously O
RARE O
. O

The O
effects O
of O
a O
1 O
- O
or O
NUM O
- O
hour O
pretreatment O
regimen O
with O
RARE O
RARE O
A O
( O
ALL_CAP O
, O
NUM O
micrograms O
/ O
kg O
i O
. O
v O
.) O
on O
RARE O
RARE O
produced O
by O
RARE O
coronary O
RARE O
were O
studied O
in O
RARE O
- O
anesthetized O
dogs O
. O

These O
RARE O
were O
studied O
by O
scanning O
electron O
microscopy O
- O
energy O
RARE O
spectroscopy O
analysis O
( O
ALL_CAP O
- O
ALL_CAP O
) O
and O
light O
microscopy O
to O
examine O
the O
RARE O
lines O
of O
RARE O
in O
the O
rat O
RARE O
RARE O
dentin O
. O

A O
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
- I-GENE
R I-GENE
) O
RARE O
containing O
RARE O
- O
NUM O
does O
not O
bind O
RARE O
to O
the O
Src I-GENE
NUM I-GENE
domain I-GENE
, O
suggesting O
it O
is O
not O
the O
ALL_CAP I-GENE
- I-GENE
R I-GENE
binding O
site O
RARE O
Src I-GENE
RARE O
previously O
reported O
. O

We O
have O
also O
tested O
Src I-GENE
NUM I-GENE
mutants O
RARE O
their O
binding O
properties O
and O
have O
interpreted O
our O
results O
in O
light O
of O
the O
recent O
RARE O
RARE O
solution O
RARE O
the O
Src I-GENE
NUM I-GENE
domain O
. O

These O
observations O
RARE O
actin I-GENE
plaque O
assembly O
to O
increased O
cell O
substrate O
adhesion O
. O

The O
early O
lethality O
of O
the O
RARE O
- O
RARE O
RARE O
was O
NUM O
% O
and O
the O
postoperative O
survival O
RARE O
5 O
- O
10 O
months O
. O

There O
are O
two O
RARE O
sites O
on O
the O
type O
A O
RARE O
A O
/ O
Japan O
/ O
57 O
( O
NUM O
) O
hemagglutinin I-GENE
( O
ALL_CAP I-GENE
) O
that O
can O
be O
RARE O
by O
class I-GENE
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
( O
MHC I-GENE
RARE O
H I-GENE
- I-GENE
NUM I-GENE
- O
restricted O
RARE O
T O
lymphocytes O
( O
RARE O
). O

This O
enhancer O
activates O
both O
the O
NUM I-GENE
and O
TK I-GENE
basal I-GENE
promoters I-GENE
in O
HeLa O
cells O
. O

Mechanism O
of O
enhancement O
of O
DNA O
RARE O
RARE O
to O
RARE O
of O
a O
replication O
- O
RARE O
adenovirus O
and O
RARE O
RARE O
DNA O
. O

Interestingly O
, O
one O
IRF I-GENE
binding I-GENE
site I-GENE
was O
found O
within O
the O
IRF I-GENE
- I-GENE
2 I-GENE
promoter I-GENE
, O
and O
RARE O
of O
the O
IRF I-GENE
- I-GENE
2 I-GENE
gene I-GENE
was O
affected O
by O
both O
transient O
and O
stable O
IRF I-GENE
- I-GENE
1 I-GENE
RARE O
. O

Therefore O
, O
we O
studied O
RARE O
RARE O
patients O
with O
the O
aim O
of O
RARE O
the O
prevalence O
of O
hepatitis I-GENE
C I-GENE
virus I-GENE
( I-GENE
HCV I-GENE
) I-GENE
antibodies I-GENE
using O
the O
ELISA O
and O
ALL_CAP O
methods O
. O

The O
highest O
decrease O
in O
RARE O
activity O
was O
observed O
when O
enzymatic O
RARE O
was O
used O
together O
with O
RARE O
. O

RARE I-GENE
B I-GENE
surface I-GENE
antigen I-GENE
was O
detected O
in O
2 O
patients O
, O
with O
negative O
hepatitis I-GENE
C I-GENE
virus I-GENE
antibody I-GENE
. O

There O
was O
also O
a O
highly O
significant O
correlation O
between O
RARE O
selenium O
intake O
and O
liver O
selenium O
concentration O
( O
RARE O
= O
NUM O
. O
NUM O
, O
p O
< O
NUM O
. O
01 O
) O
after O
1 O
mo O
of O
treatment O
, O
but O
this O
time O
liver O
selenium O
did O
not O
change O
with O
time O
, O
and O
the O
correlation O
remained O
highly O
significant O
throughout O
the O
investigation O
. O

Antibodies O
affinity O
- O
RARE O
using O
the O
bacterially O
RARE O
recombinant O
protein O
RARE O
the O
NUM I-GENE
RARE I-GENE
in O
a O
HeLa O
cell O
RARE O
. O
cDNA O
sequencing O
revealed O
that O
the O
NUM I-GENE
cDNA I-GENE
shares O
a O
high O
degree O
of O
homology O
in O
both O
nucleotide O
( O
87 O
%) O
and O
amino O
acid O
sequence O
( O
92 O
. O
5 O
%) O
with O
bovine I-GENE
RARE I-GENE
ALL_CAP I-GENE
, O
indicating O
that O
the O
NUM I-GENE
cDNA I-GENE
encodes O
the O
human I-GENE
homologue I-GENE
of I-GENE
RARE I-GENE
ALL_CAP I-GENE
, O
a O
RARE O
of O
the O
Ca I-GENE
( I-GENE
2 I-GENE
RARE I-GENE
dependent I-GENE
RARE I-GENE
binding I-GENE
protein I-GENE
family I-GENE
. O

The O
RARE I-GENE
- I-GENE
RARE I-GENE
complex I-GENE
peroxidase I-GENE
( O
ALL_CAP I-GENE
- I-GENE
P I-GENE
) O
method O
was O
used O
to O
detect O
Mycobacterium O
RARE O
, O
and O
the O
results O
were O
compared O
with O
those O
obtained O
by O
the O
RARE O
- O
RARE O
( O
ALL_CAP O
) O
technique O
. O

Its O
role O
in O
these O
processes O
suggests O
that O
the O
function O
of O
c I-GENE
- I-GENE
Myb I-GENE
may O
be O
important O
early O
in O
the O
establishment O
of O
the O
hematopoietic O
lineage O
. O

The O
transforming O
gene O
of O
the O
avian I-GENE
sarcoma I-GENE
virus I-GENE
NUM I-GENE
encodes O
a O
fusion O
protein O
( O
NUM I-GENE
- O
RARE I-GENE
or O
v I-GENE
- I-GENE
Crk I-GENE
) O
containing O
viral I-GENE
Gag I-GENE
sequences I-GENE
fused O
to O
cellular O
sequences O
consisting O
primarily O
of O
Src I-GENE
homology I-GENE
regions I-GENE
2 I-GENE
and I-GENE
3 I-GENE
( O
NUM I-GENE
and O
SH3 I-GENE
sequences I-GENE
). O

This O
specific O
methylation O
pattern O
caused O
inactivation O
of O
the O
HSV I-GENE
tk I-GENE
gene I-GENE
, O
while O
methylation O
of O
the O
cytosine O
residues O
within O
the O
nucleotide O
sequence O
from O
+ O
NUM O
to O
+ O
NUM O
had O
RARE O
effect O
on O
HSV I-GENE
tk I-GENE
gene I-GENE
activity O
. O

CONCLUSION O
: O
This O
study O
RARE O
that O
regression O
of O
RARE O
RARE O
that O
occurred O
with O
alpha I-GENE
RARE I-GENE
treatment O
was O
minimal O
. O

RARE O
- O
range O
mapping O
of O
the O
NUM O
region O
involved O
in O
RARE O
RARE O
in O
human O
tumors O
by O
pulsed O
- O
field O
gel O
electrophoresis O
with O
a O
yeast O
artificial O
RARE O
. O

ALL_CAP O
, O
ALL_CAP O
, O
and O
ALL_CAP O
oligonucleotides O
all O
compete O
more O
efficiently O
RARE O
protein O
binding O
to O
their O
labeled O
RARE O
than O
RARE O
protein O
binding O
to O
either O
of O
the O
other O
labeled O
oligonucleotides O
, O
suggesting O
that O
the O
ALL_CAP O
, O
ALL_CAP O
, O
and O
ALL_CAP O
oligonucleotides O
, O
suggesting O
that O
the O
ALL_CAP O
, O
ALL_CAP O
, O
and O
ALL_CAP O
oligonucleotides O
each O
bind O
unique O
RARE O
RARE O
RARE O
common O
proteins O
, O
likely O
to O
be O
members O
of O
the O
Jun I-GENE
/ O
Fos I-GENE
and O
cAMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
- I-GENE
binding I-GENE
protein I-GENE
/ O
activating I-GENE
transcription I-GENE
factors I-GENE
( O
CREB I-GENE
/ O
ATF I-GENE
) O
RARE O
of O
transcription O
factors O
, O
in O
RARE O
cells O
. O

One O
patient O
only O
had O
any O
test O
abnormalities O
. O

One O
antibody O
, O
NUM I-GENE
, O
and O
a O
RARE O
peptide O
RARE O
its O
RARE O
selectively O
inhibited O
in O
vitro O
transcription O
from O
TATA O
- O
containing O
, O
but O
not O
from O
TATA O
- O
less O
promoters O
, O
irrespective O
of O
whether O
they O
were O
RARE O
by O
Pol I-GENE
II I-GENE
or O
Pol I-GENE
III I-GENE
. O

The O
lymph O
nodes O
from O
two O
of O
the O
patients O
with O
rheumatoid O
arthritis O
contained O
numerous O
RARE O
like O
RARE O
, O
further O
indicating O
a O
possible O
association O
between O
RARE O
and O
rheumatoid O
arthritis O
. O

HCV O
infection O
acquired O
RARE O
or O
after O
ALL_CAP O
caused O
only O
mild O
acute O
hepatitis O
C O
, O
which O
progressed O
to O
chronic O
hepatitis O
C O
in O
one O
patient O
RARE O
10 O
years O
after O
ALL_CAP O
. O

RARE O
C O
virus O
infection O
is O
a O
risk O
factor O
RARE O
liver O
failure O
from O
RARE O
- O
RARE O
RARE O
after O
bone O
marrow O
transplantation O
. O

RARE O
plasma O
concentrations O
of O
RARE O
E I-GENE
- I-GENE
selectin I-GENE
were O
closely O
associated O
with O
multiple O
- O
organ O
dysfunction O
and O
RARE O
. O

These O
human O
IFN I-GENE
- I-GENE
beta I-GENE
- O
transformed O
cell O
populations O
have O
acquired O
a O
low O
, O
RARE O
production O
of O
human I-GENE
IFN I-GENE
, O
while O
RARE O
RARE O
a O
rate O
similar O
to O
that O
of O
RARE O
cells O
and O
of O
cells O
transformed O
with O
the O
control O
vector O
carrying O
a O
human I-GENE
IFN I-GENE
- I-GENE
beta I-GENE
sequence I-GENE
encoding O
an O
inactive O
, O
RARE O
protein O
. O

RARE O
of O
the O
RARE O
RARE O
also O
increased O
the O
RARE O
efficiency O
, O
but O
to O
a O
degree O
slightly O
less O
than O
that O
obtained O
with O
the O
branchpoint O
mutation O
. O

Liver O
transplantation O
in O
one O
patient O
resolved O
metabolic O
complications O
but O
did O
not O
improve O
ALL_CAP O
count O
or O
the O
infectious O
status O
, O
while O
neutropenia O
was O
corrected O
by O
G I-GENE
- I-GENE
CSF I-GENE
. O

RARE O
and O
F O
. O

Activation O
of O
the O
NUM I-GENE
- I-GENE
containing I-GENE
protein I-GENE
tyrosine I-GENE
phosphatase I-GENE
, O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
by O
RARE O
- O
containing O
peptides O
derived O
from O
insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
1 I-GENE
. O

RARE O
RARE O
of O
cellular O
proteins O
is O
the O
RARE O
RARE O
event O
following O
T I-GENE
- I-GENE
cell I-GENE
antigen I-GENE
receptor I-GENE
( O
TCR I-GENE
) O
RARE O
and O
is O
essential O
RARE O
activating O
RARE O
RARE O
machinery O
. O

The O
RARE I-GENE
- O
RARE O
RNA I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
PKR I-GENE
) O
is O
considered O
to O
play O
an O
important O
role O
in O
the O
cellular O
defense O
against O
viral O
infection O
and O
, O
in O
addition O
, O
has O
been O
suggested O
to O
be O
a O
tumor O
suppressor O
gene O
because O
of O
its O
growth O
- O
RARE O
properties O
. O

Moreover O
, O
RARE I-GENE
was O
RARE O
RARE O
- O
immunoprecipitated O
with O
NUM I-GENE
, O
and O
the O
RARE O
of O
binding O
increased O
in O
anti I-GENE
- I-GENE
CD3 I-GENE
- O
treated O
Jurkat O
cells O
. O

In O
contrast O
, O
injection O
of O
a O
RARE O
encoding O
simian I-GENE
virus I-GENE
40 I-GENE
small I-GENE
t I-GENE
antigen I-GENE
, O
which O
interacts O
with O
PP2A I-GENE
to O
inhibit O
its O
activity O
towards O
several O
RARE O
RARE O
, O
had O
RARE O
effect O
on O
the O
RARE O
state O
of O
CREB I-GENE
in O
RARE O
or O
unstimulated O
ALL_CAP O
3T3 O
cells O
. O

Several O
Src I-GENE
SH3 I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
were O
RARE O
in O
Src I-GENE
- O
transformed O
cells O
. O

We O
also O
examined O
the O
effect O
of O
RARE O
RARE O
in O
the O
ALL_CAP O
RARE O
RARE O
segment O
RARE O
by O
the O
viral I-GENE
RARE I-GENE
NUM I-GENE
on O
antigen O
RARE O
and O
presentation O
of O
the O
ALL_CAP O
H O
- O
NUM O
- O
restricted O
T O
cell O
determinant O
. O

A O
full I-GENE
- I-GENE
length I-GENE
PRL I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
) O
RARE O
DNA O
from O
RARE O
was O
obtained O
by O
screening O
RARE O
RARE O
RARE O
libraries O
and O
by O
reverse O
transcription O
coupled O
with O
polymerase O
chain O
reaction O
. O

After O
7 O
days O
, O
a O
spontaneous O
regression O
of O
the O
morphologic O
alterations O
caused O
by O
RARE O
- O
RARE O
acute O
pancreatitis O
occurs O
; O
however O
, O
recovery O
of O
the O
RARE O
function O
of O
the O
pancreas O
was O
only O
reached O
after O
this O
period O
of O
time O
when O
L O
- O
NUM O
, O
NUM O
was O
administered O
RARE O
( O
NUM O
. O
1 O
mg O
/ O
kg O
/ O
day O
). O

We O
observed O
that O
RARE O
severely O
inhibits O
the O
DNA O
- O
binding O
ability O
of O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
delta I-GENE
and O
its O
transactivating O
RARE O
increases O
in O
the O
presence O
of O
cellular O
phosphatase O
RARE O
, O
such O
RARE O
RARE O
acid O
and O
RARE O
RARE O
. O

Two O
promoters O
were O
identified O
by O
S1 I-GENE
RARE I-GENE
mapping O
: O
P1 O
, O
which O
lies O
about O
72 O
bp O
upstream O
from O
the O
structural O
gene O
; O
and O
P2 O
, O
which O
lies O
about O
NUM O
bp O
upstream O
. O

Interleukin I-GENE
- I-GENE
8 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
8 I-GENE
) O
is O
a O
potent O
inflammatory O
RARE O
that O
belongs O
to O
the O
family O
of O
C I-GENE
- I-GENE
X I-GENE
- I-GENE
C I-GENE
RARE I-GENE
. O

On O
the O
other O
RARE O
, O
cells O
containing O
a O
NUM I-GENE
in O
which O
the O
catalytic O
site O
had O
been O
inactivated O
through O
mutagenesis O
, O
stably O
RARE O
the O
phosphatase O
. O

We O
recently O
found O
that O
the O
NUM I-GENE
protein I-GENE
tyrosine I-GENE
kinase I-GENE
is O
physically O
associated O
with O
the O
TCR I-GENE
/ O
CD3 I-GENE
complex O
and O
is O
rapidly O
tyrosine O
RARE O
and O
activated O
by O
receptor O
RARE O
also O
in O
T O
cells O
RARE O
NUM I-GENE
. O

The O
transforming O
protein O
of O
RARE O
sarcoma O
virus O
, O
NUM I-GENE
- I-GENE
src I-GENE
, O
and O
its O
normal O
cellular O
homolog O
, O
NUM I-GENE
- I-GENE
src I-GENE
, O
differ O
not O
only O
in O
RARE O
RARE O
but O
also O
in O
their O
subcellular O
RARE O
and O
cytoskeletal O
binding O
ability O
. O
NUM I-GENE
- I-GENE
src I-GENE
has O
been O
shown O
to O
stably O
associate O
with O
a O
detergent O
- O
RARE O
cytoskeletal O
RARE O
, O
whereas O
NUM I-GENE
- I-GENE
src I-GENE
does O
not O
. O

Organization O
of O
the O
bovine O
gene O
encoding O
the O
endothelial I-GENE
RARE I-GENE
oxide I-GENE
synthase I-GENE
. O

We O
determined O
whether O
regional O
RARE O
work O
efficiency O
( O
segment O
work O
/ O
regional O
NUM O
consumption O
) O
would O
be O
elevated O
by O
surgically O
- O
augmented O
RARE O
. O

In O
female O
RARE I-GENE
( I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
( I-GENE
RARE I-GENE
) I-GENE
mice O
, O
ovarian O
RARE O
development O
is O
arrested O
RARE O
the O
one O
RARE O
RARE O
RARE O
RARE O
a O
result O
of O
RARE O
ALL_CAP I-GENE
RARE O
in O
RARE O
cells O
, O
indicating O
a O
role O
RARE O
c I-GENE
- I-GENE
kit I-GENE
in O
RARE O
growth O
. O

RARE I-GENE
- I-GENE
ALL_CAP I-GENE
- I-GENE
C I-GENE
also O
exclusively O
detected O
time O
- O
dependent O
RARE O
of O
5 I-GENE
- I-GENE
10 I-GENE
- I-GENE
kDa I-GENE
ALL_CAP I-GENE
- I-GENE
C I-GENE
forms O
in O
RARE O
RARE O
and O
RARE O
. O

In O
the O
NUM O
- O
derived O
RARE I-GENE
mutant I-GENE
NUM I-GENE
. I-GENE
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
( I-GENE
NUM I-GENE
) I-GENE
RARE O
, O
part O
of O
the O
class I-GENE
I I-GENE
RARE I-GENE
antigen I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
is O
shaped O
by O
a O
class I-GENE
I I-GENE
RARE I-GENE
- I-GENE
encoded I-GENE
sequence I-GENE
. O

Three O
mutants O
( O
NUM I-GENE
, O
NUM I-GENE
and O
NUM I-GENE
) O
isolated O
earlier O
from O
NUM O
- O
NUM O
were O
shown O
to O
correct O
in O
vitro O
constructed O
plasmids O
with O
defined O
DNA O
RARE O
( O
G O
/ O
T O
, O
A O
/ O
C O
, O
G O
/ O
G O
, O
etc O
.) O
poorly O
( O
RARE O
et O
al O
., O
NUM O
). O

Our O
findings O
confirm O
the O
high O
frequency O
of O
proximal O
nerve O
lesions O
in O
early O
ALL_CAP O
and O
ALL_CAP O
, O
not O
all O
of O
which O
are O
associated O
with O
distal O
motor O
conduction O
abnormalities O
, O
and O
suggest O
that O
assessment O
of O
multiple O
F O
wave O
parameters O
, O
in O
particular O
RARE O
, O
mean O
RARE O
and O
mean O
amplitude O
( O
in O
addition O
to O
absence O
and O
minimum O
RARE O
RARE O
increases O
the O
yield O
of O
F O
wave O
studies O
. O

RARE I-GENE
growth I-GENE
factors I-GENE
are O
being O
used O
to O
RARE O
the O
recovery O
of O
RARE O
following O
high O
- O
dose O
chemotherapy O
in O
RARE O
patients O
. O

Effects O
of O
alterations O
of O
primer O
- O
binding O
site O
sequences O
on O
human O
immunodeficiency O
virus O
type O
1 O
replication O
. O

RARE O
of O
a O
RARE I-GENE
cytochrome I-GENE
c I-GENE
peptide I-GENE
by O
multiple O
H I-GENE
- I-GENE
NUM I-GENE
class I-GENE
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
( O
MHC I-GENE
) O
molecules O
to O
C57BL O
/ O
6 O
- O
and O
NUM O
- O
derived O
cytotoxic O
T O
lymphocytes O
: O
presence O
of O
a O
single O
MHC I-GENE
RARE I-GENE
RARE I-GENE
may O
confer O
efficient O
peptide O
- O
specific O
CTL O
recognition O
. O

A O
particularly O
striking O
ALL_CAP I-GENE
RARE O
fragment O
island O
, O
extending O
over O
nearly O
2 O
, O
NUM O
RARE O
RARE O
, O
RARE O
the O
NUM I-GENE
translation I-GENE
initiation I-GENE
site I-GENE
. O

Diagnosis O
of O
RARE O
carcinoma O
: O
the O
yield O
of O
serum I-GENE
RARE I-GENE
specific I-GENE
antigen I-GENE
, O
digital O
rectal O
examination O
and O
RARE O
ultrasonography O
. O

Increased O
RARE I-GENE
- I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
( O
G I-GENE
- I-GENE
CSF I-GENE
) O
levels O
in O
neonates O
with O
RARE O
complications O
. O

The O
results O
revealed O
a O
RARE O
of O
RARE O
affinities O
that O
RARE O
their O
adhesive O
activity O
( O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
> O
fibronectin I-GENE
variants I-GENE
containing O
NUM I-GENE
RARE O
other O
fibronectin I-GENE
variants I-GENE
). O

When O
RARE O
in O
and O
RARE O
from O
Escherichia O
coli O
, O
both O
full I-GENE
- I-GENE
length I-GENE
NUM I-GENE
and O
its O
isolated O
ALL_CAP O
- O
terminal O
domain O
exhibit O
readily O
detectable O
RARE I-GENE
activity O
. O

RARE O
of O
H I-GENE
- I-GENE
NUM I-GENE
or I-GENE
H I-GENE
- I-GENE
NUM I-GENE
ALL_CAP I-GENE
peptides I-GENE
indicated O
that O
3 O
- O
4 O
RARE O
less O
H I-GENE
- I-GENE
NUM I-GENE
ALL_CAP I-GENE
peptide I-GENE
was O
required O
to O
RARE O
RARE O
target O
cells O
RARE O
CTL O
- O
specific O
lysis O
, O
suggesting O
that O
the O
RARE O
affinities O
of O
H O
- O
NUM O
and O
H O
- O
NUM O
major I-GENE
histocompatibility I-GENE
complex I-GENE
molecules I-GENE
RARE O
their O
peptides O
likely O
account O
RARE O
the O
RARE O
removal O
of O
ALL_CAP O
CTL O
in O
the O
H O
- O
NUM O
mice O
but O
only O
partial O
removal O
in O
H O
- O
NUM O
mice O
made O
to O
express O
RARE O
ALL_CAP O
. O

However O
, O
RARE O
of O
RARE I-GENE
3 I-GENE
from O
NUM I-GENE
( O
3 I-GENE
' I-GENE
UTR I-GENE
/ I-GENE
S1 I-GENE
RARE O
which O
included O
the O
PKR I-GENE
activator I-GENE
sequence I-GENE
from O
S1 I-GENE
within O
the O
3 I-GENE
'- I-GENE
UTR I-GENE
of I-GENE
NUM I-GENE
, O
was O
comparable O
to O
that O
from O
wild I-GENE
- I-GENE
type I-GENE
NUM I-GENE
. O

RARE O
were O
RARE O
in O
a O
NUM O
field O
( O
NUM O
. O
NUM O
mm2 O
) O
in O
the O
area O
of O
maximal O
angiogenesis O
. O

Although O
both O
transfected O
cell O
lines O
contain O
FGF I-GENE
- I-GENE
1 I-GENE
cell I-GENE
surface I-GENE
receptors I-GENE
RARE O
judged O
by O
RARE O
studies O
, O
the O
wild O
- O
type O
transfectants O
are O
refractory O
to O
RARE O
FGF I-GENE
- I-GENE
1 I-GENE
, O
whereas O
the O
mutant O
transfectants O
respond O
normally O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

Recent O
studies O
have O
demonstrated O
that O
the O
activated O
ALL_CAP I-GENE
receptor I-GENE
can O
stimulate O
NUM I-GENE
, O
a O
cytoplasmic O
transcription O
factor O
that O
becomes O
tyrosine O
RARE O
and O
RARE O
to O
the O
nucleus O
, O
where O
it O
can O
interact O
with O
specific O
DNA O
sequences O
to O
modulate O
gene O
RARE O
. O

In O
viral O
infections O
, O
G I-GENE
- I-GENE
CSF I-GENE
was O
correlated O
with O
mononuclear O
cells O
( O
rs O
= O
NUM O
. O
NUM O
, O
P O
< O
NUM O
. O
05 O
RARE O
RARE O
RARE O
cell O
counts O
( O
rs O
= O
NUM O
. O
NUM O
, O
P O
< O
NUM O
. O
01 O
RARE O
neutrophils O
( O
rs O
= O
NUM O
. O
NUM O
, O
P O
< O
NUM O
. O
05 O
) O
and O
CRP I-GENE
( O
rs O
= O
NUM O
. O
NUM O
, O
P O
< O
NUM O
. O
05 O
). O

RARE O
initiation O
sites O
were O
found O
RARE O
positions O
- O
NUM O
, O
- O
111 O
, O
- O
91 O
, O
and O
- O
NUM O
. O

RARE O
acid O
analysis O
of O
radiolabeled O
ALL_CAP I-GENE
subunits I-GENE
identified O
RARE O
( O
P O
) O
RARE O
the O
predominant O
( O
RARE O
NUM O
%) O
and O
RARE O
( O
P O
) O
RARE O
a O
minor O
( O
RARE O
5 O
%) O
RARE O
acid O
in O
each O
polypeptide O
and O
confirmed O
the O
presence O
of O
RARE O
( O
P O
) O
( O
RARE O
1 O
%) O
in O
NUM I-GENE
. O

To O
further O
define O
the O
structural O
requirements O
RARE O
ALL_CAP I-GENE
- I-GENE
70 I-GENE
interaction O
with O
the O
TCR I-GENE
, O
we O
developed O
a O
binding O
assay O
using O
RARE O
RARE I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion I-GENE
proteins I-GENE
containing O
the O
NH2 O
- O
and O
/ O
or O
ALL_CAP I-GENE
- I-GENE
terminal I-GENE
NUM I-GENE
domains I-GENE
of O
ALL_CAP I-GENE
- I-GENE
70 I-GENE
, O
and O
RARE O
RARE O
peptides O
with O
the O
sequence O
of O
the O
cytoplasmic O
region O
of O
the O
TCR I-GENE
RARE I-GENE
chain I-GENE
( O
TCR I-GENE
RARE I-GENE
RARE I-GENE
) O
or O
individual O
TCR I-GENE
RARE I-GENE
and O
CD3 I-GENE
epsilon I-GENE
ALL_CAP I-GENE
motifs I-GENE
. O

All O
four O
RARE O
tyrosine O
RARE O
ALL_CAP O
peptides O
cross O
- O
compete O
with O
each O
other O
RARE O
binding O
to O
the O
RARE O
NUM I-GENE
domains I-GENE
of O
ALL_CAP I-GENE
- I-GENE
70 I-GENE
. O

The O
three O
- O
dimensional O
RARE O
of O
RT I-GENE
shows O
that O
it O
is O
a O
strikingly O
asymmetric O
RARE O
consisting O
of O
two O
differently O
folded O
subunits O
( O
RARE O
weights O
NUM O
kDa O
and O
NUM O
kDa O
) O
with O
identical O
amino O
- O
terminal O
amino O
acid O
sequences O
( O
residues O
1 O
- O
NUM O
). O

RARE O
and O
pharmacokinetic O
characteristics O
of O
the O
non O
- O
ionic O
RARE O
X O
- O
ray O
contrast O
agent O
RARE O
( O
RARE O
, O
ALL_CAP O
NUM O
- O
07 O
- O
3 O
) O
were O
evaluated O
in O
RARE O
studies O
. O

All O
subsequent O
patients O
were O
treated O
RARE O
the O
maximal O
tolerated O
dose O
of O
ALL_CAP O
( O
NUM O
mg O
/ O
m2 O
/ O
day O
). O

The O
median O
post O
- O
treatment O
, O
pre O
- O
operative O
serum I-GENE
PSA I-GENE
was O
NUM O
. O
4 O
RARE O
/ O
ml O
. O

Addition O
of O
RARE O
recombinant I-GENE
human I-GENE
ALL_CAP I-GENE
to O
NUM O
- O
NUM O
cultures O
RARE O
reduction O
of O
cell O
- O
surface O
c I-GENE
- I-GENE
kit I-GENE
RARE O
and O
its O
protein O
RARE O
. O

RARE O
- O
RARE O
RARE I-GENE
factor I-GENE
induces O
more O
persistent O
tyrosine I-GENE
kinase I-GENE
activation O
and O
longer O
life O
span O
of O
c I-GENE
- I-GENE
kit I-GENE
gene O
- O
encoded O
protein O
than O
its O
RARE O
form O
. O

Analysis O
of O
the O
sequences O
with O
the O
ALL_CAP O
and O
ALL_CAP O
programs O
provided O
additional O
independent O
evidence O
that O
NUM O
of O
these O
NUM O
RARE O
contain O
coding O
sequences O
and O
that O
nine O
other O
RARE O
are O
likely O
to O
contain O
sequences O
coding O
RARE O
portions O
of O
new O
genes O
. O

Patients O
with O
more O
than O
NUM O
ALL_CAP O
/ O
NUM O
hours O
were O
RARE O
RARE O
distribution O
of O
ALL_CAP O
and O
ALL_CAP O
evaluation O
. O

RARE O
, O
I O
. O

Cell O
lines O
derived O
from O
the O
tumors O
were O
examined O
by O
RARE O
in O
situ O
hybridization O
RARE O
the O
status O
of O
the O
transferred O
human O
RARE O
and O
by O
PCR O
RARE O
marker O
RARE O
. O

The O
amino O
acid O
sequences O
of O
the O
predicted O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
homologs I-GENE
showed O
identities O
of O
NUM O
. O
7 O
% O
( O
87 O
. O
9 O
% O
RARE O
RARE O
) O
and O
NUM O
. O
NUM O
% O
( O
NUM O
. O
5 O
% O
RARE O
RARE O
RARE O
respectively O
. O

However O
, O
multiple O
alanine O
substitutions O
or O
proline O
( O
helix O
- O
RARE O
) O
substitutions O
disrupted O
both O
oligomerization O
and O
RARE O
of O
NUM I-GENE
ALL_CAP I-GENE
. O

The O
ALL_CAP I-GENE
protein I-GENE
of O
ALL_CAP O
plasmids O
binds O
ALL_CAP I-GENE
RARE I-GENE
RNA I-GENE
and O
its O
target O
, O
ALL_CAP I-GENE
mRNA I-GENE
, O
and O
promotes O
duplex O
formation O
. O

In O
this O
paper O
we O
report O
that O
RARE O
binding O
RARE O
tyrosine O
RARE O
in O
NUM O
cells O
RARE O
to O
express O
the O
murine I-GENE
RARE I-GENE
receptor I-GENE
( O
NUM O
/ O
RARE I-GENE
). O

A O
chicken I-GENE
paxillin I-GENE
cDNA I-GENE
was O
also O
RARE O
and O
is O
predicted O
to O
encode O
a O
protein O
RARE O
NUM O
% O
identical O
to O
human I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
. O

We O
RARE O
a O
4 O
. O
1 O
- O
RARE O
RARE O
HindIII I-GENE
DNA I-GENE
fragment I-GENE
from O
the O
region O
upstream O
of O
the O
human I-GENE
AP I-GENE
endonuclease I-GENE
gene I-GENE
( O
ALL_CAP I-GENE
) O
to O
the O
chloramphenicol I-GENE
RARE I-GENE
( O
CAT I-GENE
) O
gene O
. O

The O
overexpressed O
NUM I-GENE
- I-GENE
RARE I-GENE
ALL_CAP I-GENE
RARE I-GENE
were O
affinity O
- O
RARE O
, O
and O
the O
catalytic O
properties O
of O
the O
deletion O
mutants O
were O
examined O
by O
biochemical O
studies O
including O
ATP O
- O
dependent O
amino O
acid O
activation O
, O
RARE O
RARE O
formation O
, O
and O
the O
ability O
to O
RARE O
the O
covalently O
RARE O
RARE O
from O
L O
- O
to O
the O
D O
- O
RARE O
. O

NUM I-GENE
RARE O
CD3 I-GENE
- O
T O
- O
cell O
RARE O
exhibit O
V I-GENE
delta I-GENE
NUM I-GENE
delta I-GENE
3 I-GENE
RARE I-GENE
. O

NUM I-GENE
mRNA I-GENE
showed O
an O
RARE O
pattern O
distinct O
from O
NUM I-GENE
( O
human I-GENE
homologue I-GENE
of I-GENE
mouse I-GENE
NUM I-GENE
) O
and O
NUM I-GENE
, O
two O
previously O
identified O
MAP I-GENE
kinase I-GENE
RARE I-GENE
. O

These O
data O
suggest O
that O
these O
sequences O
RARE O
immediately O
3 O
' O
to O
the O
RARE O
of O
the O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
deletion I-GENE
, O
exhibit O
both O
the O
RARE O
and O
the O
function O
of O
an O
enhancer O
, O
and O
can O
modify O
the O
developmental O
RARE O
of O
the O
RARE I-GENE
gamma I-GENE
- I-GENE
globin I-GENE
genes I-GENE
, O
resulting O
in O
their O
continued O
RARE O
RARE O
adult O
life O
. O

In O
vivo O
association O
between O
RARE I-GENE
- O
SH3 I-GENE
domain O
proteins O
v I-GENE
- I-GENE
Src I-GENE
and O
NUM I-GENE
was O
detected O
by O
RARE O
. O

Our O
results O
indicate O
that O
interaction O
between O
NUM I-GENE
and O
ALL_CAP I-GENE
requires O
a O
proline O
- O
rich O
sequence O
in O
the O
membrane O
proximal O
region O
of O
the O
receptor O
, O
which O
is O
RARE O
among O
the O
different O
members O
of O
the O
RARE I-GENE
receptor I-GENE
superfamily I-GENE
. O

Transcription O
of O
the O
vascular I-GENE
cell I-GENE
adhesion I-GENE
molecule I-GENE
1 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
) O
gene O
in O
endothelial O
cells O
is O
RARE O
by O
lipopolysaccharide O
and O
the O
inflammatory O
RARE I-GENE
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
and O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
( O
TNF I-GENE
- I-GENE
alpha I-GENE
). O

Experiments O
with O
recombinant O
proteins O
showed O
that O
NUM I-GENE
/ O
NUM I-GENE
and O
high I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
I I-GENE
( I-GENE
Y I-GENE
) I-GENE
protein I-GENE
RARE O
facilitated O
the O
binding O
of O
IRF I-GENE
- I-GENE
1 I-GENE
to O
the O
NUM I-GENE
IRF I-GENE
binding I-GENE
site I-GENE
and O
that O
IRF I-GENE
- I-GENE
1 I-GENE
physically O
interacted O
with O
NUM I-GENE
and O
with O
high I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
I I-GENE
( I-GENE
Y I-GENE
) I-GENE
protein I-GENE
. O

Based O
on O
these O
results O
the O
minimal O
control O
element O
( O
ALL_CAP O
NUM O
) O
RARE O
the O
anterior O
boundary O
of O
Hox I-GENE
RARE O
was O
designated O
RARE O
RARE I-GENE
- I-GENE
7 I-GENE
enhancer I-GENE
. O

In O
this O
report O
we O
describe O
the O
isolation O
of O
a O
RARE I-GENE
fragment I-GENE
( O
RARE I-GENE
NUM I-GENE
) O
showing O
a O
high O
relative O
affinity O
RARE O
the O
receptor O
( O
NUM O
. O
5 O
nM O
). O

MBP I-GENE
- O
NUM I-GENE
delta I-GENE
- O
RARE O
DNA O
- O
RNA O
RARE O
activity O
required O
ATP O
hydrolysis O
and O
the O
presence O
of O
NUM O
+ O
ions O
and O
was O
inhibited O
by O
high O
ionic O
strength O
. O

To O
identify O
critical O
regions O
mediating O
growth O
signal O
RARE O
by O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
, O
deletions O
or O
site O
- O
directed O
amino O
acid O
substitutions O
were O
introduced O
into O
the O
cytoplasmic O
domain O
of O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
, O
and O
the O
mutant O
cDNAs O
were O
transfected O
into O
the O
murine I-GENE
interleukin I-GENE
- I-GENE
3 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
)- O
dependent O
RARE O
/ O
NUM O
and O
ALL_CAP O
cell O
lines O
. O

When O
combined O
with O
independent O
activating O
mutations O
in O
the O
c I-GENE
- I-GENE
abl I-GENE
kinase I-GENE
domain I-GENE
or O
NH2 O
- O
terminus O
, O
the O
NUM I-GENE
mutation O
blocked O
transformation O
by O
the O
double O
mutant O
, O
suggesting O
that O
the O
NUM I-GENE
mutant I-GENE
was O
unable O
to O
transform O
cells O
RARE O
RARE O
RARE O
. O

Both O
mutations O
completely O
abolished O
binding O
of O
the O
Abl I-GENE
SH3 I-GENE
domain O
to O
proline O
- O
rich O
target O
proteins O
in O
a O
filter O
- O
binding O
assay O
. O

Changes O
RARE O
in O
the O
RARE O
of O
RARE O
( O
RARE O
RARE O
RARE O
) O
RARE O
after O
acute O
exposure O
to O
RARE O
( O
RARE O
; O
P O
- O
NUM O
). O

RARE O
of O
these O
2 O
dogs O
resulted O
in O
a O
similar O
, O
but O
RARE O
, O
response O
to O
human I-GENE
immunoglobulin I-GENE
. O

The O
levels O
of O
ALL_CAP I-GENE
and O
MBP I-GENE
in O
the O
ALL_CAP O
were O
compared O
to O
those O
in O
the O
ALL_CAP O
. O

As O
expected O
, O
the O
insulin I-GENE
effect O
to O
increase O
ras I-GENE
GTP I-GENE
formation O
and O
MAP I-GENE
kinase I-GENE
activity O
was O
RARE O
in O
A O
/ O
NUM O
cells O
but O
normal O
, O
or O
RARE O
, O
in O
Y O
/ O
F2 O
cells O
. O

RARE O
variables O
included O
RARE O
volume O
, O
histologic O
grade O
, O
RARE O
penetration O
, O
RARE O
vesicle O
invasion O
, O
and O
lymph O
node O
metastasis O
. O

Sequence O
analysis O
of O
these O
regions O
showed O
a O
CAAT O
box O
upstream O
of O
RARE O
NUM O
and O
high O
G O
- O
C O
content O
regions O
within O
both O
P1 O
and O
P2 O
. O

The O
fusion O
proteins O
were O
tested O
by O
ELISA O
RARE O
reactivity O
with O
a O
panel O
of O
human I-GENE
anti I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
in O
order O
to O
define O
the O
nature O
of O
the O
RARE O
. O

NUM I-GENE
was O
RARE O
identified O
genetically O
RARE O
a O
translational O
repressor O
of O
GCN4 I-GENE
. O

NUM I-GENE
binds O
RNA O
in O
vitro O
and O
we O
present O
strong O
biochemical O
evidence O
that O
it O
is O
identical O
to O
the O
RNA O
- O
binding O
subunit O
of O
yeast I-GENE
initiation I-GENE
factor I-GENE
- I-GENE
3 I-GENE
( O
eIF I-GENE
- I-GENE
3 I-GENE
). O
eIF I-GENE
- I-GENE
3 I-GENE
is O
a O
RARE O
complex O
that O
stimulates O
translation O
initiation O
in O
vitro O
RARE O
several O
different O
steps O
. O

RARE O
of O
noise O
in O
these O
signals O
were O
evaluated O
in O
preparations O
stained O
with O
the O
RARE O
probe O
ALL_CAP O
- O
NUM O
. O

1993 O
. O

A O
transformation O
- O
competent O
mutant O
, O
like O
the O
wild I-GENE
- I-GENE
type I-GENE
NUM I-GENE
protein I-GENE
, O
RARE O
the O
receptor O
and O
RARE O
receptor O
tyrosine O
RARE O
and O
down O
- O
RARE O
. O

We O
conclude O
that O
cAMP O
, O
acting O
through O
PKA I-GENE
, O
is O
an O
essential O
regulator O
of O
basal O
CFTR I-GENE
gene I-GENE
RARE O
and O
may O
mediate O
an O
induction O
of O
CFTR I-GENE
in O
responsive O
cell O
RARE O
. O

RARE O
RARE O
sites O
allow O
one O
to O
insert O
virtually O
any O
RARE O
cDNA O
fragment O
directly O
behind O
the O
RARE O
- O
specific O
sequence O
and O
before O
a O
long O
RARE O
( O
A O
) O
RARE O
. O

Both O
ALL_CAP O
- O
1 O
and O
ALL_CAP O
- O
NUM O
cells O
display O
tumorigenesis O
and O
RARE O
in O
nude O
mice O
, O
whereas O
RARE O
cells O
exhibit O
a O
less O
malignant O
RARE O
, O
suggesting O
a O
correlation O
between O
CD44 I-GENE
variant I-GENE
( O
NUM I-GENE
) O
RARE O
and O
aggressive O
RARE O
tumor O
behavior O
. O

The O
gene O
product O
of O
ALL_CAP I-GENE
was O
confirmed O
to O
be O
identical O
to O
NUM I-GENE
- I-GENE
2 I-GENE
by O
SDS O
- O
PAGE O
and O
RARE O
from O
Escherichia O
coli O
transformed O
with O
a O
RARE O
containing O
the O
ALL_CAP I-GENE
region I-GENE
. O

Two O
such O
genes O
, O
designated O
NUM I-GENE
and O
NUM I-GENE
, O
were O
RARE O
and O
sequenced O
from O
genomic O
DNA O
. O

A O
retrospective O
epidemiological O
study O
is O
reported O
concerning O
burn O
injuries O
in O
NUM O
children O
hospitalized O
RARE O
the O
unit O
of O
burn O
care O
of O
RARE O
between O
1985 O
and O
1993 O
. O

Our O
results O
suggest O
that O
protein O
binding O
to O
the O
E2F I-GENE
- I-GENE
like I-GENE
sequences I-GENE
may O
act O
to O
reduce O
RARE O
. O

The O
NUM I-GENE
/ O
NUM I-GENE
gene O
from O
Saccharomyces O
cerevisiae O
encodes O
a O
ubiquitin I-GENE
- I-GENE
RARE I-GENE
enzyme I-GENE
involved O
in O
DNA O
repair O
, O
RARE O
mutagenesis O
, O
and O
RARE O
. O

RARE O
revealed O
right O
ventricular O
diastolic O
RARE O
( O
ALL_CAP O
) O
without O
physical O
signs O
of O
cardiac O
RARE O
. O

In O
on O
- O
RARE O
screening O
RARE O
, O
the O
RARE O
test O
consists O
of O
RARE O
RARE O
and O
a O
test O
is O
considered O
positive O
if O
RARE O
least O
one O
RARE O
is O
RARE O
. O

We O
showed O
previously O
that O
a O
fusion O
protein O
( O
GAL4 I-GENE
- O
p40 I-GENE
) O
containing O
the O
DNA O
- O
binding O
domain O
of O
GAL4 I-GENE
and O
sequences O
of O
chicken I-GENE
RARE I-GENE
RARE I-GENE
B I-GENE
- I-GENE
alpha I-GENE
( O
p40 I-GENE
) O
inhibits O
growth O
in O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

We O
have O
demonstrated O
previously O
that O
two O
binding O
sites O
in O
the O
- I-GENE
NUM I-GENE
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
promoter I-GENE
are O
RARE O
by O
widely O
distributed O
factors O
and O
that O
there O
is O
also O
a O
critical O
RARE O
site O
, O
we O
identified O
a O
binding O
site O
RARE O
a O
cell O
- O
specific O
factor O
, O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
beta I-GENE
, O
that O
may O
function O
in O
RARE O
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
gene I-GENE
RARE O
to O
hepatocytes O
. O

In O
4 O
RARE O
cats O
, O
the O
effects O
of O
RARE O
inputs O
from O
RARE O
cutaneous O
nerves O
( O
RARE O
cutaneous O
nerve O
: O
RARE O
) O
on O
mono O
- O
and O
RARE O
- O
synaptic O
reflex O
recorded O
from O
RARE O
muscle O
RARE O
were O
studied O
before O
and O
after O
RARE O
RARE O
RARE O
NUM O
- O
3 O
level O
. O

The O
flow O
rate O
of O
phosphate O
RARE O
saline O
through O
RARE O
was O
measured O
RARE O
a O
function O
of O
applied O
pressure O
. O

However O
, O
RARE O
measurements O
showed O
that O
RARE O
NUM O
, O
RARE O
of O
RARE O
sections O
does O
not O
take O
place O
. O

Although O
within O
normal O
limits O
, O
RARE O
was O
high O
. O

The O
outcome O
of O
the O
RARE O
of O
the O
RARE O
- O
field O
RARE O
RARE O
an O
investigation O
into O
the O
best O
results O
that O
could O
be O
achieved O
by O
an O
" O
RARE O
" O
RARE O
radiotherapy O
technique O
. O

Specific O
requirements O
RARE O
RARE O
- O
chain O
amino O
RARE O
, O
RARE O
, O
and O
RARE O
are O
evaluated O
. O

The O
RARE I-GENE
NUM I-GENE
intron I-GENE
is O
homologous O
to O
RARE O
in O
NUM I-GENE
and O
NUM I-GENE
in O
the O
RARE O
mitochondrial O
genome O
, O
while O
the O
RARE I-GENE
NUM I-GENE
gene I-GENE
lacks O
an O
intron O
. O

The O
optimal O
care O
of O
ALL_CAP O
patient O
includes O
the O
recognition O
and O
management O
of O
these O
RARE O
disturbances O
. O

Serum O
magnesium O
in O
NUM O
patients O
of O
gynecologic O
neoplasms O
treated O
with O
cisplatin O
and O
their O
controls O
was O
measured O
. O

METHODS O
: O
NUM I-GENE
. I-GENE
1 I-GENE
or O
human I-GENE
serum I-GENE
albumin I-GENE
was O
administered O
intravenously O
to O
fasting O
male O
volunteers O
. O

RARE I-GENE
aminotransferase I-GENE
( O
ALL_CAP I-GENE
) O
levels O
had O
been O
elevated O
RARE O
RARE O
months O
in O
all O
patients O
and O
hepatitis O
B O
viral O
infection O
was O
replicative O
. O

In O
this O
study O
we O
have O
investigated O
the O
role O
of O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
in O
initiating O
the O
RARE O
program O
by O
overexpressing O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
in O
RARE O
ALL_CAP O
- O
3T3 O
RARE O
. O

NUM I-GENE
was O
isolated O
RARE O
a O
highly O
RARE O
fusion O
clone O
from O
a O
' I-GENE
lacZ I-GENE
translational O
fusion O
library O
. O

Various O
transcripts O
are O
generated O
from O
the O
NUM I-GENE
gene I-GENE
by O
RARE O
RARE O
and O
RARE O
( O
A O
) O
RARE O
in O
the O
rat O
RARE O
RARE O
. O

However O
, O
division O
of O
the O
chest O
RARE O
muscles O
, O
usually O
with O
RARE O
, O
contributes O
to O
prolonged O
pain O
and O
morbidity O
. O

RARE O
of O
an O
RARE O
high O
below O
- O
RARE O
RARE O
RARE O
wound O
using O
a O
RARE O
- O
RARE O
device O
. O

Our O
study O
was O
addressed O
to O
the O
RARE O
of O
some O
RARE O
of O
this O
sequence O
in O
order O
to O
obtain O
both O
peptide O
RARE O
suitable O
RARE O
the O
detection O
of O
the O
Src I-GENE
- O
like O
tyrosine I-GENE
kinase I-GENE
activity O
and O
RARE O
site O
- O
directed O
RARE O
specific O
RARE O
this O
class O
of O
RARE O
. O

RARE I-GENE
synthase I-GENE
activity O
was O
increased O
in O
the O
medial O
head O
( O
NUM O
%, O
P O
< O
NUM O
. O
001 O
) O
and O
the O
RARE O
long O
head O
( O
88 O
%, O
P O
< O
NUM O
. O
001 O
) O
of O
the O
RARE O
RARE O
muscle O
in O
R O
rats O
but O
not O
in O
the O
RARE O
long O
head O
( O
NUM O
%, O
P O
= O
NUM O
. O
06 O
). O

The O
RARE O
of O
the O
putative O
operon O
ALL_CAP I-GENE
of O
Bacillus O
subtilis O
was O
studied O
by O
using O
ALL_CAP O
'- O
lacZ I-GENE
transcriptional O
fusions O
. O

Although O
eight O
contiguous O
genes O
necessary O
RARE O
urease I-GENE
activity O
have O
been O
RARE O
and O
sequenced O
, O
the O
transcriptional O
organization O
and O
RARE O
of O
specific O
genes O
within O
the O
RARE I-GENE
gene I-GENE
cluster I-GENE
has O
not O
been O
investigated O
in O
detail O
. O

The O
ALL_CAP I-GENE
operon I-GENE
from O
RARE O
RARE O
RARE O
RARE O
is O
RARE O
from O
an O
RARE I-GENE
- I-GENE
type I-GENE
promoter I-GENE
that O
RARE O
mutagenesis O
of O
the O
ALL_CAP I-GENE
gene I-GENE
. O

We O
demonstrate O
that O
a O
VT O
+ O
peptide O
was O
specifically O
RARE O
by O
protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
) O
in O
vitro O
, O
but O
not O
by O
protein I-GENE
kinase I-GENE
A I-GENE
( O
PKA I-GENE
). O

R O
. O

NUM O
, O
NUM O
- O
NUM O
; O
O O
' O
RARE O
, O
T O
. O

Control O
experiments O
showed O
that O
each O
fusion O
protein O
had O
a O
high O
affinity O
binding O
site O
RARE O
estradiol O
- O
NUM O
beta O
and O
could O
transactivate O
an O
ALL_CAP O
- O
ALL_CAP I-GENE
reporter O
gene O
in O
yeast O
similar O
to O
the O
wild I-GENE
type I-GENE
ER I-GENE
. O

Although O
RARE I-GENE
RARE I-GENE
ALL_CAP I-GENE
endonuclease I-GENE
has O
been O
reported O
to O
be O
an O
18 O
- O
kDa O
enzyme O
with O
possible O
homology O
to O
the O
16 I-GENE
- I-GENE
kDa I-GENE
endonuclease I-GENE
V I-GENE
from I-GENE
RARE I-GENE
T4 I-GENE
( O
RARE O
, O
L O
. O

Several O
different O
RARE O
and O
growth O
factors O
promote O
G1 O
RARE O
progression O
. O

Cyclin I-GENE
NUM I-GENE
promoter I-GENE
activity O
was O
RARE O
by O
overexpression O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
NUM I-GENE
) O
or O
c I-GENE
- I-GENE
Ets I-GENE
- I-GENE
2 I-GENE
through O
the O
proximal O
NUM O
RARE O
RARE O
. O

Indeed O
, O
ALL_CAP I-GENE
and O
c I-GENE
- I-GENE
Jun I-GENE
synergistically O
activated O
the O
ALL_CAP O
- O
ALL_CAP O
without O
making O
an O
apparent O
RARE O
complex O
. O

A O
mutant O
( O
residues O
1 O
- O
NUM O
) O
showed O
RARE O
NUM O
RARE O
CaM I-GENE
- O
dependent O
activity O
. O

In O
addition O
, O
the O
NUM I-GENE
HSF I-GENE
substitution O
exhibits O
RARE O
transcriptional O
activation O
from O
a O
consensus O
HSE O
( O
NUM O
). O

The O
two O
bases O
immediately O
flanking O
the O
5 O
' O
end O
of O
the O
element O
proved O
to O
be O
very O
important O
to O
its O
function O
RARE O
a O
UAS O
element O
RARE O
did O
the O
two O
bases O
immediately O
3 O
' O
of O
the O
bHLH O
core O
motif O
. O

These O
results O
indicate O
that O
the O
PCNA I-GENE
gene I-GENE
is O
a O
likely O
target O
gene O
of O
E2F I-GENE
. O

Differential O
sensitivity O
of O
the O
MMPI O
- O
2 O
depression O
RARE O
and O
RARE O
. O

After O
recovery O
, O
a O
RARE O
saline O
challenge O
was O
performed O
. O

The O
range O
of O
eosinophils O
was O
NUM O
- O
NUM O
% O
of O
the O
number O
of O
peripheral O
RARE O
RARE O
cells O
( O
mean O
RARE O
NUM O
%). O

RARE O
of O
ALL_CAP I-GENE
P1 I-GENE
- O
lacZ I-GENE
RARE O
RARE O
different O
RARE O
levels O
is O
interpreted O
RARE O
the O
ALL_CAP I-GENE
( I-GENE
NUM I-GENE
) I-GENE
mutant I-GENE
RARE O
resulting O
from O
a O
hypersensitivity O
to O
RARE O
. O

These O
intron O
RARE O
show O
that O
peripheral O
sequences O
and O
the O
elements O
that O
define O
the O
RARE O
sites O
are O
adequate O
RARE O
self O
- O
RARE O
activity O
but O
that O
the O
central O
portions O
containing O
the O
catalytic O
RARE O
of O
NUM I-GENE
and O
NUM I-GENE
are O
RARE O
; O
these O
RARE O
are O
the O
likely O
RARE O
of O
the O
RARE O
proteins O
. O

Here O
we O
demonstrate O
genetically O
that O
RARE O
- O
RARE O
DNA O
RARE O
of O
the O
yeast I-GENE
Ty1 I-GENE
element I-GENE
is O
RARE O
RARE O
two O
sites O
RARE O
RARE O
the O
5 O
' O
boundary O
of O
the O
3 O
' O
long O
terminal O
repeat O
( O
NUM I-GENE
) O
and O
near O
the O
RARE O
of O
the O
pol I-GENE
gene I-GENE
in O
the O
integrase I-GENE
coding I-GENE
sequence I-GENE
( O
NUM I-GENE
). O

Characterization O
of O
the O
3 O
' O
ends O
of O
the O
RARE O
- O
RARE O
DNA O
fragments O
reveals O
( O
1 O
) O
that O
the O
upstream O
fragment O
is O
RARE O
beyond O
NUM I-GENE
RARE O
a O
RARE O
- O
RARE O
overlap O
and O
( O
2 O
) O
that O
the O
majority O
of O
RARE O
- O
RARE O
strong O
- O
stop O
DNA O
fragments O
RARE O
a O
copy O
of O
the O
minus O
- O
RARE O
primer O
binding O
site O
in O
agreement O
with O
the O
accepted O
model O
of O
RARE O
genomic O
RNA O
reverse O
transcription O
. O

The O
patients O
undergoing O
ALL_CAP O
had O
significantly O
shorter O
operative O
times O
( O
ALL_CAP O
, O
NUM O
. O
2 O
+/- O
NUM O
. O
2 O
min O
. O
RARE O
ALL_CAP O
, O
119 O
. O
8 O
+/- O
NUM O
. O
6 O
min O
; O
p O
< O
NUM O
. O
01 O
) O
and O
less O
RARE O
RARE O
( O
ALL_CAP O
, O
4 O
. O
7 O
+/- O
14 O
. O
6 O
ml O
RARE O
ALL_CAP O
, O
65 O
. O
7 O
+/- O
77 O
. O
NUM O
ml O
; O
p O
< O
NUM O
. O
001 O
). O

By O
NUM O
minutes O
after O
NUM O
inhalation O
, O
FEV1 O
. O
NUM O
had O
decreased O
by O
NUM O
%. O

This O
combined O
intravenous O
RARE O
regimen O
gave O
good O
anaesthesia O
and O
analgesia O
to O
pigs O
RARE O
RARE O
to O
2 O
h O
RARE O
monitored O
by O
clinical O
signs O
. O

Twenty O
food O
products O
were O
contaminated O
with O
V O
. O
RARE O
NUM O
, O
RARE O
, O
RARE O
and O
not O
RARE O
strains O
: O
RARE O
, O
cream O
RARE O
, O
RARE O
RARE O
, O
hip O
rose O
RARE O
, O
RARE O
, O
RARE O
RARE O
RARE O
" O
RARE O
RARE O
" O
RARE O
de O
RARE O
RARE O
meat O
RARE O
, O
meat O
and O
RARE O
RARE O
, O
RARE O
, O
milk O
RARE O
( O
made O
with O
RARE O
, O
milk O
RARE O
, O
RARE O
and O
RARE O
RARE O
RARE O
, O
RARE O
fish O
, O
RARE O
and O
RARE O
milk O
. O

It O
is O
RARE O
to O
define O
only O
one O
clinical O
RARE O
because O
both O
symptomatic O
and O
asymptomatic O
RARE O
ALL_CAP O
may O
be O
found O
with O
gestational O
age O
RARE O
term O
and O
pre O
- O
term O
and O
when O
born O
with O
a O
RARE O
above O
or O
below O
2000 O
g O
. O

The O
RARE O
of O
the O
RARE I-GENE
gene I-GENE
, O
ALL_CAP I-GENE
, O
is O
dependent O
upon O
ALL_CAP I-GENE
and O
upon O
ALL_CAP I-GENE
. O

The O
chloramphenicol I-GENE
- I-GENE
resistance I-GENE
RARE I-GENE
NUM I-GENE
undergoes O
precise O
RARE O
deletion O
from O
its O
RARE O
RARE O
NUM O
in O
RARE O
RARE O
and O
precise O
spontaneous O
RARE O
from O
multicopy O
plasmids O
in O
Escherichia O
coli O
. O

Ras I-GENE
NUM I-GENE
inhibits O
RARE O
without O
altering O
the O
DNA O
binding O
or O
transcriptional O
activities O
of O
the O
RARE I-GENE
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
factors I-GENE
. O

In O
cells O
limited O
RARE O
RARE O
, O
increased O
RARE O
of O
RARE I-GENE
- I-GENE
2 I-GENE
and O
RARE I-GENE
- I-GENE
1 I-GENE
, O
and O
decreased O
RARE O
of O
RARE I-GENE
- I-GENE
5 I-GENE
, O
also O
had O
translational O
and O
transcriptional O
RARE O
. O

The O
peptide O
sequences O
reveal O
that O
the O
factor O
consists O
of O
GABP I-GENE
alpha I-GENE
and O
GABP I-GENE
beta I-GENE
1 I-GENE
with O
Ets I-GENE
and O
Notch I-GENE
motifs I-GENE
, O
respectively O
. O

RARE O
microscopy O
and O
cell O
fractionation O
analyses O
showed O
that O
the O
NUM O
- O
kDa O
protein O
was O
exclusively O
nuclear O
, O
whereas O
the O
NUM O
- O
kDa O
protein O
was O
present O
in O
both O
the O
cytoplasm O
and O
nucleus O
of O
human O
cells O
. O

Expression O
and O
RARE O
by O
RARE I-GENE
of O
a O
double I-GENE
- I-GENE
RARE I-GENE
- I-GENE
RNA I-GENE
- I-GENE
specific I-GENE
adenosine I-GENE
RARE I-GENE
from O
human O
cells O
: O
evidence O
RARE O
two O
forms O
of O
the O
RARE O
. O

T O
- O
cell O
RARE O
, O
RARE O
, O
and O
T O
cells O
can O
be O
RARE O
to O
undergo O
apoptotic O
cell O
RARE O
by O
activation O
through O
the O
T I-GENE
- I-GENE
cell I-GENE
receptor I-GENE
. O

RARE O
were O
examined O
in O
the O
NUM I-GENE
gene I-GENE
, O
using O
a O
set O
of O
NUM O
- O
to O
NUM O
- O
bp O
inserts O
that O
included O
inserts O
with O
RARE O
apparent O
RARE O
RARE O
secondary O
RARE O
RARE O
RARE O
RARE O
two O
RARE O
. O

Overexpression O
of O
NUM I-GENE
could O
not O
complement O
an O
NUM I-GENE
- I-GENE
RARE I-GENE
allele I-GENE
, O
indicating O
that O
suppression O
was O
not O
due O
to O
the O
RARE O
of O
NUM I-GENE
activity O
. O

The O
DNA O
binding O
domain O
of O
ALL_CAP I-GENE
was O
RARE O
RARE O
a O
fusion O
protein O
with O
the O
RARE I-GENE
S I-GENE
- I-GENE
transferase I-GENE
of O
RARE O
RARE O
. O

The O
kinase O
is O
essential O
in O
vivo O
RARE O
normal O
RARE O
of O
the O
ALL_CAP O
and O
RARE O
normal O
growth O
and O
differentiation O
. O

A O
RARE O
model O
RARE O
ALL_CAP O
- O
RARE O
mRNA O
RARE O
involving O
a O
RARE O
role O
RARE O
certain O
RARE O
nuclear O
RARE O
and O
ALL_CAP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
is O
proposed O
. O

Finally O
, O
we O
demonstrate O
that O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
can O
also O
RARE O
the O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
receptor I-GENE
alpha I-GENE
promoter O
in O
RARE O
cells O
. O

RARE O
and O
vacuolar O
RARE O
of O
the O
plasma O
membrane O
- O
localized O
NUM I-GENE
ATP I-GENE
- I-GENE
binding I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
in O
Saccharomyces O
cerevisiae O
. O

RARE O
mutations O
in O
motifs O
III O
, O
IV O
, O
and O
V O
had O
distinctive O
effects O
on O
the O
affinity O
of O
enzyme O
RARE O
GTP O
, O
the O
rate O
of O
RARE O
RARE O
( O
ALL_CAP O
formation O
RARE O
or O
the O
transfer O
of O
ALL_CAP O
from O
enzyme O
to O
RNA O
. O

Mutational O
analysis O
of O
mRNA I-GENE
RARE I-GENE
enzyme I-GENE
identifies O
amino O
RARE O
involved O
in O
GTP O
binding O
, O
enzyme O
- O
RARE O
formation O
, O
and O
ALL_CAP O
transfer O
to O
RNA O
. O

Disruption O
of O
the O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
leads O
to O
a O
dramatic O
decrease O
of O
the O
NUM I-GENE
inducibility O
in O
RARE O
cells O
, O
whereas O
RARE O
of O
NUM I-GENE
produces O
a O
RARE O
increase O
in O
wild O
- O
type O
RARE O
levels O
upon O
a O
shift O
to O
a O
high O
salt O
concentration O
. O

Deletion O
or O
inactivation O
of O
NUM I-GENE
leads O
to O
5 O
- O
to O
10 O
- O
RARE O
- O
increased O
levels O
of O
NUM I-GENE
mRNA I-GENE
. O

( O
1986 O
) O
method O
of O
separation O
of O
RARE O
RARE O
. O
RARE O
from O
RARE O
by O
using O
a O
RARE O
RARE O
density O
gradient O
appeared O
a O
method O
of O
choice O
RARE O
obtaining O
large O
numbers O
of O
RARE O
of O
C O
. O
RARE O
free O
of O
fecal O
contamination O
. O

RARE I-GENE
RARE I-GENE
A I-GENE
involvement O
in O
the O
illness O
of O
a O
20 O
- O
month O
- O
old O
burn O
patient O
. O

METHODS O
: O
We O
obtained O
maximal O
inspiratory O
and O
expiratory O
flow O
- O
volume O
curves O
in O
NUM O
RARE O
patients O
with O
essential O
tremor O
( O
14 O
males O
, O
NUM O
females O
, O
age O
NUM O
. O
7 O
+/- O
2 O
. O
14 O
years O
). O

Our O
findings O
also O
provide O
the O
basis O
RARE O
the O
development O
of O
assays O
to O
screen O
RARE O
the O
ligands O
to O
RARE I-GENE
receptor I-GENE
2 I-GENE
and O
NUM I-GENE
. O

Four O
p53 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
peptides I-GENE
bind O
RARE O
p53 I-GENE
- I-GENE
response I-GENE
elements I-GENE
and O
RARE O
the O
DNA O
. O

The O
NUM I-GENE
mRNA I-GENE
has O
a O
size O
of O
5 O
. O
6 O
kb O
and O
encodes O
a O
protein O
of O
NUM O
amino O
RARE O
. O

The O
RARE O
RARE O
revealed O
a O
rather O
hydrophilic O
N O
- O
terminal O
region O
and O
the O
absence O
of O
a O
hydrophobic O
signal O
peptide O
. O

These O
results O
suggest O
that O
G I-GENE
beta I-GENE
gamma I-GENE
- O
RARE O
Shc I-GENE
RARE O
represents O
an O
early O
step O
in O
the O
RARE O
leading O
to O
p21ras I-GENE
activation O
, O
similar O
to O
the O
mechanism O
utilized O
by O
growth I-GENE
factor I-GENE
tyrosine I-GENE
kinase I-GENE
receptors I-GENE
. O

This O
report O
focused O
on O
the O
relationship O
between O
RARE O
A O
behavior O
and O
eight O
basic O
RARE O
dimensions O
. O

All O
RARE O
resulted O
in O
contamination O
with O
aerobic O
RARE O
bacteria O
in O
the O
range O
from O
6 O
RARE O
10 O
( O
3 O
) O
to O
1 O
. O
2 O
RARE O
10 O
( O
6 O
) O
ALL_CAP O
/ O
ml O
liquid O
RARE O
, O
and O
94 O
% O
them O
with O
RARE O
bacteria O
, O
the O
threshold O
being O
under O
NUM O
ALL_CAP O
/ O
ml O
( O
RARE O
1 O
). O

As O
RARE O
NUM O
RARE O
I O
- O
II O
RARE O
RARE O
patients O
, O
ALL_CAP O
has O
been O
observed O
in O
82 O
. O
8 O
% O
of O
them O
and O
PR O
in O
NUM O
. O
8 O
%; O
the O
response O
was O
always O
assessed O
with O
chest O
RARE O
, O
ALL_CAP O
, O
ALL_CAP O
, O
RARE O
and O
/ O
or O
RARE O
. O

RARE O
medical O
RARE O
in O
a O
regional O
hospital O
: O
appropriate O
RARE O
? O

Protein O
electrophoresis O
showed O
decreased O
albumin I-GENE
levels O
in O
both O
groups O
, O
with O
lower O
values O
in O
NUM O
. O

METHODS O
: O
All O
these O
NUM O
non O
- O
responders O
received O
an O
RARE O
dose O
of O
the O
same O
vaccine O
2 O
months O
after O
RARE O
immunization O
and O
a O
RARE O
dose O
with O
a O
yeast O
- O
derived O
vaccine O
6 O
years O
later O
. O

An O
RARE O
high O
percentage O
of O
hypertensive O
patients O
( O
RARE O
NUM O
%) O
undergoing O
cardiac O
RARE O
because O
of O
RARE O
pain O
and O
/ O
or O
exercise O
- O
RARE O
ST O
- O
segment O
RARE O
has O
RARE O
normal O
coronary O
arteries O
. O

RARE O
- O
staining O
, O
RARE O
mycobacteria O
in O
RARE O
- O
stained O
smears O
. O

RARE O
( O
RARE O
40 O
- O
NUM O
) O
is O
a O
novel O
RARE O
antagonist O
from O
a O
new O
chemical O
class O
and O
is O
the O
RARE O
that O
selectively O
blocks O
the O
T O
- O
type O
RARE O
RARE O
. O

However O
, O
2 O
minimum O
alveolar O
concentration O
anesthesia O
did O
significantly O
decrease O
the O
calculated O
VE O
RARE O
a O
PCO2 O
of O
NUM O
mmHg O
( O
from O
7 O
. O
4 O
+/- O
1 O
. O
2 O
to O
4 O
. O
NUM O
+/- O
NUM O
. O
6 O
RARE O
. O
min O
- O
1 O
RARE O
indicating O
a O
RARE O
shift O
in O
the O
response O
relationship O
. O

cDNA O
encoding O
a O
RARE O
RARE I-GENE
liver I-GENE
/ I-GENE
bone I-GENE
/ I-GENE
RARE I-GENE
- I-GENE
type I-GENE
RARE I-GENE
phosphatase I-GENE
. O

Protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
RARE O
a O
widely O
- O
distributed O
enzyme O
implicated O
in O
the O
RARE O
of O
many O
physiological O
processes O
, O
consists O
of O
a O
family O
of O
RARE O
least O
RARE O
RARE O
which O
differ O
in O
tissue O
distribution O
, O
subcellular O
RARE O
, O
regulatory O
properties O
, O
etc O
. O

This O
work O
, O
therefore O
, O
also O
emphasizes O
the O
importance O
of O
RARE O
choice O
of O
RARE O
and O
cDNA O
RARE O
to O
study O
PKC I-GENE
RARE I-GENE
mRNA I-GENE
. O

This O
action O
is O
dependent O
on O
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
factors I-GENE
RARE O
to O
the O
E1 I-GENE
element O
. O

The O
RARE O
over O
RARE O
RARE O
NUM O
. O

RARE O
growth O
factors O
and O
RARE O
mediate O
their O
biochemical O
functions O
through O
their O
responsive O
receptors O
. O

However O
, O
a O
strongly O
increased O
frequency O
of O
CpG O
RARE O
was O
found O
. O

Here O
we O
focused O
on O
the O
role O
of O
the O
5 O
' O
proximal O
regulatory O
RARE O
RARE O
190 O
; O
+ O
53 O
bp O
) O
of O
the O
rat I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
gene O
in O
the O
developmental O
RARE O
of O
the O
RARE I-GENE
RARE O
. O

RARE O
, O
all O
ALL_CAP I-GENE
- I-GENE
specific I-GENE
motifs I-GENE
formed O
specific O
and O
highly O
abundant O
protein O
- O
DNA O
complexes O
when O
nuclear O
extracts O
from O
the O
human O
tumor O
cell O
line O
( O
HeLa O
RARE O
which O
does O
not O
express O
ALL_CAP I-GENE
, O
were O
used O
. O

RARE O
aged O
3 O
. O
5 O
years O
presents O
RARE O
of O
RARE O
vitreous O
body O
with O
crystalline O
dislocation O
in O
the O
RARE O
RARE O
and O
secondary O
RARE O
of O
the O
RARE O
eye O
and O
RARE O
with O
dislocation O
of O
the O
crystalline O
in O
the O
vitreous O
body O
of O
the O
right O
eye O
. O

During O
the O
dose O
- O
finding O
, O
two O
patients O
were O
RARE O
RARE O
from O
medication O
and O
one O
patient O
was O
excluded O
because O
of O
elevated O
levels O
of O
liver O
RARE O
. O

In O
comparison O
of O
cDNA O
and O
genomic O
sequences O
four O
RNA O
RARE O
events O
were O
found O
in O
both O
NUM I-GENE
genes I-GENE
. O

ALL_CAP I-GENE
- I-GENE
1 I-GENE
represses O
CAT I-GENE
reporter I-GENE
gene I-GENE
RARE O
via O
GAL4 I-GENE
binding I-GENE
sites I-GENE
in O
the O
RARE O
cell O
lines O
ALL_CAP O
3T3 O
and O
293 O
. O

As O
with O
the O
heterologous O
DNA O
binding O
domain O
, O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
represses O
reporter O
gene O
RARE O
in O
RARE O
cell O
lines O
and O
activates O
RARE O
in O
hematopoietic O
cell O
lines O
. O

RARE O
of O
ALL_CAP I-GENE
beta I-GENE
subunit I-GENE
mutants I-GENE
revealed O
two O
cytoplasmic O
regions O
involved O
in O
activation O
of O
the O
c I-GENE
- I-GENE
myc I-GENE
promoter I-GENE
, O
one O
is O
essential O
and O
the O
other O
is O
dispensable O
but O
enhances O
the O
activity O
. O

Similarly O
, O
we O
observed O
RARE O
RARE O
between O
mutations O
in O
NUM I-GENE
and O
RARE O
- O
acting O
mutations O
in O
three O
known O
yeast O
centromere O
protein O
genes O
- O
NUM I-GENE
/ O
CBF1 I-GENE
/ O
NUM I-GENE
, O
NUM I-GENE
/ O
CBF2 I-GENE
, O
and O
NUM I-GENE
/ O
NUM I-GENE
. O

Taken O
together O
, O
these O
data O
suggest O
that O
the O
NUM I-GENE
protein I-GENE
interacts O
with O
NUM I-GENE
RARE O
the O
centromere O
and O
that O
the O
yeast O
centromere O
indeed O
exists O
RARE O
a O
RARE O
order O
protein O
- O
DNA O
complex O
. O

To O
RARE O
this O
, O
actin I-GENE
RARE O
and O
RARE O
are O
RARE O
RARE O
the O
cell O
RARE O
to O
direct O
RARE O
RARE O
to O
appropriate O
sites O
RARE O
cell O
growth O
. O

The O
effects O
of O
RARE O
RARE O
oral O
RARE O
( O
ALL_CAP O
) O
on O
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
( O
t I-GENE
- I-GENE
PA I-GENE
) O
and O
plasminogen I-GENE
activator I-GENE
inhibitor I-GENE
( O
PAI I-GENE
) O
in O
the O
plasma O
of O
NUM O
patients O
of O
coronary O
RARE O
RARE O
with O
RARE O
RARE O
were O
studied O
. O

RARE O
daily O
RARE O
( O
RARE O
) O
per O
RARE O
were O
NUM O
. O
NUM O
microgram O
RARE O
RARE O
ALL_CAP O
, O
NUM O
. O
20 O
microgram O
RARE O
gamma O
- O
ALL_CAP O
, O
NUM O
. O
09 O
microgram O
RARE O
RARE O
, O
1 O
. O
NUM O
micrograms O
RARE O
RARE O
ALL_CAP O
, O
and O
NUM O
. O
NUM O
microgram O
RARE O
HCB O
. O

RARE O
features O
of O
splenic O
RARE O
cyst O
with O
pathologic O
correlation O
. O

In O
two O
further O
cases O
( O
one O
type O
I O
and O
one O
type O
III O
ALL_CAP O
RARE O
de O
RARE O
deletions O
of O
only O
one O
copy O
of O
NUM I-GENE
- I-GENE
CA I-GENE
and O
NUM I-GENE
were O
found O
. O

With O
each O
of O
the O
three O
RARE O
of O
isolates O
( O
case O
and O
RARE O
case O
RARE O
identical O
NUM O
RARE O
patterns O
were O
found O
suggesting O
identical O
ALL_CAP O
strains O
. O

ALL_CAP O
has O
been O
found O
to O
be O
clinically O
useful O
in O
assessing O
histologic O
damage O
following O
RARE O
dilatation O
and O
in O
RARE O
the O
ALL_CAP O
RARE O
the O
administration O
of O
RARE O
botulinum I-GENE
RARE I-GENE
injection O
in O
the O
treatment O
of O
RARE O
. O

These O
early O
structural O
processes O
are O
assumed O
to O
be O
RARE O
by O
the O
anterior O
parts O
of O
the O
RARE O
hemisphere O
, O
RARE O
event O
- O
related O
brain O
potentials O
show O
this O
area O
to O
be O
RARE O
activated O
when O
RARE O
RARE O
RARE O
are O
processed O
and O
RARE O
RARE O
lesions O
in O
this O
area O
lead O
to O
an O
impairment O
of O
the O
on O
- O
line O
structural O
assignment O
. O

In O
men O
with O
BMI O
< O
NUM O
, O
the O
OR O
was O
1 O
. O
NUM O
RARE O
RARE O
TG O
( O
P O
= O
. O
NUM O
) O
and O
2 O
. O
77 O
RARE O
RARE O
ALL_CAP O
( O
P O
= O
. O
NUM O
) O
in O
models O
that O
included O
fasting O
TG O
, O
LDL I-GENE
- I-GENE
C I-GENE
, O
and O
hypertension O
. O

NUM I-GENE
RARE O
- O
RARE O
specified O
by O
ALL_CAP O
- O
rich O
RARE O
RNA O
inserted O
RARE O
the O
5 O
' O
end O
of O
Caenorhabditis O
elegans O
pre O
- O
mRNA O
. O

A O
RARE O
- O
RARE O
compound O
, O
6 O
- O
RARE O
- O
4 O
RARE O
2 O
RARE O
2 O
- O
RARE O
)- O
ethyl O
] O
amino O
RARE O
3 O
- O
RARE O
- O
NUM O
- O
RARE O
RARE O
RARE O
3 O
, O
4 O
- O
b O
] O
RARE O
( O
ALL_CAP O
NUM O
RARE O
was O
identified O
based O
on O
its O
ability O
to O
RARE O
human O
RARE O
muscle O
alpha I-GENE
- I-GENE
actin I-GENE
promoter I-GENE
activity O
in O
ras I-GENE
- O
transformed O
cells O
. O

On O
the O
basis O
of O
these O
relations O
, O
a O
risk O
factor O
- O
selection O
scale O
( O
ALL_CAP O
) O
( O
range O
, O
NUM O
to O
10 O
) O
was O
developed O
by O
RARE O
appropriate O
weights O
RARE O
each O
risk O
factor O
. O

The O
Caenorhabditis I-GENE
elegans I-GENE
RARE I-GENE
RARE I-GENE
gene I-GENE
, O
RARE I-GENE
- I-GENE
3 I-GENE
, O
has O
a O
number O
of O
homologs O
in O
RARE O
species O
, O
including O
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
( I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
)- I-GENE
RARE I-GENE
enzyme I-GENE
( O
ICE I-GENE
RARE O
RARE I-GENE
- I-GENE
NUM I-GENE
, O
and O
NUM I-GENE
. O

RARE O
of O
glucocorticoid I-GENE
receptor I-GENE
- O
RARE O
transcriptional O
activation O
by O
RARE O
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( O
TR I-GENE
) O
is O
TR I-GENE
isoform O
- O
specific O
. O

The O
results O
indicate O
considerable O
RARE O
in O
the O
RARE O
between O
ALL_CAP I-GENE
regulatory O
sites O
. O

RARE O
of O
the O
ALL_CAP I-GENE
repressor I-GENE
function O
by O
the O
transactivating O
members O
of O
the O
ets I-GENE
family I-GENE
of O
genes O
( O
i O
. O
RARE O
. O
gag I-GENE
- O
myb I-GENE
- O
ets I-GENE
) O
may O
be O
essential O
RARE O
the O
control O
of O
genes O
involved O
in O
cell O
RARE O
and O
may O
also O
RARE O
their O
tumorigenic O
effects O
. O

Overexpression O
of O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
also O
induces O
apoptosis O
in O
an O
ALL_CAP O
. O

We O
show O
that O
c I-GENE
- I-GENE
Fos I-GENE
( O
the O
c I-GENE
- I-GENE
fos I-GENE
RARE I-GENE
product I-GENE
RARE O
which O
is O
an O
RARE O
unstable O
nuclear O
protein O
, O
is O
RARE O
highly O
stabilized O
, O
and O
greatly O
enhances O
the O
transforming O
efficiency O
of O
ALL_CAP O
3T3 O
cells O
, O
by O
RARE I-GENE
. O

Cloning O
, O
sequencing O
and O
RARE O
of O
the O
3 I-GENE
- I-GENE
RARE I-GENE
kinase I-GENE
gene I-GENE
of O
RARE O
RARE O
in O
Escherichia O
coli O
and O
characterization O
of O
the O
protein O
. O

These O
observations O
lead O
to O
the O
RARE O
that O
the O
RNAP I-GENE
II I-GENE
ALL_CAP I-GENE
might O
be O
an O
in O
vivo O
target O
RARE O
the O
activated O
NUM I-GENE
and O
NUM I-GENE
MAP I-GENE
kinases I-GENE
. O

We O
also O
isolated O
two O
RARE O
RARE O
forms O
of O
human I-GENE
NUM I-GENE
cDNA I-GENE
RARE O
sequences O
encoding O
membrane O
- O
proximal O
regions O
of O
the O
cytoplasmic O
domain O
which O
maintain O
the O
same O
reading O
frame O
RARE O
NUM I-GENE
- O
NUM I-GENE
. O

We O
sought O
to O
determine O
whether O
such O
differences O
in O
polyadenylation O
affect O
the O
steady O
- O
state O
levels O
of O
DHFR I-GENE
and O
mRNAs O
RARE O
from O
either O
allele O
and O
, O
in O
a O
more O
RARE O
sense O
, O
to O
RARE O
whether O
differences O
in O
3 O
' O
end O
RNA O
RARE O
in O
a O
gene O
containing O
multiple O
RARE O
( O
A O
) O
sites O
affects O
the O
final O
level O
of O
gene O
RARE O
. O

We O
have O
isolated O
a O
Drosophila O
melanogaster O
( O
RARE O
) O
cDNA O
encoding O
a O
polypeptide O
that O
has O
extensive O
sequence O
RARE O
to O
the O
mammalian I-GENE
ALL_CAP I-GENE
- I-GENE
2 I-GENE
. O

A O
2 I-GENE
. I-GENE
4 I-GENE
- I-GENE
kb I-GENE
ALL_CAP I-GENE
- I-GENE
2 I-GENE
RARE I-GENE
is O
RARE O
throughout O
development O
, O
while O
two O
shorter O
transcripts O
of O
2 O
. O
3 O
and O
1 O
. O
8 O
kb O
appear O
to O
be O
specifically O
RARE O
in O
the O
RARE O
. O

The O
finding O
that O
the O
chimeric I-GENE
ALL_CAP I-GENE
:: O
Pol I-GENE
beta I-GENE
protein I-GENE
possessed O
significant O
template O
- O
dependent O
polymerase O
activity O
suggests O
that O
RARE O
1 O
- O
NUM O
of O
Pol I-GENE
beta I-GENE
are O
involved O
in O
template O
utilization O
RARE O
the O
RARE O
reaction O
, O
RARE O
suggested O
by O
the O
previous O
finding O
that O
the O
8 O
- O
kDa O
N O
- O
terminal O
domain O
of O
Pol I-GENE
beta I-GENE
possesses O
ALL_CAP O
- O
binding O
activity O
RARE O
RARE O
et O
al O
., O
ALL_CAP O
. O

The O
average O
values O
were O
NUM O
and O
NUM O
RARE O
/ O
g O
RARE O
the O
RARE O
and O
hot O
dogs O
, O
respectively O
. O

RARE O
was O
performed O
in O
all O
cases O
and O
classified O
by O
a O
RARE O
RARE O
specifically O
developed O
RARE O
pediatric O
patients O
. O

The O
integrity O
of O
the O
cDNA O
sequence O
was O
confirmed O
by O
analysis O
of O
several O
overlapping O
genomic O
RARE O
that O
span O
the O
NUM I-GENE
gene I-GENE
. O

In O
RARE O
1 O
, O
eight O
RARE O
were O
allowed O
to O
RARE O
naturally O
( O
d O
NUM O
, O
ALL_CAP O
RARE O
) O
and O
eight O
RARE O
were O
RARE O
to O
RARE O
( O
IF O
RARE O
) O
RARE O
by O
injection O
of O
RARE O
F2 O
alpha O
on O
d O
112 O
of O
gestation O
. O

RARE O
- O
tidal O
PO2 O
and O
the O
ratio O
of O
minute O
ventilation O
to O
oxygen O
consumption O
( O
VE O
/ O
VO2 O
) O
were O
lower O
while O
NUM O
was O
RARE O
RARE O
RARE O
( O
P O
< O
or O
= O
NUM O
. O
01 O
). O

These O
results O
suggested O
that O
ALL_CAP I-GENE
negatively O
RARE O
the O
RARE O
of O
ALL_CAP I-GENE
itself O
. O

NUM O
is O
a O
broad O
- O
RARE O
- O
range O
, O
virulent O
RARE O
RARE O
RARE O
monocytogenes O
. O

The O
mechanism O
of O
RARE O
RARE O
is O
poorly O
understood O
. O

If O
NCR O
- O
RARE O
gene O
RARE O
occurs O
exclusively O
by O
this O
RARE O
, O
RARE O
has O
been O
thought O
to O
be O
the O
case O
, O
then O
the O
NCR O
sensitivity O
of O
a O
gene O
' O
s O
RARE O
should O
be O
abolished O
by O
a O
NUM I-GENE
delta I-GENE
mutation I-GENE
. O

The O
single O
- O
RARE O
DNA O
RARE I-GENE
alpha I-GENE
recognition I-GENE
element I-GENE
RARE O
these O
complexes O
. O

Association O
of O
human I-GENE
RARE I-GENE
alpha I-GENE
with O
the O
RARE I-GENE
protein I-GENE
, O
RARE I-GENE
, O
regulates O
binding O
to O
the O
single O
- O
RARE O
DNA O
RARE I-GENE
alpha I-GENE
recognition I-GENE
element I-GENE
. O

The O
insulin I-GENE
- O
RARE O
DNA O
- O
binding O
complex O
was O
identified O
RARE O
the O
NUM I-GENE
/ O
NUM I-GENE
RARE O
. O

Using O
varying O
conditions O
, O
three O
distinct O
complexes O
were O
shown O
to O
interact O
specifically O
with O
the O
ALL_CAP I-GENE
region I-GENE
, O
although O
only O
one O
correlates O
with O
repressor O
activity O
. O

RARE O
of O
the O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
RARE O
resulted O
in O
a O
reversal O
of O
the O
phospholipase I-GENE
/ O
neutral O
lipase I-GENE
ratio O
, O
RARE O
the O
important O
role O
of O
this O
region O
in O
mediating O
substrate O
RARE O
. O

The O
RARE I-GENE
- O
inducible O
protein I-GENE
kinase I-GENE
PKR I-GENE
RARE O
the O
transcriptional O
activation O
of O
immunoglobulin I-GENE
RARE I-GENE
gene I-GENE
. O

RARE O
forms O
of O
a O
novel O
yeast O
protein O
suppress O
the O
lethality O
of O
a O
G I-GENE
protein I-GENE
alpha I-GENE
subunit I-GENE
deficiency O
by O
RARE O
with O
the O
beta O
subunit O
. O

Another O
common O
mutation O
involved O
amino O
RARE O
that O
are O
thought O
to O
make O
specific O
contacts O
with O
DNA O
. O

RARE O
esters O
RARE O
RARE O
of O
ALL_CAP I-GENE
NUM I-GENE
proteins I-GENE
, O
thus O
RARE O
that O
sequences O
isolated O
according O
to O
PKC I-GENE
binding O
activity O
in O
vitro O
are O
also O
PKC I-GENE
RARE O
in O
vivo O
. O

RARE O
of O
ALL_CAP I-GENE
- I-GENE
14 I-GENE
protein I-GENE
( O
also O
termed O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
) O
become O
elevated O
in O
the O
serum O
of O
mice O
and O
humans O
after O
injection O
with O
bacterial O
lipopolysaccharide O
, O
but O
in O
contrast O
to O
conventional O
acute O
RARE O
proteins O
, O
the O
bulk O
of O
ALL_CAP I-GENE
- I-GENE
14 I-GENE
RARE O
in O
the O
RARE O
organism O
occurs O
outside O
the O
liver O
. O

The O
mouse I-GENE
beta I-GENE
2 I-GENE
- I-GENE
RARE I-GENE
gene I-GENE
( O
> O
NUM O
kilobases O
) O
contains O
RARE O
exons O
, O
all O
of O
which O
have O
RARE O
RARE O
the O
corresponding O
position O
in O
the O
alpha I-GENE
1 I-GENE
- I-GENE
RARE I-GENE
gene I-GENE
. O

Altogether O
our O
data O
indicate O
that O
ALL_CAP I-GENE
belongs O
to O
the O
subgroup O
of O
RARE O
RARE I-GENE
and O
that O
its O
N O
- O
terminal O
region O
confers O
a O
RARE O
- O
RARE O
activity O
to O
the O
protein O
. O

We O
report O
here O
the O
cloning O
of O
the O
murine O
p44 I-GENE
MAP I-GENE
kinase I-GENE
( O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
1 I-GENE
) O
gene O
, O
the O
determination O
of O
its O
intron O
/ O
RARE O
boundaries O
, O
and O
the O
characterization O
of O
its O
promoter O
. O

It O
contains O
three O
putative O
TATA O
RARE O
far O
upstream O
of O
the O
main O
RARE O
sites O
region O
, O
one O
AP I-GENE
- I-GENE
1 I-GENE
box I-GENE
, O
one O
AP I-GENE
- I-GENE
2 I-GENE
box I-GENE
, O
one O
RARE I-GENE
box I-GENE
, O
one O
ALL_CAP O
box O
, O
one O
RARE O
serum O
- O
responsive O
element O
, O
and O
putative O
binding O
sites O
RARE O
NUM I-GENE
( O
five O
RARE O
ALL_CAP I-GENE
- I-GENE
rich I-GENE
binding I-GENE
factor I-GENE
( O
five O
RARE O
ALL_CAP I-GENE
- I-GENE
NF1 I-GENE
( O
one O
RARE O
Myb I-GENE
( O
one O
RARE O
p53 I-GENE
( O
two O
RARE O
Ets I-GENE
- I-GENE
1 I-GENE
( O
one O
RARE O
ALL_CAP I-GENE
- I-GENE
IL6 I-GENE
( O
two O
RARE O
MyoD I-GENE
( O
two O
RARE O
RARE I-GENE
( O
one O
RARE O
and O
RARE I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
5 I-GENE
( O
one O
). O

One O
of O
these O
is O
RARE O
by O
an O
RARE O
- O
RARE O
rich O
region O
that O
can O
form O
an O
11 O
- O
RARE O
RARE O
RARE O
RARE O
. O

We O
conclude O
that O
this O
new O
measurement O
technique O
provides O
an O
RARE O
and O
accurate O
NUM O
. O
1 O
measurement O
using O
standard O
respiratory O
RARE O
when O
tested O
in O
a O
RARE O
model O
. O

Effects O
of O
verapamil O
and O
propranolol O
on O
early O
RARE O
and O
ventricular O
arrhythmias O
RARE O
by O
epinephrine O
in O
congenital O
long O
QT O
RARE O
. O

Deletion O
of O
the O
ALL_CAP I-GENE
- I-GENE
IL6 I-GENE
beta I-GENE
leucine I-GENE
zipper I-GENE
domain I-GENE
also O
greatly O
diminished O
the O
interaction O
between O
these O
two O
proteins O
. O

After O
cells O
were O
stably O
transfected O
with O
ALL_CAP I-GENE
, O
endogenous O
MHC I-GENE
class I-GENE
II I-GENE
genes I-GENE
were O
constitutively O
RARE O
, O
and O
MHC I-GENE
class I-GENE
II I-GENE
promoters I-GENE
, O
delivered O
by O
transfection O
, O
were O
actively O
RARE O
in O
ALL_CAP I-GENE
- O
expressing O
cells O
. O

Two O
domains O
of O
EBNA2 I-GENE
defined O
by O
deletion O
of O
amino O
RARE O
NUM O
- O
NUM O
and O
NUM O
- O
NUM O
were O
found O
to O
be O
important O
RARE O
the O
activation O
of O
both O
promoters O
, O
while O
two O
different O
domains O
corresponding O
to O
residues O
4 O
- O
18 O
and O
118 O
- O
198 O
were O
required O
solely O
RARE O
the O
LMP1 I-GENE
promoter I-GENE
. O

The O
peak O
RARE O
of O
the O
RARE O
systolic O
waves O
of O
the O
RARE O
and O
pulmonary O
venous O
flow O
RARE O
( O
A O
and O
ALL_CAP O
, O
respectively O
) O
and O
RARE O
systolic O
wave O
( O
NUM O
) O
of O
pulmonary O
venous O
flow O
, O
durations O
of O
both O
RARE O
systolic O
waves O
, O
and O
amplitude O
of O
RARE O
septal O
motion O
RARE O
RARE O
RARE O
increased O
significantly O
ten O
days O
after O
RARE O
compared O
with O
those O
measured O
within O
a O
day O
of O
RARE O
in O
all O
patients O
except O
the O
5 O
patients O
with O
RARE O
cardiomyopathy O
. O

Additionally O
, O
the O
enzyme O
shows O
activity O
towards O
RARE O
such O
RARE O
RARE O
oil O
and O
RARE O
and O
towards O
RARE O
- O
RARE O
RARE O
. O

The O
nucleotide O
sequence O
directly O
upstream O
of O
ALL_CAP I-GENE
contains O
two O
RARE O
reading O
frames O
, O
NUM O
and O
ORF1 O
, O
whose O
deduced O
protein O
products O
are O
homologous O
to O
members O
of O
a O
superfamily O
of O
ATP I-GENE
- I-GENE
binding I-GENE
RARE I-GENE
membrane I-GENE
RARE I-GENE
proteins I-GENE
, O
including O
both O
RARE O
and O
eukaryotic O
uptake O
and O
export O
RARE O
. O

The O
ORF3 O
probe O
also O
hybridized O
to O
a O
NUM O
bp O
transcript O
consistent O
with O
the O
size O
of O
ORF3 O
alone O
and O
RARE O
of O
the O
mutagenesis O
data O
of O
non O
- O
linkage O
. O

These O
results O
suggest O
that O
low O
concentrations O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
may O
be O
useful O
RARE O
RARE O
treatment O
of O
human O
vitreous O
hemorrhage O
. O

We O
conclude O
that O
pancreatic O
polypeptide O
and O
RARE I-GENE
responses O
to O
a O
RARE O
are O
different O
in O
RARE O
children O
than O
in O
children O
in O
the O
control O
group O
. O

Here O
we O
report O
the O
cloning O
, O
RARE O
, O
and O
biochemical O
characterization O
of O
the O
NUM O
- O
kDa O
subunit O
of O
human O
( O
h O
) O
TFIID I-GENE
, O
termed O
NUM I-GENE
. O

RARE O
jaundice O
due O
to O
NUM I-GENE
deficiency O
causing O
RARE O
in O
a O
female O
newborn O
. O

Two O
transcripts O
of O
1 O
. O
6 O
kb O
and O
5 O
. O
8 O
kb O
are O
5 O
' O
RARE O
and O
may O
both O
encode O
the O
novel O
glycoprotein I-GENE
gene I-GENE
NUM I-GENE
. O

Mean O
growth O
changes O
in O
this O
RARE O
II O
sample O
were O
comparable O
to O
those O
previously O
reported O
RARE O
male O
subjects O
with O
RARE O
I O
RARE O
over O
the O
same O
age O
period O
, O
suggesting O
a O
RARE O
in O
RARE O
development O
between O
these O
two O
groups O
. O

However O
, O
the O
few O
studies O
that O
address O
antimicrobial O
prophylaxis O
in O
bone O
marrow O
transplantation O
have O
not O
always O
shown O
a O
survival O
benefit O
. O

The O
fracture O
groups O
were O
significantly O
older O
and O
had O
more O
years O
since O
RARE O
than O
the O
control O
groups O
. O

In O
addition O
, O
we O
found O
differences O
in O
the O
binding O
of O
nuclear O
factors O
from O
RARE O
versus O
from O
roots O
, O
in O
agreement O
with O
the O
different O
activities O
of O
the O
promoter O
in O
these O
two O
organs O
. O

The O
prevalence O
and O
incidence O
of O
human O
immunodeficiency O
virus O
RARE O
1 O
and O
2 O
( O
HIV O
- O
1 O
, O
HIV O
- O
2 O
RARE O
human O
T O
- O
RARE O
virus O
RARE O
I O
and O
II O
( O
ALL_CAP O
- O
I O
/ O
II O
RARE O
and O
RARE O
infections O
and O
the O
association O
between O
these O
infections O
were O
determined O
in O
a O
cohort O
of O
RARE O
RARE O
in O
RARE O
- O
RARE O
. O

By O
in O
vitro O
RARE O
and O
gel O
shift O
assays O
, O
we O
identified O
two O
classes O
of O
high O
affinity O
RARE I-GENE
- I-GENE
binding I-GENE
sites I-GENE
upstream O
of O
each O
of O
the O
two O
RARE O
transcription O
RARE O
. O

RARE O
with O
a O
short O
postexposure O
time O
and O
a O
RARE O
burden O
> O
NUM O
. O
6 O
pg O
/ O
m3 O
had O
a O
significantly O
RARE O
risk O
of O
RARE O
than O
RARE O
subjects O
( O
RARE O
I O
: O
OR O
= O
9 O
. O
NUM O
, O
NUM O
% O
ALL_CAP O
= O
1 O
. O
96 O
- O
NUM O
. O
02 O
; O
RARE O
II O
: O
OR O
= O
2 O
. O
92 O
, O
NUM O
% O
ALL_CAP O
= O
1 O
. O
14 O
- O
7 O
. O
5 O
). O

Analysis O
of O
this O
sequence O
combined O
with O
that O
previously O
reported O
RARE O
the O
5 O
'- O
flanking O
region O
directly O
proximal O
to O
the O
RARE O
of O
transcription O
revealed O
several O
putative O
regulatory O
sequences O
. O

We O
now O
show O
that O
the O
NUM I-GENE
translation I-GENE
product I-GENE
is O
the O
homolog O
of O
the O
rat I-GENE
NUM I-GENE
nuclear I-GENE
protein I-GENE
, O
the O
NUM I-GENE
Drosophila I-GENE
gene I-GENE
product I-GENE
, O
and O
probably O
also O
NUM I-GENE
of O
Caenorhabditis O
elegans O
, O
all O
members O
of O
the O
ALL_CAP I-GENE
protein I-GENE
family I-GENE
of O
ATP I-GENE
- I-GENE
dependent I-GENE
RNA I-GENE
RARE I-GENE
. O

By O
using O
lacZ I-GENE
fusions I-GENE
, O
it O
was O
possible O
to O
localize O
the O
DNA O
sequences O
required O
to O
mediate O
RARE O
repression O
to O
the O
RARE I-GENE
promoter I-GENE
- I-GENE
regulatory I-GENE
region I-GENE
. O

In O
this O
report O
, O
we O
describe O
the O
characterization O
of O
two O
early O
class I-GENE
II I-GENE
RARE I-GENE
genes I-GENE
contained O
in O
the O
ALL_CAP O
- O
ALL_CAP I-GENE
locus O
. O

RARE O
adaptation O
RARE O
and O
recovery O
: O
acute O
RARE O
after O
acoustic O
RARE O
resection O
. O

The O
experimental O
design O
represents O
a O
2 O
RARE O
3 O
RARE O
arrangement O
of O
treatments O
with O
three O
dietary O
levels O
of O
incorporation O
of O
ALL_CAP O
( O
NUM O
, O
50 O
, O
and O
NUM O
%), O
and O
RARE O
either O
RARE O
or O
RARE O
. O

A O
cDNA O
clone O
corresponding O
to O
the O
putative O
ALL_CAP I-GENE
20 I-GENE
- O
oxidase I-GENE
genomic O
sequence O
was O
constructed O
with O
the O
reverse O
transcription O
- O
PCR O
method O
, O
and O
the O
identity O
of O
the O
cDNA O
clone O
was O
confirmed O
by O
analyzing O
the O
RARE O
of O
the O
fusion O
protein O
RARE O
in O
Escherichia O
coli O
to O
RARE O
NUM I-GENE
to O
NUM I-GENE
and O
NUM I-GENE
to O
NUM I-GENE
. O

There O
were O
RARE O
significant O
changes O
in O
either O
the O
fatty O
acid O
composition O
of O
biliary O
RARE O
or O
in O
the O
bile O
acid O
composition O
of O
bile O
. O

Total O
cholesterol O
was O
also O
RARE O
RARE O
week O
12 O
by O
NUM O
. O
NUM O
% O
( O
20 O
mg O
/ O
day O
) O
and O
NUM O
. O
7 O
% O
( O
20 O
- O
NUM O
mg O
/ O
day O
RARE O
and O
RARE O
week O
52 O
by O
20 O
. O
4 O
% O
(< O
or O
= O
20 O
mg O
/ O
day O
) O
and O
19 O
. O
2 O
% O
(> O
or O
= O
NUM O
mg O
/ O
day O
). O

Although O
further O
studies O
are O
required O
to O
determine O
the O
precise O
role O
of O
NUM I-GENE
in O
the O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
promoter I-GENE
activity O
, O
the O
present O
findings O
suggested O
the O
importance O
of O
the O
relative O
ratio O
of O
different O
NUM I-GENE
isoforms I-GENE
in O
RARE O
the O
levels O
of O
the O
promoter O
activity O
. O

RARE O
of O
obtaining O
RARE O
RARE O
in O
RARE O
. O

RARE O
- O
RARE O
can O
be O
used O
RARE O
the O
treatment O
of O
infections O
caused O
by O
gram O
- O
negative O
, O
gram O
- O
positive O
, O
aerobic O
, O
and O
anaerobic O
bacteria O
. O

Basal O
plasma O
renin I-GENE
activity O
( O
ALL_CAP O
) O
was O
slightly O
raised O
prior O
to O
training O
( O
P O
< O
NUM O
. O
07 O
) O
compared O
to O
the O
controls O
and O
post O
- O
training O
. O

This O
apparently O
RARE O
RARE O
/ O
activity O
relationship O
RARE O
important O
issues O
RARE O
understanding O
the O
evolution O
of O
regulatory O
peptides O
and O
the O
mechanisms O
that O
control O
their O
RARE O
. O

The O
structural O
gene O
encoding O
the O
novel O
RARE O
RARE I-GENE
NUM I-GENE
from O
RARE O
RARE O
NUM O
was O
RARE O
and O
its O
nucleotide O
sequence O
was O
determined O
. O

This O
paper O
RARE O
the O
experimental O
evidence O
upon O
which O
the O
clinical O
trials O
of O
RARE I-GENE
reductase I-GENE
RARE O
in O
diabetic O
patients O
have O
been O
RARE O
and O
the O
results O
of O
published O
drug O
trials O
in O
these O
patients O
. O

The O
spectrum O
of O
RARE O
caused O
by O
these O
mutations O
was O
strikingly O
different O
than O
mutations O
in O
the O
RARE O
RARE O
the O
VP16 I-GENE
activation I-GENE
domain I-GENE
. O

RARE O
in O
RARE O
RARE O
and O
RARE O
after O
RARE O
infusion O
. O

The O
5 O
' O
flanking O
region O
is O
highly O
ALL_CAP O
rich O
, O
with O
multiple O
CpG O
RARE O
, O
and O
contains O
multiple O
binding O
sites O
RARE O
NUM I-GENE
. O

To O
RARE O
whether O
these O
disorders O
of O
GnRH I-GENE
deficiency O
are O
associated O
with O
altered O
melatonin O
RARE O
profiles O
, O
we O
compared O
untreated O
young O
males O
ALL_CAP O
( O
RARE O
= O
7 O
) O
and O
ALL_CAP O
( O
RARE O
= O
7 O
) O
to O
normal O
RARE O
male O
controls O
( O
RARE O
= O
6 O
). O

Increased O
RARE O
pressure O
RARE O
ALL_CAP O
treatment O
was O
independent O
of O
circulating O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
levels O
. O

Analysis O
of O
several O
Tat I-GENE
mutants I-GENE
indicated O
that O
both O
the O
cysteine O
- O
rich O
and O
the O
core O
domains O
of O
this O
RARE O
are O
necessary O
and O
sufficient O
to O
activate O
transcription O
when O
TBP I-GENE
is O
overexpressed O
. O

In O
addition O
, O
depletion O
of O
Oct I-GENE
- I-GENE
1 I-GENE
from O
the O
nuclear O
RARE O
by O
using O
Oct I-GENE
- I-GENE
1 I-GENE
- O
specific O
RARE O
or O
a O
sequence O
- O
specific O
DNA O
affinity O
resin O
decreased O
in O
vitro O
transcription O
from O
the O
wild O
- O
type O
ALL_CAP O
promoter O
to O
a O
level O
identical O
to O
that O
obtained O
from O
a O
promoter O
in O
which O
all O
three O
octamer O
- O
related O
sequences O
were O
RARE O
. O

RARE O
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
by O
T3R I-GENE
alpha I-GENE
and O
several O
receptor O
mutants O
revealed O
that O
the O
50 O
- O
amino O
- O
acid O
N O
- O
terminal O
A O
/ O
B O
region O
of O
T3R I-GENE
alpha I-GENE
, O
known O
to O
interact O
with O
the O
basal I-GENE
transcription I-GENE
factor I-GENE
ALL_CAP I-GENE
, O
is O
critical O
RARE O
activation O
of O
both O
Tat I-GENE
- O
dependent O
and O
Tat I-GENE
- O
independent O
responsive O
sequences O
of O
the O
LTR O
. O

M O
. O
M O
. O
C O
. O
was O
used O
RARE O
2 O
. O
5 O
minutes O
in O
NUM O
cases O
( O
20 O
HR O
patients O
, O
NUM O
ALL_CAP O
patients O
RARE O
and O
RARE O
5 O
minutes O
in O
NUM O
cases O
( O
NUM O
HR O
patients O
, O
20 O
ALL_CAP O
patients O
). O

Finally O
, O
we O
show O
that O
complexes O
similar O
to O
the O
NUM I-GENE
, O
NUM I-GENE
and O
NUM I-GENE
complexes I-GENE
are O
formed O
by O
rat O
cortex O
nuclear O
extracts O
and O
the O
ALL_CAP O
element O
in O
EMSA O
experiments O
, O
suggesting O
the O
relevance O
of O
our O
in O
vitro O
observations O
to O
the O
in O
vivo O
functioning O
of O
the O
rat I-GENE
ALL_CAP I-GENE
promoter I-GENE
. O

RARE O
, O
clinical O
and O
psychological O
aspects O
are O
evaluated O
according O
to O
experience O
accumulated O
in O
recent O
years O
, O
with O
immediate O
and O
delayed O
reconstruction O
, O
carried O
out O
in O
the O
most O
diverse O
specialized O
centers O
. O

The O
analysis O
of O
the O
prevalence O
values O
shows O
clearly O
that O
the O
global O
MS O
- O
frequency O
is O
RARE O
related O
to O
the O
RARE O
than O
to O
the O
RARE O
RARE O
. O

RARE O
caused O
significant O
decrease O
in O
the O
ventricular O
response O
without O
conversion O
to O
sinus O
rhythm O
. O

RARE O
primates O
appear O
to O
be O
more O
RARE O
to O
reproductive O
and O
other O
adverse O
effects O
of O
RARE O
than O
humans O
. O

When O
excluding O
children O
with O
ocular O
and O
cerebral O
pathology O
, O
NUM O
matched O
RARE O
of O
premature O
and O
control O
children O
remained O
. O

The O
RARE I-GENE
antigen I-GENE
test O
was O
positive O
RARE O
1 O
: O
NUM O
by O
latex O
RARE O
. O

Functional O
analysis O
of O
DNase I-GENE
- I-GENE
I I-GENE
RARE O
sites O
RARE O
the O
mouse I-GENE
RARE I-GENE
RARE I-GENE
gene I-GENE
locus I-GENE
. O

These O
transcripts O
have O
a O
unique O
5 O
' O
RARE O
region O
and O
NH2 O
- O
terminal O
sequence O
and O
encode O
a O
predicted O
protein O
of O
NUM O
ALL_CAP O
. O

Both O
mu I-GENE
and I-GENE
gamma I-GENE
NUM I-GENE
heavy I-GENE
chain I-GENE
genes I-GENE
cause O
this O
RARE O
inhibition O
of O
heavy O
chain O
gene O
rearrangement O
. O

RARE O
ALL_CAP I-GENE
binds O
in O
vitro O
to O
the O
ALL_CAP I-GENE
control I-GENE
region I-GENE
and O
RARE O
against O
DNase I-GENE
I I-GENE
two O
RARE O
NUM O
bp O
long O
stretches O
, O
one O
of O
which O
is O
RARE O
just O
RARE O
of O
the O
ALL_CAP O
sequence O
. O

They O
include O
genes O
encoding O
three O
subunits O
of O
the O
cytochrome I-GENE
oxidase I-GENE
( O
NUM I-GENE
to I-GENE
3 I-GENE
RARE O
RARE I-GENE
b I-GENE
( O
RARE I-GENE
RARE O
RARE O
subunits O
of O
the O
ALL_CAP I-GENE
dehydrogenase I-GENE
complex I-GENE
( O
NUM I-GENE
to I-GENE
6 I-GENE
, O
NUM I-GENE
RARE O
two O
ATPase I-GENE
subunits O
( O
NUM I-GENE
and O
NUM I-GENE
RARE O
three O
ribosomal O
RNAs O
( O
NUM I-GENE
, O
RARE I-GENE
and O
RARE I-GENE
RARE O
NUM O
RARE O
and O
four O
ribosomal O
proteins O
( O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
and O
NUM I-GENE
). O

From O
day O
10 O
, O
a O
significant O
increase O
in O
platelet O
count O
was O
observed O
in O
eight O
of O
the O
ten O
patients O
treated O
with O
RARE O
( O
p O
< O
NUM O
. O
05 O
RARE O
with O
return O
to O
the O
initial O
value O
after O
RARE O
cessation O
in O
RARE O
of O
the O
responders O
. O

These O
" O
RARE O
- O
like O
" O
RARE O
were O
readily O
RARE O
by O
density O
gradient O
RARE O
. O

The O
RARE O
RARE O
RARE O
. O

RARE O
RARE O
RARE O
patients O
to O
RARE O
smoking O
. O

The O
NUM I-GENE
alpha I-GENE
proteins I-GENE
contain O
a O
NUM O
- O
amino O
- O
acid O
( O
RARE O
) O
region O
highly O
homologous O
to O
the O
Drosophila I-GENE
melanogaster I-GENE
RARE I-GENE
gene I-GENE
RARE I-GENE
. O

In O
human O
proliferative O
cells O
, O
the O
ALL_CAP O
- O
dependent O
ALL_CAP I-GENE
activity O
is O
poorly O
RARE O
and O
RARE O
inducible O
by O
thyroid O
RARE O
. O

Based O
on O
previous O
mapping O
of O
the O
G I-GENE
beta I-GENE
gamma I-GENE
binding I-GENE
region I-GENE
of O
beta I-GENE
ALL_CAP I-GENE
, O
and O
RARE O
residues O
within O
the O
ALL_CAP I-GENE
domain I-GENE
, O
we O
have O
constructed O
a O
series O
of O
mutants O
in O
the O
RARE O
terminus O
of O
beta I-GENE
ALL_CAP I-GENE
in O
order O
to O
determine O
important O
residues O
involved O
in O
G I-GENE
beta I-GENE
gamma I-GENE
and O
PIP2 O
binding O
. O

RARE O
features O
of O
RARE O
RARE O
. O

To O
RARE O
these O
mechanisms O
, O
wild O
- O
type O
and O
mutant I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
were O
studied O
in O
an O
in O
vitro O
RARE O
with O
RARE O
plasma O
membranes O
from O
v I-GENE
- I-GENE
Ras I-GENE
- O
and O
v I-GENE
- I-GENE
Src I-GENE
- O
transformed O
cells O
( O
transformed O
membranes O
). O

In O
ALL_CAP O
- O
1 O
cells O
, O
cotransfection O
of O
the O
retinoid I-GENE
and I-GENE
estrogen I-GENE
receptors I-GENE
led O
to O
RARE O
inhibition O
of O
the O
other O
' O
s O
activity O
, O
while O
an O
ALL_CAP O
- O
dependent O
inhibition O
of O
ER I-GENE
activity O
was O
observed O
in O
breast O
RARE O
cells O
. O

One O
of O
these O
factors O
, O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
recognizes O
a O
cis O
element O
consisting O
of O
an O
inverted O
palindromic O
motif O
. O

Regulation O
of O
RARE I-GENE
RARE I-GENE
gene I-GENE
transcription O
by O
a O
combination O
of O
positive O
factors O
including O
RARE I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
factor I-GENE
2 I-GENE
. O

The O
RARE O
- O
terminal O
RARE O
domain O
of O
heat I-GENE
shock I-GENE
factor I-GENE
1 I-GENE
is O
negatively O
regulated O
and O
stress O
responsive O
. O

D O
. O

It O
was O
proposed O
that O
the O
RARE O
- O
related O
sequences O
of O
GCN2 I-GENE
stimulate O
the O
activity O
of O
the O
kinase O
by O
RARE O
directly O
with O
RARE O
tRNA O
that O
accumulates O
RARE O
amino O
acid O
limitation O
. O

However O
, O
unlike O
Bcl I-GENE
- I-GENE
2 I-GENE
and O
the O
E1B I-GENE
NUM I-GENE
proteins I-GENE
, O
which O
completely O
RARE O
apoptosis O
but O
not O
p53 I-GENE
- O
dependent O
growth O
arrest O
, O
H I-GENE
- I-GENE
ras I-GENE
RARE O
permitted O
DNA O
RARE O
and O
cell O
RARE O
in O
the O
presence O
of O
high O
levels O
of O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
. O

To O
compare O
the O
NUM I-GENE
and O
putative O
NUM I-GENE
- O
ALL_CAP I-GENE
RARE O
domains O
, O
we O
fused O
C O
- O
terminal O
test O
fragments O
to O
the O
heterologous O
GAL4 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
and O
tested O
activation O
of O
a O
reporter O
gene O
RARE O
- O
transfected O
into O
four O
cell O
RARE O
. O

All O
subjects O
were O
submitted O
to O
ECG O
and O
arterial O
RARE O
pressure O
determination O
and O
were O
assayed O
RARE O
ALL_CAP I-GENE
, O
thyroid O
hormone O
, O
PRL I-GENE
, O
glucose O
, O
RARE O
, O
nitrogen O
, O
RARE I-GENE
RARE I-GENE
, O
cholesterol O
and O
RARE O
plasma O
levels O
before O
therapy O
( O
NUM O
RARE O
after O
NUM O
treatment O
days O
( O
NUM O
) O
and O
after O
a O
NUM O
days O
washout O
( O
NUM O
). O

Acute O
decrease O
in O
body O
RARE O
( O
ALL_CAP O
) O
lowered O
PaCO2 O
( O
NUM O
. O
5 O
to O
14 O
. O
5 O
mmHg O
) O
and O
RARE O
HCO3 O
RARE O
a O
( O
NUM O
. O
20 O
mEq O
/ O
L O
to O
NUM O
. O
NUM O
mEq O
/ O
L O
RARE O
increased O
RARE O
( O
7 O
. O
NUM O
to O
7 O
. O
NUM O
) O
and O
diminished O
the O
RARE O
OH O
RARE O
H O
RARE O
ratio O
, O
but O
had O
RARE O
significant O
effect O
on O
RARE O
ALL_CAP O
] O
or O
RARE O
RARE O
], O
although O
both O
RARE O
phosphorus O
RARE O
PT O
] O
and O
inorganic O
phosphate O
RARE O
RARE O
] O
increased O
. O

RARE O
B O
vaccine O
: O
still O
has O
its O
problems O
. O

Basal O
promoter O
activity O
is O
RARE O
by O
a O
RARE O
NUM O
domain O
in O
LHR I-GENE
- O
expressing O
mouse O
RARE O
tumor O
cells O
( O
ALL_CAP O
) O
but O
not O
in O
non O
- O
expressing O
CHO O
cells O
. O

The O
NUM I-GENE
gene I-GENE
encodes O
an O
NUM O
- O
amino O
acid O
protein O
without O
RARE O
to O
other O
known O
proteins O
. O

For O
Al O
, O
the O
exposure O
to O
1 O
. O
NUM O
mg O
/ O
m3 O
RARE O
the O
shift O
corresponded O
to O
a O
RARE O
concentration O
RARE O
the O
end O
of O
the O
shift O
of O
NUM O
microgram O
/ O
g O
RARE O
. O

RARE I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
alpha I-GENE
RARE O
a O
RARE O
RARE O
, O
inhibits O
cAMP O
- O
RARE O
testosterone O
production O
in O
mouse O
RARE O
cells O
. O

The O
Drosophila I-GENE
insulin I-GENE
receptor I-GENE
homolog I-GENE
: O
a O
gene O
essential O
RARE O
RARE O
development O
encodes O
two O
receptor O
isoforms O
with O
different O
RARE O
RARE O
. O

We O
show O
here O
that O
ALL_CAP O
and O
E1A I-GENE
induce O
RARE O
of O
the O
E1A I-GENE
- I-GENE
associated I-GENE
NUM I-GENE
kDa I-GENE
protein I-GENE
( O
p300 I-GENE
) O
RARE O
the O
differentiation O
of O
F9 O
cells O
. O

The O
double O
- O
RARE O
RNA O
binding O
domain O
( O
ALL_CAP O
) O
is O
an O
RARE O
65 O
amino O
acid O
motif O
that O
is O
found O
in O
a O
variety O
of O
proteins O
that O
interact O
with O
double O
- O
RARE O
( O
RARE O
) O
RNA O
, O
such O
RARE O
Escherichia O
coli O
RNase I-GENE
III I-GENE
and O
the O
ALL_CAP I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
, O
PKR I-GENE
. O

CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
isoforms I-GENE
beta I-GENE
and I-GENE
delta I-GENE
are O
RARE O
in O
mammary O
RARE O
cells O
and O
bind O
to O
multiple O
sites O
in O
the O
beta I-GENE
- I-GENE
casein I-GENE
gene I-GENE
promoter I-GENE
. O

ALL_CAP I-GENE
was O
resistant O
to O
RARE O
of O
serine O
, O
RARE O
, O
and O
RARE I-GENE
, O
but O
it O
was O
RARE O
to O
N O
- O
RARE O
. O

Mutational O
analysis O
of O
RARE O
activating O
RARE O
sites O
found O
in O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
and O
related O
protein O
kinases O
was O
performed O
on O
ALL_CAP I-GENE
. O

However O
, O
a O
similar O
mutation O
of O
a O
leucine O
RARE O
to O
RARE O
RARE O
position O
NUM O
showed O
RARE O
alteration O
of O
heterodimerization O
, O
DNA O
binding O
, O
or O
transcriptional O
activation O
. O

Expression O
of O
the O
NUM I-GENE
gene I-GENE
is O
increased O
by O
RARE O
, O
such O
RARE O
RARE I-GENE
and O
RARE I-GENE
hormone I-GENE
, O
RARE O
RARE O
RARE O
by O
a O
number O
of O
growth O
factors O
, O
suggesting O
that O
its O
promoter O
may O
contain O
regulatory O
elements O
that O
respond O
to O
multiple O
signal O
RARE O
pathways O
. O

NH2 O
- O
and O
ALL_CAP O
- O
terminal O
deletion O
analysis O
revealed O
that O
both O
the O
ALL_CAP I-GENE
and O
putative O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
domains I-GENE
are O
required O
, O
but O
the O
zinc O
RARE O
is O
dispensable O
, O
RARE O
transformation O
. O

We O
have O
found O
that O
the O
RARE O
of O
GTPase I-GENE
- O
RARE O
mutants O
of O
alpha I-GENE
12 I-GENE
( O
alpha I-GENE
NUM I-GENE
) O
or O
alpha I-GENE
NUM I-GENE
( O
alpha I-GENE
NUM I-GENE
) O
leads O
to O
RARE O
activation O
of O
the O
Jun I-GENE
kinase I-GENE
/ O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
JNK I-GENE
/ O
SAPK I-GENE
) O
RARE O
. O

The O
objective O
of O
our O
study O
was O
to O
evaluate O
the O
age O
, O
RARE O
, O
clinical O
conditions O
, O
family O
history O
, O
site O
, O
catheter O
association O
, O
means O
of O
RARE O
evaluation O
, O
development O
of O
pulmonary O
involvement O
, O
prevalence O
of O
antithrombin I-GENE
III I-GENE
, O
protein I-GENE
C I-GENE
and O
protein I-GENE
S I-GENE
deficiencies O
, O
and O
lupus O
RARE O
in O
children O
who O
RARE O
a O
thrombotic O
event O
. O

RARE O
, O
E O
. O
M O
. O

RARE O
and O
early O
RARE O
in O
RARE O
NUM O
RARE O
carcinoma O

Structural O
organization O
and O
developmental O
RARE O
pattern O
of O
the O
mouse I-GENE
ALL_CAP I-GENE
- I-GENE
repeat I-GENE
gene I-GENE
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
immediately O
upstream O
of O
the O
RARE I-GENE
RARE I-GENE
locus I-GENE
. O

The O
NUM O
procedure O
models O
the O
recorded O
signal O
RARE O
the O
sum O
of O
three O
signals O
: O
( O
a O
) O
the O
background O
EEG O
activity O
, O
RARE O
RARE O
an O
RARE O
process O
RARE O
by O
a O
RARE O
noise O
; O
( O
b O
) O
a O
RARE O
version O
of O
a O
reference O
signal O
carrying O
the O
average O
RARE O
contained O
in O
each O
RARE O
; O
( O
c O
) O
a O
signal O
due O
to O
the O
ocular O
RARE O
RARE O
. O

The O
RARE O
of O
the O
gene O
encoding O
the O
enzyme O
( O
NUM I-GENE
) O
is O
regulated O
, O
in O
part O
, O
by O
tissue O
- O
specific O
promoters O
through O
the O
use O
of O
RARE O
- O
RARE O
mechanisms O
. O

Using O
mutagenesis O
, O
we O
have O
identified O
two O
mutations O
of O
the O
second O
actin I-GENE
- I-GENE
binding I-GENE
domain I-GENE
that O
can O
also O
suppress O
the O
NUM I-GENE
mutations O
of O
interest O
. O

ALL_CAP I-GENE
mRNA I-GENE
is O
normally O
inducible O
by O
IFN I-GENE
- I-GENE
gamma I-GENE
in O
class O
II O
non O
- O
inducible O
, O
ALL_CAP O
- O
RARE O
lines O
, O
and O
in O
one O
line O
, O
re O
- O
RARE O
of O
ALL_CAP I-GENE
has O
RARE O
effect O
on O
ALL_CAP I-GENE
mRNA I-GENE
induction O
levels O
. O

The O
normal O
cell O
RARE O
is O
regulated O
by O
several O
molecules O
, O
such O
RARE O
the O
tumor I-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
pRb I-GENE
, O
the O
G1 I-GENE
RARE I-GENE
, O
the O
RARE I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
, O
and O
their O
RARE O
. O

Consistent O
with O
the O
protein O
RARE O
data O
, O
V I-GENE
beta I-GENE
8 I-GENE
. I-GENE
3 I-GENE
gene I-GENE
transcripts I-GENE
were O
found O
only O
in O
the O
transgenic O
lines O
with O
the O
wild O
- O
type O
promoter O
. O

These O
results O
are O
very O
useful O
RARE O
RARE O
on O
the O
doses O
of O
RARE O
and O
the O
expected O
serum O
estradiol O
level O
in O
ALL_CAP O
RARE O
Japanese O
women O
. O

Comparison O
of O
1 O
. O
5 O
RARE O
and O
NUM O
. O
NUM O
RARE O
field O
strength O
magnetic O
resonance O
imaging O
scans O
in O
the O
RARE O
evaluation O
of O
the O
lumbar O
RARE O
RARE O
. O

One O
month O
after O
the O
ALL_CAP O
RARE O
vaccination O
, O
both O
groups O
had O
6 O
- O
to O
40 O
- O
RARE O
increases O
in O
serum O
antibody O
concentrations O
to O
all O
antigens O
tested O
; O
the O
concentrations O
against O
the O
three O
RARE I-GENE
antigens I-GENE
were O
RARE O
in O
the O
ALL_CAP O
- O
primed O
children O
( O
p O
< O
NUM O
. O
05 O
). O

Interestingly O
, O
this O
amino O
- O
terminal O
determinant O
appears O
not O
to O
reside O
in O
the O
HSV O
- O
alpha I-GENE
TIF I-GENE
, O
which O
displays O
RARE O
independent O
amino O
- O
terminal O
activity O
. O

We O
also O
show O
that O
in O
fusions O
with O
the O
DNA O
binding O
domain O
of O
GAL4 I-GENE
, O
full O
activity O
requires O
the O
RARE O
ALL_CAP I-GENE
- I-GENE
alpha I-GENE
TIF I-GENE
, O
although O
both O
amino O
and O
RARE O
termini O
display O
some O
activity O
on O
their O
own O
. O

To O
investigate O
the O
RARE O
role O
of O
SP1 I-GENE
, O
we O
examined O
nuclear O
extracts O
from O
ALL_CAP O
- O
RARE O
cells O
. O

Here O
we O
show O
that O
RARE O
RNAs O
encoding O
RARE O
- O
RARE O
containing O
the O
repeats O
are O
not O
present O
in O
RARE O
but O
are O
abundant O
in O
RARE O
. O

From O
RARE O
1985 O
to O
RARE O
1989 O
, O
126 O
RARE O
were O
performed O
RARE O
the O
RARE O
RARE O
City O
RARE O
on O
RARE O
of O
individuals O
AIDS O
victims O
whose O
RARE O
deaths O
had O
RARE O
RARE O
investigations O
. O

A O
model O
with O
age O
and O
RARE O
described O
the O
best O
fit O
RARE O
ALL_CAP O
, O
whereas O
age O
, O
RARE O
, O
and O
height O
described O
the O
best O
fit O
RARE O
RARE O
body O
ALL_CAP O
. O

As O
retinoic O
acid O
and O
thyroid O
hormone O
are O
frequently O
involved O
in O
developmental O
regulatory O
processes O
, O
it O
is O
possible O
that O
this O
element O
may O
be O
important O
in O
the O
process O
of O
islet O
cell O
differentiation O
. O

The O
C O
- O
terminal O
peptide O
sequences O
of O
the O
human I-GENE
lymphocyte I-GENE
- I-GENE
specific I-GENE
high I-GENE
mobility I-GENE
group I-GENE
( I-GENE
HMG I-GENE
)- I-GENE
box I-GENE
transcription I-GENE
factor I-GENE
TCF I-GENE
- I-GENE
1 I-GENE
are O
determined O
by O
RARE O
RARE O
mechanisms O
affecting O
the O
exons O
VIII O
to O
X O
. O

RARE O
NUM O
increased O
( O
97 O
+/- O
NUM O
versus O
40 O
+/- O
NUM O
pg O
/ O
ml O
) O
and O
was O
significantly O
RARE O
RARE O
RARE O
free O
hemodialysis O
than O
RARE O
hemodialysis O
with O
RARE O
( O
p O
= O
NUM O
. O
01 O
, O
RARE O
matched O
RARE O
RARE O
RARE O
test O
). O

A O
new O
vector O
, O
NUM O
, O
was O
designed O
to O
facilitate O
this O
analysis O
. O

To O
explore O
the O
mechanism O
of O
ALL_CAP I-GENE
activation O
, O
a O
RARE O
human O
ALL_CAP I-GENE
cDNA O
( O
NUM I-GENE
) O
was O
used O
to O
generate O
and O
characterize O
several O
site O
- O
directed O
ALL_CAP I-GENE
mutants I-GENE
; O
NUM O
( O
N O
- O
RARE O
, O
NH2 O
- O
terminal O
ATP O
- O
binding O
mutant O
RARE O
NUM O
( O
C O
- O
RARE O
, O
ALL_CAP O
- O
terminal O
ATP O
- O
binding O
mutant O
RARE O
N O
/ O
C O
- O
RARE O
( O
double O
ATP O
- O
binding O
mutant O
) O
NUM O
( O
C O
- O
RARE O
, O
mutant O
of O
the O
putative O
ALL_CAP I-GENE
RARE O
site O
in O
RARE O
VIII O
of O
the O
C O
- O
domain O
RARE O
NUM O
( O
N O
- O
RARE O
, O
mutant O
of O
the O
corresponding O
NH2 O
- O
terminal O
RARE O
). O

In O
contrast O
, O
both O
C O
- O
RARE O
and O
C O
- O
RARE O
retained O
high O
levels O
of O
kinase O
activity O
and O
were O
capable O
of O
responding O
to O
RARE O
. O

Conversely O
, O
treatment O
of O
human I-GENE
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
alpha I-GENE
- O
overexpressing O
cells O
with O
RARE O
oxide O
led O
to O
a O
RARE O
of O
the O
RARE O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
activity O
. O

A O
TATA O
- O
less O
promoter O
containing O
binding O
sites O
RARE O
ubiquitous O
transcription O
factors O
mediates O
cell O
type O
- O
specific O
RARE O
of O
the O
gene O
RARE O
transcription I-GENE
enhancer I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
TEF I-GENE
- I-GENE
1 I-GENE
). O

Since O
electrical O
RARE O
of O
neurones O
may O
activate O
not O
only O
cell O
RARE O
but O
also O
RARE O
fibres O
, O
this O
study O
aimed O
to O
test O
a O
selectively O
cholinergic O
RARE O
RARE O
of O
the O
rat O
RARE O
RARE O
( O
ALL_CAP O
) O
by O
the O
local O
microinjection O
of O
carbachol O
; O
the O
effects O
of O
this O
RARE O
agonist O
were O
compared O
with O
RARE O
. O

Here O
we O
describe O
an O
in O
vitro O
assay O
where O
the O
NUM I-GENE
- I-GENE
NUM I-GENE
RARE I-GENE
, O
NUM I-GENE
, O
the O
serine O
RARE O
domain O
( O
the O
N O
- O
terminal O
NUM O
residues O
of O
NUM O
RARE O
and O
the O
NUM I-GENE
cofactor I-GENE
were O
produced O
by O
cell O
- O
free O
translation O
and O
tested O
RARE O
RARE O
- O
RARE O
of O
radiolabeled O
RARE O
. O

In O
contrast O
, O
over O
- O
RARE O
of O
RAR I-GENE
beta I-GENE
only O
poorly O
restored O
differentiation O
, O
although O
it O
could O
replace O
RAR I-GENE
gamma I-GENE
RARE O
the O
activation O
of O
target O
genes O
. O

We O
RARE O
both O
proteins O
from O
human O
platelet O
membranes O
using O
ALL_CAP O
- O
RARE O
chromatography O
followed O
by O
RARE I-GENE
NUM I-GENE
affinity O
chromatography O
. O

The O
RARE I-GENE
gene I-GENE
NUM I-GENE
of O
Arabidopsis O
thaliana O
is O
RARE O
in O
the O
RARE O
apex O
of O
the O
RARE O
and O
in O
RARE O
and O
RARE O
RARE O
of O
RARE O
RARE O
. O

The O
most O
likely O
explanation O
RARE O
this O
is O
that O
RARE O
RARE O
accumulates O
in O
the O
RARE O
cells O
and O
RARE O
cortex O
and O
these O
cells O
do O
not O
express O
RARE I-GENE
I I-GENE
deiodinase I-GENE
. O

These O
results O
suggest O
that O
different O
models O
of O
RARE O
ischemia O
have O
different O
RARE O
profiles O
and O
that O
the O
early O
TNF I-GENE
response O
associated O
with O
ALL_CAP O
occlusion O
model O
is O
primarily O
due O
to O
the O
RARE O
. O

Our O
evidence O
RARE O
from O
three O
principal O
observations O
: O
1 O
) O
a O
transfection O
construct O
containing O
only O
122 O
nucleotides O
( O
nt O
) O
of O
promoter O
1 O
and O
NUM O
nt O
of O
the O
5 O
'- O
UTR O
retained O
full O
PGE2 O
- O
RARE O
reporter O
RARE O
; O
2 O
) O
maximal O
PGE2 O
- O
RARE O
reporter O
RARE O
required O
the O
presence O
of O
nt O
NUM O
to O
NUM O
of O
RARE O
1 O
when O
tested O
within O
the O
context O
of O
IGF I-GENE
- I-GENE
I I-GENE
promoter I-GENE
1 I-GENE
; O
3 O
) O
cotransfection O
of O
IGF I-GENE
- I-GENE
I I-GENE
promoter I-GENE
- O
luciferase I-GENE
- O
reporter O
constructs O
with O
a O
RARE O
encoding O
the O
alpha O
- O
isoform O
of O
the O
catalytic O
subunit O
of O
murine I-GENE
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
PKA I-GENE
) O
produced O
results O
comparable O
to O
those O
seen O
with O
PGE2 O
treatment O
, O
whereas O
cotransfection O
with O
a O
RARE O
encoding O
a O
mutant O
regulatory O
subunit O
of O
PKA I-GENE
that O
cannot O
bind O
cAMP O
blocked O
PGE2 O
- O
RARE O
reporter O
RARE O
. O

The O
changes O
after O
treatment O
were O
observed O
RARE O
by O
RARE O
while O
sensory O
and O
motor O
improvement O
were O
also O
recorded O
RARE O
RARE O
indicators O
. O

RARE O
- O
shift O
assays O
and O
DNase I-GENE
I I-GENE
footprinting O
experiments O
using O
RARE O
NUM O
kDa O
repressor O
isoform O
confirmed O
that O
RARE I-GENE
5 I-GENE
and I-GENE
6 I-GENE
were O
indeed O
the O
RARE O
RARE O
binding O
of O
this O
protein O
. O

The O
5 O
'- O
terminus O
of O
the O
p I-GENE
- I-GENE
ALL_CAP I-GENE
- I-GENE
M I-GENE
mRNA I-GENE
was O
RARE O
NUM O
nucleotides O
upstream O
of O
p I-GENE
- I-GENE
ALL_CAP I-GENE
within O
p I-GENE
- I-GENE
ALL_CAP I-GENE
. O

RARE O
of O
NUM I-GENE
mutants I-GENE
with O
the O
RARE O
RARE O
from O
the O
ALL_CAP O
- O
resistant O
transformants O
resulted O
in O
RARE O
of O
both O
ALL_CAP O
and O
ALL_CAP O
resistance O
to O
wild O
- O
type O
levels O
. O

Furthermore O
, O
this O
element O
confers O
p53 I-GENE
induction O
to O
the O
otherwise O
RARE O
adenovirus O
major O
RARE O
promoter O
. O

In O
RARE O
, O
the O
RARE I-GENE
protein I-GENE
physically O
associates O
with O
the O
activated O
Drosophila I-GENE
RARE I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
homolog I-GENE
( O
DER I-GENE
) O
and O
is O
RARE O
RARE O
on O
tyrosine O
by O
DER I-GENE
. O

A O
RARE O
binding O
site O
RARE O
the O
RARE I-GENE
ALL_CAP O
domain O
is O
RARE O
RARE O
RARE O
- O
NUM O
of O
DER I-GENE
. O

A O
Drosophila I-GENE
RARE I-GENE
gene I-GENE
product I-GENE
is O
implicated O
in O
RARE O
by O
the O
DER I-GENE
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
. O

This O
inhibition O
can O
be O
overcome O
by O
RARE O
either O
the O
RARE O
' O
s O
5 O
' O
or O
3 O
' O
RARE O
site O
to O
make O
it O
correspond O
more O
closely O
to O
the O
relevant O
consensus O
sequence O
. O

Biochemical O
analysis O
shows O
that O
NUM I-GENE
is O
a O
structural O
protein O
that O
forms O
part O
of O
the O
largest O
NUM I-GENE
ribosomal I-GENE
subunit I-GENE
, O
which O
does O
not O
exist O
in O
a O
pool O
of O
free O
proteins O
. O

In O
wild O
- O
type O
cells O
, O
NUM I-GENE
transcripts I-GENE
accumulate O
to O
twice O
the O
level O
of O
NUM I-GENE
transcripts I-GENE
, O
suggesting O
that O
NUM I-GENE
is O
responsible O
RARE O
the O
majority O
of O
the O
NUM I-GENE
pool O
. O

Northern O
blot O
analysis O
revealed O
the O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
predominantly O
in O
the O
brain O
and O
the O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
in O
various O
tissues O
in O
the O
rat O
. O

However O
, O
the O
relative O
binding O
affinity O
RARE O
the O
motifs O
is O
different O
. O

On O
the O
basis O
of O
this O
anatomic O
concept O
, O
the O
RARE O
procedure O
was O
modified O
to O
provide O
RARE O
RARE O
of O
the O
RARE O
flap O
to O
the O
RARE O
RARE O
along O
with O
strong O
superficial O
RARE O
RARE O
repair O
of O
RARE O
, O
RARE O
the O
risk O
of O
RARE O
or O
migration O
of O
RARE O
and O
RARE O
RARE O
. O

Furthermore O
, O
microinjection O
of O
dominant O
negative O
forms O
of O
Rac I-GENE
and O
Cdc42 I-GENE
or O
of O
the O
Rho I-GENE
inhibitor O
NUM I-GENE
transferase I-GENE
blocked O
serum O
- O
RARE O
DNA O
RARE O
. O

ALL_CAP I-GENE
- I-GENE
alpha I-GENE
therapy O
has O
been O
a O
major O
development O
in O
the O
treatment O
of O
CML O
. O

A O
series O
of O
amino O
terminal O
deletion O
mutants O
( O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
and O
NUM O
) O
were O
compared O
RARE O
RARE O
, O
cell O
surface O
RARE O
, O
and O
RARE O
of O
their O
biological O
RARE O
by O
recombinant O
RARE O
of O
mutant O
genes O
using O
a O
RARE O
vector O
( O
ALL_CAP O
- O
SR O
alpha O
- O
296 O
) O
in O
ALL_CAP O
- O
1 O
and O
HeLa O
cells O
. O

RARE O
acetyl I-GENE
cholinesterase I-GENE
RARE O
produce O
analgesia O
that O
is O
synergistic O
with O
RARE O
and O
RARE O
in O
rats O
. O

After O
RARE O
isoflurane O
ALL_CAP O
in O
RARE O
, O
birds O
were O
given O
a O
mu O
- O
RARE O
agonist O
( O
RARE O
, O
RARE O
= O
9 O
) O
or O
a O
RARE O
- O
RARE O
agonist O
( O
NUM O
, O
RARE O
= O
9 O
). O

Max I-GENE
was O
RARE O
RARE O
RARE O
a O
relatively O
low O
level O
RARE O
cell O
RARE O
progression O
. O

The O
yeast O
enzyme O
was O
6 O
- O
RARE O
slower O
than O
the O
mammalian O
RARE O
, O
which O
made O
it O
RARE O
to O
pre O
- O
steady O
- O
state O
stopped O
- O
flow O
RARE O
kinetic O
analysis O
RARE O
NUM O
degrees O
C O
and O
pH O
6 O
. O
NUM O
. O

RARE O
areas O
of O
the O
selection O
process O
including O
medical O
and O
surgical O
RARE O
to O
transplantation O
, O
the O
composition O
of O
the O
transplant O
work O
- O
RARE O
, O
specific O
inclusion O
criteria O
RARE O
RARE O
RARE O
specific O
RARE O
factors O
and O
specific O
RARE O
RARE O
and O
RARE O
- O
RARE O
that O
might O
represent O
RARE O
were O
extensively O
reviewed O
. O

The O
RARE O
of O
a O
genetically O
RARE O
chimeric O
transmembrane O
protein O
connected O
to O
this O
ER O
RARE O
sequence O
was O
RARE O
efficient O
RARE O
that O
of O
the O
original O
protein O
from O
which O
the O
ER O
sequence O
has O
been O
derived O
. O

In O
both O
RARE O
and O
roots O
, O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
protein I-GENE
is O
undetectable O
in O
RARE O
tissue O
but O
becomes O
RARE O
RARE O
later O
stages O
of O
cellular O
development O
, O
consistent O
with O
a O
role O
in O
RARE O
to O
the O
pattern O
of O
RARE I-GENE
A I-GENE
gene I-GENE
RARE O
. O

A O
polymorphic O
bipartite O
motif O
signals O
nuclear O
targeting O
of O
early O
RARE O
- O
inducible O
proteins O
related O
to O
ALL_CAP O
- O
NUM O
from O
RARE O
( O
RARE O
RARE O
). O

Comparative O
DNA O
sequence O
analysis O
showed O
the O
RARE O
RARE I-GENE
NUM I-GENE
lies O
2 O
. O
2 O
kb O
RARE O
of O
the O
coding O
region O
of O
NUM I-GENE
, O
indicating O
that O
the O
cluster O
RARE O
the O
closely O
RARE O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
is O
RARE O
4 O
ALL_CAP O
distal O
to O
NUM I-GENE
( O
RARE O
score O
NUM O
. O
7 O
) O
and O
9 O
ALL_CAP O
proximal O
to O
NUM I-GENE
( O
RARE O
score O
11 O
. O
7 O
). O

We O
conclude O
that O
transcription O
activation O
by O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
in O
vitro O
is O
a O
chromatin O
- O
dependent O
process O
that O
requires O
a O
RARE O
RARE O
- O
activation O
domain O
in O
addition O
to O
the O
HMG I-GENE
domain I-GENE
. O

ALL_CAP I-GENE
- O
SH3 I-GENE
binding O
in O
vitro O
is O
abolished O
by O
specific O
, O
single O
amino O
acid O
substitutions O
within O
the O
RARE I-GENE
ALL_CAP I-GENE
domain I-GENE
or O
the O
Fyn I-GENE
SH3 I-GENE
domain I-GENE
. O

These O
results O
indicate O
that O
K I-GENE
- I-GENE
RARE I-GENE
is O
a O
novel O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
ALL_CAP I-GENE
involved O
in O
RARE O
development O
. O

Protein I-GENE
S I-GENE
levels O
were O
virtually O
undetectable O
RARE O
the O
time O
of O
admission O
and O
failed O
to O
respond O
to O
RARE O
of O
fresh O
RARE O
plasma O
, O
despite O
correction O
of O
other O
RARE O
and O
RARE O
factors O
. O

The O
RARE O
hormone O
RARE O
transcriptionally O
activates O
early I-GENE
genes I-GENE
. O

The O
test O
was O
not O
performed O
in O
NUM O
patients O
because O
of O
RARE O
. O

The O
ubiquitous O
transcription O
factor O
Oct I-GENE
- I-GENE
1 I-GENE
forms O
complexes O
with O
an O
octamer O
motif O
present O
within O
ALL_CAP O
by O
gel O
shift O
analysis O
with O
liver O
and O
RARE O
extracts O
, O
making O
Oct I-GENE
- I-GENE
1 I-GENE
an O
RARE O
candidate O
RARE O
RARE O
in O
RARE O
RARE O
. O

A O
new O
non O
- O
LTR O
RARE O
provides O
evidence O
RARE O
multiple O
distinct O
site O
- O
specific O
elements O
in O
RARE O
RARE O
RARE O
arrays O
. O

We O
used O
deletion O
analysis O
and O
transfection O
assays O
with O
reporter O
gene O
constructs O
to O
examine O
the O
transcription O
control O
elements O
in O
the O
5 O
' O
flanking O
region O
of O
the O
human I-GENE
ALL_CAP I-GENE
gene I-GENE
. O

The O
NUM I-GENE
. I-GENE
4 I-GENE
RARE I-GENE
transcript I-GENE
is O
the O
most O
RARE O
of O
the O
two O
RARE O
RARE O
in O
RARE O
RARE O
RARE O
10 O
d O
post O
- O
RARE O
. O

RARE O
of O
the O
RARE O
fusion O
proteins O
with O
RARE O
gamma O
- O
32P O
] O
ATP O
in O
an O
in O
vitro O
assay O
showed O
that O
both O
proteins O
were O
capable O
of O
autophosphorylation O
. O

The O
character O
of O
specific O
immune O
response O
in O
NUM O
immunized O
children O
and O
in O
12 O
adults O
belonging O
to O
a O
high O
risk O
group O
with O
respect O
to O
ALL_CAP O
. O

After O
RARE O
, O
RARE O
rate O
decreased O
RARE O
NUM O
+/- O
8 O
%), O
and O
so O
did O
ALL_CAP O
and O
ALL_CAP O
( O
8 O
. O
8 O
+/- O
3 O
. O
4 O
RARE O
. O

The O
RARE O
DNA O
sequence O
was O
constructed O
to O
achieve O
efficient O
RARE O
RARE O
with O
Escherichia I-GENE
coli I-GENE
NUM I-GENE
ribosomal I-GENE
RNA I-GENE
, O
RARE O
of O
internal O
secondary O
RARE O
, O
and O
optimal O
RARE O
usage O
RARE O
high O
- O
level O
protein O
RARE O
in O
RARE O
with O
the O
known O
RARE O
in O
E O
. O
coli O
. O

RARE O
RARE O
activation O
, O
indicated O
by O
RARE O
/ O
epinephrine O
ratio O
, O
increased O
with O
time O
in O
RARE O
males O
, O
except O
that O
after O
one O
month O
of O
RARE O
, O
turnover O
returned O
to O
levels O
that O
RARE O
those O
of O
control O
animals O
. O

RARE O
repair O
of O
type O
IV O
RARE O
- O
abdominal O
aortic O
RARE O
. O

A O
. O

Transcription O
factors O
containing O
a O
basic O
helix O
- O
loop O
- O
helix O
( O
bHLH O
) O
motif O
regulate O
the O
RARE O
of O
tissue O
- O
specific O
genes O
in O
a O
number O
of O
mammalian O
and O
insect O
RARE O
. O

Primer O
extension O
and O
cDNA O
cloning O
were O
used O
to O
isolate O
the O
RARE O
5 O
' O
end O
of O
the O
NUM I-GENE
mRNA I-GENE
. O

Primer O
extension O
and O
S1 I-GENE
RARE I-GENE
mapping O
experiments O
were O
used O
to O
RARE O
the O
transcription O
initiation O
site O
of O
NUM I-GENE
and O
revealed O
the O
presence O
of O
one O
major O
and O
several O
minor O
initiation O
sites O
. O

ALL_CAP I-GENE
can O
repress O
its O
own O
RARE O
but O
seems O
not O
to O
regulate O
the O
RARE O
of O
ALL_CAP I-GENE
. O

Sequence O
analysis O
of O
the O
5 O
'- O
flanking O
region O
of O
the O
NUM I-GENE
gene I-GENE
revealed O
the O
presence O
of O
a O
RARE O
TATA O
element O
NUM O
RARE O
RARE O
upstream O
of O
the O
major O
transcription O
initiation O
site O
and O
several O
putative O
binding O
sequences O
RARE O
inducible O
transcription O
factors O
( O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
, O
RARE I-GENE
- I-GENE
1 I-GENE
, O
AP I-GENE
- I-GENE
1 I-GENE
RARE O
which O
might O
mediate O
the O
inducible O
RARE O
of O
this O
gene O
. O

The O
RARE I-GENE
- I-GENE
derived I-GENE
D I-GENE
( I-GENE
RARE I-GENE
NUM I-GENE
- I-GENE
kDa I-GENE
) I-GENE
product I-GENE
, O
however O
, O
could O
be O
cross O
- O
RARE O
into O
ALL_CAP O
RARE O
. O

All O
clinical O
isolates O
were O
RARE O
tested O
by O
RARE O
diffusion O
and O
agar O
dilution O
procedures O
RARE O
RARE O
by O
the O
National O
Committee O
RARE O
Clinical O
Laboratory O
RARE O
. O

IgE I-GENE
levels O
showed O
RARE O
values O
compared O
to O
normal O
individuals O
and O
IgE I-GENE
levels O
were O
RARE O
in O
children O
groups O
than O
in O
adults O
regardless O
of O
the O
intensity O
of O
infection O
. O

RARE O
- O
specific O
RARE O
of O
the O
RARE I-GENE
- I-GENE
1 I-GENE
gene I-GENE
was O
determined O
by O
microinjection O
of O
a O
promoter I-GENE
/ I-GENE
lacZ I-GENE
fusion I-GENE
gene I-GENE
and O
with O
RARE O
by O
using O
affinity O
- O
RARE O
tissue I-GENE
- I-GENE
specific I-GENE
anti I-GENE
- I-GENE
RARE I-GENE
. O

The O
nucleotide O
sequence O
of O
the O
chloroplast O
( O
RARE O
) O
DNA O
from O
RARE O
( O
RARE O
RARE O
) O
has O
been O
completed O
. O

RARE O
of O
the O
control O
of O
coronavirus O
RARE O
mRNA O
transcription O
by O
using O
NUM O
- O
generated O
negative O
- O
sense O
RNA O
transcripts O
. O

RARE O
of O
translation O
of O
the O
human O
hepatitis O
C O
virus O
( O
HCV O
) O
RNA O
genome O
occurs O
by O
internal O
RARE O
entry O
into O
the O
5 O
' O
noncoding O
region O
( O
5 O
' O
NCR O
) O
in O
a O
RARE O
- O
independent O
manner O
. O

Mean O
longitudinal O
extension O
of O
the O
RARE O
lesion O
was O
2 O
. O
6 O
vertebral O
RARE O
. O

The O
association O
of O
NUM I-GENE
with O
RARE O
complexes O
is O
suggested O
by O
the O
finding O
that O
RARE I-GENE
NUM I-GENE
can O
inhibit O
in O
vitro O
RARE O
and O
RARE O
pre O
- O
RARE O
RNA O
and O
RARE O
products O
. O

L O
- O
NUM O
, O
NUM O
free O
RARE O
or O
RARE O
salt O
was O
administered O
orally O
RARE O
RARE O
, O
solution O
or O
in O
solid O
dosage O
forms O
to O
fasted O
or O
fed O
RARE O
dogs O
. O

Doppler O
ultrasound O
studies O
of O
long O
- O
term O
follow O
- O
RARE O
of O
children O
with O
RARE O
- O
RARE O
RARE O

Thus O
, O
RARE O
RARE O
of O
hepatitis O
A O
diseases O
are O
possible O
. O

( O
1991 O
). O

The O
properties O
of O
the O
RARE O
29 O
SSB I-GENE
- I-GENE
ALL_CAP I-GENE
complex O
are O
described O
. O

This O
shows O
that O
the O
RARE O
diffuse O
RARE O
pattern O
of O
RARE O
nuclear O
proteins O
RARE O
with O
the O
G O
- O
box O
is O
also O
observed O
in O
a O
binding O
assay O
using O
only O
one O
recombinant I-GENE
ALL_CAP I-GENE
. O

We O
studied O
120 O
male O
and O
NUM O
female O
patients O
with O
early O
ALL_CAP O
who O
were O
unrelated O
to O
each O
other O
but O
were O
from O
RARE O
in O
which O
RARE O
least O
one O
other O
RARE O
had O
early O
ALL_CAP O
. O

The O
physical O
linkage O
of O
the O
NUM I-GENE
and O
the O
factor I-GENE
H I-GENE
genes I-GENE
provides O
additional O
evidence O
RARE O
a O
close O
RARE O
of O
complement I-GENE
factor I-GENE
H I-GENE
and O
the O
factor I-GENE
H I-GENE
- I-GENE
related I-GENE
proteins I-GENE
. O

Genomic O
RARE O
and O
chromosomal O
location O
of O
the O
mouse I-GENE
pre I-GENE
- I-GENE
T I-GENE
- I-GENE
cell I-GENE
receptor I-GENE
alpha I-GENE
gene I-GENE
. O

The O
third O
domain O
had O
the O
motif O
of O
a O
cAMP O
response O
element O
( O
ALL_CAP O
). O

The O
tyrosine O
- O
RARE O
state O
of O
CAK I-GENE
beta I-GENE
was O
not O
RARE O
on O
RARE O
, O
nor O
RARE O
in O
response O
to O
RARE O
NUM O
cells O
onto O
fibronectin I-GENE
. O

Our O
results O
suggest O
that O
while O
many O
muscle O
gene O
E O
- O
RARE O
are O
capable O
of O
binding O
the O
previously O
characterized O
spectrum O
of O
ALL_CAP I-GENE
/ I-GENE
ALL_CAP I-GENE
- I-GENE
L I-GENE
- I-GENE
H I-GENE
RARE I-GENE
in O
vitro O
, O
ALL_CAP I-GENE
- I-GENE
L I-GENE
type O
E O
- O
RARE O
probably O
bind O
RARE O
different O
factors O
in O
vivo O
. O

A O
single O
- O
case O
experimental O
ALL_CAP O
multiple O
baseline O
design O
was O
employed O
to O
test O
RARE O
treatment O
effectiveness O
. O

These O
RARE O
were O
found O
to O
share O
a O
common O
domain O
encoded O
by O
p O
( O
CA O
) O
RARE O
repeats O
; O
a O
simple O
sequence O
length O
polymorphism O
( O
ALL_CAP O
). O

In O
one O
RARE O
cell O
line O
, O
a O
Shc I-GENE
- O
associated O
p190 I-GENE
was O
identified O
RARE O
the O
activated O
ALL_CAP I-GENE
. O

We O
conclude O
that O
, O
in O
comparison O
to O
reports O
from O
other O
regions O
, O
RARE O
RARE O
transplant O
recipients O
are O
RARE O
high O
risk O
of O
RARE O
of O
ALL_CAP O
. O

RARE O
RARE O
RARE O
RARE O
export O
. O

The O
serum O
concentration O
of O
ALL_CAP O
before O
dialysis O
( O
HD O
) O
was O
on O
average O
3 O
. O
06 O
(+/- O
NUM O
. O
NUM O
) O
mmol O
/ O
RARE O
and O
D O
was O
on O
average O
NUM O
. O
6 O
(+/- O
10 O
. O
NUM O
) O
mmol O
. O

A O
significant O
correlation O
between O
a O
number O
of O
RARE O
parameters O
of O
RARE O
RARE O
, O
RARE O
and O
histological O
changes O
of O
RARE O
mucosa O
was O
found O
in O
patients O
with O
chronic O
RARE O
. O

The O
ALL_CAP O
factor O
appears O
to O
be O
particularly O
significant O
in O
ALL_CAP O
. O

RARE O
RARE O
matter O
injury O
can O
be O
attributed O
to O
radiation O
and O
associated O
with O
neurological O
deficits O
, O
but O
RARE O
is O
rarely O
observed O
in O
the O
absence O
of O
chemotherapy O
. O

RNase I-GENE
protection O
analyses O
indicate O
that O
either O
NUM I-GENE
- I-GENE
kDa I-GENE
CaM I-GENE
ALL_CAP I-GENE
mRNA I-GENE
or O
structurally O
related O
transcripts O
encoding O
different O
CaM I-GENE
ALL_CAP I-GENE
isoforms I-GENE
are O
RARE O
in O
a O
tissue O
- O
specific O
manner O
. O

RARE O
or O
RARE O
protection O
was O
detected O
using O
adrenal O
cortex O
, O
adrenal O
RARE O
, O
liver O
, O
RARE O
cortex O
, O
RARE O
, O
or O
T O
- O
lymphocyte O
RARE O
RNA O
. O

The O
ALL_CAP I-GENE
mutants I-GENE
that O
failed O
to O
associate O
with O
PLC I-GENE
gamma I-GENE
were O
not O
able O
to O
mediate O
the O
ALL_CAP I-GENE
- O
dependent O
production O
of O
RARE O
RARE O
. O

We O
found O
a O
direct O
correlation O
between O
the O
levels O
of O
transcription O
of O
the O
RARE I-GENE
genes I-GENE
and O
the O
rate O
of O
cellular O
growth O
. O

The O
RARE O
clone O
of O
V O
. O
RARE O
chromosomal O
DNA O
complemented O
a O
V I-GENE
. I-GENE
RARE I-GENE
RARE I-GENE
mutant I-GENE
. O

We O
generated O
transformed O
B O
RARE O
cell O
lines O
from O
controls O
, O
from O
four O
patients O
with O
NUM I-GENE
- O
RARE I-GENE
- O
RARE O
chronic O
RARE O
RARE O
, O
and O
from O
three O
parents O
. O

The O
ectopic O
RARE O
of O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
in O
RARE O
cells O
under O
a O
RARE O
promoter O
is O
sufficient O
RARE O
transcriptional O
activation O
of O
an O
octamer O
- O
dependent O
promoter O
. O

RNase I-GENE
protection O
and O
primer O
extension O
assays O
confirmed O
that O
the O
5 O
' O
non O
- O
coding O
RARE O
is O
included O
in O
the O
NUM O
ALL_CAP I-GENE
mRNA I-GENE
and O
that O
a O
major O
transcription O
RARE O
site O
is O
RARE O
136 O
bp O
upstream O
of O
the O
5 O
' O
non O
- O
coding O
RARE O
RARE O
of O
this O
RARE O
. O

These O
results O
suggest O
that O
FK O
NUM O
is O
a O
useful O
immunosuppressive O
agent O
in O
RARE O
transplantation O
. O

The O
roles O
of O
phorbol O
esters O
and O
cyclic O
AMP O
in O
mediating O
the O
GnRH I-GENE
response O
were O
also O
investigated O
. O

RT O
- O
PCR O
using O
1 O
. O
D O
- O
specific O
primers O
showed O
that O
RARE O
, O
brain O
and O
RARE O
do O
not O
express O
1 O
. O
D O
mRNA O
even O
though O
RARE O
and O
brain O
are O
the O
most O
abundant O
source O
RARE O
ALL_CAP I-GENE
protein I-GENE
. O

Molecular O
cloning O
and O
characterization O
of O
two O
genes I-GENE
encoding I-GENE
NUM I-GENE
, O
a O
cell O
surface O
glycoprotein O
involved O
in O
the O
sexual O
cell O
fusion O
of O
Dictyostelium O
RARE O
. O

Two O
- O
dimensional O
RARE O
analyses O
indicate O
that O
RARE O
on O
RARE O
- O
12 O
and O
RARE O
- O
NUM O
in O
unstimulated O
cells O
is O
associated O
with O
the O
ability O
of O
overexpressed O
NUM I-GENE
- I-GENE
src I-GENE
to O
RARE O
beta O
- O
adrenergic O
signalling O
. O

RARE O
is O
a O
new O
RARE I-GENE
III I-GENE
inhibitor O
that O
RARE O
inotropic O
and O
vasodilator O
properties O
. O

RARE O
studies O
were O
performed O
in O
lymphocytes O
from O
hospital O
workers O
exposed O
to O
low O
doses O
of O
radiation O
( O
1 O
. O
6 O
- O
NUM O
. O
NUM O
RARE O
). O

To O
study O
the O
origin O
of O
different O
ALL_CAP I-GENE
- I-GENE
R I-GENE
transcripts I-GENE
, O
the O
genetic O
linkage O
of O
chemotactic O
receptor O
genes O
, O
and O
the O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
R I-GENE
gene I-GENE
RARE O
, O
we O
determined O
the O
copy O
number O
, O
chromosomal O
location O
, O
structural O
organization O
, O
and O
5 O
'- O
flanking O
sequence O
of O
the O
human I-GENE
ALL_CAP I-GENE
- I-GENE
R I-GENE
gene I-GENE
. O

The O
RARE O
RARE O
encodes O
NUM O
bp O
of O
the O
5 O
'- O
RARE O
sequence O
, O
while O
RARE O
2 O
encodes O
the O
coding O
and O
3 O
'- O
RARE O
sequences O
. O

The O
genomic O
RARE O
of O
four O
members O
of O
the O
SRC I-GENE
- I-GENE
family I-GENE
revealed O
nearly O
identical O
RARE O
/ O
intron O
boundaries O
within O
the O
catalytic O
domain O
of O
this O
family O
. O

Since O
we O
have O
observed O
effects O
of O
growth O
factors O
and O
cAMP O
RARE O
RARE O
RARE O
estradiol O
( O
E2 O
) O
on O
RARE O
of O
RARE O
of O
some O
genes O
RARE O
by O
the O
estrogen I-GENE
receptor I-GENE
( O
ER I-GENE
RARE O
we O
have O
undertaken O
studies O
to O
examine O
directly O
whether O
RARE O
of O
protein O
kinases O
can O
modulate O
transcriptional O
activity O
of O
the O
ER I-GENE
. O

Using O
the O
polymerase O
chain O
reaction O
, O
RARE O
- O
specific O
DNA O
fragments O
of O
NUM O
RARE O
RARE O
from O
the O
genome O
of O
the O
RARE O
bacterium O
( O
RARE O
RARE O
) O
were O
demonstrated O
. O

RNA I-GENE
polymerase I-GENE
RARE O
to O
the O
+ O
NUM O
promoter O
partially O
RARE O
a O
20 O
RARE O
- O
RARE O
sequence O
from O
DNase I-GENE
I I-GENE
digestion O
upstream O
of O
the O
RARE O
site O
. O

RARE O
RARE O
, O
RARE O
, O
and O
magnesium O
concentrations O
were O
significantly O
RARE O
in O
the O
SLE O
patients O
with O
systemic O
lupus O
erythematosus O
, O
whereas O
RARE O
and O
RARE O
protein O
concentrations O
and O
amylase I-GENE
activity O
did O
not O
differ O
significantly O
from O
the O
controls O
. O

Chem O
. O

Recombinant O
RARE O
NUM O
was O
subsequently O
isolated O
by O
its O
ability O
to O
complement O
B O
- O
band O
RARE O
in O
NUM I-GENE
. O

We O
here O
demonstrate O
that O
a O
RARE O
- O
RARE O
RARE O
yeast O
mutant O
which O
has O
a O
mutation O
in O
a O
homologous O
gene O
, O
and O
two O
of O
three O
additional O
( O
NUM I-GENE
/ O
NUM I-GENE
/ O
NUM I-GENE
) O
mutants O
accumulate O
nuclear O
RARE O
( O
A O
)+ O
RNA O
RARE O
37 O
degrees O
C O
. O

Since O
NUM I-GENE
acts O
RARE O
ALL_CAP I-GENE
RARE O
Ran I-GENE
, O
a O
small I-GENE
nuclear I-GENE
GTPase I-GENE
of O
the O
ras I-GENE
superfamily I-GENE
, O
we O
have O
identified O
two O
homologs O
of O
Ran I-GENE
in O
S O
. O
cerevisiae O
( O
NUM I-GENE
and O
NUM I-GENE
). O

The O
RARE O
FK506 O
inhibits O
amino O
acid O
import O
in O
Saccharomyces O
cerevisiae O
. O

RARE I-GENE
specific I-GENE
antigen I-GENE
shows O
the O
metastatic O
cases O
better O
RARE O
correction O
of O
RARE O
] O
than O
RARE I-GENE
acid I-GENE
phosphatase I-GENE
. O

Protein O
RARE O
appears O
to O
play O
a O
critical O
role O
in O
uPA I-GENE
gene I-GENE
RARE O
in O
these O
cells O
; O
protein I-GENE
kinase I-GENE
C I-GENE
- O
activating O
phorbol O
esters O
cooperate O
with O
NUM I-GENE
- I-GENE
src I-GENE
to O
synergistically O
increase O
uPA I-GENE
mRNA I-GENE
, O
whereas O
cyclic I-GENE
AMP I-GENE
( I-GENE
cAMP I-GENE
)- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
- O
activating O
agents O
( O
RARE O
. O
g O
., O
8 O
- O
RARE O
cAMP O
) O
repress O
uPA I-GENE
mRNA I-GENE
levels O
. O

Of O
these O
carriers O
NUM O
were O
diagnosed O
to O
be O
asymptomatic O
clinically O
, O
RARE O
and O
RARE O
. O

This O
NUM O
bp O
5 O
'- O
upstream O
sequence O
of O
NUM I-GENE
RARE I-GENE
gene I-GENE
, O
which O
can O
function O
in O
vitro O
RARE O
a O
RARE O
- O
specific O
promoter O
, O
contains O
two O
clusters O
of O
partially O
overlapping O
motifs O
, O
one O
with O
an O
ALL_CAP I-GENE
consensus O
sequence O
and O
another O
with O
a O
ALL_CAP O
box O
. O

Identification O
of O
mutations O
in O
the O
coding O
sequence O
of O
the O
RARE I-GENE
- I-GENE
oncogene I-GENE
c I-GENE
- I-GENE
kit I-GENE
in O
a O
human O
RARE O
cell O
leukemia O
cell O
line O
causing O
RARE O
- O
independent O
activation O
of O
c I-GENE
- I-GENE
kit I-GENE
product I-GENE
. O

BACKGROUND O
: O
RARE O
of O
the O
morphologic O
aspects O
of O
age O
- O
related O
RARE O
degeneration O
( O
ALL_CAP O
) O
is O
helpful O
in O
correlation O
with O
the O
clinical O
features O
and O
may O
contribute O
to O
understanding O
the O
pathogenesis O
. O

An O
abundant O
1 O
. O
1 O
- O
kb O
virion O
- O
sense O
polyadenylated O
RNA O
and O
four O
RARE O
- O
sense O
polyadenylated O
RNAs O
of O
1 O
. O
7 O
, O
1 O
. O
5 O
, O
1 O
. O
3 O
, O
and O
NUM O
. O
7 O
kb O
have O
been O
identified O
by O
northern O
blot O
hybridization O
, O
confirming O
the O
RARE O
transcription O
strategy O
RARE O
by O
the O
arrangement O
of O
RARE O
. O

Risk O
factors O
associated O
with O
a O
high O
RARE O
of O
hepatitis O
C O
virus O
infection O
in O
RARE O
RARE O
donors O
. O

Here O
the O
cloning O
and O
RARE O
analysis O
of O
the O
RARE I-GENE
- I-GENE
NUM I-GENE
, O
RARE I-GENE
- I-GENE
NUM I-GENE
, O
and O
RARE I-GENE
- I-GENE
NUM I-GENE
genes I-GENE
is O
presented O
. O

This O
agent O
, O
isolated O
from O
the O
RARE O
RARE O
RARE O
, O
has O
a O
mechanism O
of O
action O
similar O
to O
that O
of O
cyclosporine O
. O

DNase I-GENE
I I-GENE
footprinting O
of O
the O
proximal O
promoter O
revealed O
four O
regions O
of O
protection O
. O

Finally O
, O
the O
stability O
of O
the O
nucleotide O
binding O
function O
of O
the O
two O
proteins O
is O
similar O
RARE O
assessed O
by O
sensitivity O
to O
urea O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- I-GENE
2 I-GENE
( O
IGF I-GENE
- I-GENE
ALL_CAP I-GENE
- I-GENE
2 I-GENE
) O
transcription O
in O
rat O
liver O
RARE O
with O
developmental O
age O
and O
fasting O
. O

The O
presence O
of O
the O
RV O
5 O
RARE O
ALL_CAP O
sequence O
had O
the O
RARE O
enhancing O
effect O
on O
translation O
. O

By O
contrast O
, O
all O
proteins O
RARE O
with O
a O
methionine O
placed O
one O
RARE O
upstream O
of O
the O
RARE O
N O
terminus O
of O
PR I-GENE
failed O
to O
show O
specific O
proteolysis O
. O

RARE I-GENE
transcriptase I-GENE
and O
protease O
activities O
of O
avian O
RARE O
virus O
Gag I-GENE
- O
Pol I-GENE
fusion O
proteins O
RARE O
in O
insect O
cells O
. O

In O
addition O
, O
an O
NUM I-GENE
NUM I-GENE
NUM I-GENE
RARE O
RARE O
was O
viable O
. O

However O
, O
there O
were O
some O
properties O
of O
RARE I-GENE
that O
are O
distinct O
from O
Src I-GENE
- I-GENE
like I-GENE
kinases I-GENE
: O
( O
a O
) O
RARE O
of O
RARE I-GENE
was O
predominantly O
in O
RARE O
- O
derived O
cell O
lines O
and O
tissues O
, O
especially O
normal O
liver O
and O
RARE O
, O
and O
cell O
lines O
of O
breast O
and O
colon O
origin O
; O
( O
b O
) O
RARE I-GENE
does O
not O
harbor O
the O
NH2 O
- O
terminal O
glycine O
essential O
RARE O
RARE O
and O
membrane O
RARE O
; O
and O
( O
c O
) O
RARE I-GENE
possesses O
a O
putative O
bipartite O
nuclear O
RARE O
signal O
in O
the O
NUM I-GENE
domain I-GENE
, O
and O
subcellular O
fractionation O
studies O
revealed O
that O
NUM I-GENE
resides O
predominantly O
in O
the O
nucleus O
. O

PATIENTS O
ALL_CAP O
METHODS O
: O
We O
report O
our O
experience O
with O
RARE O
children O
with O
RARE O
small O
bowel O
Crohn O
' O
s O
RARE O
given O
a O
casein I-GENE
- O
based O
, O
RARE O
feed O
rich O
in O
TGF I-GENE
- I-GENE
beta I-GENE
2 I-GENE
( O
Specific O
RARE O
RARE O
; O
RARE O
- O
RARE O
; O
RARE O
, O
RARE O
) O
RARE O
RARE O
nutrition O
RARE O
8 O
weeks O
. O

The O
RARE O
sequence O
of O
the O
isolated O
cDNA O
clone O
contains O
several O
small O
RARE O
reading O
frames O
upstream O
of O
the O
initiation O
RARE O
of O
the O
largest O
RARE O
reading O
frame O
coding O
RARE O
the O
RARE I-GENE
protein I-GENE
. O

A O
small O
amount O
of O
NUM I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
was O
detected O
only O
in O
roots O
. O

Cell O
adhesion O
and O
migration O
assays O
demonstrate O
that O
alpha I-GENE
6 I-GENE
beta I-GENE
1 I-GENE
is O
the O
major O
RARE I-GENE
receptor I-GENE
in O
undifferentiated O
F9 O
cells O
RARE O
RARE O
RARE O
F9 O
- O
derived O
ALL_CAP O
cells O
. O

No O
local O
RARE O
by O
tumor O
or O
infection O
could O
be O
demonstrated O
apart O
from O
HIV O
infection O
. O

Among O
the O
mixed O
RARE O
persons O
one O
RARE O
- O
RARE O
had O
ALL_CAP O
, O
one O
RARE O
- O
RARE O
had O
RARE O
arthritis O
( O
ALL_CAP O
). O

Our O
data O
complement O
other O
studies O
of O
RARE O
populations O
and O
RARE O
the O
reported O
high O
RARE O
of O
ALL_CAP O
and O
HLA I-GENE
- I-GENE
NUM I-GENE
among O
those O
populations O
. O

Clinical O
studies O
NUM O
was O
administered O
to O
NUM O
patients O
with O
various O
infectious O
diseases O
( O
2 O
with O
acute O
RARE O
, O
8 O
with O
acute O
RARE O
, O
4 O
with O
RARE O
RARE O
, O
3 O
each O
with O
acute O
RARE O
, O
pneumonia O
and O
RARE O
, O
7 O
with O
RARE O
fever O
, O
3 O
with O
RARE O
RARE O
, O
6 O
with O
acute O
RARE O
RARE O
infections O
, O
2 O
with O
RARE O
and O
1 O
each O
with O
cervical O
RARE O
, O
S O
. O
S O
. O
S O
. O
S O
., O
RARE O
and O
acute O
RARE O
) O
RARE O
daily O
doses O
between O
3 O
. O
4 O
- O
10 O
mg O
/ O
kg O
, O
t O
. O
i O
. O
d O
., O
RARE O
3 O
- O
14 O
days O
. O

Although O
most O
NUM I-GENE
- O
RARE I-GENE
interactions O
occur O
between O
two O
different O
RARE O
of O
molecules O
, O
some O
appear O
to O
involve O
only O
a O
single O
RARE O
type O
. O

RESULTS O
: O
RARE O
time O
of O
RARE O
in O
patients O
receiving O
TPN O
+ O
somatostatin I-GENE
was O
significantly O
shorter O
( O
NUM O
. O
NUM O
+/- O
1 O
. O
NUM O
versus O
20 O
. O
4 O
+/- O
2 O
. O
NUM O
days O
) O
than O
in O
those O
receiving O
TPN O
alone O
. O

Experimental O
adhesion O
prophylaxis O
with O
recombinant I-GENE
tissue I-GENE
plasminogen I-GENE
activator I-GENE
. O

RARE O
RARE O
sleep O
in O
children O
with O
atopic O
dermatitis O
is O
associated O
with O
increased O
VO2 O
. O

To O
determine O
which O
sequences O
in O
the O
rat I-GENE
NUM I-GENE
promoter I-GENE
may O
be O
responsible O
RARE O
basal O
and O
cAMP O
- O
RARE O
gene O
transcription O
, O
deletion O
constructs O
containing O
between O
- O
1 O
, O
NUM O
and O
- O
53 O
RARE O
RARE O
of O
5 O
'- O
flanking O
DNA O
from O
the O
rat I-GENE
NUM I-GENE
gene I-GENE
were O
ligated O
to O
plasmids O
expressing O
the O
reporter O
gene O
luciferase I-GENE
and O
transfected O
into O
two O
mouse O
cell O
lines O
, O
adrenal O
Y O
- O
1 O
cells O
, O
and O
RARE O
RARE O
ALL_CAP O
- O
10 O
cells O
. O

Within O
- O
subject O
ALL_CAP O
differences O
between O
fish O
oil O
and O
RARE O
oil O
treatment O
were O
similar O
RARE O
RARE O
( O
3 O
. O
2 O
+/- O
1 O
. O
8 O
/ O
2 O
. O
5 O
+/- O
1 O
. O
NUM O
mm O
Hg O
) O
and O
RARE O
NUM O
- O
h O
ALL_CAP O
( O
2 O
. O
5 O
+/- O
1 O
. O
NUM O
/ O
2 O
. O
3 O
+/- O
NUM O
. O
8 O
mm O
Hg O
RARE O
but O
were O
more O
significant O
with O
the O
latter O
. O

We O
have O
RARE O
and O
sequenced O
the O
mouse I-GENE
NUM I-GENE
cDNA I-GENE
, O
which O
encodes O
the O
ALL_CAP I-GENE
( I-GENE
P I-GENE
) I-GENE
H I-GENE
: I-GENE
RARE I-GENE
oxidoreductase I-GENE
RARE O
also O
called O
ALL_CAP I-GENE
( I-GENE
P I-GENE
) I-GENE
H I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
) I-GENE
oxidoreductase I-GENE
; O
RARE I-GENE
reductase I-GENE
; O
RARE I-GENE
RARE I-GENE
reductase I-GENE
; O
ALL_CAP I-GENE
RARE I-GENE
; O
EC I-GENE
1 I-GENE
. I-GENE
6 I-GENE
. I-GENE
NUM I-GENE
. I-GENE
2 I-GENE
]. O

Escherichia O
coli O
NUM O
is O
an O
ALL_CAP I-GENE
ALL_CAP I-GENE
deletion O
RARE O
of O
RARE O
ALL_CAP O
and O
RARE O
it O
is O
RARE O
RARE O
RARE O
of O
the O
RARE O
inducible O
beta I-GENE
- I-GENE
lactamase I-GENE
gene I-GENE
of O
RARE O
RARE O
, O
carried O
on O
RARE O
NUM O
. O

Such O
a O
mechanism O
may O
allow O
RARE O
of O
RARE O
joint O
conditions O
, O
and O
may O
account O
RARE O
the O
increased O
prevalence O
of O
such O
conditions O
seen O
with O
ALL_CAP O
subjects O
. O

RARE O
thyroid O
RARE O
. O

RARE O
RARE O
: O
RARE O
RARE O
the O
future O
. O

While O
daily O
food O
intake O
was O
almost O
constant O
regardless O
of O
the O
dietary O
protein O
level O
, O
water O
intake O
and O
urine O
volume O
increased O
with O
increasing O
the O
dietary O
protein O
. O

We O
propose O
that O
RARE I-GENE
and O
RARE I-GENE
encode O
rate O
- O
limiting O
RARE O
RARE O
to O
RARE I-GENE
pathways O
throughout O
development O
. O

Transcriptional O
RARE O
of O
the O
vacuolar I-GENE
H I-GENE
RARE I-GENE
ATPase I-GENE
NUM I-GENE
subunit I-GENE
gene I-GENE
in O
differentiating O
ALL_CAP O
- O
1 O
cells O
. O

However O
, O
the O
RARE O
to O
export O
RNA O
from O
the O
nucleus O
to O
the O
cytoplasm O
was O
not O
limited O
to O
a O
particular O
RARE O
of O
the O
cell O
division O
RARE O
. O

An O
E O
box O
element O
is O
required O
RARE O
the O
RARE O
of O
the O
NUM I-GENE
gene I-GENE
, O
a O
mammalian I-GENE
homologue I-GENE
of I-GENE
RARE I-GENE
- I-GENE
NUM I-GENE
gene I-GENE
, O
which O
is O
essential O
RARE O
adrenal O
and O
RARE O
development O
. O

Inhibition O
assays O
performed O
with O
over O
NUM O
different O
RARE O
and O
RARE O
RARE O
and O
/ O
or O
RARE O
compounds O
are O
utilized O
to O
define O
in O
greater O
detail O
specific O
structural O
features O
involved O
in O
RARE O
- O
protein O
binding O
. O

The O
amino O
acid O
sequence O
of O
the O
protein O
in O
the O
region O
of O
the O
RARE O
pocket O
is O
similar O
to O
that O
of O
S I-GENE
. I-GENE
RARE I-GENE
RARE I-GENE
A I-GENE
, I-GENE
B I-GENE
, I-GENE
and I-GENE
C I-GENE
. O

Mutations O
in O
the O
NUM I-GENE
gene I-GENE
, O
a O
NUM I-GENE
homologue O
, O
result O
in O
vacuolar O
protein O
RARE O
defects O
and O
accumulation O
of O
membrane O
vesicles O
. O

In O
293 O
cells O
, O
RARE O
of O
the O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
inhibitor O
, O
I I-GENE
RARE I-GENE
B I-GENE
- I-GENE
alpha I-GENE
, O
RARE O
the O
RARE O
activity O
of O
LMP I-GENE
. O

This O
experimental O
design O
was O
used O
to O
determine O
the O
effect O
of O
RARE O
of O
the O
alpha I-GENE
4 I-GENE
- I-GENE
2 I-GENE
binding I-GENE
site I-GENE
on O
the O
repression O
of O
alpha I-GENE
4 I-GENE
gene I-GENE
transcription O
by O
ICP4 I-GENE
. O

RARE O
- O
early O
transcription O
from O
the O
RARE O
RARE O
virus O
genome O
: O
characterization O
of O
two O
immediate I-GENE
- I-GENE
early I-GENE
transcripts I-GENE
. O

The O
ALL_CAP O
RARE O
nucleotide O
NUM O
is O
a O
composite O
ALL_CAP O
( O
ALL_CAP O
) O
containing O
an O
overlapping O
activator I-GENE
protein I-GENE
- I-GENE
1 I-GENE
( O
AP I-GENE
- I-GENE
1 I-GENE
) O
motif O
RARE O
the O
c I-GENE
- I-GENE
jun I-GENE
RARE I-GENE
and O
c I-GENE
- I-GENE
jun I-GENE
/ O
c I-GENE
- I-GENE
fos I-GENE
RARE O
. O

In O
contrast O
to O
some O
results O
previously O
published O
RARE O
a O
very O
close O
sequence O
variant O
( O
RARE O
RARE O
. O

Transcriptional O
activation O
by O
thyroid O
hormone O
( O
NUM O
) O
requires O
interactions O
between O
the O
NUM I-GENE
receptor I-GENE
( O
TR I-GENE
) O
and O
NUM O
response O
elements O
( O
RARE O
) O
composed O
of O
two O
copies O
of O
sequences O
related O
to O
ALL_CAP O
. O

A O
multivariate O
analysis O
of O
risk O
factors O
RARE O
relapse O
examined O
age O
, O
WBC O
RARE O
diagnosis O
, O
RARE O
count O
RARE O
diagnosis O
, O
percentage O
of O
marrow O
RARE O
, O
ALL_CAP I-GENE
RARE O
, O
the O
number O
of O
remission O
induction O
courses O
to O
achieve O
a O
remission O
, O
RARE O
therapy O
, O
RARE O
therapy O
, O
marrow O
cell O
dose O
, O
donor O
- O
recipient O
RARE O
, O
ALL_CAP O
prophylaxis O
regimen O
and O
isolation O
and O
RARE O
in O
RARE O
RARE O
RARE O
. O

RARE I-GENE
RARE I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
II I-GENE
deficiency O
is O
the O
most O
common O
inherited O
disorder O
of O
RARE O
metabolism O
affecting O
skeletal O
muscle O
. O

We O
show O
that O
these O
three O
gain O
- O
of O
- O
function O
mutants O
differ O
considerably O
in O
their O
ability O
to O
bypass O
the O
RARE O
determination O
signal O
, O
with O
NUM I-GENE
being O
the O
strongest O
and O
NUM I-GENE
the O
RARE O
. O

We O
show O
that O
these O
three O
gain O
- O
of O
- O
function O
mutants O
differ O
considerably O
in O
their O
ability O
to O
bypass O
the O
RARE O
determination O
signal O
, O
with O
NUM I-GENE
being O
the O
strongest O
and O
NUM I-GENE
the O
RARE O
. O

Binding O
of O
RARE I-GENE
is O
necessary O
to O
activate O
transcription O
of O
the O
adaptive O
response O
genes O
; O
RARE O
, O
in O
vitro O
transcription O
of O
ALL_CAP I-GENE
is O
dependent O
on O
the O
presence O
of O
RARE I-GENE
. O

No O
significant O
differences O
were O
identified O
between O
groups O
RARE O
pH O
, O
PaCO2 O
, O
RARE O
pressure O
, O
RARE O
rate O
, O
brain O
RARE O
, O
or O
glucose O
levels O
. O

RARE O
pressure O
also O
was O
increased O
by O
lidocaine O
( O
6 O
mg O
kg O
- O
1 O
). O

RARE O
often O
use O
more O
than O
one O
drug O
in O
a O
patient O
to O
achieve O
a O
target O
response O
, O
such O
RARE O
a O
RARE O
RARE O
pressure O
. O

We O
suggest O
that O
this O
gene O
cluster O
codes O
RARE O
( O
parts O
of O
) O
a O
RARE I-GENE
cytochrome I-GENE
c I-GENE
RARE I-GENE
lyase I-GENE
. O

In O
this O
paper O
, O
a O
comparison O
between O
the O
number O
and O
shape O
of O
corneal O
endothelial O
cells O
has O
been O
performed O
in O
NUM O
patients O
before O
and O
6 O
months O
after O
PRK O
. O

RARE O
reference O
sources O
indicate O
that O
an O
able O
- O
RARE O
11 O
- O
year O
- O
old O
child O
of O
comparable O
height O
requires O
1 O
, O
NUM O
RARE O
/ O
d O
RARE O
support O
of O
basal O
metabolic O
functions O
. O

RARE O
RARE O
of O
recombinant I-GENE
RARE I-GENE
ALL_CAP I-GENE
NUM I-GENE
( O
ALL_CAP O
) O
in O
RARE O
volunteers O
. O

In O
contrast O
to O
the O
myoD I-GENE
promoter I-GENE
, O
the O
myoD I-GENE
enhancer I-GENE
shows O
striking O
conservation O
between O
humans O
and O
mice O
both O
in O
its O
sequence O
and O
its O
distal O
position O
. O

However O
, O
a O
clear O
difference O
exists O
between O
myoblasts O
and O
NUM O
/ O
2 O
cells O
( O
and O
other O
non O
- O
muscle O
cell O
RARE O
) O
in O
the O
chromatin O
RARE O
of O
the O
chromosomal O
myoD I-GENE
core I-GENE
enhancer I-GENE
, O
suggesting O
that O
the O
myoD I-GENE
enhancer I-GENE
is O
repressed O
by O
RARE O
mechanisms O
in O
NUM O
/ O
2 O
cells O
. O

Using O
RARE I-GENE
- I-GENE
ras I-GENE
- O
transformed O
3T3 O
cells O
RARE O
a O
model O
RARE O
, O
we O
show O
that O
both O
ALL_CAP O
and O
the O
' O
RARE O
' O
RARE O
inhibit O
anchorage O
- O
independent O
cell O
RARE O
, O
suggesting O
that O
retinoid O
- O
RARE O
growth O
inhibition O
may O
be O
related O
to O
AP1 I-GENE
RARE O
. O

The O
Oct I-GENE
and O
NUM I-GENE
proteins I-GENE
also O
interact O
in O
vivo O
. O

RARE O
dermatitis O
is O
an O
" O
RARE O
which O
RARE O
and O
not O
a O
rash O
which O
RARE O
" O
and O
therefore O
, O
any O
patient O
treatment O
program O
should O
address O
the O
RARE O
of O
RARE O
RARE O
factors O
that O
RARE O
this O
RARE O
. O

Primer O
extension O
experiments O
showed O
that O
there O
are O
two O
transcription O
initiation O
sites O
16 O
bp O
apart O
in O
the O
mouse I-GENE
type I-GENE
2 I-GENE
receptor I-GENE
gene I-GENE
. O

The O
beta O
subunit O
of O
the O
Fc I-GENE
epsilon I-GENE
NUM I-GENE
is O
a O
NUM O
- O
kDa O
tyrosine O
RARE O
, O
but O
the O
NUM I-GENE
Grb2 I-GENE
- I-GENE
binding I-GENE
protein I-GENE
described O
in O
the O
present O
report O
is O
not O
the O
Fc I-GENE
epsilon I-GENE
NUM I-GENE
beta I-GENE
chain I-GENE
and O
its O
identity O
is O
unknown O
. O

To O
study O
the O
mechanisms O
RARE O
RARE O
RARE O
magnitude O
of O
the O
transmembrane O
transfer O
of O
bacterial O
products O
from O
the O
RARE O
, O
we O
developed O
a O
computerized O
in O
vitro O
dialysis O
model O
which O
provides O
continuous O
pressure O
recording O
from O
the O
arterial O
, O
venous O
, O
RARE O
RARE O
and O
outflow O
RARE O
. O

After O
NUM O
hour O
incubation O
, O
RARE O
cell O
- O
associated O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
and O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
were O
measured O
by O
specific O
radioimmunoassay O
. O

Each O
dietary O
treatment O
was O
fed O
to O
RARE O
RARE O
RARE O
of O
five O
chicks O
per O
RARE O
RARE O
21 O
d O
. O

1972 O
. O

In O
contrast O
, O
recent O
evidence O
suggests O
that O
children O
with O
RARE I-GENE
- I-GENE
hemoglobin I-GENE
C I-GENE
RARE O
do O
not O
develop O
RARE O
RARE O
before O
3 O
to O
4 O
years O
of O
age O
and O
thus O
may O
not O
benefit O
from O
RARE O
prophylaxis O
. O

Deletion O
analysis O
indicates O
that O
TBP I-GENE
and O
NUM I-GENE
bind O
to O
distinct O
domains O
of O
NUM I-GENE
. O
NUM I-GENE
also O
interacts O
with O
TBP I-GENE
, O
but O
it O
interacts O
more O
strongly O
with O
NUM I-GENE
and O
NUM I-GENE
. O

The O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
proteins I-GENE
with O
amino O
acid O
substitutions O
RARE O
the O
RARE O
RARE O
RARE O
position O
were O
also O
unable O
to O
RARE O
ALL_CAP I-GENE
- O
phosphate O
in O
vitro O
. O

RARE O
endothelial O
cells O
undergo O
profound O
changes O
upon O
cellular O
activation O
including O
RARE O
of O
a O
spectrum O
of O
cell O
activation O
- O
associated O
genes O
. O

Because O
ATF I-GENE
- I-GENE
1 I-GENE
and O
ALL_CAP I-GENE
are O
known O
to O
bind O
to O
cAMP O
response O
elements O
( O
ALL_CAP O
RARE O
this O
RARE O
sequence O
was O
named O
the O
RARE O
NUM O
'- O
ALL_CAP O
. O

The O
RARE I-GENE
/ I-GENE
NUM I-GENE
and O
PKC I-GENE
- I-GENE
gamma I-GENE
genes I-GENE
have O
a O
similar O
RARE O
pattern O
in O
the O
brain O
RARE O
development O
. O

Structure O
and O
RARE O
of O
the O
gene O
encoding O
the O
RARE O
- O
specific O
protein I-GENE
kinase I-GENE
C I-GENE
substrate O
RARE I-GENE
( O
NUM I-GENE
protein I-GENE
). O

The O
amino O
acid O
sequences O
of O
the O
known O
largest O
subunits O
of O
RARE I-GENE
from O
different O
species O
contain O
highly O
RARE O
regions O
. O

The O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
gene I-GENE
has O
been O
identified O
RARE O
the O
site O
of O
chromosomal O
RARE O
in O
acute O
T O
- O
cell O
leukemia O
' O
s O
( O
T O
- O
ALL O
). O

In O
vitro O
studies O
with O
RARE O
cells O
incubated O
with O
RARE O
or O
RARE O
ions O
in O
concentrations O
, O
which O
are O
observed O
in O
vivo O
RARE O
hemodialysis O
, O
suggest O
that O
probably O
these O
ions O
do O
not O
directly O
affect O
RARE O
RARE O
generation O
, O
RARE O
SOD I-GENE
- I-GENE
1 I-GENE
and O
catalase I-GENE
activities O
and O
RARE O
membrane O
RARE O
peroxidation O
. O

Short O
therapy O
with O
omeprazole O
20 O
mg O
/ O
b O
. O
i O
. O
d O
., O
RARE O
500 O
mg O
/ O
b O
. O
i O
. O
d O
., O
and O
ALL_CAP O
120 O
mg O
/ O
RARE O
. O
i O
. O
d O
. O
is O
a O
safe O
, O
RARE O
tolerated O
combination O
that O
RARE O
a O
NUM O
. O
6 O
% O
eradication O
rate O
of O
H O
. O
RARE O
and O
duodenal O
ulcer O
healing O
rates O
RARE O
good O
RARE O
those O
achieved O
by O
omeprazole O
20 O
mg O
/ O
d O
when O
given O
RARE O
4 O
wk O
. O

The O
concentration O
of O
RARE O
RARE O
was O
very O
low O
( O
mean O
NUM O
. O
18 O
micrograms O
RARE O
p O
RARE O
RARE O
RARE O
dust O
RARE O
whereas O
that O
of O
RARE O
RARE O
was O
high O
in O
RARE O
with O
a O
RARE O
( O
NUM O
. O
8 O
micrograms O
RARE O
d O
RARE O
) O
but O
also O
in O
RARE O
with O
RARE O
RARE O
( O
3 O
. O
2 O
micrograms O
RARE O
d O
RARE O
). O

CONCLUSIONS O
: O
A O
comparison O
of O
the O
ALL_CAP I-GENE
RARE O
RARE O
with O
the O
RARE O
of O
RARE I-GENE
- I-GENE
and I-GENE
RARE I-GENE
- I-GENE
tRNA I-GENE
synthetases I-GENE
enables O
a O
RARE O
core O
to O
be O
identified O
. O

RARE O
bowel O
irrigation O
is O
a O
recently O
described O
technique O
to O
enhance O
the O
passage O
of O
drugs O
already O
beyond O
the O
RARE O
. O

The O
NUM I-GENE
RARE I-GENE
reading I-GENE
frame I-GENE
has O
been O
fused O
to O
those O
that O
encode O
the O
LexA I-GENE
protein I-GENE
or O
the O
GST I-GENE
protein I-GENE
and O
both O
of O
these O
constructs O
function O
in O
yeast O
. O

As O
in O
RARE O
, O
U6 I-GENE
is O
a O
single O
- O
copy O
gene O
and O
two O
tRNA O
genes O
, O
RARE I-GENE
and O
RARE I-GENE
, O
are O
found O
upstream O
to O
the O
gene O
. O

RARE I-GENE
growth I-GENE
factors I-GENE
have O
already O
had O
an O
RARE O
impact O
on O
transfusion O
practice O
by O
RARE O
or O
RARE O
the O
need O
RARE O
RARE O
RARE O
cell O
RARE O
in O
a O
variety O
of O
RARE O
states O
characterized O
by O
an O
absolute O
or O
relative O
decrease O
in O
erythropoietin I-GENE
. O

However O
, O
the O
mouse O
has O
previously O
been O
shown O
to O
possess O
only O
three O
forms O
of O
ADH I-GENE
. O

During O
ALL_CAP O
RARE O
and O
following O
EC O
and O
ALL_CAP O
RARE O
RARE O
rest O
, O
end O
- O
tidal O
CO2 O
pressure O
( O
PET O
, O
CO2 O
) O
fell O
by O
7 O
. O
5 O
, O
8 O
. O
5 O
and O
9 O
. O
5 O
mmHg O
, O
respectively O
. O

2 O
. O

RARE O
analyses O
of O
19 O
amino O
acid O
sequences O
of O
6 O
related O
protein O
RARE O
indicate O
that O
actin I-GENE
- O
associated O
proteins O
related O
to O
RARE I-GENE
are O
RARE O
to O
a O
common O
ancestor O
and O
include O
RARE I-GENE
proteins I-GENE
. O

No O
homologs O
of O
other O
members O
of O
the O
RARE I-GENE
gene I-GENE
cluster I-GENE
were O
detected O
in O
close O
RARE O
to O
the O
D O
. O
melanogaster O
Surf I-GENE
- I-GENE
3 I-GENE
/ O
NUM I-GENE
gene O
. O

Moreover O
, O
we O
found O
that O
RARE I-GENE
E I-GENE
, O
in O
contrast O
to O
RARE I-GENE
NUM I-GENE
, O
was O
required O
RARE O
the O
G1 O
/ O
S O
transition O
even O
in O
cells O
RARE O
RARE I-GENE
protein I-GENE
function O
. O

The O
predicted O
amino O
acid O
sequence O
of O
the O
NUM I-GENE
gene I-GENE
product I-GENE
includes O
a O
region O
with O
substantial O
RARE O
to O
the O
basic O
- O
helix O
- O
loop O
- O
helix O
domain O
of O
the O
RARE I-GENE
family I-GENE
of O
DNA O
- O
binding O
proteins O
. O

By O
RARE O
Pax I-GENE
- I-GENE
6 I-GENE
- O
ALL_CAP I-GENE
fusion O
proteins O
, O
we O
were O
able O
to O
identify O
a O
short O
amino O
acid O
stretch O
in O
the O
N O
- O
terminal O
part O
of O
the O
paired I-GENE
domain O
which O
is O
responsible O
RARE O
these O
differences O
in O
DNA O
- O
binding O
RARE O
. O

To O
establish O
a O
possible O
association O
between O
familial O
RARE O
and O
RARE O
, O
data O
on O
cases O
with O
both O
RARE O
were O
collected O
in O
a O
study O
within O
the O
RARE O
of O
the O
ALL_CAP O
RARE O
on O
RARE I-GENE
of O
the O
International O
RARE O
on O
RARE O
and O
RARE O
. O

RARE O
RARE O
RARE O
bleeding O
time O
in O
RARE O
: O
a O
possible O
role O
of O
RARE O
? O

These O
RARE O
RARE O
have O
an O
area O
of O
NUM O
, O
NUM O
NUM O
and O
RARE O
a O
population O
of O
NUM O
million O
. O

According O
to O
symptoms O
, O
signs O
, O
imaging O
features O
, O
operation O
findings O
, O
the O
original O
RARE O
and O
the O
RARE O
RARE O
of O
the O
tumor O
, O
they O
were O
divided O
into O
four O
clinical O
RARE O
: O
RARE O
, O
RARE O
, O
RARE O
- O
temporal O
and O
extent O
. O

Two O
mammalian O
RARE O
, O
the O
RARE I-GENE
- I-GENE
RARE I-GENE
repressor I-GENE
( O
ALL_CAP I-GENE
) O
and O
the O
double I-GENE
- I-GENE
RARE I-GENE
RNA I-GENE
- I-GENE
activated I-GENE
inhibitor I-GENE
( O
ALL_CAP I-GENE
RARE O
phosphorylate O
RARE O
- O
NUM O
of O
the O
alpha O
subunit O
, O
thereby O
inhibiting O
the O
exchange O
of O
RARE O
nucleotides O
on O
, O
and O
thus O
the O
RARE O
of O
, O
eIF I-GENE
- I-GENE
2 I-GENE
. O

A O
RARE O
RARE O
RARE O
RARE O
mutant O
form O
of O
yeast O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
was O
found O
to O
be O
RARE O
longer O
RARE O
by O
either O
of O
the O
yeast O
( O
or O
mammalian O
) O
casein I-GENE
kinase I-GENE
activities O
in O
vitro O
. O

The O
cases O
included O
NUM O
de O
RARE O
diffuse O
aggressive O
lymphomas O
( O
ALL_CAP O
; O
19 O
large O
- O
cell O
, O
4 O
mixed O
- O
cell O
, O
and O
12 O
large O
- O
cell O
RARE O
RARE O
52 O
transformed O
aggressive O
lymphomas O
derived O
from O
follicular O
lymphomas O
( O
ALL_CAP O
RARE O
NUM O
RARE O
follicular O
lymphomas O
( O
ALL_CAP O
RARE O
14 O
RARE O
cell O
lymphomas O
( O
ALL_CAP O
RARE O
and O
NUM O
small O
RARE O
cell O
lymphomas O
( O
ALL_CAP O
). O

RARE O
and O
beta O
- O
RARE O
in O
RARE O
children O
in O
RARE O

Female O
patients O
with O
breast O
RARE O
diagnosed O
between O
1982 O
and O
1991 O
RARE O
RARE O
RARE O
Cancer O
Institute O
( O
ALL_CAP O
) O
in O
RARE O
, O
New O
York O
, O
who O
provided O
RARE O
on O
their O
RARE O
smoking O
history O
RARE O
the O
time O
of O
their O
diagnosis O
were O
included O
. O

Upon O
analysis O
of O
the O
tissue O
distribution O
of O
ALL_CAP I-GENE
, O
it O
was O
found O
to O
be O
RARE O
strongly O
in O
endothelial O
cells O
, O
RARE O
, O
and O
poorly O
differentiated O
colon O
adenocarcinoma O
cells O
found O
in O
RARE O
. O

Data O
from O
the O
V O
- O
ALL_CAP O
II O
show O
that O
RARE O
2 O
- O
year O
follow O
- O
RARE O
, O
a O
progressive O
rise O
of O
plasma O
norepinephrine O
was O
observed O
in O
both O
treatment O
RARE O
, O
suggesting O
that O
RARE O
RARE O
despite O
treatment O
with O
either O
an O
angiotensin I-GENE
- I-GENE
RARE I-GENE
enzyme I-GENE
inhibitor O
, O
RARE O
, O
or O
vasodilator O
therapy O
with O
RARE O
/ O
RARE O
RARE O
. O

Binding O
activity O
in O
rat O
liver O
nuclear O
extracts O
includes O
these O
orphan O
receptors O
RARE O
judged O
from O
RARE O
supershift O
experiments O
and O
from O
results O
obtained O
with O
RARE O
receptors O
, O
although O
the O
element O
in O
NUM I-GENE
did O
not O
bind O
HNF I-GENE
- I-GENE
4 I-GENE
. O

RARE O
analysis O
reveals O
that O
lethal O
B I-GENE
RARE I-GENE
substitutions O
reduce O
U6 I-GENE
RNA I-GENE
RARE O
RARE O
least O
10 O
- O
RARE O
in O
vivo O
and O
20 O
- O
RARE O
in O
vitro O
. O

Analysis O
of O
Bcl I-GENE
- I-GENE
2 I-GENE
/ O
Bcl I-GENE
- I-GENE
2 I-GENE
RARE O
using O
both O
in O
vitro O
binding O
assays O
RARE O
RARE O
RARE O
a O
yeast O
two O
- O
RARE O
method O
provided O
evidence O
in O
support O
of O
a O
head O
- O
to O
- O
RARE O
model O
RARE O
Bcl I-GENE
- I-GENE
2 I-GENE
/ O
Bcl I-GENE
- I-GENE
2 I-GENE
RARE O
and O
revealed O
that O
sequences O
within O
the O
NH2 O
- O
terminal O
A O
domain O
interact O
with O
a O
RARE O
that O
requires O
the O
presence O
of O
both O
the O
RARE O
B O
and O
C O
domains O
in O
combination O
. O

The O
protein O
is O
composed O
of O
a O
central O
alpha O
- O
helical O
portion O
with O
globular O
domains O
RARE O
both O
NH2 O
and O
ALL_CAP O
termini O
, O
and O
the O
RARE O
to O
the O
monoclonal O
antibody O
resides O
in O
the O
central O
alpha O
- O
helical O
RARE O
. O

RARE O
binding O
was O
indistinguishable O
RARE O
both O
transiently O
RARE O
constructs O
. O

Diagnosis O
of O
ALL_CAP O
has O
been O
RARE O
upon O
laparoscopic O
findings O
. O

Human I-GENE
RARE I-GENE
type I-GENE
NUM I-GENE
RARE I-GENE
gene I-GENE
RARE O
is O
regulated O
through O
protein I-GENE
kinase I-GENE
C I-GENE
- O
RARE O
changes O
in O
RNA O
RARE O
. O

Interestingly O
, O
virions O
also O
contained O
smaller O
proteins O
that O
reacted O
with O
antibodies O
specific O
RARE O
the O
RARE O
proteins O
RARE O
RARE O
RARE O
ALL_CAP I-GENE
and O
CAT I-GENE
fusion I-GENE
partners O
. O

Studies O
using O
an O
inhibitor O
or O
a O
mutant I-GENE
RARE I-GENE
RARE I-GENE
indicated O
that O
RARE O
of O
ALL_CAP O
- O
RARE O
translation O
is O
RARE O
via O
proteolysis O
of O
some O
cellular O
RARE O
( O
s O
). O

Restriction O
mapping O
analysis O
localized O
this O
cDNA O
to O
the O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
( I-GENE
NUM I-GENE
) I-GENE
genomic I-GENE
BamHI I-GENE
G I-GENE
fragment I-GENE
, O
RARE O
the O
right O
end O
of O
the O
unique O
long O
segment O
of O
the O
genome O
and O
to O
the O
ALL_CAP I-GENE
L I-GENE
and O
ALL_CAP I-GENE
O I-GENE
fragments I-GENE
within O
the O
RARE O
and O
right O
terminal O
direct O
repeat O
regions O
, O
respectively O
. O

For O
replication O
reporter O
constructs O
where O
E1 I-GENE
and O
E2 I-GENE
are O
supplied O
in O
RARE O
by O
the O
respective O
RARE O
vectors O
, O
distance O
between O
the O
RARE O
sites O
seems O
to O
play O
a O
major O
role O
, O
yet O
the O
RARE O
relationships O
are O
RARE O
. O

As O
it O
had O
been O
previously O
reported O
that O
the O
18 O
- O
bp O
palindrome O
contains O
sufficient O
nucleotide O
sequence O
RARE O
RARE O
E1 I-GENE
binding O
, O
we O
RARE O
that O
a O
minimal O
E1 I-GENE
recognition O
motif O
is O
presented O
in O
each O
RARE O
site O
. O

METHODS O
: O
RARE O
of O
NUM O
patients O
receiving O
RARE O
between O
RARE O
1992 O
and O
RARE O
1993 O
, O
NUM O
patients O
with O
RARE O
RARE O
received O
RARE O
within O
72 O
hours O
from O
onset O
( O
activated O
partial O
thromboplastin I-GENE
time O
RARE O
ALL_CAP O
] O
1 O
. O
5 O
times O
control O
value O
). O

In O
the O
RARE O
available O
intravenous O
formulation O
of O
RARE O
A O
( O
RARE O
RARE O
RARE O
RARE O
oil O
( O
RARE O
ALL_CAP O
) O
is O
used O
RARE O
a O
RARE O
agent O
. O

Lung O
function O
tests O
( O
ALL_CAP O
) O
were O
performed O
on O
these O
patients O
RARE O
a O
period O
of O
19 O
. O
2 O
+/- O
3 O
. O
4 O
months O
. O

Sequence O
comparisons O
of O
RARE I-GENE
ALL_CAP I-GENE
RARE I-GENE
has O
revealed O
a O
set O
of O
three O
common O
motifs O
, O
two O
of O
which O
, O
a O
putative O
metal O
coordination O
site O
and O
a O
RARE O
RARE O
- O
site O
tyrosine O
motif O
, O
could O
be O
tentatively O
identified O
in O
RARE I-GENE
RARE I-GENE
proteins I-GENE
. O

The O
mean O
RARE O
RARE O
of O
RARE O
restorations O
was O
compared O
RARE O
restorations O
RARE O
from O
stone O
, O
low O
- O
viscosity O
RARE O
( O
vinyl O
RARE O
RARE O
and O
medium O
- O
viscosity O
RARE O
( O
vinyl O
RARE O
). O

The O
characterized O
RARE I-GENE
NUM I-GENE
is O
a O
candidate O
PC I-GENE
that O
may O
play O
an O
important O
role O
in O
the O
RARE O
of O
RARE I-GENE
- I-GENE
RARE I-GENE
hormone I-GENE
( O
ALL_CAP I-GENE
)- O
related O
RARE O
in O
the O
RARE O
cells O
of O
the O
RARE O
RARE O
. O

RARE O
treated O
with O
8 O
- O
OH O
- O
ALL_CAP O
were O
not O
impaired O
in O
their O
ability O
to O
RARE O
a O
visual O
discrimination O
in O
a O
water O
RARE O
. O

The O
term O
RARE O
RARE O
RARE O
is O
suggested O
. O

In O
addition O
, O
two O
internal O
promoters O
, O
ALL_CAP I-GENE
and O
NUM I-GENE
were O
identified O
and O
mapped O
to O
NUM O
and O
NUM O
nucleotides O
upstream O
from O
the O
respective O
translation O
RARE O
sites O
. O

These O
results O
indicate O
that O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
and O
RARE I-GENE
RARE O
could O
be O
regulated O
by O
multiple O
mechanisms O
, O
including O
degree O
of O
RARE O
from O
upstream O
genes O
, O
modulation O
of O
internal O
promoter O
strength O
, O
and O
by O
RNase I-GENE
E I-GENE
activity O
. O

Coronary O
NUM O
and O
NUM O
weighted O
images O
were O
obtained O
. O

The O
2 O
kb O
of O
5 O
'- O
flanking O
region O
and O
the O
1 O
. O
1 O
kb O
of O
the O
RARE O
ALL_CAP I-GENE
alpha I-GENE
subunit I-GENE
coding O
region O
were O
sequenced O
from O
the O
genomic O
clone O
, O
ALL_CAP I-GENE
alpha I-GENE
- I-GENE
G1 I-GENE
. O

Functional O
analysis O
of O
the O
ALL_CAP I-GENE
alpha I-GENE
subunit I-GENE
promoter I-GENE
by O
the O
transient O
transfection O
of O
several O
ALL_CAP I-GENE
alpha I-GENE
/ O
CAT I-GENE
chimeric O
plasmids O
into O
RARE O
RARE O
pituitary O
cells O
suggests O
that O
its O
pituitary O
- O
specific O
RARE O
is O
ALL_CAP I-GENE
- O
dependent O
. O

RARE O
- O
111 O
RARE O
ALL_CAP O
/ O
ALL_CAP O
and O
F O
- O
18 O
FDG O
in O
RARE O
and O
ovarian O
carcinoma O
RARE O
. O

RARE O
RARE I-GENE
RARE I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
I I-GENE
and I-GENE
II I-GENE
activities O
were O
NUM O
. O
06 O
and O
NUM O
. O
12 O
nmol O
/ O
min O
/ O
mg O
protein O
, O
RARE O
compared O
with O
a O
mean O
value O
of O
NUM O
. O
NUM O
+/- O
NUM O
. O
14 O
and O
NUM O
. O
NUM O
+/- O
NUM O
. O
07 O
nmol O
/ O
min O
/ O
mg O
protein O
, O
respectively O
, O
in O
control O
subjects O
. O

The O
RARE I-GENE
ALL_CAP I-GENE
was O
found O
to O
prevent O
RARE O
interactions O
, O
thus O
RARE O
RARE I-GENE
RARE O
to O
RARE O
efficiently O
. O

RARE O
RARE O
and O
CNS O
showed O
high O
or O
moderate O
resistance O
rates O
to O
RARE O
( O
ALL_CAP O
). O

Thus O
, O
VF O
resistant O
to O
RARE O
is O
not O
necessarily O
associated O
with O
both O
toxic O
plasma O
drug O
level O
and O
remarkably O
decreased O
conduction O
. O

The O
smallest O
RARE I-GENE
ALL_CAP I-GENE
RARE I-GENE
contained O
NUM O
amino O
acid O
residues O
RARE O
compared O
to O
the O
NUM O
residues O
of O
wild I-GENE
- I-GENE
type I-GENE
ALL_CAP I-GENE
. O

The O
gene O
RARE O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
are O
cotranscribed O
from O
opposite O
RARE O
. O

Hybridization O
signals O
were O
also O
detected O
with O
RARE O
RARE O
of O
RARE O
RARE O
RARE O
. O
RARE O
, O
RARE O
RARE O
and O
Escherichia O
coli O
, O
but O
not O
those O
of O
RARE O
RARE O
RARE O
. O
RARE O
and O
RARE O
RARE O
. O

The O
predicted O
amino O
acid O
sequence O
contains O
regions O
identical O
to O
the O
sequences O
of O
peptides O
derived O
from O
bovine I-GENE
liver I-GENE
eIF I-GENE
- I-GENE
NUM I-GENE
alpha I-GENE
subunit I-GENE
. O

Expression O
of O
this O
cDNA O
in O
vitro O
yields O
a O
peptide O
which O
RARE O
with O
RARE I-GENE
eIF I-GENE
- I-GENE
NUM I-GENE
alpha I-GENE
in O
SDS O
/ O
polyacrylamide O
gels O
. O

When O
RNA O
encoding O
the O
RARE O
domain O
of O
RARE I-GENE
was O
RARE O
with O
plakoglobin I-GENE
RNA I-GENE
, O
both O
the O
RARE O
effect O
and O
nuclear O
accumulation O
of O
plakoglobin I-GENE
were O
suppressed O
. O

Six O
of O
them O
, O
NUM I-GENE
, O
NUM I-GENE
( O
also O
called O
NUM I-GENE
RARE O
NUM I-GENE
, O
NUM I-GENE
, O
the O
gene O
encoding O
the O
ribosomal I-GENE
protein I-GENE
NUM I-GENE
and O
the O
gene O
coding O
RARE O
a O
RARE O
protein O
of O
NUM O
amino O
RARE O
, O
have O
been O
sequenced O
previously O
. O

RARE O
grafts O
of O
RARE O
and O
adrenal O
tissues O
have O
been O
found O
to O
be O
effective O
in O
RARE O
many O
of O
the O
simple O
motor O
and O
RARE O
deficits O
associated O
with O
lesions O
of O
the O
RARE O
dopamine O
RARE O
. O

OBJECTIVE O
: O
To O
determine O
the O
impact O
of O
the O
introduction O
of O
RARE O
and O
RARE O
on O
the O
treatment O
and O
survival O
of O
patients O
with O
AIDS O
and O
RARE O
Mycobacterium O
RARE O
complex O
( O
ALL_CAP O
). O

RARE O
, O
the O
RARE O
rose O
to O
the O
initial O
NUM O
% O
value O
4 O
h O
after O
drug O
application O
and O
remained O
RARE O
this O
level O
RARE O
the O
observation O
period O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

RARE O
curves O
indicated O
that O
RARE O
of O
clone O
NUM O
in O
the O
presence O
of O
10 O
% O
serum O
was O
RARE O
by O
NUM O
% O
compared O
with O
clone O
NUM O
. O

The O
protein O
coding O
region O
, O
1 O
, O
NUM O
RARE O
long O
, O
is O
divided O
by O
an O
intron O
into O
two O
exons O
. O

The O
UAS O
of O
the O
NUM I-GENE
gene I-GENE
contains O
RARE O
least O
two O
distinct O
motifs O
RARE O
DNA O
- O
binding O
transcriptional O
RARE O
, O
including O
one O
which O
is O
identical O
with O
the O
core O
NUM I-GENE
/ I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
binding I-GENE
motif I-GENE
, O
and O
a O
second O
one O
with O
the O
NUM I-GENE
consensus I-GENE
binding I-GENE
sequence I-GENE
. O

The O
RARE O
complexity O
of O
the O
5 O
' O
regulatory O
region O
of O
the O
ALL_CAP I-GENE
receptor I-GENE
gene I-GENE
was O
RARE O
by O
the O
observation O
that O
RARE O
derived O
from O
RARE O
NUM O
and O
the O
distal O
3 O
' O
intron O
boundary O
do O
not O
RARE O
with O
previously O
RARE O
genomic O
sequences O
that O
span O
the O
liver O
- O
specific O
P1 O
promoter O
and O
RARE O
2 O
. O

A O
polymorphic O
dinucleotide O
( O
ALL_CAP O
/ O
CA O
) O
RARE O
repeat O
contained O
in O
the O
NUM O
cosmid O
was O
identified O
and O
developed O
into O
a O
RARE O
PCR O
marker O
. O

The O
proteins O
are O
more O
than O
NUM O
% O
identical O
to O
each O
other O
within O
the O
protein O
kinase O
domain O
but O
only O
NUM O
- O
NUM O
% O
identical O
to O
other O
casein I-GENE
kinase I-GENE
I I-GENE
isoforms I-GENE
within O
this O
region O
. O

We O
used O
two O
approaches O
to O
RARE O
whether O
CDP I-GENE
/ O
cut I-GENE
serves O
RARE O
a O
repressor O
of O
NUM I-GENE
- O
RARE I-GENE
gene O
RARE O
. O

Serum O
induction O
of O
a O
MEF2 I-GENE
reporter I-GENE
gene I-GENE
was O
not O
observed O
in O
a O
line O
of O
ALL_CAP O
3T3 O
cells O
which O
contain O
low O
MEF2 I-GENE
site I-GENE
binding O
activity O
. O

Despite O
the O
activation O
of O
these O
RARE O
RARE O
molecules O
, O
ALL_CAP I-GENE
beta I-GENE
receptor I-GENE
activation O
elicited O
RARE O
detectable O
effect O
on O
cell O
RARE O
or O
differentiation O
. O

UAS1 O
is O
the O
binding O
site O
RARE O
the O
transcriptional O
regulator O
NUM I-GENE
. O

In O
the O
context O
of O
the O
NUM I-GENE
upstream I-GENE
regulatory I-GENE
region I-GENE
, O
including O
UAS1 O
, O
working O
in O
RARE O
with O
the O
NUM I-GENE
basal I-GENE
promoter I-GENE
elements I-GENE
, O
NUM O
- O
dependent O
gene O
activation O
was O
dependent O
on O
orientation O
, O
copy O
number O
, O
and O
helix O
RARE O
. O

Induction O
in O
AP I-GENE
- I-GENE
1 I-GENE
DNA O
binding O
correlates O
with O
a O
concomitant O
ALL_CAP I-GENE
RARE O
- O
activation O
of O
c I-GENE
- I-GENE
jun I-GENE
and O
c I-GENE
- I-GENE
fos I-GENE
genes I-GENE
described O
previously O
. O

RARE O
of O
MAP I-GENE
kinases I-GENE
occurs O
via O
a O
specific O
phosphatase O
, O
MKP I-GENE
- I-GENE
1 I-GENE
. O

Short O
- O
course O
amphotericin O
B O
therapy O
RARE O
RARE O
in O
pediatric O
patients O
. O

Furthermore O
, O
NUM O
- O
binding O
assays O
revealed O
that O
ALL_CAP I-GENE
directly O
binds O
NUM O
RARE O

Since O
AP I-GENE
- I-GENE
1 I-GENE
is O
an O
important O
RARE O
of O
tumor O
promoter O
action O
, O
these O
findings O
may O
explain O
the O
anti O
- O
tumor O
- O
RARE O
activity O
of O
RARE O
RARE O
. O

The O
second O
complex O
, O
when O
RARE O
, O
contained O
four O
protein O
RARE O
including O
the O
NUM O
- O
kDa O
protein O
. O

The O
protein O
RARE O
from O
the O
RARE O
cDNA O
is O
RARE O
into O
the O
culture O
medium O
and O
yields O
of O
RARE O
to O
40 O
mg O
per O
RARE O
have O
been O
obtained O
. O

The O
study O
was O
RARE O
after O
administration O
of O
oral O
RARE O
, O
50 O
mg O
/ O
kg O
/ O
day O
RARE O
2 O
days O
in O
8 O
divided O
doses O
( O
mean O
dose O
6 O
. O
9 O
+/- O
NUM O
. O
4 O
g O
). O

RARE O
NUM O
, O
NUM O
and O
NUM O
were O
transformed O
into O
a O
laboratory O
RARE O
of O
Saccharomyces O
cerevisiae O
, O
whereas O
NUM O
was O
stably O
introduced O
into O
two O
commercial O
RARE O
yeast O
strains O
. O

The O
maximum O
induction O
of O
ALL_CAP I-GENE
- I-GENE
oxidase I-GENE
transcripts I-GENE
occurred O
RARE O
about O
6 O
h O
after O
RARE O
, O
while O
the O
maximum O
enzyme O
activity O
was O
observed O
RARE O
NUM O
h O
. O

Within O
their O
polypeptide O
chain O
, O
they O
all O
contain O
those O
RARE O
features O
that O
define O
a O
RARE O
ALL_CAP I-GENE
; O
kinase O
catalytic O
sequences O
are O
RARE O
to O
a O
calmodulin I-GENE
- I-GENE
like I-GENE
regulatory I-GENE
domain I-GENE
through O
a O
RARE O
region O
. O

RARE O
of O
this O
RARE O
by O
homologous O
RARE O
restores O
the O
activity O
of O
the O
RARE I-GENE
locus I-GENE
, O
thus O
confirming O
the O
site O
of O
mutation O
. O

The O
timing O
of O
RARE I-GENE
gene I-GENE
RARE O
in O
the O
cell O
RARE O
is O
determined O
by O
specialized O
forms O
of O
RNA I-GENE
polymerase I-GENE
and O
the O
appearance O
and O
/ O
or O
activation O
of O
regulatory O
proteins O
. O

Primer O
extension O
experiments O
revealed O
a O
strong O
transcription O
initiation O
site O
NUM O
bp O
upstream O
of O
the O
translational O
RARE O
site O
. O

RARE O
of O
the O
same O
apparent O
sizes O
are O
detected O
in O
RARE O
of O
a O
ALL_CAP I-GENE
RARE O
mutant O
, O
on O
which O
basis O
we O
RARE O
that O
the O
products O
of O
the O
ALL_CAP I-GENE
operon I-GENE
are O
required O
RARE O
the O
normal O
formation O
of O
the O
inner O
RARE O
of O
the O
coat O
or O
are O
themselves O
structural O
RARE O
of O
the O
coat O
. O

Based O
on O
the O
estimated O
values O
of O
divergence O
of O
NUM I-GENE
sequences I-GENE
in O
terms O
of O
the O
numbers O
of O
RARE O
and O
non O
- O
RARE O
RARE O
per O
site O
, O
we O
found O
that O
NUM I-GENE
is O
a O
RARE O
rapidly O
RARE O
protein O
. O

NUM I-GENE
is O
a O
RARE O
alpha O
- O
helical O
peripheral O
membrane O
protein O
flanked O
by O
cysteine O
" O
RARE O
" O
and O
contains O
a O
calmodulin I-GENE
- I-GENE
binding I-GENE
ALL_CAP I-GENE
motif I-GENE
. O

Nucleotide O
sequences O
of O
the O
RARE O
revealed O
that O
one O
clone O
, O
NUM I-GENE
, O
contained O
an O
RARE O
reading O
frame O
( O
ORF O
) O
that O
would O
code O
RARE O
a O
NUM O
- O
amino O
acid O
, O
cysteine O
- O
rich O
peptide O
with O
significant O
homology O
to O
Neurospora I-GENE
crassa I-GENE
RARE I-GENE
RARE I-GENE
. O

RARE O
with O
RARE O
and O
biologically O
modified O
carbon O
electrodes O
. O

RARE O
of O
the O
tissues O
of O
the O
face O
is O
essentially O
vertical O
and O
acts O
on O
the O
RARE O
, O
temporal O
region O
, O
RARE O
and O
RARE O
. O

This O
region O
binds O
two O
ubiquitous O
nuclear O
factors O
, O
USF I-GENE
/ O
ALL_CAP I-GENE
and O
the O
CAAT I-GENE
- I-GENE
binding I-GENE
transcription I-GENE
factor I-GENE
/ O
nuclear I-GENE
factor I-GENE
1 I-GENE
( O
ALL_CAP I-GENE
/ O
NF1 I-GENE
). O

The O
RARE O
impact O
of O
using O
a O
rapid O
diagnostic O
test O
( O
RARE O
A O
ALL_CAP O
) O
on O
detection O
and O
treatment O
of O
group O
A O
beta O
- O
RARE O
RARE O
( O
ALL_CAP O
) O
RARE O
in O
a O
large O
- O
volume O
pediatric O
and O
adolescent O
RARE O
was O
examined O
. O

The O
bHLH I-GENE
proteins I-GENE
function O
RARE O
potent O
transcriptional O
RARE O
of O
tissue O
- O
specific O
genes O
by O
forming O
RARE O
between O
ubiquitous O
and O
cell O
- O
restricted O
family O
members O
. O

YAC O
and O
cosmid O
RARE O
spanning O
the O
BRCA1 I-GENE
region I-GENE
were O
used O
to O
select O
cDNA O
RARE O
from O
RARE O
of O
cDNAs O
derived O
from O
human O
placenta O
, O
HeLa O
cells O
, O
activated O
T O
cells O
, O
and O
RARE O
head O
. O

The O
other O
two O
RARE O
, O
RARE I-GENE
- I-GENE
m I-GENE
and I-GENE
- I-GENE
s I-GENE
, O
had O
nucleotide O
sequences O
identical O
with O
RARE I-GENE
- I-GENE
RARE I-GENE
cDNA O
in O
the O
amino O
- O
terminal O
region O
. O

This O
study O
RARE O
the O
feasibility O
and O
toxicity O
of O
RARE O
immunotherapy O
with O
tumor O
RARE O
lymphocytes O
and O
recombinant I-GENE
interleukin I-GENE
- I-GENE
2 I-GENE
in O
29 O
patients O
who O
underwent O
resection O
RARE O
RARE O
III O
non O
- O
small O
- O
cell O
RARE O
RARE O
. O

ALL_CAP O
ALL_CAP O
METHODS O
: O
Of O
the O
NUM O
men O
and O
NUM O
women O
, O
who O
were O
21 O
to O
NUM O
years O
of O
age O
, O
NUM O
had O
RARE O
motor O
and O
sensory O
RARE O
type O
I O
and O
7 O
had O
acquired O
RARE O
RARE O
. O

The O
present O
study O
describes O
the O
cell O
volume O
dynamics O
in O
RARE O
rat O
hearts O
, O
RARE O
ischemia O
and O
after O
reperfusion O
. O

In O
contrast O
, O
COUP I-GENE
- I-GENE
ALL_CAP I-GENE
alone O
had O
RARE O
effect O
on O
NUM O
- O
dependent O
reporter O
gene O
activity O
. O

DNA O
sequencing O
and O
Southern O
blot O
analyses O
established O
that O
the O
cDNA O
RARE O
are O
derived O
from O
two O
different O
genes O
. O

RARE I-GENE
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
activity O
after O
prolonged O
exercise O
, O
training O
, O
and O
selenium O
supplementation O
. O

Mutation O
of O
the O
NUM I-GENE
element I-GENE
, O
which O
abolishes O
NUM I-GENE
binding O
, O
results O
in O
a O
6 O
- O
10 O
- O
RARE O
reduction O
in O
reporter O
activity O
. O

The O
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
is O
overexpressed O
in O
a O
variety O
of O
tumor O
RARE O
and O
appears O
to O
play O
an O
important O
role O
in O
the O
abnormal O
growth O
of O
a O
number O
of O
cell O
RARE O
. O

We O
found O
that O
ALL_CAP I-GENE
was O
RARE O
RARE O
a O
lower O
level O
in O
S O
, O
NUM O
, O
and O
M O
phases O
and O
RARE O
a O
significantly O
RARE O
level O
in O
G1 O
RARE O
. O

RARE O
is O
found O
to O
be O
related O
to O
good O
health O
even O
after O
controlling O
RARE O
differences O
in O
RARE O
health O
inputs O
. O

With O
this O
RARE O
diastolic O
RARE O
, O
the O
abnormal O
echo O
disappeared O
completely O
. O

It O
acts O
on O
RARE I-GENE
in O
the O
G1 O
and O
S O
phases O
of O
the O
cell O
RARE O
, O
and O
also O
binds O
to O
RARE I-GENE
cell I-GENE
nuclear I-GENE
antigen I-GENE
( O
PCNA I-GENE
RARE O
blocking O
DNA O
replication O
in O
vitro O
. O

Two O
major O
and O
one O
minor O
transcription O
initiation O
sites O
were O
assigned O
to O
positions O
+ O
1 O
and O
+ O
NUM O
and O
position O
+ O
14 O
, O
respectively O
, O
by O
a O
combination O
of O
RARE O
protection O
, O
primer O
extension O
, O
and O
5 O
' O
RACE O
analyses O
. O

The O
RARE O
doses O
that O
were O
chosen O
RARE O
these O
studies O
were O
less O
than O
RARE O
RARE O
levels O
. O

We O
demonstrate O
here O
that O
the O
- O
ALL_CAP O
sequence O
stabilizes O
GDP O
binding O
to O
Ran I-GENE
, O
and O
that O
the O
domain O
is O
required O
RARE O
high O
affinity O
interaction O
with O
a O
Ran I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
NUM I-GENE
/ O
NUM I-GENE
. O

Further O
, O
the O
RARE O
of O
RARE O
3 O
and O
5 O
potentially O
encoded O
proteins O
of O
about O
20 O
kDa O
, O
the O
size O
of O
the O
ALL_CAP I-GENE
coat I-GENE
protein I-GENE
. O

RARE O
RARE O
strength O
data O
RARE O
2 O
patients O
were O
compared O
to O
change O
in O
RARE I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
levels O
. O

ALL_CAP I-GENE
does O
not O
have O
any O
RARE O
in O
the O
data O
- O
bases O
. O

OBJECTIVE O
: O
To O
investigate O
the O
incidence O
and O
presentation O
of O
acute O
RARE O
or O
RARE O
RARE O
in O
a O
RARE O
RARE O
hospital O
. O

Unlike O
most O
other O
small I-GENE
G I-GENE
proteins I-GENE
which O
are O
RARE O
ubiquitously O
, O
TTF I-GENE
was O
RARE O
only O
in O
RARE O
cells O
RARE O
a O
2 O
. O
2 O
kb O
transcript O
. O

An O
explanation O
explored O
RARE O
this O
lack O
of O
gene O
RARE O
was O
that O
increased O
levels O
of O
RAR I-GENE
alpha I-GENE
or O
ALL_CAP I-GENE
might O
suppress O
ALL_CAP O
cell O
growth O
. O

Transfection O
of O
non O
- O
RARE O
RARE O
vector O
into O
NIH3T3 O
cells O
results O
in O
acquisition O
of O
focus O
- O
forming O
activity O
while O
a O
RARE O
form O
of O
RARE O
vector O
fails O
to O
show O
this O
activity O
even O
in O
the O
presence O
of O
basic I-GENE
FGF I-GENE
. O

RARE O
extracts O
from O
a O
variety O
of O
mammalian O
cell O
lines O
( O
RARE O
NUM O
, O
several O
mouse O
RARE O
and O
human O
HeLa O
NUM O
) O
demonstrated O
similar O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
dependent O
RNA O
- O
protein O
band O
shifts O
RARE O
cell O
RARE O
from O
ALL_CAP O
/ O
c O
3T3 O
mouse O
RARE O
. O

All O
ribosomal I-GENE
protein I-GENE
( O
RARE I-GENE
) O
gene O
promoters O
from O
Saccharomyces O
cerevisiae O
studied O
so O
far O
contain O
either O
( O
usually O
two O
) O
binding O
sites O
RARE O
the O
global O
gene O
regulator O
NUM I-GENE
or O
one O
binding O
site O
RARE O
another O
global O
factor O
, O
NUM I-GENE
. O

The O
RARE O
reports O
are O
based O
mainly O
upon O
RARE O
findings O
, O
whereas O
the O
final O
reports O
include O
the O
RARE O
provided O
by O
supplementary O
investigations O
such O
RARE O
microscopy O
, O
RARE O
, O
more O
rarely O
electron O
microscopy O
, O
RARE O
and O
/ O
or O
RARE O
. O

RARE O
RARE I-GENE
: O
current O
knowledge O
and O
future O
RARE O

ALL_CAP O
- O
11 O
was O
administered O
RARE O
a O
NUM O
- O
minute O
i O
. O
v O
. O
infusion O
RARE O
a O
dose O
of O
350 O
mg O
/ O
m2 O
RARE O
in O
NUM O
ml O
normal O
saline O
every O
3 O
weeks O
. O

CONCLUSION O
: O
The O
ALL_CAP O
RARE O
ALL_CAP O
- O
11 O
administered O
in O
a O
3 O
consecutive O
- O
days O
- O
every O
- O
3 O
weeks O
schedule O
in O
this O
patient O
population O
is O
NUM O
mg O
/ O
m2 O
/ O
day O
. O

A O
NUM O
bp O
fragment O
( O
NUM O
region O
) O
of O
the O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
promoter I-GENE
, O
RARE O
between O
positions O
- O
NUM O
and O
- O
NUM O
, O
was O
sufficient O
to O
confer O
ethylene O
responsiveness O
to O
the O
reporter O
gene O
. O

To O
assess O
the O
function O
( O
s O
) O
of O
NUM I-GENE
RARE O
RARE O
, O
we O
have O
isolated O
and O
characterized O
recessive O
RARE O
- O
of O
- O
function O
mutations O
specific O
to O
each O
transcription O
unit O
. O

Although O
the O
extracellular O
domain O
of O
the O
ALL_CAP I-GENE
- I-GENE
R I-GENE
is O
sufficient O
RARE O
high O
affinity O
binding O
of O
ALL_CAP I-GENE
, O
we O
conclude O
that O
the O
RARE O
mutation O
in O
the O
fourth O
transmembrane O
domain O
RARE O
ALL_CAP I-GENE
binding O
. O

RARE O
was O
covalently O
conjugated O
with O
ALL_CAP O
. O

Moreover O
, O
Western O
blots O
demonstrated O
RARE O
least O
RARE O
RARE O
of O
RARE I-GENE
in O
both O
RARE O
and O
RARE O
, O
suggesting O
that O
these O
RARE I-GENE
are O
used O
RARE O
RARE O
functions O
responsible O
RARE O
vesicle O
RARE O
rather O
than O
RARE O
cellular O
differentiation O
. O

The O
absence O
of O
other O
regions O
of O
hybridization O
suggests O
that O
there O
are O
RARE O
closely O
related O
sequences O
( O
RARE O
. O
g O
., O
reverse O
RARE O
RARE O
) O
RARE O
throughout O
the O
genome O
and O
that O
if O
there O
are O
closely O
related O
genes O
, O
they O
must O
be O
clustered O
near O
NUM I-GENE
. O

However O
, O
the O
lens O
dose O
( O
3 O
. O
6 O
Gy O
/ O
NUM O
fractions O
) O
was O
RARE O
compared O
to O
the O
other O
techniques O
. O

Antibodies O
to O
the O
human I-GENE
NUM I-GENE
recognize O
this O
protein O
in O
human O
, O
RARE O
, O
rat O
, O
and O
hamster O
cells O
. O

There O
is O
a O
national O
effort O
to O
begin O
to O
RARE O
all O
female O
patients O
about O
family O
RARE O
. O

GnRH I-GENE
treatment O
was O
found O
to O
increase O
the O
RARE O
of O
tyrosine O
residues O
of O
ALL_CAP I-GENE
and O
to O
increase O
ALL_CAP I-GENE
activity O
, O
RARE O
determined O
by O
an O
immune O
complex O
kinase O
assay O
. O

Molecular O
cloning O
of O
an O
RARE I-GENE
insulin I-GENE
receptor I-GENE
substrate I-GENE
1 I-GENE
- I-GENE
like I-GENE
cDNA I-GENE
and O
involvement O
of O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
in O
insulin I-GENE
- O
RARE O
Xenopus O
RARE O
RARE O
. O

We O
report O
here O
that O
in O
cultured O
Jurkat O
T O
cells O
, O
Cbl I-GENE
is O
RARE O
with O
antibody O
against O
the O
RARE I-GENE
protein I-GENE
Grb2 I-GENE
. O

The O
effect O
of O
these O
cell O
RARE O
RARE O
is O
not O
specific O
to O
the O
NUM I-GENE
or O
RARE I-GENE
delta I-GENE
A I-GENE
mutation I-GENE
, O
since O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
mutations I-GENE
also O
suppress O
mutations O
in O
NUM I-GENE
, O
another O
gene O
implicated O
in O
the O
establishment O
of O
silencing O
. O

ICP4 I-GENE
has O
been O
shown O
to O
form O
RARE O
complexes O
RARE O
with O
the O
TATA I-GENE
box I-GENE
- I-GENE
binding I-GENE
protein I-GENE
and O
ALL_CAP I-GENE
on O
DNA O
containing O
an O
ICP4 I-GENE
binding I-GENE
site I-GENE
and O
a O
TATA O
box O
( O
C O
. O

RARE O
, O
RARE O
. O

Characterization O
of O
NUM I-GENE
of O
Schizosaccharomyces O
pombe O
: O
a O
developmentally O
RARE O
function O
needed O
RARE O
conjugation O
. O

ALL_CAP I-GENE
- I-GENE
related I-GENE
cDNA I-GENE
encoding O
a O
protein O
with O
a O
high I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
( O
HMG I-GENE
) O
box O
and O
a O
leucine O
zipper O
motif O
, O
which O
was O
designated O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
, O
was O
isolated O
from O
a O
RARE O
RARE O
RARE O
cDNA O
library O
. O

RARE O
RARE O
can O
be O
RARE O
just O
to O
the O
point O
of O
RARE O
RARE O
over O
4 O
to O
6 O
weeks O
followed O
by O
RARE O
flap O
RARE O
and O
RARE O
closure O
of O
the O
donor O
site O
. O

In O
the O
RARE O
RARE O
Human O
RARE O
in O
RARE O
, O
predictive O
DNA O
- O
testing O
RARE O
RARE O
' O
s O
RARE O
is O
available O
RARE O
a O
clinical O
RARE O
since O
RARE O
1987 O
, O
initially O
by O
DNA O
- O
linkage O
and O
since O
mid O
1993 O
by O
direct O
mutation O
analysis O
. O

RARE O
of O
RARE O
following O
acute O
hepatitis O
B O
virus O
infection O
: O
a O
review O
. O

Examination O
of O
RARE O
factors O
revealed O
a O
RARE O
sympathetic O
nervous O
RARE O
and O
an O
increase O
in O
plasma O
renin I-GENE
activity O
. O

We O
compared O
the O
RARE O
effect O
of O
naturally O
occurring O
mutant I-GENE
ALL_CAP I-GENE
beta I-GENE
1 I-GENE
, O
artificially O
created O
ALL_CAP I-GENE
alpha I-GENE
1 I-GENE
mutants I-GENE
, O
c I-GENE
- I-GENE
erbA I-GENE
alpha I-GENE
2 I-GENE
and O
the O
human I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
activated I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
) O
on O
three O
RARE O
NUM O
- O
response O
elements O
( O
RARE O
RARE O
ALL_CAP O
- O
ALL_CAP O
, O
ALL_CAP O
+ O
4 O
and O
ALL_CAP O
- O
ALL_CAP O
. O

The O
amino O
- O
terminal O
DNA O
- O
binding O
domain O
of O
RARE I-GENE
exhibits O
a O
high O
degree O
of O
homology O
to O
the O
DNA O
- O
binding O
domains O
of O
members O
of O
the O
RARE I-GENE
regulatory I-GENE
factor I-GENE
( O
IRF I-GENE
) O
family O
, O
which O
includes O
IRF I-GENE
- I-GENE
1 I-GENE
, O
IRF I-GENE
- I-GENE
2 I-GENE
, O
ALL_CAP I-GENE
, O
and O
NUM I-GENE
gamma I-GENE
. O

An O
outbreak O
of O
hepatitis O
A O
among O
RARE O
men O
in O
RARE O
, O
1991 O
- O
1993 O
. O

The O
NUM I-GENE
subunit I-GENE
of O
ALL_CAP I-GENE
alone O
contained O
the O
RARE O
activity O
and O
the O
minimal O
region O
sufficient O
RARE O
RARE O
corresponds O
to O
ALL_CAP O
- O
terminal O
residues O
NUM O
- O
NUM O
. O

We O
have O
generated O
various O
RARE O
substitutions O
and O
internal O
deletions O
in O
and O
around O
ALL_CAP O
( O
nucleotide O
positions O
- O
93 O
to O
- O
NUM O
with O
respect O
to O
the O
transcription O
initiation O
site O
) O
of O
the O
PCNA I-GENE
gene I-GENE
in O
vitro O
and O
subsequently O
examined O
their O
effects O
on O
the O
binding O
to O
ALL_CAP I-GENE
( O
ALL_CAP I-GENE
- I-GENE
binding I-GENE
factor I-GENE
) O
and O
PCNA I-GENE
gene I-GENE
promote O
activity O
in O
cultured O
Drosophila O
RARE O
cells O
RARE O
RARE O
RARE O
in O
living O
RARE O
. O

The O
hsp70 I-GENE
gene I-GENE
family I-GENE
of O
Neurospora O
crassa O
: O
cloning O
, O
sequence O
analysis O
, O
RARE O
, O
and O
genetic O
mapping O
of O
the O
major O
stress O
- O
inducible O
RARE O
. O

The O
deduced O
amino O
acid O
sequences O
of O
each O
of O
the O
NUM I-GENE
ALL_CAP I-GENE
subunits I-GENE
exhibit O
only O
RARE O
NUM O
% O
identity O
with O
the O
corresponding O
subunits O
of O
the O
ALL_CAP I-GENE
from O
human O
, O
rat O
, O
and O
RARE O
RARE O
, O
which O
RARE O
a O
group O
are O
greater O
than O
50 O
% O
identical O
. O

A O
secondary O
RARE O
of O
NUM I-GENE
RARE O
NUM O
is O
required O
RARE O
the O
cAMP O
- O
RARE O
control O
of O
gene O
RARE O
. O

A O
role O
RARE O
RARE I-GENE
synthase I-GENE
kinase I-GENE
- I-GENE
3 I-GENE
in O
the O
control O
of O
gene O
RARE O
. O

This O
last O
region O
contains O
two O
sites O
that O
bind O
Ets I-GENE
- I-GENE
related I-GENE
proteins I-GENE
present O
in O
liver O
nuclear O
extracts O
RARE O
RARE O
RARE O
recombinant I-GENE
RARE I-GENE
Ets I-GENE
- I-GENE
1 I-GENE
protein I-GENE
. O

Other O
assays O
also O
distinguished O
the O
RARE O
replication O
of O
RARE O
. O
RARE O
- O
2 O
. O
4 O
from O
the O
RARE O
labeling O
of O
control O
plasmids O
. O

RARE O
of O
complexes O
containing O
p62 I-GENE
and O
the O
src I-GENE
family I-GENE
kinase I-GENE
NUM I-GENE
in O
HeLa O
cells O
demonstrated O
that O
complex O
formation O
resulted O
in O
tyrosine O
RARE O
of O
p62 I-GENE
and O
was O
RARE O
by O
both O
the O
SH3 I-GENE
and O
NUM I-GENE
domains I-GENE
of O
NUM I-GENE
. O

Therefore O
, O
it O
is O
RARE O
that O
by O
RARE O
the O
transcriptional O
control O
of O
the O
NUM I-GENE
gene I-GENE
RARE O
into O
the O
mechanisms O
that O
control O
RARE O
fate O
and O
organization O
in O
the O
nervous O
RARE O
can O
be O
RARE O
. O

In O
contrast O
, O
a O
Maf I-GENE
- I-GENE
related I-GENE
protein I-GENE
, O
RARE I-GENE
, O
completely O
mimicked O
c I-GENE
- I-GENE
Maf I-GENE
actions O
. O

The O
NUM O
- O
RARE O
element O
interacts O
with O
a O
ALL_CAP I-GENE
- O
activated O
serine O
/ O
threonine O
RARE O
that O
is O
detected O
only O
within O
the O
nucleus O
of O
ALL_CAP O
- O
treated O
3T3 O
cells O
. O

By O
contrast O
, O
deletion O
of O
this O
Ras I-GENE
- I-GENE
binding I-GENE
site I-GENE
did O
not O
RARE O
activation O
of O
Raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
by O
Src I-GENE
, O
implying O
that O
Src I-GENE
and O
Ras I-GENE
can O
activate O
Raf I-GENE
- I-GENE
1 I-GENE
through O
independent O
mechanisms O
. O

In O
studies O
of O
many O
different O
RARE O
distinct O
cells O
, O
the O
ALL_CAP O
of O
the O
somatostatin I-GENE
gene I-GENE
promoter I-GENE
is O
a O
prototype O
of O
a O
highly O
cAMP O
- O
responsive O
element O
regulated O
by O
CREB I-GENE
. O

The O
RARE O
gene O
, O
NUM I-GENE
, O
a O
previously O
identified O
gene O
, O
encodes O
a O
protein O
involved O
in O
ribosomal O
RNA O
RARE O
and O
possibly O
in O
RARE O
of O
proteins O
into O
the O
nucleus O
. O

Characterization O
of O
the O
promoter O
RARE O
the O
human I-GENE
NUM I-GENE
kDa I-GENE
cytosolic I-GENE
phospholipase I-GENE
NUM I-GENE
gene I-GENE
. O

This O
paper O
describes O
the O
advantages O
and O
limitations O
of O
the O
main O
study O
approaches O
used O
. O

Comparative O
study O
of O
the O
differential O
RARE O
RARE O
cell O
count O
using O
three O
automated O
RARE O
: O
RARE O
ALL_CAP O
, O
RARE O
ALL_CAP O
NUM O
and O
RARE O
H O
- O
1 O
. O

Characterization O
of O
ALL_CAP I-GENE
/ O
YY1 I-GENE
, O
a O
Xenopus I-GENE
RARE I-GENE
RARE I-GENE
zinc I-GENE
- I-GENE
finger I-GENE
protein I-GENE
binding O
to O
the O
RARE O
RARE O
of O
L1 I-GENE
and O
NUM I-GENE
ribosomal I-GENE
protein I-GENE
genes I-GENE
. O

Further O
studies O
established O
that O
the O
RARE I-GENE
- O
RARE O
increase O
in O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
could O
be O
inhibited O
by O
the O
tyrosine I-GENE
kinase I-GENE
inhibitor O
RARE O
and O
the O
protein I-GENE
kinase I-GENE
C I-GENE
inhibitor O
RARE O
3 O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

This O
RARE O
of O
RARE I-GENE
suggests O
that O
it O
is O
probably O
synthesized O
RARE O
an O
inactive O
precursor O
. O

Molecular O
dissection O
of O
the O
RARE O
CD3 I-GENE
- O
TCR I-GENE
complex O
revealed O
that O
RARE O
least O
two O
associated O
polypeptides O
, O
CD3 I-GENE
RARE I-GENE
and O
CD3 I-GENE
epsilon I-GENE
, O
RARE O
RARE O
RARE O
recognition O
event O
to O
early O
and O
RARE O
events O
of O
the O
RARE O
activation O
cascade O
. O

Protein I-GENE
ALL_CAP I-GENE
binds O
preferentially O
to O
AT O
- O
rich O
DNA O
with O
a O
RARE O
- O
saturation O
value O
of O
1 O
. O
1 O
nM O
. O

This O
study O
investigated O
the O
degree O
to O
which O
RARE O
identity O
influences O
RARE O
- O
RARE O
' O
performance O
on O
the O
L O
, O
K O
, O
and O
ALL_CAP O
RARE O
of O
the O
MMPI O
- O
2 O
. O

Both O
can O
be O
elevated O
on O
a O
single O
vascular O
RARE O
based O
on O
the O
superficial O
temporal O
artery O
, O
the O
double O
- O
RARE O
temporal O
RARE O
flap O
. O

To O
do O
this O
, O
RARE O
of O
DNA O
from O
the O
5 O
' O
flank O
of O
the O
initiation O
sites O
RARE O
RARE O
epsilon O
RNA O
were O
ligated O
to O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
and O
transfected O
into O
two O
mouse O
B O
cell O
lines O
, O
one O
of O
which O
can O
be O
RARE O
to O
switch O
to O
IgE I-GENE
. O

The O
negative O
predictive O
value O
is O
92 O
%, O
RARE O
NUM O
% O
RARE O
the O
ALL_CAP O
I O
. O

RARE O
capacity O
of O
the O
E2F1 I-GENE
gene I-GENE
. O

In O
some O
of O
the O
cases O
of O
RARE O
lesion O
, O
serum I-GENE
ALL_CAP I-GENE
levels O
, O
serum I-GENE
RARE I-GENE
values O
, O
and O
131I O
protein O
RARE O
iodine O
( O
131I O
- O
ALL_CAP O
) O
were O
measured O
, O
but O
there O
were O
RARE O
significant O
differences O
between O
successful O
and O
RARE O
therapy O
. O

NUM I-GENE
transcripts I-GENE
are O
confined O
to O
the O
definitive O
RARE O
RARE O
in O
RARE O
RARE O
RARE O
; O
RARE O
RARE O
RARE O
this O
gene O
is O
RARE O
throughout O
the O
RARE O
, O
but O
later O
only O
in O
the O
RARE O
. O

A O
unique O
leucine O
- O
proline O
repeat O
element O
found O
N O
- O
terminal O
to O
the O
DNA O
- O
binding O
domain O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
does O
not O
appear O
to O
play O
a O
role O
in O
DNA O
- O
binding O
or O
RARE O
. O

Another O
full O
ORF O
was O
found O
on O
the O
opposite O
RARE O
RARE O
from O
the O
ALL_CAP I-GENE
gene I-GENE
. O

The O
U14 I-GENE
genes I-GENE
of O
mouse O
RARE O
RARE O
RARE O
rat O
, O
hamster O
, O
human O
, O
Xenopus O
and O
RARE O
are O
encoded O
within O
RARE O
of O
the O
constitutively O
RARE O
70 I-GENE
- I-GENE
kDa I-GENE
- I-GENE
RARE I-GENE
- I-GENE
heat I-GENE
- I-GENE
shock I-GENE
protein I-GENE
gene I-GENE
( O
NUM I-GENE
). O

Two O
related O
cDNAs O
were O
isolated O
that O
encode O
proteins O
that O
recognize O
the O
RARE I-GENE
TATA I-GENE
motif I-GENE
. O

Deletion O
of O
both O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
resulted O
in O
extremely O
slow O
growth O
and O
a O
reduction O
in O
RARE O
efficiency O
. O

RARE O
in O
this O
family O
of O
proteins O
suggests O
that O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
may O
participate O
in O
an O
export O
RARE O
required O
RARE O
RARE O
assembly O
. O

In O
RARE O
L O
- O
cell O
membranes O
expressing O
wild O
type O
or O
mutant I-GENE
NUM I-GENE
/ I-GENE
IGF I-GENE
II I-GENE
receptors I-GENE
, O
NUM O
nM O
IGF I-GENE
II I-GENE
also O
failed O
to O
affect O
the O
RARE I-GENE
RARE I-GENE
substrate O
activity O
. O

Chem O
. O

For O
the O
RARE O
time O
we O
describe O
deletion O
and O
point O
mutations O
within O
the O
plasma I-GENE
membrane I-GENE
family I-GENE
of I-GENE
RARE I-GENE
cyclase I-GENE
receptors I-GENE
that O
result O
in O
the O
formation O
of O
effective O
dominant O
negative O
proteins O
. O

RARE O
in O
RARE O
ALL_CAP O
was O
further O
augmented O
by O
fat O
RARE O
AA O
supplementation O
, O
but O
RARE O
changes O
in O
concentrations O
of O
RARE O
or O
RARE O
in O
RARE O
were O
found O
. O

RARE O
. O

Coronary O
RARE O
caused O
by O
endothelin I-GENE
- I-GENE
1 I-GENE
is O
RARE O
by O
ischemia O
- O
reperfusion O
and O
by O
norepinephrine O
present O
in O
concentrations O
typically O
observed O
after O
neonatal O
cardiopulmonary O
bypass O
. O

Comparison O
of O
the O
deduced O
amino I-GENE
acid I-GENE
sequence I-GENE
of I-GENE
gamma I-GENE
- I-GENE
RARE I-GENE
with O
the O
published O
sequences I-GENE
of I-GENE
gamma I-GENE
- I-GENE
RARE I-GENE
of I-GENE
RARE I-GENE
, I-GENE
and I-GENE
RARE I-GENE
revealed O
highly O
RARE O
domains O
. O

NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
and O
the O
ORF O
are O
very O
close O
to O
each O
other O
and O
organized O
in O
the O
same O
polarity O
; O
hence O
, O
the O
intergenic O
regions O
probably O
contain O
, O
within O
less O
than O
NUM O
. O
5 O
kb O
, O
all O
the O
regulatory O
elements O
necessary O
to O
govern O
initiation O
and O
RARE O
of O
transcription O
. O

Southern O
blot O
hybridization O
experiments O
suggest O
the O
presence O
of O
one O
copy O
of O
NUM I-GENE
, O
NUM I-GENE
and O
NUM I-GENE
per O
RARE O
genome O
, O
and O
Northern O
blot O
analysis O
demonstrates O
that O
the O
three O
genes O
are O
differentially O
RARE O
in O
roots O
, O
RARE O
and O
leaves O
. O

These O
results O
suggest O
that O
NUM I-GENE
may O
also O
be O
one O
of O
the O
RARE O
genes O
. O

We O
characterized O
three O
Arabidopsis O
thaliana O
cDNA O
RARE O
that O
could O
rescue O
the O
RARE O
RARE O
of O
the O
Schizosaccharomyces I-GENE
pombe I-GENE
NUM I-GENE
mutant I-GENE
, O
which O
is O
RARE O
in O
cAMP I-GENE
RARE I-GENE
. O

Furthermore O
, O
the O
identification O
of O
a O
NUM I-GENE
- I-GENE
like I-GENE
protein I-GENE
in O
A O
. O
thaliana O
strongly O
RARE O
RARE O
the O
RARE O
of O
this O
protein O
among O
eukaryotic O
RARE O
and O
RARE O
a O
RARE O
mechanism O
to O
regulate O
transcription O
initiation O
that O
involves O
NUM I-GENE
. O

Similarly O
RARE O
NUM O
bp O
of O
sequence O
RARE O
of O
the O
translation O
terminator O
ALL_CAP O
of O
the O
beta I-GENE
- I-GENE
RARE I-GENE
2 I-GENE
( O
NUM I-GENE
) O
gene O
could O
substitute O
RARE O
the O
3 O
' O
region O
of O
the O
NUM I-GENE
- I-GENE
I I-GENE
gene I-GENE
. O

These O
data O
demonstrate O
that O
the O
ALL_CAP I-GENE
family I-GENE
of O
genes O
is O
represented O
in O
a O
nematode O
whose O
ancestor O
appeared O
RARE O
before O
the O
RARE O
that O
gave O
rise O
to O
the O
RARE O
and O
RARE O
. O

The O
pre O
- O
and O
postoperative O
RARE I-GENE
concentrations O
in O
the O
autologous O
group O
were O
lower O
by O
NUM O
and O
10 O
g O
/ O
L O
, O
respectively O
, O
after O
RARE O
ALL_CAP O
and O
by O
10 O
g O
/ O
L O
in O
both O
instances O
after O
RARE O
ALL_CAP O
. O

The O
introduction O
of O
an O
RARE O
RARE O
RARE O
the O
second O
site O
was O
essential O
RARE O
suppression O
of O
the O
Asn O
- O
285 O
mutation O
because O
RARE O
- O
220 O
and O
Gln O
- O
220 O
second O
- O
site O
mutants O
of O
the O
Asn O
- O
285 O
mutant O
showed O
very O
low O
RARE O
resistance O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

RARE I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
, O
the O
RARE O
that O
participates O
in O
the O
autocrine O
growth O
control O
of O
RARE O
cell O
leukemia O
has O
strong O
bone O
RARE O
properties O
. O

( O
iv O
) O
Although O
ALL_CAP I-GENE
has O
been O
previously O
shown O
to O
act O
RARE O
a O
transcriptional O
repressor O
, O
we O
show O
here O
that O
ALL_CAP I-GENE
can O
also O
act O
RARE O
a O
positive O
RARE O
of O
a O
reporter O
RARE O
by O
ALL_CAP O
elements O
when O
used O
in O
RARE O
- O
transfection O
assays O
. O

The O
sequence O
of O
RARE I-GENE
RARE I-GENE
closely O
resembles O
the O
human O
sequence O
RARE O
the O
nucleotide O
and O
the O
amino O
acid O
levels O
, O
with O
the O
latter O
having O
only O
7 O
differences O
out O
of O
NUM O
residues O
. O

One O
complex O
appears O
to O
be O
ubiquitous O
but O
RARE O
in O
RARE O
cells O
and O
represents O
the O
binding O
of O
a O
potentially O
novel O
factor O
with O
an O
apparent O
RARE O
mass O
of O
RARE O
50 O
kDa O
. O

Chem O
. O

Conversely O
, O
activation O
of O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
promoter I-GENE
by O
RAR I-GENE
: O
RXR I-GENE
RARE I-GENE
was O
completely O
abolished O
by O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
/ O
COUP I-GENE
- I-GENE
TFI I-GENE
and O
by O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
/ O
COUP I-GENE
- I-GENE
ALL_CAP I-GENE
. O

These O
results O
demonstrate O
that O
ALL_CAP I-GENE
provides O
a O
crucial O
RARE O
function O
RARE O
globin I-GENE
RARE O
and O
further O
RARE O
the O
idea O
that O
ALL_CAP I-GENE
is O
an O
important O
regulator O
of O
ALL_CAP O
element O
- O
directed O
transcription O
in O
RARE O
cells O
. O

Using O
a O
battery O
of O
I I-GENE
RARE I-GENE
B I-GENE
alpha I-GENE
mutants I-GENE
, O
we O
show O
that O
( O
i O
) O
a O
RARE O
binds O
a O
single O
I I-GENE
RARE I-GENE
B I-GENE
alpha I-GENE
molecule I-GENE
, O
( O
ii O
) O
the O
RARE O
C O
- O
terminal O
region O
of O
I I-GENE
RARE I-GENE
B I-GENE
alpha I-GENE
is O
not O
required O
RARE O
protein O
- O
protein O
binding O
and O
does O
not O
RARE O
the O
nuclear O
RARE O
signal O
of O
the O
RARE O
, O
( O
iii O
) O
the O
same O
C O
- O
terminal O
region O
is O
required O
RARE O
inhibition O
of O
DNA O
binding O
, O
and O
( O
iv O
) O
this O
inhibition O
may O
be O
RARE O
by O
direct O
interaction O
between O
the O
ALL_CAP O
- O
like O
region O
and O
the O
DNA O
- O
binding O
region O
of O
one O
of O
the O
subunits O
of O
the O
RARE O
. O

The O
negative O
regulatory O
activity O
of O
the O
N O
- O
terminal O
domain O
was O
RARE O
by O
a O
C O
- O
terminal O
segment O
of O
NUM I-GENE
supplied O
in O
RARE O
. O

At O
different O
times O
of O
the O
surgical O
procedures O
( O
RARE O
RARE O
and O
closure O
, O
period O
of O
cardiopulmonary O
bypass O
) O
67 O
to O
NUM O
% O
of O
the O
patients O
in O
group O
1 O
had O
vancomycin O
concentrations O
in O
the O
studied O
tissues O
above O
the O
ALL_CAP O
NUM O
RARE O
RARE O
RARE O
( O
1 O
microgram O
/ O
g O
) O
and O
RARE O
RARE O
( O
2 O
micrograms O
/ O
g O
). O

On O
- O
line O
RARE O
images O
of O
tissue O
RARE O
RARE O
in O
the O
RARE O
, O
recent O
or O
structured O
RARE O
, O
artery O
RARE O
RARE O
, O
plaque O
RARE O
, O
deep O
RARE O
and O
sub O
- O
RARE O
RARE O
demonstrate O
, O
in O
live O
RARE O
, O
the O
RARE O
mechanisms O
of O
coronary O
artery O
stenosis O
. O

The O
RARE O
cysteine O
formation O
in O
a O
NUM O
RARE O
responding O
to O
RARE O
was O
also O
observed O
in O
leaf O
RARE O
. O

Each O
type O
was O
divided O
into O
two O
subgroups O
on O
the O
basis O
of O
whether O
the O
body O
and O
RARE O
of O
the O
pancreas O
showed O
intense O
fatty O
RARE O
( O
type O
a O
= O
negative O
RARE O
intense O
fatty O
RARE O
, O
type O
b O
= O
positive O
RARE O
intense O
fatty O
RARE O
). O

RARE O
the O
subgroups O
of O
dementia O
disorders O
there O
were O
RARE O
significant O
differences O
in O
basal O
cortisol O
levels O
. O

A O
new O
hypothesis O
on O
mechanisms O
RARE O
inhibiting O
catalytic O
subunits O
by O
gamma O
- O
subunits O
and O
activation O
of O
a O
RARE O
by O
RARE I-GENE

Basal O
RARE O
of O
the O
transcription O
apparatus O
( O
RNA I-GENE
polymerase I-GENE
II I-GENE
, O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
) O
contain O
activation O
domains O
: O
is O
the O
RARE O
C O
- O
terminal O
domain O
( O
ALL_CAP O
) O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
a O
" O
RARE O
enhancer O
domain O
RARE O
RARE O
rich O
in O
serine O
, O
threonine O
, O
and O
proline O
residues O
can O
be O
found O
in O
transcriptional O
activation O
domains O
, O
RARE O
RARE O
RARE O
in O
the O
N O
- O
terminal O
parts O
of O
mammalian I-GENE
TATA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
, O
where O
they O
are O
interrupted O
by O
RARE O
stretches O
. O

RARE O
of O
NUM I-GENE
enhances O
the O
ability O
of O
c I-GENE
- I-GENE
Fos I-GENE
to O
activate O
an O
AP1 I-GENE
RARE I-GENE
promoter I-GENE
. O

Binding O
of O
ALL_CAP I-GENE
to O
the O
RARE I-GENE
RARE I-GENE
element I-GENE
( O
ALL_CAP I-GENE
) O
in O
the O
proximal O
gamma I-GENE
- I-GENE
globin I-GENE
promoter I-GENE
is O
RARE O
to O
the O
competitive O
silencing O
of O
a O
RARE O
beta I-GENE
- I-GENE
promoter I-GENE
in O
RARE O
/ O
RARE O
RARE O
RARE O
( O
K562 O
) O
cells O
. O

This O
failure O
to O
RARE O
regulated O
G1 O
/ O
S O
arrest O
is O
correlated O
with O
RARE O
RARE O
of O
colony O
- O
forming O
ability O
. O

Mutations O
that O
alter O
RARE O
cell O
RARE O
and O
development O
were O
isolated O
that O
fail O
to O
complement O
these O
deletions O
. O

It O
is O
possible O
that O
the O
RARE O
of O
the O
two O
nuclei O
have O
different O
functions O
. O

The O
marker O
RARE O
from O
the O
genetic O
and O
ALL_CAP O
maps O
were O
consistent O
. O

RARE O
mapping O
analysis O
of O
the O
RARE O
RARE O
region O
of O
RARE O
8 O
. O

The O
region O
between O
NUM I-GENE
and O
RARE I-GENE
VIII I-GENE
gene I-GENE
in O
the O
human O
NUM O
chromosomal O
band O
contains O
a O
G O
+ O
C O
- O
rich O
RARE O
to O
which O
many O
genes O
have O
been O
mapped O
. O

RARE O
mapping O
and O
sequence O
analysis O
of O
the O
mouse O
RARE I-GENE
gene I-GENE
predict O
RARE O
to O
infection O
with O
RARE O
parasites O
. O

This O
utilization O
of O
an O
RARE O
polyadenylation O
site O
without O
RARE O
RARE O
usage O
is O
comparable O
to O
the O
mechanism O
RARE O
both O
RARE O
and O
membrane O
- O
RARE O
forms O
of O
the O
immunoglobulin I-GENE
mu I-GENE
heavy I-GENE
chain I-GENE
are O
made O
from O
a O
single O
genetic O
locus O
. O

To O
further O
our O
knowledge O
about O
the O
systemic O
RARE O
immune O
RARE O
response O
to O
weak O
RARE O
- O
RARE O
or O
RARE O
protein O
RARE O
( O
RARE O
and O
RARE O
products O
of O
RARE O
RARE O
RARE O
RARE O
a O
RARE O
enzyme O
- O
RARE O
immunosorbent O
assay O
( O
ELISA O
) O
method O
RARE O
testing O
RARE O
antibody O
( O
RARE O
RARE O
) O
to O
RARE O
was O
developed O
. O

In O
contrast O
, O
peak O
filling O
rate O
( O
ALL_CAP O
RARE O
normalized O
to O
end O
diastolic O
volume O
( O
ALL_CAP O
RARE O
or O
stroke O
volume O
( O
SV O
RARE O
or O
RARE O
RARE O
the O
ratio O
of O
ALL_CAP O
- O
to O
- O
ALL_CAP O
was O
RARE O
( O
p O
< O
NUM O
. O
01 O
RARE O
time O
to O
ALL_CAP O
( O
ALL_CAP O
) O
was O
prolonged O
( O
p O
< O
NUM O
. O
01 O
RARE O
and O
echocardiographic O
RARE O
ventricular O
mass O
index O
was O
RARE O
( O
p O
< O
NUM O
. O
001 O
) O
in O
patients O
with O
RARE O
compared O
to O
normals O
. O

A O
genetic O
RARE O
RARE O
was O
developed O
in O
which O
tobacco I-GENE
RARE I-GENE
virus I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
polymerase I-GENE
( O
RARE I-GENE
)- O
expressing O
transgenic O
RARE O
or O
RARE O
were O
inoculated O
with O
RARE I-GENE
- O
RARE O
ALL_CAP I-GENE
mutants I-GENE
. O

Nucleotide O
sequence O
and O
transcriptional O
analysis O
of O
the O
DNA I-GENE
polymerase I-GENE
gene I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
nuclear I-GENE
RARE I-GENE
virus I-GENE
. O

Comparison O
of O
the O
genomes O
of O
ALL_CAP O
, O
ALL_CAP O
, O
and O
ALL_CAP O
shows O
that O
RARE O
exhibit O
considerable O
heterogeneity O
in O
genome O
organization O
. O

The O
drug O
sensitivity O
was O
NUM O
% O
RARE O
vancomycin O
( O
ALL_CAP O
RARE O
NUM O
% O
RARE O
RARE O
( O
ALL_CAP O
RARE O
NUM O
% O
RARE O
RARE O
( O
ALL_CAP O
RARE O
NUM O
% O
RARE O
RARE O
( O
ALL_CAP O
RARE O
and O
7 O
% O
RARE O
RARE O
( O
ALL_CAP O
). O

RARE O
with O
RARE I-GENE
H I-GENE
showed O
that O
the O
mutant O
receptors O
had O
mainly O
high O
- O
RARE O
RARE O
chains O
. O

RARE O
RARE O
with O
fish O
oil O
and O
related O
RARE O
- O
3 O
RARE O
has O
been O
used O
to O
study O
their O
antihypertensive O
RARE O
in O
animals O
and O
humans O
with O
RARE O
and O
essential O
hypertension O
. O

The O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
encoding O
the O
RARE I-GENE
I I-GENE
and I-GENE
II I-GENE
3 I-GENE
beta I-GENE
- I-GENE
ALL_CAP I-GENE
RARE I-GENE
, O
respectively O
, O
have O
been O
previously O
assigned O
by O
in O
situ O
hybridization O
to O
the O
RARE O
NUM O
. O
1 O
region O
. O

Therefore O
the O
RARE O
of O
RARE O
diabetes O
and O
ALL_CAP O
were O
1 O
. O
19 O
% O
and O
NUM O
. O
NUM O
%, O
respectively O
. O

Insulin I-GENE
- O
RARE O
glucose O
RARE O
in O
adipocytes O
is O
RARE O
by O
the O
insulin I-GENE
receptor I-GENE
. O

After O
selection O
and O
conversion O
to O
adipocytes O
, O
the O
level O
of O
EGFR I-GENE
RARE O
was O
retained O
in O
RARE O
adipocytes O
( O
NUM O
, O
NUM O
and O
NUM O
, O
NUM O
/ O
cell O
, O
respectively O
RARE O
but O
not O
in O
the O
parental O
3T3 O
- O
L1 O
adipocytes O
(< O
NUM O
/ O
cell O
). O

RARE O
- O
RARE O
RARE O
of O
the O
RARE I-GENE
I I-GENE
RARE I-GENE
B I-GENE
alpha I-GENE
- I-GENE
encoding I-GENE
gene I-GENE
. O

RARE O
2 O
contains O
1 O
, O
NUM O
( O
OH O
) O
2 O
- O
vitamin O
NUM O
, O
vitamin O
NUM O
, O
NUM O
( O
OH O
)- O
vitamin O
NUM O
and O
1 O
, O
NUM O
, O
NUM O
( O
OH O
) O
3 O
- O
vitamin O
NUM O
. O

The O
RARE I-GENE
gene I-GENE
was O
localized O
by O
in O
situ O
hybridization O
to O
human O
RARE O
NUM O
- O
NUM O
. O
1 O
, O
close O
to O
the O
RARE I-GENE
genes I-GENE
encoding O
alpha I-GENE
1 I-GENE
- I-GENE
RARE I-GENE
, O
protein I-GENE
C I-GENE
inhibitor I-GENE
, O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
, O
and O
RARE I-GENE
- I-GENE
binding I-GENE
globulin I-GENE
. O

The O
locus O
encoding O
the O
ALL_CAP I-GENE
gene I-GENE
( O
designated O
RARE I-GENE
) O
was O
mapped O
to O
the O
distal O
part O
of O
mouse O
RARE O
NUM O
by O
RARE O
analysis O
of O
NUM O
RARE O
backcross O
mice O
. O

Some O
studies O
of O
exercise O
have O
associated O
beta I-GENE
- I-GENE
endorphin I-GENE
release O
with O
increased O
RARE O
levels O
, O
but O
other O
evidence O
suggests O
that O
acidosis O
may O
stimulate O
the O
release O
of O
beta I-GENE
- I-GENE
endorphin I-GENE
. O

An O
RARE O
RARE O
RARE O
the O
impairment O
of O
LV O
function O
after O
an O
acute O
and O
sustained O
drop O
of O
RARE O
pressure O
. O

RARE O
or O
foreign O
cellular O
proteins O
provide O
peptides O
RARE O
presentation O
by O
major I-GENE
histocompatibility I-GENE
complex I-GENE
( I-GENE
MHC I-GENE
) I-GENE
class I-GENE
I I-GENE
molecules I-GENE
on O
the O
surface O
of O
antigen O
RARE O
cells O
( O
ALL_CAP O
). O

The O
characteristics O
of O
the O
NUM I-GENE
/ O
NUM I-GENE
- O
RARE O
RARE O
reaction O
strongly O
RARE O
those O
observed O
with O
RARE O
of O
ALL_CAP O
plasmids O
involved O
in O
initiation O
of O
transfer O
DNA O
replication O
RARE O
bacterial O
conjugation O
. O

RARE O
focusing O
of O
RARE O
peptides O
generated O
from O
MHC I-GENE
- I-GENE
B I-GENE
RARE O
with O
cdc2 I-GENE
kinase I-GENE
revealed O
one O
major O
RARE O
that O
was O
RARE O
by O
reverse O
- O
RARE O
high O
performance O
liquid O
chromatography O
and O
sequenced O
. O

The O
deduced O
protein O
sequence O
was O
88 O
% O
homologous O
to O
that O
of O
ALL_CAP I-GENE
I I-GENE
, O
isolated O
from O
human O
osteosarcoma O
cells O
. O

However O
, O
cotransfection O
studies O
indicate O
that O
ALL_CAP I-GENE
does O
not O
activate O
transcription O
when O
this O
hormone O
response O
element O
is O
RARE O
to O
a O
reporter O
gene O
but O
rather O
acts O
RARE O
a O
potent O
competitive O
repressor O
of O
ALL_CAP I-GENE
alpha I-GENE
function O
. O

A O
comparison O
of O
the O
RARE O
RARE I-GENE
with O
a O
mammalian O
RARE I-GENE
revealed O
NUM O
% O
structural O
identity O
and O
NUM O
% O
overall O
RARE O
between O
the O
RARE O
and O
eukaryotic O
forms O
of O
the O
enzyme O
. O

RARE O
and O
RARE O
of O
the O
RARE O
RARE O
RARE O
an O
RARE O
. O

RARE I-GENE
dismutase I-GENE
( O
SOD I-GENE
) O
activity O
decreased O
significantly O
in O
sperm O
subjected O
to O
direct O
RARE O
current O
in O
comparison O
to O
the O
control O
or O
the O
sample O
incubated O
with O
RARE O
medium O
. O

These O
studies O
indicate O
that O
in O
vitro O
and O
in O
vivo O
electrical O
RARE O
generate O
reactive O
oxygen O
species O
and O
affect O
SOD I-GENE
activity O
, O
which O
in O
part O
are O
responsible O
RARE O
decreased O
sperm O
motion O
and O
viability O
. O

Molecular O
cloning O
and O
sequencing O
of O
a O
cDNA O
encoding O
SR I-GENE
beta I-GENE
revealed O
that O
SR I-GENE
beta I-GENE
is O
a O
transmembrane O
protein O
and O
, O
like O
SR I-GENE
alpha I-GENE
and O
NUM I-GENE
, O
is O
a O
RARE O
of O
the O
GTPase I-GENE
superfamily I-GENE
. O

To O
understand O
the O
function O
of O
receptor I-GENE
- I-GENE
RARE I-GENE
tyrosine I-GENE
RARE I-GENE
in O
RARE O
development O
, O
we O
sought O
to O
identify O
ALL_CAP I-GENE
isoforms I-GENE
preferentially O
RARE O
in O
the O
nervous O
RARE O
and O
cellular O
processes O
RARE O
ALL_CAP I-GENE
RARE O
RARE O
. O

RARE O
selection O
via O
albumin I-GENE
RARE O
: O
20 O
years O
of O
results O
. O

135 O
students O
had O
a O
count O
of O
less O
than O
50 O
eggs O
/ O
10 O
ml O
. O
urine O
and O
NUM O
had O
more O
than O
50 O
eggs O
/ O
NUM O
. O

They O
also O
reported O
that O
E I-GENE
mu I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
transgenic O
mice O
show O
greatly O
accelerated O
lymphoma O
development O
when O
RARE O
with O
wild O
- O
type O
M O
- O
MuLV O
RARE O
birth O
. O

Comparison O
of O
human I-GENE
and I-GENE
murine I-GENE
RARE I-GENE
sequences I-GENE
indicated O
that O
they O
share O
NUM O
% O
amino O
acid O
identity O
, O
the O
most O
RARE O
region O
being O
the O
catalytic O
domain O
( O
93 O
% O
identity O
). O

RARE O
RARE O
1993 O
] O
ALL_CAP O
ALL_CAP O
12 O
: O
NUM O
- O
NUM O
). O

The O
mRNAs O
of O
the O
ALL_CAP I-GENE
genes I-GENE
are O
encoded O
by O
RARE O
exons O
interrupted O
by O
five O
RARE O
. O

The O
effect O
of O
ethanol O
on O
human O
RARE O
reactivity O
was O
assessed O
by O
examining O
the O
acoustic O
RARE O
response O
. O

RARE O
RARE O
or O
beta I-GENE
- I-GENE
receptor I-GENE
antagonists O
are O
not O
helpful O
in O
the O
therapy O
of O
this O
form O
of O
RARE O
fibrillation O
whereas O
class O
I O
antiarrhythmic O
drugs O
have O
been O
shown O
to O
be O
more O
effective O
. O

RARE O
fibrillation O
and O
the O
RARE O
nervous O
RARE O

VIII O
in O
doses O
2 O
- O
3 O
times O
RARE O
than O
usually O
used O
in O
RARE O
without O
inhibitor O
were O
successful O
. O

A O
reduction O
of O
the O
RARE I-GENE
aminotransferase I-GENE
activity O
was O
observed O
from O
800 O
mg O
/ O
kg O
b O
. O
w O
RARE O
d O
RARE O
. O

Thus O
, O
these O
studies O
indicate O
that O
the O
104 O
- O
kDa O
isoform O
is O
required O
RARE O
normal O
RARE O
of O
female O
RARE O
cells O
and O
perhaps O
RARE O
RARE O
differentiation O
. O

RARE O
analysis O
maps O
NUM I-GENE
to O
RARE O
ALL_CAP O
between O
NUM I-GENE
and O
NUM I-GENE
. O

The O
newly O
RARE O
ALL_CAP O
method O
yields O
reliable O
data O
in O
measuring O
ALL_CAP O
. O

Removal O
of O
ALL_CAP O
from O
the O
cell O
medium O
resulted O
in O
reversal O
of O
the O
cell O
RARE O
changes O
, O
with O
cells O
re O
- O
RARE O
the O
S O
RARE O
. O

Rho I-GENE
GDP I-GENE
/ I-GENE
GTP I-GENE
exchange I-GENE
inhibitor I-GENE
, O
Rho I-GENE
ALL_CAP I-GENE
, O
RARE O
with O
NUM I-GENE
and O
RhoA I-GENE
, O
but O
not O
Rac1 I-GENE
. O

A O
major O
task O
RARE O
RARE O
RARE O
may O
be O
to O
RARE O
RARE O
the O
nature O
of O
an O
integrated O
model O
of O
the O
RARE O
RARE O
. O

RARE O
, O
ALL_CAP O
. O

RARE O
of O
RARE O
RARE O
encoding O
the O
RARE O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
gag I-GENE
gene I-GENE
by O
using O
a O
RARE O
RARE O
which O
provides O
the O
P1 I-GENE
RARE I-GENE
protein I-GENE
in O
RARE O
. O

Removal O
of O
the O
GST I-GENE
domain I-GENE
from O
GST I-GENE
- O
RARE I-GENE
by O
thrombin I-GENE
restores O
RARE I-GENE
' O
s O
ability O
to O
RARE O
a O
RARE O
RARE I-GENE
- O
CREB I-GENE
- O
21 O
- O
bp O
- O
repeat O
complex O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

The O
requirement O
of O
ALL_CAP I-GENE
in O
RARE O
biogenesis O
was O
confirmed O
by O
demonstrating O
that O
chromosomal I-GENE
ALL_CAP I-GENE
RARE I-GENE
mutants I-GENE
were O
RARE O
- O
and O
RARE O
- O
RARE O
RARE O
. O

The O
ALL_CAP I-GENE
gene I-GENE
product I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
, O
required O
RARE O
RARE O
biogenesis O
, O
shares O
amino O
acid O
sequence O
identity O
with O
the O
N O
- O
termini O
of O
type I-GENE
4 I-GENE
RARE I-GENE
proteins I-GENE
. O

Because O
of O
the O
RARE O
conservation O
of O
cell O
RARE O
control O
elements O
, O
the O
RARE O
of O
a O
RARE I-GENE
NUM I-GENE
or O
NUM I-GENE
homolog I-GENE
would O
be O
expected O
to O
rescue O
such O
lethal O
mutations O
in O
yeast O
. O

The O
RARE O
of O
this O
clone O
in O
a O
NUM I-GENE
/ O
NUM I-GENE
- O
RARE O
mutant O
causes O
an O
RARE O
cell O
RARE O
under O
non O
- O
permissive O
growth O
conditions O
. O

These O
data O
indicate O
that O
RARE O
of O
M I-GENE
protein I-GENE
RARE O
the O
major O
in O
vivo O
sites O
is O
not O
essential O
RARE O
virus O
assembly O
. O

RARE O
a O
third O
( O
NUM O
. O
6 O
%) O
of O
Insulin I-GENE
RARE O
and O
a O
third O
( O
NUM O
. O
NUM O
%) O
RARE O
Non O
Insulin I-GENE
RARE O
were O
of O
D O
, O
F O
, O
H O
RARE O
' O
s O
RARE O
. O

The O
activity O
of O
6 O
- O
RARE O
and O
their O
RARE O
RARE O
is O
compared O
in O
RARE O
. O

As O
the O
RARE O
- O
life O
of O
the O
compound O
did O
never O
RARE O
8 O
- O
9 O
h O
, O
the O
data O
do O
not O
support O
any O
change O
of O
RARE O
administration O
schedule O
( O
every O
NUM O
- O
12 O
h O
). O

The O
MAP I-GENE
kinase I-GENE
cascade O
is O
highly O
RARE O
in O
all O
eukaryotes O
and O
involved O
in O
numerous O
cellular O
responses O
. O

A O
comparative O
study O
by O
RARE O
RARE O
of O
ten O
RARE O
RARE O
RARE O
( O
RARE O
RARE O
- O
RARE O
ALL_CAP O
, O
two O
RARE O
and O
one O
RARE O
) O
with O
five O
human O
aortic O
RARE O
before O
and O
after O
RARE O
treatment O
is O
presented O
. O

No O
serious O
RARE O
effects O
were O
observed O
. O

This O
region O
constitutes O
the O
DNA O
- O
binding O
domain O
with O
basic O
- O
helix O
- O
loop O
- O
helix O
and O
leucine O
- O
zipper O
motifs O
, O
features O
common O
to O
the O
myc I-GENE
- I-GENE
related I-GENE
transcription I-GENE
factor I-GENE
family I-GENE
. O

Specific O
binding O
was O
not O
observed O
with O
either O
the O
RARE O
rat O
or O
mouse O
fragments O
using O
human O
or O
rodent O
extracts O
. O

The O
mean O
RARE O
and O
the O
fiber O
density O
did O
not O
change O
significantly O
from O
day O
NUM O
( O
NUM O
. O
1 O
+/- O
3 O
. O
6 O
RARE O
; O
1 O
. O
4 O
+/- O
NUM O
. O
07 O
) O
to O
day O
NUM O
( O
NUM O
. O
5 O
+/- O
2 O
. O
7 O
RARE O
; O
1 O
. O
6 O
+/- O
NUM O
. O
NUM O
). O

RARE O
of O
RARE I-GENE
D I-GENE
- O
Cdk I-GENE
complexes O
in O
RARE I-GENE
- O
negative O
cells O
correlates O
with O
high O
levels O
of O
NUM I-GENE
/ O
NUM I-GENE
RARE O
suppressor O
gene O
product O
. O

Recombinant I-GENE
human I-GENE
serum I-GENE
albumin I-GENE
( O
ALL_CAP I-GENE
) O
produced O
by O
cultured O
RARE O
has O
been O
prepared O
in O
the O
form O
of O
RARE O
RARE O
3 O
- O
5 O
microns O
in O
diameter O
and O
RARE O
with O
technetium O
- O
99m O
following O
reduction O
with O
RARE O
RARE O
. O

We O
have O
measured O
the O
release O
of O
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
( O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
) O
and O
RARE I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
) O
by O
unstimulated O
monocytes O
and O
monocytes O
RARE O
with O
lipopolysaccharide O
( O
ALL_CAP O
) O
isolated O
from O
the O
peripheral O
RARE O
of O
two O
patients O
with O
acute O
RARE O
glomerulonephritis O
( O
ALL_CAP O
) O
and O
16 O
healthy O
controls O
. O

Such O
an O
intervention O
may O
be O
of O
considerable O
use O
RARE O
the O
treatment O
of O
angiogenesis O
- O
dependent O
diseases O
involving O
FGF I-GENE
- I-GENE
2 I-GENE
. O

We O
have O
RARE O
to O
clone O
two O
recessive O
RARE O
suppressors O
of O
such O
RARE O
mutants O
( O
NUM I-GENE
RARE O
mutation I-GENE
NUM I-GENE
- I-GENE
14 I-GENE
and O
NUM I-GENE
- I-GENE
1 I-GENE
RARE O
mutation I-GENE
NUM I-GENE
- I-GENE
11 I-GENE
) O
by O
transforming O
RARE O
RARE O
strains O
NUM I-GENE
- I-GENE
14 I-GENE
NUM I-GENE
and O
NUM I-GENE
- I-GENE
11 I-GENE
NUM I-GENE
- I-GENE
1 I-GENE
with O
wild O
- O
type O
genomic O
libraries O
in O
RARE O
or O
multicopy O
vectors O
. O

ALL_CAP O
cross O
- O
linking O
experiments O
show O
that O
ALL_CAP I-GENE
has O
an O
apparent O
RARE O
mass O
of O
RARE O
65 O
kDa O
. O

In O
acute O
- O
RARE O
RARE O
, O
we O
observed O
a O
dramatic O
reduction O
in O
HNF I-GENE
- I-GENE
3 I-GENE
alpha I-GENE
RARE O
which O
correlates O
with O
a O
decrease O
in O
the O
RARE O
of O
its O
target O
gene O
, O
the O
ALL_CAP I-GENE
gene I-GENE
. O

RARE O
, O
RARE O
- O
of O
- O
function O
alleles O
of O
genes O
that O
inhibit O
ALL_CAP I-GENE
lead O
to O
the O
RARE O
to O
undergo O
sexual O
differentiation O
. O

One O
RARE O
of O
this O
family O
, O
NUM I-GENE
, O
is O
a O
transcription O
factor O
RARE O
a O
variety O
of O
viral O
and O
cellular O
genes O
. O

This O
mutant O
was O
identified O
by O
screening O
with O
a O
TGF I-GENE
- I-GENE
beta I-GENE
- O
inducible O
vector O
a O
series O
of O
RARE O
RARE O
RARE O
cell O
RARE O
that O
have O
normal O
TGF I-GENE
- I-GENE
beta I-GENE
binding O
activity O
but O
have O
lost O
RARE O
and O
transcriptional O
responses O
to O
TGF I-GENE
- I-GENE
beta I-GENE
. O

Cloning O
by O
RARE O
and O
subsequent O
physical O
and O
genetic O
analysis O
revealed O
that O
it O
maps O
to O
NUM I-GENE
. O

In O
the O
presence O
of O
RARE O
and O
RARE O
( O
repressing O
RARE O
the O
product O
of O
the O
NUM I-GENE
gene I-GENE
represses O
transcription O
RARE O
by O
the O
ALL_CAP O
element O
. O

By O
RARE O
RARE O
COS O
cells O
with O
oligonucleotides O
RARE O
to O
RARE O
, O
we O
have O
generated O
targeted O
mutations O
in O
a O
simian O
virus O
40 O
( O
SV40 O
) O
vector O
contained O
within O
the O
cells O
via O
RARE O
RARE O
helix O
formation O
. O

The O
interleukin I-GENE
2 I-GENE
receptor I-GENE
alpha I-GENE
- I-GENE
chain I-GENE
( O
ALL_CAP I-GENE
- I-GENE
2R I-GENE
alpha I-GENE
) O
gene O
is O
rapidly O
and O
RARE O
RARE O
in O
T O
cells O
in O
response O
to O
mitogenic O
stimuli O
. O

The O
RARE I-GENE
' I-GENE
RARE I-GENE
suppressor I-GENE
protein I-GENE
( O
WT1 I-GENE
) O
is O
a O
putative O
transcriptional O
regulatory O
protein O
with O
four O
zinc O
RARE O
, O
the O
last O
three O
of O
which O
have O
extensive O
sequence O
homology O
to O
the O
early I-GENE
growth I-GENE
response I-GENE
- I-GENE
1 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
) O
protein O
. O

OBJECTIVES O
: O
1 O
) O
to O
determine O
serum I-GENE
ACE I-GENE
activity O
in O
patients O
with O
COPD O
treated O
with O
and O
without O
continuous O
ambulatory O
oxygen O
therapy O
( O
ALL_CAP O
); O
2 O
) O
to O
RARE O
whether O
there O
is O
a O
correlation O
between O
ACE I-GENE
and O
any O
RARE O
, O
RARE O
or O
RARE O
parameter O
. O

In O
order O
to O
RARE O
shape O
from O
RARE O
, O
the O
human O
visual O
RARE O
must O
selectively O
RARE O
fragments O
RARE O
from O
a O
common O
RARE O
while O
RARE O
fragments O
from O
different O
objects O
separate O
. O

Among O
9 O
group O
I O
patients O
with O
a O
positive O
result O
on O
head O
- O
RARE O
tilt O
- O
RARE O
testing O
and O
RARE O
evidence O
of O
structural O
RARE O
RARE O
( O
mean O
follow O
- O
RARE O
4 O
. O
3 O
years O
RARE O
7 O
are O
without O
further O
episodes O
of O
RARE O
; O
3 O
have O
RARE O
medication O
and O
5 O
have O
RARE O
RARE O
least O
limited O
exercise O
. O

RARE O
designed O
and O
RARE O
were O
NUM O
( O
1 O
- O
98 O
RARE O
NUM O
. O
NUM O
( O
1 O
- O
NUM O
RARE O
NUM O
( O
120 O
- O
NUM O
RARE O
NUM O
. O
L2 O
( O
98 O
- O
NUM O
RARE O
and O
NUM O
. O
NUM O
. O
L2 O
( O
1 O
- O
NUM O
RARE O
where O
numbers O
in O
RARE O
give O
the O
amino O
acid O
sequence O
RARE O
the O
portions O
of O
the O
E2 I-GENE
RARE O
incorporated O
into O
a O
construct O
. O

Thus O
, O
we O
have O
produced O
RARE O
domain O
constructs O
that O
can O
be O
employed O
in O
RARE O
the O
specific O
roles O
of O
NUM I-GENE
and O
NUM I-GENE
in O
facilitating O
catalytic O
and O
regulatory O
processes O
. O

METHODS O
: O
Ten O
RARE O
A O
( O
NUM O
) O
viruses O
isolated O
RARE O
the O
RARE O
were O
examined O
RARE O
resistance O
to O
RARE O
and O
RARE O
by O
means O
of O
an O
enzyme O
immunoassay O
and O
by O
sequencing O
of O
the O
viral O
RARE O
acid O
that O
encodes O
the O
transmembrane O
domain O
of O
the O
NUM I-GENE
protein I-GENE
. O

The O
RARE O
contains O
ATF I-GENE
/ O
ALL_CAP O
and O
TBP I-GENE
/ O
TATA O
sequence O
motifs O
within O
an O
87 O
- O
bp O
region O
. O

RARE O
RARE O
occurs O
in O
a O
circadian O
rhythm O
and O
RARE O
by O
light O
in O
leaves O
of O
dark O
- O
adapted O
RARE O
. O

Our O
results O
suggested O
that O
the O
hexamer O
and O
the O
octamer O
motifs O
may O
play O
important O
role O
( O
s O
) O
in O
RARE O
of O
replication O
- O
dependent O
but O
not O
of O
replication O
- O
independent O
RARE O
of O
the O
RARE I-GENE
histone I-GENE
NUM I-GENE
gene I-GENE
. O

The O
tissue O
- O
specific O
RARE O
of O
ALL_CAP I-GENE
family I-GENE
members I-GENE
suggests O
that O
the O
combination O
of O
ALL_CAP I-GENE
/ O
E2F I-GENE
RARE O
that O
constitute O
NUM I-GENE
/ O
E2F I-GENE
is O
influenced O
by O
the O
RARE O
of O
the O
cell O
. O

Similarly O
, O
in O
mammalian O
cells O
NUM I-GENE
is O
synthesized O
RARE O
a O
pre O
- O
protein O
that O
requires O
membrane O
RARE O
- O
dependent O
import O
into O
RARE O
RARE O
its O
RARE O
. O

In O
a O
second O
experiment O
involving O
an O
18 O
- O
h O
RARE O
clearance O
assay O
, O
we O
used O
the O
RARE I-GENE
3 I-GENE
. I-GENE
2 I-GENE
. I-GENE
3 I-GENE
to O
RARE O
rats O
of O
ALL_CAP O
/ O
ALL_CAP O
cells O
with O
the O
following O
RARE O
: O
if O
ALL_CAP O
/ O
ALL_CAP O
cells O
are O
necessary O
to O
mediate O
an O
event O
, O
then O
in O
their O
absence O
, O
that O
event O
should O
not O
occur O
. O

Treatment O
of O
recurrent O
ALL_CAP O
has O
included O
high O
- O
dose O
steroids O
, O
high O
- O
dose O
cyclosporine O
( O
ALL_CAP O
RARE O
RARE O
, O
and O
ACE I-GENE
RARE O
with O
mixed O
results O
. O

Our O
results O
concluded O
that O
1 O
) O
the O
two O
RARE I-GENE
/ O
activin I-GENE
beta O
B O
- O
subunit O
mRNAs O
were O
RARE O
from O
different O
initiation O
sites O
; O
2 O
) O
both O
promoters O
may O
be O
RARE O
by O
RARE O
- O
RARE O
negative O
regulatory O
elements O
; O
and O
3 O
) O
neither O
of O
these O
promoters O
is O
responsive O
to O
cAMP O
and O
/ O
or O
phorbol O
esters O
under O
the O
conditions O
employed O
. O

Promoter O
region O
of O
the O
transcriptional O
unit O
RARE O
human I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
RARE I-GENE
, O
a O
RARE I-GENE
- I-GENE
specific I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
RARE O
NUM I-GENE
. O
alpha I-GENE
1 I-GENE
- I-GENE
RARE I-GENE
is O
a O
RARE I-GENE
- I-GENE
specific I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
RARE O
NUM I-GENE
, O
a O
protein O
involved O
in O
morphological O
events O
. O

Upstream O
from O
the O
transcription O
RARE O
point O
( O
RARE O
RARE O
a O
nucleotide O
sequence O
highly O
homologous O
to O
the O
consensus I-GENE
sequence I-GENE
motif I-GENE
RARE I-GENE
the I-GENE
RARE I-GENE
NUM I-GENE
- I-GENE
RARE I-GENE
promoters I-GENE
was O
found O
. O

In O
this O
paper O
, O
an O
analysis O
of O
the O
dynamics O
in O
the O
RARE O
RARE O
of O
the O
RARE O
of O
a O
mechanical O
RARE O
RARE O
valve O
RARE O
is O
presented O
. O

During O
ALL_CAP O
+ O
AT O
infusion O
, O
abdominal O
fat O
RARE O
flow O
was O
still O
significantly O
increased O
RARE O
compared O
with O
control O
values O
in O
lean O
and O
obese O
subjects O
. O

When O
RARE O
per O
RARE O
body O
RARE O
, O
mean O
ALL_CAP O
increased O
in O
the O
ALL_CAP O
group O
from O
NUM O
. O
14 O
% O
to O
NUM O
. O
16 O
% O
above O
ALL_CAP O
, O
with O
a O
significant O
decrease O
from O
NUM O
. O
NUM O
% O
to O
NUM O
. O
NUM O
% O
in O
the O
P O
group O
. O

In O
nucleus O
RARE O
anterior O
RARE O
- O
nucleus O
RARE O
RARE O
RARE O
neurons O
with O
an O
RARE O
input O
from O
nucleus O
RARE O
, O
a O
shortening O
of O
inhibition O
from O
NUM O
. O
5 O
+/- O
3 O
. O
6 O
to O
9 O
. O
1 O
+/- O
1 O
. O
8 O
ms O
( O
P O
< O
NUM O
. O
05 O
) O
under O
the O
haloperidol O
influence O
was O
evident O
. O

However O
, O
inclusion O
of O
the O
RARE O
ALL_CAP O
motifs O
from O
the O
ICP4 I-GENE
promoter I-GENE
, O
which O
bind O
factors O
GABP I-GENE
alpha I-GENE
and I-GENE
beta I-GENE
, O
results O
in O
a O
strong O
synergistic O
activation O
. O

The O
RARE O
RARE O
reading O
frame O
of O
the O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
genome O
encodes O
a O
putative O
replication O
- O
associated O
protein O
of O
NUM O
kDa O
( O
NUM I-GENE
). O

From O
sequence O
RARE O
with O
RARE O
related O
viruses O
, O
including O
RARE O
, O
we O
predicted O
that O
NUM I-GENE
contained O
a O
RARE I-GENE
- I-GENE
like I-GENE
RARE I-GENE
domain I-GENE
with O
a O
putative O
catalytic O
NUM O
and O
NUM O
. O

This O
finding O
represents O
both O
a O
potentially O
important O
mechanism O
by O
which O
HPV O
gene O
RARE O
can O
be O
regulated O
and O
an O
RARE O
model O
RARE O
the O
study O
of O
transcriptional O
cooperativity O
. O

Using O
this O
method O
, O
RARE O
were O
obtained O
in O
RARE O
sufficient O
RARE O
further O
characterization O
. O

Analysis O
of O
the O
sequence O
upstream O
of O
this O
initiation O
RARE O
reveals O
the O
presence O
of O
a O
RARE O
sequence O
. O

NUM I-GENE
is O
implicated O
in O
translation O
RARE O
and O
encodes O
the O
ribosomal I-GENE
protein I-GENE
NUM I-GENE
. O

To O
explore O
the O
RARE O
relationship O
between O
c I-GENE
- I-GENE
fos I-GENE
and O
RARE I-GENE
, O
a O
eukaryotic O
RARE O
RARE O
was O
constructed O
containing O
the O
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
under O
control O
of O
the O
SV40 I-GENE
promoter I-GENE
complex O
. O

The O
high O
degree O
of O
sequence O
identity O
( O
96 O
%) O
between O
RARE I-GENE
B I-GENE
and I-GENE
C I-GENE
, O
particularly O
in O
the O
3 O
' O
RARE O
region O
, O
suggests O
that O
the O
genes O
encoding O
these O
two O
RARE I-GENE
evolved O
by O
duplication O
and O
divergence O
of O
a O
common O
ancestral O
gene O
. O

The O
regions O
of O
the O
tooth O
fracture O
are O
determined O
. O

RARE O
pancreatic O
involvement O
of O
RARE O
RARE O
detected O
by O
a O
clinically O
RARE O
mass O
. O

The O
NUM O
RARE O
is O
a O
RARE O
tool O
RARE O
the O
mapping O
of O
new O
RARE O
of O
this O
region O
, O
RARE O
RARE O
RARE O
RARE O
obtaining O
new O
RARE O
RARE O
specific O
RARE O
the O
deletion O
by O
RARE O
cloning O
of O
the O
region O
. O

ALL_CAP O
RARE O
doses O
of O
NUM O
to O
500 O
mg O
/ O
kg O
significantly O
suppressed O
RARE I-GENE
oxidase I-GENE
( O
ALL_CAP I-GENE
) O
activity O
in O
the O
stomach O
tissue O
following O
its O
oral O
administration O
. O

Like O
humans O
, O
the O
ALL_CAP I-GENE
ALL_CAP I-GENE
genes I-GENE
in I-GENE
RARE I-GENE
must O
be O
closely O
RARE O
, O
based O
on O
RARE O
in O
situ O
hybridization O
( O
ALL_CAP O
) O
RARE O
of O
these O
genes O
to O
a O
single O
chicken O
RARE O
. O

Here O
, O
we O
report O
the O
characterization O
of O
an O
RARE O
processed O
form O
of O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
that O
encodes O
an O
additional O
258 O
RARE O
RARE O
( O
bp O
) O
of O
RARE O
reading O
frame O
. O

Expression O
of O
class I-GENE
IV I-GENE
ADH I-GENE
mRNA I-GENE
was O
detected O
in O
human O
stomach O
but O
not O
liver O
. O

In O
ICE I-GENE
gamma I-GENE
, O
most O
of O
the O
RARE O
( O
amino O
RARE O
20 O
- O
112 O
) O
is O
RARE O
, O
which O
suggests O
that O
it O
may O
function O
RARE O
a O
RARE O
RARE O
ICE I-GENE
RARE O
in O
vivo O
. O

RARE O
and O
RARE O
targeting O
of O
RARE I-GENE
growth I-GENE
factor I-GENE
receptors I-GENE
are O
RARE O
by O
distinct O
sequences O
independent O
of O
the O
tyrosine I-GENE
kinase I-GENE
domain I-GENE
. O

It O
is O
now O
RARE O
that O
essentially O
all O
eukaryotic O
and O
RARE O
genes O
whose O
5 O
'- O
flanking O
regions O
are O
known O
and O
that O
encode O
RARE O
- O
inducible O
proteins O
contain O
the O
RARE O
box O
element O
. O

Mutation O
of O
the O
NUM I-GENE
- I-GENE
3 I-GENE
RARE I-GENE
box I-GENE
significantly O
increased O
the O
RARE O
of O
both O
NUM I-GENE
- I-GENE
3 I-GENE
and O
NUM I-GENE
( O
another O
small O
gene O
RARE O
upstream O
of O
the O
NUM I-GENE
- I-GENE
3 I-GENE
gene I-GENE
that O
encodes O
a O
second O
putative O
regulatory O
protein O
) O
in O
response O
to O
RARE O
induction O
but O
RARE O
the O
basal O
levels O
unaffected O
. O

The O
NUM I-GENE
- O
depleted O
nuclei O
remained O
largely O
competent O
RARE O
nuclear O
protein O
import O
. O

A O
RARE O
outcome O
of O
these O
biochemical O
effects O
may O
include O
the O
limited O
responsiveness O
of O
RARE O
T O
cells O
to O
RARE O
RARE O
observed O
RARE O
HIV O
- O
1 O
infection O
. O

The O
full O
protocol O
was O
completed O
by O
NUM O
patients O
( O
NUM O
% O
of O
original O
cohort O
). O

In O
addition O
, O
we O
found O
that O
cell O
- O
specific O
suppression O
of O
ALL_CAP O
- O
RARE O
NUM I-GENE
gene I-GENE
RARE O
can O
be O
attributed O
to O
a O
29 O
RARE O
RARE O
nucleotide O
sequence O
, O
RARE O
RARE O
of O
the O
ALL_CAP O
- O
responsive O
region O
in O
the O
NUM I-GENE
gene I-GENE
. O

We O
show O
that O
CBF I-GENE
- I-GENE
A I-GENE
and O
CBF I-GENE
- I-GENE
C I-GENE
interact O
with O
each O
other O
to O
form O
a O
CBF I-GENE
- I-GENE
A I-GENE
- O
CBF I-GENE
- I-GENE
C I-GENE
complex O
and O
that O
CBF I-GENE
- I-GENE
B I-GENE
does O
not O
interact O
with O
CBF I-GENE
- I-GENE
A I-GENE
or O
CBF I-GENE
- I-GENE
C I-GENE
individually O
but O
that O
it O
associates O
with O
the O
CBF I-GENE
- I-GENE
A I-GENE
- O
CBF I-GENE
- I-GENE
C I-GENE
complex O
. O

In O
the O
RARE O
, O
homologous O
sequences O
were O
RARE O
from O
a O
mouse O
enhancer O
, O
resulting O
in O
a O
tissue O
- O
specific O
RARE O
of O
activity O
when O
assayed O
in O
transgenic O
mice O
. O

NUM I-GENE
prophylaxis O
RARE O
long O
- O
term O
RARE O
graft O
survival O
in O
high O
- O
risk O
patients O
RARE O
compared O
to O
cyclosporine O
: O
combined O
results O
from O
the O
prospective O
, O
randomized O
RARE O
and O
US O
studies O
. O

The O
major O
PKC I-GENE
beta I-GENE
transcription O
initiation O
site O
was O
identified O
by O
primer O
extension O
and O
S1 I-GENE
RARE I-GENE
protection O
. O

In O
the O
course O
of O
a O
study O
of O
low O
dose O
X O
- O
rays O
effects O
, O
we O
found O
that O
male O
ALL_CAP O
RARE O
RARE O
mice O
showed O
remarkable O
suppression O
of O
RARE O
behavior O
after O
whole O
body O
irradiation O
by O
5 O
to O
NUM O
RARE O
X O
- O
rays O
. O

A O
quantitative O
analysis O
of O
the O
RARE O
intensity O
RARE O
function O
of O
the O
accumulated O
electron O
dose O
suggests O
the O
possibility O
of O
recording O
RARE O
to O
NUM O
RARE O
patterns O
with O
3 O
. O
5 O
A O
resolution O
from O
a O
single O
RARE O
complex O
RARE O
NUM O
A O
thick O
. O

RARE O
Phase O
RARE O
ALL_CAP O
(" O
RARE O
RARE O
RARE O
RARE O
sequences O
were O
carried O
out O
in O
29 O
patients O
. O

In O
yeast O
, O
the O
products O
of O
the O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
are O
required O
RARE O
this O
RARE O
RARE O
, O
and O
in O
this O
report O
we O
focus O
on O
the O
identification O
and O
characterization O
of O
additional O
factors O
required O
RARE O
rapid O
RARE O
of O
nonsense O
- O
containing O
mRNAs O
. O

Mutations O
in O
NUM I-GENE
lead O
to O
the O
selective O
stabilization O
of O
mRNAs O
containing O
early O
nonsense O
mutations O
without O
affecting O
the O
RARE O
rates O
of O
most O
other O
mRNAs O
. O

A O
DNA O
fragment O
encoding O
the O
DNA O
- O
binding O
domain O
( O
amino O
RARE O
1 O
- O
NUM O
) O
of O
the O
Escherichia I-GENE
coli I-GENE
RARE I-GENE
transcriptional I-GENE
regulator I-GENE
was O
RARE O
into O
the O
ALL_CAP O
- O
ALL_CAP O
vector O
and O
RARE O
in O
frame O
with O
the O
fused O
gene O
encoding O
RARE I-GENE
S I-GENE
- I-GENE
transferase I-GENE
. O

Using O
gel O
retardation O
assays O
with O
NUM O
nuclear O
RARE O
, O
we O
demonstrated O
the O
presence O
of O
a O
specific O
protein O
which O
RARE O
to O
the O
ALL_CAP O
fragment O
. O

NUM O
. O
NUM O
+/- O
NUM O
. O
04 O
). O

Several O
nuclear O
factors O
that O
interact O
with O
sequences O
in O
the O
5 O
' O
flanking O
region O
of O
the O
mouse I-GENE
RARE I-GENE
gene I-GENE
were O
identified O
using O
band O
shift O
and O
methylation O
interference O
assays O
. O

With O
a O
population O
of O
NUM O
million O
there O
should O
be O
NUM O
, O
NUM O
patients O
with O
RARE O
A O
in O
RARE O
RARE O
a O
prevalence O
of O
6 O
/ O
NUM O
, O
NUM O
population O
. O

When O
combined O
with O
serum O
ferritin I-GENE
and O
hemoglobin I-GENE
determinations O
, O
the O
serum O
transferrin I-GENE
receptor I-GENE
assay O
is O
a O
valuable O
addition O
in O
RARE O
RARE O
because O
it O
provides O
a O
quantitative O
measure O
of O
RARE O
iron O
deficiency O
and O
it O
RARE O
true O
ALL_CAP O
from O
the O
RARE O
of O
chronic O
RARE O
. O

Twenty O
- O
two O
consecutive O
patients O
with O
ischaemic O
ulcers O
had O
NUM O
measured O
and O
the O
RARE O
/ O
RARE O
( O
ALL_CAP O
) O
and O
toe O
/ O
RARE O
( O
ALL_CAP O
) O
indices O
calculated O
. O

NUM O
measurement O
appears O
to O
be O
a O
reliable O
technique O
that O
can O
influence O
ischaemic O
ulcer O
management O
. O

Since O
1990 O
the O
University O
RARE O
of O
RARE O
has O
provided O
local O
hospitals O
in O
northern O
RARE O
with O
a O
RARE O
RARE O
section O
RARE O
and O
with O
access O
to O
RARE O
RARE O
RARE O
the O
review O
of O
microscopic O
findings O
and O
RARE O
the O
discussion O
of O
major O
diagnostic O
issues O
. O

Current O
status O
of O
RARE O
. O

Expression O
of O
NUM O
. O
1 O
in O
COS O
- O
1 O
cells O
led O
to O
the O
production O
of O
a O
typical O
type I-GENE
IV I-GENE
ALL_CAP I-GENE
activity O
in O
that O
cAMP O
, O
but O
not O
ALL_CAP O
, O
RARE O
RARE O
substrate O
and O
its O
activity O
was O
RARE O
to O
either O
NUM O
RARE O
CaM I-GENE
or O
ALL_CAP O
but O
was O
inhibited O
by O
low O
concentrations O
of O
RARE O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

NUM I-GENE
displays O
96 O
and O
NUM O
% O
identity O
respectively O
with O
the O
tobacco I-GENE
NUM I-GENE
and O
Arabidopsis I-GENE
NUM I-GENE
kinases I-GENE
, O
and O
only O
50 O
% O
to O
the O
more O
distantly O
related O
RARE O
MAP O
kinase O
NUM I-GENE
from O
RARE O
. O

RARE O
of O
the O
coding O
segment O
, O
which O
was O
designated O
NUM I-GENE
, O
suggested O
it O
encodes O
a O
chimeric O
40 O
, O
NUM O
RARE O
cell O
RARE O
protein O
with O
an O
amino O
- O
terminal O
signal O
sequence O
, O
a O
RARE O
proline O
- O
rich O
sequence O
, O
and O
a O
cysteine O
- O
rich O
RARE O
- O
terminal O
sequence O
homologous O
to O
nonspecific O
RARE O
transfer O
proteins O
. O

The O
presence O
of O
type O
I O
hypersensitivity O
in O
a O
subgroup O
of O
RARE O
suggests O
an O
RARE O
RARE O
to O
this O
RARE O
which O
could O
contribute O
to O
a O
chronic O
inflammatory O
response O
to O
RARE O
in O
some O
RARE O
. O

This O
concept O
is O
supported O
by O
the O
identification O
of O
ALL_CAP I-GENE
- I-GENE
like I-GENE
genes I-GENE
in O
non O
human O
primates O
. O

With O
steady O
RARE O
, O
RARE O
RARE O
( O
RARE O
) O
NUM O
decreased O
to O
1 O
. O
4 O
+/- O
NUM O
. O
9 O
ml O
NUM O
RARE O
NUM O
g O
. O
min O
RARE O
but O
inner O
RARE O
NUM O
remained O
unchanged O
RARE O
3 O
. O
7 O
+/- O
1 O
. O
5 O
ml O
NUM O
RARE O
NUM O
g O
. O
min O
) O
( O
5 O
cats O
). O

We O
have O
screened O
the O
mouse O
cDNA O
library O
of O
an O
NUM O
cell O
line O
, O
derived O
from O
pancreatic O
beta O
cells O
, O
RARE O
its O
novel O
isoform O
and O
have O
identified O
a O
cDNA O
encoding O
a O
NUM O
- O
amino O
acid O
protein O
having O
NUM O
, O
53 O
, O
and O
NUM O
% O
identity O
with O
RARE I-GENE
- I-GENE
18 I-GENE
/ I-GENE
RARE I-GENE
- I-GENE
NUM I-GENE
/ I-GENE
NUM I-GENE
, O
Caenorhabditis I-GENE
elegans I-GENE
NUM I-GENE
, O
and O
Saccharomyces I-GENE
cerevisiae I-GENE
NUM I-GENE
, O
respectively O
. O

The O
RARE I-GENE
bind O
to O
ALL_CAP I-GENE
and O
E I-GENE
- I-GENE
RARE I-GENE
in O
a O
similar O
fashion O
, O
but O
ALL_CAP I-GENE
and O
E I-GENE
- I-GENE
RARE I-GENE
do O
not O
associate O
with O
each O
other O
either O
in O
the O
presence O
or O
absence O
of O
RARE I-GENE
. O

However O
, O
addition O
of O
core I-GENE
DNA I-GENE
polymerase I-GENE
III I-GENE
to O
RARE O
complex O
, O
fully O
RARE O
RARE O
resulted O
in O
RARE O
of O
gamma O
by O
alpha O
RARE O
the O
primer O
terminus O
. O

The O
NUM I-GENE
gene I-GENE
was O
RARE O
RARE O
by O
infection O
of O
RARE O
- O
9 O
insect O
cells O
with O
recombinant O
RARE O
, O
resulting O
in O
a O
10 O
- O
RARE O
increase O
in O
ALL_CAP I-GENE
activity O
. O

RARE O
detection O
of O
abnormal O
asymmetry O
in O
digital O
chest O
radiographs O
. O

These O
results O
suggest O
that O
RARE O
genes O
are O
RARE O
upon O
binding O
of O
NUM I-GENE
, O
whose O
RARE O
depends O
on O
the O
release O
of O
NUM I-GENE
( O
NUM I-GENE
) O
from O
the O
NUM I-GENE
promoter I-GENE
. O

Like O
Epo I-GENE
, O
HNF I-GENE
- I-GENE
4 I-GENE
is O
RARE O
in O
RARE O
, O
liver O
, O
and O
NUM O
cells O
but O
not O
in O
HeLa O
cells O
. O

Moreover O
, O
the O
RARE O
- O
RARE O
RARE O
of O
the O
endogenous O
Epo I-GENE
gene I-GENE
was O
significantly O
inhibited O
in O
NUM O
cells O
stably O
transfected O
with O
HNF I-GENE
- I-GENE
4 I-GENE
delta I-GENE
C I-GENE
. O

These O
observations O
indicate O
that O
there O
are O
multiple O
mechanisms O
by O
which O
an O
individual O
transcript O
can O
be O
degraded O
following O
RARE O
. O

RARE I-GENE
Maf I-GENE
proteins I-GENE
RARE O
with O
Fos I-GENE
and O
may O
act O
RARE O
competitive O
RARE O
of O
the O
ALL_CAP I-GENE
- I-GENE
E2 I-GENE
transcription I-GENE
factor I-GENE
. O

We O
show O
here O
that O
the O
binding O
of O
NUM I-GENE
in O
vitro O
is O
RARE O
to O
the O
concentration O
of O
RARE O
ions O
. O

RARE O
after O
development O
of O
symptomatic O
infection O
( O
P O
- O
2 O
) O
did O
not O
differ O
by O
RARE O
mode O
. O

Both O
factors O
demonstrated O
significant O
correlations O
with O
rCBF O
in O
the O
medial O
RARE O
cortex O
and O
frontal O
RARE O
cortex O
while O
RARE O
each O
factor O
there O
were O
also O
unique O
patterns O
of O
correlations O
with O
posterior O
brain O
regions O
. O

These O
data O
suggest O
that O
the O
function O
of O
the O
NUM I-GENE
may O
be O
the O
protection O
of O
the O
nuclear O
DNA O
from O
RARE O
. O

RARE O
hemodynamics O
RARE O
abortion O
RARE O
by O
ALL_CAP O
NUM O
and O
sepsis O
in O
rats O
. O

The O
aim O
of O
this O
retrospective O
study O
was O
to O
demonstrate O
that O
in O
certain O
cases O
of O
RARE O
RARE O
hemorrhage O
( O
ALL_CAP O
) O
anatomical O
success O
and O
useful O
vision O
can O
be O
obtained O
with O
RARE O
RARE O
surgery O
. O

The O
function O
of O
the O
C O
- O
terminal O
RARE O
in O
RARE O
RARE O
is O
not O
RARE O
through O
the O
NUM I-GENE
RARE I-GENE
factor I-GENE
NUM I-GENE
: O
NUM I-GENE
alleles I-GENE
RARE O
in O
both O
the O
C O
- O
terminal O
RARE O
and O
NUM I-GENE
interaction I-GENE
domains I-GENE
have O
additive O
effects O
on O
RARE O
length O
. O

The O
resulting O
integrated O
physical O
, O
genetic O
, O
and O
cytogenetic O
map O
constitutes O
a O
resource O
RARE O
the O
characterization O
of O
genes O
that O
may O
be O
involved O
in O
the O
ALL_CAP O
RARE O
. O

The O
contribution O
of O
RARE O
flow O
to O
the O
changes O
in O
NUM O
- O
800 O
nm O
absorption O
was O
investigated O
by O
simultaneous O
measurement O
of O
RARE O
flow O
by O
laser O
flow O
Doppler O
and O
ALL_CAP O
recordings O
RARE O
hot O
water O
immersion O
. O

RARE O
immunoprecipitated O
from O
lysates O
of O
control O
- O
and O
VEGF I-GENE
- O
RARE O
ALL_CAP O
with O
antisera O
to O
phospholipase I-GENE
C I-GENE
- I-GENE
gamma I-GENE
( O
PLC I-GENE
- I-GENE
gamma I-GENE
) O
were O
RARE O
by O
SDS O
- O
polyacrylamide O
gel O
electrophoresis O
and O
transferred O
to O
RARE O
- O
P O
. O

RARE O
processed O
isoforms O
of O
cellular I-GENE
RARE I-GENE
acid I-GENE
- I-GENE
binding I-GENE
protein I-GENE
interact O
with O
a O
suppressor O
region O
of O
the O
human I-GENE
beta I-GENE
- I-GENE
myosin I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
. O

RARE O
of O
early I-GENE
growth I-GENE
response I-GENE
factor I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
in O
apolipoprotein I-GENE
ALL_CAP I-GENE
gene I-GENE
transcription O
. O

The O
wild O
- O
type O
and O
altered O
forms O
of O
the O
F I-GENE
protein I-GENE
were O
RARE O
in O
ALL_CAP O
- O
21 O
and O
HeLa O
T4 O
cells O
by O
use O
of O
the O
recombinant I-GENE
RARE I-GENE
virus I-GENE
- I-GENE
encoding I-GENE
NUM I-GENE
polymerase I-GENE
RARE O
. O

RARE I-GENE
delta I-GENE
- I-GENE
RARE I-GENE
acid I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
activity O
, O
RARE O
zinc O
RARE O
( O
ALL_CAP O
RARE O
heme O
ratio O
, O
and O
RARE O
RARE O
( O
ALL_CAP O
) O
concentration O
have O
been O
employed O
RARE O
biological O
indicators O
of O
moderate O
- O
to O
high O
- O
level O
lead O
exposure O
, O
corresponding O
to O
RARE O
levels O
in O
excess O
of O
50 O
micrograms O
/ O
dl O
, O
in O
human O
subjects O
. O

The O
relative O
risk O
of O
graft O
RARE O
after O
conversion O
to O
RARE O
compared O
with O
graft O
RARE O
after O
conversion O
to O
RARE O
compared O
with O
cyclosporin O
RARE O
was O
NUM O
. O
NUM O
( O
NUM O
. O
37 O
- O
1 O
. O
38 O
) O
and O
the O
relative O
risk O
of O
patient O
RARE O
was O
NUM O
. O
57 O
( O
NUM O
. O
NUM O
- O
1 O
. O
NUM O
). O

Three O
classes O
of O
test O
objects O
were O
considered O
: O
( O
1 O
) O
a O
RARE O
test O
RARE O
RARE O
NUM O
MRS O
measurements O
performed O
with O
RARE O
- O
selective O
sequences O
; O
( O
2 O
) O
a O
two O
- O
compartment O
test O
RARE O
RARE O
volume O
- O
selection O
NUM O
MRS O
; O
and O
( O
3 O
) O
two O
- O
compartment O
test O
objects O
RARE O
assessing O
the O
performance O
of O
experimental O
RARE O
using O
ALL_CAP O
RARE O
volume O
RARE O
sequence O
in O
NUM O
MRS O
. O

The O
" O
tobacco O
RARE O
". O

RARE O
screening O
by O
RARE O
artery O
Doppler O
RARE O
RARE O
which O
criterion O
RARE O
best O
? O
OBJECTIVE O
: O
To O
test O
whether O
repeating O
Doppler O
studies O
of O
the O
RARE O
circulation O
RARE O
in O
gestation O
will O
improve O
the O
test O
' O
s O
power O
RARE O
predicting O
RARE O
- O
RARE O
hypertension O
and O
RARE O
growth O
RARE O
( O
ALL_CAP O
RARE O
and O
whether O
analysis O
based O
on O
a O
combination O
of O
quantitative O
and O
qualitative O
RARE O
of O
the O
RARE O
arterial O
RARE O
will O
yield O
better O
results O
than O
analysis O
based O
on O
either O
alone O
. O

The O
effect O
of O
the O
Ca O
entry O
blocker O
RARE O
, O
the O
antioxidant O
RARE I-GENE
dismutase I-GENE
( O
SOD I-GENE
RARE O
and O
a O
combination O
of O
RARE O
and O
RARE I-GENE
dismutase I-GENE
on O
RARE O
RARE O
function O
was O
studied O
in O
four O
groups O
( O
RARE O
= O
NUM O
) O
of O
rats O
. O

PURPOSE O
: O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
RARE O
anchorage O
of O
a O
new O
implant O
( O
RARE O
RARE O
surface O
effect O
with O
RARE O
RARE O
Al O
RARE O
and O
RARE O
RARE O
of O
NUM O
mu O
). O

To O
determine O
whether O
food O
and O
/ O
or O
water O
in O
the O
RARE O
RARE O
affects O
RARE O
of O
RARE O
volume O
and O
plasma O
protein O
after O
hemorrhage O
, O
fed O
and O
NUM O
- O
h O
- O
fasted O
RARE O
rats O
received O
a O
20 O
ml O
. O
kg O
- O
1 O
RARE O
3 O
min O
- O
1 O
hemorrhage O
, O
and O
RARE O
of O
RARE O
volume O
was O
measured O
by O
RARE O
blue O
RARE O
and O
dilution O
of O
hematocrit O
. O

RARE O
RARE O
of O
paired I-GENE
class O
RARE O
domains O
on O
DNA O
. O

We O
RARE O
advantage O
of O
the O
high O
degree O
of O
RARE O
sequence O
homology O
between O
RARE I-GENE
from O
several O
species O
to O
isolate O
NUM I-GENE
RARE I-GENE
from O
the O
pathogenic O
yeast O
RARE O
RARE O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
ALL_CAP O
DNA O
enhances O
transcription O
from O
the O
RARE I-GENE
kinase I-GENE
( O
TK I-GENE
) O
promoter O
in O
various O
EC O
cells O
. O

Deletion O
analyses O
of O
the O
construct O
revealed O
that O
the O
transcription O
of O
NUM I-GENE
gene I-GENE
is O
regulated O
by O
ALL_CAP O
DNA O
, O
preferentially O
in O
undifferentiated O
EC O
cells O
versus O
differentiated O
cells O
. O

Analysis O
of O
RARE O
rates O
indicates O
that O
the O
NUM I-GENE
- O
NUM I-GENE
- O
DNA O
complex O
has O
a O
longer O
RARE O
- O
life O
than O
protein O
- O
DNA O
complexes O
that O
contain O
only O
NUM I-GENE
or O
NUM I-GENE
. O

The O
presence O
of O
an O
unusual O
transcript O
RARE O
NUM I-GENE
beta I-GENE
1 I-GENE
RARE O
the O
5 O
' O
terminus O
suggests O
that O
RARE O
of O
its O
RARE O
RARE O
is O
inefficient O
or O
negatively O
regulated O
. O

The O
mutant O
allele O
of O
the O
alpha I-GENE
1 I-GENE
- I-GENE
RARE I-GENE
gene I-GENE
was O
designated O
NUM I-GENE
- I-GENE
1 I-GENE
. O

During O
chronic O
treatment O
, O
when O
plasma O
concentrations O
RARE O
between O
NUM O
. O
5 O
RARE O
. O
ml O
- O
1 O
RARE O
8 O
h O
and O
14 O
RARE O
. O
ml O
- O
1 O
RARE O
NUM O
h O
post O
- O
RARE O
, O
ST O
segment O
depression O
RARE O
an O
individually O
comparable O
RARE O
was O
significantly O
decreased O
by O
NUM O
% O
compared O
with O
placebo O
( O
P O
< O
NUM O
. O
005 O
) O
RARE O
both O
points O
in O
time O
. O

Results O
from O
in O
vitro O
transcription O
- O
translation O
analysis O
and O
RARE O
experiments O
suggested O
that O
the O
NUM O
- O
bp O
ORF O
was O
the O
one O
being O
actively O
RARE O
. O

RARE O
experiments O
demonstrated O
that O
it O
was O
possible O
to O
produce O
ALL_CAP I-GENE
mutants I-GENE
, O
whose O
products O
RARE O
RARE O
RARE O
RARE O
export O
and O
assembly O
. O

RARE O
RARE O
response O
to O
indirect O
RARE O
RARE O
RARE O
1 O
Hz O
was O
monitored O
in O
ten O
adult O
goats O
under O
RARE O
- O
halothane O
anaesthesia O
. O

NUM O
, O
98 O
- O
NUM O
). O

Group O
6 O
was O
given O
RARE O
, O
NUM O
. O
1 O
mg O
/ O
kg O
i O
. O
v O
., O
known O
to O
inhibit O
cholinesterase I-GENE
RARE O
, O
5 O
min O
before O
RARE O
administration O
, O
and O
Group O
7 O
received O
a O
combination O
of O
RARE O
pretreatment O
and O
electrical O
RARE O
RARE O
. O

To O
examine O
the O
possibility O
that O
ALL_CAP O
performance O
of O
the O
schizophrenic O
groups O
may O
have O
been O
related O
to O
neuroleptic O
medication O
, O
analyses O
were O
completed O
on O
the O
relationship O
between O
medication O
levels O
and O
ALL_CAP O
scores O
. O

ALL_CAP O
5 O
possibilities O
. O

The O
use O
of O
specific O
antibodies O
allowed O
the O
identification O
of O
RARE O
least O
RAR I-GENE
beta I-GENE
in O
some O
of O
the O
DNA O
- O
protein O
complexes O
, O
although O
the O
four O
sequences O
bind O
single O
RARE I-GENE
transfected O
in O
COS O
cells O
much O
less O
efficiently O
, O
or O
not O
RARE O
all O
, O
when O
compared O
to O
a O
canonical O
RAR I-GENE
responsive I-GENE
element I-GENE
. O

The O
present O
treatment O
strategy O
in O
progressive O
disorders O
is O
mainly O
based O
on O
the O
RARE O
effect O
of O
intensive O
RARE O
, O
autologous O
RARE O
- O
cell O
transplantation O
and O
the O
RARE O
use O
of O
RARE O
, O
mostly O
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
. O

Our O
study O
RARE O
consisted O
of O
NUM O
patients O
who O
received O
SC O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
RARE O
doses O
of O
4 O
. O
8 O
- O
14 O
. O
4 O
million O
IU O
/ O
m2 O
/ O
day O
on O
5 O
days O
per O
week O
RARE O
a O
RARE O
of O
8 O
weeks O
, O
20 O
patients O
who O
received O
ALL_CAP I-GENE
- I-GENE
alpha I-GENE
NUM I-GENE
RARE O
3 O
. O
NUM O
- O
6 O
. O
NUM O
million O
ALL_CAP O
/ O
m2 O
/ O
day O
RARE O
weekly O
RARE O
a O
RARE O
of O
6 O
weeks O
, O
and O
72 O
patients O
who O
were O
given O
SC O
ALL_CAP I-GENE
- I-GENE
alpha I-GENE
NUM I-GENE
RARE O
6 O
. O
NUM O
million O
ALL_CAP O
/ O
m2 O
/ O
day O
RARE O
weekly O
RARE O
SC O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
RARE O
14 O
. O
4 O
- O
18 O
. O
NUM O
million O
IU O
/ O
m2 O
/ O
day O
on O
days O
1 O
and O
2 O
, O
followed O
by O
4 O
. O
8 O
million O
IU O
/ O
m2 O
/ O
day O
, O
5 O
days O
per O
week O
RARE O
6 O
consecutive O
weeks O
. O

Analysis O
of O
a O
set O
of O
deletion O
constructs O
in O
transient O
transfection O
assays O
measuring O
heterologous O
reporter O
gene O
( O
luciferase I-GENE
) O
activity O
demonstrated O
that O
the O
182 O
- O
bp O
5 O
'- O
flanking O
region O
provides O
full O
promoter O
activity O
in O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
- O
RARE O
L2 O
cells O
. O

At O
the O
ALL_CAP O
( O
8 O
mg O
/ O
m2 O
/ O
day O
RARE O
the O
dose O
- O
limiting O
toxicity O
of O
this O
agent O
is O
RARE O
. O

RARE O
- O
RARE O
lymphocyte O
RARE O
was O
diminished O
. O

A O
RARE O
promoter O
sequence O
homologous O
to O
those O
found O
in O
humans O
and O
mice O
was O
RARE O
in O
the O
5 O
' O
RARE O
region O
of O
one O
RARE O
gene O
. O

Some O
of O
these O
RARE O
were O
reported O
to O
code O
RARE O
molecules O
involved O
in O
cell O
- O
cell O
interactions O
, O
whereas O
RARE O
relationship O
has O
yet O
been O
demonstrated O
between O
Hox I-GENE
genes I-GENE
and O
other O
transcription O
factors O
involved O
in O
RARE O
and O
/ O
or O
maintaining O
tissue O
RARE O
. O

Northern O
analysis O
of O
RNA O
samples O
isolated O
from O
RARE O
- O
grown O
cultures O
of O
the O
ALL_CAP I-GENE
mutant I-GENE
showed O
RARE O
amounts O
of O
ALL_CAP I-GENE
RARE I-GENE
and O
the O
absence O
of O
a O
1 O
. O
7 O
- O
kb O
transcript O
. O

NUM I-GENE
overexpressing O
cells O
showed O
a O
single O
prominent O
DNase I-GENE
I I-GENE
RARE O
site O
near O
a O
RARE O
and O
hitherto O
RARE O
ets I-GENE
response O
element O
( O
ALL_CAP O
RARE O
RARE O
38 O
bases O
down O
- O
RARE O
from O
the O
CAAT O
box O
and O
directly O
5 O
' O
of O
the O
TATA O
box O
in O
the O
human I-GENE
NUM I-GENE
promoter I-GENE
. O

Gel O
- O
shift O
assays O
with O
nuclear O
extracts O
and O
RARE O
sequences O
spanning O
the O
NUM O
. O
NUM O
- O
kb O
promoter O
region O
detected O
an O
ALL_CAP I-GENE
- O
RARE O
complex O
, O
present O
most O
abundantly O
in O
cells O
overexpressing O
NUM I-GENE
, O
whose O
high O
- O
affinity O
binding O
RARE O
on O
the O
ALL_CAP O
response O
element O
. O

Comparison O
of O
cDNA O
sequences O
revealed O
that O
the O
two O
mRNA O
species O
arise O
RARE O
a O
result O
of O
alternate O
use O
of O
RARE O
( O
A O
)- O
addition O
sites O
. O

The O
gene O
RARE O
the O
RNA I-GENE
- I-GENE
dependent I-GENE
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
protein I-GENE
kinase I-GENE
( O
PKR I-GENE
) O
was O
isolated O
from O
mouse O
genomic O
DNA O
and O
characterized O
. O

RARE O
- O
frequency O
electrical O
RARE O
in O
the O
hippocampus O
leads O
to O
an O
increase O
in O
synaptic O
efficacy O
that O
RARE O
RARE O
many O
hours O
. O

Similar O
to O
the O
mouse O
gene O
, O
the O
5 O
' O
flanking O
region O
of O
human I-GENE
NUM I-GENE
alpha I-GENE
lacks O
a O
TATA O
box O
; O
however O
, O
unlike O
mouse I-GENE
NUM I-GENE
alpha I-GENE
, O
a O
classical O
octamer O
motif O
could O
not O
be O
identified O
in O
the O
human O
gene O
. O

RARE O
RARE O
organization O
of O
the O
coding O
and O
upstream O
regulatory O
regions O
of O
the O
murine O
RARE I-GENE
- I-GENE
containing I-GENE
gene I-GENE
, O
RARE I-GENE
- I-GENE
1 I-GENE
, O
is O
reported O
. O

We O
report O
here O
the O
cloning O
of O
the O
human I-GENE
RARE I-GENE
gene I-GENE
( O
ALL_CAP I-GENE
) O
from O
a O
genomic O
library O
and O
the O
sequence O
of O
its O
encoded O
protein O
. O

In O
order O
to O
define O
RARE O
candidate O
genes O
RARE O
inherited O
disorders O
characterized O
by O
aberrant O
gene O
RARE O
, O
we O
utilized O
RARE I-GENE
- I-GENE
related I-GENE
sequences I-GENE
to O
isolate O
zinc O
finger O
- O
containing O
cDNAs O
. O

This O
virus O
is O
not O
RARE O
a O
RARE O
African O
RARE O
of O
RARE O
RARE O
RARE O
virus O
( O
ALL_CAP O
): O
the O
deduced O
CP I-GENE
sequence I-GENE
is O
only O
distantly O
related O
to O
RARE I-GENE
of O
other O
sequenced O
strains O
of O
ALL_CAP O
, O
although O
it O
is O
part O
of O
a O
distinct O
subgroup O
of O
RARE O
related O
to O
ALL_CAP O
. O

The O
ratio O
of O
the O
activity O
of O
RARE I-GENE
dehydrogenase I-GENE
to O
that O
of O
RARE I-GENE
dehydrogenase I-GENE
( O
RARE O
3 O
: O
1 O
) O
remained O
constant O
throughout O
purification O
, O
and O
the O
two O
activities O
were O
therefore O
RARE O
. O

The O
isolated O
NUM I-GENE
RARE O
hybridized O
to O
a O
1 O
. O
4 O
kb O
RNA O
species O
, O
which O
was O
RARE O
RARE O
NUM O
- O
RARE O
when O
RARE O
was O
the O
carbon O
source O
. O

The O
Y O
. O
RARE O
genomic O
NUM I-GENE
gene O
was O
disrupted O
by O
replacing O
120 O
bp O
of O
its O
coding O
sequence O
with O
2 O
. O
7 O
RARE O
of O
DNA O
including O
the O
Y O
. O
RARE O
LEU2 I-GENE
gene I-GENE
. O

A O
leucine O
zipper O
domain O
of O
the O
suppressor I-GENE
of I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
protein I-GENE
mediates O
its O
repressive O
effect O
on O
enhancer O
function O
. O

It O
is O
concluded O
that O
ALL_CAP O
should O
be O
RARE O
employed O
in O
patients O
with O
NUM O
- O
NUM O
neck O
RARE O
to O
determine O
the O
proper O
electron O
- O
energy O
RARE O
. O

The O
predicted O
DNA O
- O
binding O
, O
zinc I-GENE
finger I-GENE
domain I-GENE
protein I-GENE
sequence O
was O
strictly O
RARE O
. O

NUM O
patients O
were O
RARE O
into O
a O
randomised O
study O
comparing O
RARE O
( O
3 O
mg O
/ O
m2 O
/ O
week O
) O
RARE O
RARE I-GENE
- I-GENE
alpha I-GENE
NUM I-GENE
( O
6 O
ALL_CAP O
/ O
m2 O
3 O
times O
per O
week O
) O
to O
RARE O
alone O
or O
to O
RARE I-GENE
alone O
RARE O
the O
treatment O
of O
metastatic O
malignant O
RARE O
. O

The O
novel O
Notch I-GENE
homologue I-GENE
mouse I-GENE
Notch I-GENE
3 I-GENE
lacks O
specific O
RARE I-GENE
growth I-GENE
factor I-GENE
- I-GENE
repeats I-GENE
and O
is O
RARE O
in O
RARE O
RARE O
. O

BACKGROUND O
: O
We O
conducted O
a O
RARE O
I O
study O
with O
ALL_CAP O
NUM O
, O
NUM O
, O
a O
new O
5 I-GENE
RARE I-GENE
3 I-GENE
( I-GENE
5 I-GENE
- I-GENE
HT3 I-GENE
) I-GENE
receptor I-GENE
antagonist O
, O
in O
NUM O
patients O
requiring O
RARE O
chemotherapy O
. O

In O
the O
presence O
of O
the O
in O
vivo O
RARE O
RARE O
( O
RARE I-GENE
, O
RARE I-GENE
reductase I-GENE
, O
and O
ALL_CAP O
RARE O
however O
, O
each O
of O
these O
mutants O
catalyzed O
the O
formation O
of O
only O
NUM O
. O
6 O
- O
NUM O
. O
8 O
RARE O
per O
RARE O
of O
enzyme O
. O

These O
genetic O
alterations O
do O
not O
affect O
RARE O
of O
the O
major O
c I-GENE
- I-GENE
myc I-GENE
protein I-GENE
, O
NUM I-GENE
, O
which O
is O
RARE O
from O
the O
RARE O
AUG O
RARE O
in O
RARE O
2 O
. O

In O
addition O
, O
both O
the O
RARE O
1 O
- O
and O
RARE O
2 O
- O
RARE O
forms O
of O
the O
c I-GENE
- I-GENE
RARE I-GENE
protein I-GENE
RARE O
transcription O
of O
a O
RARE I-GENE
/ O
Max I-GENE
- O
responsive O
reporter O
construct O
to O
a O
similar O
level O
. O

Biological O
activities O
of O
hematopoietic I-GENE
growth I-GENE
factors I-GENE
that O
lead O
to O
future O
clinical O
application O
. O

Expression O
is O
exclusively O
limited O
to O
the O
CNS O
RARE O
this O
and O
later O
stages O
. O

RARE O
ALL_CAP I-GENE
content O
in O
transfected O
COS O
- O
1 O
cells O
was O
not O
influenced O
by O
exposure O
to O
8 O
- O
Br O
- O
cAMP O
. O

Disruption O
of O
any O
one O
of O
the O
four O
genes O
encoding O
the O
newly O
identified O
SRP I-GENE
proteins I-GENE
results O
in O
slow O
cell O
growth O
and O
inefficient O
protein O
translocation O
across O
the O
ER O
membrane O
. O

Genetic O
alterations O
in O
elements O
of O
normal O
signal O
RARE O
mechanisms O
are O
known O
to O
be O
RARE O
events O
often O
resulting O
in O
aberrant O
activation O
of O
programs O
of O
gene O
transcription O
. O

The O
RARE O
pattern O
of O
NUM I-GENE
, O
RARE O
demonstrated O
by O
in O
situ O
hybridization O
, O
indicated O
that O
the O
gene O
is O
RARE O
in O
RARE O
RARE O
cells O
and O
RARE O
stages O
associated O
with O
RARE O
development O
. O

NUM I-GENE
interacts O
with O
NUM I-GENE
and O
NUM I-GENE
in O
the O
two O
- O
RARE O
assay O
, O
and O
overexpression O
of O
NUM I-GENE
or O
NUM I-GENE
suppresses O
NUM I-GENE
and O
NUM I-GENE
mutations O
. O

Binding O
site O
selection O
using O
in O
vitro O
- O
synthesized O
proteins O
reveals O
that O
the O
ALL_CAP I-GENE
alpha I-GENE
1 I-GENE
and O
ALL_CAP I-GENE
alpha I-GENE
2 I-GENE
isoforms I-GENE
bind O
DNA O
RARE O
RARE O
to O
hormone O
response O
elements O
composed O
of O
a O
6 O
- O
bp O
AT O
- O
rich O
sequence O
preceding O
a O
RARE O
- O
site O
core O
motif O
ALL_CAP O
( O
ALL_CAP I-GENE
). O

The O
NUM I-GENE
/ O
NUM I-GENE
complex O
binds O
both O
in O
vitro O
and O
in O
vivo O
to O
ALL_CAP I-GENE
but O
not O
ALL_CAP I-GENE
or O
E2F I-GENE
sites I-GENE
. O

We O
show O
that O
the O
RARE I-GENE
RARE O
RARE O
RARE O
in O
RARE I-GENE
mutant O
RARE O
and O
that O
RARE I-GENE
activity O
is O
an O
absolute O
requirement O
RARE O
RARE O
of O
RARE I-GENE
RARE O
RARE O
the O
same O
time O
that O
RARE I-GENE
transcription O
is O
dependent O
on O
RARE I-GENE
. O

The O
DNA O
sequence O
adjacent O
to O
the O
lacZ I-GENE
gene I-GENE
has O
been O
determined O
RARE O
91 O
RARE O
fusion O
genes O
whose O
products O
have O
been O
localized O
and O
RARE O
NUM O
RARE O
RARE O
fusions O
. O

ALL_CAP O
RARE I-GENE
treatment O
( O
RARE O
, O
RARE O
) O
was O
started O
( O
2 O
ml O
/ O
kg O
RARE O
on O
day O
1 O
and O
3 O
, O
and O
1 O
ml O
/ O
kg O
on O
days O
5 O
, O
7 O
and O
9 O
RARE O
which O
led O
to O
the O
eradication O
of O
the O
residual O
RARE O
and O
ALL_CAP O
- O
DNA O
in O
the O
myocardium O
. O

RARE O
biliary O
drainage O
, O
unlike O
external O
drainage O
, O
does O
not O
suppress O
the O
regeneration O
of O
RARE O
rat O
liver O
after O
partial O
RARE O
. O

ORF O
2 O
potentially O
encoded O
a O
hydrophobic O
protein O
of O
29 O
, O
NUM O
RARE O
with O
RARE O
RARE O
membrane O
- O
spanning O
regions O
. O

In O
eight O
groups O
of O
subjects O
operating O
various O
RARE O
- O
held O
RARE O
tools O
and O
aged O
from O
NUM O
to O
NUM O
years O
, O
the O
prevalence O
rates O
of O
vibration O
- O
RARE O
RARE O
finger O
( O
ALL_CAP O
) O
and O
RARE O
, O
pain O
, O
or O
stiffness O
in O
the O
upper O
and O
lower O
RARE O
were O
investigated O
. O

DNA O
sequence O
analysis O
showed O
that O
the O
gene O
was O
NUM O
bp O
long O
and O
encoded O
a O
175 O
- O
amino O
- O
acid O
protein O
with O
a O
RARE O
RARE O
of O
19 O
, O
NUM O
containing O
a O
21 O
- O
RARE O
typical O
lipoprotein O
signal O
peptide O
and O
consensus O
RARE O
RARE O
site O
. O

DNA O
sequence O
and O
functions O
of O
the O
ALL_CAP I-GENE
region I-GENE
of O
the O
RARE O
biosynthetic O
gene O
cluster O
of O
RARE O
RARE O
NUM O
( O
2 O
). O

( O
1992 O
) O
RARE O
12 O
, O
58 O
- O
NUM O
). O

A O
comparison O
of O
the O
predicted O
polypeptide O
sequence O
of O
the O
Drosophila O
protein O
with O
the O
equivalent O
subunits O
from O
mouse O
and O
yeast O
suggests O
that O
they O
are O
closely O
related O
and O
defines O
three O
RARE O
regions O
which O
are O
likely O
to O
be O
important O
RARE O
enzyme O
activity O
. O

RARE O
were O
constructed O
with O
the O
mouse O
promoter O
region O
RARE O
to O
the O
reporter I-GENE
gene I-GENE
chloramphenicol I-GENE
RARE I-GENE
( O
CAT I-GENE
RARE O
and O
transiently O
and O
stably O
transfected O
in O
the O
ALL_CAP O
- O
1 O
cells O
. O

RARE I-GENE
dynein I-GENE
is O
a O
RARE O
, O
microtubule O
- O
dependent O
RARE O
enzyme O
that O
has O
been O
proposed O
to O
function O
in O
a O
variety O
of O
RARE O
movements O
, O
including O
minus O
- O
end O
- O
directed O
RARE O
of O
RARE O
. O

Identification O
of O
the O
plakoglobin I-GENE
- O
binding O
domain O
in O
RARE I-GENE
and O
its O
role O
in O
plaque O
assembly O
and O
RARE O
RARE O
anchorage O
. O

PATIENTS O
ALL_CAP O
METHODS O
: O
One O
hundred O
RARE O
- O
four O
chemotherapy O
- O
RARE O
patients O
receiving O
high O
- O
dose O
cisplatin O
( O
NUM O
to O
120 O
mg O
/ O
m2 O
) O
were O
randomized O
to O
receive O
one O
of O
four O
RARE O
doses O
( O
5 O
, O
10 O
, O
20 O
, O
or O
40 O
micrograms O
/ O
kg O
) O
administered O
before O
chemotherapy O
. O

RARE O
new O
RARE O
related O
compounds O
( O
I O
, O
IV O
, O
V O
, O
VII O
- O
ALL_CAP O
) O
together O
with O
four O
known O
compounds O
( O
II O
, O
III O
, O
ALL_CAP O
, O
ALL_CAP O
) O
were O
isolated O
from O
the O
root O
RARE O
of O
RARE O
RARE O
RARE O
. O

Specifically O
, O
this O
study O
determined O
the O
influence O
of O
: O
( O
1 O
) O
an O
RARE O
strategy O
, O
( O
2 O
) O
a O
non O
- O
RARE O
strategy O
, O
( O
3 O
) O
a O
Five O
- O
RARE O
RARE O
strategy O
and O
( O
4 O
) O
a O
control O
condition O
. O

RARE O
RARE O
interaction O
of O
the O
adenovirus I-GENE
NUM I-GENE
- I-GENE
6 I-GENE
/ I-GENE
7 I-GENE
protein I-GENE
and O
the O
RARE I-GENE
gene I-GENE
product I-GENE
with O
internal O
domains O
of O
E2F I-GENE
- I-GENE
1 I-GENE
and O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
. O

As O
shown O
previously O
, O
EBNA2 I-GENE
transactivates O
the O
promoters O
of O
the O
viral I-GENE
latent I-GENE
membrane I-GENE
proteins I-GENE
. O

We O
previously O
showed O
that O
v I-GENE
- I-GENE
Rel I-GENE
, O
the O
RARE O
of O
the O
avian O
RARE O
RARE O
- O
T O
, O
can O
increase O
RARE O
from O
promoters O
containing O
binding O
sites O
RARE O
the O
cellular O
transcription O
factor O
NUM I-GENE
in O
chicken O
RARE O
RARE O
( O
S O
. O

Previous O
studies O
have O
demonstrated O
that O
the O
TATA O
element O
is O
critical O
RARE O
basal O
and O
Tat I-GENE
- O
RARE O
HIV O
- O
1 O
gene O
RARE O
. O

A O
comparison O
of O
the O
nucleotide O
sequence O
of O
the O
p54 I-GENE
gene I-GENE
carried O
by O
two O
virulent O
ALL_CAP O
strains O
( O
NUM O
and O
NUM O
) O
with O
that O
obtained O
from O
virus O
NUM O
showed O
NUM O
% O
RARE O
. O

The O
p55 I-GENE
mRNA I-GENE
is O
undetectable O
in O
non O
- O
ALL_CAP O
- O
RARE O
B O
- O
and O
T O
- O
cell O
lines O
or O
in O
a O
RARE O
cell O
line O
( O
U937 O
). O

A O
simple O
RARE O
RARE O
an O
RARE O
RARE O
improvement O

The O
transverse O
RARE O
RARE O
mentioned O
above O
exhibited O
two O
RARE O
, O
a O
NUM O
fast O
( O
NUM O
) O
and O
a O
NUM O
slow O
( O
NUM O
) O
RARE O
. O

RESULTS O
: O
The O
diagnostic O
quality O
of O
FDG O
images O
was O
RARE O
least O
RARE O
good O
RARE O
that O
of O
their O
Tl O
- O
NUM O
counterparts O
, O
with O
less O
liver O
background O
in O
all O
but O
one O
FDG O
study O
. O

The O
RARE O
RARE O
of O
NUM I-GENE
and O
NUM I-GENE
RARE O
T O
- O
cell O
development O
is O
tightly O
coupled O
with O
the O
RARE O
state O
of O
the O
T O
cell O
. O

Expression O
of O
a O
dominant I-GENE
- I-GENE
negative I-GENE
ras I-GENE
gene I-GENE
also O
blocks O
NUM I-GENE
/ O
NUM I-GENE
induction O
by O
v I-GENE
- I-GENE
src I-GENE
. O

The O
RARE O
ALL_CAP I-GENE
- O
transfected O
cells O
exhibit O
both O
cytoplasmic O
and O
nuclear O
changes O
characteristic O
of O
cells O
undergoing O
apoptosis O
. O

Using O
an O
RNase I-GENE
H I-GENE
- O
RARE O
mapping O
technique O
, O
we O
show O
that O
the O
NUM O
- O
kDa O
subunit O
of O
ALL_CAP I-GENE
can O
be O
RARE O
cross O
- O
RARE O
to O
pre O
- O
mRNAs O
RARE O
ALL_CAP O
- O
rich O
regions O
RARE O
RARE O
of O
the O
RARE O
site O
of O
the O
simian O
virus O
40 O
RARE O
and O
adenovirus I-GENE
NUM I-GENE
pre I-GENE
- I-GENE
mRNAs I-GENE
. O

The O
protein O
encoded O
is O
NUM O
kDa O
and O
contains O
eight O
zinc O
finger O
motifs O
, O
RARE O
of O
which O
are O
present O
in O
two O
clusters O
RARE O
opposite O
ends O
of O
the O
molecule O
. O

RARE O
- O
specific O
RARE O
of O
the O
RARE I-GENE
- I-GENE
binding I-GENE
inhibitor I-GENE
in O
Drosophila O
melanogaster O
: O
cloning O
, O
RARE O
, O
and O
RARE O
of O
the O
gene O
. O

Using O
a O
v I-GENE
- I-GENE
erbA I-GENE
probe O
, O
we O
obtained O
a O
cDNA O
which O
encodes O
a O
novel O
NUM O
- O
amino O
- O
acid O
protein O
, O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
that O
contains O
the O
characteristic O
domains O
of O
nuclear O
receptors O
. O

Only O
two O
of O
the O
isoforms O
possess O
the O
N O
- O
terminal O
zinc O
finger O
domain O
that O
is O
necessary O
and O
sufficient O
RARE O
ALL_CAP I-GENE
promoter I-GENE
binding O
. O

This O
study O
provides O
direct O
evidence O
that O
USF I-GENE
, O
a O
RARE O
of O
the O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
leucine I-GENE
zipper I-GENE
family I-GENE
, O
binds O
to O
NUM I-GENE
, O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
and O
ALL_CAP I-GENE
B I-GENE
sites I-GENE
and O
suggests O
that O
it O
is O
a O
RARE O
of O
protein O
complexes O
that O
may O
RARE O
control O
the O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
and O
alpha I-GENE
- I-GENE
myosin I-GENE
heavy I-GENE
- I-GENE
chain I-GENE
genes I-GENE
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
RARE I-GENE
activation O
of O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
/ O
Rel I-GENE
involves O
RARE O
and O
RARE O
of O
I I-GENE
RARE I-GENE
B I-GENE
alpha I-GENE
and O
ALL_CAP O
( O
NUM O
)- O
RARE O
induction O
of O
the O
c I-GENE
- I-GENE
RARE I-GENE
gene I-GENE
. O

Activation O
of O
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
RARE O
by O
a O
kinase O
- O
RARE O
RARE I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
. O

Because O
endogenous O
HSF I-GENE
DNA O
- O
binding O
activity O
is O
low O
and O
anti I-GENE
- I-GENE
NUM I-GENE
antibody I-GENE
does O
not O
recognize O
Xenopus I-GENE
HSF I-GENE
, O
we O
employed O
this O
RARE O
RARE O
mapping O
regions O
in O
NUM I-GENE
that O
are O
required O
RARE O
the O
RARE O
of O
the O
RARE O
state O
. O

RARE O
containing O
disrupted O
Ets I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sites I-GENE
were O
tested O
in O
transient O
RARE O
assays O
in O
the O
murine O
T O
- O
cell O
line O
NUM O
. O
E1 O
; O
alterations O
in O
the O
RARE O
element O
affected O
RARE O
enhancer O
activity O
, O
while O
mutation O
of O
either O
the O
RARE O
or O
RARE O
element O
disrupted O
phorbol O
ester O
- O
RARE O
enhancer O
activity O
. O

The O
predominant O
binding O
activity O
was O
not O
Ets I-GENE
- I-GENE
1 I-GENE
but O
rather O
two O
independent O
DNA O
- O
protein O
complexes O
that O
RARE O
in O
mobility O
shift O
assays O
. O

These O
ALL_CAP I-GENE
subtypes O
represent O
members O
of O
a O
new O
family O
of O
orphan I-GENE
nuclear I-GENE
receptors I-GENE
that O
most O
likely O
regulate O
specific O
gene O
RARE O
. O

Interestingly O
, O
these O
response O
elements O
display O
dramatically O
RARE O
affinity O
RARE O
retinoic I-GENE
acid I-GENE
receptor I-GENE
- O
retinoid I-GENE
- I-GENE
X I-GENE
receptor I-GENE
RARE O
. O

Treatment O
with O
amphotericin O
B O
and O
RARE O
led O
to O
improvement O
of O
the O
symptoms O
but O
did O
not O
RARE O
the O
micro O
- O
organisms O
from O
the O
RARE O
RARE O
( O
CSF O
). O

The O
RARE O
presence O
of O
the O
tRNA I-GENE
( I-GENE
RARE I-GENE
)( I-GENE
ALL_CAP I-GENE
)- I-GENE
gene I-GENE
transcript I-GENE
in I-GENE
RARE I-GENE
is O
also O
reported O
. O

The O
parameters O
of O
nonspecific O
RARE O
RARE O
RARE O
serum I-GENE
immunoglobulins I-GENE
and O
immune O
complexes O
RARE O
were O
evaluated O
in O
irradiated O
group O
of O
patients O
with O
RARE O
cervix O
carcinoma O
( O
RARE O
ALL_CAP O
and O
ALL_CAP O
RARE O
RARE O
one O
year O
follow O
RARE O
. O

Mutation O
of O
ALL_CAP O
to O
ALL_CAP O
retains O
NUM I-GENE
in O
the O
cytoplasmic O
compartment O
, O
RARE O
the O
wild O
- O
type O
protein O
is O
detected O
exclusively O
in O
the O
nucleus O
. O

To O
confirm O
the O
binding O
of O
protein O
to O
these O
sites O
in O
cells O
, O
we O
carried O
out O
an O
in O
vivo O
genomic O
footprinting O
analysis O
of O
this O
portion O
of O
the O
TGF I-GENE
alpha I-GENE
promoter I-GENE
in O
normal O
and O
transformed O
rat O
liver O
RARE O
cell O
lines O
that O
express O
the O
endogenous O
gene O
RARE O
varying O
levels O
. O

RARE O
, O
this O
RARE O
is O
also O
present O
in O
the O
otherwise O
unrelated O
N O
- O
terminal O
activating O
region O
of O
NUM I-GENE
- I-GENE
ets I-GENE
- I-GENE
2 I-GENE
and O
was O
thus O
named O
ALL_CAP I-GENE
RARE O
Ets I-GENE
- I-GENE
1 I-GENE
- I-GENE
beta I-GENE
/ O
Ets I-GENE
- I-GENE
2 I-GENE
- I-GENE
RARE I-GENE
sequence I-GENE
. O

This O
work O
RARE O
a O
new O
model O
RARE O
the O
ets I-GENE
- I-GENE
1 I-GENE
/ O
ets I-GENE
- I-GENE
2 I-GENE
gene I-GENE
' O
s O
evolution O
, O
based O
RARE O
the O
RARE O
time O
on O
both O
structural O
and O
RARE O
RARE O
. O

The O
v I-GENE
- I-GENE
ets I-GENE
oncogene I-GENE
of O
the O
avian O
RARE O
NUM O
differs O
from O
its O
cellular O
RARE O
NUM I-GENE
- I-GENE
ets I-GENE
- I-GENE
1 I-GENE
by O
two O
amino O
acid O
substitutions O
( O
alanine O
285 O
and O
RARE O
NUM O
in O
c I-GENE
- I-GENE
ets I-GENE
- I-GENE
1 I-GENE
both O
substituted O
by O
RARE O
in O
v I-GENE
- I-GENE
ets I-GENE
, O
mutations O
A O
and O
B O
respectively O
) O
and O
its O
RARE O
- O
terminal O
end O
( O
mutation O
C O
). O

RARE O
RARE O
mRNAs O
can O
be O
produced O
by O
endogenous I-GENE
RNA I-GENE
polymerase I-GENE
I O
. O

The O
individual O
subunits O
of O
RARE I-GENE
have O
been O
difficult O
to O
isolate O
from O
human O
cells O
without O
RARE O
and O
attempts O
to O
produce O
RARE I-GENE
recombinant I-GENE
RARE I-GENE
have O
been O
largely O
RARE O
. O

Using O
this O
method O
, O
we O
were O
able O
to O
select O
strong O
enhancer O
- O
type O
activation O
domains O
from O
the O
immediate I-GENE
early I-GENE
regions I-GENE
of O
two O
RARE O
, O
namely O
pseudorabies O
virus O
and O
bovine O
RARE O
1 O
. O

RARE O
, O
NUM I-GENE
contains O
a O
long O
stretch O
( O
NUM O
nt O
.) O
of O
RARE O
to O
a O
highly O
RARE O
sequence O
in O
28S I-GENE
rRNA I-GENE
. O

A O
genetic O
RARE O
was O
RARE O
to O
select O
RARE O
RARE I-GENE
protein I-GENE
mutants I-GENE
which O
RARE O
between O
IR O
and O
ALL_CAP O
( O
York O
et O
al O
., O
RARE O
( O
RARE O
.) O
NUM O
, O
7 O
- O
12 O
, O
1992 O
; O
York O
and O
RARE O
, O
ALL_CAP O
. O

RARE O
statistical O
analysis O
based O
on O
RARE O
- O
RARE O
- O
estimates O
and O
RARE O
- O
RARE O
- O
Test O
showed O
the O
following O
RARE O
beneficial O
factors O
: O
RARE O
RARE O
RARE O
( O
p O
= O
NUM O
. O
NUM O
RARE O
ALL_CAP I-GENE
serum O
level O
less O
than O
NUM O
micrograms O
/ O
RARE O
( O
p O
= O
NUM O
. O
NUM O
RARE O
serum O
RARE I-GENE
phosphatase I-GENE
less O
than O
NUM O
ALL_CAP O
/ O
RARE O
( O
p O
= O
NUM O
. O
NUM O
RARE O
normal O
serum O
albumin I-GENE
( O
p O
= O
NUM O
. O
NUM O
) O
and O
activity O
index O
of O
minimum O
of O
70 O
( O
p O
< O
NUM O
. O
001 O
). O

These O
results O
provide O
evidence O
of O
a O
bypass O
of O
p53 I-GENE
- O
RARE O
NUM I-GENE
/ O
Cip1 I-GENE
- O
RARE O
cell O
RARE O
regulatory O
pathways O
by O
a O
RARE O
of O
the O
myb I-GENE
oncogene I-GENE
family I-GENE
. O

RARE I-GENE
strongly O
RARE O
levels O
of O
GTP O
- O
RARE O
Ras I-GENE
, O
activated O
and O
RARE O
Raf I-GENE
, O
and O
tyrosine O
- O
RARE O
and O
activated O
MAP I-GENE
kinase I-GENE
. O

Role O
of O
c I-GENE
- I-GENE
myc I-GENE
in O
simian I-GENE
virus I-GENE
40 I-GENE
large I-GENE
tumor I-GENE
antigen I-GENE
- O
RARE O
DNA O
RARE O
in O
RARE O
3T3 O
- O
L1 O
mouse O
RARE O
. O

All O
groups O
were O
RARE O
subsequently O
with O
naloxone O
( O
NUM O
. O
4 O
mg O
/ O
kg O
) O
in O
the O
distinctive O
environment O
and O
then O
observed O
RARE O
signs O
of O
RARE O
withdrawal O
. O

RARE O
therapy O
of O
RARE O
carcinoma O

A O
NUM O
. O
1 O
kb O
fragment O
of O
the O
yeast O
genome O
was O
allocated O
to O
the O
RARE O
region O
of O
RARE O
ALL_CAP O
by O
genetic O
mapping O
. O

A O
third O
one O
is O
homologous O
in O
RARE O
of O
its O
length O
to O
the O
RARE I-GENE
RARE I-GENE
ALL_CAP I-GENE
and O
in O
the O
other O
RARE O
to O
RARE I-GENE
ALL_CAP I-GENE
. O

It O
was O
shown O
that O
estradiol O
concentrations O
obtained O
after O
estradiol O
RARE O
and O
RARE O
estradiol O
ingestion O
were O
dependent O
on O
the O
patient O
' O
s O
age O
RARE O
RARE O
RARE O
on O
the O
RARE O
type O
. O

There O
were O
9 O
patients O
in O
ALL_CAP O
class O
III O
and O
8 O
in O
class O
IV O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

RARE O
is O
not O
a O
risk O
factor O
RARE O
RARE O
: O
a O
case O
- O
control O
study O
of O
RARE O
RARE O
agents O
. O

Of O
NUM O
persons O
RARE O
, O
NUM O
( O
NUM O
. O
4 O
%) O
were O
antigen O
- O
positive O
with O
the O
NUM I-GENE
assay O
. O

TG O
- O
day O
and O
TG O
- O
night O
were O
19 O
. O
4 O
+/- O
6 O
. O
1 O
%, O
NUM O
. O
6 O
+/- O
5 O
. O
3 O
%, O
( O
750 O
NUM O
< O
T O
. O

RARE O
RARE O
NUM O
in O
RARE O
. O

Ten O
volunteers O
were O
tested O
RARE O
18 O
, O
NUM O
RARE O
( O
5 O
, O
NUM O
m O
RARE O
and O
through O
12 O
, O
NUM O
, O
8 O
, O
NUM O
, O
and O
5 O
, O
NUM O
RARE O
( O
3 O
, O
NUM O
, O
2 O
, O
NUM O
, O
and O
1 O
, O
NUM O
m O
) O
with O
RARE O
RARE O
recorded O
via O
a O
RARE O
head O
RARE O
and O
presented O
RARE O
. O

Upon O
differentiation O
with O
retinoic O
acid O
( O
ALL_CAP O
RARE O
transcription O
of O
the O
RARE I-GENE
- I-GENE
1 I-GENE
gene I-GENE
decreases O
rapidly O
. O

Sequence O
analysis O
of O
the O
RARE I-GENE
NUM I-GENE
coding I-GENE
region I-GENE
revealed O
a O
high O
level O
of O
homology O
to O
the O
mouse O
, O
rat O
, O
and O
human I-GENE
NUM I-GENE
genes I-GENE
with O
the O
RARE O
exception O
of O
a O
polymorphic O
, O
triplet O
nucleotide O
repeat O
sequence O
in O
the O
region O
coding O
RARE O
the O
amino O
terminus O
of O
the O
NUM I-GENE
protein I-GENE
. O

The O
fibrinogen I-GENE
, O
serum O
proteins O
, O
RARE O
RARE O
and O
membrane O
contributed O
to O
RARE O
by O
20 O
%, O
14 O
%, O
2 O
% O
and O
NUM O
%, O
respectively O
. O

In O
these O
vectors O
the O
chimeric I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
( O
ALL_CAP I-GENE
) O
RARE O
the O
RARE O
of O
the O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
( O
CAT I-GENE
) O
reporter O
gene O
that O
is O
followed O
by O
an O
internal O
SV40 I-GENE
virus I-GENE
early I-GENE
region I-GENE
promoter I-GENE
RARE O
to O
the O
RARE I-GENE
RARE I-GENE
II I-GENE
( O
ALL_CAP I-GENE
) O
gene O
. O

RARE O
) O
genomic O
library O
by O
RARE O
with O
RARE O
- O
RARE O
RARE I-GENE
synthase I-GENE
cDNA I-GENE
RARE O
a O
probe O
. O

A O
RARE O
of O
NUM O
acute O
leukemia O
adult O
patients O
were O
RARE O
with O
bone O
marrow O
( O
ALL_CAP O
) O
RARE O
by O
RARE O
( O
ALL_CAP O
Z O
) O
RARE O
the O
period O
of O
January O
1983 O
to O
January O
1993 O
. O

The O
RARE O
regimen O
consisted O
of O
cyclophosphamide O
( O
120 O
mg O
/ O
kg O
) O
and O
RARE O
body O
irradiation O
. O

The O
site O
- O
directed O
mutation O
of O
the O
RARE I-GENE
B I-GENE
motif I-GENE
in O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
/ O
CAT I-GENE
RARE O
resulted O
in O
the O
RARE O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
promoter I-GENE
activity O
in O
these O
cells O
. O

RARE O
, O
RARE O
was O
earlier O
and O
more O
widely O
used O
than O
RARE O
in O
RARE O
advanced O
breast O
carcinoma O
. O

Use O
of O
the O
RARE O
RARE O
to O
extend O
the O
right O
RARE O
RARE O
RARE O
RARE O
transplantation O
is O
RARE O
. O

RARE O
RARE O
RARE O
RARE O
flow O
RARE O
by O
RARE O
E1 O
following O
liver O
transplantation O
in O
pigs O
. O

One O
gene O
appears O
ubiquitously O
RARE O
while O
the O
other O
is O
RARE O
RARE O
in O
muscle O
. O

For O
HeLa O
, O
293 O
, O
U937 O
, O
and O
NUM O
cells O
, O
participation O
of O
E2F I-GENE
- I-GENE
1 I-GENE
, O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
RARE I-GENE
A I-GENE
, O
and O
ALL_CAP I-GENE
was O
involved O
in O
formation O
of O
some O
complexes O
only O
, O
RARE O
participation O
of O
factors O
different O
from O
E2F I-GENE
- I-GENE
1 I-GENE
or O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
in O
others O
. O

E1A I-GENE
RARE O
RARE O
by O
these O
sites O
was O
about O
twofold O
compared O
with O
a O
RARE O
activation O
described O
RARE O
the O
RARE O
E1A I-GENE
promoter I-GENE
. O

RARE O
invasion O
in O
irradiated O
RARE O
organism O
increases O
the O
negative O
effect O
of O
RARE O
radiation O
on O
the O
hamster O
immune O
RARE O
. O

During O
heat O
exposure O
, O
chicks O
that O
had O
been O
subjected O
to O
early O
NUM O
% O
RARE O
with O
non O
- O
RARE O
- O
treated O
food O
had O
lower O
H O
/ O
L O
ratios O
and O
improved O
resistance O
to O
RARE O
RARE O
RARE O
infection O
. O

RARE O
of O
additional O
tumors O
RARE O
in O
mice O
from O
two O
reciprocal O
RARE O
, O
A O
/ O
ALL_CAP O
RARE O
C3H O
/ O
ALL_CAP O
NUM O
( O
RARE O
called O
NUM O
) O
and O
C3H O
/ O
ALL_CAP O
RARE O
A O
/ O
ALL_CAP O
NUM O
( O
RARE O
called O
NUM O
RARE O
provided O
evidence O
RARE O
the O
inactivation O
of O
one O
allele O
of O
the O
putative O
RARE O
4 O
tumor O
suppressor O
gene O
by O
parental O
imprinting O
. O

NUM I-GENE
is O
involved O
in O
the O
cell O
- O
division O
RARE O
and O
the O
RARE O
of O
mitochondrial O
genomes O
in O
Saccharomyces O
cerevisiae O
. O

RARE O
diameters O
of O
greater O
than O
20 O
mm O
and O
the O
large O
RARE O
- O
type O
RARE O
were O
factors O
that O
were O
associated O
with O
incomplete O
removal O
. O

RARE O
collected O
, O
processed O
and O
stored O
breast O
RARE O
tissue O
blocks O
recovered O
from O
the O
RARE O
of O
the O
RARE O
laboratory O
in O
RARE O
RARE O
RARE O
after O
RARE O
of O
RARE O
to O
3 O
years O
were O
analysed O
by O
a O
flow O
RARE O
RARE O
DNA O
RARE O
and O
S O
- O
RARE O
fraction O
. O

NUM I-GENE
contains O
three O
proteins O
, O
NUM I-GENE
, O
NUM I-GENE
and O
NUM I-GENE
. O

Such O
an O
interaction O
could O
be O
detected O
using O
a O
GST I-GENE
- O
POU I-GENE
fusion O
protein O
RARE O
to O
RARE O
- O
agarose O
RARE O
. O

These O
mutations O
are O
localized O
in O
the O
same O
region O
where O
the O
HSV I-GENE
RARE I-GENE
VP16 I-GENE
binds O
, O
but O
did O
not O
RARE O
with O
the O
VP16 I-GENE
contacts O
. O

In O
RARE O
, O
the O
filtration O
rate O
in O
relevant O
areas O
appears O
to O
be O
an O
RARE O
and O
easily O
determined O
parameter O
, O
reflecting O
hormonal O
and O
RARE O
vascular O
RARE O
RARE O
RARE O
local O
interstitial O
control O
of O
the O
RARE O
RARE O
. O

RARE O
, O
these O
residues O
are O
RARE O
in O
different O
domains O
. O

However O
, O
RARE O
inhibited O
RARE O
of O
RARE O
/ O
NUM O
- O
NUM O
but O
not O
of O
ALL_CAP O
cells O
despite O
inhibition O
of O
p70 I-GENE
S6 I-GENE
kinase I-GENE
activity O
in O
both O
cells O
. O

RARE O
injection O
of O
( O
NUM O
, O
1 O
' O
R O
, O
2 O
' O
R O
, O
3 O
' O
R O
)- O
2 O
RARE O
2 O
, O
3 O
- O
RARE O
) O
glycine O
( O
ALL_CAP O
- O
IV O
RARE O
a O
potent O
agonist O
RARE O
RARE O
RARE I-GENE
receptors I-GENE
, O
to O
rats O
retarded O
dose O
- O
dependently O
the O
recovery O
from O
halothane O
anesthesia O
RARE O
a O
dose O
range O
from O
NUM O
to O
NUM O
RARE O
/ O
rat O
. O

The O
RARE I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
3 I-GENE
( O
HNF I-GENE
- I-GENE
3 I-GENE
RARE O
RARE I-GENE
( O
RARE I-GENE
) O
proteins O
consist O
of O
an O
extensive O
family O
of O
tissue O
- O
specific O
and O
developmental O
gene O
RARE O
which O
share O
homology O
within O
the O
RARE O
helix O
DNA O
binding O
motif O
. O

Homozygous O
RARE O
RARE O
also O
displayed O
abnormalities O
in O
RARE O
development O
, O
consistent O
with O
the O
conclusion O
that O
RARE I-GENE
is O
necessary O
RARE O
RARE O
/ O
RARE O
interactions O
RARE O
development O
. O

Interestingly O
, O
ALL_CAP I-GENE
- I-GENE
L I-GENE
/ I-GENE
S I-GENE
is O
also O
able O
to O
significantly O
enhance O
transcriptional O
activation O
by O
upstream O
transcription O
factors O
including O
NUM I-GENE
, O
VP16 I-GENE
, O
and O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
. O

A O
strong O
RARE I-GENE
binding I-GENE
site I-GENE
was O
found O
RARE O
the O
RARE O
location O
of O
the O
fork I-GENE
head I-GENE
gene I-GENE
, O
a O
region O
- O
specific O
homeotic I-GENE
gene I-GENE
not O
RARE O
within O
a O
homeotic I-GENE
complex I-GENE
. O

In O
particular O
, O
changes O
in O
RARE O
NUM O
+ O
have O
the O
RARE O
to O
either O
inhibit O
or O
RARE O
the O
ability O
of O
cAMP O
to O
stimulate O
transcription O
, O
depending O
on O
the O
presence O
of O
specific O
forms O
of O
NUM I-GENE
RARE I-GENE
calmodulin I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinases I-GENE
. O

Antibodies O
directed O
against O
the O
NUM I-GENE
protein I-GENE
immunoprecipitated O
RNase I-GENE
MRP I-GENE
RNA I-GENE
from O
whole O
- O
cell O
extracts O
without O
precipitating O
the O
structurally O
and O
functionally O
related O
RNase I-GENE
P I-GENE
RNA I-GENE
. O

C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
also O
activates O
the O
promoter O
of O
the O
rat I-GENE
class I-GENE
- I-GENE
I I-GENE
ADH I-GENE
gene I-GENE
in O
a O
sequence O
- O
specific O
manner O
RARE O
RARE O
et O
al O
., O
RARE O
. O

C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
also O
activates O
the O
promoter O
of O
the O
rat I-GENE
class I-GENE
- I-GENE
I I-GENE
ADH I-GENE
gene I-GENE
in O
a O
sequence O
- O
specific O
manner O
RARE O
RARE O
et O
al O
., O
RARE O
. O

Our O
results O
show O
that O
the O
ORF O
of O
ALL_CAP I-GENE
encodes O
NUM O
amino O
RARE O
( O
RARE O
) O
( O
NUM O
. O
NUM O
kDa O
) O
and O
is O
highly O
RARE O
with O
ALL_CAP I-GENE
with O
identities O
of O
97 O
. O
3 O
and O
NUM O
% O
RARE O
the O
RARE O
and O
nt O
levels O
, O
respectively O
. O

In O
human O
brain O
, O
RARE I-GENE
was O
RARE O
identified O
by O
amino O
terminal O
and O
peptide O
sequencing O
of O
the O
RARE I-GENE
- I-GENE
RARE I-GENE
- I-GENE
binding I-GENE
glycoprotein I-GENE
NUM I-GENE
. O

The O
RARE O
YAC O
contig O
, O
which O
consists O
of O
NUM O
overlapping O
YACs O
and O
RARE O
19 O
sequence O
- O
RARE O
sites O
( O
RARE O
RARE O
RARE O
a O
minimum O
of O
2 O
. O
2 O
Mb O
and O
spans O
the O
RARE O
sarcoma O
RARE O
. O
c I-GENE
- I-GENE
ets I-GENE
1 I-GENE
and O
RARE I-GENE
- I-GENE
1 I-GENE
, O
two O
members O
of O
the O
ets I-GENE
family I-GENE
, O
have O
been O
RARE O
within O
NUM O
kb O
of O
intervening O
DNA O
within O
this O
contig O
, O
which O
also O
comprises O
a O
polymorphic O
RARE O
, O
NUM I-GENE
( O
CA O
) O
RARE O
, O
which O
we O
have O
localized O
within O
the O
RARE I-GENE
- I-GENE
1 I-GENE
gene I-GENE
. O

A O
cDNA O
RARE O
a O
newly O
discovered O
RARE O
, O
closely O
related O
to O
the O
mouse I-GENE
RARE I-GENE
cell I-GENE
RARE I-GENE
was O
isolated O
by O
polymerase O
chain O
reaction O
amplification O
from O
a O
mouse O
RARE O
tissue O
- O
like O
RARE O
cell O
line O
. O

NUM I-GENE
consists O
of O
ten O
exons O
and O
nine O
intervening O
RARE O
spanning O
RARE O
least O
NUM O
kilobases O
( O
kb O
) O
of O
DNA O
. O

RARE O
were O
RARE O
every O
four O
weeks O
. O

RARE O
RARE O
RARE O
the O
implications O
of O
the O
RARE O
. O

Other O
adverse O
events O
with O
RARE O
significantly O
RARE O
than O
with O
placebo O
were O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
, O
and O
abnormal O
RARE O
. O

RARE O
was O
also O
detected O
between O
the O
putative O
transit O
peptide O
sequence O
of O
cysteine I-GENE
synthase I-GENE
C I-GENE
and O
other O
RARE O
- O
targeting O
RARE O
sequences O
. O

Furthermore O
, O
our O
data O
also O
show O
that O
, O
in O
addition O
to O
TEF I-GENE
- I-GENE
1 I-GENE
, O
another O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
- I-GENE
related I-GENE
factor I-GENE
may O
be O
RARE O
by O
the O
alpha I-GENE
- I-GENE
MHC I-GENE
gene I-GENE
EM O
element O
. O

RARE I-GENE
RARE I-GENE
RARE I-GENE
. O

Recombinant I-GENE
I I-GENE
- I-GENE
RARE I-GENE
B I-GENE
alpha I-GENE
inhibited O
RARE I-GENE
B I-GENE
motif I-GENE
binding O
by O
nuclear I-GENE
factor I-GENE
- I-GENE
RARE I-GENE
NUM I-GENE
, O
ALL_CAP I-GENE
, O
and O
c I-GENE
- I-GENE
Rel I-GENE
RARE O
indicated O
by O
studies O
using O
ALL_CAP O
radiation O
- O
RARE O
RARE O
cross O
- O
linking O
to O
a O
RARE O
- O
substituted O
RARE I-GENE
B I-GENE
RARE I-GENE
. O

The O
physical O
and O
chemical O
stability O
of O
a O
combination O
of O
drugs O
commonly O
administered O
into O
the O
RARE O
or O
RARE O
space O
RARE O
the O
treatment O
of O
chronic O
pain O
was O
investigated O
. O

Therefore O
, O
mechanisms O
that O
control O
activation O
of O
the O
MAP I-GENE
kinase I-GENE
cascade O
temporally O
and O
spatially O
may O
be O
important O
RARE O
RARE O
of O
cellular O
responses O
. O

A O
candidate O
gene O
RARE O
RARE I-GENE
, O
designated O
RARE I-GENE
resistance I-GENE
- I-GENE
associated I-GENE
macrophage I-GENE
protein I-GENE
( O
RARE I-GENE
RARE O
has O
been O
isolated O
and O
shown O
to O
encode O
a O
novel O
macrophage O
- O
specific O
membrane O
protein O
, O
which O
is O
altered O
in O
susceptible O
animals O
. O

This O
motif O
is O
similar O
to O
but O
distinct O
from O
the O
LIM I-GENE
domain I-GENE
and O
the O
ALL_CAP I-GENE
finger I-GENE
family I-GENE
, O
and O
is O
RARE O
of O
known O
metal O
- O
binding O
regions O
. O

The O
NUM O
ORF O
is O
followed O
in O
- O
frame O
by O
a O
second O
ORF O
which O
is O
probably O
RARE O
by O
partial O
readthrough O
of O
the O
UGA O
RARE O
RARE O
of O
the O
NUM O
ORF O
to O
produce O
a O
polypeptide O
of O
M O
( O
RARE O
) O
NUM O
( O
NUM O
). O

One O
hundred O
RARE O
patients O
were O
reviewed O
RARE O
1 O
year O
after O
RARE O
. O

RARE O
visual O
RARE O
in O
RARE O
and O
epilepsy O
. O

The O
influence O
of O
patient O
- O
related O
factors O
on O
RARE O
- O
RARE O
variability O
in O
the O
evaluation O
of O
neurological O
signs O
was O
investigated O
. O

RARE O
with O
more O
RARE O
ALL_CAP O
uptake O
than O
ALL_CAP O
uptake O
( O
RARE O
) O
showed O
either O
normal O
RARE O
motion O
or O
demonstrated O
inotropic O
reserve O
RARE O
RARE O
RARE O
. O

The O
defined O
length O
of O
the O
mRNA O
, O
1 O
, O
NUM O
nucleotides O
, O
was O
in O
agreement O
with O
that O
of O
a O
1 O
. O
9 O
- O
kb O
RNA O
RARE O
throughout O
the O
replication O
RARE O
, O
starting O
RARE O
the O
early O
stages O
of O
infection O
. O

RARE O
. O

Transient O
transfections O
of O
a O
construct O
expressing O
the O
RNA O
transcript O
defined O
by O
clone O
NUM O
. O
1 O
into O
NUM O
cells O
led O
to O
the O
RARE O
of O
an O
Env I-GENE
/ O
RARE I-GENE
- I-GENE
4 I-GENE
fusion O
protein O
with O
an O
apparent O
RARE O
mass O
of O
NUM O
kDa O
. O

RARE O
, O
ALL_CAP O
. O

RARE O
RARE O
RARE O
RARE O
RARE O
or O
RARE O
failure O
secondary O
to O
acute O
RARE O
infarction O
or O
RARE O
' O
RARE O
were O
excluded O
. O

The O
present O
data O
also O
indicate O
that O
patients O
with O
ALL_CAP O
nephropathy O
often O
have O
concomitant O
IgA I-GENE
nephropathy O
and O
RARE O
proliferative O
glomerulonephritis O
. O

All O
nuclear O
receptors O
have O
several O
RARE O
- O
characterized O
structural O
domains O
, O
including O
a O
RARE O
DNA O
- O
binding O
domain O
, O
and O
a O
RARE O
binding O
domain O
RARE O
the O
RARE O
terminus O
of O
the O
receptor O
. O

The O
sample O
includes O
all O
the O
HIV O
- O
RARE O
- O
patients O
continuously O
referred O
to O
the O
RARE O
RARE O
of O
the O
RARE O
RARE O
RARE O
. O
of O
RARE O
' O
s O
" O
RARE O
RARE O
" O
RARE O
RARE O
RARE O
some O
five O
days O
( O
19 O
- O
NUM O
, O
RARE O
1993 O
). O

Using O
in O
RARE O
footprint O
analysis O
, O
we O
demonstrate O
that O
within O
human O
RARE O
RARE O
there O
is O
a O
high O
level O
of O
protein O
- O
DNA O
binding O
RARE O
RARE O
RARE O
intervals O
throughout O
a O
500 O
- O
bp O
region O
RARE O
the O
D O
- O
loop O
DNA O
origins O
and O
two O
promoter O
regions O
. O

The O
NUM I-GENE
protein I-GENE
can O
act O
RARE O
a O
potent O
transcription O
activator O
and O
may O
function O
to O
regulate O
the O
RARE O
of O
RARE O
genes O
in O
response O
to O
extracellular O
stimuli O
. O

One O
class O
of O
plasmids O
contained O
tRNA I-GENE
( I-GENE
RARE I-GENE
) I-GENE
genes I-GENE
and O
conferred O
efficient O
suppression O
only O
when O
cells O
were O
RARE O
RARE O
RARE O
; O
these O
plasmids O
suppressed O
a O
NUM I-GENE
deletion O
much O
less O
efficiently O
than O
they O
suppressed O
NUM I-GENE
- I-GENE
NUM I-GENE
. O

Thus O
, O
the O
presence O
of O
the O
NUM I-GENE
ALL_CAP I-GENE
domain I-GENE
was O
sufficient O
to O
RARE O
a O
heterologous O
protein O
. O

Electrophoretic O
mobility O
shift O
assays O
with O
each O
of O
these O
sequences O
demonstrated O
complexes O
with O
RARE O
identical O
to O
those O
of O
the O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
site I-GENE
from O
the O
RARE I-GENE
light I-GENE
- I-GENE
chain I-GENE
gene I-GENE
. O

Although O
a O
RARE O
- O
terminal O
HSF I-GENE
transcriptional O
activation O
domain O
is O
critical O
RARE O
the O
activation O
of O
NUM I-GENE
transcription O
in O
response O
to O
both O
heat O
shock O
stress O
and O
glucose O
starvation O
, O
this O
region O
is O
dispensable O
RARE O
transient O
heat O
shock O
activation O
of O
RARE O
least O
two O
genes O
encoding O
members O
of O
the O
S O
. O
cerevisiae O
hsp70 I-GENE
family I-GENE
. O

We O
have O
recently O
detected O
high O
levels O
of O
ALL_CAP I-GENE
mRNA I-GENE
in O
HeLa O
cells O
and O
, O
in O
this O
study O
, O
have O
tested O
whether O
this O
may O
be O
due O
to O
the O
extremely O
low O
amounts O
of O
p53 I-GENE
protein I-GENE
present O
in O
HeLa O
cells O
. O

RARE O
lower O
motor O
RARE O
RARE O
with O
high O
- O
titer O
serum I-GENE
IgM I-GENE
anti I-GENE
- I-GENE
NUM I-GENE
antibodies I-GENE
: O
improvement O
following O
immunotherapy O
with O
monthly O
plasma O
exchange O
and O
intravenous O
cyclophosphamide O
. O

RARE O
responsible O
RARE O
the O
RARE O
, O
RARE O
- O
specific O
RARE O
pre O
- O
mRNA O
RARE O
characteristic O
of O
RARE O
are O
almost O
entirely O
unknown O
or O
RARE O
. O

A O
normal O
systemic O
response O
was O
obtained O
after O
IF O
, O
indicating O
that O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
retains O
activity O
in O
the O
solid O
state O
. O

A O
full O
- O
length O
cDNA O
clone O
isolated O
from O
a O
rat O
RARE O
library O
was O
predicted O
to O
encode O
a O
NUM O
- O
kDa O
protein O
containing O
RARE O
its O
amino O
terminus O
a O
targeting O
domain O
that O
binds O
to O
the O
ANP I-GENE
- I-GENE
receptor I-GENE
kinase I-GENE
- I-GENE
like I-GENE
domain I-GENE
and O
containing O
RARE O
its O
RARE O
terminus O
a O
putative O
protein I-GENE
- I-GENE
serine I-GENE
phosphatase I-GENE
domain O
. O

A O
high O
- O
resolution O
RARE O
map O
of O
over O
NUM O
kb O
of O
contiguous O
DNA O
containing O
N I-GENE
- I-GENE
myc I-GENE
has O
been O
generated O
by O
RARE O
YACs O
into O
RARE O
. O

PAI I-GENE
- I-GENE
1 I-GENE
levels O
increased O
significantly O
in O
patients O
who O
received O
RARE O
but O
not O
in O
those O
who O
received O
RARE O
. O

In O
the O
present O
article O
, O
the O
causes O
of O
RARE O
or O
RARE O
- O
being O
RARE O
found O
in O
10 O
consecutive O
RARE O
studies O
RARE O
5 O
studies O
with O
NUM O
ALL_CAP O
( O
Sprague O
- O
Dawley O
- O
derived O
) O
and O
RARE O
rats O
and O
5 O
studies O
with O
NUM O
NUM O
and O
ALL_CAP O
mice O
RARE O
were O
re O
- O
examined O
. O

Determination O
of O
RARE O
RARE O
in O
RARE O
RARE O
salt O

The O
recovery O
value O
of O
systolic O
pressure O
was O
RARE O
than O
diastolic O
pressure O
and O
pulse O
pressure O
increased O
. O

The O
importance O
of O
hepatitis O
C O
virus O
( O
HCV O
) O
infection O
RARE O
a O
cause O
of O
chronic O
liver O
RARE O
has O
become O
clear O
with O
the O
introduction O
of O
serologic O
detection O
methods O
. O

Human O
adenovirus O
type O
NUM O
contains O
two O
fibers O
. O

RARE O
obstruction O
of O
pancreatic O
juice O
, O
i O
. O
RARE O
., O
" O
relative O
stenosis O
of O
the O
minor O
RARE O
," O
was O
considered O
to O
be O
present O
in O
the O
patients O
with O
type O
II O
RARE O
, O
and O
, O
therefore O
, O
the O
patients O
with O
type O
II O
RARE O
might O
RARE O
from O
acute O
pancreatitis O
resulting O
from O
poor O
drainage O
of O
pancreatic O
juice O
and O
excessive O
pressure O
in O
the O
dorsal O
duct O
. O

Sequencing O
of O
the O
NUM I-GENE
transcripts I-GENE
from O
exons O
2 O
to O
10 O
, O
however O
, O
did O
not O
reveal O
mutations O
of O
the O
remaining O
allele O
in O
any O
of O
these O
tumors O
. O

An O
unusual O
complication O
in O
an O
RARE O
patient O
. O

In O
the O
ALL_CAP O
group O
, O
RARE O
pre O
- O
ALL_CAP O
, O
CBF O
increased O
from O
NUM O
+/- O
8 O
to O
NUM O
+/- O
19 O
mL O
. O
min O
- O
1 O
. O
NUM O
g O
- O
1 O
in O
response O
to O
hypercapnia O
( O
PCO2 O
RARE O
NUM O
mmHg O
RARE O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

All O
other O
RARE O
parameters O
( O
density O
, O
RARE O
, O
swelling O
test O
, O
penetration O
test O
) O
remained O
unchanged O
, O
and O
there O
was O
only O
one O
post O
- O
therapeutic O
RARE O
. O

NUM O
and O
RARE O
produced O
a O
dose O
- O
dependent O
increase O
in O
aortic O
and O
coronary O
RARE O
flow O
. O

In O
NUM O
rat O
hepatoma O
cells O
, O
glucocorticoids O
, O
retinoic O
acid O
and O
cyclic O
AMP O
( O
cAMP O
) O
increase O
PEPCK I-GENE
gene I-GENE
transcription O
whereas O
insulin I-GENE
and O
phorbol O
esters O
have O
the O
opposite O
effect O
. O

RARE O
NUM O
, O
NUM O
- O
120 O
]. O

Basal O
plasma O
AVP I-GENE
levels O
and O
AVP I-GENE
release O
after O
RARE O
change O
were O
assessed O
, O
and O
plasma O
ALL_CAP I-GENE
levels O
were O
measured O
in O
the O
same O
samples O
. O

A O
stretch O
of O
16 O
nucleotides O
just O
upstream O
of O
the O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
contributed O
to O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
inducibility O
and O
formed O
RARE O
complexes O
with O
RARE O
factors O
. O

Our O
previous O
study O
suggested O
that O
RARE I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
)- O
RARE O
GTP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( I-GENE
s I-GENE
) I-GENE
( O
G I-GENE
- I-GENE
protein I-GENE
) O
is O
involved O
in O
the O
process O
of O
differentiation O
by O
RARE O
/ O
ALL_CAP O
, O
accompanied O
by O
c I-GENE
- I-GENE
fos I-GENE
induction O
. O

ALL_CAP I-GENE
, O
like O
PC I-GENE
- I-GENE
1 I-GENE
, O
was O
found O
to O
RARE O
the O
type I-GENE
I I-GENE
RARE I-GENE
substrate O
p O
- O
RARE O
RARE O
- O
5 O
'- O
monophosphate O
. O

The O
effect O
of O
site O
- O
specific O
mutations O
in O
the O
mouse I-GENE
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
beta I-GENE
- I-GENE
receptor I-GENE
on O
activation O
of O
the O
RARE I-GENE
RARE I-GENE
H I-GENE
+ I-GENE
RARE I-GENE
was O
examined O
in O
normal O
murine O
mammary O
RARE O
RARE O
( O
ALL_CAP O
) O
and O
RARE O
hamster O
ovary O
( O
CHO O
) O
cells O
. O

Sequence O
analysis O
revealed O
: O
1 O
) O
a O
kinase O
catalytic O
domain O
most O
characteristic O
of O
serine I-GENE
/ I-GENE
threonine I-GENE
kinases I-GENE
but O
RARE O
between O
members O
of O
the O
family O
of O
microtubule I-GENE
- I-GENE
associated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
kinases I-GENE
and O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
family I-GENE
; O
2 O
) O
two O
putative O
alpha O
- O
helical O
leucine O
zipper O
motifs O
separated O
by O
a O
NUM O
- O
amino O
acid O
charged O
RARE O
segment O
but O
RARE O
an O
NH2 O
- O
terminal O
basic O
domain O
; O
and O
3 O
) O
ALL_CAP O
- O
terminal O
and O
NH2 O
- O
terminal O
proline O
- O
rich O
domains O
suggestive O
of O
src I-GENE
homology I-GENE
3 I-GENE
( O
SH3 I-GENE
) O
domain O
binding O
regions O
. O

RARE O
2 O
genomes O
containing O
this O
sequence O
presumably O
more O
closely O
reflect O
the O
RARE O
of O
the O
infectious O
, O
replication O
- O
competent O
RARE O
RARE O
of O
the O
ALL_CAP O
- O
K O
family O
than O
do O
type O
1 O
genomes O
that O
lack O
the O
sequence O
. O

However O
, O
when O
domain O
I O
and O
domain O
II O
were O
RARE O
on O
the O
same O
RARE O
, O
high O
levels O
of O
replication O
were O
observed O
. O

RARE O
mutations O
that O
suppressed O
the O
in O
vitro O
binding O
of O
ALL_CAP I-GENE
- I-GENE
Y I-GENE
to O
the O
internal O
palindromic O
RARE O
RARE O
the O
activity O
of O
the O
RARE O
NUM O
promoter O
, O
while O
those O
preventing O
complex O
formation O
with O
USF I-GENE
did O
not O
, O
RARE O
determined O
by O
transient O
RARE O
assays O
using O
the O
luciferase I-GENE
reporter O
gene O
. O

Surprisingly O
, O
Northern O
( O
RNA O
) O
blot O
analysis O
and O
reverse I-GENE
transcriptase I-GENE
- O
RARE O
performed O
after O
transfection O
of O
COS O
- O
7 O
or O
HeLa O
cells O
with O
these O
viral O
RNAs O
revealed O
that O
NUM I-GENE
and O
NUM I-GENE
RNAs I-GENE
RARE O
RARE O
only O
very O
low O
levels O
. O

Surprisingly O
, O
nuclear O
forms O
of O
NUM I-GENE
were O
found O
to O
RARE O
a O
cytoplasmic O
form O
of O
NUM I-GENE
into O
nuclear O
RARE O
RARE O
, O
and O
a O
cytoplasmic O
form O
of O
NUM I-GENE
was O
able O
to O
RARE O
nuclear O
forms O
of O
NUM I-GENE
in O
cytoplasmic O
RARE O
RARE O
. O

Transcription O
of O
the O
gene O
RARE O
RARE I-GENE
O I-GENE
and O
RARE O
of O
other O
genes O
of O
the O
RARE I-GENE
gene I-GENE
cluster I-GENE
in I-GENE
L I-GENE
. I-GENE
RARE I-GENE
were O
dependent O
on O
ALL_CAP I-GENE
. O

Moreover O
, O
by O
RARE O
of O
the O
ALL_CAP I-GENE
ALL_CAP I-GENE
mutant I-GENE
by O
the O
RARE O
ALL_CAP I-GENE
gene I-GENE
, O
RARE O
uptake O
and O
mouse O
RARE O
were O
restored O
. O

The O
ALL_CAP O
in O
the O
ischaemic O
cortex O
revealed O
a O
RARE O
reduction O
from O
the O
ischaemic O
RARE O
to O
the O
surrounding O
tissues O
. O

The O
treatment O
of O
RARE O
in O
children O

The O
RARE O
RARE O
of O
the O
probe O
is O
RARE O
by O
RARE O
a O
standard O
ALL_CAP O
RARE O
- O
RARE O
Y O
RARE O
and O
RARE O
this O
to O
the O
RARE O
probe O
RARE O
. O

The O
other O
element O
RARE O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
RARE I-GENE
with O
low O
affinity O
. O

The O
basal O
promoter O
strength O
of O
constructs O
that O
contained O
deletions O
in O
the O
NUM I-GENE
region I-GENE
of O
the O
LTR O
was O
analyzed O
by O
chloramphenicol I-GENE
RARE I-GENE
( O
CAT I-GENE
) O
assays O
following O
transfection O
of O
HeLa O
cells O
or O
Jurkat O
T O
- O
cells O
in O
the O
presence O
or O
absence O
of O
viral O
RARE O
RARE I-GENE
protein O
. O

In O
RARE O
a O
number O
of O
the O
most O
RARE O
studied O
RARE O
inducible O
promoters O
it O
becomes O
clear O
that O
the O
presence O
of O
two O
cis O
- O
acting O
elements O
are O
critical O
RARE O
promoter O
activity O
, O
one O
of O
which O
is O
the O
G O
- O
box O
( O
ALL_CAP O
). O

Recently O
, O
a O
protein O
designated O
NUM I-GENE
has O
been O
isolated O
that O
is O
associated O
with O
the O
ALL_CAP I-GENE
protein I-GENE
complex I-GENE
. O

New O
diagnostic O
strategies O
RARE O
lupus O
RARE O
and O
RARE O
antibodies O
. O

Moreover O
, O
the O
ability O
to O
selectivity O
arrest O
RARE O
by O
ALL_CAP I-GENE
RARE O
defined O
positions O
within O
the O
tRNA O
gene O
transcription O
unit O
has O
permitted O
the O
identification O
of O
discrete O
RARE O
properties O
of O
RARE O
mammalian I-GENE
ALL_CAP I-GENE
RARE I-GENE
complexes I-GENE
. O

RARE O
is O
RARE O
tolerated O
in O
the O
majority O
of O
young O
patients O
. O

Mutational O
analysis O
of O
yeast I-GENE
NUM I-GENE
demonstrated O
that O
four O
of O
the O
five O
RARE O
motifs O
are O
essential O
RARE O
RARE I-GENE
enzyme I-GENE
function O
in O
vivo O
. O

2 O
patients O
( O
11 O
%) O
had O
significant O
morbidity O
NUM O
and O
NUM O
days O
respectively O
after O
transplantation O
. O

A O
recent O
index O
( O
RARE O
Risk O
RARE O
) O
developed O
by O
RARE O
( O
1990 O
) O
is O
also O
included O
in O
this O
review O
. O

Alternative O
RARE O
of O
the O
cytoplasmic O
RARE O
appears O
to O
generate O
multiple O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
isoforms I-GENE
that O
may O
regulate O
RARE O
, O
cytoskeletal O
association O
, O
and O
affinity O
modulation O
of O
the O
RARE O
protein O
. O

RARE O
also O
correlated O
inversely O
with O
RARE O
juice O
pH O
( O
RARE O
= O
- O
NUM O
. O
NUM O
, O
P O
< O
NUM O
. O
02 O
). O

This O
technique O
has O
a O
sensitivity O
and O
a O
RARE O
of O
almost O
NUM O
%, O
and O
is O
currently O
the O
best O
way O
to O
RARE O
nodal O
involvement O
, O
apart O
from O
RARE O
. O

The O
data O
show O
RARE O
that O
RARE O
of O
RARE O
- O
NUM O
is O
not O
essential O
RARE O
any O
of O
the O
known O
functions O
of O
A I-GENE
. I-GENE
RARE I-GENE
ALL_CAP I-GENE
. O

The O
role O
of O
HIV I-GENE
tat I-GENE
, O
which O
is O
the O
main O
enhancing O
factor O
RARE O
viral I-GENE
LTR I-GENE
, O
in O
the O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
gene I-GENE
transcription O
has O
been O
studied O
following O
transient O
RARE O
of O
the O
tat I-GENE
gene I-GENE
in O
phorbol O
ester O
and O
RARE O
RARE O
- O
activated O
Jurkat O
cells O
transfected O
with O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
promoter O
- O
chloramphenicol I-GENE
RARE I-GENE
reporter O
constructs O
. O

RARE O
variations O
in O
genes O
coding O
RARE O
the O
transmembrane I-GENE
FGF I-GENE
receptor I-GENE
( O
FGFR I-GENE
) O
result O
in O
isoforms O
that O
vary O
in O
the O
RARE O
, O
RARE O
RARE O
domain O
, O
and O
the O
RARE O
kinase O
domain O
. O

If O
this O
is O
present O
, O
such O
patients O
should O
be O
closely O
monitored O
, O
and O
any O
atypical O
lesions O
RARE O
. O

RARE O
maximum O
RARE O
scores O
between O
ALL_CAP I-GENE
and O
NUM I-GENE
and O
between O
ALL_CAP I-GENE
and O
NUM I-GENE
are O
above O
NUM O
and O
NUM O
, O
respectively O
, O
RARE O
a O
RARE O
fraction O
of O
NUM O
, O
indicating O
that O
RARE O
events O
needed O
to O
RARE O
the O
search O
of O
the O
gene O
are O
very O
difficult O
to O
identify O
and O
RARE O
. O

A O
receptor I-GENE
- I-GENE
like I-GENE
protein I-GENE
kinase I-GENE
, O
NUM I-GENE
, O
has O
been O
RARE O
from O
RARE O
( O
RARE O
RARE O
). O

A O
sequence O
representing O
about O
50 O
% O
of O
the O
expected O
RARE O
sequence O
was O
obtained O
by O
translation O
of O
the O
two O
RARE O
reading O
frames O
present O
on O
a O
1 O
. O
6 O
kb O
DNA O
genomic O
fragment O
. O

RARE O
' O
s O
- O
like O
RARE O
and O
effect O
of O
RARE O
membrane O
RARE O
support O
. O

A O
cDNA O
clone O
NUM O
, O
with O
a O
1 O
. O
1 O
kb O
insert O
, O
was O
isolated O
from O
a O
NaCl O
- O
adapted O
tobacco O
cell O
cDNA O
library O
that O
encodes O
an O
apparently O
full O
- O
length O
29 O
kDa O
protein O
( O
NUM O
amino O
RARE O
) O
with O
a O
calculated O
ALL_CAP O
of O
5 O
. O
7 O
. O

METHODS O
RARE O
16 O
RARE O
RARE O
RARE O
with O
RARE O
RARE O
test O
including O
a O
test O
RARE O
small O
RARE O
function O
by O
volume O
of O
RARE O
gas O
( O
ALL_CAP O
). O

RARE O
of O
CDK I-GENE
- I-GENE
activating I-GENE
kinase I-GENE
and O
RNA I-GENE
polymerase I-GENE
II I-GENE
ALL_CAP O
kinase O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
. O

The O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
act O
upstream O
of O
adenylate I-GENE
cyclase I-GENE
, O
presumably O
encoding O
an O
adenylate I-GENE
cyclase I-GENE
activation O
RARE O
. O

These O
same O
regions O
showed O
remarkable O
homology O
to O
two O
RARE O
proteins O
, O
ALL_CAP I-GENE
and O
RARE I-GENE
- I-GENE
1 I-GENE
, O
postulated O
to O
regulate O
RARE O
development O
in O
Drosophila O
melanogaster O
and O
Caenorhabditis O
elegans O
, O
respectively O
. O

DNA O
sequence O
analysis O
has O
confirmed O
that O
this O
mutation O
affects O
the O
C O
- O
terminal O
region O
of O
the O
alpha O
subunit O
, O
changing O
a O
leucine O
RARE O
RARE O
position O
NUM O
to O
a O
RARE O
( O
NUM I-GENE
). O

CONCLUSIONS O
: O
These O
findings O
indicate O
a O
physical O
barrier O
of O
RARE O
RARE O
which O
could O
offer O
some O
degree O
of O
protection O
against O
RARE O
- O
RARE O
reflux O
but O
one O
which O
is O
particularly O
prone O
to O
RARE O
by O
bile O
. O

Differential O
screening O
of O
mitochondrial O
cDNA O
libraries O
from O
male O
- O
RARE O
and O
cytoplasmic O
male O
- O
RARE O
RARE O
- O
RARE O
reveals O
genome O
RARE O
RARE O
NUM I-GENE
and O
ALL_CAP I-GENE
loci I-GENE
. O

The O
effects O
of O
social O
isolation O
on O
RARE O
- O
RARE O
locomotor O
activity O
were O
compared O
in O
: O
( O
i O
) O
animals O
with O
an O
RARE O
RARE O
- O
pituitary O
- O
adrenal O
( O
ALL_CAP O
) O
axis O
; O
( O
ii O
) O
animals O
in O
which O
stress O
- O
RARE O
corticosterone O
RARE O
was O
blocked O
by O
RARE O
. O

Using O
this O
reporter O
gene O
RARE O
, O
we O
previously O
showed O
that O
EPO I-GENE
- O
RARE O
activation O
of O
the O
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
can O
be O
detected O
rapidly O
and O
RARE O
RARE O
an O
elevation O
of O
cellular I-GENE
luciferase I-GENE
activity O
. O

I O
RARE O
that O
RARE I-GENE
gene I-GENE
RARE O
from O
P I-GENE
RARE I-GENE
RARE I-GENE
] I-GENE
is O
repressed O
by O
the O
formation O
of O
a O
protein O
complex O
which O
is O
RARE O
RARE O
the O
RARE I-GENE
ALL_CAP I-GENE
sites I-GENE
and O
also O
requires O
interactions O
with O
flanking O
genomic O
DNA O
. O

NUM I-GENE
was O
RARE O
and O
sequenced O
and O
found O
to O
be O
essential O
. O
NUM I-GENE
is O
allelic O
to O
the O
previously O
identified O
suppressor I-GENE
NUM I-GENE
, O
which O
encodes O
a O
negative O
regulator O
of O
gene O
RARE O
. O

RARE O
curve O
correlation O
coefficients O
of O
NUM O
. O
NUM O
or O
greater O
were O
obtained O
RARE O
RARE O
experiments O
and O
analysis O
of O
study O
samples O
. O

To O
RARE O
if O
a O
pulse O
RARE O
can O
monitor O
the O
fetus O
RARE O
labour O
we O
recruited O
NUM O
RARE O
women O
in O
normal O
RARE O
labour O
. O

There O
was O
RARE O
difference O
in O
plasma O
concentrations O
of O
NUM O
( O
RARE O
4 O
) O
and O
NUM O
in O
patients O
with O
normal O
RARE O
pressure O
, O
mild O
RARE O
and O
hypotension O
, O
whereas O
in O
severe O
RARE O
, O
the O
plasma O
concentration O
of O
NUM O
was O
significantly O
lower O
( O
p O
< O
NUM O
. O
001 O
) O
and O
of O
NUM O
significantly O
RARE O
( O
p O
< O
NUM O
. O
001 O
). O

A O
RARE O
analysis O
of O
secondary O
variables O
showed O
that O
the O
formation O
of O
FB O
RARE O
was O
primarily O
associated O
with O
the O
level O
of O
importance O
attached O
to O
the O
event O
and O
level O
of O
affective O
response O
to O
the O
RARE O
. O

Deletion O
studies O
identified O
a O
distal O
response O
element O
that O
is O
responsible O
RARE O
the O
RARE O
response O
and O
has O
properties O
of O
an O
inducible O
transcriptional O
enhancer O
. O

The O
NUM I-GENE
gene I-GENE
is O
required O
RARE O
high O
- O
RARE O
RARE O
segregation O
in O
the O
RARE O
yeast O
Saccharomyces O
cerevisiae O
. O

2 O
. O

No O
drop O
in O
oxygen O
saturation O
( O
SaO2 O
) O
or O
visual O
evidence O
of O
transient O
RARE O
( O
EEG O
) O
RARE O
can O
be O
found O
RARE O
repeat O
RARE O
. O

The O
RARE O
gene O
organization O
was O
obtained O
by O
RARE O
the O
results O
of O
the O
sequence O
of O
these O
RARE O
and O
those O
of O
the O
characterization O
of O
polymerase O
chain O
reaction O
- O
amplified O
genomic O
RARE O
. O

NUM I-GENE
, O
a O
regulatory O
gene O
in O
yeast O
RARE O
biosynthesis O
, O
affects O
nuclear O
segregation O
and O
RARE O
pattern O
formation O
. O

The O
RARE O
RARE O
of O
RARE O
yields O
an O
intense O
ion O
fragment O
RARE O
m O
/ O
z O
NUM O
, O
and O
the O
lower O
limit O
of O
detection O
is O
NUM O
. O
NUM O
RARE O
/ O
ml O
RARE O
a O
1 O
- O
ml O
plasma O
sample O
. O

RARE I-GENE
RARE I-GENE
and O
RARE I-GENE
bind O
RARE O
steroids O
with O
high O
affinity O
, O
but O
some O
binding O
properties O
differ O
among O
species O
. O

Src I-GENE
homology I-GENE
( O
ALL_CAP I-GENE
) O
domain O
dependent O
protein O
- O
protein O
interactions O
are O
important O
to O
tyrosine I-GENE
kinase I-GENE
receptor I-GENE
signal O
RARE O
. O

RARE O
treatment O
was O
RARE O
in O
order O
to O
achieve O
a O
RARE O
extraction O
of O
RARE O
RARE O
and O
to O
avoid O
RARE O
RARE O
extraction O
. O

Under O
resting O
conditions O
, O
activity O
levels O
of O
cardiac O
RARE O
and O
sympathetic O
RARE O
are O
not O
related O
across O
young O
, O
healthy O
human O
subjects O
and O
peripheral O
interaction O
is O
not O
manifest O
between O
the O
RARE O
RARE O
. O

Both O
RARE O
and O
RARE O
RARE O
showed O
a O
progression O
of O
RARE O
fields O
from O
anterior O
to O
posterior O
body O
in O
the O
RARE O
to O
RARE O
direction O
along O
the O
length O
of O
ALL_CAP O
. O

In O
control O
patients O
, O
baseline O
images O
presented O
RARE O
I O
in O
NUM O
, O
RARE O
II O
in O
7 O
, O
and O
the O
RARE O
III O
& O
IV O
in O
NUM O
, O
and O
the O
RARE O
after O
loading O
was O
the O
same O
RARE O
the O
RARE O
RARE O
baseline O
. O

A O
more O
RARE O
analysis O
of O
dose O
response O
, O
time O
and O
mode O
of O
Ga O
administration O
( O
RARE O
or O
RARE O
RARE O
and O
availability O
of O
Ga O
across O
the O
RARE O
- O
brain O
barrier O
is O
needed O
to O
further O
evaluate O
the O
efficacy O
of O
this O
compound O
. O

The O
presence O
of O
regulatory O
sequences O
RARE O
the O
binding O
of O
transcription O
factors O
such O
RARE O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
and O
AP I-GENE
- I-GENE
2 I-GENE
, O
whose O
activation O
is O
associated O
with O
the O
immediate O
response O
of O
the O
cell O
to O
an O
injury O
, O
may O
be O
an O
indication O
of O
the O
important O
role O
which O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
may O
play O
in O
defense O
mechanisms O
against O
tissue O
injury O
. O

RARE O
, O
but O
not O
saline O
, O
abolished O
RARE O
and O
RARE O
when O
given O
RARE O
intervention O
after O
this O
combined O
RARE O
regimen O
. O

The O
RARE O
coronary O
sinus O
difference O
in O
RARE O
turned O
negative O
, O
and O
pH O
, O
PCO2 O
and O
RARE O
differences O
increased O
in O
group O
2 O
RARE O
pacing O
. O

This O
was O
obtained O
with O
the O
thermal O
RARE O
RARE O
2 O
. O
NUM O
RARE O
10 O
( O
10 O
) O
RARE O
/ O
cm2 O
. O

RARE O
RARE O
by O
gram O
- O
negative O
bacteria O
leads O
to O
RARE O
shock O
RARE O
RARE O
from O
the O
RARE O
RARE O
of O
the O
bacterial O
RARE O
RARE O
RARE O
A O
. O

The O
study O
made O
to O
define O
the O
ability O
of O
RARE I-GENE
A I-GENE
monoclonal I-GENE
antibodies I-GENE
to O
correct O
hemodynamic O
disturbances O
due O
to O
RARE O
in O
dog O
experiments O
showed O
the O
efficacy O
of O
the O
antibodies O
administration O
. O

A O
randomised O
, O
RARE O
trial O
was O
undertaken O
in O
40 O
patients O
with O
RARE O
Crohn O
' O
s O
RARE O
to O
evaluate O
clinical O
and O
nutritional O
outcomes O
after O
an O
amino O
acid O
based O
diet O
containing O
3 O
% O
fat O
was O
given O
by O
a O
feeding O
tube O
compared O
with O
a O
peptide O
based O
diet O
containing O
NUM O
% O
fat O
. O

This O
sequenced O
region O
of O
the O
V O
beta O
locus O
contains O
an O
average O
number O
of O
RARE O
DNA O
elements O
( O
21 O
Alu I-GENE
, O
three O
L1 I-GENE
, O
three O
ALL_CAP O
, O
and O
three O
RARE O
- O
related O
elements O
. O

The O
sequenced O
genomic O
region O
thus O
RARE O
RARE O
essentially O
all O
of O
the O
RARE O
known O
transcript O
( O
4 O
. O
5 O
kb O
RARE O
although O
the O
precise O
ends O
of O
this O
transcript O
have O
not O
been O
defined O
. O

The O
ALL_CAP I-GENE
upstream I-GENE
region I-GENE
contained O
NUM O
nucleotides O
within O
which O
sequences O
RARE O
the O
consensus O
RARE O
cyclic I-GENE
AMP I-GENE
receptor I-GENE
protein I-GENE
and O
RARE I-GENE
RARE I-GENE
factor I-GENE
binding O
sites O
were O
RARE O
. O

The O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
and O
RARE I-GENE
- O
ALL_CAP I-GENE
RARE O
in O
the O
RARE O
RARE O
and O
RARE O
RARE O
are O
divergently O
RARE O
from O
overlapping O
promoters O
, O
and O
both O
are O
inhibited O
by O
the O
Fur I-GENE
repressor I-GENE
protein I-GENE
under O
iron O
- O
RARE O
conditions O
. O

Sequence O
analysis O
of O
a O
6 O
. O
3 O
- O
RARE O
genomic O
EcoRI I-GENE
- O
fragment O
of O
RARE O
RARE O
, O
which O
was O
recently O
identified O
by O
using O
a O
RARE I-GENE
dehydrogenase I-GENE
- O
specific O
DNA O
probe O
( O
A O
. O

Using O
a O
previously O
published O
two O
- O
frequency O
( O
ALL_CAP O
RARE O
) O
three O
- O
electrode O
method O
, O
the O
RARE O
locus O
RARE O
( O
ALL_CAP O
) O
in O
the O
low O
- O
frequency O
region O
(< O
1000 O
Hz O
) O
has O
been O
shown O
to O
be O
very O
RARE O
RARE O
by O
a O
RARE O
line O
and O
can O
be O
described O
with O
frequency O
- O
independent O
parameters O
; O
RARE O
angle O
alpha O
RARE O
/ O
2 O
, O
RARE O
RARE O
RARE O
zero O
frequency O
NUM O
= O
1 O
/ O
NUM O
, O
and O
ion O
relaxation O
time O
RARE O
. O

RARE O
measurement O
of O
activated O
partial O
thromboplastin I-GENE
time O
and O
prothrombin I-GENE
time O
with O
a O
new O
RARE O
monitor O
. O

In O
addition O
, O
we O
sought O
to O
test O
the O
hypothesis O
that O
, O
when O
equal O
volumes O
are O
administered O
RARE O
, O
significant O
differences O
exist O
in O
the O
RARE O
to O
three O
commonly O
used O
RARE O
solutions O
to O
induce O
sensory O
impairment O
. O

In O
an O
in O
vitro O
study O
, O
10 O
/ O
NUM O
RARE O
was O
found O
to O
require O
a O
significantly O
lower O
laser O
energy O
density O
to O
produce O
RARE O
lysis O
following O
a O
single O
RARE O
than O
either O
10 O
/ O
NUM O
RARE O
or O
10 O
/ O
NUM O
RARE O
. O

The O
proteins O
encoded O
RARE O
of O
ALL_CAP I-GENE
are O
known O
to O
negatively O
regulate O
RARE I-GENE
54 I-GENE
activity O
. O

We O
report O
here O
that O
microinjection O
of O
an O
anti I-GENE
- I-GENE
CBP I-GENE
RARE I-GENE
into O
RARE O
can O
inhibit O
transcription O
from O
a O
cAMP O
responsive O
promoter O
. O

These O
results O
demonstrate O
that O
a O
class O
of O
proline O
- O
rich O
activator O
proteins O
and O
RNA I-GENE
polymerase I-GENE
II I-GENE
possess O
a O
common O
structural O
and O
RARE O
RARE O
which O
can O
interact O
with O
the O
same O
target O
in O
the O
RARE O
transcription O
machinery O
. O

Cloning O
of O
RARE I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
3 I-GENE
fatty I-GENE
acid I-GENE
RARE I-GENE
. O

65 O
, O
NUM O
- O
NUM O
, O
1991 O
RARE O
a O
truncated O
form O
of O
the O
IE I-GENE
polypeptide I-GENE
RARE O
IE I-GENE
amino I-GENE
acid I-GENE
residues I-GENE
1 I-GENE
- I-GENE
NUM I-GENE
( O
and O
, O
therefore O
lacks O
the O
deduced O
transcriptional O
activation O
domain O
RARE O
fails O
to O
transactivate O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
tk I-GENE
promoter I-GENE
, O
but O
retains O
the O
ability O
to O
down O
- O
regulate O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
IE I-GENE
promoter I-GENE
. O

However O
, O
by O
an O
NUM I-GENE
- I-GENE
specific I-GENE
RNA I-GENE
RARE O
assay O
, O
the O
RARE O
were O
shown O
to O
possess O
the O
RNA O
- O
binding O
activity O
previously O
demonstrated O
RARE O
NUM I-GENE
. O

CONCLUSION O
: O
Human O
preterm O
birth O
is O
associated O
with O
significantly O
lower O
progesterone O
/ O
NUM O
beta O
- O
estradiol O
ratios O
than O
those O
of O
women O
with O
preterm O
RARE O
delivered O
RARE O
term O
. O

RARE O
in O
the O
treatment O
of O
RARE O
RARE O
mechanical O
ventilation O
. O

In O
conclusion O
, O
the O
RARE O
of O
RARE O
and O
O O
- O
RARE O
is O
markedly O
altered O
in O
RARE O
RARE O
; O
therefore O
dosage O
adjustment O
is O
warranted O
RARE O
patients O
with O
RARE O
clearance O
values O
below O
NUM O
ml O
/ O
min O
. O

The O
availability O
of O
sequence O
from O
multiple O
species O
has O
permitted O
us O
to O
determine O
that O
the O
ALL_CAP O
site O
has O
close O
RARE O
to O
motifs O
that O
bind O
members O
of O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
. O

The O
incidence O
of O
HSV O
- O
2 O
positive O
subjects O
( O
HSV I-GENE
- I-GENE
2 I-GENE
/ I-GENE
HSV I-GENE
- I-GENE
1 I-GENE
antibody I-GENE
ratio O
> O
or O
= O
1 O
) O
was O
low O
in O
the O
RARE O
RARE O
population O
, O
compared O
to O
other O
RARE O
areas O
. O

The O
mechanism O
RARE O
RARE I-GENE
PKC I-GENE
regulates O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
most O
probably O
involves O
the O
activation O
of O
a O
putative O
I I-GENE
RARE I-GENE
B I-GENE
kinase I-GENE
of O
RARE O
mass O
RARE O
50 O
kDa O
, O
which O
phosphorylates O
and O
RARE O
I I-GENE
RARE I-GENE
B I-GENE
. O

Stable O
RARE O
of O
truncated I-GENE
RARE I-GENE
1 I-GENE
, I-GENE
4 I-GENE
, I-GENE
5 I-GENE
- I-GENE
RARE I-GENE
receptor I-GENE
subunits I-GENE
in O
3T3 O
RARE O
. O

The O
RARE O
basis O
RARE O
RARE O
of O
RARE O
to O
the O
eosinophil O
lineage O
and O
mechanisms O
by O
which O
eosinophil O
- O
specific O
genes O
are O
RARE O
and O
regulated O
RARE O
differentiation O
is O
unknown O
. O

We O
report O
the O
identification O
and O
characterization O
of O
RARE I-GENE
4 I-GENE
( O
myosin I-GENE
from I-GENE
rat I-GENE
RARE O
the O
RARE O
mammalian I-GENE
myosin I-GENE
I I-GENE
that O
is O
not O
closely O
related O
to O
RARE O
RARE O
myosin I-GENE
I I-GENE
. O

M O
., O
and O
D O
. O

In O
addition O
, O
computer O
analysis O
suggests O
that O
sequences O
similar O
to O
the O
A O
RARE O
element O
are O
present O
within O
the O
three O
ALL_CAP I-GENE
promoter I-GENE
regions O
. O

At O
least O
some O
of O
the O
difference O
in O
stability O
of O
the O
two O
RARE O
of O
complexes O
was O
due O
to O
the O
fact O
that O
the O
dissociation O
rate O
of O
the O
A O
RARE O
substrate O
from O
the O
protein O
- O
DNA O
complexes O
was O
RARE O
fourfold O
faster O
than O
that O
of O
the O
RARE O
TR I-GENE
. O

RARE O
of O
the O
NUM O
'- O
NUM I-GENE
RARE O
was O
complex O
and O
occurred O
rapidly O
. O

However O
, O
each O
promoter O
activated O
by O
NUM I-GENE
was O
synergistically O
affected O
by O
the O
addition O
of O
NUM I-GENE
. O

NUM O
labeling O
or O
RARE O
focusing O
analysis O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
from O
conditional O
casein I-GENE
kinase I-GENE
II I-GENE
mutants I-GENE
indicated O
that O
RARE O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
is O
abolished O
or O
RARE O
forms O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
are O
detected O
when O
these O
strains O
are O
grown O
RARE O
the O
restrictive O
growth O
conditions O
. O

Thus O
, O
ALL_CAP I-GENE
is O
a O
RARE O
homolog O
of O
ALL_CAP I-GENE
and O
represents O
a O
new O
RARE O
of O
the O
yeast O
mitochondrial O
import O
machinery O
. O

The O
NUM O
region O
within O
the O
class O
I O
enhancer O
acts O
RARE O
a O
negative O
element O
in O
NUM O
- O
transformed O
cells O
and O
exhibits O
a O
stronger O
binding O
activity O
than O
is O
observed O
in O
RARE O
NUM O
- O
transformed O
cells O
, O
which O
are O
not O
RARE O
in O
class O
I O
RARE O
. O

PURPOSE O
: O
To O
evaluate O
the O
kinetics O
of O
erythropoietin I-GENE
( O
EPO I-GENE
) O
production O
and O
address O
the O
pathogenesis O
of O
RARE O
of O
RARE O
, O
we O
measured O
EPO I-GENE
levels O
in O
infants O
RARE O
the O
RARE O
year O
of O
life O
. O

The O
nerve I-GENE
growth I-GENE
factor I-GENE
beta I-GENE
gene I-GENE
( O
ALL_CAP I-GENE
) O
belongs O
to O
a O
RARE O
RARE O
group O
on O
human O
RARE O
1 O
and O
mouse O
RARE O
3 O
. O

Furthermore O
, O
an O
upstream O
element O
, O
RARE O
element O
I O
RARE O
NUM O
/- O
NUM O
RARE O
which O
shares O
homology O
with O
the O
ALL_CAP I-GENE
binding O
cis O
- O
element O
of O
the O
albumin I-GENE
promoter I-GENE
( O
9 O
of O
NUM O
bp O
) O
is O
described O
. O

RARE O
and O
size O
of O
silver O
- O
stained O
RARE O
( O
RARE O
- O
ALL_CAP O
clusters O
) O
in O
canine O
RARE O
: O
correlation O
with O
histological O
features O
and O
RARE O
behaviour O
. O

We O
RARE O
that O
RARE O
cell O
RARE O
may O
be O
involved O
in O
the O
pathogenesis O
of O
RARE O
by O
altering O
fibroblast O
enzyme O
activity O
and O
/ O
or O
producing O
prolonged O
inflammatory O
reactions O
. O

Molecular O
cloning O
of O
a O
cysteine I-GENE
synthase I-GENE
cDNA I-GENE
from O
RARE O
RARE O
( O
RARE O
) O
by O
genetic O
RARE O
in O
an O
Escherichia O
coli O
RARE O
- O
RARE O
. O

In O
earlier O
studies O
we O
identified O
several O
regulatory O
elements O
that O
control O
transcriptional O
activation O
and O
aerobic O
repression O
of O
one O
of O
these O
genes O
, O
NUM I-GENE
. O

Although O
elevated O
serum O
levels O
of O
antibodies O
to O
the O
RARE I-GENE
RARE I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
) O
have O
been O
reported O
in O
neuroleptic O
treated O
patients O
with O
RARE O
RARE O
, O
such O
antibodies O
have O
not O
been O
determined O
in O
comparable O
RARE O
patients O
. O

The O
tumor O
suppressor O
and O
transcriptional O
factor O
p53 I-GENE
is O
a O
RARE O
protein O
. O

This O
DNA O
containing O
promoter O
activity O
has O
been O
sequenced O
in O
its O
RARE O
and O
found O
to O
contain O
multiple O
putative O
regulatory O
sites O
. O

However O
, O
Southern O
blot O
and O
RARE O
analyses O
did O
not O
reveal O
any O
significant O
changes O
in O
copy O
number O
or O
gross O
RARE O
of O
the O
p53 I-GENE
gene I-GENE
in O
any O
of O
the O
p53 I-GENE
- I-GENE
cell O
lines O
. O

ALL_CAP I-GENE
showed O
strong O
identity O
to O
RARE I-GENE
and O
RARE I-GENE
- I-GENE
like I-GENE
proteins I-GENE
from O
many O
other O
bacteria O
. O

The O
RARE O
RARE O
rate O
( O
P O
< O
NUM O
. O
01 O
) O
and O
the O
effective O
maximal O
rate O
of O
mitochondrial O
ATP O
RARE O
( O
P O
< O
NUM O
. O
05 O
) O
also O
improved O
. O

An O
examination O
was O
performed O
in O
NUM O
patients O
who O
had O
developed O
pronounced O
RARE O
following O
RARE O
resection O
. O

However O
, O
regional O
NUM O
increased O
to O
about O
the O
same O
extent O
in O
the O
ALL_CAP O
( O
from O
6 O
. O
NUM O
+/- O
NUM O
. O
7 O
to O
12 O
. O
4 O
+/- O
NUM O
. O
9 O
ml O
NUM O
. O
min O
- O
1 O
times O
NUM O
g O
- O
1 O
) O
and O
the O
LAD O
region O
( O
from O
7 O
. O
NUM O
+/- O
NUM O
. O
6 O
to O
14 O
. O
5 O
+/- O
1 O
. O
3 O
ml O
NUM O
. O
min O
- O
1 O
times O
NUM O
g O
- O
1 O
). O

IGF I-GENE
I I-GENE
and O
insulin I-GENE
receptors I-GENE
are O
homologous O
proteins O
that O
function O
in O
distinct O
physiological O
pathways O
. O

RARE O
was O
combined O
with O
the O
increase O
of O
glucocorticoid O
activity O
of O
adrenal O
cortex O
, O
while O
RARE O
significant O
changes O
in O
thyroid O
RARE O
were O
RARE O
. O

RARE O
RARE O
and O
peptide O
sequence O
analysis O
demonstrated O
that O
the O
98 O
- O
ALL_CAP O
protein O
is O
identical O
to O
a O
recently O
RARE O
protein O
, O
RARE I-GENE
A I-GENE
- I-GENE
T I-GENE
- I-GENE
rich I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
( O
NUM I-GENE
RARE O
that O
binds O
selectively O
to O
nuclear O
RARE O
/ O
RARE O
- O
associated O
regions O
of O
DNA O
( O
RARE O
/ O
RARE O
). O

RARE O
protein O
RARE O
RARE O
tyrosine O
is O
responsible O
RARE O
the O
growth O
- O
RARE O
action O
of O
NUM I-GENE
- I-GENE
src I-GENE
RARE O
in O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

Acute O
pancreatitis O
: O
a O
RARE O
RARE O
. O

RARE O
biosynthesis O
is O
RARE O
by O
a O
complex O
regulatory O
mechanism O
. O

The O
sequence O
upstream O
of O
the O
ALL_CAP I-GENE
promoter I-GENE
contains O
two O
inverted O
repeats O
which O
define O
putative O
binding O
sites O
RARE O
the O
ALL_CAP I-GENE
regulator I-GENE
. O

We O
have O
examined O
by O
in O
vitro O
footprinting O
a O
region O
RARE O
RARE O
of O
the O
human O
immunodeficiency O
virus O
, O
type O
1 O
( O
HIV O
- O
1 O
) O
promoter O
found O
to O
be O
RARE O
to O
DNase I-GENE
I I-GENE
digestion O
in O
vivo O
. O

Heparin O
had O
RARE O
effect O
on O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
myosin I-GENE
light I-GENE
chain I-GENE
phosphatase I-GENE
activity O
, O
while O
the O
B O
subunit O
- O
containing O
forms O
were O
RARE O
2 O
- O
3 O
- O
RARE O
. O

The O
relative O
abundance O
of O
each O
RARE O
RARE O
mRNA O
was O
determined O
by O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
in O
various O
human O
tissues O
and O
cell O
lines O
. O

BACKGROUND O
ALL_CAP O
DESIGN O
: O
Fifty O
- O
nine O
RARE O
RARE O
with O
RARE O
RARE O
of O
RARE O
(" O
small O
dark O
RARE O
RARE O
that O
measured O
primarily O
1 O
to O
2 O
mm O
in O
diameter O
were O
RARE O
examined O
to O
determine O
the O
histologic O
correlates O
of O
the O
dark O
RARE O
. O

The O
retention O
index O
of O
NUM O
SPECT O
is O
a O
useful O
indicator O
of O
metastatic O
RARE O
, O
thereby O
facilitating O
the O
prediction O
of O
prognosis O
, O
and O
provides O
insight O
into O
the O
relationship O
between O
NUM O
uptake O
and O
malignancy O
. O

The O
central O
globular O
domain O
is O
highly O
similar O
to O
those O
regions O
from O
other O
NUM I-GENE
molecules I-GENE
, O
and O
the O
RARE O
- O
terminal O
domain O
contains O
a O
repeating O
RARE O
motif O
, O
variants O
of O
which O
are O
RARE O
among O
NUM I-GENE
molecules I-GENE
. O

The O
location O
and O
RARE O
length O
of O
the O
intron O
are O
RARE O
in O
both O
the O
RARE O
and O
Arabidopsis O
genes O
, O
with O
the O
intron O
RARE O
the O
' O
RARE O
' O
region O
( O
encoded O
by O
RARE O
1 O
) O
from O
the O
central O
globular O
domain O
( O
RARE O
2 O
). O

The O
topology O
and O
chain O
folding O
of O
the O
beta O
subunits O
in O
the O
RARE O
beta O
NUM O
RARE O
are O
similar O
to O
the O
RARE I-GENE
alpha I-GENE
3 I-GENE
beta I-GENE
NUM I-GENE
enzyme I-GENE
. O

A O
single O
ALL_CAP O
was O
present O
in O
NUM O
. O
4 O
%, O
two O
in O
16 O
%, O
three O
in O
6 O
. O
4 O
%, O
four O
in O
3 O
. O
5 O
%, O
five O
to O
nine O
in O
4 O
. O
2 O
%, O
and O
NUM O
. O
5 O
% O
had O
ten O
or O
more O
. O

A O
RARE O
mutant O
form O
with O
a O
single O
substitution O
( O
NUM O
) O
in O
the O
amino O
- O
terminal O
( O
response O
regulator O
) O
region O
was O
used O
. O

RARE O
of O
the O
four O
operon O
control O
regions O
studied O
indicate O
that O
the O
ALL_CAP I-GENE
RARE I-GENE
are O
arranged O
with O
diverse O
RARE O
and O
RARE O
. O

RARE O
binding O
and O
competition O
assays O
using O
NUM O
- O
RARE O
RARE O
RARE O
representing O
the O
individual O
CBF1 I-GENE
binding I-GENE
sites I-GENE
indicated O
that O
CBF1 I-GENE
RARE O
less O
efficiently O
to O
the O
CD23 I-GENE
promoter I-GENE
and O
the O
ALL_CAP I-GENE
LMP I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
sites I-GENE
than O
to O
the O
Cp I-GENE
site I-GENE
. O

We O
have O
found O
a O
satisfactory O
reproducibility O
in O
vitro O
( O
NUM O
: O
1 O
. O
9 O
%; O
NUM O
: O
6 O
. O
2 O
%), O
while O
the O
reproducibility O
was O
less O
satisfactory O
in O
vivo O
( O
NUM O
: O
16 O
. O
4 O
%; O
NUM O
: O
NUM O
. O
4 O
%). O

The O
two O
ALL_CAP I-GENE
proteins I-GENE
that O
are O
produced O
RARE O
a O
result O
of O
independent O
translation O
initiation O
RARE O
two O
different O
RARE O
codons O
within O
the O
same O
RARE O
reading O
frame O
were O
overexpressed O
in O
Escherichia O
coli O
and O
partially O
RARE O
. O

To O
RARE O
further O
RARE O
into O
the O
RARE O
mechanisms O
that O
control O
tal I-GENE
- I-GENE
1 I-GENE
RARE O
, O
we O
have O
isolated O
5 O
' O
sequences O
of O
the O
murine O
gene O
and O
compared O
them O
to O
their O
human O
counterparts O
. O

CONCLUSION O
: O
RARE O
angiography O
has O
a O
possible O
role O
in O
the O
detection O
of O
small O
nodules O
in O
patients O
with O
ALL_CAP O
. O

Each O
RARE O
domain O
, O
RARE O
RARE O
RARE O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
itself O
, O
possesses O
RARE I-GENE
- I-GENE
RARE I-GENE
cis I-GENE
- I-GENE
RARE I-GENE
isomerase I-GENE
activity O
, O
though O
with O
much O
lower O
specific O
activities O
than O
ALL_CAP I-GENE
- I-GENE
12 I-GENE
. O

The O
RARE O
NUM O
nt O
upstream O
of O
the O
transcription O
initiation O
site O
of O
the O
mouse I-GENE
RARE I-GENE
gene I-GENE
, O
which O
contain O
an O
E O
box O
( O
E1 O
RARE O
the O
binding O
site O
of O
the O
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
RARE I-GENE
RARE I-GENE
, O
are O
sufficient O
to O
confer O
low O
level O
muscle O
- O
specific O
RARE O
. O

The O
ALL_CAP I-GENE
gene I-GENE
RARE O
NUM O
nt O
that O
are O
predicted O
to O
encode O
an O
88 O
- O
amino O
- O
acid O
( O
RARE O
) O
protein O
. O

We O
find O
that O
beta I-GENE
II I-GENE
PKC I-GENE
phosphorylates O
nuclear I-GENE
envelope I-GENE
RARE I-GENE
B I-GENE
RARE O
10 O
- O
20 O
times O
the O
rate O
of O
alpha I-GENE
PKC I-GENE
, O
whereas O
both O
kinases O
phosphorylate O
RARE I-GENE
RARE I-GENE
B I-GENE
RARE O
similar O
rates O
. O

Regulation O
of O
RARE I-GENE
hormone I-GENE
- I-GENE
related I-GENE
protein I-GENE
( O
ALL_CAP I-GENE
) O
gene O
RARE O
. O

These O
results O
demonstrate O
that O
a O
diverse O
set O
of O
RARE O
- O
terminal O
sequence O
motifs O
and O
posttranslational O
modifications O
lead O
to O
RARE O
Ras I-GENE
proteins I-GENE
in O
yeast O
. O

We O
conclude O
that O
c I-GENE
- I-GENE
Abl I-GENE
activates O
c I-GENE
- I-GENE
myc I-GENE
transcription O
indirectly O
with O
RARE O
requirement O
RARE O
DNA O
binding O
by O
c I-GENE
- I-GENE
Abl I-GENE
. O

RARE O
- O
RARE O
: O
RARE O
RARE O
responded O
to O
RARE O
with O
little O
RARE O
and O
long O
RARE O
( O
4 O
- O
11 O
ms O
). O

The O
highly O
RARE O
RARE O
RARE O
, O
which O
is O
involved O
in O
heterodimerization O
, O
appears O
to O
participate O
in O
the O
receptor O
- O
inhibitor O
interaction O
, O
suggesting O
that O
the O
inhibitor O
is O
a O
related O
RARE O
of O
the O
receptor O
gene O
family O
. O

Here O
we O
show O
that O
RARE O
RARE O
of O
ALL_CAP O
genes O
in O
RARE O
, O
a O
RARE O
RARE O
, O
the O
ALL_CAP O
and O
TATA O
elements O
are O
essential O
, O
but O
not O
sufficient O
, O
RARE O
transcription O
. O

RARE O
DNA O
rearrangement O
occurs O
RARE O
the O
development O
of O
the O
somatic O
RARE O
from O
the O
RARE O
line O
RARE O
in O
RARE O
RARE O
. O

An O
in O
vitro O
binding O
site O
selection O
procedure O
was O
used O
to O
determine O
DNA O
sequences O
preferentially O
RARE O
by O
wild I-GENE
- I-GENE
type I-GENE
ALL_CAP I-GENE
and O
chimeric O
NUM I-GENE
- O
ALL_CAP I-GENE
proteins O
isolated O
from O
various O
t O
( O
NUM O
; O
19 O
)- O
RARE O
leukemias O
. O

The O
Oct I-GENE
- I-GENE
2 I-GENE
RARE O
- O
rich O
and O
proline O
- O
rich O
activation O
domains O
can O
RARE O
with O
each O
other O
or O
RARE O
of O
themselves O
to O
activate O
transcription O
. O

Binding O
of O
NUM I-GENE
small I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
( O
snRNP O
) O
to O
the O
pre O
- O
mRNA O
is O
an O
early O
and O
important O
step O
in O
spliceosome O
assembly O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
NUM I-GENE
plays O
an O
essential O
role O
in O
RARE O
segregation O
. O

RARE O
, O
RARE O
. O

Our O
results O
indicate O
that O
the O
KRAB I-GENE
domain I-GENE
present O
in O
the O
non O
- O
finger O
region O
of O
many O
ALL_CAP I-GENE
genes I-GENE
RARE O
transcription O
possibly O
due O
to O
specific O
protein O
- O
protein O
interactions O
between O
the O
KRAB I-GENE
- I-GENE
A I-GENE
domain I-GENE
and O
RARE O
of O
the O
proximal O
transcriptional O
apparatus O
. O

RARE O
RARE O
and O
cardiovascular O
reactivity O
. O

The O
diagnostic O
significance O
of O
RARE I-GENE
RARE I-GENE
antibodies O
in O
the O
cardiac O
muscle O
in O
non O
- O
RARE O
RARE O
diseases O

According O
to O
the O
results O
of O
assays O
obtained O
with O
the O
use O
of O
assay O
RARE O
ALL_CAP O
ELISA O
and O
ALL_CAP O
HCV O
ALL_CAP O
( O
ALL_CAP O
RARE O
the O
detection O
rate O
of O
anti I-GENE
- I-GENE
HCV I-GENE
- I-GENE
NUM I-GENE
- I-GENE
3 I-GENE
among O
RARE O
RARE O
donors O
in O
RARE O
was O
1 O
. O
37 O
% O
and O
was O
not O
different O
from O
that O
among O
HBsAg I-GENE
carriers O
( O
1 O
. O
8 O
%) O
and O
among O
donors O
with O
anti I-GENE
- I-GENE
HCV I-GENE
- I-GENE
NUM I-GENE
- I-GENE
3 I-GENE
in O
the O
RARE O
( O
1 O
. O
6 O
%) O
( O
p O
< O
NUM O
. O
01 O
). O

We O
examined O
the O
hypothesis O
that O
the O
coronary O
RARE O
responses O
to O
RARE O
( O
ALL_CAP O
RARE O
RARE O
( O
ALL_CAP O
RARE O
and O
RARE O
RARE O
( O
ALL_CAP O
) O
are O
RARE O
through O
RARE O
effects O
on O
the O
resting O
RARE O
oxide O
( O
ALL_CAP O
)- O
dependent O
vasodilator O
tone O
that O
RARE O
adrenergic O
RARE O
activity O
in O
the O
RARE O
dog O
. O

Significant O
alterations O
in O
ALL_CAP O
results O
and O
serum I-GENE
CRP I-GENE
concentration O
, O
compared O
with O
baseline O
values O
, O
were O
RARE O
in O
dogs O
of O
the O
control O
group O
. O

These O
RARE O
RARE O
variants O
were O
detected O
in O
RNA O
isolated O
from O
several O
sources O
, O
including O
RARE O
RARE O
tissue O
and O
an O
established O
line O
of O
RARE O
cells O
( O
ALL_CAP O
). O

RARE O
- O
RARE O
- O
Y O
RARE O
severely O
RARE O
emptying O
of O
the O
gallbladder O
. O

RARE O
- O
RARE O
experiments O
on O
RARE O
and O
on O
human O
RARE O
muscles O
in O
vivo O
are O
presented O
. O

RARE O
RARE O
variation O
in O
peak O
ALL_CAP O
plasma O
levels O
( O
91 O
- O
NUM O
RARE O
/ O
ml O
) O
was O
seen O
, O
with O
the O
plasma O
RARE O
- O
life O
( O
t1 O
/ O
2 O
alpha O
) O
being O
RARE O
57 O
min O
in O
patients O
given O
135 O
- O
180 O
mg O
/ O
m2 O
ALL_CAP O
. O

The O
maximal O
effect O
was O
seen O
RARE O
NUM O
RARE O
/ O
ml O
ALL_CAP I-GENE
, O
with O
a O
time O
RARE O
of O
about O
5 O
h O
. O

NUM I-GENE
encodes O
an O
essential O
RARE O
of O
the O
yeast O
RARE O
pole O
body O
( O
SPB O
) O
that O
is O
required O
RARE O
RARE O
and O
SPB O
duplication O
. O

NUM I-GENE
is O
required O
RARE O
SPB O
duplication O
and O
encodes O
a O
calmodulin I-GENE
- I-GENE
like I-GENE
protein I-GENE
that O
is O
most O
closely O
related O
to O
RARE I-GENE
/ O
RARE I-GENE
, O
a O
protein O
associated O
with O
the O
RARE O
basal O
body O
. O

During O
transcript O
RARE O
, O
the O
sizes O
of O
the O
DNA O
footprint O
and O
the O
single O
- O
RARE O
transcription O
RARE O
vary O
markedly O
among O
transcription O
complexes O
RARE O
RARE O
different O
template O
positions O
. O

The O
newly O
RARE O
RARE O
RARE O
. O

All O
our O
patients O
had O
polyps O
, O
NUM O
( O
54 O
%) O
had O
asthma O
, O
12 O
( O
NUM O
%) O
had O
RARE O
sensitivity O
, O
20 O
( O
65 O
%) O
had O
RARE O
, O
and O
9 O
( O
NUM O
%) O
had O
increased O
RARE O
IgE I-GENE
levels O
. O

Ras I-GENE
- I-GENE
and I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
- I-GENE
responsive I-GENE
protein I-GENE
kinases I-GENE
that O
phosphorylate O
c I-GENE
- I-GENE
Jun I-GENE
on O
serine O
residues O
RARE O
positions O
NUM O
and O
NUM O
and O
stimulate O
its O
transcriptional O
activity O
have O
been O
identified O
. O

A O
short O
sequence O
surrounding O
the O
major O
JNK I-GENE
RARE O
site O
of O
c I-GENE
- I-GENE
Jun I-GENE
is O
RARE O
in O
c I-GENE
- I-GENE
Fos I-GENE
and O
is O
part O
of O
its O
activation O
domain O
, O
suggesting O
that O
c I-GENE
- I-GENE
Fos I-GENE
may O
be O
similarly O
regulated O
. O

c I-GENE
- I-GENE
Fos I-GENE
transcriptional O
activity O
RARE O
by O
H I-GENE
- I-GENE
Ras I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
distinct O
from O
JNK I-GENE
and O
ERK I-GENE
. O

A O
new O
generation O
of O
RARE O
RARE O
tools O
RARE O
RARE O
: O
the O
example O
of O
the O
RARE O
ALL_CAP O
RARE O
. O

RARE O
features O
of O
this O
model O
are O
RARE O
of O
the O
DNA O
double O
helix O
and O
RARE O
of O
operator O
sites O
with O
repressor O
domains O
RARE O
sequence O
homologies O
with O
the O
helix O
- O
RARE O
- O
helix O
( O
ALL_CAP O
) O
motifs O
of O
other O
DNA O
- O
binding O
proteins O
. O

The O
partial O
ORF O
was O
found O
to O
be O
identical O
to O
the O
C O
terminus O
of O
NUM I-GENE
. O

The O
partial O
ORF O
was O
found O
to O
be O
identical O
to O
the O
C O
terminus O
of O
NUM I-GENE
. O

The O
binding O
of O
transcription O
factor O
AP I-GENE
- I-GENE
1 I-GENE
and O
vitamin I-GENE
D I-GENE
receptor I-GENE
( O
VDR I-GENE
) O
to O
the O
composite O
AP I-GENE
- I-GENE
1 I-GENE
RARE I-GENE
vitamin I-GENE
- I-GENE
D I-GENE
- I-GENE
responsive I-GENE
promoter I-GENE
region O
( O
AP I-GENE
- I-GENE
1 I-GENE
+ I-GENE
ALL_CAP I-GENE
) O
of O
the O
human I-GENE
RARE I-GENE
gene I-GENE
was O
characterized O
in O
RARE I-GENE
- O
producing O
( O
ALL_CAP O
- O
NUM O
) O
and O
non O
- O
producing O
( O
NUM O
- O
RARE O
, O
RARE O
- O
2 O
) O
human O
osteosarcoma O
cell O
lines O
. O

RARE O
detection O
of O
this O
mutation O
is O
achieved O
by O
RARE O
digestion O
of O
PCR O
- O
amplified O
genomic O
DNA O
; O
a O
RARE O
primer O
combined O
with O
the O
point O
mutation O
RARE O
a O
NUM I-GENE
RARE I-GENE
site I-GENE
. O

RARE I-GENE
type I-GENE
and I-GENE
mutant I-GENE
Epo I-GENE
cDNAs I-GENE
were O
transiently O
RARE O
RARE O
high O
levels O
in O
NUM O
and O
NUM O
cells O
. O

OBJECTIVE O
RARE O
To O
assess O
the O
risk O
of O
hepatitis O
A O
in O
RARE O
RARE O
and O
to O
RARE O
RARE O
measures O
. O

The O
bactericidal O
effect O
of O
RARE O
against O
RARE O
cells O
was O
found O
to O
be O
considerably O
RARE O
by O
increasing O
the O
concentrations O
of O
the O
RARE O
. O

Expression O
of O
NUM I-GENE
cDNA I-GENE
in O
S O
. O
pombe O
suppresses O
the O
NUM I-GENE
mutation O
. O

Use O
of O
RARE O
- O
RARE O
ALL_CAP O
RARE O
RARE O
anesthesia O
in O
minor O
surgery O

2 O
. O

The O
immune O
response O
of O
past O
- O
infection O
of O
RARE O
in O
the O
patients O
of O
ALL_CAP O
is O
rather O
remarkable O
. O

RARE O
effect O
on O
deep O
receptors O
was O
not O
limited O
to O
one O
point O
but O
within O
a O
certain O
area O
, O
namely O
distant O
effect O
existed O
. O

RARE O
ALL_CAP O
activity O
correlates O
with O
RARE O
RARE O
in O
HIV O
- O
patients O
with O
RARE O
- O
resistant O
pulmonary O
tuberculosis O
. O

RARE O
history O
and O
RARE O
oxygen O
saturation O
( O
SaO2 O
) O
was O
recorded O
in O
all O
of O
them O
. O

( O
ALL_CAP I-GENE
P O
< O
NUM O
. O
05 O
, O
ALL_CAP I-GENE
/ O
FSH I-GENE
P O
< O
NUM O
. O
01 O
). O

The O
relative O
R O
- O
and O
L O
- O
brain O
weights O
were O
found O
to O
be O
inversely O
related O
to O
the O
relative O
R O
- O
L O
brain O
RARE O
only O
in O
the O
ALL_CAP O
female O
cats O
with O
R O
- O
L O
brain O
RARE O
smaller O
than O
zero O
( O
testosterone O
in O
males O
, O
estrogen O
in O
females O
). O

This O
mode O
of O
RARE O
complex O
formation O
is O
in O
contrast O
to O
the O
one O
seen O
in O
the O
promoter O
of O
the O
c I-GENE
- I-GENE
fos I-GENE
RARE I-GENE
, O
where O
formation O
of O
the O
RARE O
complex O
is O
dependent O
on O
the O
prior O
assembly O
of O
the O
serum I-GENE
response I-GENE
factor I-GENE
- I-GENE
DNA I-GENE
RARE I-GENE
complex I-GENE
. O

The O
LTR O
- O
binding O
activities O
of O
ALL_CAP I-GENE
, O
NUM I-GENE
/ I-GENE
EBP I-GENE
, O
and O
B I-GENE
- I-GENE
cell I-GENE
nuclear I-GENE
RARE I-GENE
protein I-GENE
were O
compared O
and O
mapped O
by O
gel O
shift O
, O
DNase I-GENE
I I-GENE
footprinting O
, O
and O
methylation O
interference O
assays O
. O

These O
results O
suggest O
that O
RARE O
- O
mRNA O
fusion O
in O
coronavirus O
transcription O
does O
not O
require O
direct O
RNA O
- O
RNA O
interaction O
between O
RARE O
sequences O
. O

These O
results O
suggest O
that O
RARE O
- O
mRNA O
fusion O
in O
coronavirus O
transcription O
does O
not O
require O
direct O
RNA O
- O
RNA O
interaction O
between O
RARE O
sequences O
. O

RARE O
virus O
- O
RARE O
, O
RARE O
full I-GENE
- I-GENE
length I-GENE
HPV I-GENE
- I-GENE
16 I-GENE
and I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
E2 I-GENE
proteins I-GENE
RARE O
a O
consensus O
E2 I-GENE
site I-GENE
with O
high O
specific O
affinities O
( O
RARE O
= O
RARE O
10 O
RARE O
9 O
) O
M O
) O
and O
RARE O
in O
vitro O
transcription O
RARE O
to O
RARE O
- O
to O
RARE O
. O

This O
RARE O
RARE O
transcript O
contained O
an O
RARE O
reading O
frame O
extending O
from O
the O
upstream O
ALL_CAP O
alpha O
11 O
- O
2 O
region O
to O
82 O
nucleotides O
RARE O
of O
the O
beginning O
of O
the O
TCR I-GENE
C I-GENE
alpha I-GENE
region I-GENE
, O
and O
potentially O
encoded O
a O
NUM O
amino O
acid O
polypeptide O
. O

In O
HeLa O
RARE O
fibroblast O
cell O
hybrids O
its O
RARE O
correlates O
with O
RARE O
. O

RARE O
characteristics O
and O
risk O
factor O
data O
RARE O
NUM O
, O
NUM O
RARE O
were O
studied O
to O
characterize O
the O
distribution O
of O
infection O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
and O
the O
use O
of O
RARE O
and O
testing O
RARE O
in O
RARE O
, O
RARE O
. O

Results O
indicate O
that O
ALL_CAP O
- O
ALL_CAP O
NUM O
differs O
from O
both O
human O
and O
RARE O
NUM O
in O
relative O
distances O
( O
measured O
in O
three O
dimensions O
) O
between O
RARE O
RARE O
termini O
. O

We O
describe O
NUM O
cases O
with O
RARE O
tumor O
< O
1 O
cm O
. O

Comparison O
with O
the O
bovine O
gene O
showed O
that O
the O
5 O
'- O
flanking O
region O
of O
the O
NUM I-GENE
gene I-GENE
has O
an O
RARE O
guanine O
- O
cytosine O
( O
ALL_CAP O
) O
rich O
region O
, O
including O
several O
binding O
motifs O
of O
transcriptional O
factors O
, O
such O
RARE O
NUM I-GENE
, O
AP I-GENE
- I-GENE
2 I-GENE
, O
and O
ALL_CAP I-GENE
. O

Structure O
, O
promoter O
analysis O
and O
chromosomal O
assignment O
of O
the O
human I-GENE
ALL_CAP I-GENE
gene I-GENE
. O

The O
RARE I-GENE
gene I-GENE
was O
RARE O
throughout O
the O
RARE O
life O
RARE O
with O
peaks O
in O
the O
1 O
. O
6 O
- O
kb O
mRNA O
levels O
RARE O
pre O
- O
RARE O
, O
RARE O
, O
and O
post O
- O
inversion O
. O

Thus O
, O
in O
stress O
- O
RARE O
RARE O
RARE O
RARE O
RARE O
RARE O
in O
ischemic O
RARE O
RARE O
, O
the O
main O
RARE O
links O
are O
outside O
the O
RARE O
, O
but O
they O
differ O
from O
those O
observed O
in O
ischemia O
. O

Here O
, O
we O
present O
genetic O
evidence O
in O
Saccharomyces O
cerevisiae O
RARE O
a O
RARE O
interaction O
between O
the O
ALL_CAP I-GENE
protein I-GENE
NUM I-GENE
, O
and O
the O
U6 I-GENE
and O
NUM I-GENE
RARE I-GENE
RARE I-GENE
. O

The O
consensus O
gene O
order O
deduced O
by O
RARE O
data O
from O
both O
RARE O
is O
NUM I-GENE
RARE O
RARE I-GENE
, O
NUM I-GENE
RARE O
NUM I-GENE
, O
RARE I-GENE
)- O
NUM I-GENE
- O
RARE I-GENE
RARE I-GENE
RARE O
NUM I-GENE
, O
RARE I-GENE
)- O
( O
NUM I-GENE
, O
NUM I-GENE
RARE O
NUM I-GENE
. I-GENE
2 I-GENE
, I-GENE
RARE I-GENE
, I-GENE
RARE I-GENE
)- O
RARE I-GENE
. O

The O
high O
level O
of O
transformation O
- O
associated O
deletions O
in O
the O
human O
YACs O
was O
RARE O
over O
10 O
- O
RARE O
when O
the O
RARE O
was O
a O
RARE O
- O
RARE O
RARE O
RARE O
RARE O
the O
NUM I-GENE
gene I-GENE
. O

In O
addition O
, O
the O
RARE O
region O
surrounding O
the O
ALL_CAP I-GENE
locus I-GENE
was O
mapped O
. O

These O
mutants O
had O
deletions O
of O
the O
extreme O
amino O
- O
terminal O
residues O
RARE O
far O
RARE O
amino O
acid O
RARE O
NUM O
. O

ALL_CAP O
OUTCOME O
ALL_CAP O
RARE O
Double O
- O
blind O
caffeine O
- O
withdrawal O
evaluation O
. O

Elimination O
of O
RARE O
antibodies O
in O
RARE O
RARE O

An O
8 O
- O
bp O
sequence O
( O
ALL_CAP O
) O
within O
the O
protected O
region O
shares O
significant O
homology O
with O
promoter O
sequences O
required O
RARE O
ethylene O
responsiveness O
from O
the O
RARE O
RARE O
- O
RARE O
NUM I-GENE
gene I-GENE
. O

We O
present O
evidence O
that O
DNA I-GENE
polymerase I-GENE
delta I-GENE
of I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
, O
an O
enzyme O
that O
is O
essential O
RARE O
viability O
and O
chromosomal O
replication O
, O
is O
also O
required O
RARE O
RARE O
RARE O
repair O
of O
RARE O
DNA O
methylation O
damage O
. O

We O
have O
identified O
two O
RARE O
' O
s O
RARE O
RARE O
( O
ALL_CAP O
) O
genes O
within O
the O
EcoRI I-GENE
- I-GENE
B I-GENE
fragment I-GENE
of O
ALL_CAP O
- O
ALL_CAP O
genomic O
DNA O
. O

RARE O
virus O
contains O
two O
copies O
of O
an O
early I-GENE
gene I-GENE
encoding O
a O
RARE O
RARE O
form O
of O
the O
type I-GENE
II I-GENE
TNF I-GENE
receptor I-GENE
. O

To O
determine O
whether O
NUM I-GENE
could O
activate O
the O
NUM O
promoter O
in O
the O
absence O
of O
IE1 I-GENE
, O
the O
NUM I-GENE
RARE O
reading O
frame O
was O
RARE O
under O
the O
control O
of O
the O
NUM I-GENE
promoter I-GENE
. O

RARE O
of O
each O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
motif I-GENE
in O
the O
ALL_CAP I-GENE
promoter I-GENE
gave O
substantially O
lowered O
levels O
of O
chloramphenicol I-GENE
RARE I-GENE
RARE O
, O
whereas O
mutagenesis O
of O
both O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
motifs I-GENE
resulted O
in O
the O
almost O
RARE O
RARE O
of O
RARE O
. O

DNase I-GENE
I I-GENE
footprinting O
analysis O
indicated O
that O
ALL_CAP I-GENE
binds O
to O
the O
NUM O
- O
bp O
ALL_CAP O
region O
of O
the O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
gene I-GENE
in O
which O
8 O
- O
bp O
palindromic O
sequences O
are O
centered O
. O

RARE O
8 O
- O
RARE O
RARE O
sequence O
( O
Drosophila O
DNA O
replication O
- O
related O
element O
) O
and O
specific O
binding O
factor O
involved O
in O
the O
RARE O
of O
Drosophila O
genes O
RARE O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
and O
RARE I-GENE
cell I-GENE
nuclear I-GENE
antigen I-GENE
. O

In O
addition O
, O
a O
RARE O
repeat O
polymorphism O
with O
a O
heterozygosity O
of O
NUM O
% O
RARE O
the O
RET I-GENE
locus I-GENE
and O
a O
RARE O
fragment O
length O
polymorphism O
with O
a O
heterozygosity O
of O
NUM O
% O
detected O
by O
a O
lambda O
clone O
from O
the O
NUM I-GENE
locus I-GENE
have O
been O
developed O
RARE O
high O
- O
resolution O
genetic O
linkage O
mapping O
and O
predictive O
diagnostic O
testing O
. O

However O
, O
ALL_CAP I-GENE
can O
be O
RARE O
efficiently O
from O
an O
internal O
promoter O
which O
appears O
to O
RARE O
within O
the O
3 O
' O
portion O
of O
ALL_CAP I-GENE
. O

Within O
the O
span O
of O
RARE O
region O
encoding O
the O
three O
RARE O
- O
loop O
RARE O
of O
mRNA O
secondary O
configuration O
, O
hot O
spots O
of O
RARE O
- O
RARE O
divergence O
were O
localized O
to O
RARE O
- O
out O
regions O
. O

Most O
, O
however O
, O
would O
RARE O
the O
RARE O
the O
full O
RARE O
about O
both O
diagnosis O
and O
prognosis O
. O

Previous O
studies O
showed O
that O
mutations O
in O
the O
NUM O
protein O
led O
to O
the O
slow O
release O
of O
aberrant O
, O
RARE O
- O
RARE O
infectious O
virions O
. O

RARE O
of O
RARE O
and O
vitamin O
NUM O
in O
patients O
with O
acute O
RARE O
RARE O
: O
a O
study O
of O
NUM O
patients O
with O
RARE O
RARE O
. O

Furthermore O
, O
this O
study O
demonstrates O
that O
RARE O
RARE O
with O
RARE O
RARE O
uniform O
local O
contraction O
RARE O
estimated O
by O
the O
increased O
ALL_CAP O
/ O
ALL_CAP O
ratio O
, O
a O
transition O
that O
could O
improve O
contraction O
efficacy O
. O

Effects O
of O
moderate O
hypercapnia O
on O
hypothermia O
RARE O
by O
cold O
He O
- O
NUM O
in O
rats O
. O

The O
ALL_CAP O
patterns O
of O
the O
isolates O
from O
RARE O
of O
these O
patients O
remained O
essentially O
unchanged O
( O
two O
strains O
showed O
one O
additional O
band O
) O
despite O
the O
development O
of O
drug O
resistance O
. O

We O
RARE O
that O
ovarian O
RARE O
is O
done O
only O
if O
there O
is O
a O
RARE O
indication O
after O
proper O
assessment O
of O
the O
RARE O
, O
and O
that O
women O
who O
have O
had O
ovarian O
RARE O
are O
followed O
RARE O
longer O
than O
RARE O
present O
. O

NUM O
did O
not O
induce O
any O
modifications O
of O
the O
RARE O
RARE O
, O
the O
RARE O
direct O
current O
or O
the O
frequency O
of O
the O
evoked O
RARE O
spikes O
. O

Activation O
of O
the O
RARE O
RARE I-GENE
- I-GENE
specific I-GENE
NUM I-GENE
gene I-GENE
in O
RARE O
- O
RARE O
RARE O
RARE O
RARE O
requires O
an O
upstream O
regulatory O
region O
that O
is O
part O
of O
a O
RARE O
sequence O
element O
( O
ALL_CAP O
) O
associated O
with O
all O
NUM I-GENE
/ O
NUM I-GENE
genes O
. O

A O
transcript O
of O
about O
2 O
kb O
is O
expected O
RARE O
each O
ALL_CAP I-GENE
. O

Mutations O
in O
a O
region O
RARE O
NUM O
to O
NUM O
bp O
RARE O
from O
the O
major O
transcription O
RARE O
site O
that O
shows O
good O
homology O
to O
a O
sequence O
in O
the O
RARE O
RARE O
of O
c I-GENE
- I-GENE
fos I-GENE
implicated O
RARE O
a O
negative O
regulatory O
element O
resulted O
in O
a O
significant O
increase O
in O
basal O
gene O
RARE O
but O
did O
not O
affect O
RARE O
. O

RARE O
RARE O

During O
exercise O
, O
the O
RARE O
- O
RARE O
relation O
was O
shifted O
toward O
the O
RARE O
and O
the O
slope O
RARE O
end O
- O
systolic O
RARE O
( O
RARE O
)] O
increased O
from O
7 O
. O
7 O
+/- O
2 O
. O
8 O
to O
12 O
. O
7 O
+/- O
4 O
. O
2 O
( O
SD O
) O
mmHg O
/ O
ml O
( O
P O
< O
NUM O
. O
05 O
). O

We O
show O
that O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
phosphorylate O
yeast I-GENE
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
in O
vitro O
and O
in O
vivo O
and O
functionally O
substitute O
RARE O
GCN2 I-GENE
protein I-GENE
to O
stimulate O
GCN4 I-GENE
translation O
in O
yeast O
. O

Double O
- O
staining O
confirmed O
that O
there O
were O
separate O
populations O
of O
NUM I-GENE
- O
positive O
macrophages O
and O
RARE I-GENE
- O
positive O
RARE O
. O

Interestingly O
, O
in O
the O
adult O
, O
RARE O
RARE O
patterns O
within O
the O
RARE O
in O
two O
lines O
appeared O
to O
RARE O
distinct O
anterior O
- O
posterior O
RARE O
. O

Southern O
analysis O
on O
genomic O
DNA O
isolated O
from O
tissues O
and O
cell O
lines O
from O
several O
mouse O
strains O
using O
NUM I-GENE
cDNA I-GENE
demonstrated O
that O
the O
NUM I-GENE
locus I-GENE
encoding O
NUM I-GENE
is O
a O
single O
copy O
gene O
of O
< O
or O
= O
NUM O
kb O
. O

The O
concentrations O
of O
plasma O
ACTH I-GENE
and O
cortisol O
increased O
by O
40 O
% O
and O
NUM O
% O
after O
ALL_CAP O
treatment O
, O
respectively O
. O

Instead O
, O
the O
results O
support O
the O
idea O
that O
RARE I-GENE
group I-GENE
products I-GENE
provide O
stable O
memory O
or O
imprinting O
of O
boundaries O
which O
are O
initially O
specified O
by O
RARE O
and O
RARE O
- O
RARE O
RARE O
. O

To O
investigate O
the O
RARE O
of O
RARE O
of O
the O
human I-GENE
NUM I-GENE
gene I-GENE
, O
the O
response O
of O
the O
NUM I-GENE
promoter I-GENE
to O
signals O
involved O
in O
cell O
RARE O
was O
examined O
. O

The O
tyrosine I-GENE
hydroxylase I-GENE
gene I-GENE
( O
ALL_CAP I-GENE
) O
contains O
a O
single O
copy O
of O
a O
consensus O
ALL_CAP O
RARE O
- O
NUM O
to O
- O
38 O
RARE O
RARE O
( O
bp O
) O
upstream O
of O
the O
transcription O
initiation O
site O
. O

RARE O
mosaic O
virus O
- O
RARE O
tobacco O
( O
RARE O
RARE O
RARE O
. O

RARE O
a O
stretch O
of O
NUM O
amino O
RARE O
, O
RARE O
the O
MADS I-GENE
domain I-GENE
, O
the O
two O
proteins O
are O
identical O
except O
RARE O
two O
conservative O
amino O
acid O
substitutions O
. O

Isolation O
and O
characterization O
of O
SRF I-GENE
RARE I-GENE
proteins I-GENE
. O

These O
data O
suggest O
that O
: O
( O
a O
) O
ALL_CAP I-GENE
RARE O
is O
RARE O
in O
the O
ALL_CAP O
, O
and O
( O
b O
) O
this O
reaction O
requires O
an O
RARE O
pH O
which O
is O
facilitated O
by O
a O
RARE I-GENE
- I-GENE
associated I-GENE
vacuolar I-GENE
- I-GENE
type I-GENE
ATPase I-GENE
. O

RARE O
, O
a O
dopamine I-GENE
receptor I-GENE
agonist O
, O
has O
been O
shown O
, O
in O
RARE O
experiments O
, O
to O
improve O
RARE O
perfusion O
. O

Clinical O
aspects O
of O
early O
increase O
in O
serum O
gamma I-GENE
- I-GENE
glutamyl I-GENE
transferase I-GENE
in O
cerebral O
infarction O
. O

In O
the O
3 O
' O
flanking O
region O
of O
the O
NUM I-GENE
kDa I-GENE
RARE I-GENE
gene I-GENE
, O
several O
ALL_CAP O
- O
like O
sequences O
and O
a O
sequence O
resembling O
the O
mammalian O
ALL_CAP O
- O
rich O
sequence O
are O
present O
around O
the O
polyadenylation O
sites O
. O

The O
RARE O
RARE O
concentration O
in O
the O
summer O
( O
1990 O
) O
period O
ranged O
between O
8 O
and O
NUM O
RARE O
m O
- O
3 O
, O
while O
in O
the O
RARE O
( O
1989 O
- O
1990 O
) O
it O
ranged O
between O
20 O
and O
NUM O
RARE O
m O
- O
3 O
RARE O
the O
RARE O
year O
of O
measurements O
or O
between O
8 O
and O
92 O
RARE O
m O
- O
3 O
in O
the O
summer O
( O
1991 O
) O
period O
and O
between O
12 O
and O
119 O
RARE O
m O
- O
3 O
in O
the O
RARE O
( O
1990 O
- O
1991 O
) O
RARE O
the O
second O
year O
of O
measurements O
. O

The O
results O
indicate O
that O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
are O
part O
of O
a O
regulatory O
cascade O
in O
which O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
activate O
RARE O
of O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
, O
a O
putative O
RARE I-GENE
factor I-GENE
, O
induces O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
responsive I-GENE
genes I-GENE
. O

ALL_CAP I-GENE
is O
an O
iron O
- O
dependent O
sequence O
- O
specific O
DNA O
- O
binding O
protein O
that O
binds O
to O
the O
RARE I-GENE
operator I-GENE
, O
an O
inverted O
- O
repeat O
nucleotide O
sequence O
RARE O
upstream O
from O
the O
RARE I-GENE
RARE I-GENE
gene I-GENE
. O

RARE I-GENE
( O
AVP I-GENE
RARE O
the O
RARE O
hormone O
, O
is O
a O
cyclic O
RARE O
that O
acts O
through O
binding O
to O
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
specific I-GENE
membrane I-GENE
receptors I-GENE
RARE O
divided O
into O
three O
subtypes O
( O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
) O
RARE O
to O
distinct O
second O
RARE O
. O

These O
results O
confirmed O
that O
RARE O
of O
the O
RARE O
peptide O
is O
the O
last O
step O
in O
RARE I-GENE
RARE O
and O
is O
necessary O
to O
generate O
a O
biologically O
RARE O
peptide O
. O

When O
the O
promoter O
region O
was O
RARE O
with O
a O
heterologous O
reporter O
gene O
, O
we O
found O
that O
the O
promoter O
region O
is O
inducible O
by O
both O
RARE I-GENE
( O
RARE I-GENE
- I-GENE
alpha I-GENE
and I-GENE
- I-GENE
gamma I-GENE
) O
and O
RARE I-GENE
regulatory I-GENE
factor I-GENE
1 I-GENE
. O

RARE I-GENE
- I-GENE
B I-GENE
. I-GENE
RARE I-GENE
, O
anti I-GENE
- I-GENE
B I-GENE
. I-GENE
RARE I-GENE
and O
anti I-GENE
- I-GENE
B I-GENE
. I-GENE
RARE I-GENE
antibodies I-GENE
, O
tested O
by O
the O
indirect O
RARE O
assay O
( O
ALL_CAP O
RARE O
were O
detected O
in O
10 O
. O
8 O
, O
16 O
. O
1 O
and O
8 O
. O
2 O
% O
of O
the O
serum O
samples O
tested O
, O
and O
confirmed O
by O
ALL_CAP O
- O
ALL_CAP O
in O
1 O
. O
3 O
, O
1 O
. O
3 O
and O
1 O
. O
NUM O
%, O
respectively O
. O

The O
approach O
RARE O
from O
a O
recently O
described O
strategy O
RARE O
making O
RARE O
from O
five O
overlapping O
ALL_CAP O
cosmid O
- O
RARE O
RARE O
( O
B O
. O

Evaluation O
of O
RARE O
RARE O
dental O
RARE O
in O
patients O
with O
RARE O
disorders O
. O

Comparative O
analysis O
with O
an O
RARE O
RARE O
and O
RARE I-GENE
GnRH I-GENE
was O
carried O
out O
in O
NUM O
normal O
subjects O
, O
14 O
patients O
with O
RARE O
and O
20 O
ones O
with O
secondary O
RARE O
, O
and O
in O
5 O
patients O
with O
clinical O
signs O
of O
RARE O
insufficiency O
and O
RARE O
diagnosis O
in O
order O
to O
elucidate O
the O
pituitary I-GENE
gonadotropin I-GENE
RARE O
. O

All O
other O
normal O
and O
transformed O
RARE O
and O
RARE O
cell O
lines O
and O
normal O
tissues O
were O
negative O
RARE O
ALL_CAP I-GENE
RARE O
except O
RARE O
the O
brain O
, O
RARE O
unique O
4 O
. O
NUM O
- O
and O
6 O
. O
1 O
- O
kb O
transcripts O
were O
detected O
. O

The O
cis O
- O
acting O
regulatory O
properties O
of O
an O
NUM O
bp O
promoter O
fragment O
of O
a O
B O
. O
RARE O
RARE I-GENE
gene I-GENE
were O
examined O
by O
analysis O
of O
beta I-GENE
- I-GENE
glucuronidase I-GENE
( O
GUS I-GENE
) O
RARE O
in O
transgenic O
tobacco O
RARE O
containing O
an O
RARE I-GENE
promoter I-GENE
- O
GUS I-GENE
transcriptional O
fusion O
. O

This O
indicates O
that O
the O
mechanism O
by O
which O
ALL_CAP O
blocks O
rapid O
RARE O
of O
RARE I-GENE
mRNA I-GENE
in O
vivo O
is O
not O
RARE O
by O
preventing O
its O
translation O
and O
suggests O
the O
involvement O
of O
an O
altered O
RARE O
- O
factor O
. O

L O
., O
RARE O
, O
ALL_CAP O
. O
& O
RARE O
, O
G O
. O

Increasing O
the O
extracellular O
RARE O
concentration O
RARE O
RARE O
contractility O
in O
a O
dose O
- O
dependent O
manner O
in O
both O
control O
and O
RARE O
RARE O
. O

Structural O
organization O
of O
the O
gene O
encoding O
the O
human I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
and O
RARE O
of O
the O
recombinant O
protein O
in O
Escherichia O
coli O
. O

The O
sequence O
has O
a O
NUM O
- O
bp O
RARE O
reading O
frame O
encoding O
a O
protein O
of O
NUM O
amino O
RARE O
. O

Western O
blotting O
( O
RARE O
) O
with O
an O
RARE O
to O
a O
partial O
SOD I-GENE
RARE O
in O
Escherichia O
coli O
revealed O
two O
proteins O
with O
estimated O
RARE O
masses O
of O
19 O
and O
29 O
kDa O
. O

The O
gene O
organization O
of O
ALL_CAP I-GENE
RNA I-GENE
- I-GENE
1 I-GENE
is O
similar O
to O
those O
of O
RARE O
RARE O
RARE O
mosaic O
( O
ALL_CAP O
) O
and O
RARE O
RARE O
RARE O
mosaic O
( O
ALL_CAP O
) O
RARE O
with O
the O
exception O
that O
ALL_CAP I-GENE
RNA I-GENE
- I-GENE
1 I-GENE
contains O
the O
additional O
3 O
'- O
terminal O
ORF O
. O

Members O
of O
the O
RARE I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
factor I-GENE
2 I-GENE
( O
MEF2 I-GENE
) O
family O
of O
transcription O
factors O
bind O
a O
RARE O
A O
/ O
T O
- O
rich O
sequence O
in O
the O
control O
regions O
of O
numerous O
muscle O
- O
specific O
genes O
. O

We O
have O
previously O
shown O
that O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
represses O
HIV O
- O
1 O
transcription O
by O
inhibiting O
the O
binding O
of O
TFIID I-GENE
to O
the O
TATA O
box O
. O

These O
results O
RARE O
an O
important O
role O
RARE O
RARE I-GENE
in O
RNA O
production O
by O
demonstrating O
its O
ability O
to O
clear O
the O
RARE O
sites O
of O
class O
III O
templates O
, O
thereby O
RARE O
efficient O
use O
of O
transcription O
complexes O
by O
pol I-GENE
III I-GENE
. O

The O
films O
were O
analyzed O
using O
a O
scanning O
RARE O
- O
RARE O
laser O
RARE O
with O
a O
small O
RARE O
of O
5 O
- O
10 O
microns O
. O

The O
RARE O
method O
has O
proven O
to O
be O
an O
accurate O
and O
rapid O
method O
of O
analysis O
and O
could O
be O
easily O
incorporated O
into O
a O
quality O
RARE O
program O
. O

RARE O
genomic O
RNA O
RARE O
these O
reactions O
was O
obtained O
directly O
from O
fecal O
specimens O
of O
RARE O
infant O
rats O
. O

ALL_CAP I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
was O
present O
in O
equivalent O
levels O
in O
both O
RARE O
cell O
lines O
, O
but O
RARE O
a O
low O
level O
in O
ALL_CAP O
- O
P1 O
cells O
. O

RARE I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
alpha I-GENE
) O
is O
one O
of O
several O
autocrine O
/ O
RARE O
factors O
known O
to O
exert O
potent O
RARE O
effects O
on O
bone O
. O

We O
have O
investigated O
the O
role O
of O
cellular I-GENE
p21ras I-GENE
protein I-GENE
in O
insulin I-GENE
and O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
I I-GENE
( O
IGF I-GENE
- I-GENE
I I-GENE
) O
RARE O
pathways O
. O

The O
lack O
of O
the O
C2 I-GENE
domain O
of O
the O
Ca I-GENE
( I-GENE
2 I-GENE
RARE I-GENE
dependent I-GENE
RARE I-GENE
and O
the O
presence O
of O
a O
unique O
NH2 O
- O
terminal O
sequence O
with O
a O
RARE O
signal O
peptide O
and O
a O
transmembrane O
domain O
suggest O
that O
PKC I-GENE
mu I-GENE
is O
a O
novel O
RARE O
of O
the O
subgroup O
of O
atypical O
RARE I-GENE
. O

Moreover O
, O
we O
observed O
that O
the O
function O
of O
T3R I-GENE
- O
RXR I-GENE
RARE O
on O
response O
elements O
composed O
of O
two O
RARE O
- O
sites O
in O
a O
directly O
RARE O
orientation O
RARE O
by O
4 O
nucleotides O
is O
determined O
in O
major O
parts O
by O
the O
5 O
'- O
flanking O
sequence O
of O
the O
upstream O
RARE O
- O
site O
. O

However O
, O
three O
NUM I-GENE
mutants I-GENE
that O
were O
moderately O
RARE O
in O
stimulating O
PI O
turnover O
displayed O
normal O
RARE O
, O
suggesting O
distinct O
mechanisms O
. O

Furthermore O
, O
in O
vitro O
RARE O
reaction O
RARE O
supplemented O
with O
the O
20 O
- O
nt O
sense O
RNA O
transcript O
resulted O
in O
stabilization O
of O
NUM I-GENE
RARE I-GENE
. O

Deletion O
analyses O
of O
the O
NUM I-GENE
ORF I-GENE
- I-GENE
A I-GENE
and O
the O
use O
of O
promoter O
constructs O
further O
mapped O
an O
internal O
RARE O
promoter O
within O
the O
NUM I-GENE
sequence I-GENE
that O
can O
direct O
the O
RARE O
of O
the O
RARE O
- O
activating O
protein O
. O

RARE O
of O
these O
had O
counterparts O
in O
the O
US O
of O
herpes O
simplex O
type O
1 O
( O
HSV O
- O
1 O
RARE O
pseudorabies O
virus O
( O
ALL_CAP O
RARE O
and O
RARE O
RARE O
type O
1 O
( O
ALL_CAP O
- O
1 O
). O

The O
RARE O
amino O
acid O
sequence O
of O
the O
RARE I-GENE
ALL_CAP I-GENE
protein I-GENE
indicates O
a O
significant O
difference O
in O
the O
metal O
cofactor O
requirement O
from O
the O
RARE O
- O
RARE O
RARE O
, O
which O
was O
confirmed O
by O
overexpression O
and O
biochemical O
analysis O
. O

METHODS O
ALL_CAP O
RESULTS O
: O
In O
NUM O
RARE O
- O
chest O
, O
anesthetized O
dogs O
, O
progressive O
RARE O
artery O
stenosis O
led O
to O
a O
RARE O
decrease O
of O
RARE O
artery O
resting O
and O
RARE O
flow O
, O
coronary O
flow O
reserve O
, O
and O
RARE O
angiographic O
mean O
transit O
time O
RARE O
- O
1 O
( O
P O
< O
. O
01 O
). O

However O
, O
a O
correlation O
was O
observed O
between O
ALL_CAP O
levels O
of O
ALL_CAP I-GENE
- I-GENE
8 I-GENE
with O
those O
of O
RARE O
, O
ALL_CAP I-GENE
, O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
and O
glucose O
. O

Sodium O
- O
RARE O
- O
RARE O
acute O
RARE O
pancreatitis O
does O
not O
affect O
RARE O
oxygenation O
in O
pigs O
. O

Although O
inactive O
in O
cells O
under O
normal O
conditions O
, O
the O
ALL_CAP I-GENE
gene I-GENE
is O
markedly O
RARE O
by O
a O
variety O
of O
cellular O
stresses O
, O
including O
nutrient O
deprivation O
and O
metabolic O
RARE O
. O

The O
ALL_CAP I-GENE
genes I-GENE
code O
RARE O
two O
almost O
identical O
NUM O
- O
RARE O
proteins O
which O
do O
not O
have O
any O
homology O
with O
sequences O
present O
in O
data O
libraries O
. O

RARE O
analysis O
of O
the O
disrupted O
mutant O
demonstrated O
the O
accumulation O
of O
RARE O
, O
indicating O
a O
RARE O
of O
NUM I-GENE
activity O
. O

The O
previously O
described O
RARE O
translation O
of O
RARE O
NUM I-GENE
mRNA I-GENE
from O
its O
two O
RARE O
AUG O
codons O
and O
the O
two O
RARE O
NUM I-GENE
genes I-GENE
in O
Arabidopsis O
probably O
provide O
two O
mechanisms O
RARE O
generating O
the O
four O
copies O
of O
NUM I-GENE
/ I-GENE
chloroplast I-GENE
RARE I-GENE
, O
RARE O
different O
from O
those O
RARE O
in O
RARE O
. O

In O
these O
experiments O
we O
begin O
to O
study O
the O
RARE O
functions O
of O
the O
alpha I-GENE
7 I-GENE
cytoplasmic I-GENE
domain I-GENE
by O
analyzing O
homologies O
between O
the O
rat O
and O
human O
sequences O
, O
by O
immunologic O
studies O
using O
an O
anti O
- O
cytoplasmic O
domain O
RARE O
, O
and O
by O
identifying O
two O
alternate O
forms O
. O

The O
alpha O
NUM O
form O
RNA O
contains O
an O
additional O
NUM O
nucleotides O
compared O
to O
the O
B O
form O
, O
and O
a O
common O
coding O
region O
in O
the O
A O
and O
B O
form O
RNAs O
is O
used O
in O
alternate O
reading O
frames O
. O

In O
order O
to O
evaluate O
the O
function O
of O
the O
RARE O
- O
pituitary O
- O
thyroid O
( O
ALL_CAP O
)- O
axis O
in O
RARE O
depression O
, O
the O
authors O
measured O
basal O
NUM O
plasma O
levels O
of O
free O
thyroxine O
( O
NUM O
RARE O
free O
RARE O
( O
NUM O
RARE O
and O
thyroid I-GENE
stimulating I-GENE
hormone I-GENE
( O
ALL_CAP I-GENE
) O
by O
means O
of O
the O
new O
, O
RARE O
assays O
( O
ALL_CAP O
- O
ALL_CAP O
) O
in O
NUM O
healthy O
controls O
, O
NUM O
minor O
, O
NUM O
simple O
major O
, O
and O
57 O
RARE O
depressed O
subjects O
. O

ALL_CAP I-GENE
function O
in O
a O
5 O
' O
LTR O
- O
RARE O
gene O
RARE O
assay O
correlates O
with O
the O
ability O
of O
both O
NUM I-GENE
and O
NUM I-GENE
to O
interact O
with O
5 O
' O
LTR O
RNA O
in O
vitro O
. O

RARE O
levels O
of O
RARE I-GENE
T I-GENE
and O
the O
activity O
of O
ALL_CAP I-GENE
- I-GENE
MB I-GENE
were O
measured O
6 O
, O
12 O
, O
NUM O
and O
NUM O
h O
after O
aortic O
RARE O
. O

RARE O
of O
drug O
delivery O
is O
a O
RARE O
method O
to O
avoid O
this O
problem O
. O

The O
epidemic O
occurred O
in O
a O
group O
of O
NUM O
community O
members O
( O
NUM O
men O
and O
3 O
women O
, O
mean O
age O
, O
NUM O
. O
9 O
RARE O
3 O
years O
) O
living O
and O
working O
together O
, O
who O
underwent O
acute O
and O
RARE O
serologic O
tests O
RARE O
RARE O
RARE O
, O
RARE O
RARE O
, O
RARE O
, O
adenovirus O
, O
RARE O
RARE O
, O
and O
Chlamydia O
RARE O
. O

MEK I-GENE
itself O
is O
activated O
via O
serine O
RARE O
by O
upstream I-GENE
activator I-GENE
kinases I-GENE
, O
including O
c I-GENE
- I-GENE
RARE I-GENE
, O
mos I-GENE
and O
MEK I-GENE
kinase I-GENE
. O

Genomic O
DNA O
RARE O
containing O
the O
T I-GENE
- I-GENE
cell I-GENE
- I-GENE
specific I-GENE
human I-GENE
ALL_CAP I-GENE
gene I-GENE
were O
isolated O
. O

Members O
of O
ALL_CAP I-GENE
are O
also O
present O
in O
the O
complement I-GENE
C2 I-GENE
gene I-GENE
RARE O
about O
20 O
kilobases O
upstream O
of O
NUM I-GENE
in O
the O
HLA I-GENE
and O
in O
the O
cytochrome I-GENE
NUM I-GENE
gene I-GENE
. O

Expression O
of O
the O
RARE O
RARE O
RARE O
enzyme O
RARE I-GENE
is O
directed O
by O
multiple O
promoters O
. O

European O
RARE O
RARE O
' O
s O
RARE O
RARE O
Study O
Group O
. O

The O
c I-GENE
- I-GENE
myc I-GENE
and O
skeletal I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
gene I-GENE
promoters I-GENE
contain O
YY1 I-GENE
binding I-GENE
sites I-GENE
thought O
to O
act O
either O
RARE O
positive O
or O
negative O
cis O
- O
acting O
elements O
. O

ALL_CAP I-GENE
- I-GENE
1 I-GENE
produced O
in O
E O
. O
coli O
RARE O
a O
fusion O
protein O
with O
GST I-GENE
specifically O
interacted O
with O
single O
- O
RARE O
ALL_CAP O
( O
RARE O
myc I-GENE
( O
H O
- O
P O
) O
21 O
) O
and O
ALL_CAP O
- O
ALL_CAP O
( O
in O
minus O
myc I-GENE
( O
H O
- O
P O
) O
21 O
RARE O
the O
consensus O
of O
which O
can O
be O
referred O
to O
RARE O
A O
/ O
ALL_CAP O
/ O
TA O
/ O
ALL_CAP O
. O

Within O
12 O
hours O
after O
MR O
tomography O
the O
patients O
were O
surgically O
explored O
, O
RARE O
and O
if O
necessary O
RARE O
. O

RARE O
NUM I-GENE
spontaneous O
alleles O
are O
good O
suppressors O
but O
have O
a O
normal O
growth O
rate O
, O
suggesting O
that O
the O
NUM I-GENE
protein I-GENE
may O
have O
two O
distinct O
functions O
. O

RARE O
of O
RARE O
experience O
. O

The O
results O
show O
that O
both O
the O
amino O
and O
RARE O
termini O
of O
the O
NS1 I-GENE
protein I-GENE
molecule I-GENE
and O
the O
RARE O
RARE O
residues O
NUM O
and O
NUM O
are O
essential O
RARE O
RARE O
formation O
. O

The O
3 O
' O
UTR O
has O
several O
stable O
RARE O
that O
are O
flanked O
by O
single O
- O
RARE O
( O
A O
/ O
ALL_CAP O
) O
ALL_CAP O
sequences O
. O

Moreover O
, O
the O
major O
site O
of O
transcriptional O
initiation O
, O
which O
was O
localized O
by O
primer O
extension O
NUM O
bp O
upstream O
of O
the O
5 O
' O
end O
of O
the O
Ets I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
clone I-GENE
, O
was O
shown O
to O
be O
identical O
in O
normal O
cells O
and O
tumors O
carrying O
a O
provirus O
in O
the O
RARE I-GENE
- I-GENE
1 I-GENE
locus I-GENE
. O

Specifically O
, O
by O
RARE O
- O
directed O
site O
- O
specific O
mutagenesis O
, O
we O
demonstrate O
that O
of O
10 O
cysteine O
residues O
in O
the O
NUM O
polypeptide O
, O
only O
C O
- O
NUM O
and O
C O
- O
NUM O
are O
essential O
RARE O
RARE O
function O
and O
suggest O
that O
these O
cysteine O
residues O
may O
participate O
in O
critical O
protein O
- O
protein O
interactions O
rather O
than O
protein O
- O
RARE O
acid O
interactions O
to O
mediate O
NUM O
inducibility O
. O

In O
RARE O
NUM O
cells O
, O
NUM I-GENE
RARE O
of O
phospholipase I-GENE
C I-GENE
beta I-GENE
and O
the O
marked O
rise O
in O
RARE O
RARE O
RARE O
cyclic O
AMP O
( O
cAMP O
) O
RARE O
, O
resulting O
in O
the O
activation O
of O
protein I-GENE
kinase I-GENE
A I-GENE
. O

The O
mutations O
did O
not O
affect O
the O
repression O
of O
NUM I-GENE
by O
RARE O
. O

A O
segment O
of O
mRNA O
encoding O
the O
RARE O
peptide O
of O
the O
NUM I-GENE
gene I-GENE
confers O
repression O
by O
RARE O
on O
a O
heterologous O
yeast O
gene O
transcript O
. O

To O
search O
RARE O
genes O
that O
interact O
with O
the O
NUM I-GENE
- O
NUM I-GENE
RARE O
, O
a O
RARE O
lethal O
suppression O
screen O
was O
carried O
out O
. O

Genetic O
and O
RARE O
analysis O
indicates O
that O
NUM I-GENE
and O
NUM I-GENE
function O
RARE O
of O
NUM I-GENE
. O

In O
this O
report O
, O
we O
present O
two O
lines O
of O
evidence O
that O
all O
RARE O
which O
RARE O
GCN4 I-GENE
have O
previously O
translated O
NUM O
, O
RARE O
scanning O
, O
and O
RARE O
RARE O
the O
GCN4 I-GENE
RARE O
site O
. O

RARE O
RARE O
of O
yeast O
transcription I-GENE
factor I-GENE
ALL_CAP I-GENE
are O
required O
and O
sufficient O
RARE O
transcription O
of O
TATA O
box O
- O
containing O
and O
TATA O
- O
less O
genes O
. O

RARE O
, O
it O
was O
shown O
that O
the O
ALL_CAP I-GENE
protein I-GENE
NUM I-GENE
inhibits O
differentiation O
of O
muscle O
and O
RARE O
cells O
in O
vitro O
. O

NUM I-GENE
, O
a O
new O
ribonucleoprotein O
gene O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

Crohn O
' O
s O
RARE O
in O
prolonged O
remission O
: O
should O
one O
RARE O
protein O
- O
RARE O
intake O
RARE O
compared O
to O
healthy O
subjects O
RARE O
The O
aim O
of O
our O
two O
year O
prospective O
study O
was O
to O
evaluate O
whether O
adult O
Crohn O
' O
s O
RARE O
patients O
in O
prolonged O
remission O
( O
ALL_CAP O
< O
NUM O
RARE O
in O
order O
to O
maintain O
their O
body O
RARE O
RARE O
close O
RARE O
possible O
to O
the O
RARE O
one O
, O
need O
a O
protein O
- O
RARE O
intake O
RARE O
than O
the O
predicted O
one O
and O
that O
of O
healthy O
controls O
. O

To O
achieve O
RARE O
dissection O
of O
the O
anterior O
vitreous O
, O
we O
RARE O
even O
a O
clear O
lens O
RARE O
the O
RARE O
surgical O
intervention O
in O
RARE O
cases O
. O

RARE O
of O
RARE O
function O
with O
transplantation O
of O
free O
RARE O
dorsal O
RARE O
RARE O
flap O
containing O
m O
. O
RARE O
RARE O
RARE O

Neither O
ethanol O
regimen O
impaired O
spontaneous O
RARE O
, O
but O
the O
4 O
g O
ethanol O
. O
kg O
- O
1 O
RARE O
day O
- O
1 O
regimen O
increased O
the O
percent O
completed O
trials O
. O

The O
mean O
(+/- O
RARE O
) O
RARE O
- O
vesicular O
pressure O
( O
ALL_CAP O
) O
and O
maximal O
RARE O
closure O
pressures O
( O
ALL_CAP O
) O
were O
10 O
. O
3 O
(+/- O
1 O
. O
7 O
) O
and O
NUM O
. O
8 O
(+/- O
19 O
. O
6 O
) O
cmH2O O
, O
respectively O
, O
and O
the O
ratio O
between O
ALL_CAP O
and O
ALL_CAP O
was O
NUM O
. O
2 O
(+/- O
2 O
. O
5 O
). O

Several O
highly O
RARE O
regions O
were O
identified O
RARE O
the O
near O
N O
terminus O
, O
RARE O
and O
C O
terminus O
. O

RARE I-GENE
( O
TR I-GENE
) O
is O
a O
small O
ubiquitous O
RARE I-GENE
- I-GENE
reductase I-GENE
enzyme I-GENE
RARE O
identified O
in O
bacteria O
and O
RARE O
. O

The O
mutation O
within O
the O
NUM I-GENE
allele I-GENE
was O
identified O
RARE O
an O
A O
- O
to O
- O
G O
transition O
that O
results O
in O
a O
threonine O
- O
to O
- O
alanine O
substitution O
in O
the O
predicted O
protein O
product O
. O

The O
cysteine O
- O
rich O
region O
of O
RARE I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
contains O
zinc O
, O
RARE O
to O
liposomes O
, O
and O
is O
adjacent O
to O
a O
segment O
that O
binds O
GTP I-GENE
- I-GENE
ras I-GENE
. O

RARE O
coupling O
and O
requirement O
RARE O
ATP O
hydrolysis O
. O

ATP O
by O
itself O
also O
RARE O
polypeptide O
binding O
to O
NUM I-GENE
/ I-GENE
NUM I-GENE
to O
a O
level O
that O
was O
RARE O
between O
that O
observed O
RARE O
the O
RARE I-GENE
NUM I-GENE
proteins I-GENE
tested O
and O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
. O

RARE O
of O
ALL_CAP I-GENE
- I-GENE
IL6 I-GENE
with O
RARE I-GENE
RARE I-GENE
- I-GENE
N I-GENE
produced O
a O
domain O
smaller O
than O
the O
ALL_CAP I-GENE
( O
ALL_CAP I-GENE
- I-GENE
IL6 I-GENE
ALL_CAP I-GENE
domains I-GENE
( O
ALL_CAP I-GENE
) O
( O
272 O
- O
NUM O
RARE O
a O
domain O
identified O
either O
in O
the O
absence O
or O
the O
presence O
of O
DNA O
. O

RARE O
by O
tyrosine I-GENE
kinases I-GENE
involves O
direct O
associations O
between O
proteins O
with O
Src I-GENE
homology I-GENE
2 I-GENE
( O
NUM I-GENE
) O
domains O
and O
sites O
of O
tyrosine O
RARE O
. O

RARE O
, O
RARE O
RARE O
of O
RARE O
V O
and O
subsequent O
RARE O
of O
RARE O
IV O
to O
RARE O
ALL_CAP O
caused O
a O
shift O
in O
the O
RARE O
reading O
frame O
, O
which O
RARE O
RARE I-GENE
( I-GENE
P2 I-GENE
) I-GENE
with O
an O
RARE O
new O
hydrophobic O
sequence O
RARE O
membrane O
RARE O
. O

The O
responses O
of O
the O
" O
stress O
RARE O
" O
cortisol O
, O
11 O
- O
RARE O
, O
ACTH I-GENE
, O
vasopressin I-GENE
( O
AVP I-GENE
RARE O
and O
RARE I-GENE
releasing I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
) O
were O
studied O
in O
6 O
normal O
males O
in O
response O
to O
acute O
cortisol O
deficiency O
RARE O
by O
the O
11 I-GENE
- I-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
inhibitor O
, O
RARE O
. O

Structure O
and O
RARE O
of O
the O
RARE O
RARE I-GENE
factor I-GENE
, O
ALL_CAP I-GENE
, O
in O
RARE O
RARE O
; O
physiological O
relevance O
of O
an O
RARE O
NUM I-GENE
- O
ALL_CAP I-GENE
RARE O
. O

Thus O
our O
observations O
establish O
a O
RARE O
RARE O
between O
the O
PKC I-GENE
and O
retinoid O
pathways O
, O
which O
are O
generally O
considered O
to O
have O
antagonistic O
activities O
on O
differentiation O
processes O
. O

The O
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
( O
RARE I-GENE
) O
RARE O
involved O
in O
the O
production O
of O
neutrophils O
and O
monocytes O
are O
RARE I-GENE
CSF I-GENE
, O
RARE I-GENE
- I-GENE
macrophage I-GENE
CSF I-GENE
, O
macrophage I-GENE
CSF I-GENE
, O
and O
interleukin I-GENE
3 I-GENE
( O
RARE O
called O
RARE I-GENE
- I-GENE
CSF I-GENE
). O

The O
degree O
of O
RARE O
RARE O
, O
reflected O
by O
interstitial O
hemorrhage O
was O
assessed O
by O
measuring O
hemoglobin I-GENE
content O
in O
the O
RARE O
of O
the O
RARE O
lungs O
. O

Expression O
plasmids O
harboring O
full O
- O
length O
or O
kinase O
domain O
of O
PKC I-GENE
alpha I-GENE
and O
PKC I-GENE
delta I-GENE
( O
PKC I-GENE
alpha I-GENE
K I-GENE
and O
PKC I-GENE
delta I-GENE
K I-GENE
) O
were O
constructed O
. O

These O
results O
indicate O
that O
both O
PKC I-GENE
alpha I-GENE
( O
RARE O
dependent O
) O
and O
PKC I-GENE
delta I-GENE
( O
RARE O
independent O
) O
may O
mediate O
the O
transcription O
of O
ALL_CAP O
- O
inducible O
genes O
through O
both O
AP I-GENE
- I-GENE
1 I-GENE
and O
non O
- O
AP I-GENE
- I-GENE
1 I-GENE
sequences O
. O

With O
a O
cutoff O
level O
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
of O
less O
than O
NUM O
pg O
/ O
ml O
, O
NUM O
samples O
obtained O
from O
12 O
patients O
were O
positive O
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
. O

RARE O
of O
short O
oligonucleotides O
encoding O
the O
basic O
amino O
acid O
motifs O
NUM O
- O
ALL_CAP O
- O
NUM O
from O
NUM I-GENE
and O
500 O
- O
ALL_CAP O
- O
NUM O
from O
NUM I-GENE
into O
RARE O
cytoplasmic O
forms O
of O
the O
two O
proteins O
restored O
the O
RARE O
RARE O
and O
confirmed O
that O
these O
motifs O
are O
both O
necessary O
and O
sufficient O
RARE O
proper O
nuclear O
RARE O
. O

Mapping O
of O
RARE O
RARE O
domains O
and O
evidence O
RARE O
RARE O
interactions O
between O
the O
NUM I-GENE
and O
NUM I-GENE
nuclear O
RARE O
proteins O
of O
herpes O
simplex O
virus O
. O

The O
RARE O
TATA O
RARE O
accelerated O
the O
kinetics O
of O
HIV O
replication O
when O
present O
in O
the O
context O
of O
an O
LTR O
containing O
a O
NUM I-GENE
mutation O
( O
deletion O
or O
site O
specific O
); O
RARE O
effect O
was O
observed O
on O
the O
RARE O
of O
wild O
- O
type O
HIV O
. O

RARE O
emphysema O

Since O
the O
ALL_CAP I-GENE
domain I-GENE
, O
which O
is O
localized O
in O
the O
RARE O
terminal O
region O
of O
the O
encoded O
protein O
, O
is O
NUM O
% O
and O
96 O
% O
identical O
to O
that O
of O
PEA3 I-GENE
and O
NUM I-GENE
, O
respectively O
, O
we O
named O
this O
new O
RARE O
' I-GENE
Ets I-GENE
RARE I-GENE
RARE I-GENE
PEA3 I-GENE
- I-GENE
like I-GENE
' I-GENE
( O
ALL_CAP I-GENE
). O

Gel O
shift O
analysis O
indicates O
that O
the O
full I-GENE
- I-GENE
length I-GENE
ALL_CAP I-GENE
protein I-GENE
is O
able O
to O
bind O
specifically O
to O
an O
RARE O
containing O
the O
consensus O
nucleotide O
core O
sequence O
ALL_CAP O
RARE O
by O
the O
Ets I-GENE
proteins O
. O

Effects O
of O
estradiol O
on O
RARE O
burden O
and O
peripheral O
RARE O
in O
RARE O
RARE O
- O
RARE O
rats O
. O

RARE O
produced O
arterial O
RARE O
in O
both O
systemic O
and O
pulmonary O
circulation O
: O
the O
RARE O
peripheral O
resistance O
RARE O
, O
and O
femoral O
artery O
flow O
rose O
; O
aortic O
and O
pulmonary O
artery O
mean O
and O
diastolic O
pressures O
declined O
, O
and O
systolic O
pressures O
remained O
almost O
stable O
. O

These O
issues O
include O
the O
use O
of O
RARE O
in O
patients O
with O
arterial O
thrombosis O
or O
RARE O
infarction O
( O
RARE O
. O
g O
. O
in O
conjunction O
with O
RARE O
treatment O
RARE O
and O
in O
patients O
with O
pulmonary O
RARE O
. O

The O
RARE O
of O
the O
lambda O
NUM O
and O
the O
lambda O
NUM O
cloning O
vectors O
was O
demonstrated O
by O
RARE O
large O
Neurospora O
crassa O
cDNA O
libraries O
. O

RARE O
RARE O
RARE O
RARE O
adjuvant O
treatment O
RARE O
critical O
upper O
- O
limb O
ischaemia O
. O

Sequence O
comparisons O
have O
shown O
that O
NUM I-GENE
is O
more O
similar O
to O
the O
RARE O
subunit O
of O
the O
RARE O
- O
localized O
mammalian O
AP I-GENE
- I-GENE
1 I-GENE
complex I-GENE
than O
NUM I-GENE
, O
which O
is O
more O
related O
to O
the O
plasma O
membrane O
AP I-GENE
- I-GENE
2 I-GENE
RARE I-GENE
subunit O
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
NUM I-GENE
gene I-GENE
encodes O
a O
homolog O
of O
the O
small O
subunit O
of O
the O
mammalian I-GENE
clathrin I-GENE
AP I-GENE
- I-GENE
1 I-GENE
complex I-GENE
: O
evidence O
RARE O
RARE O
interaction O
with O
clathrin I-GENE
RARE O
the O
RARE O
complex O
. O

These O
results O
are O
the O
RARE O
to O
demonstrate O
the O
structural O
organization O
of O
a O
RARE O
gene O
encoding O
an O
RARE O
membrane O
protein O
of O
the O
nuclear O
envelope O
that O
may O
be O
a O
RARE O
of O
a O
family O
of O
polypeptides O
RARE O
in O
evolution O
. O

Biochemical O
characterization O
of O
RARE I-GENE
- I-GENE
containing I-GENE
protein I-GENE
, O
a O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
substrate O
in O
hematopoietic O
cells O
. O

The O
presence O
of O
the O
foreign O
gene O
was O
confirmed O
by O
Southern O
analysis O
. O

All O
patients O
with O
RARE O
in O
mental O
status O
showed O
a O
marked O
increase O
in O
liver O
RARE O
( O
RARE I-GENE
and I-GENE
alanine I-GENE
RARE I-GENE
) O
and O
severe O
RARE O
. O

Functional O
postnatal O
development O
of O
the O
rat O
RARE O
visual O
cortex O
and O
the O
role O
of O
visual O
experience O
: O
dark O
RARE O
and O
RARE O
deprivation O
. O

RARE O
patients O
tested O
positive O
RARE O
the O
hepatitis I-GENE
B I-GENE
surface I-GENE
antigen I-GENE
( O
HBsAg I-GENE
). O

The O
RARE I-GENE
isomerase I-GENE
- I-GENE
encoding I-GENE
gene I-GENE
( O
ALL_CAP I-GENE
) O
of O
RARE O
RARE O
: O
cloning O
, O
sequencing O
and O
RARE O
of O
ALL_CAP I-GENE
RARE I-GENE
. O

Two O
phosphopeptides O
, O
identified O
RARE O
ALL_CAP O
RARE O
32P O
] O
ALL_CAP O
and O
S O
RARE O
32P O
] O
ALL_CAP O
, O
were O
obtained O
after O
RARE O
RARE O
and O
RARE O
of O
the O
peptide O
. O

RARE I-GENE
NUM I-GENE
signal I-GENE
RARE I-GENE
sequence I-GENE
. O

Altogether O
, O
these O
data O
suggest O
that O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
are O
required O
RARE O
RARE O
in O
the O
endocytic O
RARE O
and O
RARE O
correct O
RARE O
of O
vacuolar I-GENE
RARE I-GENE
suggesting O
a O
possible O
RARE O
of O
the O
endocytic O
with O
the O
vacuolar O
RARE O
RARE O
. O

All O
of O
the O
basal O
TPN O
solutions O
were O
RARE O
and O
identical O
in O
nutrient O
composition O
, O
except O
RARE O
the O
difference O
in O
energy O
level O
, O
which O
was O
adjusted O
with O
glucose O
. O

Surprisingly O
, O
ALL_CAP I-GENE
alpha I-GENE
has O
RARE O
homology O
to O
any O
of O
the O
yeast I-GENE
ALL_CAP I-GENE
subunits I-GENE
already O
RARE O
, O
suggesting O
a O
significant O
degree O
of O
evolutionary O
divergence O
RARE O
RNA I-GENE
polymerase I-GENE
III I-GENE
factors I-GENE
. O

RARE O
domain O
is O
RARE O
RARE O
of O
the O
NUM I-GENE
- I-GENE
amino I-GENE
- I-GENE
acid I-GENE
RARE I-GENE
homology I-GENE
region I-GENE
, O
referred O
to O
RARE O
the O
RARE I-GENE
domain I-GENE
. O

We O
estimate O
that O
the O
protease O
activity O
is O
RARE O
least O
NUM O
- O
RARE O
greater O
in O
RARE O
B O
cells O
than O
in O
pre O
- O
B O
cells O
. O

The O
RARE O
RARE O
RXR I-GENE
, O
9 O
- O
cis O
retinoic O
acid O
, O
has O
the O
opposite O
effect O
of O
RARE O
the O
RARE O
- O
DNA O
complex O
. O

NUM I-GENE
albumin I-GENE
was O
increased O
to O
similar O
RARE O
in O
those O
groups O
submitted O
to O
RARE O
. O

RARE O
labelled O
neurons O
significantly O
RARE O
in O
the O
ipsilateral O
RARE O
RARE O
RARE O
RARE O
. O

Response O
to O
treatment O
was O
better O
in O
patients O
with O
less O
pretreatment O
( O
one O
- O
two O
prior O
treatments O
) O
than O
in O
RARE O
pretreated O
ones O
( O
more O
than O
three O
) O
and O
this O
relation O
was O
found O
to O
be O
statistically O
significant O
( O
p O
< O
NUM O
. O
05 O
). O

Therefore O
, O
the O
amino O
- O
terminal O
sequence O
of O
the O
RARE O
ALL_CAP I-GENE
product I-GENE
is O
identical O
to O
that O
derived O
from O
the O
nucleotide O
sequence O
in O
both O
organisms O
, O
P O
. O
RARE O
having O
four O
additional O
amino O
RARE O
. O

RARE O
bone O
cyst O
of O
the O
RARE O
: O
analysis O
of O
11 O
cases O
. O

RARE O
and O
orientation O
of O
an O
activating O
region O
in O
the O
Escherichia O
coli O
transcription O
factor O
, O
ALL_CAP I-GENE
. O

RARE O
( O
RARE O
3 O
times O
the O
therapeutic O
dose O
) O
did O
not O
have O
RARE O
effects O
on O
RARE O
reproductive O
performance O
RARE O
examined O
( O
RARE O
, O
RARE O
RARE O
, O
ovulation O
, O
and O
the O
early O
RARE O
RARE O
of O
development O
). O

Northern O
- O
blot O
analysis O
of O
mRNA O
from O
RARE O
- O
grown O
N O
. O
RARE O
showed O
that O
ALL_CAP I-GENE
hybridized O
to O
a O
3 O
. O
4 O
kb O
mRNA O
species O
. O

The O
RARE O
regions O
of O
RARE O
RARE O
ALL_CAP I-GENE
isoforms I-GENE
reflect O
the O
subsequent O
addition O
and O
modification O
of O
genomic O
sequences O
to O
give O
rise O
to O
members O
of O
the O
ALL_CAP I-GENE
RARE I-GENE
family I-GENE
. O

The O
class I-GENE
II I-GENE
Escherichia I-GENE
coli I-GENE
alanine I-GENE
tRNA I-GENE
RARE I-GENE
RARE I-GENE
RNA I-GENE
RARE I-GENE
, O
which O
RARE O
the O
RARE O
end O
of O
alanine I-GENE
tRNA I-GENE
with O
the O
critical O
NUM O
: O
NUM O
RARE O
RARE O
. O

RARE O
reaction O
time O
( O
RT O
) O
to O
a O
peripheral O
visual O
target O
( O
NUM O
) O
is O
shortened O
when O
a O
non O
- O
RARE O
RARE O
( O
S1 O
) O
is O
RARE O
RARE O
the O
NUM O
location O
NUM O
- O
NUM O
ms O
before O
target O
onset O
( O
early O
RARE O
). O

A O
second O
study O
group O
, O
with O
RARE O
cardiac O
RARE O
, O
consisted O
of O
19 O
patients O
with O
stable O
angina O
pectoris O
class O
I O
to O
III O
. O

These O
viruses O
depend O
on O
the O
RARE O
cell O
machinery O
RARE O
their O
existence O
, O
and O
interference O
with O
these O
processes O
typically O
RARE O
with O
other O
important O
RARE O
physiology O
. O

Treatment O
was O
RARE O
- O
tolerated O
. O

A O
concentration O
of O
12 O
. O
5 O
ppm O
NUM O
RARE O
a O
decrease O
from O
baseline O
values O
of O
RARE O
NUM O
% O
in O
mean O
ALL_CAP O
and O
of O
RARE O
70 O
% O
in O
mean O
CBF O
. O

We O
have O
used O
these O
modified O
assay O
conditions O
to O
extend O
studies O
on O
the O
RARE O
RARE O
. O

Renal O
cell O
carcinoma O
in O
children O
: O
a O
single O
RARE O
' O
s O
experience O
. O

The O
data O
suggest O
that O
NUM I-GENE
constitutively O
increases O
ras I-GENE
activity O
, O
and O
its O
ALL_CAP O
segment O
plays O
a O
critical O
role O
in O
transformation O
- O
related O
RARE O
pathways O
. O

Thus O
, O
we O
have O
separated O
the O
signal O
function O
from O
the O
RARE O
function O
of O
the O
6 O
. O
NUM O
SA O
domain O
. O

Five O
RARE O
RARE O
A O
addition O
sites O
are O
RARE O
in O
the O
350 O
RARE O
RARE O
immediately O
following O
the O
protein I-GENE
ALL_CAP I-GENE
coding O
region O
. O

Factors O
associated O
with O
RARE O
RARE O
of O
hepatitis O
B O
virus O
infection O
in O
RARE O
. O

RARE O
to O
RARE O
ALL_CAP O
concentrations O
decreased O
the O
content O
of O
these O
transcripts O
. O

Northern O
analysis O
, O
to O
search O
RARE O
a O
ALL_CAP I-GENE
transcript I-GENE
, O
showed O
RARE O
distinct O
transcript O
and O
indicated O
severely O
degraded O
mRNA O
. O

Our O
results O
indicate O
that O
the O
minimal O
requirements O
RARE O
induction O
of O
PEPCK I-GENE
by O
PKA I-GENE
and O
inhibition O
by O
insulin I-GENE
include O
: O
1 O
) O
the O
CREB I-GENE
activation I-GENE
domain I-GENE
, O
2 O
) O
the O
PEPCK I-GENE
TATA I-GENE
sequence I-GENE
, O
and O
3 O
) O
insulin I-GENE
- O
responsive O
hepatoma O
cells O
. O

The O
high O
degree O
of O
conservation O
between O
NUM I-GENE
and O
NUM I-GENE
gene I-GENE
organization O
and O
sequence O
confirmed O
that O
NUM I-GENE
gene I-GENE
encodes O
RARE O
a O
second O
RARE O
of O
the O
ALL_CAP I-GENE
gene I-GENE
family I-GENE
in O
human O
. O

The O
efficacy O
of O
a O
RARE O
RARE O
product O
RARE O
treatment O
of O
RARE O
RARE O
was O
evaluated O
following O
RARE O
infusion O
of O
Escherichia O
coli O
. O

The O
human I-GENE
NUM I-GENE
gene I-GENE
, O
encoding O
a O
tyrosine I-GENE
kinase I-GENE
substrate O
, O
is O
RARE O
in O
evolution O
and O
maps O
to O
NUM O
- O
NUM O
. O

The O
gene O
encoding O
the O
NUM I-GENE
- I-GENE
kDa I-GENE
protein I-GENE
( I-GENE
NUM I-GENE
) I-GENE
precursor I-GENE
of O
the O
NUM I-GENE
subunit I-GENE
of O
transcription O
factor O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
also O
encodes O
a O
p70 I-GENE
I I-GENE
RARE I-GENE
B I-GENE
protein I-GENE
, O
I I-GENE
RARE I-GENE
B I-GENE
gamma I-GENE
, O
which O
is O
identical O
to O
the O
C O
- O
terminal O
NUM O
amino O
RARE O
of O
NUM I-GENE
. O

Alternative O
RARE O
of O
RNA O
transcripts O
encoded O
by O
the O
murine O
NUM I-GENE
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
gene O
generates O
I I-GENE
RARE I-GENE
B I-GENE
gamma I-GENE
isoforms I-GENE
with O
different O
RARE O
activities O
. O

RARE O
L O
- O
ALL_CAP O
attenuated O
the O
RARE O
increase O
of O
ALL_CAP O
by O
52 O
+/- O
6 O
% O
and O
ALL_CAP O
by O
29 O
+/- O
5 O
% O
after O
NUM O
- O
min O
exposure O
. O

The O
experiment O
included O
6 O
male O
and O
4 O
female O
healthy O
subjects O
who O
, O
RARE O
a O
NUM O
- O
hour O
RARE O
in O
the O
respiration O
RARE O
, O
performed O
, O
in O
the O
RARE O
and O
RARE O
, O
NUM O
min O
RARE O
with O
the O
RARE O
work O
of O
6 O
, O
750 O
kg O
m O
. O

These O
RARE O
result O
in O
the O
formation O
of O
chimeric O
genes O
showing O
the O
tyrosine I-GENE
kinase I-GENE
domain I-GENE
of O
RARE I-GENE
fused O
with O
the O
5 O
' O
end O
sequences O
of O
different O
genes O
. O

RARE O
RARE O
of O
heterozygosity O
( O
ALL_CAP O
) O
of O
> O
NUM O
% O
of O
the O
RARE O
cases O
was O
observed O
on O
chromosomes O
NUM O
( O
NUM O
. O
1 O
%), O
NUM O
( O
52 O
. O
6 O
%), O
NUM O
( O
NUM O
. O
4 O
%), O
NUM O
( O
NUM O
. O
3 O
%), O
NUM O
( O
NUM O
. O
7 O
%), O
NUM O
( O
NUM O
. O
8 O
%), O
NUM O
( O
NUM O
. O
4 O
%), O
NUM O
( O
52 O
. O
7 O
%), O
NUM O
( O
NUM O
. O
2 O
%), O
NUM O
( O
NUM O
. O
3 O
%), O
NUM O
( O
NUM O
. O
7 O
%), O
and O
NUM O
( O
NUM O
. O
4 O
%). O

A O
single O
amino O
acid O
change O
in O
the O
ALL_CAP I-GENE
vacuolar I-GENE
RARE I-GENE
signal I-GENE
prevents O
this O
interaction O
. O

RARE I-GENE
- I-GENE
tRNA I-GENE
RARE I-GENE
and O
RARE I-GENE
- I-GENE
tRNA I-GENE
RARE I-GENE
belong O
to O
different O
classes O
of O
RARE I-GENE
- I-GENE
tRNA I-GENE
synthetases I-GENE
that O
are O
thought O
to O
have O
evolved O
along O
independent O
evolutionary O
pathways O
. O

Using O
the O
sequence O
data O
obtained O
from O
the O
human O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
region O
, O
we O
have O
extended O
a O
polymerase O
chain O
reaction O
- O
based O
assay O
to O
test O
RARE O
the O
RARE O
of O
the O
individual O
ALL_CAP I-GENE
gene I-GENE
RARE I-GENE
. O

This O
analysis O
revealed O
an O
RARE O
gene O
( O
NUM I-GENE
) O
showing O
a O
high O
degree O
of O
homology O
with O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
NUM I-GENE
gene I-GENE
encoding O
the O
large O
subunit O
of O
RARE I-GENE
- I-GENE
phosphate I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
- I-GENE
A I-GENE
). O

Restriction O
analysis O
and O
Southern O
hybridization O
revealed O
the O
presence O
of O
NUM I-GENE
in O
all O
the O
RARE O
- O
RARE O
cadmium O
- O
resistant O
L O
. O
monocytogenes O
strains O
tested O
but O
not O
in O
strains O
encoding O
cadmium O
resistance O
on O
the O
RARE O
. O

The O
RARE O
RARE O
( O
from O
the O
ECG O
R O
- O
wave O
to O
the O
integrated O
ALL_CAP O
burst O
peak O
) O
was O
constant O
RARE O
RARE O
1 O
. O
20 O
s O
RARE O
sleep O
, O
suggesting O
that O
pulse O
- O
RARE O
was O
maintained O
. O

DESIGN O
RARE O
A O
randomised O
study O
was O
conducted O
in O
all O
women O
aged O
50 O
- O
70 O
years O
who O
were O
RARE O
RARE O
breast O
RARE O
screening O
and O
living O
in O
the O
RARE O
of O
RARE O
. O

Identification O
of O
an O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
in O
the O
RARE O
' O
s O
RARE O
virus O
long O
internal O
repeat O
region O
which O
encodes O
a O
unique O
14 O
- O
RARE O
polypeptide O
. O

We O
have O
used O
a O
full O
- O
length O
cDNA O
clone O
of O
a O
mouse O
hepatitis O
virus O
RARE O
NUM O
RARE O
interfering O
( O
ALL_CAP O
) O
RNA O
, O
ALL_CAP I-GENE
- I-GENE
C I-GENE
, O
and O
RARE O
mutagenesis O
to O
study O
the O
mechanism O
of O
coronavirus O
RARE O
mRNA O
RARE O
. O

To O
study O
the O
RARE O
- O
function O
of O
the O
gene I-GENE
5 I-GENE
product I-GENE
, O
wild O
- O
type O
and O
mutant O
forms O
of O
NUM I-GENE
were O
produced O
by O
using O
a O
recombinant O
RARE O
RARE O
RARE O
and O
a O
recombinant O
RARE O
virus O
/ O
NUM O
( O
NUM O
- O
3 O
) O
RARE O
RARE O
. O

Gel O
electrophoresis O
and O
Western O
RARE O
analyses O
of O
RARE O
fractions O
derived O
from O
RARE O
cells O
revealed O
that O
large O
amounts O
of O
NUM I-GENE
were O
present O
in O
the O
cytosol O
and O
in O
association O
with O
the O
cytoskeletal O
RARE O
. O

The O
transcription I-GENE
factor I-GENE
AP I-GENE
- I-GENE
2 I-GENE
is O
encoded O
by O
a O
gene O
RARE O
on O
RARE O
6 O
near O
the O
HLA I-GENE
locus I-GENE
. O

The O
RARE O
AP I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
is O
RARE O
from O
7 O
exons O
distributed O
over O
a O
region O
of O
18 O
kb O
genomic O
DNA O
. O

RARE O
RARE O
' O
s O
psychological O
RARE O
coupled O
to O
RARE O
work O
with O
RARE O
RARE O
that O
allowed O
RARE O
to O
display O
RARE O
abilities O
RARE O
RARE O
and O
RARE O
RARE O
. O

The O
RARE O
were O
RARE O
men O
in O
hepatitis O
B O
vaccine O
trials O
in O
RARE O
( O
RARE O
= O
NUM O
RARE O
New O
York O
City O
( O
RARE O
= O
120 O
RARE O
and O
RARE O
RARE O
( O
RARE O
= O
NUM O
). O

The O
7 O
- O
day O
treatment O
resulted O
in O
a O
decrease O
in O
mitochondrial O
uptake O
of O
NUM O
and O
an O
increase O
in O
ALL_CAP O
uptake O
. O

RARE O
RARE O
purpura O
in O
systemic O
lupus O
erythematosus O
. O

Comparison O
with O
the O
RARE O
RARE O
of O
RARE O
RARE O
, O
RARE O
, O
RARE I-GENE
( O
RARE O
et O
al O
., O
1991 O
) O
reveals O
a O
very O
similar O
folding O
topology O
, O
although O
several O
secondary O
structural O
elements O
are O
extended O
in O
RARE O
relative O
to O
RARE O
RARE I-GENE
. O

CONCLUSIONS O
: O
Serum I-GENE
prolactin I-GENE
concentrations O
show O
age O
related O
variations O
in O
presumably O
RARE O
men O
. O

Eight O
highly O
RARE O
male O
RARE O
were O
studied O
to O
determine O
the O
relationship O
between O
critical O
power O
( O
CP O
) O
and O
the O
onset O
of O
RARE O
RARE O
accumulation O
( O
ALL_CAP O
). O

As O
in O
S O
. O
cerevisiae O
, O
the O
sequence O
of O
NUM I-GENE
+ I-GENE
showed O
two O
ALL_CAP I-GENE
cell I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
and O
a O
putative O
DNA O
damage O
- O
responsive O
element O
in O
its O
upstream O
region O
. O

RARE O
' O
s O
RARE O
RARE O
RARE O
work O
outside O
the O
home O
are O
RARE O
by O
their O
role O
RARE O
RARE O
RARE O
within O
the O
family O
, O
RARE O
RARE O
RARE O
. O

A O
partial O
cDNA O
sequence O
indicated O
that O
the O
T I-GENE
lymphocyte I-GENE
early I-GENE
- I-GENE
activation I-GENE
gene I-GENE
( O
RARE I-GENE
) O
encodes O
a O
protein O
related O
to O
the O
dual O
- O
function O
RARE I-GENE
RARE I-GENE
receptor I-GENE
/ O
RARE I-GENE
amino I-GENE
acid I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
/ O
NUM I-GENE
RARE O
and O
RNA O
blots O
suggested O
highest O
RARE I-GENE
RARE O
in O
T O
lymphocytes O
and O
liver O
( O
RARE O
, O
C O
. O
L O
., O
RARE O
, O
K O
., O
RARE O
, O
D O
. O

Furthermore O
, O
unlike O
the O
case O
RARE O
HIS3 I-GENE
where O
only O
a O
limited O
subset O
of O
TATA O
- O
like O
sequences O
can O
activate O
transcription O
in O
conjunction O
with O
NUM I-GENE
, O
many O
divergent O
TATA O
- O
like O
sequences O
allowed O
NUM I-GENE
activation O
of O
NUM I-GENE
. O

RARE O
RARE O
protein O
, O
RARE O
RARE O
RARE O
the O
in O
vitro O
RARE O
RARE O
translation O
product O
, O
RARE O
with O
the O
RARE O
37 O
- O
kDa O
protein O
on O
RARE O
dodecyl O
RARE O
- O
polyacrylamide O
gels O
. O

In O
addition O
, O
this O
kinase O
is O
RARE O
RARE O
evolutionarily O
, O
ubiquitously O
RARE O
, O
and O
its O
genes O
map O
to O
a O
position O
on O
human O
RARE O
1 O
frequently O
RARE O
in O
the O
RARE O
stages O
of O
tumorigenesis O
. O

Deletion O
analysis O
of O
the O
NUM I-GENE
promoter I-GENE
led O
to O
the O
identification O
of O
an O
upstream O
activating O
sequence O
element O
, O
NUM O
( O
5 O
' O
ALL_CAP O
3 O
RARE O
necessary O
and O
sufficient O
RARE O
conferring O
carbon O
source O
- O
dependent O
RARE O
on O
a O
heterologous O
reporter O
gene O
. O

Interestingly O
, O
the O
interaction O
of O
ALL_CAP I-GENE
- I-GENE
70 I-GENE
with O
the O
motif O
was O
dependent O
on O
the O
presence O
of O
both O
ALL_CAP I-GENE
- I-GENE
70 I-GENE
NUM I-GENE
domains I-GENE
and O
both O
of O
the O
tyrosine O
residues O
in O
the O
motif O
, O
suggesting O
that O
ALL_CAP I-GENE
- I-GENE
70 I-GENE
interacts O
with O
two O
RARE O
residues O
and O
that O
the O
binding O
of O
the O
two O
NUM I-GENE
domains I-GENE
is O
cooperative O
. O

PRL I-GENE
- I-GENE
1 I-GENE
is O
able O
to O
RARE O
RARE O
RARE O
, O
and O
mutation O
of O
the O
RARE O
- O
site O
cysteine O
RARE O
abolishes O
this O
activity O
. O

In O
NUM O
RARE O
RARE O
cells O
, O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
and O
T I-GENE
beta I-GENE
R I-GENE
- I-GENE
I I-GENE
signal O
a O
common O
set O
of O
growth O
- O
RARE O
and O
transcriptional O
responses O
in O
association O
with O
their O
corresponding O
ligands O
and O
type I-GENE
II I-GENE
receptors I-GENE
. O

50 O
kDa O
and O
NUM O
- O
NUM O
kDa O
were O
detected O
. O

H O
- O
7 O
, O
which O
specifically O
, O
although O
weakly O
, O
inhibited O
PKC I-GENE
activation O
, O
had O
RARE O
effect O
on O
tyrosine O
RARE O
and O
RARE O
( O
3 O
, O
4 O
) O
P2 O
production O
. O

The O
effects O
of O
systemic O
glucose O
concentration O
on O
brain O
metabolism O
following O
RARE O
brain O
ischemia O
. O

This O
strategy O
was O
used O
to O
place O
both O
the O
NUM I-GENE
RARE I-GENE
gene I-GENE
and O
the O
RARE I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
lyase I-GENE
( O
ALL_CAP I-GENE
)- O
encoding O
gene O
under O
the O
transcriptional O
control O
of O
ALL_CAP I-GENE
:: O
NUM I-GENE
. O

In O
the O
case O
of O
congenital O
protein I-GENE
C I-GENE
deficiency O
, O
vitamin O
K O
antagonists O
must O
be O
started O
RARE O
due O
to O
the O
risk O
of O
RARE O
necrosis O
. O

A O
- O
NUM O
- O
year O
- O
old O
patient O
with O
postoperative O
small O
- O
bowel O
obstruction O
underwent O
RARE O
three O
times O
. O

On O
physical O
examination O
a O
mild O
RARE O
RARE O
of O
small O
and O
large O
RARE O
was O
seen O
. O

In O
addition O
, O
we O
observe O
that O
the O
ALL_CAP I-GENE
- I-GENE
promoter I-GENE
interaction O
is O
highly O
RARE O
to O
the O
antagonistic O
effects O
of O
cisplatin O
- O
DNA O
RARE O
. O

We O
conclude O
that O
the O
ALL_CAP O
is O
useful O
in O
RARE O
neonates O
from O
the O
RARE O
. O

ALL_CAP O
- O
16 O
, O
RARE O
and O
cisplatin O
( O
ALL_CAP O
) O
RARE O
extensive O
small O
cell O
RARE O
RARE O
. O

A O
RARE O
of O
7 O
( O
4 O
males O
and O
3 O
females O
) O
patients O
were O
included O
in O
this O
retrospective O
study O
to O
determine O
the O
sensitivity O
of O
RARE O
with O
I O
- O
NUM O
labeled O
anti I-GENE
ALL_CAP I-GENE
/ O
CA I-GENE
19 I-GENE
- I-GENE
9 I-GENE
monoclonal O
antibodies O
. O

RARE O
, O
bilateral O
and O
permanent O
ventilation O
with O
a O
diaphragm O
pacing O
in O
childhood O
: O
the O
implantation O
technique O
and O
RARE O

A O
genomic O
clone O
RARE O
the O
NUM I-GENE
gene I-GENE
, O
which O
is O
RARE O
specifically O
RARE O
the O
S O
RARE O
RARE O
the O
cell O
RARE O
in O
RARE O
cultures O
of O
RARE O
( O
RARE O
RARE O
) O
cells O
, O
was O
isolated O
. O

CONCLUSIONS O
: O
RARE O
of O
bacteria O
or O
RARE O
from O
the O
RARE O
RARE O
into O
the O
RARE O
has O
been O
noted O
in O
RARE O
experiments O
; O
however O
, O
translocation O
was O
not O
detected O
in O
our O
patients O
with O
hemorrhagic O
shock O
. O

The O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
genes I-GENE
encoded O
polypeptides O
with O
calculated O
RARE O
masses O
of O
19 O
. O
9 O
and O
NUM O
. O
2 O
kDa O
, O
respectively O
. O

Southern O
blotting O
analysis O
RARE O
the O
occurrence O
of O
multiple O
RARE I-GENE
genes I-GENE
in O
the O
rat O
genome O
. O

RARE O
with O
the O
RARE O
analog O
was O
prevented O
when O
RARE O
- O
2 O
was O
RARE O
to O
alanine O
, O
implying O
that O
N O
- O
RARE O
is O
required O
RARE O
RARE O
, O
and O
when O
either O
RARE O
- O
3 O
or O
RARE O
- O
6 O
was O
RARE O
to O
serine O
. O

RARE O
composition O
and O
domain O
RARE O
of O
the O
NUM I-GENE
RARE I-GENE
transcription I-GENE
factor I-GENE
of I-GENE
Bacillus I-GENE
subtilis I-GENE
. O

Electrophoretic O
mobility O
shift O
analysis O
indicates O
that O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
- I-GENE
6 I-GENE
, O
RARE O
RARE O
RARE O
other O
related O
members O
of O
this O
family O
, O
bind O
specifically O
to O
the O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
- I-GENE
6 I-GENE
site O
in O
the O
ALL_CAP I-GENE
- I-GENE
8 I-GENE
promoter I-GENE
. O

ALL_CAP O
, O
RARE O
RARE O
virus O
( O
ALL_CAP O
RARE O
RARE O
yellow O
RARE O
virus O
( O
ALL_CAP O
) O
and O
RARE O
RARE O
RARE O
virus O
templates O
produced O
1 O
kb O
amplification O
products O
, O
which O
were O
shown O
by O
sequencing O
to O
represent O
fragments O
of O
the O
respective O
HSP70 I-GENE
genes I-GENE
. O

To O
identify O
the O
precise O
location O
of O
the O
RARE O
site O
on O
the O
NUM O
- O
kDa O
protein O
, O
a O
step O
- O
by O
- O
step O
mutagenesis O
procedures O
was O
followed O
. O

The O
p53 I-GENE
tumor I-GENE
suppressor I-GENE
gene I-GENE
product I-GENE
, O
a O
sequence O
- O
specific O
DNA O
- O
binding O
protein O
, O
has O
been O
shown O
to O
act O
RARE O
a O
transcriptional O
activator O
and O
repressor O
both O
in O
vitro O
and O
in O
vivo O
. O

Mutational O
analysis O
of O
chromosomal O
segment O
NUM O
, O
a O
region O
containing O
the O
RARE I-GENE
acid I-GENE
decarboxylase I-GENE
gene I-GENE
. O

RARE O
of O
the O
NUM I-GENE
gene I-GENE
are O
associated O
with O
RARE O
RARE O
, O
but O
the O
RARE O
significance O
of O
these O
alterations O
is O
not O
known O
. O

Cloning O
and O
sequencing O
of O
the O
corresponding O
cDNAs O
indicates O
that O
, O
via O
RARE O
RARE O
, O
the O
RARE O
gene O
codes O
RARE O
two O
proteins O
of O
NUM O
and O
NUM O
ALL_CAP O
( O
NUM I-GENE
/ I-GENE
NUM I-GENE
) O
which O
RARE O
the O
DNA O
- O
binding O
RARE I-GENE
domain I-GENE
and O
the O
RARE O
five O
RARE I-GENE
repeats O
, O
but O
have O
lost O
their O
RARE O
- O
terminus O
including O
the O
RARE O
RARE I-GENE
repeat O
. O

Transient O
RARE O
- O
transfection O
assays O
involving O
NUM I-GENE
RARE O
vectors O
and O
RARE I-GENE
B I-GENE
- O
RARE O
reporter O
plasmids O
indicate O
that O
NUM I-GENE
p85 I-GENE
has O
lost O
the O
transcriptional O
repressor O
functions O
typical O
of O
normal O
NUM I-GENE
NUM I-GENE
. O

Also O
, O
NUM I-GENE
RARE O
RARE O
RARE O
NUM I-GENE
are O
specific O
in O
their O
inhibition O
of O
NUM I-GENE
binding O
. O

Intravenous O
antibiotic O
therapy O
in O
RARE O
RARE O
: O
in O
hospital O
or O
RARE O
home O
? O

RARE O
reading O
frames O
in O
a O
NUM O
nucleotide O
sequence O
within O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
BamHI I-GENE
- I-GENE
D I-GENE
DNA I-GENE
fragment I-GENE
: O
evidence O
RARE O
RARE O
of O
mRNA O
from O
a O
new O
viral O
glycoprotein O
gene O
. O

The O
NUM I-GENE
gene I-GENE
comprises O
an O
RARE O
reading O
frame O
( O
ORF O
) O
encoding O
a O
putative O
RARE O
( O
RARE O
) O
protein O
of O
NUM O
amino O
RARE O
with O
a O
predicted O
RARE O
mass O
of O
NUM O
- O
kDa O
. O

Co O
- O
transfection O
of O
a O
tat I-GENE
expressing O
RARE O
with O
these O
viruses O
containing O
the O
tat I-GENE
ORF I-GENE
mutations O
resulted O
in O
RARE O
levels O
of O
virus O
production O
demonstrating O
that O
the O
effects O
of O
both O
mutants O
are O
tat I-GENE
specific O
. O

Analysis O
of O
the O
gag I-GENE
and O
RARE I-GENE
proteins I-GENE
in O
the O
transfected O
cells O
demonstrated O
that O
these O
proteins O
were O
not O
detectable O
in O
cells O
transfected O
with O
the O
tat I-GENE
mutants I-GENE
but O
could O
be O
readily O
detected O
when O
the O
mutations O
were O
complemented O
in O
RARE O
with O
a O
tat I-GENE
RARE O
vector O
. O

The O
RARE O
profile O
of O
the O
RARE O
reveals O
the O
presence O
of O
RARE O
least O
five O
RARE O
transmembrane O
domains O
. O

Measurement O
of O
SaO2 O
RARE O
moderate O
altitude O
can O
be O
helpful O
in O
the O
care O
of O
both O
healthy O
and O
RARE O
newborns O
or O
infants O
. O

To O
determine O
whether O
the O
excess O
prevalence O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
infection O
in O
US O
black O
and O
RARE O
RARE O
men O
relative O
to O
RARE O
men O
can O
be O
explained O
by O
differences O
in O
RARE O
factors O
, O
history O
of O
RARE O
transmitted O
diseases O
, O
or O
sexual O
and O
drug O
- O
use O
RARE O
, O
the O
authors O
conducted O
a O
cross O
- O
sectional O
analysis O
of O
baseline O
HIV O
- O
1 O
RARE O
and O
HIV O
- O
1 O
risk O
factors O
among O
4 O
, O
NUM O
non O
- O
RARE O
RARE O
, O
NUM O
RARE O
RARE O
, O
and O
NUM O
black O
RARE O
men O
from O
four O
centers O
in O
the O
United O
RARE O
( O
RARE O
/ O
RARE O
, O
DC O
, O
RARE O
, O
RARE O
, O
and O
RARE O
RARE O
). O

The O
patients O
in O
one O
group O
had O
intrauterine O
RARE O
inserted O
and O
RARE I-GENE
was O
RARE O
to O
achieve O
the O
NUM O
RARE O
of O
RARE O
activity O
observed O
in O
spontaneous O
normal O
labour O
according O
to O
RARE O
. O

RARE O
development O
of O
the O
rat O
conditioning O
RARE O
is O
especially O
warranted O
because O
of O
the O
ability O
to O
record O
sympathetic O
nerve O
activity O
in O
RARE O
, O
RARE O
subjects O
and O
the O
large O
number O
of O
readily O
available O
genetic O
strains O
, O
which O
model O
human O
pathological O
states O
. O

The O
RARE O
of O
RARE O
vessels O
was O
examined O
in O
three O
eyes O
from O
diabetic O
patients O
and O
two O
eyes O
from O
control O
subjects O
. O

The O
regulatory O
region O
also O
has O
a O
sequence O
similar O
to O
the O
binding O
site O
RARE O
a O
liver O
- O
specific O
transcription O
factor O
, O
RARE I-GENE
nuclear I-GENE
factor I-GENE
1 I-GENE
( O
HNF I-GENE
- I-GENE
1 I-GENE
RARE O
RARE O
positions O
- O
120 O
to O
- O
132 O
. O

Thus O
, O
we O
have O
identified O
a O
ALL_CAP O
sufficient O
to O
account O
RARE O
full O
glucocorticoid O
inducibility O
and O
an O
HNF I-GENE
- I-GENE
1 I-GENE
site I-GENE
close O
to O
the O
promoter O
that O
are O
major O
RARE O
of O
transcriptional O
control O
of O
the O
Xenopus I-GENE
fibrinogen I-GENE
B I-GENE
beta I-GENE
subunit I-GENE
gene I-GENE
in O
cells O
from O
normal O
liver O
tissue O
. O

RARE O
. O

The O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
gene I-GENE
encodes O
RARE O
a O
basic O
- O
type O
RARE O
of O
the O
pathogenesis O
- O
related O
PR I-GENE
- I-GENE
1 I-GENE
protein I-GENE
family I-GENE
. O

RARE O
of O
the O
ALL_CAP O
with O
a O
second O
copy O
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
results O
in O
a O
level O
of O
transcriptional O
activity O
comparable O
with O
that O
of O
the O
wild O
- O
type O
sequence O
, O
but O
RARE O
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
with O
a O
ALL_CAP O
abolishes O
activity O
. O

The O
T I-GENE
- I-GENE
RARE I-GENE
promoter I-GENE
, O
although O
of O
bacterial O
origin O
is O
RARE O
in O
RARE O
and O
the O
NUM I-GENE
bp I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
element I-GENE
is O
RARE O
within O
a O
region O
that O
is O
essential O
RARE O
T I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
activity O
in O
leaf O
, O
RARE O
and O
root O
cells O
of O
tobacco O
RARE O
. O

RARE O
RARE O
: O
developing O
an O
efficient O
RARE O
. O

We O
suggest O
that O
ALL_CAP O
scan O
be O
RARE O
in O
diagnosis O
of O
tumors O
in O
that O
area O
. O

ALL_CAP O
- O
1 O
had O
RARE O
influence O
on O
either O
the O
ischemic O
parameters O
in O
the O
surface O
electrocardiogram O
( O
ECG O
) O
or O
the O
RARE O
ECG O
. O

Effect O
of O
aging O
on O
respiratory O
skeletal O
muscles O
. O

Two O
ALL_CAP O
computer O
programs O
using O
RARE O
transformation O
RARE O
the O
analysis O
of O
S O
- O
shaped O
curves O
are O
presented O
. O

The O
yeast I-GENE
NUM I-GENE
gene I-GENE
is O
essential O
RARE O
RARE O
protein O
translocation O
and O
encodes O
a O
RARE O
protein O
of O
the O
endoplasmic O
reticulum O
. O

The O
lengths O
of O
the O
RARE O
polypeptide O
chain O
of O
the O
recombinant O
enzyme O
and O
its O
transit O
peptide O
are O
NUM O
and O
53 O
residues O
, O
respectively O
. O

The O
absence O
of O
NUM O
RARE O
to O
the O
T I-GENE
protein I-GENE
in O
our O
experimental O
conditions O
demonstrates O
that O
NUM O
is O
not O
covalently O
RARE O
to O
the O
T I-GENE
protein I-GENE
. O

TATA O
and O
CCAAT O
RARE O
are O
RARE O
NUM O
- O
bp O
and O
NUM O
- O
bp O
, O
respectively O
, O
upstream O
of O
the O
transcription O
RARE O
site O
, O
the O
5 O
'- O
RARE O
RARE O
is O
NUM O
nucleotides O
long O
, O
and O
the O
intronless O
gene O
has O
RARE O
least O
two O
different O
polyadenylation O
sites O
. O

NUM I-GENE
is O
the O
same O
gene O
RARE O
NUM I-GENE
which O
was O
identified O
RARE O
encoding O
a O
subunit O
of O
the O
RARE I-GENE
- I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
synthase I-GENE
/ I-GENE
phosphatase I-GENE
complex I-GENE
and O
it O
is O
allelic O
to O
the O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
and O
NUM O
mutations O
. O

We O
also O
compared O
the O
sequence O
with O
the O
partly O
homologous O
products O
of O
the O
S O
. O
cerevisiae O
genes O
NUM I-GENE
and O
NUM I-GENE
which O
code O
RARE O
the O
larger O
subunits O
of O
the O
RARE I-GENE
synthase I-GENE
complex I-GENE
and O
with O
a O
NUM I-GENE
homologue I-GENE
, O
NUM I-GENE
, O
of O
unknown O
function O
. O

Stroop O
interference O
: O
aging O
effects O
assessed O
with O
the O
Stroop O
RARE O
- O
RARE O
Test O
. O

RARE O
of O
RARE O
3H O
] O
PA O
production O
upon O
CD3 I-GENE
cross O
- O
linking O
was O
77 O
% O
lower O
in O
RARE O
NUM I-GENE
- I-GENE
cells O
than O
in O
NUM I-GENE
+ I-GENE
cells O
, O
consistent O
with O
the O
RARE O
activity O
of O
NUM I-GENE
in O
NUM I-GENE
- I-GENE
cells O
. O

CONCLUSION O
: O
The O
study O
demonstrates O
that O
RARE O
ultrasonography O
has O
an O
efficiency O
of O
88 O
% O
in O
differentiating O
RARE O
from O
other O
ovarian O
masses O
with O
a O
RARE O
of O
NUM O
%. O

Genomic O
Southern O
blot O
analysis O
of O
rat I-GENE
EFIA I-GENE
( O
gene O
encoding O
enhancer I-GENE
factor I-GENE
I I-GENE
subunit I-GENE
A I-GENE
) O
reveals O
a O
complex O
band O
pattern O
when O
cDNA O
RARE O
RARE O
are O
used O
. O

The O
effect O
of O
RARE O
and O
furosemide O
in O
NUM O
patients O
with O
ALL_CAP O
RARE O
I O
and O
II O
RARE O
failure O
were O
studied O
in O
a O
parallel O
, O
double O
- O
blind O
, O
randomized O
placebo O
- O
RARE O
RARE O
- O
RARE O
trial O
. O

The O
RARE I-GENE
- I-GENE
3 I-GENE
gene I-GENE
of I-GENE
the I-GENE
RARE I-GENE
RARE I-GENE
Neurospora I-GENE
crassa I-GENE
encodes O
RARE I-GENE
reductase I-GENE
, O
the O
enzyme O
which O
catalyzes O
the O
RARE O
step O
in O
RARE O
RARE O
. O

RARE O
can O
be O
described O
by O
a O
two O
- O
state O
process O
since O
a O
ratio O
of O
delta O
RARE O
to O
delta O
RARE O
' O
t O
RARE O
RARE O
NUM O
. O
96 O
. O

A O
Dictyostelium O
RARE O
overexpressing O
RARE I-GENE
does O
not O
develop O
normally O
. O

This O
motif O
has O
been O
shown O
to O
mediate O
protein O
interactions O
in O
the O
case O
of O
RARE I-GENE
RARE O
RARE O
RARE O
several O
other O
repeat O
- O
RARE O
proteins O
. O

RARE I-GENE
NUM I-GENE
] I-GENE
RARE I-GENE
( I-GENE
NUM I-GENE
- I-GENE
NUM I-GENE
) I-GENE
retains O
full O
biological O
activity O
. O

We O
RARE O
that O
CaM I-GENE
binding O
by O
HIV I-GENE
envelope I-GENE
proteins I-GENE
is O
likely O
to O
exert O
diverse O
RARE O
effects O
, O
and O
the O
mechanism O
RARE O
HIV O
- O
RARE O
cytotoxicity O
may O
involve O
, O
in O
part O
, O
inhibition O
of O
CaM I-GENE
- O
regulated O
cellular O
functions O
. O

There O
was O
RARE O
apparent O
effect O
of O
growth O
RARE O
on O
the O
steady O
- O
state O
levels O
of O
NUM I-GENE
mRNA I-GENE
in O
wild O
type O
RARE O
. O

The O
major O
myosin I-GENE
- I-GENE
binding I-GENE
domain I-GENE
of O
skeletal I-GENE
muscle I-GENE
ALL_CAP I-GENE
- I-GENE
C I-GENE
( O
C I-GENE
protein I-GENE
) O
resides O
in O
the O
ALL_CAP O
- O
terminal O
, O
immunoglobulin I-GENE
C2 I-GENE
motif I-GENE
. O

A O
second O
important O
molecule O
in O
TCR I-GENE
signal O
RARE O
is O
the O
guanine I-GENE
nucleotide I-GENE
binding I-GENE
protein I-GENE
, O
p21ras I-GENE
, O
which O
is O
coupled O
to O
the O
TCR I-GENE
by O
a O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
dependent O
mechanism O
. O

Our O
results O
indicate O
that O
RARE O
RARE O
accumulation O
is O
related O
to O
cortical O
oxygenation O
. O

We O
conclude O
that O
the O
ALL_CAP O
questionnaire O
has O
good O
RARE O
RARE O
an O
instrument O
RARE O
assessing O
ALL_CAP O
in O
post O
- O
AMI O
patients O
and O
that O
it O
can O
be O
successfully O
self O
- O
administered O
. O

Most O
smokers O
would O
RARE O
to O
RARE O
smoking O
on O
their O
own O
. O

The O
RARE O
response O
to O
RARE O
is O
essentially O
a O
protective O
reflex O
which O
probably O
serves O
to O
reduce O
the O
activity O
of O
the O
jaw O
- O
RARE O
muscles O
when O
one O
RARE O
RARE O
on O
RARE O
objects O
. O

The O
action O
of O
nef I-GENE
was O
specific O
to O
the O
LTR O
, O
RARE O
RARE O
of O
nef I-GENE
had O
RARE O
effect O
on O
the O
activity O
of O
the O
simian O
virus O
40 O
, O
c I-GENE
- I-GENE
fms I-GENE
, O
urokinase I-GENE
plasminogen I-GENE
activator I-GENE
, O
or O
type I-GENE
5 I-GENE
acid I-GENE
phosphatase I-GENE
promoter I-GENE
. O
RARE O
- O
activating O
activity O
was O
also O
manifested O
by O
a O
frameshift O
mutant O
expressing O
only O
the O
RARE O
NUM O
amino O
RARE O
of O
the O
protein O
. O

The O
product O
of O
the O
RARE I-GENE
RARE I-GENE
reading I-GENE
frame I-GENE
of I-GENE
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
is O
a O
NUM O
- O
kDa O
, O
RARE O
- O
rich O
protein O
that O
is O
present O
in O
virions O
in O
RARE O
RARE O
equivalent O
to O
that O
of O
Gag I-GENE
. O

The O
recombinant I-GENE
RARE I-GENE
virus I-GENE
- I-GENE
RARE I-GENE
mutant I-GENE
P1 I-GENE
RARE I-GENE
were O
analyzed O
RARE O
RARE O
RARE O
defects O
in O
cells O
RARE O
with O
a O
recombinant O
RARE O
virus O
( O
NUM O
) O
that O
RARE O
the O
RARE I-GENE
NUM I-GENE
protease I-GENE
and O
RARE O
RARE O
and O
assembly O
defects O
by O
using O
a O
RARE O
RARE O
RARE O
in O
which O
P1 I-GENE
- O
expressing O
recombinant O
RARE O
viruses O
provide O
RARE I-GENE
precursor I-GENE
to O
a O
RARE O
RARE O
genome O
that O
does O
not O
express O
RARE O
RARE I-GENE
proteins I-GENE
( O
D O
. O

In O
contrast O
, O
RARE I-GENE
proteins I-GENE
derived O
from O
the O
P1 I-GENE
precursor I-GENE
with O
a O
RARE O
substitution O
RARE O
the O
amino O
terminus O
of O
NUM I-GENE
( O
NUM I-GENE
- I-GENE
NUM I-GENE
) O
assembled O
RARE O
RARE O
RARE O
but O
were O
RARE O
in O
RARE O
RNA O
- O
containing O
virions O
. O

RESULTS O
: O
In O
an O
18 O
RARE O
period O
and O
out O
of O
a O
RARE O
of O
NUM O
positive O
RARE O
cultures O
( O
154 O
significant O
RARE O
) O
14 O
episodes O
of O
RARE O
by O
M O
. O
tuberculosis O
were O
studied O
in O
12 O
RARE O
patients O
RARE O
by O
the O
human O
immunodeficiency O
virus O
with O
associated O
severe O
RARE O
( O
mean O
of O
NUM I-GENE
= O
NUM O
. O
NUM O
RARE O
10 O
( O
9 O
RARE O
RARE O
). O

RARE O
RARE O
on O
the O
larynx O
of O
RARE O
rabbits O
resulted O
in O
significant O
RARE O
, O
central O
, O
and O
mixed O
apnea O
. O

By O
using O
RARE O
- O
protein O
extracts O
from O
RARE O
grown O
under O
RARE O
producing O
conditions O
we O
have O
detected O
a O
DNA O
- O
binding O
activity O
that O
specifically O
shifts O
a O
promoter O
fragment O
RARE O
between O
- O
NUM O
and O
- O
NUM O
( O
relative O
to O
ALL_CAP I-GENE
RARE I-GENE
). O

A O
series O
of O
5 O
'- O
deletions O
revealed O
that O
the O
fragment O
- O
NUM O
to O
+ O
4 O
from O
the O
ALL_CAP O
had O
the O
highest O
promoter O
activity O
, O
nearly O
1000 O
- O
RARE O
greater O
than O
the O
promoterless O
chloramphenicol I-GENE
RARE I-GENE
construct I-GENE
. O

The O
NUM I-GENE
gene I-GENE
was O
RARE O
in O
the O
RARE O
vector O
ALL_CAP O
and O
transfected O
into O
wild O
- O
type O
L O
. O
RARE O
and O
the O
resulting O
transfected O
cells O
were O
resistant O
to O
RARE O
but O
RARE O
lower O
levels O
than O
in O
the O
RARE O
mutant O
cells O
. O

The O
RARE O
of O
RARE O
from O
capsules O
exposed O
to O
stressed O
conditions O
was O
compared O
in O
both O
dogs O
and O
humans O
to O
capsules O
stored O
RARE O
RT O
conditions O
. O

Similar O
synergistic O
activation O
was O
observed O
in O
the O
ALL_CAP I-GENE
- I-GENE
8 I-GENE
promoter I-GENE
, O
which O
also O
contains O
both O
ALL_CAP I-GENE
- I-GENE
IL6 I-GENE
and O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
binding I-GENE
sites I-GENE
. O

RARE O
of O
RARE O
. O

No O
homology O
was O
found O
between O
the O
NUM O
protein O
and O
known O
RARE O
of O
proteins O
. O

We O
report O
an O
RARE O
case O
of O
marked O
enlargement O
of O
RARE O
RARE O
in O
a O
patient O
with O
RARE O
RARE O
. O

As O
RARE O
RARE O
metabolism O
, O
the O
mean O
values O
RARE O
RARE O
RARE O
, O
cholesterol O
, O
LDL I-GENE
- I-GENE
cholesterol I-GENE
and O
ALL_CAP I-GENE
- I-GENE
cholesterol I-GENE
seen O
RARE O
the O
end O
of O
five O
years O
of O
RARE O
- O
2 O
RARE O
use O
and O
RARE O
months O
RARE O
were O
similar O
to O
the O
RARE O
mean O
. O

At O
a O
PaCO2 O
of O
40 O
mmHg O
, O
baseline O
brain O
RARE O
measured O
7 O
. O
03 O
+/- O
NUM O
. O
04 O
, O
while O
regional O
cortical O
RARE O
flow O
was O
NUM O
. O
NUM O
+/- O
4 O
. O
3 O
ml O
. O
NUM O
g O
- O
1 O
. O
min O
- O
1 O
. O

ALL_CAP O
RARE O
RARE O
( O
defined O
RARE O
the O
last O
common O
minute O
of O
exercise O
) O
VO2 O
and O
RARE O
in O
those O
patients O
with O
more O
severe O
RARE O
RARE O
, O
but O
these O
values O
tended O
to O
increase O
slightly O
in O
the O
patients O
with O
only O
mild O
RARE O
RARE O
. O

Effects O
of O
diltiazem O
on O
RARE O
- O
RARE O
RARE O
in O
rabbits O
. O

Four O
forms O
of O
RARE O
were O
RARE O
in O
RARE O
and O
RARE O
RARE O
by O
RARE O
: O
RARE O
, O
and O
acute O
, O
subacute O
and O
chronic O
enteric O
. O

RARE O
20 O
% O
of O
single O
- O
RARE O
DNA O
binding O
was O
observed O
in O
the O
presence O
of O
ALL_CAP O
, O
but O
none O
was O
detectable O
in O
the O
absence O
of O
nucleotides O
. O

To O
our O
knowledge O
this O
is O
the O
RARE O
case O
in O
which O
a O
probable O
association O
between O
RARE O
and O
RARE O
' O
s O
RARE O
has O
been O
recorded O
. O

Both O
4 O
, O
8 O
- O
RARE O
and O
A O
alpha O
C O
were O
found O
RARE O
< O
1 O
p O
. O
p O
. O
b O
. O

Three O
cysteine O
and O
four O
RARE O
residues O
, O
previously O
identified O
RARE O
RARE O
RARE O
RARE I-GENE
- I-GENE
oxide I-GENE
RARE I-GENE
, O
are O
found O
in O
the O
RARE O
enzyme O
. O

Recombinant I-GENE
RARE I-GENE
surface I-GENE
glycoprotein I-GENE
NUM I-GENE
is O
RARE O
in O
the O
RARE O
RARE O
RARE O
RARE O
a O
latent O
RARE I-GENE
. O

RARE O
the O
RARE O
basis O
RARE O
agonist O
- O
RARE O
RARE O
of O
mRNA O
of O
G I-GENE
- I-GENE
protein I-GENE
- I-GENE
RARE I-GENE
receptors I-GENE
that O
contributes O
to O
receptor O
down O
- O
RARE O
is O
RARE O
to O
our O
understanding O
of O
long O
- O
term O
RARE O
of O
receptors O
by O
agonist O
. O

Addition O
of O
RARE O
- O
stabilized O
F I-GENE
- I-GENE
actin I-GENE
nuclei O
and O
RARE O
restored O
NUM O
actin I-GENE
' O
s O
ability O
to O
RARE O
RARE O
4 O
degrees O
C O
. O

These O
cells O
produce O
a O
low O
level O
of O
ALL_CAP I-GENE
- I-GENE
5 I-GENE
when O
RARE O
with O
PMA O
alone O
; O
however O
, O
NUM O
, O
NUM O
- O
RARE O
cAMP O
( O
NUM O
RARE O
in O
combination O
with O
PMA O
, O
augmented O
by O
more O
than O
RARE O
the O
ALL_CAP I-GENE
- I-GENE
5 I-GENE
production O
RARE O
the O
mRNA O
and O
the O
protein O
levels O
. O

RARE I-GENE
- I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
RARE O
in O
a O
small O
number O
of O
human O
T O
cell O
tumor O
lines O
did O
not O
correlate O
with O
any O
particular O
RARE O
or O
RARE O
of O
development O
. O

Partial O
RARE O
was O
RARE O
in O
the O
treatments O
. O

Northern O
( O
RNA O
) O
analysis O
demonstrated O
RARE O
of O
human O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
in O
all O
tissues O
and O
cell O
lines O
tested O
. O

These O
results O
demonstrate O
the O
existence O
of O
different O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
isoforms I-GENE
and O
define O
a O
family O
of O
genes O
encoding O
distinct O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
catalytic I-GENE
subunits I-GENE
that O
can O
associate O
with O
p85 I-GENE
. O

In O
addition O
to O
the O
protein I-GENE
- I-GENE
tyrosine I-GENE
kinase I-GENE
domain I-GENE
, O
NUM I-GENE
possesses O
Src I-GENE
homology I-GENE
2 I-GENE
and I-GENE
3 I-GENE
( O
NUM I-GENE
and O
SH3 I-GENE
) O
domains O
RARE O
RARE O
RARE O
a O
unique O
N O
- O
terminal O
region O
. O

RARE O
RARE O
the O
NUM I-GENE
mutation I-GENE
process O
the O
20S I-GENE
precursor I-GENE
of O
the O
RARE I-GENE
NUM I-GENE
rRNA I-GENE
slowly O
and O
are O
RARE O
in O
NUM I-GENE
ribosomal I-GENE
subunits I-GENE
. O

RARE O
B O
and O
liver O
transplantation O
. O

One O
complex O
most O
likely O
contained O
NUM I-GENE
, O
and O
another O
complex O
showed O
S O
- O
RARE O
- O
specific O
binding O
, O
suggesting O
a O
direct O
role O
in O
the O
cell O
- O
RARE O
- O
dependent O
NUM I-GENE
gene I-GENE
RARE O
. O

These O
combined O
observations O
define O
a O
promoter O
and O
an O
enhancer O
RARE O
the O
chicken I-GENE
L I-GENE
- I-GENE
ALL_CAP I-GENE
gene I-GENE
. O

The O
rate O
of O
RARE O
RARE O
RARE O
by O
a O
given O
RARE O
correlates O
closely O
with O
the O
rate O
of O
measured O
ALL_CAP O
production O
from O
the O
RARE O
molecule O
. O

RARE O
resulted O
in O
a O
serious O
RARE O
of O
the O
position O
of O
the O
peak O
of O
the O
RARE O
RARE O
field O
. O

The O
duration O
of O
diabetes O
mellitus O
in O
these O
patients O
was O
from O
5 O
months O
to O
6 O
years O
, O
and O
in O
all O
patients O
this O
was O
the O
RARE O
RARE O
infarction O
. O

The O
NUM O
- O
kDa O
complex O
appears O
to O
contain O
two O
distinct O
protein O
- O
DNA O
complexes O
of O
RARE O
NUM O
and O
256 O
kDa O
and O
represents O
two O
proteins O
covalently O
cross O
- O
RARE O
to O
a O
single O
ALL_CAP O
RARE O
, O
while O
the O
97 O
, O
NUM O
, O
and O
NUM O
- O
kDa O
complexes O
represent O
single O
protein O
- O
ALL_CAP O
cross O
- O
links O
. O

The O
promoter O
and O
upstream O
region O
of O
the O
RARE I-GENE
RARE I-GENE
NUM I-GENE
RARE I-GENE
protein I-GENE
ALL_CAP I-GENE
gene I-GENE
were O
studied O
to O
identify O
cis O
- O
acting O
sequences O
involved O
in O
developmental O
RARE O
- O
specific O
RARE O
. O

However O
, O
limited O
comparisons O
reveal O
domains O
in O
the O
NH2 O
and O
ALL_CAP O
termini O
that O
have O
a O
high O
degree O
of O
RARE O
suggesting O
RARE O
conservation O
. O

RARE O
RARE O
the O
RARE O
RARE O
and O
RARE O
represents O
the O
RARE O
/ O
RARE O
pressure O
RARE O
in O
the O
RARE O
. O

We O
have O
explored O
the O
mechanism O
of O
action O
of O
the O
fibronectin I-GENE
RARE I-GENE
enhancer I-GENE
and O
found O
that O
the O
SE O
element O
is O
required O
RARE O
efficient O
assembly O
of O
early O
RARE O
complexes O
, O
allowing O
a O
more O
efficient O
interaction O
of O
the O
NUM I-GENE
snRNP I-GENE
with O
branch O
site O
sequences O
. O

RARE O
of O
enhancer O
mutants O
suggests O
that O
RARE O
- O
activation O
by O
ALL_CAP I-GENE
/ O
GAL4 I-GENE
is O
especially O
dependent O
on O
TCF I-GENE
- I-GENE
2 I-GENE
, O
a O
distinct O
T O
- O
cell O
- O
RARE O
protein O
that O
binds O
to O
sequences O
flanking O
the O
ALL_CAP I-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
the O
enhancer O
. O

We O
conclude O
that O
sequences O
outside O
of O
the O
ALL_CAP I-GENE
HMG I-GENE
box I-GENE
mediate O
cell O
- O
and O
context O
- O
specific O
activation O
of O
the O
TCR I-GENE
alpha I-GENE
enhancer I-GENE
and O
may O
facilitate O
interactions O
between O
ALL_CAP I-GENE
and O
other O
T O
- O
cell O
- O
specific O
factors O
recruited O
to O
the O
enhancer O
. O

A O
cAMP O
response O
element O
( O
ALL_CAP O
) O
consensus O
signal O
was O
identified O
in O
the O
5 O
'- O
noncoding O
region O
. O
cAMP O
regulates O
the O
RARE O
of O
NUM I-GENE
. I-GENE
5 I-GENE
gene I-GENE
in O
a O
cell O
- O
specific O
manner O
. O

A O
number O
of O
serological O
tests O
measuring O
the O
presence O
of O
RARE O
RARE O
- O
specific O
serum O
immunoglobulin I-GENE
G I-GENE
( O
IgG I-GENE
) O
are O
now O
RARE O
available O
. O

Using O
a O
series O
of O
mutant I-GENE
T I-GENE
antigens I-GENE
RARE O
by O
recombinant O
RARE O
in O
Sf9 O
cells O
, O
we O
find O
that O
the O
origin O
RARE O
activities O
of O
both O
NUM O
RARE O
A O
and O
NUM O
, O
NUM O
RARE O
A O
are O
inhibited O
by O
the O
T I-GENE
- I-GENE
antigen I-GENE
kinase I-GENE
, O
RARE O
is O
wild I-GENE
- I-GENE
type I-GENE
T I-GENE
antigen I-GENE
. O

The O
degree O
of O
RARE O
was O
slightly O
related O
to O
decrease O
in O
FEV1 O
. O
NUM O
%, O
NUM O
and O
PaO2 O
and O
increase O
in O
circulating O
RARE O
volume O
and O
peripheral O
RARE O
RARE O
cell O
counts O
. O

Two O
patients O
were O
treated O
successfully O
with O
a O
combination O
of O
RARE O
( O
a O
tissue O
RARE O
) O
and O
RARE O
( O
a O
RARE O
RARE O
). O

We O
have O
identified O
in O
the O
5 O
' O
RARE O
region O
of O
the O
Drosophila I-GENE
RARE I-GENE
RARE I-GENE
, O
3 O
' O
to O
the O
RARE O
LTR O
, O
a O
sequence O
RARE O
transcriptional O
RARE O
by O
RARE O
. O

In O
the O
present O
study O
, O
lesions O
of O
the O
ALL_CAP O
complex O
( O
the O
RARE O
source O
of O
afferents O
to O
ALL_CAP O
and O
HD O
) O
were O
found O
to O
have O
RARE O
effect O
on O
color O
- O
reversal O
learning O
performance O
. O

The O
fourth O
dose O
produced O
RARE O
results O
( O
NUM O
. O
7 O
%) O
in O
individuals O
with O
ALL_CAP I-GENE
antibodies I-GENE
between O
10 O
and O
NUM O
IU O
/ O
ml O
and O
RARE O
ones O
( O
3 O
. O
8 O
%) O
where O
the O
ALL_CAP I-GENE
antibodies I-GENE
were O
below O
10 O
IU O
/ O
ml O
. O

CONCLUSIONS O
: O
In O
our O
patients O
and O
within O
the O
range O
of O
treatment O
variables O
studied O
, O
age O
, O
RARE O
index O
, O
and O
graft O
- O
versus O
- O
RARE O
RARE O
are O
the O
most O
important O
factors O
related O
with O
early O
mortality O
. O

Nucleotide O
sequence O
analysis O
of O
the O
ALL_CAP I-GENE
gene I-GENE
in O
these O
two O
mutants O
confirmed O
the O
ALL_CAP I-GENE
- I-GENE
RARE O
. O

This O
intron O
RARE O
a O
RARE O
position O
corresponding O
to O
that O
of O
intron O
1 O
in O
the O
transit O
peptide O
region O
of O
chloroplast I-GENE
ALL_CAP I-GENE
genes I-GENE
( O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
) O
of O
RARE O
RARE O
. O

The O
drug O
- O
resistant O
cell O
lines O
P388 O
/ O
ADR O
/ O
3 O
and O
P388 O
/ O
ADR O
/ O
7 O
express O
a O
shortened O
RARE I-GENE
II I-GENE
alpha I-GENE
mRNA I-GENE
transcript I-GENE
in O
addition O
to O
the O
RARE O
transcript O
present O
in O
the O
drug O
- O
RARE O
P388 O
/ O
4 O
cell O
line O
. O

Using O
a O
3 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
strategy O
, O
we O
have O
RARE O
cDNAs O
representing O
the O
3 O
'- O
termini O
of O
both O
the O
RARE O
and O
mutant O
transcripts O
from O
both O
P388 O
/ O
ADR O
/ O
3 O
and O
P388 O
/ O
ADR O
/ O
7 O
cells O
. O

The O
RARE I-GENE
NUM I-GENE
factor I-GENE
is O
a O
nuclear O
RARE O
; O
the O
extent O
of O
its O
RARE O
is O
regulated O
RARE O
the O
cell O
RARE O
. O

Similarly O
, O
the O
N O
- O
terminal O
cytoplasmic O
domain O
of O
the O
latent I-GENE
membrane I-GENE
protein I-GENE
NUM I-GENE
( O
NUM I-GENE
) O
of O
the O
Epstein O
- O
Barr O
virus O
( O
ALL_CAP O
) O
contains O
a O
single O
copy O
of O
the O
RARE O
- O
X O
- O
X O
- O
RARE O
/ O
Ile O
- O
containing O
motif O
which O
could O
play O
a O
critical O
role O
in O
B O
cell O
transformation O
. O

The O
RARE O
homology O
of O
NUM I-GENE
with O
NUM I-GENE
, O
which O
has O
been O
implicated O
in O
the O
control O
of O
cell O
polarity O
, O
suggests O
a O
RARE O
between O
two O
RARE O
events O
such O
RARE O
establishment O
of O
cell O
polarity O
and O
cell O
RARE O
biosynthesis O
. O

Molecular O
cloning O
of O
a O
P I-GENE
- I-GENE
type I-GENE
ATPase I-GENE
gene I-GENE
from O
the O
RARE O
RARE O
RARE O
. O

The O
cloning O
of O
NUM I-GENE
represents O
the O
RARE O
example O
of O
the O
RARE O
genetic O
characterization O
of O
a O
RARE O
peptide O
RARE O
gene O
. O

By O
using O
the O
full O
- O
length O
cytoplasmic O
domain O
and O
mutants O
with O
progressive O
RARE O
- O
terminal O
deletions O
, O
internal O
deletions O
, O
or O
point O
mutations O
, O
we O
identified O
the O
RARE O
NUM O
amino O
acid O
residues O
of O
ALL_CAP I-GENE
RARE O
the O
minimal O
region O
necessary O
RARE O
RARE O
. O

To O
examine O
the O
biochemical O
basis O
of O
the O
end O
RARE O
, O
nuclear O
extracts O
were O
prepared O
from O
a O
wide O
variety O
of O
mammalian O
cell O
lines O
and O
tested O
RARE O
their O
ability O
to O
RARE O
test O
RARE O
RARE O
. O

These O
data O
indicate O
that O
the O
largest O
subunit O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
and O
ALL_CAP I-GENE
are O
important O
RARE O
of O
transcription O
RARE O
site O
selection O
in O
S O
. O
cerevisiae O
and O
suggest O
that O
this O
function O
might O
be O
conferred O
by O
interaction O
between O
these O
two O
proteins O
. O

Recombinant O
RARE O
of O
a O
chimeric O
EGFR I-GENE
/ O
ErbB I-GENE
- I-GENE
3 I-GENE
receptor I-GENE
in O
ALL_CAP O
3T3 O
RARE O
allowed O
us O
to O
investigate O
cytoplasmic O
events O
associated O
with O
ErbB I-GENE
- I-GENE
3 I-GENE
signal O
RARE O
upon O
RARE O
activation O
. O

RARE O
RARE O
were O
used O
to O
evaluate O
the O
RARE O
of O
the O
TATA O
- O
binding O
site O
in O
TIF I-GENE
- I-GENE
ALL_CAP I-GENE
, O
TFIID I-GENE
, O
and O
ALL_CAP I-GENE
. O

The O
NUM O
- O
to O
- O
239 O
region O
blocked O
ADR1 I-GENE
activity O
independently O
of O
the O
ALL_CAP I-GENE
present O
on O
ADR1 I-GENE
, O
ADR1 I-GENE
DNA O
binding O
, O
and O
specific O
NUM I-GENE
promoter I-GENE
sequences I-GENE
. O

Analysis O
of O
strains O
harboring O
an O
NUM I-GENE
RARE I-GENE
mutation I-GENE
demonstrates O
that O
NUM I-GENE
is O
not O
essential O
RARE O
normal O
RARE O
growth O
but O
appears O
to O
be O
required O
RARE O
meiosis O
. O

TGF I-GENE
beta I-GENE
1 I-GENE
RARE O
is O
largely O
RARE O
by O
three O
AP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sites I-GENE
RARE O
in O
two O
different O
promoters O
of O
this O
gene O
. O

RARE O
RARE O
RARE O
mutations O
selectively O
alter O
helix O
- O
helix O
RARE O
in O
the O
transmembrane O
segment O
of O
RARE I-GENE
NUM I-GENE
coat I-GENE
protein I-GENE
. O

RARE O
change O
in O
the O
ALL_CAP O
. O

A O
much O
less O
RARE O
solution O
than O
ALL_CAP O
, O
containing O
only O
K O
RARE O
RARE O
, O
NUM O
, O
NUM O
and O
RARE O
, O
can O
be O
used O
successfully O
RARE O
preservation O
of O
rat O
hepatocytes O
RARE O
NUM O
hr O
RARE O
drug O
RARE O
studies O
. O

RARE O
administration O
of O
NUM O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
significantly O
improved O
the O
ALL_CAP O
- O
RARE O
RARE O
deficits O
by O
increasing O
the O
ALL_CAP O
- O
decreased O
rate O
from O
NUM O
. O
8 O
+/- O
9 O
. O
6 O
to O
NUM O
. O
8 O
+/- O
4 O
. O
2 O
in O
d O
3 O
learning O
acquisition O
( O
F O
( O
1 O
, O
14 O
) O
= O
5 O
. O
6 O
, O
p O
< O
NUM O
. O
05 O
RARE O
from O
53 O
. O
4 O
+/- O
8 O
. O
4 O
to O
NUM O
. O
NUM O
+/- O
8 O
. O
2 O
in O
NUM O
h O
memory O
acquisition O
( O
F O
( O
1 O
, O
14 O
) O
= O
7 O
. O
5 O
, O
p O
< O
NUM O
. O
05 O
) O
and O
from O
NUM O
. O
NUM O
+/- O
5 O
. O
5 O
to O
88 O
. O
3 O
+/- O
2 O
. O
5 O
in O
NUM O
h O
memory O
retention O
( O
F O
( O
1 O
, O
12 O
) O
NUM O
. O
5 O
, O
p O
< O
NUM O
. O
01 O
) O
RARE O
RARE O
RARE O
from O
NUM O
. O
NUM O
+/- O
6 O
. O
8 O
to O
NUM O
. O
6 O
+/- O
6 O
. O
9 O
in O
NUM O
h O
memory O
RARE O
( O
F O
( O
1 O
, O
12 O
) O
= O
5 O
. O
2 O
, O
p O
< O
NUM O
. O
05 O
RARE O
respectively O
. O

Human I-GENE
NUM I-GENE
protein I-GENE
specifically O
RARE O
( I-GENE
NUM I-GENE
) I-GENE
2 I-GENE
- I-GENE
DNA I-GENE
complexes I-GENE
. O

The O
therapeutic O
action O
of O
cyclosporin O
A O
( O
RARE O
): O
its O
application O
in O
rheumatoid O
arthritis O
. O

In O
vitro O
translation O
experiments O
show O
that O
human O
cDNA O
derived O
RNA O
RARE O
into O
a O
protein O
with O
a O
mobility O
of O
NUM O
- O
NUM O
ALL_CAP O
on O
SDS O
polyacrylamide O
gels O
. O

After O
peripheral O
administration O
of O
both O
ALL_CAP I-GENE
and O
TRH I-GENE
, O
ACTH I-GENE
levels O
were O
significantly O
RARE O
on O
the O
tumor O
RARE O
in O
all O
patients O
. O

RARE O
analgesia O
: O
is O
there O
a O
RARE O
RARE O
RARE O
RARE O
? O
RARE O
can O
be O
a O
useful O
analgesic O
agent O
RARE O
the O
management O
of O
acute O
dental O
pain O
. O

A O
sequence O
homology O
analysis O
between O
human I-GENE
NUM I-GENE
- I-GENE
NUM I-GENE
and O
the O
homolog O
gene O
of O
the O
rat O
( O
ALL_CAP I-GENE
- I-GENE
K I-GENE
beta I-GENE
) O
shows O
that O
RARE O
- O
intron O
boundaries O
are O
RARE O
RARE O
between O
these O
two O
species O
. O

A O
favourable O
response O
was O
achieved O
with O
a O
combination O
of O
amphotericin O
B O
and O
RARE O
. O

Response O
durations O
were O
short O
. O

RESULTS O
: O
At O
the O
beginning O
of O
the O
ALL_CAP O
/ O
ALL_CAP O
process O
, O
monitoring O
of O
RARE O
administration O
RARE O
revealed O
that O
a O
RARE O
from O
RARE O
RARE O
administration O
RARE O
occurred O
RARE O
50 O
percent O
of O
RARE O
and O
RARE O
RARE O
. O

In O
addition O
, O
NUM O
RARE O
were O
resistant O
to O
an O
unusually O
broad O
range O
of O
RARE O
including O
RARE O
mosaic O
virus O
, O
tobacco O
mild O
RARE O
mosaic O
virus O
, O
ALL_CAP O
- O
NUM O
, O
RARE O
RARE O
atypical O
mosaic O
virus O
, O
and O
RARE O
mosaic O
virus O
. O

Drug O
effect O
, O
measured O
RARE O
RARE O
RARE O
, O
was O
also O
similar O
in O
the O
patients O
with O
cirrhosis O
and O
control O
subjects O
; O
therefore O
the O
ratio O
of O
effect O
area O
under O
the O
curve O
to O
concentration O
area O
under O
the O
curve O
, O
a O
measure O
of O
sensitivity O
, O
did O
not O
differ O
significantly O
between O
the O
patients O
with O
cirrhosis O
and O
the O
control O
subjects O
. O

We O
present O
evidence O
that O
YY1 I-GENE
, O
a O
ubiquitously O
RARE O
DNA O
- O
binding O
protein O
, O
regulates O
the O
activity O
of O
the O
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
primarily O
through O
an O
effect O
on O
DNA O
RARE O
. O

In O
a O
retrospective O
analysis O
of O
RARE O
- O
time O
RARE O
RARE O
in O
NUM O
patients O
, O
we O
investigated O
the O
relationship O
between O
RARE O
and O
RARE O
polyps O
. O

The O
rate O
of O
RARE O
in O
ALL_CAP O
amplitude O
over O
a O
RARE O
time O
period O
was O
utilized O
RARE O
a O
measure O
of O
RARE O
to O
the O
acoustic O
trauma O
. O

Effect O
of O
single O
RARE O
substitutions O
RARE O
glycine O
- O
NUM O
RARE O
of O
RARE I-GENE
S I-GENE
RARE I-GENE
2 I-GENE
gene I-GENE
on O
proline O
activation O
. O

The O
predicted O
NUM I-GENE
sequence I-GENE
contains O
two O
putative O
ATP O
- O
binding O
domains O
and O
shows O
structural O
relationships O
to O
other O
RARE O
ATP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
involved O
in O
biological O
processes O
RARE O
diverse O
RARE O
RARE O
biogenesis O
, O
vesicle O
- O
RARE O
protein O
RARE O
, O
cell O
RARE O
control O
, O
and O
transcriptional O
RARE O
. O

The O
results O
show O
that O
the O
RARE O
of O
the O
RARE I-GENE
gene I-GENE
promoter I-GENE
is O
different O
from O
that O
of O
any O
other O
RARE O
promoter O
characterized O
so O
far O
and O
indicate O
that O
the O
RARE O
/ O
RARE O
segment O
plays O
a O
role O
in O
the O
RARE O
of O
gene O
transcription O
. O

The O
kinase O
inhibitor O
RARE O
( O
1 O
microM O
) O
blocks O
ALL_CAP O
- O
RARE O
, O
but O
not O
RARE O
growth O
factor O
- O
RARE O
, O
activation O
of O
p21ras I-GENE
and O
MAP I-GENE
kinase I-GENE
, O
consistent O
with O
an O
RARE O
protein O
kinase O
linking O
the O
ALL_CAP I-GENE
receptor I-GENE
to O
p21ras I-GENE
activation O
. O

NUM O
, O
NUM O
- O
NUM O
)) O
indicates O
an O
overall O
identity O
of O
58 O
and O
NUM O
%, O
respectively O
, O
with O
a O
91 O
and O
92 O
% O
identity O
in O
the O
highly O
RARE O
transmembrane O
and O
cytoplasmic O
domains O
. O

S O
., O
K O
. O

The O
survival O
rate O
RARE O
RARE O
months O
in O
NUM O
patients O
with O
N2 O
RARE O
who O
underwent O
NUM O
operation O
was O
NUM O
%. O

RARE O
with O
severe O
anatomical O
abnormalities O
, O
who O
are O
HIV O
positive O
, O
have O
RARE O
ALL_CAP O
or O
whose O
children O
have O
inherited O
mono O
- O
or O
RARE O
RARE O
should O
not O
RARE O
. O

G O
. O

The O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
and O
ALL_CAP I-GENE
products I-GENE
have O
two O
isoforms O
each O
that O
are O
distinguished O
by O
different O
RARE O
in O
polyacrylamide O
gel O
electrophoresis O
, O
and O
the O
ALL_CAP I-GENE
product I-GENE
has O
four O
isoforms O
. O

When O
RARE O
- O
RARE O
ALL_CAP O
type O
V O
RARE O
were O
exposed O
to O
either O
NUM O
. O
20 O
ml O
50 O
% O
ethanol O
in O
ALL_CAP O
or O
to O
NUM O
. O
20 O
ml O
ALL_CAP O
( O
controls O
RARE O
ethanol O
- O
treated O
RARE O
showed O
a O
ALL_CAP O
incidence O
of O
NUM O
. O
1 O
% O
compared O
with O
a O
3 O
. O
6 O
% O
incidence O
in O
the O
controls O
( O
P O
= O
NUM O
. O
NUM O
). O

RARE O
RARE O
RARE O
in O
RARE O
patients O

In O
our O
studies O
, O
we O
utilized O
HIV O
- O
1 O
NUM I-GENE
and O
HIV O
- O
1 O
NUM I-GENE
core I-GENE
RARE I-GENE
because O
the O
NUM I-GENE
RARE O
has O
a O
single O
point O
mutation O
flanking O
the O
right O
ALL_CAP I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

The O
secondary O
, O
but O
not O
the O
RARE O
, O
antibody O
responses O
of O
male O
NUM O
/ O
6 O
mice O
were O
RARE O
among O
mice O
RARE O
alone O
compared O
to O
mice O
RARE O
in O
groups O
; O
differences O
were O
observed O
RARE O
both O
IgM I-GENE
and O
IgG I-GENE
anti I-GENE
- I-GENE
ALL_CAP I-GENE
antibodies I-GENE
. O

However O
, O
a O
RARE O
high O
degree O
of O
conservation O
of O
intron O
sequences O
was O
observed O
between O
both O
species O
. O

Interleukin I-GENE
- I-GENE
6 I-GENE
may O
possibly O
RARE O
metastasis O
of O
cardiac O
RARE O
. O

Other O
parameters O
of O
iron O
metabolism O
, O
including O
ferritin I-GENE
, O
were O
not O
found O
to O
contribute O
to O
the O
risk O
. O

RARE O
to O
the O
RARE O
RARE O
vaccine O
by O
NUM O
calves O
and O
70 O
adult O
cattle O
in O
RARE O
in O
1990 O
, O
through O
the O
production O
of O
IgG I-GENE
antibodies I-GENE
, O
were O
monitored O
RARE O
4 O
weeks O
using O
the O
ELISA O
assay O
. O

Because O
of O
the O
small O
number O
of O
visceral O
angiography O
procedures O
performed O
( O
38 O
RARE O
RARE O
definitive O
conclusions O
could O
be O
RARE O
RARE O
to O
the O
differences O
between O
ionic O
and O
RARE O
agents O
regarding O
grade O
- O
2 O
and O
grade O
- O
3 O
adverse O
events O
. O

RARE O
of O
the O
RARE O
RARE O
and O
RARE O
of O
NUM O
- O
RARE O
are O
possible O
only O
in O
1 O
of O
3 O
cases O
. O

RARE O
' O
RARE O
solution O
( O
with O
NUM O
% O
NUM O
: O
5 O
% O
CO2 O
) O
can O
RARE O
the O
metabolic O
demand O
of O
the O
ischaemic O
myocardium O
and O
thus O
increase O
the O
safe O
duration O
of O
cardiac O
arrest O
. O

Plasma O
, O
LDL I-GENE
and O
liver O
cholesterol O
concentrations O
were O
RARE O
in O
the O
RARE O
control O
than O
the O
RARE O
control O
and O
lower O
in O
the O
groups O
fed O
diets O
containing O
RARE I-GENE
or O
RARE O
fiber O
than O
in O
the O
RARE O
control O
group O
. O

The O
RARE O
frame O
modification O
to O
the O
standard O
RARE O
NUM O
RARE O
allows O
RARE O
improved O
visualization O
and O
RARE O
RARE O
of O
distal O
RARE O
RARE O
compared O
to O
the O
standard O
RARE O
. O

RARE O
RARE O
cells O
RARE O
an O
abundant O
1 O
. O
1 O
kb O
mRNA O
transcript O
RARE O
NUM I-GENE
, O
but O
in O
contrast O
to O
other O
cell O
RARE O
NUM I-GENE
mRNA I-GENE
was O
RARE O
in O
both O
randomly O
RARE O
cells O
and O
in O
serum O
- O
deprived O
, O
RARE O
cultures O
. O

RARE O
RARE O
screening O
of O
ALL_CAP O
patients O
may O
provide O
a O
cost O
- O
effective O
means O
of O
RARE O
RARE O
and O
RARE O
to O
the O
relatively O
high O
levels O
of O
distress O
among O
their O
patients O
. O

A O
single O
1 O
. O
8 O
- O
kb O
transcript O
mRNA O
was O
detected O
by O
Northern O
( O
RNA O
) O
blot O
analysis O
, O
and O
its O
5 O
' O
end O
maps O
to O
a O
position O
NUM O
bp O
upstream O
from O
the O
site O
of O
initiation O
of O
protein O
RARE O
. O

RARE O
this O
sequence O
RARE O
from O
NUM O
/ O
1 O
, O
the O
NUM O
/ O
1 O
- O
specific O
cDNA O
was O
generated O
from O
RARE O
( O
A O
)+ O
RNA O
of O
bovine O
RARE O
by O
reverse O
transcription O
and O
a O
combination O
of O
polymerase O
chain O
reaction O
( O
PCR O
) O
methods O
. O

The O
sequence O
RARE O
has O
suggested O
that O
NUM I-GENE
and O
RARE I-GENE
have O
been O
derived O
from O
structurally O
and O
evolutionarily O
related O
genes O
. O

These O
data O
are O
consistent O
with O
the O
idea O
that O
the O
RARE I-GENE
- I-GENE
specific I-GENE
NUM I-GENE
gene I-GENE
evolved O
by O
duplication O
and O
modification O
of O
the O
more O
broadly O
RARE O
RARE I-GENE
/ O
NUM I-GENE
gene O
. O

The O
deduced O
amino O
acid O
sequence O
of O
the O
mouse I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
gene I-GENE
is O
identical O
to O
that O
of O
NUM I-GENE
, O
initially O
identified O
RARE O
a O
stress O
- O
RARE O
protein O
in O
mouse O
RARE O
/ O
3T3 O
cells O
. O

We O
found O
that O
NUM O
( O
10 O
RARE O
8 O
) O
M O
) O
selectively O
stimulates O
transcription O
from O
ALL_CAP I-GENE
- O
ALL_CAP O
- O
and O
RARE O
RARE O
but O
not O
ALL_CAP O
- O
ALL_CAP O
- O
and O
F2 O
- O
ALL_CAP O
RARE O
containing O
templates O
in O
which O
these O
RARE O
are O
RARE O
in O
front O
of O
the O
ALL_CAP I-GENE
minimal I-GENE
promoter I-GENE
containing O
only O
the O
TATA I-GENE
box I-GENE
binding I-GENE
protein I-GENE
, O
but O
not O
any O
other O
proximal O
binding O
protein O
, O
sequence O
. O

Using O
a O
polymerase O
chain O
reaction O
- O
based O
approach O
, O
we O
RARE O
a O
NUM O
- O
RARE O
RARE O
fragment O
of O
a O
new O
RARE O
from O
human O
placenta O
mRNA O
, O
which O
was O
then O
used O
RARE O
a O
probe O
to O
clone O
the O
RARE O
coding O
sequence O
of O
the O
corresponding O
gene O
from O
a O
cDNA O
library O
. O

The O
structural O
analysis O
also O
demonstrated O
that O
the O
heterogeneity O
of O
the O
ALL_CAP I-GENE
mRNA I-GENE
is O
caused O
by O
an O
RARE O
of O
the O
RARE O
intron O
sequence O
and O
RARE O
use O
of O
the O
RARE O
RARE O
site O
RARE O
the O
NUM O
RARE O
. O

A O
RARE O
DNA O
was O
isolated O
from O
Caenorhabditis O
elegans O
that O
encoded O
a O
polypeptide O
of O
NUM O
amino O
acid O
residues O
, O
ALL_CAP I-GENE
, O
which O
contains O
a O
domain O
with O
sequence O
RARE O
to O
the O
ALL_CAP I-GENE
- I-GENE
terminal I-GENE
segment I-GENE
( I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
region I-GENE
) I-GENE
of O
RARE I-GENE
and O
other O
known O
GTPase I-GENE
- I-GENE
activating I-GENE
proteins I-GENE
of O
the O
Rho I-GENE
subfamily I-GENE
. O

RARE O
RARE I-GENE
III I-GENE
protection O
was O
observed O
beyond O
the O
core O
region O
on O
both O
the O
5 O
' O
and O
3 O
' O
sides O
, O
suggesting O
that O
E1 I-GENE
interacted O
with O
more O
distal O
sequences O
RARE O
RARE O
. O

RARE O
is O
RARE O
when O
the O
two O
( O
RARE O
E2 I-GENE
) O
or O
three O
( O
RARE O
E2 I-GENE
- I-GENE
C I-GENE
) O
promoter O
- O
proximal O
copies O
of O
E2 I-GENE
- O
ALL_CAP O
are O
RARE O
. O

A O
mutant O
in O
the O
ALL_CAP O
terminal O
resolution O
site O
( O
RARE O
) O
was O
RARE O
RARE O
DNA O
replication O
in O
the O
in O
vitro O
assay O
. O

The O
results O
indicate O
that O
RARE I-GENE
strongly O
enhances O
the O
function O
of O
negative O
regulatory O
elements O
of O
the O
LTR O
. O

However O
, O
artificially O
ventilated O
rats O
, O
pretreated O
with O
MK O
- O
801 O
, O
were O
more O
RARE O
( O
lethal O
cocaine O
dose O
, O
NUM O
. O
6 O
+/- O
8 O
. O
NUM O
mg O
/ O
kg O
, O
RARE O
= O
5 O
) O
than O
vehicle O
pretreated O
rats O
( O
NUM O
. O
4 O
+/- O
NUM O
. O
8 O
mg O
/ O
kg O
, O
RARE O
= O
6 O
RARE O
indicating O
that O
MK O
- O
801 O
may O
increase O
both O
the O
respiratory O
and O
the O
cardiac O
toxicity O
of O
cocaine O
in O
RARE O
anesthetized O
rats O
. O

The O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
gene I-GENE
product I-GENE
, O
which O
belongs O
to O
the O
POU I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
, O
is O
a O
good O
candidate O
RARE O
RARE O
initial O
differentiation O
RARE O
. O

Using O
site O
- O
directed O
mutagenesis O
, O
we O
show O
that O
the O
RARE I-GENE
contributes O
to O
the O
transcriptional O
activation O
of O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
promoter I-GENE
in O
P19 O
cells O
and O
, O
most O
RARE O
, O
mediates O
the O
ALL_CAP O
- O
RARE O
repression O
in O
ALL_CAP O
- O
differentiated O
EC O
cells O
. O

NUM O
: O
NUM O
- O
NUM O
, O
1992 O
; O
M O
. O

Furthermore O
, O
the O
negative O
transcriptional O
effect O
of O
COUP I-GENE
- I-GENE
RARE I-GENE
is O
dominant O
over O
the O
activating O
effect O
of O
the O
NUM I-GENE
RARE I-GENE
RARE I-GENE
cell I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
. O

Analysis O
of O
RARE I-GENE
/ O
CAT I-GENE
chimeric O
constructs O
transiently O
transfected O
into O
the O
ALL_CAP O
264 O
. O
7 O
mouse O
monocytic O
cell O
line O
revealed O
a O
unique O
IFN I-GENE
- I-GENE
gamma I-GENE
- I-GENE
responsive I-GENE
element I-GENE
( O
gamma I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
). O

When O
RARE O
alone O
in O
test O
cells O
, O
RARE I-GENE
- I-GENE
I I-GENE
is O
unable O
to O
bind O
TGF I-GENE
- I-GENE
beta I-GENE
, O
activin I-GENE
, O
or O
bone I-GENE
RARE I-GENE
protein I-GENE
2 I-GENE
. O

Therefore O
, O
NUM I-GENE
and O
RARE I-GENE
might O
RARE O
RARE I-GENE
function O
and O
are O
candidate O
tumor O
suppressor O
genes O
. O

To O
our O
knowledge O
, O
type O
IV O
RARE O
tubular O
acidosis O
has O
not O
been O
reported O
previously O
in O
association O
with O
RARE O
' O
s O
RARE O
in O
an O
adult O
patient O
. O

A O
cDNA O
clone O
was O
isolated O
from O
a O
chicken O
RARE O
cDNA O
library O
employing O
a O
PCR O
- O
generated O
radiolabeled O
probe O
specific O
RARE O
the O
NUM I-GENE
region I-GENE
of O
the O
RARE I-GENE
sarcoma I-GENE
virus I-GENE
LTR I-GENE
. O

Two O
basic O
patterns O
of O
locomotor O
behavior O
and O
corresponding O
RARE O
morphology O
exist O
among O
RARE O
RARE O
. O

RARE O
age O
and O
RARE O
had O
RARE O
significant O
effects O
on O
CSF O
composition O
, O
but O
serum O
IgG I-GENE
concentration O
increased O
with O
age O
. O

RARE O
continuous O
expansion O
. O

A O
randomized O
, O
RARE O
study O
comparing O
the O
efficacy O
and O
RARE O
of O
RARE O
, O
a O
new O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonist O
, O
with O
a O
RARE O
- O
containing O
RARE O
RARE O
in O
the O
prevention O
of O
cisplatin O
- O
RARE O
RARE O
. O

Each O
repeat O
consists O
of O
12 O
nt O
, O
coding O
RARE O
the O
RARE O
sequence O
, O
K O
/ O
ALL_CAP O
. O

ALL_CAP I-GENE
also O
was O
RARE O
from O
P O
. O
RARE O
using O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
alpha I-GENE
- I-GENE
factor I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
and O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
RARE I-GENE
signal I-GENE
sequence I-GENE
. O

BACKGROUND O
: O
To O
determine O
the O
predictors O
of O
desipramine O
- O
refractory O
depression O
, O
the O
authors O
examined O
the O
outcome O
in O
patients O
with O
major O
depression O
who O
were O
RARE O
to O
a O
RARE O
hospital O
and O
treated O
with O
desipramine O
adjusted O
to O
an O
adequate O
RARE O
level O
. O

Analysis O
of O
the O
RARE O
hGH I-GENE
gene I-GENE
or O
hGH I-GENE
5 I-GENE
'- I-GENE
flanking I-GENE
DNA I-GENE
( I-GENE
5 I-GENE
'- I-GENE
ALL_CAP I-GENE
) I-GENE
coupled O
to O
the O
RARE I-GENE
cDNA I-GENE
or O
chloramphenicol I-GENE
RARE I-GENE
or O
luciferase I-GENE
genes I-GENE
, O
indicated O
that O
cAMP O
primarily O
RARE O
hGH I-GENE
promoter I-GENE
activity O
. O

The O
predicted O
amino O
acid O
sequence O
of O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
showed O
that O
RARE I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
consisted O
of O
NUM O
amino O
RARE O
and O
a O
transmembrane I-GENE
- I-GENE
type I-GENE
PTP I-GENE
, O
which O
possessed O
a O
single O
PTP I-GENE
- I-GENE
RARE I-GENE
domain I-GENE
in O
the O
cytoplasmic O
region O
. O

The O
following O
evidence O
indicates O
that O
the O
NUM O
- O
ALL_CAP O
protein O
is O
a O
common O
, O
rather O
than O
a O
NUM I-GENE
- O
specific O
, O
protein O
, O
possibly O
RARE O
with O
the O
snRNP O
core O
RARE O
by O
protein O
- O
protein O
interaction O
. O

Several O
features O
of O
10 O
. O
NUM O
. O
6 O
cells O
suggest O
that O
the O
mutation O
RARE O
normal O
RARE O
formation O
of O
peptide I-GENE
/ I-GENE
ALL_CAP I-GENE
complexes I-GENE
. O

This O
distribution O
RARE O
that O
of O
the O
RARE O
RARE O
and O
RARE O
; O
however O
, O
neither O
of O
these O
RARE O
amino O
RARE O
is O
a O
substrate O
RARE O
RARE O
. O

The O
RARE O
apparatus O
is O
a O
simple O
, O
useful O
, O
cost O
- O
effective O
RARE O
to O
the O
diagnosis O
and O
treatment O
of O
this O
life O
- O
RARE O
condition O
. O

Co O
- O
transfection O
of O
RARE O
vectors O
RARE O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
binding I-GENE
protein I-GENE
( I-GENE
C I-GENE
/ I-GENE
EBP I-GENE
) I-GENE
alpha I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
RARE O
- O
activated O
the O
rat I-GENE
RARE I-GENE
protein I-GENE
gene I-GENE
promoter I-GENE
due O
to O
sequences O
in O
the O
5 O
' O
proximal O
region O
. O

It O
was O
not O
possible O
to O
study O
the O
basis O
RARE O
tissue O
- O
specific O
RARE O
of O
this O
gene O
, O
because O
the O
beta I-GENE
3 I-GENE
gene I-GENE
promoter I-GENE
had O
not O
been O
isolated O
previously O
. O

Isolation O
and O
characterization O
of O
a O
TATA O
- O
less O
promoter O
RARE O
the O
human I-GENE
beta I-GENE
3 I-GENE
integrin I-GENE
gene I-GENE
. O

RARE O
RARE O
was O
RARE O
on O
the O
RARE O
eye O
in O
19 O
eyes O
( O
52 O
. O
7 O
%) O
and O
on O
the O
better O
eye O
in O
7 O
eyes O
( O
19 O
. O
4 O
%). O

These O
data O
indicate O
that O
activation O
of O
these O
RARE O
is O
not O
sufficient O
RARE O
the O
acute O
RARE O
of O
glucose O
RARE O
. O

The O
inserted O
region O
, O
which O
represents O
an O
intron O
in O
brain O
and O
muscle O
, O
is O
RARE O
in O
the O
tumor O
cell O
lines O
either O
RARE O
a O
" O
readthrough O
" O
form O
or O
with O
NUM O
residues O
RARE O
from O
its O
5 O
' O
end O
. O

RARE O
of O
ALL_CAP O
scores O
was O
tested O
in O
NUM O
stable O
subjects O
. O

RARE O
line O
RARE O
of O
ALL_CAP O
scores O
were O
significantly O
different O
in O
patients O
who O
RARE O
from O
those O
who O
remained O
stable O
RARE O
b O
] O
< O
NUM O
. O
NUM O
; O
P O
< O
NUM O
. O
0001 O
). O

RARE O
and O
RARE O
were O
found O
effective O
in O
the O
treatment O
of O
RARE O
, O
but O
because O
of O
serious O
RARE O
effects O
RARE O
in O
some O
cases O
, O
the O
drugs O
should O
be O
used O
RARE O
in O
RARE O
cases O
only O
. O

Inhibition O
of O
RARE O
RARE O
by O
disruption O
of O
RARE I-GENE
- I-GENE
RARE I-GENE
A I-GENE
decarboxylase I-GENE
gene I-GENE
ALL_CAP I-GENE
in O
RARE O
RARE O
. O

This O
region O
is O
required O
RARE O
activation O
of O
DNA O
binding O
of O
MyoD I-GENE
and O
E12 I-GENE
homodimers I-GENE
and O
E12 I-GENE
/ O
MyoD I-GENE
RARE O
. O

Transcriptional O
analysis O
of O
a O
series O
of O
deletion O
mutants O
of O
the O
gene O
in O
the O
nuclear O
extracts O
prepared O
from O
the O
RARE O
RARE O
RARE O
of O
2 O
- O
day O
- O
old O
RARE O
RARE O
larvae O
revealed O
the O
presence O
of O
multiple O
cis O
- O
regulatory O
elements O
RARE O
both O
upstream O
and O
RARE O
of O
the O
initiation O
site O
. O

One O
of O
these O
elements O
, O
the O
RARE I-GENE
- I-GENE
binding I-GENE
element I-GENE
, O
was O
identified O
to O
mediate O
negative O
RARE O
. O

RARE O
- O
directed O
mutagenesis O
of O
the O
ALL_CAP I-GENE
structural I-GENE
gene I-GENE
and O
application O
of O
RARE O
mutant O
ALL_CAP I-GENE
proteins I-GENE
RARE O
in O
vitro O
assays O
RARE O
to O
evaluate O
the O
RARE O
importance O
of O
RARE O
amino O
acid O
residues O
. O

RARE O
action O
of O
three O
distinct O
domains O
in O
the O
DNA O
RARE O
- O
RARE O
reaction O
catalyzed O
by O
RARE I-GENE
( O
ALL_CAP I-GENE
) O
of O
RARE O
RARE O
NUM O
. O

The O
ALL_CAP O
- O
terminal O
NUM O
codons O
of O
ALL_CAP I-GENE
encode O
a O
remarkable O
RARE O
- O
rich O
peptide O
sequence O
which O
is O
RARE O
least O
partly O
dispensable O
RARE O
ALL_CAP I-GENE
function O
in O
E I-GENE
- O
RARE O
lysis O
. O

RARE O
antibodies O
raised O
against O
rat I-GENE
cytochrome I-GENE
P I-GENE
- I-GENE
NUM I-GENE
NUM I-GENE
RARE O
a O
protein O
in O
the O
RARE O
RARE O
of O
the O
double O
- O
RARE O
RARE O
, O
and O
also O
in O
those O
of O
the O
great O
blue O
RARE O
( O
RARE O
RARE O
RARE O
using O
RARE O
. O

We O
studied O
ALL_CAP O
- O
RARE O
enzyme O
activity O
in O
serum O
after O
acute O
RARE O
infarction O
( O
AMI O
) O
and O
unstable O
angina O
pectoris O
( O
ALL_CAP O
). O

The O
HGF I-GENE
- O
RARE O
cell O
RARE O
was O
mimicked O
by O
12 O
- O
NUM O
- O
RARE O
- O
phorbol O
- O
NUM O
- O
RARE O
, O
a O
protein I-GENE
kinase I-GENE
C I-GENE
- O
activating O
phorbol O
ester O
, O
but O
not O
by O
NUM O
+ O
RARE O
. O

In O
addition O
, O
RARE O
RARE O
was O
examined O
by O
RARE O
an O
identity O
RARE O
earlier O
in O
the O
RARE O
. O

METHODS O
: O
Forty O
- O
nine O
cases O
with O
intrahepatic O
multiple O
nodules O
of O
ALL_CAP O
, O
by O
gross O
examination O
, O
among O
NUM O
consecutive O
RARE O
RARE O
were O
examined O
RARE O
. O

In O
the O
present O
report O
, O
NUM O
RARE O
RARE O
RARE O
151 O
RARE O
chromosomes O
and O
182 O
normal O
chromosomes O
were O
ALL_CAP O
- O
RARE O
with O
a O
battery O
of O
RARE O
, O
including O
two O
newly O
derived O
polymorphic O
markers O
from O
the O
6 O
. O
7 O
and O
HLA I-GENE
- I-GENE
F I-GENE
loci I-GENE
RARE O
NUM O
and O
NUM O
kb O
telomeric O
to O
HLA I-GENE
- I-GENE
A I-GENE
, O
respectively O
. O

RARE O
RARE O
laparoscopic O
dissection O
of O
the O
RARE O
RARE O
. O

RARE O
cortical O
malformations O
were O
produced O
in O
rats O
by O
a O
single O
dose O
of O
X O
- O
rays O
( O
NUM O
RARE O
) O
given O
on O
different O
days O
RARE O
gestation O
. O

NUM O
cancers O
should O
not O
be O
excluded O
from O
the O
benefit O
of O
preoperative O
irradiation O
. O

IFN I-GENE
alpha I-GENE
and O
IFN I-GENE
gamma I-GENE
inducibility O
is O
RARE O
by O
a O
single O
element O
: O
a O
high O
affinity O
, O
nearly O
palindromic O
version O
of O
the O
IFN I-GENE
gamma I-GENE
activation I-GENE
site I-GENE
( O
ALL_CAP I-GENE
). O

Mutations O
in O
the O
nuclear I-GENE
gene I-GENE
NUM I-GENE
of I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
result O
in O
RARE O
of O
RARE I-GENE
encoded I-GENE
cytochrome I-GENE
b I-GENE
( O
RARE I-GENE
) O
RNA O
; O
thus O
, O
the O
cells O
are O
unable O
to O
RARE O
. O

Twenty O
- O
three O
sequence O
- O
RARE O
sites O
( O
RARE O
) O
were O
mapped O
within O
the O
contig O
, O
a O
density O
of O
RARE O
1 O
per O
NUM O
kb O
. O

In O
this O
paper O
, O
we O
demonstrate O
that O
binding O
of O
the O
ALL_CAP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
GABP I-GENE
) O
to O
ets I-GENE
sequence I-GENE
motifs I-GENE
within O
each O
RARE O
unit O
is O
required O
RARE O
transcriptional O
activation O
of O
the O
ALL_CAP I-GENE
promoter I-GENE
. O

To O
gain O
further O
insight O
into O
the O
pathogenesis O
of O
the O
adult O
respiratory O
distress O
RARE O
( O
ARDS O
RARE O
the O
authors O
studied O
possible O
relationships O
among O
the O
activation O
status O
of O
circulating O
RARE O
neutrophils O
( O
ALL_CAP O
RARE O
RARE O
levels O
, O
and O
the O
severity O
of O
RARE O
injury O
in O
NUM O
patients O
: O
NUM O
with O
ARDS O
, O
9 O
with O
severe O
pneumonia O
RARE O
by O
ARDS O
, O
and O
7 O
RARE O
ventilated O
patients O
with O
neither O
ARDS O
nor O
pneumonia O
. O

RARE O
, O
RARE O
used O
RARE O
RARE O
- O
line O
treatment O
, O
appears O
to O
be O
the O
most O
effective O
drug O
. O

These O
results O
demonstrate O
that O
dopamine I-GENE
receptor I-GENE
RARE O
by O
different O
dopamine O
agonists O
produces O
a O
different O
pattern O
of O
effects O
on O
the O
characteristics O
of O
the O
reaction O
time O
response O
. O

Two O
experiments O
were O
conducted O
to O
study O
the O
RARE O
jaw O
movements O
RARE O
in O
rats O
by O
acute O
administration O
of O
the O
RARE O
- O
RARE O
agent O
RARE O
. O

RARE O
of O
dopamine O
in O
the O
nucleus O
RARE O
led O
to O
a O
dramatic O
shift O
in O
behavior O
in O
which O
there O
was O
a O
significant O
decrease O
in O
RARE O
RARE O
but O
a O
significant O
increase O
in O
consumption O
of O
RARE O
RARE O
. O

We O
have O
investigated O
the O
influence O
of O
NUM O
+ O
EDTA O
, O
and O
of O
increasing O
dietary O
levels O
of O
NUM O
, O
on O
RARE O
, O
RARE O
and O
Ca O
metabolism O
in O
rats O
fed O
on O
RARE O
- O
sufficient O
and O
RARE O
- O
RARE O
RARE O
- O
RARE O
- O
isolate O
- O
based O
diets O
. O

RARE O
of O
RARE O
- O
RARE O
RARE O
following O
recombinant I-GENE
RARE I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
) O
administration O
. O

Thus O
, O
the O
RARE O
can O
be O
used O
to O
detect O
and O
study O
dynamic O
perfusion O
changes O
from O
the O
brain O
surface O
with O
minimal O
tissue O
damage O
. O

The O
RARE O
of O
RARE O
' O
s O
theory O
demonstrates O
the O
range O
of O
factors O
, O
other O
than O
the O
strictly O
RARE O
, O
which O
can O
be O
important O
in O
RARE O
the O
influence O
or O
otherwise O
of O
a O
psychological O
theory O
. O

The O
positive O
- O
acting O
global O
sulfur O
regulatory O
protein O
, O
NUM I-GENE
, O
of O
Neurospora O
crassa O
RARE O
on O
the O
RARE O
of O
a O
family O
of O
RARE O
structural O
genes O
that O
encode O
RARE O
of O
sulfur O
catabolism O
. O

Analysis O
of O
the O
upstream O
RARE O
region O
of O
NUM I-GENE
revealed O
the O
presence O
of O
the O
hexamer O
element O
, O
ALL_CAP O
( O
an O
ALL_CAP I-GENE
RARE I-GENE
site I-GENE
) O
controlling O
both O
the O
RARE O
RARE O
and O
coordinate O
RARE O
of O
the O
DNA O
RARE O
genes O
in O
RARE O
yeast O
. O

The O
C O
- O
terminal O
region O
of O
the O
NUM O
- O
kDa O
protein O
contains O
an O
ALL_CAP O
- O
binding O
RARE I-GENE
motif I-GENE
and O
the O
readthrough O
region O
, O
an O
RNA I-GENE
polymerase I-GENE
motif I-GENE
, O
indicating O
that O
these O
two O
overlapping O
proteins O
may O
form O
an O
RNA O
replication O
complex O
similar O
to O
those O
of O
RARE O
- O
and O
RARE O
. O

The O
5 O
' O
ends O
of O
NUM I-GENE
RARE O
transcripts O
were O
RARE O
to O
an O
A O
within O
the O
sequence O
5 O
'- O
ALL_CAP O
, O
NUM O
nt O
RARE O
from O
the O
early O
promoter O
and O
NUM O
nt O
upstream O
from O
the O
initiation O
RARE O
. O

On O
NUM O
weighted O
images O
, O
low O
intensity O
areas O
in O
the O
RARE O
, O
the O
RARE O
, O
the O
anterior O
limb O
of O
the O
internal O
RARE O
, O
the O
RARE O
of O
RARE O
, O
high O
intensity O
areas O
in O
RARE O
RARE O
RARE O
, O
the O
posterior O
limb O
of O
the O
internal O
RARE O
, O
the O
lateral O
part O
of O
the O
cerebral O
RARE O
, O
and O
the O
cerebral O
RARE O
matter O
were O
noted O
. O

Using O
the O
NUM I-GENE
alleles I-GENE
to O
generate O
wild O
- O
type O
cells O
RARE O
only O
in O
RARE O
RARE O
lengths O
, O
we O
also O
show O
that O
RARE O
position O
effects O
are O
highly O
RARE O
to O
changes O
in O
the O
size O
( O
or O
RARE O
) O
of O
the O
telomeric O
RARE O
. O

RARE O
RARE O
characterized O
by O
RARE O
fields O
, O
RARE O
and O
RARE O
capillaries O
and O
increased O
RARE O
diffusion O
of O
RARE O
RARE O
, O
was O
clearly O
RARE O
in O
the O
area O
of O
the O
nodules O
. O

RARE O
switching O
of O
transcriptional O
states O
: O
cis O
- O
and O
RARE O
- O
acting O
factors O
affecting O
establishment O
of O
silencing O
RARE O
the O
HMR I-GENE
locus I-GENE
in O
Saccharomyces O
cerevisiae O
. O

ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
NUM I-GENE
, O
NUM I-GENE
, O
and O
Rel I-GENE
functionally O
RARE O
with O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
, O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
, O
and O
C I-GENE
/ I-GENE
EBP I-GENE
delta I-GENE
. O

It O
could O
be O
detected O
exclusively O
in O
the O
culture O
medium O
of O
cDNA O
- O
transfected O
COS O
cells O
. O

The O
RARE O
group O
of O
sequential O
ALL_CAP O
showed O
a O
significant O
progress O
to O
RARE O
in O
so O
- O
called O
" O
Chronic O
RARE O
- O
RARE O
RARE O
RARE O
ALL_CAP O
RARE O
which O
corresponds O
to O
RARE O
RARE O
RARE O
- O
ALL_CAP O
- O
in O
72 O
. O
4 O
% O
( O
21 O
/ O
29 O
patients O
RARE O
RARE O
RARE O
RARE O
in O
CML O
with O
RARE O
increase O
- O
CML O
. O
MI O
- O
in O
NUM O
. O
2 O
% O
( O
20 O
/ O
NUM O
). O

The O
two O
methods O
identify O
the O
same O
patients O
only O
if O
RARE O
pressures O
are O
normal O
( O
40 O
to O
NUM O
cmH2O O
) O
to O
high O
( O
over O
NUM O
cmH2O O
) O
and O
the O
RARE O
formula O
is O
used O
with O
a O
RARE O
( O
NUM O
RARE O
) O
cutoff O
. O

There O
was O
RARE O
clear O
correlation O
between O
the O
ALL_CAP O
and O
the O
severity O
of O
the O
ALL_CAP O
RARE O
. O

RARE O
sterol I-GENE
carrier I-GENE
protein I-GENE
2 I-GENE
/ O
sterol I-GENE
carrier I-GENE
protein I-GENE
RARE I-GENE
: O
cDNA O
cloning O
reveals O
evolutionary O
conservation O
of O
RARE O
and O
regulated O
RARE O
. O

The O
RARE I-GENE
albumin I-GENE
concentration O
( O
3 O
. O
5 O
- O
4 O
. O
5 O
g O
/ O
dl O
) O
represents O
about O
NUM O
% O
of O
the O
RARE O
plasma O
protein O
. O

These O
lesions O
were O
asymptomatic O
, O
but O
both O
were O
characterized O
clinically O
by O
central O
ulceration O
. O

A O
single O
five O
minute O
period O
of O
rapid O
RARE O
pacing O
fails O
to O
limit O
infarct O
size O
in O
the O
in O
situ O
RARE O
RARE O
. O

Neither O
NUM I-GENE
nor O
NUM I-GENE
mRNA I-GENE
RARE O
was O
responsive O
to O
cold O
or O
to O
heat O
stress O
. O

Previous O
studies O
indicated O
that O
the O
20S I-GENE
proteasome I-GENE
is O
a O
catalytic O
core O
of O
the O
NUM I-GENE
RARE I-GENE
complex I-GENE
that O
possesses O
a O
latent O
RARE O
RARE O
activity O
and O
catalyzes O
an O
ATP O
- O
dependent O
, O
selective O
RARE O
of O
proteins O
ligated O
to O
ubiquitin I-GENE
. O

The O
NUM O
deficit O
was O
not O
related O
to O
RARE O
RARE O
RARE O
RARE O
exercise O
, O
muscle O
enzyme O
activity O
( O
RARE I-GENE
synthase I-GENE
, O
3 I-GENE
- I-GENE
RARE I-GENE
- I-GENE
CoA I-GENE
- I-GENE
dehydrogenase I-GENE
, O
RARE I-GENE
dehydrogenase I-GENE
RARE O
number O
of O
muscle O
capillaries O
, O
% O
ST O
fibres O
or O
muscle O
RARE O
capacity O
. O

The O
sequence O
of O
the O
putative O
NUM I-GENE
protein I-GENE
contains O
two O
copies O
of O
an O
RNA O
recognition O
motif O
, O
two O
RARE O
stretches O
, O
an O
RARE O
- O
rich O
region O
, O
a O
methionine O
- O
rich O
region O
, O
and O
two O
long O
RARE O
alpha O
- O
RARE O
. O

One O
RARE O
RNA O
with O
a O
large O
deletion O
in O
the O
p70 I-GENE
coding I-GENE
region I-GENE
was O
able O
to O
RARE O
efficiently O
, O
both O
when O
inoculated O
with O
the O
RARE O
genome O
and O
when O
inoculated O
with O
a O
second O
RARE O
RARE O
RNA O
that O
supplied O
a O
wild I-GENE
- I-GENE
type I-GENE
p70 I-GENE
. O

RARE O
of O
this O
selective O
pressure O
, O
however O
, O
gave O
way O
to O
homologous O
resolution O
of O
the O
RARE O
RARE O
. O

RARE O
nucleotide O
sequence O
of O
the O
RARE I-GENE
NUM I-GENE
RARE I-GENE
gene I-GENE
encoding O
RARE I-GENE
- I-GENE
N I-GENE
- I-GENE
RARE I-GENE
( O
RARE I-GENE
- I-GENE
N I-GENE
) O
and O
comparison O
to O
an O
RARE I-GENE
- I-GENE
N I-GENE
homolog I-GENE
in O
RARE O
NUM O
. O

Binding O
of O
NUM I-GENE
small I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
was O
partially O
inhibited O
. O

RARE O
RARE O
of O
brain O
edema O
related O
to O
experimental O
multiple O
micro O
- O
RARE O
in O
mice O
: O
assessment O
of O
RARE I-GENE
effect O
. O

One O
RARE O
of O
this O
RARE O
family O
, O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
, O
is O
most O
abundantly O
RARE O
in O
T O
lymphocytes O
, O
a O
cellular O
target O
RARE O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
infection O
and O
replication O
. O

Indeed O
, O
significant O
level O
of O
CAT I-GENE
activity O
was O
observed O
in O
human O
RARE O
adenocarcinoma O
( O
NUM O
- O
1 O
) O
cells O
which O
had O
been O
incubated O
with O
a O
complex O
of O
NUM I-GENE
RNA I-GENE
polymerase I-GENE
, O
NUM I-GENE
- I-GENE
ALL_CAP I-GENE
- I-GENE
CAT I-GENE
DNA I-GENE
and O
DC O
- O
RARE O
RARE O
liposomes O
. O

RARE O
is O
a O
rare O
condition O
that O
RARE O
little O
discussion O
in O
standard O
RARE O
of O
RARE O
. O

The O
RARE O
gene O
codes O
RARE O
a O
protein O
containing O
11 O
RARE O
residues O
in O
an O
arrangement O
typical O
RARE O
RARE I-GENE
/ I-GENE
S I-GENE
proteins I-GENE
. O

RARE O
- O
disrupted O
cells O
retained O
capacity O
RARE O
activation O
of O
the O
RARE O
by O
both O
peptide O
growth O
factors O
and O
by O
addition O
of O
GTP O
- O
RARE O
p21 I-GENE
NUM I-GENE
. O

To O
begin O
to O
examine O
the O
mechanism O
controlling O
RARE O
of O
this O
gene O
RARE O
the O
cell O
- O
RARE O
, O
a O
mouse I-GENE
B I-GENE
- I-GENE
myb I-GENE
5 I-GENE
' I-GENE
flanking I-GENE
sequence I-GENE
was O
isolated O
from O
a O
cosmid O
library O
and O
shown O
to O
promote O
efficiently O
the O
transcription O
of O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
when O
transfected O
into O
NIH3T3 O
RARE O
. O

The O
influence O
of O
a O
high O
ionic O
strength O
on O
the O
resolution O
was O
clearly O
shown O
. O

The O
number O
of O
bacteria O
in O
the O
RARE O
, O
peripheral O
RARE O
RARE O
cell O
and O
ALL_CAP O
RARE O
cell O
also O
decreased O
by O
the O
administration O
of O
FN I-GENE
. O

In O
mice O
, O
three O
major O
RARE O
of O
L1 O
elements O
, O
termed O
" O
A O
," O
" O
F O
," O
and O
" O
V O
," O
have O
been O
defined O
on O
the O
basis O
of O
the O
sequence O
found O
RARE O
the O
5 O
' O
terminus O
. O

ALL_CAP I-GENE
, O
a O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
protein I-GENE
, O
forms O
RARE O
with O
NUM I-GENE
and O
inhibits O
NUM I-GENE
- O
dependent O
transcription O
activation O
. O

The O
equivalent O
of O
the O
third O
RARE O
, O
H O
- O
87 O
, O
is O
T O
- O
NUM O
in O
the O
ALL_CAP O
sequence O
motif O
. O

Similar O
results O
were O
seen O
on O
Western O
blots O
of O
RARE O
RARE O
ALL_CAP O
( O
ALL_CAP O
)- O
RARE O
RARE O
RARE O
cells O
. O

In O
RARE O
mammalian O
cells O
, O
the O
ALL_CAP I-GENE
G I-GENE
and O
ALL_CAP I-GENE
genes I-GENE
are O
RARE O
primarily O
RARE O
a O
RARE O
mRNA O
which O
appears O
to O
extend O
from O
the O
consensus O
sequence O
( O
ALL_CAP O
) O
RARE O
the O
RARE O
of O
the O
G I-GENE
gene I-GENE
to O
the O
next O
RARE O
polyadenylation O
signal O
( O
ALL_CAP O
RARE O
A O
] O
7 O
) O
RARE O
NUM O
nucleotides O
RARE O
of O
the O
ALL_CAP I-GENE
protein I-GENE
RARE O
RARE O
. O

Molecular O
cloning O
and O
RARE O
of O
NUM I-GENE
, O
a O
novel O
RARE O
RARE O
epithelium O
- O
specific O
RARE O
protein O
that O
is O
post O
- O
transcriptionally O
regulated O
in O
vitro O
. O

The O
mean O
power O
( O
in O
mu O
ALL_CAP O
) O
required O
to O
produce O
the O
observed O
flow O
rate O
was O
estimated O
RARE O
each O
outflow O
pressure O
RARE O
the O
product O
of O
the O
flow O
rate O
and O
the O
pressure O
across O
the O
RARE O
vessel O
. O

Although O
RARE O
antibodies O
are O
associated O
with O
infertility O
, O
many O
hospital O
laboratories O
do O
not O
test O
RARE O
these O
antibodies O
. O

ALL_CAP I-GENE
- O
specific O
IgG I-GENE
RARE O
responses O
were O
evident O
to O
all O
four O
IgG I-GENE
RARE O
. O

RARE O
body O
pattern O
in O
Drosophila O
is O
specified O
by O
the O
RARE O
distribution O
of O
the O
RARE I-GENE
protein I-GENE
( O
RARE I-GENE
RARE O
which O
activates O
RARE O
genes O
in O
distinct O
anterior O
domains O
. O

ALL_CAP I-GENE
- I-GENE
N I-GENE
RARE O
constitutively O
to O
p190 I-GENE
in O
both O
serum O
- O
deprived O
and O
growth O
factor O
- O
RARE O
cells O
. O

The O
peptide O
sequence O
contains O
a O
region O
of O
NUM O
amino O
RARE O
that O
shows O
RARE O
to O
bcl I-GENE
- I-GENE
2 I-GENE
and O
to O
the O
recently O
described O
bcl I-GENE
- I-GENE
2 I-GENE
- I-GENE
related I-GENE
gene I-GENE
, O
NUM I-GENE
. O

The O
RARE O
efficiency O
is O
improved O
by O
increasing O
the O
number O
of O
N O
- O
terminal O
RARE O
residues O
and O
by O
RARE O
the O
RARE O
cluster O
one O
RARE O
further O
RARE O
from O
the O
serine O
, O
the O
RARE O
( O
Arg O
) O
4 O
- O
RARE O
- O
RARE O
- O
RARE O
- O
RARE O
- O
RARE O
being O
the O
best O
substrate O
among O
all O
the O
short O
peptides O
tested O
( O
RARE O
= O
NUM O
microM O
). O

RARE I-GENE
RARE I-GENE
: O
preferred O
treatment O
RARE O
RARE O
RARE O
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
are O
RARE O
in O
response O
to O
the O
availability O
of O
RARE O
and O
glucose O
by O
multiple O
activating O
and O
repressing O
proteins O
RARE O
RARE O
adjacent O
or O
overlapping O
sites O
in O
ALL_CAP O
. O

Surprisingly O
, O
the O
results O
of O
several O
experiments O
suggest O
that O
the O
ALL_CAP I-GENE
genes I-GENE
encode O
global O
regulatory O
factors O
. O
NUM I-GENE
to O
NUM I-GENE
mutations O
RARE O
RARE O
from O
yeast O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
RARE O
promoters O
( O
fused O
to O
lacZ I-GENE
) O
that O
harbor O
a O
variety O
of O
operator O
sequences O
, O
and O
caused O
pleiotropic O
defects O
in O
cell O
growth O
, O
RARE O
, O
and O
RARE O
. O

RARE O
of O
RARE O
( O
RARE O
2 O
) O
was O
associated O
most O
closely O
with O
RARE O
of O
RARE O
and O
head O
. O

Sequence O
comparison O
indicates O
that O
exons O
5 O
RARE O
L O
and O
L O
/ O
N O
in O
NUM I-GENE
and O
NUM I-GENE
psi I-GENE
are O
NUM O
% O
identical O
, O
except O
that O
the O
L O
/ O
N O
RARE O
in O
the O
NUM I-GENE
psi I-GENE
gene I-GENE
contains O
a O
stop O
RARE O
. O

The O
mechanisms O
that O
govern O
the O
activation O
or O
suppression O
of O
the O
NUM I-GENE
gene I-GENE
are O
likely O
to O
be O
central O
to O
the O
T O
cell O
development O
program O
. O

We O
suggest O
that O
the O
ER O
RARE O
RARE O
domain O
of O
NUM I-GENE
has O
a O
specific O
tertiary O
RARE O
that O
is O
important O
RARE O
binding O
to O
the O
polymorphic O
alpha O
1 O
and O
alpha O
2 O
domains O
of O
class I-GENE
I I-GENE
heavy I-GENE
( I-GENE
alpha I-GENE
) I-GENE
chains I-GENE
. O

We O
recently O
found O
that O
NUM O
beta O
- O
estradiol O
( O
E2 O
) O
not O
only O
suppresses O
bone O
resorption O
but O
also O
stimulates O
bone O
formation O
in O
the O
RARE O
bone O
of O
female O
rats O
. O

Recombinant I-GENE
human I-GENE
erythropoietin I-GENE
( O
RARE I-GENE
) O
is O
RARE O
to O
be O
administered O
by O
the O
intravenous O
( O
i O
. O
v O
.) O
or O
subcutaneous O
( O
SC O
) O
route O
. O

RARE O
- O
photon O
emission O
computed O
tomography O
( O
SPECT O
) O
with O
99mTc O
- O
RARE O
RARE O
( O
HMPAO O
) O
was O
used O
to O
investigate O
changes O
in O
cerebral O
RARE O
flow O
in O
RARE O
patients O
with O
cortical O
visual O
impairment O
. O

The O
rCBF O
ratio O
was O
mainly O
RARE O
in O
frontal O
RARE O
( O
65 O
%). O

METHODS O
: O
Twenty O
- O
two O
patients O
were O
RARE O
according O
to O
their O
etiology O
based O
on O
the O
study O
of O
RARE O
antibodies O
RARE O
diagnosis O
of O
the O
RARE O
: O
7 O
were O
positive O
( O
RARE O
etiology O
or O
ALL_CAP O
RARE O
11 O
were O
negative O
( O
tuberculous O
etiology O
or O
ALL_CAP O
) O
and O
in O
four O
serologic O
study O
was O
not O
available O
( O
RARE O
etiology O
or O
ALL_CAP O
). O

2 O
- O
AP O
RARE O
marked O
, O
steady O
RARE O
in O
mRNA O
accumulation O
from O
both O
transfected O
and O
RARE O
integrated O
HIV O
- O
1 O
constructs O
but O
RARE O
increases O
from O
an O
endogenous O
gene O
encoding O
gamma I-GENE
- I-GENE
actin I-GENE
or O
glucose I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
. O

The O
ALL_CAP O
induction O
of O
c I-GENE
- I-GENE
jun I-GENE
is O
RARE O
by O
two O
ALL_CAP O
response O
elements O
consisting O
of O
AP I-GENE
- I-GENE
1 I-GENE
- I-GENE
like I-GENE
sequences I-GENE
within O
its O
5 O
' O
control O
region O
. O

Protein I-GENE
tyrosine I-GENE
RARE I-GENE
( O
RARE I-GENE
RARE O
together O
with O
protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
RARE I-GENE
RARE O
are O
involved O
in O
the O
RARE O
of O
cell O
activation O
, O
growth O
, O
and O
differentiation O
. O

ST O
elevation O
occurs O
in O
5 O
patients O
( O
NUM O
. O
5 O
%) O
of O
subgroup O
A O
and O
in O
RARE O
patient O
of O
the O
subgroup O
B O
. O

Furthermore O
, O
a O
NUM I-GENE
protein I-GENE
RARE O
the O
N O
- O
terminus O
of O
NUM I-GENE
was O
RARE O
RARE O
high O
levels O
; O
our O
data O
indicate O
that O
NUM I-GENE
is O
translated O
from O
the O
1 O
. O
6 O
- O
kb O
mRNA O
which O
is O
derived O
primarily O
from O
RARE O
RARE O
. O

ALL_CAP O
- O
1 O
gene O
RARE O
by O
RARE O
RARE O
in O
an O
RARE O
T O
- O
cell O
line O
. O

Thus O
, O
it O
was O
confirmed O
that O
the O
RARE O
RARE O
RARE O
method O
of O
estimating O
hemoglobin I-GENE
concentration O
is O
an O
appropriate O
RARE O
to O
the O
RARE I-GENE
method O
and O
RARE O
the O
generation O
of O
toxic O
RARE O
. O

A O
comparison O
of O
the O
predicted O
amino O
acid O
sequences O
of O
the O
two O
human I-GENE
PKC I-GENE
- I-GENE
delta I-GENE
RARE O
with O
the O
rat O
and O
mouse O
RARE O
indicated O
a O
greater O
degree O
of O
sequence O
divergence O
( O
NUM O
- O
NUM O
% O
homology O
) O
compared O
to O
the O
high O
degree O
of O
sequence O
conservation O
observed O
with O
other O
human I-GENE
PKC I-GENE
family I-GENE
members I-GENE
and O
their O
mammalian O
counterparts O
. O

ALL_CAP O
. O

When O
comparing O
the O
RARE I-GENE
PSI I-GENE
- I-GENE
K I-GENE
and O
PSI I-GENE
- I-GENE
G I-GENE
with O
the O
reported O
PSI I-GENE
- I-GENE
K I-GENE
sequence I-GENE
from I-GENE
RARE I-GENE
RARE I-GENE
, O
the O
degree O
of O
RARE O
is O
equal O
, O
suggesting O
that O
an O
ancestral O
gene O
has O
been O
duplicated O
in O
a O
chloroplast O
RARE O
but O
not O
in O
a O
RARE O
. O

On O
the O
other O
RARE O
, O
the O
RARE O
of O
the O
b O
- O
RARE O
domain O
are O
RARE O
RARE O
among O
these O
Maf I-GENE
- I-GENE
related I-GENE
proteins I-GENE
. O

Under O
these O
conditions O
, O
transfections O
with O
cDNAs O
of O
the O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
NUM I-GENE
and O
serum I-GENE
response I-GENE
factor I-GENE
( O
SRF I-GENE
) O
produced O
a O
factor O
( O
s O
) O
that O
RARE O
RARE I-GENE
binding O
to O
the O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
site I-GENE
and O
the O
ALL_CAP O
box O
respectively O
. O

We O
show O
here O
that O
v I-GENE
- I-GENE
Rel I-GENE
specifically O
increased O
RARE O
from O
a O
reporter O
RARE O
containing O
multiple O
NUM I-GENE
binding I-GENE
sites I-GENE
RARE O
RARE O
in O
chicken O
RARE O
RARE O
( O
RARE O
RARE O
even O
though O
v I-GENE
- I-GENE
Rel I-GENE
did O
not O
bind O
directly O
to O
these O
sites O
. O
v I-GENE
- I-GENE
Rel I-GENE
also O
increased O
RARE O
from O
a O
reporter O
RARE O
containing O
a O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
( O
LTR O
) O
in O
which O
the O
RARE I-GENE
B I-GENE
binding I-GENE
sites I-GENE
were O
RARE O
but O
which O
still O
contained O
RARE O
NUM I-GENE
binding I-GENE
sites I-GENE
. O

The O
simultaneous O
recording O
of O
electrical O
activity O
from O
the O
surface O
electrocardiogram O
, O
right O
ventricular O
apex O
, O
RARE O
bundle O
, O
high O
right O
atrium O
, O
coronary O
sinus O
, O
with O
or O
without O
a O
RARE O
mapping O
catheter O
, O
enables O
us O
to O
precisely O
map O
the O
electrical O
activation O
sequence O
in O
the O
RARE O
. O

CONCLUSION O
: O
This O
retrospective O
analysis O
does O
not O
confirm O
the O
efficacy O
of O
one O
course O
of O
simultaneous O
RARE O
- O
C O
and O
5 O
- O
fluorouracil O
, O
RARE O
least O
in O
association O
with O
full O
- O
dose O
radiotherapy O
RARE O
RARE O
- O
NUM O
RARE O
. O

Despite O
the O
existence O
of O
NUM O
cysteine O
residues O
, O
RARE O
prevented O
the O
formation O
of O
most O
if O
not O
all O
disulfide O
bonds O
that O
otherwise O
occurred O
when O
the O
cells O
were O
RARE O
. O

RARE O
- O
RARE O
- O
RARE O
RARE O
( O
RARE O
- O
RARE O
RARE O
II O
) O

Most O
RARE O
, O
the O
addition O
of O
RARE O
NUM I-GENE
NUM I-GENE
RARE I-GENE
, O
but O
not O
of O
NUM I-GENE
NUM I-GENE
RARE I-GENE
, O
to O
HeLa O
RARE O
extracts O
in O
which O
the O
RARE I-GENE
NUM I-GENE
RARE I-GENE
have O
been O
functionally O
RARE O
with O
anti I-GENE
- I-GENE
NUM I-GENE
antibodies I-GENE
fully O
restores O
the O
mRNA O
- O
RARE O
activity O
of O
the O
extracts O
. O

RARE O
in O
profiles O
of O
viscosity O
variables O
between O
subgroups O
of O
ALL_CAP O
in O
ALL_CAP O
patients O
were O
observed O
. O

These O
contain O
a O
single O
NUM O
- O
bp O
RARE O
that O
encodes O
NUM O
bp O
of O
the O
5 O
' O
and O
3 O
' O
RARE O
sequences O
in O
addition O
to O
a O
NUM O
- O
bp O
RARE O
reading O
frame O
identical O
to O
that O
found O
in O
vascular I-GENE
RARE I-GENE
muscle I-GENE
cell I-GENE
NUM I-GENE
receptor I-GENE
cDNAs I-GENE
. O

Deletion O
of O
a O
53 O
- O
bp O
early O
promoter O
region O
containing O
the O
transcription O
RARE O
site O
and O
a O
putative O
TATA O
box O
completely O
abolishes O
the O
ability O
of O
upstream O
elements O
to O
drive O
transcription O
of O
the O
luciferase I-GENE
cDNA I-GENE
. O

One O
RARE O
RARE O
RARE O
the O
larger O
RARE O
4 O
RARE O
testing O
with O
a O
RARE O
RARE O
( O
2 O
- O
4 O
RARE O
and O
2 O
RARE O
showed O
RARE O
preference O
. O

RARE O
of O
RARE O
pain O
after O
RARE O
: O
implications O
RARE O
RARE O
training O
. O

Alternative O
transcript O
of O
the O
RARE O
- O
type O
endothelin I-GENE
receptor I-GENE
from O
rat O
brain O
. O

The O
Functional O
RARE O
RARE O
: O
a O
comparative O
study O
of O
RARE O
and O
self O
RARE O
. O

RARE O
B O
was O
given O
intravenously O
RARE O
1 O
week O
RARE O
in O
doses O
designed O
to O
RARE O
circulating O
RARE O
. O

NUM O
can O
be O
determined O
in O
vitro O
and O
in O
vivo O
. O

The O
transverse O
relaxation O
time O
( O
NUM O
) O
and O
apparent O
diffusion O
coefficient O
of O
water O
were O
determined O
. O

The O
Drosophila O
clathrin I-GENE
heavy I-GENE
chain I-GENE
gene O
: O
clathrin I-GENE
function O
is O
essential O
in O
a O
RARE O
organism O
. O

The O
binding O
RARE O
of O
this O
protein O
was O
compared O
to O
that O
of O
human I-GENE
E2F I-GENE
using O
a O
number O
of O
mutant I-GENE
E2F I-GENE
sites I-GENE
RARE O
RARE O
. O

To O
analyze O
the O
ALL_CAP O
regions O
of O
RARE O
antibodies O
, O
with O
particular O
attention O
RARE O
their O
RARE O
RARE O
status O
, O
we O
generated O
five O
IgG I-GENE
( O
three O
NUM I-GENE
and O
two O
NUM I-GENE
) O
RARE O
( O
using O
B O
cells O
from O
a O
healthy O
subject O
, O
a O
patient O
with O
insulin I-GENE
- O
dependent O
diabetes O
mellitus O
and O
a O
patient O
with O
SLE O
RARE O
which O
RARE O
with O
various O
RARE O
a O
number O
of O
different O
self O
and O
foreign O
RARE O
. O

It O
is O
possible O
that O
the O
patch O
RARE O
the O
proper O
conformation O
of O
the O
site O
and O
thereby O
contributes O
to O
recognition O
indirectly O
. O

These O
findings O
suggest O
a O
RARE O
cross O
- O
RARE O
between O
ALL_CAP I-GENE
protein I-GENE
and O
p21ras I-GENE
, O
which O
RARE O
the O
cell O
RARE O
between O
normal O
and O
transformed O
states O
. O

The O
7 O
- O
kb O
mRNA O
differs O
by O
RARE O
RARE O
such O
that O
it O
encodes O
a O
protein O
with O
a O
distinct O
amino O
terminus O
. O

RARE O
of O
the O
inhibition O
indicated O
that O
this O
polymerase O
domain O
can O
inhibit O
viral O
replication O
only O
RARE O
the O
RARE O
RARE O
. O

The O
other O
transmembrane O
regions O
RARE O
RARE O
RARE O
the O
RARE O
domain O
are O
not O
required O
RARE O
RARE O
. O

3 O
. O

RARE O
III O
, O
F O
. O

These O
cell O
lines O
, O
RARE O
RARE O
the O
ability O
to O
support O
the O
replication O
of O
a O
RARE O
- O
RARE O
NUM I-GENE
mutant I-GENE
, O
were O
used O
to O
isolate O
NUM I-GENE
and O
NUM I-GENE
RARE O
mutants O
. O

The O
E1 I-GENE
nuclear I-GENE
RARE I-GENE
motif I-GENE
is O
highly O
RARE O
in O
the O
RARE O
and O
human O
RARE O
and O
is O
encoded O
in O
a O
similar O
region O
in O
the O
related O
E1 I-GENE
genes I-GENE
. O

The O
E1 I-GENE
replication I-GENE
protein I-GENE
of O
bovine O
RARE O
type O
1 O
contains O
an O
extended O
nuclear O
RARE O
signal O
that O
includes O
a O
p34cdc2 I-GENE
RARE O
site O
. O

In O
order O
to O
investigate O
to O
what O
extent O
this O
interaction O
might O
contribute O
to O
tumor O
induction O
by O
the O
virus O
, O
we O
have O
introduced O
two O
different O
point O
mutations O
within O
the O
putative O
pRb I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
of O
large I-GENE
T I-GENE
antigen I-GENE
, O
and O
RARE O
a O
preliminary O
to O
in O
vivo O
experiments O
we O
have O
studied O
their O
effects O
in O
vitro O
on O
some O
biological O
activities O
relevant O
to O
tumor O
induction O
. O

We O
conclude O
that O
the O
conservation O
of O
nucleotides O
154 O
to O
NUM O
is O
likely O
to O
be O
a O
consequence O
of O
their O
role O
RARE O
a O
sequence O
- O
specific O
recognition O
element O
RARE O
the O
NUM I-GENE
protein I-GENE
. O

A O
region O
of O
the O
deduced O
protein O
shares O
extensive O
homology O
with O
a O
catalytic O
region O
of O
Raf I-GENE
kinases I-GENE
, O
a O
feature O
shared O
only O
with O
ALL_CAP I-GENE
among O
transcription O
factors O
. O

The O
low O
RARE O
mass O
polypeptide O
complex O
is O
assumed O
to O
be O
involved O
in O
antigen O
presentation O
, O
generating O
peptides O
from O
cytosolic O
protein O
antigens O
, O
which O
are O
subsequently O
presented O
to O
cytotoxic O
T O
- O
lymphocytes O
on O
the O
cell O
surface O
. O

RARE O
RARE O
of O
RT I-GENE
RARE O
RARE O
- O
NUM O
- O
RARE O
- O
NUM O
of O
Pol I-GENE
yields O
a O
truncated O
form O
RARE O
the O
C I-GENE
- I-GENE
terminal I-GENE
RNase I-GENE
H I-GENE
domain I-GENE
. O

The O
C O
- O
terminal O
RARE O
50 O
amino O
RARE O
of O
RARE I-GENE
- I-GENE
1 I-GENE
are O
shown O
to O
be O
essential O
RARE O
RARE I-GENE
- I-GENE
1 I-GENE
activity O
but O
can O
be O
effectively O
substituted O
by O
the O
C O
- O
terminal O
activation O
domain O
of O
VP16 I-GENE
. O

Since O
the O
- O
NUM O
/- O
NUM O
element O
also O
conferred O
estrogen O
and O
thyroid O
hormone O
responsiveness O
, O
it O
can O
be O
considered O
a O
composite O
hormone O
response O
element O
. O

RARE O
activation O
of O
T O
cells O
requires O
RARE O
least O
two O
signals O
. O

Together O
with O
a O
considerably O
shortened O
and O
interrupted O
aromatic O
RARE O
stretch O
in O
this O
region O
, O
these O
differences O
are O
discussed O
in O
terms O
of O
the O
RARE O
affinity O
of O
RARE I-GENE
cytochrome I-GENE
RARE I-GENE
RARE O
RARE O
c I-GENE
- I-GENE
type I-GENE
RARE I-GENE
. O

All O
four O
of O
the O
genes O
have O
a O
similar O
RARE O
, O
with O
the O
receptor O
protein O
encoded O
in O
a O
single O
RARE O
. O

RARE O
of O
GABP I-GENE
with O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
, O
a O
RARE O
activator O
of O
cytochrome I-GENE
oxidase I-GENE
RARE O
, O
reveals O
a O
cellular O
role O
RARE O
an O
ALL_CAP I-GENE
domain I-GENE
activator O
of O
viral O
promoters O
. O

In O
the O
present O
study O
, O
beta O
- O
RARE O
( O
beta O
- O
ALL_CAP O
) O
and O
RARE O
( O
ALL_CAP O
) O
( O
RARE O
mu O
- O
and O
delta O
- O
antagonist O
, O
respectively O
) O
were O
used O
to O
RARE O
withdrawal O
in O
RARE O
- O
dependent O
rats O
. O

The O
RARE O
basic I-GENE
region I-GENE
/ I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
( I-GENE
bHLH I-GENE
) I-GENE
RARE I-GENE
receptor I-GENE
mediates O
signal O
RARE O
by O
RARE O
( O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
RARE O
- O
p O
- O
RARE O
) O
and O
functions O
RARE O
a O
RARE O
- O
activated O
DNA O
binding O
protein O
directly O
RARE O
with O
target O
genes O
by O
binding O
to O
RARE O
response O
elements O
. O

The O
alpha I-GENE
NUM I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
( O
alpha I-GENE
NUM I-GENE
) O
is O
coupled O
to O
a O
variety O
of O
RARE O
via O
RARE I-GENE
RARE I-GENE
- O
RARE O
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

A O
sequence O
comparison O
reveals O
two O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
) O
consensus O
sequences O
, O
basic O
DNA O
binding O
region O
and O
leucine O
RARE O
1 O
and O
2 O
( O
NUM O
and O
NUM O
RARE O
within O
this O
region O
. O

One O
of O
these O
genes O
, O
NUM I-GENE
, O
is O
described O
here O
, O
and O
the O
data O
confirm O
that O
NUM I-GENE
is O
a O
meiosis O
- O
specific O
RARE O
gene O
with O
RARE O
detectable O
function O
in O
mitosis O
. O

The O
RARE O
function O
of O
EBNA2 I-GENE
was O
also O
observed O
in O
the O
HeLa O
RARE O
cell O
line O
, O
which O
suggests O
that O
ALL_CAP O
and O
HIV O
- O
1 O
infection O
of O
non O
- O
B O
cells O
may O
result O
in O
HIV I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
activation O
. O

Mutation O
of O
the O
C I-GENE
/ I-GENE
EBP I-GENE
binding I-GENE
sites I-GENE
in O
the O
RARE I-GENE
sarcoma I-GENE
virus I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
and O
gag I-GENE
RARE I-GENE
. O

Nuclear I-GENE
protein I-GENE
phosphatase I-GENE
NUM I-GENE
RARE O
protein I-GENE
kinase I-GENE
A I-GENE
- O
RARE O
CREB I-GENE
and O
regulates O
CREB I-GENE
transcriptional O
RARE O
. O

We O
show O
that O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
activates O
ALL_CAP I-GENE
- I-GENE
IL6 I-GENE
through O
an O
NUM O
- O
RARE O
RARE O
that O
does O
not O
involve O
protein I-GENE
kinase I-GENE
C I-GENE
, O
cyclic I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
, O
Ca I-GENE
( I-GENE
2 I-GENE
RARE I-GENE
or I-GENE
calmodulin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
, O
Ras I-GENE
, O
Raf I-GENE
- I-GENE
1 I-GENE
, O
or O
ALL_CAP I-GENE
- I-GENE
IL6 I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
). O

Mutation O
of O
the O
RARE O
RARE O
tyrosine O
and O
threonine O
residues O
of O
NUM I-GENE
individually O
to O
RARE O
and O
alanine O
, O
respectively O
, O
severely O
impaired O
NUM I-GENE
function O
. O

RARE O
factor O
RARE O
rapidly O
induces O
a O
reversible O
change O
in O
the O
electrophoretic O
mobility O
of O
the O
RARE O
complex O
, O
accompanied O
by O
increased O
RARE O
of O
the O
Elk I-GENE
- I-GENE
1 I-GENE
C I-GENE
- I-GENE
terminal I-GENE
region I-GENE
and O
by O
the O
activation O
of O
a O
NUM I-GENE
RARE I-GENE
cellular I-GENE
Elk I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
. O

In O
contrast O
to O
the O
RARE O
in O
mammalian O
cells O
, O
prolonged O
exposure O
of O
the O
agonist O
( O
NUM O
h O
) O
does O
not O
result O
in O
down O
RARE O
of O
the O
remaining O
70 O
% O
of O
the O
receptors O
. O

This O
RARE O
effect O
could O
also O
be O
elicited O
by O
c I-GENE
- I-GENE
Jun I-GENE
, O
which O
interacts O
with O
RARE I-GENE
II I-GENE
, O
but O
not O
by O
c I-GENE
- I-GENE
Fos I-GENE
, O
which O
does O
not O
bind O
RARE I-GENE
II I-GENE
in O
our O
in O
vitro O
assay O
. O

The O
RARE O
of O
RARE I-GENE
- I-GENE
5 I-GENE
and O
MyoD I-GENE
function O
by O
a O
cAMP O
- O
dependent O
RARE O
may O
partly O
explain O
how O
external O
signals O
generated O
by O
serum O
and O
certain O
peptide O
growth O
factors O
can O
be O
RARE O
to O
the O
nucleus O
and O
inhibit O
dominant O
- O
acting O
factors O
that O
are O
responsible O
RARE O
RARE O
differentiation O
. O

16 O
, O
NUM O
- O
104 O
). O

We O
have O
previously O
reported O
that O
high O
level O
human I-GENE
RARE I-GENE
RARE O
depends O
on O
a O
NUM O
- O
RARE O
RARE O
muscle O
- O
specific O
enhancer O
which O
can O
function O
not O
only O
in O
myotubes O
, O
but O
can O
also O
activate O
gene O
RARE O
in O
myoblasts O
. O

After O
surgery O
, O
patients O
self O
administered O
one O
of O
three O
possible O
RARE O
RARE O
, O
which O
included O
placebo O
, O
RARE O
NUM O
mg O
, O
and O
RARE O
NUM O
mg O
, O
when O
their O
pain O
reached O
a O
moderate O
or O
severe O
intensity O
. O

RARE O
of O
the O
wild O
- O
type O
5 O
'- O
regulatory O
region O
with O
either O
of O
the O
mutants O
' O
cis O
- O
acting O
regulatory O
element O
resulted O
in O
the O
anaerobic O
RARE O
of O
RARE I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
dismutase I-GENE
. O

The O
NUM I-GENE
gene I-GENE
product I-GENE
, O
when O
RARE O
from O
an O
RARE O
promoter O
, O
inhibited O
int I-GENE
- O
RARE O
RARE O
RARE O
the O
chromosomal I-GENE
ALL_CAP I-GENE
site I-GENE
. O

Expression O
in O
established O
RARE O
, O
occurring O
irrespective O
of O
virus O
RARE O
status O
, O
was O
not O
a O
consequence O
of O
continued O
in O
vitro O
passage O
; O
thus O
, O
RARE O
RARE O
BamHI I-GENE
- I-GENE
A I-GENE
transcripts I-GENE
could O
be O
amplified O
from O
normal O
B O
cells O
within O
1 O
day O
of O
their O
experimental O
infection O
in O
vitro O
, O
along O
with O
BamHI I-GENE
- I-GENE
C I-GENE
/ I-GENE
ALL_CAP I-GENE
promoter O
- O
RARE O
but O
not O
BamHI I-GENE
- I-GENE
F I-GENE
promoter I-GENE
- I-GENE
RARE I-GENE
mRNAs I-GENE
. O

Analysis O
by O
cell O
surface O
immunofluorescence O
showed O
that O
the O
NUM I-GENE
gene I-GENE
is O
not O
required O
RARE O
RARE O
of O
viral O
RARE O
on O
the O
surface O
of O
RARE O
cells O
. O

Furthermore O
, O
a O
mutant O
receptor O
( O
NUM O
/ O
NUM O
RARE O
PLC I-GENE
gamma I-GENE
- O
binding O
sites O
RARE O
could O
fully O
activate O
Ras I-GENE
, O
and O
the O
direct O
activation O
of O
protein I-GENE
kinase I-GENE
C I-GENE
and O
RARE O
RARE O
had O
almost O
RARE O
effect O
on O
the O
GDP O
/ O
GTP O
state O
of O
Ras I-GENE
in O
this O
cell O
line O
. O

RARE O
treatment O
in O
high O
doses O
is O
effective O
in O
RARE O
adult O
RARE O
in O
RARE O
RARE O
girls O
. O

Mutations O
RARE O
the O
extreme O
C O
- O
terminus O
of O
ALL_CAP I-GENE
Tat I-GENE
impaired O
both O
RNA O
binding O
and O
activation O
domain O
functions O
, O
suggesting O
effects O
on O
secondary O
or O
tertiary O
RARE O
. O

This O
observation O
suggests O
that O
the O
RARE O
- O
directed O
repair O
RARE O
RARE O
the O
proximal O
d O
( O
ALL_CAP O
) O
sequence O
to O
direct O
correction O
. O

RARE I-GENE
DNA I-GENE
glycosylase I-GENE
catalyzes O
the O
initial O
step O
in O
the O
repair O
RARE O
that O
RARE O
potentially O
RARE O
RARE O
from O
duplex O
DNA O
. O

Current O
clinical O
trials O
should O
RARE O
the O
question O
of O
which O
of O
the O
therapeutic O
RARE O
RARE O
quality O
of O
life O
less O
. O

RARE O
RARE O
( O
RARE O
) O
is O
a O
prototype O
of O
another O
generation O
of O
RARE O
, O
RARE O
- O
organic O
, O
RARE O
RARE O
that O
appear O
very O
useful O
RARE O
in O
vitro O
and O
in O
vivo O
electron O
RARE O
resonance O
RARE O
. O

In O
this O
report O
, O
we O
focus O
on O
the O
RARE O
of O
the O
region O
of O
the O
NUM I-GENE
RARE I-GENE
RARE I-GENE
ALL_CAP I-GENE
gene I-GENE
that O
conferred O
both O
the O
RARE O
and O
pathogenic O
RARE O
to O
NUM O
RARE O
RARE O

RARE O
with O
acute O
RARE O
in O
RARE O
remission O
or O
chronic O
RARE O
RARE O
in O
RARE O
chronic O
RARE O
were O
analysed O
RARE O
good O
risk O
, O
and O
those O
beyond O
these O
stages O
, O
RARE O
poor O
risk O
patients O
. O

RARE O
, O
P O
. O

RARE O
suppressed O
> O
or O
= O
NUM O
% O
of O
the O
RARE O
premature O
ventricular O
contractions O
in O
all O
patients O
who O
had O
both O
use O
- O
dependent O
QRS O
prolongation O
and O
reverse O
use O
- O
dependent O
QT O
prolongation O
, O
in O
NUM O
% O
of O
patients O
with O
use O
- O
dependent O
QRS O
prolongation O
alone O
, O
in O
70 O
% O
with O
reverse O
use O
- O
dependent O
QT O
prolongation O
alone O
, O
and O
in O
11 O
% O
with O
neither O
use O
- O
dependent O
QRS O
prolongation O
nor O
reverse O
use O
- O
dependent O
QT O
prolongation O
. O

RARE O
RARE O
the O
RARE O
procedure O
are O
corrected O
RARE O
using O
RARE O
estrogen O
RARE O
RARE O
the O
RARE O
steps O
and O
later O
by O
adding O
RARE O
internal O
RARE O
of O
all O
compounds O
measured O
( O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
, O
O O
- O
RARE O
, O
RARE O
, O
and O
RARE O
). O

IE2 I-GENE
- O
IE2 I-GENE
interactions O
were O
mapped O
to O
a O
domain O
containing O
a O
putative O
helix O
- O
RARE O
- O
helix O
motif O
RARE O
near O
the O
C O
terminus O
of O
IE2 I-GENE
, O
between O
amino O
RARE O
NUM O
and O
NUM O
. O

The O
NUM I-GENE
region I-GENE
, O
however O
, O
is O
converted O
to O
a O
functionally O
strong O
ALL_CAP O
by O
the O
viral I-GENE
tat I-GENE
factor I-GENE
. O

RARE O
using O
GST I-GENE
fusion I-GENE
proteins I-GENE
containing O
Fyn I-GENE
NUM I-GENE
, O
SH3 I-GENE
, O
and O
NUM I-GENE
/ O
SH3 I-GENE
domains O
revealed O
that O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
RARE O
RARE O
to O
the O
SH3 I-GENE
domain I-GENE
of O
Fyn I-GENE
. O

A O
sheep O
RARE O
cDNA O
library O
constructed O
in O
NUM O
vector O
was O
screened O
with O
a O
probe O
generated O
by O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
corresponding O
to O
a O
1 O
. O
6 O
kb O
fragment O
of O
the O
rat I-GENE
RARE I-GENE
hormone I-GENE
receptor I-GENE
cDNA I-GENE
. O

Two O
putative O
RARE I-GENE
proteins I-GENE
with O
apparent O
RARE O
masses O
of O
18 O
and O
16 O
kDa O
were O
RARE O
by O
NUM I-GENE
/ I-GENE
2 I-GENE
and O
NUM I-GENE
, O
while O
NUM I-GENE
RARE O
only O
a O
16 O
- O
kDa O
species O
. O

Three O
group O
1 O
patients O
developed O
ALL_CAP O
RARE O
; O
1 O
group O
2 O
patient O
developed O
ALL_CAP O
hepatitis O
. O

The O
ability O
of O
NUM I-GENE
mutations I-GENE
to O
suppress O
the O
transcriptional O
interference O
caused O
by O
the O
delta I-GENE
promoter I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
4 I-GENE
- I-GENE
NUM I-GENE
delta I-GENE
correlates O
with O
an O
increase O
in O
wild I-GENE
- I-GENE
type I-GENE
NUM I-GENE
mRNA I-GENE
levels O
. O

Nuclear O
RARE O
and O
protein O
sequence O
similarities O
suggested O
that O
the O
NUM I-GENE
/ O
NUM I-GENE
protein O
may O
be O
related O
to O
the O
RARE I-GENE
chromosomal I-GENE
protein I-GENE
NUM I-GENE
. O

The O
RARE O
RARE O
C O
- O
terminal O
RARE O
in O
thyroid O
hormone O
and O
retinoic I-GENE
acid I-GENE
receptors I-GENE
mediates O
diverse O
responses O
by O
affecting O
RARE O
but O
not O
RARE O
formation O
. O

Genetic O
interactions O
between O
NUM I-GENE
and O
other O
RARE O
RARE O
suggested O
that O
NUM I-GENE
functions O
on O
a O
common O
RARE O
branch O
with O
NUM I-GENE
and O
NUM I-GENE
. O

RARE I-GENE
factor I-GENE
1 I-GENE
, O
an O
orphan I-GENE
nuclear I-GENE
receptor I-GENE
, O
regulates O
the O
RARE O
of O
the O
rat I-GENE
aromatase I-GENE
gene I-GENE
in O
RARE O
tissues O
. O

To O
study O
the O
RARE O
differences O
between O
cutaneous O
NUM O
and O
NUM O
NUM I-GENE
and O
RARE I-GENE
NUM I-GENE
E7 I-GENE
, O
we O
RARE O
each O
of O
the O
E7 I-GENE
RARE O
reading O
frames O
and O
tested O
their O
RARE O
and O
transforming O
activities O
, O
the O
binding O
ability O
of O
their O
products O
with O
RARE I-GENE
protein I-GENE
( O
ALL_CAP I-GENE
) O
and O
their O
RARE O
activity O
of O
a O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
adenovirus I-GENE
E1A I-GENE
mutant I-GENE
. O

The O
ALL_CAP I-GENE
transcription I-GENE
RARE I-GENE
site I-GENE
was O
mapped O
to O
- O
NUM O
relative O
to O
the O
RARE O
of O
translation O
. O

Several O
lines O
of O
evidence O
demonstrate O
that O
this O
growth O
inhibition O
requires O
RARE O
PKA I-GENE
subunits I-GENE
and O
cAMP O
: O
( O
i O
) O
this O
RARE O
is O
dependent O
on O
cAMP O
since O
it O
is O
not O
seen O
in O
a O
RARE O
RARE O
RARE I-GENE
cyclase I-GENE
activity O
, O
but O
the O
growth O
rate O
of O
these O
transformants O
is O
slower O
when O
RARE O
cAMP O
is O
added O
; O
( O
ii O
) O
normal O
growth O
occurs O
when O
wild O
- O
type O
ALL_CAP I-GENE
cDNA O
is O
replaced O
by O
a O
mutant I-GENE
ALL_CAP I-GENE
cDNA I-GENE
encoding O
a O
ALL_CAP I-GENE
protein I-GENE
with O
RARE O
cAMP O
binding O
; O
and O
( O
iii O
) O
the O
growth O
- O
inhibited O
RARE O
of O
the O
transformed O
NUM O
( O
NUM O
) O
cells O
requires O
RARE O
, O
RARE O
C I-GENE
alpha I-GENE
protein I-GENE
. O

RARE O
, O
B O
. O

ALL_CAP I-GENE
- O
ABL I-GENE
and O
v I-GENE
- I-GENE
abl I-GENE
RARE I-GENE
induce O
distinct O
patterns O
of O
RARE O
lymphoma O
involving O
different O
lymphocyte O
RARE O
. O

These O
experiments O
confirm O
that O
the O
6 O
- O
S O
RARE O
form O
of O
the O
receptor O
identified O
in O
nuclear O
extracts O
of O
cells O
treated O
with O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
RARE O
- O
p O
- O
RARE O
( O
ALL_CAP O
) O
contains O
the O
RARE I-GENE
receptor I-GENE
protein I-GENE
and O
ALL_CAP I-GENE
but O
not O
the O
NUM I-GENE
- I-GENE
kDa I-GENE
heat I-GENE
shock I-GENE
protein I-GENE
. O

LDL I-GENE
cholesterol I-GENE
decreased O
from O
4 O
. O
NUM O
+/- O
NUM O
. O
87 O
to O
3 O
. O
NUM O
+/- O
NUM O
. O
NUM O
mmol O
/ O
RARE O
after O
8 O
weeks O
on O
RARE O
( O
P O
< O
NUM O
. O
001 O
RARE O
and O
RARE I-GENE
B I-GENE
fell O
from O
142 O
+/- O
NUM O
to O
112 O
+/- O
NUM O
mg O
/ O
dl O
( O
P O
< O
NUM O
. O
001 O
). O

LDL I-GENE
cholesterol I-GENE
decreased O
from O
4 O
. O
NUM O
+/- O
NUM O
. O
87 O
to O
3 O
. O
NUM O
+/- O
NUM O
. O
NUM O
mmol O
/ O
RARE O
after O
8 O
weeks O
on O
RARE O
( O
P O
< O
NUM O
. O
001 O
RARE O
and O
RARE I-GENE
B I-GENE
fell O
from O
142 O
+/- O
NUM O
to O
112 O
+/- O
NUM O
mg O
/ O
dl O
( O
P O
< O
NUM O
. O
001 O
). O

This O
negative O
element O
may O
, O
RARE O
least O
in O
part O
, O
be O
responsible O
RARE O
the O
cell O
type O
- O
specific O
RARE O
of O
the O
ALL_CAP I-GENE
gene I-GENE
. O

RARE O
activity O
of O
the O
distal O
promoter O
- O
like O
element O
of O
the O
human I-GENE
RARE I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
gene I-GENE
and O
secondary O
structural O
features O
of O
its O
corresponding O
transcripts O
. O

A O
new O
RARE O
technology O
RARE O
RARE O
RARE O
. O

We O
RARE O
hypersensitivity O
site O
2 O
( O
NUM O
) O
from O
the O
locus O
control O
region O
( O
ALL_CAP O
) O
to O
a O
A I-GENE
gamma I-GENE
- I-GENE
globin I-GENE
gene O
( O
A O
gamma O
RARE O
RARE O
marked O
to O
allow O
its O
transcript O
to O
be O
distinguished O
from O
endogenous O
gamma I-GENE
- I-GENE
globin I-GENE
mRNA O
. O

ALL_CAP O
RARE O
Patients O
allocated O
to O
treatment O
with O
RARE I-GENE
/ I-GENE
RARE I-GENE
decarboxylase I-GENE
inhibitor O
alone O
( O
RARE O
1 O
RARE O
RARE I-GENE
/ I-GENE
decarboxylase I-GENE
inhibitor O
/ O
RARE O
in O
combination O
( O
RARE O
2 O
RARE O
or O
RARE O
( O
RARE O
3 O
). O

It O
contains O
three O
putative O
binding O
sites O
RARE O
transcription I-GENE
factor I-GENE
NUM I-GENE
RARE O
RARE O
RARE O
several O
short O
sequences O
that O
are O
similar O
to O
known O
cis O
- O
acting O
RARE O
or O
binding O
sites O
RARE O
transcription O
factors O
. O

RARE O
RARE O
contains O
a O
small O
family O
of O
genes I-GENE
encoding I-GENE
ALL_CAP I-GENE
and O
two O
of O
these O
genes O
, O
NUM I-GENE
and O
NUM I-GENE
, O
have O
been O
shown O
to O
be O
differentially O
RARE O
RARE O
the O
mRNA O
level O
in O
RARE O
tissues O
. O

Plasma O
RARE O
NUM O
levels O
in O
the O
older O
group O
were O
about O
double O
those O
in O
RARE O
RARE O
. O

By O
RARE O
RARE O
multiple O
regression O
analysis O
, O
RARE O
magnesium O
was O
significantly O
related O
to O
cyclosporin O
trough O
level O
and O
RARE O
cholesterol O
but O
not O
to O
serum O
RARE O
, O
time O
after O
transplant O
or O
the O
dose O
of O
cyclosporin O
. O

The O
human I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
II I-GENE
( O
IGF I-GENE
- I-GENE
II I-GENE
) O
gene O
contains O
four O
promoters O
( O
P1 O
, O
P2 O
, O
NUM O
and O
NUM O
). O

Moreover O
, O
in O
transient O
transfection O
assays O
, O
ALL_CAP I-GENE
. I-GENE
1 I-GENE
alone O
activated O
reporter O
constructs O
containing O
the O
ALL_CAP O
cis O
- O
element O
, O
and O
the O
activation O
was O
shown O
to O
be O
dependent O
on O
a O
RARE O
- O
rich O
sequence O
in O
the O
amino O
- O
terminal O
portion O
of O
ALL_CAP I-GENE
. I-GENE
1 I-GENE
. O

RARE O
RARE O
given O
yellow O
fever O
vaccine O
contaminated O
with O
hepatitis O
B O
virus O
in O
NUM O
and O
controls O
and O
( O
b O
) O
a O
case O
- O
control O
study O
comparing O
RARE O
with O
RARE O
carcinoma O
in O
RARE O
RARE O
hospitals O
with O
matched O
controls O
with O
respect O
to O
RARE O
of O
contaminated O
vaccine O
in O
NUM O
. O

They O
were O
found O
to O
be O
seropositive O
RARE O
antibodies O
to O
hepatitis O
C O
virus O
by O
second O
- O
generation O
testing O
( O
ALL_CAP O
2 O
, O
RARE O
Diagnostic O
RARE O
RARE O
, O
RARE O
, O
ALL_CAP O
). O

RARE O
of O
RARE I-GENE
( O
NUM I-GENE
RARE O
a O
glycoprotein O
RARE O
of O
the O
extracellular O
RARE O
, O
cause O
RARE O
RARE O
. O

When O
introduced O
into O
ALL_CAP I-GENE
+ I-GENE
strains O
, O
ALL_CAP I-GENE
mutations O
conferred O
RARE O
and O
RARE I-GENE
- I-GENE
RARE I-GENE
RARE O
. O

RARE O
roles O
of O
the O
membrane O
- O
RARE O
and O
RARE I-GENE
RARE O
cell O
- O
cell O
adhesion O
in O
generating O
different O
RARE I-GENE
RARE I-GENE
K I-GENE
RARE I-GENE
ATPase I-GENE
RARE O
in O
RARE O
RARE O
. O

RARE O
lupus O
erythematosus O
is O
most O
often O
associated O
with O
autoantibodies O
against O
RARE I-GENE
and O
RARE I-GENE
antigens O
. O

Genetic O
abnormalities O
that O
could O
lead O
to O
mutagenesis O
include O
chromosomal O
abnormalities O
and O
single O
- O
gene O
mutations O
. O

RARE O
, O
and O
L O
. O

RARE O
absorption O
of O
amino O
RARE O
by O
the O
ALL_CAP O
carrier O
( O
RARE O
neutral O
amino O
RARE O
RARE O
the O
Y O
+ O
RARE O
( O
RARE O
RARE O
amino O
RARE O
RARE O
and O
the O
ALL_CAP O
carrier O
were O
operative O
even O
RARE O
the O
actively O
RARE O
RARE O
of O
RARE O
RARE O
due O
to O
RARE O
. O

1 O
) O
ALL_CAP O
, O
ALL_CAP O
and O
ALL_CAP O
showed O
a O
potent O
antimicrobial O
activity O
against O
H O
. O
RARE O
, O
and O
especially O
, O
ALL_CAP O
showed O
a O
marked O
bactericidal O
activity O
in O
a O
short O
time O
. O

RARE O
- O
RARE O
RARE O
and O
RARE O
RARE O
RARE O
grafts O
: O
report O
of O
two O
cases O
. O

A O
high O
mean O
intensity O
of O
ALL_CAP O
( O
standardized O
multivariate O
regression O
coefficient O
beta O
- O
NUM O
. O
NUM O
, O
p O
= O
NUM O
. O
NUM O
) O
and O
a O
high O
maximal O
oxygen O
uptake O
( O
beta O
- O
NUM O
. O
NUM O
, O
p O
< O
NUM O
. O
001 O
) O
were O
associated O
with O
RARE O
plasma I-GENE
fibrinogen I-GENE
when O
RARE O
RARE O
the O
strongest O
RARE O
. O

RARE O
young O
people O
RARE O
and O
do O
when O
the O
RARE O
RARE O
RARE O
RARE O
carrier O
testing O
is O
available O
. O

A O
patient O
matches O
a O
ALL_CAP O
patient O
if O
both O
have O
the O
same O
mechanism O
of O
injury O
, O
the O
same O
coding O
of O
RARE O
RARE O
RARE O
variables O
( O
RARE O
RARE O
Scale O
score O
, O
systolic O
RARE O
pressure O
, O
respiratory O
rate O
RARE O
the O
same O
coded O
age O
per O
A O
RARE O
Characterization O
of O
RARE O
) O
( O
ALL_CAP O
RARE O
and O
if O
they O
differ O
by O
RARE O
more O
than O
NUM O
. O
5 O
RARE O
A O
, O
B O
, O
and O
C O
( O
the O
ALL_CAP O
RARE O
RARE O
serious O
injuries O
). O

RARE O
and O
bowel O
NUM O
varied O
with O
NUM O
and O
each O
other O
( O
P O
< O
NUM O
. O
05 O
). O

A O
region O
RARE O
NUM O
bp O
upstream O
from O
the O
transcription O
RARE O
point O
of O
ALL_CAP I-GENE
was O
identified O
RARE O
being O
necessary O
RARE O
full O
activation O
of O
this O
promoter O
by O
ALL_CAP I-GENE
. O

We O
have O
isolated O
a O
cosmid O
containing O
DNA O
that O
corresponds O
to O
the O
site O
of O
RARE O
RARE O
in O
NUM O
and O
have O
localized O
NUM I-GENE
on O
an O
8 I-GENE
. I-GENE
NUM I-GENE
kb I-GENE
EcoRI I-GENE
fragment I-GENE
. O

The O
RARE I-GENE
RARE I-GENE
of O
NUM O
and O
the O
RARE I-GENE
encoded I-GENE
RARE I-GENE
RARE I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
NUM I-GENE
are O
both O
negatively O
RARE O
by O
a O
specific O
repressor O
( O
ALL_CAP I-GENE
). O

Although O
the O
RARE O
mechanisms O
involved O
in O
this O
RARE O
are O
currently O
being O
RARE O
, O
very O
little O
is O
known O
about O
the O
RARE O
- O
acting O
factors O
that O
allow O
RARE O
of O
the O
RARE I-GENE
and I-GENE
RARE I-GENE
reductase I-GENE
genes I-GENE
which O
code O
RARE O
the O
RARE O
RARE O
in O
the O
RARE O
. O

The O
NUM I-GENE
gene I-GENE
is O
present O
RARE O
a O
unique O
copy O
in O
the O
diploid O
N O
. O
RARE O
species O
. O

Transient O
transfection O
experiments O
revealed O
that O
Pax I-GENE
- I-GENE
8 I-GENE
isoforms I-GENE
a I-GENE
and I-GENE
b I-GENE
, O
but O
not O
c O
and O
d O
, O
strongly O
stimulate O
transcription O
from O
a O
promoter O
containing O
RARE O
copies O
of O
a O
paired I-GENE
- I-GENE
domain I-GENE
recognition I-GENE
sequence I-GENE
. O

The O
amino O
- O
terminal O
third O
of O
the O
protein O
contains O
a O
high I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
motif I-GENE
characteristic O
of O
DNA O
- O
binding O
proteins O
. O

We O
have O
examined O
the O
ability O
of O
various O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
subunits I-GENE
to O
bind O
to O
, O
and O
activate O
transcription O
from O
, O
the O
ALL_CAP I-GENE
- I-GENE
8 I-GENE
promoter I-GENE
. O

When O
multiple O
copies O
of O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
site I-GENE
were O
RARE O
to O
an O
RARE O
simian I-GENE
virus I-GENE
40 I-GENE
promoter I-GENE
, O
this O
element O
was O
able O
to O
mediate O
phorbol O
ester O
- O
or O
lipopolysaccharide O
- O
inducible O
gene O
RARE O
. O

We O
found O
that O
the O
3 O
'- O
end O
- O
adjacent O
sequence O
CA O
( O
N O
) O
3 O
- O
NUM O
, O
RARE O
in O
RARE O
Pol I-GENE
II I-GENE
- O
specific O
ALL_CAP I-GENE
ALL_CAP I-GENE
genes I-GENE
, O
is O
essential O
RARE O
the O
3 O
'- O
end O
formation O
of O
NUM I-GENE
transcripts I-GENE
and O
, O
similar O
to O
the O
RARE O
3 O
' O
box O
, O
is O
highly O
RARE O
to O
mutation O
. O

These O
results O
indicate O
that O
RARE I-GENE
protein I-GENE
is O
RARE O
with O
some O
RARE O
( O
s O
) O
of O
the O
cell O
RARE O
- O
regulatory O
machinery O
RARE O
NUM O
RARE O
. O

ALL_CAP I-GENE
from O
HeLa O
and O
RARE O
cells O
formed O
DNA O
- O
protein O
complexes O
with O
X O
- O
box O
oligonucleotides O
that O
RARE O
with O
those O
containing O
standard O
ALL_CAP I-GENE
sites I-GENE
. O

RARE O
mice O
harboring O
the O
rat O
TnI I-GENE
- O
CAT I-GENE
fusion O
gene O
RARE O
the O
reporter O
specifically O
in O
the O
skeletal O
muscle O
. O

METHODS O
: O
Fifty O
- O
one O
healthy O
eyes O
, O
NUM O
ocular O
hypertensive O
eyes O
with O
normal O
visual O
fields O
, O
and O
132 O
RARE O
eyes O
with O
early O
visual O
field O
defects O
were O
evaluated O
with O
qualitative O
and O
quantitative O
measures O
of O
structural O
damage O
to O
the O
optic O
nerve O
and O
nerve O
fiber O
layer O
. O

Consistent O
with O
the O
hypothesis O
that O
it O
acts O
RARE O
transcriptional O
regulator O
, O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
protein I-GENE
binds O
DNA O
and O
activates O
transcription O
of O
several O
promoters O
. O

The O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
factor I-GENE
( O
ARF I-GENE
) O
family O
is O
one O
of O
four O
RARE O
of O
the O
ALL_CAP I-GENE
superfamily I-GENE
of O
low I-GENE
RARE I-GENE
RARE I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
G I-GENE
proteins I-GENE
). O

The O
E1 I-GENE
gene I-GENE
is O
RARE O
within O
the O
RARE O
intron O
of O
the O
gene O
RARE O
NUM I-GENE
, O
a O
protein O
that O
regulates O
onset O
of O
mitosis O
. O

Genomic O
Southern O
blot O
analysis O
and O
RARE O
mapping O
showed O
that O
NUM I-GENE
RARE O
to O
two O
closely O
related O
genes O
RARE O
on O
chromosomes O
5 O
and O
NUM O
and O
are O
, O
therefore O
, O
distinct O
from O
the O
ALL_CAP I-GENE
RARE O
near O
the O
RARE I-GENE
RARE I-GENE
locus I-GENE
on O
RARE O
4 O
. O

RARE O
labeling O
studies O
in O
S O
. O
cerevisiae O
and O
RARE O
- O
RARE O
of O
NUM I-GENE
with O
several O
protein O
RARE O
of O
NUM I-GENE
in O
Escherichia O
coli O
indicate O
that O
the O
NUM O
RARE O
RARE O
substitution O
causes O
a O
reduction O
in O
the O
RARE O
of O
some O
but O
not O
all O
protein O
RARE O
. O

These O
ALL_CAP I-GENE
kinases I-GENE
, O
designated O
NUM I-GENE
and O
NUM I-GENE
, O
are O
RARE O
by O
chromatography O
on O
RARE O
ALL_CAP O
. O

Instead O
, O
mRNA O
of O
2 O
. O
NUM O
and O
2 O
. O
8 O
kb O
are O
detected O
in O
varying O
abundance O
. O

Previously O
, O
we O
identified O
a O
NUM O
- O
bp O
promoter O
fragment O
, O
NUM O
/ O
NUM O
, O
which O
conferred O
heat O
shock O
inducibility O
on O
the O
heterologous O
CYC1 I-GENE
- O
lacZ I-GENE
reporter O
gene O
in O
S O
. O
cerevisiae O
( O
N O
. O

The O
sequence O
of O
the O
NUM I-GENE
gene I-GENE
predicts O
an O
88 O
- O
kDa O
protein O
with O
three O
repeats O
of O
a O
motif O
found O
in O
the O
G I-GENE
beta I-GENE
subunit I-GENE
of O
RARE I-GENE
RARE I-GENE
and O
in O
a O
yeast O
transcriptional O
repressor O
, O
NUM I-GENE
. O

All O
of O
these O
data O
suggest O
that O
replication O
of O
ALL_CAP O
- O
damaged O
templates O
occurs O
in O
vitro O
RARE O
it O
does O
in O
vivo O
and O
that O
this O
replication O
results O
in O
mutation O
fixation O
. O

To O
identify O
factors O
that O
may O
modify O
the O
RARE O
RARE O
of O
human O
T O
cell O
leukemia O
/ O
lymphoma O
virus O
type O
I O
( O
ALL_CAP O
- O
I O
RARE O
NUM O
RARE O
RARE O
enrolled O
in O
the O
RARE O
RARE O
Study O
between O
RARE O
NUM O
and O
RARE O
1989 O
were O
studied O
: O
NUM O
RARE O
ALL_CAP O
- O
I O
- O
seropositive O
( O
H O
RARE O
RARE O
seropositive O
( O
ALL_CAP O
+), O
NUM O
H O
RARE O
ALL_CAP O
RARE O
NUM O
H O
RARE O
ALL_CAP O
RARE O
and O
NUM O
H O
RARE O
ALL_CAP O
-. O

Biol O
. O

To O
characterize O
the O
RARE O
of O
this O
DNA I-GENE
repair I-GENE
enzyme I-GENE
, O
we O
have O
isolated O
the O
corresponding O
genomic O
clone O
. O

L O
., O
RARE O
, O
G O
., O
RARE O
, O
D O
., O
RARE O
, O
ALL_CAP O
., O
RARE O
, O
X O
., O
RARE O
, O
A O
., O
RARE O
, O
M O
., O
and O
RARE O
, O
H O
. O

The O
nucleotide O
sequence O
of O
the O
gene O
predicts O
a O
polypeptide O
of O
215 O
amino O
RARE O
( O
NUM O
. O
2 O
kDa O
) O
with O
two O
putative O
membrane O
- O
spanning O
domains O
. O

ALL_CAP O
, O
echocardiography O
and O
thallium O
- O
NUM O
imaging O
were O
performed O
before O
and O
1 O
month O
after O
RARE O
RARE O
. O

They O
were O
called O
NUM I-GENE
and O
NUM I-GENE
. O

NUM O
, O
NUM O
- O
NUM O
). O

Both O
fusion O
proteins O
form O
stable O
specific O
complexes O
with O
a O
short O
DNA O
duplex O
harboring O
the O
ALL_CAP O
( O
RARE O
) O
NUM O
consensus O
sequence O
of O
the O
LexA I-GENE
repressor I-GENE
. O

Ten O
RARE O
residues O
( O
deduced O
) O
are O
present O
. O

CONCLUSIONS O
: O
RARE O
protein I-GENE
S I-GENE
deficiency O
is O
common O
among O
hospitalized O
patients O
, O
even O
in O
the O
absence O
of O
a O
RARE O
RARE O
condition O
. O

During O
the O
past O
RARE O
, O
different O
RARE O
of O
endogenous O
RARE O
sequences O
have O
been O
defined O
in O
the O
human O
genome O
usually O
by O
low O
RARE O
hybridization O
employing O
DNA O
RARE O
of O
evolutionary O
RARE O
RARE O
RARE O
genes O
. O

As O
the O
RARE O
of O
these O
complexes O
, O
RARE O
least O
five O
RARE I-GENE
( O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
) O
showing O
specific O
binding O
to O
the O
ALL_CAP O
RNA O
were O
detected O
in O
the O
RARE O
cross O
- O
linking O
assay O
. O

The O
RARE O
RARE O
RARE O
RARE O
RARE O
in O
RARE O
RARE O
is O
the O
formation O
of O
RARE O
mRNAs O
. O

The O
use O
of O
this O
model O
RARE O
RARE O
RARE O
significant O
issues O
in O
RARE O
diseases O
is O
RARE O
with O
five O
different O
sets O
of O
parameters O
. O

An O
extensive O
inverted O
repeat O
is O
present O
3 O
' O
of O
ALL_CAP I-GENE
; O
inverted O
repeats O
are O
found O
RARE O
of O
all O
ALL_CAP I-GENE
RARE I-GENE
sequenced O
to O
date O
, O
although O
the O
sequence O
is O
not O
RARE O
. O

We O
describe O
a O
novel O
cytoplasmic I-GENE
tyrosine I-GENE
kinase I-GENE
, O
termed O
ALL_CAP I-GENE
( O
B I-GENE
cell I-GENE
RARE I-GENE
kinase I-GENE
RARE O
which O
is O
RARE O
in O
all O
stages O
of O
the O
B O
lineage O
and O
in O
RARE O
cells O
. O

RARE O
differences O
between O
the O
groups O
were O
not O
observed O
in O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
enzyme I-GENE
activity O
, O
but O
RARE O
enzyme O
activity O
was O
much O
RARE O
in O
RARE O
- O
RARE O
asthma O
- O
related O
polyps O
than O
in O
other O
RARE O
of O
nasal O
polyps O
tested O
. O

In O
the O
multivariate O
analysis O
, O
RARE O
variables O
were O
independently O
correlated O
with O
survival O
: O
RARE O
urea O
nitrogen O
level O
, O
serum I-GENE
RARE I-GENE
aminotransferase I-GENE
level O
, O
community O
- O
acquired O
RARE O
. O
hospital O
- O
acquired O
RARE O
, O
age O
, O
RARE O
- O
RARE O
score O
and O
RARE O
. O

Localization O
of O
the O
intronless O
gene O
coding O
RARE O
calmodulin I-GENE
- I-GENE
like I-GENE
protein I-GENE
ALL_CAP I-GENE
to O
human O
RARE O
NUM O
- O
RARE O
. O

In O
RARE O
RARE O
larvae O
, O
the O
ALL_CAP I-GENE
transcript I-GENE
appeared O
to O
be O
RARE O
least O
NUM O
- O
RARE O
less O
abundant O
than O
ribosomal O
RNA O
. O

One O
such O
mutant O
also O
affects O
the O
overlapping O
- O
10 O
hexamer O
of O
PR O
and O
results O
in O
RARE O
RARE O
by O
both O
ALL_CAP I-GENE
and O
RNA I-GENE
polymerase I-GENE
, O
likely O
RARE O
a O
result O
of O
inefficient O
transcriptional O
initiation O
of O
ALL_CAP I-GENE
mRNA I-GENE
. O

However O
, O
L I-GENE
- I-GENE
plastin I-GENE
has O
been O
found O
in O
many O
RARE O
of O
malignant O
human O
cells O
of O
non O
- O
RARE O
origin O
suggesting O
that O
its O
RARE O
is O
RARE O
accompanying O
tumorigenesis O
in O
solid O
tissues O
. O

Finally O
, O
we O
present O
evidence O
that O
RARE I-GENE
is O
a O
third O
distinct O
plastin I-GENE
isoform I-GENE
which O
is O
specifically O
RARE O
RARE O
high O
levels O
in O
the O
small O
intestine O
. O

This O
promoter O
could O
direct O
the O
RARE O
RARE O
of O
the O
reporter O
beta I-GENE
- I-GENE
galactosidase I-GENE
RARE O
high O
frequency O
in O
transfected O
colonies O
of O
transformed O
cells O
that O
express O
L I-GENE
- I-GENE
plastin I-GENE
constitutively O
; O
by O
contrast O
, O
this O
promoter O
was O
virtually O
inactive O
in O
transfected O
colonies O
of O
normal O
RARE O
and O
it O
exhibited O
a O
low O
frequency O
of O
RARE O
activation O
in O
transfected O
colonies O
of O
in O
vitro O
SV40 O
- O
transformed O
RARE O
which O
did O
not O
exhibit O
L I-GENE
- I-GENE
plastin I-GENE
RARE O
. O

The O
RARE O
- O
life O
of O
the O
serum O
- O
RARE O
CBP I-GENE
/ O
tk I-GENE
binding O
activity O
was O
estimated O
to O
be O
less O
than O
1 O
h O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

The O
DNase I-GENE
I I-GENE
footprint O
extended O
5 O
' O
in O
the O
RARE O
region O
to O
include O
an O
inverted O
repeat O
of O
a O
RARE O
- O
nucleotide O
motif O
( O
epsilon O
- O
NUM O
to O
- O
NUM O
bp O
) O
which O
shares O
5 O
of O
6 O
bases O
with O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
consensus I-GENE
sequence I-GENE
. O

Furthermore O
, O
competitor O
containing O
the O
YY1 I-GENE
consensus I-GENE
sequence I-GENE
RARE O
RARE O
protein I-GENE
B I-GENE
binding O
, O
whereas O
competitor O
containing O
a O
perfect O
yeast I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
consensus I-GENE
sequence I-GENE
did O
not O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

The O
gene O
includes O
three O
exons O
and O
two O
RARE O
within O
1 O
. O
6 O
kilobases O
of O
DNA O
, O
and O
the O
RARE O
RARE O
reading O
frame O
RARE O
glycoprotein I-GENE
ALL_CAP I-GENE
is O
included O
within O
the O
third O
RARE O
. O

RARE O
RARE O
large O
RARE O
NUM O
carries O
the O
RARE O
RARE O
locus O
RARE I-GENE
responsible O
RARE O
the O
RARE O
efficiency O
and O
competitive O
ability O
of O
RARE O
NUM O
on O
RARE O
roots O
. O

Further O
, O
the O
ability O
of O
recombinant O
beta O
and O
/ O
or O
gamma O
chains O
to O
function O
in O
defined O
biochemical O
assays O
of O
beta O
gamma O
activity O
was O
assessed O
RARE O
membrane O
extracts O
and O
supernatant O
fractions O
from O
RARE O
Sf9 O
cells O
. O

This O
report O
describes O
the O
identification O
of O
a O
gene O
of O
related O
function O
, O
NUM I-GENE
, O
RARE O
immediately O
3 O
' O
to O
NUM I-GENE
. O

These O
data O
establish O
NUM I-GENE
RARE O
a O
required O
RARE O
of O
the O
cellular O
RARE O
apparatus O
and O
a O
factor O
in O
ALL_CAP O
RARE O
and O
stability O
. O

This O
study O
compared O
the O
gross O
and O
fine O
motor O
performance O
of O
14 O
RARE O
brain O
- O
RARE O
children O
( O
five O
to O
NUM O
years O
old O
, O
with O
RARE O
of O
RARE O
RARE O
RARE O
least O
NUM O
hours O
) O
to O
14 O
normal O
children O
group O
matched O
RARE O
age O
and O
RARE O
. O

We O
compared O
the O
parameters O
RARE I-GENE
adenosine I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
, O
determined O
in O
NUM O
patients O
RARE O
the O
ALL_CAP I-GENE
/ O
serum I-GENE
ALL_CAP I-GENE
ratio O
( O
P I-GENE
/ O
ALL_CAP I-GENE
; O
NUM O
cases O
RARE O
RARE I-GENE
lysozyme I-GENE
( O
ALL_CAP I-GENE
, O
NUM O
cases O
RARE O
the O
ALL_CAP I-GENE
/ O
serum I-GENE
ALL_CAP I-GENE
ratio O
( O
P I-GENE
/ O
ALL_CAP I-GENE
; O
NUM O
cases O
RARE O
and O
RARE I-GENE
RARE I-GENE
gamma I-GENE
( O
IFN I-GENE
, O
NUM O
cases O
) O
regarding O
their O
ability O
to O
differentiate O
tuberculous O
RARE O
RARE O
from O
others O
. O

These O
exons O
were O
identified O
by O
cloning O
and O
sequencing O
cDNAs O
obtained O
by O
polymerase O
chain O
reaction O
amplification O
of O
a O
fibroblast O
cDNA O
library O
. O

Deletion O
of O
the O
ALL_CAP I-GENE
gene I-GENE
, O
either O
with O
or O
without O
deletion O
of O
other O
RARE O
( O
protease I-GENE
IV I-GENE
and O
RARE I-GENE
N I-GENE
RARE O
did O
not O
have O
any O
effect O
on O
cell O
growth O
in O
the O
various O
media O
tested O
. O

In O
Experiment O
2 O
RARE O
RARE O
, O
NUM O
. O
5 O
and O
1 O
. O
NUM O
mg O
/ O
kg O
i O
. O
p O
., O
was O
administered O
1 O
h O
before O
each O
electrical O
RARE O
until O
each O
rat O
showed O
the O
RARE O
- O
3 O
seizure O
. O

ALL_CAP O
, O
ALL_CAP O
and O
ALL_CAP O
in O
the O
initial O
RARE O
of O
kindling O
, O
kindling O
rate O
RARE O
the O
RARE O
- O
3 O
and O
- O
5 O
seizures O
, O
seizure O
parameters O
RARE O
the O
RARE O
RARE O
- O
3 O
and O
- O
5 O
were O
recorded O
and O
compared O
to O
the O
values O
of O
saline O
- O
treated O
, O
control O
group O
. O

CONCLUSIONS O
. O

There O
was O
a O
positive O
correlation O
between O
RARE O
cross O
- O
RARE O
excretion O
and O
thyroid O
hormone O
concentrations O
. O

Mutations O
RARE O
RARE O
many O
RARE O
NUM O
C O
- O
terminal O
residues O
from O
the O
transcriptional O
activator O
encoded O
by O
the O
ALL_CAP I-GENE
gene I-GENE
, O
mediating O
nitrogen O
metabolite O
repression O
in O
RARE O
RARE O
, O
do O
not O
significantly O
reduce O
the O
ability O
of O
the O
ALL_CAP I-GENE
product I-GENE
to O
activate O
RARE O
of O
most O
genes O
under O
ALL_CAP I-GENE
control O
. O

RARE O
RARE O
who O
RARE O
RARE O
RARE O
% O
ALL_CAP O
can O
be O
separated O
from O
RARE O
RARE O
. O

RARE O
promoter O
activity O
was O
observed O
RARE O
the O
promoter O
of O
the O
C1 I-GENE
and O
C2 I-GENE
RARE O
( O
C1 I-GENE
- O
C2 I-GENE
gene O
) O
and O
RARE O
the O
promoter O
of O
the O
NUM I-GENE
ORF I-GENE
. O

The O
activity O
of O
the O
coat I-GENE
protein I-GENE
promoter I-GENE
of O
RARE O
RARE O
mosaic O
virus O
is O
RARE O
by O
its O
own O
and O
C1 I-GENE
- O
C2 I-GENE
gene O
products O
. O

The O
amino O
acid O
sequence O
alignment O
of O
ALL_CAP I-GENE
II I-GENE
with O
that O
of O
other O
Cbl I-GENE
binding I-GENE
proteins I-GENE
( O
rat I-GENE
RARE I-GENE
factor I-GENE
, O
human I-GENE
RARE I-GENE
I I-GENE
and O
RARE I-GENE
RARE I-GENE
) O
revealed O
only O
NUM O
% O
overall O
homology O
. O

This O
short O
RARE O
RARE O
a O
novel O
RARE O
RARE O
enzyme O
immunoassay O
( O
ALL_CAP O
) O
with O
a O
commercial O
time O
- O
resolved O
RARE O
RARE O
the O
determination O
of O
thyrotropin I-GENE
in O
RARE O
RARE O
spots O
. O

The O
evaluation O
was O
performed O
using O
a O
retrospective O
study O
design O
with O
newborn O
RARE O
samples O
from O
three O
screening O
RARE O
. O

A O
region O
in O
the O
C O
- O
terminus O
of O
adenovirus I-GENE
2 I-GENE
/ I-GENE
5 I-GENE
E1a I-GENE
protein I-GENE
is O
required O
RARE O
association O
with O
a O
cellular O
RARE O
and O
important O
RARE O
the O
negative O
modulation O
of O
NUM O
- O
ras I-GENE
RARE O
transformation O
, O
tumorigenesis O
and O
metastasis O
. O

These O
studies O
demonstrate O
that O
both O
G I-GENE
alpha I-GENE
i I-GENE
genes I-GENE
are O
RARE O
regulated O
in O
ALL_CAP O
- O
NUM O
cells O
by O
both O
growth O
, O
differentiation O
, O
and O
hormone O
signals O
. O

RARE O
containing O
the O
full I-GENE
- I-GENE
length I-GENE
ALL_CAP I-GENE
cDNA I-GENE
have O
been O
RARE O
in O
Escherichia O
coli O
RARE O
a O
high O
level O
to O
generate O
a O
NUM O
- O
kDa O
recombinant O
protein O
. O

When O
ligated O
to O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
RARE I-GENE
site I-GENE
- I-GENE
proximal I-GENE
region I-GENE
( O
RARE O
between O
- O
NUM O
to O
+ O
12 O
RARE O
both O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
and O
the O
simian I-GENE
virus I-GENE
40 I-GENE
enhancer I-GENE
elements I-GENE
functioned O
more O
efficiently O
in O
monocytes O
than O
in O
HeLa O
cells O
, O
which O
are O
not O
normally O
competent O
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
RARE O
. O

Therefore O
, O
PC I-GENE
- I-GENE
PLC I-GENE
is O
a O
RARE O
of O
a O
signal O
RARE O
RARE O
leading O
to O
transcription O
of O
c I-GENE
- I-GENE
fos I-GENE
and O
junB I-GENE
that O
RARE O
with O
c I-GENE
- I-GENE
myc I-GENE
and O
is O
independent O
of O
PKC I-GENE
- I-GENE
delta I-GENE
and O
Ras I-GENE
activation O
. O

In O
mitogen O
- O
RARE O
RARE O
, O
RARE I-GENE
- I-GENE
1 I-GENE
RARE O
begins O
to O
rise O
RARE O
12 O
h O
after O
RARE O
and O
RARE O
very O
high O
levels O
after O
50 O
h O
, O
suggesting O
that O
it O
may O
be O
functionally O
involved O
in O
events O
occurring O
after O
the O
interaction O
of O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
with O
its O
receptor O
, O
perhaps O
RARE O
the O
transition O
from O
the O
G1 O
to O
the O
S O
RARE O
of O
the O
cell O
RARE O
. O

We O
have O
isolated O
and O
characterized O
the O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
and O
shown O
that O
their O
products O
are O
required O
to O
repress O
GCN4 I-GENE
translation O
under O
RARE O
conditions O
. O

The O
RARE O
NUM O
value O
was O
that O
predicted O
by O
RARE O
relation O
. O

While O
the O
latter O
corresponded O
to O
a O
protein O
of O
NUM O
amino O
RARE O
, O
an O
upstream O
RARE O
reading O
frame O
( O
ALL_CAP O
) O
within O
the O
5 O
' O
RARE O
could O
potentially O
encode O
a O
54 O
amino O
acid O
peptide O
. O

The O
NUM I-GENE
protein I-GENE
kinase I-GENE
mRNA I-GENE
contains O
a O
long O
5 O
' O
RARE O
with O
a O
small O
RARE O
reading O
frame O
. O

In O
contrast O
to O
T O
cells O
, O
in O
RARE O
ALL_CAP I-GENE
gene I-GENE
RARE O
requires O
only O
one O
signal O
( O
PMA O
) O
and O
is O
not O
affected O
by O
ALL_CAP O
. O

RARE O
RARE O
of O
GUS I-GENE
revealed O
promoter O
function O
in O
leaf O
RARE O
, O
RARE O
and O
vascular O
RARE O
, O
in O
the O
cortex O
and O
vascular O
RARE O
of O
the O
root O
. O

In O
order O
to O
investigate O
how O
these O
RARE O
patterns O
are O
established O
, O
we O
fused O
promoter O
regions O
of O
an O
RARE O
and O
a O
basic O
RARE I-GENE
gene I-GENE
to O
the O
beta I-GENE
- I-GENE
glucuronidase I-GENE
( O
GUS I-GENE
) O
reporter O
gene O
and O
examined O
RARE O
of O
these O
constructs O
in O
transgenic O
tobacco O
RARE O
. O

Southern O
blot O
analysis O
using O
RARE O
from O
the O
3 O
' O
portions O
of O
the O
genomic O
and O
B I-GENE
. I-GENE
RARE I-GENE
ALL_CAP I-GENE
and O
MB I-GENE
cDNA I-GENE
RARE O
showed O
that O
ALL_CAP I-GENE
type I-GENE
RARE I-GENE
are O
encoded O
by O
RARE O
4 O
genes O
, O
while O
MB I-GENE
type I-GENE
RARE I-GENE
are O
encoded O
by O
more O
than O
10 O
genes O
in O
B O
. O
RARE O
. O

RARE O
, O
A O
. O

RARE O
RARE O
( O
RARE O
) O
are O
a O
common O
structural O
motif O
found O
in O
many O
RARE O
acid O
- O
binding O
proteins O
. O

The O
deduced O
bovine O
EFIA I-GENE
RARE I-GENE
1 I-GENE
amino O
acid O
( O
RARE O
) O
sequence O
is O
98 O
% O
identical O
to O
rat O
EFIA I-GENE
and O
NUM O
% O
identical O
to O
human O
EFIA I-GENE
/ O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
family O
RARE O
DNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
B I-GENE
( O
ALL_CAP I-GENE
). O

Effect O
of O
tracheal O
RARE O
of O
RARE O
on O
acute O
RARE O
toxicity O
in O
rats O
. O

Localization O
of O
the O
RARE O
locus O
in O
the O
yeast O
genome O
and O
RARE O
studies O
with O
the O
RARE O
- O
RARE O
mutant O
indicate O
that O
the O
two O
mutations O
are O
allelic O
. O

RARE O
of O
the O
spacer O
sequence O
between O
the O
two O
RARE O
with O
a O
shorter O
stretch O
of O
sequence O
also O
RARE O
RNA O
binding O
in O
vitro O
. O

RARE O
II O
could O
be O
divided O
further O
into O
two O
forms O
( O
ALL_CAP O
and O
ALL_CAP O
) O
that O
may O
represent O
two O
RARE O
species O
or O
developmental O
stages O
of O
the O
same O
species O
. O

Second O
, O
the O
transcription I-GENE
factor I-GENE
RARE I-GENE
- I-GENE
ER I-GENE
was O
RARE O
more O
potent O
and O
less O
susceptible O
to O
cell O
type O
- O
specific O
variation O
by O
RARE O
the O
strong O
activating O
domain O
of O
the O
RARE I-GENE
protein I-GENE
VP16 I-GENE
onto O
its O
C O
terminus O
. O

The O
RARE O
fos I-GENE
gene I-GENE
was O
rapidly O
RARE O
to O
maximal O
levels O
within O
1 O
- O
2 O
hr O
of O
estrogen O
addition O
. O

Elimination O
of O
Haemophilus O
influenzae O
type O
b O
meningitis O
after O
introduction O
of O
vaccination O

RARE O
accurately O
assessed O
tumor O
extension O
in O
two O
NUM O
tumors O
, O
14 O
NUM O
tumors O
, O
and O
RARE O
T4 O
tumors O
. O

In O
the O
present O
study O
we O
demonstrated O
a O
unique O
mechanism O
of O
action O
of O
8 O
- O
Cl O
- O
cAMP O
in O
the O
RARE O
of O
these O
kinase O
RARE O
in O
ALL_CAP O
- O
NUM O
human O
RARE O
leukemia O
cells O
. O

Analysis O
of O
cell O
RARE O
RARE O
in O
the O
RARE O
yeast O
Saccharomyces O
cerevisiae O
has O
shown O
that O
a O
central O
regulatory O
protein O
kinase O
, O
Cdc28 I-GENE
, O
undergoes O
changes O
in O
activity O
through O
the O
cell O
RARE O
by O
RARE O
with O
distinct O
groups O
of O
RARE I-GENE
that O
accumulate O
RARE O
different O
times O
. O

RARE O
RARE O
representing O
full O
- O
length O
cDNAs O
RARE O
ALL_CAP I-GENE
alpha I-GENE
were O
obtained O
from O
mouse O
brain O
. O

The O
method O
involves O
preliminary O
isolation O
of O
RARE O
and O
internal O
standard O
from O
plasma O
by O
solid O
- O
RARE O
extraction O
prior O
to O
the O
formation O
of O
their O
RARE O
- O
RARE O
RARE O
RARE O
. O

There O
are O
, O
however O
, O
several O
differences O
between O
the O
two O
new O
RARE O
sequences O
. O

RARE O
linking O
the O
olfactory O
RARE O
with O
the O
medial O
RARE O
anterior O
hypothalamus O
are O
important O
RARE O
RARE O
aggression O
in O
mice O
. O

RARE I-GENE
mitogen I-GENE
( O
ALL_CAP I-GENE
) O
or O
anti I-GENE
- I-GENE
CD3 I-GENE
significantly O
increases O
c I-GENE
- I-GENE
jun I-GENE
RARE I-GENE
RNA I-GENE
( I-GENE
mRNA I-GENE
) I-GENE
levels O
in O
T O
cells O
. O

Following O
seizure O
induction O
, O
ALL_CAP O
increased O
to O
NUM O
mm O
Hg O
and O
brain O
RARE O
fell O
to O
6 O
. O
NUM O
+/- O
NUM O
. O
03 O
within O
NUM O
min O
and O
remained O
RARE O
this O
level O
RARE O
1 O
h O
( O
P O
< O
NUM O
. O
001 O
). O

In O
contrast O
, O
rats O
receiving O
NUM O
( O
2 O
mg O
/ O
kg O
i O
. O
v O
. O
infusion O
RARE O
NUM O
min O
prior O
to O
RARE O
) O
exhibited O
RARE O
ALL_CAP O
throughout O
reperfusion O
RARE O
PI O
10 O
min O
: O
3 O
. O
NUM O
( O
2 O
. O
NUM O
- O
3 O
. O
NUM O
); O
120 O
min O
: O
2 O
. O
03 O
( O
1 O
. O
NUM O
- O
2 O
. O
NUM O
); O
240 O
min O
: O
2 O
. O
NUM O
( O
1 O
. O
NUM O
- O
2 O
. O
NUM O
RARE O
p O
< O
NUM O
. O
01 O
RARE O
. O
controls O
and O
normals O
] O
with O
RARE O
muscle O
RARE O
RARE O
ALL_CAP O
NUM O
% O
in O
all O
RARE O
muscles O
, O
p O
< O
NUM O
. O
01 O
RARE O
. O
controls O
, O
not O
significant O
( O
ALL_CAP O
) O
RARE O
. O
normals O
and O
6 O
h O
ischaemia O
RARE O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

Sequencing O
of O
a O
1 O
. O
3 O
- O
RARE O
fragment O
of O
the O
5 O
'- O
flanking O
region O
of O
the O
NUM I-GENE
gene I-GENE
identified O
TATA O
- O
like O
and O
CAAT O
sequences O
near O
the O
transcription O
RARE O
site O
. O

The O
region O
that O
RARE O
inducibility O
by O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
or O
TNF I-GENE
( O
positions O
- O
165 O
to O
- O
58 O
) O
contains O
RARE O
binding O
sites O
RARE O
IRF I-GENE
- I-GENE
1 I-GENE
and I-GENE
- I-GENE
2 I-GENE
, O
AP I-GENE
- I-GENE
1 I-GENE
, O
and O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
- I-GENE
6 I-GENE
. O

Ig I-GENE
- I-GENE
alpha I-GENE
and O
Ig I-GENE
- I-GENE
beta I-GENE
contain O
extended O
cytoplasmic O
RARE O
( O
NUM O
and O
NUM O
amino O
RARE O
, O
respectively O
) O
and O
associate O
with O
cytoplasmic O
RARE O
indicating O
that O
they O
are O
directly O
involved O
in O
signal O
RARE O
. O

RARE O
mutants O
of O
Saccharomyces O
cerevisiae O
were O
isolated O
from O
alpha O
RARE O
cells O
having O
the O
a I-GENE
/ I-GENE
alpha I-GENE
NUM I-GENE
- I-GENE
6 I-GENE
RARE O
( O
exhibiting O
alpha O
RARE O
ability O
and O
weak O
a O
RARE O
ability O
RARE O
a O
result O
of O
a O
defect O
in O
NUM I-GENE
- I-GENE
alpha I-GENE
2 I-GENE
repression O
). O

We O
studied O
the O
RARE O
interaction O
between O
human O
RARE O
RARE I-GENE
2 I-GENE
globin I-GENE
promoter O
and O
the O
alpha I-GENE
globin I-GENE
regulatory I-GENE
element I-GENE
( O
ALL_CAP I-GENE
- I-GENE
40 I-GENE
) O
RARE O
40 O
kb O
upstream O
of O
the O
RARE I-GENE
2 I-GENE
globin I-GENE
gene I-GENE
. O

It O
was O
shown O
by O
transient O
RARE O
assay O
that O
ALL_CAP I-GENE
- I-GENE
40 I-GENE
RARE O
RARE O
an O
RARE O
enhancer O
RARE O
high O
- O
level O
RARE I-GENE
2 I-GENE
globin I-GENE
promoter I-GENE
activity O
in O
K562 O
cells O
, O
an O
RARE O
cell O
line O
of O
RARE O
and O
/ O
or O
RARE O
origin O
. O

Initial O
results O
indicate O
that O
this O
NUM I-GENE
pre I-GENE
- I-GENE
rRNA I-GENE
is O
the O
same O
RARE O
the O
species O
detected O
on O
depletion O
of O
the O
small I-GENE
RARE I-GENE
RNA I-GENE
- I-GENE
associated I-GENE
proteins I-GENE
NUM I-GENE
and O
NUM I-GENE
and O
in O
an O
NUM I-GENE
mutant I-GENE
RARE O
. O

RARE O
, O
L O
. O

This O
study O
RARE O
the O
feasibility O
of O
indirect O
RARE O
RARE O
RARE O
a O
RARE O
technique O
in O
a O
canine O
model O
. O

OBJECTIVE O
: O
Our O
purpose O
was O
to O
determine O
the O
simultaneous O
concentrations O
of O
serum O
RARE O
in O
both O
RARE O
and O
RARE O
RARE O
. O

RARE O
amino O
acid O
sequence O
has O
now O
been O
obtained O
from O
this O
protein O
which O
shares O
50 O
- O
NUM O
% O
sequence O
identity O
with O
sequences O
encoded O
by O
mammalian I-GENE
G I-GENE
alpha I-GENE
11 I-GENE
and O
G I-GENE
alpha I-GENE
RARE I-GENE
cDNAs I-GENE
. O

RARE O
is O
known O
to O
induce O
RARE O
of O
certain O
RARE O
- O
RARE O
, O
and O
this O
led O
us O
to O
examine O
RARE O
regulatory O
regions O
of O
the O
cellular I-GENE
c I-GENE
- I-GENE
fos I-GENE
oncogene I-GENE
. O

RARE O
lead O
was O
not O
a O
significant O
RARE O
RARE O
. O

We O
now O
show O
that O
RARE O
of O
ALL_CAP I-GENE
transcription O
in O
vivo O
depends O
on O
a O
RARE I-GENE
54 I-GENE
promoter I-GENE
and O
two O
RARE O
elements O
RARE O
RARE O
of O
the O
transcription O
RARE O
site O
RARE O
+ O
NUM O
( O
NUM O
) O
and O
+ O
120 O
( O
NUM O
). O

5 O
micrograms O
/ O
RARE O
was O
detected O
in O
urine O
from O
some O
non O
- O
RARE O
exposed O
persons O
. O

RARE O
RARE O
with O
deficiency O
of O
the O
RARE O
. O

This O
prospective O
study O
compared O
the O
measured O
energy O
RARE O
of O
NUM O
patients O
using O
indirect O
RARE O
with O
their O
predicted O
basal O
energy O
expenditure O
according O
to O
the O
RARE O
- O
RARE O
equation O
, O
or O
their O
calculated O
energy O
expenditure O
derived O
from O
basal O
energy O
expenditure O
times O
, O
an O
activity O
factor O
, O
and O
a O
stress O
factor O
. O

However O
, O
after O
RARE O
infections O
, O
RARE O
larvae O
were O
numerous O
. O

This O
was O
performed O
in O
a O
double O
RARE O
, O
randomized O
, O
placebo O
- O
RARE O
study O
. O

Group O
I O
consisted O
of O
RARE O
RARE O
patients O
; O
group O
II O
consisted O
of O
nine O
RARE O
RARE O
patients O
with O
mild O
RARE O
impairment O
( O
conjugated O
bilirubin O
, O
NUM O
mumol O
liter O
- O
1 O
; O
RARE I-GENE
phosphatase I-GENE
, O
NUM O
IU O
liter O
- O
1 O
; O
gamma I-GENE
- I-GENE
RARE I-GENE
, O
190 O
IU O
liter O
- O
1 O
); O
group O
III O
consisted O
of O
RARE O
benign O
intrahepatic O
RARE O
patients O
with O
high O
isolated O
conjugated O
hyperbilirubinemia O
( O
98 O
. O
1 O
mumol O
liter O
- O
1 O
). O

There O
was O
either O
RARE O
change O
or O
an O
improvement O
in O
RARE O
findings O
( O
t1 O
/ O
2 O
time O
and O
/ O
or O
RARE O
function O
) O
in O
40 O
patients O
( O
93 O
%). O

We O
discuss O
the O
need O
to O
use O
animals O
older O
than O
3 O
months O
RARE O
the O
study O
of O
' O
adult O
' O
regeneration O
phenomena O
since O
3 O
- O
month O
- O
old O
rats O
may O
be O
RARE O
immature O
. O

Nuclear I-GENE
beta I-GENE
II I-GENE
PKC I-GENE
, O
like O
p34cdc2 I-GENE
kinase I-GENE
, O
may O
function O
to O
regulate O
nuclear O
RARE O
structural O
stability O
RARE O
cell O
RARE O
. O

In O
situ O
RARE O
- O
RARE O
footprinting O
of O
individual O
gel O
shift O
assembly O
RARE O
shows O
that O
on O
the O
NUM O
- O
nucleotide O
NUM O
, O
the O
RARE O
two O
SSB I-GENE
RARE I-GENE
RARE O
RARE O
random O
, O
but O
the O
addition O
of O
more O
SSB I-GENE
RARE I-GENE
results O
in O
formation O
of O
a O
unique O
RARE O
. O

Effects O
of O
RARE O
RARE O
infusion O
on O
RARE O
- O
RARE O
RARE I-GENE
release O
. O

RARE I-GENE
associated I-GENE
box I-GENE
- I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
( O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
) O
constitute O
a O
subfamily O
of O
the O
many O
NUM I-GENE
type I-GENE
RARE I-GENE
in O
Xenopus O
RARE O
. O

Further O
evidence O
RARE O
a O
clustered O
organization O
of O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
transcription O
RARE O
is O
provided O
by O
Southern O
blot O
analysis O
of O
large O
genomic O
RARE O
fragments O
separated O
by O
transverse O
field O
gel O
electrophoresis O
, O
and O
by O
in O
situ O
hybridization O
on O
RARE O
chromosomes O
. O

A O
rat O
cDNA O
that O
encodes O
eIF I-GENE
- I-GENE
5 I-GENE
has O
been O
isolated O
and O
RARE O
in O
Escherichia O
coli O
to O
yield O
a O
catalytically O
RARE O
eIF I-GENE
- I-GENE
5 I-GENE
protein I-GENE
. O

Mutational O
analyses O
have O
demonstrated O
the O
importance O
of O
sequences O
within O
the O
NUM O
bp O
segment O
that O
contain O
a O
putative O
cyclic I-GENE
AMP I-GENE
responsive I-GENE
element I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
) O
binding O
site O
RARE O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
and O
PMA O
responsiveness O
and O
putative O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
and O
NUM I-GENE
binding I-GENE
sites I-GENE
RARE O
basal O
promoter O
activity O
. O

( O
1992 O
) O
ALL_CAP O
. O

In O
NUM O
- O
RARE O
internalization O
assays O
on O
forskolin O
- O
RARE O
ALL_CAP O
- O
1 O
cells O
, O
the O
ALL_CAP I-GENE
- I-GENE
2R I-GENE
alpha I-GENE
chain I-GENE
is O
consistently O
RARE O
together O
with O
the O
ALL_CAP I-GENE
- I-GENE
2R I-GENE
beta I-GENE
subunit I-GENE
indicating O
that O
ALL_CAP I-GENE
- I-GENE
2R I-GENE
alpha I-GENE
is O
stably O
associated O
with O
the O
NUM I-GENE
- I-GENE
ALL_CAP I-GENE
- I-GENE
2R I-GENE
beta I-GENE
complex I-GENE
even O
though O
the O
alpha O
- O
subunit O
contributes O
little O
if O
any O
affinity O
to O
the O
NUM O
binding O
reaction O
. O

The O
RARE O
dynamics O
of O
RARE O
E1 O
and O
/ O
or O
RARE O
and O
their O
different O
reactions O
in O
the O
RARE O
- O
and O
RARE O
state O
of O
RARE O
shock O
in O
a O
rat O
model O

We O
obtained O
the O
prevalence O
of O
IgG I-GENE
antibodies I-GENE
against O
Trypanosoma O
RARE O
among O
NUM O
RARE O
donors O
RARE O
the O
RARE O
RARE O
de O
RARE O
" O
RARE O
RARE O
" O
in O
RARE O
City O
. O

Examination O
of O
the O
immediate O
sequence O
5 O
' O
to O
the O
mRNA O
RARE O
site O
reveals O
RARE O
TATA O
box O
and O
multiple O
known O
enhancer O
sequences O
. O

The O
short O
- O
term O
RARE O
and O
infant O
- O
regulated O
removal O
of O
milk O
in O
RARE O
women O
. O

RARE O
( O
19 O
- O
NUM O
RARE O
derived O
from O
the O
C O
- O
terminus O
of O
Ca I-GENE
- I-GENE
dependent I-GENE
PKC I-GENE
RARE I-GENE
, O
inhibited O
beta I-GENE
- I-GENE
PKC I-GENE
but O
not O
ALL_CAP I-GENE
activity O
using O
either O
RARE I-GENE
ALL_CAP I-GENE
or O
peptide O
( O
19 O
- O
NUM O
) O
RARE O
substrate O
. O

Based O
on O
these O
results O
, O
a O
new O
model O
RARE O
the O
RARE O
of O
RARE I-GENE
/ O
RARE I-GENE
gene O
RARE O
in O
A O
. O
RARE O
is O
proposed O
. O

RARE O
oxide O
inhalation O
selectively O
reduces O
pulmonary O
hypertension O
in O
RARE O
RARE O
shock O
and O
RARE O
arterial O
oxygenation O
and O
pH O
with O
a O
marked O
RARE O
of O
sympathetic O
activation O
. O

B O
cell O
- O
specific O
RARE I-GENE
- I-GENE
1 I-GENE
and O
NUM I-GENE
genes I-GENE
encode O
the O
alpha O
/ O
beta O
RARE O
of O
the O
ALL_CAP I-GENE
- I-GENE
associated I-GENE
complex I-GENE
in O
RARE O
ALL_CAP I-GENE
+ I-GENE
B O
cells O
. O

RARE O
in O
RARE O
type O
theory O
and O
the O
RARE O
- O
RARE O
RARE O
RARE O
. O

A O
variety O
of O
nuclear O
RARE O
are O
believed O
to O
associate O
directly O
with O
RARE O
RNA I-GENE
polymerase I-GENE
II I-GENE
transcripts I-GENE
and O
RARE O
associated O
RARE O
subsequent O
nuclear O
RNA O
RARE O
reactions O
, O
including O
pre O
- O
mRNA O
polyadenylation O
and O
RARE O
RARE O
RARE O
RARE O
RARE O
mRNA O
RARE O
. O

Mutations O
RARE O
three O
sites O
have O
larger O
effects O
in O
muscle O
than O
RARE O
cells O
; O
an O
A O
/ O
T O
- O
rich O
site O
mutation O
has O
a O
pronounced O
effect O
in O
both O
RARE O
muscle O
RARE O
, O
mutations O
RARE O
the O
NUM I-GENE
( I-GENE
RARE I-GENE
E I-GENE
- I-GENE
box I-GENE
) I-GENE
site I-GENE
are O
relatively O
specific O
to O
RARE O
in O
skeletal O
muscle O
, O
and O
mutations O
RARE O
the O
ALL_CAP O
site O
are O
relatively O
specific O
to O
RARE O
in O
cardiac O
muscle O
. O

Transient O
transfection O
analysis O
with O
these O
mutations O
revealed O
that O
only O
a O
10 O
- O
bp O
region O
, O
containing O
precisely O
the O
Ets I-GENE
and O
proximal O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sites I-GENE
, O
was O
needed O
RARE O
D O
' O
activity O
. O

However O
, O
despite O
its O
relationship O
to O
the O
TR I-GENE
, O
RARE I-GENE
- O
RARE I-GENE
RARE O
poorly O
to O
TR I-GENE
binding I-GENE
sites I-GENE
. O

We O
report O
here O
that O
a O
NUM O
- O
bp O
promoter O
element O
previously O
shown O
to O
be O
important O
RARE O
the O
G1 O
- O
S O
activation O
of O
the O
human I-GENE
RARE I-GENE
kinase I-GENE
( O
RARE I-GENE
) O
promoter O
in O
growth O
- O
RARE O
cells O
is O
a O
cellular O
target O
of O
RARE I-GENE
A I-GENE
and O
the O
NUM I-GENE
complexes I-GENE
. O

These O
protective O
influences O
were O
observed O
throughout O
the O
range O
of O
filling O
pressures O
measured O
, O
from O
NUM O
to O
NUM O
mmHg O
. O

DNase I-GENE
I I-GENE
footprinting O
with O
rat O
liver O
nuclear O
extracts O
identified O
7 O
major O
protein O
- O
binding O
domains O
termed O
P1 O
through O
NUM O
in O
a O
NUM O
RARE O
RARE O
DNA O
fragment O
( O
RARE O
RARE O
- O
NUM O
to O
+ O
NUM O
). O

This O
may O
account O
, O
RARE O
least O
in O
part O
, O
RARE O
the O
ability O
of O
excess O
wt I-GENE
p53 I-GENE
to O
inhibit O
cell O
RARE O
and O
to O
RARE O
with O
neoplastic O
processes O
. O

Neither O
clone O
encoded O
the O
RARE O
endonuclease O
. O

Northern O
blot O
analysis O
of O
RARE O
cellular O
RNA O
indicated O
that O
ALL_CAP I-GENE
encodes O
a O
1 O
. O
3 O
- O
kb O
transcript O
which O
is O
RARE O
by O
RARE O
. O

The O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
promoters I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
are O
divergently O
RARE O
RARE I-GENE
54 I-GENE
- I-GENE
dependent I-GENE
promoters I-GENE
that O
are O
positively O
activated O
by O
the O
ALL_CAP I-GENE
protein I-GENE
. O

These O
data O
show O
that O
ALL_CAP I-GENE
and O
cAMP O
can O
repress O
RARE I-GENE
promoter I-GENE
activity O
in O
RARE O
from O
transgenic O
mice O
, O
suggesting O
that O
the O
alpha I-GENE
1 I-GENE
( I-GENE
I I-GENE
) I-GENE
RARE I-GENE
promoter I-GENE
may O
contain O
cis O
elements O
down O
- O
RARE O
of O
- O
2 O
. O
3 O
kilobases O
that O
mediate O
ALL_CAP I-GENE
and O
cAMP O
repression O
of O
RARE I-GENE
gene I-GENE
RARE O
in O
bone O
. O

Both O
inhaled O
and O
RARE O
isoflurane O
RARE O
the O
baseline O
RARE O
diameter O
before O
RARE O
. O

RARE O
of O
rheumatoid O
arthritis O
and O
rheumatoid I-GENE
factor I-GENE
in O
women O
: O
evidence O
RARE O
a O
RARE O
decline O
. O

Although O
olfactory O
RARE O
conditioning O
in O
newborn O
rats O
produces O
marked O
structural O
and O
RARE O
changes O
in O
the O
olfactory O
bulb O
, O
recent O
evidence O
suggests O
that O
RARE O
RARE O
must O
be O
involved O
in O
RARE O
these O
early O
RARE O
. O

The O
RARE I-GENE
yeast I-GENE
NUM I-GENE
+ I-GENE
gene I-GENE
, O
a O
multicopy O
suppressor O
RARE O
cold O
- O
RARE O
NUM I-GENE
mutants I-GENE
, O
encodes O
a O
novel O
NUM O
- O
RARE O
protein O
kinase O
. O

RARE O
of O
the O
RARE O
RARE O
RARE O
with O
a O
RARE O
through O
a O
RARE O
. O

Sequence O
comparison O
between O
the O
translated O
ORF O
and O
a O
protein O
database O
reveal O
between O
NUM O
. O
5 O
and O
NUM O
. O
4 O
% O
RARE O
sequence O
homology O
to O
bacterial I-GENE
transmembrane I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
proteins I-GENE
including O
those O
mediating O
chloramphenicol O
( O
RARE O
) O
and O
RARE O
( O
Tc O
) O
resistance O
and O
an O
RARE O
- O
RARE O
RARE O
protein O
. O

The O
yeast O
gene O
that O
encodes O
eIF I-GENE
- I-GENE
5 I-GENE
, O
designated O
NUM I-GENE
, O
has O
been O
isolated O
and O
RARE O
in O
Escherichia O
coli O
to O
yield O
a O
catalytically O
RARE O
eIF I-GENE
- I-GENE
5 I-GENE
protein I-GENE
. O

The O
strategies O
by O
which O
hepatitis O
B O
and O
hepatitis O
D O
can O
be O
diminished O
and O
RARE O
RARE O
are O
: O
immunization O
, O
measures O
to O
prevent O
exposure O
to O
RARE O
RARE O
or O
RARE O
RARE O
and O
education O
( O
in O
particular O
RARE O
that O
hepatitis O
B O
is O
a O
RARE O
transmitted O
RARE O
). O

RARE O
- O
and O
RARE O
- O
containing O
polymers O
were O
better O
RARE O
than O
was O
RARE O
RARE O
both O
RARE O
. O

The O
RARE O
RARE O
of O
the O
mouth O
RARE O
is O
RARE O
, O
RARE O
is O
the O
need O
RARE O
RARE O
and O
its O
costs O
and O
the O
materials O
required O
to O
RARE O
these O
mouth O
RARE O
. O

The O
alpha O
- O
subunit O
by O
itself O
binds O
to O
telomeric O
DNA O
. O

We O
conclude O
that O
the O
alpha O
- O
subunit O
of O
the O
RARE I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
like O
many O
transcription O
factors O
, O
has O
RARE O
DNA O
- O
binding O
and O
protein O
- O
protein O
interaction O
domains O
. O

Three O
patients O
had O
RARE O
RARE O
6 O
patients O
had O
moderately O
RARE O
and O
5 O
patients O
had O
poorly O
- O
differentiated O
adenocarcinoma O
of O
the O
RARE O
. O

RARE O
burst O
RARE O
in O
RARE O
RARE O
auditory O
cortex O
: O
age O
and O
depth O
dependence O
and O
its O
effect O
on O
RARE O
interaction O
measures O
. O

By O
applying O
the O
RARE O
method O
, O
in O
aqueous O
medium O
of O
ionic O
strength O
mu O
= O
NUM O
. O
2 O
, O
the O
stability O
constants O
, O
log O
beta O
1 O
= O
4 O
. O
NUM O
and O
log O
beta O
2 O
= O
8 O
. O
57 O
were O
obtained O
. O

RARE O
RARE O
filled O
with O
media O
RARE O
additive O
are O
RARE O
below O
the O
surface O
of O
an O
RARE O
donor O
RARE O
. O

The O
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
can O
potentially O
encode O
NUM O
- O
and O
NUM O
- O
kDa O
proteins O
that O
differ O
only O
in O
their O
RARE O
tails O
because O
of O
an O
RARE O
RARE O
mechanism O
. O

The O
RARE O
RARE O
reading O
frame O
in O
the O
clone O
maps O
RARE O
NUM O
min O
on O
the O
E O
. O
coli O
RARE O
and O
is O
identical O
in O
sequence O
to O
a O
wild O
type O
RARE O
. O

RARE O
cloning O
and O
nucleotide O
sequence O
analysis O
of O
the O
S I-GENE
. I-GENE
pombe I-GENE
adenylate I-GENE
kinase I-GENE
gene I-GENE
, O
NUM I-GENE
, O
revealed O
a O
coding O
region O
of O
NUM O
nucleotides O
. O

RARE O
of O
a O
RARE O
RARE O
and O
of O
RARE O
( O
RARE O
) O
RARE O
. O

As O
a O
result O
of O
RARE O
RARE O
, O
the O
ALL_CAP I-GENE
gene I-GENE
is O
RARE O
into O
RARE O
least O
RARE O
distinct O
mRNA O
species O
. O

A O
comparison O
of O
the O
promoters O
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
and O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
reveals O
a O
RARE O
ALL_CAP O
- O
1 O
element O
, O
but O
transient O
RARE O
studies O
in O
ALL_CAP O
264 O
. O
7 O
macrophages O
with O
proximal O
fragments O
of O
either O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
or O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
5 I-GENE
' I-GENE
promoter I-GENE
fused O
to O
a O
human I-GENE
growth I-GENE
hormone I-GENE
reporter I-GENE
gene I-GENE
RARE O
ALL_CAP O
- O
inducibility O
in O
both O
to O
promoter O
RARE O
near O
to O
, O
but O
not O
identical O
with O
, O
the O
consensus O
ALL_CAP O
- O
1 O
sequence O
. O

However O
, O
essential O
contrast O
differences O
existing O
between O
the O
ALL_CAP O
sequences O
and O
their O
routine O
asymmetric O
dual O
SE O
RARE O
can O
be O
identified O
. O

Sequence O
analysis O
and O
identification O
of O
two O
RARE I-GENE
regulatory I-GENE
mutants I-GENE
. O

The O
gene O
encoding O
the O
receptor O
RARE O
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
1 I-GENE
( O
CSF I-GENE
- I-GENE
1 I-GENE
RARE O
the O
c I-GENE
- I-GENE
fms I-GENE
RARE I-GENE
, O
is O
selectively O
RARE O
in O
immature O
and O
RARE O
mononuclear O
RARE O
and O
RARE O
. O

The O
level O
of O
the O
NUM I-GENE
transcript I-GENE
was O
threefold O
RARE O
in O
the O
NUM I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
than O
in O
the O
wild O
type O
. O

This O
sequence O
RARE O
RARE O
the O
possibility O
that O
NUM I-GENE
interacts O
with O
RARE O
or O
tRNA O
molecules O
and O
functions O
in O
conjunction O
with O
GCN2 I-GENE
in O
monitoring O
RARE O
tRNA O
levels O
RARE O
the O
process O
of O
translation O
RARE O
. O

ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
( O
ALL_CAP I-GENE
) O
is O
a O
repressor O
of O
the O
murine I-GENE
immunoglobulin I-GENE
heavy I-GENE
- I-GENE
chain I-GENE
3 I-GENE
' I-GENE
alpha I-GENE
enhancer I-GENE
RARE O
early O
stages O
of O
B O
- O
cell O
differentiation O
. O

Since O
the O
RARE O
of O
SWI4 I-GENE
is O
required O
RARE O
normal O
cell O
RARE O
progression O
, O
we O
have O
characterized O
cis O
- O
and O
RARE O
- O
acting O
RARE O
of O
SWI4 I-GENE
transcription O
. O

It O
also O
suggests O
that O
there O
is O
another O
RARE O
which O
can O
activate O
SWI4 I-GENE
transcription O
in O
the O
absence O
of O
NUM I-GENE
. O

Multiple O
NUM I-GENE
- O
dependent O
cis O
- O
acting O
elements O
control O
SWI4 I-GENE
transcription O
through O
the O
cell O
RARE O
. O

In O
conclusion O
, O
changes O
in O
carotid O
sinus O
RARE O
alters O
RARE O
flow O
to O
the O
RARE O
through O
changes O
in O
both O
RARE O
and O
RARE O
. O

RARE O
PRK O
has O
been O
suggested O
to O
increase O
the O
RARE O
of O
RARE O
RARE O
RARE O
. O

In O
NUM O
patients O
with O
deletions O
, O
the O
parental O
origin O
of O
deletion O
was O
determined O
. O

The O
NUM I-GENE
gene I-GENE
, O
which O
encodes O
type I-GENE
VII I-GENE
RARE I-GENE
, O
has O
been O
implicated O
RARE O
a O
candidate O
gene O
RARE O
RARE O
and O
RARE O
inherited O
forms O
of O
RARE O
RARE O
RARE O
. O

However O
, O
study O
of O
the O
RARE O
gamma O
gene O
showed O
that O
the O
RARE O
RARE O
RARE O
was O
RARE O
by O
normal O
RARE O
signals O
and O
that O
the O
adjacent O
intron O
organization O
was O
not O
altered O
. O

We O
conclude O
that O
grade O
III O
ALL_CAP O
can O
be O
treated O
by O
modified O
RARE O
RARE O
provided O
the O
RARE O
RARE O
and O
part O
of O
the O
RARE O
are O
RARE O
. O

Second O
, O
RARE O
induction O
of O
RARE I-GENE
- I-GENE
NUM I-GENE
. I-GENE
5 I-GENE
operon I-GENE
RARE O
is O
substantially O
RARE O
in O
ALL_CAP I-GENE
RARE O
strains O
( O
M O
. O
H O
. O

This O
new O
knowledge O
has O
contributed O
to O
the O
development O
of O
a O
successful O
RARE O
strategy O
RARE O
RARE O
RARE O
RARE O
. O

The O
HMG I-GENE
CoA I-GENE
reductase I-GENE
RARE O
are O
the O
most O
effective O
cholesterol O
- O
lowering O
agents O
currently O
available O
. O

The O
etiology O
, O
pathology O
, O
brain O
ALL_CAP O
scan O
features O
, O
clinical O
manifestations O
and O
treatment O
of O
these O
RARE O
were O
discussed O
. O

Drosophila O
NUM O
- O
ALL_CAP O
TFIID I-GENE
subunit O
, O
a O
RARE O
homolog O
of O
the O
human O
cell O
RARE O
gene O
product O
, O
negatively O
regulates O
DNA O
binding O
of O
the O
TATA I-GENE
box I-GENE
- I-GENE
binding I-GENE
subunit I-GENE
of I-GENE
TFIID I-GENE
. O

One O
RARE O
RARE O
of O
ALL_CAP I-GENE
factor I-GENE
RARE O
is O
that O
several O
ALL_CAP I-GENE
proteins I-GENE
, O
which O
RARE O
share O
the O
same O
DNA O
- O
binding O
site O
RARE O
, O
are O
coexpressed O
in O
RARE O
cells O
. O

Pit I-GENE
- I-GENE
1 I-GENE
is O
a O
tissue O
- O
specific O
POU I-GENE
domain I-GENE
factor I-GENE
RARE O
RARE O
the O
appearance O
of O
three O
cell O
RARE O
in O
the O
anterior O
pituitary O
RARE O
. O

RARE O
number O
of O
strains O
( O
NUM O
. O
1 O
%) O
were O
resistant O
in O
S O
. O
RARE O
RARE O
, O
followed O
by O
S O
. O
RARE O
( O
21 O
. O
7 O
%) O
and O
least O
in O
S O
. O
RARE O
( O
NUM O
. O
4 O
%). O

Biol O
. O

Characterization O
and O
hormonal O
RARE O
of O
the O
promoter O
of O
the O
rat I-GENE
RARE I-GENE
RARE I-GENE
synthase I-GENE
2 I-GENE
gene I-GENE
in O
RARE O
cells O
. O

The O
retention O
of O
NUM O
was O
low O
. O

RARE O
characteristics O
associated O
with O
deep O
RARE O
RARE O
RARE O
RARE O
patient O
and O
wound O
characteristics O
predictive O
of O
the O
extent O
of O
healing O
and O
time O
required O
RARE O
healing O
were O
identified O
. O

Members O
of O
the O
C I-GENE
/ I-GENE
EBP I-GENE
family I-GENE
of O
basic I-GENE
- I-GENE
leucine I-GENE
zipper I-GENE
( I-GENE
RARE I-GENE
) I-GENE
transcription I-GENE
factors I-GENE
form O
RARE O
and O
bind O
to O
the O
CAAT O
box O
and O
other O
sequence O
- O
related O
enhancer O
motifs O
. O

In O
mammalian O
cells O
, O
RARE O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
inhibits O
the O
activity O
of O
eIF I-GENE
- I-GENE
NUM I-GENE
, O
the O
GDP I-GENE
- I-GENE
GTP I-GENE
exchange I-GENE
factor I-GENE
RARE O
eIF I-GENE
- I-GENE
2 I-GENE
. O

In O
conclusion O
, O
these O
observations O
demonstrated O
that O
RARE O
of O
acute O
MI O
patients O
by O
plasma O
ALL_CAP I-GENE
level O
is O
a O
useful O
non O
- O
invasive O
method O
RARE O
predicting O
prognosis O
and O
RARE O
identifying O
individuals O
RARE O
high O
risk O
of O
cardiac O
RARE O
. O

Analysis O
of O
the O
binding O
of O
RARE I-GENE
to O
a O
set O
of O
RARE O
RARE O
DNA O
fragments O
from O
this O
region O
indicates O
that O
RARE I-GENE
induces O
DNA O
RARE O
. O

RARE O
mutants O
RARE O
a O
RARE O
NUM I-GENE
gene I-GENE
can O
be O
complemented O
by O
human I-GENE
RARE I-GENE
but O
are O
RARE O
RARE O
RARE O
growth O
and O
impaired O
in O
pre O
- O
rRNA O
RARE O
. O

The O
patients O
were O
divided O
into O
ischaemia O
and O
non O
- O
ischaemia O
groups O
on O
the O
basis O
of O
the O
change O
in O
RARE O
extraction O
ratio O
RARE O
RARE O
RARE O
. O

RARE O
out O
of O
NUM O
patients O
died O
, O
giving O
a O
mortality O
rate O
of O
21 O
%. O

A O
NUM O
- O
kDa O
protein O
that O
was O
localized O
to O
the O
membrane O
fraction O
was O
detected O
in O
RARE O
containing O
plasmids O
with O
the O
ALL_CAP I-GENE
gene I-GENE
, O
confirming O
that O
ALL_CAP I-GENE
was O
a O
membrane O
protein O
. O

NUM I-GENE
, O
a O
gene O
encoding O
a O
RARE I-GENE
- I-GENE
specific I-GENE
1 I-GENE
, I-GENE
3 I-GENE
- I-GENE
beta I-GENE
- I-GENE
RARE I-GENE
in O
Saccharomyces O
cerevisiae O
. O

Expression O
of O
this O
protein O
in O
E O
. O
coli O
demonstrated O
that O
tyrosine O
was O
incorporated O
RARE O
suppression O
and O
that O
yeast I-GENE
cytoplasmic I-GENE
ALL_CAP I-GENE
activity O
was O
produced O
. O

The O
RARE O
involved O
RARE O
of O
a O
RARE O
mutant O
of O
RARE O
, O
ALL_CAP O
- O
NUM O
( O
RARE O
- O
RARE O
- O
g O
- O
2 O
. O
3 O
RARE O
which O
has O
a O
frameshift O
mutation O
in O
the O
ALL_CAP I-GENE
gene I-GENE
, O
and O
selection O
of O
RARE O
transformants O
on O
minimal O
medium O
. O

RARE O
NUM O
strains O
of O
RARE O
- O
resistant O
RARE O
RARE O
( O
ALL_CAP O
) O
isolated O
from O
1990 O
to O
1991 O
, O
minimum O
RARE O
concentrations O
( O
MICs O
) O
of O
a O
RARE O
of O
NUM O
RARE O
agents O
including O
RARE O
( O
ALL_CAP O
) O
were O
determined O
. O

It O
is O
reported O
that O
, O
RARE O
present O
, O
most O
of O
the O
RARE O
RARE O
in O
Japan O
are O
RARE O
RARE O
resistance O
to O
many O
drugs O
, O
and O
especially O
, O
they O
are O
developing O
high O
resistance O
against O
beta O
- O
RARE O
. O

NUM I-GENE
and O
NUM I-GENE
are O
regulated O
differently O
which O
may O
indicate O
variation O
in O
RARE O
or O
utilization O
properties O
among O
the O
RARE I-GENE
RARE I-GENE
. O

Here O
, O
we O
have O
more O
closely O
investigated O
RARE O
of O
the O
human I-GENE
HSP70 I-GENE
promoter I-GENE
by O
Myb I-GENE
proteins I-GENE
. O

We O
have O
found O
out O
that O
one O
- O
year O
- O
old O
RARE O
are O
extremely O
RARE O
to O
RARE O
in O
concentrations O
between O
NUM O
- O
NUM O
micrograms O
/ O
NUM O
. O

RESULTS O
: O
RARE O
significant O
differences O
were O
obtained O
between O
group O
I O
and O
II O
concerning O
the O
number O
of O
patients O
in O
whom O
RARE O
RARE O
fibrillation O
with O
conduction O
by O
the O
RARE O
RARE O
and O
RR O
< O
or O
= O
NUM O
msec O
was O
found O
( O
NUM O
RARE O
6 O
, O
p O
= O
NUM O
. O
NUM O
). O

We O
studied O
the O
effect O
of O
RARE O
thickness O
on O
the O
correlation O
between O
serum O
RARE O
bilirubin O
level O
and O
RARE O
bilirubin O
( O
ALL_CAP O
) O
RARE O
. O

Both O
RARE I-GENE
may O
have O
important O
roles O
in O
receptor O
assembly O
and O
may O
represent O
a O
new O
category O
of O
RARE O
- O
and O
RARE O
- O
dependent O
RARE O
of O
protein O
function O
. O

The O
GTPase I-GENE
activity O
of O
NUM I-GENE
is O
moderately O
RARE O
by O
human I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
, O
a O
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
RARE O
the O
related O
p21 I-GENE
NUM I-GENE
. O

Tl O
- O
NUM O
uptake O
ratio O
of O
the O
right O
ventricle O
, O
which O
represents O
the O
ratio O
of O
RARE O
counts O
of O
the O
right O
ventricle O
to O
counts O
of O
the O
administered O
dose O
of O
Tl O
- O
NUM O
, O
was O
RARE O
in O
COPD O
, O
especially O
in O
pulmonary O
emphysema O
and O
B O
type O
COPD O
by O
RARE O
classification O
than O
in O
controls O
. O

A O
second O
hydrophobic O
domain O
, O
RARE O
by O
two O
hydrophilic O
regions O
strongly O
suggests O
a O
transmembrane O
region O
. O

This O
gene O
spans O
NUM O
kb O
and O
is O
composed O
of O
five O
exons O
and O
four O
RARE O
. O

The O
remaining O
ALL_CAP I-GENE
+ I-GENE
cells O
progressed O
to O
form O
RARE O
(< O
NUM O
cells O
) O
containing O
RARE O
shaped O
RARE O
cells O
. O

The O
11 O
; O
NUM O
chromosomal O
translocation O
specifically O
RARE O
to O
RARE O
sarcoma O
and O
RARE O
RARE O
tumor O
results O
in O
a O
chimeric O
molecule O
RARE O
the O
amino O
- O
terminal O
- O
encoding O
portion O
of O
the O
EWS I-GENE
gene I-GENE
to O
the O
RARE O
- O
terminal O
DNA O
- O
binding O
domain O
encoded O
by O
the O
FLI1 I-GENE
gene I-GENE
. O

These O
findings O
suggest O
that O
a O
range O
of O
RARE O
conditions O
exist O
within O
RARE O
water O
RARE O
, O
leading O
to O
RARE O
populations O
of O
bacteria O
. O

X O
- O
RARE O
liver O
RARE O
: O
RARE O
and O
isolation O
of O
a O
candidate O
gene O
. O

This O
conclusion O
is O
based O
on O
the O
observations O
of O
the O
immunologic O
changes O
that O
characterize O
the O
acute O
stages O
of O
illness O
RARE O
RARE O
RARE O
on O
the O
demonstrated O
association O
with O
RARE O
- O
producing O
bacteria O
in O
the O
RARE O
and O
RARE O
RARE O
. O

Measurement O
of O
anti I-GENE
- I-GENE
HCV I-GENE
IgM I-GENE
antibodies I-GENE
with O
an O
experimental O
kit O

RARE O
RARE O
RARE O
may O
contribute O
to O
understand O
the O
mechanisms O
underlying O
the O
decrease O
of O
fertility O
with O
aging O
. O

These O
cell O
lines O
displayed O
methylation O
of O
the O
CpG O
island O
surrounding O
the O
RARE O
RARE O
of O
NUM I-GENE
and O
RARE O
abundant O
levels O
of O
a O
RARE O
mRNA O
containing O
an O
RARE O
RARE O
RARE O
( O
E1 O
beta O
RARE O
RARE O
did O
all O
other O
cell O
lines O
in O
which O
the O
NUM I-GENE
locus I-GENE
was O
not O
RARE O
. O

An O
RARE I-GENE
reaction O
, O
ALL_CAP I-GENE
method O
, O
with O
the O
RARE O
of O
RARE I-GENE
VIII I-GENE
RARE O
the O
RARE O
antibody O
, O
was O
carried O
out O
in O
the O
endometrial O
biopsies O
to O
detect O
the O
RARE I-GENE
VIII I-GENE
activity O
in O
the O
endometrial O
endothelium O
before O
and O
after O
RARE O
of O
ALL_CAP O
- O
ALL_CAP O
- O
20 O
. O

RARE O
. O

NUM I-GENE
is O
homologous O
to O
human I-GENE
NUM I-GENE
, O
recently O
identified O
RARE O
the O
beta O
subunit O
of O
the O
RARE I-GENE
RARE I-GENE
- I-GENE
polypeptide I-GENE
- I-GENE
associated I-GENE
complex I-GENE
( O
ALL_CAP I-GENE
) O
involved O
in O
RARE O
signal O
- O
sequence O
- O
specific O
protein O
RARE O
and O
translocation O
RARE O
RARE O
et O
al O
., O
RARE O
NUM O
( O
1994 O
) O
NUM O
- O
440 O
]. O

RARE O
ALL_CAP I-GENE
showed O
optimal O
lyase I-GENE
activity O
RARE O
pH O
10 O
. O
NUM O
. O

The O
5 O
' O
flanking O
regions O
of O
both O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
were O
RARE O
fused O
to O
the O
beta I-GENE
- I-GENE
glucuronidase I-GENE
gene I-GENE
and O
introduced O
into O
F O
. O
RARE O
RARE O
. O
RARE O
. O
RARE O
, O
and O
beta I-GENE
- I-GENE
glucuronidase I-GENE
activities O
of O
the O
transformants O
were O
measured O
. O

When O
ALL_CAP I-GENE
mRNA I-GENE
5 O
' O
RARE O
points O
were O
mapped O
by O
primer O
extension O
, O
both O
a O
minor O
upstream O
transcript O
( O
s O
) O
starting O
NUM O
bp O
distal O
to O
the O
RARE O
and O
a O
major O
RARE O
transcript O
starting O
10 O
bp O
distal O
to O
the O
RARE I-GENE
54 I-GENE
box O
were O
observed O
. O

We O
failed O
to O
find O
these O
data O
to O
be O
useful O
in O
predicting O
the O
time O
of O
onset O
of O
initial O
seizures O
after O
acute O
ischemic O
stroke O
and O
recurrence O
. O

The O
human I-GENE
RARE I-GENE
type I-GENE
16 I-GENE
E7 I-GENE
protein I-GENE
RARE O
adenovirus I-GENE
type I-GENE
5 I-GENE
E1A I-GENE
amino O
- O
terminus O
- O
dependent O
RARE O
of O
adenovirus I-GENE
type I-GENE
5 I-GENE
early I-GENE
genes I-GENE
and O
increases O
ATF I-GENE
and O
Oct I-GENE
- I-GENE
1 I-GENE
DNA O
binding O
activity O
. O

A O
RARE O
detergent O
, O
NUM O
. O
1 O
% O
RARE O
P O
- O
40 O
, O
also O
abolished O
the O
interaction O
, O
further O
supporting O
the O
hydrophobic O
nature O
of O
the O
interaction O
. O

RARE O
to O
RARE O
, O
we O
find O
a O
relatively O
high O
level O
of O
variation O
in O
the O
RARE I-GENE
2 I-GENE
enhancer O
region O
, O
including O
point O
substitutions O
and O
RARE O
/ O
deletions O
in O
binding O
sites O
, O
and O
a O
comparable O
level O
of O
variation O
in O
the O
other O
noncoding O
regions O
. O

RARE O
of O
the O
RARE I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
, I-GENE
5 I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
small I-GENE
- I-GENE
subunit I-GENE
mRNA I-GENE
, O
NUM I-GENE
, O
RARE O
with O
RARE O
RARE O
. O

Cloning O
and O
sequencing O
revealed O
that O
RARE I-GENE
contains O
a O
deletion O
spanning O
the O
basic O
region O
and O
helix O
1 O
and O
the O
loop O
of O
the O
helix O
- O
loop O
- O
helix O
region O
, O
presumably O
RARE O
a O
result O
of O
RARE O
RARE O
of O
RARE I-GENE
RNA I-GENE
. O

I O
report O
here O
that O
induction O
of O
NUM I-GENE
is O
regulated O
by O
the O
early O
RARE O
IME1 I-GENE
- O
NUM I-GENE
transcriptional O
cascade O
. O

The O
domain O
RARE O
of O
bovine I-GENE
ALL_CAP I-GENE
- I-GENE
2 I-GENE
is O
very O
similar O
to O
that O
of O
the O
human I-GENE
ALL_CAP I-GENE
- I-GENE
2 I-GENE
, O
containing O
20 O
examples O
of O
6 O
- O
cysteine O
RARE I-GENE
growth I-GENE
factor I-GENE
- I-GENE
like I-GENE
repeats I-GENE
, O
16 O
of O
which O
have O
the O
consensus O
sequence O
RARE O
RARE O
binding O
, O
together O
with O
4 O
examples O
of O
8 O
- O
cysteine O
motifs O
characteristic O
of O
RARE I-GENE
and O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
. O

Similarly O
, O
RARE O
of O
a O
transiently O
transfected O
wild I-GENE
- I-GENE
type I-GENE
RARE I-GENE
alpha I-GENE
gene I-GENE
RARE O
the O
reporter O
was O
not O
affected O
by O
a O
RARE O
of O
myc I-GENE
- I-GENE
derived I-GENE
genes I-GENE
, O
including O
myc I-GENE
itself O
and O
dominant O
or O
recessive O
negative O
myc I-GENE
mutants I-GENE
. O

Differential O
RARE O
of O
the O
alpha I-GENE
/ I-GENE
beta I-GENE
RARE I-GENE
- O
RARE O
Jak I-GENE
/ O
Stat I-GENE
RARE O
by O
the O
NUM I-GENE
domain O
- O
containing O
tyrosine I-GENE
phosphatase I-GENE
NUM I-GENE
. O

We O
now O
report O
the O
isolation O
and O
RARE O
of O
cDNAs O
encoding O
ALL_CAP I-GENE
gamma I-GENE
and O
ALL_CAP I-GENE
delta I-GENE
, O
RARE O
RARE O
RARE O
RARE O
studies O
with O
RARE O
antibodies O
that O
recognize O
the O
RARE O
ALL_CAP I-GENE
complex I-GENE
in O
HeLa O
extracts O
. O

Results O
from O
the O
mechanism O
study O
have O
revealed O
that O
YY1 I-GENE
is O
able O
to O
inhibit O
RARE O
RARE O
by O
either O
AP1 I-GENE
or O
the O
NUM I-GENE
- I-GENE
related I-GENE
protein I-GENE
, O
and O
YY1 I-GENE
RARE O
activity O
is O
DNA O
binding O
dependent O
. O

The O
NUM I-GENE
+ I-GENE
gene I-GENE
is O
not O
essential O
. O

The O
NUM I-GENE
( O
RARE I-GENE
enhancer I-GENE
activator I-GENE
) O
gene O
sequence O
predicts O
a O
protein O
of O
NUM O
. O
9 O
kDa O
whose O
N O
terminus O
contains O
a O
zinc O
cluster O
and O
RARE O
motif O
typical O
of O
the O
Gal4 I-GENE
- I-GENE
type I-GENE
family I-GENE
of O
DNA O
- O
binding O
proteins O
. O

RARE O
living O
in O
RARE O
and O
RARE O
to O
RARE O
considered O
their O
health O
RARE O
RARE O
in O
a O
RARE O
proportion O
than O
their O
RARE O
counterparts O
, O
with O
an O
odds O
ratio O
of O
3 O
. O
NUM O
( O
2 O
. O
03 O
- O
5 O
. O
NUM O
) O
and O
4 O
. O
NUM O
( O
2 O
. O
1 O
- O
10 O
. O
NUM O
) O
respectively O
. O

This O
study O
RARE O
the O
importance O
of O
terminal O
NUM I-GENE
- I-GENE
9 I-GENE
complement I-GENE
complex I-GENE
RARE O
a O
suitable O
marker O
in O
the O
evaluation O
of O
complement O
activation O
RARE O
cardiopulmonary O
bypass O
. O

RARE O
has O
been O
used O
to O
RARE O
observe O
the O
responses O
of O
the O
vestibular O
RARE O
in O
a O
population O
of O
patients O
with O
vestibular O
deficits O
. O

The O
ALL_CAP O
and O
ALL_CAP O
PI O
values O
showed O
the O
greatest O
deviation O
RARE O
any O
single O
- O
vessel O
parameter O
. O

RARE O
sequence O
similarities O
( O
57 O
and O
53 O
%) O
were O
observed O
with O
yeast O
mitochondrial O
proteins O
, O
NUM I-GENE
and O
NUM I-GENE
, O
especially O
within O
putative O
RARE O
domains O
: O
RARE O
6 O
encoding O
the O
second O
transmembrane O
spanning O
domain O
, O
site O
of O
the O
murine I-GENE
RARE I-GENE
mutation O
; O
and O
RARE O
11 O
encoding O
a O
RARE O
RARE O
motif O
. O

RARE O
contain O
distinctly O
less O
P I-GENE
protein I-GENE
mRNA I-GENE
and O
the O
relative O
level O
in O
roots O
is O
very O
low O
but O
still O
clearly O
detectable O
. O

The O
B I-GENE
. I-GENE
RARE I-GENE
RARE I-GENE
amino I-GENE
acid I-GENE
sequence I-GENE
shares O
NUM O
% O
identity O
with O
the O
cytosolic I-GENE
RARE I-GENE
isoform I-GENE
from I-GENE
Drosophila I-GENE
melanogaster I-GENE
( O
RARE I-GENE
- I-GENE
1 I-GENE
). O

Furthermore O
, O
we O
have O
identified O
a O
RARE O
form O
of O
NUM I-GENE
/ O
NUM I-GENE
by O
Western O
blotting O
and O
biosynthetic O
labeling O
. O

The O
minimal O
region O
of O
overlap O
of O
RARE O
- O
RARE O
RARE O
deletions O
, O
previously O
identified O
by O
analysis O
of O
NUM O
patients O
, O
was O
placed O
on O
the O
map O
by O
analysis O
of O
2 O
patients O
whose O
deletions O
define O
the O
RARE O
. O

Consistent O
with O
the O
RARE O
and O
RARE O
RARE O
of O
RARE I-GENE
, O
this O
finding O
suggests O
that O
RARE I-GENE
transcription O
may O
be O
regulated O
by O
these O
factors O
. O

Comparison O
of O
promoters O
repressed O
by O
c I-GENE
- I-GENE
myc I-GENE
reveals O
a O
weak O
consensus O
sequence O
of O
the O
RARE O
( O
RARE O
) O
element O
: O
ALL_CAP O
(+ O
1 O
) O
ALL_CAP O
. O

The O
human I-GENE
NUM I-GENE
promoter I-GENE
. O

Transfection O
analyses O
indicate O
that O
mutation O
of O
any O
one O
of O
these O
ALL_CAP O
motifs O
or O
RARE O
of O
the O
RARE O
HD I-GENE
ALL_CAP O
into O
a O
separate O
NUM O
and O
NUM O
element O
significantly O
RARE O
the O
transcriptional O
response O
of O
HD I-GENE
ALL_CAP O
to O
RARE O
RARE O
. O

The O
site O
of O
autophosphorylation O
is O
NUM O
which O
corresponds O
to O
the O
consensus O
autophosphorylation O
site O
of O
other O
Src I-GENE
family I-GENE
tyrosine I-GENE
kinases I-GENE
. O

This O
protein O
- O
protein O
interaction O
does O
not O
require O
the O
simultaneous O
binding O
of O
Oct I-GENE
proteins I-GENE
to O
DNA O
, O
and O
high O
resolution O
footprinting O
of O
the O
Oct I-GENE
- I-GENE
DNA I-GENE
interaction O
reveals O
that O
binding O
of O
ALL_CAP I-GENE
. I-GENE
1 I-GENE
/ O
ALL_CAP I-GENE
. I-GENE
1 I-GENE
to O
NUM I-GENE
or O
NUM I-GENE
does O
not O
alter O
the O
interaction O
with O
DNA O
. O

Together O
, O
our O
data O
suggest O
that O
the O
NUM I-GENE
orphan I-GENE
receptor I-GENE
may O
be O
a O
RARE O
regulator O
in O
RARE O
the O
activation O
of O
two O
key O
RARE O
, O
ALL_CAP O
beta O
and O
RARE O
, O
involved O
in O
the O
retinoic O
acid O
signal O
RARE O
RARE O
. O

Using O
a O
series O
of O
mutant O
proteins O
, O
we O
have O
characterized O
domains O
responsible O
RARE O
activation O
or O
repression O
. O

Unlike O
ARF I-GENE
, O
the O
ALL_CAP I-GENE
immunoreactivity O
was O
detected O
in O
plasma O
membranes O
but O
not O
in O
cytosol O
of O
RARE O
3T3 O
- O
L1 O
cells O
. O

It O
is O
considered O
that O
the O
recurrent O
RARE O
RARE O
is O
a O
specific O
RARE O
manifestation O
of O
ALL_CAP O
with O
anti I-GENE
ALL_CAP I-GENE
- I-GENE
A I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
B I-GENE
antibodies I-GENE
. O

Competition O
needs O
to O
be O
better O
studied O
, O
since O
in O
RARE O
RARE O
and O
RARE O
RARE O
this O
RARE O
of O
study O
has O
RARE O
the O
biological O
control O
of O
RARE O
species O
. O

In O
this O
paper O
we O
describe O
properties O
of O
the O
NUM I-GENE
- O
NUM O
mutant O
of O
the O
RARE O
yeast O
Schizosaccharomyces O
pombe O
. O

ALL_CAP I-GENE
RARE O
in O
ALL_CAP O
cells O
was O
highly O
RARE O
by O
TGF I-GENE
- I-GENE
beta I-GENE
and O
bone I-GENE
RARE I-GENE
protein I-GENE
- I-GENE
2 I-GENE
( O
BMP I-GENE
- I-GENE
2 I-GENE
RARE O
with O
a O
moderate O
induction O
by O
RARE I-GENE
growth I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
RARE O
but O
RARE O
induction O
by O
other O
growth O
factors O
/ O
RARE O
was O
observed O
. O

An O
infectious O
origin O
should O
always O
be O
excluded O
since O
specific O
RARE O
therapy O
may O
be O
RARE O
. O

The O
predicted O
protein O
products O
of O
RARE I-GENE
NUM I-GENE
and O
NUM I-GENE
present O
similarities O
with O
domains O
from O
proteins O
of O
other O
organisms O
: O
the O
RARE O
RARE O
RARE I-GENE
- I-GENE
resistance I-GENE
protein I-GENE
, O
the O
human O
interleukin I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
). O

In O
particular O
, O
the O
highly O
RARE O
NUM I-GENE
gene I-GENE
is O
represented O
in O
this O
database O
by O
RARE O
less O
than O
20 O
ALL_CAP O
sequences O
. O

Five O
RARE O
of O
RARE O
RARE O
RARE O
carried O
the O
NUM O
mutation O
and O
shared O
the O
same O
RARE O
RARE O
eight O
polymorphic O
markers O
spanning O
RARE O
NUM O
kb O
RARE O
BRCA1 I-GENE
. O

The O
subjects O
from O
the O
two O
regions O
with O
a O
RARE O
RARE O
level O
had O
lower O
ALL_CAP O
and O
FEV1 O
values O
than O
those O
from O
the O
RARE O
region O
. O

PTP I-GENE
- I-GENE
NUM I-GENE
differs O
from O
PTP I-GENE
- I-GENE
NUM I-GENE
in O
having O
a O
deletion O
of O
19 O
amino O
RARE O
corresponding O
to O
RARE O
E1 O
. O

All O
three O
ALL_CAP I-GENE
isoforms I-GENE
are O
RARE O
in O
cv O
. O

All O
three O
ALL_CAP I-GENE
isoforms O
are O
RARE O
in O
cv O
. O

The O
Arabidopsis I-GENE
NUM I-GENE
gene I-GENE
encodes O
a O
chloroplast I-GENE
RARE I-GENE
- I-GENE
3 I-GENE
fatty I-GENE
acid I-GENE
RARE I-GENE
that O
catalyzes O
the O
RARE O
of O
RARE O
- O
RARE O
RARE O
fatty O
RARE O
( O
18 O
: O
2 O
and O
16 O
: O
2 O
). O

When O
differentiated O
NUM O
- O
arrested O
leaf O
cells O
were O
RARE O
to O
RARE O
cell O
division O
by O
treatment O
with O
RARE O
RARE O
, O
NUM I-GENE
transcription O
was O
RARE O
before O
the O
onset O
of O
DNA O
RARE O
. O

A O
survey O
is O
given O
of O
the O
pharmacological O
RARE O
that O
are O
relevant O
RARE O
the O
drug O
treatment O
of O
essential O
hypertension O
in O
the O
elderly O
. O

Protein O
kinases O
play O
pivotal O
roles O
in O
the O
control O
of O
many O
cellular O
processes O
. O

Interestingly O
, O
internal O
and O
5 O
' O
deletions O
revealed O
RARE O
the O
distal O
promoter O
was O
not O
required O
RARE O
full O
transcriptional O
activity O
and O
that O
the O
RARE O
NUM O
RARE O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
RARE O
the O
strongest O
promoter O
activity O
. O

The O
protein O
kinase O
domains O
of O
NUM I-GENE
and O
NUM I-GENE
are O
unique O
in O
that O
they O
contain O
an O
unusual O
sequence O
motif O
RARE O
- O
RARE O
- O
Asn O
- O
RARE O
- O
RARE O
- O
Asn O
in O
RARE O
ALL_CAP O
and O
a O
highly O
basic O
insert O
between O
subdomains O
VII O
and O
VIII O
. O

A O
human O
recombinant O
cDNA O
clone O
that O
encoded O
NUM O
amino O
RARE O
residues O
of O
a O
zinc I-GENE
- I-GENE
finger I-GENE
protein I-GENE
( O
RARE I-GENE
- I-GENE
1 I-GENE
) O
was O
RARE O
by O
screening O
a O
cDNA O
library O
prepared O
from O
human O
RARE O
leukemia O
NUM O
cells O
with O
RARE O
RARE O
RARE O
that O
corresponded O
to O
the O
amino O
acid O
sequences O
of O
RARE O
peptides O
derived O
from O
the O
DNA O
- O
binding O
protein O
specific O
RARE O
the O
RARE I-GENE
- I-GENE
RARE I-GENE
element I-GENE
( O
ALL_CAP I-GENE
) O
of O
the O
human I-GENE
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
. O

RARE O
AA O
in O
ALL_CAP O
+ O
EPO I-GENE
- O
supplemented O
infants O
remained O
low O
and O
below O
breast O
- O
and O
placebo O
formula O
- O
fed O
levels O
. O

RARE O
into O
RARE O
RARE O
and O
RARE O
changes O
in O
bone O
mass O
, O
RARE O
( O
ALL_CAP O
) O
and O
regional O
body O
bone O
mineral O
content O
were O
measured O
in O
38 O
women O
treated O
with O
GnRH I-GENE
agonists O
RARE O
6 O
months O
RARE O
RARE O
or O
RARE O
. O

The O
encoded O
polypeptide O
is O
similar O
in O
sequence O
to O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
RARE I-GENE
of I-GENE
RARE I-GENE
, O
the O
NUM I-GENE
/ I-GENE
NUM I-GENE
' I-GENE
RARE I-GENE
' I-GENE
protein I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
, I-GENE
RARE I-GENE
RARE I-GENE
and I-GENE
RARE I-GENE
RARE I-GENE
, O
and O
a O
NUM I-GENE
- I-GENE
kDa I-GENE
antigen I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
. O

RARE O
transcript O
patterns O
in O
RARE O
RARE O
are O
highly O
complex O
and O
similar O
to O
those O
of O
tobacco O
RARE O
. O

RARE O
recovery O
occurs O
within O
NUM O
min O
to O
2 O
hrs O
. O

ALL_CAP I-GENE
is O
a O
70 O
ALL_CAP O
glycoprotein O
containing O
complement O
regulatory O
short O
consensus O
repeats O
( O
RARE O
); O
its O
gene O
is O
RARE O
in O
the O
RARE I-GENE
of I-GENE
complement I-GENE
activation I-GENE
( O
ALL_CAP I-GENE
) O
gene O
cluster O
on O
RARE O
1 O
and O
is O
about O
40 O
kb O
in O
size O
. O

The O
NUM I-GENE
gene I-GENE
down O
- O
regulates O
but O
does O
not O
RARE O
RARE O
of O
ALL_CAP I-GENE
genes I-GENE
and O
does O
not O
affect O
RARE O
of O
CD44 I-GENE
. O

RARE O
care O
: O
a O
RARE O
to O
the O
RARE O
needed O
to O
support O
RARE O
RARE O
RARE O
. O

There O
is O
RARE O
TATA O
box O
around O
the O
transcriptional O
RARE O
points O
( O
RARE O
RARE O
RARE O
determined O
by O
primer O
extension O
analysis O
. O

According O
to O
the O
investigation O
, O
the O
recent O
burst O
of O
RARE O
in O
this O
area O
can O
be O
attributed O
to O
the O
increased O
presence O
of O
RARE O
RARE O
, O
which O
RARE O
in O
the O
RARE O
region O
, O
then O
RARE O
to O
the O
northern O
Japan O
RARE O
and O
RARE O
the O
RARE O
RARE O
fish O
. O

In O
summary O
, O
the O
RARE O
of O
adjuvant O
RARE O
and O
of O
abdominal O
radiotherapy O
seem O
to O
be O
identical O
. O

To O
identify O
some O
of O
the O
genes O
RARE O
in O
ALL_CAP O
- O
activated O
RARE O
, O
we O
sequenced O
randomly O
chosen O
RARE O
from O
a O
RARE O
constructed O
cDNA O
library O
to O
produce O
a O
set O
of O
RARE O
sequence O
tags O
( O
RARE O
). O

Characterization O
of O
an O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
RARE O
target O
site O
that O
mediates O
ecdysone O
responsiveness O
of O
the O
Drosophila I-GENE
RARE I-GENE
- I-GENE
2 I-GENE
gene I-GENE
. O

Thus O
, O
SPECT O
was O
not O
RARE O
RARE O
RARE O
PET O
in O
this O
activation O
task O
. O

Transcriptional O
activation O
of O
the O
chicken I-GENE
lysozyme I-GENE
gene I-GENE
by O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
NUM I-GENE
( O
ALL_CAP I-GENE
) O
and O
c I-GENE
- I-GENE
Rel I-GENE
, O
but O
not O
by O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
NUM I-GENE
. O

The O
results O
indicate O
that O
the O
RARE O
agents O
RARE O
and O
RARE O
do O
not O
exert O
antiarrhythmic O
efficacy O
against O
ALL_CAP O
RARE O
RARE O
subacute O
RARE O
infarction O
in O
conscious O
dogs O
. O

In O
vivo O
, O
selective O
activation O
of O
RARE I-GENE
stimulates O
formation O
of O
the O
RARE O
complex O
containing O
Elk I-GENE
- I-GENE
1 I-GENE
, O
serum I-GENE
response I-GENE
factor I-GENE
and O
the O
serum O
response O
element O
, O
and O
enhances O
Elk I-GENE
- I-GENE
1 I-GENE
- O
dependent O
transcription O
. O

An O
epidemic O
of O
hepatitis O
B O
virus O
infection O
among O
intravenous O
drug O
users O
in O
RARE O
. O

The O
gene O
was O
RARE O
mapped O
with O
odds O
> O
1 O
, O
NUM O
: O
1 O
on O
RARE O
NUM O
in O
RARE O
d O
' O
RARE O
RARE O
RARE O
RARE O
RARE O
. O

Three O
of O
these O
subunits O
are O
also O
homologous O
to O
the O
RARE O
ALL_CAP I-GENE
from O
a O
RARE O
RARE O
, O
RARE O
RARE O
( O
21 O
% O
identity O
). O

The O
RARE O
- O
inactivated O
gene O
, O
designated O
ALL_CAP I-GENE
, O
is O
NUM O
bp O
long O
, O
potentially O
encoding O
a O
19 O
. O
1 O
- O
kDa O
protein O
precursor O
that O
contains O
a O
typical O
membrane O
lipoprotein O
RARE O
sequence O
. O

RARE O
and O
S O
. O

Upstream O
of O
the O
RARE I-GENE
gene I-GENE
an O
RARE O
reading O
frame O
of O
NUM O
amino O
RARE O
was O
identified O
. O

RARE O
- O
specific O
RARE O
of O
ALL_CAP I-GENE
was O
also O
lost O
upon O
deletion O
of O
4 O
bp O
of O
a O
palindromic O
sequence O
( O
ALL_CAP O
) O
covering O
positions O
+ O
6 O
to O
+ O
21 O
RARE O
of O
the O
ALL_CAP I-GENE
transcriptional O
RARE O
site O
. O

In O
E O
. O
coli O
, O
ALL_CAP I-GENE
mediates O
the O
physical O
coupling O
of O
the O
receptors O
to O
the O
kinase O
ALL_CAP I-GENE
. O

The O
promoter O
of O
the O
RARE O
gene O
, O
ALL_CAP I-GENE
, O
responded O
to O
the O
activator I-GENE
protein I-GENE
ALL_CAP I-GENE
and O
contained O
a O
palindromic O
sequence O
similar O
to O
the O
ALL_CAP I-GENE
binding I-GENE
site I-GENE
of O
the O
ALL_CAP I-GENE
promoter I-GENE
, O
which O
is O
also O
activated O
by O
ALL_CAP I-GENE
. O

ALL_CAP O
RARE O
bind O
to O
unique O
sets O
of O
selectivity O
RARE O
that O
can O
function O
independently O
and O
are O
broadly O
distributed O
on O
multiple O
domains O
of O
human O
interleukin I-GENE
- I-GENE
8 I-GENE
receptor I-GENE
B I-GENE
. O

RARE O
RARE O
to O
the O
predicted O
translation O
initiation O
regions O
of O
ICP4 I-GENE
and O
NUM I-GENE
mRNAs I-GENE
inhibited O
RARE O
of O
NUM O
cells O
but O
not O
ALL_CAP O
- O
NUM O
( O
NUM O
) O
RARE O
virus O
- O
transformed O
cells O
. O

RARE O
replication O
requires O
that O
a O
portion O
of O
the O
RARE O
transcripts O
generated O
from O
RARE O
DNA O
be O
RARE O
to O
serve O
RARE O
mRNA O
RARE O
the O
envelope I-GENE
protein I-GENE
and O
in O
RARE O
sarcoma O
virus O
RARE O
src I-GENE
mRNA I-GENE
. O

In O
this O
case O
the O
degree O
of O
promoter O
methylation O
, O
which O
could O
extend O
beyond O
the O
T O
- O
DNA O
RARE O
, O
was O
not O
correlated O
with O
the O
reduction O
in O
steady O
- O
state O
RARE O
( O
A O
)+ O
mRNA O
levels O
, O
the O
RARE O
state O
was O
transmitted O
through O
meiosis O
and O
RARE O
RARE O
several O
RARE O
. O

Thus O
, O
the O
consensus O
sequences O
RARE O
phosphatase O
RARE O
are O
5 O
'- O
ALL_CAP O
- O
3 O
' O
and O
5 O
'- O
ALL_CAP O
- O
3 O
' O
which O
differ O
from O
the O
binding O
sequences O
RARE O
the O
RARE I-GENE
protein O
required O
RARE O
transcription O
of O
the O
genes O
in O
methionine O
biosynthesis O
and O
RARE O
centromere O
function O
. O

Here O
we O
report O
that O
the O
proline O
- O
rich O
region O
of O
ALL_CAP I-GENE
is O
RARE O
by O
the O
SH3 I-GENE
domains I-GENE
of O
several O
proteins O
, O
including O
the O
yeast I-GENE
actin I-GENE
- I-GENE
associated I-GENE
protein I-GENE
NUM I-GENE
. O

We O
have O
identified O
and O
characterized O
a O
vitamin O
D O
response O
element O
( O
ALL_CAP O
) O
in O
the O
promoter O
of O
c I-GENE
- I-GENE
fos I-GENE
. O

In O
addition O
to O
protein O
binding O
RARE O
sequences O
known O
to O
be O
involved O
in O
the O
RARE O
of O
transcription O
, O
genomic O
footprinting O
of O
the O
RARE O
promoter O
region O
also O
showed O
that O
a O
protein O
factor O
is O
constitutively O
RARE O
to O
the O
RARE O
intron O
of O
the O
NUM I-GENE
gene I-GENE
. O

RARE O
was O
not O
observed O
after O
cellular O
RARE O
of O
GTPase I-GENE
- O
RARE O
forms O
of O
alpha I-GENE
NUM I-GENE
or O
alpha I-GENE
NUM I-GENE
, O
indicating O
selectivity O
RARE O
the O
RARE I-GENE
family I-GENE
of O
G I-GENE
proteins I-GENE
. O

Consistent O
with O
a O
possible O
role O
in O
transcription O
, O
NUM I-GENE
is O
localized O
to O
the O
nucleus O
. O

By O
comparing O
the O
RARE O
of O
many O
yeast O
transcripts O
in O
RARE O
wild O
- O
type O
and O
NUM I-GENE
mutant I-GENE
strains O
, O
we O
have O
identified O
genes O
whose O
RARE O
is O
affected O
by O
NUM I-GENE
. O

NUM I-GENE
may O
therefore O
be O
required O
RARE O
both O
positive O
and O
negative O
RARE O
of O
RARE O
of O
yeast O
genes O
. O

Using O
a O
high O
- O
copy O
suppression O
strategy O
, O
we O
have O
identified O
a O
yeast O
gene O
( O
NUM I-GENE
) O
whose O
elevated O
RARE O
suppresses O
the O
conditional O
cell O
RARE O
defects O
associated O
with O
NUM I-GENE
mutations O
. O

Molecular O
characterization O
of O
malignant O
RARE O
of O
soft O
parts O
or O
soft O
tissue O
clear O
cell O
sarcoma O
which O
shares O
t O
( O
12 O
; O
NUM O
) O
RARE O
translocation O
revealed O
fusion O
of O
EWS I-GENE
with O
a O
transcriptional O
factor O
gene I-GENE
ATF I-GENE
- I-GENE
1 I-GENE
. O

RARE O
that O
RARE O
ALL_CAP O
exhibited O
a O
dominant O
negative O
RARE O
and O
did O
not O
elicit O
RARE O
activity O
against O
vesicular O
RARE O
virus O
( O
ALL_CAP O
) O
infection O
upon O
IFN I-GENE
treatment O
. O

NUM I-GENE
preferentially O
binds O
to O
multiple O
sites O
in O
ALL_CAP I-GENE
NUM I-GENE
and O
to O
the O
DNA O
RARE O
RARE O
RARE O
d O
( O
A O
. O
T O
)]. O

Identification O
, O
purification O
, O
and O
RARE O
cloning O
of O
RARE I-GENE
RARE I-GENE
sequence I-GENE
- I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
from I-GENE
RARE I-GENE
yeast I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
. O

A O
short O
RARE O
reading O
frame O
( O
ORF2 O
RARE O
of O
unknown O
function O
, O
is O
present O
in O
all O
ALL_CAP O
isolates O
. O

The O
patient O
was O
homozygous O
RARE O
the O
underlying O
mutation O
, O
which O
was O
found O
to O
be O
a O
G O
RARE O
T O
transversion O
within O
the O
RARE O
RARE O
site O
between O
intron O
RARE O
and O
RARE O
6 O
, O
RARE O
normal O
RNA O
RARE O
. O

These O
regions O
overlap O
with O
the O
ALL_CAP I-GENE
protein I-GENE
RARE I-GENE
regions I-GENE
. O

We O
tested O
10 O
rats O
with O
RARE O
RARE O
, O
RARE O
acid O
lesions O
of O
the O
ALL_CAP O
( O
RARE O
) O
to O
determine O
whether O
they O
could O
RARE O
a O
RARE O
- O
RARE O
ALL_CAP O
to O
RARE O
- O
alanine O
( O
NUM O
. O
3 O
M O
) O
or O
demonstrate O
a O
RARE O
RARE O
following O
furosemide O
treatment O
and O
RARE O
access O
to O
RARE O
RARE O
RARE O
. O

RARE O
RARE O
- O
B O
failed O
in O
6 O
/ O
7 O
patients O
with O
culture O
- O
proven O
RARE O
who O
died O
from O
infection O
with O
RARE O
( O
RARE O
= O
2 O
) O
and O
RARE O
( O
RARE O
= O
4 O
RARE O
respectively O
. O

NUM O
+ O
and O
NUM O
+ O
compete O
RARE O
binding O
sites O
, O
with O
the O
former O
having O
lower O
affinity O
. O

Magnetic O
RARE O
indicators O
could O
be O
used O
in O
medicine O
, O
in O
RARE O
and O
RARE O
RARE O
RARE O
. O

RARE O
tobacco O
RARE O
( O
RARE I-GENE
- I-GENE
1 I-GENE
) O
constitutively O
expressing O
Escherichia I-GENE
coli I-GENE
RARE I-GENE
behind O
the O
NUM I-GENE
ALL_CAP I-GENE
promoter I-GENE
accumulate O
high O
levels O
of O
RARE O
sugars O
in O
their O
leaves O
RARE O
NUM O
]. O

Human I-GENE
ALL_CAP I-GENE
- I-GENE
4 I-GENE
readily O
hybridized O
with O
genes O
in O
mouse O
and O
chicken O
, O
thus O
showing O
that O
this O
gene O
family O
has O
been O
highly O
RARE O
RARE O
RARE O
evolution O
. O

RARE I-GENE
levels O
remained O
adequate O
( O
RARE I-GENE
= O
10 O
. O
NUM O
+/- O
NUM O
. O
77 O
g O
/ O
dl O
) O
after O
14 O
. O
6 O
+/- O
7 O
. O
NUM O
months O
. O

ALL_CAP O
is O
discussed O
in O
comparison O
with O
the O
RARE O
RARE O
RARE O
Test O
RARE O
a O
RARE O
cognitive O
activation O
task O
RARE O
RARE O
RARE O
of O
the O
frontal O
RARE O
. O

These O
data O
indicate O
that O
although O
NUM O
retains O
normal O
RARE O
activity O
on O
a O
p53 I-GENE
promoter I-GENE
in O
yeast O
RARE O
physiological O
temperatures O
, O
it O
is O
not O
capable O
of O
normal O
p53 I-GENE
function O
in O
the O
presence O
of O
a O
NUM I-GENE
allele I-GENE
in O
ALL_CAP O
- O
NUM O
cells O
. O

RARE O
were O
RARE O
every O
3 O
weeks O
. O

Neither O
class O
II O
nor O
IV O
infections O
RARE O
transplantation O
. O

Although O
a O
great O
RARE O
is O
understood O
about O
how O
bHLH I-GENE
factors I-GENE
activate O
gene O
transcription O
via O
E O
- O
box O
DNA O
consensus O
sequences O
, O
studies O
of O
bHLH I-GENE
factor I-GENE
function O
in O
RARE O
eukaryotes O
often O
have O
been O
RARE O
by O
the O
presence O
of O
multiple O
family O
members O
. O

RARE O
and O
supershift O
assays O
demonstrated O
that O
upstream I-GENE
RARE I-GENE
factor I-GENE
( O
USF I-GENE
) O
and O
NUM I-GENE
bind O
to O
the O
former O
elements O
and O
competition O
experiments O
confirmed O
that O
CREB I-GENE
/ O
ATF I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
bind O
to O
the O
ALL_CAP O
/ O
ALL_CAP O
element O
. O

Upstream O
of O
- O
37 O
, O
the O
5 O
' O
RARE O
sequences O
of O
the O
isolates O
differ O
in O
both O
length O
and O
sequence O
. O

In O
these O
cases O
, O
greatly O
increased O
human I-GENE
RARE I-GENE
gonadotropin I-GENE
( O
hCG I-GENE
) O
levels O
and O
suppressed O
ALL_CAP I-GENE
levels O
suggest O
that O
hCG I-GENE
has O
RARE O
activity O
. O

RARE O
fibrinogen I-GENE
levels O
could O
thus O
be O
a O
risk O
RARE O
RARE O
thrombosis O
. O

RARE O
RARE O
RARE O
NUM O
is O
RARE O
, O
but O
preliminary O
analysis O
indicates O
that O
it O
may O
reduce O
management O
RARE O
overall O
.( O
ABSTRACT O
TRUNCATED O
AT O
NUM O
WORDS O
) O

We O
propose O
that O
RARE O
features O
of O
tissue O
- O
specific O
control O
and O
of O
the O
control O
of O
allelic O
RARE O
are O
RARE O
RARE O
. O

This O
study O
determined O
the O
RARE O
RARE O
of O
RARE O
gel O
by O
either O
RARE O
it O
with O
bovine I-GENE
RARE I-GENE
II I-GENE
( O
ALL_CAP I-GENE
) O
or O
by O
injecting O
RARE O
gel O
alone O
in O
ALL_CAP O
rats O
. O

ALL_CAP I-GENE
binds O
to O
the O
promoter O
prior O
to O
the O
activation O
of O
transcription O
in O
RARE O
G1 O
, O
suggesting O
that O
RARE I-GENE
/ O
Cdc28 I-GENE
kinase O
regulates O
the O
ability O
of O
previously O
RARE O
ALL_CAP I-GENE
to O
activate O
transcription O
. O

However O
, O
it O
remains O
an O
RARE O
question O
whether O
RARE I-GENE
Hox I-GENE
genes I-GENE
RARE O
under O
the O
control O
of O
Drosophila O
regulatory O
sequences O
can O
substitute O
the O
function O
of O
Drosophila I-GENE
Hox I-GENE
genes I-GENE
. O

This O
approach O
RARE O
RARE I-GENE
- I-GENE
1 I-GENE
into O
the O
normal O
RARE O
RARE O
context O
in O
which O
RARE O
acts O
. O

This O
5 O
' O
RARE O
site O
sequence O
was O
required O
RARE O
RARE O
polyadenylation O
and O
was O
RARE O
by O
both O
NUM I-GENE
small I-GENE
nuclear I-GENE
RARE I-GENE
( O
RARE O
) O
and O
RARE I-GENE
RARE I-GENE
factor I-GENE
/ O
RARE I-GENE
factor I-GENE
2 I-GENE
( O
ALL_CAP I-GENE
/ O
NUM I-GENE
). O

This O
analysis O
revealed O
that O
ALL_CAP I-GENE
NUM I-GENE
, O
together O
with O
four O
other O
NUM I-GENE
/ O
NUM I-GENE
subunits O
, O
ALL_CAP O
cross O
- O
links O
to O
pre O
- O
mRNA O
in O
a O
20 O
- O
nucleotide O
region O
upstream O
of O
the O
ALL_CAP O
. O

We O
propose O
that O
NUM I-GENE
and I-GENE
NUM I-GENE
of I-GENE
RARE I-GENE
are O
members O
of O
two O
distinct O
classes O
of O
RARE I-GENE
RARE I-GENE
, O
an O
observation O
not O
previously O
reported O
RARE O
a O
single O
RARE O
. O

Although O
the O
consumption O
of O
myoglobin I-GENE
- O
RARE O
NUM O
( O
NUM O
) O
RARE O
in O
RARE O
muscles O
has O
been O
demonstrated O
in O
RARE O
muscles O
RARE O
laboratory O
RARE O
of O
RARE O
, O
this O
may O
not O
be O
a O
feature O
of O
normal O
field O
RARE O
in O
which O
measurements O
of O
RARE O
rate O
and O
RARE O
production O
show O
marked O
differences O
from O
the O
profound O
RARE O
response O
RARE O
by O
RARE O
immersion O
. O

The O
human I-GENE
ALL_CAP I-GENE
cDNA I-GENE
is O
NUM O
RARE O
RARE O
in O
length O
encoding O
RARE O
a O
NUM O
- O
amino O
acid O
RARE O
( O
Mr O
= O
NUM O
, O
NUM O
). O

The O
Saccharomyces O
cerevisiae O
RARE O
pole O
body O
duplication O
gene I-GENE
NUM I-GENE
is O
part O
of O
a O
RARE O
RARE O
. O

In O
our O
RARE O
, O
the O
ALL_CAP O
- O
ALL_CAP O
RARE O
is O
, O
despite O
some O
RARE O
in O
its O
RARE O
- O
interface O
, O
a O
useful O
and O
RARE O
instrument O
RARE O
examination O
of O
human O
semen O
samples O
, O
with O
RARE O
features O
. O

The O
purpose O
of O
the O
study O
reported O
here O
was O
to O
investigate O
whether O
differences O
in O
NUM O
and O
NUM O
between O
tumors O
are O
mainly O
a O
consequence O
of O
differences O
in O
the O
fractional O
volume O
of O
the O
extracellular O
compartment O
. O

A O
mutant I-GENE
ALL_CAP I-GENE
product I-GENE
truncated O
immediately O
after O
the O
last O
RARE O
of O
the O
highly O
RARE O
ALL_CAP I-GENE
( I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
) I-GENE
domain I-GENE
retains O
partial O
function O
. O

RARE O
, O
designed O
on O
the O
basis O
of O
RARE O
flanking O
amino O
acid O
sequence O
RARE O
within O
the O
catalytic O
domain O
of O
eukaryotic I-GENE
protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
) O
proteins O
, O
were O
used O
RARE O
primers O
RARE O
polymerase O
chain O
reactions O
to O
RARE O
a O
NUM O
- O
bp O
chromosomal O
DNA O
fragment O
from O
the O
RARE O
RARE O
RARE O
RARE O
. O

Disruption O
of O
ALL_CAP I-GENE
/ O
E2F I-GENE
- I-GENE
1 I-GENE
interaction O
by O
single O
point O
mutations O
in O
E2F I-GENE
- I-GENE
1 I-GENE
enhances O
S O
- O
RARE O
entry O
and O
apoptosis O
. O

RARE O
RARE O
of O
differentiation O
markers O
RARE O
advanced O
malignant O
neoplasms O
. O

This O
region O
contains O
a O
motif O
with O
partial O
identity O
with O
the O
binding O
site O
RARE O
the O
ubiquitous O
transcription O
factor O
upstream I-GENE
RARE I-GENE
factor I-GENE
( O
USF I-GENE
RARE O
which O
binds O
to O
the O
human I-GENE
insulin I-GENE
promoter I-GENE
. O

The O
method O
has O
been O
RARE O
applied O
to O
the O
determination O
of O
RARE O
in O
RARE O
RARE O
and O
biological O
fluids O
. O

These O
primers O
yielded O
a O
PCR O
product O
of O
a O
characteristic O
length O
within O
most O
RARE O
species O
and O
RARE O
tested O
. O

The O
NUM I-GENE
kinase I-GENE
, O
which O
promotes O
S O
RARE O
, O
remains O
RARE O
RARE O
the O
NUM O
- O
RARE O
arrest O
of O
cells O
of O
the O
parental O
RARE O
, O
but O
its O
activity O
RARE O
rapidly O
in O
RARE I-GENE
mutants I-GENE
. O

The O
C O
/ O
D O
ratio O
was O
equal O
to O
or O
over O
NUM O
. O
6 O
in O
9 O
cases O
( O
16 O
eyes O
RARE O
and O
the O
values O
were O
RARE O
between O
both O
eyes O
in O
NUM O
% O
of O
the O
patients O
. O

NUM I-GENE
mutants I-GENE
display O
a O
remarkably O
pleiotropic O
RARE O
, O
RARE O
the O
protein O
in O
DNA O
damage O
- O
RARE O
mutagenesis O
, O
RARE O
repair O
, O
repression O
of O
RARE O
, O
and O
RARE O
. O

RNase I-GENE
protection O
assays O
revealed O
a O
correlation O
between O
the O
levels O
of O
dorsal O
and O
ventral O
RARE O
RARE O
with O
RARE O
/ O
RARE O
RARE O
. O

Molecular O
cloning O
, O
RARE O
pattern O
, O
and O
chromosomal O
RARE O
of O
human O
NUM I-GENE
/ O
NUM I-GENE
, O
an O
inhibitor O
of O
RARE I-GENE
D I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
. O

RARE O
of O
ALL_CAP I-GENE
protein I-GENE
from O
a O
second O
copy O
of O
ALL_CAP I-GENE
derived O
from O
a O
RARE O
( O
ALL_CAP I-GENE
+) O
in O
B O
. O
subtilis O
wild O
- O
type O
and O
delta O
ALL_CAP I-GENE
strains O
prevented O
heat O
shock O
induction O
of O
the O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
RARE I-GENE
RARE O
the O
level O
of O
transcription O
almost O
completely O
and O
strongly O
RARE O
the O
amounts O
of O
mRNA O
RARE O
a O
low O
RARE O
RARE O
RARE O
. O

We O
report O
the O
RARE O
cloning O
and O
RARE O
characterization O
of O
NUM I-GENE
isoforms I-GENE
, O
corresponding O
to O
a O
NUM O
- O
kDa O
subunit O
, O
NUM I-GENE
, O
and O
a O
new O
38 O
- O
kDa O
subunit O
, O
NUM I-GENE
, O
generated O
by O
differential O
RARE O
. O

The O
preferential O
heterodimerization O
of O
USF I-GENE
subunits I-GENE
was O
RARE O
RARE O
vivo O
, O
while O
the O
in O
vitro O
association O
of O
RARE O
subunits O
, O
or O
recombinant I-GENE
USF I-GENE
proteins I-GENE
, O
appeared O
to O
be O
random O
. O

RARE O
PKR I-GENE
may O
exist O
RARE O
a O
RARE O
and O
phosphorylates O
the O
eukaryotic I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
2 I-GENE
alpha I-GENE
subunit I-GENE
( O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
) O
to O
inhibit O
polypeptide O
chain O
initiation O
. O

NUM I-GENE
, O
a O
RARE O
RARE O
RARE O
in O
the O
endoplasmic O
reticulum O
, O
is O
a O
" O
glucose O
- O
regulated O
protein O
" O
RARE O
by O
stress O
responses O
that O
RARE O
glucose O
or O
RARE O
RARE O
or O
otherwise O
disrupt O
glycoprotein O
trafficking O
. O

The O
ALL_CAP I-GENE
- I-GENE
8 I-GENE
receptor I-GENE
is O
a O
RARE O
- O
transmembrane O
spanning O
receptor O
coupled O
to O
specific O
heterotrimeric I-GENE
G I-GENE
proteins I-GENE
including O
RARE I-GENE
and O
NUM I-GENE
. O

In O
a O
second O
series O
of O
experiments O
, O
the O
efficacy O
of O
ALL_CAP O
/ O
ALL_CAP O
RARE O
was O
evaluated O
in O
both O
single O
and O
multiple O
dose O
RARE O
. O

To O
elucidate O
the O
RARE O
significance O
of O
Fyn I-GENE
in O
the O
RARE O
of O
viral O
promoters O
, O
we O
transfected O
a O
Fyn I-GENE
- O
RARE O
vector O
together O
with O
a O
reporter O
RARE O
containing O
the O
chloramphenicol I-GENE
RARE I-GENE
gene I-GENE
RARE O
by O
HIV I-GENE
LTR I-GENE
into O
a O
human O
T O
cell O
line O
, O
Jurkat O
. O

We O
conducted O
a O
prospective O
, O
randomized O
RARE O
trial O
of O
RARE O
, O
a O
selective O
beta O
- O
blocker O
RARE O
prevention O
of O
RARE O
bleeding O
from O
RARE O
hypertension O
in O
29 O
non O
- O
RARE O
patients O
with O
liver O
RARE O
and O
previous O
RARE O
bleeding O
. O

A O
genetic O
and O
RARE O
analysis O
of O
non O
- O
inducible O
ALL_CAP I-GENE
mutants I-GENE
showed O
that O
all O
NUM O
mutations O
analysed O
map O
within O
the O
N O
- O
terminal O
RARE O
of O
the O
encoded O
ALL_CAP I-GENE
protein I-GENE
. O

These O
studies O
indicate O
that O
the O
RARE O
test O
was O
less O
RARE O
than O
the O
RARE O
RARE O
RARE O
and O
that O
RARE O
and O
S1 O
could O
be O
used O
to O
screen O
RARE O
beta I-GENE
- I-GENE
lactamase I-GENE
production O
in O
these O
tested O
species O
. O

RARE O
of O
RARE O
silencing O
in O
yeast O
: O
effects O
on O
transcriptional O
repression O
RARE O
the O
HMR I-GENE
locus I-GENE
, O
cell O
growth O
and O
RARE O
RARE O
. O

Although O
ANP I-GENE
RARE O
systemic O
capillary O
filtration O
, O
in O
the O
RARE O
, O
filtration O
was O
RARE O
with O
ANP I-GENE
. O

Recent O
literature O
has O
suggested O
that O
beta I-GENE
- I-GENE
2 I-GENE
transferrin I-GENE
can O
also O
be O
used O
RARE O
a O
clinical O
marker O
RARE O
RARE O
. O

With O
current O
RARE O
beta I-GENE
- I-GENE
2 I-GENE
transferrin I-GENE
does O
not O
appear O
to O
be O
a O
reliable O
clinical O
marker O
RARE O
RARE O
in O
the O
operative O
setting O
. O

The O
ALL_CAP I-GENE
- I-GENE
I I-GENE
gene I-GENE
has O
two O
promoters O
, O
P1 O
and O
P2 O
. O

Gel O
mobility O
shift O
assays O
indicated O
that O
RARE O
least O
four O
nuclear O
proteins O
with O
distinct O
biochemical O
and O
binding O
properties O
possess O
the O
ability O
to O
bind O
the O
3 O
beta O
I O
- O
A O
element O
to O
produce O
four O
DNA O
- O
protein O
complexes O
( O
NUM O
to O
NUM O
). O

RARE O
- O
five O
patients O
( O
aged O
between O
3 O
years O
5 O
months O
and O
NUM O
years O
) O
suffering O
from O
RARE O
resistant O
temporal O
lobe O
epilepsy O
( O
ALL_CAP O
) O
were O
operated O
on O
over O
a O
period O
of O
NUM O
months O
in O
RARE O
RARE O
RARE O
. O

Significant O
correlations O
existed O
between O
FEV1 O
and O
the O
corresponding O
values O
of O
RARE O
, O
NUM O
and O
NUM O
, O
although O
there O
were O
considerable O
individual O
differences O
between O
test O
results O
. O

( O
1989 O
RARE O
which O
is O
identical O
to O
the O
NUM I-GENE
gene I-GENE
( O
RARE O
et O
al O
., O
1988 O
). O

This O
region O
also O
contains O
a O
gene O
RARE O
a O
RARE I-GENE
- I-GENE
tRNA I-GENE
precursor I-GENE
and O
a O
RARE O
of O
a O
RARE O
element O
. O

RARE O
exposure O
to O
hepatitis O
B O
virus O
and O
human O
immunodeficiency O
virus O
: O
a O
comparative O
risk O
analysis O
. O

RARE O
female O
mice O
( O
C57BL O
RARE O
ALL_CAP O
) O
were O
paired O
with O
RARE O
males O
( O
CD O
- O
1 O
) O
and O
ALL_CAP O
pellets O
were O
implanted O
on O
day O
NUM O
, O
the O
day O
on O
which O
RARE O
RARE O
were O
found O
, O
or O
on O
day O
2 O
or O
day O
3 O
in O
the O
RARE O
period O
. O

This O
gene O
encodes O
a O
putative O
transcription O
factor O
with O
regions O
of O
homology O
to O
several O
other O
proteins O
including O
the O
zinc O
RARE O
and O
other O
domains O
of O
the O
Drosophila I-GENE
RARE I-GENE
gene I-GENE
product I-GENE
, O
and O
the O
" O
AT O
- O
RARE O
" O
DNA O
- O
binding O
motif O
of O
high I-GENE
mobility I-GENE
group I-GENE
proteins I-GENE
. O

Using O
reference O
RARE O
RARE O
internal O
RARE O
, O
we O
show O
that O
the O
RARE I-GENE
transcription I-GENE
unit I-GENE
is O
RARE O
within O
the O
cytogenetic O
band O
interval O
NUM O
, O
2 O
on O
the O
right O
RARE O
of O
the O
third O
RARE O
, O
and O
that O
it O
exerts O
diagnostic O
RARE O
gene O
RARE O
patterns O
in O
the O
RARE O
. O

The O
RARE O
recombinant O
enzyme O
catalyzed O
specific O
RARE O
transfer O
from O
ATP O
to O
ALL_CAP O
and O
ALL_CAP O
. O

Studies O
on O
the O
life O
RARE O
of O
RARE O
RARE O
( O
RARE O
, O
NUM O
) O
RARE O
, O
NUM O
with O
morphological O
RARE O
of O
RARE O
and O
adult O
stages O
. O

RARE O
RARE O
in O
5 O
cases O
of O
hepatitis O
B O
virus O
related O
RARE O
RARE O
. O

During O
the O
following O
RARE O
RARE O
studies O
of O
the O
male O
fetus O
in O
the O
NUM O
week O
of O
gestation O
revealed O
severe O
RARE O
, O
short O
and O
wide O
RARE O
, O
and O
RARE O
RARE O
, O
and O
RARE O
RARE O
. O

Despite O
an O
overall O
survival O
rate O
of O
NUM O
%, O
survival O
to O
discharge O
varied O
greatly O
( O
NUM O
to O
NUM O
%) O
among O
the O
NUM O
diagnostic O
groups O
: O
tumor O
lysis O
RARE O
and O
systemic O
lupus O
erythematosus O
( O
3 O
/ O
3 O
patients O
each O
, O
NUM O
%), O
RARE O
RARE O
RARE O
( O
8 O
/ O
9 O
patients O
, O
NUM O
%). O

One O
hundred O
RARE O
/ O
kg O
of O
recombinant I-GENE
human I-GENE
erythropoietin I-GENE
( O
ALL_CAP I-GENE
) O
was O
given O
subcutaneously O
3 O
times O
a O
week O
RARE O
3 O
weeks O
. O

A O
3 O
- O
week O
regimen O
of O
erythropoietin I-GENE
may O
help O
prevent O
the O
donor O
' O
s O
need O
to O
receive O
RARE O
RARE O
transfusion O
, O
when O
the O
initial O
RARE I-GENE
levels O
were O
below O
NUM O
RARE O
. O

In O
these O
constructs O
, O
GUS I-GENE
RARE O
was O
RARE O
by O
promoter O
regions O
derived O
from O
the O
Arabidopsis I-GENE
RARE I-GENE
dehydrogenase I-GENE
( O
NUM I-GENE
RARE O
RARE I-GENE
ubiquitin I-GENE
( O
NUM I-GENE
RARE O
RARE I-GENE
actin I-GENE
( O
NUM I-GENE
) O
and O
ALL_CAP I-GENE
NUM I-GENE
genes I-GENE
. O

Its O
organization O
and O
RARE O
indicate O
that O
the O
S I-GENE
. I-GENE
pombe I-GENE
NUM I-GENE
gene I-GENE
product I-GENE
appears O
very O
similar O
to O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
NUM I-GENE
gene I-GENE
product I-GENE
. O

The O
mean O
body O
mass O
index O
( O
BMI O
) O
was O
NUM O
. O
8 O
+/- O
6 O
. O
3 O
kg O
/ O
m2 O
and O
NUM O
. O
5 O
+/- O
6 O
. O
3 O
kg O
/ O
m2 O
in O
women O
and O
men O
, O
respectively O
. O

These O
findings O
demonstrate O
that O
haemodialysis O
patients O
with O
chronic O
hepatitis O
C O
respond O
RARE O
to O
RARE I-GENE
treatment O
and O
that O
a O
long O
- O
term O
response O
is O
achieved O
in O
a O
high O
proportion O
of O
patients O
. O

RARE O
RARE O
of O
drugs O

RARE O
analysis O
further O
indicated O
that O
these O
RARE I-GENE
cell I-GENE
- I-GENE
specific I-GENE
NUM I-GENE
mRNAs I-GENE
are O
translated O
, O
RARE O
with O
a O
lower O
efficiency O
than O
the O
somatic O
transcript O
. O

In O
RARE O
the O
response O
of O
NUM O
but O
not O
of O
ALL_CAP O
was O
influenced O
by O
the O
values O
RARE O
rest O
. O

This O
study O
RARE O
an O
RARE O
RARE O
such O
global O
RARE O
effects O
upon O
unit O
- O
RARE O
correlations O
based O
on O
local O
field O
potentials O
( O
RARE O
). O

The O
assembly O
of O
sequence O
RARE O
, O
high O
- O
resolution O
physical O
maps O
and O
RARE O
of O
RARE O
overlapping O
RARE O
RARE O
the O
human O
RARE O
RARE O
RARE O
model O
genomes O
requires O
accurate O
determination O
of O
the O
extent O
of O
overlap O
between O
adjacent O
RARE O
RARE O
RARE O
RARE O
their O
relative O
orientation O
. O

( O
ii O
) O
RARE O
of O
ALL_CAP O
attenuates O
, O
inhibition O
of O
the O
RARE O
RARE O
RARE O
consequences O
of O
coronary O
occlusion O
, O
and O
( O
iii O
) O
ALL_CAP O
RARE O
attenuates O
reperfusion O
- O
RARE O
VF O
, O
but O
it O
triggers O
ischemia O
- O
RARE O
VF O
. O

The O
DNA O
sequences O
upstream O
of O
these O
termini O
exhibit O
homology O
to O
RARE O
mitochondrial O
- O
RARE O
sites O
, O
therefore O
the O
proximal O
5 O
' O
ends O
are O
most O
probably O
generated O
by O
RNA O
RARE O
. O

RARE O
RARE O
and O
RARE O
changes O
of O
resin O
- O
modified O
glass O
RARE O
RARE O
materials O
. O

Here O
we O
present O
genetic O
evidence O
suggesting O
that O
PP2A I-GENE
functions O
RARE O
of O
NUM I-GENE
in O
the O
RARE I-GENE
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
signal O
RARE O
RARE O
that O
specifies O
NUM O
RARE O
cell O
fate O
in O
the O
developing O
Drosophila O
eye O
. O

RARE O
RARE O
a O
5 O
% O
change O
in O
response O
( O
NUM O
) O
were O
6 O
- O
RARE O
lower O
, O
on O
average O
, O
than O
the O
corresponding O
ALL_CAP O
. O

Effects O
of O
RARE O
exposures O
of O
hydrogen O
RARE O
on O
rat O
hippocampal O
EEG O
. O

The O
gene O
encodes O
an O
ATP I-GENE
- I-GENE
binding I-GENE
RARE I-GENE
, O
ALL_CAP I-GENE
RARE I-GENE
. O

The O
T O
- O
box O
motif O
is O
present O
in O
a O
family O
of O
genes O
whose O
structural O
features O
and O
RARE O
patterns O
support O
their O
involvement O
in O
developmental O
gene O
RARE O
. O

Molecular O
analysis O
of O
a O
novel O
RARE O
pombe O
gene O
containing O
two O
ALL_CAP O
consensus O
- O
sequence O
RNA O
- O
binding O
domains O
. O

RARE O
overall O
treatment O
time O
, O
field O
size O
, O
and O
treatment O
energy O
influence O
local O
control O
of O
NUM O
- O
NUM O
squamous O
cell O
carcinomas O
of O
the O
RARE O
larynx O
? O
PURPOSE O
: O
To O
evaluate O
treatment O
and O
patient O
related O
prognostic O
factors O
that O
may O
influence O
local O
control O
in O
the O
treatment O
of O
NUM O
- O
NUM O
squamous O
cell O
carcinoma O
of O
the O
RARE O
larynx O
. O

In O
contrast O
to O
the O
RARE O
triggered O
by O
surface O
Ig I-GENE
RARE O
in O
B O
lymphocytes O
, O
NUM I-GENE
ligation O
did O
not O
appear O
to O
induce O
tyrosine O
RARE O
of O
the O
src I-GENE
- I-GENE
like I-GENE
protein I-GENE
tyrosine I-GENE
kinases I-GENE
RARE I-GENE
, O
RARE I-GENE
, O
and O
RARE I-GENE
, O
or O
of O
RARE I-GENE
- I-GENE
and I-GENE
ras I-GENE
- I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
, O
nor O
did O
it O
induce O
detectable O
changes O
in O
cytosolic O
NUM O
+ O
concentrations O
. O

Mutations O
in O
the O
alpha I-GENE
- I-GENE
RARE I-GENE
RARE O
domain O
of O
the O
largest O
subunit O
of O
yeast I-GENE
RNA I-GENE
polymerase I-GENE
III I-GENE
affect O
RARE O
, O
RNA O
RARE O
and O
transcriptional O
RARE O
. O

The O
evidence O
presented O
here O
suggests O
that O
the O
p40 I-GENE
complex I-GENE
is O
a O
ribonucleoprotein O
complex O
containing O
NUM I-GENE
RNA I-GENE
( I-GENE
s I-GENE
) I-GENE
and O
that O
protein O
- O
protein O
interactions O
in O
which O
alpha O
- O
helix O
RARE O
participate O
, O
RARE O
example O
RARE O
- O
RARE O
, O
may O
occur O
in O
the O
complex O
. O

Our O
data O
suggest O
that O
RARE O
- O
activation O
from O
the O
RARE I-GENE
intron I-GENE
enhancer I-GENE
is O
a O
RARE O
RARE O
of O
the O
transforming O
properties O
of O
the O
RARE I-GENE
protein I-GENE
. O

RARE O
RARE O
following O
bone O
marrow O
transplantation O
: O
RARE O
and O
RARE O
study O
of O
one O
case O
. O

In O
view O
of O
the O
presence O
of O
SECIS O
elements O
in O
the O
RARE O
reading O
frames O
( O
RARE O
) O
of O
bacterial I-GENE
RARE I-GENE
, O
we O
examine O
the O
effects O
in O
the O
type I-GENE
1 I-GENE
deiodinase I-GENE
of O
extending O
the O
ORF O
into O
the O
SECIS O
element O
, O
and O
find O
that O
this O
dramatically O
inhibits O
SECIS O
function O
. O

The O
5 O
' O
external O
RARE O
spacer O
( O
ALL_CAP O
) O
region O
of O
the O
pre O
- O
rRNA O
in O
Saccharomyces O
cerevisiae O
contains O
a O
sequence O
with O
10 O
bp O
of O
perfect O
RARE O
to O
the O
NUM I-GENE
ALL_CAP I-GENE
. O

These O
animals O
were O
viable O
and O
RARE O
. O

This O
RARE O
defect O
of O
NUM I-GENE
mutants I-GENE
results O
from O
a O
RARE O
- O
RARE O
step O
that O
occurs O
around O
the O
G1 O
/ O
S O
boundary O
about O
the O
time O
of O
RARE O
assembly O
. O

These O
data O
suggest O
that O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
is O
likely O
to O
be O
involved O
in O
early O
steps O
in O
the O
differentiation O
of O
RARE O
and O
RARE O
cells O
. O

In O
the O
point O
mutant O
we O
observed O
normal O
repair O
of O
endonuclease I-GENE
III I-GENE
site I-GENE
( O
i O
. O
RARE O
. O
RARE O
wild O
type O
RARE O
but O
RARE O
removal O
of O
RARE O
RARE O
the O
ALL_CAP I-GENE
alpha I-GENE
and O
ALL_CAP I-GENE
alpha I-GENE
loci I-GENE
. O

However O
, O
RARE O
the O
evaluable O
cases O
, O
the O
RARE O
of O
the O
NUM O
and O
the O
ALL_CAP O
were O
broadly O
similar O
and O
generally O
correlated O
RARE O
with O
the O
RARE O
reference O
procedure O
. O

RARE O
- O
terminal O
NUM I-GENE
RARE O
RARE O
the O
calmodulin I-GENE
binding O
site O
can O
support O
growth O
and O
are O
also O
RARE O
in O
a O
cell O
RARE O
- O
specific O
manner O
. O

Both O
EWS I-GENE
- O
FLI I-GENE
- I-GENE
1 I-GENE
and O
FLI I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
function O
RARE O
transcription O
factors O
that O
bind O
specifically O
to O
ets I-GENE
sequences O
( O
the O
ets I-GENE
RARE O
) O
present O
in O
promoter O
elements O
. O

In O
RARE O
shift O
assays O
, O
EWS I-GENE
- O
FLI I-GENE
- I-GENE
1 I-GENE
binding O
to O
the O
SRE O
is O
detectable O
in O
the O
absence O
of O
SRF I-GENE
whereas O
the O
binding O
of O
FLI I-GENE
- I-GENE
1 I-GENE
is O
not O
, O
suggesting O
that O
the O
interaction O
with O
DNA O
is O
the O
step O
which O
limits O
RARE O
complex O
formation O
by O
FLI I-GENE
- I-GENE
1 I-GENE
. O

RARE O
studies O
with O
new O
and O
RARE O
RARE O
RARE O
RARE O
comparing O
NUM O
and O
220 O
mL O
/ O
min O
RARE O
flow O
rates O
RARE O
10 O
minutes O
showed O
RARE O
change O
in O
ALL_CAP O
. O

DNA O
methylation O
, O
especially O
of O
either O
one O
or O
both O
of O
the O
RARE O
RARE O
the O
two O
ALL_CAP O
motifs O
( O
one O
in O
the O
RARE O
RARE O
and O
the O
other O
in O
the O
RARE O
intron O
of O
the O
RARE O
ALL_CAP I-GENE
gene I-GENE
RARE O
appeared O
to O
be O
responsible O
RARE O
the O
ALL_CAP I-GENE
promoter I-GENE
activity O
identified O
in O
the O
transient O
assay O
. O

The O
viral I-GENE
LTR I-GENE
was O
used O
RARE O
the O
promoter O
. O

RARE O
cDNA O
RARE O
were O
isolated O
and O
sequenced O
. O

In O
conclusion O
, O
IgM I-GENE
class O
ALL_CAP O
is O
the O
predominant O
ALL_CAP O
in O
acute O
hepatitis O
A O
and O
correlated O
with O
RARE O
activity O
. O

RARE O
mapping O
revealed O
that O
these O
three O
RARE O
appear O
to O
recognize O
an O
identical O
RARE O
domain O
present O
on O
the O
C O
- O
terminal O
ALL_CAP O
motif O
of O
the O
NUM I-GENE
protein I-GENE
. O

RARE O
evaluated O
were O
number O
of O
weekly O
RARE O
events O
, O
data O
from O
RARE O
exercise O
testing O
with O
simultaneous O
RARE O
RARE O
, O
RARE O
evaluation O
of O
Tc O
- O
99m O
2 O
- O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
scans O
and O
RARE O
variables O
. O

As O
the O
length O
of O
the O
fatty O
acid O
decreased O
, O
the O
binding O
affinity O
was O
RARE O
; O
RARE O
acid O
( O
14 O
: O
NUM O
) O
RARE O
with O
a O
K O
( O
d O
) O
of O
NUM O
+/- O
NUM O
nM O
, O
but O
medium O
- O
chain O
( O
RARE O
acid O
, O
10 O
: O
NUM O
) O
and O
short O
- O
chain O
( O
RARE O
acid O
, O
8 O
: O
NUM O
) O
lipids O
were O
not O
RARE O
RARE O
all O
. O

The O
membrane O
- O
distal O
cytoplasmic O
region O
of O
human I-GENE
RARE I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
receptor I-GENE
is O
required O
RARE O
STAT3 I-GENE
but O
not O
STAT1 I-GENE
RARE I-GENE
formation O
. O

However O
, O
whether O
or O
not O
nonsense O
RARE O
recognition O
within O
ALL_CAP I-GENE
transcripts I-GENE
RARE O
place O
prior O
to O
or O
after O
RARE O
remained O
RARE O
. O

Although O
some O
residues O
are O
found O
reactive O
toward O
RARE O
and O
RARE O
in O
regions O
predicted O
to O
be O
RARE O
by O
the O
phylogenetic O
secondary O
RARE O
model O
of O
4 I-GENE
. I-GENE
5S I-GENE
RNA I-GENE
, O
generally O
the O
reactivity O
is O
low O
, O
and O
some O
residues O
in O
internal O
loops O
are O
not O
reactive O
RARE O
all O
. O

RARE O
and O
future O
investigations O
may O
better O
define O
the O
optimal O
approach O
RARE O
local O
control O
, O
the O
optimal O
duration O
of O
RARE O
chemotherapy O
, O
and O
the O
possible O
role O
of O
RARE O
response O
RARE O
and O
growth O
factors O
in O
further O
RARE O
the O
outcome O
RARE O
patients O
with O
this O
RARE O
. O

ALL_CAP O
ALL_CAP O
ALL_CAP O
: O
We O
discuss O
the O
criteria O
that O
make O
such O
studies O
comparable O
, O
RARE O
on O
the O
RARE O
of O
recent O
studies O
performed O
around O
the O
world O
. O

Forty O
- O
five O
patients O
with O
RARE O
lesions O
identified O
on O
ALL_CAP O
scans O
were O
subsequently O
examined O
by O
MR O
imaging O
RARE O
NUM O
. O
5 O
T O
. O

RARE O
RARE O
volumes O
were O
greater O
in O
old O
compared O
with O
young O
subjects O
( O
maximal O
: O
NUM O
+/- O
10 O
cm3 O
/ O
m2 O
RARE O
NUM O
+/- O
8 O
cm3 O
/ O
m2 O
, O
p O
= O
NUM O
. O
02 O
; O
RARE O
onset O
of O
RARE O
RARE O
: O
NUM O
+/- O
8 O
cm3 O
/ O
m2 O
RARE O
NUM O
+/- O
5 O
cm3 O
/ O
m2 O
, O
p O
= O
NUM O
. O
NUM O
; O
minimal O
: O
NUM O
+/- O
5 O
cm3 O
/ O
m2 O
RARE O
9 O
+/- O
4 O
cm3 O
/ O
m2 O
, O
p O
= O
NUM O
. O
001 O
). O

RESULTS O
: O
Basal O
plasma I-GENE
IGF I-GENE
- I-GENE
I I-GENE
levels O
RARE O
RARE O
RARE O
body O
mass O
index O
( O
BMI O
) O
were O
lower O
in O
RARE O
patients O
than O
in O
healthy O
controls O
. O

We O
observed O
abundant O
levels O
of O
RARE I-GENE
- O
erbA I-GENE
alpha I-GENE
mRNA O
in O
RARE O
C2C12 O
myoblasts O
, O
which O
were O
suppressed O
when O
the O
cells O
differentiated O
into O
RARE O
RARE O
myotubes O
. O

We O
then O
demonstrated O
that O
1 O
) O
GAL4 I-GENE
- O
ALL_CAP I-GENE
- O
erbA I-GENE
alpha I-GENE
RARE O
that O
contain O
the O
' O
ALL_CAP O
' O
region O
and O
lack O
the O
' O
E O
' O
region O
activated O
transcription O
of O
GAL4 I-GENE
response I-GENE
elements I-GENE
in O
the O
presence O
of O
8 O
- O
Br O
- O
cAMP O
and O
2 O
) O
the O
RARE O
- O
binding O
domain O
( O
ALL_CAP O
) O
contains O
an O
RARE O
transcriptional O
RARE O
. O

The O
alpha O
NUM O
- O
1 O
cell O
line O
, O
a O
GnRH I-GENE
- O
responsive O
RARE O
cell O
line O
developed O
by O
targeted O
RARE O
in O
transgenic O
mice O
, O
was O
used O
to O
study O
RARE O
of O
the O
glycoprotein I-GENE
hormone I-GENE
alpha I-GENE
- I-GENE
subunit I-GENE
by O
activin I-GENE
. O

Cotransfection O
with O
the O
NUM I-GENE
gene I-GENE
resulted O
in O
a O
dramatic O
increase O
in O
the O
amount O
of O
the O
two O
RARE O
RARE O
in O
the O
transfected O
cells O
. O

As O
expected O
, O
glycosylation O
of O
Env I-GENE
produced O
from O
mutants O
was O
affected O
but O
, O
irrespective O
of O
the O
glycosylation O
RARE O
, O
( O
i O
) O
similar O
RARE O
of O
Env I-GENE
were O
synthesized O
, O
( O
ii O
) O
the O
immunoreactivity O
of O
NUM I-GENE
was O
similar O
, O
( O
iii O
) O
NUM I-GENE
was O
efficiently O
cleaved O
into O
gp120 I-GENE
and O
NUM I-GENE
, O
( O
RARE O
) O
Env I-GENE
was O
exposed O
RARE O
the O
cell O
membrane O
, O
( O
v O
) O
RARE O
gp120 I-GENE
RARE O
NUM I-GENE
, O
and O
( O
RARE O
) O
membrane O
NUM I-GENE
was O
able O
to O
induce O
membrane O
fusion O
with O
NUM I-GENE
+ I-GENE
cells O
. O

Effects O
of O
RARE O
RARE O
on O
Parkinson O
' O
s O
RARE O
. O

On O
the O
RARE O
of O
RARE O
. O

However O
, O
only O
RARE I-GENE
ALL_CAP I-GENE
can O
cooperate O
with O
ALL_CAP I-GENE
and O
a O
third O
protein O
, O
ALL_CAP I-GENE
, O
in O
RARE O
RARE I-GENE
RARE I-GENE
luciferase I-GENE
. O

The O
two O
different O
RARE O
of O
STAT5 I-GENE
have O
identical O
in O
vitro O
DNA O
binding O
RARE O
and O
reactivity O
with O
tyrosine O
phosphopeptides O
, O
but O
differ O
in O
their O
cellular O
RARE O
. O

TNF I-GENE
Treatment O
of O
cell O
activated O
the O
p38 I-GENE
MAP I-GENE
kinase I-GENE
RARE O
, O
RARE O
revealed O
by O
increased O
RARE O
of O
p38 I-GENE
MAP I-GENE
kinase I-GENE
itself O
, O
activation O
of O
the O
substrate O
protein O
ALL_CAP I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
, O
and O
RARE O
in O
the O
RARE O
of O
the O
heat I-GENE
shock I-GENE
protein I-GENE
NUM I-GENE
( O
NUM I-GENE
). O

We O
have O
isolated O
a O
novel O
protein O
from O
Drosophila O
nuclear O
extracts O
which O
binds O
specifically O
to O
a O
site O
in O
this O
second O
region O
. O

However O
, O
while O
the O
sequence O
RARE O
between O
the O
membrane O
exons O
of O
avian I-GENE
ALL_CAP I-GENE
and O
mammalian I-GENE
ALL_CAP I-GENE
and I-GENE
IgE I-GENE
is O
striking O
, O
the O
overall O
RARE O
with O
Xenopus I-GENE
ALL_CAP I-GENE
is O
very O
low O
. O

Control O
of O
transcription O
of O
the O
erbB I-GENE
- I-GENE
2 I-GENE
gene I-GENE
is O
an O
important O
determinant O
of O
receptor O
RARE O
. O

DNase I-GENE
I I-GENE
footprinting O
and O
electrophoretic O
mobility O
shift O
assays O
indicate O
that O
ALL_CAP I-GENE
binds O
to O
the O
RARE O
- O
site O
of O
each O
palindrome O
with O
the O
core O
recognition O
sequence O
ALL_CAP O
. O

These O
results O
demonstrate O
that O
sequences O
in O
the O
NUM I-GENE
/ O
SH3 I-GENE
/ O
NUM I-GENE
region O
of O
NUM I-GENE
ALL_CAP I-GENE
are O
required O
RARE O
full O
catalytic O
activity O
toward O
Ras I-GENE
. O

The O
novel O
hematopoietic I-GENE
growth I-GENE
factor I-GENE
NUM I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
is O
the O
RARE O
RARE O
RARE O
the O
NUM I-GENE
, O
tyrosine I-GENE
kinase I-GENE
receptor I-GENE
( O
R I-GENE
RARE O
also O
referred O
to O
RARE O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
and O
STK I-GENE
- I-GENE
1 I-GENE
. O

In O
contrast O
to O
the O
selective O
RARE O
of O
the O
receptor O
, O
ALL_CAP I-GENE
RARE O
was O
detected O
in O
NUM O
- O
NUM O
% O
of O
the O
various O
cell O
RARE O
of O
leukemia O
cell O
lines O
from O
all O
hematopoietic O
cell O
lineages O
. O

Further O
analysis O
of O
this O
domain O
by O
in O
vitro O
mutagenesis O
RARE O
to O
a O
core O
of O
hydrophobic O
and O
RARE O
residues O
RARE O
critical O
RARE O
the O
activity O
. O

Analysis O
of O
RAR I-GENE
alpha I-GENE
mutants I-GENE
in O
transfection O
studies O
reveals O
that O
the O
DNA O
binding O
domain O
is O
sufficient O
RARE O
inhibition O
of O
NUM I-GENE
activity O
. O

We O
measured O
serum I-GENE
RARE I-GENE
growth I-GENE
factor I-GENE
( O
HGF I-GENE
) O
in O
patients O
with O
acute O
RARE O
infarction O
, O
angina O
pectoris O
, O
and O
other O
RARE O
diseases O
. O

The O
RARE O
mechanism O
of O
RARE O
motor O
symptoms O
, O
i O
. O
RARE O
., O
RARE O
, O
tremor O
and O
RARE O
, O
which O
are O
the O
result O
of O
RARE O
dopamine O
deficiency O
, O
is O
interpreted O
from O
long O
- O
term O
observations O
on O
the O
effect O
of O
surgical O
and O
pharmacological O
treatment O
of O
the O
RARE O
in O
relation O
to O
the O
RARE O
findings O
within O
the O
RARE O
RARE O
RARE O
RARE O
( O
RARE O
). O

Protein O
RARE O
: O
evidence O
RARE O
an O
N O
- O
O O
RARE O
rearrangement O
RARE O
the O
initial O
step O
in O
the O
RARE O
process O
. O

In O
agreement O
with O
these O
data O
, O
RARE O
blot O
experiments O
using O
an O
antibody O
directed O
against O
the O
RARE O
- O
terminal O
portion O
of O
the O
mouse O
c I-GENE
- I-GENE
kit I-GENE
protein I-GENE
showed O
that O
a O
polypeptide O
, O
of O
the O
size O
predicted O
by O
the O
RARE O
reading O
frame O
of O
the O
RARE I-GENE
- I-GENE
specific I-GENE
c I-GENE
- I-GENE
kit I-GENE
cDNA I-GENE
, O
accumulates O
in O
the O
RARE O
stages O
of O
RARE O
and O
in O
RARE O
spermatozoa O
. O

It O
is O
shown O
that O
the O
( O
G O
+ O
C O
)- O
rich O
element O
of O
the O
RARE I-GENE
C I-GENE
promoter I-GENE
directs O
transcription O
in O
RARE O
RARE O
RARE O
RARE O
in O
RARE O
cells O
. O

NUM O
appears O
to O
inhibit O
uPA I-GENE
promoter I-GENE
activation O
by O
blocking O
phorbol O
ester O
- O
RARE O
binding O
of O
nuclear O
proteins O
to O
the O
uPA I-GENE
PEA3 I-GENE
/ O
12 O
- O
NUM O
- O
RARE O
NUM O
- O
RARE O
responsive O
element O
( O
ALL_CAP O
). O

Treatment O
of O
RARE O
expressing O
a O
normal O
RARE I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
( O
EGFR I-GENE
) O
with O
RARE I-GENE
or O
RARE I-GENE
growth I-GENE
factor I-GENE
RARE O
5 O
min O
RARE O
RARE I-GENE
tyrosine O
RARE O
. O

Only O
one O
of O
these O
bands O
was O
RARE O
by O
antibody O
to O
NUM I-GENE
, O
whereas O
antibodies O
to O
NUM I-GENE
or O
other O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
proteins I-GENE
had O
RARE O
effect O
. O

We O
isolated O
a O
RARE O
DNA O
( O
cDNA O
) O
clone O
from O
an O
NUM O
- O
2 O
RARE O
library O
that O
encodes O
the O
C1 I-GENE
site I-GENE
- I-GENE
binding I-GENE
protein I-GENE
. O

Biol O
. O

In O
addition O
, O
anti I-GENE
- I-GENE
RARE I-GENE
antibodies I-GENE
immunoprecipitated O
NUM I-GENE
- I-GENE
H I-GENE
from O
cell O
lysates O
of O
FGF I-GENE
- O
RARE O
but O
not O
from O
control O
RARE O
. O

The O
novel O
protein O
kinases O
, O
c I-GENE
- I-GENE
Jun I-GENE
NH2 I-GENE
- I-GENE
terminal I-GENE
kinases I-GENE
( O
RARE I-GENE
RARE O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinases I-GENE
, O
are O
also O
activated O
by O
TNF I-GENE
- I-GENE
alpha I-GENE
, O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
and O
NUM I-GENE
RARE O
. O

Thus O
, O
RARE I-GENE
potentially O
functions O
RARE O
a O
dominant O
negative O
inhibitor O
of O
RARE I-GENE
activity O
. O

NUM I-GENE
contains O
an O
NH2 O
- O
terminal O
RARE O
domain O
followed O
by O
four O
RARE I-GENE
growth I-GENE
factor I-GENE
- I-GENE
like I-GENE
repeats I-GENE
and O
RARE O
globular O
( O
G O
) O
domains O
. O

Both O
NUM I-GENE
cDNA I-GENE
RARE O
detect O
a O
single O
3 O
. O
2 O
- O
kb O
transcript O
on O
Northern O
blots O
of O
multiple O
human O
tissues O
, O
indicating O
the O
long O
cDNA O
containing O
the O
3 O
'- O
RARE O
intron O
represents O
the O
predominant O
transcript O
. O

RARE O
of O
RARE I-GENE
L I-GENE
protein I-GENE
in O
vitro O
was O
inhibited O
by O
RARE O
of O
RARE I-GENE
L I-GENE
protein I-GENE
by O
PKN I-GENE
. O

The O
protein O
RARE O
correctly O
with O
two O
disulfide O
bonds O
and O
a O
free O
RARE O
group O
RARE O
NUM O
. O

We O
and O
others O
have O
demonstrated O
that O
the O
c I-GENE
- I-GENE
cbl I-GENE
RARE I-GENE
- I-GENE
oncogene I-GENE
product I-GENE
is O
one O
of O
the O
RARE O
RARE O
of O
tyrosine O
RARE O
upon O
T I-GENE
cell I-GENE
receptor I-GENE
RARE O
. O

A O
substantial O
fraction O
of O
Cbl I-GENE
was O
constitutively O
associated O
with O
Grb2 I-GENE
and O
this O
interaction O
was O
RARE O
by O
Grb2 I-GENE
SH3 I-GENE
domains O
. O

An O
AP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sequence I-GENE
is O
essential O
RARE O
RARE O
of O
the O
human I-GENE
NUM I-GENE
( I-GENE
I I-GENE
) I-GENE
RARE I-GENE
( O
NUM I-GENE
) O
promoter O
activity O
by O
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
. O

No O
significant O
differences O
existed O
between O
the O
two O
age O
groups O
in O
baseline O
characteristics O
, O
including O
treatment O
protocol O
, O
performance O
status O
, O
and O
serum I-GENE
RARE I-GENE
dehydrogenase I-GENE
( O
ALL_CAP I-GENE
) O
level O
. O

Only O
two O
patients O
( O
NUM O
. O
3 O
%) O
had O
a O
CA I-GENE
NUM I-GENE
response O
RARE O
the O
time O
of O
clinical O
progression O
. O

The O
men O
self O
- O
RARE O
a O
RARE O
diet O
RARE O
home O
RARE O
RARE O
fat O
RARE O
the O
RARE O
fat O
RARE O
1 O
week O
. O

Conversely O
, O
when O
VDR I-GENE
is O
overexpressed O
, O
vitamin O
NUM O
attenuates O
9 O
- O
cis O
ALL_CAP O
induction O
from O
an O
RXR I-GENE
- O
responsive O
element O
. O

These O
results O
RARE O
a O
hitherto O
RARE O
function O
of O
U6 I-GENE
RNA I-GENE
: O
the O
modulation O
of O
a O
RARE O
- O
RARE O
RARE O
of O
C1 I-GENE
ALL_CAP I-GENE
protein I-GENE
that O
influences O
the O
binding O
affinity O
of O
this O
protein O
RARE O
pre O
- O
mRNA O
. O

RARE O
of O
the O
extended O
N O
terminus O
into O
the O
RARE O
reported O
protein O
resulted O
in O
a O
striking O
RARE O
to O
the O
RARE I-GENE
factor I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
. O

RARE O
mammalian I-GENE
NUM I-GENE
activates O
CBF1 I-GENE
/ O
RARE I-GENE
- O
repressed O
genes O
by O
a O
mechanism O
resembling O
that O
of O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
EBNA2 I-GENE
. O

Electrophoretic O
mobility O
shift O
assays O
( O
RARE O
) O
using O
RARE O
glucocorticoid I-GENE
receptor I-GENE
DNA I-GENE
binding I-GENE
domain I-GENE
( O
ALL_CAP O
) O
demonstrated O
that O
both O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
and I-GENE
- I-GENE
3 I-GENE
motifs I-GENE
interact O
with O
ALL_CAP O
and O
RARE O
competition O
experiments O
established O
that O
these O
have O
different O
affinities O
RARE O
ALL_CAP O
. O

The O
large O
subfamily O
of O
receptor I-GENE
tyrosine I-GENE
kinases I-GENE
( O
RARE I-GENE
) O
RARE O
which O
ALL_CAP I-GENE
is O
the O
prototype O
have O
likely O
roles O
in O
RARE O
RARE O
RARE O
normal O
mammalian O
development O
, O
but O
the O
biochemical O
signalling O
pathways O
RARE O
by O
this O
family O
are O
poorly O
RARE O
. O

The O
NUM O
- O
kDa O
protein O
is O
required O
RARE O
the O
systemic O
infection O
of O
RARE O
. O

We O
present O
here O
a O
detailed O
genomic O
sequencing O
analysis O
of O
the O
cytosine O
methylation O
patterns O
of O
the O
RARE I-GENE
binding O
sites O
within O
both O
RARE I-GENE
ends O
in O
the O
RARE I-GENE
- I-GENE
NUM I-GENE
:: O
RARE I-GENE
allele I-GENE
, O
where O
RARE I-GENE
is O
inserted O
into O
the O
RARE O
RARE O
of O
the O
RARE I-GENE
gene I-GENE
. O

Krox I-GENE
- I-GENE
20 I-GENE
, O
a O
zinc I-GENE
finger I-GENE
gene I-GENE
, O
has O
a O
highly O
RARE O
pattern O
of O
RARE O
in O
NUM O
and O
NUM O
and O
is O
functionally O
required O
RARE O
their O
RARE O
in O
mouse O
RARE O
. O

RARE O
adenylate I-GENE
cyclase I-GENE
- I-GENE
activating I-GENE
polypeptide I-GENE
regulates O
prolactin I-GENE
promoter I-GENE
activity O
via O
a O
protein I-GENE
kinase I-GENE
A I-GENE
- O
RARE O
RARE O
that O
is O
independent O
of O
the O
transcriptional O
RARE O
employed O
by O
thyrotropin I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
. O

RARE O
NUM O
and O
NUM O
encoded O
identical O
aromatase I-GENE
proteins I-GENE
of O
NUM O
amino O
RARE O
, O
but O
differed O
in O
size O
due O
to O
RARE O
polyadenylation O
signal O
usage O
RARE O
the O
corresponding O
mRNAs O
. O

In O
RARE O
bone O
marrow O
cells O
RARE O
of O
both O
ALL_CAP I-GENE
genes I-GENE
was O
detected O
in O
pro O
- O
B O
/ O
pre O
- O
ALL_CAP O
and O
large O
pre O
- O
ALL_CAP O
cells O
, O
while O
the O
RNA O
steady O
state O
levels O
were O
RARE O
least O
NUM O
- O
RARE O
lower O
in O
small O
pre O
- O
ALL_CAP O
and O
immature O
/ O
RARE O
B O
cells O
. O

We O
have O
RARE O
and O
sequenced O
a O
NUM O
- O
bp O
Bacillus O
subtilis O
( O
RARE O
) O
DNA O
fragment O
RARE O
between O
the O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
genes I-GENE
RARE O
about O
NUM O
degrees O
on O
the O
RARE O
. O

RARE O
RARE O
possesses O
two O
genes O
encoding O
homologs O
of O
the O
major I-GENE
RARE I-GENE
membrane I-GENE
protein I-GENE
, O
ALL_CAP I-GENE
. O

Expression O
of O
RARE I-GENE
was O
toxic O
to O
E O
. O
coli O
when O
the O
RARE O
RARE I-GENE
gene I-GENE
was O
present O
. O

In O
agreement O
with O
previous O
in O
vitro O
data O
, O
we O
have O
shown O
that O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
' I-GENE
are O
able O
to O
form O
both O
homodimers O
( O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
and O
ALL_CAP O
'- O
ALL_CAP O
RARE O
and O
a O
RARE O
( O
ALL_CAP I-GENE
- O
ALL_CAP O
RARE O

Lyn I-GENE
kinase I-GENE
immunoprecipitated O
from O
lysates O
of O
irradiated O
ALL_CAP O
RARE O
RARE O
RARE O
a O
full O
- O
length O
RARE I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
)- O
Lyn I-GENE
fusion O
protein O
- O
RARE O
recombinant I-GENE
human I-GENE
p34cdc2 I-GENE
on O
tyrosine O
NUM O
. O

Mutations O
within O
RARE O
region O
2 O
( O
NUM O
) O
of O
E1A I-GENE
that O
inhibit O
the O
binding O
of O
E1A I-GENE
to O
the O
RARE I-GENE
gene I-GENE
product I-GENE
( O
pRb I-GENE
) O
further O
RARE O
the O
RARE O
of O
transcription O
from O
the O
PEPCK I-GENE
promoter I-GENE
by O
2 O
3 O
- O
RARE O
compared O
with O
wild I-GENE
type I-GENE
E1A I-GENE
. O

Using O
autoantibodies O
from O
a O
RARE O
' O
s O
RARE O
patient O
, O
we O
have O
previously O
identified O
a O
NUM O
- O
kDa O
peripheral O
membrane O
protein O
associated O
with O
the O
cytosolic O
face O
of O
the O
RARE O
- O
RARE O
( O
RARE O
, O
ALL_CAP O
., O
RARE O
, O
B O
. O

RARE O
from O
two O
proline O
- O
rich O
regions O
( O
amino O
RARE O
1 O
- O
117 O
and O
239 O
- O
270 O
RARE O
NUM I-GENE
contains O
a O
very O
high O
frequency O
of O
RARE O
repeats O
, O
characteristic O
of O
alpha O
- O
helices O
that O
form O
RARE O
RARE O
- O
RARE O
RARE O
. O
NUM I-GENE
also O
includes O
the O
sequence O
ALL_CAP O
( O
amino O
RARE O
NUM O
- O
NUM O
RARE O
a O
motif O
found O
in O
the O
RARE I-GENE
family I-GENE
of O
RARE O
proteins O
present O
in O
RARE O
granules O
of O
RARE O
cells O
. O

Binding O
RARE O
and O
modulation O
of O
the O
ALL_CAP I-GENE
- I-GENE
I I-GENE
promoter I-GENE
activity O
by O
RARE O
- O
and O
RARE O
of O
nuclear O
receptors O
. O

They O
were O
found O
to O
stimulate O
RARE O
RARE O
concentrations O
the O
turnover O
of O
RARE O
labeled O
RARE O
, O
RARE O
, O
and O
RARE O
. O

There O
is O
growing O
evidence O
that O
mammalian I-GENE
AMP I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
plays O
a O
role O
in O
RARE O
cells O
from O
stresses O
that O
cause O
ATP O
depletion O
by O
switching O
off O
ATP O
- O
RARE O
biosynthetic O
pathways O
. O

RARE O
- O
RARE O
suppression O
of O
RARE O
of O
SREBP I-GENE
- I-GENE
1 I-GENE
was O
found O
to O
be O
dependent O
on O
the O
extreme O
ALL_CAP O
- O
terminal O
region O
( O
RARE O
NUM O
to O
the O
ALL_CAP O
terminus O
RARE O
which O
exists O
in O
two O
forms O
RARE O
a O
result O
of O
RARE O
RARE O
. O

RARE O
. O

EMSA O
competition O
experiments O
showed O
that O
mutations O
within O
the O
direct O
repeats O
failed O
to O
compete O
RARE O
binding O
of O
the O
nuclear O
proteins O
to O
labeled O
wild O
type O
RARE O
. O

Transcription O
from O
the O
promoter O
containing O
the O
RARE O
direct O
repeats O
was O
increased O
greatly O
, O
consistent O
with O
the O
conclusion O
that O
these O
motifs O
functions O
in O
vivo O
to O
repress O
ALL_CAP I-GENE
gene I-GENE
RARE O
. O

However O
, O
a O
> O
10 O
- O
RARE O
increase O
in O
NUM I-GENE
activity O
in O
each O
PKC I-GENE
beta I-GENE
RARE O
was O
shown O
by O
immunoprecipitation O
with O
anti I-GENE
- I-GENE
NUM I-GENE
monoclonal I-GENE
antibody I-GENE
followed O
by O
either O
immune O
complex O
kinase O
assay O
or O
by O
in O
gel O
kinase O
assay O
. O

Sequence O
analysis O
of O
this O
NUM O
- O
bp O
NUM I-GENE
enhancer I-GENE
revealed O
several O
sequence O
motifs O
similar O
to O
motifs O
present O
within O
the O
regulatory O
region O
of O
the O
RARE I-GENE
protein I-GENE
gene I-GENE
, O
another O
cartilage O
gene O
. O

RARE O
- O
dependent O
activation O
of O
the O
tissue I-GENE
RARE I-GENE
promoter I-GENE
depends O
on O
both O
a O
proximal O
regulatory O
region O
containing O
sequences O
highly O
RARE O
between O
the O
human O
and O
the O
mouse I-GENE
tissue I-GENE
RARE I-GENE
promoters I-GENE
and O
a O
distal O
region O
that O
includes O
a O
NUM O
- O
RARE O
RARE O
retinoid O
response O
element O
( O
NUM O
). O
NUM O
contains O
three O
RARE O
RARE O
- O
sites O
( O
two O
canonical O
and O
one O
non O
- O
canonical O
) O
in O
a O
NUM I-GENE
/ O
NUM I-GENE
motif O
that O
bind O
both O
RAR I-GENE
RARE O
RXR I-GENE
RARE O
and O
RXR I-GENE
homodimers I-GENE
. O

Significantly O
, O
ALL_CAP I-GENE
is O
capable O
of O
specifically O
RARE O
NUM O
in O
a O
RARE I-GENE
eIF I-GENE
- I-GENE
2alpha I-GENE
peptide I-GENE
, O
a O
key O
characteristic O
of O
the O
eIF I-GENE
- I-GENE
2alpha I-GENE
kinase I-GENE
family I-GENE
. O

RARE I-GENE
RARE I-GENE
constitute O
a O
family O
of O
synaptic O
proteins O
that O
participate O
in O
the O
RARE O
of O
RARE O
release O
. O

Electrophoretic O
mobility O
shift O
assays O
using O
crude O
extracts O
from O
NUM O
cells O
revealed O
the O
binding O
of O
a O
RARE O
( O
s O
) O
of O
the O
Ets I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
to O
the O
NUM I-GENE
ALL_CAP I-GENE
, O
RARE O
RARE O
RARE O
the O
interaction O
of O
two O
members O
of O
the O
NUM I-GENE
family I-GENE
, O
NUM I-GENE
and O
Sp3 I-GENE
, O
with O
the O
adjacent O
ALL_CAP O
box O
. O

ALL_CAP I-GENE
and O
cellular O
AP I-GENE
- I-GENE
1 I-GENE
RARE I-GENE
RARE I-GENE
, O
such O
RARE O
c I-GENE
- I-GENE
Fos I-GENE
, O
have O
homologous O
DNA O
- O
binding O
domains O
, O
and O
their O
DNA O
- O
binding O
RARE O
overlap O
. O

This O
result O
suggested O
that O
mutant O
NUM O
has O
diminished O
RARE O
- O
binding O
activity O
. O

ALL_CAP O
cross O
- O
linking O
experiments O
demonstrated O
that O
HSV O
infection O
caused O
RARE O
binding O
of O
protein O
factors O
, O
including O
the O
NUM I-GENE
- I-GENE
kDa I-GENE
RARE I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
RARE O
to O
RARE O
( O
A O
) O
site O
RNAs O
from O
virus O
genes O
of O
all O
temporal O
classes O
and O
that O
this O
RARE O
binding O
required O
RARE O
of O
NUM I-GENE
. O

ALL_CAP I-GENE
- I-GENE
NUM I-GENE
is O
RARE O
in O
RARE O
and O
is O
not O
RARE O
by O
any O
of O
the O
stimuli O
tested O
. O

We O
show O
here O
that O
these O
Jun I-GENE
/ O
NUM I-GENE
RARE O
are O
potent O
RARE O
of O
AP1 I-GENE
sites I-GENE
and O
that O
they O
can O
cooperate O
with O
c I-GENE
- I-GENE
Ha I-GENE
- I-GENE
Ras I-GENE
to O
induce O
RARE O
. O

In O
RARE O
HeLa O
cells O
, O
RARE O
of O
luciferase I-GENE
activity O
was O
RARE O
RARE O
the O
beginning O
of O
DNA O
RARE O
and O
was O
dependent O
on O
the O
presence O
of O
an O
E2F I-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
the O
NUM I-GENE
. I-GENE
1 I-GENE
promoter I-GENE
. O

RARE O
transient O
transfection O
studies O
in O
NUM O
cells O
, O
we O
have O
shown O
that O
deletion O
of O
the O
factor I-GENE
VIII I-GENE
promoter I-GENE
sequences I-GENE
distal O
to O
nucleotide O
- O
NUM O
results O
in O
a O
significant O
but O
small O
increase O
in O
promoter O
activity O
. O

We O
constructed O
a O
yeast O
reporter O
RARE O
containing O
the O
lacZ I-GENE
gene I-GENE
under O
the O
control O
of O
the O
CYC1 I-GENE
promoter I-GENE
associated O
with O
three O
copies O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
. O

If O
ALL_CAP I-GENE
K I-GENE
is O
a O
transcription O
factor O
, O
then O
interactions O
with O
the O
RNA I-GENE
polymerase I-GENE
II I-GENE
transcription O
apparatus O
are O
predicted O
. O

A O
developmentally O
regulated O
4 O
. O
6 O
kb O
mRNA O
is O
RARE O
on O
Northern O
blots O
of O
RARE O
RNA O
using O
the O
X O
. O
RARE O
cDNA O
. O

Sequence O
conservation O
is O
greatest O
RARE O
residues O
RARE O
near O
the O
RARE O
centers O
of O
the O
RARE I-GENE
and O
pol I-GENE
domains I-GENE
of O
the O
E I-GENE
. I-GENE
coli I-GENE
DNA I-GENE
polymerase I-GENE
I I-GENE
RARE O
. O

Despite O
the O
favourable O
RARE O
history O
of O
acute O
ALL_CAP O
, O
mild O
, O
moderate O
, O
and O
severe O
RARE O
changes O
were O
shown O
to O
appear O
RARE O
RARE O
- O
adhesive O
and O
RARE O
processes O
, O
RARE O
cysts O
, O
RARE O
, O
which O
result O
in O
RARE O
epilepsy O
, O
RARE O
, O
etc O
. O

These O
findings O
suggest O
that O
the O
increase O
in O
V O
NUM O
may O
have O
been O
a O
consequence O
of O
the O
increase O
in O
ALL_CAP O
NUM O
rather O
than O
a O
response O
to O
the O
procedure O
itself O
. O

Several O
RARE O
exhibit O
a O
high O
degree O
of O
temporal O
RARE O
RARE O
RARE O
RARE O
RARE O
potency O
( O
RARE O
. O
g O
., O
interleukin I-GENE
- I-GENE
1 I-GENE
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
], O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
RARE O
TNF I-GENE
- I-GENE
alpha I-GENE
RARE O

As O
pH O
and O
RARE I-GENE
can O
also O
affect O
mixed O
venous O
CO2 O
content O
, O
the O
effect O
on O
ALL_CAP O
was O
also O
assessed O
. O

No O
difference O
in O
elastin I-GENE
peptide I-GENE
concentration O
was O
observed O
between O
RARE O
patients O
and O
control O
subjects O
( O
mean O
+/- O
SD O
= O
2 O
. O
NUM O
+/- O
1 O
. O
18 O
micrograms O
/ O
ml O
in O
patients O
versus O
2 O
. O
NUM O
+/- O
1 O
. O
NUM O
micrograms O
/ O
ml O
in O
RARE O
and O
2 O
. O
NUM O
+/- O
1 O
. O
20 O
micrograms O
/ O
ml O
in O
RARE O
RARE O
). O

Identification O
of O
this O
region O
RARE O
the O
E I-GENE
. I-GENE
coli I-GENE
RARE I-GENE
gene I-GENE
was O
confirmed O
by O
RARE O
RARE O
of O
a O
yeast I-GENE
ALL_CAP I-GENE
kinase I-GENE
RARE O
- O
RARE O
mutant O
and O
by O
in O
vitro O
enzyme O
assay O
of O
the O
RARE I-GENE
kinase I-GENE
activity O
in O
cell O
extracts O
of O
E O
. O
coli O
by O
use O
of O
RARE I-GENE
- O
RARE O
plasmids O
. O

The O
structural O
gene O
RARE O
RARE I-GENE
- I-GENE
and I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
containing I-GENE
RARE I-GENE
oxidase I-GENE
( O
ALL_CAP I-GENE
) O
and O
an O
unknown O
RARE I-GENE
oxidase I-GENE
gene I-GENE
have O
been O
RARE O
RARE O
NUM O
. O
9 O
min O
on O
the O
Escherichia O
coli O
RARE O
. O

This O
interaction O
is O
RARE O
by O
the O
NUM I-GENE
domain I-GENE
of O
Crk I-GENE
and O
can O
be O
inhibited O
with O
a O
RARE O
containing O
the O
Crk I-GENE
- O
NUM I-GENE
binding O
motif O
. O

Consistent O
with O
ErbB I-GENE
- I-GENE
2 I-GENE
being O
a O
shared O
receptor O
subunit O
, O
its O
tyrosine O
RARE O
was O
increased O
by O
both O
heterologous O
ligands O
and O
it O
RARE O
a O
RARE O
- O
RARE O
effect O
of O
ALL_CAP I-GENE
on O
ALL_CAP I-GENE
binding O
. O

Identification O
of O
a O
consensus O
RARE I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
RARE I-GENE
site I-GENE
unique O
to O
the O
nuclear O
form O
of O
human I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
. O

The O
cDNA O
corresponding O
to O
the O
NUM I-GENE
gene I-GENE
was O
isolated O
by O
RARE O
RARE O
of O
a O
mutant O
yeast O
RARE O
RARE O
in O
ALL_CAP I-GENE
activity O
( O
RARE O
, O
D O
., O
RARE O
, O
F O
., O
and O
RARE O
, O
F O
. O

The O
isolated O
RARE I-GENE
fragments O
of O
VEGF I-GENE
were O
compared O
with O
respect O
to O
RARE O
binding O
, O
interaction O
with O
RARE O
VEGF I-GENE
receptors I-GENE
, O
and O
ability O
to O
promote O
endothelial O
cell O
RARE O
. O

VDR I-GENE
/ O
RXR I-GENE
RARE O
RARE O
to O
the O
RARE O
and O
to O
NUM O
and O
NUM O
using O
the O
electrophoretic O
mobility O
shift O
assay O
. O

The O
members O
of O
the O
Myb I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
are O
defined O
by O
homology O
in O
the O
DNA O
- O
binding O
domain O
; O
all O
bind O
the O
Myb I-GENE
- I-GENE
binding I-GENE
site I-GENE
( O
ALL_CAP I-GENE
) O
sequence O
( O
ALL_CAP O
( O
A O
/ O
G O
) O
C O
( O
A O
/ O
C O
/ O
G O
) O
ALL_CAP O
( O
G O
/ O
A O
RARE O

In O
contrast O
, O
when O
the O
isoform O
containing O
the O
C O
NUM O
domain O
RARE O
directly O
to O
the O
NUM O
RARE O
( O
IgE I-GENE
RARE I-GENE
) O
is O
RARE O
in O
the O
NUM O
cell O
line O
, O
it O
is O
degraded O
RARE O
, O
suggesting O
a O
cell O
line O
- O
dependent O
RARE O
of O
RARE O
. O

Human I-GENE
RARE I-GENE
immediate I-GENE
- I-GENE
early I-GENE
protein I-GENE
IE2 I-GENE
RARE O
a O
transcriptional O
repression O
domain O
to O
p53 I-GENE
. O

The O
RARE O
of O
action O
of O
C I-GENE
/ I-GENE
EBP I-GENE
family I-GENE
members I-GENE
may O
be O
derived O
from O
the O
characteristics O
of O
each O
factor O
, O
including O
the O
RARE O
profiles O
, O
the O
DNA O
binding O
affinities O
, O
the O
RARE O
, O
and O
so O
on O
, O
in O
addition O
to O
the O
DNA O
binding O
RARE O
. O

The O
antibodies O
inhibited O
specifically O
the O
transcription O
of O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
promoter O
in O
vitro O
. O

RARE O
analysis O
demonstrated O
the O
presence O
of O
ALL_CAP I-GENE
polypeptide I-GENE
in O
nuclei O
after O
the O
RARE O
nuclear O
division O
RARE O
, O
suggesting O
that O
nuclear O
accumulation O
of O
ALL_CAP I-GENE
is O
important O
RARE O
the O
coordinate O
RARE O
RARE O
of O
DNA O
replication O
- O
related O
genes O
carrying O
ALL_CAP O
sequences O
. O

A O
DNA O
fragment O
carrying O
1 O
, O
NUM O
nucleotides O
derived O
from O
the O
5 O
'- O
flanking O
region O
of O
the O
NUM I-GENE
gene I-GENE
was O
enough O
RARE O
MC O
induction O
. O

This O
result O
supports O
the O
RARE O
that O
the O
beta O
' O
subunit O
plays O
an O
essential O
role O
in O
RARE O
the O
progress O
of O
transcription O
RARE O
. O

Two O
ALL_CAP I-GENE
regions I-GENE
with O
putative O
NLS O
RARE O
amino O
acid O
( O
AA O
) O
RARE O
: O
NLS O
- O
B O
( O
AA O
NUM O
- O
NUM O
) O
and O
NLS O
- O
C O
( O
AA O
NUM O
- O
NUM O
)] O
were O
each O
shown O
to O
independently O
localize O
the O
beta I-GENE
- I-GENE
RARE I-GENE
extensively O
(> O
NUM O
%) O
to O
the O
nucleus O
of O
HeLa O
cells O
. O

The O
ALL_CAP I-GENE
gene I-GENE
was O
RARE O
in O
an O
E O
. O
coli O
- O
RARE O
RARE O
vector O
and O
was O
RARE O
both O
in O
a O
ALL_CAP I-GENE
deletion O
RARE O
of O
S O
. O
RARE O
and O
in O
a O
NUM O
- O
RARE O
RARE O
, O
L O
. O
lactis O
NUM O
. O

The O
genome O
of O
all O
RARE O
consists O
of O
two O
identical O
RNAs O
RARE O
RARE O
near O
their O
5 O
' O
end O
. O

The O
extraction O
recovery O
of O
RARE O
B O
from O
the O
RARE O
RARE O
is O
RARE O
than O
NUM O
% O
over O
the O
RARE O
RARE O
range O
. O

RARE I-GENE
- I-GENE
R I-GENE
RARE I-GENE
inhibited O
Epo I-GENE
- O
RARE O
parental O
UT O
- O
7 O
cell O
growth O
, O
but O
not O
that O
of O
cells O
of O
clone O
12 O
, O
suggesting O
that O
the O
RARE I-GENE
- I-GENE
R I-GENE
is O
able O
to O
induce O
human O
UT O
- O
7 O
cell O
RARE O
. O

The O
frequency O
of O
RARE O
that O
led O
to O
transcription O
of O
the O
lacZ I-GENE
gene I-GENE
was O
estimated O
to O
be O
NUM O
. O
5 O
% O
of O
all O
RARE O
, O
of O
which O
14 O
% O
were O
RARE O
on O
differentiation O
of O
NUM O
cells O
towards O
neutrophils O
. O

The O
sequence O
and O
isolated O
cDNAs O
will O
provide O
useful O
RARE O
RARE O
studying O
the O
RARE O
of O
NUM I-GENE
in O
the O
mouse O
, O
and O
RARE O
testing O
the O
importance O
of O
the O
evolutionarily O
RARE O
domains O
. O

A O
study O
was O
performed O
to O
compare O
the O
ALL_CAP O
and O
ALL_CAP O
II O
RARE O
with O
gas O
chromatographic O
/ O
mass O
RARE O
( O
ALL_CAP O
/ O
MS O
) O
analysis O
of O
RARE O
metabolites O
on O
urine O
using O
samples O
obtained O
from O
a O
clinical O
study O
. O

Interaction O
of O
the O
Fur I-GENE
repressor I-GENE
with O
a O
NUM O
- O
bp O
fragment O
RARE O
the O
ALL_CAP I-GENE
promoter I-GENE
was O
demonstrated O
in O
vivo O
by O
the O
Fur I-GENE
titration O
assay O
and O
confirmed O
in O
vitro O
by O
gel O
retardation O
experiments O
with O
a O
partially O
RARE O
Fur I-GENE
preparation O
. O

This O
protein O
encoded O
by O
this O
cDNA O
, O
which O
we O
have O
termed O
NUM I-GENE
( O
RARE O
TPR O
- O
containing O
, O
NUM I-GENE
- I-GENE
binding I-GENE
RARE I-GENE
RARE O
is O
RARE O
predominantly O
in O
the O
nucleus O
and O
is O
highly O
RARE O
in O
evolution O
. O

Both O
mutant O
receptors O
were O
RARE O
on O
the O
cell O
surface O
and O
RARE O
insulin I-GENE
normally O
, O
but O
showed O
markedly O
impaired O
autophosphorylation O
in O
response O
to O
insulin I-GENE
. O

ALL_CAP O
ALL_CAP O
. O

Taken O
together O
, O
our O
results O
indicate O
that O
thrombin I-GENE
- O
RARE O
vascular O
RARE O
muscle O
RARE O
is O
delayed O
and O
requires O
the O
de O
RARE O
RARE O
of O
one O
or O
more O
autocrine O
RARE O
. O

Transcription O
from O
adenovirus I-GENE
E2 I-GENE
- I-GENE
early I-GENE
promoter I-GENE
is O
RARE O
by O
a O
unique O
RARE O
of O
four O
cis O
- O
acting O
elements O
which O
include O
an O
atypical O
TBP I-GENE
site I-GENE
, O
two O
E2F I-GENE
sites I-GENE
present O
in O
an O
inverted O
orientation O
relative O
to O
each O
other O
, O
and O
an O
ATF I-GENE
site I-GENE
. O

Furthermore O
, O
we O
showed O
that O
the O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
/ O
RARE I-GENE
gamma I-GENE
( O
IFN I-GENE
gamma I-GENE
) O
response O
element O
in O
the O
IRF I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
( O
IR I-GENE
/ O
IRF I-GENE
- I-GENE
1 I-GENE
RARE O
which O
contains O
a O
Stat I-GENE
- I-GENE
binding I-GENE
site I-GENE
and O
an O
adjacent O
ALL_CAP O
- O
like O
site O
, O
also O
makes O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
- O
RARE O
binding O
complexes O
similar O
to O
ALL_CAP O
- O
IL6 I-GENE
- O
RARE O
. O

A O
second O
peptide O
( O
amino O
RARE O
58 O
- O
77 O
) O
also O
RARE O
p21 I-GENE
- O
activity O
, O
but O
this O
peptide O
did O
not O
affect O
the O
ability O
of O
p21 I-GENE
to O
interact O
with O
RARE I-GENE
E I-GENE
/ O
Cdk2 I-GENE
. O

A O
p21 I-GENE
peptide I-GENE
spanning O
amino O
RARE O
139 O
- O
NUM O
was O
found O
to O
bind O
PCNA I-GENE
in O
a O
filter O
binding O
assay O
and O
this O
peptide O
suppressed O
recombinant O
p21 I-GENE
- O
PCNA I-GENE
interaction O
. O

Results O
were O
supported O
by O
the O
agar O
diffusion O
method O
RARE O
Y O
. O
RARE O
, O
whereas O
inhibition O
activity O
was O
not O
found O
RARE O
A O
. O
RARE O
. O

ALL_CAP O
8 O
mg O
RARE O
days O
2 O
- O
3 O
, O
and O
8 O
mg O
RARE O
RARE O
days O
4 O
- O
5 O
and O
RARE O
NUM O
- O
NUM O
mg O
RARE O
days O
2 O
- O
5 O
and O
2 O
) O
ALL_CAP O
NUM O
mg O
/ O
RARE O
NUM O
mg O
i O
. O
v O
. O
before O
ALL_CAP O
and O
ALL_CAP O
20 O
mg O
p O
. O
RARE O
. O
after O
4 O
and O
8 O
h O
respectively O
. O

The O
dynamic O
properties O
of O
this O
protein O
fragment O
were O
measured O
and O
analyzed O
using O
both O
RARE O
and O
RARE O
models O
of O
RARE O
motion O
. O

RARE O
of O
the O
human I-GENE
N I-GENE
- I-GENE
ras I-GENE
RARE I-GENE
NUM I-GENE
sequence I-GENE
with O
RARE O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
)- O
7 O
, O
8 O
- O
RARE O
- O
9 O
, O
10 O
- O
RARE O
- O
7 O
, O
8 O
, O
9 O
, O
10 O
- O
RARE O
RARE O
a O
] O
RARE O
: O
structural O
RARE O
of O
the O
RARE O
ALL_CAP O
( O
NUM O
, O
2 O
) O
RARE O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
)- O
NUM O
RARE O
10 O
RARE O
7 O
, O
8 O
, O
9 O
, O
10 O
- O
RARE O
RARE O
a O
] O
RARE O
RARE O
2 O
'- O
RARE O
RARE O
from O
NUM O
NMR O
. O

Isolation O
by O
PCR O
of O
a O
cDNA O
clone O
from O
RARE O
RARE O
with O
RARE O
to O
RARE O
and O
RARE I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
. O

This O
fragment O
can O
bind O
several O
RARE O
- O
acting O
factors O
in O
vitro O
, O
including O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
and O
members O
of O
the O
Ets I-GENE
family I-GENE
. O

RARE O
of O
peripheral O
RARE O
T O
cells O
from O
young O
subjects O
to O
ALL_CAP I-GENE
or O
cross O
- O
RARE O
anti I-GENE
- I-GENE
CD3 I-GENE
monoclonal I-GENE
antibodies I-GENE
RARE O
rapid O
increases O
in O
ALL_CAP I-GENE
and O
MEK I-GENE
enzymatic O
activity O
. O

These O
different O
observations O
RARE O
a O
heterozygosity O
of O
the O
A O
RARE O
G O
mutation O
RARE O
RARE O
beta O
77 O
, O
RARE O
RARE O
RARE O
a O
deletion O
comparable O
to O
that O
of O
RARE I-GENE
RARE I-GENE
or I-GENE
RARE I-GENE
, O
or O
a O
beta I-GENE
- I-GENE
globin I-GENE
gene I-GENE
duplication O
, O
and O
point O
to O
a O
RARE O
RARE O
of O
RARE I-GENE
RARE I-GENE
RARE I-GENE
. O

This O
is O
the O
RARE O
description O
, O
to O
our O
knowledge O
, O
of O
regulatory O
elements O
that O
control O
RARE O
of O
a O
gene O
encoding O
a O
B7 I-GENE
RARE I-GENE
molecule I-GENE
. O

DNA I-GENE
- I-GENE
STAT I-GENE
complexes I-GENE
were O
detected O
in O
all O
RARE I-GENE
/ O
Abl I-GENE
- O
transformed O
cell O
lines O
and O
they O
were O
RARE O
by O
antibodies O
against O
STAT1 I-GENE
and O
STAT5 I-GENE
. O

When O
overexpressed O
in O
an O
appropriate O
cell O
line O
, O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
prevented O
RARE I-GENE
B I-GENE
- O
dependent O
RARE O
in O
transient O
reporter O
gene O
assays O
in O
a O
fashion O
similar O
to O
the O
structurally O
related O
protein O
, O
Bcl I-GENE
- I-GENE
3 I-GENE
. O

T O
cell O
leukemia O
- O
associated O
human O
Notch I-GENE
/ O
translocation O
- O
associated O
Notch I-GENE
homologue O
has O
I I-GENE
RARE I-GENE
B I-GENE
- O
like O
activity O
and O
physically O
interacts O
with O
nuclear I-GENE
factor I-GENE
- I-GENE
RARE I-GENE
B I-GENE
proteins O
in O
T O
cells O
. O

RARE O
RARE O
in O
RARE O
virus O
: O
identification O
of O
3C I-GENE
- I-GENE
like I-GENE
protease I-GENE
RARE O
sites O
by O
in O
vitro O
mutagenesis O
. O

The O
RARE I-GENE
NUM I-GENE
( O
NUM I-GENE
RARE O
RARE O
light I-GENE
chain I-GENE
RARE I-GENE
region I-GENE
glycosylation O
, O
exhibited O
RARE O
that O
were O
comparable O
to O
that O
of O
chimeric I-GENE
NUM I-GENE
( O
NUM I-GENE
RARE O
which O
was O
shown O
previously O
to O
have O
antigen O
- O
binding O
properties O
similar O
to O
its O
murine O
RARE O
, O
suggesting O
that O
the O
ALL_CAP O
- O
RARE O
RARE O
found O
in O
NUM I-GENE
are O
not O
necessary O
RARE O
antigen O
binding O
. O

An O
apparent O
N O
- O
terminal O
transit O
peptide O
in O
the O
coding O
region O
and O
a O
3 O
' O
RARE O
( O
A O
) O
RARE O
exist O
in O
the O
cDNA O
clone O
indicated O
that O
this O
chloroplast O
protein O
RARE O
nuclear O
encoded O
. O

Deletion O
analysis O
of O
ALL_CAP I-GENE
promoter I-GENE
- O
chloramphenicol I-GENE
RARE I-GENE
constructs O
demonstrates O
that O
an O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
within O
the O
proximal O
promoter O
RARE O
NUM O
to O
- O
NUM O
nt O
) O
contributes O
to O
NUM O
% O
of O
the O
level O
of O
RARE I-GENE
gene I-GENE
RARE O
. O

Thus O
, O
a O
critical O
question O
is O
how O
ALL_CAP I-GENE
proteins I-GENE
select O
the O
correct O
sets O
of O
target O
genes O
in O
vivo O
. O

NUM I-GENE
, O
a O
dominant O
activated O
form O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
NUM I-GENE
, O
stimulates O
both O
RARE O
growth O
and O
RARE O
of O
a O
transcriptional O
reporter O
ALL_CAP I-GENE
( O
ALL_CAP I-GENE
RARE O
lacZ I-GENE
but O
does O
not O
induce O
the O
RARE I-GENE
RARE I-GENE
reporter I-GENE
NUM I-GENE
:: O
lacZ I-GENE
. O

Moreover O
, O
the O
Rho I-GENE
family I-GENE
protein I-GENE
Cdc42 I-GENE
, O
a O
RARE O
RARE I-GENE
G I-GENE
protein I-GENE
, O
is O
also O
a O
potent O
regulator O
of O
RARE O
growth O
and O
ALL_CAP I-GENE
( O
ALL_CAP I-GENE
RARE O
lacZ I-GENE
RARE O
in O
S O
. O
cerevisiae O
. O

Each O
RARE O
contained O
a O
complex O
of O
NUM I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
and O
CBF1 I-GENE
. O

This O
region O
includes O
ALL_CAP I-GENE
, O
a O
structural O
gene O
previously O
shown O
to O
be O
required O
RARE O
ST O
biosynthesis O
, O
and O
NUM O
additional O
closely O
RARE O
transcripts O
ranging O
in O
size O
from O
NUM O
. O
6 O
to O
7 O
. O
2 O
kb O
that O
are O
RARE O
RARE O
only O
under O
ST O
- O
producing O
conditions O
. O

RARE O
RARE O
of O
the O
wild I-GENE
- I-GENE
type I-GENE
RARE I-GENE
and O
the O
RARE I-GENE
- O
ALL_CAP I-GENE
fusion O
protein O
were O
determined O
by O
immunofluorescence O
of O
ALL_CAP O
3T3 O
cells O
that O
RARE O
wild O
- O
type O
or O
fusion O
protein O
. O

RARE O
- O
RARE O
RARE O
did O
not O
significantly O
affect O
RARE O
variables O
in O
either O
group O
. O

We O
report O
the O
isolation O
of O
human O
cDNAs O
homologous O
to O
the O
Drosophila I-GENE
RARE I-GENE
( O
RARE I-GENE
) O
segment O
- O
polarity O
gene O
. O

Escherichia O
coli O
NUM O
( O
NUM O
) O
ALL_CAP O
, O
RARE O
a O
recombinant O
RARE O
containing O
the O
catalase I-GENE
- O
peroxidase I-GENE
gene O
, O
produced O
a O
large O
amount O
of O
proteins O
that O
RARE O
- O
RARE O
on O
SDS O
/ O
PAGE O
with O
the O
RARE O
enzyme O
. O

NUM O
+ O
decreased O
NUM O
+ O
binding O
in O
NUM I-GENE
beta I-GENE
but O
it O
did O
not O
influence O
binding O
to O
NUM I-GENE
, O
suggesting O
that O
the O
NUM O
+ O
binding O
site O
was O
distinct O
from O
and O
independent O
of O
the O
two O
NUM O
+ O
binding O
domains O
. O

Cdk2 I-GENE
formed O
a O
complex O
with O
RARE I-GENE
NUM I-GENE
in O
this O
RARE O
. O

The O
Cdk2 I-GENE
- O
RARE I-GENE
- I-GENE
NUM I-GENE
complex O
did O
not O
phosphorylate O
any O
tested O
RARE O
, O
such O
RARE O
NUM I-GENE
histone I-GENE
, O
ALL_CAP I-GENE
, O
SV40 I-GENE
large I-GENE
T I-GENE
antigen I-GENE
, O
p53 I-GENE
, O
E2F I-GENE
- I-GENE
1 I-GENE
or O
a O
preparation O
of O
nuclear O
proteins O
from O
HeLa O
cells O
; O
in O
contrast O
, O
Cdk2 I-GENE
- O
RARE I-GENE
- I-GENE
E I-GENE
and O
Cdk2 I-GENE
- O
RARE I-GENE
- I-GENE
A I-GENE
RARE O
these O
proteins O
. O

Cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
( O
Cdk2 I-GENE
) O
forms O
an O
inactive O
complex O
with O
RARE I-GENE
NUM I-GENE
since O
Cdk2 I-GENE
associated O
with O
RARE I-GENE
NUM I-GENE
is O
not O
RARE O
by O
NUM I-GENE
- O
RARE I-GENE
- I-GENE
H I-GENE
. O

Two O
overlapping O
RARE O
contained O
the O
RARE O
RARE I-GENE
- I-GENE
2 I-GENE
gene I-GENE
composed O
of O
nine O
exons O
in O
a O
12 O
- O
kb O
region O
, O
with O
the O
placement O
of O
RARE O
RARE O
that O
observed O
in O
other O
mammalian I-GENE
ADH I-GENE
genes I-GENE
. O

RARE O
of O
CD40 I-GENE
RARE O
RARE O
- O
RARE O
lymphoma O
B O
cells O
from O
RARE O
RARE O
- O
and O
antigen O
receptor O
- O
triggered O
apoptosis O
by O
inhibiting O
activation O
of O
the O
cysteine I-GENE
protease I-GENE
NUM I-GENE
/ O
RARE I-GENE
and O
RARE O
of O
its O
substrate O
ALL_CAP I-GENE
. O

RARE I-GENE
T I-GENE
antigen I-GENE
was O
RARE O
by O
antibodies O
to O
RARE O
- O
RARE O
TBP I-GENE
, O
endogenous O
TBP I-GENE
, O
ALL_CAP I-GENE
( I-GENE
II I-GENE
) I-GENE
NUM I-GENE
, O
ALL_CAP I-GENE
( I-GENE
II I-GENE
) I-GENE
NUM I-GENE
, O
and O
ALL_CAP I-GENE
( I-GENE
II I-GENE
) I-GENE
NUM I-GENE
, O
under O
conditions O
where O
RARE I-GENE
- I-GENE
TFIID I-GENE
would O
be O
precipitated O
. O

Northern O
blot O
hybridization O
demonstrated O
that O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
was O
RARE O
in O
a O
wide O
range O
of O
human O
adult O
and O
RARE O
tissues O
. O

A O
human O
cytoplasmic O
RARE O
protein O
has O
been O
RARE O
that O
possesses O
the O
same O
structural O
arrangement O
of O
SH3 I-GENE
- O
NUM I-GENE
- O
SH3 I-GENE
domains O
RARE O
Grb2 I-GENE
. O

A O
direct O
role O
RARE O
sterol I-GENE
regulatory I-GENE
element I-GENE
binding I-GENE
protein I-GENE
in O
activation O
of O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
3 I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
A I-GENE
reductase I-GENE
gene I-GENE
. O

NUM I-GENE
/ I-GENE
NUM I-GENE
resides O
in O
the O
endoplasmic O
reticulum O
where O
it O
binds O
to O
MHC I-GENE
class I-GENE
I I-GENE
molecules I-GENE
, O
thereby O
preventing O
their O
RARE O
to O
the O
cell O
surface O
. O

When O
the O
ALL_CAP O
and O
ALL_CAP O
groups O
were O
compared O
, O
RARE O
levels O
were O
significantly O
RARE O
in O
the O
ALL_CAP O
- O
ALL_CAP O
+ O
group O
than O
in O
the O
ALL_CAP O
- O
ALL_CAP O
+ O
group O
. O

Among O
the O
NUM I-GENE
deletions O
, O
only O
one O
had O
a O
RARE O
transformation O
efficiency O
, O
while O
RARE O
transformed O
cells O
RARE O
least O
RARE O
efficiently O
RARE O
wild I-GENE
- I-GENE
type I-GENE
NUM I-GENE
. O

ORF I-GENE
NUM I-GENE
RARE O
with O
ORF I-GENE
NUM I-GENE
, O
which O
could O
generate O
a O
50 O
- O
amino O
- O
acid O
protein O
with O
a O
hydrophobic O
segment O
, O
did O
not O
transform O
cells O
when O
RARE O
into O
the O
RARE O
vector O
. O

Cloning O
of O
individual O
ALL_CAP O
domains O
upstream O
of O
a O
minimal O
promoter O
demonstrated O
that O
the O
ALL_CAP O
, O
ALL_CAP O
, O
and O
ALL_CAP O
domains O
, O
but O
not O
the O
ALL_CAP O
domain O
, O
are O
ALL_CAP O
responsive O
. O

NUM I-GENE
/ O
Cdc28 I-GENE
kinase O
is O
not O
required O
RARE O
the O
repression O
of O
ALL_CAP I-GENE
- I-GENE
binding I-GENE
factor I-GENE
transcriptional O
activity O
in O
NUM O
and O
M O
RARE O
. O

The O
RARE O
terminus O
of O
NUM I-GENE
is O
sufficient O
RARE O
interaction O
with O
NUM I-GENE
, O
and O
the O
RARE O
terminus O
of O
NUM I-GENE
is O
required O
RARE O
interaction O
with O
NUM I-GENE
. O

Multiple O
single O
- O
RARE O
cis O
elements O
are O
associated O
with O
activated O
chromatin O
of O
the O
human I-GENE
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
in O
vivo O
. O

A O
new O
ALL_CAP O
consensus O
sequence O
derived O
from O
this O
mutational O
analysis O
closely O
matches O
a O
consensus O
NUM I-GENE
binding I-GENE
site I-GENE
. O

We O
have O
isolated O
and O
analyzed O
human I-GENE
CTCF I-GENE
cDNA I-GENE
RARE O
and O
show O
here O
that O
the O
ubiquitously O
RARE O
11 I-GENE
- I-GENE
zinc I-GENE
- I-GENE
finger I-GENE
factor I-GENE
CTCF I-GENE
is O
an O
RARE O
highly O
RARE O
protein O
RARE O
93 O
% O
identity O
between O
avian O
and O
human O
amino O
acid O
sequences O
. O

Mutational O
analysis O
of O
the O
P2 I-GENE
- I-GENE
proximal I-GENE
CTCF I-GENE
binding I-GENE
site I-GENE
and O
transient O
- O
cotransfection O
experiments O
demonstrate O
that O
CTCF I-GENE
is O
a O
transcriptional O
repressor O
of O
the O
human I-GENE
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
. O

A O
RARE I-GENE
RARE I-GENE
RARE I-GENE
( O
RARE I-GENE
) O
mutant O
, O
NUM O
, O
of O
Saccharomyces O
cerevisiae O
was O
identified O
by O
its O
centromere O
( O
ALL_CAP O
) O
transcriptional O
readthrough O
RARE O
, O
suggesting O
RARE O
RARE O
integrity O
in O
vivo O
. O

The O
growth O
defect O
of O
a O
NUM I-GENE
NUM I-GENE
double I-GENE
mutant I-GENE
is O
RARE O
by O
a O
RARE O
- O
of O
- O
function O
mutation O
in O
the O
NUM I-GENE
- I-GENE
encoded I-GENE
protein I-GENE
kinase I-GENE
. O

NUM I-GENE
binds O
two O
sites O
in O
the O
NUM I-GENE
promoter I-GENE
in O
vivo O
specifically O
in O
RARE O
cells O
and O
RARE O
with O
AP1 I-GENE
to O
activate O
transcription O
. O

Expression O
of O
the O
RARE I-GENE
hydroxylase I-GENE
gene I-GENE
in O
RARE O
and O
kidneys O
of O
RARE O
is O
activated O
RARE O
birth O
and O
is O
RARE O
by O
glucocorticoids O
and O
cyclic O
AMP O
in O
the O
liver O
. O

We O
found O
that O
120 O
bp O
of O
the O
enhancer O
' O
s O
transcriptional O
core O
becomes O
DNase I-GENE
I I-GENE
RARE O
early O
in O
B O
- O
cell O
development O
. O

A O
developmentally O
modulated O
chromatin O
RARE O
RARE O
the O
mouse I-GENE
immunoglobulin I-GENE
RARE I-GENE
3 I-GENE
' I-GENE
enhancer I-GENE
. O

We O
report O
here O
the O
identification O
of O
a O
cDNA O
that O
encodes O
a O
new O
RARE O
of O
the O
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
( O
ALL_CAP I-GENE
) O
family O
of O
GTPase I-GENE
RARE O
. O

In O
this O
study O
, O
we O
further O
investigated O
the O
RARE O
of O
the O
RARE O
of O
the O
c I-GENE
- I-GENE
mos I-GENE
oncogene I-GENE
product I-GENE
, O
which O
is O
necessary O
RARE O
the O
activation O
of O
Cdc2 I-GENE
. O

The O
heterogeneity O
of O
bovine I-GENE
NUM I-GENE
RARE I-GENE
VIII I-GENE
. O

The O
ability O
of O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
to O
function O
RARE O
a O
transcriptional O
repressor O
may O
contribute O
to O
its O
ability O
to O
transform O
B O
lymphocytes O
in O
diffuse O
large O
cell O
lymphoma O
. O

RARE O
this O
ALL_CAP O
, O
together O
with O
its O
accompanying O
RARE O
sequences O
, O
between O
a O
heterologous O
promoter O
from O
SV40 O
and O
a O
CAT I-GENE
reporter I-GENE
gene I-GENE
resulted O
in O
marked O
inhibition O
of O
CAT I-GENE
protein I-GENE
production O
without O
a O
decrease O
in O
CAT I-GENE
mRNA I-GENE
. O

A O
secondary O
spread O
of O
an O
RARE O
RARE O
- O
resistant O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
to O
two O
other O
patients O
occurred O
within O
a O
RARE O
surgical O
RARE O
in O
RARE O
of O
isolation O
of O
a O
RARE O
index O
- O
patient O
immediately O
after O
RARE O
from O
a O
hospital O
in O
the O
RARE O
area O
. O

RARE O
temporal O
sclerosis O
was O
characterized O
by O
severe O
RARE O
RARE O
accompanied O
by O
RARE O
occurring O
in O
the O
NUM O
/ O
RARE O
( O
NUM O
patients O
, O
NUM O
%), O
RARE O
in O
the O
RARE O
gyrus O
( O
12 O
patients O
, O
NUM O
%), O
and O
in O
the O
NUM O
region O
( O
11 O
patients O
, O
NUM O
%). O

RARE O
temporal O
sclerosis O
. O

More O
specific O
adverse O
events O
, O
also O
frequently O
considered O
RARE O
dose O
- O
limiting O
RARE O
, O
include O
hypotension O
with O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
severe O
headache O
or O
RARE O
rash O
with O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
, O
and O
nasal O
RARE O
and O
RARE O
lesions O
with O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
. O

Therefore O
, O
magnetic O
resonance O
imaging O
was O
used O
to O
determine O
liver O
volume O
in O
pediatric O
and O
adolescent O
patients O
, O
in O
whom O
systemic O
clearance O
of O
three O
model O
RARE O
RARE O
RARE O
( O
NUM O
. O
03 O
mg O
/ O
kg O
RARE O
RARE O
( O
10 O
mg O
/ O
kg O
RARE O
and O
RARE O
RARE O
( O
ALL_CAP O
; O
NUM O
. O
5 O
mg O
/ O
kg O
)] O
was O
also O
determined O
. O

A O
mutational O
analysis O
has O
resolved O
a O
region O
of O
RARE O
amino O
RARE O
( O
amino O
RARE O
NUM O
- O
NUM O
) O
in O
the O
N O
- O
terminus O
of O
NUM I-GENE
that O
are O
important O
RARE O
RARE O
the O
DNA I-GENE
binding I-GENE
POU I-GENE
domain I-GENE
of O
Oct I-GENE
- I-GENE
1 I-GENE
or O
Oct I-GENE
- I-GENE
2 I-GENE
. O

RARE I-GENE
oxygenase I-GENE
1 I-GENE
is O
an O
essential O
enzyme O
in O
heme O
catabolism O
that O
RARE O
heme O
to O
form O
RARE O
, O
iron O
, O
and O
carbon O
RARE O
. O

An O
inactive O
analog O
of O
wortmannin O
, O
NUM O
, O
did O
not O
affect O
TCR I-GENE
/ O
CD3 I-GENE
- O
RARE O
NUM I-GENE
activation O
, O
and O
wortmannin O
had O
RARE O
effect O
on O
the O
activity O
of O
NUM I-GENE
when O
added O
directly O
to O
the O
in O
vitro O
assays O
. O

NUM O
RARE O
, O
shares O
NUM O
% O
identity O
with O
the O
analogous O
region O
of O
Xenopus O
RARE O
NUM I-GENE
and O
72 O
% O
identity O
with O
the O
product O
of O
the O
more O
distantly O
related O
human O
gene O
. O

The O
transcription O
RARE O
point O
of O
the O
proximal O
promoter O
RARE O
to O
that O
of O
mouse O
promoter O
NUM O
and O
lies O
within O
a O
RARE O
region O
of O
sequence O
. O

RARE O
in O
the O
Schizosaccharomyces O
pombe O
( O
RARE O
) O
cell O
RARE O
- O
controlling O
genes O
prevent O
the O
cell O
RARE O
progression O
. O

To O
determine O
the O
signal I-GENE
recognition I-GENE
RARE I-GENE
( O
SRP I-GENE
)- O
SRP I-GENE
receptor I-GENE
( O
RARE I-GENE
) O
RARE O
in O
Bacillus O
subtilis O
( O
RARE O
RARE O
we O
RARE O
the O
RARE I-GENE
RARE I-GENE
gene I-GENE
, O
which O
encodes O
a O
homologue O
of O
the O
mammalian I-GENE
SRP I-GENE
receptor I-GENE
alpha I-GENE
- I-GENE
subunit I-GENE
RARE O
RARE O
et O
al O
., O
DNA O
RARE O
. O

A O
novel O
gene O
designated O
RARE I-GENE
, O
which O
mapped O
to O
18 O
. O
8 O
min O
of O
the O
Escherichia O
coli O
K O
- O
12 O
genome O
, O
was O
shown O
to O
mediate O
resistance O
to O
chloramphenicol O
when O
it O
was O
RARE O
from O
a O
multicopy O
vector O
. O

In O
addition O
, O
5 O
' O
deletions O
removing O
all O
but O
NUM O
bp O
upstream O
of O
the O
transcription O
RARE O
point O
retained O
greater O
than O
NUM O
% O
promoter O
activity O
, O
suggesting O
that O
the O
- O
NUM O
hexamer O
was O
not O
essential O
RARE O
promoter O
activity O
. O

The O
DNA O
sequence O
immediately O
upstream O
from O
the O
- O
10 O
hexamer O
contained O
the O
RARE O
motif O
described O
RARE O
an O
extended O
- O
10 O
region O
in O
RARE O
promoters O
. O

An O
apparent O
RARE I-GENE
mRNA I-GENE
overexpression O
was O
not O
found O
in O
any O
of O
the O
positive O
leukemia O
cell O
lines O
, O
but O
was O
identified O
in O
the O
drug O
- O
resistant O
RARE O
of O
the O
cervix O
carcinoma O
cell O
line O
HeLa O
. O

We O
conclude O
from O
these O
studies O
that O
ALL_CAP I-GENE
may O
act O
RARE O
a O
positive O
regulator O
of O
RARE O
by O
preventing O
E I-GENE
protein I-GENE
homodimers I-GENE
from O
binding O
to O
muscle O
gene O
regulatory O
elements O
. O

The O
role O
of O
negative O
RARE O
such O
RARE O
NUM I-GENE
, O
RARE O
RARE O
RARE O
the O
previously O
described O
NUM I-GENE
gene I-GENE
, O
in O
RARE O
the O
promoter O
RARE O
of O
homologous O
RARE O
is O
discussed O
. O

Transcriptional O
RARE O
utilizing O
the O
POU I-GENE
domain I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
motif I-GENE
have O
been O
shown O
to O
form O
RARE O
- O
protein O
complexes O
dependent O
on O
the O
POU I-GENE
domain I-GENE
itself O
and O
its O
RARE O
recognition O
of O
various O
octamer O
sequence O
elements O
. O

We O
found O
RARE O
selective O
repair O
in O
DNA O
fragments O
within O
two O
RARE O
genes O
, O
DHFR I-GENE
and O
an O
unknown O
gene O
adjacent O
to O
DHFR I-GENE
. O

ALL_CAP O
ALL_CAP O
METHODS O
: O
RARE O
NUM O
ALL_CAP O
imaging O
was O
used O
to O
study O
the O
RARE O
, O
RARE O
, O
and O
dorsal O
portions O
of O
the O
ALL_CAP O
in O
14 O
patients O
with O
an O
RARE O
normal O
ALL_CAP O
and O
in O
five O
RARE O
RARE O
that O
had O
a O
normal O
ALL_CAP O
proved O
with O
dissection O
. O

In O
an O
effort O
to O
contribute O
to O
the O
transcript O
map O
of O
human O
RARE O
21 O
and O
the O
understanding O
of O
the O
pathophysiology O
of O
RARE O
21 O
, O
we O
have O
used O
RARE O
RARE O
to O
identify O
fragments O
of O
RARE O
21 O
genes O
. O

RARE O
populations O
of O
this O
RARE O
were O
RARE O
detected O
in O
RARE O
RARE O
in O
RARE O
1992 O
. O

The O
model O
RARE O
the O
RARE O
of O
RARE O
- O
RARE O
dynamics O
to O
provide O
reasonable O
predictions O
of O
population O
patterns O
. O

At O
RARE O
positions O
exhibiting O
the O
RARE I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
, O
we O
have O
found O
that O
the O
RARE O
of O
the O
RARE O
RARE O
develop O
RARE O
, O
in O
that O
neurons O
and O
RARE O
( O
RARE O
) O
cells O
appear O
but O
not O
RARE O
( O
RARE O
) O
and O
RARE O
( O
RARE O
) O
cells O
. O

Transcriptional O
blockade O
was O
reversed O
by O
RARE O
- O
transfections O
of O
a O
wild I-GENE
- I-GENE
type I-GENE
SRF I-GENE
RARE O
vector O
, O
but O
was O
not O
RARE O
by O
the O
RARE O
of O
other O
RARE O
factors O
, O
such O
RARE O
MyoD I-GENE
and O
RARE I-GENE
- I-GENE
NUM I-GENE
. O

The O
NUM I-GENE
promoter I-GENE
was O
identified O
and O
contained O
TATA O
, O
CAAT O
, O
ALL_CAP O
, O
and O
AP I-GENE
- I-GENE
2 I-GENE
elements I-GENE
; O
primer O
extension O
revealed O
ALL_CAP I-GENE
transcription O
initiation O
RARE O
NUM O
bp O
upstream O
from O
the O
NUM I-GENE
translational O
initiation O
site O
. O

Human I-GENE
ALL_CAP I-GENE
/ I-GENE
NUM I-GENE
gene I-GENE
, O
a O
novel O
RARE O
of O
the O
RARE I-GENE
anhydrase I-GENE
family I-GENE
: O
RARE O
and O
RARE O
to O
protein O
domain O
relationships O
. O

The O
RARE O
- O
intron O
distribution O
of O
RARE I-GENE
appears O
strikingly O
similar O
to O
that O
of O
the O
RARE I-GENE
gene I-GENE
in O
the O
regions O
encoding O
the O
RARE O
domains O
, O
with O
a O
divergent O
RARE O
in O
the O
other O
parts O
. O

DNA O
sequence O
analysis O
reveals O
that O
the O
gene O
encodes O
a O
protein O
highly O
homologous O
to O
rat I-GENE
NUM I-GENE
. O

The O
gene O
was O
RARE O
RARE O
an O
RARE O
1 O
. O
5 O
- O
kb O
mRNA O
in O
most O
RARE O
human O
cells O
/ O
tissues O
including O
RARE O
, O
RARE O
, O
liver O
, O
and O
colon O
. O

Both O
of O
these O
domains O
have O
striking O
sequence O
homology O
with O
human O
ALL_CAP I-GENE
and O
Drosophila O
ALL_CAP I-GENE
proteins O
. O

Promoter O
activity O
was O
high O
in O
cell O
lines O
that O
RARE O
high O
levels O
of O
endogenous O
NUM I-GENE
mRNA I-GENE
, O
RARE O
indicated O
by O
Northern O
blot O
analyses O
, O
and O
was O
significantly O
RARE O
when O
the O
promoter O
was O
truncated O
to O
- O
122 O
bp O
. O

We O
have O
obtained O
the O
human I-GENE
NUM I-GENE
receptor I-GENE
gene I-GENE
sequence I-GENE
and O
determined O
its O
RARE O
relative O
to O
NUM I-GENE
cDNA I-GENE
synthesized O
from O
peripheral O
RARE O
lymphocytes O
. O

Some O
users O
will O
RARE O
RARE O
with O
management O
measures O
, O
other O
users O
will O
RARE O
in O
response O
to O
education O
, O
but O
there O
will O
be O
another O
group O
who O
will O
only O
respond O
to O
RARE O
activities O
. O

Three O
separate O
activation O
subdomains O
, O
and O
one O
negative O
- O
acting O
region O
, O
which O
function O
in O
yeast O
were O
RARE O
in O
the O
RARE O
- O
terminal O
region O
of O
NUM I-GENE
. O

The O
front O
( O
F O
) O
interaction O
occurs O
RARE O
of O
the O
growing O
end O
of O
RNA O
. O

Collectively O
, O
these O
data O
indicate O
that O
ALL_CAP I-GENE
is O
a O
membrane O
- O
associated O
ALL_CAP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
RARE O
on O
the O
surface O
of O
normal O
human O
RARE O
RARE O
and O
RARE O
RARE O
cell O
lines O
. O

The O
corresponding O
gene O
was O
identified O
in O
the O
ALL_CAP O
data O
RARE O
by O
sequence O
alignment O
and O
termed O
NUM I-GENE
. O

The O
location O
of O
multiple O
NUM I-GENE
and O
NUM I-GENE
RARE I-GENE
sites I-GENE
RARE O
the O
extreme O
RARE O
terminus O
of O
the O
NUM I-GENE
is O
highly O
RARE O
of O
NUM I-GENE
- O
RARE O
RARE O
of O
RARE I-GENE
. O

This O
RARE O
could O
not O
be O
RARE O
modified O
by O
RARE O
RARE O
of O
STAT I-GENE
proteins I-GENE
. O

RARE O
RARE O
interleukin I-GENE
( I-GENE
ALL_CAP I-GENE
)- I-GENE
10 I-GENE
and O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
- I-GENE
type I-GENE
RARE I-GENE
use O
similar O
RARE O
mechanisms O
RARE O
inducing O
transcription O
through O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
response O
elements O
. O

Specifically O
, O
the O
deduced O
ALL_CAP I-GENE
- I-GENE
19 I-GENE
amino I-GENE
acid I-GENE
sequence I-GENE
has O
NUM O
, O
77 O
, O
and O
NUM O
% O
overall O
identity O
to O
chicken I-GENE
TEF I-GENE
- I-GENE
NUM I-GENE
, O
mouse I-GENE
TEF I-GENE
- I-GENE
1 I-GENE
, O
and O
mouse I-GENE
RARE I-GENE
ALL_CAP I-GENE
domain I-GENE
- I-GENE
containing I-GENE
factor I-GENE
, O
respectively O
. O

This O
phenomenon O
did O
not O
require O
DNA O
binding O
by O
the O
" O
interfering O
" O
receptor O
but O
required O
it O
to O
be O
hormone O
- O
RARE O
, O
indicating O
that O
a O
transcriptionally O
RARE O
form O
of O
the O
interfering O
receptor O
is O
essential O
RARE O
the O
interfering O
effect O
. O

The O
receptor I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
gene I-GENE
RARE O
is O
markedly O
elevated O
in O
RARE O
exposed O
to O
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta1 I-GENE
( O
TGF I-GENE
- I-GENE
beta1 I-GENE
). O

RARE I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
activates O
p70 I-GENE
S6 I-GENE
kinase I-GENE
via O
a O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
- O
independent O
RARE O
. O

RARE O
analysis O
of O
NUM I-GENE
indicates O
structural O
homology O
to O
ALL_CAP I-GENE
, O
including O
12 O
transmembrane O
domains O
, O
a O
large O
extracellular O
loop O
with O
RARE O
N O
- O
RARE O
glycosylation O
sites O
, O
and O
cytoplasmic O
N O
- O
and O
C O
- O
terminal O
regions O
. O

A O
cis O
- O
acting O
DNA O
element O
RARE O
between O
TATA O
box O
and O
transcription O
initiation O
site O
is O
critical O
in O
response O
to O
regulatory O
sequences O
in O
human O
RARE I-GENE
gene I-GENE
. O

This O
protein O
with O
a O
hydrophobic O
amino O
terminus O
appears O
to O
be O
a O
RARE O
protein O
. O

The O
promoter O
of O
the O
rat I-GENE
ALL_CAP I-GENE
- I-GENE
2 I-GENE
gene I-GENE
contains O
a O
CAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
consensus I-GENE
site I-GENE
( I-GENE
CAAT I-GENE
box I-GENE
) I-GENE
which O
can O
confer O
hormone O
inducibility O
to O
a O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
. O
CAT I-GENE
reporter O
gene O
, O
RARE O
RARE O
RARE O
a O
putative O
E O
- O
box O
region O
. O

RARE O
, O
SRF I-GENE
has O
been O
found O
to O
be O
a O
key O
regulator O
of O
members O
of O
a O
class O
of O
cellular O
response O
genes O
termed O
immediate I-GENE
- I-GENE
early I-GENE
genes I-GENE
( O
RARE I-GENE
RARE O
many O
of O
which O
are O
believed O
to O
be O
involved O
in O
RARE O
cell O
growth O
and O
differentiation O
. O

The O
final O
NUM I-GENE
- I-GENE
dependent I-GENE
ALL_CAP I-GENE
activator I-GENE
regulates O
transcription O
of O
the O
RARE I-GENE
operon I-GENE
that O
encodes O
the O
RARE O
RARE O
catabolism O
of O
( O
RARE O
) O
RARE O
. O

In O
this O
study O
, O
we O
have O
RARE O
the O
human I-GENE
NUM I-GENE
gene I-GENE
and O
examined O
the O
transcriptional O
RARE O
of O
its O
RARE O
. O

Clinical O
evaluation O
of O
the O
RARE O
RARE O
500 O
RARE O
and O
the O
RARE O
ALL_CAP O
- O
1000 O
RARE O
. O

None O
of O
the O
five O
RARE O
RARE O
RARE O
tested O
were O
capable O
of O
RARE O
human I-GENE
pro I-GENE
- I-GENE
ALL_CAP I-GENE
, O
strongly O
suggesting O
that O
they O
are O
not O
involved O
in O
the O
RARE O
of O
this O
enzyme O
. O

These O
changes O
may O
be O
the O
result O
of O
, O
on O
the O
one O
RARE O
, O
an O
increased O
sensitivity O
of O
the O
neuromuscular O
RARE O
and O
/ O
or O
decreased O
muscle O
contractility O
and O
, O
on O
the O
other O
RARE O
, O
the O
result O
of O
a O
RARE O
plasma O
clearance O
RARE O
hypothermia O
. O

SETTING O
RARE O
RARE O
, O
RARE O
RARE O
, O
1985 O
- O
6 O
. O

By O
using O
interleukin I-GENE
- I-GENE
3 I-GENE
- O
dependent O
cells O
that O
RARE O
express O
the O
three O
ErbB I-GENE
proteins I-GENE
or O
their O
combinations O
, O
we O
found O
that O
ErbB I-GENE
- I-GENE
3 I-GENE
is O
RARE O
of O
any O
biological O
activity O
but O
both O
ErbB I-GENE
- I-GENE
1 I-GENE
and O
ErbB I-GENE
- I-GENE
2 I-GENE
can O
RARE O
its O
extremely O
potent O
mitogenic O
activity O
. O

ALL_CAP O
was O
significantly O
more O
RARE O
than O
all O
subsequent O
methods O
, O
and O
RARE O
, O
NUM O
was O
significantly O
more O
RARE O
than O
FEV1 O
. O

Selective O
translation O
initiation O
by O
RARE O
RARE O
in O
adenovirus O
- O
RARE O
and O
heat O
- O
RARE O
cells O
. O

Furthermore O
, O
we O
have O
identified O
a O
NUM O
- O
bp O
region O
of O
the O
NUM I-GENE
promoter I-GENE
required O
RARE O
the O
RARE O
responsiveness O
. O

These O
findings O
suggest O
that O
direct O
cDNA O
mapping O
using O
fluorescence O
in O
situ O
hybridization O
provides O
an O
accurate O
and O
rapid O
approach O
to O
the O
definition O
of O
a O
RARE O
map O
of O
the O
human O
genome O
. O

YAC O
and O
cosmid O
RARE O
spanning O
the O
RARE I-GENE
RARE I-GENE
( O
NUM I-GENE
) O
region O
RARE O
NUM O
. O
1 O
- O
NUM O
. O
2 O
. O

Isolation O
of O
a O
near O
full O
- O
length O
cDNA O
from O
a O
human O
RARE O
brain O
cDNA O
library O
revealed O
a O
protein I-GENE
serine I-GENE
- I-GENE
threonine I-GENE
phosphatase I-GENE
with O
a O
RARE O
motif O
, O
almost O
identical O
to O
human I-GENE
NUM I-GENE
( O
NUM I-GENE
) O
and O
highly O
homologous O
to O
rat I-GENE
ALL_CAP I-GENE
. O

RARE I-GENE
- I-GENE
NUM I-GENE
is O
a O
family I-GENE
type I-GENE
II I-GENE
transmembrane I-GENE
proteins I-GENE
encoded O
by O
a O
gene O
cluster O
on O
murine O
RARE O
6 O
. O

The O
RARE I-GENE
- I-GENE
NUM I-GENE
ORF I-GENE
RARE O
by O
the O
NUM I-GENE
promoter I-GENE
complemented O
the O
RARE O
of O
a O
RARE O
RARE O
RARE O
NUM I-GENE
. O

The O
introduction O
of O
NUM I-GENE
to O
the O
cells O
maintained O
the O
balance O
between O
cytosolic O
and O
membrane O
- O
associated O
NUM I-GENE
RARE O
. O

Our O
data O
demonstrate O
directly O
that O
NUM I-GENE
is O
RARE O
with O
its O
RARE O
, O
tRNA I-GENE
met I-GENE
RARE I-GENE
and O
RARE I-GENE
, O
from O
a O
promoter O
RARE O
upstream O
of O
the O
tRNA I-GENE
met I-GENE
RARE I-GENE
gene I-GENE
and O
suggest O
that O
a O
portion O
also O
RARE O
from O
a O
second O
promoter O
, O
RARE O
between O
the O
tRNA I-GENE
met I-GENE
RARE I-GENE
gene I-GENE
and O
NUM I-GENE
. O

Furthermore O
, O
strains O
with O
mutant I-GENE
NUM I-GENE
genes I-GENE
also O
accumulate O
precursor I-GENE
NUM I-GENE
, O
suggesting O
that O
mutations O
in O
either O
gene O
can O
lead O
to O
similar O
biogenesis O
defects O
. O

RARE O
membrane O
vesicles O
from O
NUM I-GENE
mutants I-GENE
lack O
all O
NUM O
RARE O
H O
+ O
RARE O
activity O
, O
demonstrating O
that O
NUM I-GENE
catalyzes O
the O
exchange O
of O
NUM O
+ O
RARE O
H O
+ O
across O
the O
yeast O
vacuolar O
membrane O
. O

RARE O
mutagenesis O
of O
the O
element O
' O
s O
rare O
- O
RARE O
/ O
ALL_CAP O
- O
rich O
sequence O
boundary O
revealed O
that O
the O
RARE O
activity O
of O
the O
NUM I-GENE
IE I-GENE
is O
observed O
when O
the O
terminal O
RARE O
of O
the O
element O
' O
s O
rare O
- O
RARE O
interval O
is O
translated O
. O

ALL_CAP I-GENE
is O
also O
abundantly O
RARE O
in O
the O
pancreas O
and O
may O
exert O
differentiation O
functions O
in O
RARE O
RARE O
, O
similar O
to O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
in O
RARE O
tissues O
. O

RARE O
, O
RARE O
RARE O
RARE O
RARE O
. O

RARE O
evidence O
supports O
a O
critical O
role O
RARE O
the O
activation O
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
/ O
MEK I-GENE
/ O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
RARE O
in O
RARE O
Ras I-GENE
- O
RARE O
transformation O
. O

RARE O
chain O
RARE O
: O
choice O
of O
the O
surgical O
approach O
. O

The O
incidence O
of O
cardiac O
RARE O
( O
one O
per O
group O
RARE O
ALL_CAP O
wave O
MI O
( O
RARE O
, O
RARE O
= O
7 O
; O
midazolam O
, O
RARE O
= O
3 O
; O
P O
= O
NUM O
. O
NUM O
RARE O
or O
non O
ALL_CAP O
wave O
MI O
( O
RARE O
, O
RARE O
= O
16 O
; O
midazolam O
, O
RARE O
= O
18 O
; O
P O
= O
NUM O
. O
NUM O
) O
did O
not O
differ O
between O
treatment O
groups O
. O

NUM O
. O
3 O
RARE O
/ O
1 O
, O
p O
< O
NUM O
. O
01 O
) O
and O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
RARE O
to O
RARE O
AUC O
9 O
( O
NUM O
- O
RARE O
)( O
NUM O
. O
7 O
RARE O
. O

RARE O
formation O
of O
E I-GENE
- I-GENE
RARE I-GENE
on O
the O
cell O
surface O
is O
believed O
to O
be O
of O
major O
importance O
RARE O
cell O
- O
cell O
adhesion O
. O

DNA I-GENE
polymerase I-GENE
E I-GENE
, O
DNA I-GENE
ligase I-GENE
III I-GENE
and O
a O
DNA O
RARE O
- O
specific O
endonuclease O
RARE O
- O
RARE O
with O
the O
five O
polypeptide O
complex O
. O

By O
using O
reporter O
gene O
constructs O
, O
it O
is O
shown O
that O
upstream O
sequences O
of O
the O
P1 O
promoter O
contain O
several O
regions O
that O
modulate O
the O
RARE O
either O
positively O
or O
negatively O
. O

The O
factor O
RARE O
of O
" O
RARE O
' O
RARE O
: O
a O
large O
replication O
study O
. O

Interestingly O
, O
however O
, O
it O
is O
homologous O
to O
several O
RARE O
sequence O
tags O
( O
ALL_CAP O
) O
of O
unknown O
function O
from O
Caenorhabditis O
elegans O
, O
RARE O
RARE O
and O
RARE O
RARE O
. O

RESULTS O
: O
The O
RARE O
model O
provided O
a O
significantly O
better O
fit O
to O
the O
RARE O
outcome O
data O
. O

RARE O
of O
severe O
congenital O
hypothyroidism O
. O

Mean O
increase O
of O
milk O
protein O
yield O
was O
NUM O
g O
/ O
d O
with O
RARE O
RARE O
RARE O
, O
and O
mean O
increase O
of O
true O
protein O
content O
was O
1 O
. O
1 O
g O
/ O
kg O
of O
milk O
. O

RARE O
rates O
can O
be O
used O
to O
RARE O
more O
RARE O
biological O
measures O
RARE O
reproductive O
efficiency O
, O
such O
RARE O
RARE O
rate O
and O
RARE O
rate O
, O
which O
separately O
might O
be O
more O
reliable O
than O
RARE O
rate O
itself O
to O
evaluate O
the O
fertility O
of O
a O
RARE O
or O
the O
performance O
of O
an O
ALL_CAP O
RARE O
. O

However O
, O
if O
ALL_CAP O
involves O
the O
RARE O
RARE O
or O
RARE O
area O
, O
a O
search O
RARE O
internal O
malignancy O
is O
still O
warranted O
. O

The O
mean O
values O
of O
protease O
activity O
were O
significantly O
RARE O
in O
the O
test O
groups O
than O
in O
the O
control O
group O
RARE O
baseline O
. O

Each O
RARE O
molecule O
contains O
four O
disulfide O
RARE O
and O
four O
cis O
peptides O
. O

Only O
fully O
processed O
Pra I-GENE
( O
NUM O
and O
RARE O
) O
and O
NUM I-GENE
( O
NUM I-GENE
RARE I-GENE
, I-GENE
RARE I-GENE
) O
are O
present O
in O
B O
RARE O
, O
which O
are O
believed O
to O
be O
RARE O
of O
RARE O
virions O
. O

A O
chimeric O
VP16 I-GENE
- O
Tat I-GENE
construct O
containing O
the O
leucine O
mutations O
showed O
RARE O
increased O
AP I-GENE
- I-GENE
1 I-GENE
responsiveness O
in O
comparison O
with O
that O
of O
the O
VP16 I-GENE
activation I-GENE
domain I-GENE
alone O
. O

However O
, O
one O
3 O
' O
RARE O
site O
, O
RARE O
RARE O
nucleotide O
( O
nt O
) O
NUM O
, O
is O
used O
RARE O
the O
RARE O
of O
most O
ALL_CAP O
- O
1 O
pre O
- O
mRNAs O
in O
ALL_CAP O
- O
1 O
- O
transformed O
NUM O
cells O
and O
RARE O
early O
to O
RARE O
times O
in O
RARE O
RARE O
RARE O
. O

Here O
, O
the O
cloning O
and O
characterization O
of O
S I-GENE
- I-GENE
RNase I-GENE
genes I-GENE
from O
two O
species O
of O
RARE O
, O
RARE O
( O
RARE O
RARE O
RARE O
) O
and O
Japanese O
RARE O
( O
RARE O
RARE O
) O
is O
described O
and O
these O
sequences O
are O
compared O
with O
those O
of O
other O
NUM I-GENE
- I-GENE
type I-GENE
RARE I-GENE
. O

A O
phylogenetic O
RARE O
of O
members O
of O
the O
NUM I-GENE
/ I-GENE
S I-GENE
- I-GENE
RNase I-GENE
superfamily I-GENE
in O
RARE O
was O
obtained O
. O

In O
a O
RARE O
RARE O
Group O
randomized O
study O
involving O
extensive O
- O
RARE O
ALL_CAP O
patients O
, O
ALL_CAP O
was O
superior O
to O
RARE O
/ O
cisplatin O
with O
regard O
to O
median O
time O
to O
progression O
( O
6 O
. O
6 O
v O
5 O
. O
8 O
months O
RARE O
median O
survival O
times O
( O
9 O
. O
1 O
v O
7 O
. O
3 O
months O
RARE O
and O
2 O
- O
and O
3 O
- O
year O
survival O
rates O
( O
NUM O
% O
v O
5 O
% O
and O
5 O
% O
v O
NUM O
%, O
respectively O
). O

It O
was O
shown O
that O
administration O
of O
RARE O
RARE I-GENE
( O
ALL_CAP I-GENE
) O
results O
in O
more O
steady O
RARE O
and O
retention O
of O
feeding O
and O
RARE O
behavior O
, O
and O
some O
RARE O
mechanisms O
of O
that O
phenomena O
were O
revealed O
. O

RARE O
scintigraphy O
, O
performed O
in O
70 O
patients O
, O
was O
less O
RARE O
than O
ultrasonography O
( O
NUM O
%). O

RARE O
allergy O
and O
other O
RARE O
. O

Despite O
significant O
lethality O
and O
cardiovascular O
dysfunction O
, O
in O
the O
RARE O
group O
on O
RARE O
1 O
and O
2 O
, O
RARE O
versus O
control O
animals O
had O
RARE O
significant O
differences O
in O
mean O
metabolic O
RARE O
measured O
( O
NUM O
, O
ml O
/ O
kg O
/ O
min O
; O
Day O
1 O
: O
11 O
. O
9 O
versus O
12 O
. O
4 O
, O
p O
= O
NUM O
. O
NUM O
; O
Day O
2 O
: O
14 O
. O
2 O
versus O
NUM O
. O
5 O
, O
p O
= O
NUM O
. O
72 O
, O
respectively O
) O
and O
intravascular O
catheter O
calculated O
( O
NUM O
, O
ml O
/ O
kg O
/ O
min O
; O
Day O
1 O
: O
11 O
. O
2 O
versus O
11 O
. O
2 O
, O
p O
= O
NUM O
. O
NUM O
; O
Day O
2 O
: O
12 O
. O
8 O
versus O
NUM O
. O
4 O
, O
p O
= O
NUM O
. O
NUM O
, O
respectively O
). O

After O
6 O
h O
of O
reperfusion O
, O
PO2 O
/ O
NUM O
ratio O
was O
significantly O
better O
after O
Combined O
RARE O
( O
NUM O
+/- O
52 O
mm O
Hg O
) O
than O
in O
the O
RARE O
RARE O
( O
117 O
+/- O
NUM O
mm O
Hg O
) O
and O
Control O
groups O
( O
87 O
+/- O
NUM O
mm O
Hg O
RARE O
with O
RARE O
values O
in O
RARE O
RARE O
dogs O
( O
NUM O
+/- O
NUM O
mm O
Hg O
). O

The O
RARE I-GENE
RARE O
lysis O
time O
was O
slightly O
longer O
in O
the O
smokers O
than O
in O
the O
non O
- O
smokers O
in O
all O
three O
experimental O
situations O
, O
but O
the O
differences O
were O
not O
significant O
. O

ALL_CAP O
inducibility O
required O
the O
HSE O
which O
was O
RARE O
by O
ALL_CAP I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
HSF I-GENE
- I-GENE
1 I-GENE
) O
present O
in O
extracts O
prepared O
from O
cells O
exposed O
to O
ALL_CAP O
. O

Although O
the O
NUM I-GENE
- I-GENE
1 I-GENE
mutation I-GENE
alters O
a O
RARE O
RARE O
in O
the O
NUM I-GENE
ubiquitin I-GENE
- I-GENE
like I-GENE
domain I-GENE
, O
we O
detect O
RARE O
differences O
in O
NUM I-GENE
or O
NUM I-GENE
stability O
. O

Although O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
and O
IFN I-GENE
- I-GENE
alpha I-GENE
activated O
STAT1 I-GENE
alpha I-GENE
and O
STAT5 I-GENE
, O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
predominantly O
activated O
STAT5 I-GENE
, O
while O
IFN I-GENE
- I-GENE
alpha I-GENE
predominantly O
activated O
STAT1 I-GENE
alpha I-GENE
. O

Consistent O
with O
this O
interpretation O
, O
recombinant I-GENE
CREB I-GENE
and O
activating I-GENE
transcription I-GENE
factor I-GENE
proteins I-GENE
RARE O
the O
junB I-GENE
ALL_CAP O
- O
like O
site O
, O
but O
did O
not O
interact O
with O
a O
mutant O
ALL_CAP O
- O
like O
site O
. O

Collectively O
, O
these O
results O
suggest O
that O
RARE O
of O
the O
protein I-GENE
kinase I-GENE
A I-GENE
RARE O
RARE O
are O
recruited O
by O
RARE I-GENE
to O
induce O
junB I-GENE
transcription O
. O

One O
complex O
containing O
a O
70 O
D O
protein O
was O
found O
to O
be O
associated O
specifically O
with O
transcriptionally O
RARE O
leukemia O
cells O
. O

Our O
results O
confirm O
the O
participation O
of O
intron O
1 O
in O
transcriptional O
RARE O
of O
the O
c I-GENE
- I-GENE
myb I-GENE
gene I-GENE
( O
in O
mouse O
and O
human O
) O
and O
RARE O
multiple O
and O
complex O
regulatory O
mechanisms O
of O
activation O
RARE O
RARE O
differentiation O
and O
RARE O
cell O
growth O
control O
. O

RARE O
microscopy O
revealed O
extensive O
deposition O
of O
such O
extracellular O
RARE O
RARE O
type I-GENE
IV I-GENE
RARE I-GENE
and O
RARE I-GENE
in O
the O
vascular O
RARE O
. O

OBJECTIVE O
: O
To O
compare O
RARE O
complications O
in O
women O
having O
genetic O
RARE O
RARE O
11 O
- O
14 O
weeks O
versus O
those O
undergoing O
RARE O
RARE O
16 O
- O
19 O
weeks O
' O
gestation O
. O

Three O
RARE O
( O
NUM O
, O
NUM O
and O
NUM O
) O
were O
found O
to O
be O
homologous O
with O
Schizosaccharomyces O
pombe O
RARE I-GENE
binding I-GENE
protein I-GENE
, O
Escherichia O
coli O
RARE O
38 O
. O
1 O
- O
kDa O
protein O
in O
the O
ALL_CAP I-GENE
5 O
' O
region O
, O
and O
transcription O
regulatory O
protein O
NUM I-GENE
, O
respectively O
. O

Two O
new O
RARE O
RARE O
, O
RARE O
5 O
- O
O O
- O
beta O
- O
D O
- O
RARE O
and O
RARE O
5 O
- O
O O
- O
beta O
- O
D O
- O
RARE O
( O
1 O
RARE O
6 O
) O
beta O
- O
D O
- O
RARE O
, O
have O
been O
isolated O
from O
the O
RARE O
parts O
of O
RARE O
RARE O
. O

Recently O
, O
our O
laboratory O
developed O
a O
screen O
that O
identified O
five O
multicopy O
suppressors O
that O
can O
rescue O
lethal O
strains O
of O
clathrin I-GENE
heavy O
chain O
- O
RARE O
yeast O
( O
RARE I-GENE
- O
NUM I-GENE
- I-GENE
i I-GENE
) O
to O
viability O
. O

RARE O
period O
affects O
water O
intake O
in O
heat O
- O
stressed O
RARE O
goats O
. O

The O
RARE O
regression O
analysis O
of O
the O
RARE O
method O
( O
percentage O
normal O
morphology O
) O
and O
ALL_CAP O
indicated O
that O
both O
were O
predictors O
of O
fertilization O
. O

METHODS O
: O
RARE O
received O
continuous O
RARE O
infusion O
of O
RARE O
diet O
or O
with O
supplementation O
of O
RARE O
, O
RARE O
RARE O
NUM O
, O
and O
RARE O
RARE O
ALL_CAP O
NUM O
, O
with O
and O
without O
RARE O
, O
from O
the O
beginning O
of O
the O
study O
. O

However O
, O
NUM I-GENE
binding O
was O
observed O
by O
RARE O
protection O
with O
RARE I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
like I-GENE
cell I-GENE
nuclear I-GENE
protein I-GENE
. O

RARE O
role O
RARE O
PCR O
- O
based O
diagnosis O
of O
RARE O
' O
s O
RARE O
from O
peripheral O
RARE O
mononuclear O
cells O
. O

The O
ability O
of O
NUM I-GENE
to O
RARE O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
activation O
was O
mapped O
to O
its O
C O
- O
terminal O
zinc O
finger O
domain O
. O

The O
RARE O
- O
258 O
RARE O
RARE O
( O
NUM O
) O
mutation O
caused O
RARE O
receptor O
RARE O
that O
was O
equivalent O
to O
about O
NUM O
% O
of O
the O
maximum O
level O
observed O
in O
wild O
- O
type O
cells O
RARE O
with O
alpha I-GENE
- I-GENE
factor I-GENE
. O

By O
using O
a O
DNA O
sequence O
RARE O
RARE O
its O
ability O
to O
bind O
recombinant I-GENE
ALL_CAP I-GENE
- I-GENE
6 I-GENE
in O
vitro O
, O
we O
show O
here O
that O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
is O
present O
in O
DNA O
- O
binding O
complexes O
in O
nuclear O
extracts O
from O
various O
B O
- O
cell O
lines O
. O

The O
predictive O
value O
of O
a O
positive O
RARE O
was O
77 O
. O
7 O
%. O

CONCLUSIONS O
: O
Our O
findings O
suggest O
that O
pre O
- O
treatment O
with O
RARE O
NUM O
may O
play O
a O
protective O
role O
RARE O
routine O
vascular O
procedures O
requiring O
abdominal O
aortic O
cross O
RARE O
by O
RARE O
the O
degree O
of O
RARE O
damage O
. O

Because O
RARE O
X O
is O
frequently O
involved O
in O
structural O
alterations O
in O
neoplastic O
RARE O
hamster O
cells O
transformed O
by O
chemical O
RARE O
and O
RARE O
viruses O
, O
the O
RARE O
of O
the O
RARE I-GENE
locus I-GENE
on O
this O
RARE O
supports O
the O
notion O
that O
the O
RARE I-GENE
oncogene I-GENE
plays O
a O
role O
in O
the O
malignant O
conversion O
of O
RARE O
transformed O
hamster O
RARE O
. O

In O
a O
screen O
RARE O
genes O
with O
RARE O
RARE O
RARE O
by O
the O
murine O
NUM O
RARE O
RARE O
cell O
line O
, O
we O
isolated O
a O
2 O
. O

NUM O
( O
NUM O
RARE O
one O
of O
a O
RARE O
of O
Ras I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
proteins I-GENE
, O
has O
been O
identified O
RARE O
a O
specific O
RARE I-GENE
1 I-GENE
, I-GENE
3 I-GENE
, I-GENE
4 I-GENE
, I-GENE
5 I-GENE
- I-GENE
RARE I-GENE
( I-GENE
NUM I-GENE
)- I-GENE
binding I-GENE
protein I-GENE
( O
RARE O
, O
P O
. O

We O
previously O
described O
the O
purification O
of O
an O
NUM I-GENE
- I-GENE
kDa I-GENE
RARE I-GENE
acid I-GENE
phosphatase I-GENE
( O
ALL_CAP I-GENE
) O
from O
the O
RARE O
RARE O
membranes O
( O
RARE O
, O
H O
., O
RARE O
, O
S O
RARE O
i O
., O
RARE O
, O
K O
. O
and O
RARE O
, O
F O
.( O
1992 O
) O
ALL_CAP O
. O

The O
mechanism O
involves O
Gbetagamma I-GENE
subunit O
- O
RARE O
increases O
in O
tyrosine O
RARE O
of O
the O
Shc I-GENE
RARE I-GENE
protein I-GENE
, O
Shc I-GENE
RARE O
Grb2 I-GENE
complex O
formation O
, O
and O
recruitment O
of O
Ras I-GENE
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
activity O
. O

A O
cDNA O
encoding O
the O
amino O
- O
terminal O
NUM O
% O
of O
ALL_CAP I-GENE
( O
NUM I-GENE
) O
was O
fused O
to O
a O
cDNA O
coding O
RARE O
the O
last O
37 O
amino O
RARE O
of O
RARE I-GENE
- I-GENE
RARE I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
RARE O
which O
contains O
the O
signal O
RARE O
RARE O
RARE O
RARE O
. O

RARE O
, O
we O
stably O
overexpressed O
wild I-GENE
- I-GENE
type I-GENE
Shc I-GENE
or O
NUM I-GENE
mutant I-GENE
Shc I-GENE
into O
RARE O
cells O
. O

The O
small I-GENE
GTPase I-GENE
Rho I-GENE
is O
implicated O
in O
physiological O
functions O
associated O
with O
actin I-GENE
- O
myosin I-GENE
RARE O
such O
RARE O
RARE O
, O
cell O
RARE O
, O
and O
RARE O
muscle O
contraction O
. O

Conversely O
, O
activation O
of O
this O
RARE O
RARE O
by O
RARE O
of O
a O
constitutively O
RARE O
NUM I-GENE
mutant I-GENE
dramatically O
increased O
RARE I-GENE
NUM I-GENE
promoter O
activity O
and O
RARE I-GENE
NUM I-GENE
protein I-GENE
RARE O
, O
in O
a O
growth O
factor O
- O
independent O
manner O
. O

Furthermore O
, O
upstream O
RARE O
of O
the O
NUM I-GENE
RARE I-GENE
element I-GENE
failed O
to O
inhibit O
activity O
of O
a O
heterologous O
promoter O
in O
NUM O
cells O
. O

In O
order O
to O
RARE O
structural O
motifs O
RARE O
substrate O
affinity O
and O
recognition O
RARE O
the O
human I-GENE
dopamine I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
RARE O
we O
assessed O
RARE O
3H O
] O
dopamine O
uptake O
kinetics O
and O
RARE O
3H O
] O
ALL_CAP O
binding O
characteristics O
of O
COS O
- O
7 O
cells O
transiently O
expressing O
mutant I-GENE
RARE I-GENE
in O
which O
the O
ALL_CAP O
terminus O
was O
truncated O
or O
substituted O
. O

An O
RARE O
library O
was O
constructed O
by O
inserting O
5 O
' O
portion O
- O
RARE O
cDNAs O
from O
phytohemagglutinin I-GENE
- O
RARE O
peripheral O
RARE O
mononuclear O
cells O
into O
upstream O
of O
signal I-GENE
sequence I-GENE
- I-GENE
RARE I-GENE
NUM I-GENE
cDNA I-GENE
in O
an O
Epstein O
- O
Barr O
virus O
RARE O
vector O
. O

RARE O
recombinant I-GENE
ALL_CAP I-GENE
specifically O
RARE O
to O
T O
cell O
lines O
and O
peripheral O
T O
cells O
but O
not O
to O
monocytes O
or O
RARE O
. O

The O
cis O
- O
acting O
elements O
that O
control O
promoter O
activity O
include O
binding O
sites O
RARE O
transcription O
factors O
NUM I-GENE
and O
RARE I-GENE
, O
a O
NUM I-GENE
- I-GENE
kDa I-GENE
CCAAT I-GENE
box I-GENE
- I-GENE
binding I-GENE
protein I-GENE
. O

Therefore O
, O
we O
have O
identified O
a O
cis O
- O
acting O
element O
, O
the O
E1 O
E O
- O
box O
, O
RARE O
in O
the O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
promoter O
region O
that O
RARE O
either O
positively O
or O
negatively O
the O
RARE O
of O
the O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
gene I-GENE
depending O
on O
which O
E I-GENE
- I-GENE
box I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
RARE O
this O
site O
. O

Collectively O
, O
our O
findings O
demonstrate O
that O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
plays O
a O
key O
role O
in O
controlling O
the O
basal O
and O
cAMP O
- O
RARE O
RARE O
of O
the O
ALL_CAP I-GENE
gene I-GENE
. O

There O
was O
a O
RARE O
RARE O
of O
RARE O
RARE O
RARE O
a O
three O
- O
nucleotide O
segment O
centered O
about O
the O
lesion O
site O
which O
resulted O
in O
a O
RARE O
assignment O
RARE O
the O
RARE O
RARE O
of O
the O
NUM O
RARE O
in O
the O
spectrum O
of O
the O
RARE O
duplex O
. O

Using O
one O
of O
the O
RARE O
fragments O
( O
NUM I-GENE
- I-GENE
8 I-GENE
RARE O
we O
isolated O
a O
NUM I-GENE
bp I-GENE
cDNA I-GENE
( I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
) I-GENE
from O
a O
RARE O
RARE O
lambda O
gt11 O
library O
. O

However O
, O
in O
ALL_CAP O
- O
1 O
cells O
grown O
on O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
before O
starvation O
, O
CREB I-GENE
RARE O
was O
observed O
10 O
minutes O
after O
NUM I-GENE
RARE O
. O

RARE O
RARE O
RARE O
RARE O
RARE O
risk O
. O

RESULTS O
: O
The O
LV O
maximum O
RARE O
and O
area O
under O
the O
curve O
showed O
significant O
negative O
correlations O
( O
p O
= O
< O
NUM O
. O
NUM O
) O
with O
the O
NUM O
, O
while O
the O
minimum O
RARE O
showed O
a O
significant O
positive O
correlation O
( O
p O
= O
< O
NUM O
. O
NUM O
). O

The O
results O
also O
imply O
that O
the O
absence O
of O
RARE I-GENE
RARE O
in O
non O
- O
cytotoxic O
cells O
may O
be O
due O
to O
the O
suppression O
of O
the O
induction O
of O
the O
killer O
- O
cell O
- O
specific O
RARE O
- O
acting O
factor O
ALL_CAP I-GENE
- I-GENE
P2 I-GENE
. O

We O
identify O
considerable O
RARE O
- O
temporal O
similarities O
between O
reported O
RARE O
patterns O
of O
NUM I-GENE
genes I-GENE
and O
RARE O
genes O
, O
which O
, O
together O
with O
the O
significant O
sequence O
RARE O
to O
the O
RARE I-GENE
RARE I-GENE
, O
support O
the O
hypothesis O
of O
a O
RARE O
function O
RARE O
PR I-GENE
- I-GENE
10 I-GENE
proteins I-GENE
and O
allow O
the O
prediction O
of O
possible O
biological O
roles O
. O

The O
RARE O
of O
NUM I-GENE
env I-GENE
mRNA I-GENE
was O
found O
to O
be O
differentiation O
- O
associated O
, O
with O
high O
RARE O
detected O
in O
the O
RARE O
stages O
of O
monocytic O
development O
. O

Initial O
estimates O
indicate O
that O
NUM O
, O
193 O
people O
are O
either O
in O
RARE O
of O
or O
in O
need O
of O
mental O
RARE O
RARE O
. O

It O
is O
exclusively O
observed O
in O
RARE O
muscle O
cells O
by O
Northern O
blotting O
and O
immunohistochemical O
analysis O
and O
therefore O
designated O
" I-GENE
RARE I-GENE
RARE I-GENE
A O
human O
RARE O
muscle O
cDNA O
library O
was O
screened O
with O
the O
monoclonal I-GENE
antibody I-GENE
NUM I-GENE
, O
and O
a O
full O
- O
size O
cDNA O
of O
the O
protein O
was O
RARE O
. O

Using O
RARE O
electron O
microscopy O
, O
we O
found O
that O
NUM I-GENE
/ O
NUM I-GENE
and O
p54 I-GENE
are O
localized O
on O
both O
sides O
of O
the O
nuclear O
RARE O
complex O
, O
like O
p62 I-GENE
. O

RARE O
with O
RARE O
- O
dependent O
uptake O
, O
we O
now O
show O
that O
the O
receptor O
undergoes O
RARE O
- O
RARE O
ubiquitination O
, O
suggesting O
that O
receptor O
ubiquitination O
may O
function O
in O
the O
RARE O
- O
dependent O
RARE O
of O
the O
a I-GENE
- I-GENE
factor I-GENE
receptor I-GENE
RARE O
RARE O
RARE O
in O
its O
RARE O
RARE O
. O

Transcription O
initiation O
sites O
of O
the O
rat O
II I-GENE
beta I-GENE
RARE I-GENE
III I-GENE
beta I-GENE
, I-GENE
and I-GENE
O I-GENE
beta I-GENE
- I-GENE
globin I-GENE
genes O
were O
determined O
to O
be O
52 O
RARE O
RARE O
( O
bp O
) O
5 O
'- O
upstream O
of O
the O
translation O
initiation O
RARE O
( O
ATG O
RARE O
in O
each O
gene O
by O
primer O
extension O
analysis O
. O

RARE O
process O
RARE O
by O
indomethacin O
on O
chronic O
RARE O
lesion O
in O
rat O
. O

Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
nuclear I-GENE
protein I-GENE
2 I-GENE
( O
EBNA2 I-GENE
) O
binds O
to O
a O
RARE O
of O
the O
human O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
complex O
, O
NUM I-GENE
/ O
NUM I-GENE
. O

Our O
studies O
also O
excluded O
the O
possibility O
that O
the O
RARE O
of O
RARE O
- O
2 O
, O
RARE O
- O
123 O
, O
or O
RARE O
- O
210 O
, O
had O
roles O
in O
the O
RARE O
- O
suppression O
activity O
of O
the O
large I-GENE
RARE I-GENE
, O
in O
the O
assembly O
of O
RARE O
virus I-GENE
- I-GENE
like I-GENE
RARE I-GENE
RARE I-GENE
, O
and O
in O
the O
nuclear O
RARE O
of O
RARE I-GENE
. O

RARE O
RARE O
between O
the O
RARE O
RARE O
nuclear O
RARE O
virus O
( O
ALL_CAP O
) O
genome O
and O
a O
NUM O
. O
6 O
- O
RARE O
- O
long O
DNA O
fragment O
derived O
from O
the O
putative O
DNA I-GENE
RARE I-GENE
gene I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
nuclear I-GENE
RARE I-GENE
virus I-GENE
generates O
NUM O
- O
ALL_CAP O
, O
an O
RARE O
- O
RARE O
- O
range O
ALL_CAP O
mutant O
( O
S O
. O

The O
data O
further O
indicate O
that O
the O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
alpha I-GENE
chains I-GENE
are O
directly O
involved O
in O
the O
activation O
of O
RARE I-GENE
and O
RARE I-GENE
and O
have O
a O
major O
role O
in O
proliferative O
RARE O
in O
precursor O
B O
cells O
. O

Furthermore O
, O
the O
potency O
of O
RARE O
in O
the O
treatment O
of O
RARE O
tumors O
seems O
to O
be O
RARE O
RARE O
to O
now O
. O

5 O
) O
We O
' O
RARE O
RARE O
that O
the O
mean O
value O
of O
the O
cost O
RARE O
RARE O
of O
RARE O
s O
. O
in O
class O
A O
was O
more O
than O
NUM O
% O
compared O
to O
class O
B O
and O
the O
cost O
RARE O
patient O
in O
class O
A O
was O
nearly O
double O
than O
in O
class O
B O
. O

We O
have O
been O
studying O
the O
interaction O
of O
the O
RARE O
human O
RARE O
ALL_CAP O
( O
ALL_CAP O
) O
with O
the O
tumor I-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
p53 I-GENE
to O
understand O
the O
RARE O
of O
this O
virus O
RARE O
RARE O
RARE O
to O
understand O
the O
basic O
mechanisms O
of O
p53 I-GENE
RARE O
. O

RARE O
S O
- O
II O
also O
spans O
a O
NUM O
bp O
sequence O
containing O
two O
RARE O
consensus O
binding O
sites O
with O
three O
RARE O
RARE O
RARE O
in O
each O
and O
a O
one O
RARE O
RARE O
deletion O
. O

Cbl I-GENE
constitutively O
interacts O
with O
the O
SH3 I-GENE
domains I-GENE
of O
Grb2 I-GENE
, O
with O
a O
preference O
RARE O
the O
amino O
- O
terminal O
domain O
, O
and O
is O
in O
this O
way O
recruited O
to O
Shc I-GENE
upon O
ALL_CAP I-GENE
RARE O
. O

Activation O
RARE O
by O
NUM I-GENE
was O
RARE O
longer O
detectable O
in O
a O
NUM I-GENE
mutant I-GENE
. O

Treatment O
is O
RARE O
with O
prednisone O
and O
cyclophosphamide O
. O

RARE O
attempts O
to O
RARE O
smoking O
are O
generally O
RARE O
. O

Laboratory O
evaluation O
was O
normal O
, O
and O
RARE O
failed O
to O
confirm O
obstruction O
of O
venous O
or O
RARE O
drainage O
. O

RARE O
management O
of O
chronic O
hepatitis O
B O
virus O
asymptomatic O
patients O

While O
fusion O
to O
the O
N O
- O
terminus O
required O
a O
RARE O
to O
become O
surface O
RARE O
, O
both O
fusion O
to O
the O
N O
- O
terminus O
and O
to O
the O
C O
- O
terminus O
was O
compatible O
with O
RARE O
assembly O
and O
RARE O
the O
RARE O
RARE O
and O
RARE O
of O
RARE I-GENE
. O

The O
standard O
dosage O
of O
anti I-GENE
- I-GENE
D I-GENE
currently O
given O
RARE O
all O
gestational O
ages O
is O
1 O
RARE O
containing O
NUM O
micrograms O
of O
anti I-GENE
- I-GENE
D I-GENE
. O

We O
report O
here O
the O
RARE O
cloning O
of O
a O
putative O
adhesive O
molecule O
from O
P O
. O
falciparum O
that O
shares O
both O
sequence O
and O
structural O
similarities O
with O
a O
RARE O
surface O
molecule O
from O
RARE O
termed O
the O
RARE I-GENE
- I-GENE
related I-GENE
RARE I-GENE
protein I-GENE
( O
ALL_CAP I-GENE
) O
and O
, O
to O
a O
lesser O
extent O
, O
with O
the O
RARE I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
protein I-GENE
. O

There O
are O
RARE O
RARE O
within O
the O
gene O
, O
which O
contains O
a O
NUM O
- O
bp O
RARE O
reading O
frame O
and O
encodes O
a O
NUM O
- O
kDa O
protein O
. O

METHODS O
: O
ALL_CAP O
was O
RARE O
in O
one O
eye O
chosen O
RARE O
random O
and O
ALL_CAP O
in O
the O
RARE O
eye O
of O
NUM O
normal O
subjects O
and O
in O
NUM O
patients O
with O
ALL_CAP O
. O

The O
experience O
of O
the O
lateral O
RARE O
approach O
in O
RARE O
surgery O
of O
RARE O
has O
been O
favourable O
. O

CONCLUSION O
: O
The O
results O
demonstrate O
that O
RARE O
the O
site O
of O
lumbar O
disc O
RARE O
, O
inflammatory O
RARE O
such O
RARE O
interleukin I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
are O
produced O
, O
which O
increases O
RARE O
E2 O
production O
. O

The O
predominant O
RARE O
allergens O
in O
RARE O
asthmatic O
children O
are O
RARE O
RARE O
animals O
. O

Our O
results O
demonstrate O
that O
distinct O
cytoplasmic O
domains O
of O
these O
RARE O
receptors O
elicit O
RARE O
RARE O
pathways O
and O
provide O
evidence O
that O
beta I-GENE
c I-GENE
and O
ALL_CAP I-GENE
- I-GENE
2R I-GENE
beta I-GENE
function O
RARE O
a O
RARE O
signal O
RARE O
. O

In O
addition O
, O
they O
display O
common O
features O
that O
make O
them O
strikingly O
related O
to O
ALL_CAP I-GENE
U14 I-GENE
. O

NUM I-GENE
has O
two O
separate O
12 O
nt O
long O
RARE O
to O
a O
highly O
RARE O
RARE O
of O
28S I-GENE
rRNA I-GENE
. O

This O
complex O
interacts O
RARE O
the O
GTPase I-GENE
domain I-GENE
in O
the O
large O
subunit O
rRNA O
, O
overlapping O
the O
binding O
site O
of O
the O
protein I-GENE
NUM I-GENE
- I-GENE
like I-GENE
eukaryotic I-GENE
RARE I-GENE
( O
Saccharomyces I-GENE
cerevisiae I-GENE
protein I-GENE
NUM I-GENE
and O
mammalian I-GENE
protein I-GENE
NUM I-GENE
). O

RARE O
repression O
of O
these O
RARE O
genes O
would O
be O
RARE O
, O
consistent O
with O
the O
high O
, O
RARE O
RARE O
of O
RARE O
NUM I-GENE
histone I-GENE
genes I-GENE
in O
RARE O
. O

This O
transition O
is O
regulated O
positively O
by O
G1 I-GENE
- I-GENE
specific I-GENE
RARE I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
( O
RARE I-GENE
) O
and O
negatively O
by O
the O
product O
of O
the O
RARE I-GENE
RARE I-GENE
suppressor I-GENE
gene I-GENE
, O
pRb I-GENE
. O

RARE O
relationship O
between O
RARE O
and O
glomerular O
hypertrophy O
in O
RARE O
. O

RARE O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
activity O
was O
measured O
with O
a O
RARE O
, O
using O
a O
modification O
of O
a O
previously O
described O
assay O
. O

The O
concentrations O
of O
vitamin O
A O
RARE O
and O
vitamin O
E O
in O
the O
RARE O
were O
below O
currently O
recommended O
dietary O
levels O
RARE O
RARE O
, O
and O
RARE O
RARE O
appears O
to O
provide O
an O
RARE O
source O
of O
RARE O
A O
and O
E O
in O
this O
species O
. O

Eight O
cats O
RARE O
with O
H O
. O
RARE O
were O
used O
in O
the O
study O
. O

However O
, O
RARE O
determined O
by O
PCR O
with O
primers O
specific O
RARE O
the O
NUM O
- O
kDa O
product O
, O
the O
majority O
of O
cats O
RARE O
2 O
and O
4 O
weeks O
p O
. O
t O
. O
had O
RARE O
RARE O
samples O
which O
were O
positive O
RARE O
H O
. O
RARE O
and O
three O
of O
three O
cats O
RARE O
2 O
weeks O
p O
. O
t O
. O
had O
dental O
plaque O
which O
was O
positive O
RARE O
H O
. O
RARE O
. O

To O
RARE O
quantitative O
concentration O
changes O
from O
measurements O
of O
light O
RARE O
, O
the O
optical O
RARE O
length O
must O
be O
known O
. O

ALL_CAP O
DESIGN O
. O

Following O
the O
injection O
of O
PGF2 O
alpha O
, O
heifers O
were O
observed O
RARE O
RARE O
signs O
of O
RARE O
RARE O
NUM O
and O
NUM O
( O
NUM O
min O
each O
). O

Differential O
activation O
of O
the O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
, O
Jun I-GENE
kinase I-GENE
and O
Janus I-GENE
kinase I-GENE
- O
Stat I-GENE
pathways O
by O
RARE I-GENE
M I-GENE
and O
basic I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
in O
AIDS O
- O
derived O
Kaposi O
' O
s O
sarcoma O
cells O
. O

There O
is O
RARE O
agreement O
that O
the O
hepatitis O
C O
virus O
is O
efficiently O
transmitted O
RARE O
, O
while O
data O
on O
viral O
RARE O
from O
mothers O
to O
babies O
or O
by O
sexual O
or O
non O
- O
sexual O
RARE O
RARE O
are O
RARE O
. O

Ten O
weeks O
after O
reconstruction O
, O
the O
RARE O
nerves O
already O
RARE O
normal O
nerves O
. O

The O
distribution O
and O
organization O
of O
projections O
from O
the O
RARE O
cervical O
enlargement O
to O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
and O
the O
RARE O
RARE O
nucleus O
( O
RARE O
) O
area O
was O
studied O
in O
the O
rat O
by O
using O
RARE O
of O
RARE I-GENE
RARE I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
- I-GENE
L I-GENE
) O
into O
different O
RARE O
around O
the O
NUM O
level O
. O

The O
levels O
of O
fibrinogen I-GENE
RARE O
RARE O
RARE O
antithrombin I-GENE
III I-GENE
( O
ALL_CAP I-GENE
) O
and O
RARE I-GENE
cofactor I-GENE
II I-GENE
( O
ALL_CAP I-GENE
) O
activities O
were O
RARE O
increased O
in O
loop O
- O
RARE O
animals O
. O

RARE O
and O
overexpression O
of O
the O
c I-GENE
- I-GENE
erbB I-GENE
- I-GENE
2 I-GENE
gene I-GENE
in O
NUM O
- O
2 O
and O
NUM O
- O
1 O
human O
breast O
carcinoma O
cells O
results O
in O
RARE O
elevated O
levels O
of O
constitutively O
tyrosine I-GENE
- I-GENE
RARE I-GENE
NUM I-GENE
- I-GENE
2 I-GENE
and O
is O
associated O
with O
progressive O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
( O
IGF I-GENE
) O
and O
combined O
IGF I-GENE
/ O
RARE I-GENE
growth I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
) O
RARE O
in O
culture O
. O

RARE O
muscular O
RARE O
( O
ALL_CAP O
) O
is O
an O
RARE O
dominant O
, O
neuromuscular O
disorder O
characterized O
by O
progressive O
RARE O
of O
muscles O
in O
the O
face O
, O
RARE O
and O
upper O
RARE O
. O

The O
RARE O
RARE O
4 O
NUM I-GENE
transcript I-GENE
is O
NUM O
bp O
in O
length O
and O
contains O
nine O
exons O
which O
encode O
a O
putative O
protein O
of O
258 O
amino O
acid O
residues O
. O

Patients O
who O
have O
undergone O
RARE O
RARE O
thyroid O
carcinoma O
are O
frequently O
subjected O
to O
periods O
of O
RARE O
severe O
hypothyroidism O
in O
preparation O
RARE O
131I O
whole O
body O
scanning O
and O
measurement O
of O
serum O
TG I-GENE
. O

RARE O
thyroid O
function O
testing O
was O
performed O
on O
600 O
randomly O
RARE O
samples O
with O
normal O
ALL_CAP I-GENE
values O
and O
also O
on O
subjects O
with O
abnormal O
ALL_CAP I-GENE
levels O
. O

In O
a O
third O
experiment O
, O
RARE O
ALL_CAP O
between O
RARE O
RARE O
was O
investigated O
, O
and O
it O
was O
found O
that O
the O
more O
RARE O
RARE O
carried O
the O
ALL_CAP O
. O

The O
relative O
tumor O
FDG O
- O
uptake O
( O
ALL_CAP O
- O
RARE O
) O
( O
tumor O
/ O
contralateral O
cortex O
) O
of O
all O
RARE O
was O
calculated O
with O
NUM O
. O
NUM O
+/- O
NUM O
. O
37 O
( O
NUM O
. O
NUM O
- O
1 O
. O
NUM O
). O

RARE O
weakly O
depressed O
the O
ectopic O
ventricular O
rate O
but O
not O
the O
RARE O
ratio O
of O
the O
ventricular O
arrhythmias O
RARE O
by O
two O
- O
RARE O
coronary O
ligation O
NUM O
h O
after O
the O
ligation O
in O
conscious O
dogs O
. O

RARE O
RARE O
, O
a O
RARE O
that O
has O
amphetamine O
effects O
. O

The O
predicted O
protein O
, O
NUM I-GENE
, O
consists O
of O
82 O
amino O
RARE O
and O
contains O
one O
RARE O
membrane O
- O
spanning O
region O
RARE O
the O
C O
- O
terminus O
but O
RARE O
N O
- O
terminal O
signal O
sequence O
. O

The O
NUM I-GENE
homologue O
thus O
isolated O
, O
NUM I-GENE
, O
encodes O
a O
protein O
53 O
% O
identical O
to O
NUM I-GENE
. O

RARE O
, O
that O
ventricular O
afferents O
, O
in O
certain O
RARE O
RARE O
, O
are O
able O
to O
induce O
RARE O
. O
g O
. O
RARE O
vasodilation O
and O
hypotension O
cannot O
be O
excluded O
. O

RARE O
ones O
were O
similar O
in O
size O
to O
the O
main O
lobe O
and O
small O
ones O
were O
RARE O
1 O
/ O
4 O
of O
the O
length O
of O
the O
main O
lobe O
. O

RARE O
and O
RARE O
of O
the O
hormone O
ACTH I-GENE
were O
previously O
shown O
to O
have O
beneficial O
effect O
on O
the O
outcome O
of O
head O
injury O
, O
while O
elevated O
levels O
of O
corticosterone O
( O
ALL_CAP O
) O
RARE O
it O
. O

The O
most O
frequent O
causes O
of O
the O
meningitis O
was O
the O
external O
ventricular O
drainage O
( O
14 O
. O
8 O
%), O
post O
- O
RARE O
( O
NUM O
. O
8 O
%) O
and O
head O
injury O
( O
NUM O
. O
NUM O
%). O

Fifty O
- O
one O
patients O
with O
RARE O
refractory O
or O
RARE O
malignant O
lymphoma O
( O
NUM O
non O
- O
Hodgkin O
' O
s O
lymphoma O
and O
four O
Hodgkin O
' O
s O
RARE O
) O
were O
treated O
with O
a O
new O
chemotherapeutic O
regimen O
( O
RARE O
, O
RARE O
ALL_CAP O
, O
RARE O
, O
RARE O
RARE O
). O

With O
the O
increasing O
use O
of O
ACE I-GENE
RARE O
, O
the O
incidence O
of O
rare O
adverse O
effects O
such O
RARE O
potentially O
lethal O
pancreatitis O
is O
likely O
to O
increase O
. O

In O
3 O
treatments O
the O
diet O
was O
supplemented O
with O
NUM O
, O
NUM O
and O
NUM O
mg O
RARE O
/ O
kg O
food O
. O

Low O
- O
dose O
RARE O
and O
recurrent O
RARE O
. O

Protein O
films O
are O
distinctly O
different O
in O
mechanical O
profiles O
from O
those O
films O
made O
of O
other O
materials O
. O

Furthermore O
, O
ALL_CAP I-GENE
RARE I-GENE
mutations O
suppress O
the O
toxicity O
conferred O
by O
the O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
RARE O
protein O
, O
which O
exerts O
its O
effects O
in O
the O
cytoplasm O
, O
RARE O
from O
ALL_CAP I-GENE
. O

The O
NUM I-GENE
cDNA I-GENE
encodes O
a O
protein O
of O
210 O
kDa O
, O
which O
lacks O
sequences O
implicated O
in O
linking O
NUM I-GENE
PI I-GENE
3 I-GENE
- I-GENE
kinases I-GENE
to O
p85 I-GENE
RARE I-GENE
proteins I-GENE
, O
but O
contains O
an O
amino O
- O
terminal O
proline O
- O
rich O
sequence O
, O
which O
could O
bind O
to O
SH3 I-GENE
domains I-GENE
, O
and O
a O
RARE O
- O
terminal O
C2 I-GENE
domain O
. O

In O
vitro O
interaction O
studies O
, O
using O
proteins O
fused O
to O
RARE I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
, O
showed O
that O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
RARE I-GENE
and O
RARE I-GENE
( I-GENE
H I-GENE
) I-GENE
bind O
directly O
to O
the O
NUM I-GENE
regions I-GENE
of O
mouse I-GENE
NUM I-GENE
and O
Drosophila I-GENE
Notch I-GENE
, O
respectively O
. O

ALL_CAP O
/ O
METHODS O
: O
RARE O
RARE O
function O
, O
RARE O
assessed O
by O
clearance O
of O
RARE O
bacteria O
, O
was O
evaluated O
in O
acute O
liver O
injury O
RARE O
by O
D O
- O
RARE O
in O
rats O
, O
and O
compared O
with O
that O
after O
70 O
% O
liver O
resection O
model O
. O

Our O
laboratory O
and O
others O
have O
shown O
RARE O
RARE O
of O
RARE O
to O
ten O
exons O
RARE O
a O
discrete O
extracellular O
site O
to O
be O
primarily O
responsible O
RARE O
the O
generation O
of O
CD44 I-GENE
variant I-GENE
( O
NUM I-GENE
) O
isoforms O
. O

Study O
groups O
were O
control O
, O
and O
those O
treated O
with O
the O
NUM I-GENE
- I-GENE
adrenoceptor I-GENE
- I-GENE
RARE I-GENE
blockers O
NUM O
( O
NUM O
. O
5 O
mg O
/ O
kg O
i O
. O
v O
.) O
or O
RARE O
( O
1 O
. O
9 O
mg O
/ O
kg O
i O
. O
v O
.). O

This O
caused O
severe O
cortical O
damage O
and O
RARE O
RARE O
in O
hippocampus O
RARE O
NUM O
, O
CA3 O
, O
and O
RARE O
. O

The O
occurrence O
of O
multiple O
malignancy O
was O
studied O
in O
NUM O
patients O
with O
RARE O
RARE O
who O
were O
RARE O
to O
this O
RARE O
RARE O
the O
past O
10 O
years O
. O

The O
ALL_CAP O
binds O
more O
T3R I-GENE
homodimers I-GENE
and O
less O
T3R I-GENE
- O
RXR I-GENE
RARE O
than O
the O
ALL_CAP O
, O
and O
NUM O
more O
readily O
RARE O
RARE O
binding O
to O
the O
RARE O
- O
than O
to O
the O
ALL_CAP O
. O

Transcriptional O
control O
of O
a O
nuclear O
gene O
encoding O
a O
mitochondrial O
fatty O
acid O
oxidation O
enzyme O
in O
transgenic O
mice O
: O
role O
RARE O
nuclear O
receptors O
in O
cardiac O
and O
brown O
RARE O
RARE O
. O

RARE O
, O
F O
. O
ALL_CAP O
. O

RARE O
genomic O
fragments O
containing O
novel O
response O
elements O
are O
described O
, O
and O
the O
transcription O
unit O
associated O
with O
one O
of O
them O
, O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
was O
characterized O
in O
detail O
. O

Moreover O
, O
RARE I-GENE
synthase I-GENE
activity O
, O
which O
is O
activated O
by O
NUM I-GENE
, O
was O
significantly O
RARE O
in O
the O
NUM I-GENE
mutant I-GENE
. O

In O
gel O
retardation O
assays O
, O
an O
ALL_CAP O
cell O
- O
specific O
protein O
and O
another O
closely O
related O
protein O
RARE O
only O
in O
ALL_CAP O
cells O
and O
RARE O
RARE O
RARE O
to O
a O
10 O
- O
bp O
sequence O
within O
the O
18 O
- O
RARE O
. O

Two O
classes O
of O
RARE O
pathogens O
RARE O
NUM O
RARE O
resistance O
and O
RARE O
RARE O
fitness O
were O
found O
to O
be O
specifically O
RARE O
in O
NUM I-GENE
. O

Members O
of O
the O
Ras I-GENE
subfamily I-GENE
of O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
have O
been O
shown O
to O
be O
RARE O
towards O
a O
variety O
of O
putative O
effector O
molecules O
such O
RARE O
the O
protein I-GENE
kinase I-GENE
c I-GENE
- I-GENE
Raf I-GENE
and O
the O
RARE I-GENE
- I-GENE
specific I-GENE
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
RARE I-GENE
- I-GENE
ALL_CAP I-GENE
). O

Thus O
, O
the O
characterization O
of O
the O
promoter O
region O
should O
help O
to O
define O
regulatory O
elements O
that O
control O
RARE O
- O
specific O
and O
developmental O
RARE O
of O
the O
NUM I-GENE
gene I-GENE
. O

The O
cDNA O
encoded O
a O
RARE O
protein O
of O
240 O
amino O
RARE O
, O
including O
a O
29 O
- O
amino O
acid O
signal O
sequence O
. O

RARE O
RARE O
the O
3 O
' O
RARE O
- O
loop O
exhibited O
a O
NUM O
% O
reduction O
in O
the O
level O
of O
ALL_CAP I-GENE
mRNA O
. O

The O
deduced O
amino O
acid O
sequence O
was O
highly O
RARE O
across O
the O
wide O
range O
of O
eukaryotes O
( O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
and O
RARE O
) O
in O
which O
this O
gene O
has O
now O
been O
identified O
. O

Biol O
. O

RARE O
mutations O
in O
the O
yeast I-GENE
NUM I-GENE
protein I-GENE
and O
their O
relationships O
with O
the O
NUM I-GENE
RARE I-GENE
. O

RARE O
of O
the O
NUM O
- O
NUM O
interval O
are O
frequently O
observed O
in O
RARE O
and O
RARE O
leukemia O
. O

Previous O
studies O
have O
suggested O
that O
the O
NUM O
amino O
acid O
, O
70 I-GENE
- I-GENE
kDa I-GENE
subunit I-GENE
of I-GENE
RPA I-GENE
( O
RPA I-GENE
70 I-GENE
) O
is O
composed O
of O
multiple O
structural O
/ O
RARE O
domains O
. O

RARE O
were O
held O
RARE O
- O
67 O
ALL_CAP O
to O
RARE O
voltage O
- O
dependent O
effects O
. O

This O
site O
acts O
RARE O
a O
negative O
element O
when O
transferred O
to O
the O
RARE I-GENE
kinase I-GENE
promoter I-GENE
, O
but O
does O
not O
confer O
inducibility O
. O

The O
extent O
of O
the O
ALL_CAP O
operator O
sequence O
( O
NUM O
bp O
RARE O
RARE O
defined O
by O
our O
footprinting O
analysis O
, O
would O
suggest O
the O
binding O
of O
two O
Fur I-GENE
repressor I-GENE
RARE I-GENE
. O

The O
structural O
RARE O
between O
RARE I-GENE
and O
other O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factors I-GENE
RARE O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
, O
together O
with O
the O
recent O
identification O
of O
biochemical O
routes O
specific O
RARE O
members O
of O
the O
Ras I-GENE
and O
Rho I-GENE
family I-GENE
of O
GTPases I-GENE
, O
RARE O
us O
to O
explore O
whether O
ALL_CAP I-GENE
or O
JNK I-GENE
are O
RARE O
RARE O
of O
the O
RARE I-GENE
RARE O
pathways O
. O

CONCLUSION O
: O
RARE O
daily O
treatment O
with O
inhaled O
RARE O
RARE O
50 O
micrograms O
or O
NUM O
micrograms O
was O
significantly O
more O
effective O
than O
theophylline O
in O
the O
treatment O
of O
mild O
- O
to O
- O
moderate O
asthma O
. O

Our O
results O
support O
a O
model O
where O
both O
E2F I-GENE
- O
and O
ALL_CAP O
- O
RARE O
repression O
, O
acting O
RARE O
different O
stages O
in O
the O
cell O
RARE O
, O
are O
dependent O
on O
promoter O
- O
specific O
ALL_CAP O
elements O
. O

The O
cDNA O
clone O
was O
used O
RARE O
a O
homologous O
probe O
to O
isolate O
a O
truncated O
genomic O
clone O
encoding O
NUM I-GENE
. O

Comparison O
of O
the O
deduced O
amino O
acid O
sequences O
with O
protein O
sequences O
of O
T O
. O
RARE O
NUM I-GENE
showed O
only O
two O
and O
three O
differences O
respectively O
, O
in O
a O
RARE O
of O
NUM O
amino O
RARE O
RARE O
NUM I-GENE
, O
and O
132 O
amino O
RARE O
RARE O
NUM I-GENE
, O
indicating O
the O
two O
genes O
RARE O
before O
the O
divergence O
of O
these O
two O
species O
. O

RARE O
visual O
dysfunction O
in O
a O
child O
with O
cerebral O
damage O
. O

Interaction O
was O
apparently O
determined O
by O
the O
N O
- O
terminal O
RARE O
region O
of O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
, O
RARE O
the O
NUM I-GENE
RARE O
variant O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
which O
differs O
from O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
RARE O
the O
extreme O
N O
- O
terminus O
, O
failed O
to O
associate O
with O
v I-GENE
- I-GENE
Src I-GENE
- O
SH3 I-GENE
; O
NUM I-GENE
( O
where O
NUM I-GENE
is O
rat I-GENE
' I-GENE
RARE I-GENE
- I-GENE
like I-GENE
' I-GENE
ALL_CAP I-GENE
RARE O
which O
has O
the O
N O
- O
terminal O
RARE O
region O
RARE O
, O
failed O
to O
associate O
with O
v I-GENE
- I-GENE
Src I-GENE
- O
SH3 I-GENE
, O
and O
the O
association O
of O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
and O
v I-GENE
- I-GENE
Src I-GENE
- O
SH3 I-GENE
was O
blocked O
by O
a O
fusion O
protein O
formed O
from O
the O
N O
- O
terminal O
RARE O
region O
. O

RARE O
load O
- O
RARE O
measures O
of O
ventricular O
performance O
were O
therefore O
evaluated O
in O
10 O
RARE O
- O
and O
closed O
- O
RARE O
, O
anesthetized O
rabbits O
. O

RARE O
RARE O
differences O
were O
found O
RARE O
all O
variables O
recorded O
, O
i O
. O
RARE O
., O
the O
proportion O
of O
RARE O
males O
, O
the O
time O
RARE O
in O
the O
RARE O
RARE O
box O
, O
and O
the O
number O
of O
RARE O
between O
the O
RARE O
and O
the O
dark O
RARE O
. O

The O
effect O
of O
RARE O
RARE O
( O
ALL_CAP O
) O
on O
RARE O
pulmonary O
artery O
hypertension O
has O
been O
proved O
in O
recent O
studies O
. O

It O
is O
the O
oxidation O
peak O
of O
this O
product O
, O
arising O
in O
RARE O
media O
RARE O
NUM O
. O
NUM O
V O
, O
which O
was O
analysed O
using O
ALL_CAP O
, O
again O
following O
the O
accumulation O
of O
RARE O
RARE O
the O
RARE O
- O
modified O
ALL_CAP O
. O

RARE O
is O
a O
pure O
alpha I-GENE
- I-GENE
1 I-GENE
RARE I-GENE
agonist O
known O
to O
produce O
marked O
systemic O
RARE O
and O
associated O
hypertension O
with O
RARE O
profound O
reflex O
RARE O
. O

The O
RARE O
of O
the O
RARE O
two O
genes O
RARE O
in O
this O
unit O
( O
c I-GENE
- I-GENE
ALL_CAP I-GENE
and O
c I-GENE
- I-GENE
ALL_CAP I-GENE
) O
was O
also O
monitored O
by O
Western O
blot O
( O
RARE O
) O
analyses O
using O
antisera O
raised O
against O
these O
proteins O
synthesized O
in O
Escherichia O
coli O
. O

One O
unit O
encodes O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
and O
ALL_CAP I-GENE
, O
while O
the O
second O
encodes O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
and O
ALL_CAP I-GENE
. O

A O
. O

In O
an O
effort O
to O
isolate O
genes O
with O
down O
- O
regulated O
RARE O
RARE O
the O
mRNA O
level O
RARE O
RARE O
transformation O
of O
human O
mammary O
RARE O
cells O
( O
RARE O
RARE O
we O
performed O
RARE O
hybridization O
between O
normal O
ALL_CAP O
RARE O
NUM O
and O
its O
radiation O
- O
transformed O
tumorigenic O
RARE O
NUM O
- O
NUM O
. O

ALL_CAP O
ALL_CAP O
: O
RARE O
because O
of O
a O
right O
corneal O
RARE O
with O
cellular O
reaction O
in O
anterior O
chamber O
, O
a O
patient O
was O
RARE O
and O
treated O
with O
a O
single O
RARE O
injection O
of O
NUM O
. O
2 O
ml O
( O
1 O
mg O
) O
RARE O
and O
NUM O
. O
2 O
ml O
( O
1 O
mg O
) O
RARE O
. O

In O
the O
same O
period O
we O
RARE O
out O
an O
increase O
of O
hematocrit O
( O
from O
29 O
% O
to O
NUM O
%) O
and O
of O
the O
RARE I-GENE
( O
from O
9 O
. O
3 O
to O
11 O
. O
2 O
g O
/ O
dl O
). O

The O
P I-GENE
- I-GENE
RARE I-GENE
and O
P I-GENE
- I-GENE
RARE I-GENE
cDNA I-GENE
sequences I-GENE
are O
very O
similar O
in O
their O
5 O
' O
regions O
. O

Because O
the O
NUM I-GENE
locus I-GENE
was O
mapped O
RARE O
a O
distance O
< O
NUM O
. O
1 O
RARE O
from O
the O
RARE I-GENE
C I-GENE
gene I-GENE
, O
its O
RARE O
characterization O
by O
RARE O
cloning O
is O
possible O
. O

The O
human I-GENE
MSH I-GENE
- I-GENE
2 I-GENE
gene I-GENE
product I-GENE
is O
a O
RARE O
of O
a O
highly O
RARE O
family O
of O
proteins O
which O
are O
involved O
in O
post O
- O
replication O
RARE O
repair O
. O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
is O
homologous O
to O
Escherichia O
coli O
( O
E O
. O
coli O
) O
ALL_CAP I-GENE
and O
RARE I-GENE
cerevisiae I-GENE
MSH I-GENE
- I-GENE
1 I-GENE
and O
MSH I-GENE
- I-GENE
2 I-GENE
proteins I-GENE
, O
which O
RARE O
RARE O
DNA O
RARE O
the O
sites O
of O
all O
single O
RARE O
RARE O
and O
deletions O
or O
insertions O
RARE O
to O
4 O
RARE O
RARE O
. O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
is O
one O
of O
the O
RARE I-GENE
non I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
tumor I-GENE
suppressor I-GENE
genes I-GENE
, O
and O
maps O
to O
human O
RARE O
NUM O
. O

We O
have O
recently O
shown O
that O
the O
tissue O
- O
specific O
RARE O
of O
the O
RAR I-GENE
beta I-GENE
2 I-GENE
gene I-GENE
in I-GENE
mouse I-GENE
RARE I-GENE
is O
regulated O
RARE O
the O
translational O
level O
by O
short O
upstream O
RARE O
reading O
frames O
( O
RARE O
) O
In O
the O
5 O
'- O
RARE O
region O
( O
RARE O
, O
A O
., O
A O
. O
M O
. O

We O
have O
previously O
isolated O
a O
cDNA O
RARE O
a O
transcription O
factor O
referred O
to O
RARE O
RARE I-GENE
( O
zinc I-GENE
finger I-GENE
RARE I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
) O
containing O
two O
separate O
zinc O
finger O
domains O
, O
NUM I-GENE
and O
NUM I-GENE
, O
each O
of O
which O
binds O
DNA O
, O
and O
a O
RARE O
. O

The O
RARE O
of O
these O
genes O
suggests O
a O
common O
ancestor O
RARE O
all O
RARE I-GENE
NUM I-GENE
genes I-GENE
. O

Increased O
ALL_CAP I-GENE
production O
by O
a O
tyrosine I-GENE
kinase I-GENE
oncogene I-GENE
, O
RARE I-GENE
- I-GENE
RARE I-GENE
: O
role O
of O
the O
Ras I-GENE
RARE O
RARE O
. O

RARE O
to O
their O
RARE O
, O
the O
IGF I-GENE
- I-GENE
II I-GENE
in O
NUM O
and O
NUM O
cells O
accumulated O
in O
the O
conditioned O
medium O
mostly O
RARE O
two O
partially O
processed O
species O
with O
RARE O
, O
of O
NUM O
and O
NUM O
, O
respectively O
. O

RARE O
, O
coexpression O
of O
the O
transcriptionally O
inactive O
, O
amino O
- O
RARE O
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
proteins I-GENE
, O
either O
with O
the O
wild I-GENE
- I-GENE
type I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
or O
with O
themselves O
, O
results O
in O
a O
marked O
enhancement O
of O
RARE O
of O
the O
transcriptional O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
element I-GENE
reporter I-GENE
. O

All O
patients O
had O
abnormal O
RARE I-GENE
Willebrand I-GENE
factor I-GENE
( O
vWF I-GENE
) O
RARE O
RARE O
reflected O
by O
decreased O
high O
RARE O
RARE O
and O
increased O
low O
RARE O
RARE O
vWF I-GENE
RARE I-GENE
in O
the O
circulation O
. O

In O
an O
attempt O
to O
investigate O
whether O
the O
intergenic O
region O
between O
the O
RARE I-GENE
and O
a O
second O
RARE O
reading O
frame O
( O
ALL_CAP O
) O
in O
RARE O
RARE O
( O
L O
.) O
is O
a O
divergent O
promoter O
, O
and O
also O
to O
characterize O
the O
ALL_CAP I-GENE
, O
cDNA I-GENE
RARE I-GENE
homologous I-GENE
to I-GENE
ALL_CAP I-GENE
were O
isolated O
from O
a O
leaf O
cDNA O
library O
. O

The O
ALL_CAP I-GENE
gene I-GENE
product I-GENE
is O
targeted O
to O
the O
chloroplast O
, O
which O
is O
consistent O
with O
previous O
data O
indicating O
the O
presence O
of O
ALL_CAP I-GENE
activity O
in O
the O
chloroplast O
. O

Characterization O
of O
ALL_CAP I-GENE
, O
a O
leucine I-GENE
- I-GENE
rich I-GENE
repeat I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
protein I-GENE
from I-GENE
RARE I-GENE
RARE I-GENE
that O
is O
processed O
RARE O
pathogenesis O
. O

To O
test O
whether O
NUM I-GENE
and O
NUM I-GENE
/ O
RARE I-GENE
- I-GENE
1 I-GENE
interact O
with O
this O
motif O
, O
gel O
retardation O
assays O
were O
performed O
. O

OBJECTIVES O
: O
The O
aim O
of O
the O
study O
was O
to O
analyze O
the O
clinical O
characteristics O
, O
treatment O
and O
outcome O
of O
NUM O
patients O
with O
RARE O
RARE O
. O

RARE O
transfected O
human O
RARE O
293 O
cells O
expressing O
the O
wild I-GENE
type I-GENE
rat I-GENE
ALL_CAP I-GENE
/ I-GENE
ALL_CAP I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
) O
or O
receptors O
with O
C O
- O
terminal O
tails O
truncated O
RARE O
residues O
NUM O
, O
NUM O
, O
or O
NUM O
( O
designated O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
and O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
) O
were O
used O
to O
probe O
the O
importance O
of O
this O
region O
on O
the O
RARE O
of O
hormonal O
responsiveness O
. O

RARE O
low O
NUM O
amplitudes O
a O
marker O
RARE O
schizophrenia O
. O

RARE O
was O
determined O
again O
RARE O
an O
additional O
3 O
days O
and O
6 O
hours O
. O

The O
patients O
are O
two O
healthy O
adult O
males O
. O

RARE I-GENE
RARE I-GENE
( O
RARE I-GENE
) O
of O
Arabidopsis O
is O
a O
recessive O
nuclear O
mutation O
that O
causes O
RARE O
and O
RARE O
RARE O
in O
leaves O
and O
is O
inherited O
in O
a O
non O
- O
RARE O
fashion O
. O

RARE O
concentrations O
were O
only O
weakly O
correlated O
with O
RARE O
concentrations O
, O
however O
, O
and O
personal O
exposures O
were O
even O
more O
poorly O
correlated O
with O
RARE O
concentrations O
. O

A O
RARE O
test O
battery O
was O
used O
that O
contained O
the O
RARE O
RARE O
RARE O
test O
, O
RARE O
RARE O
test O
, O
Stroop O
test O
, O
a O
RARE O
memory O
RARE O
test O
, O
and O
a O
facial O
recognition O
test O
. O

We O
present O
this O
case O
because O
of O
the O
RARE O
of O
RARE O
ventricular O
involvement O
associated O
with O
ALL_CAP O
. O

In O
a O
randomized O
single O
- O
blind O
3 O
RARE O
3 O
RARE O
- O
square O
study O
with O
RARE O
RARE O
any O
RARE O
effects O
, O
NUM O
males O
and O
NUM O
females O
RARE O
RARE O
containing O
glucose O
or O
resistant O
RARE O
( O
ALL_CAP O
) O
from O
RARE O
high O
- O
RARE O
RARE O
( O
NUM O
) O
or O
from O
RARE O
high O
- O
RARE O
RARE O
( O
NUM O
). O

The O
5 O
' O
flanking O
region O
of O
the O
mouse I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
gene I-GENE
also O
shares O
considerable O
regions O
of O
identity O
with O
the O
5 O
' O
flanking O
region O
of O
the O
rat I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
gene I-GENE
. O

The O
RARE O
18F O
] O
ALL_CAP O
ALL_CAP O
is O
a O
simple O
and O
clinically O
useful O
index O
RARE O
detecting O
RARE O
RARE O
in O
ALL_CAP O
. O

RARE O
methods O
have O
been O
developed O
RARE O
maintaining O
and O
RARE O
the O
RARE O
short O
- O
RARE O
RARE O
RARE O
, O
RARE O
RARE O
, O
in O
an O
easily O
- O
RARE O
, O
laboratory O
setting O
. O

In O
addition O
, O
the O
time O
to O
RARE O
was O
significantly O
shorter O
in O
the O
RARE O
RARE O
in O
both O
RARE O
. O

Also O
like O
the O
thrombin I-GENE
receptor I-GENE
, O
NUM I-GENE
can O
be O
activated O
by O
the O
RARE O
corresponding O
to O
its O
RARE O
RARE O
sequence O
independent O
of O
receptor O
RARE O
. O

We O
conclude O
that O
ALL_CAP O
is O
a O
useful O
investigation O
in O
the O
management O
of O
patients O
with O
cardiopulmonary O
RARE O
and O
RARE O
the O
various O
other O
investigations O
offered O
by O
a O
pulmonary O
function O
laboratory O
. O

Using O
fluorescence O
in O
situ O
hybridization O
, O
we O
mapped O
the O
RARE O
- O
NUM O
RARE O
in O
a O
patient O
with O
RARE O
ALL_CAP O
and O
RARE O
reversal O
, O
who O
carries O
a O
de O
RARE O
RARE O
t O
( O
12 O
; O
NUM O
) O
translocation O
, O
between O
two O
known O
cosmid O
markers O
in O
the O
NUM O
- O
NUM O
region O
. O

This O
is O
concluded O
from O
the O
isolation O
of O
cDNAs O
from O
RARE O
( O
RARE O
RARE O
) O
and O
RARE O
( O
RARE O
RARE O
cv O
. O

The O
data O
presented O
in O
this O
work O
indicate O
that O
NUM I-GENE
may O
also O
be O
involved O
in O
DNA O
damage O
tolerance O
in O
RARE O
cells O
. O

In O
the O
rat I-GENE
RARE I-GENE
allele I-GENE
described O
here O
, O
a O
nonsense O
mutation O
in O
RARE O
8 O
of O
the O
RARE I-GENE
gene I-GENE
was O
identified O
. O

Such O
an O
increase O
in O
the O
steady O
- O
state O
RARE I-GENE
TIMP I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
level O
apparently O
is O
not O
the O
result O
of O
an O
RARE O
- O
RARE O
by O
RARE O
cells O
because O
RARE O
cells O
RARE O
with O
RARE O
cells O
failed O
to O
elicit O
an O
increase O
in O
the O
RARE O
cell O
steady O
- O
state O
TIMP I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
level O
. O

Control O
RARE O
rats O
were O
age O
- O
matched O
to O
the O
different O
treated O
groups O
. O

DESIGN O
: O
A O
cross O
- O
sectional O
study O
. O

In O
the O
ALL_CAP O
and O
ALL_CAP O
category O
, O
anti O
- O
T O
- O
cell O
therapy O
significantly O
lowered O
the O
risk O
of O
graft O
RARE O
. O

We O
have O
identified O
a O
strong O
RARE I-GENE
- I-GENE
responsive I-GENE
element I-GENE
, O
designated O
ALL_CAP I-GENE
( O
ALL_CAP I-GENE
RARE O
near O
the O
3 O
' O
end O
of O
the O
gag I-GENE
gene I-GENE
and O
preceding O
the O
pol I-GENE
gene I-GENE
of O
ALL_CAP O
- O
1 O
. O

Although O
the O
binding O
of O
IE2 I-GENE
NUM I-GENE
to O
RARE O
full I-GENE
- I-GENE
length I-GENE
CREB I-GENE
or O
ALL_CAP I-GENE
is O
minimal O
, O
IE2 I-GENE
NUM I-GENE
does O
form O
complexes O
with O
p300 I-GENE
and O
the O
CREB I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
CBP I-GENE
RARE O
which O
in O
RARE O
bind O
to O
CREB I-GENE
and O
can O
serve O
RARE O
RARE O
proteins O
RARE O
CREB I-GENE
function O
. O

A O
transgenic O
RARE O
assay O
was O
used O
to O
test O
whether O
RARE I-GENE
supplied O
in O
RARE O
could O
rescue O
amplification O
- O
RARE O
viral O
genomes O
encoding O
altered O
RARE I-GENE
proteins I-GENE
. O

On O
the O
basis O
of O
its O
ALL_CAP O
structural O
homology O
, O
RARE I-GENE
is O
perhaps O
the O
only O
RARE O
of O
the O
jun I-GENE
- O
fos I-GENE
gene O
family O
completely O
viral O
in O
origin O
. O

The O
rCBF O
and O
RARE O
were O
recorded O
by O
laser O
- O
RARE O
RARE O
. O

Although O
basal O
vessels O
may O
RARE O
distal O
RARE O
vessels O
RARE O
to O
RARE O
after O
ALL_CAP O
. O

The O
RARE O
combination O
of O
RARE O
, O
RARE O
, O
and O
RARE O
RARE O
resulted O
in O
an O
ulcer O
healing O
rate O
of O
98 O
% O
and O
an O
H O
. O
RARE O
eradication O
rate O
of O
NUM O
%. O

Several O
lines O
of O
evidence O
presented O
here O
suggest O
that O
PKC I-GENE
- I-GENE
RARE I-GENE
plays O
a O
role O
in O
alpha I-GENE
2 I-GENE
integrin I-GENE
gene I-GENE
RARE O
. O

Plasma O
RARE I-GENE
: O
a O
marker O
RARE O
microvascular O
complications O
in O
diabetes O
mellitus O
. O

RARE O
: O
RARE O
epidemic O
in O
the O
newly O
independent O
states O
of O
the O
former O
ALL_CAP O
, O
January O
1995 O
- O
RARE O
1996 O
. O

The O
characterization O
of O
the O
promoter O
region O
indicated O
that O
three O
distinct O
regulatory O
elements O
corresponding O
to O
an O
AP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
( O
or O
ALL_CAP O
RARE O
a O
ALL_CAP I-GENE
/ O
kappaB I-GENE
domain O
, O
and O
a O
CAAT O
box O
are O
involved O
in O
the O
activation O
by O
NUM I-GENE
( I-GENE
v I-GENE
RARE I-GENE
src I-GENE
. O

RARE O
NUM O
is O
RARE O
in O
vivo O
in O
several O
cell O
lines O
, O
and O
substitution O
of O
serine O
NUM O
to O
alanine O
( O
NUM O
) O
resulted O
in O
an O
increased O
ability O
of O
Myb I-GENE
to O
transactivate O
a O
RARE O
promoter O
containing O
five O
copies O
of O
the O
RARE I-GENE
- I-GENE
NUM I-GENE
Myb I-GENE
- O
responsive O
element O
and O
a O
minimal O
herpes I-GENE
tk I-GENE
promoter I-GENE
. O

The O
DNA O
binding O
and O
RARE O
activities O
of O
c I-GENE
- I-GENE
Myb I-GENE
appear O
to O
be O
unaffected O
by O
the O
NUM O
substitution O
, O
suggesting O
that O
RARE O
of O
serine O
NUM O
may O
mediate O
its O
effect O
on O
the O
transcription O
transactivating O
activity O
of O
c I-GENE
- I-GENE
Myb I-GENE
by O
RARE O
interactions O
with O
other O
proteins O
. O

The O
amount O
of O
these O
factors O
was O
RARE O
in O
ALL_CAP O
cells O
in O
which O
the O
RARE I-GENE
- I-GENE
ALL_CAP I-GENE
gene I-GENE
is O
only O
weakly O
transcriptionally O
activated O
. O

PIP2 O
, O
when O
incorporated O
into O
RARE O
carrier O
vesicles O
, O
binds O
tightly O
to O
the O
guanine O
nucleotide O
- O
depleted O
form O
of O
NUM I-GENE
and O
weakly O
to O
the O
GDP O
- O
RARE O
form O
of O
the O
GTP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
but O
does O
not O
bind O
to O
GTP O
- O
RARE O
NUM I-GENE
, O
similar O
to O
what O
was O
observed O
RARE O
the O
RARE I-GENE
RARE I-GENE
. O

RARE O
RARE O
ALL_CAP I-GENE
accelerated O
hydrolysis O
of O
GTP O
RARE O
to O
recombinant I-GENE
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
; O
RARE O
effect O
of O
NH2 O
- O
terminal O
RARE O
was O
observed O
. O

Biol O
. O

A O
novel O
RARE O
- O
binding O
domain O
in O
the O
N O
- O
terminal O
transforming O
region O
of O
Cbl I-GENE
interacts O
directly O
and O
selectively O
with O
ALL_CAP I-GENE
- I-GENE
70 I-GENE
in O
T O
cells O
. O

RARE O
- O
NUM O
within O
the O
( O
NUM O
)- O
RARE O
- O
binding O
domain O
was O
essential O
RARE O
RARE O
enzyme O
activity O
. O

Its O
transcription O
has O
been O
shown O
to O
be O
RARE O
40 O
- O
50 O
- O
RARE O
in O
response O
to O
oxygen O
or O
heme O
deficiency O
, O
in O
part O
through O
RARE O
of O
repression O
RARE O
by O
NUM I-GENE
and O
in O
part O
by O
activation O
RARE O
by O
an O
upstream O
activation O
sequence O
( O
UAS O
). O

Altogether O
, O
our O
results O
indicate O
that O
the O
transcriptional O
activity O
of O
RARE I-GENE
proteins I-GENE
is O
modulated O
by O
PKC I-GENE
. O

RARE I-GENE
has O
been O
postulated O
to O
RARE O
through O
the O
NUM I-GENE
and O
SH3 I-GENE
domains I-GENE
. O

Furthermore O
, O
RARE O
in O
the O
presence O
of O
bovine I-GENE
RARE I-GENE
resulted O
in O
a O
good O
RARE O
of O
the O
cellular O
viability O
and O
of O
the O
ALL_CAP O
heterogeneity O
in O
respect O
to O
fresh O
cells O
. O

RARE O
RARE O
RARE O
RARE O
presentation O
form O
of O
multiple O
myeloma O

Five O
- O
year O
RARE O
RARE O
to O
NUM O
%, O
NUM O
. O
2 O
%, O
NUM O
. O
4 O
%, O
29 O
. O
8 O
%, O
and O
20 O
% O
RARE O
stages O
I O
, O
II O
, O
III O
, O
ALL_CAP O
and O
ALL_CAP O
respectively O
. O

The O
presence O
of O
unidentified O
RARE O
or O
microscopic O
clusters O
of O
neoplastic O
cells O
, O
RARE O
around O
, O
more O
or O
less O
close O
to O
, O
the O
line O
of O
RARE O
of O
lesion O
, O
could O
RARE O
any O
attempt O
to O
gain O
a O
" O
radical O
" O
RARE O
RARE O
. O

The O
partial O
categories O
of O
the O
ALL_CAP O
that O
were O
more O
affected O
were O
work O
, O
RARE O
and O
RARE O
, O
home O
management O
, O
and O
sleep O
and O
rest O
. O

Northern O
blot O
analysis O
, O
using O
the O
NUM I-GENE
- O
specific O
probe O
, O
indicated O
that O
RARE O
RARE O
RARE O
. O
RARE O
RARE O
an O
increase O
over O
basal O
levels O
of O
NUM I-GENE
mRNA I-GENE
, O
while O
RARE O
RARE O
RARE O
. O
RARE O
caused O
a O
decrease O
. O

RARE O
disruption O
of O
the O
NUM I-GENE
gene I-GENE
in O
yeast O
revealed O
a O
second O
ALL_CAP I-GENE
glycosylase I-GENE
/ I-GENE
lyase I-GENE
protein I-GENE
, O
tentatively O
named O
NUM I-GENE
, O
which O
differs O
from O
NUM I-GENE
in O
that O
it O
preferentially O
acts O
on O
ALL_CAP O
: O
G O
. O

Furthermore O
, O
the O
use O
of O
zero O
- O
RARE O
RARE O
in O
combination O
with O
RARE O
RARE O
reconstruction O
is O
considerably O
more O
effective O
RARE O
removing O
the O
effects O
of O
multiple O
elastic O
and O
RARE O
RARE O
and O
RARE O
objective O
lens O
RARE O
than O
either O
technique O
by O
itself O
. O

RARE O
RARE O
both O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
and O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
initiate O
from O
RARE O
ALL_CAP O
motifs O
, O
and O
transcripts O
are O
detected O
from O
16 O
through O
72 O
hr O
p O
. O
i O
. O

In O
order O
to O
determine O
which O
sequences O
in O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
are O
crucial O
RARE O
activation O
by O
the O
NUM I-GENE
viral I-GENE
protein I-GENE
, O
we O
made O
deletions O
of O
the O
promoter O
, O
RARE O
them O
into O
a O
luciferase I-GENE
RARE O
vector O
and O
tested O
their O
activity O
in O
mouse O
RARE O
, O
which O
do O
not O
express O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
. O

Sequence O
analysis O
of O
the O
isolated O
genomic O
clone O
revealed O
that O
the O
DNA O
binding O
domain O
of O
this O
orphan O
receptor O
is O
most O
homologous O
to O
the O
human I-GENE
NUM I-GENE
receptor I-GENE
. O

Genomic O
DNA O
hybridization O
suggests O
that O
NUM I-GENE
is O
a O
single O
- O
copy O
gene O
in O
the O
S O
. O
RARE O
genome O
. O

A O
3 O
- O
yr O
retrospective O
review O
is O
effective O
and O
RARE O
94 O
% O
of O
the O
RARE O
. O

Isolation O
and O
identification O
of O
genes O
activating O
NUM I-GENE
- I-GENE
dependent I-GENE
NUM I-GENE
RARE O
in O
Saccharomyces O
cerevisiae O
. O

METHODS O
ALL_CAP O
RESULTS O
: O
A O
NUM O
- O
year O
- O
old O
woman O
with O
confirmed O
AV O
nodal O
RARE O
tachycardia O
underwent O
a O
successful O
" O
slow O
RARE O
" O
AV O
modification O
with O
a O
single O
RARE O
application O
. O

Patients O
with O
low O
RARE O
of O
having O
aluminum O
overload O
( O
serum O
iron O
levels O
< O
40 O
micrograms O
/ O
L O
and O
ALL_CAP O
< O
NUM O
micrograms O
/ O
L O
) O
had O
significantly O
RARE O
values O
of O
serum O
iron O
, O
iron O
transferrin I-GENE
saturation O
, O
and O
serum I-GENE
ferritin I-GENE
levels O
compared O
with O
those O
patients O
with O
a O
high O
RARE O
of O
having O
aluminum O
overload O
( O
serum O
aluminum O
levels O
> O
40 O
micrograms O
/ O
L O
and O
ALL_CAP O
> O
NUM O
micrograms O
/ O
L O
). O

Although O
the O
NUM I-GENE
RARE O
are O
RARE O
RARE O
RARE O
evolution O
, O
the O
mammalian O
genes O
did O
not O
express O
the O
ALL_CAP O
- O
inducible O
RARE O
of O
their O
yeast O
RARE O
. O

Ha I-GENE
- I-GENE
NUM I-GENE
and O
activated O
proteins O
in O
both O
the O
RARE I-GENE
- I-GENE
cellular I-GENE
regulated I-GENE
kinase I-GENE
( O
ERK I-GENE
) O
and O
the O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
SAPK I-GENE
) O
or O
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
) O
RARE O
independently O
RARE O
PEA3 I-GENE
- O
RARE O
gene O
RARE O
. O

Sequence O
analysis O
of O
reverse O
RARE O
, O
amplified O
cDNA O
generated O
from O
RARE O
RNA O
isolated O
from O
transfected O
cells O
demonstrated O
the O
presence O
of O
RARE O
RARE O
products O
containing O
NUM O
and O
NUM O
additional O
bases O
RARE O
RARE O
RARE O
the O
accumulation O
of O
unspliced O
mRNA O
. O

Its O
RARE O
profile O
predicts O
RARE O
transmembrane O
spans O
and O
a O
hydrophilic O
amino O
terminus O
of O
RARE O
NUM O
residues O
, O
and O
it O
suggests O
the O
presence O
of O
an O
RARE O
alpha O
- O
helix O
( O
L O
- O
NUM O
to O
F O
- O
97 O
) O
in O
close O
RARE O
to O
the O
RARE O
strongly O
hydrophobic O
segment O
of O
ALL_CAP I-GENE
. O

A O
1 O
. O
5 O
- O
kb O
HindIII I-GENE
genomic O
fragment O
carrying O
the O
ALL_CAP I-GENE
gene O
from O
M O
. O
RARE O
NUM O
was O
RARE O
and O
sequenced O
. O

RARE O
RARE O
repression O
of O
the O
RARE I-GENE
operon I-GENE
of I-GENE
Bacillus I-GENE
subtilis I-GENE
is O
RARE O
by O
the O
RARE O
control O
protein O
ALL_CAP I-GENE
and O
by O
RARE I-GENE
, O
a O
RARE O
protein O
of O
the O
RARE O
RARE O
. O

RARE O
and O
RARE O
: O
filling O
the O
RARE O
. O

A O
subsequent O
screen O
RARE O
the O
RARE O
of O
the O
positively O
selectable O
target O
locus O
marker O
RARE O
the O
RARE O
RARE O
RARE O
RARE O
frequency O
(> O
2 O
%). O

Here O
we O
demonstrate O
that O
another O
cellular O
protein O
RARE O
to O
ALL_CAP I-GENE
/ O
ABL I-GENE
through O
the O
ALL_CAP I-GENE
- O
NUM I-GENE
domain O
is O
p130 I-GENE
( O
ALL_CAP I-GENE
). O
p130 I-GENE
( O
ALL_CAP I-GENE
) O
was O
found O
to O
be O
tyrosine O
RARE O
and O
associated O
with O
ALL_CAP I-GENE
in O
ALL_CAP I-GENE
/ O
ABL I-GENE
expressing O
cell O
lines O
and O
in O
samples O
obtained O
from O
CML O
and O
ALL O
patients O
, O
but O
not O
in O
samples O
from O
controls O
. O

There O
are O
four O
RARE O
motifs O
interspersed O
with O
RARE O
- O
rich O
regions O
. O

The O
effects O
of O
RARE O
variations O
on O
RARE O
Stroop O
effects O
. O

In O
a O
third O
experiment O
, O
a O
RARE O
gradually O
increases O
the O
number O
of O
RARE O
RARE O
can O
RARE O
with O
RARE O
than O
70 O
% O
average O
accuracy O
to O
nine O
, O
replacing O
RARE O
many O
RARE O
NUM O
RARE O
correctly O
. O

PCNA I-GENE
mRNA I-GENE
has O
a O
3 O
' O
UTR O
RARE O
to O
yellow O
RARE O
RNA O
and O
is O
localized O
in O
RARE O
eggs O
and O
RARE O
. O

A O
1 O
. O
8 O
- O
kb O
cDNA O
clone O
( O
designed O
ALL_CAP I-GENE
, O
gene I-GENE
RARE I-GENE
NUM I-GENE
) O
with O
homology O
to O
the O
RARE I-GENE
was O
isolated O
from O
a O
human O
RARE O
cDNA O
library O
. O

PCR O
/ O
Southern O
blot O
analysis O
of O
human O
RARE O
cDNA O
using O
primers O
flanking O
the O
ALL_CAP I-GENE
coding I-GENE
sequence I-GENE
revealed O
RARE O
of O
a O
full O
- O
length O
mRNA O
and O
short O
transcripts O
with O
partial O
RARE O
1 O
and O
partial O
RARE O
4 O
deletions O
. O

The O
high O
sequence O
homology O
, O
similar O
genomic O
RARE O
, O
and O
identical O
chromosomal O
loci O
of O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
and O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
suggest O
a O
ALL_CAP I-GENE
family I-GENE
gene I-GENE
cluster I-GENE
RARE O
RARE O
locus O
NUM O
. O

The O
third O
ORF O
generates O
a O
transcript O
of O
1 O
. O
6 O
kb O
and O
encodes O
a O
protein O
of O
NUM O
residues O
including O
a O
perfect O
match O
to O
the O
consensus O
sequence O
of O
a O
NUM O
zinc O
finger O
domain O
; O
it O
shares O
a O
strong O
homology O
with O
yeast I-GENE
NUM I-GENE
and O
RARE I-GENE
- I-GENE
A I-GENE
from I-GENE
RARE I-GENE
, I-GENE
RARE I-GENE
and I-GENE
E I-GENE
. I-GENE
coli I-GENE
. O

RARE O
RARE I-GENE
and O
ALL_CAP O
improved O
the O
RARE O
of O
development O
, O
RARE O
and O
arrangement O
of O
cartilage O
and O
bone O
cells O
, O
and O
RARE O
the O
effects O
of O
P O
deficiency O
on O
the O
histological O
and O
gross O
RARE O
of O
the O
RARE O
. O

The O
importance O
of O
temporal O
factors O
on O
the O
presence O
and O
severity O
of O
ethanol O
withdrawal O
signs O
in O
the O
rat O
was O
RARE O
using O
rating O
scale O
, O
tremor O
, O
and O
acoustic O
RARE O
RARE O
. O

Data O
supported O
the O
RARE O
of O
the O
ALL_CAP O
- O
III O
short O
form O
and O
the O
criterion O
- O
related O
validity O
of O
both O
the O
K O
- O
ALL_CAP O
and O
and O
RARE O
Short O
RARE O
Assessment O
RARE O
( O
K O
- O
ALL_CAP O
). O

Quantitative O
analysis O
of O
RARE O
RARE O
rates O
in O
NUM I-GENE
- I-GENE
NUM I-GENE
strains O
carrying O
plasmids O
with O
multiple O
replication O
origins O
suggests O
that O
a O
defect O
in O
initiating O
DNA O
replication O
probably O
causes O
this O
RARE O
RARE O
RARE O
. O

Thus O
, O
the O
RARE O
ALL_CAP I-GENE
alpha I-GENE
appears O
to O
be O
involved O
in O
RARE O
of O
the O
RARE O
, O
with O
the O
N O
and O
C O
termini O
acting O
RARE O
positive O
and O
negative O
RARE O
, O
respectively O
, O
of O
the O
kinase O
domain O
whose O
activity O
is O
crucial O
RARE O
formation O
of O
stress O
fibers O
and O
RARE O
adhesion O
complexes O
. O

These O
findings O
and O
the O
differential O
tissue O
distribution O
of O
p54 I-GENE
suggest O
that O
this O
novel O
SR I-GENE
protein I-GENE
may O
participate O
in O
RARE O
of O
RARE O
RARE O
in O
a O
tissue O
- O
and O
substrate O
- O
dependent O
manner O
. O

The O
elevation O
of O
cyclic O
AMP O
( O
cAMP O
) O
levels O
in O
the O
cell O
RARE O
the O
activity O
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
. O

An O
interaction O
screen O
with O
the O
repression O
domain O
of O
the O
orphan I-GENE
receptor I-GENE
RARE I-GENE
identified O
N I-GENE
- I-GENE
ALL_CAP I-GENE
, O
the O
RARE O
RARE O
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( O
TR I-GENE
) O
and O
retinoic I-GENE
acid I-GENE
receptor I-GENE
( O
RAR I-GENE
). O

These O
results O
indicate O
that O
inhibition O
of O
Jun I-GENE
kinase I-GENE
activation O
was O
sufficient O
to O
inhibit O
Ras I-GENE
transformation O
even O
in O
the O
presence O
of O
activated O
RARE I-GENE
- I-GENE
2 I-GENE
. O

Our O
analysis O
suggests O
that O
NUM I-GENE
is O
a O
RARE O
protein O
with O
RARE O
activities O
that O
can O
affect O
mRNA O
turnover O
and O
nonsense O
suppression O
. O

Identification O
of O
NUM I-GENE
RARE O
a O
RARE O
regulator O
of O
NUM I-GENE
in O
the O
sexual O
response O
RARE O
of O
Schizosaccharomyces O
pombe O
. O

Two O
closely O
related O
variants O
of O
Stat5 I-GENE
, O
Stat5a I-GENE
and O
NUM I-GENE
, O
are O
encoded O
by O
distinct O
genes O
. O

Mutations O
in O
three O
loci O
( O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
) O
were O
identified O
. O

The O
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
functions O
RARE O
of O
RARE I-GENE
in O
a O
signal O
RARE O
cascade O
which O
RARE O
mitogenic O
stimuli O
from O
the O
plasma O
membrane O
to O
the O
nucleus O
. O

RARE I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
- O
dependent O
activation O
of O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
is O
regulated O
by O
receptor O
binding O
of O
NUM I-GENE
- I-GENE
domain I-GENE
- I-GENE
containing I-GENE
proteins I-GENE
which O
influence O
Ras I-GENE
activity O
. O

In O
transient O
RARE O
E1A I-GENE
could O
induce O
the O
activity O
of O
the O
p53 I-GENE
promoter I-GENE
to O
a O
high O
level O
; O
NUM I-GENE
E1A I-GENE
was O
threefold O
RARE O
efficient O
RARE O
NUM I-GENE
E1A I-GENE
in O
this O
activity O
, O
and O
YY1 I-GENE
RARE O
to O
the O
composite O
element O
was O
shown O
to O
mediate O
NUM O
% O
of O
this O
induction O
. O

The O
retinoid I-GENE
Z I-GENE
receptor I-GENE
beta I-GENE
( O
ALL_CAP I-GENE
beta I-GENE
RARE O
an O
orphan O
receptor O
, O
is O
a O
RARE O
of O
the O
retinoic I-GENE
acid I-GENE
receptor I-GENE
( O
RAR I-GENE
RARE O
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( O
TR I-GENE
) O
subfamily O
of O
nuclear O
receptors O
. O

DNA I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
DNA I-GENE
- I-GENE
ALL_CAP I-GENE
) O
consists O
of O
a O
RARE O
protein O
( O
RARE I-GENE
) O
and O
a O
large O
catalytic O
subunit O
( O
DNA I-GENE
- I-GENE
RARE I-GENE
). O

RARE O
RARE O
sequence O
identity O
was O
found O
between O
the O
3 O
' O
end O
of O
the O
NUM I-GENE
gene I-GENE
and O
two O
RARE O
sequence O
tags O
( O
RARE O
) O
and O
between O
the O
5 O
' O
end O
of O
the O
NUM I-GENE
gene I-GENE
and O
a O
third O
ALL_CAP O
. O

Sequencing O
of O
the O
NUM O
11 O
. O
1 O
/ O
NUM O
duplication O
breakpoints O
has O
revealed O
the O
presence O
of O
RARE O
immunoglobulin I-GENE
- I-GENE
like I-GENE
ALL_CAP I-GENE
RARE I-GENE
sequences I-GENE
RARE O
or O
near O
the O
RARE O
boundaries O
. O

However O
, O
in O
a O
multivariate O
analysis O
RARE O
age O
, O
gender O
, O
and O
a O
previous O
history O
of O
cardiovascular O
diseases O
, O
female O
gender O
was O
not O
independently O
associated O
with O
RARE O
. O

Moreover O
, O
following O
a O
single O
intravenous O
injection O
of O
the O
RARE O
vector O
complexed O
to O
RARE O
liposomes O
into O
recipient O
mice O
, O
delivery O
of O
NUM I-GENE
and O
ALL_CAP I-GENE
cDNAs I-GENE
was O
achieved O
in O
all O
the O
organs O
we O
tested O
. O

The O
limits O
of O
agreement O
between O
ALL_CAP O
and O
TOF O
responses O
were O
so O
wide O
that O
they O
cannot O
be O
used O
RARE O
. O

The O
RARE I-GENE
- O
encoding O
ALL_CAP I-GENE
gene I-GENE
is O
RARE O
in O
an O
operon O
that O
also O
encodes O
RARE I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
and O
is O
part O
of O
the O
RARE O
cluster O
of O
RARE I-GENE
genes I-GENE
carried O
on O
cosmid O
NUM O
that O
enables O
RARE O
bacteria O
like O
Escherichia O
coli O
and O
RARE O
RARE O
to O
elicit O
the O
HR O
in O
tobacco O
leaves O
. O

Despite O
the O
presence O
of O
one O
additional O
RARE I-GENE
reductase I-GENE
, O
the O
ALL_CAP I-GENE
- I-GENE
encoded I-GENE
enzyme I-GENE
is O
essential O
to O
the O
aerobic O
growth O
of O
the O
cell O
because O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
mutants I-GENE
of O
both O
species O
are O
not O
viable O
in O
the O
presence O
of O
oxygen O
. O

Altogether O
, O
the O
results O
demonstrate O
that O
the O
two O
isoforms O
elicit O
similar O
responses O
in O
vivo O
despite O
differences O
in O
their O
RARE O
. O

RARE O
factors O
focusing O
on O
RARE O
, O
perceived O
RARE O
to O
RARE O
, O
and O
RARE O
factors O
were O
also O
relevant O
. O

RARE O
- O
resolution O
RARE O
of O
the O
RARE I-GENE
RARE I-GENE
repressor I-GENE
complexed O
with O
RARE O
and O
RARE O
reveals O
an O
SH3 I-GENE
- I-GENE
like I-GENE
third O
domain O
and O
suggests O
a O
possible O
role O
of O
phosphate O
RARE O
RARE O
- O
RARE O
. O

RARE O
of O
the O
human O
and O
RARE O
proteins O
with O
2 O
- O
RARE O
- O
5 O
- O
RARE O
indicates O
that O
membrane I-GENE
RARE I-GENE
additionally O
possesses O
two O
RARE O
disulfide O
bonds O
. O

FEV1 O
did O
not O
fall O
significantly O
in O
patients O
without O
acute O
or O
chronic O
ALL_CAP O
and O
recovered O
earlier O
than O
in O
patients O
without O
RARE O
pulmonary O
infection O
. O

Administration O
of O
adrenaline O
resulted O
in O
a O
large O
RARE O
of O
the O
SaO2 O
in O
6 O
of O
the O
7 O
measurements O
. O

RARE O
with O
dietary O
modification O
and O
RARE O
lowering O
drugs O
resulted O
in O
resolution O
of O
symptoms O
and O
RARE O
swelling O
in O
one O
patient O
. O

RARE O
, O
submitted O
RARE O
RARE O
). O

We O
have O
RARE O
a O
novel O
protein O
kinase O
, O
termed O
hematopoietic I-GENE
RARE I-GENE
kinase I-GENE
1 I-GENE
( O
NUM I-GENE
RARE O
that O
is O
RARE O
predominantly O
in O
hematopoietic O
cells O
, O
including O
early O
RARE O
cells O
. O

Human O
NUM I-GENE
/ O
NUM I-GENE
protein O
has O
two O
LIM I-GENE
domains O
, O
and O
each O
shares O
NUM O
. O
1 O
% O
and O
77 O
or O
NUM O
% O
identical O
residues O
with O
human I-GENE
cysteine I-GENE
- I-GENE
rich I-GENE
protein I-GENE
( O
CRP I-GENE
) O
and O
rat I-GENE
ALL_CAP I-GENE
, O
respectively O
. O

The O
fragments O
are O
separated O
and O
directly O
sized O
by O
agarose O
gel O
electrophoresis O
. O

Several O
of O
the O
RARE O
boundaries O
correspond O
to O
the O
boundaries O
of O
RARE O
domains O
in O
the O
p55 I-GENE
protein I-GENE
. O

RARE O
studies O
have O
shown O
locus O
heterogeneity O
with O
one O
ALL_CAP I-GENE
gene I-GENE
mapped O
to O
RARE O
NUM O
and O
a O
second O
to O
NUM O
. O
3 O
. O

The O
cytogenetic O
RARE O
of O
the O
RARE O
RARE O
RARE O
site O
, O
ALL_CAP I-GENE
, O
is O
due O
to O
the O
expansion O
of O
a O
ALL_CAP O
repeat O
in O
proximal O
NUM O
of O
the O
human O
X O
RARE O
and O
is O
associated O
with O
a O
mild O
form O
of O
mental O
RARE O
. O

DNA O
sequence O
analysis O
of O
a O
NUM O
bp O
BamHI I-GENE
- O
ALL_CAP I-GENE
fragment O
revealed O
that O
three O
RARE O
reading O
frames O
( O
RARE O
) O
were O
encoded O
in O
the O
same O
orientation O
. O

The O
initial O
RARE O
experience O
RARE O
individuals O
with O
HIV O
- O
related O
ALL_CAP O
may O
be O
pivotal O
to O
the O
RARE O
of O
and O
participation O
in O
RARE O
ALL_CAP O
care O
. O

RARE I-GENE
( O
ALL_CAP I-GENE
) O
is O
the O
prototype O
of O
a O
group O
of O
RARE O
transcription O
factors O
that O
contain O
two O
or O
more O
unusual O
ALL_CAP O
zinc O
RARE O
. O

This O
element O
, O
termed O
RARE O
- O
a O
( O
ALL_CAP O
RARE O
differs O
by O
one O
nucleotide O
from O
a O
palindromic O
ALL_CAP O
( O
RARE O
, O
ALL_CAP O
RARE O
which O
is O
known O
to O
bind O
CREB I-GENE
RARE O
a O
RARE O
. O

Analysis O
of O
human O
genomic O
DNA O
reveals O
an O
intronless O
sequence O
with O
strong O
homology O
to O
human I-GENE
G I-GENE
alpha I-GENE
RARE I-GENE
cDNA I-GENE
. O

The O
RARE O
RARE O
- O
intron O
RARE O
of O
the O
NUM I-GENE
- I-GENE
kb I-GENE
human I-GENE
gene I-GENE
NUM I-GENE
, O
which O
encodes O
the O
NUM I-GENE
and O
NUM I-GENE
proteins I-GENE
of O
transcription O
factors O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
and O
I I-GENE
RARE I-GENE
B I-GENE
- I-GENE
gamma I-GENE
: O
implications O
RARE O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
- O
RARE O
signal O
RARE O
. O

An O
inverted O
Alu I-GENE
repeat O
element O
, O
flanked O
by O
RARE O
direct O
repeats O
, O
was O
identified O
within O
the O
region O
- O
NUM O
/- O
NUM O
, O
relative O
to O
the O
RARE O
site O
. O

The O
RARE O
were O
returned O
to O
RARE O
, O
and O
monitoring O
was O
continued O
RARE O
1 O
h O
. O

RARE O
leukemia O
viruses O
( O
RARE O
RARE O
which O
are O
replication O
- O
competent O
RARE O
of O
the O
RARE O
RARE O
species O
, O
are O
RARE O
transmitted O
in O
RARE O
RARE O
. O

Comparison O
of O
the O
amino O
acid O
sequences O
of O
the O
NUM I-GENE
polypeptides I-GENE
of I-GENE
NUM I-GENE
, I-GENE
ALL_CAP I-GENE
, I-GENE
and I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
with O
the O
corresponding O
RARE O
, O
eukaryotic O
, O
and O
viral O
proteins O
revealed O
differences O
in O
amino O
acid O
RARE O
and O
phylogenetic O
relationships O
. O

The O
NUM I-GENE
of O
ALL_CAP O
shows O
the O
highest O
RARE O
to O
the O
NUM I-GENE
of O
NUM O
and O
significant O
lower O
RARE O
to O
the O
eukaryotic I-GENE
RARE I-GENE
II I-GENE
and I-GENE
III I-GENE
RARE O
RARE O
RARE O
to O
the O
RARE O
subunit O
. O

The O
use O
of O
RARE O
ALL_CAP O
cells O
thus O
provides O
a O
RARE O
in O
vitro O
RARE O
RARE O
further O
study O
of O
the O
endocrine O
, O
RARE O
, O
and O
autocrine O
factors O
RARE O
endometrial O
gene O
RARE O
RARE O
RARE O
. O

We O
performed O
RARE O
estimation O
of O
spikes O
and O
ALL_CAP O
RARE O
in O
identical O
patients O
. O

Both O
verapamil O
and O
propranolol O
can O
exhibit O
additive O
effects O
with O
adenosine O
in O
RARE O
AV O
nodal O
conduction O
time O
; O
however O
, O
only O
verapamil O
can O
reduce O
the O
dose O
of O
adenosine O
required O
to O
produce O
AV O
nodal O
RARE O
. O

RARE O
ALL_CAP O
was O
inversely O
correlated O
with O
bone I-GENE
RARE I-GENE
phosphatase I-GENE
( O
RARE O
= O
- O
NUM O
. O
NUM O
, O
p O
< O
NUM O
. O
01 O
) O
and O
RARE O
ALL_CAP I-GENE
( O
RARE O
= O
- O
NUM O
. O
NUM O
, O
p O
< O
NUM O
. O
05 O
). O

In O
addition O
, O
a O
comparison O
of O
the O
ALL_CAP I-GENE
gene I-GENE
sequences I-GENE
with O
available O
RARE O
indicates O
that O
a O
large O
portion O
of O
these O
genes O
, O
including O
exons O
encoding O
two O
RARE O
domains O
of O
the O
RARE O
- O
terminal O
region O
of O
these O
proteins O
, O
has O
been O
duplicated O
RARE O
part O
of O
a O
larger O
human O
telomeric O
repeat O
sequence O
found O
on O
many O
human O
chromosomes O
. O

We O
show O
here O
that O
the O
LIM I-GENE
domain I-GENE
RARE I-GENE
protein I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
activates O
the O
rat I-GENE
RARE I-GENE
promoter I-GENE
in O
both O
fibroblast O
and O
islet O
cell O
lines O
. O

Although O
RARE I-GENE
- I-GENE
1 I-GENE
binds O
to O
both O
the O
insulin I-GENE
and O
RARE I-GENE
gene I-GENE
promoter I-GENE
elements I-GENE
in O
vitro O
, O
these O
sequences O
display O
marked O
differences O
in O
their O
relative O
transcriptional O
properties O
when O
ligated O
adjacent O
to O
a O
heterologous O
promoter O
and O
transfected O
into O
NUM O
- O
NUM O
islet O
cells O
. O

It O
is O
likely O
that O
other O
pathways O
involve O
alternate O
signal O
RARE O
events O
( O
RARE O
. O
g O
., O
RARE O
RARE O
) O
and O
promoter O
response O
elements O
( O
RARE O
. O
g O
., O
SRE O
). O

The O
NUM I-GENE
count O
RARE O
which O
remission O
occurs O
may O
reflect O
severe O
immunodeficiency O
such O
that O
risk O
RARE O
AIDS O
- O
related O
infection O
is O
high O
. O

Although O
diagnostic O
RARE O
is O
still O
considered O
the O
standard O
reference O
in O
the O
diagnosis O
of O
ectopic O
RARE O
( O
ALL_CAP O
RARE O
use O
of O
high O
- O
resolution O
RARE O
RARE O
, O
in O
conjunction O
with O
qualitative O
serum O
assays O
of O
the O
beta O
subunit O
of O
human I-GENE
RARE I-GENE
gonadotropin I-GENE
( O
beta I-GENE
- I-GENE
hCG I-GENE
RARE O
allows O
detection O
of O
earlier O
and O
smaller O
RARE O
. O

RARE O
of O
the O
ALL_CAP I-GENE
homologous I-GENE
region I-GENE
sequence I-GENE
( O
NUM I-GENE
): O
enhancer O
and O
RARE O
functions O
have O
different O
sequence O
requirements O
. O

ALL_CAP I-GENE
' O
RARE O
of O
function O
' O
studies O
by O
RARE O
over O
- O
RARE O
of O
a O
dominant O
negative O
ALL_CAP I-GENE
delta I-GENE
E I-GENE
resulted O
in O
increased O
levels O
of O
NUM I-GENE
/ O
NUM I-GENE
and O
myogenin I-GENE
mRNAs I-GENE
after O
serum O
withdrawal O
. O

Neither O
NUM I-GENE
nor O
NUM I-GENE
is O
essential O
RARE O
cell O
growth O
, O
and O
a O
double O
deletion O
mutant O
is O
viable O
. O

These O
two O
repeat O
motifs O
are O
organized O
in O
an O
extremely O
RARE O
- O
RARE O
pattern O
in O
each O
domain O
, O
which O
suggests O
that O
NUM I-GENE
belongs O
to O
a O
new O
group O
of O
proteins O
having O
the O
repeat O
motifs O
of O
two O
distinct O
groups O
of O
RARE I-GENE
RARE I-GENE
. O

Their O
use O
established O
that O
the O
ALL_CAP O
activity O
catalyzed O
both O
a O
RARE O
and O
a O
RARE O
RARE O
and O
therefore O
has O
a O
RARE O
RARE O
than O
previously O
RARE O
. O

To O
explore O
the O
RARE O
significance O
of O
these O
subdomains O
in O
PRL I-GENE
binding O
and O
signal O
RARE O
, O
deletion O
mutants O
of O
S1 O
or O
/ O
and O
NUM O
subdomains O
were O
constructed O
. O

A O
stable O
heterologous O
cell O
line O
containing O
the O
mouse I-GENE
TRH I-GENE
receptor I-GENE
was O
constructed O
by O
transfection O
of O
RARE O
293 O
cells O
, O
which O
lack O
L O
RARE O
activity O
. O

To O
understand O
further O
the O
RARE O
and O
RARE O
of O
the O
NUM I-GENE
, O
we O
now O
describe O
the O
genomic O
characteristics O
, O
tissue O
RARE O
, O
chromosomal O
RARE O
, O
and O
regional O
mapping O
of O
the O
human I-GENE
NUM I-GENE
gene I-GENE
, O
NUM I-GENE
. O

The O
final O
predicted O
RARE O
has O
an O
overall O
RARE O
deviation O
of O
NUM O
. O
7 O
A O
from O
that O
of O
ras I-GENE
- O
p21 I-GENE
. O

Genomic O
organization O
of O
the O
human I-GENE
beta I-GENE
- I-GENE
catenin I-GENE
gene I-GENE
( O
NUM I-GENE
). O

Furthermore O
, O
although O
the O
regional O
distribution O
of O
lean O
tissue O
mass O
in O
the O
trunk O
and O
RARE O
remained O
RARE O
constant O
RARE O
different O
RARE O
stages O
, O
the O
regional O
distribution O
of O
fat O
was O
altered O
significantly O
, O
RARE O
more O
central O
and O
less O
peripheral O
. O

Thus O
, O
the O
predicted O
NUM I-GENE
protein I-GENE
retains O
most O
of O
the O
cytoplasmic O
region O
, O
but O
lacks O
the O
extracellular O
and O
transmembrane O
domains O
. O

RARE O
RARE O
of O
the O
NUM I-GENE
protein I-GENE
was O
demonstrated O
by O
in O
vitro O
labeling O
with O
RARE O
32P O
]. O

NUM O
. O
5 O
% O
of O
cycles O
). O

We O
report O
here O
the O
discovery O
of O
a O
new O
actin I-GENE
- I-GENE
related I-GENE
gene I-GENE
in O
this O
organism O
, O
which O
we O
have O
named O
NUM I-GENE
. O

Two O
of O
the O
RARE O
are O
completely O
internal O
to O
longer O
ones O
and O
a O
third O
is O
partially O
embedded O
in O
NUM I-GENE
. O

ALL_CAP O
RARE O
of O
rare O
- O
length O
alleles O
indicates O
that O
they O
are O
comprised O
of O
RARE O
sequences O
, O
although O
they O
usually O
RARE O
a O
RARE O
to O
one O
of O
the O
common O
alleles O
RARE O
the O
5 O
'- O
most O
end O
. O

RARE O
NUM O
contains O
the O
genetic O
RARE O
RARE O
H2 O
uptake O
( O
RARE I-GENE
) O
from O
RARE O
RARE O
RARE O
. O
RARE O
, O
including O
a O
cluster O
of O
NUM O
genes O
named O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
. O

Two O
classes O
of O
inactive O
receptors O
were O
identified O
: O
one O
in O
which O
both O
transcriptional O
activation O
and O
RARE O
were O
RARE O
and O
a O
second O
in O
which O
only O
transcriptional O
activation O
was O
abolished O
. O

Here O
we O
localize O
a O
RARE O
40 O
- O
amino O
acid O
region O
within O
the O
RARE I-GENE
of O
RXR I-GENE
, O
RAR I-GENE
, O
TR I-GENE
, O
and O
chicken I-GENE
RARE I-GENE
upstream I-GENE
promoter I-GENE
transcription I-GENE
factor I-GENE
that O
is O
critical O
RARE O
RARE O
identity O
in O
the O
RARE O
interaction O
and O
RARE O
high O
- O
affinity O
DNA O
binding O
. O

ALL_CAP O
and O
RARE O
A O
do O
not O
decrease O
ALL_CAP I-GENE
DNA O
- O
protein O
interactions O
, O
suggesting O
that O
important O
protein O
- O
protein O
interactions O
are O
phosphatase O
regulated O
. O

An O
RARE O
- O
RARE O
, O
placebo O
- O
RARE O
, O
randomized O
, O
two O
- O
way O
RARE O
study O
was O
performed O
in O
12 O
healthy O
volunteers O
( O
between O
20 O
and O
NUM O
years O
of O
age O
) O
to O
assess O
the O
effect O
of O
RARE O
, O
a O
RARE I-GENE
lipase I-GENE
inhibitor O
that O
reduces O
dietary O
fat O
absorption O
and O
is O
being O
developed O
RARE O
RARE O
control O
in O
obesity O
, O
on O
the O
absorption O
of O
RARE O
A O
and O
E O
. O

RARE O
is O
a O
novel O
RARE O
antibiotic O
developed O
RARE O
RARE O
use O
in O
RARE O
medicine O
. O

Effect O
of O
RARE O
oxide O
( O
N2O O
) O
on O
the O
RARE O
A O
- O
and O
C O
- O
RARE O
was O
investigated O
using O
artificially O
ventilated O
rats O
anesthetized O
with O
alpha O
- O
RARE O
and O
RARE O
. O

Restriction O
enzyme O
mapping O
and O
Southern O
analysis O
indicated O
further O
that O
the O
human I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
gene I-GENE
is O
a O
single O
- O
copy O
gene O
. O

In O
the O
absence O
of O
NUM I-GENE
and O
NUM I-GENE
cell O
viability O
is O
lost O
, O
but O
can O
be O
RARE O
by O
ectopic O
RARE O
of O
the O
G1 I-GENE
RARE I-GENE
encoding I-GENE
genes I-GENE
, O
NUM I-GENE
or O
NUM I-GENE
. O

The O
detection O
ratio O
RARE O
RARE O
ages O
NUM O
to O
NUM O
and O
decreased O
RARE O
RARE O
the O
next O
NUM O
years O
of O
age O
. O

RARE O
many O
RARE O
to O
transfer O
in O
patients O
undergoing O
ALL_CAP O
? O

ALL_CAP O
: O
RARE O
the O
small O
size O
of O
this O
study O
and O
the O
RARE O
of O
results O
among O
the O
few O
prospective O
studies O
of O
ovarian O
RARE O
conducted O
to O
test O
these O
associations O
, O
RARE O
of O
these O
findings O
are O
highly O
RARE O
. O

The O
RARE O
TATA O
box O
in O
promoter O
B O
plays O
a O
more O
important O
role O
in O
promoter O
activity O
than O
the O
TATA O
box O
in O
promoter O
A O
. O

These O
properties O
indicate O
that O
NUM I-GENE
is O
an O
RNA O
- O
export O
factor O
and O
that O
RARE I-GENE
may O
mediate O
viral O
RNA O
export O
by O
RARE O
the O
function O
of O
NUM I-GENE
. O

RARE O
is O
a O
reliable O
and O
RARE O
measure O
of O
RARE O
in O
the O
elderly O
. O

Two O
techniques O
based O
on O
assay O
coefficients O
of O
variation O
were O
employed O
to O
characterize O
a O
normal O
circadian O
pattern O
of O
cortisol O
. O

We O
have O
performed O
RARE O
analyses O
on O
ALL_CAP I-GENE
mRNA I-GENE
of O
RARE O
NUM O
, O
both O
free O
and O
in O
duplex O
with O
the O
RARE O
RNA O
, O
ALL_CAP I-GENE
. O

Previous O
work O
showed O
that O
ALL_CAP I-GENE
( O
RARE O
protein O
) O
RARE O
requires O
RARE I-GENE
( O
RARE O
peptide O
) O
translation O
. O

A O
RARE O
is O
described O
in O
which O
the O
volume O
flow O
rate O
of O
RARE O
in O
a O
vessel O
is O
determined O
using O
transverse O
RARE O
Doppler O
ultrasound O
imaging O
. O

The O
enzyme O
activities O
studied O
are O
important O
elements O
in O
the O
pathophysiology O
of O
dental O
RARE O
and O
may O
even O
be O
addressed O
RARE O
RARE O
factors O
. O

RARE O
is O
an O
effective O
means O
of O
prophylaxis O
RARE O
upper O
respiratory O
infection O
in O
RARE O
angina O
patients O
. O

In O
lean O
mice O
, O
the O
fat O
/ O
water O
intensity O
ratio O
was O
about O
1 O
: O
4 O
, O
about O
RARE O
that O
in O
normal O
mice O
. O

RARE O
parameters O
were O
similar O
to O
values O
given O
in O
the O
literature O
RARE O
intravenous O
( O
IV O
) O
or O
RARE O
( O
IA O
) O
bolus O
MMC O
injections O
( O
RARE O
= O
7 O
. O
NUM O
min O
following O
the O
beginning O
of O
MMC O
infusion O
, O
RARE O
= O
NUM O
. O
57 O
1 O
/ O
kg O
, O
C1 O
= O
8 O
. O
9 O
ml O
/ O
min O
. O
kg O
, O
NUM O
/ O
2 O
alpha O
= O
8 O
. O
3 O
min O
, O
NUM O
/ O
2 O
beta O
= O
58 O
. O
6 O
min O
). O

In O
this O
study O
, O
we O
identified O
four O
distinct O
E2F I-GENE
complexes I-GENE
present O
in O
aged O
and O
RARE O
normal O
, O
human O
diploid O
RARE O
. O

This O
paper O
gives O
an O
RARE O
of O
the O
global O
pattern O
of O
RARE O
in O
RARE O
which O
occurred O
RARE O
the O
NUM O
- O
month O
period O
from O
1 O
RARE O
1993 O
to O
29 O
RARE O
1996 O
. O

If O
we O
RARE O
the O
finding O
of O
non O
- O
visualization O
of O
the O
ALL_CAP O
RARE O
4 O
h O
post O
injection O
RARE O
the O
criterion O
RARE O
the O
diagnosis O
of O
ALL_CAP O
, O
the O
diagnostic O
accuracy O
was O
only O
40 O
. O
7 O
% O
( O
11 O
/ O
NUM O
). O

These O
results O
were O
RARE O
in O
a O
subsequent O
study O
in O
which O
NUM O
RARE O
men O
were O
supplemented O
with O
ALL_CAP O
5 O
mg O
three O
times O
daily O
RARE O
6 O
months O
. O

Alternative O
RARE O
of O
the O
RARE I-GENE
- I-GENE
tRNA I-GENE
RARE I-GENE
mRNA I-GENE
from O
RARE I-GENE
- O
treated O
human O
cells O
. O

Evidence O
RARE O
the O
RARE O
role O
of O
the O
RARE I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
release O
in O
the O
development O
of O
RARE O
RARE O
saline O
- O
RARE O
abortion O
. O

This O
ALL_CAP I-GENE
activity O
was O
observed O
in O
3T3 O
- O
L1 O
RARE O
lysates O
, O
and O
was O
able O
to O
RARE O
the O
hydrolysis O
of O
the O
RARE O
alpha O
- O
32P O
] O
GTP O
RARE O
to O
GST I-GENE
- O
NUM I-GENE
into O
RARE O
alpha O
- O
32P O
] O
GDP O
. O

CONCLUSION O
: O
During O
chronic O
treatment O
, O
the O
RARE O
response O
to O
oral O
RARE O
was O
attenuated O
, O
indicating O
that O
continued O
clinical O
improvement O
in O
patients O
with O
ALL_CAP O
on O
ALL_CAP O
is O
independent O
of O
to O
its O
acute O
RARE O
effects O
. O

We O
conclude O
that O
, O
in O
AIDS O
patients O
with O
RARE O
, O
tolerance O
to O
RARE O
- O
ALL_CAP O
was O
acceptable O
when O
the O
daily O
dosage O
did O
not O
RARE O
1 O
mg O
/ O
kg O
, O
but O
the O
RARE O
1 O
. O
5 O
mg O
/ O
kg O
daily O
dosage O
was O
associated O
with O
an O
RARE O
rate O
of O
RARE O
. O

Moreover O
, O
the O
second O
NUM I-GENE
- I-GENE
like I-GENE
motif I-GENE
RARE O
RARE O
the O
amino O
- O
terminus O
of O
NUM I-GENE
stimulates O
guanine O
nucleotide O
exchange O
on O
NUM I-GENE
and O
on O
members O
of O
the O
related O
RARE I-GENE
proteins I-GENE
, O
but O
not O
on O
other O
small I-GENE
GTP I-GENE
binding I-GENE
proteins I-GENE
such O
RARE O
Ran I-GENE
or O
R I-GENE
- I-GENE
NUM I-GENE
/ O
NUM I-GENE
. O

The O
reconstituted O
RNA I-GENE
RARE I-GENE
containing O
the O
mutant O
alpha O
subunits O
were O
examined O
RARE O
their O
response O
to O
transcription O
activation O
by O
cAMP I-GENE
- I-GENE
CRP I-GENE
and O
the O
NUM I-GENE
ALL_CAP I-GENE
element I-GENE
. O

Transcription O
factor O
recognition O
surface O
on O
the O
RNA I-GENE
polymerase I-GENE
alpha I-GENE
subunit I-GENE
is O
involved O
in O
RARE O
with O
the O
DNA O
enhancer O
element O
. O

Consistent O
with O
this O
RARE O
, O
the O
NUM I-GENE
- O
NUM O
mutant O
accumulates O
unspliced O
RARE O
RARE O
the O
restrictive O
RARE O
. O

A O
decrease O
of O
RARE O
RARE O
with O
age O
, O
RARE O
in O
nmol O
/ O
L O
, O
was O
noted O
( O
p O
< O
NUM O
. O
02 O
). O

Cloning O
and O
sequence O
analyses O
revealed O
a O
second O
cDNA O
with O
a O
NUM O
- O
nt O
deletion O
in O
the O
region O
coding O
RARE O
the O
putative O
second O
RARE O
loop O
and O
the O
fourth O
transmembrane O
domain O
of O
the O
5 I-GENE
- I-GENE
NUM I-GENE
- I-GENE
R I-GENE
. O

Expression O
of O
RARE I-GENE
kinase I-GENE
gene I-GENE
in O
normal O
human O
diploid O
cells O
is O
both O
cell O
RARE O
- O
and O
age O
- O
dependent O
and O
appears O
to O
be O
transcriptionally O
regulated O
. O

The O
minimum O
RARE O
concentrations O
( O
MICs O
) O
of O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
, O
and O
amphotericin O
B O
were O
significantly O
influenced O
by O
the O
RARE O
size O
, O
regardless O
of O
the O
techniques O
used O
. O

These O
bacteria O
produce O
and O
export O
proteins O
capable O
of O
specific O
interactions O
with O
key O
mammalian O
cell O
regulatory O
molecules O
in O
order O
to O
RARE O
the O
normal O
functions O
of O
the O
cells O
. O

The O
elevations O
achieved O
by O
ALL_CAP O
given O
s O
. O
c O
. O
were O
RARE O
than O
those O
achieved O
after O
i O
. O
p O
. O
administration O
and O
RARE O
RARE O
longer O
periods O
. O

Thus O
, O
although O
NUM I-GENE
may O
play O
only O
a O
limited O
role O
RARE O
the O
early O
RARE O
RARE O
, O
it O
may O
function O
later O
in O
development O
to O
establish O
a O
somatic O
type O
of O
cell O
RARE O
. O

The O
main O
aim O
of O
the O
contribution O
, O
which O
RARE O
an O
RARE O
RARE O
discussion O
on O
the O
RARE O
RARE O
' O
RARE O
is O
to O
RARE O
RARE O
published O
research O
RARE O
focusing O
both O
on O
strengths O
and O
RARE O
and O
RARE O
in O
the O
hypothesis O
formulation O
, O
methods O
and O
instruments O
used O
, O
discussion O
of O
results O
. O

Moreover O
, O
it O
also O
RARE O
the O
effects O
of O
antihypertensive O
drugs O
currently O
regarded O
RARE O
RARE O
- O
choice O
agents O
, O
i O
. O
RARE O
. O
RARE O
antagonists O
and O
the O
angiotensin I-GENE
RARE I-GENE
enzyme I-GENE
RARE O
, O
on O
RARE O
hemodynamics O
. O

Many O
human O
viruses O
are O
able O
to O
develop O
suitable O
strategies O
RARE O
RARE O
apoptosis O
in O
virus O
- O
RARE O
cells O
and O
in O
virus O
- O
primed O
T O
cells O
. O

It O
is O
suggested O
that O
the O
observed O
clinical O
phenomena O
in O
response O
to O
RARE O
can O
be O
explained O
by O
differences O
in O
RARE O
and O
sensitivity O
of O
some O
RARE I-GENE
receptor I-GENE
subtypes O
in O
RARE O
. O

Previous O
studies O
demonstrated O
that O
the O
RARE I-GENE
- I-GENE
containing I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
are O
RARE O
in O
a O
tissue O
- O
specific O
manner O
. O

Taken O
together O
, O
these O
observations O
indicate O
that O
the O
C O
- O
terminal O
NUM O
amino O
RARE O
are O
sufficient O
RARE O
ALL_CAP I-GENE
RARE O
although O
the O
region O
adjacent O
to O
this O
domain O
appears O
to O
affect O
RARE O
efficiency O
. O

Thus O
, O
despite O
the O
RARE O
RARE O
common O
regulatory O
mechanisms O
, O
the O
available O
evidence O
indicates O
that O
the O
RARE I-GENE
minimal I-GENE
promoter I-GENE
does O
not O
significantly O
affect O
NUM I-GENE
gene I-GENE
RARE O
. O

ALL_CAP I-GENE
proteins I-GENE
have O
been O
identified O
by O
their O
binding O
to O
an O
upstream O
element O
of O
c I-GENE
- I-GENE
myc I-GENE
. O

RARE I-GENE
1 I-GENE
has O
been O
completely O
sequenced O
. O

B I-GENE
cell I-GENE
antigen I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
)- O
RARE O
apoptosis O
in O
the O
ALL_CAP O
- O
231 O
B O
lymphoma O
cell O
line O
can O
be O
prevented O
by O
RARE O
CD40 I-GENE
. O

Both O
alleles O
are O
functionally O
RARE O
and O
are O
distributed O
within O
NUM I-GENE
RARE O
NUM I-GENE
+ O
T O
cell O
RARE O
. O

The O
model O
also O
predicts O
that O
RARE O
flow O
shunt O
fraction O
( O
RARE O
/ O
QT O
) O
is O
directly O
related O
to O
the O
oxygen O
RARE O
- O
wave O
amplitude O
RARE O
transmitted O
to O
end O
- O
RARE O
air O
and O
arterial O
and O
mixed O
- O
venous O
RARE O
through O
two O
simple O
RARE O
. O

The O
deduced O
amino O
acid O
sequence O
of O
NUM I-GENE
is O
nearly O
identical O
to O
NUM I-GENE
except O
RARE O
the O
amino O
end O
, O
where O
they O
are O
sharply O
divergent O
. O

ALL_CAP O
disruption O
in O
RARE O
RARE O
caused O
a O
relative O
drop O
in O
USF I-GENE
RNA I-GENE
accumulation O
levels O
to O
RARE O
NUM O
% O
of O
control O
RARE O
, O
while O
NUM I-GENE
RNA I-GENE
accumulation O
levels O
RARE O
to O
less O
than O
5 O
%. O

Five O
of O
these O
eight O
patients O
in O
group O
II O
also O
received O
8 O
- O
in O
- O
1 O
chemotherapy O
. O

RARE O
days O
after O
the O
intervention O
, O
RARE O
and O
RARE O
RARE O
remained O
dependent O
upon O
the O
extracellular O
NUM O
+ O
concentration O
RARE O
Ca O
] O
RARE O
) O
both O
in O
groups O
A O
and O
B O
. O

RARE O
between O
HIV O
- O
1 O
and O
HIV O
- O
2 O
showed O
evidence O
RARE O
the O
presence O
of O
HIV O
- O
1 O
only O
. O

However O
, O
an O
RARE O
DNA O
- O
binding O
subunit O
RARE O
ALL_CAP I-GENE
- I-GENE
D I-GENE
was O
not O
identified O
. O

The O
ALL_CAP I-GENE
- I-GENE
D I-GENE
( O
CDP I-GENE
/ O
cut I-GENE
) O
complex O
with O
the O
NUM I-GENE
promoter I-GENE
is O
RARE O
with O
antibodies O
against O
CDP I-GENE
/ O
cut I-GENE
and O
ALL_CAP I-GENE
but O
not O
p107 I-GENE
, O
whereas O
the O
CDP I-GENE
/ O
cut I-GENE
complex O
with O
a O
RARE O
promoter O
( O
NUM I-GENE
- O
RARE I-GENE
) O
RARE O
only O
with O
CDP I-GENE
and O
p107 I-GENE
antibodies O
. O

Recently O
, O
a O
distantly O
related O
ALL_CAP I-GENE
- I-GENE
homolog I-GENE
, O
ALL_CAP I-GENE
, O
has O
also O
been O
identified O
in O
E O
. O
coli O
. O

To O
study O
the O
RARE O
of O
NUM I-GENE
RARE O
, O
the O
promoter O
of O
the O
NUM I-GENE
gene I-GENE
has O
been O
isolated O
from O
a O
murine O
RARE O
- O
resistant O
cell O
line O
, O
NUM O
. O
NUM O
- O
1 O
, O
and O
characterized O
. O

The O
amplification O
was O
achieved O
using O
two O
primers O
which O
correspond O
to O
TRH I-GENE
RARE I-GENE
sequence I-GENE
( O
RARE O
/ O
Arg O
- O
Arg O
- O
Gln O
- O
RARE O
- O
RARE O
- O
RARE O
- O
RARE O
/ O
Arg O
- O
Arg O
). O

The O
RARE O
RARE O
cells O
occupied O
the O
RARE O
of O
the O
lymph O
nodes O
and O
were O
initially O
suspected O
of O
being O
metastatic O
from O
the O
ovarian O
tumor O
in O
each O
case O
. O

The O
gene I-GENE
ALL_CAP I-GENE
encoding O
the O
RARE I-GENE
control I-GENE
protein I-GENE
ALL_CAP I-GENE
of O
RARE O
RARE O
has O
been O
RARE O
and O
characterized O
. O

An O
ALL_CAP I-GENE
deletion I-GENE
mutant I-GENE
shows O
RARE O
RARE O
when O
tested O
in O
an O
intravenous O
mouse O
model O
, O
but O
RARE O
replication O
of O
the O
mutant O
in O
RARE O
- O
2 O
and O
NUM O
cells O
appears O
to O
be O
comparable O
with O
that O
of O
the O
wild O
- O
type O
RARE O
. O

Thus O
, O
the O
N I-GENE
- O
RARE I-GENE
complex O
may O
be O
affected O
through O
contacts O
with O
the O
ALL_CAP O
of O
the O
alpha O
subunit O
of O
RNA I-GENE
polymerase I-GENE
, O
RARE O
is O
a O
group O
of O
regulatory O
proteins O
that O
influences O
initiation O
of O
transcription O
. O

Administration O
of O
ALL_CAP O
RARE O
NUM O
mg O
/ O
kg O
/ O
day O
in O
combination O
with O
ALL_CAP O
RARE O
NUM O
mg O
/ O
kg O
/ O
day O
resulted O
in O
a O
marked O
prolongation O
of O
survival O
compared O
with O
that O
RARE O
mice O
that O
received O
ALL_CAP O
or O
ALL_CAP O
alone O
. O

Eight O
- O
four O
RARE O
were O
tested O
in O
order O
to O
examine O
the O
fit O
of O
the O
model O
to O
the O
data O
by O
RARE O
analysis O
with O
ALL_CAP O
VII O
. O

Two O
of O
RARE O
initiation O
sites O
were O
flanked O
by O
a O
sequence O
homologous O
to O
the O
consensus O
promoter O
motif O
that O
includes O
the O
ALL_CAP O
motif O
( O
where O
R O
is O
A O
or O
G O
) O
of O
the O
RARE O
RARE O
. O

RARE O
using O
SC O
ALL_CAP O
was O
more O
effective O
than O
RARE O
selection O
in O
RARE O
age O
RARE O
RARE O
in O
RARE O
. O

Using O
RARE O
PCR O
, O
a O
ALL_CAP I-GENE
element I-GENE
RARE O
to O
NUM I-GENE
was O
isolated O
. O

Sodium O
RARE O
RARE O
treatment O
RARE O
lithium O
toxicity O
: O
effects O
on O
serum O
RARE O
concentrations O
. O

The O
mammalian I-GENE
RARE I-GENE
proteins I-GENE
encoded O
by O
Hox I-GENE
genes I-GENE
play O
an O
important O
role O
in O
RARE O
development O
by O
providing O
RARE O
RARE O
which O
define O
developmental O
identities O
along O
the O
anteroposterior O
axis O
of O
developing O
organisms O
. O

Interferon I-GENE
RARE I-GENE
gene I-GENE
factor I-GENE
3 I-GENE
( O
NUM I-GENE
) O
is O
a O
RARE O
transcription O
factor O
activated O
on O
treatment O
of O
cells O
with O
RARE I-GENE
- I-GENE
alpha I-GENE
and I-GENE
beta I-GENE
( O
type I-GENE
I I-GENE
RARE I-GENE
). O

The O
ALL_CAP O
/ O
P1 O
resource O
, O
RARE O
RARE O
, O
and O
RARE O
constitute O
an O
RARE O
resource O
to O
further O
studies O
of O
RARE O
RARE O
and O
function O
and O
a O
means O
RARE O
physical O
and O
genetic O
map O
RARE O
and O
closure O
. O

RARE O
RARE O
included O
RARE O
2 O
of O
the O
Clinical O
RARE O
RARE O
( O
ALL_CAP O
RARE O
the O
RARE O
score O
of O
the O
RARE O
Clinical O
Assessment O
RARE O
( O
ALL_CAP O
) O
scale O
, O
the O
RARE O
' O
need O
RARE O
help O
' O
of O
the O
nurse O
' O
s O
rating O
of O
RARE O
patients O
( O
RARE O
RARE O
RARE O
RARE O
; O
ALL_CAP O
) O
and O
the O
RARE O
score O
of O
the O
Short O
RARE O
RARE O
Test O
( O
RARE O
- O
RARE O
; O
ALL_CAP O
). O

Three O
mutants O
were O
isolated O
from O
the O
widely O
used O
RARE O
, O
NUM O
. O

As O
extensively O
examined O
with O
the O
myogenin I-GENE
promoter I-GENE
, O
presence O
of O
one O
or O
multiple O
copies O
of O
RARE I-GENE
in O
the O
vectors O
elevated O
the O
RARE O
activity O
in O
myotubes O
by O
4 O
. O
5 O
- O
to O
19 O
- O
RARE O
over O
those O
without O
RARE I-GENE
, O
but O
not O
significantly O
in O
myoblasts O
. O

We O
conclude O
that O
common O
upstream O
signals O
cause O
activation O
of O
Ras I-GENE
and O
NUM I-GENE
, O
but O
activated O
NUM I-GENE
controls O
cell O
growth O
via O
distinct O
Raf I-GENE
- O
independent O
RARE O
RARE O
pathways O
. O

RARE I-GENE
yeast I-GENE
NUM I-GENE
+ I-GENE
is O
required O
RARE O
RARE O
segregation O
. O

RARE O
was O
based O
on O
RARE O
of O
an O
integrated O
DNA O
fragment O
containing O
the O
RARE I-GENE
- I-GENE
10 I-GENE
promoter I-GENE
- I-GENE
regulatory I-GENE
region I-GENE
followed O
by O
the O
initial O
segment O
of O
the O
RARE I-GENE
- I-GENE
10 I-GENE
RARE I-GENE
reading I-GENE
frame I-GENE
fused O
in O
frame O
with O
the O
bacterial I-GENE
RARE I-GENE
B I-GENE
RARE I-GENE
structural I-GENE
gene I-GENE
( O
NUM I-GENE
RARE I-GENE
RARE I-GENE
). O

Mutations O
RARE O
two O
RARE O
sites O
, O
serine O
NUM O
and O
threonine O
NUM O
, O
RARE O
the O
effect O
. O

IRF I-GENE
- I-GENE
1 I-GENE
acts O
RARE O
a O
transcriptional O
activator O
, O
while O
IRF I-GENE
- I-GENE
2 I-GENE
acts O
RARE O
a O
repressor O
. O

In O
contrast O
, O
cotransfection O
of O
ALL_CAP I-GENE
and O
IRF I-GENE
- I-GENE
1 I-GENE
into O
ALL_CAP O
3T3 O
cells O
resulted O
in O
a O
dose O
- O
dependent O
repression O
of O
promoter O
activation O
which O
occurred O
in O
a O
TATA O
- O
dependent O
manner O
. O

The O
requirement O
of O
RARE O
- O
19 O
RARE O
RARE O
RARE O
assembly O
is O
also O
observed O
under O
conditions O
in O
which O
RARE O
formation O
is O
independent O
of O
mitosis O
, O
suggesting O
that O
the O
involvement O
of O
Cdc28 I-GENE
/ O
RARE I-GENE
kinase O
in O
SPB O
separation O
is O
direct O
. O

A O
subset O
of O
these O
NUM I-GENE
recognition I-GENE
sequences I-GENE
containing O
a O
ALL_CAP O
RARE O
core O
can O
also O
function O
RARE O
Ets I-GENE
- I-GENE
responsive I-GENE
elements I-GENE
. O

In O
both O
RARE O
, O
it O
can O
be O
RARE O
by O
RARE I-GENE
D I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
, O
suggesting O
that O
its O
transcriptional O
activity O
may O
normally O
be O
regulated O
through O
such O
mechanisms O
. O

Expression O
of O
the O
RARE I-GENE
protein I-GENE
RARE I-GENE
under O
the O
control O
of O
a O
NUM I-GENE
promoter I-GENE
in O
Saccharomyces O
cerevisiae O
resulted O
in O
RARE O
- O
inducible O
cell O
RARE O
. O

This O
technique O
was O
employed O
in O
12 O
patients O
with O
a O
RARE O
bone O
cyst O
. O

RARE O
RARE O
strains O
with O
ALL_CAP O
- O
RARE O
RARE O
resistance O
were O
isolated O
by O
RARE O
culture O
from O
the O
RARE O
and O
RARE O
of O
several O
RARE O
species O
, O
mainly O
horses O
and O
dogs O
( O
8 O
% O
positive O
RARE O
RARE O
( O
7 O
% O
positive O
RARE O
and O
pigs O
( O
6 O
% O
positive O
). O

The O
amino O
- O
terminal O
region O
of O
E1A I-GENE
binds O
several O
high O
RARE O
RARE O
proteins O
and O
inhibits O
the O
transcriptional O
RARE O
function O
of O
p300 I-GENE
and O
the O
homologous O
cAMP I-GENE
response I-GENE
element I-GENE
( I-GENE
ALL_CAP I-GENE
)- I-GENE
binding I-GENE
protein I-GENE
. O

Transient O
transfection O
assays O
using O
reporter O
gene O
constructs O
containing O
various O
lengths O
of O
the O
5 I-GENE
' I-GENE
NUM I-GENE
sequences I-GENE
revealed O
that O
the O
sequence O
RARE O
between O
- O
NUM O
to O
- O
126 O
bp O
was O
important O
RARE O
the O
RARE O
of O
the O
reporter O
gene O
in O
many O
different O
cell O
lines O
. O

We O
show O
that O
the O
5 O
' O
UTR O
characteristic O
of O
RARE I-GENE
- I-GENE
specific I-GENE
c I-GENE
- I-GENE
mos I-GENE
mRNA I-GENE
strongly O
represses O
translation O
relative O
to O
the O
translation O
of O
transcripts O
that O
contain O
a O
5 O
' O
UTR O
derived O
from O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
, O
and O
this O
is O
mainly O
due O
to O
the O
four O
RARE O
. O

To O
address O
the O
biological O
effect O
of O
specific O
isoform O
RARE O
, O
NIH3T3 O
cells O
were O
transfected O
with O
a O
eukaryotic O
RARE O
vector O
containing O
cDNA O
RARE O
NUM I-GENE
, O
NUM I-GENE
, O
or O
NUM I-GENE
. O

These O
findings O
suggest O
that O
the O
F O
- O
wave O
may O
be O
elicited O
in O
RARE O
of O
different O
RARE O
threshold O
but O
primarily O
in O
larger O
and O
faster O
nerve O
fibers O
, O
with O
a O
lower O
threshold O
of O
RARE O
. O

In O
addition O
, O
RARE I-GENE
NUM I-GENE
shows O
RARE O
sequence O
homology O
to O
mammalian I-GENE
NUM I-GENE
in O
both O
the O
kinase O
- O
like O
( O
NUM I-GENE
) O
and O
kinase O
( O
NUM I-GENE
) O
domains O
( O
RARE O
70 O
% O
identity O
). O

When O
this O
DNA O
fragment O
was O
placed O
upstream O
of O
the O
chloramphenicol I-GENE
RARE I-GENE
( O
CAT I-GENE
) O
reporter O
gene O
and O
transfected O
into O
a O
RARE O
ALL_CAP O
cell O
line O
, O
it O
could O
drive O
the O
RARE O
of O
CAT I-GENE
enzyme I-GENE
16 O
times O
more O
efficiently O
than O
the O
promoterless O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
. O

Molecular O
cloning O
of O
Elk I-GENE
- I-GENE
3 I-GENE
, O
a O
new O
RARE O
of O
the O
Ets I-GENE
family I-GENE
RARE O
RARE O
mouse O
embryogenesis O
and O
analysis O
of O
its O
transcriptional O
repression O
activity O
. O

We O
report O
an O
example O
of O
an O
ALL_CAP O
- O
transformed O
T O
- O
RARE O
cell O
line O
( O
NUM O
) O
expressing O
high O
levels O
of O
a O
truncated I-GENE
C I-GENE
- I-GENE
ALL_CAP I-GENE
protein I-GENE
RARE O
a O
result O
of O
ALL_CAP O
RARE O
within O
one O
c I-GENE
- I-GENE
myb I-GENE
allele I-GENE
. O

RARE O
/ O
RARE O
RARE O
RARE O
RARE O
muscle O
tendon O
RARE O
had O
significantly O
lower O
values O
RARE O
load O
to O
failure O
( O
p O
< O
NUM O
. O
01 O
RARE O
energy O
absorbed O
to O
failure O
( O
p O
< O
NUM O
. O
01 O
RARE O
and O
RARE O
RARE O
failure O
( O
p O
< O
NUM O
. O
01 O
RARE O
and O
they O
tended O
to O
fail O
RARE O
a O
different O
anatomic O
location O
( O
p O
< O
NUM O
. O
01 O
) O
( O
broadly O
RARE O
the O
RARE O
- O
muscle O
interface O
RARE O
compared O
with O
RARE O
RARE O
the O
RARE O
RARE O
) O
than O
fresh O
RARE O
. O

Northern O
analysis O
of O
the O
3 I-GENE
. I-GENE
1 I-GENE
- I-GENE
kb I-GENE
NUM I-GENE
cDNA I-GENE
revealed O
that O
a O
3 O
. O
3 O
- O
kb O
major O
transcript O
is O
ubiquitously O
RARE O
in O
human O
adult O
tissues O
. O

Forty O
- O
eight O
10 O
- O
12 O
- O
week O
- O
old O
male O
Sprague O
- O
Dawley O
rats O
were O
randomized O
to O
receive O
, O
daily O
RARE O
NUM O
days O
: O
( O
1 O
) O
CsA O
vehicle O
p O
. O
RARE O
. O
RARE O
FB O
vehicle O
sc O
; O
( O
2 O
) O
CsA O
( O
NUM O
mg O
/ O
kg O
) O
p O
. O
RARE O
. O
RARE O
FB O
vehicle O
sc O
, O
( O
3 O
) O
CsA O
vehicle O
p O
. O
RARE O
. O
RARE O
FB O
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
sc O
; O
and O
( O
4 O
) O
CsA O
( O
NUM O
mg O
/ O
kg O
) O
p O
. O
RARE O
. O
RARE O
FB O
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
sc O
. O

CsA O
alone O
resulted O
in O
elevated O
bone O
turnover O
. O

RARE O
RARE O
the O
ALL_CAP O
RARE O
in O
the O
RARE O
RARE O
of O
RARE O
between O
1990 O
and O
1994 O
with O
the O
diagnosis O
of O
HIV O
infection O
, O
RARE O
RARE O
, O
RARE O
herpes O
, O
non O
- O
specific O
RARE O
infection O
( O
ALL_CAP O
RARE O
RARE O
and O
RARE O
were O
included O
in O
the O
study O
. O

RARE O
activation O
of O
the O
tyrosine I-GENE
kinase I-GENE
domain I-GENE
of O
the O
human I-GENE
trk I-GENE
RARE I-GENE
- I-GENE
oncogene I-GENE
by O
fusion O
to O
a O
cell O
adhesion O
molecule O
. O

Northern O
blotting O
showed O
that O
ALL_CAP I-GENE
, O
like O
NUM I-GENE
, O
is O
RARE O
in O
all O
tissues O
tested O
, O
and O
that O
several O
mRNAs O
RARE O
ALL_CAP I-GENE
can O
be O
detected O
. O

RARE O
. O

The O
nucleotide O
sequence O
of O
NUM O
, O
NUM O
bp O
of O
the O
RARE O
RARE O
of O
RARE O
IV O
is O
described O
. O

They O
suggest O
that O
decreased O
steady O
- O
state O
levels O
of O
IME1 I-GENE
and O
NUM I-GENE
mRNA I-GENE
were O
not O
RARE O
the O
result O
of O
non O
- O
specific O
adverse O
affects O
on O
RARE O
acid O
metabolism O
caused O
by O
the O
NUM I-GENE
disruption O
. O

RARE O
ALL_CAP I-GENE
protein I-GENE
has O
been O
RARE O
from O
a O
RARE O
cell O
line O
and O
shown O
to O
be O
a O
65 O
ALL_CAP O
RARE O
- O
RARE O
RARE O
glycoprotein O
comprised O
of O
NUM O
ALL_CAP O
subunits O
, O
each O
containing O
12 O
ALL_CAP O
of O
N O
- O
and O
O O
- O
RARE O
sugars O
. O

The O
objective O
of O
this O
study O
was O
to O
examine O
the O
influence O
of O
ALL_CAP O
and O
other O
serological O
factors O
upon O
the O
development O
of O
ALL_CAP O
. O

RARE O
exons O
of O
adenovirus O
RARE O
RNAs O
RARE O
with O
snRNP O
in O
a O
specific O
nuclear O
domain O
. O

Using O
RARE O
' O
s O
resin O
RARE O
a O
RARE O
medium O
, O
we O
could O
observe O
thick O
specimens O
with O
oil O
immersion O
objective O
lens O
without O
the O
use O
of O
RARE O
, O
then O
avoid O
air O
RARE O
near O
the O
RARE O
. O

The O
present O
study O
investigated O
dose O
dependence O
and O
time O
course O
effects O
of O
the O
RARE O
( O
ALL_CAP O
) O
partial O
RARE O
agonist O
, O
NUM O
- O
NUM O
( O
NUM O
. O
005 O
- O
NUM O
. O
NUM O
mg O
/ O
kg O
) O
alone O
, O
and O
in O
combination O
with O
the O
ALL_CAP I-GENE
receptor I-GENE
antagonists O
RARE O
, O
ALL_CAP O
NUM O
, O
and O
ALL_CAP O
NUM O
( O
20 O
mg O
/ O
kg O
) O
in O
selectively O
RARE O
RARE O
- O
RARE O
( O
P O
) O
rats O
provided O
a O
two O
- O
RARE O
choice O
test O
between O
ethanol O
( O
ALL_CAP O
) O
( O
10 O
% O
v O
/ O
v O
RARE O
and O
a O
RARE O
saccharin O
( O
NUM O
. O
NUM O
% O
g O
/ O
v O
) O
solution O
. O

RARE O
the O
RARE O
of O
RARE O
: O
a O
RARE O
RARE O
RARE O
. O

RARE O
with O
RARE O
RARE O
group O
B O
has O
been O
difficult O
to O
detect O
, O
partly O
because O
this O
bacterial O
group O
' O
s O
RARE O
is O
a O
weak O
RARE O
. O

RNase I-GENE
protection O
analysis O
of O
two O
rRNA O
fragments O
whose O
genes O
are O
adjacent O
provided O
evidence O
RARE O
a O
RARE O
transcript O
containing O
sequences O
from O
both O
, O
RARE O
RARE O
RARE O
separate O
small O
RNAs O
. O

NUM I-GENE
encodes O
a O
novel O
essential O
protein O
of O
NUM O
amino O
RARE O
, O
which O
contains O
an O
extended O
predicted O
RARE O
- O
RARE O
domain O
and O
is O
RARE O
both O
RARE O
nuclear O
RARE O
complexes O
( O
RARE O
) O
and O
in O
the O
cytoplasm O
. O

To O
map O
this O
regulatory O
serine O
RARE O
site O
we O
developed O
a O
RARE O
- O
RARE O
RARE O
RARE O
RARE O
wild I-GENE
- I-GENE
type I-GENE
RARE I-GENE
II I-GENE
and O
RARE O
a O
series O
of O
RARE I-GENE
II I-GENE
mutants I-GENE
which O
contained O
substitutions O
in O
one O
or O
more O
serine O
residues O
present O
in O
the O
N O
- O
terminal O
domain O
. O

The O
PAI I-GENE
- I-GENE
2 I-GENE
gene I-GENE
is O
one O
of O
the O
most O
TNF I-GENE
- I-GENE
responsive I-GENE
genes I-GENE
known O
and O
is O
also O
highly O
RARE O
by O
the O
phorbol O
ester O
phorbol O
12 O
- O
myristate O
NUM O
- O
RARE O
( O
PMA O
) O
and O
the O
phosphatase O
inhibitor O
, O
RARE O
acid O
, O
in O
both O
ALL_CAP O
- O
NUM O
RARE O
and O
ALL_CAP O
- O
NUM O
RARE O
cells O
. O

220 O
, O
NUM O
- O
NUM O
). O

These O
two O
RARE O
contain O
a O
RARE O
of O
NUM O
RARE O
reading O
frames O
( O
RARE O
) O
in O
NUM O
- O
29 O
putative O
RARE O
; O
NUM O
RARE O
could O
be O
identified O
with O
reasonable O
RARE O
. O

T O
., O
RARE O
, O
S O
. O

RARE O
factors O
induce O
the O
RARE O
of O
the O
immediate I-GENE
early I-GENE
gene I-GENE
products I-GENE
MAP I-GENE
kinase I-GENE
phosphatase I-GENE
- I-GENE
1 I-GENE
( O
MKP I-GENE
- I-GENE
1 I-GENE
RARE O
c I-GENE
- I-GENE
Fos I-GENE
and O
c I-GENE
- I-GENE
Jun I-GENE
. O

The O
RARE O
- O
RARE O
of O
E I-GENE
- I-GENE
selectin I-GENE
, O
one O
of O
the O
adhesion O
molecules O
on O
the O
endothelium O
, O
is O
an O
important O
event O
in O
the O
RARE O
of O
the O
inflammatory O
response O
. O

The O
NUM I-GENE
protein I-GENE
is O
RARE O
in O
nuclei O
and O
could O
not O
be O
detected O
in O
the O
cytoplasmic O
fraction O
of O
cells O
subjected O
to O
nitrogen O
derepression O
or O
nitrogen O
repression O
, O
indicating O
that O
the O
nuclear O
import O
of O
NUM I-GENE
is O
not O
regulated O
. O

In O
RARE O
of O
much O
effort O
, O
RARE O
one O
has O
RARE O
in O
RARE O
and O
characterizing O
the O
enzyme O
( O
s O
) O
responsible O
RARE O
RARE O
of O
RARE O
, O
the O
major O
cell O
RARE O
RARE O
of O
RARE O
. O

RARE O
responses O
to O
reactive O
RARE O
( O
with O
flow O
increase O
leading O
to O
endothelium O
- O
dependent O
RARE O
) O
and O
to O
RARE O
RARE O
RARE O
( O
ALL_CAP O
; O
endothelium O
- O
independent O
RARE O
) O
were O
recorded O
. O

During O
this O
period O
, O
administration O
of O
additional O
RARE I-GENE
PRL I-GENE
did O
not O
stimulate O
further O
activation O
( O
binding O
) O
of O
the O
Stat I-GENE
factors I-GENE
. O

RARE O
administration O
of O
L O
- O
5 O
- O
RARE O
( O
L O
- O
5 O
- O
ALL_CAP O
) O
RARE O
doses O
of O
NUM O
to O
NUM O
mg O
/ O
kg O
dramatically O
increase O
RARE O
in O
mice O
. O

In O
the O
VA O
- O
ALL_CAP O
mode O
, O
the O
RARE O
was O
made O
with O
RARE O
RARE O
from O
the O
LV O
apex O
( O
RARE O
) O
to O
the O
ascending O
aorta O
( O
outflow O
) O
( O
RARE O
= O
11 O
) O
or O
to O
the O
RARE O
( O
RARE O
= O
12 O
). O

The O
evidence O
in O
support O
of O
this O
was O
derived O
from O
the O
fact O
that O
the O
affinity O
or O
interaction O
between O
the O
two O
subunits O
was O
impaired O
RARE O
indicated O
by O
the O
RARE O
order O
rate O
constant O
of O
hCG I-GENE
alpha I-GENE
1 I-GENE
beta I-GENE
( O
RARE O
= O
4 O
. O
1 O
RARE O
10 O
RARE O
2 O
) O
min O
- O
1 O
) O
RARE O
pH O
3 O
. O
NUM O
RARE O
NUM O
degrees O
C O
which O
is O
one O
order O
of O
magnitude O
greater O
relative O
to O
ALL_CAP I-GENE
( O
RARE O
= O
4 O
. O
6 O
RARE O
10 O
RARE O
3 O
) O
min O
- O
1 O
). O

RARE O
V O
RARE O
is O
a O
genetic O
disorder O
associated O
with O
an O
increased O
risk O
of O
venous O
thrombosis O
. O

This O
is O
the O
RARE O
determination O
of O
the O
RARE O
secondary O
RARE O
of O
an O
RNA O
RARE O
in O
a O
spliceosome O
. O

The O
majority O
of O
the O
cases O
with O
NUM O
- O
I O
or O
NUM O
- O
III O
RARE O
were O
RARE O
. O
RARE O
. O

These O
patients O
appear O
to O
have O
slightly O
better O
pulmonary O
function O
and O
nutritional O
status O
; O
yet O
, O
they O
seem O
to O
have O
a O
RARE O
degree O
of O
health O
care O
utilization O
. O

This O
observation O
RARE O
RARE O
RARE O
monitoring O
of O
RARE O
and O
RARE I-GENE
phosphatase I-GENE
values O
and O
possible O
RARE O
of O
vitamin O
D O
intake O
when O
RARE O
are O
used O
RARE O
extended O
periods O
. O

We O
have O
found O
that O
NUM I-GENE
is O
also O
required O
RARE O
the O
bipolar O
RARE O
pattern O
and O
that O
it O
encodes O
a O
novel O
protein O
with O
a O
predicted O
RARE O
- O
RARE O
domain O
. O

RARE O
from O
the O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
Rac1 I-GENE
and O
Cdc42 I-GENE
to O
the O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
/ O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
RARE O
. O

RARE O
identities O
of O
the O
mouse I-GENE
NUM I-GENE
to O
mouse I-GENE
NUM I-GENE
, O
mouse O
NUM I-GENE
/ O
NUM I-GENE
and O
human I-GENE
NUM I-GENE
receptors I-GENE
are O
53 O
, O
NUM O
, O
and O
NUM O
, O
respectively O
. O

RARE O
with O
the O
previous O
observation O
that O
CBF I-GENE
binding O
to O
the O
NUM O
site O
is O
RARE O
by O
ALL_CAP O
and O
EDTA O
, O
these O
RARE O
RARE O
RARE O
specifically O
stimulate O
NUM O
- O
directed O
transcription O
. O

The O
human O
gene O
fragment O
ligated O
to O
the O
minimal O
rat O
liver O
RARE I-GENE
promoter O
was O
shown O
to O
work O
RARE O
an O
enhancer O
in O
the O
RARE O
transfection O
RARE O
. O

To O
test O
the O
role O
of O
ALL_CAP O
in O
human O
reproductive O
axis O
, O
NUM O
healthy O
children O
, O
NUM O
boys O
and O
NUM O
girls O
, O
were O
studied O
. O

However O
, O
the O
truncated O
RARE I-GENE
receptor I-GENE
lacks O
the O
most O
C O
- O
terminal O
tyrosine O
RARE O
in O
the O
RARE O
domain O
which O
is O
believed O
to O
be O
essential O
RARE O
activation O
of O
the O
beta I-GENE
- I-GENE
casein I-GENE
promoter I-GENE
. O

This O
report O
provides O
further O
evidence O
RARE O
the O
ALL_CAP O
in O
the O
control O
of O
RARE O
, O
and O
a O
RARE O
is O
postulated O
RARE O
the O
development O
of O
the O
RARE O
RARE O
nystagmus O
. O

RARE O
has O
substantial O
efficacy O
when O
combined O
with O
other O
agents O
. O

RARE O
- O
four O
percent O
of O
the O
RARE O
were O
RARE O
, O
and O
NUM O
% O
of O
the O
RARE O
exhibited O
some O
pathologic O
changes O
, O
including O
chronic O
RARE O
( O
NUM O
. O
5 O
%) O
and O
follicular O
RARE O
( O
10 O
%), O
among O
others O
. O

The O
assessment O
using O
7 O
H O
9 O
liquid O
medium O
by O
the O
former O
author O
demonstrated O
the O
potent O
activities O
of O
both O
ALL_CAP O
- O
NUM O
RARE O
and O
RARE O
( O
ALL_CAP O
RARE O
followed O
by O
ALL_CAP O
- O
NUM O
RARE O
RARE O
( O
ALL_CAP O
RARE O
RARE O
( O
ALL_CAP O
RARE O
ALL_CAP O
- O
NUM O
RARE O
ALL_CAP O
- O
NUM O
RARE O
in O
sequence O
. O

The O
NUM I-GENE
gene I-GENE
, O
encoding O
a O
protein O
kinase O
required O
RARE O
pheromone O
signal O
RARE O
, O
has O
recently O
been O
identified O
in O
a O
genetic O
screen O
RARE O
high O
- O
gene O
- O
dosage O
suppressors O
of O
a O
partly O
RARE O
G I-GENE
beta I-GENE
mutation O
. O

This O
enzyme O
is O
designated O
( I-GENE
1 I-GENE
RARE I-GENE
4 I-GENE
)- I-GENE
beta I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
X I-GENE
- I-GENE
I I-GENE
. O

Magnetic O
resonance O
imaging O
in O
RARE O
arthritis O
. O

Moloney O
murine O
leukemia O
virus O
( O
ALL_CAP O
)- O
derived O
ALL_CAP O
- O
based O
RARE O
vectors O
were O
RARE O
to O
allow O
RARE O
and O
Tat I-GENE
( O
RARE I-GENE
- I-GENE
activator I-GENE
of I-GENE
transcription I-GENE
)- O
inducible O
RARE O
of O
five O
RARE O
RARE O
targeted O
against O
highly O
RARE O
sequences O
within O
the O
group I-GENE
antigen I-GENE
( O
Gag I-GENE
RARE O
protease I-GENE
( O
RARE I-GENE
RARE O
reverse I-GENE
transcriptase I-GENE
( O
RT I-GENE
RARE O
tat I-GENE
, O
and O
envelope I-GENE
( O
Env I-GENE
) O
coding O
regions O
of O
human O
immunodeficiency O
virus O
type O
- O
1 O
( O
HIV O
- O
1 O
) O
RNA O
. O

REM O
sleep O
deprivation O
was O
performed O
using O
the O
RARE O
technique O
. O

The O
same O
ligands O
also O
exhibit O
a O
similar O
RARE O
effect O
on O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
- O
dependent O
RARE O
3H O
] O
RARE O
incorporation O
in O
ALL_CAP O
cells O
expressing O
the O
ALL_CAP I-GENE
beta I-GENE
- I-GENE
receptors I-GENE
. O

We O
analyzed O
serial O
biopsy O
specimens O
from O
eight O
patients O
with O
ALL_CAP O
RARE O
secondary O
alterations O
of O
the O
RARE I-GENE
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
in O
the O
RARE O
and O
RARE O
reading O
frame O
( O
ORF O
) O
regions O
. O

In O
all O
eight O
cases O
, O
neither O
ALL_CAP O
nor O
ALL_CAP O
cells O
showed O
alterations O
of O
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
sequences I-GENE
in O
the O
RARE O
region O
, O
suggesting O
high O
conservation O
of O
the O
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
RARE O
both O
t O
( O
14 O
; O
18 O
) O
translocation O
and O
morphologic O
transformation O
of O
the O
ALL_CAP O
cells O
. O

BACKGROUND O
: O
The O
RARE O
- O
corrected O
QT O
( O
RARE O
) O
interval O
RARE O
exercise O
has O
been O
used O
RARE O
a O
marker O
RARE O
ischemic O
RARE O
, O
RARE O
substrate O
and O
the O
long O
QT O
RARE O
. O

An O
essential O
role O
of O
c I-GENE
- I-GENE
Jun I-GENE
and O
c I-GENE
- I-GENE
Fos I-GENE
in O
basal O
and O
PMA O
- O
RARE O
transcription O
of O
the O
PAI I-GENE
- I-GENE
1 I-GENE
gene I-GENE
is O
demonstrated O
by O
our O
finding O
that O
RARE O
c I-GENE
- I-GENE
jun I-GENE
and O
c I-GENE
- I-GENE
fos I-GENE
RARE O
both O
strongly O
RARE O
basal O
and O
PMA O
- O
RARE O
PAI I-GENE
- I-GENE
1 I-GENE
RARE O
. O

RARE I-GENE
- I-GENE
RARE I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
) O
is O
a O
RARE I-GENE
able O
to O
regulate O
the O
differentiation O
and O
the O
survival O
of O
many O
cell O
RARE O
, O
which O
include O
some O
RARE O
populations O
. O

To O
analyze O
the O
mechanism O
of O
fos I-GENE
/ O
jun I-GENE
activation O
by O
ALL_CAP O
we O
have O
used O
electrophoretic O
mobility O
shift O
and O
transient O
RARE O
assays O
of O
reporter O
gene O
constructs O
containing O
response O
elements O
RARE O
12 O
- O
O O
- O
RARE O
- O
phorbol O
- O
NUM O
- O
RARE O
( O
ALL_CAP O
RARE O
serum O
( O
SRE O
RARE O
cAMP O
( O
ALL_CAP O
RARE O
and O
aromatic O
RARE O
( O
ALL_CAP O
) O
from O
the O
fos I-GENE
and O
jun I-GENE
genes I-GENE
fused O
to O
the O
RARE I-GENE
luciferase I-GENE
gene I-GENE
under O
the O
control O
of O
the O
SV40 I-GENE
minimal I-GENE
promoter I-GENE
. O

The O
optimal O
sequence O
RARE O
interaction O
with O
mu I-GENE
2 I-GENE
and O
with O
AP I-GENE
- I-GENE
2 I-GENE
has O
tyrosine O
RARE O
an O
RARE O
and O
RARE O
RARE O
RARE O
position O
Y O
+ O
2 O
and O
leucine O
RARE O
position O
Y O
+ O
3 O
. O

STK I-GENE
/ O
ALL_CAP I-GENE
- O
expressing O
RARE O
/ O
NUM O
pro O
- O
B O
cells O
( O
ALL_CAP O
/ O
STK I-GENE
) O
exhibited O
ALL_CAP I-GENE
- O
dependent O
growth O
, O
whereas O
STK I-GENE
/ O
ALL_CAP I-GENE
- O
expressing O
mouse O
RARE O
cells O
( O
ALL_CAP O
/ O
STK I-GENE
) O
displayed O
ALL_CAP I-GENE
- O
RARE O
apoptosis O
. O

In O
vitro O
DNase I-GENE
I I-GENE
footprinting O
showed O
that O
OxyR I-GENE
- I-GENE
NUM I-GENE
protected O
RARE I-GENE
from O
- O
104 O
to O
- O
NUM O
on O
the O
top O
RARE O
and O
produced O
a O
protection O
pattern O
characteristic O
of O
RARE I-GENE
wild I-GENE
- I-GENE
type I-GENE
OxyR I-GENE
. O

NUM I-GENE
binds O
specifically O
to O
a O
GST I-GENE
- O
NUM I-GENE
fusion O
in O
the O
absence O
of O
any O
other O
yeast O
protein O
. O

In O
contrast O
, O
NUM I-GENE
NUM I-GENE
cells O
constitutively O
RARE O
agar O
medium O
, O
whereas O
a O
NUM I-GENE
NUM I-GENE
NUM I-GENE
RARE O
mutant O
does O
not O
, O
indicating O
that O
NUM I-GENE
and O
NUM I-GENE
share O
a O
role O
in O
negatively O
RARE O
the O
invasive O
growth O
RARE O
. O

RARE O
activation O
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
promoter I-GENE
by O
the O
viral I-GENE
Tat I-GENE
protein I-GENE
is O
RARE O
similar O
to O
RARE O
- O
activation O
within O
a O
cell O
. O

Comparison O
of O
the O
sequences O
of O
the O
ALL_CAP O
repeat O
regions O
of O
p62 I-GENE
and O
RARE I-GENE
indicated O
that O
NUM I-GENE
was O
probably O
RARE O
with O
the O
RARE O
- O
containing O
core O
of O
these O
repeats O
and O
not O
the O
intervening O
hydrophilic O
RARE O
. O

This O
is O
the O
RARE O
report O
of O
the O
successful O
resection O
of O
a O
ALL_CAP O
RARE O
in O
the O
RARE O
RARE O
tissue O
and O
extending O
into O
the O
inferior O
RARE O
RARE O
. O

Transient O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
in O
RARE O
RARE O
RARE I-GENE
- I-GENE
1 I-GENE
dependent O
activation O
of O
the O
- I-GENE
NUM I-GENE
/ I-GENE
NUM I-GENE
. I-GENE
8 I-GENE
minimal I-GENE
promoter I-GENE
. O

RARE O
in O
RARE O
the O
limited O
range O
of O
age O
and O
RARE O
, O
advantages O
and O
RARE O
of O
the O
drug O
are O
discussed O
, O
comparing O
the O
experimental O
results O
with O
those O
derived O
from O
the O
literature O
. O

RARE O
sampling O
procedures O
were O
RARE O
. O

Analysis O
of O
one O
cDNA O
revealed O
an O
unusual O
RARE O
event O
involving O
NUM I-GENE
and O
a O
tandemly O
RARE O
gene O
NUM I-GENE
and O
suggests O
a O
RARE O
mechanism O
RARE O
RARE O
the O
NUM I-GENE
protein I-GENE
in O
the O
RARE O
C O
- O
terminal O
domain O
. O

A O
given O
standard O
input O
function O
and O
a O
given O
value O
of O
distribution O
volume O
( O
RARE O
) O
used O
RARE O
the O
rCBF O
measurement O
of O
this O
method O
were O
calculated O
from O
the O
dynamic O
study O
by O
RARE O
normal O
volunteers O
. O

They O
lack O
a O
predicted O
single O
RARE O
( O
RARE O
) O
DNA O
binding O
motif O
that O
is O
unique O
the O
large O
terminase I-GENE
proteins I-GENE
in O
T4 I-GENE
NUM I-GENE
, O
and O
that O
has O
been O
implicated O
in O
RARE O
ALL_CAP O
regions O
in O
RARE O
and O
RARE O
NUM O
RARE O
to O
be O
RARE O
. O

It O
can O
be O
concluded O
that O
in O
RARE O
subjects O
, O
uric O
acid O
and O
RARE I-GENE
oxidase I-GENE
have O
significant O
association O
with O
RARE O
pressure O
and O
thus O
are O
one O
of O
the O
many O
factors O
which O
are O
involved O
in O
the O
cause O
or O
effect O
of O
hypertension O
. O

RARE O
of O
RARE O
recombinant O
proteins O
with O
the O
monoclonal I-GENE
NUM I-GENE
antibody I-GENE
localized O
the O
NUM I-GENE
RARE O
to O
the O
RARE O
end O
of O
the O
protein O
. O

We O
RARE O
that O
the O
dominant O
negative O
inhibition O
results O
from O
both O
direct O
proteolysis O
of O
the O
beta I-GENE
- I-GENE
galactosidase I-GENE
RARE I-GENE
by O
the O
fusion O
subunit O
and O
RARE O
of O
the O
RARE O
to O
the O
RARE O
. O

The O
current O
study O
defines O
the O
RARE I-GENE
- O
and O
FAK I-GENE
- I-GENE
interaction I-GENE
domains I-GENE
on O
paxillin I-GENE
and O
identifies O
the O
principal O
paxillin I-GENE
RARE O
adhesion O
targeting O
motif O
. O

These O
data O
demonstrate O
the O
presence O
of O
a O
single O
binding O
site O
RARE O
RARE I-GENE
, O
and O
RARE O
least O
two O
binding O
sites O
RARE O
FAK I-GENE
that O
are O
separated O
by O
an O
intervening O
stretch O
of O
NUM O
amino O
RARE O
. O

These O
data O
demonstrate O
that O
paxillin I-GENE
localizes O
to O
RARE O
adhesions O
independent O
of O
interactions O
with O
RARE I-GENE
and O
/ O
or O
FAK I-GENE
, O
and O
represents O
the O
RARE O
definitive O
RARE O
of O
LIM I-GENE
domains I-GENE
functioning O
RARE O
a O
RARE O
determinant O
of O
protein O
subcellular O
RARE O
to O
RARE O
adhesions O
. O

A O
single O
protease O
- O
resistant O
RARE O
formed O
by O
the O
RARE O
of O
both O
PDZ I-GENE
repeats I-GENE
1 I-GENE
and I-GENE
2 I-GENE
( O
NUM I-GENE
- I-GENE
2 I-GENE
) O
contains O
the O
protein I-GENE
4 I-GENE
. I-GENE
1 I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

Several O
agents O
have O
been O
RARE O
RARE O
treatment O
, O
often O
limited O
by O
toxic O
RARE O
effects O
. O

RARE O
had O
RARE O
RARE O
RARE O
concentrations O
than O
did O
RARE O
on O
d O
NUM O
( O
NUM O
RARE O
. O

ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
is O
a O
NUM O
- O
kDa O
truncated O
version O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
that O
results O
from O
RARE O
RARE O
of O
a O
57 O
- O
bp O
RARE O
RARE O
confirmed O
by O
genomic O
cloning O
. O

These O
results O
are O
consistent O
with O
the O
RARE O
established O
polarity O
of O
RXR I-GENE
RARE O
binding O
to O
bipartite O
hormone O
response O
elements O
, O
with O
the O
VDR I-GENE
RARE O
the O
3 O
'- O
RARE O
- O
element O
. O

ALL_CAP I-GENE
gamma I-GENE
mRNA I-GENE
levels O
were O
RARE O
by O
NUM O
% O
with O
3 O
nM O
TNF I-GENE
alpha I-GENE
treatment O
RARE O
NUM O
h O
. O

RARE O
III O
to O
VIII O
, O
which O
RARE O
the O
coding O
region O
and O
the O
3 O
' O
RARE O
region O
, O
are O
almost O
identical O
in O
all O
RARE O
of O
ALL_CAP I-GENE
or O
ALL_CAP I-GENE
cDNAs I-GENE
. O

RARE O
factor O
allows O
effective O
dose O
- O
intensive O
regimen O
in O
advanced O
breast O
RARE O
patients O
. O

Recombinant I-GENE
erythropoietin I-GENE
( O
RARE I-GENE
- I-GENE
ALL_CAP I-GENE
) O
in O
the O
treatment O
of O
RARE O
in O
multiple O
myeloma O

In O
1993 O
and O
1994 O
and O
infection O
with O
body O
RARE O
was O
RARE O
NUM O
times O
in O
NUM O
patients O
RARE O
the O
RARE O
RARE O
RARE O
of O
the O
RARE O
Health O
RARE O
of O
RARE O
. O

RARE I-GENE
- I-GENE
ras I-GENE
and O
p53 I-GENE
mutations I-GENE
in O
pancreatic O
RARE O
adenocarcinoma O
. O

RARE O
data O
are O
quite O
RARE O
but O
RARE O
RARE O
occurring O
RARE O
RARE O
activity O
is O
probably O
not O
a O
rare O
occurrence O
. O

However O
, O
the O
ratio O
M O
/ O
RARE O
provides O
a O
useful O
index O
that O
seems O
to O
be O
independent O
of O
the O
metabolic O
demand O
. O

RARE I-GENE
liver I-GENE
catalase I-GENE
is O
RARE O
to O
RARE O
by O
its O
C O
- O
terminal O
RARE O
RARE O
- O
Asn O
- O
RARE O
, O
not O
by O
the O
internal O
RARE O
- O
RARE O
- O
RARE O
motif O
. O

The O
mobility O
shift O
assay O
of O
the O
65 O
bp O
RARE O
NUM O
/ O
- O
NUM O
) O
fragment O
with O
nuclear O
RARE O
from O
the O
dark O
- O
adapted O
sample O
showed O
an O
additional O
band O
, O
not O
seen O
with O
the O
light O
- O
grown O
sample O
. O

These O
data O
provide O
strong O
evidence O
that O
E2F I-GENE
or O
an O
E2F I-GENE
- I-GENE
related I-GENE
transcription I-GENE
factor I-GENE
is O
involved O
in O
the O
RARE O
of O
RARE I-GENE
myosin I-GENE
RARE O
. O

When O
the O
E1A I-GENE
N I-GENE
- I-GENE
terminus I-GENE
is O
used O
RARE O
a O
competitor O
in O
RARE O
experiments O
it O
abolishes O
CBP I-GENE
- O
RARE O
activation O
of O
E2F1 I-GENE
/ O
NUM I-GENE
, O
whereas O
an O
E1A I-GENE
mutant I-GENE
RARE O
CBP I-GENE
binding O
ability O
fails O
to O
do O
so O
. O

RARE O
Maf I-GENE
proteins I-GENE
interact O
with O
the O
human O
transcription O
factor O
NUM I-GENE
/ O
NUM I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
. O

On O
the O
third O
RARE O
water O
( O
ALL_CAP O
) O
was O
RARE O
throughout O
the O
run O
. O

The O
effect O
of O
RARE O
ingestion O
of O
the O
RARE O
energy O
RARE O
RARE O
was O
investigated O
in O
ALL_CAP O
: O
ALL_CAP O
RARE O
RARE O
rabbits O
. O

Moreover O
, O
the O
same O
mutations O
alter O
the O
RARE O
of O
junB I-GENE
5 O
' O
flanking O
DNA O
within O
chromatin O
. O

The O
NUM I-GENE
- I-GENE
NUM I-GENE
/ O
NUM I-GENE
- I-GENE
H2 I-GENE
gene O
transcriptional O
activity O
ratio O
varied O
depending O
on O
the O
cell O
line O
. O

CONCLUSION O
: O
Intravenous O
RARE O
administration O
before O
ALL_CAP O
produces O
a O
significant O
fall O
in O
NUM O
RARE O
the O
procedure O
, O
and O
so O
should O
be O
RARE O
; O
continuous O
monitoring O
of O
NUM O
should O
be O
done O
RARE O
ALL_CAP O
. O

The O
nucleotide O
sequence O
alignment O
between O
mouse O
and O
human I-GENE
CA I-GENE
IV I-GENE
shows O
NUM O
% O
identity O
in O
the O
coding O
region O
and O
all O
of O
the O
RARE O
- O
intron O
boundaries O
are O
RARE O
, O
RARE O
are O
the O
sizes O
of O
the O
RARE O
. O

RARE O
on O
the O
cost O
RARE O
correlated O
negatively O
with O
G I-GENE
RARE I-GENE
, O
suggesting O
better O
RARE O
control O
with O
greater O
RARE O
. O

ALL_CAP O
ALL_CAP O
: O
RARE O
studies O
, O
research O
studies O
, O
review O
RARE O
, O
and O
RARE O
reports O
RARE O
to O
RARE O
of O
RARE O
RARE O
. O

RESULTS O
: O
The O
age O
distribution O
was O
NUM O
to O
NUM O
years O
old O
( O
mean O
was O
54 O
. O
1 O
years O
). O

Histological O
changes O
, O
including O
cortical O
cell O
RARE O
and O
hemorrhage O
occurring O
RARE O
the O
neonatal O
period O
, O
would O
seem O
to O
have O
crucial O
relevance O
to O
the O
remodeling O
of O
the O
adrenal O
RARE O
. O

Furthermore O
, O
RARE O
- O
RARE O
of O
both O
NUM I-GENE
and O
p54 I-GENE
subunits I-GENE
markedly O
altered O
the O
subcellular O
distribution O
of O
NUM I-GENE
; O
RARE O
- O
RARE O
NUM I-GENE
was O
transported O
into O
the O
nucleus O
RARE O
efficiently O
RARE O
p54 I-GENE
. O

The O
results O
suggest O
that O
, O
although O
both O
the O
N O
- O
and O
C O
- O
terminal O
regions O
of O
RARE I-GENE
bind O
actin I-GENE
, O
the O
properties O
of O
these O
two O
regions O
of O
the O
protein O
are O
distinct O
. O

RARE O
.) O
RARE O
library O
. O

The O
accumulation O
of O
both O
NUM I-GENE
and O
NUM I-GENE
mRNAs I-GENE
is O
RARE O
by O
the O
addition O
of O
RARE O
sugars O
and O
this O
induction O
appears O
to O
be O
dependent O
on O
RARE O
uptake O
and O
metabolism O
, O
because O
RARE O
and O
3 O
- O
O O
- O
RARE O
do O
not O
stimulate O
mRNA O
accumulation O
. O

Using O
the O
yeast O
one O
- O
RARE O
screen O
with O
integrated O
ALL_CAP O
and O
flanking O
DNA O
RARE O
RARE O
, O
the O
predominant O
clone O
obtained O
was O
bovine I-GENE
RARE I-GENE
. O

As O
the O
rate O
of O
protein O
RARE O
decreases O
RARE O
RARE O
embryogenesis O
, O
levels O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
and O
its O
RARE O
mRNA O
decline O
RARE O
. O

These O
findings O
suggest O
that O
RARE I-GENE
proteolysis O
in O
vivo O
may O
reflect O
the O
activity O
of O
multiple O
ICE I-GENE
/ O
RARE I-GENE
- I-GENE
3 I-GENE
RARE O
whose O
partial O
sensitivity O
to O
ALL_CAP O
- O
CHO O
RARE O
a O
limited O
contribution O
from O
NUM I-GENE
, O
or O
an O
ICE I-GENE
/ O
RARE I-GENE
- I-GENE
3 I-GENE
protease O
less O
RARE O
than O
NUM I-GENE
to O
ALL_CAP O
- O
CHO O
inhibition O
. O

In O
NUM O
and O
NUM O
v I-GENE
- I-GENE
RARE I-GENE
- O
transformed O
RARE O
, O
almost O
all O
of O
the O
RARE O
NUM I-GENE
and O
about O
40 O
% O
of O
RARE O
p130 I-GENE
( O
RARE I-GENE
) O
RARE O
- O
RARE O
with O
membranes O
composed O
primarily O
of O
endoplasmic O
reticulum O
. O

RARE O
residues O
NUM O
- O
NUM O
on O
NUM O
with O
the O
RARE O
ALL_CAP O
- O
2 O
domain O
from O
the O
vitamin I-GENE
NUM I-GENE
receptor I-GENE
or O
the O
estrogen I-GENE
receptor I-GENE
results O
in O
a O
receptor O
with O
wild O
- O
type O
or O
low O
transcriptional O
activity O
, O
respectively O
. O

RARE O
G O
- O
to O
- O
A O
substitution O
in O
a O
single O
RARE O
of O
SREBP I-GENE
RARE I-GENE
- I-GENE
activating I-GENE
protein I-GENE
causes O
sterol O
resistance O
in O
three O
mutant O
RARE O
hamster O
ovary O
cell O
lines O
. O

The O
Escherichia I-GENE
coli I-GENE
RARE I-GENE
- I-GENE
repressor I-GENE
( O
ALL_CAP I-GENE
) O
operator O
RARE O
was O
used O
to O
develop O
a O
variation O
of O
the O
yeast O
two O
- O
RARE O
assay O
in O
which O
RARE O
of O
protein O
- O
protein O
interactions O
can O
be O
identified O
by O
a O
positive O
selection O
. O

Recent O
studies O
have O
suggested O
that O
SHP I-GENE
- I-GENE
1 I-GENE
regulates O
the O
function O
of O
Jak I-GENE
family O
tyrosine I-GENE
kinases I-GENE
, O
RARE O
shown O
by O
its O
RARE O
association O
with O
the O
NUM I-GENE
kinase I-GENE
and O
the O
RARE O
of O
Jak I-GENE
kinases I-GENE
in O
the O
RARE O
cells O
that O
lack O
RARE O
SHP I-GENE
- I-GENE
1 I-GENE
. O

Administration O
of O
a O
second O
dose O
of O
vaccine O
RARE O
the O
outbreak O
was O
not O
protective O
. O

RARE O
, O
RARE O
RARE O
RARE O
, O
RARE O
in O
assessing O
exposure O
have O
not O
yet O
translated O
into O
clear O
and O
consistent O
findings O
. O

Biol O
. O

Structural O
basis O
RARE O
activation O
of O
human I-GENE
lymphocyte I-GENE
kinase I-GENE
RARE I-GENE
upon O
tyrosine O
RARE O
. O

RARE O
morphology O
of O
the O
olfactory O
bulb O
in O
man O
and O
certain O
non O
- O
human O
mammals O

From O
these O
results O
, O
we O
concluded O
that O
this O
ORF O
is O
the O
ALL_CAP I-GENE
gene I-GENE
. O

FK506 O
is O
10 O
- O
to O
NUM O
- O
RARE O
more O
potent O
than O
cyclosporin O
A O
in O
preventing O
organ O
rejection O
and O
in O
toxicity O
. O

These O
results O
suggest O
that O
NUM I-GENE
regulates O
cytoskeletal O
RARE O
RARE O
least O
through O
NUM I-GENE
and O
NUM I-GENE
. O

The O
ALL_CAP I-GENE
RARE O
profile O
is O
similar O
, O
to O
that O
of O
NUM I-GENE
, O
which O
localizes O
to O
the O
RARE O
hemisphere O
of O
oocytes O
and O
is O
abundantly O
RARE O
in O
the O
RARE O
. O

RARE O
NUM O
, O
NUM O
and O
CNV O
were O
recorded O
RARE O
a O
CNV O
RARE O
in O
a O
simple O
reaction O
time O
task O
with O
a O
constant O
RARE O
interval O
( O
ALL_CAP O
) O
of O
1 O
sec O
. O

Therefore O
, O
both O
the O
RARE O
and O
the O
Japanese O
samples O
collected O
in O
high O
- O
risk O
areas O
showed O
RARE O
RARE O
rates O
than O
the O
Japanese O
ones O
in O
a O
low O
- O
risk O
area O
, O
with O
a O
statistical O
significance O
( O
p O
< O
NUM O
. O
001 O
RARE O
RARE O
- O
square O
test O
). O

Regulation O
of O
NUM I-GENE
and O
NUM I-GENE
RARE O
was O
studied O
using O
lacZ I-GENE
fusions I-GENE
and O
both O
genes O
were O
found O
to O
be O
several O
times O
less O
RARE O
in O
the O
absence O
of O
the O
transcription O
activator O
NUM I-GENE
. O

Several O
particular O
features O
of O
this O
polypeptide O
fragment O
from O
the O
hamster I-GENE
RARE I-GENE
- I-GENE
tRNA I-GENE
RARE I-GENE
suggest O
that O
it O
is O
implicated O
in O
the O
assembly O
of O
that O
enzyme O
within O
the O
RARE O
complex O
. O

He O
is O
RARE O
, O
five O
years O
after O
relapse O
. O

Comparison O
of O
the O
proportion O
of O
RARE O
( O
ALL_CAP O
) O
and O
RARE O
( O
ALL_CAP O
) O
substitutions O
occurring O
per O
site O
within O
RARE I-GENE
RARE I-GENE
region I-GENE
genes I-GENE
demonstrated O
a O
reduction O
in O
ALL_CAP O
in O
the O
RARE O
regions O
compared O
with O
ALL_CAP O
in O
the O
RARE O
MHC I-GENE
RARE I-GENE
regions I-GENE
( O
NUM I-GENE
and O
NUM I-GENE
). O

The O
effects O
of O
oral O
RARE O
RARE O
( O
NUM O
) O
( O
NUM O
. O
5 O
mg O
/ O
kg O
/ O
day O
) O
on O
RARE O
, O
body O
composition O
, O
and O
performance O
were O
investigated O
in O
a O
12 O
- O
week O
, O
double O
- O
blind O
, O
placebo O
- O
RARE O
trial O
involving O
RARE O
- O
training O
volunteers O
. O

RARE O
in O
development O
, O
NUM I-GENE
RARE O
is O
restricted O
to O
RARE O
, O
RARE O
mesoderm O
and O
to O
the O
RARE O
RARE O
, O
which O
RARE O
the O
RARE O
RARE O
the O
source O
of O
mesoderm O
. O

Disruption O
of O
re O
- O
replication O
control O
by O
overexpression O
of O
human I-GENE
NUM I-GENE
in O
RARE O
yeast O
. O

Our O
results O
demonstrate O
that O
the O
promoter O
and O
enhancer O
regions O
identified O
here O
are O
essential O
RARE O
maintaining O
the O
efficient O
promoter O
activity O
of O
the O
human I-GENE
activin I-GENE
ALL_CAP I-GENE
subunit I-GENE
gene I-GENE
. O

Recombinant O
, O
bacterially O
RARE O
NUM I-GENE
possessed O
NUM I-GENE
activity O
and O
was O
RARE O
with O
RARE I-GENE
NUM I-GENE
antibodies I-GENE
. O

Human I-GENE
acid I-GENE
RARE I-GENE
RARE O
ALL_CAP O
) O
N O
- O
RARE O
RARE O
, O
EC I-GENE
3 I-GENE
. I-GENE
5 I-GENE
. O

The O
NUM O
. O
NUM O
- O
kb O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
promoter O
exhibited O
PMA O
inducibility O
in O
RARE O
cells O
and O
contained O
a O
PMA O
- O
responsive O
element O
RARE O
by O
NUM I-GENE
and O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
transcription I-GENE
factors I-GENE
. O

Northern O
( O
RNA O
) O
blot O
analyses O
indicated O
that O
the O
RARE I-GENE
genes I-GENE
encoding O
the O
five O
subunits O
and O
an O
RARE O
reading O
frame O
( O
ORF1 O
) O
with O
unknown O
function O
are O
cotranscribed O
RARE O
growth O
on O
RARE O
. O

Two O
classes O
of O
mutations O
were O
obtained O
: O
( O
i O
) O
those O
that O
altered O
the O
coding O
region O
of O
NUM I-GENE
, O
conferring O
the O
ability O
to O
take O
RARE O
RARE O
; O
and O
( O
ii O
) O
cis O
- O
acting O
mutations O
( O
RARE O
in O
a O
mutant O
NUM I-GENE
- I-GENE
1 I-GENE
background O
) O
that O
increased O
RARE O
of O
the O
NUM I-GENE
protein I-GENE
. O

RARE O
to O
the O
ALL_CAP O
was O
judged O
by O
RARE O
of O
RARE O
RARE O
( O
ALL_CAP O
) O
RARE O
, O
which O
was O
administered O
either O
2 O
, O
3 O
, O
NUM O
or O
NUM O
h O
after O
onset O
of O
RARE O
. O

RARE O
RARE O
levels O
in O
plasma O
and O
LDL I-GENE
remained O
unchanged O
throughout O
the O
study O
. O

When O
the O
degree O
of O
exercise O
was O
maximal O
, O
ALL_CAP O
was O
maintained O
, O
ALL_CAP O
decreased O
, O
HR O
was O
unchanged O
, O
and O
ALL_CAP O
and O
VO2 O
decreased O
. O

We O
report O
a O
case O
of O
vasculitis O
( O
cutaneous O
and O
neurologic O
) O
which O
led O
to O
the O
discovery O
of O
a O
selective O
RARE O
towards O
ALL_CAP O
, O
similar O
to O
RARE O
' O
s O
RARE O
. O

To O
elucidate O
whether O
RARE O
endocrine O
changes O
resulted O
from O
acute O
RARE O
alone O
, O
the O
underlying O
RARE O
, O
or O
RARE O
influences O
connected O
with O
the O
ALL_CAP O
setting O
, O
all O
measurements O
were O
compared O
to O
those O
of O
a O
completely O
healthy O
reference O
group O
( O
ALL_CAP O
) O
with O
comparable O
acute O
experimental O
RARE O
. O

There O
were O
RARE O
significant O
differences O
in O
graft O
survival O
between O
groups O
with O
early O
graft O
function O
( O
ALL_CAP O
) O
and O
ALL_CAP O
, O
either O
in O
RARE O
RARE O
or O
RARE O
. O

These O
results O
suggested O
that O
the O
ALL_CAP O
motifs O
contributed O
to O
the O
cell O
- O
specific O
transcription O
of O
the O
human I-GENE
insulin I-GENE
gene I-GENE
in O
association O
with O
the O
binding O
of O
the O
sequence O
- O
specific O
nuclear O
factor O
. O

Abnormal O
RARE O
RARE O
levels O
in O
patients O
RARE O
by O
hepatitis O
C O
virus O
with O
or O
without O
human O
immunodeficiency O
virus O
. O

The O
determination O
of O
immunoglobulin I-GENE
E I-GENE
( O
IgE I-GENE
) O
antibodies O
by O
one O
of O
several O
laboratory O
tests O
, O
by O
RARE O
- O
RARE O
tests O
or O
by O
appropriate O
challenge O
procedures O
is O
useful O
either O
to O
identify O
atopic O
individuals O
or O
RARE O
outcome O
predictors O
in O
RARE O
children O
. O

RARE O
of O
the O
RARE O
RARE O
may O
be O
dramatic O
and O
include O
RARE O
failure O
. O

RARE O
and O
RARE O
preparations O
of O
the O
urine O
were O
studied O
and O
all O
cases O
displayed O
numerous O
RARE O
aggregates O
or O
single O
tumor O
cells O
in O
an O
inflammatory O
background O
. O

NUM O
and O
NUM O
RARE O
of O
RARE O
examinations O
from O
RARE O
hospitals O
N O
NUM O
and O
57 O
, O
respectively O
, O
were O
evaluated O
statistically O
. O

The O
promoter O
segment O
was O
inactive O
when O
introduced O
into O
the O
rat O
glioma O
cell O
line O
NUM O
, O
the O
rat O
RARE O
cell O
line O
ALL_CAP O
- O
NUM O
, O
and O
the O
rat O
pancreatic O
beta O
cell O
line O
ALL_CAP O
- O
NUM O
, O
all O
of O
which O
do O
not O
express O
the O
endogenous O
NUM I-GENE
- I-GENE
ALL_CAP I-GENE
gene I-GENE
. O

The O
sequencing O
of O
the O
conditional O
lethal O
mutation O
RARE O
- O
NUM O
, O
localized O
in O
the O
ALL_CAP I-GENE
RARE I-GENE
, O
and O
the O
lethality O
of O
RARE O
mutations O
targeted O
in O
the O
internal O
region O
of O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
, O
demonstrated O
the O
essential O
role O
of O
this O
locus O
. O

The O
RARE O
scores O
and O
their O
RARE O
- O
to O
- O
RARE O
differences O
in O
patients O
correlated O
negatively O
with O
the O
serum O
NUM O
- O
ALL_CAP O
concentration O
and O
positively O
with O
the O
degree O
of O
RARE O
. O

These O
data O
do O
not O
support O
the O
use O
of O
ALL_CAP O
to O
reduce O
risk O
of O
progression O
to O
ALL_CAP O
in O
sepsis O
. O

This O
correlated O
with O
RARE O
levels O
of O
RARE O
hepatitis I-GENE
B I-GENE
RARE I-GENE
antigen I-GENE
and O
increased O
RARE O
levels O
of O
core I-GENE
and O
Pol I-GENE
proteins I-GENE
and O
replicative O
ALL_CAP O
DNA O
RARE O
. O

In O
contrast O
, O
extracts O
of O
the O
mutant O
virions O
RARE O
the O
wild O
- O
type O
level O
of O
transcription O
from O
an O
RARE O
template O
containing O
an O
early O
promoter O
. O

The O
ALL_CAP I-GENE
ALL_CAP I-GENE
sites I-GENE
contain O
RARE O
overlapping O
core O
recognition O
binding O
motifs O
RARE O
SRF I-GENE
, O
Rel I-GENE
/ O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
and O
YY1 I-GENE
class I-GENE
transcription I-GENE
factors I-GENE
but O
fail O
to O
respond O
to O
either O
serum O
or O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
. O

Upon O
serum O
withdrawal O
RARE O
the O
permissive O
RARE O
, O
p53 I-GENE
- O
RARE O
apoptosis O
was O
RARE O
in O
50 O
to O
NUM O
% O
of O
the O
cells O
. O

To O
RARE O
this O
problem O
, O
a O
simple O
two O
- O
step O
strategy O
was O
RARE O
by O
which O
essential O
cis O
- O
acting O
sites O
like O
the O
a O
sequence O
can O
be O
readily O
RARE O
from O
their O
RARE O
loci O
in O
large O
viral O
DNA O
genomes O
. O

On O
the O
basis O
of O
serological O
studies O
, O
the O
highly O
RARE O
A O
domain O
of O
ALL_CAP I-GENE
was O
found O
to O
be O
the O
RARE O
domain O
. O

In O
Group O
IV O
dogs O
that O
received O
alpha I-GENE
- I-GENE
MSH I-GENE
only O
RARE O
reperfusion O
, O
RARE O
were O
increased O
RARE O
10 O
to O
14 O
% O
more O
than O
in O
Group O
II O
RARE O
the O
RARE O
reperfusion O
period O
. O

The O
Fas I-GENE
receptor I-GENE
mediates O
a O
signalling O
cascade O
resulting O
in O
programmed O
cell O
RARE O
( O
apoptosis O
) O
within O
hours O
of O
receptor O
cross O
- O
linking O
. O

Fas I-GENE
has O
been O
shown O
to O
require O
ICE I-GENE
( O
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
- I-GENE
RARE I-GENE
enzyme I-GENE
) O
family O
RARE O
to O
induce O
apoptosis O
from O
studies O
utilizing O
the O
RARE O
ICE I-GENE
inhibitor I-GENE
protein I-GENE
ALL_CAP I-GENE
, O
the O
RARE O
RARE O
ICE I-GENE
inhibitor O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
, O
and O
the O
RARE O
RARE O
- O
ICE I-GENE
inhibitor O
Z I-GENE
- I-GENE
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
. O

The O
imprinted O
RARE O
of O
the O
endogenous O
gene O
can O
be O
RARE O
in O
mice O
by O
using O
a O
14 O
- O
kb O
RARE O
RARE O
4 O
kb O
of O
5 O
'- O
flanking O
sequence O
, O
8 O
kb O
of O
3 O
'- O
flanking O
sequence O
, O
which O
includes O
the O
two O
endoderm O
- O
specific O
RARE O
, O
and O
an O
RARE O
RARE O
structural O
gene O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
NUM I-GENE
is O
also O
an O
ALL_CAP I-GENE
and O
has O
the O
same O
substrate O
RARE O
RARE O
NUM I-GENE
. O

The O
effect O
of O
RARE O
RARE O
mutations O
of O
oxidative O
RARE O
and O
ALL_CAP I-GENE
RARE O
. O

RARE O
RARE O
RARE O
the O
coat I-GENE
protein I-GENE
coding O
and O
adjacent O
regions O
of O
RARE O
mosaic O
virus O
( O
ALL_CAP O
) O
and O
RARE O
mosaic O
virus O
( O
ALL_CAP O
) O
were O
RARE O
and O
sequenced O
. O

In O
some O
cases O
, O
factor O
- O
RARE O
Rac I-GENE
activation O
results O
in O
Rho I-GENE
activation O
, O
and O
factor O
- O
RARE O
Cdc42 I-GENE
activation O
leads O
to O
Rac I-GENE
activation O
, O
RARE O
determined O
by O
specific O
morphological O
changes O
. O

Several O
cDNAs O
corresponding O
to O
the O
human I-GENE
NUM I-GENE
gene I-GENE
were O
identified O
and O
partially O
sequenced O
. O

Isolation O
and O
genomic O
RARE O
of O
a O
human O
homolog O
of O
the O
yeast I-GENE
RARE I-GENE
RARE I-GENE
protein I-GENE
2 I-GENE
( O
NUM I-GENE
) O
gene O
mapping O
to O
NUM O
. O
3 O
. O

RARE O
defined O
by O
combinations O
of O
normal O
and O
abnormal O
laboratory O
results O
had O
decreased O
the O
likelihood O
of O
ALL_CAP O
from O
an O
all O
- O
2 O
to O
all O
- O
NUM O
pattern O
. O

To O
examine O
whether O
RARE O
( O
vitamin O
NUM O
) O
deficiency O
is O
associated O
with O
recurrent O
RARE O
RARE O
, O
we O
studied O
vitamin O
NUM O
levels O
in O
70 O
patients O
with O
recurrent O
RARE O
RARE O
and O
in O
50 O
members O
of O
a O
control O
group O
. O

Liver O
injuries O

By O
screening O
a O
cDNA O
library O
with O
a O
probe O
derived O
from O
sequences O
RARE O
of O
the O
NUM I-GENE
RARE O
site O
, O
we O
have O
RARE O
and O
characterized O
a O
cDNA O
that O
represents O
a O
mRNA O
that O
appears O
to O
have O
been O
RARE O
from O
the O
NUM I-GENE
promoter I-GENE
. O

However O
, O
we O
did O
not O
observe O
a O
correlation O
between O
serum O
and O
RARE I-GENE
plasma I-GENE
PSA I-GENE
levels O
. O

The O
implications O
RARE O
estimates O
of O
cortical O
magnification O
and O
possible O
differences O
in O
the O
RARE O
of O
RARE O
and O
peripheral O
vision O
are O
discussed O
. O

G I-GENE
- I-GENE
CSF I-GENE
activates O
multiple O
RARE O
molecules O
, O
including O
the O
NUM I-GENE
and O
NUM I-GENE
kinases I-GENE
and O
the O
STAT I-GENE
transcription O
factors O
. O

RARE O
RARE O
any O
tyrosine O
residues O
in O
the O
cytoplasmic O
domain O
maintain O
their O
ability O
to O
activate O
STAT5 I-GENE
and O
STAT1 I-GENE
but O
cannot O
activate O
STAT3 I-GENE
, O
implying O
that O
STAT5 I-GENE
and O
STAT1 I-GENE
activation O
does O
not O
require O
receptor O
tyrosine O
RARE O
. O

The O
ALL_CAP I-GENE
alpha I-GENE
gene I-GENE
is O
composed O
of O
nine O
coding O
exons O
of O
varying O
lengths O
, O
separated O
by O
RARE O
, O
giving O
the O
gene O
a O
RARE O
length O
of O
RARE O
least O
21 O
kb O
. O
our O
recent O
cloning O
of O
a O
processed O
ALL_CAP I-GENE
alpha I-GENE
RARE I-GENE
with O
a O
5 O
'- O
noncoding O
region O
different O
from O
the O
previously O
reported O
ALL_CAP I-GENE
alpha I-GENE
RARE I-GENE
RNA I-GENE
indicated O
that O
the O
ALL_CAP I-GENE
alpha I-GENE
gene I-GENE
may O
have O
multiple O
RARE O
exons O
giving O
rise O
to O
RARE O
RARE O
RARE O
RNAs O
( O
mRNAs O
). O

This O
RARE O
NUM I-GENE
/ O
NUM I-GENE
RARE O
the O
only O
RARE O
protein O
which O
is O
required O
RARE O
all O
the O
DNA O
RARE O
RARE O
in O
both O
yeast O
model O
RARE O
. O

In O
addition O
, O
double O
mutants O
with O
either O
NUM I-GENE
- I-GENE
delta I-GENE
or O
NUM I-GENE
- I-GENE
1 I-GENE
and O
the O
RARE O
mutants I-GENE
NUM I-GENE
- I-GENE
1 I-GENE
or O
NUM I-GENE
- I-GENE
1 I-GENE
displayed O
RARE O
growth O
defects O
, O
indicating O
that O
the O
ALL_CAP I-GENE
gene I-GENE
products I-GENE
function O
in O
a O
common O
or O
parallel O
endocytic O
RARE O
. O

The O
identification O
of O
the O
hepatitis O
C O
virus O
RARE O
the O
major O
cause O
of O
liver O
RARE O
both O
in O
dialysis O
patients O
and O
in O
transplant O
patients O
has O
focused O
attention O
on O
the O
RARE O
and O
the O
impact O
of O
RARE O
infection O
in O
these O
patient O
groups O
. O

Stable O
transfection O
of O
the O
ALL_CAP O
cell O
line O
RARE O
with O
constructs O
containing O
core O
promoter O
mutations O
confirmed O
that O
the O
proximal O
NUM I-GENE
site I-GENE
and O
the O
TATA O
box O
are O
essential O
RARE O
the O
activation O
of O
promoter O
P1 O
by O
the O
Ig I-GENE
RARE I-GENE
RARE I-GENE
. O

Such O
RARE O
interactions O
can O
be O
significant O
RARE O
behavior O
. O

The O
NUM O
and O
NUM O
of O
RARE O
had O
RARE O
reversal O
relationship O
with O
the O
P2 O
and O
N2 O
recorded O
from O
the O
ALL_CAP O
, O
respectively O
. O

The O
cDNA O
of O
NUM I-GENE
encodes O
a O
closely O
related O
protein O
of O
NUM O
. O
8 O
kDa O
. O

Finally O
, O
the O
C O
- O
terminal O
region O
of O
NUM I-GENE
shows O
strong O
homology O
to O
a O
protein O
from O
rat O
that O
is O
specifically O
RARE O
in O
RARE O
tissue O
. O

The O
conservation O
of O
both O
the O
G O
- O
box O
and O
H O
- O
box O
in O
different O
ALL_CAP I-GENE
promoters I-GENE
emphasizes O
their O
importance O
RARE O
regulatory O
motifs O
. O

RARE O
on O
the O
last O
RARE O
was O
particularly O
severe O
among O
certain O
RARE O
groups O
of O
RARE O
that O
included O
RARE O
, O
RARE O
birds O
, O
and O
birds O
undergoing O
a O
RARE O
event O
such O
RARE O
artificial O
RARE O
. O

Further O
, O
the O
PIP2 O
content O
of O
the O
NUM O
- O
NUM O
kDa O
protein O
appeared O
to O
decrease O
with O
CSF I-GENE
- I-GENE
1 I-GENE
treatment O
. O

Further O
, O
the O
PIP2 O
content O
of O
the O
NUM O
- O
NUM O
kDa O
protein O
appeared O
to O
decrease O
with O
CSF I-GENE
- I-GENE
1 I-GENE
treatment O
. O

RARE O
before O
inserting O
on O
the O
anterior O
margin O
and O
apex O
of O
the O
iliac O
RARE O
it O
RARE O
, O
RARE O
the O
RARE O
of O
a O
small O
RARE O
. O

The O
RARE O
identification O
of O
the O
RARE O
NUM I-GENE
/ O
p40 I-GENE
gene O
presented O
in O
this O
study O
is O
a O
critical O
step O
toward O
the O
isolation O
of O
the O
corresponding O
human O
gene O
and O
the O
understanding O
of O
the O
RARE O
mechanisms O
involved O
in O
the O
RARE O
- O
RARE O
of O
its O
RARE O
RARE O
tumor O
invasion O
and O
metastasis O
. O

The O
promoter O
region O
( O
P1 O
) O
corresponding O
to O
the O
main O
group O
of O
transcription O
initiation O
sites O
is O
RARE O
of O
TATA O
and O
CAAT O
RARE O
but O
has O
putative O
binding O
sites O
RARE O
the O
transcription I-GENE
factor I-GENE
SP1 I-GENE
and O
is O
embedded O
in O
a O
large O
G O
+ O
C O
- O
rich O
domain O
of O
a O
CpG O
island O
, O
features O
shared O
by O
the O
promoters O
of O
constitutively O
RARE O
housekeeping O
genes O
. O

The O
STAT I-GENE
- I-GENE
1 I-GENE
RARE O
RARE O
provides O
RARE O
least O
one O
mechanism O
RARE O
activation O
of O
the O
ALL_CAP I-GENE
LTR I-GENE
by O
IFN I-GENE
- I-GENE
gamma I-GENE
in O
monocytes O
. O

RARE O
caused O
a O
transient O
reduction O
in O
RARE O
production O
and O
a O
significant O
increase O
in O
ALL_CAP I-GENE
release O
. O

To O
evaluate O
the O
RARE O
RARE O
response O
in O
patients O
with O
alcoholic O
liver O
RARE O
, O
RARE O
from O
NUM O
patients O
with O
severe O
alcoholic O
hepatitis O
and O
/ O
or O
cirrhosis O
were O
analyzed O
RARE O
RARE I-GENE
growth I-GENE
factor I-GENE
( O
HGF I-GENE
) O
and O
alpha I-GENE
- I-GENE
fetoprotein I-GENE
( O
ALL_CAP I-GENE
). O

Children O
born O
from O
chronic O
alcoholic O
mothers O
have O
shown O
behavioral O
RARE O
effects O
more O
frequently O
than O
morphological O
malformations O
. O

ALL_CAP O
( O
S O
): O
Twenty O
- O
RARE O
hemostasis O
parameters O
evaluated O
RARE O
in O
patients O
undergoing O
ALL_CAP O
- O
ALL_CAP O
. O

Here O
we O
report O
that O
RARE O
of O
the O
I I-GENE
- I-GENE
POU I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
POU I-GENE
RARE O
is O
maximal O
RARE O
in O
the O
RARE O
RARE O
of O
Drosophila O
development O
, O
and O
I I-GENE
- I-GENE
POU I-GENE
is O
the O
preferred O
RARE O
variant O
. O

Unlike O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
, O
the O
delta I-GENE
ALL_CAP I-GENE
mutant I-GENE
cDNA I-GENE
can O
be O
stably O
RARE O
in O
tumor O
derived O
cell O
lines O
with O
few O
immediate O
RARE O
effects O
. O

The O
patient O
' O
s O
role O
, O
organized O
by O
the O
RARE O
of O
RARE O
RARE O
, O
is O
RARE O
RARE O
with O
the O
RARE O
' O
s O
, O
which O
is O
structured O
to O
RARE O
RARE O
and O
understanding O
. O

The O
most O
common O
risk O
factor O
reported O
RARE O
both O
recent O
and O
all O
other O
hepatitis O
C O
cases O
was O
a O
history O
of O
injecting O
drug O
use O
, O
although O
the O
proportion O
of O
cases O
with O
that O
history O
was O
different O
in O
ALL_CAP O
from O
ALL_CAP O
and O
RARE O
. O

RARE O
can O
be O
restored O
by O
RARE O
of O
a O
RARE O
RARE O
NUM O
kb O
from O
the O
reporter O
construct O
, O
or O
by O
RARE O
of O
NUM O
bp O
of O
yeast O
telomeric O
repeat O
sequence O
RARE O
this O
site O
without O
chromosomal O
RARE O
. O

In O
contrast O
with O
previous O
two O
- O
pool O
models O
, O
RARE O
were O
made O
RARE O
RARE O
turnover O
by O
RARE O
RARE O
excretion O
( O
RARE O
measured O
here O
) O
and O
by O
fecal O
excretion O
and O
RARE O
processes O
. O

When O
voltage O
- O
operated O
NUM O
+ O
RARE O
( O
ALL_CAP O
) O
were O
blocked O
by O
nifedipine O
, O
midazolam O
, O
in O
concentrations O
more O
than O
1 O
microM O
, O
attenuated O
both O
RARE O
and O
RARE O
responses O
. O

Several O
RARE O
occurred O
that O
RARE O
with O
visualization O
of O
the O
diaphragm O
. O

Although O
NUM I-GENE
gene I-GENE
induction O
is O
dependent O
on O
STAT1 I-GENE
and O
NUM I-GENE
, O
activated O
STAT1 I-GENE
does O
not O
bind O
to O
ALL_CAP I-GENE
. O

The O
RARE O
of O
resistance O
to O
thyroid O
hormone O
is O
characterized O
by O
elevated O
serum O
free O
thyroid O
RARE O
, O
failure O
to O
suppress O
pituitary I-GENE
thyrotropin I-GENE
RARE O
, O
and O
RARE O
peripheral O
RARE O
to O
hormone O
action O
. O

Finally O
, O
RARE O
mutants O
, O
including O
the O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
I I-GENE
mutant I-GENE
, O
NUM O
, O
did O
not O
show O
evidence O
of O
light O
- O
RARE O
RNA O
RARE O
. O

The O
progression O
of O
acute O
RARE O
is O
associated O
with O
elevated O
RARE O
concentrations O
of O
acute O
- O
RARE O
proteins O
, O
ALL_CAP I-GENE
activation O
in O
the O
RARE O
and O
high O
RARE O
and O
RARE O
acid O
content O
in O
the O
RARE O
RARE O
from O
the O
RARE O
air O
. O

Because O
of O
the O
RARE O
implications O
of O
these O
findings O
in O
human O
physiology O
, O
we O
RARE O
the O
ALL_CAP I-GENE
- I-GENE
R I-GENE
gene I-GENE
. O

Differential O
RARE O
and O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
activation O
by O
four O
RARE O
variants O
of O
the O
human I-GENE
pituitary I-GENE
adenylate I-GENE
cyclase I-GENE
- I-GENE
activating I-GENE
polypeptide I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
- I-GENE
R I-GENE
). O

During O
skeletal O
muscle O
development O
, O
different O
RARE O
of O
muscle O
fibers O
are O
generated O
, O
which O
express O
different O
combinations O
of O
muscle O
- O
specific O
gene O
products O
. O

We O
discuss O
these O
results O
with O
respect O
to O
the O
transcriptional O
induction O
of O
the O
HNF I-GENE
- I-GENE
3 I-GENE
alpha I-GENE
gene I-GENE
in O
respiratory O
epithelium O
RARE O
embryogenesis O
. O

BACKGROUND O
: O
RARE O
is O
regulated O
by O
ALL_CAP I-GENE
( O
RARE I-GENE
RARE I-GENE
factor I-GENE
RARE O
the O
RARE O
form O
of O
Cdc2 I-GENE
/ I-GENE
NUM I-GENE
- O
RARE I-GENE
B I-GENE
complexes O
. O

RARE O
RARE O
of O
RARE I-GENE
- I-GENE
3 I-GENE
in O
NUM O
or O
HeLa O
cells O
RARE O
marked O
apoptosis O
. O

An O
N O
- O
terminal O
RARE O
from O
each O
subunit O
RARE O
around O
the O
dinucleotide O
- O
binding O
domain O
of O
an O
adjacent O
subunit O
, O
covering O
the O
RARE O
RARE O
of O
ALL_CAP O
. O

RARE O
is O
most O
striking O
in O
the O
zinc O
RARE O
region O
, O
a O
region O
characteristic O
of O
gag I-GENE
genes I-GENE
of O
most O
replication O
- O
competent O
RARE O
. O

D O
. O
melanogaster O
ALL_CAP I-GENE
- I-GENE
A I-GENE
coding O
sequences O
have O
a O
polymorphic O
region O
with O
insertions O
/ O
deletions O
of O
1 O
- O
NUM O
codons O
and O
many O
nucleotide O
changes O
. O

RARE I-GENE
initiation I-GENE
factor I-GENE
3 I-GENE
( O
eIF3 I-GENE
) O
is O
a O
large O
RARE O
complex O
that O
stabilizes O
the O
RARE O
complex O
, O
NUM I-GENE
RARE O
GTP O
RARE O
tRNA I-GENE
( I-GENE
RARE I-GENE
) I-GENE
i I-GENE
and O
promotes O
mRNA O
binding O
to O
the O
40 I-GENE
S I-GENE
ribosomal I-GENE
subunit I-GENE
. O
eIF3 I-GENE
also O
functions O
RARE O
a O
RARE O
subunit O
anti O
- O
association O
factor O
. O

Our O
data O
, O
combined O
with O
those O
of O
RARE O
and O
RARE O
- O
workers O
, O
suggest O
that O
mammalian I-GENE
eIF3 I-GENE
is O
composed O
of O
RARE O
least O
10 O
subunits O
: O
NUM I-GENE
, O
NUM I-GENE
( O
NUM I-GENE
RARE O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
p44 I-GENE
, O
p40 I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
. O

Identification O
of O
a O
cis O
- O
acting O
element O
in O
the O
class I-GENE
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
gene I-GENE
promoter I-GENE
responsive O
to O
activation O
by O
RARE O
sequences O
. O

The O
results O
demonstrate O
that O
( O
i O
) O
RARE O
RARE O
RARE O
were O
assembled O
when O
the O
full O
- O
length O
or O
a O
truncated O
( O
missing O
the O
C O
- O
terminal O
65 O
amino O
RARE O
) O
UL80 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
was O
tested O
; O
( O
ii O
) O
when O
the O
C O
- O
terminal O
65 O
amino O
RARE O
of O
the O
UL80 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
were O
replaced O
with O
the O
C O
- O
terminal O
NUM O
amino O
RARE O
of O
the O
UL26 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
, O
RARE O
RARE O
were O
made O
and O
direct O
interaction O
of O
the O
UL80 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
with O
NUM I-GENE
was O
detected O
; O
( O
iii O
) O
assembly O
of O
RARE O
RARE O
was O
demonstrated O
when O
the O
sequence O
of O
the O
last O
12 O
amino O
RARE O
of O
the O
UL80 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
was O
changed O
from O
ALL_CAP O
ALL_CAP O
to O
ALL_CAP O
; O
( O
iv O
) O
self O
- O
interaction O
of O
the O
RARE O
proteins O
is O
RARE O
by O
sequences O
N O
terminal O
to O
the O
RARE O
RARE O
site O
; O
and O
( O
v O
) O
the O
UL26 I-GENE
. I-GENE
5 I-GENE
and O
UL80 I-GENE
. I-GENE
5 I-GENE
proteins I-GENE
will O
not O
RARE O
into O
RARE O
RARE O
. O

RARE O
, O
the O
3 O
'- O
region O
RARE O
junctions O
of O
the O
RARE I-GENE
RARE O
latent O
and O
RARE O
infection O
were O
determined O
by O
sequencing O
RNA O
- O
PCR O
products O
generated O
with O
primers O
that O
flank O
the O
3 O
' O
RARE O
region O
. O

( O
ii O
) O
NUM I-GENE
binds O
preferentially O
to O
less O
modified O
forms O
of O
ICP4 I-GENE
, O
a O
protein O
that O
is O
extensively O
modified O
RARE O
. O

RARE O
of O
sufficient O
data O
on O
vibration O
measurements O
and O
RARE O
durations O
RARE O
to O
the O
RARE O
, O
RARE O
do O
variations O
in O
tool O
conditions O
( O
RARE O
RARE O
, O
etc O
) O
and O
RARE O
RARE O
in O
measurement O
. O

C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
V I-GENE
> O
A O
selectively O
binds O
only O
the O
subset O
of O
C I-GENE
/ I-GENE
EBP I-GENE
sites I-GENE
that O
are O
also O
ALL_CAP I-GENE
sites I-GENE
, O
both O
RARE O
oligonucleotides O
and O
within O
the O
RARE O
RARE O
of O
the O
albumin I-GENE
and O
cholesterol I-GENE
hydroxylase I-GENE
promoters I-GENE
. O

Specific O
IgG I-GENE
, O
specific O
IgE I-GENE
and O
RARE O
IgE I-GENE
immunoglobulins I-GENE
against O
RARE I-GENE
RARE I-GENE
RARE I-GENE
/ I-GENE
RARE I-GENE
antigens I-GENE
( O
ALL_CAP I-GENE
) O
were O
detected O
by O
using O
ELISA O
technique O
. O

ALL_CAP O
BACKGROUND O
ALL_CAP O
: O
RARE O
care O
has O
not O
changed O
significantly O
in O
the O
last O
20 O
years O
, O
and O
the O
RARE O
of O
RARE O
lymph O
node O
RARE O
in O
this O
RARE O
RARE O
to O
be O
discussed O
. O

The O
differences O
among O
RARE O
of O
the O
genus O
RARE O
are O
more O
significant O
. O

RARE O
the O
E O
- O
box O
in O
the O
context O
of O
the O
3 O
'- O
flanking O
region O
confirmed O
that O
it O
contributes O
to O
the O
enhancement O
of O
transcriptional O
activity O
of O
the O
NUM I-GENE
( I-GENE
I I-GENE
) I-GENE
RARE I-GENE
gene I-GENE
promoter I-GENE
. O

Expression O
of O
RARE O
RARE O
in O
pancreatic O
beta O
cells O
. O

We O
propose O
that O
RARE I-GENE
: O
Max I-GENE
: O
NUM I-GENE
complexes O
normally O
function O
to O
RARE O
RARE I-GENE
: O
Max I-GENE
activities O
associated O
with O
cell O
RARE O
. O

Its O
transcription O
product O
, O
a O
1 O
. O
3 O
kb O
mRNA O
, O
is O
polyadenylated O
RARE O
a O
site O
containing O
consensus O
eukaryotic O
polyadenylation O
signals O
and O
mapping O
87 O
bp O
RARE O
of O
the O
translation O
RARE O
RARE O
RARE O
NUM I-GENE
. O

RARE O
changes O
RARE O
by O
wild I-GENE
type I-GENE
and I-GENE
variant I-GENE
c I-GENE
- I-GENE
src I-GENE
genes I-GENE
carrying O
C O
- O
terminal O
sequence O
alterations O
. O

The O
RARE O
of O
drug O
- O
resistant O
malaria O
makes O
RARE O
the O
evaluation O
of O
new O
RARE O
agents O
. O

In O
the O
NUM I-GENE
subunit I-GENE
, O
the O
NUM O
RARE O
- O
chain O
is O
RARE O
in O
a O
similar O
direction O
to O
the O
NUM O
RARE O
- O
chain O
in O
the O
wild O
- O
type O
complex O
. O

The O
relatively O
high O
level O
transcription O
from O
this O
gene O
shows O
that O
the O
polymorphic O
RARE O
ends O
of O
P O
. O
falciparum O
, O
which O
have O
been O
proposed O
to O
be O
transcriptionally O
RARE O
, O
can O
be O
RARE O
RARE O
sites O
RARE O
RARE I-GENE
genes I-GENE
. O

NUM I-GENE
was O
previously O
identified O
by O
using O
a O
genetic O
RARE O
lethal O
screen O
( O
E O
. O

RARE O
of O
sleep O
- O
RARE O
breathing O
( O
ALL_CAP O
) O
is O
reported O
to O
increase O
in O
RARE O
women O
. O

In O
all O
cases O
the O
RARE O
was O
transient O
and O
RARE O
by O
NUM O
day O
post O
- O
vaccination O
. O

A O
RARE O
of O
NUM O
men O
aged O
NUM O
to O
NUM O
years O
, O
who O
were O
diagnosed O
RARE O
the O
RARE O
time O
by O
physicians O
RARE O
having O
ALL_CAP O
in O
1994 O
and O
who O
had O
not O
received O
treatment O
, O
RARE O
in O
the O
study O
. O

ALL_CAP I-GENE
- I-GENE
2 I-GENE
, O
an O
inhibitor O
of O
apoptosis O
in O
a O
wide O
variety O
of O
cell O
RARE O
, O
has O
been O
reported O
to O
prevent O
oxidative O
stress O
- O
RARE O
cell O
RARE O
. O

In O
vitro O
translation O
of O
the O
NUM I-GENE
cDNA I-GENE
resulted O
in O
a O
NUM O
kDa O
protein O
that O
binds O
to O
ALL_CAP O
repeat O
arrays O
. O
NUM I-GENE
displayed O
the O
same O
sequence O
RARE O
RARE O
NUM I-GENE
, O
RARE O
arrays O
of O
ALL_CAP O
repeats O
RARE O
a O
binding O
substrate O
over O
ALL_CAP O
and O
ALL_CAP O
repeats O
. O

The O
ubiquitously O
RARE O
E12 I-GENE
bHLH I-GENE
protein I-GENE
RARE O
with O
numerous O
cell O
- O
specific O
bHLH I-GENE
factors I-GENE
. O

The O
E O
- O
box O
sequence O
in O
the O
NUM I-GENE
fragment I-GENE
of O
the O
transferrin I-GENE
promoter I-GENE
was O
ALL_CAP O
and O
was O
similar O
in O
gel O
shifts O
to O
the O
consensus O
E O
- O
box O
elements O
( O
ALL_CAP O
) O
previously O
characterized O
. O

A O
5 O
. O
3 O
- O
kb O
DNA O
fragment O
, O
which O
included O
the O
RARE O
structural O
RARE I-GENE
gene I-GENE
( O
named O
RARE I-GENE
) O
and O
its O
flanking O
regions O
, O
was O
identified O
. O

RARE I-GENE
- I-GENE
length I-GENE
AT I-GENE
- I-GENE
NUM I-GENE
, O
and O
both O
AT I-GENE
- I-GENE
NUM I-GENE
and O
AT I-GENE
- I-GENE
NUM I-GENE
delta I-GENE
C I-GENE
- I-GENE
NUM I-GENE
( O
truncated O
to O
be O
RARE O
the O
size O
of O
RARE I-GENE
RARE I-GENE
genes I-GENE
) O
cDNAs O
, O
were O
overexpressed O
, O
respectively O
, O
in O
yeast O
and O
Escherichia O
coli O
mutants O
RARE O
to O
RARE O
light O
. O

The O
human I-GENE
NUM I-GENE
protein I-GENE
was O
recently O
identified O
RARE O
a O
RARE O
of O
the O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
nuclear I-GENE
antigen I-GENE
2 I-GENE
. O

However O
, O
five O
new O
mutation O
sites O
( O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
and O
NUM I-GENE
) O
are O
unique O
to O
the O
ALL_CAP I-GENE
intron O
and O
disrupt O
self O
- O
RARE O
. O

This O
report O
presents O
the O
isolation O
and O
characterization O
of O
the O
5 O
'- O
flanking O
region O
( O
1 O
. O
2 O
kb O
) O
and O
RARE O
1 O
of O
the O
human I-GENE
RII I-GENE
alpha I-GENE
gene I-GENE
. O

A O
cohort O
of O
RARE O
children O
was O
monitored O
from O
6 O
months O
to O
11 O
years O
of O
age O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
reproducibility O
of O
a O
number O
of O
RARE O
clearance O
methods O
using O
RARE O
- O
NUM O
RARE O
RARE O
acid O
( O
NUM O
- O
EDTA O
) O
and O
to O
compare O
these O
with O
the O
multiple O
RARE O
sample O
technique O
. O

The O
RARE O
RARE O
of O
a O
NUM O
bp O
DNA O
fragment O
between O
the O
RARE I-GENE
gene I-GENE
( O
encoding O
plasminogen I-GENE
activator I-GENE
) O
and O
the O
origin O
of O
replication O
of O
the O
wild O
- O
type O
RARE O
RARE O
RARE O
NUM O
was O
determined O
. O

RARE O
concentration O
in O
the O
RARE O
of O
patients O
with O
hemorrhagic O
fever O
with O
RARE O
RARE O

MAIN O
OUTCOME O
ALL_CAP O
: O
RARE O
of O
factor O
analysis O
- O
derived O
syndromes O
with O
risk O
factors O
RARE O
chemical O
interactions O
that O
inhibit O
RARE I-GENE
and O
RARE O
target O
esterase I-GENE
. O

CONCLUSION O
: O
Some O
RARE O
RARE O
RARE O
may O
have O
delayed O
, O
chronic O
RARE O
syndromes O
from O
RARE O
exposure O
to O
combinations O
of O
RARE O
that O
inhibit O
RARE I-GENE
and O
RARE I-GENE
target I-GENE
esterase I-GENE
. O

Control O
examination O
was O
performed O
RARE O
the O
end O
of O
each O
period O
. O

No O
correlation O
between O
the O
age O
of O
the O
horses O
and O
the O
antibody O
level O
could O
be O
found O
. O

The O
ALL_CAP I-GENE
mRNA I-GENE
: O
ALL_CAP I-GENE
mRNA I-GENE
ratio O
was O
1 O
. O
1 O
+/- O
NUM O
. O
12 O
and O
remained O
unchanged O
RARE O
differentiation O
. O

The O
results O
demonstrate O
( O
i O
) O
that O
the O
RARE O
- O
specific O
UGA O
RARE O
is O
readily O
suppressed O
under O
conditions O
where O
the O
homologous I-GENE
ALL_CAP I-GENE
protein I-GENE
is O
absent O
and O
( O
ii O
) O
that O
apart O
from O
the O
RARE O
of O
the O
ALL_CAP I-GENE
- I-GENE
mRNA I-GENE
interaction O
, O
a O
structural O
compatibility O
of O
the O
RARE O
complex O
with O
the O
RARE O
is O
required O
. O

One O
RARE O
- O
peptide O
RARE O
in O
the O
ALL_CAP I-GENE
C I-GENE
terminus I-GENE
( I-GENE
amino I-GENE
acid I-GENE
NUM I-GENE
) I-GENE
had O
RARE O
effect O
on O
S O
- O
layer O
biogenesis O
, O
while O
another O
( O
amino O
acid O
NUM O
) O
disrupted O
RARE O
of O
the O
protein O
, O
suggesting O
that O
ALL_CAP I-GENE
possesses O
a O
RARE O
signal O
RARE O
C O
terminal O
to O
amino O
acid O
NUM O
, O
near O
or O
including O
amino O
acid O
NUM O
. O

To O
characterize O
the O
gene O
products O
, O
the O
ALL_CAP I-GENE
gene I-GENE
was O
subcloned O
and O
RARE O
under O
the O
control O
of O
NUM I-GENE
RNA I-GENE
polymerase I-GENE
promoter I-GENE
. O

ALL_CAP I-GENE
showed O
homology O
to O
RARE I-GENE
RARE I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
and O
to O
its O
homolog O
in O
the O
RARE O
RARE O
RARE O
; O
ALL_CAP I-GENE
was O
homologous O
to O
both O
RARE I-GENE
and I-GENE
bacterial I-GENE
RARE I-GENE
RARE I-GENE
; O
ALL_CAP I-GENE
showed O
homology O
to O
yeast O
and O
Bacillus O
subtilis O
proteins O
of O
unknown O
function O
; O
ALL_CAP I-GENE
showed O
homology O
to O
acetyl I-GENE
RARE I-GENE
A I-GENE
synthetases I-GENE
. O

MAIN O
OUTCOME O
ALL_CAP O
: O
RARE O
and O
pulmonary O
hemodynamics O
, O
arterial O
RARE O
gas O
determination O
, O
RARE O
RARE O
protein O
and O
RARE O
content O
, O
RARE O
RARE O
burst O
, O
RARE I-GENE
RARE I-GENE
content O
, O
and O
scanning O
electron O
RARE O
studies O
. O

We O
have O
isolated O
a O
cDNA O
encoding O
human I-GENE
NUM I-GENE
. O

To O
investigate O
the O
mechanisms O
involved O
in O
the O
transcriptional O
control O
of O
retinoid I-GENE
X I-GENE
receptor I-GENE
( O
RXR I-GENE
) O
gene O
RARE O
, O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
NUM I-GENE
isoform I-GENE
was O
characterized O
. O

JNK I-GENE
and O
p38 I-GENE
are O
constitutively O
present O
in O
the O
nucleus O
, O
and O
DNA O
- O
RARE O
c I-GENE
- I-GENE
ALL_CAP I-GENE
and O
ATF I-GENE
- I-GENE
2 I-GENE
are O
stably O
RARE O
by O
JNK I-GENE
and O
p38 I-GENE
, O
respectively O
. O

The O
effects O
of O
dominant O
interfering O
forms O
of O
the O
JNK I-GENE
/ O
p38 I-GENE
RARE O
RARE O
demonstrate O
that O
activation O
of O
these O
kinases O
is O
critical O
RARE O
RARE O
- O
RARE O
E I-GENE
- I-GENE
selectin I-GENE
gene I-GENE
RARE O
. O

NUM I-GENE
binds O
the O
ALL_CAP O
repeat O
with O
an O
affinity O
, O
ALL_CAP O
= O
NUM O
. O
37 O
nM O
, O
RARE O
least O
RARE O
high O
RARE O
the O
consensus O
ALL_CAP O
box O
. O

Identification O
of O
the O
region O
in O
actin I-GENE
- I-GENE
binding I-GENE
protein I-GENE
that O
binds O
to O
the O
cytoplasmic O
domain O
of O
glycoprotein I-GENE
RARE I-GENE
. O

RARE O
enzyme O
forms O
were O
prepared O
to O
RARE O
the O
initial O
RARE O
site O
and O
thus O
form O
an O
RARE O
single O
- O
chain O
protein O
RARE O
RARE O
- O
function O
studies O
. O

The O
primer O
is O
generated O
by O
a O
RARE O
that O
occurs O
between O
bases O
11 O
and O
12 O
of O
the O
NUM I-GENE
mRNA I-GENE
. O

Similarly O
, O
we O
examined O
whether O
the O
NUM I-GENE
, O
NUM I-GENE
, O
FLI1 I-GENE
, O
EWS I-GENE
- O
FLI1 I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
PEA3 I-GENE
and O
ALL_CAP I-GENE
. I-GENE
1 I-GENE
proteins I-GENE
can O
form O
RARE O
complexes O
with O
SRF I-GENE
on O
the O
NUM I-GENE
ALL_CAP I-GENE
and I-GENE
II I-GENE
. O

This O
R O
- O
domain O
may O
modulate O
the O
interaction O
with O
SRF I-GENE
, O
providing O
a O
mechanism O
that O
would O
be O
unique O
to O
FLI1 I-GENE
and O
EWS I-GENE
- O
FLI1 I-GENE
, O
thus O
RARE O
a O
novel O
function O
RARE O
these O
ALL_CAP I-GENE
transcription I-GENE
factors I-GENE
in O
the O
RARE O
of O
the O
NUM I-GENE
gene I-GENE
. O

The O
RARE O
number O
of O
specimens O
was O
NUM O
with O
NUM O
RARE O
and O
53 O
smokers O
. O

The O
murine O
chromosomal O
locations O
of O
the O
five O
ALL_CAP I-GENE
receptor I-GENE
RARE I-GENE
subunits I-GENE
, O
the O
epsilon I-GENE
1 I-GENE
( O
NUM I-GENE
RARE O
epsilon I-GENE
2 I-GENE
( O
NUM I-GENE
RARE O
epsilon I-GENE
3 I-GENE
( O
NUM I-GENE
RARE O
epsilon I-GENE
4 I-GENE
( O
NUM I-GENE
) O
and O
RARE I-GENE
1 I-GENE
( O
RARE I-GENE
) O
subunits O
, O
were O
determined O
using O
an O
RARE O
backcross O
mapping O
panel O
derived O
from O
RARE O
of O
RARE O
C57BL O
/ O
NUM O
. O
RARE O
) O
NUM O
/ O
NUM O
] O
mice O
. O

ALL_CAP O
cloning O
of O
RARE I-GENE
brain I-GENE
alpha I-GENE
- I-GENE
amino I-GENE
- I-GENE
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
5 I-GENE
- I-GENE
RARE I-GENE
- I-GENE
4 I-GENE
- I-GENE
RARE I-GENE
acid I-GENE
receptors I-GENE
reveals O
conservation O
of O
RARE O
, O
function O
and O
post O
- O
transcriptional O
processes O
with O
mammalian O
receptors O
. O

RARE O
, O
both O
ALL_CAP O
- O
A O
and O
ALL_CAP O
- O
D O
defects O
are O
associated O
with O
subunits O
of O
ALL_CAP I-GENE
, O
a O
basal O
transcription O
factor O
with O
a O
second O
function O
in O
DNA O
repair O
. O

RARE O
RARE O
age O
, O
RARE O
cholesterol O
, O
ALL_CAP I-GENE
cholesterol I-GENE
, O
RARE O
, O
current O
smoking O
, O
and O
systolic O
pressure O
slightly O
RARE O
the O
association O
between O
fibrinogen I-GENE
and O
atherosclerosis O
. O

In O
Experiment O
1 O
, O
RARE O
that O
had O
received O
an O
injection O
of O
the O
RARE O
N I-GENE
- I-GENE
RARE I-GENE
- I-GENE
D I-GENE
- I-GENE
RARE I-GENE
receptor I-GENE
antagonist O
MK O
- O
801 O
( O
NUM O
. O
1 O
mg O
/ O
kg O
, O
i O
. O
p O
.) O
either O
NUM O
min O
before O
or O
immediately O
after O
conditioning O
RARE O
less O
time O
over O
the O
conditioned O
RARE O
than O
saline O
- O
treated O
controls O
. O

RARE I-GENE
RARE I-GENE
- I-GENE
chain I-GENE
RARE I-GENE
cytochrome I-GENE
P450 I-GENE
( O
NUM I-GENE
; O
NUM I-GENE
) O
gene O
RARE O
is O
regulated O
by O
RARE I-GENE
via O
cAMP O
in O
the O
ovary O
and O
by O
ACTH I-GENE
via O
cAMP O
in O
adrenal O
cortical O
cells O
. O

One O
possible O
solution O
is O
a O
thin O
RARE O
RARE O
free O
flap O
. O

Structural O
analysis O
and O
characterization O
of O
tissue O
and O
hormonal O
responsive O
RARE O
of O
the O
avian I-GENE
bone I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
gene O
. O

RARE I-GENE
receptors I-GENE
in O
suicide O
victims O
with O
major O
depression O
. O

The O
Y O
- O
type O
structural O
motif O
is O
also O
RARE O
among O
a O
number O
of O
divergent O
ALL_CAP I-GENE
mRNAs I-GENE
. O

A O
false O
positive O
marker O
screen O
was O
associated O
with O
the O
occurrence O
of O
RARE O
- O
foot O
RARE O
even O
when O
the O
effect O
of O
regimen O
was O
RARE O
RARE O
by O
RARE O
( O
p O
= O
. O
01 O
). O

The O
detection O
of O
ORF I-GENE
- I-GENE
1 I-GENE
sequences O
in O
human O
tumors O
, O
while O
not O
RARE O
per O
RARE O
, O
is O
a O
prerequisite O
RARE O
RARE O
its O
role O
in O
tumor O
development O
. O

RARE O
analysis O
gave O
evidence O
RARE O
a O
close O
evolutionary O
relationship O
between O
ALL_CAP O
- O
1 O
and O
members O
of O
the O
RARE O
genus O
of O
the O
alpha O
- O
RARE O
and O
RARE O
RARE O
in O
particular O
. O

In O
this O
method O
, O
ALL_CAP O
in O
plasma O
can O
be O
determined O
with O
high O
sensitivity O
using O
RARE O
with O
RARE O
RARE O
in O
the O
mobile O
RARE O
. O

Both O
HEF1 I-GENE
and O
RARE I-GENE
were O
found O
to O
complex O
with O
the O
related I-GENE
adhesion I-GENE
RARE I-GENE
tyrosine I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
RARE O
and O
when O
tyrosine O
RARE O
, O
with O
the O
RARE O
molecule O
ALL_CAP I-GENE
. O

NUM I-GENE
and O
NUM I-GENE
do O
not O
form O
homodimers O
, O
and O
they O
do O
not O
interact O
with O
ALL_CAP I-GENE
. O

RARE O
of O
NUM I-GENE
with O
each O
RARE O
RARE O
of O
telomeric O
DNA O
and O
with O
RARE O
forms O
of O
the O
guanine O
- O
rich O
RARE O
had O
3 O
. O
7 O
- O
14 O
. O
6 O
nM O
dissociation O
constants O
, O
RARE O
, O
whereas O
complexes O
with O
double O
- O
RARE O
telomeric O
DNA O
had O
RARE O
to O
NUM O
- O
RARE O
RARE O
RARE O
values O
. O

Moreover O
, O
the O
effect O
RARE O
by O
NUM I-GENE
appeared O
to O
be O
selective O
RARE O
the O
ALL_CAP I-GENE
promoter I-GENE
. O

Experimental O
data O
showed O
that O
these O
abnormal O
proteins O
are O
constitutively O
localized O
in O
the O
nucleus O
, O
have O
lost O
the O
transcriptional O
repressor O
functions O
typical O
of O
normal O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
NUM I-GENE
and O
may O
be O
capable O
of O
RARE O
activity O
. O

Because O
L I-GENE
- I-GENE
plastin I-GENE
RARE O
in O
tissue O
- O
specifically O
regulated O
in O
both O
humans O
and O
RARE O
, O
it O
is O
likely O
that O
similar O
mechanisms O
regulate O
L I-GENE
- I-GENE
plastin I-GENE
gene I-GENE
RARE O
in O
human O
and O
rodent O
cells O
and O
that O
they O
could O
be O
identified O
by O
comparing O
the O
function O
and O
nucleotide O
sequences O
of O
the O
human O
and O
murine O
L I-GENE
- I-GENE
plastin I-GENE
gene O
promoters O
. O

RARE O
' O
s O
new O
in O
gynecologic O
and O
RARE O
surgery O
. O

The O
ALL_CAP I-GENE
operon I-GENE
of I-GENE
Bacillus I-GENE
subtilis I-GENE
is O
RARE O
. O

Moreover O
, O
RARE O
of O
CBF1 I-GENE
in O
yeast O
was O
found O
to O
activate O
transcription O
of O
reporter O
genes O
containing O
the O
C O
- O
repeat O
/ O
ALL_CAP O
RARE O
an O
upstream O
activator O
sequence O
but O
not O
mutant O
RARE O
of O
the O
DNA O
element O
. O

Forty O
- O
one O
ALL_CAP O
physical O
status O
I O
or O
II O
adult O
patients O
undergoing O
a O
variety O
of O
1 O
- O
1 O
. O
5 O
h O
surgical O
procedures O
were O
randomly O
allocated O
to O
receive O
ALL_CAP O
with O
RARE O
or O
isoflurane O
with O
ventilation O
being O
either O
spontaneous O
or O
RARE O
. O

OBJECTIVE O
: O
Our O
goal O
was O
to O
determine O
whether O
RARE O
- O
RARE O
women O
have O
a O
RARE O
rate O
of O
RARE O
complications O
after O
RARE O
RARE O
ligation O
. O

In O
the O
electrophoresis O
mobility O
shift O
assay O
using O
nuclear O
extracts O
of O
the O
RARE O
cells O
, O
MyoD I-GENE
and O
myogenin I-GENE
RARE O
to O
the O
right O
E O
- O
box O
in O
the O
enhancer O
region O
of O
the O
ALL_CAP I-GENE
gene I-GENE
even O
in O
the O
presence O
of O
BMP I-GENE
- I-GENE
2 I-GENE
. O

A O
heterologous O
promoter O
construct O
containing O
three O
repeats O
of O
a O
consensus O
NUM I-GENE
site I-GENE
, O
RARE O
upstream O
of O
a O
single O
copy O
of O
the O
ALL_CAP I-GENE
( O
CREB I-GENE
/ I-GENE
AP1 I-GENE
) O
element O
from O
the O
NUM I-GENE
promoter I-GENE
RARE O
to O
the O
beta I-GENE
- I-GENE
globin I-GENE
TATA O
box O
, O
exhibited O
phorbol O
ester O
inducibility O
. O

RARE O
experiments O
showed O
that O
RARE O
tasks O
rather O
than O
cognitive O
aspects O
of O
the O
ALL_CAP O
task O
were O
critical O
in O
RARE O
finger O
- O
RARE O
performance O
. O

RARE O
does O
a O
nurse O
RARE O
about O
maintaining O
RARE O
level O
of O
RARE O
when O
RARE O
is O
one O
of O
the O
few O
local O
RARE O
in O
RARE O
field O
? O
RARE O
RARE O
RARE O
RARE O
RARE O
is O
RARE O
it O
by O
RARE O
a O
network O
of O
RARE O
and O
RARE O
in O
related O
fields O
both O
RARE O
home O
and O
across O
the O
RARE O
. O

Finally O
, O
antibody O
binding O
to O
site O
RARE O
on O
the O
hCG I-GENE
- I-GENE
RARE I-GENE
complex I-GENE
was O
also O
RARE O
by O
an O
anti O
- O
peptide O
RARE O
directed O
against O
a O
peptide O
encoded O
by O
the O
RARE O
RARE O
( O
ALL_CAP O
RARE O
8 O
) O
of O
the O
LHR I-GENE
. O

cDNA O
cloning O
, O
RARE O
analysis O
, O
and O
chromosomal O
RARE O
of O
a O
gene O
with O
high O
homology O
to O
RARE I-GENE
eIF I-GENE
RARE I-GENE
RARE I-GENE
) I-GENE
NUM I-GENE
and O
mammalian I-GENE
eIF I-GENE
- I-GENE
NUM I-GENE
. O

Therefore O
, O
it O
is O
important O
to O
control O
hypertension O
and O
RARE O
appropriate O
RARE O
RARE O
flow O
RARE O
living O
RARE O
transplantation O
surgery O
. O

The O
initial O
patients O
treated O
with O
ALL_CAP O
and O
RARE O
experienced O
prolonged O
bone O
marrow O
suppression O
and O
, O
therefore O
, O
subsequent O
RARE O
were O
treated O
with O
G I-GENE
- I-GENE
CSF I-GENE
, O
5 O
micrograms O
/ O
kg O
, O
beginning O
the O
day O
after O
RARE O
of O
the O
third O
RARE O
of O
chemotherapy O
. O

Human I-GENE
RARE I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
) O
activates O
a O
set O
of O
genes O
such O
RARE O
c I-GENE
- I-GENE
fos I-GENE
, O
jun I-GENE
, O
myc I-GENE
, O
and O
early I-GENE
growth I-GENE
response I-GENE
gene I-GENE
1 I-GENE
( O
RARE I-GENE
- I-GENE
1 I-GENE
). O

In O
order O
to O
provide O
adequate O
local O
control O
without O
RARE O
RARE O
outcome O
, O
the O
amount O
of O
breast O
tissue O
that O
must O
be O
RARE O
in O
ALL_CAP O
needs O
to O
be O
RARE O
. O

Surprisingly O
, O
however O
, O
TCR I-GENE
- O
RARE O
tyrosine O
RARE O
of O
phospholipase I-GENE
C I-GENE
gamma I-GENE
1 I-GENE
remains O
RARE O
in O
the O
Jurkat O
cells O
expressing O
the O
NUM I-GENE
/ O
ALL_CAP I-GENE
RARE O
. O

The O
14 I-GENE
. I-GENE
1 I-GENE
( I-GENE
NUM I-GENE
) I-GENE
gene I-GENE
is O
RARE O
in O
a O
lineage O
- O
and O
RARE O
- O
restricted O
manner O
. O

The O
RARE I-GENE
( O
IFN I-GENE
)- O
RARE O
double I-GENE
- I-GENE
RARE I-GENE
RNA I-GENE
( I-GENE
ALL_CAP I-GENE
)- I-GENE
activated I-GENE
RARE I-GENE
/ I-GENE
RARE I-GENE
protein I-GENE
kinase I-GENE
( O
PKR I-GENE
) O
plays O
a O
role O
in O
the O
RARE O
and O
RARE O
effects O
of O
IFN I-GENE
. O

Together O
, O
the O
data O
suggest O
that O
cAMP O
- O
dependent O
control O
of O
the O
amounts O
of O
the O
activator O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
RARE O
. O
the O
repressor O
COUP I-GENE
- I-GENE
ALL_CAP I-GENE
could O
influence O
NUM O
- O
dependent O
transcription O
. O

RARE O
relations O
, O
affect O
management O
, O
and O
RARE O
RARE O
formation O
. O

When O
RARE O
in O
COS O
- O
7 O
cells O
, O
MKP I-GENE
- I-GENE
4 I-GENE
blocks O
activation O
of O
MAP I-GENE
kinases I-GENE
with O
the O
selectivity O
ERK I-GENE
> O
p38 I-GENE
= O
JNK I-GENE
/ O
SAPK I-GENE
. O

In O
NUM I-GENE
mutants I-GENE
, O
telomeric O
chromatin O
is O
RARE O
: O
RARE O
silencing O
is O
RARE O
and O
NUM I-GENE
RARE O
is O
altered O
. O

Most O
kinases O
are O
not O
significantly O
inhibited O
by O
RARE O
. O
cdc2 I-GENE
/ O
RARE I-GENE
B I-GENE
, O
cdk2 I-GENE
/ O
RARE I-GENE
A I-GENE
, O
cdk2 I-GENE
/ O
RARE I-GENE
E I-GENE
and O
NUM I-GENE
/ O
NUM I-GENE
only O
are O
substantially O
inhibited O
( O
NUM O
values O
of O
NUM O
. O
65 O
, O
NUM O
. O
7 O
, O
NUM O
. O
7 O
and O
NUM O
. O
2 O
microM O
, O
respectively O
). O
NUM I-GENE
/ O
RARE I-GENE
NUM I-GENE
and O
NUM I-GENE
/ O
RARE I-GENE
NUM I-GENE
are O
very O
poorly O
inhibited O
by O
RARE O
( O
NUM O
> O
NUM O
microM O
). O

This O
NUM O
. O
NUM O
kb O
cDNA O
contains O
an O
RARE O
reading O
frame O
( O
ORF O
) O
of O
NUM O
bp O
encoding O
a O
polypeptide O
of O
NUM O
amino O
RARE O
( O
RARE O
) O
which O
differs O
RARE O
only O
one O
position O
( O
position O
65 O
) O
from O
the O
human I-GENE
NUM I-GENE
- I-GENE
C I-GENE
protein I-GENE
. O

Interaction O
of O
Ets I-GENE
- I-GENE
1 I-GENE
and O
the O
POU I-GENE
- I-GENE
RARE I-GENE
protein I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
/ O
Pit I-GENE
- I-GENE
1 I-GENE
RARE O
pituitary O
- O
specific O
gene O
RARE O
. O

Although O
NUM I-GENE
is O
not O
essential O
RARE O
viability O
, O
NUM I-GENE
, I-GENE
2 I-GENE
- O
NUM I-GENE
kinase O
complexes O
become O
essential O
RARE O
RARE O
in O
the O
absence O
of O
NUM I-GENE
, I-GENE
2 I-GENE
- O
Cdc28 I-GENE
kinases O
. O

Using O
the O
yeast O
two O
- O
RARE O
RARE O
to O
screen O
RARE O
proteins O
which O
interact O
with O
NUM I-GENE
, O
we O
isolated O
the O
B O
subunit O
of O
the O
CCAAT O
binding O
protein O
ALL_CAP I-GENE
- I-GENE
Y I-GENE
from O
a O
HeLa O
cDNA O
library O
. O

RARE O
activity O
requires O
both O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
and O
these O
adjacent O
sequences O
. O

Studies O
using O
HLA I-GENE
- I-GENE
ALL_CAP I-GENE
- O
B7 I-GENE
- I-GENE
1 I-GENE
- O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
RARE O
transfectants O
showed O
that O
the O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
- O
RARE O
ALL_CAP I-GENE
- I-GENE
AT I-GENE
DNA O
binding O
activity O
was O
negatively O
regulated O
by O
B7 I-GENE
- I-GENE
1 I-GENE
RARE O
. O

RARE O
activation O
of O
Rac1 I-GENE
and O
RhoA I-GENE
causes O
tumorigenic O
transformation O
of O
ALL_CAP O
3T3 O
cells O
, O
and O
their O
functions O
may O
be O
required O
RARE O
full O
Ras I-GENE
transformation O
. O

Furthermore O
, O
Rac1 I-GENE
activation O
of O
JNK I-GENE
or O
SRF I-GENE
, O
or O
induction O
of O
RARE O
, O
was O
neither O
necessary O
nor O
sufficient O
RARE O
Rac1 I-GENE
transforming O
activity O
. O

Overexpression O
of O
the O
RARE O
interaction O
domain O
of O
CBP I-GENE
specifically O
abolishes O
the O
positive O
cross O
RARE O
between O
TR I-GENE
and O
NUM I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
E2 I-GENE
. O

This O
RARE O
domain O
has O
been O
RARE O
in O
all O
naturally O
occurring O
ALL_CAP I-GENE
deletion I-GENE
mutants I-GENE
described O
to O
date O
. O

Identification O
of O
a O
promoter O
- O
specific O
RARE O
domain O
in O
the O
herpes I-GENE
simplex I-GENE
virus I-GENE
regulatory I-GENE
protein I-GENE
ICP4 I-GENE
. O

DNA O
sequencing O
of O
a O
NUM O
- O
kb O
segment O
RARE O
a O
RARE O
divergent O
locus O
( O
ALL_CAP O
- O
B O
) O
between O
NUM O
and O
NUM O
revealed O
the O
presence O
of O
nine O
viral O
RARE O
with O
predicted O
gene O
products O
related O
to O
cellular O
proteins O
. O

Studies O
in O
mammalian O
cells O
have O
correlated O
induction O
of O
RARE O
tyrosine O
NUM O
( O
NUM O
) O
RARE O
on O
p34cdc2 I-GENE
with O
the O
response O
to O
DNA O
damage O
. O

We O
report O
RARE O
the O
case O
of O
a O
NUM O
- O
year O
- O
old O
man O
in O
whom O
ectopic O
RARE O
RARE O
RARE O
was O
detected O
by O
99mTc O
- O
RARE O
scintigraphy O
( O
99mTc O
- O
ALL_CAP O
). O

RARE I-GENE
endothelin I-GENE
release O
and O
infarct O
size O
, O
RARE O
RARE O
flow O
, O
and O
ventricular O
function O
in O
canine O
infarction O
and O
reperfusion O
. O

The O
RARE O
included O
RARE O
tests O
( O
RARE O
to O
1 O
microgram O
/ O
ml O
, O
Pharmacia O
RARE O
measurement O
of O
specific O
serum O
IgE I-GENE
with O
RAST O
- O
ALL_CAP O
( O
Pharmacia O
RARE O
and O
ALL_CAP O
with O
three O
concentrations O
of O
RARE O
( O
RARE O
RARE O
) O
and O
RARE O
( O
RARE O
RARE O
.) O
RARE O
( O
RARE O
ALL_CAP O
). O

The O
RARE I-GENE
RARE I-GENE
protein I-GENE
- I-GENE
related I-GENE
( O
NUM I-GENE
- I-GENE
R I-GENE
) O
gene O
with O
domains O
encoding O
RARE O
nuclear O
ribonucleoprotein O
association O
and O
NUM I-GENE
binding O
shows O
repressed O
RARE O
RARE O
terminal O
differentiation O
. O

Recent O
application O
of O
recombinant O
RARE O
ALL_CAP O
/ O
HIV O
- O
1 O
vectors O
RARE O
vaccine O
RARE O
in O
HIV O
- O
1 O
RARE O
RARE O
volunteers O
has O
produced O
CTL O
responses O
in O
a O
significant O
number O
of O
RARE O
. O

The O
relevance O
of O
these O
elements O
in O
conferring O
anaerobic O
induction O
of O
NUM I-GENE
gene I-GENE
RARE O
is O
discussed O
. O

RARE O
NUM O
and O
NUM O
are O
separated O
from O
each O
other O
by O
a O
NUM O
- O
nucleotide O
intron O
. O

A O
MEK I-GENE
- O
specific O
inhibitor O
( O
NUM O
) O
( O
RARE O
, O
D O
. O

These O
data O
support O
the O
idea O
that O
the O
repression O
activity O
of O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
depends O
upon O
the O
species O
of O
promoter O
to O
which O
it O
is O
RARE O
and O
upon O
the O
proteins O
that O
bind O
to O
those O
promoters O
. O

RARE O
period O
- O
peak O
analysis O
of O
RARE O
- O
RARE O
using O
a O
fast O
RARE O
function O
. O

In O
summary O
, O
NUM I-GENE
( O
RARE I-GENE
) O
activity O
stimulates O
G1 O
/ O
S O
transition O
in O
immature O
RARE O
and O
maintains O
cell O
viability O
via O
RARE O
of O
RARE O
activation O
signals O
RARE O
to O
RARE O
of O
the O
Ras I-GENE
/ O
Raf I-GENE
/ O
ALL_CAP I-GENE
RARE O
. O

However O
, O
the O
action O
of O
each O
RARE O
RARE O
and O
the O
RARE O
cellular O
factors O
that O
can O
differentially O
regulate O
the O
transcriptional O
responses O
of O
a O
RARE O
- O
DNA O
complex O
are O
not O
RARE O
understood O
. O

We O
have O
measured O
the O
ALL_CAP O
on O
RARE O
and O
its O
direction O
in O
three O
dimensions O
RARE O
different O
jaw O
RARE O
in O
ten O
subjects O
. O

These O
findings O
suggest O
that O
RARE O
RARE O
chemotherapy O
should O
be O
effective O
on O
advanced O
cervical O
RARE O
. O

The O
ALL_CAP O
questionnaire O
did O
not O
RARE O
a O
characteristic O
basic O
symptoms O
profile O
of O
RARE O
disorder O
, O
when O
compared O
with O
bipolar O
affective O
disorder O
and O
schizophrenia O
. O

The O
RARE O
RARE I-GENE
factor I-GENE
ALL_CAP I-GENE
in I-GENE
RARE I-GENE
RARE I-GENE
: O
RARE O
of O
the O
ALL_CAP I-GENE
operon I-GENE
in O
response O
to O
growth O
RARE O
and O
heat O
shock O

RARE O
promoter O
elements O
implicated O
in O
glucocorticoid O
- O
and O
cAMP O
- O
RARE O
RARE O
RARE O
RARE O
RARE O
in O
liver O
RARE O
RARE O
RARE O
and O
lymphocyte O
- O
specific O
RARE O
are O
RARE O
within O
the O
5 O
' O
flanking O
sequence O
. O

RARE O
RARE O
decreases O
due O
to O
RARE O
alone O
within O
NUM O
minutes O
are O
unlikely O
. O

We O
have O
studied O
the O
RARE O
of O
ALL_CAP O
labeled O
with O
RARE O
- O
111 O
( O
In O
- O
111 O
). O

CD3 I-GENE
cross O
- O
linking O
RARE O
tyrosine O
RARE O
of O
NUM I-GENE
in O
RARE O
T O
cells O
. O

RARE O
- O
dependent O
RARE O
of O
the O
ALL_CAP I-GENE
operon I-GENE
could O
be O
restored O
in O
the O
E I-GENE
. I-GENE
coli I-GENE
ALL_CAP I-GENE
mutants I-GENE
by O
RARE O
a O
RARE O
carrying O
an O
RARE O
ALL_CAP I-GENE
, O
suggesting O
a O
transactivating O
function O
of O
the O
gene O
product O
. O

Mutations O
in O
the O
alpha I-GENE
and I-GENE
RARE I-GENE
- I-GENE
70 I-GENE
subunits I-GENE
of I-GENE
RNA I-GENE
polymerase I-GENE
affect O
RARE O
of O
the O
RARE I-GENE
operon I-GENE
. O

Taken O
together O
, O
we O
provide O
evidence O
RARE O
the O
existence O
of O
an O
activator O
, O
ALL_CAP I-GENE
, O
which O
in O
combination O
with O
the O
NUM I-GENE
and O
c I-GENE
- I-GENE
Rel I-GENE
proteins I-GENE
, O
are O
part O
of O
the O
transcription O
factor O
machinery O
that O
regulates O
3 O
' O
enhancer O
activity O
, O
and O
thus O
the O
control O
of O
the O
ALL_CAP I-GENE
locus I-GENE
in O
RARE O
B O
lymphocyte O
development O
. O

The O
RARE O
efficacy O
of O
the O
selective O
N O
- O
type O
voltage O
- O
RARE O
RARE O
RARE O
blocker O
, O
ALL_CAP O
- O
111 O
, O
was O
evaluated O
in O
spontaneously O
hypertensive O
rats O
subjected O
to O
NUM O
min O
of O
RARE O
cerebral O
ischemia O
by O
permanent O
ligation O
of O
the O
right O
common O
carotid O
artery O
and O
temporary O
occlusion O
of O
the O
right O
RARE O
cerebral O
artery O
. O

The O
genes O
encoding O
the O
transcription I-GENE
factor I-GENE
NUM I-GENE
, O
the O
NUM I-GENE
protein I-GENE
and O
a O
putative O
glucose O
RARE O
are O
contained O
in O
a O
12 O
. O
3 O
kb O
DNA O
fragment O
on O
the O
RARE O
RARE O
of O
Saccharomyces O
cerevisiae O
RARE O
VII O
. O

The O
RARE O
RARE O
the O
estimated O
fall O
distance O
RARE O
fracture O
of O
the O
RARE O
. O

RARE O
/ O
RARE O
usage O
was O
associated O
with O
depressed O
NUM I-GENE
+ I-GENE
counts O
and O
elevated O
amylase I-GENE
levels O
within O
the O
ALL_CAP O
subgroup O
. O

METHODS O
: O
Fifty O
- O
eight O
patients O
who O
underwent O
a O
RARE O
RARE O
resection O
RARE O
ALL_CAP O
and O
whose O
preoperative O
ALL_CAP I-GENE
levels O
were O
> O
NUM O
RARE O
/ O
ml O
, O
were O
RARE O
RARE O
this O
study O
. O

RARE I-GENE
- I-GENE
binding I-GENE
peptide I-GENE
( O
CBP I-GENE
RARE O
a O
peptide O
of O
NUM O
amino O
RARE O
derived O
from O
muscle I-GENE
myosin I-GENE
light I-GENE
chain I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
RARE O
binds O
to O
calmodulin I-GENE
with O
RARE O
affinity O
. O

Here O
we O
show O
that O
the O
type O
of O
tyrosine I-GENE
kinase I-GENE
receptor I-GENE
RARE O
also O
participates O
in O
the O
nature O
of O
the O
cAMP O
effect O
. O

To O
gain O
insight O
into O
the O
possible O
involvement O
of O
p21 I-GENE
in O
liver O
cell O
growth O
, O
the O
RARE O
and O
RARE O
of O
the O
p21 I-GENE
gene I-GENE
was O
evaluated O
in O
rodent O
models O
of O
liver O
regeneration O
and O
specimens O
of O
human O
liver O
diseases O
. O

Northern O
blot O
analysis O
of O
ALL_CAP I-GENE
( I-GENE
A I-GENE
) I-GENE
and O
ALL_CAP I-GENE
( I-GENE
B I-GENE
) I-GENE
showed O
that O
transcripts O
of O
both O
ALL_CAP I-GENE
- I-GENE
like I-GENE
genes I-GENE
were O
more O
abundant O
in O
leaves O
than O
roots O
in O
RARE O
RARE O
grown O
without O
addition O
of O
RARE O
metal O
ions O
, O
a O
characteristic O
of O
type I-GENE
II I-GENE
RARE I-GENE
. O

In O
RARE O
- O
transfection O
studies O
, O
an O
AP I-GENE
- I-GENE
2 I-GENE
but O
not O
an O
RARE I-GENE
- I-GENE
1 I-GENE
RARE O
vector O
activated O
ALL_CAP I-GENE
/ O
VEGF I-GENE
transcription O
, O
thus O
indicating O
that O
AP I-GENE
- I-GENE
2 I-GENE
protein I-GENE
is O
functionally O
important O
in O
TGF I-GENE
alpha I-GENE
- O
RARE O
ALL_CAP I-GENE
/ O
VEGF I-GENE
gene O
RARE O
. O

The O
ALL_CAP I-GENE
gene I-GENE
is O
composed O
of O
eight O
exons O
covering O
19 O
. O
5 O
kb O
on O
the O
short O
RARE O
of O
RARE O
4 O
. O

In O
some O
instances O
, O
this O
is O
partly O
RARE O
by O
the O
RARE O
of O
RARE O
encoded O
RARE O
which O
lead O
to O
the O
RARE O
of O
initiation I-GENE
factor I-GENE
NUM I-GENE
. O

The O
best O
endometrial O
ablation O
was O
seen O
when O
NUM O
was O
given O
by O
intrauterine O
administration O
with O
light O
treatment O
RARE O
NUM O
ALL_CAP O
/ O
cm O
NUM O
hours O
later O
. O

Unlike O
class O
II O
- O
and O
III O
- O
specific O
TBP I-GENE
- O
ALL_CAP I-GENE
complexes O
, O
the O
corresponding O
murine O
and O
human O
class O
I O
- O
specific O
transcription O
initiation O
factor O
TIF I-GENE
- I-GENE
ALL_CAP I-GENE
/ O
NUM I-GENE
exhibits O
a O
pronounced O
selectivity O
RARE O
its O
homologous O
promoter O
. O

RARE I-GENE
- I-GENE
1 I-GENE
, O
a O
protein O
abundant O
in O
cells O
of O
the O
immune O
RARE O
, O
has O
been O
proposed O
to O
be O
a O
human O
homolog O
of O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
NUM I-GENE
gene I-GENE
product I-GENE
, O
which O
is O
crucial O
in O
protein O
RARE O
. O

In O
this O
regard O
, O
it O
differs O
from O
a O
recently O
reported O
ALL_CAP O
- O
RARE O
ARF I-GENE
- O
ALL_CAP I-GENE
that O
contains O
a O
NUM I-GENE
domain I-GENE
. O

We O
now O
describe O
the O
identification O
of O
ALL_CAP I-GENE
RARE O
this O
NUM I-GENE
- I-GENE
kDa I-GENE
RARE I-GENE
factor I-GENE
. O

These O
elements O
comprise O
a O
binding O
site O
RARE O
Krox I-GENE
proteins I-GENE
, O
one O
RARE O
nuclear I-GENE
factor I-GENE
1 I-GENE
, O
an O
octamer O
motif O
that O
binds O
POU I-GENE
- I-GENE
RARE I-GENE
proteins I-GENE
, O
and O
a O
novel O
ALL_CAP I-GENE
control I-GENE
element I-GENE
. O

RARE O
samples O
were O
obtained O
either O
from O
rats O
that O
had O
been O
exposed O
to O
RARE O
withdrawal O
following O
a O
RARE O
day O
RARE O
infusion O
or O
sham O
treated O
control O
subjects O
. O

Therefore O
, O
the O
impaired O
RARE O
RARE O
development O
in O
RARE I-GENE
mutants I-GENE
is O
not O
caused O
by O
the O
absence O
of O
the O
RARE I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
. O

RESULTS O
: O
The O
RARE O
of O
average O
daily O
CD34 I-GENE
+ I-GENE
cell O
yields O
RARE O
patients O
who O
received O
RARE O
RARE O
ALL_CAP O
, O
ALL_CAP O
, O
and O
ALL_CAP O
with O
G I-GENE
- I-GENE
CSF I-GENE
were O
12 O
. O
9 O
, O
11 O
. O
03 O
, O
and O
5 O
. O
37 O
RARE O
10 O
( O
6 O
RARE O
kg O
, O
respectively O
, O
compared O
with O
2 O
. O
02 O
RARE O
10 O
( O
6 O
RARE O
kg O
in O
the O
reference O
group O
that O
received O
ALL_CAP O
with O
G I-GENE
- I-GENE
CSF I-GENE
( O
P O
= O
< O
. O
0001 O
, O
. O
NUM O
, O
and O
. O
09 O
, O
respectively O
). O

Increased O
p53 I-GENE
activity O
RARE O
by O
ALL_CAP O
is O
not O
due O
to O
elevated O
p53 I-GENE
mRNA I-GENE
nor O
to O
protein O
levels O
. O

CONCLUSION O
: O
Chronic O
administration O
of O
RARE O
may O
have O
caused O
a O
negative O
RARE O
effect O
in O
RARE O
patients O
with O
RARE O
. O

The O
intensity O
of O
the O
RARE O
is O
an O
order O
of O
magnitude O
larger O
than O
that O
of O
the O
RARE O
and O
RARE O
the O
signal O
contrast O
if O
both O
effects O
are O
RARE O
simultaneously O
. O

In O
eukaryotic O
cells O
, O
premature O
RARE O
of O
translation O
RARE O
nonsense O
codons O
has O
been O
implicated O
RARE O
the O
cause O
of O
a O
variety O
of O
posttranscriptional O
events O
, O
including O
rapid O
mRNA O
RARE O
in O
the O
cytoplasm O
or O
the O
nucleus O
, O
altered O
RARE O
site O
selection O
, O
and O
RARE O
RARE O
. O

The O
region O
of O
RARE O
NUM O
encoding O
the O
RARE I-GENE
locus I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
was O
mapped O
by O
deletion O
analysis O
and O
RARE O
studies O
to O
a O
1 O
. O
5 O
- O
kb O
RARE I-GENE
/ I-GENE
II I-GENE
/ O
ALL_CAP I-GENE
DNA O
fragment O
. O

Transient O
cotransfection O
of O
tat I-GENE
cDNA I-GENE
in O
sense O
orientation O
( O
tat I-GENE
/ I-GENE
S I-GENE
RARE O
together O
with O
a O
RARE O
containing O
the O
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
( O
NUM I-GENE
, O
from O
- O
NUM O
to O
+ O
NUM O
) O
in O
front O
of O
the O
bacterial I-GENE
chloramphenicol I-GENE
RARE I-GENE
( O
CAT I-GENE
) O
gene O
significantly O
RARE O
CAT I-GENE
activity O
in O
Jurkat O
cells O
activated O
by O
the O
addition O
of O
NUM O
% O
RARE O
RARE O
serum O
( O
ALL_CAP O
) O
or O
5 O
micrograms O
/ O
mL O
phytohemagglutinin I-GENE
RARE O
10 O
RARE O
7 O
) O
mol O
/ O
L O
phorbol O
myristate O
RARE O
( O
PMA O
) O
and O
U937 O
cells O
activated O
by O
NUM O
% O
ALL_CAP O
or O
10 O
RARE O
7 O
) O
mol O
/ O
L O
PMA O
. O

RARE O
mortality O
did O
not O
differ O
among O
the O
various O
treatment O
conditions O
. O

The O
recombinant O
protein O
was O
RARE O
to O
RARE O
by O
( O
NUM O
) O
NUM O
- O
precipitation O
and O
affinity O
chromatography O
on O
5 O
' O
AMP O
- O
RARE O
. O

RARE O
of O
gene O
RARE O
RARE O
by O
the O
5 O
' O
upstream O
region O
of O
the O
RARE I-GENE
lyase I-GENE
gene I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
is O
RARE O
by O
two O
distinct O
regulatory O
pathways O
in O
Saccharomyces O
cerevisiae O
. O

RARE O
- O
motor O
task O
to O
evaluate O
right O
frontal O
lobe O
damage O
. O

To O
avoid O
complications O
, O
accurate O
quantitative O
analysis O
of O
ALL_CAP O
and O
NO2 O
is O
necessary O
RARE O
this O
therapy O
. O

Our O
results O
demonstrate O
that O
cis O
elements O
positioned O
between O
the O
alpha I-GENE
3 I-GENE
and O
beta I-GENE
4 I-GENE
coding O
regions O
are O
important O
RARE O
RARE O
part O
of O
the O
restricted O
CNS O
patterns O
of O
beta I-GENE
4 I-GENE
, O
alpha I-GENE
3 I-GENE
, O
and O
alpha I-GENE
5 I-GENE
gene I-GENE
transcription O
. O

RNase I-GENE
protection O
experiments O
confirmed O
the O
presence O
of O
the O
NUM I-GENE
- I-GENE
NUM I-GENE
variant I-GENE
in O
IM O
- O
9 O
cells O
and O
human O
liver O
. O

Functional O
tests O
using O
a O
reporter O
gene O
, O
containing O
Stat5 I-GENE
- I-GENE
binding I-GENE
elements I-GENE
, O
confirmed O
that O
while O
the O
variant O
form O
was O
inactive O
by O
itself O
, O
it O
could O
inhibit O
the O
function O
of O
the O
full O
- O
length O
receptor O
. O

Conversely O
, O
activated O
glucocorticoid I-GENE
receptors I-GENE
suppressed O
the O
RARE O
function O
of O
p53 I-GENE
, O
while O
RARE O
by O
p53 I-GENE
was O
largely O
unaffected O
. O

99mTc O
- O
HMPAO O
was O
distributed O
in O
the O
RARE O
of O
the O
ALL_CAP O
and O
ALL_CAP O
in O
the O
two O
patients O
who O
were O
treated O
with O
RARE O
infusion O
of O
RARE O
from O
the O
NUM O
segment O
, O
but O
was O
distributed O
only O
to O
the O
RARE O
of O
the O
ALL_CAP O
in O
four O
patients O
who O
were O
treated O
with O
RARE O
infusion O
of O
RARE O
from O
the O
C1 O
segment O
RARE O
1 O
ml O
/ O
min O
. O

This O
brief O
review O
analyses O
these O
interactions O
and O
defines O
clinical O
RARE O
where O
antibiotic O
- O
RARE O
RARE O
release O
may O
prove O
to O
be O
clinically O
relevant O
. O

This O
promoter O
segment O
could O
drive O
RARE O
of O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
, O
could O
confer O
correct O
transcriptional O
initiation O
to O
the O
reporter O
and O
could O
confer O
the O
ALL_CAP I-GENE
- O
responsiveness O
previously O
observed O
in O
the O
RARE O
gene O
. O

This O
is O
the O
RARE O
report O
that O
an O
in O
vitro O
- O
synthesized O
RARE O
RNA O
RARE O
a O
RARE O
( O
A O
) O
RARE O
can O
initiate O
infection O
and O
produce O
3 O
' O
polyadenylated O
viral O
genome O
in O
vivo O
. O

The O
human O
RARE O
was O
RARE O
RARE O
RARE O
the O
simian O
RARE O
SIV O
entry O
. O

These O
changes O
in O
virus O
entry O
features O
may O
result O
in O
RARE O
with O
novel O
pathogenic O
properties O
. O

RESULTS O
: O
Among O
women O
, O
the O
age O
- O
related O
decline O
in O
BMD O
RARE O
all O
non O
- O
spine O
skeletal O
sites O
was O
significantly O
different O
from O
zero O
, O
with O
the O
largest O
decline O
seen O
RARE O
the O
femoral O
neck O
RARE O
NUM O
g O
/ O
cm2 O
/ O
RARE O
, O
p O
< O
. O
001 O
) O
and O
the O
smallest O
RARE O
the O
RARE O
of O
the O
hip O
RARE O
NUM O
g O
/ O
cm2 O
/ O
RARE O
, O
p O
= O
. O
03 O
). O

RARE O
- O
nine O
( O
NUM O
%) O
patients O
were O
administered O
NUM O
MBq O
( O
7 O
mCi O
) O
NUM O
- O
tetrofosmin O
RARE O
rest O
followed O
4 O
h O
later O
by O
750 O
MBq O
( O
21 O
mCi O
) O
RARE O
stress O
( O
the O
1 O
day O
protocol O
RARE O
whereas O
88 O
( O
NUM O
%) O
patients O
had O
rest O
and O
stress O
imaging O
studies O
on O
two O
separate O
days O
, O
receiving O
a O
500 O
MBq O
( O
14 O
mCi O
) O
dose O
of O
NUM O
- O
tetrofosmin O
on O
each O
RARE O
( O
the O
2 O
day O
protocol O
). O

Myocardial O
ALL_CAP O
imaging O
with O
NUM O
- O
tetrofosmin O
in O
clinical O
practice O
: O
comparison O
of O
a O
1 O
day O
and O
a O
2 O
day O
imaging O
protocol O
. O

NUM O
- O
ALL_CAP O
- O
ALL_CAP O
showed O
an O
almost O
identical O
behaviour O
to O
in O
vitro O
labelled O
RARE O
RARE O
cells O
( O
RARE O
RARE O
which O
are O
generally O
considered O
the O
reference O
standard O
RARE O
RARE O
pool O
agents O
. O

RARE O
from O
RARE O
and O
a O
subsequent O
10 O
- O
NUM O
- O
RARE O
increase O
in O
V O
( O
RARE O
) O
have O
been O
observed O
upon O
N I-GENE
- I-GENE
NUM I-GENE
domain I-GENE
RARE O
by O
a O
specific O
RARE O
RARE O
or O
upon O
deletion O
of O
the O
NUM I-GENE
domains I-GENE
to O
yield O
the O
catalytic O
RARE I-GENE
domain I-GENE
. O

We O
have O
thus O
identified O
the O
RARE O
mammalian I-GENE
homolog I-GENE
of I-GENE
yeast I-GENE
NUM I-GENE
, O
a O
protein O
that O
regulates O
levels O
of O
nonsense O
mRNA O
, O
and O
we O
tentatively O
RARE O
this O
protein O
human I-GENE
NUM I-GENE
( O
RARE O
human I-GENE
homolog I-GENE
of I-GENE
NUM I-GENE
). O

A O
RARE O
cure O
and O
its O
solution O

The O
addition O
of O
RARE O
did O
not O
influence O
this O
transfer O
. O

DNA O
RARE O
exchange O
catalyzed O
by O
NUM I-GENE
protein I-GENE
is O
also O
greatly O
RARE O
by O
RPA I-GENE
. O

NUM I-GENE
, O
which O
also O
controls O
the O
RARE O
of O
early O
RARE O
genes O
, O
represses O
NUM I-GENE
RARE O
through O
a O
sequence O
called O
ALL_CAP O
, O
RARE O
a O
function O
of O
nitrogen O
availability O
. O

The O
second O
class O
of O
cDNA O
hybridized O
to O
a O
NUM O
kb O
transcript O
, O
which O
was O
RARE O
twice O
RARE O
large O
RARE O
the O
mammalian I-GENE
RARE I-GENE
mRNA I-GENE
. O

In O
cell O
lines O
transformed O
by O
ALL_CAP I-GENE
/ O
ABL I-GENE
, O
ALL_CAP I-GENE
was O
tyrosine O
RARE O
, O
while O
ALL_CAP I-GENE
was O
not O
. O

In O
RARE O
cells O
, O
three O
major O
proteins O
RARE O
with O
ALL_CAP I-GENE
, O
identified O
RARE O
NUM I-GENE
, O
ALL_CAP I-GENE
and O
c I-GENE
- I-GENE
ABL I-GENE
. O

Effect O
of O
RARE O
RARE O
RARE O
leaf O
RARE O
on O
the O
cardiovascular O
RARE O
. O

RESULTS O
: O
RARE O
RARE O
, O
mainly O
RARE O
in O
distribution O
, O
were O
the O
most O
common O
finding O
, O
seen O
in O
21 O
( O
72 O
%) O
and O
NUM O
( O
65 O
%) O
of O
patients O
with O
ALL_CAP O
and O
ALL_CAP O
, O
respectively O
. O

RARE O
RARE I-GENE
in O
male O
RARE O
pigs O
affected O
by O
the O
female O
RARE O
and O
reproductive O
condition O
. O

In O
cellular O
supernatant O
fraction O
, O
ALL_CAP O
showed O
a O
decrease O
of O
magnesium O
in O
many O
tissues O
and O
an O
elevation O
of O
the O
RARE O
to O
magnesium O
ratio O
when O
compared O
to O
age O
- O
matched O
ALL_CAP O
and O
ALL_CAP O
. O

RARE O
transcription O
of O
a O
murine I-GENE
FGFR I-GENE
- I-GENE
3 I-GENE
RARE I-GENE
RARE O
RARE O
RARE O
. O

A O
previous O
report O
described O
that O
a O
NUM O
- O
bp O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
fragment O
has O
an O
ALL_CAP O
activity O
( O
NUM O
; O
RARE O
et O
al O
., O
RARE O
. O

The O
human I-GENE
NUM I-GENE
gene I-GENE
consists O
of O
8 O
exons O
that O
extend O
more O
than O
77 O
kb O
on O
the O
human O
genome O
. O

RARE O
IV O
RARE O
pattern O
, O
containing O
RARE O
NUM O
and O
S O
was O
found O
both O
in O
RARE O
and O
ovary O
. O

ALL_CAP I-GENE
deficiency O
may O
be O
absolute O
, O
but O
often O
is O
not O
and O
the O
diagnosis O
may O
be O
complicated O
by O
a O
RARE O
of O
physical O
and O
hormonal O
findings O
that O
are O
along O
a O
spectrum O
from O
low O
normal O
ALL_CAP I-GENE
RARE O
to O
absent O
ALL_CAP I-GENE
RARE O
. O

RARE O
CRP I-GENE
test O
were O
seen O
. O

During O
the O
RARE O
period O
, O
RARE O
was O
associated O
with O
high O
levels O
of O
IgG I-GENE
, O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
, O
TNF I-GENE
- I-GENE
alpha I-GENE
, O
and O
PGE2 O
in O
the O
RARE O
RARE O
. O

RARE O
mechanisms O
of O
the O
minus O
- O
RARE O
origin O
of O
RARE O
NUM O
by O
Escherichia I-GENE
coli I-GENE
RNA I-GENE
polymerase I-GENE
. O

The O
minimum O
and O
essential O
subunits O
RARE O
RNA O
RARE O
have O
not O
yet O
been O
identified O
. O

RARE I-GENE
- I-GENE
4 I-GENE
is O
a O
RARE O
adhesion O
RARE O
, O
and O
this O
interaction O
may O
both O
localize O
PKC I-GENE
and O
RARE O
its O
activity O
RARE O
sites O
of O
forming O
adhesions O
. O

The O
NUM O
cells O
expressing O
NUM I-GENE
with O
mutation O
of O
RARE O
- O
NUM O
, O
- O
NUM O
, O
and O
- O
NUM O
to O
alanine O
, O
or O
with O
mutation O
of O
only O
one O
serine O
in O
this O
domain O
, O
RARE O
to O
be O
RARE O
in O
response O
to O
RARE O
and O
are O
NUM O
- O
70 O
% O
RARE O
following O
the O
initial O
RARE O
challenge O
. O

Members O
of O
the O
ALL_CAP I-GENE
family I-GENE
include O
the O
extracellular I-GENE
response I-GENE
kinases I-GENE
( O
ERKs I-GENE
or O
NUM I-GENE
/ I-GENE
NUM I-GENE
( O
ALL_CAP I-GENE
RARE O
the O
c I-GENE
- I-GENE
Jun I-GENE
amino I-GENE
- I-GENE
terminal I-GENE
kinases I-GENE
( O
RARE I-GENE
RARE O
and O
the O
p38 I-GENE
/ O
RARE I-GENE
1 I-GENE
protein O
kinases O
. O

NUM I-GENE
contained O
the O
characteristic O
ALL_CAP I-GENE
domain O
and O
a O
RARE O
C O
terminus O
; O
it O
is O
possible O
that O
the O
cDNA O
contains O
a O
bHLH O
domain O
, O
but O
the O
RARE O
RARE O
reading O
frame O
has O
yet O
to O
be O
completed O
. O

The O
RARE O
ALL_CAP O
production O
in O
these O
cells O
was O
associated O
with O
low O
levels O
of O
mRNA O
of O
inducible I-GENE
ALL_CAP I-GENE
RARE I-GENE
. O

Some O
8 O
. O
8 O
kb O
of O
the O
RARE O
RARE O
RARE O
NUM O
was O
sequenced O
, O
RARE O
eight O
tightly O
clustered O
RARE O
reading O
frames O
( O
RARE O
) O
RARE O
from O
ALL_CAP I-GENE
, O
which O
encodes O
pre I-GENE
- I-GENE
RARE I-GENE
S I-GENE
. O

RARE I-GENE
Pra I-GENE
was O
also O
shown O
to O
physically O
interact O
with O
RARE I-GENE
kinase I-GENE
( O
RARE I-GENE
); O
RARE I-GENE
and O
Pra I-GENE
can O
form O
a O
complex O
, O
but O
when O
the O
12 I-GENE
- I-GENE
kDa I-GENE
RARE I-GENE
, O
RARE I-GENE
, O
and O
Pra I-GENE
are O
all O
present O
, O
RARE I-GENE
has O
a O
RARE O
affinity O
than O
Pra I-GENE
RARE O
forming O
a O
complex O
with O
the O
12 I-GENE
- I-GENE
kDa I-GENE
RARE I-GENE
. O

RARE O
from O
iron O
RARE O
, O
ALL_CAP I-GENE
RARE O
was O
affected O
by O
changes O
in O
DNA O
topology O
RARE O
by O
RARE O
A O
but O
not O
by O
the O
global O
RARE O
regulatory O
RARE I-GENE
RARE I-GENE
. O

Molecular O
characterization O
of O
a O
large O
RARE O
RARE O
RARE O
operon O
which O
is O
RARE O
by O
a O
consensus O
NUM I-GENE
promoter I-GENE
. O

M I-GENE
. I-GENE
RARE I-GENE
OxyR I-GENE
was O
RARE O
and O
RARE O
, O
and O
its O
binding O
to O
the O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
intergenic O
region O
of O
M O
. O
RARE O
was O
demonstrated O
. O

The O
binding O
site O
RARE O
OxyR I-GENE
RARE O
NUM I-GENE
, O
RARE O
of O
the O
RARE O
loops O
controlling O
RARE O
of O
ALL_CAP I-GENE
in O
enteric O
bacteria O
and O
characteristic O
of O
the O
ALL_CAP I-GENE
superfamily I-GENE
in O
RARE O
. O

In O
the O
present O
study O
, O
we O
have O
isolated O
and O
sequenced O
several O
NUM I-GENE
cDNA I-GENE
gene I-GENE
fragments I-GENE
amplified O
by O
means O
of O
polymerase O
chain O
reaction O
( O
PCR O
) O
from O
parental O
( O
NUM O
) O
and O
RARE O
( O
NUM O
/ O
ALL_CAP O
) O
RARE O
cells O
. O

Thirty O
- O
five O
patients O
were O
included O
. O

RARE O
3 O
- O
4 O
RARE O
was O
present O
in O
NUM O
% O
of O
the O
cycles O
. O

Therefore O
more O
RARE O
and O
RARE O
RARE O
regimens O
are O
needed O
. O

None O
of O
these O
organic O
manifestations O
was O
discovered O
by O
RARE O
means O
. O

While O
TGF I-GENE
- I-GENE
beta1 I-GENE
does O
not O
alter O
the O
mitogen O
- O
RARE O
RARE O
and O
abundance O
of O
G1 O
RARE O
RARE I-GENE
NUM I-GENE
and O
RARE I-GENE
4 I-GENE
and I-GENE
2 I-GENE
in O
RARE O
, O
it O
inhibits O
RARE I-GENE
E I-GENE
- O
RARE I-GENE
2 I-GENE
activity O
, O
thus O
preventing O
mitogen O
- O
elicited O
RARE O
and O
inactivation O
of O
pRb I-GENE
in O
G1 O
RARE O
and O
transition O
to O
S O
RARE O
. O

However O
, O
the O
range O
of O
values O
observed O
is O
suggestive O
of O
the O
need O
to O
investigate O
RARE O
with O
RARE O
values O
of O
ALL_CAP O
with O
respect O
to O
the O
RARE O
- O
relationships O
between O
RARE O
characteristics O
, O
duration O
of O
symptoms O
, O
clinical O
presentation O
and O
treatment O
efficacy O
. O

The O
prominent O
lesions O
were O
confined O
to O
the O
cerebral O
surface O
layer O
and O
RARE O
tissue O
including O
the O
RARE O
vessels O
, O
which O
were O
all O
RARE O
in O
the O
RARE O
RARE O
, O
suggesting O
that O
some O
RARE O
RARE O
had O
been O
RARE O
into O
the O
RARE O
by O
the O
B O
. O
RARE O
. O

This O
fragment O
contained O
the O
C O
- O
terminal O
NUM O
nucleotides O
of O
ALL_CAP I-GENE
, O
encoding O
3 I-GENE
- I-GENE
RARE I-GENE
dehydrogenase I-GENE
; O
RARE I-GENE
, O
encoding O
RARE I-GENE
- I-GENE
beta I-GENE
- I-GENE
RARE I-GENE
dehydrogenase I-GENE
( O
RARE I-GENE
); O
and O
ALL_CAP O
, O
whose O
product O
showed O
RARE O
to O
the O
RARE I-GENE
proteins I-GENE
from I-GENE
RARE I-GENE
RARE I-GENE
. O

Transcriptional O
activity O
was O
measured O
by O
RARE O
- O
blot O
hybridization O
with O
steady O
- O
state O
RNA O
isolated O
from O
lacZ I-GENE
+ I-GENE
M I-GENE
. I-GENE
RARE I-GENE
RARE O
. O

RARE O
I O
and O
RARE O
RARE O
, O
both O
of O
which O
were O
principal O
RARE O
of O
the O
RARE O
fractions O
from O
this O
RARE O
medicine O
, O
were O
found O
to O
show O
an O
RARE O
activity O
on O
the O
ethanol O
- O
RARE O
muscle O
relaxation O
in O
rats O
. O

RARE O
time O
and O
RARE O
characteristics O
were O
analyzed O
together O
with O
the O
magnitude O
of O
cerebral O
RARE O
flow O
to O
identify O
areas O
of O
brain O
activity O
RARE O
to O
task O
and O
movement O
variables O
. O

RARE O
with O
significantly O
greater O
rCBF O
RARE O
targeting O
were O
the O
RARE O
motor O
cortex O
, O
RARE O
RARE O
RARE O
, O
and O
RARE O
RARE O
. O

Recent O
studies O
have O
demonstrated O
that O
the O
NUM I-GENE
snRNP I-GENE
is O
recruited O
to O
the O
5 O
' O
RARE O
site O
by O
protein O
/ O
protein O
interactions O
involving O
the O
SR I-GENE
domains O
of O
the O
NUM I-GENE
- I-GENE
NUM I-GENE
protein I-GENE
and O
NUM I-GENE
/ O
ALL_CAP I-GENE
. O

Thus O
, O
the O
RARE O
- O
snRNP O
- O
specific O
NUM O
protein O
could O
potentially O
be O
involved O
in O
SR I-GENE
protein O
- O
RARE O
protein O
/ O
protein O
interactions O
and O
, O
additionally O
, O
its O
RARE O
state O
could O
modulate O
pre O
- O
mRNA O
RARE O
. O

RARE I-GENE
NUM I-GENE
could O
be O
assembled O
onto O
RARE O
RARE O
NUM I-GENE
and O
RARE O
RARE O
both O
P2 I-GENE
( O
RNA I-GENE
polymerase I-GENE
) O
and O
NUM I-GENE
. O

However O
, O
the O
same O
NUM I-GENE
peptide I-GENE
, O
when O
conjugated O
to O
ALL_CAP I-GENE
, O
inhibits O
RARE I-GENE
ALL_CAP I-GENE
. O

Plasma O
levels O
of O
protein I-GENE
C I-GENE
, O
protein I-GENE
S I-GENE
, O
and O
antithrombin I-GENE
III I-GENE
in O
patients O
with O
RARE O
RARE O
. O

RARE O
bilateral O
recurrent O
branch O
RARE O
arterial O
occlusion O
( O
ALL_CAP O
) O
is O
a O
rare O
RARE O
characterized O
by O
RARE O
RARE O
, O
RARE O
, O
RARE O
, O
hearing O
RARE O
, O
and O
recurrent O
branch O
RARE O
artery O
occlusion O
of O
unknown O
etiology O
. O

RARE O
and O
corneal O
thickness O
measurements O
by O
in O
vivo O
RARE O
microscopy O
through O
focusing O
( O
ALL_CAP O
). O

RARE O
RARE O
of O
the O
two O
human I-GENE
CA I-GENE
genes I-GENE
, O
possibly O
containing O
homologous O
enhancer O
elements O
, O
have O
not O
yet O
been O
reported O
. O

Recombinant O
plasmids O
containing O
the O
RARE O
NUM O
nt O
5 O
' O
UTR O
of O
RARE O
1 O
and O
a O
NUM O
nt O
segment O
of O
5 O
' O
flanking O
sequence O
RARE O
luciferase I-GENE
activity O
nearly O
70 O
times O
RARE O
than O
a O
promoterless O
control O
RARE O
. O

Analysis O
RARE O
DNA O
- O
protein O
interactions O
by O
in O
vitro O
DNase I-GENE
- I-GENE
I I-GENE
footprinting O
identified O
a O
broad O
region O
of O
protection O
extending O
from O
nt O
- O
12 O
to O
+ O
38 O
. O

It O
is O
also O
homologous O
to O
other O
RARE O
carriers O
from O
human O
, O
mouse O
and O
Escherichia O
coli O
. O

RARE O
now O
, O
each O
of O
these O
loci O
was O
considered O
to O
contain O
three O
genes O
( O
RARE O
regulator I-GENE
, O
RARE I-GENE
and O
alpha I-GENE
- I-GENE
RARE I-GENE
RARE O
but O
a O
fourth O
gene O
, O
presumably O
an O
RARE O
alpha I-GENE
- I-GENE
RARE I-GENE
gene I-GENE
, O
was O
found O
RARE O
NUM I-GENE
adjacent O
to O
the O
RARE O
cluster O
of O
three O
genes O
. O

Although O
methods O
to O
RARE O
the O
control O
and O
activation O
ALL_CAP O
images O
may O
correct O
RARE O
some O
of O
this O
RARE O
error O
, O
they O
will O
be O
incomplete O
in O
RARE O
RARE O
those O
that O
depend O
on O
spatial O
orientation O
. O

Three O
women O
have O
had O
abnormal O
RARE O
follow O
RARE O
RARE O
suggestive O
of O
residual O
RARE O
. O

RARE O
- O
forming O
cells O
are O
characterized O
by O
a O
high O
activity O
of O
RARE I-GENE
and I-GENE
acid I-GENE
RARE I-GENE
and O
low O
ALL_CAP O
- O
test O
values O
. O

Analysis O
of O
homologous O
DNA O
sequences O
within O
the O
RARE O
intron O
of O
the O
mouse I-GENE
and I-GENE
human I-GENE
NUM I-GENE
genes I-GENE
: O
ALL_CAP I-GENE
- I-GENE
like I-GENE
site I-GENE
and O
RARE O
DNA O

The O
RARE O
RARE O
the O
ALL_CAP I-GENE
ALL_CAP I-GENE
of O
the O
Jak I-GENE
- O
Stat I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
RARE O
pathways O
with O
other O
pre O
- O
existing O
proteins O
provides O
a O
cellular O
mechanism O
RARE O
cell O
- O
and O
RARE O
- O
specific O
RARE O
. O

These O
studies O
point O
to O
the O
involvement O
of O
the O
MAP I-GENE
kinase I-GENE
RARE O
in O
the O
activation O
of O
monocytic O
cells O
RARE O
RARE O
to O
inflammatory O
sites O
. O

Our O
results O
show O
that O
the O
RARE I-GENE
- I-GENE
RARE I-GENE
NUM I-GENE
- I-GENE
3 I-GENE
allele I-GENE
blocks O
RARE O
RARE O
between O
tandemly O
RARE O
NUM I-GENE
RARE I-GENE
sequences I-GENE
and O
significantly O
stabilizes O
a O
human I-GENE
NUM I-GENE
RARE O
- O
containing O
YAC O
clone O
. O

A O
NUM O
NUM O
RARE O
with O
an O
ALL_CAP O
site O
( O
NUM O
NUM O
RARE O
A O
RARE O
10 O
) O
ALL_CAP O
RARE O
RARE O
RARE O
following O
infection O
of O
these O
strains O
. O

RARE O
RARE I-GENE
/ O
RARE I-GENE
RARE O
: O
formation O
, O
RARE O
and O
fate O
. O

This O
site O
is O
upstream O
from O
the O
TATA O
box O
used O
in O
somatic O
cells O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
RARE O
of O
B I-GENE
- I-GENE
Myb I-GENE
activity O
by O
RARE I-GENE
- O
RARE I-GENE
. O

RARE O
tumor O
suppressor O
genes O
, O
NUM I-GENE
( O
NUM I-GENE
) O
and O
NUM I-GENE
( O
NUM I-GENE
RARE O
have O
been O
mapped O
to O
this O
region O
, O
but O
by O
Southern O
blot O
analysis O
, O
RARE O
homozygous O
deletions O
were O
detected O
in O
either O
gene O
. O

RARE O
repair O
RARE O
the O
level O
of O
the O
nucleotide O
in O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
NUM I-GENE
gene I-GENE
: O
mapping O
of O
where O
RARE O
repair O
in O
the O
RARE O
RARE O
begins O
or O
ends O
and O
identification O
of O
only O
a O
partial O
NUM I-GENE
RARE O
RARE O
RARE O
upstream O
control O
sequences O
. O

An O
aromatic O
RARE O
interaction O
between O
subunits O
RARE O
mediate O
DNA O
sequence O
RARE O
: O
operator O
site O
discrimination O
by O
RARE I-GENE
lambda I-GENE
ALL_CAP I-GENE
repressor I-GENE
. O

We O
have O
characterized O
a O
panel O
of O
6 O
monoclonal O
antibodies O
raised O
against O
human I-GENE
platelet I-GENE
RARE I-GENE
by O
Western O
blotting O
, O
immune O
precipitation O
, O
and O
immunofluorescence O
, O
and O
shown O
that O
antibodies I-GENE
NUM I-GENE
and O
NUM I-GENE
disrupt O
actin I-GENE
stress O
fibers O
and O
RARE O
adhesions O
, O
and O
inhibit O
cell O
RARE O
when O
RARE O
into O
human O
RARE O
. O

This O
locus O
maps O
RARE O
NUM O
RARE O
from O
the O
genes O
encoding O
RARE O
- O
associated O
proteins O
NUM I-GENE
and O
NUM I-GENE
, O
and O
yet O
insertions O
RARE O
result O
in O
RARE O
of O
these O
proteins O
and O
a O
RARE O
- O
negative O
( O
ALL_CAP O
RARE O
RARE O
, O
RARE O
the O
RARE O
RARE I-GENE
- I-GENE
regulatory I-GENE
locus I-GENE
( O
RARE I-GENE
). O

RARE I-GENE
NUM I-GENE
B I-GENE
is O
a O
72 O
- O
amino O
acid O
protein O
belonging O
to O
the O
RARE I-GENE
family O
of O
analogous O
transcription O
factors O
present O
in O
P2 O
- O
like O
RARE O
, O
which O
contain O
a O
RARE O
- O
X2 O
- O
RARE O
- O
NUM O
- O
RARE O
- O
NUM O
- O
RARE O
RARE O
zinc O
- O
finger O
motif O
. O

The O
ALL_CAP O
absorption O
spectrum O
revealed O
a O
RARE O
RARE O
NUM O
nm O
, O
characteristic O
of O
ALL_CAP O
- O
Cd O
( O
II O
) O
RARE O
- O
to O
- O
metal O
RARE O
- O
transfer O
RARE O
, O
and O
the O
difference O
absorption O
coefficient O
after O
acidification O
( O
delta O
epsilon O
NUM O
, O
NUM O
mM O
- O
1 O
cm O
- O
1 O
) O
indicated O
the O
presence O
of O
a O
Cd O
( O
RARE O
- O
S O
) O
4 O
RARE O
. O

RARE I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
attenuates O
levels O
of O
second O
RARE O
RARE O
in O
cells O
and O
produces O
another O
( O
putative O
) O
RARE O
, O
RARE O
acid O
. O

Recently O
, O
we O
have O
reported O
the O
cloning O
of O
the O
RARE O
cell O
- O
specific O
, O
nuclear O
orphan O
receptor O
RARE I-GENE
cell I-GENE
nuclear I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
RARE O
ALL_CAP I-GENE
. O

Based O
on O
the O
sequence O
of O
the O
ALL_CAP I-GENE
, O
we O
RARE O
a O
putative O
ALL_CAP I-GENE
, O
referred O
to O
RARE O
P2 I-GENE
- I-GENE
ALL_CAP I-GENE
, O
in O
the O
5 O
' O
promoter O
- O
flanking O
region O
of O
the O
mouse I-GENE
RARE I-GENE
2 I-GENE
gene I-GENE
, O
which O
is O
RARE O
RARE O
the O
same O
RARE O
of O
RARE O
RARE O
ALL_CAP I-GENE
. O

Here O
we O
report O
the O
purification O
of O
this O
larger O
form O
RARE O
an O
RARE O
NUM O
- O
kDa O
RARE O
that O
contains O
NUM I-GENE
+ I-GENE
4 I-GENE
and O
nine O
additional O
polypeptides O
, O
including O
mRNA O
- O
binding O
polypeptides O
of O
NUM O
and O
NUM O
kDa O
and O
a O
RARE O
of O
NUM O
/ O
NUM O
kDa O
that O
proved O
to O
be O
RARE I-GENE
. O

RARE O
complexes O
RARE O
RARE O
a O
RARE O
RARE O
RARE O
than O
inactive O
complexes O
, O
were O
relatively O
RARE O
in O
both O
p21 I-GENE
and O
p27 I-GENE
, O
and O
contained O
Cdk2 I-GENE
with O
increased O
threonine O
NUM O
RARE O
, O
consistent O
with O
a O
mechanism O
of O
activation O
of O
RARE I-GENE
E I-GENE
- O
Cdk2 I-GENE
involving O
both O
RARE O
CDK I-GENE
inhibitor O
association O
and O
CDK I-GENE
- I-GENE
activating I-GENE
kinase I-GENE
- O
RARE O
RARE O
of O
Cdk2 I-GENE
. O

Thirty O
RARE O
I O
and O
RARE O
II O
RARE O
in O
NUM O
patients O
were O
treated O
with O
a O
modified O
RARE O
RARE O
tissue O
graft O
procedure O
. O

The O
RARE O
of O
the O
latter O
two O
cell O
lines O
showed O
increased O
RARE O
of O
the O
NUM I-GENE
protein I-GENE
and O
inhibition O
of O
cell O
growth O
. O

The O
RARE O
mortality O
of O
all O
patients O
was O
1 O
. O
9 O
%, O
the O
mortality O
of O
patients O
older O
than O
70 O
years O
was O
4 O
. O
3 O
%. O

Chronic O
RARE O
failure O
patients O
essentially O
RARE O
from O
cardiovascular O
causes O
, O
and O
the O
frequency O
of O
malignant O
RARE O
responsible O
RARE O
RARE O
is O
estimated O
to O
be O
10 O
%. O

The O
new O
ALL_CAP O
definition O
of O
cervical O
RARE O
RARE O
IA O
: O
a O
RARE O
. O

The O
effect O
of O
RARE I-GENE
on O
class O
I O
biogenesis O
was O
analyzed O
in O
more O
detail O
using O
a O
RARE I-GENE
- O
expressing O
recombinant O
RARE O
virus O
( O
ALL_CAP O
). O

This O
study O
indicates O
that O
the O
RARE O
of O
RARE O
RARE O
seen O
in O
ALL_CAP O
patients O
which O
harbor O
either O
of O
these O
two O
mutations O
may O
not O
be O
directly O
due O
to O
the O
failure O
of O
the O
mutant I-GENE
myosin I-GENE
heavy I-GENE
chain I-GENE
protein I-GENE
to O
RARE O
and O
form O
normal O
RARE O
, O
but O
may O
rather O
be O
a O
secondary O
effect O
possibly O
resulting O
from O
the O
chronic O
stress O
of O
decreased O
beta I-GENE
MHC I-GENE
function O
. O

RARE O
coupled O
plasma O
RARE O
emission O
spectroscopy O
was O
employed O
to O
obtain O
the O
tissue O
RARE O
measurements O
. O

An O
RARE O
protein O
, O
lysozyme I-GENE
, O
is O
a O
still O
RARE O
additive O
currently O
used O
in O
RARE O
preparation O
. O

A O
method O
RARE O
the O
simultaneous O
determination O
of O
de O
( O
N O
- O
RARE O
)- O
N O
- O
ethyl O
- O
8 O
, O
9 O
- O
RARE O
A O
6 O
, O
9 O
- O
RARE O
( O
NUM O
, O
I O
) O
and O
its O
three O
metabolites O
in O
human O
plasma O
and O
urine O
has O
been O
developed O
using O
high O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
with O
RARE O
( O
CL O
) O
detection O
. O

Similarly O
, O
the O
DNA O
- O
binding O
activity O
of O
activator I-GENE
protein I-GENE
1 I-GENE
( O
AP I-GENE
- I-GENE
1 I-GENE
) O
is O
modified O
by O
a O
DNA I-GENE
repair I-GENE
enzyme I-GENE
, O
RARE I-GENE
factor I-GENE
1 I-GENE
( O
RARE I-GENE
- I-GENE
1 I-GENE
RARE O
which O
is O
identical O
to O
a O
DNA I-GENE
repair I-GENE
enzyme I-GENE
, O
AP I-GENE
endonuclease I-GENE
. O

RARE O
an O
ALL_CAP I-GENE
domain I-GENE
and O
an O
SH3 I-GENE
- I-GENE
binding I-GENE
domain I-GENE
, O
NUM I-GENE
and O
the O
C O
. O
elegans O
homologue O
define O
a O
novel O
family O
of O
RARE O
binding O
proteins O
. O

However O
, O
its O
participation O
in O
RARE O
RARE O
by O
RARE O
RARE O
is O
unclear O
. O

The O
capacity O
to O
repair O
8 O
- O
ALL_CAP O
has O
been O
measured O
in O
cell O
- O
free O
extracts O
of O
wild O
- O
type O
and O
NUM I-GENE
strains O
using O
a O
NUM O
DNA O
fragment O
containing O
a O
single O
8 O
- O
ALL_CAP O
RARE O
paired O
with O
a O
cytosine O
( O
8 O
- O
ALL_CAP O
/ O
C O
) O
RARE O
a O
substrate O
. O

Results O
from O
our O
and O
other O
laboratories O
have O
suggested O
that O
ALL_CAP O
- O
01 O
induces O
preferential O
G1 O
- O
RARE O
accumulation O
in O
several O
human O
tumor O
cell O
lines O
tested O
. O

Northern O
and O
RT O
- O
PCR O
analysis O
of O
NUM I-GENE
RARE O
in O
mouse O
tissues O
from O
animals O
with O
segmental O
, O
RARE O
RARE O
RARE O
failed O
to O
detect O
substantially O
RARE O
or O
absent O
RARE O
compared O
to O
control O
animals O
, O
RARE O
to O
provide O
any O
evidence O
RARE O
RARE O
- O
specific O
RARE O
from O
this O
locus O
. O

Two O
predominant O
effects O
were O
noted O
: O
( O
i O
) O
the O
RARE O
RARE O
in O
the O
dual O
RARE O
motif O
RARE O
- O
RARE O
- O
RARE O
RARE O
RARE O
RARE O
the O
length O
of O
NUM O
influence O
p38 I-GENE
substrate O
RARE O
, O
and O
( O
ii O
) O
the O
length O
of O
NUM O
plays O
a O
major O
role O
in O
controlling O
autophosphorylation O
. O

A O
novel O
, O
RARE I-GENE
- I-GENE
specific I-GENE
mRNA I-GENE
transcript I-GENE
encoding O
an O
NH2 I-GENE
- I-GENE
terminal I-GENE
truncated I-GENE
RARE I-GENE
- I-GENE
oxide I-GENE
synthase I-GENE
. O
mRNA O
diversity O
represents O
a O
major O
RARE O
of O
RARE I-GENE
RARE I-GENE
- I-GENE
oxide I-GENE
synthase I-GENE
( O
ALL_CAP I-GENE
) O
gene O
RARE O
in O
somatic O
cells O
/ O
tissues O
. O

Unlike O
the O
ALL_CAP O
- O
binding O
domain O
, O
the O
RARE I-GENE
when O
isolated O
binds O
poorly O
and O
with O
low O
RARE O
to O
DNA O
. O

Cotransfection O
of O
Ets I-GENE
- I-GENE
2 I-GENE
and O
p44 I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
RARE O
vectors O
strongly O
RARE O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
promoter O
activation O
in O
response O
to O
RARE I-GENE
- I-GENE
1 I-GENE
: O
ER I-GENE
. O

Cyclin I-GENE
NUM I-GENE
could O
not O
be O
RARE O
from O
NUM I-GENE
in O
the O
resistant O
NUM O
cell O
lysates O
. O

The O
importance O
of O
posttranslational O
RARE O
of O
NUM I-GENE
by O
TGF I-GENE
- I-GENE
beta I-GENE
is O
RARE O
by O
the O
observation O
that O
in O
TGF I-GENE
- I-GENE
beta I-GENE
- O
resistant O
NUM O
, O
although O
the O
NUM I-GENE
transcript I-GENE
increased O
, O
NUM I-GENE
protein I-GENE
was O
not O
stabilized O
and O
did O
not O
accumulate O
, O
and O
RARE I-GENE
NUM I-GENE
- O
RARE I-GENE
association O
and O
kinase O
activation O
were O
not O
inhibited O
. O

The O
NUM I-GENE
protein I-GENE
, O
a O
RARE O
of O
the O
MADS I-GENE
box I-GENE
family I-GENE
of O
transcription O
factors O
, O
functions O
RARE O
of O
NUM I-GENE
in O
the O
RARE O
. O

To O
identify O
cis O
- O
acting O
elements O
that O
target O
c I-GENE
- I-GENE
myc I-GENE
mRNA I-GENE
RARE O
RARE O
RARE O
RARE O
, O
we O
stably O
transfected O
C2C12 O
cells O
with O
mutant I-GENE
myc I-GENE
genes I-GENE
or O
chimeric O
genes O
in O
which O
various O
myc I-GENE
sequences I-GENE
were O
fused O
to O
the O
human I-GENE
beta I-GENE
- I-GENE
globin I-GENE
gene I-GENE
or O
to O
the O
bacterial I-GENE
chloramphenicol I-GENE
RARE I-GENE
( O
CAT I-GENE
) O
gene O
. O

Furthermore O
, O
experiments O
with O
NUM O
RARE O
- O
RARE O
p53 I-GENE
cells O
indicate O
that O
aberrant O
tal I-GENE
- I-GENE
1 I-GENE
RARE O
RARE O
the O
permissive O
RARE O
does O
not O
exert O
a O
proliferative O
effect O
but O
causes O
p53 I-GENE
- O
RARE O
apoptosis O
, O
i O
. O
RARE O
., O
the O
tal I-GENE
- I-GENE
1 I-GENE
proliferative O
effect O
depends O
on O
the O
integrity O
of O
the O
cell O
RARE O
RARE O
of O
the O
RARE O
cell O
, O
RARE O
observed O
RARE O
c I-GENE
- I-GENE
myc I-GENE
and O
other O
RARE O
. O
tal I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
experiments O
indicate O
that O
ectopic O
tal I-GENE
- I-GENE
1 I-GENE
effects O
are O
RARE O
by O
both O
the O
DNA O
- O
binding O
and O
the O
heterodimerization O
domains O
, O
while O
the O
N I-GENE
- I-GENE
RARE I-GENE
truncated I-GENE
tal I-GENE
- I-GENE
1 I-GENE
variant I-GENE
( O
NUM I-GENE
) O
RARE O
in O
T O
- O
ALL O
malignant O
cells O
RARE O
the O
effects O
of O
the O
wild O
- O
type O
protein O
. O

The O
likelihood O
that O
a O
common O
region O
of O
deletions O
would O
contain O
a O
tumor O
suppressor O
is O
strongly O
RARE O
by O
RARE O
of O
that O
region O
with O
a O
RARE O
fragment O
RARE O
RARE O
upon O
introduction O
in O
tumor O
cells O
. O

DNA O
- O
binding O
activity O
was O
not O
increased O
by O
the O
addition O
of O
forskolin O
to O
RARE O
or O
RARE O
cells O
. O

However O
, O
in O
some O
of O
them O
either O
pattern O
may O
RARE O
or O
be O
exclusively O
present O
. O

Upon O
induction O
of O
ALL_CAP O
, O
viability O
increased O
2 O
- O
6 O
- O
RARE O
. O

In O
particular O
, O
Western O
, O
supershift O
, O
and O
promoter O
deletion O
analyses O
suggested O
a O
role O
RARE O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- I-GENE
beta I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
beta I-GENE
) O
binding O
site O
between O
- O
NUM O
and O
- O
NUM O
in O
RARE O
transcription O
of O
RARE I-GENE
- I-GENE
1 I-GENE
in O
monocytic O
cells O
. O

11 O
- O
RARE O
- O
ALL_CAP O
- O
NH2 O
and O
11 O
- O
RARE O
- O
ALL_CAP O
- O
NH2 O
establish O
that O
a O
simple O
RARE O
RARE O
can O
maintain O
an O
appropriate O
distance O
between O
three O
elements O
critical O
RARE O
recognition O
by O
the O
RARE O
enzyme O
' O
s O
peptide O
- O
binding O
site O
: O
a O
simple O
RARE O
- O
terminal O
amino O
group O
, O
a O
beta O
- O
RARE O
, O
and O
an O
epsilon O
- O
amino O
group O
or O
an O
RARE O
. O

The O
RARE O
- O
terminal O
ALL_CAP O
RARE O
is O
structurally O
related O
to O
the O
DNA O
- O
binding O
domain O
of O
the O
RARE I-GENE
transcription I-GENE
factor I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
. O

Cdc2 I-GENE
RARE O
- O
RARE O
with O
NUM I-GENE
in O
S O
. O
pombe O
cell O
lysates O
, O
although O
Cdc2 I-GENE
may O
not O
be O
the O
major O
catalytic O
RARE O
of O
a O
NUM I-GENE
kinase I-GENE
in O
vivo O
. O

RARE O
is O
known O
about O
the O
mechanism O
, O
but O
the O
availability O
of O
rapid O
RARE O
assays O
RARE O
monitoring O
immunoglobulin I-GENE
RARE O
would O
greatly O
aid O
the O
development O
of O
culture O
RARE O
RARE O
RARE O
B O
cells O
RARE O
RARE O
RARE O
the O
screening O
RARE O
individuals O
RARE O
in O
the O
process O
. O

Expression O
of O
the O
human I-GENE
heat I-GENE
shock I-GENE
protein I-GENE
70 I-GENE
gene I-GENE
( O
hsp70 I-GENE
) O
is O
RARE O
by O
various O
RARE O
of O
stress O
and O
by O
RARE O
. O

Of O
these O
proteins O
, O
five O
have O
previously O
been O
shown O
to O
be O
RARE O
RARE O
mitosis O
( O
RARE I-GENE
- I-GENE
microtubule I-GENE
associated I-GENE
protein I-GENE
- I-GENE
NUM I-GENE
, O
NUM I-GENE
, O
RARE I-GENE
factor I-GENE
NUM I-GENE
, O
NUM I-GENE
and O
RARE I-GENE
protein I-GENE
NUM I-GENE
RARE O
five O
are O
related O
to O
proteins O
postulated O
to O
have O
roles O
in O
mitosis O
( O
RARE I-GENE
- I-GENE
microtubule I-GENE
associated I-GENE
protein I-GENE
- I-GENE
NUM I-GENE
, O
Schizosaccharomyces I-GENE
pombe I-GENE
NUM I-GENE
, O
RARE I-GENE
protein I-GENE
, O
NUM I-GENE
and O
the O
RNA I-GENE
RARE I-GENE
NUM I-GENE
RARE O
and O
nine O
are O
related O
to O
transcription O
factors O
( O
NUM I-GENE
, O
negative I-GENE
RARE I-GENE
- I-GENE
factor I-GENE
2alpha I-GENE
, O
NUM I-GENE
, O
S O
. O
pombe O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
and O
two O
isoforms O
of O
NUM I-GENE
). O

Thus O
, O
depending O
on O
their O
location O
, O
RARE O
cross O
- O
links O
affected O
different O
steps O
in O
the O
initiation O
process O
. O

Activation O
of O
alpha I-GENE
4 I-GENE
beta I-GENE
1 I-GENE
with O
NUM I-GENE
/ I-GENE
16 I-GENE
inhibited O
the O
cytoplasmic O
RARE O
and O
cell O
migration O
but O
did O
not O
affect O
the O
pattern O
of O
RARE O
. O

RARE O
on O
two O
RARE O
measures O
- O
the O
National O
Adult O
RARE O
Test O
- O
RARE O
( O
ALL_CAP O
- O
R O
) O
and O
the O
RARE O
RARE O
from O
the O
RARE O
Adult O
RARE O
Scale O
- O
RARE O
( O
ALL_CAP O
- O
R O
)- O
showed O
strong O
correlations O
with O
level O
of O
education O
. O

L O
- O
RARE O
, O
a O
selective O
inhibitor O
of O
the O
inducible O
RARE I-GENE
oxide I-GENE
synthase I-GENE
, O
increases O
the O
mean O
systemic O
filling O
pressure O
, O
thereby O
RARE O
venous O
return O
, O
under O
these O
conditions O
. O

RESULTS O
: O
Of O
the O
29 O
patients O
who O
received O
concurrent O
chemotherapy O
and O
G I-GENE
- I-GENE
CSF I-GENE
, O
ten O
( O
NUM O
%; O
NUM O
% O
confidence O
interval O
RARE O
ALL_CAP O
], O
NUM O
. O
9 O
to O
54 O
. O
3 O
%) O
were O
believed O
to O
have O
clinically O
significant O
RARE O
toxicity O
. O

The O
different O
RARE I-GENE
RNA I-GENE
RARE I-GENE
generated O
upon O
RARE O
these O
mutants O
independently O
with O
core I-GENE
RNA I-GENE
polymerase I-GENE
( O
NUM O
beta O
RARE O
have O
shown O
RARE O
transcriptional O
activity O
in O
comparison O
to O
the O
enzyme O
containing O
wild I-GENE
- I-GENE
type I-GENE
RARE I-GENE
factor I-GENE
. O

These O
data O
are O
consistent O
with O
a O
model O
in O
which O
ALL_CAP I-GENE
- I-GENE
5 I-GENE
RARE O
a O
unique O
temporally O
and O
spatially O
restricted O
function O
in O
the O
RARE O
RARE O
and O
RARE O
. O

The O
RARE O
sequence O
encodes O
a O
protein O
of O
NUM O
amino O
RARE O
that O
is O
nearly O
identical O
to O
the O
previously O
reported O
protein O
sequence O
of O
human I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
. O

Here O
we O
characterize O
an O
S I-GENE
. I-GENE
cerevisiae I-GENE
NUM I-GENE
homolog I-GENE
( O
NUM I-GENE
) O
and O
present O
evidence O
that O
it O
associates O
in O
a O
complex O
with O
a O
NUM I-GENE
homolog I-GENE
, O
RARE I-GENE
. O

Shc I-GENE
stimulates O
Ras I-GENE
/ O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
through O
forming O
a O
complex O
with O
Grb2 I-GENE
RARE O
the O
RARE O
tyrosine O
( O
Y O
) O
RARE O
NUM O
. O

In O
contrast O
, O
NUM I-GENE
/ I-GENE
NUM I-GENE
Shc I-GENE
, O
but O
not O
NUM I-GENE
Shc I-GENE
, O
RARE O
the O
ALL_CAP I-GENE
- O
RARE O
c I-GENE
- I-GENE
myc I-GENE
RARE O
. O

The O
Ras I-GENE
guanine I-GENE
nucleotide I-GENE
- I-GENE
binding I-GENE
protein I-GENE
functions O
RARE O
a O
RARE O
switch O
in O
signalling O
RARE O
of O
protein I-GENE
- I-GENE
tyrosine I-GENE
kinases I-GENE
. O

We O
show O
that O
NUM I-GENE
and O
NUM I-GENE
have O
MEF2 I-GENE
- O
related O
DNA O
- O
binding O
RARE O
: O
NUM I-GENE
binds O
with O
the O
same O
RARE O
RARE O
MEF2 I-GENE
, O
ALL_CAP I-GENE
( I-GENE
T I-GENE
/ I-GENE
A I-GENE
) I-GENE
NUM I-GENE
, O
while O
NUM I-GENE
binds O
a O
more O
extended O
consensus O
sequence O
, O
ALL_CAP O
( O
T O
/ O
A O
) O
NUM O
. O

RARE O
I O
and O
II O
of O
B I-GENE
" I-GENE
are O
RARE O
upon O
assembly O
of O
the O
ALL_CAP I-GENE
- I-GENE
DNA I-GENE
complex I-GENE
, O
RARE O
determined O
by O
protein O
footprinting O
. O

RARE O
switch O
experiments O
reveal O
that O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
proteins I-GENE
containing O
either O
the O
leucine O
zipper O
or O
the O
activation O
domain O
of O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
are O
unable O
to O
stimulate O
the O
NUM I-GENE
promoter I-GENE
yet O
are O
fully O
capable O
of O
transactivating O
an O
artificial O
promoter O
RARE O
a O
high O
- O
affinity O
C I-GENE
/ I-GENE
EBP I-GENE
site I-GENE
. O

The O
similar O
RARE O
of O
NUM I-GENE
and O
NUM I-GENE
( O
NUM I-GENE
) O
mutations O
suggest O
that O
NUM I-GENE
and O
NUM I-GENE
have O
related O
, O
but O
not O
identical O
, O
functions O
in O
RARE O
the O
activity O
of O
the O
RARE O
transcription O
machinery O
in O
vivo O
. O

NUM I-GENE
, O
a O
new O
nucleus O
- O
localized O
RARE O
of O
the O
ALL_CAP I-GENE
- I-GENE
box I-GENE
protein I-GENE
family I-GENE
from O
RARE O
RARE O
. O

These O
activities O
are O
all O
required O
RARE O
RARE O
of O
cell O
growth O
by O
RARE I-GENE
- I-GENE
T I-GENE
and O
activate O
members O
of O
the O
MAP I-GENE
kinase I-GENE
family I-GENE
. O

A O
role O
RARE O
the O
small I-GENE
GTPase I-GENE
Rac I-GENE
in O
RARE I-GENE
RARE I-GENE
- I-GENE
T I-GENE
antigen I-GENE
- O
RARE O
activation O
of O
the O
serum O
response O
element O
and O
in O
cell O
transformation O
. O

RARE O
- O
activity O
curves O
from O
the O
RARE O
region O
of O
interest O
were O
used O
, O
after O
RARE O
to O
appropriate O
RARE O
procedures O
, O
to O
RARE O
the O
mean O
RARE O
transit O
time O
( O
ALL_CAP O
NUM O
) O
and O
the O
fraction O
of O
the O
test O
RARE O
retained O
in O
the O
stomach O
after O
NUM O
min O
( O
NUM O
). O

This O
study O
provides O
a O
direct O
RARE O
of O
a O
role O
RARE O
G I-GENE
RARE I-GENE
in O
mediating O
the O
agonist O
- O
RARE O
translocation O
of O
NUM I-GENE
and O
NUM I-GENE
in O
an O
RARE O
cellular O
RARE O
and O
demonstrates O
isoform O
RARE O
in O
the O
interaction O
of O
these O
RARE O
. O

Our O
results O
indicate O
that O
ALL_CAP O
- O
RARE O
repression O
of O
the O
ALL_CAP I-GENE
gene I-GENE
is O
due O
to O
binding O
of O
RARE O
RAR I-GENE
/ O
RXR I-GENE
to O
a O
novel O
negative O
ALL_CAP O
response O
element O
. O

RARE O
mutations O
of O
the O
five O
tyrosine O
residues O
in O
the O
cytoplasmic O
domain O
of O
the O
receptor O
were O
subsequently O
used O
to O
confirm O
our O
conclusions O
. O

We O
describe O
a O
novel O
method O
using O
Saccharomyces O
cerevisiae O
RARE O
detecting O
protein O
- O
RARE O
mutations O
in O
any O
gene O
of O
interest O
. O

RARE O
injury O
RARE O
preservation O
of O
human O
RARE O
with O
ALL_CAP O
and O
ALL_CAP O
solution O
. O

The O
RARE O
recorded O
responses O
consisted O
of O
an O
early O
NUM O
response O
in O
the O
RARE O
RARE O
muscle O
ipsilateral O
to O
the O
RARE O
of O
RARE O
, O
a O
bilateral O
RARE O
response O
( O
ipsilateral O
NUM O
and O
contralateral O
RARE O
) O
and O
a O
third O
, O
NUM O
response O
, O
in O
the O
ipsilateral O
RARE O
RARE O
muscle O
. O

The O
prognosis O
of O
RARE O
patients O
who O
received O
ALL_CAP O
was O
significantly O
better O
than O
that O
of O
NUM O
patients O
who O
received O
conventional O
therapy O
alone O
. O

( O
1994 O
, O
RARE O
. O

The O
RARE O
intensity O
of O
both O
RARE O
colonies O
and O
RARE O
of O
ALL_CAP O
transformants O
was O
RARE O
than O
that O
of O
the O
wild O
type O
. O

RARE O
RARE O
in O
RARE O
RARE O
involves O
the O
formation O
of O
RARE I-GENE
- I-GENE
S I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
carrier I-GENE
protein I-GENE
] I-GENE
from O
acetyl I-GENE
- I-GENE
S I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
carrier I-GENE
protein I-GENE
] I-GENE
and O
RARE O
, O
RARE O
to O
a O
RARE I-GENE
protein I-GENE
and O
its O
RARE O
that O
is O
coupled O
to O
delta O
mu O
RARE O
+ O
generation O
. O

The O
RARE I-GENE
peptide O
sequence O
shows O
a O
' O
leucine O
- O
zipper O
' O
RARE O
motif O
with O
limited O
homology O
to O
Fos I-GENE
/ O
Jun I-GENE
and O
ATF I-GENE
/ O
CREB I-GENE
proteins O
and O
several O
putative O
RARE O
sites O
. O

Here O
we O
report O
the O
cloning O
of O
the O
protein O
that O
binds O
to O
enhancer O
site O
III O
. O

Further O
support O
RARE O
a O
direct O
interaction O
of O
NUM I-GENE
, O
NUM I-GENE
and O
NUM I-GENE
RARE O
from O
the O
toxicity O
of O
strong O
NUM I-GENE
overexpression O
which O
is O
suppressed O
by O
RARE O
- O
overexpression O
of O
NUM I-GENE
or O
NUM I-GENE
. O

RARE O
needed O
RARE O
iron O
- O
regulated O
RARE O
of O
NUM I-GENE
were O
localized O
to O
a O
NUM O
bp O
region O
mapping O
2 O
. O
3 O
and O
2 O
. O
6 O
kb O
upstream O
of O
the O
ATG O
. O

A O
genetic O
screen O
applied O
to O
mutants O
in O
the O
branch O
site O
region O
shows O
that O
all O
positions O
in O
the O
RARE O
ALL_CAP O
sequence O
are O
important O
RARE O
intron O
recognition O
. O

RARE O
of O
ALL_CAP I-GENE
and O
RARE I-GENE
( O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
) O
activity O
in O
periodontal O
RARE O
. O

Comparison O
of O
the O
NUM I-GENE
sequence I-GENE
to O
other O
RARE O
proteins O
revealed O
NUM O
% O
homology O
with O
a O
RARE O
- O
binding O
protein O
and O
54 O
% O
homology O
with O
Drosophila I-GENE
cell I-GENE
RARE I-GENE
control I-GENE
protein I-GENE
( I-GENE
RARE I-GENE
) I-GENE
37 O
. O

A O
polypeptide O
encoded O
by O
the O
ALL_CAP O
16 O
RARE O
reading O
frame O
has O
sequence O
RARE O
to O
the O
catalytic O
domain O
of O
several O
receptor I-GENE
protein I-GENE
kinases I-GENE
from I-GENE
RARE I-GENE
including O
the O
S I-GENE
- I-GENE
receptor I-GENE
kinases I-GENE
implicated O
in O
the O
rejection O
of O
self O
- O
pollen O
in O
RARE O
species O
and O
the O
RARE I-GENE
gene I-GENE
product I-GENE
of I-GENE
RARE I-GENE
which O
confers O
resistance O
to O
a O
bacterial O
RARE O
. O

The O
RARE I-GENE
1 I-GENE
and O
RARE I-GENE
2 I-GENE
RARE O
of O
cDNA O
sequences O
were O
the O
most O
RARE O
among O
the O
NUM O
different O
RARE I-GENE
identified O
among O
about O
NUM O
peroxidase I-GENE
encoding I-GENE
RARE I-GENE
. O

RARE O
RARE O
including O
echocardiographic O
sequences O
, O
RARE O
RARE O
sequences O
, O
RARE O
- O
ray O
analysis O
, O
RARE O
, O
etc O
. O
is O
represented O
in O
the O
program O
. O

We O
report O
here O
that O
constitutively O
RARE O
NUM I-GENE
could O
activate O
NUM I-GENE
in O
the O
absence O
of O
RARE I-GENE
Ras I-GENE
. O

In O
Schizosaccharomyces O
pombe O
, O
the O
activity O
of O
the O
M O
- O
RARE O
- O
inducing O
Cdc2 I-GENE
/ O
NUM I-GENE
RARE O
- O
dependent O
kinase O
is O
inhibited O
by O
NUM I-GENE
and O
NUM I-GENE
tyrosine I-GENE
kinases I-GENE
, O
and O
activated O
by O
NUM I-GENE
and O
NUM I-GENE
tyrosine I-GENE
RARE I-GENE
. O

RARE O
response O
to O
RARE O
, O
RARE O
and O
RARE O
RARE O
RARE O
- O
RARE O
based O
RARE O
in O
normal O
subjects O
. O

4 O
. O
NUM O
+/- O
1 O
. O
54 O
mmol O
/ O
RARE O
, O
P O
< O
NUM O
. O
01 O
RARE O
and O
systolic O
ALL_CAP O
responses O
to O
intravenous O
norepinephrine O
and O
angiotensin I-GENE
II I-GENE
were O
significantly O
RARE O
on O
RARE O
than O
on O
RARE O
( O
P O
< O
NUM O
. O
02 O
and O
P O
< O
NUM O
. O
05 O
, O
respectively O
). O

The O
sequencing O
of O
RARE I-GENE
copies O
RARE O
along O
the O
RARE O
cluster O
revealed O
a O
complex O
pattern O
of O
RARE O
. O

The O
results O
indicate O
that O
DNA O
methylation O
, O
chromatin O
RARE O
, O
and O
RARE O
RARE O
an O
NUM I-GENE
site I-GENE
contribute O
to O
the O
highly O
restricted O
RARE O
of O
this O
RARE O
lineage O
specific O
gene O
. O

In O
gel O
mobility O
shift O
assays O
, O
factors O
present O
in O
nuclear O
extracts O
derived O
from O
differentiated O
RARE O
RARE O
to O
RARE O
RARE O
containing O
the O
E O
- O
box O
1 O
and O
E O
- O
box O
2 O
elements O
. O

Laboratory O
RARE O
: O
ALL_CAP O
of O
the O
RARE I-GENE
was O
high O
positive O
, O
chest O
RARE O
shows O
RARE O
bilateral O
RARE O
, O
ALL_CAP O
RARE O
shows O
a O
tumor O
RARE O
the O
foot O
of O
the O
RARE O
and O
RARE O
RARE O
shows O
low O
differentiated O
RARE O
carcinoma O
. O

Finally O
, O
we O
show O
that O
ALL_CAP I-GENE
complexes O
, O
RARE O
least O
partially O
, O
with O
Gbetagamma I-GENE
in O
vivo O
. O

NUM I-GENE
, O
RARE O
in O
Escherichia O
coli O
, O
showed O
specific O
binding O
to O
the O
palindrome O
2 O
DNA O
fragment O
but O
not O
to O
palindrome O
1 O
or O
mutant O
palindrome O
2 O
DNA O
fragments O
, O
suggesting O
specific O
binding O
of O
NUM I-GENE
to O
palindrome O
2 O
. O

Cyclin I-GENE
NUM I-GENE
is O
highly O
RARE O
in O
the O
immune O
RARE O
where O
immunologic O
tolerance O
subjects O
self O
- O
reactive O
lymphocytes O
to O
negative O
selection O
and O
RARE O
deletion O
via O
apoptosis O
. O

A O
sterol O
- O
regulated O
protease O
RARE O
release O
of O
the O
NH2 O
- O
terminal O
RARE O
of O
sterol I-GENE
regulatory I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
RARE I-GENE
) O
from O
cell O
membranes O
, O
thereby O
allowing O
them O
to O
RARE O
the O
nucleus O
and O
to O
stimulate O
transcription O
of O
genes O
involved O
in O
the O
uptake O
and O
RARE O
of O
cholesterol O
and O
fatty O
RARE O
. O

Thus O
, O
the O
P O
. O
RARE O
ALL_CAP O
and O
RARE I-GENE
promoters I-GENE
are O
arranged O
in O
a O
back O
- O
to O
- O
back O
orientation O
rather O
than O
the O
face O
- O
to O
- O
face O
orientation O
of O
the O
RARE O
and O
RARE I-GENE
promoters I-GENE
. O

Sequence O
analysis O
of O
RARE O
PCR O
products O
confirmed O
the O
presence O
of O
two O
different O
ALL_CAP I-GENE
- I-GENE
like I-GENE
DNA I-GENE
fragments I-GENE
, O
which O
were O
subsequently O
used O
RARE O
ALL_CAP I-GENE
- O
and O
ALL_CAP I-GENE
- I-GENE
specific I-GENE
RARE I-GENE
, O
respectively O
, O
to O
clone O
ALL_CAP I-GENE
fragments I-GENE
of O
2 O
. O
1 O
RARE O
( O
NUM O
) O
and O
2 O
. O
6 O
RARE O
( O
NUM O
). O

In O
contrast O
, O
the O
RARE O
RARE O
NUM O
ALL_CAP I-GENE
gene O
did O
not O
complement O
the O
ALL_CAP I-GENE
mutation I-GENE
of O
NUM O
efficiently O
. O

( O
3 O
) O
This O
effect O
occurs O
without O
removing O
RARE I-GENE
from O
the O
ALL_CAP O
. O

Is O
RARE O
RARE O
on O
the O
island O
of O
RARE O
( O
RARE O
RARE O
A O
human O
visceral O
case O
after O
living O
NUM O
years O
in O
RARE O
. O

RESULTS O
: O
Surprisingly O
, O
ALL_CAP I-GENE
blockade O
increased O
mortality O
after O
trauma O
( O
5 O
of O
11 O
ALL_CAP O
- O
NUM O
animals O
versus O
1 O
of O
9 O
vehicle O
animals O
; O
p O
= O
NUM O
. O
NUM O
) O
and O
depressed O
cardiac O
index O
and O
NUM O
delivery O
RARE O
72 O
hours O
( O
p O
< O
NUM O
. O
05 O
). O

This O
finding O
is O
the O
RARE O
example O
of O
utilization O
of O
RARE O
dinucleotide O
primer O
by O
an O
RNA I-GENE
polymerase I-GENE
. O

RARE O
NUM O
and O
dual O
- O
NUM O
images O
were O
RARE O
evaluated O
RARE O
image O
quality O
( O
ALL_CAP O
) O
on O
a O
five O
- O
point O
scale O
( O
NUM O
= O
RARE O
to O
4 O
= O
excellent O
). O

In O
a O
model O
of O
the O
RARE O
complex O
, O
the O
segment O
of O
NFAT I-GENE
RARE O
AP I-GENE
- I-GENE
1 I-GENE
is O
the O
Rel I-GENE
insert O
region O
( O
ALL_CAP O
RARE O
a O
feature O
that O
is O
RARE O
RARE O
its O
RARE O
in O
size O
and O
in O
sequence O
RARE O
members O
of O
the O
Rel I-GENE
transcription I-GENE
factor I-GENE
family I-GENE
. O

We O
thus O
conclude O
that O
the O
NFAT I-GENE
ALL_CAP I-GENE
plays O
an O
essential O
dual O
role O
in O
DNA O
recognition O
and O
cooperative O
binding O
to O
AP I-GENE
- I-GENE
1 I-GENE
family I-GENE
transcription I-GENE
factors I-GENE
. O

Thus O
, O
the O
association O
of O
NUM I-GENE
fragments I-GENE
may O
be O
maintained O
RARE O
cycles O
of O
RARE O
/ O
RARE O
of O
the O
NUM I-GENE
ALL_CAP I-GENE
. O

This O
RARE O
features O
a O
RARE O
I O
beta O
- O
RARE O
and O
has O
extensive O
hydrophobic O
contacts O
with O
the O
NUM I-GENE
binding O
surface O
. O

This O
protein O
can O
bind O
to O
a O
region O
of O
the O
promoter O
of O
an O
Arabidopsis I-GENE
light I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
a I-GENE
/ I-GENE
b I-GENE
protein I-GENE
gene I-GENE
, O
NUM I-GENE
RARE I-GENE
3 I-GENE
, O
which O
is O
necessary O
RARE O
its O
RARE O
by O
RARE I-GENE
. O

A O
patient O
of O
Group O
B O
had O
severe O
RARE O
CP O
with O
RARE O
, O
being O
unable O
to O
right O
RARE O
trunk O
and O
neck O
. O

RARE O
movement O
of O
the O
RARE O
upper O
limb O
in O
a O
case O
of O
the O
right O
RARE O
hemorrhage O

It O
has O
RARE O
been O
shown O
that O
ALL_CAP O
IE1 I-GENE
/ O
IE2 I-GENE
can O
independently O
transactivate O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
. O

ALL_CAP I-GENE
and O
NUM I-GENE
- O
independent O
RARE O
of O
HIV I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
by O
the O
Tat I-GENE
protein I-GENE
in O
the O
presence O
of O
human O
RARE O
IE1 I-GENE
/ O
IE2 I-GENE
. O

RARE O
chain O
enzyme O
activity O
was O
normal O
. O

Children O
' O
s O
RARE O
and O
RARE O
RARE O
RARE O
RARE O
1 O
( O
RARE O
= O
NUM O
, O
aged O
2 O
- O
3 O
years O
) O
were O
considered O
predictors O
of O
future O
RARE O
, O
assessed O
using O
new O
RARE O
and O
RARE O
measures O
. O

RARE I-GENE
Csk I-GENE
was O
associated O
with O
several O
RARE O
, O
some O
of O
which O
were O
RARE O
with O
the O
Csk I-GENE
NUM I-GENE
domain I-GENE
. O

Thus O
, O
our O
studies O
suggest O
that O
ALL_CAP O
- O
RARE O
activation O
of O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
activity O
is O
RARE O
by O
the O
nuclear O
translocation O
of O
the O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
transcription I-GENE
factor I-GENE
, O
which O
is O
RARE O
by O
IkappaBalpha I-GENE
serine O
RARE O
and O
RARE O
, O
but O
also O
by O
a O
still O
RARE O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
- O
independent O
RARE O
. O

One O
P1 O
genomic O
clone O
and O
RARE O
subsequent O
RARE O
RARE O
were O
isolated O
and O
analyzed O
RARE O
the O
RARE O
- O
intron O
organization O
of O
the O
RARE I-GENE
gene I-GENE
. O

FN I-GENE
- O
RARE O
c I-GENE
- I-GENE
Src I-GENE
ALL_CAP I-GENE
activity O
was O
RARE O
by O
wild O
type O
FAK I-GENE
RARE O
, O
whereas O
FN I-GENE
- O
RARE O
activation O
of O
ERK2 I-GENE
was O
blocked O
by O
RARE O
of O
the O
c I-GENE
- I-GENE
Src I-GENE
binding I-GENE
site I-GENE
RARE I-GENE
- I-GENE
NUM I-GENE
mutant I-GENE
of O
FAK I-GENE
. O

A O
RARE O
new O
RARE O
, O
4 O
- O
ALL_CAP O
/ O
ALL_CAP O
- O
ALL_CAP O
RARE O
resin O
, O
has O
shown O
remarkable O
adhesive O
properties O
RARE O
a O
bone O
RARE O
in O
vivo O
. O

RARE O
with O
RARE O
predictions O
, O
the O
most O
RARE O
children O
perceived O
low O
control O
over O
RARE O
and O
separation O
, O
and O
RARE O
by O
RARE O
control O
. O

Each O
sample O
was O
analysed O
RARE O
RARE O
RARE O
possible O
, O
and O
RARE O
NUM O
, O
NUM O
, O
NUM O
and O
120 O
min O
after O
sampling O
. O

We O
also O
review O
the O
role O
of O
RARE O
in O
the O
formation O
of O
complex O
molecules O
in O
RARE O
RARE O
RARE O
. O

Like O
the O
RARE O
of O
the O
RARE O
reaction O
( O
HR O
) O
produced O
by O
E O
. O
RARE O
( O
RARE O
) O
and O
E O
. O
RARE O
( O
RARE O
RARE O
the O
deduced O
NUM O
- O
kDa O
protein O
does O
not O
possess O
a O
typical O
signal O
sequence O
, O
but O
it O
contains O
a O
putative O
membrane O
- O
spanning O
domain O
. O

Molecular O
characterization O
and O
RARE O
of O
the O
RARE I-GENE
RARE I-GENE
RARE I-GENE
gene I-GENE
, O
which O
encodes O
an O
RARE O
of O
the O
RARE O
reaction O
. O

The O
mRNA O
from O
this O
gene O
, O
termed O
NUM I-GENE
, O
is O
ubiquitously O
RARE O
, O
but O
strongly O
so O
in O
RARE O
and O
skeletal O
muscle O
. O

RARE O
was O
maintained O
with O
isoflurane O
( O
ALL_CAP O
RARE O
N2O O
/ O
NUM O
inhalation O
. O

They O
observed O
depressed O
protein I-GENE
C I-GENE
activity O
that O
significantly O
( O
p O
< O
NUM O
. O
005 O
) O
increased O
and O
became O
normal O
immediately O
after O
hemodialysis O
while O
factor I-GENE
X I-GENE
and O
factor I-GENE
VII I-GENE
increased O
( O
p O
< O
NUM O
. O
01 O
; O
p O
< O
NUM O
. O
05 O
) O
despite O
RARE O
together O
with O
amount O
of O
serum O
lipoprotein O
( O
a O
). O

We O
present O
a O
case O
of O
type O
II O
RARE O
in O
a O
patient O
whose O
diagnosis O
had O
been O
previously O
RARE O
, O
and O
who O
had O
previously O
been O
RARE O
with O
rheumatoid O
arthritis O
and O
later O
RARE O
. O

These O
data O
provide O
evidence O
that O
the O
2 I-GENE
. I-GENE
NUM I-GENE
- I-GENE
kb I-GENE
ALL_CAP I-GENE
is O
an O
intron O
of O
the O
ALL_CAP I-GENE
pre I-GENE
- I-GENE
mRNA I-GENE
with O
a O
unique O
branch O
point O
. O

The O
altered O
amino O
acid O
residues O
of O
the O
RARE O
mutant I-GENE
NUM I-GENE
polypeptides I-GENE
clustered O
within O
three O
separate O
regions O
referred O
to O
RARE O
region O
I O
( O
residues O
NUM O
to O
NUM O
RARE O
region O
II O
( O
residues O
NUM O
to O
91 O
RARE O
and O
C O
- O
terminal O
region O
III O
( O
residues O
122 O
to O
NUM O
). O

Rep I-GENE
- O
Rep I-GENE
protein O
interaction O
was O
confirmed O
in O
vitro O
through O
RARE O
experiments O
with O
a O
bacterially O
RARE O
RARE I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- O
NUM I-GENE
fusion O
protein O
in O
combination O
with O
RARE O
NUM O
] O
methionine O
- O
labeled O
NUM I-GENE
synthesized O
in O
a O
coupled O
in O
vitro O
transcription O
- O
translation O
RARE O
. O

The O
C O
- O
ALL_CAP O
also O
was O
compared O
with O
RARE O
arterial O
RARE O
( O
ALL_CAP O
; O
C O
- O
ALL_CAP O
followed O
by O
RARE O
RARE O
) O
and O
RARE O
ethanol O
injection O
therapy O
( O
ALL_CAP O
). O

RARE O
patients O
with O
New O
York O
RARE O
Association O
class O
II O
RARE O
RARE O
failure O
were O
enrolled O
in O
a O
double O
- O
blind O
, O
cross O
- O
over O
study O
. O

The O
main O
advantages O
of O
RARE O
- O
ALL_CAP O
analysis O
are O
: O
( O
1 O
) O
RARE O
acquisition O
of O
many O
RARE O
; O
( O
2 O
) O
simultaneous O
collection O
of O
several O
RARE O
RARE O
one O
recording O
site O
; O
( O
3 O
) O
possibility O
to O
analyze O
not O
only O
low O
threshold O
RARE O
; O
( O
4 O
) O
less O
RARE O
in O
the O
selection O
of O
RARE O
and O
( O
5 O
) O
the O
reproducibility O
of O
the O
results O
that O
allow O
the O
same O
reference O
values O
to O
be O
used O
in O
different O
laboratories O
. O

We O
also O
demonstrate O
that O
RARE O
RARE O
are O
quite O
stable O
when O
precipitated O
with O
ethanol O
and O
RARE O
in O
water O
. O

Transfection O
experiments O
using O
RARE O
RARE O
with O
a O
reporter O
RARE O
containing O
the O
RARE I-GENE
promoter I-GENE
sequence I-GENE
showed O
significant O
inhibition O
of O
transcription O
when O
compared O
with O
a O
control O
RARE O
ALL_CAP O
. O

Thus O
, O
an O
increase O
in O
plasma I-GENE
ALL_CAP I-GENE
and O
a O
shift O
from O
adrenal O
RARE O
and O
RARE O
steroid O
RARE O
towards O
cortisol O
RARE O
may O
be O
endocrine O
markers O
RARE O
progression O
of O
the O
RARE O
in O
patients O
with O
HIV O
- O
infection O
. O

In O
several O
studies O
the O
ALL_CAP O
has O
shown O
evidence O
of O
reliability O
and O
validity O
. O

RARE O
produces O
an O
additional O
reduction O
of O
RARE O
pressure O
( O
IOP O
) O
when O
used O
in O
combination O
with O
RARE O
, O
RARE O
, O
RARE O
and O
RARE O
. O

These O
results O
suggest O
that O
dietary O
RARE O
phospholipids O
may O
be O
a O
valuable O
RARE O
to O
RARE O
RARE O
RARE O
liver O
RARE O
and O
serum O
cholesterol O
without O
any O
adverse O
effects O
. O

Using O
various O
techniques O
, O
we O
have O
undertaken O
a O
systematic O
analysis O
of O
the O
RARE O
TATA O
- O
less O
human I-GENE
DNA I-GENE
polymerase I-GENE
beta I-GENE
( O
beta I-GENE
- I-GENE
pol I-GENE
) O
gene O
promoter O
. O

RARE O
RARE O
RARE O
in O
NUM I-GENE
:: O
lacZ I-GENE
mutants I-GENE
had O
an O
RARE O
RARE O
- O
lower O
affinity O
and O
twofold O
- O
lower O
Vmax O
than O
in O
the O
parental O
RARE O
. O

Transient O
overexpression O
of O
c I-GENE
- I-GENE
Jun I-GENE
RARE O
RARE I-GENE
- I-GENE
C I-GENE
RARE O
in O
RARE O
ALL_CAP O
and O
in O
NUM O
, O
an O
established O
fibroblast O
cell O
line O
. O

Inhibition O
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
by O
cyclic O
AMP O
agonists O
causes O
apoptosis O
of O
v I-GENE
- I-GENE
abl I-GENE
- O
transformed O
cells O
. O

Previous O
studies O
have O
indicated O
that O
a O
hamster O
cell O
line O
( O
NUM O
) O
with O
a O
point O
mutation O
in O
the O
ALL_CAP I-GENE
( I-GENE
II I-GENE
) I-GENE
NUM I-GENE
/ O
NUM I-GENE
( O
ALL_CAP I-GENE
( I-GENE
II I-GENE
) I-GENE
NUM I-GENE
) O
gene O
shows O
RARE O
- O
RARE O
RARE O
of O
a O
subset O
of O
genes O
and O
RARE O
in O
RARE O
G1 O
RARE O
NUM O
. O
5 O
degrees O
C O
. O

We O
show O
here O
that O
the O
protein O
kinase O
NUM I-GENE
can O
induce O
reporter O
gene O
RARE O
from O
the O
RARE I-GENE
RARE I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
) O
promoter O
, O
a O
genetic O
marker O
that O
is O
activated O
RARE O
in O
vivo O
hypertrophy O
. O

Overexpression O
of O
NUM I-GENE
in O
C O
. O
RARE O
leads O
to O
RARE O
RARE O
growth O
in O
the O
form O
of O
extended O
RARE O
in O
liquid O
and O
on O
solid O
media O
. O

RARE O
parameters O
: O
RARE O
rate O
( O
HR O
RARE O
arterial O
RARE O
pressure O
( O
ALL_CAP O
) O
and O
arterial O
NUM O
saturation O
( O
SaO2 O
) O
monitored O
by O
RARE O
were O
measured O
RARE O
the O
procedure O
. O

To O
determine O
if O
RARE O
, O
when O
established O
, O
would O
compete O
with O
ALL_CAP O
when O
both O
were O
reinforced O
, O
RARE O
was O
then O
RARE O
. O

The O
RARE O
in O
one O
of O
the O
RARE O
RARE O
was O
treated O
RARE O
hepatitis O
of O
unidentified O
etiology O
in O
an O
RARE O
RARE O
four O
years O
RARE O
. O

Both O
quantitative O
and O
qualitative O
analysis O
of O
individual O
RARE O
RARE O
of O
RARE O
' O
s O
nucleus O
RARE O
RARE O
RARE O
of O
external O
part O
of O
RARE O
nucleus O
of O
RARE O
was O
performed O
in O
RARE O
normal O
individuals O
. O

We O
have O
tested O
this O
RARE O
by O
carrying O
out O
circular O
RARE O
( O
CD O
) O
and O
NMR O
experiments O
on O
the O
RARE I-GENE
domain I-GENE
and O
five O
truncated O
proteins O
. O

RARE O
cloning O
has O
already O
produced O
the O
sequences O
of O
more O
than O
70 O
human O
genes O
associated O
with O
specific O
diseases O
. O

RARE O
RARE O
RARE I-GENE
element I-GENE
binding I-GENE
factors I-GENE
( O
RARE I-GENE
RARE O
belonging O
to O
a O
specific O
class O
of O
basic I-GENE
- I-GENE
region I-GENE
leucine I-GENE
zipper I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
transcription I-GENE
factors I-GENE
, O
have O
been O
isolated O
in O
a O
number O
of O
RARE O
. O

The O
NUM O
- O
day O
mortality O
in O
the O
CPB O
group O
and O
the O
non O
- O
CPB O
group O
were O
20 O
% O
and O
4 O
. O
6 O
%, O
respectively O
which O
was O
not O
statistically O
significant O
( O
p O
= O
NUM O
. O
06 O
). O

As O
opposed O
to O
in O
vitro O
RARE O
- O
precipitation O
studies O
, O
the O
yeast O
two O
- O
RARE O
screen O
reveals O
in O
vivo O
protein O
- O
protein O
interactions O
. O

This O
association O
appears O
to O
be O
RARE O
by O
Src I-GENE
- O
NUM I-GENE
domain O
, O
because O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
can O
be O
precipitated O
by O
a O
GST I-GENE
- O
Src I-GENE
- O
NUM I-GENE
affinity O
RARE O
. O

NUM I-GENE
autophosphorylation O
and O
activation O
of O
p38 I-GENE
was O
also O
observed O
following O
coexpression O
of O
NUM I-GENE
with O
NUM I-GENE
, O
but O
not O
with O
NUM I-GENE
. O

An O
RARE O
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
variant O
was O
identified O
that O
lacks O
RARE O
4 O
encoding O
the O
RARE I-GENE
domain O
, O
and O
may O
mediate O
RARE O
adhesion O
to O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
without O
adhesion O
to O
the O
alternate O
receptor O
, O
L I-GENE
- I-GENE
selectin I-GENE
. O

In O
summary O
, O
the O
data O
establish O
that O
the O
previously O
reported O
human I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
does O
indeed O
encode O
the O
human O
homologue O
of O
mouse I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
despite O
gross O
RARE O
in O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
C O
- O
terminal O
RARE O
. O

We O
have O
used O
a O
site O
- O
directed O
mutagenesis O
approach O
to O
examine O
how O
the O
RARE O
and O
hydroxy O
( O
RARE O
/ O
RARE O
) O
amino O
acid O
residues O
in O
RARE O
influence O
core O
- O
glycosylation O
efficiency O
. O

ALL_CAP O
ALL_CAP O
METHODS O
: O
The O
authors O
analyzed O
NUM O
persons O
RARE O
submitted O
to O
surgery O
( O
after O
8 O
years O
and O
4 O
months O
, O
RARE O
a O
mean O
RARE O
NUM O
to O
highly O
selective O
vagotomy O
, O
and O
10 O
to O
RARE O
or O
selective O
vagotomy O
RARE O
RARE O
drainage O
. O

This O
region O
does O
not O
contain O
an O
RARE O
TATA O
element O
, O
indicating O
that O
transcription O
of O
the O
RARE I-GENE
gene I-GENE
is O
RARE O
by O
a O
TATA O
- O
less O
promoter O
. O

SRE O
activity O
is O
dependent O
upon O
the O
activation O
by O
RARE O
of O
a O
RARE O
complex O
factor O
; O
included O
among O
the O
RARE O
complex O
factors O
is O
Elk I-GENE
- I-GENE
1 I-GENE
. O

Serum I-GENE
RARE I-GENE
phosphatase I-GENE
activity O
, O
bone O
mass O
measurements O
, O
dual O
energy O
RARE O
- O
ray O
RARE O
analysis O
of O
mineral O
density O
, O
and O
mechanical O
testing O
values O
in O
RARE O
and O
RARE O
of O
the O
- O
D O
RARE O
animals O
did O
not O
significantly O
differ O
from O
those O
in O
+ O
D O
RARE O
animals O
. O

The O
RARE I-GENE
LHR I-GENE
cDNA I-GENE
displayed O
NUM O
- O
94 O
% O
overall O
sequence O
homology O
with O
the O
other O
mammalian I-GENE
LHR I-GENE
cDNAs I-GENE
. O

In O
conclusion O
, O
RARE I-GENE
RARE I-GENE
LHR I-GENE
seems O
to O
lack O
the O
sequence O
corresponding O
to O
RARE O
10 O
of O
the O
LHR I-GENE
gene I-GENE
in O
other O
mammalian O
species O
. O

In O
RARE I-GENE
- I-GENE
4 I-GENE
mutants I-GENE
, O
VA O
motor O
neurons O
RARE O
the O
pattern O
of O
synaptic O
input O
normally O
RARE O
RARE O
their O
RARE O
RARE O
cells O
, O
the O
ALL_CAP O
motor O
neurons O
; O
the O
RARE O
of O
normal O
input O
to O
the O
RARE O
produces O
a O
distinctive O
RARE O
movement O
defect O
. O

RARE O
irradiation O
was O
carried O
out O
with O
a O
RARE O
ALL_CAP O
RARE O
device O
and O
usually O
NUM O
. O
5 O
Gy O
was O
given O
in O
three O
fractions O
RARE O
weekly O
. O

No O
patient O
in O
group O
2 O
developed O
ALL_CAP O
( O
P O
= O
NUM O
. O
NUM O
versus O
group O
1 O
). O

Sequence O
comparison O
of O
the O
NUM O
. O
38 O
kb O
promoter O
sequence O
with O
the O
promoters O
of O
the O
RARE I-GENE
- I-GENE
E I-GENE
gene O
and O
NUM I-GENE
ALL_CAP I-GENE
genes I-GENE
revealed O
several O
homologous O
motifs O
, O
suggesting O
that O
genes O
encoding O
the O
snRNP O
RARE O
may O
be O
RARE O
regulated O
. O

METHODS O
: O
The O
responses O
of O
a O
NUM O
- O
year O
- O
old O
woman O
with O
complex O
regional O
pain O
RARE O
type O
I O
( O
reflex O
sympathetic O
RARE O
) O
to O
a O
thermal O
RARE O
were O
evaluated O
before O
and O
after O
RARE O
RARE O
RARE O
. O

More O
recently O
, O
however O
, O
a O
number O
of O
RARE O
such O
RARE O
the O
successful O
use O
of O
the O
inhaled O
steroid O
RARE O
and O
oral O
dexamethasone O
have O
reinforced O
the O
RARE O
RARE O
using O
steroids O
. O

A O
ALL_CAP I-GENE
transcriptional I-GENE
fusion I-GENE
to O
the O
putative O
ALL_CAP I-GENE
promoter I-GENE
showed O
low O
- O
level O
RARE O
in O
wild O
- O
type O
cells O
grown O
on O
one O
- O
carbon O
( O
C1 O
) O
compounds O
and O
RARE O
detectable O
RARE O
in O
cells O
grown O
on O
RARE O
. O

In O
ALL_CAP O
- O
RARE O
Sf9 O
cells O
, O
RARE O
transcription O
initiation O
is O
detected O
from O
only O
two O
upstream O
ALL_CAP O
sites O
and O
not O
from O
three O
RARE O
ALL_CAP O
sites O
. O

Mutation O
of O
nucleotides O
adjacent O
to O
the O
AP I-GENE
- I-GENE
1 I-GENE
cis I-GENE
- I-GENE
response I-GENE
elements I-GENE
had O
RARE O
effect O
on O
RARE O
- O
activation O
. O

The O
close O
RARE O
of O
the O
two O
RARE I-GENE
Y I-GENE
receptor I-GENE
genes I-GENE
suggests O
that O
they O
have O
evolved O
from O
a O
gene O
duplication O
event O
with O
the O
small O
intron O
RARE O
the O
coding O
sequence O
of O
the O
NUM I-GENE
gene I-GENE
being O
converted O
into O
a O
RARE O
sequence O
within O
the O
NUM I-GENE
gene I-GENE
, O
while O
the O
reverse O
RARE O
sequence O
was O
utilized O
RARE O
an O
RARE O
RARE O
5 O
' O
RARE O
RARE O
the O
NUM I-GENE
gene I-GENE
. O

The O
mammalian I-GENE
RARE I-GENE
3 I-GENE
- I-GENE
kinases I-GENE
( O
NUM I-GENE
) O
NUM I-GENE
, I-GENE
beta I-GENE
, I-GENE
and I-GENE
delta I-GENE
form O
RARE O
with O
Src I-GENE
homology I-GENE
2 I-GENE
( O
NUM I-GENE
) O
domain O
- O
containing O
RARE O
such O
RARE O
NUM I-GENE
or O
p55 I-GENE
( O
ALL_CAP I-GENE
). O

In O
the O
studies O
reported O
here O
, O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
NUM I-GENE
gene I-GENE
was O
isolated O
and O
the O
transcription O
initiation O
sites O
were O
mapped O
. O

Localization O
of O
the O
RARE O
response O
element O
by O
5 O
'- O
deletion O
analysis O
and O
site O
- O
directed O
mutagenesis O
revealed O
a O
cis O
- O
acting O
binding O
site O
RARE O
activated O
STAT I-GENE
complexes O
. O

Insulin I-GENE
RARE O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
( O
MEK I-GENE
RARE O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
and O
casein I-GENE
kinase I-GENE
in O
the O
cell O
nucleus O
: O
a O
possible O
role O
in O
the O
RARE O
of O
gene O
RARE O
. O

Sequencing O
of O
the O
three O
RARE I-GENE
- I-GENE
3 I-GENE
alleles I-GENE
showed O
that O
two O
apparent O
RARE O
alleles O
encode O
a O
nonsense O
mutation O
before O
the O
zinc O
RARE O
and O
a O
missense O
mutation O
in O
the O
fourth O
zinc O
finger O
that O
changes O
a O
RARE O
RARE O
to O
a O
tyrosine O
. O

Pax I-GENE
- I-GENE
3 I-GENE
is O
a O
paired I-GENE
- I-GENE
type I-GENE
RARE I-GENE
gene I-GENE
that O
is O
specifically O
RARE O
in O
the O
dorsal O
and O
posterior O
RARE O
tube O
. O

Instead O
, O
they O
contained O
RARE O
cells O
that O
express O
RARE O
marker O
proteins O
such O
RARE O
RARE I-GENE
and O
RARE I-GENE
- I-GENE
related I-GENE
protein I-GENE
1 I-GENE
. O

These O
mutations O
create O
stop O
codons O
in O
RARE O
7 O
and O
8 O
, O
respectively O
, O
and O
probably O
result O
in O
truncated O
proteins O
RARE O
ALL_CAP O
- O
RARE O
or O
RARE O
RARE O
. O

Here O
, O
a O
case O
of O
RARE O
' O
s O
RARE O
is O
presented O
that O
was O
initially O
diagnosed O
because O
of O
dental O
RARE O
, O
and O
long O
- O
term O
treatment O
of O
RARE O
' O
s O
patients O
is O
discussed O
. O

Cloning O
and O
characterization O
of O
a O
cDNA O
encoding O
a O
RARE I-GENE
- I-GENE
type I-GENE
RNA I-GENE
polymerase I-GENE
from O
the O
RARE O
RARE O
RARE O
RARE O
. O

Similarly O
, O
overexpression O
of O
increasing O
concentration O
of O
COUP I-GENE
- I-GENE
TFI I-GENE
, O
but O
not O
COUP I-GENE
- I-GENE
TFI I-GENE
NUM I-GENE
, O
can O
RARE O
the O
silencing O
activity O
of O
the O
RARE O
RARE I-GENE
. O

These O
RARE O
amino O
RARE O
are O
part O
of O
an O
RARE O
helix O
that O
is O
highly O
RARE O
among O
nuclear I-GENE
hormone I-GENE
receptors I-GENE
and O
contains O
the O
core O
domain O
of O
the O
RARE O
- O
dependent O
RARE O
function O
, O
ALL_CAP O
- O
2 O
. O

Surprisingly O
, O
the O
RXR I-GENE
- O
specific O
RARE O
9 O
- O
cis O
- O
retinoic O
acid O
RARE O
binding O
of O
SRC I-GENE
- I-GENE
1 I-GENE
to O
the O
RXR I-GENE
RARE I-GENE
of O
the O
ALL_CAP O
- O
RARE O
RARE O
. O

In O
RARE O
, O
both O
mechanisms O
are O
readily O
observed O
. O

Based O
on O
the O
occurrence O
of O
several O
transcription O
signals O
in O
the O
RARE I-GENE
RARE I-GENE
promoter I-GENE
region I-GENE
and O
strong O
amino O
acid O
sequence O
identities O
( O
about O
NUM O
%) O
between O
RARE I-GENE
ALL_CAP I-GENE
and O
the O
ALL_CAP I-GENE
RARE I-GENE
proteins I-GENE
of O
two O
Bacillus O
RARE O
., O
we O
propose O
a O
regulatory O
mechanism O
involving O
transcriptional O
RARE O
to O
control O
RARE I-GENE
gene I-GENE
RARE O
in O
RARE O
. O

RARE O
respiratory O
responses O
to O
a O
RARE O
closed O
- O
circuit O
breathing O
apparatus O
. O

Measurement O
of O
the O
time O
constant O
of O
VO2 O
and O
oxygen O
pulse O
RARE O
constant O
work O
rate O
exercise O
are O
useful O
RARE O
the O
objective O
evaluation O
of O
the O
training O
effect O
of O
patients O
with O
COPD O
. O

Characterization O
of O
NUM I-GENE
repeat O
random O
PCR O
markers O
RARE O
mapping O
the O
chicken O
genome O
. O

A O
reversed O
- O
RARE O
high O
- O
performance O
liquid O
chromatographic O
( O
HPLC O
) O
method O
RARE O
the O
determination O
of O
cocaine O
metabolites O
produced O
in O
vitro O
by O
serum I-GENE
and I-GENE
liver I-GENE
RARE I-GENE
is O
described O
. O

Mutational O
studies O
provide O
evidence O
to O
this O
end O
and O
indicate O
that O
the O
RARE O
chains O
of O
RARE O
4 O
. O
2 O
make O
specific O
contacts O
with O
the O
nucleotides O
RARE O
- O
NUM O
. O

It O
is O
concluded O
that O
RARE O
is O
a O
highly O
useful O
agent O
in O
ALL_CAP O
. O

Three O
different O
techniques O
of O
ALL_CAP O
analysis O
were O
used O
in O
the O
study O
: O
1 O
) O
fast O
RARE O
transformation O
( O
ALL_CAP O
) O
of O
ALL_CAP O
in O
a O
broad O
band O
, O
2 O
) O
developed O
by O
us O
RARE O
method O
of O
non O
- O
RARE O
expansion O
of O
the O
EEG O
curves O
taking O
into O
account O
their O
shape O
, O
3 O
) O
factor O
analysis O
of O
the O
ALL_CAP O
spectral O
RARE O
. O

RARE O
, O
NUM I-GENE
histone I-GENE
NUM I-GENE
kinase O
activity O
increases O
in O
the O
former O
, O
but O
not O
in O
the O
latter O
cell O
lines O
, O
hence O
suggesting O
a O
role O
RARE O
this O
protein O
in O
radiation O
- O
RARE O
cell O
RARE O
. O

Using O
PRL I-GENE
- I-GENE
R I-GENE
RARE O
both O
in O
the O
N O
- O
terminal O
or O
C O
- O
terminal O
regions O
of O
the O
RARE O
receptor O
RARE O
the O
possibility O
of O
a O
cleaved O
fragment O
which O
could O
have O
been O
subsequently O
RARE O
into O
the O
nucleus O
. O

Thus O
, O
the O
B O
- O
S O
mutant O
does O
not O
mimic O
efficiently O
the O
RARE I-GENE
RARE I-GENE
, O
and O
long O
- O
range O
and O
/ O
or O
second O
- O
layer O
effects O
, O
not O
easily O
RARE O
from O
visual O
RARE O
of O
three O
- O
dimensional O
RARE O
, O
need O
to O
be O
taken O
into O
account O
RARE O
RARE O
a O
true O
" O
RARE O
- O
like O
" O
mutant O
of O
cytosolic I-GENE
ALL_CAP I-GENE
. O

Transcription O
of O
these O
genes O
was O
also O
elevated O
in O
gut O
and O
RARE O
RARE O
RARE O
, O
but O
mRNA O
levels O
in O
these O
tissues O
were O
lower O
than O
in O
liver O
. O

RARE O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
was O
developed O
to O
RARE O
ALL_CAP O
Ca O
: O
P O
RARE O
with O
clinical O
data O
to O
improve O
RARE O
Ca O
and O
P O
administration O
. O

A O
similar O
RARE O
was O
assembled O
from O
the O
two O
RARE O
of O
the O
molecule O
RARE O
separately O
in O
different O
bacteria O
and O
RARE O
together O
. O

The O
conditions O
RARE O
obtaining O
RARE O
dioxide O
from O
the O
RARE O
RARE O
RARE O
and O
oxygen O
and O
applying O
this O
to O
a O
surgical O
RARE O
RARE O
of O
the O
type O
NUM O
by O
the O
plasma O
RARE O
chemical O
RARE O
deposition O
method O
have O
been O
determined O
. O

All O
RARE O
genes O
were O
RARE O
and O
RARE O
. O

We O
analysed O
two O
regions O
involved O
in O
NUM I-GENE
/ O
S I-GENE
gene I-GENE
transcription O
of O
the O
ALL_CAP O
RARE O
RARE O
: O
the O
diverged O
TATA O
box O
and O
a O
putative O
RARE O
element O
. O

Indeed O
the O
predicted O
folding O
of O
the O
5 O
' O
and O
3 O
'- O
RARE O
regions O
revealed O
patterns O
of O
RARE O
and O
loop O
RARE O
RARE O
RARE O
all O
RARE O
- O
RARE O
RARE O
suggesting O
a O
RARE O
selection O
RARE O
preservation O
of O
essential O
RNA O
secondary O
RARE O
which O
could O
be O
involved O
in O
translational O
control O
and O
replication O
. O

ALL_CAP I-GENE
acts O
primarily O
by O
means O
of O
RARE O
domain O
ALL_CAP O
- O
1 O
, O
whereas O
cAMP O
acts O
via O
RARE O
domain O
ALL_CAP O
- O
2 O
of O
the O
ER I-GENE
. O

To O
determine O
which O
region O
of O
ALL_CAP I-GENE
is O
essential O
RARE O
the O
inhibition O
of O
cell O
division O
, O
we O
constructed O
a O
series O
of O
N O
- O
terminal O
and O
C O
- O
terminal O
deletions O
of O
ALL_CAP I-GENE
and O
a O
series O
of O
alanine O
substitution O
mutants O
. O

We O
have O
inactivated O
Krox I-GENE
- I-GENE
20 I-GENE
by O
homologous O
RARE O
in O
ES O
cells O
and O
demonstrated O
that O
the O
mutation O
leads O
to O
the O
deletion O
of O
NUM O
and O
NUM O
. O

Recently O
we O
have O
performed O
a O
detailed O
analysis O
of O
specific O
RARE O
populations O
affected O
by O
the O
mutation O
which O
RARE O
new O
light O
on O
the O
role O
of O
Krox I-GENE
- I-GENE
20 I-GENE
in O
the O
RARE O
and O
on O
the O
physiological O
consequences O
of O
its O
inactivation O
. O

The O
most O
important O
one O
among O
them O
is O
RARE O
A O
, O
which O
is O
a O
selective O
immunosuppressive O
drug O
. O

Consistent O
with O
its O
role O
in O
p53 I-GENE
ubiquitination O
, O
NUM I-GENE
- I-GENE
AP I-GENE
was O
found O
both O
in O
the O
nucleus O
and O
cytosol O
, O
while O
RARE I-GENE
- I-GENE
4 I-GENE
was O
found O
only O
in O
the O
cytosol O
. O

ALL_CAP I-GENE
also O
RARE O
transient O
tyrosine O
RARE O
of O
RARE I-GENE
adhesion I-GENE
kinase I-GENE
( O
NUM I-GENE
( O
FAK I-GENE
RARE O
a O
cytosolic I-GENE
tyrosine I-GENE
kinase I-GENE
that O
localizes O
in O
RARE O
adhesions O
, O
and O
of O
the O
RARE I-GENE
- I-GENE
associated I-GENE
protein I-GENE
paxillin I-GENE
. O

Using O
a O
conditional O
- O
lethal O
mutant O
allele O
of O
NUM I-GENE
( O
NUM I-GENE
- I-GENE
2 I-GENE
) O
and O
a O
combination O
of O
in O
vivo O
and O
in O
vitro O
approaches O
, O
we O
demonstrate O
that O
the O
product O
of O
the O
NUM I-GENE
gene I-GENE
( O
NUM I-GENE
or O
NUM I-GENE
) O
is O
a O
factor O
required O
RARE O
translation O
RARE O
in O
yeast O
. O

Evaluation O
of O
RARE O
perfusion O
by O
99mTc O
- O
tetrofosmin O
SPECT O
before O
and O
after O
RARE O
RARE O
RARE O
coronary O
RARE O
RARE O
acute O
RARE O
infarction O

A O
neonatal O
RARE O
thrombocytopenia O
with O
an O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
( O
RARE O
) O
RARE O
was O
confirmed O
. O

RARE O
was O
able O
to O
RARE O
RARE O
by O
3 O
years O
of O
age O
with O
then O
progressive O
RARE O
of O
motor O
abilities O
. O

RARE I-GENE
positive O
congenital O
muscular O
RARE O
with O
mental O
deficiency O
, O
epilepsy O
and O
MRI O
changes O
in O
the O
cerebral O
RARE O
matter O
. O

Most O
eukaryotic O
mRNAs O
are O
translated O
by O
a O
" O
scanning O
RARE O
" O
mechanism O
. O

Comparison O
of O
Tc O
- O
99m O
RARE O
perfusion O
imaging O
and O
echocardiography O
using O
an O
RARE O
infusion O
RARE O
the O
detection O
of O
coronary O
artery O
RARE O
. O

Also O
, O
transient O
overexpression O
of O
this O
protein O
in O
C2C12 O
cells O
RARE O
the O
transcription O
of O
a O
CAT I-GENE
- O
reporter O
regulated O
by O
an O
E12 I-GENE
/ O
MyoD I-GENE
RARE O
enhancer O
. O

Five O
of O
these O
have O
ocular O
or O
RARE O
RARE O
. O

RARE O
a O
126 O
- O
nucleotide O
5 O
' O
RARE O
genomic O
sequence O
and O
a O
NUM O
- O
nucleotide O
5 O
' O
noncoding O
cDNA O
sequence O
, O
the O
NUM O
- O
nucleotide O
5 O
' O
CpG O
island O
lacked O
TATA O
and O
CAAT O
RARE O
but O
displayed O
a O
high O
G O
+ O
C O
content O
, O
was O
RARE O
RARE O
CpG O
RARE O
, O
and O
contained O
a O
RARE O
NUM I-GENE
- I-GENE
binding I-GENE
site I-GENE
, O
i O
. O
RARE O
., O
features O
compatible O
with O
a O
housekeeping O
gene O
. O

ALL_CAP I-GENE
( O
pronounced O
RARE O
) O
encodes O
a O
major O
protein I-GENE
kinase I-GENE
C I-GENE
substrate O
, O
the O
RARE O
of O
which O
is O
down O
- O
regulated O
in O
src I-GENE
- O
and O
ras I-GENE
- O
transformed O
rodent O
RARE O
but O
not O
in O
RARE O
- O
transformed O
rodent O
RARE O
( O
X O
. O

RARE O
I O
position O
- O
vestibular O
- O
RARE O
( O
ALL_CAP O
I O
) O
and O
vestibular O
- O
only O
( O
V O
I O
) O
neurons O
, O
RARE O
RARE O
RARE O
a O
smaller O
number O
of O
other O
type O
I O
and O
type O
II O
eye O
- O
RARE O
- O
vestibular O
neurons O
were O
studied O
. O

The O
1 O
. O
1 O
- O
and O
1 O
. O
3 O
- O
kb O
mRNA O
species O
were O
found O
only O
in O
the O
RARE O
, O
and O
the O
2 O
. O
6 O
- O
kb O
species O
was O
found O
in O
the O
RARE O
, O
RARE O
and O
brain O
, O
but O
not O
in O
skeletal O
muscle O
or O
liver O
. O

RARE O
deficiency O
significantly O
depressed O
the O
amplitude O
of O
NUM O
and O
NUM O
. O

We O
have O
found O
that O
NUM I-GENE
- O
cells O
are O
RARE O
RARE O
activation O
of O
NUM I-GENE
in O
response O
to O
various O
forms O
of O
stress O
. O

The O
extended O
rat I-GENE
SP I-GENE
- I-GENE
A I-GENE
isoforms I-GENE
were O
RARE O
in O
the O
more O
fully O
glycosylated O
and O
RARE O
SP I-GENE
- I-GENE
A I-GENE
species O
separated O
on O
SDS O
- O
PAGE O
gels O
. O

Alternative O
RARE O
of O
NUM I-GENE
may O
therefore O
contribute O
to O
the O
control O
of O
cell O
RARE O
. O

This O
investigation O
was O
undertaken O
to O
determine O
whether O
RARE O
several O
small O
RARE O
of O
RARE O
carbohydrate O
( O
CHO O
RARE O
rather O
than O
a O
single O
bolus O
, O
would O
affect O
RARE O
glucose O
and O
insulin I-GENE
responses O
RARE O
rest O
and O
exercise O
. O

The O
findings O
suggest O
that O
ALL_CAP O
effects O
of O
distinct O
memory O
processes O
are O
differentially O
influenced O
by O
the O
encoding O
RARE O
. O

This O
coat I-GENE
protein I-GENE
consists O
of O
NUM I-GENE
, O
the O
NUM I-GENE
protein I-GENE
complex I-GENE
containing O
NUM I-GENE
and O
NUM I-GENE
, O
and O
the O
NUM I-GENE
protein I-GENE
complex I-GENE
containing O
NUM I-GENE
and O
a O
novel O
NUM I-GENE
- I-GENE
kDa I-GENE
protein I-GENE
, I-GENE
NUM I-GENE
. O

The O
second O
RARE O
mutant O
contained O
a O
proline O
- O
to O
- O
leucine O
change O
RARE O
position O
NUM O
( O
NUM O
). O

Induction O
of O
correctly O
RARE O
RARE O
transcripts O
is O
necessary O
to O
target O
a O
switch O
region O
RARE O
RARE O
and O
switching O
. O

Thus O
, O
the O
ALL_CAP I-GENE
binds O
a O
RARE I-GENE
RARE I-GENE
RARE I-GENE
that O
RARE O
unlike O
RARE I-GENE
I I-GENE
Hox I-GENE
proteins I-GENE
. O

Furthermore O
, O
the O
NH2 O
- O
terminal O
portion O
of O
the O
homologue O
was O
not O
RARE O
into O
the O
RARE O
membrane O
without O
its O
ALL_CAP O
- O
terminal O
part O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
cDNA O
, O
NUM I-GENE
, O
encoding O
a O
RARE O
receptor O
with O
a O
homology O
to O
the O
human I-GENE
C I-GENE
- I-GENE
C I-GENE
RARE I-GENE
receptor I-GENE
, O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
. O

Organization O
of O
the O
human I-GENE
ALL_CAP I-GENE
gene I-GENE
and O
RARE O
basis O
of O
the O
RARE O
( O
a O
RARE O
RARE I-GENE
( I-GENE
b I-GENE
) I-GENE
RARE O
group O
polymorphism O
. O

Using O
mouse O
- O
human O
somatic O
hybrids O
and O
ALL_CAP O
analysis O
, O
the O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
gene I-GENE
is O
localized O
to O
human O
RARE O
NUM O
. O
2 O
, O
a O
region O
involved O
in O
RARE O
and O
deletions O
in O
leukemias O
and O
several O
solid O
tumors O
, O
suggesting O
that O
this O
novel O
ALL_CAP I-GENE
factor I-GENE
may O
play O
a O
role O
in O
RARE O
. O

Whereas O
the O
mutant O
RARE O
terminate O
normally O
RARE O
the O
RARE O
terminator O
in O
NUM O
DNA O
( O
T O
( O
RARE O
)) O
and O
ALL_CAP I-GENE
NUM O
, O
they O
fail O
to O
terminate O
RARE O
one O
of O
the O
RARE O
sites O
of O
ALL_CAP I-GENE
NUM O
, O
and O
also O
fail O
to O
recognize O
the O
ALL_CAP I-GENE
and O
ALL_CAP O
signals O
. O

RARE O
data O
suggest O
that O
the O
RARE O
associate O
with O
a O
RARE O
. O

RARE I-GENE
regulatory I-GENE
unit I-GENE
1 I-GENE
( O
NUM I-GENE
) O
is O
necessary O
RARE O
and O
sufficient O
to O
mediate O
light O
- O
dependent O
activation O
of O
the O
RARE I-GENE
synthase I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
minimal I-GENE
promoter I-GENE
in O
RARE O
RARE O
. O

Sequence O
divergence O
is O
observed O
in O
RARE O
regions O
which O
allows O
the O
definition O
of O
gene O
- O
specific O
RARE O
. O

The O
RARE O
state O
is O
RARE O
by O
hydrolysis O
of O
RARE O
GTP O
, O
producing O
inactive O
ARF I-GENE
- I-GENE
GDP I-GENE
. O

We O
suggest O
that O
apart O
from O
the O
RARE O
RARE O
RARE O
Children O
' O
s O
under O
- O
five O
mortality O
target O
RARE O
the O
year O
2000 O
, O
RARE O
RARE O
to O
reduce O
RARE O
RARE O
in O
under O
- O
five O
mortality O
should O
be O
specified O
. O

The O
RARE I-GENE
, O
which O
can O
be O
of O
the O
FK506 O
- O
or O
cyclosporin O
A O
- O
binding O
class O
, O
binds O
to O
hsp90 I-GENE
via O
its O
RARE O
repeat O
( O
TPR O
) O
domain O
, O
and O
different O
receptor O
RARE O
exist O
depending O
upon O
which O
RARE I-GENE
RARE O
the O
TPR O
- O
binding O
region O
of O
hsp90 I-GENE
. O

In O
RARE O
macrophages O
, O
absence O
of O
NUM I-GENE
led O
to O
the O
RARE O
and O
RARE O
of O
NUM I-GENE
/ I-GENE
NUM I-GENE
( O
RARE I-GENE
) O
and O
p53 I-GENE
/ I-GENE
NUM I-GENE
( O
RARE I-GENE
RARE O
but O
not O
of O
NUM I-GENE
( O
c I-GENE
- I-GENE
RARE I-GENE
). O

RARE O
in O
milk O
and O
RARE O
transfer O
of O
two O
RARE O
RARE O
, O
RARE O
ALL_CAP O
and O
RARE O
, O
in O
rabbits O
. O

Sequencing O
of O
the O
ALL_CAP I-GENE
gene I-GENE
revealed O
that O
it O
encodes O
a O
protein O
that O
contains O
an O
N O
- O
terminal O
GAL4 I-GENE
- O
like O
RARE O
( O
II O
) O
NUM O
( O
or O
NUM O
zinc O
) O
RARE O
cluster O
RARE O
DNA O
binding O
, O
leucine O
zipper O
- O
like O
RARE O
repeat O
motifs O
and O
central O
and O
C O
- O
terminal O
RARE O
alpha O
- O
helical O
regions O
, O
consistent O
with O
a O
function O
RARE O
a O
DNA O
- O
binding O
transcriptional O
activator O
. O

Overexpression O
of O
NUM I-GENE
allowed O
growth O
in O
the O
absence O
of O
NUM I-GENE
. O

The O
coding O
region O
of O
NUM I-GENE
is O
contained O
within O
a O
single O
RARE O
encoding O
a O
1 O
, O
NUM O
- O
amino O
- O
acid O
protein O
. O

RARE O
, O
RARE O
association O
of O
p107 I-GENE
or O
p130 I-GENE
with O
either O
RARE I-GENE
E I-GENE
- O
cdk2 I-GENE
or O
RARE I-GENE
A I-GENE
- O
cdk2 I-GENE
RARE O
the O
activities O
of O
these O
kinases O
. O

Furthermore O
, O
NUM I-GENE
suppresses O
actin I-GENE
RARE O
, O
which O
is O
RARE O
by O
RARE I-GENE
muscle I-GENE
alpha I-GENE
- I-GENE
RARE I-GENE
. O

RARE O
of O
the O
simian O
virus O
40 O
origin O
of O
replication O
RARE O
by O
human I-GENE
replication I-GENE
protein I-GENE
A I-GENE
. O

This O
effect O
was O
abolished O
once O
the O
EM O
motif O
in O
the O
promoter O
- O
reporter O
construct O
was O
RARE O
, O
thus O
suggesting O
that O
the O
synergistic O
RARE O
function O
of O
the O
TEF I-GENE
- I-GENE
1 I-GENE
- O
Max I-GENE
RARE O
complex O
is O
RARE O
through O
binding O
of O
the O
complex O
to O
the O
EM O
motif O
. O

RARE O
residues O
within O
a O
small O
region O
of O
VP16 I-GENE
interact O
with O
Oct I-GENE
- I-GENE
1 I-GENE
, O
ALL_CAP I-GENE
, O
and O
DNA O
. O

With O
a O
view O
to O
identifying O
other O
important O
U14 I-GENE
interactions O
, O
a O
RARE O
- O
loop O
domain O
required O
RARE O
activity O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
U14 I-GENE
RNAs I-GENE
( O
the O
Y O
domain O
) O
was O
RARE O
subjected O
to O
detailed O
mutational O
analysis O
. O

Based O
on O
these O
results O
and O
because O
NUM I-GENE
has O
been O
implicated O
RARE O
a O
regulator O
of O
chromatin O
RARE O
, O
we O
RARE O
that O
polymerase I-GENE
alpha I-GENE
may O
interact O
with O
these O
proteins O
to O
gain O
access O
to O
its O
template O
or O
to O
origins O
of O
replication O
in O
vivo O
. O

RARE O
when O
the O
RARE O
size O
was O
RARE O
RARE O
( O
i O
. O
RARE O
., O
6 O
RARE O
10 O
( O
6 O
) O
ALL_CAP O
/ O
mouse O
RARE O
50 O
% O
of O
the O
NUM I-GENE
- I-GENE
NUM I-GENE
- O
treated O
animals O
died O
within O
6 O
days O
. O

In O
12 O
cases O
( O
3 O
. O
1 O
%), O
a O
change O
in O
RARE O
resulted O
. O

Promoter O
recognition O
RARE O
identified O
divergent O
promoter O
elements O
within O
the O
CpG O
island O
, O
which O
lies O
between O
the O
ALL_CAP I-GENE
and O
NUM I-GENE
/ O
ALL_CAP I-GENE
genes O
, O
and O
provide O
evidence O
RARE O
a O
putative O
second O
ALL_CAP I-GENE
promoter I-GENE
RARE O
within O
intron O
3 O
, O
immediately O
upstream O
of O
the O
RARE O
coding O
RARE O
. O

Recombinant I-GENE
RARE I-GENE
ALL_CAP I-GENE
that O
lacked O
transmembrane O
and O
cytoplasmic O
domains O
had O
factor I-GENE
I I-GENE
cofactor I-GENE
activity O
in O
NUM I-GENE
RARE O
, O
indicating O
that O
it O
is O
functionally O
, O
RARE O
RARE O
RARE O
structurally O
homologous O
to O
ALL_CAP I-GENE
. O

Clinical O
and O
RARE O
signs O
are O
not O
specific O
in O
this O
setting O
, O
and O
the O
diagnosis O
RARE O
on O
histological O
features O
, O
mainly O
bone O
marrow O
examination O
. O

RARE O
RARE O
RARE O
muscle O
RARE O
and O
the O
control O
of O
RARE O
stability O
. O

RARE O
chromatographic O
separation O
was O
achieved O
on O
a O
RARE O
ALL_CAP O
NUM O
RARE O
column O
using O
gradient O
RARE O
. O

The O
RARE O
RARE O
NUM O
from O
RARE O
RARE O
encodes O
a O
protein O
highly O
homologous O
to O
the O
NUM I-GENE
- I-GENE
RARE I-GENE
DNA I-GENE
polymerase I-GENE
. O

The O
RNA O
- O
binding O
and O
RNA I-GENE
- I-GENE
DNA I-GENE
RARE I-GENE
activities O
of O
the O
Escherichia I-GENE
coli I-GENE
transcription I-GENE
RARE I-GENE
factor I-GENE
RARE I-GENE
have O
been O
investigated O
using O
RARE O
RNA O
molecules O
that O
are O
NUM O
and O
NUM O
nucleotide O
residues O
in O
length O
and O
that O
contain O
the O
RARE I-GENE
t I-GENE
' I-GENE
RARE I-GENE
- I-GENE
dependent I-GENE
RARE I-GENE
sequence I-GENE
of O
E O
. O
coli O
. O

The O
NUM I-GENE
- I-GENE
ALL_CAP I-GENE
gene I-GENE
is O
RARE O
among O
mammals O
but O
shows O
RARE O
homology O
to O
non O
- O
RARE O
species O
. O

The O
data O
suggest O
that O
like O
in O
yeast O
, O
in O
RARE O
a O
certain O
subfamily O
of O
ALL_CAP I-GENE
is O
specifically O
involved O
in O
the O
RARE O
RARE O
of O
abnormal O
proteins O
RARE O
result O
of O
stress O
. O

The O
ALL_CAP I-GENE
- I-GENE
19 I-GENE
also O
encodes O
the O
ALL_CAP O
inverted O
terminal O
repeats O
RARE O
RARE O
and O
replication O
and O
the O
herpes O
virus O
RARE I-GENE
kinase I-GENE
promoter O
- O
RARE O
gene O
RARE O
RARE O
resistance O
( O
ALL_CAP I-GENE
). O

We O
have O
developed O
a O
ALL_CAP O
- O
RARE O
gene O
transfer O
RARE O
RARE O
the O
rat I-GENE
RARE I-GENE
II I-GENE
gene I-GENE
. O

The O
serum O
levels O
of O
beta I-GENE
- I-GENE
human I-GENE
RARE I-GENE
gonadotropin I-GENE
( O
ALL_CAP I-GENE
) O
and O
RARE I-GENE
RARE I-GENE
phosphatase I-GENE
( O
ALL_CAP I-GENE
) O
were O
not O
elevated O
. O

A O
striking O
feature O
of O
the O
recombinant I-GENE
NUM I-GENE
allele I-GENE
is O
the O
occurrence O
of O
a O
parental O
RARE O
set O
on O
the O
RARE I-GENE
RARE I-GENE
RARE I-GENE
. O

This O
indicates O
that O
recruitment O
of O
large I-GENE
T I-GENE
antigen I-GENE
to O
the O
rRNA O
promoter O
by O
NUM I-GENE
constitutes O
a O
crucial O
step O
in O
the O
activation O
process O
. O

In O
1990 O
, O
an O
International O
RARE O
RARE O
the O
RARE O
of O
RARE O
of O
RARE O
RARE O
( O
ALL_CAP O
) O
was O
established O
by O
the O
RARE O
American O
Health O
Organization O
to O
RARE O
determine O
if O
RARE O
was O
interrupted O
. O

Functional O
and O
regulatory O
analysis O
of O
the O
two O
copies O
of O
the O
ALL_CAP I-GENE
operon I-GENE
of O
RARE O
RARE O
RARE O
NUM O
. O

This O
study O
describes O
a O
new O
MADS I-GENE
box I-GENE
gene I-GENE
, O
NUM I-GENE
, O
which O
along O
with O
NUM I-GENE
( O
ALL_CAP O
. O

Thus O
NUM O
. O
NUM O
is O
a O
useful O
ES O
cell O
line O
RARE O
RARE O
the O
mouse O
genome O
using O
the O
ALL_CAP I-GENE
gene I-GENE
RARE O
a O
selection O
marker O
and O
RARE O
RARE O
RARE O
a O
high O
frequency O
into O
the O
mouse O
RARE O
line O
. O

Lung O
and O
RARE O
- O
RARE O
damage O
were O
early O
indicators O
of O
poor O
outcome O
in O
severe O
non O
- O
fatal O
RARE O
. O

The O
results O
suggest O
that O
the O
RARE O
RARE O
reflex O
evoked O
by O
bladder O
filling O
and O
L O
- O
RARE O
involves O
a O
RARE O
RARE O
where O
RARE O
is O
partly O
RARE O
by O
RARE I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
adrenoceptors I-GENE
. O

OBJECTIVE O
: O
This O
study O
was O
designed O
to O
analyze O
the O
common O
cause O
of O
RARE O
, O
mixed O
RARE O
. O

RARE O
of O
regeneration O
in O
the O
above O
pathological O
condition O
results O
from O
the O
damage O
to O
RARE O
RARE O
and O
RARE O
of O
its O
function O
RARE O
the O
support O
of O
structural O
RARE O
. O

RARE O
, O
neck O
or O
facial O
muscles O
RARE O
were O
also O
found O
in O
three O
cases O
. O

Identification O
of O
five O
new O
genes O
, O
closely O
related O
to O
the O
interleukin I-GENE
- I-GENE
1beta I-GENE
RARE I-GENE
enzyme I-GENE
gene I-GENE
, O
that O
do O
not O
encode O
RARE O
RARE O
. O

The O
C O
- O
terminal O
RARE O
region O
is O
highly O
RARE O
in O
other O
serine I-GENE
RARE I-GENE
. O

One O
RNA O
construct O
which O
consisted O
of O
112 O
nucleotides O
( O
nt O
) O
from O
nt O
NUM O
to O
nt O
750 O
formed O
a O
RARE O
complex O
with O
the O
RNA O
which O
consisted O
of O
NUM O
nucleotides O
from O
nt O
NUM O
to O
nt O
750 O
. O

Here O
we O
demonstrate O
that O
NUM I-GENE
, O
which O
solely O
has O
RARE O
effects O
RARE O
a O
transcriptional O
regulator O
, O
RARE O
suppresses O
transcriptional O
activation O
by O
NUM I-GENE
, O
and O
that O
NUM I-GENE
exhibits O
the O
RARE O
affinity O
RARE O
DNA O
- O
binding O
than O
NUM I-GENE
. O

However O
, O
we O
could O
not O
find O
the O
homologous O
regions O
with O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factors I-GENE
or O
GTPase I-GENE
- I-GENE
activating I-GENE
proteins I-GENE
in O
the O
c I-GENE
- I-GENE
cbl I-GENE
gene I-GENE
. O

However O
, O
using O
ALL_CAP O
- O
NUM O
nuclear O
RARE O
, O
we O
demonstrated O
that O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
is O
the O
only O
ALL_CAP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
that O
forms O
specific O
DNA O
- O
protein O
complex O
with O
the O
- O
70 O
ALL_CAP O
site O
. O

The O
impact O
of O
social O
support O
on O
the O
relationships O
of O
RARE O
male O
RARE O
is O
examined O
. O

The O
ubiquitously O
RARE O
RARE I-GENE
- I-GENE
inducible I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
HIF I-GENE
- I-GENE
1 I-GENE
) O
is O
involved O
in O
RARE O
of O
a O
large O
number O
of O
oxygen O
- O
regulated O
genes O
. O

RARE I-GENE
- I-GENE
1 I-GENE
, O
RARE I-GENE
RARE I-GENE
- I-GENE
3 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
RARE O
is O
an O
important O
RARE O
selectively O
RARE O
by O
somatic O
cells O
in O
organ O
tissues O
. O

RARE O
also O
shows O
a O
degree O
of O
RARE O
. O

RARE O
RARE O
RARE O
was O
conducted O
by O
RARE O
RARE O
of O
treatment O
- O
group O
RARE O
, O
using O
standardized O
measurements O
of O
RARE O
pressure O
and O
RARE O
protein O
excretion O
RARE O
RARE O
RARE O
RARE O
RARE O
, O
RARE O
RARE O
monitoring O
these O
measurements O
RARE O
the O
RARE O
RARE O
delivery O
, O
and O
RARE O
of O
medical O
records O
of O
RARE O
RARE O
RARE O
and O
all O
RARE O
. O

RARE I-GENE
hydrocarbon I-GENE
receptor I-GENE
nuclear I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
is O
a O
RARE O
of O
the O
transcription O
factors O
, O
RARE I-GENE
hydrocarbon I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
) O
and O
RARE I-GENE
- I-GENE
inducible I-GENE
factor I-GENE
1 I-GENE
, O
which O
transactivate O
their O
target O
genes O
, O
such O
RARE O
NUM I-GENE
and O
erythropoietin I-GENE
, O
in O
response O
to O
RARE O
aromatic O
RARE O
and O
to O
low O
NUM O
concentration O
, O
respectively O
. O

DNase I-GENE
I I-GENE
footprint O
analysis O
identified O
a O
protected O
region O
from O
- O
37 O
to O
- O
53 O
. O

We O
also O
provide O
evidence O
that O
NUM I-GENE
is O
RARE O
in O
vitro O
by O
a O
NUM I-GENE
( O
NUM I-GENE
)- O
RARE O
- O
RARE O
kinase O
from O
Schizosaccharomyces O
pombe O
extracts O
that O
displays O
cell O
RARE O
- O
regulated O
activity O
similar O
to O
that O
of O
the O
NUM I-GENE
( O
cdc2 I-GENE
( O
kinase O
. O

However O
, O
by O
RARE O
metal O
affinity O
chromatography O
assay O
, O
self O
- O
association O
of O
PR I-GENE
- I-GENE
A I-GENE
was O
3 O
. O
5 O
- O
RARE O
more O
efficient O
than O
that O
of O
either O
the O
ALL_CAP O
or O
ALL_CAP O
constructs O
. O

The O
overall O
results O
of O
this O
paper O
are O
consistent O
with O
the O
conclusion O
that O
the O
RARE O
- O
terminal O
ALL_CAP O
is O
not O
sufficient O
RARE O
mediating O
PR I-GENE
RARE O
and O
that O
multiple O
regions O
, O
including O
the O
RARE O
and O
amino O
- O
terminal O
sequences O
, O
contribute O
either O
directly O
or O
indirectly O
to O
RARE O
of O
PR I-GENE
. O

We O
isolated O
several O
overlapping O
A O
- O
RARE O
and O
cosmid O
RARE O
that O
RARE O
more O
than O
NUM O
kb O
of O
human O
DNA O
and O
contained O
the O
RARE O
VDR I-GENE
gene I-GENE
. O

RARE O
carcinoma O
: O
therapeutic O
approach O
in O
patients O
already O
treated O
with O
metastasis O
resection O

Here O
, O
we O
correlate O
RARE O
effects O
on O
cell O
RARE O
with O
changes O
of O
E2F I-GENE
/ O
ALL_CAP I-GENE
complexes O
and O
activity O
in O
differentiating O
C2C12 O
RARE O
. O

The O
products O
of O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
NUM I-GENE
, O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
participate O
in O
a O
RARE O
RARE O
required O
RARE O
normal O
microtubule O
function O
. O

RARE O
was O
still O
a O
significant O
risk O
factor O
when O
RARE O
RARE O
were O
excluded O
. O

RARE O
RARE O
on O
" O
Acute O
and O
chronic O
effects O
of O
exercise O
on O
leptin I-GENE
levels O
in O
humans O
". O

Both O
promoters O
lack O
a O
TATA O
box O
, O
and O
RARE I-GENE
belongs O
to O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
class O
of O
promoters O
, O
which O
initiate O
transcription O
RARE O
multiple O
sites O
. O

Serum I-GENE
response I-GENE
factor I-GENE
( O
SRF I-GENE
RARE O
a O
RARE O
of O
an O
RARE O
family O
of O
DNA O
- O
binding O
proteins O
, O
is O
generally O
assumed O
to O
be O
a O
ubiquitous O
transcription O
factor O
involved O
in O
RARE O
growth O
factor O
- O
responsive O
genes O
. O

We O
have O
RARE O
studies O
to O
identify O
candidate O
signal O
RARE O
that O
associate O
with O
the O
cytosolic O
domain O
( O
RARE O
) O
of O
the O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
. O

In O
this O
study O
, O
we O
sought O
to O
identify O
mechanisms O
that O
could O
account O
RARE O
the O
RARE O
effects O
of O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
. O

RARE O
RARE O
strains O
RARE O
patients O
with O
RARE O
RARE O
( O
ALL_CAP O
) O
RARE O
a O
RARE O
RARE O
due O
to O
RARE O
of O
RARE O
. O

RARE O
of O
ALL_CAP I-GENE
in O
the O
ALL_CAP I-GENE
mutant I-GENE
, O
in O
ALL_CAP O
and O
in O
the O
non O
- O
RARE O
RARE O
ALL_CAP O
was O
assessed O
by O
the O
use O
of O
a O
transcriptional O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
fusion O
. O

The O
NUM I-GENE
- I-GENE
RARE I-GENE
RARE O
of O
the O
cDNA O
construct O
was O
RARE O
by O
the O
observation O
that O
all O
peptide O
sequences O
derived O
from O
a O
previously O
RARE O
, O
catalytically O
RARE O
NUM O
- O
kDa O
fragment O
were O
found O
within O
the O
coding O
region O
. O

A O
RARE O
NUM O
- O
kDa O
protein O
was O
produced O
without O
the O
RARE O
RARE O
by O
inserting O
the O
coding O
sequence O
of O
amino O
RARE O
112 O
to O
NUM O
of O
ORF O
- O
2 O
in O
a O
RARE O
RARE O
vector O
and O
using O
the O
corresponding O
virus O
to O
RARE O
Sf9 O
cells O
. O

The O
CPK I-GENE
- I-GENE
MB I-GENE
RARE O
showed O
RARE O
percentage O
increase O
of O
RARE O
CPK I-GENE
RARE O
than O
5 O
%, O
measured O
RARE O
6 O
, O
12 O
, O
and O
NUM O
h O
after O
the O
shock O
, O
independent O
of O
the O
number O
of O
attempts O
of O
RARE O
. O

Serum O
and O
peritoneal O
dialysis O
RARE O
( O
ALL_CAP O
) O
were O
collected O
RARE O
assay O
throughout O
the O
course O
of O
the O
study O
and O
RARE O
5 O
days O
thereafter O
. O

Results O
support O
the O
hypothesis O
that O
endogenous I-GENE
RARE I-GENE
- I-GENE
releasing I-GENE
factor I-GENE
, O
perhaps O
acting O
RARE O
a O
peripheral O
binding O
site O
, O
suppresses O
the O
RARE O
behavioral O
response O
characteristic O
of O
RARE O
RARE O
the O
early O
RARE O
of O
isolation O
in O
novel O
RARE O
. O

Liver O
regional O
RARE O
volume O
( O
ALL_CAP O
) O
is O
altered O
by O
several O
RARE O
states O
and O
various O
drugs O
. O

The O
gray O
matter O
ALL_CAP O
/ O
ALL_CAP O
ratio O
clearly O
separated O
the O
two O
groups O
. O

As O
with O
the O
murine I-GENE
and I-GENE
human I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
genes I-GENE
, O
the O
5 O
' O
region O
of O
the O
bovine I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
gene I-GENE
lacked O
a O
TATA O
box O
. O

RARE I-GENE
RARE I-GENE
assays O
examining O
the O
ability O
of O
NUM I-GENE
to O
repress O
activity O
from O
the O
ALL_CAP O
major O
IE I-GENE
promoter I-GENE
or O
activate O
the O
ALL_CAP I-GENE
early I-GENE
promoter I-GENE
RARE O
the O
2 O
. O
2 O
- O
kb O
class O
of O
RNAs O
demonstrated O
the O
RARE O
integrity O
of O
the O
NUM I-GENE
protein I-GENE
. O

ORF O
NUM O
has O
striking O
homology O
to O
RARE O
RARE I-GENE
, O
while O
ORF O
NUM O
encodes O
a O
RARE O
homolog O
of O
Bcl I-GENE
- I-GENE
2 I-GENE
- I-GENE
like I-GENE
molecules I-GENE
encoded O
by O
other O
RARE O
( O
gene I-GENE
16 I-GENE
of O
HVS O
and O
ALL_CAP O
and O
the O
NUM I-GENE
gene I-GENE
of O
ALL_CAP O
). O

Transcription O
factor O
binding O
sites O
RARE O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
RARE O
site O
are O
important O
RARE O
virus O
RARE O
. O

RARE O
RARE O
of O
an O
RARE O
of O
RARE O
RARE O
: O
detailed O
conformational O
analysis O
of O
the O
bovine O
RARE O
complex O
and O
implications O
RARE O
their O
activation O
. O

RARE O
transient O
transfection O
of O
NIH3T3 O
fibroblast O
cells O
and O
gel O
mobility O
shift O
assays O
, O
the O
RARE O
binding O
site O
was O
localized O
to O
a O
short O
region O
RARE O
NUM O
to O
- O
NUM O
bp O
from O
the O
transcription O
RARE O
site O
) O
which O
has O
a O
ALL_CAP O
sequence O
. O

We O
RARE O
that O
this O
injection O
RARE O
( O
NUM O
. O
1 O
- O
NUM O
. O
2 O
ml O
. O
s O
- O
1 O
) O
is O
suitable O
RARE O
RARE O
anesthesia O
. O

Alternative O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
( O
a O
RARE O
of O
the O
ALL_CAP I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
family I-GENE
) O
transcripts O
generates O
three O
truncated O
isoforms O
one O
of O
which O
, O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
is O
RARE O
- O
specific O
. O

The O
current O
study O
demonstrates O
that O
NUM O
- O
activated O
transcription O
of O
the O
ALL_CAP I-GENE
: I-GENE
cytochrome I-GENE
P450 I-GENE
oxidoreductase I-GENE
( O
NUM I-GENE
) O
gene O
is O
dependent O
on O
the O
thyroid O
hormonal O
status O
of O
the O
RARE O
, O
with O
both O
transcriptional O
and O
post O
- O
transcriptional O
pathways O
being O
important O
in O
RARE O
the O
cellular O
NUM I-GENE
mRNA O
level O
. O

The O
behavior O
of O
different O
RARE O
of O
RARE O
( O
ALL_CAP O
) O
RARE O
in O
the O
RARE O
RARE O
process O
of O
abdominal O
RARE O
defects O
. O

The O
control O
group O
revealed O
significantly O
RARE O
levels O
of O
coagulation I-GENE
factors I-GENE
II I-GENE
, I-GENE
V I-GENE
and I-GENE
VIII I-GENE
, O
compared O
to O
the O
index O
group O
. O

The O
frequency O
of O
positive O
anti I-GENE
- I-GENE
NUM I-GENE
antibody I-GENE
RARE O
in O
the O
RARE O
- O
RARE O
RARE O
patients O
with O
ALL_CAP O
19 O
isolates O
was O
RARE O
than O
that O
in O
the O
RARE O
- O
RARE O
RARE O
and O
RARE O
' O
s O
RARE O
patients O
without O
ALL_CAP O
19 O
isolates O
. O

RARE O
RARE O
RARE O
of O
the O
RARE O
resulted O
in O
seizure O
remission O
without O
complications O
20 O
months O
after O
surgery O
. O

ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
/ O
Rel I-GENE
transcription O
factors O
participate O
in O
the O
activation O
of O
numerous O
genes O
involved O
in O
immune O
RARE O
/ O
inflammation O
including O
RARE O
, O
cell O
surface O
receptors O
, O
adhesion O
molecules O
, O
and O
acute O
RARE O
proteins O
. O

If O
E O
. O
coli O
is O
present O
in O
any O
source O
water O
sample O
, O
the O
RARE O
and O
any O
directly O
connected O
RARE O
should O
be O
RARE O
. O

However O
, O
mean O
food O
intake O
in O
the O
40 O
% O
group O
was O
RARE O
that O
of O
the O
ALL_CAP O
group O
( O
p O
< O
NUM O
. O
001 O
) O
and O
significantly O
less O
( O
p O
< O
NUM O
. O
01 O
) O
than O
the O
ALL_CAP O
group O
, O
which O
RARE O
amounts O
equivalent O
to O
65 O
% O
of O
daily O
requirement O
. O

The O
following O
technique O
describes O
a O
modification O
to O
a O
RARE O
RARE O
that O
provided O
the O
advantages O
of O
RARE O
, O
RARE O
, O
and O
consistent O
positioning O
even O
though O
one O
implant O
was O
lost O
and O
the O
RARE O
of O
implants O
limited O
accuracy O
. O

In O
summary O
, O
ALL_CAP O
express O
receptors O
RARE O
a O
broad O
panel O
of O
RARE O
, O
even O
receptors O
RARE O
RARE O
whose O
effects O
on O
DC O
are O
still O
unknown O
( O
i O
. O
RARE O
. O

Its O
RARE O
RARE O
a O
diagnostic O
tool O
RARE O
epidemiological O
RARE O
was O
assessed O
in O
comparison O
with O
three O
other O
diagnostic O
tests O
: O
RARE O
examination O
, O
ELISA O
with O
RARE I-GENE
RARE I-GENE
antigen I-GENE
( O
ALL_CAP I-GENE
) O
and O
the O
RARE O
RARE I-GENE
test O
( O
ALL_CAP O
). O

We O
have O
separated O
a O
RARE O
RARE O
RARE O
, O
RARE O
, O
from O
RARE I-GENE
and O
RARE O
by O
using O
RARE O
extraction O
of O
bovine O
RARE O
RARE O
cartilage O
, O
followed O
by O
sequential O
ion O
- O
exchange O
, O
gel O
RARE O
, O
hydrophobic O
, O
and O
NUM O
+ O
RARE O
chromatographic O
steps O
. O

These O
analyses O
demonstrate O
that O
the O
RARE I-GENE
isoforms O
are O
encoded O
by O
the O
same O
gene O
with O
isoform O
- O
specific O
transcripts O
arising O
through O
the O
use O
of O
RARE O
5 O
' O
exons O
. O

The O
selective O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonists O
RARE O
( O
NUM O
RARE O
NUM O
( O
ALL_CAP O
- O
NUM O
RARE O
RARE O
and O
RARE O
, O
and O
the O
substituted O
RARE O
( O
5 I-GENE
- I-GENE
NUM I-GENE
receptor I-GENE
agonist O
/ O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonists O
) O
RARE O
RARE O
and O
SC O
- O
NUM O
dose O
- O
dependently O
RARE O
RARE O
emptying O
in O
normal O
rats O
. O

Re O
- O
evaluation O
of O
the O
biopsy O
RARE O
from O
the O
right O
hip O
taken O
RARE O
the O
time O
of O
the O
initial O
operation O
showed O
areas O
of O
RARE O
arising O
in O
the O
background O
of O
synovial O
RARE O
. O

All O
corneal O
RARE O
were O
processed O
RARE O
RARE O
and O
electron O
microscopic O
studies O
. O

NUM O
- O
RARE O
to O
apparent O
RARE O
with O
a O
NUM O
% O
yield O
by O
affinity O
chromatography O
utilizing O
DNA O
- O
RARE O
; O
the O
RARE O
of O
the O
final O
preparation O
was O
assessed O
by O
SDS O
/ O
PAGE O
, O
lack O
of O
contamination O
by O
other O
RARE O
and O
production O
of O
a O
RARE O
antibody O
against O
the O
enzyme O
. O

Human I-GENE
RARE I-GENE
- I-GENE
DNA I-GENE
glycosylase I-GENE
maps O
RARE O
RARE O
NUM O
- O
NUM O
. O
1 O
: O
a O
region O
of O
high O
RARE O
of O
heterozygosity O
in O
RARE O
RARE O
. O

ALL_CAP I-GENE
is O
coexpressed O
with O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
RARE O
RARE O
development O
and O
in O
RARE O
and O
RARE O
cells O
. O

The O
mean O
times O
to O
detection O
of O
all O
mycobacteria O
with O
ALL_CAP O
NUM O
MB O
and O
ALL_CAP O
NUM O
ALL_CAP O
were O
similar O
( O
10 O
. O
3 O
and O
10 O
. O
NUM O
days O
, O
respectively O
). O

RARE O
the O
ALL_CAP O
NUM O
MB O
RARE O
is O
recommended O
RARE O
respiratory O
specimens O
, O
we O
demonstrated O
that O
it O
can O
be O
successfully O
used O
also O
RARE O
recovery O
of O
mycobacteria O
from O
clinical O
specimens O
from O
various O
RARE O
sites O
. O

We O
further O
found O
that O
NUM I-GENE
is O
fully O
RARE O
when O
RARE O
in O
S O
. O
cerevisiae O
. O

A O
pre O
- O
RARE O
RARE O
was O
simulated O
by O
RARE O
the O
central O
RARE O
. O

RARE O
neutropenia O
( O
ALL_CAP O
) O
is O
a O
frequent O
cause O
of O
chronic O
neutropenia O
especially O
in O
RARE O
children O
. O

With O
regard O
to O
the O
characteristic O
RARE O
pattern O
of O
ALL_CAP I-GENE
protein I-GENE
and O
its O
RARE O
repeat O
RARE O
possible O
RARE O
roles O
are O
discussed O
. O

RARE O
analysis O
of O
long O
- O
term O
outcome O
measures O
of O
performance O
with O
the O
implant O
will O
confirm O
or O
RARE O
the O
benefit O
of O
ear O
selection O
using O
the O
RARE O
- O
ALL_CAP O
. O

This O
protein O
, O
designated O
NUM I-GENE
based O
on O
its O
predicted O
RARE O
RARE O
( O
ALL_CAP O
ALL_CAP O
NUM O
: O
NUM O
, O
1996 O
RARE O
contains O
multiple O
structural O
domains O
including O
two O
regions O
of O
RARE O
internal O
repeats O
highly O
related O
to O
the O
cell O
RARE O
regulator O
NUM I-GENE
, O
a O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
RARE O
the O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
Ran I-GENE
, O
RARE O
beta O
- O
repeat O
domains O
characteristic O
of O
the O
beta O
subunit O
of O
heterotrimeric I-GENE
G I-GENE
proteins I-GENE
, O
three O
putative O
SH3 I-GENE
binding I-GENE
sites I-GENE
, O
a O
putative O
leucine O
- O
zipper O
and O
a O
RARE I-GENE
- I-GENE
terminal I-GENE
ALL_CAP I-GENE
domain I-GENE
characteristic O
of O
NUM I-GENE
ubiquitin I-GENE
- I-GENE
protein I-GENE
RARE I-GENE
. O

Thus O
, O
the O
NUM O
sequence O
between O
kinase O
subdomains O
IV O
and O
V O
specifies O
TGF I-GENE
- I-GENE
beta I-GENE
responsiveness O
of O
the O
type I-GENE
I I-GENE
receptor I-GENE
. O

The O
two O
mouse O
lines O
carrying O
the O
RARE O
NUM I-GENE
- O
lacZ I-GENE
YAC O
showed O
tissue O
- O
specific O
, O
copy O
number O
- O
dependent O
and O
position O
- O
independent O
RARE O
, O
RARE O
that O
NUM O
kb O
of O
the O
NUM I-GENE
locus O
contain O
all O
elements O
important O
in O
the O
RARE O
of O
NUM I-GENE
. O

Second O
, O
RARE O
- O
derived O
RARE O
and O
gene O
targeting O
of O
the O
endogenous I-GENE
NUM I-GENE
gene I-GENE
locus I-GENE
were O
used O
to O
demonstrate O
that O
the O
3 O
'- O
flanking O
region O
of O
the O
gene O
is O
necessary O
and O
sufficient O
to O
direct O
reporter O
gene O
RARE O
in O
liver O
, O
pancreas O
, O
stomach O
and O
small O
intestine O
. O

This O
RARE O
requires O
two O
HMG I-GENE
- I-GENE
box I-GENE
proteins I-GENE
: O
the O
ubiquitous O
NUM I-GENE
transcription I-GENE
factor I-GENE
and O
the O
M O
cell O
- O
controlling O
protein O
NUM I-GENE
- I-GENE
RARE I-GENE
. O

Here O
we O
have O
tested O
the O
hypothesis O
that O
the O
short O
transcripts O
, O
or O
proteins O
translated O
from O
the O
short O
transcripts O
, O
are O
also O
required O
RARE O
respiration O
. O

Upstream O
activating O
sequences O
( O
RARE O
) O
derived O
from O
known O
NUM I-GENE
- O
dependent O
genes O
have O
previously O
been O
characterized O
to O
require O
either O
multiple O
RARE O
or O
a O
single O
ALL_CAP O
coupled O
to O
a O
binding O
site O
RARE O
a O
second O
protein O
. O

RARE O
protein O
kinase O
RARE O
are O
those O
that O
activate O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinases I-GENE
. O

JNK I-GENE
is O
additionally O
regulated O
by O
the O
Ras I-GENE
- O
related O
G I-GENE
proteins I-GENE
Rac I-GENE
and O
Cdc42 I-GENE
. O

In O
this O
study O
, O
we O
tested O
this O
notion O
by O
using O
ligation O
- O
RARE O
PCR O
to O
assess O
the O
formation O
of O
RARE I-GENE
- I-GENE
activating I-GENE
gene I-GENE
( O
ALL_CAP I-GENE
)- O
dependent O
double O
- O
RARE O
RARE O
( O
RARE O
) O
RARE O
RARE O
3 O
' O
of O
NUM I-GENE
and O
5 O
' O
of O
NUM I-GENE
. O

Recent O
studies O
have O
demonstrated O
that O
Cbl I-GENE
, O
the O
120 O
- O
kDa O
protein O
product O
of O
the O
c I-GENE
- I-GENE
cbl I-GENE
RARE I-GENE
- I-GENE
oncogene I-GENE
, O
serves O
RARE O
a O
substrate O
of O
a O
number O
of O
receptor I-GENE
- I-GENE
coupled I-GENE
tyrosine I-GENE
kinases I-GENE
and O
forms O
complexes O
with O
SH3 I-GENE
and O
NUM I-GENE
domain O
- O
containing O
proteins O
, O
RARE O
to O
its O
role O
in O
signal O
RARE O
. O

Although O
neither O
constitutively O
activated O
MEK I-GENE
( O
MEK I-GENE
- I-GENE
NUM I-GENE
) O
nor O
v I-GENE
- I-GENE
Src I-GENE
was O
sufficient O
individually O
to O
differentiate O
the O
NUM O
- O
7 O
cells O
, O
coexpression O
of O
constitutively O
activated O
MEK I-GENE
and O
v I-GENE
- I-GENE
Src I-GENE
RARE O
RARE O
RARE O
. O

This O
mechanism O
is O
in O
contrast O
to O
other O
cases O
of O
RARE O
RARE O
by O
ALL_CAP I-GENE
, O
in O
which O
the O
protein O
represses O
the O
RARE O
site O
to O
which O
it O
binds O
. O

While O
important O
RARE O
RARE O
- O
dependent O
RARE O
, O
this O
interaction O
surface O
is O
not O
directly O
involved O
in O
RARE O
of O
AP I-GENE
- I-GENE
1 I-GENE
activity O
. O

Gal4 I-GENE
- O
RARE I-GENE
fusion O
protein O
represses O
transcription O
of O
a O
reporter O
gene O
RARE O
by O
a O
promoter O
that O
contains O
Gal4 I-GENE
- I-GENE
binding I-GENE
DNA I-GENE
elements I-GENE
. O

In O
situ O
hybridization O
analysis O
in O
adult O
rat O
tissue O
reveals O
good O
correlation O
with O
this O
pattern O
and O
indicates O
that O
RARE I-GENE
mRNA I-GENE
is O
most O
highly O
RARE O
in O
RARE O
and O
RARE O
differentiated O
cells O
, O
such O
RARE O
neurons O
, O
type O
1 O
RARE O
cells O
, O
and O
RARE O
cells O
. O

Neither O
of O
these O
proteins O
, O
individually O
or O
RARE O
a O
RARE O
, O
can O
bind O
the O
alpha I-GENE
- I-GENE
globin I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
unless O
they O
are O
complexed O
with O
the O
remaining O
non O
- O
RARE O
( O
C O
) O
binding O
proteins O
of O
the O
alpha I-GENE
- I-GENE
complex I-GENE
. O

A O
2 O
years O
and O
9 O
months O
old O
female O
patient O
, O
with O
the O
diagnosis O
of O
RARE O
RARE O
is O
reported O
. O

RARE O
measures O
made O
by O
RARE O
and O
additionally O
, O
ALL_CAP O
RARE O
women O
, O
seem O
to O
RARE O
this O
effect O
. O

In O
a O
series O
of O
patients O
with O
RARE O
, O
RARE O
RARE O
, O
RARE O
RARE O
RARE O
, O
RARE O
, O
partial O
or O
generalized O
, O
epilepsy O
, O
we O
have O
investigated O
RARE O
antibodies O
of O
IgG I-GENE
and O
IgM I-GENE
subtypes O
, O
together O
with O
RARE O
factors O
, O
RARE O
of O
RARE O
, O
sedimentation O
rate O
of O
RARE O
. O

( O
NUM O
) O
RARE O
NUM O
, O
NUM O
- O
NUM O
]. O

Second O
, O
the O
membrane O
RARE O
of O
alpha O
and O
beta O
subunits O
was O
mimicked O
by O
cholesterol O
and O
NUM O
- O
RARE O
, O
both O
of O
which O
inhibit O
HMG I-GENE
- I-GENE
CoA I-GENE
reductase I-GENE
. O

Our O
results O
suggest O
that O
RARE I-GENE
binds O
a O
central O
palindromic O
site O
, O
RARE O
predominantly O
with O
the O
major O
RARE O
of O
its O
DNA O
target O
, O
and O
that O
additional O
RARE O
bind O
to O
flanking O
sites O
to O
form O
a O
RARE O
activation O
complex O
. O

RARE O
activation O
of O
p21 I-GENE
RARE O
is O
proposed O
to O
be O
a O
RARE O
feature O
of O
the O
activity O
of O
ALL_CAP I-GENE
that O
contributes O
to O
PC12 O
growth O
arrest O
RARE O
differentiation O

The O
remaining O
NUM O
patients O
underwent O
recordings O
of O
ECG O
, O
RARE O
- O
to O
- O
RARE O
arterial O
oxygen O
saturation O
( O
SaO2 O
RARE O
and O
respiration O
RARE O
both O
spontaneous O
and O
RARE O
breathing O
. O

The O
mean O
RARE O
RARE O
cell O
count O
increased O
from O
a O
baseline O
of O
11 O
. O
3 O
RARE O
10 O
( O
9 O
RARE O
L O
( O
SD O
2 O
. O
3 O
) O
to O
16 O
. O
2 O
RARE O
10 O
( O
9 O
RARE O
L O
( O
SD O
4 O
. O
6 O
) O
on O
day O
1 O
, O
RARE O
thereafter O
. O

A O
prospective O
RARE O
study O
was O
conducted O
to O
identify O
early O
indicators O
of O
acute O
RARE O
virus O
infection O
. O

In O
all O
experimental O
eyes O
, O
there O
was O
a O
marked O
reduction O
, O
but O
never O
a O
RARE O
absence O
of O
adrenergic O
nerves O
in O
the O
RARE O
. O

These O
lesions O
may O
be O
treated O
by O
propranolol O
or O
RARE O
. O

Furthermore O
, O
ALL_CAP I-GENE
negatively O
RARE O
the O
RARE O
promoter O
, O
thus O
generating O
a O
RARE O
loop O
. O

This O
night O
- O
day O
RARE O
is O
RARE O
by O
the O
endogenous O
RARE O
( O
RARE O
in O
the O
RARE O
nucleus O
, O
ALL_CAP O
). O

It O
is O
present O
in O
the O
nucleus O
of O
the O
cells O
in O
which O
it O
is O
RARE O
and O
can O
phosphorylate O
and O
activate O
the O
cyclic I-GENE
AMP I-GENE
response I-GENE
element I-GENE
binding I-GENE
proteins I-GENE
CREB I-GENE
and O
ALL_CAP I-GENE
RARE I-GENE
in O
a O
manner O
analogous O
to O
protein I-GENE
kinase I-GENE
A I-GENE
. O

These O
cells O
fail O
to O
generate O
the O
signals O
to O
phosphorylate O
CREB I-GENE
and O
produce O
significantly O
less O
of O
the O
RARE O
Interleukin I-GENE
- I-GENE
2 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
) O
in O
response O
to O
agents O
that O
either O
increase O
RARE O
NUM O
+ O
and O
/ O
or O
activate O
protein I-GENE
kinase I-GENE
C I-GENE
. O

Both O
of O
these O
dogs O
had O
low O
serum O
IgG I-GENE
( O
3 O
. O
5 O
to O
7 O
. O
2 O
mg O
/ O
ml O
) O
and O
the O
second O
RARE O
also O
had O
RARE O
serum O
IgA I-GENE
(< O
NUM O
. O
1 O
to O
NUM O
. O
NUM O
mg O
/ O
ml O
). O

CONCLUSIONS O
: O
RARE O
appears O
to O
inhibit O
the O
RARE O
of O
RARE O
- O
10 O
, O
11 O
- O
RARE O
- O
RARE O
, O
and O
probably O
also O
inhibits O
the O
conversion O
of O
RARE O
- O
10 O
, O
11 O
- O
RARE O
to O
this O
RARE O
- O
RARE O
RARE O
, O
rather O
than O
RARE O
inhibiting O
the O
latter O
reaction O
only O
. O

The O
NUM I-GENE
protein I-GENE
efficiently O
RARE O
a O
DNA O
duplex O
where O
a O
RARE O
AP I-GENE
site I-GENE
is O
placed O
opposite O
a O
cytosine O
( O
AP O
/ O
C O
). O

A O
consensus O
sequence O
indicates O
a O
highly O
RARE O
RARE O
RARE O
, O
NUM O
of O
endonuclease I-GENE
III I-GENE
or O
NUM O
of O
NUM I-GENE
, O
respectively O
. O

Overall O
, O
these O
findings O
demonstrate O
that O
mutations O
NUM O
and O
NUM O
are O
gain O
- O
of O
- O
function O
mutations O
that O
confer O
to O
the O
long I-GENE
RET I-GENE
isoform I-GENE
the O
capacity O
to O
exert O
a O
biological O
effect O
, O
although O
these O
mutations O
are O
more O
weakly O
activating O
than O
the O
NUM I-GENE
and O
NUM I-GENE
mutations O
. O

RARE O
were O
irradiated O
on O
their O
RARE O
with O
RARE O
ALL_CAP O
daily O
RARE O
5 O
d O
after O
application O
of O
the O
RARE O
and O
their O
RARE O
RARE O
to O
different O
sites O
. O

E2F I-GENE
is O
a O
RARE O
complex O
consisting O
of O
E2F I-GENE
family I-GENE
members I-GENE
( I-GENE
1 I-GENE
- I-GENE
5 I-GENE
) I-GENE
and O
ALL_CAP O
proteins O
( O
1 O
- O
3 O
). O

NUM I-GENE
mRNA I-GENE
, O
a O
consistent O
marker O
of O
viral O
RARE O
, O
was O
positive O
in O
all O
ALL_CAP O
cases O
, O
although O
RARE O
lower O
levels O
than O
in O
the O
non O
- O
ALL_CAP O
controls O
due O
to O
NUM I-GENE
RARE O
by O
only O
a O
RARE O
subset O
of O
lymphoma O
cells O
. O

METHODS O
: O
Four O
hundred O
RARE O
patients O
with O
the O
diagnosis O
of O
squamous O
cell O
carcinoma O
of O
the O
oral O
cavity O
received O
their O
RARE O
treatment O
RARE O
RARE O
RARE O
Cancer O
RARE O
( O
ALL_CAP O
) O
from O
NUM O
to O
1991 O
. O

Therefore O
, O
use O
of O
RARE O
is O
recommended O
RARE O
RARE O
motion O
studies O
using O
RARE O
PC O
velocity O
data O
. O

In O
addition O
, O
the O
DNA O
- O
binding O
experiments O
show O
that O
either O
one O
of O
the O
two O
MADS I-GENE
domains I-GENE
of O
a O
RARE O
can O
be O
sufficient O
to O
confer O
a O
particular O
DNA O
- O
binding O
RARE O
to O
the O
complex O
and O
that O
sequences O
outside O
the O
amino O
- O
terminal O
basic O
region O
of O
the O
MADS I-GENE
domain O
can O
, O
in O
some O
cases O
, O
contribute O
to O
the O
DNA O
- O
binding O
RARE O
of O
the O
proteins O
. O

PURPOSE O
/ O
OBJECTIVES O
: O
To O
examine O
the O
question O
of O
whether O
an O
early O
RARE O
full O
- O
term O
RARE O
( O
ALL_CAP O
) O
RARE O
against O
breast O
RARE O
and O
whether O
RARE O
of O
the O
RARE O
with O
an O
RARE O
abortion O
increases O
breast O
RARE O
risk O
. O

Two O
related O
studies O
conducted O
over O
a O
five O
week O
period O
measured O
and O
RARE O
HLA I-GENE
- I-GENE
NUM I-GENE
from O
accumulated O
DNA O
on O
autopsy O
room O
and O
RARE O
DNA O
Laboratory O
RARE O
. O

Thirty O
- O
two O
rats O
were O
divided O
into O
four O
groups O
. O

RARE O
of O
the O
ALL_CAP I-GENE
regulatory O
region O
revealed O
the O
presence O
of O
two O
sites O
in O
which O
insertions O
RARE O
the O
RARE I-GENE
- I-GENE
1 I-GENE
RARE O
. O

BRCA1 I-GENE
, O
a O
familial O
breast O
and O
ovarian O
RARE O
RARE O
gene O
encodes O
nuclear O
RARE O
that O
function O
RARE O
tumor O
suppressors O
in O
human O
breast O
RARE O
cells O
. O

The O
RARE O
RARE O
sites O
RARE O
the O
smallest O
RARE I-GENE
isoform O
, O
beta I-GENE
- I-GENE
3 I-GENE
, O
are O
RARE O
donor O
and O
RARE O
sites O
within O
exons O
7 O
and O
12 O
. O

RARE O
in O
a O
young O
man O
. O

RARE O
blockade O
in O
chronic O
and O
RARE O
pain O
. O

Two O
new O
RARE O
- O
RARE O
alleles O
of O
NUM I-GENE
, O
1 O
of O
10 O
RARE O
- O
acting O
ALL_CAP I-GENE
genes I-GENE
required O
RARE O
targeting O
or O
fusion O
of O
post O
- O
RARE O
RARE O
vesicles O
to O
the O
plasma O
membrane O
in O
Saccharomyces O
cerevisiae O
, O
were O
isolated O
in O
a O
screen O
RARE O
RARE O
- O
RARE O
RARE O
mutants O
that O
are O
RARE O
lethal O
with O
NUM I-GENE
- I-GENE
8 I-GENE
. O

Five O
cell O
strains O
of O
human O
dermal O
RARE O
were O
each O
treated O
with O
three O
samples O
of O
burn O
RARE O
RARE O
and O
the O
effect O
compared O
with O
the O
rate O
of O
contraction O
of O
free O
RARE O
fibroblast O
RARE O
RARE I-GENE
RARE O
( O
ALL_CAP O
). O

It O
is O
thus O
one O
of O
the O
key O
RARE O
involved O
in O
the O
RARE O
- O
RARE O
control O
of O
growth O
, O
differentiation O
and O
basal O
metabolism O
in O
RARE O
. O

Cell O
NUM O
, O
NUM O
- O
NUM O
]. O

Twenty O
- O
one O
ELISA O
- O
positive O
RARE O
were O
tested O
and O
confirmed O
positive O
by O
plaque O
reduction O
RARE O
testing O
. O

Patients O
received O
either O
diltiazem O
CD O
180 O
mg O
or O
placebo O
once O
/ O
day O
in O
combination O
with O
existing O
RARE O
therapy O
. O

RARE O
RARE O
hyperplasia O
was O
found O
in O
NUM O
cases O
, O
2 O
cases O
had O
RARE O
RARE O
hyperplasia O
or O
RARE O
' O
s O
RARE O
, O
atypical O
RARE O
hyperplasia O
suggestive O
of O
malignant O
lymphoma O
was O
observed O
in O
3 O
cases O
, O
and O
malignant O
lymphoma O
was O
diagnosed O
in O
the O
remaining O
4 O
cases O
. O

We O
had O
previously O
analyzed O
repair O
rates O
of O
RARE O
pyrimidine O
RARE O
RARE O
nucleotide O
resolution O
along O
the O
human I-GENE
ALL_CAP I-GENE
gene I-GENE
in O
normal O
RARE O
and O
found O
very O
efficient O
repair O
of O
sequences O
near O
the O
transcription O
initiation O
site O
but O
slow O
repair O
along O
the O
promoter O
. O

RARE O
NUM O
forms O
a O
RARE O
binding O
site O
RARE O
the O
Grb2 I-GENE
and O
Shc I-GENE
RARE I-GENE
proteins I-GENE
, O
the O
p85 I-GENE
subunit I-GENE
of O
RARE I-GENE
3 I-GENE
'- I-GENE
kinase I-GENE
, O
phospholipase I-GENE
RARE I-GENE
, O
and O
a O
phosphatase O
, O
NUM I-GENE
. O

RARE O
we O
correlated O
ALL_CAP O
findings O
with O
the O
clinical O
features O
, O
pulmonary O
functions O
and O
RARE O
NUM O
( O
NUM O
) O
and O
studied O
their O
clinical O
significance O
. O

RARE I-GENE
mRNA I-GENE
accumulates O
in O
parallel O
with O
the O
RNAs O
encoding O
the O
major O
structural O
proteins O
of O
RARE O
, O
RARE I-GENE
basic I-GENE
protein I-GENE
( O
MBP I-GENE
RARE O
and O
RARE I-GENE
protein I-GENE
( O
ALL_CAP I-GENE
) O
RARE O
postnatal O
brain O
development O
; O
RARE I-GENE
mRNA I-GENE
decreases O
in O
parallel O
with O
MBP I-GENE
and O
ALL_CAP I-GENE
mRNAs I-GENE
in O
the O
RARE O
of O
RARE O
- O
RARE O
rats O
, O
which O
have O
a O
point O
mutation O
in O
the O
ALL_CAP I-GENE
gene I-GENE
. O

RARE O
between O
Bacillus O
subtilis O
RARE O
regulatory O
protein O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
target O
site O
. O

They O
also O
interact O
with O
GTPase I-GENE
activating I-GENE
proteins I-GENE
encoded O
by O
NUM I-GENE
and O
NUM I-GENE
. O

For O
E2 O
, O
each O
RARE O
was O
given O
either O
5 O
( O
group O
RARE O
G O
] O
1 O
) O
or O
10 O
( O
NUM O
) O
mg O
of O
RARE O
/ O
kg O
( O
capsules O
) O
twice O
daily O
RARE O
6 O
weeks O
. O

RESULTS O
: O
For O
E1 O
, O
RARE O
plasma O
drug O
concentration O
RARE O
to O
time O
zero O
( O
IV O
dose O
) O
was O
5 O
. O
2 O
+/- O
1 O
. O
4 O
micrograms O
/ O
ml O
, O
and O
mean O
RARE O
time O
( O
ALL_CAP O
) O
was O
37 O
+/- O
16 O
hours O
. O

The O
human O
U4 I-GENE
/ O
U6 I-GENE
snRNP O
contains O
NUM O
and O
NUM O
proteins O
that O
are O
structurally O
homologous O
to O
the O
yeast O
RARE O
factors O
NUM I-GENE
and O
NUM I-GENE
. O

G I-GENE
- I-GENE
CSF I-GENE
was O
started O
on O
day O
3 O
of O
each O
RARE O
( O
5 O
microg O
/ O
kg O
/ O
day O
) O
and O
was O
stopped O
the O
day O
before O
the O
last O
RARE O
or O
when O
absolute O
RARE O
count O
was O
above O
NUM O
. O
5 O
RARE O
10 O
( O
9 O
RARE O
RARE O
. O

The O
used O
RARE O
RARE O
could O
allow O
to O
produce O
RARE O
forms O
of O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
obtained O
by O
mutagenesis O
of O
the O
corresponding O
gene O
. O

RARE O
among O
the O
pathways O
may O
explain O
how O
some O
forms O
of O
stress O
can O
contribute O
to O
the O
development O
of O
a O
malignancy O
. O

RARE O
assays O
, O
using O
Jun I-GENE
and I-GENE
Fos I-GENE
family I-GENE
RARE I-GENE
- I-GENE
specific I-GENE
antibodies I-GENE
, O
showed O
that O
protein O
complexes O
formed O
by O
ALL_CAP O
- O
20 O
cell O
nuclear O
extracts O
RARE O
to O
the O
c I-GENE
- I-GENE
jun I-GENE
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
were O
comprised O
of O
Jun I-GENE
family O
members O
, O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
and O
RARE I-GENE
. O

The O
majority O
of O
PI I-GENE
kinase I-GENE
activity O
appeared O
to O
be O
cbl I-GENE
- O
associated O
after O
PRL I-GENE
RARE O
. O

Mutation O
of O
NUM I-GENE
, O
an O
essential O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
- I-GENE
like I-GENE
RARE I-GENE
in O
the O
context O
of O
the O
RARE O
enhancer O
, O
abolishes O
RARE O
activity O
, O
and O
RARE O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
RARE I-GENE
mimic O
the O
RARE O
RARE I-GENE
enhancer I-GENE
/ I-GENE
RARE I-GENE
activities O
in O
RARE O
and O
ALL_CAP O
cells O
, O
respectively O
. O

Using O
RARE I-GENE
- O
affinity O
chromatography O
, O
RARE O
between O
the O
pattern O
of O
O O
- O
glycosylation O
of O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
was O
demonstrated O
. O

Deletion O
mapping O
experiments O
determined O
that O
the O
sequences O
required O
RARE O
full O
activity O
in O
ALL_CAP O
- O
1 O
cells O
were O
included O
within O
NUM O
bp O
of O
the O
RARE O
site O
and O
identified O
several O
regions O
that O
demonstrated O
increased O
luciferase I-GENE
activity O
: O
the O
- O
NUM O
bp O
to O
- O
NUM O
bp O
, O
- O
NUM O
bp O
to O
- O
NUM O
bp O
, O
and O
- O
NUM O
bp O
to O
- O
65 O
regions O
. O

Furthermore O
, O
the O
ALL_CAP I-GENE
and O
ALL_CAP O
domains O
are O
highly O
homologous O
( O
RARE O
least O
40 O
% O
identical O
) O
to O
those O
found O
in O
insulin I-GENE
receptor I-GENE
RARE I-GENE
1 I-GENE
, I-GENE
2 I-GENE
, I-GENE
and I-GENE
3 I-GENE
( O
IRS I-GENE
- I-GENE
1 I-GENE
, O
IRS I-GENE
- I-GENE
2 I-GENE
, O
and O
IRS I-GENE
- I-GENE
3 I-GENE
). O

The O
mouse O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
2 I-GENE
gene I-GENE
. O

As O
demonstrated O
by O
gel O
mobility O
shift O
analysis O
and O
supershift O
experiments O
, O
NUM I-GENE
, O
RARE O
between O
- O
NUM O
and O
- O
NUM O
, O
is O
responsible O
RARE O
binding O
ALL_CAP I-GENE
- I-GENE
Y I-GENE
. O

MR O
imaging O
of O
RARE O
head O
injuries O
using O
ALL_CAP O
technique O

Gag I-GENE
protein O
sequence O
motifs O
of O
the O
ALL_CAP I-GENE
domain I-GENE
of O
primate O
RARE O
viruses O
assumed O
to O
be O
involved O
in O
genome O
RARE O
are O
not O
RARE O
in O
ALL_CAP O
. O

Induction O
of O
B O
cell O
apoptosis O
by O
RARE O
- O
cross O
- O
linking O
CD23 I-GENE
and O
RARE I-GENE
involves O
aberrant O
RARE O
of O
c I-GENE
- I-GENE
myc I-GENE
and O
is O
inhibited O
by O
bcl I-GENE
- I-GENE
2 I-GENE
. O

ALL_CAP O
ALL_CAP O
MAIN O
RESULTS O
: O
Lung O
RARE O
( O
ALL_CAP O
) O
and O
resistance O
( O
ALL_CAP O
) O
were O
calculated O
from O
measurements O
of O
airway O
pressure O
, O
esophageal O
pressure O
, O
and O
airway O
flow O
in O
five O
anesthetized O
, O
RARE O
dogs O
RARE O
RARE O
RARE O
RARE O
a O
constant O
mean O
airway O
pressure O
of O
10 O
cmH2O O
in O
a O
wide O
range O
of O
breathing O
frequencies O
( O
NUM O
. O
2 O
to O
1 O
. O
NUM O
Hz O
in O
intervals O
of O
NUM O
. O
2 O
) O
and O
tidal O
volumes O
( O
50 O
, O
NUM O
, O
NUM O
, O
and O
to O
NUM O
mL O
). O

Here O
, O
we O
report O
RARE O
models O
RARE O
the O
RARE O
and O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
RARE I-GENE
of O
human I-GENE
ALL_CAP I-GENE
constructed O
using O
prothrombin I-GENE
and O
factor I-GENE
X I-GENE
experimental O
RARE O
. O

The O
NUM I-GENE
subunit I-GENE
is O
likely O
to O
be O
a O
target O
RARE O
RARE O
ALL_CAP I-GENE
/ I-GENE
RARE I-GENE
function O
through O
protein O
- O
protein O
interactions O
and O
RARE O
. O

The O
dose O
was O
50 O
Gy O
/ O
20 O
fractions O
/ O
5 O
weeks O
. O

Because O
the O
biosynthetic O
RARE O
to O
the O
RARE O
RARE O
with O
the O
endocytic O
RARE O
, O
internalization O
of O
a O
bulk O
membrane O
endocytic O
marker O
ALL_CAP O
4 O
- O
NUM O
was O
assayed O
in O
the O
RARE I-GENE
mutants I-GENE
. O

All O
the O
women O
received O
NUM O
. O
5 O
mg O
RARE O
RARE O
via O
RARE O
injection O
RARE O
the O
L2 O
- O
3 O
RARE O
. O

RARE O
from O
this O
being O
the O
case O
, O
however O
, O
the O
measurement O
of O
RARE I-GENE
B I-GENE
has O
met O
every O
reasonable O
standard O
of O
laboratory O
RARE O
and O
reliability O
to O
allow O
its O
RARE O
introduction O
in O
clinical O
laboratories O
. O

Two O
RARE O
cDNA O
RARE O
, O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
and O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
, O
encoding O
putative O
protein O
kinases O
were O
isolated O
and O
characterized O
. O

RARE O
belonging O
to O
the O
ras I-GENE
superfamily I-GENE
encode O
low I-GENE
- I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
GTP I-GENE
/ I-GENE
GDP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
that O
are O
highly O
RARE O
in O
wide O
variety O
of O
organisms O
. O

RARE O
has O
been O
recently O
RARE O
by O
the O
RARE O
and O
Drug O
Administration O
RARE O
the O
treatment O
of O
RARE O
dependence O
. O

RARE I-GENE
- I-GENE
RARE I-GENE
synthase I-GENE
from I-GENE
the I-GENE
RARE I-GENE
RARE I-GENE
RARE O
. O

In O
this O
report O
, O
we O
identify O
and O
characterize O
two O
overlapping O
ALL_CAP I-GENE
RARE I-GENE
domains I-GENE
that O
govern O
its O
interaction O
with O
RNA I-GENE
polymerase I-GENE
II I-GENE
and O
the O
RARE O
RARE O
complex O
. O

Eight O
RARE O
cDNA O
sequences O
were O
identified O
and O
designated O
RARE I-GENE
RARE I-GENE
- I-GENE
regulated I-GENE
RARE I-GENE
RARE I-GENE
( I-GENE
RARE I-GENE
)- I-GENE
1 I-GENE
- I-GENE
8 I-GENE
. O

The O
position O
, O
transcription O
orientation O
, O
and O
imprinted O
status O
of O
the O
genes O
immediately O
flanking O
NUM I-GENE
have O
been O
assessed O
. O

Here O
, O
we O
describe O
RARE O
RARE O
RARE O
studies O
starting O
from O
NUM I-GENE
RARE O
RARE O
RARE O
NUM I-GENE
. O

We O
describe O
a O
novel O
zinc I-GENE
finger I-GENE
protein I-GENE
, O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
, O
isolated O
by O
screening O
an O
RARE O
library O
with O
ALL_CAP O
. O

Our O
results O
indicate O
that O
the O
RARE O
reverse I-GENE
transcriptase I-GENE
is O
RARE O
adapted O
to O
initiate O
cDNA O
RARE O
by O
RARE O
a O
3 O
' O
ALL_CAP O
sequence O
. O

RARE O
absorption O
was O
rapid O
, O
nasal O
RARE O
was O
NUM O
%, O
and O
the O
iv O
and O
nasal O
elimination O
profiles O
were O
similar O
. O

Together O
, O
these O
results O
suggest O
that O
ALL_CAP I-GENE
/ O
Ras I-GENE
/ O
Raf I-GENE
induces O
transcription O
via O
combined O
activation O
of O
NUM I-GENE
/ O
c I-GENE
- I-GENE
Jun I-GENE
and O
a O
52 O
- O
kDa O
nuclear O
factor O
, O
whereas O
ALL_CAP I-GENE
acts O
RARE O
a O
repressor O
of O
this O
response O
. O

Together O
, O
these O
data O
support O
a O
model O
in O
which O
RARE I-GENE
RARE O
CBP I-GENE
to O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
, O
with O
strong O
transcriptional O
activation O
resulting O
from O
the O
CBP I-GENE
- O
associated O
activities O
of O
RARE O
remodeling O
and O
recruitment O
of O
the O
RARE O
transcription O
machinery O
. O

DNase I-GENE
I I-GENE
and O
1 O
, O
10 O
- O
RARE O
- O
RARE O
footprinting O
of O
ALL_CAP I-GENE
- O
NUM I-GENE
ALL_CAP O
complexes O
indicate O
that O
ALL_CAP I-GENE
binds O
to O
a O
RARE O
RARE O
NUM O
- O
bp O
region O
in O
the O
ALL_CAP O
of O
NUM I-GENE
. O

Consistent O
with O
this O
model O
, O
a O
RARE O
construct O
containing O
three O
RARE O
copies O
of O
the O
RARE O
LDL I-GENE
receptor I-GENE
SREBP I-GENE
site O
RARE O
to O
a O
single O
NUM I-GENE
site I-GENE
was O
also O
significantly O
activated O
in O
a O
RARE I-GENE
- O
independent O
fashion O
. O

Various O
assays O
demonstrate O
promoter O
activity O
in O
this O
sequence O
that O
RARE O
the O
normal O
control O
of O
NUM I-GENE
RARE O
RARE O
a O
growth O
RARE O
. O

In O
the O
adult O
mouse O
, O
ALL_CAP I-GENE
alpha I-GENE
is O
most O
highly O
RARE O
in O
RARE O
, O
RARE O
, O
and O
brown O
adipocytes O
, O
tissues O
which O
preferentially O
RARE O
fatty O
RARE O
. O

The O
ALL_CAP I-GENE
nuclear I-GENE
receptor I-GENE
response I-GENE
element I-GENE
1 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
) O
interacts O
in O
vitro O
with O
ALL_CAP I-GENE
alpha I-GENE
RARE O
in O
COS O
- O
7 O
cells O
. O

Mapping O
features O
of O
HIV I-GENE
- I-GENE
1 I-GENE
integrase I-GENE
near O
RARE O
sites O
on O
viral O
and O
target O
DNA O
molecules O
in O
an O
RARE O
enzyme O
- O
DNA O
complex O
by O
RARE O
- O
cross O
- O
linking O
. O

Analysis O
of O
the O
5 O
' O
flanking O
region O
of O
the O
gene O
also O
revealed O
the O
presence O
of O
multiple O
TATA O
and O
CAAT O
sequences O
. O

Analysis O
of O
the O
5 O
' O
flanking O
region O
of O
the O
gene O
also O
revealed O
the O
presence O
of O
multiple O
TATA O
and O
CAAT O
sequences O
. O

The O
RARE O
response O
( O
ALL_CAP O
) O
rate O
was O
NUM O
% O
in O
the O
ALL_CAP O
with O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
group O
and O
NUM O
% O
in O
the O
ALL_CAP O
alone O
group O
; O
the O
median O
survival O
was O
NUM O
and O
NUM O
weeks O
, O
respectively O
, O
in O
these O
groups O
( O
P O
= O
NUM O
. O
NUM O
). O

RARE I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
NUM I-GENE
binds O
to O
the O
transcription O
- O
regulatory O
region O
of O
mouse O
hepatitis O
virus O
RNA O
. O

The O
NUM O
RARE O
RARE O
of O
eukaryotic O
mRNA O
is O
formed O
RARE O
by O
the O
sequential O
action O
of O
three O
RARE O
: O
RNA I-GENE
RARE I-GENE
, O
RNA I-GENE
RARE I-GENE
, O
and O
RNA I-GENE
( I-GENE
guanine I-GENE
- I-GENE
7 I-GENE
)- I-GENE
RARE I-GENE
. O

In O
the O
RARE O
part O
of O
our O
study O
, O
the O
highest O
RARE O
was O
revealed O
by O
NUM O
RARE O
without O
enzymatic O
activation O
, O
suggesting O
a O
direct O
- O
acting O
RARE O
prevalence O
in O
RARE O
particulate O
. O

The O
addition O
of O
culture O
to O
the O
ALL_CAP O
and O
ALL_CAP O
: O
ALL_CAP O
by O
- O
products O
resulted O
in O
pH O
values O
lower O
( O
P O
< O
NUM O
. O
05 O
) O
than O
those O
without O
culture O
on O
Day O
21 O
, O
and O
the O
NUM O
% O
carbohydrate O
treatment O
significantly O
RARE O
pH O
beyond O
the O
5 O
% O
carbohydrate O
. O

Myocardial O
interstitial O
edema O
is O
more O
likely O
a O
RARE O
mechanism O
of O
diastolic O
dysfunction O
after O
DC O
RARE O
. O

Two O
experiments O
( O
N O
= O
20 O
each O
) O
were O
carried O
out O
to O
explore O
the O
nature O
of O
ALL_CAP O
RARE O
in O
a O
RARE O
memory O
task O
and O
in O
an O
auditory O
spatial O
memory O
task O
, O
respectively O
. O

Biol O
. O

The O
pattern O
and O
timing O
of O
ALL_CAP I-GENE
mRNA I-GENE
RARE O
, O
including O
transient O
RARE O
in O
the O
RARE O
RARE O
14 O
. O
5 O
days O
p O
. O
c O
., O
RARE O
with O
that O
of O
NUM I-GENE
. I-GENE
5 I-GENE
/ O
RARE I-GENE
( O
a O
putative O
homolog O
of O
RARE I-GENE
, O
the O
Drosophila O
melanogaster O
gene O
responsible O
RARE O
cardiac O
development O
). O

Overexpression O
of O
ALL_CAP I-GENE
in O
RARE O
suppresses O
cardiac I-GENE
RARE I-GENE
C I-GENE
and O
RARE I-GENE
RARE I-GENE
factor I-GENE
transcription O
. O

RARE O
RARE O
of O
the O
RNase I-GENE
activity O
of O
yeast I-GENE
RNA I-GENE
polymerase I-GENE
III I-GENE
. O

Electrophoretic O
mobility O
shift O
assays O
and O
competition O
experiments O
showed O
that O
site O
A O
is O
RARE O
by O
an O
NF1 I-GENE
protein I-GENE
. O

Examination O
of O
the O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
NUM I-GENE
sequence I-GENE
revealed O
an O
incomplete O
Y O
- O
box O
sequence O
( O
ALL_CAP O
RARE O
which O
specifically O
interacted O
with O
recombinant I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
on O
ALL_CAP O
protection O
footprinting O
analysis O
. O

Hence O
, O
NUM I-GENE
only O
partially O
suppressed O
the O
RARE O
RARE O
and O
was O
unable O
to O
suppress O
the O
RARE O
- O
RARE O
of O
NUM I-GENE
- I-GENE
NUM I-GENE
. O

In O
contrast O
, O
both O
NUM I-GENE
and O
ALL_CAP I-GENE
proteins I-GENE
are O
required O
to O
RARE O
about O
full O
promoter O
activity O
in O
the O
Surf I-GENE
- I-GENE
1 I-GENE
direction O
. O

CONCLUSION O
: O
Patients O
RARE O
clinically O
RARE O
neck O
RARE O
( O
NUM O
- O
3 O
RARE O
histological O
evidence O
of O
metastatic O
nodal O
RARE O
, O
RARE O
spread O
, O
and O
three O
or O
more O
positive O
lymph O
nodes O
are O
RARE O
greater O
risk O
of O
developing O
failure O
RARE O
distant O
sites O
. O

We O
have O
subcloned O
into O
NUM O
RARE O
acid O
( O
DNA O
) O
sequences O
mapping O
either O
in O
the O
coding O
region O
, O
the O
5 O
' O
spacer O
, O
or O
the O
3 O
' O
spacer O
of O
the O
NUM I-GENE
histone I-GENE
gene I-GENE
. O

4 O
. O

RARE O
under O
the O
drug O
concentration O
- O
time O
curves O
( O
NUM O
- O
NUM O
hr O
) O
RARE O
ALL_CAP O
were O
NUM O
and O
NUM O
RARE O
RARE O
hr O
/ O
ml O
from O
ALL_CAP O
- O
2 O
. O
5 O
% O
RARE O
and O
ALL_CAP O
- O
7 O
. O
5 O
% O
RARE O
RARE O
respectively O
. O

The O
combination O
of O
RARE O
RARE O
and O
RARE O
RARE O
also O
RARE O
survival O
, O
but O
direct O
comparison O
of O
both O
regimens O
provided O
evidence O
RARE O
a O
less O
favourable O
effect O
than O
that O
of O
the O
ACE I-GENE
RARE O
. O

To O
address O
mechanisms O
that O
define O
interactions O
of O
RARE I-GENE
II I-GENE
regulatory I-GENE
factors I-GENE
with O
this O
cell O
RARE O
control O
element O
, O
we O
have O
investigated O
these O
RARE O
of O
transcriptional O
RARE O
RARE O
the O
G1 O
/ O
S O
RARE O
transition O
in O
ALL_CAP O
- O
P1 O
hematopoietic O
RARE O
cells O
. O

The O
goal O
of O
this O
study O
was O
to O
identify O
RARE O
cell O
cultures O
that O
express O
NUM I-GENE
/ O
RARE I-GENE
, O
to O
RARE O
whether O
they O
are O
RARE O
to O
NUM O
, O
and O
to O
examine O
the O
mechanism O
of O
RARE O
. O

There O
were O
differences O
between O
males O
( O
p O
< O
NUM O
. O
05 O
) O
RARE O
most O
of O
the O
characteristics O
studied O
. O

Their O
circadian O
responses O
to O
both O
RARE O
and O
non O
- O
RARE O
RARE O
were O
then O
tested O
. O

Although O
previous O
data O
have O
suggested O
that O
RARE I-GENE
uses O
the O
same O
export O
RARE O
RARE O
RARE O
- O
rich O
small O
nuclear O
RNAs O
and O
5S I-GENE
ribosomal I-GENE
RNA I-GENE
, O
the O
ALL_CAP O
seems O
to O
interact O
with O
evolutionarily O
RARE O
factors O
that O
are O
essential O
RARE O
cellular O
mRNA O
export O
. O

Human I-GENE
RARE I-GENE
contains O
a O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
) O
domain O
that O
is O
likely O
to O
be O
NUM I-GENE
- O
specific O
, O
a O
pleckstrin I-GENE
homology I-GENE
( O
ALL_CAP I-GENE
) O
domain O
and O
spectrin I-GENE
- I-GENE
like I-GENE
repeat I-GENE
RARE I-GENE
. O

NUM I-GENE
, O
a O
leaf O
- O
specific O
RARE O
- O
acting O
factor O
, O
binds O
to O
a O
novel O
cis O
- O
acting O
element O
and O
differentially O
activates O
the O
NUM I-GENE
gene I-GENE
. O

ALL_CAP I-GENE
was O
shown O
to O
be O
a O
RARE O
of O
two O
equal O
subunits O
, O
each O
with O
a O
RARE O
mass O
of O
37 O
, O
NUM O
RARE O
. O

Plasma I-GENE
leptin I-GENE
concentrations O
were O
RARE O
in O
women O
than O
men O
, O
even O
after O
the O
adjustment O
RARE O
differences O
in O
fat O
mass O
( O
NUM O
+/- O
3 O
RARE O
/ O
ml O
RARE O
women O
RARE O
. O

Consistent O
with O
effects O
on O
STAT I-GENE
activation O
, O
altered O
SHP I-GENE
- I-GENE
1 I-GENE
RARE O
also O
affected O
ALL_CAP I-GENE
- O
RARE O
activation O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
RARE O
; O
RARE O
of O
SHP I-GENE
- I-GENE
1 I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
) I-GENE
inhibited O
activity O
of O
MEK I-GENE
by O
RARE O
NUM O
%, O
whereas O
RARE O
of O
SHP I-GENE
- I-GENE
1 I-GENE
resulted O
in O
a O
RARE O
NUM O
% O
increase O
. O

This O
interaction O
involved O
the O
SH3 I-GENE
region I-GENE
of O
NUM I-GENE
( O
RARE I-GENE
) O
and O
a O
proline O
- O
rich O
region O
( O
ALL_CAP O
) O
outside O
the O
catalytic O
region O
of O
PTP I-GENE
- O
ALL_CAP O
. O

Following O
2 O
. O
5 O
Gy O
, O
NUM I-GENE
changes O
were O
minimal O
. O

RARE O
RARE O
of O
human O
RARE O
N I-GENE
- I-GENE
RARE I-GENE
- I-GENE
L I-GENE
- I-GENE
RARE I-GENE
- I-GENE
p I-GENE
- I-GENE
RARE I-GENE
acid I-GENE
RARE I-GENE
( O
human I-GENE
RARE I-GENE
) O
alpha O
and O
beta O
subunits O
in O
RARE O
- O
RARE O
canine O
RARE O
cells O
. O

Neither O
mutant O
exhibited O
derepression O
of O
the O
RARE I-GENE
RARE I-GENE
type I-GENE
loci I-GENE
. O

Among O
38 O
patients O
with O
inducible O
RARE O
RARE O
who O
underwent O
RARE O
study O
( O
ALL_CAP O
RARE O
10 O
RARE O
of O
RARE O
patients O
were O
RARE O
. O

The O
RARE O
length O
of O
RARE O
VT O
( O
RARE O
= O
10 O
RARE O
) O
was O
NUM O
+/- O
NUM O
msec O
. O

Transient O
RARE O
in O
an O
adult O
RARE O
RARE O
dog O
. O

We O
established O
that O
the O
2 O
. O
6 O
kb O
mRNA O
V O
- O
1 O
and O
the O
2 O
. O
3 O
kb O
ALL_CAP I-GENE
mRNA O
V O
- O
2 O
RARE O
, O
by O
alternate O
RARE O
, O
from O
a O
RARE O
transcript O
RARE O
on O
a O
distal O
promoter O
on O
the O
rat I-GENE
ALL_CAP I-GENE
gene I-GENE
. O

A O
specific O
distal O
promoter O
controls O
gamma I-GENE
- I-GENE
glutamyl I-GENE
RARE I-GENE
gene I-GENE
RARE O
in O
undifferentiated O
rat O
transformed O
liver O
cells O
. O

These O
repressor O
sites O
are O
pyrimidine O
rich O
and O
bind O
RARE O
to O
the O
RARE I-GENE
RARE I-GENE
binding I-GENE
protein I-GENE
( O
ALL_CAP I-GENE
) O
in O
HeLa O
nuclear O
extracts O
RARE O
determined O
by O
ALL_CAP O
RARE O
/ O
competition O
assays O
. O

For O
RARE O
RARE O
of O
ALL_CAP I-GENE
in O
S O
. O
RARE O
, O
the O
gene O
was O
RARE O
next O
to O
the O
strong O
ALL_CAP I-GENE
promoter I-GENE
. O

Within O
a O
135 O
- O
bp O
core O
homology O
region O
, O
the O
human I-GENE
NUM I-GENE
RARE I-GENE
are O
RARE O
NUM O
% O
identical O
to O
the O
murine O
homolog O
and O
include O
several O
motifs O
previously O
demonstrated O
to O
be O
important O
RARE O
function O
of O
the O
murine O
enhancer O
; O
additional O
RARE O
of O
high O
sequence O
conservation O
suggest O
the O
possibility O
of O
previously O
RARE O
RARE O
motifs O
. O

In O
contrast O
to O
the O
wild O
- O
type O
protein O
, O
RARE O
of O
NUM I-GENE
ALL_CAP I-GENE
- I-GENE
E2 I-GENE
RARE O
this O
activation O
domain O
in O
an O
ALL_CAP I-GENE
- I-GENE
E2 I-GENE
RARE O
cell O
line O
fails O
to O
support O
enhancer O
- O
dependent O
transcription O
in O
transient O
assays O
. O

These O
findings O
suggest O
one O
RARE O
mechanism O
RARE O
direct O
recruitment O
of O
distal O
regulatory O
regions O
of O
the O
globin I-GENE
loci I-GENE
to O
the O
individual O
promoters O
. O

The O
promoter O
region O
showed O
RARE O
consensus O
TATA O
box O
but O
it O
contains O
CCAAT O
and O
ALL_CAP I-GENE
RARE O
known O
to O
be O
involved O
in O
both O
stress O
and O
carbon O
- O
RARE O
RARE O
of O
RARE O
promoters O
. O

The O
two O
cysteine O
residues O
RARE O
in O
this O
additional O
region O
may O
be O
involved O
in O
the O
formation O
of O
a O
disulfide O
RARE O
associated O
with O
the O
activation O
process O
of O
the O
catalytic O
activity O
. O

The O
RARE I-GENE
gene I-GENE
has O
been O
RARE O
, O
RARE O
the O
RARE O
time O
, O
in O
RARE O
grown O
Escherichia O
coli O
behind O
the O
RARE O
- O
beta O
- O
D O
- O
RARE O
- O
inducible O
RARE I-GENE
promoter I-GENE
, O
resulting O
in O
the O
production O
of O
ALL_CAP I-GENE
in O
its O
RARE O
form O
. O

When O
the O
RARE O
operator O
was O
altered O
, O
there O
was O
a O
fourfold O
reduction O
in O
reporter O
enzyme O
levels O
. O

The O
ORF3 O
mutant O
produced O
RARE O
levels O
of O
RARE I-GENE
, O
indicating O
that O
ORF3 O
may O
have O
a O
role O
in O
T I-GENE
beta I-GENE
L I-GENE
biosynthesis O
. O

RARE O
Cox O
models O
using O
a O
NUM I-GENE
count O
of O
NUM O
/ O
ALL_CAP O
rather O
than O
NUM O
/ O
ALL_CAP O
to O
RARE O
NUM O
and O
NUM O
yielded O
a O
RARE O
model O
with O
better O
fit O
to O
the O
observed O
data O
. O

However O
, O
the O
published O
reports O
consist O
of O
a O
small O
number O
of O
patients O
and O
limited O
data O
. O

These O
transcripts O
contain O
the O
5 O
' O
ends O
of O
RARE O
ALL_CAP I-GENE
mRNAs I-GENE
; O
extend O
through O
ALL_CAP I-GENE
, O
across O
the O
intergenic O
region O
, O
and O
a O
significant O
distance O
3 O
' O
into O
the O
RARE I-GENE
gene I-GENE
. O

The O
distribution O
of O
RARE O
in O
the O
intestine O
and O
number O
of O
RARE O
per O
RARE O
RARE O
on O
different O
ALL_CAP O
were O
also O
estimated O
RARE O
detailed O
characterization O
of O
the O
infection O
in O
RARE O
RARE O
a O
model O
RARE O
experimental O
RARE O
. O

As O
a O
result O
, O
the O
RARE O
/ O
RARE O
RARE O
flow O
ratio O
( O
ALL_CAP O
/ O
ALL_CAP O
) O
increased O
from O
NUM O
. O
NUM O
+/- O
NUM O
. O
09 O
RARE O
control O
stenosis O
to O
NUM O
. O
NUM O
+/- O
NUM O
. O
NUM O
after O
ALL_CAP O
NUM O
( O
10 O
micrograms O
/ O
kg O
/ O
min O
i O
. O
v O
.) O
and O
to O
NUM O
. O
NUM O
+/- O
NUM O
. O
12 O
after O
ALL_CAP O
. O

RARE O
are O
the O
RARE O
protease O
involved O
in O
the O
generation O
of O
peptides O
presented O
by O
MHC I-GENE
class I-GENE
I I-GENE
molecules I-GENE
. O

In O
support O
of O
this O
interpretation O
we O
demonstrate O
that O
NUM I-GENE
binds O
strongly O
5 O
of O
NUM O
motif O
- O
positive O
, O
RARE O
- O
derived O
RARE O
peptides O
. O

RARE O
, O
H O
. O

For O
RARE I-GENE
interleukin I-GENE
- I-GENE
8 I-GENE
there O
was O
an O
estimated O
true O
treatment O
median O
difference O
of O
142 O
pg O
/ O
ml O
( O
NUM O
% O
confidence O
interval O
( O
ALL_CAP O
) O
8 O
to O
NUM O
pg O
/ O
ml O
) O
in O
RARE O
of O
placebo O
; O
while O
RARE O
maximal O
expiratory O
flow O
RARE O
NUM O
% O
( O
NUM O
%) O
remaining O
RARE O
vital O
capacity O
predicted O
RARE O
RARE O
and O
height O
there O
was O
a O
NUM O
percentage O
points O
( O
RARE O
) O
( O
NUM O
% O
ALL_CAP O
4 O
to O
NUM O
RARE O
) O
mean O
treatment O
difference O
in O
RARE O
of O
placebo O
. O

However O
, O
although O
deletion O
of O
NUM I-GENE
in O
the O
NUM I-GENE
gene I-GENE
yielded O
increased O
CAT I-GENE
activity O
, O
RARE O
toward O
a O
negative O
regulatory O
function O
RARE O
by O
this O
element O
, O
its O
RARE O
upstream O
of O
the O
NUM I-GENE
basal I-GENE
promoter I-GENE
results O
in O
an O
RARE O
positive O
RARE O
of O
CAT I-GENE
gene I-GENE
RARE O
. O

RARE O
' O
s O
RARE O
is O
a O
rare O
metabolic O
disorder O
characterized O
by O
the O
lack O
of O
beta I-GENE
- I-GENE
RARE I-GENE
enzyme I-GENE
. O

These O
RARE O
' O
s O
can O
be O
treated O
in O
several O
ways O
but O
RARE O
to O
RARE O
tooth O
RARE O
had O
to O
be O
removed O
in O
an O
irreversible O
manner O
in O
order O
to O
provide O
sufficient O
bulk O
RARE O
the O
new O
RARE O
material O
. O

The O
9 O
; O
NUM O
chromosomal O
translocation O
characteristic O
of O
CML O
results O
in O
a O
fused O
RARE I-GENE
/ O
abl I-GENE
gene O
and O
an O
abnormal O
fusion O
protein O
, O
NUM I-GENE
/ O
abl I-GENE
. O

Overexpression O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
also O
protected O
certain O
cell O
lines O
from O
heat O
shock O
- O
RARE O
cell O
RARE O
. O

The O
5 O
' O
flanking O
region O
contains O
RARE O
binding O
sites O
RARE O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
NUM I-GENE
, O
nuclear I-GENE
factor I-GENE
1 I-GENE
( O
NF1 I-GENE
RARE O
CAAT I-GENE
- I-GENE
box I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
RARE O
RARE I-GENE
nuclear I-GENE
factors I-GENE
1 I-GENE
and I-GENE
5 I-GENE
( O
NUM I-GENE
, O
NUM I-GENE
) O
and O
activator I-GENE
proteins I-GENE
1 I-GENE
and I-GENE
2 I-GENE
( O
AP1 I-GENE
, O
AP2 I-GENE
). O

The O
recognition O
RARE O
of O
the O
p55 I-GENE
PDZ I-GENE
domain I-GENE
appears O
to O
be O
unique O
, O
since O
the O
three O
PDZ I-GENE
domains I-GENE
of O
RARE I-GENE
( O
human O
lymphocyte O
homologue O
of O
the O
Drosophila I-GENE
RARE I-GENE
large I-GENE
tumor I-GENE
suppressor I-GENE
) O
do O
not O
bind O
the O
cytoplasmic O
domain O
of O
RARE I-GENE
C I-GENE
. O

By O
analyzing O
the O
ALL_CAP I-GENE
activity O
of O
a O
series O
of O
RARE O
RARE O
NUM I-GENE
mutant I-GENE
RARE O
, O
we O
show O
that O
the O
highly O
RARE O
sequence O
in O
the O
C O
- O
terminal O
domain O
of O
both O
yeast O
proteins O
is O
RARE O
RARE O
activating O
Ran I-GENE
- O
RARE O
GTP O
hydrolysis O
. O

In O
the O
absence O
of O
MHC I-GENE
class I-GENE
II I-GENE
, O
RARE I-GENE
RARE I-GENE
NUM I-GENE
TCR I-GENE
RARE O
to O
RARE I-GENE
RARE I-GENE
RARE I-GENE
C2 I-GENE
with O
an O
association O
rate O
of O
1 O
. O
NUM O
+/- O
NUM O
. O
12 O
RARE O
10 O
( O
4 O
) O
M O
RARE O
1 O
) O
sec O
RARE O
1 O
) O
and O
a O
dissociation O
rate O
of O
1 O
. O
9 O
+/- O
NUM O
. O
NUM O
RARE O
10 O
RARE O
2 O
) O
sec O
RARE O
1 O
RARE O
giving O
a O
dissociation O
constant O
of O
1 O
. O
1 O
microM O
. O

Evidence O
RARE O
such O
peak O
shifts O
has O
been O
found O
in O
the O
responses O
of O
auditory O
nerve O
fibers O
, O
cochlear O
RARE O
, O
and O
the O
responses O
of O
RARE O
RARE O
cells O
and O
supporting O
cells O
in O
the O
RARE O
, O
RARE O
RARE O
RARE O
in O
RARE O
membrane O
vibration O
measurements O
, O
and O
indirectly O
, O
in O
RARE O
data O
. O

RARE I-GENE
: O
Max I-GENE
complexes O
also O
efficiently O
suppress O
RARE I-GENE
- O
dependent O
activation O
from O
the O
same O
promoter O
. O

In O
the O
United O
RARE O
high O
- O
ALL_CAP O
ALL_CAP O
NUM O
which O
is O
difficult O
to O
RARE O
is O
most O
frequently O
used O
and O
results O
in O
a O
larger O
in O
vivo O
ALL_CAP O
and O
subsequent O
decrease O
in O
factor I-GENE
VIII I-GENE
/ O
RARE I-GENE
Willebrand I-GENE
factor I-GENE
levels O
. O

RARE O
of O
RARE O
cholesterol O
RARE O
RARE O
RARE O
the O
ALL_CAP I-GENE
, O
HDL2 I-GENE
, O
LDL I-GENE
, O
RARE O
, O
endothelin I-GENE
- I-GENE
1 I-GENE
, O
lipoprotein O
( O
a O
RARE O
estradiol O
and O
FSH I-GENE
were O
also O
obtained O
RARE O
baseline O
before O
receiving O
ALL_CAP O
and O
after O
3 O
months O
of O
ALL_CAP O
. O

Six O
RARE O
repeats O
of O
the O
P I-GENE
element I-GENE
RARE O
to O
the O
SV40 I-GENE
promoter I-GENE
responded O
to O
phorbol O
12 O
- O
myristate O
NUM O
- O
RARE O
, O
while O
that O
of O
other O
elements O
did O
not O
. O

The O
distributed O
current O
density O
ALL_CAP O
is O
calculated O
within O
the O
volume O
defined O
by O
the O
motor O
unit O
. O

The O
RARE O
RARE O
of O
NUM I-GENE
RARE I-GENE
protease I-GENE
are O
ALL_CAP O
( O
E O
RARE O
S O
( O
A O
, O
G O
). O

In O
our O
previous O
studies O
, O
transcriptional O
activation O
was O
shown O
to O
correlate O
with O
NUM I-GENE
binding O
to O
both O
the O
TATA I-GENE
- I-GENE
box I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
) O
and O
the O
transcription O
factor O
RARE O
upstream O
. O

However O
, O
we O
were O
unable O
to O
identify O
a O
NUM I-GENE
molecule O
. O

( O
iv O
) O
The O
accumulation O
of O
RARE I-GENE
NUM I-GENE
protein I-GENE
in O
RARE O
cells O
RARE O
with O
an O
NUM I-GENE
deletion I-GENE
mutant I-GENE
was O
RARE O
relative O
to O
that O
of O
cells O
RARE O
with O
wild O
- O
type O
virus O
or O
a O
recombinant O
virus O
in O
which O
the O
RARE O
NUM I-GENE
sequences I-GENE
were O
restored O
. O

We O
report O
the O
preliminary O
biochemical O
characterization O
of O
the O
T I-GENE
antigens I-GENE
encoded O
by O
three O
SV40 O
mutants O
, O
NUM O
, O
NUM O
, O
and O
NUM O
, O
each O
of O
which O
have O
altered O
residues O
within O
or O
near O
the O
ATP O
binding O
pocket O
. O

These O
effects O
were O
abrogated O
by O
RARE O
- O
RARE O
of O
kinase I-GENE
- I-GENE
RARE I-GENE
PKC I-GENE
RARE I-GENE
and O
inhibition O
of O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
NUM I-GENE
- O
NUM I-GENE
by O
wortmannin O
, O
NUM O
and O
a O
dominant O
- O
negative O
mutant O
of O
NUM I-GENE
. O

Protein I-GENE
phosphatase I-GENE
NUM I-GENE
is O
a O
critical O
regulator O
of O
protein I-GENE
kinase I-GENE
C I-GENE
RARE I-GENE
RARE O
targeted O
by O
SV40 I-GENE
small I-GENE
t I-GENE
to O
promote O
cell O
growth O
and O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
activation O
. O

Interestingly O
, O
the O
NUM I-GENE
RARE O
activity O
generated O
within O
RARE O
in O
the O
presence O
of O
NUM O
requires O
the O
integrity O
of O
both O
RXR I-GENE
and O
RAR I-GENE
ALL_CAP O
- O
2 O
domains O
. O

These O
RARE O
contain O
only O
single O
ALL_CAP I-GENE
genes I-GENE
and O
their O
RARE O
involves O
RARE O
release O
of O
the O
ALL_CAP O
from O
RARE O
intron O
RARE O
. O

Recent O
studies O
have O
shown O
that O
the O
Src I-GENE
homology I-GENE
- I-GENE
2 I-GENE
( O
NUM I-GENE
) O
domain O
- O
containing O
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
, O
SHP I-GENE
- I-GENE
2 I-GENE
, O
associates O
with O
the O
cytoplasmic O
domain O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
RARE O
it O
becomes O
tyrosine O
- O
RARE O
RARE O
platelet O
RARE O
: O
a O
process O
that O
can O
be O
mimicked O
in O
part O
by O
small O
RARE O
phosphopeptides O
corresponding O
to O
the O
cytoplasmic O
domain O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
RARE O
tyrosine O
residues O
RARE O
- O
NUM O
or O
RARE O
- O
NUM O
. O

RARE O
the O
RARE O
of O
these O
risk O
variables O
were O
three O
factors O
. O

RARE O
was O
stopped O
when O
RARE I-GENE
- I-GENE
ALL_CAP I-GENE
reached O
2 O
. O
NUM O
g O
/ O
dL O
. O

Detection O
of O
RARE O
Mycobacterium O
tuberculosis O
by O
air O
filtration O
and O
polymerase O
chain O
reaction O
. O

These O
findings O
show O
that O
NUM I-GENE
is O
a O
RARE O
relevant O
RARE I-GENE
binding I-GENE
protein I-GENE
. O

Previously O
, O
we O
reported O
that O
RARE O
translation O
, O
where O
the O
initiating O
AUG O
of O
a O
RARE O
RARE O
reading O
frame O
is O
RARE O
, O
is O
most O
likely O
to O
account O
RARE O
the O
presentation O
of O
RARE O
RARE O
from O
RARE O
reading O
frames O
within O
the O
RARE I-GENE
A I-GENE
PR I-GENE
/ I-GENE
8 I-GENE
/ I-GENE
NUM I-GENE
RARE I-GENE
gene I-GENE
. O

This O
family O
of O
proteins O
binds O
ALL_CAP O
- O
rich O
motifs O
widely O
distributed O
in O
gene O
promoters O
, O
resulting O
in O
distinct O
activation O
or O
repression O
of O
transcriptional O
activities O
. O

Deletion O
of O
the O
NUM I-GENE
gene I-GENE
alone O
had O
RARE O
detectable O
RARE O
, O
while O
RARE O
with O
deletions O
of O
both O
the O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
were O
viable O
and O
able O
to O
grow O
on O
RARE O
RARE O
NUM O
degrees O
C O
, O
RARE O
more O
slowly O
than O
delta I-GENE
NUM I-GENE
single I-GENE
mutants I-GENE
. O

Furthermore O
, O
our O
novel O
observation O
that O
RARE O
of O
a O
highly O
activated O
NUM I-GENE
kinase I-GENE
domain I-GENE
is O
able O
to O
RARE O
transform O
RARE O
suggests O
that O
RARE O
of O
NUM I-GENE
has O
the O
RARE O
to O
play O
a O
role O
in O
human O
RARE O
. O

The O
deduced O
amino O
acid O
sequence O
of O
the O
gene O
has O
significant O
homology O
to O
the O
RARE I-GENE
regulatory I-GENE
factors I-GENE
( O
RARE I-GENE
). O

RARE O
of O
AP I-GENE
- I-GENE
2 I-GENE
in O
RARE O
of O
the O
R I-GENE
- I-GENE
ALL_CAP I-GENE
gene I-GENE
in O
the O
developing O
RARE O
retina O
. O

However O
, O
NUM I-GENE
was O
found O
to O
be O
RARE O
and O
is O
highly O
homologous O
to O
the O
rat I-GENE
RARE I-GENE
protein I-GENE
NUM I-GENE
, O
which O
RARE O
with O
NUM I-GENE
and O
which O
is O
postulated O
to O
be O
involved O
in O
RARE O
- O
cytoplasmic O
RARE O
( O
ALL_CAP O
. O

This O
newly O
described O
organism O
was O
difficult O
to O
identify O
due O
to O
RARE O
between O
the O
RARE O
and O
ALL_CAP O
NUM O
identification O
RARE O
. O

Ig I-GENE
heavy I-GENE
chain I-GENE
class O
switching O
is O
directed O
by O
RARE O
inducing O
transcription O
from O
RARE O
ALL_CAP I-GENE
genes I-GENE
. O

The O
available O
data O
suggest O
that O
the O
ALL_CAP I-GENE
RARE I-GENE
NUM I-GENE
RARE I-GENE
complex I-GENE
may O
cooperate O
with O
DNA O
- O
RARE O
NUM I-GENE
to O
achieve O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
- O
dependent O
activation O
of O
the O
human I-GENE
IgE I-GENE
RARE I-GENE
gene I-GENE
. O

ALL_CAP O
ALL_CAP O
ALL_CAP O
ALL_CAP O
ALL_CAP O
ALL_CAP O
ALL_CAP O
ALL_CAP O
ALL_CAP O
ALL_CAP O
- O
ALL_CAP O
ALL_CAP O
ALL_CAP O

ALL_CAP O
ALL_CAP O
ALL_CAP O
ALL_CAP O
ALL_CAP O
ALL_CAP O
ALL_CAP O

The O
pheromone O
response O
RARE O
activates O
transcription O
of O
NUM I-GENE
RARE I-GENE
RARE O
within O
RARE O
chromatin O
of O
Saccharomyces O
cerevisiae O
. O

In O
this O
study O
we O
have O
introduced O
mutations O
into O
the O
corresponding O
elements O
of O
two O
NUM I-GENE
promoters I-GENE
and O
show O
that O
while O
the O
core O
element O
is O
essential O
RARE O
NUM I-GENE
promoter I-GENE
activity O
, O
upstream O
element O
mutations O
have O
little O
or O
RARE O
effect O
. O

We O
found O
that O
multiple O
tumor O
suppressor O
genes O
( O
RARE O
. O
g O
., O
p53 I-GENE
, O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
BRCA1 I-GENE
, O
and O
WAF1 I-GENE
/ O
NUM I-GENE
) O
were O
inactivated O
RARE O
different O
frequencies O
via O
various O
mechanisms O
RARE O
RARE O
. O
g O
., O
RARE O
of O
heterozygosity O
( O
ALL_CAP O
RARE O
RARE O
of O
RARE O
( O
ALL_CAP O
RARE O
mutation O
, O
and O
inactivation O
by O
cellular O
binding O
protein O
]. O

The O
RARE O
- O
RARE O
gene O
, O
ALL_CAP I-GENE
, O
was O
used O
to O
replace O
the O
wild O
- O
type O
allele O
in O
the O
RARE O
of O
S O
. O
RARE O
and O
S O
. O
RARE O
. O

Because O
the O
deletion O
included O
the O
TK I-GENE
gene I-GENE
, O
selection O
with O
RARE O
against O
cells O
not O
having O
undergone O
RARE O
was O
possible O
. O

The O
RARE I-GENE
synthase I-GENE
gene I-GENE
, O
NUM I-GENE
, O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
is O
transcriptionally O
regulated O
by O
the O
carbon O
source O
in O
the O
growth O
medium O
. O

By O
deletion O
analysis O
of O
the O
NUM I-GENE
control O
region O
, O
we O
identified O
two O
sites O
, O
UAS1 O
and O
NUM O
, O
RARE O
important O
RARE O
efficient O
derepression O
of O
the O
gene O
. O

RARE O
of O
RARE O
prospective O
studies O
of O
sleep O
RARE O
( O
EEG O
RARE O
and O
the O
use O
of O
medication O
, O
in O
children O
with O
developmental O
RARE O
, O
may O
RARE O
appropriate O
treatment O
strategies O
to O
children O
with O
severe O
developmental O
speech O
and O
language O
disorders O
. O

RARE O
to O
RARE O
2 O
to O
3 O
times O
daily O
, O
1 O
- O
2 O
RARE O
of O
RARE O
are O
recommended O
. O

RARE O
of O
the O
abdominal O
aortic O
RARE O
on O
an O
ultrasound O
examination O
was O
the O
key O
to O
the O
RARE O
diagnosis O
of O
a O
clinically O
RARE O
type O
B O
dissection O
. O

RARE O
process O
after O
supplementation O
of O
RARE O
, O
RARE O
, O
RARE O
acid O
bacteria O
and O
RARE O
acid O

RARE O
include O
the O
p21 I-GENE
( O
ras I-GENE
) O
proteins O
, O
nuclear I-GENE
RARE I-GENE
, O
and O
a O
series O
of O
RARE O
proteins O
. O

RARE O
of O
10 O
animals O
per O
group O
from O
16 O
studies O
in O
CD O
- O
1 O
mice O
and O
1 O
study O
each O
in O
C3H O
and O
C57BL O
/ O
6 O
mice O
were O
RARE O
RARE O
RARE O
6 O
microm O
. O

The O
RARE I-GENE
- O
ALL_CAP I-GENE
fusion O
protein O
was O
produced O
less O
efficiently O
( O
20 O
% O
of O
RARE O
RARE O
cellular O
protein O
). O

These O
results O
suggest O
that O
NUM I-GENE
may O
play O
an O
important O
role O
in O
the O
RARE O
of O
ubiquitin I-GENE
by O
hydrolysis O
of O
RARE I-GENE
RARE I-GENE
- I-GENE
ubiquitin I-GENE
chains I-GENE
generated O
by O
the O
action O
of O
NUM I-GENE
S I-GENE
proteasome I-GENE
on O
RARE O
- O
RARE O
protein O
RARE O
, O
RARE O
RARE O
RARE O
in O
the O
production O
of O
free O
ubiquitin I-GENE
from O
RARE I-GENE
RARE I-GENE
- I-GENE
ubiquitin I-GENE
chains I-GENE
and O
of O
certain O
ribosomal O
proteins O
from O
ubiquitin I-GENE
fusion I-GENE
proteins I-GENE
. O

A O
data O
RARE O
homology O
search O
revealed O
that O
the O
predicted O
NUM I-GENE
amino O
acid O
sequence O
contains O
three O
regions O
of O
RARE O
to O
the O
rat O
and O
human O
proteins O
encoded O
by O
the O
metastasis O
- O
associated O
gene O
, O
NUM I-GENE
, O
and O
two O
regions O
of O
RARE O
to O
the O
Caenorhabditis O
elegans O
sequence O
that O
is O
similar O
to O
NUM I-GENE
. O

The O
sequenced O
cDNA O
predicts O
a O
NUM O
- O
amino O
acid O
protein O
NUM O
% O
identical O
to O
human I-GENE
RARE I-GENE
B I-GENE
. O

The O
inhibition O
by O
cytosolic O
NUM O
+ O
was O
caused O
by O
a O
decrease O
in O
cooperativity O
and O
by O
a O
shift O
in O
NUM O
toward O
RARE O
NUM O
concentrations O
. O

RESULTS O
: O
The O
RARE O
mortality O
ratio O
( O
ALL_CAP O
) O
RARE O
all O
malignant O
neoplasms O
was O
94 O
( O
NUM O
% O
ALL_CAP O
NUM O
to O
118 O
). O

Sequence O
analysis O
of O
this O
region O
revealed O
three O
eight O
- O
bp O
RARE O
elements O
, O
the O
deletion O
of O
which O
restored O
wild O
- O
type O
levels O
of O
luciferase I-GENE
activity O
to O
the O
- O
NUM O
- O
bp O
reporter O
RARE O
. O

Using O
5 O
' O
RACE O
and O
reverse O
transcription O
- O
PCR O
( O
RT O
- O
PCR O
) O
RARE O
, O
we O
RARE O
these O
sequences O
from O
brain O
and O
placenta O
and O
found O
this O
material O
to O
be O
composed O
of O
RARE O
RARE O
exons O
using O
a O
previously O
reported O
noncoding O
RARE O
( O
NUM O
) O
and O
a O
novel O
97 O
- O
bp O
noncoding O
RARE O
( O
NUM O
). O

This O
is O
the O
RARE O
study O
in O
which O
mutation O
screening O
has O
been O
performed O
RARE O
both O
the O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
prior O
to O
any O
linkage O
analysis O
. O

The O
RARE O
of O
large O
vitreous O
injections O
. O

RARE O
emission O
tomography O
RARE O
RARE O
dopamine I-GENE
RARE I-GENE
and O
studies O
in O
human O
and O
RARE O
primates O
. O

RARE O
from O
the O
RARE I-GENE
NUM I-GENE
consensus O
ALL_CAP O
is O
not O
necessarily O
dependent O
on O
DNA O
binding O
RARE O
the O
TR I-GENE
alpha I-GENE
DNA O
binding O
mutant O
was O
still O
able O
to O
inhibit O
E O
- O
dependent O
RARE O
. O

Expression O
from O
this O
element O
is O
regulated O
by O
a O
RARE O
protein O
complex O
containing O
ubiquitous O
( O
i O
. O
RARE O
. O
the O
NUM I-GENE
- O
and O
ALL_CAP I-GENE
- I-GENE
encoded I-GENE
proteins I-GENE
) O
and O
islet O
- O
RARE O
members O
of O
the O
bHLH I-GENE
family I-GENE
. O

Thus O
, O
the O
CCAAT O
box O
also O
has O
tissue O
- O
specific O
characteristics O
that O
RARE O
in O
targeting O
RARE O
of O
the O
alpha I-GENE
- I-GENE
subunit I-GENE
gene I-GENE
to O
RARE O
. O

U4 I-GENE
/ O
U6 I-GENE
snRNP O
is O
one O
of O
four O
essential O
small O
nuclear O
ribonucleoprotein O
( O
snRNP O
) O
RARE O
( O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
and O
U4 I-GENE
/ O
U6 I-GENE
) O
present O
in O
the O
spliceosome O
. O

NUM I-GENE
is O
a O
77 O
kDa O
protein O
, O
which O
is O
homologous O
to O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
RARE I-GENE
factor I-GENE
NUM I-GENE
. O

The O
growth O
- O
RARE O
properties O
of O
the O
RARE I-GENE
v I-GENE
- I-GENE
erbA I-GENE
oncogene I-GENE
, O
a O
highly O
RARE O
version O
of O
the O
chicken I-GENE
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( I-GENE
TR I-GENE
) I-GENE
alpha I-GENE
, O
have O
so O
far O
exclusively O
been O
RARE O
to O
dominant O
repression O
of O
the O
RARE O
roles O
of O
TR I-GENE
and O
retinoic I-GENE
acid I-GENE
receptors I-GENE
. O

We O
RARE O
a O
RARE O
cDNA O
( O
2 O
. O
9 O
kb O
) O
RARE O
ALL_CAP I-GENE
from O
an O
ALL_CAP O
- O
7 O
cDNA O
library O
. O

The O
most O
common O
grade O
3 O
toxicity O
was O
neutropenia O
, O
thrombocytopenia O
, O
and O
RARE O
( O
observed O
in O
< O
10 O
% O
of O
cycles O
). O

Serum O
concentrations O
of O
E2 O
and O
ALL_CAP O
were O
measured O
on O
d O
NUM O
, O
1 O
, O
3 O
, O
5 O
, O
7 O
, O
NUM O
, O
21 O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
112 O
, O
and O
NUM O
in O
RARE O
heifers O
administered O
the O
following O
treatments O
: O
1 O
) O
control O
; O
2 O
) O
MGA O
, O
. O
5 O
mg O
per O
RARE O
daily O
; O
3 O
) O
RARE O
- O
H O
( O
NUM O
mg O
ALL_CAP O
+ O
14 O
mg O
E2 O
); O
4 O
) O
RARE O
- O
H O
+ O
MGA O
; O
5 O
) O
RARE O
- O
H O
( O
NUM O
mg O
ALL_CAP O
); O
and O
6 O
) O
RARE O
- O
H O
+ O
MGA O
. O

Serum O
E2 O
concentrations O
increased O
RARE O
two O
- O
to O
threefold O
from O
d O
NUM O
to O
NUM O
in O
controls O
fed O
MGA O
, O
compared O
with O
controls O
not O
fed O
MGA O
. O

Interferon I-GENE
RARE I-GENE
RARE I-GENE
( I-GENE
IRF I-GENE
)- I-GENE
1 I-GENE
has O
been O
characterized O
RARE O
an O
important O
growth O
regulatory O
and O
RARE O
transcription O
factor O
. O

The O
genomic O
RARE O
of O
RARE I-GENE
consists O
of O
8 O
exons O
, O
whose O
boundaries O
are O
distinct O
from O
other O
non O
- O
receptor O
ALL_CAP I-GENE
family I-GENE
members O
, O
again O
indicating O
a O
structural O
and O
RARE O
divergence O
. O

We O
have O
previously O
reported O
that O
RARE O
of O
a O
RARE O
derived O
RARE I-GENE
cDNA I-GENE
in O
mouse O
RARE O
RARE O
and O
human O
mammary O
RARE O
cells O
supports O
anchorage O
independent O
growth O
, O
and O
in O
the O
latter O
potentiates O
the O
mitogenic O
response O
to O
RARE I-GENE
growth I-GENE
factor I-GENE
. O

RARE I-GENE
- I-GENE
hepatitis I-GENE
A I-GENE
virus O
( O
ALL_CAP O
) O
titer O
after O
vaccination O
was O
measured O
in O
NUM O
HIV O
- O
positive O
and O
NUM O
HIV O
- O
negative O
men O
. O

One O
RARE O
does O
not O
a O
species O
make O
. O

Surprisingly O
, O
RARE I-GENE
RARE I-GENE
ALL_CAP I-GENE
contained O
an O
additional O
, O
novel O
form O
of O
the O
NUM O
- O
kDa O
subunit O
with O
a O
RARE O
mass O
of O
70 O
kDa O
. O

RARE O
mutations O
in O
RARE I-GENE
- I-GENE
3 I-GENE
suppress O
mutations O
in O
genes O
encoding O
this O
TGF I-GENE
- I-GENE
beta I-GENE
signal O
, O
its O
receptors O
, O
and O
associated O
Smad I-GENE
signal I-GENE
RARE I-GENE
proteins I-GENE
. O
RARE I-GENE
- I-GENE
3 I-GENE
encodes O
a O
Smad I-GENE
protein I-GENE
that O
is O
most O
closely O
related O
to O
mammalian I-GENE
NUM I-GENE
, O
and O
is O
RARE O
throughout O
development O
in O
many O
of O
the O
tissues O
that O
are O
RARE O
RARE O
RARE O
development O
. O

Our O
results O
RARE O
the O
possibility O
that O
the O
Drosophila I-GENE
ALL_CAP I-GENE
receptor I-GENE
DER I-GENE
/ O
RARE I-GENE
RARE O
by O
the O
ALL_CAP O
cells O
functions O
RARE O
a O
receptor O
RARE O
RARE I-GENE
. O

PATIENTS O
ALL_CAP O
METHODS O
: O
In O
NUM O
consecutive O
patients O
from O
the O
RARE O
National O
RARE O
of O
Acute O
Myocardial O
RARE O
we O
analyzed O
the O
resolution O
of O
chest O
pain O
and O
ST O
segment O
elevation O
over O
50 O
% O
within O
the O
RARE O
NUM O
min O
, O
RARE O
ALL_CAP I-GENE
rise O
within O
8 O
h O
and O
T O
wave O
inversion O
in O
infarct O
related O
ALL_CAP O
leads O
within O
the O
RARE O
NUM O
h O
after O
RARE O
. O

Because O
of O
the O
operon O
RARE O
of O
this O
organism O
, O
RARE O
methods O
such O
RARE O
RARE O
mutagenesis O
run O
the O
risk O
of O
RARE O
RARE O
effects O
on O
RARE O
genes O
or O
RARE O
secondary O
mutations O
RARE O
in O
the O
genome O
. O

It O
has O
been O
proposed O
that O
the O
ALL_CAP I-GENE
operon I-GENE
encodes O
a O
RARE O
RARE O
RARE O
( O
M O
. O

Furthermore O
, O
the O
RARE O
of O
the O
NUM I-GENE
RARE I-GENE
site I-GENE
into O
the O
NUM O
RARE O
RARE O
RARE O
the O
RARE O
region O
failed O
to O
RARE O
the O
RARE O
in O
the O
NUM O
RARE O
, O
indicating O
that O
the O
RARE O
resolution O
activity O
encoded O
by O
ALL_CAP I-GENE
is O
not O
by O
itself O
responsible O
RARE O
the O
stabilization O
activity O
observed O
RARE O
this O
operon O
. O

To O
examine O
the O
basis O
RARE O
the O
apparent O
differences O
in O
RARE O
RARE O
between O
the O
two O
E O
. O
coli O
strains O
, O
transformation O
assays O
were O
carried O
out O
to O
determine O
the O
relative O
RARE O
of O
the O
strains O
to O
the O
ALL_CAP I-GENE
RARE I-GENE
protein I-GENE
. O

RARE O
- O
RARE O
elements O
and O
RARE O
sequences O
regulate O
RARE O
RARE O
of O
the O
Drosophila O
myosin I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
transcript O
. O

Nucleotide O
sequence O
analysis O
of O
R O
has O
revealed O
similarities O
to O
the O
NUM O
RARE O
found O
in O
some O
RARE O
American O
RARE O
RARE O
with O
ALL_CAP O
cytoplasm O
, O
to O
the O
NUM O
RARE O
found O
in O
one O
source O
of O
RARE O
RARE O
RARE O
, O
to O
the O
NUM I-GENE
mitochondrial I-GENE
gene I-GENE
and O
its O
3 O
' O
flanking O
sequence O
, O
and O
also O
to O
a O
region O
3 O
' O
to O
the O
NUM I-GENE
gene I-GENE
. O

We O
have O
measured O
the O
kinetics O
of O
the O
recovery O
of O
mRNA O
RARE O
in O
the O
inducible O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
after O
exposure O
of O
yeast O
cells O
to O
RARE O
( O
ALL_CAP O
) O
radiation O
. O

Cloning O
of O
a O
human I-GENE
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
with O
a O
C2 I-GENE
domain O
that O
displays O
RARE O
sensitivity O
to O
the O
inhibitor O
wortmannin O
. O

RARE O
value O
was O
calculated O
RARE O
the O
ratio O
of O
the O
steady O
- O
state O
end O
- O
systolic O
aortic O
pressure O
( O
ALL_CAP O
) O
to O
stroke O
volume O
( O
RARE O
). O

Functional O
analysis O
of O
promoter O
activity O
of O
the O
5 O
'- O
flanking O
region O
of O
RARE I-GENE
NUM I-GENE
suggested O
that O
the O
region O
- O
1 O
, O
NUM O
to O
- O
NUM O
including O
C I-GENE
/ I-GENE
EBP I-GENE
, O
PEA3 I-GENE
, O
AP2 I-GENE
, O
ALL_CAP I-GENE
- I-GENE
Y I-GENE
, O
c I-GENE
- I-GENE
RARE I-GENE
, O
and O
NUM I-GENE
may O
have O
a O
major O
positive O
regulatory O
activity O
RARE O
RARE O
of O
RARE I-GENE
NUM I-GENE
. O

Effect O
of O
RARE O
on O
minimal O
effective O
ALL_CAP O
pressure O

In O
contrast O
, O
RARE O
of O
a O
RARE O
- O
impaired O
NUM I-GENE
mutant O
( O
NUM O
) O
was O
RARE O
following O
the O
overexpression O
of O
either O
NUM I-GENE
or O
beta I-GENE
- I-GENE
RARE I-GENE
1 I-GENE
. O

The O
medium O
chains O
of O
these O
complexes O
, O
NUM I-GENE
and O
NUM I-GENE
, O
have O
been O
implicated O
in O
two O
RARE O
of O
interaction O
: O
assembly O
with O
the O
beta1 I-GENE
and I-GENE
NUM I-GENE
chains I-GENE
of O
the O
corresponding O
complexes O
and O
recognition O
of O
tyrosine O
- O
based O
RARE O
signals O
. O

We O
have O
overexpressed O
, O
RARE O
, O
characterized O
, O
and O
RARE O
the O
BTB I-GENE
/ O
ALL_CAP O
domain O
from O
PLZF I-GENE
( O
PLZF I-GENE
- O
BTB I-GENE
/ O
ALL_CAP O
). O

RARE O
shock O
stimulates O
NUM I-GENE
translocation O
in O
NUM O
adipocytes O
by O
a O
novel O
tyrosine I-GENE
kinase I-GENE
RARE O
. O

We O
also O
identified O
NUM I-GENE
, O
Sp3 I-GENE
, O
and O
ALL_CAP I-GENE
- I-GENE
A I-GENE
/ O
RARE I-GENE
- I-GENE
1 I-GENE
RARE O
the O
RARE O
nuclear O
transcription O
factors O
binding O
to O
NUM I-GENE
which O
mediate O
RARE I-GENE
responsiveness O
. O

Interestingly O
, O
segment O
RARE O
differentially O
increases O
the O
copy O
number O
of O
genes O
encoded O
by O
segment O
ALL_CAP O
, O
suggesting O
that O
the O
unusual O
genomic O
organization O
of O
RARE O
may O
be O
directly O
RARE O
to O
the O
unique O
functions O
of O
this O
virus O
in O
its O
RARE O
RARE O
association O
with O
RARE O
RARE O
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
performed O
with O
chloramphenicol I-GENE
RARE I-GENE
constructs I-GENE
revealed O
that O
RARE I-GENE
was O
RARE O
activating O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
via O
two O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
present O
RARE O
bp O
- O
72 O
and O
- O
57 O
in O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
gene I-GENE
promoter I-GENE
, O
with O
both O
of O
them O
being O
required O
RARE O
the O
RARE I-GENE
- O
RARE O
RARE O
of O
this O
adhesion O
molecule O
. O

The O
ALL_CAP I-GENE
and I-GENE
ALL_CAP I-GENE
/ I-GENE
RARE I-GENE
mouse I-GENE
NUM I-GENE
proteins I-GENE
are O
97 O
. O
7 O
to O
98 O
. O
3 O
% O
and O
NUM O
. O
8 O
% O
identical O
to O
the O
human O
protein O
, O
respectively O
. O

RARE O
of O
DNA O
RARE O
by O
the O
mutant O
RARE O
containing O
RARE I-GENE
- I-GENE
NUM I-GENE
was O
unaffected O
on O
RARE O
( O
ALL_CAP O
) O
RARE O
RARE O
( O
dT O
) O
but O
was O
dramatically O
RARE O
on O
a O
RARE O
template O
with O
secondary O
RARE O
. O

RARE O
substitution O
mutations O
in O
the O
Zta I-GENE
activation I-GENE
domain I-GENE
which O
RARE O
the O
ability O
of O
Zta I-GENE
to O
stimulate O
the O
D I-GENE
- I-GENE
A I-GENE
complex I-GENE
were O
examined O
. O

The O
RARE I-GENE
and O
RARE I-GENE
proteins O
share O
a O
homology O
domain O
with O
38 O
% O
identity O
over O
a O
length O
of O
65 O
amino O
RARE O
, O
termed O
the O
ALL_CAP O
domain O
, O
that O
is O
RARE O
RARE O
their O
respective O
C O
termini O
. O

It O
has O
been O
previously O
shown O
that O
genes O
RARE O
by O
RNA I-GENE
polymerase I-GENE
II I-GENE
( O
RNAP I-GENE
II I-GENE
) O
are O
subject O
to O
position O
effect O
RARE O
when O
RARE O
near O
yeast O
RARE O
. O

RARE O
, O
NUM I-GENE
- I-GENE
delta I-GENE
reduces O
silencing O
of O
the O
RARE I-GENE
- I-GENE
RARE I-GENE
RNAP I-GENE
II I-GENE
- I-GENE
RARE I-GENE
genes I-GENE
NUM I-GENE
and O
NUM I-GENE
. O

The O
amplitude O
of O
RARE O
contractions O
RARE O
6 O
, O
12 O
, O
and O
NUM O
hours O
showed O
RARE O
significant O
difference O
from O
that O
in O
the O
controls O
. O

In O
the O
predicted O
transmembrane O
domain O
, O
RARE I-GENE
- I-GENE
NUM I-GENE
and O
RARE I-GENE
- I-GENE
NUM I-GENE
are O
NUM O
% O
identical O
to O
RARE I-GENE
- I-GENE
NUM I-GENE
. O

Recently O
, O
roles O
also O
have O
been O
suggested O
RARE O
the O
nuclear O
RARE O
- O
factor O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
in O
RARE O
RARE O
cell O
RARE O
. O

PET O
activation O
studies O
are O
performed O
widely O
to O
study O
human O
brain O
function O
. O

F I-GENE
- I-GENE
box I-GENE
proteins I-GENE
are O
receptors O
that O
recruit O
RARE O
RARE O
to O
the O
ALL_CAP I-GENE
ubiquitin I-GENE
- O
ligase I-GENE
complex O
. O

In O
the O
context O
of O
liver O
RARE O
RARE O
, O
our O
results O
suggest O
that O
an O
ALL_CAP O
should O
not O
be O
performed O
in O
patients O
with O
cardiac O
failure O
, O
more O
than O
two O
ALL_CAP O
, O
or O
an O
ALL_CAP O
II O
score O
RARE O
than O
NUM O
. O

The O
SH3 I-GENE
domains I-GENE
of O
Grb2 I-GENE
RARE O
in O
vitro O
to O
specific O
proline O
- O
rich O
motifs O
in O
the O
NUM I-GENE
RARE O
and O
functioned O
synergistically O
to O
direct O
the O
stable O
binding O
of O
Grb2 I-GENE
to O
NUM I-GENE
in O
transfected O
NUM O
cells O
. O

By O
far O
- O
Western O
analysis O
and O
RARE O
studies O
, O
we O
demonstrate O
that O
NUM I-GENE
interacts O
, O
via O
its O
zinc O
finger O
domain O
, O
with O
the O
RARE O
largest O
subunit O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
( O
pol I-GENE
RARE I-GENE
) O
but O
not O
with O
the O
RARE O
form O
. O

Thus O
, O
NUM I-GENE
RARE O
in O
nuclear O
domains O
RARE O
in O
pre O
- O
mRNA O
RARE O
factors O
, O
its O
RNA O
binding O
activity O
, O
and O
its O
direct O
RARE O
interaction O
with O
the O
pol I-GENE
RARE I-GENE
, O
a O
form O
of O
the O
RNA I-GENE
polymerase I-GENE
functionally O
associated O
with O
pre O
- O
mRNA O
RARE O
, O
suggest O
a O
role O
RARE O
this O
RARE O
of O
the O
KRAB I-GENE
RARE I-GENE
protein I-GENE
family I-GENE
in O
RNA O
RARE O
. O

RARE I-GENE
- I-GENE
NUM I-GENE
- I-GENE
12 I-GENE
RARE O
cells O
RARE O
2 O
- O
RARE O
elevated O
protein O
levels O
of O
the O
RARE I-GENE
cysteine I-GENE
protease I-GENE
RARE I-GENE
B I-GENE
but O
did O
not O
RARE O
- O
regulate O
RARE I-GENE
B I-GENE
mRNA I-GENE
RARE O
. O

The O
cellular O
rate O
of O
RARE I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
( O
RARE I-GENE
) O
generation O
is O
determined O
by O
the O
level O
of O
a O
RARE O
limiting O
RARE O
activity O
, O
RARE O
conversion O
activity O
, O
which O
is O
predominantly O
composed O
of O
the O
long O
sought O
RARE I-GENE
RARE I-GENE
D I-GENE
- I-GENE
RARE I-GENE
3 I-GENE
- I-GENE
O I-GENE
- I-GENE
RARE I-GENE
( O
3 I-GENE
- I-GENE
ALL_CAP I-GENE
) O
( O
RARE O
, O
N O
. O

Interestingly O
, O
ALL_CAP I-GENE
, O
but O
not O
insulin I-GENE
, O
RARE O
tyrosine O
RARE O
of O
c I-GENE
- I-GENE
cbl I-GENE
and O
its O
association O
with O
Crk I-GENE
- I-GENE
II I-GENE
. O

An O
end O
to O
the O
RARE O
. O

We O
previously O
showed O
that O
the O
N O
- O
terminal O
portion O
common O
to O
various O
chimeric I-GENE
ALL_CAP I-GENE
products I-GENE
, O
RARE O
RARE O
RARE O
to O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
and O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
localizes O
in O
the O
nuclei O
, O
and O
therefore O
suggested O
that O
it O
might O
play O
an O
important O
role O
in O
RARE O
. O

Our O
results O
suggest O
that O
the O
pattern O
of O
RARE O
supply O
is O
relevant O
to O
the O
structural O
RARE O
of O
RARE O
RARE O
bone O
around O
the O
implant O
. O

Induction O
of O
NUM I-GENE
mRNA I-GENE
accumulation O
in O
salt O
- O
treated O
seedlings O
involves O
an O
immediate O
early O
transcriptional O
response O
regulated O
by O
ALL_CAP O
signalling O
that O
is O
not O
inhibited O
by O
RARE O
, O
but O
abolished O
by O
the O
deficiency O
of O
ALL_CAP O
biosynthesis O
in O
the O
NUM I-GENE
Arabidopsis I-GENE
mutant I-GENE
. O

It O
thus O
appears O
that O
ALL_CAP I-GENE
functions O
in O
RARE O
RARE O
by O
preventing O
RARE O
eggs O
from O
RARE O
into O
RARE O
development O
. O

( O
ii O
) O
An O
ALL_CAP O
G I-GENE
- I-GENE
CSF I-GENE
level O
> O
2000 O
pg O
/ O
ml O
is O
a O
strong O
positive O
predictor O
of O
ALL_CAP O
. O

A O
positive O
correlation O
between O
serum I-GENE
myoglobin I-GENE
and O
CA I-GENE
III I-GENE
concentrations O
( O
rs O
= O
NUM O
. O
NUM O
, O
P O
< O
NUM O
. O
001 O
) O
was O
observed O
in O
RARE O
patients O
with O
chronic O
RARE O
failure O
. O

Furthermore O
, O
the O
over O
- O
replication O
RARE O
produced O
by O
this O
mutant I-GENE
NUM I-GENE
is O
resistant O
to O
increased O
RARE O
RARE I-GENE
/ O
CDK I-GENE
activity O
, O
a O
known O
inhibitor O
of O
over O
- O
replication O
. O

NUM I-GENE
is O
RARE O
, O
associated O
with O
nuclear O
RARE O
complexes O
, O
and O
structurally O
related O
to O
the O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
family I-GENE
of O
RARE O
proteins O
. O

The O
ALL_CAP O
domain O
is O
similar O
RARE O
the O
amino O
acid O
level O
to O
the O
Escherichia I-GENE
coli I-GENE
ALL_CAP I-GENE
gene I-GENE
product I-GENE
, O
while O
ALL_CAP O
is O
similar O
to O
the O
E I-GENE
. I-GENE
coli I-GENE
ALL_CAP I-GENE
product I-GENE
, O
with O
both O
E O
. O
coli O
products O
encoded O
by O
different O
RARE O
. O

RARE O
in O
each O
of O
these O
regions O
RARE O
membrane O
RARE O
of O
NUM I-GENE
and O
membrane O
RARE O
, O
suggesting O
that O
they O
function O
RARE O
. O

However O
, O
RARE O
the O
kinase O
catalytic O
domain O
and O
double O
leucine O
/ O
RARE O
RARE O
, O
there O
was O
RARE O
significant O
homology O
with O
known O
proteins O
. O

RNA I-GENE
polymerase I-GENE
II I-GENE
inhibition O
increased O
the O
binding O
of O
ALL_CAP O
( O
ALL_CAP O
activity O
) O
and O
RARE O
( O
ALL_CAP O
)- O
RARE O
by O
cytoplasmic I-GENE
ALL_CAP I-GENE
NUM I-GENE
, O
while O
nuclear I-GENE
ALL_CAP I-GENE
NUM I-GENE
binding O
was O
unaffected O
. O

RARE O
of O
ALL_CAP O
response O
element O
binding O
by O
RARE I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
NUM I-GENE
in O
human O
T O
lymphocytes O
. O

Histological O
RARE O
of O
one O
biopsy O
of O
each O
patient O
( O
formalin O
- O
fixed O
and O
RARE O
- O
embedded O
) O
were O
stained O
with O
a O
RARE O
RARE O
( O
ALL_CAP O
RARE O
the O
RARE O
- O
RARE O
( O
ALL_CAP O
RARE O
and O
an O
immunohistochemical O
method O
( O
ALL_CAP O
) O
using O
RARE O
RARE O
H O
. O
RARE O
RARE O
( O
ALL_CAP O
NUM O
). O

Their O
biosynthesis O
RARE O
via O
RARE O
RARE O
that O
become O
RARE O
by O
beta1 I-GENE
, I-GENE
6 I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
( O
NUM O
, O
RARE O
to O
RARE O
). O

These O
findings O
indicate O
that O
the O
t O
( O
4 O
; O
14 O
)( O
NUM O
. O
3 O
; O
NUM O
) O
represents O
a O
novel O
, O
recurrent O
chromosomal O
translocation O
in O
ALL_CAP O
, O
and O
suggest O
that O
the O
NUM I-GENE
gene I-GENE
may O
be O
the O
target O
of O
this O
abnormality O
and O
thus O
contribute O
to O
tumorigenesis O
in O
ALL_CAP O
. O

In O
addition O
, O
mutation O
of O
the O
NUM I-GENE
site I-GENE
also O
significantly O
RARE O
promoter O
activity O
. O

Amino O
acid O
residues O
of O
beta O
1 O
RARE O
alpha O
A O
RARE O
alpha O
B O
RARE O
and O
the O
loop O
containing O
NUM O
of O
the O
RNase I-GENE
H I-GENE
domain I-GENE
interact O
with O
the O
primer O
RARE O
of O
the O
ALL_CAP O
. O

Moreover O
, O
in O
one O
patient O
with O
a O
sarcoma O
who O
underwent O
a O
leg O
- O
RARE O
procedure O
, O
RARE O
RARE O
nerve O
enlargement O
was O
seen O
postoperatively O
. O

The O
full O
length O
cDNA O
sequence O
of O
a O
RARE I-GENE
I I-GENE
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
( I-GENE
TGF I-GENE
- I-GENE
beta I-GENE
) I-GENE
receptor I-GENE
has O
been O
isolated O
from O
the O
RARE O
RARE O
nematode O
RARE O
RARE O
. O

This O
sequence O
possessed O
homology O
with O
a O
methylation O
- O
RARE O
promoter O
element O
, O
NUM O
, O
present O
in O
the O
LTR O
of O
mouse O
RARE O
A O
- O
RARE O
. O

RARE O
RARE O
RARE O
high O
- O
level O
RARE O
of O
human I-GENE
erythropoietin I-GENE
( O
EPO I-GENE
) O
in O
mammalian O
cells O
. O

RARE O
rise O
in O
RARE I-GENE
albumin I-GENE
levels O
after O
treatment O
of O
essential O
hypertension O
. O

20 O
% O
of O
RARE O
ALL_CAP I-GENE
transcripts I-GENE
in O
human O
subcutaneous O
adipocytes O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
NUM I-GENE
/ O
NUM I-GENE
is O
RARE O
within O
the O
ALL_CAP O
through O
its O
RARE O
- O
RARE O
region O
and O
adjacent O
sequences O
. O

In O
a O
group O
of O
NUM O
patients O
with O
RARE O
RARE O
of O
the O
lower O
RARE O
the O
plasma O
levels O
of O
RARE I-GENE
( O
ALL_CAP I-GENE
RARE O
RARE I-GENE
( O
beta I-GENE
- I-GENE
TG I-GENE
RARE O
D O
- O
RARE O
( O
ALL_CAP O
) O
and O
plasminogen I-GENE
activator I-GENE
- I-GENE
inhibitor I-GENE
( O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
) O
were O
measured O
, O
and O
compared O
to O
the O
values O
obtained O
from O
10 O
healthy O
volunteers O
. O

These O
residues O
, O
NUM O
RARE O
the O
extracellular O
end O
of O
transmembrane O
helix O
3 O
, O
and O
NUM O
RARE O
the O
ALL_CAP O
- O
terminal O
portion O
of O
extracellular O
loop O
2 O
, O
are O
replaced O
by O
RARE O
and O
Ile O
in O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
receptor I-GENE
, O
respectively O
. O

We O
have O
now O
shown O
that O
in O
vivo O
RARE O
of O
14 I-GENE
- I-GENE
3 I-GENE
- I-GENE
3 I-GENE
RARE I-GENE
RARE O
the O
RARE I-GENE
site I-GENE
( I-GENE
RARE I-GENE
- I-GENE
NUM I-GENE
) I-GENE
negatively O
regulates O
its O
binding O
to O
c I-GENE
- I-GENE
Raf I-GENE
, O
and O
may O
be O
important O
in O
Raf I-GENE
- O
RARE O
signal O
RARE O
. O

RARE I-GENE
RARE I-GENE
cell I-GENE
protease I-GENE
9 I-GENE
, O
a O
novel O
RARE O
of O
the O
RARE O
14 O
family O
of O
serine I-GENE
RARE I-GENE
that O
is O
selectively O
RARE O
in O
RARE O
RARE O
cells O
. O

A O
DNase I-GENE
I I-GENE
- I-GENE
RARE I-GENE
site I-GENE
has O
also O
been O
mapped O
in O
the O
258 O
- O
RARE O
RARE O
enhancer O
region O
. O

RARE O
RARE O
vascular O
resistance O
( O
ALL_CAP O
) O
RARE O
10 O
% O
NUM O
- O
ALL_CAP O
RARE O
21 O
% O
NUM O
/ O
ALL_CAP O
RARE O
21 O
% O
NUM O
] O
RARE O
NUM O
was O
termed O
RARE O
hypoxic O
pulmonary O
RARE O
( O
HPV O
). O

Together O
, O
our O
results O
show O
that O
RARE I-GENE
is O
RARE O
by O
an O
RARE O
of O
discrete O
enhancer O
elements O
that O
are O
activated O
RARE O
by O
differential O
genetic O
inputs O
, O
RARE O
RARE O
RARE O
by O
closely O
RARE O
activator O
and O
repressor O
binding O
sites O
within O
an O
early O
- O
acting O
enhancer O
, O
which O
RARE O
RARE I-GENE
activity O
to O
specific O
areas O
within O
the O
RARE I-GENE
RARE I-GENE
domain I-GENE
. O

An O
unusual O
cysteine O
triplet O
RARE O
in O
the O
sequences O
of O
ALL_CAP I-GENE
domains I-GENE
is O
localized O
to O
the O
hydrophobic O
core O
, O
RARE O
the O
C O
- O
terminus O
of O
an O
alpha O
- O
helix O
. O

The O
RARE I-GENE
protein I-GENE
regulates O
site O
- O
specific O
DNA O
inversion O
catalyzed O
by O
a O
family O
of O
DNA I-GENE
RARE I-GENE
when O
RARE O
to O
a O
cis O
- O
acting O
RARE O
enhancer O
. O

Protein O
RARE O
play O
a O
critical O
role O
in O
the O
RARE O
of O
the O
eukaryotic O
cell O
RARE O
and O
signal O
RARE O
. O

The O
cell O
RARE O
- O
regulated O
transcription O
factor O
E2F I-GENE
is O
also O
known O
to O
RARE O
DNA O
upon O
binding O
. O

Our O
study O
reveals O
that O
the O
RARE O
RARE O
of O
the O
FSH I-GENE
receptor I-GENE
gene O
generates O
motifs O
that O
allows O
coupling O
to O
different O
RARE O
. O

Transcriptional O
RARE O
of O
NUM I-GENE
and O
NUM I-GENE
in I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

These O
studies O
serve O
RARE O
the O
basis O
RARE O
the O
further O
characterization O
of O
the O
regulatory O
mechanism O
of O
aromatase I-GENE
RARE O
in O
human O
breast O
RARE O
and O
RARE O
. O

Xenopus I-GENE
Ran I-GENE
- I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
: O
RARE O
interactions O
and O
effects O
on O
nuclear O
assembly O
in O
Xenopus O
RARE O
extracts O
. O

RARE O
improved O
with O
a O
combination O
of O
RARE O
and O
the O
RARE I-GENE
inhibitor O
RARE O
. O

METHODS O
: O
Total O
muscle O
RARE O
was O
RARE O
under O
RARE O
anesthesia O
in O
a O
group O
of O
obese O
persons O
( O
RARE O
= O
9 O
; O
body O
mass O
index O
, O
NUM O
+/- O
3 O
kg O
RARE O
2 O
RARE O
and O
in O
a O
group O
of O
RARE O
persons O
( O
RARE O
= O
9 O
; O
body O
RARE O
index O
, O
21 O
+/- O
2 O
kg O
RARE O
2 O
RARE O

PKA I-GENE
RARE O
WT1 I-GENE
RARE O
RARE O
- O
NUM O
and O
RARE O
- O
NUM O
in O
vitro O
, O
RARE O
RARE O
RARE O
RARE O
additional O
sites O
, O
and O
this O
RARE O
abolished O
the O
DNA O
- O
binding O
activity O
of O
WT1 I-GENE
in O
vitro O
. O

Our O
findings O
provide O
the O
RARE O
evidence O
that O
the O
function O
of O
WT1 I-GENE
can O
be O
modulated O
by O
its O
RARE O
in O
vivo O
. O

Re O
: O
" O
RARE O
the O
direction O
of O
RARE O
in O
cross O
- O
sectional O
studies O
". O

A O
second O
aim O
was O
to O
determine O
whether O
the O
decrease O
in O
muscle O
- O
tendon O
unit O
rest O
length O
produced O
by O
prolonged O
RARE O
in O
a O
shortened O
position O
is O
RARE O
primarily O
by O
RARE O
of O
the O
muscle O
or O
tendon O
. O

The O
presence O
of O
an O
additional O
sequence O
of O
nucleotides O
NUM O
- O
165 O
from O
the O
3 O
' O
end O
of O
NUM I-GENE
RARE O
template O
recognition O
by O
RARE I-GENE
in O
vitro O
and O
accumulation O
of O
NUM I-GENE
in O
vivo O
to O
wild O
- O
type O
levels O
. O

We O
RARE O
that O
the O
RARE O
role O
of O
RARE I-GENE
in O
controlling O
polarity O
is O
to O
cause O
anterior O
compartment O
cells O
to O
reverse O
their O
interpretation O
of O
an O
underlying O
RARE O
RARE O
. O

Restriction O
enzyme O
mapping O
, O
RARE O
, O
and O
DNA O
sequencing O
analysis O
of O
recombinant O
RARE O
lambda O
and O
P1 O
RARE O
revealed O
that O
exons O
encoding O
the O
1 O
. O
9 O
- O
kb O
mouse I-GENE
ALL_CAP I-GENE
mRNA I-GENE
are O
RARE O
over O
> O
NUM O
kb O
genomic O
DNA O
. O

Transfection O
analyses O
indicated O
that O
the O
RARE O
of O
NUM I-GENE
is O
RARE O
by O
a O
short O
( O
70 O
- O
bp O
) O
positive O
regulatory O
sequence O
and O
several O
upstream O
repressive O
elements O
. O

The O
results O
of O
this O
study O
suggest O
that O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
activity O
may O
be O
regulated O
by O
its O
interaction O
with O
the O
cell O
RARE O
regulatory O
protein O
, O
E2F I-GENE
- I-GENE
1 I-GENE
. O

The O
lysozyme I-GENE
ALL_CAP I-GENE
site O
is O
immediately O
5 O
' O
to O
a O
ALL_CAP I-GENE
. O

RARE I-GENE
( O
ALL_CAP I-GENE
) O
is O
a O
RARE I-GENE
RARE I-GENE
- I-GENE
binding I-GENE
protein I-GENE
RARE O
in O
RARE O
and O
RARE O
undergoing O
RARE O
. O

In O
this O
study O
, O
we O
examine O
the O
effects O
of O
NUM I-GENE
RARE O
on O
ALL_CAP I-GENE
promoter I-GENE
activation O
( O
luciferase I-GENE
reporter I-GENE
) O
by O
NUM I-GENE
/ O
ALL_CAP I-GENE
and O
RARE O
in O
NUM O
- O
E1 O
RARE O
. O

Thus O
, O
unlike O
other O
proteins O
reported O
to O
inhibit O
SRF I-GENE
activity O
, O
the O
repressor O
activity O
associated O
with O
the O
ALL_CAP O
- O
rich O
element O
does O
not O
appear O
to O
function O
through O
direct O
inhibition O
of O
SRF I-GENE
binding O
. O

However O
, O
one O
CAK I-GENE
- O
RARE O
RARE O
RARE O
with O
a O
Cdc2 I-GENE
- O
RARE O
RARE O
previously O
shown O
to O
be O
mitosis O
- O
specific O
, O
suggesting O
that O
, O
in O
vitro O
, O
CAK I-GENE
is O
able O
to O
phosphorylate O
RARE O
least O
one O
site O
that O
is O
also O
RARE O
in O
vivo O
. O

The O
RARE O
can O
RARE O
. O

The O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
structural I-GENE
gene I-GENE
is O
composed O
of O
NUM O
exons O
. O

However O
, O
when O
a O
second O
, O
upstream I-GENE
ALL_CAP I-GENE
- I-GENE
like I-GENE
sequence I-GENE
was O
evaluated O
by O
EMSA O
, O
a O
DNA O
binding O
pattern O
distinct O
from O
that O
seen O
following O
exposure O
to O
IFN I-GENE
- I-GENE
gamma I-GENE
alone O
was O
observed O
after O
prolonged O
RARE O
with O
both O
IFN I-GENE
- I-GENE
alpha I-GENE
and O
IFN I-GENE
- I-GENE
gamma I-GENE
. O

In O
Arabidopsis O
, O
the O
induction O
of O
a O
RARE O
- O
responsive O
gene O
, O
NUM I-GENE
, O
is O
RARE O
by O
RARE O
acid O
( O
ALL_CAP O
) O
and O
requires O
protein O
biosynthesis O
RARE O
ALL_CAP O
- O
dependent O
gene O
RARE O
. O

A O
cDNA O
encoding O
a O
ALL_CAP I-GENE
- I-GENE
related I-GENE
DNA I-GENE
binding I-GENE
protein I-GENE
was O
isolated O
by O
DNA O
- O
RARE O
binding O
screening O
, O
using O
the O
67 O
- O
bp O
region O
RARE O
a O
probe O
, O
and O
designated O
NUM I-GENE
. O

Human I-GENE
NUM I-GENE
is O
homologous O
to O
the O
Drosophila I-GENE
protein I-GENE
kinase I-GENE
NUM I-GENE
, O
which O
has O
been O
implicated O
in O
the O
RARE O
of O
RARE O
differentiation O
, O
RARE O
and O
RARE O
. O

Thus O
, O
the O
synergistic O
effects O
of O
HNF I-GENE
- I-GENE
1beta I-GENE
and O
the O
GR I-GENE
on O
dexamethasone O
- O
RARE O
promoter O
activity O
require O
that O
they O
are O
RARE O
to O
the O
HNF I-GENE
- I-GENE
1 I-GENE
site I-GENE
and O
the O
ALL_CAP O
, O
respectively O
, O
and O
may O
involve O
protein O
- O
protein O
interactions O
between O
the O
transcription O
factors O
, O
or O
between O
them O
and O
the O
basal O
transcription O
machinery O
or O
a O
steroid I-GENE
receptor I-GENE
RARE I-GENE
. O

Mutational O
analysis O
shows O
that O
both O
an O
AP I-GENE
- I-GENE
1 I-GENE
like I-GENE
sequence I-GENE
RARE O
NUM O
/- O
285 O
, O
ALL_CAP O
) O
and O
an O
A O
/ O
T O
- O
rich O
RARE I-GENE
enhancer I-GENE
factor I-GENE
( I-GENE
MEF I-GENE
)- I-GENE
2 I-GENE
like I-GENE
sequence I-GENE
RARE O
NUM O
/- O
NUM O
, O
ALL_CAP O
) O
in O
the O
NUM O
- O
bp O
region O
are O
necessary O
RARE O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
effect O
. O

Unlike O
most O
other O
members O
of O
the O
Bcl I-GENE
- I-GENE
2 I-GENE
family I-GENE
, O
ALL_CAP I-GENE
( O
Bcl I-GENE
- I-GENE
ALL_CAP I-GENE
/ I-GENE
Bcl I-GENE
- I-GENE
2 I-GENE
associated I-GENE
RARE I-GENE
promoter I-GENE
RARE O
a O
RARE I-GENE
enhancer I-GENE
, O
has O
RARE O
C O
- O
terminal O
transmembrane O
domain O
RARE O
targeting O
to O
the O
RARE O
mitochondrial O
membrane O
and O
nuclear O
envelope O
. O

RARE O
shift O
and O
cotransfection O
assays O
demonstrated O
that O
NUM I-GENE
, O
but O
not O
NUM I-GENE
, O
RARE O
to O
its O
RARE O
site O
and O
transactivated O
NUM I-GENE
gene I-GENE
RARE O
. O

An O
RARE O
reading O
frame O
of O
NUM O
bp O
encoding O
a O
NUM O
amino O
acid O
protein O
was O
identified O
. O

One O
of O
these O
, O
an O
ALL_CAP O
motif O
, O
has O
been O
shown O
to O
be O
a O
negative O
regulator O
in O
non O
- O
RARE O
tissues O
and O
has O
a O
RARE O
to O
the O
RARE O
RARE O
responsive O
element O
RARE O
by O
ALL_CAP I-GENE
- I-GENE
like I-GENE
DNA I-GENE
binding I-GENE
proteins I-GENE
. O

RARE O
NUM O
is O
an O
R O
. O
RARE O
mutant O
RARE O
by O
a O
single O
NUM I-GENE
RARE O
in O
the O
promoter O
region O
of O
the O
ALL_CAP I-GENE
gene I-GENE
cluster I-GENE
. O

Expression O
of O
RARE O
biosynthetic O
genes O
( O
ALL_CAP I-GENE
) O
and O
production O
of O
RARE I-GENE
terminal I-GENE
oxidase I-GENE
NUM I-GENE
in O
RARE O
RARE O
. O

We O
have O
RARE O
and O
sequenced O
a O
region O
encoding O
a O
lipase I-GENE
operon I-GENE
and O
a O
putative O
, O
previously O
uncharacterized O
RARE I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
NUM I-GENE
. O

Furthermore O
, O
the O
amount O
of O
tRNA I-GENE
( I-GENE
NUM I-GENE
) I-GENE
that O
was O
placed O
onto O
viral O
RNA O
in O
RARE O
viruses O
was O
significantly O
less O
than O
that O
placed O
in O
the O
wild O
- O
type O
virus O
. O

This O
protein O
is O
present O
in O
both O
HeLa O
nuclear O
extracts O
and O
NUM I-GENE
extracts O
but O
absent O
from O
SR I-GENE
protein I-GENE
preparations O
, O
suggesting O
that O
it O
is O
not O
a O
classical O
SR I-GENE
protein I-GENE
. O

Differential O
RARE O
of O
the O
pre I-GENE
- I-GENE
C I-GENE
and O
RARE O
promoters O
of O
human O
hepatitis O
B O
virus O
by O
members O
of O
the O
nuclear I-GENE
receptor I-GENE
superfamily I-GENE
. O

RARE O
. O

RARE O
containing O
IE1 I-GENE
peptides I-GENE
dramatically O
activated O
transcription O
of O
the O
basal O
promoter O
only O
when O
lac I-GENE
operator I-GENE
sequences I-GENE
were O
present O
. O

The O
results O
of O
RARE I-GENE
assays O
performed O
with O
mutant I-GENE
NUM I-GENE
containing O
a O
deletion O
in O
its O
RNA O
- O
binding O
domain O
suggests O
that O
the O
essential O
role O
RARE O
NUM I-GENE
in O
replication O
is O
RARE O
to O
the O
protein O
' O
s O
ability O
to O
bind O
the O
mRNA O
template O
RARE O
minus O
- O
RARE O
RARE O
. O

We O
previously O
described O
two O
alanine O
cluster O
mutations O
, O
NUM O
to O
A O
( O
NUM O
)- O
NUM O
and O
NUM O
- O
NUM O
, O
which O
selectively O
inactivated O
the O
RARE O
RARE O
. O

Transfection O
of O
NUM O
and O
ALL_CAP O
- O
N O
- O
MC O
cells O
with O
constructs O
RARE O
of O
additional O
5 O
'- O
flanking O
fragments O
permitted O
the O
definition O
of O
a O
minimal O
NUM O
bp O
promoter O
fragment O
containing O
the O
RARE O
- O
TATA O
box O
and O
two O
putative O
SP1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
. O

Both O
inserts O
are O
larger O
than O
their O
RARE O
in O
eIF I-GENE
- I-GENE
2alpha I-GENE
kinases I-GENE
. O

Three O
RARE O
electrodes O
were O
inserted O
into O
the O
RARE O
and O
right O
lateral O
RARE O
RARE O
( O
ALL_CAP O
) O
and O
medial O
RARE O
RARE O
( O
ALL_CAP O
) O
of O
the O
C1 O
segment O
, O
to O
determine O
the O
RARE O
of O
RARE O
. O

RARE O
of O
adhesion O
- O
RARE O
monoclonal O
antibodies O
map O
within O
a O
predicted O
alpha O
- O
helical O
domain O
of O
the O
integrin I-GENE
beta I-GENE
1 I-GENE
subunit I-GENE
. O

RARE I-GENE
and I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
may O
participate O
in O
a O
more O
RARE O
transcriptional O
mechanism O
that O
causes O
modulated O
gene O
repression O
, O
whereas O
the O
inclusion O
of O
RARE I-GENE
protein I-GENE
in O
the O
complex O
RARE O
RARE I-GENE
leads O
to O
stable O
silencing O
. O

Furthermore O
, O
both O
NUM I-GENE
proteins I-GENE
function O
in O
a O
defined O
ALL_CAP O
RARE O
reconstituted O
with O
RARE O
proteins O
, O
indicating O
direct O
involvement O
of O
NUM I-GENE
proteins I-GENE
in O
the O
DNA O
repair O
reaction O
via O
interaction O
with O
ALL_CAP I-GENE
. O

The O
yeast O
RARE I-GENE
RARE I-GENE
regulator I-GENE
NUM I-GENE
RARE O
and O
RARE O
plasmids O
. O

These O
results O
RARE O
a O
precursor O
- O
specific O
RARE O
- O
paired O
RARE O
involving O
sequences O
on O
both O
sides O
of O
the O
RARE O
RARE O
site O
in O
the O
3 O
' O
RARE O
of O
human I-GENE
NUM I-GENE
RNA I-GENE
. O

RARE O
analyses O
in O
a O
RARE O
- O
RARE O
NUM I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
and O
a O
NUM I-GENE
- O
depleted O
RARE O
reveal O
a O
decrease O
in O
the O
number O
of O
NUM I-GENE
ribosomal I-GENE
subunits I-GENE
. O

Sequence O
analysis O
identified O
some O
of O
these O
cDNA O
RARE O
RARE O
RARE I-GENE
- I-GENE
1 I-GENE
, O
a O
sequence O
encoding O
a O
small O
, O
9 I-GENE
- I-GENE
kDa I-GENE
human I-GENE
homolog I-GENE
of I-GENE
the I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
dynein I-GENE
light I-GENE
- I-GENE
chain I-GENE
protein O
. O

RARE O
, O
in O
HeLa O
and O
293 O
cells O
, O
endogenous O
and O
transfected O
I I-GENE
kappaB I-GENE
alpha I-GENE
RARE O
with O
RARE I-GENE
- O
RARE O
or O
endogenous O
RARE I-GENE
- I-GENE
1 I-GENE
. O

The O
mouse I-GENE
M I-GENE
- I-GENE
lysozyme I-GENE
RARE I-GENE
enhancer I-GENE
has O
been O
previously O
characterized O
on O
several O
levels O
of O
gene O
RARE O
. O

Identification O
of O
dynein I-GENE
heavy I-GENE
chain I-GENE
genes I-GENE
RARE O
in O
human O
and O
mouse O
RARE O
: O
chromosomal O
RARE O
of O
an O
RARE I-GENE
dynein I-GENE
gene I-GENE
. O

RARE O
RARE O
contains O
RARE O
RARE O
; O
RARE O
RARE O
them O
down O
to O
RARE O
RARE O
and O
hydrogen O
RARE O
. O

The O
proposed O
mechanism O
of O
effect O
states O
that O
mono O
( O
2 O
- O
RARE O
) O
RARE O
( O
ALL_CAP O
RARE O
the O
RARE O
hydrolysis O
product O
of O
ALL_CAP O
, O
RARE O
the O
inducing O
prostaglandins O
( O
ALL_CAP O
) O
ALL_CAP O
( O
2 O
RARE O
NUM O
, O
NUM O
, O
and O
NUM O
, O
and O
RARE O
in O
the O
lungs O
, O
thereby O
increasing O
the O
risk O
of O
inducing O
inflammation O
in O
the O
RARE O
, O
which O
is O
a O
characteristic O
of O
asthma O
. O

We O
found O
14 O
protein O
binding O
sites O
that O
were O
occupied O
in O
vivo O
. O

RARE O
protection O
of O
E2F I-GENE
recognition I-GENE
sequences I-GENE
in O
the O
human I-GENE
RARE I-GENE
kinase I-GENE
promoter I-GENE
RARE O
cell O
RARE O
progression O
. O

Comparison O
of O
genomic O
sequence O
shows O
that O
the O
RARE I-GENE
locus I-GENE
has O
been O
duplicated O
, O
and O
that O
it O
contains O
proximal O
and O
distal O
transcription O
RARE O
. O

RARE O
decreased O
the O
levels O
of O
T4 O
and O
NUM O
6 O
h O
and O
72 O
h O
in O
group O
C O
, O
in O
group O
A O
RARE O
72 O
h O
, O
in O
group O
B O
RARE O
NUM O
h O
postexposure O
. O

We O
have O
reviewed O
the O
experience O
of O
a O
major O
ALL_CAP O
RARE O
practice O
with O
hepatitis O
C O
virus O
( O
HCV O
) O
infection O
from O
1991 O
to O
1995 O
. O

The O
author O
RARE O
extensive O
own O
data O
based O
on O
study O
into O
particular O
features O
of O
cardiovascular O
disorders O
in O
chronic O
RARE O
RARE O
with O
making O
use O
of O
modern O
diagnostic O
tools O
. O

In O
this O
paper O
, O
characterization O
is O
given O
of O
clinical O
and O
biochemical O
features O
of O
ALL_CAP O
B O
course O
against O
the O
background O
of O
RARE O
. O

NUM O
microns O
RARE O
A O
. O
RARE O
and O
350 O
microns O
RARE O
A O
. O
RARE O
RARE O
and O
fewer O
testes O
per O
RARE O
( O
NUM O
- O
NUM O
RARE O
. O

The O
NUM I-GENE
cDNA I-GENE
hybridized O
to O
multiple O
transcripts O
in O
a O
thyroid O
RARE O
cell O
line O
( O
8 O
. O
NUM O
, O
4 O
. O
5 O
and O
2 O
kb O
) O
that O
increased O
after O
RARE O
treatment O
and O
RARE O
< O
2 O
h O
after O
addition O
of O
RARE O
D O
. O

RARE I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
)- O
E2F I-GENE
and O
GST I-GENE
- O
ALL_CAP I-GENE
fusion O
proteins O
were O
found O
to O
cooperate O
in O
binding O
to O
the O
three O
E2F I-GENE
sites I-GENE
in O
the O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
gene I-GENE
promoter I-GENE
in O
vitro O
. O

Two O
sterol O
regulatory O
element O
- O
like O
sequences O
mediate O
RARE O
- O
RARE O
of O
RARE I-GENE
gene I-GENE
transcription O
in O
response O
to O
low I-GENE
density I-GENE
lipoprotein I-GENE
free O
cholesterol O
. O

Furthermore O
, O
DNA O
- O
RARE O
NUM I-GENE
/ O
NUM I-GENE
RARE O
SMRT I-GENE
in O
vivo O
, O
and O
both O
overexpressed O
proteins O
completely O
RARE O
in O
nuclear O
RARE O
. O

CONCLUSIONS O
: O
We O
obtained O
normal O
EPO I-GENE
levels O
RARE O
mothers O
and O
newborns O
RARE O
our O
area O
, O
similarly O
to O
the O
previously O
described O
ones O
. O

RARE O
was O
RARE O
by O
a O
low O
flow O
rate O
of O
NUM O
. O
8 O
mL O
min O
- O
1 O
RARE O
NUM O
min O
, O
and O
was O
followed O
by O
a O
40 O
- O
minute O
reperfusion O
. O

First O
, O
two O
RARE O
using O
a O
long O
electrode O
, O
3 O
cm O
in O
size O
, O
were O
performed O
in O
the O
central O
area O
of O
the O
tumor O
, O
and O
eight O
RARE O
by O
a O
short O
electrode O
, O
2 O
cm O
in O
size O
, O
were O
done O
in O
the O
peripheral O
and O
surrounding O
area O
of O
the O
tumor O
. O

BACKGROUND O
: O
RARE O
pathways O
prevent O
cell O
- O
RARE O
progression O
in O
the O
event O
of O
DNA O
lesions O
. O

RARE O
RARE O
that O
the O
RARE O
RARE O
cellular O
apoptosis O
in O
ALL_CAP O
is O
not O
occurring O
through O
p53 I-GENE
was O
obtained O
by O
successive O
RARE O
between O
ALL_CAP O
and O
p53 I-GENE
RARE O
mice O
. O

RARE O
evidence O
indicates O
that O
, O
upon O
RARE O
with O
RARE I-GENE
- I-GENE
gamma I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
RARE O
three O
beta O
- O
type O
subunits O
, O
designated O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
, O
are O
incorporated O
into O
the O
20S I-GENE
proteasome I-GENE
by O
RARE O
the O
housekeeping O
beta O
- O
type O
subunits O
designated O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
, O
respectively O
. O

The O
major O
RNase I-GENE
E I-GENE
RARE O
product O
( O
RARE O
RARE I-GENE
- I-GENE
6 I-GENE
) O
is O
rapidly O
degraded O
by O
RARE I-GENE
RARE I-GENE
( O
RARE I-GENE
). O

This O
difference O
may O
result O
from O
the O
lower O
match O
to O
the O
ALL_CAP O
box O
consensus O
of O
the O
O I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
site I-GENE
. O

RARE O
ALL_CAP O
' O
s O
RARE O
RARE O
about O
RARE O
indicators O
. O

All O
pigs O
had O
significant O
regional O
LV O
dysfunction O
and O
RARE O
LV O
ejection O
fraction O
( O
NUM O
+/- O
11 O
%). O

The O
progress O
of O
morphological O
research O
on O
the O
RARE O
nucleus O

The O
amplitudes O
of O
ALL_CAP O
also O
recovered O
to O
a O
greater O
extent O
and O
RARE O
RARE O
cell O
RARE O
were O
less O
severe O
in O
the O
R O
- O
ALL_CAP O
- O
treated O
ears O
. O

The O
data O
provide O
evidence O
both O
RARE O
a O
signal O
RARE O
RARE O
independent O
of O
JNK I-GENE
, O
ERK I-GENE
, O
and O
p38 I-GENE
MAP I-GENE
kinase I-GENE
to O
be O
involved O
in O
the O
induction O
of O
ALL_CAP I-GENE
by O
RARE O
stress O
, O
and O
RARE O
, O
indicate O
autoregulation O
of O
ALL_CAP I-GENE
. O

In O
an O
effort O
to O
separate O
domains O
of O
ALL_CAP I-GENE
required O
RARE O
DNA O
binding O
, O
RARE O
, O
and O
RARE O
binding O
, O
chimeric O
protein O
fusions O
between O
the O
DNA O
binding O
domain O
of O
LexA I-GENE
and O
different O
regions O
of O
ALL_CAP I-GENE
were O
constructed O
. O

Inhibition O
appears O
to O
result O
from O
titration O
of O
RARE O
transcription O
factors O
because O
NUM I-GENE
overexpression O
inhibits O
c I-GENE
- I-GENE
fos I-GENE
RARE O
RARE O
RARE O
other O
promoters O
in O
vivo O
and O
basal O
transcription O
in O
vitro O
. O

4 O
) O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
lacked O
the O
canonical O
TATA O
or O
CAAT O
motifs O
, O
and O
are O
AT O
- O
rich O
. O

We O
also O
show O
by O
RARE O
electron O
microscopy O
RARE O
that O
RARE I-GENE
I I-GENE
is O
localized O
in O
the O
nerve O
terminal O
RARE O
and O
is O
partially O
associated O
with O
endocytic O
RARE O
. O

The O
mobility O
shift O
of O
both O
of O
these O
proteins O
is O
abolished O
by O
treatment O
with O
RARE O
of O
PKC I-GENE
or O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
/ O
extracellular I-GENE
signal I-GENE
- I-GENE
related I-GENE
kinase I-GENE
kinase I-GENE
. O

The O
RARE O
RARE O
RARE O
includes O
C1 O
- O
7 O
, O
NUM O
- O
9 O
and O
L2 O
- O
4 O
. O

During O
the O
RARE O
of O
RARE O
of O
the O
RARE O
sympathetic O
nerve O
by O
mental O
RARE O
, O
3 O
/ O
12 O
A O
delta O
RARE O
were O
turned O
to O
the O
RARE O
state O
with O
decreased O
mechanical O
threshold O
. O

In O
a O
similar O
fashion O
to O
RARE O
RARE O
cells O
, O
serum O
RARE O
the O
response O
to O
dexamethasone O
but O
had O
RARE O
effect O
on O
phorbol O
ester O
- O
RARE O
activity O
. O

Thus O
, O
RARE I-GENE
RARE O
RARE O
the O
RARE O
RARE O
RARE O
anteroposterior O
asymmetry O
in O
the O
mouse O
RARE O
and O
indicates O
that O
the O
anteroposterior O
axis O
of O
the O
RARE O
RARE O
from O
conversion O
of O
a O
RARE O
asymmetry O
established O
in O
the O
RARE O
endoderm O
lineage O
. O

Thus O
, O
RARE I-GENE
and O
RARE I-GENE
promote O
both O
dorsal O
leg O
cell O
fate O
RARE O
RARE O
RARE O
RARE O
- O
competent O
leg O
disc O
cells O
. O

CONCLUSIONS O
: O
While O
ALL_CAP O
correction O
may O
be O
achieved O
by O
all O
the O
above O
methods O
, O
that O
RARE O
log O
reference O
ALL_CAP O
to O
log O
local O
prothrombin I-GENE
time O
by O
RARE O
regression O
analysis O
is O
the O
RARE O
to O
perform O
. O

RESULTS O
: O
The O
overall O
ALL_CAP O
RARE O
1992 O
was O
12 O
. O
3 O
% O
and O
was O
19 O
. O
1 O
%, O
NUM O
. O
2 O
%, O
3 O
. O
8 O
% O
and O
6 O
. O
1 O
% O
per O
successive O
RARE O
in O
1992 O
. O

Western O
blot O
analysis O
of O
various O
bovine O
tissues O
with O
human O
ALL_CAP I-GENE
peptide I-GENE
antibody I-GENE
indicated O
a O
common O
prominent O
RARE O
band O
with O
an O
apparent O
RARE O
mass O
of O
NUM O
. O
5 O
- O
50 O
kDa O
in O
all O
tissues O
. O

Transcription O
RARE O
sites O
of O
the O
RARE O
RARE I-GENE
genes I-GENE
were O
estimated O
from O
the O
RARE O
cDNA O
RARE O
obtained O
by O
5 O
'- O
RACE O
( O
rapid O
amplification O
of O
cDNA O
ends O
). O

AIDS O
- O
related O
RARE O
RARE O
in O
RARE O
RARE O
, O
RARE O
. O

Thus O
, O
RARE I-GENE
acts O
RARE O
an O
RARE O
transcriptional O
activator O
RARE O
the O
RARE I-GENE
promoter I-GENE
. O

These O
observations O
provide O
strong O
support O
RARE O
the O
idea O
that O
RARE O
of O
mutant O
tRNA O
can O
confer O
a O
RARE O
RARE O
, O
including O
the O
ALL_CAP O
- O
RARE O
RARE O
observed O
in O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
cells O
. O

TNF I-GENE
- I-GENE
alpha I-GENE
exposure O
markedly O
increased O
activity O
of O
several O
RNA O
- O
binding O
proteins O
, O
especially O
a O
novel O
Mr O
50 O
, O
NUM O
- O
NUM O
, O
NUM O
RNA O
- O
binding O
protein O
. O

We O
RARE O
that O
the O
human O
RARE O
RARE O
mRNAs O
, O
produced O
from O
several O
hundred O
copies O
of O
the O
virus O
genome O
present O
in O
RARE O
cells O
, O
compete O
with O
the O
c I-GENE
- I-GENE
fos I-GENE
mRNAs I-GENE
RARE O
RARE O
cellular O
factors O
and O
that O
this O
may O
lead O
to O
elevated O
Fos I-GENE
protein I-GENE
levels O
in O
human O
RARE O
RARE O
cells O
. O

Two O
closely O
related O
ALL_CAP I-GENE
constant O
region O
genes O
, O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
, O
have O
been O
sequenced O
completely O
. O

The O
aim O
of O
this O
study O
was O
to O
find O
out O
whether O
it O
was O
possible O
to O
detect O
normal O
lymph O
nodes O
by O
high O
- O
resolution O
RARE O
US O
. O

To O
study O
the O
role O
of O
heavy O
chain O
motifs O
in O
substrate O
recognition O
, O
RARE O
variants O
of O
recombinant I-GENE
bovine I-GENE
RARE I-GENE
were O
constructed O
by O
replacing O
the O
transmembrane O
domain O
with O
a O
signal O
peptide O
. O

NUM I-GENE
- I-GENE
II I-GENE
is O
predicted O
to O
encode O
a O
type I-GENE
II I-GENE
transmembrane I-GENE
glycoprotein I-GENE
of O
NUM O
kDa O
with O
five O
RARE O
N O
- O
RARE O
glycosylation O
sites O
. O

We O
now O
demonstrate O
that O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( I-GENE
C I-GENE
/ I-GENE
EBP I-GENE
) I-GENE
delta I-GENE
is O
a O
major O
RARE O
of O
a O
PGE2 O
- O
RARE O
DNA O
- O
protein O
complex O
involving O
NUM I-GENE
and O
find O
that O
C I-GENE
/ I-GENE
RARE I-GENE
transactivates O
IGF I-GENE
- I-GENE
I I-GENE
promoter I-GENE
1 I-GENE
through O
this O
site O
. O

PATIENTS O
ALL_CAP O
METHODS O
: O
RARE O
analyses O
were O
performed O
on O
58 O
patients O
with O
stages O
I O
- O
III O
HD O
before O
, O
RARE O
, O
and O
after O
chemotherapy O
and O
after O
the O
sperm O
count O
recovered O
from O
the O
effects O
of O
abdominal O
radiotherapy O
that O
was O
given O
after O
chemotherapy O
. O

Thus O
, O
the O
absence O
of O
residual O
infarct O
- O
zone O
viability O
RARE O
patients O
who O
develop O
progressive O
RARE O
ventricular O
RARE O
after O
RARE O
AMI O
from O
those O
who O
maintain O
normal O
RARE O
ventricular O
RARE O
. O

With O
a O
BMI O
cutoff O
of O
NUM O
, O
mean O
cardiac O
ALL_CAP O
RARE O
was O
NUM O
% O
lower O
in O
the O
obese O
subjects O
when O
compared O
with O
the O
lean O
subjects O
( O
P O
=. O
NUM O
). O

The O
gene O
( O
ALL_CAP I-GENE
) O
encoding O
both O
RARE I-GENE
RARE I-GENE
peroxidase I-GENE
RARE I-GENE
was O
isolated O
and O
the O
organization O
of O
the O
gene O
was O
determined O
. O

This O
emphasizes O
the O
conclusion O
that O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
is O
not O
an O
E2F I-GENE
family I-GENE
RARE I-GENE
and O
points O
to O
profound O
differences O
in O
the O
cell O
RARE O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
and O
E2F I-GENE
. O

The O
RARE O
domain O
of O
Escherichia I-GENE
coli I-GENE
DNA I-GENE
polymerase I-GENE
I I-GENE
and O
other O
DNA I-GENE
and I-GENE
/ I-GENE
or I-GENE
RNA I-GENE
RARE I-GENE
domains I-GENE
. O

Interleukin I-GENE
- I-GENE
1 I-GENE
levels O
remained O
low O
throughout O
the O
course O
. O

RARE O
RARE O
RARE O
this O
is O
a O
RARE O
RARE O

Southern O
blot O
analysis O
of O
endonuclease O
- O
RARE O
genomic O
DNA O
from O
RARE O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
suggested O
that O
NUM I-GENE
is O
a O
single O
- O
copy O
gene O
in O
this O
RARE O
species O
. O

RARE O
required O
RARE O
interaction O
of O
NUM I-GENE
and O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
were O
localized O
to O
residues O
, O
NUM O
in O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
; O
this O
sequence O
is O
N O
- O
terminal O
to O
, O
but O
RARE O
with O
, O
a O
previously O
identified O
NUM I-GENE
binding I-GENE
motif I-GENE
, O
NUM O
, O
involved O
in O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
RARE O
. O

Here O
, O
we O
report O
that O
a O
transfected O
RARE O
hamster O
ovary O
( O
CHO O
) O
cell O
line O
expressing O
a O
murine I-GENE
NUM I-GENE
fragment I-GENE
containing O
the O
RARE O
two O
N O
- O
terminal O
domains O
RARE O
both O
RARE O
molecules O
and O
disulfide O
- O
RARE O
RARE O
. O

ALL_CAP O
V I-GENE
( O
D I-GENE
) O
ALL_CAP I-GENE
RARE O
can O
be O
partly O
RARE O
in O
T O
- O
lymphocytes O
by O
either O
DNA O
- O
RARE O
agents O
( O
gamma O
- O
irradiation O
and O
RARE O
) O
or O
a O
RARE O
mutation O
of O
the O
p53 I-GENE
gene I-GENE
, O
possibly O
because O
of O
transiently O
elevated O
DNA O
repair O
activity O
in O
response O
to O
DNA O
damage O
or O
to O
delayed O
apoptosis O
in O
the O
absence O
of O
p53 I-GENE
. O

RARE O
of O
mouse O
PKR I-GENE
( I-GENE
1 I-GENE
- I-GENE
NUM I-GENE
) I-GENE
ALL_CAP I-GENE
RARE O
a O
Gal4 I-GENE
DNA O
- O
binding O
domain O
fusion O
with O
either O
the O
catalytic O
- O
RARE O
human O
PKR I-GENE
( I-GENE
1 I-GENE
- I-GENE
NUM I-GENE
) I-GENE
NUM O
mutant O
, O
the O
RNA O
- O
binding O
- O
RARE O
human O
PKR I-GENE
( I-GENE
1 I-GENE
- I-GENE
NUM I-GENE
) I-GENE
NUM I-GENE
/ I-GENE
NUM I-GENE
double O
mutant O
, O
or O
wild O
- O
type O
mouse O
PKR I-GENE
( I-GENE
1 I-GENE
- I-GENE
NUM I-GENE
) I-GENE
ALL_CAP I-GENE
RARE O
full O
- O
length O
PKR I-GENE
- O
Gal4 I-GENE
activation O
domain O
fusions O
resulted O
in O
activation O
of O
the O
HIS3 I-GENE
and O
lacZ I-GENE
RARE O
. O

Using O
GST I-GENE
- O
PKR I-GENE
fusion O
chromatography O
, O
direct O
physical O
interaction O
between O
the O
mouse O
and O
human I-GENE
PKR I-GENE
homologs I-GENE
was O
established O
. O

An O
even O
greater O
inflammatory O
response O
was O
observed O
after O
RARE O
RARE O
of O
ALL_CAP O
, O
but O
not O
after O
ALL_CAP O
RARE O
. O

Interestingly O
, O
the O
RARE O
RARE O
NUM O
showed O
weak O
hybridization O
with O
these O
two O
RARE O
, O
suggesting O
that O
these O
genes O
might O
have O
been O
RARE O
in O
the O
RARE O
RARE O
or O
are O
present O
in O
limited O
copy O
numbers O
RARE O
opposed O
to O
those O
in O
the O
virulent O
RARE O
NUM O
. O

These O
defects O
RARE O
RARE O
RARE O
the O
folding O
and O
configuration O
necessary O
RARE O
normal O
RARE O
of O
the O
AVP I-GENE
gene I-GENE
precursor I-GENE
. O

RARE O
between O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
and O
phosphoenolpyruvate I-GENE
kinase I-GENE
( O
PEPCK I-GENE
) O
promoters O
, O
including O
regions O
conferring O
insulin I-GENE
, O
glucocorticoid O
, O
and O
cyclic O
adenosine O
- O
monophosphate O
responses O
, O
are O
consistent O
with O
our O
previous O
hypothesis O
that O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
is O
involved O
in O
RARE O
of O
glucose O
metabolism O
. O

This O
RARE O
repeat O
contains O
RARE O
DNA O
elements O
that O
include O
ALL_CAP O
, O
ALL_CAP O
, O
medium O
RARE O
frequency O
repeats O
, O
and O
a O
RARE O
- O
like O
element O
. O

At O
NUM O
days O
the O
amount O
of O
RARE O
was O
on O
average O
lower O
in O
females O
than O
in O
males O
, O
even O
if O
with O
some O
exception O
. O

RARE O
genomic O
constructs O
RARE O
RARE O
the O
endogenous O
locus O
by O
homologous O
RARE O
, O
but O
cDNA O
- O
derived O
sequences O
RARE O
long O
stretches O
of O
contiguous O
genomic O
DNA O
( O
due O
to O
intron O
RARE O
) O
typically O
RARE O
into O
chromosomal O
DNA O
by O
RARE O
RARE O
. O

The O
existence O
of O
these O
two O
categories O
of O
strains O
offers O
a O
new O
genetic O
RARE O
in O
which O
the O
properties O
of O
a O
RARE O
RARE O
RARE O
can O
be O
tested O
. O

During O
the O
conditioning O
procedure O
, O
the O
C O
- O
fiber O
reflex O
was O
facilitated O
( O
RARE O
- O
RARE O
) O
in O
a O
stimulus O
- O
dependent O
fashion O
in O
RARE O
, O
anesthetized O
animals O
RARE O
the O
application O
of O
the O
RARE O
RARE O
conditioning O
stimuli O
; O
thereafter O
, O
the O
magnitude O
of O
the O
responses O
reached O
a O
RARE O
and O
then O
decreased O
. O

As O
a O
sequence O
- O
specific O
DNA O
binding O
transcription O
factor O
, O
p53 I-GENE
specifically O
binds O
to O
a O
20 O
- O
bp O
consensus O
motif O
5 O
'- O
ALL_CAP O
( O
A O
/ O
T O
) O
( O
T O
/ O
A O
) O
ALL_CAP O
( O
A O
/ O
T O
)( O
T O
/ O
A O
) O
RARE O
- O
3 O
'. O

ALL_CAP O
treatment O
, O
however O
, O
did O
not O
RARE O
alter O
enhancer O
factor O
binding O
or O
the O
positioning O
of O
RARE I-GENE
- I-GENE
1 I-GENE
on O
the O
majority O
of O
the O
chromatin O
templates O
indicating O
that O
protein O
acetylation O
and O
chromatin O
remodeling O
may O
be O
limiting O
steps O
that O
occur O
only O
on O
transcriptionally O
competent O
templates O
, O
or O
that O
remodeling O
of O
RARE I-GENE
- I-GENE
1 I-GENE
requires O
additional O
factors O
. O

Upon O
ALL_CAP O
damage O
, O
NUM I-GENE
is O
transiently O
modified O
, O
probably O
RARE O
, O
with O
a O
similar O
timing O
of O
RARE O
in O
NUM I-GENE
kinase I-GENE
, O
which O
is O
reported O
to O
RARE O
Cdc2 I-GENE
activation O
. O

Moreover O
, O
moderate O
overexpression O
of O
NUM I-GENE
suppresses O
the O
RARE O
of O
NUM I-GENE
and O
NUM I-GENE
mutants I-GENE
. O

NUM I-GENE
/ O
NUM I-GENE
, O
a O
RARE O
- O
dependent O
transcription O
factor O
that O
differentially O
regulates O
gene O
RARE O
in O
Saccharomyces O
cerevisiae O
. O

Structure O
and O
RARE O
of O
the O
human O
gene O
encoding O
SR I-GENE
- I-GENE
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
. O

We O
introduced O
the O
gel O
technique O
RARE O
a O
routine O
assay O
RARE O
antibody O
detection O
and O
identification O
in O
1993 O
. O

RARE O
of O
RARE O
in O
a O
liquid O
dosage O
formulation O
stored O
RARE O
three O
months O
. O

Multiple O
regression O
analyses O
revealed O
that O
ALL_CAP O
- O
R O
factor O
scores O
RARE O
RARE O
and O
RARE O
from O
RARE O
RARE O
RARE O
RARE O
to O
NUM O
% O
of O
the O
RARE O
in O
ALL_CAP O
- O
R O
and O
ALL_CAP O
indices O
. O

RARE O
basal O
arteries O
were O
measured O
by O
the O
RARE O
approach O
with O
a O
2 O
RARE O
pulsed O
Doppler O
instrument O
( O
ALL_CAP O
- O
2 O
NUM O
ALL_CAP O
). O

At O
the O
genomic O
level O
, O
the O
sequences O
of O
two O
members O
of O
this O
family O
are O
known O
in O
the O
rat O
RARE O
RARE O
: O
the O
NUM I-GENE
gene I-GENE
, O
encoding O
the O
RARE I-GENE
- I-GENE
like I-GENE
polypeptide I-GENE
NUM I-GENE
, O
and O
the O
NUM I-GENE
gene I-GENE
, O
encoding O
a O
RARE O
RARE O
- O
rich O
polypeptide O
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
NUM I-GENE
gene I-GENE
, O
a O
homologue I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
, O
is O
DNA O
damage O
inducible O
and O
functions O
in O
a O
novel O
error O
- O
free O
RARE O
repair O
mechanism O
. O

However O
, O
in O
a O
new O
experiment O
in O
which O
the O
deletion O
task O
was O
presented O
RARE O
a O
RARE O
RARE O
, O
and O
with O
RARE O
and O
selection O
on O
RARE O
deletion O
, O
a O
significantly O
RARE O
level O
of O
success O
was O
achieved O
by O
the O
children O
working O
with O
the O
ALL_CAP O
material O
. O

RARE O
therapy O
with O
RARE O
proteins O
RARE O
chronic O
stomach O
ulcers O

In O
ALL_CAP O
patients O
, O
the O
ALL_CAP O
related O
to O
the O
postoperative O
rise O
in O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
level O
only O
, O
even O
though O
the O
rise O
in O
plasma O
concentrations O
of O
RARE O
RARE O
. O

Resistance O
training O
shifts O
the O
power O
curve O
in O
a O
positive O
direction O
when O
the O
measurements O
are O
determined O
with O
absolute O
RARE O
, O
but O
the O
increased O
power O
may O
not O
be O
transferred O
to O
an O
absolute O
performance O
task O
like O
the O
ALL_CAP O
. O

Gel O
- O
shift O
assays O
identified O
two O
NUM I-GENE
binding I-GENE
sites I-GENE
within O
this O
element O
. O

NUM I-GENE
( O
Surf I-GENE
- I-GENE
2 I-GENE
, O
Surf I-GENE
- I-GENE
4 I-GENE
RARE O
NUM I-GENE
( O
Surf I-GENE
- I-GENE
3 I-GENE
, O
Surf I-GENE
- I-GENE
1 I-GENE
, O
Surf I-GENE
- I-GENE
6 I-GENE
RARE O
and O
NUM I-GENE
( O
Surf I-GENE
- I-GENE
5 I-GENE
RARE O

Gel O
mobility O
shift O
and O
RARE O
- O
shift O
assays O
using O
liver O
nuclear O
extracts O
from O
either O
rat O
liver O
or O
NUM O
- O
2 O
cells O
demonstrated O
that O
the O
ALL_CAP O
in O
the O
alpha I-GENE
NUM I-GENE
- I-GENE
ALL_CAP I-GENE
gene I-GENE
RARE O
ALL_CAP I-GENE
binding I-GENE
protein I-GENE
. O

These O
results O
suggest O
that O
, O
in O
this O
experimental O
model O
, O
ACE I-GENE
RARE O
limit O
the O
arrhythmias O
following O
ischemia O
- O
reperfusion O
and O
free O
radical O
RARE O
action O
of O
these O
drugs O
does O
not O
have O
a O
major O
RARE O
role O
in O
their O
protective O
effect O
. O

The O
mean O
values O
of O
the O
RARE O
three O
RARE O
were O
not O
significantly O
different O
in O
ALL_CAP O
patients O
and O
control O
subjects O
. O

However O
, O
the O
RARE O
cascade O
utilized O
by O
the O
urokinase I-GENE
receptor I-GENE
is O
only O
RARE O
understood O
. O

The O
murine O
NUM I-GENE
- I-GENE
a I-GENE
/ O
NUM I-GENE
and O
NUM I-GENE
- I-GENE
c I-GENE
genes I-GENE
are O
divergently O
RARE O
from O
a O
shared O
TATA O
- O
less O
promoter O
. O

In O
RARE O
with O
clinical O
improvement O
we O
found O
a O
decrease O
of O
laboratory O
indicators O
of O
inflammation O
( O
C I-GENE
- I-GENE
reactive I-GENE
protein I-GENE
, O
alpha I-GENE
2 I-GENE
- I-GENE
RARE I-GENE
, O
RARE O
E2 O
). O

We O
have O
previously O
reported O
that O
depletion O
of O
protein I-GENE
kinase I-GENE
C I-GENE
by O
long O
- O
term O
treatment O
of O
NUM O
mouse O
RARE O
cells O
with O
phorbol O
RARE O
( O
RARE O
) O
prevented O
cell O
density O
- O
dependent O
RARE O
. O

RARE O
of O
residues O
in O
positions O
+ O
3 O
( O
NUM O
) O
and O
+ O
2 O
( O
NUM O
) O
of O
the O
reading O
helices O
of O
RARE O
2 O
and O
3 O
, O
respectively O
, O
prevented O
binding O
. O

Two O
RARE O
RARE O
, O
which O
are O
RARE O
in O
all O
RARE O
molecules O
and O
many O
ALL_CAP O
domains O
, O
RARE O
loop O
LA O
and O
RARE O
beta O
4 O
and O
loops O
ALL_CAP O
and O
ALL_CAP O
, O
respectively O
, O
RARE O
opposite O
RARE O
of O
the O
same O
face O
of O
the O
domain O
. O

RARE I-GENE
- I-GENE
RARE I-GENE
of O
tobacco O
: O
identification O
of O
a O
RARE I-GENE
D I-GENE
cDNA I-GENE
sequence I-GENE
encoding O
a O
third O
subunit O
, O
analysis O
of O
the O
interaction O
of O
the O
three O
subunits O
with O
the O
yeast O
two O
- O
RARE O
RARE O
, O
and O
RARE O
of O
the O
enzyme O
activity O
by O
RARE O
- O
RARE O
of O
recombinant I-GENE
ALL_CAP I-GENE
D I-GENE
, O
ALL_CAP I-GENE
H I-GENE
and O
ALL_CAP I-GENE
I I-GENE
. O

One O
R O
- O
ALL_CAP O
and O
one O
RARE I-GENE
- I-GENE
like I-GENE
sequence I-GENE
each O
mapped O
to O
two O
locations O
. O

The O
RARE O
RARE O
includes O
a O
cysteine O
- O
rich O
motif O
resembling O
those O
of O
protein I-GENE
kinase I-GENE
C I-GENE
and O
RARE I-GENE
- I-GENE
RARE I-GENE
and O
a O
putative O
pleckstrin I-GENE
homology I-GENE
domain I-GENE
. O

The O
interaction O
between O
ALL_CAP I-GENE
and O
E2F1 I-GENE
can O
also O
be O
detected O
by O
RARE O
experiments O
. O

NUM O
: O
NUM O
- O
NUM O
, O
1996 O
). O

Nevertheless O
, O
antibodies O
directed O
against O
an O
RARE O
- O
RARE O
version O
of O
NUM I-GENE
specifically O
RARE O
NUM I-GENE
ALL_CAP I-GENE
from O
yeast O
extracts O
. O

These O
results O
indicate O
that O
in O
addition O
to O
Grb2 I-GENE
- O
RARE O
activation O
of O
Ras I-GENE
, O
PLC I-GENE
- I-GENE
NUM I-GENE
- O
RARE O
ALL_CAP O
production O
is O
required O
RARE O
ALL_CAP I-GENE
- O
and O
ALL_CAP I-GENE
- O
RARE O
S O
- O
RARE O
entry O
and O
gene O
RARE O
, O
possibly O
through O
activation O
of O
PKC I-GENE
. O

In O
this O
study O
, O
we O
investigated O
STAT I-GENE
activation O
in O
a O
panel O
of O
rodent O
fibroblast O
cell O
lines O
stably O
transformed O
by O
diverse O
viral O
RARE O
. O

In O
serum O
- O
RARE O
cells O
, O
the O
binding O
of O
ALL_CAP I-GENE
- I-GENE
Y I-GENE
/ O
CBF I-GENE
to O
NUM I-GENE
increased O
gradually O
, O
RARE O
a O
RARE O
RARE O
the O
S O
RARE O
. O

CONCLUSION O
: O
In O
our O
RARE O
model O
, O
RARE O
- O
brain O
barrier O
disruption O
was O
a O
RARE O
, O
RARE O
finding O
of O
single O
- O
fraction O
, O
high O
- O
dose O
irradiation O
injury O
. O

To O
facilitate O
the O
investigation O
of O
parameters O
that O
govern O
selective O
export O
in O
adenovirus O
- O
RARE O
cells O
, O
we O
constructed O
a O
marked O
human O
beta I-GENE
- I-GENE
actin I-GENE
RARE I-GENE
under O
the O
control O
of O
the O
glucocorticoid I-GENE
- I-GENE
inducible I-GENE
enhancer I-GENE
- I-GENE
promoter I-GENE
of O
mouse O
mammary O
tumor O
virus O
and O
introduced O
it O
into O
the O
RARE O
end O
of O
the O
adenovirus O
type O
5 O
( O
NUM O
) O
genome O
. O

Cell O
factor O
- O
RARE O
regulatory O
interactions O
are O
involved O
in O
RARE O
the O
restricted O
RARE O
of O
the O
ALL_CAP I-GENE
major I-GENE
immediate I-GENE
- I-GENE
early I-GENE
( I-GENE
IE I-GENE
) I-GENE
gene I-GENE
( O
ALL_CAP O
. O

ALL_CAP I-GENE
ALL_CAP I-GENE
has O
extensive O
sequence O
RARE O
( O
92 O
%) O
with O
Escherichia I-GENE
coli I-GENE
ALL_CAP I-GENE
and O
other O
members O
of O
the O
RARE I-GENE
- I-GENE
NUM I-GENE
family I-GENE
. O

The O
critical O
mutations O
were O
likely O
to O
have O
been O
multiple O
and O
RARE O
, O
including O
RARE O
of O
the O
ALL_CAP O
and O
Nef I-GENE
coding I-GENE
sequences I-GENE
; O
changes O
in O
RNA O
RARE O
donor O
and O
RARE O
sites O
, O
TATA O
box O
sites O
, O
and O
NUM I-GENE
sites I-GENE
; O
multiple O
changes O
in O
the O
NUM I-GENE
region O
of O
ALL_CAP I-GENE
, O
including O
a O
consensus O
RARE O
RARE O
; O
and O
five O
new O
N O
- O
RARE O
glycosylation O
sites O
in O
ALL_CAP I-GENE
. O

C O
. O

These O
are O
the O
long O
terminal O
repeat O
( O
LTR O
) O
promoter O
, O
which O
regulates O
RARE O
of O
the O
viral O
structural O
proteins O
, O
and O
a O
second O
internal O
promoter O
, O
RARE O
towards O
the O
3 O
' O
end O
of O
the O
env I-GENE
gene I-GENE
, O
that O
directs O
RARE O
of O
the O
viral O
RARE O
proteins O
. O

The O
5 O
' O
end O
of O
the O
genomic O
RNA O
of O
RARE O
virus O
( O
ALL_CAP O
) O
contains O
a O
14 O
- O
nucleotide O
( O
nt O
) O
single O
- O
RARE O
RARE O
( O
RARE O
- O
RARE O
) O
followed O
by O
a O
RARE O
- O
and O
- O
loop O
RARE O
RARE O
5 O
RARE O
ALL_CAP O
] O
( O
nt O
NUM O
to O
65 O
RARE O
the O
complement O
of O
which O
RARE O
the O
3 O
' O
end O
of O
the O
minus O
- O
RARE O
RNA O
RARE O
3 O
RARE O
ALL_CAP O
] O
has O
been O
proposed O
to O
function O
RARE O
a O
promoter O
RARE O
RARE O
of O
genomic O
RARE O
RARE O
. O

To O
investigate O
the O
requirements O
RARE O
CBF2 I-GENE
binding O
, O
we O
synthesized O
a O
series O
of O
oligonucleotides O
carrying O
double O
transversion O
mutations O
spanning O
both O
the O
RARE O
core O
sequence O
and O
outside O
flanking O
sequences O
. O

In O
addition O
, O
the O
affinities O
of O
CBF2 I-GENE
RARE O
binding O
to O
the O
LMP I-GENE
- I-GENE
1 I-GENE
, O
LMP I-GENE
- I-GENE
2 I-GENE
, O
and O
CD23 I-GENE
promoters I-GENE
were O
also O
measured O
. O

CONCLUSIONS O
: O
The O
RARE O
uptake O
of O
99mTc O
RARE O
in O
normal O
subjects O
and O
patients O
with O
coronary O
artery O
RARE O
is O
comparable O
after O
exercise O
, O
RARE O
, O
and O
adenosine O
stress O
. O

The O
SR I-GENE
protein I-GENE
family I-GENE
is O
involved O
in O
RARE O
and O
regulated O
pre O
- O
mRNA O
RARE O
and O
has O
been O
found O
to O
be O
evolutionarily O
RARE O
in O
RARE O
organisms O
. O

To O
investigate O
the O
activity O
of O
NUM I-GENE
through O
this O
RARE O
site O
, O
both O
alone O
and O
in O
the O
presence O
of O
ALL_CAP I-GENE
, O
we O
have O
used O
a O
transient O
transfection O
assay O
. O

These O
and O
other O
comparisons O
suggest O
that O
, O
RARE O
evolution O
, O
both O
the O
RNA I-GENE
- I-GENE
polymerase I-GENE
RARE O
of O
telomerase I-GENE
RNA I-GENE
- I-GENE
gene I-GENE
promoters I-GENE
and O
, O
more O
recently O
, O
the O
position O
of O
the O
template O
sequence O
in O
the O
telomerase I-GENE
RNA I-GENE
changed O
. O

RARE O
and O
RARE O
of O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
in O
K562 O
cells O
is O
RARE O
slow O
compared O
with O
ALL_CAP O
3T3 O
cells O
, O
suggesting O
that O
the O
increased O
stability O
RARE O
by O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
in O
K562 O
cells O
is O
mainly O
RARE O
RARE O
the O
RARE O
step O
. O

RARE I-GENE
RARE I-GENE
RARE I-GENE
in O
Schizosaccharomyces O
pombe O
has O
identical O
endonuclease O
activity O
to O
the O
NUM I-GENE
homologue O
NUM I-GENE
. O

NUM I-GENE
RARE I-GENE
calmodulin I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
II I-GENE
( O
ALL_CAP I-GENE
II I-GENE
) O
is O
a O
RARE O
serine I-GENE
/ I-GENE
threonine I-GENE
protein I-GENE
kinase I-GENE
that O
regulates O
ion O
RARE O
, O
metabolic O
RARE O
, O
cytoskeletal O
proteins O
, O
and O
possibly O
transcription O
factors O
. O

A O
cAMP O
- O
responsive O
element O
- O
like O
( O
ALL_CAP O
- O
like O
, O
ALL_CAP O
) O
promoter O
sequence O
and O
a O
protein I-GENE
kinase I-GENE
A I-GENE
RARE O
RARE O
are O
involved O
in O
this O
induction O
, O
and O
activation O
of O
both O
ALL_CAP I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
) O
and O
activating I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
2 I-GENE
( O
ATF I-GENE
- I-GENE
2 I-GENE
) O
is O
required O
in O
the O
above O
process O
. O

ALL_CAP O
was O
named O
RARE O
an O
RARE O
RARE O
intravascular O
RARE O
. O

RARE O
, O
a O
RARE O
RARE O
was O
diagnosed O
because O
of O
the O
morphological O
features O
and O
the O
immunohistochemical O
RARE O
of O
CD34 I-GENE
and O
RARE I-GENE
VIII I-GENE
related I-GENE
antigen I-GENE
which O
were O
observed O
positive O
reactions O
in O
endothelial O
cells O
of O
the O
cysts O
. O

RARE O
activities O
in O
cultures O
of O
the O
RARE O
strains O
were O
associated O
with O
species O
of O
different O
RARE O
masses O
ranging O
from O
NUM O
to O
NUM O
kDa O
, O
suggesting O
posttranslational O
RARE O
possibly O
RARE O
a O
result O
of O
RARE O
RARE O
post O
- O
proline O
peptide O
bonds O
in O
the O
N O
- O
terminal O
parts O
of O
the O
molecules O
. O

The O
mechanism O
underlying O
such O
analgesia O
has O
been O
suggested O
to O
involve O
the O
interaction O
between O
the O
two O
separate O
but O
RARE O
RARE O
RARE O
" O
defense O
" O
and O
" O
pain O
RARE O
To O
determine O
the O
developmental O
course O
of O
defense O
and O
RARE O
, O
these O
processes O
were O
analyzed O
RARE O
early O
RARE O
in O
rats O
. O

Three O
large O
field O
placement O
RARE O
( O
two O
patients O
with O
11 O
. O
5 O
and O
16 O
. O
NUM O
mm O
distances O
of O
the O
RARE O
versus O
simulated O
RARE O
, O
respectively O
and O
one O
patient O
with O
a O
7 O
degree O
RARE O
error O
) O
were O
detected O
and O
, O
RARE O
with O
the O
smaller O
RARE O
, O
were O
immediately O
corrected O
. O

In O
addition O
, O
a O
catalytically O
inactive O
version O
of O
the O
Src I-GENE
family I-GENE
RARE O
, O
RARE I-GENE
( O
RARE I-GENE
cell I-GENE
kinase I-GENE
RARE O
was O
RARE O
, O
RARE O
, O
and O
evaluated O
RARE O
a O
Csk I-GENE
substrate O
. O

A O
., O
RARE O
, O
A O
. O

RARE O
mechanisms O
underlying O
stimulus O
- O
response O
( O
S O
- O
R O
) O
associations O
in O
S O
- O
R O
compatibility O
tasks O
were O
identified O
in O
2 O
experiments O
with O
monkeys O
. O

The O
c I-GENE
- I-GENE
myc I-GENE
/ O
TGF I-GENE
- I-GENE
alpha I-GENE
RARE O
were O
also O
characterized O
by O
a O
particularly O
strong O
RARE O
of O
TGF I-GENE
- I-GENE
alpha I-GENE
and O
very O
low O
apoptotic O
index O
in O
contrast O
to O
high O
levels O
of O
apoptosis O
in O
RARE O
tissues O
and O
c I-GENE
- I-GENE
myc I-GENE
RARE O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
the O
antagonistic O
effects O
of O
CRP I-GENE
and O
ALL_CAP I-GENE
on O
the O
RARE O
of O
the O
RARE I-GENE
genes I-GENE
occur O
by O
different O
mechanisms O
, O
including O
direct O
competition O
between O
the O
two O
RARE O
or O
between O
the O
repressor O
and O
RNA I-GENE
polymerase I-GENE
RARE O
the O
RARE O
of O
a O
common O
DNA O
region O
on O
the O
target O
genes O
. O

The O
RARE O
- O
known O
Rel I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
family O
of O
RARE O
transcription O
factors O
comprises O
a O
number O
of O
structurally O
related O
, O
RARE O
proteins O
that O
bind O
DNA O
RARE O
RARE O
and O
whose O
activity O
is O
regulated O
by O
subcellular O
location O
. O

The O
ALL_CAP I-GENE
gene I-GENE
is O
organized O
in O
an O
unusual O
operon O
which O
contains O
, O
in O
addition O
, O
two O
genes O
encoding O
stress O
- O
RARE O
RARE O
RARE O
. O

RARE I-GENE
- I-GENE
RARE I-GENE
reductase I-GENE
and O
RARE I-GENE
dehydrogenase I-GENE
from O
Arabidopsis O
thaliana O
: O
nucleotide O
sequence O
and O
characterization O
. O

The O
purpose O
of O
this O
investigation O
was O
to O
describe O
a O
new O
formulation O
of O
silver O
RARE O
in O
a O
water O
RARE O
gel O
, O
RARE O
NUM O
. O

The O
study O
RARE O
were O
to O
isolate O
a O
full O
- O
length O
clone O
encoding O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
from O
a O
bovine O
corneal O
cDNA O
library O
and O
to O
express O
this O
clone O
in O
Escherichia O
coli O
( O
E O
. O
coli O
). O

The O
RARE I-GENE
gene I-GENE
from O
an O
RARE O
RARE O
. O
encoding O
a O
RARE I-GENE
lyase I-GENE
( O
EC I-GENE
4 I-GENE
. I-GENE
2 I-GENE
. I-GENE
2 I-GENE
. I-GENE
2 I-GENE
) O
was O
isolated O
by O
activity O
screening O
a O
genomic O
DNA O
library O
in O
RARE O
RARE O
NUM O
. O

The O
gene O
contains O
RARE O
exons O
separated O
by O
1 O
. O
1 O
- O
5 O
. O
8 O
kb O
RARE O
and O
has O
been O
localized O
to O
the O
murine O
RARE O
2 O
by O
linkage O
analysis O
. O

In O
Xenopus O
RARE O
, O
the O
RARE I-GENE
ALL_CAP I-GENE
receptor I-GENE
protein I-GENE
RARE O
the O
formation O
of O
mesoderm O
from O
RARE O
- O
pole O
RARE O
in O
an O
NUM O
- O
dependent O
manner O
. O

A O
cytosolic O
variant O
of O
the O
protein O
underwent O
efficient O
RARE O
, O
yet O
failed O
to O
activate O
RARE O
either O
p70 I-GENE
( O
NUM I-GENE
) O
or O
MAP I-GENE
kinase I-GENE
following O
treatment O
with O
NUM O
. O

RARE O
- O
molecule O
control O
of O
insulin I-GENE
and O
ALL_CAP I-GENE
receptor I-GENE
RARE O
and O
the O
role O
of O
membrane O
RARE O
. O

Conversely O
, O
the O
inactive O
ALL_CAP I-GENE
subunit I-GENE
is O
RARE O
activated O
by O
1 O
) O
association O
with O
a O
ALL_CAP I-GENE
or O
ALL_CAP I-GENE
subunit I-GENE
and O
2 O
) O
the O
RARE O
RARE O
RARE O
affect O
of O
RARE I-GENE
or O
RARE I-GENE
RARE O
to O
the O
RARE O
subunit O
. O

CONCLUSIONS O
: O
A O
50 O
- O
mg O
daily O
dose O
of O
RARE O
is O
sufficient O
when O
given O
in O
combination O
with O
an O
agent O
, O
such O
RARE O
a O
ALL_CAP I-GENE
- O
A O
, O
that O
RARE O
serum O
testosterone O
, O
but O
RARE O
doses O
of O
RARE O
may O
be O
needed O
when O
the O
drug O
is O
given O
RARE O
RARE O
. O

A O
genomic O
clone O
was O
isolated O
that O
contained O
12 O
. O
5 O
kb O
of O
the O
5 O
'- O
flanking O
region O
and O
the O
RARE O
RARE O
of O
the O
NUM I-GENE
/ I-GENE
NUM I-GENE
2 I-GENE
- I-GENE
NUM I-GENE
RARE I-GENE
gene I-GENE
. O

Although O
the O
gene O
is O
substantially O
smaller O
than O
the O
human O
genes O
RARE O
other O
mitochondrial O
RARE O
, O
its O
intron O
/ O
RARE O
organization O
is O
very O
similar O
, O
especially O
to O
that O
of O
NUM I-GENE
. O

RESULTS O
: O
RARE O
RARE O
the O
question O
of O
its O
benefits O
, O
we O
were O
unable O
to O
find O
any O
RARE O
sound O
studies O
that O
have O
shown O
efficacy O
RARE O
ALL_CAP O
in O
RARE O
disorders O
, O
or O
, O
indeed O
, O
any O
psychiatric O
disorder O
. O

In O
the O
clinical O
study O
, O
the O
defect O
size O
shown O
by O
ALL_CAP O
imaging O
was O
greater O
in O
anterior O
than O
in O
inferior O
RARE O
( O
p O
< O
NUM O
. O
001 O
) O
and O
correlated O
RARE O
with O
the O
risk O
area O
revealed O
by O
contrast O
RARE O
( O
RARE O
= O
NUM O
. O
NUM O
, O
p O
< O
NUM O
. O
0001 O
) O
CONCLUSION O
: O
The O
above O
preliminary O
data O
, O
RARE O
from O
a O
small O
group O
of O
patients O
, O
suggest O
that O
RARE O
ALL_CAP O
imaging O
provides O
an O
accurate O
RARE O
of O
defect O
size O
by O
means O
of O
a O
simple O
threshold O
technique O
and O
, O
in O
the O
subacute O
RARE O
, O
permits O
determination O
of O
the O
amount O
of O
myocardium O
RARE O
risk O
after O
acute O
RARE O
infarction O
. O

Transient O
overexpression O
of O
mutant I-GENE
NUM I-GENE
receptors I-GENE
( O
NUM O
) O
blocked O
RARE I-GENE
recruitment O
to O
NUM I-GENE
, O
attenuated O
RARE O
JNK I-GENE
activation O
, O
and O
blocked O
cell O
RARE O
responses O
. O

The O
promoter O
RARE O
HMG I-GENE
- I-GENE
CoA I-GENE
synthase I-GENE
contains O
two O
binding O
sites O
RARE O
the O
sterol I-GENE
regulatory I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
RARE I-GENE
). O

S O
., O
and O
RARE O
, O
P O
. O

Here O
we O
demonstrate O
that O
RARE I-GENE
and O
RARE I-GENE
( O
RARE I-GENE
) O
act O
through O
those O
RARE I-GENE
binding O
sites O
to O
modulate O
the O
level O
of O
RARE I-GENE
- O
dependent O
transcriptional O
activation O
in O
NUM O
cells O
. O

Furthermore O
the O
median O
increase O
in O
cyclosporine O
ALL_CAP O
/ O
C O
( O
ALL_CAP O
trough O
) O
was O
18 O
RARE O
h O
- O
1 O
RARE O
3 O
. O
1 O
to O
NUM O
. O
1 O
RARE O
h O
- O
1 O
, O
RARE O
range O
). O

Patients O
and O
their O
RARE O
must O
be O
RARE O
about O
the O
available O
effective O
treatment O
possibilities O
and O
about O
the O
right O
RARE O
RARE O
their O
application O
in O
an O
individual O
patient O
. O

Several O
RARE I-GENE
were O
RARE O
abundantly O
in O
the O
5 O
- O
FU O
- O
treated O
bone O
marrow O
RARE O
cells O
. O

Expression O
of O
ALL_CAP I-GENE
was O
also O
observed O
in O
human I-GENE
CD34 I-GENE
+ I-GENE
bone O
marrow O
cells O
and O
5 O
- O
FU O
- O
treated O
murine O
RARE O
RARE O
cells O
. O

The O
organization O
of O
NUM I-GENE
genes I-GENE
involved O
in O
the O
replication O
, O
DNA O
RARE O
and O
RARE O
assembly O
proteins O
resembles O
the O
organization O
of O
genes O
of O
equivalent O
regions O
of O
different O
E O
. O
coli O
double O
- O
RARE O
DNA O
RARE O
. O

Our O
results O
showed O
that O
compared O
to O
the O
RARE O
photon O
RARE O
, O
the O
RARE O
- O
RARE O
photon O
RARE O
from O
the O
RARE O
RARE O
and O
the O
RARE O
filter O
was O
11 O
RARE O
16 O
% O
RARE O
the O
RARE O
, O
among O
which O
70 O
% O
was O
contributed O
by O
the O
RARE O
filter O
. O

The O
RARE O
RARE O
domain O
of O
RARE I-GENE
ALL_CAP I-GENE
( I-GENE
RARE I-GENE
+ I-GENE
1 I-GENE
to I-GENE
RARE I-GENE
+ I-GENE
NUM I-GENE
) I-GENE
is O
targeted O
into O
the O
E O
. O
coli O
sec O
machinery O
and O
RARE O
to O
the O
RARE O
in O
RARE O
form O
when O
fused O
in O
frame O
to O
the O
ALL_CAP O
terminus O
of O
the O
RARE I-GENE
protein I-GENE
RARE I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
MBP I-GENE
). O

RARE O
were O
differentiated O
based O
on O
the O
MS O
- O
MS O
data O
of O
the O
RARE O
- O
RARE O
RARE O
. O

Although O
NUM I-GENE
, O
NUM I-GENE
and O
NUM I-GENE
are O
not O
required O
RARE O
cell O
RARE O
arrest O
when O
S O
RARE O
is O
inhibited O
by O
RARE O
( O
ALL_CAP O
RARE O
they O
do O
contribute O
to O
the O
viability O
of O
yeast O
cells O
grown O
in O
the O
presence O
of O
ALL_CAP O
, O
possibly O
because O
they O
are O
required O
RARE O
the O
repair O
of O
ALL_CAP O
- O
RARE O
DNA O
damage O
. O

Clinical O
value O
of O
the O
estimation O
of O
growth O
kinetics O
of O
RARE O
ovarian O
RARE O
RARE O
by O
NUM I-GENE
RARE O
time O

This O
review O
RARE O
to O
RARE O
the O
RARE O
, O
to O
propose O
pathways O
of O
RARE O
and O
to O
suggest O
ways O
in O
which O
the O
" O
RARE O
" O
risk O
factors O
may O
be O
interpreted O
on O
the O
basis O
of O
RARE O
knowledge O
. O

The O
patient O
underwent O
two O
RARE O
sperm O
injection O
cycles O
with O
RARE O
RARE O
spermatozoa O
, O
in O
which O
, O
due O
to O
a O
RARE O
' O
s O
RARE O
, O
ovarian O
RARE O
was O
carried O
out O
by O
a O
combination O
of O
long O
- O
acting O
RARE I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
agonist O
( O
RARE O
RARE O
) O
and O
RARE I-GENE
. O

Protein I-GENE
C I-GENE
deficiency O
or O
protein I-GENE
S I-GENE
deficiency O
was O
the O
only O
identified O
risk O
factor O
RARE O
5 O
. O
4 O
% O
( O
2 O
patients O
) O
and O
NUM O
. O
5 O
% O
( O
5 O
patients O
RARE O
respectively O
, O
of O
these O
37 O
children O
. O

RARE O
in O
addition O
to O
, O
or O
RARE O
part O
of O
, O
its O
essential O
function O
in O
RARE O
mitosis O
, O
NUM I-GENE
is O
required O
RARE O
a O
cell O
RARE O
RARE O
function O
necessary O
RARE O
the O
initiation O
of O
the O
RARE O
pole O
body O
duplication O
. O

In O
contrast O
, O
RARE O
of O
NUM I-GENE
is O
lethal O
in O
a O
NUM I-GENE
- I-GENE
2 I-GENE
RARE O
RARE O
the O
permissive O
RARE O
of O
NUM O
degrees O
C O
. O

RARE O
baseline O
( O
day O
- O
8 O
) O
PC O
levels O
( O
NUM O
and O
NUM O
%) O
were O
markedly O
RARE O
in O
both O
patients O
RARE O
the O
time O
of O
ALL_CAP O
manifestation O
on O
day O
20 O
and O
40 O
, O
respectively O
( O
NUM O
and O
NUM O
%). O

To O
examine O
the O
role O
of O
this O
NUM O
element O
in O
RARE O
NUM I-GENE
RARE O
in O
vivo O
, O
transgenic O
mice O
were O
generated O
which O
express O
a O
NUM I-GENE
beta I-GENE
- I-GENE
galactosidase I-GENE
reporter O
gene O
that O
contains O
a O
mutation O
in O
the O
NUM O
element O
. O

An O
evolutionary O
RARE O
element O
is O
essential O
RARE O
RARE O
and O
adjacent O
mesenchymal O
RARE O
of O
the O
NUM I-GENE
gene I-GENE
. O

RESULTS O
: O
The O
bovine O
cDNA O
insert O
sequence O
was O
NUM O
nucleotides O
in O
length O
RARE O
the O
RARE O
mRNA O
coding O
region O
, O
NUM O
nucleotides O
in O
the O
5 O
' O
RARE O
region O
, O
NUM O
nucleotides O
in O
the O
3 O
' O
RARE O
region O
and O
a O
RARE O
( O
A O
) O
RARE O
. O

Altogether O
NUM O
RARE O
III O
activities O
were O
recorded O
. O

We O
have O
previously O
identified O
a O
liver O
- O
RARE O
transcription O
factor O
, O
HNF I-GENE
- I-GENE
6 I-GENE
, O
which O
is O
required O
RARE O
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
promoter I-GENE
activity O
and O
also O
recognizes O
the O
regulatory O
region O
of O
numerous O
RARE O
- O
specific O
genes O
. O

A O
cDNA O
clone O
was O
identified O
encoding O
a O
second O
ALL_CAP I-GENE
- I-GENE
R I-GENE
- I-GENE
related I-GENE
gene I-GENE
( O
NUM I-GENE
). O

( O
1997 O
) O
RARE O
NUM O
, O
NUM O
- O
NUM O
). O

P O
., O
RARE O
, O
ALL_CAP O
. O

A O
RARE O
clone O
( O
NUM O
) O
resulting O
from O
the O
fusion O
between O
ALL_CAP O
/ O
ALL_CAP O
and O
human O
RARE O
RARE O
NUM O
cells O
produced O
very O
large O
amounts O
of O
NUM I-GENE
that O
was O
RARE O
using O
RARE I-GENE
RARE I-GENE
( O
specific O
RARE O
O O
- O
RARE O
) O
and O
RARE O
. O

This O
RARE O
, O
together O
with O
estimation O
of O
the O
size O
of O
the O
RARE O
A O
subunit O
relative O
to O
a O
series O
of O
C I-GENE
- I-GENE
terminal I-GENE
truncated I-GENE
ALL_CAP I-GENE
RARE I-GENE
variants I-GENE
, O
RARE O
RARE O
RARE O
1 O
in O
the O
vicinity O
of O
, O
or O
closely O
upstream O
to O
, O
RARE O
NUM O
. O

In O
vitro O
DNase I-GENE
I I-GENE
footprinting O
of O
the O
NUM O
- O
bp O
proximal O
region O
of O
the O
promoter O
with O
a O
murine O
RARE O
1 O
- O
6 O
cell O
nuclear O
RARE O
revealed O
a O
clear O
footprint O
of O
a O
region O
corresponding O
to O
- O
NUM O
to O
- O
NUM O
bp O
of O
the O
murine I-GENE
ALL_CAP I-GENE
gene I-GENE
, O
suggesting O
that O
liver O
factors O
interact O
with O
this O
region O
of O
the O
DNA O
. O

A O
reciprocal O
binding O
assay O
using O
IM O
- O
9 O
cells O
RARE O
a O
source O
of O
SHP I-GENE
- I-GENE
1 I-GENE
and O
SHP I-GENE
- I-GENE
2 I-GENE
revealed O
specific O
association O
of O
SHP I-GENE
- I-GENE
2 I-GENE
( O
but O
not O
SHP I-GENE
- I-GENE
1 I-GENE
) O
with O
a O
RARE I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion I-GENE
RARE O
ALL_CAP I-GENE
cytoplasmic I-GENE
domain I-GENE
residues I-GENE
NUM I-GENE
- I-GENE
NUM I-GENE
, O
but O
only O
if O
the O
fusion O
was O
RARE O
RARE O
tyrosine O
- O
RARE O
. O

Both O
increasing O
basal O
FSH I-GENE
and O
age O
were O
associated O
significantly O
with O
increased O
RARE O
RARE I-GENE
dose O
, O
and O
RARE O
number O
of O
oocytes O
collected O
and O
RARE O
rate O
. O

A O
comparative O
study O
was O
undertaken O
between O
an O
enzymatic O
immunohistochemical O
technique O
( O
ALL_CAP O
) O
developed O
RARE O
the O
diagnosis O
of O
human O
RARE O
and O
the O
indirect O
immunofluorescence O
test O
( O
ALL_CAP O
RARE O
RARE O
RARE O
from O
RARE O
of O
human O
RARE O
in O
RARE O
. O

Our O
results O
establish O
ALL_CAP I-GENE
RARE O
a O
sequence O
- O
specific O
transcription O
factor O
likely O
involved O
in O
RARE O
of O
RARE O
of O
endogenous O
genes O
. O

NUM I-GENE
on O
a O
multicopy O
RARE O
was O
unable O
to O
suppress O
NUM I-GENE
- I-GENE
NUM I-GENE
. O

Here O
we O
report O
that O
in O
cultured O
cells O
from O
Drosophila O
melanogaster O
human I-GENE
NUM I-GENE
efficiently O
activates O
transcription O
from O
RARE O
promoters O
containing O
TATA O
RARE O
, O
but O
not O
from O
promoters O
that O
contain O
an O
RARE O
instead O
of O
a O
TATA O
box O
. O

No O
apparent O
clinical O
signs O
indicative O
of O
systemic O
toxicity O
were O
observed O
in O
the O
NUM O
and O
NUM O
animals O
of O
either O
RARE O
. O

We O
have O
used O
mutation O
- O
directed O
chemical O
cross O
- O
linking O
with O
RARE O
( O
RARE O
) O
RARE O
( O
NUM O
) O
to O
investigate O
the O
architecture O
of O
the O
NUM I-GENE
RARE I-GENE
. O

In O
an O
effort O
to O
identify O
the O
NUM I-GENE
RARE I-GENE
gene I-GENE
we O
have O
isolated O
the O
region O
between O
these O
markers O
in O
yeast O
artificial O
chromosomes O
( O
YACs O
) O
using O
a O
combination O
of O
ALL_CAP O
content O
mapping O
and O
Alu I-GENE
- O
PCR O
hybridization O
. O

ALL_CAP O
analysis O
identified O
RARE O
clusters O
of O
RARE O
sequence O
tags O
( O
RARE O
RARE O
two O
known O
genes O
( O
ALL_CAP I-GENE
, O
NUM I-GENE
) O
mapped O
previously O
to O
this O
region O
, O
and O
a O
previously O
characterized O
but O
RARE O
gene I-GENE
ALL_CAP I-GENE
( O
DNA I-GENE
binding I-GENE
/ I-GENE
ALL_CAP I-GENE
RARE I-GENE
/ I-GENE
RARE I-GENE
amino I-GENE
- I-GENE
acid I-GENE
- I-GENE
rich I-GENE
). O

A O
fusion O
protein O
composed O
of O
beta I-GENE
- I-GENE
galactosidase I-GENE
and O
full I-GENE
- I-GENE
length I-GENE
RARE I-GENE
RARE O
from O
the O
cytoplasm O
to O
the O
nucleus O
in O
a O
RARE O
- O
dependent O
manner O
. O

RARE O
of O
Raf I-GENE
- I-GENE
1 I-GENE
activity O
was O
observed O
only O
with O
kinase O
RARE O
NUM I-GENE
in O
both O
cell O
lines O
. O

In O
addition O
, O
negatively O
regulatory O
region O
may O
exist O
from O
- O
NUM O
to O
- O
NUM O
bp O
. O

The O
hypothesis O
of O
RARE O
( O
RARE O
RARE O
. O

The O
second O
transcript O
, O
NUM I-GENE
, O
is O
RARE O
. O

Consistent O
with O
this O
interpretation O
, O
a O
mutant O
form O
of O
NUM I-GENE
, O
which O
encodes O
a O
5 O
'- O
3 O
' O
RARE O
, O
was O
identified O
RARE O
an O
RARE O
suppressor O
that O
increases O
the O
RARE O
- O
life O
of O
NUM I-GENE
mRNA I-GENE
, O
leading O
to O
a O
10 O
- O
RARE O
increase O
in O
steady O
- O
state O
mRNA O
levels O
compared O
to O
the O
wild I-GENE
- I-GENE
type I-GENE
NUM I-GENE
mRNA I-GENE
level O
. O

NUM I-GENE
was O
initially O
identified O
by O
RARE O
of O
its O
interaction O
with O
NUM I-GENE
, O
a O
RARE O
factor O
of O
the O
SR I-GENE
family I-GENE
. O

Consistent O
with O
previous O
reports O
, O
addition O
of O
a O
RARE O
signal O
to O
NUM I-GENE
( O
NUM I-GENE
) O
RARE O
it O
transforming O
RARE O
ALL_CAP O
3T3 O
cells O
and O
deletion O
of O
the O
RARE I-GENE
C I-GENE
terminus I-GENE
( O
NUM I-GENE
- I-GENE
ALL_CAP I-GENE
) O
did O
not O
RARE O
with O
this O
activity O
. O

Such O
mutations O
are O
thought O
to O
exert O
their O
dominant O
RARE O
by O
RARE O
of O
the O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
). O

Several O
studies O
have O
characterized O
the O
upstream O
regulatory O
region O
of O
c I-GENE
- I-GENE
fos I-GENE
, O
and O
identified O
cis O
- O
acting O
elements O
termed O
the O
cyclic O
AMP O
( O
cAMP O
) O
response O
elements O
( O
RARE O
) O
that O
are O
critical O
RARE O
c I-GENE
- I-GENE
fos I-GENE
transcription O
in O
response O
to O
a O
variety O
of O
extracellular O
stimuli O
. O

We O
have O
RARE O
a O
kinase O
, O
RARE I-GENE
, O
that O
is O
a O
murine I-GENE
homolog I-GENE
of I-GENE
the I-GENE
Drosophila I-GENE
RARE I-GENE
( O
RARE I-GENE
) O
gene O
. O

Our O
findings O
suggest O
that O
RARE O
FDG O
and O
particularly O
ALL_CAP O
are O
RARE O
and O
effective O
measures O
of O
RARE O
function O
and O
may O
help O
characterizing O
patients O
with O
multiple O
RARE O
atrophy O
. O

RARE O
RARE O
and O
the O
risk O
of O
injecting O
drug O
use O
. O

Genetic O
analysis O
has O
subsequently O
identified O
RARE O
of O
the O
DNA O
RARE O
RARE O
, O
including O
the O
reversible O
arrest O
of O
DNA O
RARE O
. O

Thus O
, O
NUM I-GENE
promoters I-GENE
are O
responsive O
to O
CRP I-GENE
, O
a O
protein O
unrelated O
to O
NUM I-GENE
RARE I-GENE
, O
and O
the O
repression O
RARE O
is O
the O
direct O
result O
of O
an O
interaction O
between O
NUM I-GENE
and O
the O
CRP I-GENE
- I-GENE
cAMP I-GENE
complex I-GENE
. O

RARE O
- O
and O
NUM O
- O
ALL_CAP O
- O
RARE O
biosynthesis O
could O
be O
shown O
with O
isolated O
S O
. O
cerevisiae O
membranes O
from O
cells O
harboring O
the O
recombinant O
RARE O
and O
grown O
on O
glucose O
thus O
RARE O
transcription O
of O
the O
endogenous O
gene O
. O

RARE O
of O
tissue O
lesions O
after O
RARE O
injection O
by O
determination O
of O
RARE I-GENE
kinase I-GENE
in O
RARE O

Antibodies O
raised O
against O
GST I-GENE
NUM I-GENE
- I-GENE
B I-GENE
identified O
a O
cellular O
protein O
of O
92 O
kDa O
that O
was O
not O
found O
to O
be O
RARE O
on O
RARE O
. O

Interleukin I-GENE
- I-GENE
6 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
) O
is O
a O
pleiotropic O
RARE O
, O
which O
is O
involved O
in O
inflammatory O
and O
immune O
responses O
, O
acute O
RARE O
reactions O
, O
and O
RARE O
. O

Upon O
analysis O
of O
various O
deletion O
and O
point O
- O
RARE O
variants O
of O
the O
human I-GENE
ALL_CAP I-GENE
- I-GENE
6 I-GENE
gene I-GENE
promoter I-GENE
coupled O
to O
a O
reporter O
gene O
, O
we O
screened O
RARE O
possible O
RARE O
transcription O
factors O
. O

This O
region O
, O
however O
, O
contains O
a O
ALL_CAP O
box O
in O
the O
reverse O
complement O
and O
several O
ALL_CAP O
RARE O
that O
are O
recognition O
sites O
RARE O
SP1 I-GENE
. O

Our O
purpose O
was O
to O
determine O
if O
RARE O
RARE O
( O
NUM O
- O
5 O
) O
RARE O
RARE O
( O
ALL_CAP O
) O
and O
RARE O
( O
NUM O
- O
4 O
) O
reflex O
( O
ALL_CAP O
) O
RARE O
after O
RARE O
cord O
injury O
( O
ALL_CAP O
) O
are O
predictive O
of O
bladder O
function O
recovery O
. O

The O
correct O
RARE O
of O
RARE O
transcripts O
RARE O
the O
3 O
' O
LTR O
R O
/ O
NUM O
RARE O
is O
primarily O
dependent O
on O
the O
canonical O
ALL_CAP O
polyadenylation O
signal O
, O
so O
we O
have O
analyzed O
the O
effect O
of O
RARE O
the O
polyadenylation O
signal O
sequences O
on O
the O
properties O
of O
a O
selectable O
murine O
RARE O
vector O
. O

RARE O
of O
the O
MEK I-GENE
inhibitor O
PD98059 O
that O
RARE O
ALL_CAP I-GENE
- O
RARE O
RARE O
and O
MAP I-GENE
kinase I-GENE
RARE O
also O
abrogate O
ALL_CAP I-GENE
- O
RARE O
RARE O
adhesion O
RARE O
and O
cell O
RARE O
. O

ALL_CAP I-GENE
levels O
in O
responders O
were O
lowered O
by O
NUM O
% O
and O
ALL_CAP I-GENE
levels O
were O
lowered O
by O
NUM O
% O
after O
12 O
weeks O
of O
vitamin O
E O
treatment O
. O

Surprisingly O
, O
the O
ALL_CAP O
- O
terminal O
domain O
of O
NUM I-GENE
was O
also O
found O
to O
harbor O
a O
nuclear O
RARE O
signal O
. O

NUM O
. O
9 O
% O
( O
P O
= O
NUM O
. O
NUM O
) O
in O
the O
ALL_CAP O
versus O
the O
ALL_CAP O
groups O
, O
respectively O
. O

Our O
study O
was O
designed O
to O
investigate O
the O
effect O
of O
ALL_CAP O
on O
in O
vivo O
bone O
mineral O
metabolism O
. O

NUM O
increased O
from O
NUM O
. O
5 O
+/- O
5 O
. O
6 O
RARE O
( O
NUM O
+/- O
NUM O
mm O
Hg O
) O
to O
NUM O
. O
3 O
+/- O
6 O
. O
3 O
RARE O
( O
NUM O
+/- O
NUM O
mm O
Hg O
) O
( O
P O
< O
NUM O
. O
05 O
). O

RARE O
RARE O
of O
RARE O
stress O
factors O
of O
RARE O
RARE O
children O
and O
RARE O

RARE O
cats O
received O
ALL_CAP O
RARE O
a O
dosage O
of O
10 O
mg O
/ O
kg O
body O
RARE O
, O
nine O
cats O
received O
ALL_CAP O
RARE O
a O
dosage O
of O
NUM O
mg O
/ O
kg O
body O
RARE O
. O

Resistance O
to O
thyroid O
hormone O
: O
implications O
RARE O
RARE O
research O
on O
the O
effects O
of O
thyroid O
hormone O
RARE O
. O

Here O
, O
we O
present O
evidence O
that O
exposure O
of O
NUM O
lymphoma O
B O
cells O
to O
low O
energy O
RARE O
field O
( O
ALL_CAP O
) O
results O
in O
a O
tyrosine I-GENE
kinase I-GENE
- O
dependent O
activation O
of O
phospholipase I-GENE
NUM I-GENE
( O
PLC I-GENE
- I-GENE
NUM I-GENE
) O
leading O
to O
increased O
RARE O
RARE O
turnover O
. O

We O
present O
the O
preliminary O
results O
obtained O
on O
NUM O
patients O
which O
were O
followed O
RARE O
a O
mean O
period O
of O
12 O
months O
. O

Moreover O
, O
NUM I-GENE
could O
RARE O
the O
RARE O
of O
ventral O
mesoderm O
marker O
genes O
RARE O
by O
NUM I-GENE
or I-GENE
5 I-GENE
. O

PATIENTS O
ALL_CAP O
ALL_CAP O
: O
Since O
1986 O
, O
NUM O
patients O
were O
irradiated O
RARE O
. O

The O
assay O
exhibits O
a O
dynamic O
range O
of O
NUM O
. O
1 O
- O
NUM O
micrograms O
RARE O
- O
1 O
using O
a O
monoclonal O
antibody O
or O
RARE O
10 O
micrograms O
RARE O
- O
1 O
to O
10 O
mg O
RARE O
- O
1 O
using O
RARE O
available O
RARE O
. O

RARE O
RARE O
RARE O
. O

A O
canonical O
TATA O
box O
was O
not O
detected O
. O

Expression O
and O
characterization O
of O
recombinant I-GENE
single I-GENE
- I-GENE
chain I-GENE
RARE I-GENE
and O
RARE I-GENE
fragments I-GENE
derived O
from O
a O
set O
of O
catalytic O
antibodies O
. O

A O
putative O
inhibitor O
( O
s O
) O
appears O
to O
RARE O
- O
RARE O
in O
the O
inactive O
fraction O
that O
blocked O
the O
L I-GENE
( I-GENE
alpha I-GENE
) I-GENE
activity O
. O

RARE O
RARE O
in O
response O
to O
10 O
micrograms O
RARE I-GENE
/ O
ml O
was O
decreased O
in O
parallel O
after O
treatment O
with O
ALL_CAP O
. O

Using O
ALL_CAP I-GENE
mutants I-GENE
, O
we O
confirmed O
that O
ALL_CAP I-GENE
plays O
a O
role O
in O
the O
RARE O
- O
dependent O
RARE O
of O
ALL_CAP I-GENE
- O
lacZ I-GENE
RARE O
in O
vivo O
. O

Cross O
- O
RARE O
among O
Drosophila O
nuclear O
receptors O
RARE O
the O
RARE O
response O
element O
of O
the O
RARE I-GENE
- I-GENE
1 I-GENE
and O
RARE I-GENE
- I-GENE
2 I-GENE
RARE I-GENE
genes I-GENE
. O

The O
ipsilateral O
breast O
tumor O
relapse O
rate O
was O
similar O
between O
the O
ALL_CAP O
and O
ALL_CAP O
groups O
. O

RARE O
RARE O
of O
low I-GENE
- I-GENE
and I-GENE
high I-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
cholesterol I-GENE
and O
RARE I-GENE
B I-GENE
and I-GENE
A I-GENE
- I-GENE
I I-GENE
levels O
in O
black O
and O
RARE O
children O
: O
the O
RARE O
RARE O
Study O
. O

The O
NUM I-GENE
protein I-GENE
also O
exhibited O
several O
unique O
features O
, O
including O
a O
novel O
stretch O
of O
18 O
- O
19 O
amino O
acid O
residues O
within O
the O
X O
domain O
and O
an O
unusually O
long O
N O
- O
terminus O
which O
did O
not O
contain O
a O
RARE O
ALL_CAP O
- O
RARE O
Ca O
( O
2 O
RARE O
binding O
domain O
. O

This O
hypothesis O
is O
consistent O
with O
the O
occurrence O
of O
PEA3 I-GENE
binding I-GENE
sites I-GENE
in O
the O
PEA3 I-GENE
promoter I-GENE
and O
with O
the O
ability O
of O
PEA3 I-GENE
to O
transactivate O
this O
promoter O
. O

RARE I-GENE
- I-GENE
1 I-GENE
can O
bind O
specifically O
to O
a O
PEA3 I-GENE
ALL_CAP I-GENE
DNA O
- O
binding O
motif O
and O
can O
modulate O
transcription O
of O
RARE O
promoter O
constructs O
in O
a O
sequence O
- O
specific O
manner O
. O

The O
protein O
RARE O
by O
NUM I-GENE
cDNA I-GENE
in O
transfected O
COS O
cells O
is O
localized O
in O
the O
cytoplasm O
. O

Northern O
analysis O
indicated O
differential O
RARE O
by O
tissue O
with O
highest O
RARE O
in O
the O
RARE O
. O

As O
RARE O
, O
further O
deletion O
of O
the O
promoter O
region O
to O
nucleotide O
- O
NUM O
, O
which O
contains O
only O
one O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
, O
still O
retained O
the O
ability O
to O
respond O
to O
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
. O

The O
observation O
that O
beta I-GENE
NUM I-GENE
with O
covalently O
attached O
peptide O
can O
effectively O
create O
CTL O
target O
RARE O
in O
vitro O
offers O
new O
possibilities O
RARE O
the O
in O
vivo O
induction O
of O
RARE O
- O
specific O
CTL O
responses O
by O
either O
DNA O
immunization O
or O
injection O
of O
the O
RARE O
RARE O
- O
RARE O
beta I-GENE
NUM I-GENE
. O

The O
mRNAs O
of O
these O
genes O
contain O
respectively O
one O
( O
NUM I-GENE
ALL_CAP I-GENE
) O
and O
two O
( O
NUM I-GENE
NUM I-GENE
and O
NUM O
) O
upstream O
RARE O
reading O
frames O
. O
ALL_CAP O
- O
RARE O
modulation O
of O
post O
- O
RARE O
events O
on O
the O
5 O
'- O
RARE O
region O
( O
5 O
'- O
UTR O
) O
directs O
differential O
control O
not O
only O
of O
translation O
but O
also O
of O
mRNA O
RARE O
. O

To O
further O
investigate O
the O
nature O
of O
the O
site O
RARE O
a O
set O
of O
deletion O
mutants O
of O
the O
NUM O
bp O
sequence O
were O
analysed O
. O

In O
the O
tissues O
tested O
, O
except O
brain O
, O
the O
RARE O
RARE O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
was O
more O
abundant O
than O
that O
RARE O
RARE I-GENE
. O

BACKGROUND O
: O
RARE O
vary O
considerably O
in O
their O
RARE O
ability O
to O
cause O
allergic O
RARE O
dermatitis O
. O

RARE O
RARE O
of O
T O
cells O
is O
regulated O
by O
an O
RARE O
tyrosine O
- O
based O
activation O
motif O
- O
dependent O
mechanism O
. O

Here O
we O
have O
examined O
the O
ability O
of O
the O
cellular O
protein O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
to O
modulate O
transcription O
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
in O
a O
human O
RARE O
cell O
line O
( O
ALL_CAP O
- O
NUM O
RARE O
a O
RARE O
cell O
line O
( O
ALL_CAP O
- O
N O
- O
MC O
) O
and O
RARE O
cells O
( O
Jurkat O
) O
by O
transfection O
assay O
. O

Also O
, O
the O
deduced O
amino O
RARE O
of O
the O
RARE I-GENE
regions I-GENE
A I-GENE
, I-GENE
B I-GENE
and I-GENE
C I-GENE
of I-GENE
NUM I-GENE
were O
nearly O
RARE O
within O
the O
phylogenetic O
lineages O
. O

The O
RARE O
ALL_CAP I-GENE
gene I-GENE
provided O
in O
RARE O
restored O
these O
RARE O
RARE O
activities O
to O
the O
mutants O
. O

The O
RARE O
ALL_CAP I-GENE
gene I-GENE
provided O
in O
RARE O
restored O
these O
RARE O
RARE O
activities O
to O
the O
mutants O
. O

Copyright O
1998 O
Academic O
Press O
. O

It O
may O
also O
be O
suggested O
that O
particular O
care O
should O
be O
taken O
when O
such O
a O
RARE O
- O
dominant O
RARE I-GENE
mutant I-GENE
is O
considered O
to O
be O
used O
RARE O
a O
genetic O
therapy O
against O
HIV O
- O
I O
infection O
, O
in O
individuals O
RARE O
with O
both O
HIV O
- O
I O
and O
ALL_CAP O
- O
1 O
. O

PATIENTS O
ALL_CAP O
METHODS O
: O
RARE O
January O
1992 O
and O
RARE O
1994 O
RARE O
RARE O
. O

The O
frequency O
of O
RARE O
RARE O
both O
the O
moderate O
and O
severe O
groups O
was O
significantly O
RARE O
than O
that O
in O
patients O
with O
a O
normal O
ALL_CAP O
( O
p O
< O
. O
01 O
); O
of O
154 O
RARE O
with O
a O
normal O
ALL_CAP O
, O
only O
9 O
( O
6 O
%) O
had O
an O
SP O
. O

We O
analyzed O
the O
P O
- O
ALL_CAP O
in O
the O
time O
and O
frequency O
domain O
in O
NUM O
patients O
with O
RARE O
and O
19 O
controls O
. O

RARE O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
and O
HPLC O
analysis O
showed O
that O
ALL_CAP I-GENE
- I-GENE
1alpha I-GENE
is O
the O
progesterone O
- O
dependent O
RARE O
variant O
. O

NUM I-GENE
is O
part O
of O
two O
related O
RARE O
pathways O
RARE O
cell O
growth O
in O
Saccharomyces O
cerevisiae O
. O

RARE O
RARE O
. O

SETTING O
: O
A O
division O
of O
a O
large O
RARE O
RARE O
in O
RARE O
. O

RARE O
models O
of O
RARE O
interaction O
did O
not O
fully O
account O
RARE O
the O
kinetic O
profiles O
obtained O
with O
the O
parental O
antibodies O
and O
the O
hybrids O
, O
and O
this O
complexity O
suggested O
the O
existence O
of O
a O
conformational O
heterogeneity O
in O
these O
molecules O
. O

In O
order O
to O
RARE O
the O
RARE O
that O
leads O
to O
Hox I-GENE
gene I-GENE
induction O
, O
we O
have O
investigated O
whether O
a O
Hox I-GENE
gene I-GENE
regulator O
, O
the O
leucine O
zipper O
transcription O
factor O
ALL_CAP I-GENE
/ O
RARE I-GENE
, O
is O
itself O
transcriptionally O
regulated O
by O
the O
environmental O
signals O
. O

RARE O
RARE O
NUM I-GENE
( O
RARE I-GENE
- O
abl I-GENE
) O
are O
likely O
to O
be O
involved O
in O
the O
pathogenesis O
of O
CML O
. O

RARE O
constructs O
function O
in O
a O
parallel O
manner O
, O
demonstrating O
the O
key O
role O
of O
the O
ALL_CAP I-GENE
in O
RARE O
RARE O
RARE O
RARE O
ALL_CAP O
- O
RARE O
RARE O
of O
NUM I-GENE
in O
mouse O
RARE O
RARE O
. O

Transfection O
studies O
also O
showed O
that O
3 O
'- O
deletion O
of O
sequences O
RARE O
of O
the O
transcriptional O
RARE O
site O
(+ O
1 O
RARE O
NUM O
) O
markedly O
RARE O
ALL_CAP I-GENE
- O
RARE O
induction O
. O

RARE I-GENE
M I-GENE
stimulates O
c I-GENE
- I-GENE
Fos I-GENE
to O
bind O
a O
transcriptionally O
responsive O
AP I-GENE
- I-GENE
1 I-GENE
element I-GENE
within O
the O
tissue I-GENE
inhibitor I-GENE
of I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
. O

We O
have O
isolated O
a O
new O
human I-GENE
ALL_CAP I-GENE
- I-GENE
finger I-GENE
gene I-GENE
( O
NUM I-GENE
) O
that O
encodes O
a O
190 O
- O
amino O
- O
acid O
protein O
. O

To O
elucidate O
the O
regulatory O
mechanism O
of O
human I-GENE
ALL_CAP I-GENE
gene I-GENE
RARE O
, O
RARE O
elements O
of O
5 O
'- O
flanking O
region O
of O
ALL_CAP I-GENE
gene I-GENE
were O
studied O
in O
human O
aortic O
endothelial O
cells O
( O
ALL_CAP O
). O

The O
ALL_CAP O
- O
terminal O
region O
of O
the O
transcripts O
contained O
RARE O
triplet O
repeats O
( O
ALL_CAP O
; O
alanine O
) O
RARE O
nucleotide O
NUM O
to O
NUM O
, O
which O
is O
significantly O
RARE O
compared O
to O
the O
rat I-GENE
NUM I-GENE
. O

RARE O
ALL_CAP I-GENE
RARE O
- O
binding O
domain O
: O
high O
- O
yield O
production O
of O
RARE O
fusion O
and O
non O
- O
fusion O
recombinant O
proteins O
using O
the O
RARE O
/ O
insect O
cell O
RARE O
. O

Control O
of O
fatty O
liver O
RARE O
in O
a O
RARE O
herd O
by O
a O
change O
of O
diet O
and O
the O
use O
of O
recombinant O
bovine O
RARE I-GENE
. O

The O
inhibition O
of O
focus O
formation O
observed O
in O
the O
presence O
of O
NUM I-GENE
was O
not O
due O
to O
toxic O
effects O
on O
cell O
viability O
, O
since O
transfected O
NUM I-GENE
cells O
exhibited O
the O
same O
survival O
and O
growth O
rates O
RARE O
RARE O
NIH3T3 O
cells O
or O
cells O
transfected O
with O
RARE O
vector O
alone O
. O

C O
. O
NUM O
- O
Chr O
4 O
RARE O
strains O
harboring O
ALL_CAP O
/ O
2 O
alleles O
associated O
with O
the O
NUM I-GENE
locus I-GENE
contained O
ALL_CAP O
/ O
2 O
" O
resistant O
" O
alleles O
of O
the O
NUM I-GENE
/ O
NUM I-GENE
RARE O
NUM I-GENE
and O
NUM I-GENE
. O

When O
tested O
with O
wild O
- O
type O
( O
ALL_CAP O
/ O
2 O
) O
NUM I-GENE
, O
both O
NUM O
and O
NUM O
ALL_CAP O
/ O
c O
- O
specific O
variants O
of O
NUM I-GENE
were O
inefficient O
in O
their O
ability O
to O
inhibit O
the O
activity O
of O
RARE I-GENE
NUM I-GENE
/ O
NUM I-GENE
in O
kinase O
assays O
with O
RARE I-GENE
protein I-GENE
, O
suggesting O
this O
RARE O
, O
inherited O
allele O
plays O
an O
important O
role O
in O
the O
genetic O
RARE O
of O
ALL_CAP O
/ O
c O
mice O
RARE O
RARE O
induction O
and O
that O
NUM I-GENE
( O
NUM I-GENE
) O
is O
a O
strong O
candidate O
RARE O
the O
NUM I-GENE
locus I-GENE
. O

Despite O
this O
there O
was O
RARE O
difference O
in O
the O
RARE O
conditions O
RARE O
one O
minute O
with O
NUM O
excellent O
/ O
5 O
good O
in O
the O
RARE O
group O
and O
NUM O
excellent O
/ O
3 O
good O
in O
the O
RARE O
group O
. O

Cloning O
and O
RARE O
of O
two O
genes O
encoding O
RARE I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
from O
tobacco O
. O

Furthermore O
, O
direct O
association O
with O
NUM O
RARE O
seems O
to O
be O
essential O
RARE O
activation O
of O
PKB I-GENE
/ O
Akt I-GENE
. O

The O
ALL_CAP O
RARE O
but O
not O
the O
RARE O
NUM O
- O
NUM O
] O
cluster O
of O
the O
subunit O
appears O
to O
participate O
in O
this O
reaction O
. O

RARE O
RARE O
RARE O
RARE O
. O

METHODS O
: O
A O
population O
survey O
was O
undertaken O
in O
10 O
, O
NUM O
individuals O
to O
measure O
the O
prevalence O
and O
identify O
the O
causes O
of O
RARE O
in O
RARE O
. O

During O
RARE O
, O
ALL_CAP I-GENE
- I-GENE
8 I-GENE
RARE O
is O
found O
in O
the O
RARE O
mesoderm O
in O
close O
RARE O
of O
the O
gut O
endoderm O
, O
suggesting O
a O
role O
in O
mesenchymal O
- O
RARE O
induction O
of O
RARE O
and O
gut O
RARE O
. O

However O
, O
RARE O
failed O
to O
establish O
RARE O
in O
any O
cases O
of O
carcinoma O
spread O
to O
areas O
not O
RARE O
to O
laparoscopic O
visualization O
. O

No O
difference O
in O
RARE O
length O
was O
seen O
in O
mutants O
affected O
in O
the O
RARE O
of O
Cdc2 I-GENE
, O
whereas O
some O
of O
the O
DNA O
repair O
mutants O
examined O
had O
slightly O
longer O
RARE O
than O
did O
the O
wild O
type O
. O

The O
mean O
duration O
of O
pain O
RARE O
was O
4 O
- O
6 O
weeks O
. O

The O
ALL_CAP O
differs O
from O
conventional O
ALL_CAP O
in O
that O
RARE O
sample O
preparation O
is O
needed O
, O
RARE O
RARE O
changes O
. O

NUM I-GENE
can O
activate O
transcription O
through O
immunoglobulin I-GENE
RARE I-GENE
- I-GENE
chain I-GENE
enhancer I-GENE
or O
P I-GENE
- I-GENE
selectin I-GENE
promoter I-GENE
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
. O
NUM I-GENE
homodimers I-GENE
replace O
NUM I-GENE
from O
the O
P I-GENE
- I-GENE
selectin I-GENE
promoter I-GENE
by O
binding O
site O
competition O
and O
thereby O
either O
inhibit O
basal O
NUM I-GENE
- O
RARE O
RARE O
or O
, O
in O
RARE O
with O
Bcl I-GENE
- I-GENE
3 I-GENE
, O
stimulate O
RARE O
. O

The O
3 O
' O
fragment O
was O
shown O
to O
accumulate O
RARE O
full O
- O
length O
mRNA O
disappeared O
in O
RARE O
D O
- O
treated O
cells O
, O
indicating O
a O
precursor O
- O
product O
relationship O
. O

The O
TATA I-GENE
box I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
) O
plays O
an O
essential O
role O
in O
transcription O
by O
all O
three O
eukaryotic O
nuclear I-GENE
RNA I-GENE
RARE I-GENE
, O
RARE I-GENE
( I-GENE
Pol I-GENE
) I-GENE
I I-GENE
, I-GENE
II I-GENE
, I-GENE
and I-GENE
III I-GENE
. O

A O
RARE I-GENE
- I-GENE
mutant I-GENE
TBP I-GENE
( O
NUM O
+ O
NUM O
+ O
NUM O
) O
had O
greatly O
RARE O
activity O
RARE O
yeast I-GENE
U6 I-GENE
ALL_CAP I-GENE
gene I-GENE
transcription O
while O
remaining O
RARE O
RARE O
Pol I-GENE
II I-GENE
basal O
transcription O
. O

E2F I-GENE
activity O
is O
regulated O
in O
part O
by O
the O
RARE I-GENE
family I-GENE
of I-GENE
tumor I-GENE
suppressor I-GENE
proteins I-GENE
. O

This O
resulted O
in O
a O
RARE O
inhibition O
of O
RARE O
- O
1 O
RARE O
that O
was O
restored O
by O
concomitant O
overexpression O
of O
full O
- O
length O
ALL_CAP I-GENE
. O

To O
determine O
the O
true O
RARE O
identity O
of O
ALL_CAP I-GENE
, O
both O
the O
50 O
- O
and O
57 O
- O
kDa O
polypeptides O
were O
directly O
sequenced O
. O

Molecular O
characterization O
of O
the O
50 O
- O
and O
57 O
- O
kDa O
subunits O
of O
the O
bovine I-GENE
vacuolar I-GENE
RARE I-GENE
RARE I-GENE
. O

In O
C O
. O
RARE O
, O
NUM I-GENE
is O
RARE O
constitutively O
RARE O
high O
levels O
in O
the O
different O
cell O
RARE O
analysed O
( O
yeast O
, O
RARE O
, O
RARE O
and O
RARE O
RARE O
demonstrating O
that O
NUM I-GENE
transcription O
is O
not O
repressed O
in O
this O
diploid O
yeast O
, O
unlike O
in O
diploid O
S O
. O
cerevisiae O
, O
and O
suggesting O
a O
basic O
biological O
function O
RARE O
the O
NUM I-GENE
RARE O
in O
C O
. O
RARE O
. O

Furthermore O
, O
binding O
of O
recombinant I-GENE
Myb I-GENE
and O
Ets I-GENE
- I-GENE
2 I-GENE
protein I-GENE
to O
these O
fragments O
could O
be O
RARE O
with O
an O
excess O
of O
double O
RARE O
RARE O
containing O
canonical O
, O
but O
not O
RARE O
, O
Myb I-GENE
- O
or O
Ets I-GENE
- I-GENE
binding I-GENE
sites I-GENE
. O

This O
RARE O
RARE O
specific O
RARE O
of O
the O
basal O
RARE O
with O
the O
RARE O
RARE O
that O
RARE O
from O
the O
basal O
apparatus O
. O

To O
understand O
the O
regulatory O
mechanism O
controlling O
its O
RARE O
RARE O
low O
RARE O
, O
the O
promoter O
region O
has O
been O
characterized O
. O

In O
the O
current O
study O
, O
the O
roles O
of O
two O
putative O
cis O
- O
acting O
elements O
within O
the O
- O
NUM O
to O
+ O
NUM O
region O
in O
basal O
RARE O
2 O
promoter O
activity O
were O
evaluated O
using O
mutagenesis O
and O
nuclear O
protein O
- O
DNA O
binding O
assays O
. O

For O
the O
NUM I-GENE
receptor I-GENE
the O
addition O
of O
RARE O
resulted O
in O
a O
similar O
but O
smaller O
effect O
. O

We O
have O
examined O
reporter O
gene O
( O
beta I-GENE
- I-GENE
RARE I-GENE
) O
RARE O
directed O
by O
human I-GENE
heat I-GENE
shock I-GENE
transcription I-GENE
factors I-GENE
1 I-GENE
and I-GENE
2 I-GENE
( O
HSF1 I-GENE
and O
NUM I-GENE
) O
in O
HeLa O
cells O
and O
in O
yeast O
( O
Saccharomyces O
cerevisiae O
). O

RARE O
fluorescence O
was O
detectable O
only O
in O
cells O
containing O
a O
RARE O
RARE O
RARE O
, O
suggesting O
that O
ALL_CAP I-GENE
targeting O
normally O
occurs O
only O
RARE O
a O
RARE O
RARE O
of O
RARE O
. O

No O
TATA O
box O
was O
found O
in O
the O
putative O
promoter O
region O
, O
but O
multiple O
ALL_CAP O
RARE O
were O
found O
around O
the O
RARE O
sites O
, O
supporting O
the O
previously O
RARE O
housekeeping O
nature O
of O
NUM I-GENE
gene I-GENE
and O
the O
existence O
of O
the O
multiple O
transcription O
initiation O
sites O
. O

Structural O
and O
evolutionary O
studies O
on O
sterol I-GENE
14 I-GENE
- I-GENE
RARE I-GENE
P450 I-GENE
( O
NUM I-GENE
RARE O
the O
most O
RARE O
P450 I-GENE
RARE I-GENE
: O
I O
. O

Its O
RARE O
pattern O
is O
representative O
of O
many O
B O
cell O
- O
specific O
proteins O
, O
which O
are O
essential O
RARE O
B O
cell O
development O
and O
activation O
but O
are O
down O
- O
regulated O
after O
B O
cells O
become O
RARE O
differentiated O
plasma O
cells O
. O

The O
RARE O
gene O
junctions O
of O
vesicular O
RARE O
virus O
( O
ALL_CAP O
) O
contain O
RARE O
sequence O
elements O
that O
are O
important O
RARE O
polyadenylation O
and O
transcription O
RARE O
of O
upstream O
transcript O
RARE O
RARE O
RARE O
RARE O
of O
transcription O
of O
RARE O
transcript O
. O

RARE O
mutant O
virus O
RARE O
was O
obtained O
only O
on O
RARE O
ALL_CAP I-GENE
- O
expressing O
cells O
, O
suggesting O
that O
ALL_CAP I-GENE
has O
an O
important O
function O
in O
the O
replication O
RARE O
. O

RARE O
and O
DNA O
RARE O
reactions O
, O
carried O
out O
by O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
integrase I-GENE
, O
are O
necessary O
to O
effect O
the O
RARE O
RARE O
of O
HIV O
- O
1 O
DNA O
into O
the O
RARE O
genome O
. O

The O
ALL_CAP O
regimen O
appears O
to O
have O
significant O
activity O
in O
patients O
who O
have O
metastatic O
pancreatic O
islet O
- O
cell O
carcinoma O
, O
and O
patient O
tolerance O
of O
the O
regimen O
is O
excellent O
, O
thus O
RARE O
further O
investigation O
. O

Activation O
of O
the O
mitogen I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
is O
a O
RARE O
consequence O
of O
Ras I-GENE
activation O
and O
plays O
a O
key O
role O
in O
mediating O
Ras I-GENE
signal O
RARE O
. O

RARE I-GENE
acetylation O
levels O
in O
cells O
result O
from O
a O
dynamic O
equilibrium O
between O
RARE O
histone I-GENE
RARE I-GENE
and I-GENE
RARE I-GENE
. O

CONCLUSIONS O
: O
NUM I-GENE
may O
play O
a O
pivotal O
role O
in O
the O
transcriptional O
cascade O
that O
specifies O
RARE O
neurons O
in O
Xenopus O
RARE O
: O
by O
maintaining O
RARE I-GENE
- O
Notch I-GENE
signalling O
, O
NUM I-GENE
RARE O
the O
RARE O
RARE O
RARE O
of O
RARE O
RARE O
cells O
that O
express O
X I-GENE
- I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
, O
RARE O
the O
transition O
between O
RARE O
RARE O
and O
irreversible O
RARE O
to O
a O
RARE O
fate O
; O
and O
it O
promotes O
RARE O
differentiation O
by O
activating O
ALL_CAP I-GENE
RARE O
, O
directly O
or O
indirectly O
. O

RESULTS O
: O
Patients O
in O
Group O
A O
had O
a O
RARE O
incidence O
of O
RARE O
RARE O
motion O
abnormalities O
( O
p O
< O
NUM O
. O
001 O
) O
on O
RARE O
RARE O
, O
a O
larger O
infarct O
area O
( O
RARE O
RARE O
by O
RARE O
peak O
RARE I-GENE
kinase I-GENE
levels O
) O
( O
p O
< O
NUM O
. O
02 O
) O
and O
a O
lower O
RARE O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
RARE O
hospital O
discharge O
( O
p O
< O
NUM O
. O
NUM O
) O
than O
those O
in O
Group O
B O
. O

RARE I-GENE
transcription O
follows O
, O
and O
is O
therefore O
RARE O
of O
, O
the O
initial O
RARE O
of O
these O
RARE O
domains O
. O

RARE O
- O
RARE O
RARE O
of O
cell O
type O
RARE O
: O
a O
single O
RARE O
element O
controls O
the O
complex O
RARE O
of O
the O
RARE I-GENE
gene I-GENE
in O
RARE O
RARE O
RARE O
. O

We O
also O
present O
evidence O
that O
human I-GENE
NUM I-GENE
is O
identical O
to O
an O
uncharacterized O
gene O
RARE O
RARE O
by O
others O
from O
RARE O
NUM O
. O
3 O
that O
is O
RARE O
RARE O
in O
several O
small O
- O
cell O
RARE O
carcinoma O
cell O
lines O
. O

In O
patients O
with O
RARE O
, O
RARE O
' O
s O
RARE O
, O
RARE O
vasculitis O
and O
vascular O
diseases O
RARE I-GENE
concentrations O
were O
RARE O
than O
in O
patients O
without O
them O
. O

Although O
the O
RARE O
of O
the O
NUM I-GENE
- I-GENE
NUM I-GENE
gene I-GENE
alone O
has O
not O
yet O
been O
RARE O
, O
the O
gene O
was O
RARE O
in O
Escherichia O
coli O
RARE O
NUM O
( O
NUM O
)] O
RARE O
a O
fusion O
gene O
with O
the O
RARE I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
) O
gene O
using O
a O
RARE O
gene O
fusion O
vector O
( O
ALL_CAP O
- O
NUM O
- O
2 O
RARE O
which O
contains O
a O
gene O
sequence O
coding O
the O
RARE O
site O
RARE O
a O
specific O
protease O
, O
alpha I-GENE
- I-GENE
thrombin I-GENE
. O

RARE O
comparison O
of O
addition O
of O
autologous O
bone O
- O
marrow O
transplantation O
to O
intensive O
chemotherapy O
RARE O
acute O
RARE O
RARE O
in O
RARE O
remission O
: O
results O
of O
ALL_CAP O
ALL_CAP O
10 O
trial O
. O

RARE O
use O
of O
RARE O
. O

Analysis O
of O
RARE O
RARE O
shows O
that O
this O
function O
depends O
on O
the O
amino O
acid O
preceding O
the O
RARE O
cysteine O
RARE O
of O
the O
DNA O
- O
binding O
domain O
of O
NUM I-GENE
. O

RARE O
visual O
stimuli O
and O
RARE O
auditory O
stimuli O
were O
used O
RARE O
RARE O
. O

A O
review O
of O
studies O
published O
between O
1983 O
and O
1995 O
shows O
that O
there O
are O
some O
common O
factors O
RARE O
RARE O
the O
psychological O
distress O
and O
social O
and O
RARE O
limitations O
this O
group O
of O
patients O
has O
to O
RARE O
with O
. O

PKC I-GENE
- I-GENE
gamma I-GENE
, O
which O
is O
not O
present O
in O
RARE O
, O
also O
induces O
RARE I-GENE
gene I-GENE
RARE O
in O
a O
ALL_CAP O
- O
independent O
manner O
, O
when O
introduced O
into O
ALL_CAP O
cells O
. O

Identification O
and O
characterization O
of O
specific O
DNA O
- O
binding O
complexes O
containing O
members O
of O
the O
RARE I-GENE
/ O
Max I-GENE
/ O
RARE I-GENE
network O
of O
transcriptional O
RARE O
. O

We O
further O
show O
that O
RARE O
targeting O
by O
RARE I-GENE
II I-GENE
and O
the O
proteasome O
involves O
different O
structural O
elements O
of O
YY1 I-GENE
. O

RARE O
RARE O
subsequent O
RARE O
of O
RACE O
were O
designed O
from O
the O
5 O
'- O
ends O
of O
amplified O
RACE O
products O
. O

Human O
NUM I-GENE
protein I-GENE
is O
a O
transcriptional O
repressor O
that O
interacts O
with O
the O
transcription I-GENE
activation I-GENE
domain I-GENE
of I-GENE
RARE I-GENE
- I-GENE
specific I-GENE
activator I-GENE
protein I-GENE
. O

Surprisingly O
, O
the O
NUM I-GENE
/ O
NUM I-GENE
was O
RARE O
effective O
RARE O
the O
NUM I-GENE
/ O
IR I-GENE
in O
mediating O
CSF I-GENE
- I-GENE
1 I-GENE
protection O
of O
cells O
from O
RARE O
- O
RARE O
apoptosis O
. O

CONCLUSIONS O
: O
The O
RARE O
clinical O
presentation O
of O
our O
case O
of O
possible O
RARE O
' O
s O
RARE O
is O
discussed O
. O

These O
results O
would O
suggest O
that O
a O
high O
ALL_CAP O
sensitivity O
is O
associated O
with O
high O
RARE O
and O
low O
RARE O
levels O
, O
and O
point O
to O
the O
RARE O
/ O
RARE O
ratio O
RARE O
a O
novel O
chemical O
parameter O
that O
could O
be O
used O
RARE O
predicting O
individuals O
RARE O
high O
risk O
RARE O
RARE O
RARE O
and O
RARE O
. O

In O
RARE O
naturally O
RARE O
with O
H O
. O
RARE O
, O
a O
single O
dose O
( O
50 O
mg O
/ O
kg O
, O
per O
RARE O
) O
of O
RARE O
completely O
inhibited O
bacterial I-GENE
urease I-GENE
. O

The O
cAMP O
- O
dependent O
mitogenic O
RARE O
is O
unique O
RARE O
it O
is O
independent O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
activation O
and O
differs O
from O
growth O
factor O
- O
dependent O
pathways O
RARE O
the O
level O
of O
the O
RARE O
of O
several O
RARE O
/ O
transcription O
factors O
. O

CONCLUSIONS O
: O
Use O
of O
the O
RARE O
method O
was O
associated O
with O
a O
reduction O
in O
the O
time O
patients O
remained O
in O
the O
ALL_CAP O
before O
transfer O
to O
another O
unit O
and O
RARE O
in O
nursing O
time O
, O
but O
the O
two O
methods O
did O
not O
differ O
according O
to O
clinical O
outcomes O
. O

We O
have O
RARE O
the O
RARE O
- O
intron O
organization O
of O
the O
RARE O
human O
NUM I-GENE
gene I-GENE
, O
including O
RARE O
2 O
. O
5 O
kilobases O
( O
kb O
) O
of O
5 O
'- O
flanking O
DNA O
. O

The O
risk O
factors O
RARE O
RARE O
in O
patients O
with O
RARE O
RARE O
are O
the O
elevation O
of O
RARE O
RARE O
concentration O
and O
the O
subtypes O
of O
Post O
and O
RARE O
. O

Two O
hundred O
RARE O
- O
four O
patients O
RARE O
RARE O
ALL_CAP O
were O
randomized O
to O
receive O
intravenously O
ALL_CAP O
NUM O
. O
NUM O
mg O
( O
ALL_CAP O
- O
NUM O
RARE O
or O
ALL_CAP O
NUM O
. O
5 O
mg O
( O
ALL_CAP O
- O
50 O
RARE O
or O
ALL_CAP O
20 O
mg O
RARE O
RARE O
agent O
. O

If O
the O
RARE I-GENE
concentration O
( O
RARE I-GENE
) O
was O
less O
than O
12 O
g O
dL O
- O
1 O
they O
were O
given O
a O
four O
week O
course O
of O
RARE O
RARE O
. O

In O
all O
cells O
, O
the O
accumulation O
of O
high O
RARE I-GENE
protein I-GENE
levels O
required O
RARE O
and O
was O
not O
observed O
in O
low O
RARE O
( O
NUM O
. O
05 O
- O
NUM O
. O
07 O
mM O
) O
media O
. O

Based O
on O
RARE O
enzyme O
analysis O
, O
Southern O
blots O
, O
polymerase O
chain O
reaction O
analysis O
and O
DNA O
sequencing O
, O
it O
was O
confirmed O
that O
the O
three O
overlapping O
RARE O
isolated O
RARE O
the O
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
gene I-GENE
, O
RARE O
RARE O
RARE O
RARE O
10 O
kb O
of O
the O
flanking O
regions O
on O
both O
ends O
. O

RESULTS O
: O
Using O
RARE O
in O
the O
ALL_CAP O
database O
of O
RARE O
sequence O
tags O
, O
we O
isolated O
an O
Arabidopsis O
thaliana O
gene O
( O
NUM I-GENE
) O
that O
encodes O
a O
protein O
with O
RARE O
predicted O
membrane O
- O
spanning O
domains O
and O
other O
features O
characteristic O
of O
NUM I-GENE
receptors I-GENE
. O

E1A I-GENE
represses O
apolipoprotein I-GENE
ALL_CAP I-GENE
enhancer I-GENE
activity O
in O
liver O
cells O
through O
a O
pRb I-GENE
- O
and O
CBP I-GENE
- O
independent O
RARE O
. O

RARE O
- O
independent O
RARE O
of O
a O
human O
nerve I-GENE
growth I-GENE
factor I-GENE
- O
luciferase I-GENE
reporter O
gene O
RARE O
on O
a O
yeast O
artificial O
RARE O
vector O
. O

RARE O
therapy O
was O
associated O
with O
a O
decrease O
in O
serum O
ALL_CAP I-GENE
levels O
( O
NUM O
+/- O
NUM O
. O
9 O
RARE O
. O

RARE O
in O
DNase I-GENE
I I-GENE
reactivity O
of O
the O
ALL_CAP O
- O
response O
element O
region O
suggest O
that O
ALL_CAP I-GENE
receptor I-GENE
- I-GENE
ALL_CAP I-GENE
complexes I-GENE
may O
associate O
, O
in O
a O
transient O
manner O
, O
with O
the O
promoter O
in O
the O
actively O
RARE O
control O
state O
. O

Most O
pituitary O
hormone O
- O
coding O
gene O
promoters O
are O
activated O
by O
NUM I-GENE
. O

One O
of O
these O
small I-GENE
RARE I-GENE
might O
be O
inactive O
or O
a O
" I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
The O
results O
suggest O
a O
RARE O
architecture O
RARE O
RARE I-GENE
, O
clarify O
their O
origin O
and O
relationship O
to O
other O
protein O
RARE O
, O
and O
extend O
recent O
experimental O
findings O
on O
the O
RARE O
roles O
of O
RARE I-GENE
N I-GENE
, I-GENE
C I-GENE
, I-GENE
and I-GENE
ALL_CAP I-GENE
motifs I-GENE
. O

RARE O
of O
ALL_CAP I-GENE
RARE O
RARE O
two O
polypeptides O
of O
RARE O
RARE O
mass O
NUM O
kDa O
and O
16 O
kDa O
, O
designated O
NUM I-GENE
and O
NUM I-GENE
. O

M I-GENE
- I-GENE
NUM I-GENE
identified O
the O
14 O
- O
kDa O
protein O
in O
another O
ALL_CAP O
RARE O
T O
- O
cell O
lymphoma O
, O
ALL_CAP O
- O
4 O
. O

These O
results O
indicate O
that O
TGF I-GENE
- I-GENE
RARE I-GENE
potentiates O
the O
c I-GENE
- I-GENE
fos I-GENE
SRE O
activated O
by O
PKC I-GENE
through O
the O
SRF I-GENE
binding I-GENE
site I-GENE
. O

RT O
- O
PCR O
indicated O
that O
p21 I-GENE
mRNA I-GENE
was O
RARE O
1 O
. O
4 O
RARE O
2 O
. O
NUM O
RARE O
and O
3 O
. O
1 O
- O
RARE O
in O
the O
2 O
- O
day O
neonatal O
, O
7 O
- O
day O
neonatal O
, O
and O
adult O
stages O
, O
respectively O
, O
compared O
to O
the O
NUM O
- O
day O
RARE O
RARE O
. O

RARE O
and O
RARE O
efficacy O
in O
AIDS O
- O
related O
ALL_CAP O
RARE O
. O

BACKGROUND O
: O
RARE I-GENE
, O
also O
known O
RARE O
human I-GENE
RARE I-GENE
peptides I-GENE
, O
are O
antimicrobial O
peptides O
present O
in O
the O
RARE O
granules O
of O
neutrophils O
. O

The O
spontaneous O
mutation O
blocking O
RARE I-GENE
gene I-GENE
RARE O
was O
RARE O
in O
the O
promoter O
RARE O
the O
RARE I-GENE
operon I-GENE
. O

From O
NUM O
g O
of O
cells O
, O
we O
isolated O
1 O
mg O
of O
ALL_CAP I-GENE
complex I-GENE
with O
a O
specific O
activity O
of O
12 O
. O
6 O
ALL_CAP O
/ O
mg O
of O
protein O
. O

The O
ALL_CAP I-GENE
complex I-GENE
- I-GENE
encoding I-GENE
genes I-GENE
were O
identified O
by O
hybridization O
experiments O
and O
sequence O
analysis O
in O
two O
separate O
gene O
regions O
in O
the O
genome O
of O
Z O
. O
RARE O
. O

We O
have O
identified O
two O
RARE O
elements O
, O
both O
RARE O
RARE O
from O
the O
TATA O
motif O
, O
that O
control O
NUM I-GENE
promoter I-GENE
activity O
. O

RARE O
is O
a O
new O
generation O
RARE O
antibiotic O
with O
unusual O
and O
RARE O
pharmacokinetics O
, O
and O
seems O
to O
be O
a O
very O
RARE O
agent O
RARE O
RARE O
anti O
- O
H O
. O
RARE O
regimens O
. O

The O
study O
enrolled O
NUM O
people O
RARE O
- O
RARE O
with O
ALL_CAP O
and O
HIV O
, O
with O
RARE O
least O
one O
NUM I-GENE
count O
recorded O
< O
NUM O
RARE O
10 O
( O
6 O
) O
cells O
/ O
RARE O
. O

BACKGROUND O
ALL_CAP O
OBJECTIVES O
: O
The O
RARE O
transmitted O
diseases O
( O
ALL_CAP O
) O
control O
program O
RARE O
female O
RARE O
workers O
( O
ALL_CAP O
) O
in O
RARE O
, O
RARE O
, O
provided O
RARE O
serological O
tests O
RARE O
RARE O
and O
cervical O
smears O
RARE O
RARE O
, O
but O
not O
medication O
RARE O
ALL_CAP O
or O
RARE O
. O

National O
RARE O
: O
a O
vital O
RARE O
of O
quality O
RARE O
. O

Two O
rare O
novel O
mutations O
, O
NUM O
in O
RARE O
20 O
and O
NUM O
in O
RARE O
21 O
, O
were O
identified O
in O
the O
RARE O
nucleotide O
- O
binding O
RARE O
( O
ALL_CAP O
RARE O
a O
functionally O
important O
region O
of O
NUM I-GENE
, O
in O
one O
patient O
each O
, O
both O
RARE O
. O

RARE O
VP16 I-GENE
- O
E2 I-GENE
molecules O
suggest O
that O
the O
RARE O
specific O
transcriptional O
activation O
of O
the O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
ALL_CAP I-GENE
promoter I-GENE
is O
RARE O
by O
the O
E2 I-GENE
RARE I-GENE
domain I-GENE
. O

In O
order O
to O
examine O
the O
RARE O
role O
of O
transcriptional O
silencing O
RARE O
RARE O
HSV O
- O
1 O
infection O
, O
recombinant O
viruses O
were O
generated O
in O
which O
wild I-GENE
- I-GENE
type I-GENE
or I-GENE
mutant I-GENE
NUM I-GENE
. I-GENE
5 I-GENE
promoters I-GENE
controlling O
the O
RARE O
of O
a O
chloramphenicol I-GENE
RARE I-GENE
reporter I-GENE
gene I-GENE
were O
inserted O
into O
the O
RARE I-GENE
kinase I-GENE
gene I-GENE
of O
the O
viral O
genome O
. O

These O
changes O
correlate O
directly O
with O
an O
increase O
in O
the O
acetylation O
levels O
of O
all O
four O
core I-GENE
RARE I-GENE
in O
vivo O
. O

Drosophila I-GENE
RARE I-GENE
( O
RARE I-GENE
) O
and O
murine I-GENE
RARE I-GENE
genes I-GENE
RARE O
this O
, O
both O
in O
terms O
of O
RARE O
patterns O
and O
mutant O
RARE O
. O

NUM I-GENE
transcripts I-GENE
are O
RARE O
detected O
in O
a O
RARE O
region O
that O
will O
give O
rise O
to O
the O
RARE O
and O
RARE O
RARE O
, O
and O
RARE O
is O
maintained O
in O
this O
region O
RARE O
subsequent O
development O
of O
these O
organs O
. O

We O
also O
recovered O
mutations O
in O
the O
NUM I-GENE
gene I-GENE
which O
encodes O
another O
TGF I-GENE
- I-GENE
beta I-GENE
- I-GENE
related I-GENE
factor I-GENE
in O
Drosophila O
. O

Cell O
lines O
are O
RARE O
to O
find O
out O
whether O
they O
develop O
tumors O
in O
nude O
mice O
followed O
by O
an O
analysis O
of O
the O
RARE O
. O

RARE O
RARE I-GENE
fibronectin I-GENE
in O
the O
prediction O
of O
preterm O
labour O
in O
a O
low O
- O
risk O
population O
. O

In O
addition O
, O
IgM I-GENE
can O
be O
absent O
in O
children O
with O
congenital O
RARE O
or O
subjects O
with O
secondary O
RARE O
. O

Both O
variants O
display O
the O
RARE O
- O
transmembrane O
topology O
that O
is O
typical O
RARE O
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptors I-GENE
. O

A O
RARE O
allele O
of O
NUM I-GENE
could O
stimulate O
growth O
of O
a O
RARE O
RARE O
both O
ALL_CAP I-GENE
genes I-GENE
. O

The O
ALL_CAP O
- O
terminus O
of O
this O
new O
isoform O
, O
which O
we O
RARE O
beta I-GENE
4 I-GENE
, O
lacks O
a O
NUM O
amino O
acid O
RARE O
- O
rich O
sequence O
common O
to O
both O
the O
human I-GENE
RARE I-GENE
cell I-GENE
alpha I-GENE
- I-GENE
and I-GENE
beta I-GENE
- I-GENE
RARE I-GENE
subunits I-GENE
and O
homologous O
to O
a O
highly O
RARE O
region O
in O
ALL_CAP I-GENE
, O
a O
RARE O
actin I-GENE
- O
cross O
linking O
protein O
regulated O
by O
protein I-GENE
kinase I-GENE
C I-GENE
and O
RARE O
/ O
calmodulin I-GENE
. O
beta I-GENE
4 I-GENE
- I-GENE
RARE I-GENE
RARE O
a O
previously O
identified O
calmodulin I-GENE
binding I-GENE
domain I-GENE
. O

PCR O
analysis O
indicates O
that O
this O
new O
beta I-GENE
- I-GENE
RARE I-GENE
isoform I-GENE
is O
RARE O
in O
RARE O
brain O
and O
liver O
, O
bone O
marrow O
, O
and O
ALL_CAP O
- O
2 O
( O
RARE O
) O
cells O
, O
but O
is O
not O
detected O
in O
several O
other O
tissues O
. O

The O
gene I-GENE
lac I-GENE
- I-GENE
1 I-GENE
, O
encoding O
the O
enzyme O
RARE I-GENE
, O
is O
the O
best O
characterized O
of O
a O
number O
of O
genes O
in O
the O
RARE O
RARE O
RARE O
, O
RARE O
RARE O
, O
that O
are O
repressed O
by O
RARE O
, O
a O
group O
of O
RARE O
- O
RARE O
RARE O
. O
lac I-GENE
- I-GENE
1 I-GENE
has O
also O
been O
shown O
to O
be O
transcriptionally O
activated O
by O
low O
concentrations O
of O
the O
translational O
inhibitor O
RARE O
( O
ALL_CAP O
) O
and O
by O
the O
RARE O
cyclosporin O
A O
. O

Both O
ALL_CAP O
- O
like O
elements O
were O
capable O
of O
binding O
AP1 I-GENE
. O

The O
NUM I-GENE
gamma I-GENE
protein I-GENE
interacts O
strongly O
with O
the O
activated O
ALL_CAP I-GENE
but O
not O
with O
the O
kinase O
- O
negative O
mutant O
receptor O
. O
NUM I-GENE
gamma I-GENE
also O
interacts O
with O
the O
insulin I-GENE
receptor I-GENE
( O
IR I-GENE
) O
in O
the O
yeast O
two O
- O
RARE O
RARE O
. O

The O
RARE O
protein O
maintains O
all O
the O
RARE O
domains O
found O
in O
the O
other O
proteins O
, O
including O
nuclear O
RARE O
signal O
, O
DNA O
- O
binding O
domain O
and O
RARE I-GENE
motifs I-GENE
, O
suggesting O
that O
it O
might O
also O
act O
RARE O
part O
of O
the O
RNA O
transcription O
apparatus O
, O
RARE O
RARE O
RARE O
nucleotide O
RARE O
repair O
in O
RARE O
cells O
. O

This O
paper O
describes O
the O
genomic O
organization O
of O
mouse O
NUM I-GENE
and O
the O
characterization O
of O
its O
5 O
' O
flanking O
region O
. O

ALL_CAP I-GENE
proteins I-GENE
have O
been O
shown O
to O
regulate O
urease I-GENE
in I-GENE
RARE I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
RARE O
and O
catalase I-GENE
in I-GENE
Escherichia I-GENE
coli I-GENE
( O
OxyR I-GENE
RARE O
which O
offers O
the O
RARE O
bacterium O
protection O
from O
RARE O
damage O
. O

Also O
, O
the O
anti O
- O
inflammatory O
activities O
of O
an O
aqueous O
RARE O
of O
RARE O
RARE O
and O
its O
principal O
RARE O
RARE O
were O
evaluated O
. O

Regulation O
of O
the O
Raf I-GENE
kinase I-GENE
in O
T O
cells O
differs O
from O
findings O
with O
a O
variety O
of O
cell O
lines O
that O
the O
catalytic I-GENE
domain I-GENE
of I-GENE
Raf I-GENE
( O
Raf I-GENE
( O
NUM O
- O
NUM O
)) O
shows O
RARE O
activity O
. O

RARE I-GENE
- I-GENE
length I-GENE
ALL_CAP I-GENE
RARE O
were O
isolated O
from O
a O
mouse O
skeletal O
muscle O
cDNA O
library O
. O

Members O
of O
the O
NUM I-GENE
and O
RARE I-GENE
RARE I-GENE
protein I-GENE
RARE I-GENE
RARE O
bind O
a O
cAMP O
- O
responsive O
sequence O
( O
NUM O
) O
from O
bovine I-GENE
NUM I-GENE
. O

We O
have O
RARE O
DNA O
- O
protein O
complexes O
by O
electron O
microscopy O
and O
a O
high O
- O
affinity O
binding O
site O
of O
ALL_CAP I-GENE
Rep I-GENE
protein I-GENE
within O
the O
core O
element O
has O
been O
mapped O
to O
RARE O
NUM O
+/- O
18 O
bp O
upstream O
from O
the O
initiation O
site O
, O
between O
the O
RARE O
site O
RARE O
RARE O
- O
sense O
transcription O
and O
the O
TATA O
box O
. O

RARE I-GENE
- I-GENE
1 I-GENE
, O
a O
gene O
encoding O
a O
transcription O
factor O
RARE O
in O
the O
early O
RARE O
, O
is O
regulated O
via O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
and O
Oct I-GENE
- I-GENE
6 I-GENE
binding O
to O
an O
octamer O
site O
and O
a O
novel O
protein O
, O
RARE I-GENE
- I-GENE
1 I-GENE
, O
binding O
to O
an O
adjacent O
site O
. O

However O
, O
inhibition O
of O
both O
the O
ERK I-GENE
/ O
ALL_CAP I-GENE
and O
the O
p38 I-GENE
/ O
ALL_CAP I-GENE
kinase I-GENE
2 I-GENE
pathways O
completely O
abolished O
ALL_CAP I-GENE
- O
RARE O
CREB I-GENE
RARE O
- O
NUM O
RARE O
. O

RARE O
respond O
to O
the O
accumulation O
of O
RARE O
proteins O
in O
the O
endoplasmic O
reticulum O
( O
ER O
) O
by O
increasing O
the O
transcription O
of O
the O
genes O
encoding O
ER I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
proteins I-GENE
. O

The O
ALL_CAP I-GENE
- O
cyclic I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
ALL_CAP I-GENE
RARE O
prevents O
the O
UAS O
activity O
of O
RARE I-GENE
in O
the O
presence O
of O
glucose O
RARE O
the O
RARE O
carbon O
source O
, O
while O
the O
transcriptional O
RARE O
NUM I-GENE
and O
NUM I-GENE
promote O
the O
UAS O
activity O
of O
this O
repeat O
in O
the O
presence O
of O
RARE O
. O

The O
NUM I-GENE
+ I-GENE
gene I-GENE
of O
the O
RARE O
yeast O
Schizosaccharomyces O
pombe O
was O
RARE O
by O
RARE O
RARE O
. O

Alternative O
RARE O
of O
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
2 I-GENE
( O
FGF I-GENE
- I-GENE
NUM I-GENE
) O
is O
an O
example O
of O
highly O
regulated O
RARE O
RARE O
in O
which O
exons O
RARE O
and O
RARE O
are O
utilized O
in O
a O
RARE O
RARE O
manner O
in O
different O
cell O
RARE O
. O

In O
some O
cases O
, O
the O
aberrant O
methylation O
of O
RARE O
within O
5 O
' O
regulatory O
regions O
has O
led O
to O
suppression O
of O
gene O
activity O
. O

The O
genomic O
fragments O
were O
fused O
upstream O
of O
the O
luciferase I-GENE
reporter I-GENE
gene I-GENE
. O

Cotransfection O
analyses O
of O
the O
T I-GENE
/ I-GENE
EBP I-GENE
promoter I-GENE
- I-GENE
reporter I-GENE
constructs I-GENE
with O
a O
T I-GENE
/ I-GENE
EBP I-GENE
RARE O
vector O
into O
human O
NUM O
cells O
, O
which O
do O
not O
express O
T I-GENE
/ I-GENE
EBP I-GENE
, O
suggested O
that O
autoregulation O
may O
be O
involved O
in O
controlling O
both O
rat O
and O
human I-GENE
T I-GENE
/ I-GENE
EBP I-GENE
gene I-GENE
RARE O
. O

Deletion O
of O
the O
last O
two O
RARE O
residues O
, O
including O
one O
PKC I-GENE
consensus O
site O
in O
the O
receptor O
RARE O
, O
prevented O
only O
phorbol O
12 O
- O
myristate O
NUM O
- O
RARE O
- O
RARE O
RARE O
by O
NUM O
%. O

RARE O
survival O
depends O
on O
the O
development O
of O
a O
small O
number O
of O
vascular O
RARE O
between O
vessels O
arising O
from O
the O
RARE O
and O
RARE O
dermal O
vessels O
. O

RARE O
RARE O
RARE O
recent O
literature O
about O
lower O
respiratory O
RARE O
infection O
in O
children O
. O

RARE O
indicators O
were O
assessed O
RARE O
the O
two O
RARE O
of O
protein O
- O
energy O
RARE O
in O
the O
guidelines O
RARE O
integrated O
management O
of O
childhood O
illness O
: O
severe O
RARE O
, O
which O
requires O
immediate O
RARE O
to O
hospital O
, O
and O
very O
low O
RARE O
, O
which O
RARE O
RARE O
feeding O
assessment O
, O
nutritional O
RARE O
and O
follow O
- O
RARE O
. O

ALL_CAP O
or O
ALL_CAP O
was O
infused O
RARE O
6 O
. O
5 O
h O
, O
beginning O
NUM O
min O
before O
ischemia O
and O
RARE O
throughout O
the O
duration O
of O
reperfusion O
. O

Despite O
its O
requirement O
RARE O
enhancer O
- O
dependent O
RARE O
activity O
in O
vitro O
, O
the O
NUM I-GENE
ALL_CAP I-GENE
domain I-GENE
was O
also O
RARE O
in O
vivo O
. O

In O
vitro O
binding O
studies O
using O
GST I-GENE
fusion O
proteins O
and O
yeast O
extracts O
defined O
distinct O
binding O
sites O
on O
NUM I-GENE
RARE O
NUM I-GENE
and O
clathrin I-GENE
. O
NUM I-GENE
proteins I-GENE
and O
NUM I-GENE
, O
like O
actin I-GENE
, O
localize O
to O
peripheral O
RARE O
along O
the O
plasma O
membrane O
. O

In O
vitro O
affinity O
analyses O
demonstrated O
that O
recombinant O
NUM O
- O
ALL_CAP O
protein O
directly O
interacts O
with O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
and O
the O
cytoplasmic O
domain O
of O
RARE I-GENE
, O
but O
not O
with O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
. O

RARE I-GENE
b I-GENE
in O
human I-GENE
complex I-GENE
II I-GENE
( O
RARE I-GENE
- I-GENE
RARE I-GENE
oxidoreductase I-GENE
): O
cDNA O
cloning O
of O
the O
RARE O
in O
liver O
RARE O
and O
RARE O
assignment O
of O
the O
genes O
RARE O
the O
large O
( O
ALL_CAP I-GENE
) O
and O
small O
( O
ALL_CAP I-GENE
) O
subunits O
to O
NUM O
and O
NUM O
. O

A O
possible O
decrease O
in O
theophylline O
' O
s O
volume O
of O
distribution O
RARE O
4 O
days O
, O
but O
not O
immediately O
, O
after O
administration O
of O
RARE O
was O
suggested O
, O
although O
this O
just O
failed O
to O
achieve O
statistical O
significance O
( O
p O
= O
NUM O
. O
NUM O
). O

The O
addition O
of O
a O
RARE I-GENE
- O
containing O
RARE O
does O
not O
lead O
to O
significant O
protein O
binding O
to O
these O
two O
RARE I-GENE
target I-GENE
sequences I-GENE
in O
the O
absence O
of O
ALL_CAP I-GENE
but O
RARE O
the O
complex O
( O
ALL_CAP O
) O
consisting O
of O
ALL_CAP I-GENE
and O
the O
NUM I-GENE
bp I-GENE
RARE I-GENE
DNA I-GENE
fragment I-GENE
to O
a O
slower O
RARE O
ALL_CAP I-GENE
- O
RARE I-GENE
- O
DNA O
complex O
( O
ALL_CAP O
). O

Moreover O
, O
it O
is O
the O
RARE O
behind O
steady O
- O
state O
NUM O
uptake O
that O
do O
not O
permit O
proper O
interpretation O
of O
energy O
expenditure O
RARE O
ALL_CAP O
; O
1 O
RARE O
NUM O
not O
= O
20 O
. O
9 O
ALL_CAP O
. O

The O
predicted O
amino O
acid O
sequence O
of O
m I-GENE
- I-GENE
RARE I-GENE
is O
highly O
homologous O
to O
that O
of O
RARE I-GENE
, O
another O
RARE I-GENE
tRNA I-GENE
gene I-GENE
transcription I-GENE
activating I-GENE
factor I-GENE
of O
Xenopus O
RARE O
. O

ALL_CAP I-GENE
- I-GENE
I I-GENE
, O
RARE I-GENE
, O
and O
NUM I-GENE
can O
bind O
the O
wild O
type O
forms O
of O
both O
RhoA I-GENE
and O
Cdc42 I-GENE
in O
a O
GTP O
- O
dependent O
manner O
in O
vitro O
. O

Among O
three O
isoforms O
, O
the O
beta O
isoform O
has O
the O
greatest O
Vmax O
value O
RARE O
the O
RARE I-GENE
( I-GENE
4 I-GENE
) I-GENE
P I-GENE
kinase I-GENE
activity O
and O
the O
gamma O
isoform O
is O
most O
markedly O
RARE O
by O
RARE O
acid O
. O

The O
beta O
subunit O
of O
the O
heterotrimeric I-GENE
G I-GENE
proteins I-GENE
that O
RARE O
signals O
across O
the O
plasma O
membrane O
is O
made O
RARE O
of O
an O
amino O
- O
terminal O
alpha O
- O
helical O
segment O
followed O
by O
RARE O
repeating O
RARE O
called O
ALL_CAP O
( O
RARE O
- O
RARE O
) O
repeats O
that O
occur O
in O
about O
NUM O
different O
proteins O
. O

Two O
differentially O
RARE O
ALL_CAP I-GENE
RARE I-GENE
encode O
overlapping O
proteins O
with O
predicted O
RARE O
masses O
of O
NUM I-GENE
kDa I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
and O
70 O
kDa O
( O
ALL_CAP O
- O
b O
). O

In O
contrast O
, O
the O
contractile O
action O
of O
RARE O
acid O
, O
via O
a O
RARE O
RARE I-GENE
product O
that O
RARE O
the O
contractions O
caused O
by O
both O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
, O
was O
not O
blocked O
by O
any O
of O
the O
signal O
RARE O
probe O
RARE O
. O

Recent O
studies O
have O
revealed O
RARE O
myosin I-GENE
V I-GENE
to O
be O
an O
important O
actin I-GENE
- O
based O
RARE O
motor O
involved O
in O
vesicular O
movement O
. O

On O
a O
separate O
RARE O
the O
NUM O
weighted O
and O
NUM O
weighted O
RARE O
and O
NUM O
weighted O
axial O
sequences O
were O
reported O
blind O
in O
relation O
to O
the O
initial O
assessment O
. O

Furthermore O
, O
a O
minor O
RARE O
site O
was O
localized O
NUM O
bp O
upstream O
of O
the O
major O
site O
using O
reverse I-GENE
transcriptase I-GENE
- O
polymerase O
chain O
reaction O
with O
various O
P1 O
primers O
( O
primer O
RARE O
RARE O
primer O
extension O
, O
and O
cDNA O
cloning O
. O

Analysis O
of O
promoter O
and O
RARE O
regulatory O
sequences O
required O
RARE O
optimal O
transcription O
of O
the O
rat O
RARE I-GENE
- I-GENE
binding I-GENE
protein I-GENE
gene O
. O

The O
iron O
dependence O
of O
transcription O
and O
RARE O
of O
ALL_CAP I-GENE
, O
which O
encodes O
a O
RARE O
RARE O
protein O
, O
and O
RARE I-GENE
, O
encoding O
the O
RARE I-GENE
V I-GENE
RARE I-GENE
protein I-GENE
, O
was O
assessed O
under O
conditions O
of O
iron O
excess O
or O
depletion O
. O

In O
a O
ALL_CAP I-GENE
deletion I-GENE
mutant I-GENE
, O
the O
RARE O
of O
a O
chromosomal O
ALL_CAP I-GENE
:: O
lacZ I-GENE
fusion O
is O
both O
high O
and O
RARE O
, O
confirming O
that O
ALL_CAP I-GENE
is O
the O
negative O
regulator O
of O
ALL_CAP I-GENE
. O

Furthermore O
, O
the O
deletion O
of O
RARE I-GENE
from O
the O
RARE O
had O
RARE O
effect O
on O
RARE I-GENE
- O
lacZ I-GENE
RARE O
. O

Of O
these O
sites O
, O
PEA3 I-GENE
and O
STAT I-GENE
contributed O
specifically O
to O
induction O
by O
v I-GENE
- I-GENE
src I-GENE
, O
whereas O
the O
remaining O
elements O
were O
also O
involved O
in O
induction O
by O
the O
phorbol O
ester O
phorbol O
myristate O
RARE O
( O
PMA O
). O

BRCA1 I-GENE
protein I-GENE
contains O
an O
amino O
- O
terminal O
zinc O
finger O
motif O
and O
a O
RARE O
- O
terminal O
RARE O
region O
. O

The O
mitochondrial I-GENE
regulatory I-GENE
region I-GENE
( O
RARE I-GENE
) O
RARE O
between O
the O
RARE I-GENE
and O
RARE I-GENE
genes I-GENE
of O
mitochondrial O
DNA O
( O
ALL_CAP O
) O
is O
essential O
RARE O
RARE O
of O
replication O
and O
transcription O
of O
the O
mitochondrial O
genome O
. O

In O
this O
report O
, O
we O
investigate O
the O
mechanism O
underlying O
Ras I-GENE
activation O
upon O
RARE O
of O
these O
two O
RARE O
of O
receptors O
in O
hematopoietic O
cells O
. O

Thus O
, O
RARE I-GENE
proteins I-GENE
from O
K O
. O
lactis O
have O
roles O
in O
both O
silencing O
and O
RARE O
length O
RARE O
, O
reflecting O
RARE O
RARE O
RARE O
. O

Therefore O
, O
we O
conclude O
that O
ALL_CAP I-GENE
may O
RARE O
the O
beta O
subunit O
of O
RNA I-GENE
polymerase I-GENE
RARE O
activation O
of O
the O
ALL_CAP I-GENE
promoter I-GENE
. O

Expression O
of O
Bcl I-GENE
- I-GENE
ALL_CAP I-GENE
inhibited O
the O
association O
of O
RARE I-GENE
- I-GENE
1 I-GENE
with O
RARE I-GENE
- I-GENE
9 I-GENE
in O
mammalian O
cells O
. O

RARE O
- O
RARE O
in O
situ O
hybridization O
to O
early O
mouse O
RARE O
of O
9 O
. O
5 O
- O
10 O
. O
5 O
days O
indicated O
a O
complex O
pattern O
of O
NUM I-GENE
RARE O
spatially O
overlapping O
with O
the O
RARE O
of O
NUM I-GENE
. O

These O
mutants O
were O
tested O
RARE O
ability O
to O
bind O
each O
of O
the O
RARE I-GENE
II I-GENE
RARE I-GENE
proteins I-GENE
, O
and O
subsequently O
evaluated O
RARE O
ability O
to O
confer O
NUM I-GENE
transcriptional O
activity O
using O
chimeric O
NUM I-GENE
promoter O
/ O
CAT I-GENE
fusion O
constructs O
in O
different O
cell O
RARE O
. O

Increased O
plasma O
IgE I-GENE
was O
also O
confirmed O
in O
the O
ALL_CAP O
mice O
, O
and O
treatment O
with O
FK506 O
RARE O
RARE O
the O
plasma O
IgE I-GENE
level O
. O

RARE I-GENE
kinase I-GENE
release O
after O
RARE O
artery O
RARE O
in O
patients O
with O
RARE O
tumors O
. O

Furthermore O
, O
in O
the O
ischemia O
/ O
RARE I-GENE
II I-GENE
- O
RARE O
ALL_CAP O
model O
, O
ALL_CAP O
decreased O
RARE O
ventricular O
end O
- O
diastolic O
pressure O
( O
ALL_CAP O
). O

Group O
A O
( O
NUM O
. O
7 O
+/- O
2 O
. O
7 O
years O
) O
consisted O
of O
patients O
with O
NUM O
or O
1 O
risk O
factors O
; O
B O
( O
NUM O
. O
3 O
+/- O
4 O
. O
2 O
years O
) O
those O
with O
2 O
risk O
factors O
; O
and O
C O
( O
NUM O
. O
2 O
+/- O
3 O
. O
6 O
years O
) O
those O
with O
3 O
or O
more O
risk O
factors O
. O

We O
further O
demonstrate O
that O
NUM O
- O
PR I-GENE
- I-GENE
B I-GENE
interacts O
physically O
with O
ALL_CAP I-GENE
in O
vitro O
. O

PRL I-GENE
receptor I-GENE
also O
activates O
SHP I-GENE
- I-GENE
2 I-GENE
, O
a O
cytosolic I-GENE
tyrosine I-GENE
phosphatase I-GENE
. O

The O
dominant O
negative O
mutant O
of O
SHP I-GENE
- I-GENE
2 I-GENE
was O
found O
to O
inhibit O
the O
induction O
of O
tyrosine O
RARE O
and O
DNA O
- O
binding O
activity O
of O
m I-GENE
- I-GENE
Stat5a I-GENE
, O
m I-GENE
- I-GENE
NUM I-GENE
, O
and O
the O
RARE O
- O
terminal O
deletion O
variant O
m I-GENE
- I-GENE
NUM I-GENE
, O
RARE O
RARE O
RARE O
the O
RARE O
RARE O
of O
m I-GENE
- I-GENE
Stat5a I-GENE
and O
m I-GENE
- I-GENE
NUM I-GENE
. O

CONCLUSIONS O
: O
These O
RARE O
collected O
data O
provided O
quantitative O
estimates O
of O
changes O
in O
ALL_CAP O
Cl O
/ O
F O
due O
to O
RARE O
and O
an O
age O
- O
related O
decrease O
in O
Cl O
/ O
F O
The O
derived O
regression O
RARE O
RARE O
predicted O
concentrations O
in O
a O
separate O
RARE O
set O
. O

RARE O
1 O
and O
4 O
in O
RARE I-GENE
and O
RARE I-GENE
are O
in O
a O
homologous O
location O
. O

Our O
observations O
suggest O
that O
members O
of O
the O
HMG I-GENE
- I-GENE
I I-GENE
family I-GENE
play O
an O
important O
role O
in O
SRF I-GENE
- O
dependent O
transcription O
and O
that O
their O
effect O
is O
RARE O
primarily O
by O
a O
protein O
- O
protein O
interaction O
. O

ATP O
- O
dependent O
assembly O
of O
a O
RARE O
complex O
consisting O
of O
a O
DNA O
RARE O
and O
the O
yeast O
NUM I-GENE
- O
NUM I-GENE
and O
NUM I-GENE
- O
NUM I-GENE
protein O
complexes O
. O

Mutation O
of O
the O
central O
NUM O
to O
RARE O
blocks O
the O
tyrosine O
RARE O
of O
the O
insulin I-GENE
receptor I-GENE
substrate I-GENE
1 I-GENE
( O
NUM I-GENE
) O
and O
RARE O
RARE O
in O
response O
to O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
. O

Instead O
, O
it O
contained O
two O
RARE O
kappaB I-GENE
elements I-GENE
and O
a O
variant O
activating I-GENE
transcription I-GENE
factor I-GENE
/ I-GENE
cAMP I-GENE
response I-GENE
element I-GENE
site O
, O
which O
closely O
RARE O
sites O
in O
the O
E I-GENE
- I-GENE
selectin I-GENE
gene I-GENE
that O
are O
required O
RARE O
TNF I-GENE
- I-GENE
alpha I-GENE
- O
or O
ALL_CAP O
- O
inducible O
RARE O
. O

We O
recently O
characterized O
a O
single O
yeast I-GENE
ALL_CAP I-GENE
RARE I-GENE
( O
NUM I-GENE
). O

We O
recently O
characterized O
a O
single O
yeast I-GENE
ALL_CAP I-GENE
RARE I-GENE
( O
NUM I-GENE
). O

Recombinant I-GENE
NUM I-GENE
protein I-GENE
encoded O
by O
the O
most O
common O
5 O
'- O
variant O
exhibited O
RARE O
activity O
in O
vitro O
. O

The O
possible O
roles O
of O
NUM I-GENE
and O
NUM I-GENE
in O
human O
RARE O
are O
currently O
unknown O
. O

Identification O
and O
characterization O
of O
two O
putative O
human I-GENE
RARE I-GENE
RARE I-GENE
( O
NUM I-GENE
and O
NUM I-GENE
). O

Interestingly O
, O
the O
activated O
ALL_CAP I-GENE
beta I-GENE
- I-GENE
receptor I-GENE
was O
found O
not O
to O
bind O
Crk I-GENE
proteins I-GENE
. O

Furthermore O
, O
interactions O
were O
identified O
between O
endogenous I-GENE
E I-GENE
- I-GENE
RARE I-GENE
and O
the O
RARE O
containing O
the O
E I-GENE
- I-GENE
RARE I-GENE
extracellular I-GENE
domain I-GENE
and O
the O
RARE I-GENE
1 I-GENE
RARE I-GENE
domain I-GENE
providing O
in O
vivo O
evidence O
RARE O
previously O
predicted O
lateral O
interactions O
of O
E I-GENE
- I-GENE
RARE I-GENE
extracellular I-GENE
domains I-GENE
. O

The O
ether O
RARE O
1 O
- O
O O
- O
RARE O
- O
2 O
- O
O O
- O
RARE O
- O
RARE O
- O
RARE O
- O
3 O
- O
RARE O
( O
ALL_CAP O
- O
18 O
- O
NUM O
; O
RARE O
) O
is O
a O
potent O
RARE O
of O
apoptosis O
in O
human O
tumor O
cells O
. O

In O
addition O
to O
a O
previously O
characterized O
promoter O
( O
P1 O
RARE O
we O
now O
show O
the O
existence O
of O
a O
second O
promoter O
RARE O
the O
human I-GENE
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
gene I-GENE
. O

Serum O
levels O
of O
testosterone O
also O
showed O
RARE O
significant O
changes O
by O
exposure O
to O
p O
, O
p O
'- O
ALL_CAP O
under O
the O
conditions O
of O
this O
study O
. O

Overall O
agreement O
between O
rest O
/ O
RARE O
technetium O
- O
99m O
tetrofosmin O
ALL_CAP O
studies O
and O
rest O
/ O
RARE O
or O
rest O
/ O
RARE O
thallium O
- O
NUM O
ALL_CAP O
studies O
, O
regarding O
the O
presence O
of O
RARE O
viability O
, O
was O
87 O
% O
and O
NUM O
%, O
respectively O
. O

Their O
use O
resulted O
in O
a O
sensitivity O
of O
NUM O
% O
and O
a O
RARE O
of O
NUM O
% O
with O
regard O
to O
RARE O
of O
ALL_CAP I-GENE
levels O
increasing O
RARE O
the O
trial O
. O

One O
hundred O
RARE O
data O
sets O
of O
NUM O
subjects O
each O
were O
simulated O
RARE O
each O
missing O
data O
RARE O
. O

RARE O
accuracy O
of O
RARE O
and O
secondary O
memory O
- O
RARE O
RARE O
in O
schizophrenic O
patients O
. O

RARE O
treatment O
with O
nasal O
continuous O
positive O
airway O
pressure O
( O
8 O
. O
3 O
+/- O
1 O
. O
5 O
cmH2O O
) O
RARE O
3 O
days O
caused O
a O
significant O
decrease O
in O
mean O
RARE O
pressure O
in O
ALL_CAP O
. O

When O
data O
were O
RARE O
in O
a O
cumulative O
manner O
, O
the O
response O
to O
intravenous O
adenosine O
3 O
mg O
, O
6 O
mg O
, O
9 O
mg O
and O
12 O
mg O
in O
the O
NUM O
episodes O
of O
ALL_CAP O
were O
5 O
episodes O
( O
21 O
%), O
16 O
episodes O
( O
67 O
%), O
20 O
episodes O
( O
NUM O
%) O
and O
20 O
episodes O
( O
NUM O
%) O
respectively O
. O

RNAs O
are O
not O
only O
essential O
RARE O
of O
both O
ribosomal O
subunits O
but O
also O
transiently O
RARE O
factors O
RARE O
RARE O
formation O
. O

To O
study O
retinoid O
signalling O
in O
RARE O
RARE O
, O
we O
developed O
a O
novel O
method O
to O
detect O
endogenous O
RARE O
in O
situ O
in O
RARE O
, O
using O
a O
fusion O
protein O
of O
the O
RARE O
inducible O
RARE O
domain O
of O
a O
retinoic I-GENE
acid I-GENE
receptor I-GENE
and O
a O
heterologous O
DNA O
binding O
domain O
. O

To O
identify O
nuclear O
regulatory O
factors O
, O
we O
have O
RARE O
and O
functionally O
characterized O
the O
NUM I-GENE
gene I-GENE
promoter I-GENE
. O

RARE O
in O
situ O
hybridization O
of O
RARE O
RARE O
of O
RARE O
8 O
, O
containing O
RARE O
cell O
line O
NUM O
- O
NUM O
clone O
NUM O
( O
CL O
- O
NUM O
) O
with O
cosmid O
NUM O
, O
placed O
the O
NUM I-GENE
gene I-GENE
close O
to O
the O
RARE O
RARE O
NUM O
. O
3 O
. O

The O
interaction O
between O
RARE O
and O
RARE O
was O
studied O
by O
RARE O
- O
ray O
RARE O
( O
ALL_CAP O
RARE O
RARE O
( O
IR O
) O
spectroscopy O
and O
differential O
thermal O
analysis O
( O
ALL_CAP O
) O
with O
a O
solid O
dispersion O
, O
RARE O
, O
or O
physical O
mixture O
. O

Cell O
survival O
by O
Epo I-GENE
did O
not O
require O
activation O
of O
other O
known O
RARE O
pathways O
including O
PI I-GENE
- I-GENE
3 I-GENE
kinase I-GENE
, O
PLC I-GENE
- I-GENE
gamma I-GENE
, O
Ras I-GENE
or O
RARE I-GENE
. O

The O
N O
- O
RARE O
- O
dependent O
RARE O
RARE O
is O
inhibited O
by O
the O
tyrosine I-GENE
kinase I-GENE
RARE O
RARE O
A O
and O
NUM I-GENE
. O

An O
in O
vivo O
ALL_CAP I-GENE
- I-GENE
70 I-GENE
substrate O
, O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
implicated O
in O
RARE I-GENE
activation O
, O
also O
became O
rapidly O
tyrosine O
- O
RARE O
in O
Jurkat O
cells O
, O
but O
not O
in O
NUM O
cells O
, O
upon O
treatment O
with O
NUM O
. O

The O
pharmacokinetic O
patterns O
of O
estradiol O
( O
ALL_CAP O
50 O
- O
NUM O
- O
2 O
) O
and O
of O
RARE O
( O
ALL_CAP O
53 O
- O
16 O
- O
7 O
) O
were O
investigated O
in O
18 O
women O
in O
RARE O
or O
surgical O
RARE O
RARE O
the O
application O
of O
a O
new O
estradiol O
RARE O
patch O
with O
RARE O
RARE O
and O
without O
absorption O
RARE O
designed O
RARE O
RARE O
applications O
of O
7 O
days O
( O
RARE O
called O
" O
patch O
NUM O
RARE O

The O
results O
confirm O
that O
a O
single O
RARE O
change O
in O
the O
branchpoint O
consensus O
sequence O
of O
an O
intron O
can O
cause O
human O
RARE O
although O
this O
sequence O
is O
poorly O
RARE O
in O
mammals O
. O

Conversely O
, O
the O
central O
regions O
are O
highly O
RARE O
. O

Among O
the O
H I-GENE
/ I-GENE
ALL_CAP I-GENE
RARE I-GENE
associated O
with O
NUM I-GENE
, O
one O
can O
RARE O
a O
large O
group O
of O
RARE O
that O
are O
not O
essential O
in O
yeast O
and O
serve O
RARE O
RARE O
RARE O
RARE O
RARE O
onto O
the O
pre O
- O
rRNA O
molecule O
. O

It O
RARE O
to O
vitamin I-GENE
D I-GENE
receptor I-GENE
( O
VDR I-GENE
) O
but O
not O
retinoic I-GENE
acid I-GENE
RARE I-GENE
receptor I-GENE
( O
RARE I-GENE
) O
in O
the O
human O
T O
cell O
line O
NUM O
cells O
. O

Further O
studies O
demonstrated O
that O
the O
PPARalpha I-GENE
RARE O
8 O
( O
S O
)- O
RARE O
acid O
strongly O
promotes O
the O
interaction O
of O
PPARalpha I-GENE
with O
the O
RARE O
- O
activator O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
but O
decreases O
the O
interaction O
of O
PPARalpha I-GENE
with O
the O
RARE O
- O
repressor O
SMRT I-GENE
. O

Based O
on O
the O
current O
literature O
, O
the O
mechanisms O
involved O
in O
the O
toxicity O
of O
ALL_CAP I-GENE
indicate O
three O
major O
effects O
: O
( O
1 O
) O
inhibition O
of O
mitochondrial O
respiration O
correlated O
with O
a O
depletion O
of O
ATP O
; O
( O
2 O
) O
inhibition O
of O
tRNA I-GENE
- I-GENE
RARE I-GENE
accompanied O
by O
a O
RARE O
protein O
RARE O
; O
and O
( O
3 O
) O
RARE O
RARE O
peroxidation O
. O

We O
previously O
demonstrated O
that O
acute O
RARE O
of O
the O
bovine O
RARE O
type O
1 O
( O
NUM O
) O
E2 I-GENE
protein I-GENE
in O
HeLa O
and O
ALL_CAP O
- O
3 O
cervical O
carcinoma O
cell O
lines O
greatly O
RARE O
cellular O
RARE O
by O
RARE O
a O
specific O
G1 O
/ O
S O
RARE O
growth O
arrest O
. O

Four O
possible O
isoforms O
( O
NUM I-GENE
alpha I-GENE
, I-GENE
beta I-GENE
, I-GENE
gamma I-GENE
, I-GENE
and I-GENE
delta I-GENE
) O
are O
formed O
by O
combinations O
of O
two O
independent O
RARE O
RARE O
, O
and O
all O
the O
isoforms O
could O
bind O
to O
a O
DNA O
motif O
, O
NUM O
, O
in O
the O
LTR O
. O

RARE O
actin I-GENE
tails O
that O
RARE O
ALL_CAP O
RARE O
to O
the O
RARE O
and O
virus O
- O
RARE O
RARE O
( O
both O
common O
in O
wild O
- O
type O
- O
RARE O
cells O
) O
were O
absent O
in O
cells O
RARE O
with O
NUM O
. O

Their O
mean O
IOP O
was O
NUM O
. O
3 O
( O
SD O
3 O
. O
7 O
) O
mmHg O
prior O
to O
induction O
of O
anesthesia O
, O
NUM O
. O
5 O
( O
SD O
3 O
. O
5 O
) O
mmHg O
after O
RARE O
of O
RARE O
reflex O
following O
injection O
of O
RARE O
, O
16 O
. O
1 O
( O
SD O
2 O
. O
4 O
) O
mmHg O
after O
cessation O
of O
muscle O
RARE O
RARE O
by O
RARE O
, O
19 O
. O
2 O
( O
SD O
5 O
. O
6 O
) O
mmHg O
after O
cessation O
of O
RARE O
and O
NUM O
. O
5 O
( O
SD O
4 O
. O
4 O
) O
mmHg O
following O
RARE O
of O
regular O
spontaneous O
respiration O
. O

A O
cDNA O
, O
NUM I-GENE
, O
was O
isolated O
that O
suppressed O
the O
CAK I-GENE
mutation I-GENE
in O
RARE O
yeast O
, O
and O
it O
also O
complemented O
a O
RARE I-GENE
yeast I-GENE
CAK I-GENE
mutant I-GENE
. O
NUM I-GENE
encodes O
a O
protein O
related O
to O
RARE I-GENE
RARE I-GENE
. O

Post O
- O
translational O
modifications O
such O
RARE O
glycosylation O
and O
RARE O
could O
be O
excluded O
RARE O
RARE O
RARE O
RARE O
the O
protein O
heterogeneity O
. O

In O
addition O
to O
RARE O
RARE O
control O
, O
overexpression O
of O
NUM I-GENE
+ I-GENE
inhibits O
the O
normal O
cell O
RARE O
response O
to O
osmotic O
stress O
. O

NUM I-GENE
plays O
a O
pivotal O
role O
in O
the O
initiation O
of O
meiosis O
in O
a O
/ O
alpha O
diploid O
cells O
of O
Saccharomyces O
cerevisiae O
. O

RARE O
RARE O
and O
ALL_CAP O
/ O
c O
mice O
inoculated O
with O
the O
RARE O
virus O
SIV O
RARE O
failed O
to O
develop O
CTL O
responses O
against O
the O
SIV O
gene O
products O
, O
while O
one O
of O
the O
HIV I-GENE
- I-GENE
Nef I-GENE
RARE I-GENE
RARE O
a O
weak O
CTL O
response O
in O
mice O
directed O
to O
an O
NUM I-GENE
Nef I-GENE
peptide I-GENE
spanning O
positions O
182 O
- O
198 O
. O

RARE O
was O
most O
effective O
on O
the O
RARE O
surface O
and O
produced O
NUM O
% O
mortality O
of O
An O
. O
RARE O
adults O
RARE O
to O
12 O
weeks O
, O
even O
when O
exposed O
RARE O
the O
lowest O
dose O
/ O
12 O
. O
5 O
mg O
/ O
m2 O
. O

RARE O
, O
in O
RARE O
, O
increased O
the O
AUC O
5 O
. O
NUM O
( O
1 O
. O
9 O
- O
NUM O
. O
4 O
RARE O
NUM O
. O
8 O
( O
8 O
. O
2 O
- O
NUM O
. O
8 O
) O
and O
2 O
. O
9 O
( O
1 O
. O
6 O
- O
5 O
. O
4 O
RARE O
respectively O
, O
whereas O
the O
corresponding O
values O
RARE O
RARE O
- O
RARE O
were O
1 O
. O
9 O
( O
NUM O
. O
7 O
- O
5 O
. O
1 O
RARE O
1 O
. O
5 O
( O
NUM O
. O
5 O
- O
4 O
. O
6 O
RARE O
and O
3 O
. O
2 O
( O
1 O
. O
8 O
- O
5 O
. O
9 O
). O

RARE O
RARE O
of O
the O
IRF I-GENE
- I-GENE
2 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
: O
a O
novel O
subgroup O
of O
the O
RARE I-GENE
helix I-GENE
- I-GENE
RARE I-GENE
- I-GENE
helix I-GENE
family I-GENE
. O

In O
contrast O
, O
receptor I-GENE
/ I-GENE
G I-GENE
protein I-GENE
coupling O
appeared O
unaffected O
by O
RARE O
of O
loop O
NUM O
domains O
derived O
from O
two O
receptors O
coupled O
to O
G I-GENE
( I-GENE
i I-GENE
/ I-GENE
RARE I-GENE
) I-GENE
proteins I-GENE
( O
NUM I-GENE
- I-GENE
RARE I-GENE
and I-GENE
NUM I-GENE
- I-GENE
adrenergic I-GENE
receptors I-GENE
). O

These O
data O
indicate O
that O
the O
third O
RARE O
loop O
of O
the O
rat I-GENE
GnRH I-GENE
- I-GENE
R I-GENE
is O
involved O
in O
receptor I-GENE
G I-GENE
( I-GENE
RARE I-GENE
/ I-GENE
11 I-GENE
) I-GENE
protein I-GENE
coupling O
and O
/ O
or O
selectivity O
, O
and O
in O
the O
ALL_CAP O
( O
3 O
) O
1 O
' O
cell O
line O
, O
this O
loop O
is O
also O
involved O
in O
signal O
RARE O
RARE O
through O
the O
RARE I-GENE
protein O
RARE O
. O

RARE O
levels O
of O
NUM I-GENE
- I-GENE
RARE I-GENE
were O
also O
observed O
in O
the O
RARE O
( O
NUM O
. O
50 O
versus O
NUM O
. O
NUM O
ALL_CAP O
/ O
mL O
; O
p O
< O
NUM O
. O
05 O
). O

A O
catalytic O
domain O
of O
eukaryotic I-GENE
DNA I-GENE
topoisomerase I-GENE
I I-GENE
. O

A O
cluster O
of O
basic O
amino O
RARE O
, O
ALL_CAP O
, O
generated O
by O
RARE O
of O
the O
sequences O
encoded O
by O
the O
RARE O
RARE O
NUM O
and O
the O
RARE O
RARE O
16 O
, O
is O
necessary O
RARE O
the O
nuclear O
targeting O
of O
4 I-GENE
. I-GENE
NUM I-GENE
, O
RARE O
demonstrated O
by O
site O
- O
directed O
mutagenesis O
analysis O
. O

Another O
RARE O
- O
loop O
called O
RARE O
III O
near O
the O
3 O
'- O
end O
of O
ALL_CAP I-GENE
RARE O
both O
the O
5 O
'- O
ALL_CAP O
- O
3 O
' O
sequence O
and O
the O
ALL_CAP I-GENE
RARE I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

All O
three O
genes O
have O
been O
mapped O
precisely O
to O
a O
small O
region O
on O
human O
RARE O
NUM O
. O
1 O
- O
NUM O
. O
2 O
( O
homologous O
to O
mouse O
RARE O
7 O
RARE O
using O
somatic O
cell O
hybrids O
and O
cosmid O
RARE O
. O

In O
NUM I-GENE
mutants I-GENE
, O
the O
levels O
of O
Ty1 I-GENE
RNA I-GENE
, O
protein O
RARE O
, O
and O
RARE O
RARE O
were O
not O
altered O
relative O
to O
those O
in O
NUM I-GENE
strains O
but O
steady O
- O
state O
levels O
of O
ALL_CAP I-GENE
, O
integrase I-GENE
, O
and O
reverse I-GENE
transcriptase I-GENE
proteins O
and O
Ty1 I-GENE
cDNA I-GENE
were O
all O
increased O
. O

RARE O
RARE O
of O
Ty1 I-GENE
RARE O
by O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
NUM I-GENE
. O

The O
RARE O
transcription I-GENE
factor I-GENE
ALL_CAP I-GENE
( O
ALL_CAP I-GENE
) O
interacts O
with O
the O
TATA I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
) O
and O
promoter O
DNA O
to O
mediate O
transcription O
activation O
in O
vitro O
. O

Their O
function O
is O
not O
only O
to O
recruit O
NUM I-GENE
to O
the O
promoter O
but O
to O
allow O
cooperative O
binding O
of O
NUM I-GENE
together O
with O
NUM I-GENE
. O

Substitution O
of O
the O
RARE O
- O
RARE O
sites O
with O
the O
RARE O
RARE O
generated O
a O
constitutively O
RARE O
form O
of O
IRF I-GENE
- I-GENE
3 I-GENE
that O
functioned O
RARE O
a O
very O
strong O
activator O
of O
promoters O
containing O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
or O
ALL_CAP I-GENE
regulatory I-GENE
elements I-GENE
. O

New O
- O
onset O
angina O
preceding O
acute O
RARE O
infarction O
is O
associated O
with O
improved O
contractile O
recovery O
after O
RARE O
. O

In O
this O
study O
, O
the O
effect O
of O
acute O
administration O
of O
various O
doses O
of O
RARE O
via O
oral O
and O
dermal O
routes O
to O
mice O
and O
rats O
on O
serum O
levels O
of O
RARE O
was O
evaluated O
. O

RARE O
growth O
retardation O
RARE O
a O
cause O
of O
impaired O
ovarian O
development O
. O

Similarly O
, O
RARE O
/ O
RARE O
ratio O
in O
ALL_CAP O
RARE O
was O
lower O
than O
that O
in O
RARE O
RARE O
. O

In O
addition O
to O
DNA O
- O
protein O
interactions O
, O
protein O
- O
protein O
interactions O
with O
RARE O
proteins O
often O
play O
major O
roles O
in O
targeting O
ALL_CAP I-GENE
- I-GENE
domain I-GENE
proteins I-GENE
to O
specific O
promoters O
. O

Localization O
of O
67 O
exons O
on O
a O
YAC O
contig O
spanning O
1 O
. O
5 O
Mb O
around O
the O
RARE I-GENE
resistance I-GENE
gene I-GENE
region I-GENE
of O
human O
RARE O
NUM O
. O
1 O
. O

The O
RARE O
RARE O
- O
intron O
organization O
of O
the O
murine O
gene O
encoding O
M I-GENE
- I-GENE
protein I-GENE
, O
a O
structural O
protein O
of O
RARE O
RARE O
, O
was O
determined O
. O

PURPOSE O
: O
To O
RARE O
an O
image O
analysis O
of O
the O
RARE O
in O
RARE O
RARE O
( O
PRK O
) O
RARE O
preoperative O
and O
early O
postoperative O
determination O
of O
changes O
in O
the O
condition O
of O
the O
RARE O
. O

Mean O
+/- O
SD O
serum I-GENE
VEGF I-GENE
concentrations O
were O
significantly O
RARE O
( O
P O
< O
NUM O
. O
001 O
) O
in O
women O
with O
ALL_CAP O
and O
ALL_CAP O
( O
3 O
. O
4 O
+/- O
NUM O
. O
7 O
and O
3 O
. O
2 O
+/- O
NUM O
. O
NUM O
RARE O
/ O
ml O
respectively O
) O
compared O
with O
women O
with O
normal O
RARE O
( O
2 O
. O
3 O
+/- O
NUM O
. O
5 O
RARE O
/ O
ml O
). O

RARE O
, O
these O
cells O
contain O
a O
missense O
mutation O
of O
the O
p53 I-GENE
gene I-GENE
RARE O
RARE O
NUM O
( O
p53 I-GENE
( O
NUM O
RARE O
which O
RARE O
alanine O
RARE O
glycine O
. O

The O
new O
algorithm O
, O
called O
ALL_CAP O
- O
MAP O
, O
is O
based O
on O
the O
RARE O
RARE O
RARE O
EM O
( O
ALL_CAP O
- O
EM O
) O
algorithm O
. O

A O
third O
ORF O
, O
NUM O
, O
shows O
homology O
with O
gene I-GENE
ALL_CAP I-GENE
from O
RARE O
RARE O
, O
which O
is O
involved O
in O
the O
mechanism O
of O
RARE O
of O
the O
RARE O
RARE O
in O
this O
species O
. O

An O
association O
between O
ALL_CAP I-GENE
and O
Stat I-GENE
- I-GENE
3 I-GENE
after O
MHC I-GENE
- I-GENE
I I-GENE
ligation O
was O
directly O
demonstrated O
by O
precipitating O
Stat I-GENE
- I-GENE
3 I-GENE
from O
nuclear O
extracts O
with O
RARE O
ALL_CAP I-GENE
probe O
and O
RARE I-GENE
- O
coupled O
agarose O
. O

Transcriptional O
repression O
RARE O
by O
ALL_CAP I-GENE
- I-GENE
type I-GENE
regulator I-GENE
ALL_CAP I-GENE
RARE O
RARE O
multiple O
binding O
sites O
. O

Two O
of O
these O
resulted O
in O
increased O
levels O
of O
the O
alpha O
subunit O
, O
and O
one O
caused O
a O
substitution O
of O
glycine O
RARE O
the O
RARE O
acid O
RARE O
RARE O
position O
NUM O
, O
in O
the O
N O
- O
terminal O
domain O
. O

These O
two O
mRNA O
species O
are O
produced O
by O
differential O
polyadenylation O
site O
usage O
. O

Using O
Southern O
blot O
analysis O
and O
RARE O
mapping O
of O
genomic O
YAC O
( O
yeast O
artificial O
RARE O
) O
and O
cosmid O
RARE O
, O
we O
RARE O
the O
human I-GENE
ALL_CAP I-GENE
gene I-GENE
240 O
- O
260 O
kb O
telomeric O
to O
the O
NUM I-GENE
gene I-GENE
and O
characterized O
its O
genomic O
RARE O
. O

NUM I-GENE
contains O
C O
, O
D O
and O
D O
' O
RARE O
and O
a O
12 O
- O
nucleotide O
RARE O
RARE O
to O
the O
28S I-GENE
ribosomal I-GENE
RNA I-GENE
. O

However O
, O
mandibular O
position O
( O
S O
- O
N O
- O
B O
and O
S O
- O
N O
- O
RARE O
) O
was O
found O
to O
be O
significantly O
more O
RARE O
in O
RARE O
II O
when O
compared O
with O
RARE O
I O
subjects O
. O

RARE O
is O
RARE O
by O
RARE O
factors O
such O
RARE O
RARE O
, O
RARE O
, O
an O
RARE O
growing O
free O
- O
food O
RARE O
, O
a O
lack O
of O
RARE O
food O
RARE O
, O
poor O
or O
insufficient O
RARE O
, O
other O
RARE O
, O
and O
RARE O
RARE O
conditions O
. O

The O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
70 I-GENE
to O
the O
cell O
cortex O
is O
, O
therefore O
, O
regulated O
by O
the O
activity O
of O
SRC I-GENE
- I-GENE
family I-GENE
kinases I-GENE
, O
independently O
of O
their O
ability O
to O
phosphorylate O
RARE O
tyrosine O
- O
based O
activation O
motifs O
of O
the O
TCR I-GENE
. O

Finally O
, O
a O
role O
RARE O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
in O
preventing O
apoptosis O
RARE O
by O
ER O
RARE O
release O
was O
demonstrated O
by O
data O
showing O
that O
RARE I-GENE
prevents O
RARE O
- O
RARE O
apoptosis O
, O
an O
effect O
blocked O
by O
kappaB I-GENE
RARE O
DNA O
. O

Many O
RARE O
receptors O
RARE O
Janus I-GENE
protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
RARE I-GENE
) O
and O
signal I-GENE
RARE I-GENE
and I-GENE
RARE I-GENE
of I-GENE
transcription I-GENE
( O
RARE I-GENE
) O
RARE O
nuclear O
RARE O
. O

A O
site O
- O
directed O
NUM O
mutation O
in O
the O
Stat5 I-GENE
NUM I-GENE
domain I-GENE
abolished O
the O
RARE O
by O
NUM I-GENE
, O
while O
deletion O
of O
the O
C O
terminus O
led O
to O
Stat5 I-GENE
RARE O
. O

The O
effect O
of O
RARE I-GENE
oxide I-GENE
synthase I-GENE
inhibitor O
on O
reperfusion O
injury O
of O
the O
brain O
under O
RARE O
circulatory O
arrest O
. O

Specifically O
, O
RARE O
RARE O
HMR I-GENE
was O
used O
to O
produce O
RARE O
that O
lacked O
the O
E O
and O
I O
RARE O
. O

In O
RARE O
, O
RARE O
vessels O
in O
the O
mucosa O
appeared O
to O
contain O
less O
RARE I-GENE
type I-GENE
IV I-GENE
than O
similarly O
sized O
vessels O
in O
the O
RARE O
, O
and O
RARE O
vessels O
appeared O
in O
many O
cases O
to O
RARE O
staining O
RARE O
the O
level O
of O
the O
RARE O
RARE O
. O

We O
studied O
the O
human O
RARE O
- O
ocular O
reflex O
( O
ALL_CAP O
) O
in O
response O
to O
head O
' O
RARE O
RARE O
brief O
, O
RARE O
, O
passive O
, O
high O
- O
RARE O
( O
RARE O
to O
NUM O
degrees O
/ O
NUM O
RARE O
low O
- O
amplitude O
( O
20 O
- O
NUM O
degrees O
) O
head O
RARE O
. O

To O
clarify O
whether O
seizure O
- O
RARE O
patterns O
are O
reliable O
in O
predicting O
seizure O
outcome O
, O
we O
studied O
ALL_CAP O
/ O
ALL_CAP O
in O
a O
similar O
group O
of O
patients O
with O
temporal O
lobe O
epilepsy O
( O
ALL_CAP O
). O

In O
this O
study O
, O
to O
characterize O
the O
gene O
RARE O
protein I-GENE
Z I-GENE
, O
its O
organization O
and O
RARE O
were O
determined O
by O
a O
combination O
of O
PCR O
amplification O
of O
RARE O
DNA O
and O
isolation O
of O
RARE O
RARE O
from O
a O
human O
genomic O
library O
. O

These O
modifications O
may O
improve O
the O
RARE O
reproducibility O
of O
CD34 I-GENE
determinations O
due O
to O
the O
reduction O
in O
sample O
RARE O
and O
RARE O
of O
results O
. O

The O
present O
results O
demonstrate O
that O
rats O
with O
relatively O
small O
RARE O
of O
one O
olfactory O
bulb O
can O
perform O
a O
variety O
of O
RARE O
detection O
and O
discrimination O
tasks O
RARE O
RARE O
or O
nearly O
RARE O
RARE O
RARE O
controls O
. O

ALL_CAP I-GENE
- I-GENE
RARE I-GENE
: O
alpha I-GENE
- I-GENE
6 I-GENE
- I-GENE
D I-GENE
- I-GENE
RARE I-GENE
beta I-GENE
- I-GENE
1 I-GENE
, I-GENE
2 I-GENE
- I-GENE
N I-GENE
- I-GENE
RARE I-GENE
II I-GENE
( O
ALL_CAP I-GENE
II I-GENE
; O
EC I-GENE
2 I-GENE
. I-GENE
4 I-GENE
. I-GENE
1 I-GENE
. I-GENE
NUM I-GENE
) O
is O
essential O
RARE O
the O
normal O
assembly O
of O
complex O
Asn O
- O
RARE O
RARE O
. O

These O
patients O
failed O
to O
respond O
to O
intravenous O
cyclophosphamide O
and O
steroids O
and O
were O
then O
changed O
to O
receive O
oral O
cyclosporine O
A O
, O
RARE O
a O
dose O
of O
5 O
mg O
/ O
kg O
/ O
day O
. O

The O
predicted O
amino O
acid O
sequence O
is O
NUM O
. O
NUM O
% O
identical O
to O
the O
cytoplasmic I-GENE
dynein I-GENE
heavy I-GENE
chain I-GENE
of I-GENE
Neurospora I-GENE
crassa I-GENE
, O
70 O
. O
2 O
% O
identical O
to O
that O
of O
RARE O
RARE O
and O
NUM O
. O
8 O
% O
identical O
to O
that O
of O
Saccharomyces O
cerevisiae O
. O

The O
DNA O
binding O
activities O
of O
the O
three O
repressor O
preparations O
were O
studied O
using O
fragments O
containing O
RARE O
( O
NUM O
- O
NUM O
) O
from O
the O
essential O
early O
region O
RARE O
templates O
RARE O
DNase I-GENE
I I-GENE
footprinting O
. O

Molecular O
RARE O
suggested O
that O
the O
RARE O
domain O
was O
a O
four O
- O
helix O
bundle O
, O
stabilized O
by O
interactions O
of O
RARE O
RARE O
aromatic O
amino O
RARE O
. O

In O
the O
present O
study O
, O
we O
sought O
to O
investigate O
whether O
RARE O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
activity O
in O
RARE O
HIV O
- O
1 O
- O
RARE O
RARE O
U937 O
( O
NUM O
- O
ALL_CAP O
) O
and O
RARE O
ALL_CAP O
- O
NUM O
( O
ALL_CAP O
- O
ALL_CAP O
) O
cells O
affects O
apoptotic O
RARE O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
RARE O
may O
exert O
a O
strong O
RARE O
effect O
against O
ALL_CAP O
and O
that O
this O
effect O
is O
likely O
to O
involve O
impairment O
of O
NUM I-GENE
- O
ALL_CAP I-GENE
- O
RARE O
RARE O
RARE O
, O
induction O
of O
RARE I-GENE
, O
and O
a O
RARE O
G1 O
arrest O
. O

In O
RARE O
tissue O
, O
cell O
RARE O
contributes O
to O
type I-GENE
I I-GENE
RARE I-GENE
RARE O
. O

To O
explore O
the O
function O
of O
human O
ALL_CAP I-GENE
- I-GENE
homologous I-GENE
( I-GENE
RARE I-GENE
) I-GENE
proteins I-GENE
, O
RARE O
plasmids O
encoding O
RARE I-GENE
- I-GENE
NUM I-GENE
were O
transiently O
transfected O
into O
293 O
RARE O
cells O
and O
NUM O
fibroblast O
cells O
, O
resulting O
in O
growth O
arrest O
without O
induction O
of O
apoptosis O
. O

A O
point O
mutation O
in O
RARE I-GENE
and O
NUM I-GENE
blocks O
interaction O
with O
regulator O
of O
G I-GENE
protein I-GENE
RARE O
proteins O
. O

Indeed O
, O
it O
is O
shown O
that O
it O
mediates O
the O
formation O
of O
disulfide O
- O
RARE O
homodimers O
and O
that O
the O
formation O
of O
RARE O
- O
and O
RARE O
are O
RARE O
excluded O
. O

N O
., O
and O
RARE O
, O
E O
. O

We O
have O
shown O
previously O
that O
NUM O
cells O
transfected O
with O
the O
rat I-GENE
GnRH I-GENE
receptor I-GENE
cDNA I-GENE
( O
NUM O
- O
1 O
' O
cells O
) O
support O
the O
RARE O
of O
a O
cotransfected O
fusion O
gene O
composed O
of O
NUM O
RARE O
RARE O
of O
rat I-GENE
RARE I-GENE
gene I-GENE
5 I-GENE
'- I-GENE
flanking I-GENE
sequence I-GENE
and O
the O
RARE O
5 O
RARE O
RARE O
of O
the O
5 O
'- O
RARE O
region O
fused O
to O
a O
luciferase I-GENE
reporter I-GENE
RARE I-GENE
NUM I-GENE
RARE I-GENE
NUM I-GENE
) I-GENE
and O
respond O
to O
a O
GnRH I-GENE
agonist O
with O
a O
10 O
- O
RARE O
RARE O
of O
activity O
. O

The O
5 O
'- O
flanking O
region O
, O
from O
nucleotide O
- O
NUM O
to O
- O
NUM O
, O
contains O
TATA O
and O
inverted O
CAAT O
RARE O
RARE O
RARE O
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
/ O
SP1 I-GENE
RARE O
- O
specific O
cis O
- O
acting O
regulatory O
elements O
. O

We O
established O
the O
RARE O
cell O
line O
NUM O
from O
mammary O
carcinoma O
cell O
line O
NUM O
. O

In O
patients O
with O
type O
IA O
RARE O
RARE O
urine O
RARE O
, O
the O
NUM I-GENE
subunit I-GENE
is O
affected O
, O
resulting O
in O
the O
RARE O
of O
E1 I-GENE
and O
RARE I-GENE
- I-GENE
chain I-GENE
RARE I-GENE
dehydrogenase I-GENE
catalytic O
activities O
. O

Results O
showed O
that O
the O
mean O
bond O
strength O
of O
H O
. O
T O
. O
V O
. O
specimens O
ranged O
from O
9 O
. O
6 O
to O
NUM O
. O
12 O
kg O
/ O
cm2 O
, O
while O
the O
mean O
bond O
strength O
of O
R O
. O
T O
. O
V O
. O
specimens O
ranged O
from O
NUM O
. O
NUM O
to O
1 O
. O
NUM O
kg O
/ O
cm2 O
. O

OBJECTIVES O
: O
To O
measure O
coagulation I-GENE
factor I-GENE
VIII I-GENE
: I-GENE
RARE I-GENE
( O
F I-GENE
. I-GENE
VIII I-GENE
: I-GENE
C I-GENE
) O
and O
C1 I-GENE
- I-GENE
esterase I-GENE
inhibitor I-GENE
( O
C1 I-GENE
- I-GENE
ALL_CAP I-GENE
RARE O
hemostasis O
- O
associated O
acute O
- O
RARE O
RARE O
proteins O
and O
coagulation I-GENE
factors I-GENE
VII I-GENE
( O
F I-GENE
. I-GENE
VII I-GENE
RARE O
ALL_CAP O
( O
F I-GENE
. I-GENE
ALL_CAP I-GENE
RARE O
and O
X O
( O
F I-GENE
. I-GENE
X I-GENE
RARE O
hemostasis O
proteins O
not O
associated O
with O
an O
acute O
- O
RARE O
response O
, O
in O
a O
select O
population O
of O
horses O
with O
RARE O
and O
hemostasis O
abnormalities O
, O
and O
RARE O
to O
have O
acute O
- O
RARE O
changes O
. O

RESULTS O
: O
RARE O
with O
RARE O
had O
significantly O
RARE O
fibrinogen I-GENE
concentration O
, O
greater O
alpha I-GENE
NUM I-GENE
and O
protein I-GENE
C I-GENE
activities O
, O
and O
longer O
PT O
and O
ALL_CAP O
than O
did O
healthy O
horses O
. O

The O
data O
suggest O
that O
plasminogen I-GENE
, O
alpha I-GENE
NUM I-GENE
, O
and O
C1 I-GENE
- I-GENE
ALL_CAP I-GENE
, O
should O
be O
considered O
RARE O
acute O
- O
RARE O
proteins O
. O

None O
of O
the O
patients O
was O
obese O
. O

Marked O
elevation O
of O
RARE I-GENE
kinase I-GENE
was O
observed O
while O
serum O
albumin I-GENE
, O
immunoglobulin I-GENE
, O
and O
complement O
were O
decreased O
. O

DESIGN O
ALL_CAP O
METHODS O
: O
RARE O
study O
. O

METHODS O
: O
A O
RARE O
of O
NUM O
pigs O
were O
randomised O
to O
ligation O
of O
RARE O
RARE O
arteries O
( O
infarction O
group O
, O
RARE O
= O
5 O
RARE O
to O
ALL_CAP O
of O
the O
RARE O
lateral O
RARE O
using O
a O
RARE O
: O
RARE O
- O
RARE O
RARE O
( O
RARE O
: O
ALL_CAP O
) O
laser O
( O
laser O
group O
, O
RARE O
= O
5 O
RARE O
and O
to O
both O
( O
laser O
- O
infarction O
group O
, O
RARE O
= O
5 O
). O

NUM I-GENE
, O
a O
receptor O
RARE O
activated I-GENE
C I-GENE
kinase I-GENE
and O
a O
homolog O
of O
the O
beta O
subunit O
of O
G I-GENE
proteins I-GENE
, O
inhibits O
activity O
of O
src I-GENE
tyrosine I-GENE
kinases I-GENE
and O
growth O
of O
ALL_CAP O
3T3 O
cells O
. O

RARE O
sequences O
of O
the O
zinc I-GENE
finger I-GENE
protein I-GENE
RARE I-GENE
and O
the O
transcription I-GENE
factor I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
were O
obtained O
. O

The O
same O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
- O
inducible O
reporter O
gene O
is O
also O
synergistically O
activated O
by O
the O
endogenous I-GENE
NUM I-GENE
and O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
proteins I-GENE
in O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
- O
RARE O
I O
. O
NUM O
B O
lymphoma O
cells O
. O

HEF1 I-GENE
, O
p130 I-GENE
( O
RARE I-GENE
RARE O
and O
RARE I-GENE
/ O
RARE I-GENE
constitute O
a O
family O
of O
RARE O
RARE O
proteins O
that O
have O
been O
implicated O
in O
RARE O
the O
RARE O
of O
cell O
adhesion O
. O

In O
support O
of O
a O
role O
RARE O
the O
RARE O
, O
two O
- O
RARE O
library O
screening O
with O
HEF1 I-GENE
identifies O
the O
human O
homolog O
of O
the O
NUM I-GENE
/ I-GENE
M I-GENE
RARE I-GENE
- I-GENE
regulatory I-GENE
protein I-GENE
NUM I-GENE
RARE O
a O
specific O
RARE O
with O
a O
region O
of O
HEF1 I-GENE
RARE O
in O
p55 I-GENE
( O
HEF1 I-GENE
). O

Our O
data O
showed O
that O
activation O
of O
the O
RARE I-GENE
- O
ERK I-GENE
RARE O
led O
to O
activation O
of O
ALL_CAP I-GENE
RARE O
in O
breast O
carcinoma O
cells O
and O
suggested O
that O
RARE O
activation O
of O
this O
RARE O
leads O
to O
high O
ALL_CAP I-GENE
RARE O
in O
ALL_CAP O
- O
MB O
- O
231 O
cells O
. O

However O
, O
a O
zinc O
- O
depleted O
enzyme O
was O
obtained O
after O
prolonged O
dialysis O
against O
the O
specific O
RARE O
agent O
1 O
, O
10 O
- O
RARE O
. O

All O
patients O
diagnosed O
of O
H O
. O
RARE O
type O
b O
meningitis O
were O
less O
than O
3 O
years O
old O
. O

The O
lines O
also O
differed O
in O
RARE O
, O
but O
not O
RARE O
, O
5 I-GENE
- I-GENE
NUM I-GENE
receptors I-GENE
. O

RARE O
seizure O
RARE O
a O
treatment O
with O
RARE I-GENE
alpha I-GENE
RARE O
chronic O
viral O
hepatitis O
C O

RARE O
, O
RARE I-GENE
19 I-GENE
antibody I-GENE
revealed O
strong O
staining O
in O
both O
RARE O
and O
RARE O
ALL_CAP O
tissues O
. O

Genetic O
studies O
in O
Drosophila O
have O
led O
to O
the O
identification O
of O
several O
RARE O
of O
the O
Notch I-GENE
RARE O
. O

The O
NUM O
cDNA O
( O
NUM O
- O
NUM O
nt O
, O
1 O
. O
8 O
kb O
RARE O
excluding O
sequences O
coding O
RARE O
N O
- O
terminal O
signal O
sequence O
and O
C O
- O
terminal O
RARE O
domain O
, O
was O
PCR O
amplified O
and O
NUM I-GENE
- O
NUM I-GENE
restricted O
fragment O
RARE O
in O
frame O
RARE O
of O
the O
NUM O
promoter O
under O
the O
lac I-GENE
operator I-GENE
control O
in O
a O
ALL_CAP O
- O
NUM O
vector O
. O

Control O
subjects O
' O
evoked O
potentials O
( O
RARE O
) O
were O
characterized O
by O
an O
initial O
RARE O
in O
the O
NUM O
- O
NUM O
ms O
range O
( O
P1 O
) O
RARE O
the O
RARE O
- O
RARE O
site O
. O

RARE I-GENE
I I-GENE
NUM I-GENE
, I-GENE
2 I-GENE
- I-GENE
RARE I-GENE
play O
an O
essential O
role O
in O
the O
RARE O
of O
complex O
and O
RARE O
N O
- O
RARE O
in O
mammalian O
cells O
. O

Structural O
features O
of O
the O
minimal O
DNA O
binding O
domain O
( O
NUM O
- O
NUM O
) O
of O
human I-GENE
nucleotide I-GENE
RARE I-GENE
repair I-GENE
protein I-GENE
ALL_CAP I-GENE
. O

RARE O
other O
RARE O
, O
the O
RARE O
' O
s O
importance O
lies O
in O
the O
fact O
that O
it O
associates O
an O
RARE O
RARE O
RARE O
with O
the O
RARE O
data O
, O
working O
within O
the O
possibilities O
provided O
by O
RARE O
NUM O
- O
RARE O
RARE O
RARE O
. O

The O
results O
point O
to O
the O
effectiveness O
of O
the O
RARE O
intervention O
. O

The O
RARE O
implications O
of O
aromatic O
non O
- O
responsiveness O
of O
RARE O
RARE O
A O
- O
domain O
, O
despite O
its O
demonstrated O
ability O
to O
bind O
RARE O
, O
are O
discussed O
. O

RESULTS O
: O
RARE O
index O
returned O
to O
normal O
gradually O
RARE O
the O
time O
RARE O
by O
and O
significantly O
within O
one O
year O
after O
the O
reduction O
of O
developmental O
dislocation O
of O
the O
hip O
. O

Recently O
, O
extremely O
high O
levels O
of O
endothelin I-GENE
- I-GENE
1 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
) O
were O
detected O
in O
the O
RARE O
RARE O
of O
patients O
undergoing O
cardiac O
surgery O
. O

RARE O
, O
it O
is O
not O
known O
how O
RARE O
loading O
changes O
following O
ALL_CAP O
RARE O
, O
and O
how O
it O
contributes O
to O
cartilage O
degeneration O
. O

We O
show O
that O
the O
RARE O
of O
tracheal O
cartilage O
RARE O
are O
RARE I-GENE
- O
rich O
and O
RARE O
a O
RARE O
- O
rich O
core O
. O

Comparative O
mapping O
of O
the O
RARE I-GENE
S I-GENE
locus I-GENE
region I-GENE
and O
its O
RARE O
in O
Arabidopsis O
. O

RARE O
of O
the O
RARE I-GENE
RARE I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
homolog I-GENE
, O
NUM I-GENE
, O
in O
RARE O
development O
and O
systemic O
candidiasis O
. O

Neither O
the O
reaction O
of O
RARE O
nor O
the O
RARE O
with O
beta O
- O
alanine O
resulted O
in O
the O
formation O
of O
RARE O
. O

In O
most O
subjects O
, O
markers O
of O
bone O
formation O
and O
resorption O
were O
normal O
. O

Analysis O
of O
a O
NUM I-GENE
mutant I-GENE
, O
RARE O
RARE O
RARE O
- O
dependent O
repression O
of O
the O
RARE I-GENE
( I-GENE
I I-GENE
) I-GENE
RARE I-GENE
genes I-GENE
, O
showed O
an O
aberrant O
pattern O
of O
NUM I-GENE
RARE O
and O
RARE O
sensitivity O
. O

The O
DNA O
sequencing O
of O
the O
recombinant O
RARE O
revealed O
the O
RARE O
of O
RXR I-GENE
alpha I-GENE
and O
RXR I-GENE
beta I-GENE
. O

A O
RARE O
random O
sample O
of O
20 O
RARE O
RARE O
from O
a O
cohort O
of O
RARE O
RARE O
workers O
was O
RARE O
in O
1995 O
RARE O
RARE O
ALL_CAP O
and O
ALL_CAP O
RARE O
in O
RARE O
lipids O
to O
assess O
the O
extent O
of O
past O
ALL_CAP O
and O
ALL_CAP O
exposure O
in O
this O
cohort O
and O
whether O
that O
exposure O
might O
explain O
site O
- O
specific O
RARE O
findings O
in O
the O
RARE O
cohort O
. O

The O
clinical O
and O
laboratory O
features O
of O
72 O
children O
with O
RARE O
- O
RARE O
purpura O
( O
ALL_CAP O
) O
were O
examined O
to O
determine O
if O
there O
were O
associations O
between O
the O
laboratory O
indices O
RARE O
including O
RARE O
RARE O
cell O
( O
WBC O
) O
counts O
, O
serum I-GENE
C I-GENE
- I-GENE
reactive I-GENE
protein I-GENE
( O
CRP I-GENE
) O
levels O
, O
platelet O
( O
ALL_CAP O
) O
counts O
RARE O
and O
the O
clinical O
manifestations O
of O
acute O
ALL_CAP O
. O

We O
provide O
community O
metabolic O
data O
that O
indicate O
that O
large O
changes O
in O
CO2 O
concentration O
can O
occur O
in O
RARE O
RARE O
RARE O
via O
RARE O
processes O
not O
directly O
associated O
with O
RARE O
, O
respiration O
, O
RARE O
, O
and O
NUM O
dissolution O
. O

In O
contrast O
to O
other O
known O
RARE O
, O
the O
ALL_CAP I-GENE
pol I-GENE
genes I-GENE
are O
RARE O
via O
RARE O
transcripts O
. O

Substitution O
of O
RARE O
hydrophobic O
residues O
with O
charged O
residues O
within O
NUM I-GENE
affects O
the O
fusion O
activity O
of O
the O
S I-GENE
protein I-GENE
without O
affecting O
RARE O
and O
surface O
RARE O
. O

RARE O
and O
its O
RARE O
products O
, O
mono O
- O
and O
RARE O
- O
RARE O
, O
were O
determined O
in O
water O
birds O
collected O
from O
RARE O
RARE O
( O
the O
RARE O
RARE O
RARE O
RARE O
RARE O
United O
RARE O
, O
and O
the O
RARE O
RARE O
of O
RARE O
RARE O
, O
RARE O
. O

The O
5 O
' O
flanking O
region O
of O
the O
NUM I-GENE
gene I-GENE
contained O
the O
binding O
motifs O
RARE O
two O
RARE O
- O
inducible O
transcription O
factors O
, O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
- I-GENE
A I-GENE
and O
ALL_CAP I-GENE
- I-GENE
IL6 I-GENE
. O

RARE O
, O
M O
. O

ALL_CAP O
- O
2 O
is O
the O
only O
RARE O
, O
so O
far O
, O
that O
matches O
the O
genome O
organization O
of O
the O
type O
RARE O
of O
the O
group O
, O
ALL_CAP O
, O
and O
thus O
can O
be O
RARE O
classified O
RARE O
a O
definitive O
RARE O
of O
the O
genus O
RARE O
. O

RARE O
and O
clinical O
data O
were O
compared O
with O
a O
control O
group O
of O
NUM O
healthy O
age O
- O
matched O
women O
and O
with O
a O
sample O
of O
NUM O
women O
with O
wrist O
fracture O
. O

Combined O
RARE O
of O
c I-GENE
- I-GENE
Jun I-GENE
and O
NUM I-GENE
RARE O
RARE O
transcription O
of O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
promoter O
- O
and O
NUM I-GENE
- I-GENE
RARE I-GENE
reporter I-GENE
constructs I-GENE
in O
both O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
- O
and O
B7 I-GENE
- I-GENE
1 I-GENE
- O
RARE O
Jurkat O
cells O
. O

RARE O
results O
were O
obtained O
when O
transfections O
and O
mobility O
shift O
assays O
were O
performed O
in O
RARE O
rat O
hepatocytes O
in O
which O
the O
endogenous O
ALL_CAP I-GENE
gene I-GENE
is O
RARE O
. O

This O
E O
box O
sequence O
( O
ALL_CAP O
) O
is O
identical O
to O
the O
binding O
element O
RARE O
USF I-GENE
( O
upstream I-GENE
RARE I-GENE
factor I-GENE
RARE O
a O
RARE O
of O
the O
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
. O

Interferon I-GENE
beta I-GENE
therapy O
was O
RARE O
RARE O
4 O
weeks O
. O

RARE O
chromatographic O
method O
RARE O
analysis O
of O
all O
- O
RARE O
- O
alpha O
- O
RARE O
RARE O
and O
RARE O
RARE O
in O
milk O
- O
based O
infant O
formula O
using O
RARE O
solid O
- O
RARE O
dispersion O
. O

We O
RARE O
RARE O
3 O
RARE O
of O
RARE O
RARE O
, O
a O
RARE O
RARE O
( O
ALL_CAP O
RARE O
a O
mixed O
flow O
RARE O
( O
ALL_CAP O
RARE O
and O
an O
axial O
flow O
RARE O
( O
ALL_CAP O
RARE O
and O
analyzed O
their O
in O
vitro O
performance O
. O

Examination O
of O
the O
mitochondrial I-GENE
NUM I-GENE
complex I-GENE
RARE I-GENE
RARE I-GENE
RARE O
RARE O
, O
Z O
., O
RARE O
, O
L O
., O
RARE O
, O
V O
. O

Two O
protease O
- O
resistant O
fragments O
spanning O
the O
N O
- O
and O
C O
- O
terminal O
RARE O
of O
the O
RARE O
were O
identified O
using O
different O
RARE O
which O
RARE O
the O
protein O
in O
the O
same O
region O
. O

The O
RARE O
- O
to O
- O
RARE O
difference O
was O
statistically O
significant O
RARE O
ALL_CAP O
NUM O
degrees O
/ O
s O
and O
NUM O
degrees O
/ O
s O
( O
p O
< O
NUM O
. O
05 O
). O

CONCLUSION O
: O
In O
women O
who O
RARE O
or O
require O
conservative O
management O
of O
grade O
4 O
RARE O
and O
are O
unable O
to O
RARE O
a O
single O
RARE O
, O
the O
placement O
of O
two O
RARE O
often O
will O
be O
successful O
. O

The O
ability O
to O
maintain O
RARE O
of O
NUM I-GENE
in O
NUM I-GENE
- O
NUM I-GENE
RARE O
cells O
suggests O
the O
existence O
of O
another O
transcription O
factor O
, O
or O
factors O
, O
whose O
RARE O
/ O
activity O
is O
inversely O
related O
to O
overall O
levels O
of O
cellular O
protein O
N O
- O
RARE O
- O
RARE O
. O

RARE I-GENE
- O
RARE I-GENE
/ I-GENE
beta I-GENE
RARE O
RARE I-GENE
- I-GENE
1 I-GENE
and O
RARE I-GENE
bHLH O
- O
RARE O
proteins O
and O
the O
RARE O
PLZF I-GENE
and O
NUM I-GENE
/ O
NUM I-GENE
is O
RARE O
by O
the O
RARE O
N I-GENE
- I-GENE
ALL_CAP I-GENE
and O
SMRT I-GENE
. O

The O
identified O
isolates O
of O
CSF O
( O
20 O
of O
29 O
) O
were O
: O
ECHO O
NUM O
( O
9 O
RARE O
ECHO O
11 O
( O
7 O
RARE O
ECHO O
9 O
( O
3 O
) O
and O
ECHO O
7 O
( O
1 O
). O

There O
was O
RARE O
evidence O
of O
any O
persistent O
RARE O
within O
the O
ALL_CAP O
band O
. O

The O
RARE O
- O
F O
test O
alone O
was O
used O
to O
monitor O
serum O
antigen O
levels O
after O
treatment O
in O
NUM O
patients O
. O

The O
RARE O
recombinant O
protein O
was O
assayed O
RARE O
its O
enzyme O
activity O
by O
monitoring O
transfer O
of O
RARE O
3H O
] O
RARE O
groups O
from O
the O
substrate O
DNA O
to O
the O
ALL_CAP I-GENE
protein I-GENE
; O
the O
activity O
was O
found O
to O
be O
stable O
RARE O
NUM O
degrees O
C O
RARE O
RARE O
least O
NUM O
min O
. O

A O
RARE O
procedure O
was O
coupled O
with O
a O
reversed O
- O
RARE O
HPLC O
separation O
using O
a O
NUM O
. O
6 O
mm O
I O
. O
D O
. O

Elimination O
of O
the O
inducible O
response O
requires O
simultaneous O
mutation O
of O
both O
sequences O
, O
however O
, O
in O
the O
presence O
of O
an O
RARE O
ALL_CAP O
the O
upstream O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
is O
RARE O
to O
induction O
. O

Three O
high I-GENE
mobility I-GENE
group I-GENE
- I-GENE
like I-GENE
sequences I-GENE
within O
a O
NUM O
- O
RARE O
RARE O
enhancer O
of O
the O
NUM I-GENE
gene I-GENE
are O
required O
RARE O
cartilage O
- O
specific O
RARE O
in O
vivo O
. O

The O
sequence O
contains O
an O
RARE O
reading O
frame O
of O
NUM O
nt O
in O
the O
virus O
- O
sense O
RARE O
, O
a O
3 O
' O
RARE O
region O
of O
NUM O
nt O
and O
a O
3 O
' O
RARE O
( O
A O
) O
RARE O
. O

A O
phylogenetic O
analysis O
of O
the O
reverse I-GENE
transcriptase I-GENE
domain I-GENE
RARE O
our O
differential O
genetic O
assessment O
that O
RARE I-GENE
from O
RARE O
is O
a O
novel O
element O
with O
RARE O
specific O
relationship O
to O
the O
previously O
described O
RARE I-GENE
- I-GENE
like I-GENE
elements I-GENE
from O
RARE O
. O

At O
physiological O
doses O
, O
either O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
I I-GENE
( O
IGF I-GENE
- I-GENE
I I-GENE
) O
or O
insulin I-GENE
turned O
out O
to O
be O
RARE O
potent O
RARE O
RARE O
cAMP O
( O
ALL_CAP O
) O
in O
increasing O
NUM I-GENE
gene I-GENE
transcription O
rate O
( O
1 O
h O
) O
and O
also O
NUM I-GENE
mRNA I-GENE
accumulation O
( O
3 O
h O
RARE O
their O
maximal O
effect O
( O
NUM O
- O
RARE O
increase O
) O
reached O
upon O
treatment O
RARE O
NUM O
h O
. O

In O
addition O
, O
insulin I-GENE
RARE O
AP I-GENE
- I-GENE
1 I-GENE
DNA O
binding O
activity O
, O
this O
effect O
being O
RARE O
prevented O
in O
the O
presence O
of O
MEK I-GENE
- I-GENE
1 I-GENE
inhibitor O
. O

RARE O
, O
2 O
'- O
O O
- O
RARE O
RARE O
( O
2 O
' O
ALL_CAP O
) O
were O
delivered O
to O
the O
nuclei O
of O
RARE O
RARE O
myoblasts O
in O
culture O
. O

A O
large O
deletion O
in O
the O
ALL_CAP I-GENE
- I-GENE
binding I-GENE
motif I-GENE
blocks O
down O
- O
RARE O
but O
does O
not O
affect O
the O
essential O
function O
of O
NUM I-GENE
. O

Regulation O
of O
the O
human O
p21 I-GENE
/ O
WAF1 I-GENE
/ O
Cip1 I-GENE
promoter O
in O
RARE O
cells O
by O
RARE O
interactions O
between O
NUM I-GENE
and O
Smad I-GENE
family I-GENE
members I-GENE
. O

RESULTS O
: O
We O
isolated O
a O
C O
. O
elegans O
cDNA O
that O
encoded O
a O
protein O
which O
was O
similar O
to O
, O
but O
not O
RARE O
homologous O
with O
mammalian O
NUM I-GENE
Ras I-GENE
- O
ALL_CAP I-GENE
. O

The O
weak O
RARE O
RARE O
showed O
RARE O
dissolution O
from O
a O
tablet O
formulation O
in O
RARE O
RARE O
RARE O
without O
RARE I-GENE
( O
RARE O
) O
within O
NUM O
minutes O
, O
70 O
% O
dissolution O
in O
2 O
hours O
under O
fed O
state O
simulated O
upper O
RARE O
conditions O
but O
only O
6 O
% O
dissolution O
in O
2 O
hours O
under O
fasted O
state O
conditions O
. O

In O
mammals O
, O
the O
RARE I-GENE
protein I-GENE
interacts O
specifically O
with O
D I-GENE
- I-GENE
type I-GENE
RARE I-GENE
and O
regulates O
cell O
RARE O
by O
binding O
and O
inhibiting O
E2F I-GENE
transcription I-GENE
factors I-GENE
. O

In O
addition O
to O
the O
signals O
obtained O
by O
ligation O
of O
the O
TCR I-GENE
, O
T O
cells O
need O
additional O
, O
RARE O
- O
RARE O
signals O
to O
be O
activated O
. O

Moreover O
, O
the O
observation O
of O
RARE O
RARE I-GENE
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
RARE O
in O
vivo O
, O
in O
RARE O
RARE O
, O
when O
PKC I-GENE
- I-GENE
delta I-GENE
is O
abundant O
and O
RARE O
, O
suggests O
that O
select O
PKC I-GENE
family I-GENE
members I-GENE
contribute O
to O
ALL_CAP I-GENE
RARE O
events O
in O
vivo O
. O

We O
characterized O
the O
RARE O
of O
this O
RARE O
mRNA O
by O
using O
the O
program O
RARE O
and O
a O
combination O
of O
RARE O
and O
internal O
deletions O
transcriptionally O
fused O
to O
a O
promoterless O
lac I-GENE
operon I-GENE
. O

The O
importance O
of O
these O
sites O
RARE O
transcriptional O
activation O
was O
studied O
by O
site O
- O
directed O
mutagenesis O
followed O
by O
promoter O
function O
analysis O
of O
the O
mutants O
with O
a O
chloramphenicol I-GENE
RARE I-GENE
reporter I-GENE
RARE O
. O

RARE O
RARE O
examination O
showed O
RARE O
, O
thrombocytopenia O
, O
positive O
CRP I-GENE
, O
and O
elevated O
RARE O
RARE O
. O

Previous O
studies O
have O
suggested O
that O
moderate O
RARE O
increases O
the O
responsiveness O
of O
vascular I-GENE
NUM I-GENE
- I-GENE
adrenoceptors I-GENE
. O

Two O
members O
of O
the O
Cbl I-GENE
family I-GENE
have O
since O
been O
defined O
in O
mammals O
( O
c I-GENE
- I-GENE
Cbl I-GENE
and O
Cbl I-GENE
- I-GENE
b I-GENE
RARE O
one O
in O
C O
. O
elegans O
( O
RARE I-GENE
- I-GENE
1 I-GENE
) O
and O
one O
in O
Drosophila O
( O
D I-GENE
- I-GENE
Cbl I-GENE
). O

RARE I-GENE
- I-GENE
ALL_CAP I-GENE
antibodies I-GENE
did O
not O
inhibit O
the O
binding O
of O
ALL_CAP I-GENE
to O
RNA O
because O
they O
were O
able O
to O
supershift O
RNA I-GENE
- I-GENE
ALL_CAP I-GENE
complexes I-GENE
. O

The O
use O
of O
antibodies O
to O
the O
RARE I-GENE
RARE I-GENE
binding I-GENE
protein I-GENE
( O
ALL_CAP I-GENE
) O
to O
analyze O
the O
protein O
RARE O
that O
RARE O
on O
RARE O
RARE O
pre O
- O
mRNAs O
that O
use O
distant O
branch O
points O
. O

The O
therapeutic O
use O
of O
botulinum I-GENE
RARE I-GENE
( O
RARE I-GENE
) O
is O
increasing O
in O
RARE O
. O

The O
viral I-GENE
RARE I-GENE
E1A I-GENE
inhibits O
NFAT I-GENE
- O
dependent O
RARE O
in O
a O
p300 I-GENE
- O
dependent O
manner O
. O

We O
have O
applied O
the O
mRNA O
differential O
display O
method O
to O
compare O
and O
analyze O
mRNAs O
prepared O
from O
five O
normal O
RARE O
RARE O
cell O
cultures O
and O
five O
RARE O
carcinoma O
cell O
lines O
. O

Similar O
experiments O
with O
TR I-GENE
support O
the O
high O
affinity O
of O
NUM I-GENE
to O
the O
RXR I-GENE
subunit I-GENE
and O
also O
suggest O
that O
either O
RARE O
in O
the O
TR I-GENE
/ O
RXR I-GENE
RARE O
can O
independently O
respond O
to O
RARE O
. O

SETTING O
: O
University O
hospital O
- O
based O
, O
tertiary O
care O
infertility O
RARE O
. O

ALL_CAP O
( O
S O
): O
In O
patients O
with O
elevated O
FSH I-GENE
levels O
on O
RARE O
day O
3 O
, O
a O
low O
RARE O
yield O
was O
achieved O
( O
7 O
versus O
11 O
) O
and O
a O
high O
number O
of O
RARE O
of O
ALL_CAP I-GENE
was O
necessary O
( O
NUM O
versus O
NUM O
). O

RESULTS O
: O
Of O
the O
patients O
with O
ALL_CAP O
, O
67 O
% O
had O
significantly O
greater O
values O
of O
RARE O
RARE O
on O
the O
ALL_CAP O
test O
( O
a O
measure O
of O
RARE O
RARE O
RARE O
) O
compared O
with O
control O
subjects O
. O

In O
the O
ALL_CAP O
specimens O
, O
tissue O
RARE O
had O
increased O
. O

As O
predicted O
by O
the O
RARE O
and O
RARE O
model O
, O
the O
durations O
of O
successive O
RARE O
tended O
to O
be O
negatively O
correlated O
. O

Thus O
, O
included O
in O
the O
NUM O
ALL_CAP O
RARE O
are O
RARE O
RARE O
new O
human O
genes O
that O
may O
play O
roles O
in O
hematopoietic O
RARE O
progression O
and O
lineage O
RARE O
. O

We O
found O
the O
following O
: O
Specific O
mutations O
affected O
the O
precise O
carbohydrate O
RARE O
and O
folding O
of O
the O
ALL_CAP I-GENE
RARE I-GENE
. O

The O
results O
show O
that O
ALL_CAP O
production O
by O
viable O
spermatozoa O
is O
highly O
correlated O
with O
the O
concentration O
of O
ALL_CAP I-GENE
elastase I-GENE
and O
the O
number O
of O
both O
peroxidase I-GENE
- O
positive O
and O
round O
cells O
. O

RARE I-GENE
NUM I-GENE
snRNP I-GENE
is O
considerably O
more O
complex O
than O
its O
RARE O
RARE O
, O
which O
suggests O
possible O
differences O
between O
yeast O
and O
RARE O
in O
early O
RARE O
events O
. O

RARE I-GENE
NUM I-GENE
snRNP I-GENE
therefore O
contains O
16 O
different O
proteins O
, O
including O
RARE O
snRNP I-GENE
core I-GENE
proteins I-GENE
, O
three O
RARE O
of O
the O
RARE I-GENE
NUM I-GENE
snRNP I-GENE
- I-GENE
specific I-GENE
proteins I-GENE
, O
and O
RARE O
yeast I-GENE
- I-GENE
specific I-GENE
NUM I-GENE
snRNP I-GENE
proteins I-GENE
. O

After O
the O
RARE O
RARE O
, O
18 O
cases O
were O
treated O
RARE O
dose O
level O
1 O
, O
after O
a O
second O
RARE O
, O
NUM O
cases O
were O
treated O
RARE O
dose O
level O
2 O
. O

The O
RARE O
antagonist O
naltrexone O
( O
NUM O
. O
01 O
- O
1 O
. O
NUM O
mg O
/ O
kg O
) O
RARE O
the O
RARE O
stimulus O
effects O
of O
RARE O
, O
but O
naltrexone O
RARE O
doses O
RARE O
to O
10 O
mg O
/ O
kg O
had O
RARE O
effect O
on O
the O
RARE O
stimulus O
effects O
of O
cocaine O
. O

In O
this O
study O
we O
examined O
RARE O
RARE O
cell O
RARE O
of O
NUM I-GENE
/ O
ALL_CAP I-GENE
RARE O
and O
found O
that O
NUM I-GENE
/ O
ALL_CAP I-GENE
mRNA O
transcript O
levels O
increased O
in O
RARE O
cells O
from O
rats O
exposed O
to O
carbon O
RARE O
( O
NUM O
RARE O
a O
potent O
RARE O
RARE O
. O

One O
cDNA O
clone O
designated O
ALL_CAP O
- O
NUM O
, O
encoded O
a O
NUM O
, O
NUM O
- O
RARE O
protein O
that O
is O
highly O
related O
to O
NUM I-GENE
, O
a O
Drosophila O
melanogaster O
nuclear O
protein O
involved O
in O
ecdysone O
- O
RARE O
gene O
RARE O
. O

These O
widely O
RARE O
proteins O
share O
a O
C O
- O
terminal O
region O
that O
RARE O
significant O
sequence O
homology O
to O
a O
group O
of O
GDP I-GENE
/ I-GENE
GTP I-GENE
exchange I-GENE
proteins I-GENE
RARE O
the O
NUM I-GENE
family I-GENE
of O
small I-GENE
GTP I-GENE
binding I-GENE
proteins I-GENE
. O

Whereas O
NUM I-GENE
RARE O
had O
RARE O
effect O
on O
ERK2 I-GENE
activation O
by O
NUM I-GENE
, O
p70 I-GENE
completely O
abrogated O
this O
activity O
. O

The O
pre O
- O
mRNA O
RARE O
factor O
NUM I-GENE
( O
NUM I-GENE
small I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
RARE I-GENE
RARE I-GENE
snRNP I-GENE
] I-GENE
RARE I-GENE
factor I-GENE
) O
plays O
a O
critical O
role O
in O
3 O
' O
RARE O
site O
selection O
. O

The O
RARE O
were O
RARE O
to O
NUM O
RARE O
extracted O
bovine O
RARE O
, O
and O
, O
after O
RARE O
in O
RARE O
water O
RARE O
room O
RARE O
RARE O
NUM O
hours O
, O
they O
were O
subsequently O
tested O
in O
a O
shear O
mode O
using O
a O
RARE O
testing O
machine O
. O

RARE O
training O
has O
become O
RARE O
important O
in O
the O
treatment O
of O
RARE O
failure O
patients O
. O

The O
growth O
of O
RARE O
. O
RARE O
in O
filter O
- O
RARE O
RARE O
RARE O
was O
completely O
inhibited O
by O
NUM O
. O
1 O
% O
( O
v O
/ O
v O
) O
ALL_CAP O
whereas O
that O
of O
RARE O
. O
RARE O
was O
not O
significantly O
affected O
by O
1 O
% O
( O
v O
/ O
v O
) O
ALL_CAP O
. O

Despite O
continuous O
compliance O
, O
RARE O
RARE O
of O
serum O
ferritin I-GENE
levels O
occurred O
in O
4 O
/ O
7 O
patients O
of O
the O
' O
RARE O
' O
group O
after O
4 O
- O
5 O
years O
on O
L1 O
. O

RARE O
and O
PaO2 O
did O
not O
change O
. O

Regulation O
of O
myosin I-GENE
phosphatase I-GENE
activity O
involves O
changes O
in O
subunit O
interactions O
, O
although O
RARE O
mechanisms O
are O
not O
defined O
. O

RARE O
RARE O
RARE O
is O
sufficient O
to O
control O
a O
3 O
- O
D O
ocular O
RARE O
with O
RARE O
. O

The O
virus O
- O
associated O
ALL_CAP I-GENE
RNA O
of O
adenovirus O
is O
a O
small O
highly O
structured O
RNA O
that O
is O
required O
RARE O
the O
efficient O
translation O
of O
cellular O
and O
viral O
mRNAs O
RARE O
RARE O
times O
after O
infection O
. O

Structure O
of O
the O
gene O
encoding O
the O
human O
RARE I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor O
NUM I-GENE
and O
mutational O
analysis O
in O
breast O
RARE O
. O

The O
ALL_CAP I-GENE
protein I-GENE
was O
found O
to O
be O
degraded O
in O
an O
ALL_CAP I-GENE
- O
dependent O
manner O
in O
vivo O
and O
in O
vitro O
, O
whereas O
the O
NUM I-GENE
mutant I-GENE
protein I-GENE
, O
RARE O
eight O
amino O
acid O
residues O
within O
the O
amino O
- O
terminal O
cytoplasmic O
domain O
, O
was O
refractory O
to O
the O
RARE O
. O

The O
major O
type O
involves O
activator O
proteins O
that O
bind O
to O
DNA O
adjacent O
to O
where O
the O
RNA I-GENE
polymerase I-GENE
( O
RNAP I-GENE
) O
RARE O
binds O
, O
usually O
RARE O
in O
recruitment O
of O
the O
RNAP I-GENE
to O
the O
promoter O
. O

A O
RARE O
role O
RARE O
L1 I-GENE
RARE O
a O
transmembrane O
RARE O
between O
RARE O
adhesion O
and O
membrane O
RARE O
assembly O
. O

RARE O
RARE O
, O
RARE O
RARE O
acid O
( O
RARE O
- O
ALL_CAP O
) O
and O
RARE I-GENE
RARE I-GENE
phosphatase I-GENE
activity O
( O
ALL_CAP O
) O
were O
evaluated O
among O
NUM O
RARE O
RARE O
, O
NUM O
RARE O
RARE O
RARE O
, O
and O
NUM O
RARE O
workers O
. O

It O
contains O
a O
5 O
'- O
noncoding O
region O
( O
NCR O
) O
of O
NUM O
nucleotides O
, O
five O
RARE O
reading O
frames O
( O
RARE O
1 O
to O
5 O
) O
which O
encode O
proteins O
with O
M O
( O
RARE O
) O
NUM O
kDa O
RNA O
- O
dependent O
RNA O
polymerase O
( O
ORF1 O
RARE O
NUM O
kDa O
movement O
protein O
1 O
( O
ORF2 O
RARE O
NUM O
kDa O
movement O
protein O
2 O
( O
ORF3 O
RARE O
10 O
kDa O
movement O
protein O
3 O
( O
NUM O
RARE O
NUM O
kDa O
coat O
protein O
( O
NUM O
RARE O
and O
a O
3 O
' O
NCR O
of O
NUM O
nucleotides O
. O

After O
profound O
RARE O
RARE O
( O
RARE O
9 O
%) O
RARE O
of O
LV O
MC O
and O
LV O
diastolic O
properties O
was O
found O
, O
when O
RARE O
oxygenation O
was O
supported O
by O
i O
. O
v O
. O
RARE O
RARE O
, O
a O
temporary O
NUM O
carrier O
. O

NUM I-GENE
and O
two O
Sp3 I-GENE
isoforms I-GENE
were O
detected O
RARE O
the O
RARE O
cellular O
RARE O
of O
DNA O
- O
protein O
complexes O
formed O
with O
the O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
proximal I-GENE
site I-GENE
. O

These O
genes O
may O
represent O
RARE O
RARE O
RARE O
new O
therapeutic O
strategies O
. O

It O
could O
also O
inhibit O
NUM I-GENE
- O
dependent O
RARE O
of O
both O
IgG I-GENE
- O
and O
IgM I-GENE
- O
RARE O
RARE O
. O

3 O
) O
and O
one O
distal O
RARE O
11 O
. O
8 O
/- O
10 O
. O
9 O
RARE O
presented O
an O
enhancer O
activity O
in O
pituitary O
cells O
when O
placed O
upstream O
of O
the O
SV40 I-GENE
promoter I-GENE
. O

The O
second O
patient O
had O
received O
pituitary I-GENE
- I-GENE
derived I-GENE
growth I-GENE
hormone I-GENE
RARE O
treatment O
of O
growth I-GENE
hormone I-GENE
deficiency O
, O
secondary O
to O
a O
third O
ventricle O
RARE O
, O
RARE O
NUM O
yr O
earlier O
. O

3 O
RARE O
It O
is O
necessary O
to O
RARE O
about O
RARE O
consequences O
of O
the O
RARE O
flap O
and O
consider O
other O
possibilities O
of O
the O
flap O
choice O
. O

CONCLUSION O
: O
TNF I-GENE
alpha I-GENE
, O
TGF I-GENE
beta I-GENE
, O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
- I-GENE
1beta I-GENE
increased O
RARE I-GENE
gene I-GENE
RARE O
by O
increasing O
sterol O
- O
independent O
and O
RARE O
- O
independent O
gene O
transcription O
. O

Binding O
affinities O
of O
different O
nucleotide O
mono O
RARE O
RARE O
- O
and O
RARE O
and O
non O
- O
RARE O
RARE O
indicate O
that O
the O
beta O
- O
phosphate O
RARE O
is O
required O
RARE O
substrate O
binding O
. O

However O
, O
it O
is O
only O
one O
- O
RARE O
and O
one O
- O
third O
the O
size O
of O
the O
RARE O
from O
M O
. O
RARE O
and O
M O
. O
RARE O
, O
respectively O
. O
ALL_CAP I-GENE
is O
RARE O
in O
Escherichia O
coli O
, O
and O
it O
is O
incorporated O
into O
the O
cytoplasmic O
membrane O
despite O
the O
different O
chemical O
RARE O
of O
lipids O
from O
RARE O
and O
bacteria O
. O

In O
this O
report O
we O
studied O
the O
role O
of O
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
SHP I-GENE
- I-GENE
2 I-GENE
in O
ErbB I-GENE
- O
RARE O
activation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
by O
overexpressing O
SHP I-GENE
- I-GENE
2 I-GENE
mutants I-GENE
in O
COS O
- O
7 O
cells O
. O

RARE I-GENE
is O
a O
recently O
described O
bone O
RARE O
containing O
RARE O
RARE O
. O

RARE O
8 O
RARE O
a O
strong O
RARE O
- O
specific O
enhancer O
activity O
which O
was O
orientation O
- O
dependent O
. O

The O
intron O
8 O
enhancer O
region O
was O
not O
activated O
by O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
together O
with O
NUM I-GENE
in O
RARE O
experiments O
in O
COS O
- O
1 O
cells O
indicating O
the O
involvement O
of O
a O
related O
NUM I-GENE
protein I-GENE
or O
of O
another O
unidentified O
RARE O
factor O
. O

The O
RARE O
of O
RARE I-GENE
by O
RARE I-GENE
may O
thus O
play O
an O
important O
role O
in O
the O
RARE O
of O
the O
suicide O
program O
by O
RARE O
the O
anti O
- O
apoptotic O
function O
of O
RARE I-GENE
. O

Moreover O
, O
the O
mass O
estimated O
with O
the O
ALL_CAP O
response O
through O
the O
RARE O
equation O
and O
the O
mass O
which O
can O
be O
measured O
RARE O
to O
other O
RARE O
techniques O
, O
in O
our O
case O
an O
enzymatic O
assay O
, O
are O
different O
: O
the O
RARE O
mass O
is O
generally O
RARE O
by O
the O
ALL_CAP O
. O

RARE O
Treatment O
of O
early O
NUM O
small O
NUM O
breast O
cancers O
. O

Transcription O
initiation O
occurred O
predominantly O
RARE O
the O
putative O
ALL_CAP I-GENE
- I-GENE
dependent I-GENE
promoter I-GENE
in O
RARE O
growing O
cells O
and O
was O
RARE O
under O
stress O
conditions O
. O

The O
genes O
encoding O
( I-GENE
NUM I-GENE
- I-GENE
NUM I-GENE
) I-GENE
RARE I-GENE
- I-GENE
like I-GENE
RARE I-GENE
were O
studied O
in O
the O
widely O
used O
RARE O
RARE O
NUM O
. O

RNA O
of O
ALL_CAP O
- O
C O
was O
detected O
in O
14 O
( O
18 O
%) O
patients O
before O
ALL_CAP O
. O

A O
major O
pool O
of O
RARE I-GENE
- O
plakoglobin I-GENE
complexes O
RARE O
RARE O
NUM O
and O
exhibited O
a O
1 O
: O
1 O
RARE O
. O

Our O
results O
indicate O
that O
the O
binding O
of O
CBF I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
Y I-GENE
to O
the O
inverted O
CCAAT O
box O
is O
responsible O
RARE O
transcriptional O
activation O
of O
the O
ALL_CAP I-GENE
gene I-GENE
. O

In O
macrophages O
, O
ALL_CAP O
- O
inducible O
HIV O
- O
1 O
gene O
RARE O
is O
RARE O
in O
part O
by O
binding O
of O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
to O
identical O
RARE O
binding O
sites O
RARE O
within O
the O
long O
terminal O
repeat O
( O
LTR O
). O

The O
influence O
of O
p53 I-GENE
on O
RARE O
- O
triggered O
Janus I-GENE
kinase I-GENE
- O
STAT I-GENE
RARE O
was O
investigated O
in O
human O
hepatoma O
NUM O
cell O
lines O
RARE O
to O
constitutively O
express O
the O
RARE O
- O
RARE O
NUM I-GENE
mutant I-GENE
of I-GENE
p53 I-GENE
. O

It O
can O
also O
be O
used O
to O
examine O
various O
RARE O
parameters O
obtained O
from O
RARE O
RARE O
and O
RARE O
examinations O
. O

CONCLUSIONS O
: O
Two O
consecutive O
sets O
of O
RARE O
ultrasound O
RARE O
RARE O
biopsies O
of O
the O
RARE O
performed O
in O
a O
single O
RARE O
RARE O
represent O
a O
cost O
- O
effective O
biopsy O
strategy O
RARE O
men O
RARE O
with O
an O
abnormal O
digital O
rectal O
examination O
and O
/ O
or O
elevated O
serum I-GENE
PSA I-GENE
. O

Examination O
of O
nuclear O
magnetic O
resonance O
( O
NMR O
) O
spectra O
of O
a O
series O
of O
N I-GENE
- I-GENE
RARE I-GENE
truncated I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
variants I-GENE
reveals O
that O
these O
proteins O
possess O
a O
range O
of O
ability O
to O
RARE O
. O

Interestingly O
, O
PKA I-GENE
activity O
is O
dispensable O
in O
a O
RARE O
RARE O
NUM I-GENE
and O
NUM I-GENE
activity O
. O

They O
also O
indicate O
that O
direct O
interactions O
between O
C I-GENE
/ I-GENE
RARE I-GENE
and O
specific O
Ets I-GENE
family O
members O
, O
together O
with O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
are O
important O
RARE O
eosinophil O
lineage O
determination O
. O

Recently O
, O
a O
human I-GENE
transcription I-GENE
RARE I-GENE
factor I-GENE
P I-GENE
- I-GENE
RARE I-GENE
, O
consisting O
of O
NUM I-GENE
kinase I-GENE
, O
RARE I-GENE
T I-GENE
and O
other O
associated O
factors O
, O
has O
been O
shown O
to O
interact O
with O
Tat I-GENE
to O
RARE O
Tat I-GENE
activation O
in O
HeLa O
nuclear O
RARE O
depleted O
of O
P I-GENE
- I-GENE
RARE I-GENE
. O

We O
have O
used O
the O
hydrophobic O
repeats O
of O
the O
HSF1 I-GENE
RARE I-GENE
domain I-GENE
in O
the O
yeast O
two O
- O
RARE O
protein O
interaction O
assay O
to O
identify O
heat I-GENE
shock I-GENE
factor I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
( O
NUM I-GENE
RARE O
a O
novel O
, O
RARE O
, O
NUM O
- O
amino O
- O
acid O
protein O
that O
contains O
two O
extended O
arrays O
of O
hydrophobic O
repeats O
that O
interact O
with O
the O
HSF1 I-GENE
RARE I-GENE
repeats I-GENE
. O

Genomic O
and O
cDNA O
RARE O
homologous O
to O
the O
yeast O
GCN2 I-GENE
eIF I-GENE
- I-GENE
2alpha I-GENE
kinase O
( O
NUM O
) O
were O
isolated O
from O
Drosophila O
melanogaster O
. O

The O
RARE O
RARE O
RARE O
a O
RARE O
voltage O
of O
NUM O
V O
is O
less O
than O
2 O
% O
RARE O
dose O
- O
rates O
RARE O
to O
about O
NUM O
RARE O
min O
- O
1 O
. O

The O
low O
number O
of O
false O
RARE O
indicates O
that O
our O
RARE O
would O
not O
RARE O
the O
RARE O
by O
suggesting O
normal O
regions O
RARE O
RARE O
. O

RARE O
the O
biological O
RARE O
RARE O
and O
implications O
on O
the O
RARE O
and O
RARE O
RARE O
. O

NUM I-GENE
is O
one O
of O
the O
key O
RARE O
RARE O
proteins O
involved O
in O
T O
- O
DNA O
RARE O
and O
transfer O
. O

Taken O
together O
, O
these O
data O
indicate O
that O
the O
NUM I-GENE
RARE I-GENE
domain I-GENE
is O
important O
RARE O
efficient O
T O
- O
DNA O
RARE O
. O

The O
ALL_CAP O
levels O
in O
all O
stages O
of O
decreased O
BMD O
were O
significantly O
lower O
than O
those O
in O
the O
group O
with O
normal O
BMD O
. O

RARE O
of O
the O
nuclear O
spin O
RARE O
by O
optical O
RARE O
causes O
an O
RARE O
shift O
of O
the O
RARE O
energy O
levels O
RARE O
to O
the O
degree O
of O
nuclear O
orientation O
. O

RARE I-GENE
A I-GENE
, O
a O
cysteine I-GENE
RARE I-GENE
inhibitor O
, O
is O
one O
of O
the O
precursor O
proteins O
of O
RARE I-GENE
cell I-GENE
envelope I-GENE
of O
RARE O
and O
is O
RARE O
RARE O
the O
RARE O
RARE O
of O
RARE O
differentiation O
. O

A O
role O
RARE O
ALL_CAP I-GENE
and O
a O
novel O
Ras I-GENE
effector O
in O
the O
Ras I-GENE
- O
RARE O
inhibition O
of O
skeletal O
RARE O
. O

GTPase I-GENE
activating O
RARE O
of O
NUM I-GENE
and O
binding O
RARE O
of O
an O
RARE O
RARE O
PDZ I-GENE
( O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
/ O
RARE I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
) O
domain O
. O

However O
, O
mutations O
in O
the O
HNF I-GENE
- I-GENE
4 I-GENE
binding I-GENE
site I-GENE
on O
element I-GENE
ALL_CAP I-GENE
and O
inhibition O
of O
HNF I-GENE
- I-GENE
4 I-GENE
RARE O
in O
NUM O
cells O
by O
RARE O
HNF I-GENE
- I-GENE
4 I-GENE
constructs I-GENE
decreased O
the O
ALL_CAP I-GENE
promoter I-GENE
activity O
to O
NUM O
- O
40 O
% O
of O
the O
control O
, O
indicating O
that O
HNF I-GENE
- I-GENE
4 I-GENE
is O
a O
positive O
regulator O
of O
the O
ALL_CAP I-GENE
gene I-GENE
. O

272 O
, O
NUM O
- O
NUM O
). O

In O
addition O
, O
we O
find O
that O
E2F I-GENE
- I-GENE
1 I-GENE
can O
cause O
apoptosis O
in O
p53 I-GENE
RARE I-GENE
RARE O
cells O
and O
further O
p300 I-GENE
, O
which O
also O
functions O
RARE O
a O
RARE O
- O
activator O
RARE O
the O
E2F I-GENE
/ O
ALL_CAP I-GENE
RARE O
, O
enhances O
the O
apoptotic O
activity O
of O
E2F I-GENE
- I-GENE
1 I-GENE
. O

RARE O
shift O
/ O
supershift O
analysis O
indicates O
that O
Fos I-GENE
family I-GENE
RARE O
proteins O
especially O
RARE I-GENE
- I-GENE
1 I-GENE
and O
RARE I-GENE
- I-GENE
2 I-GENE
are O
related O
to O
progression O
and O
RARE O
changes O
found O
in O
the O
Jun I-GENE
family I-GENE
RARE O
proteins O
although O
they O
are O
present O
in O
the O
AP I-GENE
- I-GENE
1 I-GENE
/ I-GENE
DNA I-GENE
binding I-GENE
complex I-GENE
. O

RARE O
, O
we O
observed O
that O
RARE O
p53 I-GENE
is O
strongly O
RARE O
in O
RARE O
mammary O
glands O
and O
in O
mammary O
tumors O
derived O
from O
the O
ALL_CAP O
- O
c I-GENE
- I-GENE
myc I-GENE
RARE O
. O

These O
data O
show O
that O
heterologous O
virus O
RNAs O
( O
ALL_CAP O
) O
can O
serve O
RARE O
primer O
donors O
RARE O
ALL_CAP O
mRNA O
RARE O
RNA O
- O
primed O
transcription O
in O
RARE O
RARE O
RARE O
. O

Human O
isoforms O
, O
designated O
1 O
to O
4 O
, O
differ O
from O
each O
other O
by O
the O
RARE O
RARE O
used O
. O

Comparison O
of O
cDNA O
and O
genomic O
sequences O
shows O
that O
the O
NUM I-GENE
gene I-GENE
spans O
RARE O
11 O
kb O
and O
is O
organized O
into O
RARE O
least O
four O
exons O
, O
the O
large O
3 O
'- O
end O
RARE O
coding O
RARE O
the O
RARE O
zinc O
finger O
domain O
and O
the O
3 O
' O
RARE O
region O
. O

RARE O
had O
diminished O
significantly O
by O
the O
early O
NUM O
, O
and O
this O
paper O
RARE O
whether O
that O
reduction O
was O
due O
to O
the O
control O
RARE O
of O
the O
RARE O
, O
and O
, O
if O
so O
, O
whether O
such O
RARE O
should O
be O
a O
model O
RARE O
the O
current O
developing O
world O
, O
where O
malaria O
is O
a O
growing O
problem O
RARE O
. O

The O
NUM I-GENE
/ O
RARE I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
protein O
belongs O
to O
the O
low I-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
receptor I-GENE
gene I-GENE
family I-GENE
and O
is O
believed O
to O
function O
RARE O
an O
endocytic O
receptor O
RARE O
the O
uptake O
of O
RARE O
and O
many O
other O
ligands O
. O

In O
the O
DNA O
recognition O
helix O
of O
finger O
II O
, O
the O
RARE O
Arg O
RARE O
position O
NUM O
( O
N O
- O
terminal O
RARE O
of O
the O
RARE O
zinc O
- O
RARE O
RARE O
) O
was O
changed O
to O
a O
RARE O
or O
Gln O
. O

RARE O
in O
both O
cases O
was O
NUM O
. O
2 O
g O
/ O
m2 O
. O

Five O
additional O
copies O
of O
RARE I-GENE
elements I-GENE
were O
isolated O
, O
mapped O
by O
RARE O
digestion O
, O
and O
partially O
sequenced O
. O

RARE O
relationships O
among O
putative O
RNA I-GENE
- I-GENE
dependent I-GENE
RNA I-GENE
RARE I-GENE
encoded O
by O
a O
mitochondrial O
virus O
- O
like O
RNA O
in O
the O
RARE O
RARE O
RARE O
RARE O
, O
RARE O
RARE O
- O
RARE O
, O
by O
other O
viruses O
and O
virus O
- O
like O
RNAs O
and O
by O
the O
Arabidopsis O
mitochondrial O
genome O
. O

Role O
of O
the O
transcription O
RARE O
site O
core O
region O
and O
transcription I-GENE
factor I-GENE
YY1 I-GENE
in O
RARE I-GENE
sarcoma I-GENE
virus I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
promoter I-GENE
activity O
. O

RARE O
virus O
encodes O
RARE O
homologs O
of O
cellular I-GENE
alpha I-GENE
- I-GENE
ALL_CAP I-GENE
, O
PC I-GENE
- I-GENE
1 I-GENE
, O
and O
an O
orphan O
human O
homolog O
of O
a O
RARE O
nematode O
protein O
. O

Addition O
of O
RARE O
or O
NUM O
after O
exposure O
of O
cells O
to O
progesterone O
agonist O
RARE O
NUM O
had O
RARE O
effect O
on O
induction O
of O
CAT I-GENE
activity O
. O

The O
RARE I-GENE
- I-GENE
1 I-GENE
gene I-GENE
encodes O
a O
protein O
that O
is O
structurally O
related O
to O
members O
of O
the O
orphan I-GENE
nuclear I-GENE
receptor I-GENE
superfamily I-GENE
. O

He O
was O
administered O
recombinant I-GENE
IFN I-GENE
alpha I-GENE
- I-GENE
NUM I-GENE
under O
the O
diagnosis O
of O
chronic O
hepatitis O
C O
. O

Further O
, O
RARE O
/ O
RARE O
RARE O
of O
RARE O
molecules O
Akt I-GENE
and O
p70 I-GENE
S6 I-GENE
kinase I-GENE
was O
inhibited O
. O

Quantitative O
evaluation O
of O
the O
steady O
state O
kinetics O
of O
MEK I-GENE
inhibition O
by O
these O
compounds O
reveals O
that O
NUM O
has O
RARE O
NUM O
- O
RARE O
RARE O
affinity O
RARE O
NUM I-GENE
- I-GENE
NUM I-GENE
/ I-GENE
NUM I-GENE
MEK I-GENE
than O
does O
NUM O
. O

Regulation O
RARE O
37 O
degrees O
C O
, O
therefore O
, O
involves O
the O
action O
of O
three O
protein O
kinase O
RARE O
that O
repress O
HSF1 I-GENE
through O
RARE O
of O
serine O
residues O
NUM O
, O
NUM O
, O
and O
NUM O
and O
may O
promote O
growth O
by O
RARE O
the O
heat O
shock O
response O
. O

Clinical O
RARE O
of O
protein O
levels O
of O
ALL_CAP I-GENE
- I-GENE
5 I-GENE
in O
RARE O
RARE O
in O
asthmatic O
patients O
. O

In O
these O
cells O
, O
ras I-GENE
- O
RARE O
transition O
is O
accompanied O
by O
a O
strong O
induction O
of O
AP I-GENE
- I-GENE
1 I-GENE
- O
binding O
activity O
along O
with O
increased O
RARE O
of O
CD44 I-GENE
mRNA I-GENE
and O
protein O
. O

However O
, O
little O
is O
known O
regarding O
the O
genomic O
organization O
and O
developmental O
RARE O
of O
the O
RARE I-GENE
gene I-GENE
family I-GENE
. O

RARE O
bond O
strengths O
between O
resin O
composite O
and O
bovine O
dentin O
using O
dentin O
adhesive O
RARE O
( O
RARE O
RARE O
RARE O
II O
: O
ALL_CAP O
II O
; O
RARE O
RARE O
- O
RARE O
: O
MP O
) O
RARE O
RARE O
showed O
a O
large O
RARE O
among O
students O
and O
RARE O
. O

This O
distribution O
RARE O
that O
the O
RARE O
precursor O
is O
RARE O
into O
the O
RARE O
RARE O
RARE O
to O
the O
RARE O
RARE O
, O
and O
that O
the O
import O
or O
RARE O
RARE O
involves O
RARE O
RARE O
. O

RARE O
therapy O
RARE O
thyroid O
nodules O
. O

RARE O
healthy O
male O
volunteers O
completed O
the O
study O
. O

In O
the O
absence O
of O
NUM O
RARE O
a O
hydrophobic O
RARE O
site O
RARE O
over O
the O
polymerase O
site O
RARE O
RARE O
of O
the O
primer O
terminus O
. O

As O
the O
high O
- O
affinity O
NUM O
+ O
binding O
sites O
are O
filled O
, O
the O
primer O
terminus O
RARE O
from O
the O
RARE O
site O
to O
a O
highly O
based O
RARE O
polymerase O
RARE O
site O
. O

One O
missense O
allele O
( O
NUM O
) O
with O
RARE O
RARE O
of O
function O
RARE O
NUM O
ALL_CAP O
and O
four O
missense O
alleles O
( O
NUM O
, O
NUM O
, O
NUM O
and O
NUM O
) O
that O
conferred O
a O
RARE O
RARE O
RARE O
were O
identified O
. O

Structural O
analysis O
of O
the O
5 O
'- O
regulatory O
region O
reveals O
that O
the O
c I-GENE
- I-GENE
met I-GENE
promoter I-GENE
lacks O
TATA O
or O
CAAT O
elements O
but O
has O
an O
extremely O
high O
G O
- O
C O
content O
and O
multiple O
NUM I-GENE
binding I-GENE
sites I-GENE
. O

The O
report O
RARE O
the O
possible O
contribution O
of O
stress O
factors O
in O
the O
context O
of O
therapy O
resistant O
periodontal O
RARE O
, O
and O
the O
results O
seem O
to O
be O
RARE O
within O
the O
context O
of O
a O
stress O
RARE O
disorder O
RARE O
. O

Acute O
pancreatitis O
is O
a O
rather O
common O
abdominal O
disorder O
. O

To O
better O
understand O
the O
role O
of O
Ets I-GENE
proteins I-GENE
in O
Ras I-GENE
transformation O
, O
we O
have O
now O
analyzed O
the O
effects O
of O
stably O
expressing O
a O
variety O
of O
NUM I-GENE
constructs I-GENE
in O
Ras I-GENE
- O
transformed O
NIH3T3 O
( O
ALL_CAP O
) O
cells O
. O

Each O
binding O
site O
, O
however O
, O
was O
different O
in O
its O
preference O
RARE O
binding O
partners O
. O

We O
isolated O
the O
human I-GENE
FGF I-GENE
- I-GENE
ALL_CAP I-GENE
promoter I-GENE
and O
determined O
by O
deletion O
analysis O
that O
ALL_CAP O
regulatory O
elements O
were O
all O
contained O
in O
the O
RARE O
118 O
RARE O
RARE O
upstream O
of O
the O
transcription O
RARE O
site O
. O

RARE O
of O
the O
RARE O
RARE O
involved O
in O
cell O
RARE O
arrest O
and O
apoptosis O
may O
thus O
provide O
a O
novel O
strategy O
to O
RARE O
therapy O
. O

Electrophoretic O
mobility O
shift O
assays O
demonstrated O
specific O
nuclear O
protein O
binding O
to O
- O
NUM O
/- O
NUM O
, O
and O
single O
point O
mutations O
suggested O
important O
binding O
nucleotides O
between O
- O
NUM O
/- O
NUM O
with O
five O
critical O
bases O
between O
- O
NUM O
/- O
70 O
( O
5 O
'- O
ALL_CAP O
- O
3 O
RARE O

The O
diagnostic O
accuracy O
of O
serum O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
was O
NUM O
. O
NUM O
, O
and O
that O
of O
amylase I-GENE
NUM O
. O
97 O
. O

We O
demonstrate O
that O
NUM I-GENE
interacts O
physically O
in O
vivo O
with O
NUM I-GENE
, O
and O
this O
interaction O
requires O
NUM I-GENE
. O

" O
RARE O
partial O
" O
seizures O
. O

B I-GENE
cell I-GENE
antigen I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
)- O
RARE O
formation O
of O
a O
SHP I-GENE
- I-GENE
2 I-GENE
- O
NUM I-GENE
complex O
and O
its O
inhibition O
by O
Fc I-GENE
gamma I-GENE
NUM I-GENE
- O
ALL_CAP I-GENE
RARE O
. O

Chem O
., O
270 O
: O
NUM O
- O
NUM O
, O
1995 O
; O
and O
ALL_CAP O
RARE O
et O
al O
., O
ALL_CAP O
. O

RARE O
NUM I-GENE
repressed O
meiosis O
RARE O
the O
same O
three O
steps O
that O
were O
inhibited O
by O
glucose O
, O
suggesting O
that O
glucose O
blocks O
meiosis O
by O
inhibiting O
NUM I-GENE
. O

Here O
we O
investigate O
the O
role O
of O
c I-GENE
- I-GENE
Cbl I-GENE
in O
development O
and O
RARE O
in O
mice O
by O
targeted O
disruption O
of O
the O
c I-GENE
- I-GENE
Cbl I-GENE
locus I-GENE
. O
c I-GENE
- I-GENE
Cbl I-GENE
- O
RARE O
mice O
were O
viable O
, O
RARE O
, O
and O
RARE O
normal O
in O
appearance O
. O

One O
is O
to O
act O
within O
the O
visceral O
endoderm O
to O
promote O
proper O
RARE O
RARE O
. O

We O
propose O
that O
RARE I-GENE
/ O
NUM I-GENE
. I-GENE
1 I-GENE
participates O
in O
sequential O
RARE O
processes O
RARE O
a O
key O
RARE O
of O
RARE O
- O
RARE O
boundary O
development O
. O

RARE O
- O
independent O
activation O
of O
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
is O
a O
necessary O
RARE O
in O
RARE O
, O
acid O
- O
RARE O
mitogenic O
activity O
in O
L O
cells O
. O

METHODS O
: O
RARE O
changes O
involving O
bone O
marrow O
were O
evaluated O
histologically O
RARE O
using O
RARE I-GENE
fiber O
RARE O
( O
method O
of O
RARE O
). O

In O
RARE O
- O
treated O
rats O
, O
ANP I-GENE
infusion O
caused O
greater O
increases O
in O
RARE O
excretion O
( O
ALL_CAP O
from O
3 O
. O
05 O
+/- O
NUM O
. O
NUM O
to O
7 O
. O
21 O
+/- O
NUM O
. O
NUM O
%; O
P O
< O
NUM O
. O
05 O
; O
RARE O
= O
8 O
) O
than O
saline O
infusion O
( O
ALL_CAP O
from O
4 O
. O
16 O
+/- O
1 O
. O
11 O
to O
5 O
. O
NUM O
+/- O
NUM O
. O
NUM O
%; O
RARE O
= O
6 O
RARE O
despite O
the O
RARE O
. O

We O
then O
studied O
four O
unrelated O
Japanese O
RARE O
with O
ALL_CAP O
- O
RARE O
, O
and O
found O
three O
novel O
mutations O
: O
a O
four O
- O
RARE O
deletion O
/ O
two O
- O
RARE O
RARE O
, O
a O
point O
mutation O
within O
a O
consensus O
RARE O
donor O
site O
, O
and O
a O
missense O
mutation O
( O
NUM O
). O

Removal O
of O
the O
RARE O
region O
severely O
RARE O
transcriptional O
activation O
. O

A O
" O
RARE O
A O
" O
in O
vitro O
/ O
in O
vivo O
correlation O
was O
established O
RARE O
a O
sustained O
release O
theophylline O
( O
ALL_CAP O
58 O
- O
NUM O
- O
9 O
) O
preparation O
( O
RARE O
) O
under O
investigation O
. O

ALL_CAP O
: O
50 O
consecutive O
children O
aged O
from O
6 O
months O
to O
NUM O
years O
were O
included O
into O
the O
study O
which O
comprised O
RARE O
of O
patient O
and O
family O
RARE O
, O
serological O
screening O
tests O
RARE O
common O
RARE O
allergens O
( O
ALL_CAP O
NUM O
RARE O
and O
determination O
of O
RARE O
serum I-GENE
immunoglobulin I-GENE
E I-GENE
( O
IgE I-GENE
) O
and O
of O
latex O
- O
specific O
serum I-GENE
IgE I-GENE
by O
solid O
- O
RARE O
RARE O
. O

The O
NUM I-GENE
- I-GENE
subfamily I-GENE
- I-GENE
specific I-GENE
RARE I-GENE
region I-GENE
NUM O
, O
which O
joins O
NUM O
and O
NUM O
, O
is O
encoded O
by O
two O
exons O
, O
whereas O
NUM O
, O
which O
joins O
NUM O
to O
the O
catalytic O
unit O
, O
is O
encoded O
by O
a O
single O
RARE O
. O

NUM I-GENE
strains O
are O
weak O
RARE O
and O
are O
RARE O
RARE O
damage O
- O
RARE O
mutagenesis O
. O

At O
the O
same O
time O
, O
the O
results O
indicate O
that O
p53 I-GENE
plays O
a O
RARE O
role O
against O
ALL_CAP O
by O
transcriptionally O
repressing O
the O
ALL_CAP I-GENE
core I-GENE
promoter I-GENE
through O
liver I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
II I-GENE
and O
RARE I-GENE
is O
required O
to O
RARE O
this O
RARE O
function O
of O
p53 I-GENE
. O

To O
gain O
insight O
into O
the O
RARE O
of O
the O
NUM I-GENE
gene I-GENE
, O
northern O
blot O
analysis O
was O
carried O
out O
. O

The O
aim O
of O
the O
study O
was O
to O
correlate O
the O
responsiveness O
to O
RARE O
with O
RARE O
in O
subjects O
a O
with O
allergic O
RARE O
RARE O
and O
out O
of O
the O
pollen O
season O
with O
RARE O
serum O
IgE I-GENE
and O
RARE O
eosinophils O
. O

These O
results O
provide O
the O
RARE O
RARE O
that O
an O
SR I-GENE
protein I-GENE
can O
influence O
RARE O
of O
specific O
pre O
- O
mRNAs O
in O
vivo O
. O

In O
particular O
, O
the O
RARE O
RARE O
RARE O
RARE O
RARE O
using O
RARE O
anti O
- O
inflammatory O
drugs O
( O
RARE I-GENE
- I-GENE
oxygenase I-GENE
RARE O
; O
RARE O
) O
has O
received O
little O
attention O
. O

This O
study O
reports O
the O
isolation O
of O
a O
P O
. O
RARE O
gene O
, O
NUM I-GENE
, O
encoding O
a O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
protein I-GENE
that O
, O
on O
the O
basis O
of O
sequence O
homology O
and O
intron O
/ O
RARE O
RARE O
, O
represents O
the O
P O
. O
RARE O
RARE O
of O
the O
Z I-GENE
. I-GENE
RARE I-GENE
RARE I-GENE
genes I-GENE
. O

RARE O
c I-GENE
- I-GENE
NUM I-GENE
transcripts I-GENE
are O
RARE O
in O
normal O
human O
RARE O
tissues O
. O

During O
the O
past O
4 O
years O
, O
a O
RARE O
search O
was O
made O
RARE O
RARE O
with O
RARE O
reversible O
QRS O
changes O
associated O
with O
all O
acute O
injury O
pattern O
. O

RARE O
a O
RARE O
RARE O
site O
RARE O
N O
- O
terminal O
to O
the O
protease O
domain O
, O
NUM O
- O
NUM O
, O
diminished O
RARE O
. O

METHODS O
: O
RARE O
RARE O
membranes O
of O
three O
different O
RARE O
sizes O
were O
used O
RARE O
model O
RARE O
materials O
. O
The O
RARE O
membrane O
RARE O
sizes O
were O
NUM O
. O
1 O
microm O
, O
NUM O
. O
NUM O
microm O
, O
and O
3 O
microm O
; O
the O
surface O
RARE O
increased O
in O
the O
same O
order O
The O
membranes O
were O
RARE O
with O
a O
thin O
layer O
of O
RARE I-GENE
I I-GENE
and O
implanted O
in O
a O
circular O
pocket O
of O
the O
anterior O
RARE O
of O
adult O
cats O
, O
and O
were O
clinically O
evaluated O
RARE O
the O
extent O
of O
RARE O
and O
the O
RARE O
of O
RARE O
RARE O
. O

The O
role O
of O
calcitonin I-GENE
, O
and O
other O
agonists O
which O
activate O
the O
cAMP O
RARE O
, O
in O
RARE O
transcription O
of O
the O
human I-GENE
RARE I-GENE
hormone I-GENE
- I-GENE
related I-GENE
protein I-GENE
( O
ALL_CAP I-GENE
) O
gene O
was O
investigated O
in O
a O
human O
RARE O
RARE O
cell O
line O
( O
ALL_CAP O
). O

The O
combination O
of O
NUM I-GENE
and O
another O
RARE I-GENE
protein I-GENE
, O
Pit I-GENE
- I-GENE
1 I-GENE
, O
yielded O
a O
synergistic O
NUM O
- O
RARE O
activation O
of O
the O
prolactin I-GENE
promoter I-GENE
in O
transfection O
assays O
. O

The O
biochemical O
and O
RARE O
spectrum O
of O
RARE I-GENE
RARE I-GENE
deficiency O
. O

To O
further O
understand O
the O
role O
of O
cis O
- O
acting O
elements O
in O
these O
regulatory O
mechanisms O
, O
we O
have O
characterized O
a O
transcriptional O
promoter O
that O
RARE O
RARE O
RARE O
of O
TCR I-GENE
beta I-GENE
gene I-GENE
RARE I-GENE
in O
vivo O
. O

Our O
results O
suggest O
that O
the O
crucial O
role O
of O
the O
mutations O
activating O
v I-GENE
- I-GENE
erbA I-GENE
RARE O
an O
oncogene O
is O
to O
' O
RARE O
' O
c I-GENE
- I-GENE
ALL_CAP I-GENE
/ O
RARE I-GENE
in O
its O
non O
- O
RARE O
, O
repressive O
conformation O
and O
to O
facilitate O
its O
overexpression O
. O

RARE O
of O
ALL_CAP I-GENE
RARE O
in O
ALL_CAP I-GENE
/ O
ABL I-GENE
- O
expressing O
NUM O
cells O
was O
associated O
with O
suppression O
of O
growth O
factor O
- O
independent O
colony O
formation O
, O
RARE O
of O
G I-GENE
- I-GENE
CSF I-GENE
- O
RARE O
RARE O
differentiation O
and O
RARE O
tumorigenic O
RARE O
in O
vivo O
. O

In O
this O
study O
, O
we O
describe O
a O
mammalian O
cell O
- O
free O
transcription O
RARE O
reconstituted O
with O
only O
recombinant O
proteins O
and O
RARE O
- O
RARE O
RARE O
complexes O
. O

This O
repressor O
is O
however O
unlikely O
to O
mediate O
RARE I-GENE
2 I-GENE
. I-GENE
3 I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
RARE I-GENE
action O
since O
it O
was O
not O
detected O
in O
rat O
hepatocytes O
. O

A O
prerequisite O
RARE O
the O
RARE O
of O
RARE O
RARE O
is O
the O
activated O
RARE O
- O
nucleotide O
RARE O
5 O
'- O
monophosphate O
N O
- O
RARE O
acid O
( O
ALL_CAP O
- O
NUM O
RARE O
which O
provides O
a O
substrate O
RARE O
RARE I-GENE
RARE I-GENE
. O

Thus O
, O
the O
bovine I-GENE
ALL_CAP I-GENE
cDNA I-GENE
isolated O
here O
codes O
RARE O
a O
RARE O
RARE O
RARE I-GENE
ALL_CAP I-GENE
glycoprotein I-GENE
. O

We O
propose O
a O
model O
in O
which O
NUM I-GENE
function O
is O
involved O
in O
the O
targeting O
of O
the O
myosin I-GENE
proteins I-GENE
to O
their O
RARE O
pathways O
. O

We O
found O
sequences O
related O
to O
this O
RARE O
in O
wild O
- O
type O
strains O
of O
N O
. O
crassa O
and O
other O
Neurospora O
species O
. O

When O
cysteine O
is O
RARE O
through O
the O
helices O
, O
characteristic O
repeating O
patterns O
of O
solvent O
exposure O
and O
RARE O
are O
observed O
. O

Human I-GENE
NUM I-GENE
, O
a O
novel O
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
related O
to O
UNC I-GENE
- I-GENE
NUM I-GENE
kinase I-GENE
of O
Caenorhabditis O
elegans O
: O
cDNA O
cloning O
, O
RARE O
, O
and O
chromosomal O
assignment O
. O

Specifically O
, O
I O
use O
RARE O
markers O
that O
identify O
particular O
RARE O
domains O
, O
all O
neuroblasts O
or O
individual O
neuroblasts O
, O
to O
show O
that O
in O
DER I-GENE
mutant I-GENE
RARE O
( O
1 O
) O
RARE O
column O
neuroblasts O
do O
not O
form O
, O
( O
2 O
) O
medial O
column O
neuroblasts O
often O
RARE O
identities O
RARE O
RARE O
their O
position O
, O
while O
( O
3 O
) O
lateral O
neuroblasts O
develop O
normally O
. O

RARE O
RARE O
potentials O
in O
patients O
with O
vestibular O
RARE O
. O

These O
results O
with O
RARE O
RARE O
that O
ALL_CAP O
is O
RARE O
to O
RARE O
which O
differ O
in O
their O
mode O
of O
action O
and O
RARE O
RARE O
the O
value O
of O
ALL_CAP O
RARE O
a O
test O
model O
RARE O
detecting O
the O
RARE O
RARE O
of O
novel O
drugs O
. O

The O
complement I-GENE
NUM I-GENE
RARE I-GENE
receptor I-GENE
( O
NUM I-GENE
) O
is O
a O
RARE I-GENE
- I-GENE
transmembrane I-GENE
G I-GENE
- I-GENE
protein I-GENE
coupled I-GENE
RARE I-GENE
receptor I-GENE
that O
on O
binding O
the O
NUM I-GENE
peptide I-GENE
RARE I-GENE
mediates O
numerous O
cellular O
responses O
, O
including O
RARE O
release O
from O
RARE O
cells O
. O
RARE O
muscle O
contraction O
, O
and O
the O
directed O
migration O
of O
eosinophils O
. O

CONCLUSIONS O
: O
Significant O
elevations O
of O
ALL_CAP I-GENE
- I-GENE
1alpha I-GENE
and O
ALL_CAP I-GENE
- I-GENE
1beta I-GENE
occur O
in O
patients O
with O
bacterial O
RARE O
and O
microscopic O
RARE O
. O

RARE O
- O
shift O
assays O
were O
performed O
using O
the O
ALL_CAP I-GENE
- I-GENE
and I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
- I-GENE
responsive I-GENE
element I-GENE
( O
ALL_CAP I-GENE
) O
RARE O
, O
a O
gamma I-GENE
RARE I-GENE
activation I-GENE
site I-GENE
- I-GENE
like I-GENE
site I-GENE
that O
is O
present O
in O
the O
human I-GENE
ALL_CAP I-GENE
- I-GENE
1beta I-GENE
promoter I-GENE
. O

The O
C O
- O
terminal O
region O
contains O
the O
PTP I-GENE
- I-GENE
like I-GENE
domain I-GENE
, O
whereas O
the O
N O
- O
terminal O
region O
shows O
RARE O
homology O
to O
any O
known O
mammalian O
protein O
. O

In O
addition O
, O
and O
in O
support O
of O
a O
mediating O
role O
of O
RARE I-GENE
in O
the O
activation O
of O
the O
p21 I-GENE
promoter I-GENE
, O
overexpression O
of O
Stat3 I-GENE
RARE O
the O
RARE O
effect O
on O
the O
p21 I-GENE
promoter I-GENE
; O
whereas O
a O
dominant I-GENE
negative I-GENE
Stat3 I-GENE
, O
or O
a O
mutation O
of O
the O
STAT I-GENE
response I-GENE
element I-GENE
on O
the O
promoter O
, O
significantly O
RARE O
the O
RARE O
effect O
. O

The O
RARE O
nuclear I-GENE
ribonucleoprotein I-GENE
C I-GENE
protein I-GENE
RARE I-GENE
binds O
NUM I-GENE
, O
NUM I-GENE
, O
and O
U6 I-GENE
RARE I-GENE
through O
its O
high O
affinity O
RNA O
binding O
domain O
( O
the O
ALL_CAP O
- O
like O
motif O
). O

On O
the O
comparison O
of O
correlated O
RARE O
RARE O
clustered O
data O
. O

A O
safe O
and O
simple O
RARE O
RARE O
the O
detection O
of O
RARE O
infant O
RARE O
RARE O
( O
ALL_CAP O
) O
is O
proposed O
. O

The O
resulting O
mutants O
were O
coexpressed O
with O
ALL_CAP I-GENE
in O
the O
RARE O
virus O
- O
based O
NUM O
- O
3 O
RARE O
, O
and O
the O
formation O
and O
endoplasmic O
reticulum O
( O
ER O
)- O
to O
- O
RARE O
RARE O
of O
the O
RARE O
- O
RARE O
complex O
were O
monitored O
. O

Homozygous O
mutant O
mice O
, O
designated O
RARE I-GENE
/ O
NUM I-GENE
, O
display O
a O
RARE O
characterized O
by O
RARE O
RARE O
and O
RARE O
RARE O
. O

The O
mutant O
protein O
is O
present O
RARE O
levels O
slightly O
greater O
than O
wild O
- O
type O
, O
but O
exhibits O
the O
same O
tissue O
distribution O
RARE O
wild O
- O
type O
protein O
, O
and O
has O
RARE O
normal O
affinity O
RARE O
known O
target O
sequences O
( O
though O
RARE O
DNA O
RARE O
identified O
to O
date O
require O
the O
RARE O
cut O
repeat O
RARE O
binding O
). O

METHODS O
: O
We O
RARE O
reviewed O
NUM O
adult O
RARE O
RARE O
transplant O
recipients O
treated O
between O
11 O
/ O
91 O
and O
5 O
/ O
97 O
. O

The O
spectrum O
of O
age O
- O
associated O
brain O
abnormalities O
: O
their O
measurement O
and O
histopathological O
correlates O
. O

Our O
laboratory O
has O
recently O
identified O
two O
RARE I-GENE
- I-GENE
like I-GENE
orphan I-GENE
proteins I-GENE
( O
NUM I-GENE
and O
NUM I-GENE
) O
that O
lack O
the O
ability O
to O
interact O
with O
Gbetagamma I-GENE
. O

RARE I-GENE
transcriptase I-GENE
- O
polymerase O
chain O
reaction O
( O
RT I-GENE
- O
PCR O
) O
was O
performed O
using O
RARE O
RARE O
DNA O
of O
the O
RARE O
RARE O
RARE O
RARE O
. O

In O
contrast O
, O
transcription O
initiating O
from O
ALL_CAP I-GENE
P I-GENE
- I-GENE
1 I-GENE
( O
RARE I-GENE
A I-GENE
) O
rose O
in O
proportion O
to O
the O
external O
RARE O
and O
was O
maintained O
RARE O
high O
levels O
. O

RARE O
RARE O
NUM O
children O
aged O
3 O
months O
- O
3 O
yr O
were O
analysed O
over O
a O
period O
of O
one O
year O
RARE O
estimating O
prevalence O
of O
nutritional O
RARE O
. O

In O
RARE O
, O
RARE I-GENE
N I-GENE
- I-GENE
RARE I-GENE
( O
RARE I-GENE
) O
have O
been O
implicated O
in O
several O
physiological O
processes O
, O
including O
RARE O
, O
inactivation O
of O
certain O
RARE O
, O
and O
, O
similar O
to O
the O
function O
in O
RARE O
, O
RARE O
of O
the O
rate O
- O
limiting O
step O
in O
melatonin O
biosynthesis O
. O

In O
experiments O
with O
the O
NUM O
antagonist O
ALL_CAP O
NUM O
, O
RARE O
- O
RARE O
depression O
was O
consistently O
blocked O
, O
but O
RARE O
was O
unaffected O
. O

These O
results O
establish O
that O
RARE O
lead O
to O
RARE O
and O
RARE O
. O

IA O
- O
ALL_CAP O
with O
cisplatin O
50 O
mg O
and O
RARE O
NUM O
mg O
was O
administered O
by O
one O
RARE O
method O
in O
bilateral O
internal O
iliac O
arteries O
. O

NUM I-GENE
mRNA I-GENE
was O
RARE O
in O
brain O
, O
skeletal O
muscle O
, O
NUM O
. O
5 O
- O
day O
RARE O
, O
and O
P19 O
cells O
treated O
with O
retinoic O
acid O
. O

Acute O
idiopathic O
RARE O
purpura O
RARE O
a O
high O
serum O
level O
of O
immunoglobulin I-GENE
E I-GENE
and O
RARE O
in O
an O
elderly O
patient O
. O

The O
genomic O
RARE O
and O
chromosomal O
location O
of O
the O
human I-GENE
NUM I-GENE
orphan I-GENE
receptor I-GENE
, O
a O
RARE O
of O
the O
steroid I-GENE
receptor I-GENE
superfamily I-GENE
. O

RARE O
of O
RARE O
disorders O
with O
NUM I-GENE
lymphocyte O
counts O
in O
patients O
with O
HIV O
/ O
AIDS O
. O

E2F I-GENE
- I-GENE
6 I-GENE
shares O
significant O
homology O
with O
NUM I-GENE
1 I-GENE
- I-GENE
5 I-GENE
, O
especially O
within O
the O
DNA O
binding O
, O
heterodimerization O
and O
marked O
box O
domains O
. O

The O
NUM O
. O
1 O
cell O
line O
was O
able O
to O
complement O
a O
recombinant O
virus O
in O
which O
both O
copies O
of O
the O
IE I-GENE
gene I-GENE
were O
replaced O
by O
RARE O
of O
the O
Escherichia I-GENE
coli I-GENE
lacZ I-GENE
gene I-GENE
. O

DNase I-GENE
I I-GENE
footprinting O
and O
electrophoretic O
mobility O
shift O
analyses O
revealed O
two O
RARE I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
NUM I-GENE
RARE O
three O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
RARE O
and O
one O
consensus O
palindromic O
thyroid O
hormone O
response O
elements O
within O
the O
RARE O
215 O
RARE O
RARE O
( O
bp O
) O
of O
the O
promoter O
sequence O
of O
rat I-GENE
RARE I-GENE
. O

Thus O
, O
these O
studies O
on O
rat I-GENE
RARE I-GENE
promoter I-GENE
function O
indicate O
that O
( O
i O
) O
NUM I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
are O
responsible O
RARE O
liver O
RARE O
of O
the O
rat I-GENE
RARE I-GENE
gene I-GENE
; O
( O
ii O
) O
RARE O
repression O
of O
the O
gene O
requires O
the O
presence O
of O
all O
of O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
elements I-GENE
between O
positions O
- O
231 O
and O
- O
NUM O
; O
and O
( O
iii O
) O
ALL_CAP I-GENE
may O
exert O
its O
negative O
regulatory O
effect O
indirectly O
through O
transcriptional O
interference O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
rather O
than O
through O
a O
direct O
DNA I-GENE
- I-GENE
ALL_CAP I-GENE
interaction O
. O

RARE O
NUM I-GENE
phosphorylates O
the O
NUM I-GENE
( O
NUM I-GENE
) O
subunit O
of O
the O
RARE I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
protein I-GENE
complex I-GENE
RARE O
from O
RARE O
yeast O
. O

The O
yeast I-GENE
NUM I-GENE
gene I-GENE
was O
RARE O
by O
its O
ability O
to O
complement O
the O
RARE O
RARE O
sensitivity O
of O
the O
NUM I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
and O
was O
later O
shown O
to O
be O
involved O
in O
DNA O
post O
- O
replication O
repair O
. O

Expression O
of O
the O
human I-GENE
RARE I-GENE
type I-GENE
11 I-GENE
NUM I-GENE
protein I-GENE
from O
the O
NUM I-GENE
, I-GENE
NUM I-GENE
transcript I-GENE
. O

RARE O
with O
M O
/ O
K O
was O
reversed O
after O
NUM O
. O
6 O
min O
of O
RARE O
with O
RARE O
. O

There O
was O
RARE O
evident O
RARE O
agent O
of O
the O
RARE O
. O

MK O
- O
801 O
administration O
resulted O
in O
a O
biphasic O
response O
in O
seizure O
RARE O
. O

In O
contrast O
, O
the O
distribution O
of O
endocytic O
markers O
is O
not O
affected O
. O

RARE O
RARE O
the O
therapeutic O
period O
was O
not O
significant O
in O
the O
study O
group O
compared O
with O
the O
RARE O
control O
, O
treated O
with O
the O
same O
regimen O
without O
G I-GENE
- I-GENE
CSF I-GENE
. O

The O
purpose O
of O
this O
article O
is O
to O
discuss O
the O
factors O
involved O
in O
the O
selection O
of O
antibodies O
, O
RARE O
and O
labeling O
methods O
in O
the O
development O
of O
RARE O
( O
ALL_CAP O
) O
RARE O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
ALL_CAP O
) O
from O
a O
single O
clinical O
study O
site O
through O
RARE O
trials O
and O
RARE O
. O

Both O
methods O
were O
employed O
RARE O
various O
RARE O
- O
RARE O
distances O
, O
image O
RARE O
tube O
modes O
and O
laser O
RARE O
RARE O
. O

The O
effect O
of O
Rho I-GENE
on O
AP I-GENE
- I-GENE
1 I-GENE
is O
independent O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
RARE O
, O
RARE O
a O
dominant I-GENE
- I-GENE
negative I-GENE
MEK I-GENE
and O
a O
MEK I-GENE
inhibitor O
( O
PD98059 O
) O
did O
not O
affect O
Rho I-GENE
- O
RARE O
AP I-GENE
- I-GENE
1 I-GENE
activity O
. O

RARE O
- O
directed O
mutagenesis O
of O
residues O
in O
this O
domain O
( O
NUM O
, O
NUM O
, O
NUM O
, O
and O
NUM O
) O
resulted O
in O
proteins O
which O
failed O
to O
transactivate O
from O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
in O
vivo O
. O

Mutations O
within O
the O
C O
terminus O
of O
c I-GENE
- I-GENE
fos I-GENE
RARE O
serine O
residues O
that O
are O
RARE O
RARE O
RARE O
growth O
factors O
and O
MAP I-GENE
kinase I-GENE
completely O
abrogate O
RARE O
and O
RARE O
potentiation O
by O
MAP I-GENE
kinase I-GENE
. O

In O
the O
former O
cells O
, O
ets I-GENE
- I-GENE
2 I-GENE
was O
a O
CSF I-GENE
- I-GENE
1 I-GENE
immediate O
- O
early O
response O
gene O
, O
and O
RARE O
ets I-GENE
- I-GENE
2 I-GENE
was O
detected O
after O
2 O
to O
4 O
h O
, O
RARE O
with O
RARE O
of O
ets I-GENE
- I-GENE
2 I-GENE
protein I-GENE
. O

RARE O
activation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinases I-GENE
NUM I-GENE
and O
p44 I-GENE
and O
ets I-GENE
- I-GENE
2 I-GENE
RARE O
in O
response O
to O
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
1 I-GENE
/ O
c I-GENE
- I-GENE
fms I-GENE
RARE O
. O

Identification O
of O
a O
proline O
- O
rich O
sequence O
in O
the O
NUM I-GENE
cytoplasmic I-GENE
domain I-GENE
critical O
RARE O
RARE O
of O
integrin I-GENE
- O
RARE O
adhesion O
and O
activation O
of O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

NUM I-GENE
, O
a O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
- I-GENE
like I-GENE
molecule I-GENE
, O
and O
NUM I-GENE
, O
a O
RARE I-GENE
homolog I-GENE
, O
function O
together O
in O
yeast O
vacuolar O
protein O
trafficking O
. O

We O
have O
tested O
this O
possibility O
by O
RARE O
a O
consecutive O
series O
of O
cysteine O
substitutions O
in O
the O
RARE I-GENE
RARE I-GENE
domain I-GENE
in O
order O
to O
force O
RARE O
along O
a O
series O
of O
RARE O
RARE O
. O

It O
has O
been O
demonstrated O
previously O
that O
Pax I-GENE
- I-GENE
6 I-GENE
, O
a O
paired I-GENE
domain I-GENE
( O
ALL_CAP I-GENE
RARE O
RARE I-GENE
( O
HD I-GENE
) O
transcription O
factor O
critical O
RARE O
eye O
development O
, O
contributes O
to O
the O
activation O
of O
the O
ALL_CAP I-GENE
RARE I-GENE
ALL_CAP I-GENE
RARE I-GENE
NUM I-GENE
RARE I-GENE
and I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
genes O
in O
the O
lens O
. O

RARE I-GENE
- I-GENE
1 I-GENE
binding O
required O
the O
RARE O
19 O
amino O
RARE O
of O
Fyn I-GENE
and O
integrity O
of O
two O
RARE O
residues O
within O
this O
sequence O
that O
were O
previously O
shown O
to O
be O
important O
RARE O
Fyn I-GENE
interactions O
with O
the O
RARE O
tyrosine O
- O
based O
activation O
motifs O
( O
RARE O
) O
of O
lymphocyte I-GENE
RARE I-GENE
receptors I-GENE
. O

The O
prothrombin I-GENE
gene I-GENE
NUM I-GENE
mutation I-GENE
is O
not O
found O
among O
Japanese O
patients O
with O
deep O
RARE O
thrombosis O
and O
healthy O
individuals O
. O

Transcriptional O
RARE O
of O
the O
NUM I-GENE
gene I-GENE
: O
RARE O
- O
specific O
RARE O
, O
multiple O
promoters O
, O
and O
regulatory O
elements O
. O

The O
binding O
of O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
, O
although O
not O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
, O
to O
this O
enhancer O
also O
occurs O
along O
with O
ALL_CAP O
- O
I O
- O
RARE O
infection O
of O
human O
peripheral O
RARE O
T O
- O
cells O
. O

Thus O
, O
TRAF2 I-GENE
RARE O
SAPK I-GENE
and O
p38 I-GENE
activation O
by O
binding O
two O
proximal O
protein O
kinases O
: O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
. O

RARE I-GENE
necrosis I-GENE
factor I-GENE
RARE O
to O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
SAPK I-GENE
RARE O
Jun I-GENE
NH2 I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
) O
and O
p38 I-GENE
. O

The O
activity O
of O
the O
minimal O
promoter O
was O
found O
to O
be O
RARE O
by O
a O
combination O
of O
the O
activities O
of O
the O
transcription O
factors O
NUM I-GENE
, O
Sp3 I-GENE
, O
and O
ALL_CAP I-GENE
- I-GENE
Y I-GENE
. O

In O
the O
studies O
described O
in O
this O
report O
, O
we O
have O
investigated O
the O
RARE O
RARE O
( O
s O
) O
that O
are O
responsible O
RARE O
CREB I-GENE
activation O
in O
normal O
T O
cells O
. O

RARE O
who O
RARE O
with O
a O
RARE O
/ O
RARE O
only O
were O
less O
likely O
to O
have O
an O
RARE O
BMI O
status O
than O
people O
in O
the O
other O
two O
groups O
. O

Isolation O
of O
a O
novel O
NUM I-GENE
target I-GENE
gene I-GENE
from O
a O
colon O
RARE O
cell O
line O
carrying O
a O
highly O
regulated O
wild I-GENE
- I-GENE
type I-GENE
NUM I-GENE
RARE O
RARE O
. O

Overexpression O
of O
NUM I-GENE
has O
been O
demonstrated O
in O
many O
cancers O
, O
both O
in O
patient O
tumors O
and O
in O
cell O
lines O
RARE O
with O
a O
variety O
of O
chemotherapeutic O
agents O
. O

RARE O
and O
RARE O
characterization O
of O
random O
chromosomal O
RARE O
activating O
the O
drug O
resistance O
gene O
, O
NUM I-GENE
/ O
P I-GENE
- I-GENE
glycoprotein I-GENE
, O
in O
drug O
- O
RARE O
cell O
lines O
and O
patients O
with O
drug O
refractory O
ALL O
. O

BACKGROUND O
: O
It O
is O
generally O
accepted O
that O
smoking O
increases O
RARE O
pressure O
and O
inhibits O
muscle O
sympathetic O
nerve O
activity O
( O
ALL_CAP O
). O

When O
the O
RARE O
pressure O
increase O
in O
response O
to O
smoking O
was O
RARE O
by O
RARE O
infusion O
, O
there O
was O
a O
striking O
increase O
in O
muscle O
ALL_CAP O
. O

After O
that O
report O
, O
RARE I-GENE
D I-GENE
( O
ALL_CAP I-GENE
) O
was O
subsequently O
RARE O
from O
bovine O
pituitary O
and O
characterized O
RARE O
a O
novel O
RARE I-GENE
E I-GENE
( O
ALL_CAP I-GENE
)- O
like O
enzyme O
, O
with O
many O
characteristics O
in O
common O
with O
RARE O
NUM I-GENE
( O
RARE O
, O
L O
., O
RARE O
, O
L O
. O
D O
., O
1995 O
. O

ALL_CAP O
- O
treatment O
of O
these O
transfectants O
RARE O
morphologic O
and O
RARE O
RARE O
, O
changes O
in O
ALL_CAP O
- O
regulated O
genes O
, O
and O
a O
G1 O
cell O
RARE O
arrest O
in O
a O
manner O
similar O
to O
parental O
NUM O
/ O
NUM O
cells O
. O

The O
RARE O
and O
RARE O
did O
not O
RARE O
differ O
between O
RARE O
tumors O
derived O
from O
NUM I-GENE
over O
- O
expressing O
versus O
control O
transfectants O
. O

For O
smaller O
vessels O
RARE O
to O
a O
diameter O
of O
NUM O
. O
5 O
mm O
, O
treatments O
RARE O
16 O
and O
18 O
ALL_CAP O
/ O
cm2 O
showed O
good O
results O
in O
NUM O
and O
82 O
% O
respectively O
; O
RARE O
vessels O
RARE O
to O
1 O
mm O
in O
NUM O
and O
NUM O
%. O

RARE O
ulcers O
. O

RXR I-GENE
- I-GENE
gamma I-GENE
RARE O
produced O
significant O
reduction O
in O
levels O
of O
ALL_CAP O
- O
responsive O
genes O
including O
the O
RARE I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
RARE O
NUM I-GENE
/ O
WAF1 I-GENE
and O
NUM I-GENE
, O
resulting O
in O
increased O
cdc2 I-GENE
and O
cdk2 I-GENE
kinase I-GENE
activity O
and O
ALL_CAP I-GENE
RARE O
. O

TBP I-GENE
can O
be O
RARE O
in O
vitro O
by O
extracts O
of O
U937 O
cells O
or O
by O
bacterially O
RARE O
activated O
ERK2 I-GENE
; O
the O
RARE O
sites O
were O
mapped O
to O
ERK I-GENE
kinase I-GENE
consensus I-GENE
sites I-GENE
in O
the O
TBP I-GENE
amino I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
. O

During O
the O
ALL_CAP O
/ O
ALL_CAP O
diet O
only O
the O
ALL_CAP O
subjects O
did O
not O
show O
the O
stress O
- O
RARE O
rise O
in O
depression O
, O
decline O
in O
RARE O
and O
cortisol O
elevation O
that O
they O
showed O
after O
the O
PR O
/ O
CP O
diet O
. O

RARE O
ALL_CAP O
and O
ALL_CAP O
values O
decreased O
with O
increasing O
exposure O
time O
with O
rate O
constants O
ranging O
from O
NUM O
. O
03 O
to O
NUM O
. O
NUM O
day O
- O
1 O
( O
RARE O
and O
RARE O
RARE O
) O
RARE O
ALL_CAP O
and O
NUM O
. O
03 O
to O
NUM O
. O
NUM O
day O
- O
1 O
RARE O
ALL_CAP O
. O

These O
sequence O
analyses O
suggest O
that O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
is O
a O
novel O
RARE O
of O
the O
IRS I-GENE
family I-GENE
rather O
than O
a O
Xenopus O
homolog O
of O
an O
existing O
RARE O
. O

The O
present O
study O
sought O
to O
develop O
an O
equation O
to O
estimate O
NUM O
in O
peripheral O
arterial O
RARE O
RARE O
( O
ALL_CAP O
) O
patients O
with O
intermittent O
RARE O
and O
to O
determine O
independent O
predictors O
of O
NUM O
in O
this O
population O
. O

Evidence O
RARE O
a O
novel O
ALL_CAP I-GENE
- O
independent O
RARE O
controlling O
the O
stress O
activated O
NUM I-GENE
/ O
NUM I-GENE
MAP O
kinase O
in O
RARE O
yeast O
. O

The O
RARE O
RARE O
Scale O
( O
ALL_CAP O
RARE O
RARE O
RARE O
Scale O
and O
ALL_CAP O
RARE O
comprise O
a O
RARE O
sound O
RARE O
RARE O
the O
analysis O
of O
injuries O
and O
RARE O
patients O
. O

This O
hypothesis O
was O
tested O
by O
RARE O
mutations O
RARE O
each O
of O
the O
three O
RARE O
RARE O
, O
the O
NUM O
- O
X2 O
- O
NUM O
RARE O
, O
the O
NUM O
- O
X2 O
- O
NUM O
RARE O
and O
the O
NUM O
- O
NUM O
- O
NUM O
RARE O
, O
which O
constitute O
the O
RARE O
- O
rich O
region O
near O
the O
C O
terminus O
of O
NUM I-GENE
. O

Using O
backcross O
analysis O
, O
both O
exons O
1 O
and O
4 O
mapped O
to O
a O
proximal O
region O
of O
murine O
RARE O
4 O
indistinguishable O
from O
the O
RARE I-GENE
gene I-GENE
. O

Seventy O
- O
five O
percent O
of O
children O
who O
received O
a O
second O
transplant O
RARE O
HCV O
hepatitis O
had O
early O
histologic O
recurrence O
that O
led O
to O
liver O
failure O
and O
RARE O
. O

However O
, O
both O
TPN O
groups O
showed O
a O
marked O
increase O
in O
activities O
of O
liver O
RARE I-GENE
RARE I-GENE
. O

Regulation O
of O
RARE O
growth O
and O
RARE O
targeting O
by O
the O
imprinted O
NUM I-GENE
/ O
RARE I-GENE
gene O
. O

Furthermore O
, O
we O
demonstrated O
that O
NUM I-GENE
NUM I-GENE
RARE O
Src I-GENE
family I-GENE
kinase O
activity O
and O
RARE O
tyrosine O
RARE O
of O
several O
proteins O
in O
ALL_CAP O
- O
293 O
cells O
. O

The O
RARE O
pressure O
was O
significantly O
decreased O
only O
after O
injection O
with O
ALL_CAP O
- O
4 O
in O
both O
normal O
and O
RARE O
rats O
. O

RARE I-GENE
RARE I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
( O
ALL_CAP I-GENE
) O
modulate O
transcription O
by O
binding O
to O
specific O
RARE O
RARE O
- O
response O
elements O
( O
ALL_CAP O
) O
through O
heterodimerization O
with O
the O
9 I-GENE
- I-GENE
cis I-GENE
retinoic I-GENE
acid I-GENE
receptor I-GENE
( O
RXR I-GENE
). O

Furthermore O
, O
early O
- O
and O
RARE O
- O
RARE O
origins O
differ O
not O
in O
the O
timing O
of O
their O
recruitment O
of O
an O
RARE I-GENE
protein I-GENE
, O
but O
in O
the O
timing O
of O
RPA I-GENE
' I-GENE
s I-GENE
recruitment O
. O

Thus O
, O
in O
the O
presence O
of O
RARE I-GENE
S I-GENE
- I-GENE
RARE I-GENE
and O
NUM I-GENE
/ O
NUM I-GENE
, O
RARE I-GENE
may O
RARE O
origins O
and O
thereby O
facilitate O
the O
loading O
of O
RPA I-GENE
. O

RARE O
RARE O
RARE I-GENE
RARE O
and O
RARE O
into O
the O
nucleus O
to O
activate O
specific O
genes O
. O

RARE O
substitution O
in O
RARE O
sperm O
fertilization O
genes O
RARE O
substitution O
in O
RARE O
and O
mitochondrial O
DNA O
. O

Gel O
retardation O
assays O
detected O
ALL_CAP I-GENE
- O
dependent O
complexes O
forming O
with O
the O
RARE I-GENE
operator I-GENE
- I-GENE
promoter I-GENE
and O
ALL_CAP I-GENE
- O
DNA O
binding O
was O
RARE O
by O
treatment O
with O
a O
metal O
- O
RARE O
in O
vitro O
. O

CONCLUSION O
: O
Although O
quantitative O
and O
qualitative O
criteria O
RARE O
RARE O
fatty O
liver O
on O
helical O
ALL_CAP O
can O
be O
determined O
, O
they O
are O
protocol O
- O
specific O
. O

The O
PC O
- O
based O
ALL_CAP O
is O
designed O
to O
run O
in O
the O
RARE O
RARE O
3 O
. O
11 O
environment O
( O
and O
later O
RARE O
RARE O
RARE O
RARE O
RARE O
with O
NUM O
or O
RARE O
RARE O
. O

RARE O
, O
the O
RARE O
in O
apparent O
regulatory O
action O
of O
the O
genes O
may O
indicate O
allelic O
differences O
RARE O
the O
NUM I-GENE
NUM I-GENE
allele I-GENE
may O
differ O
from O
alleles O
of O
RARE O
lines O
by O
the O
RARE O
to O
regulate O
both O
NUM I-GENE
and O
NUM I-GENE
RARE O
activities O
. O

ALL_CAP O
revised O
interpretation O

Molecular O
cloning O
and O
RARE O
characterization O
of O
murine I-GENE
RARE I-GENE
kinase I-GENE
. O

A O
human O
NUM I-GENE
- O
NUM I-GENE
- O
NUM I-GENE
- O
L I-GENE
RARE I-GENE
complex O
distinct O
from O
transcription I-GENE
factor I-GENE
ALL_CAP I-GENE
. O

RARE O
RARE O
steady O
- O
state O
levels O
of O
M I-GENE
- I-GENE
ALL_CAP I-GENE
I I-GENE
mRNA I-GENE
4 O
. O
5 O
- O
RARE O
. O

Mapping O
of O
the O
DNA O
binding O
domain O
of O
the O
RARE O
- O
responsive O
transcription O
factor O
NUM I-GENE
from I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

A O
further O
mechanism O
increasing O
specific O
activation O
was O
cooperation O
of O
receptors O
RARE O
multiple O
and O
weak O
RARE O
, O
which O
was O
RARE O
in O
the O
presence O
of O
both O
the O
ALL_CAP I-GENE
N O
terminus O
and O
RARE O
binding O
domain O
. O

Previously O
, O
we O
characterized O
a O
DNA O
- O
binding O
protein O
, O
NUM I-GENE
, O
that O
RARE O
tightly O
to O
a O
RARE O
region O
within O
RARE O
site O
2 O
( O
NUM O
) O
of O
the O
human I-GENE
beta I-GENE
- I-GENE
globin I-GENE
locus I-GENE
control I-GENE
region I-GENE
( O
ALL_CAP O
) O
( O
RARE O
, O
L O
. O

The O
CBF1 I-GENE
site I-GENE
within O
NUM O
resides O
near O
sites O
RARE O
hematopoietic O
RARE O
such O
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
ALL_CAP I-GENE
- I-GENE
E2 I-GENE
, O
and O
NUM I-GENE
. O

The O
rat I-GENE
RARE I-GENE
- I-GENE
chain I-GENE
- I-GENE
2 I-GENE
- I-GENE
RARE I-GENE
- I-GENE
acid I-GENE
dehydrogenase I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
kinase I-GENE
mRNA I-GENE
is O
RARE O
from O
a O
TATA O
- O
less O
promoter O
that O
has O
ALL_CAP O
- O
rich O
sequences O
and O
two O
putative O
NUM I-GENE
binding I-GENE
sites I-GENE
near O
the O
transcription O
RARE O
site O
. O

Co O
- O
transfection O
of O
the O
NUM I-GENE
RARE O
RARE O
and O
the O
- O
58 O
promoter O
construct O
into O
Drosophila O
RARE O
cells O
revealed O
that O
NUM I-GENE
contributed O
to O
the O
kinase O
basal O
promoter O
activity O
by O
binding O
to O
the O
non O
- O
consensus O
site O
in O
the O
- O
58 O
region O
. O

RARE O
such O
investigations O
are O
performed O
, O
we O
conclude O
that O
the O
role O
RARE O
adjuvant O
treatment O
is O
RARE O
and O
that O
ALL_CAP O
surgery O
is O
preferred O
RARE O
the O
treatment O
RARE O
RARE O
Stage O
NUM O
- O
NUM O
rectal O
cancers O
. O

RARE O
, O
RARE O
NUM O
degrees O
C O
with O
2 O
% O
ALL_CAP O
the O
surface O
density O
of O
NH2 O
groups O
reached O
a O
maximum O
RARE O
NUM O
hr O
and O
remained O
relatively O
constant O
RARE O
to O
96 O
hr O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
the O
cooperation O
of O
transcription I-GENE
factors I-GENE
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
is O
essential O
RARE O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
8 I-GENE
gene I-GENE
by O
ALL_CAP I-GENE
- I-GENE
I I-GENE
RARE I-GENE
. O

This O
study O
RARE O
the O
cooperative O
effects O
of O
a O
human O
estrogen I-GENE
receptor I-GENE
- I-GENE
alpha I-GENE
( O
RARE I-GENE
) O
isoform O
on O
estrogen O
( O
E2 O
)- O
RARE O
gene O
activation O
in O
NUM O
- O
ALL_CAP O
osteosarcoma O
cells O
. O

Transfection O
of O
increasing O
amounts O
of O
NUM I-GENE
RARE O
vector O
into O
RARE O
RARE I-GENE
RARE O
ALL_CAP O
cells O
resulted O
in O
potentiation O
of O
E2 O
- O
RARE O
RARE I-GENE
activity O
in O
a O
synergistic O
, O
dose O
- O
dependent O
manner O
. O

Studies O
using O
the O
yeast O
two O
- O
RARE O
RARE O
also O
did O
not O
provide O
evidence O
RARE O
the O
formation O
of O
a O
VDR I-GENE
- O
TR I-GENE
protein O
- O
protein O
interaction O
. O

Our O
results O
show O
that O
, O
from O
a O
RARE O
RARE O
, O
melatonin O
may O
directly O
RARE O
RARE O
radicals O
both O
in O
RARE O
and O
in O
aqueous O
solution O
. O

This O
sequence O
, O
RARE O
- O
RARE O
- O
X O
- O
X O
- O
RARE O
- O
RARE O
- O
RARE O
- O
RARE O
- O
Ile O
- O
RARE O
, O
forms O
part O
of O
the O
B O
- O
loop O
and O
is O
RARE O
in O
a O
wide O
variety O
of O
organisms O
that O
include O
bacteria O
, O
RARE O
and O
RARE O
. O

We O
did O
not O
observe O
any O
changes O
in O
Bcl I-GENE
- I-GENE
2 I-GENE
or O
Bcl I-GENE
- I-GENE
2 I-GENE
- I-GENE
related I-GENE
proteins I-GENE
( O
Bcl I-GENE
- I-GENE
RARE I-GENE
, O
RARE I-GENE
, O
and O
RARE I-GENE
) O
in O
control O
or O
ALL_CAP I-GENE
- O
transfected O
cells O
before O
or O
after O
treatment O
with O
RARE O
. O

RARE O
112 O
of O
latent I-GENE
membrane I-GENE
protein I-GENE
NUM I-GENE
is O
essential O
RARE O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
loading O
and O
RARE O
of O
Epstein O
- O
Barr O
virus O
RARE O
. O

The O
only O
abundant O
viral O
transcript O
RARE O
RARE O
RARE O
is O
the O
RARE I-GENE
- I-GENE
related I-GENE
( O
ALL_CAP I-GENE
) O
RNA O
. O

To O
improve O
test O
efficiency O
, O
we O
modified O
our O
previously O
introduced O
contrast O
/ O
color O
RARE O
test O
by O
including O
a O
RARE O
test O
stimulus O
and O
RARE O
the O
number O
of O
stimuli O
in O
both O
experimental O
phases O
. O

The O
defect O
in O
these O
proteins O
was O
also O
RARE O
suppressed O
by O
either O
NUM O
RARE O
or O
the O
RARE I-GENE
B I-GENE
protein I-GENE
in O
the O
presence O
of O
ATP O
and O
target O
DNA O
. O

Using O
homology O
cloning O
techniques O
, O
we O
identified O
a O
mouse O
homologue O
of O
E O
( O
RARE O
RARE O
termed O
NUM I-GENE
, O
a O
yeast O
protein O
that O
we O
RARE O
NUM I-GENE
, O
and O
RARE O
RARE O
RARE O
additional O
RARE O
from O
Caenorhabditis O
elegans O
, O
mice O
and O
humans O
. O

Second O
, O
the O
wild I-GENE
- I-GENE
type I-GENE
NUM I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
strongly O
reduces O
accumulation O
of O
heterologous O
transcripts O
in O
vivo O
, O
an O
activity O
that O
requires O
its O
K O
box O
sequences O
. O

In O
particular O
, O
RARE I-GENE
- I-GENE
NUM I-GENE
encodes O
a O
POU I-GENE
- I-GENE
type I-GENE
RARE I-GENE
protein I-GENE
needed O
RARE O
the O
production O
of O
the O
RARE O
cells O
, O
while O
RARE I-GENE
- I-GENE
3 I-GENE
encodes O
a O
LIM I-GENE
- I-GENE
type I-GENE
RARE I-GENE
protein I-GENE
needed O
RARE O
the O
differentiation O
of O
the O
RARE O
cells O
. O

During O
the O
NUM O
resuscitation O
period O
, O
extracellular O
RARE O
and O
RARE O
concentrations O
in O
the O
cerebral O
RARE O
were O
RARE O
RARE O
RARE O
resuscitation O
( O
p O
= O
NUM O
. O
NUM O
and O
p O
= O
NUM O
. O
NUM O
, O
respectively O
) O
than O
RARE O
resuscitation O
with O
21 O
% O
NUM O
or O
NUM O
% O
NUM O
, O
suggesting O
an O
RARE O
accumulation O
of O
potent O
RARE O
RARE O
RARE O
resuscitation O
. O

Expression O
of O
constitutively O
RARE O
NUM I-GENE
, O
the O
kinase O
that O
activates O
ERKs I-GENE
, O
or O
overexpression O
of O
ERK2 I-GENE
, O
but O
not O
JNK1 I-GENE
, O
inhibited O
Stat3 I-GENE
activation O
. O

RARE I-GENE
and O
ERKs I-GENE
inhibited O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
activation O
of O
Stat3 I-GENE
harboring O
a O
mutation O
RARE O
serine O
- O
NUM O
, O
the O
major O
site O
RARE O
serine O
RARE O
, O
similar O
to O
inhibition O
of O
wild I-GENE
- I-GENE
type I-GENE
Stat3 I-GENE
, O
and O
inhibited O
Janus I-GENE
kinases I-GENE
NUM I-GENE
and O
NUM I-GENE
upstream O
of O
Stat3 I-GENE
in O
the O
Jak I-GENE
- O
STAT I-GENE
- O
RARE O
RARE O
. O

Furthermore O
, O
RARE O
( O
3 O
, O
4 O
, O
5 O
) O
RARE O
specifically O
stimulates O
the O
activity O
of O
ILK I-GENE
in O
vitro O
, O
and O
in O
addition O
, O
membrane O
RARE O
constitutively O
RARE O
RARE I-GENE
( I-GENE
3 I-GENE
) I-GENE
K I-GENE
activates O
ILK I-GENE
in O
vivo O
. O

Transfection O
and O
in O
vitro O
binding O
studies O
identified O
within O
NUM I-GENE
a I-GENE
promoter I-GENE
whose O
basal O
activity O
required O
a O
ALL_CAP O
box O
activated O
by O
NUM I-GENE
or O
Sp3 I-GENE
. O

Plasma O
was O
tested O
before O
and O
after O
( O
14 O
+/- O
7 O
. O
5 O
RARE O
SD O
] O
days O
) O
surgery O
RARE O
IgG I-GENE
antibodies I-GENE
to O
the O
complex O
of O
RARE I-GENE
/ I-GENE
platelet I-GENE
factor I-GENE
4 I-GENE
, O
using O
a O
standardized O
, O
RARE O
enzyme O
- O
RARE O
immunosorbent O
assay O
( O
ELISA O
). O

RARE O
RARE O
in O
the O
distal O
RARE O
fiber O
locus O
of O
the O
T O
- O
even O
RARE O
: O
RARE O
between O
RARE O
motifs O
RARE O
RARE I-GENE
RARE O
. O

The O
ALL_CAP I-GENE
promoter I-GENE
was O
RARE O
- O
regulated O
by O
insulin I-GENE
through O
the O
proximal O
insulin I-GENE
response I-GENE
sequence I-GENE
containing O
an O
E O
- O
box O
motif O
RARE O
the O
- O
65 O
- O
RARE O
RARE O
position O
. O

The O
effect O
of O
independent O
predictors O
on O
survival O
was O
examined O
in O
a O
Cox O
regression O
model O
with O
adjustment O
RARE O
existing O
RARE O
. O

Effects O
of O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
on O
RARE O
functions O
and O
survival O
in O
sepsis O
RARE O
diabetic O
rats O
. O

OBJECTIVE O
: O
The O
purpose O
of O
this O
article O
is O
to O
review O
balance O
instruments O
developed O
within O
the O
past O
10 O
years O
that O
can O
be O
used O
in O
the O
RARE O
or O
home O
environment O
. O

ALL_CAP O
ALL_CAP O
: O
We O
observed O
a O
congenital O
RARE O
defect O
RARE O
exclusively O
on O
the O
trunk O
. O

Whereas O
, O
in O
the O
single O
- O
RARE O
body O
box O
, O
ALL_CAP O
RARE O
( O
RARE O
RARE O
) O
reflect O
" O
effort O
of O
breathing O
RARE O
This O
is O
measured O
RARE O
the O
RARE O
between O
RARE O
and O
RARE O
. O

RARE O
is O
the O
RARE O
aromatase I-GENE
inhibitor O
to O
show O
a O
significant O
survival O
advantage O
over O
RARE O
RARE O
in O
post O
- O
RARE O
women O
with O
advanced O
breast O
RARE O
. O

ALL_CAP O
. O

RARE O
) O
and O
contains O
RARE O
- O
ALL_CAP O
. O

Mutation O
of O
either O
the O
AP I-GENE
- I-GENE
1 I-GENE
or O
the O
ets I-GENE
RARE O
of O
this O
site O
also O
prevented O
promoter O
activity O
in O
RARE O
. O

ALL_CAP O
: O
Fifty O
dogs O
with O
naturally O
developing O
DM O
. O

Surprisingly O
, O
double O
mutants O
of O
the O
NUM I-GENE
- I-GENE
NUM I-GENE
mutant I-GENE
with O
the O
RARE I-GENE
- O
RARE O
mutants O
NUM I-GENE
, O
NUM I-GENE
( O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
) O
and O
NUM I-GENE
- I-GENE
1 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
) O
showed O
RARE O
RARE O
response O
in O
RARE O
with O
a O
longer O
RARE O
, O
a O
longer O
RARE O
RARE O
, O
and O
a O
lower O
level O
RARE O
of O
the O
ALL_CAP I-GENE
gene I-GENE
than O
the O
NUM I-GENE
- I-GENE
NUM I-GENE
single I-GENE
mutant I-GENE
. O

This O
suggests O
that O
while O
RARE O
of O
pain O
do O
not O
RARE O
more O
, O
disruption O
on O
RARE O
tasks O
and O
physiological O
impact O
are O
RARE O
. O

RARE O
ablation O
has O
been O
employed O
RARE O
a O
therapeutic O
measure O
RARE O
chronic O
pulmonary O
emphysema O
. O

The O
NUM O
- O
containing O
RARE O
protein O
NUM I-GENE
interacts O
with O
ALL_CAP I-GENE
- O
ABL I-GENE
. O

Saccharomyces O
cerevisiae O
contains O
four O
known O
RARE I-GENE
- I-GENE
CoA I-GENE
synthetases I-GENE
( O
fatty I-GENE
acid I-GENE
activation I-GENE
proteins I-GENE
, O
RARE I-GENE
). O

We O
recently O
reported O
a O
placenta O
- O
specific O
enhancer O
in O
the O
human I-GENE
leukemia I-GENE
RARE I-GENE
factor I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
) O
gene O
and O
now O
show O
detailed O
characterization O
of O
the O
NUM O
- O
RARE O
RARE O
enhancer O
RARE O
NUM O
/- O
NUM O
nucleotides O
). O

Copyright O
1998 O
RARE O
RARE O
B O
. O
V O
. O

It O
may O
be O
time O
to O
RARE O
the O
RARE O
between O
AD O
and O
ALL_CAP O
. O

RARE O
NUM O
was O
a O
homolog O
of O
ALL_CAP I-GENE
, O
which O
is O
a O
gene O
involved O
in O
controlling O
the O
RARE O
time O
in O
Arabidopsis O
. O

RARE O
and O
RARE O
( O
RARE O
RARE O
1 O
( O
1 O
RARE O
3 O
- O
11 O
, O
1985 O
) O
showed O
that O
a O
thin O
vertical O
line O
induces O
RARE O
RARE O
of O
RARE O
and O
RARE O
; O
this O
study O
RARE O
those O
results O
by O
more O
closely O
examining O
the O
horizontal O
and O
vertical O
RARE O
of O
the O
RARE O
zone O
and O
by O
using O
an O
RARE O
RARE O
to O
induce O
RARE O
. O

The O
effects O
of O
high O
intensity O
light O
RARE O
, O
produced O
by O
a O
novel O
pulsed O
power O
RARE O
technique O
( O
ALL_CAP O
RARE O
on O
the O
survival O
of O
bacterial O
populations O
of O
RARE O
Escherichia O
coli O
( O
RARE O
NUM O
: O
NUM O
) O
and O
RARE O
monocytogenes O
( O
RARE O
NUM O
) O
were O
investigated O
. O

Multiple O
chemical O
sensitivity O
( O
ALL_CAP O
) O
is O
a O
RARE O
in O
which O
multiple O
symptoms O
RARE O
occur O
with O
low O
- O
level O
chemical O
exposure O
. O

POU I-GENE
- I-GENE
domain I-GENE
proteins I-GENE
, O
such O
RARE O
the O
pituitary I-GENE
- I-GENE
specific I-GENE
factor I-GENE
Pit I-GENE
- I-GENE
1 I-GENE
, O
are O
members O
of O
the O
RARE I-GENE
family I-GENE
of O
proteins O
which O
are O
important O
in O
development O
and O
RARE O
, O
acting O
constitutively O
or O
in O
response O
to O
signal O
- O
RARE O
pathways O
to O
either O
repress O
or O
activate O
the O
RARE O
of O
specific O
genes O
. O

RARE O
- O
type O
and O
mutant O
MyoD I-GENE
were O
introduced O
into O
cells O
using O
an O
E1 I-GENE
, O
NUM I-GENE
- O
RARE O
RARE O
vector O
. O

These O
results O
suggest O
that O
NUM O
may O
play O
an O
important O
role O
in O
the O
RARE O
of O
MyoD I-GENE
function O
under O
conditions O
of O
high O
RARE O
. O

This O
and O
previous O
results O
suggest O
that O
the O
ALL_CAP O
and O
NUM I-GENE
site I-GENE
may O
synergistically O
activate O
ALL_CAP I-GENE
transcription O
in O
a O
promoter O
context O
- O
dependent O
manner O
. O

RARE O
was O
inactive O
. O

RARE O
examinations O
, O
peripheral O
RARE O
RARE O
cell O
( O
WBC O
) O
counts O
, O
and O
assays O
of O
RARE I-GENE
activity O
( O
ALL_CAP I-GENE
) O
in O
RARE O
of O
colon O
mucosa O
were O
performed O
after O
one O
week O
( O
4 O
% O
ALL_CAP O
model O
) O
and O
eight O
weeks O
( O
1 O
% O
ALL_CAP O
model O
). O

NUM O
transcription O
could O
be O
RARE O
to O
achieve O
different O
levels O
of O
RARE O
RARE O
, O
through O
the O
use O
of O
promoter O
mutations O
. O

The O
primers O
were O
degenerate O
sets O
of O
oligonucleotides O
derived O
from O
known O
amino O
acid O
sequences O
of O
the O
ALL_CAP I-GENE
precursor I-GENE
. O

RARE O
transformed O
with O
the O
NUM I-GENE
- O
1 I-GENE
- I-GENE
RARE I-GENE
construct O
accumulated O
the O
RARE O
1 O
- O
RARE O
( O
NUM O
RARE O
1 O
, O
1 O
- O
RARE O
( O
NUM O
) O
and O
1 O
, O
1 O
, O
1 O
- O
RARE O
( O
NUM O
). O

Based O
on O
the O
comparison O
of O
the O
predicted O
amino O
acid O
sequences O
of O
1 I-GENE
- I-GENE
RARE I-GENE
and O
1 I-GENE
- I-GENE
RARE I-GENE
with O
those O
of O
other O
RARE O
RARE I-GENE
transferase I-GENE
genes I-GENE
, O
we O
RARE O
that O
both O
RARE O
RARE I-GENE
genes I-GENE
have O
evolved O
from O
RARE O
RARE I-GENE
genes O
. O

However O
, O
NUM I-GENE
was O
RARE O
by O
ALL_CAP O
, O
and O
along O
with O
NUM I-GENE
induction O
there O
was O
a O
decrease O
in O
Cdc2 I-GENE
- I-GENE
like I-GENE
histone I-GENE
NUM I-GENE
kinase I-GENE
activity O
. O

A O
5 O
. O
NUM O
- O
kb O
transcript O
detected O
by O
the O
differential O
display O
RARE O
NUM O
was O
found O
to O
correlate O
strongly O
with O
NUM I-GENE
mRNA I-GENE
RARE O
in O
various O
human O
cell O
lines O
. O

The O
ALL_CAP I-GENE
gene I-GENE
was O
localized O
to O
the O
long O
RARE O
of O
RARE O
10 O
( O
NUM O
). O

Here O
, O
we O
report O
that O
NUM I-GENE
- I-GENE
1 I-GENE
is O
a O
new O
RARE O
- O
RARE O
allele O
of O
the O
clathrin I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
( O
NUM I-GENE
- I-GENE
5 I-GENE
RARE O
which O
carries O
a O
frameshift O
mutation O
near O
the O
3 O
' O
end O
of O
the O
NUM I-GENE
RARE O
reading O
frame O
. O

We O
have O
determined O
the O
RARE O
lesions O
of O
nine O
RARE I-GENE
mutant I-GENE
alleles I-GENE
, O
which O
identify O
RARE O
requirements O
RARE O
specific O
domains O
. O

RARE O
, O
three O
RARE O
RARE I-GENE
mutations O
, O
which O
map O
within O
an O
RARE I-GENE
repeat I-GENE
, O
interact O
with O
ALL_CAP I-GENE
mutations I-GENE
more O
strongly O
than O
do O
RARE I-GENE
RARE O
alleles O
. O

Northern O
analysis O
revealed O
RARE O
detectable O
RARE O
of O
the O
transcript O
in O
RARE O
- O
or O
RARE O
- O
programmed O
RARE O
larvae O
, O
and O
only O
RARE O
RARE O
in O
RARE O
RARE O
. O

RARE O
the O
characterization O
and O
discussion O
of O
the O
experimental O
RARE O
used O
, O
the O
rate O
constants O
obtained O
are O
discussed O
and O
compared O
with O
estimated O
values O
. O

Genomic O
locus O
of O
ALL_CAP I-GENE
contains O
a O
ALL_CAP O
- O
rich O
RARE O
RARE O
separated O
from O
RARE O
coding O
exons O
by O
a O
long O
intron O
. O

The O
presence O
of O
PDZ I-GENE
and O
ALL_CAP O
domains O
in O
the O
NUM I-GENE
protein I-GENE
suggests O
that O
it O
may O
act O
RARE O
a O
RARE O
RARE O
, O
RARE O
and O
RARE O
RARE O
in O
a O
signal O
RARE O
RARE O
. O

BACKGROUND O
: O
RARE O
( O
ALL_CAP O
) O
are O
RARE O
in O
children O
because O
of O
the O
risk O
of O
cartilage O
damage O
. O

In O
analyses O
with O
control O
RARE O
multiple O
variables O
, O
relative O
risk O
RARE O
RARE O
( O
RARE O
albumin I-GENE
excretion O
, O
20 O
- O
NUM O
microg O
/ O
min O
) O
in O
men O
and O
women O
was O
2 O
. O
NUM O
and O
1 O
. O
NUM O
, O
respectively O
, O
with O
18 O
mm O
Hg O
RARE O
( O
1 O
SD O
) O
systolic O
RARE O
pressure O
; O
2 O
. O
NUM O
and O
2 O
. O
10 O
, O
respectively O
, O
with O
1 O
. O
NUM O
- O
mmol O
/ O
L O
( O
40 O
mg O
/ O
dL O
) O
RARE O
plasma O
cholesterol O
level O
; O
1 O
. O
NUM O
and O
1 O
. O
91 O
, O
respectively O
, O
RARE O
smokers O
RARE O
RARE O
; O
and O
1 O
. O
NUM O
and O
1 O
. O
NUM O
, O
respectively O
, O
with O
4 O
kg O
/ O
m2 O
RARE O
body O
mass O
index O
. O

However O
, O
while O
ALL_CAP I-GENE
- I-GENE
1beta I-GENE
and O
TNF I-GENE
- I-GENE
alpha I-GENE
both O
RARE O
nuclear O
binding O
of O
the O
Rel I-GENE
proteins I-GENE
NUM I-GENE
and O
NUM I-GENE
to O
an O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
consensus I-GENE
RARE I-GENE
in O
gel O
shift O
assays O
and O
caused O
transient O
RARE O
of O
inhibitor I-GENE
of I-GENE
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
alpha I-GENE
( O
ALL_CAP I-GENE
- I-GENE
alpha I-GENE
) O
in O
the O
cytoplasm O
of O
RARE O
, O
only O
ALL_CAP I-GENE
- I-GENE
1beta I-GENE
RARE O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
. O

RARE O
with O
ATF I-GENE
- I-GENE
2 I-GENE
and O
HNF I-GENE
- I-GENE
4 I-GENE
RARE O
plasmids O
resulted O
in O
additive O
RARE O
of O
the O
ALL_CAP I-GENE
promoter I-GENE
. O

RARE O
hydrolysis O
RARE O
RARE O
exercise O
: O
the O
effect O
of O
NUM O
. O

RARE O
shifts O
arise O
from O
the O
RARE O
RARE O
average O
of O
the O
RARE O
coupling O
between O
RARE O
electron O
and O
nuclei O
, O
in O
the O
presence O
of O
magnetic O
RARE O
RARE O
. O

ALL_CAP I-GENE
- I-GENE
1 I-GENE
is O
RARE O
in O
many O
tissues O
, O
but O
is O
RARE O
in O
retina O
and O
brain O
. O

The O
interaction O
of O
NUM I-GENE
- I-GENE
NUM I-GENE
with O
the O
ALL_CAP I-GENE
proteins I-GENE
is O
confirmed O
further O
in O
vitro O
using O
a O
blot O
RARE O
assay O
. O

The O
major O
RARE O
resulting O
from O
NUM I-GENE
kinase I-GENE
inactivation O
include O
RARE O
- O
RARE O
growth O
, O
vacuolar O
acidification O
defects O
, O
and O
dramatic O
increases O
in O
vacuolar O
size O
. O

RARE I-GENE
GTPases I-GENE
of O
the O
RARE I-GENE
/ O
RARE I-GENE
family O
are O
involved O
in O
the O
RARE O
of O
vesicular O
RARE O
. O

The O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
activities O
RARE O
NUM I-GENE
localize O
to O
particulate O
cellular O
fractions O
. O

RARE I-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
( O
ALL_CAP I-GENE
) O
catalyzes O
the O
conversion O
of O
dopamine O
to O
noradrenaline O
and O
is O
selectively O
RARE O
in O
noradrenergic O
and O
adrenergic O
neurons O
and O
RARE O
cells O
. O

Collectively O
, O
this O
study O
emphasizes O
a O
critical O
role O
of O
NUM I-GENE
RARE O
RARE O
RARE O
its O
RARE O
RARE O
with O
other O
transcription O
factors O
( O
RARE O
. O
g O
., O
CREB I-GENE
, O
AP2 I-GENE
, O
and O
NUM I-GENE
) O
in O
transcriptional O
activation O
of O
the O
ALL_CAP I-GENE
gene I-GENE
. O

Interestingly O
, O
an O
antibody O
against O
N I-GENE
- I-GENE
RARE I-GENE
can O
abrogate O
RARE I-GENE
- I-GENE
LDL I-GENE
- O
and O
TNF I-GENE
- I-GENE
alpha I-GENE
- O
RARE O
apoptosis O
and O
therefore O
may O
be O
useful O
RARE O
in O
vivo O
studies O
of O
apoptosis O
in O
experimental O
animals O
. O

We O
found O
that O
virulent O
RARE O
strains O
induce O
RARE O
and O
activation O
of O
JNK I-GENE
but O
not O
of O
p38 I-GENE
kinase O
. O

RARE O
RARE O
of O
classical O
light O
RARE O
elements O
of O
the O
cell O
division O
machinery O
and O
switch O
the O
RARE O
of O
hearts O
on O
a O
cellular O
basis O
. O

The O
human O
T O
cell O
RARE O
RARE O
type O
I O
( O
ALL_CAP O
- O
I O
) O
RARE O
- O
activator O
, O
RARE I-GENE
, O
interacts O
specifically O
with O
the O
basic I-GENE
- I-GENE
domain I-GENE
/ I-GENE
leucine I-GENE
- I-GENE
zipper I-GENE
( I-GENE
RARE I-GENE
) I-GENE
protein I-GENE
, O
cAMP I-GENE
response I-GENE
element I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
RARE O
RARE O
to O
the O
viral I-GENE
RARE I-GENE
- I-GENE
responsive I-GENE
element I-GENE
consisting O
of O
three O
RARE O
21 O
- O
RARE O
RARE O
repeats O
, O
each O
with O
a O
cAMP O
response O
element O
core O
flanked O
by O
G O
/ O
C O
- O
rich O
sequences O
. O

This O
sequence O
is O
very O
similar O
to O
the O
insulin I-GENE
response I-GENE
sequence I-GENE
found O
in O
the O
regulatory O
region O
of O
other O
genes O
negatively O
regulated O
by O
insulin I-GENE
such O
RARE O
those O
encoding O
phosphoenolpyruvate I-GENE
RARE I-GENE
, O
tyrosine I-GENE
aminotransferase I-GENE
, O
and O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
. O

The O
murine I-GENE
RARE I-GENE
glucose I-GENE
RARE I-GENE
isoform I-GENE
3 I-GENE
( O
RARE I-GENE
3 I-GENE
) O
is O
developmentally O
regulated O
and O
is O
predominantly O
RARE O
in O
neurons O
and O
RARE O
. O

However O
, O
changing O
the O
RARE O
- O
site O
to O
the O
consensus O
sequence O
ALL_CAP O
( O
RARE O
- O
1 O
) O
increased O
binding O
of O
ALL_CAP I-GENE
. I-GENE
ALL_CAP I-GENE
10 O
- O
RARE O
over O
RARE O
- O
1 O
and O
, O
RARE O
the O
same O
time O
, O
RARE O
the O
RARE O
of O
the O
spacer O
length O
requirement O
, O
with O
RARE O
- O
NUM O
to O
RARE O
- O
5 O
showing O
detectable O
binding O
. O

The O
levels O
of O
RARE O
are O
correlated O
with O
the O
respective O
binding O
affinities O
of O
the O
response O
elements O
( O
RARE O
- O
1 O
> O
ALL_CAP O
- O
4 O
> O
RARE O
- O
1 O
). O

The O
high O
density O
of O
RARE O
RARE O
on O
posterior O
RARE O
of O
the O
body O
and O
the O
distribution O
of O
type O
II O
RARE O
on O
dorsal O
surface O
are O
considered O
to O
be O
characteristic O
of O
C O
. O
RARE O
. O

RARE O
of O
p53 I-GENE
but O
not O
NUM I-GENE
by O
adenovirus I-GENE
type I-GENE
5 I-GENE
E1B I-GENE
NUM I-GENE
- I-GENE
RARE I-GENE
and I-GENE
NUM I-GENE
NUM I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
. O

The O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
RARE I-GENE
Zta I-GENE
triggers O
lytic O
gene O
RARE O
and O
is O
essential O
RARE O
replication O
of O
the O
lytic O
origin O
, O
RARE O
. O

Cotransfection O
of O
the O
RARE I-GENE
- O
primase I-GENE
proteins O
, O
one O
of O
which O
was O
fused O
to O
a O
heterologous O
activation O
domain O
, O
led O
to O
Zta I-GENE
- O
dependent O
RARE O
of O
CAT I-GENE
RARE O
. O

Sequence O
comparisons O
strongly O
suggest O
that O
the O
NUM I-GENE
and O
the O
ubiquitin I-GENE
coding O
sequences O
found O
in O
the O
genome O
of O
CP O
RARE O
were O
both O
derived O
from O
a O
bovine O
mRNA O
encoding O
a O
RARE O
protein O
with O
the O
RARE O
NH2 O
- O
ubiquitin I-GENE
- O
NUM I-GENE
- O
ALL_CAP O
. O

ALL_CAP O
. O

There O
was O
a O
trend O
in O
all O
studies O
RARE O
ALL_CAP O
. O

A O
single O
rectal O
dose O
of O
NUM O
mg O
/ O
kg O
will O
obtain O
this O
lower O
concentration O
within O
1 O
h O
of O
administration O
and O
maintain O
it O
RARE O
RARE O
to O
6 O
h O
. O

This O
domain O
, O
although O
adjacent O
to O
the O
5 O
' O
RARE O
of O
the O
SD O
sequence O
, O
does O
not O
inhibit O
RARE O
binding O
RARE O
long O
RARE O
the O
single O
- O
RARE O
region O
of O
domain O
3 O
is O
present O
. O

Although O
ALL_CAP I-GENE
is O
a O
highly O
RARE O
PTP I-GENE
, O
it O
preferentially O
RARE O
a O
subset O
of O
tyrosine O
- O
RARE O
proteins O
in O
RARE O
cells O
, O
including O
NUM I-GENE
. O

RARE O
position O
of O
the O
RARE O
within O
the O
RARE O
revealed O
by O
analysis O
of O
NUM I-GENE
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
sequences I-GENE
. O

Previous O
genetic O
studies O
led O
to O
the O
conclusion O
that O
RARE O
and O
RARE O
induction O
of O
ALL_CAP I-GENE
operon I-GENE
RARE O
is O
determined O
by O
a O
transcriptional O
RARE O
mechanism O
. O

The O
activation O
and O
injury O
of O
endothelial O
cells O
RARE O
by O
TNF I-GENE
and O
other O
RARE O
RARE O
may O
RARE O
the O
local O
effects O
of O
these O
RARE O
in O
vivo O
. O

A O
technique O
RARE O
thermal O
imaging O
of O
the O
RARE O
and O
human O
brain O
cortex O
using O
an O
RARE O
optical O
RARE O
is O
described O
. O

EGFR I-GENE
levels O
were O
found O
to O
be O
elevated O
5 O
RARE O
3 O
. O

Here O
we O
demonstrate O
that O
ALL_CAP I-GENE
ALL_CAP I-GENE
contains O
a O
motif O
( O
ALL_CAP O
) O
RARE O
amino O
acid O
positions O
NUM O
- O
193 O
that O
represents O
a O
classical O
bipartite O
nuclear O
RARE O
signal O
( O
NLS O
). O

As O
PP2A I-GENE
exerts O
a O
range O
of O
cellular O
functions O
including O
cell O
RARE O
RARE O
and O
cell O
fate O
determination O
, O
we O
were O
RARE O
to O
find O
that O
these O
RARE O
develop O
normally O
until O
RARE O
, O
around O
RARE O
day O
5 O
. O
5 O
/ O
6 O
. O
NUM O
. O

The O
most O
frequent O
risk O
factor O
RARE O
ischaemic O
was O
hypertension O
. O

The O
results O
indicate O
that O
RARE O
RARE O
B O
and O
RARE O
are O
weakly O
RARE O
. O

Furthermore O
, O
NUM I-GENE
gene I-GENE
mapped O
to O
RARE O
NUM O
, O
a O
region O
that O
has O
been O
involved O
RARE O
a O
chromosomal O
RARE O
in O
ALL_CAP O
. O

16 O
subjects O
were O
RARE O
tested O
to O
RARE O
RARE O
( O
RARE O
) O
and O
to O
solutions O
containing O
RARE O
mixed O
with O
L O
- O
cysteine O
and O
RARE O
, O
respectively O
. O

RARE I-GENE
- I-GENE
type I-GENE
NUM I-GENE
receptors I-GENE
, O
RARE O
in O
RARE O
hamster O
ovary O
cells O
, O
rapidly O
RARE O
after O
RARE I-GENE
II I-GENE
RARE O
RARE O
t1 O
/ O
2 O
2 O
. O
3 O
min O
; O
maximal O
level O
of O
internalization O
( O
Ymax O
) O
NUM O
. O
2 O
RARE O
RARE O
did O
mutant O
receptors O
carrying O
single O
RARE O
substitutions O
( O
NUM O
, O
t1 O
/ O
2 O
2 O
. O
7 O
min O
, O
Ymax O
NUM O
. O
3 O
%; O
NUM O
, O
t1 O
/ O
2 O
2 O
. O
4 O
min O
, O
Ymax O
NUM O
. O
7 O
%; O
NUM O
, O
t1 O
/ O
2 O
2 O
. O
5 O
min O
, O
Ymax O
NUM O
. O
2 O
%; O
NUM O
, O
t1 O
/ O
2 O
2 O
. O
6 O
min O
, O
Ymax O
NUM O
. O
4 O
%). O

The O
activated O
glucocorticoid I-GENE
receptor I-GENE
forms O
a O
complex O
with O
Stat5 I-GENE
and O
enhances O
Stat5 I-GENE
- O
RARE O
transcriptional O
induction O
. O

T O
., O
RARE O
, O
A O
., O
and O
RARE O
, O
G O
. O

The O
RARE O
- O
terminal O
portion O
of O
ALL_CAP I-GENE
contains O
three O
zinc O
RARE O
of O
the O
NUM O
- O
NUM O
type O
and O
binds O
in O
vitro O
to O
the O
ALL_CAP O
motif O
of O
the O
beta I-GENE
- I-GENE
globin I-GENE
promoter I-GENE
and O
to O
the O
NUM I-GENE
recognition I-GENE
sequence I-GENE
. O

We O
have O
recently O
identified O
a O
mouse O
enzyme O
termed O
gamma I-GENE
- I-GENE
glutamyl I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
that O
RARE O
RARE O
NUM O
( O
NUM O
) O
to O
RARE O
NUM O
( O
NUM O
). O

UGA O
RARE O
position O
affects O
the O
efficiency O
of O
RARE O
incorporation O
into O
RARE I-GENE
peroxidase I-GENE
- I-GENE
1 I-GENE
. O

RARE O
significantly O
RARE O
RARE I-GENE
- O
RARE O
RARE O
of O
RARE I-GENE
D I-GENE
and O
RARE O
of O
the O
RARE I-GENE
gene I-GENE
product I-GENE
. O

The O
ARF I-GENE
promoter I-GENE
was O
also O
found O
to O
be O
highly O
responsive O
to O
E2F1 I-GENE
RARE O
, O
in O
RARE O
with O
previous O
results O
RARE O
the O
RNA O
level O
. O

RESULTS O
: O
The O
binding O
of O
99mTc O
d O
, O
1 O
- O
HMPAO O
to O
human O
placenta O
ranged O
from O
2 O
. O
NUM O
% O
+/- O
1 O
. O
5 O
% O
to O
5 O
. O
82 O
% O
+/- O
NUM O
. O
3 O
% O
per O
1 O
ml O
standard O
solution O
. O

ALL_CAP O
RARE O
the O
nuclear O
binding O
activity O
of O
transcription I-GENE
factor I-GENE
AP I-GENE
- I-GENE
1 I-GENE
. O

ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
, O
which O
is O
probably O
important O
RARE O
basal O
activity O
of O
the O
human I-GENE
ALL_CAP I-GENE
II I-GENE
promoter I-GENE
, O
is O
unlikely O
to O
function O
RARE O
a O
major O
effector O
of O
ALL_CAP O
in O
ALL_CAP O
- O
1 O
cells O
. O

RARE O
with O
brain O
injury O
and O
control O
RARE O
performed O
a O
RARE O
task O
RARE O
which O
they O
received O
RARE O
RARE O
of O
RARE O
air O
or O
air O
RARE O
with O
RARE O
. O

A O
simple O
RARE O
method O
RARE O
RARE O
- O
RARE O
by O
high O
- O
performance O
liquid O
chromatography O
with O
a O
RARE O
RARE O
detector O
was O
established O
. O

RESULTS O
: O
The O
cardiac O
index O
significantly O
changed O
with O
varying O
PaCO2 O
levels O
( O
RARE O
, O
- O
9 O
%; O
hypercapnia O
, O
NUM O
%). O

After O
measuring O
baseline O
RARE O
RARE O
a O
partial O
pressure O
of O
carbon O
dioxide O
in O
arterial O
RARE O
( O
PaCO2 O
) O
of O
37 O
. O
7 O
+/- O
4 O
. O
5 O
mmHg O
( O
mean O
+/- O
SD O
RARE O
measurements O
were O
RARE O
RARE O
a O
ALL_CAP O
of O
NUM O
. O
2 O
+/- O
3 O
. O
8 O
mmHg O
, O
and O
the O
carbon O
dioxide O
reactivity O
( O
absolute O
value O
: O
cm O
RARE O
s O
RARE O
1 O
) O
RARE O
mmHg O
RARE O
1 O
); O
relative O
value O
: O
percentage O
of O
baseline O
RARE O
/ O
mmHg O
) O
was O
calculated O
. O

RARE O
Cox O
survival O
analysis O
identified O
baseline O
ALL_CAP O
< O
or O
= O
NUM O
%, O
presence O
of O
significant O
mitral O
RARE O
(> O
2 O
+) O
before O
ablation O
, O
and O
failure O
to O
exhibit O
improved O
cardiac O
performance O
by O
1 O
month O
after O
ablation O
RARE O
the O
only O
independent O
predictors O
of O
RARE O
. O

We O
have O
developed O
a O
new O
method O
RARE O
estimation O
of O
regional O
CBF O
( O
rCBF O
) O
and O
RARE O
reserve O
capacity O
on O
a O
RARE O
- O
by O
- O
RARE O
basis O
by O
means O
of O
dynamic O
magnetic O
resonance O
imaging O
( O
MRI O
). O

RARE O
- O
effectiveness O
analysis O
provides O
a O
RARE O
means O
of O
RARE O
limited O
health O
care O
RARE O
by O
allowing O
the O
comparison O
of O
the O
costs O
of O
RARE O
- O
lowering O
therapy O
, O
in O
particular O
, O
therapy O
with O
beta I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
beta I-GENE
- I-GENE
RARE I-GENE
- I-GENE
CoA I-GENE
( I-GENE
RARE I-GENE
A I-GENE
) I-GENE
reductase I-GENE
RARE O
( O
RARE O
RARE O
with O
the O
costs O
of O
atherosclerosis O
that O
could O
be O
prevented O
by O
lowering O
cholesterol O
. O

Although O
NUM I-GENE
lacks O
the O
RARE O
domain O
, O
it O
stimulates O
E2F I-GENE
site O
- O
dependent O
transcription O
in O
cooperation O
with O
E2F I-GENE
- I-GENE
1 I-GENE
. O

Sequencing O
of O
a O
40 O
- O
kb O
DNA O
segment O
of O
the O
FK506 O
gene O
cluster O
from O
RARE O
RARE O
. O

The O
predicted O
domain O
RARE O
of O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
are O
analogous O
to O
that O
of O
ALL_CAP I-GENE
and O
comprise O
NUM O
fatty I-GENE
- I-GENE
acid I-GENE
- I-GENE
synthase I-GENE
( O
ALL_CAP I-GENE
)- O
like O
domains O
arranged O
in O
6 O
RARE O
. O

Analysis O
of O
NUM I-GENE
mRNA I-GENE
RARE O
in O
RARE O
and O
adult O
mouse O
testes O
, O
and O
in O
isolated O
populations O
of O
RARE O
cells O
, O
reveals O
maximal O
RARE O
in O
RARE O
round O
RARE O
, O
a O
cell O
type O
with O
abundant O
amounts O
of O
stored O
RARE O
RARE O
. O

1 O
in O
RARE O
Chi O
RARE O
City O
was O
studied O
by O
culture O
and O
latex O
RARE O
of O
RARE O
, O
RARE O
RARE O
, O
urine O
and O
RARE O
RARE O
. O

RARE O
RARE O
and O
catabolism O
, O
RARE O
, O
RARE O
, O
RARE O
, O
cell O
surface O
properties O
and O
RARE O
are O
modulated O
by O
ALL_CAP I-GENE
in I-GENE
Escherichia I-GENE
coli I-GENE
, O
while O
the O
production O
of O
several O
RARE O
RARE O
factors O
, O
the O
RARE O
RARE O
response O
RARE O
ALL_CAP I-GENE
( O
RARE I-GENE
) O
and O
, O
potentially O
, O
other O
secondary O
metabolites O
are O
regulated O
by O
ALL_CAP I-GENE
in I-GENE
RARE I-GENE
RARE I-GENE
. O

The O
NUM I-GENE
- I-GENE
1 I-GENE
mutation I-GENE
was O
identified O
RARE O
a O
guanine O
to O
RARE O
substitution O
RARE O
nucleotide O
NUM O
of O
the O
coding O
region O
, O
RARE O
the O
change O
NUM O
in O
the O
NUM I-GENE
. O

Deletion O
analysis O
revealed O
that O
the O
essential O
domain O
of O
this O
promoter O
, O
termed O
the O
NUM I-GENE
/ I-GENE
ALL_CAP I-GENE
transcript I-GENE
promoter I-GENE
, O
mapped O
to O
nucleotides O
NUM O
- O
NUM O
. O

Some O
of O
the O
peptide I-GENE
: I-GENE
MBP I-GENE
fusions I-GENE
were O
also O
analyzed O
using O
surface O
RARE O
resonance O
. O

RARE I-GENE
myosin I-GENE
- I-GENE
binding I-GENE
protein I-GENE
C I-GENE
( O
ALL_CAP I-GENE
- I-GENE
C I-GENE
): O
identification O
of O
protein I-GENE
kinase I-GENE
A I-GENE
and O
protein I-GENE
kinase I-GENE
C I-GENE
RARE O
sites O
. O

RARE O
on O
ALL_CAP O
9 O
did O
not O
result O
in O
elevated O
ALL_CAP O
levels O
in O
any O
of O
the O
groups O
. O

Analysis O
of O
chromosomal O
DNA O
sequence O
immediately O
RARE O
of O
the O
RARE O
RARE O
identified O
two O
RARE O
reading O
frames O
, O
designated O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
, O
which O
exhibited O
sequence O
RARE O
to O
bacterial O
two O
- O
RARE O
regulatory O
RARE O
. O

NUM O
+/- O
258 O
aggregates O
/ O
ml O
RARE O
NUM O
RARE O
; O
P O
< O
NUM O
. O
001 O
). O

We O
previously O
RARE O
a O
region O
in O
the O
fatty I-GENE
- I-GENE
acid I-GENE
synthase I-GENE
promoter I-GENE
, O
which O
was O
responsible O
RARE O
obesity O
- O
related O
overexpression O
of O
the O
fatty I-GENE
- I-GENE
acid I-GENE
synthase I-GENE
( O
ALL_CAP I-GENE
) O
gene O
, O
by O
negatively O
RARE O
the O
activity O
of O
the O
RARE O
promoter O
in O
lean O
but O
not O
obese O
rat O
fat O
cells O
. O

Finally O
, O
using O
in O
vitro O
binding O
studies O
, O
we O
showed O
that O
NUM I-GENE
was O
able O
to O
RARE O
NUM I-GENE
/ O
NUM I-GENE
binding O
from O
the O
sterol O
regulatory O
element O
( O
SRE O
) O
site O
. O

Thus O
, O
IRF I-GENE
- I-GENE
7 I-GENE
exhibits O
RARE O
RARE O
to O
IRF I-GENE
- I-GENE
3 I-GENE
; O
however O
, O
the O
preferential O
RARE O
of O
IRF I-GENE
- I-GENE
7 I-GENE
in O
RARE O
cells O
( O
the O
cell O
type O
that O
RARE O
ALL_CAP I-GENE
) O
suggests O
that O
IRF I-GENE
- I-GENE
7 I-GENE
may O
play O
a O
critical O
role O
in O
RARE O
the O
ALL_CAP I-GENE
gene I-GENE
RARE O
. O

ALL_CAP O
. O

PURPOSE O
: O
The O
role O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
) O
in O
the O
treatment O
of O
congenital O
RARE O
is O
unknown O
. O

ALL_CAP I-GENE
RARE O
a O
CD44 I-GENE
- I-GENE
associated I-GENE
serine I-GENE
kinase I-GENE
therefore O
may O
serve O
RARE O
an O
important O
molecule O
in O
a O
RARE O
cascade O
that O
produces O
a O
variety O
of O
cellular O
responses O
in O
NUM O
breast O
RARE O
cells O
. O

RARE I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
, O
but O
not O
RARE I-GENE
, O
activate O
SRF I-GENE
through O
RhoA I-GENE
. O

Additionally O
in O
RARE O
subjects O
adrenaline O
( O
A O
) O
and O
noradrenaline O
( O
NA O
) O
concentrations O
were O
determined O
. O

Northern O
blot O
analyses O
show O
that O
the O
NUM I-GENE
mRNA I-GENE
level O
is O
abundantly O
RARE O
in O
tissues O
or O
cells O
with O
a O
high O
RARE O
index O
. O

We O
mapped O
two O
overlapping O
RARE O
sequence O
tag O
RARE O
within O
a O
genomic O
contig O
on O
human O
RARE O
5 O
, O
band O
NUM O
. O

NUM I-GENE
- I-GENE
NUM I-GENE
is O
developmentally O
regulated O
and O
RARE O
predominantly O
in O
brain O
, O
liver O
RARE O
, O
and O
weakly O
in O
RARE O
. O

NUM I-GENE
transcripts I-GENE
are O
RARE O
in O
a O
variety O
of O
tissues O
including O
both O
brain O
and O
testes O
. O

Using O
an O
RARE O
backcross O
panel O
, O
we O
localized O
both O
NUM I-GENE
and O
NUM I-GENE
to O
the O
same O
locus O
on O
RARE O
19 O
. O

We O
also O
raised O
a O
RARE O
antibody O
against O
the O
RARE I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion I-GENE
protein I-GENE
containing O
the O
NH2 O
- O
terminal O
NUM O
amino O
RARE O
of O
human I-GENE
NUM I-GENE
. O

Inhibition O
of O
the O
apolipoprotein I-GENE
B I-GENE
mRNA I-GENE
RARE O
enzyme O
- O
complex O
by O
ALL_CAP I-GENE
C1 I-GENE
protein I-GENE
and O
NUM I-GENE
ALL_CAP I-GENE
complexes I-GENE
. O

SRC I-GENE
- I-GENE
1 I-GENE
can O
RARE O
the O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
- O
RARE O
repression O
of O
GR I-GENE
activity O
. O

However O
the O
sequence O
surrounding O
the O
transcription O
RARE O
site O
ALL_CAP O
(+ O
1 O
) O
ALL_CAP O
was O
similar O
to O
the O
consensus O
ALL_CAP O
(+ O
1 O
) O
ALL_CAP O
( O
N O
is O
any O
RARE O
) O
RARE O
an O
RARE O
element O
found O
in O
terminal I-GENE
RARE I-GENE
and O
a O
number O
of O
other O
highly O
regulated O
genes O
. O

These O
results O
indicate O
that O
the O
RARE O
number O
of O
subunit O
c O
in O
NUM I-GENE
should O
be O
a O
multiple O
of O
2 O
and O
3 O
. O

Expression O
of O
a O
dominant O
- O
negative O
mutant O
of O
JNK1 I-GENE
also O
suppressed O
glucose O
deprivation O
- O
RARE O
JNK1 I-GENE
activation O
RARE O
RARE O
RARE O
HSP70 I-GENE
gene I-GENE
RARE O
. O

The O
interaction O
of O
ALL_CAP O
- O
1 O
with O
proteins O
that O
regulate O
distinct O
steps O
of O
transcription O
may O
provide O
a O
mechanism O
RARE O
synergistic O
activation O
of O
gene O
RARE O
by O
ALL_CAP O
- O
1 O
. O

The O
role O
of O
protein I-GENE
kinase I-GENE
C I-GENE
RARE O
in O
activated O
ALL_CAP I-GENE
transcription O
. O

RARE O
binding O
to O
the O
receptor O
complex O
leads O
to O
tyrosine O
RARE O
and O
activation O
of O
Janus I-GENE
kinases I-GENE
( O
Jak I-GENE
RARE O
RARE O
of O
the O
signal I-GENE
RARE I-GENE
subunit I-GENE
NUM I-GENE
, O
followed O
by O
recruitment O
and O
RARE O
of O
the O
signal I-GENE
RARE I-GENE
and I-GENE
activator I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
STAT3 I-GENE
and O
STAT1 I-GENE
and O
the O
src I-GENE
homology I-GENE
domain I-GENE
( O
NUM I-GENE
)- O
containing O
protein I-GENE
tyrosine I-GENE
phosphatase I-GENE
( O
NUM I-GENE
). O

Interestingly O
, O
an O
increase O
of O
distance O
per O
RARE O
did O
not O
have O
a O
RARE O
effect O
on O
translation O
efficiency O
. O

We O
also O
mapped O
a O
3 O
'- O
polyadenylation O
site O
NUM O
RARE O
of O
the O
ALL_CAP O
stop O
RARE O
, O
consistent O
with O
the O
2 O
. O
NUM O
transcript O
size O
. O

NUM I-GENE
protein I-GENE
turned O
out O
to O
be O
NUM I-GENE
which O
was O
isolated O
RARE O
a O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
associated I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
) O
from O
a O
sub O
- O
population O
of O
TFIID I-GENE
complexes I-GENE
( O
RARE O
A O
., O
RARE O
, O
Y O
., O
RARE O
, O
D O
. O
ALL_CAP O
., O
RARE O
, O
P O
., O
RARE O
, O
L O
., O
1996 O
. O
NUM I-GENE
, O
a O
novel O
RNA O
/ O
ALL_CAP O
- O
binding O
protein O
with O
homology O
to O
the O
RARE O
- O
RARE O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
and O
EWS I-GENE
is O
associated O
with O
both O
TFIID I-GENE
and O
RNA I-GENE
polymerase I-GENE
II I-GENE
. O

An O
electrophoretic O
mobility O
shift O
assay O
was O
performed O
to O
characterize O
the O
binding O
RARE O
of O
NUM I-GENE
and O
its O
truncated O
isoform O
. O

Gel O
- O
mobility O
shift O
analysis O
was O
also O
performed O
RARE O
the O
CCAAT O
motif O
RARE O
- O
67 O
. O

BACKGROUND O
: O
The O
c I-GENE
- I-GENE
myc I-GENE
RARE I-GENE
- I-GENE
oncogene I-GENE
has O
been O
suggested O
to O
play O
key O
roles O
in O
cell O
RARE O
, O
differentiation O
, O
transformation O
and O
apoptosis O
. O

ALL_CAP I-GENE
- I-GENE
1 I-GENE
was O
localized O
in O
the O
cytoplasm O
in O
cells O
expressing O
c I-GENE
- I-GENE
myc I-GENE
RARE O
low O
levels O
, O
but O
in O
the O
nucleus O
in O
the O
cells O
of O
a O
high O
c I-GENE
- I-GENE
myc I-GENE
RARE O
in O
transiently O
transfected O
cells O
. O

RESULTS O
: O
We O
identified O
a O
full O
- O
length O
cDNA O
with O
an O
RARE O
reading O
frame O
of O
NUM O
bp O
corresponding O
to O
a O
predicted O
protein O
of O
NUM O
amino O
RARE O
that O
shares O
greater O
than O
NUM O
% O
homology O
with O
the O
rat I-GENE
gamma I-GENE
- I-GENE
RARE I-GENE
acid I-GENE
B I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
receptor I-GENE
. O

On O
Day O
8 O
, O
the O
ALL_CAP O
- O
B O
was O
removed O
and O
500 O
micrograms O
RARE O
injected O
, O
IM O
. O

RARE O
- O
like O
properties O
of O
some O
RARE I-GENE
receptor I-GENE
ligands O
and O
RARE O
RARE O
antagonists O
measured O
with O
the O
RARE O
swimming O
test O
in O
mice O
. O

Another O
RARE O
RARE O
mutation O
in O
the O
third O
patient O
, O
a O
frame O
shift O
caused O
by O
a O
G O
nucleotide O
RARE O
in O
a O
RARE O
repeat O
of O
RARE O
RARE O
in O
ALL_CAP I-GENE
RARE I-GENE
3 I-GENE
, O
has O
been O
reported O
previously O
in O
three O
other O
ALL_CAP O
patients O
. O

SRF I-GENE
- O
RARE O
RARE O
( O
RARE I-GENE
RARE O
have O
a O
severe O
RARE O
defect O
and O
do O
not O
develop O
to O
term O
. O

These O
characteristic O
structural O
features O
were O
used O
to O
create O
the O
RARE O
NUM I-GENE
( O
RARE I-GENE
- I-GENE
rich I-GENE
RARE I-GENE
RARE I-GENE
protein I-GENE
). O

RARE O
- O
RARE O
of O
NUM I-GENE
in O
the O
yeast O
cell O
does O
not O
influence O
the O
RARE O
level O
of O
the O
mitochondrial I-GENE
transcription I-GENE
factor I-GENE
NUM I-GENE
, O
indicating O
that O
the O
influence O
of O
NUM I-GENE
on O
the O
suppression O
of O
the O
RARE O
mitochondrial I-GENE
RNA I-GENE
polymerase I-GENE
mutant I-GENE
is O
an O
indirect O
one O
. O

We O
have O
generated O
a O
computer O
model O
of O
the O
C O
- O
terminal O
domain O
of O
the O
NUM O
repressor O
based O
on O
the O
RARE O
RARE O
of O
the O
homologous I-GENE
ALL_CAP I-GENE
' I-GENE
protein I-GENE
. O

RARE O
- O
scale O
sequencing O
of O
two O
regions O
in O
human O
RARE O
NUM O
: O
analysis O
of O
NUM O
kb O
of O
genomic O
sequence O
around O
the O
EPO I-GENE
and O
NUM I-GENE
loci I-GENE
reveals O
NUM O
genes O
. O

Because O
NUM I-GENE
( O
the O
mouse I-GENE
homolog I-GENE
of I-GENE
human I-GENE
NUM I-GENE
) O
is O
RARE O
with O
NUM I-GENE
on O
RARE O
11 O
and O
is O
critical O
in O
RARE O
cellular O
responses O
following O
exposure O
to O
DNA O
RARE O
agents O
, O
we O
RARE O
to O
determine O
if O
these O
mouse O
lymphoma O
cells O
harbor O
mutations O
in O
NUM I-GENE
. O

One O
of O
these O
fragments O
shows O
the O
highest O
amino O
acid O
sequence O
homology O
to O
the O
insect O
ecdysone O
inducible O
gene I-GENE
NUM I-GENE
. O

The O
full O
- O
length O
N I-GENE
gene I-GENE
, O
encoded O
by O
RARE O
reading O
frame O
7 O
, O
was O
RARE O
from O
the O
RARE O
ALL_CAP O
virus O
, O
PA O
- O
8 O
. O

Based O
on O
sequence O
homology O
, O
the O
genes O
were O
identified O
RARE O
TEF I-GENE
, O
encoding O
translation I-GENE
RARE I-GENE
factor I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
and O
NUM I-GENE
, O
encoding O
ribosomal O
protein O
NUM I-GENE
. O

We O
have O
previously O
shown O
that O
ALL_CAP I-GENE
localizes O
to O
the O
plasma O
membrane O
in O
vivo O
and O
efficiently O
catalyzes O
NUM I-GENE
nucleotide O
exchange O
in O
vitro O
. O

Renal O
pathology O
and O
long O
- O
term O
outcome O
in O
childhood O
SLE O
. O

Transcription O
factors O
of O
the O
Stat I-GENE
family I-GENE
are O
RARE O
by O
protein O
kinases O
. O

We O
propose O
that O
two O
pathways O
regulate O
Stat5 I-GENE
serine O
RARE O
, O
one O
that O
is O
prolactin I-GENE
- O
activated O
and O
PD98059 O
- O
resistant O
and O
one O
that O
is O
constitutively O
RARE O
and O
PD98059 O
- O
RARE O
and O
preferentially O
RARE O
Stat5a I-GENE
. O

An O
RARE O
37 O
- O
kDa O
cytoplasmic O
protein O
is O
rapidly O
tyrosine O
- O
RARE O
in O
the O
response O
of O
mouse O
NUM O
. O
NUM O
macrophages O
to O
colony I-GENE
stimulating I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
CSF I-GENE
- I-GENE
1 I-GENE
). O
NUM I-GENE
was O
RARE O
from O
the O
cytosolic O
fraction O
by O
anti I-GENE
- I-GENE
RARE I-GENE
( I-GENE
P I-GENE
) I-GENE
affinity O
chromatography O
, O
size O
exclusion O
chromatography O
, O
and O
NUM O
reverse O
RARE O
high O
pressure O
liquid O
chromatography O
. O

RARE O
of O
20 O
RARE O
were O
administered O
within O
a O
RARE O
from O
NUM O
. O
1 O
to O
6 O
months O
in O
order O
to O
study O
its O
RARE O
, O
which O
was O
evaluated O
RARE O
2 O
, O
7 O
, O
and O
12 O
months O
after O
the O
RARE O
dose O
. O

The O
various O
available O
data O
strongly O
suggesting O
an O
environmental O
toxic O
origin O
RARE O
the O
" O
sperm O
fall O
" O
will O
be O
presented O
RARE O
RARE O
RARE O
the O
most O
frequently O
suspected O
class O
of O
substances O
, O
the O
RARE O
. O

This O
association O
was O
independently O
significant O
RARE O
patients O
treated O
primarily O
( O
not O
RARE O
recurrence O
). O

CONCLUSION O
: O
RARE O
control O
was O
highest O
with O
RARE O
in O
patients O
RARE O
primarily O
with O
gross O
RARE O
, O
and O
with O
RARE O
in O
patients O
RARE O
primarily O
following O
gross O
RARE O
RARE O
. O

Its O
interaction O
with O
NUM I-GENE
and O
ALL_CAP I-GENE
is O
essential O
RARE O
binding O
of O
the O
ALL_CAP I-GENE
complex I-GENE
to O
MHC I-GENE
- I-GENE
II I-GENE
promoters I-GENE
. O

We O
have O
previously O
mapped O
the O
defect O
in O
ALL_CAP O
/ O
ALL_CAP O
to O
distal O
mouse O
Chr O
11 O
, O
distinct O
from O
the O
RARE I-GENE
locus I-GENE
on O
Chr O
6 O
. O

These O
data O
may O
also O
aid O
in O
the O
RARE O
of O
other O
RARE O
loci O
mapped O
to O
this O
region O
, O
including O
the O
gene O
RARE O
RARE O
- O
RARE O
- O
RARE O
RARE O
and O
a O
murine O
locus O
RARE O
RARE O
to O
RARE O
- O
RARE O
acute O
RARE O
injury O
. O

Copyright O
1998 O
Academic O
Press O
. O

An O
RARE O
reading O
frame O
encoding O
a O
protein O
which O
shows O
significant O
RARE O
to O
RARE I-GENE
and O
RARE I-GENE
was O
RARE O
immediately O
upstream O
of O
the O
NUM I-GENE
R I-GENE
- I-GENE
M I-GENE
operon I-GENE
. O

Identification O
of O
a O
new O
gene O
in O
the O
RARE O
RARE O
NUM O
: O
the O
ALL_CAP I-GENE
gene I-GENE
. O

RARE O
, O
RARE I-GENE
is O
required O
in O
RARE O
third O
RARE O
larvae O
RARE O
appropriate O
developmental O
and O
transcriptional O
responses O
to O
the O
ecdysone O
pulse O
that O
triggers O
RARE O
formation O
. O

An O
RARE O
RARE O
supply O
is O
essential O
RARE O
the O
viability O
of O
a O
muscle O
flap O
. O

Examination O
of O
DNA O
: O
protein O
binding O
complexes O
by O
gel O
- O
shift O
analysis O
indicated O
that O
nuclear O
factors O
from O
both O
proliferative O
and O
growth O
- O
arrested O
cells O
RARE O
to O
the O
DNA O
fragment O
spanning O
- O
NUM O
- O
- O
NUM O
bp O
. O

BACKGROUND O
: O
Studies O
in O
lean O
men O
show O
poor O
RARE O
of O
energy O
( O
ALL_CAP O
) O
and O
fat O
balance O
( O
FB O
) O
RARE O
RARE O
of O
dietary O
ratios O
of O
fat O
to O
carbohydrate O
. O

RARE O
RARE O
was O
observed O
under O
following O
conditions O
: O
( O
1 O
) O
RARE O
apnea O
was O
produced O
after O
a O
single O
ALL_CAP O
microinjection O
in O
one O
RARE O
of O
the O
ALL_CAP O
- O
RARE O
( O
5 O
animals O
). O

A O
comparative O
analysis O
of O
the O
reported O
ALL_CAP O
- O
associated O
malignant O
melanomas O
emphasizes O
the O
RARE O
of O
our O
case O
in O
the O
RARE O
character O
of O
the O
RARE O
, O
its O
RARE O
and O
the O
RARE O
of O
invasive O
squamous O
cell O
carcinoma O
. O

RESULTS O
: O
An O
RARE O
RARE O
is O
observed O
with O
presence O
of O
type O
I O
herpes O
simplex O
virus O
( O
HSV O
I O
) O
RARE O
RARE O
in O
the O
recipient O
' O
s O
aqueous O
RARE O
. O

These O
results O
indicate O
that O
HIV O
- O
1 O
Gag I-GENE
sequences I-GENE
can O
influence O
the O
viral I-GENE
PR I-GENE
- O
RARE O
RARE O
of O
the O
MuLV O
ALL_CAP I-GENE
Env I-GENE
protein I-GENE
NUM O
( O
E O
). O

These O
results O
demonstrate O
a O
specific O
association O
of O
SIV O
and O
HIV I-GENE
- I-GENE
2 I-GENE
nef I-GENE
, O
but O
not O
HIV I-GENE
- I-GENE
1 I-GENE
nef I-GENE
, O
with O
RARE I-GENE
. O

Competition O
EMSA O
established O
that O
constitutively O
RARE O
nuclear O
proteins O
RARE O
the O
ALL_CAP I-GENE
element I-GENE
selectively O
; O
ALL_CAP I-GENE
protein I-GENE
binding O
activity O
correlated O
with O
promoter O
activity O
in O
the O
transient O
transfection O
reporter O
assay O
. O

Mechanism O
of O
RARE I-GENE
action O
: O
identification O
of O
essential O
positions O
within O
the O
novel O
NUM I-GENE
- I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
ALL_CAP I-GENE
element I-GENE
required O
RARE O
transcriptional O
activation O
of O
the O
RNA I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
RARE I-GENE
gene I-GENE
. O

ALL_CAP I-GENE
failed O
to O
stimulate O
RARE O
or O
activation O
of O
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
under O
the O
conditions O
used O
. O

Expression O
of O
a O
novel O
murine I-GENE
phospholipase I-GENE
D I-GENE
homolog I-GENE
RARE O
with O
RARE O
RARE O
development O
in O
the O
RARE O
. O

We O
detected O
RARE O
effect O
of O
RARE O
NUM I-GENE
, O
either O
alone O
or O
in O
combination O
with O
deletion O
of O
NUM I-GENE
. O

RARE I-GENE
is O
also O
RARE O
, O
and O
its O
mRNA O
is O
differentially O
RARE O
in O
a O
tissue O
- O
specific O
and O
developmentally O
regulated O
manner O
. O

The O
deduced O
amino O
acid O
sequence O
of O
NUM I-GENE
had O
RARE O
significant O
RARE O
to O
any O
other O
protein O
, O
but O
it O
had O
a O
proline O
- O
rich O
domain O
RARE O
the O
C O
- O
terminal O
region O
. O

The O
effect O
of O
low O
- O
profile O
serine O
substitutions O
in O
the O
NUM I-GENE
loop O
of O
HIV O
- O
1 O
gp120 I-GENE
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
on O
the O
RARE O
of O
the O
envelope I-GENE
protein O
. O

Transcription O
RARE O
site O
mapping O
identified O
the O
presence O
of O
an O
RARE O
- O
RARE O
RARE O
transcript O
arising O
from O
a O
ALL_CAP O
motif O
RARE O
RARE O
- O
NUM O
nucleotides O
and O
an O
RARE O
- O
RARE O
early O
transcript O
RARE O
from O
a O
ALL_CAP O
motif O
RARE O
NUM O
nucleotides O
RARE O
to O
a O
TATA O
box O
RARE O
- O
NUM O
nucleotides O
, O
with O
respect O
to O
the O
+ O
1 O
ATG O
of O
NUM I-GENE
. O

The O
human I-GENE
2 I-GENE
RARE I-GENE
5 I-GENE
'- I-GENE
RARE I-GENE
( I-GENE
2 I-GENE
- I-GENE
NUM I-GENE
) I-GENE
synthetases I-GENE
are O
members O
of O
a O
family O
RARE I-GENE
( O
IFN I-GENE
)- O
inducible O
anti I-GENE
- I-GENE
viral I-GENE
proteins I-GENE
. O

Our O
findings O
demonstrate O
a O
dose O
- O
dependent O
blockade O
of O
the O
mechanical O
sensitivity O
caused O
by O
a O
mild O
thermal O
injury O
by O
both O
ALL_CAP O
and O
ALL_CAP O
. O

These O
RARE O
were O
caused O
by O
RARE O
between O
the O
RARE O
RARE O
of O
the O
upper O
canine O
and O
the O
NUM O
RARE O
RARE O
( O
canine O
/ O
RARE O
complex O
). O

Low O
NUM O
RARE O
, O
however O
, O
could O
be O
caused O
by O
local O
RARE O
, O
undetectable O
on O
ALL_CAP O
or O
MRI O
. O

The O
consequences O
of O
intensive O
swine O
production O
on O
the O
environment O
and O
possible O
solutions O
by O
means O
of O
nutrition O
are O
RARE O
. O

This O
study O
demonstrates O
that O
alteration O
of O
NUM I-GENE
is O
one O
of O
the O
most O
frequent O
genetic O
abnormalities O
in O
RARE O
RARE O
and O
may O
contribute O
to O
RARE O
RARE O
. O

The O
pharmacokinetic O
parameters O
which O
RARE O
predict O
these O
RARE O
included O
area O
under O
the O
curve O
and O
peak O
plasma O
level O
. O

A O
RARE O
( O
ALL_CAP O
) O
ALL_CAP O
- O
NUM O
survey O
form O
was O
developed O
by O
an O
RARE O
translation O
process O
. O

However O
, O
the O
use O
of O
cyclosporin O
A O
is O
associated O
with O
an O
increased O
prevalence O
of O
hypertension O
in O
RARE O
transplant O
recipients O
. O

PURPOSE O
: O
To O
determine O
the O
effects O
of O
RARE O
and O
atherosclerosis O
- O
RARE O
chronic O
RARE O
arterial O
insufficiency O
on O
RARE O
RARE O
muscle O
tone O
, O
RARE I-GENE
oxide I-GENE
synthase I-GENE
( O
ALL_CAP I-GENE
) O
activity O
and O
RARE O
tissue O
RARE O
of O
RARE O
RARE O
. O

Characterization O
of O
the O
regulatory O
regions O
of O
the O
human I-GENE
aromatase I-GENE
( O
NUM I-GENE
) O
gene O
involved O
in O
placenta O
- O
specific O
RARE O
. O

Recombinant I-GENE
RARE I-GENE
was O
stable O
in O
the O
infusion O
RARE O
RARE O
several O
days O
RARE O
room O
RARE O
and O
RARE O
NUM O
h O
RARE O
body O
RARE O
. O

NUM I-GENE
lymphocyte O
and O
viral O
load O
levels O
suggested O
an O
optimal O
response O
to O
ALL_CAP O
therapy O
RARE O
the O
time O
ALL_CAP O
developed O
. O

( O
1992 O
) O
RARE O
NUM O
, O
NUM O
- O
NUM O
]. O

RARE O
of O
serum O
IgE I-GENE
were O
measured O
monthly O
, O
and O
nasal O
IgE I-GENE
was O
measured O
RARE O
the O
height O
and O
end O
of O
the O
season O
. O

A O
mutation O
in O
the O
5 O
' O
NUM O
repeat O
causes O
RARE O
of O
NUM I-GENE
, O
whereas O
mutations O
in O
the O
3 O
' O
NUM O
repeat O
cause O
the O
accumulation O
of O
two O
novel O
RNAs O
that O
RARE O
in O
the O
500 O
- O
nt O
range O
. O

By O
directly O
RARE O
with O
both O
RARE I-GENE
and O
tyrosine I-GENE
kinases I-GENE
involved O
in O
RARE O
cell O
growth O
and O
cytoskeletal O
organization O
, O
NUM I-GENE
could O
coordinate O
membrane O
remodeling O
events O
with O
these O
processes O
. O

By O
DNase I-GENE
I I-GENE
footprint O
analysis O
of O
the O
ALL_CAP O
element O
, O
a O
palindrome O
of O
two O
high O
- O
affinity O
Ets I-GENE
- I-GENE
binding I-GENE
sites I-GENE
( O
ALL_CAP O
) O
was O
identified O
. O

These O
RARE I-GENE
RARE I-GENE
also O
associated O
with O
the O
long O
isoform O
of O
the O
leptin I-GENE
receptor I-GENE
but O
not O
with O
the O
short O
and O
medium O
isoforms O
. O

RARE I-GENE
are O
cis I-GENE
- I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
that O
bind O
to O
and O
are O
inhibited O
by O
the O
RARE O
cyclosporin O
A O
( O
CsA O
). O

In O
vitro O
protein O
retention O
experiments O
in O
which O
NUM I-GENE
RARE I-GENE
were O
precipitated O
resulted O
in O
RARE O
of O
NUM I-GENE
. O

The O
Ras I-GENE
- I-GENE
related I-GENE
GTPases I-GENE
are O
small O
, O
20 O
- O
to O
NUM O
- O
kDa O
proteins O
which O
RARE O
between O
an O
inactive O
GDP O
- O
RARE O
form O
and O
an O
RARE O
GTP O
- O
RARE O
state O
. O

To O
modulate O
transcription O
, O
regulatory O
factors O
RARE O
with O
basal O
transcription O
factors O
and O
/ O
or O
RNA I-GENE
RARE I-GENE
in O
a O
variety O
of O
ways O
. O

RARE O
ALL_CAP I-GENE
was O
RARE O
detected O
RARE O
with O
assembled O
NUM I-GENE
in O
RNA I-GENE
polymerase I-GENE
in O
mammalian O
cells O
. O

In O
this O
study O
, O
rabbits O
were O
used O
to O
evaluate O
the O
RARE O
wound O
reaction O
with O
RARE O
or O
RARE O
in O
the O
RARE O
flap O
1 O
, O
4 O
, O
7 O
, O
14 O
and O
NUM O
days O
after O
RARE O
surgery O
with O
or O
without O
the O
use O
of O
RARE O
- O
C O
. O

The O
mapping O
was O
completed O
with O
Southern O
blotting O
and O
RARE O
analysis O
. O

The O
RARE O
RARE O
( O
ALL_CAP O
RARE O
the O
extracellular O
RARE O
that O
RARE O
the O
RARE O
, O
is O
RARE O
known O
to O
mediate O
homologous O
RARE O
interaction O
. O

RARE O
use O
of O
continuous O
subcutaneous O
infusion O
of O
recombinant I-GENE
human I-GENE
erythropoietin I-GENE
in O
RARE O
RARE O
RARE O
patients O
with O
diabetic O
nephropathy O
. O

Although O
pathological O
thyroid O
function O
is O
related O
to O
changes O
in O
energy O
expenditure O
and O
body O
composition O
, O
its O
possible O
influence O
on O
leptin I-GENE
levels O
remains O
to O
be O
determined O
. O

These O
cognitive O
deficits O
were O
prevented O
in O
animals O
treated O
with O
MK O
- O
801 O
RARE O
SE O
. O

Here O
we O
demonstrate O
that O
the O
mechanism O
of O
activation O
of O
HIF I-GENE
- I-GENE
1alpha I-GENE
is O
a O
RARE O
- O
step O
process O
which O
includes O
RARE O
- O
dependent O
nuclear O
import O
and O
activation O
( O
derepression O
) O
of O
the O
RARE O
domain O
, O
resulting O
in O
recruitment O
of O
the O
CREB I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
CBP I-GENE
RARE O
p300 I-GENE
RARE I-GENE
. O

Thus O
, O
RARE O
- O
inducible O
nuclear O
import O
and O
RARE O
by O
recruitment O
of O
CBP I-GENE
can O
be O
functionally O
separated O
from O
one O
another O
and O
play O
critical O
roles O
in O
signal O
RARE O
by O
HIF I-GENE
- I-GENE
1alpha I-GENE
. O

The O
rat I-GENE
RARE I-GENE
C I-GENE
gene I-GENE
encodes O
a O
RARE O
enzyme O
strongly O
RARE O
in O
adult O
brain O
. O

A O
synergistic O
effect O
on O
ALL_CAP I-GENE
promoter I-GENE
activity O
was O
observed O
RARE O
high O
concentrations O
of O
NUM I-GENE
. O

RARE O
- O
binding O
domain O
and O
amino O
acid O
residues O
involved O
in O
RARE O
binding O
. O

Western O
analyses O
with O
antisera O
raised O
against O
RARE I-GENE
- I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
peptides I-GENE
show O
that O
the O
N O
- O
terminal O
region O
of O
the O
predicted O
RARE O
reading O
frame O
is O
present O
only O
in O
the O
larger O
size O
proteins O
( O
i O
. O
RARE O
. O

RARE O
sperm O
RARE O
is O
regulated O
by O
a O
cascade O
of O
cAMP O
- O
dependent O
protein O
RARE O
events O
RARE O
by O
protein I-GENE
kinase I-GENE
A I-GENE
. O

In O
this O
paper O
, O
we O
show O
that O
, O
like O
NUM I-GENE
, O
the O
RARE O
of O
the O
NUM I-GENE
gene I-GENE
in O
S O
. O
cerevisiae O
is O
RARE O
by O
the O
addition O
of O
RARE O
- O
chain O
amino O
RARE O
to O
the O
medium O
. O

Effect O
of O
RARE O
nutritional O
products O
RARE O
in O
carbohydrate O
and O
fat O
on O
indices O
of O
carbohydrate O
and O
RARE O
metabolism O
in O
patients O
with O
ALL_CAP O
. O

Low O
- O
grade O
RARE O
ALL_CAP O
lymphoma O
and O
RARE O
RARE O
( O
RARE O
RARE O

These O
studies O
support O
the O
view O
that O
HMG I-GENE
I I-GENE
( I-GENE
Y I-GENE
) I-GENE
is O
an O
important O
cofactor O
RARE O
HLA I-GENE
- I-GENE
ALL_CAP I-GENE
gene I-GENE
activation O
by O
Oct I-GENE
- I-GENE
NUM I-GENE
and O
provide O
RARE O
into O
its O
mechanism O
of O
action O
. O

In O
contrast O
to O
hemodynamic O
and O
histopathological O
predictors O
of O
survival O
, O
vWF I-GENE
: O
RARE O
does O
not O
require O
invasive O
techniques O
to O
be O
determined O
. O

CONCLUSION O
: O
We O
were O
unable O
to O
identify O
features O
of O
RARE O
likely O
to O
be O
associated O
with O
a O
clinically O
useful O
response O
to O
inhaled O
ALL_CAP O
therapy O
using O
the O
parameters O
studied O
. O

We O
find O
that O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
ALL_CAP O
domain O
mutations O
that O
disrupt O
the O
interaction O
with O
N I-GENE
- I-GENE
ALL_CAP I-GENE
and O
SMRT I-GENE
RARE O
longer O
repress O
transcription O
. O

Partial O
characterization O
of O
the O
RARE O
site O
human I-GENE
platelet I-GENE
cAMP I-GENE
RARE I-GENE
, O
NUM I-GENE
, O
by O
site O
- O
directed O
mutagenesis O
. O

This O
core O
sequence O
, O
along O
with O
additional O
nonspecific O
RARE O
nucleotides O
, O
is O
sufficient O
RARE O
partial O
suppression O
of O
spliceosome O
assembly O
and O
RARE O
of O
ALL_CAP O
- O
1 O
pre O
- O
mRNAs O
. O

RARE O
- O
RARE O
of O
the O
cofactor O
p300 I-GENE
, O
which O
functions O
RARE O
a O
RARE O
of O
myoD I-GENE
- O
RARE O
transcription O
, O
RARE O
repression O
by O
COUP I-GENE
- I-GENE
ALL_CAP I-GENE
II I-GENE
. O

RARE O
RARE O
hepatitis O
and O
NUM I-GENE
deficiency O

No O
mutations O
were O
found O
in O
follicular O
RARE O
. O

Since O
RARE I-GENE
peroxidase I-GENE
( O
ALL_CAP I-GENE
) O
and O
RARE I-GENE
dismutase I-GENE
( O
SOD I-GENE
) O
play O
a O
significant O
role O
in O
RARE O
RARE O
RARE O
, O
it O
is O
very O
important O
to O
determine O
their O
activity O
in O
RARE O
exposed O
workers O
. O

RARE I-GENE
RARE I-GENE
proteins I-GENE
( O
RARE I-GENE
) O
are O
ALL_CAP I-GENE
- I-GENE
type I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
that O
mediate O
virion O
RNA O
binding O
activities O
associated O
with O
RARE O
assembly O
and O
genomic O
RNA O
RARE O
. O

The O
Schizosaccharomyces I-GENE
pombe I-GENE
NUM I-GENE
+ I-GENE
cell I-GENE
RARE I-GENE
RARE I-GENE
control I-GENE
gene I-GENE
is O
required O
RARE O
S O
- O
RARE O
and O
NUM O
/ O
M O
arrest O
in O
response O
to O
both O
DNA O
damage O
and O
incomplete O
DNA O
replication O
. O

It O
is O
now O
RARE O
established O
that O
progression O
through O
the O
eukaryotic O
cell O
RARE O
is O
RARE O
by O
RARE O
in O
the O
activity O
of O
RARE I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
( O
RARE I-GENE
). O

RARE O
genetic O
RARE O
RARE O
inhibition O
of O
RARE I-GENE
/ O
CDK I-GENE
function O
were O
characterized O
using O
the O
E I-GENE
. I-GENE
coli I-GENE
RARE I-GENE
and O
yeast I-GENE
LEU2 I-GENE
genes I-GENE
. O

The O
hematopoietic I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
( O
CSF I-GENE
) O
have O
been O
introduced O
into O
clinical O
practice O
RARE O
additional O
RARE O
measures O
that O
can O
reduce O
the O
incidence O
of O
infectious O
complications O
in O
patients O
with O
RARE O
and O
neutropenia O
. O

All O
injections O
of O
CSF I-GENE
were O
given O
after O
the O
initiation O
of O
neutropenia O
and O
continued O
until O
the O
occurrence O
of O
an O
absolute O
RARE O
recovery O
. O
RARE I-GENE
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
and O
RARE I-GENE
G I-GENE
- I-GENE
CSF I-GENE
, O
administered O
once O
daily O
RARE O
the O
NUM O
microg O
m O
RARE O
2 O
) O
day O
RARE O
1 O
) O
and O
5 O
microg O
kg O
RARE O
1 O
) O
day O
RARE O
1 O
) O
level O
, O
were O
effective O
in O
increasing O
the O
absolute O
RARE O
count O
and O
RARE O
function O
, O
RARE O
measured O
by O
an O
automated O
RARE O
RARE O
. O

Expression O
of O
lacZ I-GENE
from O
the O
promoter O
of O
the O
Escherichia I-GENE
coli I-GENE
RARE I-GENE
operon I-GENE
RARE O
into O
vectors O
carrying O
the O
NUM O
RARE I-GENE
- O
lac I-GENE
fusion O
. O

We O
evaluated O
regional O
right O
ventricular O
RARE O
motion O
RARE O
RARE O
in O
patients O
with O
surgically O
RARE O
RARE O
of O
RARE O
( O
TOF O
) O
using O
color O
RARE O
imaging O
. O

RT O
- O
PCR O
analysis O
showed O
that O
ALL_CAP I-GENE
- I-GENE
H I-GENE
RARE O
RARE O
RARE O
ALL_CAP I-GENE
- I-GENE
C I-GENE
and O
ALL_CAP I-GENE
- I-GENE
D I-GENE
are O
RARE O
in O
all O
rat O
strains O
examined O
, O
confirming O
that O
ALL_CAP I-GENE
diversity O
is O
not O
due O
to O
RARE O
differences O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
new O
RARE O
of O
the O
rat I-GENE
RARE I-GENE
prolactin I-GENE
( O
PRL I-GENE
) O
family O
, O
PRL I-GENE
- O
like O
protein I-GENE
H I-GENE
. O

Interestingly O
, O
we O
find O
that O
the O
interaction O
between O
Tat I-GENE
and O
NUM I-GENE
requires O
zinc O
RARE O
RARE O
RARE O
essential O
cysteine O
residues O
in O
both O
proteins O
. O

Thus O
, O
we O
have O
identified O
an O
activation O
target O
of O
a O
human O
activator O
, O
Oct I-GENE
- I-GENE
1 I-GENE
, O
within O
its O
RARE O
basal O
transcription O
complex O
. O

During O
early O
RARE O
, O
RARE I-GENE
protein I-GENE
is O
restricted O
to O
ventral O
column O
RARE O
and O
neuroblasts O
; O
later O
it O
is O
detected O
in O
a O
complex O
pattern O
of O
neurons O
. O

The O
repression O
domain O
, O
and O
indeed O
the O
RARE O
NUM I-GENE
protein I-GENE
, O
is O
highly O
RARE O
, O
RARE O
shown O
by O
the O
sequence O
of O
the O
NUM I-GENE
RARE I-GENE
homolog I-GENE
from O
the O
yeast O
RARE O
lactis O
and O
by O
database O
RARE O
. O

The O
RARE O
alone O
has O
the O
high O
affinity O
hormone O
binding O
site O
but O
is O
not O
capable O
of O
generating O
hormonal O
signal O
. O

RARE O
RARE O
, O
a O
potent O
transcriptional O
inhibitor O
of O
the O
viral I-GENE
LTR I-GENE
, O
abrogated O
the O
RARE O
responses O
in O
both O
NUM O
and O
ALL_CAP O
- O
2 O
cells O
, O
suggesting O
a O
common O
TNF I-GENE
- I-GENE
alpha I-GENE
- O
RARE O
transcriptional O
mechanism O
in O
these O
cell O
RARE O
despite O
their O
different O
modes O
of O
provirus O
RARE O
. O

Furthermore O
, O
synergistic O
activation O
of O
ERK2 I-GENE
occurred O
in O
the O
absence O
of O
changes O
in O
RARE O
NUM O
RARE O
and O
was O
not O
blocked O
by O
inhibition O
of O
protein I-GENE
kinase I-GENE
C I-GENE
activity O
and O
represents O
a O
separate O
RARE O
by O
which O
NUM I-GENE
regulates O
B O
cell O
function O
. O

The O
RARE O
RARE O
cyst O
is O
a O
very O
rare O
site O
. O

Biochemical O
analysis O
reveals O
that O
NUM I-GENE
is O
a O
nuclear O
protein O
containing O
two O
transcriptional O
repressor O
domains O
, O
NUM O
and O
NUM O
. O

However O
, O
the O
ALL_CAP O
group O
showed O
inferior O
gross O
motor O
performance O
on O
the O
RARE O
- O
RARE O
Test O
of O
RARE O
RARE O
( O
RARE O
NUM O
). O

The O
results O
RARE O
the O
possibility O
that O
pH O
RARE O
post O
- O
translational O
modifications O
of O
ALL_CAP I-GENE
are O
involved O
in O
events O
that O
RARE O
cell O
RARE O
and O
induce O
differentiation O
in O
Dictyostelium O
. O

We O
report O
here O
that O
, O
RARE O
a O
constant O
amount O
of O
transfected O
DNA O
, O
the O
level O
of O
chloramphenicol I-GENE
RARE I-GENE
( O
CAT I-GENE
) O
mRNA O
is O
increased O
in O
RARE I-GENE
- O
expressing O
cells O
using O
either O
HIV O
- O
1 O
or O
a O
murine O
leukemia I-GENE
virus I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
NUM I-GENE
- I-GENE
3 I-GENE
LTR I-GENE
- O
CAT I-GENE
reporter O
construct O
. O

We O
identified O
ALL_CAP I-GENE
mutations O
in O
11 O
of O
these O
unrelated O
ALL_CAP O
- O
like O
individuals O
who O
carry O
a O
single O
copy O
of O
ALL_CAP I-GENE
: O
these O
include O
two O
frameshift O
mutations O
( O
NUM O
and O
NUM O
) O
and O
three O
missense O
mutations O
( O
NUM O
, O
NUM O
, O
and O
NUM O
). O

The O
decrease O
of O
TNF I-GENE
receptors I-GENE
by O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
was O
accompanied O
by O
down O
- O
RARE O
of O
TNF I-GENE
- O
RARE O
activities O
, O
including O
cytotoxicity O
, O
RARE I-GENE
- I-GENE
3 I-GENE
activation O
, O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
activation O
, O
and O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
induction O
. O

RARE I-GENE
2 I-GENE
deiodinase I-GENE
( O
NUM I-GENE
) O
catalyzes O
the O
5 O
'- O
RARE O
of O
thyroxine O
to O
form O
3 O
, O
5 O
, O
3 O
'- O
RARE O
. O

We O
have O
identified O
two O
overlapping O
RARE O
sequence O
tag O
RARE O
, O
which O
contain O
the O
missing O
4 O
. O
4 O
- O
kb O
3 O
'- O
UTR O
of O
the O
human I-GENE
NUM I-GENE
( O
NUM I-GENE
) O
cDNA O
. O

Biol O
. O

Here O
we O
have O
investigated O
the O
structural O
requirements O
and O
consequences O
of O
regulatory O
RARE O
RARE O
the O
interaction O
between O
c I-GENE
- I-GENE
Jun I-GENE
and O
JNK I-GENE
in O
vivo O
. O

P I-GENE
- I-GENE
NUM I-GENE
, O
a O
novel O
protein O
that O
interacts O
with O
the O
cytosolic O
domain O
of O
RARE I-GENE
alpha I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
, O
is O
associated O
with O
RARE O
. O

RARE O
of O
NUM I-GENE
revealed O
a O
cytoplasmic O
distribution O
and O
cell O
fractionation O
studies O
showed O
that O
a O
significant O
fraction O
of O
NUM I-GENE
was O
recovered O
in O
a O
RARE O
fraction O
of O
the O
cytosolic O
material O
. O

RARE O
activation O
of O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
/ O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
JNK I-GENE
/ O
SAPK I-GENE
). O

Here O
we O
report O
the O
full O
- O
length O
coding O
cDNA O
sequence O
of O
the O
mouse I-GENE
homologue I-GENE
of I-GENE
NUM I-GENE
. O

The O
method O
also O
RARE O
RARE O
of O
venous O
RARE O
and O
RARE O
about O
asymmetric O
RARE O
transfer O
effects O
. O

Consistent O
with O
this O
, O
RARE O
RARE I-GENE
RARE O
core O
RARE I-GENE
NUM I-GENE
, O
NUM I-GENE
and O
NUM I-GENE
RARE O
RARE O
RARE O
and O
endogenous O
histone I-GENE
NUM I-GENE
in O
kinase O
assays O
with O
nuclear O
extracts O
. O

In O
this O
study O
we O
provide O
evidence O
that O
B I-GENE
- I-GENE
Myb I-GENE
is O
a O
direct O
physiological O
target O
RARE O
RARE I-GENE
A I-GENE
/ O
Cdk2 I-GENE
. O

Neither O
Ha I-GENE
- I-GENE
Ras I-GENE
( O
NUM O
, O
NUM O
) O
( O
Ha I-GENE
- I-GENE
NUM I-GENE
RARE O
which O
activates O
the O
RARE I-GENE
RARE O
RARE O
, O
nor O
Ha I-GENE
- I-GENE
Ras I-GENE
( I-GENE
NUM I-GENE
, I-GENE
NUM I-GENE
) I-GENE
( O
Ha I-GENE
- I-GENE
NUM I-GENE
RARE O
which O
stimulates O
the O
ALL_CAP I-GENE
RARE O
, O
did O
not O
have O
significant O
effects O
on O
factor O
- O
withdrawal O
apoptosis O
of O
RARE O
cells O
. O

We O
have O
isolated O
a O
novel O
human I-GENE
RARE I-GENE
, O
RARE I-GENE
E2 I-GENE
, O
that O
contains O
significant O
homology O
to O
RARE I-GENE
E I-GENE
. O

Initial O
experience O
with O
the O
new O
technology O
indicates O
that O
RARE O
is O
an O
RARE O
to O
other O
methods O
such O
RARE O
ALL_CAP O
and O
MRI O
. O

The O
dopamine I-GENE
NUM I-GENE
receptor I-GENE
RARE O
RARE O
RARE O
many O
other O
RARE I-GENE
receptors I-GENE
contain O
several O
putative O
SH3 I-GENE
binding I-GENE
domains I-GENE
. O

The O
highly O
RARE O
NUM O
- O
RARE O
form O
of O
RARE I-GENE
( O
NUM I-GENE
) O
is O
the O
RARE O
species O
to O
be O
RARE O
in O
both O
RARE O
and O
familial O
AD O
. O

This O
model O
is O
supported O
by O
experiments O
showing O
that O
NUM I-GENE
associates O
with O
the O
N I-GENE
- I-GENE
terminal I-GENE
regulatory I-GENE
domain I-GENE
of I-GENE
NUM I-GENE
in O
cell O
lysates O
and O
phosphorylates O
NUM I-GENE
in O
vitro O
. O

Schizosaccharomyces O
pombe O
cells O
respond O
to O
nutrient O
deprivation O
by O
altering O
NUM O
/ O
M O
cell O
size O
control O
. O

A O
- O
RARE O
functioned O
best O
when O
positioned O
close O
to O
the O
- O
NUM O
hexamer O
rather O
than O
one O
helical O
RARE O
RARE O
upstream O
, O
similar O
to O
the O
positioning O
optimal O
RARE O
ALL_CAP O
element O
function O
. O

NUM I-GENE
RARE O
increased O
upon O
RARE O
of O
ALL_CAP O
29 O
. O
1 O
cells O
to O
fibronectin I-GENE
and O
to O
NUM O
RARE O
cells O
. O

Raf I-GENE
is O
a O
key O
serine I-GENE
- I-GENE
threonine I-GENE
protein I-GENE
kinase I-GENE
which O
participates O
in O
the O
RARE O
of O
growth O
, O
anti O
- O
apoptotic O
and O
differentiation O
RARE O
. O

The O
US O
National O
Institute O
on O
RARE O
RARE O
and O
RARE O
( O
ALL_CAP O
) O
recognizes O
two O
forms O
of O
RARE O
drinking O
: O
' O
RARE O
RARE O
RARE O
RARE O
a O
RARE O
problem O
, O
and O
' O
RARE O
dependence O
RARE O
a O
true O
medical O
disorder O
, O
which O
includes O
a O
genetic O
RARE O
, O
that O
can O
be O
RARE O
understood O
and O
RARE O
treated O
. O

RARE I-GENE
was O
extracted O
from O
the O
RARE O
, O
and O
the O
lack O
of O
type I-GENE
III I-GENE
RARE I-GENE
was O
determined O
by O
means O
of O
RARE O
dodecyl O
RARE O
- O
polyacrylamide O
gel O
electrophoresis O
( O
SDS O
- O
PAGE O
). O

RESULTS O
: O
During O
the O
7 O
- O
year O
period O
, O
10 O
, O
NUM O
symptomatic O
duodenal O
ulcer O
diseases O
were O
diagnosed O
. O

RESULTS O
: O
Significant O
changes O
from O
pretreatment O
to O
RARE O
were O
observed O
( O
p O
< O
NUM O
. O
001 O
). O

In O
RARE O
, O
assembly O
of O
this O
complex O
mediates O
the O
enzymatic O
activation O
of O
the O
p21 I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
1 I-GENE
and O
RARE O
actin I-GENE
RARE O
. O

The O
RARE O
of O
the O
RARE O
caused O
a O
RARE O
of O
the O
posterior O
stomach O
RARE O
, O
leading O
to O
RARE O
. O

RARE O
RARE O
virus O
( O
ALL_CAP O
) O
is O
a O
newly O
identified O
bovine O
RARE O
that O
is O
closely O
related O
to O
the O
bovine O
immunodeficiency O
virus O
( O
ALL_CAP O
). O

Approximately O
50 O
% O
of O
the O
residues O
are O
RARE O
among O
all O
three O
sequences O
, O
yet O
all O
three O
viruses O
have O
retained O
response O
elements O
RARE O
glucocorticoids O
, O
two O
RARE O
RARE O
CCAAT O
RARE O
, O
and O
RARE O
RARE O
TATA O
RARE O
. O

NUM I-GENE
is O
a O
highly O
basic O
protein O
that O
belongs O
to O
a O
family O
of O
putative O
RNA O
- O
binding O
proteins O
. O

This O
survey O
included O
NUM O
randomly O
RARE O
RARE O
above O
18 O
years O
of O
age O
who O
received O
the O
European O
Organization O
RARE O
Research O
and O
Treatment O
of O
Cancer O
RARE O
RARE O
of O
RARE O
RARE O
( O
ALL_CAP O
ALL_CAP O
- O
NUM O
(+ O
3 O
) O
by O
RARE O
. O

During O
presentation O
of O
RARE O
facial O
RARE O
, O
we O
detected O
a O
signal O
increase O
predominantly O
in O
the O
RARE O
anterior O
RARE O
gyrus O
, O
bilateral O
posterior O
RARE O
RARE O
, O
medial O
frontal O
cortex O
and O
right O
RARE O
gyrus O
, O
brain O
regions O
previously O
implicated O
in O
RARE O
and O
RARE O
RARE O
tasks O
. O

RARE O
- O
RARE O
of O
IRS I-GENE
- I-GENE
1 I-GENE
is O
RARE O
to O
its O
serine O
RARE O
dependent O
on O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
activity O
and O
appears O
required O
RARE O
differentiation O
to O
occur O
, O
RARE O
IRS I-GENE
- I-GENE
1 I-GENE
is O
not O
modified O
and O
RARE O
to O
accumulate O
in O
a O
RARE O
RARE O
cell O
line O
. O

This O
study O
RARE O
the O
mammalian O
two O
- O
RARE O
RARE O
to O
examine O
the O
role O
of O
RARE O
in O
the O
RARE O
of O
human I-GENE
progesterone I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
). O

One O
of O
its O
unique O
features O
appears O
to O
be O
the O
unusually O
short O
5 O
'- O
RARE O
regions O
( O
UTR O
) O
( O
1 O
- O
6 O
nucleotides O
( O
RARE O
)) O
and O
the O
apparent O
absence O
of O
5 O
'- O
RARE O
RARE O
from O
its O
mRNAs O
. O

The O
gene I-GENE
encoding I-GENE
human I-GENE
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
( O
t I-GENE
- I-GENE
PA I-GENE
) O
is O
regulated O
in O
a O
cell O
- O
type O
- O
specific O
manner O
. O

Both O
the O
presence O
of O
RARE O
and O
RARE O
are O
needed O
to O
RARE O
induction O
of O
the O
RARE O
. O

Competition O
with O
a O
putative O
MADS I-GENE
box I-GENE
consensus O
binding O
site O
from O
the O
promoter O
of O
the O
RARE O
regulated O
RARE I-GENE
- I-GENE
RARE I-GENE
- I-GENE
specific I-GENE
gene I-GENE
NUM I-GENE
( O
NUM I-GENE
) O
and O
the O
human I-GENE
MADS I-GENE
box I-GENE
consensus I-GENE
binding I-GENE
site I-GENE
RARE O
serum I-GENE
response I-GENE
factor I-GENE
demonstrated O
that O
one O
of O
the O
three O
complexes O
formed O
was O
specific O
to O
the O
NUM I-GENE
sequence I-GENE
. O

The O
human I-GENE
SHBG I-GENE
proximal I-GENE
promoter I-GENE
was O
analyzed O
by O
DNase I-GENE
I I-GENE
footprinting O
, O
and O
the O
RARE O
significance O
of O
6 O
RARE O
regions O
( O
NUM O
- O
NUM O
) O
within O
the O
proximal O
promoter O
was O
studied O
in O
human O
NUM O
RARE O
cells O
. O

In O
vitro O
translation O
and O
in O
vivo O
RARE O
profile O
analysis O
indicated O
that O
transcripts I-GENE
C I-GENE
and I-GENE
E I-GENE
were O
translated O
with O
similar O
translational O
RARE O
that O
are O
substantially O
greater O
than O
that O
of O
transcript I-GENE
D I-GENE
, O
suggesting O
that O
5 O
'- O
RARE O
regions O
play O
a O
role O
in O
translational O
control O
. O

We O
have O
introduced O
a O
mutation O
( O
NUM O
RARE O
Asn O
) O
into O
this O
domain O
of O
p190 I-GENE
that O
decreased O
its O
ability O
to O
bind O
guanine O
nucleotide O
when O
RARE O
RARE O
a O
hemagglutinin I-GENE
( O
ALL_CAP I-GENE
)- O
RARE O
protein O
in O
COS O
cells O
. O

RARE O
type O
ALL_CAP I-GENE
- O
p190 I-GENE
RARE O
a O
RARE O
of O
RARE O
cells O
with O
long O
, O
RARE O
RARE O
similar O
to O
that O
seen O
when O
Rho I-GENE
function O
is O
disrupted O
by O
ALL_CAP O
- O
RARE O
. O

We O
RARE O
that O
ALL_CAP I-GENE
- O
associated O
vasculitis O
is O
another O
important O
complication O
of O
ALL_CAP O
. O

The O
RARE O
, O
TATA O
- O
less O
promoter O
has O
high O
G O
+ O
C O
content O
, O
and O
RARE O
NUM O
RARE O
among O
abundantly O
RARE O
mRNA O
species O
. O

Although O
we O
predicted O
that O
overexpression O
of O
the O
ALL_CAP O
- O
terminal O
domains O
, O
which O
were O
thought O
to O
be O
involved O
in O
the O
RARE O
of O
SREBP I-GENE
RARE O
, O
would O
result O
in O
disruption O
of O
the O
SREBP I-GENE
- O
dependent O
transcriptional O
RARE O
of O
several O
genes O
, O
the O
mRNA O
levels O
RARE O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
3 I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
A I-GENE
( I-GENE
HMG I-GENE
CoA I-GENE
) I-GENE
synthase I-GENE
in O
these O
two O
cell O
lines O
were O
regulated O
in O
a O
sterol O
- O
dependent O
manner O
. O

RARE O
matter O
intake O
, O
apparent O
nutrient O
RARE O
, O
serum O
chemistry O
profiles O
, O
RARE O
concentrations O
, O
and O
RARE O
of O
NUM O
in O
tissues O
were O
evaluated O
. O

However O
, O
RARE O
studies O
have O
been O
conducted O
to O
further O
investigate O
this O
potentially O
hazardous O
effect O
of O
lidocaine O
. O

E O
., O
RARE O
, O
ALL_CAP O
. O

NUM I-GENE
is O
constitutively O
nuclear O
in O
a O
NUM I-GENE
mutant I-GENE
, O
and O
NUM I-GENE
binds O
to O
a O
nuclear O
export O
sequence O
( O
ALL_CAP O
)- O
like O
sequence O
in O
NUM I-GENE
in O
the O
presence O
of O
ALL_CAP I-GENE
. O

Mean O
intake O
of O
vitamin O
A O
RARE O
to O
1 O
. O
1 O
and O
NUM O
. O
9 O
mg O
ALL_CAP O
/ O
day O
RARE O
men O
and O
women O
, O
respectively O
; O
the O
RARE O
of O
meat O
, O
RARE O
and O
RARE O
, O
RARE O
and O
RARE O
products O
to O
RARE O
intake O
were O
NUM O
%, O
NUM O
%, O
16 O
%, O
and O
16 O
%, O
respectively O
. O

Also O
, O
the O
amplitude O
of O
the O
RARE O
potentials O
( O
NUM O
+ O
NUM O
+ O
NUM O
+ O
NUM O
) O
was O
significantly O
RARE O
in O
the O
early O
postoperative O
period O
. O

Furthermore O
, O
NUM I-GENE
overexpression O
results O
in O
RARE O
RARE O
of O
the O
RARE O
- O
RARE O
c I-GENE
- I-GENE
jun I-GENE
and O
c I-GENE
- I-GENE
fos I-GENE
. O

The O
yeast I-GENE
NUM I-GENE
gene I-GENE
, O
identified O
by O
endoplasmic O
reticulum O
protein O
RARE O
mutations O
, O
encodes O
cis I-GENE
- I-GENE
RARE I-GENE
, O
a O
key O
enzyme O
in O
RARE O
RARE O
. O

The O
yeast O
RARE I-GENE
NUM I-GENE
preferentially O
RARE O
into O
regions O
of O
RARE O
chromatin O
. O

The O
RARE O
of O
NUM I-GENE
completely O
restored O
NUM I-GENE
RARE O
in O
a O
NUM I-GENE
mutant I-GENE
and O
partially O
suppressed O
the O
osmotic O
stress O
sensitivity O
, O
RARE O
NUM I-GENE
RARE O
a O
RARE O
effector O
of O
the O
ALL_CAP I-GENE
RARE O
. O

RARE O
RARE O
of O
a O
previously O
uncharacterized O
gene O
, O
NUM I-GENE
, O
efficiently O
suppresses O
the O
growth O
and O
RARE O
defects O
of O
a O
RARE O
- O
RARE O
( O
RARE O
) O
mutant I-GENE
NUM I-GENE
- I-GENE
1 I-GENE
. O

The O
slower O
- O
electrophoretic O
- O
mobility O
form O
of O
NUM I-GENE
was O
absent O
in O
human O
cells O
in O
G1 O
/ O
S O
and O
appeared O
RARE O
the O
cells O
RARE O
NUM O
/ O
M O
. O

We O
have O
identified O
amino O
acid O
sequences O
in O
mammalian O
and O
Xenopus O
NUM I-GENE
/ O
NUM I-GENE
that O
are O
necessary O
RARE O
insulin I-GENE
gene I-GENE
RARE O
and O
ectopic O
RARE O
. O

Both O
NUM I-GENE
- O
NUM I-GENE
RARE O
transformed O
ALL_CAP O
3T3 O
RARE O
, O
and O
this O
transformation O
required O
the O
NUM I-GENE
domains I-GENE
RARE O
DNA O
binding O
and O
ALL_CAP I-GENE
interaction O
. O

Recent O
studies O
have O
suggested O
that O
NUM O
also O
positively O
regulate O
ALL_CAP I-GENE
- I-GENE
70 I-GENE
function O
. O

Genetic O
and O
RARE O
data O
indicate O
that O
wild I-GENE
- I-GENE
type I-GENE
RARE I-GENE
and O
ALL_CAP I-GENE
compete O
RARE O
binding O
to O
RARE I-GENE
, O
leading O
to O
a O
RARE O
RARE O
of O
the O
RARE I-GENE
signal O
in O
RARE O
ALL_CAP I-GENE
RARE I-GENE
animals O
and O
to O
a O
dramatic O
enhancement O
of O
the O
gain O
- O
of O
- O
function O
activity O
of O
ALL_CAP I-GENE
in O
homozygous O
mutants O
. O

Another O
ORF O
, O
RARE I-GENE
. I-GENE
2 I-GENE
RARE O
between O
ALL_CAP I-GENE
and O
RARE I-GENE
, O
shares O
sequence O
RARE O
with O
NUM I-GENE
, O
and O
we O
RARE O
it O
RARE I-GENE
. O

The O
location O
of O
the O
ALL_CAP O
within O
the O
ALL_CAP I-GENE
structural I-GENE
gene I-GENE
, O
the O
cooperativity O
observed O
in O
footprinting O
studies O
and O
RARE O
studies O
suggest O
that O
the O
ALL_CAP O
participates O
in O
the O
interaction O
of O
ALL_CAP I-GENE
with O
the O
upstream O
binding O
sites O
by O
RARE O
out O
the O
intervening O
DNA O
. O

In O
vitro O
transcription O
assays O
demonstrate O
that O
the O
ALL_CAP O
- O
RARE O
RARE O
, O
RARE O
, O
directly O
and O
specifically O
inhibits O
the O
formation O
of O
the O
ALL_CAP I-GENE
transcript I-GENE
. O

RARE O
analysis O
gave O
a O
RARE O
of O
4 O
. O
4 O
RARE O
10 O
( O
10 O
) O
M O
- O
1 O
RARE O
the O
binding O
of O
N I-GENE
- I-GENE
NUM I-GENE
to O
NUM I-GENE
. I-GENE
1 I-GENE
and O
2 O
. O
2 O
RARE O
10 O
( O
10 O
) O
M O
- O
1 O
RARE O
the O
binding O
of O
N I-GENE
- I-GENE
NUM I-GENE
to O
NUM I-GENE
. I-GENE
NUM I-GENE
. O

Expression O
of O
p130 I-GENE
( O
RARE I-GENE
) O
( O
RARE I-GENE
RARE O
a O
major O
binding O
protein O
RARE O
the O
Crk I-GENE
NUM I-GENE
- I-GENE
domain I-GENE
, O
also O
RARE O
JNK I-GENE
activation O
, O
which O
was O
blocked O
by O
the O
NUM I-GENE
- I-GENE
mutant I-GENE
of O
Crk I-GENE
. O

RARE O
correlations O
were O
seen O
between O
the O
measurements O
RARE O
protein O
intake O
( O
RARE O
=. O
58 O
, O
P O
=. O
NUM O
) O
energy O
intake O
( O
RARE O
=. O
NUM O
, O
P O
RARE O
NUM O
RARE O
with O
mean O
differences O
of O
. O
NUM O
g O
/ O
kg O
/ O
d O
( O
SD O
. O
38 O
) O
2 O
. O
04 O
RARE O
/ O
kg O
/ O
day O
( O
SD O
6 O
. O
67 O
RARE O
respectively O
. O

The O
NUM I-GENE
enzyme O
- O
RARE O
immunosorbent O
assay O
( O
ELISA O
) O
to O
detect O
circulating O
RARE I-GENE
RARE I-GENE
antigen I-GENE
uses O
50 O
ALL_CAP O
of O
serum O
. O

We O
now O
show O
that O
NUM I-GENE
- O
NUM I-GENE
ligation O
can O
also O
mimic O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
and O
have O
an O
anti O
- O
proliferative O
pro O
- O
RARE O
influence O
within O
the O
immune O
RARE O
, O
causing O
RARE O
- O
RARE O
of O
RARE O
- O
RARE O
molecules O
on O
B O
lymphocytes O
. O

The O
NUM I-GENE
repressor I-GENE
is O
a O
zinc I-GENE
finger I-GENE
protein I-GENE
that O
mediates O
glucose O
repression O
in O
yeast O
. O

RARE O
is O
involved O
in O
RARE O
RARE O
and O
high O
- O
level O
ALL_CAP I-GENE
I I-GENE
RARE O
; O
but O
, O
it O
does O
not O
affect O
the O
spatial O
and O
temporal O
pattern O
of O
ALL_CAP I-GENE
I I-GENE
RARE O
. O

The O
divergence O
in O
RARE O
RARE O
between O
the O
sheep O
NUM I-GENE
and O
the O
other O
mammalian I-GENE
NUM I-GENE
is O
primarily O
localized O
to O
the O
extracellular O
amino O
terminal O
domain O
of O
the O
receptor O
( O
18 O
of O
NUM O
divergent O
residues O
, O
RARE O
RARE O
human I-GENE
NUM I-GENE
). O

RARE O
- O
RARE O
receptor O
internalization O
, O
determined O
RARE O
the O
percent O
of O
RARE O
RARE O
NUM O
] O
NUM I-GENE
- I-GENE
ALL_CAP I-GENE
RARE O
RARE O
in O
the O
acid O
- O
resistant O
fraction O
of O
transfected O
RARE O
7 O
cells O
, O
increased O
with O
time O
( O
NUM O
- O
NUM O
min O
RARE O
37 O
degrees O
C O
) O
RARE O
both O
wild O
- O
type O
and O
variant O
NUM I-GENE
. O

RARE O
arterial O
thrombotic O
RARE O
on O
young O
onset O
and O
protein I-GENE
S I-GENE
deficiency O
. O

We O
showed O
that O
Stat3 I-GENE
and O
NUM I-GENE
were O
affinity O
RARE O
using O
phosphopeptides O
containing O
NUM O
and O
NUM O
but O
not O
by O
RARE O
peptide O
analogues O
or O
by O
phosphopeptides O
containing O
NUM O
and O
NUM O
. O

Taken O
together O
, O
our O
results O
indicate O
that O
the O
NUM I-GENE
gene I-GENE
RARE O
RARE O
a O
negative O
regulator O
of O
drug O
resistance O
in O
C O
. O
RARE O
and O
constitute O
the O
RARE O
evidence O
that O
ALL_CAP O
resistance O
can O
result O
from O
the O
inactivation O
of O
a O
regulatory O
factor O
such O
RARE O
NUM I-GENE
. O

These O
findings O
suggest O
that O
RARE O
ALL_CAP O
/ O
M O
is O
more O
useful O
than O
washout O
rate O
to O
assess O
the O
effect O
of O
treatment O
on O
RARE O
failure O
due O
to O
ALL_CAP O
. O

This O
study O
was O
undertaken O
to O
evaluate O
how O
RARE O
and O
their O
placement O
affect O
the O
NUM O
RARE O
spectral O
properties O
. O

CONCLUSIONS O
: O
RARE O
with O
RARE O
prior O
to O
pituitary O
suppression O
in O
the O
early O
follicular O
RARE O
decreases O
ovarian O
cyst O
formation O
, O
without O
an O
apparent O
effect O
on O
subsequent O
follicular O
recruitment O
or O
RARE O
rates O
. O

With O
regard O
to O
the O
optimal O
threshold O
values O
, O
sensitivity O
and O
RARE O
were O
NUM O
RARE O
97 O
% O
and O
NUM O
RARE O
NUM O
% O
with O
FDG O
PET O
, O
compared O
to O
NUM O
RARE O
92 O
% O
and O
77 O
RARE O
82 O
% O
with O
ALL_CAP O
, O
respectively O
. O

This O
c I-GENE
- I-GENE
Jun I-GENE
activity O
is O
inhibited O
by O
c I-GENE
- I-GENE
Fos I-GENE
, O
another O
RARE O
that O
can O
RARE O
with O
c I-GENE
- I-GENE
Jun I-GENE
to O
form O
the O
transcription O
factor O
AP I-GENE
- I-GENE
1 I-GENE
. O

RARE O
root O
RARE O
RARE O
- O
specific O
promoter O
activity O
of O
the O
RARE I-GENE
beta I-GENE
- I-GENE
RARE I-GENE
NUM I-GENE
, I-GENE
2 I-GENE
- I-GENE
RARE I-GENE
gene I-GENE
. O

CONCLUSION O
: O
Our O
study O
shows O
that O
( O
1 O
) O
RARE O
body O
BMD O
and O
femoral O
neck O
BMD O
were O
significantly O
RARE O
in O
the O
study O
group O
that O
performed O
RARE O
- O
RARE O
RARE O
than O
in O
control O
subjects O
, O
( O
2 O
) O
swimming O
exercise O
had O
RARE O
effect O
on O
BMD O
, O
and O
( O
3 O
) O
although O
swimming O
is O
not O
a O
bone O
- O
RARE O
exercise O
, O
it O
can O
significantly O
improve O
RARE O
, O
back O
, O
and O
RARE O
muscle O
strength O
. O

This O
suggests O
roles O
RARE O
both O
the O
NUM O
and O
NUM O
elements O
in O
RARE O
NUM I-GENE
gene I-GENE
RARE O
RARE O
development O
. O

ALL_CAP O
gain O
RARE O
to O
4 O
. O
2 O
+/- O
1 O
. O
3 O
mm O
, O
NUM O
% O
of O
the O
defects O
showing O
ALL_CAP O
gain O
> O
or O
= O
4 O
mm O
. O

RARE O
with O
other O
known O
RARE I-GENE
and O
RARE I-GENE
- I-GENE
like I-GENE
proteins I-GENE
indicate O
that O
these O
Arabidopsis O
ALL_CAP I-GENE
RARE O
are O
unique O
from O
RARE O
RARE I-GENE
. O

RARE O
fixation O
in O
dogs O
achieved O
with O
ALL_CAP O
energy O
. O

However O
, O
there O
has O
not O
been O
any O
evidence O
of O
A O
. O
RARE O
infections O
, O
specifically O
RARE O
, O
associated O
with O
the O
fish O
in O
this O
RARE O
. O

Further O
, O
we O
show O
that O
this O
ALL_CAP I-GENE
- O
inducible O
CBF O
/ O
cdc2 I-GENE
is O
related O
to O
the O
CBF I-GENE
which O
was O
shown O
to O
activate O
the O
heat I-GENE
shock I-GENE
protein I-GENE
70 I-GENE
promoter I-GENE
. O

The O
RARE O
absorption O
of O
clindamycin O
was O
studied O
in O
healthy O
male O
volunteers O
, O
comparing O
two O
RARE O
clindamycin O
RARE O
w O
/ O
v O
RARE O
RARE O
( O
NUM O
. O
NUM O
% O
w O
/ O
v O
) O
gels O
, O
containing O
clindamycin O
phosphate O
ester O
and O
clindamycin O
RARE O
, O
respectively O
, O
relative O
to O
a O
clindamycin O
phosphate O
RARE O
( O
1 O
% O
clindamycin O
; O
RARE O
T O
). O

The O
ALL_CAP O
concentrations O
of O
the O
nine O
RARE O
evaluated O
RARE O
the O
more O
and O
less O
affected O
lungs O
were O
compared O
: O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
RARE O
ALL_CAP I-GENE
- I-GENE
8 I-GENE
, O
ALL_CAP I-GENE
- I-GENE
12 I-GENE
, O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
- I-GENE
alpha I-GENE
RARE O
and O
RARE I-GENE
gamma I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
) O
showed O
significant O
differences O
( O
p O
ranged O
between O
NUM O
. O

RARE O
analyses O
indicated O
that O
inhibition O
of O
ERK I-GENE
- I-GENE
1 I-GENE
/ I-GENE
2 I-GENE
decreased O
RARE O
acid O
- O
elevated O
RARE O
of O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
. O

Two O
- O
way O
analysis O
of O
RARE O
was O
used O
to O
determine O
whether O
composite O
knowledge O
score O
differed O
among O
patient O
groups O
. O

The O
human O
pathogenic O
bacterium O
group O
A O
RARE O
produces O
an O
extracellular O
cysteine I-GENE
protease I-GENE
RARE O
RARE I-GENE
RARE I-GENE
RARE I-GENE
B I-GENE
( O
ALL_CAP I-GENE
)] O
that O
is O
a O
critical O
RARE O
factor O
RARE O
invasive O
RARE O
episodes O
. O

The O
RARE O
, O
RARE O
, O
and O
RARE O
part O
of O
the O
dorsal O
RARE O
areas O
were O
preferentially O
activated O
by O
the O
self O
- O
RARE O
RARE O
movement O
task O
( O
ALL_CAP O
). O

RARE O
the O
evidence O
RARE O
RARE O
anaesthesia O
. O

Plasma O
ALL_CAP I-GENE
levels O
were O
determined O
RARE O
regular O
intervals O
. O

The O
RARE O
biogenesis O
disorders O
( O
RARE O
) O
are O
a O
set O
of O
lethal O
genetic O
diseases O
characterized O
by O
RARE O
metabolic O
deficiencies O
, O
RARE O
abnormalities O
, O
mental O
retardation O
, O
and O
premature O
RARE O
. O

The O
RARE O
site O
includes O
the O
RARE O
RARE O
NUM O
( O
the O
site O
of O
RARE O
RARE O
NUM O
and O
NUM O
. O

Consistent O
with O
these O
findings O
, O
relatively O
weak O
transcriptional O
silencing O
by O
the O
RARE O
VDR I-GENE
was O
observed O
using O
the O
RARE I-GENE
ALL_CAP O
. O

In O
ALL_CAP O
- O
3 O
, O
the O
E1A I-GENE
region I-GENE
is O
RARE O
between O
1 O
. O
5 O
and O
3 O
. O
8 O
map O
RARE O
. O

Six O
putative O
ALL_CAP O
genome O
products O
, O
including O
one O
Rep I-GENE
and O
five O
non O
- O
Rep I-GENE
proteins O
, O
show O
high O
( O
70 O
. O
4 O
- O
NUM O
. O
9 O
%) O
amino O
acid O
identity O
to O
the O
corresponding O
RARE O
ALL_CAP I-GENE
proteins I-GENE
, O
whereas O
two O
other O
Rep I-GENE
proteins I-GENE
encoded O
by O
ALL_CAP I-GENE
- I-GENE
C2 I-GENE
and O
NUM I-GENE
are O
82 O
. O
3 O
% O
and O
NUM O
. O
NUM O
% O
identical O
to O
those O
encoded O
by O
ALL_CAP I-GENE
- I-GENE
C2 I-GENE
and O
NUM I-GENE
, O
respectively O
. O

ALL_CAP I-GENE
was O
labeled O
with O
1 O
mCi O
NUM O
by O
a O
technique O
of O
self O
- O
labeling O
in O
the O
presence O
of O
10 O
RARE O
4 O
) O
M O
hydrogen O
RARE O
. O

It O
is O
related O
to O
a O
variety O
of O
mammalian O
RARE O
- O
associated O
proteins O
and O
to O
the O
yeast O
NUM I-GENE
, O
an O
essential O
protein O
involved O
in O
RARE O
of O
endoplasmic O
reticulum O
- O
derived O
vesicles O
to O
the O
cis O
- O
RARE O
. O

The O
data O
indicate O
that O
NUM I-GENE
is O
directly O
regulated O
by O
retinoic O
acid O
- O
RARE O
receptors O
and O
NUM I-GENE
. O

Both O
proteins O
were O
shown O
to O
be O
constitutively O
associated O
with O
RARE I-GENE
. O

ALL_CAP I-GENE
was O
found O
to O
bind O
to O
ALL_CAP I-GENE
protein I-GENE
in O
vitro O
, O
RARE O
efficiently O
RARE O
in O
vivo O
in O
yeast O
cells O
. O

Fas I-GENE
- O
resistant O
ALL_CAP O
- O
40 O
lymphoma O
B O
- O
cells O
RARE O
ALL_CAP I-GENE
- O
RARE O
through O
targeted O
disruption O
of O
the O
RARE I-GENE
gene I-GENE
by O
homologous O
RARE O
RARE O
underwent O
apoptosis O
after O
Fas I-GENE
ligation O
, O
but O
wild O
- O
type O
ALL_CAP O
- O
40 O
cells O
or O
ALL_CAP I-GENE
- O
RARE O
ALL_CAP O
- O
40 O
cells O
reconstituted O
with O
wild I-GENE
- I-GENE
type I-GENE
human I-GENE
RARE I-GENE
gene I-GENE
did O
not O
. O

A O
motif O
( O
ALL_CAP O
) O
which O
matches O
a O
CREB I-GENE
site I-GENE
and O
is O
similar O
to O
an O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
is O
embedded O
within O
NUM I-GENE
. O

RARE O
, O
four O
RARE O
RARE O
variants O
, O
NUM O
, O
NUM O
, O
NUM O
and O
NUM O
have O
been O
shown O
to O
be O
RARE O
- O
RARE O
RARE O
RARE O
the O
NUM I-GENE
gene I-GENE
locus I-GENE
. O

Therefore O
, O
in O
order O
to O
search O
RARE O
the O
latent O
genes O
, O
we O
used O
RARE O
- O
specific O
oligonucleotides O
RARE O
NUM O
, O
NUM O
and O
NUM O
to O
probe O
RARE O
from O
both O
normal O
and O
T O
. O
RARE O
- O
RARE O
rabbits O
by O
Southern O
blotting O
. O

TRAF2 I-GENE
is O
known O
to O
associate O
with O
ALL_CAP I-GENE
, O
and O
RARE O
of O
a O
dominant O
- O
negative O
N O
- O
terminal O
deletion O
TRAF2 I-GENE
mutant I-GENE
was O
found O
to O
partially O
inhibit O
LMP1 I-GENE
- O
RARE O
JNK I-GENE
activation O
in O
293 O
cells O
. O

These O
data O
further O
define O
a O
role O
RARE O
ALL_CAP I-GENE
and O
TRAF2 I-GENE
in O
JNK I-GENE
activation O
and O
confirm O
that O
LMP1 I-GENE
RARE O
signalling O
mechanisms O
used O
by O
the O
TNF I-GENE
receptor I-GENE
/ O
CD40 I-GENE
family O
to O
elicit O
its O
pleiotropic O
activities O
. O

Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
- I-GENE
encoded I-GENE
latent I-GENE
membrane I-GENE
protein I-GENE
1 I-GENE
activates O
the O
JNK I-GENE
RARE O
through O
its O
extreme O
C O
terminus O
via O
a O
mechanism O
involving O
ALL_CAP I-GENE
and O
TRAF2 I-GENE
. O

In O
contrast O
, O
transiently O
transfected O
cells O
expressing O
EBNA I-GENE
- I-GENE
3 I-GENE
revealed O
a O
RARE O
increase O
in O
EBNA I-GENE
- I-GENE
3 I-GENE
protein I-GENE
RARE O
from O
the O
genomic O
EBNA I-GENE
- I-GENE
3 I-GENE
gene I-GENE
compared O
to O
EBNA I-GENE
- I-GENE
3 I-GENE
cDNA I-GENE
. O

However O
, O
serial O
RARE O
of O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
cells O
, O
which O
are O
RARE O
to O
infection O
with O
ALL_CAP O
, O
after O
transient O
transfection O
revealed O
that O
mutation O
of O
a O
second O
tyrosine O
RARE O
in O
the O
N O
- O
terminal O
motif O
completely O
prevented O
the O
RARE O
of O
the O
virus O
. O

RARE I-GENE
- I-GENE
RARE I-GENE
virus I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
glycoprotein I-GENE
ALL_CAP I-GENE
is O
a O
type I-GENE
1 I-GENE
transmembrane I-GENE
glycoprotein I-GENE
which O
is O
one O
RARE O
of O
the O
RARE O
ALL_CAP I-GENE
: O
ALL_CAP I-GENE
Fc I-GENE
receptor I-GENE
complex O
. O

To O
this O
end O
, O
we O
analyzed O
the O
RARE O
status O
of O
a O
RARE O
tyrosine I-GENE
kinase I-GENE
substrate O
, O
the O
transforming O
Shc I-GENE
RARE I-GENE
protein I-GENE
, O
in O
RARE O
expressing O
the O
viral O
oncogene O
. O

These O
genes O
were O
RARE O
in O
a O
Saccharomyces O
cerevisiae O
mutant O
in O
which O
the O
endogenous I-GENE
RARE I-GENE
gene I-GENE
( O
NUM I-GENE
) O
had O
been O
RARE O
, O
and O
the O
RARE O
of O
the O
transformants O
were O
characterized O
. O

In O
this O
study O
, O
evidence O
is O
presented O
that O
temporally O
and O
spatially O
specific O
NUM I-GENE
RARE O
is O
RARE O
by O
a O
complex O
RARE O
of O
cis O
- O
acting O
regulatory O
RARE O
that O
are O
responsive O
to O
different O
genetic O
signals O
. O

Furthermore O
, O
using O
transgenic O
mouse O
technology O
we O
localized O
independent O
cis O
- O
regulatory O
elements O
controlling O
the O
tissue O
- O
specific O
RARE O
of O
NUM I-GENE
. O

In O
the O
second O
experiment O
, O
a O
stable O
nickel O
RARE O
, O
NUM O
, O
was O
given O
in O
drinking O
water O
to O
20 O
nickel O
- O
RARE O
women O
and O
20 O
age O
- O
matched O
controls O
, O
both O
groups O
having O
vesicular O
RARE O
RARE O
of O
the O
RARE O
type O
. O

RARE O
tissue O
and O
RARE O
RARE I-GENE
fibers O
in O
the O
RARE O
RARE O
permit O
its O
expansion O
RARE O
RARE O
. O

RARE O
of O
patients O
RARE O
with O
RARE O
mycobacteria O
( O
ALL_CAP O
) O
is O
increasing O
world O
- O
wide O
in O
recent O
years O
. O

Comparison O
of O
the O
sequences O
of O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
and O
bacteria O
- O
RARE O
junctions O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
showed O
a O
NUM O
bp O
common O
core O
sequence O
, O
where O
RARE O
RARE O
place O
, O
near O
the O
5 O
' O
end O
of O
the O
integrase I-GENE
gene I-GENE
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
treatment O
of O
RARE O
RARE O
disorder O
in O
recipients O
of O
solid O
organ O
RARE O
. O

RARE O
testing O
was O
performed O
on O
all O
RARE O
workers O
and O
some O
control O
volunteers O
using O
RARE O
RARE O
testing O
with O
RARE O
, O
RARE O
, O
and O
yeast O
antigens O
RARE O
RARE O
RARE O
other O
RARE O
allergens O
, O
and O
by O
RARE O
RARE O
serum I-GENE
IgE I-GENE
levels O
. O

OBJECTIVE O
: O
To O
evaluate O
the O
accuracy O
of O
working O
RARE O
RARE O
RARE O
and O
RARE O
restorations O
made O
from O
RARE O
RARE O
RARE O
/ O
RARE O
RARE O
RARE O
RARE O
materials O
using O
different O
RARE O
of O
RARE O
RARE O
. O

OBJECTIVES O
: O
To O
assess O
the O
ability O
of O
pretreatment O
and O
post O
- O
treatment O
RARE I-GENE
- I-GENE
specific I-GENE
antigen I-GENE
( O
PSA I-GENE
) O
measurements O
, O
clinical O
tumor O
RARE O
, O
tumor O
grade O
, O
RARE O
sum O
, O
RARE O
, O
age O
, O
and O
radiation O
dose O
to O
predict O
the O
recurrence O
of O
RARE O
RARE O
following O
external O
beam O
radiation O
therapy O
( O
ALL_CAP O
) O
since O
the O
introduction O
of O
PSA I-GENE
RARE O
a O
tumor O
marker O
RARE O
one O
tertiary O
care O
RARE O
. O

To O
evaluate O
whether O
the O
human O
gene O
is O
also O
a O
target O
of O
thyroid O
hormone O
we O
have O
RARE O
RARE O
NUM O
- O
responsive O
elements O
in O
ALL_CAP I-GENE
RARE O
genomic O
fragments O
spanning O
the O
whole O
gene O
. O

The O
transcriptional O
activity O
of O
PPARgamma I-GENE
is O
positively O
modulated O
by O
RARE O
binding O
and O
negatively O
regulated O
by O
RARE O
RARE O
by O
the O
MEK I-GENE
/ O
ERK I-GENE
RARE O
RARE O
. O

BACKGROUND O
: O
RARE O
, O
one O
of O
the O
RARE O
group O
of O
RARE O
, O
is O
used O
RARE O
an O
RARE O
drug O
RARE O
sedation O
and O
RARE O
RARE O
of O
anxiety O
in O
the O
treatment O
of O
epilepsy O
. O

RARE O
granuloma O
presents O
with O
RARE O
shaped O
RARE O
RARE O
of O
varying O
size O
containing O
RARE O
, O
RARE O
, O
RARE O
foreign O
RARE O
whereas O
RARE O
granuloma O
shows O
numerous O
round O
RARE O
nearly O
identical O
in O
size O
and O
shape O
RARE O
round O
and O
sharply O
RARE O
, O
RARE O
, O
RARE O
foreign O
RARE O
. O

This O
NUM I-GENE
- I-GENE
subfamily I-GENE
gene I-GENE
is O
likely O
to O
participate O
in O
RARE O
mesoderm O
formation O
and O
RARE O
in O
human O
RARE O
. O

Structure O
- O
function O
analysis O
of O
the O
Z O
- O
DNA O
- O
binding O
domain O
RARE O
of O
ALL_CAP I-GENE
adenosine I-GENE
RARE I-GENE
type I-GENE
I I-GENE
reveals O
RARE O
to O
the O
( I-GENE
alpha I-GENE
+ I-GENE
beta I-GENE
) I-GENE
family I-GENE
of O
helix I-GENE
- I-GENE
RARE I-GENE
- I-GENE
helix I-GENE
proteins I-GENE
. O

In O
addition O
, O
the O
RARE O
of O
RARE I-GENE
- I-GENE
1 I-GENE
gene I-GENE
RARE O
also O
has O
RARE O
applications O
to O
gene O
therapy O
, O
since O
RARE O
vectors O
carrying O
RARE I-GENE
RARE I-GENE
leukemia I-GENE
virus I-GENE
envelope I-GENE
proteins I-GENE
are O
used O
RARE O
gene O
delivery O
into O
different O
cell O
RARE O
. O

RARE O
and O
RARE O
RARE O
methods O
. O

Molecular O
cloning O
of O
mouse I-GENE
RARE I-GENE
oxidase I-GENE
. O

In O
such O
a O
manner O
, O
activated O
PKR I-GENE
inhibits O
cell O
growth O
and O
induces O
apoptosis O
, O
whereas O
disruption O
of O
normal O
PKR I-GENE
RARE O
results O
in O
RARE O
cell O
growth O
. O

We O
isolated O
a O
ribosomal I-GENE
protein I-GENE
NUM I-GENE
by O
interaction O
with O
PKR I-GENE
. O

RARE O
of O
the O
RARE O
precursor O
requires O
RARE O
also O
involved O
in O
rRNA O
RARE O
, O
i O
. O
RARE O
., O
NUM I-GENE
and O
NUM I-GENE
. O

To O
search O
RARE O
transcriptional O
RARE O
, O
we O
used O
a O
fragment O
of O
the O
ALL_CAP I-GENE
promoter I-GENE
containing O
several O
individual O
elements O
instead O
of O
the O
conventional O
RARE O
that O
contains O
a O
RARE O
cis O
element O
. O

As O
expected O
RARE O
a O
positive O
ALL_CAP I-GENE
transcriptional I-GENE
regulator I-GENE
, O
the O
timing O
of O
NUM I-GENE
gene I-GENE
RARE O
RARE O
the O
transient O
RARE O
of O
ALL_CAP I-GENE
in O
the O
very O
early O
RARE O
RARE O
RARE O
. O

Furthermore O
, O
ALL_CAP I-GENE
- O
RARE O
SRE O
activation O
was O
blocked O
by O
dominant O
negative O
mutants O
of O
PKC I-GENE
- I-GENE
alpha I-GENE
or O
PKC I-GENE
- I-GENE
epsilon I-GENE
. O

NUM I-GENE
- O
depleted O
cells O
exhibited O
the O
same O
defects O
RARE O
NUM I-GENE
- O
depleted O
cells O
, O
except O
that O
they O
accumulated O
NUM I-GENE
RARE I-GENE
. O

We O
show O
that O
the O
RARE I-GENE
- I-GENE
binding I-GENE
site I-GENE
and O
RARE O
- O
loop O
III O
RARE O
are O
necessary O
RARE O
correct O
3 O
'- O
end O
formation O
. O

Five O
different O
subtypes O
of O
RARE O
( O
ALL_CAP O
) O
are O
now O
RARE O
. O

Further O
experiments O
will O
be O
required O
to O
RARE O
the O
in O
vivo O
role O
of O
NUM I-GENE
in O
nuclear O
receptor O
functioning O
. O

Overexpression O
of O
ALL_CAP I-GENE
in O
transfected O
ALL_CAP O
3T3 O
cells O
also O
RARE O
RARE O
and O
RARE O
of O
basic I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
, O
a O
human I-GENE
pituitary I-GENE
tumor I-GENE
growth I-GENE
- I-GENE
RARE I-GENE
factor I-GENE
. O

The O
RARE O
RARE O
tissue O
RARE O
is O
important O
in O
RARE O
the O
contraction O
of O
the O
myocardium O
by O
preventing O
lateral O
spread O
of O
conduction O
and O
by O
RARE O
RARE O
of O
the O
RARE O
only O
RARE O
the O
RARE O
of O
the O
RARE O
fibre O
. O

E1 I-GENE
, O
a O
DNA I-GENE
RARE I-GENE
, O
RARE O
with O
the O
HPV I-GENE
E2 I-GENE
protein I-GENE
in O
RARE O
- O
dependent O
replication O
. O

Here O
we O
describe O
a O
mutant O
alpha O
subunit O
designed O
to O
inhibit O
receptor O
- O
RARE O
hormonal O
activation O
of O
RARE I-GENE
, O
the O
RARE O
regulator O
of O
RARE I-GENE
cyclase I-GENE
. O

A O
RARE O
search O
with O
the O
C O
- O
terminal O
region O
of O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
revealed O
a O
NUM O
- O
NUM O
% O
RARE O
to O
several O
proteins O
related O
to O
signal O
RARE O
and O
cell O
replication O
, O
such O
RARE O
NUM I-GENE
and O
ALL_CAP I-GENE
. O

Northern O
blot O
analysis O
demonstrated O
the O
ubiquitous O
RARE O
of O
2 O
. O
9 O
kb O
and O
3 O
. O

Additionally O
, O
a O
variety O
of O
regulatory O
RARE O
contribute O
temporal O
and O
/ O
or O
spatial O
RARE O
to O
TGF I-GENE
- I-GENE
beta I-GENE
responses O
. O

Induction O
of O
anaesthesia O
was O
RARE O
: O
fentanyl O
( O
3 O
micrograms O
/ O
kg O
RARE O
RARE O
( O
5 O
mg O
/ O
kg O
RARE O
RARE O
( O
NUM O
. O
4 O
mg O
/ O
kg O
). O

A O
comparison O
of O
the O
clinical O
profile O
of O
RARE O
malformations O
with O
and O
without O
associated O
venous O
malformations O
. O

RARE O
and O
distinct O
roles O
of O
RARE I-GENE
in O
RARE O
of O
the O
RARE O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
. O

RARE O
RARE O
optical O
self O
- O
RARE O
in O
a O
RARE O
RARE O
. O

RARE O
RARE O
: O
A O
simple O
model O
of O
wave O
- O
RARE O
RARE O
and O
RARE O
cooperative O
phenomena O
. O

RARE O
rates O
and O
energy O
levels O
of O
triplet O
RARE O
, O
v O
= O
1 O
RARE O
states O
of O
H2 O
. O

RARE O
- O
group O
approach O
to O
spin O
- O
dependent O
RARE O
. O

RARE O
approach O
to O
RARE O
in O
a O
one O
- O
dimensional O
problem O
. O

RARE O
- O
RARE O
- O
ray O
RARE O
RARE O
NUM O
. O
6 O
nm O
in O
RARE O
- O
like O
RARE O
ions O
RARE O
by O
40 O
ALL_CAP O
of O
energy O
from O
two O
NUM O
- O
RARE O
laser O
RARE O
. O

RARE O
, O
to O
identify O
regions O
of O
the O
promoter O
involved O
, O
we O
examined O
a O
series O
of O
RARE I-GENE
- I-GENE
C I-GENE
promoter I-GENE
constructs I-GENE
with O
5 O
' O
deletions O
and O
showed O
that O
RARE O
RARE I-GENE
- I-GENE
dependent I-GENE
promoter I-GENE
activity O
was O
retained O
by O
a O
122 O
- O
RARE O
RARE O
element O
, O
RARE O
- O
NUM O
to O
- O
165 O
bp O
upstream O
of O
the O
RNA O
RARE O
site O
. O

Nuclear I-GENE
factor I-GENE
RARE I-GENE
B I-GENE
( O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
) O
is O
an O
important O
transcription O
factor O
RARE O
the O
genes O
of O
many O
pro O
- O
inflammatory O
proteins O
and O
is O
strongly O
activated O
by O
the O
RARE O
interleukin I-GENE
- I-GENE
1 I-GENE
and O
tumor I-GENE
necrosis I-GENE
factor I-GENE
( I-GENE
TNF I-GENE
) I-GENE
alpha I-GENE
under O
various O
pathological O
conditions O
. O

Moreover O
, O
this O
enhancement O
of O
transcriptional O
activation O
by O
COUP I-GENE
- I-GENE
TFI I-GENE
requires O
specifically O
the O
ALL_CAP O
- O
1 O
RARE O
function O
of O
ER I-GENE
and O
can O
be O
observed O
in O
the O
presence O
of O
E2 O
or O
4 O
- O
RARE O
but O
not O
ALL_CAP O
NUM O
. O

Recombinant I-GENE
RARE I-GENE
has O
a O
RARE O
point O
of O
RARE O
= O
NUM O
ALL_CAP O
. O

RARE O
RARE O
occlusion O
and O
the O
rat O
RARE O
olfactory O
bulb O
. O

This O
region O
of O
hsp90 I-GENE
mediates O
ATP O
- O
independent O
RARE O
activity O
, O
RARE O
the O
hsp90 I-GENE
RARE I-GENE
domain I-GENE
, O
and O
includes O
structural O
elements O
important O
RARE O
steroid I-GENE
receptor I-GENE
interaction O
. O

The O
promoter O
of O
the O
rat O
NUM I-GENE
/ O
NUM I-GENE
gene O
has O
a O
ALL_CAP O
- O
rich O
region O
( O
NUM I-GENE
) O
that O
is O
highly O
RARE O
in O
RARE I-GENE
genes I-GENE
and O
contains O
an O
consensus O
NUM I-GENE
site I-GENE
. O

NUM I-GENE
' O
s O
role O
in O
RARE O
of O
the O
NUM I-GENE
/ O
NUM I-GENE
promoter O
was O
tested O
in O
Drosophila O
RARE O
cells O
. O

Measurements O
included O
bone O
mineral O
density O
of O
the O
lumbar O
spine O
and O
proximal O
femur O
( O
by O
dual O
- O
energy O
X O
- O
ray O
RARE O
) O
and O
biochemical O
markers O
of O
bone O
remodeling O
( O
serum O
bone O
- O
specific O
RARE I-GENE
phosphatase I-GENE
by O
immunoassay O
and O
urine O
RARE O
by O
high O
- O
pressure O
liquid O
chromatography O
). O

Human I-GENE
ALL_CAP I-GENE
is O
a O
10 I-GENE
- I-GENE
ALL_CAP I-GENE
skeletal I-GENE
extracellular I-GENE
RARE I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
protein I-GENE
that O
consists O
of O
an O
NUM O
- O
RARE O
RARE O
protein O
and O
a O
19 O
- O
RARE O
transmembrane O
signal O
peptide O
. O

RARE O
roles O
of O
NUM I-GENE
, O
the O
RARE O
ALL_CAP I-GENE
homolog I-GENE
, O
in O
cytoplasmic O
polyadenylation O
and O
translational O
RARE O
. O

The O
RNA I-GENE
polymerase I-GENE
III I-GENE
- I-GENE
RARE I-GENE
factor I-GENE
ALL_CAP I-GENE
induces O
a O
DNA O
RARE O
between O
the O
TATA O
box O
and O
the O
transcriptional O
RARE O
site O
. O

The O
pattern O
of O
RNase I-GENE
E I-GENE
digestion O
of O
NUM I-GENE
RNA I-GENE
differed O
from O
ALL_CAP I-GENE
, O
and O
GST I-GENE
- O
ALL_CAP I-GENE
did O
not O
protect O
NUM I-GENE
RNA I-GENE
from O
RARE O
in O
vitro O
. O

Transcription O
readthrough O
into O
the O
inverted O
repeats O
has O
little O
effect O
on O
this O
event O
. O

Analysis O
of O
hematopoietic I-GENE
growth I-GENE
factor I-GENE
RARE O
in O
19 O
RARE O
RARE O
centers O

In O
the O
second O
case O
, O
an O
RARE O
cyst O
was O
diagnosed O
. O

ALL_CAP I-GENE
also O
binds O
a O
DNA O
sequence O
( O
a O
ALL_CAP I-GENE
box I-GENE
RARE O
centered O
RARE O
position O
- O
NUM O
. O

We O
suggest O
that O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
may O
function O
like O
certain O
eukaryotic I-GENE
RARE I-GENE
( O
TATA I-GENE
binding I-GENE
protein I-GENE
( I-GENE
TBP I-GENE
) I-GENE
associated I-GENE
factors I-GENE
) O
whose O
binding O
to O
TBP I-GENE
results O
in O
transcription O
from O
new O
core O
promoter O
sequences O
. O

The O
NUM O
variant O
can O
better O
RARE O
modified O
bases O
but O
does O
not O
tightly O
RARE O
the O
RARE O
RARE O
into O
the O
RARE O
- O
binding O
pocket O
, O
suggesting O
that O
NUM O
could O
form O
a O
RARE O
to O
the O
RARE O
RARE O
. O

The O
high O
conservation O
of O
the O
3 O
' O
terminus O
suggests O
that O
this O
region O
directs O
the O
assembly O
of O
proteins O
required O
RARE O
the O
initiation O
of O
RNA O
replication O
. O

All O
RARE O
were O
down O
- O
regulated O
with O
GnRH I-GENE
- I-GENE
a I-GENE
RARE O
on O
day O
21 O
in O
a O
long O
protocol O
before O
gonadotropin I-GENE
RARE O
. O

The O
sequence O
RARE O
to O
- O
NUM O
bp O
relative O
to O
the O
transcription O
RARE O
site O
was O
sufficient O
to O
enhance O
reporter O
gene O
RARE O
depending O
on O
the O
RARE O
differentiation O
of O
P19 O
cells O
. O

Chem O
. O

No O
significant O
differences O
between O
the O
substituted O
and O
wild O
type O
peptides O
were O
observed O
, O
suggesting O
that O
this O
substitution O
in O
the O
RARE O
protein O
may O
cause O
disruption O
of O
global O
rather O
than O
local O
RARE O
. O

These O
results O
suggest O
that O
the O
c I-GENE
- I-GENE
met I-GENE
gene I-GENE
is O
also O
a O
target O
of O
p53 I-GENE
gene I-GENE
RARE O
. O

NUM I-GENE
RARE I-GENE
completely O
inhibited O
RhoA I-GENE
function O
, O
partially O
inhibited O
SRE O
: O
RARE I-GENE
activity O
, O
but O
had O
RARE O
effect O
on O
ALL_CAP O
- O
RARE O
c I-GENE
- I-GENE
Fos I-GENE
RARE O
. O

However O
, O
NUM I-GENE
RARE I-GENE
alone O
or O
in O
combination O
with O
growth O
factors O
did O
not O
stimulate O
AP I-GENE
- I-GENE
1 I-GENE
: O
RARE I-GENE
activity O
and O
RARE O
RARE O
the O
synergistic O
activation O
of O
AP I-GENE
- I-GENE
1 I-GENE
: O
RARE I-GENE
observed O
in O
response O
to O
RARE O
- O
RARE O
with O
growth O
factors O
and O
RARE O
- O
NUM O
- O
NUM O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
examine O
the O
antimicrobial O
RARE O
to O
10 O
currently O
used O
antimicrobial O
agents O
of O
50 O
strains O
of O
P O
. O
RARE O
isolated O
from O
RARE O
lesions O
and O
identified O
using O
a O
RARE O
ALL_CAP O
ALL_CAP O
II O
panel O
. O

The O
role O
of O
RARE O
echocardiography O
in O
surgery O
of O
the O
RARE O
and O
large O
vessels O

Taken O
together O
, O
our O
results O
demonstrate O
that O
NUM I-GENE
is O
involved O
in O
RARE O
resistance O
and O
oxidative O
stress O
response O
in O
C O
. O
RARE O
. O

RARE O
is O
a O
small O
, O
RARE O
, O
RARE O
, O
RARE O
patch O
with O
an O
absorption O
promoter O
, O
RARE O
in O
two O
dose O
- O
strengths O
( O
5 O
mg O
/ O
NUM O
h O
and O
10 O
mg O
/ O
NUM O
h O
) O
by O
RARE O
RARE O
. O

The O
ALL_CAP O
was O
tested O
RARE O
RARE O
reliability O
using O
three O
simulated O
and O
10 O
actual O
patients O
. O

The O
starting O
point O
is O
the O
RARE O
that O
the O
RARE O
underlying O
the O
ALL_CAP O
are O
not O
suitable O
to O
serve O
RARE O
a O
RARE O
of O
a O
model O
RARE O
RARE O
in O
RARE O
because O
they O
do O
not O
reflect O
essential O
characteristics O
of O
the O
diagnostic O
process O
which O
is O
the O
basis O
RARE O
intervention O
. O

RARE I-GENE
RARE I-GENE
protein I-GENE
( O
ALL_CAP I-GENE
) O
from O
RARE O
RARE O
is O
a O
highly O
specific O
N I-GENE
- I-GENE
RARE I-GENE
removing O
RARE O
residues O
( O
NUM O
in O
28S I-GENE
rRNA I-GENE
and O
NUM O
in O
NUM I-GENE
rRNA I-GENE
) O
from O
RARE O
RARE O
of O
both O
eukaryotes O
and O
RARE O
. O

OBJECTIVE O
: O
This O
RARE O
- O
analysis O
of O
67 O
RARE O
trials O
was O
performed O
to O
RARE O
the O
cholesterol O
- O
lowering O
effect O
of O
major O
dietary O
fibers O
. O

Among O
these O
NUM O
RARE I-GENE
, O
a O
novel O
ALL_CAP I-GENE
cDNA I-GENE
named O
ALL_CAP I-GENE
( O
human I-GENE
RARE I-GENE
RARE I-GENE
ALL_CAP I-GENE
) O
with O
sequence O
homology O
to O
a O
RARE I-GENE
- I-GENE
associated I-GENE
box I-GENE
( O
KRAB I-GENE
) O
was O
identified O
. O

The O
3 O
. O
3 O
- O
RARE O
RARE O
RARE O
in O
the O
RARE O
RARE O
than O
in O
the O
adult O
RARE O
suggests O
that O
ALL_CAP I-GENE
mRNA I-GENE
is O
RARE O
in O
the O
process O
of O
development O
. O

When O
the O
high O
affinity O
ALL_CAP I-GENE
NUM I-GENE
binding I-GENE
site I-GENE
was O
inserted O
into O
the O
beta I-GENE
- I-GENE
globin I-GENE
reporter I-GENE
, O
RARE I-GENE
was O
able O
to O
increase O
the O
cytoplasmic O
levels O
of O
unspliced O
mRNAs O
to O
14 O
%. O

To O
date O
, O
two O
such O
proteins O
, O
PLZF I-GENE
and O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
, O
have O
been O
implicated O
in O
RARE O
. O

Overexpression O
of O
NUM I-GENE
inhibits O
alpha I-GENE
- I-GENE
factor I-GENE
- O
RARE O
G1 O
arrest O
and O
transcriptional O
repression O
of O
the O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
. O

We O
now O
show O
that O
NUM I-GENE
RARE O
can O
be O
RARE O
by O
transfection O
with O
an O
RARE O
vector O
encoding O
NUM I-GENE
E1B I-GENE
NUM O
kDa O
alone O
but O
not O
by O
an O
E1 I-GENE
vector O
encoding O
all O
E1 I-GENE
products I-GENE
( O
3 O
E1A I-GENE
proteins I-GENE
, O
RARE O
RARE O
RARE O
the O
E1B I-GENE
19 O
kDa O
and O
NUM O
kDa O
proteins O
). O

RARE O
EMSA O
assays O
revealed O
that O
multiple O
proteins O
were O
involved O
in O
RARE O
complex O
formation O
with O
ALL_CAP I-GENE
, O
one O
of O
which O
was O
identified O
RARE O
factor O
NUM O
. O

RARE O
of O
DNA O
binding O
and O
transcriptional O
RARE O
by O
Caenorhabditis I-GENE
elegans I-GENE
ALL_CAP I-GENE
- I-GENE
3 I-GENE
and O
Drosophila I-GENE
melanogaster I-GENE
ALL_CAP I-GENE
suggests O
conservation O
of O
RARE O
RARE O
mechanisms O
. O

ALL_CAP O
: O
RARE O
, O
RARE O
, O
and O
RARE O
are O
3 O
new O
RARE O
that O
increase O
the O
sensitivity O
and O
cost O
of O
cervical O
RARE O
screening O
. O

Experiments O
on O
RARE O
cats O
demonstrated O
that O
the O
RARE O
of O
2 O
- O
RARE O
RARE O
the O
properties O
of O
specific O
RARE O
agents O
and O
coded O
RARE O
ALL_CAP O
- O
NUM O
, O
ALL_CAP O
- O
NUM O
, O
and O
ALL_CAP O
- O
NUM O
, O
reduce O
the O
mean O
rise O
of O
segment O
ST O
on O
numerous O
leads O
of O
the O
RARE O
RARE O
RARE O
5 O
- O
min O
occlusion O
of O
the O
anterior O
RARE O
branch O
of O
the O
RARE O
coronary O
artery O
. O

Neither O
the O
NUM I-GENE
/ I-GENE
NUM I-GENE
nor O
the O
JNK I-GENE
RARE O
was O
involved O
in O
the O
action O
of O
ALL_CAP I-GENE
- I-GENE
1beta I-GENE
. O

In O
protocol O
2 O
, O
eight O
different O
subjects O
performed O
RARE O
and O
RARE O
RARE O
RARE O
to O
RARE O
, O
followed O
by O
RARE O
muscle O
ischemia O
, O
by O
using O
the O
same O
resistance O
RARE O
in O
protocol O
1 O
. O

RARE O
was O
measured O
with O
a O
RARE O
- O
designed O
RARE O
and O
a O
NUM O
- O
RARE O
RARE O
long O
RARE O
to O
reach O
the O
volume O
- O
measuring O
RARE O
. O

Both O
mutations O
confer O
amino O
acid O
substitutions O
in O
the O
viral I-GENE
coat I-GENE
protein I-GENE
but O
differ O
in O
their O
relative O
abilities O
to O
RARE O
the O
foreign O
RARE I-GENE
protein I-GENE
. O

RARE O
recovery O
of O
liver O
function O
after O
this O
surgery O
tended O
to O
be O
slow O
. O

Although O
both O
transcripts O
share O
the O
RARE O
nine O
exons O
, O
RARE O
10 O
of O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
is O
RARE O
in O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
and O
instead O
, O
RARE O
11 O
( O
NUM O
RARE O
) O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
is O
larger O
in O
size O
, O
leading O
to O
the O
longer O
3 O
'- O
UTR O
. O

Expression O
of O
the O
second O
gene O
( O
NUM I-GENE
) O
was O
found O
to O
be O
RARE O
in O
human O
RARE O
, O
and O
partial O
sequence O
was O
obtained O
from O
a O
human O
cDNA O
library O
. O

IFN I-GENE
- I-GENE
gamma I-GENE
was O
elevated O
RARE O
RARE O
ALL_CAP O
when O
compared O
with O
healthy O
controls O
, O
RARE O
RARE O
and O
after O
treatment O
. O

The O
missing O
5 O
' O
sequences O
were O
obtained O
by O
5 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
and O
by O
analysis O
of O
an O
NUM I-GENE
genomic I-GENE
clone I-GENE
, O
and O
the O
missing O
3 O
' O
sequences O
were O
obtained O
by O
3 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
. O

If O
RARE O
RARE O
are O
detected O
, O
further O
analysis O
to O
define O
a O
role O
of O
drug O
- O
related O
or O
autoantibodies O
is O
required O
. O

This O
dependence O
, O
however O
, O
can O
be O
overcome O
to O
a O
large O
extent O
by O
RARE O
min O
ALL_CAP O
/ O
dt O
by O
mean O
aortic O
pressure O
. O

RARE O
, O
RARE O
, O
NUM O
- O
NUM O
August O
1997 O
. O

RARE O
RARE O
of O
delta O
- O
plutonium O
and O
of O
single O
Al O
, O
Ga O
, O
and O
RARE O
RARE O
in O
delta O
- O
plutonium O
. O

RARE O
- O
RARE O
transfer O
and O
RARE O
RARE O
spectra O
RARE O
RARE O
in O
RARE O
. O

RARE O
theory O
of O
RARE O
- O
RARE O
organic O
RARE O
- O
transfer O
RARE O
: O
Magnetic O
properties O
. O

RARE O
modes O
of O
a O
RARE O
. O

II O
. O

RARE O
- O
function O
RARE O
conditions O
RARE O
RARE O
RARE O
Al O
, O
Ga O
) O
As O
RARE O
. O

RARE O
RARE O
measurements O
of O
critical O
RARE O
in O
NUM O
: O
A O
NUM O
& O
RARE O
RARE O
1 O
RARE O
. O

( O
2 O
) O
RARE O
NUM O
NUM I-GENE
cells O
showed O
a O
lower O
level O
of O
bulk O
PKC I-GENE
catalytic O
activity O
, O
lacked O
the O
RARE O
of O
epsilon I-GENE
and I-GENE
RARE I-GENE
PKC I-GENE
isoforms I-GENE
, O
and O
showed O
a O
weak O
or O
absent O
RARE O
of O
the O
remaining O
isoforms O
, O
except O
ALL_CAP I-GENE
, O
upon O
RARE O
of O
Epo I-GENE
to O
growth O
factor O
- O
RARE O
cells O
. O

We O
used O
RARE O
cloning O
to O
identify O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
) O
RARE O
one O
factor O
that O
suppressed O
growth O
of O
a O
pre O
- O
B O
- O
cell O
variant O
line O
, O
NUM O
- O
M O
. O

RARE O
through O
the O
dust O
RARE O
was O
RARE O
with O
a O
RARE O
RARE O
. O

Thus O
, O
in O
normal O
RARE O
RARE O
RARE O
cells O
, O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
can O
respond O
to O
autocrine O
but O
not O
RARE O
TGF I-GENE
- I-GENE
beta I-GENE
without O
the O
participation O
of O
ALL_CAP I-GENE
. O

The O
history O
of O
exposure O
and O
RARE I-GENE
levels O
should O
RARE O
the O
RARE O
to O
this O
diagnosis O
. O

The O
odds O
ratio O
RARE O
ALL_CAP O
was O
1 O
. O
21 O
( O
NUM O
% O
confidence O
interval O
, O
NUM O
. O
NUM O
- O
1 O
. O
NUM O
) O
given O
a O
positive O
RARE O
of O
specific O
IgG I-GENE
antibodies O
after O
adjustment O
RARE O
RARE O
. O

Another O
group O
of O
ALL_CAP O
- O
and O
ALL_CAP O
- O
lesioned O
animals O
RARE O
on O
the O
tasks O
after O
the O
lesion O
showed O
RARE O
RARE O
of O
the O
type O
described O
above O
, O
suggesting O
that O
RARE O
RARE O
RARE O
after O
the O
lesion O
can O
RARE O
the O
role O
of O
the O
hippocampus O
to O
some O
degree O
. O

The O
case O
RARE O
RARE O
from O
ALL_CAP O
NUM O
. O

RARE O
of O
fluctuations O
in O
one O
- O
dimensional O
interface O
and O
RARE O
models O
. O

RARE O
of O
RARE O
dynamics O
of O
RARE O
- O
RARE O
motion O
. O

NMR O
of O
RARE O
RARE O
in O
a O
RARE O
RARE O
medium O
in O
the O
presence O
of O
a O
RARE O
magnetic O
field O
. O

RARE O
and O
RARE O
of O
RARE O
RARE O
RARE O
. O

RARE O
heat O
RARE O
in O
the O
RARE O
( O
NUM O
) O
liquid O
RARE O
. O

RARE O
approach O
to O
the O
study O
of O
RARE O
RARE O
. O

Mutations O
affecting O
only O
NUM I-GENE
RARE O
mapped O
to O
residues O
previously O
shown O
to O
mediate O
the O
binding O
of O
Nef I-GENE
to O
this O
receptor O
, O
such O
RARE O
NUM O
and O
NUM O
, O
RARE O
RARE O
RARE O
to O
an O
AP I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
motif I-GENE
and O
to O
an O
RARE O
RARE O
in O
the O
C O
- O
terminal O
region O
of O
the O
protein O
. O

Several O
mutations O
disrupted O
the O
endonuclease O
and O
RARE I-GENE
activities O
; O
however O
, O
only O
one O
amino I-GENE
- I-GENE
terminal I-GENE
- I-GENE
RARE I-GENE
cluster I-GENE
mutant I-GENE
protein I-GENE
( O
NUM O
- O
NUM O
- O
NUM O
) O
completely O
lost O
ALL_CAP O
hairpin O
DNA O
binding O
activity O
. O

The O
lytic O
RARE O
of O
ALL_CAP O
, O
probably O
under O
the O
initial O
control O
of O
the O
ALL_CAP I-GENE
/ I-GENE
RARE I-GENE
gene I-GENE
, O
may O
directly O
contribute O
to O
tumor O
pathogenesis O
. O

We O
conclude O
that O
( O
i O
) O
we O
have O
identified O
several O
candidate O
RARE O
genes O
of O
murine O
NUM O
, O
( O
ii O
) O
RARE O
of O
genes O
RARE O
RARE O
may O
be O
different O
in O
different O
organs O
, O
consistent O
with O
multiple O
RARE O
programs O
and O
/ O
or O
multiple O
cellular O
sites O
of O
RARE O
, O
and O
( O
iii O
) O
regions O
of O
the O
viral O
genome O
( O
v I-GENE
- I-GENE
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
, O
v I-GENE
- I-GENE
ALL_CAP I-GENE
gene I-GENE
, O
and O
gene I-GENE
NUM I-GENE
) O
are O
RARE O
RARE O
RARE O
with O
both O
NUM O
and O
primate O
RARE O
. O

These O
data O
indicate O
a O
RARE O
role O
RARE O
NUM I-GENE
in O
ALL_CAP I-GENE
- O
RARE O
RARE O
inhibition O
. O

This O
suggests O
that O
the O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
RARE O
RARE O
to O
external O
RARE O
. O

Here O
we O
describe O
the O
identification O
and O
characterization O
of O
several O
NUM I-GENE
RARE I-GENE
variant I-GENE
proteins I-GENE
and O
support O
their O
existence O
by O
RARE O
of O
the O
3 O
'- O
end O
of O
the O
NUM I-GENE
gene I-GENE
. O

RARE O
in O
the O
specific O
heat O
of O
RARE O
RARE O
RARE O
by O
critical O
spin O
- O
wave O
dynamics O
. O

RARE O
: O
RARE O
of O
precursor O
effects O
above O
the O
RARE O
transformation O
in O
a O
RARE O
RARE O
of O
Li O
metal O

RARE O
coupling O
in O
the O
RARE O
NUM O
RARE O
revealed O
by O
ALL_CAP O
spin O
- O
echo O
double O
resonance O
. O

RARE O
RARE O
of O
a O
RARE O
NUM O
or O
NUM O
layer O
in O
bulk O
RARE O
. O

RARE O
investigation O
of O
NUM O
- O
NUM O
RARE O
. O

Effects O
of O
point O
defects O
on O
RARE O
parameters O
of O
RARE O
. O

RARE O
electron O
dynamics O
around O
a O
single O
RARE O
shaped O
RARE O
. O

However O
, O
deletions O
of O
the O
C O
terminal O
11 O
or O
14 O
amino O
RARE O
had O
more O
substantial O
effects O
. O

RARE O
months O
after O
the O
initial O
vaccination O
, O
all O
RARE O
who O
received O
annual O
follow O
- O
RARE O
still O
had O
protective O
levels O
of O
anti I-GENE
- I-GENE
ALL_CAP I-GENE
. O

However O
, O
after O
PRK O
RARE O
5 O
weeks O
of O
age O
, O
partial O
RARE O
may O
be O
necessary O
due O
to O
regression O
of O
the O
PRK O
effect O
. O

Its O
early O
lesions O
were O
characterized O
by O
RARE O
, O
RARE O
, O
and O
RARE O
of O
RARE O
and O
RARE O
. O

Molecular O
cloning O
of O
human O
cDNA O
encoding O
a O
novel O
beta1 I-GENE
, I-GENE
6 I-GENE
- I-GENE
N I-GENE
- I-GENE
RARE I-GENE
forming O
core O
2 O
and O
core O
4 O
. O

RARE O
mouse O
back O
- O
cross O
analysis O
identified O
the O
loci O
RARE O
mouse I-GENE
NUM I-GENE
genes I-GENE
and O
RARE O
RARE O
of O
corresponding O
human O
RARE O
were O
confirmed O
by O
the O
identification O
of O
mapped O
sequence O
- O
RARE O
site O
markers O
. O

The O
RARE O
of O
RARE O
RARE O
RARE O
From O
RARE O
RARE O
( O
ALL_CAP O
RARE O
a O
battery O
based O
on O
commonly O
used O
dementia O
rating O
instruments O
, O
was O
tested O
on O
the O
records O
of O
NUM O
RARE O
RARE O
, O
elderly O
schizophrenia O
patients O
, O
RARE O
the O
purpose O
of O
RARE O
evaluating O
the O
long O
- O
term O
course O
of O
cognitive O
change O
in O
schizophrenia O
and O
RARE O
it O
to O
available O
autopsy O
materials O
. O

It O
was O
demonstrated O
that O
the O
RARE O
signals O
in O
the O
transcript O
, O
i O
. O
RARE O
. O
both O
donor O
RARE O
sites O
and O
the O
polyadenylation O
site O
RARE O
in O
the O
muscle O
- O
specific O
intron O
, O
have O
to O
be O
weak O
. O

Most O
recently O
, O
the O
use O
of O
the O
product O
of O
brain O
RARE O
and O
clearance O
has O
been O
proposed O
. O

RARE O
and O
transcription O
of O
the O
endogenous I-GENE
Ig I-GENE
heavy I-GENE
chain I-GENE
locus I-GENE
is O
RARE O
by O
the O
Ig I-GENE
heavy I-GENE
chain I-GENE
RARE I-GENE
enhancer I-GENE
core I-GENE
region I-GENE
in O
the O
absence O
of O
the O
RARE O
RARE O
regions O
. O

Two O
of O
these O
motifs O
are O
part O
of O
a O
highly O
RARE O
and O
inducible O
RARE O
RARE O
element O
shown O
previously O
to O
control O
a O
RARE O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
enhancer I-GENE
and O
the O
NUM I-GENE
promoter I-GENE
. O

In O
RARE O
with O
the O
RARE O
CREB I-GENE
binding I-GENE
protein I-GENE
/ O
p300 I-GENE
, O
which O
interacts O
with O
RARE I-GENE
, O
the O
binding O
of O
RARE I-GENE
and I-GENE
- I-GENE
beta I-GENE
to O
the O
RARE O
RARE O
element O
controls O
the O
induction O
of O
ALL_CAP I-GENE
- I-GENE
16 I-GENE
promoter I-GENE
in O
T O
cells O
. O

ALL_CAP I-GENE
by O
itself O
did O
not O
activate O
ERK1 I-GENE
, O
ERK2 I-GENE
and O
protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
RARE O
whereas O
ALL_CAP I-GENE
directly O
RARE O
the O
PKC I-GENE
- O
dependent O
activation O
of O
ERKs I-GENE
RARE O
by O
other O
agonists O
including O
thrombin I-GENE
and O
phorbol O
esters O
, O
without O
affecting O
the O
PKC I-GENE
activation O
by O
those O
agonists O
. O

BACKGROUND O
: O
In O
the O
ubiquitin I-GENE
- O
dependent O
proteolysis O
RARE O
, O
a O
ubiquitin I-GENE
ligase I-GENE
( O
NUM I-GENE
) O
is O
responsible O
RARE O
substrate O
selectivity O
and O
timing O
of O
RARE O
. O

CONCLUSIONS O
: O
RARE I-GENE
yeast I-GENE
ALL_CAP I-GENE
is O
composed O
of O
NUM I-GENE
and O
NUM I-GENE
, O
two O
structurally O
related O
but O
functionally O
independent O
F I-GENE
- I-GENE
box I-GENE
/ I-GENE
ALL_CAP I-GENE
- I-GENE
repeat I-GENE
proteins I-GENE
. O

NUM O
NMR O
studies O
in O
NUM O
- O
type O
RARE O
RARE O
. O

RARE O
- O
absorption O
spectra O
, O
RARE O
- O
field O
energy O
levels O
, O
and O
transition O
line O
strengths O
of O
RARE O
in O
RARE O
NUM O

RARE O
of O
RARE O
interactions O
between O
NUM O
defects O
RARE O
the O
( O
111 O
) O
RARE O
/ O
NUM O
interface O
. O

RARE O
- O
statistical O
theory O
of O
high O
- O
field O
RARE O
phenomena O
. O

NUM O
and O
ALL_CAP O
interaction O
with O
RARE O
( O
NUM O
RARE O
2 O
RARE O
1 O
) O
RARE O
. O

RARE O
- O
glass O
and O
spin O
- O
glass O
correlations O
in O
the O
two O
- O
dimensional O
random O
- O
bond O
ALL_CAP O
model O
. O

RARE O
modulation O
in O
NUM O
RARE O
NUM O
. O

RARE O
of O
RARE O
- O
light O
emission O
from O
RARE O
- O
RARE O
RARE O
RARE O
. O

RARE O
- O
RARE O
RARE O
RARE O
in O
the O
ALL_CAP O
chains O
of O
a O
single O
- O
domain O
NUM O
- O
delta O
RARE O
. O

RARE O
spin O
waves O
in O
a O
RARE O
RARE O
with O
a O
single O
- O
ion O
RARE O
( O
RARE O
and O
RARE O
). O

RARE O
detected O
RARE O
and O
RARE O
in O
crystalline O
NUM O
. O

RARE O
- O
relaxation O
RARE O
and O
RARE O
RARE O
of O
a O
ALL_CAP O
( O
111 O
) O
surface O
. O

RARE O
dependence O
of O
the O
RARE O
spontaneous O
RARE O
of O
NUM O
. O

ALL_CAP O
RARE O
RARE O
RARE O
electron O
self O
- O
RARE O
in O
RARE O
and O
RARE O
. O

RARE O
measurement O
of O
the O
RARE O
mass O
difference O
m O
RARE O
RARE O
m O
RARE O
NUM O
. O

RARE O
RARE O
to O
second O
post O
- O
RARE O
order O
: O
A O
field O
- O
theory O
approach O
. O

Genetic O
experiments O
using O
mutants O
RARE O
in O
RARE I-GENE
and O
RARE I-GENE
reveal O
a O
RARE O
interaction O
between O
these O
genes O
. O

In O
the O
current O
model O
, O
RARE I-GENE
/ O
Wnt I-GENE
signal O
stabilizes O
RARE I-GENE
/ O
beta I-GENE
- I-GENE
catenin I-GENE
, O
which O
then O
accumulates O
in O
nuclei O
and O
binds O
TCF I-GENE
/ O
ALL_CAP I-GENE
family O
proteins O
, O
forming O
bipartite O
transcription O
factors O
which O
activate O
transcription O
of O
RARE I-GENE
/ O
Wnt I-GENE
responsive O
genes O
. O

In O
support O
of O
clinical O
RARE O
studies O
, O
the O
vasodilator O
RARE O
( O
ALL_CAP O
) O
was O
combined O
with O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
antagonists O
propranolol O
( O
ALL_CAP O
) O
and O
RARE O
( O
ALL_CAP O
) O
and O
with O
the O
RARE O
RARE O
blocker O
diltiazem O
( O
ALL_CAP O
) O
to O
determine O
their O
cardiovascular O
and O
pharmacokinetic O
interactions O
. O

Factors O
influencing O
direct O
- O
immersion O
( O
ALL_CAP O
)- O
ALL_CAP O
process O
were O
also O
RARE O
and O
chosen O
experimentally O
. O

In O
contrast O
, O
an O
amino O
- O
terminal O
fragment O
containing O
the O
C O
/ O
NUM O
domain O
was O
sufficient O
RARE O
RARE O
of O
Zta I-GENE
transcription O
and O
viral O
RARE O
function O
. O

In O
addition O
, O
a O
potent O
RARE O
enhancer O
sequence O
isolated O
in O
the O
selection O
specifically O
binds O
a O
20 I-GENE
- I-GENE
kDa I-GENE
SR I-GENE
protein I-GENE
. O

Elimination O
of O
NUM I-GENE
in O
NUM I-GENE
strains O
also O
increased O
spontaneous O
mutation O
rates O
9 O
- O
or O
NUM O
- O
RARE O
compared O
to O
the O
wild O
type O
RARE O
determined O
by O
RARE O
to O
RARE O
or O
RARE O
RARE O
, O
respectively O
. O

Elimination O
of O
NUM I-GENE
in O
NUM I-GENE
strains O
also O
increased O
spontaneous O
mutation O
rates O
9 O
- O
or O
NUM O
- O
RARE O
compared O
to O
the O
wild O
type O
RARE O
determined O
by O
RARE O
to O
RARE O
or O
RARE O
RARE O
, O
respectively O
. O

These O
data O
suggest O
that O
other O
Ras I-GENE
RARE I-GENE
can O
RARE O
with O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
and O
with O
each O
other O
to O
activate O
RARE I-GENE
. O

RARE O
Ras I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
( O
ALL_CAP I-GENE
RARE O
NUM I-GENE
Ras I-GENE
- O
ALL_CAP I-GENE
, O
has O
been O
implicated O
RARE O
both O
a O
RARE O
and O
effector O
of O
Ras I-GENE
proteins I-GENE
, O
but O
its O
precise O
role O
in O
Ras I-GENE
- O
RARE O
signal O
RARE O
pathways O
is O
unclear O
. O

Three O
RARE I-GENE
- I-GENE
1 I-GENE
alleles I-GENE
possess O
premature O
stop O
codons O
and O
are O
likely O
to O
be O
RARE O
alleles O
, O
and O
one O
is O
a O
missense O
mutation O
and O
is O
likely O
to O
RARE O
residual O
activity O
. O
RARE I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
is O
RARE O
in O
both O
RARE O
line O
and O
somatic O
tissues O
and O
appears O
to O
be O
ubiquitous O
. O

However O
, O
unlike O
the O
NUM I-GENE
gene I-GENE
of O
Saccharomyces O
cerevisiae O
, O
NUM I-GENE
RARE I-GENE
is O
essential O
RARE O
cell O
viability O
. O

The O
NUM I-GENE
protein I-GENE
sequence I-GENE
does O
not O
contain O
readily O
RARE O
motifs O
of O
known O
function O
. O

The O
distribution O
of O
the O
various O
repeats O
suggests O
its O
organization O
is O
similar O
to O
the O
beta O
- O
RARE O
regions O
near O
the O
RARE O
of O
the O
major O
RARE O
RARE O
. O

RARE I-GENE
simultaneously O
regulates O
both O
RARE O
RARE O
and O
RARE O
RARE O
in O
the O
RARE O
RARE O
mouse O
( O
RARE I-GENE
/ O
RARE I-GENE
) O
in O
vivo O
. O

Electrophoretic O
mobility O
- O
shift O
assays O
performed O
with O
the O
HNF I-GENE
- I-GENE
3 I-GENE
X O
and O
Y O
sites O
demonstrated O
that O
both O
sites O
are O
capable O
of O
binding O
HNF I-GENE
- I-GENE
NUM I-GENE
and O
HNF I-GENE
- I-GENE
NUM I-GENE
. O

In O
addition O
, O
we O
also O
show O
that O
NUM I-GENE
may O
phosphorylate O
the O
RARE O
- O
terminal O
domain O
( O
ALL_CAP O
) O
of O
RNA I-GENE
pol I-GENE
II I-GENE
in O
the O
absence O
of O
promoter O
RARE O
. O

The O
therapy O
with O
a O
H2 I-GENE
- I-GENE
receptor I-GENE
antagonist O
is O
less O
effective O
than O
the O
RARE O
RARE O
with O
omeprazole O
or O
RARE O
. O

In O
humans O
, O
three O
tissue I-GENE
- I-GENE
specific I-GENE
plastin I-GENE
isoforms I-GENE
have O
been O
identified O
. O

No O
TATA O
or O
RARE O
sequence O
was O
found O
. O

The O
inhibition O
by O
the O
RARE I-GENE
subunit I-GENE
is O
reversed O
by O
addition O
of O
RARE O
concentrations O
of O
cAMP O
( O
RARE O
= O
40 O
nM O
RARE O
thus O
demonstrating O
that O
ALL_CAP I-GENE
is O
a O
novel O
, O
type I-GENE
I I-GENE
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
that O
is O
activated O
RARE O
lower O
cAMP O
concentrations O
than O
the O
RARE O
with O
the O
RARE I-GENE
subunit I-GENE
of O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
. O

RARE O
known O
to O
bind O
the O
PEPCK I-GENE
ALL_CAP O
include O
the O
ALL_CAP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
) O
and O
members O
of O
the O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
) O
family O
. O

This O
construct O
, O
termed O
ALL_CAP I-GENE
/ O
EBP I-GENE
, O
binds O
C I-GENE
/ I-GENE
RARE I-GENE
and I-GENE
beta I-GENE
but O
not O
CREB I-GENE
, O
yet O
it O
confers O
a O
nearly O
RARE O
glucocorticoid O
response O
when O
transiently O
transfected O
into O
NUM O
rat O
hepatoma O
cells O
. O

In O
addition O
, O
in O
vitro O
mutagenesis O
of O
both O
RARE I-GENE
and O
NUM I-GENE
sites I-GENE
indicated O
that O
other O
unidentified O
sites O
are O
responsible O
RARE O
the O
transcriptional O
enhancement O
observed O
with O
the O
RARE O
fragment O
. O

Several O
secondary O
RARE O
elements O
were O
identified O
. O

Here O
, O
we O
evidence O
that O
the O
developmental O
functions O
of O
the O
family O
of O
transcription O
factors O
characterized O
by O
the O
POU I-GENE
DNA I-GENE
binding I-GENE
motif I-GENE
exerts O
roles O
in O
mammalian O
development O
. O

RARE O
- O
affinity O
site O
- O
specific O
DNA O
binding O
by O
POU I-GENE
domain I-GENE
transcription I-GENE
factors I-GENE
requires O
both O
the O
POU I-GENE
- I-GENE
specific I-GENE
and O
the O
POU I-GENE
- I-GENE
RARE I-GENE
. O

In O
the O
Oct I-GENE
- I-GENE
1 I-GENE
RARE O
, O
the O
POU I-GENE
- I-GENE
specific I-GENE
domain I-GENE
recognizes O
a O
ALL_CAP O
RARE O
- O
site O
, O
while O
the O
corresponding O
sequence O
RARE O
by O
the O
Pit I-GENE
- I-GENE
1 I-GENE
POU I-GENE
- O
specific O
domain O
, O
ALL_CAP O
, O
is O
on O
the O
RARE O
RARE O
. O

RARE O
RARE O
analysis O
of O
NUM I-GENE
/ I-GENE
NUM I-GENE
RARE I-GENE
receptors I-GENE
showed O
that O
the O
second O
RARE O
loop O
of O
the O
NUM I-GENE
receptor I-GENE
is O
required O
and O
sufficient O
RARE O
efficient O
coupling O
to O
RARE I-GENE
/ I-GENE
11 I-GENE
, O
whereas O
the O
third O
RARE O
loop O
of O
the O
NUM I-GENE
receptor I-GENE
is O
required O
and O
sufficient O
RARE O
coupling O
to O
RARE I-GENE
. O

Most O
other O
end O
points O
were O
highly O
significant O
, O
and O
RARE O
, O
which O
was O
monitored O
across O
the O
ALL_CAP O
. O
S O
. O
program O
, O
was O
different O
with O
p O
< O
NUM O
. O
0001 O
. O

The O
other O
is O
RARE O
RARE O
- O
NUM O
, O
outside O
this O
highly O
RARE O
region O
. O

The O
RARE O
exercise O
showed O
relatively O
high O
RARE O
RARE O
concentration O
RARE O
12 O
. O
5 O
( O
SD O
2 O
. O
6 O
) O
mmol O
RARE O
RARE O
RARE O
1 O
)] O
and O
an O
increase O
of O
serum I-GENE
RARE I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
activity O
delayed O
by O
2 O
days O
RARE O
NUM O
( O
SD O
NUM O
) O
ALL_CAP O
RARE O
RARE O
RARE O
1 O
)]. O

RARE O
RARE O
aspects O
were O
distributed O
in O
two O
categories O
: O
1 O
) O
type O
I O
- O
RARE O
RARE O
RARE O
filling O
. O

Results O
demonstrated O
that O
the O
presence O
of O
RARE O
varied O
considerably O
from O
case O
to O
case O
and O
was O
always O
related O
to O
RARE O
muscle O
cell O
dispersion O
, O
which O
occurred O
around O
medium O
- O
sized O
damaged O
RARE O
RARE O
RARE O
. O

New O
RARE O
RARE O
RARE O
a O
RARE O
and O
simultaneously O
RARE O
asymmetric O
top O
. O

RARE O
RARE O
to O
beta O
RARE O
and O
the O
possibility O
of O
a O
fourth O
generation O
. O

RARE O
- O
RARE O
RARE O
- O
incidence O
RARE O
of O
RARE O
RARE O
radiation O
. O

RARE O
exchange O
of O
RARE O
between O
RARE O
containing O
RARE O
RARE O
. O

Structure O
determination O
of O
an O
RARE O
- O
RARE O
RARE O
reconstruction O
: O
( O
1 O
RARE O
2 O
)- O
H O
/ O
RARE O
( O
NUM O
). O

Magnetic O
RARE O
of O
spin O
- O
RARE O
RARE O
hydrogen O
. O

Northern O
blot O
and O
in O
situ O
hybridization O
analyses O
revealed O
NUM I-GENE
mRNA I-GENE
transcripts I-GENE
in O
several O
human O
and O
rat O
brain O
regions O
. O

The O
RARE I-GENE
- I-GENE
ALL_CAP I-GENE
( O
ALL_CAP I-GENE
) O
subfamily O
of O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
leucine I-GENE
zipper I-GENE
( I-GENE
bHLH I-GENE
- I-GENE
ALL_CAP I-GENE
) I-GENE
transcription I-GENE
factors I-GENE
, O
including O
NUM I-GENE
, O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
and O
RARE I-GENE
, O
has O
been O
implicated O
in O
the O
RARE O
of O
tissue O
- O
specific O
gene O
RARE O
in O
several O
cell O
lineages O
. O

Fifty O
- O
RARE O
patients O
aged O
< O
NUM O
years O
with O
acute O
RARE O
leukemia O
( O
ALL O
) O
in O
second O
or O
third O
bone O
marrow O
( O
ALL_CAP O
) O
relapse O
or O
refractory O
to O
RARE O
- O
line O
therapy O
were O
enrolled O
in O
an O
Italian O
cooperative O
study O
. O

The O
dorsal O
nerves O
of O
the O
RARE O
were O
anesthetized O
RARE O
with O
lidocaine O
. O

In O
the O
brain O
, O
RARE I-GENE
receptors I-GENE
mediate O
motor O
and O
memory O
function O
by O
interaction O
with O
their O
RARE O
RARE O
. O

Early O
- O
onset O
RARE O
necrosis O
after O
iodine O
I O
NUM O
plaque O
radiotherapy O
RARE O
RARE O
RARE O
. O

RARE O
interaction O
of O
ARF I-GENE
and O
PKC I-GENE
- I-GENE
alpha I-GENE
with O
NUM I-GENE
was O
not O
achieved O
, O
but O
a O
C O
- O
terminal O
fragment O
of O
human I-GENE
NUM I-GENE
( O
RARE O
" O
NUM O
RARE O
interacted O
with O
the O
RARE O
mutant O
of O
RhoA I-GENE
, O
RARE I-GENE
- I-GENE
14 I-GENE
. O

In O
this O
study O
, O
we O
investigated O
the O
signal O
RARE O
pathways O
that O
are O
involved O
in O
ALL_CAP I-GENE
- O
RARE O
ALL_CAP I-GENE
transcription O
. O

RARE O
RARE O
RARE O
RARE O
a O
feature O
of O
RARE O
- O
dispersion O
theory O
: O
Analysis O
and O
experimental O
observations O
. O

RARE O
- O
pressure O
effects O
on O
RARE O
- O
relaxation O
kinetics O
of O
RARE O
in O
RARE O
NUM O
. O

RARE O
reduction O
in O
RARE O
RARE O
by O
polymers O
. O

RARE O
scale O
RARE O
RARE O
RARE O
. O

Current O
world O
literature O
. O

These O
results O
show O
that O
RARE I-GENE
is O
a O
RARE O
of O
the O
ALL_CAP I-GENE
complex I-GENE
and O
that O
RARE I-GENE
is O
required O
RARE O
the O
transcriptional O
repression O
RARE O
by O
this O
complex O
. O

Recombinant O
RARE I-GENE
acts O
synergistically O
with O
recombinant O
ALL_CAP I-GENE
to O
stimulate O
translation O
dependent O
on O
the O
RARE O
ALL_CAP O
. O

Analysis O
of O
the O
consensus O
binding O
sequence O
and O
the O
DNA O
- O
binding O
domain O
of O
NUM I-GENE
. O

Mapping O
of O
the O
human I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
isoforms I-GENE
1 I-GENE
and I-GENE
2 I-GENE
RARE O
. O

Identification O
of O
RNase I-GENE
T I-GENE
RARE O
a O
high O
- O
copy O
suppressor O
of O
the O
ALL_CAP O
sensitivity O
associated O
with O
single I-GENE
- I-GENE
RARE I-GENE
DNA I-GENE
RARE I-GENE
deficiency O
in O
Escherichia O
coli O
. O

Inhibition O
of O
RARE I-GENE
- I-GENE
3 I-GENE
kinase I-GENE
did O
not O
have O
a O
significant O
effect O
on O
p53 I-GENE
conformation O
but O
did O
have O
a O
weak O
but O
significant O
effect O
on O
RARE I-GENE
- O
RARE O
viability O
. O

No O
difference O
in O
percentage O
of O
males O
in O
semen O
production O
was O
noted O
between O
strains O
, O
CP O
levels O
, O
or O
feeding O
regimens O
. O

The O
RARE I-GENE
mouse I-GENE
mutant I-GENE
provides O
a O
model O
RARE O
the O
severe O
human O
RARE O
tube O
defect O
( O
ALL_CAP O
RARE O
RARE O
- O
RARE O
. O

Further O
analysis O
of O
AP I-GENE
- I-GENE
1 I-GENE
DNA O
binding O
activities O
in O
7 O
- O
to O
14 O
- O
day O
culture O
activated O
RARE O
led O
to O
the O
discovery O
of O
high I-GENE
mobility I-GENE
AP I-GENE
- I-GENE
1 I-GENE
complexes I-GENE
( O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
). O

Mutations O
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
of O
the O
TIMP I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
that O
prevented O
formation O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
caused O
a O
70 O
% O
RARE O
of O
activity O
in O
transfected O
activated O
RARE O
. O

ALL_CAP O
DESIGN O
: O
RARE I-GENE
immunoglobulin I-GENE
A I-GENE
levels O
of O
each O
of O
20 O
subjects O
were O
determined O
on O
3 O
RARE O
: O
RARE O
, O
while O
the O
subject O
was O
still O
smoking O
; O
second O
, O
7 O
days O
after O
cessation O
of O
smoking O
; O
third O
, O
on O
the O
NUM O
day O
after O
cessation O
. O

Therefore O
, O
high O
set O
- O
RARE O
accuracy O
and O
reproducibility O
are O
RARE O
. O

Role O
of O
NUM O
in O
RARE O
the O
RARE O
and O
RARE O
- O
RARE O
- O
RARE O
sum O
RARE O
. O

RARE O
of O
negative O
ions O
utilizing O
RARE O
RARE O
in O
a O
RARE O
coupling O
RARE O
. O

RARE O
RARE O
effects O
of O
RARE O
properties O
in O
RARE O
RARE O
. O

RARE O
RARE O
spectra O
in O
the O
RARE O
RARE O
. O

Two O
- O
RARE O
RARE O
RARE O
: O
An O
RARE O
RARE O
. O

Basal O
RARE O
lower O
esophageal O
RARE O
pressure O
was O
similar O
in O
the O
study O
group O
( O
mean O
RARE O
SD O
] O
20 O
. O
1 O
RARE O
9 O
. O
1 O
] O
mmHg O
) O
and O
controls O
( O
NUM O
. O
6 O
RARE O
6 O
. O
NUM O
] O
mmHg O
); O
the O
pressure O
did O
not O
change O
following O
ALL_CAP O
or O
ALL_CAP O
. O

RARE O
RARE O
these O
three O
sites O
may O
partially O
RARE O
ALL_CAP I-GENE
, O
thereby O
RARE O
rapid O
repair O
. O

There O
was O
RARE O
difference O
in O
the O
hormone O
receptor O
status O
between O
the O
cases O
without O
lymph O
node O
metastases O
and O
with O
lymph O
node O
metastases O
, O
' O
RARE O
' O
or O
RARE O
. O

On O
the O
other O
RARE O
, O
subjects O
with O
air O
RARE O
( O
residual O
volume O
( O
RV O
RARE O
RARE O
RARE O
capacity O
( O
ALL_CAP O
) O
> O
37 O
%) O
RARE O
not O
only O
a O
RARE O
RARE O
( O
RARE O
) O
( O
NUM O
. O
NUM O
+/- O
NUM O
. O
NUM O
versus O
NUM O
. O
NUM O
+/- O
NUM O
. O
07 O
RARE O
RARE O
microm O
RARE O
2 O
RARE O
p O
< O
NUM O
. O
05 O
) O
but O
shorter O
RARE O
( O
L O
( O
RARE O
)) O
than O
subjects O
without O
this O
RARE O
abnormality O
( O
2 O
. O
NUM O
+/- O
NUM O
. O
16 O
to O
2 O
. O
NUM O
+/- O
NUM O
. O
NUM O
microm O
, O
p O
< O
NUM O
. O
05 O
). O

Gel O
filtration O
, O
sedimentation O
velocity O
, O
and O
immunoprecipitation O
experiments O
revealed O
that O
NUM O
is O
a O
RARE O
of O
a O
RARE O
complex O
( O
AP I-GENE
- I-GENE
4 I-GENE
) O
that O
also O
contains O
the O
NUM O
polypeptide O
and O
two O
additional O
RARE O
subunit O
homologs O
named O
NUM O
( O
mu O
- O
NUM O
) O
and O
epsilon O
. O

Cyclin I-GENE
NUM I-GENE
- I-GENE
associated I-GENE
kinase I-GENE
activity O
and O
protein O
levels O
were O
increased O
in O
mammary O
tumors O
from O
murine O
mammary O
tumor O
virus O
- O
NUM I-GENE
( O
c I-GENE
- I-GENE
NUM I-GENE
) O
transgenic O
mice O
. O

The O
NUM I-GENE
domain I-GENE
- I-GENE
containing I-GENE
RARE I-GENE
5 I-GENE
'- I-GENE
phosphatase I-GENE
( O
ALL_CAP I-GENE
) O
RARE O
the O
p85 I-GENE
subunit I-GENE
of O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
RARE O
NUM I-GENE
- O
RARE O
inhibition O
of O
B I-GENE
cell I-GENE
receptor I-GENE
RARE O
. O

We O
show O
that O
the O
mouse O
genome O
contains O
four O
copies O
of O
the O
RARE I-GENE
- I-GENE
9 I-GENE
gene I-GENE
. O

An O
increase O
in O
bone O
mineral O
density O
RARE O
the O
spine O
, O
RARE O
hip O
, O
and O
RARE O
body O
has O
been O
reported O
with O
RARE O
but O
seems O
to O
be O
less O
than O
that O
seen O
with O
estrogen O
or O
RARE O
therapy O
. O

However O
, O
in O
those O
studies O
due O
to O
the O
presence O
of O
RARE O
agents O
in O
the O
PKC I-GENE
preparations O
, O
the O
RARE O
reaction O
of O
ALL_CAP O
with O
RARE O
- O
RARE O
cysteine O
residues O
in O
PKC I-GENE
was O
not O
observed O
. O

Interestingly O
, O
RARE I-GENE
/ O
NUM I-GENE
. O

We O
also O
identified O
an O
RARE O
RARE O
form O
of O
RARE I-GENE
RNA I-GENE
, O
NUM I-GENE
. O

The O
costs O
were O
DM O
11 O
, O
NUM O
RARE O
a O
ALL_CAP O
, O
DM O
12 O
, O
NUM O
RARE O
a O
ALL_CAP O
and O
DM O
7 O
, O
NUM O
RARE O
a O
MR O
. O

We O
now O
provide O
evidence O
RARE O
physical O
and O
RARE O
interaction O
between O
NUM I-GENE
and O
the O
proteasome O
. O

RARE O
RARE O
events O
involve O
three O
previously O
described O
RARE O
exons O
, O
which O
are O
predicted O
to O
encode O
most O
of O
the O
second O
transmembrane O
domain O
. O

Each O
of O
these O
genes O
contains O
a O
putative O
upstream O
ORF O
, O
while O
NUM I-GENE
has O
two O
additional O
in O
- O
frame O
AUG O
codons O
5 O
' O
to O
the O
major O
RARE O
. O

RARE O
RARE O
RARE O
RARE O
O O
. O
RARE O
. O

In O
addition O
, O
mapping O
of O
the O
promoter O
region O
and O
the O
identification O
of O
putative O
promoter O
regulatory O
sequences O
should O
give O
insight O
into O
the O
transcriptional O
RARE O
of O
NUM I-GENE
RARE O
RARE O
in O
particular O
by O
RARE O
of O
the O
above O
mentioned O
factors O
RARE O
in O
vitro O
and O
in O
vivo O
. O

The O
rate O
of O
RARE O
is O
low O
and O
5 O
- O
year O
survival O
is O
very O
poor O
. O

In O
order O
to O
better O
characterize O
the O
distribution O
of O
ALL_CAP O
and O
MAP O
estimates O
under O
these O
conditions O
, O
we O
RARE O
a O
point O
RARE O
to O
density O
values O
of O
the O
conditional O
distribution O
of O
such O
estimates O
. O

RT O
- O
PCR O
was O
performed O
using O
previously O
reported O
degenerate O
RARE O
primers O
to O
the O
RARE O
binding O
domain O
( O
ALL_CAP O
) O
of O
known O
beta I-GENE
integrin I-GENE
subunits I-GENE
and O
RARE I-GENE
cDNA I-GENE
. O

The O
lowest O
culture O
failure O
rate O
of O
NUM O
. O
2 O
per O
cent O
was O
found O
after O
ALL_CAP O
compared O
with O
NUM O
. O
9 O
per O
cent O
among O
ALL_CAP O
. O

RARE O
RARE O
of O
d I-GENE
- I-GENE
RARE I-GENE
inhibited O
RARE I-GENE
RARE O
. O

The O
corresponding O
differences O
in O
RARE I-GENE
and O
PAI I-GENE
- I-GENE
1 I-GENE
were O
not O
statistically O
significant O
. O

Primary O
and O
secondary O
structural O
elements O
required O
RARE O
RARE O
of O
RARE O
yellow O
RARE O
virus O
RARE O
NUM O
. O

On O
the O
other O
RARE O
, O
when O
the O
aortic O
RARE O
was O
perfused O
with O
L O
- O
ALL_CAP O
( O
ALL_CAP O
- O
RARE O
inhibitor O
) O
or O
methylene O
blue O
( O
RARE O
RARE I-GENE
inhibitor O
RARE O
the O
changes O
could O
be O
attenuated O
. O

Nevertheless O
, O
inactivation O
of O
the O
RARE I-GENE
E I-GENE
- O
Cdk2 I-GENE
complex O
in O
response O
to O
mitogen O
starvation O
occurs O
normally O
in O
RARE O
that O
have O
a O
homozygous O
deletion O
of O
the O
p27 I-GENE
gene I-GENE
. O

Identification O
and O
characterization O
of O
NUM I-GENE
and O
NUM I-GENE
: O
two O
distinct O
RARE O
sequences O
RARE O
detection O
of O
Mycobacterium O
RARE O
by O
PCR O
. O

Taken O
together O
, O
these O
results O
are O
consistent O
with O
the O
possibility O
that O
NUM I-GENE
protein I-GENE
contributes O
to O
the O
cell O
growth O
retardation O
activity O
of O
the O
RARE I-GENE
, O
RARE O
least O
in O
part O
, O
by O
RARE O
p21 I-GENE
protein I-GENE
levels O
. O

Similar O
results O
were O
also O
obtained O
with O
a O
NUM O
RARE O
cell O
line O
carrying O
wt I-GENE
p53 I-GENE
. O

Partial O
sequencing O
of O
the O
region O
RARE O
of O
ORF I-GENE
- I-GENE
RARE I-GENE
revealed O
homology O
to O
the O
RARE I-GENE
/ I-GENE
ALL_CAP I-GENE
genes I-GENE
, O
involved O
in O
ALL_CAP O
resistance O
, O
from O
RARE O
NUM O
. O

The O
NUM I-GENE
associated O
kinase O
is O
not O
casein I-GENE
kinase I-GENE
2 I-GENE
, O
the O
kinase O
believed O
to O
phosphorylate O
NUM I-GENE
+ I-GENE
4 I-GENE
in O
oocytes O
, O
but O
a O
yet O
unidentified O
kinase O
. O

This O
suggests O
that O
RARE I-GENE
- I-GENE
like I-GENE
genes I-GENE
may O
be O
involved O
in O
the O
biosynthesis O
of O
RARE O
RARE O
and O
proteins O
, O
and O
that O
the O
genes O
can O
be O
transcriptionally O
activated O
by O
heat O
shock O
to O
RARE O
RARE O
the O
repressed O
RARE O
of O
mRNA O
and O
protein O
. O

These O
data O
provide O
the O
RARE O
tools O
RARE O
the O
final O
identification O
of O
the O
ALL_CAP I-GENE
and O
the O
ALL_CAP I-GENE
genes I-GENE
. O

The O
H O
- O
reflex O
recovery O
curve O
was O
obtained O
after O
RARE O
of O
the O
median O
nerve O
RARE O
the O
RARE O
and O
recording O
from O
the O
RARE O
RARE O
RARE O
. O

The O
origins O
of O
reflected O
light O
changes O
associated O
with O
RARE O
activity O
( O
optical O
signals O
) O
were O
investigated O
in O
rat O
RARE O
cortex O
with O
optical O
imaging O
, O
RARE O
, O
and O
laser O
- O
Doppler O
RARE O
, O
and O
dynamic O
changes O
in O
local O
hemoglobin I-GENE
concentration O
and O
oxygenation O
were O
focused O
on O
. O

Human I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
like I-GENE
proteins I-GENE
contain O
three O
ALL_CAP O
- O
type O
RNA O
recognition O
motifs O
( O
RARE O
). O

Comparison O
of O
frequencies O
of O
RARE O
fibrillation O
after O
coronary O
artery O
bypass O
RARE O
with O
and O
without O
the O
use O
of O
cardiopulmonary O
bypass O
. O

The O
results O
of O
supershift O
analysis O
using O
specific O
antibodies O
against O
transcription O
factors O
suggested O
that O
both O
binding O
complexes O
contained O
the O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
RARE O
NUM I-GENE
and O
NUM I-GENE
, O
and O
did O
not O
contain O
other O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
proteins I-GENE
( O
NUM I-GENE
, O
c I-GENE
- I-GENE
Rel I-GENE
, O
Rel I-GENE
B I-GENE
RARE O
AP I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
( O
c I-GENE
- I-GENE
Fos I-GENE
, O
C I-GENE
- I-GENE
Jun I-GENE
RARE O
CREB I-GENE
or O
C I-GENE
/ I-GENE
EBPbeta I-GENE
( O
ALL_CAP I-GENE
- I-GENE
IL6 I-GENE
). O

A O
set O
of O
peptides O
corresponding O
to O
the O
individual O
elements O
of O
secondary O
RARE O
derived O
from O
the O
N O
- O
terminal O
domain O
of O
the O
ribosomal I-GENE
protein I-GENE
NUM I-GENE
have O
been O
synthesized O
. O

The O
results O
showed O
that O
IFN I-GENE
- I-GENE
gamma I-GENE
RARE O
the O
rapid O
accumulation O
of O
RARE I-GENE
regulated I-GENE
factor I-GENE
( I-GENE
IRF I-GENE
)- I-GENE
1 I-GENE
mRNA I-GENE
, O
followed O
by O
a O
delayed O
and O
dose O
- O
dependent O
inhibition O
of O
NUM I-GENE
( I-GENE
I I-GENE
) I-GENE
RARE I-GENE
mRNA I-GENE
RARE O
in O
RARE O
RARE O
from O
several O
different O
donors O
. O

Functional O
domains O
of O
c I-GENE
- I-GENE
myc I-GENE
promoter I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
involved O
in O
transcriptional O
repression O
and O
cell O
growth O
RARE O
. O

Therefore O
, O
we O
have O
named O
this O
gene O
NUM I-GENE
. O

These O
results O
RARE O
to O
support O
the O
hypothesis O
that O
NUM O
, O
NUM O
, O
and O
NUM O
act O
RARE O
a O
single O
, O
RARE O
unit O
to O
regulate O
human I-GENE
globin I-GENE
gene I-GENE
transcription O
RARE O
a O
RARE O
, O
but O
they O
can O
also O
be O
interpreted O
to O
RARE O
that O
formation O
of O
a O
DNase I-GENE
I I-GENE
RARE O
RARE O
alone O
is O
not O
sufficient O
RARE O
mediating O
high O
- O
level O
globin I-GENE
gene I-GENE
transcription O
. O

To O
identify O
additional O
non O
- O
RARE I-GENE
factors I-GENE
that O
affect O
ALL_CAP O
silencing O
, O
we O
performed O
a O
genetic O
screen O
designed O
to O
isolate O
mutations O
which O
alter O
the O
RARE O
of O
reporter O
genes O
integrated O
within O
the O
ALL_CAP O
. O

Because O
there O
is O
great O
need O
RARE O
iron O
in O
the O
EPO I-GENE
- O
RARE O
RARE O
RARE O
, O
it O
is O
essential O
that O
serum I-GENE
ferritin I-GENE
and O
transferrin I-GENE
saturation O
levels O
should O
be O
maintained O
over O
NUM O
microg O
/ O
liter O
and O
NUM O
%, O
respectively O
. O

These O
results O
indicate O
that O
the O
NUM I-GENE
subunit I-GENE
of O
eIF3 I-GENE
plays O
an O
important O
role O
in O
the O
initiation O
RARE O
of O
protein O
RARE O
and O
that O
its O
RNA O
- O
binding O
domain O
is O
required O
RARE O
optimal O
activity O
. O

In O
this O
study O
, O
we O
elucidate O
RARE O
pathways O
RARE O
by O
RARE O
therapy O
( O
ALL_CAP O
) O
with O
RARE O
. O

These O
results O
indicate O
that O
ATF I-GENE
- I-GENE
2 I-GENE
plays O
a O
central O
role O
in O
TGF I-GENE
- I-GENE
beta I-GENE
RARE O
by O
acting O
RARE O
a O
common O
nuclear O
target O
of O
both O
Smad I-GENE
and O
NUM I-GENE
pathways O
. O

ALL_CAP O
WORDS O
: O
RARE O
; O
RARE O
RARE O
; O
RARE O
zone O
; O
RARE O
level O
; O
Regulation O
schedule O

The O
systolic O
peak O
of O
pulmonary O
RARE O
was O
RARE O
than O
the O
diastolic O
peak O
in O
NUM O
out O
of O
NUM O
cases O
. O

RARE O
were O
assayed O
RARE O
alpha I-GENE
- I-GENE
fetoprotein I-GENE
, O
RARE O
RARE O
, O
free O
alpha I-GENE
hCG I-GENE
, O
and O
RARE O
hCG I-GENE
. O

ALL_CAP O
RARE O
RARE O
RARE O
RARE O
ALL_CAP O
2000 O
. O

The O
following O
data O
were O
recorded O
RARE O
RARE O
in O
the O
intensive O
care O
unit O
6 O
, O
12 O
, O
NUM O
, O
and O
NUM O
hours O
after O
RARE O
of O
CPB O
: O
RARE O
rate O
, O
RARE O
pressure O
, O
RARE O
RARE O
pressure O
, O
central O
- O
peripheral O
RARE O
difference O
, O
arterial O
- O
central O
venous O
oxygen O
saturation O
difference O
, O
urine O
output O
, O
serum O
RARE O
, O
RARE O
and O
RARE I-GENE
elastase I-GENE
levels O
, O
the O
Doppler O
echocardiographic O
factors O
shortening O
fraction O
and O
RARE O
period O
/ O
RARE O
- O
ventricular O
ejection O
time O
, O
and O
cumulative O
doses O
of O
catecholamines O
( O
epinephrine O
RARE O
RARE O
, O
and O
furosemide O
. O

NUM I-GENE
/ O
NUM I-GENE
, O
RARE O
on O
RARE O
3 O
band O
NUM O
, O
encodes O
a O
zinc I-GENE
- I-GENE
finger I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
transcription I-GENE
activator I-GENE
not O
detected O
in O
normal O
hematopoietic O
cells O
but O
RARE O
in O
several O
normal O
tissues O
. O

Analysis O
of O
the O
protein O
sequences O
of O
these O
two O
RARE I-GENE
, O
together O
with O
previously O
characterized O
H I-GENE
. I-GENE
RARE I-GENE
RARE I-GENE
replication I-GENE
proteins I-GENE
, O
supports O
the O
formation O
of O
a O
distinct O
class O
of O
H I-GENE
. I-GENE
RARE I-GENE
RARE I-GENE
proteins I-GENE
. O

The O
RARE O
delta O
among O
the O
three O
groups O
did O
not O
differ O
RARE O
RARE O
: O
RARE O
delta O
of O
the O
VT O
group O
was O
70 O
ms O
+/- O
NUM O
ms O
, O
the O
RARE O
delta O
of O
the O
ALL_CAP O
group O
was O
NUM O
msec O
+/- O
NUM O
msec O
, O
and O
the O
RARE O
delta O
of O
the O
control O
group O
was O
70 O
ms O
+/- O
NUM O
ms O
. O

In O
contrast O
, O
deletion O
of O
the O
upstream O
portion O
of O
the O
delta O
promoter O
led O
to O
a O
10 O
RARE O
decrease O
in O
RARE O
. O

RARE O
- O
directed O
mutagenesis O
of O
binding O
sites O
RARE O
the O
repressor I-GENE
proteins I-GENE
NUM I-GENE
and O
NUM I-GENE
in O
the O
upstream O
portion O
of O
the O
beta I-GENE
globin I-GENE
gene I-GENE
flanking I-GENE
region I-GENE
led O
to O
a O
4 O
- O
6 O
RARE O
increase O
in O
promoter O
activity O
. O

However O
, O
with O
the O
NUM O
antagonist O
RARE O
( O
5 O
RARE O
10 O
RARE O
8 O
)- O
5 O
RARE O
10 O
RARE O
7 O
) O
M O
RARE O
RARE O
relaxation O
occurred O
. O

Differential O
RARE O
of O
AP I-GENE
- I-GENE
2alpha I-GENE
and O
AP I-GENE
- I-GENE
NUM I-GENE
in O
the O
developing O
RARE O
retina O
: O
repression O
of O
R I-GENE
- I-GENE
ALL_CAP I-GENE
promoter I-GENE
activity O
by O
AP I-GENE
- I-GENE
2 I-GENE
. O

The O
algorithm O
also O
limited O
TG O
to O
20 O
and O
NUM O
%, O
ALL_CAP I-GENE
to O
6 O
and O
20 O
%, O
and O
RARE I-GENE
( I-GENE
a I-GENE
) I-GENE
to O
NUM O
and O
NUM O
%, O
of O
low O
- O
and O
high O
- O
risk O
groups O
, O
respectively O
. O

The O
mean O
value O
of O
the O
NUM I-GENE
to O
the O
NUM I-GENE
RARE O
RARE O
ratio O
was O
NUM O
. O
NUM O
+/- O
NUM O
. O
20 O
SD O
in O
normal O
donors O
and O
NUM O
. O
NUM O
+/- O
NUM O
. O
NUM O
SD O
in O
B O
- O
ALL_CAP O
( O
P O
=. O
01 O
). O

As O
normal O
B O
cells O
also O
present O
this O
variant O
, O
the O
mechanism O
of O
NUM I-GENE
posttranscriptional O
RARE O
might O
reflect O
the O
activation O
RARE O
of O
the O
normal O
B O
cell O
from O
which O
B O
- O
ALL_CAP O
RARE O
. O

RARE O
studies O
RARE O
secondary O
RARE O
predictions O
, O
CD O
and O
NMR O
spectroscopy O
together O
with O
ELISA O
assays O
, O
showed O
that O
the O
greater O
is O
the O
propensity O
of O
the O
RARE O
RARE O
helix O
formation O
the O
RARE O
is O
the O
recognition O
by O
anti I-GENE
- I-GENE
NUM I-GENE
. O

RARE O
and O
RARE O
ALL_CAP O
scores O
in O
the O
" O
off O
" O
state O
were O
improved O
by O
18 O
% O
and O
in O
the O
" O
on O
" O
state O
the O
scores O
declined O
by O
2 O
%. O

RARE O
- O
level O
RARE O
( O
RARE O
) O
indicative O
of O
gene O
RARE O
were O
identified O
RARE O
NUM O
in O
two O
cases O
, O
and O
in O
one O
case O
each O
RARE O
NUM O
- O
NUM O
, O
NUM O
- O
29 O
, O
NUM O
. O
1 O
- O
NUM O
. O
2 O
, O
NUM O
- O
NUM O
, O
NUM O
. O
2 O
, O
NUM O
. O
2 O
- O
12 O
, O
and O
NUM O
. O

With O
respect O
to O
the O
distribution O
of O
RARE O
RARE O
over O
the O
promoter O
region O
, O
the O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
gene I-GENE
is O
largely O
different O
from O
the O
mouse O
RARE I-GENE
- I-GENE
I I-GENE
gene I-GENE
, O
suggesting O
that O
ALL_CAP O
arrangement O
is O
not O
an O
important O
factor O
RARE O
metal O
RARE O
. O

The O
cDNA O
was O
RARE O
in O
Saccharomyces O
cerevisiae O
under O
the O
control O
of O
the O
yeast I-GENE
RARE I-GENE
phosphate I-GENE
isomerase I-GENE
promoter I-GENE
. O

Interestingly O
, O
the O
RNA O
sequences O
RARE O
by O
the O
RARE O
zinc I-GENE
RARE I-GENE
NUM I-GENE
variant I-GENE
are O
efficiently O
RARE O
by O
NUM I-GENE
, O
in O
agreement O
with O
the O
fact O
that O
the O
ALL_CAP O
of O
NUM I-GENE
and O
NUM I-GENE
are O
similar O
. O

RARE I-GENE
II I-GENE
is O
a O
major O
target O
of O
the O
protein I-GENE
kinase I-GENE
casein I-GENE
kinase I-GENE
2 I-GENE
( O
ALL_CAP I-GENE
NUM I-GENE
) O
in O
vivo O
. O

Recent O
work O
in O
this O
laboratory O
has O
shown O
that O
the O
gene O
coding O
RARE O
RARE I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
in O
RARE O
RARE O
is O
RARE O
- O
regulated O
in O
response O
to O
phosphate O
limitation O
. O

All O
numbers O
RARE O
to O
nucleotide O
positions O
on O
the O
wild O
- O
type O
HIV O
- O
1 O
transcript O
. O

Sequence O
analysis O
revealed O
that O
the O
ALL_CAP I-GENE
protein I-GENE
is O
identical O
with O
a O
NUM I-GENE
kDa I-GENE
nuclear I-GENE
' I-GENE
domain I-GENE
rich I-GENE
in I-GENE
RARE I-GENE
' I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
protein I-GENE
occurring O
free O
in O
the O
RARE O
and O
in O
NUM I-GENE
- I-GENE
ribonucleoprotein I-GENE
RARE I-GENE
. O

Here O
, O
we O
report O
the O
RARE O
RARE O
of O
the O
human I-GENE
topoisomerase I-GENE
RARE I-GENE
gene I-GENE
, O
which O
consists O
of O
NUM O
exons O
spanning O
NUM O
. O
5 O
kb O
. O

RARE O
modulation O
of O
RARE O
activity O
of O
RARE O
motor O
cortical O
neurons O
. O

Previous O
studies O
characterized O
a O
RARE O
- O
inducible O
, O
RARE O
nuclear I-GENE
factor I-GENE
( I-GENE
ALL_CAP I-GENE
)- I-GENE
kappaB I-GENE
consensus I-GENE
element I-GENE
in O
the O
immediate O
5 O
' O
regulatory O
region O
of O
the O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
alpha I-GENE
gene O
RARE O
- O
NUM O
bp O
. O

An O
RARE O
that O
prevents O
RARE O
of O
a O
RARE O
mRNA O
. O

Four O
CsA O
- O
treated O
patients O
developed O
RARE O
elevated O
ALL_CAP O
> O
NUM O
mg O
/ O
NUM O
h O
( O
RARE O
= O
3 O
with O
RARE O
RARE O
whereas O
all O
the O
NUM O
placebo O
- O
treated O
patients O
had O
normal O
ALL_CAP O
(< O
NUM O
mg O
/ O
NUM O
h O
) O
after O
7 O
years O
of O
follow O
- O
RARE O
. O

Mutational O
analysis O
of O
the O
- O
NUM O
/- O
NUM O
DNA O
showed O
that O
ALL_CAP O
- O
3 O
nuclear O
proteins O
RARE O
to O
a O
site O
containing O
, O
but O
not O
identical O
to O
, O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
sequence I-GENE
. O

In O
contrast O
, O
RARE O
change O
was O
detected O
in O
the O
RARE O
of O
' O
RARE O
' O
RARE O
, O
with O
respect O
to O
any O
of O
the O
following O
parameters O
: O
RARE O
rate O
in O
RARE O
, O
serum O
- O
dependence O
RARE O
RARE O
or O
survival O
, O
RARE O
, O
cellular O
morphology O
, O
or O
tissue O
- O
specific O
differentiation O
markers O
. O

A O
high O
RARE O
pH O
(+/- O
8 O
RARE O
a O
short O
solid O
retention O
time O
(< O
NUM O
days O
RARE O
and O
the O
presence O
of O
a O
substantial O
ALL_CAP O
population O
in O
the O
RARE O
may O
considerably O
reduce O
the O
time O
required O
RARE O
RARE O
- O
RARE O
ALL_CAP O
to O
RARE O
MB O
. O

In O
RARE O
RARE O
, O
the O
aim O
is O
to O
correlate O
the O
effect O
of O
shear O
to O
a O
parameter O
related O
to O
the O
inner O
RARE O
of O
the O
valve O
and O
to O
operating O
conditions O
. O

The O
RARE O
respiratory O
burst O
was O
investigated O
by O
the O
RARE O
oxidative O
transformation O
of O
RARE O
123 O
to O
the O
RARE O
RARE O
RARE O
123 O
via O
flow O
RARE O
. O

A O
mutation O
RARE O
to O
the O
NUM I-GENE
gene I-GENE
, O
previously O
defined O
by O
recessive O
mutations O
that O
suppress O
NUM I-GENE
RARE I-GENE
alleles I-GENE
and O
RARE O
many O
mitochondrial O
mRNAs O
, O
was O
also O
isolated O
. O

A O
deletion O
mutation O
analysis O
of O
the O
recombinant O
protein O
has O
shown O
that O
the O
N O
- O
terminal O
region O
and O
the O
two O
leucine O
RARE O
are O
necessary O
RARE O
the O
binding O
. O

A O
database O
search O
has O
revealed O
RARE O
the O
most O
RARE O
homology O
a O
match O
with O
the O
human I-GENE
mitochondrial I-GENE
transcription I-GENE
RARE I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
RARE O
a O
protein O
that O
also O
binds O
DNA O
RARE O
a O
RARE O
and O
contains O
three O
leucine O
RARE O
forming O
RARE O
interactions O
. O

In O
all O
trials O
, O
antigen O
challenge O
followed O
1 O
h O
after O
the O
last O
treatment O
. O

NUM O
, O
1997 O
, O
40 O
patients O
had O
died O
( O
NUM O
in O
the O
ALL_CAP O
- O
II O
group O
and O
5 O
in O
the O
ALL_CAP O
- O
III O
group O
RARE O
RARE O
a O
crude O
mortality O
rate O
of O
8 O
. O
NUM O
%. O

We O
found O
that O
RARE O
PSA I-GENE
can O
be O
detected O
in O
all O
cyst O
fluids O
and O
in O
about O
NUM O
% O
of O
female O
RARE O
. O

RARE O
I O
cysts O
( O
with O
a O
high O
K O
RARE O
RARE O
+ O
ratio O
) O
RARE O
to O
have O
RARE O
RARE O
PSA I-GENE
than O
RARE O
II O
cysts O
. O

Despite O
this O
DNA O
binding O
activity O
, O
AP I-GENE
- I-GENE
1 I-GENE
reporter I-GENE
activity O
was O
suppressed O
in O
these O
cells O
. O

A O
single O
N O
- O
glycosylation O
site O
present O
in O
chicken I-GENE
NUM I-GENE
is O
RARE O
among O
all O
five O
of O
these O
proteins O
: O
carbohydrate O
analysis O
of O
NUM I-GENE
revealed O
the O
presence O
of O
a O
complex O
type O
RARE O
chain O
RARE O
this O
site O
. O

Here O
we O
describe O
the O
RARE O
and O
characterization O
of O
a O
NUM O
- O
RARE O
fragment O
, O
containing O
the O
RARE I-GENE
domain I-GENE
of O
NUM I-GENE
, O
which O
is O
suitable O
RARE O
structural O
studies O
. O

RARE O
RARE O
RARE O
' O
RARE O
RARE O
RARE O
hospital O
. O

ALL_CAP O
RARE O
laparoscopic O
RARE O
bladder O
guidelines O
. O

RARE O
RARE O
RARE O
RARE O
RARE O
RARE O
RARE O
gas O
RARE O
RARE O
- O
source O
. O

RARE O
RARE O
RARE O
RARE O
from O
largest O
RARE O
RARE O
in O
RARE O
. O

ALL_CAP O
RARE O
RARE O
hospitals O
' O
RARE O
. O

RARE O
provides O
excellent O
RARE O
evaluation O
of O
RARE O
cord O
injury O
. O

ALL_CAP O
is O
not O
the O
only O
organization O
RARE O
RARE O
ALL_CAP O
organ O
RARE O
, O
however O
. O

Because O
of O
RARE O
regarding O
RARE O
transfusion O
- O
related O
RARE O
RARE O
( O
RARE O
, O
acquired O
immune O
deficiency O
RARE O
and O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
RARE O
there O
has O
been O
increasing O
research O
effort O
into O
postoperative O
hemorrhage O
related O
to O
cardiopulmonary O
bypass O
with O
RARE O
circulation O
. O

They O
contrast O
RARE O
in O
fertility O
, O
life O
RARE O
ratios O
, O
and O
gender O
differences O
in O
these O
RARE O
with O
the O
RARE O
population O
of O
the O
United O
RARE O
. O

RARE O
v O
. O

RARE O
RARE O
RARE O
RARE O
ALL_CAP O
physicians O
. O

Overexpression O
of O
either O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
or O
RARE I-GENE
causes O
apoptosis O
of O
TNF I-GENE
- O
RARE O
NUM O
fibroblast O
cell O
line O
, O
RARE O
RARE O
RARE O
TNF I-GENE
- O
resistant O
osteosarcoma O
cell O
line O
, O
NUM O
. O

This O
is O
in O
contrast O
to O
NUM I-GENE
, O
which O
was O
previously O
shown O
to O
be O
RARE O
RARE O
a O
single O
site O
in O
a O
motif O
that O
is O
not O
homologous O
to O
the O
sites O
now O
described O
in O
PPARalpha I-GENE
. O

These O
results O
suggest O
NUM I-GENE
is O
a O
new O
RARE O
of O
the O
ALL_CAP I-GENE
family I-GENE
that O
is O
under O
distinct O
RARE O
from O
NUM I-GENE
. O

We O
have O
screened O
the O
elastin I-GENE
gene I-GENE
RARE O
mutations O
responsible O
RARE O
RARE O
aortic O
stenosis O
( O
ALL_CAP O
) O
in O
two O
large O
, O
independently O
collected O
RARE O
with O
isolated O
( O
RARE O
) O
ALL_CAP O
. O

RARE O
RARE O
of O
the O
NUM I-GENE
gene I-GENE
is O
tightly O
regulated O
RARE O
development O
. O

NUM O
- O
OH O
- O
NUM O
did O
not O
RARE O
affect O
RARE O
health O
RARE O
the O
proposed O
use O
level O
of O
NUM O
micrograms O
/ O
kg O
feed O
when O
replacing O
vitamin O
NUM O
in O
RARE O
RARE O
. O

A O
RARE O
of O
12 O
RARE O
RARE O
the O
RARE O
and O
37 O
diagnostic O
criteria O
were O
proposed O
to O
a O
RARE O
RARE O
of O
12 O
Italian O
RARE O
who O
RARE O
them O
in O
order O
so O
RARE O
to O
identify O
a O
core O
set O
of O
criteria O
. O

RARE O
fluoride O
( O
ALL_CAP O
): O
a O
double O
- O
blind O
, O
placebo O
- O
RARE O
study O
of O
safety O
and O
efficacy O
in O
the O
treatment O
of O
senile O
dementia O
of O
the O
RARE O
type O
. O

METHODS O
: O
RARE O
August O
1991 O
and O
RARE O
1994 O
, O
198 O
men O
with O
clinical O
NUM O
or O
NUM O
classified O
( O
ALL_CAP O
) O
RARE O
carcinoma O
( O
bone O
scan O
negative O
) O
who O
were O
RARE O
high O
risk O
of O
lymph O
node O
involvement O
underwent O
a O
NUM O
- O
RARE O
RARE O
scan O
prior O
to O
RARE O
RARE O
. O

RARE O
RARE O
RARE O
did O
not O
significantly O
increase O
estimated O
alanine O
or O
RARE O
RARE O
or O
absolute O
RARE O
RARE O
. O

RARE O
after O
surgery O
, O
RARE O
PGE2 O
and O
adenosine O
concentrations O
were O
3 O
. O
7 O
+/- O
NUM O
. O
7 O
and O
296 O
+/- O
NUM O
nM O
, O
respectively O
. O

Because O
of O
the O
probable O
RARE O
relationship O
between O
RARE O
NUM I-GENE
( O
RARE I-GENE
/ O
abl I-GENE
) O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
activity O
and O
manifestations O
of O
chronic O
- O
RARE O
chronic O
RARE O
leukemia O
( O
CML O
; O
RARE O
expansion O
RARE O
a O
key O
goal O
is O
to O
identify O
relevant O
NUM I-GENE
RARE O
in O
RARE O
chronic O
- O
RARE O
CML O
hematopoietic O
RARE O
cells O
. O

In O
vitro O
precipitation O
with O
a O
RARE I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
- I-GENE
fusion I-GENE
protein I-GENE
containing O
the O
C O
- O
terminal O
RARE O
domain O
of O
NUM I-GENE
showed O
ALL_CAP I-GENE
- O
regulated O
association O
of O
ERK1 I-GENE
/ I-GENE
2 I-GENE
with O
the O
fusion O
protein O
, O
while O
this O
was O
not O
seen O
when O
serine O
NUM O
in O
NUM I-GENE
was O
changed O
to O
alanine O
. O

One O
such O
element O
, O
NUM O
, O
was O
employed O
to O
clone O
from O
a O
rat O
pituitary O
cDNA O
RARE O
library O
a O
novel O
NUM I-GENE
- I-GENE
amino I-GENE
acid I-GENE
ALL_CAP I-GENE
protein I-GENE
, O
designated O
ALL_CAP I-GENE
( I-GENE
PRL I-GENE
regulatory I-GENE
element I-GENE
binding I-GENE
) I-GENE
protein I-GENE
. O

Characterization O
of O
the O
transcription I-GENE
factor I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
from O
the O
Japanese O
RARE O
( O
RARE O
RARE O
) O
reveals O
evolutionary O
conservation O
of O
heavy O
metal O
stress O
response O
. O

The O
RARE I-GENE
RARE I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
( O
RARE I-GENE
) O
are O
members O
of O
the O
nuclear I-GENE
hormone I-GENE
receptor I-GENE
superfamily I-GENE
. O

However O
, O
F I-GENE
- I-GENE
SRC I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
RARE O
CBP I-GENE
- I-GENE
RARE I-GENE
domain I-GENE
still O
RARE O
enhancing O
activity O
. O

The O
catalytic O
site O
has O
an O
S1 O
pocket O
RARE O
with O
RARE O
hydrophobic O
residues O
to O
RARE O
the O
RARE O
RARE O
. O

The O
RARE O
circular O
ALL_CAP O
genome O
contained O
a O
novel O
sequence O
of O
NUM O
nt O
( O
nt O
NUM O
to O
NUM O
RARE O
NUM O
RARE O
in O
between O
the O
known O
3 O
'- O
and O
5 O
'- O
end O
RARE O
, O
forming O
a O
117 O
- O
nt O
ALL_CAP O
- O
rich O
stretch O
( O
ALL_CAP O
content O
, O
NUM O
. O
6 O
% O
RARE O
nt O
NUM O
to O
NUM O
). O

The O
RARE O
mouse O
RARE O
RARE O
is O
resistant O
to O
infection O
by O
the O
RARE O
RARE O
cell O
focus O
- O
inducing O
( O
ALL_CAP O
) O
subgroup O
of O
murine O
leukemia O
viruses O
( O
RARE O
). O

To O
determine O
the O
function O
of O
ALL_CAP I-GENE
ALL_CAP I-GENE
in O
virus O
growth O
, O
a O
series O
of O
ALL_CAP I-GENE
deletion I-GENE
mutants I-GENE
were O
constructed O
with O
ALL_CAP O
cosmid O
DNA O
derived O
from O
the O
RARE O
RARE O
. O

CCAAT I-GENE
RARE I-GENE
protein I-GENE
binds O
to O
and O
negatively O
regulates O
human O
RARE O
type O
6 O
NUM I-GENE
, O
E7 I-GENE
, O
and O
E1 I-GENE
promoters O
. O

As O
such O
the O
findings O
support O
existing O
studies O
that O
have O
identified O
given O
social O
characteristics O
of O
RARE O
RARE O
. O

Three O
different O
site O
- O
directed O
mutations O
of O
the O
cyclic O
AMP O
response O
element O
each O
RARE O
the O
nerve I-GENE
growth I-GENE
factor I-GENE
effect O
by O
> O
NUM O
%. O

Using O
an O
RNase I-GENE
H I-GENE
protection O
assay O
and O
specific O
blocking O
oligonucleotides O
, O
we O
find O
that O
recognition O
of O
the O
5 O
' O
RARE O
- O
site O
( O
5 O
' O
RARE O
) O
and O
branchpoint O
sequence O
( O
ALL_CAP O
) O
elements O
by O
NUM I-GENE
and O
NUM I-GENE
RARE I-GENE
, O
respectively O
, O
displays O
strong O
cooperativity O
, O
requiring O
both O
sites O
in O
the O
pre O
- O
mRNA O
substrate O
RARE O
efficient O
complex O
formation O
. O

Analysis O
of O
lacZ I-GENE
transcriptional I-GENE
fusions I-GENE
shows O
that O
the O
ALL_CAP I-GENE
- I-GENE
binding I-GENE
sites I-GENE
negatively O
affect O
the O
RARE O
of O
ALL_CAP I-GENE
. O

Many O
eukaryotic O
cell O
surface O
proteins O
are O
RARE O
in O
the O
RARE O
RARE O
through O
RARE O
( O
ALL_CAP O
). O

In O
the O
cell O
- O
free O
import O
assay O
, O
beta I-GENE
- I-GENE
catenin I-GENE
rapidly O
RARE O
into O
the O
nucleus O
without O
the O
RARE O
addition O
of O
cytosol O
, O
Ran I-GENE
, O
or O
ATP O
/ O
GTP O
. O

In O
ischemic O
and O
hypoxic O
RARE O
, O
a O
strong O
correlation O
was O
found O
between O
RARE O
a O
, O
NUM O
oxidation O
level O
and O
VO2 O
in O
both O
ischemic O
and O
hypoxic O
RARE O
( O
NUM O
=. O
NUM O
and O
. O
87 O
, O
respectively O
). O

An O
endogenous O
mammalian O
regulator O
of O
this O
process O
, O
named O
RARE I-GENE
, O
has O
been O
identified O
( O
RARE O
RARE O
RARE I-GENE
include O
ALL_CAP I-GENE
, O
RARE I-GENE
, O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
ALL_CAP I-GENE
, O
I I-GENE
- I-GENE
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
). O

Plasma O
glucose O
, O
RARE I-GENE
insulin I-GENE
( O
ALL_CAP I-GENE
RARE O
C I-GENE
- I-GENE
peptide I-GENE
, O
glucagon I-GENE
, O
and O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
levels O
RARE O
each O
time O
point O
RARE O
ALL_CAP O
were O
measured O
. O

Each O
recombinant O
product O
was O
a O
fusion O
protein O
with O
a O
B O
domain O
of O
RARE I-GENE
protein I-GENE
A I-GENE
( O
ALL_CAP I-GENE
). O

RARE O
and O
ALL_CAP O
binding O
by O
the O
isolated O
ALL_CAP I-GENE
domain I-GENE
of O
immunization O
- O
RARE O
anti O
- O
Z O
- O
DNA O
RARE O
resembles O
the O
activity O
of O
RARE O
autoantibodies O
and O
suggests O
that O
ALL_CAP I-GENE
- O
dependent O
binding O
to O
a O
RARE O
mimicked O
by O
RARE O
may O
play O
a O
role O
in O
B O
cell O
selection O
before O
immunization O
with O
Z O
- O
DNA O
. O

RARE O
- O
99m O
methylene O
RARE O
RARE O
RARE O
evaluation O
of O
RARE O
breast O
masses O
. O

ALL_CAP O
: O
Study O
patients O
were O
randomly O
divided O
into O
four O
parallel O
groups O
to O
receive O
either O
RARE O
NUM O
mg O
a O
day O
RARE O
12 O
or O
16 O
weeks O
( O
groups O
NUM O
and O
NUM O
) O
or O
RARE O
NUM O
mg O
a O
day O
RARE O
1 O
week O
in O
every O
4 O
weeks O
RARE O
12 O
or O
16 O
weeks O
( O
groups O
NUM O
and O
NUM O
). O

Nuclear O
receptors O
( O
RARE O
) O
can O
function O
RARE O
RARE O
RARE O
in O
both O
mammalian O
and O
yeast O
cells O
, O
indicating O
that O
important O
features O
of O
transcriptional O
control O
have O
been O
RARE O
throughout O
evolution O
. O

When O
RARE O
to O
a O
heterologous O
DNA O
- O
binding O
domain O
, O
NUM I-GENE
can O
activate O
transcription O
on O
its O
own O
. O

OBJECTIVE O
: O
To O
follow O
- O
RARE O
RARE O
patients O
with O
arthritis O
after O
infection O
with O
beta O
- O
RARE O
RARE O
of O
RARE O
group O
A O
( O
beta O
ALL_CAP O
RARE O
with O
RARE O
on O
clinical O
characteristics O
and O
serological O
features O
. O

RARE O
can O
also O
cause O
a O
RARE O
acting O
directly O
on O
the O
inner O
ear O
: O
among O
these O
, O
RARE O
RARE O
, O
a O
RARE O
which O
causes O
RARE O
and O
RARE O
RARE O
, O
a O
RARE O
that O
causes O
RARE O
RARE O
, O
must O
be O
mentioned O
. O

We O
found O
that O
the O
RARE O
of O
the O
protein O
was O
maximum O
in O
mitosis O
and O
minimum O
in O
G1 O
, O
which O
correlated O
with O
the O
RARE O
of O
its O
RARE O
RNA O
. O

These O
findings O
demonstrate O
that O
RARE O
- O
RARE O
mutagenesis O
is O
a O
viable O
approach O
to O
identify O
bacterial O
genes O
associated O
with O
the O
ability O
to O
RARE O
the O
RARE O
RARE O
. O

RARE O
. O

The O
eukaryotic O
cell O
RARE O
is O
RARE O
in O
part O
by O
the O
RARE O
transcription O
of O
RARE I-GENE
genes I-GENE
, O
whose O
protein O
products O
associate O
with O
and O
positively O
regulate O
the O
RARE I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
. O

The O
NUM I-GENE
gene I-GENE
encodes O
the O
regulatory O
subunit O
RARE O
a O
type I-GENE
1 I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
RARE I-GENE
phosphatase I-GENE
, O
NUM I-GENE
. O

The O
results O
demonstrate O
that O
the O
NUM I-GENE
phosphatase I-GENE
and O
its O
NUM I-GENE
regulatory O
subunit O
play O
positive O
roles O
in O
HSF I-GENE
activation O
of O
NUM I-GENE
transcription O
. O

MEF I-GENE
and O
NUM I-GENE
synergistically O
transactivated O
an O
interleukin I-GENE
3 I-GENE
promoter I-GENE
reporter I-GENE
gene I-GENE
construct I-GENE
, O
yet O
the O
activating O
activity O
of O
MEF I-GENE
was O
abolished O
when O
MEF I-GENE
was O
coexpressed O
with O
NUM I-GENE
/ O
ALL_CAP I-GENE
. O

RARE O
, O
the O
presence O
of O
the O
ALL_CAP O
appears O
to O
stop O
further O
RARE O
of O
NUM I-GENE
and O
to O
RARE O
the O
molecule O
. O

This O
RARE O
can O
be O
catalyzed O
by O
a O
RARE O
- O
RARE O
double O
- O
RARE O
DNA O
- O
activated O
protein O
kinase O
activity O
from O
the O
RARE O
RARE O
nucleus O
in O
vitro O
. O

RARE O
, O
the O
RARE O
cellular O
level O
of O
p21 I-GENE
increased O
RARE O
via O
a O
posttranscriptional O
mechanism O
. O

Moreover O
, O
when O
added O
to O
the O
RARE O
cultures O
, O
RARE I-GENE
- I-GENE
N I-GENE
markedly O
RARE O
the O
formation O
of O
resorption O
RARE O
on O
RARE O
RARE O
. O

Overall O
, O
our O
results O
suggest O
that O
resistant O
RARE O
exist O
among O
the O
ALL_CAP O
RARE O
population O
. O

The O
RARE O
mechanism O
by O
which O
NUM I-GENE
and O
the O
NUM I-GENE
- O
NUM I-GENE
interaction O
function O
in O
mRNA O
export O
is O
unknown O
. O

The O
Fyn I-GENE
NH2 I-GENE
terminus I-GENE
was O
necessary O
but O
not O
sufficient O
RARE O
interaction O
with O
RARE O
and O
both O
Fyn I-GENE
kinase I-GENE
and O
NUM I-GENE
domains I-GENE
were O
required O
, O
RARE O
RARE O
of O
RARE I-GENE
ALL_CAP I-GENE
RARE O
and O
binding O
to O
RARE I-GENE
ALL_CAP I-GENE
RARE O
. O

In O
RARE O
yeast O
, O
the O
protein O
NUM I-GENE
, O
the O
RARE I-GENE
- I-GENE
family I-GENE
RARE I-GENE
NUM I-GENE
, O
and O
the O
F O
- O
box O
/ O
ALL_CAP O
- O
repeat O
protein O
NUM I-GENE
form O
the O
NUM I-GENE
ubiquitin I-GENE
ligase I-GENE
complex O
, O
which O
RARE O
the O
RARE I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
( O
Cdk I-GENE
) O
inhibitor O
NUM I-GENE
RARE O
proteolysis O
RARE O
3 O
] O
RARE O
4 O
] O
RARE O
5 O
] O
RARE O
6 O
] O
RARE O
7 O
] O
RARE O
8 O
]. O

We O
show O
here O
that O
, O
despite O
their O
structural O
and O
RARE O
similarities O
, O
the O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
fail O
to O
complement O
each O
other O
' O
s O
deletion O
RARE O
, O
indicating O
that O
they O
perform O
non O
- O
RARE O
, O
but O
potentially O
RARE O
, O
functions O
in O
proteolysis O
. O

RARE I-GENE
III I-GENE
prevents O
NUM O
min O
RARE O
RARE O
ischemia O
reperfusion O
injury O
in O
rats O
. O

In O
RARE O
, O
the O
RARE O
were O
RARE O
applying O
RARE O
criteria O
. O

These O
observations O
of O
elevated O
serum I-GENE
lipase I-GENE
and O
serum O
CA I-GENE
19 I-GENE
- I-GENE
9 I-GENE
in O
RARE O
' O
s O
RARE O
without O
evidence O
of O
malignancy O
may O
reflect O
pancreatic O
involvement O
in O
this O
disorder O
. O

Acute O
pancreatitis O
RARE O
a O
complication O
of O
RARE O
RARE O
. O

Significantly O
greater O
improvement O
( O
p O
< O
NUM O
. O
05 O
) O
in O
the O
RARE O
group O
RARE O
became O
apparent O
by O
the O
end O
of O
week O
3 O
on O
the O
Y O
- O
ALL_CAP O
and O
the O
ALL_CAP O
RARE O
scale O
, O
and O
by O
the O
end O
of O
weeks O
6 O
and O
8 O
, O
respectively O
, O
on O
the O
ALL_CAP O
and O
ALL_CAP O
RARE O
scale O
. O

RARE I-GENE
- I-GENE
inducible I-GENE
protein I-GENE
kinases I-GENE
capable O
of O
activating O
c I-GENE
- I-GENE
jun I-GENE
RARE O
include O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
/ O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
protein I-GENE
kinase I-GENE
( O
SAPK I-GENE
/ O
JNK I-GENE
) O
and O
p38 I-GENE
members O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
superfamily O
of O
RARE O
molecules O
. O

RARE I-GENE
growth I-GENE
factor I-GENE
( I-GENE
TGF I-GENE
)- I-GENE
beta1 I-GENE
induces O
extracellular O
RARE O
deposition O
and O
RARE O
of O
mesenchymal O
cells O
. O

RARE O
in O
cardiovascular O
RARE O
. O

Group O
RARE O
functions O
RARE O
RARE O
with O
hearing O
RARE O
do O
not O
show O
a O
decrease O
in O
performance O
RARE O
the O
largest O
values O
of O
delta O
RARE O
included O
in O
this O
study O
. O

RARE O
can O
detect O
RARE O
, O
which O
may O
be O
poorly O
perceived O
or O
even O
unknown O
to O
the O
subjects O
themselves O
. O

Marked O
RARE O
variation O
in O
RARE O
RARE O
by O
gestational O
age O
was O
evident O
. O

Significant O
correlations O
between O
mental O
status O
RARE O
measured O
by O
the O
RARE O
- O
RARE O
State O
Examination O
and O
NA O
/ O
ALL_CAP O
, O
ALL_CAP O
/ O
RARE O
and O
NA O
were O
found O
. O

RARE I-GENE
also O
RARE O
ALL_CAP I-GENE
activity O
very O
strongly O
when O
the O
NUM O
and O
NUM O
sites O
were O
combined O
; O
induction O
of O
the O
( O
NUM O
) O
3 O
( O
NUM O
) O
NUM O
- O
ALL_CAP I-GENE
constructs O
was O
positively O
modulated O
by O
the O
NUM O
. O

In O
this O
study O
, O
we O
report O
the O
isolation O
and O
characterization O
of O
the O
RARE O
rat I-GENE
NUM I-GENE
( O
ALL_CAP I-GENE
NUM I-GENE
) O
subunit O
gene O
. O

RARE O
RARE O
following O
intravenous O
infusion O
of O
RARE O
RARE O
. O

Initial O
control O
of O
bleeding O
is O
similar O
, O
but O
eradication O
is O
achieved O
in O
fewer O
RARE O
with O
ALL_CAP O
. O

Finally O
, O
we O
determined O
the O
genomic O
organization O
of O
the O
human I-GENE
NUM I-GENE
gene I-GENE
, O
which O
consists O
of O
18 O
exons O
spanning O
about O
67 O
kb O
, O
and O
its O
chromosomal O
RARE O
RARE O
position O
NUM O
. O
2 O
. O

The O
RARE O
of O
this O
study O
were O
to O
determine O
and O
RARE O
the O
frequency O
of O
self O
reported O
visual O
RARE O
in O
daily O
tasks O
performed O
by O
glaucoma O
patients O
; O
to O
examine O
the O
RARE O
between O
RARE O
using O
factor O
analysis O
; O
to O
study O
the O
relation O
between O
perceived O
visual O
RARE O
and O
a O
measure O
of O
the O
severity O
of O
visual O
field O
RARE O
; O
to O
develop O
a O
glaucoma O
specific O
subgroup O
of O
questions O
; O
and O
examine O
the O
validity O
and O
reliability O
of O
this O
subgroup O
of O
questions O
. O

Furthermore O
, O
the O
validity O
of O
this O
new O
subset O
of O
questions O
was O
shown O
to O
be O
significant O
( O
RARE O
= O
NUM O
. O
NUM O
, O
p O
< O
NUM O
. O
05 O
) O
RARE O
the O
correlation O
between O
a O
measure O
of O
the O
severity O
of O
RARE O
visual O
field O
RARE O
and O
the O
mean O
score O
of O
the O
variables O
used O
in O
the O
glaucoma O
specific O
subgroup O
of O
questions O
. O

Sequence O
comparison O
of O
RARE I-GENE
RARE I-GENE
and O
their O
homologs O
from O
various O
organisms O
demonstrates O
that O
the O
proteins O
can O
be O
classified O
into O
two O
RARE O
, O
a O
RARE O
type O
including O
E I-GENE
. I-GENE
coli I-GENE
RARE I-GENE
and O
a O
more O
widely O
distributed O
type O
including O
the O
B O
. O
RARE O
enzyme O
, O
suggesting O
that O
the O
latter O
type O
is O
evolutionarily O
older O
. O

RARE O
RARE O
is O
the O
RARE O
of O
treatment O
. O

RARE O
RARE O
and O
mechanism O
of O
the O
ALL_CAP I-GENE
RARE I-GENE
. O

In O
11 O
eyes O
that O
had O
been O
RARE O
RARE O
random O
10 O
micrograms O
of O
recombinant I-GENE
tissue I-GENE
plasminogen I-GENE
activator I-GENE
were O
injected O
RARE O
NUM O
hrs O
later O
. O

RESULTS O
ALL_CAP O
CONCLUSIONS O
: O
RARE O
' O
s O
double O
RARE O
- O
RARE O
( O
NUM O
) O
RARE O
in O
RARE O
RARE O
increase O
of O
RARE O
- O
pressure O
RARE O
anaesthesia O
with O
N2O O
. O

RARE O
, O
we O
designated O
this O
gene I-GENE
NUM I-GENE
( O
RARE I-GENE
enzyme I-GENE
RARE I-GENE
- I-GENE
like I-GENE
1 I-GENE
). O

The O
binding O
of O
ALL_CAP I-GENE
domains I-GENE
to O
Gbetagamma I-GENE
was O
inhibited O
by O
RARE O
of O
Gbetagamma I-GENE
with O
the O
GDP O
- O
RARE O
but O
not O
the O
GTP O
- O
RARE O
form O
of O
RARE I-GENE
. O

Their O
RARE O
are O
RARE O
than O
RARE O
and O
therefore O
are O
called O
RARE O
. O

RARE O
RARE O
and O
RARE O
RARE O
RARE O
to O
RARE O
dopamine O
agonist O
therapy O
( O
RARE O
) O
RARE O
Parkinson O
' O
s O
RARE O
. O

An O
RARE O
type O
of O
ALL_CAP O
is O
frequently O
associated O
with O
ALL_CAP O
and O
we O
RARE O
, O
therefore O
, O
that O
RARE O
should O
be O
RARE O
of O
a O
possible O
RARE O
of O
ALL_CAP O
and O
ALL_CAP O
. O

In O
addition O
, O
we O
also O
constructed O
and O
RARE O
chimeric O
fusion O
protein O
that O
contains O
HIV I-GENE
- I-GENE
2 I-GENE
gag I-GENE
with O
NUM I-GENE
domains O
of O
HIV O
- O
NUM O
, O
HIV O
- O
NUM O
, O
HIV O
- O
NUM O
and O
HIV O
- O
NUM O
. O

Our O
results O
indicate O
that O
NUM I-GENE
peptides O
from O
all O
major O
RARE O
of O
HIV O
- O
1 O
carried O
by O
HIV I-GENE
- I-GENE
2 I-GENE
gag I-GENE
can O
be O
used O
RARE O
a O
RARE O
HIV O
/ O
AIDS O
vaccine O
. O

RARE O
was O
determined O
by O
responses O
to O
question O
3 O
( O
ability O
to O
achieve O
an O
RARE O
) O
and O
question O
4 O
( O
ability O
to O
maintain O
an O
RARE O
) O
of O
the O
NUM O
- O
RARE O
International O
RARE O
of O
RARE O
RARE O
( O
ALL_CAP O
). O

Evidence O
RARE O
the O
involvement O
of O
the O
NUM I-GENE
- O
NUM I-GENE
phosphatase O
and O
the O
NUM I-GENE
- O
NUM I-GENE
kinase O
in O
the O
RARE O
of O
NUM I-GENE
transcription O
in O
Saccharomyces O
cerevisiae O
. O

In O
ALL_CAP O
males O
, O
two O
RARE I-GENE
- I-GENE
1 I-GENE
mRNAs I-GENE
, O
RARE I-GENE
- I-GENE
NUM I-GENE
and O
RARE I-GENE
- I-GENE
NUM I-GENE
, O
are O
RARE O
from O
two O
separate O
promoters O
: O
P1 O
, O
RARE O
in O
the O
5 O
'- O
flanking O
region O
, O
and O
P2 O
, O
RARE O
in O
the O
large O
second O
intron O
. O

Induction O
of O
Fas I-GENE
RARE I-GENE
RARE O
by O
HIV O
involves O
the O
interaction O
of O
Nef I-GENE
with O
the O
T I-GENE
cell I-GENE
receptor I-GENE
RARE I-GENE
chain I-GENE
. O

RARE I-GENE
protein I-GENE
tyrosine I-GENE
RARE I-GENE
( O
RARE I-GENE
) O
comprise O
a O
family O
of O
proteins O
that O
feature O
RARE O
phosphatase O
domains O
and O
an O
RARE O
with O
putative O
RARE O
- O
binding O
motifs O
. O

These O
RARE O
- O
characterized O
brain O
regions O
may O
provide O
a O
basis O
RARE O
future O
studies O
of O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
function O
. O

RARE O
used O
RARE O
are O
mental O
RARE O
, O
speech O
tasks O
, O
the O
Stroop O
test O
, O
RARE O
RARE O
, O
films O
or O
RARE O
and O
RARE O
. O

The O
control O
group O
included O
8 O
RARE O
samples O
from O
physiological O
full O
- O
term O
RARE O
. O

However O
, O
we O
identified O
a O
gene O
between O
the O
NUM I-GENE
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
with O
homology O
to O
the O
RARE I-GENE
ORF I-GENE
( I-GENE
ORF I-GENE
- I-GENE
1 I-GENE
) I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
type I-GENE
1 I-GENE
and O
corresponding O
gene O
identified O
in O
pseudorabies O
virus O
. O

In O
contrast O
, O
the O
RARE O
of O
NUM I-GENE
staining O
in O
meiosis O
was O
not O
correlated O
with O
initial O
microtubule O
RARE O
but O
was O
correlated O
with O
a O
measure O
of O
tension O
: O
the O
distance O
between O
homologous O
or O
RARE O
RARE O
( O
in O
meiosis O
I O
and O
II O
, O
respectively O
). O

In O
RARE O
cells O
, O
the O
ALL_CAP I-GENE
domain I-GENE
of O
Akt I-GENE
/ O
PKB I-GENE
RARE O
to O
sites O
of O
cell O
- O
cell O
and O
cell O
- O
RARE O
RARE O
, O
distinct O
from O
RARE O
contacts O
, O
even O
in O
the O
absence O
of O
serum O
. O

The O
5 O
' O
RARE O
and O
coding O
regions O
are O
contained O
within O
12 O
exons O
, O
with O
the O
translation O
RARE O
site O
RARE O
within O
the O
RARE O
RARE O
. O

The O
RARE O
of O
sperm O
, O
except O
RARE O
those O
adjacent O
to O
both O
electrodes O
, O
did O
not O
change O
after O
RARE O
RARE O
NUM O
, O
despite O
a O
high O
electrical O
energy O
. O

Induction O
of O
the O
ALL_CAP I-GENE
promoter I-GENE
by O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
in O
ALL_CAP O
- O
6 O
cells O
was O
TNF I-GENE
receptor I-GENE
- I-GENE
associated I-GENE
factor I-GENE
- I-GENE
6 I-GENE
( O
NUM I-GENE
RARE O
but O
not O
TRAF2 I-GENE
, O
dependent O
. O

NUM I-GENE
may O
be O
critical O
RARE O
tumor O
development O
and O
suppression O
through O
RARE O
of O
beta I-GENE
- I-GENE
catenin I-GENE
protein I-GENE
stability O
. O

A O
NUM I-GENE
- O
dependent O
RARE O
RARE O
RARE O
regulates O
the O
NUM I-GENE
kinase I-GENE
in I-GENE
RARE I-GENE
yeast I-GENE
. O

We O
analyzed O
the O
RARE O
organization O
of O
DNA I-GENE
polymerase I-GENE
beta I-GENE
and O
found O
that O
residues O
making O
RARE O
with O
DNA O
RARE O
were O
localized O
to O
five O
RARE O
. O

RESULTS O
: O
RARE O
nerves O
are O
mainly O
involved O
in O
the O
RARE O
of O
enteric O
nerve O
responses O
to O
ALL_CAP O
in O
the O
normal O
ALL_CAP O
. O

Two O
- O
dimensional O
gel O
electrophoresis O
of O
anti I-GENE
- I-GENE
NUM I-GENE
RARE O
obtained O
from O
non O
- O
transformed O
resting O
human O
T O
lymphocytes O
resulted O
in O
the O
identification O
of O
an O
RARE O
protein O
complex O
which O
is O
constitutively O
formed O
between O
Fyn I-GENE
and O
several O
additional O
RARE O
( O
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
the O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
NUM I-GENE
, O
RARE O
RARE O
RARE O
the O
two O
recently O
RARE O
RARE O
proteins O
, O
NUM I-GENE
and O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
). O

We O
show O
that O
other O
NUM I-GENE
mutants I-GENE
also O
arrest O
in O
G1 O
. O

A O
NUM I-GENE
- I-GENE
1 I-GENE
RARE O
expressing O
either O
stable O
NUM I-GENE
( O
NUM I-GENE
- I-GENE
NUM I-GENE
) O
or O
a O
RARE O
NUM I-GENE
5 I-GENE
'- I-GENE
NUM I-GENE
mRNA O
, O
whose O
translation O
displays O
decreased O
dependence O
on O
NUM I-GENE
, O
arrested O
randomly O
in O
the O
cell O
RARE O
. O

RARE O
motifs O
RARE O
gene O
RARE O
such O
RARE O
nuclear I-GENE
- I-GENE
factor I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
binding I-GENE
- I-GENE
site I-GENE
- I-GENE
like I-GENE
sequence I-GENE
( O
kappaB I-GENE
site I-GENE
) O
and O
nuclear I-GENE
- I-GENE
factor I-GENE
- I-GENE
interleukin I-GENE
- I-GENE
6 I-GENE
- I-GENE
binding I-GENE
- I-GENE
site I-GENE
- I-GENE
like I-GENE
sequence I-GENE
( O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
- I-GENE
6 I-GENE
site I-GENE
) O
were O
found O
in O
the O
5 O
'- O
upstream O
regulatory O
region O
. O

The O
gene O
RARE O
of O
NUM I-GENE
spans O
NUM O
. O
2 O
kb O
and O
consists O
of O
RARE O
exons O
and O
RARE O
RARE O
. O

Total O
serum O
RARE O
was O
7 O
. O
8 O
+/- O
NUM O
. O
8 O
mg O
/ O
dl O
, O
whereas O
RARE O
RARE O
was O
5 O
. O
7 O
+/- O
NUM O
. O
7 O
mg O
/ O
dl O
, O
phosphorus O
3 O
. O
2 O
+/- O
1 O
. O
2 O
mg O
/ O
dl O
, O
and O
RARE I-GENE
phosphatase I-GENE
NUM O
+/- O
NUM O
. O
6 O
ALL_CAP O
/ O
liter O
. O

Sequence O
analysis O
suggests O
that O
ALL_CAP I-GENE
contains O
a O
RARE O
guanine O
dinucleotide O
cofactor O
and O
a O
RARE O
NUM O
- O
NUM O
] O
cluster O
, O
that O
ALL_CAP I-GENE
binds O
four O
RARE O
NUM O
- O
NUM O
] O
clusters O
, O
and O
that O
ALL_CAP I-GENE
is O
an O
RARE O
membrane O
protein O
containing O
a O
RARE O
oxidation O
site O
. O

RARE O
- O
RARE O
differences O
in O
RARE O
tissue O
formation O
: O
an O
experimental O
study O
in O
the O
rat O
. O

RARE O
- O
directed O
mutagenesis O
showed O
that O
two O
adjacent O
SP1 I-GENE
sites I-GENE
proximal O
to O
RARE O
1 O
were O
equally O
important O
in O
RARE O
basal O
promoter O
activity O
. O

RARE O
- O
fed O
newborn O
infants O
RARE O
RARE O
- O
6 O
long O
- O
chain O
RARE O
fatty O
RARE O
already O
RARE O
the O
RARE O
week O
of O
life O
, O
but O
the O
contribution O
of O
endogenous O
RARE O
to O
the O
RARE O
plasma O
long O
- O
chain O
RARE O
pool O
is O
small O
. O

RARE O
and O
reperfusion O
markedly O
increased O
the O
release O
of O
6 O
- O
RARE O
- O
NUM O
alpha O
and O
NUM O
. O

RARE I-GENE
- I-GENE
specific I-GENE
antigen I-GENE
( O
PSA I-GENE
) O
promoter O
- O
RARE O
RARE O
- O
inducible O
RARE O
of O
RARE I-GENE
RARE I-GENE
RARE I-GENE
in O
RARE O
RARE O
cell O
lines O
. O

It O
is O
clear O
that O
subclinical O
and O
RARE O
CD O
exist O
in O
a O
large O
subgroup O
of O
the O
RARE O
population O
. O

NUM I-GENE
activates O
invasive O
growth O
using O
either O
of O
two O
RARE O
RARE O
pathways O
, O
the O
RARE O
ALL_CAP I-GENE
( O
NUM I-GENE
/ O
NUM I-GENE
/ O
ALL_CAP I-GENE
) O
cascade O
or O
the O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
NUM I-GENE
/ O
cAMP O
/ O
PKA I-GENE
) O
RARE O
. O

Consistent O
with O
this O
prediction O
, O
transfections O
into O
the O
hematopoietic O
cell O
line O
Jurkat O
showed O
a O
9 O
. O
NUM O
- O
and O
2 O
. O
5 O
- O
RARE O
activation O
of O
the O
RARE I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
by O
the O
NUM I-GENE
and O
NUM I-GENE
isoforms I-GENE
, O
respectively O
. O

Previous O
work O
has O
shown O
that O
RARE I-GENE
necrosis I-GENE
virus I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
long I-GENE
terminal I-GENE
repeats I-GENE
( O
RARE O
) O
are O
associated O
with O
RARE I-GENE
/ O
RARE I-GENE
- O
responsive O
element O
- O
independent O
RARE O
of O
bovine O
leukemia O
virus O
RNA O
and O
supports O
the O
hypothesis O
that O
ALL_CAP O
RNA O
contains O
a O
cis O
- O
acting O
element O
that O
interacts O
with O
cellular I-GENE
RARE I-GENE
- I-GENE
like I-GENE
proteins I-GENE
. O

Despite O
the O
reported O
RARE O
effects O
on O
CNS O
development O
, O
a O
number O
of O
RARE O
studies O
have O
shown O
that O
pretreatment O
with O
corticosteroids O
RARE O
protect O
the O
brain O
from O
RARE O
- O
ischemic O
injury O
; O
however O
, O
clinically O
such O
treatment O
is O
RARE O
longer O
RARE O
. O

In O
one O
mechanism O
, O
a O
specialized O
ubiquitin I-GENE
- O
dependent O
RARE O
RARE O
( O
called O
the O
ALL_CAP O
- O
dependent O
proteolysis O
machinery O
) O
RARE O
the O
RARE O
( O
RARE I-GENE
) O
RARE I-GENE
subunit I-GENE
. O

RARE O
of O
success O
in O
RARE O
RARE O
: O
ALL_CAP O
RARE O
. O
other O
admission O
criteria O
. O

RARE O
survey O
reveals O
RARE O
RARE O
among O
physicians O
. O

In O
a O
series O
of O
16 O
full O
- O
scale O
RARE O
tests O
, O
RARE O
RARE O
the O
ALL_CAP O
Research O
Institute O
have O
concluded O
that O
automatic O
RARE O
control O
in O
the O
room O
of O
RARE O
origin O
can O
significantly O
reduce O
the O
spread O
of O
toxic O
smoke O
and O
gases O
. O

RARE O
ALL_CAP O
demonstrates O
a O
shift O
in O
identification O
of O
the O
library O
RARE O
an O
isolated O
unit O
to O
an O
RARE O
resource O
RARE O
. O

RARE O
of O
adverse O
events O
occurring O
RARE O
clinical O
trials O
of O
RARE O
drugs O
is O
a O
complex O
and O
RARE O
RARE O
. O

RARE O
ALL_CAP O
benefits O
revised O
RARE O
again O
. O

In O
this O
paper O
, O
the O
current O
status O
of O
the O
understanding O
of O
the O
interaction O
mechanisms O
of O
ultrasound O
with O
biological O
media O
and O
the O
factors O
that O
govern O
different O
biological O
effects O
are O
RARE O
. O

Members O
of O
the O
mitogen I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
family I-GENE
, O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
, O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
- I-GENE
1 I-GENE
/ O
c I-GENE
- I-GENE
Jun I-GENE
NH2 I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
, O
and O
p38 I-GENE
, O
are O
central O
elements O
that O
RARE O
the O
signal O
generated O
by O
growth O
factors O
, O
RARE O
, O
and O
RARE O
agents O
. O

In O
the O
present O
study O
, O
we O
have O
investigated O
the O
RARE O
role O
of O
the O
other O
MAP I-GENE
kinases I-GENE
in O
ALL_CAP I-GENE
- O
RARE O
cellular O
responses O
. O

RARE O
of O
tyrosine O
RARE O
- O
RARE O
ALL_CAP I-GENE
receptors I-GENE
show O
that O
Src I-GENE
homology I-GENE
2 I-GENE
domain I-GENE
- I-GENE
containing I-GENE
proteins I-GENE
including O
Src I-GENE
family I-GENE
kinases I-GENE
, O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
, O
the O
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
of O
Ras I-GENE
, O
the O
Src I-GENE
homology I-GENE
2 I-GENE
domain I-GENE
- I-GENE
containing I-GENE
phosphatase I-GENE
SHP I-GENE
- I-GENE
2 I-GENE
, O
phospholipase I-GENE
C I-GENE
- I-GENE
gamma I-GENE
, O
and O
Crk I-GENE
do O
not O
play O
a O
major O
role O
in O
mediating O
the O
ALL_CAP I-GENE
- O
RARE O
activation O
of O
p38 I-GENE
. O

Here O
we O
show O
that O
RARE I-GENE
inhibits O
tyrosine I-GENE
RARE I-GENE
, O
enhancing O
tyrosine O
RARE O
particularly O
of O
paxillin I-GENE
. O

Three O
- O
dimensional O
structural O
studies O
using O
electron O
RARE O
showed O
that O
the O
binding O
of O
one O
RARE I-GENE
( O
NUM O
/ O
NUM O
) O
does O
not O
affect O
the O
conformation O
of O
the O
RARE O
, O
and O
the O
efficiency O
of O
mRNA O
production O
is O
similar O
to O
that O
of O
the O
RARE O
RARE O
RARE O
. O

Further O
, O
mutational O
analysis O
of O
NUM I-GENE
assigned O
the O
SH3 I-GENE
- I-GENE
binding I-GENE
region I-GENE
to O
a O
proline O
- O
rich O
motif O
that O
is O
highly O
RARE O
among O
HCV O
RARE O
. O

Taken O
together O
, O
these O
findings O
show O
that O
NUM I-GENE
ALL_CAP I-GENE
inhibits O
the O
VEGF I-GENE
- O
RARE O
Ras I-GENE
activation O
; O
this O
RARE O
represents O
a O
novel O
and O
potentially O
important O
mechanism O
RARE O
the O
control O
of O
angiogenesis O
. O

Analysis O
of O
SRE O
RARE O
gel O
mobility O
shift O
assays O
with O
nuclear O
extracts O
from O
RARE O
cells O
demonstrated O
the O
presence O
of O
both O
the O
SRF I-GENE
and O
the O
ubiquitously O
RARE O
bHLH O
protein O
E12 I-GENE
/ O
NUM I-GENE
. O

We O
calculated O
differences O
in O
RARE O
occlusion O
rates O
by O
the O
NUM O
( O
RARE O
- O
square O
) O
test O
, O
and O
found O
these O
differences O
were O
significant O
( O
P O
=. O
04 O
). O

RARE O
RARE O
over O
the O
surface O
of O
the O
temporal O
lobe O
and O
depth O
electrode O
recordings O
in O
the O
amygdala O
and O
hippocampus O
were O
obtained O
, O
followed O
by O
10 O
min O
of O
recording O
before O
and O
after O
the O
i O
. O
v O
. O
administration O
of O
both O
RARE O
50 O
microg O
/ O
kg O
and O
fentanyl O
10 O
microg O
/ O
kg O
. O

We O
describe O
a O
genetic O
RARE O
RARE O
further O
characterizing O
the O
role O
of O
the O
extreme O
C O
- O
terminus O
of O
the O
beta O
subunit O
of O
E I-GENE
. I-GENE
coli I-GENE
RNA I-GENE
polymerase I-GENE
. O

We O
suggest O
that O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
are O
substrate O
- O
specific O
RARE O
RARE O
that O
prevent O
oligomerization O
of O
the O
RARE I-GENE
by O
binding O
to O
their O
helical O
domains O
before O
export O
. O

Post O
and O
core O
RARE O
RARE O
divergent O
RARE O
with O
a O
RARE O
post O
and O
core O
and O
a O
RARE O
RARE O
. O

NUM O
( O
NUM O
amino O
RARE O
RARE O
RARE O
RARE O
encoded O
by O
the O
largest O
ORF O
, O
displayed O
strong O
RARE O
( O
40 O
% O
identity O
) O
to O
the O
replication O
proteins O
from O
plasmids O
NUM O
, O
NUM O
, O
and O
NUM O
, O
indicating O
that O
the O
NUM O
RARE O
belongs O
to O
the O
NUM O
family O
of O
gram O
- O
positive O
RARE O
- O
RARE O
plasmids O
. O

Here O
we O
report O
the O
cloning O
and O
characterization O
of O
Xenopus I-GENE
Pax I-GENE
- I-GENE
5 I-GENE
and O
Pax I-GENE
- I-GENE
8 I-GENE
, O
two O
RARE O
of O
the O
Pax I-GENE
- I-GENE
2 I-GENE
/ I-GENE
5 I-GENE
/ I-GENE
8 I-GENE
gene I-GENE
family I-GENE
. O

RARE O
values O
RARE O
RARE O
, O
2 O
- O
RARE O
, O
ALL_CAP O
, O
RARE O
and O
ALL_CAP O
+ O
were O
6 O
. O
5 O
, O
3 O
. O
5 O
, O
NUM O
. O
06 O
, O
37 O
. O
1 O
and O
NUM O
. O
NUM O
mM O
, O
respectively O
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
may O
RARE O
RARE O
- O
related O
ischemic O
manifestations O
: O
an O
adverse O
effect O
potentially O
related O
to O
its O
anti O
- O
RARE O
activity O
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
may O
RARE O
RARE O
- O
related O
ischemic O
manifestations O
: O
an O
adverse O
effect O
potentially O
related O
to O
its O
anti O
- O
RARE O
activity O
. O

In O
addition O
, O
we O
demonstrate O
that O
the O
production O
of O
RARE I-GENE
recombinant I-GENE
telomerase I-GENE
requires O
a O
factor O
in O
RARE O
RARE O
RARE O
that O
promotes O
ribonucleoprotein O
assembly O
. O

The O
RARE O
binding O
of O
c I-GENE
- I-GENE
Abl I-GENE
to O
DNA O
containing O
5 O
- O
RARE O
residues O
may O
result O
from O
an O
increased O
propensity O
of O
the O
double O
helix O
to O
RARE O
locally O
coupled O
with O
a O
protein O
- O
RARE O
reduction O
in O
the O
RARE O
RARE O
interaction O
. O

Homozygous O
mutation O
in O
two O
children O
led O
to O
RARE O
of O
RARE O
due O
to O
purpura O
RARE O
. O

According O
to O
RARE O
experiments O
which O
considered O
various O
durations O
of O
global O
RARE O
- O
flow O
ischemia O
ranging O
from O
10 O
to O
20 O
minutes O
, O
two O
durations O
were O
chosen O
RARE O
the O
present O
study O
: O
20 O
minutes O
( O
group O
20 O
) O
in O
which O
ventricular O
fibrillation O
( O
VF O
) O
was O
the O
predominant O
form O
of O
arrhythmias O
, O
and O
18 O
minutes O
( O
group O
18 O
) O
in O
which O
the O
prevalence O
of O
VF O
was O
markedly O
lower O
despite O
the O
small O
difference O
in O
the O
duration O
of O
ischemia O
. O

An O
end O
- O
to O
- O
end O
RARE O
using O
a O
mechanical O
RARE O
- O
RARE O
device O
. O

We O
further O
demonstrate O
that O
the O
RARE I-GENE
- I-GENE
RARE I-GENE
- I-GENE
Protein I-GENE
- I-GENE
RARE I-GENE
( O
SAPK I-GENE
) O
target O
sites O
of O
NUM I-GENE
, O
NUM O
and O
NUM O
are O
not O
required O
RARE O
the O
formation O
of O
the O
p300 I-GENE
/ O
CBP I-GENE
- O
NUM I-GENE
RARE O
complex O
. O

RARE O
samples O
were O
obtained O
daily O
RARE O
this O
supplementation O
period O
and O
5 O
d O
thereafter O
( O
d O
11 O
to O
NUM O
). O

These O
results O
suggest O
that O
mitochondrial O
RARE O
interact O
with O
the O
RARE I-GENE
- I-GENE
hsp70 I-GENE
RARE O
or O
after O
mitochondrial O
protein O
import O
. O

The O
3 O
' O
terminus O
of O
the O
genome O
can O
be O
folded O
into O
a O
tRNA O
- O
like O
secondary O
RARE O
that O
has O
a O
RARE O
RARE O
; O
the O
tRNA O
- O
like O
RARE O
lacks O
a O
RARE O
in O
the O
RARE O
RARE O
, O
a O
feature O
common O
to O
both O
RARE O
of O
RARE O
. O

O I-GENE
. I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
RNA I-GENE
- I-GENE
7 I-GENE
, O
previously O
believed O
to O
be O
a O
RARE O
- O
like O
RNA O
, O
is O
shown O
to O
be O
a O
RARE O
RNA O
, O
derived O
from O
NUM I-GENE
- I-GENE
RARE I-GENE
RNA I-GENE
by O
multiple O
internal O
deletions O
. O

Only O
one O
gene O
, O
fibronectin I-GENE
( O
FN I-GENE
RARE O
was O
highly O
overexpressed O
(> O
NUM O
- O
RARE O
) O
in O
ALL_CAP O
- O
RARE O
cells O
, O
consistent O
with O
previously O
reported O
overexpression O
of O
FN I-GENE
in O
RARE O
RARE O
. O

We O
also O
observed O
that O
cell O
surface O
NUM I-GENE
RARE O
NUM I-GENE
RARE O
CD3 I-GENE
RARE O
cells O
with O
RARE I-GENE
TCR I-GENE
genes I-GENE
developed O
from O
NUM I-GENE
- O
RARE O
but O
not O
from O
control O
- O
RARE O
pre O
- O
T O
cells O
in O
an O
ALL_CAP O
. O

As O
determined O
in O
a O
modified O
yeast O
two O
- O
RARE O
RARE O
, O
NUM I-GENE
RARE O
strongly O
to O
the O
p85 I-GENE
subunit I-GENE
of O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

Insulin I-GENE
RARE O
promoted O
the O
association O
of O
NUM I-GENE
with O
p85 I-GENE
, O
NUM I-GENE
, O
RARE I-GENE
, O
and O
Shc I-GENE
. O

The O
mRNA O
RARE O
of O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
was O
detected O
ubiquitously O
, O
but O
in O
transient O
- O
transfection O
assays O
, O
RARE I-GENE
ALL_CAP I-GENE
binding I-GENE
sites I-GENE
in O
front O
of O
a O
basal O
promoter O
efficiently O
functioned O
in O
a O
tissue O
- O
and O
lineage O
- O
specific O
manner O
. O

In O
the O
case O
of O
the O
RARE O
intron O
, O
repression O
of O
luciferase I-GENE
RARE O
likely O
involved O
two O
NUM I-GENE
- I-GENE
binding I-GENE
sequences I-GENE
, O
since O
luciferase I-GENE
RARE O
was O
increased O
by O
deletion O
of O
these O
sites O
. O

Thus O
, O
VDR I-GENE
acts O
selectively O
on O
the O
two O
RARE O
required O
RARE O
activation O
of O
this O
promoter O
/ O
enhancer O
: O
it O
RARE O
with O
NUM I-GENE
RARE O
binding O
to O
the O
composite O
site O
, O
positioning O
itself O
adjacent O
to O
Jun I-GENE
- O
Fos I-GENE
on O
the O
DNA O
. O

Two O
evolutionarily O
RARE O
kinases O
, O
the O
RARE I-GENE
B I-GENE
( O
RARE I-GENE
RARE O
RARE I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
( O
Cdk I-GENE
/ O
NUM I-GENE
) O
and O
NUM I-GENE
along O
with O
its O
RARE O
factor O
NUM I-GENE
, O
are O
required O
RARE O
in O
G1 O
to O
initiate O
DNA O
replication O
. O

The O
NUM I-GENE
RARE O
leads O
to O
accumulation O
of O
NUM I-GENE
RARE O
the O
cytoplasmic O
RARE O
of O
the O
nuclear O
RARE O
complex O
( O
ALL_CAP O
) O
in O
association O
with O
the O
p62 I-GENE
complex I-GENE
and O
RARE I-GENE
/ O
NUM I-GENE
. O

All O
of O
the O
elements O
exhibited O
a O
uniform O
RARE O
. O

In O
contrast O
, O
the O
deduced O
amino O
acid O
sequence O
of O
a O
second O
family O
( O
NUM I-GENE
) O
of O
RARE O
, O
RARE O
from O
murine O
lymphoma O
cells O
and O
RARE O
in O
high O
abundance O
in O
RARE O
, O
displays O
a O
hydrophobic O
amino O
terminus O
, O
consistent O
with O
a O
signal O
sequence O
, O
but O
lacks O
a O
hydrophobic O
signal O
sequence O
RARE O
its O
RARE O
terminus O
, O
suggesting O
that O
the O
protein O
is O
RARE O
RARE O
export O
. O

RESULTS O
: O
Each O
year O
, O
on O
average O
NUM O
% O
of O
cases O
seen O
in O
RARE O
are O
RARE O
; O
NUM O
( O
40 O
%) O
of O
the O
NUM O
patients O
RARE O
RARE O
the O
study O
period O
were O
never O
seen O
by O
regional O
medical O
RARE O
. O

This O
RARE O
interface O
is O
likely O
important O
RARE O
increasing O
the O
DNA O
- O
binding O
RARE O
and O
affinity O
of O
the O
RARE O
form O
of O
HSF I-GENE
, O
RARE O
RARE O
RARE O
RARE O
increasing O
cooperativity O
between O
adjacent O
RARE O
. O

The O
RARE I-GENE
fusion I-GENE
( I-GENE
F I-GENE
) I-GENE
protein I-GENE
mediates O
membrane O
fusion O
. O

Additionally O
, O
deletion O
analysis O
of O
the O
NUM I-GENE
promoter O
- O
ALL_CAP I-GENE
constructs O
indicated O
that O
the O
minimal O
region O
exhibiting O
the O
promoter O
activity O
was O
RARE O
between O
nt O
- O
NUM O
and O
+ O
NUM O
, O
and O
that O
a O
strong O
enhancer O
was O
present O
within O
NUM O
bp O
of O
the O
5 O
'- O
promoter O
region O
. O

The O
ALL_CAP I-GENE
gene I-GENE
RARE O
more O
than O
NUM O
and O
consists O
of O
16 O
exons O
. O

Both O
ALL_CAP I-GENE
mRNA I-GENE
and O
RARE I-GENE
levels O
are O
increased O
in O
RARE O
21 O
. O

In O
reperfusion O
B O
, O
only O
the O
diabetic O
group O
demonstrated O
a O
significant O
increase O
in O
ALL_CAP I-GENE
- I-GENE
8 I-GENE
concentrations O
RARE O
1 O
and O
NUM O
min O
compared O
to O
RARE O
. O

This O
repression O
was O
reversed O
agonists O
of O
either O
receptor O
demonstrating O
a O
RARE O
interaction O
between O
ALL_CAP I-GENE
and O
PPARalpha I-GENE
. O
RARE I-GENE
RARE O
complexes O
in O
mammalian O
cells O
. O

In O
the O
present O
study O
, O
we O
show O
that O
NUM I-GENE
/ I-GENE
NUM I-GENE
is O
required O
RARE O
a O
RARE O
- O
rich O
ALL_CAP I-GENE
to O
promote O
the O
RARE O
of O
a O
pre O
- O
mRNA O
derived O
from O
the O
Drosophila I-GENE
RARE I-GENE
gene I-GENE
. O

NUM I-GENE
also O
was O
identified O
RARE O
a O
RARE O
of O
a O
cytoplasmic O
SPB O
RARE O
containing O
NUM I-GENE
/ O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
. O

The O
average O
coefficients O
of O
correlation O
were O
NUM O
. O
NUM O
and O
NUM O
. O
NUM O
RARE O
the O
ALL_CAP O
and O
the O
ALL_CAP O
RARE O
, O
respectively O
. O

The O
5 O
- O
year O
ALL_CAP O
RARE O
RARE O
ALL_CAP O
was O
NUM O
. O
9 O
%, O
compared O
to O
7 O
. O
8 O
% O
RARE O
RARE O
IV O
. O

Furthermore O
, O
RARE I-GENE
lyase I-GENE
treatment O
of O
extracts O
of O
cells O
expressing O
recombinant I-GENE
ALL_CAP I-GENE
- I-GENE
repeat I-GENE
protein I-GENE
RARE O
this O
protein O
from O
high O
RARE O
mass O
aggregates O
. O

The O
coefficient O
of O
determination O
, O
NUM O
, O
of O
the O
other O
scores O
ranged O
from O
NUM O
. O
NUM O
to O
NUM O
. O
NUM O
. O

While O
determination O
of O
the O
protein O
content O
of O
the O
RARE O
gave O
RARE O
RARE O
RARE O
, O
RAST O
/ O
ALL_CAP O
inhibition O
was O
highest O
RARE O
RARE O
' O
s O
milk O
, O
followed O
by O
the O
partially O
RARE O
RARE O
formula O
, O
partially O
RARE O
RARE O
/ O
casein I-GENE
formula O
, O
RARE I-GENE
/ I-GENE
RARE I-GENE
RARE I-GENE
formula O
, O
and O
the O
amino O
acid O
formula O
. O

In O
light O
of O
the O
importance O
of O
ALL_CAP I-GENE
, O
the O
RARE O
mechanisms O
underlying O
the O
transcriptional O
RARE O
of O
the O
human I-GENE
ALL_CAP I-GENE
( O
ALL_CAP I-GENE
) O
gene O
become O
a O
key O
RARE O
in O
understanding O
human O
RARE O
. O

RARE O
mobility O
shift O
assays O
using O
either O
NUM O
- O
1 O
nuclear O
RARE O
or O
recombinant I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
protein I-GENE
clearly O
indicated O
that O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
is O
able O
to O
interact O
specifically O
with O
this O
ALL_CAP I-GENE
element I-GENE
positioned O
RARE O
- O
NUM O
. O

RARE O
3 O
RARE O
was O
reported O
in O
1 O
patient O
. O

NUM I-GENE
kinase I-GENE
activities O
were O
unaffected O
, O
RARE O
were O
the O
levels O
of O
the O
CDK I-GENE
inhibitor O
NUM I-GENE
present O
in O
RARE I-GENE
E I-GENE
RARE I-GENE
. O

The O
recombinant O
RARE O
protein O
RARE O
in O
the O
RARE O
RARE O
had O
an O
RARE O
RARE O
size O
20 O
kDa O
with O
amino O
- O
terminal O
sequence O
of O
ALL_CAP O
. O

Induction O
of O
the O
urokinase I-GENE
promoter I-GENE
by O
HGF I-GENE
/ O
ALL_CAP I-GENE
via O
the O
RARE I-GENE
receptor I-GENE
was O
blocked O
by O
RARE O
- O
RARE O
of O
a O
dominant O
- O
negative O
Grb2 I-GENE
and O
NUM I-GENE
RARE O
construct O
. O

RARE O
RARE O
of O
STAT3 I-GENE
was O
only O
apparent O
after O
somatostatin I-GENE
treatment O
and O
was O
abolished O
by O
RARE I-GENE
RARE I-GENE
or O
ALL_CAP O
NUM O
, O
together O
with O
the O
associated O
increases O
in O
RARE O
. O

Nevertheless O
, O
we O
demonstrate O
that O
the O
RARE O
three O
- O
RARE O
yeast O
RARE O
apparatus O
, O
consisting O
of O
RNA I-GENE
5 I-GENE
'- I-GENE
RARE I-GENE
( O
NUM I-GENE
RARE O
RNA I-GENE
RARE I-GENE
( O
NUM I-GENE
RARE O
and O
NUM I-GENE
could O
be O
replaced O
in O
vivo O
by O
the O
two O
- O
RARE O
mammalian O
apparatus O
consisting O
of O
a O
RARE O
RARE I-GENE
- I-GENE
RARE I-GENE
NUM I-GENE
and O
the O
RARE I-GENE
NUM I-GENE
( I-GENE
NUM I-GENE
- I-GENE
NUM I-GENE
) I-GENE
p I-GENE
. O

The O
NUM O
values O
RARE O
rat O
and O
dog O
RARE O
bladder O
were O
3 O
. O
9 O
RARE O
10 O
RARE O
6 O
) O
M O
and O
3 O
. O
8 O
RARE O
10 O
RARE O
6 O
) O
M O
, O
respectively O
. O

Although O
it O
has O
two O
RARE O
binding O
sites O
, O
the O
RARE O
ALL_CAP I-GENE
RARE I-GENE
binds O
only O
one O
Hg O
( O
II O
) O
ion O
, O
employing O
NUM O
from O
one O
RARE O
and O
NUM O
and O
NUM O
from O
the O
other O
. O

The O
influence O
of O
Epstein O
- O
Barr O
virus O
RARE O
on O
the O
efficacy O
of O
intravenous O
immune I-GENE
globulin I-GENE
in O
children O
with O
immune O
RARE O
purpura O
. O

The O
results O
of O
the O
RARE O
and O
field O
tests O
yielded O
high O
levels O
of O
RARE O
in O
larvae O
with O
values O
ranging O
from O
NUM O
to O
NUM O
% O
and O
from O
NUM O
to O
NUM O
%, O
respectively O
. O

RARE O
NUM O
mg O
had O
several O
adverse O
effects O
on O
RARE O
and O
, O
although O
less O
severe O
, O
on O
cognitive O
performance O
on O
the O
RARE O
day O
only O
. O

ALL_CAP I-GENE
is O
an O
RARE I-GENE
- I-GENE
DNA I-GENE
glycosylase I-GENE
with O
RARE O
RARE O
RARE O
involving O
8 O
- O
RARE O
( O
ALL_CAP O
. O
A O
) O
or O
guanine O
( O
G O
. O
A O
). O

The O
kinetics O
of O
kinase O
activity O
within O
these O
complexes O
compared O
to O
ALL_CAP I-GENE
alone O
indicate O
RARE O
a O
50 O
% O
decrease O
in O
the O
ALL_CAP O
RARE O
ATP O
and O
a O
NUM O
- O
RARE O
increase O
in O
the O
Vmax O
. O

RARE I-GENE
, O
a O
RARE I-GENE
A I-GENE
inhibitor O
, O
is O
RARE O
in O
a O
cell O
type O
- O
specific O
manner O
in O
both O
central O
and O
peripheral O
nervous O
RARE O
in O
the O
rat O
. O

RARE O
analyses O
identified O
7 O
risk O
and O
7 O
protective O
factors O
with O
minimal O
overlap O
. O

During O
1985 O
, O
1990 O
, O
and O
1995 O
, O
respectively O
, O
11 O
. O
7 O
, O
11 O
. O
3 O
, O
and O
11 O
. O
4 O
infants O
per O
NUM O
, O
NUM O
live O
births O
had O
a O
diagnosis O
of O
HSV O
( O
P O
=. O
98 O
). O

RARE O
of O
patients O
were O
performed O
according O
to O
the O
severity O
of O
trauma O
( O
ALL_CAP O
< O
9 O
; O
9 O
- O
NUM O
; O
18 O
- O
NUM O
; O
> O
NUM O
RARE O
based O
on O
the O
different O
injury O
pattern O
, O
and O
RARE O
versus O
RARE O
RARE O
RARE O
. O

The O
median O
age O
was O
NUM O
years O
( O
range O
NUM O
- O
NUM O
years O
). O

RARE O
follow O
- O
RARE O
RARE O
age O
2 O
years O
was O
performed O
. O

In O
the O
whole O
group O
of O
RARE O
children O
, O
an O
age O
- O
specific O
z O
score O
< O
- O
2 O
RARE O
RARE O
and O
RARE O
ALL_CAP O
was O
significantly O
associated O
with O
an O
increased O
risk O
of O
RARE O
RARE O
relative O
risk O
( O
NUM O
% O
ALL_CAP O
) O
= O
11 O
. O
4 O
( O
3 O
. O
1 O
, O
NUM O
. O
NUM O
) O
and O
5 O
. O
1 O
( O
1 O
. O
5 O
, O
18 O
. O
2 O
RARE O
respectively O
RARE O
when O
only O
children O
with O
more O
severe O
RARE O
were O
considered O
, O
only O
z O
score O
RARE O
RARE O
was O
significantly O
associated O
with O
an O
increased O
risk O
RARE O
4 O
. O
6 O
( O
1 O
. O
4 O
, O
14 O
. O
9 O
)]. O

In O
addition O
, O
these O
cells O
contained O
one O
, O
two O
, O
or O
multiple O
nuclei O
indicative O
of O
a O
NUM O
/ O
M O
delay O
in O
nuclear O
division O
and O
also O
a O
defect O
in O
RARE O
and O
/ O
or O
cell O
separation O
. O

NUM I-GENE
is O
known O
to O
be O
a O
RARE O
of O
a O
RARE O
RARE O
that O
has O
been O
partially O
RARE O
genetically O
and O
includes O
RARE O
of O
the O
insulin I-GENE
/ O
IGF I-GENE
- I-GENE
1 I-GENE
receptor I-GENE
, O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
and O
PKB I-GENE
. O

However O
, O
neu I-GENE
differentiation O
factor O
- O
RARE O
RARE O
of O
NUM I-GENE
and O
NUM I-GENE
activated O
Stat5 I-GENE
. O

Although O
RARE O
regions O
in O
transcription O
factors O
are O
known O
to O
modulate O
DNA O
binding O
RARE O
, O
our O
studies O
suggest O
that O
the O
human I-GENE
HSF1 I-GENE
RARE O
plays O
RARE O
role O
in O
RARE O
HSF1 I-GENE
binding O
RARE O
in O
vivo O
but O
is O
a O
critical O
determinant O
in O
RARE O
the O
HSF1 I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
equilibrium O
. O

RARE O
of O
human I-GENE
heat I-GENE
shock I-GENE
factor I-GENE
RARE O
by O
the O
RARE O
domain O
. O

Both O
RARE O
analyses O
in O
undifferentiated O
and O
differentiated O
F9 O
cells O
and O
characterization O
of O
DNA O
- O
protein O
complexes O
in O
vitro O
have O
identified O
the O
sequence O
motifs O
ALL_CAP O
( O
C O
RARE O
ALL_CAP O
, O
and O
ALL_CAP O
RARE O
the O
key O
transcription O
factor O
binding O
sites O
. O

These O
results O
suggest O
that O
the O
RARE O
of O
ALL_CAP O
may O
result O
from O
RARE O
RARE O
not O
only O
through O
ALL_CAP I-GENE
, O
but O
also O
other O
cell O
surface O
molecules O
that O
RARE O
ALL_CAP I-GENE
RARE O
a O
RARE O
RARE O
protein O
. O

We O
also O
localized O
the O
RARE I-GENE
- I-GENE
2 I-GENE
RARE I-GENE
sites I-GENE
by O
ALL_CAP I-GENE
to O
three O
threonine O
and O
three O
serine O
residues O
in O
the O
ALL_CAP O
- O
terminal O
region O
by O
means O
of O
site O
- O
directed O
mutagenesis O
and O
showed O
that O
the O
threonine O
residues O
were O
more O
susceptible O
to O
ALL_CAP I-GENE
. O

Nevertheless O
, O
they O
are O
functionally O
distinct O
in O
that O
ALL_CAP I-GENE
binds O
human I-GENE
IgA I-GENE
( O
ALL_CAP I-GENE
) O
but O
not O
bovine I-GENE
NUM I-GENE
( O
NUM I-GENE
RARE O
whereas O
NUM I-GENE
binds O
NUM I-GENE
but O
not O
ALL_CAP I-GENE
. O

NUM I-GENE
was O
found O
to O
bind O
the O
NUM I-GENE
homologue I-GENE
NUM I-GENE
. O

In O
a O
heterologous O
transcriptional O
RARE O
in O
which O
the O
upstream O
regions O
of O
RARE I-GENE
were O
inserted O
in O
front O
of O
simian I-GENE
virus I-GENE
40 I-GENE
( I-GENE
SV40 I-GENE
) I-GENE
promoter I-GENE
, O
the O
regions O
between O
bases O
- O
NUM O
and O
- O
NUM O
were O
determined O
RARE O
being O
the O
enhancer O
region O
required O
RARE O
RARE I-GENE
- O
SV40 O
- O
CAT I-GENE
RARE O
. O

In O
RARE O
- O
transfection O
studies O
, O
the O
RARE O
of O
c I-GENE
- I-GENE
Jun I-GENE
RARE O
c I-GENE
- I-GENE
Fos I-GENE
RARE O
the O
RARE O
of O
RARE I-GENE
- O
CAT I-GENE
but O
the O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
or O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
did O
not O
. O

To O
identify O
these O
sites O
, O
Cdk2 I-GENE
- O
RARE O
ALL_CAP I-GENE
was O
RARE O
with O
RARE I-GENE
RARE I-GENE
and O
analysed O
by O
RARE O
MS O
. O

The O
yeast I-GENE
NUM I-GENE
gene I-GENE
encoding O
RARE I-GENE
dehydrogenase I-GENE
is O
subject O
to O
the O
RARE O
control O
of O
amino O
acid O
biosynthesis O
RARE O
by O
the O
GCN4 I-GENE
transcription I-GENE
factor I-GENE
. O

The O
relatively O
mild O
defects O
observed O
in O
NUM I-GENE
mutants I-GENE
suggest O
that O
the O
recently O
identified O
RARE I-GENE
and O
ALL_CAP I-GENE
RARE I-GENE
proteins I-GENE
do O
not O
function O
solely O
through O
the O
recruitment O
of O
histone I-GENE
RARE I-GENE
. O

However O
, O
the O
serum I-GENE
TNF I-GENE
- I-GENE
a I-GENE
concentration O
decreased O
significantly O
in O
patients O
receiving O
RARE O
( O
basal O
NUM O
+/- O
NUM O
pg O
/ O
ml O
; O
NUM O
month O
NUM O
+/- O
NUM O
pg O
/ O
ml O
, O
p O
< O
NUM O
. O
01 O
RARE O
but O
not O
in O
the O
control O
group O
. O

In O
addition O
, O
we O
show O
that O
the O
RARE O
of O
individual O
members O
of O
one O
subfamily O
of O
KRAB I-GENE
zinc I-GENE
finger I-GENE
genes I-GENE
is O
restricted O
to O
specific O
hematopoietic O
cell O
lineages O
. O

RARE O
fluorescence O
spectroscopy O
and O
circular O
RARE O
, O
we O
showed O
that O
the O
binding O
of O
NUM O
+ O
to O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
RARE O
significant O
conformational O
changes O
in O
both O
the O
N O
- O
terminal O
and O
C O
- O
terminal O
domains O
of O
the O
protein O
. O

They O
also O
occur O
in O
similar O
locations O
in O
the O
promoters O
of O
several O
other O
ribosomal I-GENE
protein I-GENE
genes I-GENE
. O

Both O
carbachol O
( O
NUM O
microM O
) O
and O
ALL_CAP I-GENE
( O
10 O
nM O
) O
RARE O
Ras I-GENE
activation O
. O

RARE O
negative O
Sos I-GENE
did O
not O
affect O
carbachol O
RARE O
of O
ALL_CAP I-GENE
- O
ERK2 I-GENE
but O
inhibited O
the O
RARE O
effect O
of O
ALL_CAP I-GENE
by O
NUM O
%. O

RESULTS O
: O
RARE O
passage O
of O
contrast O
occurred O
in O
sufficient O
amounts O
to O
enhance O
the O
intensity O
of O
the O
Doppler O
signal O
significantly O
, O
but O
the O
duration O
of O
this O
effect O
was O
short O
. O

In O
this O
paper O
, O
such O
lesions O
in O
two O
cases O
were O
evaluated O
by O
ultrasonography O
. O

These O
regions O
contain O
inverted O
E O
- O
box O
palindromic O
or O
direct O
repeat O
motifs O
and O
bind O
SREBP I-GENE
- I-GENE
1 I-GENE
with O
different O
affinities O
. O

To O
address O
these O
questions O
, O
a O
recombinant O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
protein O
and O
a O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
RARE O
were O
utilized O
in O
in O
vitro O
kinase O
assays O
to O
phosphorylate O
NUM I-GENE
- I-GENE
NUM I-GENE
. O

RARE I-GENE
has O
a O
ALL_CAP O
double O
zinc O
finger O
domain O
, O
which O
specifically O
binds O
RARE O
( O
3 O
)- O
phosphate O
and O
is O
RARE O
in O
several O
proteins O
involved O
in O
vesicular O
RARE O
. O

The O
coexpression O
of O
full O
- O
length O
RARE O
constructs O
RARE O
both O
ALL_CAP I-GENE
and O
RARE I-GENE
leukemia I-GENE
factor I-GENE
resulted O
in O
a O
dramatic O
increase O
in O
activation O
RARE O
by O
the O
GAL4 I-GENE
- O
ALL_CAP I-GENE
fusion O
proteins O
, O
suggesting O
the O
involvement O
of O
a O
regulated O
RARE O
in O
this O
process O
. O

Three O
RARE O
also O
comprised O
NUM O
to O
NUM O
nucleotides O
derived O
from O
the O
5 O
' O
part O
of O
the O
NUM I-GENE
gene I-GENE
. O

Cp I-GENE
is O
normally O
the O
main O
promoter O
RARE O
EBNA I-GENE
mRNA I-GENE
initiation O
, O
so O
it O
appears O
that O
NUM I-GENE
contributes O
to O
a O
negative O
RARE O
control O
loop O
. O

These O
RARE O
of O
RARE O
signalling O
in O
the O
absence O
of O
tyrosine O
118 O
were O
RARE O
by O
sustained O
activation O
of O
STAT3 I-GENE
. O

With O
RARE O
RARE O
, O
we O
could O
isolate O
five O
RARE O
exons O
from O
the O
YAC O
NUM O
that O
spans O
the O
region O
, O
four O
of O
which O
could O
be O
placed O
in O
the O
contig O
in O
the O
vicinity O
of O
the O
breakpoints O
. O

RARE O
dysplasia O
translocation O
breakpoints O
are O
RARE O
over O
1 O
Mb O
proximal O
to O
NUM I-GENE
: O
evidence O
RARE O
an O
extended O
control O
region O
. O

The O
most O
common O
characteristics O
of O
ALL_CAP O
patients O
were O
recent O
prior O
vancomycin O
use O
, O
recent O
prior O
susceptible O
RARE O
infection O
, O
RARE O
with O
other O
RARE O
pathogens O
, O
and O
concurrent O
RARE O
infection O
. O

A O
RARE O
- O
RARE O
domain O
, O
RARE O
within O
each O
encoded O
protein O
, O
serves O
RARE O
a O
RARE O
interaction O
motif O
RARE O
FLI I-GENE
ALL_CAP I-GENE
. O

Binding O
affinities O
of O
these O
recombinant O
RARE O
RARE O
determined O
by O
the O
retention O
of O
these O
RARE O
by O
a O
RARE O
- O
tag O
RARE O
NUM I-GENE
column O
, O
and O
by O
RARE O
- O
immunoprecipitation O
with O
RARE O
terminase I-GENE
supported O
the O
specific O
nature O
of O
the O
RARE I-GENE
protein I-GENE
and O
terminase I-GENE
interaction I-GENE
sites I-GENE
. O

Although O
the O
terminase I-GENE
apparently O
interacts O
with O
this O
NUM I-GENE
RARE I-GENE
peptide I-GENE
, O
RARE O
antibody O
against O
the O
RARE O
peptide O
appears O
unable O
to O
access O
it O
in O
the O
RARE O
RARE O
, O
suggesting O
RARE O
association O
of O
NUM I-GENE
and O
NUM I-GENE
possibly O
RARE O
terminase I-GENE
regions I-GENE
within O
the O
RARE O
in O
the O
RARE O
complex O
. O

The O
RARE O
viruses O
were O
found O
to O
accumulate O
to O
high O
levels O
in O
RARE O
RARE O
, O
to O
form O
stable O
virions O
, O
and O
to O
be O
RARE O
RARE O
. O

cDNA O
and O
structural O
organization O
of O
the O
gene I-GENE
NUM I-GENE
RARE O
the O
mouse I-GENE
DNA I-GENE
polymerase I-GENE
epsilon I-GENE
catalytic I-GENE
subunit I-GENE
. O

Nevertheless O
RARE O
of O
spermatozoa O
in O
a O
medium O
containing O
neither O
SP O
nor O
biological O
substances O
could O
offer O
an O
acceptable O
RARE O
of O
spermatozoa O
to O
be O
used O
in O
RARE O
fertilization O
procedures O
, O
especially O
RARE O
RARE O
sperm O
injection O
. O

A O
liquid O
chromatographic O
method O
is O
described O
RARE O
analysis O
of O
beta O
- O
RARE O
in O
medical O
food O
. O

The O
ALL_CAP O
conditions O
were O
RARE O
follows O
: O
2 O
ALL_CAP O
maximum O
electrical O
power O
consumption O
, O
800 O
V O
maximum O
RARE O
voltage O
, O
NUM O
RARE O
RARE O
( O
180 O
RARE O
rise O
time O
RARE O
and O
5 O
- O
NUM O
Hz O
frequency O
. O

RARE O
RARE O
resulted O
in O
statistically O
significant O
changes O
in O
the O
mean O
values O
of O
the O
above O
RARE O
in O
addition O
to O
the O
following O
increases O
: O
alanine I-GENE
aminotransferase I-GENE
, O
RARE O
, O
and O
serum I-GENE
RARE I-GENE
( O
P O
< O
NUM O
. O
001 O
) O
and O
albumin I-GENE
and O
RARE O
protein O
( O
P O
< O
NUM O
. O
01 O
). O

EMSA O
with O
crude O
nuclear O
extracts O
demonstrated O
that O
RARE O
with O
NUM I-GENE
results O
in O
the O
induction O
of O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
complexes I-GENE
that O
bind O
to O
each O
of O
the O
three O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
and O
are O
composed O
mainly O
of O
NUM I-GENE
and O
ALL_CAP I-GENE
, O
but O
also O
include O
c I-GENE
- I-GENE
Rel I-GENE
and O
NUM I-GENE
. O

RARE O
monitoring O
of O
ALL_CAP O
remains O
RARE O
. O

The O
major O
transcription O
factors O
controlling O
RARE O
metabolism O
in O
Escherichia O
coli O
and O
Bacillus O
subtilis O
, O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
, O
respectively O
, O
are O
homologous O
RARE O
proteins O
that O
form O
RARE O
- O
RARE O
- O
dependent O
DNA O
- O
binding O
complexes O
capable O
of O
repressing O
transcription O
of O
the O
biosynthetic O
genes O
( O
both O
RARE O
activating O
transcription O
of O
RARE O
genes O
( O
ALL_CAP I-GENE
only O
) O
or O
facilitating O
RARE O
RARE O
resolution O
( O
both O
). O

The O
studied O
protein O
fragments O
consist O
of O
residues O
NUM O
- O
NUM O
of O
the O
human I-GENE
ER I-GENE
and O
residues O
NUM O
- O
NUM O
of O
the O
rat O
GR I-GENE
. O

The O
RARE O
: O
intron O
RARE O
of O
chicken I-GENE
NUM I-GENE
corresponds O
almost O
RARE O
to O
that O
of O
human I-GENE
NUM I-GENE
and O
differs O
from O
those O
of O
other O
known O
mammalian I-GENE
ALL_CAP I-GENE
RARE I-GENE
genes I-GENE
. O

The O
RARE I-GENE
- I-GENE
NUM I-GENE
gene I-GENE
, O
specifically O
RARE O
RARE O
RARE O
differentiation O
of O
the O
RARE O
RARE O
RARE O
, O
was O
RARE O
. O

The O
main O
causes O
of O
liver O
RARE O
in O
the O
patients O
with O
ALL_CAP O
were O
hepatitis O
C O
virus O
( O
HCV O
) O
( O
77 O
%), O
RARE O
RARE O
( O
NUM O
%), O
and O
the O
combination O
of O
HCV O
and O
RARE O
RARE O
( O
50 O
%). O

Three O
new O
aromatase I-GENE
RARE O
have O
recently O
completed O
RARE O
III O
evaluation O
RARE O
treatment O
of O
metastatic O
breast O
RARE O
in O
post O
- O
RARE O
women O
whose O
RARE O
has O
progressed O
despite O
RARE O
therapy O
: O
RARE O
( O
ALL_CAP O
, O
RARE O
RARE O
RARE O
( O
ALL_CAP O
, O
RARE O
) O
and O
RARE O
( O
ALL_CAP O
, O
RARE O
). O

CONCLUSIONS O
: O
RARE O
is O
a O
valuable O
tool O
in O
asthmatic O
patients O
' O
training O
, O
allowing O
identification O
and O
improvement O
of O
an O
RARE O
inhalation O
technique O
with O
RARE O
. O

Of O
those O
injuries O
, O
NUM O
cases O
were O
RARE O
related O
and O
NUM O
cases O
were O
RARE O
related O
. O

The O
femoral O
artery O
/ O
RARE O
and O
the O
RARE O
and O
RARE O
muscles O
were O
examined O
in O
healthy O
human O
male O
volunteers O
. O

NUM I-GENE
acts O
RARE O
a O
naturally O
occurring O
dominant O
negative O
regulatory O
mutant O
that O
blocks O
SRF I-GENE
- O
dependent O
skeletal I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
, O
cardiac I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
, O
RARE I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
, O
NUM I-GENE
, O
and O
SRF I-GENE
promoter O
- O
luciferase I-GENE
reporter O
activities O
. O

In O
serum O
- O
free O
media O
, O
NUM I-GENE
accelerated O
E1A I-GENE
- O
RARE O
apoptosis O
. O

The O
potency O
of O
the O
effect O
of O
RARE O
( O
NUM O
. O
5 O
mg O
. O
kg O
- O
1 O
i O
. O
p O
.) O
was O
similar O
to O
that O
of O
ALL_CAP O
( O
10 O
mg O
. O
kg O
- O
1 O
i O
. O
p O
.). O

CONCLUSION O
: O
ALL_CAP O
pre O
- O
treatment O
or O
post O
- O
treatment O
markedly O
RARE O
the O
rCBF O
to O
RARE O
in O
ALL_CAP O
rats O
. O

RARE O
after O
RARE O
- O
line O
chemotherapy O
was O
associated O
with O
significantly O
RARE O
survival O
RARE O
patients O
with O
metastasis O
. O

Mutations O
within O
human O
NUM O
modulate O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
RARE O
by O
interfering O
with O
mRNA O
translational O
efficiency O
in O
transfected O
cells O
and O
in O
an O
in O
vitro O
translation O
RARE O
. O

As O
is O
deduced O
from O
the O
nucleotide O
sequence O
of O
the O
cDNA O
, O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
contains O
an O
RARE O
reading O
frame O
consisting O
of O
182 O
amino O
RARE O
, O
with O
a O
RARE O
RARE O
of O
19 O
. O
NUM O
. O

RARE O
and O
RARE O
input O
RARE O
from O
the O
RARE O
motor O
area O
in O
the O
RARE O
RARE O
: O
comparison O
with O
the O
input O
RARE O
from O
the O
supplementary O
motor O
area O
. O

RARE I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
) O
has O
been O
shown O
to O
induce O
angiogenesis O
in O
various O
RARE O
models O
, O
but O
the O
methods O
of O
administration O
used O
experimentally O
are O
not O
clinically O
RARE O
. O

Both O
RARE O
equally O
contributed O
to O
elevation O
of O
iliac O
venous O
pressure O
( O
median O
, O
9 O
. O
3 O
and O
7 O
. O
2 O
mm O
Hg O
RARE O
RARE O
= O
9 O
] O
with O
the O
RARE O
filter O
and O
NUM O
filter O
, O
respectively O
). O

12 O
healthy O
women O
( O
age O
18 O
- O
38 O
years O
) O
were O
examined O
using O
the O
2 O
- O
hour O
' O
s O
method O
of O
passive O
leg O
RARE O
( O
ALL_CAP O
) O
in O
follicular O
( O
ALL_CAP O
) O
and O
RARE O
( O
ALL_CAP O
) O
phases O
of O
normal O
RARE O
RARE O
. O

Thus O
, O
NUM I-GENE
has O
the O
3 O
' O
ALL_CAP O
in O
its O
5 O
' O
UTR O
. O

These O
single O
mutational O
defects O
in O
the O
NUM I-GENE
- O
NUM I-GENE
interaction O
became O
evident O
when O
either O
truncated O
protein O
NUM I-GENE
or O
C O
- O
RARE O
altered O
NUM I-GENE
proteins O
were O
used O
RARE O
the O
RARE O
protein O
, O
providing O
further O
support O
RARE O
the O
presence O
of O
a O
C O
- O
terminal O
interaction O
. O

Removal O
of O
each O
of O
three O
contiguous O
RARE O
from O
the O
N O
- O
terminal O
RARE O
specifically O
inhibits O
the O
formation O
of O
5 I-GENE
. I-GENE
NUM I-GENE
rRNA I-GENE
, O
whereas O
RARE O
part O
of O
the O
C O
- O
terminal O
region O
of O
the O
protein O
only O
blocks O
the O
production O
of O
NUM I-GENE
rRNA I-GENE
. O

Ras I-GENE
is O
not O
associated O
with O
the O
RARE O
. O

RARE O
RARE O
protein O
- O
RARE O
UNC I-GENE
- I-GENE
NUM I-GENE
and O
UNC I-GENE
- I-GENE
NUM I-GENE
subunits I-GENE
are O
coexpressed O
in O
muscle O
cells O
and O
are O
RARE O
to O
synaptic O
regions O
. O

We O
show O
that O
a O
protein O
, O
NUM I-GENE
, O
interacts O
specifically O
with O
ALL_CAP I-GENE
in O
vitro O
and O
in O
vivo O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
spontaneous O
reports O
of O
suspected O
adverse O
drug O
reactions O
, O
observed O
in O
elderly O
patients O
( O
over O
65 O
years O
of O
age O
) O
in O
RARE O
( O
RARE O
) O
RARE O
the O
period O
from O
1 O
January O
1995 O
to O
NUM O
RARE O
1997 O
. O

RARE O
of O
NUM O
are O
capable O
of O
RARE O
RARE O
radiation O
( O
ALL_CAP O
). O

The O
major O
findings O
of O
our O
studies O
are O
RARE O
follows O
: O
1 O
) O
There O
are O
RARE O
detectable O
signals O
around O
ALL_CAP I-GENE
- I-GENE
9 I-GENE
- O
RARE O
RARE O
RARE O
several O
RARE O
cell O
layer O
markers O
RARE O
i O
. O
RARE O
. O

Interestingly O
, O
highly O
charged O
residues O
were O
abundantly O
possessed O
in O
the O
RARE O
- O
terminal O
part O
of O
the O
NUM I-GENE
NUM I-GENE
protein I-GENE
. O

Identification O
and O
RARE O
of O
the O
RARE I-GENE
' I-GENE
s I-GENE
RARE I-GENE
virus I-GENE
RARE I-GENE
2 I-GENE
glycoprotein I-GENE
M I-GENE
gene I-GENE
: O
comparison O
with O
glycoprotein I-GENE
M I-GENE
genes I-GENE
of O
RARE O
family O
. O

OBJECTIVE O
: O
To O
perform O
a O
cost O
- O
effectiveness O
analysis O
( O
ALL_CAP O
) O
between O
a O
standard O
RARE O
regimen O
- O
RARE O
+ O
dexamethasone O
( O
ALL_CAP O
- O
ALL_CAP O
)- O
and O
a O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonist O
- O
RARE O
( O
ALL_CAP O
RARE O
in O
the O
control O
of O
acute O
RARE O
RARE O
by O
highly O
RARE O
chemotherapy O
in O
children O
, O
RARE O
two O
RARE O
RARE O
: O
hospital O
and O
patients O
. O

RARE O
data O
were O
obtained O
from O
10 O
adults O
. O

A O
comparison O
of O
the O
nucleotide O
and O
deduced O
amino O
acid O
sequences O
of O
the O
core O
regions O
of O
the O
RNA I-GENE
- I-GENE
dependent I-GENE
RNA I-GENE
polymerase I-GENE
domains I-GENE
found O
in O
these O
three O
RARE O
suggested O
that O
these O
RARE O
probably O
evolved O
independently O
within O
each O
RARE O
RARE O
from O
a O
common O
ancestor O
. O

Consistent O
with O
this O
possibility O
, O
a O
non O
- O
ALL_CAP I-GENE
region O
of O
NUM I-GENE
was O
sufficient O
to O
recruit O
a O
repression O
function O
to O
DNA O
that O
was O
unrelated O
to O
histone I-GENE
RARE I-GENE
. O

Forty O
- O
eight O
sequences O
, O
NUM O
not O
previously O
identified O
RARE O
IR O
- O
responsive O
, O
were O
significantly O
regulated O
by O
IR O
. O

A O
recently O
described O
protein O
, O
RARE I-GENE
1 I-GENE
, O
serves O
RARE O
a O
RARE O
of O
a O
RARE O
import O
complex O
in O
the O
RARE O
membrane O
of O
the O
mammalian O
RARE O
. O

Molecular O
cloning O
of O
rat I-GENE
NUM I-GENE
- I-GENE
containing I-GENE
RARE I-GENE
phosphatase I-GENE
2 I-GENE
( O
NUM I-GENE
) O
and O
its O
role O
in O
the O
RARE O
of O
insulin I-GENE
RARE O
. O

NUM I-GENE
represses O
transcription O
via O
this O
binding O
site O
in O
yeast O
cells O
, O
consistent O
with O
its O
role O
RARE O
a O
direct O
repressor O
of O
RARE I-GENE
RARE O
in O
RARE O
regions O
RARE O
RARE O
stages O
of O
embryogenesis O
. O

The O
results O
of O
these O
studies O
support O
a O
model O
in O
which O
NUM I-GENE
RARE I-GENE
or O
RARE O
contribute O
structural O
RARE O
RARE O
the O
assembly O
of O
a O
RARE O
RARE O
competent O
RARE O
RARE O
DNA O
transfer O
, O
whereas O
an O
ATP O
- O
dependent O
activity O
is O
required O
RARE O
RARE O
this O
RARE O
RARE O
a O
RARE O
export O
machine O
. O

The O
RARE I-GENE
binding I-GENE
proteins I-GENE
( O
RARE I-GENE
) O
RARE O
and O
RARE O
RARE O
, O
the O
structural O
RARE O
of O
the O
bacterial O
cell O
RARE O
. O

TCR I-GENE
alpha I-GENE
( O
ALL_CAP I-GENE
) O
RARE O
was O
examined O
in O
RNA O
samples O
from O
ALL_CAP O
and O
isolated O
populations O
of O
NUM O
RARE O
NUM O
RARE O
and O
ALL_CAP O
T O
cells O
from O
NUM O
healthy O
individuals O
. O

Similar O
results O
were O
obtained O
with O
RARE O
, O
an O
activator O
of O
the O
RARE O
phosphate O
RARE O
. O

The O
high I-GENE
density I-GENE
lipoprotein I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
receptor I-GENE
mediates O
the O
uptake O
of O
cholesterol O
and O
RARE O
esters O
, O
RARE O
RARE O
RARE O
, O
from O
an O
ALL_CAP I-GENE
RARE O
in O
the O
adrenal O
RARE O
and O
RARE O
. O

NUM I-GENE
is O
physically O
RARE O
RARE O
or O
near O
the O
ALL_CAP I-GENE
locus I-GENE
, O
while O
NUM I-GENE
and O
NUM I-GENE
are O
flanking O
the O
locus O
RARE O
about O
NUM O
. O
5 O
ALL_CAP O
genetic O
distance O
each O
RARE O
. O

The O
RARE O
of O
recovery O
decreased O
with O
RARE O
time O
, O
although O
the O
addition O
of O
RARE O
( O
RARE O
- O
RARE O
NUM O
) O
before O
RARE O
appeared O
to O
partially O
prevent O
adhesion O
. O

RARE O
mutations O
of O
the O
site O
that O
suppressed O
Pit I-GENE
- I-GENE
1 I-GENE
binding O
in O
vitro O
restored O
full O
ALL_CAP I-GENE
promoter I-GENE
activity O
. O

A O
human I-GENE
Raf I-GENE
- I-GENE
responsive I-GENE
zinc I-GENE
- I-GENE
finger I-GENE
protein I-GENE
that O
binds O
to O
divergent O
sequences O
. O

We O
are O
RARE O
an O
autopsy O
case O
of O
so O
- O
called O
" O
acute O
multiple O
sclerosis O
" O
that O
was O
difficult O
to O
differentiate O
from O
a O
brain O
tumor O
on O
MRI O
findings O
. O

Furthermore O
, O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
and O
NUM I-GENE
bind O
related O
proteins O
that O
promote O
their O
kinase O
activities O
. O

BACKGROUND O
: O
The O
ALL_CAP O
- O
III O
is O
the O
surgical O
treatment O
of O
choice O
RARE O
RARE O
refractory O
RARE O
fibrillation O
. O

NUM I-GENE
, O
a O
new O
pleckstrin I-GENE
homology O
domain O
- O
containing O
RARE O
protein O
, O
acts O
to O
RARE O
RARE O
from O
ERK I-GENE
kinase I-GENE
to O
Elk I-GENE
- I-GENE
1 I-GENE
. O

The O
presence O
of O
cutaneous O
RARE O
with O
normal O
serum O
RARE O
levels O
is O
due O
to O
the O
RARE O
activity O
of O
the O
monoclonal I-GENE
immunoglobulin I-GENE
. O

In O
an O
attempt O
to O
reduce O
the O
incidence O
of O
NSAID O
- O
RARE O
RARE O
lesions O
, O
the O
following O
approaches O
have O
been O
proposed O
: O
( O
i O
) O
use O
of O
the O
RARE O
analogue O
RARE O
, O
which O
is O
an O
RARE O
drug O
which O
has O
been O
proven O
to O
be O
RARE O
effective O
in O
the O
prevention O
of O
NSAID O
- O
RARE O
RARE O
and O
duodenal O
ulcers O
RARE O
in O
the O
reduction O
of O
serious O
upper O
RARE O
complications O
; O
( O
ii O
) O
RARE I-GENE
H2 I-GENE
receptor I-GENE
antagonists O
( O
H2 O
antagonists O
RARE O
RARE O
. O
g O
. O
ranitidine O
, O
cimetidine O
and O
RARE O
, O
which O
are O
useful O
in O
the O
prevention O
of O
NSAID O
- O
RARE O
duodenal O
ulcers O
RARE O
long O
term O
treatment O
, O
but O
not O
in O
the O
prevention O
of O
NSAID O
- O
RARE O
RARE O
ulcers O
; O
( O
iii O
) O
RARE O
RARE O
RARE O
, O
RARE O
. O
g O
omeprazole O
, O
and O
RARE O
, O
whose O
efficacy O
in O
preventing O
NSAID O
- O
associated O
ulcers O
has O
been O
recently O
demonstrated O
; O
and O
( O
iv O
) O
barrier O
agents O
, O
RARE O
. O
g O
. O
RARE O
, O
which O
cannot O
be O
recommended O
RARE O
prophylactic O
agents O
to O
prevent O
NSAID O
- O
RARE O
RARE O
. O

Lung O
RARE O
serves O
RARE O
a O
' O
RARE O
' O
RARE O
of O
RARE O
RARE O
by O
secreting O
RARE O
peptide O
growth O
factors O
. O

The O
activation O
of O
the O
HIV O
promoter O
required O
the O
nuclear O
RARE O
of O
c I-GENE
- I-GENE
Abl I-GENE
and O
could O
be O
correlated O
with O
increased O
tyrosine O
RARE O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
. O

The O
bovine I-GENE
RARE I-GENE
E2 I-GENE
protein I-GENE
can O
inhibit O
the O
RARE O
of O
ALL_CAP O
- O
3 O
cells O
, O
a O
p53 I-GENE
- O
negative O
cervical O
carcinoma O
cell O
line O
containing O
integrated O
human O
RARE O
type O
NUM O
DNA O
. O

E2 I-GENE
point O
mutants O
unable O
to O
inhibit O
cell O
growth O
did O
not O
repress O
NUM I-GENE
and O
NUM I-GENE
RARE O
, O
nor O
did O
the O
cell O
RARE O
RARE O
RARE O
and O
RARE O
. O

BACKGROUND O
/ O
PURPOSE O
: O
RARE O
arrangement O
of O
the O
RARE O
duct O
( O
ALL_CAP O
) O
is O
closely O
related O
to O
congenital O
biliary O
dilatation O
and O
frequently O
associated O
with O
biliary O
RARE O
malignancy O
. O

Neurospora O
crassa O
ALL_CAP I-GENE
- I-GENE
18 I-GENE
, O
can O
rescue O
the O
RARE O
RARE O
and O
intron O
mutants O
which O
cause O
a O
structural O
defect O
. O

NUM I-GENE
also O
localizes O
to O
RARE O
in O
RARE O
nuclei O
of O
RARE O
neuroblasts O
. O

In O
a O
reconstituted O
human O
DNA O
repair O
RARE O
containing O
DNA I-GENE
polymerase I-GENE
beta I-GENE
and O
DNA I-GENE
ligase I-GENE
III I-GENE
- O
NUM I-GENE
, O
accurate O
RARE O
of O
a O
3 O
' O
RARE O
RARE O
RARE O
RARE O
a O
single O
- O
RARE O
RARE O
is O
dependent O
on O
addition O
of O
the O
RARE O
. O

The O
ALL_CAP O
clone O
with O
an O
insert O
size O
of O
NUM O
was O
isolated O
and O
mapped O
by O
RARE O
analysis O
. O

Sequence O
of O
NUM I-GENE
locus I-GENE
surrounding O
the O
NUM I-GENE
oncogene I-GENE
reveals O
a O
new O
gene O
NUM I-GENE
RARE O
in O
a O
T O
- O
ALL O
cell O
line O
. O

RARE O
20 O
kb O
upstream O
of O
NUM I-GENE
we O
found O
a O
gene O
encoding O
a O
RARE O
, O
non O
- O
processed O
NUM I-GENE
- I-GENE
like I-GENE
RARE I-GENE
( O
NUM I-GENE
). O

RARE O
- O
directed O
mutagenesis O
of O
the O
NUM I-GENE
protein I-GENE
was O
used O
to O
provide O
evidence O
that O
this O
motif O
is O
also O
part O
of O
the O
RARE O
site O
of O
the O
endonuclease O
encoded O
by O
this O
element O
. O

The O
RARE I-GENE
cell I-GENE
protein I-GENE
RARE I-GENE
. I-GENE
NUM I-GENE
( O
NUM I-GENE
) O
of O
herpes O
simplex O
virus O
1 O
is O
a O
RARE O
RARE O
shown O
to O
enhance O
the O
RARE O
of O
genes O
RARE O
into O
cells O
by O
infection O
or O
transfection O
. O

RARE O
measurement O
of O
RARE O
pressure O
: O
some O
critical O
RARE O
to O
RARE O
. O

G O
- O
box O
- O
directed O
RARE O
in O
leaves O
required O
the O
presence O
of O
an O
enhancer O
region O
from O
the O
RARE O
mosaic O
virus O
( O
ALL_CAP O
) O
NUM I-GENE
promoter I-GENE
. O

Another O
element O
necessary O
RARE O
RARE O
the O
amplitude O
of O
the O
RARE O
lies O
between O
- O
NUM O
and O
- O
264 O
. O

This O
RARE O
was O
therefore O
used O
RARE O
control O
in O
experiments O
where O
another O
anti I-GENE
- I-GENE
Ras I-GENE
RARE I-GENE
( O
NUM I-GENE
RARE I-GENE
, O
derived O
from O
the O
RARE O
anti I-GENE
- I-GENE
Ras I-GENE
RARE I-GENE
NUM I-GENE
- I-GENE
NUM I-GENE
) O
blocked O
the O
Ras I-GENE
RARE O
in O
vitro O
and O
led O
to O
tumor O
regression O
in O
a O
nude O
mouse O
model O
RARE O
RARE O
, O
O O
., O
RARE O
, O
M O
., O
RARE O
, O
I O
., O
RARE O
- O
RARE O
, O
A O
., O
RARE O
, O
M O
. O
C O
., O
RARE O
, O
ALL_CAP O
. O
H O
., O
RARE O
, O
F O
., O
RARE O
, O
ALL_CAP O
. O
L O
., O
RARE O
, O
B O
., O
1998 O
. O

There O
was O
RARE O
competition O
between O
activin I-GENE
A I-GENE
and O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
RARE O
availability O
of O
NUM I-GENE
, O
indicating O
that O
the O
concentration O
of O
this O
common O
signal O
RARE O
is O
not O
limiting O
RARE O
generating O
the O
observed O
biological O
responses O
. O

Our O
data O
therefore O
indicate O
that O
it O
is O
possible O
to O
RARE O
the O
ALL_CAP I-GENE
envelope I-GENE
glycoprotein I-GENE
by O
RARE O
ligands O
to O
its O
amino O
- O
terminal O
end O
without O
affecting O
its O
fusion O
activity O
. O

However O
, O
the O
RARE O
, O
parallel O
beta O
helix O
model O
is O
a O
RARE O
RARE O
of O
ten O
RARE O
arranged O
beta O
RARE O
forming O
two O
parallel O
beta O
RARE O
RARE O
. O

This O
is O
predicted O
to O
encode O
a O
NUM O
- O
RARE O
protein O
containing O
RARE O
hydrophobic O
helical O
regions O
and O
a O
NUM O
amino O
acid O
motif O
characteristic O
of O
the O
NUM I-GENE
family I-GENE
of O
G I-GENE
- I-GENE
protein I-GENE
coupled I-GENE
membrane I-GENE
- I-GENE
RARE I-GENE
receptors I-GENE
. O

RARE O
of O
the O
chicken I-GENE
apolipoprotein I-GENE
A I-GENE
- I-GENE
I I-GENE
gene I-GENE
5 O
'- O
flanking O
region O
. O

These O
results O
suggest O
that O
members O
of O
the O
ATF I-GENE
family I-GENE
are O
involved O
in O
mediating O
the O
transcriptional O
RARE O
of O
the O
ALL_CAP I-GENE
gene I-GENE
in O
response O
to O
extracellular O
stimuli O
via O
a O
novel O
ALL_CAP O
regulatory O
element O
. O

Moreover O
, O
a O
high O
proportion O
of O
RARE O
samples O
from O
a O
random O
sample O
of O
the O
rest O
of O
the O
RARE O
tested O
positive O
RARE O
RARE O
- O
specific O
DNA O
by O
PCR O
( O
NUM O
. O
9 O
% O
RARE O
T O
. O
b O
. O
RARE O
and O
NUM O
. O
9 O
% O
RARE O
T O
. O
b O
. O
RARE O
). O

A O
RARE O
- O
RARE O
evaluation O
of O
the O
RARE O
indirect O
RARE O
test O
RARE O
RARE O
( O
RARE O
ALL_CAP O
). O

Results O
RARE O
men O
who O
RARE O
RARE O
to O
two O
RARE O
per O
day O
suggest O
that O
if O
the O
dependence O
criteria O
were O
RARE O
, O
reductions O
in O
the O
prevalence O
of O
specific O
indicators O
of O
RARE O
dependence O
would O
range O
from O
NUM O
. O
3 O
% O
to O
5 O
. O
2 O
%. O

RARE O
of O
the O
ALL_CAP O
/ O
ALL_CAP O
elements O
and O
NUM I-GENE
sites I-GENE
in O
this O
region O
, O
alone O
or O
in O
combination O
, O
RARE O
transcriptional O
activity O
by O
40 O
- O
NUM O
% O
in O
RARE O
growing O
cells O
and O
abolished O
cell O
RARE O
RARE O
in O
NUM O
- O
M O
- O
RARE O
cells O
. O

Using O
RARE O
' O
s O
procedure O
RARE O
an O
RARE O
, O
comparisons O
are O
made O
to O
RARE O
sample O
size O
methods O
that O
RARE O
RARE O
the O
RARE O
nature O
of O
NUM O
. O

The O
RARE O
RARE O
of O
the O
VP16 I-GENE
core I-GENE
has O
been O
determined O
RARE O
2 O
. O
1 O
A O
resolution O
. O

RARE O
, O
RARE O
, O
RARE O
and O
RARE O
were O
more O
effective O
than O
RARE O
in O
increasing O
rCBF O
RARE O
the O
ALL_CAP O
. O

The O
latter O
method O
RARE O
RARE O
of O
the O
inferior O
RARE O
RARE O
, O
which O
results O
in O
hypotension O
, O
requiring O
invasive O
RARE O
management O
. O

By O
contrast O
, O
ALL_CAP I-GENE
or O
RARE I-GENE
promoter I-GENE
constructs I-GENE
yielded O
RARE O
NUM I-GENE
only O
if O
NUM I-GENE
was O
coexpressed O
with O
NUM I-GENE
. O

RARE O
RARE O
virus O
5 O
( O
NUM O
) O
is O
a O
prototype O
of O
the O
RARE O
family O
of O
RARE O
negative O
- O
sense O
RNA O
viruses O
. O

To O
investigate O
the O
functions O
of O
ALL_CAP O
, O
ALL_CAP O
, O
and O
ALL_CAP O
sequences O
in O
transcription O
, O
we O
constructed O
plasmids O
containing O
cDNAs O
of O
the O
full O
- O
length O
NUM O
genome O
in O
which O
the O
gene O
RARE O
sequences O
( O
ALL_CAP O
, O
ALL_CAP O
, O
and O
ALL_CAP O
sequences O
) O
RARE O
between O
the O
hemagglutinin I-GENE
- I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
and O
the O
polymerase I-GENE
( I-GENE
L I-GENE
) I-GENE
genes I-GENE
were O
replaced O
with O
the O
RARE O
sequences O
from O
other O
gene O
junctions O
. O

NUM I-GENE
is O
a O
RARE O
receptor O
and O
a O
RARE O
RARE O
T O
- O
cell O
- O
line O
- O
RARE O
( O
NUM O
) O
and O
dual O
- O
RARE O
( O
NUM O
) O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
isolates O
. O

These O
data O
will O
help O
us O
to O
better O
detail O
the O
NUM I-GENE
structural O
requirements O
exhibited O
by O
different O
HIV O
- O
1 O
strains O
and O
will O
direct O
further O
mutagenesis O
RARE O
aimed O
RARE O
better O
RARE O
the O
domains O
in O
NUM I-GENE
involved O
in O
the O
HIV O
- O
1 O
Env I-GENE
- O
RARE O
fusion O
process O
. O

The O
results O
of O
these O
analyses O
indicate O
that O
the O
RARE O
RARE O
RARE O
amino O
acid O
residues O
NUM O
- O
NUM O
, O
NUM O
- O
NUM O
, O
NUM O
- O
NUM O
, O
and O
NUM O
- O
NUM O
; O
however O
, O
the O
RARE O
efficiency O
is O
varied O
. O

RARE O
. O

ALL_CAP I-GENE
is O
also O
shown O
to O
be O
associated O
in O
vivo O
with O
other O
RARE O
of O
the O
ALL_CAP I-GENE
1 I-GENE
export O
RARE O
, O
including O
the O
small I-GENE
GTPase I-GENE
Ran I-GENE
and O
the O
RARE O
ALL_CAP I-GENE
/ O
NUM I-GENE
. O

Identification O
of O
a O
RARE O
gene O
from O
Kaposi O
' O
s O
sarcoma O
- O
associated O
RARE O
encoding O
a O
protein O
with O
similarities O
to O
latent I-GENE
membrane I-GENE
proteins I-GENE
1 I-GENE
and I-GENE
NUM I-GENE
of I-GENE
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
. O

RARE O
RARE O
were O
given O
RARE O
a O
rate O
of O
20 O
s O
RARE O
1 O
). O

RARE I-GENE
light I-GENE
chain I-GENE
kinase I-GENE
functions O
RARE O
of O
Ras I-GENE
/ O
ERK I-GENE
to O
promote O
migration O
of O
urokinase I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
- O
RARE O
cells O
in O
an O
integrin I-GENE
- O
selective O
manner O
. O

The O
inhibition O
of O
ALL_CAP I-GENE
gene I-GENE
transcription O
by O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
was O
dose O
- O
dependent O
RARE O
transcription O
to O
6 O
% O
of O
control O
levels O
. O

In O
a O
prospective O
randomized O
study O
, O
NUM O
patients O
with O
advanced O
non O
- O
small O
cell O
RARE O
RARE O
( O
ALL_CAP O
) O
RARE O
RARE O
or O
IV O
with O
ALL_CAP O
performance O
status O
( O
ALL_CAP O
) O
NUM O
- O
1 O
or O
2 O
were O
randomly O
assigned O
to O
receive O
either O
best O
RARE O
care O
( O
ALL_CAP O
) O
or O
RARE O
care O
RARE O
combination O
chemotherapy O
( O
ALL_CAP O
regimen O
: O
RARE O
3 O
RARE O
/ O
m2 O
IV O
with O
RARE O
RARE O
, O
RARE O
NUM O
mg O
/ O
m2 O
IV O
on O
day O
1 O
and O
cisplatin O
NUM O
mg O
/ O
m2 O
IV O
on O
day O
2 O
; O
or O
ALL_CAP O
regimen O
: O
RARE O
- O
C O
8 O
mg O
/ O
m2 O
, O
cisplatin O
NUM O
mg O
/ O
m2 O
IV O
on O
day O
1 O
, O
RARE O
4 O
mg O
/ O
m2 O
IV O
on O
days O
1 O
and O
NUM O
). O

Using O
sequence O
RARE O
from O
human I-GENE
NUM I-GENE
( O
NUM I-GENE
) O
cDNAs O
previously O
reported O
by O
our O
laboratory O
, O
we O
have O
isolated O
and O
characterized O
cDNAs O
encoding O
three O
RARE O
variants O
of O
the O
mouse I-GENE
NUM I-GENE
( O
NUM I-GENE
) O
gene O
. O

Comparison O
with O
the O
bHLH I-GENE
/ O
ALL_CAP I-GENE
family O
genes O
revealed O
that O
the O
intron O
/ O
RARE O
RARE O
pattern O
of O
NUM I-GENE
most O
closely O
matches O
that O
of O
the O
RARE I-GENE
, O
which O
suggests O
that O
NUM I-GENE
and O
RARE I-GENE
belong O
to O
the O
same O
RARE O
and O
may O
be O
derived O
from O
a O
common O
RARE O
gene O
. O

The O
transcriptional O
activities O
of O
the O
full O
- O
length O
promoter O
RARE O
NUM O
to O
+ O
NUM O
) O
and O
of O
three O
deletion O
constructs O
RARE O
NUM O
, O
- O
154 O
and O
- O
NUM O
to O
+ O
NUM O
) O
were O
significantly O
down O
- O
regulated O
in O
resistant O
cells O
. O

We O
were O
able O
to O
detect O
significant O
differences O
in O
RARE O
residual O
capacity O
adjusted O
RARE O
RARE O
or O
height O
, O
and O
compliance O
of O
the O
respiratory O
RARE O
adjusted O
RARE O
RARE O
or O
RARE O
volume O
in O
the O
ALL_CAP O
infants O
compared O
to O
the O
healthy O
controls O
or O
infants O
who O
had O
ALL_CAP O
, O
indicating O
that O
these O
RARE O
were O
RARE O
enough O
to O
determine O
abnormal O
RARE O
function O
in O
this O
age O
group O
. O

A O
NUM O
- O
bp O
cis O
- O
regulatory O
element O
in O
the O
LTR O
promoter O
of O
the O
tobacco I-GENE
RARE I-GENE
NUM I-GENE
is O
involved O
in O
responsiveness O
to O
tissue O
culture O
, O
RARE O
, O
RARE O
RARE O
and O
RARE O
RARE O
. O

In O
this O
study O
we O
describe O
that O
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
RARE O
12 O
- O
O O
- O
RARE O
- O
phorbol O
- O
RARE O
( O
ALL_CAP O
RARE O
and O
forskolin O
RARE O
CREB I-GENE
( O
cAMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
- I-GENE
binding I-GENE
protein I-GENE
) O
RARE O
- O
NUM O
RARE O
with O
comparable O
magnitude O
and O
kinetics O
in O
ALL_CAP O
3T3 O
cells O
. O

This O
constitutes O
evidence O
RARE O
an O
in O
vivo O
role O
of O
SRC I-GENE
- I-GENE
1 I-GENE
in O
RARE O
- O
RARE O
activation O
by O
NUM I-GENE
/ O
RARE I-GENE
. O

By O
contrast O
, O
NUM I-GENE
RARE O
in O
vivo O
with O
another O
RARE O
of O
the O
ALL_CAP I-GENE
complex I-GENE
( O
NUM I-GENE
RARE O
which O
directly O
contacts O
TR I-GENE
and O
the O
vitamin I-GENE
D I-GENE
receptor I-GENE
in O
a O
RARE O
- O
dependent O
manner O
. O

This O
sequence O
also O
confers O
VDR I-GENE
and O
vitamin O
D O
responsiveness O
to O
a O
heterologous O
promoter O
. O

RARE O
RARE O
- O
activated O
nuclear O
receptors O
( O
RARE O
. O
g O
. O
thyroid I-GENE
hormone I-GENE
receptor I-GENE
, O
retinoic I-GENE
acid I-GENE
receptor I-GENE
RARE O
orphan I-GENE
nuclear I-GENE
receptors I-GENE
( O
RARE O
. O
g O
. O

Expression O
of O
RARE I-GENE
- I-GENE
ALL_CAP I-GENE
mRNA I-GENE
in O
tobacco O
leaves O
was O
detected O
using O
RT O
- O
PCR O
. O

Chemical O
stability O
tests O
and O
site O
- O
specific O
mutagenesis O
identified O
amino O
RARE O
NUM O
and O
NUM O
of O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
, O
respectively O
, O
RARE O
the O
RARE O
residues O
. O

An O
overexpression O
of O
the O
ALL_CAP I-GENE
gene I-GENE
in O
certain O
areas O
of O
the O
AD O
brain O
has O
been O
suggested O
to O
be O
an O
important O
factor O
in O
the O
RARE O
of O
AD O
. O

For O
RARE O
studies O
, O
two O
promoter O
regions O
were O
RARE O
upstream O
of O
the O
reporter O
gene O
, O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
( O
CAT I-GENE
): O
( O
i O
) O
ALL_CAP O
- O
B O
- O
the O
RARE O
that O
contains O
the O
human O
( O
h O
) O
promoter O
region O
RARE O
NUM O
to O
+ O
NUM O
) O
including O
ALL_CAP O
, O
and O
( O
ii O
) O
ALL_CAP O
- O
B O
- O
the O
RARE O
that O
contains O
the O
RARE O
( O
RARE O
) O
promoter O
region O
excluding O
ALL_CAP O
RARE O
it O
lacks O
a O
270 O
bp O
region O
of O
the O
ALL_CAP I-GENE
promoter I-GENE
RARE O
NUM O
to O
- O
NUM O
). O

67 O
NUM O
bp O
of O
contiguous O
DNA O
RARE O
between O
markers O
NUM I-GENE
and O
NUM I-GENE
on O
the O
right O
RARE O
of O
RARE O
yeast O
RARE O
II O
has O
been O
sequenced O
RARE O
part O
of O
the O
European O
RARE O
Schizosaccharomyces O
pombe O
genome O
sequencing O
RARE O
. O

67 O
NUM O
bp O
of O
contiguous O
DNA O
RARE O
between O
markers O
NUM I-GENE
and O
NUM I-GENE
on O
the O
right O
RARE O
of O
RARE O
yeast O
RARE O
II O
has O
been O
sequenced O
RARE O
part O
of O
the O
European O
RARE O
Schizosaccharomyces O
pombe O
genome O
sequencing O
RARE O
. O

G I-GENE
- I-GENE
CSF I-GENE
( O
NUM O
micrograms O
subcutaneously O
( O
s O
. O
c O
RARE O
were O
used O
in O
NUM O
and O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
( O
NUM O
micrograms O
s O
. O
c O
.) O
in O
NUM O
chemotherapeutic O
cycles O
. O

Overexpression O
of O
NUM I-GENE
cDNA I-GENE
in O
the O
ALL_CAP O
264 O
. O
7 O
macrophage O
cell O
line O
promoted O
an O
increased O
growth O
rate O
, O
suggesting O
that O
RARE O
of O
NUM I-GENE
is O
part O
of O
the O
proliferative O
cell O
response O
to O
ALL_CAP O
. O

Human O
RARE O
sequence O
tag O
RARE O
were O
identified O
by O
sequence O
RARE O
to O
mammalian I-GENE
and I-GENE
yeast I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
, O
and O
the O
full O
- O
length O
coding O
region O
of O
the O
putative O
RARE I-GENE
homolog I-GENE
was O
isolated O
by O
a O
combination O
of O
5 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
and O
direct O
polymerase O
chain O
reaction O
from O
human O
RARE O
cDNA O
. O

Activation O
of O
ERK1 I-GENE
/ I-GENE
2 I-GENE
is O
correlated O
with O
induction O
of O
the O
immediate I-GENE
- I-GENE
early I-GENE
response I-GENE
genes I-GENE
. O

The O
transcription O
of O
most O
ALL_CAP I-GENE
genes I-GENE
is O
activated O
by O
two O
NUM I-GENE
binding I-GENE
sites I-GENE
, O
NUM O
to O
NUM O
bp O
upstream O
from O
the O
initiation O
of O
transcription O
. O

We O
have O
isolated O
three O
mutant O
alleles O
of O
NUM I-GENE
( O
NUM I-GENE
- I-GENE
10 I-GENE
, O
NUM I-GENE
- I-GENE
11 I-GENE
, O
and O
NUM I-GENE
- I-GENE
16 I-GENE
) O
which O
suppress O
the O
nuclear O
division O
defect O
of O
NUM I-GENE
- I-GENE
1 I-GENE
cells O
. O

Role O
of O
secondary O
RARE O
in O
discrimination O
between O
RARE O
and O
inducible O
RARE O
. O

In O
summary O
, O
Ca O
( O
2 O
RARE O
dependent O
activation O
of O
ALL_CAP O
production O
mediates O
apoptosis O
after O
TG I-GENE
exposure O
in O
ALL_CAP O
/ O
RARE O
cells O
. O

RARE O
of O
the O
U4 I-GENE
/ O
U6 I-GENE
duplex O
was O
RARE O
by O
overexpression O
of O
wild I-GENE
- I-GENE
type I-GENE
NUM I-GENE
. O

Our O
results O
, O
when O
combined O
with O
previously O
published O
in O
vitro O
results O
, O
support O
a O
direct O
role O
RARE O
NUM I-GENE
in O
RARE O
of O
the O
U4 I-GENE
/ O
U6 I-GENE
helix O
. O

This O
RARE O
NUM O
- O
nt O
RNA O
proved O
to O
arise O
via O
RNase I-GENE
E I-GENE
RARE O
from O
the O
3 O
'- O
terminal O
region O
of O
the O
mRNAs O
RARE O
the O
terminator O
. O

The O
RARE O
of O
RARE O
variability O
in O
RARE O
RARE O
RARE O
incidence O
. O

In O
Saccharomyces O
cerevisiae O
the O
cAMP I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
( O
RARE I-GENE
) O
promote O
cytoplasmic O
growth O
and O
modulate O
the O
growth O
- O
regulated O
mechanism O
RARE O
the O
begin O
of O
DNA O
RARE O
. O

We O
have O
shown O
previously O
that O
in O
contrast O
to O
other O
extracellular O
RARE O
molecules O
RARE I-GENE
- O
RARE O
RARE I-GENE
ALL_CAP I-GENE
( O
ALL_CAP I-GENE
) O
can O
stimulate O
DNA O
RARE O
of O
various O
mesenchymal O
cell O
RARE O
, O
apparently O
independent O
of O
integrin I-GENE
- O
RARE O
signal O
RARE O
. O

A O
recombinant O
RARE O
harboring O
the O
NUM O
replication O
region O
proved O
to O
be O
compatible O
with O
NUM O
, O
a O
RARE O
containing O
the O
iron O
acquisition O
RARE O
required O
RARE O
the O
RARE O
of O
V O
. O
RARE O
NUM O
, O
another O
important O
RARE O
that O
causes O
RARE O
. O

FAK I-GENE
localizes O
to O
sites O
of O
transmembrane I-GENE
integrin I-GENE
receptor I-GENE
RARE O
and O
RARE O
RARE O
RARE O
events O
. O

Expression O
of O
various O
FAK I-GENE
mutants I-GENE
in O
the O
FAK I-GENE
- O
cells O
showed O
that O
FAK I-GENE
kinase I-GENE
activity O
, O
the O
RARE I-GENE
- I-GENE
NUM I-GENE
/ I-GENE
NUM I-GENE
domain I-GENE
binding I-GENE
site I-GENE
, O
and O
the O
RARE O
proline O
- O
rich O
SH3 I-GENE
binding I-GENE
region I-GENE
in O
the O
FAK I-GENE
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
were O
individually O
needed O
to O
promote O
full O
FAK I-GENE
- O
RARE O
FAK I-GENE
- O
cell O
migration O
to O
FN I-GENE
whereas O
direct O
paxillin I-GENE
binding O
to O
FAK I-GENE
was O
not O
required O
. O

This O
dominant O
- O
negative O
effect O
of O
ALL_CAP I-GENE
was O
reversed O
by O
a O
point O
mutation O
( O
RARE O
- O
NUM O
to O
RARE O
) O
which O
prevented O
ALL_CAP I-GENE
RARE O
to O
RARE O
RARE O
sites O
. O

Fifty O
RARE O
young O
patients O
( O
age O
< O
NUM O
yr O
) O
with O
RARE O
- O
proven O
ALL_CAP O
were O
investigated O
RARE O
the O
presence O
of O
resistance O
to O
activated I-GENE
protein I-GENE
C I-GENE
( O
ALL_CAP I-GENE
- I-GENE
R I-GENE
RARE O
lupus O
RARE O
( O
LA O
RARE O
RARE I-GENE
antibodies I-GENE
and O
deficiencies O
of O
protein I-GENE
C I-GENE
, O
protein I-GENE
S I-GENE
, O
ALL_CAP I-GENE
activities O
. O

DESIGN O
: O
Comparison O
of O
number O
of O
women O
with O
ALL_CAP O
aged O
NUM O
- O
NUM O
years O
on O
the O
ALL_CAP O
ALL_CAP O
database O
( O
observed O
number O
) O
with O
expected O
number O
derived O
from O
population O
data O
. O

PURPOSE O
: O
The O
RARE O
of O
the O
present O
study O
were O
to O
assess O
the O
effects O
of O
a O
12 O
- O
wk O
laboratory O
based O
aerobic O
exercise O
program O
on O
cardiopulmonary O
function O
, O
NUM I-GENE
cell O
count O
, O
and O
RARE O
- O
assessed O
health O
status O
among O
symptomatic O
pre O
- O
AIDS O
HIV O
- O
RARE O
individuals O
( O
N O
= O
NUM O
) O
and O
to O
assess O
the O
degree O
to O
which O
RARE O
health O
was O
associated O
with O
exercise O
relapse O
. O

The O
enzyme O
displays O
optimal O
activity O
RARE O
about O
NUM O
. O
5 O
mM O
RARE O
( O
RARE O
( O
RARE O
) O
NUM O
. O
NUM O
s O
RARE O
1 O
)) O
and O
RARE O
pH O
7 O
. O
8 O
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
the O
ALL_CAP I-GENE
, O
like O
the O
20S I-GENE
proteasome I-GENE
, O
is O
functionally O
and O
structurally O
RARE O
among O
eukaryotes O
and O
indicate O
that O
the O
RARE I-GENE
ALL_CAP I-GENE
subunits I-GENE
, O
like O
their O
yeast O
counterparts O
, O
have O
non O
- O
RARE O
functions O
. O

RARE O
evidence O
indicates O
that O
estrogen O
RARE O
therapy O
after O
RARE O
increases O
breast O
RARE O
risk O
. O

In O
addition O
to O
its O
RARE O
activity O
, O
ALL_CAP I-GENE
contains O
a O
novel O
type O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
interaction I-GENE
domain I-GENE
that O
is O
capable O
of O
repressing O
polymerase O
activity O
in O
promoter O
- O
specific O
transcription O
. O

A O
diagnosis O
of O
IgA I-GENE
lambda I-GENE
multiple O
myeloma O
with O
peritoneal O
involvement O
was O
made O
. O

The O
radiation O
burden O
associated O
with O
the O
majority O
of O
examinations O
in O
nuclear O
medicine O
RARE O
RARE O
the O
effective O
dose O
is O
comparable O
with O
the O
radiation O
burden O
of O
RARE O
examinations O
, O
only O
after O
administration O
of O
preparations O
with O
131I O
, O
NUM O
, O
NUM O
and O
NUM O
it O
is O
markedly O
RARE O
. O

Although O
the O
risk O
of O
RARE O
in O
children O
born O
after O
ALL_CAP O
is O
not O
increased O
there O
is O
an O
increased O
risk O
to O
RARE O
genetic O
abnormalities O
in O
case O
of O
ALL_CAP O
( O
such O
RARE O
the O
rate O
of O
RARE O
RARE O
, O
or O
RARE O
of O
the O
Y O
RARE O
) O
and O
in O
case O
of O
congenital O
ALL_CAP O
( O
mutations O
of O
the O
RARE I-GENE
RARE I-GENE
gene I-GENE
). O

ALL_CAP O
RARE O
have O
a O
RARE O
density O
of O
1 O
. O
296 O
g O
/ O
cm3 O
in O
RARE O
and O
consist O
of O
two O
RARE I-GENE
proteins I-GENE
of O
NUM O
and O
6 O
kDa O
. O

CONCLUSION O
: O
These O
results O
suggest O
that O
vibration O
- O
RARE O
RARE O
involvement O
can O
be O
considered O
neither O
pure O
digital O
RARE O
, O
nor O
definite O
ALL_CAP O
, O
RARE O
previously O
described O
. O

In O
about O
NUM O
bp O
upstream O
region O
of O
NUM I-GENE
that O
has O
been O
RARE O
and O
sequenced O
, O
multiple O
transcription O
factor O
binding O
sites O
including O
a O
ALL_CAP O
( O
cAMP O
- O
responsive O
element O
) O
were O
found O
. O

The O
in O
vitro O
RARE O
of O
the O
complex O
is O
16 O
. O
NUM O
s O
RARE O
1 O
) O
mM O
RARE O
1 O
). O

Structure O
and O
RARE O
of O
the O
mouse I-GENE
growth I-GENE
hormone I-GENE
receptor I-GENE
/ O
growth I-GENE
hormone I-GENE
binding I-GENE
protein I-GENE
gene I-GENE
. O

RARE O
recovery O
of O
SA O
from O
the O
liver O
/ O
RARE O
and O
the O
RARE O
RARE O
in O
RARE O
RARE O
and O
ALL_CAP O
from O
RARE O
chicks O
treated O
with O
ILK I-GENE
was O
dramatically O
RARE O
when O
compared O
to O
non O
- O
treated O
RARE O
RARE O
and O
chicks O
. O

The O
results O
of O
the O
ALL_CAP O
- O
2 O
trial O
and O
the O
data O
from O
the O
RARE O
RARE O
' O
RARE O
indicated O
that O
RARE O
is O
RARE O
in O
patients O
with O
acute O
RARE O
infarction O
and O
RARE O
secondary O
prevention O
. O

This O
study O
was O
performed O
to O
assess O
the O
role O
of O
additional O
diagnostic O
RARE O
in O
the O
preoperative O
RARE O
of O
patients O
with O
adenocarcinoma O
of O
the O
RARE O
, O
RARE O
RARE O
and O
pancreatic O
RARE O
prior O
to O
RARE O
RARE O
surgery O
. O

This O
report O
presents O
state O
- O
specific O
RARE O
RARE O
1987 O
- O
1996 O
, O
focusing O
on O
persistent O
RARE O
in O
RARE O
mortality O
between O
black O
and O
RARE O
women O
. O

RARE O
ALL_CAP I-GENE
mass O
level O
did O
not O
significantly O
differ O
in O
individuals O
from O
19 O
to O
70 O
years O
old O
, O
RARE O
both O
men O
and O
women O
. O

A O
decrease O
in O
insulin I-GENE
- O
RARE O
receptor O
kinase O
activity O
was O
observed O
RARE O
RARE O
chimeric O
receptors O
. O

RARE I-GENE
- I-GENE
1 I-GENE
is O
identical O
to O
the O
recently O
identified O
binding O
RARE O
RARE O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
or O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
RARE O
which O
was O
shown O
to O
have O
RARE I-GENE
- O
ALL_CAP I-GENE
activity O
. O

RARE I-GENE
proteins I-GENE
are O
tyrosine O
- O
RARE O
when O
RARE O
- O
RARE O
in O
cells O
with O
the O
RARE I-GENE
adhesion I-GENE
kinase I-GENE
RARE I-GENE
and O
Src I-GENE
. O

RARE O
experiments O
using O
ALL_CAP I-GENE
- I-GENE
specific I-GENE
antibodies I-GENE
revealed O
an O
interaction O
between O
endogenous I-GENE
ALL_CAP I-GENE
and O
a O
NUM O
- O
kDa O
protein O
that O
is O
tyrosine O
- O
RARE O
in O
ALL_CAP I-GENE
- O
RARE O
ALL_CAP O
/ O
3 O
cells O
. O

RARE I-GENE
are O
a O
family O
of O
proteins O
that O
RARE O
long O
- O
term O
extension O
of O
isolated O
RARE O
cell O
RARE O
due O
to O
an O
RARE O
yet O
unknown O
biochemical O
mechanism O
. O

This O
review O
RARE O
the O
clinical O
evidence O
to O
support O
current O
RARE O
in O
RARE O
bowel O
RARE O
( O
ALL_CAP O
). O

The O
responsive O
region O
of O
the O
alpha I-GENE
2 I-GENE
( I-GENE
V I-GENE
) I-GENE
RARE I-GENE
gene I-GENE
was O
localized O
to O
a O
fragment O
including O
NUM O
bp O
of O
basal O
promoter O
and O
NUM O
bp O
of O
RARE O
1 O
sequences O
, O
which O
contained O
two O
ALL_CAP O
- O
like O
elements O
. O

Furthermore O
, O
addition O
of O
B I-GENE
- I-GENE
Myb I-GENE
- O
RARE I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion O
protein O
inhibited O
complex O
formation O
. O

ALL_CAP I-GENE
- O
NUM O
count O
predicts O
age O
when O
prevalence O
of O
AD O
increases O
, O
then O
RARE O
: O
the O
RARE O
RARE O
Study O
. O

RARE O
of O
double O
- O
RARE O
RARE O
( O
RARE O
) O
in O
chromosomal O
DNA O
by O
RARE O
end O
- O
RARE O
( O
ALL_CAP O
) O
is O
not O
RARE O
characterized O
in O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

A O
new O
DNA I-GENE
repair I-GENE
gene I-GENE
from O
Schizosaccharomyces O
pombe O
with O
homology O
to O
ALL_CAP I-GENE
was O
identified O
and O
characterized O
. O

Among O
mucus O
- O
secreting O
cells O
, O
the O
RARE O
RARE O
RARE O
cells O
, O
RARE O
' O
s O
glands O
, O
RARE O
glands O
of O
RARE O
RARE O
, O
and O
pancreatic O
RARE O
exhibiting O
RARE O
RARE O
are O
unique O
in O
that O
they O
express O
class I-GENE
III I-GENE
RARE I-GENE
identified O
by O
RARE O
RARE I-GENE
A I-GENE
staining O
composed O
of O
RARE O
oxidation O
, O
RARE O
RARE O
reduction O
, O
RARE I-GENE
A I-GENE
, O
and O
RARE I-GENE
peroxidase I-GENE
reaction O
. O

The O
C O
- O
terminal O
mutants O
were O
strongly O
dominant O
over O
ALL_CAP I-GENE
, O
suggesting O
that O
they O
can O
form O
RARE O
with O
the O
wild O
- O
type O
activator O
. O

Thus O
, O
RARE I-GENE
C I-GENE
is O
found O
to O
RARE O
in O
solution O
and O
to O
undergo O
significant O
structural O
RARE O
upon O
binding O
of O
two O
different O
RARE O
proteins O
. O

The O
data O
imply O
that O
ALL_CAP I-GENE
/ O
STAT I-GENE
RARE O
has O
a O
role O
in O
ALL_CAP O
- O
associated O
RARE O
. O

There O
were O
NUM O
men O
and O
NUM O
women O
. O

A O
., O
RARE O
, O
K O
. O
E O
, O
and O
RARE O
, O
C O
. O

NUM I-GENE
is O
RARE O
in O
one O
RARE O
reading O
frame O
that O
contains O
the O
DNA O
binding O
domain O
, O
nuclear O
RARE O
signal O
and O
RARE O
domain O
. O

The O
RARE O
mechanism O
of O
RARE I-GENE
- O
RARE O
RARE O
- O
activation O
has O
been O
RARE O
investigated O
. O

Gel O
filtration O
and O
RARE O
- O
immunoprecipitation O
analyses O
reveal O
that O
NUM I-GENE
tightly O
associates O
with O
another O
RARE O
RARE O
RARE O
, O
NUM I-GENE
. O

METHODS O
: O
NUM O
suspected O
cases O
with O
ALL_CAP O
underwent O
the O
biopsies O
. O

We O
also O
identify O
several O
regulatory O
domain O
mutants O
in O
which O
Cd O
( O
2 O
+) O
tolerance O
of O
the O
mutant O
RARE O
and O
RARE O
activity O
of O
the O
protein O
are O
RARE O
. O

The O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
- I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
Tat I-GENE
protein I-GENE
regulates O
transcription O
by O
stimulating O
RNA I-GENE
polymerase I-GENE
RARE O
. O

One O
of O
these O
RARE I-GENE
, O
NUM I-GENE
, O
was O
shown O
to O
be O
the O
product O
of O
the O
homeotic I-GENE
gene I-GENE
fork I-GENE
head I-GENE
. O

RARE O
elements O
in O
tRNA O
RARE O
mono O
- O
and O
RARE O
reactions O
by O
the O
recombinant I-GENE
NUM I-GENE
were O
identified O
using O
in O
vitro O
NUM O
transcripts O
of O
NUM O
variants O
of O
tRNA I-GENE
( I-GENE
RARE I-GENE
) I-GENE
and O
tRNA I-GENE
( I-GENE
RARE I-GENE
) I-GENE
from O
yeast O
. O

In O
insulin I-GENE
- O
responsive O
cells O
, O
Akt I-GENE
phosphorylates O
and O
RARE O
the O
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
RARE I-GENE
synthase I-GENE
kinase I-GENE
- I-GENE
3 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
). O

The O
B I-GENE
cell I-GENE
antigen I-GENE
receptor I-GENE
activates O
the O
Akt I-GENE
( O
protein I-GENE
kinase I-GENE
B I-GENE
RARE O
RARE I-GENE
synthase I-GENE
kinase I-GENE
- I-GENE
3 I-GENE
RARE O
RARE O
via O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

RARE O
RARE O
events O
are O
detected O
in O
four O
different O
B O
and O
T O
cell O
lines O
that O
do O
not O
undergo O
switch O
RARE O
of O
their O
endogenous O
genes O
. O

ALL_CAP I-GENE
- I-GENE
1 I-GENE
and O
TNF I-GENE
increase O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
transcript I-GENE
levels O
in O
RARE O
cortical O
RARE O
, O
RARE O
nurse O
, O
and O
fibroblast O
cell O
lines O
. O

To O
determine O
what O
role O
NUM I-GENE
might O
play O
in O
c I-GENE
- I-GENE
myc I-GENE
RARE O
, O
the O
c I-GENE
- I-GENE
myc I-GENE
5 I-GENE
' I-GENE
RARE I-GENE
region I-GENE
( I-GENE
UTR I-GENE
) I-GENE
was O
fused O
in O
- O
frame O
to O
CAT I-GENE
RARE I-GENE
, O
and O
several O
more O
RARE O
constructs O
were O
made O
. O

Analysis O
of O
cell O
RARE O
proteins O
showed O
that O
NUM O
h O
of O
RARE O
treatment O
in O
the O
control O
cells O
caused O
an O
elevation O
in O
the O
levels O
of O
the O
RARE I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor O
p27 I-GENE
( O
NUM I-GENE
RARE O
inhibition O
of O
both O
RARE I-GENE
E I-GENE
- I-GENE
and I-GENE
RARE I-GENE
A I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
activity O
, O
and O
decreased O
levels O
of O
RARE O
RARE I-GENE
protein I-GENE
( O
pRb I-GENE
). O

RESULTS O
: O
RARE O
leptin I-GENE
concentrations O
in O
ALL_CAP O
were O
3 O
. O
5 O
+/- O
NUM O
. O
5 O
versus O
7 O
. O
6 O
+/- O
1 O
. O
2 O
RARE O
/ O
ml O
in O
control O
subjects O
. O

Copyright O
NUM O
Academic O
Press O
. O

RARE O
RARE O
corresponding O
to O
wild O
- O
type O
and O
mutant O
ALL_CAP O
sequences O
were O
used O
in O
gel O
- O
shift O
and O
RARE O
- O
shift O
analyses O
to O
identify O
proteins O
binding O
. O

RARE I-GENE
had O
high O
sequence O
homology O
with O
RARE I-GENE
, O
RARE O
isolated O
PKN I-GENE
, O
especially O
in O
the O
repeats O
of O
charged O
amino O
acid O
- O
rich O
region O
with O
leucine O
- O
zipper O
like O
sequences O
( O
ALL_CAP O
region O
/ O
NUM O
RARE O
in O
the O
RARE O
- O
terminal O
catalytic O
domain O
, O
and O
in O
RARE O
NUM O
amino O
acid O
stretch O
( O
D O
region O
/ O
NUM O
RARE O
RARE O
between O
ALL_CAP O
region O
/ O
NUM O
and O
the O
catalytic O
domain O
. O

At O
baseline O
, O
serum O
levels O
of O
RARE O
and O
ALL_CAP O
were O
RARE O
high O
and O
serum O
ALL_CAP O
was O
correlated O
significantly O
with O
plasma O
cyclosporine O
levels O
( O
RARE O
= O
NUM O
. O
NUM O
, O
p O
= O
NUM O
. O
NUM O
). O

BACKGROUND O
: O
Chronic O
RARE O
consumption O
has O
been O
demonstrated O
to O
be O
RARE O
to O
bone O
health O
. O

Interestingly O
, O
following O
induction O
of O
stress O
by O
heat O
shock O
, O
high O
salt O
, O
or O
ethanol O
, O
conditions O
under O
which O
most O
mRNA O
export O
is O
blocked O
, O
NUM I-GENE
is O
still O
RARE O
from O
the O
nucleus O
. O

For O
symptomatic O
RARE O
and O
inhibition O
of O
the O
growth O
of O
the O
metastases O
RARE I-GENE
- I-GENE
a I-GENE
and O
somatostatin I-GENE
analogues O
can O
be O
employed O
. O

In O
summary O
, O
the O
RARE O
- O
adverse O
- O
effect O
- O
level O
RARE O
this O
study O
was O
determined O
to O
be O
1000 O
ppm O
, O
based O
on O
decreased O
RARE O
gain O
in O
female O
rats O
, O
and O
on O
slight O
organ O
RARE O
changes O
in O
both O
RARE O
RARE O
NUM O
ppm O
. O

Some O
of O
them O
produce O
RARE O
sperm O
several O
times O
the O
RARE O
male O
body O
length O
. O

RARE O
RARE O
RARE O

ALL_CAP I-GENE
A I-GENE
- I-GENE
chain I-GENE
levels O
increase O
in O
cultured O
vascular O
RARE O
muscle O
cells O
( O
RARE O
) O
exposed O
to O
ALL_CAP I-GENE
. O

M I-GENE
- I-GENE
Ras I-GENE
interacted O
poorly O
in O
a O
yeast O
two O
- O
RARE O
assay O
with O
multiple O
Ras I-GENE
RARE O
, O
including O
c I-GENE
- I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
, O
A I-GENE
- I-GENE
Raf I-GENE
, O
B I-GENE
- I-GENE
Raf I-GENE
, O
RARE I-GENE
- I-GENE
3 I-GENE
kinase I-GENE
delta I-GENE
, O
ALL_CAP I-GENE
, O
and O
NUM I-GENE
. O

Deletion O
mapping O
of O
the O
human I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
( O
NUM I-GENE
) O
promoter O
RARE O
the O
most O
RARE O
fragment O
from O
- O
118 O
to O
+ O
NUM O
in O
relation O
to O
the O
transcription O
RARE O
site O
mapped O
in O
this O
study O
, O
in O
both O
human O
neuroblastoma O
ALL_CAP O
- O
N O
- O
ALL_CAP O
and O
hepatoma O
NUM O
cells O
. O

RARE O
oxygenation O
and O
RARE O
in O
sepsis O
and O
shock O
. O

Analysis O
of O
the O
E2F1 I-GENE
gene I-GENE
promoter I-GENE
showed O
that O
the O
- O
NUM O
to O
- O
54 O
region O
was O
required O
RARE O
E2 I-GENE
- O
responsiveness O
in O
transient O
transfection O
assays O
, O
and O
subsequent O
deletion O
/ O
mutation O
analysis O
showed O
that O
a O
single O
upstream O
ALL_CAP O
- O
rich O
and O
two O
RARE O
CCAAT O
- O
binding O
sites O
were O
required O
RARE O
RARE O
by O
E2 I-GENE
. O

In O
the O
course O
of O
RARE O
the O
mechanisms O
by O
which O
NUM I-GENE
and O
NUM I-GENE
regulated O
NUM I-GENE
transcription O
, O
we O
found O
that O
NUM I-GENE
and O
NUM I-GENE
RARE O
NUM I-GENE
and O
Sp3 I-GENE
in O
ALL_CAP O
- O
3 O
cells O
. O

In O
contrast O
, O
the O
differentiation O
of O
RARE O
transformed O
cells O
does O
not O
repress O
mitogenic O
responsiveness O
or O
junB I-GENE
or O
c I-GENE
- I-GENE
fos I-GENE
inducibility O
. O

RARE O
differentiation O
of O
RARE O
cells O
also O
markedly O
represses O
the O
ability O
of O
SRF I-GENE
to O
bind O
to O
the O
junB I-GENE
SRE O
, O
the O
c I-GENE
- I-GENE
fos I-GENE
SRE O
, O
and O
other O
RARE O
, O
RARE O
determined O
by O
mobility O
shift O
and O
gel O
supershift O
assays O
, O
without O
affecting O
the O
DNA O
binding O
characteristics O
of O
the O
nuclear O
protein O
SP O
- O
1 O
. O

RARE O
blocks O
differentiation O
- O
RARE O
inhibition O
of O
serum I-GENE
response I-GENE
factor I-GENE
interactions O
with O
serum O
response O
elements O
. O

The O
core I-GENE
enzyme I-GENE
is O
homologous O
to O
those O
of O
RARE O
NUM O
, O
NUM O
and O
NUM O
whereas O
the O
RARE O
factor O
shows O
similarities O
with O
bacterial I-GENE
RARE I-GENE
factors I-GENE
. O

The O
RARE I-GENE
. I-GENE
ALL_CAP I-GENE
- I-GENE
4 I-GENE
ORF I-GENE
contains O
an O
H O
- O
N O
- O
H O
motif O
, O
and O
possibly O
a O
ALL_CAP O
- O
ALL_CAP O
motif O
. O

The O
interaction O
of O
NUM I-GENE
- I-GENE
6 I-GENE
with O
full I-GENE
- I-GENE
length I-GENE
5 I-GENE
S I-GENE
RNA I-GENE
was O
far O
more O
RARE O
to O
non O
- O
specific O
competitor O
concentration O
than O
was O
the O
NUM I-GENE
- I-GENE
7 I-GENE
: O
5 I-GENE
S I-GENE
RNA I-GENE
interaction O
, O
suggesting O
that O
finger O
RARE O
contributes O
to O
both O
affinity O
and O
RARE O
in O
this O
protein O
: O
RNA O
interaction O
. O

The O
STAT I-GENE
protein I-GENE
accumulation O
resulting O
from O
C I-GENE
/ I-GENE
EBP I-GENE
RARE O
was O
tightly O
coupled O
to O
the O
morphological O
conversion O
of O
RARE O
to O
adipocytes O
and O
represents O
an O
RARE O
profile O
identical O
to O
that O
reported O
RARE O
RARE O
adipocytes O
in O
vivo O
. O

The O
median O
durations O
RARE O
response O
and O
survival O
time O
in O
the O
RARE O
RARE O
II O
trial O
were O
2 O
. O
3 O
months O
and O
5 O
. O
8 O
months O
, O
respectively O
. O

The O
role O
of O
' O
RARE O
RARE O
' O
in O
understanding O
patients O
with O
chronic O
schizophrenia O
or O
severe O
RARE O
disorder O
. O

Myocardial O
antioxidant O
RARE O
, O
catalase I-GENE
, O
RARE I-GENE
peroxidase I-GENE
and O
RARE I-GENE
dismutase I-GENE
, O
in O
the O
ALL_CAP O
- O
treated O
rats O
were O
not O
different O
compared O
to O
control O
rats O
. O

The O
second O
goal O
was O
to O
RARE O
the O
RARE O
arrangement O
of O
the O
RARE O
in O
ALL_CAP O
. O

These O
overall O
results O
indicate O
that O
there O
is O
generally O
one O
ALL_CAP O
copy O
per O
RARE O
site O
. O

The O
present O
investigation O
conducted O
in O
a O
population O
of O
258 O
RARE O
RARE O
individuals O
in O
the O
age O
range O
20 O
- O
NUM O
years O
, O
was O
RARE O
to O
elucidate O
the O
relationship O
between O
tobacco O
smoking O
and O
RARE O
RARE O
, O
taking O
into O
account O
possible O
RARE O
factors O
such O
RARE O
age O
, O
gender O
, O
oral O
RARE O
and O
RARE O
inflammation O
. O

OBJECTIVE O
: O
To O
determine O
whether O
administration O
of O
RARE O
prevents O
RARE O
hemorrhage O
in O
healthy O
dogs O
treated O
with O
high O
doses O
of O
RARE O
RARE O
RARE O
( O
ALL_CAP O
). O

Patients O
were O
assessed O
RARE O
cardiac O
ALL_CAP O
uptake O
, O
circulating O
norepinephrine O
concentration O
, O
LVEF O
, O
peak O
NUM O
, O
RARE O
- O
ray O
RARE O
ratio O
, O
M O
- O
mode O
RARE O
end O
- O
diastolic O
diameter O
and O
right O
- O
RARE O
RARE O
RARE O
parameters O
. O

Nuclear O
hormone O
receptors O
( O
RARE O
) O
are O
RARE O
- O
inducible O
transcription O
factors O
that O
mediate O
critical O
functions O
in O
many O
species O
. O

These O
cells O
were O
able O
to O
present O
RARE O
virus O
RARE O
to O
HLA I-GENE
- I-GENE
NUM I-GENE
- O
restricted O
T O
cell O
RARE O
. O

Sequencing O
of O
RARE O
( O
RARE O
RARE O
) O
bacterial O
artificial O
RARE O
and O
P1 O
artificial O
RARE O
genomic O
clone O
fragments O
and O
of O
cDNA O
RARE O
has O
led O
to O
the O
identification O
of O
five O
new O
loci O
coding O
RARE O
beta O
subunits O
of O
RARE O
( O
ALL_CAP I-GENE
). O

In O
addition O
to O
RARE O
of O
the O
human I-GENE
genes I-GENE
NUM I-GENE
through O
NUM I-GENE
, O
two O
new O
genes O
, O
NUM I-GENE
and O
NUM I-GENE
, O
have O
been O
found O
RARE O
which O
there O
are O
RARE O
known O
corresponding O
genes O
in O
humans O
. O

It O
RARE O
RARE O
' O
s O
RARE O
RARE O
, O
which O
attempts O
to O
RARE O
the O
biological O
and O
RARE O
models O
of O
RARE O
sexual O
and O
reproductive O
behaviour O
. O

RARE O
and O
height O
z O
- O
scores O
were O
significantly O
associated O
with O
BMD O
z O
- O
scores O
. O

A O
limited O
sampling O
strategy O
was O
used O
based O
on O
a O
RARE O
parameter O
estimation O
algorithm O
that O
is O
part O
of O
the O
ALL_CAP O
II O
RARE O
RARE O
. O

Interaction O
of O
ALL_CAP I-GENE
with O
NUM I-GENE
was O
required O
RARE O
the O
transformation O
of O
ALL_CAP I-GENE
, O
RARE O
the O
NUM I-GENE
antagonist O
RARE O
acid O
inhibited O
the O
folding O
of O
ALL_CAP I-GENE
into O
a O
RARE O
- O
competent O
conformation O
. O

The O
amino O
acid O
changes O
NUM O
and O
NUM O
RARE O
RARE O
or O
in O
combination O
the O
RARE O
activity O
in O
vivo O
. O

Previous O
experimental O
evidence O
had O
indicated O
that O
NUM I-GENE
might O
target O
NUM I-GENE
to O
nuclear O
RARE O
such O
RARE O
the O
NUM I-GENE
kinase I-GENE
complex I-GENE
. O

In O
the O
RARE O
yeast O
, O
Saccharomyces O
cerevisiae O
, O
RARE O
can O
function O
outside O
the O
RARE O
RARE O
RARE O
RARE O
sequence O
( O
ALL_CAP O
) O
elements O
; O
however O
, O
within O
RARE O
III O
, O
certain O
RARE O
near O
the O
transcriptionally O
RARE O
ALL_CAP I-GENE
locus I-GENE
show O
RARE O
replication O
origin O
activity O
. O

These O
results O
suggest O
that O
, O
RARE O
the O
ALL_CAP I-GENE
ALL_CAP O
cluster O
( O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
RARE O
RARE O
of O
origins O
is O
independent O
of O
local O
transcriptional O
silencing O
, O
even O
though O
origins O
and O
RARE O
share O
key O
cis O
- O
and O
RARE O
- O
acting O
RARE O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
IkappaBalpha I-GENE
blocked O
phorbol O
myristate O
RARE I-GENE
- I-GENE
phytohemagglutinin I-GENE
or O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
- O
RARE O
IkappaBalpha I-GENE
gene I-GENE
transcription O
and O
abolished O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
DNA O
binding O
activity O
, O
due O
to O
the O
continued O
cytoplasmic O
RARE O
of O
ALL_CAP I-GENE
( O
NUM I-GENE
) O
by O
ALL_CAP I-GENE
- I-GENE
IkappaBalpha I-GENE
. O

( O
i O
) O
RARE O
NUM I-GENE
RARE O
from O
cDNA O
with O
an O
ecdysone O
- O
regulated O
transient O
RARE O
RARE O
RARE O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
RARE O
IGF I-GENE
- I-GENE
I I-GENE
, O
and O
insulin I-GENE
- O
but O
not O
RARE I-GENE
growth I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
)- O
RARE O
DNA O
RARE O
in O
an O
ecdysone O
dose O
- O
responsive O
fashion O
. O

The O
analysis O
of O
two O
distinct O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathways O
shows O
that O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
- O
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
activation O
, O
resulting O
in O
the O
RARE O
of O
ATF I-GENE
- I-GENE
2 I-GENE
, O
c I-GENE
- I-GENE
Jun I-GENE
, O
and O
ALL_CAP I-GENE
, O
is O
required O
not O
only O
RARE O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
- O
but O
also O
RARE O
the O
ALL_CAP O
- O
dependent O
induction O
, O
while O
the O
extracellular I-GENE
signal I-GENE
- I-GENE
related I-GENE
kinase I-GENE
1 I-GENE
( O
ERK I-GENE
- I-GENE
1 I-GENE
) O
and O
ERK I-GENE
- I-GENE
2 I-GENE
activation O
is O
involved O
in O
the O
ALL_CAP O
- O
but O
not O
in O
the O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
- O
dependent O
RARE O
of O
the O
uPA I-GENE
enhancer I-GENE
. O

CONCLUSIONS O
: O
In O
healthy O
individuals O
, O
whole O
body O
insulin I-GENE
sensitivity O
is O
related O
, O
or O
" O
coupled O
, O
" O
to O
the O
anaerobic O
threshold O
. O

RARE O
RARE O
in O
a O
two O
- O
domain O
fragment O
of O
the O
human I-GENE
glucocorticoid I-GENE
receptor I-GENE
. O

In O
contrast O
, O
the O
ALL_CAP I-GENE
( O
RARE I-GENE
) O
gene O
needs O
the O
binding O
of O
the O
RARE O
RARE I-GENE
zinc I-GENE
RARE I-GENE
, O
but O
not O
Oct I-GENE
- I-GENE
1 I-GENE
, O
RARE O
optimal O
transcriptional O
capacity O
. O

Collectively O
, O
these O
results O
show O
that O
the O
differential O
utilization O
of O
RARE I-GENE
zinc I-GENE
finger I-GENE
1 I-GENE
represents O
a O
new O
, O
critical O
determinant O
of O
the O
transcriptional O
activation O
mechanism O
RARE O
the O
Xenopus I-GENE
tRNA I-GENE
( O
RARE I-GENE
) O
and O
human I-GENE
U6 I-GENE
ALL_CAP I-GENE
genes I-GENE
. O

In O
B O
cells O
, O
HEF1 I-GENE
is O
RARE O
by O
a O
RARE O
- O
dependent O
mechanism O
that O
is O
triggered O
by O
integrin I-GENE
ligation O
. O

The O
calcitonin I-GENE
- O
RARE O
tyrosine O
RARE O
of O
HEF1 I-GENE
increased O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
. O

RARE O
RARE O
muscle O
RARE O
increased O
ALL_CAP O
, O
RARE O
( O
peak O
increase O
NUM O
%, O
P O
< O
NUM O
. O
05 O
RARE O
did O
not O
change O
RARE O
, O
and O
decreased O
RARE O
( O
peak O
decrease O
of O
NUM O
%, O
P O
< O
NUM O
. O
05 O
). O

We O
report O
the O
RARE O
of O
an O
RARE O
1 O
. O
7 O
- O
Mb O
sequence O
- O
RARE O
YAC O
/ O
ALL_CAP O
clone O
contig O
of O
NUM O
- O
NUM O
. O

The O
human I-GENE
NUM I-GENE
and O
mouse I-GENE
NUM I-GENE
mRNA I-GENE
transcripts I-GENE
, O
like O
many O
repair O
proteins O
, O
are O
highly O
RARE O
in O
the O
RARE O
. O

Analysis O
of O
the O
mouse I-GENE
ALL_CAP I-GENE
gene I-GENE
isolated O
from O
the O
genomic O
library O
revealed O
that O
the O
ALL_CAP I-GENE
gene I-GENE
spans O
a O
region O
of O
over O
11 O
kb O
and O
comprises O
eight O
exons O
. O

A O
RARE O
RARE O
distribution O
and O
RARE O
cell O
density O
were O
observed O
RARE O
the O
RARE O
aged O
. O

After O
10 O
months O
of O
treatment O
with O
the O
conjugated O
estrogen O
, O
both O
RARE O
height O
and O
RARE O
showed O
improvement O
, O
while O
RARE O
bone O
mineral O
density O
and O
bone O
age O
were O
increased O
. O

RARE O
experiments O
on O
the O
catalytic O
fragment O
kinase O
reaction O
demonstrated O
that O
the O
chemical O
( O
RARE O
transfer O
) O
step O
had O
a O
RARE O
rate O
. O

RARE O
sedimentation O
, O
cross O
- O
linking O
, O
and O
immunoprecipitation O
analyses O
of O
detergent O
- O
RARE O
rat O
brain O
revealed O
that O
the O
NUM O
and O
NUM O
kDa O
polypeptides O
reside O
within O
RARE O
. O

In O
vitro O
RARE O
levels O
of O
the O
different O
plasmids O
differed O
by O
RARE O
much O
RARE O
RARE O
. O

In O
EEG O
only O
single O
slow O
waves O
above O
RARE O
temporal O
region O
were O
revealed O
. O

Molecular O
characterization O
of O
type O
- O
specific O
RARE O
RARE O
biosynthesis O
genes O
of O
RARE O
RARE O
type O
RARE O
. O

( O
1998 O
) O
ALL_CAP O
ALL_CAP O
. O

ALL_CAP I-GENE
- I-GENE
1beta I-GENE
( O
10 O
RARE O
/ O
ml O
) O
RARE O
increased O
both O
ALL_CAP I-GENE
and O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
delta I-GENE
( O
C I-GENE
/ I-GENE
RARE I-GENE
) O
mRNA O
levels O
in O
a O
time O
dependent O
manner O
. O

The O
recruitment O
of O
constitutively O
RARE O
NUM I-GENE
( O
neu I-GENE
) O
and O
the O
activated O
mitogenic O
RARE O
proteins O
to O
this O
membrane O
- O
RARE O
interaction O
site O
provides O
a O
physical O
model O
RARE O
RARE O
the O
assembly O
of O
the O
mitogenic O
RARE O
with O
the O
RARE O
of O
growth O
factor O
signal O
to O
the O
RARE O
. O

Transient O
tyrosine O
RARE O
of O
Crk I-GENE
in O
fibroblast I-GENE
growth I-GENE
factor I-GENE
- I-GENE
2 I-GENE
- O
RARE O
endothelial O
cells O
was O
dependent O
on O
the O
RARE O
tyrosine O
RARE O
NUM O
in O
FGFR I-GENE
- I-GENE
1 I-GENE
, O
and O
a O
Crk I-GENE
NUM I-GENE
domain I-GENE
precipitated O
FGFR I-GENE
- I-GENE
1 I-GENE
via O
RARE O
RARE O
- O
NUM O
, O
indicating O
direct O
complex O
formation O
between O
Crk I-GENE
and O
FGFR I-GENE
- I-GENE
1 I-GENE
. O

ECG O
- O
gated O
RARE O
RARE O
- O
99m O
RARE O
SPECT O
is O
a O
useful O
technique O
to O
measure O
RARE O
perfusion O
and O
function O
simultaneously O
. O

Role O
of O
the O
3 O
' O
RARE O
region O
of O
RARE I-GENE
NUM I-GENE
mRNA I-GENE
in O
high O
- O
level O
RARE O
of O
foreign O
genes O
. O

The O
intron O
RNA O
consists O
of O
NUM O
nucleotides O
which O
can O
be O
folded O
into O
a O
secondary O
RARE O
with O
all O
the O
expected O
sequence O
motifs O
of O
subgroup O
- O
NUM O
RARE O
( O
RARE O
et O
al O
. O

The O
intron O
is O
capable O
of O
RARE O
despite O
the O
fact O
that O
both O
the O
NUM I-GENE
/ O
NUM I-GENE
and O
the O
NUM I-GENE
/ O
NUM I-GENE
sequence O
motifs O
, O
thought O
to O
be O
necessary O
RARE O
correct O
RARE O
, O
extend O
over O
5 O
instead O
of O
6 O
bp O
. O

The O
RARE I-GENE
/ I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
receptor I-GENE
mediates O
the O
rapid O
activation O
of O
a O
number O
of O
RARE O
RARE O
proteins O
, O
including O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
( O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
). O

The O
RARE O
of O
significance O
testing O
: O
RARE O
and O
RARE O
. O

Chemical O
uptake O
into O
human O
RARE O
RARE O
in O
vivo O
from O
volatile O
and O
non O
- O
volatile O
RARE O
. O

Like O
DNA O
binding O
, O
transcriptional O
enhancement O
required O
amino O
- O
RARE O
RARE O
basic O
amino O
acid O
residues O
but O
not O
the O
RARE O
- O
terminal O
portion O
of O
NUM I-GENE
known O
to O
participate O
in O
hsp70 I-GENE
interaction O
. O

We O
have O
tested O
the O
function O
of O
two O
RARE O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
like I-GENE
sites I-GENE
present O
in O
the O
PAI I-GENE
- I-GENE
2 I-GENE
proximal I-GENE
promoter I-GENE
RARE O
responsiveness O
to O
RARE I-GENE
using O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
reporter I-GENE
gene I-GENE
deletion O
and O
mutation O
analyses O
. O

N O
- O
terminal O
sequence O
analysis O
and O
NMR O
measurements O
revealed O
that O
this O
fragment O
RARE O
from O
the O
C O
- O
terminal O
NUM O
residues O
of O
NUM I-GENE
and O
form O
a O
RARE O
structured O
C O
- O
terminal O
domain O
of O
NUM I-GENE
, O
NUM I-GENE
. O

The O
RARE O
response O
associated O
with O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
induction O
is O
RARE O
via O
RARE O
MAP I-GENE
kinase I-GENE
RARE I-GENE
: O
NUM I-GENE
RARE O
a O
RARE O
histone I-GENE
NUM I-GENE
/ O
HMG I-GENE
- I-GENE
14 I-GENE
kinase O
. O

The O
arrangement O
of O
these O
cutoff O
- O
levels O
leads O
to O
a O
sensitivity O
of O
NUM O
% O
RARE O
a O
RARE O
of O
NUM O
% O
RARE O
Protein I-GENE
NUM I-GENE
when O
measured O
by O
ALL_CAP O
, O
and O
to O
a O
sensitivity O
of O
77 O
% O
RARE O
a O
RARE O
of O
NUM O
% O
when O
measured O
by O
ALL_CAP O
. O

272 O
, O
NUM O
]. O

Using O
16 O
strains O
of O
C O
. O
RARE O
in O
RARE O
assays O
, O
we O
found O
the O
RT O
- O
PCR O
method O
consistently O
more O
RARE O
than O
the O
conventional O
technique O
RARE O
all O
eight O
RARE O
tested O
, O
with O
RARE O
MICs O
determined O
by O
RT O
- O
PCR O
ranging O
from O
1 O
. O
6 O
- O
RARE O
RARE O
( O
RARE O
) O
to O
>/= O
NUM O
- O
RARE O
RARE O
( O
amoxicillin O
). O

RARE O
alleles O
of O
NUM I-GENE
and O
NUM I-GENE
RARE O
the O
role O
of O
the O
NUM I-GENE
binding I-GENE
site I-GENE
of O
the O
HMR I-GENE
- I-GENE
E I-GENE
RARE I-GENE
but O
not O
the O
role O
of O
the O
ALL_CAP I-GENE
or O
NUM I-GENE
binding I-GENE
site I-GENE
. O

Recent O
RARE O
analysis O
has O
revealed O
that O
the O
S I-GENE
locus I-GENE
is O
highly O
polymorphic O
and O
contains O
several O
genes O
, O
i O
. O
RARE O
., O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
the O
RARE O
- O
yet O
- O
unidentified O
pollen O
S O
gene O
( O
s O
RARE O
and O
other O
RARE O
genes O
. O

A O
cDNA O
encoding O
a O
putative O
RNA I-GENE
and I-GENE
/ I-GENE
or I-GENE
DNA I-GENE
RARE I-GENE
has O
been O
isolated O
from O
Arabidopsis O
thaliana O
cDNA O
libraries O
. O

In O
vivo O
, O
MyoD I-GENE
requires O
this O
RARE O
motif O
to O
RARE O
chromatin O
remodeling O
in O
the O
RARE I-GENE
promoter I-GENE
and O
to O
activate O
RARE I-GENE
transcription O
. O

RESULTS O
: O
256 O
RARE O
of O
ALL_CAP O
or O
ALL_CAP O
were O
reported O
by O
men O
and O
NUM O
by O
women O
. O

RARE O
intake O
and O
ALL_CAP O
RARE O
were O
decreased O
( O
P O
< O
NUM O
. O
05 O
) O
by O
dietary O
treatments O
containing O
M O
. O

The O
N O
terminus O
of O
beta O
( O
NUM O
kDa O
) O
corresponds O
to O
alpha O
with O
the O
integrase I-GENE
domain I-GENE
attached O
to O
the O
C O
terminus O
( O
NUM O
kDa O
). O

RARE I-GENE
- I-GENE
NUM I-GENE
RARE O
the O
C O
- O
terminal O
region O
completely O
lost O
RARE O
ability O
, O
irrespective O
of O
the O
promoter O
tested O
, O
and O
was O
able O
to O
RARE O
RARE O
by O
normal O
RARE I-GENE
- I-GENE
NUM I-GENE
in O
competition O
assays O
. O

In O
early O
Xenopus O
RARE O
, O
the O
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
RARE O
activin I-GENE
induces O
the O
gene I-GENE
RARE I-GENE
. I-GENE
2 I-GENE
by O
stimulating O
the O
formation O
of O
a O
RARE O
complex O
, O
activin I-GENE
- I-GENE
responsive I-GENE
factor I-GENE
( O
ARF I-GENE
). O

To O
further O
characterize O
the O
RARE O
and O
evolutionary O
RARE O
of O
the O
NUM O
- O
ALL_CAP O
repeat O
, O
RARE O
in O
situ O
hybridization O
( O
ALL_CAP O
) O
analysis O
and O
heterologous O
PCR O
- O
based O
assays O
were O
carried O
out O
RARE O
a O
series O
of O
primates O
. O

RARE O
. O

In O
the O
face O
of O
the O
outbreak O
, O
there O
was O
a O
delay O
before O
vaccination O
was O
able O
to O
stop O
deaths O
. O

Here O
we O
show O
that O
a O
novel O
isoform O
of O
RARE I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
, O
called O
NUM I-GENE
, O
binds O
specifically O
to O
the O
alpha O
- O
subunits O
of O
the O
G I-GENE
( I-GENE
i I-GENE
) I-GENE
family I-GENE
of O
heterotrimeric I-GENE
G I-GENE
- I-GENE
proteins I-GENE
. O

The O
B O
- O
RARE O
of O
RARE I-GENE
RARE I-GENE
RARE O
ALL_CAP I-GENE
RARE I-GENE
receptor I-GENE
5 I-GENE
and O
blocks O
entry O
of O
M O
- O
RARE O
HIV O
- O
1 O
strains O
. O

Cross O
- O
linking O
the O
B I-GENE
cell I-GENE
RARE I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
) O
to O
surface I-GENE
Fc I-GENE
receptors I-GENE
RARE O
IgG I-GENE
( O
Fc I-GENE
gamma I-GENE
R I-GENE
) O
inhibits O
G1 O
- O
to O
- O
S O
progression O
; O
the O
mechanism O
by O
which O
this O
occurs O
is O
not O
completely O
known O
. O

Cross O
- O
linking O
the O
B I-GENE
cell I-GENE
RARE I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
) O
to O
surface I-GENE
Fc I-GENE
receptors I-GENE
RARE O
IgG I-GENE
( O
Fc I-GENE
gamma I-GENE
R I-GENE
) O
inhibits O
G1 O
- O
to O
- O
S O
progression O
; O
the O
mechanism O
by O
which O
this O
occurs O
is O
not O
completely O
known O
. O

TRAF2 I-GENE
is O
a O
potent O
activator O
of O
a O
NUM I-GENE
- I-GENE
kDa I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
termed O
RARE I-GENE
RARE I-GENE
kinase I-GENE
related I-GENE
( O
ALL_CAP I-GENE
, O
also O
referred O
to O
RARE O
NUM I-GENE
RARE O
which O
signals O
activation O
of O
the O
SAPK I-GENE
RARE O
. O

An O
activation O
- O
responsive O
element O
in O
single I-GENE
C I-GENE
motif I-GENE
- I-GENE
1 I-GENE
/ O
RARE I-GENE
promoter O
is O
a O
site O
of O
RARE O
and O
inducible O
DNA O
- O
protein O
interactions O
involving O
nuclear O
factor O
of O
activated O
T O
cell O
. O

RARE O
- O
RARE O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
DNA O
binding O
activity O
, O
ALL_CAP I-GENE
nuclear O
translocation O
, O
I I-GENE
RARE I-GENE
B I-GENE
alpha I-GENE
RARE O
, O
I I-GENE
RARE I-GENE
B I-GENE
serine O
NUM O
RARE O
, O
and O
I I-GENE
RARE I-GENE
B I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
activity O
were O
blocked O
by O
RARE O
treatment O
. O

A O
portion O
of O
NUM I-GENE
is O
nuclear O
and O
localizes O
to O
the O
RARE O
RARE O
. O

The O
main O
issues O
are O
the O
need O
to O
explain O
a O
number O
of O
still O
unknown O
mechanisms O
, O
to O
determine O
which O
" O
RARE O
diet O
" O
carries O
the O
minimum O
coronary O
risk O
and O
whether O
" O
new O
" O
RARE O
produced O
by O
modern O
technology O
are O
RARE O
needed O
to O
contrast O
this O
epidemic O
. O

Cotransfection O
of O
the O
RARE O
CREB I-GENE
- I-GENE
binding I-GENE
protein I-GENE
RARE O
the O
transcriptional O
repression O
of O
RARE I-GENE
by O
RARE I-GENE
, O
suggesting O
that O
the O
dominant O
negative O
effect O
of O
RARE I-GENE
might O
occur O
through O
competition O
RARE O
essential O
RARE O
. O

ALL_CAP I-GENE
- I-GENE
1 I-GENE
does O
not O
have O
an O
N O
- O
terminal O
NUM O
domain O
. O

To O
estimate O
the O
locations O
of O
sources O
with O
the O
ALL_CAP O
- O
ALL_CAP O
algorithm O
, O
we O
RARE O
set O
the O
target O
region O
on O
the O
RARE O
of O
the O
RARE O
responses O
. O

We O
discuss O
these O
results O
in O
terms O
of O
the O
influence O
that O
time O
and O
nutritional O
RARE O
have O
on O
RARE O
development O
patterns O
and O
fitness O
. O

OBJECTIVE O
: O
1998 O
RARE O
, O
RARE O
, O
and O
RARE O
Results O
( O
ALL_CAP O
) O
data O
estimate O
an O
NUM O
. O
1 O
% O
5 O
- O
year O
survival O
rate O
RARE O
RARE O
RARE O
adenocarcinoma O
ALL_CAP O
RARE O
II O
. O

A O
novel O
Drosophila I-GENE
A I-GENE
kinase I-GENE
RARE I-GENE
protein I-GENE
, O
Drosophila I-GENE
A I-GENE
kinase I-GENE
RARE I-GENE
protein I-GENE
NUM I-GENE
( O
NUM I-GENE
RARE O
is O
predicted O
to O
be O
involved O
in O
RARE O
, O
mediating O
, O
and O
RARE O
signals O
carried O
by O
cAMP O
, O
Ca O
( O
2 O
+), O
and O
RARE O
( O
Li O
, O
Z O
., O
RARE O
, O
E O
. O

In O
vitro O
transcription O
results O
indicate O
that O
this O
5 O
' O
RARE O
functions O
in O
the O
RARE O
mechanism O
, O
since O
deletion O
of O
the O
RARE O
- O
loop O
caused O
an O
increase O
in O
transcription O
readthrough O
. O

A O
5 O
' O
RNA O
RARE O
- O
loop O
participates O
in O
the O
transcription O
RARE O
mechanism O
that O
controls O
RARE O
of O
the O
Bacillus I-GENE
subtilis I-GENE
ALL_CAP I-GENE
operon I-GENE
. O

RARE O
- O
alanine O
- O
substitution O
mutations O
had O
minimal O
, O
if O
any O
, O
effects O
on O
S O
- O
RARE O
cell O
- O
to O
- O
cell O
fusion O
. O

Furthermore O
, O
we O
demonstrate O
that O
transcription O
from O
the O
ALL_CAP I-GENE
5 I-GENE
' I-GENE
LTR I-GENE
is O
highly O
RARE O
in O
the O
absence O
of O
Stat5a I-GENE
, O
a O
transcription O
factor O
that O
had O
been O
shown O
previously O
to O
be O
required O
RARE O
transcription O
from O
the O
ALL_CAP I-GENE
LTR I-GENE
. O

RARE O
RARE O
mutagenesis O
of O
specific O
genes O
on O
the O
NUM I-GENE
/ O
NUM I-GENE
locus O
of O
Arabidopsis O
thaliana O
RARE O
5 O
using O
the O
RARE I-GENE
/ O
RARE I-GENE
RARE O
in O
combination O
with O
the O
cDNA O
scanning O
method O
. O

RESULTS O
: O
ALL_CAP I-GENE
- O
MB I-GENE
elevation O
was O
detected O
in O
NUM O
patients O
( O
18 O
. O
7 O
%), O
with O
1 O
- O
NUM O
in O
12 O
. O
8 O
%, O
3 O
- O
NUM O
in O
3 O
. O
5 O
% O
and O
> O
NUM O
normal O
in O
2 O
. O
4 O
% O
of O
patients O
. O

Thus O
, O
ALL_CAP O
- O
R O
performance O
may O
not O
be O
a O
RARE O
estimate O
of O
baseline O
ALL_CAP O
RARE O
patients O
with O
neurologic O
disorders O
with O
suspected O
language O
impairment O
. O

RARE O
areas O
have O
been O
identified O
by O
means O
of O
cross O
- O
correlation O
analysis O
. O

RARE O
Haemophilus O
influenzae O
type O
b O
RARE O
RARE O
antibodies O
in O
NUM O
infants O
and O
children O
from O
RARE O
RARE O
( O
RARE O
- O
RARE O
) O
and O
RARE O
: O
a O
cross O
- O
sectional O
RARE O
. O

In O
this O
study O
, O
we O
identified O
NUM I-GENE
and O
Sp3 I-GENE
RARE O
major O
factors O
binding O
to O
the O
NUM I-GENE
sites I-GENE
of O
the O
p21 I-GENE
/ O
WAF1 I-GENE
/ O
Cip1 I-GENE
promoter O
in O
NUM O
cells O
through O
electrophoretic O
mobility O
shift O
assays O
and O
showed O
that O
ALL_CAP O
treatment O
did O
not O
change O
their O
binding O
activities O
. O

RARE O
has O
RARE O
the O
results O
of O
RARE O
discovery O
of O
RARE O
RARE O
. O

To O
study O
the O
RARE O
of O
its O
RARE O
, O
the O
human I-GENE
RARE I-GENE
reductase I-GENE
gene I-GENE
and O
promoter O
were O
RARE O
and O
characterized O
. O

RARE O
staining O
with O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
and O
p53 I-GENE
antibodies I-GENE
showed O
low O
(< O
1 O
%) O
and O
negative O
reaction O
. O

The O
NUM I-GENE
- O
RARE I-GENE
is O
encoded O
RARE O
a O
RARE O
of O
NUM O
amino O
RARE O
containing O
a O
putative O
chloroplast O
- O
targeting O
signal O
of O
65 O
amino O
RARE O
RARE O
its O
N O
- O
terminus O
. O

RARE O
before O
surgery O
patients O
received O
either O
intravenous O
RARE O
NUM O
mg O
or O
placebo O
in O
random O
, O
double O
- O
blind O
order O
. O

A O
tyrosine O
- O
based O
RARE O
signal O
in O
the O
NUM I-GENE
integrin I-GENE
cytoplasmic I-GENE
domain I-GENE
mediates O
its O
RARE O
to O
the O
plasma O
membrane O
and O
is O
required O
RARE O
RARE O
- O
supported O
migration O
. O

The O
injection O
of O
NUM I-GENE
protein I-GENE
into O
RARE O
Xenopus O
eggs O
blocked O
RARE O
cell O
division O
. O

Using O
transgenic O
Xenopus O
RARE O
, O
we O
demonstrate O
that O
the O
integrity O
of O
these O
two O
sequences O
is O
necessary O
RARE O
correct O
spatial O
RARE O
of O
a O
NUM I-GENE
promoter I-GENE
- I-GENE
RARE I-GENE
reporter I-GENE
gene I-GENE
. O

In O
order O
to O
screen O
RARE O
such O
RARE O
, O
we O
have O
used O
a O
transcriptionally O
inactive O
mutant O
of O
Xenopus I-GENE
NUM I-GENE
in O
a O
yeast O
two O
- O
RARE O
screen O
. O

NUM I-GENE
has O
an O
apparent O
RARE O
mass O
of O
1 O
. O
3 O
RARE O
. O

NUM I-GENE
transcription O
is O
negatively O
regulated O
by O
RARE O
fatty O
RARE O
and O
oxygen O
. O

Two O
patients O
with O
recurrent O
tumors O
had O
high O
S O
- O
RARE O
fractions O
both O
on O
the O
RARE O
RARE O
specimens O
and O
RARE O
the O
time O
of O
the O
second O
operation O
. O

Mutation O
of O
TTF I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
1 I-GENE
, I-GENE
3 I-GENE
, I-GENE
and I-GENE
4 I-GENE
in O
combination O
markedly O
decreased O
transcriptional O
activity O
of O
SP I-GENE
- I-GENE
A I-GENE
promoter O
- O
chloramphenicol I-GENE
RARE I-GENE
constructs O
containing O
SP I-GENE
- I-GENE
A I-GENE
gene I-GENE
sequences O
from O
- O
256 O
to O
+ O
NUM O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
I I-GENE
induces O
bcl I-GENE
- I-GENE
2 I-GENE
promoter I-GENE
through O
the O
transcription O
factor O
cAMP I-GENE
- I-GENE
response I-GENE
element I-GENE
- I-GENE
binding I-GENE
protein I-GENE
. O

RARE O
of O
RARE O
RNA O
and O
S O
RARE O
- O
dependent O
binding O
of O
E2F I-GENE
complexes I-GENE
in O
intron O
1 O
. O

Identification O
of O
RARE I-GENE
- I-GENE
3 I-GENE
will O
further O
promote O
our O
understanding O
of O
the O
control O
of O
eosinophil O
trafficking O
and O
other O
NUM I-GENE
- O
RARE O
biological O
phenomena O
. O

ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
plays O
a O
critical O
role O
in O
activation O
of O
HIV O
- O
1 O
gene O
RARE O
by O
RARE O
and O
other O
stimuli O
, O
but O
the O
signal O
RARE O
pathways O
that O
regulate O
the O
switch O
from O
latent O
to O
RARE O
infection O
have O
not O
been O
defined O
. O

These O
studies O
suggest O
that O
ALL_CAP I-GENE
acts O
by O
stimulating O
AP I-GENE
- I-GENE
1 I-GENE
and O
a O
subsequent O
physical O
and O
RARE O
interaction O
of O
AP I-GENE
- I-GENE
1 I-GENE
with O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
, O
resulting O
in O
a O
complex O
that O
synergistically O
transactivates O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
. O

ERK I-GENE
MAP I-GENE
kinase I-GENE
links O
RARE O
signals O
to O
activation O
of O
latent O
HIV O
- O
1 O
infection O
by O
stimulating O
a O
cooperative O
interaction O
of O
AP I-GENE
- I-GENE
1 I-GENE
and O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
. O

A O
human O
nuclear O
- O
localized O
RARE O
that O
regulates O
RARE O
, O
DNA O
binding O
, O
and O
transcriptional O
activity O
of O
ALL_CAP I-GENE
proteins I-GENE
. O

Clinical O
differentiation O
of O
patients O
with O
mild O
RARE O
cerebral O
RARE O
( O
CP O
) O
and O
idiopathic O
toe O
RARE O
( O
ALL_CAP O
) O
can O
be O
difficult O
. O

RARE I-GENE
ALL_CAP I-GENE
- I-GENE
8 I-GENE
and O
ALL_CAP I-GENE
were O
significantly O
increased O
after O
ALL_CAP O
in O
both O
ALL_CAP O
- O
and O
RARE O
dust O
- O
asthma O
( O
P O
< O
NUM O
. O
05 O
). O

RARE O
reduces O
airway O
RARE O
inflammation O
in O
asthma O
: O
a O
randomized O
, O
RARE O
trial O
. O

Treatment O
of O
unstable O
angina O
: O
role O
of O
RARE O
therapy O
. O

Here O
, O
we O
demonstrate O
that O
kinase O
- O
RARE O
but O
not O
wild O
- O
type O
forms O
of O
Fyn I-GENE
, O
RARE I-GENE
, O
and O
ALL_CAP I-GENE
- I-GENE
70 I-GENE
RARE O
NUM O
Cbl I-GENE
- O
RARE O
NFAT I-GENE
activation O
. O

RARE O
of O
region O
I O
with O
RARE O
sequences O
showed O
that O
RARE O
specific O
sequence O
but O
rather O
repeats O
of O
three O
or O
more O
consecutive O
RARE O
or O
RARE O
, O
without O
RARE O
by O
guanine O
or O
cytosine O
, O
are O
required O
RARE O
the O
ALL_CAP O
activity O
. O

In O
Saccharomyces O
cerevisiae O
, O
NUM I-GENE
encodes O
a O
RARE I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
Cdk I-GENE
) O
catalytic O
subunit O
with O
multiple O
regulatory O
roles O
thought O
to O
be O
specified O
by O
association O
with O
different O
RARE I-GENE
partners O
( O
RARE I-GENE
). O

RARE O
with O
mild O
RARE I-GENE
alleles I-GENE
grow O
to O
become O
adults O
with O
multiple O
aberrant O
RARE O
in O
the O
RARE O
, O
compound O
eye O
, O
and O
RARE O
. O

In O
fact O
, O
ALL_CAP I-GENE
activity O
in O
the O
RARE O
expressing O
RARE O
- O
RARE O
RARE I-GENE
was O
absorbed O
by O
RARE O
- O
specific O
antibody O
. O

Mutations O
of O
the O
RET I-GENE
gene I-GENE
, O
encoding O
a O
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
, O
have O
been O
associated O
with O
the O
inherited O
RARE O
syndromes O
ALL_CAP O
NUM O
and O
ALL_CAP O
NUM O
. O

These O
results O
show O
that O
targeting O
of O
Ras I-GENE
- O
ALL_CAP I-GENE
could O
represent O
a O
novel O
RARE O
approach O
. O

ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
a O
tyrosine I-GENE
kinase I-GENE
signal I-GENE
RARE I-GENE
gene I-GENE
, O
is O
transcriptionally O
activated O
in O
the O
t O
( O
1 O
; O
19 O
) O
subset O
of O
pre O
- O
B O
ALL O
, O
which O
express O
RARE O
NUM I-GENE
- O
NUM I-GENE
. O

Protein I-GENE
kinase I-GENE
A I-GENE
- I-GENE
RARE I-GENE
subunit O
- O
directed O
RARE O
inhibition O
of O
ovarian O
RARE O
cell O
growth O
: O
RARE O
with O
tyrosine I-GENE
kinase I-GENE
RARE O
RARE O
. O

NUM I-GENE
encodes O
a O
ALL_CAP I-GENE
/ I-GENE
RARE I-GENE
finger I-GENE
protein I-GENE
, O
a O
RARE O
similar O
to O
that O
of O
many O
Drosophila O
developmental O
RARE O
and O
to O
another O
protein O
involved O
in O
a O
human O
hematopoietic O
malignancy O
, O
PLZF I-GENE
. O

RARE I-GENE
1 I-GENE
integrin I-GENE
- O
and O
RARE O
- O
RARE O
RARE O
of O
T O
lymphoma O
cell O
adhesion O
and O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
RARE O
by O
RARE I-GENE
- I-GENE
1 I-GENE
and O
RARE I-GENE
- I-GENE
1 I-GENE
peptides I-GENE
. O

RARE O
CD O
, O
and O
spectral O
and O
activity O
analyses O
were O
used O
to O
examine O
reactivity O
of O
ALL_CAP I-GENE
RARE I-GENE
with O
ALL_CAP O
species O
produced O
by O
ALL_CAP O
donors O
. O

The O
RARE O
RARE O
( O
ALL_CAP O
) O
of O
RARE O
RARE O
identification O
and O
biochemical O
analysis O
of O
a O
RARE I-GENE
RARE I-GENE
protein I-GENE
RARE I-GENE
encoded O
by O
the O
gene O
ALL_CAP I-GENE
. O

Serum O
concentrations O
of O
bone I-GENE
specific I-GENE
RARE I-GENE
phosphatase I-GENE
( O
ALL_CAP I-GENE
) O
and O
RARE I-GENE
( O
bone I-GENE
RARE I-GENE
protein I-GENE
, O
ALL_CAP I-GENE
RARE O
RARE O
levels O
of O
RARE O
( O
RARE O
) O
and O
RARE O
( O
RARE O
) O
and O
computed O
tomography O
( O
ALL_CAP O
) O
measurements O
of O
the O
cross O
- O
sectional O
areas O
of O
the O
RARE O
and O
the O
RARE O
, O
the O
apparent O
density O
of O
RARE O
bone O
in O
the O
RARE O
, O
and O
the O
volume O
and O
the O
material O
density O
of O
cortical O
bone O
in O
the O
RARE O
were O
determined O
in O
126 O
boys O
and O
NUM O
girls O
, O
ages O
7 O
- O
18 O
years O
. O

In O
another O
study O
, O
intravenous O
administration O
of O
RARE O
, O
a O
specific O
RARE I-GENE
- I-GENE
A I-GENE
receptor I-GENE
antagonist O
, O
RARE O
a O
dose O
of O
NUM O
. O
1 O
mg O
/ O
kg O
/ O
hr O
was O
RARE O
NUM O
min O
before O
RARE O
saline O
intake O
and O
continued O
RARE O
1 O
hr O
. O

This O
cluster O
consisted O
of O
four O
apparently O
unrelated O
RARE O
and O
two O
genes O
, O
RARE I-GENE
- I-GENE
associated I-GENE
plasma I-GENE
protein I-GENE
- I-GENE
A I-GENE
( O
ALL_CAP I-GENE
- I-GENE
A I-GENE
) O
and O
a O
novel O
gene O
( O
tentatively O
named O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
). O

RARE O
value O
of O
a O
RARE O
exercise O
score O
in O
symptomatic O
patients O
with O
nonspecific O
ST O
- O
T O
abnormalities O
on O
resting O
ECG O
. O

Structural O
changes O
in O
the O
C O
- O
terminus O
of O
NUM O
RARE O
RARE O
rat I-GENE
NUM I-GENE
( O
beta I-GENE
beta I-GENE
) O
upon O
binding O
to O
a O
peptide O
derived O
from O
the O
C O
- O
terminal O
regulatory O
domain O
of O
p53 I-GENE
. O

We O
propose O
that O
NUM O
is O
part O
of O
a O
putative O
" O
RARE O
RARE O
" O
involved O
in O
the O
stabilization O
of O
the O
transition O
state O
similar O
to O
the O
C I-GENE
group I-GENE
of O
the O
esterase I-GENE
/ O
lipase I-GENE
family O
. O

The O
solution O
RARE O
of O
the O
RARE O
derived O
from O
the O
RARE O
RARE O
of O
the O
RARE O
region O
RARE O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
) O
RARE O
of O
anti O
- O
11 O
, O
12 O
- O
RARE O
- O
NUM O
, O
14 O
- O
RARE O
- O
11 O
, O
12 O
, O
NUM O
, O
14 O
- O
RARE O
RARE O
g O
] O
RARE O
, O
RARE O
anti O
- O
B O
RARE O
g O
] O
ALL_CAP O
, O
to O
the O
RARE O
N O
( O
6 O
) O
amino O
group O
of O
the O
RARE O
RARE O
NUM O
, O
( O
designated O
RARE O
RARE O
- O
anti O
RARE O
B O
RARE O
g O
] O
C O
) O
NUM O
RARE O
positioned O
opposite O
a O
RARE O
RARE O
NUM O
in O
the O
DNA O
sequence O
context O
d O
( O
C1 O
- O
NUM O
- O
NUM O
- O
T4 O
- O
NUM O
RARE O
B O
RARE O
g O
] O
C O
) O
NUM O
- O
NUM O
- O
NUM O
- O
NUM O
- O
NUM O
- O
NUM O
). O
d O
( O
NUM O
- O
NUM O
- O
NUM O
- O
NUM O
- O
NUM O
- O
NUM O
- O
NUM O
- O
NUM O
- O
NUM O
RARE O
RARE O
NUM O
- O
NUM O
) O
( O
designated O
( O
B O
RARE O
g O
] O
C O
) O
ALL_CAP O
. O
dT O
11 O
- O
RARE O
duplex O
RARE O
has O
been O
studied O
using O
structural O
RARE O
derived O
from O
NMR O
data O
in O
combination O
with O
RARE O
dynamics O
( O
ALL_CAP O
) O
RARE O
. O

Since O
RARE O
RARE O
on O
the O
RARE O
, O
it O
seems O
that O
the O
place O
of O
ALL_CAP O
is O
RARE O
because O
comparative O
studies O
give O
better O
results O
RARE O
RARE O
than O
ALL_CAP O
( O
70 O
% O
RARE O
40 O
%) O
and O
of O
course O
with O
a O
better O
RARE O
. O

Serum O
antibodies O
were O
detected O
in O
RARE O
least O
NUM O
% O
of O
the O
RARE O
RARE O
pigs O
between O
4 O
- O
NUM O
ALL_CAP O
and O
rats O
between O
3 O
- O
16 O
ALL_CAP O
. O

During O
both O
RARE O
episodes O
, O
CSF O
protein O
and O
immunoglobulin I-GENE
G I-GENE
( O
IgG I-GENE
) O
levels O
were O
elevated O
without O
an O
increased O
IgG I-GENE
index O
or O
IgG I-GENE
RARE O
rate O
. O

CONCLUSIONS O
: O
These O
results O
show O
that O
once O
daily O
oral O
RARE O
can O
produce O
exposures O
of O
RARE O
( O
NUM O
) O
RARE O
those O
RARE O
using O
intravenous O
RARE O
10 O
mg O
/ O
kg O
. O

RARE O
RARE O
RARE O
of O
RARE O
RARE O
vessels O
RARE O
a O
light O
dose O
of O
NUM O
ALL_CAP O
/ O
cm2 O
, O
RARE O
other O
adverse O
events O
were O
of O
RARE O
. O

RARE O
RARE O
RARE O
of O
RARE O
RARE O
vessels O
RARE O
a O
light O
dose O
of O
NUM O
ALL_CAP O
/ O
cm2 O
, O
RARE O
other O
adverse O
events O
were O
of O
RARE O
. O

The O
healing O
rate O
in O
HIV O
- O
positive O
patients O
was O
NUM O
percent O
after O
14 O
weeks O
and O
NUM O
percent O
after O
NUM O
weeks O
; O
the O
corresponding O
RARE O
RARE O
patients O
with O
acquired O
immunodeficiency O
RARE O
were O
NUM O
and O
50 O
percent O
. O

The O
P I-GENE
mRNA I-GENE
also O
contains O
a O
third O
ORF O
RARE O
the O
V I-GENE
protein I-GENE
, O
although O
it O
is O
unclear O
how O
or O
whether O
this O
ORF O
is O
RARE O
. O

A O
genetic O
screen O
in O
yeast O
has O
allowed O
us O
to O
identify O
a O
novel O
transcriptional O
factor O
binding O
to O
the O
ALL_CAP O
, O
i O
. O
RARE O
. O
the O
chicken I-GENE
RARE I-GENE
upstream I-GENE
promoter I-GENE
- I-GENE
transcription I-GENE
factor I-GENE
II I-GENE
( O
COUP I-GENE
- I-GENE
ALL_CAP I-GENE
). O

We O
have O
RARE O
the O
single O
- O
copy O
gene O
RARE O
the O
RARE I-GENE
- I-GENE
RARE I-GENE
NUM I-GENE
ALL_CAP I-GENE
from O
the O
RARE O
species O
RARE O
RARE O
, O
using O
NUM I-GENE
RNA I-GENE
affinity O
selection O
and O
cDNA O
cloning O
. O

The O
MMPI O
- O
A O
( O
RARE O
et O
al O
., O
1992 O
RARE O
like O
the O
older O
MMPI O
( O
RARE O
& O
RARE O
, O
1983 O
RARE O
RARE O
between O
RARE O
and O
RARE O
. O

On O
the O
other O
RARE O
, O
RARE O
RARE O
4 O
, O
5 O
RARE O
( O
PIP2 O
) O
hydrolysis O
requires O
direct O
RARE O
RARE O
tyrosine O
RARE O
of O
the O
PLC I-GENE
- I-GENE
NUM I-GENE
RARE I-GENE
. O

A O
NUM I-GENE
mutant I-GENE
of O
M I-GENE
- I-GENE
Ras I-GENE
was O
constitutively O
RARE O
and O
its O
RARE O
in O
an O
interleukin I-GENE
- I-GENE
3 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
)- O
dependent O
RARE O
cell O
/ O
RARE O
cell O
line O
resulted O
in O
increased O
survival O
in O
the O
absence O
of O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
, O
increased O
growth O
in O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
, O
and O
, O
RARE O
high O
RARE O
levels O
, O
in O
factor O
- O
independent O
growth O
. O

RARE I-GENE
M I-GENE
- I-GENE
Ras I-GENE
and O
a O
Caenorhabditis O
elegans O
RARE O
exhibit O
RARE O
structural O
features O
, O
and O
these O
are O
likely O
to O
mediate O
activation O
of O
distinctive O
RARE O
RARE O
that O
function O
in O
parallel O
to O
those O
RARE O
of O
p21 I-GENE
Ras I-GENE
. O

Taken O
together O
, O
our O
data O
suggest O
that O
ALL_CAP I-GENE
attenuates O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
RARE O
rather O
than O
acting O
RARE O
a O
true O
repressor O
like O
ALL_CAP I-GENE
. O

These O
observations O
establish O
that O
ALL_CAP I-GENE
negatively O
regulates O
ALL_CAP I-GENE
transcription O
but O
positively O
affects O
ALL_CAP I-GENE
production O
. O

All O
were O
experienced O
hearing O
aid O
users O
who O
RARE O
RARE O
RARE O
D O
instruments O
with O
input O
compression O
limiting O
RARE O
the O
time O
of O
their O
RARE O
in O
this O
study O
. O

ALL_CAP O
testing O
of O
food O
- O
restricted O
animals O
, O
using O
a O
multiple O
fixed O
ratio O
( O
ALL_CAP O
RARE O
fixed O
interval O
( O
ALL_CAP O
) O
schedule O
( O
NUM O
: O
NUM O
RARE O
was O
conducted O
prior O
to O
each O
exposure O
to O
maintain O
the O
RARE O
behavior O
; O
the O
data O
from O
RARE O
- O
1 O
, O
4 O
, O
8 O
, O
and O
NUM O
were O
evaluated O
RARE O
evidence O
of O
neurotoxicity O
. O

RARE O
protection O
assays O
revealed O
that O
NUM I-GENE
and O
NUM I-GENE
are O
differentially O
RARE O
in O
a O
developmentally O
- O
and O
spatially O
- O
modulated O
manner O
RARE O
RARE O
of O
specialized O
RARE O
- O
containing O
RARE O
glands O
in O
RARE O
. O

Differential O
RARE O
was O
confirmed O
by O
Northern O
blot O
analysis O
employing O
multiple O
normal O
and O
tumor O
cell O
lines O
. O

RARE O
of O
the O
Neurospora I-GENE
crassa I-GENE
mitochondrial I-GENE
RARE I-GENE
membrane I-GENE
protein I-GENE
NUM I-GENE
by O
repeat O
- O
RARE O
point O
mutation O
( O
ALL_CAP O
) O
causes O
defects O
in O
mitochondrial O
protein O
import O
and O
morphology O
. O

Several O
genes O
or O
transcriptional O
RARE O
were O
identified O
, O
including O
the O
3 O
' O
end O
of O
ribosomal I-GENE
NUM I-GENE
kinase I-GENE
( O
NUM I-GENE
); O
two O
apparently O
intronless O
and O
ORF O
- O
less O
genes O
; O
and O
NUM I-GENE
, O
an O
intronless O
, O
putative O
G I-GENE
- I-GENE
protein I-GENE
coupled I-GENE
receptor I-GENE
. O

The O
results O
suggest O
that O
ALL_CAP I-GENE
- I-GENE
5 I-GENE
may O
have O
specific O
RARE O
RARE O
and O
that O
ALL_CAP I-GENE
- I-GENE
4 I-GENE
, I-GENE
- I-GENE
5 I-GENE
, I-GENE
and I-GENE
- I-GENE
6 I-GENE
can O
only O
partially O
substitute O
RARE O
each O
other O
in O
RARE O
. O

This O
study O
was O
designed O
to O
compare O
the O
efficacy O
of O
RARE O
RARE O
RARE I-GENE
versus O
RARE O
RARE O
accelerated O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
( O
ALL_CAP I-GENE
) O
in O
coronary O
reperfusion O
in O
acute O
MI O
. O

Recently O
, O
cell O
- O
surface O
ALL_CAP I-GENE
has O
been O
shown O
to O
be O
RARE O
by O
activated O
human O
and O
mouse O
T O
lymphocytes O
, O
RARE O
the O
possibility O
that O
ALL_CAP I-GENE
might O
be O
involved O
in O
T O
cell O
- O
RARE O
cytotoxicity O
and O
/ O
or O
immune O
RARE O
. O

A O
panel O
of O
RARE O
RARE O
was O
used O
to O
investigate O
the O
signal O
RARE O
pathways O
involved O
in O
ALL_CAP I-GENE
gene I-GENE
induction O
following O
T O
lymphocyte O
activation O
. O

From O
RARE O
1991 O
to O
August O
1997 O
, O
NUM O
patients O
with O
endometrial O
carcinoma O
were O
treated O
postoperatively O
with O
high O
- O
dose O
- O
rate O
vaginal O
RARE O
RARE O
RARE O
the O
only O
adjuvant O
treatment O
. O

RARE O
patients O
had O
RARE O
NUM O
, O
14 O
had O
NUM O
, O
9 O
had O
NUM O
, O
and O
3 O
had O
NUM O
RARE O
. O

RARE O
provirus O
genomes O
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
are O
frequently O
detected O
in O
lymphocytes O
from O
RARE O
individuals O
and O
in O
RARE O
cell O
lines O
. O

A O
RARE O
of O
NUM O
primer O
RARE O
gave O
RARE O
RARE O
patterns O
, O
NUM O
( O
NUM O
%) O
of O
which O
revealed O
RARE O
least O
two O
alleles O
on O
RARE O
polyacrylamide O
gels O
. O

A O
population O
pharmacokinetic O
study O
of O
cyclosporin O
in O
organ O
transplant O
patients O
, O
including O
elderly O
RARE O
recipients O
RARE O
to O
NUM O
years O
of O
age O
, O
did O
not O
identify O
age O
RARE O
a O
RARE O
influencing O
cyclosporin O
pharmacokinetics O
. O

RARE O
data O
indicated O
that O
once O
RARE O
to O
the O
mutant O
receptor O
, O
RARE O
- O
labeled O
ALL_CAP I-GENE
RARE O
- O
localized O
with O
markers O
of O
the O
RARE O
RARE O
, O
whereas O
, O
in O
cells O
expressing O
the O
wild O
- O
type O
receptor O
, O
ALL_CAP I-GENE
fluorescence O
RARE O
- O
localized O
with O
RARE O
markers O
. O

Interleukin I-GENE
- I-GENE
12 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
12 I-GENE
) O
is O
a O
RARE O
produced O
by O
peripheral O
RARE O
mononuclear O
cells O
( O
ALL_CAP O
) O
that O
causes O
RARE I-GENE
- I-GENE
gamma I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
) O
production O
and O
enhancement O
of O
cell O
- O
RARE O
cytotoxicity O
. O

ALL_CAP I-GENE
- I-GENE
12 I-GENE
production O
was O
correlated O
with O
NUM O
concentration O
measured O
RARE O
the O
RARE O
of O
RARE O
after O
NUM O
min O
of O
dialysis O
( O
RARE O
= O
NUM O
. O
NUM O
, O
P O
< O
NUM O
. O
01 O
). O

In O
HeLa O
cells O
, O
the O
NUM I-GENE
- O
JNK1 I-GENE
fusion O
protein O
showed O
significant O
JNK I-GENE
activity O
, O
which O
was O
comparable O
with O
that O
of O
JNK1 I-GENE
activated O
by O
many O
stimuli O
and O
RARE O
, O
including O
ALL_CAP I-GENE
, O
TNF I-GENE
- I-GENE
alpha I-GENE
, O
RARE O
, O
ALL_CAP O
irradiation O
, O
NUM I-GENE
, O
and O
small I-GENE
GTP I-GENE
binding I-GENE
proteins I-GENE
Rac1 I-GENE
and O
NUM I-GENE
. O

ALL_CAP O
. O

Our O
results O
RARE O
TGF I-GENE
- I-GENE
beta I-GENE
RII I-GENE
RARE O
a O
direct O
target O
of O
EWS I-GENE
- O
FLI1 I-GENE
. O

The O
reduction O
in O
RARE O
fatty O
RARE O
intake O
led O
to O
RARE O
( O
but O
in O
group O
1 O
significant O
) O
NUM O
. O
NUM O
mmol O
/ O
RARE O
( O
2 O
. O
5 O
%) O
reduction O
in O
RARE O
serum O
cholesterol O
level O
. O

RARE O
, O
an O
ethanol O
repression O
autoregulation O
( O
ALL_CAP O
RARE O
RARE O
- O
RARE O
TA O
repeat O
( O
ALL_CAP O
) O
repressor O
element O
was O
identified O
within O
the O
promoter O
region O
of O
the O
NUM I-GENE
gene I-GENE
. O

A O
crucial O
transcription O
factor O
in O
this O
process O
is O
NUM I-GENE
, O
which O
binds O
to O
a O
specific O
DNA O
element O
upon O
RARE O
activation O
. O

CONCLUSIONS O
: O
RARE O
horizontal O
RARE O
RARE O
is O
rare O
and O
its O
cause O
is O
unknown O
. O

A O
local O
, O
high O
- O
density O
, O
single O
- O
nucleotide O
polymorphism O
map O
used O
to O
clone O
Caenorhabditis I-GENE
elegans I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
. O

This O
machinery O
involves O
a O
secondary O
RARE O
, O
SECIS O
element O
, O
in O
the O
RARE I-GENE
- O
encoding O
mRNA O
, O
RARE O
RARE O
RARE O
RARE O
the O
position O
of O
an O
RARE O
( O
UGA O
) O
RARE O
, O
normally O
conferring O
RARE O
of O
translation O
. O

RARE O
- O
level O
RARE O
in O
Escherichia O
coli O
of O
RARE O
- O
containing O
rat I-GENE
RARE I-GENE
reductase I-GENE
utilizing O
gene O
fusions O
with O
RARE O
bacterial O
- O
type O
SECIS O
elements O
and O
RARE O
- O
RARE O
with O
the O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
genes I-GENE
. O

In O
Wnt I-GENE
RARE O
, O
beta I-GENE
- I-GENE
catenin I-GENE
and O
plakoglobin I-GENE
RARE O
signals O
to O
the O
nucleus O
through O
interactions O
with O
TCF I-GENE
- I-GENE
type I-GENE
transcription I-GENE
factors I-GENE
. O

RARE O
of O
a O
complex O
between O
FAK I-GENE
and O
Src I-GENE
kinases I-GENE
may O
serve O
to O
regulate O
the O
subcellular O
RARE O
and O
the O
enzymatic O
activity O
of O
members O
of O
the O
Src I-GENE
family I-GENE
of O
kinases O
. O

For O
ALL_CAP O
3 O
, O
10 O
, O
or O
40 O
, O
the O
RARE O
RARE O
NUM O
% O
RARE O
7 O
, O
3 O
, O
and O
1 O
in O
the O
8 O
- O
predictor O
model O
respectively O
, O
when O
a O
conventional O
selection O
criterion O
was O
used O
( O
alpha O
= O
NUM O
. O
05 O
). O

Our O
study O
also O
demonstrated O
significant O
increases O
in O
the O
number O
of O
larger O
RARE O
fibers O
RARE O
the O
repair O
site O
in O
comparison O
with O
the O
neonatal O
and O
adult O
groups O
( O
p O
< O
NUM O
. O
04 O
). O

RARE O
( O
2 O
) O
ALL_CAP O
- O
RARE O
RARE O
differentiation O
of O
NUM O
- O
NUM O
neuroblastoma O
cells O
increased O
both O
the O
RARE O
of O
the O
endogenous I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
gene I-GENE
and O
reporter O
genes O
RARE O
by O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
sequences I-GENE
by O
3 O
- O
4 O
- O
RARE O
. O

RARE O
RARE O
, O
RARE O
, O
and O
RARE O
. O

In O
the O
work O
reported O
here O
, O
we O
used O
peptide O
mapping O
, O
mass O
spectrometry O
, O
and O
site O
- O
directed O
mutagenesis O
to O
identify O
two O
sets O
of O
ALL_CAP I-GENE
RARE O
sites O
. O

Both O
ALL_CAP O
- O
K O
type O
1 O
and O
2 O
RARE O
were O
isolated O
. O

RARE O
, O
and O
F O
. O

At O
all O
time O
- O
points O
, O
most O
patients O
RARE O
87 O
%) O
were O
receiving O
RARE O
/ O
ALL_CAP O
alone O
. O

RARE O
of O
dopamine I-GENE
NUM I-GENE
receptor I-GENE
activity O
by O
RARE O
in O
Parkinson O
' O
s O
RARE O
: O
an O
in O
vivo O
study O
by O
PET O
. O

RARE O
- O
affinity O
binding O
sites O
RARE O
both O
GR I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
RARE I-GENE
were O
identified O
RARE O
adjacent O
elements O
within O
the O
ALL_CAP O
. O

When O
the O
NUM O
- O
bp O
fragment O
was O
fused O
to O
an O
NUM I-GENE
- I-GENE
globin I-GENE
promoter O
- O
CAT I-GENE
construct O
and O
cotransfected O
with O
CCAAT I-GENE
transcription I-GENE
factor I-GENE
1 I-GENE
( O
NUM I-GENE
RARE O
NF1 I-GENE
into O
Drosophila O
RARE O
NUM O
insect O
cells O
( O
which O
lack O
NF1 I-GENE
- I-GENE
like I-GENE
proteins I-GENE
) O
RARE O
- O
activation O
of O
CAT I-GENE
activity O
was O
observed O
. O

Western O
blot O
analysis O
showed O
a O
rapid O
corresponding O
increase O
in O
NUM I-GENE
/ O
NUM I-GENE
protein O
, O
whereas O
protein O
levels O
of O
another O
RARE O
of O
the O
RARE I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor I-GENE
family I-GENE
, O
NUM I-GENE
, O
were O
unchanged O
. O

RARE O
of O
NUM I-GENE
- O
RARE O
RARE O
RARE O
cells O
with O
wild O
- O
type O
RARE O
RARE O
, O
which O
contribute O
exclusively O
to O
RARE O
tissues O
, O
RARE O
RARE O
lethality O
and O
allows O
development O
to O
progress O
to O
early O
RARE O
. O

RARE I-GENE
- I-GENE
1 I-GENE
and O
RARE I-GENE
- I-GENE
2 I-GENE
, O
two O
genes O
related O
to O
Drosophila I-GENE
RARE I-GENE
, O
regulate O
RARE O
RARE O
cell O
development O
and O
survival O
in O
Caenorhabditis O
elegans O
. O

Although O
upstream O
RARE O
of O
RARE I-GENE
family I-GENE
kinases I-GENE
are O
relatively O
RARE O
characterized O
, O
little O
is O
known O
of O
the O
RARE O
RARE O
of O
these O
RARE O
. O

RARE O
RARE O
of O
NUM I-GENE
by O
RARE I-GENE
required O
the O
ALL_CAP I-GENE
and O
NUM I-GENE
domains I-GENE
RARE O
RARE O
RARE O
the O
kinase O
domain O
of O
the O
latter O
. O

CONCLUSION O
: O
These O
findings O
imply O
that O
RARE O
either O
is O
RARE O
involved O
in O
acute O
asthma O
or O
serves O
RARE O
a O
RARE O
RARE O
activity O
of O
the O
NUM I-GENE
receptor I-GENE
RARE I-GENE
RARE O
, O
which O
is O
functionally O
RARE O
to O
asthma O
. O

The O
RARE O
analysis O
of O
the O
NUM I-GENE
gene I-GENE
under O
phosphate O
starvation O
or O
high O
RARE O
supply O
shows O
that O
factors O
, O
such O
RARE O
NUM I-GENE
or O
NUM I-GENE
, O
involved O
in O
the O
basal O
control O
may O
also O
RARE O
in O
a O
different O
way O
in O
K O
. O
lactis O
. O

These O
thyroid O
hormone O
changes O
may O
be O
RARE O
in O
part O
by O
RARE O
or O
other O
inflammatory O
RARE O
, O
acting O
RARE O
the O
level O
of O
the O
hypothalamus O
and O
pituitary O
RARE O
, O
the O
thyroid O
RARE O
, O
and O
the O
RARE I-GENE
deiodinase I-GENE
RARE O
. O

ALL_CAP O
type O
1 O
, O
with O
NUM O
low O
and O
NUM O
and O
ALL_CAP I-GENE
normal O
, O
is O
the O
most O
frequent O
form O
. O

METHODS O
: O
We O
studied O
20 O
symptomatic O
patients O
with O
ALL_CAP O
( O
12 O
men O
RARE O
mean O
age O
52 O
+/- O
NUM O
years O
, O
before O
and O
after O
septal O
reduction O
using O
echocardiography O
and O
electrocardiogram O
( O
ECG O
). O

RARE O
data O
from O
the O
RARE O
RARE O
, O
used O
RARE O
a O
RARE O
RARE O
RARE O
surface O
RARE O
, O
reveal O
that O
surface O
slope O
RARE O
RARE O
of O
the O
RARE O
RARE O
experienced O
RARE O
RARE O
the O
RARE O
RARE O
RARE O
of O
the O
NUM O
to O
NUM O
RARE O
and O
support O
the O
notion O
of O
an O
ALL_CAP O
- O
RARE O
coupled O
RARE O
. O

This O
effect O
required O
( O
i O
) O
IR I-GENE
activation O
since O
it O
was O
abrogated O
by O
IR I-GENE
mutation O
RARE O
RARE O
NUM O
and O
NUM O
and O
( O
ii O
) O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
activation O
since O
it O
was O
abolished O
by O
overexpression O
of O
dominant I-GENE
- I-GENE
negative I-GENE
ALL_CAP I-GENE
- I-GENE
alpha I-GENE
( I-GENE
NUM I-GENE
/ I-GENE
NUM I-GENE
) I-GENE
and O
mimicked O
by O
overexpression O
of O
the O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
c I-GENE
- I-GENE
Rel I-GENE
subunit I-GENE
. O

The O
factor O
designated O
B O
formed O
a O
complex O
centered O
on O
the O
sequence O
ALL_CAP O
, O
a O
core O
motif O
RARE O
by O
members O
of O
the O
ALL_CAP I-GENE
/ I-GENE
RARE I-GENE
transcription I-GENE
factor I-GENE
family I-GENE
. O

Furthermore O
, O
overexpression O
of O
NUM I-GENE
/ O
NUM I-GENE
could O
rescue O
the O
NUM I-GENE
- O
ALL_CAP I-GENE
repression O
. O

We O
examined O
Akt I-GENE
activation O
in O
Lyn I-GENE
RARE O
RARE I-GENE
- O
and O
RARE I-GENE
- O
RARE O
NUM O
cells O
and O
B O
cells O
from O
Lyn I-GENE
RARE I-GENE
mice O
. O

RARE O
of O
G I-GENE
protein I-GENE
RARE I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
proteins I-GENE
that O
contain O
ALL_CAP I-GENE
( O
RARE I-GENE
, O
ALL_CAP I-GENE
- I-GENE
10 I-GENE
, O
pleckstrin I-GENE
) O
and O
ALL_CAP I-GENE
( O
G I-GENE
protein I-GENE
gamma I-GENE
subunit I-GENE
- I-GENE
like I-GENE
) O
domains O
form O
a O
subfamily O
that O
includes O
the O
mammalian I-GENE
ALL_CAP I-GENE
proteins I-GENE
NUM I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
. O

Cloning O
and O
RARE O
of O
a O
specific O
human I-GENE
alpha I-GENE
1 I-GENE
, I-GENE
2 I-GENE
- I-GENE
RARE I-GENE
that O
RARE O
NUM O
to O
NUM O
RARE O
B O
RARE O
N O
- O
RARE O
biosynthesis O
. O

The O
RARE O
of O
ALL_CAP O
, O
adjusted O
RARE O
age O
and O
RARE O
, O
varied O
from O
NUM O
. O
1 O
, O
RARE O
those O
with O
baseline O
RARE O
of O
superficial O
RARE O
RARE O
( O
IM O
RARE O
to O
29 O
. O
3 O
, O
RARE O
those O
with O
deep O
IM O
or O
mild O
dysplasia O
( O
ALL_CAP O
) O
or O
IM O
with O
RARE O
atrophy O
and O
neck O
hyperplasia O
, O
to O
104 O
. O
2 O
, O
RARE O
those O
with O
moderate O
or O
severe O
ALL_CAP O
, O
RARE O
compared O
with O
subjects O
with O
superficial O
RARE O
( O
ALL_CAP O
) O
or O
chronic O
RARE O
RARE O
( O
ALL_CAP O
) O
RARE O
baseline O
. O

Here O
we O
report O
that O
NUM I-GENE
and O
NUM I-GENE
interact O
through O
their O
RARE O
domains O
. O

Thus O
, O
the O
nematode O
genes O
could O
be O
the O
homologs I-GENE
of I-GENE
RARE I-GENE
molecules I-GENE
in O
other O
RARE O
. O

A O
subset O
of O
mutations O
in O
the O
RARE I-GENE
synthase I-GENE
domain I-GENE
RARE O
association O
of O
the O
altered O
NUM I-GENE
proteins I-GENE
with O
RARE O
box O
H I-GENE
/ I-GENE
ALL_CAP I-GENE
RARE I-GENE
, O
suggesting O
that O
the O
RARE O
catalytic O
domain O
is O
essential O
RARE O
that O
interaction O
. O

Although O
the O
Src I-GENE
tyrosine I-GENE
kinase I-GENE
induces O
RARE O
Stat3 I-GENE
RARE O
on O
tyrosine O
, O
activation O
of O
Stat3 I-GENE
- O
RARE O
gene O
RARE O
requires O
both O
tyrosine O
and O
serine O
RARE O
of O
Stat3 I-GENE
. O

The O
transcription I-GENE
factor I-GENE
ALL_CAP I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
homologous I-GENE
protein I-GENE
10 I-GENE
) O
is O
a O
ALL_CAP I-GENE
protein I-GENE
RARE O
by O
a O
variety O
of O
stimuli O
that O
RARE O
cellular O
stress O
responses O
and O
has O
been O
shown O
to O
arrest O
cell O
growth O
and O
to O
promote O
programmed O
cell O
RARE O
. O

Thus O
, O
ALL_CAP I-GENE
not O
only O
is O
a O
negative O
or O
a O
positive O
regulator O
of O
C I-GENE
/ I-GENE
EBP I-GENE
target O
genes O
but O
also O
, O
when O
RARE O
to O
AP I-GENE
- I-GENE
1 I-GENE
factors I-GENE
, O
can O
activate O
AP I-GENE
- I-GENE
1 I-GENE
target O
genes O
. O

This O
motif O
, O
RARE O
described O
RARE O
the O
Drosophila I-GENE
RARE I-GENE
activator I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
identifies O
an O
RARE O
group O
of O
RARE O
transcriptional O
RARE O
. O

RNase I-GENE
MRP I-GENE
is O
a O
ribonucleoprotein O
RARE O
that O
has O
been O
shown O
to O
have O
roles O
in O
both O
mitochondrial O
DNA O
replication O
and O
nuclear I-GENE
5 I-GENE
. I-GENE
NUM I-GENE
rRNA I-GENE
RARE O
. O

We O
have O
examined O
the O
RARE O
of O
the O
FGFR I-GENE
- I-GENE
1 I-GENE
gene I-GENE
( O
RARE I-GENE
- I-GENE
1 I-GENE
) O
in O
avian O
RARE O
cultures O
by O
RARE O
and O
Northern O
blot O
analysis O
. O

Regulation O
of O
avian I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
1 I-GENE
( O
FGFR I-GENE
- I-GENE
1 I-GENE
) O
gene O
RARE O
RARE O
skeletal O
muscle O
differentiation O
. O

The O
RARE O
dynamics O
of O
residues O
RARE O
in O
the O
folded O
part O
of O
NUM I-GENE
( O
NUM I-GENE
) O
NUM I-GENE
have O
been O
characterized O
by O
RARE O
- O
detected O
( O
NUM O
) O
N O
NMR O
spectroscopy O
. O

Rac I-GENE
causes O
RARE O
of O
actin I-GENE
RARE I-GENE
( O
F I-GENE
- I-GENE
actin I-GENE
) O
RARE O
the O
RARE O
- O
ends O
, O
through O
RARE O
4 O
, O
5 O
RARE O
( O
PIP2 O
RARE O
and O
RARE O
induces O
membrane O
RARE O
. O

However O
, O
a O
specific O
ICE I-GENE
/ O
RARE I-GENE
- I-GENE
1 I-GENE
inhibitor O
called O
NUM O
completely O
abolished O
the O
ALL_CAP I-GENE
- O
RARE O
apoptosis O
by O
RARE O
PKB I-GENE
, O
but O
without O
affecting O
the O
ALL_CAP I-GENE
- O
RARE O
suppression O
of O
Ras I-GENE
transformation O
. O

OBJECTIVE O
: O
Although O
the O
RARE O
of O
findings O
offer O
support O
RARE O
transient O
( O
where O
is O
it O
RARE O
RARE O
opposed O
to O
sustained O
( O
what O
is O
it O
RARE O
deficit O
, O
a O
need O
remains O
RARE O
specific O
RARE O
of O
the O
deficit O
. O

The O
ALL_CAP O
- O
NUM O
ALL_CAP O
: O
the O
next O
generation O
RARE O
RARE O
RARE O
plutonium O
RARE O
RARE O
the O
ALL_CAP O
RARE O
RARE O
. O

RESULTS O
: O
Factors O
associated O
with O
significantly O
( O
P O
RARE O
05 O
) O
increased O
risk O
of O
treatment O
failure O
in O
a O
Cox O
multivariate O
analysis O
included O
age O
older O
than O
NUM O
years O
( O
relative O
RARE O
, O
1 O
. O
NUM O
; O
NUM O
% O
confidence O
interval O
RARE O
ALL_CAP O
], O
1 O
. O
02 O
- O
1 O
. O
NUM O
RARE O
RARE O
performance O
score O
less O
than O
NUM O
% O
( O
1 O
. O
NUM O
; O
NUM O
% O
ALL_CAP O
, O
1 O
. O
07 O
- O
1 O
. O
NUM O
RARE O
absence O
of O
hormone O
receptors O
( O
1 O
. O
NUM O
; O
NUM O
% O
ALL_CAP O
, O
1 O
. O
NUM O
- O
1 O
. O
NUM O
RARE O
prior O
use O
of O
adjuvant O
chemotherapy O
( O
1 O
. O
NUM O
; O
NUM O
% O
ALL_CAP O
, O
1 O
. O
10 O
- O
1 O
. O
NUM O
RARE O
initial O
RARE O
- O
free O
survival O
interval O
after O
adjuvant O
treatment O
of O
RARE O
more O
than O
18 O
months O
( O
1 O
. O
NUM O
; O
NUM O
% O
ALL_CAP O
, O
1 O
. O
NUM O
- O
2 O
. O
NUM O
RARE O
metastases O
in O
the O
liver O
( O
1 O
. O
NUM O
; O
NUM O
% O
ALL_CAP O
, O
1 O
. O
20 O
- O
1 O
. O
NUM O
) O
or O
central O
nervous O
RARE O
( O
1 O
. O
NUM O
; O
NUM O
% O
ALL_CAP O
, O
NUM O
. O
NUM O
- O
2 O
. O
NUM O
RARE O
approaches O
significance O
RARE O
RARE O
soft O
tissue O
, O
bone O
, O
or O
RARE O
, O
3 O
or O
more O
sites O
of O
metastatic O
RARE O
( O
1 O
. O
NUM O
; O
NUM O
% O
ALL_CAP O
, O
1 O
. O
NUM O
- O
1 O
. O
54 O
RARE O
and O
incomplete O
response O
RARE O
RARE O
response O
to O
standard O
- O
dose O
chemotherapy O
( O
1 O
. O
65 O
; O
NUM O
% O
ALL_CAP O
, O
1 O
. O
NUM O
- O
1 O
. O
NUM O
). O

One O
form O
of O
the O
ALL_CAP I-GENE
gene I-GENE
transcript I-GENE
in O
12 O
- O
day O
old O
RARE O
contained O
the O
RARE O
I O
+ O
II O
+ O
III O
combination O
RARE O
the O
5 O
' O
end O
, O
whereas O
other O
forms O
differed O
by O
inclusion O
of O
intron O
1 O
or O
exclusion O
of O
RARE O
II O
sequences O
. O

In O
PC O
, O
rare O
RARE O
had O
RARE O
RARE O
and O
RARE O
. O

16 O
percent O
, O
P O
< O
NUM O
. O
001 O
RARE O
and O
sustained O
RARE O
of O
serum I-GENE
alanine I-GENE
aminotransferase I-GENE
levels O
( O
NUM O
percent O
RARE O
. O

Its O
C O
- O
terminal O
catalytic O
domain O
was O
found O
to O
be O
highly O
RARE O
in O
the O
RARE O
NUM I-GENE
( O
ras I-GENE
- O
ALL_CAP I-GENE
) O
and O
Sos I-GENE
. O

NUM O
, O
93 O
- O
98 O
]. O

The O
proteasome O
is O
a O
large O
complex O
consisting O
of O
two O
RARE O
RARE O
, O
the O
20S I-GENE
and O
NUM I-GENE
( O
NUM I-GENE
) O
or O
NUM I-GENE
complexes I-GENE
, O
that O
RARE O
to O
form O
the O
NUM I-GENE
RARE I-GENE
. O

In O
assays O
with O
RARE O
RARE O
, O
wild O
- O
type O
but O
not O
ALL_CAP I-GENE
- O
NUM I-GENE
was O
a O
specific O
substrate O
RARE O
the O
ALL_CAP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
type I-GENE
I I-GENE
and I-GENE
II I-GENE
. O

R O
., O
RARE O
, O
R O
., O
RARE O
, O
ALL_CAP O
. O

The O
N O
- O
terminal O
domain O
of O
RARE O
70 O
kDa O
exhibits O
11 O
RARE O
amino O
acid O
repeats O
that O
show O
some O
homology O
to O
RARE O
surface O
RARE O
of O
the O
NUM I-GENE
/ O
NUM I-GENE
complex O
. O

In O
contrast O
to O
previously O
characterized O
RARE O
, O
the O
NUM I-GENE
gene O
product O
is O
predominantly O
membrane O
- O
associated O
and O
it O
is O
RARE O
on O
the O
RARE O
cell O
surface O
. O

Most O
important O
, O
infection O
of O
the O
cells O
with O
an O
RARE O
construct O
expressing O
this O
mutant O
inhibited O
the O
induction O
of O
VEGF I-GENE
mRNA I-GENE
under O
conditions O
that O
mimic O
RARE O
. O

RARE I-GENE
stimulates O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
, O
members O
of O
the O
ErbB I-GENE
family I-GENE
of O
receptor I-GENE
tyrosine I-GENE
kinases I-GENE
. O

Our O
results O
suggest O
that O
NUM I-GENE
is O
the O
yeast I-GENE
homologue I-GENE
of I-GENE
mammalian I-GENE
epsilon I-GENE
- I-GENE
ALL_CAP I-GENE
and O
the O
RARE O
accumulation O
of O
the O
ER O
membrane O
caused O
by O
a O
RARE O
of O
the O
early O
protein O
RARE O
RARE O
leads O
to O
alteration O
of O
nuclear O
morphology O
of O
the O
RARE O
yeast O
cells O
. O

In O
PC12 O
cells O
, O
nerve I-GENE
growth I-GENE
factor I-GENE
induces O
RARE O
differentiation O
and O
repressed O
RARE O
of O
RARE I-GENE
- I-GENE
1 I-GENE
. O

In O
a O
PC12 O
cell O
mutant O
that O
is O
RARE O
in O
protein I-GENE
kinase I-GENE
A I-GENE
activity O
( O
ALL_CAP O
. O
11 O
RARE O
all O
three O
differentiating O
agents O
were O
unable O
to O
down O
- O
regulate O
RARE I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
. O

NUM I-GENE
mutations I-GENE
include O
two O
nonsense O
mutations O
, O
four O
insertions O
, O
and O
three O
RARE O
mutations O
. O

RARE O
patients O
without O
abnormalities O
in O
the O
ALL_CAP O
are O
assumed O
to O
harbor O
missense O
mutations O
, O
probably O
in O
NUM I-GENE
. O

The O
RARE O
algorithm O
, O
ALL_CAP O
, O
is O
a O
fast O
- O
RARE O
RARE O
algorithm O
that O
allows O
RARE O
of O
the O
3 O
- O
D O
RARE O
correction O
factors O
( O
ALL_CAP O
' O
s O
) O
directly O
from O
a O
two O
- O
dimensional O
( O
2 O
- O
D O
) O
RARE O
scan O
, O
without O
RARE O
RARE O
the O
RARE O
map O
and O
then O
RARE O
a O
3 O
- O
D O
RARE O
RARE O
. O

We O
have O
RARE O
cDNA O
and O
genomic O
DNA O
RARE O
a O
mouse O
gene O
encoding O
a O
protein O
with O
significant O
sequence O
RARE O
to O
RARE O
domains O
found O
in O
proteins O
of O
the O
NUM I-GENE
family I-GENE
. O

RT O
- O
PCR O
and O
in O
situ O
hybridization O
analyses O
of O
a O
time O
course O
of O
juvenile O
RARE O
development O
indicate O
that O
NUM I-GENE
RARE O
begins O
in O
early O
RARE O
RARE O
I O
, O
prior O
to O
the O
RARE O
RARE O
, O
with O
increasing O
accumulation O
of O
mRNA O
through O
the O
RARE O
RARE O
. O

Animals O
were O
RARE O
to O
RARE O
8 O
weeks O
later O
and O
the O
grafts O
were O
RARE O
RARE O
and O
analyzed O
via O
RARE O
culture O
and O
standard O
histologic O
procedures O
RARE O
evidence O
of O
infection O
. O

The O
ALL_CAP O
was O
measured O
twice O
in O
each O
RARE O
and O
found O
to O
be O
similar O
( O
F O
( O
1 O
, O
18 O
) O
= O
NUM O
. O
NUM O
) O
across O
the O
follicular O
( O
NUM O
ALL_CAP O
/ O
NUM O
h O
) O
and O
the O
RARE O
( O
NUM O
ALL_CAP O
/ O
NUM O
h O
) O
phases O
. O

RARE O
( O
NUM O
RARE O
which O
can O
be O
administered O
orally O
, O
is O
the O
RARE O
of O
NUM O
, O
a O
potent O
and O
selective O
inhibitor O
of O
RARE I-GENE
RARE I-GENE
. O

In O
gel O
mobility O
shift O
assays O
, O
we O
found O
RARE O
evidence O
RARE O
VDR I-GENE
- O
TR I-GENE
RARE O
interaction O
with O
any O
tested O
element O
. O

The O
relative O
importance O
of O
these O
two O
mechanisms O
differed O
in O
a O
response O
element O
- O
specific O
manner O
. O

After O
14 O
d O
of O
RARE O
, O
RARE O
ALL_CAP O
profiles O
were O
identical O
in O
the O
two O
RARE O
and O
similar O
to O
that O
in O
control O
RARE O
; O
RARE O
- O
containing O
ALL_CAP O
RARE O
RARE O
NUM O
% O
of O
RARE O
ALL_CAP O
. O

C O
- O
SP O
duration O
was O
significantly O
RARE O
in O
ALL_CAP O
patients O
compared O
to O
controls O
RARE O
low O
RARE O
intensity O
corresponding O
to O
an O
ALL_CAP O
threshold O
increased O
by O
NUM O
%. O

These O
data O
show O
that O
the O
RARE I-GENE
RARE I-GENE
genes I-GENE
belong O
simultaneously O
to O
several O
RARE O
in O
the O
cell O
, O
RARE O
the O
possibility O
that O
RARE I-GENE
RARE O
can O
be O
fine O
- O
RARE O
in O
response O
to O
multiple O
environmental O
inputs O
. O

RARE O
RARE O
of O
ALL_CAP I-GENE
in O
the O
cells O
of O
microvascular O
RARE O
RARE O
of O
their O
high O
RARE O
activity O
, O
and O
the O
RARE O
of O
DNA O
in O
them O
showed O
their O
ability O
RARE O
RARE O
, O
i O
. O
g O
RARE O
RARE O
growth O
. O

RARE O
RARE O
combined O
with O
RARE O
ligation O
( O
ALL_CAP O
& O
ALL_CAP O
) O
RARE O
a O
reduction O
of O
19 O
. O
9 O
% O
( O
RARE O
. O
s O
.). O

RARE O
- O
RARE O
erbB I-GENE
proteins I-GENE
RARE O
RARE I-GENE
growth I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
)- O
RARE O
tyrosine O
RARE O
of O
endogenous O
Shc I-GENE
proteins I-GENE
and O
also O
RARE O
immediate O
and O
sustained O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
ERK I-GENE
ALL_CAP I-GENE
activities O
in O
human O
RARE O
cells O
, O
although O
basal O
ERK I-GENE
ALL_CAP I-GENE
activities O
were O
unaffected O
. O

Using O
RARE O
, O
we O
observe O
that O
NUM I-GENE
, O
a O
440 O
- O
bp O
RARE O
element O
that O
contains O
RARE O
sufficient O
to O
drive O
amplification O
, O
directs O
ALL_CAP I-GENE
RARE O
in O
RARE O
cells O
. O

Therefore O
, O
homozygous O
RARE O
- O
deletions O
of O
NUM I-GENE
and O
NUM I-GENE
rather O
than O
mutations O
targeting O
individual O
transcripts O
are O
frequently O
RARE O
RARE O
in O
these O
tumors O
. O

Here O
, O
we O
show O
that O
aortic O
RARE O
isolated O
from O
PPARalpha I-GENE
- O
RARE O
mice O
display O
an O
RARE O
response O
to O
inflammatory O
stimuli O
, O
such O
RARE O
lipopolysaccharide O
( O
ALL_CAP O
RARE O
RARE O
demonstrated O
by O
increased O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
RARE O
. O

RARE O
RARE O
is O
maintained O
in O
the O
liver O
by O
a O
combination O
of O
liver O
- O
RARE O
transcription O
factors O
such O
RARE O
CAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( I-GENE
C I-GENE
/ I-GENE
EBP I-GENE
) I-GENE
alpha I-GENE
and O
C I-GENE
/ I-GENE
EBPbeta I-GENE
. O

The O
requirement O
RARE O
RARE O
activity O
of O
both O
RARE I-GENE
and O
RARE I-GENE
suggests O
that O
protease O
- O
activated O
receptors O
may O
be O
involved O
. O

RARE I-GENE
beta I-GENE
- I-GENE
protein I-GENE
( O
RARE I-GENE
) O
is O
the O
main O
RARE O
of O
RARE O
RARE O
found O
in O
senile O
RARE O
and O
cerebral O
vessels O
in O
RARE O
' O
s O
RARE O
( O
AD O
) O
and O
is O
derived O
by O
proteolysis O
from O
the O
beta I-GENE
- I-GENE
RARE I-GENE
precursor I-GENE
protein I-GENE
( O
ALL_CAP I-GENE
). O

We O
also O
show O
that O
activation O
of O
protein I-GENE
kinase I-GENE
A I-GENE
( O
PKA I-GENE
) O
RARE O
is O
sufficient O
to O
down O
- O
regulate O
RARE I-GENE
- I-GENE
1 I-GENE
protein I-GENE
RARE O
and O
promoter O
activity O
. O

The O
RARE I-GENE
alpha I-GENE
. I-GENE
beta I-GENE
RARE I-GENE
mediates O
nuclear O
import O
of O
proteins O
containing O
classical O
nuclear O
RARE O
signals O
. O

The O
RARE O
G1 I-GENE
- O
NUM I-GENE
RARE O
to O
both O
RARE O
and O
RARE I-GENE
protein I-GENE
indicating O
that O
the O
immunoglobulin I-GENE
- I-GENE
RARE I-GENE
motif I-GENE
and O
RARE O
RARE O
repeat O
loops O
of O
the O
G1 I-GENE
domain I-GENE
were O
correctly O
folded O
. O

The O
results O
suggest O
that O
the O
presence O
or O
absence O
per O
RARE O
of O
RARE O
RARE O
on O
RARE O
G1 O
- O
NUM O
does O
not O
affect O
the O
activity O
of O
RARE O
C O
toward O
the O
two O
sites O
. O

Despite O
i O
. O
v O
. O
steroid O
therapy O
, O
RARE O
RARE O
] O
remained O
elevated O
throughout O
recovery O
( O
37 O
. O
9 O
+/- O
4 O
. O
8 O
ppb O
, O
p O
< O
NUM O
. O
001 O
) O
until O
discharge O
( O
40 O
. O
9 O
+/- O
4 O
. O
3 O
ppb O
, O
p O
< O
NUM O
. O
001 O
). O

It O
contains O
binding O
sites O
RARE O
several O
transcription O
factors O
, O
RARE O
example O
: O
( O
i O
) O
a O
RARE O
- O
characterized O
binding O
site O
RARE O
RARE I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
transcription O
factors O
in O
its O
3 O
'- O
end O
( O
the O
NUM I-GENE
or O
NUM I-GENE
element I-GENE
RARE O
( O
ii O
) O
a O
second O
kappaB I-GENE
site I-GENE
( O
the O
NUM I-GENE
element I-GENE
RARE O
which O
is O
RARE O
immediately O
adjacent O
5 O
' O
to O
the O
NUM I-GENE
element I-GENE
and O
which O
is O
RARE O
by O
NUM I-GENE
/ O
ALL_CAP I-GENE
in O
the O
human I-GENE
HLA I-GENE
RARE O
, O
and O
( O
iii O
) O
an O
AP I-GENE
- I-GENE
1 I-GENE
/ O
ATF I-GENE
recognition O
sequence O
in O
the O
5 O
' O
end O
( O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
). O

The O
tumorigenic O
E1A I-GENE
+ O
RARE I-GENE
- I-GENE
ras I-GENE
cells O
are O
characterized O
by O
high O
and O
RARE O
DNA O
binding O
activities O
of O
AP I-GENE
- I-GENE
1 I-GENE
, O
in O
contrast O
to O
RARE O
cells O
and O
the O
E1A I-GENE
cells O
. O

The O
yeast O
C I-GENE
- I-GENE
type I-GENE
RARE I-GENE
NUM I-GENE
/ O
NUM I-GENE
and O
its O
RARE I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
( O
Cdk I-GENE
) O
NUM I-GENE
are O
required O
RARE O
the O
full O
repression O
of O
genes O
involved O
in O
the O
stress O
response O
or O
meiosis O
. O

In O
particular O
, O
the O
S1 I-GENE
' I-GENE
RARE I-GENE
site I-GENE
is O
a O
deep O
and O
highly O
hydrophobic O
cavity O
. O

NUM I-GENE
is O
homologous O
to O
NUM I-GENE
and O
NUM I-GENE
, O
and O
overall O
amino O
acid O
identity O
is O
RARE O
follows O
: O
NUM I-GENE
RARE O
NUM I-GENE
, O
NUM O
. O
6 O
%; O
NUM I-GENE
RARE O
NUM I-GENE
, O
NUM O
. O
2 O
%; O
NUM I-GENE
RARE O
NUM I-GENE
, O
65 O
. O
7 O
%. O

The O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
responsive O
reporter O
construct O
, O
( O
ALL_CAP O
)( O
4 O
)- O
CAT I-GENE
, O
was O
used O
to O
explore O
transcription O
resulting O
from O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
activated O
by O
Tat I-GENE
. O

The O
RNA O
transcripts O
structurally O
equivalent O
to O
I I-GENE
( I-GENE
2 I-GENE
) I-GENE
RARE I-GENE
of O
ALL_CAP I-GENE
NUM I-GENE
and O
ALL_CAP O
, O
but O
containing O
a O
hairpin O
RARE O
( O
H O
) O
immediately O
upstream O
of O
ALL_CAP I-GENE
( I-GENE
MP I-GENE
, I-GENE
NUM I-GENE
) I-GENE
( I-GENE
ALL_CAP I-GENE
( I-GENE
MP I-GENE
RARE I-GENE
( I-GENE
NUM I-GENE
)( I-GENE
ALL_CAP I-GENE
)- I-GENE
MP I-GENE
- I-GENE
CP I-GENE
- I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
; O
ALL_CAP I-GENE
( I-GENE
MP I-GENE
, I-GENE
NUM I-GENE
)( I-GENE
NUM I-GENE
)- I-GENE
MP I-GENE
- I-GENE
CP I-GENE
- I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
RARE O
were O
able O
to O
express O
the O
MP I-GENE
gene I-GENE
in O
vitro O
. O

ALL_CAP I-GENE
LTR I-GENE
sequence I-GENE
variability O
is O
confined O
mostly O
to O
a O
small O
portion O
of O
the O
enhancer O
within O
the O
NUM O
segment O
of O
the O
LTR O
. O

RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
requirement O
in O
activation O
of O
the O
ras I-GENE
/ O
C I-GENE
- I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
/ O
MEK I-GENE
/ O
ERK I-GENE
and O
p70 I-GENE
( O
NUM I-GENE
) O
RARE O
cascade O
by O
the O
RARE O
agent O
RARE O
RARE O
. O

The O
core O
of O
this O
enhancer O
contains O
two O
evolutionarily O
RARE O
binding O
sites O
RARE O
the O
RARE I-GENE
protein I-GENE
RARE I-GENE
( O
RARE I-GENE
RARE O
RARE O
in O
developing O
cardiac O
, O
somatic O
, O
and O
visceral O
muscle O
lineages O
. O

For O
example O
, O
introduction O
of O
RARE O
and O
purification O
tag O
sequences O
into O
the O
C O
- O
terminal O
coding O
region O
significantly O
decreased O
RARE I-GENE
gene I-GENE
mRNA I-GENE
and O
protein O
accumulation O
. O

Furthermore O
, O
the O
striking O
ability O
of O
RARE I-GENE
RARE I-GENE
T I-GENE
antigens I-GENE
to O
promote O
retinoic O
acid O
- O
RARE O
differentiation O
appears O
to O
RARE O
ERK I-GENE
, O
but O
not O
JNK I-GENE
/ O
ALL_CAP I-GENE
or O
p38 I-GENE
RARE O
. O

We O
RARE O
that O
RARE O
RARE O
with O
RARE O
should O
be O
used O
in O
conjunction O
with O
i O
. O
v O
. O
sedation O
/ O
analgesia O
RARE O
RARE O
collection O
performed O
through O
the O
RARE O
route O
under O
ultrasound O
RARE O
( O
ALL_CAP O
) O
to O
reduce O
the O
pain O
of O
the O
procedure O
. O

All O
loci O
have O
a O
similar O
organization O
, O
except O
RARE O
NUM I-GENE
. I-GENE
8 I-GENE
that O
RARE O
two O
NUM I-GENE
genes I-GENE
arranged O
in O
RARE O
and O
separated O
by O
a O
short O
RARE O
sequence O
, O
named O
ALL_CAP O
( O
short O
interspersed O
RARE O
element O
RARE O
which O
is O
also O
found O
upstream O
of O
the O
RARE O
gene O
of O
the O
RARE O
and O
RARE O
of O
the O
second O
. O

A O
proportion O
of O
ALL_CAP I-GENE
wild O
- O
type O
colon O
carcinomas O
and O
melanomas O
also O
contains O
RARE O
nuclear O
RARE I-GENE
- I-GENE
4 I-GENE
/ O
beta I-GENE
- I-GENE
catenin I-GENE
complexes O
RARE O
a O
result O
of O
dominant O
mutations O
in O
the O
N O
terminus O
of O
beta I-GENE
- I-GENE
catenin I-GENE
that O
RARE O
it O
RARE O
to O
RARE O
by O
ALL_CAP I-GENE
, O
NUM I-GENE
beta I-GENE
, O
and O
RARE I-GENE
/ O
RARE I-GENE
. O

Similar O
mechanisms O
leading O
to O
RARE O
of O
RARE I-GENE
target I-GENE
gene I-GENE
activity O
are O
likely O
to O
be O
involved O
in O
RARE O
and O
other O
forms O
of O
RARE O
. O

This O
report O
describes O
a O
patient O
with O
a O
previous O
inferior O
acute O
RARE O
infarction O
who O
developed O
right O
ventricular O
infarction O
with O
significant O
anterior O
lead O
ST O
segment O
elevation O
( O
NUM O
- O
NUM O
) O
caused O
by O
the O
RARE O
of O
two O
large O
right O
ventricular O
RARE O
RARE O
a O
coronary O
RARE O
of O
the O
right O
coronary O
artery O
. O

PATIENTS O
ALL_CAP O
METHODS O
: O
RARE O
before O
radical O
RARE O
, O
bone O
marrow O
RARE O
from O
both O
sides O
of O
the O
iliac O
RARE O
were O
taken O
from O
NUM O
patients O
. O

PURPOSE O
: O
Previous O
WR O
- O
2721 O
human O
pharmacokinetic O
studies O
were O
limited O
to O
plasma O
levels O
in O
patients O
receiving O
RARE O
- O
based O
compounds O
, O
and O
none O
includes O
the O
effects O
of O
WR O
- O
2721 O
on O
endogenous O
RARE O
. O

With O
regard O
to O
RARE O
RARE O
, O
RARE O
, O
infection O
and O
elevated O
serum I-GENE
RARE I-GENE
phosphatase I-GENE
of O
grade O
3 O
or O
over O
were O
observed O
in O
2 O
% O
of O
cycles O
, O
but O
were O
RARE O
and O
reversible O
. O

RARE I-GENE
is O
RARE O
in O
pituitary O
RARE O
cells O
and O
RARE I-GENE
is O
RARE O
in O
RARE O
RARE O
cells O
. O

Regulation O
of O
HIV O
- O
1 O
transcription O
. O

Human I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
is O
known O
to O
exist O
in O
different O
forms O
. O

In O
an O
earlier O
study O
( O
RARE O
, O
Y O
., O
RARE O
, O
K O
., O
RARE O
, O
M O
., O
and O
RARE O
, O
D O
. O

It O
consists O
of O
NUM O
amino O
acid O
residues O
encoded O
by O
a O
9 O
- O
RARE O
RARE O
mRNA O
; O
several O
RARE O
variants O
have O
been O
detected O
in O
human O
and O
rat O
cDNA O
libraries O
. O

RARE I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
binding O
to O
A I-GENE
- I-GENE
kinase I-GENE
RARE O
proteins O
in O
living O
cells O
by O
fluorescence O
resonance O
energy O
transfer O
of O
RARE I-GENE
RARE I-GENE
protein I-GENE
fusion O
proteins O
. O

CONCLUSIONS O
: O
In O
addition O
to O
the O
RARE O
of O
RARE O
- O
filled O
microspheres O
to O
air O
- O
filled O
microspheres O
RARE O
LV O
RARE O
, O
the O
efficacy O
of O
ALL_CAP O
is O
relatively O
unaffected O
by O
impaired O
LV O
function O
and O
is O
less O
susceptible O
to O
the O
effects O
of O
poor O
RARE O
than O
ALL_CAP O
. O

RARE I-GENE
ALL_CAP I-GENE
deficiency O
is O
a O
rare O
RARE O
bleeding O
disorder O
affecting O
the O
RARE O
RARE O
. O

The O
RARE O
samples O
show O
a O
range O
RARE O
three O
RARE O
levels O
. O

The O
more O
RARE O
ALL_CAP O
, O
RARE O
RARE O
and O
RARE O
, O
will O
be O
reviewed O
along O
with O
such O
modern O
drugs O
RARE O
RARE O
and O
RARE O
, O
with O
RARE O
upon O
their O
actions O
on O
breast O
, O
RARE O
, O
bone O
and O
lipids O
. O

RARE O
exhibited O
a O
RARE O
- O
like O
morphology O
. O

This O
organization O
suggests O
that O
duplication O
events O
that O
have O
generated O
the O
primate O
NUM I-GENE
- O
NUM I-GENE
- O
NUM I-GENE
cluster O
might O
have O
occurred O
through O
a O
long O
- O
interspersed O
- O
nuclear O
- O
element O
- O
based O
mechanism O
of O
RARE O
RARE O
over O
, O
RARE O
described O
RARE O
the O
globin I-GENE
cluster I-GENE
. O

S O
., O
RARE O
, O
S O
. O

The O
RARE I-GENE
region I-GENE
also O
RARE O
a O
region O
of O
RARE O
RARE O
, O
RARE I-GENE
, O
RARE O
a O
RARE O
- O
loop O
RARE O
, O
the O
ALL_CAP I-GENE
promoter I-GENE
, O
RARE I-GENE
, O
RARE O
RARE O
RARE O
two O
distinct O
ALL_CAP I-GENE
binding I-GENE
sites I-GENE
, O
ALL_CAP O
- O
1 O
and O
ALL_CAP O
- O
2 O
. O

ALL_CAP O
constructs O
RARE O
RARE O
and O
positive O
RARE O
, O
and O
RARE O
kinetics O
indicated O
slow O
RARE O
of O
RARE O
to O
the O
two O
RARE O
. O

The O
ALL_CAP I-GENE
protein I-GENE
family I-GENE
includes O
members O
from O
yeast O
to O
humans O
, O
which O
function O
in O
various O
biological O
RARE O
, O
and O
share O
a O
DNA O
- O
binding O
domain O
and O
a O
RARE O
C O
- O
terminal O
region O
. O

Binding O
to O
RARE O
and O
the O
alpha I-GENE
- I-GENE
RARE I-GENE
receptor I-GENE
was O
much O
stronger O
and O
required O
RARE O
least O
two O
ALL_CAP I-GENE
RARE I-GENE
. O

Here O
, O
we O
propose O
that O
an O
antagonistic O
, O
BMP I-GENE
/ O
NUM I-GENE
/ O
Smad I-GENE
- O
RARE O
RARE O
RARE O
is O
RARE O
on O
the O
right O
RARE O
of O
the O
Xenopus O
RARE O
. O

These O
kinases O
belong O
to O
a O
new O
subfamily O
related O
to O
the O
RARE I-GENE
subfamily I-GENE
. O

The O
data O
indicate O
that O
RARE I-GENE
- I-GENE
1 I-GENE
is O
essential O
RARE O
muscle O
development O
in O
C O
. O
elegans O
, O
perhaps O
by O
RARE O
a O
role O
in O
post O
- O
transcriptional O
RARE O
of O
some O
muscle O
RARE O
, O
and O
thus O
suggesting O
a O
possible O
conservation O
of O
gene O
function O
with O
human I-GENE
ALL_CAP I-GENE
- I-GENE
bp I-GENE
. O

RARE O
given O
by O
ALL_CAP O
and O
ALL_CAP O
significantly O
decreased O
the O
RARE O
RARE O
density O
( O
p O
< O
NUM O
. O
05 O
RARE O
by O
almost O
one O
order O
of O
magnitude O
. O

CONCLUSIONS O
: O
The O
largest O
value O
of O
the O
joint O
space O
may O
be O
used O
when O
evaluating O
rheumatoid O
ALL_CAP O
joint O
space O
. O

An O
analysis O
of O
sequence O
of O
the O
mutant I-GENE
ALL_CAP I-GENE
gene I-GENE
revealed O
a O
G O
: O
C O
to O
T O
: O
A O
transversion O
near O
the O
3 O
' O
end O
of O
the O
coding O
region O
. O

Nevertheless O
, O
in O
view O
of O
the O
RARE O
RARE O
rates O
of O
ALL_CAP O
and O
the O
lack O
of O
effective O
immunization O
, O
ALL_CAP O
should O
be O
regarded O
RARE O
a O
RARE O
RARE O
RARE O
RARE O
medical O
and O
dental O
RARE O
. O

Detection O
of O
poisoning O
by O
RARE O
( O
RARE O
RARE O
) O
in O
a O
RARE O
and O
child O
. O

We O
have O
previously O
identified O
mouse I-GENE
and I-GENE
human I-GENE
cDNAs I-GENE
encoding I-GENE
UNC I-GENE
- I-GENE
NUM I-GENE
- I-GENE
like I-GENE
kinase I-GENE
( O
NUM I-GENE
). O

RARE I-GENE
and O
UNC I-GENE
- I-GENE
NUM I-GENE
share O
a O
typical O
domain O
RARE O
of O
an O
amino O
- O
terminal O
kinase O
domain O
, O
a O
central O
proline O
/ O
serine O
rich O
( O
ALL_CAP O
) O
domain O
, O
and O
a O
RARE O
- O
terminal O
( O
C O
) O
domain O
. O

These O
results O
suggest O
that O
NUM I-GENE
is O
involved O
in O
a O
previously O
uncharacterized O
RARE O
RARE O
in O
mammalian O
cells O
. O

RARE I-GENE
enhancer I-GENE
of I-GENE
ALL_CAP I-GENE
( O
ALL_CAP I-GENE
) O
is O
a O
RARE O
protein O
required O
RARE O
ALL_CAP I-GENE
RARE O
. O

In O
RARE O
organisms O
, O
the O
ATP I-GENE
RARE I-GENE
and O
ALL_CAP I-GENE
kinase I-GENE
reactions O
are O
catalyzed O
by O
separate O
RARE O
encoded O
by O
two O
or O
three O
genes O
, O
suggesting O
that O
a O
fusion O
of O
separate O
genes O
RARE O
the O
course O
of O
evolution O
generated O
the O
RARE O
enzyme O
. O

Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
latent I-GENE
membrane I-GENE
protein I-GENE
1 I-GENE
( O
LMP1 I-GENE
) O
is O
essential O
RARE O
ALL_CAP O
- O
RARE O
transformation O
of O
RARE O
B O
lymphocytes O
. O

The O
amino O
- O
terminal O
RARE O
of O
NUM I-GENE
is O
a O
distant O
homolog I-GENE
of I-GENE
RARE I-GENE
RARE I-GENE
protein I-GENE
NUM I-GENE
, O
which O
has O
been O
implicated O
in O
RARE O
viral O
RNAs O
. O

Moreover O
, O
a O
recombinant O
RARE O
expressing O
NUM I-GENE
NUM I-GENE
/ I-GENE
7 I-GENE
RARE O
apoptosis O
in O
rat O
cells O
when O
RARE O
with O
wild O
- O
type O
p53 I-GENE
- O
expressing O
RARE O
. O

In O
ALL_CAP O
( O
RARE O
)- O
RARE O
ALL_CAP O
cells O
RARE O
NUM O
to O
NUM O
h O
, O
IE2 I-GENE
also O
accumulated O
in O
newly O
formed O
viral O
DNA O
replication O
RARE O
containing O
the O
polymerase I-GENE
RARE I-GENE
factor I-GENE
( O
NUM I-GENE
RARE O
the O
single I-GENE
- I-GENE
RARE I-GENE
DNA I-GENE
binding I-GENE
protein I-GENE
( O
SSB I-GENE
; O
NUM I-GENE
RARE O
the O
NUM I-GENE
- I-GENE
NUM I-GENE
RARE I-GENE
protein I-GENE
, O
and O
newly O
incorporated O
RARE O
( O
ALL_CAP O
). O

RARE O
RARE O
on O
RARE O
RARE O
have O
indicated O
that O
the O
RARE O
of O
the O
RARE O
RARE O
differs O
from O
that O
of O
the O
normal O
myocardium O
. O

CONCLUSION O
( O
S O
): O
RARE O
RARE O
ALL_CAP I-GENE
levels O
is O
an O
excellent O
method O
RARE O
RARE O
ovulation O
. O

However O
, O
RARE O
RARE O
RARE O
cervical O
RARE O
( O
group O
3 O
) O
rarely O
results O
in O
normal O
calcitonin I-GENE
levels O
and O
is O
associated O
with O
a O
high O
incidence O
of O
permanent O
RARE O
. O

We O
present O
a O
case O
of O
carcinoma O
of O
the O
breast O
RARE O
RARE O
with O
RARE O
that O
subsequently O
progressed O
to O
dialysis O
- O
dependent O
RARE O
failure O
in O
just O
1 O
month O
. O

PURPOSE O
: O
To O
evaluate O
the O
RARE O
- O
free O
survival O
( O
ALL_CAP O
) O
and O
overall O
survival O
( O
ALL_CAP O
RARE O
prognostic O
factors O
, O
and O
treatment O
- O
related O
mortality O
of O
women O
with O
RARE O
ALL_CAP O
inflammatory O
breast O
RARE O
( O
ALL_CAP O
) O
treated O
with O
combined O
modality O
therapy O
( O
ALL_CAP O
) O
and O
high O
- O
dose O
chemotherapy O
( O
ALL_CAP O
) O
with O
autologous O
RARE O
- O
cell O
transplantation O
. O

The O
ALL_CAP O
RARE O
RARE O
is O
either O
absent O
or O
present O
RARE O
a O
very O
low O
level O
in O
the O
polypeptide O
RARE O
from O
the O
cDNA O
that O
contained O
both O
the O
signal O
peptide O
and O
ALL_CAP O
signal O
sequences O
. O

We O
have O
RARE O
a O
novel O
NUM O
- O
kDa O
mammalian O
protein O
, O
which O
was O
RARE O
by O
an O
anti O
- O
peptide O
antibody O
against O
an O
RARE O
- O
containing O
nuclear O
RARE O
signal O
of O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
NUM I-GENE
subunit I-GENE
. O

Insulin I-GENE
- O
regulated O
events O
, O
however O
, O
occur O
in O
all O
cells O
. O

RARE O
regions O
in O
the O
promoter O
and O
third O
intron O
of O
the O
growth I-GENE
hormone I-GENE
gene I-GENE
in I-GENE
RARE I-GENE
RARE I-GENE
, O
RARE O
RARE O
RARE O
. O

Although O
most O
ALL_CAP O
genes O
have O
homologs O
encoded O
by O
other O
RARE O
, O
the O
ALL_CAP O
genome O
lacks O
a O
key O
gene O
required O
RARE O
the O
production O
of O
extracellular O
RARE O
virus O
. O

They O
self O
- O
completed O
the O
ALL_CAP O
- O
NUM O
questionnaire O
and O
their O
ALL_CAP O
was O
described O
and O
RARE O
compared O
to O
that O
of O
RARE O
controls O
. O

There O
was O
a O
trend O
toward O
an O
association O
between O
ALL_CAP O
and O
RARE O
nerve O
RARE O
fiber O
RARE O
( O
RARE O
= O
NUM O
. O
NUM O
, O
p O
= O
NUM O
. O
NUM O
). O

In O
addition O
, O
media O
containing O
F I-GENE
beta I-GENE
alpha I-GENE
/ O
ALL_CAP I-GENE
beta I-GENE
displayed O
high O
- O
affinity O
binding O
to O
both O
ALL_CAP I-GENE
and I-GENE
FSH I-GENE
receptors I-GENE
. O

In O
contrast O
, O
AP I-GENE
- I-GENE
2 I-GENE
binding O
activity O
was O
significantly O
greater O
in O
NUM O
cells O
, O
and O
Western O
blots O
confirmed O
increased O
AP I-GENE
- I-GENE
2 I-GENE
protein I-GENE
levels O
in O
these O
cells O
. O

N O
. O
RARE O
RARE O
, O
and O
M O
. O

Here O
, O
we O
describe O
a O
tyrosine O
- O
RARE O
nuclear O
protein O
, O
NUM I-GENE
- I-GENE
B I-GENE
, O
and O
show O
that O
it O
interacts O
with O
the O
nuclear I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
factor I-GENE
B I-GENE
, O
and O
the O
NUM I-GENE
- I-GENE
kDa I-GENE
Src I-GENE
substrate O
associated O
RARE O
mitosis O
, O
NUM I-GENE
. O

These O
mutants O
all O
failed O
to O
interact O
with O
the O
ALL_CAP I-GENE
fusion I-GENE
in O
the O
two O
- O
RARE O
RARE O
. O

ALL_CAP I-GENE
- O
ALL_CAP I-GENE
RARE O
in O
RARE O
RARE O
regulate O
RARE O
of O
the O
RARE I-GENE
- I-GENE
membrane I-GENE
protein I-GENE
ALL_CAP I-GENE
and O
RARE O
B O
resistance O
. O

Deletion O
of O
ALL_CAP I-GENE
revealed O
a O
dual O
regulatory O
effect O
of O
ALL_CAP I-GENE
on O
the O
RARE I-GENE
operon I-GENE
by O
acting O
RARE O
transcriptional O
activator O
in O
the O
presence O
of O
formate O
or O
RARE O
repressor O
in O
the O
absence O
of O
formate O
. O

With O
constructs O
containing O
the O
binding O
site O
of O
one O
gene O
fused O
to O
the O
promoter O
of O
the O
other O
, O
we O
demonstrated O
that O
the O
RARE O
requirements O
are O
a O
function O
of O
the O
specific O
binding O
site O
, O
not O
the O
promoter O
. O

In O
addition O
, O
all O
three O
RARE I-GENE
proteins I-GENE
of O
NUM O
bind O
equally O
RARE O
to O
HeLa O
cells O
transfected O
with O
cDNA O
encoding O
the O
RARE I-GENE
antigen I-GENE
RARE O
ALL_CAP I-GENE
( O
NUM I-GENE
)] O
subgroup O
of O
the O
NUM I-GENE
family I-GENE
, O
but O
show O
distinct O
RARE O
RARE O
NUM I-GENE
- O
( O
NUM I-GENE
) O
and O
ALL_CAP I-GENE
( O
NUM I-GENE
)- O
expressing O
cells O
. O

ALL_CAP O
using O
a O
whole O
RARE O
4 O
RARE O
demonstrated O
multiple O
RARE O
involving O
RARE O
4 O
in O
ALL_CAP O
- O
7 O
NUM O
and O
ALL_CAP O
- O
7 O
ALL_CAP O
, O
while O
S1 O
- O
NUM O
- O
NUM O
contained O
only O
a O
simple O
reciprocal O
translocation O
. O

The O
ALL_CAP I-GENE
gene I-GENE
encodes O
a O
RARE O
- O
RARE O
and O
the O
absence O
of O
cytogenetic O
evidence O
of O
RARE O
of O
other O
regions O
suggests O
that O
a O
RARE O
may O
not O
be O
overexpressed O
, O
and O
instead O
the O
ALL_CAP I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
RARE O
to O
mediate O
drug O
RARE O
. O

The O
effect O
of O
smoking O
was O
not O
examined O
in O
this O
study O
, O
RARE O
such O
data O
were O
not O
available O
. O

Serum I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
I I-GENE
( O
IGF I-GENE
- I-GENE
I I-GENE
) O
SD O
score O
increased O
from O
- O
2 O
. O
2 O
and O
- O
4 O
. O
2 O
in O
men O
and O
women O
, O
respectively O
, O
to O
1 O
. O
8 O
and O
- O
NUM O
. O
9 O
RARE O
6 O
months O
and O
NUM O
. O
8 O
and O
- O
NUM O
. O
7 O
RARE O
12 O
months O
. O

BACKGROUND O
: O
Measurement O
of O
RARE O
RARE O
varying O
distances O
, O
by O
real O
or O
simulated O
depth O
RARE O
tests O
, O
is O
helpful O
in O
the O
evaluation O
of O
patients O
with O
RARE O
RARE O
or O
RARE O
. O

RARE O
studies O
revealed O
that O
bovine I-GENE
brain I-GENE
RARE I-GENE
( I-GENE
RARE I-GENE
/ I-GENE
11 I-GENE
) I-GENE
could O
also O
bind O
to O
an O
N O
- O
terminal O
construct O
of O
NUM I-GENE
, O
while O
RARE O
binding O
of O
RARE O
( O
RARE O
/ O
11 O
RARE O
RARE O
( O
s O
RARE O
RARE O
( O
i O
RARE O
or O
RARE I-GENE
( I-GENE
12 I-GENE
/ I-GENE
NUM I-GENE
) I-GENE
to O
comparable O
constructs O
of O
NUM I-GENE
or O
NUM I-GENE
was O
observed O
. O

The O
NUM I-GENE
kinase I-GENE
functions O
in O
a O
RARE O
RARE O
network O
in O
RARE O
yeast O
. O

RARE O
transcription O
( O
RT O
)- O
PCR O
products O
were O
synthesized O
with O
two O
degenerate O
primers O
derived O
from O
the O
RARE O
motifs O
of O
various O
tyrosine I-GENE
kinases I-GENE
. O

In O
addition O
, O
the O
RARE O
activity O
of O
p300 I-GENE
was O
observed O
to O
be O
distinct O
from O
the O
broadly O
essential O
activation O
function O
of O
the O
NUM I-GENE
domain I-GENE
/ O
E1A I-GENE
- O
binding O
region O
. O

The O
RARE O
- O
specific O
HNF I-GENE
- I-GENE
3 I-GENE
/ O
fork I-GENE
head I-GENE
homolog I-GENE
- I-GENE
NUM I-GENE
protein O
( O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
; O
also O
known O
RARE O
RARE I-GENE
and O
RARE I-GENE
) O
is O
a O
family O
RARE O
of O
the O
RARE I-GENE
helix I-GENE
/ O
fork I-GENE
head I-GENE
transcription O
factors O
and O
in O
RARE O
liver O
its O
RARE O
is O
RARE O
prior O
to O
RARE O
entry O
into O
DNA O
replication O
( O
S O
RARE O
). O

In O
the O
mouse O
, O
NUM I-GENE
is O
RARE O
from O
RARE O
to O
adult O
, O
but O
NUM I-GENE
is O
mainly O
RARE O
RARE O
embryogenesis O
. O

The O
multiple O
functions O
of O
NUM I-GENE
described O
here O
suggest O
that O
several O
nuclear O
proteins O
are O
regulated O
by O
NUM I-GENE
conjugation O
. O

The O
role O
of O
RARE O
by O
RARE O
RARE O
from O
the O
RARE O
RARE O
into O
the O
RARE O
RARE O
was O
assessed O
by O
a O
small O
subgroup O
RARE O
ALL_CAP O
. O

We O
determined O
whether O
a O
single O
injection O
of O
slow O
- O
release O
estradiol O
- O
NUM O
( O
NUM O
) O
would O
induce O
RARE O
in O
RARE O
and O
whether O
NUM O
would O
RARE O
the O
RARE O
RARE O
( O
CL O
) O
of O
RARE O
. O

The O
level O
of O
serum I-GENE
RARE I-GENE
kinase I-GENE
was O
significantly O
high O
2 O
days O
after O
ALL_CAP O
, O
but O
it O
recovered O
in O
a O
week O
. O

Among O
the O
remaining O
NUM O
sites O
, O
RARE O
are O
in O
the O
promoters O
of O
known O
alpha O
- O
specific O
genes O
and O
two O
other O
sites O
have O
an O
NUM I-GENE
- O
NUM I-GENE
- O
dependent O
role O
in O
RARE O
the O
direction O
of O
RARE O
type O
switching O
. O

Activation O
of O
T O
cells O
via O
the O
TCR I-GENE
and O
other O
RARE O
receptors O
triggers O
a O
number O
of O
RARE O
RARE O
. O

A O
phylogenetic O
analysis O
with O
the O
TK I-GENE
domains I-GENE
from O
these O
sequences O
and O
a O
fourth O
, O
from O
a O
novel O
RARE I-GENE
ALL_CAP I-GENE
( O
all O
domains O
comprise O
the O
RARE O
RARE O
the O
TK I-GENE
class I-GENE
II I-GENE
receptors I-GENE
RARE O
showed O
that O
they O
are O
distantly O
related O
to O
the O
insulin I-GENE
and O
insulin I-GENE
- I-GENE
like I-GENE
receptors I-GENE
. O

Several O
NUM I-GENE
RNA I-GENE
- I-GENE
encoding I-GENE
sequences I-GENE
and O
various O
intergenic O
RARE O
were O
amplified O
from O
the O
individual O
HindIII I-GENE
fragments I-GENE
of O
about O
1 O
. O
3 O
and O
2 O
. O
8 O
kb O
. O

Results O
confirmed O
that O
stress O
produced O
CA3 O
RARE O
atrophy O
and O
RARE O
prevented O
it O
. O

We O
have O
isolated O
a O
binding O
RARE O
RARE O
the O
RARE I-GENE
RARE I-GENE
group I-GENE
C I-GENE
protein I-GENE
( O
ALL_CAP I-GENE
) O
by O
yeast O
two O
- O
RARE O
screening O
. O

These O
results O
suggest O
that O
both O
transcription O
RARE O
depend O
on O
or O
interact O
with O
different O
subunits O
of O
RNA I-GENE
polymerase I-GENE
, O
although O
their O
role O
in O
formation O
of O
proper O
DNA O
RARE O
may O
also O
be O
crucial O
. O

RARE O
RARE O
can O
RARE O
RARE O
and O
RARE O
by O
using O
RARE O
encoded O
by O
the O
ALL_CAP I-GENE
operon I-GENE
. O

Marked O
RARE O
significantly O
increased O
plasma O
values O
of O
RARE O
, O
phosphorus O
, O
RARE O
protein O
, O
and O
RARE I-GENE
aminotransferase I-GENE
. O

Studies O
have O
RARE O
the O
involvement O
of O
numerous O
loci O
on O
certain O
chromosomes O
; O
in O
excess O
of O
10 O
chromosomes O
are O
thought O
to O
be O
involved O
. O

By O
negatively O
RARE O
ALL_CAP I-GENE
- O
RARE O
receptor O
RARE O
, O
beta I-GENE
- I-GENE
RARE I-GENE
- O
RARE O
processes O
such O
RARE O
Src I-GENE
recruitment O
and O
clathrin I-GENE
- O
RARE O
internalization O
, O
which O
are O
required O
RARE O
ALL_CAP I-GENE
- O
RARE O
ERK I-GENE
activation O
, O
are O
inhibited O
, O
thus O
RARE O
further O
ERK I-GENE
activation O
. O

Based O
on O
subcellular O
fractionation O
, O
the O
NUM I-GENE
- I-GENE
kDa I-GENE
P I-GENE
- I-GENE
NUM I-GENE
protein I-GENE
is O
mostly O
cytosolic O
. O

RARE O
RARE O
identified O
that O
upstream I-GENE
RARE I-GENE
factor I-GENE
- I-GENE
1 I-GENE
and I-GENE
- I-GENE
2 I-GENE
( O
USF I-GENE
- I-GENE
1 I-GENE
and I-GENE
- I-GENE
2 I-GENE
) O
were O
part O
of O
these O
complexes O
. O

Conversely O
, O
E1A I-GENE
binding O
to O
only O
p300 I-GENE
/ O
CBP I-GENE
results O
in O
an O
increase O
in O
ALL_CAP I-GENE
enzyme I-GENE
activity O
and O
RARE O
in O
cell O
RARE O
RARE O
to O
irradiation O
, O
which O
is O
effectively O
RARE O
by O
the O
ALL_CAP I-GENE
chemical O
inhibitor O
3 O
- O
RARE O
. O

Analysis O
of O
its O
genomic O
region O
revealed O
that O
the O
NUM O
- O
kb O
NUM I-GENE
gene I-GENE
is O
divided O
into O
12 O
exons O
by O
11 O
RARE O
. O

These O
include O
the O
ALL_CAP O
and O
CAAT O
motifs O
. O

RARE O
pH O
changes O
associated O
with O
RARE O
. O

This O
RARE O
was O
based O
upon O
whether O
the O
diagnosis O
provided O
a O
RARE O
range O
of O
RARE O
or O
an O
RARE O
clinical O
RARE O
. O

The O
availability O
of O
potent O
regulatory O
DNA O
RARE O
harboring O
the O
murine I-GENE
NUM I-GENE
gene I-GENE
promoter I-GENE
could O
aid O
testing O
the O
RARE O
- O
specific O
RARE O
of O
RARE O
in O
vivo O
. O

It O
may O
be O
dependent O
on O
location O
of O
a O
focus O
( O
according O
to O
EEG O
) O
RARE O
RARE O
RARE O
on O
the O
character O
and O
manifestation O
of O
the O
accompanying O
RARE O
RARE O
. O

The O
results O
of O
these O
studies O
demonstrate O
that O
the O
rat O
ALL_CAP O
receptor O
SR I-GENE
- I-GENE
ALL_CAP I-GENE
promoter O
contains O
two O
sterol O
response O
elements O
( O
ALL_CAP O
and O
ALL_CAP O
) O
through O
which O
SREBP I-GENE
- I-GENE
NUM I-GENE
can O
bind O
and O
activate O
transcription O
of O
this O
gene O
. O

RARE O
of O
myosin I-GENE
- I-GENE
binding I-GENE
subunit I-GENE
( O
ALL_CAP I-GENE
) O
of O
myosin I-GENE
phosphatase I-GENE
by O
Rho I-GENE
- I-GENE
kinase I-GENE
in O
vivo O
. O

Of O
these O
patients O
, O
NUM O
, O
NUM O
were O
placed O
on O
a O
RARE O
RARE O
RARE O
transplantation O
, O
NUM O
, O
NUM O
of O
whom O
received O
a O
RARE O
RARE O
transplant O
between O
1991 O
and O
1997 O
. O

In O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
RARE O
this O
NUM I-GENE
repressor I-GENE
element I-GENE
( O
NUM I-GENE
) O
generated O
specific O
bands O
with O
nuclear O
extracts O
from O
RARE O
, O
but O
not O
from O
adipocytes O
. O

RARE O
of O
abnormal O
fat O
RARE O
and O
metabolic O
complications O
in O
HIV O
- O
RARE O
patients O
. O

RARE O
with O
RARE O
in O
radiotherapy O
or O
RARE O
- O
chemotherapy O
of O
head O
and O
neck O
tumors O

RARE O
staining O
was O
positive O
RARE O
S I-GENE
- I-GENE
NUM I-GENE
in O
all O
9 O
cases O
stained O
, O
positive O
RARE O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
in O
9 O
( O
NUM O
%) O
of O
10 O
, O
and O
negative O
RARE O
RARE I-GENE
in O
all O
9 O
cases O
in O
which O
RARE O
RARE O
remained O
in O
the O
RARE O
after O
previous O
sections O
. O

Patients O
with O
RARE O
I O
and O
III O
ALL_CAP O
did O
not O
differ O
in O
age O
RARE O
apparent O
onset O
, O
age O
RARE O
diagnosis O
, O
or O
interval O
from O
apparent O
onset O
of O
symptoms O
to O
diagnosis O
( O
biopsy O
). O

RARE O
RARE O
abnormalities O
were O
significantly O
more O
frequent O
in O
patients O
with O
type O
III O
than O
type O
I O
ALL_CAP O
. O

Taken O
together O
, O
differences O
in O
RARE O
and O
tissue O
RARE O
suggest O
that O
the O
human I-GENE
RARE I-GENE
RARE I-GENE
differs O
from O
the O
long I-GENE
RARE I-GENE
in O
physiological O
function O
. O

We O
describe O
here O
a O
Drosophila I-GENE
melanogaster I-GENE
FAK I-GENE
homologue I-GENE
, O
NUM I-GENE
, O
which O
maps O
to O
band O
NUM O
on O
the O
right O
RARE O
of O
the O
second O
RARE O
. O

Because O
the O
Pit I-GENE
- I-GENE
1 I-GENE
sites I-GENE
in O
the O
hGH I-GENE
- I-GENE
N I-GENE
gene I-GENE
promoter I-GENE
are O
insufficient O
RARE O
such O
gene O
activation O
in O
vivo O
, O
these O
data O
suggested O
a O
unique O
chromatin O
- O
RARE O
developmental O
role O
RARE O
Pit I-GENE
- I-GENE
1 I-GENE
in O
the O
hGH I-GENE
ALL_CAP I-GENE
. O

Recombinant I-GENE
RARE I-GENE
lyase I-GENE
was O
produced O
in O
a O
RARE O
- O
Sf9 O
RARE O
RARE O
. O

We O
show O
here O
that O
the O
third O
SH3 I-GENE
domain I-GENE
binds O
to O
Sos I-GENE
, O
a O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
RARE O
Ras I-GENE
and O
Rac I-GENE
, O
both O
in O
vitro O
and O
in O
vivo O
. O

RARE O
mutations O
in O
the O
third O
SH3 I-GENE
domain I-GENE
abolished O
the O
RARE I-GENE
- O
Sos I-GENE
interaction O
. O

In O
gel O
mobility O
shift O
assays O
, O
low O
binding O
activity O
of O
CBF I-GENE
to O
the O
wild I-GENE
- I-GENE
type I-GENE
ALL_CAP I-GENE
promoter I-GENE
sequence I-GENE
was O
observed O
with O
nuclear O
extracts O
from O
tissue O
with O
low O
ALL_CAP I-GENE
RARE O
levels O
, O
i O
. O
RARE O
. O
extracts O
from O
RARE O
and O
RARE O
seedlings O
, O
whereas O
high O
binding O
activity O
was O
detectable O
with O
extracts O
from O
tissues O
with O
high O
ALL_CAP I-GENE
RARE O
levels O
, O
i O
. O
RARE O
. O
extracts O
from O
light O
- O
grown O
seedlings O
and O
RARE O
seedlings O
treated O
with O
RARE I-GENE
. O

RARE O
RARE O
infections O
are O
easily O
RARE O
because O
conventional O
methods O
RARE O
bacterial O
detection O
may O
fail O
. O

For O
this O
purpose O
, O
we O
used O
a O
series O
of O
RARE O
constructs O
encoding O
different O
forms O
of O
the O
envelope I-GENE
glycoprotein I-GENE
E I-GENE
of I-GENE
the I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
virus I-GENE
. O

They O
are O
RARE O
into O
two O
RARE O
that O
activate O
RARE O
pathways O
via O
different O
cell O
surface O
receptors O
. O

We O
report O
here O
that O
out O
of O
the O
major O
pro O
- O
inflammatory O
RARE O
examined O
, O
ALL_CAP I-GENE
- I-GENE
1alpha I-GENE
, O
ALL_CAP I-GENE
- I-GENE
1beta I-GENE
, O
TNF I-GENE
- I-GENE
alpha I-GENE
and O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
, O
only O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
was O
generated O
and O
RARE O
in O
RARE I-GENE
- O
expressing O
cells O
without O
any O
additional O
RARE O
in O
serum O
- O
supplemented O
cultures O
( O
10 O
% O
ALL_CAP O
). O

RARE O
diseases O
involving O
the O
RARE O
matter O
were O
very O
rare O
, O
but O
we O
must O
consider O
the O
presence O
of O
RARE O
RARE O
involvement O
in O
patients O
with O
ALL_CAP O
. O

To O
define O
the O
minimal O
ALL_CAP O
binding O
domain O
RARE O
human I-GENE
VDR I-GENE
( O
ALL_CAP I-GENE
RARE O
a O
series O
of O
C O
- O
RARE O
truncated O
ALL_CAP I-GENE
mutants I-GENE
( O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
and O
NUM O
) O
was O
generated O
and O
RARE O
in O
bacteria O
. O

By O
an O
RARE O
- O
fit O
mechanism O
, O
contacts O
with O
the O
RARE O
can O
activate O
formation O
of O
a O
RARE O
transition O
state O
RARE O
a O
site O
over O
70 O
A O
RARE O
. O

These O
RARE O
, O
or O
clusters O
of O
RARE O
loci O
, O
are O
NUM O
- O
NUM O
kb O
and O
harbor O
RARE O
least O
four O
RARE O
and O
an O
RARE O
NUM I-GENE
RARE I-GENE
. O

This O
revealed O
a O
minimum O
of O
RARE O
novel O
ALL_CAP I-GENE
- I-GENE
related I-GENE
proteins I-GENE
, O
designated O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
to O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
. O

In O
part O
RARE O
a O
result O
of O
its O
RARE O
to O
RARE O
RARE O
RARE O
, O
the O
ALL_CAP O
RARE O
has O
extremely O
low O
ALL_CAP O
power O
requirements O
. O

In O
addition O
, O
ALL_CAP I-GENE
RARE O
was O
RARE O
RARE O
20 O
- O
RARE O
RARE O
in O
RARE O
- O
RARE O
canine O
RARE O
RARE O
cells O
and O
16 O
- O
RARE O
in O
RARE O
RARE O
medium O
, O
which O
is O
believed O
to O
mimic O
the O
RARE O
RARE O
. O

However O
, O
mechanisms O
underlying O
HIV O
- O
1 O
gene O
RARE O
in O
the O
CNS O
are O
poorly O
understood O
. O

Is O
radical O
RARE O
a O
safe O
RARE O
to O
radical O
hysterectomy O
RARE O
patients O
with O
RARE O
IA O
- O
B O
carcinoma O
of O
the O
cervix O
? O
BACKGROUND O
: O
The O
prognosis O
associated O
with O
lymph O
node O
negative O
, O
early O
RARE O
carcinoma O
of O
the O
cervix O
is O
excellent O
, O
with O
5 O
- O
year O
survival O
rates O
greater O
than O
NUM O
%. O

A O
key O
event O
in O
this O
process O
is O
the O
selective O
recognition O
of O
the O
target O
membrane O
by O
the O
vesicle O
and O
the O
current O
view O
is O
that O
ALL_CAP I-GENE
protein I-GENE
interactions O
likely O
play O
a O
central O
role O
in O
vesicle O
- O
target O
recognition O
and O
or O
membrane O
fusion O
. O

RARE O
with O
a O
RARE O
I O
configuration O
were O
found O
to O
have O
low O
values O
RARE O
the O
RARE O
- O
RARE O
angle O
and O
RARE O
overlap O
, O
which O
are O
known O
to O
be O
associated O
with O
a O
short O
RARE O
- O
RARE O
distance O
. O

Measurements O
in O
the O
ALL_CAP O
p O
. O
a O
. O
, O
ALL_CAP O
RARE O
. O
and O
RARE O
RARE O
' O
s O
RARE O
were O
made O
in O
a O
RARE O
of O
NUM O
patients O
. O

A O
group O
of O
NUM O
ALL_CAP O
- O
IV O
RARE O
schizophrenic O
in O
- O
patients O
were O
assessed O
three O
times O
using O
the O
ALL_CAP O
, O
ALL_CAP O
, O
ALL_CAP O
and O
ALL_CAP O
. O

In O
conclusion O
: O
( O
i O
) O
ALL_CAP O
kit O
is O
suggested O
to O
be O
used O
RARE O
screening O
SE O
producing O
strains O
; O
( O
ii O
) O
ALL_CAP O
- O
ALL_CAP O
and O
ALL_CAP O
RARE O
are O
suitable O
RARE O
epidemiological O
investigation O
of O
SE O
RARE O
, O
but O
the O
lack O
of O
ability O
RARE O
detecting O
ALL_CAP O
, O
long O
time O
required O
RARE O
testing O
with O
ALL_CAP O
- O
ALL_CAP O
kit O
and O
high O
background O
when O
using O
ALL_CAP O
kit O
must O
be O
overcome O
; O
and O
( O
iii O
) O
because O
of O
the O
complicated O
test O
procedures O
and O
the O
lack O
of O
ability O
RARE O
detecting O
ALL_CAP O
, O
the O
RARE O
of O
ALL_CAP O
- O
ALL_CAP O
kit O
in O
screening O
and O
epidemiological O
research O
RARE O
is O
low O
. O

Comparison O
of O
immunoassay O
RARE O
RARE O
detection O
of O
RARE I-GENE
RARE I-GENE
produced O
by O
RARE O
RARE O

Despite O
the O
high O
frequency O
of O
RARE O
infection O
, O
the O
seropositive O
rates O
of O
ALL_CAP O
antibody O
still O
correlated O
RARE O
with O
the O
dose O
of O
vaccine O
received O
, O
i O
. O
RARE O
., O
67 O
% O
( O
NUM O
/ O
NUM O
RARE O
NUM O
% O
( O
65 O
/ O
97 O
RARE O
NUM O
% O
( O
4 O
/ O
12 O
) O
and O
40 O
% O
( O
19 O
/ O
NUM O
) O
RARE O
children O
receiving O
3 O
, O
2 O
, O
1 O
, O
and O
NUM O
dose O
of O
ALL_CAP O
vaccines O
, O
respectively O
( O
P O
< O
NUM O
. O
0001 O
Chi O
- O
square O
RARE O
trend O
test O
). O

Furthermore O
, O
in O
vivo O
and O
in O
vitro O
protein O
- O
protein O
interaction O
experiments O
have O
shown O
that O
NUM I-GENE
protein I-GENE
interacts O
with O
itself O
and O
with O
NUM I-GENE
protein I-GENE
but O
not O
with O
two O
other O
members O
( O
NUM I-GENE
and O
NUM I-GENE
) O
of O
the O
SR I-GENE
family I-GENE
that O
are O
known O
to O
interact O
with O
the O
Arabidopsis O
full O
- O
length O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
only O
. O

In O
summary O
, O
WT1 I-GENE
is O
RARE O
by O
RARE O
( O
dT O
) O
chromatography O
, O
RARE O
are O
NUM I-GENE
, O
the O
NUM I-GENE
small I-GENE
nuclear I-GENE
ALL_CAP I-GENE
- I-GENE
associated I-GENE
protein I-GENE
NUM I-GENE
and O
ALL_CAP O
NUM I-GENE
. O

Six O
out O
of O
ten O
hearts O
from O
RARE O
RARE O
infants O
showed O
varying O
degrees O
of O
positive O
staining O
. O

NUM I-GENE
maps O
to O
distal O
mouse O
Chr O
1 O
and O
human O
Chr O
NUM O
, O
chromosomal O
regions O
that O
have O
not O
shown O
evidence O
RARE O
imprinting O
and O
, O
in O
contrast O
to O
RARE I-GENE
, O
NUM I-GENE
is O
RARE O
equally O
from O
both O
parental O
alleles O
. O

A O
novel O
pleckstrin I-GENE
homology I-GENE
- I-GENE
related I-GENE
gene I-GENE
family I-GENE
defined O
by O
RARE I-GENE
/ O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
: O
tissue O
- O
specific O
RARE O
, O
chromosomal O
location O
, O
and O
parental O
imprinting O
. O

The O
RARE O
RARE O
highly O
reactive O
RARE O
( O
ALL_CAP O
) O
to O
RARE O
RARE O
, O
i O
. O
RARE O
. O
to O
RARE O
highly O
toxic O
substances O
such O
RARE O
the O
RARE O
agents O
ALL_CAP O
, O
ALL_CAP O
, O
HD O
and O
ALL_CAP O
, O
has O
been O
demonstrated O
in O
the O
laboratory O
. O

There O
were O
minimal O
negative O
effects O
on O
RARE O
parameters O
, O
acid O
- O
RARE O
status O
, O
and O
RARE O
gases O
. O

RARE O
out O
of O
NUM O
RARE O
failure O
patients O
had O
RARE I-GENE
I I-GENE
NUM O
. O
NUM O
- O
NUM O
. O
9 O
microg O
/ O
RARE O
using O
RARE O
method O
and O
4 O
had O
levels O
of O
NUM O
. O
07 O
- O
NUM O
. O
NUM O
microg O
/ O
RARE O
using O
RARE O
1 O
. O

Therefore O
, O
we O
propose O
that O
p27 I-GENE
represents O
a O
crucial O
molecule O
in O
ALL_CAP O
RARE O
that O
cannot O
be O
replaced O
by O
p21 I-GENE
. O

Transient O
, O
high O
- O
level O
Ras I-GENE
- O
RARE O
induces O
transcriptional O
activation O
of O
p21 I-GENE
RARE O
by O
a O
ALL_CAP O
- O
rich O
region O
in O
p21 I-GENE
promoter I-GENE
- O
NUM O
- O
54 O
bp O
relative O
to O
the O
transcription O
initiation O
site O
containing O
binding O
sites O
RARE O
NUM I-GENE
- I-GENE
family I-GENE
transcription I-GENE
factors I-GENE
. O

The O
RET I-GENE
/ O
NUM I-GENE
rearrangement O
is O
formed O
by O
fusion O
of O
the O
NUM I-GENE
and O
RET I-GENE
genes I-GENE
, O
and O
is O
highly O
RARE O
in O
radiation O
- O
RARE O
post O
- O
RARE O
RARE O
thyroid O
carcinomas O
. O

RARE O
of O
small O
cells O
is O
still O
observed O
after O
RARE O
- O
transfection O
of O
ALL_CAP I-GENE
and O
LMP1 I-GENE
but O
in O
addition O
a O
few O
apoptotic O
HD O
- O
ALL_CAP O
cells O
with O
large O
fused O
nuclear O
masses O
are O
identified O
suggesting O
that O
specific O
inhibition O
of O
JNK I-GENE
leads O
also O
to O
apoptosis O
of O
LMP1 I-GENE
RARE O
ALL_CAP O
cells O
. O

In O
addition O
to O
the O
ALL_CAP I-GENE
protein I-GENE
NUM I-GENE
( O
NUM I-GENE
RARE O
there O
are O
other O
RARE O
RARE O
nuclear O
proteins O
that O
recognize O
the O
NUM I-GENE
box I-GENE
in O
NUM O
kDa O
RARE I-GENE
gene O
promoters O
. O

The O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
protein I-GENE
can O
activate O
transcription O
from O
a O
truncated O
promoter O
containing O
a O
RARE O
of O
the O
NUM I-GENE
site I-GENE
in O
yeast O
cells O
; O
however O
, O
it O
inhibited O
regulated O
transcription O
of O
a O
NUM I-GENE
kDa I-GENE
RARE I-GENE
promoter I-GENE
in O
a O
transient O
RARE O
assay O
using O
cultured O
RARE O
RARE O
cells O
. O

ALL_CAP O
, O
2 O
ALL_CAP O
, O
ALL_CAP O
, O
are O
some O
of O
these O
recent O
substances O
. O

There O
were O
NUM O
deaths O
, O
RARE O
of O
which O
were O
RARE O
to O
be O
RARE O
. O

With O
this O
ALL_CAP I-GENE
and O
estrogen O
treatment O
regimen O
, O
most O
girls O
with O
ALL_CAP O
can O
grow O
and O
develop O
much O
more O
in O
RARE O
with O
their O
healthy O
RARE O
. O

We O
propose O
that O
the O
RARE O
responsiveness O
of O
NUM I-GENE
is O
the O
result O
of O
preferential O
binding O
of O
COUP I-GENE
- I-GENE
ALL_CAP I-GENE
RARE O
the O
NUM I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
site I-GENE
. O

RARE O
NUM I-GENE
basal O
activity O
appears O
to O
be O
due O
to O
an O
E O
- O
box O
in O
NUM I-GENE
that O
interacts O
with O
NUM I-GENE
, O
a O
ubiquitous O
bHLH I-GENE
/ I-GENE
leucine I-GENE
zipper I-GENE
transcription I-GENE
factor I-GENE
. O

The O
RARE O
one O
is O
a O
ALL_CAP O
- O
responsive O
element O
that O
controls O
the O
RARE O
- O
line O
NUM I-GENE
promoter I-GENE
activity O
but O
is O
not O
required O
RARE O
its O
activation O
. O

To O
understand O
the O
basis O
RARE O
the O
increased O
cell O
surface O
stability O
compared O
with O
wild O
- O
type O
peptide O
and O
to O
understand O
the O
differences O
in O
T O
cell O
recognition O
between O
NUM I-GENE
and O
NUM I-GENE
, O
we O
determined O
the O
RARE O
- O
ray O
RARE O
RARE O
of O
the O
two O
class I-GENE
I I-GENE
MHC I-GENE
- I-GENE
peptide I-GENE
complexes I-GENE
. O

RARE O
of O
RARE I-GENE
I I-GENE
was O
also O
observed O
in O
cells O
incubated O
RARE O
NUM O
degrees O
C O
. O

In O
addition O
, O
using O
biochemical O
activity O
assays O
RARE O
Rho I-GENE
- O
like O
GTPases I-GENE
, O
we O
show O
that O
the O
RARE O
of O
NUM I-GENE
, O
NUM I-GENE
, O
or O
NUM I-GENE
- O
NUM I-GENE
in O
NUM O
or O
NUM O
cells O
triggers O
activation O
of O
both O
RhoA I-GENE
and O
Rac1 I-GENE
, O
but O
not O
of O
Cdc42 I-GENE
. O

In O
conclusion O
, O
our O
data O
do O
not O
support O
a O
role O
RARE O
RARE I-GENE
in O
the O
RARE O
of O
stable O
multiple O
sclerosis O
lesions O
RARE O
measured O
by O
central O
conduction O
time O
. O

The O
RARE O
NUM O
growing O
on O
the O
right O
flank O
of O
male O
ALL_CAP O
/ O
RARE O
rats O
was O
RARE O
RARE O
2 O
or O
4 O
h O
RARE O
20 O
degrees O
C O
or O
37 O
degrees O
C O
. O

RARE O
to O
RARE O
control O
RARE O
( O
RARE O
. O
g O
., O
RARE O
RARE O
these O
RARE O
- O
dependent O
RARE O
anomalies O
elicited O
a O
large O
NUM O
effect O
that O
RARE O
RARE O
about O
NUM O
to O
NUM O
msec O
after O
RARE O
onset O
. O

These O
synergistic O
effects O
were O
strongly O
RARE I-GENE
- I-GENE
1 I-GENE
dose O
- O
dependent O
. O

Like O
the O
RARE I-GENE
protein I-GENE
, O
NUM I-GENE
inhibited O
cell O
RARE O
progression O
from O
the O
NUM O
/ O
G1 O
to O
S O
phases O
. O

The O
coordinate O
increase O
in O
RARE I-GENE
NUM I-GENE
and O
p21 I-GENE
had O
the O
effect O
of O
decreasing O
the O
specific O
but O
not O
absolute O
activity O
of O
RARE I-GENE
NUM I-GENE
/ O
NUM I-GENE
. O
p53 I-GENE
was O
not O
involved O
since O
CSF I-GENE
- I-GENE
1 I-GENE
induction O
of O
p21 I-GENE
was O
unaffected O
by O
dominant I-GENE
- I-GENE
negative I-GENE
p53 I-GENE
RARE O
. O

In O
addition O
, O
ALL_CAP I-GENE
displays O
high O
homology O
to O
microtubule I-GENE
and I-GENE
nuclear I-GENE
associated I-GENE
protein I-GENE
( O
M I-GENE
- I-GENE
ALL_CAP I-GENE
) O
and O
NUM I-GENE
- I-GENE
NUM I-GENE
, O
both O
of O
unknown O
function O
. O

In O
this O
study O
NUM O
patients O
( O
20 O
females O
and O
6 O
males O
) O
were O
evaluated O
. O

The O
signalling O
molecules O
NUM I-GENE
and O
RARE I-GENE
RARE I-GENE
, O
implicated O
in O
the O
activation O
of O
NUM I-GENE
in O
RARE O
RARE O
cells O
in O
the O
RARE O
, O
are O
also O
produced O
in O
the O
RARE O
of O
the O
NUM I-GENE
RARE I-GENE
domain I-GENE
in O
the O
RARE O
. O

ALL_CAP O
DESIGN O
ALL_CAP O
METHODS O
: O
A O
study O
was O
RARE O
to O
compare O
the O
collection O
of O
RARE O
with O
the O
new O
device O
, O
the O
ALL_CAP O
( O
version O
RARE O
V O
] O
6 O
. O
NUM O
with O
ALL_CAP O
RARE O
set O
RARE O
and O
that O
with O
the O
ALL_CAP O
( O
mononuclear O
cell O
) O
procedure O
( O
NUM O
. O
7 O
with O
RARE O
cell O
RARE O
set O
RARE O
RARE O
patients O
and O
healthy O
donors O
. O

RARE I-GENE
dialysis O
: O
effective O
removal O
of O
RARE O
in O
a O
patient O
with O
RARE O
RARE O
RARE O
and O
successful O
RARE O
to O
liver O
transplantation O
: O
a O
new O
possibility O
RARE O
the O
elimination O
of O
protein O
- O
RARE O
RARE O
. O

Some O
artificial O
promoter O
constructs O
containing O
multiple O
NUM I-GENE
sites I-GENE
were O
highly O
responsive O
to O
ethanol O
, O
but O
others O
were O
not O
, O
suggesting O
that O
the O
organization O
of O
the O
proximal O
promoter O
region O
was O
an O
additional O
factor O
that O
affected O
the O
ethanol O
response O
. O

Overexpression O
of O
CDP I-GENE
/ O
cut I-GENE
in O
ALL_CAP O
NUM O
/ O
2 O
. O
8 O
osteosarcoma O
cells O
results O
in O
repression O
of O
ALL_CAP I-GENE
promoter I-GENE
activity O
; O
this O
repression O
is O
abrogated O
by O
RARE O
ALL_CAP I-GENE
box I-GENE
I I-GENE
. O

RARE O
of O
double O
- O
RARE O
RNA O
into O
C O
. O
elegans O
results O
in O
RARE O
lethality O
; O
thus O
, O
the O
NUM I-GENE
gene I-GENE
is O
essential O
not O
only O
in O
yeast O
but O
also O
in O
RARE O
least O
one O
RARE O
. O

Both O
domains O
were O
required O
RARE O
specific O
DNA O
binding O
to O
the O
beta I-GENE
- I-GENE
retinoic I-GENE
acid I-GENE
receptor I-GENE
element I-GENE
, O
producing O
a O
DNase I-GENE
I I-GENE
footprint O
covering O
predominantly O
one O
RARE O
. O

RARE I-GENE
family I-GENE
proteins I-GENE
are O
zinc O
finger O
transcriptional O
RARE O
RARE O
identified O
in O
Drosophila O
which O
play O
critical O
roles O
in O
cell O
fate O
determination O
. O

Consistent O
with O
this O
finding O
, O
beta I-GENE
- I-GENE
catenin I-GENE
interacted O
directly O
with O
the O
ALL_CAP I-GENE
receptor I-GENE
( O
RAR I-GENE
) O
in O
a O
retinoid O
- O
dependent O
manner O
, O
but O
not O
with O
the O
retinoid I-GENE
X I-GENE
receptor I-GENE
( O
RXR I-GENE
RARE O
and O
RAR I-GENE
RARE O
with O
TCF I-GENE
RARE O
beta I-GENE
- I-GENE
catenin I-GENE
binding O
. O

Sequence O
analysis O
of O
the O
promoter O
region O
showed O
RARE O
TATA O
box O
but O
identified O
consensus O
binding O
motifs O
RARE O
NUM I-GENE
, O
CREB I-GENE
, O
and O
RARE O
sites O
of O
the O
estrogen I-GENE
receptor I-GENE
binding I-GENE
site I-GENE
. O

RARE I-GENE
kinase I-GENE
gene O
RARE O
and O
transcriptional O
RARE O
. O

RARE O
was O
followed O
by O
a O
similar O
increase O
of O
platelet O
activity O
with O
maximal O
values O
reached O
RARE O
the O
NUM O
hour O
in O
both O
groups O
( O
NUM O
+/- O
NUM O
IU O
/ O
ml O
in O
Group O
1 O
and O
NUM O
+/- O
NUM O
in O
Group O
2 O
: O
p O
& O
RARE O
; O
NUM O
baseline O
and O
p O
ALL_CAP O
between O
the O
groups O
). O

Similar O
to O
NUM I-GENE
, O
isolated O
NUM I-GENE
binds O
DNA O
with O
moderate O
strength O
and O
was O
a O
RARE O
RARE O
double O
- O
RARE O
primer O
- O
template O
DNA O
. O

Finally O
, O
three O
new O
missense O
mutations O
, O
NUM O
, O
NUM O
, O
and O
NUM O
, O
were O
identified O
in O
the O
human I-GENE
ALL_CAP I-GENE
gene I-GENE
from O
ALL_CAP O
patients O
. O

These O
data O
indicate O
that O
the O
interaction O
of O
NUM I-GENE
with O
the O
RARE O
region O
of O
NUM I-GENE
is O
necessary O
RARE O
translation O
, O
whereas O
the O
interaction O
of O
NUM I-GENE
with O
the O
C O
- O
terminal O
region O
plays O
a O
RARE O
role O
. O

The O
NUM I-GENE
/ O
NUM I-GENE
apoptotic O
form O
was O
more O
potent O
than O
NUM I-GENE
/ O
NUM I-GENE
in O
these O
RARE O
assays O
. O

12 O
: O
NUM O
- O
NUM O
, O
1998 O
): O
a O
key O
step O
of O
this O
model O
is O
the O
activation O
of O
the O
ALL_CAP I-GENE
NUM I-GENE
through O
the O
G O
( O
RARE O
)- O
dependent O
RARE O
of O
the O
NUM I-GENE
- O
ALL_CAP I-GENE
cascade O
to O
the O
plasma O
membrane O
. O

Consistent O
with O
this O
finding O
, O
wild I-GENE
- I-GENE
type I-GENE
ALL_CAP I-GENE
inhibits O
TBP I-GENE
binding O
to O
the O
HIS3 I-GENE
promoter I-GENE
in O
vitro O
, O
while O
ALL_CAP I-GENE
RARE O
NUM I-GENE
or O
NUM I-GENE
is O
not O
RARE O
. O

Saccharomyces O
cerevisiae O
contains O
a O
genetically O
and O
RARE O
proven O
CAK I-GENE
gene I-GENE
, O
NUM I-GENE
, O
that O
encodes O
a O
RARE O
NUM I-GENE
- I-GENE
kDa I-GENE
NUM I-GENE
protein I-GENE
unrelated O
to O
NUM I-GENE
. O

Northern O
blot O
and O
reverse O
transcription O
- O
PCR O
analyses O
of O
human O
mRNA O
samples O
demonstrate O
that O
ALL_CAP I-GENE
is O
RARE O
exclusively O
in O
the O
retina O
, O
with O
transcripts O
of O
RARE O
7 O
. O
5 O
kb O
, O
RARE O
3 O
. O
NUM O
kb O
, O
and O
RARE O
2 O
. O
3 O
kb O
by O
Northern O
blot O
analysis O
. O

RARE O
striking O
was O
the O
conservation O
of O
an O
AP I-GENE
- I-GENE
4 I-GENE
binding I-GENE
site I-GENE
within O
NUM O
nucleotides O
upstream O
of O
the O
transcription O
initiation O
site O
in O
both O
RARE I-GENE
- O
NUM I-GENE
and O
RARE I-GENE
- O
NUM I-GENE
genes O
. O

Based O
on O
a O
type O
I O
error O
of O
NUM O
. O
05 O
, O
our O
study O
had O
a O
power O
greater O
than O
or O
equal O
to O
NUM O
% O
to O
detect O
group O
differences O
in O
treatment O
effect O
of O
greater O
than O
or O
equal O
to O
NUM O
% O
to O
20 O
%. O

CONCLUSIONS O
: O
Serum O
levels O
of O
S I-GENE
- I-GENE
NUM I-GENE
are O
reliable O
markers O
RARE O
adverse O
neurologic O
outcomes O
after O
cardiac O
surgery O
. O

However O
, O
RARE O
genetic O
alteration O
was O
detected O
in O
any O
of O
the O
cancers O
examined O
. O

All O
problems O
were O
associated O
with O
RARE O
or O
lost O
RARE O
. O

RARE I-GENE
: O
lower O
lipids O
and O
better O
RARE O
? O
Although O
RARE O
are O
widely O
used O
RARE O
cholesterol O
- O
lowering O
drugs O
, O
a O
recent O
study O
suggests O
that O
these O
compounds O
have O
RARE O
effects O
on O
bone O
and O
could O
be O
developed O
into O
new O
treatments O
RARE O
common O
metabolic O
bone O
diseases O
such O
RARE O
RARE O

The O
accumulated O
products O
of O
RARE O
duplication O
events O
can O
be O
readily O
observed O
among O
the O
genes O
encoding O
voltage O
- O
dependent O
Ca O
( O
2 O
+) O
ion O
RARE O
. O

The O
ALL_CAP I-GENE
response I-GENE
regulator I-GENE
from O
RARE O
RARE O
binds O
independently O
to O
two O
RARE O
direct O
repeats O
RARE O
upstream O
of O
the O
ALL_CAP I-GENE
promoter I-GENE
. O

Cloning O
and O
sequencing O
of O
the O
upstream O
region O
of O
ALL_CAP I-GENE
revealed O
the O
presence O
of O
two O
RARE O
of O
NUM O
and O
1 O
, O
NUM O
bp O
that O
were O
shown O
to O
be O
able O
to O
encode O
proteins O
with O
high O
homology O
to O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
proteins I-GENE
, O
respectively O
. O

RARE O
: O
To O
evaluate O
endometrial O
thickness O
and O
the O
incidence O
of O
RARE O
bleeding O
in O
RARE O
women O
using O
either O
RARE O
2 O
. O
5 O
mg O
or O
continuous O
combined O
2 O
mg O
estradiol O
and O
1 O
mg O
RARE O
RARE O
( O
E O
+ O
ALL_CAP O
) O
daily O
RARE O
hormone O
RARE O
therapy O
. O

RARE O
cultures O
, O
prepared O
from O
RARE O
RARE O
from O
these O
18 O
children O
RARE O
6 O
months O
of O
age O
, O
produced O
lower O
yields O
of O
IFN I-GENE
than O
those O
of O
the O
remaining O
53 O
children O
, O
when O
RARE O
with O
adenovirus O
( O
P O
< O
NUM O
. O
001 O
RARE O
coronavirus O
( O
P O
< O
NUM O
. O
001 O
) O
or O
RARE O
( O
P O
= O
NUM O
. O
NUM O
). O

In O
the O
ALL_CAP O
ALL_CAP O
group O
the O
- O
age O
based O
dose O
would O
have O
been O
similarly O
dependent O
on O
the O
initial O
seizure O
threshold O
level O
. O

Histological O
analysis O
showed O
that O
the O
RARE O
RARE O
in O
the O
ALL_CAP O
- O
treated O
group O
was O
RARE O
RARE O
in O
the O
hippocampal O
area O
( O
NUM O
) O
of O
ischemic O
rats O
and O
in O
the O
RARE O
gyrus O
and O
hippocampal O
area O
( O
NUM O
and O
CA3 O
) O
of O
EC O
- O
lesioned O
rats O
compared O
with O
the O
RARE O
group O
. O

The O
RARE O
of O
RARE O
of O
NUM O
and O
NUM O
were O
1 O
: O
1 O
, O
whereas O
those O
of O
the O
four O
minor O
sites O
all O
together O
were O
< O
NUM O
% O
of O
the O
major O
one O
. O

Serum O
ALL_CAP O
- O
DNA O
, O
viral O
RARE O
, O
and O
liver O
RARE O
were O
measured O
RARE O
; O
liver O
RARE O
was O
taken O
before O
and O
RARE O
treatment O
in O
12 O
patients O
. O

Chem O
. O

RARE O
induction O
of O
AP I-GENE
- I-GENE
1 I-GENE
was O
reached O
RARE O
a O
concentration O
of O
NUM O
nmol O
/ O
L O
of O
ALL_CAP O
. O

RARE O
RARE O
RARE O
. O
g O
., O
RARE O
. O
RARE O
. O

RARE O
were O
RARE O
and O
RARE O
size O
was O
estimated O
by O
RARE O
RARE O
each O
time O
period O
. O

RARE O
studies O
showed O
that O
beam O
RARE O
significantly O
improved O
RARE O
and O
angiographic O
image O
quality O
. O

Role O
of O
estrogen I-GENE
receptor I-GENE
RARE O
and O
estrogen O
response O
element O
sequence O
on O
interaction O
with O
chicken I-GENE
RARE I-GENE
upstream I-GENE
promoter I-GENE
transcription I-GENE
factor I-GENE
( O
COUP I-GENE
- I-GENE
ALL_CAP I-GENE
). O

CONCLUSION O
: O
In O
RARE I-GENE
functioning O
throughout O
the O
cell O
RARE O
, O
tyrosine O
RARE O
is O
RARE O
to O
the O
activation O
of O
kinase O
, O
whereas O
the O
RARE O
of O
threonine O
in O
the O
T O
- O
loop O
is O
essential O
RARE O
activation O
. O

We O
also O
report O
that O
ALL_CAP I-GENE
interacts O
with O
COUP I-GENE
- I-GENE
ALL_CAP I-GENE
in O
transfected O
ALL_CAP O
- O
1 O
cells O
. O

NUM I-GENE
. O

The O
prevalence O
of O
hepatitis O
C O
virus O
( O
HCV O
) O
infection O
is O
relatively O
low O
in O
childhood O
, O
with O
anti I-GENE
- I-GENE
HCV I-GENE
prevalence O
rates O
of O
NUM O
. O
1 O
- O
NUM O
. O
4 O
% O
in O
the O
Western O
world O
. O

RARE O
and O
RARE O
- O
based O
RARE O
should O
be O
provided O
to O
patients O
RARE O
to O
the O
means O
of O
prevention O
with O
RARE O
attention O
to O
individual O
risk O
groups O
such O
RARE O
IV O
drug O
RARE O
. O

During O
RARE O
, O
more O
than O
1 O
% O
of O
neurons O
in O
RARE O
that O
RARE O
the O
RARE O
RARE O
beta I-GENE
- I-GENE
galactosidase I-GENE
, O
with O
the O
number O
of O
positive O
cells O
remaining O
constant O
RARE O
RARE O
least O
5 O
months O
. O

As O
an O
RARE O
approach O
to O
this O
question O
, O
we O
have O
studied O
the O
effects O
of O
RARE O
RARE O
ALL_CAP I-GENE
, O
SHP I-GENE
- I-GENE
1 I-GENE
, O
or O
SHP I-GENE
- I-GENE
2 I-GENE
NUM O
- O
containing O
RARE O
proteins O
on O
Fc I-GENE
gamma I-GENE
NUM I-GENE
RARE O
. O

RARE O
to O
those O
with O
normal O
RARE O
functions O
, O
these O
patients O
were O
older O
( O
P O
< O
or O
= O
NUM O
. O
01 O
RARE O
had O
significantly O
elevated O
RARE O
pressures O
( O
P O
< O
NUM O
. O
01 O
or O
P O
= O
NUM O
. O
0001 O
RARE O
and O
in O
the O
case O
of O
RARE O
1 O
DM O
, O
with O
a O
RARE O
body O
mass O
index O
( O
P O
= O
NUM O
. O
0001 O
) O
and O
RARE O
- O
hip O
ratio O
( O
P O
< O
NUM O
. O
01 O
). O

In O
all O
tissues O
examined O
only O
transcripts O
positive O
RARE O
insert O
3 O
, O
an O
18 O
bp O
RARE O
in O
repeat O
21 O
, O
were O
amplified O
, O
even O
under O
conditions O
in O
which O
a O
NUM O
% O
level O
of O
insert O
3 O
negative O
transcript O
could O
be O
easily O
detected O
in O
artificially O
prepared O
control O
samples O
. O

These O
results O
show O
that O
the O
CAAT O
- O
region O
is O
involved O
in O
RARE O
the O
NUM I-GENE
promoter I-GENE
in O
NUM O
/ O
ALL_CAP O
cells O
. O

Both O
receptors O
RARE O
protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
RARE I-GENE
) O
RARE O
the O
RARE O
of O
various O
RARE O
molecules O
, O
a O
process O
that O
is O
critical O
RARE O
the O
function O
of O
both O
receptors O
. O

RARE O
After O
RARE O
RARE O
( O
ALL_CAP O
) O
Study O
Group O
. O

The O
synergistic O
effect O
due O
to O
the O
5 O
'- O
3 O
' O
cooperation O
was O
RARE O
least O
fourfold O
greater O
than O
the O
sum O
of O
the O
RARE O
of O
the O
individual O
RARE O
. O

We O
demonstrate O
that O
both O
R I-GENE
and O
Z I-GENE
activate O
the O
cellular O
stress O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinases I-GENE
, O
p38 I-GENE
and O
JNK I-GENE
, O
resulting O
in O
RARE O
( O
and O
activation O
) O
of O
the O
cellular I-GENE
transcription I-GENE
factor I-GENE
NUM I-GENE
. O

Two O
US O
commercial O
RARE O
( O
RARE O
and O
RARE O
RARE O
three O
European O
commercial O
RARE O
( O
RARE O
, O
139 O
, O
NUM O
) O
and O
five O
New O
RARE O
RARE O
( O
RARE O
, O
RARE O
' O
s O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
) O
were O
evaluated O
. O

RARE O
of O
the O
RARE O
artery O
. O

However O
, O
activation O
of O
the O
cAMP O
RARE O
, O
which O
is O
known O
to O
regulate O
RARE I-GENE
alpha I-GENE
RARE O
, O
greatly O
RARE O
the O
actions O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
. O

Deletion O
and O
site O
- O
directed O
mutagenesis O
localized O
a O
novel O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
regulatory I-GENE
element I-GENE
( O
ALL_CAP O
ALL_CAP O
; O
- O
NUM O
to O
- O
NUM O
) O
adjacent O
to O
a O
variant O
cAMP O
- O
response O
element O
( O
ALL_CAP O
; O
- O
120 O
to O
- O
NUM O
). O

Previously O
, O
we O
showed O
that O
the O
ALL_CAP O
is O
a O
RARE O
RARE O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
RARE I-GENE
RARE O
inducible O
enhancer O
by O
binding O
the O
RARE I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
kappaB I-GENE
( O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
) O
complex O
Rel I-GENE
A I-GENE
RARE O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
. O

RARE I-GENE
II I-GENE
induces O
nuclear I-GENE
factor I-GENE
( I-GENE
ALL_CAP I-GENE
)- I-GENE
NUM I-GENE
isoforms I-GENE
to O
bind O
the O
RARE I-GENE
gene I-GENE
acute O
- O
RARE O
response O
element O
: O
a O
stimulus O
- O
specific O
RARE O
RARE O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
activation O
. O

RARE O
ligands O
have O
been O
identified O
that O
RARE O
and O
RARE O
the O
RARE O
of O
RARE O
ALL_CAP I-GENE
RARE O
by O
RARE O
with O
the O
orphan I-GENE
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
- I-GENE
R I-GENE
). O

The O
collection O
of O
mutants O
RARE O
ALL_CAP O
RARE O
defects O
includes O
members O
with O
mutations O
in O
previously O
identified O
vacuolar I-GENE
protein I-GENE
RARE I-GENE
genes I-GENE
( O
ALL_CAP I-GENE
RARE O
including O
the O
RARE I-GENE
family O
RARE O
NUM I-GENE
. O

Also O
in O
the O
spectrum O
of O
mutants O
with O
ALL_CAP O
RARE O
defects O
are O
isolates O
with O
mutations O
in O
the O
following O
: O
NUM I-GENE
, O
encoding O
a O
product O
RARE O
proposed O
to O
participate O
in O
RARE O
biogenesis O
; O
NUM I-GENE
, O
encoding O
a O
product O
potentially O
involved O
in O
RARE O
and O
microtubule O
organization O
; O
and O
NUM I-GENE
, O
encoding O
a O
RARE I-GENE
- I-GENE
like I-GENE
RARE I-GENE
RARE I-GENE
5 I-GENE
- I-GENE
phosphatase I-GENE
. O

The O
single O
RARE O
is O
manifested O
RARE O
a O
terminal O
extension O
of O
the O
G O
- O
rich O
RARE O
( O
G O
tails O
) O
that O
can O
occur O
independently O
of O
telomerase I-GENE
, O
suggesting O
that O
NUM I-GENE
/ O
NUM I-GENE
mutants O
exhibit O
defects O
in O
telomeric O
RARE O
- O
RARE O
RARE O
. O

In O
addition O
, O
NUM I-GENE
formed O
specific O
complexes O
with O
the O
NUM O
region O
of O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
NUM I-GENE
gene I-GENE
. O

Furthermore O
, O
the O
wide O
distribution O
of O
the O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
protein O
to O
all O
RARE O
of O
the O
RARE O
apparatus O
provides O
a O
valuable O
tool O
RARE O
future O
studies O
on O
cell O
RARE O
RARE O
development O
. O

An O
ALL_CAP O
- O
RARE O
RARE O
RARE O
depth O
analysis O
in O
RARE O
- O
real O
- O
time O
based O
on O
visual O
cortical O
cell O
behavior O
. O

However O
, O
RARE O
C O
, O
a O
specific O
inhibitor O
of O
PKC I-GENE
, O
abolished O
the O
ALL_CAP O
- O
RARE O
increase O
in O
ALL_CAP I-GENE
mRNA I-GENE
levels O
. O

RARE I-GENE
IgG I-GENE
, O
anti I-GENE
- I-GENE
ALL_CAP I-GENE
RARE I-GENE
fragments I-GENE
, O
RARE O
polymers O
and O
RARE O
N O
- O
RARE O
had O
RARE O
effect O
. O

RARE O
RARE O
, O
NUM O
is O
maintained O
RARE O
a O
RARE O
of O
RARE O
because O
the O
RARE O
between O
two O
and O
three O
RARE O
RARE O
is O
made O
RARE O
when O
the O
transition O
between O
the O
RARE O
and O
RARE O
RARE O
is O
RARE O
. O

We O
describe O
a O
case O
of O
RARE O
RARE O
that O
was O
treated O
with O
both O
hemodialysis O
( O
HD O
) O
and O
ALL_CAP O
due O
to O
severe O
RARE O
and O
slow O
drug O
clearance O
. O

Following O
conditioning O
, O
a O
single O
coat O
of O
adhesive O
was O
applied O
and O
light O
- O
RARE O
. O

RARE O
of O
the O
G O
- O
A O
anastomosis O
, O
the O
ALL_CAP O
, O
ALL_CAP O
, O
E O
( O
p O
) O
and O
loop O
areas O
were O
significantly O
different O
from O
ALL_CAP O
, O
but O
significantly O
different O
from O
A O
- O
A O
. O

RARE O
RARE O
of O
c I-GENE
- I-GENE
myc I-GENE
is O
likely O
to O
contribute O
to O
the O
RARE O
of O
NUM I-GENE
- O
RARE O
cells O
in O
response O
to O
RARE I-GENE
. O

RARE O
RARE O
RARE O
Group O
trial O
NUM O
was O
RARE O
to O
explore O
this O
question O
. O

We O
determined O
how O
DNA O
repair O
is O
affected O
by O
NUM I-GENE
conditional O
mutations O
. O

These O
RARE O
both O
report O
the O
results O
of O
RARE O
- O
RARE O
, O
randomized O
, O
RARE O
3 O
trials O
RARE O
the O
treatment O
of O
patients O
with O
localized O
( O
NUM O
- O
3 O
NUM O
- O
1 O
NUM O
) O
esophageal O
squamous O
cell O
carcinoma O
( O
ALL_CAP O
) O
or O
esophageal O
adenocarcinoma O
. O

Studies O
of O
ALL_CAP I-GENE
gene I-GENE
RARE O
can O
help O
to O
elucidate O
the O
mechanism O
of O
normal O
and O
abnormal O
RARE O
differentiation O
. O

ALL_CAP I-GENE
/ O
NUM I-GENE
was O
RARE O
- O
precipitated O
with O
PKN I-GENE
from O
the O
RARE O
of O
COS O
- O
7 O
cells O
transfected O
with O
both O
RARE O
constructs O
RARE O
ALL_CAP I-GENE
/ O
NUM I-GENE
and O
PKN I-GENE
. O

Transient O
transfection O
assays O
using O
P19 O
cells O
revealed O
that O
RARE O
of O
ALL_CAP I-GENE
/ O
NUM I-GENE
increased O
the O
RARE O
of O
the O
rat I-GENE
insulin I-GENE
promoter I-GENE
element I-GENE
3 I-GENE
( O
NUM I-GENE
) O
enhancer O
RARE O
to O
RARE O
12 O
- O
RARE O
and O
that O
RARE O
- O
RARE O
of O
catalytically O
RARE O
form O
of O
PKN I-GENE
, O
but O
not O
kinase O
- O
RARE O
RARE O
, O
resulted O
in O
a O
further O
threefold O
increase O
of O
ALL_CAP I-GENE
/ O
NUM I-GENE
- O
RARE O
transcription O
. O

Two O
NUM I-GENE
/ I-GENE
5 I-GENE
/ I-GENE
8 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
in O
NUM I-GENE
are O
required O
RARE O
proper O
initiation O
of O
endogenous O
mid O
- O
RARE O
RARE O
. O

Upon O
tyrosine O
RARE O
RARE O
the O
RARE O
, O
these O
molecules O
recruit O
NUM I-GENE
domain O
- O
containing O
RARE O
such O
RARE O
NUM I-GENE
- O
containing O
tyrosine I-GENE
phosphatase I-GENE
- I-GENE
1 I-GENE
and O
negatively O
regulate O
cell O
activity O
. O

NUM I-GENE
. O

RARE O
of O
the O
cervical O
spine O
, O
vertebral O
abnormalities O
, O
and O
disc O
changes O
also O
were O
evaluated O
. O

The O
concomitant O
interaction O
of O
NUM I-GENE
with O
hsp70 I-GENE
and O
hsp90 I-GENE
RARE O
its O
N O
- O
and O
C O
- O
termini O
respectively O
is O
RARE O
by O
the O
RARE O
repeat O
( O
TPR O
) O
motifs O
in O
these O
regions O
. O

Competition O
experiments O
demonstrate O
a O
negative O
RARE O
relationship O
between O
these O
ALL_CAP O
recognition O
sites O
. O

Sequence O
analysis O
showed O
that O
the O
5 O
'- O
flanking O
region O
upstream O
to O
the O
ATG O
RARE O
did O
not O
contain O
a O
conventional O
TATA O
box O
. O

After O
i O
. O
v O
. O
administration O
of O
500 O
mg O
RARE O
and O
RARE O
of O
the O
RARE O
, O
50 O
micrograms O
RARE I-GENE
- I-GENE
PA I-GENE
in O
NUM O
. O
1 O
ml O
( O
ALL_CAP O
) O
and O
NUM O
. O
5 O
ml O
NUM O
were O
injected O
RARE O
. O

These O
results O
suggest O
that O
NUM I-GENE
was O
efficiently O
transported O
to O
the O
nucleus O
and O
localized O
in O
the O
discrete O
RARE O
regions O
, O
possibly O
with O
NUM I-GENE
and O
NUM I-GENE
. O

Differential O
RARE O
and O
RARE O
by O
20 O
- O
RARE O
of O
RARE O
RARE O
isoforms O
. O

The O
three O
isoforms O
RARE O
with O
anti I-GENE
- I-GENE
ALL_CAP I-GENE
antibody I-GENE
affinity O
column O
transferred O
RARE O
to O
RARE O
RARE O
and O
RARE O
but O
not O
to O
other O
RARE O
. O

The O
differentiation O
and O
RARE O
of O
a O
RARE O
RARE O
is O
RARE O
by O
the O
interaction O
of O
RARE O
RARE O
with O
RARE O
genetic O
machinery O
. O

Analysis O
of O
RARE O
domains O
of O
RARE I-GENE
reveals O
an O
N O
- O
terminal O
activation O
domain O
and O
a O
C O
- O
terminal O
repression O
domain O
. O

BACKGROUND O
: O
RARE O
ventricular O
hypertrophy O
is O
a O
RARE O
disorder O
with O
distinct O
RARE O
. O

RARE O
predictors O
were O
RARE O
remodeling O
( O
P O
< O
NUM O
. O
0001 O
; O
odds O
ratio O
, O
NUM O
. O
5 O
RARE O
RARE O
ventricular O
ejection O
fraction O
> O
2 O
SD O
above O
normal O
( O
P O
< O
NUM O
. O
0001 O
RARE O
and O
single O
- O
vessel O
RARE O
RARE O
RARE O
( O
P O
< O
NUM O
. O
NUM O
; O
odds O
ratio O
, O
7 O
. O
6 O
). O

The O
case O
RARE O
RARE O
the O
RARE O
when O
positive O
lymph O
nodes O
are O
found O
RARE O
radical O
hysterectomy O
RARE O
cervical O
carcinoma O
. O

Overexpression O
of O
NUM I-GENE
in O
COS O
- O
1 O
- O
transfected O
cells O
RARE O
an O
RARE O
RARE O
of O
endogenous I-GENE
topoisomerase I-GENE
RARE I-GENE
. O

The O
RNA O
RARE O
contains O
three O
RARE O
separated O
by O
a O
RARE O
of O
two O
- O
RARE O
RARE O
, O
and O
RARE O
an O
RARE O
RARE O
in O
which O
both O
RARE O
sites O
are O
RARE O
through O
RARE O
RARE O
formation O
. O

The O
study O
suggests O
the O
presence O
of O
an O
anatomical O
RARE O
RARE O
the O
ALL_CAP O
which O
seems O
to O
regulate O
the O
passage O
of O
RARE O
from O
the O
RARE O
colon O
to O
the O
RARE O
. O

Isolation O
of O
cDNAs I-GENE
encoding I-GENE
RARE I-GENE
and I-GENE
RARE I-GENE
platelet I-GENE
and I-GENE
T I-GENE
cell I-GENE
activation I-GENE
antigen I-GENE
1 I-GENE
( O
NUM I-GENE
). O

To O
RARE O
any O
mechanical O
RARE O
effect O
of O
nasal O
intermittent O
positive O
pressure O
ventilation O
( O
ALL_CAP O
) O
on O
inspiratory O
activity O
of O
the O
diaphragm O
we O
ventilated O
five O
conscious O
RARE O
subjects O
on O
two O
RARE O
RARE O
respiratory O
rates O
similar O
to O
RARE O
breathing O
( O
ALL_CAP O
) O
and O
RARE O
three O
levels O
of O
applied O
pressure O
( O
RARE O
RARE O
6 O
, O
9 O
and O
12 O
cmH2O O
, O
each O
RARE O
RARE O
( O
P O
( O
CO2 O
) O
allowed O
to O
decrease O
) O
and O
RARE O
( O
CO2 O
added O
to O
RARE O
gas O
). O

METHODS O
: O
RARE I-GENE
Willebrand I-GENE
factor I-GENE
( O
vWF I-GENE
) O
and O
the O
RARE O
factors O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
( O
ALL_CAP I-GENE
RARE O
measured O
RARE O
ALL_CAP I-GENE
capacity O
, O
and O
plasminogen I-GENE
activator I-GENE
inhibitor I-GENE
1 I-GENE
( O
PAI I-GENE
- I-GENE
1 I-GENE
RARE O
platelets O
, O
fibrinogen I-GENE
, O
and O
inflammatory O
markers O
were O
measured O
in O
NUM O
patients O
with O
RARE O
seropositive O
ALL_CAP O
. O

RARE O
RARE O
properties O
are O
largely O
determined O
by O
the O
RARE O
and O
combination O
of O
ion O
RARE O
RARE O
. O

Treatment O
also O
led O
to O
a O
significant O
dose O
dependent O
reduction O
in O
the O
sum O
of O
ST O
segment O
depression O
RARE O
both O
trough O
and O
peak O
concentrations O
. O

We O
have O
investigated O
the O
contribution O
of O
specific O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
)- O
TATA O
interactions O
to O
the O
promoter O
activity O
of O
a O
constitutively O
RARE O
RARE I-GENE
tRNA I-GENE
( I-GENE
C I-GENE
)( I-GENE
RARE I-GENE
) I-GENE
gene I-GENE
and O
have O
also O
RARE O
whether O
the O
lack O
of O
similar O
interactions O
RARE O
RARE O
the O
low O
promoter O
activity O
of O
a O
RARE I-GENE
RARE I-GENE
- I-GENE
specific I-GENE
tRNA I-GENE
( I-GENE
ALL_CAP I-GENE
)( I-GENE
RARE I-GENE
) I-GENE
gene I-GENE
. O

The O
sequences O
showed O
extensive O
homologies O
with O
RARE I-GENE
synthase I-GENE
genes I-GENE
and O
RARE O
from O
a O
number O
of O
other O
organisms O
and O
extreme O
amino O
acid O
conservation O
within O
the O
binding O
and O
catalytic O
domains O
. O

All O
RARE O
and O
strains O
produced O
have O
been O
RARE O
in O
the O
ALL_CAP O
genetic O
RARE O
RARE O
( O
ALL_CAP O
, O
RARE O
). O

Two O
episodes O
of O
RARE O
occurred O
while O
the O
patient O
received O
ALL_CAP O
( O
1 O
RARE O
/ O
3 O
. O
5 O
patient O
- O
months O
). O

Copyright O
2000 O
The O
RARE O
RARE O
of O
RARE O
. O

Two O
estrogen I-GENE
receptor I-GENE
( O
ER I-GENE
) O
isoforms O
with O
different O
estrogen O
RARE O
are O
generated O
from O
the O
RARE I-GENE
ER I-GENE
gene I-GENE
. O

Induction O
was O
reversed O
by O
coexpression O
of O
A I-GENE
- I-GENE
Fos I-GENE
, O
a O
dominant O
negative O
to O
AP I-GENE
- I-GENE
1 I-GENE
. O

In O
RARE O
ALL_CAP O
, O
both O
isoforms O
of O
the O
progesterone I-GENE
receptor I-GENE
, O
PR I-GENE
- I-GENE
B I-GENE
and O
PR I-GENE
- I-GENE
A I-GENE
, O
caused O
a O
RARE O
- O
dependent O
activation O
of O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
/ O
NUM I-GENE
. O

RARE O
B O
RARE O
NUM O
/- O
NUM O
) O
shows O
more O
than O
NUM O
% O
homology O
to O
a O
consensus I-GENE
c I-GENE
- I-GENE
myb I-GENE
element I-GENE
, O
but O
formed O
two O
specific O
complexes O
that O
differed O
from O
that O
of O
c I-GENE
- I-GENE
myb I-GENE
in O
the O
electrophoretic O
mobility O
shift O
assay O
. O

RARE O
resolution O
computed O
tomography O
of O
the O
lungs O
in O
patients O
with O
rheumatoid O
arthritis O
. O

Stable O
transfection O
of O
the O
truncated O
RARE I-GENE
RARE I-GENE
carrier I-GENE
cDNA I-GENE
into O
mouse O
NUM O
leukemia O
cells O
: O
increased O
RARE O
accumulation O
, O
decreased O
their O
RARE O
and O
RARE O
acid O
growth O
requirements O
, O
and O
increased O
their O
sensitivity O
to O
methotrexate O
. O

Characterization O
of O
a O
human I-GENE
RARE I-GENE
RARE I-GENE
truncated I-GENE
RARE I-GENE
RARE I-GENE
carrier I-GENE
increasing O
RARE O
accumulation O
in O
parental O
leukemia O
cells O
. O

RARE O
microscopic O
and O
enzymatic O
analyses O
revealed O
that O
the O
NUM O
genome O
is O
a O
RARE O
, O
RARE O
RARE O
, O
RARE O
RARE O
collection O
of O
double O
- O
RARE O
DNA O
molecules O
. O

Moreover O
, O
increasing O
the O
dosage O
of O
wild I-GENE
- I-GENE
type I-GENE
NUM I-GENE
RARE O
the O
inhibition O
of O
both O
Ty1 I-GENE
RARE O
and O
invasive O
growth O
. O

RARE O
, O
activation O
of O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
RARE O
of O
Rho I-GENE
family I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
was O
also O
RARE O
when O
RARE I-GENE
was O
tyrosine O
- O
RARE O
. O

However O
, O
its O
participation O
in O
RARE I-GENE
binding O
has O
not O
been O
shown O
. O

Together O
, O
these O
data O
suggest O
that O
the O
RARE O
terminus O
of O
CFTR I-GENE
contains O
a O
tyrosine O
- O
based O
internalization O
signal O
that O
interacts O
with O
the O
endocytic O
RARE O
complex O
AP I-GENE
- I-GENE
2 I-GENE
to O
facilitate O
efficient O
entry O
of O
CFTR I-GENE
into O
clathrin I-GENE
- O
RARE O
vesicles O
. O

The O
insulin I-GENE
therapy O
regimen O
did O
not O
affect O
the O
evolution O
of O
the O
patients O
and O
RARE O
significant O
relationship O
existed O
between O
the O
age O
RARE O
diagnosis O
, O
duration O
of O
diabetes O
, O
daily O
insulin I-GENE
dosage O
or O
metabolic O
control O
and O
height O
or O
BMI O
. O

NUM I-GENE
maps O
to O
NUM O
- O
NUM O
. O
1 O
in O
mice O
. O

The O
RARE O
of O
laparoscopic O
donor O
RARE O
( O
ALL_CAP O
) O
has O
not O
been O
assessed O
in O
the O
obese O
donor O
. O

RARE O
treatment O
RARE O
RARE I-GENE
remodeling O
in O
the O
peripheral O
region O
and O
inhibited O
swelling O
of O
the O
RARE O
RARE O
in O
the O
inner O
region O
. O

We O
have O
addressed O
these O
issues O
by O
RARE O
and O
characterizing O
the O
KRAB I-GENE
: O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
- O
ALL_CAP I-GENE
interaction O
using O
RARE O
RARE O
. O

The O
ALL_CAP O
finger O
, O
NUM O
box O
, O
and O
RARE O
- O
RARE O
region O
are O
required O
RARE O
oligomerization O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
- O
ALL_CAP I-GENE
and O
KRAB I-GENE
binding O
, O
RARE O
mutations O
in O
these O
domains O
RARE O
abolished O
these O
functions O
. O

RARE I-GENE
show O
two O
different O
forms O
of O
N O
- O
terminal O
RARE O
dependent O
on O
their O
N O
- O
terminal O
sequence O
. O

All O
four O
domains O
were O
RARE O
via O
proline O
- O
threonine O
- O
rich O
peptides O
. O

ALL_CAP O
53 O
, O
resulting O
in O
a O
compression O
ratio O
of O
1 O
: O
21 O
, O
does O
not O
RARE O
the O
diagnostic O
performance O
in O
RARE O
. O

We O
RARE O
assess O
current O
systematic O
RARE O
and O
determine O
the O
RARE O
Li O
abundance O
within O
new O
, O
much O
RARE O
limits O
: O
& O
RARE O
; O
NUM O
; O
Li O
& O
RARE O
; O
NUM O
; O
H O
& O
RARE O
; O
NUM O
; O
p O
= O
1 O
. O
NUM O
+ O
NUM O
. O
NUM O
- O
NUM O
. O
NUM O
- O
10 O
. O

Like O
their O
yeast O
RARE O
, O
the O
mouse O
GCN2 I-GENE
isoforms O
contain O
ALL_CAP I-GENE
- I-GENE
related I-GENE
sequences I-GENE
RARE O
to O
the O
kinase O
catalytic O
domain O
. O

Five O
women O
( O
NUM O
. O
6 O
%) O
met O
criteria O
RARE O
ALL_CAP O
. O

ALL_CAP O
and O
ALL_CAP O
showed O
similar O
RARE O
values O
, O
but O
the O
former O
disappeared O
slower O
in O
the O
serum O
than O
the O
latter O
and O
resulted O
in O
its O
larger O
AUC O
values O
. O

Another O
long O
RARE O
in O
the O
RARE I-GENE
X I-GENE
amino I-GENE
acid I-GENE
sequence I-GENE
forms O
a O
beta O
- O
hairpin O
RARE O
RARE O
from O
the O
RARE O
site O
. O

Transfection O
experiments O
demonstrated O
that O
the O
5 O
'- O
flanking O
region O
RARE O
NUM O
to O
+ O
37 O
) O
of O
the O
RARE I-GENE
gene I-GENE
RARE O
transcription O
in O
mouse O
ALL_CAP O
cells O
and O
that O
a O
construct O
containing O
a O
fragment O
from O
- O
NUM O
to O
+ O
37 O
showed O
the O
highest O
transcriptional O
activity O
. O

Further O
studies O
in O
T O
- O
NUM O
cells O
demonstrated O
that O
ALL_CAP O
fragments O
also O
RARE O
I I-GENE
RARE I-GENE
B I-GENE
alpha I-GENE
RARE O
and O
RARE O
, O
RARE I-GENE
B I-GENE
- I-GENE
RARE I-GENE
reporter I-GENE
gene I-GENE
RARE O
, O
and O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
activity O
in O
an O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
B I-GENE
- O
dependent O
manner O
. O

RARE O
of O
cells O
or O
mouse O
RARE O
with O
RARE O
oligonucleotides O
of O
RARE I-GENE
impaired O
ALL_CAP O
- O
RARE O
activation O
of O
AP I-GENE
- I-GENE
1 I-GENE
in O
NUM O
cells O
RARE O
RARE O
RARE O
in O
AP I-GENE
- I-GENE
1 I-GENE
- O
luciferase I-GENE
transgenic O
mice O
. O

The O
level O
of O
subclinical O
infection O
was O
NUM O
% O
among O
seropositive O
dogs O
. O

METHODS O
: O
The O
former O
group O
included O
patients O
who O
had O
been O
treated O
with O
RARE O
least O
four O
NUM O
alpha O
- O
RARE O
, O
short O
- O
term O
treatment O
cycles O
per O
year O
while O
the O
latter O
was O
a O
RARE O
reference O
group O
RARE O
without O
prostaglandins O
. O

RARE O
NUM O
and O
RARE O
2 O
would O
be O
more O
potent O
against O
RARE O
than O
ALL_CAP O
in O
vitro O
against O
two O
strains O
( O
NUM O
and O
NUM O
) O
of O
RARE O
falciparum O
. O

The O
NUM I-GENE
, I-GENE
NUM I-GENE
mutant I-GENE
was O
partially O
RARE O
by O
inactivation O
of O
NUM I-GENE
or O
NUM I-GENE
, O
suggesting O
an O
interaction O
between O
the O
ALL_CAP I-GENE
genes I-GENE
and O
the O
NUM I-GENE
signal I-GENE
RARE I-GENE
RARE I-GENE
. O

Members O
of O
the O
ALL_CAP I-GENE
/ O
RARE I-GENE
family O
of O
tyrosine I-GENE
kinases I-GENE
mediate O
RARE O
of O
STAT3 I-GENE
RARE O
NUM O
RARE O
ALL_CAP I-GENE
RARE O
; O
however O
, O
the O
kinase O
responsible O
RARE O
RARE O
RARE O
STAT3 I-GENE
NUM O
appears O
to O
depend O
on O
both O
the O
extracellular O
stimulus O
and O
the O
cellular O
context O
. O

In O
vivo O
, O
RARE I-GENE
/ O
RARE I-GENE
activated O
transcription O
from O
an O
HD I-GENE
- O
ALL_CAP O
luciferase I-GENE
reporter I-GENE
construct I-GENE
. O

RARE O
RARE I-GENE
( O
RARE I-GENE
) O
encodes O
a O
RARE I-GENE
RARE I-GENE
RARE I-GENE
beta I-GENE
( O
RARE I-GENE
) O
RARE O
factor O
closely O
related O
to O
mouse O
RARE I-GENE
. O

Thus O
, O
NUM I-GENE
is O
a O
good O
candidate O
gene O
RARE O
to O
the O
mental O
retardation O
RARE O
seen O
in O
ALL_CAP O
- O
16 O
patients O
. O

The O
genome O
organization O
of O
the O
RARE O
- O
transmitted O
RARE O
RARE O
mosaic O
virus O
( O
ALL_CAP O
) O
appears O
to O
parallel O
that O
of O
members O
of O
the O
RARE O
with O
RARE O
genomes O
, O
but O
there O
are O
substantial O
amino O
acid O
RARE O
with O
other O
RARE O
RARE O
. O

The O
two O
- O
RARE O
assay O
was O
then O
performed O
using O
full O
- O
length O
genes O
of O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
, O
P1 I-GENE
, O
NUM I-GENE
, O
and O
CP I-GENE
, O
but O
RARE O
heterologous O
interactions O
were O
detected O
. O

RARE O
endogenous O
light O
chains O
contribute O
to O
RARE O
membrane O
reactivity O
in O
RARE O
mice O
transgenic O
RARE O
an O
anti I-GENE
- I-GENE
RARE I-GENE
Ig I-GENE
heavy I-GENE
chain I-GENE
. O

RARE O
test O
results O
obtained O
with O
RARE O
allergic O
patients O
tested O
with O
a O
large O
RARE O
series O
RARE O
the O
earlier O
classification O
of O
RARE O
molecules O
in O
four O
groups O
of O
cross O
- O
RARE O
molecules O
: O
i O
. O
RARE O
., O
group O
A O
( O
RARE O
type O
RARE O
group O
B O
( O
RARE O
RARE O
group O
C O
( O
RARE O
type O
- O
non O
RARE O
) O
and O
group O
D O
( O
esters O
). O

RARE O
of O
RARE O
in O
regional O
anesthesia O
of O
long O
duration O

An O
increase O
in O
the O
level O
of O
serum O
RARE O
, O
such O
RARE O
RARE I-GENE
RARE I-GENE
, O
RARE I-GENE
phosphatase I-GENE
, O
RARE I-GENE
RARE I-GENE
, O
RARE I-GENE
dehydrogenase I-GENE
after O
D O
. O
RARE O
RARE O
injection O
in O
RARE O
rats O
is O
indicative O
of O
cell O
or O
tissue O
damage O
. O

The O
partial O
RARE O
RARE O
RARE O
the O
importance O
of O
RARE O
sub O
- O
clinical O
lesions O
in O
a O
RARE O
. O

Surprisingly O
, O
3 O
full I-GENE
- I-GENE
length I-GENE
murine I-GENE
RARE I-GENE
cDNA I-GENE
RARE O
were O
isolated O
, O
predicting O
the O
existence O
of O
3 O
distinct O
RARE I-GENE
proteins I-GENE
. O

Thus O
, O
the O
induction O
of O
E2F I-GENE
binding O
to O
the O
E2F I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
by O
the O
NUM I-GENE
- I-GENE
6 I-GENE
/ I-GENE
7 I-GENE
protein I-GENE
observed O
in O
vitro O
correlates O
with O
RARE O
of O
E2F I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
activity O
in O
vivo O
. O

We O
show O
that O
stabilization O
of O
the O
hairpin O
RARE O
the O
amount O
of O
tRNA O
primer O
that O
is O
RARE O
to O
the O
ALL_CAP O
. O

RARE O
- O
RARE O
biphasic O
arrhythmias O
were O
suppressed O
in O
both O
RARE O
and O
propranolol O
groups O
. O

NUM I-GENE
and O
NUM I-GENE
genes I-GENE
appear O
to O
be O
the O
RARE O
variants O
RARE O
from O
the O
same O
gene O
. O

CONCLUSION O
: O
RARE O
of O
ALL_CAP I-GENE
NUM I-GENE
RARE I-GENE
seems O
to O
increase O
the O
risk O
RARE O
dementia O
and O
AD O
independently O
of O
its O
effect O
on O
RARE O
and O
RARE O
. O

No O
definite O
conclusions O
are O
possible O
because O
of O
the O
small O
number O
of O
patients O
involved O
in O
this O
RARE O
II O
trial O
. O

Two O
distinct O
RARE I-GENE
RARE I-GENE
, O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
, O
RARE O
thin O
RARE O
RARE O
NUM I-GENE
and O
NUM I-GENE
, O
respectively O
, O
were O
each O
genetically O
RARE O
to O
carry O
NUM I-GENE
, O
an O
alpha O
- O
helical O
16 O
- O
amino O
acid O
RARE O
T O
- O
cell O
RARE O
derived O
from O
the O
RARE I-GENE
NUM I-GENE
. O

In O
marked O
contrast O
to O
ALL_CAP I-GENE
, O
none O
of O
the O
chimeric I-GENE
ALL_CAP I-GENE
proteins I-GENE
were O
RARE O
or O
assembled O
into O
RARE O
. O

RARE O
growth O
of O
RARE O
NUM O
in O
wild O
- O
type O
RARE O
RARE O
correlates O
with O
the O
presence O
of O
NUM I-GENE
, O
but O
is O
independent O
of O
the O
absolute O
level O
of O
ATP I-GENE
- I-GENE
dependent I-GENE
RARE I-GENE
activity O
, O
suggesting O
a O
qualitative O
change O
in O
the O
nature O
of O
NUM I-GENE
- O
modified O
ALL_CAP I-GENE
RARE I-GENE
activity O
relative O
to O
the O
RARE O
enzyme O
. O

In O
this O
study O
, O
we O
investigated O
the O
RARE O
mechanisms O
underlying O
the O
inducible O
RARE O
of O
the O
RARE I-GENE
- I-GENE
1 I-GENE
gene I-GENE
RARE O
the O
activation O
of O
ALL_CAP O
- O
1 O
cells O
. O

There O
was O
a O
2 O
. O
4 O
- O
RARE O
difference O
in O
CAT I-GENE
produced O
from O
these O
transcripts O
in O
HeLa O
cells O
, O
which O
contain O
a O
greater O
RARE O
abundance O
of O
ALL_CAP I-GENE
. O

Multiple O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
RARE O
pathways O
RARE O
the O
RARE I-GENE
RARE I-GENE
to O
the O
c I-GENE
- I-GENE
jun I-GENE
promoter I-GENE
and O
to O
cellular O
transformation O
. O

RARE O
is O
RARE O
exception O
. O

4 O
. O

In O
the O
present O
study O
we O
have O
investigated O
the O
regulatory O
mechanism O
RARE O
NUM I-GENE
RARE O
. O

Protein O
sequence O
analysis O
reveals O
that O
NUM I-GENE
shares O
a O
RARE O
globular O
domain O
of O
RARE O
40 O
amino O
RARE O
, O
which O
we O
term O
the O
ALL_CAP I-GENE
RARE I-GENE
, O
with O
inner O
nuclear O
membrane O
proteins O
RARE I-GENE
- I-GENE
associated I-GENE
polypeptide I-GENE
2 I-GENE
and O
RARE I-GENE
. O

Molecular O
cloning O
of O
a O
novel O
human I-GENE
I I-GENE
- I-GENE
RARE I-GENE
domain I-GENE
- I-GENE
containing I-GENE
protein I-GENE
that O
differently O
regulates O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
and O
HIV O
- O
1 O
RARE O
. O

The O
encoded O
amino O
acid O
sequences O
in O
the O
full O
- O
length O
bovine O
and O
RARE O
cDNAs O
were O
identical O
, O
consisting O
of O
NUM O
amino O
acid O
residues O
, O
and O
were O
nearly O
the O
same O
RARE O
the O
published O
sequence O
determined O
by O
RARE O
RARE O
. O

With O
chemical O
shift O
imaging O
, O
the O
signal O
intensity O
decreased O
on O
the O
out O
- O
of O
- O
RARE O
images O
in O
RARE O
of O
RARE O
( O
NUM O
%) O
patients O
with O
ALL_CAP O
and O
in O
eight O
of O
nine O
( O
NUM O
%) O
patients O
with O
ALL_CAP O
. O

For O
each O
night O
, O
the O
RARE O
allowed O
the O
RARE O
measurement O
of O
RARE O
, O
RARE O
time O
, O
time O
in O
RARE O
( O
ALL_CAP O
RARE O
sleep O
efficiency O
, O
number O
of O
minutes O
of O
RARE O
after O
sleep O
onset O
( O
ALL_CAP O
RARE O
RARE O
on O
RARE O
, O
and O
percentage O
of O
RARE O
RARE O
an O
RARE O
( O
or O
a O
RARE O
functioning O
RARE O
one O
). O

RARE O
. O

Copyright O
2000 O
Academic O
Press O
. O

The O
central O
( O
R O
) O
domain O
is O
responsible O
RARE O
receptor O
- O
binding O
activity O
whereas O
the O
N O
- O
terminal O
( O
T O
) O
domain O
mediates O
translocation O
, O
the O
process O
by O
which O
the O
C O
- O
terminal O
cytotoxic O
domain O
is O
transported O
from O
the O
receptor O
to O
the O
site O
of O
its O
cytotoxicity O
. O

We O
have O
previously O
demonstrated O
that O
RARE O
of O
the O
gene O
RARE O
the O
reproductive O
RARE O
, O
GnRH I-GENE
, O
is O
repressed O
by O
the O
RARE O
/ O
ALL_CAP O
/ O
cyclic O
ALL_CAP O
( O
ALL_CAP O
) O
signal O
RARE O
RARE O
through O
ALL_CAP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
in O
the O
RARE O
GnRH I-GENE
- O
secreting O
RARE O
cell O
line O
NUM O
- O
7 O
. O

These O
data O
suggest O
that O
combined O
lesions O
of O
cholinergic O
and O
RARE O
neurons O
in O
the O
rat O
brain O
do O
not O
alter O
olfactory O
RARE O
or O
olfactory O
short O
- O
term O
memory O
. O

RARE O
potency O
of O
botulinum I-GENE
RARE I-GENE
. O

In O
contrast O
, O
c I-GENE
- I-GENE
Src I-GENE
activated O
by O
isoproterenol O
led O
to O
tyrosine O
RARE O
of O
Shc I-GENE
and O
subsequent O
RARE I-GENE
activation O
, O
but O
not O
tyrosine O
RARE O
of O
RARE I-GENE
or O
Stat3 I-GENE
. O

RARE I-GENE
are O
believed O
to O
regulate O
DNA O
replication O
, O
transcription O
, O
RARE O
and O
cell O
RARE O
progression O
by O
RARE O
with O
the O
C I-GENE
- I-GENE
ALL_CAP I-GENE
protein I-GENE
. O

For O
wild O
type O
ALL_CAP I-GENE
and O
its O
NUM I-GENE
and O
NUM I-GENE
mutants I-GENE
, O
RARE O
of O
log O
( O
RARE O
( O
RARE O
)) O
versus O
pH O
exhibited O
a O
limiting O
slope O
of O
1 O
on O
the O
ascending O
limb O
and O
then O
a O
RARE O
, O
i O
. O
RARE O
., O
a O
sharply O
defined O
maximum O
near O
pH O
8 O
followed O
by O
a O
RARE O
, O
RARE O
apparent O
ALL_CAP O
( O
a O
) O
values O
of O
7 O
. O
6 O
+/- O
NUM O
. O
3 O
and O
8 O
. O
4 O
+/- O
NUM O
. O
4 O
RARE O
an O
essential O
RARE O
and O
a O
RARE O
acid O
RARE O
, O
respectively O
, O
in O
the O
RARE O
RARE O
ALL_CAP I-GENE
- O
RARE O
( O
2 O
RARE O
ALL_CAP O
- O
RARE O
( O
2 O
+) O
complex O
. O

Structural O
changes O
in O
the O
RARE O
more O
damaged O
NUM O
mutant O
detected O
in O
( O
1 O
) O
H O
RARE O
NUM O
) O
N O
ALL_CAP O
spectra O
were O
largely O
limited O
to O
the O
loop O
I O
- O
helix O
I O
motif O
, O
suggesting O
that O
Glu O
- O
NUM O
stabilizes O
the O
RARE O
site O
region O
. O

In O
vitro O
RARE O
of O
four O
different O
naturally O
occurring O
nonsense O
and O
missense O
mutations O
revealed O
a O
dramatically O
altered O
subcellular O
location O
of O
the O
protein O
in O
cultured O
cells O
. O

After O
i O
. O
v O
. O

RARE O
acquired O
by O
mice O
RARE O
I O
. O
RARE O
RARE O
activity O
in O
early O
summer O
may O
RARE O
a O
large O
proportion O
of O
the O
mouse O
population O
from O
maintaining O
E O
. O
RARE O
RARE O
the O
period O
of O
RARE O
activity O
later O
in O
the O
season O
. O

The O
RARE O
view O
based O
on O
studies O
in O
yeast O
is O
that O
each O
class O
of O
RARE O
is O
composed O
of O
a O
unique O
set O
of O
proteins O
. O

ALL_CAP I-GENE
cross O
- O
linking O
also O
led O
to O
increased O
ALL_CAP I-GENE
- O
activated O
protein I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
activity O
, O
an O
enzyme O
that O
lies O
immediately O
RARE O
from O
p38 I-GENE
ALL_CAP I-GENE
; O
ALL_CAP I-GENE
- O
activated O
protein I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
immune O
complexes O
RARE O
a O
peptide O
substrate O
containing O
the O
CREB I-GENE
serine I-GENE
NUM I-GENE
RARE I-GENE
motif I-GENE
. O

Activation O
of O
a O
ALL_CAP O
- O
dependent O
junB I-GENE
promoter I-GENE
/ O
chloramphenicol I-GENE
RARE I-GENE
( O
CAT I-GENE
) O
reporter O
gene O
by O
the O
ALL_CAP I-GENE
was O
also O
blocked O
by O
NUM O
. O

We O
present O
evidence O
that O
the O
upstream O
RARE O
reading O
frame O
( O
ALL_CAP O
) O
represses O
the O
translation O
of O
the O
RARE O
major O
RARE O
reading O
frame O
( O
ALL_CAP O
). O

METHODS O
: O
ALL_CAP O
measurements O
were O
performed O
in O
NUM O
female O
RARE O
with O
breast O
carcinoma O
who O
were O
undergoing O
standard O
cyclophosphamide O
, O
methotrexate O
, O
and O
5 O
- O
fluorouracil O
( O
ALL_CAP O
)- O
based O
chemotherapy O
( O
median O
age O
, O
NUM O
years O
; O
range O
, O
NUM O
- O
77 O
years O
). O

A O
NUM O
bp O
RARE O
Response O
RARE O
( O
ALL_CAP O
) O
was O
identified O
whose O
glucocorticoid O
induction O
was O
RARE O
by O
RARE O
- O
cAMP O
and O
RARE O
by O
phorbol O
esters O
. O

No O
somatic O
mutations O
were O
found O
in O
any O
of O
the O
samples O
, O
suggesting O
that O
NUM I-GENE
is O
not O
a O
tumor O
suppressor O
gene O
target O
in O
head O
and O
neck O
RARE O
. O

Ras I-GENE
- O
NUM I-GENE
transiently O
RARE O
with O
v I-GENE
- I-GENE
Src I-GENE
was O
tyrosine O
- O
RARE O
and O
showed O
significant O
ALL_CAP I-GENE
activity O
toward O
Rac I-GENE
, O
but O
not O
Rho I-GENE
and O
Cdc42 I-GENE
, O
which O
was O
comparable O
with O
that O
RARE O
by O
Gbetagamma I-GENE
. O

As O
RARE O
RARE O
PPARgamma I-GENE
antagonists O
have O
been O
described O
hitherto O
, O
we O
have O
constructed O
a O
dominant O
- O
negative O
mutant O
receptor O
to O
inhibit O
wild O
- O
type O
PPARgamma I-GENE
action O
. O

EMSA O
showed O
that O
nuclear O
proteins O
from O
PC12 O
but O
not O
NUM O
or O
NUM O
cells O
bind O
the O
ALL_CAP O
RARE O
a O
complex O
containing O
activating I-GENE
transcription I-GENE
factor I-GENE
( I-GENE
ATF I-GENE
)- I-GENE
4 I-GENE
and O
CCAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
beta I-GENE
, O
while O
both O
PC12 O
and O
NUM O
cell O
nuclear O
extracts O
were O
recruited O
by O
the O
CCAAT O
- O
box O
RARE O
a O
complex O
containing O
nuclear I-GENE
factor I-GENE
Y I-GENE
. O

EMSA O
showed O
that O
nuclear O
proteins O
from O
PC12 O
but O
not O
NUM O
or O
NUM O
cells O
bind O
the O
ALL_CAP O
RARE O
a O
complex O
containing O
activating I-GENE
transcription I-GENE
factor I-GENE
( I-GENE
ATF I-GENE
)- I-GENE
4 I-GENE
and O
CCAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
beta I-GENE
, O
while O
both O
PC12 O
and O
NUM O
cell O
nuclear O
extracts O
were O
recruited O
by O
the O
CCAAT O
- O
box O
RARE O
a O
complex O
containing O
nuclear I-GENE
factor I-GENE
Y I-GENE
. O

Despite O
resolution O
of O
the O
solid O
portion O
of O
the O
tumor O
, O
serial O
MRI O
showed O
enlargement O
of O
a O
RARE O
tumor O
cyst O
3 O
years O
after O
the O
original O
diagnosis O
. O

ALL_CAP O
and O
SOD I-GENE
levels O
were O
measured O
RARE O
five O
points O
before O
and O
RARE O
the O
operation O
. O

RARE O
ventricular O
tachycardia O
and O
its O
successful O
prophylaxis O
RARE O
high O
- O
dose O
bolus O
interleukin I-GENE
- I-GENE
2 I-GENE
therapy O
RARE O
metastatic O
RARE O
cell O
carcinoma O
. O

Second O
, O
when O
the O
NUM I-GENE
+ I-GENE
R I-GENE
protein I-GENE
, O
the O
NUM I-GENE
protein I-GENE
, O
and O
a O
mixture O
of O
the O
two O
proteins O
were O
folded O
separately O
and O
analyzed O
by O
RARE O
RARE O
RARE O
, O
the O
mixture O
was O
found O
to O
RARE O
prior O
to O
either O
NUM I-GENE
+ I-GENE
R I-GENE
or O
NUM I-GENE
. O

Collectively O
, O
these O
experiments O
demonstrate O
that O
CFTR I-GENE
' I-GENE
s I-GENE
NUM I-GENE
+ I-GENE
R I-GENE
region I-GENE
and O
its O
NUM I-GENE
domain I-GENE
, O
after O
folding O
separately O
RARE O
distinct O
RARE O
, O
have O
a O
strong O
propensity O
to O
interact O
and O
that O
this O
interaction O
is O
stable O
in O
the O
absence O
of O
added O
nucleotides O
or O
RARE O
RARE O
RARE O
. O

Copyright O
2000 O
Academic O
Press O
. O

RARE O
titration O
with O
RARE O
, O
monitored O
by O
RARE O
the O
residual O
RARE O
after O
reaction O
with O
a O
RARE O
RARE O
of O
RARE O
, O
revealed O
a O
striking O
difference O
in O
the O
apparent O
ALL_CAP O
( O
a O
) O
values O
of O
the O
RARE O
RARE O
the O
two O
RARE O
junctions O
. O

After O
RARE O
oxide O
inhalation O
, O
the O
results O
showed O
moderate O
increases O
in O
PaO2 O
and O
SaO2 O
( O
P O
> O
NUM O
. O
05 O
) O
and O
a O
significant O
decrease O
in O
RARE O
/ O
ALL_CAP O
RARE O
ratio O
( O
P O
< O
NUM O
. O
01 O
). O

The O
results O
showed O
that O
ALL_CAP O
, O
ALL_CAP O
, O
ALL_CAP O
, O
RARE O
, O
NUM O
. O
1 O
and O
minute O
ventilation O
( O
RARE O
) O
were O
significantly O
increased O
after O
administration O
of O
RARE O
and O
RARE O
. O

Forty O
4 O
- O
month O
old O
SD O
female O
rats O
were O
randomly O
divided O
into O
four O
groups O
, O
namely O
sham O
operation O
, O
bilateral O
RARE O
, O
RARE O
RARE O
supplementary O
RARE O
estradiol O
( O
NUM O
. O
2 O
microgram O
/ O
NUM O
g O
B O
. O

It O
has O
also O
been O
shown O
that O
a O
variety O
of O
extracellular O
factors O
stimulate O
a O
RARE O
of O
ALL_CAP O
p44 I-GENE
and O
ALL_CAP O
NUM I-GENE
of O
ALL_CAP I-GENE
family I-GENE
members I-GENE
. O

RARE O
modification O
of O
the O
RARE O
protein O
IE2 I-GENE
- O
NUM I-GENE
of O
human O
RARE O
by O
conjugation O
to O
the O
ubiquitin I-GENE
- I-GENE
homologous I-GENE
proteins I-GENE
ALL_CAP I-GENE
- I-GENE
1 I-GENE
and O
NUM I-GENE
. O

NUM O
: O
NUM O
- O
NUM O
, O
NUM O
). O

The O
interaction O
between O
ALL_CAP O
( O
L O
) O
3 O
. O

RARE I-GENE
and O
RARE O
doses O
, O
their O
sum O
( O
RARE O
- O
dose O
) O
and O
differential O
( O
RARE O
- O
dose O
) O
doses O
, O
and O
activated O
RARE O
times O
were O
RARE O
. O

In O
this O
study O
, O
a O
common O
mechanism O
has O
been O
identified O
to O
coordinate O
the O
growth O
- O
and O
ALL_CAP O
- O
dependent O
RARE O
of O
RARE I-GENE
. O

Comparison O
of O
the O
RARE O
nuclear O
tRNA O
3 O
' O
RARE O
enzyme O
with O
the O
RARE O
mitochondrial O
one O
suggests O
that O
both O
activities O
are O
different O
RARE O
. O

The O
requirement O
of O
3 O
' O
RARE O
RARE O
a O
ligation O
reaction O
is O
RARE O
by O
results O
from O
1 O
nt O
insertions O
on O
either O
the O
3 O
'- O
or O
5 O
'- O
RARE O
of O
the O
RARE O
. O

NUM I-GENE
. I-GENE
1 I-GENE
is O
a O
RARE O
of O
the O
NUM I-GENE
family I-GENE
of O
RARE I-GENE
- I-GENE
containing I-GENE
transcription I-GENE
factors I-GENE
whose O
targeted O
disruption O
in O
mouse O
results O
in O
the O
absence O
of O
thyroid O
tissue O
and O
a O
severely O
abnormal O
RARE O
RARE O
. O

National O
abortion O
RARE O
usually O
do O
not O
allow O
abortion O
when O
a O
RARE O
is O
independently O
viable O
, O
i O
. O
RARE O
. O
from O
a O
gestational O
age O
of O
about O
NUM O
weeks O
. O

Expression O
in O
early O
postnatal O
pituitary O
and O
in O
pre O
- O
RARE O
cells O
suggests O
that O
RARE I-GENE
- I-GENE
16 I-GENE
could O
play O
a O
role O
in O
pituitary O
development O
prior O
to O
RARE O
differentiation O
. O

RARE I-GENE
growth I-GENE
hormone I-GENE
transcription I-GENE
factor I-GENE
RARE I-GENE
- I-GENE
16 I-GENE
: O
unique O
bipartite O
RARE O
containing O
tandemly O
RARE O
zinc O
finger O
domains O
not O
reported O
in O
rat I-GENE
RARE I-GENE
- I-GENE
NUM I-GENE
. O

The O
CCAAT O
core O
sequence O
mutants O
in O
which O
both O
ALL_CAP O
and O
ALL_CAP O
/ O
ALL_CAP O
were O
abolished O
, O
also O
increased O
the O
promoter O
activity O
. O

RARE O
is O
considered O
to O
be O
immature O
in O
infants O
and O
to O
RARE O
RARE O
. O

This O
repression O
does O
not O
require O
the O
ALL_CAP I-GENE
. I-GENE
1 I-GENE
RARE O
or O
ALL_CAP O
domains O
and O
cannot O
be O
reversed O
by O
p300 I-GENE
RARE O
. O

First O
, O
human O
RARE O
K562 O
cells O
stably O
integrated O
with O
various O
ALL_CAP I-GENE
- I-GENE
40 I-GENE
mutants I-GENE
cis O
RARE O
to O
a O
human I-GENE
alpha I-GENE
- I-GENE
globin I-GENE
promoter I-GENE
- O
growth I-GENE
hormone I-GENE
RARE O
gene O
were O
analyzed O
by O
genomic O
footprinting O
and O
RARE O
analysis O
. O

Interestingly O
, O
addition O
of O
RARE O
CBP I-GENE
to O
the O
nuclear O
extracts O
of O
NUM O
cells O
markedly O
RARE O
progesterone O
- O
and O
PR I-GENE
- O
dependent O
transcription O
from O
a O
RARE O
- O
free O
, O
progesterone O
response O
element O
( O
ALL_CAP O
)- O
RARE O
reporter O
DNA O
template O
. O

Its O
RARE O
binding O
protein O
, O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
, O
is O
an O
essential O
transcription O
factor O
; O
its O
RARE O
mutations O
result O
in O
RARE O
lethality O
, O
and O
its O
dominant O
negative O
mutants O
produce O
aberrant O
RARE O
of O
RARE O
- O
specific O
genes O
. O

Removal O
of O
all O
core I-GENE
histone I-GENE
RARE O
domains O
by O
limited O
trypsin I-GENE
proteolysis O
or O
acetylation O
of O
the O
core I-GENE
histone I-GENE
tails O
significantly O
RARE O
this O
inhibition O
and O
allows O
ALL_CAP I-GENE
to O
exhibit O
high O
- O
affinity O
binding O
to O
RARE O
DNA O
. O

Finally O
, O
the O
mechanism O
of O
NUM I-GENE
activation O
involves O
, O
in O
part O
, O
RARE O
- O
oligomerization O
. O

OUTCOME O
: O
RARE I-GENE
receptor I-GENE
antibodies I-GENE
and O
single O
- O
fibre O
RARE O
were O
useful O
in O
the O
diagnosis O
of O
RARE O
RARE O
. O

Two O
other O
patients O
underwent O
ALL_CAP O
. O

The O
variations O
were O
caused O
by O
opposite O
shifts O
in O
ALL_CAP I-GENE
frequency O
distribution O
in O
mothers O
and O
neonates O
. O

Characterization O
of O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
RARE I-GENE
resistance I-GENE
protein I-GENE
2 I-GENE
( O
NUM I-GENE
) O
gene O
and O
its O
RARE O
in O
comparison O
RARE O
RARE I-GENE
resistance I-GENE
protein I-GENE
3 I-GENE
( O
NUM I-GENE
) O
gene O
. O

However O
, O
such O
a O
mechanism O
was O
not O
detected O
in O
preliminary O
observations O
on O
M O
. O
RARE O
. O

These O
results O
suggest O
that O
the O
M O
. O
RARE O
RARE O
RARE O
RARE O
related O
RARE I-GENE
20S I-GENE
RARE I-GENE
require O
a O
RARE O
complex O
such O
RARE O
ALL_CAP I-GENE
to O
mediate O
the O
energy O
- O
dependent O
hydrolysis O
of O
folded O
- O
substrate O
proteins O
and O
that O
the O
N O
- O
terminal O
NUM O
amino O
acid O
residues O
of O
ALL_CAP I-GENE
are O
not O
RARE O
required O
RARE O
this O
reaction O
. O

The O
transcription O
factor O
E2F I-GENE
plays O
an O
important O
role O
in O
G O
( O
1 O
) O
to O
S O
RARE O
transition O
in O
the O
RARE O
eukaryotic O
cell O
RARE O
. O

In O
two O
- O
field O
nodal O
dissection O
, O
two O
RARE O
are O
included O
with O
( O
modern O
two O
- O
field O
) O
or O
without O
( O
RARE O
two O
- O
field O
) O
nodal O
dissection O
around O
both O
recurrent O
RARE O
nerve O
chains O
in O
the O
upper O
RARE O
. O

Of O
the O
NUM O
patients O
studied O
, O
ALL_CAP I-GENE
- I-GENE
MB I-GENE
results O
were O
positive O
in O
91 O
( O
NUM O
%) O
patients O
; O
ECG O
revealed O
AMI O
in O
72 O
( O
NUM O
%) O
patients O
. O

The O
effect O
of O
ALL_CAP O
on O
the O
dose O
- O
response O
curve O
of O
RARE O
applied O
noradrenaline O
was O
also O
studied O
. O

The O
regional O
blockade O
of O
NUM I-GENE
was O
observed O
mainly O
in O
the O
frontal O
, O
temporal O
and O
anterior O
RARE O
RARE O
, O
and O
the O
intravenous O
administration O
of O
d O
- O
RARE O
RARE O
a O
therapeutic O
dose O
( O
2 O
mg O
) O
blocked O
over O
NUM O
% O
of O
NUM I-GENE
in O
the O
frontal O
RARE O
. O

The O
RARE O
of O
the O
NUM I-GENE
RARE I-GENE
cDNA I-GENE
in O
the O
NUM I-GENE
mutant I-GENE
cells O
partially O
RARE O
the O
mid O
RARE O
and O
resulted O
in O
a O
slight O
increase O
in O
Ca O
( O
2 O
+) O
uptake O
activity O
. O

RARE O
overall O
infection O
rates O
( O
events O
/ O
NUM O
patient O
- O
days O
) O
were O
2 O
. O
05 O
+/- O
NUM O
. O
NUM O
( O
RARE O
- O
RARE O
) O
and O
2 O
. O
NUM O
+/- O
NUM O
. O
NUM O
( O
double O
- O
RARE O
; O
P O
= O
ALL_CAP O
) O
RARE O
3 O
months O
. O

RARE O
and O
dynamic O
compliance O
was O
measured O
after O
induction O
of O
anesthesia O
, O
before O
and O
immediately O
after O
filtration O
in O
the O
operating O
RARE O
, O
1 O
hour O
after O
return O
to O
the O
pediatric O
intensive O
care O
unit O
, O
and O
NUM O
hours O
after O
the O
operation O
. O

RARE O
therapy O
: O
RARE O
RARE O
, O
diagnostic O
implications O
, O
and O
clinical O
consequences O
. O

There O
is O
RARE O
correlation O
between O
C2 O
- O
NUM O
RARE O
morphology O
and O
the O
RARE O
RARE O
response O
. O

ALL_CAP I-GENE
, O
a O
NUM I-GENE
- I-GENE
like I-GENE
kinase I-GENE
with O
mitogenic O
RARE O
and O
RARE O
to O
activate O
the O
SAPK I-GENE
/ O
JNK I-GENE
RARE O
. O

NUM I-GENE
has O
an O
RARE O
kinase O
activity O
required O
RARE O
RARE O
- O
RARE O
of O
a O
subset O
of O
apoptotic O
genes O
. O

We O
have O
mapped O
the O
human I-GENE
NUM I-GENE
gene I-GENE
to O
the O
NUM O
region O
of O
RARE O
7 O
; O
RARE O
human I-GENE
NUM I-GENE
- I-GENE
related I-GENE
genes I-GENE
have O
also O
been O
mapped O
: O
two O
RARE O
NUM O
near O
the O
RARE O
gene O
, O
one O
RARE O
NUM O
. O
NUM O
, O
and O
three O
RARE O
NUM O
. O
NUM O
, O
two O
of O
them O
flanking O
the O
breakpoints O
commonly O
associated O
with O
the O
RARE I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
deletion I-GENE
. O

RARE O
time O
( O
RT O
) O
and O
NUM O
were O
collected O
simultaneously O
. O

In O
experiment O
2 O
the O
rats O
had O
free O
access O
to O
two O
RARE O
, O
one O
of O
which O
contained O
RARE O
water O
, O
and O
the O
other O
contained O
either O
an O
ethanol O
( O
6 O
%) O
or O
a O
sucrose O
( O
5 O
%) O
solution O
. O

Furthermore O
, O
RARE O
' O
s O
method O
is O
used O
to O
balance O
the O
number O
of O
patients O
allocated O
to O
the O
two O
groups O
within O
each O
RARE O
( O
M O
. O

RESULTS O
: O
In O
this O
group O
of O
patients O
, O
male O
gender O
( O
P O
= O
NUM O
. O

Selective O
visual O
attention O
involves O
dynamic O
RARE O
between O
RARE O
control O
RARE O
and O
sensory O
brain O
RARE O
. O

The O
patient O
had O
developed O
RARE O
- O
RARE O
low O
- O
frequency O
tremor O
and O
RARE O
after O
a O
severe O
head O
trauma O
sustained O
RARE O
NUM O
years O
of O
age O
. O

However O
, O
the O
NUM O
isoform O
is O
RARE O
most O
RARE O
in O
brain O
and O
RARE O
, O
NUM O
in O
liver O
and O
RARE O
, O
and O
NUM O
in O
liver O
, O
RARE O
, O
RARE O
, O
brain O
, O
RARE O
, O
and O
RARE O
. O

During O
the O
cloning O
by O
reverse I-GENE
transcriptase I-GENE
- O
polymerase O
chain O
reaction O
of O
the O
human I-GENE
HIF I-GENE
- I-GENE
1alpha I-GENE
subunit I-GENE
, O
we O
isolated O
two O
cDNA O
RARE O
which O
corresponded O
to O
RARE O
RARE O
of O
the O
HIF I-GENE
- I-GENE
1alpha I-GENE
gene I-GENE
. O

To O
assess O
the O
relationship O
between O
G O
( O
RARE O
RARE O
G I-GENE
( I-GENE
11 I-GENE
) I-GENE
function O
with O
the O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
dependent O
RARE O
, O
RARE O
of O
a O
dominant O
- O
interfering O
p85 I-GENE
regulatory I-GENE
subunit I-GENE
, O
RARE O
RARE O
RARE O
wortmannin O
treatment O
inhibited O
insulin I-GENE
- O
RARE O
but O
not O
G I-GENE
( I-GENE
RARE I-GENE
RARE I-GENE
NUM I-GENE
- O
RARE O
NUM I-GENE
- O
ALL_CAP I-GENE
translocation O
. O

In O
RARE O
ALL_CAP O
, O
the O
NUM I-GENE
/ O
p130 I-GENE
gene O
is O
RARE O
in O
most O
of O
the O
cases O
, O
and O
the O
protein O
is O
restricted O
to O
the O
cytoplasm O
. O

Together O
, O
these O
data O
identify O
ERK2 I-GENE
RARE O
a O
specific O
and O
direct O
target O
of O
ALL_CAP I-GENE
and O
are O
consistent O
with O
a O
model O
in O
which O
ALL_CAP I-GENE
negatively O
regulates O
ERK2 I-GENE
activity O
RARE O
part O
of O
a O
RARE O
mechanism O
. O

Cross O
- O
reaction O
between O
a O
monoclonal O
antibody O
and O
two O
alpha I-GENE
beta I-GENE
T I-GENE
cell I-GENE
receptors I-GENE
. O

RARE O
RARE O
mixed O
with O
RARE O
acid O
, O
in O
comparison O
with O
RARE O
acid O
alone O
, O
markedly O
( O
p O
< O
NUM O
. O
01 O
) O
shortened O
the O
duration O
of O
the O
RARE O
RARE O
from O
NUM O
. O
4 O
+/- O
4 O
. O
1 O
( O
mean O
+/- O
ALL_CAP O
) O
min O
to O
8 O
. O
9 O
+/- O
3 O
. O
7 O
( O
mean O
+/- O
ALL_CAP O
) O
min O
, O
and O
significantly O
( O
p O
< O
NUM O
. O
05 O
) O
RARE O
the O
mean O
magnitude O
of O
the O
RARE O
RARE O
RARE O
all O
time O
points O
( O
overall O
). O

The O
ALL_CAP O
- O
reactive O
RARE O
groups O
were O
RARE O
exclusively O
in O
the O
RARE O
RARE O
of O
the O
plasma O
membrane O
and O
, O
when O
presented O
in O
a O
helical O
model O
, O
RARE O
along O
one O
RARE O
of O
the O
helices O
. O

Analysis O
of O
1 O
Mb O
of O
published O
sequence O
from O
the O
region O
of O
RARE O
RARE O
on O
human O
RARE O
NUM O
- O
NUM O
identified O
NUM O
gene O
RARE O
, O
including O
NUM O
RARE O
genes O
in O
the O
human I-GENE
ALL_CAP I-GENE
- I-GENE
4 I-GENE
RARE I-GENE
gene I-GENE
cluster I-GENE
. O

Human I-GENE
AP I-GENE
- I-GENE
NUM I-GENE
repressed O
both O
reporter O
RARE O
from O
a O
transiently O
transfected O
AP I-GENE
- I-GENE
2alpha I-GENE
promoter I-GENE
and O
the O
endogenous O
AP I-GENE
- I-GENE
2alpha I-GENE
gene I-GENE
and O
inversely O
was O
negatively O
regulated O
by O
AP I-GENE
- I-GENE
2alpha I-GENE
. O

In O
order O
to O
gain O
RARE O
insight O
into O
the O
role O
of O
the O
amino O
- O
terminal O
domain O
of O
the O
NUM I-GENE
( O
CA I-GENE
) O
protein O
RARE O
viral O
replication O
, O
eight O
highly O
RARE O
proline O
residues O
known O
to O
promote O
RARE O
and O
to O
terminate O
alpha O
- O
helices O
within O
the O
NUM I-GENE
tertiary O
RARE O
were O
replaced O
by O
a O
leucine O
RARE O
( O
P O
- O
position O
- O
L O
). O

RARE I-GENE
/ O
Cdc28 I-GENE
kinases O
promote O
nuclear O
export O
of O
the O
replication I-GENE
RARE I-GENE
proteins I-GENE
NUM I-GENE
- I-GENE
7 I-GENE
. O

RARE O
, O
PC12 O
- O
E2 O
cells O
were O
submitted O
to O
treatment O
with O
antibodies O
to O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
( I-GENE
FGF I-GENE
) I-GENE
receptor I-GENE
, O
RARE O
of O
the O
RARE I-GENE
tyrosine I-GENE
kinase I-GENE
NUM I-GENE
( O
RARE I-GENE
RARE O
PLC I-GENE
, O
PKC I-GENE
and O
MEK I-GENE
and O
an O
activator O
of O
PKC I-GENE
, O
phorbol O
- O
12 O
- O
myristate O
- O
NUM O
- O
RARE O
( O
PMA O
). O

RARE O
roles O
of O
RARE I-GENE
/ O
RARE I-GENE
and O
RARE I-GENE
- I-GENE
related I-GENE
proteins I-GENE
in O
the O
formation O
of O
the O
dorsal O
RARE O
in O
RARE O
. O

RARE O
RARE O
administered O
RARE O
NUM O
and O
10 O
min O
before O
or O
5 O
, O
10 O
and O
NUM O
min O
after O
exposure O
to O
ALL_CAP O
- O
5 O
, O
but O
not O
thereafter O
, O
significantly O
attenuated O
ALL_CAP O
- O
RARE O
neurotoxicity O
compared O
with O
controls O
. O

We O
also O
show O
that O
RARE O
activated O
RARE O
transcripts O
are O
restricted O
to O
RARE O
- O
posterior O
specific O
regions O
and O
RARE O
by O
ALL_CAP O
- O
irradiation O
and O
BMP I-GENE
- I-GENE
4 I-GENE
overexpression O
in O
RARE O
- O
dependent O
way O
. O
RARE O
NUM O
: O
198 O
- O
NUM O
, O
2000 O
. O

In O
all O
other O
cases O
, O
vestibular O
RARE O
or O
chemical O
vestibular O
RARE O
, O
by O
means O
of O
RARE O
low O
concentration O
RARE O
( O
20 O
mg O
/ O
mL O
RARE O
are O
indicated O
. O

However O
, O
when O
, O
where O
and O
how O
the O
ALL_CAP I-GENE
is O
cleaved O
into O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
is O
not O
clear O
. O

It O
has O
a O
RARE O
prognosis O
with O
> O
70 O
% O
mortality O
in O
3 O
months O
, O
despite O
mechanical O
ventilation O
. O

We O
found O
that O
TCR I-GENE
RARE O
induces O
AP I-GENE
- I-GENE
1 I-GENE
binding O
to O
this O
site O
and O
regulates O
the O
RARE I-GENE
promoter I-GENE
function O
in O
a O
fashion O
dependent O
on O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
binding O
. O

Thus O
, O
patients O
with O
metastatic O
RARE O
are O
not O
RARE O
to O
NUM I-GENE
RARE I-GENE
based O
on O
the O
detection O
of O
NUM I-GENE
+ I-GENE
T O
cells O
specific O
RARE O
multiple O
HLA I-GENE
- I-GENE
A I-GENE
RARE I-GENE
NUM I-GENE
- O
restricted O
, O
NUM I-GENE
- O
derived O
RARE O
. O

Approximately O
20 O
% O
of O
RARE O
that O
express O
ALL_CAP I-GENE
do O
not O
contain O
the O
t O
( O
2 O
; O
5 O
RARE O
suggesting O
that O
other O
genetic O
abnormalities O
can O
result O
in O
aberrant O
ALL_CAP I-GENE
RARE O
. O

In O
addition O
, O
expected O
decreases O
in O
ALL_CAP I-GENE
enzymatic O
function O
in O
ALL_CAP I-GENE
- O
ALL_CAP I-GENE
- O
containing O
lymphomas O
may O
RARE O
these O
tumors O
more O
RARE O
to O
RARE O
drugs O
such O
RARE O
methotrexate O
. O

Following O
the O
observation O
that O
non O
- O
organ O
- O
specific O
antibodies O
are O
related O
with O
RARE O
RARE O
and O
RARE O
, O
the O
role O
of O
organ O
- O
specific O
antibodies O
is O
currently O
being O
extensively O
investigated O
. O

RARE O
ions O
were O
found O
to O
be O
essential O
RARE O
autophosphorylation O
of O
NUM I-GENE
, O
and O
magnesium O
can O
stimulate O
the O
activity O
. O

The O
NUM I-GENE
5 I-GENE
' I-GENE
flanking I-GENE
region I-GENE
contains O
a O
RARE O
ER O
stress O
- O
responsive O
element O
which O
is O
sufficient O
RARE O
induction O
by O
RARE O
. O

RARE O
point O
feature O
RARE O
using O
RARE O
RARE O
. O

RARE O
is O
a O
RARE O
antagonist O
and O
has O
been O
demonstrated O
to O
reduce O
wound O
RARE O
flow O
and O
edema O
formation O
. O

Serum O
leptin I-GENE
concentrations O
in O
women O
RARE O
gonadotropin I-GENE
RARE O
cycles O
. O

RARE O
RARE O
: O
social O
work O
practice O
with O
RARE O
from O
a O
strengths O
RARE O
. O

PURPOSE O
: O
A O
two O
- O
generation O
RARE O
RARE O
family O
with O
RARE O
recessive O
RARE O
congenital O
RARE O
( O
ALL_CAP O
, O
ALL_CAP O
NUM O
, O
NUM O
) O
and O
RARE O
was O
identified O
. O

NUM I-GENE
was O
targeted O
to O
the O
plasma O
membrane O
even O
in O
the O
absence O
of O
RARE O
or O
RARE O
. O

Here O
, O
we O
show O
that O
IRF I-GENE
- I-GENE
1 I-GENE
is O
degraded O
via O
the O
ubiquitin I-GENE
- O
proteasome O
RARE O
. O

An O
amino O
- O
acid O
sequence O
comparison O
revealed O
that O
Bacillus I-GENE
NUM I-GENE
- I-GENE
1 I-GENE
RARE I-GENE
shared O
NUM O
% O
homology O
with O
Bacillus I-GENE
subtilis I-GENE
RARE I-GENE
and O
NUM O
% O
with O
Escherichia O
coli O
and O
RARE I-GENE
RARE I-GENE
RARE I-GENE
. O

RARE O
to O
this O
RARE O
, O
the O
activity O
of O
ALL_CAP I-GENE
is O
negatively O
modulated O
by O
an O
RARE O
called O
ALL_CAP I-GENE
. O

As O
assessed O
by O
a O
genetic O
assay O
that O
measures O
ALL_CAP O
- O
dependent O
DNA O
binding O
, O
ALL_CAP I-GENE
inhibited O
ALL_CAP I-GENE
function O
before O
and O
after O
the O
transcription O
factor O
had O
RARE O
to O
its O
DNA O
recognition O
site O
. O

Here O
we O
show O
that O
RARE O
pre O
- O
mRNA O
RARE O
is O
activated O
more O
than O
NUM O
- O
RARE O
in O
nuclear O
extracts O
prepared O
from O
RARE O
adenovirus O
- O
RARE O
cells O
( O
RARE O
- O
ALL_CAP O
) O
compared O
to O
RARE O
HeLa O
cell O
nuclear O
extracts O
( O
HeLa O
- O
ALL_CAP O
). O

RARE O
of O
NUM I-GENE
also O
suppresses O
several O
NUM I-GENE
( I-GENE
RARE I-GENE
) I-GENE
defects O
, O
and O
the O
double O
mutant O
accumulates O
far O
fewer O
NUM I-GENE
- I-GENE
protein I-GENE
RARE O
than O
either O
single O
mutant O
. O

Collectively O
, O
the O
results O
suggest O
that O
ARF I-GENE
binding O
to O
NUM I-GENE
induces O
a O
conformational O
change O
that O
RARE O
RARE O
import O
of O
the O
ARF I-GENE
- O
NUM I-GENE
complex O
and O
p53 I-GENE
- O
dependent O
cell O
RARE O
arrest O
. O

Cyclin I-GENE
A I-GENE
RARE O
is O
repressed O
in O
RARE O
cells O
by O
E2F I-GENE
acting O
in O
conjunction O
with O
its O
pocket O
protein O
partners O
RARE I-GENE
, O
p107 I-GENE
, O
and O
p130 I-GENE
; O
however O
, O
v I-GENE
- I-GENE
Jun I-GENE
RARE O
this O
control O
, O
causing O
RARE O
RARE I-GENE
and O
RARE O
- O
specific O
E2F I-GENE
- O
p107 I-GENE
complexes O
to O
RARE O
after O
mitogen O
withdrawal O
. O

D I-GENE
- I-GENE
RARE I-GENE
- O
RARE I-GENE
activity O
is O
required O
RARE O
RARE I-GENE
RARE O
in O
v I-GENE
- I-GENE
Jun I-GENE
- O
transformed O
cells O
, O
since O
ectopic O
RARE O
of O
the O
NUM I-GENE
- O
and O
NUM I-GENE
- O
specific O
inhibitor O
NUM I-GENE
( O
NUM I-GENE
) O
inhibits O
both O
DNA O
RARE O
and O
cell O
RARE O
. O

CONCLUSION O
: O
A O
valve O
- O
like O
mechanism O
formed O
by O
the O
RARE O
RARE O
partially O
RARE O
to O
the O
ALL_CAP O
optic O
can O
occur O
postoperatively O
. O

The O
protein O
RARE O
identified O
by O
the O
monoclonal I-GENE
antibody I-GENE
NUM I-GENE
is O
encoded O
by O
a O
gene O
RARE O
in O
NUM O
on O
RARE O
chromosomes O
and O
has O
been O
RARE O
named O
NUM I-GENE
. O

3 O
' O
RNA O
boundary O
experiments O
indicate O
that O
the O
5 O
' O
RARE O
reduces O
the O
number O
of O
( O
G O
/ O
ALL_CAP O
) O
ALL_CAP O
repeats O
required O
RARE O
stable O
ALL_CAP I-GENE
- O
RARE I-GENE
RARE O
RNA O
association O
. O

RARE O
silencing O
associated O
with O
RARE O
DNA O
sequences O
has O
been O
reported O
RARE O
many O
eukaryotes O
, O
including O
RARE O
. O

The O
ALL_CAP I-GENE
genes I-GENE
were O
differentially O
regulated O
by O
ethylene O
and O
by O
RARE O
stress O
conditions O
, O
such O
RARE O
RARE O
, O
cold O
, O
high O
RARE O
, O
or O
RARE O
, O
via O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
( O
NUM I-GENE
)- O
dependent O
or O
- O
independent O
pathways O
. O

Animals O
received O
a O
dose O
of O
dexamethasone O
( O
10 O
mg O
/ O
kg O
i O
. O
p O
.) O
prior O
to O
the O
protein O
- O
free O
RARE O
preparation O
RARE O
( O
pure O
phospholipids O
containing O
RARE O
, O
RARE O
ALL_CAP O
, O
RARE O
, O
RARE O
) O
and O
a O
ALL_CAP O
- O
C O
based O
RARE O
, O
respectively O
. O

BACKGROUND O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
response O
rates O
and O
toxicity O
of O
two O
regimens O
containing O
RARE I-GENE
- I-GENE
macrophage I-GENE
- I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
) O
in O
combination O
with O
interleukin I-GENE
- I-GENE
2 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
) O
in O
the O
treatment O
of O
patients O
with O
metastatic O
RARE O
cell O
carcinoma O
. O

We O
show O
, O
by O
injection O
of O
RARE O
mRNAs O
, O
that O
the O
cis O
- O
acting O
sequences O
responsible O
RARE O
repression O
of O
RARE I-GENE
NUM I-GENE
mRNA I-GENE
reside O
within O
its O
3 O
' O
UTR O
. O

These O
data O
indicate O
that O
expansion O
of O
the O
RARE O
repeat O
RARE O
in O
the O
proximal O
promoter O
of O
ALL_CAP I-GENE
severely O
RARE O
the O
function O
of O
the O
promoter O
and O
thereby O
reduces O
transcription O
of O
ALL_CAP I-GENE
. O

Thus O
, O
while O
the O
genomic O
organization O
of O
ALL_CAP I-GENE
is O
similar O
to O
the O
RARE O
- O
restricted O
members O
of O
the O
RARE I-GENE
family I-GENE
, O
the O
promoter O
element O
differs O
substantially O
both O
by O
sequence O
analysis O
and O
transcriptional O
activity O
in O
non O
- O
RARE O
cell O
RARE O
. O

Analysis O
of O
the O
5 O
' O
end O
of O
the O
mouse I-GENE
NUM I-GENE
( O
ALL_CAP I-GENE
) O
gene O
reveals O
a O
transcriptional O
regulatory O
element O
and O
evidence O
RARE O
RARE O
genomic O
organization O
. O
ALL_CAP I-GENE
( O
NUM I-GENE
) O
belongs O
to O
a O
highly O
RARE O
family O
of O
genes O
encoding O
RNA O
- O
binding O
proteins O
and O
has O
been O
RARE O
to O
cell O
growth O
and O
RARE O
through O
its O
RARE O
of O
mRNA O
stability O
. O

Electrophoretic O
mobility O
shift O
assays O
revealed O
that O
NUM I-GENE
binds O
to O
two O
different O
regions O
in O
the O
proximal O
promoter O
, O
a O
typical O
NUM I-GENE
site I-GENE
RARE O
RARE O
RARE O
38 O
; O
- O
NUM O
) O
and O
a O
G O
/ O
C O
- O
rich O
region O
between O
RARE O
67 O
; O
- O
NUM O
). O

NUM I-GENE
and O
NUM I-GENE
share O
a O
high O
degree O
of O
sequence O
identity O
that O
spans O
> O
NUM O
contiguous O
amino O
acid O
residues O
. O

Molecular O
cloning O
of O
mouse I-GENE
RARE I-GENE
RARE I-GENE
. O

The O
HPLC O
method O
involves O
an O
RARE O
column O
RARE O
NUM O
degrees O
C O
, O
a O
mixture O
of O
water O
- O
RARE O
- O
RARE O
acid O
( O
NUM O
: O
220 O
: O
1 O
, O
v O
/ O
v O
) O
RARE O
mobile O
RARE O
and O
detection O
RARE O
NUM O
nm O
. O

Eight O
patients O
received O
1 O
. O
5 O
mg O
of O
RARE O
RARE O
per O
kg O
of O
body O
RARE O
, O
and O
RARE O
patients O
received O
3 O
. O
NUM O
mg O
of O
RARE O
RARE O
per O
kg O
. O

NUM I-GENE
encodes O
a O
NUM O
- O
kDa O
protein O
that O
has O
sequence O
identity O
to O
the O
Neurospora I-GENE
crassa I-GENE
NUM I-GENE
and O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
NUM I-GENE
RARE I-GENE
. O

To O
determine O
if O
NUM I-GENE
is O
found O
in O
a O
complex O
with O
previously O
identified O
RARE I-GENE
cdc2 I-GENE
- I-GENE
related I-GENE
kinases I-GENE
( O
RARE I-GENE
RARE O
the O
NUM I-GENE
gene I-GENE
was O
fused O
to O
the O
ALL_CAP I-GENE
RARE I-GENE
tag O
, O
integrated O
into O
the O
RARE O
genome O
, O
and O
RARE O
under O
inducible O
control O
. O

These O
findings O
indicate O
the O
involvement O
of O
NUM I-GENE
and O
an O
RARE O
in O
non O
- O
cell O
- O
specific O
RARE O
and O
a O
RARE I-GENE
- I-GENE
like I-GENE
transcription I-GENE
factor I-GENE
and O
NUM I-GENE
in O
the O
cell O
- O
specific O
RARE O
of O
the O
ALL_CAP I-GENE
( I-GENE
4 I-GENE
) I-GENE
S I-GENE
gene I-GENE
. O

Here O
we O
review O
progress O
to O
date O
in O
this O
area O
. O

Additionally O
, O
the O
mouse O
promoter O
contains O
NUM O
copies O
of O
a O
ALL_CAP O
dinucleotide O
repeat O
sequence O
RARE O
RARE O
NUM O
bp O
5 O
' O
to O
RARE O
1 O
. O

The O
newly O
defined O
region O
contains O
an O
intron O
that O
may O
be O
RARE O
RARE O
and O
RARE O
polyadenylation O
signal O
sequences O
. O

RARE O
and O
RARE O
NUM O
standard O
reference O
materials O
were O
used O
to O
RARE O
the O
RARE O
. O

Therefore O
, O
the O
positive O
cAMP O
control O
of O
the O
hypoxic O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
was O
RARE O
from O
the O
ALL_CAP I-GENE
RARE O
. O

Most O
likely O
they O
might O
represent O
regulatory O
RNAs O
or O
RARE O
RARE O
elements O
. O

This O
paper O
RARE O
the O
RARE O
- O
based O
approach O
adopted O
by O
ALL_CAP O
ALL_CAP O
NUM O
- O
1 O
and O
the O
RARE O
necessary O
RARE O
the O
RARE O
record O
based O
on O
ALL_CAP O
ALL_CAP O
NUM O
' O
RARE O
RARE O
RARE O
RARE O
'. O

Sequence O
analyses O
of O
NUM I-GENE
mutant I-GENE
alleles I-GENE
reveal O
that O
both O
the O
N O
- O
terminal O
catalytic O
domain O
and O
the O
C O
- O
terminal O
regulatory O
domain O
of O
NUM I-GENE
are O
functionally O
essential O
. O

A O
mutation O
which O
RARE O
the O
binding O
of O
these O
factors O
reduces O
RARE I-GENE
reporter I-GENE
activity O
specifically O
in O
B O
cell O
lines O
, O
whereas O
a O
mutation O
which O
RARE O
the O
site O
to O
a O
consensus O
CREB I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
maintains O
wild O
- O
type O
promoter O
function O
. O

Here O
we O
describe O
the O
cloning O
, O
tissue O
- O
specific O
RARE O
pattern O
, O
and O
RARE O
characterization O
of O
two O
novel O
TEF I-GENE
- I-GENE
1 I-GENE
isoforms I-GENE
, O
TEF I-GENE
- I-GENE
1beta I-GENE
and O
TEF I-GENE
- I-GENE
NUM I-GENE
. O

Therefore O
the O
binding O
sites O
RARE O
liver O
- O
RARE O
factors O
, O
present O
in O
the O
hamster I-GENE
NUM I-GENE
proximal I-GENE
promoter I-GENE
in O
close O
vicinity O
and O
RARE O
between O
species O
, O
constitute O
a O
regulatory O
unit O
important O
RARE O
basal O
RARE O
RARE O
and O
tissue O
RARE O
of O
the O
action O
of O
RARE O
such O
RARE O
insulin I-GENE
. O

The O
kinase O
activity O
of O
NUM I-GENE
is O
RARE O
to O
CDK I-GENE
RARE O
such O
RARE O
RARE O
and O
RARE O
. O

Although O
MAP I-GENE
( I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
) I-GENE
kinases I-GENE
are O
implicated O
in O
cell O
RARE O
and O
differentiation O
in O
many O
cell O
RARE O
, O
the O
role O
of O
MAP I-GENE
kinases I-GENE
in O
cardiac O
hypertrophy O
remains O
unclear O
. O

Transfection O
with O
a O
CSF I-GENE
- I-GENE
NUM I-GENE
RARE O
RARE O
permitted O
CSF I-GENE
- I-GENE
1 I-GENE
- O
dependent O
activation O
of O
the O
signalling O
RARE O
targeting O
an O
Ets I-GENE
/ O
AP1 I-GENE
( O
activator I-GENE
protein I-GENE
1 I-GENE
) O
element O
in O
the O
uPA I-GENE
promoter I-GENE
that O
has O
been O
shown O
previously O
to O
be O
a O
target O
of O
RARE I-GENE
ras I-GENE
and O
protein O
kinase O
C O
pathways O
. O

Regulation O
of O
urokinase I-GENE
plasminogen I-GENE
activator I-GENE
gene I-GENE
transcription O
in O
the O
NUM O
murine O
macrophage O
cell O
line O
by O
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
CSF I-GENE
- I-GENE
1 I-GENE
) O
is O
dependent O
upon O
the O
level O
of O
cell O
- O
surface O
receptor O
. O

RARE O
( O
s O
) O
RARE O
by O
RARE O
cultures O
contribute O
to O
this O
induction O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
but O
little O
is O
known O
about O
the O
RARE O
pathways O
mediating O
this O
RARE O
. O

RARE O
of O
endogenous O
or O
RARE O
G I-GENE
( I-GENE
RARE I-GENE
)- I-GENE
coupled I-GENE
receptors I-GENE
with O
the O
delta I-GENE
- I-GENE
RARE I-GENE
receptor I-GENE
produced O
strong O
RARE O
of O
RARE I-GENE
and O
such O
responses O
could O
be O
partially O
blocked O
by O
RARE I-GENE
RARE I-GENE
. O

Patients O
enrolled O
in O
the O
RARE O
to O
RARE O
RARE O
RARE O
and O
Coronary O
RARE O
- O
II O
( O
ALL_CAP O
- O
II O
) O
trial O
were O
analyzed O
. O

The O
Wnt I-GENE
RARE O
RARE O
functions O
RARE O
RARE O
RARE O
development O
to O
control O
cell O
fate O
RARE O
. O

This O
mutation O
RARE O
longer O
repressed O
the O
HPV O
- O
11 O
upstream O
regulatory O
region O
- O
RARE O
reporter O
RARE O
. O

In O
the O
RARE O
RARE O
RARE O
, O
this O
sequence O
forms O
the O
RARE O
end O
of O
the O
RARE O
beta O
- O
RARE O
I O
( O
ALL_CAP O
RARE O
and O
all O
its O
basic O
residues O
are O
RARE O
positioned O
RARE O
the O
face O
that O
in O
the O
RARE O
subunit O
would O
be O
exposed O
to O
solvent O
. O

The O
two O
contiguous O
NUM I-GENE
( O
human I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
II I-GENE
) O
and O
NUM I-GENE
genes I-GENE
are O
RARE O
imprinted O
in O
both O
human O
and O
mouse O
. O

The O
asymmetric O
methylation O
was O
associated O
with O
tissue O
- O
specific O
disruption O
of O
NUM I-GENE
genomic O
imprinting O
in O
RARE O
brain O
. O

The O
comparison O
of O
the O
RARE O
patterns O
of O
the O
known O
NUM I-GENE
family I-GENE
members I-GENE
shows O
RARE O
RARE O
with O
significant O
RARE O
. O

Early O
treatment O
RARE O
of O
the O
RARE O
II O
division O
2 O
RARE O
. O

RARE O
use O
of O
the O
RARE O
RARE O
RARE O
RARE O
would O
support O
further O
development O
RARE O
a O
research O
tool O
RARE O
a O
simple O
assessment O
of O
RARE O
severity O
that O
could O
be O
used O
in O
epidemiological O
studies O
. O

The O
consensus O
RARE O
the O
importance O
of O
residues O
other O
than O
the O
eight O
motifs O
that O
are O
often O
associated O
with O
ALL_CAP I-GENE
- I-GENE
box I-GENE
RNA I-GENE
RARE I-GENE
, O
RARE O
RARE O
RARE O
de O
- O
RARE O
the O
importance O
of O
the O
" O
A O
" O
RARE O
within O
the O
" O
ALL_CAP O
" O
motif O
. O

RARE O
RARE O
was O
defined O
RARE O
an O
RARE O
larger O
than O
10 O
mm O
or O
an O
RARE O
of O
any O
size O
with O
RARE O
RARE O
, O
high O
- O
grade O
dysplasia O
or O
invasive O
carcinoma O
. O

In O
transient O
assays O
, O
using O
RARE O
RARE O
- O
cultured O
cells O
transformed O
by O
RARE O
RARE O
, O
we O
showed O
previously O
that O
NUM I-GENE
can O
transcriptionally O
repress O
the O
activity O
of O
reporter O
gene O
constructs O
with O
upstream O
HD I-GENE
- I-GENE
RARE I-GENE
binding O
sites O
. O

Results O
of O
two O
- O
RARE O
assays O
and O
electrophoretic O
mobility O
shift O
assays O
strongly O
suggest O
that O
all O
HD I-GENE
- I-GENE
RARE I-GENE
proteins I-GENE
of O
RARE O
I O
and O
II O
can O
form O
homodimers O
and O
also O
RARE O
with O
all O
HD I-GENE
- I-GENE
RARE I-GENE
proteins I-GENE
of O
the O
same O
family O
. O

Among O
mammalian I-GENE
RARE I-GENE
, O
HSF1 I-GENE
has O
been O
shown O
to O
be O
important O
RARE O
RARE O
of O
the O
heat O
- O
RARE O
stress O
gene O
RARE O
, O
whereas O
the O
function O
of O
NUM I-GENE
in O
stress O
response O
is O
unclear O
. O

RARE O
, O
concomitant O
RARE O
of O
RARE O
activated O
Raf I-GENE
and O
NUM I-GENE
Ras I-GENE
results O
in O
almost O
RARE O
RARE O
of O
TTF I-GENE
- I-GENE
1 I-GENE
activity O
. O

They O
share O
many O
RARE O
RARE O
, O
including O
remodeling O
of O
the O
actin I-GENE
RARE O
, O
activation O
of O
p70 I-GENE
( I-GENE
S6 I-GENE
) I-GENE
kinase I-GENE
and O
c I-GENE
- I-GENE
jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
RARE O
and O
RARE O
of O
transcription O
and O
cell O
RARE O
. O

Expression O
of O
activated O
Cdc42 I-GENE
results O
in O
the O
translocation O
of O
RARE I-GENE
from O
the O
nucleus O
into O
the O
cytosol O
, O
and O
Cdc42 I-GENE
and O
RARE I-GENE
RARE O
RARE O
the O
plasma O
membrane O
and O
in O
the O
cytoplasm O
. O

Copyright O
2000 O
Academic O
Press O
. O

To O
understand O
whether O
Shc I-GENE
RARE O
in O
membrane O
RARE O
is O
sufficient O
to O
regulate O
Shc I-GENE
function O
, O
we O
constructed O
a O
Shc I-GENE
RARE I-GENE
containing O
the O
Ras I-GENE
membrane I-GENE
RARE I-GENE
motif I-GENE
RARE O
the O
C O
- O
terminus O
. O

Southern O
blotting O
and O
single O
RARE O
conformation O
polymorphism O
analyses O
did O
not O
show O
tumor O
- O
specific O
alterations O
of O
this O
gene O
in O
RARE O
and O
RT O
- O
PCR O
studies O
showed O
RARE O
in O
glioma O
cell O
lines O
, O
suggesting O
that O
ALL_CAP I-GENE
is O
not O
the O
RARE O
NUM O
glioma O
tumor O
suppressor O
gene O
. O

ALL_CAP I-GENE
is O
a O
positive O
yet O
RARE O
regulator O
of O
RARE I-GENE
- O
ALL_CAP I-GENE
RARE O
. O

RARE I-GENE
I I-GENE
of O
the O
phosphoenolpyruvate I-GENE
: I-GENE
RARE I-GENE
RARE I-GENE
RARE O
. O

Based O
on O
these O
data O
, O
we O
conclude O
that O
transcription O
of O
ALL_CAP I-GENE
is O
RARE O
from O
the O
RARE I-GENE
promoter I-GENE
in O
ALL_CAP I-GENE
, O
and O
ALL_CAP I-GENE
RARE O
its O
transcription O
either O
by O
mediating O
transcriptional O
readthrough O
or O
increasing O
mRNA O
stability O
. O

It O
was O
established O
that O
RARE O
or O
RARE O
ALL_CAP O
, O
elevated O
the O
RARE O
threshold O
RARE O
mechanical O
stimuli O
in O
the O
formalin O
test O
in O
rats O
. O

Molecular O
RARE O
of O
human O
RARE O
and O
RARE O
response O
RARE O
genes O
by O
ALL_CAP O
. O

RARE O
environment O
was O
an O
important O
influence O
on O
RARE O
relationships O
, O
RARE O
use O
, O
and O
social O
support O
. O

By O
electrophoresis O
mobility O
shift O
assays O
using O
RARE O
corresponding O
to O
different O
RARE O
of O
the O
putative O
human I-GENE
c I-GENE
- I-GENE
myb I-GENE
intron I-GENE
1 I-GENE
transcription I-GENE
RARE I-GENE
region I-GENE
and O
nuclear O
extracts O
from O
RARE O
leukemia O
ALL_CAP O
NUM O
and O
fibroblast O
ALL_CAP O
38 O
cells O
, O
we O
detected O
a O
ALL_CAP O
- O
NUM O
- O
specific O
DNA O
- O
protein O
complex O
with O
a O
123 O
- O
bp O
fragment O
containing O
binding O
sites O
RARE O
the O
RARE I-GENE
regulatory I-GENE
factors I-GENE
( O
RARE I-GENE
) O
nuclear O
proteins O
. O

ALL_CAP O
DESIGN O
: O
RARE O
RARE O
RARE O
RARE O
smears O
from O
21 O
cases O
of O
invasive O
RARE O
carcinoma O
( O
ALL_CAP O
) O
of O
breast O
were O
subjected O
to O
detailed O
RARE O
analysis O
. O

RARE O
Response O
RARE O
( O
RARE O
RARE O
RARE O
in O
5 O
'- O
flanking O
sequences O
of O
both O
the O
RARE I-GENE
and O
RARE I-GENE
subunit I-GENE
genes I-GENE
, O
are O
RARE O
to O
RARE O
least O
partially O
mediate O
gene O
induction O
following O
RARE O
exposure O
. O

A O
new O
technique O
to O
create O
an O
artificial O
stenosis O
in O
the O
RARE O
LAD O
using O
a O
RARE O
. O

NUM I-GENE
is O
RARE O
in O
the O
X O
- O
ray O
- O
RARE O
mouse I-GENE
mutant I-GENE
RARE I-GENE
( O
RARE I-GENE
RARE O
causing O
a O
variety O
of O
RARE O
defects O
similar O
to O
SD O
RARE O
. O

RARE O
, O
ALL_CAP O
. O

NUM I-GENE
behaviour O
was O
also O
studied O
RARE O
the O
cell O
RARE O
; O
NUM I-GENE
always O
RARE O
to O
a O
discrete O
RARE O
that O
duplicated O
very O
early O
in O
mitosis O
and O
RARE O
to O
daughter O
cells O
in O
a O
coordinate O
manner O
with O
the O
basal O
body O
and O
RARE O
, O
suggesting O
the O
involvement O
of O
RARE O
. O

The O
early O
RARE O
. O
of O
rejection O
and O
especially O
acute O
rejection O
, O
it O
' O
s O
adequate O
management O
, O
decreased O
risk O
RARE O
the O
future O
chronic O
rejection O
nephropathy O
. O

RARE I-GENE
are O
responsible O
RARE O
the O
RARE O
of O
sucrose O
to O
RARE O
and O
glucose O
. O

To O
investigate O
the O
RARE O
mechanisms O
of O
this O
RARE I-GENE
- O
RARE O
inhibition O
, O
we O
analyzed O
its O
effect O
on O
the O
transcriptional O
activity O
of O
the O
RARE O
MyoD I-GENE
protein I-GENE
, O
which O
was O
used O
RARE O
a O
RARE O
of O
bHLH I-GENE
factors I-GENE
. O

The O
human I-GENE
T I-GENE
cell I-GENE
leukemia I-GENE
/ I-GENE
RARE I-GENE
virus I-GENE
type I-GENE
1 I-GENE
RARE I-GENE
protein I-GENE
represses O
MyoD I-GENE
- O
dependent O
transcription O
by O
inhibiting O
MyoD I-GENE
- O
binding O
to O
the O
ALL_CAP I-GENE
domain I-GENE
of O
p300 I-GENE
. O

RARE O
and O
RARE O
pole O
body O
RARE O
of O
the O
NUM I-GENE
RARE I-GENE
regulatory I-GENE
protein I-GENE
kinase I-GENE
in I-GENE
RARE I-GENE
yeast I-GENE
. O

Thus O
, O
both O
the O
hyperplasia O
and O
thrombotic O
complications O
which O
often O
follow O
RARE O
might O
be O
RARE O
by O
employing O
RARE O
RARE O
, O
which O
have O
a O
greater O
capacity O
than O
RARE O
in O
supporting O
a O
RARE O
RARE O
- O
endothelium O
. O

The O
cell O
RARE O
and O
transcriptional O
defects O
caused O
by O
NUM I-GENE
( O
NUM I-GENE
- I-GENE
1 I-GENE
) O
are O
consistent O
with O
the O
role O
of O
ALL_CAP I-GENE
( I-GENE
II I-GENE
) I-GENE
s I-GENE
RARE O
RARE O
of O
transcriptional O
activation O
and O
may O
reflect O
a O
role O
RARE O
NUM I-GENE
in O
RARE O
activation O
by O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
. O

RARE I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
( O
ERK I-GENE
) O
activation O
and O
RARE O
coupling O
of O
the O
RARE O
proteins O
p130 I-GENE
Crk I-GENE
- I-GENE
associated I-GENE
substrate I-GENE
( O
ALL_CAP I-GENE
) O
and O
c I-GENE
- I-GENE
ALL_CAP I-GENE
( O
Crk I-GENE
) O
represent O
two O
distinct O
pathways O
that O
induce O
cell O
invasion O
and O
protect O
cells O
from O
apoptosis O
in O
a O
three O
- O
dimensional O
RARE I-GENE
RARE O
. O

RARE O
of O
NUM I-GENE
and O
NUM I-GENE
DNA I-GENE
- I-GENE
protein I-GENE
complexes I-GENE
has O
revealed O
the O
extent O
of O
these O
sequences O
, O
and O
C O
- O
RARE O
extended O
molecules O
with O
substantially O
RARE O
DNA O
binding O
activity O
compared O
to O
the O
core O
domains O
alone O
have O
been O
produced O
. O

The O
evolution O
of O
the O
NUM I-GENE
cis I-GENE
- I-GENE
regulatory I-GENE
region I-GENE
versus O
the O
RARE O
reading O
frame O
RARE O
RARE O
RARE O
among O
different O
domains O
of O
the O
RARE O
reading O
frame O
differed O
from O
one O
another O
. O

These O
results O
indicate O
that O
RARE O
NUM O
serves O
RARE O
a O
" O
protein O
RARE O
" O
of O
altered O
minor O
RARE O
interactions O
and O
identifies O
which O
RARE O
RARE O
interactions O
are O
altered O
by O
these O
lesions O
. O

The O
recombinant O
RARE O
exist O
RARE O
RARE O
. O

A O
RARE O
RARE O
RARE O
of O
B I-GENE
lymphocyte I-GENE
antigen I-GENE
receptor I-GENE
- O
RARE O
RARE O
RARE O
. O

We O
now O
describe O
a O
second O
ALL_CAP I-GENE
protein I-GENE
, O
called O
NUM I-GENE
, O
that O
is O
highly O
homologous O
to O
NUM I-GENE
and O
also O
RARE O
primarily O
in O
brain O
. O

RARE I-GENE
- I-GENE
1 I-GENE
( O
I I-GENE
- I-GENE
1 I-GENE
) O
and O
inhibitor I-GENE
- I-GENE
2 I-GENE
( O
I I-GENE
- I-GENE
2 I-GENE
) O
selectively O
inhibit O
type I-GENE
1 I-GENE
protein I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
RARE I-GENE
( O
NUM I-GENE
). O

RARE O
mutations O
throughout O
the O
ALL_CAP O
element O
RARE O
with O
induction O
but O
allowed O
us O
to O
define O
five O
overlapping O
sites O
RARE O
regulatory O
factors O
in O
ALL_CAP O
and O
to O
design O
RARE O
binding O
just O
one O
or O
two O
factors O
. O

The O
RARE O
RARE O
RARE O
RARE O
in O
the O
RARE O
of O
the O
RARE O
are O
nucleotide O
sugars O
that O
must O
be O
transported O
from O
the O
cytosol O
by O
specific O
membrane O
- O
RARE O
RARE O
. O

RARE O
targeting O
of O
the O
RARE I-GENE
density I-GENE
protein I-GENE
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
RARE O
by O
a O
tyrosine O
- O
based O
trafficking O
signal O
. O

( O
1998 O
) O
ALL_CAP O
. O

RARE O
by O
two O
species O
of O
RARE O
( O
RARE O
RARE O
and O
RARE O
RARE O
) O
can O
lead O
to O
extensive O
swelling O
with O
RARE O
failure O
. O

Both O
normal O
and O
transforming O
ALL_CAP I-GENE
proteins I-GENE
have O
RARE I-GENE
RARE I-GENE
activity O
but O
only O
the O
RARE O
RARE O
with O
Ras I-GENE
in O
activating O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
ERK1 I-GENE
. O

These O
results O
indicate O
that O
RARE O
- O
associated O
genes O
and O
their O
overall O
chromosomal O
arrangement O
are O
relatively O
RARE O
RARE O
between O
B O
. O
RARE O
and O
other O
gram O
- O
negative O
bacteria O
such O
RARE O
A O
. O
RARE O
. O

An O
important O
mechanism O
by O
which O
the O
tumor O
suppressor O
p53 I-GENE
maintains O
genomic O
stability O
is O
to O
induce O
cell O
RARE O
arrest O
through O
activation O
of O
the O
RARE I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor O
p21 I-GENE
( O
WAF1 I-GENE
/ O
Cip1 I-GENE
) O
gene O
. O

RARE I-GENE
acts O
RARE O
an O
RARE O
molecule O
in O
integrin I-GENE
RARE O
. O

Thus O
, O
growth O
factor O
activation O
of O
ER I-GENE
can O
mediate O
RARE O
RARE O
ER I-GENE
/ O
NUM I-GENE
binding O
to O
ALL_CAP O
- O
rich O
sites O
and O
represents O
a O
novel O
RARE O
RARE O
RARE O
- O
independent O
ER I-GENE
action O
. O

Furthermore O
, O
analysis O
of O
deletion O
promoter O
- O
reporter O
constructs O
found O
that O
the O
basal O
activity O
of O
P2 O
RARE O
in O
the O
proximal O
region O
of O
P2 O
. O

RESULTS O
: O
RARE O
RARE O
collected O
RARE O
RARE O
tests O
increased O
gradually O
in O
proportion O
with O
age O
, O
especially O
in O
the O
hypertensive O
group O
( O
p O
< O
NUM O
. O
05 O
). O

In O
addition O
, O
the O
transcription O
of O
c I-GENE
- I-GENE
NUM I-GENE
promoter I-GENE
was O
strongly O
RARE O
- O
regulated O
when O
CD40 I-GENE
or O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
latent I-GENE
membrane I-GENE
protein I-GENE
1 I-GENE
was O
overexpressed O
. O

A O
variety O
of O
RARE O
and O
self O
- O
applied O
fluoride O
products O
are O
available O
and O
new O
fluoride O
delivery O
RARE O
have O
recently O
RARE O
the O
RARE O
. O

These O
studies O
identify O
several O
of O
the O
signal O
- O
RARE O
events O
involved O
in O
the O
apoptosis O
of O
malignant O
B O
cells O
that O
RARE O
following O
ligation O
of O
NUM I-GENE
by O
anti I-GENE
- I-GENE
NUM I-GENE
antibodies I-GENE
in O
the O
presence O
of O
Fc I-GENE
- I-GENE
receptor I-GENE
- O
expressing O
cells O
or O
secondary O
RARE O
anti I-GENE
RARE I-GENE
mouse I-GENE
Ig I-GENE
) I-GENE
antibodies I-GENE
and O
which O
may O
contribute O
to O
the O
tumor O
RARE O
observed O
in O
mouse O
models O
and O
clinical O
trials O
. O

CONCLUSION O
: O
Treatment O
of O
sepsis O
with O
the O
platelet I-GENE
- I-GENE
activating I-GENE
factor I-GENE
antagonist O
ALL_CAP O
- O
NUM O
offers O
RARE O
advantage O
over O
placebo O
on O
survival O
, O
hemodynamic O
status O
, O
respiratory O
function O
, O
or O
organ O
failure O
scores O
. O

RARE O
potentiates O
the O
local O
RARE O
effect O
of O
lidocaine O
in O
mice O
. O

The O
RARE O
of O
all O
the O
RARE O
proteins O
was O
remarkably O
RARE O
. O

Recently O
, O
identical O
ALL_CAP I-GENE
sequences I-GENE
have O
been O
identified O
RARE O
other O
locations O
in O
the O
human O
genome O
. O

EM O
analysis O
demonstrated O
that O
only O
one O
Rep I-GENE
- I-GENE
DNA I-GENE
complex I-GENE
was O
formed O
on O
RARE O
- O
19 O
target O
DNA O
. O

The O
protein O
was O
associated O
with O
RARE O
RARE O
virus O
RARE O
and O
with O
membranes O
of O
immature O
and O
RARE O
virions O
that O
were O
RARE O
by O
electron O
microscopy O
of O
RARE O
cells O
. O

In O
vivo O
dimethyl O
RARE O
footprinting O
of O
the O
RARE I-GENE
E I-GENE
promoter I-GENE
revealed O
several O
regions O
of O
protection O
and O
hypersensitivity O
that O
were O
unique O
to O
RARE O
cells O
. O

A O
RARE O
of O
NUM O
RARE O
map O
to O
this O
interval O
of O
3 O
Mb O
, O
giving O
an O
average O
marker O
resolution O
of O
RARE O
one O
per O
NUM O
kb O
. O

Recently O
, O
a O
mutation O
in O
the O
amino O
- O
terminus O
of O
NUM I-GENE
was O
associated O
with O
diabetes O
. O

CONCLUSION O
: O
More O
than O
50 O
% O
of O
patients O
with O
RARE O
RARE O
and O
ALL_CAP O
do O
not O
improve O
after O
surgery O
, O
a O
response O
that O
may O
be O
predicted O
by O
more O
cells O
expressing O
ALL_CAP I-GENE
- I-GENE
5 I-GENE
mRNA I-GENE
in O
the O
RARE O
RARE O
. O

Biol O
. O

On O
the O
basis O
of O
size O
, O
the O
ALL_CAP O
sequence O
to O
which O
it O
binds O
, O
and O
its O
RARE O
identification O
RARE O
a O
zinc I-GENE
finger I-GENE
protein I-GENE
, O
RARE I-GENE
factor I-GENE
has O
been O
identified O
RARE O
a O
RARE I-GENE
- I-GENE
like I-GENE
zinc I-GENE
finger I-GENE
protein I-GENE
( O
a O
mouse I-GENE
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
homologue I-GENE
). O

METHODS O
: O
The O
most O
distal O
muscle O
fibres O
from O
the O
deep O
and O
superficial O
finger O
RARE O
were O
measured O
relative O
to O
the O
RARE O
bone O
in O
18 O
RARE O
specimens O
. O

Here O
we O
report O
on O
the O
isolation O
of O
NUM I-GENE
, O
and O
show O
that O
it O
interacts O
with O
NUM I-GENE
, O
but O
not O
with O
a O
second O
CDK I-GENE
from I-GENE
Arabidopsis I-GENE
, O
NUM I-GENE
. O

RARE O
impact O
of O
risk O
- O
RARE O
RARE O
. O

METHODS O
: O
We O
determined O
an O
odds O
ratio O
( O
OR O
RARE O
RARE O
a O
measure O
of O
the O
relative O
risk O
of O
being O
exposed O
to O
a O
RARE O
interaction O
, O
comparing O
the O
use O
of O
the O
H2 I-GENE
- I-GENE
receptor I-GENE
antagonist O
, O
cimetidine O
, O
with O
that O
of O
the O
RARE O
agents O
ranitidine O
, O
RARE O
and O
RARE O
in O
users O
and O
RARE O
of O
RARE O
, O
phenytoin O
and O
theophylline O
. O

The O
prevalence O
of O
RARE O
was O
NUM O
% O
in O
the O
NUM O
patients O
without O
ALL_CAP O
and O
was O
significantly O
RARE O
( O
70 O
%, O
P O
< O
NUM O
. O
001 O
) O
in O
the O
70 O
patients O
with O
ALL_CAP O
, O
who O
also O
had O
lower O
RARE O
, O
RARE O
, O
plasma I-GENE
IGF I-GENE
- I-GENE
1 I-GENE
, O
serum O
RARE O
( O
RARE O
RARE O
and O
RARE I-GENE
hemoglobin I-GENE
. O

Our O
data O
suggest O
that O
, O
RARE O
least O
RARE O
high O
RARE O
, O
a O
critical O
minimal O
level O
of O
RARE I-GENE
protein I-GENE
RARE O
is O
required O
RARE O
maintaining O
vesicle O
RARE O
. O

The O
second O
RARE O
RARE O
of O
ALL_CAP I-GENE
sites I-GENE
is O
RARE O
between O
the O
two O
transcription O
initiation O
sites O
. O

A O
distinct O
staining O
pattern O
RARE O
the O
N I-GENE
- I-GENE
RARE I-GENE
was O
not O
detectable O
, O
although O
it O
was O
expected O
to O
RARE O
RARE O
the O
actin I-GENE
stress O
fibers O
. O

The O
' O
RARE O
' O
model O
, O
which O
is O
based O
on O
RARE O
' O
s O
NUM O
RARE O
, O
proved O
to O
be O
more O
RARE O
and O
diagnosed O
a O
systematic O
RARE O
RARE O
three O
RARE O
patients O
. O

The O
ALL_CAP I-GENE
, I-GENE
ALL_CAP I-GENE
, I-GENE
and I-GENE
ALL_CAP I-GENE
RARE I-GENE
are O
not O
homologs O
; O
however O
, O
like O
the O
ALL_CAP I-GENE
RARE I-GENE
gene I-GENE
, O
the O
genes O
encoding O
the O
ALL_CAP I-GENE
and I-GENE
ALL_CAP I-GENE
RARE I-GENE
each O
contain O
a O
single O
in O
- O
frame O
RARE O
RARE O
. O

After O
RARE O
, O
STAT I-GENE
proteins I-GENE
are O
transported O
into O
the O
nucleus O
and O
exhibit O
transcriptional O
activity O
. O

Overexpression O
of O
RARE I-GENE
- I-GENE
1 I-GENE
is O
sufficient O
to O
protect O
against O
apoptosis O
, O
while O
transfection O
of O
a O
RARE I-GENE
- I-GENE
1 I-GENE
RARE O
RARE O
causes O
cell O
RARE O
. O

Thus O
, O
although O
multiple O
RARE O
pathways O
are O
activated O
in O
response O
to O
a O
ras I-GENE
oncogene I-GENE
, O
inactivation O
of O
NUM I-GENE
RARE O
or O
response O
is O
sufficient O
to O
RARE O
the O
RARE O
program O
. O

In O
this O
study O
, O
the O
abilities O
of O
RARE O
and O
conditional O
forms O
of O
the O
three O
Raf I-GENE
kinases I-GENE
to O
abrogate O
the O
RARE O
RARE O
of O
ALL_CAP O
- O
P1 O
cells O
were O
examined O
. O

RARE O
of O
the O
method O
to O
a O
representative O
set O
of O
50 O
known O
genes O
from O
Arabidopsis O
thaliana O
showed O
significant O
improvement O
in O
prediction O
accuracy O
compared O
to O
previous O
RARE O
alignment O
methods O
. O

The O
RARE O
cDNA O
sequence O
of O
human I-GENE
ALL_CAP I-GENE
spectrin I-GENE
is O
available O
from O
RARE O
( O
ALL_CAP O
) O
RARE O
RARE O
number O
. O

RARE O
of O
naturally O
occurring O
HIV I-GENE
- I-GENE
1 I-GENE
long I-GENE
terminal I-GENE
repeats I-GENE
by O
the O
JNK I-GENE
RARE O
RARE O
. O

These O
data O
show O
that O
the O
alpha O
- O
helix O
domain O
of O
NUM I-GENE
( O
NUM I-GENE
RARE O
which O
is O
RARE O
in O
the O
RARE I-GENE
/ O
RARE I-GENE
proteins O
, O
is O
implicated O
in O
protein O
- O
protein O
interaction O
and O
confers O
a O
specific O
regulatory O
mechanism O
, O
outside O
of O
their O
Cdk I-GENE
- O
RARE O
activity O
, O
by O
which O
the O
NUM I-GENE
( O
NUM I-GENE
) O
family O
members O
positively O
act O
on O
RARE O
differentiation O
. O

The O
mode O
of O
resistance O
to O
RARE O
/ O
RARE O
was O
not O
evident O
( O
RARE O
A O
- O
negative O
by O
PCR O
); O
and O
these O
cases O
RARE O
the O
existence O
of O
RARE O
- O
resistant O
isolates O
before O
the O
introduction O
of O
this O
antimicrobial O
class O
into O
human O
clinical O
practice O
. O

This O
study O
was O
carried O
out O
to O
analyze O
PRL I-GENE
RARE O
in O
metastatic O
RARE O
RARE O
patients O
both O
RARE O
basal O
conditions O
and O
in O
response O
to O
L O
- O
RARE O
and O
RARE O
, O
which O
represents O
the O
most O
classical O
RARE O
and O
RARE O
tests O
RARE O
PRL I-GENE
RARE O
, O
respectively O
. O

RARE I-GENE
adhesion I-GENE
receptors I-GENE
RARE O
signals O
that O
control O
complex O
cell O
functions O
which O
require O
the O
RARE O
of O
gene O
RARE O
, O
such O
RARE O
RARE O
, O
differentiation O
and O
survival O
. O

RARE O
, O
replication O
, O
repair O
: O
from O
complexity O
to O
RARE O
. O

The O
RARE O
RARE O
: O
a O
question O
of O
RARE O
RARE O
. O

RARE O
- O
operative O
ultrasound O
( O
ALL_CAP O
) O
has O
been O
widely O
used O
in O
an O
attempt O
to O
overcome O
these O
RARE O
, O
but O
is O
limited O
by O
its O
two O
- O
dimensional O
nature O
, O
RARE O
- O
RARE O
variability O
, O
and O
image O
RARE O
with O
RARE O
or O
RARE O
techniques O
. O

CONCLUSIONS O
: O
This O
randomized O
study O
shows O
that O
RARE O
fibrin I-GENE
RARE O
is O
effective O
in O
preventing O
air O
RARE O
after O
small O
RARE O
RARE O
in O
pigs O
, O
even O
RARE O
high O
inspiratory O
pressures O
. O

RARE O
- O
RARE O
RARE O
is O
caused O
by O
mutations O
in O
NUM I-GENE
encoding O
a O
novel O
Ca O
( O
2 O
+) O
RARE O
. O

RARE I-GENE
is O
RARE O
in O
the O
developing O
liver O
RARE O
with O
the O
RARE I-GENE
/ O
RARE I-GENE
helix I-GENE
transcription O
factor O
, O
RARE I-GENE
Nuclear I-GENE
RARE I-GENE
NUM I-GENE
( O
NUM I-GENE
). O

As O
an O
extension O
of O
our O
structural O
characterization O
of O
the O
RARE O
- O
intron O
organization O
of O
the O
mouse I-GENE
RARE I-GENE
gene I-GENE
, O
we O
now O
have O
isolated O
and O
characterized O
the O
mouse I-GENE
RARE I-GENE
promoter I-GENE
region I-GENE
required O
RARE O
IFN I-GENE
- O
inducible O
transcription O
. O

The O
ALL_CAP O
, O
5 O
'- O
ALL_CAP O
- O
3 O
RARE O
has O
been O
described O
RARE O
the O
consensus O
sequence O
RARE O
the O
cis O
- O
element O
that O
directs O
cAMP O
- O
regulated O
gene O
RARE O
. O

RARE O
length O
did O
not O
significantly O
differ O
between O
right O
and O
RARE O
, O
however O
, O
RARE O
RARE O
, O
cortical O
thickness O
and O
size O
did O
( O
p O
< O
NUM O
. O
05 O
). O

The O
clinical O
RARE O
was O
I O
( O
NUM O
RARE O
and O
NUM O
RARE O
RARE O
with O
lymph O
node O
dissection O
( O
R O
2 O
b O
) O
was O
performed O
. O

RARE O
RARE O
RARE O
- O
RARE O
night O
RARE O
. O

A O
cause O
of O
increase O
of O
RARE I-GENE
phosphatase I-GENE
in O
children O

The O
physicians O
in O
RARE O
of O
all O
patients O
with O
evidence O
of O
acute O
ALL_CAP O
fever O
( O
RARE O
and O
/ O
or O
presence O
of O
IgM I-GENE
) O
or O
chronic O
ALL_CAP O
fever O
( O
prolonged O
RARE O
and O
/ O
or O
IgG I-GENE
antibody I-GENE
titer O
to O
RARE O
I O
of O
RARE O
RARE O
> O
or O
= O
800 O
) O
were O
RARE O
to O
RARE O
a O
questionnaire O
, O
which O
was O
computerized O
. O

Copyright O
2000 O
Academic O
Press O
. O

RARE O
cell O
- O
to O
- O
cell O
movement O
of O
ALL_CAP I-GENE
CP I-GENE
mutant I-GENE
was O
complemented O
in O
RARE O
RARE O
cv O
. O

Induction O
of O
NUM I-GENE
RARE O
by O
RARE O
of O
U937 O
cells O
with O
IFN I-GENE
- I-GENE
gamma I-GENE
revealed O
the O
presence O
of O
two O
RARE O
ALL_CAP I-GENE
( O
gamma I-GENE
- I-GENE
RARE I-GENE
activation I-GENE
site I-GENE
) O
elements O
. O

Significantly O
, O
two O
proximal O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
RARE O
118 O
/- O
NUM O
and O
- O
98 O
/- O
93 O
) O
and O
a O
region O
RARE O
within O
- O
NUM O
to O
- O
NUM O
of O
the O
mouse I-GENE
NUM I-GENE
promoter I-GENE
were O
essential O
RARE O
transcriptional O
activation O
RARE O
RARE O
RARE O
differentiation O
of O
ALL_CAP O
cells O
, O
implying O
their O
importance O
in O
conferring O
RARE O
RARE O
to O
the O
NUM I-GENE
transcriptional O
activation O
. O

ALL_CAP I-GENE
- I-GENE
NUM I-GENE
plays O
an O
important O
role O
in O
the O
RARE O
of O
vesicle O
trafficking O
in O
mammalian O
cells O
. O

The O
HMG I-GENE
domain I-GENE
of O
both O
NUM I-GENE
proteins I-GENE
is O
most O
similar O
to O
that O
of O
yeast I-GENE
NUM I-GENE
( O
38 O
% O
to O
NUM O
%). O

IgM I-GENE
and O
IgG I-GENE
anti I-GENE
A I-GENE
and O
anti I-GENE
B I-GENE
antibody I-GENE
status O
of O
NUM O
RARE O
O O
group O
mothers O
( O
who O
had O
non O
O O
group O
RARE O
) O
were O
studied O
. O

In O
an O
attempt O
to O
understand O
NUM I-GENE
RARE O
RARE O
cell O
RARE O
, O
yeast O
two O
- O
RARE O
screening O
was O
used O
to O
identify O
NUM O
- O
binding O
protein O
( O
s O
). O

RARE O
RARE O
of O
T I-GENE
/ I-GENE
T I-GENE
( I-GENE
L I-GENE
) I-GENE
causes O
a O
rapidly O
fatal O
RARE O
RARE O
in O
a O
murine O
bone O
marrow O
transplant O
( O
ALL_CAP O
) O
model O
, O
whereas O
T I-GENE
/ I-GENE
T I-GENE
( I-GENE
F I-GENE
) I-GENE
causes O
a O
long O
- O
RARE O
, O
pre O
- O
B O
- O
cell O
RARE O
lymphoma O
. O

RARE O
- O
ALL_CAP O
strains O
expressing O
NUM I-GENE
/ O
NUM I-GENE
failed O
to O
transform O
ALL_CAP O
3T3 O
cells O
and O
demonstrated O
a O
greatly O
RARE O
capacity O
to O
mediate O
RARE O
events O
associated O
with O
the O
Ras I-GENE
- O
dependent O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
RARE O
. O

The O
RARE O
usage O
is O
particularly O
marked O
RARE O
the O
gag I-GENE
, O
pol I-GENE
, O
and O
env I-GENE
genes I-GENE
. O

The O
p53 I-GENE
- I-GENE
homolog I-GENE
NUM I-GENE
also O
activated O
the O
NUM I-GENE
promoter I-GENE
, O
but O
in O
contrast O
to O
p53 I-GENE
, O
the O
proline O
- O
rich O
domain O
of O
NUM I-GENE
( I-GENE
residues I-GENE
NUM I-GENE
- I-GENE
NUM I-GENE
) I-GENE
was O
dispensable O
to O
induce O
the O
NUM I-GENE
promoter I-GENE
. O

Results O
from O
transient O
assays O
using O
these O
mutants O
showed O
that O
the O
NUM O
received O
signals O
from O
RARE I-GENE
A I-GENE
and I-GENE
B I-GENE
, O
demonstrating O
that O
this O
element O
is O
indeed O
a O
light O
- O
responsive O
element O
. O

Co O
- O
immunoprecipitation O
and O
DNA O
affinity O
chromatography O
prove O
that O
NUM I-GENE
RARE O
with O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
when O
RARE O
to O
the O
RARE O
element O
to O
yield O
a O
DNA O
- O
protein O
complex O
whose O
mobility O
is O
indistinguishable O
from O
that O
displayed O
by O
HeLa O
nuclear O
RARE O
in O
band O
shift O
assays O
. O

The O
NUM I-GENE
gene I-GENE
is O
mapped O
distal O
to O
marker O
ALL_CAP O
NUM O
1 O
in O
the O
human O
RARE O
NUM O
region O
, O
by O
ALL_CAP O
mapping O
. O

The O
C I-GENE
- I-GENE
terminal I-GENE
Cdk2 I-GENE
RARE O
, O
however O
, O
were O
non O
- O
RARE O
in O
these O
strains O
and O
thus O
dependent O
RARE O
activity O
on O
the O
NUM I-GENE
coding I-GENE
region I-GENE
which O
remained O
in O
the O
mutant I-GENE
NUM I-GENE
:: O
HIS3 I-GENE
chromosomal I-GENE
locus I-GENE
. O

We O
report O
here O
on O
the O
RARE O
nature O
of O
an O
ALL_CAP O
- O
RARE O
mutant O
, O
NUM I-GENE
- I-GENE
NUM I-GENE
, O
a O
RARE O
RARE O
allele O
of O
the O
NUM I-GENE
( O
NUM I-GENE
) O
RARE O
locus O
that O
encodes O
a O
RARE I-GENE
- I-GENE
specific I-GENE
cell I-GENE
RARE I-GENE
RARE I-GENE
, O
NUM I-GENE
. O

We O
conclude O
that O
, O
both O
in O
RARE O
RARE O
and O
in O
Xenopus O
oocytes O
, O
beta O
- O
adrenergic O
RARE O
potentiates O
the O
RARE O
- O
evoked O
ALL_CAP I-GENE
RARE I-GENE
via O
a O
RARE O
that O
involves O
PKA I-GENE
- O
catalyzed O
RARE O
RARE O
from O
beta I-GENE
( I-GENE
2 I-GENE
) I-GENE
ALL_CAP I-GENE
. O

RARE I-GENE
negatively O
regulates O
Src I-GENE
mitogenic O
function O
but O
does O
not O
RARE O
Src I-GENE
- O
RARE O
cell O
morphology O
changes O
. O

Identification O
of O
a O
novel O
NUM I-GENE
product I-GENE
suggests O
a O
mechanism O
RARE O
RARE O
RARE O
of O
repression O
by O
RARE I-GENE
proteins I-GENE
. O

In O
DNase I-GENE
I I-GENE
footprinting O
protection O
analysis O
, O
both O
ALL_CAP I-GENE
and O
ALL_CAP O
regions O
were O
protected O
by O
RARE I-GENE
S I-GENE
- I-GENE
transferase I-GENE
- O
NUM I-GENE
fusion O
protein O
. O

RARE O
the O
RARE O
, O
NUM I-GENE
or O
NUM I-GENE
, O
further O
enhances O
NUM I-GENE
- O
RARE O
transcriptional O
activity O
. O

RARE I-GENE
receptor I-GENE
- I-GENE
related I-GENE
receptor I-GENE
alpha I-GENE
1 I-GENE
interacts O
with O
RARE O
and O
constitutively O
activates O
the O
estrogen O
response O
elements O
of O
the O
human I-GENE
RARE I-GENE
gene I-GENE
. O

We O
examine O
current O
models O
of O
the O
effects O
of O
aging O
on O
mean O
response O
time O
and O
show O
how O
they O
might O
be O
RARE O
. O

The O
effects O
of O
these O
mutations O
on O
protein O
function O
require O
further O
examination O
. O

The O
median O
levels O
of O
RARE O
with O
50 O
% O
cut O
- O
off O
RARE O
diameters O
of O
10 O
( O
NUM O
) O
and O
2 O
. O
5 O
microm O
( O
NUM O
. O
5 O
) O
were O
NUM O
( O
range O
NUM O
- O
NUM O
) O
and O
NUM O
( O
range O
NUM O
- O
NUM O
) O
micro O
RARE O
m O
- O
3 O
, O
respectively O
. O

Kaposi O
' O
s O
sarcoma O
- O
associated O
RARE O
viral I-GENE
RARE I-GENE
regulatory I-GENE
factor I-GENE
confers O
resistance O
to O
the O
RARE O
effect O
of O
RARE I-GENE
- I-GENE
alpha I-GENE
. O

Specific O
and O
RARE O
genetic O
interference O
by O
double O
- O
RARE O
RNA O
in O
Arabidopsis O
thaliana O
. O

Comparison O
of O
sequences O
from O
- O
215 O
to O
+ O
1 O
bp O
identified O
consensus O
binding O
sites O
RARE O
the O
RARE I-GENE
transcription I-GENE
factor I-GENE
thyroid I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
TTF I-GENE
- I-GENE
1 I-GENE
). O

Two O
additional O
cis O
- O
acting O
sequences O
, O
RARE O
in O
both O
the O
region O
1 O
and O
3 O
promoters O
, O
were O
identified O
, O
suggesting O
a O
role O
RARE O
these O
sequences O
in O
the O
coordinate O
RARE O
of O
transcription O
from O
these O
promoters O
. O

RARE O
RARE O
bacteria O
are O
capable O
of O
generating O
cellular O
energy O
from O
several O
sources O
, O
including O
RARE O
, O
respiration O
, O
and O
H O
( O
2 O
) O
oxidation O
. O

An O
analysis O
of O
RARE O
peptides O
revealed O
a O
minimal O
ALL_CAP O
sequence O
that O
is O
sufficient O
to O
bind O
to O
the O
second O
NUM I-GENE
ALL_CAP I-GENE
domain I-GENE
( O
NUM I-GENE
NUM I-GENE
) O
in O
vitro O
and O
in O
yeast O
two O
- O
RARE O
assays O
. O

Furthermore O
, O
bone O
marrow O
- O
derived O
macrophages O
from O
ALL_CAP I-GENE
- O
RARE O
mice O
displayed O
RARE O
phagocytic O
efficiency O
in O
comparison O
to O
the O
macrophages O
from O
wild O
- O
type O
mice O
. O

NUM O
- O
weighted O
MRI O
on O
the O
NUM O
postoperative O
day O
demonstrated O
bilateral O
and O
RARE O
RARE O
lesions O
in O
the O
RARE O
RARE O
. O

The O
method O
is O
applied O
to O
determine O
RARE O
constants O
of O
a O
NUM O
ALL_CAP O
/ O
UT O
RARE O
with O
correction O
of O
the O
three O
- O
RARE O
RARE O
. O

The O
interaction O
does O
not O
depend O
on O
the O
presence O
of O
the O
correct O
amino O
- O
terminal O
DNA O
binding O
domain O
or O
the O
amino O
acid O
sequences O
between O
the O
DNA O
binding O
domain O
and O
the O
last O
ten O
amino O
RARE O
. O

ALL_CAP O
: O
The O
sample O
of O
subjects O
was O
RARE O
from O
the O
RARE O
RARE O
RARE O
Health O
RARE O
, O
a O
longitudinal O
RARE O
study O
of O
RARE O
- O
hospitalized O
subjects O
with O
RARE O
disorders O
; O
the O
present O
study O
focused O
on O
patients O
with O
schizophrenic O
disorders O
. O

RARE O
dysplasia O
is O
a O
major O
characteristic O
of O
patients O
with O
RARE O
RARE O
( O
ALL_CAP O
RARE O
along O
with O
marrow O
RARE O
, O
RARE O
and O
cytogenetic O
anomalies O
. O

Eight O
of O
the O
non O
- O
acceptable O
RARE O
/ O
RARE O
and O
five O
of O
the O
direct O
restorations O
were O
replaced O
, O
while O
the O
other O
ones O
were O
RARE O
with O
resin O
composite O
. O

RARE O
RARE O
respond O
to O
RARE O
by O
the O
range O
of O
RARE O
and O
pathogens O
that O
RARE O
them O
in O
the O
field O
is O
the O
subject O
of O
considerable O
research O
by O
both O
RARE O
RARE O
and O
RARE O
. O

CONCLUSION O
: O
The O
RARE O
of O
cardiopulmonary O
complications O
increases O
significantly O
when O
patients O
develop O
class O
1 O
ALL_CAP O
RARE O
. O

The O
rate O
- O
limiting O
step O
RARE O
telomerase I-GENE
activity O
seems O
to O
be O
the O
RARE O
of O
the O
catalytic O
subunit O
of O
the O
enzyme O
, O
encoded O
by O
the O
human I-GENE
telomerase I-GENE
reverse I-GENE
transcriptase I-GENE
( O
ALL_CAP I-GENE
) O
gene O
. O

In O
the O
control O
group O
, O
platelet O
markers O
increased O
1 O
h O
after O
surgery O
. O

However O
, O
the O
element O
proximal O
to O
the O
transcription O
RARE O
site O
is O
dependent O
on O
the O
SRE O
- O
1 O
. O

ALL_CAP O
RARE O
paper O
identifies O
ways O
to O
improve O
RARE O
care O
in O
RARE O
. O

Since O
proteins O
containing O
TPR O
elements O
are O
typically O
involved O
in O
multiple O
protein O
- O
protein O
interactions O
, O
we O
suggest O
that O
the O
NUM O
protein O
interacts O
within O
the O
RARE O
- O
snRNP O
with O
both O
the O
NUM I-GENE
and O
U4 I-GENE
/ O
U6 I-GENE
RARE O
, O
thus O
RARE O
the O
two O
RARE O
. O

Antibodies O
raised O
against O
a O
C O
- O
terminal O
portion O
of O
NUM I-GENE
RARE O
- O
RARE O
NUM I-GENE
and O
inhibit O
ER O
- O
RARE O
RARE O
of O
RARE O
- O
arrested O
vesicular O
RARE I-GENE
G I-GENE
protein I-GENE
in O
a O
RARE O
- O
RARE O
cell O
assay O
. O

Regulation O
of O
mitochondrial O
single O
- O
RARE O
DNA O
- O
binding O
protein O
gene O
RARE O
links O
nuclear O
and O
mitochondrial O
DNA O
replication O
in O
RARE O
. O

Genetic O
and O
RARE O
complexity O
of O
the O
position O
effect O
RARE O
RARE O
RARE I-GENE
( O
NUM I-GENE
) O
in O
Drosophila O
. O
RARE I-GENE
( O
NUM I-GENE
RARE O
also O
known O
RARE O
E I-GENE
( I-GENE
RARE I-GENE
) I-GENE
3 I-GENE
- I-GENE
NUM I-GENE
, O
is O
involved O
in O
a O
variety O
of O
processes O
, O
such O
RARE O
gene O
silencing O
in O
position O
effect O
RARE O
( O
ALL_CAP O
RARE O
the O
control O
of O
RARE I-GENE
RARE I-GENE
sequences I-GENE
, O
RARE O
of O
homeotic I-GENE
gene I-GENE
RARE O
, O
and O
programmed O
cell O
RARE O
. O

They O
are O
present O
in O
many O
RARE O
of O
living O
RARE O
, O
but O
their O
functions O
, O
especially O
those O
in O
humans O
, O
are O
unclear O
. O

This O
tendency O
is O
likely O
due O
to O
the O
RARE O
nucleotide O
composition O
of O
the O
RARE O
genome O
, O
rather O
than O
to O
the O
translational O
selection O
RARE O
specific O
codons O
. O

RARE O
of O
the O
human O
RARE O
cell O
line O
K562 O
showed O
that O
viral O
NUM I-GENE
- O
NUM O
RARE O
RARE O
transfer O
the O
NUM I-GENE
gene I-GENE
to O
RARE O
NUM O
% O
of O
target O
K562 O
cells O
, O
of O
which O
RARE O
least O
one O
third O
are O
capable O
of O
RARE O
in O
the O
presence O
of O
otherwise O
toxic O
concentrations O
of O
RARE O
. O

Regulation O
of O
pituitary O
vasopressin I-GENE
NUM I-GENE
receptors I-GENE
plays O
a O
critical O
role O
in O
RARE O
pituitary I-GENE
RARE I-GENE
hormone I-GENE
( O
ACTH I-GENE
) O
RARE O
RARE O
adaptation O
to O
stress O
. O

Identification O
of O
an O
ALL_CAP I-GENE
homologue I-GENE
( O
ALL_CAP I-GENE
) O
from O
RARE O
RARE O
RARE O
a O
pleiotropic O
regulator O
controlling O
RARE O
biosynthesis O
, O
RARE O
biosynthesis O
and O
RARE O
NUM O
resistance O
. O

Because O
the O
mutant O
RARE O
in O
DNA O
binding O
also O
fails O
to O
stimulate O
NUM I-GENE
NUM O
DNA O
- O
binding O
activity O
, O
our O
results O
suggest O
that O
NUM I-GENE
DNA O
- O
binding O
activity O
may O
play O
a O
pivotal O
role O
in O
the O
initiation O
of O
DNA O
replication O
. O

RARE O
its O
relative O
RARE O
on O
the O
RARE O
, O
ALL_CAP O
RARE O
have O
been O
in O
a O
unique O
position O
to O
observe O
RARE O
in O
RARE O
. O

The O
structural O
study O
of O
peptides O
belonging O
to O
the O
terminal O
domains O
of O
histone I-GENE
NUM I-GENE
can O
be O
considered O
RARE O
a O
step O
toward O
the O
understanding O
of O
the O
function O
of O
NUM I-GENE
in O
chromatin O
. O

The O
recovery O
rates O
RARE O
the O
MB O
/ O
ALL_CAP O
, O
ALL_CAP O
NUM O
, O
and O
solid O
media O
were O
91 O
. O
6 O
, O
87 O
. O
4 O
, O
and O
54 O
. O
7 O
%, O
respectively O
, O
RARE O
all O
mycobacteria O
; O
the O
recovery O
rates O
were O
93 O
. O
6 O
, O
88 O
. O
9 O
, O
and O
NUM O
. O
4 O
%, O
respectively O
, O
RARE O
M O
. O
tuberculosis O
complex O
alone O
, O
and O
87 O
. O
5 O
, O
NUM O
. O
4 O
, O
and O
37 O
. O
5 O
%, O
respectively O
, O
RARE O
all O
RARE O
mycobacteria O
. O

RARE O
vasculitis O
secondary O
to O
Crohn O
' O
s O
RARE O
seems O
to O
be O
a O
very O
rare O
phenomenon O
. O

ALL_CAP O
ALL_CAP O
: O
RARE O
and O
possibly O
randomised O
trials O
using O
RARE O
to O
treat O
asthma O
and O
asthma O
- O
like O
symptoms O
. O

ALL_CAP O
ALL_CAP O
: O
RARE O
trials O
comparing O
children O
undergoing O
systematic O
therapy O
focusing O
on O
the O
family O
in O
conjunction O
with O
asthma O
medication O
, O
with O
children O
taking O
asthma O
medication O
only O
. O

To O
test O
the O
hypothesis O
that O
RARE O
- O
RARE O
increases O
in O
resting O
core O
RARE O
and O
the O
core O
RARE O
threshold O
RARE O
RARE O
onset O
are O
RARE O
by O
estrogen O
, O
we O
studied O
eight O
women O
( O
NUM O
+/- O
2 O
yr O
) O
RARE O
NUM O
degrees O
C O
rest O
, O
RARE O
20 O
min O
of O
passive O
RARE O
( O
NUM O
degrees O
C O
RARE O
and O
RARE O
40 O
min O
of O
exercise O
RARE O
NUM O
degrees O
C O
. O

The O
models O
were O
tested O
by O
studying O
their O
response O
to O
disturbances O
of O
the O
RARE O
signal O
from O
the O
bladder O
. O

Our O
data O
show O
also O
that O
phagocytic O
RARE O
of O
RARE O
is O
probably O
a O
more O
consistent O
assay O
than O
antibody O
titer O
levels O
RARE O
RARE O
RARE O
, O
especially O
in O
ALL_CAP O
- O
RARE O
patients O
. O

These O
studies O
suggest O
an O
additional O
RARE O
or O
cellular O
environment O
is O
required O
RARE O
ALL_CAP I-GENE
activation O
by O
Cdc42 I-GENE
. O

M O
. O

RARE I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
sites I-GENE
were O
not O
required O
RARE O
this O
activation O
, O
and O
a O
mutant I-GENE
EBNA I-GENE
- I-GENE
3C I-GENE
protein I-GENE
unable O
to O
bind O
RARE I-GENE
activated O
transcription O
RARE O
efficiently O
RARE O
wild I-GENE
- I-GENE
type I-GENE
EBNA I-GENE
- I-GENE
3C I-GENE
, O
indicating O
that O
EBNA I-GENE
- I-GENE
3C I-GENE
can O
regulate O
transcription O
through O
a O
mechanism O
that O
is O
independent O
of O
RARE I-GENE
. O

Thus O
, O
both O
YY1 I-GENE
and O
CDP I-GENE
appear O
to O
be O
negative O
RARE O
of O
the O
differentiation O
- O
RARE O
HPV I-GENE
- I-GENE
6 I-GENE
E1 I-GENE
promoter I-GENE
and O
thereby O
the O
HPV O
life O
RARE O
. O

RARE O
RARE O
by O
RARE I-GENE
and O
RARE O
is O
involved O
in O
RARE O
HIV I-GENE
- I-GENE
1 I-GENE
ALL_CAP I-GENE
RARE I-GENE
RARE O
endogenous O
MHC I-GENE
class I-GENE
I I-GENE
antigen I-GENE
presentation O
. O

Cloning O
and O
characterization O
of O
human I-GENE
RARE I-GENE
, O
an O
RARE O
protein O
with O
pleckstrin I-GENE
homology O
and O
Src I-GENE
homology I-GENE
2 I-GENE
domains I-GENE
that O
can O
inhibit O
T O
cell O
activation O
. O

RARE O
data O
were O
analyzed O
according O
to O
a O
one O
- O
compartment O
RARE O
model O
with O
use O
of O
ALL_CAP O
population O
pharmacokinetic O
RARE O
. O

Finally O
, O
RARE I-GENE
existed O
mainly O
in O
cytosol O
and O
membrane O
RARE O
fractions O
in O
the O
resting O
state O
, O
and O
remained O
unchanged O
RARE O
platelet O
RARE O
, O
when O
FAK I-GENE
RARE O
to O
the O
cytoskeletal O
fraction O
. O

We O
also O
show O
that O
NUM I-GENE
binds O
to O
these O
RARE O
with O
almost O
equal O
affinity O
and O
that O
different O
residues O
have O
RARE O
roles O
in O
binding O
different O
kappaB I-GENE
RARE I-GENE
. O

Transcriptional O
RARE O
of O
the O
yeast I-GENE
NUM I-GENE
promoter I-GENE
in O
comparison O
to O
the O
RARE O
NUM I-GENE
promoter I-GENE
. O

The O
RARE I-GENE
are O
a O
subfamily O
of O
I I-GENE
- I-GENE
type I-GENE
RARE I-GENE
( O
immunoglobulin I-GENE
superfamily I-GENE
proteins I-GENE
that O
bind O
sugars O
) O
that O
specifically O
recognize O
RARE O
RARE O
. O

Our O
data O
provide O
a O
biochemical O
explanation O
RARE O
the O
RARE O
in O
RARE O
between O
A O
- O
T O
and O
ALL_CAP O
. O

PATIENTS O
OR O
ALL_CAP O
ALL_CAP O
: O
Twenty O
children O
met O
the O
criteria O
RARE O
being O
learning O
RARE O
. O

RARE O
on O
RARE O
- O
RARE O
infections O
by O
hepatitis O
C O
, O
HIV O
and O
RARE O

In O
the O
present O
study O
, O
we O
characterized O
cis O
- O
elements O
of O
the O
human I-GENE
PCI I-GENE
gene I-GENE
required O
RARE O
RARE O
in O
the O
hepatoma O
- O
derived O
cell O
line O
, O
NUM O
cells O
, O
and O
also O
evaluated O
rat I-GENE
PCI I-GENE
mRNA I-GENE
RARE O
, O
particularly O
on O
the O
effect O
of O
RARE O
in O
rat O
reproductive O
tissues O
. O

In O
the O
study O
on O
PCI I-GENE
mRNA I-GENE
RARE O
in O
the O
reproductive O
organs O
, O
we O
RARE O
RARE O
rat I-GENE
PCI I-GENE
cDNA I-GENE
and O
then O
evaluated O
the O
effect O
of O
RARE O
on O
the O
PCI I-GENE
mRNA I-GENE
RARE O
. O

To O
RARE O
its O
performance O
, O
measurements O
of O
RARE O
in O
RARE O
/ O
RARE O
RARE O
are O
presented O
. O

The O
RARE O
of O
the O
complexes O
formed O
with O
the O
RARE O
- O
RARE O
C O
RARE O
suggests O
that O
, O
in O
NUM I-GENE
, O
the O
NUM O
consecutive O
ALL_CAP O
domains O
are O
organized O
such O
that O
they O
define O
two O
RARE O
acid O
binding O
RARE O
. O

Mutational O
analysis O
of O
mammalian I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
5 I-GENE
( O
NUM I-GENE
): O
role O
of O
interaction O
between O
the O
beta O
subunit O
of O
NUM I-GENE
and O
NUM I-GENE
in O
NUM I-GENE
function O
in O
vitro O
and O
in O
vivo O
. O

RARE O
evidence O
indicates O
that O
p38 I-GENE
is O
an O
activator O
of O
MyoD I-GENE
: O
( O
i O
) O
p38 I-GENE
kinase I-GENE
activity O
is O
required O
RARE O
the O
RARE O
of O
MyoD I-GENE
- O
responsive O
genes O
, O
( O
ii O
) O
RARE O
induction O
of O
p38 I-GENE
stimulates O
the O
transcriptional O
activity O
of O
a O
Gal4 I-GENE
- O
MyoD I-GENE
fusion O
protein O
and O
allows O
efficient O
activation O
of O
chromatin O
- O
integrated O
RARE O
by O
MyoD I-GENE
, O
and O
( O
iii O
) O
MyoD I-GENE
- O
dependent O
RARE O
conversion O
is O
RARE O
in O
mouse O
RARE O
RARE O
derived O
from O
NUM I-GENE
RARE I-GENE
RARE O
. O

This O
activity O
is O
RARE O
by O
complex O
formation O
with O
the O
other O
NUM I-GENE
subunits I-GENE
. O

Our O
analysis O
of O
nonsense O
mutations O
indicates O
that O
the O
C O
terminus O
of O
NUM I-GENE
( I-GENE
residues I-GENE
NUM I-GENE
to I-GENE
NUM I-GENE
) I-GENE
is O
required O
RARE O
both O
catalytic O
activity O
and O
interaction O
with O
NUM I-GENE
. O

In O
contrast O
, O
mutations O
affecting O
the O
other O
two O
NUM I-GENE
- I-GENE
related I-GENE
kinases I-GENE
in O
S O
. O
cerevisiae O
, O
NUM I-GENE
and O
NUM I-GENE
, O
produce O
RARE O
detectable O
effect O
on O
RARE I-GENE
organization O
. O

CONCLUSIONS O
: O
RARE O
pacing O
provides O
little O
benefit O
over O
ventricular O
pacing O
RARE O
the O
prevention O
of O
stroke O
or O
RARE O
due O
to O
cardiovascular O
causes O
. O

Among O
non O
- O
RARE O
, O
lack O
of O
RARE O
RARE O
RARE O
had O
a O
NUM O
% O
sensitivity O
, O
88 O
% O
RARE O
, O
94 O
% O
negative O
predictive O
value O
, O
and O
NUM O
% O
positive O
predictive O
value O
in O
the O
diagnosis O
of O
pre O
- O
RARE O
RARE O
hypertension O
. O

NUM I-GENE
/ I-GENE
NUM I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
or O
NUM I-GENE
/ I-GENE
NUM I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
RARE O
substitution O
mutants O
displayed O
a O
RARE O
order O
of O
potency O
and O
agonist O
affinities O
virtually O
RARE O
wild I-GENE
- I-GENE
type I-GENE
( I-GENE
wt I-GENE
) I-GENE
NUM I-GENE
receptors I-GENE
, O
RARE O
RARE O
by O
both O
RARE O
binding O
and O
dopamine O
- O
RARE O
cAMP O
accumulation O
assays O
, O
and O
, O
similar O
to O
wt O
NUM I-GENE
receptors I-GENE
, O
did O
not O
exhibit O
receptor O
RARE O
activity O
or O
responsiveness O
to O
RARE O
agonists O
. O

RARE O
also O
revealed O
a O
very O
hydrophobic O
surface O
due O
to O
the O
absence O
of O
NUM O
, O
RARE O
residues O
from O
NUM O
, O
loop O
3 O
- O
4 O
, O
NUM O
, O
and O
NUM O
. O

The O
serine I-GENE
- I-GENE
threonine I-GENE
kinase I-GENE
gene I-GENE
is O
likely O
RARE O
, O
whereas O
the O
zinc O
finger O
motif O
is O
likely O
RARE O
. O

Stat I-GENE
activation O
in O
response O
to O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
was O
determined O
by O
reporter O
gene O
induction O
. O

ALL_CAP O
NUM O
had O
a O
greater O
tendency O
to O
take O
RARE O
RARE O
from O
the O
environment O
than O
did O
ALL_CAP O
NUM O
. O

RESULTS O
: O
Abnormal O
color O
RARE O
was O
found O
in O
NUM O
% O
of O
the O
epilepsy O
patients O
treated O
with O
RARE O
RARE O
and O
NUM O
% O
of O
the O
epilepsy O
patients O
treated O
with O
RARE O
RARE O
. O

In O
the O
NUM O
screening O
test O
, O
a O
few O
plates O
were O
not O
seen O
in O
both O
groups O
. O

RARE I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
phosphatase I-GENE
- I-GENE
3 I-GENE
( O
MKP I-GENE
- I-GENE
3 I-GENE
) O
is O
a O
dual O
RARE O
phosphatase O
that O
RARE O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
( O
ERK I-GENE
) O
MAP I-GENE
kinases I-GENE
. O

Consistent O
with O
this O
, O
we O
show O
that O
peptides O
representing O
RARE O
sites O
within O
the O
target O
RARE O
Elk I-GENE
- I-GENE
1 I-GENE
and O
NUM I-GENE
( O
RARE I-GENE
) O
inhibit O
ERK I-GENE
- O
dependent O
activation O
of O
MKP I-GENE
- I-GENE
3 I-GENE
. O

HPLC O
RARE O
mapping O
, O
amino O
acid O
sequencing O
, O
and O
site O
- O
directed O
mutagenesis O
determined O
that O
ALL_CAP I-GENE
phosphorylates O
RARE O
( O
67 O
) O
of O
I I-GENE
- I-GENE
1 I-GENE
. O

When O
the O
RARE O
diet O
consisted O
of O
ALL_CAP O
, O
RARE O
feed O
intake O
was O
RARE O
, O
indicating O
that O
ALL_CAP O
should O
not O
be O
fed O
to O
RARE O
RARE O
the O
RARE O
dietary O
RARE O
. O

RARE O
C O
virus O
infection O
and O
RARE O
diseases O
in O
RARE O
: O
a O
national O
study O
. O

The O
immune O
RARE O
is O
closely O
integrated O
with O
the O
RARE O
RARE O
, O
and O
infection O
- O
RARE O
increases O
in O
RARE O
such O
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
, O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
and O
TNF I-GENE
have O
numerous O
effects O
on O
the O
central O
nervous O
RARE O
. O

Interestingly O
, O
a O
decreased O
transcription O
from O
the O
endogenous O
c I-GENE
- I-GENE
Myb I-GENE
promoter I-GENE
was O
observed O
in O
several O
ALL_CAP O
- O
I O
transformed O
T O
- O
cell O
lines O
. O

NUM I-GENE
and O
NUM I-GENE
RARE O
RARE O
is O
regulated O
in O
two O
distinct O
ways O
by O
a O
shared O
cis O
acting O
regulatory O
region O
upstream O
of O
NUM I-GENE
. O

C O
. O
elegans O
ALL_CAP I-GENE
- I-GENE
11 I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
/ O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
: O
RARE O
of O
the O
RARE I-GENE
RARE I-GENE
RARE I-GENE
- I-GENE
II I-GENE
, O
and O
mouse O
NUM I-GENE
/ O
ALL_CAP I-GENE
/ O
NUM I-GENE
RARE I-GENE
complexes O
. O

RARE O
from O
RARE O
RARE O
. O

BACKGROUND O
: O
RARE O
RARE O
is O
a O
RARE O
RARE O
associated O
with O
acute O
liver O
failure O
, O
chronic O
RARE O
liver O
RARE O
or O
RARE O
systemic O
anastomosis O
. O

These O
RARE O
RARE O
S I-GENE
transcripts I-GENE
RARE O
- O
exist O
with O
several O
less O
abundant O
sense O
S I-GENE
transcripts I-GENE
. O

RARE O
is O
such O
adjustment O
possible O
unless O
one O
RARE O
a O
model O
that O
RARE O
the O
missing O
observations O
to O
other O
observed O
RARE O
RARE O
each O
subject O
- O
models O
that O
are O
RARE O
RARE O
. O

However O
, O
the O
presence O
of O
RARE O
seems O
to O
be O
a O
more O
reliable O
and O
RARE O
parameter O
that O
will O
be O
preferred O
in O
that O
prediction O
. O

The O
data O
are O
compatible O
with O
the O
idea O
that O
NUM I-GENE
RARE O
the O
RARE O
to O
the O
inner O
NUM O
- O
2 O
- O
RARE O
RARE O
, O
i O
. O
RARE O
. O
the O
group O
that O
links O
the O
ALL_CAP O
RARE O
RARE O
to O
proteins O
, O
whereas O
NUM I-GENE
and O
NUM I-GENE
transfer O
RARE O
onto O
the O
NUM O
- O
4 O
- O
and O
NUM O
- O
6 O
- O
RARE O
RARE O
of O
the O
ALL_CAP O
RARE O
, O
respectively O
. O

The O
C O
terminus O
of O
ALL_CAP I-GENE
binds O
to O
CBP I-GENE
/ O
p300 I-GENE
and O
NUM I-GENE
, O
a O
RARE O
of O
the O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
/ O
ALL_CAP I-GENE
complex O
, O
which O
suggests O
that O
ALL_CAP I-GENE
may O
activate O
transcription O
by O
means O
of O
such O
interactions O
. O

The O
patients O
who O
presented O
with O
RARE O
RARE O
also O
had O
low O
NUM I-GENE
+ I-GENE
T O
lymphocyte O
counts O
, O
and O
most O
of O
them O
had O
AIDS O
RARE O
RARE O
. O

Increased O
dietary O
energy O
decreased O
ALL_CAP O
and O
the O
use O
of O
added O
dietary O
ALL_CAP O
rather O
than O
ALL_CAP O
decreased O
ALL_CAP O
in O
RARE O
RARE O
between O
NUM O
and O
NUM O
wk O
of O
age O
. O

The O
gene O
amplification O
model O
of O
RARE O
et O
al O
. O

RARE O
of O
protein I-GENE
tyrosine I-GENE
kinases I-GENE
in O
interleukin I-GENE
- I-GENE
2 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
) O
RARE O
: O
activation O
of O
RARE I-GENE
depends O
on O
NUM I-GENE
; O
however O
, O
neither O
RARE I-GENE
nor O
RARE I-GENE
is O
required O
RARE O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
- O
RARE O
STAT I-GENE
activation O
. O

RARE O
RARE O
of O
N I-GENE
- I-GENE
RARE I-GENE
- O
Fc I-GENE
RARE O
mimic O
RARE O
- O
RARE O
cell O
RARE O
formation O
: O
contribution O
of O
both O
outside O
- O
in O
and O
RARE O
- O
out O
signals O
. O

Although O
the O
ALL_CAP I-GENE
promoter I-GENE
is O
activated O
in O
a O
C O
terminus O
dependent O
manner O
, O
the O
ALL_CAP I-GENE
, O
LTR O
and O
ALL_CAP I-GENE
promoters I-GENE
are O
repressed O
by O
three O
distinct O
mechanisms O
, O
either O
independent O
of O
or O
involving O
the O
ALL_CAP I-GENE
C I-GENE
terminus I-GENE
, O
or O
requiring O
only O
the O
RARE O
C O
- O
terminal O
RARE O
ALL_CAP O
. O

The O
monoclonal O
immunoglobulin I-GENE
products O
of O
plasma O
cell O
RARE O
can O
give O
rise O
to O
a O
variety O
of O
manifestations O
including O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
, O
and O
RARE O
failure O
. O

RARE O
of O
the O
structural O
basis O
of O
the O
interaction O
between O
human I-GENE
RARE I-GENE
and O
gp120 I-GENE
shows O
that O
the O
viral I-GENE
gp120 I-GENE
RARE I-GENE
can O
interact O
only O
with O
a O
subset O
of O
human I-GENE
V I-GENE
( I-GENE
H I-GENE
) I-GENE
3 I-GENE
+ I-GENE
RARE I-GENE
. O

Double O
- O
blind O
, O
placebo O
- O
RARE O
trial O
. O

Here O
, O
it O
is O
shown O
that O
NUM I-GENE
, O
the O
largest O
subunit O
of O
TFIID I-GENE
, O
contains O
two O
RARE O
RARE O
RARE O
that O
bind O
selectively O
to O
RARE O
RARE O
histone I-GENE
NUM I-GENE
peptides I-GENE
. O

RARE O
treatment O
RARE O
10 O
minutes O
or O
NUM O
hours O
RARE O
tyrosine O
RARE O
of O
RARE I-GENE
and O
formation O
of O
RARE O
complexes O
. O

Therefore O
, O
RARE O
of O
vitamin O
NUM O
have O
been O
investigated O
in O
a O
number O
of O
trials O
showing O
improvement O
of O
psoriasis O
. O

The O
transcript O
was O
initially O
identified O
RARE O
a O
partial O
cDNA O
sequence O
in O
the O
course O
of O
RARE O
a O
transcript O
map O
of O
the O
region O
between O
markers O
NUM I-GENE
and O
RARE I-GENE
known O
to O
RARE O
the O
gene O
causing O
RARE O
RARE O
. O

The O
real O
challenge O
RARE O
the O
future O
will O
be O
the O
management O
of O
patients O
who O
do O
not O
respond O
to O
RARE O
- O
line O
treatment O
. O

RARE O
deficiency O
disorders O
in O
RARE O
. O

The O
network O
evolution O
was O
interpreted O
by O
an O
approach O
based O
on O
the O
RARE O
model O
. O

RESULTS O
: O
RARE O
CD23 I-GENE
levels O
were O
significantly O
RARE O
in O
women O
with O
RARE O
before O
treatment O
than O
in O
ten O
normal O
controls O
. O

CONCLUSION O
: O
Our O
findings O
suggest O
that O
RARE O
increases O
RARE O
CD23 I-GENE
levels O
, O
which O
can O
be O
suppressed O
with O
either O
RARE O
or O
RARE O
RARE O
injection O
. O

To O
isolate O
this O
gene O
, O
a O
P O
- O
1 O
artificial O
RARE O
( O
ALL_CAP O
) O
library O
was O
screened O
with O
a O
full I-GENE
length I-GENE
NUM I-GENE
probe O
and O
a O
clone O
of O
RARE O
NUM O
kb O
in O
length O
was O
isolated O
. O

RARE O
>/= O
50 O
years O
( O
odds O
ratio O
RARE O
OR O
], O
14 O
. O
1 O
RARE O
BMI O
>/= O
NUM O
kg O
/ O
m O
( O
2 O
) O
( O
OR O
, O
5 O
. O
7 O
RARE O
RARE O
>/= O
1 O
. O
7 O
mmol O
/ O
L O
( O
OR O
, O
5 O
RARE O
and O
alanine I-GENE
aminotransferase I-GENE
( O
ALL_CAP I-GENE
) O
>/= O
NUM O
( O
OR O
, O
4 O
. O
6 O
) O
were O
independently O
associated O
with O
septal O
RARE O
. O

RARE O
significant O
amounts O
of O
platelet I-GENE
activating I-GENE
factor I-GENE
were O
RARE O
from O
the O
RARE O
RARE O
the O
RARE O
treatment O
time O
. O

However O
, O
the O
elderly O
group O
showed O
significantly O
longer O
mean O
RARE O
times O
( O
RARE O
) O
and O
lower O
plasma O
clearance O
of O
lidocaine O
RARE O
the O
period O
compared O
with O
the O
adult O
group O
( O
P O
< O
. O
05 O
). O

Here O
, O
we O
show O
that O
the O
zinc I-GENE
finger I-GENE
protein I-GENE
NUM I-GENE
acts O
RARE O
a O
dosage O
- O
dependent O
suppressor O
of O
the O
NUM I-GENE
defect O
in O
nutrient O
limitation O
- O
RARE O
transcriptional O
derepression O
of O
NUM I-GENE
. O

The O
so O
- O
called O
" I-GENE
SH3 I-GENE
" I-GENE
segment I-GENE
of O
the O
RARE O
domain O
, O
in O
contrast O
, O
shows O
species O
- O
specific O
sequence O
identity O
in O
all O
but O
one O
amino O
acid O
residues O
in O
both O
factors O
, O
in O
cattle O
, O
human O
, O
and O
mouse O
. O

No O
differences O
in O
RARE O
cholesterol O
levels O
were O
observed O
between O
RARE O
and O
RARE O
. O

RARE O
to O
NUM O
% O
of O
the O
RARE O
ALL_CAP O
exposure O
received O
is O
in O
the O
ALL_CAP O
- O
A O
RARE O
( O
NUM O
- O
NUM O
nm O
). O

To O
begin O
to O
characterize O
the O
role O
of O
the O
RNA O
subunits O
in O
enzyme O
function O
and O
substrate O
RARE O
, O
we O
RARE O
two O
hairpin O
RARE O
( O
NUM O
and O
NUM O
) O
between O
RNase I-GENE
MRP I-GENE
RNA I-GENE
and O
RNase I-GENE
P I-GENE
RNA I-GENE
of I-GENE
S I-GENE
. I-GENE
cerevisiae I-GENE
. O

Among O
genes O
RARE O
by O
added O
NUM I-GENE
is O
RARE I-GENE
- I-GENE
8 I-GENE
, O
a O
RARE O
factor O
that O
induces O
a O
similar O
RARE O
of O
marker O
genes O
and O
a O
similar O
cellular O
RARE O
. O

RARE O
, O
RARE O
Ha I-GENE
- I-GENE
ras I-GENE
RARE I-GENE
12 I-GENE
mutations O
are O
found O
in O
the O
ALL_CAP O
- O
RARE O
mammary O
tumors O
. O

RARE O
positive O
PET O
FDG O
corresponded O
to O
RARE O
infection O
, O
RARE O
bone O
RARE O
, O
and O
reconstruction O
RARE O
. O

RARE O
stages O
were O
ALL_CAP O
( O
NUM O
NUM O
) O
in O
52 O
%, O
ALL_CAP O
in O
NUM O
%, O
and O
ALL_CAP O
in O
NUM O
% O
of O
patients O
. O

Similarly O
, O
comparison O
of O
percentage O
reductions O
of O
RARE O
rate O
RARE O
supine O
, O
RARE O
and O
exercise O
by O
RARE O
measure O
analysis O
showed O
the O
RARE O
to O
have O
significantly O
RARE O
change O
compared O
to O
the O
RARE O
( O
p O
= O
NUM O
. O
NUM O
). O

Consistent O
with O
our O
model O
, O
CTCF I-GENE
binding O
is O
abolished O
by O
DNA O
methylation O
. O

OBJECTIVE O
: O
To O
determine O
the O
efficacy O
and O
safety O
of O
amphotericin O
B O
oral O
RARE O
( O
ALL_CAP O
) O
RARE O
the O
treatment O
of O
RARE O
refractory O
oral O
candidiasis O
in O
persons O
with O
HIV O
infection O
. O

RARE I-GENE
gene I-GENE
RARE O
has O
been O
shown O
to O
be O
altered O
in O
many O
RARE O
diseases O
and O
especially O
cancers O
of O
the O
RARE O
RARE O
. O

The O
experimentally O
mapped O
regions O
of O
NUM I-GENE
involved O
in O
these O
interactions O
correspond O
to O
distinct O
and O
surface O
- O
exposed O
alpha O
- O
helical O
RARE O
. O

The O
model O
indicates O
that O
a O
NUM O
. O
NUM O
% O
reduction O
in O
RARE O
consumption O
is O
associated O
with O
the O
availability O
of O
nicotine O
RARE O
after O
1992 O
. O

RARE O
RARE O
. O

The O
RARE I-GENE
locus I-GENE
also O
contains O
RARE O
least O
four O
RARE I-GENE
- I-GENE
like I-GENE
RARE I-GENE
, O
including O
RARE I-GENE
, O
a O
gene O
RARE O
in O
dogs O
but O
not O
in O
humans O
. O

The O
cellular O
part O
of O
the O
third O
chimeric O
clone O
shows O
significant O
homology O
to O
an O
RARE O
of O
the O
human I-GENE
tyrosine I-GENE
phosphatase I-GENE
1 I-GENE
gene I-GENE
, O
although O
RARE O
in O
the O
RARE O
direction O
compared O
to O
the O
adjacent O
LTR O
. O

OBJECTIVE O
: O
This O
study O
was O
conducted O
to O
assess O
the O
relative O
roles O
of O
99mTc O
- O
RARE O
RARE O
and O
RARE O
in O
the O
evaluation O
of O
breast O
lesions O
that O
are O
RARE O
or O
RARE O
on O
RARE O
or O
clinical O
examination O
. O

Mutational O
analyses O
showed O
that O
in O
- O
frame O
stop O
codons O
introduced O
into O
five O
of O
RARE O
RNA I-GENE
2 I-GENE
RARE I-GENE
did O
not O
affect O
accumulation O
of O
RARE O
ALL_CAP I-GENE
RNA I-GENE
1 I-GENE
or O
RNA I-GENE
2 I-GENE
, O
confirming O
that O
RNA I-GENE
2 I-GENE
does O
not O
encode O
proteins O
necessary O
RARE O
ALL_CAP O
RNA O
replication O
. O

Role O
of O
ALL_CAP O
( O
2 O
)- O
and O
ALL_CAP O
- O
terminal O
domains O
of O
the O
P I-GENE
protein I-GENE
of O
human O
RARE O
virus O
type O
3 O
in O
transcription O
and O
replication O
. O

RARE O
of O
tyrosine O
residues O
in O
the O
kinase O
domain O
and O
RARE O
region O
regulates O
the O
biological O
and O
catalytic O
activities O
of O
RARE I-GENE
receptors I-GENE
. O

RESULTS O
: O
RARE O
' O
s O
RARE O
occurs O
RARE O
. O

Genomic O
DNA O
sequencing O
in O
the O
vicinity O
of O
RARE I-GENE
- I-GENE
CoA I-GENE
RARE I-GENE
gene I-GENE
( O
ALL_CAP I-GENE
) O
from O
a O
RARE O
SV O
- O
producing O
RARE O
RARE O
NUM O
allowed O
us O
to O
clone O
, O
sequence O
, O
and O
identify O
a O
gene O
encoding O
a O
novel O
serine I-GENE
/ I-GENE
threonine I-GENE
protein I-GENE
kinase I-GENE
( O
RARE I-GENE
). O

ALL_CAP I-GENE
- I-GENE
2 I-GENE
is O
accepted O
RARE O
a O
standard O
treatment O
used O
alone O
, O
or O
in O
combination O
with O
chemotherapy O
or O
RARE O
in O
the O
management O
of O
metastatic O
RARE O
and O
metastatic O
RARE O
cell O
carcinoma O
. O

Moreover O
, O
RARE O
of O
RARE I-GENE
Ha I-GENE
- I-GENE
Ras I-GENE
or O
dominant I-GENE
negative I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
abrogated O
the O
mitogenic O
effect O
of O
TGF I-GENE
- I-GENE
beta1 I-GENE
in O
ALL_CAP O
- O
NUM O
, O
and O
the O
TGF I-GENE
- I-GENE
beta1 I-GENE
inhibition O
of O
NUM O
was O
RARE O
to O
RARE O
by O
NUM I-GENE
- I-GENE
Ras I-GENE
transfection O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
RARE O
carcinomas O
with O
the O
Ras I-GENE
/ O
ALL_CAP I-GENE
RARE O
activation O
might O
have O
a O
selective O
growth O
advantage O
by O
autocrine O
TGF I-GENE
- I-GENE
beta1 I-GENE
production O
. O

RARE I-GENE
RARE O
are O
RARE O
to O
RARE I-GENE
RARE O
, O
with O
little O
or O
RARE O
direct O
RARE I-GENE
to O
RARE I-GENE
RARE O
, O
despite O
12 O
/ O
NUM O
compatibility O
of O
RARE I-GENE
NUM I-GENE
- I-GENE
RARE I-GENE
and O
NUM I-GENE
- I-GENE
RARE I-GENE
. O

For O
oral O
administration O
, O
NUM O
- O
RARE O
was O
58 O
. O
NUM O
+/- O
16 O
. O
37 O
microg O
RARE O
h O
/ O
ml O
, O
t1 O
/ O
NUM O
was O
18 O
. O
NUM O
+/- O
NUM O
. O
06 O
hours O
, O
maximum O
concentration O
( O
RARE O
) O
was O
2 O
. O
12 O
+/- O
00 O
. O
NUM O
microg O
/ O
ml O
, O
time O
to O
RARE O
was O
2 O
. O
20 O
+/- O
2 O
. O
NUM O
hours O
, O
mean O
absorption O
time O
was O
2 O
. O
09 O
+/- O
NUM O
. O
NUM O
hours O
, O
and O
RARE O
was O
NUM O
+/- O
NUM O
. O
NUM O
%. O

In O
experiment O
2 O
, O
RARE O
difference O
in O
RARE O
emptying O
of O
40 O
% O
RARE O
or O
NUM O
% O
glucose O
was O
found O
between O
rats O
receiving O
TPN O
and O
those O
receiving O
RARE O
nutrition O
RARE O
10 O
to O
12 O
days O
. O

In O
contrast O
, O
H I-GENE
- I-GENE
ALL_CAP I-GENE
negative O
RARE O
operated O
only O
in O
the O
absence O
of O
Fur I-GENE
. O

Thus O
, O
ALL_CAP I-GENE
appears O
to O
control O
cell O
RARE O
progression O
in O
yeast O
by O
RARE O
ubiquitination O
and O
RARE O
of O
cell O
RARE O
regulatory O
proteins O
. O

E2F I-GENE
- I-GENE
1 I-GENE
is O
a O
transcription O
factor O
that O
regulates O
cell O
RARE O
progression O
into O
S O
- O
RARE O
. O

It O
RARE O
about O
RARE O
, O
negative O
RARE O
, O
and O
impaired O
health O
, O
sleep O
, O
safety O
, O
and O
working O
capacity O
. O

This O
demonstrates O
that O
treatment O
of O
the O
graft O
recipient O
RARE O
a O
relatively O
short O
period O
RARE O
and O
after O
surgery O
has O
a O
RARE O
effect O
on O
the O
survival O
of O
RARE O
dopaminergic O
neurons O
. O

The O
relationships O
among O
RARE O
concentrations O
of O
thyroid O
RARE O
and O
selenium O
, O
zinc O
, O
RARE O
, O
and O
alpha O
- O
RARE O
were O
studied O
in O
NUM O
healthy O
Northern O
Italian O
RARE O
- O
old O
subjects O
( O
age O
range O
, O
NUM O
- O
NUM O
yr O
RARE O
RARE O
by O
the O
criteria O
of O
the O
ALL_CAP O
protocol O
. O

RARE O
RARE O
( O
ALL_CAP O
) O
carrying O
the O
ALL_CAP I-GENE
gene I-GENE
to O
those O
of O
a O
RARE O
deletion O
line O
of O
ALL_CAP O
, O
namely O
, O
NUM O
, O
which O
lacks O
NUM O
% O
of O
NUM O
including O
the O
ALL_CAP I-GENE
gene I-GENE
. O

RARE O
using O
hippocampal O
RARE O
maintained O
in O
vitro O
have O
demonstrated O
that O
RARE O
of O
RARE O
field O
potentials O
in O
the O
gamma O
frequency O
range O
( O
NUM O
- O
NUM O
Hz O
) O
are O
followed O
by O
a O
slower O
RARE O
in O
the O
beta O
1 O
range O
( O
12 O
- O
20 O
Hz O
). O

RARE O
ALL_CAP O
, O
RARE O

During O
surgery O
bone O
cysts O
were O
RARE O
and O
filled O
by O
bone O
grafts O
. O

RARE O
NUM O
increased O
after O
both O
RARE O
the O
rise O
being O
RARE O
following O
oral O
RARE O
compared O
to O
inhalation O
RARE O
( O
p O
= O
NUM O
. O
0001 O
). O

Basal O
ALL_CAP O
was O
RARE O
by O
RARE O
18 O
% O
by O
ALL_CAP O
and O
ALL_CAP O
, O
but O
ALL_CAP O
responses O
to O
noradrenaline O
, O
angiotensin I-GENE
II I-GENE
, O
RARE O
and O
RARE O
were O
unaffected O
. O

Three O
FGF I-GENE
- I-GENE
ALL_CAP I-GENE
cDNAs I-GENE
were O
isolated O
; O
the O
full I-GENE
- I-GENE
length I-GENE
FGF I-GENE
- I-GENE
ALL_CAP I-GENE
mRNA I-GENE
and O
two O
RARE O
RARE O
variants O
RARE O
RARE O
2 O
or O
exons O
2 O
and O
3 O
of O
the O
FGF I-GENE
- I-GENE
ALL_CAP I-GENE
sequence I-GENE
. O

Taken O
together O
, O
these O
results O
indicate O
that O
MAP I-GENE
kinase I-GENE
stimulates O
the O
ALL_CAP I-GENE
- I-GENE
B I-GENE
enhancer I-GENE
by O
an O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
- I-GENE
6 I-GENE
- O
dependent O
RARE O
. O

Characterization O
of O
polymorphic O
RARE O
in O
novel O
and O
even O
known O
genes O
RARE O
in O
human O
RARE O
cord O
is O
likely O
to O
help O
in O
the O
identification O
of O
new O
RARE O
RARE O
genes O
involved O
in O
RARE O
disorders O
. O

Finally O
, O
in O
situ O
RNA O
hybridization O
studies O
revealed O
a O
very O
specific O
pattern O
of O
NUM I-GENE
gene I-GENE
RARE O
restricted O
to O
the O
RARE O
region O
of O
RARE O
RARE O
RARE O
RARE O
development O
. O

Transfection O
of O
cDNAs O
RARE O
three O
mutant O
RARE O
into O
ALL_CAP I-GENE
- O
RARE O
RARE O
hamster O
ovary O
cells O
restored O
a O
RARE O
level O
of O
RARE O
growth O
, O
whereas O
a O
NUM O
mutant O
supported O
growth O
RARE O
a O
level O
comparable O
to O
that O
of O
the O
wild O
- O
type O
enzyme O
. O

SETTING O
: O
University O
of O
RARE O
VII O
hospital O
. O
RARE O
( O
s O
): O
RARE O
women O
had O
RARE O
RARE O
symptomatic O
RARE O
, O
with O
12 O
RARE O
observed O
. O

RARE O
RARE O
RARE O
quality O
: O
mechanical O
preparation O
and O
filling O
level O
. O

The O
RARE O
- O
RARE O
- O
Scale O
( O
MRS O
I O
) O
was O
used O
in O
clinical O
practice O
since O
1992 O
. O

The O
MRS O
II O
RARE O
a O
high O
RARE O
standard O
RARE O
an O
instrument O
standardized O
in O
the O
population O
. O

The O
protein O
encoded O
by O
the O
ALL_CAP I-GENE
transcript I-GENE
is O
RARE O
RARE O
with O
the O
D I-GENE
. I-GENE
melanogaster I-GENE
type I-GENE
A I-GENE
protein I-GENE
, O
particularly O
the O
BTB I-GENE
protein I-GENE
- O
protein O
- O
binding O
domain O
, O
which O
is O
encoded O
by O
exons O
I O
and O
II O
and O
is O
NUM O
% O
RARE O
. O

In O
addition O
, O
the O
mouse O
RARE O
( O
RARE I-GENE
/ O
NUM I-GENE
) O
was O
RARE O
, O
and O
the O
Caenorhabditis O
elegans O
RARE O
( O
ALL_CAP I-GENE
) O
was O
identified O
in O
the O
RARE O
database O
. O

RARE O
and O
RARE O
were O
evaluated O
against O
RARE O
RARE O
NUM O
and O
RARE O
RARE O
NUM O
, O
respectively O
. O

ALL_CAP I-GENE
and O
RARE I-GENE
levels O
in O
serum O
were O
measured O
before O
and O
after O
the O
last O
oral O
challenge O
. O

RARE O
users O
were O
7 O
. O
5 O
times O
more O
likely O
to O
have O
received O
another O
RARE O
drug O
( O
RR O
7 O
. O
5 O
, O
NUM O
% O
ALL_CAP O
4 O
. O
8 O
to O
11 O
. O
9 O
). O

For O
an O
RARE O
program O
, O
the O
costs O
were O
estimated O
RARE O
RARE O
NUM O
RARE O
the O
RARE O
year O
and O
RARE O
NUM O
RARE O
all O
additional O
years O
. O

The O
presence O
of O
such O
a O
putative O
RNA O
- O
binding O
domain O
suggests O
a O
mechanism O
RARE O
the O
observed O
autoregulation O
of O
RARE O
T4 I-GENE
DNA I-GENE
polymerase I-GENE
RARE O
by O
binding O
to O
its O
own O
mRNA O
. O

Deletion O
and O
mutational O
analyses O
revealed O
two O
positive O
cis O
- O
regulatory O
elements O
in O
this O
region O
that O
are O
essential O
RARE O
NUM I-GENE
RARE O
in O
RARE O
. O

Functional O
studies O
which O
introduced O
a O
mutation O
in O
the O
AP2 I-GENE
core I-GENE
binding I-GENE
region I-GENE
RARE O
RARE O
RARE O
cotransfection O
experiments O
using O
an O
AP2 I-GENE
RARE O
vector O
revealed O
that O
AP2 I-GENE
exerts O
a O
repressive O
role O
on O
the O
HGF I-GENE
gene I-GENE
promoter I-GENE
activity O
. O

Using O
RARE O
transfer O
of O
IkappaBalpha I-GENE
( O
IkappaBalpha I-GENE
overexpression O
RARE O
the O
production O
of O
TNF I-GENE
- I-GENE
alpha I-GENE
RARE O
by O
whole O
ALL_CAP O
was O
inhibited O
by O
only O
20 O
%. O

In O
RARE O
experiments O
, O
we O
RARE O
showed O
that O
RARE O
in O
the O
ALL_CAP O
264 O
. O
7 O
cell O
line O
of O
C I-GENE
- I-GENE
terminal I-GENE
Src I-GENE
kinase I-GENE
( O
Csk I-GENE
) O
inhibited O
and O
that O
of O
a O
membrane O
- O
RARE O
, O
gain O
- O
of O
- O
function O
Csk I-GENE
abolished O
the O
Fc I-GENE
gamma I-GENE
R I-GENE
- O
RARE O
RARE O
that O
leads O
to O
RARE O
in O
a O
kinase O
- O
dependent O
manner O
. O

In O
contrast O
, O
c I-GENE
- I-GENE
Src I-GENE
- I-GENE
derived I-GENE
construct I-GENE
( O
a I-GENE
- I-GENE
Src I-GENE
RARE O
that O
was O
excluded O
from O
detergent O
- O
resistant O
membranes O
, O
could O
not O
RARE O
the O
series O
of O
RARE O
RARE O
. O

The O
delta I-GENE
NUM I-GENE
mutation I-GENE
also O
influenced O
on O
the O
transcript O
levels O
of O
meiosis O
- O
inducing O
genes O
called O
IME1 I-GENE
and O
NUM I-GENE
: O
the O
mutation O
elevated O
the O
transcript O
level O
of O
IME1 I-GENE
but O
RARE O
that O
of O
NUM I-GENE
, O
resulting O
in O
partial O
defects O
in O
RARE O
DNA O
RARE O
and O
meiosis O
. O

We O
also O
found O
that O
environmental O
conditions O
RARE O
meiosis O
RARE O
regulate O
the O
transcript O
levels O
of O
NUM I-GENE
and O
NUM I-GENE
, O
such O
that O
nitrogen O
starvation O
RARE O
RARE O
them O
but O
subsequent O
RARE O
of O
medium O
decreases O
them O
. O

The O
ALL_CAP O
vectors O
differ O
among O
them O
in O
: O
( O
a O
) O
the O
selectable O
marker O
( O
Saccharomyces O
cerevisiae O
ALL_CAP I-GENE
2 I-GENE
gene I-GENE
, O
which O
RARE O
S I-GENE
. I-GENE
pombe I-GENE
NUM I-GENE
- I-GENE
gene I-GENE
and O
S O
. O
pombe O
NUM I-GENE
+ I-GENE
and O
NUM I-GENE
+ I-GENE
genes I-GENE
); O
( O
b O
) O
the O
RARE O
- O
RARE O
NUM I-GENE
promoter I-GENE
( O
NUM O
, O
NUM O
and O
NUM O
with O
extremely O
high O
, O
moderate O
or O
low O
transcription O
efficiency O
, O
respectively O
); O
and O
( O
c O
) O
the O
multiple O
cloning O
site O
( O
two O
multiple O
cloning O
sites O
, O
with O
12 O
RARE O
sites O
each O
). O

( O
ALL_CAP O
) O
RARE O
of O
NUM O
RARE O
negative O
healthy O
adults O
( O
age O
/ O
RARE O
matched O
) O
were O
taken O
RARE O
control O
by O
detecting O
IgG I-GENE
anti I-GENE
RARE I-GENE
to O
NUM I-GENE
antigen I-GENE
. O

The O
effect O
of O
acute O
, O
mid O
- O
cervical O
RARE O
cord O
lesions O
on O
RARE O
and O
reflex O
activity O
evoked O
by O
the O
RARE O
visceral O
stimulus O
, O
RARE O
RARE O
( O
ALL_CAP O
; O
NUM O
mmHg O
, O
20 O
s O
RARE O
was O
determined O
in O
halothane O
- O
anesthetized O
rats O
. O

RARE O
RARE O
RARE O
RARE O
life O
, O
RARE O
and O
diseases O

The O
results O
suggest O
that O
the O
role O
of O
S O
. O
RARE O
in O
the O
RARE O
of O
RARE O
larvae O
in O
nature O
is O
limited O
in O
comparison O
to O
the O
role O
played O
by O
mammals O
with O
RARE O
and O
RARE O
behavior O
. O

The O
equilibrium O
dissociation O
binding O
constant O
RARE O
the O
interaction O
of O
ALL_CAP I-GENE
with O
the O
ALL_CAP I-GENE
promoter I-GENE
fragment I-GENE
was O
7 O
. O
7 O
nM O
under O
the O
conditions O
used O
here O
. O

These O
results O
demonstrate O
that O
N O
- O
RARE O
flanking O
the O
receptor O
- O
binding O
site O
of O
the O
ALL_CAP I-GENE
molecule I-GENE
are O
potent O
RARE O
of O
RARE O
virus O
growth O
, O
with O
the O
RARE O
RARE O
NUM O
being O
dominant O
and O
that O
RARE O
NUM O
being O
less O
effective O
. O

RESULTS O
: O
The O
introduction O
of O
the O
ALL_CAP O
resulted O
in O
a O
significant O
( O
p O
< O
NUM O
. O
001 O
) O
reduction O
in O
RARE O
RARE O
( O
median O
, O
NUM O
, O
NUM O
) O
from O
the O
numbers O
seen O
with O
ALL_CAP O
( O
median O
, O
2 O
, O
NUM O
, O
NUM O
) O
while O
maintaining O
the O
separation O
efficacy O
( O
NUM O
%) O
and O
separation O
time O
. O

All O
were O
tested O
RARE O
serum O
ferritin I-GENE
( O
ALL_CAP I-GENE
RARE O
hemoglobin I-GENE
( O
RARE I-GENE
) O
level O
and O
RARE O
RARE O
detailed O
RARE O
of O
RARE O
and O
iron O
supplementation O
. O

RARE I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
( O
VEGF I-GENE
RARE O
a O
potent O
agonist O
RARE O
by O
virtually O
all O
cells O
, O
controls O
migration O
and O
division O
of O
vascular O
endothelial O
cells O
. O

The O
antioxidant O
agent O
RARE O
RARE O
( O
ALL_CAP O
) O
has O
been O
shown O
to O
protect O
endothelial O
cells O
( O
EC O
) O
from O
pro O
- O
inflammatory O
- O
RARE O
and O
pro O
- O
RARE O
- O
RARE O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
activation O
. O

We O
further O
studied O
the O
effects O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
RARE O
on O
NUM I-GENE
induction O
by O
STAT I-GENE
activation O
. O

RARE I-GENE
antibody O
- O
RARE O
peptides O
are O
seen O
in O
light O
- O
adapted O
mouse O
RARE O
cytosolic O
and O
nuclear O
extracts O
. O

In O
the O
pRb I-GENE
RARE I-GENE
ALL_CAP O
- O
2 O
cell O
line O
transiently O
transfected O
with O
a O
reporter O
RARE O
containing O
RARE O
tal I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
, O
pRb I-GENE
enhances O
the O
transcriptional O
activity O
of O
tal I-GENE
- I-GENE
1 I-GENE
- O
E12 I-GENE
- O
NUM I-GENE
and O
tal I-GENE
- I-GENE
1 I-GENE
- O
E12 I-GENE
- O
NUM I-GENE
- O
NUM I-GENE
complexes O
but O
not O
that O
of O
a O
tal I-GENE
- I-GENE
1 I-GENE
- O
E12 I-GENE
RARE O
. O

This O
effect O
was O
not O
seen O
in O
conjunction O
with O
RARE O
, O
a O
RARE I-GENE
- I-GENE
like I-GENE
mu I-GENE
- I-GENE
receptor I-GENE
agonist O
. O

In O
contrast O
to O
the O
morphological O
criteria O
, O
the O
few O
data O
available O
from O
recent O
studies O
RARE O
the O
genetic O
level O
have O
suggested O
that O
RARE O
RARE O
different O
insect O
RARE O
are O
RARE O
distant O
. O

RARE O
of O
the O
breast O
in O
a O
patient O
with O
RARE O
RARE O
RARE O

In O
the O
RARE O
period O
male O
rate O
of O
aggression O
was O
not O
significantly O
correlated O
with O
testosterone O
level O
. O

These O
results O
support O
the O
hypothesis O
that O
in O
the O
presence O
of O
RARE O
the O
RARE O
RARE O
ALL_CAP I-GENE
blocks O
Rho I-GENE
' O
s O
access O
to O
the O
ALL_CAP I-GENE
and O
RARE I-GENE
sites I-GENE
, O
thereby O
preventing O
transcription O
RARE O
. O

In O
situ O
hybridization O
with O
the O
RARE O
RNA O
RARE O
further O
supported O
the O
RARE O
changes O
of O
these O
RARE O
RARE O
and O
localized O
the O
changes O
in O
multiple O
RARE O
cell O
stages O
RARE O
RARE O
RARE O
other O
cell O
RARE O
( O
RARE O
, O
interstitial O
and O
RARE O
cells O
). O

The O
administration O
of O
the O
GnRH I-GENE
agonist O
RARE O
the O
bone O
mineral O
density O
in O
the O
whole O
femur O
to O
91 O
. O
NUM O
% O
of O
that O
in O
the O
control O
group O
. O

Prevention O
, O
differential O
diagnosis O
and O
therapy O
of O
RARE O
RARE O

This O
study O
shows O
that O
C I-GENE
/ I-GENE
EBPbeta I-GENE
is O
the O
predominant O
C I-GENE
/ I-GENE
EBP I-GENE
isoform I-GENE
found O
in O
activated O
RARE O
cells O
and O
that O
increased O
C I-GENE
/ I-GENE
EBPbeta I-GENE
protein I-GENE
and O
C I-GENE
/ I-GENE
EBPbeta I-GENE
binding O
to O
a O
proximal O
C I-GENE
/ I-GENE
EBP I-GENE
binding I-GENE
site I-GENE
in O
the O
promoter O
mediates O
the O
activating O
effect O
of O
RARE O
. O

Mutation O
analysis O
demonstrates O
that O
the O
motif O
ALL_CAP O
is O
critical O
RARE O
NUM I-GENE
interaction O
. O

As O
with O
VP16 I-GENE
, O
the O
RARE O
function O
of O
RARE I-GENE
is O
also O
regulated O
by O
ALL_CAP I-GENE
. O

After O
two O
successive O
RARE O
of O
selection O
by O
focus O
formation O
assay O
, O
a O
transforming O
RARE O
( O
NUM I-GENE
) O
was O
identified O
. O

G O
., O
and O
RARE O
, O
C O
. O

Our O
results O
suggest O
that O
proteasome O
inhibition O
leads O
to O
RARE O
of O
specific O
members O
of O
transcription O
factor O
RARE O
controlling O
cellular O
stress O
response O
and O
RARE O
. O

The O
ALL_CAP O
- O
X O
RARE O
results O
from O
mutations O
of O
the O
NUM I-GENE
gene I-GENE
, O
RARE O
on O
the O
X O
RARE O
( O
NUM O
. O
3 O
) O
and O
coding O
RARE O
a O
RARE O
factor O
which O
regulates O
gene O
RARE O
. O

ALL_CAP O
: O
To O
evaluate O
the O
role O
of O
environmental O
RARE O
- O
RARE O
factors O
in O
RARE O
the O
RARE O
of O
RARE O
with O
increased O
RARE O
to O
diabetes O
and O
RARE O
RARE O
abnormal O
responses O
to O
the O
oral O
glucose O
tolerance O
test O
( O
ALL_CAP O
) O
and O
RARE O
the O
possible O
association O
of O
within O
- O
RARE O
RARE O
differences O
and O
metabolic O
abnormalities O
in O
adult O
life O
. O

In O
ALL_CAP O
III O
, O
a O
RARE O
RARE O
occurred O
that O
allocated O
a O
RARE O
number O
of O
patients O
with O
RARE O
motor O
deficit O
( O
and O
therefore O
RARE O
RARE O
RARE O
recovery O
) O
to O
the O
lower O
dose O
control O
group O
. O

RARE I-GENE
RARE I-GENE
( O
PA I-GENE
) O
from O
Escherichia O
coli O
NUM O
is O
a O
RARE O
RARE O
consisting O
of O
a O
NUM O
kDa O
small O
subunit O
and O
a O
65 O
kDa O
large O
subunit O
. O

A O
murine O
RARE O
sequence O
tag O
( O
ALL_CAP O
) O
showing O
homology O
with O
erythropoietin I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
) O
was O
identified O
in O
the O
ALL_CAP O
database O
. O

When O
the O
RARE O
was O
partially O
occluded O
, O
mild O
ALL_CAP O
- O
RARE O
tachycardia O
resulted O
in O
decreased O
ALL_CAP O
( O
P O
= O
NUM O
. O
NUM O
) O
RARE O
RARE O
RARE O
in O
decreased O
SV O
( O
P O
= O
NUM O
. O
NUM O
); O
the O
ALL_CAP O
remained O
high O
( O
P O
= O
NUM O
. O
NUM O
). O

Activation O
of O
nuclear I-GENE
factor I-GENE
( I-GENE
ALL_CAP I-GENE
)- I-GENE
kappaB I-GENE
and O
subsequent O
RARE O
gene O
RARE O
in O
human O
airway O
RARE O
cells O
can O
be O
evoked O
by O
oxidative O
stress O
. O

ALL_CAP O
ALL_CAP O
ALL_CAP O
ALL_CAP O
ALL_CAP O
: O
ALL_CAP O
. O

We O
have O
isolated O
and O
functionally O
characterized O
the O
mouse O
gene O
RARE O
the O
C2 O
subunit O
of O
the O
20S I-GENE
proteasome I-GENE
. O

Furthermore O
, O
RARE O
in O
the O
human O
gene O
, O
the O
3 O
' O
end O
of O
the O
NUM I-GENE
gene I-GENE
maps O
within O
5 O
kb O
of O
the O
5 O
' O
end O
of O
the O
mouse I-GENE
RARE I-GENE
gene I-GENE
in O
a O
region O
RARE O
to O
NUM O
. O
NUM O
. O

With O
the O
human I-GENE
RARE I-GENE
cDNA I-GENE
RARE O
a O
probe O
, O
Northern O
hybridization O
revealed O
that O
a O
4 O
. O
NUM O
- O
kb O
transcript O
was O
RARE O
RARE O
a O
high O
level O
in O
RARE O
and O
RARE O
a O
RARE O
level O
in O
NUM O
of O
16 O
tissues O
examined O
, O
but O
it O
cannot O
be O
detected O
in O
liver O
and O
RARE O
tissues O
. O

Similarly O
, O
RARE O
- O
RARE O
of O
a O
dominant O
- O
negative O
mutant O
of O
NUM I-GENE
, O
but O
not O
of O
ERK1 I-GENE
, O
ERK2 I-GENE
, O
JNK1 I-GENE
, O
or O
NUM I-GENE
, O
reduces O
basal O
and O
cadmium O
- O
RARE O
NUM I-GENE
- I-GENE
RARE I-GENE
activity O
. O

BACKGROUND O
: O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
is O
a O
safe O
and O
effective O
RARE O
to O
surgery O
RARE O
RARE O
lesions O
. O

In O
RARE O
patients O
( O
Epo I-GENE
and O
Non O
- O
Epo I-GENE
group O
) O
leptin I-GENE
levels O
were O
significantly O
RARE O
when O
compared O
to O
ALL_CAP O
patients O
( O
Epo I-GENE
and O
Non O
- O
Epo I-GENE
group O
, O
respectively O
). O

It O
is O
mainly O
RARE O
in O
RARE O
RARE O
and O
in O
developing O
organs O
characterized O
by O
RARE O
- O
mesenchymal O
interactions O
. O

CONCLUSION O
: O
The O
NUM O
- O
adrenergic O
antagonist O
RARE O
increases O
glucose O
- O
RARE O
sympathetic O
activity O
but O
not O
energy O
expenditure O
in O
obese O
subjects O
. O

ALL_CAP O
- O
ALL_CAP O
RARE I-GENE
RARE I-GENE
RARE O
RARE O
diagnostic O
agent O
RARE O
by O
RARE O
ALL_CAP O
, O
RARE O
, O
was O
RARE O
RARE O
RARE O
laboratory O
of O
Institute O
of O
RARE O
RARE O
in O
RARE O
. O

RARE O
, O
we O
show O
that O
two O
ALL_CAP O
- O
RARE O
mutations O
, O
previously O
shown O
to O
interact O
genetically O
with O
zipper O
( O
RARE I-GENE
RARE O
disrupt O
the O
RhoA I-GENE
locus I-GENE
. O

Therefore O
, O
the O
results O
indicate O
that O
RARE O
exposure O
to O
amphetamine O
or O
RARE O
RARE O
the O
context O
- O
dependent O
RARE O
of O
sensitization O
of O
amphetamine O
- O
or O
RARE O
- O
RARE O
RARE O
behavior O
. O

RARE O
RARE O
serum I-GENE
IgM I-GENE
binding O
to O
NUM O
RARE O
in O
clinical O
practice O
. O

RARE O
responses O
also O
occurred O
in O
studies O
that O
explored O
sequential O
use O
of O
RARE O
after O
failure O
of O
RARE O
( O
NUM O
% O
with O
RARE O
NUM O
mg O
/ O
day O
) O
or O
other O
RARE O
aromatase I-GENE
RARE O
( O
6 O
. O
6 O
% O
with O
RARE O
NUM O
mg O
/ O
day O
). O

RARE O
reviewed O
here O
include O
: O
data O
supporting O
the O
association O
of O
myositis O
with O
RARE O
and O
the O
appropriate O
RARE O
RARE O
malignancy O
in O
a O
myositis O
patient O
; O
an O
approach O
to O
the O
assessment O
of O
patients O
with O
RARE O
RARE O
myositis O
; O
the O
RARE O
of O
the O
RARE O
and O
serological O
RARE O
; O
a O
discussion O
of O
whether O
childhood O
and O
adult O
myositis O
are O
the O
same O
or O
different O
RARE O
; O
a O
review O
of O
those O
prognostic O
factors O
to O
consider O
in O
the O
clinical O
management O
of O
myositis O
patients O
; O
current O
approaches O
and O
their O
limitations O
RARE O
assessing O
RARE O
activity O
and O
damage O
. O

The O
RARE O
of O
tissue O
RARE O
. O

RARE I-GENE
III I-GENE
( O
RARE I-GENE
) O
of O
Escherichia O
coli O
is O
a O
DNA I-GENE
glycosylase I-GENE
essential O
RARE O
the O
removal O
of O
RARE O
pyrimidine O
RARE O
residues O
from O
DNA O
. O

The O
duration O
of O
reactive O
RARE O
decreased O
with O
aging O
, O
but O
the O
difference O
between O
males O
and O
females O
was O
not O
significant O
RARE O
any O
age O
. O

RARE O
bile O
duct O
RARE O
: O
entry O
of O
RARE O
agent O
into O
an O
intrahepatic O
abscess O
. O

Furthermore O
, O
this O
study O
RARE O
RARE O
the O
impact O
of O
RARE O
conditions O
on O
RARE O
length O
and O
RARE O
, O
and O
the O
impact O
of O
the O
blocking O
on O
both O
, O
RARE O
and O
RARE O
of O
the O
polymers O
. O

However O
, O
little O
was O
understood O
about O
the O
normal O
function O
of O
CREB I-GENE
- I-GENE
2 I-GENE
in O
mammalian O
development O
or O
organ O
physiology O
. O

The O
RARE O
diameter O
and O
the O
thickness O
of O
the O
RARE O
are O
NUM O
mm O
and O
8 O
mm O
, O
respectively O
. O

Both O
the O
ALL_CAP O
and O
the O
maximum O
EMG O
activity O
in O
the O
right O
RARE O
and O
the O
RARE O
anterior O
RARE O
muscles O
were O
significantly O
decreased O
RARE O
muscle O
pain O
when O
the O
subjects O
RARE O
on O
the O
RARE O
RARE O
. O

CONCLUSIONS O
: O
There O
is O
a O
relation O
in O
the O
RARE O
of O
some O
visual O
field O
areas O
assessed O
by O
ALL_CAP O
and O
the O
RARE O
RARE O
RARE O
area O
, O
which O
may O
play O
a O
role O
in O
the O
diagnosis O
and O
follow O
- O
RARE O
of O
suspected O
glaucoma O
. O

The O
RARE O
RARE O
contained O
in O
the O
RARE O
of O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
, O
RARE O
, O
and O
RARE O
was O
lower O
than O
the O
limits O
recommended O
RARE O
food O
safety O
. O

The O
detection O
success O
rate O
was O
determined O
RARE O
different O
markers O
using O
this O
MEK I-GENE
. O

RARE O
, O
we O
show O
that O
NUM I-GENE
physically O
interacts O
with O
the O
HMG I-GENE
box O
domain O
of O
NUM I-GENE
and O
that O
RARE I-GENE
and O
Wnt I-GENE
pathways O
RARE O
to O
activate O
transcription O
of O
the O
Xenopus O
RARE O
gene O
RARE I-GENE
( O
RARE I-GENE
). O

The O
transmembrane O
topology O
of O
RARE O
RARE O
H O
RARE O
RARE O
NUM I-GENE
has O
been O
studied O
using O
in O
vitro O
transcription O
/ O
translation O
of O
two O
RARE O
of O
fusion O
vectors O
designed O
to O
test O
membrane O
RARE O
properties O
of O
cDNA O
sequences O
encoding O
putative O
NUM I-GENE
membrane O
spanning O
domains O
( O
RARE O
). O

ACE I-GENE
- I-GENE
2 I-GENE
has O
a O
hydrophobic O
C O
terminus O
of O
H O
type O
. O

Members O
of O
the O
RARE I-GENE
/ O
myosin I-GENE
light I-GENE
chain I-GENE
kinase I-GENE
family O
play O
an O
essential O
role O
in O
the O
organization O
of O
the O
actin I-GENE
/ O
myosin I-GENE
RARE O
, O
especially O
in O
RARE O
assembly O
and O
function O
. O

We O
concluded O
that O
activation O
of O
c I-GENE
- I-GENE
ALL_CAP I-GENE
RARE O
transcriptional O
inhibition O
of O
p21 I-GENE
( O
Cip1 I-GENE
/ O
WAF1 I-GENE
) O
through O
a O
previously O
uncharacterized O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
, O
RARE O
an O
important O
role O
RARE O
c I-GENE
- I-GENE
fos I-GENE
in O
negative O
control O
of O
cell O
RARE O
regulatory O
genes O
. O

Furthermore O
, O
a O
NUM I-GENE
Shc I-GENE
RARE I-GENE
selectively O
RARE O
Grb2 I-GENE
, O
NUM I-GENE
, O
ALL_CAP I-GENE
, O
and O
the O
p85 I-GENE
subunit I-GENE
of O
RARE I-GENE
3 I-GENE
' I-GENE
kinase I-GENE
from O
RARE O
cells O
, O
RARE O
characterized O
by O
mass O
spectrometry O
. O

Although O
increased O
RARE O
of O
the O
HMG I-GENE
- I-GENE
I I-GENE
/ I-GENE
Y I-GENE
proteins I-GENE
is O
associated O
with O
cellular O
RARE O
, O
neoplastic O
transformation O
, O
and O
several O
human O
cancers O
, O
the O
role O
of O
these O
proteins O
in O
the O
pathogenesis O
of O
malignancy O
remains O
unclear O
. O

The O
naltrexone O
/ O
RARE O
combination O
was O
associated O
with O
a O
more O
rapid O
resolution O
of O
the O
RARE O
withdrawal O
RARE O
than O
a O
7 O
- O
day O
RARE O
- O
only O
treatment O
schedule O
, O
without O
substantial O
increases O
in O
withdrawal O
symptoms O
or O
hypotensive O
RARE O
- O
effects O
. O

The O
RARE O
symptoms O
of O
RARE O
RARE O
were O
noted O
in O
RARE O
1998 O
, O
when O
some O
of O
the O
cows O
developed O
locomotor O
abnormalities O
. O

RARE O
, O
RARE O
, O
and O
treatment O
RARE O
RARE O
and O
RARE O
drug O
use O
should O
be O
essential O
RARE O
in O
RARE O
ALL_CAP O
care O
. O

Transcriptional O
RARE O
of O
the O
mouse I-GENE
cytosolic I-GENE
RARE I-GENE
subunit I-GENE
gene I-GENE
RARE I-GENE
/ I-GENE
t I-GENE
- I-GENE
complex I-GENE
polypeptide I-GENE
1 I-GENE
by O
RARE I-GENE
tRNA I-GENE
gene I-GENE
transcription I-GENE
activating I-GENE
factor I-GENE
family I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
. O

The O
RARE O
protein O
response O
regulates O
multiple O
aspects O
of O
RARE O
and O
membrane O
protein O
biogenesis O
and O
endoplasmic O
reticulum O
quality O
control O
. O

ALL_CAP I-GENE
: O
a O
proline O
- O
rich O
nuclear O
receptor O
RARE O
protein O
that O
RARE O
transcriptional O
activation O
of O
multiple O
nuclear O
receptors O
including O
orphan O
receptors O
NUM I-GENE
( O
RARE I-GENE
factor I-GENE
1 I-GENE
) O
and O
NUM I-GENE
( O
estrogen I-GENE
related I-GENE
receptor I-GENE
alpha I-GENE
- I-GENE
1 I-GENE
). O

Studies O
using O
a O
reporter O
RARE O
with O
a O
functionally O
disrupted O
sterol O
- O
responsive O
element O
( O
SRE O
)- O
1 O
revealed O
a O
RARE O
RARE O
response O
to O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
. O

However O
, O
there O
is O
still O
a O
subset O
of O
tumors O
that O
displayed O
RARE O
changes O
in O
these O
genes O
. O

We O
have O
shown O
that O
the O
RARE O
( O
ALL_CAP O
) O
delivery O
of O
RARE O
RARE O
in O
RARE O
liposomes O
( O
RARE O
drug O
delivery O
RARE O
) O
produces O
a O
sustained O
clearance O
of O
RARE O
and O
a O
prolonged O
analgesia O
. O

Following O
ALL_CAP O
- O
NUM O
, O
but O
not O
saline O
or O
RARE O
vehicle O
, O
there O
were O
transient O
(< O
72 O
hr O
) O
decreases O
in O
food O
consumption O
, O
RARE O
, O
RARE O
muscle O
tone O
, O
and O
body O
RARE O
. O

RARE O
RARE O
and O
RARE O
RARE O
RARE O
were O
the O
most O
accurate O
with O
NUM O
% O
RARE O
within O
+/- O
1 O
. O
NUM O
g O
of O
10 O
g O
. O

ALL_CAP O
: O
RARE O
sample O
of O
ambulatory O
RARE O
with O
RARE O
motor O
and O
sensory O
RARE O
, O
type O
I O
( O
RARE O
= O
9 O
RARE O
RARE O
muscular O
RARE O
( O
RARE O
= O
10 O
RARE O
and O
able O
- O
RARE O
controls O
( O
RARE O
= O
11 O
). O

The O
effect O
of O
water O
deprivation O
RARE O
19 O
h O
on O
RARE O
RARE O
excretion O
of O
conscious O
RARE O
( O
ALL_CAP O
) O
sheep O
maintained O
on O
a O
constant O
intravenous O
infusion O
of O
aldosterone O
and O
cortisol O
( O
ALL_CAP O
- O
constant O
steroid O
sheep O
) O
was O
investigated O
. O

Neither O
is O
it O
a O
major O
cause O
of O
RARE O
- O
RARE O
RARE O
RARE O
retention O
. O

CONCLUSION O
: O
RARE O
fever O
in O
the O
RARE O
area O
is O
still O
manifest O
. O

RARE I-GENE
III I-GENE
deficiency O
: O
when O
substitute O
, O
when O
RARE O
? O
RARE O
ALL_CAP O
, O
3 O
: O
The O
role O
of O
antithrombin I-GENE
III I-GENE

Specific O
class I-GENE
I I-GENE
and I-GENE
II I-GENE
histone I-GENE
RARE I-GENE
( O
RARE I-GENE
) O
interact O
in O
vivo O
with O
ALL_CAP I-GENE
, O
suggesting O
that O
ALL_CAP I-GENE
may O
functionally O
RARE O
these O
two O
classes O
of O
RARE I-GENE
. O

This O
is O
the O
RARE O
example O
of O
a O
eukaryotic O
transcription O
factor O
complex O
containing O
both O
a O
MADS I-GENE
- I-GENE
box I-GENE
and O
a O
RARE I-GENE
protein I-GENE
, O
and O
it O
has O
important O
implications O
RARE O
the O
RARE O
of O
mammalian O
gene O
RARE O
. O

After O
screening O
the O
RARE O
Drosophila O
RARE O
RARE O
database O
with O
sequences O
from O
a O
recently O
characterized O
RARE I-GENE
- I-GENE
rich I-GENE
repeats I-GENE
- I-GENE
containing I-GENE
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
) O
from O
Drosophila O
( O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
RARE O
we O
identified O
a O
second O
gene O
RARE O
a O
different O
ALL_CAP I-GENE
( O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
) O
and O
RARE O
its O
cDNA O
. O

RARE O
primers O
homologous O
to O
highly O
RARE O
regions O
of O
known O
NUM I-GENE
sequences I-GENE
were O
used O
RARE O
initial O
RT O
- O
RARE O
. O

When O
cells O
were O
RARE O
with O
RARE O
designed O
to O
bind O
to O
a O
NUM O
- O
bp O
RARE O
site O
situated O
between O
the O
two O
TK I-GENE
genes I-GENE
, O
RARE O
was O
observed O
RARE O
frequencies O
in O
the O
range O
of O
1 O
%, O
2 O
, O
500 O
- O
RARE O
above O
the O
background O
. O

RARE O
was O
used O
RARE O
the O
internal O
standard O
. O

Resistance O
ratios O
RARE O
the O
other O
field O
strains O
obtained O
by O
comparison O
with O
the O
NUM O
RARE O
ranged O
from O
NUM O
. O
5 O
to O
239 O
RARE O
RARE O
application O
and O
from O
1 O
. O
2 O
to O
9 O
. O
8 O
RARE O
the O
glass O
RARE O
method O
. O

Only O
transcripts O
specific O
RARE O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
are O
detected O
in O
ovary O
and O
testes O
tissues O
of O
adults O
RARE O
RARE O
RARE O
in O
RARE O
, O
while O
neither O
gene O
is O
RARE O
RARE O
the O
RARE O
developmental O
stages O
. O

In O
a O
gel O
retardation O
assay O
using O
NUM O
nuclear O
extracts O
, O
the O
5 O
' O
flanking O
sequence O
from O
- O
NUM O
to O
- O
NUM O
showed O
a O
shifted O
band O
. O

RARE O
of O
cervical O
range O
of O
motion O
using O
the O
ALL_CAP O
CA O
NUM O
spine O
motion O
RARE O
on O
asymptomatic O
and O
symptomatic O
subjects O
. O

RARE O
experiments O
performed O
in O
transfected O
cells O
showed O
that O
ALL_CAP I-GENE
associates O
with O
ALL_CAP I-GENE
- I-GENE
associated I-GENE
factor I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
1 I-GENE
, O
TRAF2 I-GENE
, O
and O
NUM I-GENE
RARE I-GENE
proteins I-GENE
. O

Since O
the O
ALL_CAP I-GENE
gene I-GENE
is O
likely O
an O
RARE O
of O
the O
RARE I-GENE
NUM I-GENE
gene I-GENE
, O
it O
has O
been O
named O
NUM I-GENE
by O
the O
Human O
RARE O
RARE O
Committee O
. O

The O
chromosomal O
RARE O
on O
distal O
RARE O
7 O
RARE O
it O
in O
a O
cluster O
of O
imprinted O
genes O
, O
flanked O
by O
the O
previously O
described O
NUM I-GENE
and O
NUM I-GENE
genes I-GENE
. O

Activation O
of O
PKA I-GENE
by O
8 O
- O
RARE O
- O
cyclic O
AMP O
or O
forskolin O
, O
and O
inhibition O
of O
PKC I-GENE
by O
RARE O
C O
, O
resulted O
in O
a O
significant O
decrease O
in O
NUM I-GENE
activity O
RARE O
RARE O
RARE O
in O
vitro O
ERK I-GENE
kinase I-GENE
activity O
in O
ALL_CAP O
. O

The O
present O
study O
was O
designed O
to O
evaluate O
the O
sensitivity O
and O
RARE O
of O
AMP O
ALL_CAP O
( O
RARE O
- O
RARE O
RARE O
, O
RARE O
RARE O
, O
CA O
, O
ALL_CAP O
) O
on O
RARE O
specimens O
taken O
from O
symptomatic O
patients O
and O
on O
RARE O
RARE O
urine O
( O
ALL_CAP O
) O
specimens O
from O
asymptomatic O
patients O
. O

NUM I-GENE
also O
shares O
homology O
with O
motifs O
found O
in O
the O
ALL_CAP I-GENE
endonuclease I-GENE
superfamily I-GENE
. O

Double O
mutant O
analysis O
suggests O
that O
NUM I-GENE
and O
NUM I-GENE
act O
in O
one O
RARE O
RARE O
the O
repair O
of O
, O
or O
tolerance O
to O
, O
ALL_CAP O
- O
RARE O
DNA O
damage O
. O

The O
RARE O
RARE O
NUM O
from O
the O
yeast O
RARE O
lactis O
normally O
RARE O
in O
the O
cytoplasm O
, O
with O
the O
aid O
of O
the O
RARE O
RARE O
RARE O
NUM O
, O
using O
terminal I-GENE
protein I-GENE
( O
ALL_CAP I-GENE
) O
RARE O
a O
primer O
. O

The O
RARE O
RARE I-GENE
( O
early I-GENE
RARE I-GENE
) O
family O
of O
sequences O
represents O
an O
RARE O
" O
mobile O
RARE O
" O
in O
the O
mouse O
genome O
. O

The O
two O
main O
experimental O
variables O
were O
the O
RARE O
RARE O
( O
RARE O
or O
right O
) O
and O
the O
proportion O
of O
trials O
requiring O
a O
shift O
within O
that O
RARE O
( O
20 O
% O
or O
NUM O
%). O

The O
measurement O
of O
ALL_CAP O
in O
biological O
RARE O
using O
RARE O
. O

Biochemical O
examinations O
of O
RARE O
- O
phosphorus O
metabolism O
included O
ions O
and O
ALL_CAP I-GENE
concentrations O
in O
RARE O
serum O
, O
and O
the O
activity O
of O
bone O
RARE O
of O
AP I-GENE
. O

RARE O
was O
the O
most O
cost O
- O
effective O
HMG I-GENE
- I-GENE
CoA I-GENE
reductase I-GENE
inhibitor O
. O

RARE O
assessment O
of O
HMG I-GENE
- I-GENE
CoA I-GENE
reductase I-GENE
inhibitor O
therapy O
: O
an O
analysis O
based O
on O
the O
ALL_CAP O
study O
. O

Interestingly O
, O
although O
E O
domains O
of O
these O
two O
receptors O
are O
much O
less O
RARE O
, O
RARE O
of O
this O
domain O
in O
ALL_CAP I-GENE
by O
its O
human O
RARE O
resulted O
in O
RARE O
estradiol O
sensitivity O
but O
RARE O
increase O
in O
the O
magnitude O
of O
RARE O
. O

G O
- O
DNA O
is O
a O
four O
- O
RARE O
DNA O
RARE O
with O
diverse O
putative O
biological O
roles O
. O

The O
effectiveness O
of O
ALL_CAP O
appears O
to O
be O
largely O
independent O
of O
the O
intensity O
of O
additional O
support O
provided O
to O
the O
RARE O
. O

ALL_CAP O
ALL_CAP O
: O
All O
RARE O
trials O
where O
adults O
with O
schizophrenia O
or O
similar O
RARE O
were O
randomised O
to O
RARE O
, O
placebo O
or O
other O
neuroleptic O
drugs O
and O
where O
clinically O
relevant O
outcomes O
were O
reported O
. O

8 O
% O
( O
NUM O
% O
ALL_CAP O
, O
21 O
. O
3 O
- O
NUM O
. O
3 O
%). O

In O
contrast O
, O
the O
action O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
RARE O
the O
ALL_CAP O
was O
not O
blocked O
by O
cotransfection O
with O
NUM I-GENE
- I-GENE
CREB I-GENE
, O
an O
isoform O
that O
lacks O
a O
consensus O
serine O
RARE O
RARE O
RARE O
substrate O
RARE O
PKA I-GENE
- O
RARE O
RARE O
. O

Because O
all O
ALL_CAP I-GENE
fusions I-GENE
described O
thus O
far O
result O
in O
RARE O
to O
a O
common O
RARE O
of O
this O
gene O
, O
we O
performed O
5 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
PCR O
on O
patient O
RNA O
. O

CONCLUSIONS O
: O
In O
essential O
hypertension O
an O
acute O
protein O
load O
induces O
a O
decrease O
in O
GFR O
that O
may O
RARE O
under O
antihypertensive O
treatment O
. O

This O
finding O
suggested O
that O
the O
NUM I-GENE
- O
Akt I-GENE
activation O
RARE O
plays O
some O
role O
in O
the O
RARE O
effect O
of O
EPO I-GENE
. O

RARE O
DNA O
fragments O
that O
were O
specifically O
RARE O
and O
RARE O
by O
RARE O
- O
RARE O
ALL_CAP I-GENE
were O
isolated O
by O
cycles O
of O
a O
gel O
mobility O
shift O
- O
PCR O
method O
. O

To O
determine O
whether O
the O
ALL_CAP O
- O
binding O
motif O
is O
important O
RARE O
NUM I-GENE
function O
, O
we O
RARE O
the O
RARE O
RARE O
( O
NUM O
) O
RARE O
in O
this O
motif O
. O

The O
RARE O
- O
terminal O
proline O
- O
rich O
domain O
of O
NUM I-GENE
is O
involved O
in O
the O
interaction O
with O
the O
PLC I-GENE
- I-GENE
NUM I-GENE
SH3 I-GENE
domain I-GENE
. O

From O
transient O
RARE O
studies O
, O
we O
could O
demonstrate O
that O
the O
SH3 I-GENE
domain I-GENE
of O
PLC I-GENE
- I-GENE
NUM I-GENE
is O
necessary O
RARE O
the O
association O
with O
NUM I-GENE
in O
vivo O
. O

Six O
distinct O
Ets I-GENE
mRNAs I-GENE
were O
identified O
: O
NUM I-GENE
, O
NUM I-GENE
, O
RARE I-GENE
, O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
. O

A O
2 O
kb O
transcript O
was O
isolated O
from O
brain O
that O
encodes O
a O
RARE O
57 O
kDa O
protein O
; O
the O
predicted O
protein O
contains O
the O
known O
N I-GENE
- I-GENE
terminal I-GENE
Ets I-GENE
domain I-GENE
of O
NUM I-GENE
and O
a O
novel O
C O
- O
terminal O
domain O
with O
RARE O
homology O
to O
murine I-GENE
ALL_CAP I-GENE
. O

Twenty O
RARE O
patients O
with O
cirrhosis O
were O
randomized O
into O
two O
groups O
: O
10 O
patients O
treated O
with O
6 O
million O
RARE O
of O
RARE O
IFN I-GENE
- I-GENE
beta I-GENE
twice O
a O
week O
RARE O
NUM O
months O
and O
10 O
patients O
without O
IFN I-GENE
therapy O
. O

Wnt I-GENE
- I-GENE
1 I-GENE
overexpression O
in O
mammary O
RARE O
cells O
RARE O
RARE I-GENE
NUM I-GENE
mRNA I-GENE
and O
targeted O
overexpression O
of O
Wnt I-GENE
- I-GENE
1 I-GENE
in O
the O
mammary O
RARE O
of O
transgenic O
mice O
increased O
both O
ILK I-GENE
activity O
and O
RARE I-GENE
NUM I-GENE
levels O
. O

Intravenous O
versus O
oral O
administration O
of O
RARE O
in O
patients O
with O
major O
depression O
. O

Deletion O
of O
the O
ALL_CAP I-GENE
domain I-GENE
resulted O
in O
RARE O
of O
Ca O
( O
2 O
RARE O
dependent O
activation O
. O

RARE O
regression O
analysis O
revealed O
that O
physicians O
were O
3 O
. O
6 O
times O
more O
likely O
to O
detect O
thin O
lesions O
RARE O
NUM O
. O
NUM O
mm O
) O
compared O
with O
RARE O
RARE O
( O
NUM O
% O
confidence O
interval O
RARE O
NUM O
% O
ALL_CAP O
], O
2 O
. O
1 O
, O
6 O
. O
5 O
; O
P O
= O
NUM O
. O
0001 O
). O

RARE O
RARE O
RARE O
RARE O
by O
RARE I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
in O
an O
RARE O
peripheral O
RARE O
RARE O
cell O
donor O
. O

ALL_CAP O
and O
ALL_CAP O
RARE O
- O
immunoprecipitated O
with O
NUM I-GENE
, O
but O
not O
with O
NUM I-GENE
, O
NUM I-GENE
, O
or O
NUM I-GENE
. O

While O
interactions O
of O
ALL_CAP O
and O
variant O
TGF I-GENE
- I-GENE
alpha I-GENE
with O
the O
RARE I-GENE
all O
result O
in O
NUM I-GENE
activation O
, O
they O
produce O
different O
biological O
consequences O
, O
suggesting O
that O
the O
various O
TGF I-GENE
- I-GENE
alpha I-GENE
RARE I-GENE
differentially O
modulate O
ErbB I-GENE
RARE O
. O

It O
is O
now O
RARE O
accepted O
that O
the O
p53 I-GENE
C I-GENE
- I-GENE
terminus I-GENE
plays O
a O
central O
role O
in O
controlling O
the O
activity O
of O
the O
wild O
- O
type O
molecule O
. O

In O
contrast O
to O
full I-GENE
- I-GENE
length I-GENE
E2F I-GENE
- I-GENE
3 I-GENE
, O
which O
is O
RARE O
only O
RARE O
the O
G1 O
/ O
S O
boundary O
, O
E2F I-GENE
- I-GENE
NUM I-GENE
is O
detected O
throughout O
the O
cell O
RARE O
with O
peak O
levels O
in O
ALL_CAP O
where O
it O
is O
associated O
with O
RARE I-GENE
. O

The O
transcription O
factor O
Jun I-GENE
( O
c I-GENE
- I-GENE
Jun I-GENE
) O
functions O
RARE O
a O
recipient O
of O
extracellular O
growth O
signals O
and O
RARE O
them O
into O
patterns O
of O
gene O
RARE O
. O

RARE O
toxicity O
of O
the O
class O
III O
antiarrhythmic O
agent O
RARE O
in O
mice O
. O

This O
compound O
is O
the O
main O
RARE O
metabolite O
of O
RARE O
II O
( O
RARE O
, O
ALL_CAP O
NUM O
- O
NUM O
- O
8 O
RARE O
an O
RARE O
widely O
used O
RARE O
RARE O
diseases O
since O
NUM O
. O

In O
addition O
to O
its O
effect O
in O
RARE O
the O
RARE O
response O
to O
RARE O
exercise O
, O
vitamin O
E O
causes O
a O
greater O
increase O
in O
circulating O
RARE I-GENE
kinase I-GENE
activity O
, O
perhaps O
indicating O
increased O
skeletal O
muscle O
repair O
. O

This O
RARE O
the O
formation O
of O
RARE O
- O
loop O
templates O
with O
the O
fusion O
point O
of O
the O
chimeric O
transcript O
in O
the O
loop O
and O
the O
use O
of O
ALL_CAP I-GENE
primers O
in O
two O
- O
RARE O
PCR O
. O

CONCLUSION O
: O
The O
authors O
RARE O
that O
the O
initial O
management O
of O
RARE O
ALL_CAP O
should O
be O
adequate O
and O
suggest O
that O
RARE O
margin O
of O
> O
or O
= O
2 O
cm O
should O
be O
RARE O
to O
. O

Measurements O
were O
compared O
with O
two O
RARE O
treatment O
planning O
RARE O
RARE O
RARE O
NUM O
and O
ALL_CAP O
NUM O
NUM O
. O
NUM O
. O

Activation O
was O
biphasic O
; O
RARE O
RARE O
5 O
- O
10 O
min O
and O
NUM O
h O
after O
treatment O
. O

Whereas O
NUM I-GENE
is O
clearly O
detectable O
in O
crude O
lysates O
, O
cytosolic O
and O
ribosomal O
salt O
- O
RARE O
fractions O
, O
and O
in O
nuclear O
extracts O
, O
NUM I-GENE
is O
preferentially O
found O
in O
the O
ribosomal O
salt O
- O
RARE O
preparation O
. O

It O
contains O
NUM O
exons O
coding O
RARE O
a O
4 O
. O
NUM O
transcript O
including O
large O
5 O
'- O
and O
3 O
'- O
( O
NUM O
and O
NUM O
, O
respectively O
) O
RARE O
regions O
( O
RARE O
). O

Five O
of O
the O
NUM I-GENE
isoforms I-GENE
differ O
by O
the O
substitution O
or O
RARE O
of O
amino O
RARE O
RARE O
or O
near O
the O
N O
- O
terminal O
of O
the O
protein O
. O

The O
RARE O
technique O
RARE O
the O
pathological O
examination O
of O
RARE O
lymph O
nodes O
( O
RARE O
) O
is O
still O
under O
RARE O
. O

Partial O
correction O
of O
RARE O
with O
recombinant I-GENE
human I-GENE
erythropoietin I-GENE
likely O
reduces O
RARE O
ventricular O
mass O
and O
volume O
. O

This O
study O
demonstrated O
that O
the O
ALL_CAP O
- O
NUM O
RARE O
can O
accurately O
assess O
vWF I-GENE
- O
dependent O
platelet O
function O
and O
detect O
other O
platelet O
defects O
under O
high O
shear O
stress O
in O
complex O
patient O
populations O
. O

We O
recently O
reported O
the O
RARE O
cloning O
of O
a O
ALL_CAP I-GENE
RARE I-GENE
of O
human O
( O
NUM I-GENE
) O
and O
mouse O
origin O
, O
respectively O
. O

To O
analyze O
the O
regulatory O
activity O
of O
RARE I-GENE
, O
we O
RARE O
identified O
the O
optimal O
RARE I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
using O
an O
in O
vitro O
DNA O
- O
binding O
assay O
. O

Using O
an O
RARE O
duplex O
5 O
'- O
A O
( O
ALL_CAP O
)( O
5 O
)- O
3 O
RARE O
5 O
RARE O
ALL_CAP O
)( O
5 O
) O
T O
- O
3 O
' O
RARE O
a O
template O
- O
primer O
, O
we O
show O
that O
both O
the O
RARE I-GENE
fragment I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
DNA I-GENE
polymerase I-GENE
I I-GENE
and O
HIV I-GENE
reverse I-GENE
transcriptase I-GENE
could O
RARE O
RARE O
DNA O
sequences O
RARE O
RARE O
, O
giving O
products O
greater O
than O
the O
size O
of O
the O
template O
DNA O
. O

Cdk2 I-GENE
and O
ALL_CAP I-GENE
RARE O
from O
untreated O
tumor O
lysates O
RARE O
recombinant I-GENE
wild I-GENE
- I-GENE
type I-GENE
p27 I-GENE
but O
not O
the O
NUM O
mutant O
in O
vitro O
. O

The O
RARE O
of O
RARE O
activity O
because O
of O
mutations O
in O
the O
RARE O
transcriptional O
activation O
domain O
was O
restored O
by O
addition O
of O
the O
activation O
domain O
from O
the O
herpes I-GENE
simplex I-GENE
viral I-GENE
protein I-GENE
VP16 I-GENE
. O

Mutations O
in O
the O
NUM I-GENE
locus I-GENE
RARE I-GENE
NUM I-GENE
. I-GENE
3 I-GENE
were O
found O
in O
a O
further O
10 O
- O
20 O
% O
of O
ALL_CAP O
patients O
, O
RARE O
predicted O
from O
linkage O
studies O
. O

The O
limit O
between O
the O
RARE O
and O
the O
ascending O
colon O
was O
RARE O
marked O
by O
the O
RARE O
RARE O
RARE O
and O
RARE O
. O

RARE O
, O
HD O
inhibited O
healing O
because O
it O
significantly O
delayed O
RARE O
and O
caused O
RARE O
inflammation O
. O

The O
effectiveness O
of O
the O
RARE O
RARE O
RARE O
second O
- O
RARE O
wound O
healing O
in O
horses O
and O
RARE O
. O

Although O
there O
is O
little O
evidence O
that O
diet O
composition O
plays O
a O
clinically O
important O
role O
in O
the O
absorption O
or O
expenditure O
of O
energy O
, O
it O
does O
appear O
to O
play O
a O
role O
in O
food O
intake O
. O

These O
findings O
were O
reinforced O
by O
an O
analysis O
that O
was O
restricted O
to O
living O
donor O
RARE O
without O
acute O
rejection O
. O

These O
results O
further O
support O
an O
important O
role O
RARE O
CBF2 I-GENE
in O
mediating O
EBNA2 I-GENE
RARE O
; O
they O
identify O
the O
ALL_CAP I-GENE
protein I-GENE
NUM I-GENE
RARE O
a O
major O
RARE O
of O
CBF2 I-GENE
and O
are O
also O
the O
RARE O
evidence O
of O
a O
cis O
- O
acting O
sequence O
other O
than O
a O
CBF1 I-GENE
binding I-GENE
element I-GENE
that O
is O
able O
to O
confer O
responsiveness O
to O
EBNA2 I-GENE
. O

The O
genome O
of O
the O
human O
RARE O
8 O
( O
ALL_CAP O
- O
8 O
) O
contains O
a O
cluster O
of O
RARE O
reading O
frames O
( O
RARE O
) O
encoding O
proteins O
with O
homology O
to O
the O
cellular O
transcription O
factors O
of O
the O
RARE I-GENE
regulatory I-GENE
factor I-GENE
( O
IRF I-GENE
) O
family O
. O

Despite O
these O
limitations O
the O
ALL_CAP O
monitor O
provides O
an O
RARE O
to O
record O
physiological O
data O
previously O
RARE O
in O
the O
home O
. O

ALL_CAP O
ALL_CAP O
: O
RARE O
ultrasound O
has O
been O
shown O
to O
improve O
upon O
demonstrated O
RARE O
of O
coronary O
angiography O
. O

ALL_CAP O
bone O
area O
( O
p O
< O
NUM O
. O
001 O
RARE O
height O
( O
p O
< O
NUM O
. O
01 O
RARE O
years O
in O
present O
colony O
( O
p O
= O
NUM O
. O
03 O
RARE O
and O
RARE O
( O
p O
< O
NUM O
. O
01 O
) O
predicted O
ALL_CAP O
ALL_CAP O
. O

ALL_CAP O
RARE O
; O
a O
changing O
clinical O
significance O

RARE O
also O
RARE O
an O
endogenous I-GENE
PPARgamma I-GENE
target I-GENE
gene I-GENE
in O
NUM O
cells O
, O
RARE I-GENE
- I-GENE
type I-GENE
fatty I-GENE
acid I-GENE
binding I-GENE
protein I-GENE
( O
A I-GENE
- I-GENE
ALL_CAP I-GENE
RARE O
the O
RARE O
of O
which O
correlates O
with O
bladder O
RARE O
differentiation O
. O

RARE O
were O
isolated O
from O
9 O
lungs O
: O
7 O
with O
PI O
- O
NUM O
, O
1 O
with O
ALL_CAP O
ALL_CAP O
type O
1 O
, O
and O
1 O
with O
both O
ALL_CAP O
- O
1 O
and O
ALL_CAP O
. O

The O
NUM I-GENE
human I-GENE
RARE I-GENE
RARE I-GENE
RARE I-GENE
sequence I-GENE
encodes O
a O
novel O
RARE O
enzyme O
with O
a O
RARE O
promoter O
. O

Previous O
experience O
and O
RARE O
RARE O
are O
essential O
elements O
in O
the O
generation O
of O
a O
RARE O
prediction O
. O

To O
characterize O
this O
effect O
, O
we O
RARE O
RARE O
RARE O
of O
NS1 I-GENE
RARE I-GENE
virus I-GENE
protein I-GENE
among O
cellular O
translation O
factors O
. O

Collectively O
, O
these O
and O
previously O
published O
data O
suggest O
a O
model O
where O
NS1 I-GENE
RARE O
NUM I-GENE
specifically O
to O
the O
5 O
' O
RARE O
region O
( O
5 O
' O
UTR O
) O
of O
the O
viral O
mRNA O
, O
allowing O
RARE O
the O
preferential O
translation O
of O
the O
RARE O
virus O
RARE O
. O

RARE I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
NUM I-GENE
is O
a O
cellular O
target O
RARE O
NS1 I-GENE
protein I-GENE
, O
a O
translational O
activator O
of O
RARE O
virus O
. O

RARE O
of O
the O
K I-GENE
- I-GENE
ALL_CAP I-GENE
RARE O
RARE O
of O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
2 I-GENE
gene I-GENE
is O
RARE O
dependent O
on O
the O
ALL_CAP O
- O
rich O
sequence O
NUM I-GENE
RARE O
immediately O
RARE O
from O
its O
5 O
' O
RARE O
site O
. O

( O
iii O
) O
In O
these O
cells O
, O
RARE I-GENE
plays O
a O
unique O
Ras I-GENE
- O
independent O
role O
in O
mediating O
insulin I-GENE
but O
not O
ALL_CAP I-GENE
or O
other O
growth O
factor O
mitogenic O
signals O
. O

However O
, O
it O
is O
not O
known O
whether O
the O
recently O
identified O
isoforms O
NUM I-GENE
and O
NUM I-GENE
, O
which O
are O
broadly O
RARE O
, O
can O
RARE O
with O
similar O
classes O
of O
receptors O
, O
nor O
is O
it O
known O
whether O
all O
RARE I-GENE
isoforms I-GENE
possess O
identical O
RARE O
activities O
. O

Transcriptional O
RARE O
of O
NUM I-GENE
promoter I-GENE
constructs I-GENE
containing O
only O
UAS1 O
or O
NUM O
RARE O
that O
the O
PKA I-GENE
and O
ALL_CAP I-GENE
RARE O
is O
targeted O
to O
both O
sites O
. O

X O
- O
ray O
RARE O
data O
show O
that O
the O
PLZF I-GENE
BTB I-GENE
/ O
ALL_CAP O
domain O
forms O
an O
RARE O
RARE O
via O
an O
extensive O
interface O
. O

The O
ability O
of O
SMRT I-GENE
to O
associate O
with O
these O
transcription O
factors O
and O
thereby O
to O
mediate O
repression O
is O
strongly O
inhibited O
by O
activation O
of O
tyrosine I-GENE
kinase I-GENE
RARE O
pathways O
, O
such O
RARE O
that O
represented O
by O
the O
RARE I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
. O

In O
addition O
, O
the O
RARE O
- O
treated O
rats O
had O
more O
neurons O
and O
RARE O
cells O
surrounding O
the O
ventricles O
. O

The O
differences O
were O
RARE O
follows O
: O
RARE O
overall O
response O
rate O
p O
= O
NUM O
. O
NUM O
; O
power O
( O
RARE O
p O
= O
NUM O
. O
05 O
) O
NUM O
%; O
RARE O
survival O
p O
= O
NUM O
. O
09 O
; O
RARE O
grade O
IV O
RARE O
p O
= O
NUM O
. O
3 O
; O
and O
RARE O
RARE O
neutropenia O
p O
= O
NUM O
. O
NUM O
. O

Patients O
were O
randomly O
assigned O
to O
treatment O
with O
the O
ACE I-GENE
inhibitor O
RARE O
( O
and O
the O
diuretic O
RARE O
RARE O
those O
with O
RARE O
definite O
indication O
RARE O
or O
RARE O
to O
treatment O
with O
a O
diuretic O
) O
or O
RARE O
placebo O
( O
s O
). O

The O
results O
indicate O
that O
the O
RARE O
- O
section O
effect O
decreases O
the O
RARE O
stiffness O
and O
stress O
concentration O
effects O
decrease O
the O
RARE O
strength O
of O
a O
long O
bone O
with O
a O
longitudinal O
defect O
. O

These O
regions O
may O
be O
differentially O
involved O
in O
tissue O
- O
RARE O
, O
and O
/ O
or O
circadian O
RARE O
, O
of O
the O
human I-GENE
NUM I-GENE
gene I-GENE
transcription O
. O

Additionally O
, O
putative O
NUM I-GENE
/ O
ALL_CAP I-GENE
and O
RARE I-GENE
RARE I-GENE
NUM I-GENE
transcription O
factor O
elements O
were O
found O
in O
the O
upstream O
regions O
of O
ALL_CAP I-GENE
and O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
genes O
respectively O
. O

Sequence O
analysis O
reveals O
that O
the O
newly O
discovered O
NUM I-GENE
gene I-GENE
represents O
a O
RARE O
that O
is O
still O
RARE O
, O
but O
is O
not O
functionally O
translated O
. O

Genomic O
and O
RARE O
characterization O
of O
the O
RARE I-GENE
gene I-GENE
family I-GENE
encoding O
O I-GENE
- I-GENE
RARE I-GENE
( I-GENE
RARE I-GENE
) I-GENE
RARE I-GENE
, O
RARE O
RARE O
the O
final O
step O
in O
cysteine O
biosynthesis O
in O
Arabidopsis O
thaliana O
. O

Two O
distinct O
recessive O
RARE O
loci O
RARE O
vasculitis O
were O
mapped O
on O
RARE O
( O
Chr O
) O
4 O
RARE O
NUM I-GENE
and O
NUM I-GENE
in O
both O
RARE O
. O

During O
treatment O
, O
the O
RARE O
state O
of O
RARE I-GENE
shifted O
to O
a O
RARE O
form O
. O
mRNA O
RARE O
the O
HPV O
NUM I-GENE
/ O
E7 I-GENE
genes O
decreased O
; O
however O
, O
significant O
changes O
in O
the O
E7 I-GENE
protein I-GENE
were O
not O
observed O
, O
while O
increased O
levels O
of O
RARE I-GENE
immunoprecipitated O
with O
anti I-GENE
- I-GENE
E7 I-GENE
antibodies I-GENE
were O
observed O
. O

Further O
characterization O
of O
these O
putative O
RARE I-GENE
- I-GENE
1 I-GENE
target I-GENE
genes I-GENE
will O
aid O
in O
RARE O
the O
functions O
of O
the O
RARE I-GENE
- I-GENE
1 I-GENE
protein I-GENE
in O
the O
differentiation O
processes O
which O
occur O
RARE O
embryogenesis O
. O

The O
ability O
of O
U6 I-GENE
- O
NUM I-GENE
mutants O
to O
influence O
the O
RARE O
of O
both O
branch O
site O
and O
3 O
' O
RARE O
site O
recognition O
suggests O
that O
this O
nucleotide O
may O
participate O
in O
the O
formation O
of O
the O
RARE O
site O
( O
s O
) O
of O
the O
spliceosome O
. O

We O
have O
determined O
the O
RARE O
of O
the O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
gene I-GENE
. O

The O
role O
of O
RARE O
in O
induction O
therapy O
RARE O
adult O
acute O
RARE O
leukemia O

Five O
of O
the O
RARE O
strains O
and O
one O
of O
V O
RARE O
non O
- O
NUM O
were O
positive O
RARE O
RARE O
activity O
. O

TNF I-GENE
- I-GENE
alpha I-GENE
RARE O
a O
dose O
- O
and O
time O
- O
dependent O
increase O
in O
RARE I-GENE
- I-GENE
2 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
) O
RARE O
and O
PGE2 O
formation O
in O
human O
ALL_CAP O
- O
NUM O
RARE O
cells O
. O

The O
therapy O
time O
to O
RARE O
the O
ALL_CAP O
therapeutic O
dose O
of O
NUM O
ALL_CAP O
- O
RARE O
, O
is O
NUM O
times O
longer O
when O
NUM O
is O
used O
instead O
of O
NUM O
. O

NUM I-GENE
is O
needed O
RARE O
the O
formation O
of O
NUM I-GENE
RARE I-GENE
RNA I-GENE
, O
and O
may O
hence O
direct O
the O
level O
of O
proteins O
required O
RARE O
the O
coupling O
. O

RARE O
RARE O
For O
RARE O
. O

CONCLUSION O
: O
RARE O
RARE O
vitreous O
hemorrhage O
in O
RARE O
RARE O
is O
a O
safe O
and O
effective O
procedure O
, O
RARE O
a O
rapid O
and O
prolonged O
improvement O
in O
vision O
. O

RNA O
in O
situ O
hybridization O
on O
brain O
sections O
of O
normal O
human O
RARE O
revealed O
a O
strong O
labeling O
in O
restricted O
areas O
of O
the O
cerebral O
cortex O
. O

To O
facilitate O
RARE O
of O
large O
genomic O
sequences O
, O
we O
developed O
a O
method O
of O
RARE O
Escherichia O
coli O
P1 O
artificial O
chromosomes O
( O
RARE O
) O
into O
yeast O
artificial O
chromosomes O
( O
YACs O
). O

After O
gamma O
- O
irradiation O
, O
the O
majority O
of O
F9 O
cells O
undergo O
apoptosis O
implying O
that O
wt I-GENE
- I-GENE
p53 I-GENE
likely O
triggers O
pro O
- O
apoptotic O
gene O
RARE O
in O
DNA O
damaged O
cells O
. O

RARE O
with O
cyclophosphamide O
and O
RARE I-GENE
- I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
was O
effective O
in O
terms O
of O
CD34 I-GENE
+ I-GENE
cell O
shift O
to O
peripheral O
RARE O
and O
the O
good O
quality O
RARE O
RARE O
led O
to O
RARE O
recovery O
after O
RARE O
. O

This O
suggests O
that O
cardiovascular O
magnetic O
resonance O
is O
the O
preferred O
technique O
RARE O
volume O
and O
ejection O
fraction O
estimation O
in O
RARE O
failure O
patients O
, O
because O
of O
its O
NUM O
approach O
RARE O
non O
- O
RARE O
ventricles O
and O
superior O
image O
quality O
. O

A O
degenerate O
DNA O
RARE O
, O
RARE I-GENE
, O
was O
identified O
in O
the O
genomes O
of O
various O
wild O
- O
type O
strains O
of O
the O
RARE O
RARE O
RARE O
RARE O
. O

However O
, O
the O
presence O
of O
RARE I-GENE
I I-GENE
increased O
the O
extent O
and O
altered O
the O
profile O
of O
proteins O
binding O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
in O
vivo O
. O

We O
have O
also O
identified O
a O
RARE O
domain O
in O
the O
ORF O
50 O
protein O
, O
an O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
product I-GENE
that O
is O
mainly O
encoded O
by O
ORF O
50 O
. O

A O
2 O
. O
3 O
- O
kb O
full O
- O
length O
cDNA O
clone O
of O
an O
RARE I-GENE
RARE I-GENE
RARE I-GENE
gene I-GENE
was O
isolated O
from O
a O
liver O
cDNA O
library O
. O

ALL_CAP O
- O
3 O
is O
a O
new O
RARE O
protocol O
of O
RARE O
speech O
in O
3 O
- O
year O
- O
old O
children O
. O

Once O
ALL_CAP O
II O
is O
suspected O
, O
RARE O
( O
and O
low O
- O
RARE O
- O
RARE O
RARE O
) O
should O
be O
stopped O
immediately O
. O

The O
RARE O
efficiency O
in O
the O
glycosylase I-GENE
activity O
is O
also O
reflected O
in O
a O
RARE O
ability O
of O
NUM I-GENE
ALL_CAP I-GENE
to O
prevent O
DNA O
mutations O
in O
vivo O
. O

METHODS O
ALL_CAP O
RESULTS O
: O
We O
RARE O
compared O
the O
automated O
measurements O
of O
RARE O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
and O
volumes O
from O
rest O
- O
injected O
gated O
RARE O
99m O
( O
NUM O
) O
perfusion O
SPECT O
with O
equilibrium O
RARE O
RARE O
( O
ALL_CAP O
) O
in O
NUM O
patients O
and O
the O
assessment O
of O
regional O
function O
with O
echocardiography O
in O
NUM O
patients O
. O

The O
2 O
cDNAs O
differed O
in O
the O
length O
of O
their O
respective O
3 O
' O
RARE O
regions O
, O
of O
NUM O
bp O
in O
Cp I-GENE
. I-GENE
NUM I-GENE
and O
72 O
bp O
in O
Cp I-GENE
. I-GENE
NUM I-GENE
, O
in O
both O
of O
which O
a O
putative O
polyadenylation O
signal O
was O
identified O
. O

This O
RARE O
RARE O
, O
known O
RARE O
the O
RARE O
protein O
response O
( O
ALL_CAP O
RARE O
is O
RARE O
by O
the O
cis O
- O
acting O
ER O
stress O
response O
element O
( O
ALL_CAP O
) O
in O
mammals O
. O

A O
Y I-GENE
. I-GENE
RARE I-GENE
NUM I-GENE
mutant I-GENE
was O
isolated O
that O
restored O
interaction O
with O
an O
NUM I-GENE
mutant I-GENE
, O
suggesting O
that O
the O
interaction O
with O
NUM I-GENE
could O
be O
nucleotide O
and O
/ O
or O
conformation O
dependent O
. O

We O
have O
carried O
out O
a O
RARE O
and O
systematic O
mutagenesis O
of O
the O
NUM I-GENE
N I-GENE
terminus I-GENE
to O
analyze O
its O
function O
. O

The O
RARE O
of O
the O
essential O
N O
- O
terminal O
domain O
( O
ALL_CAP O
) O
relative O
to O
the O
ALL_CAP I-GENE
can O
be O
changed O
significantly O
without O
an O
apparent O
effect O
on O
NUM I-GENE
function O
. O

The O
bases O
of O
this O
comparison O
are O
reviewed O
and O
discussed O
. O

In O
RARE O
, O
RARE I-GENE
is O
encoded O
RARE O
a O
fusion O
protein O
with O
RARE I-GENE
, O
a O
RARE O
of O
the O
RARE I-GENE
superfamily I-GENE
. O

RARE O
counts O
and O
function O
RARE O
RARE O
RARE O
fibrinogen I-GENE
and O
RARE I-GENE
Willebrand I-GENE
factor I-GENE
( O
vWF I-GENE
) O
levels O
were O
determined O
in O
each O
sample O
. O

The O
manifestations O
often O
include O
a O
moderate O
thrombocytopenia O
and O
, O
less O
commonly O
, O
RARE O
. O

A O
NUM I-GENE
ALL_CAP I-GENE
reporter I-GENE
construct I-GENE
in O
which O
the O
methylation O
- O
susceptible O
RARE O
in O
the O
sense O
RARE O
were O
replaced O
by O
RARE O
displayed O
marked O
RARE O
of O
activity O
in O
a O
RARE O
chromatin O
- O
dependent O
manner O
. O

Non O
- O
RARE O
ALL_CAP O
rate O
had O
increased O
from O
NUM O
. O
9 O
in O
1997 O
to O
2 O
. O
8 O
in O
1998 O
. O

RARE O
is O
connected O
with O
attention O
, O
working O
memory O
and O
RARE O
. O

RARE O
had O
a O
protective O
effect O
with O
NUM O
. O
NUM O
less O
risk O
( O
NUM O
% O
ALL_CAP O
NUM O
. O
NUM O
- O
NUM O
. O
NUM O
). O

RARE O
the O
RARE O
. O

The O
aim O
of O
our O
study O
was O
to O
evaluate O
the O
level O
of O
oxidative O
stress O
in O
healthy O
controls O
( O
CTL O
) O
compared O
with O
ALL_CAP O
and O
HD O
patients O
before O
( O
pre O
- O
HD O
) O
and O
after O
( O
post O
- O
HD O
) O
the O
dialysis O
session O
, O
carried O
out O
on O
a O
high O
RARE O
RARE O
membrane O
NUM O
. O

RARE O
plasma O
parameters O
such O
RARE O
vitamin O
E O
, O
RARE O
and O
uric O
acid O
levels O
were O
also O
RARE O
. O

Only O
two O
of O
NUM O
RARE O
( O
7 O
. O
4 O
%) O
with O
definite O
ALL_CAP O
had O
been O
previously O
diagnosed O
and O
treated O
, O
and O
NUM O
. O
7 O
% O
of O
the O
previously O
RARE O
had O
IOP O
less O
than O
NUM O
mmHg O
. O

Taken O
together O
, O
they O
RARE O
the O
RARE O
RARE O
that O
women O
with O
ER I-GENE
RARE I-GENE
cancers O
may O
not O
benefit O
significantly O
from O
endocrine O
treatment O
if O
the O
tumors O
also O
RARE O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
. O

Promoter O
activity O
was O
dose O
- O
dependently O
inhibited O
by O
cotransfection O
with O
either O
ras I-GENE
or O
mos I-GENE
RARE I-GENE
, O
but O
oncogene O
inhibition O
was O
reversed O
and O
the O
overall O
activity O
increased O
when O
cells O
were O
treated O
with O
the O
MAP I-GENE
kinase I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
inhibitor O
PD98059 O
. O

Our O
results O
indicate O
that O
the O
RARE O
of O
NUM I-GENE
, O
a O
gene O
associated O
with O
early O
development O
and O
cell O
transformation O
, O
is O
RARE O
to O
ALL_CAP I-GENE
levels O
and O
may O
be O
regulated O
via O
multiple O
transcription O
factor O
complexes O
. O

ALL_CAP O
: O
RARE O
tissue O
PO2 O
and O
PCO2 O
RARE O
were O
measured O
directly O
in O
patients O
with O
RARE O
RARE O
and O
in O
healthy O
volunteers O
RARE O
RARE O
and O
RARE O
conditions O
. O

Because O
ALL_CAP I-GENE
- O
RARE O
Akt I-GENE
activation O
was O
completely O
inhibited O
in O
both O
cells O
by O
the O
same O
concentration O
of O
NUM O
, O
these O
findings O
indicate O
that O
the O
wortmannin O
sensitivity O
of O
both O
the O
IRS I-GENE
- I-GENE
1 I-GENE
- O
independent O
and O
- O
dependent O
ALL_CAP I-GENE
- O
RARE O
MAP I-GENE
kinase I-GENE
activation O
may O
reflect O
the O
activity O
of O
another O
wortmannin O
- O
RARE O
target O
( O
s O
) O
in O
addition O
to O
NUM I-GENE
in O
RARE O
of O
ALL_CAP I-GENE
- O
RARE O
MAP I-GENE
kinase I-GENE
activation O
in O
these O
cells O
. O

Insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
1 I-GENE
- O
RARE O
enhancement O
of O
growth I-GENE
hormone I-GENE
- O
RARE O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
activation O
. O

Functional O
magnetic O
resonance O
imaging O
( O
ALL_CAP O
) O
has O
been O
RARE O
used O
in O
studying O
human O
brain O
function O
given O
its O
non O
- O
invasive O
feature O
and O
good O
spatial O
resolution O
. O

After O
RARE O
of O
the O
aorta O
, O
there O
were O
also O
severe O
edema O
, O
local O
fibre O
necrosis O
, O
and O
adhesion O
of O
RARE O
, O
whereas O
muscle O
fibre O
areas O
became O
3 O
, O
NUM O
. O
18 O
micro O
NUM O
microm O
( O
2 O
) O
RARE O
type O
I O
and O
5 O
, O
NUM O
+/- O
1 O
, O
NUM O
microm O
( O
2 O
) O
RARE O
type O
II O
. O

The O
results O
indicate O
that O
the O
relationship O
between O
RARE O
and O
production O
is O
different O
RARE O
different O
stages O
in O
development O
. O

It O
was O
found O
that O
increase O
in O
the O
ALL_CAP O
level O
RARE O
the O
current O
values O
by O
2 O
- O
3 O
RARE O
of O
magnitude O
; O
RARE O
, O
the O
voltage O
values O
rise O
by O
about O
three O
times O
with O
drop O
in O
the O
ALL_CAP O
. O

On O
long O
- O
term O
follow O
- O
RARE O
, O
there O
was O
RARE O
significant O
difference O
in O
the O
incidence O
of O
RARE O
( O
1 O
per O
2 O
. O
1 O
RARE O
. O

Genomic O
libraries O
were O
stored O
RARE O
RARE O
cultures O
in O
a O
96 O
- O
RARE O
RARE O
, O
each O
RARE O
containing O
RARE O
NUM O
- O
600 O
colonies O
( O
12 O
plates O
RARE O
small O
library O
, O
four O
RARE O
medium O
- O
size O
library O
and O
four O
RARE O
large O
library O
). O

In O
several O
cell O
lines O
, O
ALL_CAP I-GENE
or O
its O
RARE O
RARE O
can O
be O
regulated O
by O
RARE I-GENE
( I-GENE
PI I-GENE
) I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
; O
protein I-GENE
kinases I-GENE
A I-GENE
, I-GENE
B I-GENE
, I-GENE
and I-GENE
C I-GENE
; O
heterotrimeric I-GENE
G I-GENE
- I-GENE
proteins I-GENE
; O
a O
PD98059 O
- O
RARE O
kinase O
or O
RARE O
; O
RARE O
RARE O
RARE O
by O
amino O
RARE O
. O

The O
tumor I-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
p53 I-GENE
is O
involved O
in O
maintaining O
genomic O
stability O
. O

RARE O
of O
p53 I-GENE
function O
by O
NUM I-GENE
resulted O
in O
an O
increase O
in O
the O
spontaneous O
mutation O
frequencies O
RARE O
the O
RARE O
RARE I-GENE
kinase I-GENE
( O
TK I-GENE
) O
locus O
but O
not O
RARE O
the O
RARE O
RARE I-GENE
RARE I-GENE
transferase I-GENE
( O
ALL_CAP I-GENE
) O
locus O
. O

RARE O
analysis O
of O
ALL_CAP O
mutants O
by O
RARE O
RARE O
indicated O
a O
mosaic O
of O
chromosomal O
RARE O
involving O
RARE O
NUM O
, O
in O
which O
partial O
RARE O
deletions O
, O
RARE O
, O
and O
multiple O
RARE O
appeared O
RARE O
in O
a O
single O
mutant O
. O

These O
results O
support O
a O
model O
in O
which O
p53 I-GENE
protein I-GENE
contributes O
to O
the O
RARE O
of O
genomic O
integrity O
through O
RARE O
repair O
. O

The O
importance O
of O
this O
new O
epidemiological O
profile O
of O
RARE O
in O
the O
State O
of O
RARE O
RARE O
on O
the O
fact O
that O
it O
can O
be O
related O
with O
the O
RARE O
human O
interference O
on O
the O
environment O
. O

In O
patients O
with O
type O
II O
tumors O
, O
the O
pattern O
of O
RARE O
spread O
was O
primarily O
directed O
toward O
the O
RARE O
, O
lesser O
RARE O
, O
and O
RARE O
RARE O
artery O
nodes O
; O
RARE O
offered O
RARE O
survival O
benefit O
over O
extended O
RARE O
in O
these O
patients O
. O

RESULTS O
: O
No O
significant O
RARE O
in O
vertebral O
artery O
flow O
was O
noted O
in O
the O
RARE O
- O
RARE O
Stage O
I O
injuries O
within O
the O
RARE O
range O
of O
cervical O
RARE O
. O

We O
screened O
a O
K562 O
cDNA O
library O
and O
identified O
novel O
transcripts O
, O
NUM I-GENE
and O
NUM I-GENE
. O

The O
human O
cDNA O
clone O
NUM O
( O
previously O
designated O
NUM O
) O
encodes O
a O
novel O
protein O
( O
NUM O
amino O
RARE O
in O
length O
; O
calculated O
RARE O
mass O
NUM O
, O
440 O
D O
) O
with O
possible O
ALL_CAP I-GENE
domains I-GENE
RARE O
its O
RARE O
terminus O
( O
amino O
acid O
residues O
NUM O
- O
NUM O
). O

RESULTS O
: O
Neither O
basal O
FSH I-GENE
level O
nor O
RARE O
FSH I-GENE
level O
alone O
were O
statistically O
significant O
predictors O
of O
ALL_CAP O
success O
; O
however O
, O
RARE O
patient O
with O
a O
day O
3 O
FSH I-GENE
level O
> O
11 O
. O
1 O
ALL_CAP O
/ O
ml O
or O
a O
RARE O
day O
10 O
FSH I-GENE
level O
> O
NUM O
. O
5 O
ALL_CAP O
/ O
ml O
RARE O
and O
carried O
a O
RARE O
. O

RARE I-GENE
hormone I-GENE
RARE O
of O
bone I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
gene O
transcription O
is O
RARE O
through O
a O
pituitary I-GENE
- I-GENE
specific I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
Pit I-GENE
- I-GENE
1 I-GENE
) O
motif O
in O
the O
rat I-GENE
ALL_CAP I-GENE
gene I-GENE
promoter I-GENE
. O

Recent O
target O
ALL_CAP O
RARE O
RARE O
by O
the O
RARE O
RARE O
from O
the O
RARE O
National O
Committee O
( O
ALL_CAP O
ALL_CAP O
) O
are O
based O
on O
the O
RARE O
that O
the O
intensity O
of O
treatment O
directly O
corresponds O
to O
the O
magnitude O
of O
pretreatment O
risk O
. O

RARE O
continuous O
community O
- O
based O
morbidity O
recording O
of O
RARE O
- O
like O
illness O
( O
ALL_CAP O
) O
with O
RARE O
sampling O
has O
consistently O
proved O
its O
value O
RARE O
one O
of O
the O
RARE O
indicators O
of O
circulating O
RARE O
activity O
. O

The O
RARE O
is O
a O
new O
RARE O
record O
RARE O
T O
. O
RARE O
. O

These O
include O
ALL_CAP O
repeats O
, O
a O
leucine O
RARE O
repeat O
RARE O
in O
charged O
residues O
, O
and O
a O
proline O
- O
rich O
SH3 I-GENE
- I-GENE
like I-GENE
and O
/ O
or O
ALL_CAP O
domain O
- O
binding O
site O
in O
the O
N O
- O
terminal O
domain O
, O
which O
is O
followed O
by O
a O
membrane O
core O
containing O
four O
putative O
transmembrane O
spans O
and O
three O
RARE O
RARE O
that O
are O
the O
most O
highly O
RARE O
structural O
elements O
. O

We O
show O
here O
that O
this O
difference O
is O
due O
to O
the O
presence O
of O
a O
NUM I-GENE
binding I-GENE
site I-GENE
in O
ALL_CAP I-GENE
. O

The O
article O
RARE O
with O
the O
RARE O
and O
correction O
of O
reversible O
ischemia O
of O
the O
intestine O
. O

RARE O
application O
of O
ALL_CAP O
- O
NUM O
, O
however O
, O
did O
not O
cause O
ALL_CAP O
reduction O
and O
luminal O
H O
+ O
RARE O
, O
but O
produced O
a O
marked O
RARE O
, O
resulting O
in O
RARE O
damage O
in O
the O
stomach O
of O
both O
normal O
and O
ALL_CAP O
- O
diabetic O
rats O
. O

Functional O
recognition O
of O
5 O
' O
RARE O
site O
by O
U4 I-GENE
/ O
U6 I-GENE
. O
NUM I-GENE
RARE O
- O
snRNP O
defines O
a O
novel O
ATP O
- O
dependent O
step O
in O
early O
spliceosome O
assembly O
. O

As O
control O
, O
the O
cells O
were O
transfected O
with O
DNA O
RARE O
containing O
vector O
NUM O
- O
C1 O
or O
NUM O
- O
C2 O
. O

The O
amino O
acid O
sequence O
of O
RARE I-GENE
- I-GENE
2 I-GENE
also O
contains O
a O
threonine O
RARE O
adjacent O
to O
the O
RARE O
- O
binding O
site O
that O
has O
been O
defined O
RARE O
a O
specific O
feature O
of O
RARE I-GENE
. O

In O
this O
regard O
, O
we O
have O
recently O
observed O
that O
a O
constitutively O
RARE O
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
) O
encoded O
by O
the O
Kaposi O
' O
s O
sarcoma O
- O
associated O
herpes O
virus O
( O
ALL_CAP O
RARE O
human O
herpes O
virus O
8 O
is O
RARE O
and O
stimulates O
angiogenesis O
by O
increasing O
the O
RARE O
of O
vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
( O
VEGF I-GENE
RARE O
which O
is O
a O
key O
RARE O
RARE O
and O
a O
critical O
mitogen O
RARE O
the O
development O
of O
Kaposi O
' O
s O
sarcoma O
. O

No O
specific O
subgroup O
of O
RARE O
RARE O
more O
from O
ALL_CAP O
, O
although O
a O
prospective O
study O
employing O
random O
assignment O
might O
be O
more O
successful O
in O
identifying O
such O
a O
group O
. O

In O
the O
RARE O
, O
NUM O
% O
of O
the O
sites O
are O
occupied O
, O
NUM O
% O
of O
the O
RARE O
are O
in O
the O
lowest O
energy O
magnetic O
RARE O
, O
and O
37 O
% O
are O
in O
the O
lowest O
NUM O
RARE O
state O
. O

RARE O
vertical O
and O
horizontal O
one O
and O
a O
RARE O
syndromes O
. O

As O
in O
the O
other O
three O
members O
whose O
gene O
RARE O
is O
altered O
RARE O
tumorigenesis O
, O
NUM I-GENE
RARE O
was O
found O
to O
be O
down O
- O
regulated O
in O
tumor O
brain O
tissues O
and O
in O
two O
brain O
RARE O
cell O
lines O
: O
ALL_CAP O
- O
87 O
ALL_CAP O
and O
NUM O
. O

RARE O
" O
the O
relation O
between O
sexual O
orientation O
and O
RARE O
size O
," O
by O
A O
. O

This O
slope O
was O
further O
significantly O
decreased O
RARE O
5 O
min O
ischemia O
RARE O
NUM O
. O
5 O
+/- O
8 O
. O
8 O
microm O
/ O
mmHg O
) O
but O
returned O
toward O
control O
values O
in O
short O
- O
term O
RARE O
myocardium O
RARE O
NUM O
min O
ischemia O
RARE O
NUM O
. O
2 O
+/- O
6 O
. O
6 O
microm O
/ O
mmHg O
). O

Whereas O
both O
MAP O
and O
ALL_CAP O
increase O
RARE O
ALL_CAP O
, O
the O
transition O
from O
ALL_CAP O
to O
ALL_CAP O
is O
characterized O
by O
a O
transient O
reduction O
in O
MAP O
but O
sustained O
elevation O
in O
ALL_CAP O
, O
facilitating O
separation O
of O
these O
factors O
in O
vivo O
. O

Analysis O
of O
RARE O
RARE O
RARE O
NUM O
, O
RARE O
RARE O
, O
gave O
a O
mean O
value O
of O
NUM O
. O
NUM O
+/- O
NUM O
. O
NUM O
mg O
vitamin O
K O
/ O
kg O
( O
K O
or O
NUM O
RARE O
( O
RARE O
= O
NUM O
) O
with O
a O
coefficient O
of O
variation O
of O
9 O
. O
NUM O
. O

We O
have O
recently O
discovered O
that O
ALL_CAP I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- I-GENE
beta I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
beta I-GENE
) O
induces O
gene O
transcription O
through O
a O
novel O
IFN I-GENE
response I-GENE
element I-GENE
called O
the O
gamma I-GENE
- I-GENE
IFN I-GENE
- I-GENE
activated I-GENE
transcriptional I-GENE
element I-GENE

Northern O
blot O
analysis O
demonstrated O
that O
the O
ALL_CAP I-GENE
gene I-GENE
has O
a O
ubiquitous O
pattern O
of O
RARE O
similar O
to O
that O
of O
the O
ALL_CAP I-GENE
gene I-GENE
. O

In O
the O
ALL_CAP O
patients O
the O
ALL_CAP O
: O
RARE O
ratios O
were O
RARE O
in O
the O
seizure O
focus O
, O
while O
in O
the O
ALL_CAP O
patients O
they O
were O
not O
always O
RARE O
in O
the O
seizure O
focus O
. O

The O
NUM I-GENE
residues I-GENE
making O
RARE O
the O
hydrophobic O
patch O
are O
very O
similar O
in O
all O
response O
RARE O
suggesting O
that O
the O
binding O
is O
RARE O
through O
the O
same O
residues O
in O
all O
RARE O
response O
regulator O
- O
kinase O
RARE O
. O

The O
RARE O
factors O
associated O
RARE O
serious O
illness O
, O
terminal O
RARE O
, O
and O
RARE O
RARE O
the O
RARE O
even O
more O
RARE O
compared O
with O
that O
of O
RARE O
pain O
. O

However O
, O
if O
the O
spatial O
resolution O
is O
not O
critical O
and O
interest O
is O
to O
compare O
a O
pathologic O
area O
with O
a O
contralateral O
ALL_CAP O
, O
then O
the O
acquisition O
of O
two O
single O
- O
RARE O
spectra O
may O
be O
preferred O
. O

Quantitative O
evaluation O
of O
RARE O
- O
optical O
parameters O
is O
necessary O
in O
order O
to O
RARE O
scanning O
near O
- O
field O
optical O
RARE O
( O
ALL_CAP O
) O
technology O
to O
the O
study O
of O
RARE O
on O
the O
RARE O
scale O
. O

We O
found O
that O
the O
amplitude O
of O
the O
cortical O
evoked O
potentials O
( O
amplitude O
of O
the O
N2 O
/ O
P2 O
peak O
) O
increased O
from O
5 O
. O
1 O
+/- O
NUM O
. O
7 O
ALL_CAP O
RARE O
5 O
ALL_CAP O
to O
16 O
. O
3 O
+/- O
1 O
. O
1 O
ALL_CAP O
RARE O
20 O
ALL_CAP O
. O

While O
mutations O
in O
K I-GENE
- I-GENE
RARE I-GENE
that O
RARE O
any O
one O
of O
these O
properties O
also O
blocked O
K I-GENE
- I-GENE
RARE I-GENE
- O
dependent O
nuclear O
RNA O
export O
, O
several O
K I-GENE
- I-GENE
RARE I-GENE
mutants I-GENE
were O
comparable O
to O
wild O
type O
when O
assayed O
RARE O
any O
of O
these O
individual O
activities O
yet O
RARE O
RARE O
RARE O
RNA O
export O
. O

LMP I-GENE
- I-GENE
1 I-GENE
is O
targeted O
to O
the O
plasma O
membrane O
, O
where O
it O
binds O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
, O
and O
ALL_CAP I-GENE
molecules I-GENE
to O
activate O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
RARE O
AP I-GENE
- I-GENE
1 I-GENE
RARE O
and O
STAT I-GENE
- O
dependent O
pathways O
RARE O
does O
CD40 I-GENE
. O

Identification O
of O
an O
enhancer O
and O
an O
RARE O
promoter O
in O
the O
RARE O
intron O
of O
the O
alpha I-GENE
- I-GENE
fetoprotein I-GENE
gene I-GENE
. O

RARE O
RARE O
RARE O
pathways O
, O
which O
may O
be O
involved O
in O
malignant O
transformation O
of O
RARE I-GENE
- I-GENE
NUM I-GENE
expressing O
NIH3T3 O
cells O
, O
we O
could O
demonstrate O
RARE I-GENE
- I-GENE
NUM I-GENE
dependent O
RARE O
of O
insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
2 I-GENE
( O
IRS I-GENE
- I-GENE
2 I-GENE
) O
with O
consecutive O
activation O
of O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
( O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
) O
and O
protein I-GENE
kinase I-GENE
B I-GENE
( O
PKB I-GENE
/ O
ALL_CAP I-GENE
). O

METHODS O
: O
In O
the O
current O
study O
the O
authors O
reported O
on O
ALL_CAP O
cases O
from O
a O
national O
retrospective O
search O
performed O
in O
18 O
Italian O
RARE O
RARE O
RARE O
RARE O
and O
RARE O
centers O
. O

RARE O
analysis O
showed O
that O
the O
ALL_CAP O
isolates O
from O
RARE O
constitute O
a O
group O
of O
viruses O
separated O
from O
those O
of O
Northern O
RARE O
. O

RARE O
the O
NUM I-GENE
- O
binding O
motif O
ALL_CAP O
in O
the O
NUM I-GENE
( O
NUM I-GENE
) O
subunit O
of O
ALL_CAP I-GENE
to O
ALL_CAP O
led O
to O
both O
RARE O
RARE O
in O
certain O
NUM I-GENE
NUM I-GENE
double O
mutants O
and O
a O
RARE O
ability O
of O
NUM I-GENE
to O
activate O
transcription O
when O
it O
is O
artificially O
RARE O
to O
a O
promoter O
. O

These O
results O
suggest O
that O
NUM I-GENE
is O
in O
fact O
required O
RARE O
pheromone O
response O
and O
that O
interaction O
with O
the O
ALL_CAP I-GENE
NUM I-GENE
is O
critical O
RARE O
that O
role O
. O

Deletion O
of O
an O
intergenic O
DNA O
- O
binding O
site O
RARE O
this O
complex O
from O
a O
human I-GENE
beta I-GENE
- I-GENE
globin I-GENE
locus I-GENE
construct I-GENE
results O
in O
delayed O
human I-GENE
gamma I-GENE
- I-GENE
to I-GENE
beta I-GENE
- I-GENE
globin I-GENE
switching O
in O
transgenic O
mice O
, O
suggesting O
that O
the O
ALL_CAP I-GENE
complex I-GENE
acts O
to O
facilitate O
the O
switch O
. O

The O
product O
of O
rat I-GENE
gene I-GENE
NUM I-GENE
was O
identified O
RARE O
an O
ErbB I-GENE
- I-GENE
2 I-GENE
- I-GENE
RARE I-GENE
protein I-GENE
in O
a O
two O
- O
RARE O
screen O
employing O
the O
ErbB I-GENE
- I-GENE
2 I-GENE
RARE I-GENE
and I-GENE
kinase I-GENE
domains I-GENE
RARE O
RARE O
. O

Studies O
suggest O
that O
the O
ALL_CAP O
without O
acid O
reflux O
may O
result O
in O
symptoms O
but O
unless O
acid O
reflux O
is O
present O
simultaneously O
, O
it O
does O
not O
cause O
RARE O
. O

RARE O
, O
however O
, O
appear O
to O
correlate O
poorly O
with O
RARE O
; O
hence O
, O
severe O
symptoms O
do O
not O
indicate O
there O
is O
greater O
RARE O
damage O
. O

OBJECTIVE O
: O
To O
evaluate O
the O
relationship O
between O
RARE O
flow O
in O
the O
tumor O
assessed O
by O
color O
Doppler O
ultrasound O
, O
RARE O
density O
, O
and O
vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
levels O
in O
endometrial O
carcinoma O
. O

These O
results O
demonstrate O
Ras I-GENE
- O
and O
Raf I-GENE
- O
independent O
ERK I-GENE
ALL_CAP O
activation O
maintains O
cell O
viability O
following O
heat O
shock O
. O

Three O
cDNAs O
encoding O
basic I-GENE
leucine I-GENE
zipper I-GENE
( I-GENE
ALL_CAP I-GENE
)- I-GENE
type I-GENE
ALL_CAP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
were O
isolated O
by O
using O
the O
yeast O
one O
- O
RARE O
RARE O
and O
were O
designated O
NUM I-GENE
, O
NUM I-GENE
, O
and O
NUM I-GENE
( O
ALL_CAP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
binding I-GENE
protein I-GENE
). O

Recombinant O
ALL_CAP I-GENE
- O
NUM I-GENE
displayed O
high O
binding O
to O
single O
- O
RARE O
DNA O
and O
RARE O
( O
A O
) O
RARE O
suggesting O
that O
this O
protein O
could O
play O
a O
role O
in O
mRNA O
RARE O
/ O
metabolism O
. O

The O
protein I-GENE
- I-GENE
tyrosine I-GENE
kinase I-GENE
RARE I-GENE
associates O
with O
RARE O
complexes O
containing O
insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
1 I-GENE
and O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

The O
RARE O
RARE O
of O
the O
RARE O
could O
not O
be O
explained O
by O
RARE O
abnormalities O
. O

In O
the O
ALL_CAP O
target O
area O
but O
not O
in O
the O
RARE O
area O
an O
improvement O
in O
regional O
RARE O
flow O
reserve O
occurs O
in O
RARE O
RARE O
with O
initially O
severely O
or O
moderately O
RARE O
stress O
perfusion O
. O

Analysis O
of O
intron O
/ O
RARE O
boundaries O
of O
the O
genomic O
ALL_CAP O
RARE O
demonstrate O
that O
RARE I-GENE
, O
RARE I-GENE
, O
and O
RARE I-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
result O
from O
RARE O
RARE O
of O
the O
same O
gene O
. O

It O
is O
now O
estimated O
that O
inactivation O
mutants O
of O
ALL_CAP I-GENE
exist O
in O
NUM O
% O
of O
all O
forms O
of O
solid O
tumors O
. O

We O
have O
demonstrated O
that O
the O
activity O
of O
ILK I-GENE
is O
constitutively O
elevated O
in O
ALL_CAP I-GENE
mutant I-GENE
cells O
. O

The O
growth I-GENE
factor I-GENE
receptor I-GENE
- I-GENE
RARE I-GENE
protein I-GENE
2 I-GENE
( O
Grb2 I-GENE
) O
RARE O
when O
complexed O
with O
Sos I-GENE
( O
RARE I-GENE
of I-GENE
RARE I-GENE
RARE O
the O
exchange O
factor O
of O
Ras I-GENE
, O
RARE O
the O
signal O
RARE O
by O
tyrosine I-GENE
kinase I-GENE
- I-GENE
activated I-GENE
receptor I-GENE
to O
Ras I-GENE
by O
RARE O
Sos I-GENE
to O
the O
membrane O
, O
allowing O
activation O
of O
Ras I-GENE
. O

Mutations O
in O
genes O
encoding O
NUM I-GENE
/ I-GENE
A I-GENE
subunits I-GENE
have O
been O
identified O
in O
several O
different O
human O
cancers O
and O
the O
PP2A I-GENE
inhibitor O
, O
termed O
RARE O
, O
is O
being O
tested O
RARE O
an O
RARE O
drug O
. O

For O
this O
purpose O
, O
a O
segment O
of O
RARE I-GENE
was O
amplified O
from O
RARE O
RARE O
ALL_CAP O
NUM O
- O
1 O
DNA O
via O
PCR O
using O
oligonucleotides O
RARE O
RARE O
regions O
. O

RARE O
learning O
RARE O
a O
pattern O
discrimination O
task O
. O

The O
detector O
has O
the O
advantage O
of O
finding O
both O
ST O
segment O
RARE O
and O
RARE O
ST O
- O
T O
complex O
changes O
thereby O
providing O
a O
RARE O
characterization O
of O
the O
RARE O
ischemic O
events O
. O

While O
this O
Saccharomyces O
cerevisiae O
NUM I-GENE
gene I-GENE
product I-GENE
is O
a O
RARE O
of O
a O
RARE O
complex O
associated O
with O
RNA I-GENE
polymerase I-GENE
II I-GENE
, O
various O
studies O
suggest O
the O
involvement O
of O
NUM I-GENE
in O
the O
alteration O
of O
RARE O
- O
order O
chromatin O
RARE O
. O

Primary O
adrenal O
hypersensitivity O
to O
ACTH I-GENE
drive O
in O
obesity O
has O
also O
been O
suggested O
. O

In O
addition O
, O
a O
RARE O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
binding I-GENE
site I-GENE
within O
the O
NUM I-GENE
promoter I-GENE
where O
C I-GENE
/ I-GENE
EBPbeta I-GENE
and O
C I-GENE
/ I-GENE
RARE I-GENE
could O
bind O
, O
was O
identified O
by O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
and O
reporter O
gene O
analysis O
. O

Src I-GENE
activation O
RARE O
by O
NUM I-GENE
was O
blocked O
by O
the O
NUM I-GENE
domain I-GENE
of O
Src I-GENE
and O
NUM I-GENE
, O
a O
specific O
inhibitor O
of O
Src I-GENE
. O

The O
use O
of O
the O
RARE I-GENE
RARE I-GENE
peptide I-GENE
, O
RARE O
and O
the O
RARE O
RARE O
ALL_CAP O
- O
ALL_CAP O
on O
oocytes O
expressing O
NUM I-GENE
or O
the O
RARE O
by O
ALL_CAP I-GENE
- I-GENE
ALL_CAP I-GENE
of O
oocytes O
expressing O
ALL_CAP I-GENE
- O
NUM I-GENE
RARE O
on O
the O
RARE I-GENE
binding I-GENE
site I-GENE
, O
prevented O
ALL_CAP O
and O
ERK2 I-GENE
RARE O
. O

Multiple O
transcription O
RARE O
sites O
were O
revealed O
by O
primer O
extension O
analysis O
of O
the O
mouse O
gene O
, O
and O
transfection O
constructs O
containing O
the O
prospective O
promoter O
generated O
transcriptional O
activity O
comparable O
to O
that O
of O
the O
SV40 I-GENE
promoter I-GENE
. O

From O
two O
inhibitor O
RARE O
, O
we O
have O
identified O
potent O
and O
selective O
RARE O
RARE O
RARE O
kinases O
from O
five O
distinct O
RARE O
. O

To O
determine O
whether O
interaction O
of O
RARE O
with O
the O
hormone O
- O
binding O
domain O
results O
in O
receptor O
activation O
, O
COS O
- O
1 O
cells O
were O
transiently O
cotransfected O
with O
the O
chimeric I-GENE
receptors I-GENE
ALL_CAP I-GENE
- I-GENE
ER I-GENE
, O
which O
contains O
the O
hormone O
- O
binding O
domain O
of O
RARE I-GENE
and O
the O
DNA O
- O
binding O
domain O
of O
the O
transcription O
factor O
GAL4 I-GENE
, O
and O
a O
GAL4 I-GENE
- O
responsive O
CAT I-GENE
reporter I-GENE
gene I-GENE
. O

By O
progressive O
5 O
'- O
deletion O
studies O
, O
we O
have O
identified O
a O
NUM O
- O
bp O
DNA O
fragment O
RARE O
NUM O
to O
- O
NUM O
, O
relative O
to O
the O
translation O
RARE O
site O
) O
RARE O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
ALL_CAP I-GENE
gene I-GENE
that O
is O
responsible O
RARE O
the O
RARE O
- O
RARE O
down O
- O
RARE O
of O
human I-GENE
ALL_CAP I-GENE
promoter I-GENE
activity O
. O

The O
mean O
day O
of O
diagnosis O
of O
RARE O
RARE O
was O
3 O
+/- O
2 O
days O
( O
range O
1 O
- O
11 O
days O
RARE O
and O
of O
RARE O
ALL_CAP O
21 O
+/- O
8 O
days O
( O
range O
2 O
- O
NUM O
days O
). O

The O
ALL_CAP I-GENE
protein O
kinase O
encoded O
by O
the O
RARE I-GENE
locus I-GENE
of O
Drosophila O
is O
required O
in O
both O
somatic O
and O
RARE O
cells O
and O
is O
RARE O
RARE O
both O
nuclear O
and O
cytoplasmic O
isoforms O
throughout O
development O
. O

We O
have O
RARE O
to O
cysteine O
, O
one O
RARE O
a O
time O
, O
21 O
consecutive O
residues O
in O
the O
fourth O
ALL_CAP O
( O
NUM O
). O

( O
1995 O
) O
ALL_CAP O
. O

ALL_CAP O
: O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
oxidative O
RARE O
of O
apolipoprotein I-GENE
B I-GENE
- I-GENE
containing I-GENE
RARE I-GENE
and O
antioxidant O
status O
in O
patients O
with O
acute O
coronary O
syndromes O
and O
chronic O
stable O
angina O
pectoris O
. O

In O
group O
B O
37 O
MBq O
in O
NUM O
ALL_CAP O
of O
99mTc O
- O
ALL_CAP O
RARE O
was O
additionally O
injected O
RARE O
18 O
h O
before O
surgery O
( O
3 O
- O
6 O
RARE O
injected O
RARE O
). O

Post O
- O
operative O
RARE O
outcome O
is O
related O
to O
pre O
- O
operative O
RARE O
status O
. O

We O
RARE O
a O
DNA O
fragment O
encoding O
the O
N O
- O
terminal O
part O
of O
a O
protein O
with O
significant O
RARE O
to O
members O
of O
the O
ALL_CAP I-GENE
family I-GENE
of I-GENE
transcriptional I-GENE
RARE I-GENE
( O
RARE I-GENE
). O

NUM I-GENE
is O
similar O
to O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
required O
RARE O
RARE O
and O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
required O
RARE O
RARE O
. O

RARE O
RARE O
studies O
using O
the O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
/ O
ALL_CAP I-GENE
fusion O
protein O
, O
cell O
fractionation O
and O
protease O
protection O
experiments O
localized O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
to O
the O
mitochondrial O
RARE O
. O

We O
could O
demonstrate O
the O
involvement O
of O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
PKA I-GENE
) O
in O
the O
RARE O
of O
NUM I-GENE
in O
RARE O
overexpressing O
this O
ALL_CAP I-GENE
RARE O
RARE O
RARE O
in O
mouse O
brain O
RARE O
membranes O
. O

RARE O
gene O
RARE O
analyses O
indicate O
that O
both O
ALL_CAP I-GENE
promoters I-GENE
show O
high O
levels O
of O
RARE O
in O
different O
hematopoietic O
cell O
lines O
. O

We O
find O
that O
NUM O
- O
NUM O
RARE O
has O
a O
pronounced O
effect O
on O
the O
line O
shape O
and O
RARE O
RARE O
rate O
of O
emission O
from O
the O
NUM O
state O
and O
that O
the O
extent O
of O
RARE O
depends O
RARE O
on O
the O
magnitude O
of O
RARE O
RARE O
. O

A O
RARE O
of O
NUM O
1 O
- O
day O
- O
old O
RARE O
RARE O
chicks O
were O
RARE O
in O
RARE O
treatment O
groups O
RARE O
RARE O
RARE O
of O
16 O
each O
; O
control O
, O
ALL_CAP O
( O
NUM O
g O
kg O
RARE O
1 O
) O
diet O
RARE O
50 O
parts O
per O
RARE O
( O
ppb O
) O
ALL_CAP I-GENE
, O
50 O
ppb O
ALL_CAP I-GENE
RARE O
ALL_CAP O
, O
NUM O
ppb O
ALL_CAP I-GENE
, O
NUM O
ppb O
ALL_CAP I-GENE
RARE O
ALL_CAP O
] O
RARE O
NUM O
days O
. O

The O
cost O
per O
test O
is O
less O
than O
those O
RARE O
ALL_CAP O
, O
ALL_CAP O
and O
NUM O
. O

Altogether O
these O
results O
suggest O
that O
, O
in O
NUM O
cells O
, O
RARE I-GENE
can O
stimulate O
in O
parallel O
PC I-GENE
- I-GENE
PLC I-GENE
and O
ALL_CAP I-GENE
, O
whose O
RARE O
products O
activate O
in O
RARE O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAP I-GENE
kinase I-GENE
) O
and O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
signalling O
respectively O
. O

RARE O
, O
we O
monitored O
RARE O
conditions O
and O
used O
time O
- O
activity O
RARE O
data O
of O
free O
- O
living O
birds O
and O
laboratory O
data O
on O
resting O
metabolic O
rate O
to O
construct O
time O
- O
activity O
laboratory O
( O
ALL_CAP O
) O
estimates O
of O
daily O
energy O
expenditure O
( O
ALL_CAP O
) O
and O
to O
RARE O
the O
RARE O
' O
energy O
RARE O
into O
RARE O
, O
activity O
and O
basal O
RARE O
. O

L O
/ O
H O
> O
NUM O
. O
NUM O
( O
RARE O
( O
2 O
RARE O
10 O
. O
8 O
; O
P O
RARE O
NUM O
. O
001 O
) O
and O
a O
restrictive O
filling O
pattern O
( O
RARE O
( O
2 O
RARE O
3 O
. O
6 O
; O
P O
RARE O
NUM O
. O
05 O
) O
were O
independent O
predictors O
of O
events O
. O

The O
high O
selectivity O
of O
RARE I-GENE
RARE O
this O
particular O
RARE O
form O
of O
receptor O
RARE O
their O
RARE O
binding O
and O
dissociation O
. O

When O
cotransfected O
in O
RARE O
with O
a O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
RARE O
vector O
, O
reporter O
gene O
RARE O
increased O
3 O
- O
RARE O
only O
in O
the O
wild O
- O
type O
constructs O
. O

Expression O
of O
a O
dominant I-GENE
negative I-GENE
NUM I-GENE
significantly O
reduces O
the O
level O
of O
luciferase I-GENE
reporter I-GENE
activity O
RARE O
by O
nodal O
treatment O
. O

RARE O
NUM I-GENE
( I-GENE
I I-GENE
) I-GENE
RARE I-GENE
mRNA I-GENE
showed O
RARE O
significant O
reduction O
when O
ALL_CAP O
or O
IR O
was O
RARE O
from O
the O
RARE O
- O
1 O
- O
RARE O
vector O
and O
a O
small O
( O
10 O
- O
20 O
%) O
but O
significant O
reduction O
when O
either O
RARE O
was O
RARE O
from O
the O
ALL_CAP O
. O
RARE O
vector O
. O

RARE O
NUM O
, O
NUM O
- O
NUM O
) O
that O
the O
amino O
acid O
sequences O
of O
peptide O
fragments O
obtained O
from O
a O
polypeptide O
found O
in O
a O
complex O
of O
proteins O
that O
alters O
chromatin O
RARE O
( O
ALL_CAP I-GENE
) O
are O
identical O
to O
portions O
of O
the O
deduced O
RARE O
reading O
frame O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
. O

RARE O
of O
plasma I-GENE
RARE I-GENE
were O
observed O
only O
in O
patients O
with O
delayed O
RARE O
emptying O
. O

5 O
( O
RARE O
RARE O
ALL_CAP O
) O
were O
determined O
using O
liquid O
chromatography O
/ O
mass O
spectrometry O
( O
ALL_CAP O
/ O
MS O
) O
with O
RARE O
RARE O
. O

RARE O
and O
NUM I-GENE
RARE I-GENE
fractions O
were O
severely O
decreased O
in O
the O
NUM I-GENE
mutant I-GENE
and O
NUM I-GENE
- O
depleted O
cells O
. O

They O
also O
negatively O
modulate O
the O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
catalytic O
activity O
but O
to O
different O
RARE O
, O
dependent O
on O
the O
unique O
N O
- O
terminal O
RARE O
of O
each O
isoform O
. O

RARE I-GENE
kinase I-GENE
II I-GENE
induces O
in O
vivo O
RARE O
of O
NUM I-GENE
and O
NUM I-GENE
and O
, O
to O
a O
lesser O
extent O
, O
NUM I-GENE
. O

The O
Drosophila I-GENE
melanogaster I-GENE
suppressor I-GENE
of I-GENE
RARE I-GENE
gene I-GENE
, O
RARE O
( O
s O
RARE O
encodes O
a O
novel O
, O
NUM O
- O
kDa O
nuclear O
RNA O
binding O
protein O
, O
ALL_CAP O
( O
S O
RARE O
that O
negatively O
regulates O
RNA O
accumulation O
from O
mutant O
alleles O
of O
other O
genes O
that O
have O
RARE O
insertions O
in O
the O
5 O
' O
RARE O
region O
. O

As O
a O
result O
, O
we O
have O
defined O
two O
RARE O
- O
rich O
motifs O
( O
NUM O
and O
NUM O
) O
that O
mediate O
the O
RNA O
binding O
activity O
of O
ALL_CAP O
( O
S O
). O

This O
interaction O
inhibits O
the O
histone I-GENE
RARE I-GENE
activity O
of O
p300 I-GENE
, O
resulting O
in O
RARE O
reduction O
of O
RARE O
histone I-GENE
acetylation O
and O
alteration O
of O
chromatin O
RARE O
. O

Recombinant I-GENE
NUM I-GENE
- I-GENE
ALL_CAP I-GENE
RARE O
on O
serine O
( O
RARE O
) O
and O
threonine O
( O
RARE O
) O
residues O
with O
p O
- O
RARE O
RARE O
. O

RARE O
RARE O
was O
used O
RARE O
cell O
RARE O
analysis O
. O

Further O
research O
is O
required O
to O
better O
measure O
treatment O
effects O
, O
modification O
of O
MS O
RARE O
history O
, O
and O
RARE O
RARE O
costs O
of O
IFN I-GENE
beta I-GENE
- I-GENE
NUM I-GENE
in O
ALL_CAP O
. O

RARE O
- O
effectiveness O
of O
RARE I-GENE
beta I-GENE
- I-GENE
NUM I-GENE
in O
RARE O
multiple O
sclerosis O
RARE O
progression O
. O

Both O
the O
RARE O
and O
AUC O
values O
were O
almost O
RARE O
with O
RARE O
the O
dose O
. O

RARE O
of O
Cdc2 I-GENE
in O
RARE O
yeast O
causes O
cells O
to O
undergo O
a O
lethal O
premature O
mitosis O
called O
RARE O
RARE O
. O

RARE O
. O

RARE O
differentiate O
in O
response O
to O
various O
extracellular O
stimuli O
. O

RARE I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta1 I-GENE
( O
TGF I-GENE
- I-GENE
beta1 I-GENE
) O
can O
act O
RARE O
a O
tumor O
suppressor O
or O
a O
tumor O
promoter O
depending O
on O
the O
characteristics O
of O
the O
malignant O
cell O
. O

RARE I-GENE
RARE I-GENE
peptide I-GENE
and O
pituitary I-GENE
adenylate I-GENE
cyclase I-GENE
- I-GENE
activating I-GENE
polypeptide I-GENE
inhibit O
nuclear I-GENE
factor I-GENE
- I-GENE
RARE I-GENE
B I-GENE
- I-GENE
dependent I-GENE
gene I-GENE
activation O
RARE O
multiple O
levels O
in O
the O
human O
monocytic O
cell O
line O
ALL_CAP O
- O
1 O
. O

NUM O
+ O
increased O
both O
the O
RARE O
binding O
and O
RARE O
activities O
of O
the O
mutant O
proteins O
. O

While O
RARE I-GENE
; I-GENE
ALL_CAP I-GENE
; I-GENE
1 I-GENE
and O
RARE I-GENE
; I-GENE
ALL_CAP I-GENE
; I-GENE
1 I-GENE
were O
RARE O
in O
all O
tissues O
examined O
, O
the O
transcripts O
accumulated O
abundantly O
in O
RARE O
cells O
. O

Moreover O
, O
an O
in O
vitro O
RARE O
- O
down O
assay O
showed O
that O
RARE I-GENE
; I-GENE
ALL_CAP I-GENE
; I-GENE
1 I-GENE
specifically O
RARE O
to O
NUM I-GENE
but O
not O
to O
other O
RARE I-GENE
RARE I-GENE
. O

In O
transient O
analysis O
using O
RARE O
RARE O
of O
tobacco O
leaf O
sections O
, O
a O
RARE O
of O
the O
ALL_CAP O
ALL_CAP O
( O
RARE O
acid O
- O
responsive O
element O
) O
RARE O
RARE O
by O
NUM I-GENE
and O
NUM I-GENE
- O
dependent O
response O
to O
ALL_CAP O
, O
whereas O
a O
RARE O
of O
the O
composite O
ALL_CAP O
/ O
G O
complex O
, O
containing O
ALL_CAP O
repeats O
and O
a O
G O
- O
box O
, O
RARE O
only O
ALL_CAP O
- O
independent O
RARE O
by O
NUM I-GENE
. O

The O
major O
neurological O
manifestations O
of O
brain O
injury O
in O
these O
babies O
are O
RARE O
motor O
deficits O
. O

RARE O
from O
RARE O
RARE O
were O
RARE O
in O
RARE O
water O
( O
1 O
RARE O
10 O
( O
6 O
) O
RARE O
/ O
mL O
) O
and O
used O
RARE O
RARE O
. O

Overexpression O
of O
NUM I-GENE
in O
a O
NUM O
RARE O
NUM I-GENE
/ I-GENE
NUM I-GENE
RARE I-GENE
S O
. O
pombe O
diploid O
resulted O
in O
a O
4 O
- O
RARE O
increase O
in O
specific O
ALL_CAP I-GENE
synthase I-GENE
activity O
. O

The O
ALL_CAP I-GENE
FGF I-GENE
- I-GENE
2 I-GENE
RARE O
- O
regulated O
the O
PKC I-GENE
epsilon I-GENE
levels O
by O
1 O
. O
6 O
- O
RARE O
; O
by O
contrast O
the O
ALL_CAP I-GENE
isoform I-GENE
down O
- O
regulated O
the O
level O
of O
this O
PKC I-GENE
RARE I-GENE
by O
about O
3 O
- O
RARE O
and O
increased O
the O
amount O
of O
PKC I-GENE
delta I-GENE
by O
1 O
. O
7 O
- O
RARE O
. O

RARE O
RARE O
and O
stomach O
diseases O
: O
from O
clinical O
point O
of O
view O

For O
this O
purpose O
, O
the O
RARE O
test O
, O
RARE O
and O
formalin O
RARE O
- O
pain O
in O
mice O
were O
used O
. O

2000 O
RARE O
of O
RARE O
RARE O
the O
use O
of O
hematopoietic I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
: O
evidence O
- O
based O
, O
clinical O
practice O
guidelines O
. O

RARE O
findings O
were O
chronic O
pancreatitis O
with O
RARE O
and O
RARE O
RARE O
, O
RARE O
and O
RARE O
RARE O
RARE O
, O
RARE O
RARE O
, O
RARE O
atrophy O
, O
candidiasis O
and O
bacterial O
RARE O
RARE O
. O

Taken O
together O
, O
our O
data O
indicate O
that O
multiple O
survival O
pathways O
are O
triggered O
via O
this O
receptor O
, O
whereas O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
/ O
Rel I-GENE
and O
PI I-GENE
- I-GENE
NUM I-GENE
are O
crucial O
RARE O
CD40 I-GENE
- O
RARE O
RARE O
. O

In O
vitro O
, O
RARE I-GENE
and O
RARE I-GENE
form O
DNA O
- O
independent O
RARE O
and O
exhibit O
cooperative O
binding O
to O
the O
NUM I-GENE
regulatory I-GENE
element I-GENE
, O
which O
contains O
two O
RARE I-GENE
recognition I-GENE
sites I-GENE
. O

We O
conclude O
from O
this O
study O
that O
RARE I-GENE
and O
RARE I-GENE
exhibit O
indistinguishable O
and O
independent O
transcriptional O
regulatory O
properties O
on O
the O
ALL_CAP I-GENE
promoter I-GENE
. O

METHODS O
ALL_CAP O
RESULTS O
: O
Studies O
were O
undertaken O
in O
9 O
isolated O
RARE O
RARE O
hearts O
, O
which O
demonstrated O
reverse O
use O
- O
dependent O
prolongation O
of O
cardiac O
RARE O
by O
NUM O
nmol O
/ O
L O
RARE O
. O

The O
N O
- O
terminal O
small O
segment O
of O
yeast I-GENE
NUM I-GENE
( O
NUM I-GENE
) O
binds O
to O
TBP I-GENE
and O
thereby O
inhibits O
TBP I-GENE
function O
. O

OBJECTIVE O
: O
To O
evaluate O
the O
overall O
performance O
of O
a O
new O
RARE O
wrist O
RARE O
pressure O
monitor O
( O
RARE O
RARE O
, O
RARE O
ALL_CAP O
, O
RARE O
, O
RARE O
) O
RARE O
defined O
by O
the O
ALL_CAP O
/ O
ALL_CAP O
NUM O
- O
1992 O
guidelines O
, O
and O
to O
analyze O
the O
data O
RARE O
the O
RARE O
selection O
of O
the O
algorithm O
that O
RARE O
the O
RARE O
pressure O
values O
from O
the O
RARE O
RARE O
pressure O
curves O
. O

Following O
the O
results O
of O
toxicological O
experiments O
in O
the O
target O
animals O
" O
RARE O
RARE O
RARE O
RARE O
RARE O
Animals O
" O
can O
be O
established O
. O

An O
increase O
in O
RARE O
RARE O
of O
RARE O
least O
two O
of O
the O
erbB I-GENE
receptors I-GENE
is O
RARE O
before O
the O
RARE O
RARE O
of O
RARE O
steroid O
RARE O
and O
is O
completed O
on O
the O
day O
of O
the O
RARE O
RARE O
RARE O
of O
RARE I-GENE
. O

RARE I-GENE
is O
required O
RARE O
two O
different O
pathways O
, O
the O
Wnt I-GENE
RARE O
and O
RARE O
polarity O
RARE O
in O
Drosophila O
. O

RARE O
- O
RARE O
growth O
and O
RARE O
dimensions O
following O
administration O
of O
the O
RARE O
agent O
vincristine O
to O
young O
rats O
. O

CONCLUSIONS O
: O
ALL_CAP O
RARE O
, O
like O
other O
inner O
ear O
malformations O
such O
RARE O
large O
vestibular O
RARE O
and O
X O
- O
RARE O
mixed O
RARE O
with O
RARE O
RARE O
, O
can O
be O
associated O
with O
ALL_CAP O
, O
ALL_CAP O
, O
or O
normal O
hearing O
. O

RARE O
to O
180 O
mg O
/ O
m2 O
was O
to O
be O
carried O
out O
if O
RARE O
RARE O
cell O
RARE O
count O
was O
> O
2 O
. O
NUM O
RARE O
10 O
( O
9 O
RARE O
RARE O
and O
platelet O
RARE O
count O
was O
> O
NUM O
RARE O
10 O
( O
9 O
RARE O
RARE O
. O

RARE O
formate O
was O
used O
RARE O
the O
solvent O
of O
RARE O
RARE O
RARE O
the O
RARE O
of O
microspheres O
with O
RARE O
bovine I-GENE
serum I-GENE
albumin I-GENE
( O
ALL_CAP I-GENE
). O

The O
small I-GENE
RARE I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
of O
the O
ALL_CAP I-GENE
subfamily I-GENE
are O
key O
regulatory O
elements O
of O
the O
machinery O
that O
controls O
membrane O
RARE O
in O
eukaryotic O
cells O
. O

Furthermore O
, O
RARE O
of O
methylation O
also O
greatly O
RARE O
the O
association O
of O
another O
yeast O
B O
- O
type O
subunit O
, O
NUM I-GENE
. O

Thus O
, O
methylation O
of O
NUM I-GENE
is O
important O
RARE O
formation O
of O
PP2A I-GENE
RARE I-GENE
and I-GENE
RARE I-GENE
complexes I-GENE
, O
and O
RARE O
, O
RARE O
PP2A I-GENE
function O
. O

The O
purpose O
of O
this O
study O
was O
to O
analyze O
the O
temporal O
characteristics O
and O
the O
spatial O
mapping O
of O
the O
independent O
RARE O
identified O
by O
ALL_CAP O
when O
the O
subject O
RARE O
a O
finger O
- O
RARE O
task O
. O

The O
authors O
present O
the O
only O
two O
studies O
that O
have O
proved O
successful O
in O
RARE O
RARE O
models O
of O
RARE O
using O
gene O
therapy O
, O
and O
propose O
an O
RARE O
of O
several O
strategies O
RARE O
the O
development O
of O
gene O
therapy O
in O
RARE O
treatment O
in O
the O
future O
. O

Together O
, O
these O
results O
indicate O
that O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
induces O
VEGF I-GENE
gene I-GENE
RARE O
RARE O
both O
transcriptional O
and O
post O
- O
transcriptional O
levels O
, O
and O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
RARE O
p38 I-GENE
ALL_CAP O
and O
JNK I-GENE
RARE O
, O
which O
in O
RARE O
stimulate O
the O
transcription O
of O
the O
VEGF I-GENE
gene I-GENE
through O
NUM I-GENE
- I-GENE
binding I-GENE
sites I-GENE
. O

Binding O
of O
ALL_CAP I-GENE
to O
RNA O
in O
the O
presence O
of O
alpha O
or O
N O
involves O
an O
amino I-GENE
- I-GENE
terminal I-GENE
S1 I-GENE
homology I-GENE
region I-GENE
that O
is O
otherwise O
inactive O
in O
full I-GENE
- I-GENE
length I-GENE
ALL_CAP I-GENE
. O

The O
subjects O
were O
diagnosed O
on O
the O
basis O
of O
ALL_CAP O
- O
IV O
pathological O
RARE O
criteria O
and O
completed O
the O
RARE O
RARE O
of O
RARE O
RARE O
RARE O
RARE O
( O
ALL_CAP O
). O

RARE O
( O
193 O
) O
and O
Arg O
( O
NUM O
RARE O
RARE O
RARE O
the O
ALL_CAP O
- O
terminal O
end O
of O
HD I-GENE
, O
are O
essential O
RARE O
RARE O
. O

RARE O
of O
RARE O
Ca O
( O
2 O
+) O
levels O
are O
also O
involved O
because O
treatment O
with O
receptor O
- O
associated O
protein O
, O
nifedipine O
, O
NUM O
, O
removal O
of O
Ca O
( O
2 O
+) O
from O
the O
medium O
and O
RARE O
all O
RARE O
to O
inhibit O
RARE O
elevation O
and O
RARE O
the O
activation O
of O
CREB I-GENE
. O

The O
present O
study O
shows O
that O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
- O
dependent O
p38 I-GENE
kinase I-GENE
activation O
regulates O
Akt I-GENE
RARE O
and O
activity O
in O
human O
neutrophils O
. O

When O
ALL_CAP O
was O
taken O
RARE O
the O
reference O
, O
ALL_CAP O
/ O
A O
Z O
scores O
showed O
consistent O
positive O
RARE O
, O
from O
birth O
in O
girls O
and O
1 O
mo O
in O
boys O
. O

These O
probable O
RARE O
sequences O
are O
closely O
related O
to O
those O
of O
other O
known O
T O
- O
regions O
and O
define O
a O
second O
T O
- O
region O
of O
NUM O
, O
called O
T O
- O
right O
( O
TR O
RARE O
that O
confers O
production O
of O
the O
RARE O
. O

Using O
RARE O
recombinant I-GENE
HMG I-GENE
I I-GENE
, O
we O
have O
identified O
several O
high O
- O
affinity O
binding O
sites O
which O
overlap O
important O
transcription O
factor O
binding O
sites O
. O

RARE I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
protein I-GENE
I I-GENE
can O
modulate O
binding O
of O
transcription O
factors O
to O
the O
NUM I-GENE
region I-GENE
of O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
RARE I-GENE
promoter I-GENE
. O

Another O
cis O
- O
acting O
element O
, O
RARE O
RARE O
suppressor O
1 O
( O
NUM O
RARE O
represses O
use O
of O
the O
nt O
NUM O
3 O
' O
RARE O
site O
. O

RARE O
does O
not O
correlate O
with O
the O
actual O
or O
mean O
RARE O
pressure O
reading O
nor O
with O
RARE O
of O
hypertension O
according O
to O
the O
ALL_CAP O
classification O
. O

5 O
'- O
RACE O
analysis O
suggested O
a O
single O
transcription O
initiation O
site O
NUM O
bp O
upstream O
from O
the O
translational O
RARE O
site O
. O

Thus O
, O
RARE O
treatment O
of O
nuclear O
extracts O
strongly O
reduces O
the O
binding O
of O
ALL_CAP I-GENE
proteins I-GENE
, O
and O
the O
addition O
of O
RARE O
concentrations O
of O
RARE O
to O
nuclear O
extracts O
from O
TG I-GENE
- O
treated O
cells O
restores O
ALL_CAP I-GENE
- I-GENE
DNA I-GENE
binding O
to O
levels O
in O
extracts O
from O
untreated O
cells O
. O

NUM I-GENE
enhances O
Lyn I-GENE
and O
RARE I-GENE
ubiquitination O
in O
vivo O
in O
a O
fashion O
that O
depends O
on O
the O
activity O
of O
NUM I-GENE
family O
members O
and O
correlates O
with O
RARE O
of O
the O
Lyn I-GENE
tyrosine I-GENE
kinase I-GENE
. O

Further O
, O
RARE I-GENE
- O
RARE O
apoptosis O
was O
effectively O
prevented O
by O
ectopic O
RARE O
of O
the O
p300 I-GENE
RARE I-GENE
. O

Our O
results O
, O
however O
, O
were O
obtained O
RARE O
Z O
itself O
and O
not O
RARE O
RARE O
Z O
]. O

RARE O
' O
s O
RARE O
test O
or O
RARE O
' O
s O
NUM O
test O
were O
used O
RARE O
statistical O
analysis O
. O

RESULTS O
: O
In O
the O
RARE O
group O
, O
serum O
NUM I-GENE
concentrations O
were O
markedly O
increased O
after O
ALL_CAP O
, O
and O
a O
significant O
difference O
between O
the O
RARE O
group O
and O
the O
RARE O
group O
was O
observed O
8 O
days O
following O
ALL_CAP O
( O
p O
< O
NUM O
. O
01 O
). O

RARE O
is O
a O
test O
that O
could O
potentially O
correlate O
with O
the O
degree O
of O
RARE O
produced O
by O
low O
RARE O
RARE O
RARE O
. O

RARE O
RARE O
of O
the O
RARE I-GENE
RARE I-GENE
- I-GENE
activated I-GENE
receptor I-GENE
alpha I-GENE
( O
PPARalpha I-GENE
) O
RARE O
brown O
fat O
from O
RARE O
, O
and O
is O
related O
to O
its O
high O
capacity O
of O
RARE O
oxidation O
. O

This O
- O
NUM O
/- O
NUM O
element O
RARE O
PPARalpha I-GENE
and O
PPARgamma I-GENE
from O
brown O
fat O
nuclei O
. O

These O
results O
provide O
direct O
evidence O
RARE O
differential O
RARE O
to O
endonuclease O
- O
RARE O
mRNA O
RARE O
resulting O
from O
the O
differential O
affinity O
of O
a O
RNA O
- O
binding O
protein O
RARE O
cis O
- O
acting O
stability O
RARE O
. O

RESULTS O
: O
Twenty O
- O
two O
( O
NUM O
%) O
patients O
had O
ALL_CAP O
before O
( O
group O
A O
) O
and O
NUM O
( O
NUM O
%) O
developed O
ALL_CAP O
after O
RARE O
eradication O
( O
group O
B O
). O

Response O
was O
extremely O
poor O
in O
African O
RARE O
and O
those O
with O
HCV O
RARE O
1 O
. O

RARE O
causes O
RARE O
ulcers O
RARE O
by O
RARE O
RARE I-GENE
RARE I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
activity O
and O
RARE O
RARE O
. O

A O
RARE O
of O
NUM O
RARE O
were O
randomly O
RARE O
RARE O
sequencing O
of O
one O
end O
. O

Expression O
of O
a O
RARE O
protein O
containing O
the O
cytoplasmic O
C O
- O
terminal O
RARE O
of O
ALL_CAP I-GENE
fused O
to O
RARE I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
) O
also O
RARE O
with O
RARE I-GENE
RARE O
. O

CONCLUSIONS O
: O
The O
surgical O
or O
RARE O
treatment O
of O
ALL_CAP O
has O
provided O
a O
good O
RARE O
control O
( O
NUM O
%) O
and O
NUM O
% O
10 O
- O
year O
survival O
in O
a O
series O
of O
patients O
treated O
RARE O
the O
RARE O
RARE O
of O
a O
RARE O
hospital O
in O
RARE O
, O
RARE O
. O

RESULTS O
: O
RARE O
RARE O
were O
divided O
into O
two O
groups O
according O
to O
their O
ALL_CAP O
results O
: O
high O
risk O
( O
with O
ALL_CAP O
abnormalities O
) O
and O
low O
risk O
( O
with O
normal O
ALL_CAP O
result O
). O

The O
gene O
is O
separated O
into O
four O
exons O
by O
three O
short O
RARE O
, O
and O
the O
RARE O
reading O
frame O
consists O
of O
NUM O
RARE O
RARE O
( O
bp O
) O
capable O
of O
encoding O
a O
polypeptide O
of O
NUM O
amino O
acid O
residues O
. O

Like O
the O
p190 I-GENE
- I-GENE
B I-GENE
RARE O
, O
the O
RARE O
RARE O
of O
p190 I-GENE
- I-GENE
A I-GENE
is O
extremely O
large O
( O
3 O
. O
7 O
kb O
in O
length O
RARE O
encoding O
both O
the O
GTPase I-GENE
and O
RARE O
domains O
( O
residues O
1 O
- O
NUM O
RARE O
but O
not O
the O
remaining O
ALL_CAP I-GENE
domain I-GENE
, O
suggesting O
a O
high O
conservation O
of O
genomic O
RARE O
between O
two O
p190 I-GENE
genes I-GENE
. O

The O
RARE O
human I-GENE
RARE I-GENE
- I-GENE
1 I-GENE
( O
NUM I-GENE
) O
gene O
is O
contained O
in O
eight O
ALL_CAP O
RARE O
representing O
part O
of O
the O
chromosomal O
locus O
NUM O
. O

The O
RARE O
RARE O
and O
multiple O
localized O
RARE O
are O
characteristic O
of O
NF1 I-GENE
. O

In O
RARE O
RARE O
, O
all O
patients O
who O
received O
RARE O
before O
being O
tested O
RARE O
hepatitis O
C O
are O
RARE O
to O
undergo O
testing O
. O

The O
proposed O
algorithm O
consists O
of O
several O
steps O
. O

It O
contained O
RARE O
RARE O
amino O
RARE O
of O
ALL_CAP O
; O
this O
short O
stretch O
of O
RARE O
sequence O
was O
found O
between O
Gln O
( O
NUM O
) O
and O
RARE O
( O
NUM O
) O
within O
the O
ALL_CAP I-GENE
( O
NUM I-GENE
- I-GENE
9 I-GENE
, O
RARE I-GENE
- I-GENE
of I-GENE
- I-GENE
RARE I-GENE
, O
RARE I-GENE
) O
RARE O
domain O
( O
ALL_CAP O
) O
of O
ALL_CAP I-GENE
. O

NUM I-GENE
has O
a O
weak O
glycosylase I-GENE
activity O
on O
the O
RARE O
RARE O
3 O
, O
N O
( O
4 O
)- O
RARE O
, O
a O
metabolite O
of O
vinyl O
RARE O
and O
ethyl O
RARE O
. O

There O
were O
RARE O
instances O
of O
major O
flap O
necrosis O
although O
two O
RARE O
showed O
RARE O
ischaemia O
. O

These O
results O
suggest O
that O
NUM I-GENE
is O
a O
novel O
cytoplasmic I-GENE
GTPase I-GENE
involved O
in O
nuclear O
RARE O
of O
ALL_CAP I-GENE
. O

One O
of O
these O
factors O
, O
IRF I-GENE
- I-GENE
2 I-GENE
, O
was O
initially O
RARE O
RARE O
an O
antagonistic O
RARE O
to O
IRF I-GENE
- I-GENE
1 I-GENE
with O
RARE O
RARE O
. O

Among O
the O
RARE O
RARE O
, O
8 O
. O
8 O
% O
match O
sequences O
of O
proteins O
found O
only O
in O
Bacillus O
subtilis O
and O
NUM O
. O
7 O
% O
are O
widely O
RARE O
in O
comparison O
with O
the O
proteins O
of O
various O
organisms O
, O
including O
B O
. O
subtilis O
. O

RARE O
- O
RARE O
ALL_CAP O
administered O
i O
. O
v O
. O
showed O
a O
prolonged O
circulation O
time O
compared O
to O
the O
i O
. O
v O
. O
administered O
RARE O
solution O
. O

RARE O
. O

RARE I-GENE
RARE I-GENE
transferase I-GENE
- O
RARE O
RARE O
end O
labeling O
assays O
revealed O
that O
hormonal O
activation O
of O
the O
NUM I-GENE
RARE I-GENE
RARE O
extensive O
apoptosis O
that O
correlated O
with O
down O
- O
RARE O
of O
ALL_CAP I-GENE
- I-GENE
X I-GENE
( I-GENE
L I-GENE
) I-GENE
RARE O
. O

VEGF I-GENE
promoter I-GENE
activity O
in O
transient O
transfections O
was O
decreased O
by O
either O
pharmacological O
or O
genetic O
inhibition O
of O
EGFR I-GENE
, O
Ras I-GENE
, O
or O
RARE I-GENE
3 I-GENE
'- I-GENE
kinase I-GENE
RARE O
PI O
( O
3 O
) O
kinase O
]. O

RARE I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
transcriptionally O
RARE O
- O
regulates O
vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
RARE O
in O
human O
RARE O
cells O
via O
a O
RARE O
involving O
RARE I-GENE
3 I-GENE
'- I-GENE
kinase I-GENE
and O
distinct O
from O
that O
RARE O
by O
RARE O
. O

Thus O
, O
ALL_CAP O
is O
closely O
related O
to O
RARE O
of O
the O
genus O
RARE O
in O
the O
family O
RARE O
, O
and O
we O
therefore O
propose O
to O
RARE O
this O
virus O
RARE O
RARE O
RARE O
( O
ALL_CAP O
). O

RARE I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
1 I-GENE
( O
NUM I-GENE
RARE O
also O
called O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
RARE O
becomes O
activated O
in O
vivo O
in O
response O
to O
pro O
- O
inflammatory O
RARE O
or O
cellular O
stresses O
. O

RARE O
activation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
phosphatase I-GENE
- I-GENE
1 I-GENE
by O
binding O
to O
p38 I-GENE
MAP I-GENE
kinase I-GENE
: O
critical O
role O
of O
the O
p38 I-GENE
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
in O
its O
negative O
RARE O
. O

Thus O
, O
the O
class I-GENE
C I-GENE
- O
RARE I-GENE
complex O
directs O
multiple O
reactions O
RARE O
the O
RARE O
and O
fusion O
of O
vesicles O
with O
the O
RARE O
, O
each O
of O
which O
contributes O
to O
the O
overall O
RARE O
and O
efficiency O
of O
this O
RARE O
process O
. O

Combined O
intravenous O
and O
RARE O
- O
arterial O
recombinant O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
in O
acute O
ischemic O
stroke O
. O

To O
begin O
to O
understand O
this O
role O
, O
we O
overexpressed O
ATF I-GENE
- I-GENE
2 I-GENE
in O
a O
human O
RARE O
cell O
line O
. O

RARE O
RARE O
via O
modulation O
of O
RARE O
after O
selective O
inhibition O
of O
protein I-GENE
phosphatase I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
1 I-GENE
and O
/ O
or O
PP2A I-GENE
appears O
to O
play O
a O
role O
in O
RARE O
acid O
( O
ALL_CAP O
)- O
RARE O
effects O
. O

RARE I-GENE
RARE I-GENE
A I-GENE
in O
the O
treatment O
of O
RARE O
RARE O
foot O
drop O
RARE O
clinical O
and O
RARE O
outcomes O
. O

RARE O
A O
is O
RARE O
RARE O
7 O
kb O
5 O
' O
to O
the O
ALL_CAP I-GENE
translation I-GENE
RARE I-GENE
site I-GENE
. O

ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
is O
a O
RARE O
- O
RARE O
transcription O
factor O
known O
to O
be O
activated O
by O
oxidative O
stress O
RARE O
RARE O
RARE O
chemical O
and O
biological O
RARE O
. O

RARE O
risk O
factors O
and O
antihypertensive O
treatment O
. O

RARE O
to O
RARE O
RARE O
RARE O
a O
compliance O
review O
: O
10 O
common O
RARE O
made O
by O
RARE O
. O

CONCLUSIONS O
: O
ALL_CAP O
technology O
allows O
RARE O
invasive O
evaluation O
of O
RARE O
RARE O
function O
and O
permits O
assessment O
of O
microvascular O
ALL_CAP O
distribution O
in O
different O
RARE O
RARE O
. O

These O
two O
RARE O
used O
the O
same O
V O
( O
H O
) O
and O
ALL_CAP O
( O
H O
) O
gene O
RARE O
, O
but O
different O
D O
, O
RARE O
, O
and O
RARE O
genes O
. O

ALL_CAP O
experiments O
were O
carried O
out O
in O
RARE O
- O
scale O
RARE O
( O
RARE O
with O
CO2 O
and O
volatile O
organic O
RARE O
) O
containing O
a O
mixture O
of O
RARE O
materials O
and O
a O
radiolabeled O
RARE O
. O

Characterization O
of O
a O
Xenopus I-GENE
RARE I-GENE
ALL_CAP I-GENE
RARE I-GENE
receptor I-GENE
4 I-GENE
: O
implications O
RARE O
hematopoietic O
cell O
development O
in O
the O
RARE O
RARE O
. O

Patients O
had O
to O
have O
adequate O
liver O
, O
RARE O
, O
and O
marrow O
functions O
. O

Inhibition O
of O
NUM I-GENE
translation O
was O
selective O
, O
with O
RARE O
effect O
on O
RARE O
cellular O
translation O
or O
translation O
of O
ALL_CAP O
NUM I-GENE
- O
encoded O
replication I-GENE
factor I-GENE
NUM I-GENE
, O
and O
was O
independent O
of O
NUM I-GENE
, O
a O
cellular O
antagonist O
of O
NUM I-GENE
function O
in O
translation O
. O

RARE O
: O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
- I-GENE
associated I-GENE
substrate I-GENE
; O
ALL_CAP I-GENE
, O
RARE I-GENE
- I-GENE
homology I-GENE
domain I-GENE
; O
ALL_CAP I-GENE
, O
C I-GENE
- I-GENE
terminal I-GENE
SRC I-GENE
kinase I-GENE
; O
NUM I-GENE
, O
RARE I-GENE
NUM I-GENE
protein I-GENE
; O
FAK I-GENE
, O
RARE I-GENE
adhesion I-GENE
kinase I-GENE
; O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
RARE I-GENE
; O
ALL_CAP I-GENE
, O
heterotrimeric I-GENE
- I-GENE
G I-GENE
- I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptor I-GENE
; O
ALL_CAP I-GENE
, O
G I-GENE
- I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
- I-GENE
receptor I-GENE
kinase I-GENE
; O
ALL_CAP I-GENE
, O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
ERK I-GENE
, O
p38 I-GENE
, O
JNK I-GENE
); O
ALL_CAP I-GENE
, O
p21 I-GENE
- I-GENE
activated I-GENE
kinase I-GENE
; O
ALL_CAP I-GENE
, O
paxillin I-GENE
- I-GENE
binding I-GENE
RARE I-GENE
; O
ALL_CAP I-GENE
, O
ALL_CAP I-GENE
- I-GENE
RARE I-GENE
exchange I-GENE
factor I-GENE
; O
ALL_CAP I-GENE
, O
paxillin I-GENE
kinase I-GENE
RARE I-GENE
; O
NUM I-GENE
, O
RARE I-GENE
of I-GENE
Rac I-GENE
; O
ALL_CAP O
, O
RARE O
; O
PT O
, O
RARE O
; O
ALL_CAP O
, O
RARE O
; O
ALL_CAP I-GENE
, O
growth I-GENE
factor I-GENE
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
; O
ALL_CAP I-GENE
, O
SRC I-GENE
- I-GENE
homology I-GENE
domain I-GENE
. O

In O
NUM O
RARE O
- O
dependent O
, O
ALL_CAP O
, O
and O
actively O
RARE O
patients O
, O
we O
found O
that O
the O
difference O
ALL_CAP O
( O
i O
RARE O
RARE O
- O
RARE O
, O
RARE O
RARE O
( O
mean O
+/- O
SD O
, O
5 O
. O
7 O
+/- O
1 O
. O
9 O
cm O
H O
( O
2 O
) O
O O
) O
was O
quite O
similar O
to O
ALL_CAP O
( O
i O
RARE O
RARE O
RARE O
( O
5 O
. O
3 O
+/- O
1 O
. O
9 O
cm O
H O
( O
2 O
) O
O O
). O

Of O
NUM O
RARE O
subjects O
, O
82 O
received O
RARE O
ALL_CAP O
RARE O
a O
dose O
of O
NUM O
mg O
twice O
weekly O
RARE O
6 O
mo O
( O
RARE O
A O
RARE O
NUM O
received O
RARE O
ALL_CAP O
NUM O
mg O
twice O
weekly O
RARE O
6 O
mo O
( O
RARE O
B O
RARE O
and O
53 O
received O
RARE O
ALL_CAP O
NUM O
mg O
daily O
RARE O
6 O
mo O
( O
RARE O
C O
). O

There O
were O
122 O
cases O
of O
tuberculosis O
over O
an O
average O
10 O
. O
3 O
yr O
of O
follow O
- O
RARE O
( O
crude O
annual O
incidence O
, O
NUM O
. O
2 O
/ O
NUM O
, O
NUM O
). O

These O
results O
suggested O
that O
NUM I-GENE
RARE O
NUM I-GENE
to O
the O
nucleus O
through O
BTB I-GENE
domain O
- O
RARE O
interaction O
. O

The O
NUM I-GENE
/ O
NUM I-GENE
and O
the O
NUM I-GENE
+ I-GENE
gene I-GENE
products I-GENE
transactivated O
the O
HIV I-GENE
LTR I-GENE
. O

Transcription O
of O
the O
RARE O
EBNA I-GENE
genes I-GENE
, O
which O
are O
RARE O
in O
ALL_CAP O
- O
RARE O
RARE O
B O
cells O
, O
RARE O
from O
one O
of O
two O
promoters O
, O
Cp I-GENE
and O
RARE I-GENE
, O
RARE O
near O
the O
RARE O
end O
of O
the O
viral O
genome O
. O

The O
RARE I-GENE
- I-GENE
2 I-GENE
sequences I-GENE
possess O
RARE O
to O
the O
ALL_CAP I-GENE
domain I-GENE
of O
RARE I-GENE
- O
NUM I-GENE
, O
a O
RARE I-GENE
non I-GENE
- I-GENE
LTR I-GENE
RARE I-GENE
. O

This O
dynamic O
response O
strongly O
suggests O
that O
the O
p53 I-GENE
and O
RARE I-GENE
tumor O
suppressor O
pathways O
are O
RARE O
in O
HeLa O
cells O
and O
that O
repression O
of O
HPV I-GENE
NUM I-GENE
and O
E7 I-GENE
RARE O
these O
pathways O
in O
an O
RARE O
fashion O
to O
RARE O
growth O
RARE O
signals O
to O
the O
cells O
. O

Thus O
, O
blocks O
in O
the O
RARE I-GENE
- O
specific O
RARE O
of O
retinoid O
- O
RARE O
differentiation O
may O
be O
RARE O
RARE O
retinoid O
induction O
of O
ALL_CAP I-GENE
- I-GENE
beta I-GENE
RARE O
. O

Is O
more O
better O
? O
RARE O
dose O
levels O
of O
ACE I-GENE
RARE O
in O
chronic O
RARE O
failure O
. O

To O
test O
whether O
or O
not O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
also O
binds O
to O
the O
ALL_CAP I-GENE
, O
we O
RARE O
human I-GENE
ALL_CAP I-GENE
- I-GENE
3 I-GENE
by O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
from O
human O
skeletal O
muscle O
mRNA O
. O

A O
protein O
RARE O
the O
NUM I-GENE
and O
ALL_CAP O
finger O
domains O
has O
RARE O
activity O
, O
but O
a O
chimeric O
protein O
with O
the O
NUM I-GENE
and O
ALL_CAP O
finger O
domains O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
replaced O
by O
the O
equivalent O
domains O
of O
c I-GENE
- I-GENE
Cbl I-GENE
has O
activity O
. O

To O
evaluate O
the O
effects O
of O
ALL_CAP O
on O
those O
factors O
in O
end O
- O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
patients O
, O
we O
evaluated O
the O
changes O
of O
RARE O
profile O
, O
coagulation O
and O
RARE O
markers O
, O
and O
plasma O
RARE O
levels O
after O
treatment O
. O

There O
was O
a O
weak O
significant O
correlation O
between O
TGF I-GENE
beta I-GENE
1 I-GENE
levels O
and O
normal O
cell O
RARE O
( O
lymphocyte O
NUM O
). O

Acute O
feasibility O
and O
safety O
of O
a O
smoking O
reduction O
strategy O
RARE O
smokers O
with O
schizophrenia O
. O

RARE O
RARE O
RARE O
RARE O
of O
proteins O
critical O
RARE O
cell O
RARE O
control O
RARE O
a O
role O
of O
the O
proteasome O
in O
maintaining O
cell O
RARE O
and O
cell O
survival O
. O

The O
RARE O
nucleotide O
was O
RARE O
out O
to O
allow O
RARE O
of O
this O
ALL_CAP O
. O
G O
RARE O
on O
the O
adjacent O
helical O
region O
. O

Functional O
analysis O
of O
the O
mutant I-GENE
RARE I-GENE
in O
NUM O
( O
RARE I-GENE
RARE O
cells O
showed O
RARE O
of O
abnormal O
RARE O
RARE O
of O
RARE I-GENE
positive O
material O
RARE O
throughout O
the O
cytoplasm O
. O

Patients O
with O
lesions O
affecting O
the O
ALL_CAP O
but O
RARE O
the O
ALL_CAP O
, O
and O
patients O
with O
lesions O
affecting O
both O
ALL_CAP O
and O
ALL_CAP O
, O
performed O
an O
RARE O
delayed O
response O
task O
with O
RARE O
varied O
memory O
RARE O
of O
RARE O
to O
NUM O
s O
. O

In O
addition O
, O
NUM O
amino O
acid O
residues O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
NUM O
, O
and O
NUM O
( O
mouse O
ALL_CAP I-GENE
RARE O
RARE O
all O
of O
which O
are O
implicated O
in O
the O
formation O
of O
the O
RARE O
phosphate O
- O
binding O
domain O
and O
the O
substrate O
- O
binding O
domain O
and O
in O
RARE O
stabilization O
with O
the O
eukaryotic O
RARE I-GENE
, O
were O
also O
RARE O
in O
S O
. O
RARE O
ALL_CAP I-GENE
. O

The O
NUM I-GENE
cDNA I-GENE
contained O
an O
RARE O
reading O
frame O
homologous O
to O
NUM I-GENE
family I-GENE
proteins I-GENE
. O

Our O
results O
indicate O
that O
RARE I-GENE
can O
drive O
continued O
RARE O
in O
immature O
, O
RARE O
RARE O
. O

The O
QT O
interval O
was O
related O
to O
various O
RARE O
of O
the O
insulin I-GENE
resistance O
RARE O
, O
including O
ALL_CAP O
and O
insulin I-GENE
sensitivity O
. O

The O
RARE O
corresponding O
to O
the O
normal O
modes O
of O
vibration O
were O
calculated O
using O
the O
ALL_CAP O
( O
NUM O
/ O
6 O
- O
NUM O
RARE O
RARE O
and O
their O
agreement O
with O
the O
measured O
values O
improved O
after O
RARE O
of O
the O
associated O
force O
field O
. O

The O
data O
provide O
strong O
evidence O
that O
ALL_CAP I-GENE
is O
involved O
in O
the O
metabolism O
of O
both O
acid O
and O
solvent O
formation O
, O
whereas O
the O
physiological O
function O
of O
ALL_CAP I-GENE
has O
yet O
to O
be O
RARE O
. O

In O
addition O
, O
NUM I-GENE
, O
which O
is O
usually O
RARE O
with O
NUM I-GENE
by O
ALL_CAP O
RARE O
, O
was O
not O
RARE O
- O
regulated O
by O
RARE O
in O
SC O
- O
3 O
cells O
. O

Experiments O
with O
RARE O
- O
RARE O
proteins O
show O
that O
NUM I-GENE
is O
a O
nuclear O
protein O
, O
whereas O
both O
RARE I-GENE
and O
RARE I-GENE
- O
ALL_CAP I-GENE
localize O
to O
cytoplasmic O
RARE O
, O
indicating O
that O
the O
RARE I-GENE
domain I-GENE
RARE O
the O
cytoplasmic O
RARE O
of O
RARE I-GENE
- O
ALL_CAP I-GENE
. O

RARE O
RARE O
of O
human I-GENE
p53 I-GENE
RARE O
NUM O
stimulates O
p53 I-GENE
- O
dependent O
transcription O
. O
p53 I-GENE
protein I-GENE
activity O
RARE O
a O
transcription O
factor O
can O
be O
activated O
in O
vivo O
by O
antibodies O
that O
target O
its O
C O
- O
terminal O
negative O
regulatory O
domain O
suggesting O
that O
cellular O
RARE O
that O
target O
this O
domain O
may O
play O
a O
role O
in O
stimulating O
p53 I-GENE
- O
dependent O
gene O
RARE O
. O

Interestingly O
, O
this O
mutant O
cell O
line O
lacks O
RARE O
of O
the O
ALL_CAP I-GENE
regulatory I-GENE
protein I-GENE
, O
RARE I-GENE
. O

The O
RARE I-GENE
/ O
RARE I-GENE
interaction O
serves O
to O
recruit O
RARE I-GENE
to O
the O
ALL_CAP I-GENE
catalytic I-GENE
subunits I-GENE
, O
RARE I-GENE
and O
RARE I-GENE
, O
and O
this O
recruitment O
appears O
to O
be O
an O
essential O
mechanism O
by O
which O
RARE I-GENE
stimulates O
the O
activity O
of O
ALL_CAP I-GENE
. O

An O
RARE O
ALL_CAP O
- O
and O
RARE O
- O
based O
map O
of O
diploid O
RARE O
. O

In O
addition O
, O
we O
identified O
a O
novel O
type O
of O
RARE O
domain O
in O
the O
N O
- O
terminal O
NUM O
amino O
RARE O
of O
IRF I-GENE
- I-GENE
1 I-GENE
which O
strongly O
inhibits O
its O
transcriptional O
activity O
. O

Effects O
of O
spatial O
and O
temporal O
RARE O
on O
RARE O
RARE O
RARE O
in O
the O
independent O
- O
hot O
- O
RARE O
model O
limit O
The O
influence O
of O
laser O
beam O
RARE O
on O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
is O
studied O
RARE O
in O
the O
limit O
of O
the O
independent O
hot O
RARE O
model O
. O

RARE O
determination O
of O
theophylline O
and O
its O
metabolites O
by O
HPLC O
] O
A O
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
method O
has O
been O
developed O
RARE O
the O
simultaneous O
determination O
of O
theophylline O
and O
its O
metabolites O
, O
with O
caffeine O
and O
its O
metabolites O
. O

Ten O
males O
performed O
both O
test O
conditions O
and O
oxygen O
uptake O
VO2 O
, O
RARE O
rate O
, O
minute O
ventilation O
VE O
, O
perceived O
RARE O
and O
RARE O
RARE O
were O
recorded O
. O

CONCLUSION O
: O
ALL_CAP O
is O
more O
useful O
than O
ALL_CAP O
in O
differentiating O
patients O
RARE O
to O
RARE O
. O

RARE O
groups O
were O
( O
1 O
) O
untreated O
control O
, O
RARE O
= O
12 O
; O
( O
2 O
) O
FK O
- O
1 O
, O
RARE O
= O
8 O
; O
( O
3 O
) O
FK O
- O
3 O
, O
RARE O
= O
8 O
. O

DNA O
binding O
and O
RARE I-GENE
S I-GENE
- I-GENE
transferase I-GENE
RARE O
- O
down O
assays O
demonstrate O
that O
binding O
requires O
Elk I-GENE
- I-GENE
1 I-GENE
( I-GENE
1 I-GENE
- I-GENE
NUM I-GENE
) I-GENE
but O
not O
the O
C O
- O
terminal O
RARE O
domain O
. O

RARE O
, O
NUM I-GENE
RARE O
produced O
a O
remarkable O
change O
in O
cell O
morphology O
characterized O
by O
cell O
RARE O
and O
RARE O
of O
RARE O
, O
short O
cell O
processes O
. O

The O
NUM I-GENE
- I-GENE
1 I-GENE
allele I-GENE
recovered O
from O
the O
original O
screen O
carries O
a O
point O
mutation O
in O
its O
RARE O
repeat O
( O
TPR O
) O
domain O
, O
a O
motif O
not O
found O
in O
RARE I-GENE
but O
known O
in O
other O
proteins O
to O
mediate O
interaction O
with O
heat I-GENE
- I-GENE
shock I-GENE
proteins I-GENE
. O

Association O
of O
stress O
RARE O
delivery O
with O
increased O
numbers O
of O
RARE O
cells O
and O
hematopoietic O
RARE O
cells O
in O
RARE O
cord O
RARE O
. O

In O
slightly O
older O
RARE O
, O
the O
RARE O
was O
RARE O
to O
one O
RARE O
of O
the O
RARE O
and O
by O
NUM O
. O
5 O
, O
RARE O
the O
onset O
of O
RARE O
, O
RARE O
was O
seen O
in O
the O
RARE O
, O
visceral O
endoderm O
, O
RARE O
mesoderm O
, O
and O
the O
RARE O
RARE O
. O

RARE O
of O
the O
NUM I-GENE
mutant I-GENE
with O
ALL_CAP I-GENE
+ I-GENE
restores O
the O
wild O
- O
type O
RARE O
. O

The O
authors O
proposed O
that O
the O
highly O
RARE O
inputs O
to O
the O
RARE O
cortex O
indicate O
this O
region O
may O
be O
particularly O
important O
RARE O
RARE O
or O
RARE O
RARE O
. O

Influence O
of O
oil O
RARE O
and O
RARE O
on O
post O
- O
RARE O
RARE O
changes O
in O
RARE O
RARE O
( O
RARE O
RARE O
) O
was O
studied O
. O

RARE O
analysis O
of O
NUM I-GENE
, I-GENE
NUM I-GENE
transcripts I-GENE
revealed O
two O
major O
RARE O
RARE O
patterns O
in O
the O
5 O
'- O
RARE O
region O
( O
5 O
'- O
UTR O
) O
and O
evidence O
RARE O
minor O
RARE O
activity O
that O
occurs O
in O
a O
tissue O
- O
specific O
manner O
. O

A O
thermal O
RARE O
- O
RARE O
- O
RARE O
condition O
RARE O
due O
to O
the O
coupling O
of O
a O
computer O
to O
a O
strong O
RARE O
source O
, O
namely O
, O
the O
daily O
and O
weekly O
usage O
patterns O
of O
the O
RARE O
. O

The O
non O
- O
homologous O
sequences O
in O
the O
5 O
' O
RARE O
regions O
might O
be O
acquired O
RARE O
or O
after O
transcription O
RARE O
RARE O
of O
the O
ALL_CAP O
elements O
. O

The O
time O
course O
of O
NUM I-GENE
replication O
and O
NUM I-GENE
RARE O
in O
RARE O
yeast O
RARE O
that O
in O
yeast O
transfected O
with O
RARE O
ALL_CAP O
virion O
RNA O
. O

The O
transcription O
and O
RARE O
RARE O
of O
human I-GENE
NUM I-GENE
and O
ALL_CAP I-GENE
are O
cell O
- O
type O
specific O
. O

RESULTS O
: O
The O
main O
effect O
of O
muscle O
pain O
, O
compared O
to O
non O
- O
RARE O
RARE O
, O
was O
a O
significant O
and O
long O
- O
lasting O
increase O
of O
delta O
( O
1 O
- O
3 O
Hz O
) O
power O
and O
an O
alpha O
- O
1 O
( O
9 O
- O
11 O
Hz O
) O
power O
increase O
over O
the O
contralateral O
RARE O
locus O
. O

The O
extraction O
was O
subsequently O
RARE O
RARE O
' O
RARE O
' O
or O
' O
difficult O
'. O
RARE O
RARE O
- O
RARE O
class O
C O
RARE O
a O
predictor O
of O
a O
' O
difficult O
' O
extraction O
, O
RARE O
was O
88 O
% O
but O
sensitivity O
was O
low O
RARE O
NUM O
%. O

In O
addition O
, O
our O
results O
show O
that O
ERKs I-GENE
and O
NUM I-GENE
can O
RARE O
to O
RARE O
RARE O
into O
mesoderm O
. O

Based O
on O
NUM I-GENE
rRNA I-GENE
gene I-GENE
sequence I-GENE
analysis O
, O
the O
11 O
species O
having O
two O
RARE I-GENE
genes I-GENE
all O
have O
a O
common O
ancestor O
, O
while O
the O
RARE O
species O
having O
only O
one O
copy O
diverged O
from O
the O
RARE O
lineage O
before O
that O
common O
ancestor O
. O

Nevertheless O
, O
protein I-GENE
kinase I-GENE
A I-GENE
RARE O
induces O
RARE I-GENE
to O
activate O
the O
complex O
RARE O
promoter O
in O
the O
phosphoenolpyruvate I-GENE
RARE I-GENE
( O
PEPCK I-GENE
) O
gene O
. O

Another O
putative O
NUM I-GENE
site I-GENE
in O
close O
RARE O
to O
a O
NF1 I-GENE
/ O
ALL_CAP I-GENE
site O
was O
localized O
upstream O
of O
the O
RARE O
- O
like O
element O
. O

This O
transcriptional O
RARE O
occurs O
through O
modulation O
of O
the O
RARE I-GENE
transcription I-GENE
factor I-GENE
ALL_CAP I-GENE
- I-GENE
L1 I-GENE
, O
and O
ALL_CAP I-GENE
- I-GENE
3 I-GENE
inhibited O
ALL_CAP I-GENE
- I-GENE
L1 I-GENE
activity O
in O
a O
NUM I-GENE
- O
dependent O
manner O
. O

Taken O
together O
, O
these O
observations O
indicate O
that O
inhibition O
of O
p27 I-GENE
( O
NUM I-GENE
) O
transcription O
through O
NUM I-GENE
- O
RARE O
ALL_CAP I-GENE
- I-GENE
L1 I-GENE
RARE O
provides O
a O
novel O
mechanism O
of O
RARE O
RARE O
- O
RARE O
survival O
and O
RARE O
. O

DNase I-GENE
I I-GENE
genomic O
footprinting O
revealed O
that O
the O
c I-GENE
- I-GENE
Myb I-GENE
site I-GENE
is O
occupied O
in O
a O
tissue O
- O
specific O
fashion O
in O
vivo O
. O

We O
conclude O
that O
c I-GENE
- I-GENE
Myb I-GENE
regulates O
the O
ALL_CAP I-GENE
- I-GENE
2 I-GENE
promoter I-GENE
in O
T O
cells O
by O
binding O
to O
this O
consensus I-GENE
c I-GENE
- I-GENE
Myb I-GENE
binding I-GENE
site I-GENE
. O

A O
recently O
reported O
new O
RARE O
of O
the O
RARE I-GENE
family I-GENE
proteins I-GENE
, O
NUM I-GENE
has O
been O
identified O
RARE O
a O
RARE I-GENE
receptor I-GENE
protein I-GENE
tyrosine I-GENE
kinase I-GENE
( O
ALL_CAP I-GENE
) O
RARE O
protein O
by O
yeast O
two O
- O
RARE O
screening O
. O

RARE O
, O
we O
show O
that O
the O
RARE O
of O
the O
RARE I-GENE
- I-GENE
RARE I-GENE
gene I-GENE
in O
highly O
malignant O
rat O
thyroid O
cells O
transformed O
by O
RARE O
carrying O
the O
v I-GENE
- I-GENE
mos I-GENE
and O
v I-GENE
- I-GENE
ras I-GENE
- I-GENE
RARE I-GENE
RARE I-GENE
suppresses O
their O
malignant O
RARE O
. O

RARE O
RARE O
of O
NUM I-GENE
is O
associated O
with O
transformation O
of O
RARE O
RARE O
cells O
by O
the O
Raf I-GENE
- O
MEK I-GENE
- O
extracellular O
signal O
- O
regulated O
kinase O
RARE O
. O

The O
activity O
of O
the O
transcription I-GENE
factor I-GENE
CREB I-GENE
is O
regulated O
by O
extracellular O
stimuli O
that O
result O
in O
its O
RARE O
RARE O
a O
critical O
serine O
RARE O
, O
NUM O
. O

RESULTS O
: O
RARE O
age O
RARE O
RARE O
onset O
was O
NUM O
. O
2 O
years O
. O

When O
10 O
fields O
were O
analysed O
, O
a O
strong O
relationship O
was O
found O
between O
the O
presence O
of O
bacteria O
on O
Gram O
staining O
and O
the O
final O
diagnosis O
of O
ALL_CAP O
( O
RARE O
ALL_CAP O
and O
ALL_CAP O
respectively O
: O
sensitivity O
NUM O
and O
NUM O
%, O
RARE O
94 O
and O
NUM O
%, O
positive O
predictive O
value O
91 O
and O
NUM O
%, O
negative O
predictive O
value O
82 O
and O
88 O
%). O

Unlike O
the O
mammalian O
proteins O
, O
NUM I-GENE
is O
efficiently O
RARE O
RARE O
a O
Mr O
NUM O
, O
NUM O
glycoprotein O
, O
NUM I-GENE
, O
which O
undergoes O
RARE O
RARE O
to O
produce O
an O
NH2 O
- O
RARE O
truncated O
product O
, O
NUM I-GENE
. O

NH2 O
- O
terminal O
RARE O
of O
Xenopus O
and O
mammalian I-GENE
NUM I-GENE
may O
therefore O
be O
a O
prerequisite O
of O
optimal O
biological O
activity O
. O

Here O
, O
we O
identified O
three O
cis O
- O
elements O
required O
RARE O
replication O
within O
the O
NUM O
bp O
promoter O
, O
using O
RARE O
RARE O
plasmids O
carrying O
various O
mutations O
and O
deletions O
. O

RARE O
in O
the O
RARE O
of O
Coronary O
RARE O
RARE O
. O

The O
RARE O
of O
the O
present O
study O
were O
to O
evaluate O
the O
effects O
of O
adding O
RARE O
to O
a O
ALL_CAP O
- O
RARE O
, O
RARE O
the O
semen O
in O
1 O
or O
2 O
steps O
, O
RARE O
according O
to O
2 O
methods O
, O
RARE O
RARE O
2 O
rates O
, O
and O
the O
interactions O
between O
these O
treatments O
, O
on O
the O
post O
- O
RARE O
survival O
of O
dog O
spermatozoa O
RARE O
38 O
degrees O
C O
. O

This O
study O
is O
a O
further O
and O
more O
extensive O
RARE O
of O
the O
RARE O
RARE O
ALL_CAP O
- O
ALL_CAP O
- O
p O
. O

The O
NUM I-GENE
locus I-GENE
was O
mapped O
to O
mouse O
RARE O
NUM O
- O
NUM O
by O
RARE O
in O
situ O
hybridization O
. O

RARE O
disorders O
in O
children O
and O
RARE O
carry O
considerable O
morbidity O
, O
RARE O
development O
, O
and O
carry O
a O
significant O
mortality O
by O
suicide O
. O

Molecular O
cloning O
and O
RARE O
of O
human I-GENE
ALL_CAP I-GENE
- I-GENE
d I-GENE
- I-GENE
RARE I-GENE
: I-GENE
RARE I-GENE
core I-GENE
protein I-GENE
beta I-GENE
- I-GENE
d I-GENE
- I-GENE
RARE I-GENE
and O
its O
RARE O
isoform I-GENE
ALL_CAP I-GENE
- I-GENE
II I-GENE
. O

RARE O
due O
to O
RARE O
is O
difficult O
to O
treat O
and O
is O
further O
complicated O
by O
the O
pro O
- O
RARE O
RARE O
of O
RARE O
and O
the O
RARE O
antiarrhythmic O
effect O
after O
RARE O
withdrawal O
. O

RARE O
/ O
RARE I-GENE
thus O
play O
important O
roles O
within O
cell O
RARE O
processes O
. O

RARE O
signalling O
by O
E2F1 I-GENE
has O
recently O
been O
RARE O
to O
stabilization O
and O
activation O
of O
the O
RARE O
suppressor O
p53 I-GENE
( O
RARE O
1 O
, O
3 O
, O
4 O
). O

This O
study O
allows O
us O
to O
RARE O
conclusions O
about O
the O
identity O
of O
proteins O
required O
RARE O
the O
development O
of O
the O
nervous O
RARE O
in O
Drosophila O
and O
provides O
an O
example O
of O
a O
RARE O
approach O
to O
characterize O
RARE O
RARE O
RARE O
- O
RARE O
mutations O
identified O
in O
genetic O
RARE O
. O

We O
describe O
the O
identification O
and O
initial O
characterization O
of O
RARE I-GENE
, O
a O
RARE O
- O
specific O
RARE O
protein O
of O
NUM O
kDa O
with O
a O
high O
- O
affinity O
binding O
site O
( O
K O
( O
d O
RARE O
10 O
nm O
) O
RARE O
the O
type I-GENE
II I-GENE
regulatory I-GENE
subunit I-GENE
of I-GENE
protein I-GENE
kinase I-GENE
A I-GENE
( O
PKA I-GENE
RII I-GENE
). O

Children O
with O
ALL_CAP O
showed O
an O
attenuated O
frontal O
CNV O
- O
1 O
amplitude O
and O
a O
trend O
towards O
increased O
CNV O
- O
1 O
and O
CNV O
- O
2 O
RARE O
amplitudes O
. O

RARE O
ALL_CAP O
is O
RARE O
. O

Overexpression O
of O
c I-GENE
- I-GENE
RARE I-GENE
in O
serum O
- O
RARE O
human O
or O
mouse O
RARE O
cells O
leads O
to O
apoptosis O
which O
is O
significantly O
RARE O
in O
the O
presence O
of O
growth O
factor O
- O
containing O
serum O
. O
c I-GENE
- I-GENE
RARE I-GENE
- O
RARE O
apoptosis O
appears O
to O
be O
RARE O
in O
RARE I-GENE
- O
RARE O
RARE O
compared O
with O
RARE I-GENE
- O
wild O
- O
type O
mouse O
RARE O
RARE O
. O

RARE O
RARE O
of O
RARE O
RARE O
RARE O
RARE I-GENE
- I-GENE
RARE I-GENE
beta I-GENE
- I-GENE
lactamase I-GENE
( O
ALL_CAP I-GENE
) O
RARE O
in O
RARE O
in O
RARE O
. O

CONCLUSION O
: O
Our O
results O
suggest O
that O
ALL_CAP O
peak O
saturation O
leads O
to O
a O
significant O
systematic O
error O
in O
the O
determination O
of O
ALL_CAP O
and O
CBF O
values O
and O
has O
necessarily O
to O
be O
taken O
into O
account O
RARE O
dynamic O
contrast O
- O
RARE O
MR O
perfusion O
studies O
. O

METHODS O
: O
NUM O
RARE O
weighted O
, O
three O
- O
dimensional O
gradient O
- O
echo O
images O
were O
acquired O
by O
RARE O
the O
magnetic O
RARE O
difference O
between O
RARE O
and O
RARE O
hemoglobin I-GENE
in O
the O
RARE O
and O
RARE O
. O

In O
the O
COPD O
patients O
, O
the O
variability O
of O
RARE O
- O
RARE O
RARE O
( O
NUM O
%) O
was O
greater O
than O
that O
of O
ALL_CAP O
RARE O
( O
21 O
%). O

RARE O
this O
end O
, O
we O
prepared O
RARE O
proteins O
with O
either O
the O
catalytic O
domain O
of O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
( I-GENE
C I-GENE
- I-GENE
terminal I-GENE
NUM I-GENE
amino I-GENE
RARE I-GENE
) I-GENE
or O
its O
inactive O
form O
( O
NUM O
RARE O
RARE O
) O
fused O
to O
RARE I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
). O

Thus O
, O
NUM I-GENE
could O
play O
dual O
roles O
in O
both O
membrane O
RARE O
and O
RARE O
of O
NUM I-GENE
RARE O
within O
RARE O
. O

Furthermore O
, O
transfection O
of O
cells O
with O
the O
spacer O
- O
ALL_CAP O
domain O
alone O
suppressed O
the O
RARE O
function O
of O
the O
N O
- O
terminal O
ALL_CAP I-GENE
domain O
of O
c I-GENE
- I-GENE
NUM I-GENE
and O
RARE O
apoptosis O
. O

The O
determination O
of O
the O
double O
RARE O
in O
RARE O
serum O
lipids O
by O
titration O
with O
RARE O
: O
the O
pathophysiology O
and O
diagnostic O
significance O
] O
In O
this O
article O
the O
method O
of O
definition O
of O
double O
RARE O
in O
lipids O
of O
RARE O
serum O
in O
patients O
with O
different O
diseases O
RARE O
atherosclerosis O
and O
ischemic O
RARE O
RARE O
, O
with O
use O
titration O
by O
RARE O
is O
given O
. O

RARE I-GENE
II I-GENE
- O
RARE O
fibronectin I-GENE
mRNA O
was O
not O
affected O
by O
PKC I-GENE
RARE O
or O
PKC I-GENE
depletion O
, O
whereas O
specific O
inhibition O
of O
ALL_CAP I-GENE
- I-GENE
R I-GENE
function O
by O
a O
dominant I-GENE
negative I-GENE
ALL_CAP I-GENE
- I-GENE
R I-GENE
mutant I-GENE
and O
RARE O
NUM O
abolished O
induction O
of O
fibronectin I-GENE
mRNA I-GENE
. O

RARE O
. O

RARE O
images O
of O
the O
RARE O
were O
RARE O
and O
then O
analyzed O
RARE O
area O
, O
RARE O
, O
RARE O
, O
principal O
axis O
, O
RARE O
about O
the O
major O
and O
minor O
RARE O
( O
NUM O
, O
NUM O
RARE O
RARE O
, O
RARE O
, O
lateral O
RARE O
, O
RARE O
angle O
, O
and O
RARE O
angle O
. O

MS O
characteristics O
of O
RARE O
, O
RARE O
and O
RARE O
RARE O
with O
different O
substitution O
patterns O
were O
determined O
on O
the O
basis O
of O
the O
response O
obtained O
with O
the O
ALL_CAP O
interface O
. O

RARE O
fish O
( O
RARE O
RARE O
) O
were O
exposed O
to O
RARE O
( O
micro O
g O
) O
RARE O
9 O
to O
10 O
days O
RARE O
space O
RARE O
ALL_CAP O
- O
NUM O
and O
ALL_CAP O
- O
NUM O
, O
or O
to O
RARE O
( O
RARE O
) O
RARE O
9 O
days O
. O

NUM I-GENE
is O
highly O
homologous O
to O
NUM I-GENE
in O
the O
core O
kinase O
and O
RARE O
regulatory O
domains O
but O
differs O
from O
NUM I-GENE
in O
the O
N O
- O
and O
C O
- O
terminal O
regions O
and O
is O
differently O
localized O
primarily O
to O
the O
nucleus O
because O
of O
a O
C O
- O
terminal O
nuclear O
RARE O
signal O
unique O
to O
NUM I-GENE
. O

RARE O
of O
cells O
with O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
- I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
kinase I-GENE
( O
MEK I-GENE
) O
inhibitor O
NUM O
inhibited O
NUM I-GENE
activation O
to O
a O
greater O
extent O
than O
NUM I-GENE
. O

T O
cells O
express O
two O
isoforms O
of O
NUM I-GENE
: O
a O
70 O
kDa O
cytoplasmic O
kinase O
and O
an O
NUM O
kDa O
isoform O
that O
has O
a O
RARE O
nuclear O
RARE O
. O

RARE O
, O
a O
hypotensive O
drug O
with O
5 I-GENE
- I-GENE
HT2 I-GENE
receptor I-GENE
RARE O
, O
when O
administered O
by O
RARE O
infusion O
of O
a O
NUM O
. O
NUM O
% O
w O
/ O
v O
solution O
by O
corneal O
and O
RARE O
applications O
, O
was O
found O
to O
lower O
RARE O
pressure O
with O
four O
times O
more O
activity O
than O
its O
metabolite O
, O
RARE O
. O

A O
RARE O
gated O
NUM O
axial O
sequence O
with O
velocity O
encoding O
in O
the O
RARE O
direction O
in O
the O
cervical O
region O
was O
set O
RARE O
a O
velocity O
of O
+/- O
10 O
cm O
/ O
s O
. O

It O
was O
subsequently O
shown O
that O
NUM I-GENE
had O
histone I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
activity O
. O

Our O
data O
show O
that O
multiple O
NUM I-GENE
transcripts I-GENE
, O
both O
constitutively O
RARE O
and O
inducible O
, O
are O
present O
in O
cultured O
RARE O
RARE O
cells O
, O
and O
suggest O
that O
NUM I-GENE
RARE O
can O
be O
regulated O
RARE O
the O
level O
of O
both O
transcription O
and O
mRNA O
RARE O
. O

Copyright O
2000 O
Academic O
Press O
. O

RARE I-GENE
and O
RARE I-GENE
have O
ALL_CAP O
- O
containing O
domains O
RARE O
their O
C O
- O
termini O
and O
we O
further O
demonstrate O
that O
the O
ALL_CAP O
- O
containing O
domain O
of O
RARE I-GENE
, O
but O
not O
RARE I-GENE
, O
can O
bind O
to O
RARE O
in O
vivo O
. O

Characterization O
of O
the O
microtubule O
binding O
domain O
of O
microtubule I-GENE
actin I-GENE
RARE I-GENE
factor I-GENE
( O
ALL_CAP I-GENE
): O
identification O
of O
a O
novel O
group O
of O
microtubule I-GENE
associated I-GENE
proteins I-GENE
. O

These O
results O
also O
suggest O
the O
involvement O
of O
additional O
elements O
in O
the O
ALL_CAP O
. O

We O
show O
that O
in O
contrast O
to O
NUM I-GENE
, O
direct O
binding O
of O
CBP I-GENE
to O
the O
estrogen I-GENE
receptor I-GENE
is O
weak O
, O
suggesting O
that O
NUM I-GENE
functions O
primarily O
RARE O
an O
RARE O
to O
recruit O
CBP I-GENE
and O
p300 I-GENE
. O

RARE O
, O
a O
construct O
corresponding O
to O
residues O
NUM O
to O
NUM O
, O
which O
contains O
only O
the O
ALL_CAP O
motifs O
and O
the O
NUM O
region O
of O
NUM I-GENE
, O
retained O
strong O
RARE O
activity O
in O
our O
assays O
. O

Since O
MEK I-GENE
acts O
RARE O
a O
cytoplasmic O
RARE O
RARE O
the O
ERKs I-GENE
, O
the O
lack O
of O
a O
MEK I-GENE
interaction O
resulted O
in O
the O
aberrant O
nuclear O
RARE O
of O
ERK2 I-GENE
- O
NUM I-GENE
- I-GENE
NUM I-GENE
mutants O
in O
serum O
- O
RARE O
cells O
. O

NUM I-GENE
is O
a O
RARE O
of O
a O
RARE O
- O
protein O
family O
in O
yeast O
that O
catalyzes O
the O
RARE O
step O
in O
O O
RARE O
of O
target O
proteins O
. O

RARE O
samples O
were O
collected O
RARE O
the O
beginning O
and O
end O
of O
each O
trial O
period O
and O
were O
analyzed O
RARE O
RARE O
nematode O
eggs O
and O
RARE O
cyst O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
risk O
factors O
RARE O
background O
diabetic O
RARE O
( O
ALL_CAP O
) O
and O
ALL_CAP O
by O
following O
NUM O
Japanese O
patients O
with O
early O
- O
onset O
type O
2 O
diabetes O
diagnosed O
before O
NUM O
years O
of O
age O
( O
mean O
age O
NUM O
, O
mean O
RARE O
pressure O
RARE O
entry O
NUM O
/ O
NUM O
mm O
Hg O
). O

Of O
the O
21 O
RARE O
positive O
in O
the O
controls O
, O
NUM O
were O
correlated O
with O
previously O
detected O
jaw O
RARE O
. O

Four O
cases O
of O
synovial O
RARE O
are O
presented O
. O

Previous O
studies O
have O
shown O
that O
the O
pro O
- O
inflammatory O
RARE O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
and O
RARE I-GENE
gamma I-GENE
reduce O
the O
RARE O
of O
the O
RARE I-GENE
RARE I-GENE
transmembrane I-GENE
RARE I-GENE
regulator I-GENE
( O
CFTR I-GENE
) O
gene O
( O
CFTR I-GENE
) O
in O
ALL_CAP O
- O
29 O
and O
NUM O
cells O
by O
acting O
post O
- O
transcriptionally O
. O

Regulation O
of O
RhoA I-GENE
is O
required O
to O
maintain O
adhesion O
in O
stationary O
cells O
, O
but O
is O
also O
critical O
RARE O
cell O
RARE O
and O
migration O
RARE O
3 O
]. O

Here O
we O
show O
in O
mouse O
RARE O
stably O
transformed O
by O
v I-GENE
- I-GENE
Src I-GENE
that O
mRNA O
and O
protein O
levels O
of O
p21 I-GENE
( O
WAF1 I-GENE
/ O
NUM I-GENE
RARE O
RARE I-GENE
NUM I-GENE
, O
and O
RARE I-GENE
E I-GENE
are O
elevated O
. O

ALL_CAP O
and O
ALL_CAP I-GENE
were O
constitutively O
cotranscribed O
RARE O
determined O
by O
primer O
extension O
analysis O
. O

RARE I-GENE
RARE I-GENE
is O
a O
RARE O
RARE O
gene O
encoding O
an O
evolutionarily O
RARE O
protein O
of O
unknown O
function O
. O

These O
cells O
produced O
NUM I-GENE
( I-GENE
11 I-GENE
) I-GENE
mRNA I-GENE
RARE O
culture O
. O

RARE O
studies O
indicate O
that O
insulin I-GENE
and O
PKB I-GENE
suppress O
RARE O
by O
C I-GENE
/ I-GENE
EBPbeta I-GENE
, O
but O
not O
C I-GENE
/ I-GENE
RARE I-GENE
, O
and O
that O
N O
- O
terminal O
RARE O
domains O
in O
C I-GENE
/ I-GENE
EBPbeta I-GENE
are O
required O
. O

Among O
eight O
RARE O
species O
tested O
, O
NUM I-GENE
RARE O
was O
observed O
only O
in O
RARE O
- O
RARE O
roots O
of O
H O
. O
RARE O
and O
RARE O
RARE O
. O
which O
not O
only O
RARE O
2 O
'- O
RARE O
acid O
( O
ALL_CAP O
RARE O
but O
also O
RARE O
acid O
( O
ALL_CAP O
) O
and O
3 O
- O
RARE O
acid O
( O
ALL_CAP O
, O
H O
. O
RARE O
RARE O
and O
3 O
- O
RARE O
acid O
( O
ALL_CAP O
, O
S O
. O
RARE O
). O

In O
contrast O
, O
high O
COUP I-GENE
- I-GENE
TFI I-GENE
RARE O
RARE O
the O
RARE O
differentiation O
of O
P19 O
cells O
RARE O
with O
ALL_CAP O
, O
resulting O
in O
cell O
cultures O
RARE O
neurons O
. O

Because O
PET O
is O
also O
useful O
RARE O
the O
pretreatment O
and O
follow O
- O
RARE O
evaluation O
, O
the O
use O
of O
RARE O
PET O
in O
these O
patients O
can O
RARE O
an O
accurate O
comparison O
of O
PET O
- O
based O
metabolic O
data O
with O
MR O
- O
based O
anatomical O
data O
. O

Therefore O
, O
in O
our O
in O
vitro O
model O
, O
the O
RARE O
of O
the O
mutation O
in O
the O
K I-GENE
- I-GENE
ras I-GENE
gene I-GENE
RARE O
to O
a O
different O
level O
of O
RARE O
in O
the O
transforming O
RARE O
. O

Here O
, O
we O
describe O
the O
isolation O
of O
NUM I-GENE
, O
a O
NUM I-GENE
homologue O
from O
the O
RARE O
species O
RARE O
( O
RARE O
RARE O
) O
and O
show O
that O
it O
has O
the O
same O
RARE O
- O
specific O
substrate O
RARE O
and O
can O
be O
inhibited O
by O
RARE O
in O
vitro O
, O
RARE O
is O
the O
case O
RARE O
NUM I-GENE
. O

Differential O
association O
of O
products O
of O
RARE O
transcripts O
of O
the O
candidate O
tumor I-GENE
suppressor I-GENE
NUM I-GENE
with O
the O
NUM I-GENE
/ O
NUM I-GENE
transcriptional O
RARE O
complex O
. O

These O
and O
other O
data O
presented O
suggest O
that O
RARE I-GENE
' O
re O
- O
models O
' O
RARE O
cell O
transcription O
factors O
that O
are O
used O
early O
in O
viral O
infection O
, O
and O
thereby O
RARE O
an O
event O
that O
naturally O
occurs O
RARE O
transformation O
. O

This O
sensitivity O
analysis O
showed O
that O
the O
RARE O
limits O
of O
the O
accuracy O
of O
the O
used O
screening O
test O
RARE O
the O
estimation O
of O
the O
true O
herd O
prevalence O
within O
reasonable O
confidence O
limits O
, O
because O
the O
within O
- O
herd O
ALL_CAP O
true O
prevalence O
was O
low O
. O
For O
this O
RARE O
we O
augmented O
the O
herd O
RARE O
RARE O
RARE O
with O
larger O
adult O
herd O
size O
(> O
5 O
). O

NUM I-GENE
. I-GENE
5 I-GENE
encodes O
a O
protein O
, O
RARE I-GENE
- I-GENE
associated I-GENE
nuclear I-GENE
antigen I-GENE
2 I-GENE
( O
NUM I-GENE
RARE O
which O
is O
RARE O
in O
ALL_CAP O
- O
RARE O
hematopoietic O
tissues O
, O
including O
ALL_CAP O
and O
CD O
but O
not O
KS O
lesions O
. O

As O
RARE O
, O
RARE O
showed O
relatively O
RARE O
right O
RARE O
activation O
and O
RARE O
RARE O
asymmetry O
of O
RARE O
complexity O
. O

In O
Xenopus O
, O
RARE I-GENE
act O
RARE O
RARE O
RARE O
and O
also O
RARE O
negative O
RARE O
of O
RARE O
. O

RARE O
four O
unique O
variants O
carrying O
distinct O
ALL_CAP I-GENE
sequences I-GENE
in O
the O
N O
- O
terminal O
region O
have O
been O
identified O
. O

Genomic O
organization O
of O
the O
human O
RARE I-GENE
NUM I-GENE
gene I-GENE
. O

The O
present O
findings O
revealed O
that O
the O
RARE I-GENE
- I-GENE
2 I-GENE
protein I-GENE
was O
a O
unique O
NUM I-GENE
, I-GENE
4 I-GENE
- I-GENE
N I-GENE
- I-GENE
RARE I-GENE
involved O
in O
the O
biosynthetic O
initiation O
and O
RARE O
of O
RARE O
RARE O
. O

Inhibition O
of O
the O
RARE I-GENE
/ O
RARE I-GENE
RARE O
in O
NUM O
/ O
ras I-GENE
cells O
, O
using O
the O
RARE I-GENE
inhibitor O
, O
PD98059 O
, O
resulted O
in O
RARE O
cytoskeletal O
recovery O
, O
indistinguishable O
from O
that O
RARE O
by O
NUM O
. O

The O
transcription O
factor O
ALL_CAP I-GENE
/ O
NUM I-GENE
gene O
is O
RARE O
by O
cellular O
stress O
and O
is O
involved O
in O
mediating O
apoptosis O
. O

Addition O
of O
RARE O
tyrosine O
- O
RARE O
peptides O
derived O
from O
RARE O
cytoplasmic O
RARE O
prior O
to O
ALL_CAP I-GENE
- I-GENE
CSF I-GENE
RARE O
inhibited O
the O
in O
vitro O
activation O
of O
STAT5 I-GENE
. O

MAIN O
OUTCOME O
ALL_CAP O
: O
RARE O
change O
in O
the O
apnea O
- O
RARE O
index O
( O
ALL_CAP O
; O
apnea O
events O
+ O
RARE O
events O
per O
hour O
of O
sleep O
) O
and O
odds O
of O
developing O
moderate O
- O
to O
- O
severe O
ALL_CAP O
( O
defined O
by O
an O
ALL_CAP O
> O
or O
= O
NUM O
events O
per O
hour O
of O
sleep O
RARE O
with O
respect O
to O
change O
in O
RARE O
. O

RARE O
RARE O
syndromes O
. O

This O
article O
RARE O
recent O
RARE O
on O
the O
frequency O
, O
characteristics O
, O
and O
possible O
pathogenic O
mechanisms O
of O
the O
RARE O
occurring O
in O
patients O
with O
the O
main O
RARE O
tissue O
diseases O
. O

RARE I-GENE
kinase I-GENE
RARE O
in O
T O
cells O
is O
regulated O
by O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
and O
the O
RARE I-GENE
pleckstrin I-GENE
homology I-GENE
domain I-GENE
. O

Current O
evidence O
RARE O
this O
type O
of O
DNA O
RARE O
- O
dependent O
transcriptional O
coupling O
, O
based O
largely O
on O
the O
in O
vivo O
activities O
of O
promoters O
contained O
in O
RARE O
DNA O
constructs O
, O
suggests O
that O
the O
transcription O
complex O
must O
be O
physically O
RARE O
to O
generate O
DNA O
RARE O
and O
to O
prevent O
their O
diffusion O
throughout O
the O
DNA O
duplex O
. O

The O
RARE O
of O
the O
free O
NUM I-GENE
domain I-GENE
has O
been O
compared O
to O
that O
of O
the O
NUM I-GENE
complexed O
with O
a O
RARE O
RARE O
peptide O
derived O
from O
RARE I-GENE
RARE I-GENE
T I-GENE
antigen I-GENE
( O
ALL_CAP I-GENE
). O

We O
have O
identified O
three O
binding O
sites O
RARE O
protein O
complexes O
: O
a O
palindrome O
, O
a O
direct O
repeat O
, O
and O
a O
C O
+ O
T O
sequence O
that O
corresponds O
to O
RARE O
ALL_CAP O
motifs O
on O
the O
RARE O
RARE O
. O

Copyright O
2000 O
Academic O
Press O
. O

Nucleotide O
sequence O
, O
genome O
organization O
and O
phylogenetic O
analysis O
of O
RARE O
RARE O
RARE O
- O
associated O
virus O
- O
2 O
. O

Patients O
underwent O
pretreatment O
RARE O
and O
detailed O
tumor O
mapping O
, O
and O
were O
treated O
with O
NUM O
mg O
. O
/ O
m O
. O
2 O
cisplatin O
on O
day O
1 O
and O
1 O
RARE O
RARE O
m O
. O
2 O
daily O
, O
5 O
- O
fluorouracil O
on O
days O
1 O
to O
4 O
and O
definitive O
radiotherapy O
. O

All O
9 O
untreated O
patients O
underwent O
RARE O
, O
which O
identified O
3 O
RARE O
- O
abdominal O
, O
3 O
RARE O
and O
2 O
RARE O
testes O
, O
and O
1 O
RARE O
RARE O
in O
the O
RARE O
RARE O
. O

This O
RARE O
was O
RARE O
RARE O
the O
compound O
ALL_CAP O
NUM O
, O
a O
specific O
RARE I-GENE
IV I-GENE
inhibitor O
, O
that O
was O
being O
developed O
simultaneously O
RARE O
delivery O
by O
both O
oral O
and O
pulmonary O
routes O
of O
administration O
. O

Increased O
levels O
of O
RARE I-GENE
immunoglobulin I-GENE
G I-GENE
may O
also O
cause O
bleeding O
. O

RESULTS O
: O
RARE O
of O
obesity O
( O
BMI O
SDS O
> O
2 O
. O
NUM O
) O
was O
< O
2 O
% O
RARE O
diagnosis O
, O
but O
increased O
to O
16 O
% O
RARE O
NUM O
. O

One O
of O
the O
RARE O
of O
the O
RARE O
- O
antibodies O
is O
an O
impaired O
RARE O
circulation O
. O

RARE O
to O
aid O
smoking O
cessation O
. O

Using O
a O
RARE O
dominant O
negative O
RARE O
AP I-GENE
- I-GENE
1 I-GENE
transcriptional O
activity O
in O
ALL_CAP O
NUM O
/ O
2 O
. O
8 O
cells O
, O
we O
then O
showed O
that O
AP I-GENE
- I-GENE
1 I-GENE
transcription I-GENE
factors I-GENE
RARE O
TGF I-GENE
- I-GENE
beta1 I-GENE
- O
and O
BMP I-GENE
- I-GENE
2 I-GENE
- O
regulated O
RARE O
of O
the O
( I-GENE
NUM I-GENE
) I-GENE
RARE I-GENE
I I-GENE
gene I-GENE
RARE O
RARE O
RARE O
TGF I-GENE
- I-GENE
beta1 I-GENE
- O
regulated O
RARE O
of O
the O
RARE I-GENE
hormone I-GENE
( O
ALL_CAP I-GENE
RARE O
ALL_CAP I-GENE
- I-GENE
related I-GENE
peptide I-GENE
( I-GENE
ALL_CAP I-GENE
) I-GENE
receptor I-GENE
. O

ALL_CAP O
12 O
or O
18 O
mg O
/ O
kg O
daily O
RARE O
a O
standard O
dose O
of O
ALL_CAP O
RARE O
21 O
days O
was O
statistically O
more O
effective O
than O
ALL_CAP O
in O
producing O
a O
final O
cure O
RARE O
patients O
with O
ALL_CAP O
in O
RARE O
, O
RARE O
. O

RARE O
therapy O
RARE O
colon O
RARE O
] O
RARE O
alone O
may O
fail O
to O
cure O
a O
considerable O
number O
of O
locally O
advanced O
colon O
cancers O
. O

There O
were O
significant O
differences O
( O
p O
< O
NUM O
. O
05 O
) O
between O
the O
fracture O
and O
RARE O
groups O
in O
the O
RARE O
femur O
BMD O
( O
NUM O
%), O
RARE O
BMD O
in O
the O
distal O
RARE O
( O
4 O
%), O
and O
the O
RARE O
RARE O
in O
the O
radiographs O
( O
NUM O
) O
( O
3 O
%). O

BACKGROUND O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
and O
compare O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
ALL_CAP I-GENE
- I-GENE
6 I-GENE
) O
levels O
in O
RARE O
RARE O
RARE O
( O
ALL_CAP O
) O
and O
clinical O
periodontal O
findings O
in O
patients O
with O
rheumatoid O
arthritis O
( O
ALL_CAP O
) O
and O
adult O
RARE O
( O
AP O
). O

In O
a O
prospective O
, O
RARE O
trial O
the O
efficacy O
of O
an O
RARE O
RARE O
RARE O
L O
RARE O
RARE O
440 O
was O
investigated O
in O
50 O
patients O
with O
pre O
- O
menstrual O
RARE O
( O
ALL_CAP O
). O

Studies O
are O
necessary O
to O
assess O
the O
source O
of O
contamination O
and O
RARE O
role O
of O
ALL_CAP O
- O
contaminated O
milk O
in O
the O
RARE O
of O
ALL_CAP O
to O
neonates O
. O

Effects O
of O
Trypanosoma O
RARE O
on O
RARE O
of O
RARE O
sheep O
and O
the O
results O
of O
RARE O
RARE O
chemotherapy O
. O

ALL_CAP I-GENE
RARE I-GENE
B I-GENE
was O
activated O
to O
a O
much O
greater O
extent O
by O
RARE O
in O
the O
ALL_CAP O
cells O
than O
in O
NUM O
cells O
. O

RARE O
on O
treatment O
exposures O
, O
this O
RARE O
- O
risk O
population O
may O
experience O
life O
- O
RARE O
RARE O
effects O
, O
such O
RARE O
cirrhosis O
secondary O
to O
hepatitis O
C O
or O
RARE O
- O
onset O
RARE O
- O
RARE O
cardiomyopathy O
, O
or O
life O
- O
changing O
RARE O
effects O
, O
such O
RARE O
cognitive O
dysfunction O
. O

The O
presence O
of O
locus O
- O
specific O
residues O
throughout O
the O
RARE O
promoter O
region O
strongly O
suggests O
that O
the O
various O
HLA I-GENE
class I-GENE
I I-GENE
loci I-GENE
are O
differentially O
regulated O
. O

Because O
the O
number O
of O
parameters O
required O
by O
a O
RARE O
series O
RARE O
rapidly O
with O
both O
the O
length O
of O
its O
memory O
and O
the O
order O
of O
its O
RARE O
, O
methods O
RARE O
identifying O
these O
models O
from O
measurements O
of O
input O
/ O
output O
data O
are O
limited O
to O
low O
- O
order O
RARE O
with O
relatively O
short O
RARE O
. O

The O
standard O
method O
RARE O
RARE O
the O
composite O
score O
on O
the O
S O
- O
B O
IV O
RARE O
RARE O
with O
a O
RARE O
score O
of O
NUM O
, O
which O
RARE O
cognitive O
functioning O
in O
young O
biologically O
high O
risk O
children O
. O

RARE O
( O
2 O
)- O
RARE O
ALL_CAP I-GENE
- I-GENE
1 I-GENE
RARE O
required O
activation O
of O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
since O
mutation O
of O
ALL_CAP I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
binding I-GENE
sites I-GENE
in O
the O
promoter O
resulted O
in O
RARE O
RARE O
of O
inducible O
promoter O
activity O
. O

RARE O
of O
human I-GENE
NUM I-GENE
by O
mitogenic O
RARE O
of O
anti I-GENE
- I-GENE
NUM I-GENE
RARE I-GENE
induces O
tyrosine O
RARE O
of O
a O
number O
of O
RARE O
proteins O
including O
a O
120 O
kDa O
RARE O
that O
we O
identify O
RARE O
the O
RARE I-GENE
- I-GENE
oncogene I-GENE
c I-GENE
- I-GENE
Cbl I-GENE
. O

RARE O
of O
ALL_CAP O
spectroscopy O
RARE O
RARE O
measuring O
muscle O
oxidative O
metabolic O
rate O
in O
exercise O
. O

Previous O
studies O
have O
demonstrated O
that O
tissue O
- O
restricted O
transcription O
factors O
including O
ALL_CAP I-GENE
. I-GENE
1 I-GENE
and O
ALL_CAP I-GENE
. I-GENE
1 I-GENE
interaction I-GENE
RARE I-GENE
( O
ALL_CAP I-GENE
) O
function O
synergistically O
with O
c I-GENE
- I-GENE
Fos I-GENE
RARE O
c I-GENE
- I-GENE
Jun I-GENE
to O
stimulate O
the O
NUM I-GENE
'- I-GENE
enhancer I-GENE
in O
3T3 O
cells O
. O

The O
murine I-GENE
int I-GENE
- I-GENE
6 I-GENE
locus I-GENE
, O
identified O
RARE O
a O
frequent O
RARE O
site O
of O
mouse O
mammary O
tumor O
viruses O
, O
encodes O
the O
NUM I-GENE
- I-GENE
kDa I-GENE
NUM I-GENE
subunit I-GENE
of I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
eIF3 I-GENE
. O

An O
NUM I-GENE
deletion I-GENE
( O
NUM I-GENE
) O
mutant O
was O
viable O
but O
RARE O
slowly O
in O
minimal O
medium O
. O

Additionally O
, O
ALL_CAP I-GENE
- I-GENE
NUM I-GENE
RARE O
cell O
growth O
regulatory O
role O
of O
MBP I-GENE
- I-GENE
1 I-GENE
. O

We O
produced O
transgenic O
RARE O
expressing O
the O
RARE I-GENE
Arabidopsis I-GENE
HD I-GENE
( O
NUM I-GENE
) O
gene O
. O

3 O
. O
04 O
+/- O
1 O
. O
2 O
, O
P O
< O
NUM O
. O
0001 O
RARE O
large O
RARE O
/ O
NUM O
min O
( O
1 O
. O
NUM O
+/- O
1 O
. O
96 O
RARE O
. O

Four O
transcription O
initiation O
sites O
have O
been O
identified O
by O
full O
- O
length O
RNA I-GENE
ligase I-GENE
- O
RARE O
rapid O
amplification O
of O
cDNA O
ends O
( O
ALL_CAP O
- O
RACE O
) O
between O
- O
NUM O
and O
- O
NUM O
bp O
from O
the O
translation O
initiation O
RARE O
. O
RARE O
transcription O
- O
PCR O
analysis O
revealed O
that O
PFK I-GENE
- I-GENE
A I-GENE
, O
PFK I-GENE
- I-GENE
B I-GENE
and O
PFK I-GENE
- I-GENE
C I-GENE
genes I-GENE
were O
RARE O
, O
in O
all O
mouse O
tissues O
tested O
, O
RARE O
varying O
levels O
. O

PFK I-GENE
- I-GENE
A I-GENE
mRNA O
was O
more O
abundantly O
RARE O
in O
all O
tissues O
than O
were O
the O
PFK I-GENE
- I-GENE
B I-GENE
and O
PFK I-GENE
- I-GENE
C I-GENE
genes I-GENE
. O

We O
used O
the O
RARE O
ALL_CAP O
RARE O
, O
which O
is O
composed O
of O
an O
X O
- O
ray O
ALL_CAP O
RARE O
and O
a O
digital O
image O
RARE O
circuit O
. O

In O
whole O
RARE O
, O
RARE O
acid O
was O
detected O
in O
levels O
RARE O
RARE O
the O
regulatory O
limit O
. O

In O
addition O
, O
we O
identified O
two O
mutations O
, O
RARE O
NUM O
and O
NUM O
+ O
NUM O
RARE O
A O
, O
in O
a O
RARE O
NUM I-GENE
patient O
. O

RARE O
: O
a O
resource O
RARE O
RARE O
who O
smoke O
. O

RARE O
18F O
RARE O
4 O
- O
RARE O
( O
ALL_CAP O
RARE O
which O
selectively O
binds O
to O
the O
vesicular O
RARE I-GENE
RARE I-GENE
in O
the O
RARE O
cholinergic O
RARE O
, O
has O
previously O
been O
shown O
to O
be O
a O
useful O
RARE O
RARE O
the O
study O
of O
cholinergic O
terminal O
density O
in O
the O
basal O
RARE O
with O
PET O
. O

We O
demonstrate O
that O
the O
protein O
is O
a O
murine I-GENE
homologue I-GENE
of I-GENE
ALL_CAP I-GENE
- I-GENE
A I-GENE
which O
has O
been O
shown O
to O
bind O
selectively O
to O
RARE O
and O
is O
responsible O
RARE O
the O
RARE I-GENE
- O
binding O
activity O
in O
the O
chromatographic O
fractions O
. O

The O
RARE O
associations O
RARE O
ALL_CAP I-GENE
behavior O
RARE O
mitosis O
are O
currently O
unknown O
. O

RARE I-GENE
II I-GENE
significantly O
RARE O
NUM I-GENE
mRNA I-GENE
RARE O
without O
affecting O
NUM I-GENE
or O
NUM I-GENE
RARE O
, O
which O
was O
inhibited O
by O
protein I-GENE
kinase I-GENE
C I-GENE
RARE O
and O
by O
RARE O
Ca O
( O
2 O
+) O
RARE O
agents O
. O

Promoter O
analysis O
demonstrated O
that O
the O
sequence O
identical O
to O
consensus O
cAMP O
- O
responsive O
element O
( O
ALL_CAP O
) O
RARE O
RARE O
- O
NUM O
of O
the O
RARE I-GENE
promoter I-GENE
was O
critical O
RARE O
RARE I-GENE
responsiveness O
. O

ALL_CAP I-GENE
/ I-GENE
ALL_CAP I-GENE
receptor I-GENE
activation O
of O
ALL_CAP I-GENE
is O
not O
RARE O
by O
activation O
of O
RARE I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
( O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
) O
or O
by O
G I-GENE
protein I-GENE
beta I-GENE
gamma I-GENE
subunits I-GENE
. O

Deletion O
analysis O
showed O
that O
the O
- O
NUM O
RARE O
NUM O
sequence O
was O
sufficient O
RARE O
both O
the O
RARE O
promoter O
activity O
and O
RARE O
- O
activation O
and O
electrophoretic O
mobility O
shift O
assays O
identified O
the O
interaction O
of O
C I-GENE
/ I-GENE
RARE I-GENE
and O
NUM I-GENE
to O
this O
region O
. O

RARE O
of O
RARE O
VT O
on O
the O
RARE O
attempt O
was O
comparable O
with O
ALL_CAP O
pacing O
( O
87 O
. O
4 O
%) O
versus O
RV O
pacing O
( O
NUM O
. O
6 O
%). O

We O
compare O
the O
results O
of O
this O
algorithm O
with O
the O
results O
obtained O
with O
two O
other O
RARE O
, O
the O
optimal O
algorithm O
RARE O
RARE O
RARE O
noise O
and O
the O
optimal O
algorithm O
RARE O
RARE O
additive O
noise O
, O
and O
we O
show O
that O
in O
both O
cases O
improvement O
can O
be O
obtained O
. O

Changes O
in O
RARE O
levels O
over O
time O
in O
nucleus O
NUM O
cochlear O
implant O
users O
. O

RARE O
RARE O
and O
RARE O
- O
directed O
mutagenesis O
revealed O
that O
the O
NUM O
- O
nt O
ALL_CAP O
( O
NUM O
) O
forms O
a O
RARE O
secondary O
RARE O
containing O
four O
helices O
connected O
by O
single O
- O
RARE O
regions O
. O

RARE O
- O
RARE O
has O
the O
RARE O
RARE O
of O
operating O
in O
live O
RARE O
situations O
using O
RARE O
input O
. O

A O
marked O
decrease O
in O
the O
type I-GENE
1 I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
( I-GENE
IGF I-GENE
) I-GENE
receptor I-GENE
( O
IGF I-GENE
- I-GENE
IR I-GENE
) O
occurs O
in O
RARE O
RARE O
cells O
RARE O
transformation O
from O
the O
benign O
to O
the O
metastatic O
state O
. O

The O
NUM O
cell O
line O
was O
derived O
by O
RARE O
of O
human O
RARE O
RARE O
RARE O
cells O
with O
simian I-GENE
virus I-GENE
- I-GENE
40 I-GENE
T I-GENE
antigen I-GENE
and O
is O
rarely O
tumorigenic O
. O

We O
determined O
whether O
the O
human I-GENE
ALL_CAP I-GENE
promoter I-GENE
is O
responsive O
to O
sterol I-GENE
regulatory I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
RARE I-GENE
). O

Expression O
of O
SREBP I-GENE
- I-GENE
NUM I-GENE
RARE O
ALL_CAP I-GENE
promoter I-GENE
activity O
in O
the O
context O
of O
COS O
- O
1 O
cells O
and O
human O
RARE O
- O
RARE O
cells O
. O

Because O
the O
high I-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
receptor I-GENE
( O
ALL_CAP I-GENE
- I-GENE
R I-GENE
) O
is O
a O
key O
element O
in O
cholesterol O
RARE O
and O
a O
RARE O
therapeutic O
target O
RARE O
RARE O
drugs O
, O
an O
understanding O
of O
ALL_CAP I-GENE
- I-GENE
R I-GENE
RARE O
is O
essential O
. O

IFN I-GENE
- I-GENE
RARE I-GENE
gene I-GENE
factor I-GENE
- I-GENE
3 I-GENE
and O
STAT1 I-GENE
homodimers I-GENE
formed O
and O
RARE O
an O
IFN I-GENE
- I-GENE
RARE I-GENE
response I-GENE
element I-GENE
( O
ALL_CAP I-GENE
) O
and O
gamma I-GENE
- I-GENE
activated I-GENE
sequence I-GENE
( O
ALL_CAP I-GENE
) O
element O
, O
respectively O
. O

We O
have O
therefore O
studied O
the O
RARE O
mechanisms O
of O
TGF I-GENE
- I-GENE
beta1 I-GENE
action O
on O
RARE I-GENE
( O
TG I-GENE
) O
gene O
RARE O
by O
focusing O
our O
attention O
on O
TGF I-GENE
- I-GENE
beta1 I-GENE
RARE O
of O
thyroid O
- O
specific O
transcription O
factors O
. O

The O
RARE O
- O
protected O
RARE O
( O
K O
) O
was O
present O
in O
a O
NUM I-GENE
- I-GENE
RARE I-GENE
ALL_CAP I-GENE
fragment I-GENE
that O
, O
by O
N O
- O
terminal O
sequencing O
, O
was O
found O
to O
be O
NUM O
. O

To O
understand O
the O
RARE O
RARE O
of O
these O
genes O
in O
thyroid O
cells O
, O
the O
effect O
of O
thyroid I-GENE
transcription I-GENE
factor I-GENE
1 I-GENE
( O
TTF I-GENE
- I-GENE
1 I-GENE
) O
and O
the O
paired I-GENE
domain I-GENE
- I-GENE
containing I-GENE
protein I-GENE
8 I-GENE
( O
Pax I-GENE
- I-GENE
8 I-GENE
) O
on O
the O
transcriptional O
activity O
of O
the O
deiodinase I-GENE
promoters I-GENE
were O
studied O
. O
